PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DA
J	Torrey, EF; Bartko, JJ; Yolken, RH				Torrey, E. Fuller; Bartko, John J.; Yolken, Robert H.			Toxoplasma gondii and Other Risk Factors for Schizophrenia: An Update	SCHIZOPHRENIA BULLETIN			English	Article						schizophrenia; Toxoplasma gondii; risk factors	METAANALYSIS; ANTIBODIES; CANNABIS; BIRTH; COMPLICATIONS; INDIVIDUALS; 1ST-EPISODE; INFECTION; PSYCHOSIS; SEASON	The failure to find genes of major effect in schizophrenia has refocused attention on nongenetic, including infectious factors. In a previous study, antibodies to Toxoplasma gondii were found to be elevated in 23 studies of schizophrenia (OR 2.73; 95% CI 2.10-3.60). The current study replicates this finding with 15 additional studies (OR 2.71; 95% CI 1.93-3.80) and compares this with other identified schizophrenia risk factors. The highest risk factors are having an affected mother (relative risks [RR] 9.31; 95% CI 7.24-11.96), father (RR 7.20; 95% CI 5.10-10.16), or sibling (RR 6.99; 95% CI 5.38-9.08) or being the offspring of immigrants from selected countries (RR 4.5; 95% CI 1.5-13.1). Intermediate risk factors, in addition to infection with T. gondii, include being an immigrant from and to selected countries (RR 2.7; 95% CI 2.3-3.2), being born in (RR 2.24; 95% CI 1.92-2.61) or raised in (RR 2.75; 95% CI 2.31-3.28) an urban area, cannabis use (OR 2.10-2.93; 95% CI 1.08-6.13), having minor physical anomalies (OR 2.23; 95% CI 1.42-3.58), or having a father 55 or older (OR 2.21-5.92; 95% CI 1.46-17.02). Low-risk factors include a history of traumatic brain injury (OR 1.65; 95% CI 1.17-2.32), sex abuse in childhood (OR 1.46; 95% CI 0.84-2.52), obstetrical complications (OR 1.29-1.38; 95% CI 1.00-1.84), having a father 45 or older (OR 1.21-1.66; 95% CI 1.09-2.01), specific genetic polymorphisms (OR 1.09-1.24; 95% CI 1.06-1.45), birth seasonality (OR 1.07-1.95; 95% CI 1.05-2.91), maternal exposure to influenza (RR 1.05; 95% CI 0.98-1.12), or prenatal stress (RR 0.98-1.00; 95% CI 0.85-1.16).	[Torrey, E. Fuller; Bartko, John J.] Stanley Med Res Inst, Chevy Chase, MD 20815 USA; [Yolken, Robert H.] Johns Hopkins Univ, Med Ctr, Dept Pediat, Stanley Lab Dev Neurovirol, Baltimore, MD 21218 USA	Torrey, EF (corresponding author), Stanley Med Res Inst, 8401 Connecticut Ave,Suite 200, Chevy Chase, MD 20815 USA.	torreyf@stanleyresearch.org			Stanley Medical Research Institute	Stanley Medical Research Institute.	Allen NC, 2008, NAT GENET, V40, P827, DOI 10.1038/ng.171; Alvarado-Esquivel C, 2011, PARASITOL INT, V60, P151, DOI 10.1016/j.parint.2010.12.003; Cannon M, 2002, AM J PSYCHIAT, V159, P1080, DOI 10.1176/appi.ajp.159.7.1080; Cantor-Graae E, 2005, AM J PSYCHIAT, V162, P12, DOI 10.1176/appi.ajp.162.1.12; Cetinkaya Z, 2007, SCHIZOPHRENIA BULL, V33, P789, DOI 10.1093/schbul/sbm021; Chen LP, 2010, MAYO CLIN PROC, V85, P618, DOI 10.4065/mcp.2009.0583; Chen X, 2011, MOL PSYCHIATR, V16, P1117, DOI 10.1038/mp.2010.96; Daryani A, 2010, TROP BIOMED, V27, P476; Davies G, 2003, SCHIZOPHRENIA BULL, V29, P587, DOI 10.1093/oxfordjournals.schbul.a007030; Dogruman-Al F, 2009, INT J PSYCHIAT CLIN, V13, P82, DOI 10.1080/13651500802624738; El-Sahn Amel A, 2005, J Egypt Public Health Assoc, V80, P509; Fisher LD, 2004, BIOSTATISTICS METHOD, P165; Gaskell EA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004801; Geddes JR, 1999, SCHIZOPHRENIA BULL, V25, P413, DOI 10.1093/oxfordjournals.schbul.a033389; Gershon ES, 2011, AM J PSYCHIAT, V168, P253, DOI 10.1176/appi.ajp.2010.10091340; Hamidinejat H, 2010, INT J INFECT DIS, V14, pE978, DOI 10.1016/j.ijid.2010.05.018; Henquet C, 2005, SCHIZOPHRENIA BULL, V31, P608, DOI 10.1093/schbul/sbi027; Hinze-Selch D, 2007, SCHIZOPHRENIA BULL, V33, P782, DOI 10.1093/schbul/sbm010; Liu M, 2011, ACTA PARASITOL, V56, P353, DOI 10.2478/s11686-011-0082-2; Matheson SL, 2011, SCHIZOPHR RES, V133, P133, DOI 10.1016/j.schres.2011.09.020; Messias E, 2004, ARCH GEN PSYCHIAT, V61, P985, DOI 10.1001/archpsyc.61.10.985; Miller B, 2011, SCHIZOPHRENIA BULL, V37, P1039, DOI 10.1093/schbul/sbq011; Molloy C, 2011, SCHIZOPHRENIA BULL, V37, P1104, DOI 10.1093/schbul/sbr091; Moore THM, 2007, LANCET, V370, P319, DOI 10.1016/S0140-6736(07)61162-3; Mortensen PB, 1999, NEW ENGL J MED, V340, P603, DOI 10.1056/NEJM199902253400803; Pedersen CB, 2001, ARCH GEN PSYCHIAT, V58, P1039, DOI 10.1001/archpsyc.58.11.1039; Saraei-Sahnesaraei M, 2009, IJPCP, V15, P3; Schwarcz R, 2007, SCHIZOPHRENIA BULL, V33, P652, DOI 10.1093/schbul/sbm030; Selten JP, 2010, SCHIZOPHRENIA BULL, V36, P219, DOI 10.1093/schbul/sbp147; Selten JP, 2003, SCHIZOPHR RES, V63, P131, DOI 10.1016/S0920-9964(02)00375-4; Semple DM, 2005, J PSYCHOPHARMACOL, V19, P187, DOI 10.1177/0269881105049040; Shi JJ, 2008, SCHIZOPHR RES, V104, P96, DOI 10.1016/j.schres.2008.06.016; Stefansson H, 2009, NATURE, V460, P744, DOI 10.1038/nature08186; Sun S, 2005, CHIN J PARASIT DIS C, V18, P157; Tamer GS, 2008, ADV THER, V25, P703, DOI 10.1007/s12325-008-0063-5; Tanyuksel M, 2010, TURK J MED SCI, V40, P399, DOI 10.3906/sag-0904-11; Tedla Yared, 2011, Ethiop Med J, V49, P211; Torrey EF, 2007, SCHIZOPHRENIA BULL, V33, P729, DOI 10.1093/schbul/sbl050; Torrey EF, 2009, SCHIZOPHR RES, V114, P1, DOI 10.1016/j.schres.2009.06.017; Weinberg SM, 2007, SCHIZOPHR RES, V89, P72, DOI 10.1016/j.schres.2006.09.002; Wohl M, 2007, EUR PSYCHIAT, V22, P22, DOI 10.1016/j.eurpsy.2006.08.007; Xu XZ, 2005, RE DAI YI XUE, V3, P133; Yolken RH, 2008, MOL PSYCHIATR, V13, P470, DOI 10.1038/mp.2008.5; Yuksel P, 2010, FOLIA PARASIT, V57, P121, DOI 10.14411/fp.2010.015; Zhu SY, 2003, ZHONGGUO MIN KANG YI, V15, P405	45	239	248	1	75	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0586-7614	1745-1701		SCHIZOPHRENIA BULL	Schizophr. Bull.	MAY	2012	38	3					642	647		10.1093/schbul/sbs043			6	Psychiatry	Psychiatry	930VB	WOS:000303169000032	22446566	Green Published, Bronze	Y	N	2021-06-18	
J	Tayal, VS; Neulander, M; Norton, HJ; Foster, T; Saunders, T; Blaivas, M				Tayal, Vivek S.; Neulander, Matthew; Norton, H. James; Foster, Troy; Saunders, Timothy; Blaivas, Michael			Emergency department sonographic measurement of optic nerve sheath diameter to detect findings of increased intracranial pressure in adult head injury patients	ANNALS OF EMERGENCY MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the Society-for-Academic-Emergency-Medicine (SAEM)	MAY 22-25, 2005	New York, NY	Soc Acad Emergency Med			FUNDAMENTALS; HYPERTENSION; EXPANSION	Study objective: Our objective is to determine whether a bedside ultrasonographic measurement of optic nerve sheath diameter can accurately predict the computed tomographic (CT) findings of elevated intracranial pressure in adult head injury patients in the emergency department (ED). Methods: We conducted a prospective, blinded observational study on adult ED patients with suspected intracranial injury with possible elevated intracranial pressure. Exclusion criteria were age younger than 18 years or obvious ocular trauma. Using a 7.5-MHz ultrasonographic probe on the closed eyelids, a single optic nerve sheath diameter was measured 3 mm behind the globe in each eye. A mean binocular optic nerve sheath diameter greater than 5.00 mm was considered abnormal. Cranial CT findings of shift, edema, or effacement suggestive of elevated intracranial pressure were used to evaluate optic nerve sheath diameter accuracy. Results: Fifty-nine patients were enrolled in the study. Average age was 38 years, and median Glasgow Coma Scale score was 15 (interquartile 6 to 15). Eight patients with an optic nerve sheath diameter of 5.00 mm or more had CT findings that correlated with elevated intracranial pressure. The sensitivity for the ultrasonography in detecting elevated intracranial pressure was 100% (95% confidence interval [Cl] 68% to 100%) and specificity was 63% (95% Cl 50% to 76%). The sensitivity of ultrasonography for detection of any traumatic intracranial injury found by CT was 84% (95% Cl 60% to 97%) and specificity was 73% (95% CI 59% to 86%). Conclusion: Bedside ED optic nerve sheath diameter ultrasonography has potential as a sensitive screening test for elevated intracranial pressure in adult head injury.	Carolinas Med Ctr, Dept Emergency Med, Charlotte, NC 28203 USA; Carolinas Med Ctr, Dept Biostat, Charlotte, NC 28203 USA; Charlotte Eye Ear Nose & Throat Assoc, Charlotte, NC USA; Med Coll Georgia, Dept Emergency Med, Augusta, GA 30912 USA	Tayal, VS (corresponding author), Box 32861, Charlotte, NC 28232 USA.	vtayal@carolinas.org					American College of Surgeons, 1997, HEAD TRAUM, P181; Biros M H, 2001, Curr Opin Crit Care, V7, P444, DOI 10.1097/00075198-200112000-00012; Blaivas M, 2003, ACAD EMERG MED, V10, P376, DOI 10.1197/aemj.10.4.376; GALETTA S, 1989, J CLIN NEURO-OPHTHAL, V9, P79; Hansen HC, 1997, J NEUROSURG, V87, P34, DOI 10.3171/jns.1997.87.1.0034; Helmke K, 1996, PEDIATR RADIOL, V26, P706, DOI 10.1007/BF01383384; Helmke K, 1996, PEDIATR RADIOL, V26, P701, DOI 10.1007/BF01383383; Malayeri AA, 2005, J ULTRAS MED, V24, P143, DOI 10.7863/jum.2005.24.2.143; Miller MT, 2004, J TRAUMA, V56, P967, DOI 10.1097/01.TA.0000123699.16465.8B; Romagnuolo L, 2005, AM J EMERG MED, V23, P686, DOI 10.1016/j.ajem.2004.11.004; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P597, DOI [10.1089/neu.2000.17.597, DOI 10.1089/NEU.2000.17.597]; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P463; The Brain Trauma Foundation The American Association of Neurological Surgeons The Joint Section on Neurotrauma and Critical Care, 2000, J NEUROTRAUM, V17, P497	13	239	244	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644	1097-6760		ANN EMERG MED	Ann. Emerg. Med.	APR	2007	49	4					508	514		10.1016/j.annemergmed.2006.06.040			7	Emergency Medicine	Emergency Medicine	151ME	WOS:000245293700018	16997419				2021-06-18	
J	Schmidt, OI; Heyde, CE; Ertel, W; Stahel, PF				Schmidt, OI; Heyde, CE; Ertel, W; Stahel, PF			Closed head injury - an inflammatory disease?	BRAIN RESEARCH REVIEWS			English	Article; Proceedings Paper	OASI Workshop 2004	MAY 13-17, 2004	Troina, ITALY			head injury; neuroinflammation; blood-brain barrier; complement; cytokines; chemokines	TUMOR-NECROSIS-FACTOR; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; MEMBRANE ATTACK COMPLEX; INTERLEUKIN-1 RECEPTOR ANTAGONIST; MESSENGER-RNA EXPRESSION; GROWTH-FACTOR PRODUCTION; NEURONAL C5A RECEPTOR; TNF-ALPHA; RAT-BRAIN	Closed head injury (CHI) remains the leading cause of death and persisting neurological impairment in young individuals in industrialized nations. Research efforts in the past years have brought evidence that the intracranial inflammatory response in the injured brain contributes to the neuropathological sequelae which are, in large part, responsible for the adverse outcome after head injury. The presence of hypoxia and hypotension in the early resuscitative period of brain-injured patients further aggravates the inflammatory response in the brain due to ischemia/reperfusion-mediated injuries. The profound endogenous neuroinflammatory response after CHI, which is phylogenetically aimed at defending the intrathecal compartment from invading pathogens and repairing lesioned brain tissue, contributes to the development of cerebral edema, breakdown of the blood-brain barrier, and ultimately to delayed neuronal cell death. However, aside from these deleterious effects, neuroinflammation has been recently shown to mediate neuroreparative mechanisms after brain injury as well. This "dual effect" of neuroinflammation was the focus of extensive experimental and clinical research in the past years and has lead to an expanded basic knowledge on the cellular and molecular mechanisms which regulate the intracranial inflammatory response after CHI. Thus, head injury has recently evolved as an inflammatory and immunological disease much more than a pure traumatological, neurological, or neurosurgical entity. The present review will summarize the so far known mechanisms of posttraumatic neuroinflammation after CHI, based on data from clinical and experimental studies, with a special focus on the role of pro-inflammatory cytokines, chemokines, and the complement system. (c) 2004 Elsevier B.V. All rights reserved.	Univ Berlin, Sch Med, Charite, Dept Trauma & Reconstruct Surg, D-12200 Berlin, Germany	Stahel, PF (corresponding author), Univ Berlin, Sch Med, Charite, Dept Trauma & Reconstruct Surg, Campus Benjamin Franklin,Hindenburgdamm 30, D-12200 Berlin, Germany.	pfstahel@aol.com					Allan SM, 2000, P NATL ACAD SCI USA, V97, P5580, DOI 10.1073/pnas.090464197; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Arnett HA, 2001, NAT NEUROSCI, V4, P1116, DOI 10.1038/nn738; Asensio VC, 1999, TRENDS NEUROSCI, V22, P504, DOI 10.1016/S0166-2236(99)01453-8; Babcock AA, 2003, J NEUROSCI, V23, P7922; Barnum SR, 1999, MOL MED, V5, P569, DOI 10.1007/BF03402070; Barnum SR, 2002, IMMUNOL RES, V26, P7, DOI 10.1385/IR:26:1-3:007; Bell MD, 1996, NEUROSCIENCE, V74, P283, DOI 10.1016/0306-4522(96)00083-8; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Bellander BM, 1996, J NEUROSURG, V85, P468, DOI 10.3171/jns.1996.85.3.0468; Bellander BM, 2001, J NEUROTRAUM, V18, P1295, DOI 10.1089/08977150152725605; Berman JW, 1996, J IMMUNOL, V156, P3017; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; Casarsa C, 2003, EUR J IMMUNOL, V33, P1260, DOI 10.1002/eji.200323574; Chao CC, 1995, BRAIN BEHAV IMMUN, V9, P355, DOI 10.1006/brbi.1995.1033; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Davoust N, 1999, GLIA, V26, P201, DOI 10.1002/(SICI)1098-1136(199905)26:3<201::AID-GLIA2>3.0.CO;2-M; deVries HE, 1996, J NEUROIMMUNOL, V64, P37, DOI 10.1016/0165-5728(95)00148-4; Elward K, 2003, MOL IMMUNOL, V40, P85, DOI 10.1016/S0161-5890(03)00109-3; Ember JA, 1997, IMMUNOPHARMACOLOGY, V38, P3, DOI 10.1016/S0162-3109(97)00088-X; Emmerling MR, 2000, BBA-MOL BASIS DIS, V1502, P158, DOI 10.1016/S0925-4439(00)00042-9; Eugenin EA, 2003, METHODS, V29, P351, DOI 10.1016/S1046-2023(02)00359-6; Eugster HP, 1998, EUR J IMMUNOL, V28, P2178, DOI 10.1002/(SICI)1521-4141(199807)28:07<2178::AID-IMMU2178>3.0.CO;2-D; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Farkas I, 1998, J PHYSIOL-LONDON, V507, P679, DOI 10.1111/j.1469-7793.1998.679bs.x; Fassbender K, 1999, NEUROLOGY, V53, P1104, DOI 10.1212/WNL.53.5.1104; Fassbender K, 2000, NEUROSCI LETT, V284, P135, DOI 10.1016/S0304-3940(00)00977-0; Feuerstein GZ, 1998, NEUROIMMUNOMODULAT, V5, P143, DOI 10.1159/000026331; Fischer WH, 1999, J IMMUNOL, V162, P453; Gadient RA, 1997, PROG NEUROBIOL, V52, P379, DOI 10.1016/S0301-0082(97)00021-X; Galasso JM, 2000, NEUROREPORT, V11, P231, DOI 10.1097/00001756-200002070-00002; GASQUE P, 1995, J IMMUNOL, V154, P4726; Gasque P, 1998, J IMMUNOL, V160, P3543; GASQUE P, 1995, J IMMUNOL, V155, P4882; Gasque P, 2000, IMMUNOPHARMACOLOGY, V49, P171, DOI 10.1016/S0162-3109(00)80302-1; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Glabinski AR, 1999, J NEUROVIROL, V5, P3, DOI 10.3109/13550289909029740; Glabinski AR, 2003, J INTERF CYTOK RES, V23, P457, DOI 10.1089/107999003322277874; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Gourin CG, 1997, J TRAUMA, V42, P1101, DOI 10.1097/00005373-199706000-00020; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Gruol DL, 1997, MOL NEUROBIOL, V15, P307, DOI 10.1007/BF02740665; Hausmann EHS, 1998, BRAIN RES, V788, P49, DOI 10.1016/S0006-8993(97)01160-8; Hedtjarn M, 2002, J NEUROSCI, V22, P5910; Heese K, 1998, J NEUROCHEM, V70, P699; Hicks RR, 2002, J NEUROTRAUM, V19, P705, DOI 10.1089/08977150260139093; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; HOPKINS SJ, 1995, TRENDS NEUROSCI, V18, P83; Horuk R, 1997, J IMMUNOL, V158, P2882; Hosokawa M, 2003, GLIA, V42, P417, DOI 10.1002/glia.10234; HURWITZ AA, 1992, J EXP MED, V176, P1631, DOI 10.1084/jem.176.6.1631; Jander S, 2002, J CEREBR BLOOD F MET, V22, P62, DOI 10.1097/00004647-200201000-00008; KACZOROWSKI SL, 1995, J CEREBR BLOOD F MET, V15, P860, DOI 10.1038/jcbfm.1995.107; Keeling KL, 2000, J NEUROIMMUNOL, V105, P20, DOI 10.1016/S0165-5728(00)00183-1; KIM KS, 1992, LYMPHOKINE CYTOK RES, V11, P293; Klein MA, 2001, NAT MED, V7, P488, DOI 10.1038/86567; Klein MA, 1997, GLIA, V19, P227, DOI 10.1002/(SICI)1098-1136(199703)19:3<227::AID-GLIA5>3.0.CO;2-W; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kossmann T, 1997, J NEUROIMMUNOL, V73, P63, DOI 10.1016/S0165-5728(96)00164-6; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; KOSSMANN T, 2001, PRACTICE GEN SURG, P101; LACY M, 1995, J NEUROIMMUNOL, V61, P71, DOI 10.1016/0165-5728(95)00075-D; Lavine SD, 1998, J CEREBR BLOOD F MET, V18, P52, DOI 10.1097/00004647-199801000-00005; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; LEVISTRAUSS M, 1987, J IMMUNOL, V139, P2361; Lindsberg PJ, 1996, ANN NEUROL, V40, P587, DOI 10.1002/ana.410400408; Liou AKF, 2003, PROG NEUROBIOL, V69, P103, DOI 10.1016/S0301-0082(03)00005-4; Lynch NJ, 2004, MOL IMMUNOL, V40, P709, DOI 10.1016/j.molimm.2003.08.009; Maas A. I., 2000, CURR OPIN CRIT CARE, V6, P281; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; McGeer EG, 1998, DRUGS, V55, P739, DOI 10.2165/00003495-199855060-00001; Mead RJ, 2002, J IMMUNOL, V168, P458, DOI 10.4049/jimmunol.168.1.458; MEGYERI P, 1992, NEUROSCI LETT, V148, P137, DOI 10.1016/0304-3940(92)90823-P; Menge T, 2001, J NEUROSCI RES, V65, P332, DOI 10.1002/jnr.1158; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; Mollnes Tom E., 2002, Trends in Immunology, V23, P61, DOI 10.1016/S1471-4906(01)02129-9; Morgan BP, 1996, IMMUNOL TODAY, V17, P461, DOI 10.1016/0167-5699(96)20028-F; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Mukherjee P, 2001, J NEUROCHEM, V77, P43, DOI 10.1046/j.1471-4159.2001.00167.x; Nataf S, 2001, BRAIN RES, V894, P321, DOI 10.1016/S0006-8993(01)02003-0; Nataf S, 1999, TRENDS NEUROSCI, V22, P397, DOI 10.1016/S0166-2236(98)01390-3; O'Barr SA, 2001, J IMMUNOL, V166, P4154, DOI 10.4049/jimmunol.166.6.4154; Osaka H, 1999, J CELL BIOCHEM, V73, P303, DOI 10.1002/(SICI)1097-4644(19990601)73:3<303::AID-JCB2>3.0.CO;2-2; Otto VI, 2001, NEUROREPORT, V12, P2059, DOI 10.1097/00001756-200107030-00053; Otto VI, 2000, J NEUROSCI RES, V60, P733, DOI 10.1002/1097-4547(20000615)60:6<733::AID-JNR5>3.0.CO;2-X; Patel HC, 2003, ANN NY ACAD SCI, V992, P39, DOI 10.1111/j.1749-6632.2003.tb03136.x; Penkowa M, 2000, GLIA, V32, P271, DOI 10.1002/1098-1136(200012)32:3<271::AID-GLIA70>3.0.CO;2-5; Penkowa M, 2003, J NEUROSCI RES, V73, P481, DOI 10.1002/jnr.10681; Penkowa M, 1999, GLIA, V25, P343; Probert L, 1997, J NEUROIMMUNOL, V72, P137, DOI 10.1016/S0165-5728(96)00184-1; QUAGLIARELLO VJ, 1991, J CLIN INVEST, V87, P1360, DOI 10.1172/JCI115140; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; RAMILO O, 1990, J EXP MED, V172, P497, DOI 10.1084/jem.172.2.497; Rancan M, 2003, J CEREBR BLOOD F MET, V23, P1070, DOI 10.1097/01.WCB.0000084250.20114.2C; Ransohoff RM, 2002, ANN NY ACAD SCI, V961, P346, DOI 10.1111/j.1749-6632.2002.tb03120.x; Ransohoff RM, 2002, J INFECT DIS, V186, pS152, DOI 10.1086/344266; Ransohoff RM, 1998, TRENDS NEUROSCI, V21, P154, DOI 10.1016/S0166-2236(97)01198-3; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Rothwell N, 2003, BRAIN BEHAV IMMUN, V17, P152, DOI 10.1016/S0889-1591(02)00098-3; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Sedgwick JD, 2000, IMMUNOL TODAY, V21, P110, DOI 10.1016/S0167-5699(99)01573-X; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Singhrao SK, 2000, AM J PATHOL, V157, P905, DOI 10.1016/S0002-9440(10)64604-4; Stahel PF, 1997, AM J PATHOL, V151, P897; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stahel PF, 1997, J IMMUNOL, V159, P861; Stahel PF, 1997, MOL BRAIN RES, V50, P205, DOI 10.1016/S0169-328X(97)00189-7; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; Stahel PF, 2001, J NEUROTRAUM, V18, P773, DOI 10.1089/089771501316919139; Stahel PF, 1997, IMMUNOPHARMACOLOGY, V38, P65, DOI 10.1016/S0162-3109(97)80150-6; Stahel PF, 2000, J NEUROIMMUNOL, V109, P164, DOI 10.1016/S0165-5728(00)00304-0; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Swartz KR, 2001, BRAIN RES, V896, P86, DOI 10.1016/S0006-8993(01)02013-3; Takabayashi T, 1996, J IMMUNOL, V156, P3455; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TCHELINGERIAN JL, 1993, NEURON, V10, P213, DOI 10.1016/0896-6273(93)90312-F; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; Thomas A, 2000, INT IMMUNOL, V12, P1015, DOI 10.1093/intimm/12.7.1015; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; Tran PB, 2003, J COMP NEUROL, V457, P1, DOI 10.1002/cne.10546; Trembovler V, 1999, J INTERF CYTOK RES, V19, P791, DOI 10.1089/107999099313640; Van Beek J, 2003, ANN NY ACAD SCI, V992, P56; van Beek J, 2001, NEUROREPORT, V12, P289, DOI 10.1097/00001756-200102120-00022; Vecil GG, 2000, J NEUROSCI RES, V61, P212, DOI 10.1002/1097-4547(20000715)61:2<212::AID-JNR12>3.0.CO;2-9; Wang CX, 2002, PROG NEUROBIOL, V67, P161, DOI 10.1016/S0301-0082(02)00010-2; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003; Wheeler RD, 2003, J NEUROCHEM, V85, P1412, DOI 10.1046/j.1471-4159.2003.01787.x; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; Xiong ZQ, 2003, J NEUROSCI, V23, P955; YAN HQ, 1992, EUR J IMMUNOL, V22, P2963, DOI 10.1002/eji.1830221131; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; Yu JX, 2002, J NEUROIMMUNOL, V123, P91, DOI 10.1016/S0165-5728(01)00483-0; ZHUANG J, 1993, J TRAUMA, V35, P415, DOI 10.1097/00005373-199309000-00014	145	239	248	1	10	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0173	1872-6321		BRAIN RES REV	Brain Res. Rev.	APR	2005	48	2			SI		388	399		10.1016/j.brainresrev.2004.12.028			12	Neurosciences	Neurosciences & Neurology	933KV	WOS:000229628200028	15850678				2021-06-18	
J	Watson, GA; Sperry, JL; Rosengart, MR; Minei, JP; Harbrecht, BG; Moore, EE; Cuschieri, J; Maier, RV; Billiar, TR; Peitzman, AB				Watson, Gregory A.; Sperry, Jason L.; Rosengart, Matthew R.; Minei, Joseph P.; Harbrecht, Brian G.; Moore, Ernest E.; Cuschieri, Joseph; Maier, Ronald V.; Billiar, Timothy R.; Peitzman, Andrew B.		Inflammation Host Response Injury	Fresh Frozen Plasma Is Independently Associated With a Higher Risk of Multiple Organ Failure and Acute Respiratory Distress Syndrome	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	67th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma/Meeting of the Association-for-Acute-Medicine	SEP 24-27, 2008	Maui, HI	Amer Assoc Surg Trauma, Assoc Acute Med		Fresh frozen plasma; Cryoprecipitate; Multiple organ failure; Nosocomial infection	STANDARD OPERATING PROCEDURES; SCALE COLLABORATIVE PROJECT; ORIENTED RESEARCH CORE; RECEIVING MASSIVE TRANSFUSIONS; BINDING GLYCOPROTEIN THERAPY; I TRAUMA CENTER; BLOOD-TRANSFUSION; CLINICAL CARE; CRITICALLY-ILL; HOST RESPONSE	Background: Blood transfusion is known to be an independent risk factor for mortality, multiple organ failure (MOF), acute respiratory distress syndrome (ARDS), and nosocomial infection after injury. Less is known about the independent risks associated with plasma-rich transfusion components including fresh frozen plasma (FFP), platelets (PLTS), and cryoprecipitate (CRYO) after injury. We hypothesized that plasma-rich transfusion components would be independently associated with a lower risk of mortality but result in a greater risk of morbid complications. Methods: Data were obtained from a multicenter prospective cohort study evaluating clinical outcomes in bluntly injured adults with hemorrhagic shock. All patients required blood transfusion for enrollment. Patients with isolated traumatic brain injury and those not surviving beyond 48 hours were excluded. Cox proportional hazard regression models were used to estimate the outcome risks (per unit) associated with plasma-rich transfusion requirements during the initial 24 hours after injury after controlling for important confounders. Results: For the entire study population (n = 1,175), 65%, 41%, and 28% of patients received FFP, PLTS and CRYO, respectively. There was no association with plasma-rich transfusion components and mortality or nosocomial infection. For every unit given, FFP was independently associated with a 2.1% and 2.5% increased risk of MOF and ARDS, respectively. CRYO was associated with a 4.4% decreased risk of MOF (per unit), and PLTS were not associated with any of the outcomes examined. When early deaths (within 48 hours) were included in the model, FFP was associated with a 2.9%, decreased risk of mortality per unit transfused. Conclusions: In patients who survive their initial injury, FFP was independently associated with a greater risk of developing MOF and ARDS, whereas CRYO was associated with a lower risk of MOF. Further investigation into the mechanisms by which these plasma-rich component transfusions are associated with these effects are required.	[Watson, Gregory A.; Sperry, Jason L.; Rosengart, Matthew R.; Billiar, Timothy R.; Peitzman, Andrew B.] Univ Pittsburgh, Med Ctr, Dept Surg, Div Gen Surg & Trauma, Pittsburgh, PA 15213 USA; [Minei, Joseph P.] Univ Texas SW Med Ctr Dallas, Dept Surg, Div Burn, Dallas, TX 75390 USA; [Harbrecht, Brian G.] Univ Louisville, Dept Surg, Div Gen Surg & Trauma, Louisville, KY 40292 USA; [Moore, Ernest E.] Denver Hlth Med Ctr, Dept Surg, Denver, CO USA; [Moore, Ernest E.] Univ Colorado, Hlth Sci Ctr, Denver, CO USA; [Cuschieri, Joseph; Maier, Ronald V.] Univ Washington, Harborview Med Ctr, Div Gen Surg & Trauma, Seattle, WA 98104 USA; [Cuschieri, Joseph; Maier, Ronald V.] Univ Washington, Dept Surg, Seattle, WA 98195 USA	Sperry, JL (corresponding author), Univ Pittsburgh, Med Ctr, Dept Surg, Div Gen Surg & Trauma, 200 Lothrop St, Pittsburgh, PA 15213 USA.	sperryjl@upmc.edu		Watson, Gregory/0000-0001-7729-4818	NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [KL2RR024154] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [U54GM062119] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [KL2 RR024154-03] Funding Source: Medline; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [U54 GM062119-1] Funding Source: Medline		Acosta JA, 1998, J AM COLL SURGEONS, V186, P528, DOI 10.1016/S1072-7515(98)00082-9; ANNEST SJ, 1980, J TRAUMA, V20, P726, DOI 10.1097/00005373-198009000-00003; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Bochicchio GV, 2008, WORLD J SURG, V32, P2185, DOI 10.1007/s00268-008-9655-0; Borgman MA, 2007, J TRAUMA, V63, P805, DOI 10.1097/TA.0b013e3181271ba3; CARRICO CJ, 1986, ARCH SURG-CHICAGO, V121, P196; Claridge JA, 2002, AM SURGEON, V68, P566; Duchesne JC, 2008, J TRAUMA, V65, P272, DOI 10.1097/TA.0b013e31817e5166; Feickert HJ, 2001, PEDIATR TRANSPLANT, V5, P266, DOI 10.1034/j.1399-3046.2001.005004266.x; FERRARA A, 1990, AM J SURG, V160, P515, DOI 10.1016/S0002-9610(05)81018-9; Gajic O, 2006, CRIT CARE MED, V34, pS170, DOI 10.1097/01.CCM.0000214288.88308.26; Gentilello LM, 2001, AM J RESP CRIT CARE, V163, P604, DOI 10.1164/ajrccm.163.3.2004106; Gordon B, 1998, BONE MARROW TRANSPL, V22, P999, DOI 10.1038/sj.bmt.1701464; Gunst MA, 2007, CURR OPIN CRIT CARE, V13, P428, DOI 10.1097/MCC.0b013e32826385ef; Harbrecht BG, 2007, J TRAUMA, V63, P703, DOI 10.1097/TA.0b013e31811eadea; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Holcomb JB, 2007, J TRAUMA, V62, pS36, DOI 10.1097/TA.0b013e3180654134; Huber-Wagner S, 2007, RESUSCITATION, V75, P276, DOI 10.1016/j.resuscitation.2007.04.018; Kashuk JL, 2008, J TRAUMA, V65, P261, DOI 10.1097/TA.0b013e31817de3e1; Kauvar DS, 2006, J TRAUMA, V60, pS3, DOI 10.1097/01.ta.0000199961.02677.19; Ketchum L, 2006, J TRAUMA, V60, pS51, DOI 10.1097/01.ta.0000199432.88847.0c; Kian H, 2007, CHEST, V131, P1308, DOI 10.1378/chest.06-3048; MacLennan S, 2006, J TRAUMA, V60, pS46, DOI 10.1097/01.ta.0000199546.22925.31; Malone DL, 2006, J TRAUMA, V60, pS91, DOI 10.1097/01.ta.0000199549.80731.e6; Malone DL, 2003, J TRAUMA, V54, P898, DOI 10.1097/01.TA.0000060261.10597.5C; Marik PE, 2008, CRIT CARE MED, V36, P2667, DOI 10.1097/CCM.0b013e3181844677; MARIK PE, 1993, JAMA-J AM MED ASSOC, V269, P3024, DOI 10.1001/jama.269.23.3024; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; Minei JP, 2006, J TRAUMA, V60, P1106, DOI 10.1097/01.ta.0000220424.34835.f1; Mitra B, 2007, INJURY, V38, P1023, DOI 10.1016/j.injury.2007.03.021; Moore EE, 1996, AM J SURG, V172, P405, DOI 10.1016/S0002-9610(96)00216-4; Moore FA, 1997, ARCH SURG-CHICAGO, V132, P620; Moore FA, 2006, J TRAUMA, V61, P82, DOI 10.1097/01.ta.0000225933.08478.65; Napolitano Lena M, 2004, Curr Opin Crit Care, V10, P311; Nathens AB, 2005, J TRAUMA, V59, P764, DOI 10.1097/01.ta.0000177759.17704.35; Robinson WP, 2005, J TRAUMA, V58, P437, DOI 10.1097/01.TA.0000153935.18997.14; SABA TM, 1978, SCIENCE, V201, P622, DOI 10.1126/science.675246; Sarani B, 2008, CRIT CARE MED, V36, P1114, DOI 10.1097/CCM.0b013e318168f89d; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; SCOVILL WA, 1979, SURGERY, V86, P284; SCOVILL WA, 1978, ANN SURG, V188, P521, DOI 10.1097/00000658-197810000-00009; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; Shapiro MB, 2007, J TRAUMA, V63, P945, DOI 10.1097/TA.0b013e318142d21b; Shorr AF, 2005, CURR OPIN CRIT CARE, V11, P468, DOI 10.1097/01.ccx.0000176689.18433.f4; Silverboard H, 2005, J TRAUMA, V59, P717, DOI 10.1097/01.ta.0000174919.35240.21; Sperry JL, 2008, J TRAUMA, V65, P986, DOI 10.1097/TA.0b013e3181878028; Spinella PC, 2008, J TRAUMA, V64, pS69, DOI 10.1097/TA.0b013e318160ba2f; Stanworth SJ, 2004, BRIT J HAEMATOL, V126, P139, DOI 10.1111/j.1365-2141.2004.04973.x; Stinger HK, 2008, J TRAUMA, V64, pS79, DOI 10.1097/TA.0b013e318160a57b; Tate CC, 2007, EXP NEUROL, V207, P13, DOI 10.1016/j.expneurol.2007.05.008; Tinmouth A, 2006, TRANSFUSION, V46, P2014, DOI 10.1111/j.1537-2995.2006.01026.x; West MA, 2006, J TRAUMA, V61, P436, DOI 10.1097/01.ta.0000232517.83039.c4; WILSON RF, 1987, AM SURGEON, V53, P410; Zallen G, 1999, J SURG RES, V83, P83, DOI 10.1006/jsre.1999.5569	54	238	242	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	AUG	2009	67	2					221	227		10.1097/TA.0b013e3181ad5957			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	482OL	WOS:000268898500001	19667872				2021-06-18	
J	Corneli, G; Di Somma, C; Baldelli, R; Rovere, S; Gasco, V; Croce, CG; Grottoli, S; Maccario, M; Colao, A; Lombardi, G; Ghigo, E; Camanni, F; Aimaretti, G				Corneli, G; Di Somma, C; Baldelli, R; Rovere, S; Gasco, V; Croce, CG; Grottoli, S; Maccario, M; Colao, A; Lombardi, G; Ghigo, E; Camanni, F; Aimaretti, G			The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index	EUROPEAN JOURNAL OF ENDOCRINOLOGY			English	Article; Proceedings Paper	86th Annual Meeting of the Endocrine-Society	JUN 12-15, 2004	New Orleans, LA	Endocrine Soc			TRAUMATIC BRAIN-INJURY; INSULIN TOLERANCE-TEST; GROWTH-FACTOR-I; PLUS ARGININE; SUBARACHNOID HEMORRHAGE; PROVOCATIVE TESTS; DEFICIENCY; DIAGNOSIS; ADULTS; SECRETION	Objective: The diagnosis of growth hormone (GH) deficiency (GHD) in adults is based on a reduced peak GH response to provocative tests, such as the insulin tolerance test (ITT) and the GH-releasing hormone-arginine (GHRH-ARG) test. However, the cut-off limits of peak GH response in lean subjects are not reliable in obese patients; this is noteworthy since adult GHD is often associated with obesity. Aim of this study was to evaluate the diagnostic cut-off limits of peak GH response to the GHRH-ARG test in overweight and obese as well as in lean population. Design and methods: The GH responses to the GHRH-ARG test were studied in 322 patients with organic hypothalamic-pituitary disease and in 318 control subjects. Patients were subdivided into two groups on the basis of the number of pituitary hormone deficits, except for GH deficiency: (a) patients with total pituitary hormone deficit (TPHD) and (b) patients without or with no more than two pituitary hormone deficits (PHD). Both patients and control subjects were divided into three subgroups according to body mass index (BMI): lean (BMI < 25kg/m(2)), overweight (BMI >= 25 and < 30kg/m(2)) and obese (BMI >= 30 kg/m(2)). TPHD patients were assumed to be GH deficient, whereas PHD patients may include subjects with either normal or impaired GH secretion. The statistical analysis was carried out by the Receiver-Operating Characteristic curve analysis (Medcale 7.2). The diagnostic cut-off points were calculated for lean, overweight and obese subjects to provide optimal separation of GH-deficient patients and control subjects according to two criteria: (1) a balance between high sensitivity and high specificity; (2) to provide the highest pair of sensitivity/specificity values for GH deficiency. Results: In the lean population the best pair of values, with highest sensitivity as 98.7% and highest specificity as 83.7%, was found using a peak GH cut-off point of 11.5 mu g/l. In the overweight population the best pair of values, 96.7 and 75.5%, respectively, was found using a peak GH cut-off point of 8.0 mu g/l. In the obese population the best pair of values, 93.5 and 78.3%, respectively, was found using a peak GH cut-off point of 4.2 mu g/l. Applying the above mentioned cut-off points, among PHD patients we found that 80 subjects (72%) were GHD whereas 31 (28%) had normal GH secretion. Conclusions: In conclusion the GHRH-ARG test is a reliable tool for the diagnosis of adult GH deficiency in lean, overweight and obese patients, provided that specific BMI-related cut-off limits are assumed.	Univ Turin, Dept Internal Med, Div Endocrinol & Metab Dis, I-10126 Turin, Italy; Univ Naples Federico II, Div Endocrinol, Naples, Italy	Aimaretti, G (corresponding author), Univ Turin, Dept Internal Med, Div Endocrinol & Metab Dis, Corso Dogliotti 14, I-10126 Turin, Italy.	gianluca.aimaretti@unito.it	Di Somma, Carolina/K-7772-2016	Di Somma, Carolina/0000-0002-5724-1951			Abs R, 2003, EUR J ENDOCRINOL, V148, pS3, DOI 10.1530/eje.0.148S003; Aimaretti G, 2005, J ENDOCRINOL INVEST, V28, P247, DOI 10.1007/BF03345381; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Aimaretti G, 2001, Pituitary, V4, P129, DOI 10.1023/A:1015306705154; Aimaretti G, 1998, J CLIN ENDOCR METAB, V83, P1615, DOI 10.1210/jc.83.5.1615; Aimaretti G, 2003, CLIN ENDOCRINOL, V59, P56, DOI 10.1046/j.1365-2265.2003.01794.x; Aimaretti G, 2000, EUR J ENDOCRINOL, V142, P347, DOI 10.1530/eje.0.1420347; Attanasio A, 1998, J CLIN ENDOCR METAB, V83, P379; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Bidlingmaier M, 2000, BEST PRACT RES CL EN, V14, P99, DOI 10.1053/beem.2000.0057; Biller BMK, 2002, J CLIN ENDOCR METAB, V87, P2067, DOI 10.1210/jcem.87.5.8509; BINNERTS A, 1992, CLIN ENDOCRINOL, V37, P79, DOI 10.1111/j.1365-2265.1992.tb02287.x; Bonert VS, 2004, J CLIN ENDOCR METAB, V89, P3397, DOI 10.1210/jc.2003-032213; Carroll PV, 2000, TRENDS ENDOCRIN MET, V11, P231, DOI 10.1016/S1043-2760(00)00268-X; Clasey JL, 2001, J CLIN ENDOCR METAB, V86, P3845, DOI 10.1210/jc.86.8.3845; CLEMMONS DR, 1984, CLIN ENDOCRINOL META, V13, P113, DOI 10.1016/S0300-595X(84)80011-0; Cook D M, 2000, Adv Intern Med, V45, P297; COPELAND KC, 1990, METABOLISM, V39, P584, DOI 10.1016/0026-0495(90)90022-5; Cordido F, 2003, EUR J ENDOCRINOL, V149, P117, DOI 10.1530/eje.0.1490117; CORDIDO F, 1991, HORM RES, V36, P187, DOI 10.1159/000182158; Cordido F, 1998, J CLIN ENDOCR METAB, V83, P4350, DOI 10.1210/jc.83.12.4350; CUNEO RC, 1992, CLIN ENDOCRINOL, V37, P387, DOI 10.1111/j.1365-2265.1992.tb02347.x; De Marinis L, 2004, J CLIN ENDOCR METAB, V89, P174, DOI 10.1210/jc.2002-021308; DEBOER H, 1995, ENDOCR REV, V16, P63, DOI 10.1210/er.16.1.63; Gharib Hossein, 2003, Endocr Pract, V9, P64; Ghigo E, 1996, EUR J ENDOCRINOL, V134, P352, DOI 10.1530/eje.0.1340352; Ghigo E, 2001, ENDOCRINE, V15, P29, DOI 10.1385/ENDO:15:1:029; GHIGO E, 1992, METABOLISM, V41, P560, DOI 10.1016/0026-0495(92)90220-5; Hartman ML, 2002, J CLIN ENDOCR METAB, V87, P477, DOI 10.1210/jc.87.2.477; HOECK HC, 1995, EUR J ENDOCRINOL, V133, P305, DOI 10.1530/eje.0.1330305; HOFFMAN DM, 1994, LANCET, V343, P1064, DOI 10.1016/S0140-6736(94)90181-3; IRANMANESH A, 1991, J CLIN ENDOCR METAB, V73, P1081, DOI 10.1210/jcem-73-5-1081; Johannsson G., 1999, Journal of Endocrinological Investigation, V22, P41; JONES SL, 1994, CLIN ENDOCRINOL, V41, P123, DOI 10.1111/j.1365-2265.1994.tb03793.x; JORGENSEN JOL, 1989, LANCET, V1, P1221; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; KOPELMAN PG, 1985, CLIN ENDOCRINOL, V23, P87, DOI 10.1111/j.1365-2265.1985.tb00187.x; Korbonits M, 2004, EUR J ENDOCRINOL, V151, pS67, DOI 10.1530/eje.0.151S067; Lanzi R, 1999, METABOLISM, V48, P1152, DOI 10.1016/S0026-0495(99)90130-0; Maccario M, 1999, J ENDOCRINOL INVEST, V22, P424, DOI 10.1007/BF03343585; Maccario M, 1997, INT J OBESITY, V21, P27, DOI 10.1038/sj.ijo.0800356; Marzullo P, 2001, J CLIN ENDOCR METAB, V86, P3001, DOI 10.1210/jc.86.7.3001; Popovic V, 2000, LANCET, V356, P1137, DOI 10.1016/S0140-6736(00)02755-0; REUTENS AT, 1995, J CLIN ENDOCR METAB, V80, P480, DOI 10.1210/jc.80.2.480; ROSEN T, 1990, LANCET, V336, P285, DOI 10.1016/0140-6736(90)91812-O; SALOMON F, 1989, NEW ENGL J MED, V321, P1797, DOI 10.1056/NEJM198912283212605; Scacchi M, 1999, INT J OBESITY, V23, P260, DOI 10.1038/sj.ijo.0800807; Shakoor SKA, 2003, J ENDOCRINOL INVEST, V26, P911, DOI 10.1007/BF03345243; Shalet SM, 1998, ENDOCR REV, V19, P203, DOI 10.1210/er.19.2.203; THORNER MO, 1995, J CLIN ENDOCR METAB, V80, P3097, DOI 10.1210/jc.80.10.3097; TOOGOOD AA, 1994, CLIN ENDOCRINOL, V41, P511, DOI 10.1111/j.1365-2265.1994.tb02583.x; VELDHUIS JD, 1991, J CLIN ENDOCR METAB, V72, P51, DOI 10.1210/jcem-72-1-51; ZWEIG MH, 1993, CLIN CHEM, V39, P561	53	238	239	1	2	BIOSCIENTIFICA LTD	BRISTOL	EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLAND	0804-4643	1479-683X		EUR J ENDOCRINOL	Eur. J. Endocrinol.	AUG	2005	153	2					257	264		10.1530/eje.1.01967			8	Endocrinology & Metabolism	Endocrinology & Metabolism	961YS	WOS:000231698400011	16061832	Bronze			2021-06-18	
J	McCrea, M; Barr, WB; Guskiewicz, K; Randolph, C; Marshall, SW; Cantu, R; Onate, JA; Kelly, JP				McCrea, M; Barr, WB; Guskiewicz, K; Randolph, C; Marshall, SW; Cantu, R; Onate, JA; Kelly, JP			Standard regression-based methods for measuring recovery after sport-related concussion	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						brain injury; brain concussion; athletic injuries	NEUROPSYCHOLOGICAL TEST-PERFORMANCE; TRAUMATIC BRAIN-INJURY; COLLEGIATE FOOTBALL PLAYERS; CONTACT SPORTS; GUIDELINES; DEFICITS; RETURN	Clinical decision making about an athlete's return to competition after concussion is hampered by a lack of systematic methods to measure recovery. We applied standard regression-based methods to statistically measure individual rates of impairment at several time points after concussion in college football players. Postconcussive symptoms, cognitive functioning, and balance were assessed in 94 players with concussion (based on American Academy of Neurology Criteria) and 56 noninjured controls during preseason baseline testing, and immediately, 3 hr, and 1, 2, 3, 5, and 7 days postinjury. Ninety-five percent of injured players exhibited acute concussion symptoms and impairment on cognitive or balance testing immediately after injury, which diminished to 4% who reported elevated symptoms on postinjury day 7. In addition, a small but clinically significant percentage of players who reported being symptom free by day 2 continued to be classified as impaired on the basis of objective balance and cognitive testing. These data suggest that neuropsychological testing may be of incremental utility to subjective symptom checklists in identifying the residual effects of sport-related concussion. The implementation of neuropsychological testing to detect subtle cognitive impairment is most useful once postconcussive symptoms have resolved. This management model is also supported by practical and other methodological considerations.	Waukesha Mem Hosp, Ctr Neurosci, Waukesha, WI 53188 USA; Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; NYU, Sch Med, Dept Neurol, New York, NY USA; NYU, Sch Med, Dept Psychiat, New York, NY USA; Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC USA; Univ N Carolina, Dept Orthoped, Chapel Hill, NC USA; Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC USA; Loyola Univ, Sch Med, Dept Neurol, Maywood, IL 60153 USA; Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA; Boston Univ, Sargent Coll Hlth & Rehabil Sci, Dept Rehabil Sci, Athlet Training Program, Boston, MA 02215 USA; Univ Colorado, Hlth Sci Ctr, Dept Neurosurg, Denver, CO 80202 USA	McCrea, M (corresponding author), Waukesha Mem Hosp, Ctr Neurosci, 721 Amer Ave,Suite 501, Waukesha, WI 53188 USA.	michael.mccrea@phci.org	Onate, James/E-3790-2011	Guskiewicz, Kevin/0000-0002-8682-2130; Barr, William/0000-0001-7711-7758; Marshall, Stephen/0000-0002-2664-9233			Aubry Mark, 2002, Phys Sportsmed, V30, P57, DOI 10.3810/psm.2002.02.176; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Barr William B, 2002, CNS Spectr, V7, P300; Barres PE, 2003, THINK REASONING, V9, P1, DOI 10.1080/13546780244000097; Benton AL, 1983, MULTILINGUAL APHASIA; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; *COL MED SOC, 1991, REP SPORTS MED COMM; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; DICK R, 2003, NATL COLL ATHLETIC A; Diggle PJ, 1994, ANAL LONGITUDINAL DA; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Golden J. C., 1978, STROOP COLOR WORD TE; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Halstead WC, 1985, HALSTEAD REITAN NEUR; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; Kelly JP, 1999, JAMA-J AM MED ASSOC, V282, P989, DOI 10.1001/jama.282.10.989; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrea M., 2000, STANDARDIZED ASSESSM; MCSWEENY AJ, 1993, CLIN NEUROPSYCHOL, V7, P460; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Rubin DB, 1996, J AM STAT ASSOC, V91, P473, DOI 10.1080/01621459.1996.10476908; RUBIN DB, 1976, BIOMETRIKA, V63, P581, DOI 10.2307/2335739; Schafer JL., 1997, ANAL INCOMPLETE MULT; Shapiro AM, 1999, CLIN NEUROPSYCHOL, V13, P348, DOI 10.1076/clin.13.3.348.1749; Smith A., 1991, SYMBOL DIGIT MODALIT; *SPSS, 1999, SPSS ADV MOD 10 0; Temkin NR, 1999, J INT NEUROPSYCH SOC, V5, P357, DOI 10.1017/S1355617799544068; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Vastag B, 2002, JAMA-J AM MED ASSOC, V287, P437, DOI 10.1001/jama.287.4.437	50	238	239	0	21	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	2005	11	1					58	69		10.1017/S1355617705050083			12	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	906CA	WOS:000227616900007	15686609				2021-06-18	
J	Popovich, PG; Guan, Z; McGaughy, V; Fisher, L; Hickey, WF; Basso, DM				Popovich, PG; Guan, Z; McGaughy, V; Fisher, L; Hickey, WF; Basso, DM			The neuropathological and behavioral consequences of intraspinal microglial/macrophage activation	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						axonal injury; demyelination; functional recovery; funiculotomy; neuroinflammation; spinal cord injury	SPINAL-CORD INJURY; CENTRAL-NERVOUS-SYSTEM; MARROW-DERIVED ELEMENTS; NECROSIS-FACTOR-ALPHA; KAPPA-B ACTIVATION; GROWTH-FACTOR-BETA; INFLAMMATORY RESPONSE; DORSOLATERAL FUNICULI; MYELIN PHAGOCYTOSIS; MICROGLIAL CELLS	Activated microglia and macrophages (CNS macrophages) have been implicated in the secondary or "bystander" pathology (e.g. axon injury, demyelination) that accompanies traumatic or autoimmune injury to the brain and spinal cord. These cells also can provide neurotrophic support and promote axonal regeneration, Studying the divergent functional potential of CNS macrophages in trauma models is especially difficult due to the various degradative mechanisms that are initiated prior to or concomitant with microglial/macrophage activation (e.g. hemorrhage, edema, excitotoxicity, lipid peroxidation). To study the potential impact of activated CNS macrophages on the spinal cord parenchyma. we have characterized an in vivo model of non-traumatic spinal cord neuroinflammation. Specifically, focal activation of CNS macrophages 4 as achieved using stereotaxic microinjections of zymosan. Although microinjection does not cause direct mechanical trauma. localized activation of macrophages with zymosan acts as an "inflammatory scalpel" causing tissue injury at and nearby the injection site. The present data reveal that activation of CNS macrophages in vivo can result in permanent axonal injury and demyelination. Moreover, the Pathology can be graded and localized to specific white matter tracts to produce quantifiable behavioral deficits. Further development of this model will help to clarify the biological potential of microglia and macrophages and the molecular signals that control their function within the spinal cord.	Ohio State Univ, Coll Med & Publ Hlth, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; Ohio State Univ, Coll Med & Publ Hlth, Div Phys Therapy, Columbus, OH 43210 USA; Sch Allied Med Profess, Columbus, OH USA; DHMC, Dartmouth Med Sch, Lebanon, NH USA	Popovich, PG (corresponding author), Ohio State Univ, Coll Med & Publ Hlth, Dept Mol Virol Immunol & Med Genet, 2078 Graves Hall,333 W 10th Ave, Columbus, OH 43210 USA.		Basso, Michele/B-3817-2011; Popovich, Phillip/C-9187-2009	Popovich, Phillip/0000-0003-1329-7395	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS37846] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037846] Funding Source: NIH RePORTER		Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; ANDERSSON PB, 1992, NEUROSCIENCE, V48, P169, DOI 10.1016/0306-4522(92)90347-5; Bartholdi D, 1997, EUR J NEUROSCI, V9, P1422, DOI 10.1111/j.1460-9568.1997.tb01497.x; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Bell MD, 1996, NEUROSCIENCE, V74, P283, DOI 10.1016/0306-4522(96)00083-8; Bethea JR, 1998, J NEUROSCI, V18, P3251; BLAKEMORE WF, 1982, NEUROPATH APPL NEURO, V8, P365, DOI 10.1111/j.1365-2990.1982.tb00305.x; BLIGHT AR, 1994, NEUROSCIENCE, V60, P263, DOI 10.1016/0306-4522(94)90220-8; Brown GD, 2001, NATURE, V413, P36, DOI 10.1038/35092620; BRUCK W, 1990, ACTA NEUROPATHOL, V80, P415; Brustein E, 1998, J NEUROPHYSIOL, V80, P1245; DAVID S, 1990, NEURON, V5, P463, DOI 10.1016/0896-6273(90)90085-T; Dougherty KD, 2000, NEUROBIOL DIS, V7, P574, DOI 10.1006/nbdi.2000.0318; Fitch MT, 1999, J NEUROSCI, V19, P8182; Fitch MT, 1997, EXP NEUROL, V148, P587, DOI 10.1006/exnr.1997.6701; GIULIAN D, 1993, J NEUROSCI, V13, P29; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; GORSKA T, 1993, BRAIN RES BULL, V32, P241, DOI 10.1016/0361-9230(93)90183-C; GOTTSCHALL PE, 1995, J NEUROSCI RES, V42, P335, DOI 10.1002/jnr.490420307; Hall SM, 2000, J NEUROIMMUNOL, V106, P130, DOI 10.1016/S0165-5728(00)00213-7; Hartlage-Rubsamen M, 1999, J NEUROSCI RES, V57, P388, DOI 10.1002/(SICI)1097-4547(19990801)57:3<388::AID-JNR11>3.0.CO;2-2; Heese K, 1998, J NEUROCHEM, V70, P699; HICKEY WF, 1992, J NEUROPATH EXP NEUR, V51, P246, DOI 10.1097/00005072-199205000-00002; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Jeffery ND, 1997, BRAIN, V120, P27, DOI 10.1093/brain/120.1.27; Jiang W, 1996, J NEUROPHYSIOL, V76, P849; Kopp EB, 1999, CURR OPIN IMMUNOL, V11, P13, DOI 10.1016/S0952-7915(99)80003-X; Laflamme N, 2001, J NEUROCHEM, V79, P648, DOI 10.1046/j.1471-4159.2001.00603.x; LASSMANN H, 1993, GLIA, V7, P19, DOI 10.1002/glia.440070106; LAWSON LJ, 1990, NEUROSCIENCE, V39, P151, DOI 10.1016/0306-4522(90)90229-W; Leon S, 2000, J NEUROSCI, V20, P4615, DOI 10.1523/JNEUROSCI.20-12-04615.2000; Magnuson DSK, 1999, EXP NEUROL, V156, P191, DOI 10.1006/exnr.1999.7016; McDonald JW, 1998, NAT MED, V4, P291, DOI 10.1038/nm0398-291; McMillian MK, 1997, J NEUROPATH EXP NEUR, V56, P301, DOI 10.1097/00005072-199703000-00009; Newman TA, 2001, BRAIN, V124, P2203, DOI 10.1093/brain/124.11.2203; Phillips LM, 1999, J COMP NEUROL, V405, P322, DOI 10.1002/(SICI)1096-9861(19990315)405:3<322::AID-CNE3>3.0.CO;2-S; Pitt D, 2000, NAT MED, V6, P67, DOI 10.1038/71555; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Popovich PG, 2001, J NEUROPATH EXP NEUR, V60, P676, DOI 10.1093/jnen/60.7.676; Popovich PG, 2000, PROG BRAIN RES, V128, P43; Rabchevsky AG, 1997, J NEUROSCI RES, V47, P34; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; Reichert F, 2001, NEUROBIOL DIS, V8, P504, DOI 10.1006/nbdi.2001.0383; ROSS GD, 1993, CLIN EXP IMMUNOL, V92, P181; Schnell L, 1999, EUR J NEUROSCI, V11, P3648, DOI 10.1046/j.1460-9568.1999.00792.x; Schnell L, 1999, J NEUROPATH EXP NEUR, V58, P245, DOI 10.1097/00005072-199903000-00004; SCHRIMSHER GW, 1993, EXP NEUROL, V120, P264, DOI 10.1006/exnr.1993.1060; Schwartz M, 1999, J MOL MED, V77, P713, DOI 10.1007/s001099900047; SIMMONS RD, 1990, J NEUROL SCI, V100, P37, DOI 10.1016/0022-510X(90)90010-K; Smith GM, 1997, J NEUROSCI, V17, P9624; Stern EL, 2000, J NEUROIMMUNOL, V106, P114, DOI 10.1016/S0165-5728(00)00194-6; Streilein JW, 2000, J LEUKOCYTE BIOL, V67, P479; Streit WJ, 1998, EXP NEUROL, V152, P74, DOI 10.1006/exnr.1998.6835; TVETEN L, 1976, ACTA RADIOL DIAGN, V17, P653, DOI 10.1177/028418517601705B01; WILBANKS GA, 1992, EUR J IMMUNOL, V22, P165, DOI 10.1002/eji.1830220125; Xu J, 1998, MOL BRAIN RES, V59, P135, DOI 10.1016/S0169-328X(98)00142-9; Young SH, 2001, J BIOL CHEM, V276, P20781, DOI 10.1074/jbc.M101111200	58	238	245	0	13	AMER ASSN NEUROPATHOLOGISTS INC	LAWRENCE	1041 NEW HAMPSHIRE ST, LAWRENCE, KS 66044 USA	0022-3069			J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	JUL	2002	61	7					623	633		10.1093/jnen/61.7.623			11	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	569LV	WOS:000176604600006	12125741	Bronze			2021-06-18	
J	Kernie, SG; Erwin, TM; Parada, LF				Kernie, SG; Erwin, TM; Parada, LF			Brain remodeling due to neuronal and astrocytic proliferation after controlled cortical injury in mice	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						stem cell; regeneration; astrogliosis; traumatic brain injury; neurogenesis	CENTRAL-NERVOUS-SYSTEM; ADULT-RAT HIPPOCAMPUS; NEURAL STEM-CELL; SPINAL-CORD; REACTIVE ASTROCYTES; NEUROTROPHIC FACTOR; NEUROGENESIS; RECOVERY; CORTEX; CNS	The persistence of neural stem cells into adulthood has been an area of intense investigation in recent years. There is limited knowledge about how an acquired brain injury might affect the ability of neural precursor cells to proliferate and repopulate injured areas. In the present study we utilize a controlled cortical impact model of traumatic brain injury in adult mice and subsequent BrdU labeling to demonstrate that there is significant proliferation of neural precursors in response to traumatic brain injury in areas both proximal and distal to the injury site. The fate of the proximal proliferation is almost exclusively astrocytic at 60-days post injury and demonstrates that newly generated cells make up much of the astrogilotic scar. Moreover, in areas more distal from the injury site, neurogenesis occurs within the granular layer of the dentate gyrus at a level more than five-fold greater than in controls. These data demonstrate that neural proliferation plays key roles in the remodeling that occurs after traumatic brain injury and suggests a mechanism as to how functional recovery after traumatic brain injuries continues to occur long after the injury itself. (C) 2001 Wiley-Liss, Inc.	Univ Texas, SW Med Ctr, Ctr Basic Res Nerve Growth & Regenerat, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Kent Waldrep Fdn Ctr Basic Res Nerve Growth & Reg, Dept Pediat, Dallas, TX 75390 USA	Kernie, SG (corresponding author), Univ Texas, SW Med Ctr, Ctr Basic Res Nerve Growth & Regenerat, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.	Steven.Kernie@utsouthwestern.edu	Kernie, Steven/AAT-9912-2020; Parada, luis F/B-9400-2014	Kernie, Steven/0000-0003-1371-0549	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08 HD001470] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD001470] Funding Source: NIH RePORTER		Aberg MAI, 2000, J NEUROSCI, V20, P2896; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Chu CJ, 2000, EXP NEUROL, V166, P403, DOI 10.1006/exnr.2000.7509; Clark JH, 1999, GREEN CHEM, V1, P1, DOI 10.1039/a807961g; Conover JC, 2000, NAT NEUROSCI, V3, P1091, DOI 10.1038/80606; Csuka E, 2000, NEUROREPORT, V11, P2587, DOI 10.1097/00001756-200008030-00047; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; DELRIO JA, 1989, DEV BRAIN RES, V49, P311, DOI 10.1016/0165-3806(89)90033-3; Demeurisse G, 2000, ACTA NEUROL BELG, V100, P77; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Fineman I, 2000, J NEUROTRAUM, V17, P739, DOI 10.1089/neu.2000.17.739; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; GOLDSTEIN LB, 1993, J NEUROSCI METH, V48, P35, DOI 10.1016/S0165-0270(05)80005-6; Graham SH, 2000, J NEUROTRAUM, V17, P831, DOI 10.1089/neu.2000.17.831; Herx LM, 2000, J IMMUNOL, V165, P2232, DOI 10.4049/jimmunol.165.4.2232; Hinkle DA, 1997, J NEUROTRAUM, V14, P729, DOI 10.1089/neu.1997.14.729; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; Kempermann G, 1998, J NEUROSCI, V18, P3206; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kondo T, 2000, SCIENCE, V289, P1754, DOI 10.1126/science.289.5485.1754; Koshinaga M, 2000, J NEUROTRAUM, V17, P185, DOI 10.1089/neu.2000.17.185; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Levin HS, 1998, CURR OPIN NEUROL, V11, P643, DOI 10.1097/00019052-199812000-00006; Lim DA, 2000, NEURON, V28, P713, DOI 10.1016/S0896-6273(00)00148-3; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Magavi SS, 2000, NATURE, V405, P951; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; McTigue DM, 1998, J NEUROSCI, V18, P5354; McTigue DM, 2001, J NEUROSCI, V21, P3392, DOI 10.1523/JNEUROSCI.21-10-03392.2001; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Parent JM, 1997, J NEUROSCI, V17, P3727; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; Schnell L, 1999, EUR J NEUROSCI, V11, P3648, DOI 10.1046/j.1460-9568.1999.00792.x; Schnell L, 1999, J NEUROPATH EXP NEUR, V58, P245, DOI 10.1097/00005072-199903000-00004; Smith C, 2001, EUR J NEUROSCI, V13, P443, DOI 10.1046/j.1460-9568.2001.01400.x; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Sun Y, 2001, CELL, V104, P365, DOI 10.1016/S0092-8674(01)00224-0; Taupin P, 2000, NEURON, V28, P385, DOI 10.1016/S0896-6273(00)00119-7; TUNON T, 1992, BRAIN RES, V589, P24, DOI 10.1016/0006-8993(92)91157-A; Wei LH, 2001, INT J GYNECOL CANCER, V11, P81, DOI 10.1046/j.1525-1438.2001.011001081.x; Weidner N, 2001, P NATL ACAD SCI USA, V98, P3513, DOI 10.1073/pnas.051626798; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Wilson SW, 2000, NEURON, V28, P641, DOI 10.1016/S0896-6273(00)00171-9; Witte OW, 1998, CURR OPIN NEUROL, V11, P655, DOI 10.1097/00019052-199812000-00008; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857	55	238	252	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	NOV 1	2001	66	3					317	326		10.1002/jnr.10013			10	Neurosciences	Neurosciences & Neurology	488LH	WOS:000171936300002	11746349	Bronze			2021-06-18	
J	Buki, A; Okonkwo, DO; Wang, KKW; Povlishock, JT				Buki, A; Okonkwo, DO; Wang, KKW; Povlishock, JT			Cytochrome c release and caspase activation in traumatic axonal injury	JOURNAL OF NEUROSCIENCE			English	Article						traumatic axonal injury; spectrin; calpain; caspase; cyto-c; axolemma; calcium; mitochondrial membrane permeability transition	MITOCHONDRIAL PERMEABILITY TRANSITION; EXPERIMENTAL BRAIN INJURY; HEAD-INJURY; COGNITIVE DEFICITS; NEURONAL APOPTOSIS; CELL-DEATH; CALPAIN; SPECTRIN; DAMAGE; RATS	Axonal injury is a feature of traumatic brain injury (TBI) contributing to both morbidity and mortality. The traumatic axon injury (TAI) results from focal perturbations of the axolemma, allowing for calcium influx triggering local intraaxonal cytoskeletal and mitochondrial damage. This mitochondrial damage has been posited to cause local bioenergetic failure, leading to axonal failure and disconnection; however, this mitochondrial damage may also lead to the release of cytochrome c (cyto-c), which then activates caspases with significant adverse intraaxonal consequences. In the current communication, we examine this possibility. Rats were subjected to TBI, perfused with aldehydes at 15-360 min after injury, and processed for light microscopic (LM) and electron microscopic (EM) single-labeling immunohistochemistry to detect extramitochondrially localized cytochrome c (cyto-c) and the signature protein of caspase-3 activation (120 kDa breakdown product of alpha-spectrin) in TAI. Combinations of double-labeling fluorescent immunohistochemistry (D-FIHC) were also used to demonstrate colocalization of calpain activation with cyto-c release and caspase-3-induction. In foci of TAI qualitative-quantitative LM demonstrated a parallel, significant increase in cyto-c release and caspase-3 activation over time after injury. EM analysis demonstrated that cyto-c and caspase-3 immunoreactivity were associated with mitochondrial swelling-disruption in sites of TAI. Furthermore, D-IFHC revealed a colocalization of calpain activation, cyto-c release, and caspase-3 induction in these foci, which also revealed progressive TAI. The results demonstrate that cyto-c and caspase-3 participate in the terminal processes of TAI. This suggests that those factors that play a role in the apoptosis in the neuronal soma are also major contributors to the demise of the axonal appendage.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Richmond, VA 23298 USA; Med Sch Pecs, Dept Neurosurg, H-7623 Pecs, Hungary; Warner Lambert Parke Davis, Parke Davis Pharmaceut Res, Dept Neurosci Therapeut, Ann Arbor, MI 48105 USA	Povlishock, JT (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Richmond, VA 23298 USA.		Buki, Andras/B-1960-2010	Wang, Kevin/0000-0002-9343-6473	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020193] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 20193, R01 NS020193] Funding Source: Medline		ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ADAMS JH, 1982, INJURY, V13, P444, DOI 10.1016/0020-1383(82)90105-X; Bartus RT, 1999, EXP NEUROL, V155, P315, DOI 10.1006/exnr.1998.7001; Bartus RT, 1998, BRAIN RES, V790, P1, DOI 10.1016/S0006-8993(97)01414-5; Bartus RT, 1997, NEUROSCIENTIST, V3, P314, DOI 10.1177/107385849700300513; Buki A, 1999, EXP NEUROL, V159, P319, DOI 10.1006/exnr.1999.7139; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Buki A, 2000, J HISTOCHEM CYTOCHEM, V48, P153; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Cai JY, 1998, BBA-BIOENERGETICS, V1366, P139, DOI 10.1016/S0005-2728(98)00109-1; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Clark RSB, 1997, J NEUROSCI, V17, P9172; Conti AC, 1998, J NEUROSCI, V18, P5663; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Fujimura M, 1998, J CEREBR BLOOD F MET, V18, P1239, DOI 10.1097/00004647-199811000-00010; Fujimura M, 1999, J NEUROSCI, V19, P3414; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GOODMAN SR, 1995, BRAIN RES BULL, V36, P593, DOI 10.1016/0361-9230(94)00264-2; Gorman AM, 1999, EUR J NEUROSCI, V11, P1067, DOI 10.1046/j.1460-9568.1999.00512.x; Hirsch T, 1998, CELL BIOL TOXICOL, V14, P141, DOI 10.1023/A:1007486022411; Hunyady B, 1996, J HISTOCHEM CYTOCHEM, V44, P1353, DOI 10.1177/44.12.8985127; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Martinou I, 1999, J CELL BIOL, V144, P883, DOI 10.1083/jcb.144.5.883; Maxwell WL, 1997, J NEUROTRAUM, V14, P755; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Montal M, 1998, BBA-BIOENERGETICS, V1366, P113, DOI 10.1016/S0005-2728(98)00124-8; Morita-Fujimura Y, 1999, NEUROSCI LETT, V267, P201, DOI 10.1016/S0304-3940(99)00327-4; Nath R, 1998, J NEUROCHEM, V71, P186; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; PETRUSZ P, 1980, HISTOCHEM J, V12, P333, DOI 10.1007/BF01006954; PETRUSZ P, 1976, J HISTOCHEM CYTOCHEM, V24, P1110, DOI 10.1177/24.10.789759; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Pike BR, 1998, J NEUROSCI RES, V52, P505, DOI 10.1002/(SICI)1097-4547(19980601)52:5<505::AID-JNR3>3.3.CO;2-Y; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Povlishock JT, 1996, ACT NEUR S, V66, P81; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; RINK A, 1995, AM J PATHOL, V147, P1575; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Saikumar P, 1998, ONCOGENE, V17, P3341, DOI 10.1038/sj.onc.1202579; Schendel SL, 1998, CELL DEATH DIFFER, V5, P372, DOI 10.1038/sj.cdd.4400365; Siesjo BK, 1999, J CEREBR BLOOD F MET, V19, P19, DOI 10.1097/00004647-199901000-00002; SIMAN R, 1989, J NEUROSCI, V9, P1579; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Trost LC, 1996, J PHARMACOL EXP THER, V278, P1000; Uehara T, 1999, J NEUROCHEM, V72, P196, DOI 10.1046/j.1471-4159.1999.0720196.x; vanGijlswijk RPM, 1997, J HISTOCHEM CYTOCHEM, V45, P375, DOI 10.1177/002215549704500305; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wang KKW, 1998, ARCH BIOCHEM BIOPHYS, V356, P187, DOI 10.1006/abbi.1998.0748; Wood DE, 1999, J BIOL CHEM, V274, P8309, DOI 10.1074/jbc.274.12.8309; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; ZAGON IS, 1986, J NEUROSCI, V6, P2977; Zhao X, 1999, NEUROCHEM RES, V24, P371, DOI 10.1023/A:1020933616351; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	75	238	243	1	12	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	APR 15	2000	20	8					2825	2834					10	Neurosciences	Neurosciences & Neurology	303FR	WOS:000086412100012	10751434				2021-06-18	
J	Reece, RM; Sege, R				Reece, RM; Sege, R			Childhood head injuries - Accidental or inflicted?	ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE			English	Article							WALKER-RELATED INJURIES; SHAKEN-BABY-SYNDROME; PERMANENT BRAIN-DAMAGE; NO IMPACT INJURIES; MENTAL-RETARDATION; CONTINUING PROBLEM; YOUNG-CHILDREN; INFANT WALKER; FALLS; SHAKING	Objectives: To determine the relative incidence of accidental and abusive causes of head injuries in children younger than 6.5 years, to identify the types of craniocerebral damage resulting from reported mechanisms of injury, and to assess the likelihood of injuries being accidental or inflicted. Methods: Retrospective review of medical records of 287 children with head injuries aged 1 week to 6.5 years admitted to a metropolitan children's hospital from January 1986 through December 1991. Those patients with diagnoses of skull fracture; concussion; subarachnoid hemorrhage (SAH); subgaleal, epidural, or subdural hematoma (SDH); parenchymal contusion or laceration; and closed head injury were included. Criteria were used for inclusion in categories of definite abuse or accident. Results: Accidents accounted for 81% of cases and definite abuse for 19%. The mean age of the accident group was 2.5 years and for the definite abuse group, 0.7 years. Major differences were seen in the incidence of the following: SDH, 10% in the the accident group and 46% in the the definite abuse group; SAH, 8% in accident group and 31% in the definite abuse abuse; and retinal hemorrhages, 2% in the accident group and 33% in the definite abuse group. Associated cutaneous injuries consistent with inflicted injury were seen in 16% of the accident group and 50% of the definite abuse group. Twenty-three percent of those in the accident group were injured in motor vehicle crashes (MVCs), 58% by falls, 2% in play activities, and the rest had insufficient medical record information. In 56% of those in the definite abuse group, there was no history to account for the injuries and no history of MVC. In 17%, a fall was said to have been the mechanism of injury. In 24%, inflicted injury was admitted. Mortality rates were 13% in the definite abuse group and 2% in the accident group. Median hospital stay was 9.5 days for the definite abuse group and 3 days for the accident group. In falls less than 4 feet in the accident group, 8% had SDH, 2% had SAH, and none had retinal hemorrhages; among those in the definite abuse group reportedly falling less than 4 feet, 38% had SDH, 38% had SAH, and 25% had retinal hemorrhages. Conclusions: A substantial percentage of head injuries requiring hospitalization in children younger than 6.5 years are attributable to inflicted injury. Subdural hematoma, subarachnoid hemorrhage, retinal hemorrhages, and associated cutaneous, skeletal, and visceral injuries are significantly more common in inflicted head injury than in accidental injury.	Tufts Univ, Floating Hosp Children, New England Med Ctr, Sch Med,Dept Pediat,Pediat & Adolescent Hlth Res, Boston, MA 02111 USA	Reece, RM (corresponding author), Tufts Univ, Floating Hosp Children, New England Med Ctr, Sch Med,Dept Pediat,Pediat & Adolescent Hlth Res, Box 351,750 Harrison Ave, Boston, MA 02111 USA.			Sege, Robert/0000-0003-1260-4787			ALEXANDER R, 1990, AM J DIS CHILD, V144, P724, DOI 10.1001/archpedi.1990.02150300124032; ALEXANDER R, 1990, AM J DIS CHILD, V144, P58, DOI 10.1001/archpedi.1990.02150250068033; Annegers J. F., 1983, PEDIATRIC HEAD TRAUM, P1; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; BARLOW B, 1983, J PEDIATR SURG, V18, P509, DOI 10.1016/S0022-3468(83)80210-3; BILLMIRE ME, 1985, PEDIATRICS, V75, P340; BRUCE DA, 1989, PEDIATR ANN, V18, P482, DOI 10.3928/0090-4481-19890801-07; CAFFEY J, 1974, PEDIATRICS, V54, P396; CAFFEY J, 1946, AM J ROENTGENOL, V56, P163; CAFFEY J, 1972, AM J DIS CHILD, V124, P161, DOI 10.1001/archpedi.1972.02110140011001; CHADWICK DL, 1991, J TRAUMA, V31, P1353, DOI 10.1097/00005373-199110000-00006; CHIAVIELLO CT, 1994, PEDIATRICS, V93, P974; COATS TJ, 1991, ARCH EMERG MED, V8, P52; DiScala C, 2000, ARCH PEDIAT ADOL MED, V154, P16; DUHAIME AC, 1992, PEDIATRICS, V90, P179; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; DUHAIME AC, 1997, PRACTICE NEUROSURGER; DUHAIME AC, 1977, PRACTICAL GUIDE EVAL, P147; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; FAZEN LE, 1982, PEDIATRICS, V70, P106; GENNARELLI TA, 1985, NEUROSURGERY, P1531; Gilliland MGF, 1996, J FORENSIC SCI, V41, P114; GUTHKELCH AN, 1971, BMJ-BRIT MED J, V2, P430, DOI 10.1136/bmj.2.5759.430; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; HANIGAN WC, 1987, PEDIATRICS, V80, P618; HOLFER RE, 1977, PEDIATRICS, V60, P533; KAVANAGH CA, 1982, AM J DIS CHILD, V136, P205, DOI 10.1001/archpedi.1982.03970390019005; KEMPE CH, 1962, JAMA-J AM MED ASSOC, V181, P105; Kleinman PK, 1998, DIAGNOSTIC IMAGING C, P285; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; KRAVITZ H, 1969, PEDIATRICS, V44, P869; Levitt CJ, 1994, CHILD ABUSE MED DIAG, P1; LUDWIG S, 1984, ANN EMERG MED, V13, P104, DOI 10.1016/S0196-0644(84)80571-5; LYONS TJ, 1993, PEDIATRICS, V92, P125; MERTEN DF, 1983, PEDIATR ANN, V12, P882, DOI 10.3928/0090-4481-19831201-06; MUSEMECHE CA, 1991, J TRAUMA, V31, P1347, DOI 10.1097/00005373-199110000-00004; *NATL CTR HLTH STA, 1987, MONTHL VIT STAT R S2, V5; NIMITYONGSKUL P, 1987, J PEDIATR ORTHOPED, V7, P184, DOI 10.1097/01241398-198703000-00014; PARTINGTON MD, 1991, ANN EMERG MED, V20, P652, DOI 10.1016/S0196-0644(05)82386-8; REIDER MJ, 1986, PEDIATRICS, V78, P488; RIVARA FP, 1993, PEDIATRICS, V92, P61; SMITH MD, 1975, J TRAUMA, V15, P987, DOI 10.1097/00005373-197511000-00008; STOFFMAN JM, 1984, CAN MED ASSOC J, V131, P573; Taff ML, 1996, J FORENSIC SCI, V41, P729; *US CONS PROD SAF, 1992, BAB WALK; WELLMAN S, 1984, CLIN PEDIATR, V23, P98, DOI 10.1177/000992288402300206; WILLIAMS RA, 1991, J TRAUMA, V31, P1350, DOI 10.1097/00005373-199110000-00005	48	238	241	0	18	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	1072-4710			ARCH PEDIAT ADOL MED	Arch. Pediatr. Adolesc. Med.	JAN	2000	154	1					11	15					5	Pediatrics	Pediatrics	271KC	WOS:000084591900002	10632244				2021-06-18	
J	Azbill, RD; Mu, XJ; BruceKeller, AJ; Mattson, MP; Springer, JE				Azbill, RD; Mu, XJ; BruceKeller, AJ; Mattson, MP; Springer, JE			Impaired mitochondrial function, oxidative stress and altered antioxidant enzyme activities following traumatic spinal cord injury	BRAIN RESEARCH			English	Article						reactive oxygen species; mitochondrial metabolic activity; lipid peroxidation; excitotoxicity; neuron degeneration; superoxide dismutase; catalase; glutathione peroxidase	CENTRAL-NERVOUS-SYSTEM; CUZN SUPEROXIDE-DISMUTASE; OXYGEN-FREE RADICALS; METHYL-D-ASPARTATE; LIPID-PEROXIDATION; NITRIC-OXIDE; GLUTAMATE RELEASE; TRANSGENIC MICE; BRAIN INJURY; CELL-DEATH	Glutamate-induced excitotoxicity involving the formation of reactive oxygen species (ROS) has been implicated in neuronal dysfunction and cell loss following ischemic and traumatic injury to the central nervous system (CNS). ROS are formed in mitochondria when energy metabolism is compromised, and are inactivated by the ROS scavengers superoxide dismutase (SOD), catalase, and glutathione (GSH). ROS can impair the function of several cellular components including proteins, nucleic acids, and lipids. In the present study, we measured indicators of mitochondrial metabolic activity, ROS formation, Lipid peroxidation, and antioxidant enzyme activities in synaptosomes obtained from rat spinal cord at early times following traumatic injury. Mitochondrial metabolic activity was found to significantly decrease as early as 1 h following injury, and continued to be compromised over the remaining postinjury time points. ROS formation was found to be significantly increased at 4 and 24 h following injury, while lipid peroxidation levels were found to be significantly increased in the injured spinal cord at 1 and 24 h, but not 4 h following injury. SOD enzyme activity was unchanged at all postinjury time points, while catalase activity and GSH levels were significantly increased at 24 h following injury. These findings indicate that impaired mitochondrial function, ROS, and lipid peroxidation occur soon after traumatic spinal cord injury, while the compensatory activation of molecules important for neutralizing ROS occurs at later time points. Therapeutic strategies aimed at facilitating the actions of antioxidant enzymes or inhibiting ROS formation and lipid peroxidation in the CNS may prove beneficial in treating traumatic spinal cord injury, provided such treatments are initiated at early stages following injury. (C) 1997 Elsevier Science B.V.	UNIV KENTUCKY,MED CTR,DEPT ANAT & NEUROBIOL,LEXINGTON,KY 40536; UNIV KENTUCKY,MED CTR,SANDERS BROWN CTR AGING,LEXINGTON,KY 40536			Bruce-Keller, Annadora/N-1954-2017; Mattson, Mark P/F-6038-2012	Azbill, David/0000-0001-7989-1771	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS29001, NS-30583, NS-30248] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS030248, R01NS030583, R01NS029001] Funding Source: NIH RePORTER		ANDERSON DK, 1993, ANN EMERG MED, V22, P987, DOI 10.1016/S0196-0644(05)82739-8; BARUT S, 1993, NEUROSURG REV, V16, P53, DOI 10.1007/BF00308614; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; BEAL MF, 1995, ANN NEUROL, V38, P357, DOI 10.1002/ana.410380304; BECKMAN JS, 1993, BIOCHEM SOC T, V21, P330, DOI 10.1042/bst0210330; BONDY SC, 1993, FREE RADICAL BIO MED, V14, P633, DOI 10.1016/0891-5849(93)90144-J; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BRAUGHLER JM, 1992, J NEUROTRAUM, V9, pS1; BRAUGHLER JM, 1987, J NEUROSURG, V67, P102, DOI 10.3171/jns.1987.67.1.0102; Bullock R, 1992, Acta Neurochir Suppl (Wien), V55, P49; Carrillo MC, 1996, LIFE SCI, V59, P1047, DOI 10.1016/0024-3205(96)00420-1; CHAN PH, 1994, ANN NY ACAD SCI, V738, P93; CHAN PH, 1992, J NEUROTRAUM, V9, pS417; CHOI DW, 1987, J NEUROSCI, V7, P369; CONSTANTINI S, 1994, J NEUROSURG, V80, P97, DOI 10.3171/jns.1994.80.1.0097; Cook JA, 1996, NEUROCHEM INT, V28, P609, DOI 10.1016/0197-0186(95)00125-5; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; DUGAN LL, 1995, J NEUROSCI, V15, P6377; DYKENS JA, 1994, J NEUROCHEM, V63, P584; EADY JJ, 1995, BRIT J CANCER, V72, P1089, DOI 10.1038/bjc.1995.470; EVANS PH, 1993, BRIT MED BULL, V49, P577, DOI 10.1093/oxfordjournals.bmb.a072632; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; FLOYD RA, 1992, ANN NEUROL, V32, pS22, DOI 10.1002/ana.410320706; FRIGUET B, 1994, J BIOL CHEM, V269, P21639; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Goodman YD, 1996, J NEUROCHEM, V66, P1836; GRUNER JA, 1992, J NEUROTRAUM, V9, P123, DOI 10.1089/neu.1992.9.123; GUNASEKAR PG, 1995, J NEUROCHEM, V65, P2016; HALL ED, 1993, CELL MOL NEUROBIOL, V13, P415, DOI 10.1007/BF00711581; HALL ED, 1993, ANN EMERG MED, V22, P1022, DOI 10.1016/S0196-0644(05)82745-3; HALL ED, 1989, CRIT CARE CLIN, V5, P793; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; Halliwell Barry, 1993, American Journal of Clinical Nutrition, V57, p715S, DOI 10.1093/ajcn/57.5.715S; HAWTIN SR, 1995, BIOCHEM SOC T, V23, pS56, DOI 10.1042/bst023056s; HAYES RL, 1992, J NEUROTRAUMA S1, V9, P173; HENDERSON L, 1993, EUR J BIOCHEM, V217, P273; HEXUM TD, 1979, NEUROCHEM RES, V4, P73, DOI 10.1007/BF00963833; HOLTZ A, 1992, Neurological Research, V14, P49; IKEDA Y, 1989, Neurological Research, V11, P213; JACOBSEN EJ, 1990, J MED CHEM, V33, P1145, DOI 10.1021/jm00166a010; Jamme I, 1995, NEUROREPORT, V7, P333; KATAYAMA Y, 1991, BRAIN RES, V558, P136, DOI 10.1016/0006-8993(91)90730-J; KELLER J, IN PRESS NEUROSCIENC; KINOUCHI H, 1991, P NATL ACAD SCI USA, V88, P11158, DOI 10.1073/pnas.88.24.11158; KOOY NW, 1994, FREE RADICAL BIO MED, V16, P149, DOI 10.1016/0891-5849(94)90138-4; KOSTYUK VA, 1989, BIOCHEM INT, V19, P1117; LAFONCAZAL M, 1993, NATURE, V364, P535, DOI 10.1038/364535a0; MARK B, IN PRESS J NEUROSCI; Mark RJ, 1997, J NEUROCHEM, V68, P255; MATTSON MP, 1995, J NEUROCHEM, V65, P1740; Mayer B, 1996, NEUROSCI LETT, V209, P169, DOI 10.1016/0304-3940(96)12639-2; McCall J M, 1987, Acta Anaesthesiol Belg, V38, P417; McCall J M, 1987, Acta Anaesthesiol Belg, V38, P373; MOYNER H, 1990, NEURON, V5, P121; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; NOVELLI A, 1988, BRAIN RES, V451, P205, DOI 10.1016/0006-8993(88)90765-2; OLIVER CN, 1990, P NATL ACAD SCI USA, V87, P5144, DOI 10.1073/pnas.87.13.5144; PAGE B, 1993, INT J ONCOL, V3, P473; Patel M, 1996, NEURON, V16, P345, DOI 10.1016/S0896-6273(00)80052-5; PUTTFARCKEN PS, 1993, BRAIN RES, V624, P223, DOI 10.1016/0006-8993(93)90081-W; Schinder AF, 1996, J NEUROSCI, V16, P6125; SHAHAN TA, 1994, J IMMUNOL METHODS, V175, P181, DOI 10.1016/0022-1759(94)90361-1; SIESJPO B K, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P165; TAOKA Y, 1995, PARAPLEGIA, V33, P450, DOI 10.1038/sc.1995.98; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; TEPPERMAN BL, 1995, EUR J PHARM-ENVIRON, V293, P259, DOI 10.1016/S0922-4106(05)80052-5; VOLTERRA A, 1994, J NEUROSCI, V14, P2924; White RJ, 1996, J NEUROSCI, V16, P5688; YOUNG W, 1994, ANN NY ACAD SCI, V743, P241, DOI 10.1111/j.1749-6632.1994.tb55796.x; ZEEVALK GD, 1990, J PHARMACOL EXP THER, V253, P1285	72	238	246	1	15	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	AUG 15	1997	765	2					283	290		10.1016/S0006-8993(97)00573-8			8	Neurosciences	Neurosciences & Neurology	XV686	WOS:A1997XV68600012	9313901				2021-06-18	
J	Dutton, RP; Stansbury, LG; Leone, S; Kramer, E; Hess, JR; Scalea, TM				Dutton, Richard P.; Stansbury, Lynn G.; Leone, Susan; Kramer, Elizabeth; Hess, John R.; Scalea, Thomas M.			Trauma Mortality in Mature Trauma Systems: Are We Doing Better? An Analysis of Trauma Mortality Patterns, 1997-2008	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Trauma epidemiology; Trauma cause of death; Trauma time to death	INJURY SEVERITY SCORE; 753 CONSECUTIVE DEATHS; IMPROVES ACCURACY; EPIDEMIOLOGY; CARE; REASSESSMENT; PREVENTION; ARGUMENT	Background: Advances in care such as damage control surgery, hemostatic resuscitation, protocol-driven cerebral perfusion management, and lung-protective ventilation have promised to improve survival after major trauma. We examined injury severity, mortality, and preventability in a mature trauma system during a 12-year period to assess the overall benefits of these and other improvements. Methods: Using the institutional trauma registry and the quality management database, we analyzed the outcome and the cause of death for all primary trauma admissions from July 1, 1996, to June 30, 2008, and linked these data with patient demographics, hospital length of stay, time to death, predicted probability of survival, and peer review of in-hospital deaths. Results: Through fiscal year (FY) 2007, primary trauma admissions increased in number, injury severity, and age. Performance benchmarked against predicted probability of survival improved. Mortality through this era ranged from 3% to 3.7% and worsened slightly overall (p = 0.04). However, among those patients admitted with Injury Severity Score 17-25, survival improved significantly (p = 0.0003). Traumatic brain injury (TBI) accounted for 51.6% of deaths; acute hemorrhage, 30%; and multiple organ failure, 10.5%. Median time to death for uncontrollable hemorrhage, TBI, multiple organ failure was 2 hours, 24 hours, and 15 days, respectively. These patterns did not change significantly over time. Conclusion: Survival after severe trauma and survival benchmarked against predicted risk improved significantly at our center during the past 12 years despite generally increasing age and worsening injuries. Advances in trauma care have kept pace with an aging population and greater severity of injury, but overall survival has not improved.	[Dutton, Richard P.; Stansbury, Lynn G.; Leone, Susan; Kramer, Elizabeth; Hess, John R.; Scalea, Thomas M.] Univ Maryland, Sch Med, Program Trauma, Baltimore, MD 21201 USA	Stansbury, LG (corresponding author), Shock Trauma & Anesthesia Res Program, 419 W Redwood St,Suite 225, Baltimore, MD 21201 USA.	lynn.stansbury@gmail.com					BAKER CC, 1980, AM J SURG, V140, P144, DOI 10.1016/0002-9610(80)90431-6; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; CHAMPION HR, 1990, J TRAUMA, V30, P1356, DOI 10.1097/00005373-199011000-00008; Cothren CC, 2007, WORLD J SURG, V31, P1507, DOI 10.1007/s00268-007-9087-2; Flaherty S, 2003, J TRAUMA, V54, P70; FLEISS JL, 1973, STATISTICAL METHODS, P17; Klein Allison, 2007, WASH POST, pB1; Larsen Richard J., 2000, INTRO MATH STAT ITS, P282; Moore EE, 2009, J AM COLL SURGEONS, V208, P1, DOI 10.1016/j.jamcollsurg.2008.09.023; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; Potenza BM, 2004, J TRAUMA, V56, P68, DOI 10.1097/01.TA.0000101490.32972.9F; REDDY S, 2007, BALTIMORE SUN   1123; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; SHACKFORD SR, 1986, J TRAUMA, V26, P812, DOI 10.1097/00005373-198609000-00006; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; SHACKFORD SR, 1987, ARCH SURG-CHICAGO, V122, P523; Soderstrom CA, 1997, J TRAUMA, V43, P925; Stewart RM, 2003, J TRAUMA, V54, P66, DOI 10.1097/00005373-200301000-00009; 2005, NATL VITAL STAT REPO, V53, P13; 1960, MARYLAND CRIME RATES; BALTIMORE CITY HOMIC	23	237	246	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	2010	69	3					620	626		10.1097/TA.0b013e3181bbfe2a			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	649HX	WOS:000281760800034	20093983				2021-06-18	
J	Prior, L				Prior, L			Belief, knowledge and expertise: the emergence of the lay expert in medical sociology	SOCIOLOGY OF HEALTH & ILLNESS			English	Article						lay health beliefs; lay expertise; Alzheimer's; traumatic brain injury; vaccinations	DOWNS-SYNDROME; ALZHEIMERS-DISEASE; DEMENTIA; CONSTRUCTION; HEALTH; ADULTS; DIAGNOSIS; CHILDREN; ILLNESS; AIDS	The paper has three main aims. First, to trace - through the pages of Sociology of Health and Illness - the changing ways in which lay understandings of health and illness have been represented during the 1979-2002 period. Second, to say something about the limits of lay knowledge (and particularly lay expertise) in matters of health and medicine. Third, to call for a re-assessment of what lay people can offer to a democratised and customer-sensitive system of health care and to attempt to draw a boundary around the domain of expertise. In following through on those aims, the author calls upon data derived from three current projects. These latter concern the diagnosis of Alzheimer's disease in people with Down's syndrome; the development of an outcome measure for people who have suffered a traumatic brain injury; and a study of why older people might reject annual influenza vaccinations.	Cardiff Univ, Cardiff CF1 1XL, S Glam, Wales	Prior, L (corresponding author), Cardiff Sch Social Sci, Glamorgan Bldg,King Edward VII Ave, Cardiff CF10 3WT, S Glam, Wales.	PriorL@cardiff.ac.uk		Prior, Lindsay/0000-0001-9903-5841			ARKSEY H, 1994, SOCIOL HEALTH ILL, V16, P448, DOI 10.1111/1467-9566.ep11347516; ARKSEY H, 1998, RSI EXPERTS; ARMSTRONG D, 1985, SOCIOL HEALTH ILL, V7, P108, DOI 10.1111/1467-9566.ep10831391; BACKETT K, 1992, SOCIOLOGY HLTH ILLNE, V7, P110; Beck U, 1992, RISK SOC NEW MODERNI; BLAXTER M, 1983, SOC SCI MED, V17, P59, DOI 10.1016/0277-9536(83)90356-8; BROWN S, 1987, T I BRIT GEOGR, V12, P4, DOI 10.2307/622573; BURY MR, 1986, SOCIOL HEALTH ILL, V8, P137, DOI 10.1111/1467-9566.ep11340129; Busby H, 1997, SOCIOL HLTH ILLN MON, P79; CALNAN M, 1992, SOCIOL HEALTH ILL, V14, P233, DOI 10.1111/1467-9566.ep11343706; Collins HM, 2002, SOC STUD SCI, V32, P235, DOI 10.1177/0306312702032002003; DAVISON C, 1991, SOCIOL HEALTH ILL, V13, P1, DOI 10.1111/1467-9566.ep11340301; Deb S, 1999, J INTELL DISABIL RES, V43, P400, DOI 10.1046/j.1365-2788.1999.043005400.x; DEB S, 1992, ACTA PSYCHIAT SCAND, V86, P340, DOI 10.1111/j.1600-0447.1992.tb03277.x; *DEP HLTH, 1999, 1999210 HSC NHS DEP; Elwyn G, 2000, BRIT J GEN PRACT, V50, P892; Emslie C, 2001, SOCIOL HEALTH ILL, V23, P203, DOI 10.1111/1467-9566.00248; EPSTEIN S, 1995, SCI TECHNOL HUM VAL, V20, P408, DOI 10.1177/016224399502000402; Epstein Steven., 1996, IMPURE SCI AIDS ACTI; EVENHUIS HM, 1992, J INTELL DISABIL RES, V36, P337; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Freidson E., 1970, PROFESSIONAL DOMINAN; GEDYE A, 1995, DEMENTIA SCALE DOWN; Habermas J., 1987, THEORY COMMUNICATIVE, V2; Hibbert D, 2002, SOCIOL HEALTH ILL, V24, P46, DOI 10.1111/1467-9566.00003; Hunt S M, 1980, Sociol Health Illn, V2, P231; HUNT SM, 1986, MEASURING HLTH STATU; MANN DMA, 1988, HISTOPATHOLOGY, V13, P125, DOI 10.1111/j.1365-2559.1988.tb02018.x; MAZUR D, 2002, NEW MEDICAL CONVERSA; Monaghan L, 1999, SOCIOL HEALTH ILL, V21, P707, DOI 10.1111/1467-9566.00180; MORGAN M, 1988, SOCIOL HEALTH ILL, V10, P561, DOI 10.1111/1467-9566.ep10837256; *NAT ASS WAL HLTH, 2002, WAL FIG; PARSONS E, 1992, SOCIOL HEALTH ILL, V14, P437, DOI 10.1111/1467-9566.ep10493083; PINDER R, 1992, SOCIOL HEALTH ILL, V14, P1, DOI 10.1111/1467-9566.ep10940102; Popay J, 1998, SOCIOL HEALTH ILL, V20, P619, DOI 10.1111/1467-9566.00122; PRASHER VP, 1995, INT J GERIATR PSYCH, V10, P25, DOI 10.1002/gps.930100106; Prior L, 2000, SOCIOL HEALTH ILL, V22, P815, DOI 10.1111/1467-9566.00232; Sarangi S., 2001, TEXT TALK, V21, P3; Segall A, 1980, Sociol Health Illn, V2, P317, DOI 10.1111/1467-9566.ep11340704; Stewart M., 1995, PATIENT CTR MED TRAN; Taylor B, 2002, BRIT MED J, V324, P393, DOI 10.1136/bmj.324.7334.393; Tuckett D., 1985, M EXPERTS APPROACH S; Turner S, 2001, SOC STUD SCI, V31, P123, DOI 10.1177/030631201031001007; Wakefield AJ, 1998, LANCET, V351, P637, DOI 10.1016/S0140-6736(97)11096-0; Wakefield Andrew J., 2000, Adverse Drug Reactions and Toxicological Reviews, V19, P265; WARWICK I, 1988, SOCIOL HEALTH ILL, V10, P213, DOI 10.1111/1467-9566.ep11340140; Weber M., 1948, M WEBER ESSAYS SOCIO, P129; Willems D., 1992, SOCIAL CONSTRUCTION, P105; WILLIAMS G, 1984, SOCIOL HEALTH ILL, V6, P175, DOI 10.1111/1467-9566.ep10778250; Wolfe RM, 2002, JAMA-J AM MED ASSOC, V287, P3245, DOI 10.1001/jama.287.24.3245; WYNNE B, 1989, ENVIRONMENT, V31, P10, DOI 10.1080/00139157.1989.9928930; Wynne B., 1996, RISK ENV MODERNITY, P44, DOI DOI 10.4135/9781446221983.N3	52	237	243	2	70	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0141-9889	1467-9566		SOCIOL HEALTH ILL	Sociol. Health Ill.		2003	25	3			SI		41	57		10.1111/1467-9566.00339			17	Public, Environmental & Occupational Health; Social Sciences, Biomedical; Sociology	Public, Environmental & Occupational Health; Biomedical Social Sciences; Sociology	680NA	WOS:000182983200004	14498929	Bronze			2021-06-18	
J	Barrash, J; Tranel, D; Anderson, SW				Barrash, J; Tranel, D; Anderson, SW			Acquired personality disturbances associated with bilateral damage to the ventromedial prefrontal region	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							TRAUMATIC BRAIN INJURY; ANTERIOR COMMUNICATING ARTERY; HEAD-INJURY; NEUROPSYCHOLOGICAL SEQUELAE; BEHAVIORAL SYMPTOMS; DECISION-MAKING; FRONTAL DAMAGE; RATING-SCALE; CORTEX; PATIENT	Personality changes in 7 participants with bilateral ventromedial prefrontal lesions (PF-BVM), 14 participants with prefrontal lesions but not bilateral ventromedial. involvement (PF-NBVM), and 36 with nonprefrontal lesions (NPF) were investigated with the Iowa Rating Scales of Personality Change. Informants rated 30 specific characteristics for degree of disturbance and change from premorbid personality. PF-BVM participants showed a higher rate of acquired disturbances than NPF participants in blunted emotional experience, apathy, low emotional expressiveness, inappropriate affect, poor frustration tolerance, irritability, lability, indecisiveness, poor judgment, social inappropriateness, lack of planning, lack of initiation and persistence, and lack of insight. Differences between the PF-BVM and PF-NBVM groups were significant for several of these characteristics. All 7 PF-BVM participants developed a syndrome, including general dampening of emotional experience; poorly modulated emotional reactions; defective decision making, especially in the social realm; impaired goal-directed behavior; and striking lack of insight. Similarities between this syndrome of "acquired sociopathy" and developmental psychopathy in characteristic personality disturbances and psychophysiological abnormalities suggest that diminished emotionality, impaired decision making, and psychosocial dysfunction may be related to ventromedial prefrontal dysfunction in both groups.	Univ Iowa, Coll Med, Div Behav Neurol & Cognit Neurosci, Dept Neurol, Iowa City, IA 52242 USA	Barrash, J (corresponding author), Univ Iowa, Coll Med, Div Behav Neurol & Cognit Neurosci, Dept Neurol, 200 Hawkins Dr, Iowa City, IA 52242 USA.	joseph-barrash@uiowa.edu		Tranel, Daniel/0000-0002-1338-1389; Anderson, Steven/0000-0002-7364-1680; Barrash, Joseph/0000-0001-9827-0110	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS019632] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS19632] Funding Source: Medline		ALFANO DP, 1993, NEUROPSYCHOLOGY BEHA, V2, P117; Anderson S. W., 1989, CLIN NEUROPSYCHOL, V3, P327, DOI DOI 10.1080/13854048908401482; Anderson SW, 1999, NAT NEUROSCI, V2, P1032; Anderson SW, 2000, DEV NEUROPSYCHOL, V18, P281, DOI 10.1207/S1532694202Anderson; ANDERSON SW, 1992, J CLIN EXP NEUROPSYC, V14, P83; BARRASH J, 1993, J CLIN EXP NEUROPSYC, V15, P66; Barrash J., 1993, IOWA RATINGS SCALES; BARRASH J, 1997, 25 ANN M INT NEUR SO; Bechara A, 2000, CEREB CORTEX, V10, P295, DOI 10.1093/cercor/10.3.295; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Bechara A, 1996, CEREB CORTEX, V6, P215, DOI 10.1093/cercor/6.2.215; Bechara A, 1997, SCIENCE, V275, P1293, DOI 10.1126/science.275.5304.1293; BENES FM, 1997, DEV PREFRONTAL CORTE, P211; BLACK DW, 1999, BAD BOYS MEN CONFRON; Blair RJR, 2000, BRAIN, V123, P1122, DOI 10.1093/brain/123.6.1122; Blumer D., 1975, PSYCHIAT ASPECTS NEU, P151; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Butcher JN, 1989, MANUAL ADM SCORING M; CUMMINGS JL, 1993, ARCH NEUROL-CHICAGO, V50, P873, DOI 10.1001/archneur.1993.00540080076020; Damasio A., 1994, DESCARTESERROR EMOTI; Damasio A. R., 1993, CLIN NEUROPSYCHOLOGY, V3, P409; Damasio AR, 2000, ARCH GEN PSYCHIAT, V57, P128, DOI 10.1001/archpsyc.57.2.128; Damasio AR, 1998, BRAIN RES REV, V26, P83, DOI 10.1016/S0165-0173(97)00064-7; DAMASIO AR, 1990, BEHAV BRAIN RES, V41, P81, DOI 10.1016/0166-4328(90)90144-4; DAMASIO H, 1992, ARCH NEUROL-CHICAGO, V49, P137, DOI 10.1001/archneur.1992.00530260037016; DAMASIO H, 1994, SCIENCE, V264, P1102, DOI 10.1126/science.8178168; Deckel AW, 1996, J CLIN PSYCHOL, V52, P639; DELUCA J, 1995, J CLIN EXP NEUROPSYC, V17, P100, DOI 10.1080/13803399508406586; Dywan J, 1996, J HEAD TRAUMA REHAB, V11, P79, DOI 10.1097/00001199-199604000-00008; Eisenberg, 1987, NEUROBEHAVIORAL RECO, P215; Elsass L, 1989, P 14 ANN BRAIN IMP C, P124; ESLINGER P, 1984, SEMIN NEUROL, V4, P385, DOI 10.1055/s-2008-1041568; Eslinger Paul J., 1996, P415; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; Eslinger PJ, 1998, EUR NEUROL, V39, P193, DOI 10.1159/000007933; Eysenck H.J., 1975, EYSENCK PERSONALITY; Frank RJ, 1997, NEUROIMAGE, V5, P13, DOI 10.1006/nimg.1996.0250; GAINOTTI G, 1993, NEUROPSYCHOL REHABIL, V3, P259, DOI 10.1080/09602019308401440; Godefroy O, 1997, NEUROLOGY, V49, P695, DOI 10.1212/WNL.49.3.695; Grace J, 1992, FRONTAL LOBE PERSONA; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; Handler J., 1994, HANDB NEUR, P125; HARE R, 1970, PSYCHOPHYSIOLOGY, V7, P408, DOI 10.1111/j.1469-8986.1970.tb01766.x; HARE RD, 1971, J ABNORM PSYCHOL, V77, P223, DOI 10.1037/h0031012; Hare RD., 1970, PSYCHOPATHY THEORY R; Harlow J. M., 1993, HIST PSYCHIATR, V4, P274, DOI [10.1177/0957154X9300401407, DOI 10.1177/0957154X9300401407]; HATHAWAY SR, 1983, MINNESOTA MULTIPHASI; Hauser MD, 1999, CURR OPIN NEUROBIOL, V9, P214, DOI 10.1016/S0959-4388(99)80030-0; HUNTER R, 1968, BMJ-BRIT MED J, V3, P9, DOI 10.1136/bmj.3.5609.9; KATZ MM, 1963, PSYCHOL REP, V13, P503, DOI 10.2466/pr0.1963.13.2.503; Kertesz A, 2000, J INT NEUROPSYCH SOC, V6, P460, DOI 10.1017/S1355617700644041; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; Kuruoglu AC, 1996, BRIT J PSYCHIAT, V169, P348, DOI 10.1192/bjp.169.3.348; Leathem JM, 1998, J CLIN EXP NEUROPSYC, V20, P694, DOI 10.1076/jcen.20.5.694.1122; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Lezak M. D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI [10.1097/00001199-198703000-00009, DOI 10.1097/00001199-198703000-00009]; LEZAK MD, 1989, ASSESSMENT BEHAV CON, V7, P113; Luria A. R., 1969, HDB CLINICAL NEUROLO, V2, P725; LYKKEN DT, 1957, J ABNORM SOC PSYCH, V55, P6, DOI 10.1037/h0047232; MALIA K, 1995, BRAIN INJURY, V9, P697, DOI 10.3109/02699059509008226; MALLOY P, 1993, ARCH CLIN NEUROPSYCH, V8, P185, DOI 10.1016/0887-6177(93)90035-Y; NELSON LD, 1989, J CONSULT CLIN PSYCH, V1, P266; NEWMAN JP, 1987, J ABNORM PSYCHOL, V96, P145, DOI 10.1037/0021-843X.96.2.145; Owen AM, 1997, PROG NEUROBIOL, V53, P431, DOI 10.1016/S0301-0082(97)00042-7; Pfohl B., 1989, STRUCTURED INTERVIEW; Prigatano G. P., 1991, AWARENESS DEFICIT BR; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P96; Raine A, 2000, ARCH GEN PSYCHIAT, V57, P119, DOI 10.1001/archpsyc.57.2.119; Raine A, 1998, NEUROPSY NEUROPSY BE, V11, P1; REISBERG B, 1987, J CLIN PSYCHIAT, V48, P9; RempelClower NL, 1996, J NEUROSCI, V16, P5233; Sarazin M, 1998, NEUROLOGY, V51, P142, DOI 10.1212/WNL.51.1.142; SAVER JL, 1991, NEUROPSYCHOLOGIA, V29, P1241, DOI 10.1016/0028-3932(91)90037-9; Scarpa A, 1997, PSYCHIAT CLIN N AM, V20, P375, DOI 10.1016/S0193-953X(05)70318-X; SCHMAUK F J, 1970, Journal of Abnormal Psychology, V76, P325, DOI 10.1037/h0030398; Schwarz N, 1999, AM PSYCHOL, V54, P93, DOI 10.1037/0003-066X.54.2.93; Siegel S., 1988, NONPARAMETRIC STAT B; STEINMAN DR, 1986, INT J CLIN NEUROPSYC, V8, P135; Strauss ME, 1997, ARCH NEUROL-CHICAGO, V54, P257, DOI 10.1001/archneur.1997.00550150021010; Stuss D.T., 1986, FRONTAL LOBES; Tate RL, 1999, CORTEX, V35, P39, DOI 10.1016/S0010-9452(08)70784-6; Tate RL, 1998, NEUROPSYCHOL REHABIL, V8, P1, DOI 10.1080/713755554; Tranel D, 1994, Prog Exp Pers Psychopathol Res, P285; TRANEL D, 1999, NEW COGNITIVE NEUROS, P1047; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Zlotnick C, 1999, J PERS DISORD, V13, P90, DOI 10.1521/pedi.1999.13.1.90	87	237	241	2	57	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.		2000	18	3					355	381		10.1207/S1532694205Barrash			27	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	432UW	WOS:000168714900005	11385830				2021-06-18	
J	McKee, AC; Stein, TD; Kiernan, PT; Alvarez, VE				McKee, Ann C.; Stein, Thor D.; Kiernan, Patrick T.; Alvarez, Victor E.			The Neuropathology of Chronic Traumatic Encephalopathy	BRAIN PATHOLOGY			English	Article						Alzheimer's disease; chronic traumatic encephalopathy; tauopathy; TDP-43; traumatic brain injury	COLLEGIATE FOOTBALL PLAYERS; BRAIN-INJURY; DEMENTIA-PUGILISTICA; AXONAL INJURY; AMYLOID-BETA; NEUROFIBRILLARY TANGLES; NATIONAL INSTITUTE; ALZHEIMER-DISEASE; TDP-43 EXPRESSION; TAU PATHOLOGY	Repetitive brain trauma is associated with a progressive neurological deterioration, now termed as chronic traumatic encephalopathy (CTE). Most instances of CTE occur in association with the play of sports, but CTE has also been reported in association with blast injuries and other neurotrauma. Symptoms of CTE include behavioral and mood changes, memory loss, cognitive impairment and dementia. Like many other neurodegenerative diseases, CTE is diagnosed with certainty only by neuropathological examination of brain tissue. CTE is a tauopathy characterized by the deposition of hyperphosphorylated tau (p-tau) protein as neurofibrillary tangles, astrocytic tangles and neurites in striking clusters around small blood vessels of the cortex, typically at the sulcal depths. Severely affected cases show p-tau pathology throughout the brain. Abnormalities in phosphorylated 43kDa TAR DNA-binding protein are found in most cases of CTE; beta-amyloid is identified in 43%, associated with age. Given the importance of sports participation and physical exercise to physical and psychological health as well as disease resilience, it is critical to identify the genetic risk factors for CTE as well as to understand how other variables, such as stress, age at exposure, gender, substance abuse and other exposures, contribute to the development of CTE.	[McKee, Ann C.; Stein, Thor D.] VA Boston Healthcare Syst, Boston, MA USA; [McKee, Ann C.; Stein, Thor D.] Boston Univ, Sch Med, Dept Pathol & Lab Sci, Boston, MA 02118 USA; [McKee, Ann C.; Kiernan, Patrick T.; Alvarez, Victor E.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [McKee, Ann C.; Stein, Thor D.] Boston Univ, Alzheimers Dis Ctr, Boston, MA 02215 USA; [McKee, Ann C.; Stein, Thor D.; Kiernan, Patrick T.; Alvarez, Victor E.] Boston Univ, Chron Traumat Encephalopathy Ctr Program, Boston, MA 02215 USA	McKee, AC (corresponding author), 72 E Concord St,Suite B-7800, Boston, MA 02118 USA.	amckee@bu.edu		Stein, Thor/0000-0001-6954-4477	National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1UO1NS086659-01]; Department of Veterans Affairs, the Veterans Affairs Biorepository [CSP 501]; Translational Research Center for Traumatic Brain Injury and Stress Disorders (TRACTS), Veterans Affairs Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence [B6796-C]; National Institute of Aging Boston University Alzheimer's Disease Center [P30AG13846, 0572063345-5]; National Institute of Aging Boston University Framingham Heart Study [AG1649]; National Operating Committee on Standards for Athletic Equipment; Sports Legacy Institute; Andlinger Foundation; WWE; National Football League; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086659] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG013846] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01CX001038] Funding Source: NIH RePORTER	The authors gratefully acknowledge the use of the resources and facilities at the Edith Nourse Rogers Memorial Veterans Hospital (Bedford, MA, USA). We also gratefully acknowledge the help of all members of the Chronic Traumatic Encephalopathy Program at Boston University School of Medicine, the Boston VA, as well as the individuals and families whose participation and contributions made this work possible. This work was supported by the National Institute of Neurological Disorders and Stroke (1UO1NS086659-01), Department of Veterans Affairs, the Veterans Affairs Biorepository (CSP 501), the Translational Research Center for Traumatic Brain Injury and Stress Disorders (TRACTS), Veterans Affairs Rehabilitation Research and Development Traumatic Brain Injury Center of Excellence (B6796-C), the National Institute of Aging Boston University Alzheimer's Disease Center (P30AG13846; supplement 0572063345-5), the National Institute of Aging Boston University Framingham Heart Study R01 (AG1649), the National Operating Committee on Standards for Athletic Equipment and the Sports Legacy Institute. This work was also supported by unrestricted gifts from the Andlinger Foundation, the WWE and the National Football League.	Amadoro G, 2006, P NATL ACAD SCI USA, V103, P2892, DOI 10.1073/pnas.0511065103; Anthony IC, 2010, BRAIN, V133, P3685, DOI 10.1093/brain/awq263; Baugh CM, 2014, CURR TREAT OPTION NE, V16, DOI 10.1007/s11940-014-0306-5; Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Bieniek KF, 2014, BRAIN PATHOL, V24, P39; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; BRANDENBURG W, 1954, Virchows Arch Pathol Anat Physiol Klin Med, V325, P680, DOI 10.1007/BF00955101; Buerger K, 2006, BRAIN, V129, P3035, DOI 10.1093/brain/awl269; Cairns NJ, 2007, AM J PATHOL, V171, P227, DOI 10.2353/ajpath.2007.070182; Chen LJ, 2010, J NEUROTRAUM, V27, P1657, DOI 10.1089/neu.2010.1308; Chien DT, 2013, J ALZHEIMERS DIS, V34, P457, DOI 10.3233/JAD-122059; Clavaguera F, 2015, NEUROPATH APPL NEURO, V41, P47, DOI 10.1111/nan.12197; Clavaguera F, 2013, PROTEOPATHIC SEEDS N, P87; Cloots RJH, 2008, ANN BIOMED ENG, V36, P1203, DOI 10.1007/s10439-008-9510-3; Cloots RJH, 2011, BIOMECH MODEL MECHAN, V10, P413, DOI 10.1007/s10237-010-0243-5; Constantinidis J, 1967, Schweiz Arch Neurol Neurochir Psychiatr, V100, P117; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Costanza A, 2011, NEUROPATH APPL NEURO, V37, P570, DOI 10.1111/j.1365-2990.2011.01186.x; COURVILLE CYRIL B., 1962, BULL LOS ANGELES NEUROL SOC, V27, P160; Critchley M., 1949, HOMMAGE CLOVIS VINCE; de Calignon A, 2012, NEURON, V73, P685, DOI 10.1016/j.neuron.2011.11.033; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Frost B, 2009, J BIOL CHEM, V284, P12845, DOI 10.1074/jbc.M808759200; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Geddes JF, 1996, NEUROPATH APPL NEURO, V22, P12, DOI 10.1111/j.1365-2990.1996.tb00840.x; Giza CC, 2005, BEHAV BRAIN RES, V157, P11, DOI 10.1016/j.bbr.2004.06.003; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; GORELL JM, 1994, NEUROLOGY, V44, P1865, DOI 10.1212/WNL.44.10.1865; Grahmann H, 1956, PSYCHIAT NEUROL BASE, V134, P261; Green KN, 2006, J NEUROSCI, V26, P9047, DOI 10.1523/JNEUROSCI.2797-06.2006; Guo JL, 2011, J BIOL CHEM, V286, P15317, DOI 10.1074/jbc.M110.209296; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Hall GF, 2012, PRION, V6, P223, DOI 10.4161/pri.19912; Hazrati LN, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00222; HOF PR, 1991, ACTA NEUROPATHOL, V82, P321, DOI 10.1007/BF00308819; HOF PR, 1992, ACTA NEUROPATHOL, V85, P23, DOI 10.1007/BF00304630; Hyman BT, 1997, J NEUROPATH EXP NEUR, V56, P1095, DOI 10.1097/00005072-199710000-00002; Iliff JJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003748; Jicha GA, 2010, J ALZHEIMERS DIS, V19, P253, DOI 10.3233/JAD-2010-1237; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Jordan BD, 1993, MED ASPECTS BOXING, V1, P177; Kalaria RN, 2000, NEUROBIOL AGING, V21, P321, DOI 10.1016/S0197-4580(00)00125-1; Kanaan NM, 2011, J NEUROSCI, V31, P9858, DOI 10.1523/JNEUROSCI.0560-11.2011; Khlistunova I, 2006, J BIOL CHEM, V281, P1205, DOI 10.1074/jbc.M507753200; Kim W, 2010, J ALZHEIMERS DIS, V19, P647, DOI 10.3233/JAD-2010-1273; King A, 2010, NEUROPATHOLOGY, V30, P408, DOI 10.1111/j.1440-1789.2009.01085.x; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Lin AP, 2012, BRAIN IMAGING BEHAV, V6, P208, DOI 10.1007/s11682-012-9181-4; Liu L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031302; Margulies SS, 2015, BRAIN PATHOL, V25, P289, DOI 10.1111/bpa.12247; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCCOWN IA, 1959, JAMA-J AM MED ASSOC, V169, P1409, DOI 10.1001/jama.1959.03000300005002; McKee AC, 2015, BRAIN PATHOL, V25, P350, DOI 10.1111/bpa.12248; McKee AC, 2014, ALZHEIMERS DEMENT, V10, pS242, DOI 10.1016/j.jalz.2014.04.003; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Millspaugh J, 1937, US NAVAL MED B, V35; Mitsis EM, 2014, TRANSL PSYCHIAT, V4, DOI 10.1038/tp.2014.91; Moisse K, 2009, BRAIN RES, V1296, P176, DOI 10.1016/j.brainres.2009.07.023; Moisse K, 2009, BRAIN RES, V1249, P202, DOI 10.1016/j.brainres.2008.10.021; Montenigro PH, 2015, BRAIN PATHOL, V25, P304, DOI 10.1111/bpa.12250; Montenigro PH, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0068-z; Morales R, 2009, CNS NEUROL DISORD-DR, V8, P363, DOI 10.2174/187152709789541998; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; NEUBUERGER KT, 1959, ARCH NEURO PSYCHIATR, V81, P403, DOI 10.1001/archneurpsyc.1959.02340160001001; Newell KL, 1999, J NEUROPATH EXP NEUR, V58, P1147, DOI 10.1097/00005072-199911000-00004; Okawa Y, 2003, FEBS LETT, V535, P183, DOI 10.1016/S0014-5793(02)03883-8; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu Bennet I, 2010, J Forensic Nurs, V6, P130, DOI 10.1111/j.1939-3938.2010.01078.x; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Park SY, 2005, J NEUROSCI, V25, P5365, DOI 10.1523/JNEUROSCI.1125-05.2005; Parker HL, 1934, J NEUROL PSYCHOPATHO, V15, P20; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROBERTS GW, 1990, LANCET, V335, P918, DOI 10.1016/0140-6736(90)90520-F; Sato T, 2009, NEUROSCIENCE, V164, P1565, DOI 10.1016/j.neuroscience.2009.09.050; Sephton CF, 2012, BIOL CHEM, V393, P589, DOI 10.1515/hsz-2012-0115; Sephton CF, 2011, J BIOL CHEM, V286, P1204, DOI 10.1074/jbc.M110.190884; Smith C, 2015, BRAIN PATHOL, V25, P287, DOI 10.1111/bpa.12251; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Sonnen JA, 2007, ANN NEUROL, V62, P406, DOI 10.1002/ana.21208; Sotiropoulos I, 2008, J NEUROCHEM, V107, P385, DOI 10.1111/j.1471-4159.2008.05613.x; Sotiropoulos I, 2011, J NEUROSCI, V31, P7840, DOI 10.1523/JNEUROSCI.0730-11.2011; Stein TD, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt234; Stieler JT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014530; Strong MJ, 2011, J MOL NEUROSCI, V45, P648, DOI 10.1007/s12031-011-9609-0; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Thal Dietmar R, 2006, Sci Aging Knowledge Environ, V2006, pre1, DOI 10.1126/sageke.2006.6.re1; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P280, DOI 10.1007/BF00308813; Van der Jeugd A, 2012, ACTA NEUROPATHOL, V123, P787, DOI 10.1007/s00401-012-0987-3; Waite LM, 1997, MED J AUSTRALIA, V167, P429, DOI 10.5694/j.1326-5377.1997.tb126655.x; Williams DJ, 1996, PATHOLOGY, V28, P102, DOI 10.1080/00313029600169653; Wolozin B, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-56; Zhukareva V, 2001, ACTA NEUROPATHOL, V101, P518; Zilka N, 2006, FEBS LETT, V580, P3582, DOI 10.1016/j.febslet.2006.05.029	105	236	236	9	96	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1015-6305	1750-3639		BRAIN PATHOL	Brain Pathol.	MAY	2015	25	3					350	364		10.1111/bpa.12248			15	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	CG6CX	WOS:000353384200010	25904048	Green Accepted	Y	N	2021-06-18	
J	Ponsford, J; Willmott, C; Rothwell, A; Cameron, P; Kelly, AM; Nelms, R; Curran, C				Ponsford, J; Willmott, C; Rothwell, A; Cameron, P; Kelly, AM; Nelms, R; Curran, C			Impact of early intervention on outcome following mild head injury in adults	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							CONTROLLED TRIAL	Background: The impact of mild head injury is variable and determinants of outcome remain poorly understood. Results of previous intervention studies have been mixed. Objectives: To evaluate the impact on outcome of the provision of information, measured in terms of reported symptoms, cognitive performance, and psychological adjustment three months postinjury. Methods: 202 adults with mild head injury were studied: 79 were assigned to an intervention group and were assessed one week and three months after injury; 123 were assigned to a non-intervention control group and were seen at three months only. Participants completed measures of preinjury psychological adjustment, concurrent life stresses, post-concussion symptoms, and tests of attention, speed of information processing, and memory. Subjects seen at one week were given an information booklet outlining the symptoms associated with mild head injury and suggested coping strategies. Those seen only at three months after injury did not receive this booklet, Results: Patients in the intervention group who were seen at one week and given the information booklet reported fewer symptoms overall and were significantly less stressed at three months after the injury. Conclusions: The provision of an information booklet reduces anxiety and reporting of ongoing problems.	Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Richmond, Vic 3121, Australia; Julia Farr Serv, Fullarton, Australia; Royal Melbourne Hosp, Melbourne, Vic, Australia; Western Hosp, Melbourne, Vic, Australia	Ponsford, J (corresponding author), Epworth Med Fdn, Dept Psychol, Bethesda Rehabil Ctr, 30 Erin St, Richmond, Vic 3121, Australia.		Willmott, Catherine/AAA-5105-2019	Willmott, Catherine/0000-0001-8517-9035; Cameron, Peter/0000-0002-1443-557X			Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Baddeley A.D., 1992, SPEED CAPACITY LANGU; BERROL S, 1992, REHABILITATION POST, P1; Daniel A. E., 1983, POWER PRIVILEGE PRES; DEROGATIS LR, 1977, SYMPTOM CHECKLIST SC, V1; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Gronwall D, 1986, J HEAD TRAUMA REHAB, V1, P53, DOI DOI 10.1097/00001199-198606000-00009; Gronwall D, 1991, NEUROPSYCHOLOGY, V5, P253, DOI DOI 10.1037/0894-4105.5.4.253; Gronwall D.M., 1974, PSYCHOL EFFECTS CONC; HOLMES TH, 1967, J PSYCHOSOM RES, V11, P213, DOI 10.1016/0022-3999(67)90010-4; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; RELANDER M, 1972, BMJ-BRIT MED J, V4, P777, DOI 10.1136/bmj.4.5843.777; Rey A, 1964, EXAMEN CLIN PSYCHOL; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Wilson, 1991, NATL ADULT READING T	18	236	237	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	SEP	2002	73	3					330	332		10.1136/jnnp.73.3.330			3	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	588LL	WOS:000177702900026	12185174	Bronze, Green Published			2021-06-18	
J	Davis, KE; Straff, DJ; Weinstein, EA; Bannerman, PG; Correale, DM; Rothstein, JD; Robinson, MB				Davis, KE; Straff, DJ; Weinstein, EA; Bannerman, PG; Correale, DM; Rothstein, JD; Robinson, MB			Multiple signaling pathways regulate cell surface expression and activity of the excitatory amino acid carrier 1 subtype of Glu transporter in C6 glioma	JOURNAL OF NEUROSCIENCE			English	Article						glutamate transport; EAAC1; excitatory amino acid; protein kinase C; phosphatidylinositol 3-kinase; trafficking; C6 glioma	PROTEIN-KINASE-C; TRAUMATIC BRAIN INJURY; PHOSPHATIDYLINOSITOL 3-KINASE; GLUTAMATE TRANSPORTER; NMDA RECEPTOR; RAT-BRAIN; STIMULATION; TRANSLOCATION; EXCITOTOXICITY; LOCALIZATION	Neuronal and glial sodium-dependent transporters are crucial for the control of extracellular glutamate levels in the CNS. The regulation of these transporters is relatively unexplored, but the activity of other transporters is regulated by protein kinase C (PKC)- and phosphatidylinositol 3-kinase (PI3K)-mediated trafficking to and from the cell surface. In the present study the C6 glioma cell line was used as a model system that endogenously expresses the excitatory amino acid carrier 1 (EAAC1) subtype of neuronal glutamate transporter. As previously observed, phorbol 12-myristate 13-acetate (PMA) caused an 80% increase in transporter activity within minutes that cannot be attributed to the synthesis of new transporters. This increase in activity correlated with an increase in cell surface expression of EAAC1 as measured by using a membrane-impermeant biotinylation reagent, Both effects of PMA were blocked by the PKC inhibitor bisindolylmaleimide II (Bis II). The putative PI3K inhibitor, wortmannin, decreased L-[H-3]-glutamate uptake activity by >50% within minutes, Wortmannin decreased the V-max of L-[H-3]-glutamate and D-[H-3]-aspartate transport, but it did not affect Na+-dependent [H-3]-glycine transport. Wortmannin also decreased cell surface expression of EAAC1. Although wortmannin did not block the effects of PMA on activity, it prevented the PMA-induced increase in cell surface expression. This trafficking of EAAC1 also was examined with immunofluorescent confocal microscopy, which supported the biotinylation studies and also revealed a clustering of EAAC1 at cell surface after treatment with PMA. These studies suggest that the trafficking of the neuronal glutamate transporter EAAC1 is regulated by two independent signaling pathways and also may suggest a novel endogenous protective mechanism to limit glutamate-induced excitotoxicity.	Univ Penn, Childrens Seashore House, Childrens Hosp Philadelphia, Dept Neurosci, Philadelphia, PA 19104 USA; Univ Penn, Childrens Seashore House, Childrens Hosp Philadelphia, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Childrens Seashore House, Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA; Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21287 USA	Robinson, MB (corresponding author), Abramson Pediat Res Ctr, Room 502,34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA.		rothstein, jeffrey d/C-9470-2013		NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [F30MH011977] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036465, R01NS029868] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH11977] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS36465, NS29868] Funding Source: Medline		Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; ATTWELL D, 1993, NEURON, V11, P401, DOI 10.1016/0896-6273(93)90145-H; CAPOGNA M, 1995, J NEUROSCI, V15, P1249; CASADO M, 1993, J BIOL CHEM, V268, P27313; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEN CC, 1993, FEBS LETT, V332, P169, DOI 10.1016/0014-5793(93)80506-P; Chen CC, 1995, MOL PHARMACOL, V48, P995; Chew CS, 1997, AM J PHYSIOL-GASTR L, V272, pG246; CLARKE JF, 1994, BIOCHEM J, V300, P631, DOI 10.1042/bj3000631; DEKKER LV, 1991, PROG BRAIN RES, V89, P209; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; Dowd LA, 1996, J NEUROCHEM, V67, P508, DOI 10.1046/j.1471-4159.1996.67020508.x; Dowd LA, 1996, MOL PHARMACOL, V49, P465; EHLERS MD, 1995, SCIENCE, V269, P1734, DOI 10.1126/science.7569904; Ettinger SL, 1996, J BIOL CHEM, V271, P14514, DOI 10.1074/jbc.271.24.14514; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; Furuta A, 1997, NEUROSCIENCE, V81, P1031, DOI 10.1016/S0306-4522(97)00252-2; Gomez J, 1996, EUR J IMMUNOL, V26, P1781, DOI 10.1002/eji.1830260818; Greene JG, 1996, PROG NEUROBIOL, V48, P613, DOI 10.1016/0301-0082(96)00006-8; Haugeto O, 1996, J BIOL CHEM, V271, P27715, DOI 10.1074/jbc.271.44.27715; HOLMAN GD, 1994, BIOESSAYS, V16, P753, DOI 10.1002/bies.950161010; JAMES DE, 1994, J CELL BIOL, V126, P1123, DOI 10.1083/jcb.126.5.1123; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; Kim E, 1996, NEURON, V17, P103, DOI 10.1016/S0896-6273(00)80284-6; LEVI G, 1993, TRENDS NEUROSCI, V16, P415, DOI 10.1016/0166-2236(93)90010-J; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Mizukami Y, 1997, FEBS LETT, V401, P247, DOI 10.1016/S0014-5793(96)01481-0; MUNIR M, 1997, SOC NEUR ABSTR, V23; NAKANISHI S, 1995, CELL SIGNAL, V7, P545, DOI 10.1016/0898-6568(95)00033-L; Nave BT, 1996, BIOCHEM J, V318, P203, DOI 10.1042/bj3180203; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; NISHIMURA H, 1994, BIOCHEM J, V302, P271, DOI 10.1042/bj3020271; NIXON JS, 1992, BIOCHEM SOC T, V20, P419, DOI 10.1042/bst0200419; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Palos TP, 1996, MOL BRAIN RES, V37, P297, DOI 10.1016/0169-328X(95)00331-L; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; Qian Y, 1997, J NEUROSCI, V17, P45; Quick MW, 1997, J NEUROSCI, V17, P2967; Robinson M B, 1997, Adv Pharmacol, V37, P69; ROSENBERG PA, 1992, J NEUROSCI, V12, P56; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; ROTHSTEIN JD, 1995, ANN NEUROL, V38, P73, DOI 10.1002/ana.410380114; SARGIACOMO M, 1989, J MEMBRANE BIOL, V107, P277, DOI 10.1007/BF01871942; Sternini C, 1996, P NATL ACAD SCI USA, V93, P9241, DOI 10.1073/pnas.93.17.9241; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Ubl JJ, 1997, PFLUG ARCH EUR J PHY, V433, P312; VONZASTROW M, 1994, J BIOL CHEM, V269, P18448; YANO H, 1995, BIOCHEM J, V312, P145, DOI 10.1042/bj3120145; Zhu SJ, 1997, J PHARMACOL EXP THER, V282, P1358	53	236	244	0	4	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	APR 1	1998	18	7					2475	2485					11	Neurosciences	Neurosciences & Neurology	ZE302	WOS:000072778700018	9502808				2021-06-18	
J	Esposito, E; Cuzzocrea, S				Esposito, Emanuela; Cuzzocrea, Salvatore			Antiinflammatory Activity of Melatonin in Central Nervous System	CURRENT NEUROPHARMACOLOGY			English	Article						Melatonin; inflammation; neurodegeneration; mitochondria; antioxidant; free radical	SPINAL-CORD-INJURY; NITRIC-OXIDE SYNTHASE; ISCHEMIA-REPERFUSION INJURY; TRANSGENIC MOUSE MODEL; OXIDATIVE STRESS; MATRIX METALLOPROTEINASES; IN-VIVO; ALZHEIMERS-DISEASE; CELL-DEATH; NEURODEGENERATIVE DISORDERS	Melatonin is mainly produced in the mammalian pineal gland during the dark phase. Its secretion from the pineal gland has been classically associated with circadian and circanual rhythm regulation. However, melatonin production is not confined exclusively to the pineal gland, but other tissues including retina, Harderian glands, gut, ovary, testes, bone marrow and lens also produce it. Several studies have shown that melatonin reduces chronic and acute inflammation. The immunomodulatory properties of melatonin are well known; it acts on the immune system by regulating cytokine production of immunocompetent cells. Experimental and clinical data showing that melatonin reduces adhesion molecules and pro-inflammatory cytokines and modifies serum inflammatory parameters. As a consequence, melatonin improves the clinical course of illnesses which have an inflammatory etiology. Moreover, experimental evidence supports its actions as a direct and indirect antioxidant, scavenging free radicals, stimulating antioxidant enzymes, enhancing the activities of other antioxidants or protecting other antioxidant enzymes from oxidative damage. Several encouraging clinical studies suggest that melatonin is a neuroprotective molecule in neurodegenerative disorders where brain oxidative damage has been implicated as a common link. In this review, the authors examine the effect of melatonin on several neurological diseases with inflammatory components, including dementia, Alzheimer disease, Parkinson disease, multiple sclerosis, stroke, and brain ischemia/reperfusion but also in traumatic CNS injuries (traumatic brain and spinal cord injury)	[Cuzzocrea, Salvatore] Univ Messina, Sch Med, Dept Clin & Expt Med & Pharmacol, Torre Biol Policlin Univ, I-98100 Messina, Italy; [Cuzzocrea, Salvatore] IRCCS Ctr Neurol Bonino Pulejo, Messina, Italy	Cuzzocrea, S (corresponding author), Univ Messina, Sch Med, Dept Clin & Expt Med & Pharmacol, Torre Biol Policlin Univ, Via C Valeria Gazzi, I-98100 Messina, Italy.	salvator@unime.it					Agez L, 2009, J PINEAL RES, V46, P95, DOI 10.1111/j.1600-079X.2008.00636.x; Altun A, 2007, INT J CLIN PRACT, V61, P835, DOI 10.1111/j.1742-1241.2006.01191.x; Anderson Aileen J, 2002, J Spinal Cord Med, V25, P70; ANDERSON DK, 1993, ANN EMERG MED, V22, P987, DOI 10.1016/S0196-0644(05)82739-8; Andrabi SA, 2004, FASEB J, V18, P869, DOI 10.1096/fj.03-1031fje; Antolin I, 1996, FASEB J, V10, P882; Ates O, 2007, NEUROL RES, V29, P533, DOI 10.1179/016164107X172121; Bar-Peled O, 1999, J NEUROSCI RES, V55, P542, DOI 10.1002/(SICI)1097-4547(19990301)55:5<542::AID-JNR2>3.0.CO;2-7; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Beattie MS, 2004, TRENDS MOL MED, V10, P580, DOI 10.1016/j.molmed.2004.10.006; Beattie MS, 2000, J NEUROTRAUM, V17, P915, DOI 10.1089/neu.2000.17.915; BECKERANDRE M, 1994, J BIOL CHEM, V269, P28531; BENITEZKING G, 1993, EXPERIENTIA, V49, P635; Bethea JR, 2002, CURR OPIN NEUROL, V15, P355, DOI 10.1097/00019052-200206000-00021; Bilici D, 2002, PHARMACOL RES, V46, P133, DOI 10.1016/S1043-6618(02)00089-0; Bogaerts V, 2008, GENES BRAIN BEHAV, V7, P129, DOI 10.1111/j.1601-183X.2007.00342.x; Bolanos JP, 1997, J NEUROCHEM, V68, P2227; BOND WS, 1977, AM J HOSP PHARM, V34, P479, DOI 10.1093/ajhp/34.5.0479; Borlongan CV, 2000, NEUROREPORT, V11, P923, DOI 10.1097/00001756-200004070-00005; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; Budh CN, 2005, SPINAL CORD, V43, P85, DOI 10.1038/sj.sc.3101680; Caballero B, 2009, J PINEAL RES, V46, P106, DOI 10.1111/j.1600-079X.2008.00637.x; Calabrese V, 2004, IN VIVO, V18, P245; Calabrese V, 2001, NEUROCHEM RES, V26, P739, DOI 10.1023/A:1010955807739; Camello-Almaraz C, 2008, J PINEAL RES, V45, P191, DOI 10.1111/j.1600-079X.2008.00576.x; Carlson Gregory D, 2002, Spine J, V2, P116, DOI 10.1016/S1529-9430(01)00029-8; Carrillo-Vico A, 2005, J PINEAL RES, V39, P400, DOI 10.1111/j.1600-079X.2005.00265.x; Carrillo-Vico A, 2005, J CLIN ENDOCR METAB, V90, P992, DOI 10.1210/jc.2004-1429; Casha S, 2001, NEUROSCIENCE, V103, P203, DOI 10.1016/S0306-4522(00)00538-8; Cayli SR, 2004, EUR SPINE J, V13, P724, DOI 10.1007/s00586-003-0550-y; Cervantes M, 2008, J PINEAL RES, V45, P1, DOI 10.1111/j.1600-079X.2007.00551.x; CHATHAM WW, 1993, ARTHRITIS RHEUM, V36, P51; Chattoraj A, 2009, REV ENDOCR METAB DIS, V10, P237, DOI 10.1007/s11154-009-9125-5; Cheung RTF, 2006, J PINEAL RES, V41, P337, DOI 10.1111/j.1600-079X.2006.00372.x; CHITTENDEN T, 1995, NATURE, V374, P733, DOI 10.1038/374733a0; Chung SY, 2003, J PINEAL RES, V34, P95, DOI 10.1034/j.1600-079X.2003.00010.x; Costa EJX, 1997, FEBS LETT, V416, P103, DOI 10.1016/S0014-5793(97)01178-2; Costantino G, 1998, EUR J PHARMACOL, V363, P57, DOI 10.1016/S0014-2999(98)00673-6; Crespo E, 1999, FASEB J, V13, P1537; Cuzzocrea S, 1997, J PINEAL RES, V23, P106, DOI 10.1111/j.1600-079X.1997.tb00342.x; Cuzzocrea S, 2001, PHARMACOL REV, V53, P135; Dawson VL, 1996, J CHEM NEUROANAT, V10, P179, DOI 10.1016/0891-0618(96)00148-2; Deng YQ, 2005, ACTA PHARMACOL SIN, V26, P519, DOI 10.1111/j.1745-7254.2005.00102.x; Droge W, 2003, ADV EXP MED BIOL, V543, P191; Duchossoy Y, 2001, CLIN CHEM LAB MED, V39, P362, DOI 10.1515/CCLM.2001.057; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; Emerit J, 2004, BIOMED PHARMACOTHER, V58, P39, DOI 10.1016/j.biopha.2003.11.004; ENDOH M, 1994, BRAIN RES, V651, P92, DOI 10.1016/0006-8993(94)90683-1; Escames G, 2003, FASEB J, V17, P932, DOI 10.1096/fj.02-0692fje; Esposito E, 2008, J PINEAL RES, V45, P149, DOI 10.1111/j.1600-079X.2008.00569.x; Esposito E, 2009, J PINEAL RES, V46, P79, DOI 10.1111/j.1600-079X.2008.00633.x; Feng Z, 2006, FREE RADICAL BIO MED, V40, P101, DOI 10.1016/j.freeradbiomed.2005.08.014; Feng Z, 2004, FREE RADICAL BIO MED, V37, P1790, DOI 10.1016/j.freeradbiomed.2004.08.023; Feng Z, 2004, J PINEAL RES, V37, P198, DOI 10.1111/j.1600-079X.2004.00158.x; Feng Z, 2004, J PINEAL RES, V37, P129, DOI 10.1111/j.1600-079X.2004.00144.x; Floyd RA, 2002, NEUROBIOL AGING, V23, P795, DOI 10.1016/S0197-4580(02)00019-2; FLOYD RA, 1993, TOXICOL IND HEALTH, V9, P197, DOI 10.1177/0748233793009001-214; Fu XY, 2001, J BIOL CHEM, V276, P41279, DOI 10.1074/jbc.M106958200; Fujimoto T, 2000, SPINE, V25, P769, DOI 10.1097/00007632-200004010-00003; Garcia JJ, 1999, J BIOENERG BIOMEMBR, V31, P609, DOI 10.1023/A:1005425213253; Garcia-Navarro A, 2007, J PINEAL RES, V43, P195, DOI 10.1111/j.1600-079X.2007.00463.x; Gegg ME, 2003, J NEUROCHEM, V86, P228, DOI 10.1046/j.1471-4159.2003.01821.x; Genovese T, 2005, J PINEAL RES, V38, P198, DOI 10.1111/j.1600-079X.2004.00194.x; Genovese T, 2006, J NEUROSURG-SPINE, V4, P145, DOI 10.3171/spi.2006.4.2.145; Genovese T, 2007, J PINEAL RES, V43, P140, DOI 10.1111/j.1600-079X.2007.00454.x; Gilad E, 1998, FASEB J, V12, P685; Gitto E, 2005, J PINEAL RES, V39, P287, DOI 10.1111/j.1600-079X.2005.00251.x; Guenther AL, 2005, J PINEAL RES, V39, P251, DOI 10.1111/j.1600-079X.2005.00242.x; GUINJOAN SM, 2008, WORLD J BIOL PSYCHIA, V20, P1; Gul S, 2005, SURG NEUROL, V64, P355, DOI 10.1016/j.surneu.2005.03.036; Gutierrez-Cuesta J, 2008, J PINEAL RES, V45, P497, DOI 10.1111/j.1600-079X.2008.00626.x; HAGAN RM, 1995, TRENDS PHARMACOL SCI, V16, P81, DOI 10.1016/S0165-6147(00)88985-3; Hardeland R, 2007, J PINEAL RES, V43, P382, DOI 10.1111/j.1600-079X.2007.00489.x; HARLAN JM, 1987, SEMIN THROMB HEMOST, V13, P434, DOI 10.1055/s-2007-1003520; Hausmann O, 2003, SPINAL CORD, V41, P369, DOI 10.1038/sj.sc.3101483; HILL JM, 1984, NEUROSCIENCE, V11, P595, DOI 10.1016/0306-4522(84)90046-0; HIRATA F, 1974, J BIOL CHEM, V249, P1311; Hsu JYC, 2006, J NEUROSCI, V26, P9841, DOI 10.1523/JNEUROSCI.1993-06.2006; HUERTODELGADILLO L, 1994, J PINEAL RES, V17, P55, DOI 10.1111/j.1600-079X.1994.tb00114.x; Iacovitti L, 1997, BRAIN RES, V768, P317, DOI 10.1016/S0006-8993(97)00668-9; Iacovitti L, 1999, BRAIN RES, V816, P276, DOI 10.1016/S0006-8993(98)00955-X; Jacob S, 2002, J PINEAL RES, V33, P186, DOI 10.1034/j.1600-079X.2002.02943.x; Jahnke G, 1999, TOXICOL SCI, V50, P271, DOI 10.1093/toxsci/50.2.271; Jan JE, 2000, J PINEAL RES, V29, P34, DOI 10.1034/j.1600-079X.2000.290105.x; Jang MH, 2005, NEUROSCI LETT, V380, P26, DOI 10.1016/j.neulet.2005.01.003; Jesudason EP, 2007, MOL CELL BIOCHEM, V298, P69, DOI 10.1007/s11010-006-9353-x; Jockers R, 2008, BRIT J PHARMACOL, V154, P1182, DOI 10.1038/bjp.2008.184; Joo JY, 1998, RESTOR NEUROL NEUROS, V13, P185; Jou MJ, 2007, J PINEAL RES, V43, P389, DOI 10.1111/j.1600-079X.2007.00490.x; Jou MJ, 2004, J PINEAL RES, V37, P55, DOI 10.1111/j.1600-079X.2004.00140.x; Kaptanoglu E, 2000, J NEUROSURG, V93, P77, DOI 10.3171/spi.2000.93.1.0077; Kilic E, 2004, J PINEAL RES, V36, P171, DOI 10.1046/j.1600-079X.2003.00115.x; Kilic U, 2005, J PINEAL RES, V38, P67, DOI 10.1111/j.1600-079X.2004.00178.x; KIRWAN JR, 1995, NEW ENGL J MED, V333, P142, DOI 10.1056/NEJM199507203330302; Klusman I, 1997, BRAIN RES, V762, P173, DOI 10.1016/S0006-8993(97)00381-8; KNEISLEY LW, 1978, J NEURAL TRANSM, P311; Koh PO, 2008, J PINEAL RES, V44, P101, DOI 10.1111/j.1600-079X.2007.00495.x; Koh PO, 2008, J VET MED SCI, V70, P1219, DOI 10.1292/jvms.70.1219; Korkmaz A, 2009, MOL MED, V15, P43, DOI 10.2119/molmed.2008.00117; Kostrzewa RM, 2003, NEUROTOX RES, V5, P375, DOI 10.1007/BF03033166; LaFleur M, 1996, J EXP MED, V184, P2311; Leon J, 2005, J PINEAL RES, V38, P1, DOI 10.1111/j.1600-079X.2004.00181.x; Leon J, 2006, J NEUROCHEM, V98, P2023, DOI 10.1111/j.1471-4159.2006.04029.x; Leonard BE, 1996, PHARMACOL BIOCHEM BE, V54, P299, DOI 10.1016/0091-3057(95)02158-2; Li XC, 2005, EUR J PHARMACOL, V510, P25, DOI 10.1016/j.ejphar.2005.01.023; LI Y, 1989, CLIN ENDOCRINOL, V30, P47, DOI 10.1111/j.1365-2265.1989.tb03726.x; Limson J, 1998, J PINEAL RES, V24, P15, DOI 10.1111/j.1600-079X.1998.tb00361.x; Lin AMY, 2000, FREE RADICAL BIO MED, V28, P904, DOI 10.1016/S0891-5849(00)00169-6; LINDSEY RZG, 2003, TRAUMA, P459; Ling X, 1999, ACTA PHARMACOL SIN, V20, P409; Liu JB, 2004, CHINESE MED J-PEKING, V117, P571; Liu RY, 1999, J CLIN ENDOCR METAB, V84, P323, DOI 10.1210/jc.84.1.323; Liu SJ, 2002, ACTA PHARMACOL SIN, V23, P183; Lopez A, 2009, J PINEAL RES, V46, P188, DOI 10.1111/j.1600-079X.2008.00647.x; Lu B, 2006, J IMMUNOL, V176, P6785, DOI 10.4049/jimmunol.176.11.6785; Mahlberg R, 2008, NEUROBIOL AGING, V29, P203, DOI 10.1016/j.neurobiolaging.2006.10.003; Mailliet F, 2005, BIOCHEM PHARMACOL, V71, P74, DOI 10.1016/j.bcp.2005.09.030; Maldonado MD, 2007, J PINEAL RES, V42, P1, DOI 10.1111/j.1600-079X.2006.00376.x; Maldonado MD, 2006, NEUROENDOCRINOL LETT, V27, P601; Manda K, 2007, J PINEAL RES, V42, P386, DOI 10.1111/j.1600-079X.2007.00432.x; MARCHETTI B, 1997, FRONT BIOSCI, V5, pD88; Martin M, 2000, FASEB J, V14, P1677; Martin V, 2002, J PINEAL RES, V33, P204, DOI 10.1034/j.1600-079X.2002.02113.x; Martinez GR, 2005, ENDOCRINE, V27, P111, DOI 10.1385/ENDO:27:2:111; Mayo JC, 2005, J NEUROIMMUNOL, V165, P139, DOI 10.1016/j.jneuroim.2005.05.002; Mayo JC, 2003, FREE RADICAL RES, V37, P543, DOI 10.1080/1071576031000083206; McTigue DM, 1998, J NEUROSCI RES, V53, P368, DOI 10.1002/(SICI)1097-4547(19980801)53:3<368::AID-JNR11>3.0.CO;2-1; MENENDEZPELAEZ A, 1987, BIOCHEM BIOPH RES CO, V145, P1231, DOI 10.1016/0006-291X(87)91569-5; Minagar A, 2002, J NEUROL SCI, V202, P13, DOI 10.1016/S0022-510X(02)00207-1; Mohan N, 1995, BIOCHEM MOL BIOL INT, V37, P1063; Morera AL, 2006, J PINEAL RES, V41, P279, DOI 10.1111/j.1600-079X.2006.00365.x; Mott JD, 2004, CURR OPIN CELL BIOL, V16, P558, DOI 10.1016/j.ceb.2004.07.010; Murphy MP, 1999, BBA-BIOENERGETICS, V1411, P401, DOI 10.1016/S0005-2728(99)00029-8; Nesic O, 2008, J NEUROCHEM, V105, P628, DOI 10.1111/j.1471-4159.2007.05177.x; Nesic-Taylor O, 2005, J NEUROSCI RES, V79, P628, DOI 10.1002/jnr.20400; Noble LJ, 2002, J NEUROSCI, V22, P7526; Nosjean O, 2000, J BIOL CHEM, V275, P31311, DOI 10.1074/jbc.M005141200; Onuki J, 2005, J PINEAL RES, V38, P107, DOI 10.1111/j.1600-079X.2004.00180.x; Ozcankaya R, 2002, CROAT MED J, V43, P28; Pajovic SB, 2003, PHYSIOL RES, V52, P189; Paparrigopoulos T, 2001, J AFFECT DISORDERS, V65, P307, DOI 10.1016/S0165-0327(00)00270-6; Pappolla MA, 2002, J PINEAL RES, V32, P135, DOI 10.1034/j.1600-079x.2002.1o838.x; Pappolla MA, 1997, J NEUROSCI, V17, P1683; Pappolla MA, 2000, J NEURAL TRANSM, V107, P203, DOI 10.1007/s007020050018; Peyrot F, 2008, J PINEAL RES, V45, P235, DOI 10.1111/j.1600-079X.2008.00580.x; PIERI C, 1994, LIFE SCI, V55, pPL271, DOI 10.1016/0024-3205(94)00666-0; POEGGELER B, 1993, J PINEAL RES, V14, P151, DOI 10.1111/j.1600-079X.1993.tb00498.x; Pozo D, 1997, J CELL BIOCHEM, V65, P430, DOI 10.1002/(SICI)1097-4644(19970601)65:3<430::AID-JCB12>3.0.CO;2-J; Ravindra T, 2006, Indian J Med Sci, V60, P523; Rebrin I, 2005, FREE RADICAL BIO MED, V39, P549, DOI 10.1016/j.freeradbiomed.2005.04.008; Reiter RJ, 2007, ADV MED SCI-POLAND, V52, P11; Reiter RJ, 2007, J PHYSIOL PHARMACOL, V58, P5; Reiter RJ, 1999, ANN NY ACAD SCI, V890, P471, DOI 10.1111/j.1749-6632.1999.tb08028.x; Reiter RJ, 2005, EXP BIOL MED, V230, P104; Reiter RJ, 2000, BIOL SIGNAL RECEPT, V9, P160; Reiter RJ, 2003, BEST PRACT RES CL EN, V17, P273, DOI 10.1016/S1521-690X(03)00016-2; Reiter RJ, 1999, BIOL SIGNAL RECEPT, V8, P56; Reiter RJ, 2001, ANN NY ACAD SCI, V939, P200; REITER RJ, 1995, FASEB J, V9, P526; REITER RJ, 1991, MOL CELL ENDOCRINOL, V79, pC153, DOI 10.1016/0303-7207(91)90087-9; Reiter RJ, 2008, NEUROENDOCRINOL LETT, V29, P391; REPPERT SM, 1979, ENDOCRINOLOGY, V104, P295, DOI 10.1210/endo-104-2-295; Reppert SM, 1997, J BIOL RHYTHM, V12, P528, DOI 10.1177/074873049701200606; Ressmeyer AR, 2003, REDOX REP, V8, P205, DOI 10.1179/135100003225002709; Rodriguez MI, 2008, EXP GERONTOL, V43, P749, DOI 10.1016/j.exger.2008.04.003; Rodriguez MI, 2007, J PINEAL RES, V42, P272, DOI 10.1111/j.1600-079X.2006.00416.x; Rodriguez MI, 2007, FREE RADICAL RES, V41, P15, DOI 10.1080/10715760600936359; Rosen J, 2006, J PINEAL RES, V41, P374, DOI 10.1111/j.1600-079X.2006.00379.x; Rosenberg GA, 1996, NEUROLOGY, V46, P1626, DOI 10.1212/WNL.46.6.1626; Rosenberg GA, 1998, STROKE, V29, P2189, DOI 10.1161/01.STR.29.10.2189; ROSENBLUTH J, 1980, J COMP NEUROL, V194, P639, DOI 10.1002/cne.901940310; Samantaray S, 2008, J PINEAL RES, V44, P348, DOI 10.1111/j.1600-079X.2007.00534.x; Sanchez-Hidalgo M, 2007, AM J PHYSIOL-REG I, V292, pR2208, DOI 10.1152/ajpregu.00013.2007; Sanchez-Moreno C, 2004, J NUTR, V134, P655; Scheer FAJL, 2006, SPINAL CORD, V44, P78, DOI 10.1038/sj.sc.3101784; Seabra WDV, 2000, J PINEAL RES, V29, P193; Sewerynek E, 2002, NEUROENDOCRINOL LETT, V23, P79; SHAPIRO SD, 2000, J CELL SCI 19, V113, P3355; Smirnov AN, 2001, BIOCHEMISTRY-MOSCOW+, V66, P19, DOI 10.1023/A:1002821427018; Southgate G, 1999, METAB BRAIN DIS, V14, P165, DOI 10.1023/A:1020610708637; Soybir G, 2003, SURG TODAY, V33, P896, DOI 10.1007/s00595-003-2621-3; Srinivasan V, 2008, NEUROIMMUNOMODULAT, V15, P93, DOI 10.1159/000148191; STEINHILBER D, 1995, J BIOL CHEM, V270, P7037, DOI 10.1074/jbc.270.13.7037; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; STOVER SL, 1987, PARAPLEGIA, V25, P225, DOI 10.1038/sc.1987.40; Sugden D, 2004, PIGM CELL RES, V17, P454, DOI 10.1111/j.1600-0749.2004.00185.x; Sun FY, 2002, J PINEAL RES, V33, P48, DOI 10.1034/j.1600-079X.2002.01891.x; Swarnakar S, 2007, J PINEAL RES, V43, P56, DOI 10.1111/j.1600-079X.2007.00443.x; Szczepanik A, 2007, J PHYSIOL PHARMACOL, V58, P115; Tan DX, 2007, J PINEAL RES, V42, P28, DOI 10.1111/j.1600-079X.2006.00407.x; Tan DX, 2007, J PINEAL RES, V43, P317, DOI 10.1111/j.1600-079X.2007.00513.x; Tan Dun-Xian, 2002, Current Topics in Medicinal Chemistry, V2, P181, DOI 10.2174/1568026023394443; Tan DX, 2003, J PINEAL RES, V34, P75, DOI 10.1034/j.1600-079X.2003.02111.x; Tan DX, 1999, BBA-GEN SUBJECTS, V1472, P206, DOI 10.1016/S0304-4165(99)00125-7; Tan DX, 2000, FREE RADICAL BIO MED, V29, P1177, DOI 10.1016/S0891-5849(00)00435-4; Tan DX, 2000, BIOL SIGNAL RECEPT, V9, P137; Taskiran D, 2000, INT J NEUROSCI, V104, P63, DOI 10.3109/00207450009035009; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; Taupin Philippe, 2008, Int J Med Sci, V5, P127; Tjong YW, 2008, J PINEAL RES, V44, P234, DOI 10.1111/j.1600-079X.2007.00515.x; Tomas-Zapico C, 2005, J PINEAL RES, V39, P99, DOI 10.1111/j.1600-079X.2005.00248.x; Topsakal C, 2003, SPINE, V28, P1643, DOI 10.1097/00007632-200308010-00004; Tu YJ, 2004, PAIN, V109, P340, DOI 10.1016/j.pain.2004.01.027; Tunez I, 2004, J PINEAL RES, V37, P252, DOI 10.1111/j.1600-079X.2004.00163.x; Tyor WR, 2002, J NEUROL SCI, V200, P33, DOI 10.1016/S0022-510X(02)00113-2; Vaillant C, 1999, J NEUROSCI, V19, P4994; Vane JR, 1998, INFLAMM RES, V47, pS78; Veneroso C, 2009, J PINEAL RES, V47, P184, DOI 10.1111/j.1600-079X.2009.00699.x; Wang DL, 2004, J PINEAL RES, V37, P11, DOI 10.1111/j.1600-079X.2004.00130.x; Wang FM, 2005, TELLUS A, V57, P12, DOI 10.1111/j.1600-0870.2005.00088.x; Wang JZ, 2006, ACTA PHARMACOL SIN, V27, P41, DOI 10.1111/j.1745-7254.2006.00260.x; Wang X, 2009, STROKE, V40, P1877, DOI 10.1161/STROKEAHA.108.540765; Weishaupt JH, 2006, J PINEAL RES, V41, P313, DOI 10.1111/j.1600-079X.2006.00377.x; Wells JEA, 2003, J NEUROSCI, V23, P10107, DOI 10.1523/jneurosci.23-31-10107.2003; Witt-Enderby PA, 2003, LIFE SCI, V72, P2183, DOI 10.1016/S0024-3205(03)00098-5; Xiong YQ, 2007, J NEUROCHEM, V100, P639, DOI 10.1111/j.1471-4159.2006.04312.x; Xu Z, 2006, LIFE SCI, V79, P1895, DOI 10.1016/j.lfs.2006.06.023; Yeung HM, 2008, J PINEAL RES, V45, P373, DOI 10.1111/j.1600-079X.2008.00601.x; Yong VW, 2001, NAT REV NEUROSCI, V2, P502, DOI 10.1038/35081571; Yun HY, 1997, MOL PSYCHIATR, V2, P300, DOI 10.1038/sj.mp.4000272; Yune TY, 2003, J NEUROTRAUM, V20, P207, DOI 10.1089/08977150360547116; Zeitzer JM, 2000, J CLIN ENDOCR METAB, V85, P2189, DOI 10.1210/jc.85.6.2189; Zeitzer JM, 2005, J SPINAL CORD MED, V28, P55, DOI 10.1080/10790268.2005.11753798; Zhou JF, 2008, J PINEAL RES, V45, P157, DOI 10.1111/j.1600-079X.2008.00570.x	224	235	249	1	25	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1570-159X	1875-6190		CURR NEUROPHARMACOL	Curr. Neuropharmacol.	SEP	2010	8	3					228	242		10.2174/157015910792246155			15	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	645FK	WOS:000281436200008	21358973	Green Published			2021-06-18	
J	Kharatishvili, I; Nissinen, JP; McIntosh, TK; Pitkanen, A				Kharatishvili, I.; Nissinen, J. P.; McIntosh, T. K.; Pitkanen, A.			A model of posttraumatic epilepsy induced by lateral fluid-percussion brain injury in rats	NEUROSCIENCE			English	Article						traumatic brain injury; video-EEG; recurrent seizures; hippocampal damage	TEMPORAL-LOBE EPILEPSY; STEREOLOGICAL ESTIMATION; ELECTRICAL-STIMULATION; SEIZURE ACTIVITY; HEAD-INJURY; HIPPOCAMPUS; TRAUMA; TIME; PROGRESSION; MECHANISMS	Although traumatic brain injury is a major cause of symptomatic epilepsy, the mechanism by which it leads to recurrent seizures is unknown. An animal model of posttraumatic epilepsy that reliably reproduces the clinical sequelae of human traumatic brain injury is essential to identify the molecular and cellular substrates of posttraumatic epileptogenesis, and perform preclinical screening of new antiepileptogenic compounds. We studied the electrophysiologic, behavioral, and structural features of posttraumatic epilepsy induced by severe, non-penetrating lateral fluid-percussion brain injury in rats. Data from two independent experiments indicated that 43% to 50% of injured animals developed epilepsy, with a latency period between 7 weeks to 1 year. Mean seizure frequency was 0.3 +/- 0.2 seizures per day and mean seizure duration was 113 +/- 46 s. Behavioral seizure severity increased over time in the majority of animals. Secondarily-generalized seizures comprised an average of 66 +/- 37% of all seizures. Mossy fiber sprouting was increased in the ipsilateral hippocampus of animals with posttraumatic epilepsy compared with those subjected to traumatic brain injury without epilepsy. Stereologic cell counts indicated a loss of dentate hilar neurons ipsilaterally following traumatic brain injury. Our data suggest that posttraumatic epilepsy occurs with a frequency of 40% to 50% after severe non-penetrating fluid-percussion brain injury in rats, and that the lateral fluid percussion model can serve as a clinically-relevant tool for pathophysiologic and preclinical studies. (c) 2006 IBRO. Published by Elsevier Ltd. All rights reserved.	Univ Kuopio, AI Virtanen Inst Mol Sci, Epilepsy Res Lab, FIN-70211 Kuopio, Finland; Univ Penn, Dept Neurosurg, Traumat Brain Injury Lab, Philadelphia, PA 19014 USA; Kuopio Univ Hosp, Dept Neurol, FIN-70211 Kuopio, Finland	Pitkanen, A (corresponding author), Univ Kuopio, AI Virtanen Inst Mol Sci, Epilepsy Res Lab, POB 1627, FIN-70211 Kuopio, Finland.	asla.pitkanen@uku.fi			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, P01NS008803, R01NS040978] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS40978, NS08803] Funding Source: Medline		Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; BERTRAM EH, 1994, BRAIN RES, V661, P157, DOI 10.1016/0006-8993(94)91192-4; CAVAZOS JE, 1991, J NEUROSCI, V11, P2795; CAVENESS WF, 1976, EPILEPSIA, V17, P207, DOI 10.1111/j.1528-1157.1976.tb03398.x; Coulter DA, 1996, EPILEPSY RES, V26, P81, DOI 10.1016/S0920-1211(96)00044-7; D'Ambrosio R, 2005, BRAIN, V128, P174, DOI 10.1093/brain/awh337; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; DASILVA AM, 1990, ACT NEUR S, V50, P48; Diaz-Arrastia R, 2000, ARCH NEUROL-CHICAGO, V57, P1611, DOI 10.1001/archneur.57.11.1611; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; Floyd CL, 2002, J NEUROTRAUM, V19, P303, DOI 10.1089/089771502753594873; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Golarai G, 2001, J NEUROSCI, V21, P8523; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Haltiner AM, 1997, ARCH PHYS MED REHAB, V78, P835, DOI 10.1016/S0003-9993(97)90196-9; HAUSER WA, 1991, EPILEPSIA, V32, P429, DOI 10.1111/j.1528-1157.1991.tb04675.x; Haut SR, 2005, EPILEPSIA, V46, P146, DOI 10.1111/j.0013-9580.2005.29004.x; Herman ST, 2002, NEUROLOGY, V59, pS21, DOI 10.1212/WNL.59.9_suppl_5.S21; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hudak AM, 2004, J HEAD TRAUMA REHAB, V19, P290, DOI 10.1097/00001199-200407000-00003; Langendorf F, 1997, EPILEPSY COMPREHENSI, P2469; Laurer HL, 1999, CURR OPIN NEUROL, V12, P715, DOI 10.1097/00019052-199912000-00010; Lehnertz K, 2005, CLIN NEUROPHYSIOL, V116, P493, DOI 10.1016/j.clinph.2004.08.020; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MATHERN GW, 1995, BRAIN, V118, P105, DOI 10.1093/brain/118.1.105; Mathern GW, 1996, EPILEPSY RES, V26, P151, DOI 10.1016/S0920-1211(96)00052-6; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McKee JA, 2005, CRIT CARE MED, V33, P661, DOI 10.1097/01.ccm.0000156293.35868.b2; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; Nissinen J, 2000, EPILEPSY RES, V38, P177, DOI 10.1016/S0920-1211(99)00088-1; Nissinen J, 2001, HIPPOCAMPUS, V11, P299, DOI 10.1002/hipo.1044; Pitkanen A, 2006, MODELS OF SEIZURES AND EPILEPSY, P465, DOI 10.1016/B978-012088554-1/50039-6; PohlmannEden B, 1997, ACTA NEUROL SCAND, V95, P257, DOI 10.1111/j.1600-0404.1997.tb00206.x; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; SALZMAN SK, 1993, RES COMMUN CHEM PATH, V80, P59; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; SLOVITER RS, 1982, BRAIN RES BULL, V8, P771, DOI 10.1016/0361-9230(82)90104-6; Stables James P., 2002, Epilepsia, V43, P1410, DOI 10.1046/j.1528-1157.2002.06702.x; Statler KD, 2000, J NEUROTRAUM, V17, P1179, DOI 10.1089/neu.2000.17.1179; Sutula TP, 2005, EPILEPSY BEHAV, V6, P296, DOI 10.1016/j.yebeh.2005.02.009; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Temkin N R, 1995, New Horiz, V3, P518; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; THEODORE WH, 1994, NEUROLOGY, V44, P1403, DOI 10.1212/WNL.44.8.1403; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Toth Z, 1997, J NEUROSCI, V17, P8106; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411	51	235	236	0	15	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		2006	140	2					685	697		10.1016/j.neuroscience.2006.03.012			13	Neurosciences	Neurosciences & Neurology	047TU	WOS:000237902400024	16650603				2021-06-18	
J	Collins, MW; Iverson, GL; Lovell, MR; McKeag, DB; Norwig, J; Maroon, J				Collins, MW; Iverson, GL; Lovell, MR; McKeag, DB; Norwig, J; Maroon, J			On-field predictors of neuropsychological and symptom deficit following sports-related concussion	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; sports; grading systems; severity; loss of consciousness; ImPACT	MILD HEAD-INJURY; CEREBRAL CONCUSSION; TEST-PERFORMANCE; SAFE RETURN; CONSCIOUSNESS; RETROGRADE; RECOVERY; AMNESIA; PATHOPHYSIOLOGY; IMPAIRMENT	Objective: Investigate the relationship between on-field markers of concussion severity and postinjury neuropsychological and symptom presentation in an athlete-specific population. Design: Case control study. Setting: Multicenter analysis of high school and college athletes. Participants: A total of 78 athletes sustaining sports-related concussion were selected from a larger sample of 139 concussed athletes. Assessment of Predictor Variables: On-field presence of disorientation, posttraumatic amnesia, retrograde amnesia, and loss of consciousness. Main Outcome Measures: ImPACT, a computerized neuropsychological test battery, was administered pre-season and, on average, 2 days postinjury. Good postinjury presentation (n = 44) was defined as no measurable change, relative to baseline, in terms of both ImPACT memory and symptom composite scores. Poor presentation (n = 34) was defined as a 10-point increase in symptom reporting and 10-point decrease in memory functioning (exceeding the 80% confidence interval for measurement error on ImPACT). Athletes failing to meet good or poor selection criteria (n = 61) were not included in the analysis. Results: Odds ratios revealed that athletes demonstrating poor presentation at 2 days postinjury were over 10 times more likely (P < 0.001) to have exhibited retrograde amnesia following concussive injury when compared with athletes exhibiting good presentation. Similarly, athletes with poor presentation were over 4 times more likely (P < 0.013) to have exhibited posttraumatic amnesia and at least 5 minutes of mental status change. There were no differences between good and poor presentation groups in terms of on-field loss of consciousness. Conclusions: The presence of amnesia, not loss of consciousness, appears predictive of symptom and neurocognitive deficits following concussion in athletes. Athletes presenting with on-field amnesia should undergo comprehensive and individualized assessment prior to returning to sport participation. Continued refinement of sports concussion grading scales is war-ranted in lieu of consistent findings that brief loss of consciousness is not predictive of concussion injury severity.	Univ Pittsburgh, Med Ctr, Dept Orthopaed Surg, Ctr Sports Med,Sports Concuss Program, Pittsburgh, PA 15203 USA; Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Pittsburgh, PA USA; Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada; Indiana Univ, Sch Med, Dept Family Med, Indianapolis, IN USA; Indiana Univ, Sch Med, Ctr Sports Med, Indianapolis, IN USA; Pittsburgh Steelers Football Club, Pittsburgh, PA USA	Collins, MW (corresponding author), Univ Pittsburgh, Med Ctr, Dept Orthopaed Surg, Ctr Sports Med,Sports Concuss Program, 3200 S Water St, Pittsburgh, PA 15203 USA.			Iverson, Grant/0000-0001-7348-9570			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; BENSON DF, 1967, J NEUROL NEUROSUR PS, V30, P539, DOI 10.1136/jnnp.30.6.539; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Cartlidge N E, 1981, HEAD INJURY; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P224; Collins Michael W, 2002, Curr Sports Med Rep, V1, P12; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; FISHER CM, 1966, NEUROLOGY, V16, P826, DOI 10.1212/WNL.16.8.826; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Giza CC, 2001, J ATHL TRAINING, V36, P228; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; Iverson GL, 2000, ARCH CLIN NEUROPSYCH, V15, P643, DOI 10.1016/S0887-6177(99)00048-7; IVERSON GL, 2002, NAT AC NEUR ANN C OC; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Johnston KM, 2001, CLIN J SPORT MED, V11, P166, DOI 10.1097/00042752-200107000-00007; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 2001, J ATHL TRAINING, V36, P249; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Lovell MR, 2000, NEUROLOGIC ATHLETIC, P32; LOVELL MR, 2001, NEUROSURGICAL TOPICS, P24; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrory P, 2001, CLIN J SPORT MED, V11, P160, DOI 10.1097/00042752-200107000-00006; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PLUM F, 1982, DIAGNOSIS STUPOR COM, P3; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002; Schnirring L, 2001, PHYSICIAN SPORTSMED, V29, P11; SYMONDS C, 1962, LANCET, V1, P1; SYMONDS CP, 1928, BRIT MED J, V4, P829; WILSON JTL, 1994, J NEUROL NEUROSUR PS, V56, P198; YARNELL PR, 1970, LANCET, V1, P863	40	235	239	0	32	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1050-642X			CLIN J SPORT MED	Clin. J. Sport Med.	JUL	2003	13	4					222	229		10.1097/00042752-200307000-00005			8	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	705AQ	WOS:000184374400005	12855924				2021-06-18	
J	MCINTOSH, TK				MCINTOSH, TK			NOVEL PHARMACOLOGICAL THERAPIES IN THE TREATMENT OF EXPERIMENTAL TRAUMATIC BRAIN INJURY - A REVIEW	JOURNAL OF NEUROTRAUMA			English	Article							SPINAL-CORD INJURY; FOCAL CEREBRAL-ISCHEMIA; PLATELET-ACTIVATING FACTOR; CENTRAL NERVOUS-SYSTEM; EXCITATORY AMINO-ACIDS; D-ASPARTATE ANTAGONIST; SEVERE HEAD-INJURY; EXTRACELLULAR POTASSIUM CONCENTRATION; EXPERIMENTAL SUBARACHNOID HEMORRHAGE; IMPROVES NEUROLOGICAL RECOVERY	Delayed or secondary neuronal damage following traumatic injury to the central nervous system (CNS) may result from pathologic changes in the brain's endogenous neurochemical systems. Although the precise mechanisms mediating secondary damage are poorly understood, posttraumatic neurochemical changes may include overactivation of neurotransmitter release or re-uptake, changes in presynaptic or postsynaptic receptor binding, or the pathologic release or synthesis of endogenous ''autodestructive'' factors. The identification and characterization of these factors and the timing of the neurochemical cascade after CNS injury provides a window of opportunity for treatment with pharmacologic agents that modify synthesis, release, receptor binding, or physiologic activity with subsequent attenuation of neuronal damage and improvement in outcome. Over the past decade, a number of studies have suggested that modification of postinjury events through pharmacologic intervention can promote functional recovery in both a variety of animal models and clinical CNS injury. This article summarizes recent work suggesting that pharmacologic manipulation of endogenous systems by such diverse pharmacologic agents as anticholinergics, excitatory amino acid antagonists, endogenous opioid antagonists, catecholamines, serotonin antagonists, modulators of arachidonic acid, antioxidants and free radical scavengers, steroid and lipid peroxidation inhibitors, platelet activating factor antagonists, anion exchange inhibitors, magnesium, gangliosides, and calcium channel antagonists may improve functional outcome after brain injury.		MCINTOSH, TK (corresponding author), UNIV PENN, DEPT NEUROSURG, DIV NEUROSURG, 3400 SPRUCE ST, PHILADELPHIA, PA 19104 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS008803, R55NS026818, R01NS026818, P50NS008803] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS26818, NS08803] Funding Source: Medline		ABE K, 1987, J NEUROCHEM, V48, P503, DOI 10.1111/j.1471-4159.1987.tb04121.x; ABE K, 1988, STROKE, V19, P480, DOI 10.1161/01.STR.19.4.480; ABE K, 1988, J CEREBR BLOOD F MET, V8, P436, DOI 10.1038/jcbfm.1988.81; AGNATI LF, 1983, ACTA PHYSIOL SCAND, V119, P347, DOI 10.1111/j.1748-1716.1983.tb07350.x; Aikawa J.W., 1981, MAGNESIUM ITS BIOL S, P21; ALBERS GW, 1989, ANN NEUROL, V25, P398, DOI 10.1002/ana.410250412; ALLEN GS, 1983, NEW ENGL J MED, V308, P619, DOI 10.1056/NEJM198303173081103; ALTURA BM, 1984, SCIENCE, V223, P1315, DOI 10.1126/science.6701524; ALTURA BT, 1982, MAGNESIUM EXP CLIN R, V1, P277; Anderson D K, 1985, Cent Nerv Syst Trauma, V2, P257; ANDERSON DK, 1988, J NEUROSURG, V69, P562, DOI 10.3171/jns.1988.69.4.0562; ANDERSON DK, 1986, J NEUROTRAUME, V2, P257; Anderson DK, 1988, J NEUROTRAUM, V5, P61, DOI 10.1089/neu.1988.5.61; Anderson DK, 1991, J NEUROTRAUM, V8, P187, DOI 10.1089/neu.1991.8.187; ANDINE P, 1991, J NEUROCHEM, V57, P222, DOI 10.1111/j.1471-4159.1991.tb02119.x; ARMSTEAD WM, 1988, CIRC RES, V62, P1, DOI 10.1161/01.RES.62.1.1; ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; Ashford CA, 1935, BIOCHEM J, V29, P157, DOI 10.1042/bj0290157; ASTRUP J, 1976, BRAIN RES, V103, P418, DOI 10.1016/0006-8993(76)90817-9; ASTRUP J, 1977, STROKE, V8, P51, DOI 10.1161/01.STR.8.1.51; ASTRUP J, 1980, BRAIN RES, V199, P161, DOI 10.1016/0006-8993(80)90238-3; ATTALI B, 1982, NEUROPEPTIDES, V3, P53, DOI 10.1016/0143-4179(82)90065-8; AULT B, 1980, J PHYSIOL-LONDON, V307, P413, DOI 10.1113/jphysiol.1980.sp013443; BABA T, 1991, J CEREBR BLOOD F MET, V11, P638, DOI 10.1038/jcbfm.1991.115; BAETHMANN A, 1986, EUR NEUROL, V25, P102, DOI 10.1159/000116105; BAKAY R, 1985, CENTRAL NERVOUS SYST, P89; BAKSHI R, 1990, NEUROSCI LETT, V110, P113, DOI 10.1016/0304-3940(90)90797-D; BAKSHI R, 1990, J NEUROSCI, V10, P3793; BARON KD, 1990, ACTA NEUROPATHOL, V39, P340; BASKIN DS, 1985, NEUROPEPTIDES, V5, P307, DOI 10.1016/0143-4179(85)90014-9; BECKER DP, 1985, CENTRAL NERVOUS SYST, P229; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; BENVENISTE H, 1991, CEREBROVAS BRAIN MET, V3, P213; BENVENISTE H, 1988, J CEREBR BLOOD F MET, V8, P713, DOI 10.1038/jcbfm.1988.118; BENVENISTE H, 1990, J CEREB BLOOD FLOW M, V59, P1; BIELENBERG GW, 1987, J CEREBR BLOOD F MET, V7, P480, DOI 10.1038/jcbfm.1987.91; BLACK KL, 1985, ANN NEUROL, V18, P349, DOI 10.1002/ana.410180313; BLACK KL, 1984, STROKE, V15, P65, DOI 10.1161/01.STR.15.1.65; BOAST CA, 1988, BRAIN RES, V442, P345, DOI 10.1016/0006-8993(88)91522-3; BOND M, 1988, CELL CALCIUM, V9, P201, DOI 10.1016/0143-4160(88)90001-2; BORNSTEIN MB, 1946, J NEUROPHYSIOL, V9, P349; BOSLEY TM, 1983, J NEUROCHEM, V40, P189, DOI 10.1111/j.1471-4159.1983.tb12670.x; BOURGAIN RH, 1985, PROSTAGLANDINS, V30, P185, DOI 10.1016/0090-6980(85)90184-4; Bourke R S, 1980, Adv Neurol, V28, P99; BOURKE RS, 1978, BRAIN RES, V154, P196, DOI 10.1016/0006-8993(78)91072-7; BOURKE RS, 1983, NEUROCHEM RES, V8, P5, DOI 10.1007/BF00965650; BOURKE RS, 1975, J NEUROCHEM, V25, P323, DOI 10.1111/j.1471-4159.1975.tb06974.x; BOURKE RS, 1981, J NEUROSURG, V55, P364, DOI 10.3171/jns.1981.55.3.0364; BOURKE RS, 1979, NEURAL TRAUMA, P95; BOXER PA, 1991, J CEREB BLOOD FLO S1, V2, P5429; BOYESON M G, 1984, Society for Neuroscience Abstracts, V10, P68; BRAAKMAN R, 1983, J NEUROSURG, V58, P326, DOI 10.3171/jns.1983.58.3.0326; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BRACKEN MB, 1992, J NEUROSURG, V76, P23, DOI 10.3171/jns.1992.76.1.0023; BRAQUET P, 1989, TRENDS PHARMACOL SCI, V10, P23, DOI 10.1016/0165-6147(89)90103-X; BRAQUET P, 1987, PHARMACOL REV, V39, P97; BRAUGHLER J, 1986, J NEUROTRAUM, V3, P153; Braughler J M, 1985, Cent Nerv Syst Trauma, V2, P269; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V7, P125, DOI 10.1016/0891-5849(89)90003-8; BRAUGHLER JM, 1987, J BIOL CHEM, V262, P10438; BRAUGHLER JM, 1988, J PHARMACOL EXP THER, V244, P423; BRAUGHLER JM, 1982, J NEUROSURG, V56, P838, DOI 10.3171/jns.1982.56.6.0838; BRAUGHLER JM, 1988, J NEUROSURG, V64, P985; BUCHAN A, 1991, J NEUROSCI, V11, P1049; BUCHAN A, 1990, J NEUROSCI, V10, P311; BUCHAN AM, 1990, CEREBROVAS BRAIN MET, V2, P1; BUCHAN AM, 1991, NEUROSCI LETT, V132, P255, DOI 10.1016/0304-3940(91)90314-J; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; BULLOCK R, 1990, J CEREBR BLOOD F MET, V10, P668, DOI 10.1038/jcbfm.1990.120; CAROLEI A, 1991, CEREBROVAS BRAIN MET, V3, P134; CAUDLE RM, 1988, BRAIN RES, V443, P329, DOI 10.1016/0006-8993(88)91628-9; Cavaliere F, 1985, Recenti Prog Med, V76, P563; CHAN PH, 1992, J NEUROTRAUM, V9, pS417; CHAN PH, 1987, ANN NEUROL, V21, P540, DOI 10.1002/ana.410210604; CHAN PH, 1980, J NEUROCHEM, V35, P1004, DOI 10.1111/j.1471-4159.1980.tb07100.x; CHAN PH, 1985, BRAIN EDEMA, P317; CHOI D, 1989, NEUR ABSTR, V2, P1113; CHOI D, 1989, TRENDS NEUROSCI, V11, P21; CHOI DW, 1990, CEREBROVAS BRAIN MET, V2, P105; CHOI DW, 1987, J NEUROSCI, V7, P369; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; CHOI DW, 1987, J NEUROSCI, V7, P357; CHURCH J, 1991, NEUROSCI LETT, V123, P65, DOI 10.1016/0304-3940(91)90159-Q; CLARK AF, 1980, J BIOL CHEM, V255, P6556; CLIFTON G L, 1989, Journal of Neurotrauma, V6, P71, DOI 10.1089/neu.1989.6.71; CLIFTON GL, 1983, J NEUROSURG, V59, P447, DOI 10.3171/jns.1983.59.3.0447; CLIFTON GL, 1981, NEUROSURGERY, V8, P309, DOI 10.1227/00006123-198103000-00002; CLIFTON GL, 1985, CENTRAL NERVOUS SYST, P139; COHN M, 1962, J BIOL CHEM, V237, P176; COLES JC, 1986, ANN THORAC SURG, V41, P551, DOI 10.1016/S0003-4975(10)63040-8; COMPTON J S, 1990, British Journal of Neurosurgery, V4, P9, DOI 10.3109/02688699009000676; COOPER PR, 1979, J NEUROSURG, V51, P307, DOI 10.3171/jns.1979.51.3.0307; COOPER PR, 1985, CENTRAL NERVOUS SYST, P217; CORBETT D, 1990, BRAIN RES, V514, P300, DOI 10.1016/0006-8993(90)91424-F; CORDON JJ, 1990, NEUR ABSTR, V2, P934; CORKEY BE, 1986, J BIOL CHEM, V261, P2567; COTMAN CW, 1987, TRENDS NEUROSCI, V10, P263, DOI 10.1016/0166-2236(87)90170-6; COX B, 1982, LIFE SCI, V31, P1655; COX JA, 1989, BRAIN RES, V499, P267, DOI 10.1016/0006-8993(89)90774-9; COYLE JT, 1983, J NEUROCHEM, V41, P1; COYLE JT, 1976, NATURE, V263, P244, DOI 10.1038/263244a0; CRAGOE EJ, 1987, MED RES REV, V7, P271, DOI 10.1002/med.2610070302; CROCKARD HA, 1977, J NEUROSURG, V46, P784, DOI 10.3171/jns.1977.46.6.0784; DAIL WG, 1981, BRAIN RES, V211, P79, DOI 10.1016/0006-8993(81)90068-8; DEFEUDIS FV, 1989, TRENDS PHARMACOL SCI, V10, P215, DOI 10.1016/0165-6147(89)90262-9; DELGADO TJ, 1986, J CEREBR BLOOD F MET, V6, P600, DOI 10.1038/jcbfm.1986.107; DEMEDIUK P, 1985, P NATL ACAD SCI USA, V82, P7071, DOI 10.1073/pnas.82.20.7071; DEMOPOULOS HB, 1982, PATHOLOGY OXYGEN, P127; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DESALLES AF, 1987, J CEREB BLOOD FLOW M, V7, pS627; DEVLIN T, 1990, J PHARMACOL EXP THER, V253, P749; DeWitt DS, 1988, J NEUROTRAUM, V5, P303, DOI 10.1089/neu.1988.5.303; DEZSI L, 1992, J CEREBR BLOOD F MET, V12, P390, DOI 10.1038/jcbfm.1992.56; DOHERTY P, 1985, NEUROSCI LETT, V62, P193, DOI 10.1016/0304-3940(85)90354-4; DOMINGO MT, 1988, BIOCHEM BIOPH RES CO, V151, P730, DOI 10.1016/S0006-291X(88)80341-3; DORSCH NWC, 1989, ACTA NEUROCHIR, V99, P65, DOI 10.1007/BF01407779; DYKENS JA, 1987, J NEUROCHEM, V49, P1222, DOI 10.1111/j.1471-4159.1987.tb10014.x; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; Eidelberg E, 1975, Surg Neurol, V3, P317; EISENBERG H, 1983, INTRACRANIAL PRESSUR, P549; ELAM R, 1988, EUR J PHARMACOL, V154, P19, DOI 10.1016/0014-2999(88)90358-5; ELLIS E F, 1989, Journal of Neurotrauma, V6, P31, DOI 10.1089/neu.1989.6.31; ELLIS EF, 1981, J NEUROCHEM, V37, P892, DOI 10.1111/j.1471-4159.1981.tb04476.x; ELLIS EF, 1987, STROKE, V18, P792, DOI 10.1161/01.STR.18.4.792; ENEVOLDSEN EM, 1976, J NEUROSURG, V44, P191, DOI 10.3171/jns.1976.44.2.0191; FADEN A I, 1989, Society for Neuroscience Abstracts, V15, P1112; FADEN AI, 1981, SCIENCE, V211, P493, DOI 10.1126/science.7455690; FADEN AI, 1992, J NEUROSCI, V12, P425; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; FADEN AI, 1981, ANN NEUROL, V10, P326, DOI 10.1002/ana.410100403; FADEN AI, 1987, J NEUROCHEM, V48, P1809, DOI 10.1111/j.1471-4159.1987.tb05740.x; FADEN AI, 1989, BRAIN RES, V486, P228, DOI 10.1016/0006-8993(89)90509-X; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FADEN AI, 1988, J PHARMACOL EXP THER, V245, P742; FADEN AI, 1986, ARCH NEUROL-CHICAGO, V43, P501, DOI 10.1001/archneur.1986.00520050073026; Faden AI, 1988, J NEUROTRAUM, V5, P33, DOI 10.1089/neu.1988.5.33; FAGG GE, 1985, TRENDS NEUROSCI, V8, P207, DOI 10.1016/0166-2236(85)90080-3; FARBER JL, 1990, ENVIRON HEALTH PERSP, V84, P107, DOI 10.2307/3430711; FARFINKEL L, 1985, MAGNESIUM, V14, P60; FASS B, 1984, J NEUROSCI RES, V12, P445, DOI 10.1002/jnr.490120228; FAVARON M, 1988, P NATL ACAD SCI USA, V85, P7351, DOI 10.1073/pnas.85.19.7351; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FEENEY DM, 1985, BRAIN RES, V342, P352, DOI 10.1016/0006-8993(85)91135-7; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1987, CRIT REV NEUROBIOL, V3, P135; FEENEY DM, 1985, PHYSIOL PSYCHOL, V13, P197; FEENEY DM, 1981, P W PHARMACOL SOC, V24, P15; FEENEY DM, 1983, PSYCHOPHARMACOLOGY, V79, P67, DOI 10.1007/BF00433018; FEENEY DM, 1988, PHARM APPROACHES TRE, P121; FEHLINGS MG, 1989, J NEUROSURG, V71, P403, DOI 10.3171/jns.1989.71.3.0403; FERRIERO DM, 1988, ANN NEUROL, V24, P670, DOI 10.1002/ana.410240512; FISHMAN PH, 1976, SCIENCE, V194, P906, DOI 10.1126/science.185697; FLAMM ES, 1982, NEUROSURGERY, V10, P227, DOI 10.1227/00006123-198202000-00009; FLAMM ES, 1978, STROKE, V9, P445, DOI 10.1161/01.STR.9.5.445; FLEISCHER JE, 1989, J CEREBR BLOOD F MET, V9, P795, DOI 10.1038/jcbfm.1989.113; Ford R W, 1985, Cent Nerv Syst Trauma, V2, P9; FORSMAN M, 1988, ACTA ANAESTH SCAND, V32, P152, DOI 10.1111/j.1399-6576.1988.tb02705.x; FRANCESCANGELI E, 1989, BIOCHEM BIOPH RES CO, V161, P107, DOI 10.1016/0006-291X(89)91567-2; FRERICHS KU, 1990, CEREBROVAS BRAIN MET, V2, P148; FRERICHS KU, 1992, IN PRESS J NEUROSURG; FUJISAWA A, 1986, STROKE, V17, P748, DOI 10.1161/01.STR.17.4.748; FUKUDA N, 1979, FOLIA PHARMACOL JPN, V75, P321, DOI 10.1254/fpj.75.321; GAUDET RJ, 1979, BIOCHEM BIOPH RES CO, V86, P893, DOI 10.1016/0006-291X(79)91796-0; GEISLER FH, 1991, NEW ENGL J MED, V324, P1829, DOI 10.1056/NEJM199106273242601; GEISLER FH, 1992, J NEUROTRAUM, V9, pS517; GELMERS HJ, 1988, NEW ENGL J MED, V318, P203, DOI 10.1056/NEJM198801283180402; Gennarelli T.A., 1985, CENTRAL NERVOUS SYST, P391; Gennarelli T.A., 1982, HEAD INJURY BASIC CL, P129; GEORGE CP, 1988, BRAIN RES, V440, P375, DOI 10.1016/0006-8993(88)91011-6; GERMANO IM, 1987, ANN NEUROL, V22, P730, DOI 10.1002/ana.410220609; GERMANO IM, 1987, J NEUROSURG, V67, P81, DOI 10.3171/jns.1987.67.1.0081; GIANNOTTA SL, 1984, NEUROSURGERY, V15, P497, DOI 10.1227/00006123-198410000-00004; GILL R, 1987, J NEUROSCI, V7, P3343; GILL R, 1988, NEUROSCIENCE, V25, P847, DOI 10.1016/0306-4522(88)90040-1; GILL R, 1992, J CEREBR BLOOD F MET, V12, P371, DOI 10.1038/jcbfm.1992.54; GINSBERG MD, 1988, NEUROCHEM PATHOL, V9, P171; GLOBUS MYT, 1989, J CEREBR BLOOD F MET, V9, P892, DOI 10.1038/jcbfm.1989.123; GLOBUS MYT, 1988, J NEUROCHEM, V51, P1455, DOI 10.1111/j.1471-4159.1988.tb01111.x; GORDON K, 1990, J NEUROCHEM, V54, P605, DOI 10.1111/j.1471-4159.1990.tb01914.x; GORIO A, 1980, BRAIN RES, V197, P236, DOI 10.1016/0006-8993(80)90451-5; GRICE SC, 1987, STROKE, V18, P787, DOI 10.1161/01.STR.18.4.787; GROSMAN M, 1987, GEN PHARMACOL, V18, P369, DOI 10.1016/0306-3623(87)90093-0; GROTTA JC, 1990, ANN NEUROL, V27, P612, DOI 10.1002/ana.410270605; GUDEMAN SK, 1979, J NEUROSURG, V51, P301, DOI 10.3171/jns.1979.51.3.0301; GUIRAMAND J, 1991, J NEUROCHEM, V57, P1501, DOI 10.1111/j.1471-4159.1991.tb06344.x; GUPTA RK, 1983, PHYSIOL CHEM PHYS, V15, P265; GUPTA RK, 1978, J BIOL CHEM, V253, P6172; Gurdjian E. S., 1944, SURG GYNECOL AND OBSTET, V78, P618; HAGBERG H, 1986, NEUROSCI LETT, V68, P311, DOI 10.1016/0304-3940(86)90508-2; HAGBERG H, 1985, J CEREBR BLOOD F MET, V5, P413, DOI 10.1038/jcbfm.1985.56; HAKIM AM, 1991, J CEREBR BLOOD F MET, V11, P762, DOI 10.1038/jcbfm.1991.133; HALKSMILLER M, 1986, J NEUROPATH EXP NEUR, V45, P471, DOI 10.1097/00005072-198607000-00008; Hall E D, 1987, Acta Anaesthesiol Belg, V38, P421; Hall E D, 1985, Cent Nerv Syst Trauma, V2, P75; Hall E D, 1986, Cent Nerv Syst Trauma, V3, P281; HALL E D, 1989, Journal of Neurotrauma, V6, P163, DOI 10.1089/neu.1989.6.163; HALL E D, 1989, Journal of Neurotrauma, V6, P169, DOI 10.1089/neu.1989.6.169; HALL ED, 1990, BRAIN RES, V513, P244, DOI 10.1016/0006-8993(90)90462-K; HALL ED, 1988, STROKE, V19, P340, DOI 10.1161/01.STR.19.3.340; HALL ED, 1982, SURG NEUROL, V18, P320, DOI 10.1016/0090-3019(82)90140-9; HALL ED, 1987, BRAIN RES, V435, P174, DOI 10.1016/0006-8993(87)91599-X; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HALL ED, 1988, STROKE, V19, P997, DOI 10.1161/01.STR.19.8.997; HALL ED, 1988, EXP NEUROL, V102, P244, DOI 10.1016/0014-4886(88)90100-8; HALL ED, 1987, J PHARMACOL EXP THER, V242, P137; HALL ED, 1992, J NEUROTRAUM, V9, pS425; HALL ED, 1986, J NEUROSURG, V64, P951, DOI 10.3171/jns.1986.64.6.0951; HALL ED, 1990, IN PRESS STROKE; HALL ED, 1989, CEREBROVASC DIS, P387; HALLENBECK JM, 1983, J NEUROSURG, V58, P749, DOI 10.3171/jns.1983.58.5.0749; HALLENBECK JM, 1979, STROKE, V10, P629, DOI 10.1161/01.STR.10.6.629; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; HANSEN AJ, 1978, ACTA PHYSIOL SCAND, V102, P324, DOI 10.1111/j.1748-1716.1978.tb06079.x; HANSEN AJ, 1985, PHYSIOL REV, V65, P101; HARRIS RJ, 1981, J CEREBR BLOOD F MET, V1, P203, DOI 10.1038/jcbfm.1981.21; Hashimoto I, 1979, Neurol Res, V1, P39; HAYES R, 1987, IEEE T SOFTWARE ENG, V13, P1254, DOI 10.1109/TSE.1987.232879; Hayes R L, 1986, Cent Nerv Syst Trauma, V3, P163; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYES RL, 1984, SCIENCE, V223, P301, DOI 10.1126/science.6701514; HAYES RL, 1983, J NEUROSURG, V58, P720, DOI 10.3171/jns.1983.58.5.0720; HAYES RL, 1984, BRAIN RES, V311, P267, DOI 10.1016/0006-8993(84)90089-1; HAYES RL, IN PRESS J NEUROSURG; HEGESTATT ED, 1981, CEREBRAL MICROCIRCUL, P141; HEIZER ML, 1988, FASEB J, V2, pA1519; HERTZ L, 1973, BRAIN RES, V60, P517, DOI 10.1016/0006-8993(73)90814-7; HERTZ L, 1981, J CEREB BLOOD FLOW M, V1, P203; HERTZ L, 1982, HDB NEUROCHEMISTRY, P319; HERTZ L, 1978, DYNAMIC PROPERTIES G, P121; HILLERED L, 1989, J CEREBR BLOOD F MET, V9, P607, DOI 10.1038/jcbfm.1989.87; HOGAN MJ, 1991, J CEREBR BLOOD F MET, V11, P771, DOI 10.1038/jcbfm.1991.134; HOLADAY JW, 1978, LIFE SCI, V22, P1537, DOI 10.1016/0024-3205(78)90009-7; HOLADAY JW, 1980, BRAIN RES, V189, P295, DOI 10.1016/0006-8993(80)90032-3; HOSSMANN KA, 1977, STROKE, V8, P77, DOI 10.1161/01.STR.8.1.77; HOSSMANN KA, 1977, BRAIN HEART INFARCT, P107; HOVDA DA, 1984, BRAIN RES, V298, P358, DOI 10.1016/0006-8993(84)91437-9; HOVDA DA, 1991, P AM ASS NEUROL SURG, V1, P452; HSU CY, 1986, J NEUROL SCI, V74, P289, DOI 10.1016/0022-510X(86)90114-0; HSU CY, 1985, NEUROLOGY, V35, P1003, DOI 10.1212/WNL.35.7.1003; HSUEH W, 1986, AM J PATHOL, V122, P231; HUBSCHMANN OR, 1985, J NEUROSURG, V62, P698, DOI 10.3171/jns.1985.62.5.0698; HUBSCHMANN OR, 1982, J NEUROSURG, V56, P216, DOI 10.3171/jns.1982.56.2.0216; HUBSCHMANN OR, 1983, J NEUROSURG, V59, P289, DOI 10.3171/jns.1983.59.2.0289; HUDSON CJ, 1991, BRAIN RES, V564, P261, DOI 10.1016/0006-8993(91)91462-A; HUETTNER JE, 1989, SCIENCE, V243, P1611, DOI 10.1126/science.2467381; IKONOMIDOU C, 1989, J NEUROSCI, V9, P1693; ISAAC L, 1989, Society for Neuroscience Abstracts, V15, P762; ISAAC L, 1990, BRAIN RES, V531, P83, DOI 10.1016/0006-8993(90)90760-9; IZUMI Y, 1991, J CEREBR BLOOD F MET, V11, P1025, DOI 10.1038/jcbfm.1991.170; JACEWICZ M, 1990, J CEREBR BLOOD F MET, V10, P89, DOI 10.1038/jcbfm.1990.11; JACEWICZ M, 1990, J CEREBR BLOOD F MET, V10, P903, DOI 10.1038/jcbfm.1990.147; Jenkins LW, 1988, J NEUROTRAUM, V5, P275, DOI 10.1089/neu.1988.5.275; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JENKINS LW, 1986, MECHANISMS SECONDARY, P273; JENKINS LW, 1989, CONT ISSUES NEUROLOG, V3, P14; JENNETT B, 1981, CONT NEUROLOGY SERIE, V20; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; JOHNSON JW, 1991, MG2PLUS EXCITABLE ME, P105; JOHSHITA H, 1989, STROKE, V20, P788, DOI 10.1161/01.STR.20.6.788; JONSSON HT, 1976, PROSTAGLANDINS, V11, P51, DOI 10.1016/0090-6980(76)90172-6; KARPIAK SE, 1984, J NEUROSCI RES, V12, P485, DOI 10.1002/jnr.490120231; KARPIAK SE, 1983, EXP NEUROL, V81, P330, DOI 10.1016/0014-4886(83)90267-4; KARPIAK SE, 1988, PHARM APPROACHES TRE, P219; KASS IS, 1988, ANESTHESIOLOGY, V69, P710, DOI 10.1097/00000542-198811000-00012; KATAYAMA Y, 1985, BRAIN RES, V334, P366, DOI 10.1016/0006-8993(85)90234-3; KATAYAMA Y, 1985, BRAIN RES, V335, P392, DOI 10.1016/0006-8993(85)90502-5; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KATAYAMA Y, 1984, BRAIN RES, V296, P241, DOI 10.1016/0006-8993(84)90062-3; KATAYAMA Y, 1989, INTRACRANIAL PRESSUR, V7, P584; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KEMP JA, 1987, TRENDS NEUROSCI, V10, P294, DOI 10.1016/0166-2236(87)90176-7; Kimelberg H K, 1987, Cent Nerv Syst Trauma, V4, P3; Kimelberg H.K., 1982, HEAD INJURY BASIC CL, P31; KIMELBERG HK, 1979, BRAIN RES, V173, P111; KIMELBERG HK, 1979, NEURAL TRAUMA, P137; KIWAK KJ, 1985, J NEUROSURG, V62, P865, DOI 10.3171/jns.1985.62.6.0865; KLECKNER NW, 1988, SCIENCE, V241, P835, DOI 10.1126/science.2841759; Kobrine A I, 1975, Surg Neurol, V3, P261; KOCHANEK PM, 1987, LIFE SCI, V41, P2639, DOI 10.1016/0024-3205(87)90278-5; KOCHANEK PM, 1988, J CEREBR BLOOD F MET, V8, P546, DOI 10.1038/jcbfm.1988.95; KOCHHAR A, 1988, ARCH NEUROL-CHICAGO, V45, P148, DOI 10.1001/archneur.1988.00520260034016; Kochhar A, 1991, J NEUROTRAUM, V8, P175, DOI 10.1089/neu.1991.8.175; KOHLER C, 1983, EXCITOTOXINS, V39, P99; KOHMURA E, 1990, J CEREBR BLOOD F MET, V10, P877, DOI 10.1038/jcbfm.1990.144; KOIDE T, 1986, J CEREBR BLOOD F MET, V6, P559, DOI 10.1038/jcbfm.1986.102; KOJIMA H, 1984, NEUROSCIENCE, V13, P1011, DOI 10.1016/0306-4522(84)90285-9; KONTOS H, 1986, J NEUROTRAUM, V3, P257; KONTOS HA, 1985, CIRC RES, V57, P508, DOI 10.1161/01.RES.57.4.508; KONTOS HA, 1985, CIRC RES, V57, P142, DOI 10.1161/01.RES.57.1.142; KONTOS HA, 1981, FED PROC, V40, P2326; KONTOS HA, 1989, CHEM-BIOL INTERACT, V72, P229, DOI 10.1016/0009-2797(89)90001-X; KORNECKI E, 1988, SCIENCE, V240, P1792, DOI 10.1126/science.3381103; Kostron H, 1985, Neurochirurgia (Stuttg), V28 Suppl 1, P103; KOSTRON H, 1984, Neurological Research, V6, P29; KRAIG RP, 1983, J NEUROPHYSIOL, V49, P831; KWO S, 1989, Journal of Neurotrauma, V6, P13, DOI 10.1089/neu.1989.6.13; LAMBERT P D, 1991, Molecular Neuropharmacology, V1, P77; LANDOLT H, 1992, J CEREBR BLOOD F MET, V12, P96, DOI 10.1038/jcbfm.1992.12; LANGFITT T, 1985, NEUROLOGY, V15, P622; LANIER WL, 1990, J CEREBR BLOOD F MET, V10, P252, DOI 10.1038/jcbfm.1990.42; LASON W, 1989, BRAIN RES, V482, P333, DOI 10.1016/0006-8993(89)91196-7; LEDEEN RW, 1978, J SUPRAMOL STR CELL, V8, P1, DOI 10.1002/jss.400080102; LEMKE M, 1987, BIOCHEM BIOPH RES CO, V147, P1170, DOI 10.1016/S0006-291X(87)80192-4; LEMKE M, 1990, NEUROSCI LETT, V108, P201, DOI 10.1016/0304-3940(90)90731-N; LESLIE JB, 1985, J NEUROSURG, V63, P659, DOI 10.3171/jns.1985.63.5.0659; LEVERE TE, 1989, BEHAV NEUROSCI, V103, P561, DOI 10.1037/0735-7044.103.3.561; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LIM KH, 1986, ANN THORAC SURG, V42, P282, DOI 10.1016/S0003-4975(10)62735-X; LIN BW, 1990, STROKE, V21, P1734, DOI 10.1161/01.STR.21.12.1734; LINDSBERG PJ, 1990, STROKE, V21, P1452, DOI 10.1161/01.STR.21.10.1452; LIPARTITI M, 1991, EXP NEUROL, V113, P301, DOI 10.1016/0014-4886(91)90019-9; LIU TH, 1989, AM J PHYSIOL, V256, pH589; LONG JB, 1987, BRAIN RES, V436, P374, DOI 10.1016/0006-8993(87)91683-0; LONG JB, 1988, J PHARMACOL EXP THER, V246, P1167; LONG JB, 1988, J PHARMACOL EXP THER, V246, P1158; LONG JB, 1989, BRAIN RES, V10, P1; LUCAS DR, 1957, ARCH OPHTHALMOL-CHIC, V58, P193; LUNDGREN J, 1991, J CEREBR BLOOD F MET, V11, P587, DOI 10.1038/jcbfm.1991.108; LYETH BG, 1992, J NEUROTRAUM, V9, pS463; LYETH BG, 1992, BRAIN RES, V569, P281, DOI 10.1016/0006-8993(92)90640-U; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; LYETH BG, 1990, NERUOTRAUMA MONITORI, P109; MABE H, 1986, STROKE, V17, P501, DOI 10.1161/01.STR.17.3.501; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MAGNONI MS, 1988, J CEREBR BLOOD F MET, V8, P96, DOI 10.1038/jcbfm.1988.12; MANAKA S, 1978, NEUROSCI LETT, V8, P255, DOI 10.1016/0304-3940(78)90131-3; MARTZ D, 1990, J CEREBR BLOOD F MET, V10, P352, DOI 10.1038/jcbfm.1990.64; MATSUMIYA N, 1992, IN PRESS STROKE; MATSUMOTO K, 1991, BRAIN RES, V543, P236, DOI 10.1016/0006-8993(91)90033-R; MAYER ML, 1990, TRENDS PHARMACOL SCI, V11, P254, DOI 10.1016/0165-6147(90)90254-6; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCBURNEY RN, 1992, J NEUROTRAUM, V9, pS531; MCDONALD JW, 1989, BRAIN RES, V490, P33, DOI 10.1016/0006-8993(89)90427-7; McINTOSH T., 1988, NEUROL NEUR, P653; MCINTOSH T K, 1988, Society for Neuroscience Abstracts, V14, P1152; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565; MCINTOSH TK, 1987, BRAIN RES, V425, P225, DOI 10.1016/0006-8993(87)90505-1; MCINTOSH TK, 1992, J NEUROTRAUM, V9, P33, DOI 10.1089/neu.1992.9.33; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1988, AM J PHYSIOL, V254, pR785; MCINTOSH TK, 1987, J CEREB BLOOD FLOW M, V7, pS620; MCINTOSH TK, 1988, PHARM APPROACH TREAT, P89; MCINTOSH TK, 1990, NEUROCHEM INT, V30, P115; MCINTOSH TK, 1988, PERSPECTIVES SHOCK R, P415; MCINTOSH TK, 1991, J CEREB BLOOD FLOW M, V11, pS734; MCINTOSH TK, 1989, J CEREB BLOOD FLO S1, V9, pS78; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MCLENNAN H, 1983, PROG NEUROBIOL, V20, P251, DOI 10.1016/0301-0082(83)90004-7; MELDRUM B, 1990, CEREBROVAS BRAIN MET, V2, P27; MELDRUM B, 1985, CLIN SCI, V68, P113, DOI 10.1042/cs0680113; MELDRUM B, 1987, NEUROTOXINS THEIR PH, P33; MEYER FB, 1990, J CEREBR BLOOD F MET, V10, P97, DOI 10.1038/jcbfm.1990.12; MEYER FB, 1990, J CEREBR BLOOD F MET, V10, P895, DOI 10.1038/jcbfm.1990.146; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MOISES HC, 1985, EUR J PHARMACOL, V108, P85, DOI 10.1016/0014-2999(85)90286-9; MONYER H, 1990, NEURON, V5, P121, DOI 10.1016/0896-6273(90)90302-V; MOORE SA, 1991, J NEUROCHEM, V56, P518, DOI 10.1111/j.1471-4159.1991.tb08180.x; MOSKOWITZ MA, 1984, SCIENCE, V224, P886, DOI 10.1126/science.6719118; NAKAYAMA H, 1988, NEUROLOGY, V38, P1667, DOI 10.1212/WNL.38.11.1667; NATALE JE, 1988, STROKE, V19, P1371, DOI 10.1161/01.STR.19.11.1371; NELLGARD B, 1991, ANESTHESIOLOGY, V75, P279, DOI 10.1097/00000542-199108000-00016; NELLGARD B, 1992, J CEREBR BLOOD F MET, V12, P2, DOI 10.1038/jcbfm.1992.2; NELSON LR, 1979, NEURAL TRAUMA, P291; NELSON LR, 1982, HEAD INJURY BASIC CL, P117; NICHOLSON C, 1980, TRENDS NEUROSCI, V3, P216, DOI 10.1016/0166-2236(80)90081-8; Nicholson C., 1979, NEUROSCIENCES 4TH ST, P457; NICOLETTI F, 1989, NEUROPHARMACOLOGY, V28, P1283, DOI 10.1016/0028-3908(89)90224-4; NIGAM R, 1986, PROSTAGLANDINS LEUKO, V233, P1; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; NUGLISCH J, 1990, J CEREBR BLOOD F MET, V10, P654, DOI 10.1038/jcbfm.1990.118; OBERPICHLER H, 1990, J CEREBR BLOOD F MET, V10, P133, DOI 10.1038/jcbfm.1990.17; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; OHMAN J, 1988, J NEUROSURG, V69, P683, DOI 10.3171/jns.1988.69.5.0683; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; OKIYAMA K, 1991, J CEREB BLOOD FLOW S, V11, pS708; OKIYAMA K, 1993, IN PRESS J NEUROTRAU; OLNEY J, 1987, EUR J PHARMACOL, V141, P357, DOI 10.1016/0014-2999(87)90552-8; Olney J, 1978, KAINIC ACID TOOL NEU, P95; OLNEY JW, 1971, EXP BRAIN RES, V14, P61; OLNEY JW, 1969, SCIENCE, V164, P719, DOI 10.1126/science.164.3880.719; OLNEY JW, 1989, J NEUROSCI, V9, P1701; ONO H, 1991, EUR J PHARMACOL, V203, P283; ONODERA H, 1989, J CEREBR BLOOD F MET, V9, P623, DOI 10.1038/jcbfm.1989.89; ORKAND RK, 1977, HDB PHYSL NERVOUS  2, V1, P855; OZYURT E, 1988, J CEREBR BLOOD F MET, V8, P138, DOI 10.1038/jcbfm.1988.18; PANETTA T, 1987, BIOCHEM BIOPH RES CO, V149, P580, DOI 10.1016/0006-291X(87)90407-4; PANTER SS, 1992, J NEUROTRAUM, V9, P47, DOI 10.1089/neu.1992.9.47; PAPPIUS HM, 1987, J NEUROCHEM, V49, P321, DOI 10.1111/j.1471-4159.1987.tb03433.x; PAPPIUS HM, 1983, J CEREBR BLOOD F MET, V3, P448, DOI 10.1038/jcbfm.1983.71; PAPPIUS HM, 1988, J CEREBR BLOOD F MET, V8, P324, DOI 10.1038/jcbfm.1988.67; PAPPIUS HM, 1983, NEUROCHEM RES, V8, P63, DOI 10.1007/BF00965654; PAPPIUS HM, 1981, ANN NEUROL, V9, P484, DOI 10.1002/ana.410090511; PARK CK, 1988, J CEREBR BLOOD F MET, V8, P757, DOI 10.1038/jcbfm.1988.124; PARK CK, 1989, J CEREBR BLOOD F MET, V9, P617, DOI 10.1038/jcbfm.1989.88; PATEL PM, 1992, J CEREBR BLOOD F MET, V12, P88, DOI 10.1038/jcbfm.1992.11; Perkins W J, 1989, J Neurosurg Anesthesiol, V1, P118, DOI 10.1097/00008506-198906000-00008; PETERS S, 1987, SCIENCE, V236, P589, DOI 10.1126/science.2883728; PHILIPPON J, 1986, ACTA NEUROCHIR, V82, P110, DOI 10.1007/BF01456369; PICKARD JD, 1989, BRIT MED J, V298, P636, DOI 10.1136/bmj.298.6674.636; PICONE CM, 1989, J CEREBR BLOOD F MET, V9, P805, DOI 10.1038/jcbfm.1989.114; PIELRONIGRA DD, 1983, J NEUROCHEM, V41, P1072; PIROTZKY E, 1984, MICROCIRC ENDOTH LYM, V1, P107; PRANZATELLI MR, 1988, J RECEPTOR RES, V8, P667, DOI 10.3109/10799898809049018; PREHN JHM, 1992, J CEREBR BLOOD F MET, V12, P78, DOI 10.1038/jcbfm.1992.10; PRIESTLEY T, 1990, BRAIN RES, V531, P183, DOI 10.1016/0006-8993(90)90772-4; Puniak MA, 1991, J NEUROTRAUM, V8, P193, DOI 10.1089/neu.1991.8.193; RAMIREZ JJ, 1991, BEHAV BRAIN RES, V43, P99, DOI 10.1016/S0166-4328(05)80057-9; RAMIREZ JJ, 1987, NEUROSCI LETT, V75, P283, DOI 10.1016/0304-3940(87)90535-0; RAMIREZ JJ, 1987, BRAIN RES, V414, P85, DOI 10.1016/0006-8993(87)91328-X; RAPPAPORT ZH, 1987, STROKE, V18, P760, DOI 10.1161/01.STR.18.4.760; ROBERTSON CS, 1986, J NEUROSURG, V64, P633, DOI 10.3171/jns.1986.64.4.0633; ROBERTSON CS, 1983, J NEUROSURG, V59, P455, DOI 10.3171/jns.1983.59.3.0455; ROBICHAUD L J, 1990, Journal of Neurotrauma, V7, P193, DOI 10.1089/neu.1990.7.193; ROBINSON MJ, 1990, CEREBROVAS BRAIN MET, V2, P205; ROBINSON SE, 1988, NEUR ABSTR, V2, P1254; ROISEN FJ, 1981, SCIENCE, V214, P577, DOI 10.1126/science.7291999; RORDORF G, 1991, J NEUROSCI, V11, P1829; ROSNER MJ, 1985, CENTRAL NERVOUS SYST, P405; ROSNER MJ, 1982, HEAD INJURY BASIC CL, P103; Ross IB, 1991, J NEUROTRAUM, V8, P229, DOI 10.1089/neu.1991.8.229; ROTHMAN SM, 1983, SCIENCE, V220, P536, DOI 10.1126/science.6836300; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; ROTHMAN SM, 1987, TRENDS NEUROSCI, V10, P299, DOI 10.1016/0166-2236(87)90177-9; RUBIN H, 1976, J CELL PHYSIOL, V89, P613, DOI 10.1002/jcp.1040890418; RUBIO I, 1991, J NEUROCHEM, V57, P1159, DOI 10.1111/j.1471-4159.1991.tb08274.x; RUGE D, 1954, J NEUROSURG, V11, P77, DOI 10.3171/jns.1954.11.1.0077; RYBAK S, 1983, BIOCHEM BIOPH RES CO, V116, P974, DOI 10.1016/S0006-291X(83)80237-X; SABEL BA, 1984, J NEUROSCI RES, V12, P429, DOI 10.1002/jnr.490120227; SABEL BA, 1984, SCIENCE, V225, P340, DOI 10.1126/science.6740316; SADEE W, 1982, J NEUROCHEM, V39, P659, DOI 10.1111/j.1471-4159.1982.tb07943.x; SAIJA A, 1988, Journal of Neurotrauma, V5, P161, DOI 10.1089/neu.1988.5.161; SAIJA A, 1988, BRAIN RES, V452, P303, DOI 10.1016/0006-8993(88)90034-0; SAKAKI S, 1988, J CEREBR BLOOD F MET, V8, P1; Salzman S K, 1987, Cent Nerv Syst Trauma, V4, P181; SALZMAN SK, 1991, ANN NEUROL, V30, P533, DOI 10.1002/ana.410300405; SALZMAN SK, 1992, J NEUROTRAUM, V9, P69; SATO PH, 1992, J NEUROCHEM, V58, P2263, DOI 10.1111/j.1471-4159.1992.tb10972.x; SAUNDERS ML, 1979, J NEUROSURG, V51, P18, DOI 10.3171/jns.1979.51.1.0018; SAUNDERS RD, 1987, J NEUROCHEM, V49, P24, DOI 10.1111/j.1471-4159.1987.tb03388.x; SCATTON B, 1992, EXCITATORY AMINO ACI, P95; SCHOEPP DD, 1992, J NEUROCHEM, V58, P1184, DOI 10.1111/j.1471-4159.1992.tb09381.x; SCHOEPP DD, 1991, J NEUROCHEM, V56, P1789, DOI 10.1111/j.1471-4159.1991.tb02082.x; SEELIG JM, 1983, AM J PHYSIOL, V202, pH22; SHAPIRA Y, 1989, Neurological Research, V11, P169; SHAPIRA Y, 1988, J CEREBR BLOOD F MET, V8, P395, DOI 10.1038/jcbfm.1988.75; SHER PK, 1987, PEDIATR NEUROL, V3, P197; Shi RY, 1989, J NEUROTRAUM, V6, P261, DOI 10.1089/neu.1989.6.261; SHIGEMORI M, 1990, Journal of Neurotrauma, V7, P89, DOI 10.1089/neu.1990.7.89; SHIMADA N, 1990, STROKE, V21, P1445, DOI 10.1161/01.STR.21.10.1445; SHIMADA N, 1989, J CEREBR BLOOD F MET, V9, P603, DOI 10.1038/jcbfm.1989.86; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; SHOHAMI E, 1982, STROKE, V13, P494, DOI 10.1161/01.STR.13.4.494; SHOHAMI E, 1988, NEUROSURGERY, V22, P859, DOI 10.1227/00006123-198805000-00007; Siesj_o B K, 1978, BRAIN ENERGY METABOL; SIESJO BK, 1981, J CEREBR BLOOD F MET, V1, P155, DOI 10.1038/jcbfm.1981.18; SIESJO BK, 1985, CENTRAL NERVOUS SYST, P513; SILVIA RC, 1987, BRAIN RES, V403, P52, DOI 10.1016/0006-8993(87)90121-1; SIMON R, 1990, ANN NEUROL, V27, P606, DOI 10.1002/ana.410270604; SIMON RP, 1984, SCIENCE, V226, P850, DOI 10.1126/science.6093256; SIMPSON RE, 1992, J NEUROCHEM, V58, P1683, DOI 10.1111/j.1471-4159.1992.tb10041.x; SKAPER SD, 1991, J PHARMACOL EXP THER, V259, P452; SKAPER SD, 1992, J NEUROTRAUM, V9, pS507; SKAPER SD, 1989, NEUROENDOCRINE PERSP, P85; SMITH DA, 1993, IN PRESS NEUROSCIENC; SMITH DH, 1993, IN PRESS NEUROSCI LE; SMITH DH, 1990, NEUR ABST, V11, P779; SMITH DH, 1991, IN PRESS J CEREB B S; SMITH DH, 1990, FED PROC, V12, pA400; SPINNEWYN B, 1987, PROSTAGLANDINS, V34, P337, DOI 10.1016/0090-6980(87)90079-7; STANFIELD PR, 1988, TRENDS NEUROSCI, V11, P475, DOI 10.1016/0166-2236(88)90003-3; STEEN PA, 1983, J CEREBR BLOOD F MET, V3, P38, DOI 10.1038/jcbfm.1983.4; Stein DG, 1991, J NEUROTRAUM, V8, P281, DOI 10.1089/neu.1991.8.281; STEIN DT, 1988, J CEREBR BLOOD F MET, V8, P834, DOI 10.1038/jcbfm.1988.140; STEINBERG GK, 1991, J CEREBR BLOOD F MET, V11, P1015, DOI 10.1038/jcbfm.1991.169; STEINKE DE, 1989, NEUROSURGERY, V24, P179, DOI 10.1227/00006123-198902000-00005; STEVENS MK, 1988, J CEREBR BLOOD F MET, V8, P790, DOI 10.1038/jcbfm.1988.134; STEWART P, 1989, LIFE SCI, V44, P1505, DOI 10.1016/0024-3205(89)90330-5; STOKES BT, 1983, EXP NEUROL, V80, P561, DOI 10.1016/0014-4886(83)90307-2; SUGAYA E, 1975, J NEUROPHYSIOL, V38, P822; SVENDGAARD NA, 1987, J CEREBR BLOOD F MET, V7, P21, DOI 10.1038/jcbfm.1987.4; SVENDGAARD NA, 1986, J CEREBR BLOOD F MET, V6, P650, DOI 10.1038/jcbfm.1986.120; SWAN JH, 1990, J CEREBR BLOOD F MET, V10, P343, DOI 10.1038/jcbfm.1990.63; SWAN JH, 1988, J CEREBR BLOOD F MET, V8, P64, DOI 10.1038/jcbfm.1988.9; SZABO L, 1989, ARZNEIMITTEL-FORSCH, V39-1, P309; SZABO L, 1989, ARZNEIMITTELFORSCH, V39-1, P314; TAKAHASHI H, 1981, J NEUROSURG, V55, P708, DOI 10.3171/jns.1981.55.5.0708; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; TANG AH, 1985, LIFE SCI, V37, P1475, DOI 10.1016/0024-3205(85)90178-X; TEASDALE G, 1992, J NEUROTRAUM, V9, pS545; THOMAS M, 1990, NEUR ABSTR, V1, P777; TOFFANO G, 1984, BRAIN RES, V296, P233, DOI 10.1016/0006-8993(84)90061-1; TOFFANO G, 1983, BRAIN RES, V261, P163, DOI 10.1016/0006-8993(83)91298-2; TOMBAUGH GC, 1990, J CEREBR BLOOD F MET, V10, P527, DOI 10.1038/jcbfm.1990.94; TORNHEIM PA, 1978, J NEUROSURG, V48, P220, DOI 10.3171/jns.1978.48.2.0220; TOULMOND S, 1991, J CEREB BLOOD FLOW M, V11, pS313; TOWER DB, 1948, J CLIN INVEST, V27, P558; TRAVIS MA, 1987, SOC NEUR ABSTR, V13, P114; TRAYSTMAN RJ, 1991, J APPL PHYSIOL, V71, P1185; TRIGGLE DJ, 1987, ANNU REV PHARMACOL, V27, P347; TRUMP BF, 1989, TOXICOL APPL PHARM, V97, P6, DOI 10.1016/0041-008X(89)90051-3; UNTERBERG A, 1991, J NEUROSURG, V74, P773, DOI 10.3171/jns.1991.74.5.0773; UNTERBERG A, 1986, MECHANISMS SECONDARY, P139; URCA G, 1990, BRAIN RES, V529, P7, DOI 10.1016/0006-8993(90)90805-L; VACANTI FX, 1984, STROKE, V15, P695, DOI 10.1161/01.STR.15.4.695; VIBULSRESTH S, 1987, STROKE, V18, P210, DOI 10.1161/01.STR.18.1.210; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1988, BRAIN RES, V460, P184, DOI 10.1016/0006-8993(88)91221-8; Vink R, 1990, Magnes Res, V3, P163; VINK R, 1987, BIOCHEM BIOPH RES CO, V149, P594, DOI 10.1016/0006-291X(87)90409-8; VINK R, 1990, J NEUROSCI, V10, P3524; VINK R, 1988, J BIOL CHEM, V263, P757; VINK R, 1988, MAGNET RESON MED, V6, P37, DOI 10.1002/mrm.1910060105; Vink R, 1988, J NEUROTRAUM, V5, P315, DOI 10.1089/neu.1988.5.315; VOLLMER DG, 1989, SURG NEUROL, V31, P190, DOI 10.1016/0090-3019(89)90115-8; WARNER MA, 1991, J CEREBR BLOOD F MET, V11, P600, DOI 10.1038/jcbfm.1991.110; WEAVER MS, 1988, NEUR ABSTR, V14, P1451; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; WEIGANDT H, 1971, ADV LIPID RES, V9, P249; WEST M, 1981, BRAIN RES, V225, P271, DOI 10.1016/0006-8993(81)90835-0; WESTBROOK GL, 1987, NATURE, V328, P640, DOI 10.1038/328640a0; WESTERBERG E, 1989, J NEUROSCI, V9, P798; WIELOCH T, 1985, SCIENCE, V230, P681, DOI 10.1126/science.2996146; WILLMORE LJ, 1981, NEUROLOGY, V31, P63, DOI 10.1212/WNL.31.1.63; WOLFE LS, 1979, ANNU REV PHYSIOL, V41, P669, DOI 10.1146/annurev.ph.41.030179.003321; WOOLF PD, 1987, J NEUROSURG, V66, P875, DOI 10.3171/jns.1987.66.6.0875; Xu J, 1991, J NEUROTRAUM, V8, P11, DOI 10.1089/neu.1991.8.11; YAMAMOTO M, 1983, STROKE, V14, P977, DOI 10.1161/01.STR.14.6.977; YERGEY JA, 1990, J CEREBR BLOOD F MET, V10, P143, DOI 10.1038/jcbfm.1990.20; YOSHIDA S, 1984, J CEREBR BLOOD F MET, V4, P466, DOI 10.1038/jcbfm.1984.66; YOSHIDA S, 1983, NEUROLOGY, V33, P166, DOI 10.1212/WNL.33.2.166; YOSHIDA S, 1985, J NEUROCHEM, V44, P1593, DOI 10.1111/j.1471-4159.1985.tb08800.x; Young W, 1985, Cent Nerv Syst Trauma, V2, P109; Young W, 1986, Cent Nerv Syst Trauma, V3, P215; YOUNG W, 1982, BRAIN RES, V253, P105, DOI 10.1016/0006-8993(82)90677-1; YOUNG W, 1987, STROKE, V18, P751, DOI 10.1161/01.STR.18.4.751; YOUNG W, 1986, BRAIN RES, V365, P42, DOI 10.1016/0006-8993(86)90720-1; YOUNG W, 1988, STROKE, V19, P1013, DOI 10.1161/01.STR.19.8.1013; Young W, 1986, Cent Nerv Syst Trauma, V3, P235; Young W, 1987, Cent Nerv Syst Trauma, V4, P27; YOUNG W, 1982, J NEUROSURG, V57, P667, DOI 10.3171/jns.1982.57.5.0667; YOUNG W, 1981, J NEUROSURG, V55, P209, DOI 10.3171/jns.1981.55.2.0209; YUAN XQ, 1990, AM J PHYSIOL, V258, pH1395; YUE TL, 1990, J NEUROCHEM, V54, P1809, DOI 10.1111/j.1471-4159.1990.tb01239.x; YUM SW, 1990, ARCH NEUROL-CHICAGO, V47, P277, DOI 10.1001/archneur.1990.00530030043014; ZIEGLGANSBERGER W, 1979, SCIENCE, V205, P415, DOI 10.1126/science.451610; ZUCCARELLO M, 1989, J NEUROSURG, V71, P98, DOI 10.3171/jns.1989.71.1.0098; ZUKIN RS, 1988, P NATL ACAD SCI USA, V85, P4061, DOI 10.1073/pnas.85.11.4061; ZUKIN RS, 1981, LIFE SCI, V29, P2681	557	235	240	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FAL	1993	10	3					215	261		10.1089/neu.1993.10.215			47	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	MC021	WOS:A1993MC02100001	8258838				2021-06-18	
J	Ponsford, JL; Downing, MG; Olver, J; Ponsford, M; Acher, R; Carty, M; Spitz, G				Ponsford, Jennie L.; Downing, Marina G.; Olver, John; Ponsford, Michael; Acher, Rose; Carty, Meagan; Spitz, Gershon			Longitudinal Follow-Up of Patients with Traumatic Brain Injury: Outcome at Two, Five, and Ten Years Post-Injury	JOURNAL OF NEUROTRAUMA			English	Article						functional outcome; structured outcome questionnaire; traumatic brain injury	SEVERE HEAD-INJURY; COGNITIVE RECOVERY; MODERATE; LIMITATIONS; DEPRESSION; DISORDERS; ABILITIES; RELATIVES; RETURN; WORK	The deleterious consequences of traumatic brain injury (TBI) impair capacity to return to many avenues of pre-morbid life. However, there has been limited longitudinal research examining outcome beyond five years post-injury. The aim of this study was to examine aspects of function, previously shown to be affected following TBI, over a span of 10 years. One hundred and forty one patients with TBI were assessed at two, five, and 10 years post-injury using the Structured Outcome Questionnaire. Fatigue and balance problems were the most common neurological symptoms, with reported rates decreasing only slightly during the 10-year period. Mobility outcomes were good in more than 75% of patients, with few participants requiring aids for mobility. Changes in cognitive, communication, behavioral, and emotional functions were reported by approximately 60% of the sample at all time points. Levels of independence in activities of daily living were high during the 10-year period, and as many as 70% of subjects returned to driving. Nevertheless, approximately 40% of patients required more support than before their injury. Only half the sample returned to previous leisure activities and fewer than half were employed at each assessment time post-injury. Although marital status remained stable over time, approximately 30% of participants reported difficulties in personal relationships. Older age at injury did not substantially alter the pattern of changes over time, except in employment. Overall, problems that were evident at two years post-injury persisted until 10 years post-injury. The importance of these findings is discussed with reference to rehabilitation programs.	[Ponsford, Jennie L.; Downing, Marina G.; Spitz, Gershon] Monash Univ, Sch Psychol & Psychiat, Melbourne, Vic 3004, Australia; [Olver, John] Monash Univ, Sch Med, Melbourne, Vic 3004, Australia; [Ponsford, Jennie L.; Downing, Marina G.; Carty, Meagan; Spitz, Gershon] Epworth Healthcare, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [Ponsford, Jennie L.] Natl Trauma Res Inst, Melbourne, Vic, Australia; [Ponsford, Jennie L.; Olver, John; Ponsford, Michael; Acher, Rose; Carty, Meagan] Epworth HealthCare, Melbourne, Vic, Australia	Ponsford, JL (corresponding author), Monash Univ, Dept Psychol, Clayton, Vic 3800, Australia.	jennie.ponsford@monash.edu	Spitz, Gershon/H-7755-2014; Downing, Marina/AAX-2380-2020	Spitz, Gershon/0000-0002-7810-1480; Downing, Marina/0000-0002-3126-6632; Olver, John/0000-0001-7069-1191	Transport Accident Commission, through the Institute for Safety, Compensation and Recovery Research	This project is funded by the Transport Accident Commission, through the Institute for Safety, Compensation and Recovery Research. We would also like to thank all participants involved in this project who gave so generously of their time.	Ahmed S, 2000, BRAIN INJURY, V14, P765; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Ashman TA, 2008, J HEAD TRAUMA REHAB, V23, P139, DOI 10.1097/01.HTR.0000319930.69343.64; Ashman TA, 2009, ARCH PHYS MED REHAB, V90, P733, DOI 10.1016/j.apmr.2008.11.005; Australian Institute of Health and Welfare, 2007, BULLETIN, V55; Benedictus MR, 2010, ARCH PHYS MED REHAB, V91, P1436, DOI 10.1016/j.apmr.2010.06.019; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Draper K, 2009, NEUROPSYCHOL REHABIL, V19, P645, DOI 10.1080/17405620802613935; Grauwmeijer E, 2012, ARCH PHYS MED REHAB, V93, P993, DOI 10.1016/j.apmr.2012.01.018; Green RE, 2008, ARCH PHYS MED REHAB, V89, pS16, DOI 10.1016/j.apmr.2008.09.551; Hart T, 2009, NEUROPSYCHOL REHABIL, V19, P161, DOI 10.1080/09602010802188393; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Hoofien D, 2001, BRAIN INJURY, V15, P189; Leblanc J, 2006, BRAIN INJURY, V20, P779, DOI 10.1080/02699050600831835; O'Connor C, 2005, PSYCHOL REP, V97, P169, DOI 10.2466/PR0.97.5.169-179; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Pagulayan KF, 2008, ARCH PHYS MED REHAB, V89, P1887, DOI 10.1016/j.apmr.2008.03.019; Pagulayan KF, 2006, ARCH PHYS MED REHAB, V87, P611, DOI 10.1016/j.apmr.2006.01.018; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; Schonberger M, 2011, J NEUROL NEUROSUR PS, V82, P936, DOI 10.1136/jnnp.2010.210021; Senathi-Raja D, 2010, NEUROPSYCHOLOGY, V24, P336, DOI 10.1037/a0018239; Senathi-Raja D, 2009, J REHABIL MED, V41, P666, DOI 10.2340/16501977-0396; Sigurdardottir S, 2009, J INT NEUROPSYCH SOC, V15, P740, DOI 10.1017/S1355617709990452; Sloan S., 2012, TRAUMATIC BRAIN INJU, P99; Tate R., 2005, BRAIN IMPAIR, V6, P75, DOI DOI 10.1375/BRIM.2005.6.2.75; Tate RL, 1999, PSYCHOL MED, V29, P713, DOI 10.1017/S0033291799008466; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Wood RLI, 2006, J NEUROL NEUROSUR PS, V77, P1180, DOI 10.1136/jnnp.2006.091553	41	234	234	3	47	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2014	31	1					64	77		10.1089/neu.2013.2997			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	302WJ	WOS:000330635500007	23889321		Y	N	2021-06-18	
J	Crisco, JJ; Fiore, R; Beckwith, JG; Chu, JJ; Brolinson, PG; Duma, S; McAllister, TW; Duhaime, AC; Greenwald, RM				Crisco, Joseph J.; Fiore, Russell; Beckwith, Jonathan G.; Chu, Jeffrey J.; Brolinson, Per Gunnar; Duma, Stefan; McAllister, Thomas W.; Duhaime, Ann-Christine; Greenwald, Richard M.			Frequency and Location of Head Impact Exposures in Individual Collegiate Football Players	JOURNAL OF ATHLETIC TRAINING			English	Article						biomechanics; concussions; accelerometers	TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL; PROFESSIONAL FOOTBALL; AXONAL INJURY; UNITED-STATES; CONCUSSION; ACCELERATION; EPIDEMIOLOGY; SPORTS; SYSTEM	Context: Measuring head impact exposure is a critical step toward understanding the mechanism and prevention of sport-related mild traumatic brain (concussion) injury, as well as the possible effects of repeated subconcussive impacts. Objective: To quantify the frequency and location of head impacts that individual players received in 1 season among 3 collegiate teams, between practice and game sessions, and among player positions. Design: Cohort study. Setting: Collegiate football field. Patients or Other Participants: One hundred eighty-eight players from 3 National Collegiate Athletic Association football teams. Intervention(s): Participants wore football helmets instrumented with an accelerometer-based system during the 2007 fall season. Main Outcome Measure(s): The number of head impacts greater than log and location of the impacts on the player's helmet were recorded and analyzed for trends and interactions among teams (A, B, or C), session types, and player positions using Kaplan-Meier survival curves. Results: The total number of impacts players received was nonnormally distributed and varied by team, session type, and player position. The maximum number of head impacts for a single player on each team was 1022 (team A), 1412 (team B), and 1444 (team C). The median number of head impacts on each team was 4.8 (team A), 7.5 (team B), and 6.6 (team C) impacts per practice and 12.1 (team A), 14.6 (team B), and 16.3 (team C) impacts per game. Linemen and linebackers had the largest number of impacts per practice and per game. Offensive linemen had a higher percentage of impacts to the front than to the back of the helmet, whereas quarterbacks had a higher percentage to the back than to the front of the helmet. Conclusions: The frequency of head impacts and the location on the helmet where the impacts occur are functions of player position and session type. These data provide a basis for quantifying specific head impact exposure for studies related to understanding the biomechanics and clinical aspects of concussion injury, as well as the possible effects of repeated subconcussive impacts in football.	[Crisco, Joseph J.] Brown Univ, Warren Alpert Med Sch, Dept Orthopaed, Bioengn Lab, Providence, RI 02903 USA; [Crisco, Joseph J.] Rhode Isl Hosp, Providence, RI 02903 USA; [Fiore, Russell] Brown Univ, Dept Athlet & Phys Educ, Providence, RI 02903 USA; [Beckwith, Jonathan G.; Chu, Jeffrey J.; Greenwald, Richard M.] Simbex, Lebanon, NH USA; [Brolinson, Per Gunnar] Edward Via Virginia Coll Osteopath Med, Blacksburg, VA USA; [Duma, Stefan] Virginia Tech Wake Forest, Ctr Injury Biomech, Blacksburg, VA USA; [McAllister, Thomas W.] Dartmouth Hitchcock Med Sch, Dept Psychiat & Neurol, Lebanon, NH USA; [Duhaime, Ann-Christine] Dartmouth Hitchcock Med Ctr, Hanover, NH USA; [Greenwald, Richard M.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA	Crisco, JJ (corresponding author), Brown Univ, Warren Alpert Med Sch, Dept Orthopaed, Bioengn Lab, Suite 404,1 Hoppin St, Providence, RI 02903 USA.	joseph_crisco@brown.edu	Duma, Stefan/A-8368-2012		National Center for Medical Rehabilitation Research at the National Institute of Child Health and Human Development at the National Institutes of Health [R01 HD048638]; National Institute for Neurological Disorders and Stroke at the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS055020]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R44 HD40473]; Riddell Inc (Elyria, OH); Riddell Inc; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055020] Funding Source: NIH RePORTER	This study was supported in part by research grant R01 HD048638 from the National Center for Medical Rehabilitation Research at the National Institute of Child Health and Human Development at the National Institutes of Health (Dr Greenwald) and by research grant R01 NS055020 from the National Institute for Neurological Disorders and Stroke at the National Institutes of Health (Dr McAllister). The HIT System technology was developed in part through research grant R44 HD40473 from the National Institutes of Health (Drs Greenwald and Crisco) and with research and development support from Riddell Inc (Elyria, OH). We thank the researchers and institutions from which the data were collected: Mike Goforth, ATC, Virginia Tech Sports Medicine; Steve Rowson, MS, Virginia Polytechnic Institute and State University; Dave Dieter, Edward Via Virginia College of Osteopathic Medicine; Jeff Frechette, ATC, and Scott Roy, ATC, Dartmouth College Sports Medicine; Mary Hynes, RN, MPH, Dartmouth Medical School; and David J. Murray, ATC, and Kevin R. Francis, Brown University. We thank Lindley Brainard of Simbex for coordination of all data collection. We also thank Tor Tosteson, PhD, and Jason T. Machan, PhD, for their assistance with statistical analysis.; Joseph J. Crisco, PhD; Jonathan G. Beckwith, MS; Jeffrey J. Chu, MS; Richard M. Greenwald, PhD, and Simbex reported having a financial interest in the instruments (HIT System, Sideline Response System [Riddell Inc]) that were used to collect the data in this study.	Beckwith JG, 2007, J APPL BIOMECH, V23, P238, DOI 10.1123/jab.23.3.238; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Dick R, 2007, J ATHL TRAINING, V42, P173; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gerberding J.L., 2003, REPORT C MILD TRAUMA; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Gurdjian E S, 1964, Clin Neurosurg, V12, P112; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Moon D W, 1971, Med Sci Sports, V3, P44; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Ommaya A. K., 1967, P 11 STAPP CAR CRASH, V670906; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Powell JW, 1999, J ATHL TRAINING, V34, P277; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; REID SE, 1971, SURG GYNECOL OBSTETR, V133, P929; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Shankar PR, 2007, AM J SPORT MED, V35, P1295, DOI 10.1177/0363546507299745; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003	29	234	234	2	40	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050			J ATHL TRAINING	J. Athl. Train.	NOV-DEC	2010	45	6					549	559		10.4085/1062-6050-45.6.549			11	Sport Sciences	Sport Sciences	682ZT	WOS:000284442200003	21062178	Green Published			2021-06-18	
J	Fann, JR; Burington, B; Leonetti, A; Jaffe, K; Katon, WJ; Thompson, RS				Fann, JR; Burington, B; Leonetti, A; Jaffe, K; Katon, WJ; Thompson, RS			Psychiatric illness following traumatic brain injury in an adult health maintenance organization population	ARCHIVES OF GENERAL PSYCHIATRY			English	Article							HEAD-INJURY; ALCOHOL-USE; AXIS-I; DISORDERS; DEPRESSION; INDIVIDUALS; SYMPTOMS	Background: Psychiatric illness after traumatic brain injury (TBI) has been shown to be prevalent in hospitalized and tertiary care patient populations. Objective: To determine the risk of psychiatric illness after TBI in an adult health maintenance organization population. Design: Prospective cohort study. Setting: Large staff-model health maintenance organization. Participants: Nine hundred thirty-nine health plan members diagnosed as having TBI in 1993 and enrolled in the prior year, during which no TBI was ascertained. Three health plan members per TBI-exposed subject were randomly selected as unexposed comparisons, matched for age, sex, and reference date. Main Outcome Measure: Psychiatric illness in the 3 years after the TBI reference date, determined using computerized records of psychiatric diagnoses according to the International Classification of Diseases, Ninth Revision, Clinical Modification, prescriptions, and service utilization. Results: Prevalence of any psychiatric illness in the first year was 49% following moderate to severe TBI, 34% following mild TBI, and 18% in the comparison group. Among subjects without psychiatric illness in the prior year, the adjusted relative risk for any psychiatric illness in the 6 months following moderate to severe TBI was 4.0 (95% confidence interval [CI], 2.4-6.8) and following mild TBI was 2.8 (95% CI, 2.1-3.7; P<.001) compared with those without TBI. Among subjects with prior psychiatric illness, the adjusted relative risk for any psychiatric illness in the 6 months following moderate to severe TBI was 2.1 (95% CI, 1.3-3.3) and following mild TBI was 1.6 (95% CI, 1.2-2.0; P = .005). Prior psychiatric illness significantly modified the relationship between TBI and subsequent psychiatric illness (P = .04) and was a significant predictor (P<.001). Persons with mild TBI and prior psychiatric illness had evidence of persisting psychiatric illness. Conclusions: Both moderate to severe and mild TBI are associated with an increased risk of subsequent psychiatric illness. Whereas moderate to severe TBI is associated with a higher initial risk, mild TBI may be associated with persistent psychiatric illness.	Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Dept Pediat, Seattle, WA 98195 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA; Univ Washington, Harborview Med Ctr, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA	Fann, JR (corresponding author), Univ Washington, Dept Psychiat & Behav Sci, Box 356560, Seattle, WA 98195 USA.	fann@u.washington.edu					Alexander M. P., 1997, SEMIN CLIN NEUROPSYC, V2, P177; BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; Deb S, 1999, AM J PSYCHIAT, V156, P374; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Fann JR, 2002, J NEUROL NEUROSUR PS, V72, P615, DOI 10.1136/jnnp.72.5.615; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; Fujii D, 2002, J NEUROPSYCH CLIN N, V14, P130, DOI 10.1176/appi.neuropsych.14.2.130; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hosmer DW, 1999, APPL SURVIVAL ANAL; *J HOPK U, 1998, ACG CAS MIX ADJ SYST; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; Katon W, 2001, ANN INTERN MED, V134, P917, DOI 10.7326/0003-4819-134-9_Part_2-200105011-00017; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Kreutzer JS, 1996, J HEAD TRAUMA REHAB, V11, P58, DOI 10.1097/00001199-199610000-00006; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LEVINE DN, 1982, NEUROLOGY, V32, P267, DOI 10.1212/WNL.32.3.267; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; *PHS, 1988, INT CLASS DIS; Piccinelli M, 1999, J PSYCHOSOM RES, V46, P455, DOI 10.1016/S0022-3999(98)00126-3; ROBINS LN, 1991, PSYCHIAT DISORDERS A; Saunders KW, 1994, PHARMACOEPIDEM DR S, P171; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Stergachis AS, 1991, PHARMACOPEIDEMIOLOGY, P222; THURMAN DJ, 1996, ANN M AM PUBL HLTH A; Thurman DJ., 1995, GUIDELINES SURVEILLA; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; WEINER JP, 1991, MED CARE, V29, P452, DOI 10.1097/00005650-199105000-00006	34	234	236	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0003-990X			ARCH GEN PSYCHIAT	Arch. Gen. Psychiatry	JAN	2004	61	1					53	61		10.1001/archpsyc.61.1.53			9	Psychiatry	Psychiatry	761GW	WOS:000187894000006	14706944	Bronze			2021-06-18	
J	Davis, DP; Hoyt, DB; Ochs, M; Fortlage, D; Holbrook, T; Marshall, LK; Rosen, P				Davis, DP; Hoyt, DB; Ochs, M; Fortlage, D; Holbrook, T; Marshall, LK; Rosen, P			The effect of paramedic rapid sequence intubation on outcome in patients with severe traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	61st Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 26-28, 2002	ORLANDO, FLORIDA	Amer Assoc Surg Trauma		brain injury; head trauma; intubation; paramedics; RSI outcome	SEVERE HEAD-INJURIES; ENDOTRACHEAL INTUBATION; HYPOTENSION; SERVICES; SCOPE	Objective:. To evaluate the effect of paramedic rapid sequence intubation (RSI) on outcome in patients with severe traumatic brain injury. Methods. Adult major trauma victims were prospectively enrolled over two years using the following inclusion criteria: Glasgow Coma Scale (GCS) 3-8, suspected head injury by mechanism or physical examination, transport time > 10," and inability to intubate without RSI. Midazolam and succinylcholine were administered before laryngoscopy; rocuronium was given after tube placement was confirmed using physical examination, capnometry, syringe aspiration, and pulse oximetry. The Combitube was used as a salvage airway device. For this analysis, trial patients were excluded for absence of a head injury (Head/Neck AIS score < 2), failure to fulfill major trauma outcome study criteria, unsuccessful intubation or Combitube insertion, or death in the field or in the resuscitation suite within 30" of arrival. Each study patient was hand matched to three nonintubated historical controls from our trauma registry using the following parameters: age, sex, mechanism of injury, trauma center, and AIS score for each body system. Controls were excluded for Head/Neck AIS defined by a c-spine injury or death in the field or in the resuscitation suite within 30" of arrival. &chi;(2), odds ratios, and logistic regression were used to investigate the impact of RSI on the primary outcome measures of mortality and incidence of a "good outcome," defined as discharge to home, rehabilitation, psychiatric facility, jail, or signing out against medical advice.. Results.' A total of 209 trial patients were hand matched to 627 controls. The groups were similar with regard to all matching parameters, admission vital signs, frequency of specific head injury diagnoses, and incidence of invasive procedures. Mortality was significantly increased in the trial cohort versus controls for all patients (33.0% versus 24.2%, p < 0.05) and in those with Head/Neck AIS scores of 3 or greater (41.1% versus 30.3%, p < 0.05). The incidence of a "good outcome" was lower in the trial cohort versus controls (45.5% versus 57.9%, p < 0.01). Factors that may have contributed to the increase in mortality include transient hypoxia, inadvertent hyperventilation, and longer scene times associated with the RSI procedure. Conclusion. Paramedic RSI protocols to facilitate intubation of head-injured patients were associated with an increase in mortality and decrease in good outcomes versus matched historical controls.	Univ Calif San Diego, Dept Emergency Med, San Diego, CA 92103 USA; Univ Calif San Diego, Dept Surg, Div Trauma, San Diego, CA 92103 USA; Univ Calif San Diego, Div Neurosurg, San Diego, CA 92103 USA; San Diego Cty Emergency Med Serv, San Diego, CA USA	Davis, DP (corresponding author), Univ Calif San Diego, Dept Emergency Med, 200 W Arbor Dr,8676, San Diego, CA 92103 USA.						APRAHAMIAN C, 1985, ANN EMERG MED, V14, P583, DOI 10.1016/S0196-0644(85)80785-X; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; DAVIS DP, IN PRESS J TRAUMA; DONEY M, 2002, PREHOSP EMERG CARE, V6, P148; Doran J V, 1995, Prehosp Disaster Med, V10, P259; Falcone R E, 1996, Air Med J, V15, P163, DOI 10.1016/S1067-991X(96)90024-3; Garner A, 2001, INJURY, V32, P455, DOI 10.1016/S0020-1383(01)00013-4; Hatley T, 1998, J Emerg Med, V16, P731, DOI 10.1016/S0736-4679(98)00087-0; HEDGES JR, 1988, ANN EMERG MED, V17, P469, DOI 10.1016/S0196-0644(88)80238-5; Karch SB, 1996, AM J EMERG MED, V14, P617, DOI 10.1016/S0735-6757(96)90073-X; Katz SH, 2001, ANN EMERG MED, V37, P32, DOI 10.1067/mem.2001.112098; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; McDonald C C, 1998, Prehosp Emerg Care, V2, P29, DOI 10.1080/10903129808958836; Ochs M, 2002, ANN EMERG MED, V40, P159, DOI 10.1067/mem.2002.126397; Omert L, 2001, J TRAUMA, V51, P1065, DOI 10.1097/00005373-200112000-00007; Pace SA, 2000, ANN EMERG MED, V35, P568, DOI 10.1016/S0196-0644(00)70029-1; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Sing RF, 1996, ACAD EMERG MED, V3, P41, DOI 10.1111/j.1553-2712.1996.tb03301.x; SMITH JP, 1985, JAMA-J AM MED ASSOC, V253, P544, DOI 10.1001/jama.253.4.544; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; SYVERUD SA, 1988, ANN EMERG MED, V17, P236, DOI 10.1016/S0196-0644(88)80114-8; Thomas SH, 2002, J TRAUMA, V52, P47, DOI 10.1097/00005373-200201000-00010; Vilke Gary M., 1994, Journal of Emergency Medicine, V12, P217, DOI 10.1016/0736-4679(94)90702-1; Wayne M A, 1999, Prehosp Emerg Care, V3, P107, DOI 10.1080/10903129908958916; Winchell RJ, 1997, ARCH SURG-CHICAGO, V132, P592	25	234	243	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	2003	54	3					444	453		10.1097/01.TA.0000053396.02126.CD			10	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	660EA	WOS:000181819800004	12634522				2021-06-18	
J	Geddes, JF; Vowles, GH; Hackshaw, AK; Nickols, CD; Scott, IS; Whitwell, HL				Geddes, JF; Vowles, GH; Hackshaw, AK; Nickols, CD; Scott, IS; Whitwell, HL			Neuropathology of inflicted head injury in children II. Microscopic brain injury in infants	BRAIN			English	Article						cervical hyperextension; diffuse axonal injury; infant head injury; non-accidental head injury	DIFFUSE AXONAL INJURY; BETA-APP; SHAKING; TRAUMA; HYPEREXTENSION; DIAGNOSIS; MARKER; DAMAGE; MRI	There are very few reports in the literature dealing with the neuropathology of infant head injury, and the question of whether diffuse traumatic brain damage [diffuse axonal injury (DAI)] occurs in such children has not yet been reliably established by detailed neuropathological studies. We report the findings in the brains of a series of 37 infants aged 9 months or less, all of whom died from inflicted head injuries, and 14 control infants who died of other causes. Axonal damage was identified using immunohistochemistry for beta -amyloid precursor protein. Full clinical details were available for each case, the most constant of which in the study cohort was an episode of significant apnoea at presentation, found to have been recorded in 75% of cases. Global hypoxic damage was the most common histological finding. Widespread axonal damage, interpreted as vascular, was present in 13 cases, but widespread traumatic axonal injury was found in only two children, both of whom had severe head injuries with multiple skull fractures. Epidural cervical haemorrhage and focal axonal damage to the brainstem and the spinal nerve roots, found in 11 cases but not in controls, indicate that the craniocervical junction is vulnerable in infant head injury, the neuropathology being that of stretch injury from cervical hyperextension/flexion. Damage to this region could account for the observed apnoea, which could in turn lead to hypoxic damage and brain swelling, The observation that the predominant histological abnormality in cases of inflicted head injury in the very young is diffuse hypoxic brain damage, not DAI, can be explained in one of two ways: either the unmyelinated axon of the immature cerebral hemispheres is relatively resistant to traumatic damage, or in shaking-type injuries the brain is not exposed to the forces necessary to produce DAI.	Univ London, Dept Histopathol & Morbid Anat, London WC1E 7HU, England; Univ London, Dept Environm & Preventat Med, London WC1E 7HU, England; Addenbrookes Hosp, Dept Histopathol, Cambridge CB2 2QQ, England; Univ Sheffield, Dept Forens Pathol, Sheffield S10 2TN, S Yorkshire, England	Geddes, JF (corresponding author), Royal London Hosp, Dept Histopathol & Morbid Anat, London E1 1BB, England.	j.f.geddes@mds.qmw.ac.uk					ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; BOHN D, 1990, J TRAUMA, V30, P463, DOI 10.1097/00005373-199030040-00017; BROWN JK, 1993, DEV MED CHILD NEUROL, V35, P849; CAFFEY J, 1974, PEDIATRICS, V54, P396; CALDER IM, 1984, J CLIN PATHOL, V37, P1095, DOI 10.1136/jcp.37.10.1095; David TJ, 1999, J ROY SOC MED, V92, P556, DOI 10.1177/014107689909201105; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Feldman KW, 1997, CHILD ABUSE NEGLECT, V21, P199, DOI 10.1016/S0145-2134(96)00145-7; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Gleckman AM, 1999, ARCH PATHOL LAB MED, V123, P146; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; Hardman J M, 1979, Adv Neurol, V22, P15; Hart BL, 1996, AM J FOREN MED PATH, V17, P217, DOI 10.1097/00000433-199609000-00008; Johnson DL, 1995, PEDIATR NEUROSURG, V23, P305, DOI 10.1159/000120976; Jones M, 2000, BRAIN PATHOL, V10, P719; Koch LE, 1998, FORENSIC SCI INT, V97, P1, DOI 10.1016/S0379-0738(98)00124-8; Kriss VM, 1996, CLIN PEDIATR, V35, P119, DOI 10.1177/000992289603500302; Lancon JA, 1998, ANAT REC, V253, P13, DOI 10.1002/(SICI)1097-0185(199802)253:1<13::AID-AR8>3.0.CO;2-F; Leestma J. E., 1997, NEUROPATHOLOGY DIAGN, P518; LINDENBERG R, 1970, ARCH PATHOL, V90, P509; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; MUNGER CE, 1993, AM J FOREN MED PATH, V14, P193, DOI 10.1097/00000433-199309000-00004; RIGGS JE, 1995, MIL MED, V160, P94; Saternus KS, 2000, FORENSIC SCI INT, V109, P203, DOI 10.1016/S0379-0738(00)00144-4; Shannon P, 1998, ACTA NEUROPATHOL, V95, P625, DOI 10.1007/s004010050849; VOWLES GH, 1987, J CLIN PATHOL, V40, P185, DOI 10.1136/jcp.40.2.185	31	234	240	1	11	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	JUL	2001	124		7				1299	1306		10.1093/brain/124.7.1299			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	454AA	WOS:000169949200004	11408325	Bronze			2021-06-18	
J	Moler, FW; Silverstein, FS; Holubkov, R; Slomine, BS; Christensen, JR; Nadkarni, VM; Meert, KL; Clark, AE; Browning, B; Pemberton, VL; Page, K; Shankaran, S; Hutchison, JS; Newth, CJL; Bennett, KS; Berger, JT; Topjian, A; Pineda, JA; Koch, JD; Schleien, CL; Dalton, HJ; Ofori-Amanfo, G; Goodman, DM; Fink, EL; McQuillen, P; Zimmerman, JJ; Thomas, NJ; van der Jagt, EW; Porter, MB; Meyer, MT; Harrison, R; Pham, N; Schwarz, AJ; Nowak, JE; Alten, J; Wheeler, DS; Bhalala, US; Lidsky, K; Lloyd, E; Mathur, M; Shah, S; Wu, T; Theodorou, AA; Sanders, RC; Dean, JM				Moler, Frank W.; Silverstein, Faye S.; Holubkov, Richard; Slomine, Beth S.; Christensen, James R.; Nadkarni, Vinay M.; Meert, Kathleen L.; Clark, Amy E.; Browning, Brittan; Pemberton, Victoria L.; Page, Kent; Shankaran, Seetha; Hutchison, Jamie S.; Newth, Christopher J. L.; Bennett, Kimberly S.; Berger, John T.; Topjian, Alexis; Pineda, Jose A.; Koch, Joshua D.; Schleien, Charles L.; Dalton, Heidi J.; Ofori-Amanfo, George; Goodman, Denise M.; Fink, Ericka L.; McQuillen, Patrick; Zimmerman, Jerry J.; Thomas, Neal J.; van der Jagt, Elise W.; Porter, Melissa B.; Meyer, Michael T.; Harrison, Rick; Nga Pham; Schwarz, Adam J.; Nowak, Jeffrey E.; Alten, Jeffrey; Wheeler, Derek S.; Bhalala, Utpal S.; Lidsky, Karen; Lloyd, Eric; Mathur, Mudit; Shah, Samir; Wu, Theodore; Theodorou, Andreas A.; Sanders, Ronald C., Jr.; Dean, J. Michael		THAPCA Trial Investigators	Therapeutic Hypothermia after Out-of-Hospital Cardiac Arrest in Children	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HYPOXIC-ISCHEMIC ENCEPHALOPATHY; AMERICAN-HEART-ASSOCIATION; TRAUMATIC BRAIN-INJURY; WHOLE-BODY HYPOTHERMIA; CARE; CARDIOPULMONARY; RESUSCITATION; TEMPERATURE; EXPERIENCE; EPIDEMIOLOGY	BACKGROUND Therapeutic hypothermia is recommended for comatose adults after witnessed out-of-hospital cardiac arrest, but data about this intervention in children are limited. METHODS We conducted this trial of two targeted temperature interventions at 38 children's hospitals involving children who remained unconscious after out-of-hospital cardiac arrest. Within 6 hours after the return of circulation, comatose patients who were older than 2 days and younger than 18 years of age were randomly assigned to therapeutic hypothermia (target temperature, 33.0 degrees C) or therapeutic normothermia (target temperature, 36.8 degrees C). The primary efficacy outcome, survival at 12 months after cardiac arrest with a Vineland Adaptive Behavior Scales, second edition (VABS-II), score of 70 or higher (on a scale from 20 to 160, with higher scores indicating better function), was evaluated among patients with a VABS-II score of at least 70 before cardiac arrest. RESULTS A total of 295 patients underwent randomization. Among the 260 patients with data that could be evaluated and who had a VABS-II score of at least 70 before cardiac arrest, there was no significant difference in the primary outcome between the hypothermia group and the normothermia group (20% vs. 12%; relative likelihood, 1.54; 95% confidence interval [CI], 0.86 to 2.76; P=0.14). Among all the patients with data that could be evaluated, the change in the VABS-II score from baseline to 12 months was not significantly different (P=0.13) and 1-year survival was similar (38% in the hypothermia group vs. 29% in the normothermia group; relative likelihood, 1.29; 95% CI, 0.93 to 1.79; P=0.13). The groups had similar incidences of infection and serious arrhythmias, as well as similar use of blood products and 28-day mortality. CONCLUSIONS In comatose children who survived out-of-hospital cardiac arrest, therapeutic hypothermia, as compared with therapeutic normothermia, did not confer a significant benefit in survival with a good functional outcome at 1 year.	[Moler, Frank W.; Silverstein, Faye S.] Univ Michigan, Ann Arbor, MI 48109 USA; [Meert, Kathleen L.; Shankaran, Seetha] Wayne State Univ, Detroit, MI USA; [Holubkov, Richard; Clark, Amy E.; Browning, Brittan; Page, Kent; Bennett, Kimberly S.; Dean, J. Michael] Univ Utah, Salt Lake City, UT USA; [Slomine, Beth S.; Christensen, James R.] Kennedy Krieger Inst, Baltimore, MD USA; [Slomine, Beth S.; Christensen, James R.] Johns Hopkins Univ, Baltimore, MD USA; [Bhalala, Utpal S.] Johns Hopkins Childrens Ctr, Baltimore, MD USA; [Pemberton, Victoria L.] NHLBI, Bethesda, MD 20892 USA; [Nadkarni, Vinay M.; Topjian, Alexis] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Fink, Ericka L.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA; [Thomas, Neal J.] Penn State Hershey Childrens Hosp, Hershey, PA USA; [Hutchison, Jamie S.] Hosp Sick Children, Toronto, ON M5G 1X8, Canada; [Newth, Christopher J. L.] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA; [Harrison, Rick] Mattel Childrens Hosp UCLA, Los Angeles, CA USA; [McQuillen, Patrick] Univ Calif San Francisco, Benioff Childrens Hosp, San Francisco, CA 94143 USA; [Schwarz, Adam J.] Childrens Hosp Orange Cty, Orange, CA 92668 USA; [Mathur, Mudit] Loma Linda Univ, Childrens Hosp, Loma Linda, CA 92350 USA; [Berger, John T.] Childrens Natl Med Ctr, Washington, DC 20010 USA; [Pineda, Jose A.] Washington Univ, St Louis, MO 63130 USA; [Koch, Joshua D.] Childrens Med Ctr Dallas, Dallas, TX USA; [Koch, Joshua D.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA; [Wu, Theodore] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA; [Schleien, Charles L.] Columbia Univ, Med Ctr, New York Presbyterian Morgan Stanley Childrens Ho, New York, NY USA; [van der Jagt, Elise W.] Univ Rochester, Med Ctr, Golisano Childrens Hosp, Rochester, NY 14642 USA; [Dalton, Heidi J.] Phoenix Childrens Hosp, Phoenix, AZ USA; [Theodorou, Andreas A.] Diamond Childrens Med Ctr, Tucson, AZ USA; [Ofori-Amanfo, George] Duke Childrens Hosp & Hlth Ctr, Durham, NC USA; [Goodman, Denise M.] Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL 60611 USA; [Zimmerman, Jerry J.] Seattle Childrens Hosp, Seattle, WA USA; [Porter, Melissa B.] Univ Louisville, Kosair Childrens Hosp, Louisville, KY 40292 USA; [Meyer, Michael T.] Med Coll Wisconsin, Milwaukee, WI 53226 USA; [Nga Pham] Childrens Healthcare Atlanta, Atlanta, GA USA; [Nowak, Jeffrey E.] Childrens Hosp & Clin Minnesota, Minneapolis, MN USA; [Alten, Jeffrey] Childrens Alabama, Birmingham, AL USA; [Wheeler, Derek S.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA; [Lidsky, Karen] Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA; [Lloyd, Eric] Nationwide Childrens Hosp, Columbus, OH USA; [Shah, Samir] Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA; [Sanders, Ronald C., Jr.] Arkansas Childrens Hosp, Little Rock, AR 72202 USA	Moler, FW (corresponding author), Univ Michigan Hlth Syst, F-6900 UH South,SPF 5243,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	fmoler@umich.edu	Pineda, Jose/W-2806-2019; McQuillen, Patrick/AAF-7119-2020; Hahn, Cecil/J-3372-2016	Hahn, Cecil/0000-0002-0887-8761; McQuillen, Patrick/0000-0002-8837-364X; Stavinoha, Peter L/0000-0002-3955-9579; Thomas, Neal/0000-0002-7991-7510; Goodman, Denise/0000-0001-9766-9453; Michelson, David/0000-0002-0600-3523; Holubkov, Richard/0000-0003-0431-3381	National Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U10HD050096, U10HD049981, U10HD049983, U01HD049934, U10HD050012, UG1HD050096] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R34HD050531, R21HD044955, U10HD049945] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000433] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [U01HL094339, U01HL094345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS075363] Funding Source: NIH RePORTER	Funded by the National Heart, Lung, and Blood Institute and others; THAPCA-OH ClinicalTrials.gov number, NCT00878644.	Adelson PD, 2013, LANCET NEUROL, V12, P546, DOI 10.1016/S1474-4422(13)70077-2; [Anonymous], 1995, MULL SCAL EARL LEARN; Azzopardi DV, 2009, NEW ENGL J MED, V361, P1349, DOI 10.1056/NEJMoa0900854; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; BOHN DJ, 1986, CRIT CARE MED, V14, P529, DOI 10.1097/00003246-198606000-00002; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; Doherty DR, 2009, CIRCULATION, V119, P1492, DOI 10.1161/CIRCULATIONAHA.108.791384; Donoghue AJ, 2005, ANN EMERG MED, V46, P512, DOI 10.1016/j.annemergmed.2005.05.028; Field D, 2013, PEDIATRICS, V132, pE1247, DOI 10.1542/peds.2013-1754; Fink EL, 2010, PEDIATR CRIT CARE ME, V11, P66, DOI 10.1097/PCC.0b013e3181c58237; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; Hickey RW, 2000, PEDIATRICS, V106, P118, DOI 10.1542/peds.106.1.118; Holubkov R, 2015, PEDIATR CRIT CARE ME, V16, P1, DOI 10.1097/PCC.0000000000000272; Holzer M, 2002, NEW ENGL J MED, V346, P549; Hutchison J, 2006, DEV NEUROSCI-BASEL, V28, P291, DOI 10.1159/000094155; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Jacobs SE, 2011, ARCH PEDIAT ADOL MED, V165, P692, DOI 10.1001/archpediatrics.2011.43; Kochanek PM, 2009, J NEUROTRAUM, V26, P421, DOI 10.1089/neu.2008.0587; Laptook A, 2008, PEDIATRICS, V122, P491, DOI 10.1542/peds.2007-1673; Marshall LF, 2001, J NEUROSURG, V95, P733, DOI 10.3171/jns.2001.95.5.0733; Moler FW, 2013, PEDIATR CRIT CARE ME, V14, pE304, DOI 10.1097/PCC.0b013e31828a863a; Moler FW, 2011, CRIT CARE MED, V39, P141, DOI 10.1097/CCM.0b013e3181fa3c17; Moler FW, 2009, CRIT CARE MED, V37, P2259, DOI 10.1097/CCM.0b013e3181a00a6a; Neumar RW, 2008, CIRCULATION, V118, P2452, DOI 10.1161/CIRCULATIONAHA.108.190652; Nielsen N, 2013, NEW ENGL J MED, V369, P2197, DOI 10.1056/NEJMoa1310519; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Papile LA, 2014, PEDIATRICS, V133, P1146, DOI 10.1542/peds.2014-0899; Peberdy MA, 2010, CIRCULATION, V122, pS768, DOI 10.1161/CIRCULATIONAHA.110.971002; Pemberton VL, 2013, PEDIATR CRIT CARE ME, V14, P19, DOI 10.1097/PCC.0b013e31825b860b; Scholefield B, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009442.pub2; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Sparrow S, 2005, VINELAND ADAPTIVE BE; The Psychological Corporation, 1999, WECHSL ABBR SCAL INT; VANELTEREN P, 1960, B INT STATIST INST, V37, P351; Young KD, 2004, PEDIATRICS, V114, P157, DOI 10.1542/peds.114.1.157; Zeiner A, 2001, ARCH INTERN MED, V161, P2007, DOI 10.1001/archinte.161.16.2007	37	233	240	1	26	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 14	2015	372	20					1898	1908		10.1056/NEJMoa1411480			11	Medicine, General & Internal	General & Internal Medicine	CI1HB	WOS:000354493300005	25913022	Green Accepted, Bronze	Y	N	2021-06-18	
J	Liu, NK; Wang, XF; Lu, QB; Xu, XM				Liu, Nai-Kui; Wang, Xiao-Fei; Lu, Qing-Bo; Xu, Xiao-Ming			Altered microRNA expression following traumatic spinal cord injury	EXPERIMENTAL NEUROLOGY			English	Article						Spinal cord injury; MicroRNA; Inflammation; Oxidation; Apoptosis; Gene expression	MICROARRAY ANALYSIS; DEGENERATION; APOPTOSIS; IDENTIFICATION; NEURONS; SYSTEM; BRAIN; MOUSE; SHOWS; RATS	MicroRNAs (miRNAs) are a novel class of small non-coding RNAs that negatively regulate gene expression at the posttranscriptional level by binding to the 3' untranslated region of target mRNAs leading to their translational inhibition or sometimes degradation. We uncovered a previously unknown alteration in temporal expression of a large set of miRNAs following a contusive spinal cord injury (SCI) in adult rats using microarray analysis. These altered miRNAs can be classified into 3 categories: (1) up-regulation, (2) downregulation and (3) an early up-regulation at 4 h followed by down-regulation at 1 and 7 days post-SCI. The bioinformatics analysis indicates that the potential targets for miRNAs altered after SCI include genes encoding components that are involved in the inflammation, oxidation, and apoptosis that are known to play important roles in the pathogenesis of SCI. These findings suggest that abnormal expression of miRNAs may contribute to the pathogenesis of SCI and are potential targets for therapeutic interventions following SCI. (C) 2009 Elsevier Inc. All rights reserved.	[Xu, Xiao-Ming] Indiana Univ, Sch Med, Spinal Cord & Brain Injury Res Grp, Stark Neurosci Res Inst, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Neurol Surg, Indianapolis, IN 46202 USA	Xu, XM (corresponding author), Indiana Univ, Sch Med, Spinal Cord & Brain Injury Res Grp, Stark Neurosci Res Inst, 950 W Walnut St,R-2 Bldg,Room 402, Indianapolis, IN 46202 USA.	xu26@iupui.edu		Xu, Xiao-ming/0000-0002-7229-0081	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS36350, NS52290, NS50243]; Hulman George Endowment Funds a; State of Indiana [91910, 91913]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050243, R01NS036350, R01NS052290] Funding Source: NIH RePORTER	This work was supported by NIH NS36350, NS52290, NS50243, Mari Hulman George Endowment Funds and the State of Indiana (Grant # 91910 and 91913).	Bak M, 2008, RNA, V14, P432, DOI 10.1261/rna.783108; Bareyre FM, 2003, TRENDS NEUROSCI, V26, P555, DOI 10.1016/j.tins.2003.08.004; Beattie MS, 2000, J NEUROTRAUM, V17, P915, DOI 10.1089/neu.2000.17.915; Bilen J, 2006, MOL CELL, V24, P157, DOI 10.1016/j.molcel.2006.07.030; Chan CS, 2005, PLOS COMPUT BIOL, V1, P564, DOI 10.1371/journal.pcbi.0010069; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Di Giovanni S, 2003, ANN NEUROL, V53, P454, DOI 10.1002/ana.10472; Esau CC, 2007, ADV DRUG DELIVER REV, V59, P101, DOI 10.1016/j.addr.2007.03.007; Kim J, 2004, P NATL ACAD SCI USA, V101, P360, DOI 10.1073/pnas.2333854100; Kim J, 2007, SCIENCE, V317, P1220, DOI 10.1126/science.1140481; Kosik KS, 2006, NAT REV NEUROSCI, V7, P911, DOI 10.1038/nrn2037; Krichevsky AM, 2003, RNA, V9, P1274, DOI 10.1261/rna.5980303; Lagos-Quintana M, 2002, CURR BIOL, V12, P735, DOI 10.1016/S0960-9822(02)00809-6; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Liu N, 2004, J NEUROSCI RES, V77, P391, DOI 10.1002/jnr.20167; Liu NK, 2006, ANN NEUROL, V59, P606, DOI 10.1002/ana.20798; Liu XZ, 1997, J NEUROSCI, V17, P5395; Medina PP, 2009, NAT METHODS, V6, P37, DOI 10.1038/nmeth0109-37; Mirnezami AHF, 2009, EJSO-EUR J SURG ONC, V35, P339, DOI 10.1016/j.ejso.2008.06.006; Miska EA, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r68; Nesic O, 2002, J NEUROSCI RES, V68, P406, DOI 10.1002/jnr.10171; Schaefer A, 2007, J EXP MED, V204, P1553, DOI 10.1084/jem.20070823; Weiler J, 2006, GENE THER, V13, P496, DOI 10.1038/sj.gt.3302654	23	233	250	0	25	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	OCT	2009	219	2					424	429		10.1016/j.expneurol.2009.06.015			6	Neurosciences	Neurosciences & Neurology	498QN	WOS:000270157300008	19576215	Green Accepted			2021-06-18	
J	Ponsford, J; Draper, K; Schonberger, M				Ponsford, Jennie; Draper, Kristy; Schonberger, Michael			Functional outcome 10 years after traumatic brain injury: Its relationship with demographic, injury severity, and cognitive and emotional status	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						closed head injuries; assessment; patient outcomes; Glasgow Outcome Scale	SEVERE HEAD-INJURY; FOLLOW-UP; PSYCHOSOCIAL ADJUSTMENT; COMMUNITY INTEGRATION; PREDICTION; WORK; TBI; RETURN; REHABILITATION; DEPRESSION	previous investigations of long-term outcome following traumatic brain injury (TB1) have yielded mixed results there regarding the predictive power of injury severity and demographic factors. Furthermore, there has been limited investigation of the association between long-term outcome and current cognitive functioning and psychiatric State. The aim of this study was to investigate the association of injury Severity, demographic factors, and concurrent cognitive and psychiatric functioning With functional outcome 10 years following mild to severe TBI. Outcome was rated using the Extended Glasgow Outcome Scale (GOSE) for 60 participants, who also completed neuropsychological measures of attention, speed of processing, memory and executive function and the Hospital Anxiety and Depression Scale (HADS). Outcome on the GOSE ranged from upper good recovery (32%) to lower severe disability (2%). Participants showing poorer outcome on the GOSE had significantly longer posttraumatic amnesia duration less education performed more poorly on cognitive measures of information processing speed, attention, memory and executive function and showed higher levels of anxiety on the HADS.	[Ponsford, Jennie; Draper, Kristy; Schonberger, Michael] Monash Univ, Dept Psychol, Sch Psychol Psychiat & Psychol Med, Clayton, Vic 3800, Australia; [Schonberger, Michael] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [Ponsford, Jennie] Natl Trauma Res Inst, Melbourne, Vic, Australia	Ponsford, J (corresponding author), Monash Univ, Dept Psychol, Sch Psychol Psychiat & Psychol Med, Clayton, Vic 3800, Australia.	jennie.ponsford@med.monash.edu.au					Baddeley A, 1994, DOORS PEOPLE; Benton A., 1994, MULTILINGUAL APHASIA; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Cattelani R, 2002, BRAIN INJURY, V16, P51, DOI 10.1080/02699050110088821; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Doig E, 2001, BRAIN INJURY, V15, P747, DOI 10.1080/02699050110034343; DRAPER K, COGNITIVE FUNC UNPUB; Faul F., 1992, GPOWER PRIORI POSTHO; Fleming J, 1999, BRAIN INJURY, V13, P417; Franulic A, 2004, BRAIN INJURY, V18, P119, DOI 10.1080/0269905031000149515; GODFREY HPD, 1993, NEW ZEAL MED J, V106, P301; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Hoofien D, 2001, BRAIN INJURY, V15, P189; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; Johnson R, 1998, NEUROPSYCHOL REHABIL, V8, P61, DOI 10.1080/713755552; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Lezak M. D., 1976, NEUROPSYCHOLOGICAL A; Medd J, 2000, NEUROPSYCHOL REHABIL, V10, P185, DOI 10.1080/096020100389246; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Pastorek NJ, 2004, J INT NEUROPSYCH SOC, V10, P807, DOI 10.1017/S1355617704106012; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Porteus S.D., 1965, PORTEUS MAZE TEST 50; Powell J, 2002, J NEUROL NEUROSUR PS, V72, P193, DOI 10.1136/jnnp.72.2.193; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Reitan RM, 1988, HALSTEADREITAN NEURO; Rey A., 1958, LEXAMEN CLINIQUE PSY; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Rothweiler B, 1998, ARCH PHYS MED REHAB, V79, P881, DOI 10.1016/S0003-9993(98)90082-X; Shallice, 1997, HAYLING BRIXTON TEST; Sherer M, 2002, CLIN NEUROPSYCHOL, V16, P157, DOI 10.1076/clin.16.2.157.13238; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Smith A., 1973, SYMBOL DIGIT MODALIT; Snaith R.P., 1994, HOSP ANXIETY DEPRESS; Tate R., 2005, BRAIN IMPAIR, V6, P75, DOI DOI 10.1375/BRIM.2005.6.2.75; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204; Wood RL, 2006, J NEUROL NEUROSUR PS, V77, P71, DOI 10.1136/jnnp.2005.065540; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498	49	233	235	0	35	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAR	2008	14	2					233	242		10.1017/S1355617708080272			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	338VJ	WOS:000258537200006	18282321	Bronze			2021-06-18	
J	Rechel, JA; Yard, EE; Comstock, RD				Rechel, Julie A.; Yard, Ellen E.; Comstock, R. Dawn			An epidemiologic comparison of high school sports injuries sustained in practice and competition	JOURNAL OF ATHLETIC TRAINING			English	Article						injury surveillance; injury rates	RISK-FACTORS; FOOTBALL PLAYERS; NORTH-CAROLINA; UNITED-STATES; CONCUSSION; COLLEGIATE; BASKETBALL; PATTERNS; SOCCER; GIRLS	Context: More than 7 million US high school students play sports. Objective: To compare practice and competition injury rates and patterns in 5 boys' sports (football, soccer, basketball, wrestling, and baseball) and 4 girls' sports (soccer, volleyball, basketball, and softball) during the 2005-2006 school year. Design: Prospective injury surveillance study. Setting: Injury data were collected from 100 nationally representative United States high schools via High School RIO (Reporting Information Online). Patients or Other Participants: Athletes from participating high schools injured while participating in a school-sanctioned practice or competition in one of the above sports. Main Outcome Measure(s): Practice and competition injury rates, body site, diagnosis, and severity. Results: High school athletes participating in these 9 sports at participating schools sustained 4350 injuries during the 20052006 school year, which corresponds to an estimated 1442 533 injuries nationally. The rate of injury per 1000 athlete-exposures was higher in competition (4.63) than in practice (1.69) (rate ratio [RR] = 2.73, 95% confidence interval [CI] = 2.58, 2.90). Of all sports, football had the highest competition (12.09) and practice (2.54) injury rates per 1000 athlete-exposures. Compared with injuries sustained during practice, higher proportions of competition injuries were head/face/neck injuries (proportion ratio [PR] = 1.61, 95% CI = 1.34, 1.94), particularly in boys' soccer (PR = 7.74, 95% CI = 2.53, 23.65) and girls' basketball (PR = 6.03, 95% CI = 2.39, 15.22). Competition injuries were more likely to be concussions (PR 2.02, 95% CI = 1.56, 2.62), especially in boys' soccer (PR 6.94, 95% CI = 2.01, 23.95) and girls' basketball (PR = 5.83, 95% CI = 2.06, 16.49). Higher proportions of competition injuries caused the athlete to miss more than 3 weeks of play (PR = 1.28, 95% CI = 1.08, 1.52), particularly in baseball (PR = 3.47, 95% CI = 1.48, 8.11) and volleyball (PR = 2.88, 95% CI = 1.01, 8.24). Conclusions: Rates and patterns of high school sport injuries differed between practice and competition. Providing athletic trainers with this information is a crucial step in developing the targeted, evidence-based interventions required to effectively reduce injury rates among the millions of high school student-athletes.	[Rechel, Julie A.; Yard, Ellen E.; Comstock, R. Dawn] Nationwide Childrens Hosp, Res Inst, Ctr Injury Res & Policy, Columbus, OH 43205 USA; [Comstock, R. Dawn] Ohio State Univ, Columbus, OH 43210 USA	Yard, EE (corresponding author), Nationwide Childrens Hosp, Res Inst, Ctr Injury Res & Policy, 700 Childrens Dr, Columbus, OH 43205 USA.	Ellen.Yard@NationwideChildrens.org	Patterson, Julie/AAG-2848-2019		NCIPC CDC HHS [R49 CE000674, R49/CE000674-01] Funding Source: Medline; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE000674] Funding Source: NIH RePORTER		[Anonymous], CAS HIGH SCH ACT; Beynnon BD, 2005, AM J SPORT MED, V33, P1485, DOI 10.1177/0363546505275490; Comstock R. D., 2006, Morbidity and Mortality Weekly Report, V55, P1037; Emery CA, 2005, AM J SPORT MED, V33, P1882, DOI 10.1177/0363546505279576; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gomez E, 1996, AM J SPORT MED, V24, P684, DOI 10.1177/036354659602400521; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; HALPERN B, 1987, AM J SPORT MED, V15, P316, DOI 10.1177/036354658701500404; Hinton RY, 2005, AM J SPORT MED, V33, P1305, DOI 10.1177/0363546504274148; INKLAAR H, 1994, SPORTS MED, V18, P55, DOI 10.2165/00007256-199418010-00006; Ireland ML, 1999, J ATHL TRAINING, V34, P150; Knowles SB, 2006, AM J EPIDEMIOL, V164, P1209, DOI 10.1093/aje/kwj337; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; Messina DF, 1999, AM J SPORT MED, V27, P294, DOI 10.1177/03635465990270030401; Mueller FO, 2001, J ATHL TRAINING, V36, P312; *NAT FED STAT HIGH, 2005 06 HIGH SCH ATH; Pasque CB, 2000, AM J SPORT MED, V28, P509, DOI 10.1177/03635465000280041101; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Powell JW, 2001, J ATHL TRAINING, V36, P307; Powell JW, 1999, J ATHL TRAINING, V34, P277; Ramirez M, 2006, AM J SPORT MED, V34, P1147, DOI 10.1177/0363546505284385; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Shankar PR, 2007, AM J SPORT MED, V35, P1295, DOI 10.1177/0363546507299745; Stuart Michael J, 2005, Med Sport Sci, V49, P62, DOI 10.1159/000085392; Turbeville SD, 2003, AM J SPORT MED, V31, P974, DOI 10.1177/03635465030310063801; Willer B, 2005, MED SCI SPORT EXER, V37, P1658, DOI 10.1249/01.mss.0000181839.86170.06; WROBLE RR, 1986, AM J SPORT MED, V14, P55, DOI 10.1177/036354658601400110	27	233	233	1	17	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050			J ATHL TRAINING	J. Athl. Train.	MAR-APR	2008	43	2					197	204		10.4085/1062-6050-43.2.197			8	Sport Sciences	Sport Sciences	293TX	WOS:000255359200013	18345346	Green Published, Bronze			2021-06-18	
J	McKinlay, A; Grace, RC; Horwood, LJ; Fergusson, DM; Ridder, EM; Macfarlane, MR				McKinlay, A.; Grace, R. C.; Horwood, L. J.; Fergusson, D. M.; Ridder, E. M.; Macfarlane, M. R.			Prevalence of traumatic brain injury among children, adolescents and young adults: Prospective evidence from a birth cohort	BRAIN INJURY			English	Article						children; traumatic brain injury; incidence; prevalence; young adults	MILD HEAD-INJURY; NEW-ZEALAND; HEALTH	Background: Little is known about the incidence and prevalence of traumatic brain injury (TBI), particularly for infants, children and young adults. Primary objective: The purpose of this study was to provide an accurate estimate of the incidence and prevalence of TBIs for individuals between 0-25 years of age. Method and procedures: A birth cohort of 1265 individuals was used, for which information regarding TBI events, both hospitalized and non-hospitalized, had been recorded. Main outcomes and results: The average incidence for this age group ranged from 1.10-2.36 per 100 per year, with an overall prevalence of 30%. The most common source of injury was falls for individuals 0-14 years of age and contact sports and motor vehicle accidents for 15-25 year olds. Approximately one third of the individuals who experienced a TBI went on to have one or more additional injuries. Conclusions: The incidence rates reported here are much higher than those previously found. It is clear that TBIs constitute a major health issue and therefore it is important to have accurate information to enable planning for primary healthcare services and to inform prevention programmes.	[McKinlay, A.; Grace, R. C.] Univ Canterbury, Dept Psychol, Christchurch 1, New Zealand; [Horwood, L. J.; Fergusson, D. M.; Ridder, E. M.] Univ Otago, Christchurch Hlth & Dev Study, Christchurch, New Zealand; [Macfarlane, M. R.] Christchurch Hosp, Dept Neurosurg, Christchurch, New Zealand	McKinlay, A (corresponding author), Univ Canterbury, Dept Psychol, Private Bag 4800, Christchurch 1, New Zealand.	aco24@student.canterbury.ac.nz		Grace, Randolph/0000-0003-1115-6089; Fergusson, David/0000-0002-8117-017X; McKinlay, Audrey/0000-0001-9846-8514; Horwood, L./0000-0003-4881-1956			Body C, 1996, BRAIN INJURY, V10, P567, DOI 10.1080/026990596124133; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Fergusson D M, 1989, Paediatr Perinat Epidemiol, V3, P302; Fergusson DM, 2001, AUST NZ J PSYCHIAT, V35, P287, DOI 10.1046/j.1440-1614.2001.00902.x; FIFE D, 1987, AM J PUBLIC HEALTH, V77, P810, DOI 10.2105/AJPH.77.7.810; Gaultieri T, 1991, BRAIN INJURY, V5, P219; Gronwall D, 1997, J Int Neuropsychol Soc, V3, P592; Hawley CA, 2003, INJURY, V34, P256, DOI 10.1016/S0020-1383(02)00193-6; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; Peloso PM, 2004, J REHABIL MED, V36, P22, DOI 10.1080/16501960410023714; SEGALOWITZ SJ, 1991, J LEARN DISABIL, V24, P551, DOI 10.1177/002221949102400907; Sosin DM, 1996, BRAIN INJURY, V10, P47; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; WRIGHTSON P, 1995, J NEUROL NEUROSUR PS, V59, P375, DOI 10.1136/jnnp.59.4.375; Wrightson P, 1998, NEW ZEAL MED J, V111, P99	16	233	235	0	25	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	2					175	181		10.1080/02699050801888824			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	258DW	WOS:000252849600008	18240046				2021-06-18	
J	Pelinka, LE; Kroepfl, A; Leixnering, M; Buchinger, W; Raabe, A; Redl, H				Pelinka, LE; Kroepfl, A; Leixnering, M; Buchinger, W; Raabe, A; Redl, H			GFAP versus S100B in serum after traumatic brain injury: Relationship to brain damage and outcome	JOURNAL OF NEUROTRAUMA			English	Article						computerized tomography; GFAP; intracranial pressure; neuromarkers; perfusion pressure; S100B protein	FIBRILLARY ACIDIC PROTEIN; NEURON-SPECIFIC ENOLASE; CEREBROSPINAL-FLUID; CEREBRAL-ISCHEMIA; CARDIAC-SURGERY; S-100 PROTEIN; HEAD-INJURY; BLOOD; RELEASE; MARKERS	Research indicates that glial fibrillary acidic protein (GFAP), part of the astroglial skeleton, could be a marker of traumatic brain injury (TBI). S100B, an astroglial protein, is an acknowledged marker of TBI. Our goal was to analyze the relationship of GFAP/S100B to brain damage and outcome, and to compare the accuracy of GFAP/S100B for prediction of mortality after TBI. Our prospective study included 92 patients admitted <12 h after TBI (median injury severity score 25, median Glasgow Coma Scale 6). TBI was verfied by computerized tomography. GFAP/S100B were measured immunoluminometrically at admission and daily in the intensive care unit (average 10 days, range 1-21 days). We compared GFAP/S100B in non-survivors versus survivors, accuracy for mortality prediction according to receiver operated characteristic curve analysis, correlation between GFAP and S100B, relationship of GFAP/S100B to computerized tomography, cerebral perfusion pressure (CPP), mean arterial pressure (MAP) and 3-month Glasgow Outcome Score (GOS). GFAP (p < 0.005) and S100B (p < 0.0005) were higher in non-survivors than survivors. Both GFAP and S100B were accurate for mortality prediction (area under curve 0.84 versus 0.78 at <12 h after TBI). GFAP and S100B release correlated better later than 36 h after TBI (r = 0.75) than earlier (r = 0.58). GFAP was lower in focal lesions of <25 mL than in shifts of >0.5 cm (P < 0.0005) and non-evacuated mass lesions of >25 mL (p < 0.005). S100B was lower in focal lesions of <25 mL than in non-evacuated mass lesions (p < 0.0005) and lower in swelling than in shifts of >0.5 cm (p < 0.005). GFAP and S100B were lower in ICP < 25 than ICP greater than or equal to 25 (p < 0.0005), in CPP greater than or equal to 60 than CPP < 60 (p < 0.0005), in MAP > 70 than MAP:5 70 nun Hg, and in GOS 4-5 than GOS 1 (p < 0.0005). Both measurement of GFAP and S100B is a useful non-invasive means of identifying brain damage with some differences based on the pattern of TBI and accompanying multiple trauma and/or shock.	Ludwig Boltzmann Inst Expt & Clin Traumatol, A-1200 Vienna, Austria; Austrian Workers Compensat Board, Res Unit, AUVA, Vienna, Austria; AUVA, Trauma Hosp Linz, Linz, Austria; Waldviertel Clin, Dept Traumatol, Horn, Austria; Goethe Univ Frankfurt, Dept Neurosurg, Neuroctr, D-6000 Frankfurt, Germany	Pelinka, LE (corresponding author), Ludwig Boltzmann Inst Expt & Clin Traumatol, Donaueschingenstr 13, A-1200 Vienna, Austria.	lindapel@via.at	Redl, Heinz/AAD-8157-2019				ALBRECHTSEN M, 1985, J NEUROCHEM, V44, P560, DOI 10.1111/j.1471-4159.1985.tb05449.x; Anderson RE, 2001, ANN THORAC SURG, V71, P1512, DOI 10.1016/S0003-4975(01)02399-2; Baydas G, 2003, EUR J PHARMACOL, V462, P67, DOI 10.1016/S0014-2999(03)01294-9; BLENNOW M, 1995, PEDIATR RES, V37, P260, DOI 10.1203/00006450-199503000-00002; Blennow M, 1996, ACTA PAEDIATR, V85, P485, DOI 10.1111/j.1651-2227.1996.tb14068.x; Blow O, 1999, J TRAUMA, V47, P964, DOI 10.1097/00005373-199911000-00028; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Chatfield DA, 2002, BRIT J NEUROSURG, V16, P471, DOI 10.1080/0268869021000030285; Duchen L. W, 1984, GREENFIELDS NEUROPAT, P1; ENG LF, 1971, BRAIN RES, V28, P351, DOI 10.1016/0006-8993(71)90668-8; HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Heizmann CW, 2002, FRONT BIOSCI-LANDMRK, V7, pD1356, DOI 10.2741/heizmann; Herrmann M, 2000, STROKE, V31, P2670, DOI 10.1161/01.STR.31.11.2670; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Hinkle DA, 1997, J NEUROTRAUM, V14, P729, DOI 10.1089/neu.1997.14.729; Hu JR, 1997, J NEUROCHEM, V69, P2294; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; ISOBE T, 1984, J NEUROCHEM, V43, P1494, DOI 10.1111/j.1471-4159.1984.tb05415.x; JENNETT B, 1975, LANCET, V1, P480; Johnsson P, 2003, ANN THORAC SURG, V75, P162, DOI 10.1016/S0003-4975(02)04318-7; Kapural M, 2002, BRAIN RES, V940, P102, DOI 10.1016/S0006-8993(02)02586-6; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Martinez G, 1998, INT J DEV NEUROSCI, V16, P519, DOI 10.1016/S0736-5748(98)00035-5; Mauritz W, 1998, ANASTH INTENSIV NOTF, V33, P441, DOI 10.1055/s-2007-994281; McAdory BS, 1998, BRAIN RES, V813, P211, DOI 10.1016/S0006-8993(98)01014-2; Missler U, 1997, STROKE, V28, P1956, DOI 10.1161/01.STR.28.10.1956; Missler U, 1999, CLIN CHEM, V45, P138; NOPPE M, 1986, CLIN CHIM ACTA, V155, P143, DOI 10.1016/0009-8981(86)90275-5; PELINKA L, 2003, BRIT J ANAESTH, V91, P1; Pelinka LE, 2003, SHOCK, V19, P422, DOI 10.1097/01.shk.0000055345.58165.52; Pelinka LE, 2003, SHOCK, V19, P195, DOI 10.1097/00024382-200303000-00001; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; Petersson KH, 2002, PEDIATR RES, V51, P768, DOI 10.1203/01.PDR.0000017486.64723.D1; Petzold A, 2002, CRIT CARE MED, V30, P2705, DOI 10.1097/00003246-200212000-00015; Pleines UE, 2001, J NEUROTRAUM, V18, P491, DOI 10.1089/089771501300227297; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Regner A, 2001, J NEUROTRAUM, V18, P783, DOI 10.1089/089771501316919148; ROSENGREN LE, 1994, J NEUROSCI METH, V51, P197, DOI 10.1016/0165-0270(94)90011-6; Townend WJ, 2002, J NEUROL NEUROSUR PS, V73, P542, DOI 10.1136/jnnp.73.5.542; VAAGE JAR, 2003, J THORAC CARDIOVASC, V125, pS31; Valentim LM, 1999, NEUROSCIENCE, V91, P1291, DOI 10.1016/S0306-4522(98)00707-6; van Geel WJA, 2002, CLIN CHIM ACTA, V326, P151, DOI 10.1016/S0009-8981(02)00330-3; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	44	233	244	2	16	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2004	21	11					1553	1561		10.1089/0897715042441846			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	872IL	WOS:000225200800003	15684648				2021-06-18	
J	Aimaretti, G; Ambrosio, MR; Di Somma, C; Fusco, A; Cannavo, S; Gasperi, M; Scaroni, C; De Marinis, L; Benvenga, S; degli Uberti, E; Lombardi, G; Mantero, F; Martino, E; Giordano, G; Ghigo, E				Aimaretti, G; Ambrosio, MR; Di Somma, C; Fusco, A; Cannavo, S; Gasperi, M; Scaroni, C; De Marinis, L; Benvenga, S; degli Uberti, E; Lombardi, G; Mantero, F; Martino, E; Giordano, G; Ghigo, E			Traumatic brain injury and subarachnoid haemorrhage are conditions at high risk for hypopituitarism: screening study at 3 months after the brain injury	CLINICAL ENDOCRINOLOGY			English	Article							GROWTH-HORMONE DEFICIENCY; GH DEFICIENCY; NEUROENDOCRINE DYSFUNCTION; PLUS-ARGININE; DIAGNOSIS; ADULTS; TESTS	OBJECTIVE Acquired hypopituitarism in adults is obviously suspected in patients with primary hypothalamic-pituitary diseases, particularly after neurosurgery and/or radiotherapy. That brain injuries (BI) can cause hypopituitarism is commonly stated and has been recently emphasized but the management of BI patients does not routinely include neuroendocrine evaluations. AIM To clarify the occurrence of hypopituitarism in patients after traumatic brain injury (TBI) or subarachnoid haemorrhage (SAH) 3 months after the BI. SUBJECTS AND METHODS The occurrence of hypopituitarism in conscious patients after traumatic brain injury [TBI, n = 100, 31 women, 69 men; age 37.1 +/- 1.8 years; body mass index (BMI) 23.7 +/- 0.4 kg/m(2); Glasgow Coma Scale (GCS) 3-15] or subarachnoid haemorrhage [SAH, n = 40, 14 men, 26 wpmen, 51.0 +/- 2.0 years; 25.0 +/- 0.6 kg/m(2); Fisher's scale 1-4] was studied in a multicentre study 3 months after the BI. All patients underwent wide basal hormonal evaluation; the GH/IGF-I axis was evaluated by GHRH + arginine test and IGF-I measurement. RESULTS In TBI patients, some degree of hypopituitarism was shown in 35%. Total, multiple and isolated deficits were present in 4, 6 and 25%, respectively. Diabetes insipidus was present in 4%. Secondary adrenal, thyroid and gonadal deficit was present in 8, 5 and 17%, respectively. Severe GH deficiency (GHD) was the most frequent pituitary defect (25%). In SAH patients, some degree of hypopituitarism was shown in 37.5%. Despite no total hypopituitarism, multiple and isolated deficits were present in 10 and 27.5%, respectively. Diabetes insipidus was present in 7.5%. Secondary adrenal, thyroid and gonadal deficit was present in 2.5, 7.5 and 12.5%, respectively. Severe GHD was the most frequent defect (25%). CONCLUSIONS TBI and SAH are conditions associated with high risk of acquired hypopituitarism. The pituitary defect is often multiple and severe GHD is the most frequent defect. Thus neuroendocrine evaluations are always mandatory in patients after brain injuries.	Univ Turin, Dept Internal Med, Div Endocrinol & Metab, I-10126 Turin, Italy; Univ Ferrara, Dept Biomed Sci & Adv Therapies, Endocrinol Sect, I-44100 Ferrara, Italy; Univ Naples Federico II, Dept Mol & Clin Endocrinol & Oncol, Naples, Italy; Catholic Univ, Div Endocrinol, Rome, Italy; Univ Messina, Dept Med & Pharmacol, Endocrinol Sect, Messina, Italy; Univ Pisa, Dept Endocrinol & Metab, Pisa, Italy; Univ Padua, Dept Surg & Med Sci, Div Endocrinol, Padua, Italy; Italian Soc Endocrinol, Genoa, Italy	Ghigo, E (corresponding author), Univ Turin, Dept Internal Med, Div Endocrinol & Metab Dis, Cso Dogliotti 14, I-10126 Turin, Italy.	ezio.ghigo@unito.it	Scaroni, Carla/G-3853-2017; Cannavo, Salvatore/D-7608-2013; Di Somma, Carolina/K-7772-2016	Scaroni, Carla/0000-0001-9396-3815; Cannavo, Salvatore/0000-0001-8779-7283; Di Somma, Carolina/0000-0002-5724-1951; degli Uberti, Ettore/0000-0002-9441-7223; ambrosio, maria rosaria/0000-0002-7911-9770			Aimaretti G, 2001, J Pediatr Endocrinol Metab, V14 Suppl 5, P1233; Aimaretti G, 1998, J CLIN ENDOCR METAB, V83, P1615, DOI 10.1210/jc.83.5.1615; Aimaretti G, 2003, CLIN ENDOCRINOL, V59, P56, DOI 10.1046/j.1365-2265.2003.01794.x; Aimaretti G, 2000, J CLIN ENDOCR METAB, V85, P3693, DOI 10.1210/jc.85.10.3693; Attanasio A, 1998, J CLIN ENDOCR METAB, V83, P379; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Biller BMK, 2002, J CLIN ENDOCR METAB, V87, P2067, DOI 10.1210/jcem.87.5.8509; Carroll PV, 1998, J CLIN ENDOCR METAB, V83, P382, DOI 10.1210/jc.83.2.382; Ceballos R, 1966, Ala J Med Sci, V3, P185; Childers MK, 1998, BRAIN INJURY, V12, P517, DOI 10.1080/026990598122476; Cornelia G, 2003, GROWTH HORM IGF RES, V13, P104, DOI 10.1016/S1096-6374(03)00010-8; De Marinis L, 1999, CLIN ENDOCRINOL, V50, P741; DEBOER H, 1995, ENDOCR REV, V16, P63, DOI 10.1210/er.16.1.63; EDWARDS OM, 1986, MEDICINE, V65, P281; FABLIA G, 2001, ENDOCRINOL METAB, P73; Ghigo E, 2001, ENDOCRINE, V15, P29, DOI 10.1385/ENDO:15:1:029; Goetz CG., 1999, TXB CLIN NEUROLOGY; Hartman ML, 2002, J CLIN ENDOCR METAB, V87, P477, DOI 10.1210/jc.87.2.477; HOFFMAN DM, 1994, LANCET, V343, P1064, DOI 10.1016/S0140-6736(94)90181-3; Israel E, 2000, J CLIN ENDOCR METAB, V85, P3990; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Lamberts SWJ, 1998, LANCET, V352, P127; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; LISSETT CA, 1996, ENDOCRINOLOGY, P145; Maccario M, 2002, ANN ENDOCRINOL-PARIS, V63, P140; Pombo M, 2001, Eat Weight Disord, V6, P22; Shalet SM, 1998, ENDOCR REV, V19, P203, DOI 10.1210/er.19.2.203; THORNER MO, 1998, WILLIAMS TXB ENDOCRI, P165	28	233	242	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0300-0664	1365-2265		CLIN ENDOCRINOL	Clin. Endocrinol.	SEP	2004	61	3					320	326		10.1111/j.1365-2265.2004.02094.x			7	Endocrinology & Metabolism	Endocrinology & Metabolism	851VA	WOS:000223712900004	15355447				2021-06-18	
J	Ajiboye, AB; Willett, FR; Young, DR; Memberg, WD; Murphy, BA; Miller, JP; Walter, BL; Sweet, JA; Hoyen, HA; Keith, MW; Peckham, PH; Simeral, JD; Donoghue, JP; Hochberg, LR; Kirsch, RF				Ajiboye, A. Bolu; Willett, Francis R.; Young, Daniel R.; Memberg, William D.; Murphy, Brian A.; Miller, Jonathan P.; Walter, Benjamin L.; Sweet, Jennifer A.; Hoyen, Harry A.; Keith, Michael W.; Peckham, P. Hunter; Simeral, John D.; Donoghue, John P.; Hochberg, Leigh R.; Kirsch, Robert F.			Restoration of reaching and grasping movements through brain-controlled muscle stimulation in a person with tetraplegia: a proof-of-concept demonstration	LANCET			English	Article							FUNCTIONAL ELECTRICAL-STIMULATION; HIGH-LEVEL TETRAPLEGIA; SPINAL-CORD-INJURY; HAND GRASP; CORTICAL CONTROL; IMPLANTED NEUROPROSTHESIS; ARM; DEVICES; PEOPLE	Background People with chronic tetraplegia, due to high-cervical spinal cord injury, can regain limb movements through coordinated electrical stimulation of peripheral muscles and nerves, known as functional electrical stimulation (FES). Users typically command FES systems through other preserved, but unrelated and limited in number, volitional movements (eg, facial muscle activity, head movements, shoulder shrugs). We report the findings of an individual with traumatic high-cervical spinal cord injury who coordinated reaching and grasping movements using his own paralysed arm and hand, reanimated through implanted FES, and commanded using his own cortical signals through an intracortical brain-computer interface (iBCI). Methods We recruited a participant into the BrainGate2 clinical trial, an ongoing study that obtains safety information regarding an intracortical neural interface device, and investigates the feasibility of people with tetraplegia controlling assistive devices using their cortical signals. Surgical procedures were performed at University Hospitals Cleveland Medical Center (Cleveland, OH, USA). Study procedures and data analyses were performed at Case Western Reserve University (Cleveland, OH, USA) and the US Department of Veterans Affairs, Louis Stokes Cleveland Veterans Affairs Medical Center (Cleveland, OH, USA). The study participant was a 53-year-old man with a spinal cord injury (cervical level 4, American Spinal Injury Association Impairment Scale category A). He received two intracortical microelectrode arrays in the hand area of his motor cortex, and 4 months and 9 months later received a total of 36 implanted percutaneous electrodes in his right upper and lower arm to electrically stimulate his hand, elbow, and shoulder muscles. The participant used a motorised mobile arm support for gravitational assistance and to provide humeral abduction and adduction under cortical control. We assessed the participant's ability to cortically command his paralysed arm to perform simple single-joint arm and hand movements and functionally meaningful multi-joint movements. We compared iBCI control of his paralysed arm with that of a virtual three-dimensional arm. This study is registered with ClinicalTrials.gov, number NCT00912041. Findings The intracortical implant occurred on Dec 1, 2014, and we are continuing to study the participant. The last session included in this report was Nov 7, 2016. The point-to-point target acquisition sessions began on Oct 8, 2015 (311 days after implant). The participant successfully cortically commanded single-joint and coordinated multi-joint arm movements for point-to-point target acquisitions (80-100% accuracy), using first a virtual arm and second his own arm animated by FES. Using his paralysed arm, the participant volitionally performed self-paced reaches to drink a mug of coffee (successfully completing 11 of 12 attempts within a single session 463 days after implant) and feed himself (717 days after implant). Interpretation To our knowledge, this is the first report of a combined implanted FES+iBCI neuroprosthesis for restoring both reaching and grasping movements to people with chronic tetraplegia due to spinal cord injury, and represents a major advance, with a clear translational path, for clinically viable neuroprostheses for restoration of reaching and grasping after paralysis.	[Ajiboye, A. Bolu; Willett, Francis R.; Young, Daniel R.; Memberg, William D.; Murphy, Brian A.; Peckham, P. Hunter; Kirsch, Robert F.] Case Western Reserve Univ, Dept Biomed Engn, Cleveland, OH 44106 USA; [Ajiboye, A. Bolu; Willett, Francis R.; Young, Daniel R.; Memberg, William D.; Murphy, Brian A.; Miller, Jonathan P.; Walter, Benjamin L.; Sweet, Jennifer A.; Hoyen, Harry A.; Keith, Michael W.; Peckham, P. Hunter; Kirsch, Robert F.] Case Western Reserve Univ, Sch Med, Cleveland, OH USA; [Ajiboye, A. Bolu; Willett, Francis R.; Young, Daniel R.; Murphy, Brian A.; Miller, Jonathan P.; Walter, Benjamin L.; Sweet, Jennifer A.; Peckham, P. Hunter; Kirsch, Robert F.] US Dept Vet Affairs, Louis Stokes Cleveland Vet Affairs Med Ctr, Funct Elect Stimulat Ctr Excellence, Rehabil R&D Serv, Cleveland, OH USA; [Walter, Benjamin L.] Univ Hosp Cleveland, Med Ctr, Dept Neurol, Cleveland, OH 44106 USA; [Miller, Jonathan P.; Sweet, Jennifer A.; Kirsch, Robert F.] Univ Hosp Cleveland, Med Ctr, Dept Neurol Surg, Cleveland, OH 44106 USA; [Hoyen, Harry A.; Keith, Michael W.] MetroHlth Med Ctr, Dept Orthopaed, Cleveland, OH USA; [Simeral, John D.; Hochberg, Leigh R.] Brown Univ, Sch Engn, Providence, RI 02912 USA; [Simeral, John D.; Donoghue, John P.; Hochberg, Leigh R.] Brown Univ, Brown Inst Brain Sci, Providence, RI 02912 USA; [Donoghue, John P.] Brown Univ, Dept Neurosci, Providence, RI 02912 USA; [Simeral, John D.; Donoghue, John P.; Hochberg, Leigh R.] Rehabil R&D Serv, Ctr Neurorestorat & Neurotechnol, Dept Vet Affairs, Med Ctr, Providence, RI USA; [Simeral, John D.; Hochberg, Leigh R.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; [Hochberg, Leigh R.] Harvard Med Sch, Dept Neurol, Boston, MA USA; [Donoghue, John P.] Wyss Ctr Bio & Neuroengn, Geneva, Switzerland	Ajiboye, AB (corresponding author), Case Western Reserve Univ, Dept Biomed Engn, Cleveland, OH 44106 USA.	aba20@case.edu	Hochberg, Leigh/R-6872-2019; Walter, Benjamin/J-1481-2019; Walter, Benjamin L/A-6148-2012	Hochberg, Leigh/0000-0003-0261-2273; Walter, Benjamin/0000-0002-8323-6873; Walter, Benjamin L/0000-0002-8323-6873; Kirsch, Robert/0000-0003-2564-1800; Young, Daniel/0000-0003-1861-971X; Memberg, William/0000-0002-2545-8574	National Institutes of Health, Department of Veterans AffairsUS Department of Veterans AffairsUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD077220] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R03HD053403] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [T32EB004314] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01DC009899] Funding Source: NIH RePORTER	National Institutes of Health, Department of Veterans Affairs.	Aflalo T, 2015, SCIENCE, V348, P906, DOI 10.1126/science.aaa5417; Ajiboye AB, 2012, IEEE T BIO-MED ENG, V59, P2755, DOI 10.1109/TBME.2012.2209882; Blana D, 2009, MED BIOL ENG COMPUT, V47, P533, DOI 10.1007/s11517-009-0479-3; Bouton CE, 2016, NATURE, V533, P247, DOI 10.1038/nature17435; Capogrosso M, 2016, NATURE, V539, P284, DOI 10.1038/nature20118; Chadwick EK, 2011, J NEURAL ENG, V8, DOI 10.1088/1741-2560/8/3/034003; Collinger JL, 2013, LANCET, V381, P557, DOI 10.1016/S0140-6736(12)61816-9; Dickey AS, 2009, J NEUROPHYSIOL, V102, P1331, DOI 10.1152/jn.90920.2008; Ethier C, 2012, NATURE, V485, P368, DOI 10.1038/nature10987; Flesher SN, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf8083; Fromm B, 2001, Handchir Mikrochir Plast Chir, V33, P149, DOI 10.1055/s-2001-15129; Hochberg LR, 2006, NATURE, V442, P164, DOI 10.1038/nature04970; Hochberg LR, 2012, NATURE, V485, P372, DOI 10.1038/nature11076; Jorfi M, 2015, J NEURAL ENG, V12, DOI 10.1088/1741-2560/12/1/011001; Keith MW, 1996, J HAND SURG-AM, V21A, P89, DOI 10.1016/S0363-5023(96)80160-2; Kilgore KL, 2008, J HAND SURG-AM, V33A, P539, DOI 10.1016/j.jhsa.2008.01.007; KILGORE KL, 1989, IEEE T BIO-MED ENG, V36, P761, DOI 10.1109/10.32109; Koyama S, 2010, J COMPUT NEUROSCI, V29, P73, DOI 10.1007/s10827-009-0196-9; Lauer RT, 1999, NEUROREPORT, V10, P1767, DOI 10.1097/00001756-199906030-00026; Maynard EM, 1997, ELECTROEN CLIN NEURO, V102, P228, DOI 10.1016/S0013-4694(96)95176-0; Memberg W. D., 1993, IEEE Transactions on Rehabilitation Engineering, V1, P126, DOI 10.1109/86.242426; Memberg WD, 2014, ARCH PHYS MED REHAB, V95, P1201, DOI 10.1016/j.apmr.2014.01.028; Moritz CT, 2008, NATURE, V456, P639, DOI 10.1038/nature07418; Peckham PH, 2001, ARCH PHYS MED REHAB, V82, P1380, DOI 10.1053/apmr.2001.25910; Pfurtscheller G, 2003, NEUROSCI LETT, V351, P33, DOI 10.1016/S0304-3940(03)00947-9; Serruya MD, 2002, NATURE, V416, P141, DOI 10.1038/416141a; Taylor DM, 2002, SCIENCE, V296, P1829, DOI 10.1126/science.1070291; Taylor P, 2002, SPINAL CORD, V40, P560, DOI 10.1038/sj.sc.3101373; Velliste M, 2008, NATURE, V453, P1098, DOI 10.1038/nature06996; Yousry TA, 1997, BRAIN, V120, P141, DOI 10.1093/brain/120.1.141	30	232	241	18	170	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 6	2017	389	10081					1821	1830		10.1016/S0140-6736(17)30601-3			10	Medicine, General & Internal	General & Internal Medicine	ET8KW	WOS:000400549300031	28363483	Green Accepted	Y	N	2021-06-18	
J	Blaser, AR; Starkopf, J; Alhazzani, W; Berger, MM; Casaer, MP; Deane, AM; Fruhwald, S; Hiesmayr, M; Ichai, C; Jakob, SM; Loudet, CI; Malbrain, MLNG; Gonzalez, JCM; Paugam-Burtz, C; Poeze, M; Preiser, JC; Singer, P; Van Zanten, ARH; De Waele, J; Wendon, J; Wernerman, J; Whitehouse, T; Wilmer, A; Oudemans-van Straaten, H				Blaser, Annika Reintam; Starkopf, Joel; Alhazzani, Waleed; Berger, Mette M.; Casaer, Michael P.; Deane, Adam M.; Fruhwald, Sonja; Hiesmayr, Michael; Ichai, Carole; Jakob, Stephan M.; Loudet, Cecilia I.; Malbrain, Manu L. N. G.; Gonzalez, Juan C. Montejo; Paugam-Burtz, Catherine; Poeze, Martijn; Preiser, Jean-Charles; Singer, Pierre; Van Zanten, Arthur R. H.; De Waele, Jan; Wendon, Julia; Wernerman, Jan; Whitehouse, Tony; Wilmer, Alexander; Oudemans-van Straaten, Heleen M.			Early enteral nutrition in critically ill patients: ESICM clinical practice guidelines	INTENSIVE CARE MEDICINE			English	Article						Abdominal problems; Parenteral nutrition; Contraindications; GI symptoms; Early enteral nutrition; Delay of enteral nutrition	INTENSIVE-CARE-UNIT; SEVERE ACUTE-PANCREATITIS; INTRAABDOMINAL HYPERTENSION; GASTROINTESTINAL SURGERY; PARENTERAL-NUTRITION; INDUCED HYPOTHERMIA; STRESS ULCERATION; AORTIC-SURGERY; RISK-FACTORS; METAANALYSIS	To provide evidence-based guidelines for early enteral nutrition (EEN) during critical illness. We aimed to compare EEN vs. early parenteral nutrition (PN) and vs. delayed EN. We defined "early" EN as EN started within 48 h independent of type or amount. We listed, a priori, conditions in which EN is often delayed, and performed systematic reviews in 24 such subtopics. If sufficient evidence was available, we performed meta-analyses; if not, we qualitatively summarized the evidence and based our recommendations on expert opinion. We used the GRADE approach for guideline development. The final recommendations were compiled via Delphi rounds. We formulated 17 recommendations favouring initiation of EEN and seven recommendations favouring delaying EN. We performed five meta-analyses: in unselected critically ill patients, and specifically in traumatic brain injury, severe acute pancreatitis, gastrointestinal (GI) surgery and abdominal trauma. EEN reduced infectious complications in unselected critically ill patients, in patients with severe acute pancreatitis, and after GI surgery. We did not detect any evidence of superiority for early PN or delayed EN over EEN. All recommendations are weak because of the low quality of evidence, with several based only on expert opinion. We suggest using EEN in the majority of critically ill under certain precautions. In the absence of evidence, we suggest delaying EN in critically ill patients with uncontrolled shock, uncontrolled hypoxaemia and acidosis, uncontrolled upper GI bleeding, gastric aspirate > 500 ml/6 h, bowel ischaemia, bowel obstruction, abdominal compartment syndrome, and high-output fistula without distal feeding access.	[Blaser, Annika Reintam; Starkopf, Joel] Univ Tartu, Dept Anaesthesiol & Intens Care, Tartu, Estonia; [Blaser, Annika Reintam] Lucerne Cantonal Hosp, Ctr Intens Care Med, Luzern, Switzerland; [Starkopf, Joel] Tartu Univ Hosp, Dept Anaesthesiol & Intens Care, Tartu, Estonia; [Alhazzani, Waleed] McMaster Univ, Div Crit Care, Dept Med, Hamilton, ON, Canada; [Alhazzani, Waleed] McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; [Berger, Mette M.] Univ Lausanne Hosp, Serv Adult Intens Care Med & Burns, Lausanne, Switzerland; [Casaer, Michael P.] Univ Hosp Leuven, Dept Intens Care Med, Louvain, Belgium; [Deane, Adam M.] Univ Adelaide, Discipline Acute Care Med, Adelaide, SA, Australia; [Fruhwald, Sonja] Med Univ Graz, Dept Anaesthesiol & Intens Care Med, Graz, Austria; [Hiesmayr, Michael] Med Univ Wien, Klin Abt Herz Thorax Gefasschirurg Anasthesie &, Vienna, Austria; [Ichai, Carole] Univ Nice, Hop Pasteur 2, Intens Care Unit, Nice, France; [Jakob, Stephan M.] Univ Bern, Univ Hosp, Dept Intens Care Med, Bern, Switzerland; [Loudet, Cecilia I.] Hosp Interzonal Gen Agudos Gen San Martin de La P, Intens Care Unit, Buenos Aires, DF, Argentina; [Malbrain, Manu L. N. G.] ZNA Stuivenberg, Ziekenhuis Netwerk Antwerpen, Intens Care Unit, Antwerp, Belgium; [Gonzalez, Juan C. Montejo] Hosp Univ 12 Octubre, Dept Intens Care Med, Madrid, Spain; [Paugam-Burtz, Catherine] Hop Beaujon, APHP, Anesthesiol & Perioperat Care Med Dept, Clichy, France; [Poeze, Martijn] Maastricht Univ, Med Ctr, Dept Surg IntensiveCare Med, Maastricht, Netherlands; [Preiser, Jean-Charles] Univ Libre Bruxelles, Erasme Univ Hosp, Dept Intens Care, Brussels, Belgium; [Singer, Pierre] Rabin Med Ctr, Dept Intens Care, Beilinson Campus, Petah Tiqwa, Israel; [Singer, Pierre] Tel Aviv Univ, Sackler Sch Med, Anesthesia & Intens Care Div, Tel Aviv, Israel; [Van Zanten, Arthur R. H.] Gelderse Vallei Hosp, Dept Intens Care Med, Ede, Netherlands; [De Waele, Jan] Ghent Univ Hosp, Dept Crit Care Med, Ghent, Belgium; [Wendon, Julia] Kings Coll London, Kings Coll Hosp, Div Immunobiol & Transplantat, Dept Intens Care Med, London, England; [Wernerman, Jan] Karolinska Univ, Huddinge Hosp, Dept Anaesthesiol & Intens Care Med, Stockholm, Sweden; [Wernerman, Jan] Karolinska Inst, Stockholm, Sweden; [Whitehouse, Tony] Queen Elizabeth Hosp, Dept Crit Care & Anaesthesia, Birmingham, W Midlands, England; [Wilmer, Alexander] Univ Hosp Leuven, Med Intens Care Unit, Leuven, Belgium; [Oudemans-van Straaten, Heleen M.] Vrije Univ Amsterdam, Med Ctr, Dept Intens Care Med, Amsterdam, Netherlands	Blaser, AR (corresponding author), Univ Tartu, Dept Anaesthesiol & Intens Care, Tartu, Estonia.; Blaser, AR (corresponding author), Lucerne Cantonal Hosp, Ctr Intens Care Med, Luzern, Switzerland.	annika.reintam.blaser@ut.ee	Malbrain, Manu LNG/B-3680-2017; Hiesmayr, Michael Joerg/AAR-1969-2020; Starkopf, Joel/C-7538-2013; Blaser, Annika Reintam/M-1573-2013; Whitehouse, Tony/AAC-1215-2020; Deane, Adam/AAF-7370-2020; De Waele, Jan J/E-2704-2013; casaer, michael P/Y-7131-2019; Preiser, Jean-Charles/AAL-2355-2021; Wilmer, Alexander/H-7784-2018	Malbrain, Manu LNG/0000-0002-1816-5255; Starkopf, Joel/0000-0003-4321-3287; Blaser, Annika Reintam/0000-0003-1211-7372; Whitehouse, Tony/0000-0002-4387-3421; Deane, Adam/0000-0002-7620-5577; casaer, michael P/0000-0002-7087-0795; Preiser, Jean-Charles/0000-0003-3163-0390; Wilmer, Alexander/0000-0002-4176-3608; van Zanten, Arthur/0000-0001-6276-7192; Paugam-Burtz, Catherine/0000-0002-8168-7152			Arabi YM, 2015, NEW ENGL J MED, V372, P2398, DOI 10.1056/NEJMoa1502826; Bakiner O, 2013, CRIT CARE, V17, DOI 10.1186/cc12795; Bernard SA, 2003, CRIT CARE MED, V31, P2041, DOI 10.1097/01.CCM.0000069731.18472.61; Bernard SA, 1999, CRIT CARE, V3, P167, DOI 10.1186/cc371; Blaser AR, 2015, CURR OPIN CRIT CARE, V21, P142, DOI 10.1097/MCC.0000000000000188; Burlew CC, 2012, J TRAUMA ACUTE CARE, V73, P1380, DOI 10.1097/TA.0b013e318259924c; CABRE E, 1990, GASTROENTEROLOGY, V98, P715, DOI 10.1016/0016-5085(90)90293-A; Cabre E, 2000, HEPATOLOGY, V32, P36, DOI 10.1053/jhep.2000.8627; Cao YF, 2008, ANN NUTR METAB, V53, P268, DOI 10.1159/000189382; Casaer MP, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2015.07.22; Casaer MP, 2014, NEW ENGL J MED, V370, P1227, DOI 10.1056/NEJMra1304623; Chuntrasakul Chomchark, 1996, Journal of the Medical Association of Thailand, V79, P21; Cook D, 1999, CRIT CARE MED, V27, P2812, DOI 10.1097/00003246-199912000-00034; Dejong CHC, 2007, J NUTR, V137, p1579S, DOI 10.1093/jn/137.6.1579S; Dennis M, 2005, LANCET, V365, P2005, DOI 10.1016/S0140-6736(05)66691-3; Doig GS, 2011, INJURY, V42, P50, DOI 10.1016/j.injury.2010.06.008; Dvorak MF, 2004, SPINE, V29, pE175, DOI 10.1097/00007632-200405010-00020; Fernandez-Ortega JF, 2011, NUTR HOSP, V26, P7, DOI 10.1590/S0212-16112011000800002; Ferrie Suzie, 2007, Aust Crit Care, V20, P7, DOI 10.1016/j.aucc.2006.10.001; Lasierra JLF, 2015, JPEN-PARENTER ENTER, V39, P154, DOI 10.1177/0148607113504219; Fontaine E, 2011, CURR OPIN CLIN NUTR, V14, P171, DOI 10.1097/MCO.0b013e328342bad4; Frost P, 1997, INTENS CARE MED, V23, P243, DOI 10.1007/s001340050322; HASSE JM, 1995, JPEN-PARENTER ENTER, V19, P437, DOI 10.1177/0148607195019006437; Hebuterne X, 2011, CURR OPIN CLIN NUTR, V14, P197, DOI 10.1097/MCO.0b013e3283436dc5; Helling G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150440; HEYLAND D, 1995, CRIT CARE MED, V23, P1055, DOI 10.1097/00003246-199506000-00010; Hurt RT, 2012, JPEN-PARENTER ENTER, V36, P721, DOI 10.1177/0148607112436978; Khalid I, 2010, AM J CRIT CARE, V19, P261, DOI 10.4037/ajcc2010197; Khoshbaten M, 2013, DIGEST ENDOSC, V25, P125, DOI 10.1111/j.1443-1661.2012.01347.x; Kirkpatrick AW, 2013, INTENS CARE MED, V39, P1190, DOI 10.1007/s00134-013-2906-z; Kreymann KG, 2006, CLIN NUTR, V25, P210, DOI 10.1016/j.clnu.2006.01.021; Ksienski MR, 2013, JPEN-PARENTER ENTER, V37, P261, DOI 10.1177/0148607112464654; Lee JS, 2010, J KOREAN NEUROSURG S, V48, P99, DOI 10.3340/jkns.2010.48.2.99; Leone M, 2015, INTENS CARE MED, V41, P667, DOI 10.1007/s00134-015-3690-8; Lewis SJ, 2001, BRIT MED J, V323, P773, DOI 10.1136/bmj.323.7316.773; Lewis SJ, 2009, J GASTROINTEST SURG, V13, P569, DOI 10.1007/s11605-008-0592-x; MacLaren R, 2001, ANN PHARMACOTHER, V35, P1614, DOI 10.1345/aph.1A083; Mancl EE, 2013, JPEN-PARENTER ENTER, V37, P641, DOI 10.1177/0148607112470460; Marik PE, 2010, CRIT CARE MED, V38, P2222, DOI 10.1097/CCM.0b013e3181f17adf; Marshall Andrea P, 2006, Intensive Crit Care Nurs, V22, P95, DOI 10.1016/j.iccn.2005.09.004; Marvin RG, 2000, AM J SURG, V179, P7, DOI 10.1016/S0002-9610(99)00261-5; Mentec H, 2001, CRIT CARE MED, V29, P1955, DOI 10.1097/00003246-200110000-00018; Montejo JC, 2010, INTENS CARE MED, V36, P1386, DOI 10.1007/s00134-010-1856-y; Montejo JC, 1999, CRIT CARE MED, V27, P1447, DOI 10.1097/00003246-199908000-00006; Needham DM, 2013, BMJ, V346, pf1532, DOI DOI 10.1136/BMJ.F1532; Nguyen NQ, 2008, INTENS CARE MED, V34, P454, DOI 10.1007/s00134-007-0942-2; Oshima T, 2015, RESUSCITATION, V88, P81, DOI 10.1016/j.resuscitation.2014.12.025; Osland E, 2011, JPEN-PARENTER ENTER, V35, P473, DOI 10.1177/0148607110385698; Petrov MS, 2008, ARCH SURG-CHICAGO, V143, P1111, DOI 10.1001/archsurg.143.11.1111; Pilkington KB, 2012, ANAESTH INTENS CARE, V40, P253, DOI 10.1177/0310057X1204000207; Polk TM, 2012, WORLD J SURG, V36, P524, DOI 10.1007/s00268-011-1315-0; Raff T, 1997, BURNS, V23, P313, DOI 10.1016/S0305-4179(97)89875-0; Rahman A, 2015, JPEN-PARENTER ENTER, V39, P104, DOI 10.1177/0148607113501695; Reignier J, 2004, CRIT CARE MED, V32, P94, DOI 10.1097/01.CCM.0000104208.23542.A8; Reignier J, 2013, JAMA-J AM MED ASSOC, V309, P249, DOI 10.1001/jama.2012.196377; Reignier J, 2010, CLIN NUTR, V29, P210, DOI 10.1016/j.clnu.2009.08.004; Reintam A, 2009, ACTA ANAESTH SCAND, V53, P318, DOI 10.1111/j.1399-6576.2008.01860.x; REINTAM BA, 2012, INTENSIVE CARE MED, V0038, P00384, DOI DOI 10.1007/S00134-011-2459-Y; Rice TW, 2012, JAMA-J AM MED ASSOC, V307, P795, DOI 10.1001/jama.2012.137; Rosset E, 2014, EUR J VASC ENDOVASC, V47, P470, DOI 10.1016/j.ejvs.2014.02.013; Rowan CJ, 2004, INJURY, V35, P238, DOI 10.1016/S0020-1383(03)00203-1; Saur J, 2008, IN VIVO, V22, P143; Sun JK, 2013, WORLD J SURG, V37, P2053, DOI 10.1007/s00268-013-2087-5; Tamion F, 2003, INTENS CARE MED, V29, P1717, DOI 10.1007/s00134-003-1898-5; Taylor BE, 2016, CRIT CARE MED, V44, P390, DOI 10.1097/CCM.0000000000001525; Thapa P B, 2011, J Nepal Health Res Counc, V9, P1; Thibault R, 2013, CRIT CARE, V17, DOI 10.1186/cc12832; van der Voort PHJ, 2001, CRIT CARE, V5, P216, DOI 10.1186/cc1026; van Zanten ARH, 2013, JPEN-PARENTER ENTER, V37, P172, DOI 10.1177/0148607112464499; VERBOEKETVANDEVENNE WPHG, 1995, GUT, V36, P110, DOI 10.1136/gut.36.1.110; Weijs PJM, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0701-z; Wells DL, 2012, NUTR CLIN PRACT, V27, P521, DOI 10.1177/0884533612448480; Williams ML, 2014, RESUSCITATION, V85, P1469, DOI 10.1016/j.resuscitation.2014.08.018; Windsant ICV, 2012, ANN SURG, V255, P796, DOI 10.1097/SLA.0b013e31824b1e16; Xu ZW, 2012, HEPATOB PANCREAT DIS, V11, P586, DOI 10.1016/S1499-3872(12)60229-X	75	232	258	4	37	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	MAR	2017	43	3					380	398		10.1007/s00134-016-4665-0			19	Critical Care Medicine	General & Internal Medicine	EM0CU	WOS:000394987200004	28168570	Green Published, Other Gold	Y	N	2021-06-18	
J	Gardner, RC; Yaffe, K				Gardner, Raquel C.; Yaffe, Kristine			Epidemiology of mild traumatic brain injury and neurodegenerative disease	MOLECULAR AND CELLULAR NEUROSCIENCE			English	Article						Chronic traumatic encephalopathy; Traumatic brain injury; Mild traumatic brain injury; Concussion; Neurodegenerative disease; Epidemiology	ENVIRONMENTAL RISK-FACTORS; FOOTBALL-LEAGUE PLAYER; HEAD-INJURY; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; FRONTOTEMPORAL DEMENTIA; CLINICAL-OUTCOMES; PUNCH DRUNK; HIGH-SCHOOL; ENCEPHALOPATHY	Every year an estimated 42 million people worldwide suffer a mild traumatic brain injury (MTBI) or concussion. More severe traumatic brain injury (TBI) is a well-established risk factor for a variety of neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). Recently, large epidemiological studies have additionally identified MTBI as a risk factor for dementia. The role of MTBI in risk of PD or ALS is less well established. Repetitive MTBI and repetitive sub-concussive head trauma have been linked to increased risk for a variety of neurodegenerative diseases including chronic traumatic encephalopathy (CTE). CTE is a unique neurodegenerative tauopathy first described in boxers but more recently described in a variety of contact sport athletes, military veterans, and civilians exposed to repetitive MTBI. Studies of repetitive MTBI and CTE have been limited by referral bias, lack of consensus clinical criteria for CTE, challenges of quantifying MTBI exposure, and potential for confounding. The prevalence of CTE is unknown and the amount of MTBI or subconcussive trauma exposure necessary to produce CTE is unclear. This review will summarize the current literature regarding the epidemiology of MTBI, post-TBI dementia and Parkinson's disease, and CTE while highlighting methodological challenges and critical future directions of research in this field. This article is part of a Special Issue entitled SI:Traumatic Brain Injury. Published by Elsevier Inc.	[Gardner, Raquel C.; Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; [Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA; [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol Biostat, San Francisco, CA 94143 USA; [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA	Gardner, RC (corresponding author), 4150 Clement St, San Francisco, CA 94121 USA.	raquel.gardner@ucsf.edu		Gardner, Raquel C./0000-0003-4028-440X	Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Mental Illness Research and TreatmentUS Department of Veterans Affairs; Medical Research Service of the San Francisco Veterans Affairs Medical Center; Department of Veterans Affairs Sierra-Pacific Mental Illness Research, Education, and Clinical Center (MIRECC)US Department of Veterans Affairs; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K24 AG031155]; Department of DefenseUnited States Department of Defense [W81XWH-12-1-0581]; Department of Veterans AffairsUS Department of Veterans Affairs; California Department of Public Health; Bright Focus FoundationBrightFocus Foundation; Alzheimer's AssociationAlzheimer's Association; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K24AG031155] Funding Source: NIH RePORTER	RCG is supported by the Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Mental Illness Research and Treatment, the Medical Research Service of the San Francisco Veterans Affairs Medical Center, and the Department of Veterans Affairs Sierra-Pacific Mental Illness Research, Education, and Clinical Center (MIRECC). KY has received research support from the National Institutes of Health (NIH) via K24 AG031155, the Department of Defense via W81XWH-12-1-0581, the Department of Veterans Affairs, the California Department of Public Health, the Bright Focus Foundation, and the Alzheimer's Association.	Bernick C, 2013, AM J EPIDEMIOL, V178, P280, DOI 10.1093/aje/kws456; Bower JH, 2003, NEUROLOGY, V60, P1610, DOI 10.1212/01.WNL.0000068008.78394.2C; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Chen HL, 2007, AM J EPIDEMIOL, V166, P810, DOI 10.1093/aje/kwm153; Clausen H, 2005, BRIT J SPORT MED, V39, P661, DOI 10.1136/bjsm.2004.017046; Constantinidis J, 1967, Schweiz Arch Neurol Neurochir Psychiatr, V100, P117; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Dams-O'Connor K, 2013, J NEUROL NEUROSUR PS, V84, P177, DOI 10.1136/jnnp-2012-303938; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Fischer BL, 2014, J NEUROTRAUM, V31, P169, DOI 10.1089/neu.2013.2877; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Gardner A., 2013, BR J SPORTS MED, V26; Gardner R.C, 2015, ANN NEUROL; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Godbolt Alison K, 2014, Arch Phys Med Rehabil, V95, pS245, DOI 10.1016/j.apmr.2013.06.036; Goldman SM, 2006, ANN NEUROL, V60, P65, DOI 10.1002/ana.20882; Goldman SM, 2012, ANN NEUROL, V71, P40, DOI 10.1002/ana.22499; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Hagel B, 2004, CLIN J SPORT MED, V14, P193, DOI 10.1097/00042752-200407000-00001; Hazrati LN, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00222; Helmes E, 2011, BRAIN INJURY, V25, P338, DOI 10.3109/02699052.2011.556104; Jafari S, 2013, MOVEMENT DISORD, V28, P1222, DOI 10.1002/mds.25458; Jordan Barry D, 2014, Continuum (Minneap Minn), V20, P1588, DOI 10.1212/01.CON.0000458972.94013.e1; Jordan BD, 2013, NAT REV NEUROL, V9, P222, DOI 10.1038/nrneurol.2013.33; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Kalkonde YV, 2012, ALZHEIMERS DEMENT, V8, P204, DOI 10.1016/j.jalz.2011.03.011; Kristman Vicki L, 2014, Arch Phys Med Rehabil, V95, pS265, DOI 10.1016/j.apmr.2013.04.026; Kuopio AM, 1999, MOVEMENT DISORD, V14, P928, DOI 10.1002/1531-8257(199911)14:6<928::AID-MDS1004>3.0.CO;2-Z; Lee P.C., 2014, EUR J NEUROL, V5; Lee PC, 2012, NEUROLOGY, V79, P2061, DOI 10.1212/WNL.0b013e3182749f28; Lee YK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062422; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Lolekha P, 2010, MOVEMENT DISORD, V25, P1895, DOI 10.1002/mds.23210; Mac Donald CL, 2014, JAMA NEUROL, V71, P994, DOI 10.1001/jamaneurol.2014.1114; Marras Connie, 2014, Arch Phys Med Rehabil, V95, pS238, DOI 10.1016/j.apmr.2013.08.298; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; McCrory P, 2013, BRIT J SPORT MED, V47, P327, DOI 10.1136/bjsports-2013-092248; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Millspaugh J., 1937, US NAVAL MED B, V35, P297; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; NINDS Common Data Elements, 2012, TRAUMATIC BRAIN INJU; Nordstrom P, 2014, ANN NEUROL, V75, P374, DOI 10.1002/ana.24101; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Parker HL, 1934, J NEUROL PSYCHOPATHO, V15, P20; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Roberts AH., 1969, BRAIN DAMAGE BOXERS; Rosso SM, 2003, J NEUROL NEUROSUR PS, V74, P1574, DOI 10.1136/jnnp.74.11.1574; Rugbjerg K, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a2494; Savica R, 2012, MAYO CLIN PROC, V87, P335, DOI 10.1016/j.mayocp.2011.12.016; Schmidt S, 2010, J NEUROL SCI, V291, P22, DOI 10.1016/j.jns.2010.01.011; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Seidler A, 1996, NEUROLOGY, V46, P1275, DOI 10.1212/WNL.46.5.1275; Setnik L, 2007, BRAIN INJURY, V21, P1, DOI 10.1080/02699050601111419; Spiotta AM, 2011, WORLD NEUROSURG, V75, P175, DOI 10.1016/j.wneu.2011.01.019; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; TAYLOR RB, 1953, BRIT MED J, V1, P200, DOI 10.1136/bmj.1.4803.200; Villemagne VL, 2015, LANCET NEUROL, V14, P114, DOI 10.1016/S1474-4422(14)70252-2; Wilk JE, 2012, PSYCHOSOM MED, V74, P249, DOI 10.1097/PSY.0b013e318244c604	73	232	235	7	143	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1044-7431	1095-9327		MOL CELL NEUROSCI	Mol. Cell. Neurosci.	MAY	2015	66		B		SI		75	80		10.1016/j.mcn.2015.03.001			6	Neurosciences	Neurosciences & Neurology	CK7FT	WOS:000356398900002	25748121	Green Accepted	Y	N	2021-06-18	
J	Coronado, VG; McGuire, LC; Sarmiento, K; Bell, J; Lionbarger, MR; Jones, CD; Geller, AI; Khoury, N; Xu, LK				Coronado, Victor G.; McGuire, Lisa C.; Sarmiento, Kelly; Bell, Jeneita; Lionbarger, Michael R.; Jones, Christopher D.; Geller, Andrew I.; Khoury, Nayla; Xu, Likang			Trends in Traumatic Brain Injury in the US and the public health response: 1995-2009	JOURNAL OF SAFETY RESEARCH			English	Article						Traumatic brain injury; Surveillance; Trends; Prevention; Congressional mandates	DEATH CERTIFICATE COMPLETION; UNITED-STATES; POPULATION; MILD; SURVEILLANCE; ACCURACY; OUTCOMES; NEED	Problem: Traumatic Brain Injury (TBI) is a public health problem in the United States. In 2009, approximately 3.5 million patients with a TBI listed as primary or secondary diagnosis were hospitalized and discharged alive (N = 300,667) or were treated and released from emergency departments (EDs; N = 2,077,350), outpatient departments (ODs; N = 83,857), and office-based physicians (OB-P; N = 1,079,338). In addition, 52,695 died with one or more TBI-related diagnoses. Methods: Federal TBI-related laws that have guided CDC since 1996 were reviewed. Trends in TBI were obtained by analyzing data from nationally representative surveys conducted by the National Center for Health Statistics (NCHS). Findings: CDC has developed and is implementing a strategy to reduce the burden of TBI in the United States. Currently, 20 states have TBI surveillance and prevention systems. From 1995-2009, the TBI rates per 100,000 population increased in EDs (434.1 vs. 686.0) and OB-Ps (234.6 vs. 352.3); and decreased in ODs (42.6 vs. 28.1) and in TBI-related deaths (19.9 vs. 16.6). TBI Hospitalizations decreased from 95.5 in 1995 to 77.9 in 2000 and increased to 95.7 in 2009. Conclusions: The rates of TBI have increased since 1995 for ED and PO visits. To reduce of the burden and mitigate the impact of TBI in the United States, an improved state- and territory-specific TBI surveillance system that accurately measures burden and includes information on the acute and long-term outcomes of TBI is needed. National Safety Council and Elsevier Ltd. All rights reserved.	[Coronado, Victor G.; McGuire, Lisa C.; Sarmiento, Kelly; Bell, Jeneita; Lionbarger, Michael R.; Jones, Christopher D.; Xu, Likang] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Injury Response, Atlanta, GA USA; [Geller, Andrew I.] Emory Univ, Sch Med, Dept Phys Med & Rehabil, Atlanta, GA 30322 USA	Coronado, VG (corresponding author), 4770 Buford Highway NE,MS F62, Atlanta, GA 30341 USA.	vgc1@cdc.gov					Anonymous, 2006, Morbidity and Mortality Weekly Report, V55, P201; [Anonymous], 2007, J NEUROTRAUMA S1, V24, pS1, DOI DOI 10.1089/NEU.2006.0209; [Anonymous], 1999, MMWR, V48, P369; Barker-Collo SL, 2009, NEUROEPIDEMIOLOGY, V32, P1, DOI 10.1159/000170084; Bazarian JJ, 2006, ACAD EMERG MED, V13, P31, DOI 10.1197/j.aem.2005.07.038; Benzinger TLS, 2009, J NEUROTRAUM, V26, P2127, DOI 10.1089/neu.2009-0885; (CDC). National Center for Injury Prevention and Control, 2007, HEADS BRAIN INJ YOUR; *CDCP, 2003, HEADS BRAIN INJ YOUR; Centers for Disease Control and Prevention, 1999, TRAUM BRAIN INJ US R; Centers for Disease Control and Prevention, 2010, HEADS SCH KNOW YOUR; Centers for Disease Control and Prevention, 2007, TRAUM BRAIN INJ PRIS; Centers for Disease Control and Prevention and American College of Emergency Physicians, 2010, HEADS CLIN MILD TRAU; Centers for Disease Control Prevention [CDC], 2011, CDC POL IMP SAF BELT; Centers for Disease Control Prevention [CDC], 2010, INJ PREV CONTR FIELD; Centers for Disease Control Prevention [CDC], 2007, HEADS CONC YOUTH SPO; Centers for Disease Control Prevention [CDC], 2010, BRIDG RAC POP EST DA; Centers for Disease Control Prevention [CDC], 2011, HEADS CLIN ADDR CONC; Centers for Disease Control Prevention [CDC], 2007, TRAUM BRAIN INJ; Centers for Disease Control Prevention [CDC], 2005, HEADS CONC HIGH SCH; Centers for Disease Control Prevention [CDC], 2011, INJURY CTR CONNE FAL; Coronado V., 2012, BRAIN INJURY MED; Coronado V. G., 2007, Morbidity and Mortality Weekly Report, V56, P167; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Coronado VG, 2009, NEUROTRAUMA CRITICAL, P3; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; DAVIES M, 2001, STATE INJURY INDICAT; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Finkelstein EA., 2006, INCIDENCE EC BURDEN; HADDON W, 1972, J TRAUM, V12, P193, DOI 10.1097/00005373-197203000-00002; HANZLICK R, 1993, AM J FOREN MED PATH, V14, P249, DOI 10.1097/00000433-199309000-00015; Hardman JM, 2002, NEUROIMAG CLIN N AM, V12, P175, DOI 10.1016/S1052-5149(02)00009-6; Injury Surveillance Workgroup, 1999, CONS REC INJ SURV ST; Institute of Medicine, 2011, HLTH IT SAF BUILD SA, P16; Institute of Medicine, 2011, COGN REH THER TRAUM; Institute of Medicine, 2009, GULF WAR HLTH, V7; Johnson R, 2009, STATE INJURY INDICAT; Johnson R. L., 2010, STATE INJURY INDICAT; Jones C. D., 2011, EVALUATION CORE STAT; JORDAN JM, 1993, CLIN INVEST MED, V16, P249; Koppel R, 2005, JAMA-J AM MED ASSOC, V293, P1197, DOI 10.1001/jama.293.10.1197; Langlois J, 2005, TRAUMATIC BRAIN INJU; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; Langlois Orman J. A., 2011, TXB TRAUMATIC BRAIN; Leibson CL, 2011, EPIDEMIOLOGY, V22, P836, DOI 10.1097/EDE.0b013e318231d535; Liu BC, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004333.pub3; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; Mackersie RC, 2006, PREHOSP EMERG CARE, V10, P287, DOI 10.1080/10903120600721636; Marr AL., 2004, CENTRAL NERVOUS SYST; McCaffrey MA, 2007, NEUROSURGERY, V61, P1236, DOI 10.1227/01.neu.0000306102.91506.8b; Messite J, 1996, JAMA-J AM MED ASSOC, V275, P794, DOI 10.1001/jama.275.10.794; Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128; Myers KA, 1998, CAN MED ASSOC J, V158, P1317; NCIPC, 2003, REP C MILD TRAUM BRA; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; O'Malley KJ, 2005, HEALTH SERV RES, V40, P1620, DOI 10.1111/j.1475-6773.2005.00444.x; Ovretveit J, 2007, HEALTH POLICY, V84, P181, DOI 10.1016/j.healthpol.2007.05.013; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; Pickelsimer EE, 2007, J HEAD TRAUMA REHAB, V22, P1, DOI 10.1097/00001199-200701000-00001; Pickelsimer EE, 2006, J HEAD TRAUMA REHAB, V21, P491, DOI 10.1097/00001199-200611000-00004; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Rodriguez SR, 2006, PUBLIC HEALTH REP, V121, P282, DOI 10.1177/003335490612100310; Runyan CW, 2003, EPIDEMIOL REV, V25, P60, DOI 10.1093/epirev/mxg005; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Sarmiento K, 2010, J SCHOOL HEALTH, V80, P112, DOI 10.1111/j.1746-1561.2010.00491.x; Sasser S. M., 2009, MORBIDITY MORTALITY, V58; Sasser Scott M, 2012, MMWR Recomm Rep, V61, P1; Shiroma Eric J, 2010, J Correct Health Care, V16, P273, DOI 10.1177/1078345810378253; Shiroma Eric J, 2010, J Correct Health Care, V16, P147, DOI 10.1177/1078345809356538; Sosin DM, 1996, BRAIN INJURY, V10, P47; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Thurman DJ., 1995, GUIDELINES SURVEILLA; Thurman DKJRC, 1995, STANDARDS SURVEILLAN; Tilford JM, 2005, CRIT CARE MED, V33, P2074, DOI 10.1097/01.CCM.0000171839.65687.F5; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Vos Pieter E, 2011, Crit Care, V15, P183, DOI 10.1186/cc10290; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, pS73, DOI 10.1016/j.apmr.2003.08.107; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zink BJ, 2001, ANN EMERG MED, V37, P318, DOI 10.1067/mem.2001.113505	82	232	235	2	32	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0022-4375	1879-1247		J SAFETY RES	J. Saf. Res.	SEP	2012	43	4					299	307		10.1016/j.jsr.2012.08.011			9	Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation	Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation	042JE	WOS:000311466700012	23127680		Y	N	2021-06-18	
J	Ohta, M; Suzuki, Y; Noda, T; Ejiri, Y; Dezawa, M; Kataoka, K; Chou, H; Ishikawa, N; Matsumoto, N; Iwashita, Y; Mizuta, E; Kuno, S; Ide, C				Ohta, M; Suzuki, Y; Noda, T; Ejiri, Y; Dezawa, M; Kataoka, K; Chou, H; Ishikawa, N; Matsumoto, N; Iwashita, Y; Mizuta, E; Kuno, S; Ide, C			Bone marrow stromal cells infused into the cerebrospinal fluid promote functional recovery of the injured rat spinal cord with reduced cavity formation	EXPERIMENTAL NEUROLOGY			English	Article						bone marrow stromal cell; spinal cord injury; transplantation; cerebrospinal fluid; behavioral improvement	MESENCHYMAL STEM-CELLS; PLEXUS EPENDYMAL CELLS; TRAUMATIC BRAIN INJURY; ADULT RATS; IN-VITRO; NEUROSPHERE CELLS; INTRACEREBRAL TRANSPLANTATION; NEUROTROPHIC FACTORS; HEMATOPOIETIC-CELLS; PROGENITOR CELLS	The effects of bone marrow stromal cells (BMSCs) on the repair of injured spinal cord and on the behavioral improvement were studied in the rat. The spinal cord was injured by contusion using a weight-drop at the level of T8-9, and the BMSCs from the bone marrow of the same strain were infused into the cerebrospinal fluid (CSF) through the 4th ventricle. BMSCs were conveyed through the CSF to the spinal cord, where most BMSCs attached to the spinal surface although a few invaded the lesion. The BBB score was higher, and the cavity volume was smaller in the rats with transplantation than in the control rats. Transplanted cells gradually decreased in number and disappeared from the spinal cord 3 weeks after injection. The medium supplemented by CSF (250 mul in 3 ml medium) harvested from the rats in which BMSCs had been injected 2 days previously promoted the neurosphere cells to adhere to the culture dish and to spread into the periphery. These results suggest that BMSCs can exert effects by producing some trophic factors into the CSF or by contacting with host spinal tissues on the reduction of cavities and on the improvement of behavioral function in the rat. Considering that BMSCs can be used for autologous transplantation, and that the CSF infusion of transplants imposes a minimal burden on patients, the results of the present study are important and promising for the clinical use of BMSCs in spinal cord injury treatment. (C) 2004 Elsevier Inc. All rights reserved.	Kyoto Univ, Grad Sch Med, Dept Plast & Reconstruct Surg, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Dept Anat & Neurobiol, Sakyo Ku, Kyoto 6068501, Japan; Natl Utano Hosp, Dept Orthoped Surg, Kyoto 6168255, Japan; Natl Utano Hosp, Dept Neurol, Kyoto 6168255, Japan; Natl Utano Hosp, Clin Res Ctr, Kyoto 6168255, Japan	Suzuki, Y (corresponding author), Kyoto Univ, Grad Sch Med, Dept Plast & Reconstruct Surg, Sakyo Ku, Kyoto 6068507, Japan.	utsubo@kuhp.kyoto-u.ac.jp			Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [15390342, 15790106, 16015262, 15300114, 14207073] Funding Source: KAKEN		Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; Bai HL, 2003, J NEUROSCI METH, V124, P181, DOI 10.1016/S0165-0270(03)00007-4; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Bjorklund A, 2000, NAT NEUROSCI, V3, P537, DOI 10.1038/75705; BLANCO P, 2001, STEM CELLS, V19, P180; Chen JL, 2000, NEUROPHARMACOLOGY, V39, P711, DOI 10.1016/S0028-3908(00)00006-X; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; CONSTANTINI S, 1994, J NEUROSURG, V80, P97, DOI 10.3171/jns.1994.80.1.0097; Deng WW, 2001, BIOCHEM BIOPH RES CO, V282, P148, DOI 10.1006/bbrc.2001.4570; Dezawa M, 2001, EUR J NEUROSCI, V14, P1771, DOI 10.1046/j.0953-816x.2001.01814.x; DOUCETTE R, 1995, HISTOL HISTOPATHOL, V10, P503; EAVES CJ, 1991, BLOOD, V78, P110; Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Fitch MT, 1999, J NEUROSCI, V19, P8182; Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299; Ide C, 2001, EXP NEUROL, V167, P242, DOI 10.1006/exnr.2000.7566; Ito T, 2001, EXP NEPHROL, V9, P444; IWASHITA Y, 1994, NATURE, V367, P167, DOI 10.1038/367167a0; Kitada M, 2001, GLIA, V36, P364, DOI 10.1002/glia.1123; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; KORDOWER JH, 1995, NEW ENGL J MED, V332, P1118, DOI 10.1056/NEJM199504273321702; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; LazarovSpiegler O, 1996, FASEB J, V10, P1296; Li Y, 2001, NEUROLOGY, V56, P1666, DOI 10.1212/WNL.56.12.1666; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; Majumdar MK, 1998, J CELL PHYSIOL, V176, P57, DOI 10.1002/(SICI)1097-4652(199807)176:1<57::AID-JCP7>3.0.CO;2-7; Martin D, 1996, J NEUROSCI RES, V45, P588; McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Mezey E, 2003, P NATL ACAD SCI USA, V100, P1364, DOI 10.1073/pnas.0336479100; Ogawa Y, 2002, J NEUROSCI RES, V69, P925, DOI 10.1002/jnr.10341; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Ousman SS, 2000, GLIA, V30, P92, DOI 10.1002/(SICI)1098-1136(200003)30:1<92::AID-GLIA10>3.0.CO;2-W; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; Phinney DG, 1999, J CELL BIOCHEM, V72, P570; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; Reyes M, 2002, J CLIN INVEST, V109, P337, DOI 10.1172/JCI200214327; Reyes M, 2001, ANN NY ACAD SCI, V938, P231; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; Schwarz EJ, 1999, HUM GENE THER, V10, P2539, DOI 10.1089/10430349950016870; Takami T, 2002, J NEUROTRAUM, V19, P653, DOI 10.1089/089771502753754118; Wang L, 2002, EXP HEMATOL, V30, P831, DOI 10.1016/S0301-472X(02)00829-9; West NR, 2001, NEUROPATHOLOGY, V21, P188, DOI 10.1046/j.1440-1789.2001.00398.x; Widenfalk J, 2001, J NEUROSCI, V21, P3457, DOI 10.1523/JNEUROSCI.21-10-03457.2001; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; Wu SF, 2002, NEUROSCI LETT, V318, P81, DOI 10.1016/S0304-3940(01)02488-0; Wu SF, 2002, J NEUROSCI RES, V69, P940, DOI 10.1002/jnr.10346; Wu SF, 2003, J NEUROSCI RES, V72, P343, DOI 10.1002/jnr.10587; Wu SF, 2001, NEUROSCI LETT, V312, P173, DOI 10.1016/S0304-3940(01)02219-4; Zhang ZY, 1997, EXP NEUROL, V143, P141, DOI 10.1006/exnr.1996.6355	59	232	260	0	15	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JUN	2004	187	2					266	278		10.1016/j.expneurol.2004.01.021			13	Neurosciences	Neurosciences & Neurology	823HU	WOS:000221602200006	15144853				2021-06-18	
J	Munch, E; Horn, P; Schurer, L; Piepgras, A; Paul, T; Schmiedek, P				Munch, E; Horn, P; Schurer, L; Piepgras, A; Paul, T; Schmiedek, P			Management of severe traumatic brain injury by decompressive craniectomy	NEUROSURGERY			English	Article						craniectomy; head injury; intracranial hypertension; outcome	SEVERE HEAD-INJURY; ACUTE SUBDURAL HEMATOMAS; INTRA-CRANICAL PRESSURE; INTRACRANIAL HYPERTENSION; CEREBRAL EDEMA; CT SCAN; HEMICRANIECTOMY; CRANIOTOMY; REDUCTION; CHILDREN	OBJECTIVE: The beneficial effect of decompressive craniectomy in the treatment of head trauma patients is controversial. The aim of our study was to assess the value of unilateral decompressive craniectomy in patients with severe traumatic brain injury. METHODS: We retrospectively investigated 49 patients who underwent decompressive craniectomy. Intracranial pressure, cerebral perfusion pressure, therapy intensity level, and cranial computed tomographic scan features (midline shift, visibility of ventricles, gyral pattern, and mesencephalic cisterns) were evaluated before and after craniectomy. The gain of intracranial space was calculated from cranial computed tomographic scans. Patient outcome was graded using the Glasgow Outcome Scale. RESULTS: Thirty-one patients (63.3%) underwent rapid surgical decompression within 4.5 +/- 3.8 hours after trauma; in 18 patients (36.7%), delayed surgical decompression was performed 56.2 +/- 57.0 hours after injury. Patients younger than 50 years or patients who underwent rapid surgical decompression had a significantly better outcome than older patients or patients who underwent delayed surgical decompression. Craniectomy significantly decreased midline shift and improved visibility of the mesencephalic cisterns. The state of the mesencephalic cisterns correlated with the distance of the lower border of the craniectomy to the temporal cranial base. Alterations in intracranial pressure, cerebral perfusion pressure, and therapy intensity level were not significant. The overall mortality of the patients corresponded to the reports of the Traumatic Coma Data Bank (1991). CONCLUSION: Although there was a significant decrease in midline shift after craniectomy, this did not translate into decompressive craniectomy demonstrating a beneficial effect on patient outcome.	Heidelberg Univ, Klinikum Mannheim, Dept Neurosurg, D-68167 Mannheim, Germany; Heidelberg Univ, Klinikum Mannheim, Dept Anesthesiol, D-68167 Mannheim, Germany; Stadt Krankenhaus Munchen Bogenhausen, Dept Neurosurg, Munich, Germany	Munch, E (corresponding author), Heidelberg Univ, Klinikum Mannheim, Dept Neurosurg, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.	Elke.Muench@t-online.de					ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; Alexander E, 1987, Br J Neurosurg, V1, P427, DOI 10.3109/02688698708999632; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BRITT RH, 1978, NEUROSURGERY, V2, P195, DOI 10.1227/00006123-197805000-00001; Burkert W, 1989, Zentralbl Neurochir, V50, P106; CLARK K, 1968, J NEUROSURG, V29, P367, DOI 10.3171/jns.1968.29.4.0367; Cooper P R, 1976, Surg Neurol, V5, P25; COOPER PR, 1979, NEUROSURGERY, V4, P296, DOI 10.1227/00006123-197904000-00004; Doerfler A, 1996, J NEUROSURG, V85, P853, DOI 10.3171/jns.1996.85.5.0853; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FELL DA, 1975, J NEUROSURG, V42, P37, DOI 10.3171/jns.1975.42.1.0037; GAAB M, 1979, CHILD BRAIN, V5, P484; GAAB MR, 1990, ACT NEUR S, V51, P326; GERL A, 1980, Zentralblatt fuer Neurochirurgie, V41, P125; GOWER DJ, 1988, NEUROSURGERY, V23, P417, DOI 10.1227/00006123-198810000-00002; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; GUTTERMAN P, 1970, J NEUROSURG, V32, P330, DOI 10.3171/jns.1970.32.3.0330; Harrington ML, 1996, AM J VET RES, V57, P1659; HASE U, 1978, ACTA NEUROCHIR, V45, P1, DOI 10.1007/BF01774379; HASELSBERGER K, 1988, ACTA NEUROCHIR, V90, P111, DOI 10.1007/BF01560563; Hatashita Shizuo, 1993, Neurologia Medico-Chirurgica, V33, P13, DOI 10.2176/nmc.33.13; Hieu PD, 1996, CHILD NERV SYST, V12, P270; HOWARD MA, 1989, J NEUROSURG, V71, P858, DOI 10.3171/jns.1989.71.6.0858; JAMIESON KG, 1972, J NEUROSURG, V37, P137, DOI 10.3171/jns.1972.37.2.0137; JENNETT B, 1975, LANCET, V1, P480; JOURDAN C, 1993, NEUROCHIRURGIE, V39, P304; KARLEN J, 1987, NEUROCHIRURGIA, V30, P35; KERR FWL, 1968, MAYO CLIN PROC, V43, P852; KJELLBERG RN, 1971, J NEUROSURG, V34, P488, DOI 10.3171/jns.1971.34.4.0488; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Makino H, 1979, Acta Neurochir Suppl (Wien), V28, P193; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; MASET AL, 1987, J NEUROSURG, V67, P832, DOI 10.3171/jns.1987.67.6.0832; Mathew P, 1996, J NEUROTRAUM, V13, P465, DOI 10.1089/neu.1996.13.465; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MOODY RA, 1968, J NEUROSURG, V29, P586, DOI 10.3171/jns.1968.29.6.0586; MORANTZ RA, 1973, J NEUROSURG, V39, P622, DOI 10.3171/jns.1973.39.5.0622; MORGALLA MH, 1995, SURG NEUROL, V43, P583, DOI 10.1016/0090-3019(95)00034-8; Morris GF, 1998, NEUROSURGERY, V43, P1369, DOI 10.1097/00006123-199812000-00063; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Ogawa M, 1974, Med J Osaka Univ, V25, P73; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; RANSOHOFF J, 1971, J NEUROSURG, V34, P70, DOI 10.3171/jns.1971.34.1.0070; RINALDI A, 1990, ACT NEUR S, V51, P394; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Shigemori M, 1979, Acta Neurochir Suppl (Wien), V28, P195; SHISHIDO T, 1980, Neurologia Medico-Chirurgica, V20, P53, DOI 10.2176/nmc.20.53; STENING WA, 1986, AUST NZ J SURG, V56, P549, DOI 10.1111/j.1445-2197.1986.tb07098.x; TABADDOR K, 1982, SURG NEUROL, V18, P212, DOI 10.1016/0090-3019(82)90395-0; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P140; TEASDALE G, 1974, LANCET, V2, P81; TOUTANT SM, 1984, J NEUROSURG, V61, P691, DOI 10.3171/jns.1984.61.4.0691; VANDONGEN KJ, 1983, J NEUROSURG, V59, P951, DOI 10.3171/jns.1983.59.6.0951; VENES JL, 1975, J NEUROSURG, V42, P429, DOI 10.3171/jns.1975.42.4.0429; WARME PE, 1991, ACTA NEUROCHIR, V110, P57, DOI 10.1007/BF01402049; WHITFIELD P, 1995, STROKE, V26, P1125; Yamakami Iwao, 1993, Neurologia Medico-Chirurgica, V33, P616, DOI 10.2176/nmc.33.616; YAMAURA A, 1979, Neurologia Medico-Chirurgica, V19, P717, DOI 10.2176/nmc.19.717	59	232	254	0	9	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	AUG	2000	47	2					315	322					8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	339WZ	WOS:000088502000022	10942004				2021-06-18	
J	Weiner, MW; Friedl, KE; Pacifico, A; Chapman, JC; Jaffee, MS; Little, DM; Manley, GT; McKee, A; Petersen, RC; Pitman, RK; Yaffe, K; Zetterberg, H; Obana, R; Bain, LJ; Carrillo, MC				Weiner, Michael W.; Friedl, Karl E.; Pacifico, Anthony; Chapman, Julie C.; Jaffee, Michael S.; Little, Deborah M.; Manley, Geoffrey T.; McKee, Ann; Petersen, Ronald C.; Pitman, Roger K.; Yaffe, Kristine; Zetterberg, Henrik; Obana, Robert; Bain, Lisa J.; Carrillo, Maria C.			Military risk factors for Alzheimer's disease	ALZHEIMERS & DEMENTIA			English	Article						Alzheimer's disease; Risk factors; Military medicine; Traumatic brain injury; Posttraumatie stress disorder; Tau; Beta-amyloid; Apolipoprotein E e4; Biomarkers; Alzheimer's Disease Neuroimaging Initiative; Vietnam; Veterans; Chronic traumatic encephalopathy; Blast injury	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; POSTCONCUSSIVE SYMPTOMS; COGNITIVE RESERVE; HEAD-INJURY; BLAST; ENCEPHALOPATHY; HEALTH; CARE; AFGHANISTAN	Traumatic brain injury (TBI) and post-traumatic stress disorder (PTSD) are signature injuries of the wars in Iraq and Afghanistan and have been linked to an increased risk of Alzheimer's disease (AD) and other dementias. A meeting hosted by the Alzheimer's Association and the Veterans' Health Research Institute (NCIRE) in May 2012 brought together experts from the U.S. military and academic medical centers around the world to discuss current evidence and hypotheses regarding the pathophysiological mechanisms linking TBI, PTSD, and AD. Studies underway in civilian and military populations were highlighted, along with new research initiatives such as a study to extend the Alzheimer's Disease Neuroimaging Initiative (ADNI) to a population of veterans exposed to TBI and PTSD. Greater collaboration and data sharing among diverse research groups is needed to advance an understanding and appropriate interventions in this continuum of military injuries and neurodegenerative disease in the aging veteran. (C) 2013 The Alzheimer's Association. All rights reserved.	[Weiner, Michael W.; Yaffe, Kristine] San Francisco Vet Adm Med Ctr, San Francisco, CA USA; [Weiner, Michael W.; Manley, Geoffrey T.; Yaffe, Kristine] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Friedl, Karl E.; Pacifico, Anthony] US Army Med Res & Mat Command, Telemed & Adv Technol Res Ctr, Ft Detrick, MD USA; [Chapman, Julie C.] Vet Affairs Med Ctr, War Related Illness & Injury Study Ctr, Washington, DC 20422 USA; [Chapman, Julie C.] Georgetown Univ, Sch Med, Washington, DC USA; [Jaffee, Michael S.] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA; [Little, Deborah M.] Texas A&M Hlth Sci Coll Med, College Stn, TX USA; [McKee, Ann] Boston Univ, Sch Med, New England Vet Healthcare Syst, Boston, MA 02118 USA; [McKee, Ann] Boston Univ, Sch Med, Brain Banks, Boston, MA 02118 USA; [McKee, Ann] Ctr Study Traumat Encephalopathy, Boston, MA USA; [Petersen, Ronald C.] Mayo Clin, Rochester, MN USA; [Pitman, Roger K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA; [Zetterberg, Henrik] Univ Gothenburg, Sahlgrenska Acad, Gothenburg, Sweden; [Obana, Robert] Vet Hlth Res Inst, Northern Calif Inst Res & Educ, San Francisco, CA USA; [Carrillo, Maria C.] Alzheimers Assoc, Chicago, IL USA; [Zetterberg, Henrik] UCL Inst Neurol, London WC1N 3BG, England	Carrillo, MC (corresponding author), Alzheimers Assoc, Chicago, IL USA.	Maria.Carrillo@alz.org	Schmidt, Mark/I-5052-2016; Jack, Clifford R/F-2508-2010; Friedl, Karl/M-1803-2019	Schmidt, Mark/0000-0003-3417-8977; Jack, Clifford R/0000-0001-7916-622X; Friedl, Karl/0000-0002-3134-8427; Beckett, Laurel/0000-0002-2418-9843; Siuciak, Judith/0000-0002-3945-3555	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30 AG013846] Funding Source: Medline; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30 AG010133, U24 AG021886, R01 AG019771] Funding Source: Medline		Apfel BA, 2011, BIOL PSYCHIAT, V69, P541, DOI 10.1016/j.biopsych.2010.09.044; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Barth J., 2010, MILITARY NEUROPSYCHO, P127; Bell RS, 2009, J TRAUMA, V66, pS104, DOI 10.1097/TA.0b013e31819d88c8; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Blennow K, 2011, ACTA NEUROL SCAND, V123, P245, DOI 10.1111/j.1600-0404.2010.01408.x; Bremner JD, 2007, NEUROIMAG CLIN N AM, V17, P523, DOI 10.1016/j.nic.2007.07.003; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Cardenas VA, 2011, PSYCHIAT RES-NEUROIM, V193, P93, DOI 10.1016/j.pscychresns.2011.01.013; Carrillo MC, 2012, ALZHEIMERS DEMENT, V8, P337, DOI 10.1016/j.jalz.2012.04.007; Consolidation of traumatic brain injury initiatives in the Department of Defense, 2007, CONS TRAUM BRAIN INJ; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Fay TB, 2010, J INT NEUROPSYCH SOC, V16, P94, DOI 10.1017/S1355617709991007; Fischer H, 2010, US MILITARY CASUALTY; Freeman T, 2005, J NEUROPSYCH CLIN N, V17, P541, DOI 10.1176/appi.neuropsych.17.4.541; French L., 2008, J SPEC OPER MED, V8, P68; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gilbertson MW, 2010, J CLIN PSYCHIAT, V71, P1324, DOI 10.4088/JCP.10m06121blu; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Jack CR, 2010, LANCET NEUROL, V9, P119, DOI 10.1016/S1474-4422(09)70299-6; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Kennedy JE, 2010, NEUROREHABILITATION, V26, P223, DOI 10.3233/NRE-2010-0558; Kremen WS, 2007, ARCH GEN PSYCHIAT, V64, P361, DOI 10.1001/archpsyc.64.3.361; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Maas AIR, 2012, LANCET NEUROL, V11, P12, DOI 10.1016/S1474-4422(11)70267-8; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Martland H, 1928, JAMA-J AM MED ASSOC, V911, P103; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; National Council on Disability, 2009, INV WOUNDS SERV SERV; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Rowe CC, 2011, J NUCL MED, V52, P1733, DOI 10.2967/jnumed.110.076315; Scarmeas N, 2003, J CLIN EXP NEUROPSYC, V25, P625, DOI 10.1076/jcen.25.5.625.14576; Seal KH, 2009, AM J PUBLIC HEALTH, V99, P1651, DOI 10.2105/AJPH.2008.150284; Shively S, 2012, ARCH NEUROL-CHICAGO, V69, P1; Stomrud E, 2010, ARCH NEUROL-CHICAGO, V67, P217, DOI 10.1001/archneurol.2009.316; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thurmond VA, 2010, ARCH PHYS MED REHAB, V91, P1633, DOI 10.1016/j.apmr.2010.06.034; Weiner Michael W, 2012, Alzheimers Dement, V8, pS1, DOI 10.1016/j.jalz.2011.09.172; Yaffe K, 2010, ARCH GEN PSYCHIAT, V67, P608, DOI 10.1001/archgenpsychiatry.2010.61; Yehuda R, 2010, PSYCHOPHARMACOLOGY, V212, P405, DOI 10.1007/s00213-010-1969-6; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277; Zhou WD, 2008, J NEUROTRAUM, V25, P279, DOI 10.1089/neu.2007.0489	48	231	234	2	51	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1552-5260			ALZHEIMERS DEMENT	Alzheimers. Dement.	JUL	2013	9	4					445	451		10.1016/j.jalz.2013.03.005			7	Clinical Neurology	Neurosciences & Neurology	182GF	WOS:000321729000013	23932184	Green Accepted			2021-06-18	
J	Long, JB; Bentley, TL; Wessner, KA; Cerone, C; Sweeney, S; Bauman, RA				Long, Joseph B.; Bentley, Timothy L.; Wessner, Keith A.; Cerone, Carolyn; Sweeney, Sheena; Bauman, Richard A.			Blast Overpressure in Rats: Recreating a Battlefield Injury in the Laboratory	JOURNAL OF NEUROTRAUMA			English	Article						axonal injury; blast; hemorrhage; learning and memory; protective vest; traumatic brain injury	TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; HEMORRHAGIC-SHOCK; PRESSURE; DEATH; AFGHANISTAN; CASUALTIES; IMPACT; WARS; IRAQ	Blast injury to the brain is the predominant cause of neurotrauma in current military conflicts, and its etiology is largely undefined. Using a compression-driven shock tube to simulate blast effects, we assessed the physiological, neuropathological, and neurobehavioral consequences of airblast exposure, and also evaluated the effect of a Kevlar (R) protective vest on acute mortality in rats and on the occurrence of traumatic brain injury (TBI) in those that survived. This approach provides survivable blast conditions under which TBI can be studied. Striking neuropathological changes were caused by both 126- and 147-kPa airblast exposures. The Kevlar vest, which encased the thorax and part of the abdomen, greatly reduced airblast mortality, and also ameliorated the widespread fiber degeneration that was prominent in brains of rats not protected by a vest during exposure to a 126-kPa airblast. This finding points to a significant contribution of the systemic effects of airblast to its brain injury pathophysiology. Airblast of this intensity also disrupted neurologic and neurobehavioral performance (e. g., beam walking and spatial navigation acquisition in the Morris water maze). When immediately followed by hemorrhagic hypotension, with MAP maintained at 30 mm Hg, airblast disrupted cardiocompensatory resilience, as reflected by reduced peak shed blood volume, time to peak shed blood volume, and time to death. These findings demonstrate that shock tube-generated airblast can cause TBI in rats, in part through systemic mediation, and that the resulting brain injury significantly impacts acute cardiovascular homeostatic mechanisms as well as neurobehavioral function.	[Long, Joseph B.; Bentley, Timothy L.; Wessner, Keith A.; Cerone, Carolyn; Sweeney, Sheena; Bauman, Richard A.] Walter Reed Army Inst Res, Div Mil Casualty Res, Silver Spring, MD 20910 USA	Long, JB (corresponding author), Walter Reed Army Inst Res, Div Mil Casualty Res, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.	joseph.long@amedd.army.mil					Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Chesnut RM, 2007, SURG CLIN N AM, V87, P119, DOI 10.1016/j.suc.2006.09.018; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Drobin D, 2007, J TRAUMA, V63, P405, DOI 10.1097/01.ta.0000236015.68105.48; Elsayed NM, 1997, TOXICOLOGY, V121, P1, DOI 10.1016/S0300-483X(97)03651-2; Frykberg ER, 2002, J TRAUMA, V53, P201, DOI 10.1097/00005373-200208000-00001; Garner Jeff, 2007, Anesthesiol Clin, V25, P147; GORANSSON AM, 1988, J TRAUMA, V28, pS204; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; HANLEY CJ, 2007, WASHINGTON POST 0820; Law MM, 1996, SHOCK, V6, P213, DOI 10.1097/00024382-199609010-00010; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Martin EM, 2008, AM J NURS, V108, P40, DOI 10.1097/01.NAJ.0000315260.92070.3f; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McMahon CG, 2008, CRIT CARE MED, V36, P216, DOI 10.1097/01.CCM.0000295425.41831.85; McMahon CG, 1999, J TRAUMA, V47, P891, DOI 10.1097/00005373-199911000-00013; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; PHILLIPS YY, 1988, J TRAUMA, V28, pS149, DOI 10.1097/00005373-198801001-00030; SHANKER T, 2007, NY TIMES        0602, P1; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Singleton RH, 2002, J NEUROSCI, V22, P791, DOI 10.1523/JNEUROSCI.22-03-00791.2002; SUNESON A, 1990, J TRAUMA, V30, P295, DOI 10.1097/00005373-199003000-00007; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wightman JM, 2001, ANN EMERG MED, V37, P664, DOI 10.1067/mem.2001.114906; YOUNG AJ, 1985, AVIAT SPACE ENVIR MD, V56, P49; YUAN XQ, 1992, SURG GYNECOL OBSTET, V174, P305; YUAN XQ, 1991, J NEUROSURG, V75, P408, DOI 10.3171/jns.1991.75.3.0408	33	231	237	1	46	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	2009	26	6					827	840		10.1089/neu.2008.0748			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	455OV	WOS:000266773600003	19397422				2021-06-18	
J	Kim, SJ; Son, TG; Park, HR; Park, M; Kim, MS; Kim, HS; Chung, HY; Mattson, MP; Lee, J				Kim, So Jung; Son, Tae Gen; Park, Hee Ra; Park, Mikyung; Kim, Min-Sun; Kim, Hyung Sik; Chung, Hae Young; Mattson, Mark P.; Lee, Jaewon			Curcumin stimulates proliferation of embryonic neural progenitor cells and neurogenesis in the adult hippocampus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRAUMATIC BRAIN-INJURY; DIETARY RESTRICTION; NEUROTROPHIC FACTOR; OXIDATIVE DAMAGE; HEME OXYGENASE-1; DENTATE GYRUS; STEM-CELLS; NEURONS; INCREASES; EXPRESSION	Curcumin is a natural phenolic component of yellow curry spice, which is used in some cultures for the treatment of diseases associated with oxidative stress and inflammation. Curcumin has been reported to be capable of preventing the death of neurons in animal models of neurodegenerative disorders, but its possible effects on developmental and adult neuroplasticity are unknown. In the present study, we investigated the effects of curcumin on mouse multi-potent neural progenitor cells (NPC) and adult hippocampal neurogenesis. Curcumin exerted biphasic effects on cultured NPC; low concentrations stimulated cell proliferation, whereas high concentrations were cytotoxic. Curcumin activated extracellular signal-regulated kinases (ERKs) and p38 kinases, cellular signal transduction pathways known to be involved in the regulation of neuronal plasticity and stress responses. Inhibitors of ERKs and p38 kinases effectively blocked the mitogenic effect of curcumin in NPC. Administration of curcumin to adult mice resulted in a significant increase in the number of newly generated cells in the dentate gyrus of hippocampus, indicating that curcumin enhances adult hippocampal neurogenesis. Our findings suggest that curcumin can stimulate developmental and adult hippocampal neurogenesis, and a biological activity that may enhance neural plasticity and repair.	[Kim, So Jung; Park, Hee Ra; Park, Mikyung; Kim, Min-Sun; Kim, Hyung Sik; Chung, Hae Young; Lee, Jaewon] Pusan Natl Univ, Dept Pharm, Coll Pharm, Pusan 609735, South Korea; [Kim, So Jung; Park, Hee Ra; Park, Mikyung; Kim, Min-Sun; Kim, Hyung Sik; Chung, Hae Young; Lee, Jaewon] Pusan Natl Univ, Res Inst Drug Dev, Longev Life Sci & Technol Inst, Pusan 609735, South Korea; [Son, Tae Gen; Mattson, Mark P.] NIA, Neurosci Lab, NIH, Baltimore, MD 21224 USA	Lee, J (corresponding author), Pusan Natl Univ, Dept Pharm, Coll Pharm, Pusan 609735, South Korea.	neuron@pusan.ac.kr	Mattson, Mark P/F-6038-2012; Lee, Jaewon/N-9064-2013	Lee, Jaewon/0000-0003-3203-2130	NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [Z01AG000312, ZIAAG000324, Z01AG000315, ZIAAG000312, ZIAAG000331, ZIAAG000315, ZIAAG000314, Z01AG000324, Z01AG000314] Funding Source: NIH RePORTER		Aggarwal BB, 2007, BIOCHEM PHARMACOL, V73, P1024, DOI 10.1016/j.bcp.2006.12.010; Al-Omar FA, 2006, NEUROCHEM RES, V31, P611, DOI 10.1007/s11064-006-9059-1; Alvarez-Buylla A, 2001, NAT REV NEUROSCI, V2, P287, DOI 10.1038/35067582; Aoki H, 2007, MOL PHARMACOL, V72, P29, DOI 10.1124/mol.106.033167; Baek OS, 2003, CLIN CHIM ACTA, V338, P135, DOI 10.1016/j.cccn.2003.08.015; Balogun E, 2003, BIOCHEM J, V371, P887, DOI 10.1042/BJ20021619; Baron W, 2000, MOL CELL NEUROSCI, V15, P314, DOI 10.1006/mcne.1999.0827; Calabrese Vittorio, 2003, Ital J Biochem, V52, P177; Cameron HA, 1999, NAT NEUROSCI, V2, P894, DOI 10.1038/13197; Chen H, 1999, ANTICANCER RES, V19, P3675; Cheng AW, 2004, DEV BIOL, V272, P203, DOI 10.1016/j.ydbio.2004.04.031; Cheng AW, 2001, J BIOL CHEM, V276, P43320, DOI 10.1074/jbc.M107698200; Chuang SE, 2000, CARCINOGENESIS, V21, P331, DOI 10.1093/carcin/21.2.331; Duvoix A, 2005, CANCER LETT, V223, P181, DOI 10.1016/j.canlet.2004.09.041; Frautschy SA, 2001, NEUROBIOL AGING, V22, P993, DOI 10.1016/S0197-4580(01)00300-1; Goel A, 2008, BIOCHEM PHARMACOL, V75, P787, DOI 10.1016/j.bcp.2007.08.016; Gould E, 2007, NAT REV NEUROSCI, V8, P481, DOI 10.1038/nrn2147; Haughey NJ, 2002, J NEUROCHEM, V83, P1509, DOI 10.1046/j.1471-4159.2002.01267.x; HUANG MT, 1991, CANCER RES, V51, P813; Jackson-Guilford J, 2000, NEUROSCI LETT, V293, P91, DOI 10.1016/S0304-3940(00)01502-0; Kalluri HSG, 2007, NEUROSCI LETT, V426, P145, DOI 10.1016/j.neulet.2007.08.047; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Lee J, 2002, J NEUROCHEM, V82, P1367, DOI 10.1046/j.1471-4159.2002.01085.x; Lee J, 2002, J NEUROCHEM, V80, P539, DOI 10.1046/j.0022-3042.2001.00747.x; Lee J, 2000, J MOL NEUROSCI, V15, P99, DOI 10.1385/JMN:15:2:99; Lim GP, 2001, J NEUROSCI, V21, P8370; Lim MS, 2007, BIOCHEM BIOPH RES CO, V357, P903, DOI 10.1016/j.bbrc.2007.04.045; Lin JK, 2007, ADV EXP MED BIOL, V595, P227; Lodha R., 2000, Annals Academy of Medicine Singapore, V29, P37; Mattson MP, 2006, TRENDS NEUROSCI, V29, P632, DOI 10.1016/j.tins.2006.09.001; McNally SJ, 2007, INT J MOL MED, V19, P165; Menard C, 2002, NEURON, V36, P597, DOI 10.1016/S0896-6273(02)01026-7; Niles LP, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-41; Nilsson M, 1999, J NEUROBIOL, V39, P569, DOI 10.1002/(SICI)1097-4695(19990615)39:4<569::AID-NEU10>3.0.CO;2-F; Parent JM, 2007, PROG BRAIN RES, V163, P529, DOI 10.1016/S0079-6123(07)63028-3; Parent JM, 1997, J NEUROSCI, V17, P3727; Piper JT, 1998, INT J BIOCHEM CELL B, V30, P445, DOI 10.1016/S1357-2725(98)00015-6; Rao CV, 1995, ANN NY ACAD SCI, V768, P201, DOI 10.1111/j.1749-6632.1995.tb12122.x; RUBY AJ, 1995, CANCER LETT, V94, P79, DOI 10.1016/0304-3835(95)03827-J; Salvioli S, 2007, EVID-BASED COMPL ALT, V4, P181, DOI 10.1093/ecam/nem043; Scapagnini G, 2006, ANTIOXID REDOX SIGN, V8, P395, DOI 10.1089/ars.2006.8.395; Schmidt HD, 2007, BEHAV PHARMACOL, V18, P391, DOI 10.1097/FBP.0b013e3282ee2aa8; Shin HJ, 2007, NEUROSCI LETT, V416, P49, DOI 10.1016/j.neulet.2007.01.060; Shishodia S, 2005, ANN NY ACAD SCI, V1056, P206, DOI 10.1196/annals.1352.010; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; SNYDER EY, 1992, CELL, V68, P33, DOI 10.1016/0092-8674(92)90204-P; Suh HW, 2007, MOL CELL BIOCHEM, V298, P187, DOI 10.1007/s11010-006-9365-6; Sumanont Y, 2006, LIFE SCI, V78, P1884, DOI 10.1016/j.lfs.2005.08.028; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Thiyagarajan M, 2004, LIFE SCI, V74, P969, DOI 10.1016/j.lfs.2003.06.042; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; van Praag H, 1999, NAT NEUROSCI, V2, P266; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Xiao ZF, 2007, CELL RES, V17, P73, DOI 10.1038/sj.cr.7310126; Xu Y, 2007, BRAIN RES, V1162, P9, DOI 10.1016/j.brainres.2007.05.071; Yang FS, 2005, J BIOL CHEM, V280, P5892, DOI 10.1074/jbc.M404751200; Yang Y, 2006, NEUROREPORT, V17, P235, DOI 10.1097/01.wnr.0000199470.29357.8f; Zbarsky V, 2005, FREE RADICAL RES, V39, P1119, DOI 10.1080/10715760500233113; Zhang M, 2006, INT IMMUNOPHARMACOL, V6, P1233, DOI 10.1016/j.intimp.2006.02.013; Zhu YG, 2004, ACTA PHARMACOL SIN, V25, P1606	60	231	237	0	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2008	283	21					14497	14505		10.1074/jbc.M708373200			9	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	302BL	WOS:000255941400037	18362141	Green Published, Other Gold			2021-06-18	
J	KATZ, DI; ALEXANDER, MP				KATZ, DI; ALEXANDER, MP			TRAUMATIC BRAIN INJURY - PREDICTING COURSE OF RECOVERY AND OUTCOME FOR PATIENTS ADMITTED TO REHABILITATION	ARCHIVES OF NEUROLOGY			English	Article							SEVERE HEAD-INJURY; DIFFUSE AXONAL INJURY; PRACTICAL SCALE; PROGNOSIS; COMA	Objective: To demonstrate that the prognosis for patients with traumatic brain injury (TBI) admitted to rehabilitation can be established with use of principled neurologic diagnosis and predictor variables of established value in neurosurgical populations. Design: A cohort of patients with TBI accumulated at rehabilitation admission were followed up for 1 year. Severity measures (Glasgow Coma Scale score, length of coma, and duration of posttraumatic amnesia) and information to generate neuropathologic profiles were gathered retrospectively and prospectively; outcome measures were obtained prospectively. Setting: The TBI rehabilitation unit in a freestanding rehabilitation hospital. Patients: A consecutive sample of 243 patients with TBI admitted to a rehabilitation unit (age range, 8 through 89 years). Main Outcome Measures: Functional outcome measured by the Glasgow Outcome Scale at 6 and 12 months after injury. Results: Posttraumatic amnesia had a clear, predictable relationship to length of coma in patients with diffuse axonal injury (R(2)=.58, P<.0001). Severity measures, particularly duration of posttraumatic amnesia, correlated with the Glasgow Outcome Scale score at 6 and 12 months after injury (R(2)=.45, P<.0001, R(2)=.48, P<.0001), strongly in patients with diffuse axonal injury but poorly in patients with primarily focal brain injury. Age was an important factor in recovery, beginning at age 40 years; older patients had significantly longer posttraumatic amnesia and worse functional outcome at any severity. Conclusions: The early course of recover); and functional outcome in TBI can be characterized in neurorehabilitation populations and is highly dependent on specific neuropathologic diagnosis, severity, and age. Predictions that employ traditional measures of severity are most relevant in patients with diffuse axonal injury. Age has a potent, complex effect on recovery, particularly beyond age 40 years.	BRAINTREE HOSP REHABIL NETWORK,TRAUMAT BRAIN INJURY PROGRAM,BRAINTREE,MA; BOSTON UNIV,SCH MED,DEPT NEUROL,BOSTON,MA 02118	KATZ, DI (corresponding author), BRAINTREE HOSP REHABIL NETWORK,DEPT NEUROL,250 POND ST,BRAINTREE,MA 02184, USA.			Katz, Douglas/0000-0002-7502-8505			ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; AMACHER AL, 1979, NEUROSURGERY, V20, P954; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; Damasio H., 1989, LESION ANAL NEUROPSY; Frowein R A, 1979, Acta Neurochir Suppl (Wien), V28, P3; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; HEISKANEN O, 1970, ACTA NEUROL SCAND, V46, P343, DOI 10.1111/j.1600-0404.1970.tb05798.x; HERNESNIEMI J, 1979, ACTA NEUROCHIR, V49, P67, DOI 10.1007/BF01809175; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; JENNETT B, 1975, LANCET, V1, P480; Jennett B, 1981, MANAGEMENT HEAD INJU; KATZ DI, 1992, J HEAD TRAUMA REHAB, V7, P1; KIRKPATRICK JB, 1987, J AM GERIATR SOC, V26, P489; KURTZKE JF, 1987, CLIN NEUROLOGY, P1; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; LOKKEBERG AR, 1984, J NEUROSURG, V61, P254, DOI 10.3171/jns.1984.61.2.0254; MARSHALL LF, 1991, NEUROSURGERY S, V75, P28; MARSHALL LF, 1991, NEUROSURGERY S, V75, P14; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PENTLAND B, 1986, AGE AGEING, V15, P193, DOI 10.1093/ageing/15.4.193; ROY CW, 1986, INJURY, V17, P220, DOI 10.1016/0020-1383(86)90222-6; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; STABLEIN DM, 1980, NEUROSURGERY, V6, P243; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P140; TEASDALE G, 1974, LANCET, V2, P81; VOLLMER DG, 1993, HEAD INJURY, P553; Vollmer DG, 1991, NEUROSURGERY, V75, P37; Wilson J A, 1987, Brain Inj, V1, P183, DOI 10.3109/02699058709034456	33	231	236	0	14	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0003-9942			ARCH NEUROL-CHICAGO	Arch. Neurol.	JUL	1994	51	7					661	670		10.1001/archneur.1994.00540190041013			10	Clinical Neurology	Neurosciences & Neurology	NW479	WOS:A1994NW47900007	8018038				2021-06-18	
J	Rowson, S; Duma, SM; Beckwith, JG; Chu, JJ; Greenwald, RM; Crisco, JJ; Brolinson, PG; Duhaime, AC; McAllister, TW; Maerlender, AC				Rowson, Steven; Duma, Stefan M.; Beckwith, Jonathan G.; Chu, Jeffrey J.; Greenwald, Richard M.; Crisco, Joseph J.; Brolinson, P. Gunnar; Duhaime, Ann-Christine; McAllister, Thomas W.; Maerlender, Arthur C.			Rotational Head Kinematics in Football Impacts: An Injury Risk Function for Concussion	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Mild traumatic brain injury; Head; Helmet; Angular; Acceleration; Sports; HITS	CHRONIC TRAUMATIC ENCEPHALOPATHY; HIGH-SCHOOL FOOTBALL; DIFFUSE AXONAL INJURY; COLLEGIATE FOOTBALL; BRAIN-INJURY; LEAGUE PLAYER; DIVISION-I; ACCELERATION; EPIDEMIOLOGY; BIOMECHANICS	Recent research has suggested a possible link between sports-related concussions and neurodegenerative processes, highlighting the importance of developing methods to accurately quantify head impact tolerance. The use of kinematic parameters of the head to predict brain injury has been suggested because they are indicative of the inertial response of the brain. The objective of this study is to characterize the rotational kinematics of the head associated with concussive impacts using a large head acceleration dataset collected from human subjects. The helmets of 335 football players were instrumented with accelerometer arrays that measured head acceleration following head impacts sustained during play, resulting in data for 300,977 subconcussive and 57 concussive head impacts. The average subconcussive impact had a rotational acceleration of 1230 rad/s(2) and a rotational velocity of 5.5 rad/s, while the average concussive impact had a rotational acceleration of 5022 rad/s(2) and a rotational velocity of 22.3 rad/s. An injury risk curve was developed and a nominal injury value of 6383 rad/s(2) associated with 28.3 rad/s represents 50% risk of concussion. These data provide an increased understanding of the biomechanics associated with concussion and they provide critical insight into injury mechanisms, human tolerance to mechanical stimuli, and injury prevention techniques.	[Rowson, Steven; Duma, Stefan M.] Virginia Tech Wake Forest Univ, Sch Biomed Engn & Sci, Blacksburg, VA 24061 USA; [Beckwith, Jonathan G.; Chu, Jeffrey J.; Greenwald, Richard M.] Simbex, Lebanon, NH USA; [Greenwald, Richard M.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA; [Crisco, Joseph J.] Brown Univ, Warren Alpert Med Sch, Dept Orthopaed, Providence, RI 02912 USA; [Crisco, Joseph J.] Rhode Isl Hosp, Providence, RI USA; [Brolinson, P. Gunnar] Edward Via Virginia Coll Osteopath Med, Blacksburg, VA USA; [Duhaime, Ann-Christine] Dartmouth Hitchcock Med Ctr, Hanover, NH USA; [McAllister, Thomas W.] Dartmouth Hitchcock Med Sch, Dept Psychiat & Neurol, Lebanon, NH USA; [Maerlender, Arthur C.] Dartmouth Hitchcock Med Ctr, Dept Psychiat, Hanover, NH USA	Rowson, S (corresponding author), Virginia Tech Wake Forest Univ, Sch Biomed Engn & Sci, 440 ICTAS Bldg,Stanger St, Blacksburg, VA 24061 USA.	srowson@vt.edu	Rowson, Steven/B-1270-2012; Duma, Stefan/A-8368-2012; Lang, Steven/AAE-8102-2021	Rowson, Steven/0000-0002-3227-0596; Lang, Steven/0000-0003-1669-9146	National Highway Traffic Safety Administration; Toyota Central Research and Development Labs; National Institutes of Health (National Institute for Child Health and Human Development)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638]; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055020]; HIT System, Sideline Response System (Riddell, Inc); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS055020] Funding Source: NIH RePORTER	The authors gratefully acknowledge our sponsors for this research including the National Highway Traffic Safety Administration, Toyota Central Research and Development Labs, and the National Institutes of Health (National Institute for Child Health and Human Development) R01HD048638 and (National Institute of Neurological Disorders and Stroke) R01NS055020. The authors also thank Josh Tan and the Center for Biomedical Imaging at Wake Forest University for assistance with the imaging illustration.; Joseph J. Crisco, Richard M. Greenwald, Jeffrey J. Chu and Simbex have a financial interest in the instruments (HIT System, Sideline Response System (Riddell, Inc)) that were used to collect the data reported in this study.	Booher MA, 2003, CLIN J SPORT MED, V13, P93, DOI 10.1097/00042752-200303000-00005; Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Chu JJ, 2006, J BIOMECH S1, V39, pS534; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Davidsson J., 2009, P INT RES C BIOM IMP; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Duma SM, 2011, EXERC SPORT SCI REV, V39, P2, DOI 10.1097/JES.0b013e318203dfdb; Fournier E., 2000, IRCOBI INT RES COUNC, V2000, P223; Gadd CW, 1966, P 10 STAPP CAR CRASH; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; GURDJIAN ES, 1966, J TRAUM, V6, P600, DOI 10.1097/00005373-196609000-00005; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Gwin JT, 2010, J BIOMECH ENG-T ASME, V132, DOI 10.1115/1.4000249; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; HARDY WN, 1994, INT J IMPACT ENG, V15, P561, DOI 10.1016/0734-743X(94)80034-7; Hootman JM, 2007, J ATHL TRAINING, V42, P311; King A.I., 2003, P INT RES C BIOM IMP; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; McAllister TW, 2010, PM&R, V2, pS241, DOI 10.1016/j.pmrj.2010.10.005; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McElhaney J. H., 1971, P 15 STAPP CAR CRASH; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Newman J, 1999, INT RES COUNC BIOM I, P17; Newman J A, 2000, Stapp Car Crash J, V44, P215; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Ommaya AK, 1967, P 11 STAPP CAR CRASH, P670906; Ommaya AK, 1985, BIOMECHANICS TRAUMA; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Rowson S, 2008, CLIN J SPORT MED, V18, P316, DOI 10.1097/JSM.0b013e31817f016a; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; Rowson S, 2011, J APPL BIOMECH, V27, P8, DOI 10.1123/jab.27.1.8; Rowson S, 2010, CLIN J SPORT MED, V20, P344, DOI 10.1097/JSM.0b013e3181ed7e50; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Shain KS, 2010, CLIN J SPORT MED, V20, P422, DOI 10.1097/JSM.0b013e3181f7db25; STALNAKER RL, 1971, J BIOMECH, V4, P127, DOI 10.1016/0021-9290(71)90023-6; Takhounts EG, 2008, STAPP CAR C, V52, P1; Unterharnscheidt F. J, 1971, P 15 STAPP CAR CRASH; Versace J., 1971, SAE TECHNICAL PAPER; Ward C, 1980, SAE TECHNICAL PAPER; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	56	230	231	2	71	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	JAN	2012	40	1			SI		1	13		10.1007/s10439-011-0392-4			13	Engineering, Biomedical	Engineering	895HJ	WOS:000300486700001	22012081	Green Published			2021-06-18	
J	Kuan, CY; Schloemer, AJ; Lu, AG; Burns, KA; Weng, WL; Williams, MT; Strauss, KI; Vorhees, CV; Flavell, RA; Davis, RJ; Sharp, FR; Rakic, P				Kuan, CY; Schloemer, AJ; Lu, AG; Burns, KA; Weng, WL; Williams, MT; Strauss, KI; Vorhees, CV; Flavell, RA; Davis, RJ; Sharp, FR; Rakic, P			Hypoxia-ischemia induces DNA synthesis without cell proliferation in dying neurons in adult rodent brain	JOURNAL OF NEUROSCIENCE			English	Article						neurogenesis; apoptosis; cell cycle; BrdU; ischemia; hypoxia	DEPENDENT KINASE INHIBITORS; CENTRAL-NERVOUS-SYSTEM; ALZHEIMERS-DISEASE; CEREBRAL-ISCHEMIA; CYCLE CHECKPOINT; DENTATE GYRUS; GRANULE CELLS; MICE LACKING; DEATH; RAT	Recent studies suggest that postmitotic neurons can reenter the cell cycle as a prelude to apoptosis after brain injury. However, most dying neurons do not pass the G(1)/S-phase checkpoint to resume DNA synthesis. The specific factors that trigger abortive DNA synthesis are not characterized. Here we show that the combination of hypoxia and ischemia induces adult rodent neurons to resume DNA synthesis as indicated by incorporation of bromodeoxyuridine ( BrdU) and expression of G(1)/S-phase cell cycle transition markers. After hypoxia-ischemia, the majority of BrdU-and neuronal nuclei (NeuN)-immunoreactive cells are also terminal deoxynucleotidyl transferase-mediated biotinylated UTP nick end labeling (TUNEL)-stained, suggesting that they undergo apoptosis. BrdU(+) neurons, labeled shortly after hypoxia-ischemia, persist for >5 d but eventually disappear by 28 d. Before disappearing, these BrdU(+)/NeuN(+)/TUNEL+ neurons express the proliferating cell marker Ki67, lose the G(1)-phase cyclin-dependent kinase (CDK) inhibitors p16INK4 and p27Kip1 and show induction of the late G(1)/S-phase CDK2 activity and phosphorylation of the retinoblastoma protein. This contrasts to kainic acid excitotoxicity and traumatic brain injury, which produce TUNEL-positive neurons without evidence of DNA synthesis or G(1)/S-phase cell cycle transition. These findings suggest that hypoxia-ischemia triggers neurons to reenter the cell cycle and resume apoptosis-associated DNA synthesis in brain. Our data also suggest that the demonstration of neurogenesis after brain injury requires not only BrdU uptake and mature neuronal markers but also evidence showing absence of apoptotic markers. Manipulating the aberrant apoptosis-associated DNA synthesis that occurs with hypoxia-ischemia and perhaps neurodegenerative diseases could promote neuronal survival and neurogenesis.	Childrens Hosp Res Fdn, Div Dev Biol, Dept Pediat, Cincinnati, OH 45229 USA; Childrens Hosp Res Fdn, Div Neurol, Dept Pediat, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Dept Neurol, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Dept Neurosurg, Cincinnati, OH 45229 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT 06510 USA; Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA	Kuan, CY (corresponding author), Childrens Hosp Res Fdn, Div Dev Biol, Dept Pediat, Room 3464,3333 Burnet Ave, Cincinnati, OH 45229 USA.	alex.kuan@chmcc.org		Vorhees, Charles/0000-0003-3558-8812; Williams, Michael/0000-0001-9841-9683	NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P50CA095817] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038654] Funding Source: NIH RePORTER; NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P50 CA095817] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS038654] Funding Source: Medline		ALUBAIDI MR, 1992, P NATL ACAD SCI USA, V89, P1194, DOI 10.1073/pnas.89.4.1194; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; Benchoua A, 2001, J NEUROSCI, V21, P7127, DOI 10.1523/JNEUROSCI.21-18-07127.2001; Busser J, 1998, J NEUROSCI, V18, P2801; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; COBRINIK D, 1992, TRENDS BIOCHEM SCI, V17, P312, DOI 10.1016/0968-0004(92)90443-D; Cooper-Kuhn CM, 2002, DEV BRAIN RES, V134, P13, DOI 10.1016/S0165-3806(01)00243-7; Copani A, 2001, TRENDS NEUROSCI, V24, P25, DOI 10.1016/S0166-2236(00)01663-5; de Bruin A, 2003, P NATL ACAD SCI USA, V100, P6546, DOI 10.1073/pnas.1031853100; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Herrup K, 2002, J ALZHEIMERS DIS, V4, P243, DOI 10.3233/JAD-2002-4315; HU Z, 1977, J NEUROSCI, V17, P3981; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Katchanov J, 2001, J NEUROSCI, V21, P5045, DOI 10.1523/JNEUROSCI.21-14-05045.2001; Klein JA, 2002, NATURE, V419, P367, DOI 10.1038/nature01034; Kruman II, 2004, NEURON, V41, P549, DOI 10.1016/S0896-6273(04)00017-0; Kuan CY, 2003, P NATL ACAD SCI USA, V100, P15184, DOI 10.1073/pnas.2336254100; LEVINE S, 1960, AM J PATHOL, V36, P1; Liu DX, 2001, CELL TISSUE RES, V305, P217, DOI 10.1007/s004410100396; Liu JL, 1998, J NEUROSCI, V18, P7768; MILLER MW, 1988, BRAIN RES, V457, P44, DOI 10.1016/0006-8993(88)90055-8; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Osuga H, 2000, P NATL ACAD SCI USA, V97, P10254, DOI 10.1073/pnas.170144197; Packard D S Jr, 1973, Differentiation, V1, P397, DOI 10.1111/j.1432-0436.1973.tb00137.x; Park DS, 1997, J NEUROSCI, V17, P8975; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Rakic P, 2002, J NEUROSCI, V22, P614, DOI 10.1523/JNEUROSCI.22-03-00614.2002; RICE JE, 1981, ANN NEUROL, V9, P131, DOI 10.1002/ana.410090206; SANES JR, 1972, J CELL BIOL, V53, P587, DOI 10.1083/jcb.53.2.587; Schauwecker PE, 1997, P NATL ACAD SCI USA, V94, P4103, DOI 10.1073/pnas.94.8.4103; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Shackelford RE, 2000, FREE RADICAL BIO MED, V28, P1387, DOI 10.1016/S0891-5849(00)00224-0; Sheaff RJ, 1997, METHOD ENZYMOL, V283, P173; SLOVITER RS, 1989, SCIENCE, V243, P535, DOI 10.1126/science.2911756; SLOVITER RS, 1993, J COMP NEUROL, V330, P337, DOI 10.1002/cne.903300305; Smith DS, 2000, CELL GROWTH DIFFER, V11, P625; Steindler DA, 2002, LANCET, V359, P1047, DOI 10.1016/S0140-6736(02)08096-0; Strauss KI, 2000, J NEUROTRAUM, V17, P695, DOI 10.1089/089771500415436; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Vincent I, 1996, J CELL BIOL, V132, P413, DOI 10.1083/jcb.132.3.413; Wen Y, 2004, J BIOL CHEM, V279, P22684, DOI 10.1074/jbc.M311768200; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yang Y, 2001, J NEUROSCI, V21, P2661, DOI 10.1523/JNEUROSCI.21-08-02661.2001; Yang Y, 2003, J NEUROSCI, V23, P2557; Zindy F, 1999, P NATL ACAD SCI USA, V96, P13462, DOI 10.1073/pnas.96.23.13462	47	230	242	0	13	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	NOV 24	2004	24	47					10763	10772		10.1523/JNEUROSCI.3883-04.2004			10	Neurosciences	Neurosciences & Neurology	874EG	WOS:000225333100023	15564594	Green Published, Green Accepted, Bronze			2021-06-18	
J	Vespa, P; Prins, M; Ronne-Engstrom, E; Caron, M; Shalmon, E; Hovda, DA; Martin, NA; Becker, DP				Vespa, P; Prins, M; Ronne-Engstrom, E; Caron, M; Shalmon, E; Hovda, DA; Martin, NA; Becker, DP			Increase in extracellular glutamate caused by reduced cerebral perfusion pressure and seizures after human traumatic brain injury: a microdialysis study	JOURNAL OF NEUROSURGERY			English	Article						cerebral microdialysis; glutamate; traumatic brain injury; human head injury; amino acid; seizure	VENOUS OXYGEN-SATURATION; EXCITATORY AMINO-ACIDS; INDUCED NEURONAL DEATH; INTRACEREBRAL MICRODIALYSIS; BLOOD-FLOW; RAT-BRAIN; GLUCOSE-UTILIZATION; INTENSIVE-CARE; KAINIC ACID; ISCHEMIA	Object. To determine the extent and duration of change in extracellular glutamate levels after human traumatic brain injury (TBI), 17 severely brain injured adults underwent implantation of a cerebral microdialysis probe and systematic sampling was conducted for 1 to 9 days postinjury. Methods. A total of 772 hourly microdialysis samples were obtained in 17 patients (median Glasgow Coma Scale score 5 +/- 2.5, mean age 39.4 +/- 20.4 years). The mean (+/- standard deviation) glutamate levels in the dialysate were evaluated for 9 days, during which the mean peak concentration reached 25.4 +/- 13.7 mu M On postinjury Day 3. In each patient transient elevations in glutamate were seen each day. However, these elevations were most commonly seen on Day 3. In all patients there was a mean of 4.5 +/- 2.5 transient elevations in glutamate lasting a mean duration of 4.4 +/- 4.9 hours. These increases were seen in conjunction with seizure activity. However, in many seizure-free patients the increase in extracellular glutamate occurred when cerebral perfusion pressure was less than 70 mm Hg (p < 0.001). Given the potential injury-induced uncoupling of cerebral blood flow and metabolism after TBI, these increases in extracellular glutamate may reflect a degree of enhanced cellular crisis, which in severe head injury in humans appears to last up to 9 days. Conclusions. Extracellular neurochemical measurements of excitatory amino acids may provide a marker for secondary insults that can compound human TBI.	Univ Calif Los Angeles, Dept Surg, Div Neurosurg, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Dept Neurol, Sch Med, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Sch Med, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Inst Brain Res, Sch Med, Los Angeles, CA 90024 USA	Vespa, P (corresponding author), Univ Calif Los Angeles, Dept Surg, Div Neurosurg, 10833 Le Conte Ave, Los Angeles, CA 90024 USA.	vespa@ucla.edu	Prins, Mayumi/J-9571-2015	Prins, Mayumi/0000-0001-7694-9739; Martin, Neil/0000-0002-6565-4131			ACKERMANN RF, 1989, J CEREBR BLOOD F MET, V9, P774, DOI 10.1038/jcbfm.1989.111; ANDERSEN BJ, 1989, INTRACRANIAL PRESSUR, V7, P575; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; BACK T, 1995, J CEREBR BLOOD F MET, V15, P566, DOI 10.1038/jcbfm.1995.70; BENVENISTE H, 1989, J NEUROCHEM, V52, P1667, DOI 10.1111/j.1471-4159.1989.tb07243.x; BENVENISTE H, 1987, ACTA NEUROPATHOL, V74, P234, DOI 10.1007/BF00688186; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; BULLOCK R, 1991, J NEUROSURG, V74, P794, DOI 10.3171/jns.1991.74.5.0794; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; CHAPMAN AG, 1984, J NEUROCHEM, V43, P62, DOI 10.1111/j.1471-4159.1984.tb06679.x; CHOI DW, 1987, J NEUROSCI, V7, P369; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; DESSI F, 1993, J NEUROCHEM, V60, P1953, DOI 10.1111/j.1471-4159.1993.tb13427.x; DOBERSTEIN C, 1994, ACTA NEUROCHIR, P41; DREJER J, 1985, J NEUROCHEM, V45, P145, DOI 10.1111/j.1471-4159.1985.tb05486.x; DURING MJ, 1994, J NEUROCHEM, V62, P2356; DURING MJ, 1993, LANCET, V341, P1607; FADEN AI, 1990, EUR J PHARMACOL, V175, P165, DOI 10.1016/0014-2999(90)90227-W; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; FRANDSEN A, 1990, INT J DEV NEUROSCI, V8, P209, DOI 10.1016/0736-5748(90)90013-R; GARTHWAITE G, 1992, EUR J NEUROSCI, V4, P353, DOI 10.1111/j.1460-9568.1992.tb00882.x; GLOBUS MYT, 1988, J NEUROCHEM, V51, P1455, DOI 10.1111/j.1471-4159.1988.tb01111.x; Goodman JC, 1996, J NEUROTRAUM, V13, P549, DOI 10.1089/neu.1996.13.549; HAGBERG H, 1985, J CEREBR BLOOD F MET, V5, P413, DOI 10.1038/jcbfm.1985.56; HILLERED L, 1990, ACTA NEUROCHIR, V102, P91, DOI 10.1007/BF01405420; HILLERED L, 1989, J CEREBR BLOOD F MET, V9, P607, DOI 10.1038/jcbfm.1989.87; Hillered L, 1992, Clin Neuropharmacol, V15 Suppl 1 Pt A, p695A; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; LANDOLT H, 1994, ACTA NEUROCHIR, P475; LEE SM, 1995, NEUROSCIENCE, V21, P762; LEHMANN A, 1987, NEUROSCIENCE, V22, P573, DOI 10.1016/0306-4522(87)90354-X; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MELDRUM BS, 1995, ANN NY ACAD SCI, V757, P492, DOI 10.1111/j.1749-6632.1995.tb17509.x; MILLAN MH, 1991, EPILEPSY RES, V9, P86, DOI 10.1016/0920-1211(91)90017-A; NAHORSKI SR, 1970, J NEUROCHEM, V17, P621, DOI 10.1111/j.1471-4159.1970.tb00542.x; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; Pellerin L, 1996, DEV NEUROSCI-BASEL, V18, P336, DOI 10.1159/000111426; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; Persson L, 1996, J NEUROSURG, V84, P606, DOI 10.3171/jns.1996.84.4.0606; RONNEENGSTROM E, 1992, J CEREBR BLOOD F MET, V12, P873, DOI 10.1038/jcbfm.1992.119; ROSENBERG PA, 1989, NEUROSCI LETT, V103, P162, DOI 10.1016/0304-3940(89)90569-7; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Sechi G, 1997, BRAIN RES, V764, P230, DOI 10.1016/S0006-8993(97)00487-3; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; TEASDALE G, 1974, LANCET, V2, P81; Vespa PM, 1997, ELECTROEN CLIN NEURO, V103, P607, DOI 10.1016/S0013-4694(97)00071-0; VESPA PM, 1997, CRIT CARE MED S, V25, pA22; VEZZANI A, 1985, J NEUROCHEM, V45, P335, DOI 10.1111/j.1471-4159.1985.tb03993.x; WADE JV, 1987, J NEUROCHEM, V49, P645, DOI 10.1111/j.1471-4159.1987.tb02912.x; Wilson CL, 1996, EPILEPSY RES, V26, P245, DOI 10.1016/S0920-1211(96)00057-5; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	59	230	231	0	11	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	DEC	1998	89	6					971	982		10.3171/jns.1998.89.6.0971			12	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	168TF	WOS:000078708200011	9833824				2021-06-18	
J	Bendlin, BB; Ries, ML; Lazar, M; Alexander, AL; Dempsey, RJ; Rowley, HA; Sherman, JE; Johnson, SC				Bendlin, Barbara B.; Ries, Michele L.; Lazar, Mariana; Alexander, Andrew L.; Dempsey, Robert J.; Rowley, Howard A.; Sherman, Jack E.; Johnson, Sterling C.			Longitudinal changes in patients with traumatic brain injury assessed with diffusion-tensor and volumetric imaging	NEUROIMAGE			English	Article							WHITE-MATTER; AXONAL INJURY; QUANTITATIVE-ANALYSIS; ATROPHY; LESIONS; FORNIX; IMAGES; MEMORY; DEGENERATION; MORPHOLOGY	Traumatic brain injury (TBI) is associated with brain Volume loss, but there is little information on the regional gray matter (GM) and white matter (WM) changes that contribute to overall loss. Since axonal injury is a common occurrence in TBI, imaging methods that are sensitive to WM damage Such as diffusion-tensor imaging (DTI) may be useful for characterizing microstructural brain injury contributing to regional WM loss in TBI. High-resolution T1-weighted imaging and DTI were used to evaluate regional changes in TBI patients compared to matched controls. Patients received neuropsychological testing and were imaged approximately 2 months and 12.7 months post-injury. Paradoxically, neuropsychological function improved from Visit I to Visit 2, while voxel-based analyses of fractional anisotropy (FA), and mean diffusivity (MD) from the DTI images, and voxel-based analyses of the GM and WM probability maps from the T1-weighted images, mainly revealed significantly greater deleterious GM and WM change over time in patients compared to controls. Cross-sectional comparisons of the DTI measures indicated that patients have decreased FA and increased MID compared to controls over large regions of the brain. TBI affected virtually all of the major fiber bundles in the brain including the corpus callosum, cingulum, the superior and inferior longitudinal fascicules, the uncinate fasciculus, and brain stern fiber tracts. The results indicate that both GM and WM degeneration are significant contributors to brain volume loss in the months following brain injury, and also suggest that DTI measures may be more useful than high-resolution anatomical images in assessment of group differences. Published by Elsevier Inc.	[Bendlin, Barbara B.; Ries, Michele L.; Johnson, Sterling C.] William S Middleton Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Madison, WI USA; [Bendlin, Barbara B.; Ries, Michele L.; Johnson, Sterling C.] Univ Wisconsin, Sch Med, Dept Med, Madison, WI USA; [Lazar, Mariana] NYU, Dept Radiol, Sch Med, New York, NY 10016 USA; [Alexander, Andrew L.] Univ Wisconsin, Sch Med, Dept Med Phys, Madison, WI 53706 USA; [Dempsey, Robert J.] Univ Wisconsin, Sch Med, Dept Neurosurg, Madison, WI USA; [Rowley, Howard A.] Univ Wisconsin, Dept Radiol, Sch Med, Madison, WI 53706 USA; [Sherman, Jack E.] Univ Wisconsin, Sch Med, Dept Rehabil Med & Orthoped Surg, Madison, WI USA	Johnson, SC (corresponding author), William S Middleton Mem VA Hosp, Ctr Geriatr Res Educ & Clin, 2500 Overlook Terrace 11G, Madison, WI 53705 USA.	scj@medicine.wisc.edu	Kennedy, Kristen M/B-4699-2008	Kennedy, Kristen M/0000-0001-5373-9026; Bendlin, Barbara/0000-0002-0580-9875; Johnson, Sterling/0000-0002-8501-545X; Lazar, Mariana/0000-0001-9285-8124	Department of Veterans AffairsUS Department of Veterans Affairs; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [MH65723, MH62015]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH065723, R01MH062015] Funding Source: NIH RePORTER	This study was supported by a Merit Review Grant from the Department of Veterans Affairs, the NIH MH65723 (SCJ), MH62015 (ALA), and by the facilities and resources at the William S. Middleton Memorial Veterans Hospital. The assistance of Britta Jabbar, Shelly Fitzgerald, Gemma Gliori, and Erik Kastman is greatly appreciated. We would also like to acknowledge the kind Support of researchers and staff at the Waisman Center, University of Wisconsin, Madison, where MR imaging took place. Finally, we thank all the patients who took part in this Study.	Anderson CV, 1995, J CLIN EXP NEUROPSYC, V17, P900, DOI 10.1080/01688639508402438; [Anonymous], 1998, REH PERS TRAUM BRAIN; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ariza M, 2004, ARCH NEUROL-CHICAGO, V61, P541, DOI 10.1001/archneur.61.4.541; Ariza M, 2006, NEUROPSYCHOLOGIA, V44, P1956, DOI 10.1016/j.neuropsychologia.2005.11.007; Bergeson AG, 2004, CLIN NEUROPSYCHOL, V18, P509, DOI 10.1080/1385404049052414; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; *CDC, 2006, MMWR-MORBID MORTAL W, V55, P201; Chan JHM, 2003, NEURORADIOLOGY, V45, P34, DOI 10.1007/s00234-002-0891-y; Courchesne E, 2000, RADIOLOGY, V216, P672, DOI 10.1148/radiology.216.3.r00au37672; Field AS, 2003, AM J NEURORADIOL, V24, P1461; Filippi CG, 2001, AM J NEURORADIOL, V22, P277; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GALE SD, 1993, BRAIN RES BULL, V32, P345, DOI 10.1016/0361-9230(93)90198-K; GALE SD, 1994, WHITE MATTER PATHWAY; GRAHAM DI, 2002, GREENFIELDS NEUROPAT, V1, P823; Himanen L, 2005, BRAIN INJURY, V19, P93, DOI 10.1080/02699050410001720031; JEZZARD P, 1995, MAGNET RESON MED, V34, P65, DOI 10.1002/mrm.1910340111; KATZ D, 1997, NEUROLOGICAL REHABIL; KRAUS J, 1996, NEUROTRAUMA; Le Bihan D, 1991, Magn Reson Q, V7, P1; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Pierpaoli C, 2001, NEUROIMAGE, V13, P1174, DOI 10.1006/nimg.2001.0765; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Salat DH, 2005, NEUROBIOL AGING, V26, P1215, DOI 10.1016/j.neurobiolaging.2004.09.017; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Schwartz ED, 2003, EXP NEUROL, V182, P49, DOI 10.1016/S0014-4886(03)00036-0; Serra-Grabulosa JM, 2005, J NEUROL NEUROSUR PS, V76, P129, DOI 10.1136/jnnp.2004.027631; Sherer M, 2006, BRAIN INJURY, V20, P997, DOI 10.1080/02699050600677055; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tomaiuolo F, 2005, J NEUROTRAUM, V22, P76, DOI 10.1089/neu.2005.22.76; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Yount R, 2002, J NEUROPSYCH CLIN N, V14, P416, DOI 10.1176/appi.neuropsych.14.4.416; Zhang L, 2006, AM J NEURORADIOL, V27, P2000	41	229	231	0	22	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	AUG 15	2008	42	2					503	514		10.1016/j.neuroimage.2008.04.254			12	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	341DU	WOS:000258695200007	18556217	Green Accepted			2021-06-18	
J	Ewing-Cobbs, L; Kramer, L; Prasad, M; Canales, DN; Louis, PT; Fletcher, JM; Vollero, H; Landry, SH; Cheung, K				Ewing-Cobbs, L; Kramer, L; Prasad, M; Canales, DN; Louis, PT; Fletcher, JM; Vollero, H; Landry, SH; Cheung, K			Neuroimaging, physical, and developmental findings after inflicted and noninflicted traumatic brain injury in young children	PEDIATRICS			English	Article						child abuse; shaken baby syndrome; traumatic brain injury; cognition; outcome; infants; children; neuroimaging; Glasgow Outcome Scale; retinal hemorrhage	ACCIDENTAL HEAD TRAUMA; SHAKEN BABY SYNDROME; MENTAL-RETARDATION; RETINAL HEMORRHAGE; IMPACT SYNDROME; ABUSE; INFANTS; SHAKING; COMA; SCALE	Objective. To characterize neuroimaging, physical, neurobehavioral, and developmental findings in children with inflicted anti noninflicted traumatic brain injury (TBI) and to identify characteristic features of inflicted TBI. Methods and Patients, Forty children, 0 to 6 years of age, hospitalized for TBI who had no documented history of previous brain injury were enrolled in a prospective longitudinal study. TBI was categorized as either inflicted (n = 20) or noninflicted (n = 20) based on the assessment of hospital and county protective services. Glasgow Coma Scale scores and neonatal history were comparable in both groups. Outcome Measures. Acute computed tomography/magnetic resonance imaging studies and physical findings were evaluated. Glasgow Outcome Scale scores, cognitive development, and motor functioning were assessed an average of 1.3 months after TBI. chi(2) analyses assessed differences in the distribution of findings in the inflicted and noninflicted TBI groups. Results. Signs of preexisting brain injury, including cerebral atrophy, subdural hygroma, and ex vacuo ventriculomegaly, were present in 45% of children with inflicted TBI and in none of the children with noninflicted TBI. Subdural hematomas and seizures occurred significantly more often in children with inflicted TBI. Intraparenchymal hemorrhage, edema, skull fractures, and cephalohematomas were similar in both groups. Retinal hemorrhage was only identified in the inflicted TBI group. Glasgow Outcome Stale scores indicated a significantly less favorable outcome after inflicted than noninflicted TBI. Mental deficiency was present in 45% of the inflicted and 5% of the noninflicted TBI groups. Conclusions. Characteristic features of inflicted TBI included acute computed tomography/magnetic resonance imaging findings of preexisting brain injury, extraaxial hemorrhages, seizures, retinal hemorrhages, and significantly impaired cognitive function without prolonged impairment of consciousness.	Univ Texas, Hlth Sci Ctr, Dept Pediat, Houston, TX 77030 USA; Univ Texas, Hlth Sci Ctr, Dept Radiol, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA	Ewing-Cobbs, L (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pediat, 6431 Fannin, Houston, TX 77030 USA.		Fletcher, Jack/AAX-2931-2020; fletcher, jack/Q-5975-2019		NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR002558] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01-RR-02558] Funding Source: Medline		ALEXANDER R, 1990, AM J DIS CHILD, V144, P724, DOI 10.1001/archpedi.1990.02150300124032; ALEXANDER RC, 1986, J PEDIATR-US, V109, P975, DOI 10.1016/S0022-3476(86)80279-7; BAYLEY N, 1993, BAYLEYS SCALES INFAN; Betz P, 1996, FORENSIC SCI INT, V78, P71, DOI 10.1016/0379-0738(95)01866-2; BILLMIRE ME, 1985, PEDIATRICS, V75, P340; BRUCE DA, 1989, PEDIATR ANN, V18, P482, DOI 10.3928/0090-4481-19890801-07; CAFFEY J, 1974, PEDIATRICS, V54, P396; CAFFEY J, 1972, AM J DIS CHILD, V124, P161, DOI 10.1001/archpedi.1972.02110140011001; CARREY NJ, 1995, J AM ACAD CHILD PSY, V34, P1067, DOI 10.1097/00004583-199508000-00017; CHIAVIELLO CT, 1994, PEDIATRICS, V94, P679; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 1996, PEDIATR NEUROSURG, V24, P292, DOI 10.1159/000121058; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; ELDER JE, 1991, J PAEDIATR CHILD H, V27, P286, DOI 10.1111/j.1440-1754.1991.tb02539.x; ELLISON PH, 1978, PEDIATRICS, V62, P151; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; EWINGCOBBS L, 1995, J HEAD TRAUMA REHAB, V10, P13, DOI 10.1097/00001199-199510000-00004; GENNARELLI TA, 1985, NEUROSURGERY, V2; Greer A L, 1981, J Med Syst, V5, P129, DOI 10.1007/BF02222066; HAHN YS, 1983, CHILD BRAIN, V10, P229; HELFER RE, 1977, PEDIATRICS, V60, P533; JENNETT B, 1975, LANCET, V1, P480; JESSEE SA, 1995, J DENT CHILD, V62, P245; JOFFE M, 1988, PEDIATRICS, V82, P457; JOHNSON DL, 1993, NEUROSURGERY, V33, P231; KRAUS JF, 1986, AM J DIS CHILD, V140, P687, DOI 10.1001/archpedi.1986.02140210085032; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; LEVIN A V, 1989, Pediatric Emergency Care, V5, P181, DOI 10.1097/00006565-198909000-00011; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LIEHLAI MW, 1992, J PEDIATR-US, V120, P195, DOI 10.1016/S0022-3476(05)80426-3; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; LYONS TJ, 1993, PEDIATRICS, V92, P125; McCarthy D., 1972, MCCARTHY SCALES CHIL; MCCLELLAND CQ, 1980, CHILD BRAIN, V7, P225; MICHAUD LJ, 1992, NEUROSURGERY, V31, P254, DOI 10.1227/00006123-199208000-00010; MUSEMECHE CA, 1991, J TRAUMA, V31, P1347, DOI 10.1097/00005373-199110000-00004; NIMITYONGSKUL P, 1987, J PEDIATR ORTHOPED, V7, P184, DOI 10.1097/01241398-198703000-00014; RAIMONDI AJ, 1984, CHILD BRAIN, V11, P12; RODRIGUEZ JG, 1990, AM J DIS CHILD, V144, P627; SATO Y, 1989, RADIOLOGY, V173, P653, DOI 10.1148/radiology.173.3.2813768; TEASDALE G, 1974, LANCET, V2, P81; Thorndike RL., 1986, STANFORD BINET INTEL, V4; WILLIAMS RA, 1991, J TRAUMA, V31, P1350, DOI 10.1097/00005373-199110000-00005; WISSOW LS, 1995, NEW ENGL J MED, V332, P1425, DOI 10.1056/NEJM199505253322107	45	229	232	0	26	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	AUG	1998	102	2					300	307		10.1542/peds.102.2.300			8	Pediatrics	Pediatrics	106JH	WOS:000075125800003	9685430				2021-06-18	
J	Hicks, R; Soares, H; Smith, D; McIntosh, T				Hicks, R; Soares, H; Smith, D; McIntosh, T			Temporal and spatial characterization of neuronal injury following lateral fluid-percussion brain injury in the rat	ACTA NEUROPATHOLOGICA			English	Article						traumatic brain injury; contusion	TRANSIENT FOREBRAIN ISCHEMIA; ELECTRON-MICROSCOPIC FINDINGS; SUBSTANTIA-NIGRA-RETICULATA; CONCUSSIVE HEAD-INJURY; CEREBRAL BLOOD-FLOW; GERBIL HIPPOCAMPUS; KAINIC ACID; SELECTIVE VULNERABILITY; DAMAGE; DEATH	The pattern of neuronal injury following lateral fluid-percussion (FP) brain injury in the rat was systematically characterized at sequential time points to identify selectively vulnerable regions and to determine the temporal contribution of primary and delayed neuropathological events. Male Sprague-Dawley rats (n = 28) were killed 10 min, 2 h, 12 h, 24 h, 4 days, and 7 days following a lateral FP brain injury of moderate severity (2.2 arm), or 24 h after a sham injury. Brain sections were stained and analyzed using Nissl, acid fuchsin, and silver staining methods to identify regions with injured neurons or with visible lesions. Extensive numbers of acid fuchsin or silver-stained neurons were observed as early as 10 min after the FP brain injury in regions extending from the caudate/putamen to the pens. The frequency of injured neurons was greatest in the ipsilateral cortex, hippocampus, and thalamus, and a visible loss of Nissl-stained neurons was observed in these regions beginning at 12 h after the FP brain injury. Acid fuchsin-stained neurons were restricted to the same brain regions for all of the survival periods and gradually decreased in numbers between 24 h and 7 days after injury. These findings suggest that lateral FP brain injury in the rat produces a combination of focal cortical contusion and diffuse subcortical neuronal injury, which is present within minutes of the impact, progresses to a loss of neurons by 12 h, and does not markedly expand into other brain regions with survival periods up to 7 days. Furthermore, the acute onset and rapid evolution of the neuronal injury process may have important implications when considering a window of opportunity for pharmacological intervention.	UNIV PENN, DIV NEUROSURG, PHILADELPHIA, PA 19104 USA; ST JUDE CHILDRENS RES HOSP, DEPT DEV NEUROBIOL, MEMPHIS, TN 38101 USA	Hicks, R (corresponding author), UNIV KENTUCKY, DIV PHYS THERAPY, ANNEX 1, RM 5, LEXINGTON, KY 40536 USA.		smith, douglas/A-1321-2007; Ritter, Stefanie L/D-9312-2012		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, R55NS026818, R01NS026818, P01NS008803] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS26818, NS08803] Funding Source: Medline		Adams JH, 1992, GREENFIELDS NEUROPAT, P106; AUER RN, 1984, ACTA NEUROPATHOL, V64, P177, DOI 10.1007/BF00688108; AUER RN, 1985, ACTA NEUROPATHOL, V67, P13, DOI 10.1007/BF00688120; BALABAN CD, 1988, NEUROSCIENCE, V26, P337, DOI 10.1016/0306-4522(88)90150-9; BLUMBERG PC, 1988, J NEUROL NEUROSUR PS, V52, P838; CHANG D, 1994, DEV BRAIN RES, V77, P133, DOI 10.1016/0165-3806(94)90220-8; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; COTMAN CW, 1987, TRENDS NEUROSCI, V10, P273, DOI 10.1016/0166-2236(87)90172-X; CRAIN BJ, 1988, NEUROSCIENCE, V27, P387; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIXON C E, 1988, Journal of Neurotrauma, V5, P91, DOI 10.1089/neu.1988.5.91; Duchen L. W., 1992, GREENFIELDS NEUROPAT, P1; FELTEN DL, 1992, ANN NEUROL, V32, pS133, DOI 10.1002/ana.410320723; GALLYAS F, 1992, ACTA NEUROPATHOL, V83, P394, DOI 10.1007/BF00713531; GALLYAS F, 1992, ACTA NEUROPATHOL, V83, P386, DOI 10.1007/BF00713530; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; GRUENTHAL M, 1986, EXP NEUROL, V93, P621, DOI 10.1016/0014-4886(86)90181-0; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HICKS RR, 1994, BRAIN RES, V655, P91, DOI 10.1016/0006-8993(94)91601-2; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; HUNTLEY CW, 1994, TRENDS NEUROSCI, V17, P536; IIZUKA H, 1990, STROKE, V21, P790, DOI 10.1161/01.STR.21.5.790; JENNET B, 1981, MANAGEMENT HEAD INJU, P1; KALIMO H, 1985, ACTA NEUROPATHOL, V67, P37, DOI 10.1007/BF00688122; KIRINO T, 1984, ACTA NEUROPATHOL, V64, P139, DOI 10.1007/BF00695577; KIRINO T, 1984, ACTA NEUROPATHOL, V62, P209, DOI 10.1007/BF00691854; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; KIRINO T, 1984, ACTA NEUROPATHOL, V62, P201, DOI 10.1007/BF00691853; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LANGFITT TW, 1982, J NEUROSURG, V56, P19, DOI 10.3171/jns.1982.56.1.0019; LEES GJ, 1989, ACTA NEUROPATHOL, V77, P519, DOI 10.1007/BF00687254; Lillie R.D., 1976, HJ CONNS BIOL STAINS; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MOREHEAD M, 1994, J NEUROTRAUM, V11, P657, DOI 10.1089/neu.1994.11.657; NADLER JV, 1978, NATURE, V271, P676, DOI 10.1038/271676a0; NADLER JV, 1983, METHOD ENZYMOL, V103, P393; NEDERGAARD M, 1987, ACTA NEUROPATHOL, V73, P267, DOI 10.1007/BF00686621; Paxinos G, 1986, RAT BRAIN STEREOTAXI; PIERCE JES, 1993, BRAIN RES, V624, P199, DOI 10.1016/0006-8993(93)90078-2; POLLARD H, 1994, NEUROSCIENCE, V63, P7, DOI 10.1016/0306-4522(94)90003-5; Povlishock John T., 1993, P185; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; POVLISHOCK JT, 1992, J NEUROTRAUMA, V9, P189; PRASAD MR, 1994, J NEUROCHEM, V63, P773; PREHN JHM, 1993, BRAIN RES, V630, P10, DOI 10.1016/0006-8993(93)90636-2; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; RAGHUPATHI R, 1995, J CEREBR BLOOD F MET, V15, P467, DOI 10.1038/jcbfm.1995.58; SABEL BA, 1981, EXP NEUROL, V73, P507, DOI 10.1016/0014-4886(81)90284-3; SCHMIDTKASTNER R, 1990, NEUROSCIENCE, V38, P527, DOI 10.1016/0306-4522(90)90048-9; SCHMIDTKASTNER R, 1990, J CHEM NEUROANAT, V3, P179; SCHMIDTKASTNER R, 1988, ACTA NEUROPATHOL, V76, P411, DOI 10.1007/BF00686979; SEMCHUK KM, 1993, NEUROLOGY, V43, P1173, DOI 10.1212/WNL.43.6.1173; SHIMOSAKA S, 1992, NEUROSCI LETT, V138, P202, DOI 10.1016/0304-3940(92)90915-T; SHUAIB A, 1992, BRAIN RES, V590, P13, DOI 10.1016/0006-8993(92)91076-Q; SHUAIB A, 1992, BRAIN RES, V574, P120, DOI 10.1016/0006-8993(92)90807-L; SIMON RP, 1991, J NEUROSCI, V11, P881; SMITH DH, 1993, J NEUROSCI, V13, P5383; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; STALHAMMAR D, 1990, HDB CLIN NEUROLOGY, V13, P17; THIBAULT LE, 1992, J NEUROTRAUM, V9, P311, DOI 10.1089/neu.1992.9.311; TOULMOND S, 1993, BRAIN RES, V620, P32, DOI 10.1016/0006-8993(93)90267-Q; WARNER MA, 1991, J CEREBR BLOOD F MET, V11, P600, DOI 10.1038/jcbfm.1991.110; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289; ZHOU JG, 1994, J CEREBR BLOOD F MET, V14, P166, DOI 10.1038/jcbfm.1994.22	73	229	230	0	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322			ACTA NEUROPATHOL	Acta Neuropathol.	MAR	1996	91	3					236	246		10.1007/s004010050421			11	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	TV293	WOS:A1996TV29300003	8834535				2021-06-18	
J	Kondo, A; Shahpasand, K; Mannix, R; Qiu, JH; Moncaster, J; Chen, CH; Yao, YD; Lin, YM; Driver, JA; Sun, Y; Wei, S; Luo, ML; Albayram, O; Huang, PY; Rotenberg, A; Ryo, A; Goldstein, LE; Pascual-Leone, A; McKee, AC; Meehan, W; Zhou, XZ; Lu, KP				Kondo, Asami; Shahpasand, Koorosh; Mannix, Rebekah; Qiu, Jianhua; Moncaster, Juliet; Chen, Chun-Hau; Yao, Yandan; Lin, Yu-Min; Driver, Jane A.; Sun, Yan; Wei, Shuo; Luo, Man-Li; Albayram, Onder; Huang, Pengyu; Rotenberg, Alexander; Ryo, Akihide; Goldstein, Lee E.; Pascual-Leone, Alvaro; McKee, Ann C.; Meehan, William; Zhou, Xiao Zhen; Lu, Kun Ping			Antibody against early driver of neurodegeneration cis P-tau blocks brain injury and tauopathy	NATURE			English	Article							PROLYL ISOMERASE PIN1; CHRONIC TRAUMATIC ENCEPHALOPATHY; ALZHEIMERS-DISEASE; HEAD-INJURY; PATHOLOGY; PROTEIN; IMMUNOTHERAPY; MODEL; ONSET; TRANSMISSION	Traumatic brain injury (TBI), characterized by acute neurological dysfunction, is one of the best known environmental risk factors for chronic traumatic encephalopathy and Alzheimer's disease, the defining pathologic features of which include tauopathy made of phosphorylated tau protein (P-tau). However, tauopathy has not been detected in the early stages after TBI, and how TBI leads to tauopathy is unknown. Here we find robust cis P-tau pathology after TBI in humans and mice. After TBI in mice and stress in vitro, neurons acutely produce cis P-tau, which disrupts axonal microtubule networks and mitochondrial transport, spreads to other neurons, and leads to apoptosis. This process, which we term 'cistauosis', appears long before other tauopathy. Treating TBI mice with cis antibody blocks cistauosis, prevents tauopathy development and spread, and restores many TBI-related structural and functional sequelae. Thus, cis P-tau is a major early driver of disease after TBI and leads to tauopathy in chronic traumatic encephalopathy and Alzheimer's disease. The cis antibody may be further developed to detect and treat TBI, and prevent progressive neurodegeneration after injury.	[Kondo, Asami; Shahpasand, Koorosh; Chen, Chun-Hau; Yao, Yandan; Lin, Yu-Min; Driver, Jane A.; Wei, Shuo; Luo, Man-Li; Albayram, Onder; Huang, Pengyu; Zhou, Xiao Zhen; Lu, Kun Ping] Harvard Univ, Beth Israel Deaconess Med Ctr, Div Translat Therapeut, Dept Med,Med Sch, Boston, MA 02215 USA; [Kondo, Asami; Shahpasand, Koorosh; Chen, Chun-Hau; Yao, Yandan; Lin, Yu-Min; Wei, Shuo; Luo, Man-Li; Albayram, Onder; Huang, Pengyu; Zhou, Xiao Zhen; Lu, Kun Ping] Harvard Univ, Beth Israel Deaconess Med Ctr, Canc Res Inst, Sch Med, Boston, MA 02215 USA; [Mannix, Rebekah; Qiu, Jianhua] Harvard Univ, Sch Med, Childrens Hosp Boston, Div Emergency Med, Boston, MA 02115 USA; [Moncaster, Juliet; Goldstein, Lee E.; McKee, Ann C.] Boston Univ, Sch Med, Alzheimers Dis Ctr, CTE Program, Boston, MA 02118 USA; [Driver, Jane A.] Harvard Univ, Sch Med, Geriatr Res Educ & Clin Ctr, VA Boston Healthcare Syst, Boston, MA 02130 USA; [Sun, Yan; Rotenberg, Alexander] Harvard Univ, Sch Med, Childrens Hosp Boston, Dept Neurol, Boston, MA 02115 USA; [Ryo, Akihide] Yokohama City Univ, Dept Microbiol, Sch Med, Yokohama, Kanagawa 2360004, Japan; [Pascual-Leone, Alvaro] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Neurol, Boston, MA 02215 USA; [Meehan, William] Harvard Univ, Sch Med, Childrens Hosp Boston, Micheli Ctr Sports Injury Prevent, Boston, MA 02115 USA	Lu, KP (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Div Translat Therapeut, Dept Med,Med Sch, Boston, MA 02215 USA.	xzhou@bidmc.harvard.edu; klu@bidmc.harvard.edu	Mannix, Rebekah/AAD-8702-2020; Pascual-Leone, Alvaro/AAC-5101-2019	Pascual-Leone, Alvaro/0000-0001-8975-0382; Moncaster, Juliet/0000-0002-7849-4325; Albayram, Onder/0000-0002-2028-1458	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [S10RR017927, T32HD040128, UO1NS086659-01, P30AG13846, R01AG029385, R01CA167677, R01HL111430, R01AG046319]; NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA); VA Career Development Award; Susan G. Komen postdoctoral fellowshipSusan G. Komen Breast Cancer Foundation; Boston Children's Hospital Pilot Grant Award; NFLPA; VAUS Department of Veterans Affairs; Sports Legacy Institute; Andlinger Foundation; NFL; WWE; Alzheimer's AssociationAlzheimer's Association [DVT-14-322623]; BIDMC; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040128] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA167677] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10RR017927] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL111430] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086659] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG029385, P30AG013846, R01AG046319] Funding Source: NIH RePORTER	We thank T. Hunter and M. Zeidel for advice; S. Hagen for Microscopy Facility (NIH grantS10RR017927) and P. Davies for tauopathy antibodies. C.-H.C., Y.-M.L., J.A.D. and S.W. are recipients of NIA-funded T32 Translational Research in Aging Training Grant, National Science Council Postdoctoral Fellowship from Taiwan, a VA Career Development Award, and Susan G. Komen postdoctoral fellowship, respectively. R.M. is supported by Boston Children's Hospital Pilot Grant Award and NIH training grant T32HD040128, and A.P.-L. and W.M. by NFLPA. The CTE and blast samples used are supported by grants from NIH (UO1NS086659-01, P30AG13846), VA, Sports Legacy Institute, Andlinger Foundation, NFL and WWE. The work is supported by NIH grants R01AG029385, R01CA167677, R01HL111430 and R01AG046319, and Alzheimer's Association grant DVT-14-322623 to K.P.L. and BIDMC and NFLPA pilot grants to K.P.L. and X.Z.Z.	Adhikari A, 2011, NEURON, V71, P898, DOI 10.1016/j.neuron.2011.07.027; Asuni AA, 2007, J NEUROSCI, V27, P9115, DOI 10.1523/JNEUROSCI.2361-07.2007; Ballatore C, 2007, NAT REV NEUROSCI, V8, P663, DOI 10.1038/nrn2194; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Chen CH, 2015, NEUROBIOL DIS, V76, P13, DOI 10.1016/j.nbd.2014.12.027; Clavaguera F, 2015, NEUROPATH APPL NEURO, V41, P47, DOI 10.1111/nan.12197; Clavaguera F, 2014, ACTA NEUROPATHOL, V127, P299, DOI 10.1007/s00401-013-1231-5; Clavaguera F, 2009, NAT CELL BIOL, V11, P909, DOI 10.1038/ncb1901; Congdon EE, 2013, J BIOL CHEM, V288, P35452, DOI 10.1074/jbc.M113.491001; Cruz JC, 2003, NEURON, V40, P471, DOI 10.1016/S0896-6273(03)00627-5; de Calignon A, 2012, NEURON, V73, P685, DOI 10.1016/j.neuron.2011.11.033; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Driver J.A., 2015, BIOCH BIOPHYS ACTA; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Hampel H, 2010, EXP GERONTOL, V45, P30, DOI 10.1016/j.exger.2009.10.010; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Kim BM, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.216; Lasagna-Reeves CA, 2012, FASEB J, V26, P1946, DOI 10.1096/fj.11-199851; Lee TH, 2011, MOL CELL, V42, P147, DOI 10.1016/j.molcel.2011.03.005; Lee TH, 2011, EXPERT REV MOL MED, V13, DOI 10.1017/S1462399411001906; Lim J, 2008, J CLIN INVEST, V118, P1877, DOI 10.1172/JCI34308; Liou YC, 2003, NATURE, V424, P556, DOI 10.1038/nature01832; Liu L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031302; Lu KP, 1996, NATURE, V380, P544; Lu KP, 2007, NAT REV MOL CELL BIO, V8, P904, DOI 10.1038/nrm2261; Lu PJ, 1999, NATURE, V399, P784; Luna-Munoz J, 2007, J ALZHEIMERS DIS, V12, P365; Ma SL, 2012, NEUROBIOL AGING, V33, P804, DOI 10.1016/j.neurobiolaging.2010.05.018; Mallery DL, 2010, P NATL ACAD SCI USA, V107, P19985, DOI 10.1073/pnas.1014074107; Mandelkow EM, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006247; Mannix R, 2013, ANN NEUROL, V74, P65, DOI 10.1002/ana.23858; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Nakamura K, 2012, CELL, V149, P232, DOI 10.1016/j.cell.2012.02.016; Nordstrom P, 2014, ANN NEUROL, V75, P374, DOI 10.1002/ana.24101; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Pastorino L, 2006, NATURE, V440, P528, DOI 10.1038/nature04543; Rosenmann H, 2013, CURR ALZHEIMER RES, V10, P217, DOI 10.2174/1567205011310030001; Schwarzbold ML, 2010, J NEUROTRAUM, V27, P1883, DOI 10.1089/neu.2010.1318; Sigurdsson EM, 2014, NEURODEGENER DIS, V13, P103, DOI 10.1159/000354491; Smith C, 2003, NEUROPATH APPL NEURO, V29, P496, DOI 10.1046/j.1365-2990.2003.00488.x; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Wijsman EM, 2004, AM J HUM GENET, V75, P398, DOI 10.1086/423393; Williams S, 2001, ACTA NEUROPATHOL, V102, P581, DOI 10.1007/s004010100410; Wright DW, 2013, MMWR-MORBID MORTAL W, V62, P549; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X	50	228	230	3	97	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 23	2015	523	7561					431	U118		10.1038/nature14658			26	Multidisciplinary Sciences	Science & Technology - Other Topics	CN4DD	WOS:000358378900030	26176913	Green Accepted	Y	N	2021-06-18	
J	Register-Mihalik, JK; Guskiewicz, KM; McLeod, TCV; Linnan, LA; Mueller, FO; Marshall, SW				Register-Mihalik, Johna K.; Guskiewicz, Kevin M.; McLeod, Tamara C. Valovich; Linnan, Laura A.; Mueller, Frederick O.; Marshall, Stephen W.			Knowledge, Attitude, and Concussion-Reporting Behaviors Among High School Athletes: A Preliminary Study	JOURNAL OF ATHLETIC TRAINING			English	Article						education; brain injuries; care seeking	RECURRENT CONCUSSION; MOTIVATIONAL CLIMATE; FOOTBALL PLAYERS; SPORT; RISK; ASSOCIATION; MANAGEMENT; STATEMENT; HISTORY; SOCCER	Context: Many athletes continue to participate in practices and games while experiencing concussion-related symptoms, potentially predisposing them to subsequent and more complicated brain injuries. Limited evidence exists about factors that may influence concussion-reporting behaviors. Objective: To examine the influence of knowledge and attitude on concussion-reporting behaviors in a sample of high school athletes. Design: Cross-sectional study. Setting: Participants completed a validated survey instrument via mail. Patients or Other Participants: A total of 167 high school athletes (97 males, 55 females, 5 sex not indicated; age = 15.7 +/- 1.4 years) participating in football, soccer, lacrosse, or cheerleading. Intervention(s): Athlete knowledge and attitude scores served as separate predictor variables. Main Outcome Measure(s): We examined the proportion of athletes who reported continuing to participate in games and practices while symptomatic from possible concussion and the self-reported proportion of recalled concussion and bell-ringer events disclosed after possible concussive injury. Results: Only 40% of concussion events and 13% of bell-ringer recalled events in the sample were disclosed after possible concussive injury. Increased athlete knowledge of concussion topics (increase of 1 standard deviation = 2.8 points) was associated with increased reporting prevalence of concussion and bell-ringer events occurring in practice (prevalence ratio [PR] = 2.27, 95% confidence interval [CI] = 1.60, 3.21) and the reporting prevalence of bell-ringer-only events overall (PR = 1.87, 95% CI = 1.38, 2.54). Athlete attitude scores (increase of 1 standard deviation = 11.5 points) were associated with decreases in the proportion of athletes stating they participated in games (PR = 0.74, 95% CI = 0.66, 0.82) and practices (PR = 0.67, 95% CI = 0.59, 0.77) while symptomatic from concussions. Conclusions: Most recalled concussion events in our study were not reported to a supervising adult. Clinicians should be aware that knowledge and attitude influence concussion reporting. Clinicians and administrators should make concussion education a priority and encourage an optimal reporting environment to better manage and prevent concussive injuries in young athletes.	[Register-Mihalik, Johna K.] WakeMed Hlth & Hosp, Emergency Serv Inst, Raleigh, NC USA; [Register-Mihalik, Johna K.; Guskiewicz, Kevin M.; Mueller, Frederick O.] Univ N Carolina, Dept Exercise & Sport Sci, Matthew Gfeller Sport Related Traumat Brain Injur, Chapel Hill, NC USA; [McLeod, Tamara C. Valovich] AT Still Univ, Athlet Training Program, Mesa, AZ USA; [Linnan, Laura A.] Univ N Carolina, Dept Hlth Behav & Hlth Educ, Chapel Hill, NC USA; [Marshall, Stephen W.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA; [Marshall, Stephen W.] Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC USA	Register-Mihalik, JK (corresponding author), 3024 New Bern Ave,Suite G01, Raleigh, NC 27610 USA.	jmihalik@wakemed.org	McLeod, Tamara/AAU-9435-2020	Guskiewicz, Kevin/0000-0002-8682-2130; Register-Mihalik, Johna/0000-0002-4229-4743; Marshall, Stephen/0000-0002-2664-9233	National Football League Charities Medical Research Grant (New York, NY)	This study was funded by a National Football League Charities Medical Research Grant (New York, NY).	Baumert PW, 1998, J ADOLESCENT HEALTH, V22, P460, DOI 10.1016/S1054-139X(97)00242-5; Boden BP, 2007, AM J SPORT MED, V35, P1075, DOI 10.1177/0363546507299239; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cobb Sarah, 2004, J Sch Nurs, V20, P262; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Delaney JS, 2001, CLIN J SPORT MED, V11, P234, DOI 10.1097/00042752-200110000-00005; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10186; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Fishbein M., 1975, BELIEF ATTITUDE INTE; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Lovell MR, 2008, CURR SPORT MED REP, V7, P12, DOI 10.1097/01.CSMR.0000308671.45558.e2; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Malinauskas R, 2008, J SPORT MED PHYS FIT, V48, P107; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140; Miller BW, 2004, SCAND J MED SCI SPOR, V14, P193, DOI 10.1111/j.1600-0838.2003.00320.x; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; National Athletic Trainers' Association, 2009, ATHL TRAIN FILL NEC; Ommundsen Y, 2005, J SPORT SCI, V23, P977, DOI 10.1080/02640410500127975; Park CL, 2007, ANN BEHAV MED, V34, P115, DOI 10.1007/BF02872667; Raudsepp L, 2010, PERCEPT MOTOR SKILL, V110, P3, DOI 10.2466/PMS.110.1.3-18; Register-Mihalik J, 2007, CLIN J SPORT MED, V17, P282, DOI 10.1097/JSM.0b013e31804ca68a; Register-Mihalik JK, 2009, SPORTS HEALTH, V1, P61, DOI 10.1177/1941738108325920; Rosenbaum AM, 2010, J CLIN EXP NEUROPSYC, V32, P44, DOI 10.1080/13803390902806535; Sarmiento K, 2010, J SCHOOL HEALTH, V80, P112, DOI 10.1111/j.1746-1561.2010.00491.x; Setnik L, 2007, BRAIN INJURY, V21, P1, DOI 10.1080/02699050601111419; McLeod TCV, 2008, CLIN J SPORT MED, V18, P235, DOI 10.1097/JSM.0b013e3181705756; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	35	228	228	9	44	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	SEP-OCT	2013	48	5					645	653		10.4085/1062-6050-48.3.20			9	Sport Sciences	Sport Sciences	268AR	WOS:000328140600008	23848520	Green Published	Y	N	2021-06-18	
J	Baumann, CR; Werth, E; Stocker, R; Ludwig, S; Bassetti, CL				Baumann, Christian R.; Werth, Esther; Stocker, Reto; Ludwig, Silke; Bassetti, Claudio L.			Sleep-wake disturbances 6 months after traumatic brain injury: a prospective study	BRAIN			English	Article						sleep; sleep-wake disorder; traumatic brain injury; excessive daytime sleepiness; hypersomnia	EXCESSIVE DAYTIME SLEEPINESS; HYPOCRETIN-1 OREXIN-A; CLOSED-HEAD INJURY; OBJECTIVE MEASURES; CLINICAL-TRIALS; LATENCY TEST; NARCOLEPSY; VALIDATION; ADULTS; QUESTIONNAIRE	Sleep-wake disturbances (SWD) are common after traumatic brain injury (TBI). In acute TBI, we recently found decreased CSF levels of hypocretin-I, a wake-promoting neurotransmitter. In the present study, we aimed to delineate the frequency and clinical characteristics of post-traumatic SWD, to assess CSF hypocretin-I levels 6 months after TBI, and to identify risk factors for posttraumatic SWD. A total of 96 consecutive patients were enrolled within the first 4 days after TBI. Six months later, out of 76 TBI patients, who did not die and who did not move to foreign countries, we included 65 patients (86%, 53 males, mean age 39 years) in our study. Patients were examined using interviews, questionnaires, clinical examinations, computed tomography of the brain, laboratory tests (including CSF hypocretin-I levels, and HLA typing), conventional polysomnography, maintenance of wakefulness and multiple sleep latency tests (MSLT) and actigraphy. Potential causes of post-traumatic SWD were assessed according to international criteria. New-onset sleep-wake disturbances following TBI were found in 47 patients (72%): subjective excessive daytime sleepiness (EDS; defined by the Epworth Sleepiness Scale >= 10) was found in 18 (28%), objective EDS (as defined by mean sleep latency <5 min on MSLT) in 16 (25%), fatigue (daytime tiredness without signs of subjective or objective EDS) in 11 (17%), post-traumatic hypersomnia 'sensu strictu' (increased sleep need of >= 2 h per 24 h compared to pre-TBI) in 14 (22%) patients and insomnia in 3 patients (5%). In 28 patients (43% of the study population), we could not identify a specific cause of the post-traumatic SWD other than TBI. Low CSF hypocretin-I levels were found in 4 of 21 patients 6 months after TBI, as compared to 25 of 27 patients in the first days after TBI. Hypocretin levels 6 months after TBI were significantly lower in patients with post-traumatic EDS. There were no associations between post-traumatic SWD and severity or localization of TBI, general clinical outcome, gender, pathological neurological findings and HLA typing. However, post-traumatic SWD correlated with impaired quality of life. These results suggest that sleep-wake disturbances, particularly EDS, fatigue and hypersomnia are common after TBI, and significantly impair quality of life. In almost one out of two patients, post-traumatic SWD appear to be directly related to the TBI. An involvement of the hypocretin system in the pathophysiology of post-traumatic SWD appears possible. Other risk factors predisposing towards the development of post-traumatic SWD were not identified.	Univ Zurich Hosp, Dept Neurol, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Trauma Surg, CH-8091 Zurich, Switzerland	Bassetti, CL (corresponding author), Univ Zurich Hosp, Dept Neurol, Frauenklinikstrasse 26, CH-8091 Zurich, Switzerland.	claudio.bassetti@usz.ch	Sanguansri, Luz/B-6630-2011; Lang, Steven/AAE-8102-2021; Werth, E/AAN-7955-2021	Sanguansri, Luz/0000-0003-1908-7604; Lang, Steven/0000-0003-1669-9146; Baumann, Christian/0000-0003-3417-1978; Werth, Esther/0000-0002-5099-3122			American Academy of Sleep Medicine, 2005, INT CLASS SLEEP DIS, V2nd; Anic-Labat S, 1999, SLEEP, V22, P77; Bassetti C, 2003, SLEEP MED, V4, P7, DOI 10.1016/S1389-9457(02)00191-0; Baumann CR, 2005, NEUROLOGY, V65, P147, DOI 10.1212/01.wnl.0000167605.02541.f2; Baumann CR, 2004, EUR NEUROL, V52, P73, DOI 10.1159/000079749; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Carmichael ST, 2002, J NEUROSCI, V22, P6062; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; COHEN M, 1992, J NEUROL NEUROSUR PS, V55, P313, DOI 10.1136/jnnp.55.4.313; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; Danker-Hopfe H, 2005, SOMNOLOGY, V9, P3; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; DOUGLASS AB, 1994, SLEEP, V17, P160, DOI 10.1093/sleep/17.2.160; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Gerashchenko D, 2003, EXP NEUROL, V184, P1010, DOI 10.1016/S0014-4886(03)00388-1; GUILLEMINAULT C, 1983, NEUROLOGY, V33, P1584, DOI 10.1212/WNL.33.12.1584; Guilleminault C, 2000, NEUROLOGY, V54, P653, DOI 10.1212/WNL.54.3.653; HUBLIN C, 1994, J SLEEP RES, V3, P52, DOI 10.1111/j.1365-2869.1994.tb00104.x; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Kaufman Y, 2001, PEDIATR NEUROL, V24, P129, DOI 10.1016/S0887-8994(00)00254-X; King MA, 2005, SLEEP MED, V6, P507, DOI 10.1016/j.sleep.2004.12.010; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; LANKFORD DA, 1994, SLEEP, V17, pS25, DOI 10.1093/sleep/17.suppl_8.S25; Littner MR, 2005, SLEEP, V28, P113, DOI 10.1093/sleep/28.1.113; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; MARSHALL LF, 1992, J NEUROTRAUMA, V9, P287; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; Mignot E, 2006, BRAIN, V129, P1609, DOI 10.1093/brain/awl079; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nishino S, 2000, LANCET, V355, P39, DOI 10.1016/S0140-6736(99)05582-8; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; Quinto C, 2000, NEUROLOGY, V54, P250, DOI 10.1212/WNL.54.1.250; Rao Vani, 2002, Curr Treat Options Neurol, V4, P77, DOI 10.1007/s11940-002-0006-4; Rechtschaffen A, 1968, MANUAL STANDARDIZED; Ripley B, 2001, NEUROLOGY, V57, P2253, DOI 10.1212/WNL.57.12.2253; Scammell T., 2007, SLEEP DISORDERS NEUR, P117; Schmidgen H, 1994, Zentralbl Neurochir, V55, P185; Steele DL, 2005, CHRONOBIOL INT, V22, P89, DOI 10.1081/CBI-200042428; Stickgold R, 2001, SCIENCE, V294, P1052, DOI 10.1126/science.1063530; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; Sturzenegger C, 2004, J SLEEP RES, V13, P395, DOI 10.1111/j.1365-2869.2004.00422.x; Tison F, 2005, NEUROLOGY, V65, P239, DOI 10.1212/01.wnl.0000168910.48309.4a	49	228	233	2	23	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	JUL	2007	130		7				1873	1883		10.1093/brain/awm109			11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	191SC	WOS:000248151300016	17584779	Green Published, Bronze			2021-06-18	
J	Holm, L; Cassidy, JD; Carroll, LJ; Borg, J				Holm, L; Cassidy, JD; Carroll, LJ; Borg, J			Summary of the WHO collaborating centre for neurotrauma task force on mild traumatic brain injury	JOURNAL OF REHABILITATION MEDICINE			English	Article						Mild Traumatic Brain Injury; MTBI; brain concussion; systematic review		This report aims to summarize the key findings of a recent, systematic review of the literature performed by the WHO Collaborating Centre for Neurotrauma Task Force on Mild Traumatic Brain Injury published in a supplement of the Journal of Rehabilitation Medicine (1). The Task Force performed a comprehensive search and critical review of the literature published between 1980 and 2002 to assemble the best evidence on the epidemiology, diagnosis, prognosis and treatment of MTBI. The Task Force identified citations and 743 relevant studies, of which 313 (42%) were accepted on scientific merit and formed the basis of the best evidence synthesis.	Univ Uppsala Hosp, Dept Neurosci, SE-75185 Uppsala, Sweden; Karolinska Inst, Inst Environm Med, Dept Epidemiol, S-10401 Stockholm, Sweden; Karolinska Inst, Dept Clin Neurosci, Sect Personal Injury Prevent, Stockholm, Sweden; Univ Toronto, Fac Med, Dept Publ Hlth Sci, Toronto, ON, Canada; Univ Hlth Network, Toronto Western Hosp, Res Inst, Div Outcomes & Populat Hlth, Toronto, ON, Canada; Univ Alberta, Dept Publ Hlth Sci, Alberta Ctr Injury Control & Res, Edmonton, AB, Canada	Borg, J (corresponding author), Univ Uppsala Hosp, Dept Neurosci, SE-75185 Uppsala, Sweden.	jorgen.borg@rehab.uu.se		Carroll, Linda/0000-0003-0876-2336; Borg, Jorgen/0000-0002-2372-7478			Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Carroll LJ, 2004, J REHABIL MED, V36, P11, DOI 10.1080/16501960410023660; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; CASSIDY JD, 2004, J REHABIL MED S43, V36, P1; Peloso PM, 2004, J REHABIL MED, V36, P106, DOI 10.1080/16501960410023868	8	228	231	0	16	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	MAY	2005	37	3					137	141		10.1080/16501970510027321			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	931IM	WOS:000229479000002	16040469	DOAJ Gold			2021-06-18	
J	Chen, JK; Johnston, KM; Frey, S; Petrides, M; Worsley, K; Ptito, A				Chen, JK; Johnston, KM; Frey, S; Petrides, M; Worsley, K; Ptito, A			Functional abnormalities in symptomatic concussed athletes: an MRI study	NEUROIMAGE			English	Article						athlete; concussion; fMRI	TRAUMATIC BRAIN-INJURY; POSITRON-EMISSION-TOMOGRAPHY; EVENT-RELATED POTENTIALS; VISUAL WORKING-MEMORY; MINOR HEAD-INJURY; FRONTAL-CORTEX; NEUROPSYCHOLOGICAL DEFICITS; MILD; ACTIVATION; EPIDEMIOLOGY	Our aim was to quantify with functional magnetic resonance imaging (fMRI) changes in brain activity in concussed athletes and compare the results with those of normal control subjects. Regional brain activations associated with a working memory task were obtained from a group of concussed athletes (15 symptomatic, I asymptomatic) and eight matched control subjects, using blood oxygen level dependent (BOLD) fMRI. The average percent signal change from baseline to working memory condition in each region of interest was computed. Symptomatic concussed athletes demonstrated task-related activations in some but not all the regions of interest, even when they performed as well as the control subjects. Furthermore, several concussed athletes had additional increases in activity outside the regions of interest, not seen in the control group. Quantitative analysis of BOLD signals within regions of interest revealed that, in general, concussed athletes had different BOLD responses compared to the control subjects. The task-related activation pattern of the one symptom-free athlete was comparable to that of the control group. We also repeated the study in one athlete whose symptoms had resolved. On the first study, when he was still symptomatic, less task-related activations were observed. On follow-up, once his symptoms had disappeared, the task-related activations became comparable to those of the control group. These results demonstrate the potential of fMRI, in conjunction with the working memory task, to identify an underlying pathology in symptomatic concussed individuals with normal structural imaging results. (C) 2004 Elsevier Inc. All rights reserved.	McGill Univ, Montreal Neurol Inst, Neuropsychol Dept, Cognit Neurosci Unit, Montreal, PQ H3A 2B4, Canada; McGill Univ, Dept Neurosurg Kinesiol & Phys Educ, Montreal, PQ, Canada; McGill Univ, Dept Math & Stat, Montreal, PQ, Canada	Ptito, A (corresponding author), McGill Univ, Montreal Neurol Inst, Neuropsychol Dept, Cognit Neurosci Unit, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.						ABDELDAYEM HM, 1987, RADIOLOGY, V165, P221, DOI 10.1148/radiology.165.1.3498184; ALAVI A, 1987, J CEREB BLOOD FLO S1, V7, pS646; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; BOHNEN N, 1992, NEUROSURGERY, V30, P692; Chen SHA, 2003, J NEUROL NEUROSUR PS, V74, P326, DOI 10.1136/jnnp.74.3.326; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Evans A C, 1992, Neuroimage, V1, P43, DOI 10.1016/1053-8119(92)90006-9; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; Jansen HML, 1996, J NEUROL NEUROSUR PS, V60, P221, DOI 10.1136/jnnp.60.2.221; JENNETT B, 1979, CENTRAL NERVOUS SYST, P204; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; LANGFITT TW, 1982, CLIN NEUR, V29, P353; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Levine B, 2002, J NEUROL NEUROSUR PS, V73, P173, DOI 10.1136/jnnp.73.2.173; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; METZ B, 1971, J NEUROSURG, V35, P523, DOI 10.3171/jns.1971.35.5.0523; NELL V, 1991, SOC SCI MED, V33, P289, DOI 10.1016/0277-9536(91)90363-H; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; NEWTON MR, 1992, J NEUROL NEUROSUR PS, V55, P92, DOI 10.1136/jnnp.55.2.92; PETRIDES M, 1991, P ROY SOC B-BIOL SCI, V246, P293, DOI 10.1098/rspb.1991.0157; PETRIDES M, 1995, J NEUROSCI, V15, P359; Petrides M, 2000, J NEUROSCI, V20, P7496; PETRIDES M, 1993, P NATL ACAD SCI USA, V90, P878, DOI 10.1073/pnas.90.3.878; PETRIDES M, 2000, HDB NEUROPSYCHOLOGY, V2, P67; Potter DD, 2001, NEUROPSYCHOLOGIA, V39, P1464, DOI 10.1016/S0028-3932(01)00057-4; POVLISHOCK J, 1982, HEAD INJURY BASIC CL, P15; Ricker JH, 2001, J HEAD TRAUMA REHAB, V16, P191, DOI 10.1097/00001199-200104000-00007; SAIJA A, 1988, BRAIN RES, V452, P303, DOI 10.1016/0006-8993(88)90034-0; Stern CE, 2000, NEUROIMAGE, V11, P392, DOI 10.1006/nimg.2000.0569; Strebel S, 1997, SURG NEUROL, V47, P128, DOI 10.1016/S0090-3019(96)00459-4; Talairach J, 1988, CO PLANAR STEREOTAXI; TAYLOR AR, 1966, LANCET, V2, P178; VAZQUEZBARQUERO A, 1992, EUR J EPIDEMIOL, V8, P832, DOI 10.1007/BF00145328; Worsley KJ, 2002, NEUROIMAGE, V15, P1, DOI 10.1006/nimg.2001.0933; Worsley KJ, 1996, HUM BRAIN MAPP, V4, P58, DOI 10.1002/(SICI)1097-0193(1996)4:1<58::AID-HBM4>3.0.CO;2-O	42	228	235	0	4	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	MAY	2004	22	1					68	82		10.1016/j.neuroimage.2003.12.032			15	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	817PU	WOS:000221190200007	15109998				2021-06-18	
J	Manley, GT; Binder, DK; Papadopoulos, MC; Verkman, AS				Manley, GT; Binder, DK; Papadopoulos, MC; Verkman, AS			New insights into water transport and edema in the central nervous system from phenotype analysis of aquaporin-4 null mice	NEUROSCIENCE			English	Article						brain injury; cytotoxic edema; epilepsy; stroke; vasogenic edema water channel	CUZN-SUPEROXIDE DISMUTASE; FOCAL CEREBRAL-ISCHEMIA; DYSTROPHIC MDX-MICE; INDUCED BRAIN EDEMA; ORTHOGONAL ARRAYS; CHANNEL PROTEIN; GLIAL-CELLS; EXTRACELLULAR-SPACE; EPILEPTIFORM BURSTS; SKELETAL-MUSCLE	Aquaporin-4 (AQP4) is the major water channel in the CNS. Its expression at fluid-tissue barriers (blood-brain and brain-cerebrospinal fluid barriers) throughout the brain and spinal cord suggests a role in water transport under normal and pathological conditions. Phenotype studies of transgenic mice lacking AQP4 have provided evidence for a role of AQP4 in cerebral water balance and neural signal transduction. Primary cultures of astrocytes from AQP4-null mice have greatly reduced osmotic water permeability compared with wild-type astrocytes, indicating that AQP4 is the principal water channel in these cells. AQP4-null mice have reduced brain swelling and improved neurological outcome following water intoxication and focal cerebral ischemia, establishing a role of AQP4 in the development of cytotoxic (cellular) cerebral edema. In contrast, brain swelling and clinical outcome are worse in AQP4-null mice in models of vasogenic (fluid leak) edema caused by freeze-injury and brain tumor, probably due to impaired AQP4-dependent brain water clearance. AQP4-null mice also have markedly reduced acoustic brainstem response potentials and significantly increased seizure threshold in response to chemical convulsants, implicating AQP4 in modulation of neural signal transduction. Pharmacological modulation of AQP4 function may thus provide a novel therapeutic strategy for the treatment of stroke, tumor-associated edema, epilepsy, traumatic brain injury, and other disorders of the CNS associated with altered brain water balance. (C) 2004 IBRO. Published by Elsevier Ltd. All rights reserved.	Univ Calif San Francisco, Dept Neurol Surg, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med & Physiol, Cardiovasc Res Inst, San Francisco, CA 94143 USA	Manley, GT (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, Cardiovasc Res Inst, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94143 USA.	manley@itsa.ucsf.edu		Papadopoulos, Marios/0000-0001-9174-4176			Abbott NJ, 2004, NEUROCHEM INT, V45, P545, DOI 10.1016/j.neuint.2003.11.006; Agre P, 2002, J PHYSIOL-LONDON, V542, P3, DOI 10.1113/jphysiol.2002.020818; Amiry-Moghaddam M, 2003, NAT REV NEUROSCI, V4, P991, DOI 10.1038/nrn1252; Amiry-Moghaddam M, 2003, P NATL ACAD SCI USA, V100, P13615, DOI 10.1073/pnas.2336064100; Amiry-Moghaddam M, 2003, P NATL ACAD SCI USA, V100, P2106, DOI 10.1073/pnas.0437946100; ANDREW RD, 1989, BRAIN RES, V498, P175, DOI 10.1016/0006-8993(89)90417-4; Badaut J, 2001, J CEREBR BLOOD F MET, V21, P477, DOI 10.1097/00004647-200105000-00001; Badaut T, 2002, J CEREBR BLOOD F MET, V22, P367, DOI 10.1097/00004647-200204000-00001; Binder DK, 2004, NEUROREPORT, V15, P259, DOI 10.1097/00001756-200402090-00009; CHAN PH, 1991, ANN NEUROL, V29, P482, DOI 10.1002/ana.410290506; CHEBABO SR, 1995, BRAIN RES, V695, P203, DOI 10.1016/0006-8993(95)00778-O; CUEVAS P, 1985, ANAT EMBRYOL, V172, P171, DOI 10.1007/BF00319599; Dalloz C, 2003, HUM MOL GENET, V12, P1543, DOI 10.1093/hmg/ddg170; DUDEK FE, 1990, NEUROSCI LETT, V120, P267, DOI 10.1016/0304-3940(90)90056-F; FISHMAN RA, 1975, NEW ENGL J MED, V293, P706, DOI 10.1056/NEJM197510022931407; FRIGERI A, 1995, J CELL SCI, V108, P2993; Frigeri A, 2001, FASEB J, V15, P90, DOI 10.1096/fj.00-0260com; Furman CS, 2003, P NATL ACAD SCI USA, V100, P13609, DOI 10.1073/pnas.2235843100; Hamann S, 2002, J FLUORESC, V12, P139, DOI 10.1023/A:1016832027325; HASEGAWA H, 1994, J BIOL CHEM, V269, P5497; HOCHMAN DW, 1995, SCIENCE, V270, P99, DOI 10.1126/science.270.5233.99; Horio Y, 2001, JPN J PHARMACOL, V87, P1, DOI 10.1254/jjp.87.1; Hossmann KA, 1998, CARDIOVASC RES, V39, P106, DOI 10.1016/S0008-6363(98)00075-3; JOHNSTONE BM, 1989, J PHYSIOL-LONDON, V408, P77, DOI 10.1113/jphysiol.1989.sp017448; JUNG JS, 1994, P NATL ACAD SCI USA, V91, P13052, DOI 10.1073/pnas.91.26.13052; Kofuji P, 2000, J NEUROSCI, V20, P5733; Kondo T, 1997, J NEUROSCI, V17, P4180; LANDIS DMD, 1974, J CELL BIOL, V60, P316, DOI 10.1083/jcb.60.1.316; Li J, 2001, J BIOL CHEM, V276, P31233, DOI 10.1074/jbc.M104368200; Ma TH, 1997, J CLIN INVEST, V100, P957, DOI 10.1172/JCI231; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; MARMAROU A, 1994, AM J PHYSIOL, V267, pH514; MCBAIN CJ, 1990, SCIENCE, V249, P674, DOI 10.1126/science.2382142; Meinild AK, 1998, J BIOL CHEM, V273, P32446, DOI 10.1074/jbc.273.49.32446; Mhatre AN, 2002, HEARING RES, V170, P59, DOI 10.1016/S0378-5955(02)00452-5; Nagelhus EA, 1998, J NEUROSCI, V18, P2506; Neely JD, 1999, BIOCHEMISTRY-US, V38, P11156, DOI 10.1021/bi990941s; Neely JD, 2001, P NATL ACAD SCI USA, V98, P14108, DOI 10.1073/pnas.241508198; Nicchia GP, 2003, FASEB J, V17, P1508, DOI 10.1096/fj.02-1183fje; Nicchia GP, 2000, GLIA, V31, P29, DOI 10.1002/(SICI)1098-1136(200007)31:1<29::AID-GLIA30>3.0.CO;2-3; Nico B, 2003, GLIA, V42, P235, DOI 10.1002/glia.10216; Nielsen S, 1997, J NEUROSCI, V17, P171; Oshio K, 2004, NEUROSCIENCE, V127, P685, DOI 10.1016/j.neuroscience.2004.03.016; OSHIO K, 2004, IN PRESS FASEB J; OURY TD, 1993, J BIOL CHEM, V268, P15394; Pan EH, 1996, NEUROSCI LETT, V207, P9, DOI 10.1016/0304-3940(96)12477-0; Papadopoulos MC, 2004, NEUROSCIENCE, V129, P1011, DOI 10.1016/j.neuroscience.2004.05.044; Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje; Ransom B, 2003, TRENDS NEUROSCI, V26, P520, DOI 10.1016/j.tins.2003.08.006; Rash JE, 1998, P NATL ACAD SCI USA, V95, P11981, DOI 10.1073/pnas.95.20.11981; REULEN HJ, 1977, J NEUROSURG, V46, P24, DOI 10.3171/jns.1977.46.1.0024; ROPER SN, 1992, ANN NEUROL, V31, P81, DOI 10.1002/ana.410310115; SHI LB, 1995, BIOCHEMISTRY-US, V34, P8250, DOI 10.1021/bi00026a006; Shi LB, 1996, BIOCHEMISTRY-US, V35, P538, DOI 10.1021/bi9520038; Solenov E, 2004, AM J PHYSIOL-CELL PH, V286, pC426, DOI 10.1152/ajpcell.00298.2003; Speake T, 2003, BBA-BIOMEMBRANES, V1609, P80, DOI 10.1016/S0005-2736(02)00658-2; Stringer JL, 1997, BRAIN RES, V745, P328, DOI 10.1016/S0006-8993(96)01253-X; Takumi Y, 1998, EUR J NEUROSCI, V10, P3584, DOI 10.1046/j.1460-9568.1998.00360.x; TRAYNELIS SF, 1989, J NEUROPHYSIOL, V61, P927; Vajda Z, 2002, P NATL ACAD SCI USA, V99, P13131, DOI 10.1073/pnas.192457099; Verbavatz JM, 1997, J CELL SCI, V110, P2855; Verkman AS, 2002, ANN MED, V34, P192, DOI 10.1080/713782138; Weed LH, 1919, AM J PHYSIOL, V48, P531; WOLBURG H, 1995, J BRAIN RES, V36, P239; Yang BX, 1996, J BIOL CHEM, V271, P4577; Yang BX, 2000, AM J PHYSIOL-CELL PH, V278, pC1108	66	228	261	0	17	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		2004	129	4					983	991		10.1016/j.neuroscience.2004.06.088			9	Neurosciences	Neurosciences & Neurology	879OB	WOS:000225726000012	15561413				2021-06-18	
J	Laurer, HL; Bareyre, FM; Lee, VMYC; Trojanowski, JQ; Longhi, L; Hoover, R; Saatman, KE; Raghupathi, R; Hoshino, S; Grady, MS; McIntosh, TK				Laurer, HL; Bareyre, FM; Lee, VMYC; Trojanowski, JQ; Longhi, L; Hoover, R; Saatman, KE; Raghupathi, R; Hoshino, S; Grady, MS; McIntosh, TK			Mild head injury increasing the brain's vulnerability to a second concussive impact	JOURNAL OF NEUROSURGERY			English	Article						axonal injury; blood-brain barrier; cognition; dendritic injury; histology; neurodegeneration; mouse	CONTROLLED CORTICAL IMPACT; AMYLOID PRECURSOR PROTEIN; FLUID-PERCUSSION INJURY; SHAKEN-BABY SYNDROME; TRANSGENIC MICE; COGNITIVE DEFICITS; ALZHEIMERS-DISEASE; SOCCER PLAYERS; AXONAL INJURY; MEMORY IMPAIRMENT	Object. Mild, traumatic repetitive head injury (RHI) leads to neurobehavioral impairment and is associated with the early onset of neurodegenerative disease. The authors developed an animal model to investigate the behavioral and pathological changes associated with RHI. Methods. Adult male C57BL/6 mice were subjected to a single injury (43 mice), repetitive injury (two injuries 24 hours apart 49 m ice), or no impact (36 mice). Cognitive function was assessed using the Morris water maze test, and neurological motor function was evaluated using a battery of neuroscore, rotarod, and rotating pole tests. The animals were also evaluated for cardiovascular changes, blood-brain barrier (BBB) breakdown, traumatic axonal injury, and neurodegenerative and histopathological changes between 1 day and 56 days after brain trauma. No cognitive dysfunction was detected in any group. The single-impact group showed mild impairment according to the neuroscore test at only 3 days postinjury, whereas RHI caused pronounced deficits at 3 days and 7 days following the second injury. Moreover, RHI led to functional impairment during the rotarod and rotating pole tests that was not observed in any animal after a single impact. Small areas of cortical BBB breakdown and axonal injury, observed after a single brain injury, were profoundly exacerbated after RHI. Immunohistochemical staining for microtubule-associated protein-2 revealed marked regional loss of immunoreactivity only in animals subjected to RHI. No deposits of beta -amyloid or tau were observed in any brain-injured animal. Conclusions. On the basis of their results, the authors suggest that the brain has an increased vulnerability to a second traumatic insult for at least 24 hours following an initial episode of mild brain trauma.	Univ Penn, Sch Med, Dept Neurosurg, Head Injury Ctr, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pathol & Med Lab, Philadelphia, PA 19104 USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA	McIntosh, TK (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, Head Injury Ctr, 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.		Longhi, Luca/AAF-9903-2021	Longhi, Luca/0000-0001-9894-8788	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, R01NS040978] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG011542, P30AG010124] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01-AG11542, P30-AG10124] Funding Source: Medline; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50-NS08803, R01-NS40978] Funding Source: Medline		Bareyre FM, 1999, J NEUROCHEM, V73, P271, DOI 10.1046/j.1471-4159.1999.0730271.x; Barone FC, 1998, STROKE, V29, P1937, DOI 10.1161/01.STR.29.9.1937; BECK WT, 1975, CANCER RES, V35, P1333; Bijur PE, 1996, J DEV BEHAV PEDIATR, V17, P143, DOI 10.1097/00004703-199606000-00001; Blasko I, 1999, FASEB J, V13, P63; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; Carbonell WS, 1998, J NEUROTRAUM, V15, P217, DOI 10.1089/neu.1998.15.217; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Chorley Joseph N., 1998, Current Opinion in Pediatrics, V10, P350, DOI 10.1097/00008480-199808000-00004; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; DIXON CE, 1994, J NEUROTRAUM, V11, P275, DOI 10.1089/neu.1994.11.275; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Fox GB, 1999, J NEUROTRAUM, V16, P377, DOI 10.1089/neu.1999.16.377; Franklin K. B. J., 1997, MOUSE BRAIN STEREOTA; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Geddes JF, 1996, NEUROPATH APPL NEURO, V22, P12, DOI 10.1111/j.1365-2990.1996.tb00840.x; GENTLEMAN SM, 1993, PROG BRAIN RES, V96, P237; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Gordon WR, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199812000-00006; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; Green GA, 1998, CLIN SPORT MED, V17, P795, DOI 10.1016/S0278-5919(05)70120-4; GUSKIEWICZ KM, 1997, MED SCI SPORTS EXERC, V29, P213; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hogg S, 1998, BEHAV BRAIN RES, V93, P143, DOI 10.1016/S0166-4328(97)00146-0; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; HOVDA DA, 1992, J NEUROTRAUMA S1, V9, P47; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; Ishihara T, 1999, NEURON, V24, P751, DOI 10.1016/S0896-6273(00)81127-7; Jenkins LW, 1999, BRAIN RES, V817, P132, DOI 10.1016/S0006-8993(98)01237-2; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; Johansson BB, 1996, EXP NEUROL, V139, P322, DOI 10.1006/exnr.1996.0106; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Kanayama G, 1996, METHOD FIND EXP CLIN, V18, P105; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Koelfen W, 1997, EUR J PEDIATR, V156, P230, DOI 10.1007/s004310050590; KREGE JH, 1995, HYPERTENSION, V25, P1111, DOI 10.1161/01.HYP.25.5.1111; Lancon JA, 1998, ANAT REC, V253, P13, DOI 10.1002/(SICI)1097-0185(199802)253:1<13::AID-AR8>3.0.CO;2-F; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Masdeu J C, 1994, J Neuroimaging, V4, P177; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Mattiasson GJ, 2000, J NEUROSCI METH, V95, P75, DOI 10.1016/S0165-0270(99)00162-4; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MELVIN JW, 1993, BIOMECHANICS IMPACT, P661; Mills J, 1999, J NEUROCHEM, V72, P443, DOI 10.1046/j.1471-4159.1999.0720443.x; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; Nakamura M, 1999, J COMP NEUROL, V412, P681, DOI 10.1002/(SICI)1096-9861(19991004)412:4<681::AID-CNE9>3.0.CO;2-F; Nakamura M, 1999, J CEREBR BLOOD F MET, V19, P762, DOI 10.1097/00004647-199907000-00006; *NAT RES COUNC, 1996, GUID CAR US LAB; NEDD K, 1993, BRAIN INJURY, V7, P469, DOI 10.3109/02699059309008174; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; OLSSON Y, 1971, ACTA NEUROPATHOL, V19, P225, DOI 10.1007/BF00684599; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; Perez-Pinzon MA, 1999, NEUROREPORT, V10, P2951, DOI 10.1097/00001756-199909290-00014; Pierce JES, 1996, J NEUROSCI, V16, P1083; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Piper IR, 1996, J NEUROSCI METH, V69, P171, DOI 10.1016/S0165-0270(96)00046-5; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROBERTS GW, 1990, LANCET, V335, P918, DOI 10.1016/0140-6736(90)90520-F; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Samii A, 1999, J NEUROTRAUM, V16, P879, DOI 10.1089/neu.1999.16.879; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Stagliano NE, 1999, J CEREBR BLOOD F MET, V19, P757, DOI 10.1097/00004647-199907000-00005; STRUGAR J, 1993, J TRAUMA, V34, P555, DOI 10.1097/00005373-199304000-00012; Tang YP, 1997, J NEUROTRAUM, V14, P863, DOI 10.1089/neu.1997.14.863; Tang YP, 1997, J NEUROTRAUM, V14, P851, DOI 10.1089/neu.1997.14.851; Tannock GW, 1992, LACTIC ACID BACTERIA, P21; Tokutomi T, 1997, ACT NEUR S, V70, P80; TYSVAER AT, 1989, ACTA NEUROL SCAND, V80, P151, DOI 10.1111/j.1600-0404.1989.tb03858.x; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8	98	228	228	0	28	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	NOV	2001	95	5					859	870		10.3171/jns.2001.95.5.0859			12	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	487WC	WOS:000171901200020	11702878				2021-06-18	
J	Guskiewicz, KM				Guskiewicz, KM			Postural stability assessment following concussion: One piece of the puzzle	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						cerebral concussion; central nervous system; postural stability; balance; sensory organization testing	MILD HEAD-INJURY; STANDARDIZED ASSESSMENT; SENSORY INTERACTION; FOOTBALL PLAYERS; BALANCE; STANCE; SWAY; STABILIZATION; ADAPTATION; WHIPLASH	Clinicians regularly assess concussion according to the symptoms that an athlete manifests at the time of injury, as well as during subsequent evaluations. The subjectivity involved with symptom assessment, however, often leaves the clinician without a clear picture of the athlete's true mental status. Neuropsychologic testing has become very popular in the sports medicine community for assessing the cognitive domain of neurologic functioning, and postural stability testing is gaining credence for assessing the motor domain. The objective of this review was to determine the efficacy of postural stability testing as an adjunct to concussion assessment of athletes. Multiple studies, using both sophisticated force plate technology, as well as those using less sophisticated clinical balance tests, have identified postural stability deficits lasting several days following sport-related concussion. It appears that postural stability testing provides a useful tool for objectively assessing the motor domain of neurologic functioning, and should be considered a reliable and valid adjunct to the assessment of athletes suffering from concussion. Although symptom severity, neurocognitive function. anti postural stability are often affected initially following concussion, they are not necessarily related or even affected to the same degree.	Univ N Carolina, Sports Med Res Lab, Dept Exercise & Sport Sci, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Orthopaed, Chapel Hill, NC 27599 USA	Guskiewicz, KM (corresponding author), Univ N Carolina, Sports Med Res Lab, Dept Exercise & Sport Sci, 211 Fetzer CB-8700, Chapel Hill, NC 27599 USA.	gus@email.unc.edu		Guskiewicz, Kevin/0000-0002-8682-2130			ARCAN M, 1977, SCAND J REHABIL MED, V9, P165; ARNHEIM DD, 1997, PRINCIPLES ATHLETIC; Barth JT., 1989, MILD HEAD INJURY, P257; BOOHER JM, 1994, ATHLETIC INJURY ASSE; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; DIENER HC, 1984, BRAIN RES, V296, P103, DOI 10.1016/0006-8993(84)90515-8; DIETZ V, 1989, PROG BRAIN RES, V80, P419; DORNAN J, 1978, ARCH PHYS MED REHAB, V59, P586; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 1996, J SPORT REHABIL, V5, P45, DOI 10.1123/jsr.5.1.45; Guyton A., 1986, TXB MED PHYSL, P1610; Hellebrandt FA, 1939, AM J PHYS ANTHROPOL, V24, P347, DOI 10.1002/ajpa.1330240318; HORSTMANN GA, 1988, NEUROSCI LETT, V95, P179, DOI 10.1016/0304-3940(88)90653-2; INGERSOLL CD, 1992, MED SCI SPORT EXER, V24, P739; JANSEN EC, 1982, ACTA NEUROL SCAND, V66, P93; Kelly JP, 1997, NEUROLOGY, V48, P581; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Mallinson AI, 1998, AM J OTOL, V19, P814; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; MAURITZ KH, 1979, BRAIN, V102, P461, DOI 10.1093/brain/102.3.461; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; NASHNER L, 1978, BRAIN RES, V150, P403, DOI 10.1016/0006-8993(78)90291-3; NASHNER LM, 1982, J NEUROSCI, V2, P536; NASHNER LM, 1982, TRENDS NEUROSCI, V5, P358, DOI 10.1016/0166-2236(82)90204-1; NASHNER LM, 1976, EXP BRAIN RES, V26, P59; NORRE ME, 1993, J LARYNGOL OTOL, V107, P496, DOI 10.1017/S0022215100123564; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Riemann BL, 1997, J SPORT REHABIL, V6, P283, DOI 10.1123/jsr.6.3.283; Riemann BL, 2000, J ATHL TRAINING, V35, P19; ROSS S, 2000, J ATHL TRAINING, V35, pS53; RUBIN AM, 1995, AM J OTOL, V16, P216; SHUMWAYCOOK A, 1986, PHYS THER, V66, P1548, DOI 10.1093/ptj/66.10.1548; SORENSON SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI DOI 10.1097/00001199-199106000-00003; SUGANO H, 1970, JPN J PHYSL, P296; Vander A., 1990, HUMAN PHYSL MECH BOD; WOBER C, 1993, ARCH PHYS MED REHAB, V74, P1151	40	228	228	1	27	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	JUL	2001	11	3					182	189		10.1097/00042752-200107000-00009			8	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	454YG	WOS:000169998900008	11495323				2021-06-18	
J	Graham, DI; McIntosh, TK; Maxwell, WL; Nicoll, JAR				Graham, DI; McIntosh, TK; Maxwell, WL; Nicoll, JAR			Recent advances in neurotrauma	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						ApoE genotype; apoptosis; outcome; traumatic brain injury	TRAUMATIC BRAIN INJURY; AMYLOID PRECURSOR PROTEIN; DIFFUSE AXONAL INJURY; OPTIC-NERVE FIBERS; HEAD-INJURY; ALZHEIMERS-DISEASE; CORTICAL IMPACT; NEURONAL DAMAGE; TRANSGENIC MICE; STRETCH-INJURY	The frequency of and outcome from acute traumatic brain injury (TBI) in humans are detailed together with a classification of the principal focal and diffuse pathologies, and their mechanisms in extract laboratory models are outlined. Particular emphasis is given to diffuse axonal injury, which is a major determinant of outcome. Cellular and molecular cascades triggered by injury are described with reference to the induction of axolemmal and cytoskeletal abnormalities, necrotic and apoptotic cell death, the role of Ca2+. cytokines and free radicals, and damage to DNA. It is concluded that TBI in humans is heterogeneous, reflecting various pathologies in differing proportions in patients whose genetic background (APOE gene polymorphisms) contributes to the outcome at 6 months. Although considerable progress has been made in the understanding of TBI, much remains to be determined. However, a deeper understanding of the pathophysiological events may lead to the possibility of improving outcome from rational targeted therapy.	Univ Glasgow, So Gen Hosp, Inst Neurol Sci, Dept Neuropathol,NHS Trust, Glasgow G51 4TF, Lanark, Scotland; Univ Penn, Sch Med, Philadelphia, PA 19104 USA; Univ Glasgow, IBLS Div Neurosci & Biomed Syst, Glasgow, Lanark, Scotland	Graham, DI (corresponding author), Univ Glasgow, So Gen Hosp, Inst Neurol Sci, Dept Neuropathol,NHS Trust, 1345 Govan Rd, Glasgow G51 4TF, Lanark, Scotland.		Nicoll, James/I-9253-2017	Nicoll, James/0000-0002-9444-7246			Adams JH, 1999, J CLIN PATHOL, V52, P804, DOI 10.1136/jcp.52.11.804; BELLOSTA S, 1995, J BIOL CHEM, V270, P27063, DOI 10.1074/jbc.270.45.27063; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Buttini M, 1999, J NEUROSCI, V19, P4867; Clark RSB, 1997, J NEUROSCI, V17, P9172; Clark RSB, 1999, FASEB J, V13, P813; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; CORSELLIS JAN, 1989, BRIT MED J, V298, P105, DOI 10.1136/bmj.298.6666.105; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; EMERY DL, IN PRESS J COMP NEUR; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; GEHRMANN J, 1995, NEUROPATH APPL NEURO, V21, P277, DOI 10.1111/j.1365-2990.1995.tb01062.x; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Goss JR, 1997, EXP NEUROL, V146, P291, DOI 10.1006/exnr.1997.6515; GRAHAM DI, 1997, GREENFIELDS NEUROPAT, P197; Griffin WST, 1998, BRAIN PATHOL, V8, P65; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Horsburgh K, 1999, J NEUROPATH EXP NEUR, V58, P227, DOI 10.1097/00005072-199903000-00002; Horsburgh K, 2000, J CEREBR BLOOD F MET, V20, P458, DOI 10.1097/00004647-200003000-00003; Horsburgh K, 1999, NEUROREPORT, V10, P837, DOI 10.1097/00001756-199903170-00031; Hulsebosch CE, 1998, NEUROSCI LETT, V255, P83, DOI 10.1016/S0304-3940(98)00712-5; Iwata N, 2000, NAT MED, V6, P143; Jafari SS, 1998, J NEUROTRAUM, V15, P955, DOI 10.1089/neu.1998.15.955; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kawase M, 1999, STROKE, V30, P441, DOI 10.1161/01.STR.30.2.441; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; LaPlaca MC, 1999, J NEUROCHEM, V73, P205, DOI 10.1046/j.1471-4159.1999.0730205.x; Macfarlane DP, 1999, NEUROREPORT, V10, P3945, DOI 10.1097/00001756-199912160-00040; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; Maxwell WL, 1995, J NEUROCYTOL, V24, P925, DOI 10.1007/BF01215643; Maxwell WL, 1999, J NEUROTRAUM, V16, P273, DOI 10.1089/neu.1999.16.273; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; McCracken E, 1999, J NEUROTRAUM, V16, P749, DOI 10.1089/neu.1999.16.749; McIntosh TK, 1997, NEUROSCIENTIST, V3, P169, DOI 10.1177/107385849700300310; McIntosh TK, 1996, LAB INVEST, V74, P315; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; Morrison B, 2000, NEUROSCIENCE, V96, P131, DOI 10.1016/S0306-4522(99)00537-0; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Nakagawa Y, 1999, J COMP NEUROL, V411, P390; Nakamura M, 1999, J CEREBR BLOOD F MET, V19, P762, DOI 10.1097/00004647-199907000-00006; Napieralski JA, 1999, MOL BRAIN RES, V71, P78, DOI 10.1016/S0169-328X(99)00155-2; Nemetz PN, 1999, AM J EPIDEMIOL, V149, P32; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; PATTERSON SL, 1993, BRAIN RES, V605, P43, DOI 10.1016/0006-8993(93)91354-U; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Poirier J, 1998, J NEURAL TRANSM-SUPP, P199; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; RINK A, 1995, AM J PATHOL, V147, P1575; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROSES AD, 1995, NAT MED, V1, P603, DOI 10.1038/nm0795-603; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Sanderson KL, 1999, J CEREBR BLOOD F MET, V19, P1118, DOI 10.1097/00004647-199910000-00008; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH F, IN PRESS ACTA NEUROP; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zhang C, 1999, J NEUROCHEM, V73, P1650, DOI 10.1046/j.1471-4159.1999.0731650.x	88	228	246	0	5	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	AUG	2000	59	8					641	651		10.1093/jnen/59.8.641			11	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	343QJ	WOS:000088712800001	10952055	Bronze			2021-06-18	
J	Fox, GB; Fan, L; Levasseur, RA; Faden, AI				Fox, GB; Fan, L; Levasseur, RA; Faden, AI			Sustained sensory/motor and cognitive deficits with neuronal apoptosis following controlled cortical impact brain injury in the mouse	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; brain trauma; histology; motor and cognitive tests	CLOSED-HEAD INJURY; MEMORY DEFICITS; CELL-DEATH; LONG-TERM; RAT; MODEL; MOTOR; DYSFUNCTION; ISCHEMIA; MICE	A mouse model of traumatic brain injury was developed using a device that produces controlled cortical impact (CCI), permitting independent manipulation of tissue deformation and impact velocity. The left parietotemporal cortex was subjected to CCI [1 mm tissue deformation and 4.5 m/s tip velocity (mild), or 6.0 m/s (moderate)] or sham surgery. Injured animals showed delayed recovery of pedal withdrawal and righting reflexes compared to sham-operated controls. Significant severity-related deficits in forepaw contraflexion and performance on a rotarod device were evident for up to 7 days. Using a beam walking task to measure fine motor coordination, pronounced deficits were apparent for at least 2 and 4 weeks following mild and moderate CCI, respectively. Cognitive function was evaluated using the water maze. Impairment of place learning, related to injury severity, was observed in mice trained 7-10 days following CCI. Similarly, working memory deficits were evident in a variation of this task when examined 21-23 days postinjury. Mild CCI caused necrosis of subcortical white matter with minimal damage to somatosensory cortex. Moderate CCI produced extensive cortical and subcortical white matter damage. Triple fluorescence labeling with terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL), antineuronal nuclear protein (NeuN), and Hoechst 33258 of parallel sections showed frequent apoptotic neurons. These findings demonstrate sustained and reproducible deficits in sensory/motor function and spatial learning in the CCI-injured mouse correlating with injury severity. Mechanisms of neuronal cell death after trauma as well as strategies for evaluating novel pharmacological treatment strategies may be identified using this model.	Georgetown Univ, Med Ctr, Georgetown Inst Cognit & Computat Sci, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Dept Neurol, Washington, DC 20007 USA	Faden, AI (corresponding author), Georgetown Univ, Med Ctr, Georgetown Inst Cognit & Computat Sci, 3970 Reservoir Rd NW,Rm EP-04, Washington, DC 20007 USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [CCR 306634] Funding Source: Medline		Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; BURSCH W, 1990, CARCINOGENESIS, V11, P847, DOI 10.1093/carcin/11.5.847; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Clark RSB, 1997, J NEUROSCI, V17, P9172; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dixon CE, 1996, NEUROTRAUMA, P1337; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Franklin K. B. J., 1997, MOUSE BRAIN STEREOTA; GORMAN LK, 1993, BRAIN RES, V614, P29, DOI 10.1016/0006-8993(93)91014-J; Hamm RJ, 1996, J NEUROTRAUM, V13, P317, DOI 10.1089/neu.1996.13.317; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Johansson BB, 1996, EXP NEUROL, V139, P322, DOI 10.1006/exnr.1996.0106; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; Levin H.S., 1996, TRAUMATIC BRAIN INJU, P105; LI Y, 1995, J CEREBR BLOOD F MET, V15, P389, DOI 10.1038/jcbfm.1995.49; LI Y, 1995, AM J PATHOL, V146, P1045; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LINNIK MD, 1993, STROKE, V24, P2002, DOI 10.1161/01.STR.24.12.2002; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Morris R, 1982, J NEUROSCI METH, V22, P47; Povlishock JT., 1996, NEUROTRAUMA, P1325; RINK A, 1995, AM J PATHOL, V147, P1575; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Wood NI, 1996, BEHAV BRAIN RES, V78, P113, DOI 10.1016/0166-4328(95)00237-5; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	33	228	235	1	15	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	1998	15	8					599	614		10.1089/neu.1998.15.599			16	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	111KP	WOS:000075436500004	9726259				2021-06-18	
J	Chirumamilla, S; Sun, D; Bullock, MR; Colello, RJ				Chirumamilla, S; Sun, D; Bullock, MR; Colello, RJ			Traumatic brain injury induced cell proliferation in the adult mammalian central nervous system	JOURNAL OF NEUROTRAUMA			English	Article						bromodeoxyuridine; fluid percussion injury; hippocampus; progenitor cells; subventricular zone; thymidine	DENTATE GYRUS; GLIAL-CELLS; RAT; NEUROGENESIS; MICROGLIA; NEURONS; MIGRATION; ISCHEMIA; PATTERNS; NESTIN	Recent studies indicate the existence of progenitor cells and their potential for neurogenesis in the subventricular zone (SVZ) and the hippocampus of the normal adult mammalian brain. However, the proliferative response and the specific cell types generated following traumatic brain injury have not been examined. This cellular response to CNS injury was investigated using the fluid percussion injury (FPI) model, a widely accepted rat model that simulates moderate head injury sustained in humans. Forty-eight hours following moderate FPI, adult rats received intraperitoneal injections of the thymidine analogs, 5-bromodeoxyuridine (BrdU) or tritiated thymidine (H-3-thymidine), which are markers for mitotic activity. Injured and control animals receiving BrdU were used to determine the total number of cells induced to proliferate. To determine the cellular identity of these proliferating cells, animals receiving 3H-thymidine were sacrificed and sections through the injured area were immunostained with markers for immature and mature astrocytes, activated microglia, neural precursors and mature neurons. These studies showed that the total number of proliferating cells was significantly increased in the injury group for both the SVZ and the hippocampus. However, the proliferating cells in the SVZ did not express any of the cellular markers used, suggesting that they have not yet begun to differentiate. In contrast, there was a significant increase in the number of immature astrocytes and activated microglia, but not neurons, at this early time point in the hippocampus. Taken together, these experiments demonstrate the compensatory capacity of the adult brain to injury and should lead to a new generation of studies aimed at enhancing the neuronal proliferative response.	Virginia Commonwealth Univ, Dept Pediat Crit Care, Med Coll Virginia, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Neurosurg, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Richmond, VA 23298 USA	Chirumamilla, S (corresponding author), Virginia Commonwealth Univ, Dept Pediat Crit Care, Med Coll Virginia, POB 980530, Richmond, VA 23298 USA.	schiruma@hsc.vcu.edu					Amat JA, 1996, GLIA, V16, P368, DOI 10.1002/(SICI)1098-1136(199604)16:4<368::AID-GLIA9>3.0.CO;2-W; Barres BA, 1999, CELL, V97, P667, DOI 10.1016/S0092-8674(00)80777-1; BIGNAMI A, 1982, DEV BIOL, V91, P286, DOI 10.1016/0012-1606(82)90035-5; CAMERON HA, 1993, NEUROSCIENCE, V56, P337, DOI 10.1016/0306-4522(93)90335-D; Chiasson BJ, 1999, J NEUROSCI, V19, P4462; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DAHL D, 1976, BRAIN RES, V116, P150, DOI 10.1016/0006-8993(76)90257-2; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; ELDRIDGE SR, 1990, CARCINOGENESIS, V11, P2245, DOI 10.1093/carcin/11.12.2245; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; GALL C, 1979, J COMP NEUROL, V183, P539, DOI 10.1002/cne.901830306; GIORDANA MT, 1994, NEUROPATH APPL NEURO, V20, P163, DOI 10.1111/j.1365-2990.1994.tb01175.x; GIULIAN D, 1989, J NEUROSCI, V9, P4416; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; GRATZNER HG, 1982, SCIENCE, V218, P474, DOI 10.1126/science.7123245; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; Hill-Felberg SJ, 1999, J NEUROSCI RES, V57, P271, DOI 10.1002/(SICI)1097-4547(19990715)57:2<271::AID-JNR13>3.0.CO;2-Z; Isacson O, 1999, BRAIN PATHOL, V9, P495; JANECZKO K, 1989, BRAIN RES, V485, P236, DOI 10.1016/0006-8993(89)90566-0; Kempermann G, 2000, NOVART FDN SYMP, V231, P220, DOI 10.1002/0470870834.ch14; Kukekov VG, 1997, GLIA, V21, P399, DOI 10.1002/(SICI)1098-1136(199712)21:4<399::AID-GLIA7>3.0.CO;2-Z; Liu JL, 1998, J NEUROSCI, V18, P7768; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; Messam CA, 2000, EXP NEUROL, V161, P585, DOI 10.1006/exnr.1999.7319; MILLER MW, 1988, BRAIN RES, V457, P44, DOI 10.1016/0006-8993(88)90055-8; Parent JM, 1997, J NEUROSCI, V17, P3727; POLVISHOCK JT, 1992, J NEUROTRAUMA S, V9, pS189; ROGERS AW, 1976, TECHNIQUES AUTORADIO; Sarnat HB, 1998, BRAIN DEV-JPN, V20, P88, DOI 10.1016/S0387-7604(97)00111-3; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; Soares HD, 1995, J NEUROSCI, V15, P8223; STRICH SJ, 1961, LANCET, V2, P443; Takagi Y, 1999, BRAIN RES, V831, P283, DOI 10.1016/S0006-8993(99)01411-0; Thompson LU, 1992, CONT NUTR, V17, P1; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tzeng SF, 1999, NEUROREPORT, V10, P2287, DOI 10.1097/00001756-199908020-00012; van der Kooy D, 2000, SCIENCE, V287, P1439, DOI 10.1126/science.287.5457.1439; ZERLIN M, 1995, J NEUROSCI, V15, P7238; Zhang RL, 2001, NEUROSCIENCE, V105, P33, DOI 10.1016/S0306-4522(01)00117-8	45	227	243	4	21	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2002	19	6					693	703		10.1089/08977150260139084			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	569EZ	WOS:000176588900002	12165131				2021-06-18	
J	Shohami, E; Bass, R; Wallach, D; Yamin, A; Gallily, R				Shohami, E; Bass, R; Wallach, D; Yamin, A; Gallily, R			Inhibition of tumor necrosis factor alpha (TNF alpha) activity in rat brain is associated with cerebroprotection after closed head injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						tumor necrosis factor alpha (TNF alpha); brain injury; pentoxifylline; tumor necrosis factor binding protein	FACTOR-BINDING-PROTEIN; PERMEABILITY; MECHANISM; RECEPTOR; CELLS	We recently demonstrated that closed head injury (CHI) in the rat triggers the production of tumor necrosis factor alpha (TNF alpha) in the contused hemisphere. Other investigations have shown that this cytokine plays a role in the inflammatory response following trauma. The present study was designed to determine whether inhibition of TNF alpha production or activity affects the development of cerebral edema as well as neurological dysfunction and hippocampal cell loss after CHI. To this end, we used two pharmacological agents, each acting via a different mechanism: pentoxifylline (PTX), which attenuates the production of TNF alpha, and tumor necrosis factor binding protein (TBP), a physiological inhibitor of TNF alpha activity. Both agents significantly lessened peak edema formation at 24 h and facilitated the recovery of motor function for less than or equal to 14 days postinjury. In addition, TBP attenuated disruption Of the blood-brain barrier and protected hippocampal cells. PTX significantly lowered the brain TNF alpha level (by similar to 80%), and TBP completely abolished the activity Of recombinant human TNF when they were added at the same time in the in vitro bioassay. We suggest, therefore, that a decrease in TNF alpha level or the inhibition of its activity is accompanied by reduced brain damage.	HEBREW UNIV JERUSALEM,SCH PHARM,DEPT IMMUNOL,IL-91120 JERUSALEM,ISRAEL; WEIZMANN INST SCI,DEPT MOLEC GENET & VIROL,IL-76100 REHOVOT,ISRAEL	Shohami, E (corresponding author), HEBREW UNIV JERUSALEM,SCH PHARM,DEPT PHARMACOL,IL-91120 JERUSALEM,ISRAEL.						BRENNER T, 1993, BRAIN RES, V608, P273, DOI 10.1016/0006-8993(93)91468-8; DINARELLO CA, 1988, INFLAMMATION BASIC P, P1195; DOHERTY GM, 1991, SURGERY, V110, P192; EMERSON TE, 1992, CIRC SHOCK, V38, P75; ENGELMANN H, 1989, J BIOL CHEM, V264, P11974; GALLILY R, 1989, CELL IMMUNOL, V121, P141; GASCON MP, 1992, DRUG METAB DISPOS, V20, P592; HINSHAW L, 1989, CIRC SHOCK, V27, P362; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; MEGYERI P, 1992, NEUROSCI LETT, V148, P137, DOI 10.1016/0304-3940(92)90823-P; NOPHAR Y, 1990, EMBO J, V9, P3269, DOI 10.1002/j.1460-2075.1990.tb07526.x; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; PARHAR RS, 1993, MEDIAT INFLAMM, V2, P379, DOI 10.1155/S0962935193000535; PEETRE C, 1988, EUR J HAEMATOL, V41, P414; QUAGLIARELLO VJ, 1991, J CLIN INVEST, V87, P1360, DOI 10.1172/JCI115140; RELTON JK, 1992, BRAIN RES BULL, V29, P243, DOI 10.1016/0361-9230(92)90033-T; SECKINGER P, 1989, J BIOL CHEM, V264, P11966; SEMENZATO G, 1990, BRIT J CANCER, V61, P354, DOI 10.1038/bjc.1990.78; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHER T, 1990, CANCER IMMUNOL IMMUN, V31, P86, DOI 10.1007/BF01742371; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; SHOHAMI E, 1989, J NEUROCHEM, V53, P1541, DOI 10.1111/j.1471-4159.1989.tb08550.x; STREITER RM, 1988, BIOCHEM BIOPH RES CO, V155, P1230; TERADA LS, 1992, INFLAMMATION, V16, P13, DOI 10.1007/BF00917511; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; UYAMA O, 1988, J CEREBR BLOOD F MET, V8, P282, DOI 10.1038/jcbfm.1988.59; ZABEL P, 1989, LANCET, V2, P1474	30	227	235	0	1	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAY	1996	16	3					378	384		10.1097/00004647-199605000-00004			7	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	UF710	WOS:A1996UF71000004	8621742	Bronze			2021-06-18	
J	Oddo, M; Carrera, E; Claassen, J; Mayer, SA; Hirsch, LJ				Oddo, Mauro; Carrera, Emmanuel; Claassen, Jan; Mayer, Stephan A.; Hirsch, Lawrence J.			Continuous electroencephalography in the medical intensive care unit	CRITICAL CARE MEDICINE			English	Article						acute brain dysfunction; ICU delirium; septic encephalopathy; sepsis-associated encephaloapathy; electrographic seizures; nonconvulsive seizures; medical ICU; outcome	TRAUMATIC BRAIN-INJURY; CONTINUOUS EEG; CRITICALLY-ILL; ELECTROGRAPHIC SEIZURES; INTRACEREBRAL HEMORRHAGE; NEUROLOGIC COMPLICATIONS; ENCEPHALOPATHY; IMPACT; DISCHARGES; PHENYTOIN	Objectives. To examine predictors and the prognostic value of electrographic seizures (ESZs) and periodic epileptiform discharges (PEDs) in medical intensive care unit (MICU) patients without a primary acute neurologic condition. Design: Retrospective study. Setting. MICU in a university hospital. Patients. A total of 201 consecutive patients admitted to the MICU between July 2004 and January 2007 without known acute neurologic injury and who underwent continuous electroencephalography monitoring (cEEG) for investigation of possible seizures or changes in mental status. Intervention: None. Measurements and Main Results. Median time from intensive care unit (ICU) admission to cEEG was I day (interquartile range 1-4). The majority of patients (60%) had sepsis as the primary admission diagnosis and 48% were comatose at the time of cEEG. Ten percent (n = 21) of patients had ESZs, 17% (n = 34) had PEDs, 5% (n = 10) had both, and 22% (n = 45) had either ESZs or PEDs. Seizures during cEEG were purely electrographic (no detectable clinical correlate) in the majority (67%) of patients. Patients with sepsis had a higher rate of ESZs or PEDs than those without sepsis (32% vs. 9%, p < 0.001). On multivariable analysis, sepsis at ICU admission was the only significant predictor of ESZs or PEDs (odds ratio 4.6, 95% confidence interval 1.9-12.7, p = 0.002). After controlling for age, coma, and organ dysfunction, the presence of ESZs or PEDs was associated with death or severe disability at hospital discharge (89% with ESZs or PEDs, vs. 39% if not; odds ratio 19.1, 95% confidence interval 6.3-74.6, p < 0.001). Conclusion: In this retrospective study of MICU patients monitored with cEEG, ESZs and PEDs were frequent, predominantly in patients with sepsis. Seizures were mainly nonconvulsive. Both seizures and periodic discharges were associated with poor outcome. Prospective studies are warranted to determine more precisely the frequency and clinical impact of nonconvulsive seizures and periodic discharges, particularly in septic patients. (Crit Care Med 2009; 37:2051-2056)	[Claassen, Jan; Hirsch, Lawrence J.] Columbia Univ, Med Ctr, Neurol Inst, Comprehens Epilepsy Ctr, New York, NY 10027 USA; [Oddo, Mauro; Carrera, Emmanuel; Claassen, Jan; Mayer, Stephan A.] Columbia Univ, Med Ctr, Neurol Inst, Dept Neurol,Div Crit Care, New York, NY USA	Hirsch, LJ (corresponding author), Columbia Univ, Med Ctr, Neurol Inst, Comprehens Epilepsy Ctr, New York, NY 10027 USA.	ljh3@columbia.edu	Oddo, Mauro/R-3370-2016; Claassen, Jan/AAA-5451-2020	Oddo, Mauro/0000-0002-6155-2525; Hirsch, Lawrence/0000-0002-6333-832X; Carrera, Emmanuel/0000-0003-0045-5382	SICPA Foundation, Lausanne, Switzerland; Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission [PBLAB-119620]	Supported, in part, by Research Grants from the SICPA Foundation, Lausanne, Switzerland (to MO and EC) and the Swiss National Science Foundation, Grant PBLAB-119620 (to EC).	Bleck TP, 2006, SEMIN RESP CRIT CARE, V27, P201, DOI 10.1055/s-2006-945531; BLECK TP, 1993, CRIT CARE MED, V21, P98, DOI 10.1097/00003246-199301000-00019; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; Calabresi P, 1999, BRIT J PHARMACOL, V126, P689, DOI 10.1038/sj.bjp.0702361; Chong DJ, 2005, J CLIN NEUROPHYSIOL, V22, P79, DOI 10.1097/01.WNP.0000158699.78529.AF; Claassen J, 2007, NEUROLOGY, V69, P1356, DOI 10.1212/01.wnl.0000281664.02615.6c; Claassen J, 2006, NEUROCRIT CARE, V4, P103, DOI 10.1385/NCC:4:2:103; Claassen J, 2003, NEUROLOGY, V60, P208, DOI 10.1212/01.WNL.0000038906.71394.DE; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; Ebersoldt M, 2007, INTENS CARE MED, V33, P941, DOI 10.1007/s00134-007-0622-2; Eidelman LA, 1996, JAMA-J AM MED ASSOC, V275, P470, DOI 10.1001/jama.275.6.470; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; Hirsch LJ, 2005, J CLIN NEUROPHYSIOL, V22, P128, DOI 10.1097/01.WNP.0000158701.89576.4C; Hirsch LJ, 2004, J CLIN NEUROPHYSIOL, V21, P332; Jirsch J, 2007, CLIN NEUROPHYSIOL, V118, P1660, DOI 10.1016/j.clinph.2006.11.312; JORDAN KG, 1993, J CLIN NEUROPHYSIOL, V10, P445, DOI 10.1097/00004691-199310000-00006; Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B; Milbrandt EB, 2005, CURR OPIN CRIT CARE, V11, P355, DOI 10.1097/01.ccx.0000170508.63067.04; Naidech AM, 2005, STROKE, V36, P583, DOI 10.1161/01.STR.0000141936.36596.1e; SPRUNG CL, 1990, CRIT CARE MED, V18, P801, DOI 10.1097/00003246-199008000-00001; Stevens RD, 2006, SEMIN NEUROL, V26, P440, DOI 10.1055/s-2006-948325; Towne AR, 2000, NEUROLOGY, V54, P340, DOI 10.1212/WNL.54.2.340; Vespa P, 2005, J CLIN NEUROPHYSIOL, V22, P99, DOI 10.1097/01.WNP.0000154919.54202.E0; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 1997, ELECTROEN CLIN NEURO, V103, P607, DOI 10.1016/S0013-4694(97)00071-0; Vespa PM, 2003, NEUROLOGY, V60, P1441, DOI 10.1212/01.WNL.0000063316.47591.B4; Vespa PM, 1999, J CLIN NEUROPHYSIOL, V16, P1, DOI 10.1097/00004691-199901000-00001; Wittman JJ, 2005, NEUROCRIT CARE, V2, P330, DOI 10.1385/NCC:2:3:330; YOUNG GB, 1990, CLIN INVEST MED, V13, P297; YOUNG GB, 1995, NEUROL CLIN, V13, P645, DOI 10.1016/S0733-8619(18)30037-9	31	226	230	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JUN	2009	37	6					2051	2056		10.1097/CCM.0b013e3181a00604			6	Critical Care Medicine	General & Internal Medicine	448ZK	WOS:000266300300031	19384197				2021-06-18	
J	Geeraerts, T; Merceron, S; Benhamou, D; Vigue, B; Duranteau, J				Geeraerts, Thomas; Merceron, Sybille; Benhamou, Dan; Vigue, Bernard; Duranteau, Jacques			Non-invasive assessment of intracranial pressure using ocular sonography in neurocritical care patients	INTENSIVE CARE MEDICINE			English	Article						Ocular ultrasound; Traumatic brain injury; Subarachnoid hemorrhage; Elevated intracranial pressure; Optic nerve sheath	OPTIC-NERVE SHEATH; HEAD-INJURY; ULTRASOUND; ULTRASONOGRAPHY; HYPERTENSION; FUNDAMENTALS; MANAGEMENT; EXPANSION; FAILURE; EDEMA	Objective: To assess the relationship between optic nerve sheath diameter (ONSD) and intracranial pressure (ICP) in neurocritical care patients. Design: Prospective, observational study. Setting: Surgical critical care unit, level 1 trauma center. Patients: A total number of 37 adult patients requiring sedation and ICP monitoring after severe traumatic brain injury, subarachnoid hemorrhage, intracranial hematoma, or stroke. Measurements and main results: Optic nerve sheath diameter was measured with a 7.5 MHz linear ultrasound probe. ICP was measured invasively via a parenchymal device. Simultaneous measurements were performed atleast once a day during the first 2 days after ICP insertion and in cases of acute changes. There was a significant relationship between ONSD and ICP (78 simultaneous measures, r = 0.71, P < 0.0001). Changes in ICP were strongly correlated with changes in ONSD (39 measures, r = 0.73, P < 0.0001). Enlarged ONSD was a suitable predictor of elevated ICP (> 20 mmHg) (area under ROC curve = 0.91). When ONSD was less than 5.86 mm, the negative likehood ratio for raised ICP was 0.06. Conclusion: In sedated neurocritical care patients, non-invasive sonographic measurements of ONSD are correlated with invasive ICP, and the probability to have raised ICP if ONSD is less than 5.86 mm is very low. This method could be used as a screening test when raised ICP is suspected.	[Geeraerts, Thomas; Merceron, Sybille; Benhamou, Dan; Vigue, Bernard; Duranteau, Jacques] Univ Paris Sud, CHU Bicetre, AP HP, Dept Anesthesie Reanimat Chirurg, F-94275 Le Kremlin Bicetre, France	Geeraerts, T (corresponding author), Univ Paris Sud, CHU Bicetre, AP HP, Dept Anesthesie Reanimat Chirurg, F-94275 Le Kremlin Bicetre, France.	thgeeraerts@hotmail.com					Ballantyne S A, 2002, Eur J Ultrasound, V15, P145, DOI 10.1016/S0929-8266(02)00036-8; BARLOW P, 1985, J NEUROSURG, V63, P578, DOI 10.3171/jns.1985.63.4.0578; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Berges O, 2006, J RADIOL, V87, P345, DOI 10.1016/S0221-0363(06)74012-4; Blaivas M, 2003, ACAD EMERG MED, V10, P376, DOI 10.1197/aemj.10.4.376; Blaivas M, 2002, ACAD EMERG MED, V9, P791, DOI 10.1197/aemj.9.8.791; CIVIL ID, 1988, J TRAUMA, V28, P87, DOI 10.1097/00005373-198801000-00012; GEERAERTS T, 2008, CRIT CARE S2, V12, pS46; Geeraerts T, 2007, INTENS CARE MED, V33, P1704, DOI 10.1007/s00134-007-0797-6; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Han MLK, 2006, CRIT CARE MED, V34, pS225, DOI 10.1097/01.CCM.0000231882.85350.71; Hansen HC, 1997, J NEUROSURG, V87, P34, DOI 10.3171/jns.1997.87.1.0034; Hansen HC, 1996, SURG RADIOL ANAT, V18, P323, DOI 10.1007/BF01627611; HAYREH SS, 1968, DOC OPHTHALMOL, V24, P289, DOI 10.1007/BF02550944; Helmke K, 2000, TRANSPLANTATION, V70, P392, DOI 10.1097/00007890-200007270-00029; Helmke K, 1996, PEDIATR RADIOL, V26, P706, DOI 10.1007/BF01383384; Helmke K, 1996, PEDIATR RADIOL, V26, P701, DOI 10.1007/BF01383383; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Lichtenstein D, 1992, ECHOGRAPHIE GEN REAN, P115; LIU D, 1993, AM J OPHTHALMOL, V116, P548, DOI 10.1016/S0002-9394(14)73195-2; MARSHALL LF, 1979, J NEUROSURG, V50, P26, DOI 10.3171/jns.1979.50.1.0026; Newman WD, 2002, BRIT J OPHTHALMOL, V86, P1109, DOI 10.1136/bjo.86.10.1109; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Ragauskas A, 2005, ACT NEUR S, V95, P357; Stocchetti N, 2007, INTENS CARE MED, V33, P1682, DOI 10.1007/s00134-007-0798-5; Tayal VS, 2006, ANN EMERG MED, V48, pS105; Villain MA, 2003, J FR OPHTALMOL, V26, P191; WARE AJ, 1971, GASTROENTEROLOGY, V61, P877	28	226	234	0	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	NOV	2008	34	11					2062	2067		10.1007/s00134-008-1149-x			6	Critical Care Medicine	General & Internal Medicine	364AN	WOS:000260308700018	18509619				2021-06-18	
J	Sykova, E; Homola, A; Mazanec, R; Lachmann, H; Konradova, SL; Kobylka, P; Padr, R; Neuwirth, J; Komrska, V; Vavra, V; Stulik, J; Bojar, M				Sykova, Eva; Homola, Ales; Mazanec, Radim; Lachmann, Hynek; Konradova, Simona Langkramer; Kobylka, Petr; Padr, Radek; Neuwirth, Jiri; Komrska, Vladimir; Vavra, Vladimir; Stulik, Jan; Bojar, Martin			Autologous bone marrow transplantation in patients with subacute and chronic spinal cord injury	CELL TRANSPLANTATION			English	Article						evoked potentials; magnetic resonance imaging; mesenchymal stem cells; regeneration; spinal cord injury; stem cells	MAGNETIC-RESONANCE TRACKING; COLONY-STIMULATING FACTOR; TRAUMATIC BRAIN INJURY; CENTRAL-NERVOUS-SYSTEM; EMBRYONIC STEM-CELLS; STROMAL CELLS; FUNCTIONAL RECOVERY; ADULT-RAT; PROMOTE REGENERATION; NEURONAL PHENOTYPES	Stem cell transplants into spinal cord lesions may help to improve regeneration and spinal cord function. Clinical studies are necessary for transferring preclinical findings from animal experiments to humans. We investigated the transplantation of unmanipulated autologous bond marrow in patients with transversal spinal cord injury (SCI) with respect to safety, therapeutic time window, implantation strategy, method of administration, and functional improvement. We report data from 20 patients with complete SCI who received transplants 10 to 467 days postinjury. The follow-up examinations were done at 3, 6,and 12 months after implantation by two independent neurologists using standard neurological classification of SCI, including the ASIA protocol, the Frankel score, the recording of motor and somatosensory evoked potentials, and MRI evaluation of lesion size. We compared intra-arterial (via catheterization of a. vertebralis) versus intravenous administration of all mononuclear cells in groups of acute (10-30 days post-SCI, n = 7) and chronic patients (2-17 months postinjury, n = 13). Improvement in motor and/or sensory functions was observed within 3 months in 5 of 6 patients with intra-arterial application, in 5 of 7 acute, and in 1 of 13 chronic patients. Our case study shows that the implantation of autologous bone marrow cells appears to be safe, as there have been no complications following implantation to date (11 patients followed up for more than 2 years), but longer follow-ups are required to determine that implantation is definitively safe. Also, we cannot yet confirm that the observed beneficial effects were due to the cell therapy. However, the outcomes following transplantation in acute patients, and in one chronic patient who was in stable condition for several months prior to cell implantation, are promising. It is evident that transplantation within a therapeutic window of 3-4 weeks following injury will play an important role in any type of stem cell SCI treatment. Trials involving a larger population of patients and different cell types are needed before further conclusions can be drawn.	Acad Sci Czech Republ, Inst Expt Med, Prague 14220 4, Czech Republic; Charles Univ Prague, Ctr Cell Therapy & Tissue Repair, Prague, Czech Republic; Charles Univ Prague, Dept Neurosci, Fac Med 2, Prague, Czech Republic; Univ Hosp Motol, Dept Neurol, Prague, Czech Republic; Inst Hematol & Blood Transfus, CR-12820 Prague, Czech Republic; Univ Hosp Motol, Dept Pediat Hematol & Oncol, Prague, Czech Republic; Univ Hosp Motol, Dept Imaging Methods, Prague, Czech Republic; Univ Hosp Motol, Dept Spondylosurg, Prague, Czech Republic	Sykova, E (corresponding author), Acad Sci Czech Republ, Inst Expt Med, Videnska 1083, Prague 14220 4, Czech Republic.	sykova@biomed.cas.cz	Neuwirth, Jiri/L-6052-2017; Sykova, Eva/H-2659-2014; Homola, Ales/H-2579-2014; Stulik, Jan/I-6650-2017	Neuwirth, Jiri/0000-0002-7004-4186; Stulik, Jan/0000-0002-8980-849X			Akiyama Y, 2002, GLIA, V39, P229, DOI 10.1002/glia.10102; Akiyama Y, 2002, J NEUROSCI, V22, P6623; Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; Bjorklund A, 2000, NAT NEUROSCI, V3, P537, DOI 10.1038/75705; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Burns AS, 2003, J NEUROTRAUM, V20, P477, DOI 10.1089/089771503765355540; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; Chong ZZ, 2002, J CEREBR BLOOD F MET, V22, P503, DOI 10.1097/00004647-200205000-00001; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; Dame C, 2003, DEV BRAIN RES, V143, P217, DOI 10.1016/S0165-3806(03)00134-2; Ditunno JF, 2004, SPINAL CORD, V42, P383, DOI 10.1038/sj.sc.3101603; EAVES CJ, 1991, BLOOD, V78, P110; Eglitis MA, 1999, NEUROREPORT, V10, P1289, DOI 10.1097/00001756-199904260-00025; Flanders AE, 1999, AM J NEURORADIOL, V20, P926; Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299; Inoue M, 2003, GLIA, V44, P111, DOI 10.1002/glia.10285; Iwanami A, 2005, J NEUROSCI RES, V80, P182, DOI 10.1002/jnr.20436; Jendelova P, 2003, MAGNET RESON MED, V50, P767, DOI 10.1002/mrm.10585; Jendelova P, 2004, J NEUROSCI RES, V76, P232, DOI 10.1002/jnr.20041; Kalyani AJ, 1998, J NEUROSCI, V18, P7856; Krause DS, 2002, GENE THER, V9, P754, DOI 10.1038/sj.gt.3301760; Kroger N, 2002, ANN HEMATOL, V81, P627, DOI 10.1007/s00277-002-0566-0; Lesny P, 2006, J MATER SCI-MATER M, V17, P829, DOI 10.1007/s10856-006-9842-1; Lesny P, 2002, J CHEM NEUROANAT, V23, P243, DOI 10.1016/S0891-0618(02)00011-X; Liu Y, 1999, J NEUROSCI, V19, P4370; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; Majumdar MK, 1998, J CELL PHYSIOL, V176, P57, DOI 10.1002/(SICI)1097-4652(199807)176:1<57::AID-JCP7>3.0.CO;2-7; Marino RJ, 1999, ARCH PHYS MED REHAB, V80, P1391, DOI 10.1016/S0003-9993(99)90249-6; MEHLER MF, 1993, NATURE, V362, P62, DOI 10.1038/362062a0; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Ogawa Y, 2002, J NEUROSCI RES, V69, P925, DOI 10.1002/jnr.10341; Ohta M, 2004, EXP NEUROL, V187, P266, DOI 10.1016/j.expneurol.2004.01.021; Okada S, 2005, FASEB J, V19, P1839, DOI 10.1096/fj.05-4082fje; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Park HC, 2005, TISSUE ENG, V11, P913, DOI 10.1089/ten.2005.11.913; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Saporta S, 2003, J HEMATOTH STEM CELL, V12, P271, DOI 10.1089/152581603322023007; Sasaki M, 2001, GLIA, V35, P26, DOI 10.1002/glia.1067; Sykova E, 2005, EXP NEUROL, V193, P261; Sykova E, 2005, ANN NY ACAD SCI, V1049, P146, DOI 10.1196/annals.1334.014; Sykova E, 2006, NEURODEGENER DIS, V3, P62, DOI 10.1159/000092095; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; Urdzikova L, 2006, J NEUROTRAUM, V23, P1379, DOI 10.1089/neu.2006.23.1379; Wang L, 2002, EXP HEMATOL, V30, P831, DOI 10.1016/S0301-472X(02)00829-9; Woerly S, 1998, J BIOMAT SCI-POLYM E, V9, P681, DOI 10.1163/156856298X00091; Woerly S, 2001, BIOMATERIALS, V22, P1095, DOI 10.1016/S0142-9612(00)00354-9; Woerly S, 2001, INT J DEV NEUROSCI, V19, P63, DOI 10.1016/S0736-5748(00)00064-2; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; Wu SF, 2003, J NEUROSCI RES, V72, P343, DOI 10.1002/jnr.10587	51	226	250	0	22	COGNIZANT COMMUNICATION CORP	ELMSFORD	3 HARTSDALE ROAD, ELMSFORD, NY 10523-3701 USA	0963-6897			CELL TRANSPLANT	Cell Transplant.		2006	15	8-9					675	687		10.3727/000000006783464381			13	Cell & Tissue Engineering; Medicine, Research & Experimental; Transplantation	Cell Biology; Research & Experimental Medicine; Transplantation	124MF	WOS:000243371200001	17269439				2021-06-18	
J	Wilson, BA; Emslie, HC; Quirk, K; Evans, JJ				Wilson, BA; Emslie, HC; Quirk, K; Evans, JJ			Reducing everyday memory and planning problems by means of a paging system: a randomised control crossover study	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						memory; rehabilitation; brain injury		Objectives-To evaluate a paging system designed to improve independence in people with memory problems and executive deficits. Methods-After a successful pilot study, a randomised control trial was conducted involving a crossover design with 143 people aged between 8 and 83 years. All had one or more of the following: memory, planning, attention, or organisation problems. Most had sustained a traumatic head injury or a stroke although a few had developmental learning difficulties or other conditions. The crossover design ensured that some people received a pager after a 2 week baseline whereas others were required to wait for 7 weeks after the baseline before receiving the pager. Participants were assessed at three time periods-namely, at baseline, 7 weeks, and at 14 weeks postbaseline. Results-More than 80% of those who completed the 16 week trial were significantly more successful in carrying out everyday activities (such as self care, self medication, and keeping appointments) when using the pager in comparison with the baseline period. For most of these, significant improvement was maintained when they were monitored 7 weeks after returning the pager. Conclusions-This particular paging system significantly reduces everyday failures of memory and planning in people with brain injury.	Addenbrookes Hosp, MRC, Cognit & Brain Sci Unit, Cambridge CB2 2QQ, England; Princess Wales Hosp, Oliver Zangwill Ctr Neuropsychol Rehabil, Ely CB6 1DN, England	Wilson, BA (corresponding author), Addenbrookes Hosp, MRC, Cognit & Brain Sci Unit, Box 58, Cambridge CB2 2QQ, England.						Baddeley A.D., 1992, SPEED CAPACITY LANGU; Evans JJ, 1998, J INT NEUROPSYCH SOC, V4, P399, DOI 10.1017/S1355617798003993; EVERITT BS, 1995, CAMBRIDGE DICT STAT; Hersh N A, 1994, NeuroRehabilitation, V4, P187, DOI 10.3233/NRE-1994-4309; Robertson I. H., 1994, TEST EVERYDAY ATTENT; ROBINSON BC, 1983, J GERONTOL, V38, P344, DOI 10.1093/geronj/38.3.344; Wilson B. A., 1985, RIVERMEAD BEHAV MEMO; Wilson BA, 1997, J NEUROL NEUROSUR PS, V63, P113, DOI 10.1136/jnnp.63.1.113; Wilson BA, 1999, REHABIL PSYCHOL, V44, P284, DOI 10.1037/0090-5550.44.3.284; Wilson BA, 1996, MEMORY, V4, P465, DOI 10.1080/741940776; Wilson BA, 1996, BEHAV ASSESSMENT DYS	11	226	227	0	18	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	APR	2001	70	4					477	482		10.1136/jnnp.70.4.477			6	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	416KB	WOS:000167778600011	11254770	Bronze, Green Published			2021-06-18	
J	PONSFORD, JL; OLVER, JH; CURRAN, C				PONSFORD, JL; OLVER, JH; CURRAN, C			A PROFILE OF OUTCOME - 2 YEARS AFTER TRAUMATIC BRAIN INJURY	BRAIN INJURY			English	Article							SEVERE HEAD-INJURY; FOLLOW-UP; RELATIVES VIEW	A group of 175 traumatic brain injury (TBI) patients who had undergone intensive rehabilitation at Bethesda Hospital attended a follow-up interview 2 years after injury. The majority of patients had suffered severe TBI. Outcome was documented in ten areas: medical/physical, mobility, activities of daily living (ADLs) accommodation, marital status, leisure and recreation, employment/study, communication, cognition and behaviour. Whilst most patients were physically independent and competent in personal and domestic activities of daily living, a third of the group were still reliant on assistance with community skills and transport, and more than half of those who previously had a job, were not working at 2 years post-injury. Around two-thirds of the sample reported cognitive, behavioural and emotional changes. There is clearly a need for ongoing community-based support and assistance in dealing with practical difficulties and psychological problems as they are experienced after return to the community.	BETHESDA HOSP,MELBOURNE,VIC,AUSTRALIA				Olver, John/0000-0001-7069-1191			BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; BROWN DSO, 1992, ARCH PHYS MED REHAB, V73, P758; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; KINSELLA G, 1990, J NEUROL NEUROSUR PS, V54, P422; Lezak M. D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI [10.1097/00001199-198703000-00009, DOI 10.1097/00001199-198703000-00009]; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P1; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P117; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019	15	226	232	0	18	TAYLOR & FRANCIS LTD LONDON	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	JAN	1995	9	1					1	10		10.3109/02699059509004565			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	QB052	WOS:A1995QB05200001	7874089				2021-06-18	
J	Polusny, MA; Kehle, SM; Nelson, NW; Erbes, CR; Arbisi, PA; Thuras, P				Polusny, Melissa A.; Kehle, Shannon M.; Nelson, Nathaniel W.; Erbes, Christopher R.; Arbisi, Paul A.; Thuras, Paul			Longitudinal Effects of Mild Traumatic Brain Injury and Posttraumatic Stress Disorder Comorbidity on Postdeployment Outcomes in National Guard Soldiers Deployed to Iraq	ARCHIVES OF GENERAL PSYCHIATRY			English	Article							MEDICALLY UNEXPLAINED SYMPTOMS; MENTAL-HEALTH PROBLEMS; PRIMARY-CARE; POSTCONCUSSIVE SYMPTOMS; COMBAT EXPOSURE; GULF-WAR; VETERANS; AFGHANISTAN; PTSD; ASSOCIATION	Context: Troops deployed to Iraq and Afghanistan are at high risk for exposure to combat events resulting in mild traumatic brain injury (MTBI) or concussion and posttraumatic stress disorder (PTSD). The longer-term impact of combat-related concussion/MTBI and comorbid PTSD on troops' health and well-being is unknown. Objective: To assess longitudinal associations between concussion/MTBI and PTSD symptoms reported in theater and longer-term psychosocial outcomes in combat-deployed National Guard soldiers. Design: Longitudinal cohort study. Participants were surveyed in Iraq 1 month before returning home (time 1) and 1 year later (time 2). Self-reports of concussion/MTBI and PTSD were assessed at times 1 and 2. Based on time 1 concussion/MTBI status (defined as an injury during deployment with loss of consciousness or altered mental status) and time 2 postdeployment probable PTSD status, soldiers were compared on a range of time 2 psychosocial outcomes. Participants: Nine hundred fifty-three US National Guard soldiers. Setting: The time 1 sample was assessed during redeployment transition briefings held at military installations in the Iraq combat theater. The time 2 sample was assessed using mailed surveys sent to the homes of US National Guard service members. Main Outcome Measures: Postconcussive, depression, and physical symptoms; alcohol use; social functioning; and quality of life assessed at time 2 using valid clinical instruments. Results: The rate of self-reported concussion/MTBI during deployment was 9.2% at time 1 and 22.0% at time 2. Soldiers with a history of concussion/MTBI were more likely than those without to report postdeployment postconcussive symptoms and poorer psychosocial outcomes. However, after adjusting for PTSD symptoms, concussion/MTBI was not associated with postdeployment symptoms or outcomes. Time 1 PTSD symptoms more strongly predicted postdeployment symptoms and outcomes than did concussion/MTBI history. Conclusions: Although combat-related PTSD was strongly associated with postconcussive symptoms and psychosocial outcomes 1 year after soldiers returned from Iraq, there was little evidence of a long-term negative impact of concussion/MTBI history on these outcomes after accounting for PTSD. These findings and the 2-fold increase in reports of deployment-related concussion/MTBI history have important implications for screening and treatment.	[Polusny, Melissa A.; Nelson, Nathaniel W.; Erbes, Christopher R.; Arbisi, Paul A.; Thuras, Paul] Minneapolis Vet Affairs Hlth Care Syst, Mental Hlth Patient Serv Line, Minneapolis, MN USA; [Kehle, Shannon M.] Minneapolis Vet Affairs Hlth Care Syst, Res Serv, Minneapolis, MN USA; [Polusny, Melissa A.; Kehle, Shannon M.] Univ Minnesota, Sch Med, Ctr Chron Dis Outcomes Res, Minneapolis, MN 55455 USA; [Polusny, Melissa A.; Nelson, Nathaniel W.; Erbes, Christopher R.; Arbisi, Paul A.; Thuras, Paul] Univ Minnesota, Sch Med, Dept Psychiat, Minneapolis, MN 55455 USA; [Arbisi, Paul A.] Univ Minnesota, Sch Med, Dept Psychol, Minneapolis, MN 55455 USA	Polusny, MA (corresponding author), Minneapolis Vet Affairs Hlth Care Syst 116A9, 1 Vet Dr, Minneapolis, MN 55417 USA.	melissa.polusny@va.gov	Polusny, Melissa/X-8158-2019; Polusny, Melissa Anderson/N-8112-2014	Polusny, Melissa/0000-0002-4932-305X; Polusny, Melissa Anderson/0000-0002-4932-305X	VA, Veterans Health Administration, Office of Research and Development [08-252]	Funding/Support: This study is based on work supported in part by Rapid Response Project 08-252 from the VA, Veterans Health Administration, Office of Research and Development, and is the result of work supported with resources and the use of facilities at the Minneapolis VA Health Care System.	Allen JP, 1997, ALCOHOL CLIN EXP RES, V21, P613, DOI 10.1097/00000374-199706000-00008; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Beck AT., 1996, BECK DEPRESSION INVE, V2; Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272; Bonomi A, 1997, USERS MANUAL INTERPR; Bush K, 1998, ARCH INTERN MED, V158, P1789, DOI 10.1001/archinte.158.16.1789; Carlson K, 2009, ASSESSMENT TREATMENT; Cohen BE, 2010, J GEN INTERN MED, V25, P18, DOI 10.1007/s11606-009-1117-3; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; [Department of Veterans Affairs Office of Research and Development National Institute of Mental Health United States Army Medical Research and Materiel Command], 2006, MAPP LANDSC DEPL REL; Dohrenwend BP, 2007, J TRAUMA STRESS, V20, P449, DOI 10.1002/jts.20296; Engel CC, 2000, PSYCHOSOM MED, V62, P739, DOI 10.1097/00006842-200011000-00001; Fear NT, 2009, PSYCHOL MED, V39, P1379, DOI 10.1017/S0033291708004595; Ferrier-Auerbach AG, 2010, J PSYCHIATR RES, V44, P470, DOI 10.1016/j.jpsychires.2009.10.010; Grubaugh AL, 2005, J NERV MENT DIS, V193, P658, DOI 10.1097/01.nmd.0000180740.02644.ab; Gunstad J, 2002, J INT NEUROPSYCH SOC, V8, P37, DOI 10.1017/S1355617701020045; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Howe LLS, 2009, CLIN NEUROPSYCHOL, V23, P1315, DOI 10.1080/13854040903266928; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Iverson GL, 2009, CLIN NEUROPSYCHOL, V23, P1299, DOI 10.1080/13854040903153902; Kehle S, 2010, J PSYCHIATR RES, DOI [10.1016/j.jpsychires.2010.050013, DOI 10.1016/J.JPSYCHIRES.2010.050013]; King LA, 2006, MIL PSYCHOL, V18, P89, DOI 10.1207/s15327876mp1802_1; Koenen KC, 2003, J TRAUMA STRESS, V16, P433, DOI 10.1023/A:1025786925483; Marx BP, 2009, ARCH GEN PSYCHIAT, V66, P996, DOI 10.1001/archgenpsychiatry.2009.109; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2008, MILD TRAUMATIC BRAIN; McCrea M, 2008, CLIN NEUROPSYCHOL, V22, P10, DOI 10.1080/13854040701760981; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Paniak C, 2002, ARCH CLIN NEUROPSYCH, V17, P319, DOI 10.1016/S0887-6177(01)00115-9; *PC CAR AM RET WOU, 2007, SERV SUPP SIMPL REP; Pietrzak RH, 2009, J NERV MENT DIS, V197, P748, DOI 10.1097/NMD.0b013e3181b97a75; Polusny MA, PSYCHOL MED IN PRESS; Prigerson HG, 2001, J NERV MENT DIS, V189, P99, DOI 10.1097/00005053-200102000-00005; Richardson RD, 2004, NEUROLOGIST, V10, P18, DOI 10.1097/01.nrl.0000106921.76055.24; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Savoca Elizabeth, 2000, J Ment Health Policy Econ, V3, P199, DOI 10.1002/mhp.102; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schnurr PP, 1999, J NERV MENT DIS, V187, P353, DOI 10.1097/00005053-199906000-00004; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Smith RC, 2006, J GEN INTERN MED, V21, P671, DOI 10.1111/j.1525-1497.2006.00460.x; Smith RC, 2003, J GEN INTERN MED, V18, P478, DOI 10.1046/j.1525-1497.2003.20815.x; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Sundin J, 2010, PSYCHOL MED, V40, P367, DOI 10.1017/S0033291709990791; Task Force on Returning Global War on Terror Heroes, 2007, TASK FORC REP; Terhakopian A, 2008, J TRAUMA STRESS, V21, P290, DOI 10.1002/jts.20341; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; US Government Accountability Office, 2008, VA HLTH CAR MILD TRA; Vasterling JJ, 2009, CLIN PSYCHOL REV, V29, P674, DOI 10.1016/j.cpr.2009.08.004; Vogt DS, 2008, ASSESSMENT, V15, P381, DOI 10.1177/1073191108316030; Weathers F.W., 1993, PTSD CHECKLIST PCL R; WEISSMAN MM, 1976, ARCH GEN PSYCHIAT, V33, P1111; Wessely S, 2003, BRIT J PSYCHIAT, V183, P314, DOI 10.1192/bjp.183.4.314; Widome R, AM J HLTH B IN PRESS	64	225	226	1	33	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0003-990X	1538-3636		ARCH GEN PSYCHIAT	Arch. Gen. Psychiatry	JAN	2011	68	1					79	89		10.1001/archgenpsychiatry.2010.172			11	Psychiatry	Psychiatry	702WY	WOS:000285927800015	21199967	Bronze			2021-06-18	
J	Tiainen, M; Roine, RO; Pettila, V; Takkunen, O				Tiainen, M; Roine, RO; Pettila, V; Takkunen, O			Serum neuron-specific enolase and S-100B protein in cardiac arrest patients treated with hypothermia	STROKE			English	Article						heart arrest; hypothermia; nerve tissue protein S-100; neuron-specific enolase	TRAUMATIC BRAIN INJURY; REGAINING CONSCIOUSNESS; CEREBROSPINAL-FLUID; COMATOSE SURVIVORS; EARLY PREDICTOR; DAMAGE; STROKE; SURGERY; MARKER; S100B	Background and Purpose - High serum levels of neuron- specific enolase ( NSE) and S- 100B protein are known to be associated with ischemic brain injury and poor outcome after cardiac arrest. Therapeutic hypothermia has been shown to improve neurological outcome after cardiac arrest. The aim of this study was to evaluate the effect of therapeutic hypothermia on levels of serum NSE and S- 100B protein, their time course, and their prognostic value in predicting unfavorable outcome after out- of- hospital cardiac arrest. Methods - Seventy patients resuscitated from ventricular fibrillation were randomly assigned to hypothermia of 33 +/- 1degreesC for 24 hours or to normothermia. Serum NSE and S- 100B were sampled at 24, 36, and 48 hours after cardiac arrest. Neurological outcome was dichotomized into good or poor at 6 months after cardiac arrest. Results - The levels of NSE ( P = 0.007 by analysis of variance for repeated measurements) but not S- 100B were lower in hypothermia- than normothermia- treated patients. A decrease in NSE values between 24 and 48 hours was observed in 30 of 34 patients ( 88%) in the hypothermia group and in 16 of 32 patients ( 50%) in the normothermia group ( P < 0.001). The decrease in NSE values was associated with good outcome at 6 months after cardiac arrest ( P = 0.005), recovery of consciousness ( P < 0.001), and survival for at least 6 months after cardiac arrest ( P = 0.012). Conclusions - Decreasing levels of serum NSE but not S- 100B over time may indicate selective attenuation of delayed neuronal death by therapeutic hypothermia in victims of cardiac arrest.	Univ Helsinki, Cent Hosp, Dept Neurol, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Anesthesiol & Intens Care Med, FIN-00014 Helsinki, Finland	Tiainen, M (corresponding author), Meilahti Hosp, Dept Neurol, Haartmaninkatu 4,PB 340, FIN-00029 Hus, Finland.						ABRAMSON NS, 1991, NEW ENGL J MED, V324, P1225; Anderson RE, 2001, ANN THORAC SURG, V71, P1512, DOI 10.1016/S0003-4975(01)02399-2; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Bottiger BW, 2001, CIRCULATION, V103, P2694; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; CUNNINGHAM RT, 1991, EUR J CLIN INVEST, V21, P497, DOI 10.1111/j.1365-2362.1991.tb01401.x; Elting JW, 2000, J NEUROL SCI, V181, P104, DOI 10.1016/S0022-510X(00)00442-1; Fogel W, 1997, CRIT CARE MED, V25, P1133, DOI 10.1097/00003246-199707000-00012; GINSBERG MD, 1992, CEREBROVAS BRAIN MET, V4, P189; Hachimi-Idrissi S, 2002, RESUSCITATION, V53, P251, DOI 10.1016/S0300-9572(02)00027-8; Holzer M, 2002, NEW ENGL J MED, V346, P549; JENNETT B, 1975, LANCET, V1, P480; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; Jonsson H, 2001, ANN THORAC SURG, V71, P1433, DOI 10.1016/S0003-4975(00)02612-6; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; Martens P, 1996, ACAD EMERG MED, V3, P126, DOI 10.1111/j.1553-2712.1996.tb03399.x; Martens P, 1998, STROKE, V29, P2363, DOI 10.1161/01.STR.29.11.2363; Meynaar IA, 2003, INTENS CARE MED, V29, P189, DOI 10.1007/s00134-002-1573-2; Missler U, 1997, STROKE, V28, P1956, DOI 10.1161/01.STR.28.10.1956; ROINE RO, 1989, ARCH NEUROL-CHICAGO, V46, P753, DOI 10.1001/archneur.1989.00520430047015; Rosen H, 1998, STROKE, V29, P473, DOI 10.1161/01.STR.29.2.473; Rosen H, 2001, RESUSCITATION, V49, P183, DOI 10.1016/S0300-9572(00)00348-8; SCHMECHEL D, 1978, SCIENCE, V199, P313, DOI 10.1126/science.339349; SCHMECHEL D, 1978, NATURE, V276, P834, DOI 10.1038/276834a0; Schoerkhuber W, 1999, STROKE, V30, P1598, DOI 10.1161/01.STR.30.8.1598; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	28	225	242	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0039-2499			STROKE	Stroke	DEC	2003	34	12					2881	2886		10.1161/01.STR.0000103320.90706.35			6	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	750FP	WOS:000186980900023	14631087	Bronze			2021-06-18	
J	Thurman, DJ; Branche, CM; Sniezek, JE				Thurman, DJ; Branche, CM; Sniezek, JE			The epidemiology of sports-related traumatic brain injuries in the United States: Recent developments	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; epidemiology; incidence; mortality; primary prevention; public health; sports		We examined recent population-based data from the National Health Interview Survey, Consumer Product Safety Commission, and state-based traumatic brain injury (TBI) surveillance programs that provide estimates of the overall incidence of sports-related TBI in the United States. Available data indicate that sports-related TBI is an important public health problem because of the large number of people mho incur these injuries each year (approximately 300,000), the generally young age of patients at the time of injury (with possible long-term disability), and the potential cumulative effects of repeated injuries. The importance of this problem indicates the need for more effective prevention measures. The public health approach can guide efforts in injury prevention and control. The steps in this approach are (1) identifying the problem, (2) identifying risk factors, (3) developing and testing interventions, and (4) implementing programs and evaluating outcomes. Each of these steps requires adequate data. This article examines the limitations of current sports-related TBI data and suggests ways to improve data in order to develop more effective injury prevention strategies. The impact of sports-related TBI on the public indicates that this task deserves a high priority.	Ctr Dis Control & Prevent, Div Acute Care Rehabil Res & Disabil Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA; Ctr Dis Control & Prevent, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA	Thurman, DJ (corresponding author), Ctr Dis Control & Prevent, Div Acute Care Rehabil Res & Disabil Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Highway NE,Mailstop F41, Atlanta, GA 30341 USA.			Thurman, David/0000-0002-0533-7062			ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Baker SP, 1992, THE INJURY FACT BOOK; Caine C, 1996, EPIDEMIOLOGY SPORTS; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P224; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P8; DACEY RG, 1993, HEAD INJURY; FRYE RE, 1994, ASTM STP, V1229; HOERNER EF, 1994, ASTM STP, V1229; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; KRAUS JF, 1984, ANNU REV PUBL HEALTH, V5, P163; Mueller F O, 1991, Exerc Sport Sci Rev, V19, P261; *NAT COMM INJ PREV, 1989, INJ PREV M CHALL; NELSON DE, 1994, AM J PREV MED, V10, P15; NELSON DE, 1994, PHYSICIAN SPORTSMED, V22, P53, DOI 10.1080/00913847.1994.11710501; Sosin DM, 1996, BRAIN INJURY, V10, P47; Thurman DJ., 1995, GUIDELINES SURVEILLA; *US DEP HHS, 1989, INT CLASS DIS; Wallace R B, 1988, Am J Sports Med, V16 Suppl 1, pS22; World Health Organization, 1992, ICD 10 INT STAT CLAS	19	225	229	1	17	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	APR	1998	13	2					1	8		10.1097/00001199-199804000-00003			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	ZF451	WOS:000072898800003	9575252				2021-06-18	
J	Hansen, ECA; Battaglia, D; Spiegler, A; Deco, G; Jirsa, VK				Hansen, Enrique C. A.; Battaglia, Demian; Spiegler, Andreas; Deco, Gustavo; Jirsa, Viktor K.			Functional connectivity dynamics: Modeling the switching behavior of the resting state	NEUROIMAGE			English	Article						Functional connectivity; Functional connectivity dynamics; Structural connectivity; Resting state; Brain dynamics; Whole brain computational model	CEREBRAL-CORTEX; BRAIN; NETWORKS; PATTERNS; OSCILLATIONS; CRITICALITY; INTEGRATION	Functional connectivity (FC) sheds light on the interactions between different brain regions. Besides basic research, it is clinically relevant for applications in Alzheimer's disease, schizophrenia, presurgical planning, epilepsy, and traumatic brain injury. Simulations of whole-brain mean-field computational models with realistic connectivity determined by tractography studies enable us to reproduce with accuracy aspects of average FC in the resting state. Most computational studies, however, did not address the prominent non-stationarity in resting state FC, which may result in large intra-and inter-subject variability and thus preclude an accurate individual predictability. Here we show that this non-stationarity reveals a rich structure, characterized by rapid transitions switching between a few discrete FC states. We also show that computational models optimized to fit time-averaged FC do not reproduce these spontaneous state transitions and, thus, are not qualitatively superior to simplified linear stochastic models, which account for the effects of structure alone. We then demonstrate that a slight enhancement of the non-linearity of the network nodes is sufficient to broaden the repertoire of possible network behaviors, leading to modes of fluctuations, reminiscent of some of the most frequently observed Resting State Networks. Because of the noise-driven exploration of this repertoire, the dynamics of FC qualitatively change now and display non-stationary switching similar to empirical resting state recordings (Functional Connectivity Dynamics (FCD)). Thus FCD bear promise to serve as a better biomarker of resting state neural activity and of its pathologic alterations. (C) 2014 The Authors. Published by Elsevier Inc.	[Hansen, Enrique C. A.; Battaglia, Demian; Spiegler, Andreas; Jirsa, Viktor K.] Univ Aix Marseille, INSERM, Inst Neurosci Syst, UMR 1106, F-13005 Marseille, France; [Battaglia, Demian] Bernstein Ctr Computat Neurosci, D-37077 Gottingen, Germany; [Deco, Gustavo] Univ Pompeu Fabra, Ctr Brain & Cognit, Barcelona, Spain	Battaglia, D (corresponding author), Univ Aix Marseille, INSERM, Inst Neurosci Syst, UMR 1106, 27 Bd Jean Moulin, F-13005 Marseille, France.	enrique-carlos.hansen@etu.univ-amu.fr; demian.battaglia@univ-amu.fr; andreas.spiegler@univ-amu.fr; gustavo.deco@upf.edu; viktor.jirsa@univ-amu.fr	Jirsa, Viktor/M-4630-2016; Battaglia, Demian/C-1281-2017; DECO, GUSTAVO/A-6341-2008	Jirsa, Viktor/0000-0002-8251-8860; Battaglia, Demian/0000-0003-2021-7920; DECO, GUSTAVO/0000-0002-8995-7583; Spiegler, Andreas/0000-0002-6673-052X	Brain Network Recovery Group through the James S. McDonnell Foundation; European Union Seventh Framework Programme (FP7-ICT BrainScales and Human Brain Project) [60402]; Marie Curie career development fellowship FP7-IEF [330792]; Federal Ministry of Education and Research (BMBF) GermanyFederal Ministry of Education & Research (BMBF) [01GQ1005B]	The research reported herein was supported by the Brain Network Recovery Group through the James S. McDonnell Foundation and funding from the European Union Seventh Framework Programme (FP7-ICT BrainScales and Human Brain Project (grant no. 60402)). DB was supported by the Marie Curie career development fellowship FP7-IEF 330792 (DynViB) and by the Federal Ministry of Education and Research (BMBF) Germany under grant number 01GQ1005B. We thank Patrick Hagmann and his group for providing the empirical data.	Allen E.A., 2012, CEREB CORTEX; Battaglia D, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002438; Beggs JM, 2003, J NEUROSCI, V23, P11167; Birn RM, 2006, NEUROIMAGE, V31, P1536, DOI 10.1016/j.neuroimage.2006.02.048; Bressler SL, 2001, TRENDS COGN SCI, V5, P26, DOI 10.1016/S1364-6613(00)01564-3; Britz J, 2010, NEUROIMAGE, V52, P1162, DOI 10.1016/j.neuroimage.2010.02.052; Cabral J, 2011, NEUROIMAGE, V57, P130, DOI 10.1016/j.neuroimage.2011.04.010; Damoiseaux JS, 2006, P NATL ACAD SCI USA, V103, P13848, DOI 10.1073/pnas.0601417103; Damoiseaux JS, 2009, BRAIN STRUCT FUNCT, V213, P525, DOI 10.1007/s00429-009-0208-6; Deco G, 2013, J NEUROSCI, V33, P11239, DOI 10.1523/JNEUROSCI.1091-13.2013; Deco G, 2013, TRENDS NEUROSCI, V36, P268, DOI 10.1016/j.tins.2013.03.001; Deco G, 2012, FRONT COMPUT NEUROSC, V6, DOI 10.3389/fncom.2012.00068; Deco G, 2012, J NEUROSCI, V32, P3366, DOI 10.1523/JNEUROSCI.2523-11.2012; Deco G, 2011, NAT REV NEUROSCI, V12, P43, DOI 10.1038/nrn2961; Deco G, 2009, P NATL ACAD SCI USA, V106, P10302, DOI 10.1073/pnas.0901831106; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Doucet G, 2012, NEUROIMAGE, V59, P3194, DOI 10.1016/j.neuroimage.2011.11.059; Ferreira LK, 2013, NEUROSCI BIOBEHAV R, V37, P384, DOI 10.1016/j.neubiorev.2013.01.017; Friston KJ, 2011, BRAIN CONNECT, V1, P13, DOI 10.1089/brain.2011.0008; Friston KJ, 2003, NEUROIMAGE, V19, P1273, DOI 10.1016/S1053-8119(03)00202-7; Galan RF, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002148; Ghosh A, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000196; Goni J, 2014, P NATL ACAD SCI USA, V111, P833, DOI 10.1073/pnas.1315529111; Gusnard DA, 2001, NAT REV NEUROSCI, V2, P685, DOI 10.1038/35094500; Hagmann P, 2008, PLOS BIOL, V6, P1479, DOI 10.1371/journal.pbio.0060159; Hartigan J. A., 1979, Applied Statistics, V28, P100, DOI 10.2307/2346830; Honey CJ, 2007, P NATL ACAD SCI USA, V104, P10240, DOI 10.1073/pnas.0701519104; Horsthemke W., 2006, NOISE INDUCED TRANSI, Vsecond; Hutchison RM, 2013, NEUROIMAGE, V80, P360, DOI 10.1016/j.neuroimage.2013.05.079; Jones DT, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039731; Laird AR, 2011, J COGNITIVE NEUROSCI, V23, P4022, DOI 10.1162/jocn_a_00077; Leon PS, 2013, FRONT NEUROINFORM, V7, DOI 10.3389/fninf.2013.00010; Liu X, 2013, P NATL ACAD SCI USA, V110, P4392, DOI 10.1073/pnas.1216856110; Mannella R, 2002, INT J MOD PHYS C, V13, P1177, DOI 10.1142/S0129183102004042; Mantini D, 2007, P NATL ACAD SCI USA, V104, P13170, DOI 10.1073/pnas.0700668104; Manuca R, 1996, PHYSICA D, V99, P134, DOI 10.1016/S0167-2789(96)00139-X; Menon V, 2011, TRENDS COGN SCI, V15, P483, DOI 10.1016/j.tics.2011.08.003; Messe A, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003530; Miller P, 2003, CEREB CORTEX, V13, P1208, DOI 10.1093/cercor/bhg101; Moretti P, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3521; Mueller S, 2013, NEURON, V77, P586, DOI 10.1016/j.neuron.2012.12.028; Rabinovich M, 2008, SCIENCE, V321, P48, DOI 10.1126/science.1155564; Raichle ME, 2006, ANNU REV NEUROSCI, V29, P449, DOI 10.1146/annurev.neuro.29.051605.112819; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Saad ZS, 2012, BRAIN CONNECT, V2, P25, DOI 10.1089/brain.2012.0080; Sakoglu U, 2010, MAGN RESON MATER PHY, V23, P351, DOI 10.1007/s10334-010-0197-8; Van de Ville D, 2010, P NATL ACAD SCI USA, V107, P18179, DOI 10.1073/pnas.1007841107; Wong KF, 2006, J NEUROSCI, V26, P1314, DOI 10.1523/JNEUROSCI.3733-05.2006	48	224	224	2	71	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	JAN 15	2015	105						525	535		10.1016/j.neuroimage.2014.11.001			11	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	AW1LG	WOS:000346050300047	25462790	Green Published, Other Gold	Y	N	2021-06-18	
J	Mathias, JL; Alvaro, PK				Mathias, J. L.; Alvaro, P. K.			Prevalence of sleep disturbances, disorders, and problems following traumatic brain injury: A meta-analysis	SLEEP MEDICINE			English	Article						Traumatic brain injury; Sleep; Sleep disorders; Sleep problems; Prevalence; Meta-analysis	EXCESSIVE DAYTIME SLEEPINESS; PSYCHIATRIC-DISORDERS; GENERAL-POPULATION; HEAD-INJURY; INSOMNIA; COMPLAINTS; QUALITY; APNEA; CONSEQUENCES; FREQUENCY	Background: Sleep is often disrupted following a traumatic brain injury (TBI), which may compromise recovery and quality of life. Prevalence rates vary widely, reflecting differences in the criteria and measures that are used to assess sleep, as well as sample differences. This meta-analysis examined the prevalence of general and specific, and formally and informally diagnosed, sleep disturbances following TBI in order to establish the nature and extent of these sequelae and their potential impact on recovery. Methods: Data from 21 studies, which assessed (1) sleep disturbances, regardless of type or severity, (2) diagnosed sleep disorders, and (3) specific sleep problems following TBI, were analyzed and compared to data for the general population. Results: Overall, 50% of people suffered from some form of sleep disturbance after a TBI and 25-29% had a diagnosed sleep disorder (insomnia, hypersomnia, apnea) - rates that are much higher than those seen in the general population. They were also two to four times more likely to experience problems with sleep maintenance and efficiency, nightmares, excessive sleepiness, early awakenings, and sleep walking. Conclusion: Sleep disturbances are very common after TBI and have the potential to seriously undermine patient rehabilitation, recovery, and outcomes; making it important to routinely screen for such problems in order to assess both treatment needs and their potential impact on recovery and outcome. Crown Copyright (C) 2012 Published by Elsevier B.V. All rights reserved.	[Mathias, J. L.; Alvaro, P. K.] Univ Adelaide, Sch Psychol, Adelaide, SA 5005, Australia	Mathias, JL (corresponding author), Univ Adelaide, Sch Psychol, Adelaide, SA 5005, Australia.	jane.mathias@adelaide.edu.au	Mathias, J L/L-6295-2013; Lang, Steven/AAE-8102-2021	Lang, Steven/0000-0003-1669-9146; Mathias, Jane/0000-0001-8957-8594			American Academy of Sleep Medicine, 2001, INT CLASS SLEEP DIS, P208; American Academy of Sleep Medicine, 1990, INT CLASS SLEEP DIS; American Academy of Sleep Medicine, 2005, INT CLASS SLEEP DIS, V2nd; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Bixler EO, 2005, J CLIN ENDOCR METAB, V90, P4510, DOI 10.1210/jc.2005-0035; Bixler EO, 2001, AM J RESP CRIT CARE, V163, P608, DOI 10.1164/ajrccm.163.3.9911064; Breslau N, 1996, BIOL PSYCHIAT, V39, P411, DOI 10.1016/0006-3223(95)00188-3; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P17, DOI 10.1097/01.HTR.0000308717.80590.22; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Castriotta RJ, 2009, J CLIN SLEEP MED, V5, P137; Chaumet G, 2008, NEUROLOGY, V71, P1609, DOI 10.1212/01.wnl.0000334753.49193.48; COHEN M, 1992, J NEUROL NEUROSUR PS, V55, P313, DOI 10.1136/jnnp.55.4.313; Datta SGS, 2009, NEUROL INDIA, V57, P594, DOI 10.4103/0028-3886.57810; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; Deb S, 2007, BRAIN INJURY, V21, P301, DOI 10.1080/02699050701253137; Fichtenberg NL, 2000, BRAIN INJURY, V14, P659; Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940; Fichtenberg NL, 2001, AM J PHYS MED REHAB, V80, P339, DOI 10.1097/00002060-200105000-00003; FINDLEY LJ, 1989, NEW ENGL J MED, V320, P868; FORD DE, 1989, JAMA-J AM MED ASSOC, V262, P1479, DOI 10.1001/jama.262.11.1479; HAIMOV I, 1994, BRIT MED J, V309, P167, DOI 10.1136/bmj.309.6948.167; Hedges L.V., 1985, STAT METHODS META AN; Hossain Jamil L, 2002, Sleep Breath, V6, P85, DOI 10.1055/s-2002-32322; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Kaiser PR, 2010, NEUROLOGY, V75, P1780, DOI 10.1212/WNL.0b013e3181fd62a2; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; KLINK M, 1987, CHEST, V91, P540, DOI 10.1378/chest.91.4.540; Lipsey M.W., 2001, PRACTICAL META ANAL; Mahmood O, 2004, J HEAD TRAUMA REHAB, V19, P378, DOI 10.1097/00001199-200409000-00003; Makley MJ, 2008, NEUROREHAB NEURAL RE, V22, P341, DOI 10.1177/1545968308315598; Makley MJ, 2009, NEUROREHAB NEURAL RE, V23, P320, DOI 10.1177/1545968308325268; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; NORTON PG, 1985, BRIT MED J, V291, P630, DOI 10.1136/bmj.291.6496.630; Ohayon MM, 1999, J CLIN PSYCHIAT, V60, P268, DOI 10.4088/JCP.v60n0413; Ohayon MM, 2002, J PSYCHOSOM RES, V53, P547, DOI 10.1016/S0022-3999(02)00443-9; Ohayon MM, 2001, J PSYCHOSOM RES, V51, P745, DOI 10.1016/S0022-3999(01)00285-9; Ohayon MM, 2002, NEUROLOGY, V58, P1826, DOI 10.1212/WNL.58.12.1826; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Ouellet MC, 2004, NEUROREHAB NEURAL RE, V18, P187, DOI 10.1177/1545968304271405; Parcell DL, 2008, ARCH PHYS MED REHAB, V89, P843, DOI 10.1016/j.apmr.2007.09.057; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; Perlis ML, 1997, PERCEPT MOTOR SKILL, V84, P595, DOI 10.2466/pms.1997.84.2.595; POCETA JS, 1998, SLEEP DISORDERS DIAG; Rao V, 2011, J NEUROPSYCH CLIN N, V23, P201, DOI 10.1176/appi.neuropsych.23.2.201; Rao Vani, 2002, Curr Treat Options Neurol, V4, P77, DOI 10.1007/s11940-002-0006-4; ROSENTHAL R, 1995, PSYCHOL BULL, V118, P183, DOI 10.1037/0033-2909.118.2.183; Schreiber S, 2008, SLEEP MED, V9, P481, DOI 10.1016/j.sleep.2007.04.014; Silver MJ, 2005, TXB TRAUMATIC BRAIN; Sumpter RE, 2006, BRAIN INJURY, V20, P93, DOI 10.1080/02699050500394090; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Watson NF, 2007, J CLIN SLEEP MED, V3, P363; Webster JB, 2001, ARCH PHYS MED REHAB, V82, P316, DOI 10.1053/apmr.2001.20840; Welstein L, 1983, SLEEP WAKE DISORDERS, P29; Wilde MC, 2007, ARCH PHYS MED REHAB, V88, P1284, DOI 10.1016/j.apmr.2007.07.012; Worthington AD, 2006, BRAIN INJURY, V20, P327, DOI 10.1080/02699050500488249; Wu H, 1996, NEUROLOGY, V46, P1254, DOI 10.1212/WNL.46.5.1254; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; Zeitzer JM, 2009, J REHABIL RES DEV, V46, P827, DOI 10.1682/JRRD.2008.08.0099	62	224	227	1	21	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	1389-9457	1878-5506		SLEEP MED	Sleep Med.	AUG	2012	13	7					898	905		10.1016/j.sleep.2012.04.006			8	Clinical Neurology	Neurosciences & Neurology	992AL	WOS:000307747000022	22705246				2021-06-18	
J	Young, AE; Wasiak, R; Roessler, RT; McPherson, KM; Anema, JR; van Poppel, MNM				Young, AE; Wasiak, R; Roessler, RT; McPherson, KM; Anema, JR; van Poppel, MNM			Return-to-work outcomes following work disability: Stakeholder motivations, interests and concerns	JOURNAL OF OCCUPATIONAL REHABILITATION			English	Article						return to work; work disability; stakeholders; outcomes research; outcome measurement; employment outcomes	LOW-BACK-PAIN; COMPENSATION HEALTH-CARE; TRAUMATIC BRAIN-INJURY; WASHINGTON-STATE; GOAL COMMITMENT; OCCUPATIONAL-MEDICINE; UPPER EXTREMITY; UNITED-STATES; RISK-FACTORS; REHABILITATION	Introduction: Satisfaction with return-to-work (RTW) outcomes is dependent on many factors, including a clear exposition of what people define as a "good outcome" and the information they use to determine if such an outcome has been achieved. This paper defines the key stakeholders involved in the RTW process and discusses the need to understand their motivations, interests, and concerns. Methods:A review of the literature and discussions with RTW researchers conducted by a multidisciplinary group of academic researchers. Results: Our analysis suggests that RTW stakeholders can share the goal of a successful RTW; however, this consensus has to be viewed in light of other, sometimes competing, goals and the environments in which stakeholders operate. Conclusions: It is suggested that more clearly articulating and operationalizing stakeholders' perspectives will allow researchers to advance the understanding of RTW interventions and outcomes.	Liberty Mutual Res Inst Safety, Ctr Disabil Res, Hopkinton, MA 01748 USA; Univ Arkansas, Coll Educ & Hlth Profess, Rrehabil Human Resources & Commun Disorders Dept, Fayetteville, AR 72701 USA; Auckland Univ Technol, Div Rehabil & Occupat Studies, Ctr Phys Rehabil Res, Auckland, New Zealand; Vrije Univ Amsterdam, Ctr Med, Dept Publ & Occupat Hlth, Inst Res Extramural Med, NL-1081 HV Amsterdam, Netherlands	Young, AE (corresponding author), Liberty Mutual Res Inst Safety, Ctr Disabil Res, 71 Frankland Rd, Hopkinton, MA 01748 USA.	amandae.young@libertymutual.com	Van Poppel, Mireille/AAL-8228-2020; Young, Amanda/H-8851-2016	Van Poppel, Mireille/0000-0001-5694-4324; McPherson, Kathryn/0000-0003-1240-8882; Young, Amanda/0000-0002-7288-3469; McPherson, Kath/0000-0003-0487-8497			ABENHAIM L, 1988, BRIT J IND MED, V45, P829; Amick BC, 2000, SPINE, V25, P3152, DOI 10.1097/00007632-200012150-00010; Amick BC, 2000, J OCCUP REHABIL, V10, P21, DOI 10.1023/A:1009437728024; Anema JR, 2002, OCCUP ENVIRON MED, V59, P729, DOI 10.1136/oem.59.11.729; Atlas SJ, 2004, SPINE, V29, P1041, DOI 10.1097/00007632-200405010-00017; BICKENBACH JE, 2001, HDB DISABILITY STUDI, P565, DOI DOI 10.4135/9781412976251; BLOCH F, 2001, RETURNS WORK WHY 6 C, V5; BROOKER AS, 2000, EFFECTIVE DISABILITY; Bruckman RZ, 1998, OCCUP MED, V13, P679; BURTON JF, 2004, WORKERS COMPENS POLI, V4, P2; Burton WN, 1999, J OCCUP ENVIRON MED, V41, P863, DOI 10.1097/00043764-199910000-00007; Cater BI, 2000, J LABOR ECON, V18, P74, DOI 10.1086/209951; CHANDLER D, 2003, WORKERS COMPENSATION; Cott CA, 2004, DISABIL REHABIL, V26, P1411, DOI 10.1080/09638280400000237; CREEN M, 2002, J ONT OCCUP HLTH WIN, P4; *DEP WORK PENS, 2002, PATHW WORK HELP PEOP; Drake R. E., 2001, HDB DISABILITY STUDI, P412; Drake RE, 2004, BIOL PSYCHIAT, V56, P749, DOI 10.1016/j.biopsych.2004.08.020; Fisher Thomas F, 2003, Work, V21, P211; Frank JW, 1996, SPINE, V21, P2918, DOI 10.1097/00007632-199612150-00025; Fulton-Kehoe D, 2000, AM J IND MED, V37, P656, DOI 10.1002/(SICI)1097-0274(200006)37:6<656::AID-AJIM10>3.0.CO;2-C; Guzman J, 2003, PREVENTING MANAGING, P87; HOFFMAN H, 1994, PRIMARY CARE, V21, P225; HUNT H, 1993, 930004 UPJOHN I EMPL; JAKOBSEN K, 2001, SCAND J OCCUP THER, V8, P40, DOI DOI 10.1080/11038120120825; Johnstone B, 2003, ARCH PHYS MED REHAB, V84, P161, DOI 10.1053/apmr.2003.50098; Keogh JP, 2000, AM J IND MED, V38, P498, DOI 10.1002/1097-0274(200011)38:5<498::AID-AJIM2>3.3.CO;2-9; KLEIN HJ, 1991, ORGAN BEHAV HUM DEC, V49, P230, DOI 10.1016/0749-5978(91)90050-4; Klein HJ, 1999, J APPL PSYCHOL, V84, P885, DOI 10.1037/0021-9010.84.6.885; Kyes KB, 2003, J OCCUP ENVIRON MED, V45, P234, DOI 10.1097/01.jom.0000058337.05741.a1; Larsson A, 2003, J OCCUP REHABIL, V13, P169, DOI 10.1023/A:1024953218252; Lerner D, 2001, MED CARE, V39, P72, DOI 10.1097/00005650-200101000-00009; Lerner DJ, 2000, DISABIL REHABIL, V22, P225, DOI 10.1080/096382800296791; Levack W, 2004, DISABIL REHABIL, V26, P290, DOI 10.1080/09638280310001647615; LOCKE EA, 1988, ACAD MANAGE REV, V13, P23, DOI 10.2307/258352; Loisel P, 1997, SPINE, V22, P2911, DOI 10.1097/00007632-199712150-00014; Loisel P, 2001, IEEE ENG MED BIOL, V20, P35; Malec JF, 2000, ARCH PHYS MED REHAB, V81, P1007, DOI 10.1053/apmr.2000.6980; MARGOSHES B, 2000, OCCUPATIONAL MUSCULO; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; Mittag O, 2001, SOC SCI MED, V52, P1441, DOI 10.1016/S0277-9536(00)00250-1; Pimentel R., 1995, RETURN WORK PROCESS; POWER P, 2001, HDB MEASUREMENT EVAL, P339; Pransky G, 2000, AM J IND MED, V37, P400, DOI 10.1002/(SICI)1097-0274(200004)37:4<400::AID-AJIM10>3.0.CO;2-C; Pransky G, 2002, SPINE, V27, P864, DOI 10.1097/00007632-200204150-00017; Pransky G, 2002, DISABIL REHABIL, V24, P867, DOI 10.1080/09638280210142176; Pransky G, 2001, CLIN OCCUPATIONAL EN, V1, P829; Pransky GS, 2005, AM J IND MED, V47, P104, DOI 10.1002/ajim.20122; Robinson JP, 1997, ARCH PHYS MED REHAB, V78, pS3, DOI 10.1016/S0003-9993(97)90400-7; RUBIN SE, 2001, FDN VOCATIONAL REHAB; Rudolph L, 2002, J OCCUP ENVIRON MED, V44, P425, DOI 10.1097/00043764-200205000-00011; Scheel IB, 2002, SPINE, V27, P654, DOI 10.1097/00007632-200203150-00016; SCHRINER K, 2001, HDB DISABILITY STUDI, P642, DOI DOI 10.4135/9781412976251.N29; Shaw W S, 2001, AAOHN J, V49, P378; Shaw WS, 2004, J OCCUP REHABIL, V14, P207, DOI 10.1023/B:JOOR.0000022762.66807.2d; SHILTS J, 2003, WCDS INJURED WORKER; Sim J, 1999, SOC SECUR BULL, V62, P41; Strunin L, 2004, SOC SCI MED, V58, P1385, DOI 10.1016/S0277-9536(03)00333-2; Strunin L, 2004, AM J IND MED, V45, P338, DOI 10.1002/ajim.10356; SUM J, 2001, RETURN WORK CALIFORN; SZYMANSKI EM, 2003, WORK DISABILITY ISSU, P1; THOMASON T, 2003, PREVENTING MANAGING; WADDEL G, 2002, BACK PAIN INCAPACITY; Wasiak R, 2004, J OCCUP ENVIRON MED, V46, P68, DOI 10.1097/01.jom.0000105987.32375.3d; Westmorland M, 2002, DISABIL REHABIL, V24, P746, DOI 10.1080/09638280210124347; Westmorland MG, 2002, DISABIL REHABIL, V24, P802, DOI 10.1080/09638280110113421; Westmorland Muriel G, 2002, Work, V18, P29; Wickizer TM, 2004, HEALTH SERV RES, V39, P727, DOI 10.1111/j.1475-6773.2004.00255.x; Wickizer TM, 2001, MILBANK Q, V79, P5, DOI 10.1111/1468-0009.00194; WILLIAMS CT, 2003, WORKERS COMPENSATION; Williams Renee M, 2002, Work, V19, P87; WOFFORD JC, 1992, J MANAGE, V18, P595, DOI 10.1177/014920639201800309; *WORKPL HLTH SAF C, 2001, REP STAK WORK HARD W; World Health Organization, 2002, INT CLASS FUNCT DIS; YASSI A, 1990, J OCCUP ENVIRON MED, V32, P582, DOI 10.1097/00043764-199007000-00007	75	224	227	1	27	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1053-0487			J OCCUP REHABIL	J. Occup. Rehabil.	DEC	2005	15	4					543	556		10.1007/s10926-005-8033-0			14	Rehabilitation; Social Issues	Rehabilitation; Social Issues	979AK	WOS:000232914300008	16254754				2021-06-18	
J	Cao, QL; Xu, XM; DeVries, WH; Enzmann, GU; Ping, PP; Tsoulfas, P; Wood, PM; Bunge, MB; Whittemore, SR				Cao, QL; Xu, XM; DeVries, WH; Enzmann, GU; Ping, PP; Tsoulfas, P; Wood, PM; Bunge, MB; Whittemore, SR			Functional recovery in traumatic spinal cord injury after transplantation of multineurotrophin-expressing glial-restricted precursor cells	JOURNAL OF NEUROSCIENCE			English	Article						spinal cord injury; remyelination; glial-restricted precursor cells; transplantation; rat; myelin repair	ADULT-RAT; AXONAL REGENERATION; STEM-CELLS; PROGENITOR CELLS; IN-VITRO; SCHWANN-CELLS; NEUROTROPHIC FACTOR; CONTUSION INJURIES; DIFFERENTIATION; PROLIFERATION	Demyelination contributes to the physiological and behavioral deficits after contusive spinal cord injury ( SCI). Therefore, remyelination may be an important strategy to facilitate repair after SCI. We show here that rat embryonic day 14 spinal cord- derived glial- restricted precursor cells ( GRPs), which differentiate into both oligodendrocytes and astrocytes, formed normal- appearing central myelin around axons of cultured DRG neurons and had enhanced proliferation and survival in the presence of neurotrophin 3 ( NT3) and brain- derived neurotrophin factor ( BDNF). We infected GRPs with retroviruses expressing the multineurotrophin D15A ( with both BDNF and NT3 activities) and then transplanted them into the contused adult thoracic spinal cord at 9 d after injury. Expression of D15A in the injured spinal cord is five times higher in animals receiving D15A - GRP grafts than ones receiving enhanced green fluorescent protein ( EGFP) - GRP or DMEM grafts. Six weeks after transplantation, the grafted GRPs differentiated into mature oligodendrocytes expressing both myelin basic protein ( MBP) and adenomatus polyposis coli ( APC). Ultrastructural analysis showed that the grafted GRPs formed morphologically normal- appearing myelin sheaths around the axons in the ventrolateral funiculus ( VLF) of spinal cord. Expression of D15A significantly increased the percentage of APC (+) oligodendrocytes of grafted GRPs ( 15 - 30%). Most importantly, 8 of 12 rats receiving grafts of D15A - GRPs recovered transcranial magnetic motor- evoked potential responses, indicating that conduction through the demyelinated VLF axons was restored. Such electrophysiological recovery was not observed in rats receiving grafts of EGFP - GRPs, D15A - NIH3T3 cells, or an injection of an adenovirus expressing D15A. Recovery of hindlimb locomotor function was also significantly enhanced only in the D15A - GRP- grafted animals at 4 and 5 weeks after transplantation. Therefore, combined treatment with neurotrophins and GRP grafts can facilitate functional recovery after traumatic SCI and may prove to be a useful therapeutic strategy to repair the injured spinal cord.	Univ Louisville, Sch Med, Dept Neurol Surg, Kentucky Spinal Cord Injury Res Ctr, Louisville, KY 40202 USA; Univ Louisville, Dept Anat Sci & Neurobiol, Louisville, KY 40202 USA; Univ Louisville, Dept Med, Louisville, KY 40202 USA; Univ Miami, Miami Project Cure Paralysis, Miami, FL 33136 USA; Univ Miami, Dept Neurol Surg, Miami, FL 33136 USA; Univ Miami, Dept Cell Biol & Anat, Miami, FL 33136 USA	Whittemore, SR (corresponding author), Univ Louisville, Sch Med, Dept Neurol Surg, Kentucky Spinal Cord Injury Res Ctr, Med Dent Res Bldg 616,511 S Floyd St, Louisville, KY 40202 USA.	swhittemore@louisville.edu	Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763; Ping, Peipei/0000-0003-3583-3881; Xu, Xiao-ming/0000-0002-7229-0081; Tsoulfas, Pantelis/0000-0003-1974-6366	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR15576, P20 RR015576, P20 RR015576-04] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS038665-050003, NS38665, NS36350, R01 NS036350, P01 NS038665] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR015576] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS038665, R01NS036350] Funding Source: NIH RePORTER		Alexeeva N, 1997, EXP NEUROL, V148, P399, DOI 10.1006/exnr.1997.6689; Alexeeva N, 1998, ELECTROMYOGR MOTOR C, V109, P297, DOI 10.1016/S0924-980X(98)00021-6; Bambakidis Nicholas C, 2004, Spine J, V4, P16, DOI 10.1016/j.spinee.2003.07.004; BARRES BA, 1994, NEURON, V12, P935, DOI 10.1016/0896-6273(94)90305-0; BARRES BA, 1994, NATURE, V367, P371, DOI 10.1038/367371a0; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; BLIGHT AR, 1983, NEUROSCIENCE, V10, P521, DOI 10.1016/0306-4522(83)90150-1; Blight AR, 2002, NAT NEUROSCI, V5, P1051, DOI 10.1038/nn939; BLIGHT AR, 1993, ADV NEUROL, V59, P91; Brustle O, 1999, SCIENCE, V285, P754, DOI 10.1126/science.285.5428.754; BUNGE RP, 1993, ADV NEUROL, V59, P75; Cao QL, 2001, EXP NEUROL, V167, P48, DOI 10.1006/exnr.2000.7536; Cao QL, 2005, EXP NEUROL, V191, pS3, DOI 10.1016/j.expneurol.2004.08.026; Cao QL, 2002, EXP NEUROL, V177, P349, DOI 10.1006/exnr.2002.7981; Chow SY, 2000, BRAIN RES, V874, P87, DOI 10.1016/S0006-8993(00)02443-4; Coggeshall RE, 1996, J COMP NEUROL, V364, P6, DOI 10.1002/(SICI)1096-9861(19960101)364:1<6::AID-CNE2>3.0.CO;2-9; Cosgaya JM, 2002, SCIENCE, V298, P1245, DOI 10.1126/science.1076595; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Engel U, 1996, GLIA, V16, P16, DOI 10.1002/(SICI)1098-1136(199601)16:1<16::AID-GLIA3>3.3.CO;2-I; FEHLINGS MG, 1987, NEUROSURGERY, V20, P125; Franklin R J, 2001, Prog Brain Res, V132, P185; Gao MH, 1998, P NATL ACAD SCI USA, V95, P1038, DOI 10.1073/pnas.95.3.1038; Gensert JM, 1997, NEURON, V19, P197, DOI 10.1016/S0896-6273(00)80359-1; GLEDHILL RF, 1973, EXP NEUROL, V38, P472, DOI 10.1016/0014-4886(73)90169-6; Guest JD, 2005, EXP NEUROL, V192, P384, DOI 10.1016/j.expneurol.2004.11.033; Han SSW, 2004, GLIA, V45, P1, DOI 10.1002/glia.10282; Hill CE, 2004, EXP NEUROL, V190, P289, DOI 10.1016/j.expneurol.2004.05.043; Hofstetter CP, 2005, NAT NEUROSCI, V8, P346, DOI 10.1038/nn1405; Horner PJ, 2000, J NEUROSCI, V20, P2218; Ishii K, 2001, J NEUROSCI RES, V65, P500, DOI 10.1002/jnr.1180; Jean I, 2003, BRAIN RES, V972, P110, DOI 10.1016/S0006-8993(03)02510-1; Keirstead HS, 2005, J NEUROSCI, V25, P4694, DOI 10.1523/JNEUROSCI.0311-05.2005; Keirstead HS, 1999, J NEUROSCI, V19, P7529, DOI 10.1523/JNEUROSCI.19-17-07529.1999; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; Kumar S, 1998, J NEUROSCI RES, V54, P754, DOI 10.1002/(SICI)1097-4547(19981215)54:6<754::AID-JNR3>3.0.CO;2-K; Liu S, 2000, P NATL ACAD SCI USA, V97, P6126, DOI 10.1073/pnas.97.11.6126; Liu XZ, 1997, J NEUROSCI, V17, P5395; Loy DN, 2002, J NEUROSCI, V22, P315, DOI 10.1523/JNEUROSCI.22-01-00315.2002; Lu P, 2004, J NEUROSCI, V24, P6402, DOI 10.1523/JNEUROSCI.1492-04.2004; Magnuson DSK, 1999, EXP NEUROL, V156, P191, DOI 10.1006/exnr.1999.7016; MayerProschel M, 1997, NEURON, V19, P773, DOI 10.1016/S0896-6273(00)80960-5; McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986; McTigue DM, 1998, J NEUROSCI, V18, P5354; McTigue DM, 2001, J NEUROSCI, V21, P3392, DOI 10.1523/JNEUROSCI.21-10-03392.2001; Mujtaba T, 1999, DEV BIOL, V214, P113, DOI 10.1006/dbio.1999.9418; Ogawa Y, 2002, J NEUROSCI RES, V69, P925, DOI 10.1002/jnr.10341; Onifer SM, 2000, NEUROSCI NEWS, V3, P50; OORSCHOT DE, 1994, PROG NEUROBIOL, V44, P233, DOI 10.1016/0301-0082(94)90040-X; Pearse DD, 2004, NAT MED, V10, P610, DOI 10.1038/nm1056; Plant GW, 2002, J NEUROSCI, V22, P6083; Privat A, 2003, GLIA, V43, P91, DOI 10.1002/glia.10249; Rubio N, 2004, GLIA, V47, P78, DOI 10.1002/glia.20035; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; Schucht P, 2002, EXP NEUROL, V176, P143, DOI 10.1006/exnr.2002.7909; Shihabuddin LS, 2000, J NEUROSCI, V20, P8727; Sim FJ, 2002, J NEUROSCI, V22, P2451, DOI 10.1523/JNEUROSCI.22-07-02451.2002; Sivasankaran R, 2004, NAT NEUROSCI, V7, P261, DOI 10.1038/nn1193; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; Strohmaier C, 1996, EMBO J, V15, P3332, DOI 10.1002/j.1460-2075.1996.tb00698.x; Talbott JF, 2005, EXP NEUROL, V192, P11, DOI 10.1016/j.expneurol.2004.05.038; Totoiu MO, 2005, J COMP NEUROL, V486, P373, DOI 10.1002/cne.20517; TSOULFAS P, 1993, NEURON, V10, P975, DOI 10.1016/0896-6273(93)90212-A; URFER R, 1994, EMBO J, V13, P5896, DOI 10.1002/j.1460-2075.1994.tb06935.x; WAXMAN SG, 1989, J NEUROL SCI, V91, P1, DOI 10.1016/0022-510X(89)90072-5; XU XM, 1995, EXP NEUROL, V134, P261, DOI 10.1006/exnr.1995.1056; Yamamoto S, 2001, EXP NEUROL, V172, P115, DOI 10.1006/exnr.2001.7798; Yan HL, 2000, J NEUROSCI RES, V62, P329, DOI 10.1002/1097-4547(20001101)62:3<329::AID-JNR2>3.0.CO;2-C	67	224	235	0	16	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUL 27	2005	25	30					6947	6957		10.1523/JNEUROSCI.1065-05.2005			11	Neurosciences	Neurosciences & Neurology	949WB	WOS:000230817700002	16049170	Green Accepted, Bronze, Green Published			2021-06-18	
J	Hsieh, FY; Lin, HH; Hsu, SH				Hsieh, Fu-Yu; Lin, Hsin-Hua; Hsu, Shan-hui			3D bioprinting of neural stern cell-laden thermoresponsive biodegradable polyurethane hydrogel and potential in central nervous system repair	BIOMATERIALS			English	Article						3D bioprinting; Thermoresponsive; Polyurethane; Neural stem cells; Neural tissue engineering	GLIAL-CELLS; SCAFFOLDS; REGENERATION; CONSTRUCTION	The 3D bioprinting technology serves as a powerful tool for building tissue in the field of tissue engineering. Traditional 3D printing methods involve the use of heat, toxic organic solvents, or toxic photoinitiators for fabrication of synthetic scaffolds. In this study, two thermoresponsive water-based biodegradable polyurethane dispersions (PU1 and PU2) were synthesized which may form gel near 37 degrees C without any crosslinker. The stiffness of the hydrogel could be easily fine-tuned by the solid content of the dispersion. Neural stem cells (NSCs) were embedded into the polyurethane dispersions before gelation. The dispersions containing NSCs were subsequently printed and maintained at 37 degrees C. The NSCs in 25-30% PU2 hydrogels (similar to 680-2400 Pa) had excellent proliferation and differentiation but not in 25 -30% PU1 hydrogels. Moreover, NSC-laden 25-30% PU2 hydrogels injected into the zebrafish embryo neural injury model could rescue the function of impaired nervous system. However, NSC-laden 25-30% PU1 hydrogels only showed a minor repair effect in the zebrafish model. In addition, the function of adult zebrafish with traumatic brain injury was rescued after implantation of the 3D-printed NSC-laden 25% PU2 constructs. Therefore, the newly developed 3D bioprinting technique involving NSCs embedded in the thermoresponsive biodegradable polyurethane ink offers new possibilities for future applications of 3D bioprinting in neural tissue engineering. (C) 2015 Elsevier Ltd. All rights reserved.	[Hsieh, Fu-Yu; Lin, Hsin-Hua; Hsu, Shan-hui] Natl Taiwan Univ, Inst Polymer Sci & Engn, Taipei 10617, Taiwan; [Hsu, Shan-hui] Natl Taiwan Univ, Res Ctr Dev Biol & Regenerat Med, Taipei 10617, Taiwan; [Hsu, Shan-hui] Natl Taiwan Univ, Res & Dev Ctr Med Devices, Taipei 10617, Taiwan	Hsu, SH (corresponding author), Natl Taiwan Univ, Inst Polymer Sci & Engn, 1,Sec 4,Roosevelt Rd, Taipei 10617, Taiwan.	shhsu@ntu.edu.tw		Hsu, Shan-hui/0000-0003-3399-055X	Program for Additive Manufacturing, Ministry of Science and Technology, Taiwan, R.O.C [MOST 104-2218-E-002 -010]; University Cutting-Edge Steering Research Project [NTU-CESRP-103R104941]	This research was supported by the Program for Additive Manufacturing, Ministry of Science and Technology (MOST 104-2218-E-002 -010), Taiwan, R.O.C, and the University Cutting-Edge Steering Research Project (NTU-CESRP-103R104941). We thank Dr. Ing-Ming Chiu (Institute of Cellular and Systems Medicine, National Health Research Institutes, Zhunan, Taiwan) for providing murine neural stem cells. We also thank the Taiwan Zebrafish Core Facility at National Taiwan University (NTU-ERP-104R8600) for the facility and technical supports.	Akhyari P, 2008, EUR J CARDIO-THORAC, V34, P229, DOI 10.1016/j.ejcts.2008.03.062; Angius D, 2012, BIOMATERIALS, V33, P8034, DOI 10.1016/j.biomaterials.2012.07.056; Billiet T, 2012, BIOMATERIALS, V33, P6020, DOI 10.1016/j.biomaterials.2012.04.050; BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; Chang CC, 2011, J BIOMED MATER RES B, V98B, P160, DOI 10.1002/jbm.b.31831; Cheng H, 1996, SCIENCE, V273, P510, DOI 10.1126/science.273.5274.510; Chiu IM, 2000, ONCOGENE, V19, P6229, DOI 10.1038/sj.onc.1204021; Das S., 2014, ACTA BIOMATER, V11, P233; Deister C, 2006, J NEURAL ENG, V3, P172, DOI 10.1088/1741-2560/3/2/011; Giraud MN, 2012, CARDIOL RES PRACT, V2012, DOI 10.1155/2012/971614; Gorna K, 2006, J BIOMED MATER RES A, V79A, P128, DOI 10.1002/jbm.a.30708; Gunatillake Pathiraja A., 2003, European Cells & Materials, V5, P1; Hamilton N, 2014, LARYNGOSCOPE, V124, P961, DOI 10.1002/lary.24469; Hausner T, 2007, ACTA NEUROCHIR SUPPL, V100, P69; Horner PJ, 2000, NATURE, V407, P963, DOI 10.1038/35039559; Hsu SH, 2014, J MATER CHEM B, V2, P5083, DOI 10.1039/c4tb00572d; Hsu YC, 2009, DEV DYNAM, V238, P302, DOI 10.1002/dvdy.21753; Hung KC, 2014, ADV HEALTHC MATER, V3, P1578, DOI 10.1002/adhm.201400018; Katzman R, 2008, ALZHEIMERS DEMENT, V4, P378, DOI 10.1016/j.jalz.2008.10.003; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Lee W, 2009, NEUROREPORT, V20, P798, DOI 10.1097/WNR.0b013e32832b8be4; Lee YB, 2010, EXP NEUROL, V223, P645, DOI 10.1016/j.expneurol.2010.02.014; Liu CZ, 2008, J BIOMED MATER RES B, V85B, P519, DOI 10.1002/jbm.b.30975; Lorber B, 2014, BIOFABRICATION, V6, DOI 10.1088/1758-5082/6/1/015001; Lu YB, 2006, P NATL ACAD SCI USA, V103, P17759, DOI 10.1073/pnas.0606150103; Luo Y., ADV HEALTHC MAT, V2, P777; Luo YX, 2013, ADV HEALTHC MATER, V2, P777, DOI 10.1002/adhm.201200303; Malda J, 2013, ADV MATER, V25, P5011, DOI 10.1002/adma.201302042; Nair LS, 2007, PROG POLYM SCI, V32, P762, DOI 10.1016/j.progpolymsci.2007.05.017; Ou CW, 2014, ACS APPL MATER INTER, V6, P5685, DOI 10.1021/am500213t; Park A, 1996, J BIOMED MATER RES, V31, P117; Riboldi SA, 2005, BIOMATERIALS, V26, P4606, DOI 10.1016/j.biomaterials.2004.11.035; Saha K, 2008, BIOPHYS J, V95, P4426, DOI 10.1529/biophysj.108.132217; SCHAKENRAAD J M, 1991, Clinical Materials, V7, P253; Siepe M, 2007, ARTIF ORGANS, V31, P425, DOI 10.1111/j.1525-1594.2007.00385.x; Stichel CC, 1998, PROG NEUROBIOL, V56, P119, DOI 10.1016/S0301-0082(98)00033-1; Szycher M, 1991, HIGH PERFORMANCE BIO; Wang XH, 2006, TISSUE ENG, V12, P83, DOI 10.1089/ten.2006.12.83; Westerfield M, 2007, ZEBRAFISH BOOK GUIDE; Wu CC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097902; Xiao L, 2014, NEURAL REGEN RES, V9, P1253, DOI 10.4103/1673-5374.137570; Xu W, 2007, J BIOACT COMPAT POL, V22, P363, DOI 10.1177/0883911507079451; Yan YN, 2005, J BIOACT COMPAT POL, V20, P259, DOI 10.1177/0883911505053658	43	223	236	17	461	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0142-9612	1878-5905		BIOMATERIALS	Biomaterials	DEC	2015	71						48	57		10.1016/j.biomaterials.2015.08.028			10	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	CT2DS	WOS:000362612800005	26318816				2021-06-18	
J	Alsalaheen, BA; Mucha, A; Morris, LO; Whitney, SL; Furman, JM; Camiolo-Reddy, CE; Collins, MW; Lovell, MR; Sparto, PJ				Alsalaheen, Bara A.; Mucha, Anne; Morris, Laura O.; Whitney, Susan L.; Furman, Joseph M.; Camiolo-Reddy, Cara E.; Collins, Michael W.; Lovell, Mark R.; Sparto, Patrick J.			Vestibular Rehabilitation for Dizziness and Balance Disorders After Concussion	JOURNAL OF NEUROLOGIC PHYSICAL THERAPY			English	Article						mild traumatic brain injury (TBI); vertigo; posture	TRAUMATIC BRAIN-INJURY; SPORT-RELATED CONCUSSION; HEAD-INJURY; HIGH-SCHOOL; SENSORY ORGANIZATION; PERFORMANCE; MANAGEMENT; CHILDREN; RESPONSIVENESS; IMPAIRMENTS	Background and Purpose: Management of dizziness and balance dysfunction is a major challenge after concussion. The purpose of this study was to examine the effect of vestibular rehabilitation in reducing dizziness and to improve gait and balance function in people after concussion. Methods: A retrospective chart review of 114 patients (67 children aged 18 years and younger [mean, 16 years; range, 8-18 years]; 47 adults older than 18 years [mean, 41 years; range, 19-73 years]) referred for vestibular rehabilitation after concussion was performed. At the time of initial evaluation and discharge, recordings were made of outcome measures of self-report (eg, dizziness severity, Activities-specific Balance Confidence Scale, and Dizziness Handicap Inventory) and gait and balance performance (eg, Dynamic Gait Index, gait speed, and the Sensory Organization Test). A mixed-factor repeated-measures analysis of variance was used to test whether there was an effect of vestibular rehabilitation therapy and age on the outcome measures. Results: The median length of time between concussion and initial evaluation was 61 days. Of the 114 patients who were referred, 84 returned for at least 1 visit. In these patients, improvements were observed in all self-report, gait, and balance performance measures at the time of discharge (P < .05). Children improved by a greater amount in dizziness severity (P = .005) and conditions 1 (eyes open, fixed support) and 2 (eyes closed, fixed support) of the Sensory Organization Test (P = .025). Discussion: Vestibular rehabilitation may reduce dizziness and improve gait and balance function after concussion. For most measures, the improvement did not depend on age, indicating that vestibular rehabilitation may equally benefit both children and adults. Conclusions: Vestibular rehabilitation should be considered in the management of individuals post concussion who have dizziness and gait and balance dysfunction that do not resolve with rest.	[Alsalaheen, Bara A.; Whitney, Susan L.; Sparto, Patrick J.] Univ Pittsburgh, Dept Phys Therapy, Pittsburgh, PA 15260 USA; [Furman, Joseph M.] Univ Pittsburgh, Dept Otolaryngol, Pittsburgh, PA 15260 USA; [Camiolo-Reddy, Cara E.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA; [Collins, Michael W.; Lovell, Mark R.] Univ Pittsburgh, Dept Orthoped Surg, Pittsburgh, PA USA; [Mucha, Anne; Morris, Laura O.] Univ Pittsburgh, Med Ctr, Ctr Rehab Serv, Pittsburgh, PA USA	Sparto, PJ (corresponding author), Univ Pittsburgh, Dept Phys Therapy, Pittsburgh, PA 15260 USA.	psparto@pitt.edu		Sparto, Patrick/0000-0002-8351-3789			Alla S, 2009, BRIT J SPORT MED, V43, pI3, DOI 10.1136/bjsm.2009.058339; Broglio SP, 2008, CLIN J SPORT MED, V18, P148, DOI 10.1097/JSM.0b013e318164f42a; Brown KE, 2006, ARCH PHYS MED REHAB, V87, P76, DOI 10.1016/j.apmr.2005.08.003; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Covassin T, 2009, J ATHL TRAINING, V44, P400, DOI 10.4085/1062-6050-44.4.400; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gagnon I, 1998, BRAIN INJURY, V12, P843, DOI 10.1080/026990598122070; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Gill-Body KM, 2000, PHYS THER, V80, P748, DOI 10.1093/ptj/80.8.748; GRIFFITHS MV, 1979, J LARYNGOL OTOL, V93, P253, DOI 10.1017/S0022215100086990; Gurr B, 2001, BRAIN INJURY, V15, P387, DOI 10.1080/02699050010005904; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2004, NEUROSURGERY, V55, P891, DOI 10.1227/01.NEU.0000143800.49798.19; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Herdman S. J., 1990, J HEAD TRAUMA REHAB, V5, P63; HIRABAYASHI S, 1995, BRAIN DEV-JPN, V17, P111, DOI 10.1016/0387-7604(95)00009-Z; Hoffer ME, 2004, OTOL NEUROTOL, V25, P135, DOI 10.1097/00129492-200403000-00009; HORAK FB, 1992, OTOLARYNG HEAD NECK, V106, P175, DOI 10.1177/019459989210600220; JACOBSON GP, 1990, ARCH OTOLARYNGOL, V116, P424; Kisilevski V, 2001, Int Tinnitus J, V7, P118; Lord SR, 2002, J GERONTOL A-BIOL, V57, pM539, DOI 10.1093/gerona/57.8.M539; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Maskell F, 2006, BRAIN INJURY, V20, P293, DOI 10.1080/02699050500488041; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Meli A, 2006, ACTA OTO-LARYNGOL, V126, P259, DOI 10.1080/00016480500388885; Meretta BM, 2006, J VESTIBUL RES-EQUIL, V16, P233; Oliaro S, 2001, J ATHL TRAINING, V36, P257; Perera S, 2006, J AM GERIATR SOC, V54, P743, DOI 10.1111/j.1532-5415.2006.00701.x; Peterson ML, 2006, GAIT POSTURE, V23, P455, DOI 10.1016/j.gaitpost.2005.05.003; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x; POLISSAR NL, 1994, BRAIN INJURY, V8, P249, DOI 10.3109/02699059409150977; POWELL LE, 1995, J GERONTOL A-BIOL, V50, pM28, DOI 10.1093/gerona/50A.1.M28; Reddy CC, 2008, PHYS MED REH CLIN N, V19, P247, DOI 10.1016/j.pmr.2007.12.002; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; SHEPARD NT, 1993, ANN OTO RHINOL LARYN, V102, P198, DOI 10.1177/000348949310200306; SHEPARD NT, 1990, NEUROL CLIN, V8, P459, DOI 10.1016/S0733-8619(18)30367-0; Shumway-Cook A., 1995, MOTOR CONTROL THEORY; Shumway-Cook A, 1990, J HEAD TRAUMA REHAB, V5, P51, DOI DOI 10.1097/00001199-199012000-00007; VARTIAINEN E, 1985, INT J PEDIATR OTORHI, V9, P135, DOI 10.1016/S0165-5876(85)80013-6; Whitney SL, 2002, LARYNGOSCOPE, V112, P1785, DOI 10.1097/00005537-200210000-00015; Wrisley DM, 2003, ARCH PHYS MED REHAB, V84, P1528, DOI 10.1016/S0003-9993(03)00274-0; Wrisley DM, 2002, OTOL NEUROTOL, V23, P483, DOI 10.1097/00129492-200207000-00016	46	223	227	2	71	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1557-0576	1557-0584		J NEUROL PHYS THER	J. Neurol. Phys. Ther.	JUN	2010	34	2					87	93		10.1097/NPT.0b013e3181dde568			7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	V21PD	WOS:000208218600007	20588094	Green Accepted			2021-06-18	
J	Bleiberg, J; Cernich, AN; Cameron, K; Sun, WY; Peck, K; Ecklund, J; Reeves, D; Uhorchak, J; Sparling, MB; Warden, DL				Bleiberg, J; Cernich, AN; Cameron, K; Sun, WY; Peck, K; Ecklund, J; Reeves, D; Uhorchak, J; Sparling, MB; Warden, DL			Duration of cognitive impairment after sports concussion	NEUROSURGERY			English	Article							MILD HEAD-INJURY; NEUROPSYCHOLOGICAL IMPAIRMENT; ATTENTION DEFICITS; BRAIN; PERFORMANCE; RECOVERY; EFFICIENCY; PROTOCOL	OBJECTIVE: We sought to determine the duration of cognitive impairment after sports concussion. METHODS: We conducted a study with a prospective design in which 729 athletes underwent preseason baseline testing by being administered a computerized neuropsychological test battery, followed by retesting at regular intervals after they sustained sports-related concussions. A control group consisting of nonconcussed athletes drawn from the same baseline population underwent testing at parallel intervals. RESULTS: Cognitive impairment in this primarily American Academy of Neurology Grade 11 sample of boxing concussions was apparent on the day of injury and at I to 2 days postinjury. Recovery of cognitive performance occurred during the 3- to 7-day interval. Comparison with control subjects showed that absent or attenuated practice effects, in addition to frank deterioration from baseline, were indications of recent concussion. CONCLUSION: The present findings of recovery during the 3- to 7-day interval postinjury are consistent with the American Academy of Neurology Grade 11 return-to-play practice parameters suggesting a I-week time-out from participation in contact sports.	Natl Rehabil Hosp, Washington, DC 20010 USA; US Mil Acad, West Point, NY 10996 USA; Walter Reed Army Med Hosp, Def & Vet Brain Injury Ctr, Washington, DC USA; USN, San Diego, CA 92152 USA	Bleiberg, J (corresponding author), Natl Rehabil Hosp, 102 N Irving St,NW, Washington, DC 20010 USA.	joseph.bleiberg@medstar.net		Cameron, Kenneth/0000-0002-6276-4482			Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Bleiberg J, 1997, NEUROPSY NEUROPSY BE, V10, P247; Bleiberg J, 2000, CLIN NEUROPSYCHOL, V14, P287, DOI 10.1076/1385-4046(200008)14:3;1-P;FT287; BLEIBERG J, 2002, 54 ANN M AM AC NEUR; Cameron KL, 1999, J ATHL TRAINING, V34, P34; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; CREMONAMETEYARD SL, 1994, NEUROPSYCHOLOGIA, V32, P649, DOI 10.1016/0028-3932(94)90026-4; Daniel JC, 1999, NEUROPSY NEUROPSY BE, V12, P167; Downs DS, 2002, J SPORT MED PHYS FIT, V42, P103; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Farmer K, 2000, HEADACHE, V40, P657, DOI 10.1046/j.1526-4610.2000.040008657.x; Farmer K, 2001, HEADACHE, V41, P377, DOI 10.1046/j.1526-4610.2001.111006377.x; Gestaldo E, 2001, ARCH CLIN NEUROPSYCH, V16, P825; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; Hinton-Bayre AD, 2002, NEUROLOGY, V59, P1068, DOI 10.1212/WNL.59.7.1068; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; IVERSON GL, 2002, NAT AC NRU 22 ANN C; Kelly JP, 1997, NEUROLOGY, V48, P581; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; Myers JL., 2003, RES DESIGN STAT ANAL; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; REEVES D, 1996, ANAM V3 11A 96 USERS; TYSVAER AT, 1989, ACTA NEUROL SCAND, V80, P151, DOI 10.1111/j.1600-0404.1989.tb03858.x; WARDEN D, 2003, 55 ANN M AM AC NEUR; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524	36	223	227	0	35	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	MAY	2004	54	5					1073	1078		10.1227/01.NEU.0000118820.33396.6A			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	819JA	WOS:000221310000018	15113460				2021-06-18	
J	Marshall, LF; Maas, AIR; Marshall, SB; Bricolo, A; Fearnside, M; Iannotti, F; Klauber, MR; Lagarrigue, J; Lobato, R; Persson, L; Pickard, JD; Piek, J; Servadei, F; Wellis, GN; Morris, GF; Means, ED; Musch, B				Marshall, LF; Maas, AIR; Marshall, SB; Bricolo, A; Fearnside, M; Iannotti, F; Klauber, MR; Lagarrigue, J; Lobato, R; Persson, L; Pickard, JD; Piek, J; Servadei, F; Wellis, GN; Morris, GF; Means, ED; Musch, B			A multicenter trial on the efficacy of using tirilazad mesylate in cases of head injury	JOURNAL OF NEUROSURGERY			English	Article						tirilazad mesylate; severe head injury; 21-aminosteroid; neurotrauma; moderate head injury	21-AMINOSTEROID U74006F; SUBARACHNOID HEMORRHAGE; BRAIN INJURY	Object. The authors prospectively studied the efficacy of tirilazad mesylate, a novel aminosteroid, in humans with head injuries. Methods. A cohort of 1120 head-injured patients received at least one dose of study medication (tirilazad or placebo). Eighty-five percent (957) of the patients had suffered a severe head injury (Glasgow Coma Scale [GCS] score 4-8) and 15% (163) had sustained a moderate head injury (GCS score 9-12). Six-month outcomes for the tirilazad- and placebo-treated groups for the Glasgow Outcome Scale categories of both good recovery and death showed no significant difference (good recovery in the tirilazad-treated group was 39% compared with the placebo group in which it was 42% [p = 0.461]; death in the tirilazad-treated group occurred in 26% of patients compared with the placebo group, in which it occurred in 25% [p = 0.750]). Subgroup analysis suggested that tirilazad mesylate may be effective in reducing mortality rates in males suffering from severe head injury with accompanying traumatic subarachnoid hemorrhage (death in the tirilazad-treated group occurred in 34% of patients; in the placebo group it occurred in 43% [p = 0.0261). No significant differences in frequency or types of serious adverse events were shown between the treatment and placebo groups. Conclusions. Striking problems with imbalance concerning basic prognostic variables were observed in spite of the large population studied. These imbalances concerned pretreatment hypotension, pretreatment hypoxia, and the incidence of epidural hematomas. In future trials of pharmacological therapy for severe head injury, serious consideration must be given to alternative randomization strategies. Given the heterogeneous nature of head injury and the identification of populations that do relatively well with standard therapy, target populations with a higher risk for mortality and morbidity may be more suitable for clinical trials of such agents.	Univ Calif San Diego, Div Neurol Surg, San Diego, CA 92103 USA; Univ Calif San Diego, Dept Family Med, San Diego, CA 92103 USA; Int Tirilazad Trial, Execut Comm, Paris, France; Pharmacia & Upjohn Inc, Kalamazoo, MI 49001 USA	Marshall, LF (corresponding author), Univ Calif San Diego, Div Neurol Surg, 200 W Arbor Dr,0825, San Diego, CA 92103 USA.		Maas, Andrew IR/C-5584-2013	Maas, Andrew IR/0000-0003-1612-1264; Servadei, Franco/0000-0002-3595-3464			CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HALL ED, 1992, J NEUROTRAUMA, V9, P425; HALL ED, 1993, MOL CELLULAR APPROAC, P79; JENNETT B, 1975, LANCET, V1, P480; Kassell NF, 1996, J NEUROSURG, V84, P221, DOI 10.3171/jns.1996.84.2.0221; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MCINTOSH TK, 1992, J NEUROTRAUM, V9, P33, DOI 10.1089/neu.1992.9.33; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; Murray GD, 1996, ACTA NEUROCHIR, V138, P1163, DOI 10.1007/BF01809745; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; Young B, 1996, JAMA-J AM MED ASSOC, V276, P538, DOI 10.1001/jama.276.7.538	13	223	226	1	3	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	OCT	1998	89	4					519	525		10.3171/jns.1998.89.4.0519			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	122LL	WOS:000076073000002	9761043				2021-06-18	
J	NILSSON, P; HILLERED, L; OLSSON, Y; SHEARDOWN, MJ; HANSEN, AJ				NILSSON, P; HILLERED, L; OLSSON, Y; SHEARDOWN, MJ; HANSEN, AJ			REGIONAL CHANGES IN INTERSTITIAL K+ AND CA2+ LEVELS FOLLOWING CORTICAL COMPRESSION CONTUSION TRAUMA IN RATS	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						TRAUMATIC BRAIN INJURY; RAT; CALCIUM ION; POTASSIUM ION; ION-SELECTIVE MICROELECTRODE; INTERSTITIAL FLUID; CORTICAL SPREADING DEPRESSION	CONCUSSIVE BRAIN INJURY; SPINAL-CORD CONTUSION; EXTRACELLULAR POTASSIUM; SPREADING DEPRESSION; IONIC ACTIVITY; AMINO-ACIDS; ISCHEMIA; CORTEX	Brain trauma is associated with acute functional impairment and neuronal injury. At present, it is unclear to what extent disturbances in ion homeostasis are involved in these changes. We used ion-selective microelectrodes to register interstitial potassium ([K+]e) and calcium ([Ca2+]e) concentrations in the brain cortex following cerebral compression contusion in the rat. The trauma was produced by dropping a 21 g weight from a height of 35 cm onto a piston that compressed the cortex 1.5 mm. Ion measurements were made in two different locations of the contused region: in the perimeter, i.e., the shear stress zone (region A), and in the center (region B). The trauma resulted in an immediate increase in [K+]e from a control level of 3 mM to a level >60 mM in both regions, and a concomitant negative shift in DC potential. In both regions, there was a simultaneous, dramatic decrease in [Ca2+]e from a baseline of 1.1 mM to 0.3-0.1 mM. Interstitial [K+] and the DC potential normalized within 3 min after trauma. In region B, [Ca2+]e recovered to near control levels within 5 min after ictus. In region A, however, recovery of [Ca2+]e was significantly slower, with a return to near baseline values within 50 min after trauma. The prolonged lowering of [Ca2+]e in region A was associated with an inability to propagate cortical spreading depression, suggesting a profound functional disturbance. Histologic evaluation 72 h after trauma revealed that neuronal injury was confined exclusively to region A. The results indicate that compression contusion trauma produces a transient membrane depolarization associated with a pronounced cellular release of K+ and a massive Ca2+ entry into the intracellular compartment. We suggest that the acute functional impairment and the subsequent neuronal injury in region A is caused by the prolonged disturbance of cellular calcium homeostasis mediated by leaky membranes exposed to shear stress.	UNIV HOSP UPPSALA,DEPT CLIN CHEM,S-75185 UPPSALA,SWEDEN; UNIV HOSP UPPSALA,DEPT NEUROSURG,S-75185 UPPSALA,SWEDEN; UNIV HOSP UPPSALA,DEPT NEUROPATHOL,S-75185 UPPSALA,SWEDEN; NOVO NORDISK,DIV CNS,MALOV,DENMARK							BURES J, 1974, MECHANISM APPLICATIO; CHESLER M, 1991, BRAIN RES, V556, P71, DOI 10.1016/0006-8993(91)90548-A; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; GILL R, 1992, J CEREBR BLOOD F MET, V12, P371, DOI 10.1038/jcbfm.1992.54; HANSEN AJ, 1988, NEUROCHEM PATHOL, V9, P195; HANSEN AJ, 1985, PHYSIOL REV, V65, P101; HANSEN AJ, 1981, ACTA PHYSIOL SCAND, V113, P437, DOI 10.1111/j.1748-1716.1981.tb06920.x; HARRIS RJ, 1984, J CEREBR BLOOD F MET, V4, P187, DOI 10.1038/jcbfm.1984.27; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HILLERED L, 1992, J NEUROTRAUM, V9, P62; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KUBOTA M, 1989, Neurosurgical Review, V12, P393, DOI 10.1007/BF01790681; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359; MARTINSFERREIRA H, 1974, J NEUROPHYSIOL, V37, P773; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; SACHS F, 1991, MOL CELL BIOCHEM, V104, P57; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; TAKAHASHI H, 1981, J NEUROSURG, V55, P708, DOI 10.3171/jns.1981.55.5.0708; Walker AE, 1944, J NEUROSURG, V1, P103, DOI 10.3171/jns.1944.1.2.0103; YOUNG W, 1982, BRAIN RES, V253, P105, DOI 10.1016/0006-8993(82)90677-1; YOUNG W, 1982, BRAIN RES, V253, P115, DOI 10.1016/0006-8993(82)90678-3	23	223	226	0	4	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAR	1993	13	2					183	192		10.1038/jcbfm.1993.22			10	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	KM808	WOS:A1993KM80800001	8436609	Bronze			2021-06-18	
J	Greer, DM; Funk, SE; Reaven, NL; Ouzounelli, M; Uman, GC				Greer, David M.; Funk, Susan E.; Reaven, Nancy L.; Ouzounelli, Myrsini; Uman, Gwen C.			Impact of Fever on Outcome in Patients With Stroke and Neurologic Injury A Comprehensive Meta-Analysis	STROKE			English	Article						fever; meta-analysis; outcome; stroke; traumatic brain injury	INTENSIVE-CARE-UNIT; ADMISSION BODY-TEMPERATURE; INTRACEREBRAL HEMORRHAGE; SUBARACHNOID HEMORRHAGE; HYPERTHERMIA; MORTALITY; PYREXIA; SEVERITY; ISCHEMIA	Background and Purpose-Many studies associate fever with poor outcome in patients with neurological injury, but this relationship is blurred by divergence in populations and outcome measures. We sought to incorporate all recent scholarship addressing fever in brain-injured patients into a comprehensive meta-analysis to evaluate disparate clinical findings. Methods-We conducted a Medline search for articles since January 1, 1995 (in English with abstracts, in humans) and hand searches of references in bibliographies and review articles. Search terms covered stroke, neurological injury, thermoregulation, fever, and cooling. A total of 1139 citations were identified; we retained 39 studies with 67 tested hypotheses contrasting outcomes of fever/higher body temperature and normothermia/lower body temperature in patients with neurological injury covering 14 431 subjects. A separate meta-analysis was performed for each of 7 outcome measures. Significance was evaluated with Zc developed from probability values or t values. Correlational effect size, r((es)), was calculated for each study and used to derive Cohen's d unbiased combined effect size and relative risk. Results-Fever or higher body temperature was significantly associated with worse outcome in every measure studied. Relative risk of worse outcome with fever was: mortality, 1.5; Glasgow Outcome Scale, 1.3; Barthel Index, 1.9; modified Rankin Scale, 2.2; Canadian Stroke Scale, 1.4; intensive care length of stay, 2.8; and hospital length of stay, 3.2. Conclusions-In the pooled analyses covering 14 431 patients with stroke and other brain injuries, fever is consistently associated with worse outcomes across multiple outcome measures. (Stroke. 2008; 39: 3029-3035.)	[Greer, David M.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; [Funk, Susan E.; Reaven, Nancy L.; Ouzounelli, Myrsini] Strateg Hlth Resources, La Canada Flintridge, CA USA; [Uman, Gwen C.] Vital Res LLC, Los Angeles, CA USA	Greer, DM (corresponding author), Massachusetts Gen Hosp, Dept Neurol, ACC 835,55 Fruit St, Boston, MA 02114 USA.	Zgreer@partners.org		Greer, David/0000-0002-2026-8333	Medivance, Inc	S.E.F., N.L.R., M.O., and G.C.U. report financial support from Medivance, Inc under an agreement that the study be conducted independently to reduce funding bias. Accordingly, the study was designed, conducted, analyzed, interpreted, and written by investigators independent of Medivance and was not sent to agents of Medivance for prepublication review or approval.	Baena RC, 1997, NEUROLOGY, V48, P768, DOI 10.1212/WNL.48.3.768; Becker Betsy J., 1994, HDB RES SYNTHESIS; Boysen G, 2001, STROKE, V32, P413, DOI 10.1161/01.STR.32.2.413; Cohen J., 1977, STAT POWER ANAL BEHA, P1; Commichau C, 2003, NEUROLOGY, V60, P837, DOI 10.1212/01.WNL.0000047344.28843.EB; Diringer MN, 2004, CRIT CARE MED, V32, P1489, DOI 10.1097/01.CCM.0000129484.61912.84; Hajat C, 2000, STROKE, V31, P410, DOI 10.1161/01.STR.31.2.410; Kammersgaard LP, 2002, STROKE, V33, P1759, DOI 10.1161/01.STR.0000019910.90280.F1; Kilpatrick MM, 2000, NEUROSURGERY, V47, P850, DOI 10.1097/00006123-200010000-00011; Leira R, 2004, NEUROLOGY, V63, P461, DOI 10.1212/01.WNL.0000133204.81153.AC; Morimoto T, 1997, BRAIN RES, V746, P43, DOI 10.1016/S0006-8993(96)01154-7; Oliveira J, 2001, NEUROLOGY, V56, P1299, DOI 10.1212/WNL.56.10.1299; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; Rosenthal R, 2000, CONTRASTS EFFECT SIZ; Roy M K, 2004, J Assoc Physicians India, V52, P959; Schwarz S, 2000, NEUROLOGY, V54, P354, DOI 10.1212/WNL.54.2.354; Stocchetti N, 2005, J NEUROL NEUROSUR PS, V76, P1135, DOI 10.1136/jnnp.2004.041269; Stocchetti N, 2002, INTENS CARE MED, V28, P1555, DOI 10.1007/s00134-002-1513-1; SUZUKI S, 1995, STROKE, V26, P1020, DOI 10.1161/01.STR.26.6.1020; Wang Y, 2000, STROKE, V31, P404, DOI 10.1161/01.STR.31.2.404; Wartenberg KE, 2006, CRIT CARE MED, V34, P617, DOI 10.1097/01.CCM.0000201903.46435.35; WOLF F, 1986, METAANAL QUANTITATIV; Zeiner A, 2001, ARCH INTERN MED, V161, P2007, DOI 10.1001/archinte.161.16.2007	23	222	230	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0039-2499			STROKE	Stroke	NOV	2008	39	11					3029	3035		10.1161/STROKEAHA.108.521583			7	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	365SC	WOS:000260427100020	18723420	Bronze			2021-06-18	
J	Mosenthal, AC; Lavery, RF; Addis, M; Kaul, S; Ross, S; Marburger, R; Deitch, EA; Livingston, DH				Mosenthal, AC; Lavery, RF; Addis, M; Kaul, S; Ross, S; Marburger, R; Deitch, EA; Livingston, DH			Isolated traumatic brain injury: Age is an independent predictor of mortality and early outcome	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	59th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 16-18, 1999	BOSTON, MASSACHUSETTS	Amer Assoc Surg Trauma		traumatic brain injury; elderly; mortality; Glasgow Outcome Scale	GERIATRIC-PATIENTS; HEAD-INJURY; ELDERLY PATIENTS; MAJOR TRAUMA; DISABILITY; HEMATOMAS; SURVIVAL; ADULTS	Background: Geriatric trauma patients have a worse outcome than the young with comparable injuries. The contribution of traumatic brain injury (TBI) to this increased mortality is unknown and has been confounded by the presence of other injuries. The purpose of this study was to investigate the role of age in the mortality and early outcome from isolated TBI. Methods: This was a retrospective analysis of all adult patients with isolated TBI (Abbreviated Injury Scale score : 3) admitted during a 5-year period to two Level I trauma centers. Mortality, Glasgow Outcome Scale score at discharge, therapy, and complications were compared for elderly (age : 65 years) and younger patients. Results: Of 694 patients, 22% were defined as elderly. The mortality for the elderly group was twice that of their younger counterparts (30% vs. 14%, p < 0.001), even for those with mild to moderate TBI (Glasgow Coma Scale score of 9-15). Thirteen percent of elderly survivors had a poor functional outcome (Glasgow Outcome Scale score of 2 or 3) at hospital discharge versus 5% in the young group (p < 0.01). Independent factors associated with a high mortality were age and Glasgow Coma Scale score. Conclusion. The mortality from TBI is higher in the geriatric population at all levels of head injury. In addition, functional outcome at hospital discharge is worse. Although some of this increased mortality may be explained by complications or type of head injury, age itself is an independent predictor for mortality in TBI.	Univ Med & Dent New Jersey, Dept Surg, Newark, NJ 07103 USA; Univ Med & Dent New Jersey, Cooper Hosp, Med Ctr, Dept Surg, Camden, NJ 08103 USA; Cooper Hosp Univ Med Ctr, Med Ctr, Dept Surg, Camden, NJ USA	Mosenthal, AC (corresponding author), Univ Med & Dent New Jersey, Dept Surg, MSB G506,185 S Orange Ave, Newark, NJ 07103 USA.						AMACHER AL, 1987, NEUROSURGERY, V20, P954; [Anonymous], 1999, RES OPT CAR INJ PAT; CAGETTI B, 1992, BRIT J NEUROSURG, V6, P227, DOI 10.3109/02688699209002930; CHAMPION HR, 1989, AM J PUBLIC HEALTH, V79, P1278, DOI 10.2105/AJPH.79.9.1278; CHESTNUT RM, 1993, J TRAUMA, V43, P216; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; FINELLI FC, 1989, J TRAUMA, V29, P541, DOI 10.1097/00005373-198905000-00001; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; Grant PT, 2000, INJURY, V31, P519, DOI 10.1016/S0020-1383(00)00038-3; HOWARD MA, 1989, J NEUROSURG, V71, P858, DOI 10.3171/jns.1989.71.6.0858; Kilaru S, 1996, J TRAUMA, V41, P957, DOI 10.1097/00005373-199612000-00003; KOTWICA Z, 1992, ACTA NEUROCHIR, V118, P98, DOI 10.1007/BF01401293; MORRIS JA, 1990, J TRAUMA, V30, P1476, DOI 10.1097/00005373-199012000-00006; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; Reeder KP, 1996, J HEAD TRAUMA REHAB, V11, P22, DOI 10.1097/00001199-199606000-00006; Rothweiler B, 1998, ARCH PHYS MED REHAB, V79, P881, DOI 10.1016/S0003-9993(98)90082-X; SCALEA TM, 1990, J TRAUMA, V30, P129, DOI 10.1097/00005373-199002000-00001; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; VANAALST JA, 1991, J TRAUMA, V31, P1096; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; WALD SL, 1993, J TRAUMA, V34, P377, DOI 10.1097/00005373-199303000-00012	21	222	224	1	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAY	2002	52	5					907	911		10.1097/00005373-200205000-00015			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	552DM	WOS:000175603600024	11988658				2021-06-18	
J	Golarai, G; Greenwood, AC; Feeney, DM; Connor, JA				Golarai, G; Greenwood, AC; Feeney, DM; Connor, JA			Physiological and structural evidence for hippocampal involvement in persistent seizure susceptibility after traumatic brain injury	JOURNAL OF NEUROSCIENCE			English	Article						traumatic brain injury; hippocampal sclerosis; mossy fiber synaptic reorganization; sprouting; seizures; neuron death; epilepsy; optical recording; voltage-sensitive dye di-2-ANEPEQ	FIBER SYNAPTIC REORGANIZATION; TEMPORAL-LOBE EPILEPSY; LONG-TERM POTENTIATION; DENTATE GRANULE CELLS; KAINATE-TREATED RATS; MOSSY FIBERS; NEURONAL DEGENERATION; FASCIA DENTATA; HEAD TRAUMA; FLUORO-JADE	Epilepsy is a common outcome of traumatic brain injury (TBI), but the mechanisms of posttraumatic epileptogenesis are poorly understood. One clue is the occurrence of selective hippocampal cell death after fluid-percussion TBI in rats, consistent with the reported reduction of hippocampal volume bilaterally in humans after TBI and resembling hippocampal sclerosis, a hallmark of temporal-lobe epilepsy. Other features of temporal-lobe epilepsy, such as long-term seizure susceptibility, persistent hyperexcitability in the dentate gyrus (DG), and mossy fiber synaptic reorganization, however, have not been examined after TBI. To determine whether TBI induces these changes, we used a well studied model of TBI by weight drop on somatosensory cortex in adult rats. First, we confirmed an early and selective cell loss in the hilus of the DG and area CA3 of hippocampus, ipsilateral to the impact. Second, we found persistently enhanced susceptibility to pentylenetetrazole-induced convulsions 15 weeks after TBI. Third, by applying GABA(A) antagonists during field-potential and optical recordings in hippocampal slices 3 and 15 weeks after TBI, we unmasked a persistent, abnormal APV-sensitive hyperexcitability that was bilateral and localized to the granule cell and molecular layers of the DG. Finally, using Timm histochemistry, we detected progressive sprouting of mossy fibers into the inner molecular layers of the DG bilaterally 2-27 weeks after TBI. These findings are consistent with the development of posttraumatic epilepsy in an animal model of impact head injury, showing a striking similarity to the enduring behavioral, functional, and structural alterations associated with temporal-lobe epilepsy.	Univ New Mexico, Dept Neurosci, Albuquerque, NM 87131 USA; Univ New Mexico, Dept Psychol, Albuquerque, NM 87133 USA	Golarai, G (corresponding author), Stanford Univ, Dept Psychol, Jordan Hall Bldg 420, Stanford, CA 94305 USA.	ggolarai@psych.stanford.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K01HD001324] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035644] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K01HD01324] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-35644] Funding Source: Medline		Aamodt S M, 1999, Adv Neurol, V79, P133; Annegers JF, 1996, MAYO CLIN PROC, V71, P570, DOI 10.4065/71.6.570; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Babb T L, 1997, Adv Neurol, V72, P45; Bausch S B, 1999, Curr Opin Neurol, V12, P203, DOI 10.1097/00019052-199904000-00012; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; CAVAZOS JE, 1991, BRAIN RES, V541, P179; CAVAZOS JE, 1992, HIPPOCAMPUS, V2, P363, DOI 10.1002/hipo.450020404; CAVAZOS JE, 1990, BRAIN RES, V527, P1, DOI 10.1016/0006-8993(90)91054-K; CAVAZOS JE, 1991, J NEUROSCI, V11, P2795; CAVAZOS JE, 1994, J NEUROSCI, V14, P3106; CLAUSSEN CD, 1977, J COMPUT ASSIST TOMO, V1, P472, DOI 10.1097/00004728-197710000-00014; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Cotman C W, 1979, Prog Brain Res, V51, P203; Coulter DA, 1996, EPILEPSY RES, V26, P81, DOI 10.1016/S0920-1211(96)00044-7; CRAIG CR, 1988, PHARMACOL BIOCHEM BE, V31, P867, DOI 10.1016/0091-3057(88)90397-8; CRONIN J, 1992, BRAIN RES, V573, P305, DOI 10.1016/0006-8993(92)90777-7; D'Ambrosio R, 1999, J NEUROSCI, V19, P8152; DANSCHER G, 1981, HISTOCHEMISTRY, V71, P1, DOI 10.1007/BF00592566; DUDEK FE, 1994, HIPPOCAMPUS, V4, P259, DOI 10.1002/hipo.450040306; EYSEL UT, 1997, ADV NEUROL, P573; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Feeney DM, 1997, ADV NEUROL, V73, P383; FEENEY DM, 1979, ARCH NEUROL-CHICAGO, V36, P8, DOI 10.1001/archneur.1979.00500370038005; FRICKE RA, 1984, J NEUROPHYSIOL, V51, P195; FROTSCHER M, 1983, J COMP NEUROL, V215, P299, DOI 10.1002/cne.902150306; GLANTZ SA, 1997, BIOSTATISTICS; GOLARAI G, 1992, BRAIN RES, V593, P257, DOI 10.1016/0006-8993(92)91316-7; Golarai G, 1996, J NEUROPHYSIOL, V75, P343; GOLARAI G, 1999, NEUR ABSTR, V25, P980; GRAFSTEIN B, 1957, ELECTROEN CLIN NEURO, V9, P723, DOI 10.1016/0013-4694(57)90096-2; Hagemann G, 2000, J NEUROPHYSIOL, V84, P600; HEINEMANN U, 1992, DENTATE GYRUS ITS S, V7, P273; HERNANDEZ TD, 1988, EXP NEUROL, V102, P318, DOI 10.1016/0014-4886(88)90226-9; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Jacobs KM, 1996, CEREB CORTEX, V6, P514, DOI 10.1093/cercor/6.3.514; Jacobs KM, 2000, EPILEPSIA, V41, pS153, DOI 10.1111/j.1528-1157.2000.tb01574.x; JONES TA, 1994, J NEUROSCI, V14, P2140; Kolb B, 1999, CAN J EXP PSYCHOL, V53, P62, DOI 10.1037/h0087300; KOO AH, 1977, RADIOLOGY, V123, P345, DOI 10.1148/123.2.345; Kotti T, 1996, EUR J NEUROSCI, V8, P2371, DOI 10.1111/j.1460-9568.1996.tb01200.x; KROBERT KA, 1992, J NEUROTRAUM, V9, P64; LAURBERG S, 1981, J COMP NEUROL, V200, P433, DOI 10.1002/cne.902000310; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Lynch M, 2000, J NEUROPHYSIOL, V84, P2868; Lynch MW, 1996, CURR OPIN NEUROL, V9, P97, DOI 10.1097/00019052-199604000-00007; MASON CR, 1972, EPILEPSIA, V13, P663, DOI 10.1111/j.1528-1157.1972.tb04401.x; Mitchell TW, 1999, J COMP NEUROL, V411, P563; MODY I, 1988, J NEUROPHYSIOL, V59, P1033; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; OKAZAKI MM, 1995, J COMP NEUROL, V352, P515, DOI 10.1002/cne.903520404; Olney J W, 1986, Adv Neurol, V44, P857; Osteen C. L., 2000, Journal of Neurotrauma, V17, P958; Parent JM, 1997, CURR OPIN NEUROL, V10, P103, DOI 10.1097/00019052-199704000-00006; Pierallini A, 2000, NEURORADIOLOGY, V42, P860, DOI 10.1007/s002340000447; Prince D A, 1999, Adv Neurol, V79, P665; PRINCE DA, 1993, J NEUROPHYSIOL, V69, P1276; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; Ribak CE, 1998, J COMP NEUROL, V401, P266; Sacks J, 1941, J PHARMACOL EXP THER, V73, P289; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Schallert T, 1997, ADV NEUROL, V73, P229; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Schmued LC, 2000, TOXICOL PATHOL, V28, P91, DOI 10.1177/019262330002800111; SERESS L, 1983, EXP BRAIN RES, V50, P173; SLOVITER RS, 1992, NEUROSCI LETT, V137, P91, DOI 10.1016/0304-3940(92)90306-R; Snedecor G.W., 1980, STAT METHODS, V7th; STANFIELD BB, 1989, BRAIN RES, V480, P294, DOI 10.1016/0006-8993(89)90195-9; SUTULA T, 1988, SCIENCE, V239, P1147, DOI 10.1126/science.2449733; Sutula T, 1996, J NEUROSCI, V16, P7398; SUTULA T, 1992, J NEUROSCI, V12, P4173; Sutula T, 1998, J COMP NEUROL, V390, P578, DOI 10.1002/(SICI)1096-9861(19980126)390:4<578::AID-CNE9>3.0.CO;2-Y; SUTULA T, 1989, ANN NEUROL, V26, P321, DOI 10.1002/ana.410260303; SUTULA TP, 1992, EPILEPSY RES, P251; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; TAUCK DL, 1985, J NEUROSCI, V5, P1016; Toth Z, 1998, J NEUROSCI, V18, P4285; Toth Z, 1997, J NEUROSCI, V17, P8106; WEISEND MP, 1994, J NEUROSURG, V80, P120, DOI 10.3171/jns.1994.80.1.0120; Wuarin JP, 1996, J NEUROSCI, V16, P4438; Yang D N, 1997, J Am Optom Assoc, V68, P519; YOSHII N, 1978, NEURORADIOLOGY, V16, P311, DOI 10.1007/BF00395285	86	222	230	1	15	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	NOV 1	2001	21	21					8523	8537					15	Neurosciences	Neurosciences & Neurology	482ZL	WOS:000171608600032	11606641				2021-06-18	
J	DIKMEN, SS; TEMKIN, NR; MACHAMER, JE; HOLUBKOV, AL; FRASER, RT; WINN, R				DIKMEN, SS; TEMKIN, NR; MACHAMER, JE; HOLUBKOV, AL; FRASER, RT; WINN, R			EMPLOYMENT FOLLOWING TRAUMATIC HEAD-INJURIES	ARCHIVES OF NEUROLOGY			English	Article							POSTTRAUMATIC SEIZURES; BRAIN; PHENYTOIN; SEVERITY; SCALE	Objective: Determine rates of, and factors predictive of, return to work in patients with civilian traumatic head injuries. Design: Inception cohort study with 1- to 2-year follow-up. Setting: Hospitalized patients in a level I trauma center. Patients: Three hundred sixty-six hospitalized head-injured subjects who were workers before injury and 95 comparison subjects participated in prospective, longitudinal investigations of employment following head injury. Head-injured and comparison subjects were similar on basic demographics and preinjury employment status. The comparison subjects consisted of patients who sustained traumatic injury to the body but not to the head. Main Outcome Measure: Time taken to return to work following head injury. Results: Survival methodology was used for analysis. Whether patients returned to work and when related to both the characteristics of the injured patients leg, education, preinjury work history), the severity of head injury and associated neuropsychologic problems, and se verity of other system injuries. More precise predictions were possible using the multivariate model. Conclusions: The present study provides a means of assessing employment potential predictively. This can be useful for clinical and research purposes. The results should be used cautiously and should stimulate discussions of appropriate use of services and resources to meet individual patients' needs.	UNIV WASHINGTON,DEPT NEUROL SURG,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT PSYCHIAT & BEHAV SCI,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT BIOSTAT,SEATTLE,WA 98195	DIKMEN, SS (corresponding author), UNIV WASHINGTON,DEPT REHABIL MED,RJ-30,SEATTLE,WA 98195, USA.				AHRQ HHSUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [HS06497, HS05304, HS04146] Funding Source: Medline		BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Bruckner F E, 1972, Rheumatol Phys Med, V11, P344, DOI 10.1093/rheumatology/11.7.344; COX DR, 1972, J R STAT SOC B, V34, P187; DACEY R, 1991, J TRAUMA, V31, P217, DOI 10.1097/00005373-199131020-00011; DIKMEN S, 1987, J NEUROL NEUROSUR PS, V50, P1613, DOI 10.1136/jnnp.50.12.1613; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271; DRESSER AC, 1973, ARCH NEUROL-CHICAGO, V29, P111, DOI 10.1001/archneur.1973.00490260055011; FRASER R, 1988, REHABIL COUNS BULL, V31, P276; Halstead WC, 1985, HALSTEAD REITAN NEUR; HEISKANEN O, 1970, ACTA NEUROL SCAND, V46, P343, DOI 10.1111/j.1600-0404.1970.tb05798.x; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAY T, 1984, PUBLICATION NEW YORK, V1851; MACKENZIE EJ, 1987, AM J PUBLIC HEALTH, V77, P329, DOI 10.2105/AJPH.77.3.329; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; PETRUCELLI E, 1981, ACCIDENT ANAL PREV, V13, P29, DOI 10.1016/0001-4575(81)90040-3; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; TEASDALE G, 1974, LANCET, V2, P81; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; WEHMAN P, 1991, TRAUMATIC BRAIN INJU; 1977, DICT OCCUPATIONAL TI	25	222	223	0	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0003-9942			ARCH NEUROL-CHICAGO	Arch. Neurol.	FEB	1994	51	2					177	186		10.1001/archneur.1994.00540140087018			10	Clinical Neurology	Neurosciences & Neurology	MW625	WOS:A1994MW62500012	8304843				2021-06-18	
J	Roberts, I; Shakur, H; Coats, T; Hunt, B; Balogun, E; Barnetson, L; Cook, L; Kawahara, T; Perel, P; Prieto-Merino, D; Ramos, M; Cairns, J; Guerriero, C				Roberts, I.; Shakur, H.; Coats, T.; Hunt, B.; Balogun, E.; Barnetson, L.; Cook, L.; Kawahara, T.; Perel, P.; Prieto-Merino, D.; Ramos, M.; Cairns, J.; Guerriero, C.			The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients	HEALTH TECHNOLOGY ASSESSMENT			English	Article							COAGULOPATHY; HEMORRHAGE; SURGERY	Background: Among trauma patients who survive to reach hospital, exsanguination is a common cause of death. A widely practicable treatment that reduces blood loss after trauma could prevent thousands of premature deaths each year. The CRASH-2 trial aimed to determine the effect of the early administration of tranexamic acid on death and transfusion requirement in bleeding trauma patients. In addition, the effort of tranexamic acid on the risk of vascular occlusive events was assessed. Objective: Tranexamic acid (TXA) reduces bleeding in patients undergoing elective surgery. We assessed the effects and cost-effectiveness of the early administration of a short course of TXA on death, vascular occlusive events and the receipt of blood transfusion in trauma patients. Design: Randomised placebo-controlled trial and economic evaluation. Randomisation was balanced by centre, with an allocation sequence based on a block size of eight, generated with a computer random number generator. Both participants and study staff (site investigators and trial co-ordinating centre staff) were masked to treatment allocation. All analyses were by intention to treat. A Markov model was used to assess cost-effectiveness. The health outcome was the number of life-years (LYs) gained. Cost data were obtained from hospitals, the World Health Organization database and UK reference costs. Cost-effectiveness was measured in international dollars ($) per LY. Deterministic and probabilistic sensitivity analyses were performed to test the robustness of the results to model assumptions. Setting: Two hundred and seventy-four hospitals in 40 countries. Participants: Adult trauma patients (n = 20,211) with, or at risk of, significant bleeding who were within 8 hours of injury. Interventions: Tranexamic acid (loading dose 1 g over 10 minutes then infusion of 1 g over 8 hours) or matching placebo. Main outcome measures: The primary outcome was death in hospital within 4 weeks of injury, and was described with the following categories: bleeding, vascular occlusion (myocardial infarction, stroke and pulmonary embolism), multiorgan failure, head injury and other. Results: Patients were allocated to TXA (n = 10,096) and to placebo (n = 10,115), of whom 10,060 and 10,067 patients, respectively, were analysed. All-cause mortality at 28 days was significantly reduced by TXA [1463 patients (14.5%) in the TXA group vs 1613 patients (16.0%) in the placebo group; relative risk (RR) 0.91; 95% confidence interval (CI) 0.85 to 0.97; p = 0.0035]. The risk of death due to bleeding was significantly reduced [489 patients (4.9%) died in the TXA group vs 574 patients (5.7%) in the placebo group; RR 0.85; 95% CI 0.76 to 0.96; p = 0.0077]. We recorded strong evidence that the effect of TXA on death due to bleeding varied according to the time from injury to treatment (test for interaction p < 0.0001). Early treatment (= 1 hour from injury) significantly reduced the risk of death due to bleeding [198 out of 3747 patients (5.3%) died in the TXA group vs 286 out of 3704 patients (7.7%) in the placebo group; RR 0.68; 95% CI 0.57 to 0.82; p < 0.0001]. Treatment given between 1 and 3 hours also reduced the risk of death due to bleeding [147 out of 3037 patients (4.8%) died in the TXA group vs 184 out of 2996 patients (6.1%) in the placebo group; RR 0.79; 95% CI 0.64 to 0.97; p = 0.03]. Treatment given after 3 hours seemed to increase the risk of death due to bleeding [144 out of 3272 patients (4.4%) died in the TXA group vs 103 out of 3362 patients (3.1%) in the placebo group; RR 1.44; 95% CI 1.12 to 1.84; p = 0.004]. We recorded no evidence that the effect of TXA on death due to bleeding varied by systolic blood pressure, Glasgow Coma Scale score or type of injury. Administering TXA to bleeding trauma patients within 3 hours of injury saved an estimated 755 LYs per 1000 trauma patients in the UK. The cost of giving TXA to 1000 patients was estimated at $30,830. The incremental cost of giving TXA compared with not giving TXA was $48,002. The incremental cost per LY gained of administering TXA was $64. Conclusions: Early administration of TXA safely reduced the risk of death in bleeding trauma patients and is highly cost-effective. Treatment beyond 3 hours of injury is unlikely to be effective. Future work [the Clinical Randomisation of an Antifibrinolytic in Significant Head injury-3 (CRASH-3) trial] will evaluate the effectiveness and safety of TXA in the treatments of isolated traumatic brain injury (http://crash3.lshtm.ac.uk/).	[Roberts, I.; Shakur, H.; Balogun, E.; Barnetson, L.; Cook, L.; Kawahara, T.; Perel, P.; Prieto-Merino, D.; Ramos, M.] London Sch Hyg & Trop Med, Clin Trials Unit, London WC1, England; [Coats, T.] Univ Leicester, Dept Cardiovasc Sci, Leicester, Leics, England; [Hunt, B.] Kings Coll London, Guys & St Thomas NHS Fdn Trust, London WC2R 2LS, England; [Cairns, J.; Guerriero, C.] London Sch Hyg & Trop Med, Fac Publ Hlth & Policy, London WC1, England	Roberts, I (corresponding author), London Sch Hyg & Trop Med, Clin Trials Unit, London WC1, England.		Cairns, John/AAD-1168-2020	Shakur-Still, Haleema/0000-0002-6511-109X; Prieto-Merino, David/0000-0001-5001-0061; Coats, Timothy/0000-0003-2736-2784	Bupa Foundation; J P Moulton Charitable Foundation; NIHR Health Technology Assessment programmeNational Institute for Health Research (NIHR); National Institute for Health ResearchNational Institute for Health Research (NIHR) [06/303/20] Funding Source: researchfish	The project was funded by the Bupa Foundation, the J P Moulton Charitable Foundation and the NIHR Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 17, No. 10. See HTA programme website for further project information.	[Anonymous], 2004, MED HUMAN USE CLIN T; [Anonymous], 2006, MED HUMAN USE CLIN T; Assmann SF, 2000, LANCET, V355, P1064, DOI 10.1016/S0140-6736(00)02039-0; AYLWARD GW, 1994, EYE, V8, P440, DOI 10.1038/eye.1994.104; Brohi K, 2008, J TRAUMA, V64, P1211, DOI 10.1097/TA.0b013e318169cd3c; Bureau of Labor Statistics, 2009, HIST CONS PRIC IND U; Burnett J, 2007, BMJ-BRIT MED J, V334, P671; Casati V, 1999, ANN THORAC SURG, V68, P2252, DOI 10.1016/S0003-4975(99)00866-8; Chalmers I, 2007, INT J PHARM MED, V21, P395, DOI 10.2165/00124363-200721060-00004; Cleves M., 2008, INTRO SURVIVAL ANAL, V2; Commission on Macroeconomics and Health, 2001, MACR HLTH INV HLTH E; Curtis L. A., 2009, UNIT COSTS HLTH SOCI; Department of Health, 2010, NHS REF COSTS 2008 2; Duley L, 2008, CLIN TRIALS, V5, P40, DOI 10.1177/1740774507087704; Dziekan G, 2003, B WORLD HEALTH ORGAN, V81, P277; Eaton MP, 2008, ANESTH ANALG, V106, P1087, DOI 10.1213/ane.0b013e3181679555; Edwards P, 2006, BMJ-BRIT MED J, V333, P119, DOI 10.1136/bmj.38875.757488.4F; Ferrer P, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-29; Fiechtner BK, 2001, ANESTH ANALG, V92, P1131; Goodnough LT, 2003, LANCET, V361, P161, DOI 10.1016/S0140-6736(03)12195-2; Government Medical College, 2010, CHAND HOSP IND; Guerriero C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018987; Henry DA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001886.pub2; Henry DA, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001886.pub4; Hess JR, 2008, J TRAUMA, V65, P748, DOI 10.1097/TA.0b013e3181877a9c; HEYMANN SJ, 1992, AM J INFECT CONTROL, V20, P256, DOI 10.1016/S0196-6553(05)80199-3; HORROW JC, 1995, ANESTHESIOLOGY, V82, P383, DOI 10.1097/00000542-199502000-00009; Kenet G, 1999, LANCET, V354, P1879, DOI 10.1016/S0140-6736(99)05155-7; Kiwanuka N, 2004, AIDS, V18, P342, DOI 10.1097/00002030-200401230-00032; Lawson JH, 2004, SEMIN HEMATOL, V41, P55, DOI 10.1053/j.seminhematol.2003.11.012; Levy JH, 2010, LANCET, V376, P3, DOI 10.1016/S0140-6736(10)60939-7; Murray CJL., 1996, GLOBAL HLTH STAT COM; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Nantulya Vinand M, 2003, Inj Control Saf Promot, V10, P13, DOI 10.1076/icsp.10.1.13.14116; National Institute for Clinical Excellence (NICE), 2008, UPD GUID METH TECHN, P29; NORTON R, 2006, UNINTENTIONAL INJURI, P737, DOI DOI 10.1596/978-0-821-36179-5/CHPT-39; Organisation for Economic Cooperation and Development (OECD), 2008, OECD EC SURVEYS INDO; Pennsylvania University, 2010, PENN WORLD TABL; Perel P, 2012, HLTH TECHNOL ASSESS, V16; Perel P, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-72; Peto R, 1998, BMJ-BRIT MED J, V317, P1170, DOI 10.1136/bmj.317.7167.1170; Porte RJ, 2002, DRUGS, V62, P2193, DOI 10.2165/00003495-200262150-00003; Prentice C R, 1980, J Clin Pathol Suppl (R Coll Pathol), V14, P35; Roberts I, 2004, EMERG MED J, V21, P703, DOI 10.1136/emj.2002.004788; Roberts I, 2011, LANCET, V377, P1096, DOI 10.1016/S0140-6736(11)60278-X; Roberts I, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004896.pub3; RODGERS A, 1995, THROMB HAEMOSTASIS, V73, P167; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Sawamura A, 2009, THROMB RES, V124, P608, DOI 10.1016/j.thromres.2009.06.034; Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5; Shakur H, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-40; Sterne JAC, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2393; Subaiya S, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-31; Sun X, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c117; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P591; The CRASH Trials Co-ordinating Centre, 2005, PROT 05PRT 1 CRASH 2; Thomas A, 2004, INVOLVEMENT IMPACT R; Tien H, 2004, CURR ORTHOPAED, V18, P304, DOI 10.1016/j.cuor.2004.04.006; World Bank, 2010, GDP CURR US; *WORLD BANK, 2010, COUNTR CLASS; World Health Organization, 2005, CHOSING INT COST EFF; World Medical Association, 2008, DECL HELS ETH PRINC; YUSUF S, 1991, JAMA-J AM MED ASSOC, V266, P93, DOI 10.1001/jama.266.1.93; PROTECTION HUMAN SUB	64	221	232	1	32	NIHR JOURNALS LIBRARY	SOUTHAMPTON	UNIV SOUTHAMPTON, EVALUATION, TRIALS & STUDIES COORDINATING CENTRE, ALPHA HOUSE, ENTERPRISE RD, SOUTHAMPTON, SO16 7NS, ENGLAND	1366-5278	2046-4924		HEALTH TECHNOL ASSES	Health Technol. Assess.	MAR	2013	17	10					1	+		10.3310/HTA17100			77	Health Care Sciences & Services	Health Care Sciences & Services	120OQ	WOS:000317180700001	23477634	DOAJ Gold, Green Published, Green Accepted	Y	N	2021-06-18	
J	Maugans, TA; Farley, C; Altaye, M; Leach, J; Cecil, KM				Maugans, Todd A.; Farley, Chad; Altaye, Mekibib; Leach, James; Cecil, Kim M.			Pediatric Sports-Related Concussion Produces Cerebral Blood Flow Alterations	PEDIATRICS			English	Article						concussion; pediatrics; MRI; cerebral blood flow; magnetic resonance spectroscopy	MAGNETIC-RESONANCE-SPECTROSCOPY; TRAUMATIC BRAIN-INJURY; PROTON MR SPECTROSCOPY; HIGH-SCHOOL; TEMPORAL WINDOW; NEUROCOGNITIVE PERFORMANCE; INTRACRANIAL-PRESSURE; BIPOLAR DEPRESSION; AXONAL INJURY; FRONTAL-LOBE	OBJECTIVE: The pathophysiology of sports-related concussion (SRC) is incompletely understood. Human adult and experimental animal investigations have revealed structural axonal injuries, decreases in the neuronal metabolite N-acetyl aspartate, and reduced cerebral blood flow (CBF) after SRC and minor traumatic brain injury. The authors of this investigation explore these possibilities after pediatric SRC. PATIENTS AND METHODS: Twelve children, ages 11 to 15 years, who experienced SRC were evaluated by ImPACT neurocognitive testing, T1 and susceptibility weighted MRI, diffusion tensor imaging, proton magnetic resonance spectroscopy, and phase contrast angiography at <72 hours, 14 days, and 30 days or greater after concussion. A similar number of age-and gender-matched controls were evaluated at a single time point. RESULTS: ImPACT results confirmed statistically significant differences in initial total symptom score and reaction time between the SRC and control groups, resolving by 14 days for total symptom score and 30 days for reaction time. No evidence of structural injury was found on qualitative review of MRI. No decreases in neuronal metabolite N-acetyl aspartate or elevation of lactic acid were detected by proton magnetic resonance spectroscopy. Statistically significant alterations in CBF were documented in the SRC group, with reduction in CBF predominating (38 vs 48 mL/100 g per minute; P = .027). Improvement toward control values occurred in only 27% of the participants at 14 days and 64% at >30 days after SRC. CONCLUSIONS: Pediatric SRC is primarily a physiologic injury, affecting CBF significantly without evidence of measurable structural, metabolic neuronal or axonal injury. Further study of CBF mechanisms is needed to explain patterns of recovery. Pediatrics 2012;129:28-37	[Maugans, Todd A.] Cincinnati Childrens Hosp Med Ctr, Div Neurosurg, Dept Surg, Cincinnati, OH 45229 USA; [Altaye, Mekibib] Cincinnati Childrens Hosp Med Ctr, Div Epidemiol & Biostat, Cincinnati, OH 45229 USA; [Altaye, Mekibib; Cecil, Kim M.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA; [Leach, James; Cecil, Kim M.] Cincinnati Childrens Hosp Med Ctr, Dept Radiol, Cincinnati, OH 45229 USA; [Maugans, Todd A.; Farley, Chad] Univ Cincinnati Coll Med, Dept Neurosurg, Cincinnati, OH USA	Maugans, TA (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Pediat Neurosurg, MLC 2016,3333 Burnet Ave, Cincinnati, OH 45229 USA.	todd.maugans@cchmc.org	Altaye, Mekibib/N-5274-2015	Cecil, Kim/0000-0001-8233-5485	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NIH/NCRRUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [5UL1RR026314-02]; Mayfield Neuroscience Foundation, Division of Pediatric Neurosurgery within the Department of Surgery, Imaging Research Center within the Department of Radiology, at the University of Cincinnati College of Medicine; Research Foundation at Cincinnati Children's Hospital Medical Center; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000077] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR026314] Funding Source: NIH RePORTER	Funded by the National Institutes of Health (NIH).; This project was supported by an Institutional Clinical and Translational Science Award, NIH/NCRR grant 5UL1RR026314-02 and a competitive grant from the Mayfield Neuroscience Foundation, Division of Pediatric Neurosurgery within the Department of Surgery, Imaging Research Center within the Department of Radiology, at the University of Cincinnati College of Medicine and the Research Foundation at Cincinnati Children's Hospital Medical Center. We appreciate the assistance of Rachel Wolf, Kendall O'Brien, Amanda Golsch, and Travis Beckwith, Jon Divine, MD, Todd Arthur, MD, Lynn Babcock-Cimpello, MD, in conducting the study.	Adelson PD, 2011, CHILD NERV SYST, V27, P1465, DOI 10.1007/s00381-011-1476-z; Ayr LK, 2009, J INT NEUROPSYCH SOC, V15, P19, DOI 10.1017/S1355617708090188; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Biagi L, 2007, J MAGN RESON IMAGING, V25, P696, DOI 10.1002/jmri.20839; Botteri M, 2008, CRIT CARE MED, V36, P3089, DOI 10.1097/CCM.0b013e31818bd7df; Bouma G J, 1995, New Horiz, V3, P384; Broglio SP, 2011, J NEUROTRAUMA; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Broglio SP, 2009, CLIN J SPORT MED, V19, P377, DOI 10.1097/JSM.0b013e3181b625fe; Buzzini SRR, 2006, CURR OPIN PEDIATR, V18, P376, DOI 10.1097/01.mop.0000236385.26284.ec; Cantu RC, 2007, NEUROSURGERY, V61, P223, DOI 10.1227/01.NEU.0000255514.73967.90; Cecil KM, 2011, ENVIRON HEALTH PERSP, V119, P403, DOI 10.1289/ehp.1002176; Cecil Kim M, 2006, Top Magn Reson Imaging, V17, P275, DOI 10.1097/RMR.0b013e318033787e; Cecil KM, 1998, J NEUROCHEM, V70, P2038; Cecil KM, 2006, NEUROIMAG CLIN N AM, V16, P87, DOI 10.1016/j.nic.2005.10.004; Cecil KM, 2003, J CHILD ADOL PSYCHOP, V13, P545, DOI 10.1089/104454603322724931; Cecil KM, 1999, NEUROPSYCHOPHARMACOL, V20, P131, DOI 10.1016/S0893-133X(98)00063-3; Cecil KM, 2002, BIPOLAR DISORD, V4, P357, DOI 10.1034/j.1399-5618.2002.02235.x; Cecil KM, 2002, J COMPUT ASSIST TOMO, V26, P818, DOI 10.1097/00004728-200209000-00026; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Cecil KM, 1998, NEUROIMAG CLIN N AM, V8, P863; Cernak I, 2010, DEV NEUROSCI-BASEL, V32, P442, DOI 10.1159/000320085; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Cohen JS, 2009, CURR OPIN PEDIATR, V21, P288, DOI 10.1097/MOP.0b013e32832b1195; Covassin T, 2010, PHYSICIAN SPORTSMED, V38, P87, DOI 10.3810/psm.2010.12.1830; Covassin T, 2009, J ATHL TRAINING, V44, P639, DOI 10.4085/1062-6050-44.6.639; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Della Corte F, 1997, ACTA NEUROCHIR WIEN, V139, P636; DellaCorte F, 1997, ACTA NEUROCHIR, V139, P636; Dinopoulos A, 2005, NEUROPEDIATRICS, V36, P290, DOI 10.1055/s-2005-872807; Ellemberg D, 2009, J NEUROTRAUM, V26, P2365, DOI 10.1089/neu.2009.0906; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Figaji AA, 2009, J NEUROSURG-PEDIATR, V4, P420, DOI 10.3171/2009.6.PEDS096; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Ge YL, 2009, BRAIN INJURY, V23, P666, DOI 10.1080/02699050903014899; Gergont Aleksandra, 2007, Przegl Lek, V64, P937; Giza CC, 2001, J ATHL TRAINING, V36, P228; Gosselin N, 2010, PHYSICIAN SPORTSMED, V38, P27, DOI 10.3810/psm.2010.10.1805; Guskiewicz KM, 2011, PM&R, V3, P353, DOI 10.1016/j.pmrj.2010.12.006; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Hlatky R, 2004, NEUROCRIT CARE, V1, P69, DOI 10.1385/NCC:1:1:69; Inoue Y, 2005, J NEUROTRAUM, V22, P1411, DOI 10.1089/neu.2005.22.1411; Isa Ruwaida, 2003, Neurosurg Focus, V15, pE1; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Johnson EW, 2011, CLIN SPORT MED, V30, P73, DOI 10.1016/j.csm.2010.08.007; Lange R. T., 2011, J HEAD TRAUMA REHABI; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; Lee Michael A, 2010, Conn Med, V74, P149; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Maerlender A, 2010, CLIN NEUROPSYCHOL, V24, P1309, DOI 10.1080/13854046.2010.516072; Makoroff KL, 2005, PEDIATR RADIOL, V35, P668, DOI 10.1007/s00247-005-1441-7; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrory P, 2011, CLIN J SPORT MED, V21, P6, DOI 10.1097/JSM.0b013e318204db50; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; McLeod TCV, 2011, J SPORT REHABIL, V20, P46, DOI 10.1123/jsr.20.1.46; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Meehan WP, 2010, J PEDIATR-US, V157, P889, DOI 10.1016/j.jpeds.2010.06.040; Meehan WP, 2011, CLIN SPORT MED, V30, P115, DOI 10.1016/j.csm.2010.08.003; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; Nesmith J Darrell, 2010, J Ark Med Soc, V107, P111; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Nowak Agnieszka, 2008, Przegl Lek, V65, P777; Omalu Bennet I, 2010, J Forensic Nurs, V6, P130, DOI 10.1111/j.1939-3938.2010.01078.x; Patel NC, 2008, J CHILD ADOL PSYCHOP, V18, P132, DOI 10.1089/cap.2007.0088; Patel NC, 2008, J CHILD ADOL PSYCHOP, V18, P623, DOI 10.1089/cap.2007.151; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; ROACH ES, 1989, HEADACHE, V29, P379, DOI 10.1111/j.1526-4610.1989.hed2906379.x; Sabini RC, 2010, PHYSICIAN SPORTSMED, V38, P139, DOI 10.3810/psm.2010.04.1771; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2011, CLIN NEUROPSYCHOL, V25, P1042, DOI 10.1080/13854046.2011.556669; Schrader Harald, 2009, BMC Med Imaging, V9, P11, DOI 10.1186/1471-2342-9-11; Schramm P, 2011, J NEUROSURG ANESTH, V23, P41, DOI 10.1097/ANA.0b013e3181f35854; Schutt S, 2001, J NEUROTRAUM, V18, P595, DOI 10.1089/089771501750291837; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P145, DOI 10.1136/jnnp.58.2.145; Sinson G, 2001, AM J NEURORADIOL, V22, P143; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Smith DH, 1998, J NEUROTRAUM, V15, P665, DOI 10.1089/neu.1998.15.665; Solomon GS, 2011, CLIN SPORT MED, V30, P165, DOI 10.1016/j.csm.2010.09.002; Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Thomas DG, 2011, ACAD EMERG MED, V18, P246, DOI 10.1111/j.1553-2712.2011.01015.x; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; van Santbrink H, 2002, ACTA NEUROCHIR, V144, P1141, DOI 10.1007/s00701-002-1012-8; Vavilala MS, 2007, J NEUROTRAUM, V24, P87, DOI 10.1089/neu.2006.0058; Vavilala Monica S, 2004, Pediatr Crit Care Med, V5, P257, DOI 10.1097/01.PCC.0000123545.69133.C3; Walz NC, 2008, J NEUROTRAUM, V25, P94, DOI 10.1089/neu.2007.0362; Watanabe T, 2010, PM&R, V2, P671, DOI 10.1016/j.pmrj.2010.06.002; Wetjen NM, 2010, J AM COLL SURGEONS, V211, P553, DOI 10.1016/j.jamcollsurg.2010.05.020; Wiebe DJ, 2011, INJURY PREV, V17, P69, DOI 10.1136/ip.2010.031211; Yeates KO, 2010, J INT NEUROPSYCH SOC, V16, P953, DOI 10.1017/S1355617710000986; Zweifel C, 2010, NEUROL RES, V32, P425, DOI 10.1179/174313209X459165; Zwienenberg M, 2001, NEUROL RES, V23, P167, DOI 10.1179/016164101101198505	103	221	223	3	58	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	JAN	2012	129	1					28	37		10.1542/peds.2011-2083			10	Pediatrics	Pediatrics	870BT	WOS:000298644800039	22129537	Green Published	Y	N	2021-06-18	
J	Niogi, SN; Mukherjee, P; Ghajar, J; Johnson, CE; Kolster, R; Lee, H; Suh, M; Zimmerman, RD; Manley, GT; McCandliss, BD				Niogi, Sumit N.; Mukherjee, Pratik; Ghajar, Jamshid; Johnson, Carl E.; Kolster, Rachel; Lee, Hana; Suh, Minah; Zimmerman, Robert D.; Manley, Geoffrey T.; McCandliss, Bruce D.			Structural dissociation of attentional control and memory in adults with and without mild traumatic brain injury	BRAIN			English	Article							DIFFUSE AXONAL INJURY; WHITE-MATTER PATHWAYS; HEAD-INJURY; COGNITIVE-DEVELOPMENT; EPISODIC MEMORY; FRONTAL LOBES; REACTION-TIME; TRACTOGRAPHY; PERFORMANCE; COEFFICIENT	Memory and attentional control impairments are the two most common forms of dysfunction following mild traumatic brain injury (TBI) and lead to significant morbidity in patients, yet these functions are thought to be supported by different brain networks. This 3 T magnetic resonance diffusion tensor imaging (DTI) study investigates whether microstructural integrity of white matter, as measured by fractional anisotropy (FA) within a small set of individually localized regions of interest (ROIs), is associated with these cognitive domains in normal adults and adults with mild TBI. Results in a sample of 23 normal controls reveal a significant correlation between attentional control and FA within a ROI in the left hemisphere anterior corona radiata. Furthermore, the controls demonstrate a correlation between memory performance and FA in a ROI placed in the uncinate fasciculus. Next, to examine whether these relationships are found in the pathological ranges of attention, memory and microstructural white matter integrity associated with mild TBI, these analyses were applied to a group of 43 mild TBI patients. Results, which generally demonstrated a wider range of attention, memory and FA scores, replicated the correlation between attentional control and FA in left hemisphere anterior corona radiata, as well as the correlation between memory performance and FA in the uncinate fasciculus. These two sets of brain-behaviour relationships were highly specific, as shown by a lack of correlation between attention and uncinate fasciculus FA and the lack of correlation between memory performance and anterior corona radiata FA. Furthermore, a correlational double dissociation was demonstrated to exist between two distinct frontal structures independently associated with attention and memory, respectively, via a series of multiple regression analyses in both normal controls and adults with mild TBI. The results of the multiple regression analyses provide direct evidence that tract-specific variation in microstructural white matter integrity among normal controls and among mild TBI patients can account for much of the variation in performance in specific cognitive domains. More generally, such findings suggest that diffusion anisotropy measurement can be used as a quantitative biomarker for neurocognitive function and dysfunction.	[Niogi, Sumit N.; Kolster, Rachel] Weill Cornell Med Coll, Sackler Inst Dev Psychobiol, New York, NY USA; [Mukherjee, Pratik] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA; [Ghajar, Jamshid] Weill Cornell Med Coll, Brain Trauma Fdn, New York, NY USA; [Ghajar, Jamshid; Suh, Minah] Weill Cornell Med Coll, Dept Neurol Surg, New York, NY USA; [Johnson, Carl E.; Zimmerman, Robert D.] Weill Cornell Med Coll, Dept Radiol, New York, NY USA; [Lee, Hana; Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; [Suh, Minah] Sungkyunkwan Univ, Dept Biol Sci, Suwon, South Korea; [McCandliss, Bruce D.] Vanderbilt Univ, Dept Psychol & Human Dev, Nasville, TN USA	McCandliss, BD (corresponding author), 1300 York Ave,Box 140, New York, NY 10021 USA.	bdm2001@med.cornell.edu	Mukherjee, Pratik/A-5446-2008	Mukherjee, Pratik/0000-0001-7473-7409	NSFNational Science Foundation (NSF) [REC-0337715]; John Merck Scholars	This work was supported by a Collaborative grant from the James S. McDonnell Foundation to the Brain Trauma Foundation with lead investigators from Weill Cornell Medical College, University of California, San Francisco and University of California Berkeley as part of the Cognitive Neurobiological Research Consortium in Traumatic Brain Injury. The first and last authors were supported by NSF grant REC-0337715 (PI: B. D. M.), and a John Merck Scholars Award (PI: B. D. M.).	ARCIA E, 1994, BRAIN INJURY, V8, P395, DOI 10.3109/02699059409150991; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1; Basser PJ, 1996, J MAGN RESON SER B, V111, P209, DOI 10.1016/j.jmr.2011.09.022; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P794, DOI 10.1017/S1355617704105146; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; Cabeza Roberto, 2000, Current Opinion in Neurology, V13, P415, DOI 10.1097/00019052-200008000-00008; Casey BJ, 2000, P NATL ACAD SCI USA, V97, P8728, DOI 10.1073/pnas.97.15.8728; Catani M, 2006, CURR OPIN NEUROL, V19, P599, DOI 10.1097/01.wco.0000247610.44106.3f; Delis DC, 2000, CALIFORNIA VERBAL LE; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; Durston S, 2006, NEUROPSYCHOLOGIA, V44, P2149, DOI 10.1016/j.neuropsychologia.2005.10.010; Fan J, 2002, J COGNITIVE NEUROSCI, V14, P340, DOI 10.1162/089892902317361886; Fan J, 2005, NEUROIMAGE, V26, P471, DOI 10.1016/j.neuroimage.2005.02.004; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; Gennarelli T. A., 1998, SEM CLIN NEUR, V3, P160; Goetz P, 2004, J NEUROTRAUM, V21, P645, DOI 10.1089/0897715041269731; Grieve SM, 2007, AM J NEURORADIOL, V28, P226; Gruber SA, 2002, NEUROIMAGE, V16, P349, DOI 10.1006/nimg.2002.1089; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; Hammoud DA, 2002, NEUROIMAG CLIN N AM, V12, P205, DOI 10.1016/S1052-5149(02)00011-4; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Hess CP, 2007, NEUROIMAG CLIN N AM, V17, P407, DOI 10.1016/j.nic.2007.07.002; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jiang HY, 2006, COMPUT METH PROG BIO, V81, P106, DOI 10.1016/j.cmpb.2005.08.004; Jones DK, 2005, NEUROIMAGE, V26, P546, DOI 10.1016/j.neuroimage.2005.02.013; KAPUR S, 1994, P NATL ACAD SCI USA, V91, P2008, DOI 10.1073/pnas.91.6.2008; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; LANDFIELD PW, 1988, NEUROBIOL AGING, V9, P571, DOI 10.1016/S0197-4580(88)80116-7; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Le TH, 2005, NEUROSURGERY, V56, P189, DOI 10.1227/01.NEU.0000144846.00569.3A; LEVIN HS, 1990, J CLIN EXP NEUROPSYC, V12, P129, DOI 10.1080/01688639008400960; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; Levine B, 1998, BRAIN, V121, P1951, DOI 10.1093/brain/121.10.1951; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Mabbott DJ, 2006, NEUROIMAGE, V33, P936, DOI 10.1016/j.neuroimage.2006.07.024; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Malojcic B, 2008, J NEUROTRAUM, V25, P30, DOI 10.1089/neu.2007.0384; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Medina D, 2006, NEUROBIOL AGING, V27, P663, DOI 10.1016/j.neurobiolaging.2005.03.026; MILNER B, 1985, HUM NEUROBIOL, V4, P137; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Mori S., 2005, MRI ATLAS HUMAN WHIT; Moseley M, 2002, BRAIN COGNITION, V50, P396, DOI 10.1016/S0278-2626(02)00524-9; Mukherjee P, 2006, NEUROIMAG CLIN N AM, V16, P19, DOI 10.1016/j.nic.2005.11.004; Mukherjee P, 2006, NEUROIMAG CLIN N AM, V16, pXIII, DOI 10.1016/j.nic.2006.01.001; Nestor PG, 2004, NEUROPSYCHOLOGY, V18, P629, DOI 10.1037/0894-4105.18.4.629; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2006, NEUROPSYCHOLOGIA, V44, P2178, DOI 10.1016/j.neuropsychologia.2006.01.011; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Schmithorst VJ, 2005, HUM BRAIN MAPP, V26, P139, DOI 10.1002/hbm.20149; Shanmuganathan K, 2004, AM J NEURORADIOL, V25, P539; Shu SY, 2003, J NEUROSCI RES, V71, P609, DOI 10.1002/jnr.10545; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Sperling R, 2007, ANN NY ACAD SCI, V1097, P146, DOI 10.1196/annals.1379.009; STUSS D T, 1981, Journal of Clinical Neuropsychology, V3, P13, DOI 10.1080/01688638108403110; STUSS DT, 1984, PSYCHOL BULL, V95, P3, DOI 10.1037/0033-2909.95.1.3; Stuss DT, 2000, PSYCHOL RES-PSYCH FO, V63, P289, DOI 10.1007/s004269900007; Tuch DS, 2005, P NATL ACAD SCI USA, V102, P12212, DOI 10.1073/pnas.0407259102; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; VENDRELL P, 1995, NEUROPSYCHOLOGIA, V33, P341, DOI 10.1016/0028-3932(94)00116-7	68	221	222	0	25	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	DEC	2008	131		12				3209	3221		10.1093/brain/awn247			13	Clinical Neurology; Neurosciences	Neurosciences & Neurology	388CA	WOS:000261996700012	18952679	Bronze			2021-06-18	
J	Giulian, D; Haverkamp, LJ; Yu, JH; Karshin, W; Tom, D; Li, J; Kirkpatrick, J; Kuo, YM; Roher, AE				Giulian, D; Haverkamp, LJ; Yu, JH; Karshin, W; Tom, D; Li, J; Kirkpatrick, J; Kuo, YM; Roher, AE			Specific domains of beta-amyloid from Alzheimer plaque elicit neuron killing in human microglia	JOURNAL OF NEUROSCIENCE			English	Article						Alzheimer's disease; microglia; beta-amyloid; neurotoxicity; plaques; immune system	CENTRAL-NERVOUS-SYSTEM; MONOCLONAL-ANTIBODIES O1; SENILE PLAQUES; MONONUCLEAR PHAGOCYTES; CHEMICAL CHARACTERIZATION; BRAIN MACROPHAGES; TRAUMATIC INJURY; CORTICAL-NEURONS; FIBRIL FORMATION; MAMMALIAN BRAIN	Alzheimer's disease (AD) is found to have striking brain inflammation characterized by clusters of reactive microglia that surround senile plaques. A recent study has shown that microglia placed in contact with isolated plaque fragments release neurotoxins. To explore further this process of immunoactivation in AD, we fractionated plaque proteins and tested for the ability to stimulate microglia. Three plaque-derived fractions, each containing full-length native A beta 1-40 or A beta 1-42 peptides, elicited neurotoxin release from microglia. Screening of various synthetic peptides (A beta 1-16, A beta 1-28, A beta 12-28, A beta 25-35, A beta 17-43, A beta 1-40, and A beta 1-42) confirmed that microglia killed neurons only after exposure to nanomolar concentrations of human A beta 1-40 or human A beta 1-42, whereas the rodent A beta 1-40 (5(Arg-->Gly), 10(Tyr-->Phe), 13(His-->Arg) was not active. These findings suggested that specific portions of human A beta were necessary for microglia-plaque interactions. When coupled to microspheres, N-terminal portions of human A beta(A beta 1-16, A beta 1-28, A beta 12-28) provided anchoring sites for microglial adherence whereas C-terminal regions did not. Although itself not toxic, the 10-16 domain of human A beta was necessary for both microglial binding and activation. Peptide blockade of microglia-plaque interactions that occur in AD might prevent the immune-driven injury to neurons.	BAYLOR COLL MED,DEPT PATHOL,ALZHEIMERS DIS RES CTR,HOUSTON,TX 77030; SUN HLTH RES INST,HALDERMAN LAB ALZHEIMERS DIS RES,SUN CITY,AZ 85351	Giulian, D (corresponding author), BAYLOR COLL MED,DEPT NEUROL,ALZHEIMERS DIS RES CTR,HOUSTON,TX 77030, USA.		Kuo, Yu-Min/A-9050-2013	Kuo, Yu-Min/0000-0003-4867-2482	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG12548, R01 AG012548] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS52637, NS35972, R01 NS052637] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035972, R01NS052637] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG012548] Funding Source: NIH RePORTER		BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; BANSAL R, 1989, J NEUROSCI RES, V24, P548, DOI 10.1002/jnr.490240413; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BOLSI DINO, 1927, RIV PAT NERV E MENT, V32, P65; BREITNER JCS, 1994, NEUROLOGY, V44, P227, DOI 10.1212/WNL.44.2.227; COTMAN CW, 1992, NEUROBIOL AGING, V13, P587, DOI 10.1016/0197-4580(92)90060-B; Davies Peter, 1994, P327; DAVIS TL, 1989, BRAIN RES, V504, P216, DOI 10.1016/0006-8993(89)91360-7; DENIS M, 1994, J LEUKOCYTE BIOL, V55, P682; EIKELENBOOM P, 1994, TRENDS PHARMACOL SCI, V15, P447, DOI 10.1016/0165-6147(94)90057-4; FRASER PE, 1992, BIOCHEMISTRY-US, V31, P10716, DOI 10.1021/bi00159a011; GAMES D, 1992, NEUROBIOL AGING, V13, P569, DOI 10.1016/0197-4580(92)90057-5; GIACCONE G, 1989, NEUROSCI LETT, V97, P232, DOI 10.1016/0304-3940(89)90169-9; GIULIAN D, 1993, J NEUROSCI, V13, P29; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1995, J NEUROSCI, V15, P7712; GIULIAN D, 1994, DEV NEUROSCI-BASEL, V16, P128, DOI 10.1159/000112099; GIULIAN D, 1986, J NEUROSCI, V6, P2163; GIULIAN D, 1993, J NEUROSCI RES, V36, P681, DOI 10.1002/jnr.490360609; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; GIULIAN D, 1995, NEUROCHEM INT, V27, P119, DOI 10.1016/0197-0186(95)00067-I; Giulian D., 1992, CURRENT TOPICS NEURO, V12, P23; GOWING E, 1994, J BIOL CHEM, V269, P10987; HARRIS ME, 1995, NEUROREPORT, V6, P1875, DOI 10.1097/00001756-199510020-00013; HENSLEY K, 1994, P NATL ACAD SCI USA, V91, P3270, DOI 10.1073/pnas.91.8.3270; HOWLETT DR, 1995, NEURODEGENERATION, V4, P23, DOI 10.1006/neur.1995.0003; IGNARRO LJ, 1990, HYPERTENSION, V16, P477, DOI 10.1161/01.HYP.16.5.477; KOH JY, 1990, BRAIN RES, V533, P315, DOI 10.1016/0006-8993(90)91355-K; KOO EH, 1993, P NATL ACAD SCI USA, V90, P4748, DOI 10.1073/pnas.90.10.4748; Kuo YM, 1996, J BIOL CHEM, V271, P4077; LEES GJ, 1993, J NEUROL SCI, V114, P119, DOI 10.1016/0022-510X(93)90285-7; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; LUCCA U, 1994, BIOL PSYCHIAT, V36, P854, DOI 10.1016/0006-3223(94)90598-3; MASLIAH E, 1990, AM J PATHOL, V137, P1293; MASLIAH E, 1993, J NEUROPATH EXP NEUR, V52, P619, DOI 10.1097/00005072-199311000-00009; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; MATTSON MP, 1992, NEUROBIOL AGING, V13, P617, DOI 10.1016/0197-4580(92)90068-9; MAY PC, 1992, NEUROBIOL AGING, V13, P605, DOI 10.1016/0197-4580(92)90064-5; MCGEER PL, 1987, NEUROSCI LETT, V79, P195, DOI 10.1016/0304-3940(87)90696-3; MCGEER PL, 1990, LANCET, V335, P1037, DOI 10.1016/0140-6736(90)91101-F; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; MIRRA S, 1993, CERAD GUIDE NEUROPAT; MRAK RE, 1995, HUM PATHOL, V26, P816, DOI 10.1016/0046-8177(95)90001-2; PERLMUTTER LS, 1992, J NEUROSCI RES, V33, P549, DOI 10.1002/jnr.490330407; PIANI D, 1991, NEUROSCI LETT, V133, P159, DOI 10.1016/0304-3940(91)90559-C; PIKE CJ, 1993, J NEUROSCI, V13, P1676; PIKE CJ, 1991, EUR J PHARM-MOLEC PH, V207, P367, DOI 10.1016/0922-4106(91)90014-9; PIKE CJ, 1995, J BIOL CHEM, V270, P23895, DOI 10.1074/jbc.270.41.23895; PODLISNY MB, 1992, NEUROBIOL AGING, V13, P561, DOI 10.1016/0197-4580(92)90056-4; POLLACK SJ, 1995, NEUROSCI LETT, V197, P211, DOI 10.1016/0304-3940(95)11939-T; PRICE DL, 1992, NEUROBIOL AGING, V13, P623, DOI 10.1016/0197-4580(92)90069-A; RIOHORTEGA P, 1932, CYTOLOGY CELLULAR PA, P481; ROGERS J, 1988, NEUROBIOL AGING, V9, P339, DOI 10.1016/S0197-4580(88)80079-4; ROGERS J, 1992, P NATL ACAD SCI USA, V89, P10016, DOI 10.1073/pnas.89.21.10016; ROHER AE, 1993, J BIOL CHEM, V268, P3072; ROHER AE, 1993, J NEUROCHEM, V61, P1916, DOI 10.1111/j.1471-4159.1993.tb09834.x; ROHER AE, 1988, J CELL BIOL, V107, P2703, DOI 10.1083/jcb.107.6.2703; SCHNABEL J, 1993, SCIENCE, V260, P1719, DOI 10.1126/science.8323582; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; SIMMONS LK, 1994, MOL PHARMACOL, V45, P373; SOMMER I, 1981, DEV BIOL, V83, P311, DOI 10.1016/0012-1606(81)90477-2; STEPHENSON DT, 1992, BRAIN RES, V586, P235, DOI 10.1016/0006-8993(92)91632-O; Terry R. D., 1994, ALZHEIMERS DIS; Terry Robert D., 1994, P179; THERY C, 1991, EUR J NEUROSCI, V3, P1155, DOI 10.1111/j.1460-9568.1991.tb00050.x; VERGA L, 1989, NEUROSCI LETT, V105, P294, DOI 10.1016/0304-3940(89)90636-8; WHITSON JS, 1989, SCIENCE, V243, P1488, DOI 10.1126/science.2928783; Wujek JR, 1996, NEUROBIOL AGING, V17, P107, DOI 10.1016/0197-4580(95)02020-9; YAMAGUCHI H, 1988, ACTA NEUROPATHOL, V77, P113; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531; YANKNER BA, 1991, NEW ENGL J MED, V325, P1849; YOUNKIN SG, 1995, ANN NEUROL, V37, P287, DOI 10.1002/ana.410370303	73	221	228	0	6	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513	0270-6474			J NEUROSCI	J. Neurosci.	OCT 1	1996	16	19					6021	6037					17	Neurosciences	Neurosciences & Neurology	VH858	WOS:A1996VH85800014	8815885				2021-06-18	
J	Plog, BA; Dashnaw, ML; Hitomi, E; Peng, WG; Liao, YH; Lou, NH; Deane, R; Nedergaard, M				Plog, Benjamin A.; Dashnaw, Matthew L.; Hitomi, Emi; Peng, Weiguo; Liao, Yonghong; Lou, Nanhong; Deane, Rashid; Nedergaard, Maiken			Biomarkers of Traumatic Injury Are Transported from Brain to Blood via the Glymphatic System	JOURNAL OF NEUROSCIENCE			English	Article						biomarker; CSF; clearance; lymphatic; traumatic brain injury	DEEP CERVICAL LYMPH; IN-VIVO MEASUREMENT; CEREBROSPINAL-FLUID; INTERSTITIAL FLUID; EXPERIMENTAL-MODEL; AQUAPORIN-4 AQP4; DISRUPTION; CLEARANCE; DELETION; EDEMA	The nonspecific and variable presentation of traumatic brain injury (TBI) has motivated an intense search for blood-based biomarkers that can objectively predict the severity of injury. However, it is not known how cytosolic proteins released from traumatized brain tissue reach the peripheral blood. Here we show in a murine TBI model that CSF movement through the recently characterized glymphatic pathway transports biomarkers to blood via the cervical lymphatics. Clinically relevant manipulation of glymphatic activity, including sleep deprivation and cisternotomy, suppressed or eliminated TBI-induced increases in serum S100 beta, GFAP, and neuron specific enolase. We conclude that routine TBI patient management may limit the clinical utility of blood-based biomarkers because their brain-toblood transport depends on glymphatic activity.	[Plog, Benjamin A.; Dashnaw, Matthew L.; Hitomi, Emi; Peng, Weiguo; Liao, Yonghong; Lou, Nanhong; Deane, Rashid; Nedergaard, Maiken] Univ Rochester, Med Ctr, Dept Neurosurg, Ctr Translat Neuromed, Rochester, NY 14642 USA; [Plog, Benjamin A.] Univ Rochester, Med Ctr, Dept Pathol, Rochester, NY 14642 USA	Nedergaard, M (corresponding author), Univ Rochester, Med Ctr, Sch Med & Dent, 601 Elmwood Ave,Box 645, Rochester, NY 14642 USA.	Maiken_Nedergaard@URMC.Rochester.edu		Nedergaard, Maiken/0000-0001-6502-6031	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; United States Department of DefenseUnited States Department of Defense; Harold and Leila Y. Mathers Charitable Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01HD076892] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS078167, R01NS075177, R01NS078304] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG048769] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health (to M.N.), the United States Department of Defense (to M.N.), and the Harold and Leila Y. Mathers Charitable Foundation (to M.N.).	Akdemir G, 2014, NEUROSCI LETT, V574, P70, DOI 10.1016/j.neulet.2014.03.073; Amiry-Moghaddam M, 2004, FASEB J, V18, P542, DOI 10.1096/fj.03-0869fje; AMTORP O, 1979, J PHYSIOL-LONDON, V294, P81, DOI 10.1113/jphysiol.1979.sp012916; Binder DK, 2004, J NEUROSCI, V24, P8049, DOI 10.1523/JNEUROSCI.2294-04.2004; Boulton M, 1996, NEUROPATH APPL NEURO, V22, P325, DOI 10.1111/j.1365-2990.1996.tb01111.x; BRADBURY MWB, 1983, J PHYSIOL-LONDON, V339, P519, DOI 10.1113/jphysiol.1983.sp014731; BRADBURY MWB, 1980, J PHYSIOL-LONDON, V305, pP52; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Brenner M, 2001, NAT GENET, V27, P117; Calvo CF, 2011, GENE DEV, V25, P831, DOI 10.1101/gad.615311; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Cirrito JR, 2005, NEURON, V48, P913, DOI 10.1016/j.neuron.2005.10.028; CSERR HF, 1974, EXP NEUROL, V45, P50, DOI 10.1016/0014-4886(74)90099-5; CSERR HF, 1992, BRAIN PATHOL, V2, P269, DOI 10.1111/j.1750-3639.1992.tb00703.x; Darwish H, 2012, BRAIN INJURY, V26, P1763, DOI [10.3109/02699052.2012.741452, 10.3109/02699052.2011.635362]; Deane R, 2008, J CLIN INVEST, V118, P4002, DOI 10.1172/JCI36663; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Haj-Yasein NN, 2011, P NATL ACAD SCI USA, V108, P17815, DOI 10.1073/pnas.1110655108; Herrmann M, 2001, NEUROSURGERY, V49, P1272, DOI 10.1097/00006123-200111000-00058; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Iliff JJ, 2014, J NEUROSCI, V34, P16180, DOI 10.1523/JNEUROSCI.3020-14.2014; Iliff JJ, 2013, J NEUROSCI, V33, P18190, DOI 10.1523/JNEUROSCI.1592-13.2013; Iliff JJ, 2013, J CLIN INVEST, V123, P1299, DOI 10.1172/JCI67677; Iliff JJ, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003748; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Johnston M, 2002, NEWS PHYSIOL SCI, V17, P227, DOI 10.1152/nips.01400.2002; Johnston Miles, 2004, Cerebrospinal Fluid Res, V1, P2, DOI 10.1186/1743-8454-1-2; KAIPAINEN A, 1995, P NATL ACAD SCI USA, V92, P3566, DOI 10.1073/pnas.92.8.3566; Katada R, 2014, FASEB J, V28, P705, DOI 10.1096/fj.13-231274; Kovesdi E, 2010, ACTA NEUROCHIR, V152, P1, DOI 10.1007/s00701-009-0463-6; Kurland D, 2012, J NEUROTRAUM, V29, P19, DOI 10.1089/neu.2011.2122; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P187, DOI 10.1097/00001199-200505000-00001; Liang Danny, 2007, Neurosurg Focus, V22, pE2, DOI 10.3171/foc.2007.22.5.3; Manaenko A, 2011, J NEUROSCI METH, V195, P206, DOI 10.1016/j.jneumeth.2010.12.013; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Mannix R, 2013, ANN NEUROL, V74, P65, DOI 10.1002/ana.23858; Marmarou A, 2007, NEUROSURG FOCUS, V22, pE1, DOI DOI 10.3171/F0C.2007.22.5.2; Marmarou Anthony, 2004, Cleve Clin J Med, V71 Suppl 1, pS6; Mondello S, 2011, EXPERT REV MOL DIAGN, V11, P65, DOI 10.1586/ERM.10.104; Murtha LA, 2014, FLUIDS BARRIERS CNS, V11, DOI 10.1186/2045-8118-11-12; Obermeier B, 2013, NAT MED, V19, P1584, DOI 10.1038/nm.3407; Olsson B, 2011, PROG NEUROBIOL, V95, P520, DOI 10.1016/j.pneurobio.2011.04.006; Papa L, 2013, J NEUROTRAUM, V30, P324, DOI 10.1089/neu.2012.2545; Papadopoulos MC, 2007, PEDIATR NEPHROL, V22, P778, DOI 10.1007/s00467-006-0411-0; Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje; Papadopoulos MC, 2005, J BIOL CHEM, V280, P13906, DOI 10.1074/jbc.M413627200; Ren ZG, 2013, J CEREBR BLOOD F MET, V33, P834, DOI 10.1038/jcbfm.2013.30; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Simard JM, 2007, LANCET NEUROL, V6, P258, DOI 10.1016/S1474-4422(07)70055-8; Simard JM, 2012, J CEREBR BLOOD F MET, V32, P1699, DOI 10.1038/jcbfm.2012.91; Simard JM, 2010, J NEUROSURG, V113, P622, DOI 10.3171/2009.11.JNS081052; Simard M, 2004, NEUROSCIENCE, V129, P877, DOI 10.1016/j.neuroscience.2004.09.053; Statler KD, 2006, BRAIN RES, V1076, P216, DOI 10.1016/j.brainres.2005.12.106; Stone JJ, 2014, NEUROL RES, V36, P164, DOI 10.1179/1743132813Y.0000000285; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Takeda S, 2011, NEUROSCIENCE, V186, P110, DOI 10.1016/j.neuroscience.2011.04.035; Thorne RG, 2006, P NATL ACAD SCI USA, V103, P5567, DOI 10.1073/pnas.0509425103; Thrane AS, 2011, P NATL ACAD SCI USA, V108, P846, DOI 10.1073/pnas.1015217108; Thrane VR, 2013, SCI REP-UK, V3, DOI 10.1038/srep02582; Ulrich JD, 2013, MOL NEURODEGENER, V8, DOI 10.1186/1750-1326-8-13; VOGH BP, 1987, J PHARMACOL EXP THER, V243, P35; Xie LL, 2013, SCIENCE, V342, P373, DOI 10.1126/science.1241224; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yamada K, 2011, J NEUROSCI, V31, P13110, DOI 10.1523/JNEUROSCI.2569-11.2011; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9	67	220	225	2	71	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JAN 14	2015	35	2					518	526		10.1523/JNEUROSCI.3742-14.2015			9	Neurosciences	Neurosciences & Neurology	CB1SW	WOS:000349409300009	25589747	Green Published, Bronze	Y	N	2021-06-18	
J	Vos, PE; Jacobs, B; Andriessen, TMJC; Lamers, KJB; Borm, GF; Beems, T; Edwards, M; Rosmalen, CF; Vissers, JLM				Vos, P. E.; Jacobs, B.; Andriessen, T. M. J. C.; Lamers, K. J. B.; Borm, G. F.; Beems, T.; Edwards, M.; Rosmalen, C. F.; Vissers, J. L. M.			GFAP and S100B are biomarkers of traumatic brain injury An observational cohort study	NEUROLOGY			English	Article							SEVERE HEAD-INJURY; NEURON-SPECIFIC ENOLASE; FIBRILLARY ACIDIC PROTEIN; SERUM S-100B PROTEIN; MULTIPLE TRAUMA; DAMAGE; PREDICTION; MARKERS; TOMOGRAPHY; VALIDATION	Background: Biomarker levels in blood after traumatic brain injury (TBI) may offer diagnostic and prognostic tools in addition to clinical indices. This study aims to validate glial fibrillary acidic protein (GFAP) and S100B concentrations in blood as outcome predictors of TBI using cutoff levels of 1.5 mu g/L for GFAP and 1.13 mu g/L for S100B from a previous study. Methods: In 79 patients with TBI (Glasgow Coma Scale score [GCS] <12), serum, taken at hospital admission, was analyzed for GFAP and S100B. Data collected included injury mechanism, age, gender, mass lesion on CT, GCS, pupillary reactions, Injury Severity Score (ISS), presence of hypoxia, and hypotension. Outcome was assessed, using the Glasgow Outcome Scale Extended (dichotomized in death vs alive and unfavorable vs favorable), 6 months post injury. Results: In patients who died compared to alive patients, median serum levels were increased: GFAP 33.4-fold and S100B 2.1-fold. In unfavorable compared to favorable outcome, GFAP was increased 19.8-fold and S100B 2.1-fold. Univariate logistic regression analysis revealed that mass lesion, GFAP, absent pupils, age, and ISS, but not GCS, hypotension, or hypoxia, predicted death and unfavorable outcome. Multivariable analysis showed that models containing mass lesion, pupils, GFAP, and S100B were the strongest in predicting death and unfavorable outcome. S100B was the strongest single predictor of unfavorable outcome with 100% discrimination. Conclusion: This study confirms that GFAP and S100B levels in serum are adjuncts to the assessment of brain damage after TBI and may enhance prognostication when combined with clinical variables. Neurology (R) 2010;75:1786-1793	[Vos, P. E.; Jacobs, B.; Andriessen, T. M. J. C.] Radboud Univ Nijmegen, Med Ctr, Dept Neurol, NL-6500 HB Nijmegen, Netherlands; [Borm, G. F.] Radboud Univ Nijmegen, Med Ctr, Dept Epidemiol & Biostat, NL-6500 HB Nijmegen, Netherlands; [Beems, T.] Radboud Univ Nijmegen, Med Ctr, Dept Neurosurg, NL-6500 HB Nijmegen, Netherlands; [Edwards, M.] Radboud Univ Nijmegen, Med Ctr, Dept Surg, NL-6500 HB Nijmegen, Netherlands; [Lamers, K. J. B.; Rosmalen, C. F.; Vissers, J. L. M.] Future Diagnost, Wijchen, Netherlands	Vos, PE (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Neurol, Hp 935,POB 9101, NL-6500 HB Nijmegen, Netherlands.	p.vos@neuro.umcn.nl	Vos, Pieter/A-6043-2012		Dutch Brain Foundation (Hersenstichting); Trauma Centrum Oost	Dr. Vos has received research support from the Dutch Brain Foundation (Hersenstichting). Dr. Jacobs reports no disclosures. T.M.J.C. Andriessen has received research support from Trauma Centrum Oost and the Dutch Brain Foundation (Hersenstichting). Dr. Lamers serves as a consultant for Future Diagnostics B. V. Dr. Borm, Dr. Beems, and Dr. Edwards report no disclosures. C. F. Rosmalen is an employee of Future Diagnostics B. V. Dr. Vissers is an employee of Future Diagnostics B. V.	Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Berger RP, 2007, J NEUROTRAUM, V24, P1793, DOI 10.1089/neu.2007.0316; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Cremer OL, 2006, J TRAUMA, V61, P1484, DOI 10.1097/01.ta.0000195981.63776.ba; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Dimopoulou I, 2003, NEUROLOGY, V60, P947, DOI 10.1212/01.WNL.0000049931.77887.7F; Ergun R, 1998, NEUROL RES, V20, P418; Foerch C, 2006, J NEUROL NEUROSUR PS, V77, P181, DOI 10.1136/jnnp.2005.074823; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Ingebrigtsen T, 2000, BRAIN INJURY, V14, P1047; Korfias S, 2007, INTENS CARE MED, V33, P255, DOI 10.1007/s00134-006-0463-4; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Nylen K, 2008, ACTA NEUROCHIR, V150, P221, DOI 10.1007/s00701-007-1489-2; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Pelinka LE, 2003, SHOCK, V19, P195, DOI 10.1097/00024382-200303000-00001; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Petzold A, 2002, CRIT CARE MED, V30, P2705, DOI 10.1097/00003246-200212000-00015; Puri ML., 1971, NONPARAMETRIC METHOD; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Raabe A, 1998, ACTA NEUROCHIR, V140, P787, DOI 10.1007/s007010050180; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Rainey T, 2009, RESUSCITATION, V80, P341, DOI 10.1016/j.resuscitation.2008.11.021; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Savola O, 2004, J TRAUMA, V56, P1229, DOI 10.1097/01.TA.0000096644.08735.72; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; Shaw GJ, 2002, ANN EMERG MED, V39, P254, DOI 10.1067/mem.2002.121214; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Vissers JLM, 2006, CLIN CHIM ACTA, V366, P336, DOI 10.1016/j.cca.2005.11.017; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Watt SE, 2006, BRAIN INJURY, V20, P1007, DOI 10.1080/02699050600909698; Wijdicks EFM, 2006, NEUROLOGY, V67, P203, DOI 10.1212/01.wnl.0000227183.21314.cd; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; Woertgen C, 2000, ACT NEUR S, V76, P371; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6; Zandbergen EGJ, 2006, NEUROLOGY, V66, P62, DOI 10.1212/01.wnl.0000191308.22233.88	40	220	240	1	24	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	NOV 16	2010	75	20					1786	1793		10.1212/WNL.0b013e3181fd62d2			8	Clinical Neurology	Neurosciences & Neurology	680EO	WOS:000284215400008	21079180				2021-06-18	
J	Meares, S; Shores, EA; Taylor, AJ; Batchelor, J; Bryant, RA; Baguley, IJ; Chapman, J; Gurka, J; Dawson, K; Capon, L; Marosszeky, JE				Meares, S.; Shores, E. A.; Taylor, A. J.; Batchelor, J.; Bryant, R. A.; Baguley, I. J.; Chapman, J.; Gurka, J.; Dawson, K.; Capon, L.; Marosszeky, J. E.			Mild traumatic brain injury does not predict acute postconcussion syndrome	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							POSTTRAUMATIC-STRESS-DISORDER; MINOR HEAD-INJURY; PSYCHIATRIC-ILLNESS; DSM-IV; SYMPTOMS; MODERATE; VALIDATION; SEQUELAE; CRITERIA; ICD-10	Background: The aetiology of postconcussion syndrome (PCS) following mild traumatic brain injury (mTBI) remains controversial. Identifying acute PCS (within the first 14 days after injury) may optimise initial recovery and rehabilitation, identify those at risk and increase understanding of PCS. Objective: To examine predictors of acute outcome by investigating the relationship between preinjury psychiatric disorder, demographic factors, injury related characteristics, neuropsychological and psychological variables and acute PCS. Methods: Prospective study of consecutive trauma admissions to a level 1 trauma hospital. The final sample comprised 90 patients with mTBI and 85 non-brain injured trauma controls. Individuals were administered a PCS checklist, and neuropsychological and psychological measures. Multiple imputation of missing data in multi-variable logistic regression and bivariate logistic regressions were used to predict acute PCS at a mean of 4.90 days after injury. Results: Diagnosis of acute PCS was not specific to mTBI (mTBI 43.3%; controls 43.5%). Pain was associated with acute PCS in mTBI. The strongest effect for acute PCS was a previous affective or anxiety disorder (OR 5.76, 95% CI 2.19 to 15.0). Females were 3.33 times more likely than males to have acute PCS (95% CI 1.20 to 9.21). The effect of acute post-traumatic stress and neuropsychological function on acute PCS was relatively small. Higher IQ was associated with acute PCS. Conclusions: There is a high rate of acute PCS in both mTBI and non-brain injured trauma patients. PCS was not found to be specific to mTBI. The use of the term PCS may be misleading as it incorrectly suggests that the basis of PCS is a brain injury.	[Meares, S.; Shores, E. A.; Taylor, A. J.; Batchelor, J.; Dawson, K.; Capon, L.] Macquarie Univ, Dept Psychol, N Ryde, NSW 2109, Australia; [Bryant, R. A.; Dawson, K.] Univ New S Wales, Sydney, NSW, Australia; [Baguley, I. J.; Chapman, J.; Gurka, J.; Marosszeky, J. E.] Westmead Hosp, Dept Rehabil Med, Sydney, NSW, Australia	Shores, EA (corresponding author), Macquarie Univ, Dept Psychol, N Ryde, NSW 2109, Australia.	ashores@psy.mq.edu.au	Baguley, Ian J/K-6878-2013; Bryant, Richard/AAA-6479-2019; Baguley, Ian/AAM-5828-2021	Baguley, Ian J/0000-0001-5650-3705; Bryant, Richard/0000-0002-9607-819X; Meares, Susanne/0000-0002-3859-9974; Batchelor, Jennifer/0000-0003-4438-4993; Shores, Edwin A/0000-0003-1553-5131			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Babor TF., 2001, AUDIT ALCOHOL USE DI, V2nd; Boake C, 2004, J NEUROPSYCH CLIN N, V16, P493, DOI 10.1176/appi.neuropsych.16.4.493; Bryant RA, 2000, PSYCHOL ASSESSMENT, V12, P61, DOI 10.1037/1040-3590.12.1.61; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; *COMM INJ SCAL, 2001, ABBR INJ SCAL 1990 R; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Fann JR, 2002, J NEUROL NEUROSUR PS, V72, P615, DOI 10.1136/jnnp.72.5.615; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; Iverson GL, 2006, BRAIN INJURY MED PRI, P373; Jensen M.P., 2001, HDB PAIN ASSESSMENT, P15; Jones C, 2005, J TRAUMA STRESS, V18, P181, DOI 10.1002/jts.20031; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; Landre N, 2006, ARCH CLIN NEUROPSYCH, V21, P255, DOI 10.1016/j.acn.2005.12.007; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; MCMILLAN TM, 1987, J NEUROL NEUROSUR PS, V50, P393, DOI 10.1136/jnnp.50.4.393; Meares S, 2006, J INT NEUROPSYCH SOC, V12, P792, DOI 10.1017/S1355617706060978; MILLER EN, 1989, CALCAP CALIFORNIA CO; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; O'Donnell ML, 2004, AM J PSYCHIAT, V161, P507, DOI 10.1176/appi.ajp.161.3.507; Olff M, 2007, PSYCHOL BULL, V133, P183, DOI 10.1037/0033-2909.133.2.183; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Royston P, 2005, STATA J, V5, P527, DOI 10.1177/1536867X0500500404; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Smith A., 1982, SYMBOL DIGIT MODALIT; Strauss I, 1934, ARCH NEURO PSYCHIATR, V31, P893, DOI 10.1001/archneurpsyc.1934.02250050011001; WALL PD, 1999, TXB PAIN; World Health Organization, 1992, ICD 10 CLASS MENT BE	38	220	223	0	21	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAR	2008	79	3					300	306		10.1136/jnnp.2007.126565			7	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	271WC	WOS:000253818400016	17702772				2021-06-18	
J	Singh, IN; Sullivan, PG; Deng, Y; Mbye, LH; Hall, ED				Singh, Indrapal N.; Sullivan, Patrick G.; Deng, Ying; Mbye, Lamin H.; Hall, Edward D.			Time course of post-traumatic mitochondrial oxidative damage and dysfunction in a mouse model of focal traumatic brain injury: implications for neuroprotective therapy	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						mitochondria; mitochondrial permeability transition; oxidative damage; traumatic brain injury	NITRIC-OXIDE SYNTHASE; CONTROLLED CORTICAL IMPACT; CYTOCHROME-C RELEASE; CYCLOSPORINE-A; HEAD-INJURY; PERMEABILITY TRANSITION; LIPID-PEROXIDATION; CELL-DEATH; IMPAIRED MITOCHONDRIAL; NEUROLOGICAL DEFICIT	In the present study, we investigate the hypothesis that mitochondrial oxidative damage and dysfunction precede the onset of neuronal loss after controlled cortical impact traumatic brain injury (TBI) in mice. Accordingly, we evaluated the time course of post-traumatic mitochondrial dysfunction in the injured cortex and hippocampus at 30 mins, 1, 3, 6, 12, 24, 48, and 72 h after severe TBI. A significant decrease in the coupling of the electron transport system with oxidative phosphorylation was observed as early as 30 mins after injury, followed by a recovery to baseline at 1 h after injury. A statistically significant (P < 0.0001) decline in the respiratory control ratio was noted at 3 h, which persisted at all subsequent time-points up to 72 h after injury in both cortical and hippocampal mitochondria. Structural damage seen in purified cortical mitochondria included severely swollen mitochondria, a disruption of the cristae and rupture of outer membranes, indicative of mitochondrial permeability transition. Consistent with this finding, cortical mitochondrial calcium-buffering capacity was severely compromised by 3 h after injury, and accompanied by significant increases in mitochondrial protein oxidation and lipid peroxidation. A possible causative role for reactive nitrogen species was suggested by the rapid increase in cortical mitochondrial 3-nitrotyrosine levels shown as early as 30 mins after injury. These findings indicate that post-traumatic oxidative lipid and protein damage, mediated in part by peroxynitrite, occurs in mitochondria with concomitant ultrastructural damage and impairment of mitochondrial bioenergetics. The data also indicate that compounds which specifically scavenge peroxynitrite (ONOO-) or ONOO--derived radicals (e.g. ONOO-+ H+ -> ONOOH -> (NO2)-N-center dot + (OH)-O-center dot) may be particularly effective for the treatment of TBI, although the therapeutic window for this neuroprotective approach might only be 3 h.	Univ Kentucky, Med Ctr, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; Univ Kentucky, Med Ctr, Dept Anat & Neurobiol, Lexington, KY 40536 USA	Hall, ED (corresponding author), Univ Kentucky, Med Ctr, Spinal Cord & Brain Injury Res Ctr, B383 BBSRB,741 S Limestone St, Lexington, KY 40536 USA.	edhall@uky.edu	Hall, Edward D/F-8930-2013		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048191, R01NS046566] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS048191, NS 1R01 NS46566] Funding Source: Medline		Althaus JS, 2000, FREE RADICAL BIO MED, V29, P1085, DOI 10.1016/S0891-5849(00)00350-6; Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; BeitYannai E, 1996, BRAIN RES, V717, P22, DOI 10.1016/0006-8993(95)01492-6; Bonini MG, 2002, CHEM RES TOXICOL, V15, P506, DOI 10.1021/tx015571z; Bringold U, 2000, FREE RADICAL BIO MED, V29, P343, DOI 10.1016/S0891-5849(00)00318-X; Brown MR, 2004, J NEUROSCI METH, V137, P299, DOI 10.1016/j.jneumeth.2004.02.028; Brustovetsky N, 2002, J NEUROCHEM, V80, P207, DOI 10.1046/j.0022-3042.2001.00671.x; Bustamante J, 2002, NITRIC OXIDE-BIOL CH, V6, P333, DOI 10.1006/niox.2001.0420; Carroll RT, 2000, CHEM RES TOXICOL, V13, P294, DOI 10.1021/tx990159t; Cirak B, 1999, PEDIATR NEUROSURG, V31, P298, DOI 10.1159/000028879; Elfering SL, 2002, J BIOL CHEM, V277, P38079, DOI 10.1074/jbc.M205256200; Finkel E, 2001, SCIENCE, V292, P624, DOI 10.1126/science.292.5517.624; Ghafourifar P, 1999, J BIOL CHEM, V274, P31185, DOI 10.1074/jbc.274.44.31185; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; HALL ED, 1995, ACTA NEUROCHIR SUPP, P66; HALL ED, 1999, ANN NY ACAD SCI, V890, P492; Hannay HJ, 1999, J NEUROTRAUM, V16, P1103, DOI 10.1089/neu.1999.16.1103; Heales SJR, 1999, BBA-BIOENERGETICS, V1410, P215, DOI 10.1016/S0005-2728(98)00168-6; Hunot S, 2001, SCIENCE, V292, P865, DOI 10.1126/science.1060885; Jiang DM, 2001, J BIOL CHEM, V276, P47524, DOI 10.1074/jbc.M108834200; Kanai AJ, 2001, P NATL ACAD SCI USA, V98, P14126, DOI 10.1073/pnas.241380298; KRISTIAN T, 2005, IN PRESS J NEUROSCI; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Lopez-Figueroa MO, 2000, BIOCHEM BIOPH RES CO, V272, P129, DOI 10.1006/bbrc.2000.2748; Matsushita M, 1997, J COMP NEUROL, V377, P251, DOI 10.1002/(SICI)1096-9861(19970113)377:2<251::AID-CNE7>3.0.CO;2-2; Mesenge C, 1998, J PINEAL RES, V25, P41, DOI 10.1111/j.1600-079X.1998.tb00384.x; Mesenge C, 1998, EUR J PHARMACOL, V353, P53, DOI 10.1016/S0014-2999(98)00432-4; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; Mesenge C, 1996, J NEUROTRAUM, V13, P11, DOI 10.1089/neu.1996.13.11; Nicholls DG, 1998, BBA-BIOENERGETICS, V1366, P97, DOI 10.1016/S0005-2728(98)00123-6; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; Robertson CL, 2004, J BIOENERG BIOMEMBR, V36, P363, DOI 10.1023/B:JOBB.0000041769.06954.e4; Rohn TT, 1998, BIOCHEM PHARMACOL, V56, P1371, DOI 10.1016/S0006-2952(98)00266-4; Sarrafzadeh AS, 2000, ACTA NEUROCHIR, V142, P1293, DOI 10.1007/s007010070028; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Sensi SL, 2003, P NATL ACAD SCI USA, V100, P6157, DOI 10.1073/pnas.1031598100; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Spierings D, 2005, SCIENCE, V310, P66, DOI 10.1126/science.1117105; Stout AK, 1998, NAT NEUROSCI, V1, P366; Sullivan PG, 2004, J BIOENERG BIOMEMBR, V36, P353, DOI 10.1023/B:JOBB.0000041767.30992.19; Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5&lt;723::AID-ANA5&gt;3.0.CO;2-W; Sullivan PG, 2005, EPILEPSY BEHAV, V7, pS12, DOI 10.1016/j.yebeh.2005.08.004; Sullivan PG, 2005, PROG NEURO-PSYCHOPH, V29, P407, DOI 10.1016/j.pnpbp.2004.12.007; Sullivan PG, 2004, J COMP NEUROL, V474, P524, DOI 10.1002/cne.20130; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Sullivan PG, 2003, ANN NEUROL, V53, P711, DOI 10.1002/ana.10543; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wada K, 1999, NEUROSURGERY, V45, P601, DOI 10.1097/00006123-199909000-00031; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; Wallis RA, 1996, BRAIN RES, V710, P169, DOI 10.1016/0006-8993(95)01278-8; White RJ, 1996, J NEUROSCI, V16, P5688; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Zanella B, 2002, BIOCHEM BIOPH RES CO, V290, P1010, DOI 10.1006/bbrc.2001.6284; Zhang NF, 1998, TECHNOMETRICS, V40, P24, DOI 10.2307/1271390	65	220	229	0	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	NOV	2006	26	11					1407	1418		10.1038/sj.jcbfm.9600297			12	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	098AZ	WOS:000241493700006	16538231	Bronze			2021-06-18	
J	Guo, L; Moss, SE; Alexander, RA; Ali, RR; Fitzke, FW; Cordeiro, MF				Guo, L; Moss, SE; Alexander, RA; Ali, RR; Fitzke, FW; Cordeiro, MF			Retinal ganglion cell apoptosis in glaucoma is related to intraocular pressure and IOP-induced effects on extracellular matrix	INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE			English	Article							OPTIC-NERVE HEAD; TRAUMATIC BRAIN-INJURY; HEPATIC STELLATE CELLS; OPEN-ANGLE GLAUCOMA; GROWTH-FACTOR-BETA; GENE KNOCK-OUT; RAT MODEL; TGF-BETA; MOLECULAR-MECHANISMS; TISSUE INHIBITORS	PURPOSE. To investigate the effect of IOP on retinal ganglion cell (RGC) apoptosis and correlate the effects with IOP-induced changes in extracellular matrix (ECM) in the retina and optic nerve head (ONH) in glaucomatous rat eyes. METHODS. Thirty-seven Dark Agouti rats had elevated IOP induced in the left eye by hypertonic saline episcleral vein injections. Eyes were examined at 3 months histologically for RGC apoptosis and expression of specific ECM components. RESULTS. RGC apoptosis was significantly related to IOP exposure ( integral Delta IOP P < 0.001; peak IOP P < 0.01). In the RGC layer, elevated IOP correlated positively to a significant increase in MMP-9 activity ( P < 0.001), tissue inhibitor of matrix metalloproteinase (TIMP-1) ( P < 0.05), and collagen I ( P < 0.01), and negatively correlated to deposition of laminin ( P < 0.05) and TGF-beta2 ( P < 0.05). There was a significant correlation between MMP-9 activity and both RGC apoptosis ( P < 0.001) and loss of laminin ( P < 0.01). IOP exposure was also associated with increased deposition of TGF-beta 2 and collagen I at the ONH ( P < 0.01). CONCLUSIONS. The results demonstrated that RGC apoptosis in glaucoma correlates strongly with elevated IOP and is significantly associated with IOP-induced changes in specific ECM components in the RGC layer. The study shows for the first time a link between MMP-9, laminin degradation, RGC apoptosis, and IOP exposure in glaucoma. The findings suggest that abnormal ECM remodeling in the glaucomatous retina may relate to RGC death and support the notion that the retina is a primary site of injury in glaucoma.	Inst Ophthalmol, Dept Pathol, Glaucoma & Opt Nerve Head Res Grp, London, England; Inst Ophthalmol, Dept Cell Biol, London, England; Inst Ophthalmol, Dept Mol Genet, London, England; Inst Ophthalmol, Visual Sci Div, London, England	Cordeiro, MF (corresponding author), UCL, Inst Ophthalmol, Glaucoma & Opt Nerve Head Res Grp, 11-43 Bath St, London EC1V 9EL, England.	m.cordeiro@ucl.ac.uk	Fitzke, Fred/C-3535-2008	Guo, Li/0000-0002-3124-4505; Cordeiro, Maria Francesca/0000-0001-8663-6525; Ali, Robin/0000-0003-3126-6517	Wellcome TrustWellcome TrustEuropean Commission [063658] Funding Source: Medline		Agapova OA, 2003, NEUROBIOL DIS, V14, P63, DOI 10.1016/S0969-9961(03)00101-3; Agapova OA, 2001, GLIA, V33, P205, DOI 10.1002/1098-1136(200103)33:3<205::AID-GLIA1019>3.0.CO;2-D; Agar A, 2000, J NEUROSCI RES, V60, P495, DOI 10.1002/(SICI)1097-4547(20000515)60:4<495::AID-JNR8>3.0.CO;2-S; Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Asahi M, 2001, J NEUROSCI, V21, P7724; Chauhan BC, 2002, INVEST OPHTH VIS SCI, V43, P2969; Chintala SK, 2002, J BIOL CHEM, V277, P47461, DOI 10.1074/jbc.M204824200; Cordeiro MF, 2003, GENE THER, V10, P59, DOI 10.1038/sj.gt.3301865; Cordeiro MF, 2004, P NATL ACAD SCI USA, V101, P13352, DOI 10.1073/pnas.0405479101; Cordeiro MF, 1999, INVEST OPHTH VIS SCI, V40, P2225; Cordeiro MF, 2000, INVEST OPHTH VIS SCI, V41, P756; Cordeiro MF, 2002, PROG RETIN EYE RES, V21, P75, DOI 10.1016/S1350-9462(01)00021-0; Cordeiro MF, 1999, BRIT J OPHTHALMOL, V83, P132, DOI 10.1136/bjo.83.2.132; Cordeiro MF, 1999, INVEST OPHTH VIS SCI, V40, P1975; Darby IA, 2002, J PATHOL, V197, P117, DOI 10.1002/path.1074; GARCIAVALENZUELA E, 1995, EXP EYE RES, V61, P33, DOI 10.1016/S0014-4835(95)80056-5; Grossmann J, 2002, APOPTOSIS, V7, P247, DOI 10.1023/A:1015312119693; Hernandez MR, 2000, PROG RETIN EYE RES, V19, P297, DOI 10.1016/S1350-9462(99)00017-8; HERNANDEZ MR, 1990, AM J OPHTHALMOL, V109, P180, DOI 10.1016/S0002-9394(14)75984-7; Johnson EC, 1996, EXP EYE RES, V62, P663, DOI 10.1006/exer.1996.0077; Kerrigan LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P1031, DOI 10.1001/archopht.1997.01100160201010; Levkovitch-Verbin H, 2002, INVEST OPHTH VIS SCI, V43, P402; Martin J, 2001, J AM SOC NEPHROL, V12, P88, DOI 10.1681/ASN.V12188; Martin KRG, 2002, INVEST OPHTH VIS SCI, V43, P2236; Mittag TW, 2000, INVEST OPHTH VIS SCI, V41, P3451; Morrison JC, 1997, EXP EYE RES, V64, P85, DOI 10.1006/exer.1996.0184; Murphy FR, 2002, J BIOL CHEM, V277, P11069, DOI 10.1074/jbc.M111490200; Murphy G, 2003, BIOCHEM SOC SYMP, V70, P65, DOI 10.1042/bss0700065; Naskar R, 2002, INVEST OPHTH VIS SCI, V43, P2962; Pena JDO, 1999, BRIT J OPHTHALMOL, V83, P209, DOI 10.1136/bjo.83.2.209; QUIGLEY HA, 1981, ARCH OPHTHALMOL-CHIC, V99, P137; QUIGLEY HA, 1995, INVEST OPHTH VIS SCI, V36, P774; Rivera S, 2002, EUR J NEUROSCI, V15, P19, DOI 10.1046/j.0953-816x.2001.01838.x; Ruiz-Ederra J, 2004, MOL VIS, V10, P83; Sakata R, 2004, EUR J CLIN INVEST, V34, P129, DOI 10.1111/j.1365-2362.2004.01302.x; SHAH M, 1994, J CELL SCI, V107, P1137; SOMMER A, 1989, AM J OPHTHALMOL, V107, P186, DOI 10.1016/0002-9394(89)90221-3; Szklarczyk A, 2002, J NEUROSCI, V22, P920, DOI 10.1523/JNEUROSCI.22-03-00920.2002; Tan HK, 2003, MOL CELL NEUROSCI, V22, P98, DOI 10.1016/S1044-7431(02)00024-6; Tezel G, 2003, J GLAUCOMA, V12, P63, DOI 10.1097/00061198-200302000-00014; Tsirka SE, 1996, NATURE, V384, P123, DOI 10.1038/384123b0; Vaillant C, 2003, MOL CELL NEUROSCI, V24, P395, DOI 10.1016/S1044-7431(03)00196-9; Vorwerk CK, 2000, INVEST OPHTH VIS SCI, V41, P3615; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Werb Z, 1997, CELL, V91, P439, DOI 10.1016/S0092-8674(00)80429-8; WoldeMussie E, 2001, INVEST OPHTH VIS SCI, V42, P2849; Yan XM, 2000, ARCH OPHTHALMOL-CHIC, V118, P666, DOI 10.1001/archopht.118.5.666; Zhang X, 2004, INVEST OPHTH VIS SCI, V45, P2374, DOI 10.1167/iovs.03-1239; Zhang X, 2004, NEUROSCI LETT, V356, P140, DOI 10.1016/j.neulet.2003.10.084	49	220	236	0	13	ASSOC RESEARCH VISION OPHTHALMOLOGY INC	ROCKVILLE	12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA	0146-0404			INVEST OPHTH VIS SCI	Invest. Ophthalmol. Vis. Sci.	JAN	2005	46	1					175	182		10.1167/iovs.04-0832			8	Ophthalmology	Ophthalmology	889UV	WOS:000226469100027	15623771	Green Accepted			2021-06-18	
J	Chen, XG; Katakowski, M; Li, Y; Lu, DY; Wang, L; Zhang, LJ; Chen, JL; Xu, YX; Gautam, S; Mahmood, A; Chopp, M				Chen, XG; Katakowski, M; Li, Y; Lu, DY; Wang, L; Zhang, LJ; Chen, JL; Xu, YX; Gautam, S; Mahmood, A; Chopp, M			Human bone marrow stromal cell cultures conditioned by traumatic brain tissue extracts: Growth factor production	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						marrow stromal cells; traumatic brain injury; neurotrophins; angiogenesis; growth factors	STEM-CELLS; NERVOUS-SYSTEM; RAT-BRAIN; INJURY; EXPRESSION; NEURONS; HEMATOPOIESIS; CYTOKINE; SURVIVAL; MODEL	Treatment of traumatic brain injury (TBI) with bone marrow stromal cells (MSCs) improves functional outcome in the rat. However, the specific mechanisms by which introduced MSCs provide benefit remain to be elucidated. Currently, the ability of therapeutically transplanted MSCs to replace injured parenchymal CNS tissue appears limited at best. Tissue replacement, however, is not the only possible compensatory avenue in cell transplantation therapy. Various growth factors have been shown to mediate the repair and replacement of damaged tissue, so trophic support provided by transplanted MSCs may play a role in the treatment of damaged tissue. We therefore investigated the temporal profile of various growth factors, brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), and hepatocyte growth factor (HGF), within cultures of human MSCs (hMSCs) conditioned with cerebral tissue extract from TBI. hMSCs were cultured with TBI extracts of rat brain in vitro and quantitative sandwich enzyme-linked immunosorbent assays (ELISAs) were performed. TBI-conditioned hMSCs cultures demonstrated a time-dependent increase of BDNF, NGF, VEGF, and HGF, indicating a responsive production of these growth factors by the hMSCs. The ELISA data suggest that transplanted hMSCs may provide therapeutic benefit via a responsive secretion of an array of growth factors that can foster neuroprotection and angiogenesis. (C) 2002 Wiley-Liss, Inc.	Henry Ford Hlth Sci Ctr, Dept Neurol, Detroit, MI USA; Oakland Univ, Dept Phys, Rochester, MI USA; Henry Ford Hlth Sci Ctr, Dept Neurosurg, Detroit, MI USA; Henry Ford Hlth Sci Ctr, Bone Marrow Transplant Program, Div Hematol Med Oncol, Detroit, MI USA	Chopp, M (corresponding author), Henry Ford Hosp, Dept Neurol, 2799 W Grand Blvd, Detroit, MI 48202 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS023393] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS23393] Funding Source: Medline		Ay H, 1999, CEREBROVASC DIS, V9, P131, DOI 10.1159/000015941; BEREZOVSKAYA O, 1995, INT J DEV NEUROSCI, V13, P285, DOI 10.1016/0736-5748(95)00013-7; Bjorklund A, 2000, NAT NEUROSCI, V3, P537, DOI 10.1038/75705; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; CANEVA L, 1995, BLOOD CELL MOL DIS, V21, P73, DOI 10.1006/bcmd.1995.0011; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dormady SP, 2001, J HEMATOTH STEM CELL, V10, P125, DOI 10.1089/152581601750098372; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; HEFTI F, 1986, J NEUROSCI, V6, P2155; Hicks RR, 1999, J NEUROTRAUM, V16, P501, DOI 10.1089/neu.1999.16.501; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; KOLIATSOS VE, 1993, NEURON, V10, P359, DOI 10.1016/0896-6273(93)90326-M; KROMER LF, 1987, SCIENCE, V235, P214, DOI 10.1126/science.3798108; Labouyrie E, 1999, AM J PATHOL, V154, P405, DOI 10.1016/S0002-9440(10)65287-X; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Majumdar MK, 2000, J HEMATOTH STEM CELL, V9, P841, DOI 10.1089/152581600750062264; Majumdar MK, 1998, J CELL PHYSIOL, V176, P57, DOI 10.1002/(SICI)1097-4652(199807)176:1<57::AID-JCP7>3.0.CO;2-7; Mizuno S, 2000, KIDNEY INT, V57, P937; Papavassiliou E, 1997, J NEUROSCI RES, V49, P451, DOI 10.1002/(SICI)1097-4547(19970815)49:4<451::AID-JNR6>3.0.CO;2-7; Sondell M, 1999, J NEUROSCI, V19, P5731, DOI 10.1523/JNEUROSCI.19-14-05731.1999; Sondell M, 2001, NEUROREPORT, V12, P105, DOI 10.1097/00001756-200101220-00028; Sugimori H, 2001, NEUROSCI LETT, V300, P13, DOI 10.1016/S0304-3940(01)01549-X; Takai K, 1997, BLOOD, V89, P1560, DOI 10.1182/blood.V89.5.1560.1560_1560_1565; Zhang LL, 2000, J NEUROSCI RES, V59, P489, DOI 10.1002/(SICI)1097-4547(20000215)59:4<489::AID-JNR3>3.3.CO;2-0; Zhang ZG, 2000, J CLIN INVEST, V106, P829, DOI 10.1172/JCI9369	27	220	281	0	14	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	SEP 1	2002	69	5					687	691		10.1002/jnr.10334			5	Neurosciences	Neurosciences & Neurology	589EL	WOS:000177745500014	12210835				2021-06-18	
J	LEVIN, HS; WILLIAMS, DH; EISENBERG, HM; HIGH, WM; GUINTO, FC				LEVIN, HS; WILLIAMS, DH; EISENBERG, HM; HIGH, WM; GUINTO, FC			SERIAL MRI AND NEUROBEHAVIORAL FINDINGS AFTER MILD TO MODERATE CLOSED HEAD-INJURY	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							MAGNETIC-RESONANCE; COMPUTED-TOMOGRAPHY; PRACTICAL SCALE; TRAUMA; BRAIN; LESIONS	Fifty patients who sustained mild to moderate closed head injury (CHI) underwent a CT scan, MRI, and neurobehavioural testing. At baseline 40 patients had intracranial hyperintensities detected by MRI which predominated in the frontal and temporal regions, whereas 10 patients had lesions detected by CT. Neurobehavioural data obtained during the first admission to hospital disclosed no distinctive pattern in subgroups of patients characterised by lesions confined to the frontal, temporal, or frontotemporal regions, whereas all three groups exhibited pervasive deficits in relation to normal control subjects. The size of extraparenchymal lesion was significantly related to the initial Glasgow Coma Scale score, whereas this relation was not present in parenchymal lesions. One and three month follow up MRI findings showed substantial resolution of lesion while neuropsychological data reflected impressive recovery. The follow up data disclosed a trend from pervasive deficits to more specific impairments which were inconsistently related to the site of brain lesion. These results corroborate and extend previous findings, indicating that intracranial lesions detected by MRI are present in most patients hospitalised after mild to moderate CHI. Individual differences in the relation between site of lesion and the pattern of nueropsychological findings, which persist over one to three months after mild to moderate CHI, remain unexplained.	UNIV TEXAS, MED BRANCH, DIV NEURORADIOL, GALVESTON, TX 77550 USA; LARELWOOD HOSP, NEUROBEHAV UNIT, THE WOODLANDS, TX USA	LEVIN, HS (corresponding author), UNIV TEXAS, MED BRANCH, DIV NEUROSURG, D-73, GALVESTON, TX 77550 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline		ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; BENTON AL, 1968, NEUROPSYCHOLOGIA, V6, P53, DOI 10.1016/0028-3932(68)90038-9; BENTON AL, 1978, MANUAL MULTILINGUAL; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; BYDDER GM, 1982, AM J ROENTGENOL, V139, P215, DOI 10.2214/ajr.139.2.215; GANDY SE, 1984, ANN NEUROL, V16, P254, DOI 10.1002/ana.410160217; HAN JS, 1984, RADIOLOGY, V150, P71, DOI 10.1148/radiology.150.1.6689790; Holbourn AHS, 1943, LANCET, V2, P438; JENKINS A, 1986, LANCET, V2, P445; JONESGOTMAN M, 1977, NEUROPSYCHOLOGIA, V15, P653, DOI 10.1016/0028-3932(77)90070-7; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; KIMURA D, 1963, ARCH NEUROL-CHICAGO, V8, P264, DOI 10.1001/archneur.1963.00460030048004; Levin H. S., 1983, SOC NEUR ABSTR, V9, P918; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; SNOW RB, 1986, NEUROSURGERY, V18, P45, DOI 10.1227/00006123-198601000-00008; TEASDALE G, 1974, LANCET, V2, P81; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391	22	220	223	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	APR	1992	55	4					255	262		10.1136/jnnp.55.4.255			8	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	HP519	WOS:A1992HP51900004	1583509	Green Published, Bronze			2021-06-18	
J	RUTHERFORD, WH; MERRETT, JD; MCDONALD, JR				RUTHERFORD, WH; MERRETT, JD; MCDONALD, JR			SEQUELAE OF CONCUSSION CAUSED BY MINOR HEAD-INJURIES	LANCET			English	Article									QUEENS UNIV BELFAST,DEPT ACCIDENT & EMERGENCY,BELFAST BT7 1NN,NORTH IRELAND; QUEENS UNIV BELFAST,DEPT MED STATISTICS,BELFAST BT7 1NN,NORTH IRELAND							GRONWALL, 1974, LANCET, V2, P605; KAY DWK, 1971, LANCET, V2, P1092; LEWIN W, 1968, BMJ-BRIT MED J, V1, P465, DOI 10.1136/bmj.1.5590.465; LIDVALL HF, 1974, ACTA NEUROL SCAN S56, V50; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; MILLER H, 1966, P ROY SOC MED, V59, P257, DOI 10.1177/003591576605900327; STEADMAN JH, 1970, P ROY SOC MED, V63, P23, DOI 10.1177/003591577006300109; TAYLOR AR, 1967, BRIT MED J, V3, P67, DOI 10.1136/bmj.3.5557.67	8	220	220	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet		1977	1	8001					1	4					4	Medicine, General & Internal	General & Internal Medicine	CQ936	WOS:A1977CQ93600001	63653				2021-06-18	
J	Wu, HT; Lu, DY; Jiang, H; Xiong, Y; Qu, CS; Li, B; Mahmood, A; Zhou, D; Chopp, M				Wu, Hongtao; Lu, Dunyue; Jiang, Hao; Xiong, Ye; Qu, Changsheng; Li, Bo; Mahmood, Asim; Zhou, Dong; Chopp, Michael			Simvastatin-mediated upregulation of VEGF and BDNF, activation of the PI3K/Akt pathway, and increase of neurogenesis are associated with therapeutic improvement after traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						neurogenesis; PI3K/Akt pathway; simvastatin; spatial memory; traumatic brain injury	CONTROLLED CORTICAL IMPACT; ELEMENT-BINDING PROTEIN; FOCAL CEREBRAL-ISCHEMIA; HIPPOCAMPAL CA3 REGION; BORN GRANULE CELLS; MORRIS WATER MAZE; DENTATE GYRUS; NEUROTROPHIC FACTOR; SPATIAL MEMORY; MESSENGER-RNA	This study was undertaken to evaluate the effect of simvastatin, a cholesterol-lowering agent, on the Akt-mediated signaling pathway and neurogenesis in the dentate gyrus (DG) of the hippocampus in rats after traumatic brain injury (TBI). Adult male Wistar rats were divided into three groups: (1) sham group (n = 8); (2) saline control group (n = 40); and (3) simvastatin-treated group (n = 40). Controlled cortical impact (CCI) injury was performed over the left parietal lobe. Simvastatin was administered orally at a dose of 1 mg/kg starting at day I after TBI and then daily for 14 days. Brornodeoxyuridine (BrdU) was injected intraperitoneally into rats. A modified Morris Water Maze (WM) task was performed between 31 and 35 days after treatment to test spatial memory (n = 8/group). Animals were sacrificed at 1, 3, 7, 14, and 35 days after treatment (n = 8/group/time point). Western blot was utilized to investigate the changes in the Akt-mediated signaling pathway. Enzyme-linked immunosorbent assay (ELISA) analyses were employed to measure vascular endothelial growth factor (VEGF) and brain-derived neurotrophin factor (BDNF) expression. Immunohistochemical and fluorescent staining were performed to detect the BrdU- and neuronal nuclei(NeuN)/BrdU-positive cells. Our data show that simvastatin treatment increases phosphorylation of v-akt murine thymoma viral oncogene homolog (Akt), glycogen synthase kinase-3 beta (GSK-3 beta), and cAMP response element-binding proteins (CREB); elevates the expression of BDNF and VEGF in the DG; increases cell proliferation and differentiation in the DG; and enhances the recovery of spatial learning. These data suggest that the neurorestorative effect of simvastatin may be mediated through activation of the Akt-mediated signaling pathway, subsequently upregulating expression of growth factors and inducing neurogenesis in the DG of the hippocampus, thereby leading to restoration of cognitive function after TBI in rats.	[Wu, Hongtao; Xiong, Ye; Qu, Changsheng; Li, Bo; Mahmood, Asim; Chopp, Michael] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI USA; [Jiang, Hao; Chopp, Michael] Henry Ford Hlth Syst, Dept Neurol, Detroit, MI USA; [Wu, Hongtao; Zhou, Dong] Sichuan Univ, W China Hosp, Dept Neurol, Chengdu 610064, Peoples R China; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI USA; [Lu, Dunyue] SUNY Brooklyn, Dept Psychiat, Brooklyn, NY USA	Chopp, M (corresponding author), Henry Ford Hosp, Dept Neurol, E&R Bldg 3056,2799 W Grand Blvd, Detroit, MI 48202 USA.	chopp@neuro.hfh.edu	Wu, Hongtao/A-8602-2011	Xiong, Ye/0000-0001-9770-6031	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052280] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS052280-01A1] Funding Source: Medline		Asahi M, 2005, J CEREBR BLOOD F MET, V25, P722, DOI 10.1038/sj.jcbfm.9600070; Bingman Verner P, 2006, Behav Cogn Neurosci Rev, V5, P80, DOI 10.1177/1534582306289578; Brightwell JJ, 2007, LEARN MEMORY, V14, P195, DOI 10.1101/lm.395407; Castelo-Branco GA, 2003, P NATL ACAD SCI USA, V100, P12747, DOI 10.1073/pnas.1534900100; Chen JL, 2005, J CEREBR BLOOD F MET, V25, P281, DOI 10.1038/sj.jcbfm.9600034; Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Cimino A, 2005, NEUROTOXICOLOGY, V26, P929, DOI 10.1016/j.neuro.2005.03.009; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Emery DL, 2005, J NEUROTRAUM, V22, P978, DOI 10.1089/neu.2005.22.978; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Heldt SA, 2007, MOL PSYCHIATR, V12, P656, DOI 10.1038/sj.mp.4001957; Hicks RR, 1999, J NEUROTRAUM, V16, P501, DOI 10.1089/neu.1999.16.501; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Hoglund K, 2005, DEMENT GERIATR COGN, V19, P256, DOI 10.1159/000084550; Horwood JM, 2006, EUR J NEUROSCI, V23, P3375, DOI 10.1111/j.1460-9568.2006.04859.x; Jeon SH, 2007, MOL CELLS, V23, P23; Johnson-Anuna LN, 2007, J NEUROCHEM, V101, P77, DOI 10.1111/j.1471-4159.2006.04375.x; Kesner RP, 2006, BIOL PSYCHOL, V73, P3, DOI 10.1016/j.biopsycho.2006.01.004; Kretz A, 2006, NEUROBIOL DIS, V21, P421, DOI 10.1016/j.nbd.2005.08.003; Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510; Laufs U, 2000, TRENDS CARDIOVAS MED, V10, P143, DOI 10.1016/S1050-1738(00)00044-X; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813; Matsuzaki H, 2001, FASEB J, V15, P1218; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Otaegi G, 2006, J CELL SCI, V119, P2739, DOI 10.1242/jcs.03012; Peng Y, 2004, J BIOL CHEM, V279, P28509, DOI 10.1074/jbc.M402294200; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; PORTE Y, 2007, NEUROBIOL AGING; Rhodes JS, 2003, BEHAV NEUROSCI, V117, P1006, DOI 10.1037/0735-7044.117.5.1006; Royo NC, 2003, CURR OPIN PHARMACOL, V3, P27, DOI 10.1016/S1471-4892(02)00006-1; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Schmeer C, 2006, RESTOR NEUROL NEUROS, V24, P79; Shapiro LA, 2007, BRAIN RES, V1149, P30, DOI 10.1016/j.brainres.2006.07.032; Sparks DL, 2002, ANN NY ACAD SCI, V977, P356, DOI 10.1111/j.1749-6632.2002.tb04838.x; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Truettner J, 1999, J NEUROTRAUM, V16, P471, DOI 10.1089/neu.1999.16.471; Vaughan CJ, 1999, STROKE, V30, P1969, DOI 10.1161/01.STR.30.9.1969; Vojtek AB, 2003, MOL CELL BIOL, V23, P4417, DOI 10.1128/MCB.23.13.4417-4427.2003; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Wang L, 2005, J CEREBR BLOOD F MET, V25, P1150, DOI 10.1038/sj.jcbfm.9600112; Zhu DY, 2004, P NATL ACAD SCI USA, V101, P9453, DOI 10.1073/pnas.0401063101	45	219	228	2	26	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2008	25	2					130	139		10.1089/neu.2007.0369			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	266RZ	WOS:000253456000006	18260796				2021-06-18	
J	Broglio, SP; Macciocchi, SN; Ferrara, MS				Broglio, Steven P.; Macciocchi, Stephen N.; Ferrara, Michael S.			Sensitivity of the concussion assessment battery	NEUROSURGERY			English	Article						HeadMinder Concussion Resolution Index; Immediate Post-Concussion Assessment and Cognitive Testing; neurocognitive assessment; postural control	COLLEGIATE FOOTBALL PLAYERS; HIGH-SCHOOL; IMPACT; SPORT; PERFORMANCE; RECOVERY; VALIDITY; EPIDEMIOLOGY; SYMPTOMS	Objective: Sports medicine clinicians commonly use multiple tests when evaluating patients with concussion. The specific tests vary but often include symptom inventories, posturography, and neurocognitive examinations. The sensitivity of these tests to concussion is vital in reducing the risk for additional injury by prematurely returning an athlete to play. Our study investigated the sensitivity of concussion-related symptoms, a postural control evaluation, and neurocognitive functioning in concussed collegiate athletes. Methods: From 1998 to 2005, all high-risk athletes completed a baseline concussion-assessment battery that consisted of a self-reported symptom inventory, a postural control evaluation, and a neurocognitive assessment. Postconcussion assessments were administered within 24 hours of injury to 75 athletes who had physician-diagnosed concussion. Individual tests and the complete battery were evaluated for sensitivity to concussion. Results: The computerized Immediate Post-Concussion Assessment and Cognitive Testing and HeadMinder Concussion Resolution Index (neurocognitive tests) were the most sensitive to concussion (79.2 and 78.6%, respectively). These tests were followed by self-reported symptoms (68.0%), the postural control evaluation (61.9%), and a brief pencil-and-paper assessment of neurocognitive function (43.5%). When the complete battery was assessed, sensitivity exceeded 90%. Conclusion: Currently recommended concussion-assessment batteries accurately identified decrements in one or more areas in most of the athletes with concussion. These findings support previous recommendations that sports-related concussion should be approached through a multifaceted assessment with components focusing on distinct aspects of the athlete's function.	Univ Illinois, Dept Kinesiol & Community Hlth, Urbana, IL 61801 USA; Univ Georgia, Dept Kinesiol, Athens, GA 30602 USA; Univ Georgia, Shepherd Ctr, Athens, GA 30602 USA	Broglio, SP (corresponding author), Univ Illinois, Dept Kinesiol & Community Hlth, 906 S Goodwin Ave, Urbana, IL 61801 USA.	broglio@uiuc.edu					Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Benton AL, 1978, MULTILINGUAL APHASIA; Brandt J., 1991, CLIN NEUROPSYCHOL, V5, P125, DOI 10.1080/13854049108403297.; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; CLACKAMAS OR, 2001, NEUROCOM SYSTEM OPER; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Erlanger D, 2001, J ATHL TRAINING, V36, P280; ERLANGER DM, 2002, PROFESSIONAL MANUAL; Ferrara MS, 2001, J ATHL TRAINING, V36, P145; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Kelly JP, 1997, NEUROLOGY, V48, P581; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Piland SG, 2006, MED SCI SPORT EXER, V38, P27, DOI 10.1249/01.mss.0000183186.98212.d5; Piland SG, 2003, J ATHL TRAINING, V38, P104; Raymond PD, 2006, EUR J CARDIO-THORAC, V29, P82, DOI 10.1016/j.ejcts.2005.10.016; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Smith A., 1982, SYMBOL DIGIT MODALIT; Thurman DJ, 1999, TRAUMATIC BRAIN INJU; Weschler D., 1997, WECHSLER ADULT INTEL	37	219	219	1	33	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUN	2007	60	6					1050	1057		10.1227/01.NEU.0000255479.90999.C0			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	174VY	WOS:000246972100029	17538379				2021-06-18	
J	van Reekum, R; Stuss, DT; Ostrander, L				van Reekum, R; Stuss, DT; Ostrander, L			Apathy: Why care?	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article; Proceedings Paper	12th Annual Rotman Conference	MAR 25-26, 2002	Toronto, CANADA				TRAUMATIC BRAIN-INJURY; FRONTAL-LOBE SYNDROME; PROGRESSIVE SUPRANUCLEAR PALSY; BLIND OLANZAPINE TRIAL; CEREBRAL BLOOD-FLOW; ALZHEIMERS-DISEASE; NEGATIVE SYMPTOMS; PARKINSONS-DISEASE; NEUROPSYCHIATRIC INVENTORY; LEWY BODIES	This review presents data showing that apathy is common across a number of disorders. Apathy is not only common, but is also associated with significant problems: reduced functional level, decreased response to treatment, poor illness outcome, caregiver distress, and chronicity. Preliminary evidence of treatment efficacy exists for dopaminergic drugs and for amphetamines. Strong evidence of efficacy exists for acetylcholinesterase inhibitors in Alzheimer's disease, and for atypical antipsychotics in schizophrenia. Frontal-subcortical system(s) dysfunction is implicated in the causation of apathy; apathy subtypes based on the various frontal-subcortical loops may thus exist. Further research involving diagnosis, pathophysiology, and treatment is suggested.	Baycrest Ctr Geriatr Care, Dept Psychiat, Toronto, ON M6A 2E1, Canada; Baycrest Ctr Geriatr Care, Kunin Lunenfeld Appl Res Unit, Toronto, ON M6A 2E1, Canada; Univ Toronto, Div Geriatr Psychiat, Toronto, ON, Canada; Baycrest Ctr Geriatr Care, Rotman Res Inst, Toronto, ON M6A 2E1, Canada; Univ Toronto, Dept Med Neurol Rehabil Sci, Toronto, ON, Canada; Univ Toronto, Dept Psychol, Toronto, ON M5S 1A1, Canada	van Reekum, R (corresponding author), Baycrest Ctr Geriatr Care, Dept Psychiat, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada.	rvanreekum@baycrest.org					Aarsland D, 1999, J NEUROL NEUROSUR PS, V67, P492, DOI 10.1136/jnnp.67.4.492; Aarsland D, 2001, J NEUROPSYCH CLIN N, V13, P42, DOI 10.1176/appi.neuropsych.13.1.42; Aarsland D, 2001, INT J GERIATR PSYCH, V16, P184, DOI 10.1002/1099-1166(200102)16:2<184::AID-GPS304>3.0.CO;2-K; Aharon-Peretz J, 2000, DEMENT GERIATR COGN, V11, P294, DOI 10.1159/000017252; ANANTH J, 1991, J PSYCHIATR NEUROSCI, V16, P12; Andersson S, 1999, PSYCHOL MED, V29, P447, DOI 10.1017/S0033291798008046; Andersson S, 1999, BRAIN INJURY, V13, P393, DOI 10.1080/026990599121458; Barrash J, 2000, DEV NEUROPSYCHOL, V18, P355, DOI 10.1207/S1532694205Barrash; Beasley CM, 1996, PSYCHOPHARMACOLOGY, V124, P159, DOI 10.1007/BF02245617; Beasley CM, 1997, EUR NEUROPSYCHOPHARM, V7, P125, DOI 10.1016/S0924-977X(96)00392-6; Beasley CM, 1996, NEUROPSYCHOPHARMACOL, V14, P111, DOI 10.1016/0893-133X(95)00069-P; Benoit M, 1999, DEMENT GERIATR COGN, V10, P511, DOI 10.1159/000017198; BHATIA KP, 1994, BRAIN, V117, P859, DOI 10.1093/brain/117.4.859; BOZZOLA FG, 1992, ARCH NEUROL-CHICAGO, V49, P297, DOI 10.1001/archneur.1992.00530270117027; Buchanan RW, 1997, AM J PSYCHIAT, V154, P363; CANTELLO R, 1989, J NEUROL NEUROSUR PS, V52, P724, DOI 10.1136/jnnp.52.6.724; Castellon SA, 1998, J NEUROPSYCH CLIN N, V10, P320, DOI 10.1176/jnp.10.3.320; Castellon SA, 2000, J INT NEUROPSYCH SOC, V6, P336, DOI 10.1017/S1355617700633088; CATSMANBERREVOETS CE, 1988, NEUROLOGY, V38, P647, DOI 10.1212/WNL.38.4.647; CHATURVEDI SK, 1986, ACTA PSYCHIAT SCAND, V74, P183, DOI 10.1111/j.1600-0447.1986.tb10603.x; CLARK ANG, 1979, J AM GERIATR SOC, V27, P174, DOI 10.1111/j.1532-5415.1979.tb06442.x; COHEN RA, 1989, ARCH NEUROL-CHICAGO, V46, P676, DOI 10.1001/archneur.1989.00520420096030; Craig AH, 1996, ARCH NEUROL-CHICAGO, V53, P1116, DOI 10.1001/archneur.1996.00550110056012; CRISMON ML, 1988, CLIN NEUROPHARMACOL, V11, P462, DOI 10.1097/00002826-198810000-00007; Cummings JL, 1998, NEUROLOGY, V50, pA251; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; Daffner KR, 1999, NEUROPSY NEUROPSY BE, V12, P58; Daffner KR, 2000, BRAIN, V123, P927, DOI 10.1093/brain/123.5.927; Daffner KR, 2000, J NEUROL NEUROSUR PS, V68, P18, DOI 10.1136/jnnp.68.1.18; Daffner KR, 2001, NEUROLOGY, V56, P1377, DOI 10.1212/WNL.56.10.1377; Del Ser T, 2000, INT J GERIATR PSYCH, V15, P1034, DOI 10.1002/1099-1166(200011)15:11<1034::AID-GPS231>3.0.CO;2-5; Devanand D P, 1992, Int Psychogeriatr, V4 Suppl 2, P161; Diaz-Olavarrieta C, 1999, J NEUROPSYCH CLIN N, V11, P51, DOI 10.1176/jnp.11.1.51; DOODY RS, 1995, J NEUROPSYCH CLIN N, V7, P54; Engelborghs S, 2000, STROKE, V31, P1762, DOI 10.1161/01.STR.31.7.1762; ERKULWATER S, 1989, SOUTHERN MED J, V82, P550, DOI 10.1097/00007611-198905000-00004; FILLEY CM, 1995, WESTERN J MED, V163, P19; Finset A, 2000, BRAIN INJURY, V14, P887; FONES C, 1995, BRIT J CLIN PRACT, V49, P97; Galynker I, 1997, J NEUROPSYCH CLIN N, V9, P231; GALYNKER II, 1995, AM J GERIAT PSYCHIAT, V3, P52, DOI 10.1097/00019442-199524310-00007; Ghika-Schmid F, 2000, ANN NEUROL, V48, P220, DOI 10.1002/1531-8249(200008)48:2<220::AID-ANA12>3.0.CO;2-M; Godefroy O, 1997, NEUROLOGY, V49, P695, DOI 10.1212/WNL.49.3.695; GRACE JG, 1996, 1996 P NAT AC NEUR D; Hargrave R, 2000, J NEUROL NEUROSUR PS, V68, P41, DOI 10.1136/jnnp.68.1.41; HORIGUCHI J, 1990, CLIN NEUROPHARMACOL, V13, P84, DOI 10.1097/00002826-199002000-00009; Kant R, 1998, BRAIN INJURY, V12, P87, DOI 10.1080/026990598122908; KAPLITZ SE, 1975, J AM GERIATR SOC, V23, P271, DOI 10.1111/j.1532-5415.1975.tb00317.x; Kaufer D I, 1999, Curr Psychiatry Rep, V1, P78, DOI 10.1007/s11920-999-0013-1; Kaufer DI, 1998, NEUROLOGY, V50, pA89; Kaufer DI, 1998, J AM GERIATR SOC, V46, P210, DOI 10.1111/j.1532-5415.1998.tb02542.x; Kopelowicz A, 1997, AM J PSYCHIAT, V154, P424; Kraus MF, 1997, BRAIN INJURY, V11, P455, DOI 10.1080/026990597123430; Kraus MF, 1997, J NEUROPSYCH CLIN N, V9, P222; Kuzis G, 1999, NEUROLOGY, V52, P1403, DOI 10.1212/WNL.52.7.1403; Lampe IK, 2001, J GERIATR PSYCH NEUR, V14, P11, DOI 10.1177/089198870101400104; Lavretsky H, 1999, AM J GERIAT PSYCHIAT, V7, P309; LEVASSEUR M, 1992, BRAIN, V115, P795, DOI 10.1093/brain/115.3.795; Levy ML, 1998, J NEUROPSYCH CLIN N, V10, P314, DOI 10.1176/jnp.10.3.314; Litvan I, 1996, NEUROLOGY, V47, P1184, DOI 10.1212/WNL.47.5.1184; Litvan I, 1998, J NEUROL NEUROSUR PS, V65, P717, DOI 10.1136/jnnp.65.5.717; Lopez OL, 2001, J NEUROPSYCH CLIN N, V13, P56, DOI 10.1176/appi.neuropsych.13.1.56; Lyketsos CG, 2000, AM J PSYCHIAT, V157, P708, DOI 10.1176/appi.ajp.157.5.708; Maletta Gabe J, 1993, Am J Geriatr Psychiatry, V1, P234, DOI 10.1097/00019442-199300130-00008; MARIN RS, 1993, J AFFECT DISORDERS, V28, P117, DOI 10.1016/0165-0327(93)90040-Q; MARIN RS, 1991, PSYCHIAT RES, V38, P143, DOI 10.1016/0165-1781(91)90040-V; MARIN RS, 1991, J NEUROPSYCH CLIN N, V3, P243; MARIN RS, 1990, AM J PSYCHIAT, V147, P22; MARIN RS, 1994, J NERV MENT DIS, V182, P235, DOI 10.1097/00005053-199404000-00008; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Max JE, 2001, J NEUROPSYCH CLIN N, V13, P161, DOI 10.1176/appi.neuropsych.13.2.161; MCGILCHRIST I, 1993, BRIT J PSYCHIAT, V163, P113, DOI 10.1192/bjp.163.1.113; McKeith IG, 2000, INT J GERIATR PSYCH, V15, P387, DOI 10.1002/(SICI)1099-1166(200005)15:5<387::AID-GPS131>3.0.CO;2-9; Mega MS, 1999, ARCH NEUROL-CHICAGO, V56, P1388, DOI 10.1001/archneur.56.11.1388; MENDEZ MF, 1989, NEUROLOGY, V39, P349, DOI 10.1212/WNL.39.3.349; Migneco O, 2001, NEUROIMAGE, V13, P896, DOI 10.1006/nimg.2000.0741; MILLER DD, 1994, COMPR PSYCHIAT, V35, P8, DOI 10.1016/0010-440X(94)90164-3; Okada K, 1997, STROKE, V28, P2437, DOI 10.1161/01.STR.28.12.2437; Ott BR, 1996, J NEUROPSYCH CLIN N, V8, P41; Paradiso S, 1999, J NEUROL NEUROSUR PS, V67, P664, DOI 10.1136/jnnp.67.5.664; PARKS RW, 1992, J NEUROPSYCH CLIN N, V4, P109; Paulsen JS, 2001, J NEUROL NEUROSUR PS, V71, P310, DOI 10.1136/jnnp.71.3.310; Paulsen JS, 1996, ASSESSMENT, V3, P327; Petry S, 1989, J Geriatr Psychiatry Neurol, V2, P203, DOI 10.1177/089198878900200406; PHILLIPS S, 1987, ARCH NEUROL-CHICAGO, V44, P1134, DOI 10.1001/archneur.1987.00520230024008; Powell JH, 1996, J NEUROL NEUROSUR PS, V60, P416, DOI 10.1136/jnnp.60.4.416; RABEJA RK, 1995, J GERIATR PSYCH NEUR, V8, P159; Rabkin JG, 2000, J NEUROPSYCH CLIN N, V12, P451, DOI 10.1176/appi.neuropsych.12.4.451; Ramirez SM, 2001, PSYCHOL REP, V88, P189, DOI 10.2466/PR0.88.1.189-200; Rapoport MJ, 2001, INT J GERIATR PSYCH, V16, P123, DOI 10.1002/1099-1166(200102)16:2<123::AID-GPS260>3.0.CO;2-1; Reichman WE, 1996, AM J PSYCHIAT, V153, P424; Resnick B, 1998, Rehabil Nurs, V23, P141; ROCA RP, 1990, J AM GERIATR SOC, V38, P675, DOI 10.1111/j.1532-5415.1990.tb01428.x; Rubinsztein JS, 1998, J NEUROL NEUROSUR PS, V64, P510, DOI 10.1136/jnnp.64.4.510; SANDSON TA, 1991, ARCH NEUROL-CHICAGO, V48, P1300, DOI 10.1001/archneur.1991.00530240106031; SCHNEIDER F, 1995, SCHIZOPHR RES, V17, P67, DOI 10.1016/0920-9964(95)00031-G; Selten JP, 2000, SCHIZOPHRENIA BULL, V26, P737, DOI 10.1093/oxfordjournals.schbul.a033490; Simard M, 2000, J NEUROPSYCH CLIN N, V12, P425, DOI 10.1176/appi.neuropsych.12.4.425; STARKSTEIN SE, 1992, J NEUROPSYCH CLIN N, V4, P134; STARKSTEIN SE, 1993, STROKE, V24, P1625, DOI 10.1161/01.STR.24.11.1625; Starkstein SE, 2001, AM J PSYCHIAT, V158, P872, DOI 10.1176/appi.ajp.158.6.872; STRUB RL, 1989, ARCH NEUROL-CHICAGO, V46, P1024, DOI 10.1001/archneur.1989.00520450096027; STUSS DT, 1988, BRAIN COGNITION, V8, P348, DOI 10.1016/0278-2626(88)90059-0; Stuss DT., 2000, DIFFERENTIATION STAT, P340; TATEMICHI TK, 1992, NEUROLOGY, V42, P1966, DOI 10.1212/WNL.42.10.1966; Tattan TMG, 2001, SCHIZOPHRENIA BULL, V27, P149, DOI 10.1093/oxfordjournals.schbul.a006853; Tekin S, 2001, ANN NEUROL, V49, P355, DOI 10.1002/ana.72.abs; Thomas P, 2001, INT J GERIATR PSYCH, V16, P192, DOI 10.1002/1099-1166(200102)16:2<192::AID-GPS301>3.0.CO;2-Y; Tollefson GD, 1997, AM J PSYCHIAT, V154, P457; Tran PV, 1997, J CLIN PSYCHOPHARM, V17, P407, DOI 10.1097/00004714-199710000-00010; VANREEKUM R, 1995, BRAIN INJURY, V9, P49, DOI 10.3109/02699059509004571; Volkow ND, 1997, AM J PSYCHIAT, V154, P50; WATANABE MD, 1995, J NEUROPSYCH CLIN N, V7, P502; Wood S, 2000, AM J GERIAT PSYCHIAT, V8, P75, DOI 10.1097/00019442-200002000-00010	114	219	225	0	33	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	FEB	2005	17	1					7	19		10.1176/appi.neuropsych.17.1.7			13	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	902RP	WOS:000227374500002	15746478				2021-06-18	
J	Rizzo, AA; Schultheis, M; Kerns, KA; Mateer, C				Rizzo, AA; Schultheis, M; Kerns, KA; Mateer, C			Analysis of assets for virtual reality applications in neuropsychology	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							COGNITIVE REHABILITATION; BRAIN-INJURY; ENVIRONMENTS; PERFORMANCE; TECHNOLOGY; MEMORY; AMNESIA; SYSTEMS; HUMANS; TASK	Virtual reality (VR) technology offers new opportunities for the development of innovative neuropsychological assessment and rehabilitation tools. VR-based testing and training scenarios that would be difficult, if not impossible, to deliver using conventional neuropsychological methods are now being developed that take advantage of the assets available with VR technology. If empirical studies continue to demonstrate effectiveness, virtual environment applications could provide new options for targeting cognitive and functional impairments due to traumatic brain injury, neurological disorders, and learning disabilities. This article focuses on specifying the assets that are available with VR for neuropsychological applications along with discussion of current VR-based research that serves to illustrate each asset. VR allows for the precise presentation and control of dynamic multi-sensory 3D stimulus environments, as well as providing advanced methods for recording behavioural responses. This serves as the basis for a diverse set of VR assets for neuropsychological approaches that are detailed in this article. We take the position that when combining these assets within the context of functionally relevant, ecologically valid virtual environments, fundamental advancements can emerge in how human cognition and functional behaviour is assessed and rehabilitated.	Univ So Calif, Integrated Media Syst Ctr, Virtual Environm Lab, Los Angeles, CA 90089 USA; Univ So Calif, Sch Gerontol, Los Angeles, CA 90089 USA; Kessler Med Rehabil Res & Educ Corp, W Orange, NJ USA; Univ Victoria, Dept Psychol, Victoria, BC V8W 2Y2, Canada	Rizzo, AA (corresponding author), Univ So Calif, Integrated Media Syst Ctr, Virtual Environm Lab, 3740 McClintock Ave,Suite 131, Los Angeles, CA 90089 USA.	arizzo@use.edu		Schultheis, Maria/0000-0002-6558-548X			Alessi NE, 2000, CYBERPSYCHOL BEHAV, V3, P321, DOI 10.1089/10949310050078751; ANDERSON P, IN PRESS COGNITIVE B; Astur RS, 1998, BEHAV BRAIN RES, V93, P185, DOI 10.1016/S0166-4328(98)00019-9; BIEDERMAN I, 2002, 9 JOINT S NEUR COMP; Blascovich J, 2002, PSYCHOL INQ, V13, P103, DOI 10.1207/S15327965PLI1302_01; Bowman DA, 2001, PRESENCE-TELEOP VIRT, V10, P96, DOI 10.1162/105474601750182342; Brooks BM, 1999, NEUROPSYCHOL REHABIL, V9, P63, DOI 10.1080/713755589; BROWN DJ, 1998, P 2 EUR C DIS VIRT R, P11; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; CHARNESS N, 1988, BRAIN COGNITION, V8, P253, DOI 10.1016/0278-2626(88)90053-X; Christiansen C, 1998, ARCH PHYS MED REHAB, V79, P888, DOI 10.1016/S0003-9993(98)90083-1; COHEN NJ, 1980, SCIENCE, V210, P207, DOI 10.1126/science.7414331; CONNOR B, 2002, P 4 INT C DIS VIRT R, P77; COSTAS R, 2000, P 3 INT C DIS VIRT R, P305; CROMBY J, 1996, P 1 EUR C DIS VIRT R, P305; DAVIES RC, 1998, P 2 EUR C DIS VIRT R, P61; DAVIS ES, 2000, 8 ANN MED M VIRT REA; Deutsch JE, 2001, PRESENCE-VIRTUAL AUG, V10, P416, DOI 10.1162/1054746011470262; DOHERTY E, 1999, CYBERPSYCHOLOGY BEHA, V3, P249; Elkind JS, 2001, CYBERPSYCHOL BEHAV, V4, P489, DOI 10.1089/109493101750527042; GRAF P, 1985, J EXP PSYCHOL LEARN, V11, P501, DOI 10.1037/0278-7393.11.3.501; Greenhill LL, 1998, J CLIN PSYCHIAT, V59, P31; Harrison A, 2002, DISABIL REHABIL, V24, P599, DOI 10.1080/09638280110111360; Jack D, 2001, IEEE T NEUR SYS REH, V9, P308, DOI 10.1109/7333.948460; Jacobs WJ, 1997, LEARN MOTIV, V28, P521, DOI 10.1006/lmot.1997.0977; JAFFE DL, 1998, TECHN PERS DIS C LOS; Jansson G., 2000, P 3 INT C DIS VIRT R, P33; Johnston R., 1995, VIRTUAL REALITY SPEC, V2, P53; KRUEGER MW, 1993, PRESENCE-TELEOP VIRT, V2, P162, DOI DOI 10.1162/PRES.1993.2.2.162; LAPLANTE WP, 2001, ACM SIGCHI 2001 STAT; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Liu L, 1999, Cyberpsychol Behav, V2, P53, DOI 10.1089/cpb.1999.2.53; LOWENSTEIN D, 2002, ESSENTIAL FACTS VIDE; Lumbreras M., 2000, P 3 INT C DIS VIRT R, P129; McComas J, 2002, CYBERPSYCHOL BEHAV, V5, P185, DOI 10.1089/109493102760147150; McGeorge P, 2001, PRESENCE-TELEOP VIRT, V10, P375, DOI 10.1162/1054746011470235; MCLAUGHLIN ML, 2002, TOUCH VIRTUAL ENV; MENDOZZI L, 1998, CYBERPSYCHOLOGY BEHA, V1, P79, DOI DOI 10.1089/CPB.1998.1.79; Moore K, 2002, CYBERPSYCHOL BEHAV, V5, P197, DOI 10.1089/109493102760147178; Morrison J. E., 1999, 42 US ARM RES I BEH; MOWAFY L, 1995, ABILITY, V15, P18; Naveh Y., 2000, P 3 INT C DIS VIRT R, P243; Neisser U., 1978, PRACTICAL ASPECTS ME, P3; North MM, 2002, HUM FAC ER, P1065; Park NW, 2001, NEUROPSYCHOLOGY, V15, P199, DOI 10.1037/0894-4105.15.2.199; Pertaub DP, 2002, PRESENCE-TELEOP VIRT, V11, P68, DOI 10.1162/105474602317343668; Prensky M., 2001, DIGITAL GAME BASED L; Prigatano GP, 1997, J INT NEUROPSYCH SOC, V3, P497, DOI 10.1017/S1355617797004979; Psotka J, 1995, INSTR SCI, V23, P405, DOI 10.1007/BF00896880; PUGNETTI L, 1995, COMPUT BIOL MED, V25, P213, DOI 10.1016/0010-4825(94)00040-W; Pugnetti L., 1998, CYBERPSYCHOL BEHAV, V1, P151; Rickel J, 2002, IEEE INTELL SYST, V17, P32, DOI 10.1109/MIS.2002.1024750; Rickel J, 1999, APPL ARTIF INTELL, V13, P343, DOI 10.1080/088395199117315; Riva G, 1999, J BEHAV THER EXP PSY, V30, P221, DOI 10.1016/S0005-7916(99)00018-X; Rizzo AA, 2002, HUM FAC ER, P1027; Rizzo AA, 2001, CYBERPSYCHOL BEHAV, V4, P471, DOI 10.1089/109493101750527033; Rizzo AA, 2000, CYBERPSYCHOL BEHAV, V3, P483, DOI 10.1089/10949310050078940; Rizzo AA, 2001, PRESENCE-TELEOP VIRT, V10, P359, DOI 10.1162/1054746011470226; RIZZO AA, 1994, P 2 INT C VIRT REAL; RIZZO AA, 2001, USABILITY EVALUATION, P792; Rizzo AS, 2002, STUD NEUROPSYCHOL DE, P243; Rizzo M, 1997, ARCH NEUROL-CHICAGO, V54, P545, DOI 10.1001/archneur.1997.00550170027011; ROBERTSON I, 1990, APHASIOLOGY, V4, P381, DOI 10.1080/02687039008249090; Rose FD, 2001, PRESENCE-VIRTUAL AUG, V10, P345, DOI 10.1162/1054746011470208; Rose FD, 1996, CURR OPIN NEUROL, V9, P461, DOI 10.1097/00019052-199612000-00012; Rosenthal DSH, 2000, USENIX ASSOCIATION PROCEEDINGS OF THE FREENIX TRACK, P129; Sadowski W, 2002, HUM FAC ER, P791; Schultheis MT, 2001, PRESENCE-TELEOP VIRT, V10, P431, DOI 10.1162/1054746011470271; SCHULTHEIS MT, 2002, 10 ANN MED M VIRT RE; SHALLICE T, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P125; Skelton RW, 2000, J CLIN EXP NEUROPSYC, V22, P157, DOI 10.1076/1380-3395(200004)22:2;1-1;FT157; Sohlberg M. M., 2001, COGNITIVE REHABILITA; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; STANTON D, 1998, VIRTUAL ENV CLIN PSY, P219; Sternberg RJ, 1997, AM PSYCHOL, V52, P1134; STRICKLAND D, 2001, ACM SIGGRAPH 2001 C; Weiss P L, 1998, Work, V11, P277, DOI 10.3233/WOR-1998-11305; WIEDERHOLD BK, 1998, CYBERPSYCHOLOGY BEHA, V1, P45, DOI DOI 10.1089/CPB.1998.1.45; Wilson B.A., 1996, BADS BEHAV ASSESSMEN; Wilson BA, 1996, J HEAD TRAUMA REHAB, V11, P54, DOI 10.1097/00001199-199604000-00006; Wilson BA, 1997, J INT NEUROPSYCH SOC, V3, P487, DOI 10.1017/S1355617797004876; Ylvisaker M., 1998, TRAUMATIC BRAIN INJU; ZIMAND E, IN PRESS PRIMARY PSY	83	219	229	2	43	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	MAR-MAY	2004	14	1-2					207	239		10.1080/09602010343000183			33	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	809UU	WOS:000220662400010					2021-06-18	
J	Solenov, E; Watanabe, H; Manley, GT; Verkman, AS				Solenov, E; Watanabe, H; Manley, GT; Verkman, AS			Sevenfold-reduced osmotic water permeability in primary astrocyte cultures from AQP-4-deficient mice, measured by a fluorescence quenching method	AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY			English	Article						water transport; aquaporin-4; fluorescence quenching; brain swelling; cerebral edema	AQUAPORIN-4 KNOCKOUT MICE; MESSENGER-RNA EXPRESSION; TRAUMATIC BRAIN-INJURY; CELL-VOLUME; CORRELATION SPECTROSCOPY; CHANNEL HOMOLOGS; RAT ASTROCYTES; MICROSCOPY; TRANSPORT; EDEMA	A calcein fluorescence quenching method was applied to measure osmotic water permeability in highly differentiated primary cultures of brain astrocytes from wild-type and aquaporin-4 (AQP-4)-deficient mice. Cells grown on coverglasses were loaded with calcein for measurement of volume changes after osmotic challenge. Hypotonic shock producing twofold cell swelling resulted in a reversible similar to12% increase in calcein fluorescence, which was independent of cytosolic calcein concentration at levels well below where calcein self-quenching occurs. Calcein fluorescence was quenched in <200 ms in response to addition of cytosol in vitro, indicating that the fluorescence signal arises from changes in cytosol concentration. In astrocytes from wild-type CD1 mice, calcein fluorescence increased reversibly in response to hypotonic challenge with a half-time of 0.92 +/- 0.05 s at 23 degrees C, corresponding to an osmotic water permeability (P-f) of similar to 0.05 cm/s. P-f was reduced 7.1-fold in astrocytes from AQP-4-deficient mice. Temperature dependence studies indicated an increased Arrhenius activation energy for water transport in AQP-4-deficient astrocytes (11.3 +/- 0.5 vs. 5.5 +/- 0.4 kcal/mol). Our studies establish a calcein quenching method for measurement of cell membrane water permeability and indicate that AQP-4 provides the principal route for water transport in astrocytes.	Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA	Verkman, AS (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, 1246 Hlth Sci E Tower, San Francisco, CA 94143 USA.	verkman@itsa.ucsf.edu			NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY013574] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL059198, R01HL073856] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R37EB000415, R01EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK035124, R37DK035124] Funding Source: NIH RePORTER; NEI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [EY-13574] Funding Source: Medline; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL-73856, HL-59198] Funding Source: Medline; NIBIB NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [EB-00415] Funding Source: Medline; NIDDK NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [DK-35124] Funding Source: Medline		Aoki K, 2003, ACTA NEUROPATHOL, V106, P121, DOI 10.1007/s00401-003-0709-y; Chou CL, 1998, AM J PHYSIOL-CELL PH, V274, pC549; Farinas J, 1996, BIOPHYS J, V71, P3511, DOI 10.1016/S0006-3495(96)79546-2; Farinas J, 1997, J GEN PHYSIOL, V110, P283, DOI 10.1085/jgp.110.3.283; FARINAS J, 1995, BIOPHYS J, V68, P1613, DOI 10.1016/S0006-3495(95)80335-8; FISCHBARG J, 1993, AM J PHYSIOL, V265, pC1412; FRIGERI A, 1995, J CELL SCI, V108, P2993; Gu F, 2003, J NEUROSCI RES, V72, P709, DOI 10.1002/jnr.10603; Hamann S, 2002, J FLUORESC, V12, P139, DOI 10.1023/A:1016832027325; Hom EFY, 2002, BIOPHYS J, V83, P533, DOI 10.1016/S0006-3495(02)75189-8; KAO HP, 1994, BIOPHYS J, V67, P1291, DOI 10.1016/S0006-3495(94)80601-0; Ke CS, 2002, EXP NEUROL, V178, P194, DOI 10.1006/exnr.2002.8037; Kiening KL, 2002, NEUROSCI LETT, V324, P105, DOI 10.1016/S0304-3940(02)00180-5; KUNDROT CE, 1983, P NATL ACAD SCI-BIOL, V80, P1608, DOI 10.1073/pnas.80.6.1608; Li J, 2002, INVEST OPHTH VIS SCI, V43, P573; Li J, 2001, J BIOL CHEM, V276, P31233, DOI 10.1074/jbc.M104368200; MA TH, 1993, J BIOL CHEM, V268, P22756; Ma TH, 1997, J CLIN INVEST, V100, P957, DOI 10.1172/JCI231; Maiti S, 1997, P NATL ACAD SCI USA, V94, P11753, DOI 10.1073/pnas.94.22.11753; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Maric K, 2001, BIOPHYS J, V80, P1783, DOI 10.1016/S0006-3495(01)76148-6; Mhatre AN, 2002, BIOCHEM BIOPH RES CO, V297, P987, DOI 10.1016/S0006-291X(02)02296-9; Nakahama K, 1999, GLIA, V25, P240, DOI 10.1002/(SICI)1098-1136(19990201)25:3<240::AID-GLIA4>3.3.CO;2-3; Nicchia GP, 2003, FASEB J, V17, P1508, DOI 10.1096/fj.02-1183fje; Nicchia GP, 2000, GLIA, V31, P29, DOI 10.1002/(SICI)1098-1136(200007)31:1<29::AID-GLIA30>3.0.CO;2-3; Nielsen S, 1997, J NEUROSCI, V17, P171; Papadopoulos MC, 2002, MT SINAI J MED, V69, P242; Saadoun S, 2002, J NEUROL NEUROSUR PS, V72, P262, DOI 10.1136/jnnp.72.2.262; Solenov EI, 2002, J NEUROSCI METH, V113, P85, DOI 10.1016/S0165-0270(01)00481-2; Sun MC, 2003, J NEUROSURG, V98, P565, DOI 10.3171/jns.2003.98.3.0565; Swanson RA, 1997, J NEUROSCI, V17, P932; Taniguchi M, 2000, MOL BRAIN RES, V78, P131, DOI 10.1016/S0169-328X(00)00084-X; Vajda Z, 2000, BIOCHEM BIOPH RES CO, V270, P495, DOI 10.1006/bbrc.2000.2472; Venero JL, 2001, PROG NEUROBIOL, V63, P321, DOI 10.1016/S0301-0082(00)00035-6; Verkman AS, 2000, J MEMBRANE BIOL, V173, P73, DOI 10.1007/s002320001009; Verkman AS, 2002, TRENDS BIOCHEM SCI, V27, P27, DOI 10.1016/S0968-0004(01)02003-5; Vizuete ML, 1999, NEUROBIOL DIS, V6, P245, DOI 10.1006/nbdi.1999.0246; Wang KS, 2000, AM J PHYSIOL-GASTR L, V279, pG448; Yamamoto N, 2001, MOL BRAIN RES, V95, P110, DOI 10.1016/S0169-328X(01)00254-6; Yamamoto N, 2001, MOL BRAIN RES, V90, P26, DOI 10.1016/S0169-328X(01)00064-X; YANG B, 2000, AM J PHYSIOL, V278, pC1008; Yoneda K, 2001, MOL BRAIN RES, V89, P94, DOI 10.1016/S0169-328X(01)00067-5; Zelenina M, 2000, EUR BIOPHYS J BIOPHY, V29, P165, DOI 10.1007/PL00006645	43	219	231	1	13	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0363-6143	1522-1563		AM J PHYSIOL-CELL PH	Am. J. Physiol.-Cell Physiol.	FEB 1	2004	286	2					C426	C432		10.1152/ajpcell.00298.2003			7	Cell Biology; Physiology	Cell Biology; Physiology	760BR	WOS:000187791200026	14576087				2021-06-18	
J	Djebaili, M; Hoffman, SW; Steins, DG				Djebaili, M; Hoffman, SW; Steins, DG			Allopregnanolone and progesterone decrease cell death and cognitive deficits after a contusion of the rat pre-frontal cortex	NEUROSCIENCE			English	Article						traumatic brain injury; neurosteroids; apoptosis; neuroprotection; caspase-3; memory deficits	TRAUMATIC BRAIN-INJURY; CORTICAL CONTUSION; SPINAL-CORD; NEUROACTIVE STEROIDS; HIPPOCAMPAL-NEURONS; NERVOUS-SYSTEM; HEAD-INJURY; APOPTOSIS; NEUROPROTECTION; EXPRESSION	We compared the effects of three different doses of allopregnanolone (4, 8 or 16 mg/kg), a metabolite of progesterone, to progesterone (16 mg/kg) in adult rats with controlled cortical impact to the pre-frontal cortex. Injections were given 1 h, 6 h and every day for 5 consecutive days after the injury. One day after injury, both progesterone-treated (16 mg/kg) and allopregnanolone (8 or 16 mg/kg)-treated rats showed less caspase-3 activity, and rats treated with allopregnanolone (16 mg/kg) showed less DNA fragmentation in the lesion area, indicating reduced apoptosis. Nineteen days after the injury, rats treated with progesterone and allopregnanolone (8 or 16 mg/kg) showed no difference in necrotic cavity size but had less cell loss in the medio-dorsal nucleus of the thalamus and less learning and memory impairments compared with the injured vehicle-treated rats. On that same day the injured rats treated with progesterone showed more weight gain compared with the injured rats treated with the vehicle. These results can be taken to show that progesterone and allopregnanolone have similar neuroprotective effects after traumatic brain injury, but allopregnanolone appears to be more potent than progesterone in facilitating CNS repair. (C) 2003 IBRO. Published by Elsevier Ltd. All rights reserved.	Emory Univ, Brain Res Lab, Dept Emergency Med, Atlanta, GA 30322 USA	Steins, DG (corresponding author), Emory Univ, Brain Res Lab, Dept Emergency Med, 1648 Pierce Dr,Cell Biol Bldg,Room 261, Atlanta, GA 30322 USA.	dstei04@emory.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038664, R01NS040825] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1 R01 NS38664, 1 R01 NS40825] Funding Source: Medline		Alkayed NJ, 1998, STROKE, V29, P159, DOI 10.1161/01.STR.29.1.159; ATTELLA MJ, 1987, BEHAV NEURAL BIOL, V48, P352, DOI 10.1016/S0163-1047(87)90918-6; BAULIEU EE, 1990, J STEROID BIOCHEM, V37, P395, DOI 10.1016/0960-0760(90)90490-C; Beer R, 2001, J NEUROCHEM, V78, P862, DOI 10.1046/j.1471-4159.2001.00460.x; BITRAN D, 1993, PHARMACOL BIOCHEM BE, V45, P423, DOI 10.1016/0091-3057(93)90260-Z; Cernak I, 2002, J CLIN NEUROSCI, V9, P565, DOI 10.1054/jocn.2002.1132; Chen SW, 1996, PHARMACOL BIOCHEM BE, V53, P777, DOI 10.1016/0091-3057(95)02142-6; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1999, FASEB J, V13, P813; COMPAGNONE NA, 1995, ENDOCRINOLOGY, V136, P2689, DOI 10.1210/en.136.6.2689; CORPECHOT C, 1985, STEROIDS, V45, P229, DOI 10.1016/0039-128X(85)90072-8; CUELLO AC, 1990, ACTA NEUROBIOL EXP, V50, P451; DENICOLA AF, 1993, ADV NEUROL, V59, P199; Deniselle MCG, 2002, NEUROBIOL DIS, V11, P457, DOI 10.1006/nbdi.2002.0564; Djebaili M, 2001, MOL BRAIN RES, V93, P190, DOI 10.1016/S0169-328X(01)00197-8; Dubois B, 1997, J NEUROL, V244, P2, DOI 10.1007/pl00007725; DUVDEVANI R, 1995, J NEUROTRAUM, V12, P65, DOI 10.1089/neu.1995.12.65; ELLIOTT PJ, 1989, NEUROSCIENCE, V31, P63, DOI 10.1016/0306-4522(89)90030-4; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; Everitt BJ, 1997, ANNU REV PSYCHOL, V48, P649, DOI 10.1146/annurev.psych.48.1.649; Garcia-Segura LM, 1999, J NEUROBIOL, V40, P574, DOI 10.1002/(SICI)1097-4695(19990915)40:4<574::AID-NEU12>3.0.CO;2-8; Garcia-Segura LM, 1998, NEUROREPORT, V9, P593, DOI 10.1097/00001756-199803090-00006; GARCIAESTRADA J, 1993, BRAIN RES, V628, P271, DOI 10.1016/0006-8993(93)90964-O; Goodman YD, 1996, J NEUROCHEM, V66, P1836; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Hoffman GE, 2001, EXP NEUROL, V171, P272, DOI 10.1006/exnr.2001.7783; Hoffman SW, 1997, RESTOR NEUROL NEUROS, V11, P1, DOI 10.3233/RNN-1997-111201; Jung-Testas I, 1999, J STEROID BIOCHEM, V69, P97, DOI 10.1016/S0960-0760(98)00149-6; JUNGTESTAS I, 1989, J STEROID BIOCHEM, V34, P511, DOI 10.1016/0022-4731(89)90136-2; Keane RW, 2001, J CEREBR BLOOD F MET, V21, P1189, DOI 10.1097/00004647-200110000-00007; KOENIG HL, 1995, SCIENCE, V268, P1500, DOI 10.1126/science.7770777; Labombarda F, 2002, J NEUROTRAUM, V19, P343, DOI 10.1089/089771502753594918; Liu JL, 2000, MOL BRAIN RES, V80, P7, DOI 10.1016/S0169-328X(00)00122-4; Lockhart EM, 2002, NEUROSCI LETT, V328, P33, DOI 10.1016/S0304-3940(02)00448-2; Luo Chun, 2002, Chin J Traumatol, V5, P24; Luo YM, 2002, J CEREBR BLOOD F MET, V22, P15, DOI 10.1097/00004647-200201000-00002; MAJCHRZAK M, 1990, BEHAV BRAIN RES, V37, P45, DOI 10.1016/0166-4328(90)90071-L; MAYER M, 1994, P NATL ACAD SCI USA, V91, P7496, DOI 10.1073/pnas.91.16.7496; McEwen BS, 1999, ANNU REV NEUROSCI, V22, P105, DOI 10.1146/annurev.neuro.22.1.105; Nilsen J, 2002, ENDOCRINOLOGY, V143, P205, DOI 10.1210/en.143.1.205; OGATA T, 1993, NEUROSCIENCE, V55, P445, DOI 10.1016/0306-4522(93)90513-F; ORCHINIK M, 1994, BRAIN RES, V646, P258, DOI 10.1016/0006-8993(94)90087-6; PAUL SM, 1992, FASEB J, V6, P2311; Pravdenkova SV, 1996, BRAIN RES, V729, P151, DOI 10.1016/0006-8993(96)00222-3; Rabiee AR, 2001, ANIM REPROD SCI, V67, P205, DOI 10.1016/S0378-4320(01)00130-0; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Reddy DS, 1998, PSYCHOPHARMACOLOGY, V137, P391; RINK A, 1995, AM J PATHOL, V147, P1575; Robertson GS, 2000, BRAIN PATHOL, V10, P283, DOI 10.1111/j.1750-3639.2000.tb00262.x; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; Roof RL, 1999, PHYSIOL BEHAV, V68, P81, DOI 10.1016/S0031-9384(99)00162-6; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Schumacher M, 2000, J NEUROCYTOL, V29, P307, DOI 10.1023/A:1007152904926; Shah PT, 1997, NEUROSCIENCE, V79, P999, DOI 10.1016/S0306-4522(97)00013-4; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Springer JE, 2001, CLIN CHEM LAB MED, V39, P299, DOI 10.1515/CCLM.2001.046; Sullivan PG, 2002, BRAIN RES, V949, P88, DOI 10.1016/S0006-8993(02)02968-2; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wang XY, 2001, BIOL NEONATE, V79, P172; Wennersten A, 2003, ACTA NEUROPATHOL, V105, P281, DOI 10.1007/s00401-002-0649-y; WIELAND S, 1991, BRAIN RES, V565, P263, DOI 10.1016/0006-8993(91)91658-N; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820; Yakovlev AG, 2001, MOL NEUROBIOL, V24, P131; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yang Xinyu, 2002, Chin J Traumatol, V5, P250; Zinder O, 1999, ACTA PHYSIOL SCAND, V167, P181	71	219	234	1	9	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience		2004	123	2					349	359		10.1016/j.neuroscience.2003.09.023			11	Neurosciences	Neurosciences & Neurology	761BX	WOS:000187880500004	14698743				2021-06-18	
J	Yakovlev, AG; Ota, K; Wang, GP; Movsesyan, V; Bao, WL; Yoshihara, K; Faden, AI				Yakovlev, AG; Ota, K; Wang, GP; Movsesyan, V; Bao, WL; Yoshihara, K; Faden, AI			Differential expression of apoptotic protease-activating factor-1 and caspase-3 genes and susceptibility to apoptosis during brain development and after traumatic brain injury	JOURNAL OF NEUROSCIENCE			English	Article						brain; development; injury; apoptosis; caspase; gene expression; Apaf-1	PROGRAMMED CELL-DEATH; NEURONAL APOPTOSIS; CYTOCHROME-C; MOLECULAR-MECHANISMS; CYSTEINE PROTEASES; HEAD-INJURY; APAF-1; PATHWAYS; ISCHEMIA; CHILDREN	Neuronal apoptosis plays an essential role in early brain development and contributes to secondary neuronal loss after acute brain injury. Recent studies have provided evidence that neuronal susceptibility to apoptosis induced by traumatic or ischemic injury decreases during brain development. However, the molecular mechanisms responsible for this age-dependent phenomenon remain unclear. Here we demonstrate that, during brain maturation, the potential of the intrinsic apoptotic pathway is progressively reduced and that such repression is associated with downregulation of apoptotic protease-activating factor-1 (Apaf-1) and caspase-3 gene expression. A similar decline in apoptotic susceptibility associated with downregulation of Apaf-1 expression as a function of developmental age was also found in cultured primary rat cortical neurons. Injury-induced cytochrome c-specific cleavage of caspase-9 followed by activation of caspase-3 in mature brain correlated with marked increases in Apaf-1 and caspase-3 mRNA and protein expression. These results suggest that differential expression of Apaf-1 and caspase-3 genes may underlie regulation of apoptotic susceptibility during brain development, as well as after acute injury to mature brain, through the intrinsic pathway of caspase activation.	Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20007 USA; Nara Med Univ, Dept Biochem, Nara 6348521, Japan	Yakovlev, AG (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, Res Bldg,WP-14,3970 Reservoir Rd NW, Washington, DC 20007 USA.	yakovlev@giccs.georgetown.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS38941, R01 NS36537] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036537, R01NS038941] Funding Source: NIH RePORTER		Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; Beattie MS, 2000, J NEUROTRAUM, V17, P915, DOI 10.1089/neu.2000.17.915; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Bredesen DE, 2000, J NEUROTRAUM, V17, P801, DOI 10.1089/neu.2000.17.801; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; Brown GC, 1999, BIOCHEM SOC SYMP, V66, P17, DOI 10.1042/bss0660017; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; De Bilbao F, 1999, J COMP NEUROL, V409, P339, DOI 10.1002/(SICI)1096-9861(19990705)409:3<339::AID-CNE1>3.0.CO;2-Q; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Eldadah BA, 1997, J NEUROSCI, V17, P6105; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Gillardon F, 1997, MOL BRAIN RES, V50, P16, DOI 10.1016/S0169-328X(97)00162-9; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Haydar TF, 1999, CEREB CORTEX, V9, P621, DOI 10.1093/cercor/9.6.621; Honarpour N, 2000, DEV BIOL, V218, P248, DOI 10.1006/dbio.1999.9585; Hu BR, 2000, J CEREBR BLOOD F MET, V20, P1294, DOI 10.1097/00004647-200009000-00003; Ivins KJ, 1999, NEUROBIOL DIS, V6, P440, DOI 10.1006/nbdi.1999.0268; Krajewski S, 1999, P NATL ACAD SCI USA, V96, P5752, DOI 10.1073/pnas.96.10.5752; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Kuida K, 2000, INT J BIOCHEM CELL B, V32, P121, DOI 10.1016/S1357-2725(99)00024-2; Kulms D, 2000, PHOTODERMATOL PHOTO, V16, P195, DOI 10.1034/j.1600-0781.2000.160501.x; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lipton P, 1999, PHYSIOL REV, V79, P1431; Matsushita K, 2000, J NEUROSCI, V20, P6879, DOI 10.1523/JNEUROSCI.20-18-06879.2000; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Napieralski JA, 1999, MOL BRAIN RES, V71, P78, DOI 10.1016/S0169-328X(99)00155-2; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Raoul C, 1999, J CELL BIOL, V147, P1049, DOI 10.1083/jcb.147.5.1049; Richter C, 1999, BIOCHEM SOC SYMP, V66, P27, DOI 10.1042/bss0660027; Robertson JD, 2000, CRIT REV TOXICOL, V30, P609, DOI 10.1080/10408440008951122; Robles R, 1999, ENDOCRINOLOGY, V140, P2641, DOI 10.1210/en.140.6.2641; Sanchez I, 1999, NEURON, V22, P623, DOI 10.1016/S0896-6273(00)80716-3; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Snider BJ, 1999, ANN NY ACAD SCI, V893, P243, DOI 10.1111/j.1749-6632.1999.tb07829.x; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; Yakovlev AG, 2000, J BIOL CHEM, V275, P21302, DOI 10.1074/jbc.M001087200; YAKOVLEV AG, 1994, MOL CHEM NEUROPATHOL, V23, P179, DOI 10.1007/BF02815410; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yamashima T, 2000, PROG NEUROBIOL, V62, P273, DOI 10.1016/S0301-0082(00)00006-X; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	50	219	225	0	3	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474	1529-2401		J NEUROSCI	J. Neurosci.	OCT 1	2001	21	19					7439	7446					8	Neurosciences	Neurosciences & Neurology	475GL	WOS:000171154000005	11567033				2021-06-18	
J	Temkin, NR; Dikmen, SS; Anderson, GD; Wilensky, AJ; Holmes, MD; Cohen, W; Newell, DW; Nelson, P; Awan, A; Winn, HR				Temkin, NR; Dikmen, SS; Anderson, GD; Wilensky, AJ; Holmes, MD; Cohen, W; Newell, DW; Nelson, P; Awan, A; Winn, HR			Valproate therapy for prevention of posttraumatic seizures: a randomized trial	JOURNAL OF NEUROSURGERY			English	Article						brain injury; traumatic epilepsy; valproate; phenytoin; primary prevention; clinical trial	PROPHYLACTICALLY ADMINISTERED PHENYTOIN; ACID HEPATIC FATALITIES; POST-TRAUMATIC SEIZURES; SEVERE BRAIN INJURIES; SODIUM VALPROATE; EPILEPSY; FAILURE; DETERMINANTS; PROPHYLAXIS; MK-801	Object. Seizures frequently accompany moderate to severe traumatic brain injury. Phenytoin and carbamazepine are effective in preventing early, but not late, posttraumatic seizures. In this study the authors compare the safety and effectiveness of valproate with those of short-term phenytoin for prevention of seizures following traumatic brain injury. Methods. The study was a randomized, double-blind, single-center, parallel-group clinical trial. Treatment began within 24 hours of injury. One hundred thirty-two patients at high risk for seizures were assigned to receive a 1-week course of phenytoin, 120 were assigned to receive a I-month course of valproate, and 127 were assigned to receive a 6-month course of valproate. The cases were followed for up to 2 years. The rates of early seizures were low and similar when using either valproate or phenytoin (1.5% in the phenytoin treatment group and 4.5% in the valproate arms of the study; p = 0.14, relative risk [RR] = 2.9, 95% confidence interval [CI] 0.7-13.3). The rates of late seizures did not differ among treatment groups (15% in patients receiving the 1-week course of phenytoin, 16% in patients receiving the I-month course of valproate, and 24% in those receiving the 6-month course of valproate; p = 0.19, RR = 1.4, 95% CI 0.8-2.4). The rates of mortality were not significantly different between treatment groups, but there was a trend toward a higher mortality rate in patients treated with valproate (7.2% in patients receiving phenytoin and 13.4% in those receiving valproate; p = 0.07, RR = 2.0, 95% CI 0.9-4.1). The incidence of serious adverse events: including coagulation problems and liver abnormalities, was similar in phenytoin- and valproate-treated patients. Conclusions. Valproate therapy shows no benefit over short-term phenytoin therapy for prevention of early seizures and neither treatment prevents late seizures. There was a trend toward a higher mortality rate among valproate-treated patients. The lack of additional benefit and the potentially higher mortality rate suggest that valproate should not be routinely used for the prevention of posttraumatic seizures.	Univ Washington, Harborview Med Ctr, Dept Neurol Surg, Seattle, WA 98104 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Dept Pharm, Seattle, WA 98195 USA; Univ Washington, Dept Neurol, Seattle, WA 98195 USA; Univ Washington, Dept Radiol, Seattle, WA 98195 USA	Temkin, NR (corresponding author), Univ Washington, Harborview Med Ctr, Dept Neurol Surg, Box 359924,325 9th Ave, Seattle, WA 98104 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019643] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS19643] Funding Source: Medline		Applegate CD, 1997, EPILEPSIA, V38, P631, DOI 10.1111/j.1528-1157.1997.tb01231.x; BARR RD, 1982, ARCH DIS CHILD, V57, P681, DOI 10.1136/adc.57.9.681; BIRKMAYER W, 1951, WIEN KLIN WOCHENSCHR, V63, P603; DIKMEN S, 1995, J HEAD TRAUMA REHAB, V10, P74, DOI 10.1097/00001199-199502000-00008; DIKMEN S, 1996, NEUROPSYCHOLOGICAL A, P552; DREIFUSS FE, 1987, NEUROLOGY, V37, P379, DOI 10.1212/WNL.37.3.379; DREIFUSS FE, 1989, NEUROLOGY, V39, P201, DOI 10.1212/WNL.39.2.201; GANICK DJ, 1990, AM J PEDIAT HEMATOL, V12, P80; GLOTZNER FL, 1983, NEUROCHIRURGIA, V26, P66; Hoff H, 1947, MON PSYCHIATR NEUROL, V114, P105; Jennett B, 1981, MANAGEMENT HEAD INJU; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; LOCKARD JS, 1976, EPILEPSIA, V17, P49, DOI 10.1111/j.1528-1157.1976.tb03381.x; LOISEAU P, 1981, EPILEPSIA, V22, P141, DOI 10.1111/j.1528-1157.1981.tb04094.x; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MARSHALL LF, 1991, J NEUROSURG S, V75, P28; MCNAMARA JO, 1988, NEUROPHARMACOLOGY, V27, P563, DOI 10.1016/0028-3908(88)90176-1; PECHADRE JC, 1991, PRESSE MED, V20, P841; PENRY JK, 1979, NEUROLOGY, V29, P600; RACINE R, 1975, ELECTROEN CLIN NEURO, V38, P355, DOI 10.1016/0013-4694(75)90260-6; RANGANATHAN C, 1993, J EPILEPSY, V6, P142, DOI 10.1016/S0896-6974(05)80081-7; SCHEFFNER D, 1988, EPILEPSIA, V29, P530, DOI 10.1111/j.1528-1157.1988.tb03757.x; SCHMUTZ M, 1988, J NEURAL TRANSM, V72, P245, DOI 10.1007/BF01243423; SILVER JM, 1991, ANN NEUROL, V29, P356, DOI 10.1002/ana.410290404; SMITH FR, 1980, ANN NEUROL, V8, P197, DOI 10.1002/ana.410080213; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; WADA JA, 1996, ARCH NEUROL-CHICAGO, V33, P1834; YOUNG B, 1983, J NEUROSURG, V58, P236, DOI 10.3171/jns.1983.58.2.0236; YOUNG B, 1983, J NEUROSURG, V58, P231, DOI 10.3171/jns.1983.58.2.0231	30	219	223	3	9	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	OCT	1999	91	4					593	600		10.3171/jns.1999.91.4.0593			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	239HV	WOS:000082763400010	10507380				2021-06-18	
J	Bryant, RA; Harvey, AG				Bryant, RA; Harvey, AG			Relationship between acute stress disorder and posttraumatic stress disorder following mild traumatic brain injury	AMERICAN JOURNAL OF PSYCHIATRY			English	Article							MOTOR-VEHICLE ACCIDENTS; PTSD; INTRUSION; DISASTER; ASSAULT; VICTIMS; PREDICTORS; SURVIVORS; AVOIDANCE; RAPE	Objective: The aim of this study was to index the frequency of occurrence of-acute stress disorder following mild traumatic brain injury and to determine its utility in predicting post traumatic stress disorder (PTSD). Method: Consecutive adult patients who sustained a mild traumatic brain injury following a mo tor vehicle accident (N = 79) were assessed for acute stress disorder within 1 month of their trauma with the Acute Stress Disorder Inventory, a structured clinical interview based on DSM-IV criteria. Patients were followed up 6 months after the trauma (N = 63) and were administered the PTSD module of the Composite International Diagnostic Interview. Results: Acute stress disorder was diagnosed in 14% of patients, and at follow-up 24% satisfied criteria for PTSD. Six months after the trauma PTSD was diagnosed in 82% of patients who had been diagnosed with acute stress disorder and in 11% of those who had not been diagnosed with acute stress disorder. Conclusions: These findings point to the frequency of PTSD following mild traumatic brain injury. While the criteria for acute stress disorder are useful in identifying those individuals who are at risk of developing chronic PTSD, the findings suggest that current criteria require modification in order to optimally predict PTSD following mild traumatic brain injury.	Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia	Bryant, RA (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.		Bryant, Richard/AAA-6479-2019	Bryant, Richard/0000-0002-9607-819X			*ASS ADV AUT MED, 1990, ABBR INJ SCAL; Blanchard EB, 1996, BEHAV RES THER, V34, P775, DOI 10.1016/0005-7967(96)00038-1; Blanchard EB, 1996, BEHAV RES THER, V34, P1, DOI 10.1016/0005-7967(95)00058-6; Bohnen N., 1992, J NERV MENT DIS, V180, P183; BRYANT RA, 1995, AUST J PUBLIC HEALTH, V19, P185; Bryant RA, 1997, CLIN PSYCHOL REV, V17, P757, DOI 10.1016/S0272-7358(97)00052-4; BRYANT RA, 1995, PSYCHOL MED, V25, P869, DOI 10.1017/S0033291700035121; BRYANT RA, IN PRESS J CONSULT C; CREAMER M, 1992, J ABNORM PSYCHOL, V101, P452, DOI 10.1037/0021-843X.101.3.452; Dancu CV, 1996, J TRAUMA STRESS, V9, P253, DOI 10.1002/jts.2490090208; Epstein Richard S., 1994, P285; Fleiss JL, 1981, STAT METHODS RATES P, V2nd; FOA EB, 1995, AM J PSYCHIAT, V152, P116; FOA EB, 1995, CURR DIR PSYCHOL SCI, V4, P61, DOI 10.1111/1467-8721.ep10771786; GRIGSBY J, 1993, BRAIN INJURY, V7, P507, DOI 10.3109/02699059309008178; GRIGSBY JP, 1986, INT J CLIN NEUROPSYC, V8, P65; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; HARVEY AG, IN PRESS J CONSULT C; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KOOPMAN C, 1995, J TRAUMA STRESS, V8, P29, DOI 10.1007/BF02105405; Lahz S, 1996, ARCH PHYS MED REHAB, V77, P889, DOI 10.1016/S0003-9993(96)90275-0; LAYTON BS, 1995, CLIN NEUROPSYCHOL, V9, P2, DOI 10.1080/13854049508402050; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; MCFARLANE AC, 1986, J NERV MENT DIS, V174, P4, DOI 10.1097/00005053-198601000-00002; MCFARLANE AC, 1988, J NERV MENT DIS, V176, P22, DOI 10.1097/00005053-198801000-00003; MCFARLANE AC, 1992, J NERV MENT DIS, V180, P439, DOI 10.1097/00005053-199207000-00006; MIDDELBOE T, 1991, Acta Neurologica Scandinavica, V85, P5; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106; PERRY S, 1992, AM J PSYCHIAT, V149, P931; Peters L, 1996, INT J METHOD PSYCH, V6, P167, DOI 10.1002/(SICI)1234-988X(199610)6:3<167::AID-MPR159>3.3.CO;2-Z; RATTOK J, 1993, J CLIN EXP NEUROPSYC, V15, P403; ROTHBAUM BO, 1992, J TRAUMA STRESS, V5, P455, DOI 10.1007/BF00977239; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; SHALEV AY, 1992, J NERV MENT DIS, V180, P505, DOI 10.1097/00005053-199208000-00005; Shalev AY, 1996, AM J PSYCHIAT, V153, P219	35	219	228	0	13	AMER PSYCHIATRIC ASSOCIATION	WASHINGTON	1400 K ST NW, WASHINGTON, DC 20005 USA	0002-953X			AM J PSYCHIAT	Am. J. Psychiat.	MAY	1998	155	5					625	629		10.1176/ajp.155.5.625			5	Psychiatry	Psychiatry	ZL237	WOS:000073412500010	9585713				2021-06-18	
J	GERBERICH, SG; PRIEST, JD; BOEN, JR; STRAUB, CP; MAXWELL, RE				GERBERICH, SG; PRIEST, JD; BOEN, JR; STRAUB, CP; MAXWELL, RE			CONCUSSION INCIDENCES AND SEVERITY IN SECONDARY-SCHOOL VARSITY FOOTBALL PLAYERS	AMERICAN JOURNAL OF PUBLIC HEALTH			English	Article									UNIV MINNESOTA,DEPT NEUROSURG,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,BIOMETRY CONSULTING LAB,MINNEAPOLIS,MN 55455; FAIRVIEW HOSP,INST ATHLET MED,MINNEAPOLIS,MN	GERBERICH, SG (corresponding author), UNIV MINNESOTA,SCH PUBL HLTH,DEPT ENVIRONM HLTH,MINNEAPOLIS,MN 55455, USA.		Gerberich, Susan G/K-9956-2019	Gerberich, Susan G/0000-0001-6424-7131			ALLEN MA, 1966, JAMA, V206, P2053; ALLEY RJ, 1965, JAMA, V188, P418; ALLMAN F L Jr, 1964, J Med Assoc Ga, V53, P381; BAKER EP, 1974, TRAUMA MANAGEMENT; BLYTH CS, 1974, FOOTBALL INJURIES; BOOHER JM, 1976, THESIS U UTAH SALT L; BROOKS WH, 1976, SOUTHERN MED J, V69, P1258, DOI 10.1097/00007611-197610000-00004; CLARK DM, 1964, JAMA, V190, P36; Duff J F, 1974, J Sports Med, V2, P175; FISHER CM, 1965, NEUROL, V15, P826; Friedman G, 1974, PRIMER EPIDEMIOLOGY; Garrick J G, 1981, Phys Sportsmed, V9, P115, DOI 10.1080/00913847.1981.11711015; GARRICK JG, 1978, PEDIATRICS, V61, P465, DOI 10.1542/peds.61.3.465; GENNARELLI TA, 1982, ATHLETIC INJURIES HE; GERBERICH SG, 1982, MINN MED, V65, P691; GERBERICH SG, 1980, THESIS U MINNESOTA M; GERBERICH SG, 1977, THESIS U MINNESOTA M; GODSHAL RW, 1975, J SPORTS MED, V3, P142; GONZALES TA, 1951, JAMA-J AM MED ASSOC, V146, P1506, DOI 10.1001/jama.1951.03670160048012; GURDJIAN ES, 1967, WISCONSIN INTER 1111, P36; HENRY NH, 1949, THESIS U OREGON EUGE; KRAUSE MA, 1959, THESIS U OREGON EUGE; LANNIN DR, CITED INDIRECTLY; LILIENFELD AM, 1980, F EPIDEMIOLOGY; MacMahon B., 1970, EPIDEMIOLOGY PRINCIP; Maroon J C, 1980, Clin Neurosurg, V27, P414; Meek T D, 1970, Tex Med, V66, P58; Meggyesy Dave, 1970, OUT THEIR LEAGUE, P125; *MN HIGH SCH LEAG, 1980, MAJ INJ FAT 1971 198; MORETZ A, 1978, OKLA STATE MED ASS J, V71, P85; Murphy R J, 1978, Phys Sportsmed, V6, P94, DOI 10.1080/00913847.1978.11710760; *NAT ATHL INJ ILL, 1976, NAIRS SPORT REL INC; *NAT FED STAT HIGH, 1979, FOOTB RUL; *NAT FED STAT HIGH, 1976, FOOTB RUL 1976 1977; *NAT FED STAT HIGH, 1981, PROGR REP 34TH ANN S; PETERSON LR, 1960, SCI AM, V215, P90; ROBINSON RL, 1975, J PHYS ED REC, V46, P45; RYAN AJ, 1975, PHYSICIAN SPORTSMED, V3, P50; RYAN AJ, 1974, SPORTS MED; Schneider R., 1973, HEAD NECK INJURIES F; SCHNEIDER RC, 1961, JAMA, V177, P262; SLOVUT GL, 1977, MINNEAPOLIS STAR D, V6; TENBENSEL RW, 1975, GUIDES PEDIATRIC CAR, P35; TORG JS, 1979, JAMA-J AM MED ASSOC, V241, P1477, DOI 10.1001/jama.241.14.1477; TORG JS, 1975, PHYSICIAN SPORTS MED, V3, P45; YARNELL PR, 1970, LANCET, V1, P863; YARNELL PR, 1973, NEUROL, V23, P1967; 1966, CLIN NEUROSURG, V12, P386	48	219	221	0	14	AMER PUBLIC HEALTH ASSOC INC	WASHINGTON	1015 FIFTEENTH ST NW, WASHINGTON, DC 20005	0090-0036			AM J PUBLIC HEALTH	Am. J. Public Health		1983	73	12					1370	1375		10.2105/AJPH.73.12.1370			6	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	RS171	WOS:A1983RS17100005	6638230	Green Published, Bronze			2021-06-18	
J	Tong, KA; Ashwal, S; Obenaus, A; Nickerson, JP; Kido, D; Haacke, EM				Tong, K. A.; Ashwal, S.; Obenaus, A.; Nickerson, J. P.; Kido, D.; Haacke, E. M.			Susceptibility-weighted MR imaging: A review of clinical applications in children	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article; Proceedings Paper	43rd Annual Meeting of the American-Society-of-Neuroradiology	MAY 21-27, 2005	Toronto, CANADA	Amer Soc Neuroradiol			TRAUMATIC BRAIN-INJURY; DIFFUSE AXONAL INJURY; STURGE-WEBER-SYNDROME; HEAD-INJURY; VENOGRAPHY; LESIONS; CONTRAST; DEOXYHEMOGLOBIN; ADOLESCENTS; MODEL	Susceptibility-weighted imaging (SWI) is a high-spatial-resolution 3D gradient-echo MR imaging technique with phase postprocessing that accentuates the paramagnetic properties of blood products such as deoxyhemoglobin, intracellular methemoglobin, and hemosiderin. It is particularly useful for detecting intravascular venous deoxygenated blood as well as extravascular blood products. It is also quite sensitive to the presence of other substances such as iron, some forms of calcification, End air. We have used this technique in the past several years to study a wide variety of pediatric neurologic disorders. We present a review with selected case histories to demonstrate its clinical usefulness in the improvement of the following: 1) detection of hemorrhagic lesions seen in various conditions, including traumatic brain injury and coagulopathic or other hemorrhagic disorders; 2) detection of vascular malformations such as cavernous angiomas, telangiectasias, or pial angiomas associated with Sturge-Weber syndrome; 3) demonstration of venous thrombosis and/or increased oxygen extraction in the setting of infarction, hypoxic/anoxic injury, or brain death; 4) delineation of neoplasms with hemorrhage, calcification, or increased vascularity; and 5) depiction of calcium or iron deposition in neurodegenerative disorders. SWI has provided new understanding of some of these disease processes. It is hoped that as SWI becomes more widely available, it will provide additional diagnostic and prognostic information that will improve the care and outcome of affected children.	[Tong, K. A.; Kido, D.] Loma Linda Univ, Med Ctr, Dept Radiol, Sch Med, Loma Linda, CA 92354 USA; [Ashwal, S.] Loma Linda Univ, Sch Med, Dept Pediat, Loma Linda, CA 92354 USA; [Obenaus, A.] Loma Linda Univ, Sch Med, Dept Radiat Med, Loma Linda, CA 92354 USA; [Nickerson, J. P.] Univ Vermont, Burlington, VT USA; [Haacke, E. M.] Wayne State Univ, Detroit, MI USA	Tong, KA (corresponding author), Loma Linda Univ, Med Ctr, Dept Radiol, Sch Med, Loma Linda, CA 92354 USA.	ktong@llu.edu					Ashwal S, 2006, DEV NEUROSCI-BASEL, V28, P309, DOI 10.1159/000094157; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Barth M, 2003, INVEST RADIOL, V38, P409, DOI 10.1097/00004424-200307000-00005; Bell MJ, 2001, CRIT CARE MED, V29, P399, DOI 10.1097/00003246-200102000-00033; CHO ZH, 1992, MAGNET RESON MED, V28, P25, DOI 10.1002/mrm.1910280104; Deistung A, 2006, Z MED PHYS, V16, P261, DOI 10.1078/0939-3889-00324; Essig M, 2001, RADIOLOGE, V41, P288, DOI 10.1007/s001170050989; Fischbein NJ, 1998, NEURORADIOLOGY, V40, P177, DOI 10.1007/s002340050563; Grados MA, 2001, J NEUROL NEUROSUR PS, V70, P350, DOI 10.1136/jnnp.70.3.350; Haacke EM, 2005, MAGN RESON IMAGING, V23, P1, DOI 10.1016/j.mri.2004.10.001; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; Hermier M, 2004, STROKE, V35, P1989, DOI 10.1161/01.STR.0000133341.74387.96; Juhasz C, 2007, AM J NEURORADIOL, V28, P900; Lee BCP, 1999, AM J NEURORADIOL, V20, P1239; Lee DH, 2000, CAN J NEUROL SCI, V27, pS35, DOI 10.1017/S0317167100000627; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; NEELAVALLI J, 2007, P INT SOC MAGN RES M, V15, P1016; Reichenbach JR, 2001, NMR BIOMED, V14, P453, DOI 10.1002/nbm.722; Reichenbach JR, 2001, NEURORADIOLOGY, V43, P364, DOI 10.1007/s002340000503; Reichenbach JR, 1997, RADIOLOGY, V204, P272, DOI 10.1148/radiology.204.1.9205259; Schad LR, 2001, NMR BIOMED, V14, P478, DOI 10.1002/nbm.714; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Sehgal V, 2005, J MAGN RESON IMAGING, V22, P439, DOI 10.1002/jmri.20404; Sehgal V, 2006, J MAGN RESON IMAGING, V24, P41, DOI 10.1002/jmri.20598; Tan IL, 2000, AM J NEURORADIOL, V21, P1039; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Xu YB, 2006, MAGN RESON IMAGING, V24, P155, DOI 10.1016/j.mri.2005.10.030	28	218	254	0	18	AMER SOC NEURORADIOLOGY	OAK BROOK	2210 MIDWEST RD, OAK BROOK, IL 60521 USA	0195-6108			AM J NEURORADIOL	Am. J. Neuroradiol.	JAN	2008	29	1					9	17		10.3174/ajnr.A0786			9	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	252VT	WOS:000252475600008	17925363	Green Published, Other Gold			2021-06-18	
J	Baskaya, MK; Rao, AM; Dogan, A; Donaldson, D; Dempsey, RJ				Baskaya, MK; Rao, AM; Dogan, A; Donaldson, D; Dempsey, RJ			The biphasic opening of the blood-brain barrier in the cortex and hippocampus after traumatic brain injury in rats	NEUROSCIENCE LETTERS			English	Article						blood-brain barrier; brain edema; controlled cortical impact; traumatic brain injury	CEREBRAL EDEMA; ISCHEMIA; PERMEABILITY	This study examined the time course of the blood-brain barrier (BBB) opening and correlated this with brain edema formation after a lateral controlled cortical impact (CCI) brain injury in rats. Quantitative measurement of Evans blue (EB) extravasation using fluorescence was employed at 2, 4, 6 h and 1, 2, 3, 4 and 7 days after injury. Brain edema was measured by specific gravity of the tissue at corresponding time points. Two prominent EB extravasations were observed at 4-6 h and 3-day after injury in the injury-site cortex and the ipsilateral hippocampus. Brain edema became progressively more severe over time and peaked at 24 h after injury and began to decline after day 3. These results suggest that there is a biphasic opening of the BBB after CCI brain injury and the second opening of the BBB does not contribute to a further increase in edema formation. (C) 1997 Elsevier Science Ireland Ltd.	UNIV WISCONSIN, DEPT NEUROL SURG, MADISON, WI 53792 USA; VET ADM MED CTR, MADISON, WI USA			Dogan, Aclan/AAF-8305-2019		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS031220] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS 31220] Funding Source: Medline		Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Baskaya MFK, 1996, NEUROSURGERY, V38, P140; Baskaya MK, 1996, J NEUROSURG, V85, P112, DOI 10.3171/jns.1996.85.1.0112; Belayev L, 1996, BRAIN RES, V739, P88, DOI 10.1016/S0006-8993(96)00815-3; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Hall Edward D., 1993, Journal of Emergency Medicine, V11, P31; HATASHITA S, 1990, STROKE, V21, P582, DOI 10.1161/01.STR.21.4.582; HOLMIN S, 1995, NEUROSCI LETT, V194, P97, DOI 10.1016/0304-3940(95)11737-H; KLATZO I, 1985, BRIT J ANAESTH, V57, P18, DOI 10.1093/bja/57.1.18; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARMAROU A, 1978, J NEUROSURG, V49, P530, DOI 10.3171/jns.1978.49.4.0530; MARMAROU A, 1994, ACTA NEUROCHIR, P421; PRESTON E, 1993, NEUROSCI LETT, V149, P75, DOI 10.1016/0304-3940(93)90351-K; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Soares HD, 1995, J NEUROSCI, V15, P8223; SUTTON RL, 1994, ACTA NEUROCHIR, P446; SUZUKI R, 1983, ACTA NEUROPATHOL, V60, P207, DOI 10.1007/BF00691868; UYAMA O, 1988, J CEREBR BLOOD F MET, V8, P282, DOI 10.1038/jcbfm.1988.59; WAHL M, 1988, J CEREBR BLOOD F MET, V8, P621, DOI 10.1038/jcbfm.1988.109	22	218	227	0	6	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	APR 18	1997	226	1					33	36					4	Neurosciences	Neurosciences & Neurology	WW389	WOS:A1997WW38900009	9153635				2021-06-18	
J	Klein, MA; Moller, JC; Jones, LL; Bluethmann, H; Kreutzberg, GW; Raivich, G				Klein, MA; Moller, JC; Jones, LL; Bluethmann, H; Kreutzberg, GW; Raivich, G			Impaired neuroglial activation in interleukin-6 deficient mice	GLIA			English	Article						microglia; astrocytes; cytokines; knockout; regeneration	FACIAL-NERVE AXOTOMY; COLONY-STIMULATING FACTORS; CHOLINERGIC NEURONS; MOTOR NEURONS; MOUSE-BRAIN; CYTOKINES; RAT; ASTROCYTES; EXPRESSION; LOCALIZATION	Astrocyte activation is a ubiquitous hallmark of the damaged brain and has been suggested to play an important regulatory role in the activation, survival, and regeneration of adjacent neurons, microglia, and oligodendrocytes. Little is known, however, about the endogenous signals that lead to this activation of astrocytes. Here we examined the regulation of interleukin 6 (IL6), a proinflammatory cytokine, its receptors, and the effects of IL6-deficiency in a model of traumatic central nervous system injury in the axotomized mouse facial motor nucleus. Facial nerve transection led to a massive but transient upregulation of IL6 mRNA in the disconnected motor nucleus, while IL6-receptor subunits were constitutively expressed on motoneurons and astrocytes. Absence of IL6 in genetically IL6-deficient mice led to massive reduction in the number of activated GFAP-positive astrocytes, a more moderate decrease in microglial activation and proliferation, and an increase in the late neuronal response to axotomy. These results emphasize the role of ILG in the global regulation of neurons, astrocytes, and microglia and their activation in the injured nervous system. (C) 1997 Wiley-Liss, Inc.	MAX PLANCK INST PSYCHIAT,DEPT NEUROMORPHOL,D-82152 MARTINSRIED,GERMANY; HOFFMANN LA ROCHE AG,PHARMA RES GEN TECHNOL,CH-4002 BASEL,SWITZERLAND			Raivich, Gennadij/A-6770-2011; Raivich, Gennadij/AAL-7229-2021				ADERKA D, 1989, J IMMUNOL, V143, P3517; ALOISI F, 1992, J IMMUNOL, V149, P2358; BALASINGAM V, 1994, J NEUROSCI, V14, P846; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BLINZING.K, 1968, Z ZELLFORSCH MIK ANA, V85, P145, DOI 10.1007/BF00325030; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; CURTIS R, 1994, NEURON, V12, P191, DOI 10.1016/0896-6273(94)90163-5; EDDLESTON M, 1993, NEUROSCIENCE, V54, P1; FABRY Z, 1993, J NEUROIMMUNOL, V47, P23, DOI 10.1016/0165-5728(93)90281-3; Fattori E, 1995, EUR J NEUROSCI, V7, P2441, DOI 10.1111/j.1460-9568.1995.tb01042.x; FREI K, 1989, EUR J IMMUNOL, V19, P689, DOI 10.1002/eji.1830190418; GAUDIE J, 1987, P NATL ACAD SCI USA, V84, P7251; GLUCKMAN P, 1992, BIOCHEM BIOPH RES CO, V182, P593, DOI 10.1016/0006-291X(92)91774-K; GRAEBER MB, 1988, J NEUROCYTOL, V17, P209, DOI 10.1007/BF01674208; GRAEBER MB, 1986, J NEUROCYTOL, V15, P363; GRAEBER MB, 1988, NEUROSCI LETT, V85, P317, DOI 10.1016/0304-3940(88)90585-X; HAMA T, 1991, NEUROSCIENCE, V40, P445, DOI 10.1016/0306-4522(91)90132-8; HERMANSON M, 1995, EXP BRAIN RES, V102, P415; HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0; HOPKINS SJ, 1995, TRENDS NEUROSCI, V18, P83; IKEBUCHI K, 1987, P NATL ACAD SCI USA, V84, P9035, DOI 10.1073/pnas.84.24.9035; IP NY, 1993, NEURON, V10, P89, DOI 10.1016/0896-6273(93)90245-M; KIEFER R, 1993, EUR J NEUROSCI, V5, P775, DOI 10.1111/j.1460-9568.1993.tb00929.x; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; Kreutzberg Georg W., 1995, P355; KUSHIMA Y, 1992, NEUROSCI LETT, V143, P110, DOI 10.1016/0304-3940(92)90244-2; LIU X, 1994, MOL CELL NEUROSCI, V5, P418, DOI 10.1006/mcne.1994.1052; LOTZ M, 1988, J EXP MED, V167, P1253, DOI 10.1084/jem.167.3.1253; MALIPIERO UV, 1990, J IMMUNOL, V144, P3816; Moller JC, 1996, GLIA, V17, P121; MOORE RY, 1989, J COMP NEUROL, V282, P512, DOI 10.1002/cne.902820404; MORGANTIKOSSMANN MC, 1992, TRENDS PHARMACOL SCI, V13, P286, DOI 10.1016/0165-6147(92)90087-M; MURPHY PG, 1995, J NEUROSCI, V15, P5130; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; OTSUKA M, 1994, KIDNEY INT, V45, P1340, DOI 10.1038/ki.1994.175; PATTERSON PH, 1993, NEURON S, V10, P123; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; PERRY VH, 1985, NEUROSCIENCE, V15, P313, DOI 10.1016/0306-4522(85)90215-5; Raivich G, 1995, PROG BRAIN RES, V104, P3; RAIVICH G, 1994, EUR J NEUROSCI, V6, P1615, DOI 10.1111/j.1460-9568.1994.tb00552.x; RAIVICH G, 1993, J HISTOCHEM CYTOCHEM, V41, P579, DOI 10.1177/41.4.8450197; SCHOBITZ B, 1993, EUR J NEUROSCI, V5, P1426, DOI 10.1111/j.1460-9568.1993.tb00210.x; SENDTNER M, 1992, J CELL BIOL, V118, P139, DOI 10.1083/jcb.118.1.139; SHABO Y, 1988, BLOOD, V72, P2070; Shibuki K, 1996, NEURON, V16, P587, DOI 10.1016/S0896-6273(00)80078-1; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; TOULMOND S, 1992, NEUROSCI LETT, V144, P49, DOI 10.1016/0304-3940(92)90713-H	48	218	221	0	9	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012	0894-1491			GLIA	Glia	MAR	1997	19	3					227	233		10.1002/(SICI)1098-1136(199703)19:3<227::AID-GLIA5>3.0.CO;2-W			7	Neurosciences	Neurosciences & Neurology	WL667	WOS:A1997WL66700005	9063729				2021-06-18	
J	Zhang, R; Liu, Y; Yan, K; Chen, L; Chen, XR; Li, P; Chen, FF; Jiang, XD				Zhang, Run; Liu, Yi; Yan, Ke; Chen, Lei; Chen, Xiang-Rong; Li, Peng; Chen, Fan-Fan; Jiang, Xiao-Dan			Anti-inflammatory and immunomodulatory mechanisms of mesenchymal stem cell transplantation in experimental traumatic brain injury	JOURNAL OF NEUROINFLAMMATION			English	Article							PRO-INFLAMMATORY CYTOKINES; NECROSIS-FACTOR-ALPHA; MICROGLIAL ACTIVATION; STROMAL CELLS; IMMUNE-RESPONSE; TNF-ALPHA; RAT MODEL; NEUROPROTECTION; CHEMOKINES; EXPRESSION	Background: Previous studies have shown beneficial effects of mesenchymal stem cell (MSC) transplantation in central nervous system (CNS) injuries, including traumatic brain injury (TBI). Potential repair mechanisms involve transdifferentiation to replace damaged neural cells and production of growth factors by MSCs. However, few studies have simultaneously focused on the effects of MSCs on immune cells and inflammation-associated cytokines in CNS injury, especially in an experimental TBI model. In this study, we investigated the anti-inflammatory and immunomodulatory properties of MSCs in TBI-induced neuroinflammation by systemic transplantation of MSCs into a rat TBI model. Methods/results: MSCs were transplanted intravenously into rats 2 h after TBI. Modified neurologic severity score (mNSS) tests were performed to measure behavioral outcomes. The effect of MSC treatment on neuroinflammation was analyzed by immunohistochemical analysis of astrocytes, microglia/macrophages, neutrophils and T lymphocytes and by measuring cytokine levels [interleukin (IL)-1 alpha, IL-1 beta, IL-4, IL-6, IL-10, IL-17, tumor necrosis factor-alpha, interferon-gamma, RANTES, macrophage chemotactic protein-1, macrophage inflammatory protein 2 and transforming growth factor-beta 1] in brain homogenates. The immunosuppression-related factors TNF-alpha stimulated gene/protein 6 (TSG-6) and nuclear factor-kappa B (NF-kappa B) were examined by reverse transcription-polymerase chain reaction and Western blotting. Intravenous MSC transplantation after TBI was associated with a lower density of microglia/macrophages and peripheral infiltrating leukocytes at the injury site, reduced levels of proinflammatory cytokines and increased anti-inflammatory cytokines, possibly mediated by enhanced expression of TSG-6, which may suppress activation of the NF-kappa B signaling pathway. Conclusions: The results of this study suggest that MSCs have the ability to modulate inflammation-associated immune cells and cytokines in TBI-induced cerebral inflammatory responses. This study thus offers a new insight into the mechanisms responsible for the immunomodulatory effect of MSC transplantation, with implications for functional neurological recovery after TBI.	[Zhang, Run; Liu, Yi; Yan, Ke; Chen, Xiang-Rong; Li, Peng; Chen, Fan-Fan; Jiang, Xiao-Dan] Southern Med Univ, Zhujiang Hosp, Neurosurg Inst Guangdong Prov, Natl Key Clin Specialty,Dept Neurosurg,Guandong P, Guangzhou 510282, Guangdong, Peoples R China; [Chen, Lei] Shenzhen Univ, Affiliated Hosp 1, Shenzhen Peoples Hosp 2, Dept Neurosurg, Shenzhen 518000, Peoples R China	Jiang, XD (corresponding author), Southern Med Univ, Zhujiang Hosp, Neurosurg Inst Guangdong Prov, Natl Key Clin Specialty,Dept Neurosurg,Guandong P, Guangzhou 510282, Guangdong, Peoples R China.	jiangxiao_dan@163.com			funds for National Key Clinic Department; Natural Science Fund of ChinaNational Natural Science Foundation of China (NSFC) [81171179, 81272439]; Funds for Key Sci-Tech Research Project of Guangdong [2008A030201019]; Funds for Key Sci-Tech Research Project of Guangzhou [09B52120112-2009J1-C418-2, 2008A1-E4011-6]	This work was supported by grants from the funds for National Key Clinic Department, the Natural Science Fund of China (nos. 81171179, 81272439), the Funds for Key Sci-Tech Research Projects of Guangdong (no. 2008A030201019) and Guangzhou (no. 09B52120112-2009J1-C418-2, no. 2008A1-E4011-6) to Prof. Xiaodan Jiang.	Aggarwal S, 2005, BLOOD, V105, P1815, DOI 10.1182/blood-2004-04-1559; Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Arneth BM, 2010, J NEUROIMMUNOL, V219, P123, DOI 10.1016/j.jneuroim.2009.12.011; Biber K, 2007, TRENDS NEUROSCI, V30, P596, DOI 10.1016/j.tins.2007.08.007; Brait VH, 2012, J CEREBR BLOOD F MET, V32, P598, DOI 10.1038/jcbfm.2012.6; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Chen G, 2007, MEDIAT INFLAMM, V2007, DOI 10.1155/2007/93431; Chen Y, 2003, J CEREBR BLOOD F MET, V23, P748, DOI 10.1097/01.WCB.0000071885.63724.20; Choi H, 2011, BLOOD, V118, P330, DOI 10.1182/blood-2010-12-327353; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Clausen F, 2007, J NEUROTRAUM, V24, P1295, DOI 10.1089/neu.2006.0258; Correale J, 2004, J NEUROL, V251, P1304, DOI 10.1007/s00415-004-0649-z; d'Avila JC, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-31; Di Nicola M, 2002, BLOOD, V99, P3838, DOI 10.1182/blood.V99.10.3838; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; Du YY, 2008, CYTOTHERAPY, V10, P469, DOI 10.1080/14653240802129893; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Gerdoni E, 2007, ANN NEUROL, V61, P219, DOI 10.1002/ana.21076; Gonzalez R, 2003, EXP NEUROL, V184, P456, DOI 10.1016/S0014-4886(03)00257-7; Gupta N, 2007, J IMMUNOL, V179, P1855, DOI 10.4049/jimmunol.179.3.1855; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Kassis I, 2008, ARCH NEUROL-CHICAGO, V65, P753, DOI 10.1001/archneur.65.6.753; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Konsman JP, 2007, CLIN SCI, V112, P1, DOI 10.1042/CS20060043; Koshinaga M, 2007, HISTOL HISTOPATHOL, V22, P129, DOI 10.14670/HH-22.129; Koshinaga M, 2000, J NEUROTRAUM, V17, P185, DOI 10.1089/neu.2000.17.185; Kremlev SG, 2005, J NEUROIMMUNOL, V162, P71, DOI 10.1016/j.jneuroim.2005.01.010; Lau LT, 2001, J NEUROTRAUM, V18, P351, DOI 10.1089/08977150151071035; Le Blanc K, 2004, LANCET, V363, P1439, DOI 10.1016/S0140-6736(04)16104-7; Lee JK, 2010, STEM CELLS, V28, P329, DOI 10.1002/stem.277; Lee RH, 2009, CELL STEM CELL, V5, P54, DOI 10.1016/j.stem.2009.05.003; Lee ST, 2008, BRAIN, V131, P616, DOI 10.1093/brain/awm306; Li M, 2011, J TRAUMA, V71, P141, DOI [10.1097/TA.0b013e3181f30fc9, 10.1088/1742-5468/2011/12/P12001]; Liu N, 2009, CELL MOL IMMUNOL, V6, P207, DOI 10.1038/cmi.2009.28; Lu M, 2003, J NEUROSCI METH, V128, P183, DOI 10.1016/S0165-0270(03)00188-2; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; Lumpkins K, 2008, J TRAUMA, V64, P358, DOI 10.1097/TA.0b013e318160df9b; Meirelles LD, 2009, CYTOKINE GROWTH F R, V20, P419, DOI 10.1016/j.cytogfr.2009.10.002; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Nemeth K, 2009, NAT MED, V15, P42, DOI 10.1038/nm.1905; Ooi YY, 2010, INT IMMUNOPHARMACOL, V10, P1532, DOI 10.1016/j.intimp.2010.09.001; Ortiz LA, 2007, P NATL ACAD SCI USA, V104, P11002, DOI 10.1073/pnas.0704421104; Parr AM, 2007, BONE MARROW TRANSPL, V40, P609, DOI 10.1038/sj.bmt.1705757; Prockop DJ, 2012, MOL THER, V20, P14, DOI 10.1038/mt.2011.211; Qu CS, 2010, J NEUROTRAUM, V27, P1625, DOI 10.1089/neu.2010.1359; Raffaghello L, 2008, STEM CELLS, V26, P151, DOI 10.1634/stemcells.2007-0416; Rancan M, 2001, J NEUROSCI RES, V63, P438, DOI 10.1002/1097-4547(20010301)63:5<438::AID-JNR1039>3.0.CO;2-P; Rasouli J, 2011, Einstein J Biol Med, V27, P74; Ren GW, 2008, CELL STEM CELL, V2, P141, DOI 10.1016/j.stem.2007.11.014; Rhodes J, 2011, CURR OPIN CRIT CARE, V17, P122, DOI 10.1097/MCC.0b013e3283447948; Rhodes JKJ, 2009, J NEUROTRAUM, V26, P507, DOI 10.1089/neu.2008.0686; Roddy GW, 2011, STEM CELLS, V29, P1572, DOI 10.1002/stem.708; Schafer S, 2012, J NEUROIMMUNOL, V249, P40, DOI 10.1016/j.jneuroim.2012.04.018; Scuteri A, 2011, CURR STEM CELL RES T, V6, P82, DOI 10.2174/157488811795495486; Semple BD, 2010, NEUROBIOL DIS, V40, P394, DOI 10.1016/j.nbd.2010.06.015; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Sheikh AM, 2011, NEUROBIOL DIS, V41, P717, DOI 10.1016/j.nbd.2010.12.009; Shi YF, 2012, TRENDS IMMUNOL, V33, P136, DOI 10.1016/j.it.2011.11.004; Si YL, 2011, AGEING RES REV, V10, P93, DOI 10.1016/j.arr.2010.08.005; Stemberger S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019808; Togel F, 2005, AM J PHYSIOL-RENAL, V289, pF31, DOI 10.1152/ajprenal.00007.2005; Turrin NP, 2006, J NEUROSCI, V26, P143, DOI 10.1523/JNEUROSCI.4032-05.2006; Uccelli A, 2008, NAT REV IMMUNOL, V8, P726, DOI 10.1038/nri2395; Vendrame M, 2005, STEM CELLS DEV, V14, P595, DOI 10.1089/scd.2005.14.595; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Wisniewski Hans-Georg, 1997, Cytokine and Growth Factor Reviews, V8, P143, DOI 10.1016/S1359-6101(97)00008-7; Xiong Y, 2010, DISCOV MED, V10, P434; Yanez R, 2006, STEM CELLS, V24, P2582, DOI 10.1634/stemcells.2006-0228; Zappia E, 2005, BLOOD, V106, P1755, DOI 10.1182/blood-2005-04-1496; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	73	217	240	1	64	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	AUG 23	2013	10								106	10.1186/1742-2094-10-106			12	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	207ET	WOS:000323580900001	23971414	DOAJ Gold, Green Published			2021-06-18	
J	Hopkins, RO; Jackson, JC				Hopkins, Ramona O.; Jackson, James C.			Long-term neurocognitive function after critical illness	CHEST			English	Article						critical care outcomes; critical illness; neurocognitive impairments	RESPIRATORY-DISTRESS-SYNDROME; QUALITY-OF-LIFE; REQUIRING INTENSIVE-CARE; COGNITIVE IMPAIRMENT; OLDER-ADULTS; SURVIVORS; DYSFUNCTION; DEMENTIA; DISEASE; ASSOCIATION	Background: Until relatively recently, critical care practitioners have focused on the survival of their patients and not on long-term outcomes. The incidence of chronic neurocognitive dysfunction has been underestimated and underreported, and only recently has it been studied in critically ill patients. However, neurocognitive outcomes have been the subject of extensive investigation in other medical populations for many years. Methods: Review of the current literature regarding long-term neurocognitive outcomes following critical illness. Results: Data from studies to date indicate that critical illness can lead to significant neurocognitive impairments. The neurocognitive impairments persist for months and years, and may have important consequences for quality of life, the ability to return to work, overall functional ability, and substantial economic costs. The mechanisms of the neurocognitive impairments are not fully understood but likely include delirium, hypoxia, glucose dysregulation, metabolic derangements, inflammation, and the effects of sedatives and narcotics among other factors. The contributions of these factors may be particularly significant in patients with preexisting vulnerabilities for the development of cognitive impairments such as mild cognitive impairment, dementia, prior traumatic brain injury, or other comorbid disorders associated with neurocognitive impairments. Conclusions: Current research indicates that neurocognitive sequelae following critical illness are common, may be permanent, and are associated with impairments in daily function, decreased quality of life, and an inability to return to work. Research needs to be done to better understand the prevalence, nature, risk factors, and nuances of the neurocognitive impairments observed in ICU survivors.	Latter Day St Hosp, Dept Internal Med, Pulm & Crit Care Div, Salt Lake City, UT 84143 USA; Vanderbilt Univ, Sch Med, Div Allergy Pulm Crit Care Med, Nashville, TN 37212 USA	Hopkins, RO (corresponding author), Latter Day St Hosp, Dept Internal Med, Pulm & Crit Care Div, 8th Ave & C St, Salt Lake City, UT 84143 USA.	Ramona.Hopkins@intermountainmail.org					ALSAIDI F, 2003, AM J RESP CRIT CARE, V167, pA737; Angus DC, 2000, JAMA-J AM MED ASSOC, V284, P2762, DOI 10.1001/jama.284.21.2762; Angus DC, 2001, AM J RESP CRIT CARE, V163, P1389, DOI 10.1164/ajrccm.163.6.2005123; CALLAHAN CM, 1995, ANN INTERN MED, V122, P422, DOI 10.7326/0003-4819-122-6-199503150-00004; CHELLURI L, 1993, JAMA-J AM MED ASSOC, V269, P3119, DOI 10.1001/jama.269.24.3119; Christie JD, 2006, J CRIT CARE, V21, P125, DOI 10.1016/j.jcrc.2005.11.004; CHRISTIE JD, 2004, AM J RESP CRIT CARE, V169, pA781; CHURCHILL S, 2002, UNDERSEA HYPERBAR M, V29, P139; Cohen I L, 1994, New Horiz, V2, P283; COVINSKY KE, 1994, JAMA-J AM MED ASSOC, V272, P1839, DOI 10.1001/jama.272.23.1839; Esteban A, 2000, AM J RESP CRIT CARE, V161, P1450, DOI 10.1164/ajrccm.161.5.9902018; Gordon SM, 2004, INTENS CARE MED, V30, P1997, DOI 10.1007/s00134-004-2418-y; Griffith HR, 2003, NEUROLOGY, V60, P449, DOI 10.1212/WNL.60.3.449; Halpern NA, 2004, CRIT CARE MED, V32, P1254, DOI 10.1097/01.CCM.0000128577.31689.4C; Herridge MS, 2003, NEW ENGL J MED, V348, P683, DOI 10.1056/NEJMoa022450; Hopkins RO, 2005, AM J RESP CRIT CARE, V171, P340, DOI 10.1164/rccm.200406-763OC; Hopkins RO, 2006, BRAIN INJURY, V20, P263, DOI 10.1080/02699050500488199; Hopkins RO, 2005, NEUROPSYCHOLOGY, V19, P233, DOI 10.1037/0894-4105.19.2.233; Hopkins RO, 2004, J INT NEUROPSYCH SOC, V10, P1005, DOI 10.1017/S135561770410711X; Hopkins RO, 1999, AM J RESP CRIT CARE, V160, P50, DOI 10.1164/ajrccm.160.1.9708059; Inouye SK, 1996, JAMA-J AM MED ASSOC, V275, P852, DOI 10.1001/jama.275.11.852; Jackson JC, 2004, NEUROPSYCHOL REV, V14, P87, DOI 10.1023/B:NERV.0000028080.39602.17; Jackson JC, 2003, ARCH CLIN NEUROPSYCH, V18, P688; Jackson JC, 2003, CRIT CARE MED, V31, P1226, DOI 10.1097/01.CCM.0000059996.30263.94; Jones C, 2006, INTENS CARE MED, V32, P923, DOI 10.1007/s00134-006-0112-y; Kwa VIH, 1996, J NEUROL, V243, P405, DOI 10.1007/BF00869000; Langa KM, 2001, J GEN INTERN MED, V16, P770, DOI 10.1111/j.1525-1497.2001.10123.x; Lee TA, 2005, J ALZHEIMERS DIS, V7, P319; Lyketsos CG, 2005, AM J GERIAT PSYCHIAT, V13, P656, DOI 10.1176/appi.ajgp.13.8.656; MARQUIS K, 2000, AM J RESP CRIT CARE, V161, pA383; Newman MF, 2001, NEW ENGL J MED, V344, P395, DOI 10.1056/NEJM200102083440601; Nygard L, 2003, ACTA NEUROL SCAND, V107, P42, DOI 10.1034/j.1600-0404.107.s179.8.x; Orme J, 2003, AM J RESP CRIT CARE, V167, P690, DOI 10.1164/rccm.200206-542OC; Pisani MA, 2003, CHEST, V124, P2267, DOI 10.1378/chest.124.6.2267; Raja PV, 2004, CNS SPECTRUMS, V9, P763, DOI 10.1017/S1092852900022409; Rockwood K, 2002, STROKE, V33, P1605, DOI 10.1161/01.STR.0000017878.85274.44; Rothenhausler HB, 2001, GEN HOSP PSYCHIAT, V23, P88, DOI 10.1016/S0163-8343(01)00123-2; Russell JA, 2000, CRIT CARE MED, V28, P3405, DOI 10.1097/00003246-200010000-00005; SCHMITZ R, 1998, FUTURE WORKFORCE NEE; Selnes OA, 2003, ANN THORAC SURG, V75, P1377, DOI 10.1016/S0003-4975(03)00021-3; STARR JM, 1994, DRUG SAFETY, V11, P310, DOI 10.2165/00002018-199411050-00003; Strain LA, 2003, INT PSYCHOGERIATR, V15, P351, DOI 10.1017/S1041610203009608; Suchyta MR, 2005, P AM THORAC SOC, V2, pA426; SUCHYTA MR, 2004, AM J RESP CRIT CARE, V169, pA18; Sukantarat KT, 2005, ANAESTHESIA, V60, P847, DOI 10.1111/j.1365-2044.2005.04148.x; THIAGARAJAN J, 1994, ANAESTHESIA, V49, P211; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Wallace C.J., 2005, INT NEUR SOC 33 ANN, P361; Weaver LK, 2002, NEW ENGL J MED, V347, P1057, DOI 10.1056/NEJMoa013121; Weinert CR, 1997, AM J RESP CRIT CARE, V156, P1120, DOI 10.1164/ajrccm.156.4.9611047; Wilkes MM, 2001, ANN INTERN MED, V135, P149, DOI 10.7326/0003-4819-135-3-200108070-00007; YOUNG GB, 1995, NEUROL CLIN, V13, P645, DOI 10.1016/S0733-8619(18)30037-9	52	217	236	1	26	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0012-3692			CHEST	Chest	SEP	2006	130	3					869	878		10.1378/chest.130.3.869			10	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	085EG	WOS:000240585600039	16963688				2021-06-18	
J	Adelson, PD; Ragheb, J; Muizelaar, JP; Kanev, P; Brockmeyer, D; Beers, SR; Brown, SD; Cassidy, LD; Chang, YF; Levin, H				Adelson, PD; Ragheb, J; Muizelaar, JP; Kanev, P; Brockmeyer, D; Beers, SR; Brown, SD; Cassidy, LD; Chang, YF; Levin, H			Phase II clinical trial of moderate hypothermia after severe traumatic brain injury in children	NEUROSURGERY			English	Article						clinical trial; hypothermia; pediatric; traumatic brain injury	SEVERE HEAD-INJURY; COMA DATA-BANK; IMMATURE RAT; PERINATAL ASPHYXIA; INTRACRANIAL HYPERTENSION; THERAPEUTIC HYPOTHERMIA; CEREBRAL HYPOTHERMIA; MILD HYPOTHERMIA; NEWBORN-INFANTS; GUIDELINES	OBJECTIVE: To determine whether moderate hypothermia (HYPO) (32-33 degrees C) begun in the early period after severe traumatic brain injury (TBI) and maintained for 48 hours is safe compared with normothermia (NORM) (36.5-37.5 degrees C). METHODS: After severe (Glasgow Coma Scale score <= 8) nonpenetrating TBI, 48 children less than 13 years of age admitted within 6 hours of injury were randomized after stratification by age to moderate HYPO (32-33 degrees C) treatment in conjunction with standardized head injury management versus NORM in a multicenter trial. An additional 27 patients were entered into a parallel single-institution trial of excluded patients because of late transfer or consent (delayed in transfer > 6 h but within 24 h of admission), unknown time of injury (e.g., child abuse), and adolescence (e.g., aged 13-18 yr). Assessments of safety included mortality, infection, coagulopathy, arrhythmias, and hemorrhage as well as ability to maintain temperature, mean intracranial pressure (ICP), and percent time of ICP less than 20 mm Hg during the cooling and subsequent rewarming phases. Additionally, assessments of neurocognitive outcomes were obtained at 3 and 6 months of follow-up. RESULTS: Moderate HYPO after severe TBI in children was found to be safe relative to standard management and NORM in children of all ages and in children with delay of initiation of treatment up to 24 hours. Although there was decreased mortality in HYPO in both studies, there was an increased potential for arrhythmias with HYPO, although they were manageable with fluid administration or rewarming. Additionally, there was a reduction in mean ICP during the first 72 hours after injury in both studies, although rebound ICP elevations in HYPO compared with those in NORM were noted for up to 10 to 12 hours after rewarming. Although functional outcome at 3 or 6 months did not differ between treatment groups, functional outcome tended to improve from the 3- to 6-month cognitive assessment in HYPO compared with NORM, although the sample size was too small for any definitive conclusions. CONCLUSION: HYPO is likely a safe therapeutic intervention for children after severe TBI up to 24 hours after injury. Further studies are necessary and warranted to determine its effect on functional outcome and intracanial hypertension.	Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15261 USA; Univ Miami, Dept Neurosurg, Miami, FL 33152 USA; Univ Calif Davis, Dept Neurol Surg, Davis, CA 95616 USA; Penn State Univ, Dept Neurosurg, State Coll, PA 16804 USA; Primary Childrens Med Ctr, Salt Lake City, UT USA; Univ Pittsburgh, Sch Med, Dept Biostat, Pittsburgh, PA USA; Baylor Coll Med, Dept Phys Med & Rehabil, Dallas, TX USA	Adelson, PD (corresponding author), Childrens Hosp Pittsburgh, Dept Neurosurg, 3705 5th Ave, Pittsburgh, PA 15213 USA.	david.adelson@chp.edu	Adelson, David/W-2083-2019		NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR00084] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS 38448-01] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000084] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038448] Funding Source: NIH RePORTER		Adelson P David, 2003, Pediatr Crit Care Med, V4, pS2, DOI 10.1097/01.CCM.0000066600.71233.01; Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Arias E, 2003, PEDIATRICS, V112, P1215, DOI 10.1542/peds.112.6.1215; Battin MR, 2001, PEDIATRICS, V107, P480, DOI 10.1542/peds.107.3.480; Biswas AK, 2002, CRIT CARE MED, V30, P2742, DOI 10.1097/00003246-200212000-00020; BLAIR E, 1964, CLIN HYPOTHERMIA, P142; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Choi SC, 1998, J NEUROTRAUM, V15, P771, DOI 10.1089/neu.1998.15.771; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Fletcher JM, 1987, NEUROBEHAVIORAL RECO, P279; FRANKOWSKI RF, 1985, 1985 NIH NINCDS, P33; GRAY TC, 1957, LANCET, V1, P383; Gruszkiewicz J, 1973, Surg Neurol, V1, P197; Gunn AJ, 2000, CURR OPIN PEDIATR, V12, P111, DOI 10.1097/00008480-200004000-00004; Gunn AJ, 1998, EARLY HUM DEV, V53, P19, DOI 10.1016/S0378-3782(98)00033-4; Gunn AJ, 1998, PEDIATRICS, V102, P885, DOI 10.1542/peds.102.4.885; HENDRICK E, 1963, CLIN NEUROSURG, V11, P46; Jaffe J., 1998, CURRENT CONCEPTS PED, P1; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; KRAUS JF, 1987, PEDIATRICS, V79, P501; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; KRAUS JF, 1987, HEAD INJURY, P1; Landgraf JM, 1996, CHILD HLTH QUESTIONN, V1st; LAZORTHES G, 1958, J NEUROSURG, V15, P162, DOI 10.3171/jns.1958.15.2.0162; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Mansfield RT, 1996, J CEREBR BLOOD F MET, V16, P244, DOI 10.1097/00004647-199603000-00009; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; SANDS MP, 1979, CRYOBIOLOGY, V16, P229, DOI 10.1016/0011-2240(79)90036-1; SEDZIMIR CB, 1959, J NEUROSURG, V16, P407, DOI 10.3171/jns.1959.16.4.0407; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Simbruner G, 1999, INTENS CARE MED, V25, P1111, DOI 10.1007/s001340051020; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	45	217	229	0	16	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	APR	2005	56	4					740	753		10.1227/01.NEU.0000156471.50726.26			14	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	915EH	WOS:000228280200023	15792513				2021-06-18	
J	Jeremitsky, E; Omert, LA; Dunham, CM; Wilberger, J; Rodriguez, A				Jeremitsky, E; Omert, LA; Dunham, CM; Wilberger, J; Rodriguez, A			The impact of hyperglycemia on patients with severe brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						hyperglycemia; traumatic brain injury; critical care; outcome; nutrition; diabetes	HEAD-INJURY; SECONDARY INSULTS; DIABETES-MELLITUS; ISCHEMIC BRAIN; CARDIAC-ARREST; GLUCOSE; DAMAGE; ADMISSION; SURVIVAL; RATS	Background: This study aimed to analyze the relation of hyperglycemia to outcome in cases of severe traumatic brain injury, and to examine factors that may be responsible for the hyperglycemic state. Methods: A retrospective analysis in an intensive care unit of a level I trauma center investigated 77 patients with severe traumatic brain injury. Patients with a Glasgow Coma Scale (GCS) of 8 or lower who survived more than 5 days were reviewed. Serum glucose, base deficit, GCS, use of steroids, and amounts of insulin and carbohydrates were recorded for 5 days, along with age. The Injury Severity Score (ISS) and the Abbreviated Injury Score (AIS) for the head, chest, and abdomen also were recorded. A hyperglycemia score (HS) was calculated as follows. A value of 1 was assigned each day the glucose exceeded 170 mg/dL (range, 0-5). A hyperglycemia score for days 3, 4, and 5 (HS day 3-5) also was calculated (range, 0-3). Outcomes included mortality, day 5 GCS, intensive care unit length of stay, and hospital length of stay. Results: Of the 77 patients, 24 (31.2%) died. Nonsurvivors had higher glucose levels each day. The HS was higher for those who died: 2.4 +/- 1.7 versus 1.5 +/- 1.4 (p = 0.02). Univariate analysis showed that only HS and ISS correlated with all four outcome variables studied. Cox's regression analysis showed that mortality was related to age and ISS. Head AIS and HS were independent predictors of lower day 5 GCS, whereas HS 3-5 and day 4 GCS were related to prolonged hospital length of stay. Older age, diabetes, and lower day 1 GCS were associated with higher HS, whereas carbohydrate infusion rate, ISS, head AIS, and steroid administration were not. Conclusions: Early hyperglycemia is associated with poor outcomes for patients with severe traumatic brain injury. Tighter control of serum glucose without reduction of nutritional support may improve the prognosis for these critically ill patients.	Allegheny Gen Hosp, Dept Surg, Pittsburgh, PA 15212 USA; Allegheny Gen Hosp, Dept Neurosurg, Pittsburgh, PA 15212 USA; St Elizabeth Hosp, Dept Surg, Youngstown, OH USA	Omert, LA (corresponding author), Allegheny Gen Hosp, Dept Surg, 5th Floor S Tower,320 E N Ave, Pittsburgh, PA 15212 USA.						BESSEY PQ, 2002, ACS SURG PRINCIPLES, P1495; Cherian L, 1997, CRIT CARE MED, V25, P1378, DOI 10.1097/00003246-199708000-00027; Cherian L, 1998, J NEUROTRAUM, V15, P307, DOI 10.1089/neu.1998.15.307; HOFFMAN WE, 1990, ANESTHESIOLOGY, V72, P1045, DOI 10.1097/00000542-199006000-00015; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Kelly DF, 1996, NEUROTRAUMA, P71; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; LONGSTRETH WT, 1984, ANN NEUROL, V15, P59, DOI 10.1002/ana.410150111; Malmberg K, 1997, BRIT MED J, V314, P1512, DOI 10.1136/bmj.314.7093.1512; MYERS RE, 1977, ARCH NEUROL-CHICAGO, V34, P65, DOI 10.1001/archneur.1977.00500140019003; OTT L, 1989, NUTRITION, P5; PIETROPAOLI JA, 1992, J TRAUMA, V33, P403, DOI 10.1097/00005373-199209000-00011; PING AL, 2000, STROKE           JAN, P183; PULSINELLI WA, 1983, AM J MED, V74, P540, DOI 10.1016/0002-9343(83)91007-0; PULSINELLI WA, 1982, NEUROLOGY, V32, P1239, DOI 10.1212/WNL.32.11.1239; RAPP RP, 1983, J NEUROSURG, V58, P906, DOI 10.3171/jns.1983.58.6.0906; Sarrafzadeh AS, 2001, CRIT CARE MED, V29, P1116, DOI 10.1097/00003246-200106000-00004; Schurr A, 2001, CURR OPIN CLIN NUTR, V4, P287, DOI 10.1097/00075197-200107000-00007; Taylor SJ, 1999, CRIT CARE MED, V27, P2525, DOI 10.1097/00003246-199911000-00033; TWYMAN D L, 1986, Henry Ford Hospital Medical Journal, V34, P41; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; WALD S, 1991, J TRAUMA, V31, P104; YOUNG B, 1989, ANN SURG, V210, P466, DOI 10.1097/00000658-198910000-00007	23	217	241	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JAN	2005	58	1					47	50		10.1097/01.TA.0000135158.42242.B1			4	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	894HS	WOS:000226782300009	15674149				2021-06-18	
J	Kumar, K; Toth, C; Nath, RK				Kumar, K; Toth, C; Nath, RK			Deep brain stimulation for intractable pain: A 15-year experience	NEUROSURGERY			English	Article						chronic pain; deep brain electrical stimulation; periaqueductal gray matter; sensory thalamus	PERIAQUEDUCTAL GRAY-MATTER; ELECTRICAL-STIMULATION; INTERNAL CAPSULE; CEREBROSPINAL-FLUID; BETA-ENDORPHIN; THALAMIC-STIMULATION; HUMANS; RELIEF; MANAGEMENT; ANALGESIA	OBJECTIVE: During the past 15 years, we prospectively followed 68 patients with chronic pain syndromes who underwent deep brain stimulation (DBS). The objective of our study was to analyze the long-term outcomes to clarify patient selection criteria for DBS. METHODS: Patients were referred from a multidisciplinary pain clinic after conservative treatment failed. Electrodes for DBS were implanted within the periventricular gray matter, specific sensory thalamic nuclei, or the internal capsule. Each patient was followed on a 6-monthly follow-up basis and evaluated with a modified Visual analog scale. RESULTS: Follow-up periods ranged from 6 months to 15 years, with an average follow-up period of 78 months. The mean age of the 54 men and 14 women in the study was 51.3 years. Indications for DBS included 43 patients with failed back syndrome, 6 with peripheral neuropathy or radiculopathy, 5 with thalamic pain, 4 with trigeminal neuropathy, 3 with traumatic spinal cord lesions, 2 with causalgic pain, 1 with phantom limb pain, and 1 with carcinoma pain. After initial screening, 53 of 68 patients (77%) elected internalization of their devices; 42 of the 53 (79%) continue to receive adequate relief of pain. Therefore, effective pain control was achieved in 42 of 68 of our initially referred patients (62%), Patients with failed back syndrome, trigeminal neuropathy, and peripheral neuropathy fared well with DBS, whereas those with thalamic pain, spinal cord injury, and postherpetic neuralgia did poorly. CONCLUSION: DBS in selected patients provides long-term effective pain control with few side effects or complications.	UNIV SASKATCHEWAN,NEUROSURG SECT,DEPT SURG,PLAINS HLTH CTR,REGINA,SK,CANADA							ADAMS J E, 1977, Applied Neurophysiology, V40, P111; ADAMS JE, 1974, J NEUROSURG, V41, P740, DOI 10.3171/jns.1974.41.6.0740; AKIL H, 1978, SCIENCE, V201, P468; BASKIN DS, 1986, BRAIN RES, V371, P231, DOI 10.1016/0006-8993(86)90358-6; CARLSSON AM, 1983, PAIN, V16, P87, DOI 10.1016/0304-3959(83)90088-X; DIECKMANN G, 1982, APPL NEUROPHYSIOL, V45, P167; DIONNE RA, 1984, PAIN, V20, P313, DOI 10.1016/0304-3959(84)90109-X; Emmers R., 1975, HUMAN SOMESTHETIC TH; FIELDS HL, 1974, BRAIN, V97, P169, DOI 10.1093/brain/97.1.169; FIELDS HL, 1979, ADV PAIN RES THER, V3, P427; HOSOBUCHI Y, 1980, PAIN, V9, P161, DOI 10.1016/0304-3959(80)90004-4; HOSOBUCHI Y, 1977, SCIENCE, V197, P183, DOI 10.1126/science.301658; HOSOBUCHI Y, 1973, ARCH NEUROL-CHICAGO, V29, P158, DOI 10.1001/archneur.1973.00490270040005; HOSOBUCHI Y, 1986, J NEUROSURG, V64, P543, DOI 10.3171/jns.1986.64.4.0543; Hosobuchi Y, 1993, Adv Neurol, V63, P215; HOSOBUCHI Y, 1987, PACE, V10, P213, DOI 10.1111/j.1540-8159.1987.tb05951.x; HOSOBUCHI Y, 1979, ADV PAIN RES THER, V3, P515; HOSOBUCHI Y, 1980, ACTA NEUROCHIR WIE S, V30, P79; HUGHES J, 1975, BRAIN RES, V88, P295, DOI 10.1016/0006-8993(75)90391-1; HUGHES J, 1975, OPIATE NARCOTICS NEU, P1; HUKKISON S, 1903, PAIN MEASUREMENT ASS, P33; KUMAR K, 1985, CAN J SURG, V28, P20; KUMAR K, 1990, NEUROSURGERY, V26, P774, DOI 10.1227/00006123-199005000-00007; KUMAR K, 1991, J NEUROSURG, V75, P402, DOI 10.3171/jns.1991.75.3.0402; KUMAR K, 1987, TRANSPLANT IMPLANT T, V4, P43; LEVY RM, 1987, NEUROSURGERY, V21, P885, DOI 10.1227/00006123-198712000-00017; MAYER DJ, 1984, PROG NEURO-PSYCHOPH, V8, P557, DOI 10.1016/0278-5846(84)90015-0; MAYER DJ, 1971, SCIENCE, V174, P1351, DOI 10.1126/science.174.4016.1351; MAZARS G, 1974, NEUROCHIRURGIE, V20, P117; Mazars G, 1979, ADV PAIN RES THER, V3, P541; Mazars G J, 1975, Surg Neurol, V4, P93; MELZACK R, 1978, PAIN, V4, P195, DOI 10.1016/0304-3959(77)90133-6; MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971; Melzack R., 1983, PAIN MEASUREMENT ASS, P41; Meyerson B A, 1980, Acta Neurochir Suppl (Wien), V30, P229; MEYERSON BA, 1983, ADV PAIN RES THER, V5, P495; MUNDINGER F, 1982, APPL NEUROPHYSIOL, V45, P102; NAMBA S, 1984, APPL NEUROPHYSIOL, V47, P137; NAMBA S, 1985, J NEUROSURG, V63, P224, DOI 10.3171/jns.1985.63.2.0224; NISHIMOTO A, 1984, APPL NEUROPHYSIOL, V47, P117; NORTH RB, 1994, NEUROSURGERY, V34, P756, DOI 10.1227/00006123-199404000-00031; O'Doherty, 1960, ELECTRICAL STUDIES U, P214; OJEMANN GA, 1980, CONT NEUROSURG, V2, P1; PILCHER WH, 1988, J NEUROSURG, V68, P621, DOI 10.3171/jns.1988.68.4.0621; PLOTKIN R, 1982, MODERN NEUROSURGERY, P454; POOL JL, 1956, HYPOTHALAMIC HYPOPHY, P114; PUDENZ RH, 1977, FUNCTIONAL ELECTRICA, P437; Ray C D, 1981, Clin Neurosurg, V28, P564; Ray C D, 1980, Acta Neurochir Suppl (Wien), V30, P289; RAY CD, 1982, APPL NEUROPHYSIOL, V45, P160; REYNOLDS DV, 1969, SCIENCE, V164, P444, DOI 10.1126/science.164.3878.444; RICHARDSON DE, 1995, NEUROSURG CLIN N AM, V6, P135; RICHARDSON DE, 1982, MODERN NEUROSURGERY, P449; RICHARDSON DE, 1977, J NEUROSURG, V41, P178; ROIZEN MF, 1985, ANESTHESIOLOGY, V62, P120, DOI 10.1097/00000542-198502000-00004; SIEGFRIED J, 1983, PAIN THERAPY, P463; TSUBOKAWA T, 1984, PAIN, V18, P115, DOI 10.1016/0304-3959(84)90879-0; TURNBULL IM, 1980, J NEUROSURG, V52, P486, DOI 10.3171/jns.1980.52.4.0486; Wahren W, 1977, ATLAS STEREOTAXY HUM; WHITE JC, 1969, PAIN NEUROSURGEON; YOUNG RF, 1987, J NEUROSURG, V66, P364, DOI 10.3171/jns.1987.66.3.0364; YOUNG RF, 1993, J NEUROSURG, V79, P816, DOI 10.3171/jns.1993.79.6.0816; YOUNG RF, 1985, J NEUROSURG, V62, P389, DOI 10.3171/jns.1985.62.3.0389; Young RF, 1994, TXB PAIN, P1225	64	217	227	0	18	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	APR	1997	40	4					736	746		10.1097/00006123-199704000-00015			11	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	WQ299	WOS:A1997WQ29900044	9092847				2021-06-18	
J	CLARK, RSB; SCHIDING, JK; KACZOROWSKI, SL; MARION, DW; KOCHANEK, PM				CLARK, RSB; SCHIDING, JK; KACZOROWSKI, SL; MARION, DW; KOCHANEK, PM			NEUTROPHIL ACCUMULATION AFTER TRAUMATIC BRAIN INJURY IN RATS - COMPARISON OF WEIGHT DROP AND CONTROLLED CORTICAL IMPACT MODELS	JOURNAL OF NEUROTRAUMA			English	Article							MYELOPEROXIDASE ACTIVITY; INFLAMMATION; ASSAY; INFILTRATION; TISSUE	Previous work in our laboratory and others using the weight drop (WD) model of traumatic brain injury (TBI) has shown that neutrophils accumulate in brain tissue during the initial 24 h posttrauma as measured by myeloperoxidase (MPO) activity and immunohistochemistry. This study compares the acute inflammatory response to TBI over time, as measured by MPO activity, in the WD and controlled cortical impact (CCI) models. Anesthetized adult Sprague-Dawley rats were traumatized using WD (10-g weight dropped 5 cm) or CCI (4 m/sec, 2.5 mm depth). At 2, 24, 48, or 168 h after trauma, rats (n = 4-5/group at each time) were anesthetized and killed, the brains were removed, and 6-mm coronal slices from traumatized and contralateral hemispheres were assayed for MPO activity. Nontraumatized rats (n = 4) served as controls. Three additional rats underwent a more severe CCI (3 mm depth) with MPO activity assayed at 24 h. A separate group of rats (n = 6) was subjected to WD trauma and killed at 2 weeks after injury for analysis of lesion volume. MPO activity in the traumatized hemisphere was demonstrated at 24 and 48 h in both the WD (0.3152 +/- 0.0472 and 0.3017 +/- 0.0228 U/g, respectively, p < 0.05 vs controls) and CCI (0.1866 +/- 0.0225 and 0.1937 +/- 0.0772 U/g, respectively, p < 0.05 vs controls) models. MPO activity was below the sensitivity of the assay in the control, 2 h, and 168 h groups in both models. MPO activity at 24 h after CCI increased with the depth of injury (0.1866 +/- 0.0225 vs 0.3011 +/- 0.0141 U/g, 2.5 vs 3.0 mm depth, respectively, p < 0.05). Lesion volume at 2 weeks after WD trauma was 16.0 +/- 2.7 mm(3), 17.5% larger than lesion volume after CCI (previously published data), but the difference between groups was not statistically significant. These data indicate that (1) MPO activity after traumatic brain injury is increased at 24 and 48 h and resolves by 168 h in both the WD and CCI models, and (2) MPO activity in the CCI model increases with the severity of trauma.	UNIV PITTSBURGH,SAFAR CTR RESUSCITAT RES,DEPT PEDIAT,PITTSBURGH,PA 15260; UNIV PITTSBURGH,SAFAR CTR RESUSCITAT RES,DEPT ANESTHESIOL & CRIT CARE MED,PITTSBURGH,PA; UNIV PITTSBURGH,SAFAR CTR RESUSCITAT RES,DEPT NEUROL SURG,PITTSBURGH,PA; UNIV PITTSBURGH,BRAIN TRAUMA RES CTR,PITTSBURGH,PA			Marion, Donald/AAR-5749-2021; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X			BARMAN TE, 1969, ENZYME HDB, V1, P234; BARONE FC, 1991, J NEUROSCI RES, V29, P336, DOI 10.1002/jnr.490290309; Biagas K. V., 1992, Society for Neuroscience Abstracts, V18, P1088; BIAGAS KV, 1992, J NEUROTRAUM, V9, P363, DOI 10.1089/neu.1992.9.363; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; CHEN H, 1993, J CEREBR BLOOD FL S1, V13, pS122; CLARK WM, 1991, STROKE, V22, P877, DOI 10.1161/01.STR.22.7.877; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; GRANERT C, 1994, J CLIN INVEST, V93, P929, DOI 10.1172/JCI117098; Horner H. C., 1992, Society for Neuroscience Abstracts, V18, P173; ISSEKUTZ AC, 1981, LAB INVEST, V45, P435; KOCHANEK PM, 1992, STROKE, V23, P1367, DOI 10.1161/01.STR.23.9.1367; KRAWISZ JE, 1984, GASTROENTEROLOGY, V87, P1344; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; MONTASSER A, 1994, J NEUROTRAUM, V11, P108; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PALMER AM, 1994, J NEUROTRAUM, V10, P363; PERSSON L, 1976, VIRCHOWS ARCH B, V22, P21; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; TATE RM, 1983, AM REV RESPIR DIS, V128, P552, DOI 10.1164/arrd.1983.128.3.552; TOUMANEN EI, 1989, J EXP MED, V170, P959; UHL MW, 1994, J NEUROTRAUM, V11, P303, DOI 10.1089/neu.1994.11.303; XU J, 1990, J NEUROCHEM, V55, P907, DOI 10.1111/j.1471-4159.1990.tb04577.x	26	217	222	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	1994	11	5					499	506		10.1089/neu.1994.11.499			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	PR237	WOS:A1994PR23700004	7861443				2021-06-18	
J	Ballard, C; Jones, E; Gauge, N; Aarsland, D; Nilsen, OB; Saxby, BK; Lowery, D; Corbett, A; Wesnes, K; Katsaiti, E; Arden, J; Amaoko, D; Prophet, N; Purushothaman, B; Green, D				Ballard, Clive; Jones, Emma; Gauge, Nathan; Aarsland, Dag; Nilsen, Odd Bjarte; Saxby, Brian K.; Lowery, David; Corbett, Anne; Wesnes, Keith; Katsaiti, Eirini; Arden, James; Amaoko, Derek; Prophet, Nicholas; Purushothaman, Balaji; Green, David			Optimised Anaesthesia to Reduce Post Operative Cognitive Decline (POCD) in Older Patients Undergoing Elective Surgery, a Randomised Controlled Trial	PLOS ONE			English	Article							MAJOR ABDOMINAL-SURGERY; TRAUMATIC BRAIN-INJURY; GENERAL-ANESTHESIA; ELDERLY-PATIENTS; NONCARDIAC SURGERY; BISPECTRAL INDEX; DYSFUNCTION; IMPAIRMENT; DEMENTIA; PREDICTION	Background: The study determined the one year incidence of post operative cognitive decline (POCD) and evaluated the effectiveness of an intra-operative anaesthetic intervention in reducing post-operative cognitive impairment in older adults (over 60 years of age) undergoing elective orthopaedic or abdominal surgery. Methods and Trial Design: The design was a prospective cohort study with a nested randomised, controlled intervention trial, using intra-operative BiSpectral index and cerebral oxygen saturation monitoring to enable optimisation of anaesthesia depth and cerebral oxygen saturation in older adults undergoing surgery. Results: In the 52 week prospective cohort study (192 surgical patients and 138 controls), mild (chi(2) = 17.9 p<0.0001), moderate (chi(2) = 7.8 p = 0.005) and severe (chi(2) = 5.1 p = 0.02) POCD were all significantly higher after 52 weeks in the surgical patients than among the age matched controls. In the nested RCT, 81 patients were randomized, 73 contributing to the data analysis (34 intervention, 39 control). In the intervention group mild POCD was significantly reduced at 1, 12 and 52 weeks (Fisher's Exact Test p = 0.018, chi(2) = 5.1 p = 0.02 and chi(2) = 5.9 p = 0.015), and moderate POCD was reduced at 1 and 52 weeks (chi(2) = 4.4 p = 0.037 and chi(2) = 5.4 p = 0.02). In addition there was significant improvement in reaction time at all time-points (Vigilance Reaction Time MWU Z = -2.1 p = 0.03, MWU Z = -2.7 p = 0.004, MWU Z = -3.0 p = 0.005), in MMSE at one and 52 weeks (MWU Z = -2.9 p = 0.003, MWU Z = -3.3 p = 0.001), and in executive function at 12 and 52 weeks (Trail Making MWU Z = -2.4 p =.0.018, MWU Z = -2.4 p = 0.019). Conclusion: POCD is common and persistent in older adults following surgery. The results of the nested RCT indicate the potential benefits of intra-operative monitoring of anaesthetic depth and cerebral oxygenation as a pragmatic intervention to reduce post-operative cognitive impairment.	[Ballard, Clive; Jones, Emma; Gauge, Nathan; Katsaiti, Eirini] Kings Coll London, Wolfson Ctr Age Related Dis, London WC2R 2LS, England; [Aarsland, Dag] Karolinska Inst, Dept Neurobiol Ward & Soc, Stockholm, Sweden; [Aarsland, Dag; Nilsen, Odd Bjarte] Stavanger Univ Hosp, Fac Sci & Technol, Stavanger, Norway; [Saxby, Brian K.] Univ Newcastle, Inst Ageing & Hlth, Newcastle, England; [Lowery, David] Univ London Univ Coll, Res Dept Primary Care & Populat Hlth, London, England; [Corbett, Anne] Alzheimers Soc UK, Res Directorate, London, England; [Wesnes, Keith] Swinburne Univ, Ctr Human Psychopharmacol, Melbourne, Vic, Australia; [Arden, James; Amaoko, Derek; Prophet, Nicholas; Purushothaman, Balaji; Green, David] Kings Coll Hosp London, Dept Anaesthet, London, England	Ballard, C (corresponding author), Kings Coll London, Wolfson Ctr Age Related Dis, London WC2R 2LS, England.	Clive.ballard@kcl.ac.uk	Wesnes, Keith A/D-7148-2018; Corbett, Anne/B-3223-2014; Saxby, Brian K/A-9903-2010	Corbett, Anne/0000-0003-2015-0316; Saxby, Brian K/0000-0003-2912-5176; Wesnes, Keith/0000-0002-4498-8511; Aarsland, Dag/0000-0001-6314-216X; Ballard, Clive/0000-0003-0022-5632	BUPA foundation	The authors would like to thank the BUPA foundation for supporting the project. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Avidan MS, 2011, J ALZHEIMERS DIS, V24, P201, DOI 10.3233/JAD-2011-101680; Ballard C, 2003, INT PSYCHOGERIATR, V15, P123, DOI 10.1017/S1041610203009074; BEDFORD PD, 1955, LANCET, V2, P259; Casati A, 2005, ANESTH ANALG, V101, P740, DOI 10.1213/01.ane.0000166974.96219.cd; Culley DJ, 2007, CURR OPIN ANESTHESIO, V20, P408, DOI 10.1097/ACO.0b013e3282efd18b; Farag E, 2006, ANESTH ANALG, V103, P633, DOI 10.1213/01.ane.0000228870.48028.b5; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Green DW, 2007, EUR J ANAESTH, V24, P230, DOI 10.1017/S0265021506001645; Howard R, 2011, INT J GERIATR PSYCH, V26, P812, DOI 10.1002/gps.2607; Johnson T, 2002, ANESTHESIOLOGY, V96, P1351, DOI 10.1097/00000542-200206000-00014; Kojima Y, 2006, ACTA ANAESTH SCAND, V50, P19, DOI 10.1111/j.1399-6576.2005.00882.x; Linstedt U, 2002, ACTA ANAESTH SCAND, V46, P384, DOI 10.1034/j.1399-6576.2002.460409.x; Lowery DP, 2007, DEMENT GERIATR COGN, V23, P390, DOI 10.1159/000101453; Lowery DP, 2008, INT J GERIATR PSYCH, V23, P1253, DOI 10.1002/gps.2059; Mitchell J, 2009, J NEUROL, V256, P1500, DOI 10.1007/s00415-009-5152-0; Moller JT, 1998, LANCET, V351, P857, DOI 10.1016/S0140-6736(97)07382-0; Myles PS, 2009, ANESTHESIOLOGY, V110, P1106, DOI 10.1097/ALN.0b013e31819daef6; Newman S, 2007, ANESTHESIOLOGY, V106, P572, DOI 10.1097/00000542-200703000-00023; Nylen K, 2008, ACTA NEUROCHIR, V150, P221, DOI 10.1007/s00701-007-1489-2; Perouansky M, 2009, ANESTHESIOLOGY, V111, P1365, DOI 10.1097/ALN.0b013e3181bf1d61; Petersen RC, 2004, J INTERN MED, V256, P183, DOI 10.1111/j.1365-2796.2004.01388.x; Price CC, 2008, ANESTHESIOLOGY, V108, P8, DOI 10.1097/01.anes.0000296072.02527.18; Punjasawadwong Y, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003843.pub2; Rasmussen LS, 2003, ACTA ANAESTH SCAND, V47, P260, DOI 10.1034/j.1399-6576.2003.00057.x; Ritchie K, 2001, NEUROLOGY, V56, P37, DOI 10.1212/WNL.56.1.37; Sanders RD, 2005, BEST PRACT RES-CLIN, V19, P461, DOI 10.1016/j.bpa.2005.01.005; Schneider G, 1997, EUR J ANAESTH, V14, P21, DOI 10.1097/00003643-199705001-00005; SIMPSON PM, 1991, INT J GERIATR PSYCH, V6, P95, DOI 10.1002/gps.930060208; Slater JP, 2009, ANN THORAC SURG, V87, P36, DOI 10.1016/j.athoracsur.2008.08.070; Steinmetz J, 2009, ANESTHESIOLOGY, V110, P548, DOI 10.1097/ALN.0b013e318195b569; Terrando N, 2010, P NATL ACAD SCI USA, V107, P20518, DOI 10.1073/pnas.1014557107; van Dijk D, 2000, J THORAC CARDIOV SUR, V120, P632, DOI 10.1067/mtc.2000.108901; Wan YJ, 2007, ANESTHESIOLOGY, V106, P436, DOI 10.1097/00000542-200703000-00007; Wan YJ, 2010, CRIT CARE MED, V38, P2190, DOI 10.1097/CCM.0b013e3181f17bcb; Wiesmann M, 2010, ACTA NEUROL SCAND, V121, P178, DOI 10.1111/j.1600-0404.2009.01196.x	35	216	226	0	44	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 15	2012	7	6							e37410	10.1371/journal.pone.0037410			9	Multidisciplinary Sciences	Science & Technology - Other Topics	959WX	WOS:000305350000006	22719840	DOAJ Gold, Green Published			2021-06-18	
J	Toplak, ME; Bucciarelli, S; Jain, U; Tannock, R				Toplak, Maggie E.; Bucciarelli, Stefania M.; Jain, Umesh; Tannock, Rosemary			Executive Functions: Performance-Based Measures and the Behavior Rating Inventory of Executive Function (BRIEF) in Adolescents with Attention Deficit/Hyperactivity Disorder (ADHD)	CHILD NEUROPSYCHOLOGY			English	Article						Executive function; Adolescents; Attention deficit; hyperactivity disorder (ADHD); Behavior Rating Inventory of Executive Function (BRIEF)	TRAUMATIC BRAIN-INJURY; LATENT VARIABLE ANALYSIS; INHIBITORY CONTROL; WORKING-MEMORY; CHILDREN; VALIDITY; DEFICIT; CHILDHOOD; PROFILES; SUBTYPES	Performance-based measures and ratings of executive functions were examined in a sample of adolescents with attention deficit/hyperactivity disorder (ADHD) and comparison controls. Performance-based measures of executive function included inhibition, working memory, set shifting, and planning, and ratings of these same executive functions were completed by parents and teachers. Adolescents with ADHD demonstrated lower executive function performance than controls and displayed elevated ratings on the executive function ratings by parents and teachers. Significant associations were obtained between the performance-based measures and the parent and teacher ratings, but each measure was not uniquely associated with its respective scale on the rating scales. When performance-based measures and ratings were examined as predictors of ADHD status, the parent and teacher ratings entered as significant predictors of ADHD status. Further commonality analyses indicated that performance-based measures accounted for little unique variance in predicting ADHD status and also displayed little overlap with the behavioral ratings. These findings highlight the diagnostic utility of behavioral ratings of executive function in predicting ADHD status; however, behavioral ratings should not be assumed to be a proxy for performance on measures of executive function in clinical practice.	[Toplak, Maggie E.] York Univ, Dept Psychol, Toronto, ON M3J 1P3, Canada; [Bucciarelli, Stefania M.] Univ Western Ontario, Dept Psychol, London, ON N6A 3K7, Canada; [Jain, Umesh] Univ Toronto, Ontario Inst Studies Educ, Ctr Addict & Mental Hlth, Toronto, ON M5S 1A1, Canada; [Tannock, Rosemary] Univ Toronto, Ontario Inst Studies Educ, Neurosci & Mental Hlth Res Program, SickKids Hosp,Dept Human Dev & Appl Psychol, Toronto, ON M5S 1A1, Canada	Toplak, ME (corresponding author), York Univ, Dept Psychol, 126 BSB,4700 Keele St, Toronto, ON M3J 1P3, Canada.	mtoplak@yorku.ca			National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R21-MH066393]; SickKids Psychiatry Endowment Fund; Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR); NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R21MH066393] Funding Source: NIH RePORTER	This research was supported in part by research grants from the National Institute of Mental Health (Grant R21-MH066393), SickKids Psychiatry Endowment Fund, and a Canadian Institutes of Health Research (CIHR) Fellowship granted to M. Toplak. The authors also thank Rebecca Stewart for assistance with data collection and data entry, Anne-Claude Bedard on advising regarding the procedures, scoring, and description of the stop task, and Dave Flora for statistical consultation.	American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Anderson VA, 2002, CHILD NEUROPSYCHOL, V8, P231, DOI 10.1076/chin.8.4.231.13509; Barkley RA, 2006, ATTENTION DEFICIT HY; Bodnar LE, 2007, CHILD NEUROPSYCHOL, V13, P345, DOI 10.1080/09297040600899867; Castellanos FX, 2006, TRENDS COGN SCI, V10, P117, DOI 10.1016/j.tics.2006.01.011; Conners CK., 1997, CONNERS RATING SCALE; Denckla MB, 2002, CHILD NEUROPSYCHOL, V8, P304, DOI 10.1076/chin.8.4.304.13512; Donders J, 2002, CHILD NEUROPSYCHOL, V8, P229, DOI 10.1076/chin.8.4.229.13508; Fischer M, 2005, DEV NEUROPSYCHOL, V27, P107, DOI 10.1207/s15326942dn2701_5; Gilotty L, 2002, CHILD NEUROPSYCHOL, V8, P241, DOI 10.1076/chin.8.4.241.13504; Gioia G. A., 2000, BRIEF BEHAV RATING I; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P249, DOI 10.1076/chin.8.4.249.13513; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P121, DOI 10.1076/chin.8.2.121.8727; Halperin JM, 2006, PSYCHOL BULL, V132, P560, DOI 10.1037/0033-2909.132.4.560; Huizinga M, 2006, NEUROPSYCHOLOGIA, V44, P2017, DOI 10.1016/j.neuropsychologia.2006.01.010; Jonsdottir S, 2006, ARCH CLIN NEUROPSYCH, V21, P383, DOI 10.1016/j.acn.2006.05.003; KAPLAN E, 1999, WISC 3 PI MANUAL; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; Logan GD, 1997, PSYCHOL SCI, V8, P60, DOI 10.1111/j.1467-9280.1997.tb00545.x; LOGAN GD, 1984, PSYCHOL REV, V91, P295, DOI 10.1037/0033-295X.91.3.295; Mahone EM, 2002, CHILD NEUROPSYCHOL, V8, P258, DOI 10.1076/chin.8.4.258.13510; Mahone EM, 2002, CHILD NEUROPSYCHOL, V8, P52, DOI 10.1076/chin.8.1.52.8719; Mahone EM, 2002, ARCH CLIN NEUROPSYCH, V17, P643, DOI 10.1016/S0887-6177(01)00168-8; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; Martel M, 2007, J AM ACAD CHILD PSY, V46, P1437, DOI 10.1097/chi.0b013e31814cf953; McCandless Stephen, 2007, J Atten Disord, V10, P381, DOI 10.1177/1087054706292115; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Nigg JT, 2005, BIOL PSYCHIAT, V57, P1224, DOI 10.1016/j.biopsych.2004.08.025; Pennington BF, 1996, J CHILD PSYCHOL PSYC, V37, P51, DOI 10.1111/j.1469-7610.1996.tb01380.x; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Riccio CA, 2006, ARCH CLIN NEUROPSYCH, V21, P657, DOI 10.1016/j.acn.2006.05.010; ROBBINS TW, 1994, DEMENTIA, V5, P266, DOI 10.1159/000106735; Rucklidge JJ, 2002, J CHILD PSYCHOL PSYC, V43, P988, DOI 10.1111/1469-7610.00227; Sagvolden T, 2005, BEHAV BRAIN SCI, V28, P397, DOI 10.1017/S0140525X05000075; Salimpoor V. N., 2006, DEV DISABILITIES B, V34, P15; Schachar R, 2000, J ABNORM CHILD PSYCH, V28, P227, DOI 10.1023/A:1005140103162; Seidman LJ, 2005, BIOL PSYCHIAT, V57, P1263, DOI 10.1016/j.biopsych.2004.11.019; Sergeant JA, 2002, BEHAV BRAIN RES, V130, P3, DOI 10.1016/S0166-4328(01)00430-2; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Silver CH, 2000, J HEAD TRAUMA REHAB, V15, P973, DOI 10.1097/00001199-200008000-00002; Slick DJ, 2006, CHILD NEUROPSYCHOL, V12, P181, DOI 10.1080/09297040600611320; Sonuga-Barke EJS, 2003, NEUROSCI BIOBEHAV R, V27, P593, DOI 10.1016/j.neubiorev.2003.08.005; Spreen O., 1998, COMPENDIUM NEUROPSYC; Stevens J, 2002, DEV NEUROPSYCHOL, V21, P117, DOI 10.1207/S15326942DN2102_1; Sullivan Jeremy R, 2007, J Atten Disord, V11, P398, DOI 10.1177/1087054707299399; Tabachnick B., 2001, USING MULTIVARIATE S; Toplak M, 2005, J ABNORM CHILD PSYCH, V33, P639, DOI 10.1007/s10802-005-6743-6; Tsujimoto S, 2007, EXP PSYCHOL, V54, P30, DOI 10.1027/1618-3169.54.1.30; Unsworth N, 2007, PSYCHOL BULL, V133, P1038, DOI 10.1037/0033-2909.133.6.1038; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; Wechsler D., 2011, WECHLSER ABBREVIATED; Wechsler D., 1991, WECHSLER INTELLIGENC; Wilkinson GS, 1993, WRAT 3 ADM MANUAL; Willcutt EG, 2005, BIOL PSYCHIAT, V57, P1336, DOI 10.1016/j.biopsych.2005.02.006; Williams BR, 1999, DEV PSYCHOL, V35, P205, DOI 10.1037/0012-1649.35.1.205	56	216	218	3	60	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0929-7049			CHILD NEUROPSYCHOL	Child Neuropsychol.		2009	15	1					53	72	PII 794041160	10.1080/09297040802070929			20	Clinical Neurology	Neurosciences & Neurology	384SS	WOS:000261765100005	18608232				2021-06-18	
J	Voss, HU; Ulug, AM; Dyke, JP; Watts, R; Kobylarz, EJ; McCandliss, BD; Heier, LA; Beattie, BJ; Hamacher, KA; Vallabhajosula, S; Goldsmith, SJ; Ballon, D; Giacino, JT; Schiff, ND				Voss, Henning U.; Ulug, Aziz M.; Dyke, Jonathan P.; Watts, Richard; Kobylarz, Erik J.; McCandliss, Bruce D.; Heier, Linda A.; Beattie, Bradley J.; Hamacher, Klaus A.; Vallabhajosula, Shankar; Goldsmith, Stanley J.; Ballon, Douglas; Giacino, Joseph T.; Schiff, Nicholas D.			Possible axonal regrowth in late recovery from the minimally conscious state	JOURNAL OF CLINICAL INVESTIGATION			English	Article							DIFFUSION-TENSOR; CORTICAL REORGANIZATION; FIBER TRACKING; BRAIN-INJURY; DEAFFERENTATION; MRI	We used diffusion tensor imaging (DTI) to study 2 patients with traumatic brain injury. The first patient recovered reliable expressive language after 19 years in a minimally conscious state (MCS); the second had remained in MCS for 6 years. Comparison of white matter integrity in the patients and 20 normal subjects using histograms of apparent diffusion constants and diffusion anisotropy identified widespread altered diffusivity and decreased anisotropy in the damaged white matter. These findings remained unchanged over an 18-month interval between 2 studies in the first patient. In addition, in this patient, we identified large, bilateral regions of posterior white matter with significantly increased anisotropy that reduced over 18 months. In contrast, notable increases in anisotropy within the midline cerebellar white matter in the second study correlated with marked clinical improvements in motor functions. This finding was further correlated with an increase in resting metabolism measured by PET in this subregion. Aberrant white matter structures were evident in the second patient's DTI images but were not clinically correlated. We propose that axonal regrowth may underlie these findings and provide a biological mechanism for late recovery. Our results are discussed in the context of recent experimental studies that support this inference.	Cornell Univ, Citigrp Biomed Imaging Ctr, Weill Med Coll, New York, NY 10021 USA; Cornell Univ, Dept Radiol, Weill Med Coll, New York, NY 10021 USA; Univ Canterbury, Dept Phys & Astron, Christchurch 1, New Zealand; Cornell Univ, Sackler Inst Dev Psychobiol, Weill Med Coll, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Neurooncol Lab, New York, NY 10021 USA; JFK Johnson Rehabil Inst, Edison, NJ USA	Voss, HU (corresponding author), Cornell Univ, Citigrp Biomed Imaging Ctr, Weill Med Coll, 516 E 72nd St, New York, NY 10021 USA.	hev2006@med.cornell.edu	Dyke, Jonathan P/AAX-4362-2020; Giacino, Joseph/AAF-1952-2021; Voss, Henning/C-2194-2009; Ulug, Aziz M/F-6592-2011; Beattie, Bradley J/K-8981-2012	Dyke, Jonathan P/0000-0001-7170-488X; Giacino, Joseph/0000-0002-7916-9698; Voss, Henning/0000-0003-2811-2074; Ulug, Aziz M/0000-0002-2315-0322; Beattie, Bradley J/0000-0001-9891-8271; Ballon, Douglas/0000-0002-7162-9020	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR000047, M01 RR00047] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000047] Funding Source: NIH RePORTER		Basser PJ, 2002, NMR BIOMED, V15, P456, DOI 10.1002/nbm.783; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; Bengtsson SL, 2005, NAT NEUROSCI, V8, P1148, DOI 10.1038/nn1516; Carmichael ST, 2005, EXP NEUROL, V193, P291, DOI 10.1016/j.expneurol.2005.01.004; Chklovskii DB, 2004, NATURE, V431, P782, DOI 10.1038/nature03012; Conturo TE, 1995, NMR BIOMED, V8, P307, DOI 10.1002/nbm.1940080706; Dancause N, 2005, J NEUROSCI, V25, P10167, DOI 10.1523/JNEUROSCI.3256-05.2005; Fins JJ, 2003, NAT REV NEUROSCI, V4, P323, DOI 10.1038/nrn1079; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Hallett M, 2005, J REHABIL RES DEV, V42, pXVII, DOI 10.1682/JRRD.2005.07.0126; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; McKinstry RC, 2002, CEREB CORTEX, V12, P1237, DOI 10.1093/cercor/12.12.1237; McMillan TM, 2004, BRAIN INJURY, V18, P935, DOI 10.1080/02699050410001675915; Mukherjee P, 2006, NEUROIMAG CLIN N AM, V16, P19, DOI 10.1016/j.nic.2005.11.004; Napieralski JA, 1996, J COMP NEUROL, V373, P484; Pajevic S, 1999, MAGNET RESON MED, V42, P526, DOI 10.1002/(SICI)1522-2594(199909)42:3<526::AID-MRM15>3.0.CO;2-J; Pearson PP, 2001, EXP BRAIN RES, V138, P8, DOI 10.1007/s002210100678; Peters A, 2003, J COMP NEUROL, V460, P238, DOI 10.1002/cne.10639; PONS TP, 1991, SCIENCE, V252, P1857, DOI 10.1126/science.1843843; Schiff ND, 2005, NEUROLOGY, V64, P514, DOI 10.1212/01.WNL.0000150883.10285.44; Schiff ND, 2002, BRAIN, V125, P1210, DOI 10.1093/brain/awf131; Voss HU, 2006, MAGN RESON IMAGING, V24, P231, DOI 10.1016/j.mri.2005.12.007; VOSS HU, 2005, P INT SOC MAG RESON, V13, P1368; VOSS HU, 2005, P INT SOC MAG RESON, V13, P11; Wakana S, 2004, RADIOLOGY, V230, P77, DOI 10.1148/radiol.2301021640; Watts R, 2003, MENT RETARD DEV D R, V9, P168, DOI 10.1002/mrdd.10077	26	216	223	0	19	AMER SOC CLINICAL INVESTIGATION INC	ANN ARBOR	2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA	0021-9738	1558-8238		J CLIN INVEST	J. Clin. Invest.	JUL	2006	116	7					2005	2011		10.1172/JCI27021			7	Medicine, Research & Experimental	Research & Experimental Medicine	062DN	WOS:000238924900033	16823492	Green Published, Bronze			2021-06-18	
J	Ponsford, J; Willmott, C; Rothwell, A; Cameron, P; Ayton, G; Nelms, R; Curran, C; Ng, K				Ponsford, J; Willmott, C; Rothwell, A; Cameron, P; Ayton, G; Nelms, R; Curran, C; Ng, K			Impact of early intervention on outcome after mild traumatic brain injury in children	PEDIATRICS			English	Article						mild head injury; mild traumatic brain injury; intervention; outcome	CLOSED-HEAD-INJURY; CONTROLLED TRIAL; SEQUELAE; AMNESIA; SCALE	Objectives. The impact of mild head injury or mild traumatic brain injury (TBI) in children is variable, and determinants of outcome remain poorly understood. There have been no previous attempts to evaluate the impact of interventions to improve outcome. Results of previous intervention studies in adults have been mixed. This study aimed to evaluate the impact of providing information on outcome measured in terms of reported symptoms, cognitive performance, and psychological adjustment in children 3 months after injury. Methods. A total of 61 children with mild TBI were assessed 1 week and 3 months after injury, and 58 children with mild TBI were assessed 3 months after injury only. They were compared with 2 control groups (N = 45 and 47) of children with minor injuries not involving the head. Participants completed measures of preinjury behavior and psychological adjustment, postconcussion symptoms, and tests of attention, speed of information processing, and memory. Children with mild TBI seen at 1 week were also given an information booklet outlining symptoms associated with mild TBI and suggested coping strategies. Those seen 3 months after injury only did not receive this booklet. Results. Children with mild TBI reported more symptoms than controls at 1 week but demonstrated no impairment on neuropsychological measures. Initial symptoms had resolved for most children by 3 months after injury, but a small group of children who had previous head injury or a history of learning or behavioral difficulties reported ongoing problems. The group not seen at 1 week and not given the information booklet reported more symptoms overall and was more stressed 3 months after injury. Conclusions. Providing an information booklet reduces anxiety and thereby lowers the incidence of ongoing problems.	Monash Univ, Melbourne, Vic 3004, Australia; Epworth Med Fdn, Bethesda Rehabil Unit, Melbourne, Vic, Australia; Julia Farr Serv, Adelaide, SA, Australia; Royal Melbourne Hosp, Melbourne, Vic, Australia; Western Hosp, Melbourne, Vic, Australia	Ponsford, J (corresponding author), Epworth Med Fdn, Dept Psychol, Bethesda Rehabil Unit, 30 Erin St, Richmond, Vic 3121, Australia.		Willmott, Catherine/AAA-5105-2019	Willmott, Catherine/0000-0001-8517-9035; Cameron, Peter/0000-0002-1443-557X			Achenbach TM, 1983, MANUAL CHILD BEHAV C; Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR; BERROL S, 1992, PHYSICAL MED REHABIL, V6, P1; Bijur P., 1995, TRAUMATIC HEAD INJUR; BOLL TJ, 1983, J CLIN CHILD PSYCHOL, V12, P74, DOI 10.1080/15374418309533114; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Daniel A. E., 1983, POWER PRIVILEGE PRES; Dunn L., 1981, PEABODY PICTURE VOCA; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; FARMER MY, 1987, PEDIATR NEUROSCI, V13, P304, DOI 10.1159/000120348; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Gronwall D, 1986, J HEAD TRAUMA REHAB, V1, P53, DOI DOI 10.1097/00001199-198606000-00009; GULBRANDSEN GB, 1984, J CLIN NEUROPSYCHOL, V6, P257, DOI 10.1080/01688638408401217; JOHNSON DA, 1988, J CHILD PSYCHOL PSYC, V29, P199, DOI 10.1111/j.1469-7610.1988.tb00704.x; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P74, DOI DOI 10.1097/00001199-199309000-00009; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; KRAUS JF, 1995, TRAUMATIC HEAD INJUR; Lawler KA, 1996, J HEAD TRAUMA REHAB, V11, P18, DOI 10.1097/00001199-199612000-00005; Levin HS, 1989, MILD HEAD INJURY; MAROSSZEKY NEV, 1993, CLIN NEUROPSYCHOL, V7, P85, DOI 10.1080/13854049308401890; MATEER CA, 1992, PHYSICAL MED REHABIL, V6, P143; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; PRIOER M, 1994, AUST PSYCHOL, V29, P116, DOI 10.1080/00050069408257334; RELANDER M, 1972, BMJ-BRIT MED J, V4, P777, DOI 10.1136/bmj.4.5843.777; ROWE KJ, 1993, ASSESSING EXTERNALIS; RUTTER M, 1983, DEV NEUROPSYCHIATRY; Sheslow D., 1990, WIDE RANGE ASSESSMEN; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Sparrow S., 1984, VINELAND ADAPTIVE BE; TAYLOR HG, 1987, J PEDIATR PSYCHOL, V12, P394; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; WECHSLER D, 1991, WECHSLER INTELLIGENC, V3	37	216	216	0	18	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	DEC	2001	108	6					1297	1303		10.1542/peds.108.6.1297			7	Pediatrics	Pediatrics	498EZ	WOS:000172498000028	11731651				2021-06-18	
J	Geddes, JF; Vowles, GH; Nicoll, JAR; Revesz, T				Geddes, JF; Vowles, GH; Nicoll, JAR; Revesz, T			Neuronal cytoskeletal changes are an early consequence of repetitive head injury	ACTA NEUROPATHOLOGICA			English	Article						head injury; chronic traumatic brain injury; neurofibrillary tangles; dementia pugilistica; hyperphosphorylation of tau	TRAUMATIC BRAIN INJURY; AMYLOID-BETA-PROTEIN; NONDISRUPTIVE AXONAL INJURY; PATHOLOGICAL TAU-PROTEINS; ALZHEIMERS-DISEASE; NEUROFIBRILLARY TANGLES; DEMENTIA-PUGILISTICA; IMMUNOREACTIVE NEURONS; PRECURSOR PROTEIN; CEREBRAL-ISCHEMIA	While neuropathological studies have established the pathology of dementia pugilistica to be similar to that of Alzheimer's disease, there is little information about the early histological changes caused by the repetitive trauma that eventually produces dementia pugilistica. We have examined the brains of four young men and a frontal lobectomy specimen from a fifth, age range 23-28 years, all of whom suffered mild chronic head injury. There were two boxers, a footballer, a mentally subnormal man with a long history of head banging, and an epileptic patient who repeatedly hit his head during seizures. The four autopsy cases were widely sampled; the lobectomy specimen was serially sliced after fixation. Routine stains were performed; immunostaining included P-amyloid precursor protein, amyloid beta-protein (A beta), tau and apolipoprotein E (apoE). Pathological findings in all five cases were of neocortical neurofibrillary tangles (NFTs) and neuropil threads, with groups of tangles consistently situated around blood vessels in the worst affected regions. No A beta immunoreactivity was detected. The amount of neuronal apoE expression varied widely between the cases with no clear relation to the NFTs. The apoE genotype was determined in only two cases (both epsilon 3/epsilon 3). It appears that repetitive head injury in young adults is initially associated with neocortical NFT formation in the absence of A beta deposition. The distribution of the tau pathology suggests that the pathogenesis of cytoskeletal abnormalities may involve damage to blood vessels or perivascular elements.	St Bartholomews & Royal London Sch Med & Dent, Dept Morbid Anat, London E1 1BB, England; Univ Glasgow, Inst Neurol Sci, Dept Neuropathol, Glasgow G51 4TF, Lanark, Scotland; Inst Neurol, Dept Neuropathol, London WC1N 3BG, England	Geddes, JF (corresponding author), St Bartholomews & Royal London Sch Med & Dent, Dept Morbid Anat, London E1 1BB, England.		Revesz, Tamas/A-8732-2010; Nicoll, James/I-9253-2017	Revesz, Tamas/0000-0003-2501-0259; Nicoll, James/0000-0002-9444-7246			Aotsuka A, 1990, Rinsho Shinkeigaku, V30, P1243; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; BRAAK E, 1994, ACTA NEUROPATHOL, V87, P554, DOI 10.1007/s004010050124; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; BueeScherrer V, 1997, ANN NEUROL, V42, P356, DOI 10.1002/ana.410420312; BUEESCHERRER V, 1995, AM J PATHOL, V146, P924; Cairns NJ, 1997, NEUROSCI LETT, V230, P49, DOI 10.1016/S0304-3940(97)00474-6; CASSON IR, 1984, JAMA-J AM MED ASSOC, V251, P2663, DOI 10.1001/jama.251.20.2663; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; DALE GE, 1991, J NEUROL NEUROSUR PS, V54, P116, DOI 10.1136/jnnp.54.2.116; Delacourte A, 1997, INT REV CYTOL, V171, P167; DEWAR D, 1994, DEMENTIA, V5, P168, DOI 10.1159/000106716; ELLIOTT EM, 1993, J NEUROCHEM, V61, P57, DOI 10.1111/j.1471-4159.1993.tb03537.x; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Geddes JF, 1996, NEUROPATH APPL NEURO, V22, P12, DOI 10.1111/j.1365-2990.1996.tb00840.x; GEDDES JW, 1994, J CEREBR BLOOD F MET, V14, P554, DOI 10.1038/jcbfm.1994.69; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; GENTLEMAN SM, 1993, PROG BRAIN RES, V96, P237; Green SL, 1997, NEUROCHEM INT, V31, P617, DOI 10.1016/S0197-0186(97)00012-0; HARVEY PKP, 1974, LANCET, V2, P928; HESTAD K, 1995, SCAND J PSYCHOL, V36, P246, DOI 10.1111/j.1467-9450.1995.tb00984.x; HIRANO A, 1962, ARCH NEUROL-CHICAGO, V7, P227, DOI 10.1001/archneur.1962.04210030065009; HOF PR, 1991, ACTA NEUROPATHOL, V82, P321, DOI 10.1007/BF00308819; HOF PR, 1992, ACTA NEUROPATHOL, V85, P23, DOI 10.1007/BF00304630; Hoshino S, 1998, NEUROREPORT, V9, P1879, DOI 10.1097/00001756-199806010-00039; Hyman BT, 1997, NEUROBIOL AGING, V18, pS27, DOI 10.1016/S0197-4580(97)00066-3; Irving EA, 1997, J CEREBR BLOOD F MET, V17, P612; Jafari SS, 1997, J NEUROCYTOL, V26, P207, DOI 10.1023/A:1018588114648; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kanayama G, 1996, METHOD FIND EXP CLIN, V18, P105; KASTE M, 1982, LANCET, V2, P1186; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Maxwell WL, 1995, J NEUROCYTOL, V24, P925, DOI 10.1007/BF01215643; MAXWELL WL, 1991, J NEUROCYTOL, V20, P157, DOI 10.1007/BF01186989; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MAXWELL WL, 1996, NEUROPATHOL APPL NEU, V22, P158; MCKENZIE JE, 1994, NEUROREPORT, V6, P161, DOI 10.1097/00001756-199412300-00041; MULOT SFC, 1994, FEBS LETT, V349, P359, DOI 10.1016/0014-5793(94)00702-0; Nicoll JAR, 1997, ANN NEUROL, V41, P716, DOI 10.1002/ana.410410607; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; Parker RS, 1996, J CLIN PSYCHOL, V52, P32, DOI 10.1002/(SICI)1097-4679(199601)52:1<32::AID-JCLP5>3.0.CO;2-Y; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; Revesz T, 1999, ACTA NEUROPATHOL, V97, P170, DOI 10.1007/s004010050970; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROBERTS GW, 1990, LANCET, V335, P918, DOI 10.1016/0140-6736(90)90520-F; ROBERTS GW, 1988, LANCET, V2, P1456; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Shackelford DA, 1996, J NEUROCHEM, V66, P286; Spillantini MG, 1996, ACTA NEUROPATHOL, V92, P42, DOI 10.1007/s004010050487; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P280, DOI 10.1007/BF00308813; TYSVAER A T, 1992, Tidsskrift for den Norske Laegeforening, V112, P1268; TYSVAER AT, 1989, AM J SPORT MED, V17, P573, DOI 10.1177/036354658901700421; UCHIHARA T, 1995, STROKE, V26, P2145, DOI 10.1161/01.STR.26.11.2145; WILBERGER JE, 1993, SPORTS MED, V15, P338, DOI 10.2165/00007256-199315050-00005; Williams DJ, 1996, PATHOLOGY, V28, P102, DOI 10.1080/00313029600169653; WISNIEWSKI HM, 1976, J NEUROPATH EXP NEUR, V35, P367; WRIGHTSON P, 1995, J NEUROL NEUROSUR PS, V59, P375, DOI 10.1136/jnnp.59.4.375; 1976, LANCET, V1, P401	63	216	218	2	17	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0001-6322			ACTA NEUROPATHOL	Acta Neuropathol.	AUG	1999	98	2					171	178		10.1007/s004010051066			8	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	220DD	WOS:000081648500009	10442557				2021-06-18	
J	Dixon, CE; Kochanek, PM; Yan, HQ; Schiding, JK; Griffith, RG; Baum, E; Marion, DW; DeKosky, ST				Dixon, CE; Kochanek, PM; Yan, HQ; Schiding, JK; Griffith, RG; Baum, E; Marion, DW; DeKosky, ST			One-year study of spatial memory performance, brain morphology, and cholinergic markers after moderate controlled cortical impact in rats	JOURNAL OF NEUROTRAUMA			English	Article						cholinergic; cortical impact; cortical lesions; M-2 muscarinic; rat; VAChT	FLUID-PERCUSSION INJURY; CLOSED-HEAD-INJURY; CELL LOSS; MODEL; ACETYLCHOLINE; IMPAIRMENT; LESIONS; ACETYLTRANSFERASE; DISSOCIATION; HIPPOCAMPUS	Persistent cognitive deficits are one of the most important sequelae of head injury in humans. In an effort to model some of the structural and neuropharmacological changes that occur in chronic postinjury brains, we examined the longitudinal effects of moderate vertical controlled cortical impact (CCI) on place learning and memory using the Morris water maze (MWM) test, morphology, and vesicular acetylcholine (ACh) transporter (VAChT) and muscarinic receptor subtype 2 (M-2) immunohistochemistry. Vertical CCI (left parietal cortex, 4 m/sec, 2.5 mm; n = 10) or craniotomy (sham) was produced in male Sprague-Dawley rats (n = 10). Place learning was tested at 2 weeks, 4 weeks, 3 months, 6 months, and 12 months postinjury with the escape platform in a different maze quadrant for each time point. At each interval, rats received 5 days of water maze acquisition (latency to find hidden platform), a probe trial to measure place memory, and 2 days of visible platform trials to control for nonspecific deficits. At 3 weeks, half the animals were sacrificed for histology. At these injury parameters, CCI produced no significant differences in place learning between injured and sham rats at 2 weeks, 4 weeks, or 6 months after injury. However, at 3 and 12 months, the injured rats took significantly longer to find the hidden platform than the sham rats. Probe trial performance differed only at 12 months postinjury between injured (25.73 +/- 2.1%, standard error of the mean) and sham rats (44.09 +/- 7.0%, p < 0.05). The maze deficits at 1 year were not due to a worsening of performance, but may have resulted from a reduced ability of injured rats to benefit from previous water maze experience. Hemispheric loss of 30.4 +/- 5.5 mm(3) was seen at 3 weeks after injury (versus respective sham). However, hemispheric loss almost doubled by 1 year after injury (51.5 +/- 8.5 mm(3), p < 0.05 versus all other groups). Progressive tissue loss was also reflected by a three- to fourfold increase in ipsilateral ventricular volume between 3 weeks and 1 year after injury. At 1 year after injury, immunostaining for VAChT was dramatically increased in all sectors of the hippocampus and cortex after injury. Muscarinic receptor subtype 2 (M-2) immunoreactivity was dramatically decreased in the ipsilateral hippocampus. This suggests ai compensatory response of cholinergic neurons to increase the efficiency of ACh neurotransmission. Moderate CCI in rats produces subtle MWM performance deficits accompanied by persistent alteration in M-2 and VAChT immunohistochemistry and progressive tissue atrophy. The inability of injured rats to benefit from repeated exposures to the MWM may represent a deficit in procedural memory that is independent of changes in hippocampal cholinergic systems.	Univ Pittsburgh, Med Ctr, Dept Neurosurg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Med Ctr, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Med Ctr, Dept Psychiat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Med Ctr, Dept Neurol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Med Ctr, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Med Ctr, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA	Dixon, CE (corresponding author), Univ Pittsburgh, Med Ctr, Dept Neurosurg, 3434 5th Ave,Ste 201, Pittsburgh, PA 15260 USA.	edixon@neuronet.pitt.edu	Kochanek, Patrick M/D-2371-2015; Marion, Donald/AAR-5749-2021	Kochanek, Patrick M/0000-0002-2627-913X; 	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS033150, P20NS030318, P50NS030318] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS33150, NS312296, NS30318] Funding Source: Medline		Anderson CV, 1995, J CLIN EXP NEUROPSYC, V17, P900, DOI 10.1080/01688639508402438; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; BERGERSWEENEY J, 1994, J NEUROSCI, V14, P4507; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Ciallella JR, 1998, EXP NEUROL, V152, P11, DOI 10.1006/exnr.1998.6831; DEKOSKY ST, 1985, NEUROBIOL AGING, V6, P277, DOI 10.1016/0197-4580(85)90004-1; DESALLES AAF, 1987, J NEUROSURG, V66, P102, DOI 10.3171/jns.1987.66.1.0102; Dewar D, 1996, J NEUROTRAUM, V13, P181, DOI 10.1089/neu.1996.13.181; DIXON CE, 1995, BEHAV BRAIN RES, V70, P125, DOI 10.1016/0166-4328(95)80002-6; DIXON CE, 1994, NEUROSCI LETT, V180, P127, DOI 10.1016/0304-3940(94)90503-7; Dixon CE, 1997, BRAIN RES, V749, P127, DOI 10.1016/S0006-8993(96)01310-8; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DOW RS, 1945, J NEUROPHYSIOL, V8, P161; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; GALE SD, 1995, J NEUROTRAUM, V12, P151, DOI 10.1089/neu.1995.12.151; Gorman LK, 1996, J NEUROTRAUM, V13, P457, DOI 10.1089/neu.1996.13.457; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; KATAYAMA Y, 1985, BRAIN RES, V334, P366, DOI 10.1016/0006-8993(85)90234-3; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; LEVEY AI, 1995, J NEUROSCI, V15, P4077; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MOSER E, 1993, J NEUROSCI, V13, P3916; Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295; NISSEN MJ, 1987, NEUROLOGY, V37, P789, DOI 10.1212/WNL.37.5.789; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PARKER SA, 1976, ACTA NEUROCHIR, V34, P71, DOI 10.1007/BF01405864; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Rouse ST, 1997, LIFE SCI, V60, P1031, DOI 10.1016/S0024-3205(97)00044-1; SCHMIDT RH, 1995, J NEUROSURG, V83, P496, DOI 10.3171/jns.1995.83.3.0496; SHAO L, UNPUB J NEUROTRAUMA; SINSON G, 1995, J NEUROCHEM, V65, P2209; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; SQUIRE LR, 1987, MEMORY BRAIN	44	216	221	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	1999	16	2					109	122		10.1089/neu.1999.16.109			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	173BA	WOS:000078960000001	10098956				2021-06-18	
J	Shahim, P; Tegner, Y; Wilson, DH; Randall, J; Skillback, T; Pazooki, D; Kallberg, B; Blennow, K; Zetterberg, H				Shahim, Pashtun; Tegner, Yelverton; Wilson, David H.; Randall, Jeffrey; Skillback, Tobias; Pazooki, David; Kallberg, Birgitta; Blennow, Kaj; Zetterberg, Henrik			Blood Biomarkers for Brain Injury in Concussed Professional Ice Hockey Players	JAMA NEUROLOGY			English	Article							NEURON-SPECIFIC ENOLASE; SERUM S-100B LEVELS; CEREBROSPINAL-FLUID; TRAUMA PATIENTS; INTERNATIONAL-CONFERENCE; TAU PROTEINS; HEAD; CSF; STATEMENT; DIAGNOSIS	IMPORTANCE Lack of objective biomarkers for brain damage hampers acute diagnosis and clinical decision making about return to play after sports-related concussion. OBJECTIVES To determine whether sports-related concussion is associated with elevated levels of blood biochemical markers of injury to the central nervous system and to assess whether plasma levels of these biomarkers predict return to play in professional ice hockey players with sports-related concussion. DESIGN, SETTING, AND PARTICIPANTS Multicenter prospective cohort study involving all 12 teams of the top professional ice hockey league in Sweden, the Swedish Hockey League. Two hundred eighty-eight professional ice hockey players from 12 teams contesting during the 2012-2013 season consented to participate. All players underwent clinical preseason baseline testing regarding concussion assessment measures. Forty-seven players from 2 of the 12 ice hockey teams underwent blood sampling prior to the start of the season. Thirty-five players had a concussion from September 13, 2012, to January 31, 2013; of these players, 28 underwent repeated blood sampling at 1, 12, 36, and 144 hours and when the players returned to play. MAIN OUTCOMES AND MEASURES Total tau, S-100 calcium-binding protein B, and neuron-specific enolase concentrations in plasma and serum were measured. RESULTS Concussed players had increased levels of the axonal injury biomarker total tau (median, 10.0 pg/mL; range, 2.0-102 pg/mL) compared with preseason values (median, 4.5 pg/mL; range, 0.06-22.7 pg/mL) (P <.001). The levels of the astroglial injury biomarker S-100 calcium-binding protein B were also increased in players with sports-related concussion (median, 0.075 mu g/L; range, 0.037-0.24 mu g/L) compared with preseason values (median, 0.045 mu g/L; range, 0.005-0.45 mu g/L) (P <.001). The highest biomarker concentrations of total tau and S-100 calcium-binding protein B were measured immediately after a concussion, and they decreased during rehabilitation. No significant changes were detected in the levels of neuron-specific enolase from preseason values (median, 6.5 mu g/L; range, 3.45-18.0 mu g/L) to postconcussion values (median, 6.1 mu g/L; range, 3.6-12.8 mu g/L) (P =.10). CONCLUSIONS AND RELEVANCE Sports-related concussion in professional ice hockey players is associated with acute axonal and astroglial injury. This can be monitored using blood biomarkers, which may be developed into clinical tools to guide sport physicians in the medical counseling of athletes in return-to-play decisions.	[Shahim, Pashtun; Skillback, Tobias; Blennow, Kaj; Zetterberg, Henrik] Univ Gothenburg, Sahlgrenska Univ Hosp, Sahlgrenska Acad, Clin Neurochem Lab,Inst Neurosci & Physiol, Molndal, Sweden; [Tegner, Yelverton] Lulea Univ Technol, Dept Hlth Sci, Div Med Sci, S-95187 Lulea, Sweden; [Wilson, David H.; Randall, Jeffrey] Quanterix Corp, Lexington, MA USA; [Pazooki, David] Sahlgrens Univ Hosp, Dept Surg, Gothenburg, Sweden; [Kallberg, Birgitta] Sahlgrens Univ Hosp, Clin Chem Lab, S-43180 Molndal, Sweden; [Zetterberg, Henrik] UCL, Inst Neurol, Dept Mol Neurosci, Reta Lila Weston Labs, London, England	Shahim, P (corresponding author), Sahlgrens Univ Hosp, Clin Neurochem Lab, S-43180 Molndal, Sweden.	pashtun.shahim@neuro.gu.se		Tegner, Yelverton/0000-0003-3628-0705; Skillback, Tobias/0000-0002-9114-0193	Swedish Medical Research CouncilSwedish Medical Research Council (SMRC)European Commission	This study was supported by grants from the Swedish Medical Research Council.	Alla S, 2011, BRIT J SPORT MED, V45, P132, DOI 10.1136/bjsm.2010.074088; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Bohmer AE, 2011, NEUROSURGERY, V68, P1624, DOI 10.1227/NEU.0b013e318214a81f; Chiaretti A, 2009, NEUROLOGY, V72, P609, DOI 10.1212/01.wnl.0000342462.51073.06; Cifu DX, 2014, ANN NEUROL, V75, P277, DOI 10.1002/ana.24067; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Ellenbogen RG, 2010, WORLD NEUROSURG, V74, P560, DOI 10.1016/j.wneu.2010.11.016; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Graham MR, 2011, INT J IMMUNOPATH PH, V24, P119, DOI 10.1177/039463201102400114; Hall RCW, 2005, PSYCHOSOMATICS, V46, P195, DOI 10.1176/appi.psy.46.3.195; Hesse Camilla, 2000, Journal of Alzheimer's Disease, V2, P199; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Jeppsson A, 2013, NEUROLOGY, V80, P1385, DOI 10.1212/WNL.0b013e31828c2fda; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mondello S, 2011, EXPERT REV MOL DIAGN, V11, P65, DOI 10.1586/ERM.10.104; Neselius S, 2013, BRAIN INJURY, V27, P425, DOI 10.3109/02699052.2012.750752; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Nylen K, 2006, NEUROSCI LETT, V404, P132, DOI 10.1016/j.neulet.2006.05.029; Ost M, 2006, NEUROLOGY, V67, P1600, DOI 10.1212/01.wnl.0000242732.06714.0f; Ramont L, 2005, CLIN CHEM LAB MED, V43, P1215, DOI 10.1515/CCLM.2005.210; Randall J, 2013, RESUSCITATION, V84, P351, DOI 10.1016/j.resuscitation.2012.07.027; Rissin DM, 2010, NAT BIOTECHNOL, V28, P595, DOI 10.1038/nbt.1641; Romner B, 2001, NEUROSURGERY, V49, P1490, DOI 10.1097/00006123-200112000-00053; Ross SA, 1996, BRIT J NEUROSURG, V10, P471, DOI 10.1080/02688699647104; Rothoerl RD, 2001, NEUROSURGERY, V49, P1490, DOI 10.1097/00006123-200112000-00054; SCARNA H, 1982, NEUROCHEM INT, V4, P405, DOI 10.1016/0197-0186(82)90083-3; Stalnacke BM, 2006, BRIT J SPORT MED, V40, P313, DOI 10.1136/bjsm.2005.021584; Stalnacke BM, 2003, CLIN J SPORT MED, V13, P292; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; TROJANOWSKI JQ, 1989, J HISTOCHEM CYTOCHEM, V37, P209, DOI 10.1177/37.2.2492045; Varma S, 2003, J NEUROTRAUM, V20, P781, DOI 10.1089/089771503767870005; Wu AHB, 1998, CLIN CHEM, V44, P1198; Zemlan FP, 2002, BRAIN RES, V947, P131, DOI 10.1016/S0006-8993(02)02920-7; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zetterberg H, 2009, BRAIN INJURY, V23, P723, DOI 10.1080/02699050903120399	43	215	216	1	40	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6149	2168-6157		JAMA NEUROL	JAMA Neurol.	JUN	2014	71	6					684	692		10.1001/jamaneurol.2014.367			9	Clinical Neurology	Neurosciences & Neurology	AN3IF	WOS:000340479800005	24627036	Bronze	Y	N	2021-06-18	
J	McCrory, P; Meeuwisse, W; Aubry, M; Cantu, R; Dvorak, J; Echemendia, RJ; Engebretsen, L; Johnston, K; Kutcher, JS; Raftery, M; Sills, A; Benson, BW; Davis, GA; Ellenbogen, RG; Guskiewicz, KM; Herring, SA; Iverson, G; Jordan, BD; Kissick, J; McCrea, M; McIntosh, AS; Maddocks, DL; Makdissi, M; Purcell, L; Putukian, M; Turner, M; Schneider, K; Tator, CH				McCrory, Paul; Meeuwisse, Willem; Aubry, Mark; Cantu, Robert; Dvorak, Jiri; Echemendia, Ruben J.; Engebretsen, Lars; Johnston, Karen; Kutcher, Jeffrey S.; Raftery, Martin; Sills, Allen; Benson, Brian W.; Davis, Gavin A.; Ellenbogen, Richard G.; Guskiewicz, Kevin M.; Herring, Stanley A.; Iverson, Grant; Jordan, Barry D.; Kissick, James; McCrea, Michael; McIntosh, Andrew S.; Maddocks, David L.; Makdissi, Michael; Purcell, Laura; Putukian, Margot; Turner, Michael; Schneider, Kathryn; Tator, Charles H.			Consensus Statement on Concussion in Sport-the 4th International Conference on Concussion in Sport Held in Zurich, November 2012	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; PROFESSIONAL FOOTBALL PLAYERS; HIGH-SCHOOL; HEAD-INJURY; POSTURAL CONTROL; LONG-TERM; POSTCONCUSSION SYNDROME; RECURRENT CONCUSSION; COGNITIVE IMPAIRMENT; CEREBRAL CONCUSSION		[McCrory, Paul] Florey Inst Neurosci & Mental Hlth, Heidelberg, Vic, Australia; [Meeuwisse, Willem] Univ Calgary, Fac Kinesiol, Sport Injury Prevent Res Ctr, Calgary, AB, Canada; [Meeuwisse, Willem] Univ Calgary, Fac Med, Hotchkiss Brain Inst, Calgary, AB, Canada; [Aubry, Mark] Ottawa Sport Med Ctr, Ottawa, ON, Canada; [Cantu, Robert] Boston Univ, Med Ctr, Ctr Study Traumat Encephalopathey, Boston, MA USA; [Dvorak, Jiri] Univ Zurich, CH-8006 Zurich, Switzerland; [Dvorak, Jiri] Schulthess Clin Zurich, Zurich, Switzerland; [Dvorak, Jiri] FMARC FIFA Med Assessment & Res Ctr, Zurich, Switzerland; [Echemendia, Ruben J.] Univ Missouri, Kansas City, KS USA; [Engebretsen, Lars] Univ Oslo, Oslo Univ Hosp, Dept Orthopaed, Oslo, Norway; [Engebretsen, Lars] Univ Oslo, Fac Med, Oslo, Norway; [Engebretsen, Lars] Oslo Sports Trauma Res Ctr, Oslo, Norway; [Engebretsen, Lars] Int Olymp Comm, Lausanne, Switzerland; [Johnston, Karen] Univ Toronto, Div Neurosurg, Toronto, ON M5S 1A1, Canada; [Johnston, Karen] Athlet Edge Sports Med,Toronto, Concuss Management Program, Toronto, ON, Canada; [Kutcher, Jeffrey S.] Univ Michigan, Dept Neurol, Ann Arbor, MI USA; [Raftery, Martin] Int Rugby Board, Dublin, Ireland; [Sills, Allen] Vanderbilt Univ, Med Ctr, Orthopaed Surg & Rehabil Vanderbilt Sports Concus, Nashville, TN USA; [Benson, Brian W.] Univ Calgary, Fac Med, Dept Clin Neurosci, Calgary, AB, Canada; [Benson, Brian W.] Univ Calgary, Fac Kinesiol, Dept Family Med, Calgary, AB, Canada; [Benson, Brian W.] Univ Calgary, Fac Kinesiol, Sport Med Ctr, Calgary, AB, Canada; [Davis, Gavin A.] Austin Cabrini Hosp, Dept Neurosurg, Melbourne, Vic, Australia; [Davis, Gavin A.] Florey Inst Neurosci & Mental Hlth, Melbourne, Vic, Australia; [Ellenbogen, Richard G.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Guskiewicz, Kevin M.] Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC USA; [Guskiewicz, Kevin M.] Univ N Carolina, Matthew Gfeller Sport Related Traumat Brain Injur, Chapel Hill, NC USA; [Herring, Stanley A.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Herring, Stanley A.] Univ Washington, Dept Orthopaed, Seattle, WA 98195 USA; [Herring, Stanley A.] Univ Washington, Dept Sports Med, Seattle, WA 98195 USA; [Herring, Stanley A.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Herring, Stanley A.] Seattle Seahawks & Seattle Mariners, Team Phys, Seattle Sports Concuss Program, Seattle, WA USA; [Iverson, Grant] Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada; [Jordan, Barry D.] Cornell Univ, Weill Med Coll, New York, NY 10021 USA; [Jordan, Barry D.] Burke Rehabil Hosp, White Plains, NY USA; [Kissick, James] Ottawa Sport Med Ctr, Ottawa, ON, Canada; [Kissick, James] Univ Ottawa, Dept Family Med, Ottawa, ON, Canada; [McCrea, Michael] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [McCrea, Michael] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; [McIntosh, Andrew S.] Monash Univ, Monash Injury Res Inst, Australian Ctr Res Injury Sports & Prevent, Clayton, Vic 3800, Australia; [McIntosh, Andrew S.] Univ New S Wales, Fac Sci, Sydney, NSW 2052, Australia; [McIntosh, Andrew S.] McIntosh Consultancy & Res Pty Ltd, Sydney, NSW, Australia; [Maddocks, David L.] Perry Maddocks Trollope Lawyers, Melbourne, Vic, Australia; [Makdissi, Michael] Melbourne Brain Ctr, Florey Inst Neurosci & Mental Hlth, Melbourne, Vic, Australia; [Maddocks, David L.] Univ Melbourne, Ctr Hlth Exercise & Sports Med, Melbourne, Vic, Australia; [Makdissi, Michael] Univ Melbourne, Physiotherapy Dept, Melbourne, Vic, Australia; [Purcell, Laura] McMaster Univ, Dept Pediat, Hamilton, ON, Canada; [Purcell, Laura] McMaster Univ, David Braley Sport Med & Rehabil Ctr, Hamilton, ON, Canada; [Putukian, Margot] Princeton Univ, Head Team Phys, Princeton, NJ 08544 USA; [Putukian, Margot] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Newark, NJ 07103 USA; [Schneider, Kathryn] Univ Calgary, Sport Injury Prevent Res Ctr, Calgary, AB, Canada; [Tator, Charles H.] Toronto Western Hosp, Toronto, ON M5T 2S8, Canada; [Tator, Charles H.] Univ Toronto, Toronto, ON M5S 1A1, Canada; [Turner, Michael] British Horseracing Author, London, England	McCrory, P (corresponding author), Melbourne Brain Ctr, Florey Inst Neurosci & Mental Hlth, Austin Campus,245 Burgundy St, Heidelberg, Vic 3084, Australia.	paulmccr@bigpond.net.au	Echemendia, Ruben/R-6939-2019; McCrory, Paul/Q-8688-2019	McCrory, Paul/0000-0003-4850-0568; Guskiewicz, Kevin/0000-0002-8682-2130; Echemendia, Ruben/0000-0001-6116-8462			Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; Anderson SD, 2004, CAN MED ASSOC J, V170, P16; Anderson SD, 2004, CMAJ; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bazarian JJ, 2001, CLIN PEDIATR, V40, P207, DOI 10.1177/000992280104000405; Begaz T, 2006, J NEUROTRAUM, V23, P1201, DOI 10.1089/neu.2006.23.1201; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Bleiberg Joseph, 2005, Neurosurgery, V56, pE1166; Bloom GA, 2004, BRIT J SPORT MED, V38, P519, DOI 10.1136/bjsm.2004.011999; Boutin D, 2008, NEUROCASE, V14, P239, DOI 10.1080/13554790802247543; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broshek DK, 2005, CLIN SPORT MED, V24, P663, DOI 10.1016/j.csm.2005.04.005; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cavanaugh JT, 2005, SPORTS MED, V35, P935, DOI 10.2165/00007256-200535110-00002; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Chen JK, 2004, CLIN J SPORT MED, V14, P379; Chen JK, 2004, BRIT J SPORT MED, V38, P659; Collie A, 2003, BRIT J SPORT MED, V37, P556, DOI 10.1136/bjsm.37.6.556; Collie A, 2003, BRIT J SPORT MED, V37, P2, DOI 10.1136/bjsm.37.1.2; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Curnow WJ, 2008, HEALTH PROMOT J AUST, V19, P10; Davidhizar R, 2002, Accid Emerg Nurs, V10, P149, DOI 10.1054/aaen.2002.0365; Davidson JA, 2005, EUR J EMERG MED, V12, P24, DOI 10.1097/00063110-200502000-00007; Lima DPD, 2008, INJURY, V39, P604, DOI 10.1016/j.injury.2007.11.008; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; de Boussard CN, 2005, J REHABIL MED, V37, P53, DOI 10.1080/16501970410015587; Delaney JS, 2008, BRIT J SPORT MED, V42, P110, DOI 10.1136/bjsm.2007.037689; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Denke NJ, 2008, J EMERG NURS, V34, P363, DOI 10.1016/j.jen.2008.04.013; Dvorak J, 2007, BRIT J SPORT MED, V41, pI44, DOI 10.1136/bjsm.2007.037960; Dvorak J, 2007, BRIT J SPORT MED, V41, DOI 10.1136/bjsm.2007.039362; Eckner JT, 2012, PSYCHOL ASSESSMENT, V24, P249, DOI 10.1037/a0025042; Eckner JT, 2011, J ATHL TRAINING, V46, P409; Finch C, 2005, INJURY PREV, V11, P242, DOI 10.1136/ip.2004.006882; Finch C, 2000, SPORT HLTH, V18, P35; Finch C, 1993, 51 MON U ACC RES CTR; Finch CF, 2003, J SCI MED SPORT, V6, P505, DOI 10.1016/S1440-2440(03)80275-X; Finch CF, 2001, BRIT J SPORT MED, V35, P89, DOI 10.1136/bjsm.35.2.89; Fleminger S, 2008, EUR J ANAESTH, V25, P123, DOI 10.1017/S0265021507003250; Fox ZG, 2008, J ATHL TRAINING, V43, P456, DOI 10.4085/1062-6050-43.5.456; FUKUHARA T, 1994, BRAIN RES, V657, P333, DOI 10.1016/0006-8993(94)90987-3; Gabbe B, 2003, J SCI MED SPORT, V6, P231, DOI 10.1016/S1440-2440(03)80259-1; Gaetz M, 2000, BRAIN INJURY, V14, P815; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gianotti S, 2007, NEUROREHABILITATION, V22, P181; Gioia G, 2004, BRIT J SPORT MED, V38, P657; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Guilmette TJ, 2007, BRAIN INJURY, V21, P1039, DOI 10.1080/02699050701633080; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hagel B, 2004, CLIN J SPORT MED, V14, P193, DOI 10.1097/00042752-200407000-00001; Hagel BE, 2005, BRIT MED J, V330, P281, DOI 10.1136/bmj.38314.480035.7C; Hang CH, 2006, BRAIN RES, V1109, P14, DOI 10.1016/j.brainres.2006.06.045; Hansen Kari Schroder, 2003, Traffic Inj Prev, V4, P285, DOI 10.1080/714040486; Hayden MG, 2007, CHILD NERV SYST, V23, P431, DOI 10.1007/s00381-006-0277-2; Hewson Paul J, 2005, Traffic Inj Prev, V6, P127, DOI 10.1080/15389580590931590; Hinkle DA, 1997, J NEUROTRAUM, V14, P729, DOI 10.1089/neu.1997.14.729; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; JENNETT B, 1975, LANCET, V1, P480; Johnston Karen M, 2004, Curr Sports Med Rep, V3, P316; Johnston KM, 2001, J AM COLL SURGEONS, V192, P515, DOI 10.1016/S1072-7515(01)00797-9; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; Kashluba S, 2004, ARCH CLIN NEUROPSYCH, V19, P805, DOI 10.1016/j.acn.2003.09.005; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Kristman VL, 2008, CLIN J SPORT MED, V18, P322, DOI 10.1097/JSM.0b013e31817e6f3e; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; Lee LK, 2007, PEDIATR EMERG CARE, V23, P580, DOI 10.1097/PEC.0b013e31813444ea; Lee Michael A, 2006, Conn Med, V70, P377; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Lovell Mark R, 2002, Curr Sports Med Rep, V1, P7; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Ma M, 2008, AM J EMERG MED, V26, P763, DOI 10.1016/j.ajem.2007.10.029; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MADDOCKS D, 1989, SPORT HLTH S, V7, P6; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; McCrea M., 2000, STANDARDIZED ASSESSM; McCrory P, 2004, CLIN J SPORT MED, V14, P139, DOI 10.1097/00042752-200405000-00006; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2002, BRIT J SPORT MED, V36, P316, DOI 10.1136/bjsm.36.5.316; McCrory P, 2002, BRIT J SPORT MED, V36, P314, DOI 10.1136/bjsm.36.5.314; McCrory P, 2002, BRIT J SPORT MED, V36, P3, DOI 10.1136/bjsm.36.1.3; McCrory P, 2011, CLIN J SPORT MED, V21, P6, DOI 10.1097/JSM.0b013e318204db50; McCrory P, 2011, CLIN SPORT MED, V30, P201, DOI 10.1016/j.csm.2010.08.002; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; McCrory PR, 2000, NEUROLOGY, V54, P1488, DOI 10.1212/WNL.54.7.1488; McCrory PR, 1997, BRIT MED J, V314, P171, DOI 10.1136/bmj.314.7075.171; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; McIntosh A, 2005, RUGBY HEADGEAR STUDY; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; McIntosh AS, 2000, BRIT J SPORT MED, V34, P337, DOI 10.1136/bjsm.34.5.337; McIntosh AS, 2001, BRIT J SPORT MED, V35, P167, DOI 10.1136/bjsm.35.3.167; McKee AC, 2010, J NEUROPATHOL EXP NE; McKee AC, 2012, BRAIN; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Mueller BA, 2008, EPIDEMIOLOGY, V19, P270, DOI 10.1097/EDE.0b013e318163567c; Nandoe RDS, 2002, J ALZHEIMERS DIS, V4, P303, DOI 10.3233/JAD-2002-4405; Nordqvist ACS, 1996, MOL BRAIN RES, V38, P285; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Pellman EJ, 2003, NEUROSURGERY, V53, P797, DOI 10.1093/neurosurgery/53.3.797; Peng Rui-yun, 2003, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V15, P213; Ptito A, 2007, NEUROREHABILITATION, V22, P217; Purcell L, 2008, CLIN PEDIATR, V47, P106, DOI 10.1177/0009922807306053; Reece RM, 2000, ARCH PEDIAT ADOL MED, V154, P11; Rousseff R T, 2006, Electromyogr Clin Neurophysiol, V46, P275; Schnadower D, 2007, CURR OPIN PEDIATR, V19, P258, DOI 10.1097/MOP.0b013e3281084e85; Shaw NH, 2004, CAN MED ASSOC J, V170, P15; Stalnacke BM, 2004, BRAIN INJURY, V18, P899, DOI 10.1080/02699050410001671865; Stalnacke BM, 2003, CLIN J SPORT MED, V13, P292; STERN MB, 1991, MOVEMENT DISORD, V6, P95, DOI 10.1002/mds.870060202; Sulheim S, 2006, JAMA-J AM MED ASSOC, V295, P919, DOI 10.1001/jama.295.8.919; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Terrell TR, 2008, CLIN J SPORT MED, V18, P10, DOI 10.1097/JSM.0b013e31815c1d4c; Theye Fred, 2004, Clin Med Res, V2, P165; Townend W, 2006, INJURY, V37, P1098, DOI 10.1016/j.injury.2006.07.014; Vagnozzi R, 2007, NEUROSURGERY, V61, P388, DOI DOI 10.1227/01.NEU.0000280002.41696; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Viano DC, 2006, NEUROSURGERY, V59, P591, DOI 10.1227/01.NEU.0000231851.97287.C2; Weiss MR, 2005, RES Q EXERCISE SPORT, V76, pS71, DOI 10.1080/02701367.2005.10599291; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; YARNELL PR, 1973, NEUROLOGY, V23, P196, DOI 10.1212/WNL.23.2.196; YARNELL PR, 1970, LANCET, V1, P863; Yunoki M, 1998, ACT NEUR S, V71, P142	157	215	215	0	38	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAR	2013	23	2					89	117		10.1097/JSM.0b013e31828b67cf			29	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	106CS	WOS:000316119800004	23478784	Green Accepted	Y	N	2021-06-18	
J	Zetterberg, H; Hietala, MA; Jonsson, M; Andreasen, N; Styrud, E; Karlsson, I; Edman, A; Popa, C; Rasulzada, A; Wahlund, LO; Mehta, PD; Rosengren, L; Blennow, K; Wallin, A				Zetterberg, Henrik; Hietala, M. Albert; Jonsson, Michael; Andreasen, Niels; Styrud, Ewa; Karlsson, Ingvar; Edman, Ake; Popa, Cornel; Rasulzada, Abdullah; Wahlund, Lars-Olof; Mehta, Pankaj D.; Rosengren, Lars; Blennow, Kaj; Wallin, Anders			Neurochemical aftermath of amateur boxing	ARCHIVES OF NEUROLOGY			English	Article							FIBRILLARY ACIDIC PROTEIN; HUMAN CEREBROSPINAL-FLUID; TRAUMATIC BRAIN-INJURY; ALZHEIMER-DISEASE; TAU-PROTEIN; NEUROFILAMENT; CSF; SCLEROSIS; DAMAGE; ELISA	Background: Little solid information is available on the possible risks for neuronal injury in amateur boxing. Objective: To determine whether amateur boxing and severity of hits are associated with elevated levels of biochemical markers for neuronal injury in cerebrospinal fluid. Design: Longitudinal study. Setting: Referral center specializing in evaluation of neurodegenerative disorders. Participants: Fourteen amateur boxers(11 men and 3 women) and 10 healthy male nonathletic control subjects. Interventions: The boxers underwent lumbar puncture 7 to 10 days and 3 months after a bout. The control subjects underwent LP once. Main Outcome Measures: Neurofilament light protein, total tau, glial fibrillary acidic protein, phosphorylated tau, and beta-amyloid protein 1-40(A beta([1-40])) and 1-42(A beta([1-42])) concentrations in cerebrospinal fluid were measured. Results: Increased levels after a bout compared with after 3 months of rest from boxing were found for 2 markers for neuronal and axonal injury, neurofilament light protein (mean +/- SD, 845 +/- 1140 ng/L vs 208 +/- 108 ng/L; P=.008) and total tau (mean +/- SD, 449 +/- 176 ng/L vs 306 +/- 78 ng/L; P=.006), and for the astroglial injury marker glial fibrillary acidic protein (mean +/- SD, 541 +/- 199 ng/L vs 405 +/- 138 ng/L; P=.003). The increase was significantly higher among boxers who had received many hits (> 15) or high-impact hits to the head compared with boxers who reported few hits. In the boxers, concentrations of neurofilament light protein and glial fibrillary acidic protein, but not total tau, were significantly elevated after a bout compared with the nonathletic control subjects. With the exception of neurofilament light protein, there were no significant differences between boxers after 3 months of rest from boxing and the nonathletic control subjects. Conclusions: Amateur boxing is associated with acute neuronal and astroglial injury. If verified in longitudinal studies with extensive follow-up regarding the clinical outcome, analyses of cerebrospinal fluid may provide a scientific basis for medical counseling of athletes after boxing or head injury.	Univ Gothenburg, Sahlgrenska Acad, Dept Expt Neurosci, Gothenburg, Sweden; Univ Gothenburg, Sahlgrenska Acad, Dept Clin Chem, Gothenburg, Sweden; Univ Gothenburg, Sahlgrenska Acad, Dept Psychiat, Gothenburg, Sweden; Karolinska Univ Hosp, Karolinska Inst, Neurotec Dept, Sect Clin Geratr, Stockholm, Sweden; Inst Basic Res Dev Disabil, Dept Immunol, Staten Isl, NY USA	Zetterberg, H (corresponding author), Sahlgrens Univ Hosp, Sect Neurochem, Dept Expt Neurosci, S-43180 Molndal, Sweden.	henrik.zetterberg@clinchem.gu.se		Rosengren, Lars/0000-0003-0505-8896			Andreasen N, 1999, ARCH NEUROL-CHICAGO, V56, P673, DOI 10.1001/archneur.56.6.673; Blennow K, 1995, MOL CHEM NEUROPATHOL, V26, P231, DOI 10.1007/BF02815140; Blennow Kaj, 2004, NeuroRx, V1, P213, DOI 10.1602/neurorx.1.2.213; CASSON IR, 1984, JAMA-J AM MED ASSOC, V251, P2663, DOI 10.1001/jama.251.20.2663; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; FRIEDE RL, 1970, ANAT REC, V167, P379, DOI 10.1002/ar.1091670402; GOEDERT M, 1993, TRENDS NEUROSCI, V16, P460, DOI 10.1016/0166-2236(93)90078-Z; HAGLUND Y, 1993, AM J SPORT MED, V21, P97, DOI 10.1177/036354659302100117; Hansson O, 2006, LANCET NEUROL, V5, P228, DOI 10.1016/S1474-4422(06)70355-6; Hesse C, 2001, NEUROSCI LETT, V297, P187, DOI 10.1016/S0304-3940(00)01697-9; Hu YY, 2002, NEUROSCI LETT, V320, P156, DOI 10.1016/S0304-3940(02)00047-2; Hu YY, 2002, AM J PATHOL, V160, P1269, DOI 10.1016/S0002-9440(10)62554-0; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Kemp P L, 1995, J R Nav Med Serv, V81, P182; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; Mehta PD, 2000, ARCH NEUROL-CHICAGO, V57, P100, DOI 10.1001/archneur.57.1.100; Millspaugh J., 1937, US NAVAL MED B, V35, P297; Norgren N, 2004, NEUROLOGY, V63, P1586, DOI 10.1212/01.WNL.0000142988.49341.D1; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROSENGREN LE, 1994, J NEUROSCI METH, V51, P197, DOI 10.1016/0165-0270(94)90011-6; Rosengren LE, 1996, J NEUROCHEM, V67, P2013, DOI 10.1046/j.1471-4159.1996.67052013.x; Vanmechelen E, 2000, NEUROSCI LETT, V285, P49, DOI 10.1016/S0304-3940(00)01036-3	24	215	218	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0003-9942			ARCH NEUROL-CHICAGO	Arch. Neurol.	SEP	2006	63	9					1277	1280		10.1001/archneur.63.9.1277			4	Clinical Neurology	Neurosciences & Neurology	083DG	WOS:000240435500010	16966505	Bronze			2021-06-18	
J	Iverson, GL; Brooks, BL; Collins, MW; Lovell, MR				Iverson, GL; Brooks, BL; Collins, MW; Lovell, MR			Tracking neuropsychological recovery following concussion in sport	BRAIN INJURY			English	Article						concussion; mild traumatic brain injury; outcome; sports	COLLEGIATE FOOTBALL PLAYERS; TRUAX RELIABLE CHANGE; PROFESSIONAL FOOTBALL; HIGH-SCHOOL; CLINICAL-SIGNIFICANCE; COGNITIVE IMPAIRMENT; INTERPRETING CHANGE; CLASSICAL APPROACH; STANDARD ERROR; JACOBSON	Primary objective: The purpose of this study was to illustrate the serial use of computerized neuropsychological screening with ImPACT to monitor recovery in a clinical case series of injured athletes. Methods and procedures: Amateur athletes with concussions ( n = 30, average age = 16.1, SD = 2.1 years) underwent pre-season testing and three post-concussion evaluations within the following intervals: 1 - 2 days, 3 - 7 days ( M = 5.2 days) and 1 - 3 weeks ( M = 10.3 days). The study selection criteria increased the probability of including athletes with slow recovery. Results: Repeated measures ANOVAs revealed significant main effects for all five composite scores ( verbal memory, visual memory, reaction time, processing speed and total symptoms). In group analyses, performance decrements and symptoms relating to concussion appeared to largely resolve by 5 days post-injury and fully resolve by 10 days. Athletes' scores were examined individually using the reliable change methodology. At 1 day post-injury, 90% had two or more reliable declines in performance or increases in symptom reporting. At 10 days, 37% were still showing two or more reliable changes from pre-season levels. Conclusions: This study illustrates the importance of analysing individual athletes' test data because group analyses can obscure slow recovery in a substantial minority of athletes.	Univ British Columbia, Dept Psychiat, Vancouver, BC V6T 2A1, Canada; Riverview Hosp, Vancouver, BC, Canada; Univ Calgary, Calgary, AB, Canada; Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15260 USA	Iverson, GL (corresponding author), Univ British Columbia, Dept Psychiat, 2255 Wesbrook Mall, Vancouver, BC V6T 2A1, Canada.	giverson@interchange.ubc.ca		Iverson, Grant/0000-0001-7348-9570; Brooks, Brian/0000-0002-5428-8375			Anastasi A., 1988, PSYCHOL TESTING; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Chelune GJ, 1993, NEUROPSYCHOLOGY, V7, P41, DOI DOI 10.1037/0894-4105.7.1.41; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Delaney JS, 2001, CLIN J SPORT MED, V11, P234, DOI 10.1097/00042752-200110000-00005; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; HAGEMAN WJJM, 1993, BEHAV RES THER, V31, P693, DOI 10.1016/0005-7967(93)90122-B; Hageman WJJM, 1999, BEHAV RES THER, V37, P1219; Heaton RK, 2001, ARCH CLIN NEUROPSYCH, V16, P75, DOI 10.1016/S0887-6177(99)00062-1; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; HSU LM, 1989, BEHAV ASSESS, V11, P459; Iverson GL, 2004, ARCH CLIN NEUROPSYCH, V19, P961; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Iverson GL, 2002, ARCH CLIN NEUROPSYCH, V17, P770; Iverson GL, 2001, PSYCHOL REP, V89, P457, DOI 10.2466/pr0.2001.89.2.457; Iverson GL, 2004, STUD NEUROPSYCHOL DE, P323; Iverson GL, 1998, INT J GERIATR PSYCH, V13, P661, DOI 10.1002/(SICI)1099-1166(1998100)13:10<661::AID-GPS838>3.0.CO;2-0; Iverson GL, 2001, ARCH CLIN NEUROPSYCH, V16, P183, DOI 10.1016/S0887-6177(00)00060-3; IVERSON GL, J CLIN EXPT NEUROPSY, V27, P683; IVERSON GL, 1999, J COGNITIVE REH 0720; Jacobson NS, 1999, J CONSULT CLIN PSYCH, V67, P300, DOI 10.1037/0022-006X.67.3.300; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; JACOBSON NS, 1988, BEHAV ASSESS, V10, P133; Janusz A, 2004, BRIT J SPORT MED, V38, P659; LOVELL M, IN PRESS APPL NEUROP; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Maassen GH, 2004, J INT NEUROPSYCH SOC, V10, P888, DOI 10.1017/S1355617704106097; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; Ogles B.M., 1996, ASSESSING OUTCOME CL; Pellman E, 2004, NEUROSURGERY, V55, P860, DOI 10.1227/01.NEU.0000137657.00146.7D; Pellman EJ, 2005, NEUROSURGERY, V56, P79, DOI 10.1227/01.NEU.0000150180.16552.8D; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Pellman EJ, 2004, NEUROSURGERY, V55, P1100, DOI 10.1227/01.NEU.0000147063.12873.F5; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P797, DOI 10.1093/neurosurgery/53.3.797; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; *PSYCH CORP, 1997, WAISIIIWMSIII TECHN; SPEER DC, 1995, J CONSULT CLIN PSYCH, V63, P1044, DOI 10.1037/0022-006X.63.6.1044; SPEER DC, 1992, J CONSULT CLIN PSYCH, V60, P402, DOI 10.1037/0022-006X.60.3.402; Speer DC, 1999, BEHAV RES THER, V37, P1203; Temkin NR, 1999, J INT NEUROPSYCH SOC, V5, P357, DOI 10.1017/S1355617799544068; Temkin NR, 2004, J INT NEUROPSYCH SOC, V10, P899, DOI 10.1017/S1355617704106115; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	61	215	216	0	41	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2006	20	3					245	252		10.1080/02699050500487910			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	021GT	WOS:000235972400004	16537266				2021-06-18	
J	Okonkwo, DO; Povlishock, JT				Okonkwo, DO; Povlishock, JT			An intrathecal bolus of cyclosporin A before injury preserves mitochondrial integrity and attenuates axonal disruption in traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						cyclosporin A; trauma; neuroprotection; membrane failure; permeability transition; permeability transition pore	CORTICAL IMPACT INJURY; RAT OPTIC-NERVE; PERMEABILITY TRANSITION; AXOLEMMAL PERMEABILITY; REPERFUSION INJURY; MEMORY DEFICITS; NEURONAL DEATH; ANOXIC INJURY; NITRIC-OXIDE; HEAD-INJURY	Traumatic brain injury evokes multiple axonal pathologies that contribute to the ultimate disconnection of injured axons. In severe traumatic brain injury, the axolemma is perturbed focally, presumably allowing for the influx of Ca2+ and initiation of Ca2+-sensitive, proaxotomy processes. Mitochondria in foci of axolemmal failure may act as Ca2+ sinks that sequester Ca2+ to preserve low cytoplasmic calcium concentrations. This Ca2+ load within mitochondria, however, may cause colloid osmotic swelling and loss of function by a Ca2+-induced opening of the permeability transition pore. Local failure of mitochondria, in turn, can decrease production of high-energy phosphates necessary to maintain membrane pumps and restore ionic balance in foci of axolemmal permeability change. The authors evaluated the ability of the permeability transition pore inhibitor cyclosporin A (CsA) to prevent mitochondrial swelling in injured axonal segments demonstrating altered axolemmal permeability after impact acceleration injury in rat. At the electron microscopic level, statistically fewer abnormal mitochondria were seen in traumatically injured axons from CsA-pretreated injured animals. Further, this mitochondrial protection translated into axonal protection in a second group of injured rats, whose brains were reacted with antibodies against amyloid precursor protein, a known marker of injured axons. Pretreatment with CsA significantly reduced the number of axons undergoing delayed axotomy, as evidenced by a decrease in the density of amyloid precursor protein-immunoreactive axons. Collectively, these studies demonstrate that CsA protects both mitochondria and the related axonal shaft, suggesting that this agent may be of therapeutic use in traumatic brain injury.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Div Neurosurg, Richmond, VA 23298 USA	Povlishock, JT (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Box 980-709, Richmond, VA 23298 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020193] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 20193] Funding Source: Medline		ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Balakirev MY, 1997, EUR J BIOCHEM, V246, P710, DOI 10.1111/j.1432-1033.1997.00710.x; BEGLEY DJ, 1990, J NEUROCHEM, V55, P1222, DOI 10.1111/j.1471-4159.1990.tb03128.x; BUCHAN A, 1990, J NEUROSCI, V10, P311; CHADHURI B, 1995, BIOCHEM BIOPH RES CO, V215, P781; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; DAWSON TM, 1993, P NATL ACAD SCI USA, V90, P9808, DOI 10.1073/pnas.90.21.9808; DAWSON TM, 1994, NEUROSCIENCE, V62, P569, DOI 10.1016/0306-4522(94)90389-1; DUCHEN MR, 1993, CARDIOVASC RES, V27, P1790, DOI 10.1093/cvr/27.10.1790; Folbergrova J, 1997, EXP BRAIN RES, V114, P44, DOI 10.1007/PL00005622; Gallant PE, 1997, J NEUROTRAUM, V14, P811, DOI 10.1089/neu.1997.14.811; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GEORGE EB, 1995, J NEUROSCI, V15, P6445; Gold BG, 1997, MOL NEUROBIOL, V15, P285, DOI 10.1007/BF02740664; GUNTER TE, 1990, AM J PHYSIOL, V258, P755; HALESTRAP AP, 1990, BIOCHEM J, V268, P153, DOI 10.1042/bj2680153; Halestrap AP, 1997, MOL CELL BIOCHEM, V174, P167, DOI 10.1023/A:1006879618176; Li PA, 1997, BRAIN RES, V753, P133, DOI 10.1016/S0006-8993(97)00005-X; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LOPACHIN RM, 1995, J NEUROSCI, V15, P6735; LoPachin RM, 1997, TOXICOL APPL PHARM, V143, P233, DOI 10.1006/taap.1997.8106; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Petit PX, 1997, MOL CELL BIOCHEM, V174, P185, DOI 10.1023/A:1006848205880; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Povlishock JT, 1996, ACT NEUR S, V66, P81; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; Sabatini DM, 1997, MOL NEUROBIOL, V15, P223, DOI 10.1007/BF02740635; SCHREIBER SL, 1992, IMMUNOL TODAY, V13, P136, DOI 10.1016/0167-5699(92)90111-J; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; SHIGA Y, 1992, BRAIN RES, V595, P145, DOI 10.1016/0006-8993(92)91465-Q; Siesjo BK, 1996, EUR J ANAESTH, V13, P247, DOI 10.1046/j.1365-2346.1996.00976.x; STEINER JP, 1992, NATURE, V358, P584, DOI 10.1038/358584a0; Steiner JP, 1996, MOL MED, V2, P325, DOI 10.1007/BF03401630; STONE J, 1997, 27 ANN M SOC NEUR, P2194; STYS PK, 1992, J NEUROSCI, V12, P430; Uchino H, 1995, ACTA PHYSIOL SCAND, V155, P469, DOI 10.1111/j.1748-1716.1995.tb09999.x; WAXMAN SG, 1994, BRAIN RES, V644, P197, DOI 10.1016/0006-8993(94)91680-2; WAXMAN SG, 1992, BRAIN RES, V547, P104; Xiong Y, 1997, J NEUROTRAUM, V14, P907, DOI 10.1089/neu.1997.14.907; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	46	215	220	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	APR	1999	19	4					443	451		10.1097/00004647-199904000-00010			9	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	263FP	WOS:000084115000010	10197514	Bronze			2021-06-18	
J	Clark, RSB; Chen, J; Watkins, SC; Kochanek, PM; Chen, MZ; Stetler, RA; Loeffert, JE; Graham, SH				Clark, RSB; Chen, J; Watkins, SC; Kochanek, PM; Chen, MZ; Stetler, RA; Loeffert, JE; Graham, SH			Apoptosis-suppressor gene bcl-2 expression after traumatic brain injury in rats	JOURNAL OF NEUROSCIENCE			English	Article						apoptosis; bcl-2; hippocampus; neuron; rat; traumatic brain injury	PROGRAMMED CELL-DEATH; CEREBRAL-ISCHEMIA; NEURONAL DEATH; IL-1-BETA-CONVERTING ENZYME; GERBIL HIPPOCAMPUS; PROTEIN EXPRESSION; IN-VIVO; C-MYC; BAX; IDENTIFICATION	Neuronal death after experimental traumatic brain injury (TBI) has features of both apoptosis and necrosis. Neurons in the peritrauma cortex, hippocampus, and dentate gyrus are particularly vulnerable. The apoptosis-suppressor gene bcl-2 is induced in brain after ischemia and epilepsy-induced injury and may serve to regulate neuronal death. We studied expression of bcl-2 mRNA and protein after experimental TBI in rats. To determine whether bcl-2 protein expression occurred in cells with evidence of apoptosis, triple-labeling studies were performed using (1) antibody against bcl-2, (2) bis-benzimide dye to examine gross nuclear morphology, and (3) terminal deoxynucleotidyl transferase-mediated biotin-dUTP nick-end labeling (TUNEL) to assess for DNA fragmentation. At 6 and 24 hr, bcl-2 mRNA was induced in ipsilateral peritrauma cortex, hippocampus, and dentate gyrus. By 72 hr the increase in bcl-2 mRNA was detected only in cortex. bcl-2 protein was induced at 8, 24, 72, and 168 hr in ipsilateral cortex and hippocampus. Cells expressing bcl-2 protein included neurons in the peritrauma cortex, hippocampus, hilus, and dentate gyrus. The gross nuclear morphology of neurons expressing bcl-2 appeared normal. Furthermore, biochemical evidence of DNA fragmentation, in a pattern characteristic of either apoptosis or necrosis, was seldom seen in neurons expressing bcl-2 protein (bcl-2 colocalized with TUNEL in 0-2% of TUNEL-positive cells observed). These data suggest that bcl-2 may play an important role in the regulation of neuronal death after TBI, and they support a role for bcl-2 as an inducible neuroprotective gene.	UNIV PITTSBURGH, DEPT NEUROL, PITTSBURGH, PA 15261 USA; UNIV PITTSBURGH, DEPT ANESTHESIOL & CRIT CARE MED, PITTSBURGH, PA 15261 USA; UNIV PITTSBURGH, DEPT PEDIAT, PITTSBURGH, PA 15261 USA; UNIV PITTSBURGH, DEPT CELL BIOL & PHYSIOL, PITTSBURGH, PA 15261 USA; UNIV PITTSBURGH, SAFAR CTR RESUSCITAT RES, PITTSBURGH, PA 15261 USA; UNIV PITTSBURGH, BRAIN TRAUMA RES CTR, PITTSBURGH, PA 15261 USA; DEPT VET AFFAIRS MED CTR, NEUROL SERV, PITTSBURGH, PA 15261 USA				watkins, simon/0000-0003-4092-1552; Kochanek, Patrick/0000-0002-2627-913X	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5P30 HD28836] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [2P50 NS30318-04A1, 1KO8 NS01946] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD028836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS001946, P50NS030318] Funding Source: NIH RePORTER		ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; BATISTATOU A, 1993, J NEUROSCI, V13, P4422; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CharriautMarlangue C, 1995, NEUROREPORT, V7, P61, DOI 10.1097/00001756-199512000-00014; CHEN J, 1995, NEUROREPORT, V6, P394, DOI 10.1097/00001756-199501000-00040; Chen J, 1996, J NEUROCHEM, V67, P64; Chen J, 1997, J CEREBR BLOOD F MET, V17, P2, DOI 10.1097/00004647-199701000-00002; CHREST FJ, 1993, CYTOMETRY, V14, P883, DOI 10.1002/cyto.990140806; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DESHPANDE J, 1992, EXP BRAIN RES, V88, P91, DOI 10.1007/BF02259131; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FERNANDEZSARABIA MJ, 1993, NATURE, V366, P274, DOI 10.1038/366274a0; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GENARO AM, 1995, J CLIN INVEST, V95, P1884, DOI 10.1172/JCI117869; GONZALEZGARCIA M, 1995, P NATL ACAD SCI USA, V92, P4304, DOI 10.1073/pnas.92.10.4304; GOTTSCHALK AR, 1994, P NATL ACAD SCI USA, V91, P7350, DOI 10.1073/pnas.91.15.7350; Graham SH, 1996, RESTOR NEUROL NEUROS, V9, P243, DOI 10.3233/RNN-1996-9407; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOCKENBERY DM, 1995, BIOESSAYS, V17, P631, DOI 10.1002/bies.950170709; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; KANE DJ, 1995, J NEUROSCI RES, V40, P269, DOI 10.1002/jnr.490400216; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; KRAJEWSKI S, 1995, J NEUROSCI, V15, P6364; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Lawrence MS, 1996, J NEUROSCI, V16, P486; LEBRUN DP, 1993, AM J PATHOL, V142, P743; LI Y, 1995, J CEREBR BLOOD F MET, V15, P389, DOI 10.1038/jcbfm.1995.49; LINNIK MD, 1995, STROKE, V26, P1670, DOI 10.1161/01.STR.26.9.1670; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; MARVEL J, 1994, ONCOGENE, V9, P1117; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NEGRINI M, 1987, CELL, V49, P455, DOI 10.1016/0092-8674(87)90448-X; NITATORI T, 1995, J NEUROSCI, V15, P1001; NOVACK DV, 1994, AM J PATHOL, V145, P61; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PorteraCailliau C, 1997, J COMP NEUROL, V378, P88, DOI 10.1002/(SICI)1096-9861(19970203)378:1<88::AID-CNE5>3.0.CO;2-G; PorteraCailliau C, 1997, J COMP NEUROL, V378, P70; PREHN JHM, 1994, P NATL ACAD SCI USA, V91, P12599, DOI 10.1073/pnas.91.26.12599; RINK A, 1995, AM J PATHOL, V147, P1575; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; SATO T, 1994, GENE, V140, P291, DOI 10.1016/0378-1119(94)90561-4; SAUNDERS JW, 1966, SCIENCE, V154, P604, DOI 10.1126/science.154.3749.604; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; SHIMAZAKI K, 1994, NEUROSCI RES, V20, P95, DOI 10.1016/0168-0102(94)90026-4; Srinivasan A, 1996, J NEUROSCI, V16, P5654; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wu DY, 1997, SCIENCE, V275, P1126, DOI 10.1126/science.275.5303.1126; Yakovlev A. G., 1996, Society for Neuroscience Abstracts, V22, P20; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YOUNG W, 1992, J NEUROTRAUM, V9, pS9; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533	63	215	242	1	5	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	DEC 1	1997	17	23					9172	9182					11	Neurosciences	Neurosciences & Neurology	YG470	WOS:A1997YG47000025	9364064				2021-06-18	
J	MARON, BJ; POLIAC, LC; KAPLAN, JA; MUELLER, FO				MARON, BJ; POLIAC, LC; KAPLAN, JA; MUELLER, FO			BLUNT IMPACT TO THE CHEST LEADING TO SUDDEN-DEATH FROM CARDIAC-ARREST DURING SPORTS ACTIVITIES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LONG-QT SYNDROME; COMMOTIO-CORDIS; MYOCARDIAL-INFARCTION; YOUNG-ADULTS	Background. Sudden death from cardiac arrest in a young person may occur during sports play after a blunt blow to the chest in the absence of structural cardiovascular disease or traumatic injury (cardiac concussion or commotio cordis). We studied the clinical features of this apparently uncommon but important phenomenon. Methods. We identified cases from the registries of relevant agencies and organizations, as well as news-media accounts, and developed a clinical profile of 25 children and young adults, 3 to 19 years of age. Results. Each victim collapsed with cardiac arrest immediately after an unexpected blow to the chest, which was usually inflicted by a projectile (such as a baseball or hockey puck), Incidents took place during organized competitive sports in 16 cases and in recreational settings at home, at school, or on the playground in 9, in each instance, the impact to the chest was not judged to be extraordinary for the sport involved and did not appear to have sufficient force to cause death. Twelve victims collapsed virtually instantaneously on impact, whereas 13 remained conscious and physically active for a brief time before cardiac arrest. Cardiopulmonary resuscitation was administered within about three minutes to 19 victims, but normal cardiac rhythm could be restored in only 2 (both incurred irreversible brain damage and died shortly thereafter), Seven victims (28 percent) were wearing some form of protective chest padding. Conclusions. We speculate that most sudden deaths related to impact to the chest (not associated with traumatic injury) are due to ventricular dysrhythmia induced by an abrupt, blunt precordial blow, presumably delivered at an electrically vulnerable phase of ventricular excitability. This profile of blunt chest impact leading to cardiac arrest adds to our understanding of the range of causes of sudden death on the athletic field and may help in the development of preventive measures.	DARTMOUTH COLL SCH MED,DEPT PATHOL,LEBANON,NH; OFF NEW HAMPSHIRE STATE MED EXAMINER,LEBANON,NH; NATL CTR CATASTROPH SPORTS INJURY RES,CHAPEL HILL,NC; UNIV N CAROLINA,CHAPEL HILL,NC 27515	MARON, BJ (corresponding author), MINNEAPOLIS HEART INST FDN,DIV CARDIOVASC RES,920 E 28TH ST,SUITE 40,MINNEAPOLIS,MN 55407, USA.						ABRUNZO TJ, 1991, AM J DIS CHILD, V145, P1279, DOI 10.1001/archpedi.1991.02160110071023; BURKE AP, 1991, AM HEART J, V121, P568, DOI 10.1016/0002-8703(91)90727-Y; CHEITLIN MD, 1974, CIRCULATION, V50, P780, DOI 10.1161/01.CIR.50.4.780; COHN PF, 1977, CIRCULATION, V56, P598, DOI 10.1161/01.CIR.56.4.598; Cooper G J, 1989, J R Army Med Corps, V135, P58; CORRADO D, 1990, AM J MED, V89, P588, DOI 10.1016/0002-9343(90)90176-E; EDLICH R F JR, 1987, Journal of Emergency Medicine, V5, P181, DOI 10.1016/0736-4679(87)90176-4; FERSTLE J, 1978, PHYSICIAN SPORTSMED, V6, P21; FRAZER M, 1984, AM J FOREN MED PATH, V5, P249, DOI 10.1097/00000433-198409000-00015; FURLANELLO F, 1984, ANN NY ACAD SCI, V427, P253, DOI 10.1111/j.1749-6632.1984.tb20789.x; GREEN ED, 1980, ANN EMERG MED, V9, P155, DOI 10.1016/S0196-0644(80)80272-1; GROSSFELD PD, 1993, MED SCI SPORT EXER, V25, P901; JAMES TN, 1967, ANN INTERN MED, V67, P1013, DOI 10.7326/0003-4819-67-5-1013; Janda DH, 1992, CLIN J SPORT MED, V2, P172; KAPLAN JA, 1993, J TRAUMA, V34, P151, DOI 10.1097/00005373-199301000-00030; KING AI, 1986, CPSCC841170 CONS PRO; KULBS F, 1909, MITT GRENZGEB MED CH, V19, P678; LOWN B, 1969, AM J MED, V46, P705, DOI 10.1016/0002-9343(69)90022-9; MARON BJ, 1993, NEW ENGL J MED, V329, P55, DOI 10.1056/NEJM199307013290113; MARON BJ, 1986, J AM COLL CARDIOL, V7, P204, DOI 10.1016/S0735-1097(86)80283-2; MARON BJ, 1980, CIRCULATION, V62, P218, DOI 10.1161/01.CIR.62.2.218; MARON BJ, 1993, CIRCULATION, V88, P50; MOSS AJ, 1985, CIRCULATION, V71, P17, DOI 10.1161/01.CIR.71.1.17; PRINGLE SD, 1987, BRIT HEART J, V57, P375; RAGOSTA M, 1984, MED SCI SPORT EXER, V16, P339; RUTHERFORD G, 1981, OVERVIEW SPORTS RELA; SMIRK FH, 1960, AM J CARDIOL, V6, P620, DOI 10.1016/0002-9149(60)90265-4; SWIFT EM, 1993, SPORTS ILLUSTRA 1206, P66; THIENE G, 1983, HUM PATHOL, V14, P704, DOI 10.1016/S0046-8177(83)80143-9; TOPAZ O, 1985, CHEST, V87, P476, DOI 10.1378/chest.87.4.476; TSUNG SH, 1982, ARCH PATHOL LAB MED, V106, P168; VIANO DC, 1978, J TRAUMA, V18, P452, DOI 10.1097/00005373-197806000-00010; Viano DC, 1992, CLIN J SPORT MED, V2, P166; VIANO DC, 1992, CLIN J SPORT MED, V2, P161; VINCENT GM, 1992, NEW ENGL J MED, V327, P846, DOI 10.1056/NEJM199209173271204; ZOLL PM, 1976, NEW ENGL J MED, V294, P1274, DOI 10.1056/NEJM197606032942307	36	215	221	0	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 10	1995	333	6					337	342		10.1056/NEJM199508103330602			6	Medicine, General & Internal	General & Internal Medicine	RN082	WOS:A1995RN08200002	7609749				2021-06-18	
J	BOUMA, GJ; MUIZELAAR, JP; BANDOH, K; MARMAROU, A				BOUMA, GJ; MUIZELAAR, JP; BANDOH, K; MARMAROU, A			BLOOD-PRESSURE AND INTRACRANIAL PRESSURE-VOLUME DYNAMICS IN SEVERE HEAD-INJURY - RELATIONSHIP WITH CEREBRAL BLOOD-FLOW	JOURNAL OF NEUROSURGERY			English	Article						AUTOREGULATION; CEREBRAL BLOOD FLOW; CEREBRAL METABOLISM; HEAD INJURY; INTRACRANIAL PRESSURE; PRESSURE-VOLUME INDEX	PERFUSION-PRESSURE; AUTO-REGULATION; INDEX; ICP; HYPERTENSION; METABOLISM; ELEVATION; CHILDREN; CSF	Increased brain tissue stiffness following severe traumatic brain injury is an important factor in the development of raised intracranial pressure (ICP). However, the mechanisms involved in brain tissue stiffness are not well understood, particularly the effect of changes in systemic blood pressure. Thus, controversy exists as to the optimum management of blood pressure in severe head injury, and diverging treatment strategies have been proposed. In the present study, the effect of induced alterations in blood pressure on ICP and brain stiffness as indicated by the pressure-volume index (PVI) was studied during 58 tests of autoregulation of cerebral blood flow in 47 comatose head-injured patients. In patients with intact autoregulation mechanisms, lowering the blood pressure caused a steep increase in ICP (from 20 +/- 3 to 30 +/- 2 mm Hg, mean +/- standard error of the mean), while raising blood pressure did not change the ICP. When autoregulation was defective, ICP varied directly with blood pressure. Accordingly, with intact autoregulation, a weak positive correlation between PVI and cerebral perfusion pressure was found; however, with defective autoregulation, the PVI was inversely related to cerebral perfusion pressure. The various blood pressure manipulations did not significantly alter the cerebral metabolic rate of oxygen, irrespective of the status of autoregulation. It is concluded that the changes in ICP can be explained by changes in cerebral blood volume due to cerebral vasoconstriction or dilatation, while the changes in PVI can be largely attributed to alterations in transmural pressure, which may or may not be attenuated by cerebral arteriolar vasoconstriction, depending on the autoregulatory status. The data indicate that a decline in blood pressure should be avoided in head-injured patients, even when baseline blood pressure is high. On the other hand, induced hypertension did not consistently reduce ICP in patients with intact autoregulation and should only be attempted after thorough assessment of the cerebrovascular status and under careful monitoring of its effects.	VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DIV NEUROSURG, MCV STN BOX 631, RICHMOND, VA 23298 USA				Bouma, Gerrit/0000-0002-2772-7475			ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; AVEZAAT CJJ, 1980, J NEUROL NEUROSUR PS, V43, P222, DOI 10.1136/jnnp.43.3.222; BOUMA GJ, 1990, J NEUROSURG, V73, P368, DOI 10.3171/jns.1990.73.3.0368; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; GRAY WJ, 1987, J NEUROSURG, V67, P369, DOI 10.3171/jns.1987.67.3.0369; GRAY WJ, 1987, J NEUROSURG, V67, P377, DOI 10.3171/jns.1987.67.3.0377; KENNEDY C, 1957, J CLIN INVEST, V36, P1130, DOI 10.1172/JCI103509; KONTOS HA, 1978, AM J PHYSIOL, V234, pH371; LEECH P, 1974, J NEUROL NEUROSUR PS, V37, P1099, DOI 10.1136/jnnp.37.10.1099; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARMAROU A, 1978, J NEUROSURG, V48, P332, DOI 10.3171/jns.1978.48.3.0332; MARMAROU A, 1987, J NEUROSURG, V66, P883, DOI 10.3171/jns.1987.66.6.0883; MARSHALL WJ, 1969, ARCH NEUROL-CHICAGO, V21, P545, DOI 10.1001/archneur.1969.00480170117012; MASET AL, 1987, J NEUROSURG, V67, P832, DOI 10.3171/jns.1987.67.6.0832; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; MUIZELAAR JP, 1989, INTRACRANIAL PRESSUR, V7, P825; MUIZELAAR JP, 1989, INTRACRANIAL PRESSUR, V7, P508; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; ROSNER MJ, 1986, J NEUROSURG, V65, P636, DOI 10.3171/jns.1986.65.5.0636; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; ROSNER MJ, 1984, J NEUROSURG, V60, P312, DOI 10.3171/jns.1984.60.2.0312; SHAPIRO K, 1980, ANN NEUROL, V7, P508, DOI 10.1002/ana.410070603; SIMARD JM, 1989, AM J CARDIOL, V63, pC32, DOI 10.1016/0002-9149(89)90403-7; Takagi H, 1980, INTRACRANIAL PRESSUR, VIV, P163	27	215	219	0	13	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUL	1992	77	1					15	19		10.3171/jns.1992.77.1.0015			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	HZ931	WOS:A1992HZ93100003	1607958				2021-06-18	
J	Yuh, EL; Mukherjee, P; Lingsma, HF; Yue, JK; Ferguson, AR; Gordon, WA; Valadka, AB; Schnyer, DM; Okonkwo, DO; Maas, AIR; Manley, GT				Yuh, Esther L.; Mukherjee, Pratik; Lingsma, Hester F.; Yue, John K.; Ferguson, Adam R.; Gordon, Wayne A.; Valadka, Alex B.; Schnyer, David M.; Okonkwo, David O.; Maas, Andrew I. R.; Manley, Geoffrey T.		TRACK-TBI Investigators	Magnetic resonance imaging improves 3-month outcome prediction in mild traumatic brain injury	ANNALS OF NEUROLOGY			English	Article							DIFFUSE AXONAL INJURY; COMMON DATA ELEMENTS; MINOR HEAD-INJURY; COMPUTED-TOMOGRAPHY; CLINICAL-TRIALS; CT; CLASSIFICATION; MODERATE; SCALE; MR	Objective To determine the clinical relevance, if any, of traumatic intracranial findings on early head computed tomography (CT) and brain magnetic resonance imaging (MRI) to 3-month outcome in mild traumatic brain injury (MTBI). Methods One hundred thirty-five MTBI patients evaluated for acute head injury in emergency departments of 3 LEVEL I trauma centers were enrolled prospectively. In addition to admission head CT, early brain MRI was performed 12 +/- 3.9 days after injury. Univariate and multivariate logistic regression were used to assess for demographic, clinical, socioeconomic, CT, and MRI features that were predictive of Extended Glasgow Outcome Scale (GOS-E) at 3 months postinjury. Results Twenty-seven percent of MTBI patients with normal admission head CT had abnormal early brain MRI. CT evidence of subarachnoid hemorrhage was associated with a multivariate odds ratio of 3.5 (p = 0.01) for poorer 3-month outcome, after adjusting for demographic, clinical, and socioeconomic factors. One or more brain contusions on MRI, and 4 foci of hemorrhagic axonal injury on MRI, were each independently associated with poorer 3-month outcome, with multivariate odds ratios of 4.5 (p = 0.01) and 3.2 (p = 0.03), respectively, after adjusting for head CT findings and demographic, clinical, and socioeconomic factors. Interpretation In this prospective multicenter observational study, the clinical relevance of abnormal findings on early brain imaging after MTBI is demonstrated. The addition of early CT and MRI markers to a prognostic model based on previously known demographic, clinical, and socioeconomic predictors resulted in a >2-fold increase in the explained variance in 3-month GOS-E. ANN NEUROL 2013;73:224235	[Yuh, Esther L.; Mukherjee, Pratik; Yue, John K.; Ferguson, Adam R.; Manley, Geoffrey T.] Brain & Spinal Injury Ctr, San Francisco, CA USA; [Yuh, Esther L.; Mukherjee, Pratik] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94110 USA; [Lingsma, Hester F.] Erasmus MC Univ, Dept Publ Hlth, Med Ctr, Rotterdam, Netherlands; [Yue, John K.; Ferguson, Adam R.; Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94110 USA; [Gordon, Wayne A.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA; [Valadka, Alex B.] Seton Brain & Spine Inst, Austin, TX USA; [Schnyer, David M.] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA; [Okonkwo, David O.] Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Pittsburgh, PA 15260 USA; [Okonkwo, David O.] Univ Pittsburgh, Med Ctr, Neurotrauma Clin Trials Ctr, Pittsburgh, PA USA; [Maas, Andrew I. R.] Univ Antwerp Hosp, Dept Neurosurg, Edegem, Belgium	Manley, GT (corresponding author), Univ Calif San Francisco, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94110 USA.	manleyg@neurosurg.ucsf.edu	Yue, John K/P-1348-2015; Maas, Andrew IR/C-5584-2013	Yue, John K/0000-0001-9694-7722; Maas, Andrew IR/0000-0003-1612-1264; Ferguson, Adam/0000-0001-7102-1608; Schnyer, David/0000-0002-7472-2853; Mukherjee, Pratik/0000-0001-7473-7409	NIH National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS069409]; Wings for Life Foundation [WFL-US-008/12-60]; DoDUnited States Department of Defense; TRACK-TBI; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; GE HealthcareGE Healthcare; NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); Craig H. Neilsen Foundation; NIMHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH); European CommissionEuropean CommissionEuropean Commission Joint Research Centre; GlaxoSmithKlineGlaxoSmithKline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RC2NS069409] Funding Source: NIH RePORTER; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10090] Funding Source: researchfish	This study was supported by grants from the NIH National Institute of Neurological Disorders and Stroke (NS069409; principal investigator, G.T.M.) and Wings for Life Foundation (WFL-US-008/12-60; A.R.F.).; E.L.Y.: grants/grants pending, DoD, TRACK-TBI; paid educational presentations, UCSF. P.M.: grants/grants pending, NIH; speaking fees, GE Healthcare. A.R.F.: grants/grants pending, DoD, TRACK-TBI, NIH/NINDS, Craig H. Neilsen Foundation; travel expenses, Society for Neuroscience, National Neurotrauma Symposium, International Symposium on Neural Regeneration, Wings for Life Grant Holders Meeting. D.M.S.: grants/grants pending, NIMH. D.O.O.: grants/grants pending, NIH. A.I.R.M.: consultancy, NeuroVive, Sanofi-Aventis, Shire Pharmaceuticals; travel expenses, EuroNeuro 2012, Keystone Symposia Colorado, Neurocritical Care Conference Houston, AOCMF Davos, Israel Neurosurgical Society Meeting. G.T.M.: paid review activities, NIH DSMB. D.K.M.: consultancy, Solvay, GlaxoSmithKline, Brainscope, Ornim Medical, Shire Medical, Neurovive; grants/grants pending, European Commission; speaking fees, GlaxoSmithKline; royalties, Cambridge University Press.	ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1982, RECENT ADV NEUROPATH, V2, P165; Altman DG, 2006, BRIT MED J, V332, P1080, DOI 10.1136/bmj.332.7549.1080; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bazarian JJ, 2005, EMERG MED J, V22, P473, DOI 10.1136/emj.2004.019273; Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; Haacke EM, 2010, J MAGN RESON IMAGING, V32, P516, DOI 10.1002/jmri.22259; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Hessen E, 2009, BRAIN INJURY, V23, P234, DOI 10.1080/02699050902748349; Holbourn AHS, 1943, LANCET, V2, P438; Hudak AM, 2005, J NEUROTRAUM, V22, P1319, DOI 10.1089/neu.2005.22.1319; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2010, BRAIN INJURY, V24, P1246, DOI 10.3109/02699052.2010.490513; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; JENKINS A, 1986, LANCET, V2, P445; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; Kleinbaum D., 2010, LOGISTIC REGRESSION, P463, DOI [DOI 10.1007/978-1-4419-1742-3_13, 10.1007/978-1-4419-1742-3_13]; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P127, DOI 10.1016/j.nurt.2009.10.020; Mannion RJ, 2007, J NEUROTRAUM, V24, P128, DOI 10.1089/neu.2006.0127; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; National Center for Injury Prevention and Control, 2003, C MILD TRAUM BRAIN I; Nichol AD, 2011, INJURY, V42, P281, DOI 10.1016/j.injury.2010.11.047; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Roozenbeek B, 2011, CRIT CARE, V15, DOI 10.1186/cc10240; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Sadowski-Cron C, 2006, BRAIN INJURY, V20, P1131, DOI 10.1080/02699050600832569; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Shukla D, 2011, CLIN NEUROL NEUROSUR, V113, P435, DOI 10.1016/j.clineuro.2011.02.013; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; The Mild Traumatic Brain Injury Committee of the Head Injury Interdisciplinary Special Interest Group of the American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Van Boven RW, 2009, J REHABIL RES DEV, V46, P717, DOI 10.1682/JRRD.2008.12.0161; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; Whyte J, 2010, ARCH PHYS MED REHAB, V91, P1692, DOI 10.1016/j.apmr.2010.06.031; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; Zumstein MA, 2011, J TRAUMA, V71, P120, DOI 10.1097/TA.0b013e3181f2d670	60	214	215	0	27	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	FEB	2013	73	2					224	235		10.1002/ana.23783			12	Clinical Neurology; Neurosciences	Neurosciences & Neurology	113UA	WOS:000316693200011	23224915	Green Accepted			2021-06-18	
J	Draper, K; Ponsford, J				Draper, Kristy; Ponsford, Jennie			Cognitive functioning ten years following traumatic brain injury and rehabilitation	NEUROPSYCHOLOGY			English	Article						traumatic brain injury; cognitive outcome	CLOSED-HEAD-INJURY; EXECUTIVE DYSFUNCTION; ATTENTIONAL DEFICITS; MODERATE; SCALE; COMPLAINTS; ABILITIES; AWARENESS; SURVIVORS; SEVERITY	Many previous studies investigating long-term cognitive impairments following traumatic brain injury (TBI) have focused on extremely severely injured patients, relied on subjective reports of change and failed to use demographically relevant control data. The aim of this study was to investigate cognitive impairments 10 years following TBI and their association with injury severity. Sixty TBI and 43 control participants were assessed on tests of attention, processing speed, memory, and executive function. The TBI group demonstrated significant cognitive impairment on measures of processing speed (Symbol Digit Modalities Test [SDMT], Smith, 1973; Digit Symbol Coding, Wechsler, 1997), memory (Rey Auditory Verbal Learning Test [RAVLT]; Rey, 1958; Lezak, 1976), Doors and People tests; Baddeley, Emslie & Nimmo-Smith, 1994) and executive function (Hayling C [Burgess & Shallice, 19971 and SART errors, Robertson, Manly, Andrade, Baddeley & Yiend, 1997). Logistic Regression analyses indicated that the SDMT, Rey AVLT and Hayling C and SART errors most strongly differentiated the groups in the domains of attention/processing speed, memory and executive function, respectively. Greater injury severity was significantly correlated with poorer test performances across all domains. This study shows that cognitive impairments are present many years following TBI and are associated with injury severity.	[Ponsford, Jennie] Monash Univ, Dept Psychol, Natl Trauma Res Inst, Monash Epworth Rehabil Res Ctr, Clayton, Vic 3800, Australia	Ponsford, J (corresponding author), Monash Univ, Dept Psychol, Natl Trauma Res Inst, Monash Epworth Rehabil Res Ctr, Clayton, Vic 3800, Australia.	Jennie.ponsford@med.monash.edu.au					Baddeley A, 1994, DOORS PEOPLE; Bennett PC, 2005, J INT NEUROPSYCH SOC, V11, P606, DOI 10.1017/S1355617705050721; Benton A., 1994, MULTILINGUAL APHASIA; Boake C, 2001, ARCH PHYS MED REHAB, V82, P761, DOI 10.1053/apmr.2001.23753; Burgess PW, 1996, NEUROPSYCHOLOGIA, V34, P263, DOI 10.1016/0028-3932(95)00104-2; Chan RCK, 2000, BRAIN INJURY, V14, P227, DOI 10.1080/026990500120709; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Groom KN, 1998, ARCH CLIN NEUROPSYCH, V13, P695, DOI 10.1016/S0887-6177(98)00005-5; Hart T, 2004, ARCH PHYS MED REHAB, V85, P1450, DOI 10.1016/j.apmr.2004.01.030; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Hoofien D, 2001, BRAIN INJURY, V15, P189; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Kraus J. F., 1999, REHABILITATION ADULT, P3; Langeluddecke PM, 2003, CLIN NEUROPSYCHOL, V17, P273, DOI 10.1076/clin.17.2.273.16499; Lehtonen S, 2005, BRAIN INJURY, V19, P239, DOI 10.1080/0269905040004310; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; Malec JF, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199706000-00002; McAvinue L, 2005, NEUROPSYCHOL REHABIL, V15, P569, DOI 10.1080/09602010443000119; MCWILLIAMS S, 1991, BRIT J OCCUPATIONAL, V54, P246; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; O'Connor C, 2005, PSYCHOL REP, V97, P169, DOI 10.2466/PR0.97.5.169-179; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; PONSFORD J, J INT NEURO IN PRESS; Ponsford J., 1995, TRAUMATIC BRAIN INJU; Porteus S.D., 1965, PORTEUS MAZE TEST 50; Raskin SA, 1996, NEUROPSYCHOLOGY, V10, P416, DOI 10.1037/0894-4105.10.3.416; Reitan RM, 1988, HALSTEADREITAN NEURO; REY A, 1955, EXAMEN CLIN PSYCHOL; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Satz P, 1998, BRAIN INJURY, V12, P555, DOI 10.1080/026990598122322; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; Shallice, 1997, HAYLING BRIXTON TEST; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Smith A., 1973, SYMBOL DIGIT MODALIT; Tate R., 2005, BRAIN IMPAIR, V6, P75, DOI DOI 10.1375/BRIM.2005.6.2.75; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; Tate RL, 1999, CORTEX, V35, P39, DOI 10.1016/S0010-9452(08)70784-6; Teasdale TW, 2005, BRAIN INJURY, V19, P1041, DOI 10.1080/02699050500110397; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wood RLI, 2006, J NEUROL NEUROSUR PS, V77, P1180, DOI 10.1136/jnnp.2006.091553; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498	51	214	221	1	46	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	SEP	2008	22	5					618	625		10.1037/0894-4105.22.5.618			8	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	345KC	WOS:000258994300007	18763881				2021-06-18	
J	Vanderploeg, RD; Curtiss, G; Luis, CA; Salazar, AM				Vanderploeg, Rodney D.; Curtiss, Glenn; Luis, Cheryl A.; Salazar, Andres M.			Long-term morbidities following self-reported mild traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							MINOR HEAD-INJURY; DIAGNOSTIC INTERVIEW SCHEDULE; PSYCHIATRIC-ILLNESS; GAIT DISTURBANCE; AXIS-I; SYMPTOMS; CONCUSSION; MODERATE; DISABILITY; DISORDERS	The objective of this study was to examine the prevalence of long-term psychiatric, neurologic, and psychosocial morbidities of self-reported mild traumatic brain injury ( MTBI). A cross-sectional cohort sample of three groups was examined: those who had not been injured in a motor vehicle accident nor had a MTBI ( n=3,214); those who had been injured in an accident but did not have a MTBI ( n=539); and those who had a MTBI with altered consciousness ( n=254). Logistic regression analyses were used to model odds ratios for the association between group and outcome variables while controlling demographic characteristics, comorbid medical conditions, and early-life psychiatric problems. Compared with uninjured controls, MTBI increased the likelihood of depression and post-concussion syndrome. MTBI also was associated with peripheral visual imperceptions and impaired tandem gait. Similarly, the MTBI group had poorer psychosocial outcomes including an increased likelihood of self-reported disability, underemployment, low income, and marital problems. Results suggest that MTBI can have adverse long-term psychiatric, neurologic, and psychosocial morbidities.	James A Haley Vet Adm Med Ctr, Dept Mental Hlth & Behav Sci, Tampa, FL 33612 USA; Def & Vet Brain Injury Ctr, Tampa, FL USA; Univ S Florida, Dept Psychiat & Behav Med, Tampa, FL USA; Univ S Florida, Dept Psychol, Tampa, FL 33620 USA; Ribopharm Inc, Washington, DC USA	Vanderploeg, RD (corresponding author), James A Haley Vet Adm Med Ctr, Dept Mental Hlth & Behav Sci, 13000 N Bruce B Downs Blvd, Tampa, FL 33612 USA.	Rodney.Vanderploeg@med.va.gov	Curtiss, Glenn/ABB-5566-2020				ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; ALVES WM, 1987, CLIN SPORT MED, V6, P211; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; *CTRS DIS CONTR, 1988, JAMA-J AM MED ASSOC, V18, P2708; *CTRS DIS CONTR, 1988, JAMA-J AM MED ASSOC, V18, P2701; Deb S, 1999, AM J PSYCHIAT, V156, P374; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; Dunn L, 2003, J NEUROL NEUROSUR PS, V74, P1060, DOI 10.1136/jnnp.74.8.1060; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Fann JR, 2002, J NEUROL NEUROSUR PS, V72, P615, DOI 10.1136/jnnp.72.5.615; Gaetz M, 2000, BRAIN INJURY, V14, P815; Greiffenstein MF, 2001, CLIN NEUROPSYCHOL, V15, P162, DOI 10.1076/clin.15.2.162.1895; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; Heilman KM, 1994, LOCALIZATION NEUROIM, P495; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; KLONOFF PS, 1986, NEUROSURGERY, V19, P735, DOI 10.1227/00006123-198611000-00004; Kolakowsky-Hayner SA, 1999, BRAIN INJURY, V13, P571; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Levin HS, 1989, MILD HEAD INJURY; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; MESULAM MM, 1990, ANN NEUROL, V28, P597, DOI 10.1002/ana.410280502; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; MONTAGUE E K, 1957, U S Armed Forces Med J, V8, P883; Nakamura T, 1997, ALZ DIS ASSOC DIS, V11, P132, DOI 10.1097/00002093-199709000-00005; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Reitan R, 1984, APHASIA SENSORY PERC; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROBERTSON E, 1994, CLIN NEUROPSYCHOL, V8, P69; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; Rossor MN, 1999, J NEUROL NEUROSUR PS, V67, P345, DOI 10.1136/jnnp.67.3.345; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; SHAFFER D, 1993, J AM ACAD CHILD PSY, V32, P643, DOI 10.1097/00004583-199305000-00023; Sosin DM, 1996, BRAIN INJURY, V10, P47; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vanderploeg RD, 2003, J HEAD TRAUMA REHAB, V18, P148, DOI 10.1097/00001199-200303000-00006; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3; World Health Organization, 1992, ICD 10 INT STAT CLAS	57	214	217	0	16	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2007	29	6					585	598		10.1080/13803390600826587			14	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	208ZS	WOS:000249358500002	17691031				2021-06-18	
J	Tong, KA; Ashwal, S; Holshouser, BA; Nickerson, JP; Wall, CJ; Shutter, LA; Osterdock, RJ; Haacke, EM; Kido, D				Tong, KA; Ashwal, S; Holshouser, BA; Nickerson, JP; Wall, CJ; Shutter, LA; Osterdock, RJ; Haacke, EM; Kido, D			Diffuse axonal injury in children: Clinical correlation with hemorrhagic lesions	ANNALS OF NEUROLOGY			English	Article							TRAUMATIC BRAIN INJURY; CLOSED-HEAD-INJURY; COMPUTERIZED-TOMOGRAPHY; MR; NEUROPATHOLOGY; VENOGRAPHY; MODERATE; DEPTH; MILD; CT	An inception cohort of 40 children and adolescents with traumatic brain injury and suspected diffuse axonal injury were studied using a new high-resolution magnetic resonance imaging susceptibility-weighted technique that is very sensitive for hemorrhage. A blinded comparison was performed between the extent of parenchymal hemorrhage and initial clinical variables as well as outcomes measured at 6 to 12 months after injury. Children with lower Glasgow Coma Scale scores (less than or equal to8, n = 30) or prolonged coma (>4 days, n = 20) had a greater average number (p = 0.007) and volume (p = 0.008) of hemorrhagic lesions. Children with normal outcomes or mild disability (n = 30) at 6 to 12 months had, on average, fewer hemorrhagic lesions (p = 0.003) and lower volume (p = 0.003) of lesions than those who were moderately or severely disabled or in a vegetative state. Significant differences also, were observed when comparing regional injury to clinical variables. Because susceptibility-weighted imaging is much more sensitive than conventional T2*-weighted gradient-echo sequences in detecting hemorrhagic diffuse axonal injury, more accurate and objective assessment of injury can be obtained early after insult, and may provide better prognostic information regarding duration of coma as well as long-term outcome.	Loma Linda Univ, Med Ctr, Dept Radiol, Loma Linda, CA 92354 USA; Loma Linda Univ, Med Ctr, Dept Pediat, Loma Linda, CA 92354 USA; Loma Linda Univ, Med Ctr, Sch Med, Loma Linda, CA 92354 USA; Univ Saskatchewan, Royal Univ Hosp, Dept Med Imaging, Saskatoon, SK, Canada; Univ Cincinnati, Dept Neurosurg, Cincinnati, OH USA; Univ Cincinnati, Dept Neurol, Cincinnati, OH USA; Loma Linda Univ, Med Ctr, Dept Neurosurg, Loma Linda, CA USA; Wayne State Univ, Dept Radiol, Detroit, MI USA	Tong, KA (corresponding author), Loma Linda Univ, Med Ctr, Dept Radiol, 11234 Anderson St, Loma Linda, CA 92354 USA.	ktong@ahs.llumc.edu	Shutter, Lori A/G-2957-2013	Shutter, Lori/0000-0002-1390-0628	NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL 062983] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL062983] Funding Source: NIH RePORTER		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; ATLAS SW, 1988, RADIOLOGY, V168, P803, DOI 10.1148/radiology.168.3.3406410; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Chiaretti A, 1998, Pediatr Med Chir, V20, P393; CORDOBES F, 1986, ACTA NEUROCHIR, V81, P27, DOI 10.1007/BF01456261; Fiser DH, 2000, CRIT CARE MED, V28, P2616, DOI 10.1097/00003246-200007000-00072; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; Gleckman AM, 1999, ARCH PATHOL LAB MED, V123, P146; Gorrie C, 1999, CHILD NERV SYST, V15, P322, DOI 10.1007/s003810050403; Gorrie C, 2001, J NEUROTRAUM, V18, P849, DOI 10.1089/089771501750451776; Grados MA, 2001, J NEUROL NEUROSUR PS, V70, P350, DOI 10.1136/jnnp.70.3.350; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Kurihara Mana, 1999, No To Hattatsu, V31, P408; KURTH SM, 1994, BRAIN INJURY, V8, P489, DOI 10.3109/02699059409151001; Kuzma BB, 2000, SURG NEUROL, V53, P400; LANG DA, 1994, J NEUROSURG, V80, P675, DOI 10.3171/jns.1994.80.4.0675; Lee BCP, 1999, AM J NEURORADIOL, V20, P1239; Lee TT, 1998, ACTA NEUROCHIR, V140, P41, DOI 10.1007/s007010050055; LEVI L, 1990, NEUROSURGERY, V27, P429, DOI 10.1227/00006123-199009000-00015; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; LEVIN HS, 1989, NEUROSURGERY, V24, P223, DOI 10.1227/00006123-198902000-00011; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Lubillo S, 2000, ACT NEUR S, V76, P415; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; REIBER GD, 1993, AM J FOREN MED PATH, V14, P201, DOI 10.1097/00000433-199309000-00005; Reichenbach JR, 1997, RADIOLOGY, V204, P272, DOI 10.1148/radiology.204.1.9205259; SGANZERLA EP, 1989, CHILD NERV SYST, V5, P168, DOI 10.1007/BF00272121; Tomberg T, 1996, ACTA NEUROCHIR, V138, P543, DOI 10.1007/BF01411174; TONG K, 2003, P INT SOC MAGN RESON, V11, P333; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; VOWLES GH, 1987, J CLIN PATHOL, V40, P185, DOI 10.1136/jcp.40.2.185; YOKOTA H, 1992, Neurological Surgery, V20, P217	45	214	250	1	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	JUL	2004	56	1					36	50		10.1002/ana.20123			15	Clinical Neurology; Neurosciences	Neurosciences & Neurology	834QM	WOS:000222425600007	15236400				2021-06-18	
J	Matsushita, K; Meng, W; Wang, XY; Asahi, M; Asahi, K; Moskowitz, MA; Lo, EH				Matsushita, K; Meng, W; Wang, XY; Asahi, M; Asahi, K; Moskowitz, MA; Lo, EH			Evidence for apoptosis after intracerebral hemorrhage in rat striatum	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						apoptosis; caspase; caspase inhibitor; gelsolin; hemorrhage; trauma	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN INJURY; NECROSIS-FACTOR-ALPHA; METHYL-D-ASPARTATE; BLOOD-FLOW; NEURONAL APOPTOSIS; DNA FRAGMENTATION; OXIDATIVE STRESS; CELL-DEATH; EDEMA	The overall hypothesis that cell death after intracerebral hemorrhage is mediated in part by apoptolic mechanisms was tested. Intracerebral hemorrhage was induced in rats using stereotactic infusions of 0.5 U of collagenase (1-mu L volume) into the striatum. After 24 hours, large numbers of TUNEL-positive stained cells with morphologies suggestive of apoptosis were present in the center and periphery of the hemorrhage. Double staining with Nissl and immunocytochemical labeling with antibodies against neuronal nuclei and glial fibrillary acidic protein suggested that these TUNEL-positive cells were mostly neurons and astrocytes. Electrophoresis of hemorrhagic brain extracts showed evidence of DNA laddering into similar to 200-bp fragments. Western blots showed cleavage of the cytosolic caspase substrate gelsolin. The density of TUNEL-positive cells at 24 and 48 hours after hemorrhage was significantly reduced by treatment with the broad-spectrum caspase inhibitor zVADfmk. It was unlikely that apoptotic changes were due to neurotoxicity of injected collagenase because TUNEL-positive cells and DNA laddering were also obtained in an alternative model of hemorrhage where autologous blood. was infused into the striatum. Furthermore, equivalent doses of collagenase did not induce cell death in primary neuronal cultures. These results provide initial evidence that apoptotic mechanisms may mediate some of the injury in brain after intracerebral hemorrhage.	Harvard Univ, Sch Med, Massachusetts Gen Hosp E, Dept Neurol,Neuroprotect Res Lab, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp E, Dept Neurol,Stroke & Neurovasc Regulat Lab, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp E, Dept Neurosurg, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp E, Dept Radiol, Charlestown, MA 02129 USA	Lo, EH (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp E, Dept Neurol,Neuroprotect Res Lab, 149-2322, Charlestown, MA 02129 USA.		Moskowitz, Michael A/D-9916-2011		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R29-NS32806, R01-NS37074, R01-NS38731] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038731, R01NS037074, R29NS032806] Funding Source: NIH RePORTER		Barinaga M, 1998, SCIENCE, V281, P1302, DOI 10.1126/science.281.5381.1302; Bennett SAL, 1998, NEUROREPORT, V9, P161; BONDY SC, 1993, FREE RADICAL BIO MED, V14, P633, DOI 10.1016/0891-5849(93)90144-J; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Botchkina GI, 1997, MOL MED, V3, P765, DOI 10.1007/BF03401714; Brott T, 1997, STROKE, V28, P2109, DOI 10.1161/01.STR.28.11.2109; Brown M S, 1995, J Neuroimaging, V5, P23; BULLOCK R, 1988, SURG NEUROL, V29, P101, DOI 10.1016/0090-3019(88)90065-1; Chan PH, 1996, STROKE, V27, P1124, DOI 10.1161/01.STR.27.6.1124; CharriautMarlangue C, 1996, TRENDS NEUROSCI, V19, P109, DOI 10.1016/S0166-2236(96)80039-7; Choi DW, 1996, CURR OPIN NEUROBIOL, V6, P667, DOI 10.1016/S0959-4388(96)80101-2; Chopp M, 1996, ACT NEUR S, V66, P21; DelBigio MR, 1996, STROKE, V27, P2312, DOI 10.1161/01.STR.27.12.2312; Donovan FM, 1997, J NEUROSCI, V17, P5316; Du C, 1996, J CEREBR BLOOD F MET, V16, P195, DOI 10.1097/00004647-199603000-00003; ELGER B, 1994, STROKE, V25, P1836, DOI 10.1161/01.STR.25.9.1836; Endres H, 1998, J CEREBR BLOOD F MET, V18, P238, DOI 10.1097/00004647-199803000-00002; FELDMANN E, 1990, Current Concepts of Cerebrovascular Disease and Stroke, V25, P31; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; Fink K, 1998, J CEREBR BLOOD F MET, V18, P1071, DOI 10.1097/00004647-199810000-00003; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; Heo JH, 1999, J CEREBR BLOOD F MET, V19, P624, DOI 10.1097/00004647-199906000-00005; Hua Y., 1998, Society for Neuroscience Abstracts, V24, P1230; JENKINS A, 1990, British Journal of Neurosurgery, V4, P45, DOI 10.3109/02688699009000681; JONES TH, 1981, J NEUROSURG, V54, P773, DOI 10.3171/jns.1981.54.6.0773; JORGENSEN HS, 1995, ANN NEUROL, V38, P45, DOI 10.1002/ana.410380110; KATAOKA K, 1987, STROKE, V18, P188, DOI 10.1161/01.STR.18.1.188; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; Keller JN, 1998, J NEUROSCI, V18, P687; KOBARI M, 1988, STROKE, V19, P991, DOI 10.1161/01.STR.19.8.991; Koeppen AH, 1995, J NEUROL SCI, V134, P102, DOI 10.1016/0022-510X(95)00215-N; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kruman I, 1997, J NEUROSCI, V17, P5089; Li Y, 1998, J NEUROL SCI, V156, P119, DOI 10.1016/S0022-510X(98)00036-7; LIU T, 1994, STROKE, V25, P1481, DOI 10.1161/01.STR.25.7.1481; LO EH, 1991, J CEREBR BLOOD F MET, V11, P803, DOI 10.1038/jcbfm.1991.138; Lyden PD, 1997, STROKE, V28, P387, DOI 10.1161/01.STR.28.2.387; LYDEN PD, 1993, CEREBROVAS BRAIN MET, V5, P1; MACMANUS JP, 1995, J CEREBR BLOOD F MET, V15, P728, DOI 10.1038/jcbfm.1995.93; MacManus JP, 1997, J CEREBR BLOOD F MET, V17, P815, DOI 10.1038/aj.jcbfm.9590266; MacManus JP, 1999, J CEREBR BLOOD F MET, V19, P502, DOI 10.1097/00004647-199905000-00004; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Marti T, 1998, HELV CHIM ACTA, V81, P109, DOI 10.1002/hlca.19980810112; Matsushima K, 1998, J ENDODONT, V24, P252, DOI 10.1016/S0099-2399(98)80107-6; MATSUYAMA T, 1995, MOL BRAIN RES, V34, P166, DOI 10.1016/0169-328X(95)00162-L; MATSUYAMA T, 1994, BRAIN RES, V657, P342, DOI 10.1016/0006-8993(94)90989-X; Mun-Bryce S, 1998, J CEREBR BLOOD F MET, V18, P1163, DOI 10.1097/00004647-199811000-00001; Murakami K, 1997, NEUROSCIENCE, V81, P231, DOI 10.1016/S0306-4522(97)00197-8; Murphy AN, 1999, J CEREBR BLOOD F MET, V19, P231, DOI 10.1097/00004647-199903000-00001; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Namura S, 1998, J NEUROSCI, V18, P3659; Panahian N, 1999, J NEUROCHEM, V72, P1187; PAXINOS G, 1982, RAT BRAIN STEREOTACT; PorteraCailliau C, 1997, J COMP NEUROL, V378, P88, DOI 10.1002/(SICI)1096-9861(19970203)378:1<88::AID-CNE5>3.0.CO;2-G; Qin ZH, 1996, BRAIN RES, V725, P166, DOI 10.1016/0006-8993(96)00200-4; RINK A, 1995, AM J PATHOL, V147, P1575; Romanic AM, 1998, STROKE, V29, P1020, DOI 10.1161/01.STR.29.5.1020; ROPPER AH, 1982, ANN NEUROL, V11, P266, DOI 10.1002/ana.410110306; ROSENBERG GA, 1993, NEUROSCI LETT, V160, P117, DOI 10.1016/0304-3940(93)90927-D; ROSENBERG GA, 1990, STROKE, V21, P801, DOI 10.1161/01.STR.21.5.801; Simonian NA, 1996, NEUROSCIENCE, V75, P1047, DOI 10.1016/0306-4522(96)00326-0; TAKAGI K, 1995, BRAIN RES, V691, P160, DOI 10.1016/0006-8993(95)00657-C; VONSATTEL JPG, 1995, J NEUROPATH EXP NEUR, V54, P42; Wagner KR, 1996, STROKE, V27, P490, DOI 10.1161/01.STR.27.3.490; Wang XY, 1999, NEUROSCI LETT, V274, P79, DOI 10.1016/S0304-3940(99)00682-5; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YANG GY, 1994, J NEUROSURG, V81, P93, DOI 10.3171/jns.1994.81.1.0093	69	214	268	0	8	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	FEB	2000	20	2					396	404		10.1097/00004647-200002000-00022			9	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	285JE	WOS:000085385300022	10698078	Bronze			2021-06-18	
J	Knoblach, SM; Faden, AI				Knoblach, SM; Faden, AI			Interleukin-10 improves outcome and alters proinflammatory cytokine expression after experimental traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						injury; TNF; IL-1; IL-10; inflammation	TUMOR-NECROSIS-FACTOR; GROWTH-FACTOR-BETA; CLOSED-HEAD INJURY; STAPHYLOCOCCAL-ENTEROTOXIN-B; CENTRAL-NERVOUS-SYSTEM; FACTOR-ALPHA; TNF-ALPHA; POLYMORPHONUCLEAR LEUKOCYTES; PROCOAGULANT ACTIVITY; ENDOTHELIAL-CELLS	Traumatic injury to the central nervous system initiates inflammatory processes that are implicated in secondary tissue damage. These processes include the synthesis of proinflammatory cytokines, leukocyte extravasation, vasogenic edema, and blood-brain barrier breakdown. Interleukin-10 (IL-10), a cytokine with antiinflammatory properties, negatively modulates proinflammatory cascades at multiple levels. We examined the hypothesis that IL-10 treatment can improve outcome in a clinically relevant model of traumatic brain injury (TBI). IL-10 was administered via different routes and dosing schedules in a lateral fluid-percussion model of TBI in rats. Intravenous administration of IL-10 (100 mu g) at 30 min before and 1 h after TBI improved neurological recovery and significantly reduced TNF expression in the traumatized cortex at 4 h after injury. Such treatment was associated with lower IL-1 expression in the injured hippocampus, and to a lesser extent, in the injured cortex. Subcutaneous IL-10 administration (100 mu g) at 10 min, 1, 3, 6, 9, and 12 h after TBI also enhanced neurological recovery. In contrast, intracerebroventricular administration of IL-10 (1 or 6 mu g) at 15 min, 2, 4, 6, and 8 h after TBI was not beneficial. These results indicate that IL-10 treatment improves outcome after TBI and suggest that this improvement may relate, in part, to reductions in proinflammatory cytokine synthesis. (C) 1998 Academic Press.	Georgetown Univ, Med Ctr, Inst Cognit & Computat Sci, Dept Neurol, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Inst Cognit & Computat Sci, Dept Pharmacol, Washington, DC 20007 USA	Faden, AI (corresponding author), Georgetown Univ, Med Ctr, Inst Cognit & Computat Sci, Dept Neurol, Washington, DC 20007 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD007459] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5T 32HD07459] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49 CCR 306634-07] Funding Source: Medline		Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; Balasingam V, 1996, J NEUROSCI, V16, P2945; BEAN AGD, 1993, INFECT IMMUN, V61, P4937, DOI 10.1128/IAI.61.11.4937-4939.1993; BENVENISTE EN, 1995, INT J DEV NEUROSCI, V13, P341, DOI 10.1016/0736-5748(94)00061-7; BEVILACQUA MP, 1984, J EXP MED, V160, P618, DOI 10.1084/jem.160.2.618; BEVILACQUA MP, 1985, J CLIN INVEST, V76, P2003, DOI 10.1172/JCI112200; BOGDAN C, 1992, J BIOL CHEM, V267, P23301; BOGDAN C, 1993, ANN NY ACAD SCI, V685, P713, DOI 10.1111/j.1749-6632.1993.tb35934.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brodie C, 1996, FEBS LETT, V394, P117, DOI 10.1016/0014-5793(96)00911-8; CASSATELLA MA, 1994, J EXP MED, V179, P1695, DOI 10.1084/jem.179.5.1695; CHAO CC, 1995, DEV NEUROSCI-BASEL, V17, P97, DOI 10.1159/000111278; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; CRISI GM, 1995, EUR J IMMUNOL, V25, P3035, DOI 10.1002/eji.1830251108; DEWAALMALEFYT R, 1991, J EXP MED, V174, P1209; FADEN AI, 1992, AM J PHYSIOL, V263, pR909; FEIGENBAUM JJ, 1989, P NATL ACAD SCI USA, V86, P9584, DOI 10.1073/pnas.86.23.9584; GERARD C, 1993, J EXP MED, V177, P547, DOI 10.1084/jem.177.2.547; GIULIAN D, 1993, J NEUROSCI RES, V36, P681, DOI 10.1002/jnr.490360609; Giulian D, 1996, NEUROCHEM INT, V29, P65, DOI 10.1016/0197-0186(95)00140-9; GIULIAN D, 1994, NEUROBIOLOGY CNS TRA, P155; HEMPEL L, 1995, SCAND J IMMUNOL, V41, P462, DOI 10.1111/j.1365-3083.1995.tb03593.x; JOYCE DA, 1994, EUR J IMMUNOL, V24, P2699, DOI 10.1002/eji.1830241119; JUNGI TW, 1994, THROMB RES, V76, P463, DOI 10.1016/0049-3848(95)90178-I; KIMELBERG HK, NEUROBIOLOGY CENTRAL, P193; Koedel U, 1996, J IMMUNOL, V157, P5185; KRAKAUER T, 1995, IMMUNOL LETT, V45, P61, DOI 10.1016/0165-2478(94)00226-H; KREMLEV SG, 1994, AM J PHYSIOL-LUNG C, V267, pL712; LANDIS DMD, 1994, ANNU REV NEUROSCI, V17, P133, DOI 10.1146/annurev.ne.17.030194.001025; LEVY Y, 1994, J CLIN INVEST, V93, P424, DOI 10.1172/JCI116977; Lodge PA, 1996, J LEUKOCYTE BIOL, V60, P502; MAGYARI P, 1992, NEUROSCI LETT, V148, P137; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MULLER R, 1979, J MED, V10, P307; OTT L, 1989, INTRO STAT METHODS D; Paxinos G, 1986, RAT BRAIN STEREOTAXI; PERRETTI M, 1995, BRIT J PHARMACOL, V116, P2251, DOI 10.1111/j.1476-5381.1995.tb15061.x; PIANI D, 1992, EUR J IMMUNOL, V22, P2429, DOI 10.1002/eji.1830220936; PIZARRO TT, 1993, TRANSPLANTATION, V56, P399, DOI 10.1097/00007890-199308000-00029; Rosenberg GA, 1995, BRAIN RES, V703, P151, DOI 10.1016/0006-8993(95)01089-0; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; SEITZ M, 1995, EUR J IMMUNOL, V25, P1129, DOI 10.1002/eji.1830250443; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Soares HD, 1995, J NEUROSCI, V15, P8223; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; Troy CM, 1996, P NATL ACAD SCI USA, V93, P5635, DOI 10.1073/pnas.93.11.5635; WRIGHT JL, 1994, J NEURO-ONCOL, V20, P17, DOI 10.1007/BF01057957; YAKOVLEV AG, 1995, J NEUROTRAUM, V12, P767, DOI 10.1089/neu.1995.12.767; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zhai Qi-Hui, 1996, Society for Neuroscience Abstracts, V22, P5	55	214	223	2	8	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	SEP	1998	153	1					143	151		10.1006/exnr.1998.6877			9	Neurosciences	Neurosciences & Neurology	124KJ	WOS:000076181200015	9743576				2021-06-18	
J	PRIGATANO, GP; ALTMAN, IM				PRIGATANO, GP; ALTMAN, IM			IMPAIRED AWARENESS OF BEHAVIORAL LIMITATIONS AFTER TRAUMATIC BRAIN INJURY	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article										PRIGATANO, GP (corresponding author), ST JOSEPHS HOSP,BARROW NEUROL INST,DIV NEUROL,NEUROPSYCHOL SECT,350 W THOMAS RD,PHOENIX,AZ 85013, USA.						ADAMS JH, 1985, CENTRAL NERVOUS SYST, P65; Ben-Yishay Y., 1990, REHABILITATION ADULT, P393; BENYISHAY Y, 1985, SEMIN NEUROL, V5, P252, DOI 10.1055/s-2008-1041522; CUTTING J, 1978, J NEUROL NEUROSUR PS, V41, P548, DOI 10.1136/jnnp.41.6.548; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; Friedland R P, 1977, Adv Neurol, V18, P1; Heaton R. K, 1981, WISCONSIN CARD SORTI; Jennett B, 1981, MANAGEMENT HEAD INJU; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; McGlynn S.M., 1991, AWARENESS DEFICIT BR, P84; MESULAM MM, 1985, PRINCIPLES BEHAVIORA; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; PRIBRAM KH, 1987, FRONTAL LOBES REVISI, P11; Prigatano G.P, 1988, BNI Q, V4, P40; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Prigatano G. P, 1988, BRAIN INJURY RECOVER, P335; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; PRIGATANO GP, 1989, B MENNINGER CLIN, V53, P414; PRIGATANO GP, 1983, J CONSULT CLIN PSYCH, V51, P108, DOI 10.1037/0022-006X.51.1.108; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; PRIGATANO GP, 1987, J LEARN DISABIL-US, V20, P603, DOI 10.1177/002221948702001006; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; Prigatano GP., 1988, J HEAD TRAUMA REHAB, V3, P45; PRIGATANO GP, 1991, AWARENESS DEFICIT BR, P3; Reitan R, 1974, CLIN NEUROPSYCHOLOGY; ROMANO MD, 1974, SCAND J REHABIL MED, V6, P1; Rubens A. B., 1991, AWARENESS DEFICIT BR, P40; RUSSELL EW, 1970, ASSESSMENT BRAIN DAM; Schacter D. L., 1991, AWARENESS DEFICIT BR, P258; Schacter DL., 1991, AWARENESS DEFICIT BR, P17; Stuss D.T., 1986, FRONTAL LOBES; SUNDERLAND A, 1983, J VERB LEARN VERB BE, V22, P341, DOI 10.1016/S0022-5371(83)90229-3; SUNDERLAND A, 1984, J CLIN NEUROPSYCHOL, V6, P127, DOI 10.1080/01688638408401204; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WECHSLER D, 1981, WMS R WESCHLER MEMOR; Weinstein E. A., 1955, DENIAL ILLNESS SYMBO; 1987, DIAGNOSTIC STATISTIC	37	214	216	0	6	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	1990	71	13					1058	1064					7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	EN093	WOS:A1990EN09300004	2256806				2021-06-18	
J	Ponsford, J; Cameron, P; Fitzgerald, M; Grant, M; Mikocka-Walus, A; Schonberger, M				Ponsford, Jennie; Cameron, Peter; Fitzgerald, Mark; Grant, Michele; Mikocka-Walus, Antonina; Schoenberger, Michael			Predictors of Postconcussive Symptoms 3 Months After Mild Traumatic Brain Injury	NEUROPSYCHOLOGY			English	Article						traumatic brain injury; concussion; outcome assessment	WESTMEAD PTA SCALE; HEAD-INJURY; TASK-FORCE; CONCUSSION SYMPTOMS; HOSPITAL ANXIETY; RECOVERY; OUTCOMES; VALIDITY; DISABILITY; PREVENTION	Objective: There is continuing controversy regarding predictors of poor outcome following mild traumatic brain injury (mTBI). This study aimed to prospectively examine the influence of preinjury factors, injury-related factors, and postinjury factors on outcome following mTBI. Method: Participants were 123 patients with mTBI and 100 trauma patient controls recruited and assessed in the emergency department and followed up 1 week and 3 months postinjury. Outcome was measured in terms of reported postconcussional symptoms. Measures included the ImPACT Post-Concussional Symptom Scale and cognitive concussion battery, including Attention, Verbal and Visual memory, Processing Speed and Reaction Time modules, pre- and postinjury SF-36 and MINI Psychiatric status ratings, VAS Pain Inventory, Hospital Anxiety and Depression Scale, PTSD Checklist Specific, and Revised Social Readjustment Scale. Results: Presence of mTBI predicted postconcussional symptoms 1 week postinjury, along with being female and premorbid psychiatric history, with elevated HADS anxiety a concurrent indicator. However, at 3 months, preinjury physical or psychiatric problems but not mTBI most strongly predicted continuing symptoms, with concurrent indicators including HADS anxiety, PTSD symptoms, other life stressors and pain. HADS anxiety and age predicted 3-month PCS in the mTBI group, whereas PTSD symptoms and other life stressors were most significant for the controls. Cognitive measures were not predictive of PCS at I week or 3 months. Conclusions: Given the evident influence of both premorbid and concurrent psychiatric problems, especially anxiety, on postinjury symptoms, managing the anxiety response in vulnerable individuals with mTBI may be important to minimize ongoing sequelae.	[Ponsford, Jennie; Grant, Michele; Schoenberger, Michael] Monash Univ, Monash Epworth Rehabil Res Ctr, Epworth Hosp, Melbourne, Vic 3004, Australia; [Ponsford, Jennie; Cameron, Peter; Fitzgerald, Mark; Grant, Michele] Natl Trauma Res Inst, Melbourne, Vic, Australia; [Cameron, Peter; Fitzgerald, Mark] Monash Univ, Alfred Hosp, Melbourne, Vic 3181, Australia; [Mikocka-Walus, Antonina] Univ S Australia, Sch Nursing & Midwifery, Monash Univ, Natl Trauma Res Inst, Melbourne, Vic, Australia; [Schoenberger, Michael] Univ Freiburg, Inst Psychol, Dept Rehabil Psychol, Freiburg, Germany	Ponsford, J (corresponding author), Monash Univ, Sch Psychol & Psychiat, Clayton, Vic 3800, Australia.	jennie.ponsford@monash.edu	Mikocka-Walus, Antonina/R-2363-2017; Mikocka-Walus, Antonina/B-4160-2010	Fitzgerald, Mark/0000-0003-0183-7761; Mikocka-Walus, Antonina/0000-0003-4864-3956; Cameron, Peter/0000-0002-1443-557X	Victorian Neurotrauma Initiative	This research was funded by a grant from the Victorian Neurotrauma Initiative. The authors also gratefully acknowledge the assistance of staff in the Alfred Hospital Emergency and Trauma Care Department.	Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Benton A. L, 1989, MILD HEAD INJURY, P3; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cicerone KD, 2002, BRAIN INJURY, V16, P185, DOI 10.1080/02699050110103959; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Forbes D, 2001, BEHAV RES THER, V39, P977, DOI 10.1016/S0005-7967(00)00084-X; Ghaffar O, 2006, J PSYCHOSOM RES, V61, P153, DOI 10.1016/j.jpsychores.2005.07.018; Hirtz D, 2007, NEUROLOGY, V68, P326, DOI 10.1212/01.wnl.0000252807.38124.a3; Hodgson J, 2005, BRAIN IMPAIR, V6, P169, DOI DOI 10.1375/BRIM.2005.6.3.169; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; HOLMES TH, 1967, J PSYCHOSOM RES, V11, P213, DOI 10.1016/0022-3999(67)90010-4; HOROWITZ M, 1977, PSYCHOSOM MED, V39, P413, DOI 10.1097/00006842-197711000-00005; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; HUSKISSON EC, 1974, LANCET, V2, P1127, DOI 10.1016/S0140-6736(74)90884-8; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; JENKINSON C, 1993, BRIT MED J, V306, P1437, DOI 10.1136/bmj.306.6890.1437; Kashluba S, 2008, CLIN NEUROPSYCHOL, V22, P195, DOI 10.1080/13854040701263655; Kraus J, 2005, J HEAD TRAUMA REHAB, V20, P239, DOI 10.1097/00001199-200505000-00007; Kwok FY, 2008, BRAIN INJURY, V22, P740, DOI 10.1080/02699050802336989; Landre N, 2006, ARCH CLIN NEUROPSYCH, V21, P255, DOI 10.1016/j.acn.2005.12.007; Lange RT, 2009, BRAIN INJURY, V23, P83, DOI 10.1080/02699050802635281; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Lo C, 2009, J COMPUT ASSIST TOMO, V33, P293, DOI 10.1097/RCT.0b013e31817579d1; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Malojcic B, 2008, J NEUROTRAUM, V25, P30, DOI 10.1089/neu.2007.0384; McLean SA, 2009, AM J EMERG MED, V27, P182, DOI 10.1016/j.ajem.2008.01.054; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meares S, 2006, J INT NEUROPSYCH SOC, V12, P792, DOI 10.1017/S1355617706060978; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Peterson SE, 2009, ANN EMERG MED, V53, P796, DOI 10.1016/j.annemergmed.2008.10.015; Ponsford J, 2005, CURR OPIN NEUROL, V18, P692, DOI 10.1097/01.wco.0000186840.61431.44; Ponsford J, 2004, BRAIN INJURY, V18, P603, DOI 10.1080/02699050310001646152; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Sadowski-Cron C, 2006, BRAIN INJURY, V20, P1131, DOI 10.1080/02699050600832569; Schonberger M, 2010, PSYCHIAT RES, V179, P342, DOI 10.1016/j.psychres.2009.07.003; Sheedy J, 2006, J CLIN EXP NEUROPSYC, V28, P755, DOI 10.1080/13803390591000864; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Shores EA, 2008, J NEUROL NEUROSUR PS, V79, P1100, DOI 10.1136/jnnp.2007.132571; SNAITH RP, 1986, BRIT MED J, V292, P344, DOI 10.1136/bmj.292.6516.344; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; Stulemeijer M, 2007, J PSYCHOSOM RES, V63, P637, DOI 10.1016/j.jpsychores.2007.06.023; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Whelan-Goodinson R, 2009, J AFFECT DISORDERS, V114, P94, DOI 10.1016/j.jad.2008.06.007; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; Yang CC, 2007, J TRAUMA, V62, P657, DOI 10.1097/01.ta.0000203577.68764.b8	60	213	213	0	62	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	MAY	2012	26	3					304	313		10.1037/a0027888			10	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	937AG	WOS:000303630800004	22468823		Y	N	2021-06-18	
J	Semple, BD; Bye, N; Rancan, M; Ziebell, JM; Morganti-Kossmann, MC				Semple, Bridgette D.; Bye, Nicole; Rancan, Mario; Ziebell, Jenna M.; Morganti-Kossmann, M. Cristina			Role of CCL2 (MCP-1) in traumatic brain injury (TBI): evidence from severe TBI patients and CCL2-/- mice	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						brain trauma; chemokines; inflammation; macrophages	MONOCYTE CHEMOATTRACTANT PROTEIN-1; CLOSED-HEAD INJURY; CELL-DEATH; MICROGLIAL ACTIVATION; BARRIER DYSFUNCTION; CEREBROSPINAL-FLUID; IMMUNE-RESPONSE; MESSENGER-RNA; EXPRESSION; RECRUITMENT	Cerebral inflammation involves molecular cascades contributing to progressive damage after traumatic brain injury (TBI). The chemokine CC ligand-2 (CCL2) (formerly monocyte chemoattractant protein-1, MCP-1) is implicated in macrophage recruitment into damaged parenchyma after TBI. This study analyzed the presence of CCL2 in human TBI, and further investigated the role of CCL2 in physiological and cellular mechanisms of secondary brain damage after TBI. Sustained elevation of CCL2 was detected in the cerebrospinal fluid (CSF) of severe TBI patients for 10 days after trauma, and in cortical homogenates of C57Bl/6 mice, peaking at 4 to 12 h after closed head injury (CHI). Neurological outcome, lesion volume, macrophage/microglia infiltration, astrogliosis, and the cerebral cytokine network were thus examined in CCL2-deficient (-/-) mice subjected to CHI. We found that CCL2-/- mice showed altered production of multiple cytokines acutely (2 to 24 h); however, this did not affect lesion size or cell death within the first week after CHI. In contrast, by 2 and 4 weeks, a delayed reduction in lesion volume, macrophage accumulation, and astrogliosis were observed in the injured cortex and ipsilateral thalamus of CCL2-/- mice, corresponding to improved functional recovery as compared with wild-type mice after CHI. Our findings confirm the significant role of CCL2 in mediating post-traumatic secondary brain damage. Journal of Cerebral Blood Flow & Metabolism (2010) 30, 769-782; doi:10.1038/jcbfm.2009.262; published online 23 December 2009	[Semple, Bridgette D.; Bye, Nicole; Ziebell, Jenna M.; Morganti-Kossmann, M. Cristina] Alfred Hosp, Natl Trauma Res Inst, Melbourne, Vic 3004, Australia; [Semple, Bridgette D.; Bye, Nicole; Morganti-Kossmann, M. Cristina] Monash Univ, Dept Med, Melbourne, Vic 3004, Australia; [Rancan, Mario] Triemli Hosp, Dept Surg, Zurich, Switzerland	Morganti-Kossmann, MC (corresponding author), Alfred Hosp, Natl Trauma Res Inst, Commercial Rd, Melbourne, Vic 3004, Australia.	cristina.morganti-kossmann@med.monash.edu.au	Ziebell, Jenna/Y-4496-2019	Morganti-Kossmann, Cristina/0000-0002-0807-2063; Ziebell, Jenna/0000-0003-2497-4347	Victorian Neurotrauma Initiative (VNI); Australian GovernmentAustralian GovernmentCGIAR; Transport Accident Commission (TAC); National Health and Medical Research Council (NHMRC)National Health and Medical Research Council of Australia	This study was supported by the Victorian Neurotrauma Initiative (VNI), Australian Government (Australian Postgraduate Award to BD Semple), Transport Accident Commission (TAC), and National Health and Medical Research Council (NHMRC).	Banisadr G, 2002, J NEUROCHEM, V81, P257, DOI 10.1046/j.1471-4159.2002.00809.x; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Berman JW, 1996, J IMMUNOL, V156, P3017; Buttram SDW, 2007, J NEUROTRAUM, V24, P1707, DOI 10.1089/neu.2007.0349; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Chen Y, 2003, J CEREBR BLOOD F MET, V23, P748, DOI 10.1097/01.WCB.0000071885.63724.20; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Conti AC, 1998, J NEUROSCI, V18, P5663; Dzenko KA, 2001, J NEUROSCI, V21, P9214, DOI 10.1523/JNEUROSCI.21-23-09214.2001; Eugenin EA, 2003, J NEUROCHEM, V85, P1299, DOI 10.1046/j.1471-4159.2003.01775.x; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; FUENTES ME, 1995, J IMMUNOL, V155, P5769; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Glabinski AR, 1996, J IMMUNOL, V156, P4363; Gourmala NG, 1997, J NEUROIMMUNOL, V74, P35, DOI 10.1016/S0165-5728(96)00203-2; Hausmann EHS, 1998, BRAIN RES, V788, P49, DOI 10.1016/S0006-8993(97)01160-8; Hermann DM, 2000, ACTA NEUROPATHOL, V99, P147, DOI 10.1007/PL00007418; Huang DR, 2001, J EXP MED, V193, P713, DOI 10.1084/jem.193.6.713; HUGHES CA, 2002, LEARNING DISABILITIE, V17, P1; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kuziel WA, 1997, P NATL ACAD SCI USA, V94, P12053, DOI 10.1073/pnas.94.22.12053; Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601; Ma MH, 2002, J NEUROSCI RES, V68, P691, DOI 10.1002/jnr.10269; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Muessel MJ, 2002, MOL BRAIN RES, V103, P12, DOI 10.1016/S0169-328X(02)00158-4; Muessel MJ, 2000, BRAIN RES, V870, P211, DOI 10.1016/S0006-8993(00)02450-1; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Rancan M, 2001, J NEUROSCI RES, V63, P438, DOI 10.1002/1097-4547(20010301)63:5<438::AID-JNR1039>3.0.CO;2-P; Rhodes J, 2009, J TRAUMA, V66, P1591, DOI 10.1097/TA.0b013e31819a0344; Rhodes JKJ, 2009, J NEUROTRAUM, V26, P507, DOI 10.1089/neu.2008.0686; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schilling M, 2009, NEUROSCIENCE, V161, P806, DOI 10.1016/j.neuroscience.2009.04.025; Schnell L, 1999, EUR J NEUROSCI, V11, P3648, DOI 10.1046/j.1460-9568.1999.00792.x; Schroeter M, 1997, STROKE, V28, P382, DOI 10.1161/01.STR.28.2.382; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P459, DOI 10.1038/jcbfm.2009.240; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stamatovic SM, 2005, J CEREBR BLOOD F MET, V25, P593, DOI 10.1038/sj.jcbfm.9600055; Tylaska LA, 2002, CYTOKINE, V18, P184, DOI 10.1006/cyto.2002.1031	40	213	215	2	21	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	APR	2010	30	4					769	782		10.1038/jcbfm.2009.262			14	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	577BZ	WOS:000276197200011	20029451	Green Published, Bronze			2021-06-18	
J	Jager, TE; Weiss, HB; Coben, JH; Pepe, PE				Jager, TE; Weiss, HB; Coben, JH; Pepe, PE			Traumatic brain injuries evaluated in US emergency departments, 1992-1994	ACADEMIC EMERGENCY MEDICINE			English	Article						traumatic brain injury; incidence; emergency department	TRENDS	Objective: To describe the incidence and patient characteristics of traumatic brain injuries (TBIs) treated in U.S. emergency departments (EDs). Methods: A secondary analysis was performed on data from the National Hospital Ambulatory Medical Care Survey administered from 1992 to 1994. An ED visit was determined to represent a case of TBI if the case record contained ICD-9-CM codes of 800.0-801.9, 803.0-804.9, or 850.0-854.1. Results: The average annual estimate of new TBI treated in U.S. EDs was 1,144,807, equaling 444 per 100,000 persons (95% CI = 390 to 498), which represents approximately 3,136 new cases of TBI per day and accounts for 1.3% of all ED visits. Males were 1.6 times as Likely as females to suffer TBT until the age of 65 years, when the female rate exceeded the male. The rate for blacks was 35% higher than that for whites. The highest overall incidence rate of TBI occurred in the less-than-5-year age group (1,091 per 100,000), closely followed by the more-than-85-year age group (1,026 per 100,000). Falls represented the most common mechanism of TBI injury, followed by motor vehicle-related trauma. Conclusions: This study underscores the ongoing need for effective surveillance of all ty-pes of TBT and evaluation of prevention strategies targeting high-risk individuals. It serves as a clinically grounded and ED-based corroboration of prior survey research, providing a basis for comparison of incidence rates over time and a tool with which to measure the efficacy of future interventions.	Allegheny Univ Hlth Sci, Dept Emergency Med, Allegheny Gen Hosp, Pittsburgh, PA USA; Allegheny Univ Hlth Sci, Ctr Violence & Injury Control, Allegheny Gen Hosp, Pittsburgh, PA USA	Coben, JH (corresponding author), One Allegheny Ctr, Ctr Violence & Injury Control, Suite 510, Pittsburgh, PA 15212 USA.		Weiss, Hank/D-1052-2010				Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Diamond PT, 1996, BRAIN INJURY, V10, P413, DOI 10.1080/026990596124278; Kraus JF, 1993, HEAD INJURY, P1; MACCIOCCHI SN, 1993, CURR OPIN NEUROL, V6, P773, DOI 10.1097/00019052-199310000-00016; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; McCaig L F, 1994, Vital Health Stat 1, P1; MCCAIG LF, 1994, ADV DTA VITAL HLTH S, V245; NOURHAH P, 1999, ADVDATA VITAL HLTH S, V304; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sosin DM, 1996, BRAIN INJURY, V10, P47; STUSSMAN BJ, 1996, ADV DATA VITAL HLTH, V274; STUSSMAN BJ, 1996, ADV DATA VITAL HLTH, V271; Thurman DJ., 1995, GUIDELINES SURVEILLA; *US DEP HHS CTR DI, 1997, TRAUM BRAIN INJ INJ; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509	16	213	215	0	7	HANLEY & BELFUS INC	PHILADELPHIA	210 S 13TH ST, PHILADELPHIA, PA 19107 USA	1069-6563			ACAD EMERG MED	Acad. Emerg. Med.	FEB	2000	7	2					134	140		10.1111/j.1553-2712.2000.tb00515.x			7	Emergency Medicine	Emergency Medicine	293XN	WOS:000085880700005	10691071				2021-06-18	
J	Iverson, GL; McCracken, LM				Iverson, GL; McCracken, LM			'Postconcussive' symptoms in persons with chronic pain	BRAIN INJURY			English	Article							COMPLAINT BASE RATES; MILD HEAD-INJURY; CLAIMANTS	The purpose of this study was to examine the base rate of cognitive and neurobehavioural complaints in patients with chronic pain (N = 170) who had not sustained a head injury. The patients completed a packet of questionnaires that contained numerous questions regarding physical, cognitive, and psychological symptoms. The 'postconcussive-like' symptoms were selected and analysed. Specific symptom endorsement rates ranged from 5% to 76.5%. Disturbed sleep, fatigue, and irritability were reported by the majority of chronic pain patients. Cognitive complaints relating to forgetfulness (29%), difficulty maintaining attention (18%), and difficulty with concentration or thinking (16.5%) were endorsed by a significant minority of patients. Most patients (80.6%) endorsed three or more symptoms from Category C of the DSM-IV Postconcussional Disorder research criteria. This study further illustrates that postconcussive-like symptoms are not unique sequelae of mild head injury, and the presence of chronic pain should be considered when interpreting patients' physical, cognitive, and psychological complaints following closed head injury.	RIVERVIEW HOSP,DEPT PSYCHOL,PORT COQUITLAM,BC,CANADA; UNIV CHICAGO,DEPT PSYCHIAT,CHICAGO,IL 60637; UNIV CHICAGO,DEPT ANESTHESIA & CRIT CARE,CHICAGO,IL 60637	Iverson, GL (corresponding author), UNIV BRITISH COLUMBIA,DEPT PSYCHIAT,2255 WESBROOK MALL,VANCOUVER,BC V6T 2A1,CANADA.			Iverson, Grant/0000-0001-7348-9570			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; CARDENA E, 1993, AM J PSYCHIAT, V150, P474; DUNN JT, 1995, J CLIN PSYCHOL, V51, P577, DOI 10.1002/1097-4679(199507)51:4<577::AID-JCLP2270510418>3.0.CO;2-E; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; MAIN CJ, 1983, J PSYCHOSOM RES, V27, P503, DOI 10.1016/0022-3999(83)90040-5; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; PARMELEE PA, 1993, J AM GERIATR SOC, V41, P517, DOI 10.1111/j.1532-5415.1993.tb01888.x; SCHNURR RF, 1995, CLIN J PAIN, V11, P101; SMITH EM, 1990, AM J PSYCHIAT, V147, P202; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3	18	213	215	0	8	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	NOV	1997	11	11					783	790		10.1080/026990597122990			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	YA149	WOS:A1997YA14900002	9354255				2021-06-18	
J	Tinetti, ME; Han, L; Lee, DSH; McAvay, GJ; Peduzzi, P; Gross, CP; Zhou, BQ; Lin, HQ				Tinetti, Mary E.; Han, Ling; Lee, David S. H.; McAvay, Gail J.; Peduzzi, Peter; Gross, Cary P.; Zhou, Bingqing; Lin, Haiqun			Antihypertensive Medications and Serious Fall Injuries in a Nationally Representative Sample of Older Adults	JAMA INTERNAL MEDICINE			English	Article							ADVERSE DRUG EVENTS; BLOOD-PRESSURE; ELDERLY-PATIENTS; BIAS REDUCTION; UNITED-STATES; RISK-FACTORS; HYPERTENSION; METAANALYSIS; POPULATION; HEALTH	IMPORTANCE The effect of serious injuries, such as hip fracture and head injury, on mortality and function is comparable to that of cardiovascular events. Concerns have been raised about the risk of fall injuries in older adults taking antihypertensive medications. The low risk of fall injuries reported in clinical trials of healthy older adults may not reflect the risk in older adults with multiple chronic conditions. OBJECTIVE To determine whether antihypertensive medication use was associated with experiencing a serious fall injury in a nationally representative sample of older adults. DESIGN, PARTICIPANTS, AND SETTING Competing risk analysis as performed with propensity score adjustment and matching in the nationally representative Medicare Current Beneficiary Survey cohort during a 3-year follow-up through 2009. Participants included 4961 community-living adults older than 70 years with hypertension. EXPOSURES Antihypertensive medication intensity based on the standardized daily dose for each antihypertensive medication class that participants used. MAIN OUTCOMES AND MEASURES Serious fall injuries, including hip and other major fractures, traumatic brain injuries, and joint dislocations, ascertained through Centers for Medicare & Medicaid Services claims. RESULTS Of the 4961 participants, 14.1% received no antihypertensive medications; 54.6% were in the moderate-intensity and 31.3% in the high-intensity antihypertensive groups. During follow-up, 446 participants (9.0%) experienced serious fall injuries, and 837 (16.9%) died. The adjusted hazard ratios for serious fall injury were 1.40 (95% CI, 1.03-1.90) in the moderate-intensity and 1.28 (95% CI, 0.91-1.80) in the high-intensity antihypertensive groups compared with nonusers. Although the difference in adjusted hazard ratios across the groups did not reach statistical significance, results were similar in the propensity score-matched subcohort. Among 503 participants with a previous fall injury, the adjusted hazard ratios were 2.17 (95% CI, 0.98-4.80) for the moderate-intensity and 2.31 (95% CI, 1.01-5.29) for the high-intensity antihypertensive groups. CONCLUSIONS AND RELEVANCE Antihypertensive medications were associated with an increased risk of serious fall injuries, particularly among those with previous fall injuries. The potential harms vs benefits of antihypertensive medications should be weighed in deciding to continue treatment with antihypertensive medications in older adults with multiple chronic conditions.	[Tinetti, Mary E.; Han, Ling; McAvay, Gail J.; Gross, Cary P.] Yale Univ, Sch Med, Dept Internal Med, Sect Geriatr, New Haven, CT 06520 USA; [Tinetti, Mary E.; Peduzzi, Peter; Zhou, Bingqing; Lin, Haiqun] Yale Univ, Sch Publ Hlth, New Haven, CT 06520 USA; [Lee, David S. H.] Oregon Hlth & Sci Univ, Oregon State Univ, Coll Pharm, Portland, OR 97201 USA	Tinetti, ME (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Sect Geriatr, 333 Cedar St,POB 208025, New Haven, CT 06520 USA.	mary.tinetti@yale.edu			National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01 AG038528, P30 AG021342]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG021342, R01AG038528] Funding Source: NIH RePORTER	This research was funded by the National Institute on Aging (grant R01 AG038528 and grant P30 AG021342 to the Yale Pepper Center).	Agostini JV, 2004, J AM GERIATR SOC, V52, P1719, DOI 10.1111/j.1532-5415.2004.52467.x; Allison P., 1999, LOGISTIC REGRESSION; Aronow WS, 2011, CIRCULATION, V123, P2434, DOI [10.1161/CIR.0b013e318222d03f, 10.1161/CIR.0b013e31821daaf6]; Austin PC, 2008, STAT MED, V27, P2037, DOI 10.1002/sim.3150; Barrett M., 2011, HCUP METHODS SERIES; Bejan-Angoulvant T, 2010, J HYPERTENS, V28, P1366, DOI 10.1097/HJH.0b013e328339f9c5; Berry SD, 2013, OSTEOPOROSIS INT, V24, P689, DOI 10.1007/s00198-012-2053-3; Butt DA, 2012, ARCH INTERN MED, V172, P1739, DOI 10.1001/2013.jamainternmed.469; Chobanian AV, 2003, JAMA-J AM MED ASSOC, V289, P2560, DOI 10.1001/jama.289.19.2560; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; Denardo SJ, 2010, AM J MED, V123, P719, DOI 10.1016/j.amjmed.2010.02.014; Dhruva SS, 2008, ARCH INTERN MED, V168, P136, DOI 10.1001/archinternmed.2007.56; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Faries D, 2010, ANAL OBSERVATIONAL H; Field TS, 2004, J AM GERIATR SOC, V52, P1349, DOI 10.1111/j.1532-5415.2004.52367.x; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Fried TR, 2008, J AM GERIATR SOC, V56, P1839, DOI 10.1111/j.1532-5415.2008.01923.x; Fried TR, 2011, ARCH INTERN MED, V171, P923, DOI 10.1001/archinternmed.2011.32; Gandhi TK, 2003, NEW ENGL J MED, V348, P1556, DOI 10.1056/NEJMsa020703; Gangavati A, 2011, J AM GERIATR SOC, V59, P383, DOI 10.1111/j.1532-5415.2011.03317.x; Goldstein LB, 2011, STROKE, V42, P517, DOI 10.1161/STR.0b013e3181fcb238; Gray SL, 1998, J GERONTOL A-BIOL, V53, pM59, DOI 10.1093/gerona/53A.1.M59; Gray SL, 1999, ANN PHARMACOTHER, V33, P1147, DOI 10.1345/aph.19036; Gribbin J, 2011, PHARMACOEPIDEM DR S, V20, P879, DOI 10.1002/pds.2176; Gribbin J, 2010, AGE AGEING, V39, P592, DOI 10.1093/ageing/afq092; Gu QP, 2012, CIRCULATION, V126, P2105, DOI 10.1161/CIRCULATIONAHA.112.096156; Gurwitz JH, 2003, JAMA-J AM MED ASSOC, V289, P1107, DOI 10.1001/jama.289.9.1107; Hajjar I, 2012, ARCH INTERN MED, V172, P442, DOI 10.1001/archinternmed.2011.1391; Hosmer D.W, 1999, APPL SURVIVAL ANAL R; Jatos Study Grp, 2008, HYPERTENS RES, V31, P2115, DOI 10.1291/hypres.31.2115; Johnson ES, 2013, PHARMACOEPIDEM DR S, V22, P1, DOI 10.1002/pds.3334; Kohl M, 2012, TECHNICAL REPORT; Kuo HK, 2004, J GERONTOL A-BIOL, V59, P1191, DOI 10.1093/gerona/59.11.1191; Leipzig RM, 1999, J AM GERIATR SOC, V47, P40, DOI 10.1111/j.1532-5415.1999.tb01899.x; Leon AC, 2007, STAT MED, V26, P110, DOI 10.1002/sim.2458; Messerli FH, 2006, ANN INTERN MED, V144, P884, DOI 10.7326/0003-4819-144-12-200606200-00005; Musini VM, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000028.pub2; Ogihara T, 2011, GERIATR GERONTOL INT, V11, P414, DOI 10.1111/j.1447-0594.2011.00690.x; Rozenfeld Suely, 2003, Rev Panam Salud Publica, V13, P369, DOI 10.1590/S1020-49892003000500005; Smith SC, 2011, CIRCULATION, V124, P2458, DOI 10.1161/CIR.0b013e318235eb4d; Solomon DH, 2011, J BONE MINER RES, V26, P1561, DOI 10.1002/jbmr.356; Tajeu GS, 2014, J GERONTOL A-BIOL, V69, P346, DOI 10.1093/gerona/glt105; Tinetti ME, 2008, J AM GERIATR SOC, V56, P1409, DOI 10.1111/j.1532-5415.2008.01815.x; TINETTI ME, 1995, J AM GERIATR SOC, V43, P1214, DOI 10.1111/j.1532-5415.1995.tb07396.x; Van Spall HGC, 2007, JAMA-J AM MED ASSOC, V297, P1233, DOI 10.1001/jama.297.11.1233; Voko Z, 1999, HYPERTENSION, V34, P1181, DOI 10.1161/01.HYP.34.6.1181; WESSLING A, 1990, EUR J CLIN PHARMACOL, V39, P207, DOI 10.1007/BF00315097; Woolcott JC, 2009, ARCH INTERN MED, V169, P1952, DOI 10.1001/archinternmed.2009.357; Xu R, 2000, Biostatistics, V1, P423, DOI 10.1093/biostatistics/1.4.423; Zhou BQ, 2012, BIOSTATISTICS, V13, P371, DOI 10.1093/biostatistics/kxr032	51	212	219	1	21	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6106	2168-6114		JAMA INTERN MED	JAMA Intern. Med.	APR	2014	174	4					588	595		10.1001/jamainternmed.2013.14764			8	Medicine, General & Internal	General & Internal Medicine	AI4NK	WOS:000336841900021	24567036	Bronze, Green Accepted	Y	N	2021-06-18	
J	Donkin, JJ; Vink, R				Donkin, James J.; Vink, Robert			Mechanisms of cerebral edema in traumatic brain injury: therapeutic developments	CURRENT OPINION IN NEUROLOGY			English	Article						aquaporins; cytotoxic edema; neurogenic inflammation; neurotrauma; neurovascular unit; trauma; vasogenic edema	SUBSTANCE-P IMMUNOREACTIVITY; B-2 RECEPTOR ANTAGONIST; BRADYKININ B2 RECEPTOR; GENE KNOCK-OUT; MATRIX METALLOPROTEINASES; NEUROGENIC INFLAMMATION; ISCHEMIC-STROKE; BARRIER PERMEABILITY; FUNCTIONAL DEFICITS; TISSUE INHIBITOR	Purpose of review Although a number of factors contribute to the high mortality and morbidity associated with traumatic brain injury (TBI), the development of cerebral edema with brain swelling remains the most significant predictor of outcome. The present review summarizes the most recent advances in the understanding of mechanisms associated with development of posttraumatic cerebral edema, and highlights areas of therapeutic promise. Recent findings Despite the predominance of cytotoxic (or cellular) edema in the first week after traumatic brain injury, brain swelling can only occur with addition of water to the cranial vault from the vasculature. As such, regulation of blood-brain barrier permeability has become a focus of recent research seeking to manage brain edema. Aquaporins, matrix metalloproteinases and vasoactive inflammatory agents have emerged as potential mediators of cerebral edema following traumatic brain injury. In particular, kinins (bradykinins) and tachykinins (substance P) seem to play an active physiological role in modulating blood-brain barrier permeability after trauma. Substance P neurokinin-1 receptor antagonists show particular promise as novel therapeutic agents. Summary Attenuating blood-brain barrier permeability has become a promising approach to managing brain edema and associated swelling given that increases in cranial water content can only be derived from the vasculature. Inflammation, both classical and neurogenic, offers a number of attractive targets.	[Donkin, James J.] Univ British Columbia, Dept Pathol & Lab Med, Child & Family Res Inst, Vancouver, BC V5Z 4H4, Canada; [Vink, Robert] Univ Adelaide, Discipline Anat & Pathol, Adelaide, SA, Australia	Donkin, JJ (corresponding author), Univ British Columbia, Dept Pathol & Lab Med, Child & Family Res Inst, 950 W 28th Ave, Vancouver, BC V5Z 4H4, Canada.	jdonkin@cmmt.ubc.ca	Vink, Robert/J-7351-2012; AM, Robert Vink/S-5616-2019	Vink, Robert/0000-0002-4885-0667; AM, Robert Vink/0000-0002-4885-0667	Neurosurgical Research Foundation, Australia; Alzheimer's Society of Canada	R. V. is supported by the Neurosurgical Research Foundation, Australia. J.J.D is supported by the Alzheimer's Society of Canada Postdoctoral Fellowship. We thank Tavik Morgenstern for the medical illustration.	Abbott NJ, 2000, CELL MOL NEUROBIOL, V20, P131, DOI 10.1023/A:1007074420772; Aoki K, 2003, ACTA NEUROPATHOL, V106, P121, DOI 10.1007/s00401-003-0709-y; Asahi M, 2001, J NEUROSCI, V21, P7724; Badaut T, 2002, J CEREBR BLOOD F MET, V22, P367, DOI 10.1097/00004647-200204000-00001; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; BRAIN SD, 1985, BRIT J PHARMACOL, V86, P855, DOI 10.1111/j.1476-5381.1985.tb11107.x; Candelario-Jalil E, 2009, NEUROSCIENCE, V158, P983, DOI 10.1016/j.neuroscience.2008.06.025; Ding JY, 2009, BRAIN RES, V1268, P125, DOI 10.1016/j.brainres.2009.02.060; Ding JY, 2009, NEUROSCI LETT, V453, P68, DOI 10.1016/j.neulet.2009.01.077; Donkin JJ, 2009, J CEREBR BLOOD F MET, V29, P1388, DOI 10.1038/jcbfm.2009.63; Donkin JJ, 2004, PROCEEDINGS OF THE 7TH INTERNATIONAL NEUROTRAUMA SYMPOSIUM, P75; Falo MC, 2006, J NEUROSCI RES, V84, P768, DOI 10.1002/jnr.20986; Fazzina G, 2009, J NEUROTRAUMA; Feickert HJ, 1999, J TRAUMA, V47, P33, DOI 10.1097/00005373-199907000-00008; Fujimoto M, 2008, J CEREBR BLOOD F MET, V28, P1674, DOI 10.1038/jcbfm.2008.59; Gasche Y, 1999, J CEREBR BLOOD F MET, V19, P1020, DOI 10.1097/00004647-199909000-00010; GEPPETTI P, 1995, CAN J PHYSIOL PHARM, V73, P843, DOI 10.1139/y95-115; Ghabriel MN, 2006, ACTA NEUROCHIR SUPPL, V96, P402; Gidday JM, 2005, AM J PHYSIOL-HEART C, V289, pH558, DOI 10.1152/ajpheart.01275.2004; Grossetete M, 2009, NEUROSURGERY, V65, P702, DOI 10.1227/01.NEU.0000351768.11363.48; Habgood MD, 2007, EUR J NEUROSCI, V25, P231, DOI 10.1111/j.1460-9568.2006.05275.x; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; Hayashi T, 2009, BRAIN RES, V1280, P172, DOI 10.1016/j.brainres.2009.05.040; Homsi S, 2009, BRAIN RES, V1291, P122, DOI 10.1016/j.brainres.2009.07.031; Ker K, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006686.pub2; Kikuchi K, 2009, BIOCHEM BIOPH RES CO, V390, P1121, DOI 10.1016/j.bbrc.2009.09.015; KLATZO I, 1987, ACTA NEUROPATHOL, V72, P236, DOI 10.1007/BF00691095; Luh C, 2010, J NEUROCHEM, V112, P1015, DOI 10.1111/j.1471-4159.2009.06514.x; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Marmarou A, 1980, Adv Neurol, V28, P345; Marmarou A, 2003, ACT NEUR S, V86, P7; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Nag S, 2009, ACTA NEUROPATHOL, V118, P197, DOI 10.1007/s00401-009-0541-0; Nimmo AJ, 2004, NEUROPEPTIDES, V38, P40, DOI 10.1016/j.npep.2003.12.003; O'Connor CA, 2006, ACTA NEUROCHIR SUPPL, V96, P121; Papadopoulos MC, 2007, PEDIATR NEPHROL, V22, P778, DOI 10.1007/s00467-006-0411-0; Papadopoulos MC, 2008, PROG BRAIN RES, V170, P589, DOI 10.1016/S0079-6123(08)00446-9; Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje; PASANTESMORALES H, 2009, NEUROSCIENCE; Plesnila N, 2001, J NEUROTRAUM, V18, P1049, DOI 10.1089/08977150152693746; REULEN HJ, 1977, J NEUROSURG, V46, P24, DOI 10.3171/jns.1977.46.1.0024; Rosenberg Gary A, 2007, Neurosurg Focus, V22, pE4; Rosenberg GA, 2009, LANCET NEUROL, V8, P205, DOI 10.1016/S1474-4422(09)70016-X; Shakur H, 2009, TRIALS, V10, DOI 10.1186/1745-6215-10-109; Simard JM, 2007, LANCET NEUROL, V6, P258, DOI 10.1016/S1474-4422(07)70055-8; Sorani MD, 2008, HUM MOL GENET, V17, P2379, DOI 10.1093/hmg/ddn138; Su JJ, 2009, BIOCHEM BIOPH RES CO, V388, P205, DOI 10.1016/j.bbrc.2009.07.135; Sun MC, 2003, J NEUROSURG, V98, P565, DOI 10.3171/jns.2003.98.3.0565; Taya K, 2010, J NEUROTRAUM, V27, P229, DOI 10.1089/neu.2009.0933; Taya K, 2008, ACTA NEUROCHIR SUPPL, V102, P425, DOI 10.1007/978-3-211-85578-2_83; Tejima E, 2009, J NEUROTRAUM, V26, P1935, DOI 10.1089/neu.2009.0959; Trabold R, 2010, J CEREBR BLOOD F MET, V30, P130, DOI 10.1038/jcbfm.2009.196; TRAN N, 2009, J NEUROSURG; Turner RJ, 2006, ACTA NEUROCHIR SUPPL, V96, P263; Turner R, 2007, DRUG NEWS PERSPECT, V20, P221, DOI 10.1358/dnp.2007.20.4.1103527; Vajtr D, 2009, PHYSIOL RES, V58, P263, DOI 10.33549/physiolres.931253; Vilalta A, 2008, INTENS CARE MED, V34, P1384, DOI 10.1007/s00134-008-1056-1; Vink R, 2003, ACT NEUR S, V86, P257; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Zacest AC, 2010, ACTA NEUROCHIR SUPPL, V106, P211, DOI 10.1007/978-3-211-98811-4_39; Zausinger S, 2003, ACT NEUR S, V86, P205; Zhao BQ, 2006, NAT MED, V12, P441, DOI 10.1038/nm1387; Zweckberger K, 2009, NEUROSCI LETT, V454, P115, DOI 10.1016/j.neulet.2009.02.014	66	212	236	0	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1350-7540	1473-6551		CURR OPIN NEUROL	Curr. Opin. Neurol.	JUN	2010	23	3					293	299		10.1097/WCO.0b013e328337f451			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	599QR	WOS:000277928700015	20168229				2021-06-18	
J	Riddell, DR; Zhou, H; Atchison, K; Warwick, HK; Atkinson, PJ; Jefferson, J; Xu, L; Aschmies, S; Kirksey, Y; Hu, Y; Wagner, E; Parratt, A; Xu, J; Li, ZT; Zaleska, MM; Jacobsen, JS; Pangalos, MN; Reinhart, PH				Riddell, David R.; Zhou, Hua; Atchison, Kevin; Warwick, Helen K.; Atkinson, Peter J.; Jefferson, Julius; Xu, Lin; Aschmies, Suzan; Kirksey, Yolanda; Hu, Yun; Wagner, Erik; Parratt, Adrienne; Xu, Jane; Li, Zhuting; Zaleska, Margaret M.; Jacobsen, J. Steve; Pangalos, Menelas N.; Reinhart, Peter H.			Impact of Apolipoprotein E (ApoE) Polymorphism on Brain ApoE Levels	JOURNAL OF NEUROSCIENCE			English	Article						apolipoprotein E; astrocyte; degradation; Alzheimer's disease; immunoassay; liver X receptor	A-BETA LEVELS; AMYOTROPHIC-LATERAL-SCLEROSIS; CLOSED-HEAD INJURY; LIVER-X-RECEPTOR; E-DEFICIENT MICE; ALZHEIMERS-DISEASE; TRANSGENIC MICE; E GENOTYPE; CHOLESTEROL EFFLUX; MOUSE MODEL	Inheritance of the apoE4 allele (epsilon 4) increases the risk of developing Alzheimer's disease; however, the mechanisms underlying this association remain elusive. Recent data suggest that inheritance of epsilon 4 may lead to reduced apoE protein levels in the CNS. We therefore examined apoE protein levels in the brains, CSF and plasma of epsilon 2/2, epsilon 3/3, and epsilon 4/4 targeted replacement mice. These apoE mice showed a genotype-dependent decrease in apoE levels; epsilon 2/2 > epsilon 3/3 > epsilon 4/4. Next, we sought to examine the relative contributions of apoE4 and apoE3 in the epsilon 3/4 mouse brains. ApoE4 represented 30-40% of the total apoE. Moreover, the absolute amount of apoE3 per allele was similar between epsilon 3/3 and epsilon 3/4 mice, implying that the reduced levels of total apoE in epsilon 3/4 mice can be explained by the reduction in apoE4 levels. In culture medium from epsilon 3/4 human astrocytoma or epsilon 3/3, epsilon 4/4 and epsilon 3/4 primary astrocytes, apoE4 levels were consistently lower than apoE3. Secreted cholesterol levels were also lower from epsilon 4/4 astrocytes. Pulse-chase experiments showed an enhanced degradation and reduced half-life of newly synthesized apoE4 compared with apoE3. Together, these data suggest that astrocytes preferentially degrade apoE4, leading to reduced apoE4 secretion and ultimately to reduced brain apoE levels. Moreover, the genotype-dependent decrease in CNS apoE levels, mirror the relative risk of developing AD, and suggest that low levels of total apoE exhibited by epsilon 4 carriers may directly contribute to the disease progression, perhaps by reducing the capacity of apoE to promote synaptic repair and/or A beta clearance.	[Riddell, David R.; Zhou, Hua; Atchison, Kevin; Warwick, Helen K.; Atkinson, Peter J.; Jefferson, Julius; Xu, Lin; Aschmies, Suzan; Kirksey, Yolanda; Hu, Yun; Wagner, Erik; Parratt, Adrienne; Xu, Jane; Li, Zhuting; Zaleska, Margaret M.; Jacobsen, J. Steve; Pangalos, Menelas N.; Reinhart, Peter H.] Wyeth Ayerst Res, Discovery Neurosci, Princeton, NJ 08543 USA	Riddell, DR (corresponding author), Wyeth Ayerst Res, Discovery Neurosci, CN8000, Princeton, NJ 08543 USA.	riddeld@wyeth.com			Wyeth PharmaceuticalsWyeth	This work was supported by Wyeth Pharmaceuticals.	Beffert U, 1999, BRAIN RES, V843, P87, DOI 10.1016/S0006-8993(99)01894-6; BERTRAND P, 1995, MOL BRAIN RES, V33, P174, DOI 10.1016/0169-328X(95)00097-C; BOYLES JK, 1985, J CLIN INVEST, V76, P1501, DOI 10.1172/JCI112130; Brecht WJ, 2004, J NEUROSCI, V24, P2527, DOI 10.1523/JNEUROSCI.4315-03.2004; Burns MP, 2006, J NEUROCHEM, V98, P792, DOI 10.1111/j.1471-4159.2006.03925.x; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Corder EH, 2004, ANN NY ACAD SCI, V1019, P24, DOI 10.1196/annals.1297.005; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; DeMattos RB, 2002, J NEUROCHEM, V81, P229, DOI 10.1046/j.1471-4159.2002.00889.x; DeMattos RB, 2004, NEURON, V41, P193, DOI 10.1016/S0896-6273(03)00850-X; DENG JT, 1995, J LIPID RES, V36, P2129; Enzinger C, 2004, ANN NEUROL, V55, P563, DOI 10.1002/ana.20027; ETO M, 1986, CLIN GENET, V29, P477; Fagan AM, 1998, EXP NEUROL, V151, P314, DOI 10.1006/exnr.1998.6818; Fazekas F, 2001, NEUROLOGY, V57, P853, DOI 10.1212/WNL.57.5.853; FernandezMiranda C, 1997, CLIN TRANSPLANT, V11, P325; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Fryer JD, 2005, J NEUROSCI, V25, P2803, DOI 10.1523/JNEUROSCI.5170-04.2005; Fukumoto H, 2003, EXP NEUROL, V183, P249, DOI 10.1016/S0014-4886(03)00088-8; Glockner F, 2002, NEUROSCIENCE, V114, P1103; GREGG RE, 1986, J CLIN INVEST, V78, P815, DOI 10.1172/JCI112645; Guerrero AL, 2008, ACTA NEUROL SCAND, V117, P21, DOI 10.1111/j.1600-0404.2007.00908.x; HANDELMANN GE, 1992, J LIPID RES, V33, P1677; Hara M, 2003, ARTERIOSCL THROM VAS, V23, P269, DOI 10.1161/01.ATV.0000054199.78458.4B; Hatters DM, 2006, TRENDS BIOCHEM SCI, V31, P445, DOI 10.1016/j.tibs.2006.06.008; HIXSON JE, 1990, J LIPID RES, V31, P545; Huang YD, 2001, P NATL ACAD SCI USA, V98, P8838, DOI 10.1073/pnas.151254698; Jasinska-Myga B, 2007, ARCH NEUROL-CHICAGO, V64, P261, DOI 10.1001/archneur.64.2.261; Ji Y, 2003, NEUROSCIENCE, V122, P305, DOI 10.1016/j.neuroscience.2003.08.007; Karussis D, 2003, MULT SCLER, V9, P476, DOI 10.1191/1352458503ms950oa; Knouff C, 1999, J CLIN INVEST, V103, P1579, DOI 10.1172/JCI6172; Kockx M, 2004, J BIOL CHEM, V279, P25966, DOI 10.1074/jbc.M401177200; Koistinaho M, 2004, NAT MED, V10, P719, DOI 10.1038/nm1058; Koldamova T, 2005, J BIOL CHEM, V280, P4079, DOI 10.1074/jbc.M411420200; Krul ES, 1996, METHOD ENZYMOL, V263, P170; LaDu MJ, 1998, J NEUROCHEM, V70, P2070; Lai MKP, 2006, NEUROBIOL DIS, V22, P555, DOI 10.1016/j.nbd.2005.12.016; Laskowitz DT, 1997, J CEREBR BLOOD F MET, V17, P753; Liang Y, 2004, J NEUROCHEM, V88, P623, DOI 10.1111/j.1471-4159.2004.02183.x; Manelli AM, 2004, J MOL NEUROSCI, V23, P235, DOI 10.1385/JMN:23:3:235; Mann KM, 2004, HUM MOL GENET, V13, P1959, DOI 10.1093/hmg/ddh199; Marriott DR, 1995, NEURAL CELL CULTURE; Mauch DH, 2001, SCIENCE, V294, P1354, DOI 10.1126/science.294.5545.1354; Morrow JA, 2002, J BIOL CHEM, V277, P50380, DOI 10.1074/jbc.M204898200; Moulard B, 1996, J NEUROL SCI, V139, P34, DOI 10.1016/0022-510X(96)00085-8; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; O'Donnell HC, 2000, NEW ENGL J MED, V342, P240, DOI 10.1056/NEJM200001273420403; Pankratz N, 2006, MOVEMENT DISORD, V21, P45, DOI 10.1002/mds.20663; Pfrieger FW, 2003, BBA-BIOMEMBRANES, V1610, P271, DOI 10.1016/S0005-2736(03)00024-5; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; Poirier J, 2005, NEUROBIOL AGING, V26, P355, DOI 10.1016/j.neurobiolaging.2004.09.003; Quinet EM, 2004, J LIPID RES, V45, P1929, DOI 10.1194/jlr.M400257-JLR200; Raber J, 2004, NEUROBIOL AGING, V25, P641, DOI 10.1016/j.neurobiolaging.2003.12.023; Raffai RL, 2001, P NATL ACAD SCI USA, V98, P11587, DOI 10.1073/pnas.201279298; Ramaswamy G, 2005, J NEUROSCI, V25, P10658, DOI 10.1523/JNEUROSCI.1922-05.2005; Riddell DR, 2007, MOL CELL NEUROSCI, V34, P621, DOI 10.1016/j.mcn.2007.01.011; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; Santucci R, 2008, MINI-REV MED CHEM, V8, P57, DOI 10.2174/138955708783331522; Schneider JA, 2005, STROKE, V36, P954, DOI 10.1161/01.STR.0000160747.27470.2a; Sheng HX, 1998, J CEREBR BLOOD F MET, V18, P361, DOI 10.1097/00004647-199804000-00003; Sheng HX, 1999, STROKE, V30, P1118, DOI 10.1161/01.STR.30.5.1118; Siddique T, 1998, NEUROGENETICS, V1, P213, DOI 10.1007/s100480050031; Stratman NC, 2005, CHEM PHYS LIPIDS, V137, P52, DOI 10.1016/j.chemphyslip.2005.06.005; Sullivan PM, 2004, NEUROSCIENCE, V124, P725, DOI 10.1016/j.neuroscience.2003.10.011; Trommer BL, 2005, NEUROBIOL DIS, V18, P75, DOI 10.1016/j.nbd.2004.08.011; Weisgraber KH, 1996, FASEB J, V10, P1485; White F, 2001, NEUROBIOL DIS, V8, P611, DOI 10.1006/nbdi.2001.0401; YE SQ, 1993, J BIOL CHEM, V268, P8497	68	212	214	0	7	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	NOV 5	2008	28	45					11445	11453		10.1523/JNEUROSCI.1972-08.2008			9	Neurosciences	Neurosciences & Neurology	369AV	WOS:000260665900003	18987181	Green Published, Other Gold			2021-06-18	
J	Schwab, KA; Ivins, B; Cramer, G; Johnson, W; Sluss-Tiller, M; Kiley, K; Lux, W; Warden, D				Schwab, Karen A.; Ivins, Brian; Cramer, Gayle; Johnson, Wayne; Sluss-Tiller, Melissa; Kiley, Kevin; Lux, Warren; Warden, Deborah			Screening for traumatic brain injury in troops returning from deployment in Afghanistan and Iraq: Initial investigation of the usefulness of a short screening tool for traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						traumatic brain injury (TBI); US Army; screening; validation study	HEAD-INJURY; MILD; CONCUSSION; SPORTS	Objective: Preliminary assessment of a new instrument, the Brief Traumatic Brain Injury Screen (BTBIS). Design: Cross-sectional study of 596 soldiers returning from Iraq and/or Afghanistan, comparing the consistency of their reports of traumatic brain injury (TBI) across instruments with similar TBI questions, and in a brief follow-up interview. Setting: Military base. Measures: Self-reported probable TBI on the BTBIS and on 2 longer questionnaires, and a brief follow-up interview. Results: Self-reports of probable TBI were higher on the BTBIS, than on the longer instruments. Participants who screened positive on the BTBIS generally provided consistent information about probable TBI in the follow-up interview. Conclusions: In this initial study, the BTBIS demonstrated promise as part of a triage process in mass casualty situations, permitting individuals with probable TBI to self-report injury and continued symptoms. Further study, including full validation and reliability assessment, is warranted and required before these screening tools can be fully evaluated.	Walter Reed Army Med Ctr, Defense & Vet Brain Injury Ctr, Washington, DC 20012 USA; Womack Army Med Ctr, Dept Behav Hlth, Ft Bragg, NC USA; USA, Off Surg Gen, Arlington, VA USA	Schwab, KA (corresponding author), Walter Reed Army Med Ctr, Defense & Vet Brain Injury Ctr, Washington, DC 20012 USA.						Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; De Monte VE, 2004, J CLIN EXP NEUROPSYC, V26, P628, DOI 10.1080/13803390490504443; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; Harmon KG, 1999, AM FAM PHYSICIAN, V60, P887; *HARR INT INC BRAI, HARR POLL 2000 PUBL; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; McCrea M., 2000, STANDARDIZED ASSESSM; McCullagh S, 2003, J NEUROL NEUROSUR PS, V74, P39, DOI 10.1136/jnnp.74.1.39; Moss NEG, 1996, INJURY, V27, P159, DOI 10.1016/0020-1383(95)00217-0; Mower WR, 2002, ANN EMERG MED, V40, P505, DOI 10.1067/mem.2002.129245; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Pickelsimer EE, 2007, J HEAD TRAUMA REHAB, V22, P1, DOI 10.1097/00001199-200701000-00001; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Sosin DM, 1996, BRAIN INJURY, V10, P47; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; World Health Organization, 1992, ICD 10 CLASS MENT BE	26	212	212	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2007	22	6					377	389		10.1097/01.HTR.0000300233.98242.87			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	234RN	WOS:000251181500008	18025970				2021-06-18	
J	Zhang, XP; Chen, J; Graham, SH; Du, LN; Kochanek, PM; Draviam, R; Guo, FL; Nathaniel, PD; Szabo, C; Watkins, SC; Clark, RSB				Zhang, XP; Chen, J; Graham, SH; Du, LN; Kochanek, PM; Draviam, R; Guo, FL; Nathaniel, PD; Szabo, C; Watkins, SC; Clark, RSB			Intranuclear localization of apoptosis-inducing factor (AIF) and large scale dna fragmentation after traumatic brain injury in rats and in neuronal cultures exposed to peroxynitrite	JOURNAL OF NEUROCHEMISTRY			English	Article						apoptosis; brain injury; controlled cortical impact; DNA damage; programmed cell death	CORTICAL IMPACT INJURY; PROGRAMMED CELL-DEATH; HEAD-INJURY; DENTATE GYRUS; ACTIVATION; BCL-2; CASPASE-3; CLEAVAGE; PROTEASE; EXPRESSION	Programmed cell death occurs after ischemic, excitotoxic, and traumatic brain injury (TBI). Recently, a caspase-independent pathway involving intranuclear translocation of mitochondrial apoptosis-inducing factor (AIF) has been reported in vitro; but whether this occurs after acute brain injury was unknown. To address this question adult rats were sacrificed at various times after TBI. Western blot analysis on subcellular protein fractions demonstrated intranuclear localization of AIF in ipsilateral cortex and hippocampus at 2-72 h. Immunocytochemical analysis showed AIF labeling in neuronal nuclei with DNA fragmentation in the ipsilateral cortex and hippocampus. Immunoelectronmicroscopy verified intranuclear localization of AIF in hippocampal neurons after TBI, primarily in regions of euchromatin. Large-scale DNA fragmentation (similar to50 kbp), a signature event in AIF-mediated cell death, was detected in ipsilateral cortex and hippocampi by 6 h. Neuron-enriched cultures exposed to peroxynitrite also demonstrated intranuclear AIF and large-scale DNA fragmentation concurrent with impaired mitochondrial respiration and cell death, events that are inhibited by treatment with a peroxynitrite decomposition catalyst. Intranuclear localization of AIF and large-scale DNA fragmentation occurs after TBI and in neurons under conditions of oxidative/nitrosative stress, providing the first evidence of this alternative mechanism by which programmed cell death may proceed in neurons after brain injury.	Safar Ctr Resuscitat Res, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA 15260 USA; Safar Ctr Resuscitat Res, Dept Neurol, Pittsburgh, PA USA; Safar Ctr Resuscitat Res, Dept Pediat, Pittsburgh, PA USA; Safar Ctr Resuscitat Res, Dept Cell Biol & Physiol, Pittsburgh, PA USA; Univ Pittsburgh, Brain Trauma Res Ctr, Pittsburgh, PA USA; Vet Affairs Pittsburgh Hlth Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA; Inotek Corp, Beverly, MA USA	Clark, RSB (corresponding author), Safar Ctr Resuscitat Res, Dept Anesthesiol & Crit Care Med, 3434 5th Ave, Pittsburgh, PA 15260 USA.		Szabo, Csaba/D-1882-2013; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; watkins, simon/0000-0003-4092-1552	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038620, P50NS030318] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50 NS 30318, R01 NS 38620] Funding Source: Medline		Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Braun JS, 2001, J INFECT DIS, V184, P1300, DOI 10.1086/324013; BREWER GJ, 1995, J NEUROSCI RES, V42, P674, DOI 10.1002/jnr.490420510; Buki A, 2000, J NEUROSCI, V20, P2825; Cao GD, 2001, J NEUROSCI, V21, P4678, DOI 10.1523/JNEUROSCI.21-13-04678.2001; CHARRIAUTMARLANGUE C, 1995, J CEREBR BLOOD F MET, V15, P385, DOI 10.1038/jcbfm.1995.48; Chen DX, 2000, J BIOL CHEM, V275, P38508, DOI 10.1074/jbc.M003906200; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Clark RSB, 2001, J NEUROTRAUM, V18, P675, DOI 10.1089/089771501750357627; Clark RSB, 1997, J NEUROSCI, V17, P9172; Clark RSB, 1999, FASEB J, V13, P813; Clark RSB, 2000, J PEDIATR-US, V137, P197, DOI 10.1067/mpd.2000.106903; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; Daugas E, 2000, FEBS LETT, V476, P118, DOI 10.1016/S0014-5793(00)01731-2; Daugas E, 2000, FASEB J, V14, P729; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dumont C, 2000, BLOOD, V96, P1030, DOI 10.1182/blood.V96.3.1030.015k21_1030_1038; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Henshall DC, 2000, J NEUROCHEM, V74, P1215; Hill IE, 2000, EXP NEUROL, V162, P73, DOI 10.1006/exnr.2000.7322; Joza N, 2001, NATURE, V410, P549, DOI 10.1038/35069004; Loeffler M, 2001, FASEB J, V15, P758, DOI 10.1096/fj.00-0388com; MacManus JP, 2000, J NEUROTRAUM, V17, P899, DOI 10.1089/neu.2000.17.899; MacManus JP, 1997, J CEREBR BLOOD F MET, V17, P376, DOI 10.1097/00004647-199704000-00003; MACMANUS JP, 1995, J CEREBR BLOOD F MET, V15, P728, DOI 10.1038/jcbfm.1995.93; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Pravdenkova SV, 1996, BRAIN RES, V729, P151, DOI 10.1016/0006-8993(96)00222-3; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; RINK A, 1995, AM J PATHOL, V147, P1575; Scott GS, 1999, ANN NEUROL, V45, P120, DOI 10.1002/1531-8249(199901)45:1<120::AID-ART18>3.0.CO;2-I; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Smith FM, 2000, ACTA NEUROPATHOL, V100, P537, DOI 10.1007/s004010000222; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; SUN XM, 1994, J BIOL CHEM, V269, P14857; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Szabo C, 2002, FASEB J, V16, pA1166; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; WALKER PR, 1993, BIOTECHNIQUES, V15, P1032; WALKER PR, 1994, EXP CELL RES, V213, P100, DOI 10.1006/excr.1994.1178; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zhang C, 1999, J NEUROCHEM, V73, P1650, DOI 10.1046/j.1471-4159.1999.0731650.x; ZHIVOTOVSKY B, 1994, FEBS LETT, V351, P150, DOI 10.1016/0014-5793(94)00827-2	49	212	217	0	3	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0022-3042			J NEUROCHEM	J. Neurochem.	JUL	2002	82	1					181	191		10.1046/j.1471-4159.2002.00975.x			11	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	566QC	WOS:000176438900021	12091479				2021-06-18	
J	Tang-Schomer, MD; Patel, AR; Baas, PW; Smith, DH				Tang-Schomer, Min D.; Patel, Ankur R.; Baas, Peter W.; Smith, Douglas H.			Mechanical breaking of microtubules in axons during dynamic stretch injury underlies delayed elasticity, microtubule disassembly, and axon degeneration	FASEB JOURNAL			English	Article						traumatic brain injury; traumatic axonal injury; taxol; micropattern	AMYLOID PRECURSOR PROTEIN; TRAUMATIC BRAIN-INJURY; HEAD-INJURY; SODIUM-CHANNELS; BETA-APP; CYTOSKELETAL; ELONGATION; GROWTH; TETRODOTOXIN; ACCUMULATION	Little is known about which components of the axonal cytoskeleton might break during rapid mechanical deformation, such as occurs in traumatic brain injury. Here, we micropatterned neuronal cell cultures on silicone membranes to induce dynamic stretch exclusively of axon fascicles. After stretch, undulating distortions formed along the axons that gradually relaxed back to a straight orientation, demonstrating a delayed elastic response. Subsequently, swellings developed, leading to degeneration of almost all axons by 24 h. Stabilizing the microtubules with taxol maintained the undulating geometry after injury but greatly reduced axon degeneration. Conversely, destabilizing microtubules with nocodazole prevented undulations but greatly increased the rate of axon loss. Ultrastructural analyses of axons postinjury revealed immediate breakage and buckling of microtubules in axon undulations and progressive loss of microtubules. Collectively, these data suggest that dynamic stretch of axons induces direct mechanical failure at specific points along microtubules. This microtubule disorganization impedes normal relaxation of the axons, resulting in undulations. However, this physical damage also triggers progressive disassembly of the microtubules around the breakage points. While the disintegration of microtubules allows delayed recovery of the "normal" straight axon morphology, it comes at a great cost by interrupting axonal transport, leading to axonal swelling and degeneration.-Tang-Schomer, M. D., Patel, A. R,, Baas, P. W., Smith, D. H. Mechanical breaking of microtubules in axons during dynamic stretch injury underlies delayed elasticity, microtubule disassembly, and axon degeneration. FASEB J. 24, 1401-1410 (2010). www.fasebj.org	[Tang-Schomer, Min D.; Patel, Ankur R.; Smith, Douglas H.] Univ Penn, Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA; [Tang-Schomer, Min D.; Patel, Ankur R.; Smith, Douglas H.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; [Baas, Peter W.] Drexel Univ, Coll Med, Dept Neurobiol & Anat, Philadelphia, PA 19104 USA	Smith, DH (corresponding author), 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.	smithdou@mail.med.upenn.edu	Tang-Schomer, Min/AAD-9501-2020; smith, douglas/A-1321-2007; Tang-Schomer, Min/C-1967-2013	Tang-Schomer, Min/0000-0001-7585-3890; 	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS-056202, NS-038104, NS-048949]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048949, P01NS056202, R01NS038104] Funding Source: NIH RePORTER	The authors thank Tracy Yuen, Catherine von Reyn, and Matthew Weingard from the Center for Brain Injury and Repair, University of Pennsylvania, for technical assistance; Ray Meade from the Biomedical Imaging Core, University of Pennsylvania, for electron microscopic assistance; and Dr. David Meaney from the Department of Bioengineering, University of Pennsylvania, for insightful discussions. This work is supported by NIH grants NS-056202, NS-038104, and NS-048949 (to D. H. S.).	ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; AHMAD FJ, 1993, J NEUROSCI, V13, P856; BAAS PW, 1993, J NEUROSCI, V13, P2177; Chen XH, 1999, J NEUROPATH EXP NEUR, V58, P588, DOI 10.1097/00005072-199906000-00003; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Chuckowree JA, 2003, J NEUROSCI, V23, P3715; DENNERLL TJ, 1989, J CELL BIOL, V109, P3073, DOI 10.1083/jcb.109.6.3073; Dent EW, 2003, NEURON, V40, P209, DOI 10.1016/S0896-6273(03)00633-0; Dimitrov A, 2008, SCIENCE, V322, P1353, DOI 10.1126/science.1165401; DRECHSEL DN, 1994, CURR BIOL, V4, P1053, DOI 10.1016/S0960-9822(00)00243-8; DYE RB, 1993, J BIOL CHEM, V268, P6847; Erturk A, 2007, J NEUROSCI, V27, P9169, DOI 10.1523/JNEUROSCI.0612-07.2007; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GITTES F, 1993, J CELL BIOL, V120, P923, DOI 10.1083/jcb.120.4.923; Gorrie C, 2002, J NEUROTRAUM, V19, P1171, DOI 10.1089/08977150260337976; Hammarlund M, 2007, J CELL BIOL, V176, P269, DOI 10.1083/jcb.200611117; Howard J, 2003, NATURE, V422, P753, DOI 10.1038/nature01600; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; Jafari SS, 1997, J NEUROCYTOL, V26, P207, DOI 10.1023/A:1018588114648; Jordan MA, 1998, METHOD ENZYMOL, V298, P252, DOI 10.1016/S0076-6879(98)98024-7; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; MCINTOSH JR, 1984, NATURE, V312, P196, DOI 10.1038/312196b0; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; MICKEY B, 1995, J CELL BIOL, V130, P909, DOI 10.1083/jcb.130.4.909; Myers KA, 2007, J CELL BIOL, V178, P1081, DOI 10.1083/jcb.200702074; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Shi R, 2002, NEUROSCIENCE, V110, P765, DOI 10.1016/S0306-4522(01)00596-6; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Smith DH, 1999, J NEUROSCI, V19, P4263; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; TANAKA EM, 1991, J CELL BIOL, V115, P345, DOI 10.1083/jcb.115.2.345; Tang MD, 2003, J AM CHEM SOC, V125, P12988, DOI 10.1021/ja037677h; VanBuren V, 2005, BIOPHYS J, V89, P2911, DOI 10.1529/biophysj.105.060913; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; ZHENG J, 1991, J NEUROSCI, V11, P1117	43	211	216	0	38	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2010	24	5					1401	1410		10.1096/fj.09-142844			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	589OD	WOS:000277158900013	20019243	Green Published			2021-06-18	
J	HALL, ED; ANDRUS, PK; YONKERS, PA				HALL, ED; ANDRUS, PK; YONKERS, PA			BRAIN HYDROXYL RADICAL GENERATION IN ACUTE EXPERIMENTAL HEAD-INJURY	JOURNAL OF NEUROCHEMISTRY			English	Article						HYDROXYL RADICAL; CONCUSSION; SALICYLATE TRAPPING; BRAIN	NERVOUS-SYSTEM TRAUMA; LIPID-PEROXIDATION; ENDOTHELIAL-CELLS; ARACHIDONIC-ACID; RAT-BRAIN; ISCHEMIA; METHYLPREDNISOLONE; SUPEROXIDE; DAMAGE; ABNORMALITIES	The time course and intensity of brain hydroxyl radical (.OH) generation were examined in male CF-1 mice during the first hour after moderate or severe concussive head injury. Hydroxyl radical production was measured using the salicylate trapping method in which the production of 2,3- and/or 2,5-dihydroxybenzoic acid (DHBA) in brain 15 min after salicylate administration was used as an index of .OH formation. In mice injured with a concussion of moderate severity as defined by the 1-h posttraumatic neurologic recovery (grip score), a 60% increase in 2,5-DHBA formation was observed by 1 min after injury compared with that observed in uninjured mice. The peak in DHBA formation occurred at 15 min after injury (+67.5%; p < 0.02, compared with uninjured). At 30 min, the increase in DHBA lost significance, indicating that the posttraumatic increase in brain .OH formation is a transient phenomenon. In severely injured mice, the peak increase in DHBA (both 2,3- and 2,5-) was observed at 30 min after injury, but also fell off thereafter as with the moderate injury severity. Preinjury dosing of the mice with SKF-525A (50 mg/kg i.p.), an inhibitor of microsomal drug oxidations, did not blunt the posttraumatic increase in salicylate-derived 2,5-DHBA, thus showing that it is not due to increased metabolic hydroxylation. Neither injury nor SKF-525A administration affected the DHBA plasma levels. However, saline perfusion of the injured mice to remove the intravascular blood before brain removal eliminated the injury-induced increase in 2,5-DHBA, but did not affect the baseline levels seen in uninjured mice. This implies that the source of the increased DHBA in the injured mice is the microvasculature, probably the endothelium. The administration of the 21-aminosteroid lipid antioxidant, tirilazad mesylate. which possesses .OH scavenging properties, also attenuated the posttraumatic increase in DHBA, further supporting that it reflects an increase in .OH radical formation. These results are the first direct demonstration of the occurrence and time course of increased .OH production in injured brain.		HALL, ED (corresponding author), UPJOHN CO,CENT NERVOUS SYST DIS RES,301 HENRIETTA ST,KALAMAZOO,MI 49001, USA.		Hall, Edward D/F-8930-2013				ALTHAUS J S, 1991, Society for Neuroscience Abstracts, V17, P164; Anderson D K, 1985, Cent Nerv Syst Trauma, V2, P257; AUDUS KL, 1991, FREE RADICAL BIO MED, V11, P361, DOI 10.1016/0891-5849(91)90152-S; AXELROD J, 1954, J PHARMACOL EXP THER, V112, P49; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; CAO W, 1988, NEUROSCI LETT, V88, P233, DOI 10.1016/0304-3940(88)90132-2; DEMOPOULOS HB, 1982, CAN J PHYSIOL PHARM, V60, P1415, DOI 10.1139/y82-210; Dimlich R V, 1990, Adv Neurol, V52, P365; ELLIS EF, 1981, J NEUROCHEM, V37, P892, DOI 10.1111/j.1471-4159.1981.tb04476.x; Hall E.D., 1986, CNS TRAUMA, V2, P75; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HALL ED, 1982, J NEUROSURG, V57, P247, DOI 10.3171/jns.1982.57.2.0247; HALL ED, 1987, J PHARMACOL EXP THER, V242, P137; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HALL ED, 1992, J NEUROTRAUM, V9, pS425; HALL ED, 1986, J NEUROSURG, V64, P951, DOI 10.3171/jns.1986.64.6.0951; HALL ED, 1991, J PHARMACOL EXP THER, V258, P688; HALLIWELL B, 1991, FREE RADICAL BIO MED, V10, P439, DOI 10.1016/0891-5849(91)90052-5; INGELMANSUNDBERG M, 1991, BIOCHEM J, V276, P753, DOI 10.1042/bj2760753; JENNER S, 1972, BIOCHEM PHARMACOL, V21, P1921, DOI 10.1016/0006-2952(72)90004-4; KINNULA VL, 1992, AM J RESP CELL MOL, V6, P175, DOI 10.1165/ajrcmb/6.2.175; KIWAK KJ, 1985, J NEUROSURG, V62, P865, DOI 10.3171/jns.1985.62.6.0865; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KONTOS HA, 1980, SCIENCE, V209, P1242, DOI 10.1126/science.7403881; KUKREJA RC, 1986, CIRC RES, V59, P612, DOI 10.1161/01.RES.59.6.612; LEVASSEUR JE, 1985, AM J PHYSIOL, V248, pH534; LIU GJ, 1991, FASEB J, V5, pA704; PANTER SS, 1992, J NEUROTRAUM, V9, P47, DOI 10.1089/neu.1992.9.47; SADRZADEH SMH, 1987, J CLIN INVEST, V79, P662, DOI 10.1172/JCI112865; SCHINETTI ML, 1989, CARDIOVASC RES, V23, P76, DOI 10.1093/cvr/23.1.76; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; SHOHAMI E, 1989, J NEUROCHEM, V53, P1541, DOI 10.1111/j.1471-4159.1989.tb08550.x; SHOHAMI E, 1988, NEUROSURGERY, V22, P859, DOI 10.1227/00006123-198805000-00007; TERADA LS, 1991, J CELL PHYSIOL, V148, P191, DOI 10.1002/jcp.1041480202; TORBATI D, 1991, FASEB J, V5, pA891; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95	39	211	211	0	5	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0022-3042			J NEUROCHEM	J. Neurochem.	FEB	1993	60	2					588	594		10.1111/j.1471-4159.1993.tb03189.x			7	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	KG671	WOS:A1993KG67100025	8380437				2021-06-18	
J	Zuckerman, SL; Kerr, ZY; Yengo-Kahn, A; Wasserman, E; Covassin, T; Solomon, GS				Zuckerman, Scott L.; Kerr, Zachary Y.; Yengo-Kahn, Aaron; Wasserman, Erin; Covassin, Tracey; Solomon, Gary S.			Epidemiology of Sports-Related Concussion in NCAA Athletes From 2009-2010 to 2013-2014: Incidence, Recurrence, and Mechanisms	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						sports concussion; TBI (traumatic brain injury); collegiate athletics; NCAA	INJURY SURVEILLANCE SYSTEM; COLLEGIATE FOOTBALL PLAYERS; STATES HIGH-SCHOOL; DESCRIPTIVE EPIDEMIOLOGY; SOCCER INJURIES; ASSOCIATION; SYMPTOMS; RATES	Background: The epidemiology of sports-related concussion (SRC) among student-athletes has been extensively researched. However, recent data at the collegiate level are limited. Purpose: To describe the epidemiology of SRC in 25 National Collegiate Athletic Association (NCAA) sports. Study Design: Descriptive epidemiology study. Methods: SRC data from the NCAA Injury Surveillance Program during the 2009-2010 to 2013-2014 academic years were analyzed. Concussion injury rates, rate ratios (RRs), and injury proportion ratios were reported with 95% CIs. National estimates were also calculated to examine linear trends across time. Results: During the study period, 1670 SRCs were reported, representing a national estimate of 10,560 SRCs reported annually. Among the 25 sports, the overall concussion rate was 4.47 per 10,000 athlete-exposures (AEs) (95% CI, 4.25-4.68). Overall, more SRCs occurred in competitions (53.2%). The competition rate (12.81 per 10,000 AEs) was larger than the practice rate (2.57 per 10,000 AEs) (competition vs practice, RR = 4.99; 95% CI, 4.53-5.49). Of all SRCs, 9.0% were recurrent. Most SRCs occurred from player contact (68.0%). The largest concussion rates were in men's wrestling (10.92 per 10,000 AEs; 95% CI, 8.62-13.23), men's ice hockey (7.91 per 10,000 AEs; 95% CI, 6.87-8.95), women's ice hockey (7.50 per 10,000 AEs; 95% CI, 5.91-9.10), and men's football (6.71 per 10,000 AEs; 95% CI, 6.17-7.24). However, men's football had the largest annual estimate of reported SRCs (n = 3417), followed by women's soccer (n = 1113) and women's basketball (n = 998). Among all SRCs, a linear trend did not exist in national estimates across time (P = .17). However, increases were found within specific sports, such as men's football, women's ice hockey, and men's lacrosse. Conclusion: The estimated number of nationally reported SRCs has increased within specific sports. However, it is unknown whether these increases are attributable to increased reporting or frequency of concussions. Many sports report more SRCs in practice than in competition, although competition rates are higher. Men's wrestling and men's and women's ice hockey have the highest reported concussion rates. Men's football had the highest annual national estimate of reported SRCs, although the annual participation count was also the highest. Future research should continue to longitudinally examine SRC incidence while considering differences by sex, division, and level of competition.	[Zuckerman, Scott L.; Yengo-Kahn, Aaron; Solomon, Gary S.] Vanderbilt Univ, Sch Med, Vanderbilt Sports Concuss Ctr, Dept Neurol Surg, Nashville, TN 37212 USA; [Kerr, Zachary Y.] Datalys Ctr Sports Injury Res & Prevent Inc, Indianapolis, IN 46202 USA; [Wasserman, Erin] Univ Rochester, Sch Med & Dent, Dept Publ Hlth Sci, Rochester, NY USA; [Covassin, Tracey] Michigan State Univ, Dept Kinesiol, E Lansing, MI 48824 USA	Kerr, ZY (corresponding author), Datalys Ctr Sports Injury Res & Prevent Inc, NCAA Injury Surveillance Program, 401 West Michigan St,Suite 500, Indianapolis, IN 46202 USA.	zkerr@datalyscenter.org	Yengo-Kahn, Aaron/AAV-7647-2020; Solomon, Gary/K-9011-2019	Yengo-Kahn, Aaron/0000-0002-5989-3064; Kerr, Zachary/0000-0003-1423-1259; Wasserman, Erin/0000-0001-5957-5878	NCAA	One or more of the authors has declared the following potential conflict of interest or source of funding: The NCAA Injury Surveillance Program (ISP) data were provided by the Datalys Center for Sports Injury Research and Prevention. The ISP was funded by the NCAA. Z.Y.K. is the director of the NCAA ISP. The content of this manuscript is solely the responsibility of the authors and does not necessarily represent the official views of the NCAA.	Agel J, 2007, J ATHL TRAINING, V42, P272; Agel J, 2007, J ATHL TRAINING, V42, P270; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Baugh CM, 2015, AM J SPORT MED, V43, P47, DOI 10.1177/0363546514553090; Covassin T, 2003, J ATHL TRAINING, V38, P238; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Dick R, 2007, J ATHL TRAINING, V42, P278; Dick R, 2007, J ATHL TRAINING, V42, P221; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Kerr ZY, 2015, AM J SPORT MED, V43, P1134, DOI 10.1177/0363546515570622; Kerr ZY, 2014, J ATHL TRAINING, V49, P552, DOI 10.4085/1062-6050-49.3.58; Kerr ZY, 2014, BRAIN INJURY, V28, P1009, DOI 10.3109/02699052.2014.904049; Kilcoyne KG, 2014, SPORTS HEALTH, V6, P402, DOI 10.1177/1941738113491545; Kroshus E, 2015, HEALTH EDUC BEHAV, V42, P153, DOI 10.1177/1090198114543011; Kroshus E, 2014, BRIT J SPORT MED, V48, P135, DOI 10.1136/bjsports-2013-092498; Kucera KL, 2011, J ATHL TRAINING, V46, P489; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Llewellyn T, 2014, CLIN J SPORT MED, V24, P76, DOI 10.1097/01.jsm.0000432853.77520.3d; Lumley T, 2002, ANNU REV PUBL HEALTH, V23, P151, DOI 10.1146/annurev.publhealth.23.100901.140546; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Mueller FO, 2011, PREVENTING SUDDEN DE, P1; National Collegiate Athletic Association, FOOTB PRACT GUID; National Collegiate Athletic Association, 2014 15 SPORTS MED H; National Federation of High Schools, HIGH SCH PART INCR 2; National Federation of High Schools, 2013 14 HIGH SCH ATH; Rosenthal JA, 2014, AM J SPORT MED, V42, P1710, DOI 10.1177/0363546514530091; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA; Torres Daniel M, 2013, Neurol Clin Pract, V3, P279; Weber AF, 2013, J ATHL TRAINING, V48, P153, DOI 10.4085/1062-6050-48.1.07; Zemek RL, 2013, JAMA PEDIATR, V167, P259, DOI 10.1001/2013.jamapediatrics.216	35	210	211	1	71	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	NOV	2015	43	11					2654	2662		10.1177/0363546515599634			9	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	CV3XF	WOS:000364199100005	26330572		Y	N	2021-06-18	
J	Rajajee, V; Vanaman, M; Fletcher, JJ; Jacobs, TL				Rajajee, Venkatakrishna; Vanaman, Monique; Fletcher, Jeffrey James; Jacobs, Teresa Lee			Optic Nerve Ultrasound for the Detection of Raised Intracranial Pressure	NEUROCRITICAL CARE			English	Article						Optic nerve; Intracranial hypertension; Ultrasonography; Intracranial pressure; Papilledema; Brain injuries	TRANSORBITAL SONOGRAPHIC EVALUATION; SHEATH DIAMETER; ULTRASONOGRAPHY; HYPERTENSION; HEMORRHAGE	Optic nerve ultrasonography (ONUS) may help identify raised intracranial pressure (ICP). The optimal optic nerve sheath diameter (ONSD) cut-off for the identification of intracranial hypertension has not been established, with some clinical studies suggesting a higher cut-off than may be expected on the basis of prior laboratory investigation. To validate ONUS performed by neurointensivists as a technique for the detection of intracranial hypertension and identify the optimal ONSD criterion for the detection of ICP > 20 mmHg. Prospective blinded observational study. Patients in the ICU with either external ventricular drains or intraparenchymal ICP monitors at risk for intracranial hypertension were enrolled. The ONSD was measured by neurointensivists at the bedside with simultaneous invasive ICP measurement. An ROC curve was constructed to determine the optimal ONSD for the detection of ICP > 20 mmHg. A total of 536 ONSD measurements were performed on 65 patients. Diagnoses included subarachnoid hemorrhage, traumatic brain injury, intracerebral hemorrhage, ischemic stroke and brain tumor. ROC curve analysis revealed area under the curve (AUC) = 0.98 (95% CI 0.96-0.99; P < 0.0001 for AUC = 0.5). Optimal ONSD for detection of ICP > 20 mmHg was a parts per thousand yen0.48 cm sensitivity 96% (95% CI 91-99%); specificity 94% (92-96%). Sensitivity of the higher cutoff of a parts per thousand yen0.52 cm proposed by some authors was only 67% (58-75%), with specificity 98% (97-99%). Bedside ONSD measurement, performed by neurointensivists, is an accurate, non-invasive method to identify ICP > 20 mmHg in a heterogeneous group of patients with acute brain injury. ONSD a parts per thousand yen0.48 cm has the greatest accuracy, however, internal validation of ONSD criteria may be required.	[Rajajee, Venkatakrishna; Vanaman, Monique; Fletcher, Jeffrey James; Jacobs, Teresa Lee] Univ Michigan Hlth Syst, Dept Neurosurg, Taubman Hlth Care Ctr 3552, Ann Arbor, MI 48109 USA; [Rajajee, Venkatakrishna; Fletcher, Jeffrey James; Jacobs, Teresa Lee] Univ Michigan Hlth Syst, Dept Neurol, Taubman Hlth Care Ctr 3552, Ann Arbor, MI 48109 USA	Rajajee, V (corresponding author), Univ Michigan Hlth Syst, Dept Neurosurg, Taubman Hlth Care Ctr 3552, 1500 E Med Ctr Dr,SPC 5338, Ann Arbor, MI 48109 USA.	vrajajee@yahoo.com; mvanaman@med.umich.edu; jeffletc@med.umich.edu; teresmit@med.umich.edu		Rajajee, Venkatakrishna/0000-0002-7183-8324			Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Copetti R, 2009, INTENS CARE MED, V35, P1488, DOI 10.1007/s00134-009-1494-4; Craig DGN, 2010, J HEPATOL, V52, pS321, DOI 10.1016/S0168-8278(10)60825-2; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Geeraerts T, 2008, INTENS CARE MED, V34, P2062, DOI 10.1007/s00134-008-1149-x; Geeraerts T, 2007, INTENS CARE MED, V33, P1704, DOI 10.1007/s00134-007-0797-6; Grant EG, 2003, RADIOLOGY, V229, P340, DOI 10.1148/radiol.2292030516; Hansen HC, 2011, ACTA OPHTHALMOL, V89, pE528, DOI 10.1111/j.1755-3768.2011.02159.x; Hansen HC, 1997, J NEUROSURG, V87, P34, DOI 10.3171/jns.1997.87.1.0034; HAYREH S S, 1964, Br J Ophthalmol, V48, P522, DOI 10.1136/bjo.48.10.522; Helmke K, 1996, PEDIATR RADIOL, V26, P701, DOI 10.1007/BF01383383; Jang TB, 2010, ACAD EMERG MED, V17, P1024, DOI 10.1111/j.1553-2712.2010.00850.x; Kimberly HH, 2008, ACAD EMERG MED, V15, P201, DOI 10.1111/j.1553-2712.2007.00031.x; Miller MT, 2004, J TRAUMA, V56, P967, DOI 10.1097/01.TA.0000123699.16465.8B; Moretti R, 2009, NEUROCRIT CARE, V11, P406, DOI 10.1007/s12028-009-9250-8; Moretti R, 2009, J NEUROSURG ANESTH, V21, P16, DOI 10.1097/ANA.0b013e318185996a; Morgenstern LB, 2010, STROKE, V41, P2108, DOI 10.1161/STR.0b013e3181ec611b; Ngo QN, 2009, PEDIATR CRIT CARE ME, V10, P346, DOI 10.1097/PCC.0b013e3181a320cd; Rajajee V, 2010, NEUROL INDIA, V58, P812, DOI 10.4103/0028-3886.72202; Rosenberg JB, 2011, NEUROCRIT CARE, V15, P599, DOI 10.1007/s12028-011-9545-4; Ross IB, 2003, AM J NEURORADIOL, V24, P1528; Soldatos T, 2008, CRIT CARE, V12, DOI 10.1186/cc6897; Strumwasser A, 2011, J SURG RES, V170, P265, DOI 10.1016/j.jss.2011.03.009; Wang D, 2004, J TRAUMA, V56, P972	24	210	224	0	11	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	DEC	2011	15	3					506	515		10.1007/s12028-011-9606-8			10	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	852NT	WOS:000297365400022	21769456				2021-06-18	
J	Timofeev, I; Carpenter, KLH; Nortje, J; Al-Rawi, PG; O'Connell, MT; Czosnyka, M; Smielewski, P; Pickard, JD; Menon, DK; Kirkpatrick, PJ; Gupta, AK; Hutchinson, PJ				Timofeev, Ivan; Carpenter, Keri L. H.; Nortje, Juergens; Al-Rawi, Pippa G.; O'Connell, Mark T.; Czosnyka, Marek; Smielewski, Peter; Pickard, John D.; Menon, David K.; Kirkpatrick, Peter J.; Gupta, Arun K.; Hutchinson, Peter J.			Cerebral extracellular chemistry and outcome following traumatic brain injury: a microdialysis study of 223 patients	BRAIN			English	Article						brain metabolism; microdialysis; traumatic brain injury (human); outcome	SEVERE HEAD-INJURY; CORTICAL CONTUSION INJURY; AMINO-ACID RELEASE; INTRACRANIAL-PRESSURE; AGGRESSIVE TREATMENT; PERFUSION-PRESSURE; METABOLIC CRISIS; ISCHEMIA; PYRUVATE; LACTATE	Secondary insults can adversely influence outcome following severe traumatic brain injury. Monitoring of cerebral extracellular chemistry with microdialysis has the potential for early detection of metabolic derangements associated with such events. The objective of this study was to determine the relationship between the fundamental biochemical markers and neurological outcome in a large cohort of patients with traumatic brain injury. Prospectively collected observational neuromonitoring data from 223 patients were analysed. Monitoring modalities included digitally recorded intracranial pressure, cerebral perfusion pressure, cerebrovascular pressure reactivity index and microdialysis markers glucose, lactate, pyruvate, glutamate, glycerol and the lactate/pyruvate ratio. Outcome was assessed using the Glasgow Outcome Scale at 6 months post-injury. Patient-averaged values of parameters were used in statistical analysis, which included univariate non-parametric methods and multivariate logistic regression. Monitoring with microdialysis commenced on median (interquartile range) Day 1 (1-2) from injury and median (interquartile range) duration of monitoring was 4 (2-7) days. Averaged over the total monitoring period levels of glutamate (P = 0.048), lactate/pyruvate ratio (P = 0.044), intracranial pressure (P = 0.006) and cerebrovascular pressure reactivity index (P = 0.01) were significantly higher in patients who died. During the initial 72 h of monitoring, median glycerol levels were also higher in the mortality group (P = 0.014) and median lactate/pyruvate ratio (P = 0.026) and lactate (P = 0.033) levels were significantly lower in patients with favourable outcome. In a multivariate logistic regression model (P < 0.0001), which employed data averaged over the whole monitoring period, significant independent positive predictors of mortality were glucose (P = 0.024), lactate/pyruvate ratio (P = 0.016), intracranial pressure (P = 0.029), cerebrovascular pressure reactivity index (P = 0.036) and age (P = 0.003), while pyruvate was a significant independent negative predictor of mortality (P = 0.004). The results of this study suggest that extracellular metabolic markers are independently associated with outcome following traumatic brain injury. Whether treatment-related improvement in biochemistry translates into better outcome remains to be established.	[Timofeev, Ivan; Carpenter, Keri L. H.; Al-Rawi, Pippa G.; O'Connell, Mark T.; Czosnyka, Marek; Smielewski, Peter; Pickard, John D.; Kirkpatrick, Peter J.; Hutchinson, Peter J.] Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Div Neurosurg, Cambridge CB2 0QQ, England; [Carpenter, Keri L. H.; Nortje, Juergens; O'Connell, Mark T.; Pickard, John D.; Menon, David K.; Hutchinson, Peter J.] Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Wolfson Brain Imaging Ctr, Cambridge CB2 0QQ, England; [Nortje, Juergens; Menon, David K.; Gupta, Arun K.] Univ Cambridge, Addenbrookes Hosp, Dept Med, Div Anaesthesia, Cambridge CB2 0QQ, England	Carpenter, KLH (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Div Neurosurg, Box 167,Hills Rd, Cambridge CB2 0QQ, England.	klc1000@wbic.cam.ac.uk	Timofeev, Ivan/AAE-7019-2019	Carpenter, Keri/0000-0001-8236-7727; Timofeev, Ivan/0000-0002-1168-0393; O'Connell, Mark/0000-0001-6272-8767; Smielewski, Peter/0000-0001-5096-3938	Codman Inc; Evelyn Trust; MRC RESCUEicpUK Research & Innovation (UKRI)Medical Research Council UK (MRC); BP-TNK; British Journal of Anaesthesia/Royal College; Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission; National Institute for Health Research Biomedical Research Centre, CambridgeNational Institute for Health Research (NIHR); Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390 ID 65883, G0600986 ID79068]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001237, G0601025, G0600986, G1000183B, G0001354, G0001354B, G9439390] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish	Codman Inc grant, the Evelyn Trust grant, MRC RESCUEicp trial grant and BP-TNK Kapitza Scholarship (to I.T.); British Journal of Anaesthesia/Royal College of Anaesthetists Fellowship (to J.N.); Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship (to P.J.H.); Medical Research Council (Acute Brain Injury Programme Grant) and National Institute for Health Research Biomedical Research Centre, Cambridge (to K. L. H. C.); Medical Research Council (G9439390 ID 65883 and G0600986 ID79068).	Balestreri M, 2006, NEUROCRIT CARE, V4, P8, DOI 10.1385/NCC:4:1:008; Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Czosnyka M, 2005, J NEUROSURG, V102, P450, DOI 10.3171/jns.2005.102.3.0450; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Diaz-Parejo P, 2003, INTENS CARE MED, V29, P544, DOI 10.1007/s00134-003-1669-3; Fukushima M, 2009, J NEUROTRAUM, V26, P1095, DOI 10.1089/neu.2008.0771; Gilmer LK, 2009, J NEUROTRAUM, V26, P1271, DOI 10.1089/neu.2008.0857; Goodman JC, 2009, CURR OPIN CRIT CARE, V15, P110, DOI 10.1097/MCC.0b013e328325d142; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Gupta AK, 2004, J NEUROTRAUM, V21, P678, DOI 10.1089/0897715041269722; Hlatky R, 2004, J NEUROTRAUM, V21, P894, DOI 10.1089/0897715041526195; Holbein M, 2009, CRIT CARE, V13, DOI 10.1186/cc7711; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; Hutchinson PJA, 2002, ACT NEUR S, V81, P359; Koura SS, 1998, ACT NEUR S, V71, P244; Lee JY, 2001, J NEUROSCI, V21; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; Meierhans R, 2010, CRIT CARE, V14, DOI 10.1186/cc8869; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Moro N, 2010, EXP NEUROL, V225, P391, DOI 10.1016/j.expneurol.2010.07.013; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Opii WO, 2007, J NEUROTRAUM, V24, P772, DOI 10.1089/neu.2006.0229; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Reinert M, 2007, NEUROL RES, V29, P455, DOI 10.1179/016164107X164175; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Sarrafzadeh A, 2004, J NEUROSURG, V100, P400, DOI 10.3171/jns.2004.100.3.0400; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa PM, 2007, CRIT CARE MED, V35, P1153, DOI 10.1097/01.CCM.0000259466.66310.4F; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Winter CD, 2004, BRAIN, V127, P315, DOI 10.1093/brain/awh039; Zauner A, 1998, NEUROL RES, V20, pS85; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011	44	210	215	1	14	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	FEB	2011	134		2				484	494		10.1093/brain/awq353			11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	716RI	WOS:000286990800015	21247930	Bronze			2021-06-18	
J	Schachtrup, C; Ryu, JK; Helmrick, MJ; Vagena, E; Galanakis, DK; Degen, JL; Margolis, RU; Akassoglou, K				Schachtrup, Christian; Ryu, Jae K.; Helmrick, Matthew J.; Vagena, Eirini; Galanakis, Dennis K.; Degen, Jay L.; Margolis, Richard U.; Akassoglou, Katerina			Fibrinogen Triggers Astrocyte Scar Formation by Promoting the Availability of Active TGF-beta after Vascular Damage	JOURNAL OF NEUROSCIENCE			English	Article							GROWTH-FACTOR-BETA; CHONDROITIN SULFATE PROTEOGLYCANS; REACTIVE ASTROCYTES; MOLECULAR-MECHANISMS; MULTIPLE-SCLEROSIS; LATENT TGF-BETA-1; BINDING-PROTEIN; CELL-ADHESION; IN-VIVO; INTEGRIN	Scar formation in the nervous system begins within hours after traumatic injury and is characterized primarily by reactive astrocytes depositing proteoglycans that inhibit regeneration. A fundamental question in CNS repair has been the identity of the initial molecular mediator that triggers glial scar formation. Here we show that the blood protein fibrinogen, which leaks into the CNS immediately after blood-brain barrier (BBB) disruption or vascular damage, serves as an early signal for the induction of glial scar formation via the TGF-beta/Smad signaling pathway. Our studies revealed that fibrinogen is a carrier of latent TGF-beta and induces phosphorylation of Smad2 in astrocytes that leads to inhibition of neurite outgrowth. Consistent with these findings, genetic or pharmacologic depletion of fibrinogen in mice reduces active TGF-beta, Smad2 phosphorylation, glial cell activation, and neurocan deposition after cortical injury. Furthermore, stereotactic injection of fibrinogen into the mouse cortex is sufficient to induce astrogliosis. Inhibition of the TGF-beta receptor pathway abolishes the fibrinogen-induced effects on glial scar formation in vivo and in vitro. These results identify fibrinogen as a primary astrocyte activation signal, provide evidence that deposition of inhibitory proteoglycans is induced by a blood protein that leaks in the CNS after vasculature rupture, and point to TGF-beta as a molecular link between vascular permeability and scar formation.	[Schachtrup, Christian; Ryu, Jae K.; Helmrick, Matthew J.; Vagena, Eirini; Akassoglou, Katerina] Univ Calif San Francisco, Gladstone Inst Neurol Dis, San Francisco, CA 94158 USA; [Akassoglou, Katerina] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94158 USA; [Galanakis, Dennis K.] SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA; [Degen, Jay L.] Univ Cincinnati, Coll Med, Cincinnati, OH 45229 USA; [Degen, Jay L.] Childrens Hosp Res Fdn, Cincinnati, OH 45229 USA; [Margolis, Richard U.] NYU, Med Ctr, Dept Pharmacol, New York, NY 10016 USA	Akassoglou, K (corresponding author), Univ Calif San Francisco, Gladstone Inst Neurol Dis, San Francisco, CA 94158 USA.	kakassoglou@gladstone.ucsf.edu		Akassoglou, Katerina/0000-0002-2632-1465	German Research Foundation (Deutsche Forschungsgemeinschaft)German Research Foundation (DFG); American Heart AssociationAmerican Heart Association; National Institutes of Health/National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS051470, R01NS052189]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS051470, R01NS052189] Funding Source: NIH RePORTER	This work was supported by a German Research Foundation (Deutsche Forschungsgemeinschaft) postdoctoral fellowship (to C. S.), an American Heart Association postdoctoral fellowship (to J.K.R.), and National Institutes of Health/National Institute of Neurological Disorders and Stroke Grants R01NS051470 and R01NS052189 (to K. A.). We thank Aristoteles A. Alexandrou, Caroline Miller, and Jo Dee Fish for technical assistance and Stephen Ordway for editorial assistance.	Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Adams RA, 2007, CURR MED CHEM, V14, P2925, DOI 10.2174/092986707782360015; Adams RA, 2004, MOL INTERV, V4, P163; Adams RA, 2007, J EXP MED, V204, P571, DOI 10.1084/jem.20061931; Adhami F, 2006, AM J PATHOL, V169, P566, DOI 10.2353/ajpath.2006.051066; Akassoglou K, 2004, P NATL ACAD SCI USA, V101, P6698, DOI 10.1073/pnas.0303859101; Akassoglou K, 2002, NEURON, V33, P861, DOI 10.1016/S0896-6273(02)00617-7; Akassoglou K, 2002, BIOL CHEM, V383, P37, DOI 10.1515/BC.2002.004; Annes JP, 2004, J CELL BIOL, V165, P723, DOI 10.1083/jcb.200312172; Annes JP, 2003, J CELL SCI, V116, P217, DOI 10.1242/jcs.00229; Araya J, 2006, AM J PATHOL, V169, P405, DOI 10.2353/ajpath.2006.060049; Asher RA, 2000, J NEUROSCI, V20, P2427; ATTISANO L, 1994, BIOCHIM BIOPHYS ACTA, V71, P1222; Belkin AM, 2005, BLOOD, V105, P3561, DOI 10.1182/blood-2004-10-4089; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Buffo A, 2008, P NATL ACAD SCI USA, V105, P3581, DOI 10.1073/pnas.0709002105; Burton RA, 2006, BIOCHEMISTRY-US, V45, P2257, DOI 10.1021/bi052380c; Busch SA, 2009, J NEUROSCI, V29, P9967, DOI 10.1523/JNEUROSCI.1151-09.2009; Cambier S, 2005, AM J PATHOL, V166, P1883, DOI 10.1016/S0002-9440(10)62497-2; Chernousov MA, 2003, EXP CELL RES, V291, P514, DOI 10.1016/S0014-4827(03)00409-9; de Maat MPM, 2005, CURR OPIN HEMATOL, V12, P377, DOI 10.1097/01.moh.0000169287.51594.3b; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Fitch MT, 1999, J NEUROSCI, V19, P8182; FRIEDLANDER DR, 1994, J CELL BIOL, V125, P669, DOI 10.1083/jcb.125.3.669; Galanakis DK, 2007, BLOOD COAGUL FIBRIN, V18, P731, DOI 10.1097/MBC.0b013e3282f10157; GAY D, 1991, BRAIN, V114, P557, DOI 10.1093/brain/114.1.557; GENTRY LE, 1990, BIOCHEMISTRY-US, V29, P6851, DOI 10.1021/bi00481a014; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GRAINGER DJ, 1995, NAT MED, V1, P932, DOI 10.1038/nm0995-932; Grainger DJ, 2000, CYTOKINE GROWTH F R, V11, P133, DOI 10.1016/S1359-6101(99)00037-4; Huang XZ, 1996, J CELL BIOL, V133, P921, DOI 10.1083/jcb.133.4.921; Jones LL, 2003, EXP NEUROL, V182, P399, DOI 10.1016/S0014-4886(03)00087-6; Kim AH, 2002, NEURON, V35, P697, DOI 10.1016/S0896-6273(02)00821-8; Lagord C, 2002, MOL CELL NEUROSCI, V20, P69, DOI 10.1006/mcne.2002.1121; Li MO, 2008, CELL, V134, P392, DOI 10.1016/j.cell.2008.07.025; Li MO, 2007, IMMUNITY, V26, P579, DOI 10.1016/j.immuni.2007.03.014; Lin AH, 2005, J IMMUNOL, V175, P547, DOI 10.4049/jimmunol.175.1.547; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lord ST, 2007, CURR OPIN HEMATOL, V14, P236, DOI 10.1097/MOH.0b013e3280dce58c; Marik C, 2007, BRAIN, V130, P2800, DOI 10.1093/brain/awm236; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; McKeon RJ, 1999, J NEUROSCI, V19, P10778; Medved L, 2003, THROMB HAEMOSTASIS, V89, P409; Milev P, 1996, J BIOL CHEM, V271, P15716, DOI 10.1074/jbc.271.26.15716; Milner R, 2001, MOL CELL NEUROSCI, V18, P108, DOI 10.1006/mcne.2001.1003; MIYAZONO K, 1988, J BIOL CHEM, V263, P6407; Moro L, 2002, J BIOL CHEM, V277, P9405, DOI 10.1074/jbc.M109101200; MOSESSON MW, 1966, BIOCHEMISTRY-US, V5, P2829, DOI 10.1021/bi00873a008; Mosesson MW, 2001, ANN NY ACAD SCI, V936, P11; MOSESSON MW, 1972, J BIOL CHEM, V247, P5210; Mu DZ, 2002, J CELL BIOL, V157, P493, DOI 10.1083/jcb.200109100; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; Niederost BP, 1999, J NEUROSCI, V19, P8979, DOI 10.1523/JNEUROSCI.19-20-08979.1999; Passino MA, 2007, SCIENCE, V315, P1853, DOI 10.1126/science.1137603; Paul J, 2007, J EXP MED, V204, P1999, DOI 10.1084/jem.20070304; Pickford F, 2008, J CLIN INVEST, V118, P2190, DOI 10.1172/JCI33585; Preston E, 2001, J NEUROTRAUM, V18, P83, DOI 10.1089/089771501750055794; Ryu JK, 2009, J CELL MOL MED, V13, P2911, DOI 10.1111/j.1582-4934.2008.00434.x; Saharinen J, 1999, CYTOKINE GROWTH F R, V10, P99, DOI 10.1016/S1359-6101(99)00010-6; Sahni A, 2000, BLOOD, V96, P3772, DOI 10.1182/blood.V96.12.3772.h8003772_3772_3778; Sahni A, 2004, BLOOD, V104, P409, DOI 10.1182/blood-2004-01-0126; Sahni A, 2003, J THROMB HAEMOST, V1, P1304, DOI 10.1046/j.1538-7836.2003.00250.x; Sanford LP, 1997, DEVELOPMENT, V124, P2659; Schachtrup C, 2007, P NATL ACAD SCI USA, V104, P11814, DOI 10.1073/pnas.0704045104; Schnell L, 1999, EUR J NEUROSCI, V11, P3648, DOI 10.1046/j.1460-9568.1999.00792.x; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Smith GM, 2005, GLIA, V52, P209, DOI 10.1002/glia.20236; Sofroniew MV, 2005, NEUROSCIENTIST, V11, P400, DOI 10.1177/1073858405278321; Spraggon G, 1998, P NATL ACAD SCI USA, V95, P9099, DOI 10.1073/pnas.95.16.9099; SUH TT, 1995, GENE DEV, V9, P2020, DOI 10.1101/gad.9.16.2020; Tesseur I, 2006, J CLIN INVEST, V116, P3060, DOI 10.1172/JCI27341; Unsold C, 2001, J CELL SCI, V114, P187; Wang KC, 2002, NATURE, V417, P941, DOI 10.1038/nature00867; Wipff PJ, 2008, EUR J CELL BIOL, V87, P601, DOI 10.1016/j.ejcb.2008.01.012; Wipff PJ, 2007, J CELL BIOL, V179, P1311, DOI 10.1083/jcb.200704042; Yang ZW, 2007, J CELL BIOL, V176, P787, DOI 10.1083/jcb.200611044	79	210	218	0	13	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	APR 28	2010	30	17					5843	5854		10.1523/JNEUROSCI.0137-10.2010			12	Neurosciences	Neurosciences & Neurology	589OF	WOS:000277159200004	20427645	Green Published, Bronze, Green Accepted			2021-06-18	
J	Mac Donald, CL; Dikranian, K; Song, SK; Bayly, PV; Holtzman, DM; Brody, DL				Mac Donald, C. L.; Dikranian, K.; Song, S. K.; Bayly, P. V.; Holtzman, D. M.; Brody, D. L.			Detection of traumatic axonal injury with diffusion tensor imaging in a mouse model of traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						traumatic brain injury; diffusion tensor imaging; traumatic axonal injury; diffuse axonal injury; magnetic resonance imaging; white matter; anisotropy; amyloid precursor protein; stereology; controlled cortical impact	AMYLOID PRECURSOR PROTEIN; CONTROLLED CORTICAL IMPACT; INTRAAXONAL NEUROFILAMENT COMPACTION; MULTIPLE-SCLEROSIS BRAIN; CLOSED-HEAD INJURY; SPINAL-CORD-INJURY; WHITE-MATTER; FIBER TRACKING; POSTTRAUMATIC HYPOTHERMIA; CORPUS-CALLOSUM	Traumatic axonal injury (TAI) is thought to be a major contributor to cognitive dysfunction following traumatic brain injury (TBI), however TAI is difficult to diagnose or characterize non-invasively. Diffusion tensor imaging (DTI) has shown promise in detecting TAI, but direct comparison to histologically-confirmed axonal injury has not been performed. In the current study, mice were imaged with DTI, subjected to a moderate cortical controlled impact injury, and re-imaged 4-6 h and 24 h post-injury. Axonal injury was detected by amyloid beta precursor protein (APP) and neurofilament immunohistochemistry in pericontusional white matter tracts. The severity of axonal injury was quantified using stereological methods from APP stained histological sections. Two DTI parameters - axial diffusivity and relative anisotropy - were significantly reduced in the injured, pericontusional corpus callosum and external capsule, while no significant changes were seen with conventional MRI in these regions. The contusion was easily detectable on all MRI sequences. Significant correlations were found between changes in relative anisotropy and the density of APP stained axons across mice and across subregions spanning the spatial gradient of injury. The predictive value of DTI was tested using a region with DTI changes (hippocampal commissure) and a region without DTI changes (anterior commissure). Consistent with DTI predictions, there was histological detection of axonal injury in the hippocampal commissure and none in the anterior commissure. These results demonstrate that DTI is able to detect axonal injury, and support the hypothesis that DTI may be more sensitive than conventional imaging methods for this purpose. (C) 2007 Elsevier Inc. All rights reserved.	Washington Univ, Dept Neurol, Sch Med, St Louis, MO 63110 USA; Washington Univ, Dept Biomed Engn, St Louis, MO 63110 USA; Washington Univ, Dept Anat & Neurobiol, Sch Med, St Louis, MO 63110 USA; Washington Univ, Dept Radiol, Sch Med, St Louis, MO 63110 USA; Washington Univ, Dept Aerosp & Mech Engn, St Louis, MO 63110 USA; Washington Univ, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Washington Univ, Hope Ctr Neurol Disorders, St Louis, MO 63110 USA	Brody, DL (corresponding author), Washington Univ, Dept Neurol, Sch Med, 660 S Euclid,Campus Box 8111, St Louis, MO 63110 USA.	brodyd@neuro.wustl.edu		Bayly, Philip/0000-0003-4303-0704	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21 NS045237, R21 NS45237, R21 NS045237-01A1, P01 NS032636, R21 NS045237-02, R01 NS047592, K08 NS049237, NS049237] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS045237, R01NS047592, K08NS049237, P01NS032636] Funding Source: NIH RePORTER		ADAMS JH, 1984, LANCET, V2, P1420; ADAMS JH, 1982, INJURY, V13, P444, DOI 10.1016/0020-1383(82)90105-X; Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bammer R, 2000, MAGNET RESON MED, V44, P583, DOI 10.1002/1522-2594(200010)44:4<583::AID-MRM12>3.0.CO;2-O; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Bo L, 2004, NEUROPATH APPL NEURO, V30, P106, DOI 10.1111/j.1365-2990.2003.00521.x; Brody D, 2006, J NEUROTRAUM, V23, P1021; Buki A, 1999, EXP NEUROL, V159, P319, DOI 10.1006/exnr.1999.7139; Cervos-Navarro J., 1991, J NEUROL SCI, V103, P3; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; De Groot CJA, 2001, BRAIN, V124, P1635, DOI 10.1093/brain/124.8.1635; Deo AA, 2006, J NEUROSCI RES, V83, P801, DOI 10.1002/jnr.20783; Ducreux D, 2005, NEURORADIOLOGY, V47, P604, DOI 10.1007/s00234-005-1389-1; Empey PE, 2006, J NEUROTRAUM, V23, P109, DOI 10.1089/neu.2006.23.109; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; Filippi M, 2001, NEUROLOGY, V56, P304, DOI 10.1212/WNL.56.3.304; Franklin K. B. J., 1997, MOUSE BRAIN STEREOTA; Garbow JR, 2004, CONCEPT MAGN RESON B, V21B, P40, DOI 10.1002/cmr.b.20010; Gaviria M, 2006, NEUROBIOL DIS, V22, P694, DOI 10.1016/j.nbd.2006.01.011; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; Gulani V, 2001, MAGNET RESON MED, V45, P191, DOI 10.1002/1522-2594(200102)45:2<191::AID-MRM1025>3.0.CO;2-9; Gupta RK, 2005, EPILEPSIA, V46, P1465, DOI 10.1111/j.1528-1167.2005.01205.x; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Kessens CC, 2005, J NEUROTRAUM, V22, P1253; Kim JH, 2006, NEUROBIOL DIS, V21, P626, DOI 10.1016/j.nbd.2005.09.009; King JT, 2005, J NEUROTRAUM, V22, P947, DOI 10.1089/neu.2005.22.947; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; Le Bihan D, 2003, NAT REV NEUROSCI, V4, P469, DOI 10.1038/nrn1119; LEBIHAN D, 1986, RADIOLOGY, V161, P401, DOI 10.1148/radiology.161.2.3763909; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; Longhi L, 2001, J CEREBR BLOOD F MET, V21, P1241, DOI 10.1097/00004647-200111000-00001; Marmarou CR, 2006, EXP NEUROL, V197, P353, DOI 10.1016/j.expneurol.2005.10.003; Marmarou CR, 2005, J NEUROTRAUM, V22, P1066, DOI 10.1089/neu.2005.22.1066; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Mazzeo AT, 2006, J NEUROTRAUM, V23, P962, DOI 10.1089/neu.2006.23.962; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Mori S, 2002, NMR BIOMED, V15, P468, DOI 10.1002/nbm.781; Mori S, 2006, NEURON, V51, P527, DOI 10.1016/j.neuron.2006.08.012; Nair G, 2005, NEUROIMAGE, V28, P165, DOI 10.1016/j.neuroimage.2005.05.049; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Neil J, 2002, NMR BIOMED, V15, P543, DOI 10.1002/nbm.784; NEVIN NC, 1967, J NEUROPATH EXP NEUR, V26, P77, DOI 10.1097/00005072-196701000-00006; Nevo U, 2001, MAGN RESON MED, V45, P1, DOI 10.1002/1522-2594(200101)45:1<1::AID-MRM1001>3.0.CO;2-I; Nowinski WL, 2006, J COMPUT ASSIST TOMO, V30, P629, DOI 10.1097/00004728-200607000-00013; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; ONO J, 1995, BRAIN RES, V671, P141, DOI 10.1016/0006-8993(94)01335-F; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; Pilz P, 1983, Acta Neurochir Suppl (Wien), V32, P119; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; POVLISHOCK JT, 1992, J NEUROTRAUMA, V9, P189; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Schmierer K, 2003, NEUROPATH APPL NEURO, V29, P596, DOI 10.1046/j.0305-1846.2003.00497.x; Schwartz ED, 2005, J NEUROTRAUM, V22, P1388, DOI 10.1089/neu.2005.22.1388; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Smith DH, 2003, J NEUROSURG, V98, P1072, DOI 10.3171/jns.2003.98.5.1072; Song SK, 2005, NEUROIMAGE, V26, P132, DOI 10.1016/j.neuroimage.2005.01.028; Song SK, 2004, NEUROBIOL DIS, V15, P640, DOI 10.1016/j.nbd.2003.12.003; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; STERIO DC, 1984, J MICROSC-OXFORD, V134, P127, DOI 10.1111/j.1365-2818.1984.tb02501.x; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; Sundgren PC, 2004, NEURORADIOLOGY, V46, P339, DOI 10.1007/s00234-003-1114-x; Susil RC, 2006, J UROLOGY, V175, P113, DOI 10.1016/S0022-5347(05)00065-0; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; WARACH S, 1992, NEUROLOGY, V42, P1717, DOI 10.1212/WNL.42.9.1717; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wieshmann UC, 1999, LANCET, V353, P1242, DOI 10.1016/S0140-6736(99)00248-2; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006	88	210	212	0	18	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	MAY	2007	205	1					116	131		10.1016/j.expneurol.2007.01.035			16	Neurosciences	Neurosciences & Neurology	166TO	WOS:000246403400015	17368446	Green Accepted			2021-06-18	
J	Kotchoubey, B; Lang, S; Mezger, G; Schmalohr, D; Schneck, M; Semmler, A; Bostanov, V; Birbaumer, N				Kotchoubey, B; Lang, S; Mezger, G; Schmalohr, D; Schneck, M; Semmler, A; Bostanov, V; Birbaumer, N			Information processing in severe disorders of consciousness: Vegetative state and minimally conscious state	CLINICAL NEUROPHYSIOLOGY			English	Article; Proceedings Paper	Seminar of the Reuth Rehabilitation Center	MAY, 2004	Tel Aviv, ISRAEL			consciousness; event-related potentials; minimally conscious state; P300; vegetative state	EVENT-RELATED POTENTIALS; AUDITORY-EVOKED POTENTIALS; BRAIN POTENTIALS; HEAD-INJURY; MISMATCH NEGATIVITY; DIAGNOSIS; RECOVERY; APHASIA; TASK; METABOLISM	Objective: To study the presence of electrophysiological indicators of remaining cortical functions in patients with persistent vegetative state (PVS) and minimally conscious state (MCS). Previous electrophysiological and PET data indicated that some PVS patients have partially intact cortical processing functions. However, it remains unclear whether the reported patients were representative for PVS population or just some exceptional cases. Methods: Event-related brain responses to stimuli of different complexity levels, recorded in 98 patients with extremely severe diffuse brain injuries, 50 of which in PVS. Four main indicators of cortical functions were: (i) N1-P2 complex as an index of simple, undifferentiated cortical processing; (ii) mismatch negativity as an index of pre-attentive, probably unconscious, cortical orientation; (iii) P3 wave as an index of deep cortical analysis of physical stimuli, and (iv) brain responses to semantic stimuli. Results: Cortical responses were found in all PVS patients with a background EEG activity > 4 Hz. All responses investigated, including those to semantic stimuli that indicated comprehension of meaning, occurred significantly above chance, though less frequently than in patients with severe brain injuries who were conscious. Conclusions: Cortical responses were lacking in most patients with severe EEG slowing (< 4 Hz). Follow-up data revealed that the presence of a mismatch negativity, a short disease duration, and the traumatic etiology were related to a better outcome. Significance: The data show that in a subpopulation of PVS patients with preserved thalamocortical feedback connections, remaining cortical information processing is a consistent finding and may even involve semantic levels of processing. (c) 2005 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.	Univ Tubingen, Inst Med Psychol & Behav Neurobiol, D-72074 Tubingen, Germany; Ctr Mental Hlth, Mannheim, Germany; Neurorehabil Clin, Wangen Im Allgau, Germany; Jugendwerk Hegau, Gailingen, Germany; Munster Clin, Zwiefalten, Germany; Neurorehabil Clin, Neresheim, Germany; Univ Trent, Ctr Cognit Neurosci, Trento, Italy	Kotchoubey, B (corresponding author), Univ Tubingen, Inst Med Psychol & Behav Neurobiol, Gartenstr 29, D-72074 Tubingen, Germany.	boris.kotchoubey@uni-tuebingen.de		Bostanov, Vladimir/0000-0002-2946-0786; Birbaumer, Niels/0000-0002-6786-5127			Andrews K, 1997, J ROY SOC MED, V90, P593, DOI 10.1177/014107689709001102; Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; BENTIN S, 1993, PSYCHOPHYSIOLOGY, V30, P161, DOI 10.1111/j.1469-8986.1993.tb01729.x; BERLAD I, 1995, EVOKED POTENTIAL, V96, P472, DOI 10.1016/0168-5597(95)00116-A; Bernat J L, 1992, J Clin Ethics, V3, P176; Boly M, 2004, ARCH NEUROL-CHICAGO, V61, P233, DOI 10.1001/archneur.61.2.233; Bostanov V, 2004, IEEE T BIO-MED ENG, V51, P1057, DOI 10.1109/TBME.2004.826702; Bostanov V, 2004, PSYCHOPHYSIOLOGY, V41, P259, DOI 10.1111/j.1469-8986.2003.00142.x; BRAAKMAN R, 1988, ACTA NEUROCHIR, V95, P49, DOI 10.1007/BF01793082; Byrne JM, 1995, CHILD NEUROPSYCHOL, V1, P211, DOI 10.1080/09297049508400226; Celesia GG, 1997, THEOR MED, V18, P221, DOI 10.1023/A:1005709410296; CHILDS NL, 1993, NEUROLOGY, V43, P1465, DOI 10.1212/WNL.43.8.1465; Connolly JF, 2000, INT J PSYCHOPHYSIOL, V37, P31, DOI 10.1016/S0167-8760(00)00093-3; CONNOLLY JF, 1992, BRAIN LANG, V43, P1, DOI 10.1016/0093-934X(92)90018-A; Connolly JF, 1999, ARCH PHYS MED REHAB, V80, P1309, DOI 10.1016/S0003-9993(99)90035-7; Cossa FM, 1999, BRAIN INJURY, V13, P583; D'Arcy RCN, 2000, CLIN NEUROPHYSIOL, V111, P40, DOI 10.1016/S1388-2457(99)00210-2; D'Arcy RCN, 2003, CLIN NEUROPHYSIOL, V114, P662, DOI 10.1016/S1388-2457(03)00007-5; DANZE F, 1994, NEUROCHIRURGIE, V40, P348; deJong BM, 1997, CLIN NEUROL NEUROSUR, V99, P213, DOI 10.1016/S0303-8467(97)00024-3; Fischer C, 1999, CLIN NEUROPHYSIOL, V110, P1601, DOI 10.1016/S1388-2457(99)00131-5; GERSTENBRAND F, 1987, APALLIC SYNDROME, P14; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P36, DOI 10.1097/00001199-199708000-00005; Giacino JT, 1997, SEMIN NEUROL, V17, P105, DOI 10.1055/s-2008-1040919; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GIACINO JT, 1995, ARCH PHYS MED REHAB, V76, P205; GRANOVSKY Y, 1998, ELECTROEN CLIN NEURO, V554, P559; GRATTON G, 1983, ELECTROEN CLIN NEURO, V55, P468, DOI 10.1016/0013-4694(83)90135-9; Grossman P, 1996, DISABIL REHABIL, V18, P1; Hagoort P, 1996, BRAIN, V119, P627, DOI 10.1093/brain/119.2.627; Hall DA, 2002, CEREB CORTEX, V12, P140, DOI 10.1093/cercor/12.2.140; Hinterberger T, 2005, IEEE T BIO-MED ENG, V52, P211, DOI 10.1109/TBME.2004.840190; Howard RC, 2001, J PSYCHOPHYSIOL, V15, P69, DOI 10.1027//0269-8803.15.2.69; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 2002, VEGETATIVE STATE; Jones SJ, 2000, BRAIN, V123, P1007, DOI 10.1093/brain/123.5.1007; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Kampfl A, 1998, J NEUROSURG, V88, P809, DOI 10.3171/jns.1998.88.5.0809; Kane NM, 1998, ELECTROEN CLIN NEURO, V106, P244, DOI 10.1016/S0013-4694(97)00141-7; Kane NM, 2000, AUDIOL NEURO-OTOL, V5, P186, DOI 10.1159/000013879; KENNARD C, 1995, J NEUROL NEUROSUR PS, V59, P347, DOI 10.1136/jnnp.59.4.347; KINNEY HC, 1994, J NEUROPATH EXP NEUR, V53, P548, DOI 10.1097/00005072-199411000-00002; Kotchoubey B, 2002, NEWS PHYSIOL SCI, V17, P38; Kotchoubey B, 2003, NEUROSCI LETT, V352, P129, DOI 10.1016/j.neulet.2003.08.045; Kotchoubey B, 2002, J PSYCHOPHYSIOL, V16, P129, DOI 10.1027//0269-8803.16.3.129; Kotchoubey B, 2001, NEUROSCI LETT, V310, P93, DOI 10.1016/S0304-3940(01)02057-2; Kotchoubey B, 2001, NEUROSCI LETT, V301, P37, DOI 10.1016/S0304-3940(01)01600-7; Kotchoubey B., 2004, BRAINWAVES MIND RECE, P75; Kretschmer E, 1940, Z GESAMTE NEUROL PSY, V169, P576, DOI 10.1007/BF02871384; KUTAS M, 1980, SCIENCE, V207, P203, DOI 10.1126/science.7350657; Lang S, 2002, CLIN NEUROPHYSIOL, V113, P1734, DOI 10.1016/S1388-2457(02)00267-5; Laureys S, 2000, LANCET, V355, P1790, DOI 10.1016/S0140-6736(00)02271-6; Laureys S, 2000, BRAIN, V123, P1589, DOI 10.1093/brain/123.8.1589; Marchand Y, 2002, CLIN NEUROPHYSIOL, V113, P1715, DOI 10.1016/S1388-2457(02)00224-9; MAROSI M, 1993, LANCET, V341, P1473, DOI 10.1016/0140-6736(93)90914-3; Menon DK, 1998, LANCET, V352, P200, DOI 10.1016/S0140-6736(05)77805-3; MUNTE TF, 1994, ARCH NEUROL-CHICAGO, V51, P482, DOI 10.1001/archneur.1994.00540170058017; Naatanen R, 1999, PSYCHOL BULL, V125, P826, DOI 10.1037/0033-2909.125.6.826; Naatanen R, 2000, INT J PSYCHOPHYSIOL, V37, P3, DOI 10.1016/S0167-8760(00)00091-X; Naatanen R., 1992, ATTENTION BRAIN FUNC; Neumann N, 2004, BRAIN RES PROTOC, V14, P25, DOI 10.1016/j.brainresprot.2004.09.001; Owen AM, 2002, NEUROCASE, V8, P394, DOI 10.1076/neur.8.4.394.16184; Phipps E, 1999, AM J PHYS MED REHAB, V78, P77, DOI 10.1097/00002060-199901000-00020; Piguet O, 1999, BRAIN INJURY, V13, P829, DOI 10.1080/026990599121223; Pilon M, 1996, BRAIN INJURY, V10, P421, DOI 10.1080/026990596124287; Plum F, 1998, PHILOS T ROY SOC B, V353, P1929, DOI 10.1098/rstb.1998.0345; Rappaport M, 1991, J Neuropsychiatry Clin Neurosci, V3, P180; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rauschecker JP, 1997, ACTA OTO-LARYNGOL, P34; Reuter B M, 1989, Arch Psychol (Frankf), V141, P155; Rudolf J, 1999, J NEUROSURG ANESTH, V11, P17, DOI 10.1097/00008506-199901000-00004; SAZBON L, 1990, J NEUROSURG, V72, P75, DOI 10.3171/jns.1990.72.1.0075; Schiff N, 1999, J COGNITIVE NEUROSCI, V11, P650, DOI 10.1162/089892999563715; Schiff ND, 2000, J CLIN NEUROPHYSIOL, V17, P438, DOI 10.1097/00004691-200009000-00002; Schiff ND, 2002, BRAIN, V125, P1210, DOI 10.1093/brain/awf131; Shevrin H, 2001, INT J PSYCHOPHYSIOL, V42, P209, DOI 10.1016/S0167-8760(01)00165-9; Shewmon DA, 1999, DEV MED CHILD NEUROL, V41, P364, DOI 10.1017/S0012162299000821; Shiel A, 1998, BRAIN INJURY, V12, P809, DOI 10.1080/026990598122043; Strauss DJ, 2000, PEDIATR NEUROL, V23, P312, DOI 10.1016/S0887-8994(00)00194-6; SUDNBERG J, 1991, SCI MUSICAL SOUNDS; Tervaniemi M, 2000, NEUROSCI LETT, V290, P66, DOI 10.1016/S0304-3940(00)01290-8; TOMMASINO C, 1995, J NEUROSURG ANESTH, V7, P109, DOI 10.1097/00008506-199504000-00006; VALDESSOSA MJ, 1987, AUDIOLOGY, V26, P166; Wade DT, 1999, BMJ-BRIT MED J, V319, P841, DOI 10.1136/bmj.319.7213.841; Whyte J, 1999, ARCH PHYS MED REHAB, V80, P653, DOI 10.1016/S0003-9993(99)90168-5; WITZKE W, 1996, NEUROL REHAB, V2, P68; Yingling CD, 2001, CLIN NEUROPHYSIOL, V112, P157, DOI 10.1016/S1388-2457(00)00507-1	88	210	225	0	19	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457	1872-8952		CLIN NEUROPHYSIOL	Clin. Neurophysiol.	OCT	2005	116	10					2441	2453		10.1016/j.clinph.2005.03.028			13	Clinical Neurology; Neurosciences	Neurosciences & Neurology	969KP	WOS:000232233300018	16002333				2021-06-18	
J	Hall, ED; Sullivan, PG; Gibson, TR; Pavel, KM; Thompson, BM; Scheff, SW				Hall, ED; Sullivan, PG; Gibson, TR; Pavel, KM; Thompson, BM; Scheff, SW			Spatial and temporal characteristics of neurodegeneration after controlled cortical impact in mice: More than a focal brain injury	JOURNAL OF NEUROTRAUMA			English	Article						calpain; controlled cortical impact; de Olmos silver staining; neurodegeneration; alpha-spectrin	TRAUMATIC AXONAL INJURY; COGNITIVE DEFICITS; CYCLOSPORINE-A; RECEPTOR AGONIST; ALPHA-SPECTRIN; MOUSE MODEL; HEAD-INJURY; NEUROLOGICAL DYSFUNCTION; HIPPOCAMPAL-NEURONS; CALPAIN ACTIVATION	The present study examined the neuropathology of the lateral controlled cortical impact (CCI) traumatic brain injury (TBI) model in mice utilizing the de Olmos silver staining method that selectively identifies degenerating neurons and their processes. The time course of ipsilateral and contralateral neurodegeneration was assessed at 6, 24, 48, 72, and 168 h after a severe (1.0 mm, 3.5 M/sec) injury in young adult CF-1 mice. At 6 hrs, neurodegeneration was apparent in all layers of the ipsilateral cortex at the epicenter of the injury. A low level of degeneration was also detected within the outer molecular layer of the underlying hippocampal dentate gyrus and to the mossy fiber projections in the CA3 pyramidal subregions. A time-dependent increase in cortical and hippocampal neurodegeneration was observed between 6 and 72 hrs post-injury. At 24 h, neurodegeneration was apparent in the CA1 and CA3 pyramidal and dentate gyral granule neurons and in the dorsolateral portions of the thalamus. Image analysis disclosed that the overall volume of ipsilateral silver staining was maximal at 48 h. In the case of the hippocampus, staining was generalized at 48 and 72 h, indicative of damage to all of the major afferent pathways: perforant path, mossy fibers and Schaffer collaterals as well as the efferent CA1 pyramidal axons. The hippocampal neurodegeneration was preceded by a significant increase in the levels of calpain-mediated breakdown products of the cytoskeletal protein a-spectrin that began at 6 h, and persisted out to 72 h post-injury. Damage to the corpus callosal. fibers was observed as early as 24 h. An anterior to posterior examination of neurodegeneration showed that the cortical damage included the visual cortex. At 168 h (7 days), neurodegeneration in the ipsilateral cortex and hippocampus had largely abated except for ongoing staining in the cortical areas surrounding the contusion lesion and in hippocampal mossy fiber projections. Callosal and thalamic neurodegeneration was also very intense. This more complete neuropathological examination of the CCI model shows that the associated damage is much more widespread than previously appreciated. The extent of ipsilateral and contralateral neurodegeneration provides a more complete anatomical correlate for the cognitive and motor dysfunction seen in this paradigm and suggests that visual disturbances are also likely to be involved in the post-CCI neurological deficits.	Univ Kentucky, Albert B Chandler Med Ctr, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA	Hall, ED (corresponding author), Univ Kentucky, Albert B Chandler Med Ctr, Spinal Cord & Brain Injury Res Ctr, 800 Rose St,Room 232 HSRB, Lexington, KY 40536 USA.	edhall@uky.edu	Hall, Edward D/F-8930-2013; Ritter, Stefanie L/D-9312-2012		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R01 NS046566] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS046566] Funding Source: NIH RePORTER		Albensi BC, 2000, EXP NEUROL, V162, P385, DOI 10.1006/exnr.1999.7338; Amaral David G., 1995, P443; Aoyama N, 2002, BRAIN RES, V934, P117, DOI 10.1016/S0006-8993(02)02366-1; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Bartus RT, 1997, NEUROSCIENTIST, V3, P314, DOI 10.1177/107385849700300513; Buki A, 2000, J NEUROSCI, V20, P2825; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Cherian L, 2003, J PHARMACOL EXP THER, V304, P617, DOI 10.1124/JPET.102.043430; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Dempsey RJ, 2003, J NEUROSURG, V98, P867, DOI 10.3171/jns.2003.98.4.0867; DEOLMOS JS, 1994, NEUROTOXICOL TERATOL, V16, P545, DOI 10.1016/0892-0362(94)90033-7; Dixon CE, 2003, CRIT CARE MED, V31, P2222, DOI 10.1097/01.CCM.0000080493.04978.73; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P355, DOI 10.1097/01.WCB.0000046144.31247.33; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; GRAFE MR, 1980, J NEUROPATH EXP NEUR, V39, P555, DOI 10.1097/00005072-198009000-00005; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; Hannay HJ, 1999, J NEUROTRAUM, V16, P1103, DOI 10.1089/neu.1999.16.1103; HARRIS AS, 1988, J NEUROSCI, V8, P2640; Igarashi T, 2001, EXP NEUROL, V172, P332, DOI 10.1006/exnr.2001.7820; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kim BT, 2001, J NEUROSURG, V95, P674, DOI 10.3171/jns.2001.95.4.0674; Kline AE, 2002, NEUROSCI LETT, V333, P179, DOI 10.1016/S0304-3940(02)01101-1; Kline AE, 2001, NEUROSCIENCE, V106, P547, DOI 10.1016/S0306-4522(01)00300-1; Kupina NC, 2001, J NEUROTRAUM, V18, P1229, DOI 10.1089/089771501317095269; Kupina NC, 2002, J CEREBR BLOOD F MET, V22, P1212; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Longhi L, 2001, J CEREBR BLOOD F MET, V21, P1241, DOI 10.1097/00004647-200111000-00001; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Maxwell WL, 2003, J NEUROTRAUM, V20, P151, DOI 10.1089/08977150360547071; McCracken E, 1999, J NEUROTRAUM, V16, P749, DOI 10.1089/neu.1999.16.749; McCullers D, 2002, NEUROSCIENCE, V109, P219, DOI 10.1016/S0306-4522(01)00477-8; McIntosh TK, 1997, NEUROSCIENTIST, V3, P169, DOI 10.1177/107385849700300310; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; Rao VLR, 2001, BRAIN RES, V911, P96; Ringger NC, 2004, J NEUROTRAUM, V21, P829, DOI 10.1089/0897715041526177; RINK A, 1995, AM J PATHOL, V147, P1575; ROSS DT, 1994, EXP NEUROL, V126, P291, DOI 10.1006/exnr.1994.1067; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Saatman KE, 2003, J CEREBR BLOOD F MET, V23, P34, DOI 10.1097/01.WCB.0000035040.10031.B0; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Shreiber DI, 1999, J NEUROPATH EXP NEUR, V58, P153, DOI 10.1097/00005072-199902000-00005; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Stover JF, 2003, J NEUROTRAUM, V20, P315, DOI 10.1089/089771503765172273; Stover JF, 2000, J NEUROTRAUM, V17, P1171, DOI 10.1089/neu.2000.17.1171; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5&lt;723::AID-ANA5&gt;3.0.CO;2-W; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Switzer RC, 2000, TOXICOL PATHOL, V28, P70, DOI 10.1177/019262330002800109; Wang KKW, 2000, TRENDS NEUROSCI, V23, P59, DOI 10.1016/S0166-2236(99)01536-2; Whalen MJ, 2000, ACT NEUR S, V76, P61; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YAMAMOTO T, 1986, BRAIN RES, V374, P419, DOI 10.1016/0006-8993(86)90442-7; YUEN PW, 1996, EXPERT OPIN INV DRUG, V5, P1291	71	210	219	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2005	22	2					252	265		10.1089/neu.2005.22.252			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	900XU	WOS:000227248400005	15716631				2021-06-18	
J	McCrea, M; Kelly, JP; Kluge, J; Ackley, B; Randolph, C				McCrea, M; Kelly, JP; Kluge, J; Ackley, B; Randolph, C			Standardized assessment of concussion in football players	NEUROLOGY			English	Article								The recent formulation of guidelines for the management of concussion in sports adopted by the American Academy of Neurology specifically calls for the development of a standardized, systematic sideline evaluation for the immediate assessment of concussion in athletes, The present study involved the preliminary investigation of the feasibility and clinical validity of a standardized version of a brief sideline examination complied in accordance with these guidelines, This examination, intended for use by athletic trainers, was administered by three trainers to 141 nonconcussed high school football players at three separate schools, All players suspected of suffering a concussion (N = 6) during the fall 1995 season were also tested immediately following their injury. The examination was easily administered and scored, The concussed players as a group scored significantly below the nonconcussed controls and below their own baseline (pre-injury) performance, despite their all having been considered by the trainers to have suffered mild, grade 1 concussions. Although preliminary, these data suggest that a standardized sideline examination of this type can be useful in detecting concussion and determining fitness to return to play.	NORTHWESTERN UNIV,SCH MED,CHICAGO,IL; REHABIL INST CHICAGO,CHICAGO,IL 60611; COVENANT MED CTR,WATERLOO,IA				Ackley, Brian/0000-0002-1257-2407			Barth JT, 1989, MILD HEAD INJURY; *CO MED SOC, 1991, REP SPORTS MED COMM; KELLY J, 1995, CURRENT THERAPY SPOR; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P581; LANDRY G, 1994, P MILD BRAIN INJ SUM; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; YARNELL PR, 1970, LANCET, V1, P863	8	210	214	0	14	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0028-3878			NEUROLOGY	Neurology	MAR	1997	48	3					586	588		10.1212/WNL.48.3.586			3	Clinical Neurology	Neurosciences & Neurology	XC475	WOS:A1997XC47500007	9065531	Green Published			2021-06-18	
J	Sandberg, M; Patil, J; D'Angelo, B; Weber, SG; Mallard, C				Sandberg, Mats; Patil, Jaspal; D'Angelo, Barbara; Weber, Stephen G.; Mallard, Carina			NRF2-regulation in brain health and disease: Implication of cerebral inflammation	NEUROPHARMACOLOGY			English	Article						Neuroinflammation; NRF2; Anti-oxidants	ANTIOXIDANT-RESPONSE-ELEMENT; TRANSCRIPTION FACTOR NRF2; PROTEIN-KINASE-C; OXIDATIVE STRESS; GENE-EXPRESSION; HEME OXYGENASE-1; MEDITERRANEAN DIET; FUNCTIONAL-CHARACTERIZATION; COGNITIVE IMPAIRMENT; SELECTIVE AUTOPHAGY	The nuclear factor erythroid 2 related factor 2 (NRF2) is a key regulator of endogenous inducible defense systems in the body. Under physiological conditions NRF2 is mainly located in the cytoplasm. However, in response to oxidative stress, NRF2 translocates to the nucleus and binds to specific DNA sites termed "anti-oxidant response elements" or "electrophile response elements" to initiate transcription of cytoprotective genes. Acute oxidative stress to the brain, such as stroke and traumatic brain injury is increased in animals that are deficient in NRF2. Insufficient NRF2 activation in humans has been linked to chronic diseases such as Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis. New findings have also linked activation of the NRF2 system to anti-inflammatory effects via interactions with NF-kappa B. Here we review literature on cellular mechanisms of NRF2 regulation, how to maintain and restore NRF2 function and the relationship between NRF2 regulation and brain damage. We bring forward the hypothesis that inflammation via prolonged activation of key kinases (p38 and GSK-3 beta) and activation of histone deacetylases gives rise to dysregulation of the NRF2 system in the brain, which contributes to oxidative stress and injury. (C) 2013 Elsevier Ltd. All rights reserved.	[Sandberg, Mats; Patil, Jaspal] Univ Gothenburg, Sahlgrenska Acad, Dept Med Biochem & Cell Biol, Inst Biomed, S-40530 Gothenburg, Sweden; [D'Angelo, Barbara; Mallard, Carina] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Physiol, S-40530 Gothenburg, Sweden; [Weber, Stephen G.] Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15260 USA	Mallard, C (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Box 432, S-40530 Gothenburg, Sweden.	carina.mallard@neuro.gu.se	Weber, Stephen G/AAJ-9255-2020	Weber, Stephen/0000-0002-7970-2632; Mallard, Carina/0000-0001-8953-919X; Patil, Jaspal/0000-0001-6647-5576	Swedish Research CouncilSwedish Research CouncilEuropean Commission [VR2009-2630, 2012-2992, ALFGBG-142881]; European UnionEuropean Commission [HEALTHF2-2009-241778]; Leducq foundationLeducq Foundation [DSRR_234404]; Ahlen-stiftelsen; Wilhelm and Martina Lundgren Foundation; Swedish Brain Foundation [FO2013-095]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 GM044842]; Foundation Olle Engkvist Byggmastare; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM044842] Funding Source: NIH RePORTER	This research received financial assistance from the Swedish Research Council (VR2009-2630, 2012-2992), a Government grant to a researcher in Public Health Service at the Sahlgrenska University Hospital (ALFGBG-142881), European Union grant FP7, (Neurobid, HEALTHF2-2009-241778), the Leducq foundation (DSRR_234404), Ahlen-stiftelsen, Wilhelm and Martina Lundgren Foundation, Swedish Brain Foundation (FO2013-095) and the National Institutes of Health (R01 GM044842). Barbara D'Angelo was supported by Foundation Olle Engkvist Byggmastare.	Bardai FH, 2011, J NEUROSCI, V31, P1746, DOI 10.1523/JNEUROSCI.5704-10.2011; Bjorkoy G, 2005, J CELL BIOL, V171, P603, DOI 10.1083/jcb.200507002; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Bloom DA, 2003, J BIOL CHEM, V278, P44675, DOI 10.1074/jbc.M307633200; Burton NC, 2006, NEUROTOXICOLOGY, V27, P1094, DOI 10.1016/j.neuro.2006.07.019; Cai ZW, 2013, DEV NEUROSCI-BASEL, V35, P155, DOI 10.1159/000346156; Chen L, 2014, J SCI FOOD AGR, V94, P180, DOI 10.1002/jsfa.6216; Chowdhry S, 2013, ONCOGENE, V32, P3765, DOI 10.1038/onc.2012.388; Clements CM, 2006, P NATL ACAD SCI USA, V103, P15091, DOI 10.1073/pnas.0607260103; Cook AL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021907; Correa F, 2013, NEUROIMMUNOMODULAT, V20, P185, DOI 10.1159/000347161; Correa F, 2012, NEUROCHEM RES, V37, P2842, DOI 10.1007/s11064-012-0878-y; Correa F, 2011, NEUROBIOL DIS, V44, P142, DOI 10.1016/j.nbd.2011.06.016; Correa F, 2011, GLIA, V59, P785, DOI 10.1002/glia.21151; Cotman CW, 2007, TRENDS NEUROSCI, V30, P464, DOI 10.1016/j.tins.2007.06.011; Cullinan SB, 2003, MOL CELL BIOL, V23, P7198, DOI 10.1128/MCB.23.20.7198-7209.2003; Cummings C, 2012, PAED CHILD HEALT-CAN, V17, P331, DOI 10.1093/pch/17.6.331; D'Angelo B, 2013, J INHERIT METAB DIS, V36, P479, DOI 10.1007/s10545-012-9551-5; Devos D, 2013, NEUROBIOL DIS, V50, P42, DOI 10.1016/j.nbd.2012.09.007; Dhakshinamoorthy S, 2005, J BIOL CHEM, V280, P16891, DOI 10.1074/jbc.M500166200; Dhakshinamoorthy S, 2001, ONCOGENE, V20, P3906, DOI 10.1038/sj.onc.1204506; Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899; Espada S, 2009, J NEUROCHEM, V110, P1107, DOI 10.1111/j.1471-4159.2009.06208.x; Fragoulis A, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4059; Gan L, 2012, J NEUROSCI, V32, P17775, DOI 10.1523/JNEUROSCI.3049-12.2012; Gao L, 2007, J BIOL CHEM, V282, P2529, DOI 10.1074/jbc.M607622200; Gemma C, 2002, J NEUROSCI, V22, P6114; Gold R, 2012, NEW ENGL J MED, V367, P1098, DOI 10.1056/NEJMoa1114287; Gounder SS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045697; Harada N, 2011, ARCH BIOCHEM BIOPHYS, V508, P101, DOI 10.1016/j.abb.2011.02.001; Holmes C, 2009, NEUROLOGY, V73, P768, DOI 10.1212/WNL.0b013e3181b6bb95; Huang HC, 2012, J ALZHEIMERS DIS, V32, P981, DOI 10.3233/JAD-2012-120688; Huang HC, 2000, P NATL ACAD SCI USA, V97, P12475, DOI 10.1073/pnas.220418997; Hubbs AF, 2007, AM J PATHOL, V170, P2068, DOI 10.2353/ajpath.2007.060898; Innamorato NG, 2008, J IMMUNOL, V181, P680, DOI 10.4049/jimmunol.181.1.680; Innamorato NG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011838; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jain AK, 2007, J BIOL CHEM, V282, P16502, DOI 10.1074/jbc.M611336200; Jain A, 2010, J BIOL CHEM, V285, P22576, DOI 10.1074/jbc.M110.118976; Jakel RJ, 2007, BRAIN RES, V1144, P192, DOI 10.1016/j.brainres.2007.01.131; Jin W, 2009, J NEUROTRAUM, V26, P131, DOI 10.1089/neu.2008.0655; Jin YNN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057932; Jyrkkanen HK, 2011, BIOCHEM J, V440, P167, DOI 10.1042/BJ20110526; Kaidery NA, 2013, ANTIOXID REDOX SIGN, V18, P139, DOI 10.1089/ars.2011.4491; Kanninen K, 2008, MOL CELL NEUROSCI, V39, P302, DOI 10.1016/j.mcn.2008.07.010; Kanninen Katja, 2011, Int J Alzheimers Dis, V2011, P985085, DOI 10.4061/2011/985085; Kapeta S, 2010, J BIOL CHEM, V285, P8171, DOI 10.1074/jbc.M109.031575; Kappos L, 2008, LANCET, V372, P1463, DOI 10.1016/S0140-6736(08)61619-0; Kaspar JW, 2010, J BIOL CHEM, V285, P21349, DOI 10.1074/jbc.M110.121863; Keum YS, 2006, CANCER RES, V66, P8804, DOI 10.1158/0008-5472.CAN-05-3513; Kim HJ, 2010, AM J PHYSIOL-RENAL, V298, pF662, DOI 10.1152/ajprenal.00421.2009; Kim JE, 2010, CELL SIGNAL, V22, P1645, DOI 10.1016/j.cellsig.2010.06.004; Kim KH, 2011, BIOCHEM BIOPH RES CO, V404, P46, DOI 10.1016/j.bbrc.2010.11.051; Kirby J, 2005, BRAIN, V128, P1686, DOI 10.1093/brain/awh503; Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004; Kobayashi A, 2006, MOL CELL BIOL, V26, P221, DOI 10.1128/MCB.26.1.221-229.2006; Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035; Komatsu M, 2010, NAT CELL BIOL, V12, P213, DOI 10.1038/ncb2021; Konstantinidou V, 2013, MOL NUTR FOOD RES, V57, P772, DOI 10.1002/mnfr.201200613; Ku CS, 2013, BBA-GEN SUBJECTS, V1830, P2981, DOI 10.1016/j.bbagen.2013.01.018; Kwak MK, 2007, FREE RADICAL BIO MED, V43, P809, DOI 10.1016/j.freeradbiomed.2007.05.029; Kwak MK, 2003, MOL CELL BIOL, V23, P8786, DOI 10.1128/MCB.23.23.8786-8794.2003; Kwak MK, 2003, J BIOL CHEM, V278, P8135, DOI 10.1074/jbc.M211898200; Lamark T, 2009, CELL CYCLE, V8, P1986, DOI 10.4161/cc.8.13.8892; Lastres-Becker I, 2012, HUM MOL GENET, V21, P3173, DOI 10.1093/hmg/dds143; Lau A, 2010, MOL CELL BIOL, V30, P3275, DOI 10.1128/MCB.00248-10; Levonen AL, 2004, BIOCHEM J, V378, P373, DOI 10.1042/BJ20031049; Liu F, 2008, J NEUROCHEM, V105, P2435, DOI 10.1111/j.1471-4159.2008.05333.x; Liu GH, 2008, BBA-MOL CELL RES, V1783, P713, DOI 10.1016/j.bbamcr.2008.01.002; Lourida I, 2013, EPIDEMIOLOGY, V24, P479, DOI 10.1097/EDE.0b013e3182944410; Meng PF, 2013, NEUROSCI RES, V75, P94, DOI 10.1016/j.neures.2012.11.007; Milder JB, 2010, NEUROBIOL DIS, V40, P238, DOI 10.1016/j.nbd.2010.05.030; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Morrison CD, 2010, J NEUROCHEM, V114, P1581, DOI 10.1111/j.1471-4159.2010.06865.x; Myzak MC, 2004, CANCER RES, V64, P5767, DOI 10.1158/0008-5472.CAN-04-1326; Naidu S, 2009, J IMMUNOL, V182, P7048, DOI 10.4049/jimmunol.0900006; Nair S, 2008, BRIT J CANCER, V99, P2070, DOI 10.1038/sj.bjc.6604703; Nakaso K, 2003, FEBS LETT, V546, P181, DOI 10.1016/S0014-5793(03)00517-9; Narasimhan M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051111; Niture SK, 2012, J BIOL CHEM, V287, P9873, DOI 10.1074/jbc.M111.312694; Niture SK, 2011, J BIOL CHEM, V286, P28821, DOI 10.1074/jbc.M111.255042; Niture SK, 2009, J CELL SCI, V122, P4452, DOI 10.1242/jcs.058537; Pergola PE, 2011, NEW ENGL J MED, V365, P327, DOI 10.1056/NEJMoa1105351; Pi JB, 2007, FREE RADICAL BIO MED, V42, P1797, DOI 10.1016/j.freeradbiomed.2007.03.001; Piantadosi CA, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.207738; Pickering AM, 2012, J BIOL CHEM, V287, P10021, DOI 10.1074/jbc.M111.277145; Psaltopoulou T, 2013, ANN NEUROL, V74, P580, DOI 10.1002/ana.23944; Rada P, 2012, MOL CELL BIOL, V32, P3486, DOI 10.1128/MCB.00180-12; Ramsey CP, 2007, J NEUROPATH EXP NEUR, V66, P75, DOI 10.1097/nen.0b013e31802d6da9; Rojo AI, 2010, GLIA, V58, P588, DOI 10.1002/glia.20947; Sakata H, 2012, J NEUROSCI, V32, P3462, DOI 10.1523/JNEUROSCI.5686-11.2012; Salazar M, 2006, J BIOL CHEM, V281, P14841, DOI 10.1074/jbc.M513737200; Salminen A, 2012, PROG NEUROBIOL, V96, P87, DOI 10.1016/j.pneurobio.2011.11.005; Sarlette A, 2008, J NEUROPATH EXP NEUR, V67, P1055, DOI 10.1097/NEN.0b013e31818b4906; Scannevin RH, 2012, J PHARMACOL EXP THER, V341, P274, DOI 10.1124/jpet.111.190132; Sequea DA, 2012, J GERONTOL A-BIOL, V67, P1279, DOI 10.1093/gerona/gls085; Shah ZA, 2007, NEUROSCIENCE, V147, P53, DOI 10.1016/j.neuroscience.2007.02.066; Shih AY, 2005, J NEUROSCI, V25, P10321, DOI 10.1523/JNEUROSCI.4014-05.2005; Shimazu T, 2013, SCIENCE, V339, P211, DOI 10.1126/science.1227166; Son TG, 2008, NEUROMOL MED, V10, P236, DOI 10.1007/s12017-008-8037-y; Sporn MB, 2012, NAT REV CANCER, V12, P564, DOI 10.1038/nrc3278; Stack C, 2010, FREE RADICAL BIO MED, V49, P147, DOI 10.1016/j.freeradbiomed.2010.03.017; Su ZY, 2013, CHEM RES TOXICOL, V26, P477, DOI 10.1021/tx300524p; Sun Z, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006588; Sun Z, 2009, MOL CELL BIOL, V29, P2658, DOI 10.1128/MCB.01639-08; Tanji K, 2013, J NEUROPATH EXP NEUR, V72, P18, DOI 10.1097/NEN.0b013e31827b5713; Teiten MH, 2013, MOL NUTR FOOD RES, V57, P1619, DOI 10.1002/mnfr.201300201; Vargas MR, 2008, J NEUROSCI, V28, P13574, DOI 10.1523/JNEUROSCI.4099-08.2008; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Villaran RF, 2010, J NEUROCHEM, V114, P1687, DOI 10.1111/j.1471-4159.2010.06879.x; von Otter M, 2010, BMC MED GENET, V11, DOI 10.1186/1471-2350-11-36; von Otter M, 2010, MECH AGEING DEV, V131, P105, DOI 10.1016/j.mad.2009.12.007; Wang B, 2012, FREE RADICAL BIO MED, V52, P928, DOI 10.1016/j.freeradbiomed.2011.12.006; Wang JS, 2011, N-S ARCH PHARMACOL, V383, P159, DOI 10.1007/s00210-010-0586-6; Wang Steven, 2010, Curr Drug Discov Technol, V7, P67; Wang WW, 2013, BRAIN INJURY, V27, P924, DOI 10.3109/02699052.2013.793397; Wang XY, 2007, ANN NEUROL, V61, P263, DOI 10.1002/ana.21066; Wang Z, 2012, J PINEAL RES, V53, P129, DOI 10.1111/j.1600-079X.2012.00978.x; White E, 2010, CURR OPIN CELL BIOL, V22, P212, DOI 10.1016/j.ceb.2009.12.008; Xu CJ, 2006, MOL CANCER THER, V5, P1918, DOI 10.1158/1535-7163.MCT-05-0497; Yang LC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005757; Yasuda S., 2011, Central Nervous System Agents in Medicinal Chemistry, V11, P45; Yates MS, 2007, MOL CANCER THER, V6, P154, DOI 10.1158/1535-7163.MCT-06-0516; Yu MA, 2011, CELL SIGNAL, V23, P883, DOI 10.1016/j.cellsig.2011.01.014; Zhang DD, 2005, J BIOL CHEM, V280, P30091, DOI 10.1074/jbc.M501279200; Zhang DD, 2013, ANTIOXID REDOX SIGN, V19, P517, DOI 10.1089/ars.2012.5118; Zhu YG, 2007, NEUROCHEM INT, V50, P671, DOI 10.1016/j.neuint.2006.12.013	128	209	218	0	44	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	APR	2014	79						298	306		10.1016/j.neuropharm.2013.11.004			9	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	AE1ZX	WOS:000333774200031	24262633	Green Accepted	Y	N	2021-06-18	
J	Taylor, BC; Hagel, EM; Carlson, KF; Cifu, DX; Cutting, A; Bidelspach, DE; Sayer, NA				Taylor, Brent C.; Hagel, Emily M.; Carlson, Kathleen F.; Cifu, David X.; Cutting, Andrea; Bidelspach, Douglas E.; Sayer, Nina A.			Prevalence and Costs of Co-occurring Traumatic Brain Injury With and Without Psychiatric Disturbance and Pain Among Afghanistan and Iraq War Veteran VA Users	MEDICAL CARE			English	Article						veterans; health care costs; traumatic injury; brain injuries; traumatic stress syndrome; utilization	POSTTRAUMATIC-STRESS-DISORDER; ENDURING FREEDOM; NONCANCER PAIN; RISK-FACTORS; HEALTH-CARE; DIAGNOSES; OPIOIDS; TRENDS	Background: Traumatic brain injury (TBI) is the "signature injury" in the Afghanistan and Iraq wars [Operation Enduring Freedom in Afghanistan (OEF)/Operation Iraqi Freedom (OIF)]. Patients with combat-related TBI also have high rates of psychiatric disturbances and pain. Objectives: To determine the prevalence of TBI alone and TBI with other conditions and the average cost of medical care for veterans with these diagnoses. Methods: Observational study using national inpatient, outpatient, and pharmacy data from Veterans Health Administration (VHA) datasets. Costs are estimated from utilization related to care within the VHA system. Participants were all OEF/OIF VHA users in 2009. Results: Among 327,388 OEF/OIF veterans using VHA services in 2009, 6.7% were diagnosed with TBI. Among those with TBI diagnoses, 89% were diagnosed with a psychiatric diagnosis [the most frequent being posttraumatic stress disorder (PTSD) at 73%], and 70% had a diagnosis of head, back, or neck pain. The rate of comorbid PTSD and pain among those with and without TBI was 54% and 11%, respectively. The median annual cost per patient was nearly 4-times higher for TBI-diagnosed veterans as compared with those without TBI ($5831 vs. $1547). Within the TBI group, cost increased as diagnostic complexity increased, such that those with TBI, pain, and PTSD demonstrated the highest median cost per patient ($7974). Conclusions: The vast majority of VHA patients diagnosed with TBI also have a diagnosed mental disorder and more than half have both PTSD and pain. Patients with these comorbidities incur substantial medical costs and represent a target population for future research aimed at improving health care efficiency.	[Taylor, Brent C.; Hagel, Emily M.; Cutting, Andrea; Sayer, Nina A.] Dept Vet Affairs Hlth Care Syst, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA; [Taylor, Brent C.; Sayer, Nina A.] Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA; [Taylor, Brent C.] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN USA; [Carlson, Kathleen F.] VA Med Ctr, Portland Ctr Study Chron Comorbid Mental & Phys D, Portland, OR USA; [Carlson, Kathleen F.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA; [Cifu, David X.] Hunter Holmes McGuire VA Med Ctr, Phys Med & Rehabil Serv, Vet Hlth Adm, Richmond, VA USA; [Cifu, David X.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA; [Bidelspach, Douglas E.] VA Med Ctr, Vet Hlth Adm, Lebanon, PA USA; [Sayer, Nina A.] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA	Taylor, BC (corresponding author), VA Hlth Care Syst 152 2E, 1 Vet Dr, Minneapolis, MN 55417 USA.	Brent.Taylor2@va.gov	Sayer, Nina/E-3249-2016; Taylor, Brent C/A-8069-2009; MUNOZ, ROSA ANA/H-3964-2018	Taylor, Brent C/0000-0002-2140-8377; MUNOZ, ROSA ANA/0000-0002-7504-2163; Cifu, David/0000-0003-1600-9387	US Department of Veterans Affairs, Office of Research and Development, Health Services Research & Development Service (HSR&D), Washington, DC through Polytrauma and Blast-Related Injuries (PT/BRI) QUERI [PLY 05-2010-2]; VA HSR&D career development [CDA 08-025]	Funding for the study was provided by the US Department of Veterans Affairs, Office of Research and Development, Health Services Research & Development Service (HSR&D), Washington, DC through local initiated project grant (#PLY 05-2010-2) from the Polytrauma and Blast-Related Injuries (PT/BRI) QUERI. Dr Carlson's efforts were supported, in part, through a VA HSR&D career development grant (CDA 08-025). The funding source had no role in the study design, analysis, interpretation of the data, the writing of the paper, or the decision to submit the paper for publication.	ALEXANDRE LM, 1990, MED CARE, V28, P112, DOI 10.1097/00005650-199002000-00002; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P315, DOI 10.1097/01.HTR.0000300226.67748.3e; Department of Veterans Affairs, 2011, COMPR TBI EV SUMM RE; Edlund MJ, 2007, PAIN, V129, P355, DOI 10.1016/j.pain.2007.02.014; Eibner C., 2008, INVISIBLE WOUNDS WAR; Engelhard IM, 2007, BRIT J PSYCHIAT, V191, P140, DOI 10.1192/bjp.bp.106.034884; Gironda RJ, 2006, PAIN MED, V7, P339, DOI 10.1111/j.1526-4637.2006.00146.x; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Kulka R. A., 1990, TRAUMA VIETNAM WAR G; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Magruder KM, 2005, GEN HOSP PSYCHIAT, V27, P169, DOI 10.1016/j.genhosppsych.2004.11.001; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Phibbs CS, 2003, MED CARE RES REV, V60, p54S, DOI 10.1177/1077558703256725; Ramchand R, 2008, INVISIBLE WOUNDS WAR; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ruff RL, 2008, J REHABIL RES DEV, V45, P941, DOI 10.1682/JRRD.2008.02.0028; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Sayer NA, 2009, PM&R, V1, P23, DOI 10.1016/j.pmrj.2008.10.003; SCHELL TL, 2008, INVISIBLE WOUNDS WAR; Seal KH, 2009, AM J PUBLIC HEALTH, V99, P1651, DOI 10.2105/AJPH.2008.150284; Sullivan MD, 2008, PAIN, V138, P440, DOI 10.1016/j.pain.2008.04.027; SUTKER PB, 1993, AM J PSYCHIAT, V150, P240; VHA Health Information Management Office of Health Data and Informatics, 2008, FACT SHEET INT COD G; VHA Health Information Management Office of Health Data and Informatics, 2009, FACT SHEET INT COD G; Wagner TH, 2003, MED CARE RES REV, V60, p15S, DOI 10.1177/1077558703256485; Wallsten S., 2005, 0519 AEI BROOK JOINT; West AN, 2010, J RURAL HEALTH, V26, P301, DOI 10.1111/j.1748-0361.2010.00298.x	29	209	209	0	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0025-7079			MED CARE	Med. Care	APR	2012	50	4					342	346		10.1097/MLR.0b013e318245a558			5	Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health	Health Care Sciences & Services; Public, Environmental & Occupational Health	907SH	WOS:000301437600011	22228249		Y	N	2021-06-18	
J	Vespa, PM; McArthur, D; O'Phelan, K; Glenn, T; Etchepare, M; Kelly, D; Bergsneider, M; Martin, NA; Hovda, DA				Vespa, PM; McArthur, D; O'Phelan, K; Glenn, T; Etchepare, M; Kelly, D; Bergsneider, M; Martin, NA; Hovda, DA			Persistently low extracellular glucose correlates with poor outcome 6 months after human traumatic brain injury despite a lack of increased lactate: A microdialysis study	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						brain trauma; microdialysis; glucose; lactate; hyperglycolysis	POSITRON-EMISSION-TOMOGRAPHY; CEREBRAL BLOOD-FLOW; HUMAN HEAD-INJURY; INTRACEREBRAL MICRODIALYSIS; SUBARACHNOID HEMORRHAGE; AEROBIC GLYCOLYSIS; PERFUSION-PRESSURE; SUBSTRATE DELIVERY; DYNAMIC CHANGES; METABOLISM	Disturbed glucose brain metabolism after brain trauma is reflected by changes in extracellular glucose levels. The authors hypothesized that posttraumatic reductions in extracellular glucose levels are not due to ischemia and are associated with poor outcome. lntracerebral microdialysis, electroencephalography, and measurements of brain tissue oxygen levels and jugular venous oxygen saturation were performed in 30 patients with traumatic brain injury. Levels of glucose, lactate. pyruvate, glutamate, and urea were analyzed hourly. The 6-month Glasgow Outcome Scale extended (GOSe6) score was assessed for each patient. In regions of increased glucose utilization defined by positron emission tomography, the extracellular glucose concentration was less than 0.2 mmol/l. Extracellular glucose values were less than 0.2 mmol during postinjury days 0 to 7 in 19% to 30% of hourly samples on each day. Transient decreases in glucose levels occurred with electrographic seizures and nonischemic reductions in cerebral perfusion pressure and jugular venous oxygen saturation. Glutamate levels were elevated in the majority of low-glucose samples, but the lactate/pyruvate ratio did not indicate focal ischemia. Terminal herniation resulted in reductions in glucose with increases in the lactate/pyruvate ratio but not in lactate concentration alone. GOSe6 scores correlated with persistently low glucose levels, combined early low glucose levels and low lactate/glucose ratio, and with the overall lactate/glucose ratio. These results suggest that the level of extracellular glucose is typically reduced after traumatic brain injury and associated with poor outcome, but is not associated with ischemia.	Univ Calif Los Angeles, David Geffen Sch Med, Div Neurosurg, Los Angeles, CA USA	Vespa, PM (corresponding author), 10833 le Conte Ave,CHS 18-218, Los Angeles, CA 90095 USA.	Pvespa@mednet.ucla.edu		Glenn, Thomas/0000-0003-4273-3408; Martin, Neil/0000-0002-6565-4131	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030308] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 030308, NS 02089] Funding Source: Medline		Abi-Saab WM, 2002, J CEREBR BLOOD F MET, V22, P271, DOI 10.1097/00004647-200203000-00004; Alessandri B, 1999, ACT NEUR S, V75, P21; ANDERSEN BJ, 1989, INTRACRANIAL PRESSUR, V7, P575; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BENVENISTE H, 1989, J NEUROCHEM, V52, P1667, DOI 10.1111/j.1471-4159.1989.tb07243.x; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Cesarini KG, 2002, ACTA NEUROCHIR, V144, P1121, DOI 10.1007/s00701-002-1011-9; Cornford EM, 1996, J NEUROTRAUM, V13, P523, DOI 10.1089/neu.1996.13.523; ENGLAD P, 1996, J CEREB BLOOD FLOW M, V6, P637; FEENEY DM, 1986, STROKE, V17, P817, DOI 10.1161/01.STR.17.5.817; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Gupta AK, 2002, J NEUROSURG, V96, P263, DOI 10.3171/jns.2002.96.2.0263; Hamlin GP, 2001, J NEUROTRAUM, V18, P1011, DOI 10.1089/08977150152693700; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; Hillered L, 1999, SCAND J CLIN LAB INV, V59, P9, DOI 10.1080/00365519950185904; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; HOVDA DA, 1996, NEUROTRAUMA, P1459; Hutchinson PJ, 2000, J NEUROSURG, V93, P37, DOI 10.3171/jns.2000.93.1.0037; Hutchinson PJ, 2002, J CEREBR BLOOD F MET, V22, P735, DOI 10.1097/00004647-200206000-00012; Hutchinson PJA, 2000, ACT NEUR S, V76, P431; IP EY, 2001, J CEREB BLOOD FLO S1, V21, P5187; Jones DA, 2000, J NEUROCHEM, V75, P1703, DOI 10.1046/j.1471-4159.2000.0751703.x; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; Kelly DF, 1997, J NEUROSURG, V86, P633, DOI 10.3171/jns.1997.86.4.0633; KETY SS, 1945, AM J PHYSIOL, V143, P53; LANDOLT H, 1994, ACTA NEUROCHIR, P475; Langemann H, 2001, NEUROL RES, V23, P531, DOI 10.1179/016164101101198785; Lee JH, 2001, J NEUROSURG, V95, P222, DOI 10.3171/jns.2001.95.2.0222; Marklund N, 1997, NEUROREPORT, V8, P1457, DOI 10.1097/00001756-199704140-00026; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Moore AH, 2000, J CEREBR BLOOD F MET, V20, P1492, DOI 10.1097/00004647-200010000-00011; Nilsson P, 1996, J NEUROTRAUM, V13, P201, DOI 10.1089/neu.1996.13.201; Pellerin L, 1996, DEV NEUROSCI-BASEL, V18, P336, DOI 10.1159/000111426; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; Persson L, 1996, J NEUROSURG, V84, P606, DOI 10.3171/jns.1996.84.4.0606; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Ronne-Engstrom E, 2001, J NEUROSURG, V94, P397, DOI 10.3171/jns.2001.94.3.0397; Ros J, 2001, J NEUROSCI RES, V66, P790, DOI 10.1002/jnr.10043; Stahl N, 2001, INTENS CARE MED, V27, P1215, DOI 10.1007/s001340101004; Stahl N, 2001, ACTA ANAESTH SCAND, V45, P977, DOI 10.1034/j.1399-6576.2001.450810.x; Unterberg AW, 2001, J NEUROSURG, V94, P740, DOI 10.3171/jns.2001.94.5.0740; Valadka AB, 1998, J NEUROTRAUM, V15, P509, DOI 10.1089/neu.1998.15.509; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Vespa P, 2002, ACTA NEUROCHIR SUPPL, V81, P355; Vink R, 1988, J NEUROTRAUM, V5, P315, DOI 10.1089/neu.1988.5.315; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; YOSHINO A, 1992, J CEREBR BLOOD F MET, V12, P996, DOI 10.1038/jcbfm.1992.137; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	52	209	218	0	7	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JUL	2003	23	7					865	877		10.1097/01.WCB.0000076701.45782.EF			13	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	698EU	WOS:000183985300010	12843790	Bronze			2021-06-18	
J	Maroon, JC; Lovell, MR; Norwig, J; Podell, K; Powell, JW; Hartl, ATCR				Maroon, JC; Lovell, MR; Norwig, J; Podell, K; Powell, JW; Hartl, ATCR			Cerebral concussion in athletes: Evaluation and neuropsychological testing	NEUROSURGERY			English	Article						brain concussion; cerebral metabolism head injuries; neuropsychological tests; sports medicine	TRAUMATIC BRAIN INJURY; MINOR HEAD-INJURY; FOOTBALL PLAYERS; EXTRACELLULAR POTASSIUM; 2ND IMPACT; BLOOD-FLOW; RAT; SPORTS; RECOVERY; PH	OBJECTIVE: To conduct a topic review of studies related to cerebral concussion in athletes, as an aid to improving decision-making and outcomes. METHODS: We review the literature to provide an historical perspective on the incidence and definition of and the management guidelines for mild traumatic brain injury in sports. In addition, metabolic changes resulting from cerebral concussion and the second-impact syndrome are reviewed, to provide additional principles for decisionmaking. Neuropsychological testing, as it applies to athletes, is discussed in detail, to delineate baseline assessments, the characteristics of the neuropsychological evaluation, the neuropsychological tests used, and the methods for in-season identification of cerebral concussion. future directions in the management of concussions are presented. RESULTS: The incidence of cerebral concussions has been reduced from approximately 19 per 100 participants in football per season to approximately 4 per 100, i.e., 40,000 to 50,000 concussions per year in football alone. The most commonly used definitions of concussion are those proposed by Cantu and the American Academy of Neurology. Each has associated management guidelines. Concussion or loss of consciousness occurs when the extracellular potassium concentration increases beyond the upper normal limit of approximately 4 to 5 mmol/L, to levels of 20 to 50 mmol/L, inhibiting the action potential and leading to loss of consciousness. This phenomenon helps to explain the delayed effects of symptoms after trauma. CONCLUSION: Neuropsychological testing seems to be an effective way to obtain useful data on the short-term and long-term effects of mild traumatic brain injury. Moreover, knowledge of the various definitions and management strategies, as well as the utility of neuropsychological testing, is essential for those involved in decision-making with athletes with mild traumatic brain injuries.	Univ Pittsburgh, Med Ctr, Dept Neurosurg, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Med Ctr, Dept Orthoped & Sports Med, Pittsburgh, PA 15213 USA; Henry Ford Hlth Syst, Dept Behav Serv, Detroit, MI USA; Pittsburgh Steelers Football, Pittsburgh, PA USA; Michigan State Univ, E Lansing, MI 48824 USA; Cornell Univ, Dept Neurosurg, New York, NY USA	Maroon, JC (corresponding author), Univ Pittsburgh, Med Ctr, Dept Neurosurg, Pittsburgh, PA 15213 USA.	maroonjc@msx.upmc.edu					*AD HOC COMM STUD, 1996, CLIN NEUROSURG, V46, P386; Barth JT., 1989, MILD HEAD INJURY, P257; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bleiberg J, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199804000-00006; BOURKE RS, 1983, NEUROCHEM RES, V8, P5, DOI 10.1007/BF00965650; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; DESALLES AAF, 1987, NEUROSURGERY, V20, P297, DOI 10.1227/00006123-198702000-00017; ERICHSEN JE, 1882, CONCUSSION SPINE NER; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GRONWALL D, 1975, LANCET, V2, P995; GRONWALL D, 1974, LANCET, V2, P605; HOVDA DA, 1996, NEUROTRAUMA, P1459; Jordan BD, 1996, PHYSICIAN SPORTSMED, V24, P87, DOI 10.3810/psm.1996.05.1358; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KAY G, 1995, GOGSCREEN; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P581; KUTNER KC, 1997, NAT FOOTB LEAG PHYS; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 1999, SPORTS-RELATED CONCUSSION, P200; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; Marmarou A, 1993, Acta Neurochir Suppl (Wien), V57, P160; Maroon J C, 1980, Clin Neurosurg, V27, P414; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; NILSSON B, 1977, J NEUROSURG, V47, P252, DOI 10.3171/jns.1977.47.2.0252; NILSSON B, 1977, J NEUROSURG, V47, P274, DOI 10.3171/jns.1977.47.2.0274; NOVDA D, 1999, SPORTS RELATED CONCU, P12; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; REEVES D, AUTOMATED NEUROPSYCH; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Schneider R., 1973, HEAD NECK INJURIES F, P77; TAKAHASHI H, 1981, J NEUROSURG, V55, P708, DOI 10.3171/jns.1981.55.5.0708; TORG JS, 1991, ATHLETIC INJURIES HE, P272; Vink R, 1988, J NEUROTRAUM, V5, P315, DOI 10.1089/neu.1988.5.315; Walton G. L., 1881, BOSTON MED SURG J, V109, P337, DOI 10.1056/NEJM188310111091501; WILBERGER J, 1991, AM ASS NEUR SURG ANN; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YARNELL PR, 1970, LANCET, V1, P863; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	52	209	210	0	37	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	SEP	2000	47	3					659	669		10.1097/00006123-200009000-00027			11	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	349GJ	WOS:000089037100056	10981754				2021-06-18	
J	Sullivan, PG; Bruce-Keller, AJ; Rabchevsky, AG; Christakos, S; St Clair, DK; Mattson, MP; Scheff, SW				Sullivan, PG; Bruce-Keller, AJ; Rabchevsky, AG; Christakos, S; St Clair, DK; Mattson, MP; Scheff, SW			Exacerbation of damage and altered NF-kappa B activation in mice lacking tumor necrosis factor receptors after traumatic brain injury	JOURNAL OF NEUROSCIENCE			English	Article						neurotrauma; blood-brain barrier; transgenic; cortical impact; oxidative stress; TNF alpha	MANGANESE SUPEROXIDE-DISMUTASE; CLOSED-HEAD INJURY; INDUCED NEURONAL DEGENERATION; PROTECTS HIPPOCAMPAL-NEURONS; FOCAL CEREBRAL-ISCHEMIA; BETA-PEPTIDE TOXICITY; NERVOUS-SYSTEM TRAUMA; DNA-BINDING ACTIVITY; SPINAL-CORD INJURY; ACUTE CNS INJURY	Tumor necrosis factor alpha (TNF alpha) is widely expressed in both neurons and glia and has been shown to be upregulated after traumatic brain injury (TBI). TNF alpha receptor activation results in activation of the transcription factor nuclear factor kappa B(NF-kappa B), which may serve an antiapoptotic role via the induction of target genes manganese superoxide dismutase (MnSOD) and/or calbindin. In the present study, we used a controlled cortical impact model of TBI with pertinent lines of transgenic mice to combine both morphological characterization and molecular analysis to elucidate the role of TNF alpha after TBI. Measurements of both the lesion volume and the blood-brain barrier breach indicated exacerbations in mice rendered genetically deficient in both the p55 and p75 TNF alpha receptors (TNFR-KO) compared with wild-type animals. Additionally, animals genetically altered to overexpress MnSOD showed a significant decrease in lesion volume compared with that of control littermates, whereas no alterations were observed in mice lacking the calcium-binding protein calbindin D28k. Analysis of NF-kappa B activation and relative levels of MnSOD revealed delayed responses in the injured cortex of TNFR-KO animals compared with wild-type animals, implying that endogenous TNF alpha may be neuroprotective after TBI.	Univ Kentucky, Sanders Brown Ctr Aging 229, Lexington, KY 40536 USA; Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; Univ Kentucky, Grad Ctr Toxicol, Lexington, KY 40536 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA	Scheff, SW (corresponding author), Univ Kentucky, Sanders Brown Ctr Aging 229, Lexington, KY 40536 USA.		Mattson, Mark P/F-6038-2012; Rabchevsky, Alexander/AAQ-2451-2021; Bruce-Keller, Annadora/N-1954-2017	Rabchevsky, Alexander/0000-0002-1991-0915; 	NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA059835] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS031220, R01NS029001] Funding Source: NIH RePORTER; NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [CA59835] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS31220, NS29001] Funding Source: Medline		Airaksinen MS, 1997, P NATL ACAD SCI USA, V94, P1488, DOI 10.1073/pnas.94.4.1488; ANDERSSON PB, 1991, NEUROSCIENCE, V42, P201, DOI 10.1016/0306-4522(91)90159-L; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.iy.12.040194.001041; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; BARGER SW, 1995, P NATL ACAD SCI USA, V92, P9328, DOI 10.1073/pnas.92.20.9328; Barger SW, 1996, MOL BRAIN RES, V40, P116; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Baskaya MK, 1997, NEUROSURGERY, V40, P364; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BELAYEV L, 1995, BRAIN RES, V702, P266, DOI 10.1016/0006-8993(95)01127-9; Bellas RE, 1997, AM J PATHOL, V151, P891; Bethea JR, 1998, J NEUROSCI, V18, P3251; BEUTLER B, 1994, ANN NY ACAD SCI, V730, P118, DOI 10.1111/j.1749-6632.1994.tb44244.x; BEUTLER B, 1994, SCIENCE, V264, P667, DOI 10.1126/science.8171316; BRAUGHLER JM, 1992, J NEUROTRAUM, V9, pS1; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; CHAN PH, 1995, J NEUROTRAUM, V12, P815, DOI 10.1089/neu.1995.12.815; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; COFFEY PJ, 1990, NEUROSCIENCE, V35, P121, DOI 10.1016/0306-4522(90)90126-O; DAS KC, 1995, MOL CELL BIOCHEM, V148, P45, DOI 10.1007/BF00929502; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Du C, 1996, J NEUROTRAUM, V13, P215, DOI 10.1089/neu.1996.13.215; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Feuerstein GZ, 1997, ANN NY ACAD SCI, V825, P179, DOI 10.1111/j.1749-6632.1997.tb48428.x; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Goodman Y, 1996, J NEUROCHEM, V66, P869, DOI 10.1046/j.1471-4159.1996.66020869.x; Hachiya M, 1997, BIOCHEM J, V328, P615, DOI 10.1042/bj3280615; HALL ED, 1993, RES P ARNMD, V71, P81; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; Isoherranen K, 1997, J PHOTOCH PHOTOBIO B, V40, P288, DOI 10.1016/S1011-1344(97)00071-7; Jensen MB, 1997, EXP NEUROL, V143, P103, DOI 10.1006/exnr.1996.6337; Jones PL, 1997, MOL CELL BIOL, V17, P6970, DOI 10.1128/MCB.17.12.6970; KALTSCHMIDT B, 1993, MOL ASPECTS MED, V14, P171, DOI 10.1016/0098-2997(93)90004-W; KALTSCHMIDT C, 1993, MECH DEVELOP, V43, P135, DOI 10.1016/0925-4773(93)90031-R; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; Keller JN, 1998, J NEUROSCI, V18, P687; KINOUCHI K, 1991, BIOCHEM BIOPH RES CO, V181, P1532, DOI 10.1016/0006-291X(91)92113-X; KOENIG H, 1992, BRAIN RES, V588, P297, DOI 10.1016/0006-8993(92)91589-7; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; Lezoualc'h F, 1998, J NEUROSCI, V18, P3224; Liu JL, 1998, NAT MED, V4, P78, DOI 10.1038/nm0198-078; LIU T, 1994, STROKE, V25, P1481, DOI 10.1161/01.STR.25.7.1481; LOWENSTEIN DH, 1994, MOL BRAIN RES, V22, P299, DOI 10.1016/0169-328X(94)90058-2; Mattson MP, 1997, J NEUROSCI RES, V49, P681, DOI 10.1002/(SICI)1097-4547(19970915)49:6<681::AID-JNR3>3.0.CO;2-3; Mattson MP, 1997, BRAIN RES REV, V23, P47, DOI 10.1016/S0165-0173(96)00014-8; Mattson MP, 1997, NEUROSCI BIOBEHAV R, V21, P193, DOI 10.1016/S0149-7634(96)00010-3; MATTSON MP, 1995, J NEUROSCI RES, V42, P357, DOI 10.1002/jnr.490420310; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; MATTSON MP, 1991, NEURON, V6, P41, DOI 10.1016/0896-6273(91)90120-O; McIntosh TK, 1995, NEUROPATH APPL NEURO, V21, P477; MERRILL JE, 1991, DEV NEUROSCI-BASEL, V13, P130, DOI 10.1159/000112150; MESULAM MM, 1978, J HISTOCHEM CYTOCHEM, V26, P106, DOI 10.1177/26.2.24068; MEYER M, 1994, CHEM-BIOL INTERACT, V91, P91, DOI 10.1016/0009-2797(94)90029-9; MICHEL RP, 1988, J MICROSC-OXFORD, V150, P117, DOI 10.1111/j.1365-2818.1988.tb04603.x; Miller RD, 1996, J NEUROL SCI, V136, P37, DOI 10.1016/0022-510X(95)00309-P; MORGANTIKOSSMANN MC, 1992, TRENDS PHARMACOL SCI, V13, P286, DOI 10.1016/0165-6147(92)90087-M; NADLER V, 1995, BRAIN RES, V685, P1, DOI 10.1016/0006-8993(95)00367-Y; NAG S, 1992, ACTA NEUROPATHOL, V84, P471, DOI 10.1007/BF00304465; Nawashiro H, 1997, J CEREBR BLOOD F MET, V17, P483, DOI 10.1097/00004647-199705000-00001; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; Paxinos G., 1982, RAT BRAIN STEREOTAXI; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Povlishock J T, 1992, Hum Cell, V5, P345; PRASAD AV, 1994, NEUROSCI LETT, V170, P145, DOI 10.1016/0304-3940(94)90260-7; RICHTER C, 1995, BBA-MOL BASIS DIS, V1271, P67, DOI 10.1016/0925-4439(95)00012-S; SAWADA M, 1989, BRAIN RES, V491, P394, DOI 10.1016/0006-8993(89)90078-4; SCHARFMAN HE, 1989, SCIENCE, V246, P257, DOI 10.1126/science.2508225; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; SELMAJ KW, 1988, ANN NEUROL, V23, P339, DOI 10.1002/ana.410230405; SHEARMAN MS, 1995, J NEUROCHEM, V65, P218, DOI 10.1046/j.1471-4159.1995.65010218.x; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; SIESJO BK, 1995, J NEUROTRAUM, V12, P943, DOI 10.1089/neu.1995.12.943; Soares HD, 1995, J NEUROSCI, V15, P8223; STEVENS MK, 1990, J CEREBR BLOOD F MET, V10, P77, DOI 10.1038/jcbfm.1990.10; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Tracey K J, 1990, Adv Surg, V23, P21; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VANDERPOLL T, 1995, SHOCK, V3, P1; WOLVERS DAW, 1993, EUR CYTOKINE NETW, V4, P377; Wong G H, 1996, EXS, V77, P321; WONG GHW, 1995, BBA-MOL BASIS DIS, V1271, P205, DOI 10.1016/0925-4439(95)00029-4; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; YANG KY, 1995, NEUROSCI LETT, V197, P101, DOI 10.1016/0304-3940(95)11919-N; Yen HC, 1996, J CLIN INVEST, V98, P1253, DOI 10.1172/JCI118909; Yen HC, 1997, J CLIN INVEST, V99, P1141; ZAJICEK JP, 1992, BRAIN, V115, P1611, DOI 10.1093/brain/115.6.1611; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0	98	209	224	0	7	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	AUG 1	1999	19	15					6248	6256					9	Neurosciences	Neurosciences & Neurology	220DC	WOS:000081648400004	10414954				2021-06-18	
J	Roof, RL; Duvdevani, R; Heyburn, JW; Stein, DG				Roof, RL; Duvdevani, R; Heyburn, JW; Stein, DG			Progesterone rapidly decreases brain edema: Treatment delayed up to 24 hours is still effective	EXPERIMENTAL NEUROLOGY			English	Article							CAT SPINAL-CORD; CONTUSION INJURY; METHYLPREDNISOLONE; METABOLISM; PEROXIDATION; STEROIDS	Cerebral edema is a serious side effect of traumatic brain injury. We have previously established that progesterone injections, initiated within 1 h after cortical contusion injury, reduced edema when assessed 3 days later. To determine how rapidly progesterone can reduce edema, male and female rats were given the hormone 1 h after damage to the medial frontal cortex, and edema levels were assessed between 2 h and 7 days postinjury. Progesterone decreased edema within 6 h of the injury and continued to be effective for the duration of treatment. In addition, we assessed whether progesterone injections are effective when delays are imposed between injury and initiation of treatment. Male and female rats received progesterone after postinjury delays of 6, 24, or 48 h. Progesterone was effective in reducing edema when treatment was delayed until 24 h after injury. (C) 1996 Academic Press, Inc.	RUTGERS STATE UNIV,INST ANIM BEHAV,BRAIN RES LAB,DEPT PSYCHOL,NEWARK,NJ 07102			Stein, Donald/AAJ-5139-2020				BETZ A L, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P133; Braughler J M, 1986, Cent Nerv Syst Trauma, V3, P153; BRAUGHLER JM, 1983, J NEUROSURG, V59, P256, DOI 10.3171/jns.1983.59.2.0256; BRAUGHLER JM, 1984, J NEUROSURG, V61, P290, DOI 10.3171/jns.1984.61.2.0290; BREMER AM, 1980, NEUROSURGERY, V6, P149, DOI 10.1227/00006123-198002000-00006; CERVOSNAVARRO J, 1991, J NEUROL SCI, V103, pS3; DEMARIA EJ, 1985, ANN SURG, V202, P248, DOI 10.1097/00000658-198508000-00017; DEUTSCHMAN CS, 1987, J NEUROSURG, V66, P388, DOI 10.3171/jns.1987.66.3.0388; DUVDEVANI R, 1995, J NEUROTRAUM, V12, P65, DOI 10.1089/neu.1995.12.65; FENSKE A, 1980, J NEUROL, V220, P199; GOODMAN LS, 1990, PHARM BASIS THERAPEU; HALL ED, 1993, CELL MOL NEUROBIOL, V13, P415, DOI 10.1007/BF00711581; HALL ED, 1993, ANN EMERG MED, V22, P1022, DOI 10.1016/S0196-0644(05)82745-3; HALL ED, 1981, EXP NEUROL, V73, P321, DOI 10.1016/0014-4886(81)90067-4; HALL ED, 1982, J NEUROSURG, V57, P247, DOI 10.3171/jns.1982.57.2.0247; HOSSMANN KA, 1982, J CEREBR BLOOD F MET, V2, P275, DOI 10.1038/jcbfm.1982.30; ROBERTSON CS, 1985, J NEUROSURG, V63, P203; ROOF RL, 1992, RESTOR NEUROL NEUROS, V4, P425, DOI 10.3233/RNN-1992-4608; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; TAMADA H, 1980, ENDOCRINOL JAPON, V27, P163; TERAURA T, 1972, J NEUROSCI, V32, P728	23	209	213	0	12	ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495	0014-4886			EXP NEUROL	Exp. Neurol.	APR	1996	138	2					246	251		10.1006/exnr.1996.0063			6	Neurosciences	Neurosciences & Neurology	UF078	WOS:A1996UF07800008	8620923				2021-06-18	
J	PRIGATANO, GP; FORDYCE, DJ; ZEINER, HK; ROUECHE, JR; PEPPING, M; WOOD, BC				PRIGATANO, GP; FORDYCE, DJ; ZEINER, HK; ROUECHE, JR; PEPPING, M; WOOD, BC			NEUROPSYCHOLOGICAL REHABILITATION AFTER CLOSED HEAD-INJURY IN YOUNG-ADULTS	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article									UNIV OKLAHOMA,HLTH SCI CTR,NEUROSURG SECT,OKLAHOMA CITY,OK 73190	PRIGATANO, GP (corresponding author), PRESBYTERIAN HOSP,DEPT CLIN NEUROPSYCHOL,OKLAHOMA CITY,OK 73104, USA.						Barr A. J, 1976, USERS GUIDE SAS 76; BENYISHAY Y, 1982, REHABILITATION MONOG, V64; BOND MR, 1976, SCAND J REHABIL MED, V8, P127; BOND MR, 1975, CIBA F S, V34; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; Bruckner F E, 1972, Rheumatol Phys Med, V11, P344, DOI 10.1093/rheumatology/11.7.344; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; GILCHRIST M, 1979, ARCH NEUROL, V36, P355; Green PE, 1978, ANAL MULTIVARIATE DA; HEATON RK, 1981, J CONSULT CLIN PSYCH, V49, P807, DOI 10.1037/0022-006X.49.6.807; HOGARTY GE, 1971, ARCH GEN PSYCHIAT, V25, P470; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; LISHMAN WA, 1968, BRIT J PSYCHIAT, V114, P373, DOI 10.1192/bjp.114.509.373; PARSONS OA, 1978, J CONSULT CLIN PSYCH, V46, P608, DOI 10.1037/0022-006X.46.4.608; PRIGATANO GP, 1983, J CONSULT CLIN PSYCH, V51, P108, DOI 10.1037/0022-006X.51.1.108; PRIGATANO GP, 1978, J CLIN PSYCHOL, V34, P816, DOI 10.1002/1097-4679(197810)34:4<816::AID-JCLP2270340402>3.0.CO;2-Q; PRIGATANO GP, 1982, J NEUROL NEUROSUR PS, V45, P78, DOI 10.1136/jnnp.45.1.78; PRIGATANO GP, NEUROPSYCHOLOGICAL R; PRIGATANO GP, 1978, ARCH BEHAVIORAL SCI, V54; PRIGATANO GP, HDB CONT REHABILITAT; Reitan R, 1974, CLIN NEUROPSYCHOLOGY; ROSENBAUM M, 1978, SCAND J REHABIL MED, V10, P1; RUSSELL EW, 1970, ASSESSMENT BRAIN DAM; WECHSLER D, 1945, MANUAL WECHSLER MEMO; Wechsler D, MANUAL WECHSLER ADUL; Wechsler D., 1955, MANUAL WECHSLER ADUL; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019	29	209	212	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry		1984	47	5					505	513		10.1136/jnnp.47.5.505			9	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	SR152	WOS:A1984SR15200012	6736983	Green Published, Bronze			2021-06-18	
J	Gardner, RC; Burke, JF; Nettiksimmons, J; Kaup, A; Barnes, DE; Yaffe, K				Gardner, Raquel C.; Burke, James F.; Nettiksimmons, Jasmine; Kaup, Allison; Barnes, Deborah E.; Yaffe, Kristine			Dementia Risk After Traumatic Brain Injury vs Nonbrain Trauma The Role of Age and Severity	JAMA NEUROLOGY			English	Article							YOUNG ONSET DEMENTIA; ALZHEIMERS-DISEASE; HEAD-INJURY; ADMINISTRATIVE DATA; PARKINSONS-DISEASE; OLDER-ADULTS; POPULATION; COHORT; MORTALITY; ACCURACY	IMPORTANCE Epidemiologic evidence regarding the importance of traumatic brain injury (TBI) as a risk factor for dementia is conflicting. Few previous studies have used patients with non-TBI trauma (NTT) as controls to investigate the influence of age and TBI severity. OBJECTIVE To quantify the risk of dementia among adults with recent TBI compared with adults with NTT. DESIGN, SETTING, AND PARTICIPANTS This retrospective cohort study was performed from January 1, 2005, through December 31, 2011 (follow-up, 5-7 years). All patients 55 years or older diagnosed as having TBI or NTT in 2005 and 2006 and who did not have baseline dementia or die during hospitalization (n = 164 661) were identified in a California statewide administrative health database of emergency department (ED) and inpatient visits. EXPOSURES Mild vs moderate to severe TBI diagnosed by Centers for Disease Control and Prevention criteria using International Classification of Diseases, Ninth Revision (ICD-9) codes, and NTT, defined as fractures excluding fractures of the head and neck, diagnosed using ICD-9 codes. MAIN OUTCOMES AND MEASURES Incident ED or inpatient diagnosis of dementia (using ICD-9 codes) 1 year or more after initial TBI or NTT. The association between TBI and risk of dementia was estimated using Cox proportional hazards models before and after adjusting for common dementia predictors and potential confounders. We also stratified by TBI severity and age category (55-64, 65-74, 75-84, and >85 years). RESULTS A total of 51 799 patients with trauma (31.5%) had TBI. Of these, 4361 (8.4%) developed dementia compared with 6610 patients with NTT (5.9%) (P < .001). We found that TBI was associated with increased dementia risk (hazard ratio [HR], 1.46; 95% CI, 1.41-1.52; P < .001). Adjustment for covariates had little effect except adjustment for age category (fully adjusted model HR, 1.26; 95% CI, 1.21-1.32; P < .001). In stratified adjusted analyses, moderate to severe TBI was associated with increased risk of dementia across all ages (age 55-64: HR, 1.72; 95% CI, 1.40-2.10; P < .001; vs age 65-74: HR, 1.46; 95% CI, 1.30-1.64; P < .001), whereas mild TBI may be a more important risk factor with increasing age (age 55-64: HR, 1.11; 95% CI, 0.80-1.53; P = .55; vs age 65-74: HR, 1.25; 95% CI, 1.04-1.51; P = .02; age interaction P < .001). CONCLUSIONS AND RELEVANCE Among patients evaluated in the ED or inpatient settings, those with moderate to severe TBI at 55 years or older or mild TBI at 65 years or older had an increased risk of developing dementia. Younger adults may be more resilient to the effects of recent mild TBI than older adults.	[Gardner, Raquel C.; Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, Memory & Aging Ctr, San Francisco, CA 94143 USA; [Gardner, Raquel C.; Nettiksimmons, Jasmine; Kaup, Allison; Barnes, Deborah E.; Yaffe, Kristine] San Francisco VA Med Ctr, Dept Vet Affairs, San Francisco, CA 94121 USA; [Burke, James F.] Univ Michigan, Dept Neurol, Ann Arbor, MI USA; [Burke, James F.] Ann Arbor Vet Affairs Healthcare Syst, Vet Affairs Ctr Clin Management & Res, Dept Vet Affairs, Ann Arbor, MI USA; [Nettiksimmons, Jasmine; Barnes, Deborah E.; Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; [Kaup, Allison; Barnes, Deborah E.; Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA	Gardner, RC (corresponding author), San Francisco VA Med Ctr, Dept Vet Affairs, 4150 Clement St,Campus Mailbox 127, San Francisco, CA 94121 USA.	raquel.gardner@ucsf.edu		Gardner, Raquel C./0000-0003-4028-440X	Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Mental Illness Research and TreatmentUS Department of Veterans Affairs; Medical Research Service of the San Francisco Veterans Affairs Medical Center; Department of Veterans Affairs Sierra-Pacific Mental Illness Research, Education, and Clinical CenterUS Department of Veterans Affairs; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K24 AG031155, K08 NS082597]; Department of Defense, the Department of Veterans Affairs [W81XWH-12-1-0581]; California Department of Public Health; Bright Focus FoundationBrightFocus Foundation; Alzheimer's AssociationAlzheimer's Association; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS082597] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG044281, T32AG023481, P50AG023501, K24AG031155] Funding Source: NIH RePORTER	Drs Gardner and Kaup reported having received support from the Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Mental Illness Research and Treatment, the Medical Research Service of the San Francisco Veterans Affairs Medical Center, and the Department of Veterans Affairs Sierra-Pacific Mental Illness Research, Education, and Clinical Center. Dr Yaffe reported having received research support from grant K24 AG031155 from the National Institutes of Health, grant W81XWH-12-1-0581 from the Department of Defense, the Department of Veterans Affairs, the California Department of Public Health, the Bright Focus Foundation, and the Alzheimer's Association. Dr Burke reported having received research support from grant K08 NS082597 from the National Institutes of Health. No other disclosures were reported.	Agency for Healthcare Research and Quality (AHRQ), HCUP CLIN CLASS SOFT; Agency for Healthcare Research and Quality (AHRQ) Healthcare Cost and Utilization Project (HCUP), 2013, OV STAT INP DAT; [Anonymous], 2013, STAT STAT SOFTW REL; Burke JF, 2013, NEUROLOGY, V81, P33, DOI 10.1212/WNL.0b013e318297eecf; Byers AL, 2012, AM J GERIAT PSYCHIAT, V20, P664, DOI 10.1097/JGP.0b013e31822001c1; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cheng PL, 2014, SCAND J TRAUMA RESUS, V22, DOI 10.1186/1757-7241-22-7; Dams-O'Connor K, 2013, J NEUROL NEUROSUR PS, V84, P177, DOI 10.1136/jnnp-2012-303938; Davis DHJ, 2012, BRAIN, V135, P2809, DOI 10.1093/brain/aws190; Faul M, 2010, INJURY PREV, V16, pA268, DOI 10.1136/ip.2010.029215.951; FISHER ES, 1992, AM J PUBLIC HEALTH, V82, P243, DOI 10.2105/AJPH.82.2.243; Gardner RC, 2014, ANN NEUROL, V75, P339, DOI 10.1002/ana.24121; Gardner RC, 2014, BEHAV NEUROLOGY DEME; Godbolt Alison K, 2014, Arch Phys Med Rehabil, V95, pS245, DOI 10.1016/j.apmr.2013.06.036; Goldman SM, 2012, ANN NEUROL, V71, P40, DOI 10.1002/ana.22499; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; Green RE, 2008, ARCH PHYS MED REHAB, V89, pS16, DOI 10.1016/j.apmr.2008.09.551; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Helmes E, 2011, BRAIN INJURY, V25, P338, DOI 10.3109/02699052.2011.556104; KATZMAN R, 1989, ANN NEUROL, V25, P317, DOI 10.1002/ana.410250402; Koyama A, 2013, J GERONTOL A-BIOL, V68, P433, DOI 10.1093/gerona/gls187; Lavoie A, 2004, J TRAUMA, V56, P1312, DOI 10.1097/01.TA.0000075342.36072.EF; Lee PC, 2012, NEUROLOGY, V79, P2061, DOI 10.1212/WNL.0b013e3182749f28; Lee YK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062422; LeMier M, 2001, Inj Prev, V7, P334, DOI 10.1136/ip.7.4.334; Lindsay J, 2002, AM J EPIDEMIOL, V156, P445, DOI 10.1093/aje/kwf074; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; MOLGAARD CA, 1990, NEUROEPIDEMIOLOGY, V9, P233, DOI 10.1159/000110778; MORTIMER JA, 1985, NEUROLOGY, V35, P264, DOI 10.1212/WNL.35.2.264; National Center for Injury Prevention and Control, 2003, C MILD TRAUM BRAIN I; Nordstrom P, 2014, ANN NEUROL, V75, P374, DOI 10.1002/ana.24101; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; Quan HD, 2002, MED CARE, V40, P675, DOI 10.1097/00005650-200208000-00007; Quan H, 2008, HEALTH SERV RES, V43, P1424, DOI 10.1111/j.1475-6773.2007.00822.x; Rapoport M, 2008, J NEUROPSYCH CLIN N, V20, P68, DOI 10.1176/jnp.2008.20.1.68; Rugbjerg K, 2008, BMJ-BRIT MED J, V337, pa2494, DOI [10.1136/bmj.a2494, DOI 10.1136/BMJ.A2494]; Salib E, 1997, INT J GERIATR PSYCH, V12, P363, DOI 10.1002/(SICI)1099-1166(199703)12:3<363::AID-GPS515>3.0.CO;2-F; Setnik L, 2007, BRAIN INJURY, V21, P1, DOI 10.1080/02699050601111419; St Germaine-Smith C, 2012, NEUROLOGY, V79, P1049, DOI 10.1212/WNL.0b013e3182684707; Susman M, 2002, J TRAUMA, V53, P219, DOI 10.1097/00005373-200208000-00004; Thurman DJ., 1995, GUIDELINES SURVEILLA; Yaffe K, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f7051	42	208	212	1	23	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6149	2168-6157		JAMA NEUROL	JAMA Neurol.	DEC	2014	71	12					1490	1497		10.1001/jamaneurol.2014.2668			8	Clinical Neurology	Neurosciences & Neurology	AW1YA	WOS:000346083500006	25347255	Bronze, Green Accepted	Y	N	2021-06-18	
J	Ramchand, R; Schell, TL; Karney, BR; Osilla, KC; Burns, RM; Caldarone, LB				Ramchand, Rajeev; Schell, Terry L.; Karney, Benjamin R.; Osilla, Karen Chan; Burns, Rachel M.; Caldarone, Leah Barnes			Disparate Prevalence Estimates of PTSD Among Service Members Who Served in Iraq and Afghanistan: Possible Explanations	JOURNAL OF TRAUMATIC STRESS			English	Article							POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; MENTAL-HEALTH PROBLEMS; DEPLOYMENT; VETERANS; WAR; SYMPTOMS; PERSONNEL; CARE; DEPRESSION	The authors reviewed 29 studies that provide prevalence estimates of posttraumatic stress disorder (PTSD) among service members previously deployed to Operations Enduring and Iraqi Freedom and their non-U.S. military counterparts. Studies vary widely, particularly in their representativeness and the way PTSD is defined. Among previously deployed personnel not seeking treatment, most prevalence estimates range from 5 to 20%. Prevalence estimates are generally higher among those seeking treatment: As many as 50% of veterans seeking treatment screen positive for PTSD, through much fewer receive a PTSD diagnosis. Combat exposure is the only correlate consistently associated with PTSD. When evaluating PTSD prevalence estimates among this population, researchers and policymakers should carefully consider the method used to define PTSD and the population the study sample represents.	[Ramchand, Rajeev] RAND Corp, Arlington, VA 22202 USA; [Schell, Terry L.; Osilla, Karen Chan; Caldarone, Leah Barnes] RAND Corp, Santa Monica, CA USA; [Karney, Benjamin R.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA; [Burns, Rachel M.] RAND Corp, Pittsburgh, PA USA	Ramchand, R (corresponding author), RAND Corp, 1200 S Hayes St, Arlington, VA 22202 USA.	rajeev_ramchand@rand.org	Karney, Benjamin/AAG-1632-2019	Karney, Benjamin/0000-0002-9063-6162			*ABT ASS INC, 2006, 2003 2004 ACT DUT HL; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272; Bliese PD, 2007, PSYCHOL SERV, V4, P141, DOI DOI 10.1037/1541-1559.4.3.141; Brewin CR, 2005, J TRAUMA STRESS, V18, P53, DOI 10.1002/jts.20007; Dohrenwend BP, 2007, J TRAUMA STRESS, V20, P449, DOI 10.1002/jts.20296; Engelhard IM, 2007, BRIT J PSYCHIAT, V191, P140, DOI 10.1192/bjp.bp.106.034884; Erbes C, 2007, MIL MED, V172, P359, DOI 10.7205/MILMED.172.4.359; FOA EB, 1993, J TRAUMA STRESS, V6, P459, DOI 10.1002/jts.2490060405; Gaylord KM, 2008, J TRAUMA, V64, pS200, DOI 10.1097/TA.0b013e318160ba42; Grieger TA, 2007, MIL MED, V172, P451, DOI 10.7205/MILMED.172.5.451; Grieger TA, 2006, AM J PSYCHIAT, V163, P1777, DOI 10.1176/appi.ajp.163.10.1777; Helmer DA, 2007, J OCCUP ENVIRON MED, V49, P475, DOI 10.1097/JOM.0b013e318042d682; Herman D., 1993, ANN CONV INT SOC TRA; Hoge CW, 2008, AM J EPIDEMIOL, V168, P1095, DOI 10.1093/aje/kwn261; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Hoge CW, 2006, LANCET, V368, P837, DOI 10.1016/S0140-6736(06)69315-X; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Hotopf M, 2006, LANCET, V367, P1731, DOI 10.1016/S0140-6736(06)68662-5; Jakupcak M, 2008, J NERV MENT DIS, V196, P425, DOI 10.1097/NMD.0b013e31817108ed; Kulka R. A., 1990, TRAUMA VIETNAM WAR G; Lapierre CB, 2007, J TRAUMA STRESS, V20, P933, DOI 10.1002/jts.20278; Larson GE, 2008, AM J EPIDEMIOL, V167, P1269, DOI 10.1093/aje/kwn084; Larson GE, 2006, JAMA-J AM MED ASSOC, V296, P514, DOI 10.1001/jama.296.5.514-b; Martin C. B., 2007, MSMR MED SURVEILLANC, V14, P2; McGhee LL, 2008, J TRAUMA, V64, pS195, DOI 10.1097/TA.0b013e318160ba1d; Mclay RN, 2008, AM J PSYCHIAT, V165, P775, DOI 10.1176/appi.ajp.2008.07121960; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; National Center for Health Statistics (NCHS) Centers for Medicare & Medicaid Services (CMS), 2008, INT CLASS DIS; Ouimette P., 2008, TRAUMATOLOGY, V14, P51, DOI [10.1177/1534765608320330, DOI 10.1177/1534765608320330]; Prins A, 2003, PRIMARY CARE PSYCHIA, V9, P9; Rundell JR, 2006, GEN HOSP PSYCHIAT, V28, P352, DOI 10.1016/j.genhosppsych.2006.04.006; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Schell T.L., 2008, INVISIBLE WOUNDS WAR, DOI [10.7249/mg720-1ccf.12, DOI 10.7249/MG720-1CCF.12]; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Seal KH, 2008, AM J PUBLIC HEALTH, V98, P714, DOI 10.2105/AJPH.2007.115519; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Smith TC, 2008, BMJ-BRIT MED J, V336, P366, DOI 10.1136/bmj.39430.638241.AE; Sollinger J. M., 2008, INVISIBLE WOUNDS WAR, P19; Stecker T, 2007, PSYCHIAT SERV, V58, P1358, DOI 10.1176/appi.ps.58.10.1358; *US DEP VET AFF VE, 2008, AN VA HLTH CAR UT US; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; WATERHOUSE M, 2007, NATL GUARD PERSONNEL; Wessely S, 2004, WAR SOC, V22, P89, DOI DOI 10.1179/072924704791202130	46	208	210	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-9867	1573-6598		J TRAUMA STRESS	J. Trauma Stress	FEB	2010	23	1					59	68		10.1002/jts.20486			10	Psychology, Clinical; Psychiatry	Psychology; Psychiatry	571FW	WOS:000275738100009	20135699				2021-06-18	
J	Corrigan, JD; Bogner, JA; Mysiw, WJ; Clinchot, D; Fugate, L				Corrigan, JD; Bogner, JA; Mysiw, WJ; Clinchot, D; Fugate, L			Life satisfaction after traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; outcome assessment; quality of life	FUNCTIONAL INDEPENDENCE MEASURE; COMMUNITY INTEGRATION QUESTIONNAIRE; REHABILITATION OUTCOMES; DISABILITY; RELIABILITY; IMPAIRMENT; HANDICAP; VALIDITY	Objective: To investigate correlates of life satisfaction after traumatic brain injury (TBI). Design: Prospective, longitudinal study of patients with TBI studied 1 and 2 years after injury. Setting: A specialized inpatient TBI rehabilitation unit in a midwestern academic medical center. Subjects: Two hundred eighteen consecutive patients admitted for rehabilitation, at least 14 years of age, with a primary diagnosis of TBI, consented to participate, and interviewed 1 and/or 2 years after injury (112 interviewed both years, 58 at year 1 only; 48 at year 2 only). Main Outcome Measures: Satisfaction With Life Scale. Results: Stepwise multiple regressions accounted for statistically significant, but small, proportions of variance. Not having a preinjury history of substance abuse and having gainful employment at the time of follow-up were associated with higher life satisfaction both 1 and 2 years after injury Motor independence at rehabilitation discharge was also associated at 1 year. Current social integration and the absence of depressed mood were associated at 2 years. Life satisfaction was relatively stable between years. Change that did occur was associated with marital status and depressed mood 2 years after injury. Conclusions: Life satisfaction after TBI seems to be related to attaining healthy and productive lifestyles. Future research should investigate other factors that affect life satisfaction to increase prediction and appreciate all influences on subjective well being after TBI.	Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA	Corrigan, JD (corresponding author), 480 W 9th Ave, Columbus, OH 43210 USA.	corrigan.1@osu.edu	Bogner, Jennifer/E-2773-2011; Corrigan, John D./E-2921-2011; Mysiw, Walter/E-3724-2011	Clinchot, Daniel/0000-0002-2810-7227			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Argyle M., 1999, WELL BEING FDN HEDON, P353, DOI DOI 10.7758/9781610443258.22; ASTROM M, 1992, STROKE, V23, P527, DOI 10.1161/01.STR.23.4.527; BERRIDGE KC, 1999, SUBJECTIVE WELL BEIN, P525; Bogner JA, 1997, J HEAD TRAUMA REHAB, V12, P57, DOI 10.1097/00001199-199710000-00006; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; *CDCP, 1999, REP REC TRAUM BRAIN; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P828, DOI 10.1016/S0003-9993(97)90195-7; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; CORRIGAN JD, 1988, ARCH PHYS MED REHAB, V69, P487; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P29; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P41, DOI 10.1097/00001199-199508000-00005; DIENER E, 1984, PSYCHOL BULL, V95, P542, DOI 10.1037/0033-2909.95.3.542; Diener E., 1999, WELL BEING FDN HEDON, P213; Dijkers M, 1999, AM J PHYS MED REHAB, V78, P286, DOI 10.1097/00002060-199905000-00022; DIJKERS M, 1997, ASSESSING MED REHABI, P153; Dijkers MPJM, 1999, ARCH PHYS MED REHAB, V80, P867, DOI 10.1016/S0003-9993(99)90076-X; DITTMAR SS, 1997, FUNCTIONAL ASSESSMEN; DODDS TA, 1993, ARCH PHYS MED REHAB, V74, P531, DOI 10.1016/0003-9993(93)90119-U; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FREDERICK S, 1999, SUBJECTIVE WELL BEIN, P303; FUHRER MJ, 1992, ARCH PHYS MED REHAB, V73, P552; FUHRER MJ, 1994, AM J PHYS MED REHAB, V73, P358, DOI 10.1097/00002060-199409000-00010; GRANGER CV, 1995, AM J PHYS MED REHAB, V74, P107; Granger CV, 1986, TOP GERIATR REHABIL, V1, P59, DOI 10.1097/00013614-198604000-00007; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; HAMILTON BB, 1994, SCAND J REHABIL MED, V26, P115; HEINEMANN AW, 1995, AM J PHYS MED REHAB, V74, P315, DOI 10.1097/00002060-199507000-00011; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; HEINEMANN AW, 1994, ARCH PHYS MED REHAB, V75, P133; Heinemann AW, 1994, TOP STROKE REHABIL, V1, P1; KIDD D, 1995, DISABIL REHABIL, V17, P10, DOI 10.3109/09638289509166622; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; Myers DG, 2000, AM PSYCHOL, V55, P56, DOI 10.1037/0003-066X.55.1.56; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; Pavot W., 1993, PSYCHOL ASSESSMENT, V5, P164, DOI DOI 10.1037/1040-3590.5.2.164; ROBINS LN, 1982, ARCH GEN PSYCHIAT, V39, P1443; ROST K, 1993, MED CARE, V31, P189, DOI 10.1097/00005650-199303000-00001; Salovey P, 2000, AM PSYCHOL, V55, P110, DOI 10.1037/0003-066X.55.1.110; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; SCHULZ R, 1985, J PERS SOC PSYCHOL, V48, P1162, DOI 10.1037/0022-3514.48.5.1162; Segal ME, 1996, REHABIL PSYCHOL, V41, P303, DOI 10.1037/0090-5550.41.4.303; Soderback I, 1992, Disabil Rehabil, V14, P30; SOKOL K, 1999, ARCH PHYS MED REHAB, V80, P974; TEASDALE G, 1974, LANCET, V2, P81; Warren L, 1996, J REHABIL RES DEV, V33, P404; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B., 1993, BRAIN INJURY REHABIL, P355; Willer B., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI DOI 10.1097/00001199-199308020-00009	51	208	212	0	24	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	DEC	2001	16	6					543	555		10.1097/00001199-200112000-00003			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	501AL	WOS:000172660800003	11732970				2021-06-18	
J	KREUTZER, JS; GERVASIO, AH; CAMPLAIR, PS				KREUTZER, JS; GERVASIO, AH; CAMPLAIR, PS			PRIMARY CAREGIVERS PSYCHOLOGICAL STATUS AND FAMILY FUNCTIONING AFTER TRAUMATIC BRAIN INJURY	BRAIN INJURY			English	Article							SEVERE HEAD-INJURY; ASSESSMENT DEVICE; RELATIVES VIEW; FOLLOW-UP; CHILDREN; PATIENT	This study investigated the prevalence of psychological distress and unhealthy family functioning among primary caregivers of 62 adult outpatients with traumatic brain injury, using the Brief Symptom Inventory (BSI) and the Family Assessment Device (FAD). Approximately half of the caregivers reported elevated distress as indicated by scores on the BSI General Stress Index. Elevations on the Anxiety scale were evident among one-third of the sample, and one-fourth demonstrated elevations on the Depression subscale. Elevated scores on the Paranoid Ideation and Psychoticism scales suggested that feelings of burden and alienation were commonly reported. As indicated by the FAD, caregivers showed greater levels of unhealthy functioning relative to published norms for non-patient and medical patient samples, but showed better functioning than psychiatric samples. Spouses were significantly more likely to report elevated depression scores compared to parents. There was also a trend for spouses to report greater unhealthy family functioning than parents. Findings are consistent with those reported by European researchers. Experience indicates that the BSI and FAD are potentially valuable clinical and research tools.	VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT NEUROL SURG, RICHMOND, VA 23298 USA; HAMILTON COLL, DEPT PSYCHOL, CLINTON, NY 13323 USA; TUALATIN VALLEY MENTAL HLTH CTR, TUALATIN, OR USA	KREUTZER, JS (corresponding author), VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT PHYS MED & REHABIL, RICHMOND, VA 23298 USA.						BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; BROOKS N, 1984, CLOSED HEAD INJURY P, P123; BUCHANAN K, 1992, SEP C COGN REH COMM; CAMPLAIR PS, 1990, COMMUNITY INTEGRATIO, P207; DEPOMPEI R, 1991, HEAD INJURY FAMILY M, P101; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; Derogatis LR, 1975, BRIEF SYMPTOM INVENT; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; EPSTEIN NB, 1978, J MARRIAGE FAM COUNS, V4, P19, DOI 10.1111/j.1752-0606.1978.tb00537.x; GATZ M, 1990, HDB PSYCHOL AGING, P404; HOROWITZ A, 1985, ANN REV GERONTOLOGY, V5; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Kabacoff R.I., 1990, J FAMILY PSYCHOL, V3, P431, DOI [10.1037/h0080547, DOI 10.1037/H0080547]; KLONOFF H, 1971, AM J PUBLIC HEALTH N, V61, P2405, DOI 10.2105/AJPH.61.12.2405; Kozloff R, 1987, J HEAD TRAUMA REHAB, V2, P14, DOI DOI 10.1097/00001199-198709000-00004; KREUTZER J S, 1991, Brain Injury, V5, P177, DOI 10.3109/02699059109008088; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LITMAN TJ, 1974, SOC SCI MED, V8, P495, DOI 10.1016/0037-7856(74)90072-9; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; McKinlay W W, 1987, Brain Inj, V1, P3, DOI 10.3109/02699058709034438; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; ODDY M, 1984, CLOSED HEAD INJURY P, P108; Panting A., 1972, REHABILITATION, V38, P33; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P29; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; ZARSKI J, 1988, J HEAD TRAUMA REHAB, V3, P31	40	208	208	0	13	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	APR	1994	8	3					197	210		10.3109/02699059409150973			14	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	ND714	WOS:A1994ND71400002	8004079				2021-06-18	
J	Bryan, MA; Rowhani-Rahbar, A; Comstock, RD; Rivara, F				Bryan, Mersine A.; Rowhani-Rahbar, Ali; Comstock, R. Dawn; Rivara, Frederick		Seattle Sports Concussion Res Coll	Sports- and Recreation-Related Concussions in US Youth	PEDIATRICS			English	Article							TRAUMATIC BRAIN-INJURY; STATES HIGH-SCHOOL; UNITED-STATES; FOOTBALL PLAYERS; RISK-FACTORS; EPIDEMIOLOGY; MANAGEMENT; TRENDS; SYMPTOMS	OBJECTIVE: The incidence of sports- and recreation-related concussions (SRRCs) in the United States is unknown. More than 44 million youth participate in sports annually, thus understanding the frequency of SRRCs in children is important on a population level. Our objective was to determine the number of SRRCs occurring annually among US youth <= 18 years old. METHODS: We identified SRRCs using 3 national databases: MarketScan, National Electronic Injury Surveillance System, and National High School Sports Related Injury Surveillance System, Reporting Injury Online. We determined the number of SRRCs seen in health care settings (outpatient, inpatient, and emergency department) and SRRCs reported to certified high school athletic trainers (ATCs). We used these data and findings in recently published literature to generate a national estimate of SRRCs. RESULTS: We estimate that between 1.1 and 1.9 million SRRCs occur annually in US children aged <= 18 years. Most children with SRRCs, 511 590 to 1 240 972, were not seen in health care settings. Of children with SRRCs seen in health care settings, most were seen as outpatients with 377 978 visits, compared with between 115 479 and 166 929 ED visits, and between 2886 and 4936 hospitalizations. CONCLUSIONS: This study provides the most accurate and precise estimate to date of the number of concussions among US children annually. SRRCs are a common injury in children. Providers in all health care settings need to be trained in concussion care. There is a need for better surveillance to enhance our understanding of the epidemiology of concussions in youth.	[Bryan, Mersine A.; Rowhani-Rahbar, Ali; Rivara, Frederick] Univ Washington, Dept Pediat, M-S CW8-6,POB 5371, Seattle, WA 98145 USA; [Rowhani-Rahbar, Ali; Rivara, Frederick] Univ Washington, Dept Epidemiol, M-S CW8-6,POB 5371, Seattle, WA 98145 USA; [Rowhani-Rahbar, Ali; Rivara, Frederick] Univ Washington, Harborview Injury Prevent & Res Ctr, M-S CW8-6,POB 5371, Seattle, WA 98145 USA; [Bryan, Mersine A.; Rowhani-Rahbar, Ali; Rivara, Frederick] Seattle Childrens Res Inst, Ctr Child Hlth Behav & Dev, Seattle, WA USA; [Comstock, R. Dawn] Univ Colorado Anschutz, Colorado Sch Publ Hlth, Dept Epidemiol, Program Injury Prevent Educ & Res, Aurora, CO USA; [Comstock, R. Dawn] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO USA	Bryan, MA (corresponding author), Univ Washington, Dept Pediat, M-S CW8-6,POB 5371, Seattle, WA 98145 USA.	mersine@uw.edu		, Mersine/0000-0002-3259-7628			Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Comstock RD., HIGH SCH RIO REPORTI; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Dompier TP, 2015, JAMA PEDIATR, V169, P659, DOI 10.1001/jamapediatrics.2015.0210; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Gordon KE, 2006, PEDIATR NEUROL, V34, P376, DOI 10.1016/j.pediatrneurol.2005.09.007; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hansen LG, 2009, HLTH RES DATA REAL W; Hanson HR, 2013, PEDIATRICS, V132, pE859, DOI 10.1542/peds.2013-1704; Institute of Medicine and National Research Council, 2014, SPORTS RELATED CONCU; Kelleher E, 2014, J PEDIATR SURG, V49, P341, DOI 10.1016/j.jpedsurg.2013.10.016; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Macpherson A, 2014, PAED CHILD HEALT-CAN, V19, P543, DOI 10.1093/pch/19.10.543; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Marshall S.W., 2015, INJURY EPIDEMIOLOGY, V2, P1, DOI [10.1186/s40621-015-0045-4, DOI 10.1186/S40621-015-0045-4]; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McKeon JMM, 2013, J ATHL TRAINING, V48, P836, DOI 10.4085/1062-6050-48.6.17; Meehan WP, 2013, CLIN J SPORT MED, V23, P339, DOI 10.1097/JSM.0b013e318291d3b3; Meehan WP, 2011, AM J SPORT MED, V39, P2304, DOI 10.1177/0363546511423503; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Meehan WP, 2010, J PEDIATR-US, V157, P889, DOI 10.1016/j.jpeds.2010.06.040; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; O'Kane JW, 2014, JAMA PEDIATR, V168, P258, DOI 10.1001/jamapediatrics.2013.4518; Rivara FP, 2014, AM J SPORT MED, V42, P1197, DOI 10.1177/0363546514521774; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Selassie AW, 2013, ANN EPIDEMIOL, V23, P750, DOI 10.1016/j.annepidem.2013.07.022; Selassie AW, 2004, AM J EMERG MED, V22, P465, DOI 10.1016/j.ajem.2004.07.024; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Zemek R, 2016, JAMA-J AM MED ASSOC, V315, P1014, DOI 10.1001/jama.2016.1203	34	207	207	2	22	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	JUL	2016	138	1							e20154635	10.1542/peds.2015-4635			8	Pediatrics	Pediatrics	DP9YD	WOS:000378853100034	27325635	Bronze	Y	N	2021-06-18	
J	Sun, AY; Wang, Q; Simonyi, A; Sun, GY				Sun, Albert Y.; Wang, Qun; Simonyi, Agnes; Sun, Grace Y.			Resveratrol as a Therapeutic Agent for Neurodegenerative Diseases	MOLECULAR NEUROBIOLOGY			English	Article						Neurodegenerative disorders; Stroke; Resveratrol; Antioxidant; Anti-inflammatory; SIRT1; Ischemia/reperfusion; Polyphenols; Mitochondria dysfunction; Apoptosis	AMYLOID-BETA-PEPTIDE; TRAUMATIC BRAIN-INJURY; OXIDATIVE STRESS; ALZHEIMERS-DISEASE; CHRONIC ETHANOL; DIETARY ANTIOXIDANTS; CEREBRAL-ISCHEMIA; GRAPE POLYPHENOLS; NITRIC-OXIDE; CALORIC RESTRICTION	Excess production of reactive oxygen species in the brain has been implicated as a common underlying risk factor for the pathogenesis of a number of neurodegenerative disorders, including Alzheimer's disease (AD), Parkinson's disease (PD), and stroke. In recent years, there is considerable interest concerning investigation of antioxidative and anti-inflammatory effects of phenolic compounds from different botanical sources. In this review, we first describe oxidative mechanisms associated with stroke, AD, and PD, and subsequently, we place emphasis on recent studies implicating neuroprotective effects of resveratrol, a polyphenolic compound derived from grapes and red wine. These studies show that the beneficial effects of resveratrol are not only limited to its antioxidant and anti-inflammatory action but also include activation of sirtuin 1 (SIRT1) and vitagenes, which can prevent the deleterious effects triggered by oxidative stress. In fact, SIRT1 activation by resveratrol is gaining importance in the development of innovative treatment strategies for stroke and other neurodegenerative disorders. The goal here is to provide a better understanding of the mode of action of resveratrol and its possible use as a potential therapeutic agent to ameliorate stroke damage as well as other age-related neurodegenerative disorders.	[Sun, Albert Y.; Sun, Grace Y.] Univ Missouri, Sch Med, Dept Pathol & Anat Sci, Columbia, MO 65212 USA; [Sun, Albert Y.; Wang, Qun] Univ Missouri, Dept Med Pharmacol & Physiol, Columbia, MO 65212 USA; [Simonyi, Agnes; Sun, Grace Y.] Univ Missouri, Dept Biochem, Columbia, MO 65212 USA	Sun, AY (corresponding author), Univ Missouri, Sch Med, Dept Pathol & Anat Sci, 1 Hosp Dr, Columbia, MO 65212 USA.	suna@health.missouri.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [2P01 AG018357]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG018357] Funding Source: NIH RePORTER	This work was supported in part by NIH grant 2P01 AG018357.	de la Lastral CA, 2007, BIOCHEM SOC T, V35, P1156, DOI 10.1042/BST0351156; Albani D, 2009, J NEUROCHEM, V110, P1445, DOI 10.1111/j.1471-4159.2009.06228.x; Allard JS, 2009, MOL CELL ENDOCRINOL, V299, P58, DOI 10.1016/j.mce.2008.10.018; Anderson R, 2009, BBA-GEN SUBJECTS, V1790, P1059, DOI 10.1016/j.bbagen.2009.04.005; Rubiolo JA, 2008, EUR J PHARMACOL, V591, P66, DOI 10.1016/j.ejphar.2008.06.067; Anekonda TS, 2006, BRAIN RES REV, V52, P316, DOI 10.1016/j.brainresrev.2006.04.004; Ates O, 2007, MOL CELL BIOCHEM, V294, P137, DOI 10.1007/s11010-006-9253-0; Barber SC, 2009, FREE RADICAL BIO MED, V46, P1127, DOI 10.1016/j.freeradbiomed.2009.01.019; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; Baur JA, 2006, NAT REV DRUG DISCOV, V5, P493, DOI 10.1038/nrd2060; Beckman KB, 1998, PHYSIOL REV, V78, P547; Bi XL, 2005, INT IMMUNOPHARMACOL, V5, P185, DOI 10.1016/j.intimp.2004.08.008; Bravo L, 1998, NUTR REV, V56, P317, DOI 10.1111/j.1753-4887.1998.tb01670.x; Butterfield DA, 2007, FREE RADICAL BIO MED, V43, P658, DOI 10.1016/j.freeradbiomed.2007.05.037; Calabrese V, 2008, NEUROCHEM RES, V33, P2444, DOI 10.1007/s11064-008-9775-9; Calabrese V, 2009, FRONT BIOSCI-LANDMRK, V14, P376, DOI 10.2741/3250; Caughey B, 2003, ANNU REV NEUROSCI, V26, P267, DOI 10.1146/annurev.neuro.26.010302.081142; Chanvitayapongs S, 1997, NEUROREPORT, V8, P1499, DOI 10.1097/00001756-199704140-00035; Chen CY, 2005, BIOCHEM BIOPH RES CO, V331, P993, DOI 10.1016/j.bbrc.2005.03.237; Collins MA, 1998, FASEB J, V12, P221; Conte A, 2003, BRAIN RES BULL, V62, P29, DOI 10.1016/j.brainresbull.2003.08.001; Crews FT, 2006, ALCOHOL CLIN EXP RES, V30, P720, DOI 10.1111/j.1530-0277.2006.00084.x; Crews FT, 2009, ALCOHOL ALCOHOLISM, V44, P115, DOI 10.1093/alcalc/agn079; Csiszar A, 2009, AM J PHYSIOL-HEART C, V297, pH13, DOI 10.1152/ajpheart.00368.2009; Curin Y., 2006, Cardiovascular & Hematological Agents in Medicinal Chemistry, V4, P277, DOI 10.2174/187152506778520691; Dasgupta B, 2007, P NATL ACAD SCI USA, V104, P7217, DOI 10.1073/pnas.0610068104; de la Monte SM, 2005, J ALZHEIMERS DIS, V7, P45; Deschamps V, 2001, NEUROEPIDEMIOLOGY, V20, P7, DOI 10.1159/000054752; Esposito E, 2002, NEUROBIOL AGING, V23, P719, DOI 10.1016/S0197-4580(02)00078-7; Farooqui T, 2009, MECH AGEING DEV, V130, P203, DOI 10.1016/j.mad.2008.11.006; Fuenzalida K, 2007, J BIOL CHEM, V282, P37006, DOI 10.1074/jbc.M700447200; Gil JM, 2008, EUR J NEUROSCI, V27, P2803, DOI 10.1111/j.1460-9568.2008.06310.x; HARMAN AW, 1995, ANNU REV PHARMACOL, V35, P129, DOI 10.1146/annurev.pa.35.040195.001021; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Jin F, 2008, EUR J PHARMACOL, V600, P78, DOI 10.1016/j.ejphar.2008.10.005; Kim D, 2007, EMBO J, V26, P3169, DOI 10.1038/sj.emboj.7601758; Kim YA, 2006, INT J MOL MED, V17, P1069; Koshimura I, 1997, BRAIN RES, V773, P108, DOI 10.1016/S0006-8993(97)00922-0; Kriz J, 2009, ACTA NEUROPATHOL, V117, P497, DOI 10.1007/s00401-009-0496-1; Kumar P, 2006, BEHAV PHARMACOL, V17, P485, DOI 10.1097/00008877-200609000-00014; Lamming DW, 2004, MOL MICROBIOL, V53, P1003, DOI 10.1111/j.1365-2958.2004.04209.x; LANGSTON JW, 1987, EUR NEUROL, V26, P2; Lazarov O, 2005, CELL, V120, P701, DOI 10.1016/j.cell.2005.01.015; Lev N, 2009, J MOL NEUROSCI, V38, P94, DOI 10.1007/s12031-008-9138-7; Lin TN, 2004, J NEUROCHEM, V90, P637, DOI 10.1111/j.1471-4159.2004.02540.x; Loeber S, 2009, ALCOHOL ALCOHOLISM, V44, P372, DOI 10.1093/alcalc/agp030; Lu KT, 2008, J AGR FOOD CHEM, V56, P6910, DOI 10.1021/jf8007212; Lunn JS, 2009, GROWTH FACTORS, V27, P133, DOI 10.1080/08977190902814855; Mancuso C, 2007, EXPERT OPIN INV DRUG, V16, P1921, DOI 10.1517/13543784.16.12.1921; Marambaud P, 2005, J BIOL CHEM, V280, P37377, DOI 10.1074/jbc.M508246200; Martin S, 2002, BRIT J PHARMACOL, V135, P1579, DOI 10.1038/sj.bjp.0704603; Miller RL, 2007, BRAIN RES, V1167, P129, DOI 10.1016/j.brainres.2007.06.046; Miller RL, 2009, NEUROCHEM RES, V34, P55, DOI 10.1007/s11064-008-9656-2; Moselhy HF, 2001, ALCOHOL ALCOHOLISM, V36, P357, DOI 10.1093/alcalc/36.5.357; Muyderman H, 2009, NEUROCHEM RES, V34, P1847, DOI 10.1007/s11064-009-9974-z; Ndiaye M, 2004, FASEB J, V18, DOI 10.1096/fj.04-2146fje; OLDFIELD FF, 1991, NEUROCHEM RES, V16, P83, DOI 10.1007/BF00965833; Ono K, 2006, J NEUROCHEM, V97, P105, DOI 10.1111/j.1471-4159.2006.03707.x; Ono K, 2006, CURR PHARM DESIGN, V12, P4357, DOI 10.2174/138161206778793010; Pallas M, 2009, CURR NEUROVASC RES, V6, P70, DOI 10.2174/156720209787466019; Perez-Campo R, 1998, J COMP PHYSIOL B, V168, P149, DOI 10.1007/s003600050131; Qian YP, 2009, J MED CHEM, V52, P1963, DOI 10.1021/jm8015415; Qiu WQ, 2006, NEUROBIOL AGING, V27, P190, DOI 10.1016/j.neurobiolaging.2005.01.004; Ranney A, 2009, BEHAV PHARMACOL, V20, P330, DOI 10.1097/FBP.0b013e32832f0193; Rasouri S, 2007, M S-MED SCI, V23, P840, DOI 10.1051/medsci/20072310840; Reddy PH, 2005, BRAIN RES REV, V49, P618, DOI 10.1016/j.brainresrev.2005.03.004; RiceEvans C, 1997, PROSTAG LEUKOTR ESS, V57, P499, DOI 10.1016/S0952-3278(97)90435-X; Robb EL, 2008, BIOCHEM BIOPH RES CO, V372, P254, DOI 10.1016/j.bbrc.2008.05.028; Saiko P, 2008, MUTAT RES-REV MUTAT, V658, P68, DOI 10.1016/j.mrrev.2007.08.004; Selkoe DJ, 2001, J ALZHEIMERS DIS, V3, P75, DOI 10.3233/JAD-2001-3111; Selkoe DJ, 2004, ANN INTERN MED, V140, P627, DOI 10.7326/0003-4819-140-8-200404200-00047; Selkoe DJ, 2002, ANNU REV GENOM HUM G, V3, P67, DOI 10.1146/annurev.genom.3.022502.103022; Sharma M, 2002, LIFE SCI, V71, P2489, DOI 10.1016/S0024-3205(02)02083-0; Shelat PB, 2008, J NEUROCHEM, V106, P45, DOI 10.1111/j.1471-4159.2008.05347.x; Simonyi A, 1996, NEUROREPORT, V7, P2115, DOI 10.1097/00001756-199609020-00010; Simonyi A, 2005, MOL NEUROBIOL, V31, P135, DOI 10.1385/MN:31:1-3:135; Simonyi A, 2002, ALCOHOL CLIN EXP RES, V26, P352, DOI 10.1111/j.1530-0277.2002.tb02545.x; Sinclair DA, 2005, MECH AGEING DEV, V126, P987, DOI 10.1016/j.mad.2005.03.019; Sonmez U, 2007, NEUROSCI LETT, V420, P133, DOI 10.1016/j.neulet.2007.04.070; Sun AY, 2008, NEUROMOL MED, V10, P259, DOI 10.1007/s12017-008-8052-z; Sun AY, 2001, J BIOMED SCI, V8, P37, DOI 10.1159/000054011; SUN AY, 1993, ANN NY ACAD SCI, V679, P358; Sun AY, 2002, FREE RADICAL BIO MED, V32, P314, DOI 10.1016/S0891-5849(01)00803-6; Sun AY, 1997, NEUROCHEM RES, V22, P1187, DOI 10.1023/A:1021968526696; Sun GY, 1999, NEUROREPORT, V10, P93, DOI 10.1097/00001756-199901180-00018; Sun GY, 1999, J NUTR, V129, P1814; Sundararajan S, 2005, NEUROSCIENCE, V130, P685, DOI 10.1016/j.neuroscience.2004.10.021; Tang BL, 2008, MOL ASPECTS MED, V29, P187, DOI 10.1016/j.mam.2007.02.001; Tanzi RE, 2005, CELL, V120, P545, DOI 10.1016/j.cell.2005.02.008; Tchantchou F, 2005, J ALZHEIMERS DIS, V8, P283; TIPTON KF, 1993, J NEUROCHEM, V61, P1191, DOI 10.1111/j.1471-4159.1993.tb13610.x; Traystman RJ, 2003, ILAR J, V44, P85, DOI 10.1093/ilar.44.2.85; Voko Z, 2003, NEUROLOGY, V61, P1273, DOI 10.1212/01.WNL.0000090458.67821.A3; Wang J, 2006, FASEB J, V20, P2313, DOI 10.1096/fj.06-6281com; Wang Q, 2005, MOL NUTR FOOD RES, V49, P443, DOI 10.1002/mnfr.200500019; Wang Q, 2002, BRAIN RES, V958, P439, DOI 10.1016/S0006-8993(02)03543-6; Wang Q, 2009, J NUTR BIOCHEM, V20, P369, DOI 10.1016/j.jnutbio.2008.04.007; Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789; Wu JS, 2009, CIRCULATION, V119, P1124, DOI 10.1161/CIRCULATIONAHA.108.812537; Youdim KA, 2001, FREE RADICAL BIO MED, V30, P583, DOI 10.1016/S0891-5849(00)00510-4; Zagami CJ, 2009, GLIA, V57, P119, DOI 10.1002/glia.20739	101	207	218	0	71	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	JUN	2010	41	2-3			SI		375	383		10.1007/s12035-010-8111-y			9	Neurosciences	Neurosciences & Neurology	601WI	WOS:000278095800031	20306310	Green Accepted			2021-06-18	
J	Van Kampen, DA; Lovell, MR; Pardini, JE; Collins, MW; Fu, FH				Van Kampen, Derk A.; Lovell, Mark R.; Pardini, Jamie E.; Collins, Michael W.; Fu, Freddie H.			The "value added" of neurocognitive testing after sports-related concussion	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						concussion; neurocognitive testing; neuropsychological testing; Immediate Postconcussion Assessment and Cognitive; Testing (ImPACT)	HIGH-SCHOOL; PROFESSIONAL FOOTBALL; CEREBRAL CONCUSSION; RECOVERY; IMPACT; SPECIFICITY; SENSITIVITY; PERFORMANCE; MANAGEMENT; RETURN	Background: Neurocognitive testing has been endorsed as a "cornerstone" of concussion management by recent Vienna and Prague meetings of the Concussion in Sport Group. Neurocognitive testing is important given the potential unreliability of athlete self-report after injury. Relying only on athletes' reports of symptoms may result in premature return of athletes to contact sport, potentially exposing them to additional injury. Hypothesis: Use of computer-based neurocognitive testing results in an increased capacity to detect postconcussive abnormalities after injury. Study Design. Case control study; Level of evidence, 3. Methods: High school and college athletes with a diagnosed concussion were tested 2 days after injury. Postinjury neurocognitive performance (immediate Postconcussion Assessment and Cognitive Testing) and symptom (postconcussion symptom) scores were compared with preinjury (baseline) scores and with those of an age- and education-matched noninjured athlete control group. "Abnormal" test performance was determined statistically with Reliable Change Index scores. Results: Sixty-four percent of concussed athletes reported a significant increase in symptoms, as judged by postconcussion symptom scores, compared with preinjury baseline at 2 days after injury. Eighty-three percent of the concussed sample demonstrated significantly poorer neurocognitive test results relative to their own baseline performance. The addition of neurocognitive testing resulted in a net increase in sensitivity of 19%. Ninety-three percent of the sample had either abnormal neurocognitive test results or a significant increase in symptoms, relative to their own baseline; 30% of a control group demonstrated either abnormalities in neurocognitive testing or elevated symptoms, as judged by postconcussion symptom scores. For the concussed group, use of symptom and neurocognitive test results resulted in an increased yield of 29% overreliance on symptoms alone. In contrast, 0% of the control group had both symptoms and abnormal neurocognitive testing. Conclusion: Reliance on patients' self-reported symptoms after concussion is likely to result in underdiagnosis of concussion and may result in premature return to play. Neurocognitive testing increases diagnostic accuracy when used in conjunction with self-reported symptoms.	Univ Pittsburgh, Med Ctr, Dept Orthopaed Surg, Pittsburgh, PA 15203 USA; Univ Groningen, Med Ctr, Dept Orthopaed, Groningen, Netherlands	Lovell, MR (corresponding author), Univ Pittsburgh, Med Ctr, Dept Orthopaed Surg, 3200 S Water St, Pittsburgh, PA 15203 USA.	lovellmr@upmc.edu					Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bailes JE, 2001, NEUROSURGERY, V48, P26, DOI 10.1097/00006123-200101000-00005; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Lovell M. R., 2002, Medicine & Science in Sports & Exercise, V34, pS298, DOI 10.1097/00005768-200205001-01680; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Lovell MR, 2004, STUD NEUROPSYCHOL DE, P209; Lovell MR, 2004, STUD NEUROPSYCHOL DE, P221; LOVELL MR, 2001, 1 ANN M CONC SPORT N; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McCrory Paul, 2005, Clin J Sport Med, V15, P48; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; NAUGLE RI, 1993, ARCH CLIN NEUROPSYCH, V8, P381, DOI 10.1016/0887-6177(93)90002-I; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001	31	207	208	0	25	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	OCT	2006	34	10					1630	1635		10.1177/0363546506288677			6	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	088TG	WOS:000240833400011	16816151				2021-06-18	
J	Menon, DK; Coles, JP; Gupta, AK; Fryer, TD; Smielewski, P; Chatfield, DA; Aigbirhio, F; Skepper, JN; Minhas, PS; Hutchinson, PJ; Carpenter, TA; Pickard, JD				Menon, DK; Coles, JP; Gupta, AK; Fryer, TD; Smielewski, P; Chatfield, DA; Aigbirhio, F; Skepper, JN; Minhas, PS; Hutchinson, PJ; Carpenter, TA; Pickard, JD			Diffusion limited oxygen delivery following head injury	CRITICAL CARE MEDICINE			English	Article						trauma; head injury; positron emission tomography; cerebral ischemia; oxygen delivery	CEREBRAL-BLOOD-FLOW; POSITRON-EMISSION-TOMOGRAPHY; TRAUMATIC BRAIN-INJURY; ISCHEMIC PENUMBRA; COMPUTERIZED-TOMOGRAPHY; TISSUE OXYGEN; METABOLISM; PRESSURE; HYPERVENTILATION; TENSION	Objective: To use a range of techniques to explore diffusion limitation as a mechanism of cellular hypoxia in the setting of head injury. Design: A prospective interventional study. Setting: A specialist neurocritical care unit. Patients: Thirteen patients within 7 days of closed head injury Underwent imaging studies. Tissue for ultrastructural studies was obtained from a cohort of seven patients who required surgery. Interventions: Cerebral tissue Po-2 (Pto(2)) was obtained using a multi pie-variable sensor, and images of oxygen extraction fraction (OEF), derived from positron emission tomography, were used to calculate cerebral venous Po-2 (Pvo(2)). These data were used to derive the PVo(2)-Pto(2) gradient in a region of interest around the sensor, which provided a measure of the efficiency of microvascular oxygen delivery. Measurements were repeated after Paco(2) was reduced from 37 +/- 3 to 29 +/- 3 torr (4.9 +/- 0.4 to 3.9 +/- 0.4 kPa) to assess the ability of the microvasculature to increase oxygen unloading during hypocapnia-induced hypoperfusion. Pericontusional tissue was submitted to electron microscopy to illustrate the structural correlates of physiologic findings. Measurements and Main Results: Tissue regions with hypoxic levels of Pto(2) (< 10 torr) had similar levels Of Pvo(2) compared with nonhypoxic areas and hence displayed larger Pvo(2)-Pto(2) gradients (27 +/- 2 vs. 9 +/- 8 torr, p < .001). Despite similar cerebral blood flow reductions with hyperventilation, hypoxic regions achieved significantly smaller OEF increases compared with normoxic regions (7 +/- 5 vs. 16 +/- 6%, p < .05). Pericontusional tissue showed varying degrees of endothelial swelling, microvascular collapse, and perivascular edema. Conclusions: Increased diffusion barriers may reduce cellular oxygen delivery following head injury and attenuate the ability of the brain to increase oxygen extraction in response to hypoperfusion. Global or regional OF underestimates tissue hypoxia due to such mechanisms.	Univ Cambridge, Dept Anat, Multiimaging Ctr, Cambridge, England; Univ Cambridge, Addenbrookes Hosp, Dept Neurosurg, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Cambridge CB2 2QQ, England	Menon, DK (corresponding author), Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Box 93, Cambridge CB2 2QQ, England.	dkm13@wbic.cam.ac.uk		Smielewski, Peter/0000-0001-5096-3938	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001237, G9439390] Funding Source: Medline		ALPERT NM, 1988, J CEREBR BLOOD F MET, V8, P403, DOI 10.1038/jcbfm.1988.76; ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; Baron JC, 1999, CEREBROVASC DIS, V9, P193, DOI 10.1159/000015955; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; Chesnut R M, 1995, New Horiz, V3, P366; Clausen T, 2001, BRAIN RES, V908, P35, DOI 10.1016/S0006-8993(01)02566-5; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Coles J. P., 2002, Clinical Science (London), V103, p62P; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Coles JP, 2002, CRIT CARE MED, V30, P1950, DOI 10.1097/00003246-200209000-00002; Dings J, 1998, NEUROSURGERY, V43, P1082, DOI 10.1097/00006123-199811000-00045; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; Diringer MN, 2000, J NEUROSURG, V92, P7, DOI 10.3171/jns.2000.92.1.0007; Doppenberg EMR, 1998, ACT NEUR S, V71, P166; FRACKOWIAK RSJ, 1980, J COMPUT ASSIST TOMO, V4, P727, DOI 10.1097/00004728-198012000-00001; GRAHAM DI, 1971, LANCET, V1, P265; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Gupta AK, 1999, ANESTH ANALG, V88, P549, DOI 10.1097/00000539-199903000-00016; Gupta AK, 2002, J NEUROSURG, V96, P263, DOI 10.3171/jns.2002.96.2.0263; Heiss WD, 2000, J CEREBR BLOOD F MET, V20, P1276, DOI 10.1097/00004647-200009000-00002; HERSCOVITCH P, 1985, J CEREBR BLOOD F MET, V5, P65, DOI 10.1038/jcbfm.1985.9; Hoffman WE, 1999, SURG NEUROL, V51, P654, DOI 10.1016/S0090-3019(99)00011-7; JENNETT B, 1975, LANCET, V2, P480; KELMAN GR, 1966, J APPL PHYSIOL, V21, P1375; LAMMERTSMA AA, 1987, J CEREBR BLOOD F MET, V7, P372, DOI 10.1038/jcbfm.1987.75; Lubbers DW, 1997, KIDNEY INT, V51, P372, DOI 10.1038/ki.1997.49; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; PHELPS ME, 1979, J NUCL MED, V20, P328; POWERS WJ, 1992, NEUROL CLIN, V10, P31; Sarrafzadeh AS, 1998, ACT NEUR S, V71, P186; SMIELEWSKI P, 2003, J CLIN MONITOR COMP, V17, P427; Stocchetti N, 1998, ACT NEUR S, V71, P162; Studholme C, 1997, MED PHYS, V24, P25, DOI 10.1118/1.598130; TEASDALE G, 1974, LANCET, V2, P81; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; Vaz R, 1997, ACTA NEUROCHIR, V139, P215, DOI 10.1007/BF01844754; 2000, J NEUROTRAUMA, V17, P457	44	207	210	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	JUN	2004	32	6					1384	1390		10.1097/01.CCM.0000127777.16609.08			7	Critical Care Medicine	General & Internal Medicine	831NQ	WOS:000222201600023	15187523				2021-06-18	
J	Vialet, R; Albanese, J; Thomachot, L; Antonini, F; Bourgouin, A; Alliez, B; Martin, C				Vialet, R; Albanese, J; Thomachot, L; Antonini, F; Bourgouin, A; Alliez, B; Martin, C			Isovolume hypertonic solutes (sodium chloride or mannitol) in the treatment of refractory posttraumatic intracranial hypertension: 2 mL/kg 7.5% saline is more effective than 2 mL/kg 20% mannitol	CRITICAL CARE MEDICINE			English	Article						intracranial hypertension; head trauma; hypertonic saline solution; mannitol	TRAUMATIC BRAIN INJURY; CEREBRAL WATER-CONTENT; HEAD-INJURY; BLOOD-FLOW; PRESSURE; RESUSCITATION; EDEMA; ELECTROLYTES; OSMOLALITY; SHOCK	Objective: To evaluate the clinical benefit of increasing the osmotic load of the hypertonic solution administered for the treatment of refractory intracranial hypertension episodes in patients with severe head injury. Design: Prospective, randomized study. Settings. A trauma center in a university hospital. Patients. Twenty consecutive patients with head trauma and persistent coma who required infusions of an osmotic agent to treat episodes of intracranial hypertension resistant to well-conducted standard modes of therapy were studied. Intracranial hypertension was considered refractory when it persisted despite deep sedation, optimal hemodynamic status, and, in some patients, drainage of cerebral spinal fluid. Interventions. Patients were randomly assigned to receive isovolume infusions of either 7.5% hypertonic saline solution (2400 mOsm/kg/H2O) or 20% mannitol (1160 mOsm/kg/H2O). The patients were given 2 mL/kg (body weight) of either solution, i.e., 361 +/- 13 mOsm of saline or 175 +/- 12 mOsm of mannitol per injection. Measurements and Main Results. The main variables studied were the number and the duration of episodes of intracranial hypertension per day during the study period, which was stopped after the last episode of intracranial hypertension was recorded from intracranial pressure monitoring or after the allocated treatment failure. Patients in the HHS group were monitored for 7 +/- 5 days and those in the mannitol group for 7 +/- 6 days (not significant). The rate of failure for each treatment was also evaluated. Failure was defined as the persistence of intracranial hypertension despite two successive infusions of the same osmotic agent. The mean number of osmotic solute infusions was 3.7 +/- 5.3 in the mannitol group and 3.3 +/- 4.1 in the hypertonic saline solution group (not significant). The mean number (6.9 +/- 5.6 vs. 13.3 +/- 14.6 episodes) of intracranial hypertension episodes per day and the daily duration (67 +/- 85 vs. 131 +/- 123 min) of intracranial hypertension episodes were significantly lower in the hypertonic saline solution group (p < .01). The rate of clinical failure was also significantly lower in the hypertonic saline solution group: 1 of 10 patients vs. 7 of 10 patients (p < .01). Conclusion: In this study, when a hypertonic solute was required for the treatment of refractory intracranial hypertension episodes in patients with severe head trauma, increasing the osmotic load by giving 2 mL/kg (body weight) of 7.5% saline (361 +/- 13 mOsm) was more effective than giving 2 mL/kg (body weight) of 20% mannitol (175 +/- 12 mOsm). Within the limitations of the present study, these data suggest that giving 2 mL/kg hypertonic saline solution (approximately 480 mOsm/70 kg body weight) is an effective and safe initial treatment for intracranial hypertension episodes in head-trauma patients when osmotherapy is indicated.	Marseilles Univ Hosp Syst, Marseilles Sch Med, Dept Anesthesia & Intens Care, Marseille, France; Marseilles Univ Hosp Syst, Marseilles Sch Med, Ctr Trauma, Marseille, France; Marseilles Univ Hosp Syst, Marseilles Sch Med, Dept Neurosurg, Marseille, France	Martin, C (corresponding author), CHU Nord, Blvd Pierre Dramard, F-13915 Marseille 20, France.						ARCHER DP, 1995, ANN FR ANESTH, V14, P77, DOI 10.1016/S0750-7658(05)80154-6; ARIEFF AI, 1976, KIDNEY INT, V10, P104, DOI 10.1038/ki.1976.82; ARIEFF AI, 1996, CURR OPIN CRIT CARE, V2, P418; BAILAR JC, 1992, NEW ENGLAND J MED; BARRY KG, 1961, NEW ENGL J MED, V264, P1085, DOI 10.1056/NEJM196105252642105; BERGER S, 1994, ACT NEUR S, V60, P494; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Cote CJ, 1979, ANESTHESIOLOGY, V47, P28; COTTRELL JE, 1977, ANESTHESIOLOGY, V47, P28, DOI 10.1097/00000542-197707000-00006; DOMINGUEZ R, 1947, J LAB CLIN MED, V32, P1192; FISHER B, 1992, J NEUROSURG ANESTH, V4, P4, DOI 10.1097/00008506-199201000-00002; Fortune JB, 1995, J TRAUMA, V39, P1091, DOI 10.1097/00005373-199512000-00014; FRESHMAN SP, 1993, J TRAUMA, V35, P344, DOI 10.1097/00005373-199309000-00003; GARCIASOLA R, 1991, ACTA NEUROCHIR, V109, P114, DOI 10.1007/BF01403005; Gemma M, 1997, J NEUROSURG ANESTH, V9, P329, DOI 10.1097/00008506-199710000-00007; GUNNAR W, 1988, SURGERY, V103, P398; HARTWELL RC, 1993, NEUROSURGERY, V32, P444, DOI 10.1227/00006123-199303000-00017; HUANG PP, 1995, ANN SURG, V221, P543, DOI 10.1097/00000658-199505000-00012; KAUFMANN AM, 1992, J NEUROSURG, V77, P584, DOI 10.3171/jns.1992.77.4.0584; Khanna S, 2000, CRIT CARE MED, V28, P1144, DOI 10.1097/00003246-200004000-00038; Kirkpatrick PJ, 1996, NEUROSURGERY, V39, P714, DOI 10.1097/00006123-199610000-00013; LARSSON A, 1995, YB INTENSIVE CARE EM, P866; MATTAR JA, 1989, CRIT CARE MED, V17, P297, DOI 10.1097/00003246-198903000-00020; Meier-Hellmann A, 1990, EUR SURG RES, V22, P303; Meier-Hellmann A, 1995, YB INTENSIVE CARE EM, P935; Miller J D, 1993, Acta Neurochir Suppl (Wien), V57, P152; NATH F, 1986, NEUROSURGERY, V41, P41; Peterson B, 2000, CRIT CARE MED, V28, P1136, DOI 10.1097/00003246-200004000-00037; Qureshi AI, 2000, CRIT CARE MED, V28, P3301, DOI 10.1097/00003246-200009000-00032; RUDEHILL A, 1993, J NEUROSURG ANESTH, V5, P4; Schell RM, 1996, J NEUROSURG ANESTH, V8, P178, DOI 10.1097/00008506-199604000-00022; SCHELLER MS, 1991, J NEUROSURG ANESTH, V3, P291, DOI 10.1097/00008506-199112000-00009; SHACKFORD SR, 1992, J NEUROSURG, V76, P91, DOI 10.3171/jns.1992.76.1.0091; SHACKFORD SR, 1994, J TRAUMA, V37, P899, DOI 10.1097/00005373-199412000-00005; TRACHTMAN H, 1992, PEDIATR NEPHROL, V6, P104, DOI 10.1007/BF00856852; VASSAR MJ, 1993, ARCH SURG-CHICAGO, V128, P1003; Velasco IT, 1980, AM J PHYSIOL, V222, P1406; Weed LH, 1919, AM J PHYSIOL, V48, P531; WEINSTABL C, 1991, ANESTHESIOLOGY, V75, pA201; WINKLER SR, 1995, SURG NEUROL, V43, P59, DOI 10.1016/0090-3019(95)80039-J; WISE BL, 1962, J NEUROSURG, V19, P1038, DOI 10.3171/jns.1962.19.12.1038; WISNER DH, 1990, J TRAUMA, V30, P75, DOI 10.1097/00005373-199001000-00011; ZORNOW MH, 1989, J TRAUMA, V29, P484, DOI 10.1097/00005373-198904000-00011; Zornow MH, 1996, J NEUROSURG ANESTH, V8, P175, DOI 10.1097/00008506-199604000-00021	44	207	221	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	JUN	2003	31	6					1683	1687		10.1097/01.CCM.0000063268.91710.DF			5	Critical Care Medicine	General & Internal Medicine	691DC	WOS:000183588700011	12794404				2021-06-18	
S	Stoll, G; Jander, S; Schroeter, M		Alzheimer, C		Stoll, G; Jander, S; Schroeter, M			Detrimental and beneficial effects of injury-induced inflammation and cytokine expression in the nervous system	MOLECULAR AND CELLULAR BIOLOGY OF NEUROPROTECTION IN THE CNS	Advances in Experimental Medicine and Biology		English	Article							CEREBRAL-ARTERY OCCLUSION; TUMOR-NECROSIS-FACTOR; ISCHEMIC BRAIN-INJURY; TRANSIENT FOREBRAIN ISCHEMIA; MESSENGER-RNA EXPRESSION; MONOCYTE CHEMOATTRACTANT PROTEIN-1; INTERCELLULAR-ADHESION MOLECULE-1; CORTICAL SPREADING DEPRESSION; INDUCED FOCAL ISCHEMIA; INTERLEUKIN-1-BETA CONVERTING-ENZYME	Lesions in the nervous system induce rapid activation of glial cells and under certain conditions additional recruitment Of granulocytes, T-cells and monocytes/macrophages from the blood stream triggered by upregulation of cell adhesion molecules, chemokines and cytokines. Hematogenous cell infiltration is not restricted to infectious or autoimmune disorders of the nervous system, but also occurs in response to cerebral ischemia and traumatic lesions. Neuroinflammation can cause neuronal damage, but also confers neuroprotection. Granulocytes occlude vessels during reperfusion after transient focal ischemia, while the functional role of T-cells and macrophages in stroke development awaits further clarification. After focal cerebral ischemia neurotoxic: mediators released by microglia such as the inducible nitric oxide synthase (leading to NO synthesis) and the cytokines interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha) are upregulated prior to cellular inflammation in the evolving lesion and functionally contribute to secondary infarct growth as revealed by numerous pharmacological experiments and by use of transgenic animals. On the other hand, cytokine induction remote from ischemic lesions involves NMDA-mediated signalling pathways and confers neuroprotection. After nerve injury T cells can rescue CNS neurons. In the peripheral nervous system neuroinflammation is a prerequisite for successful regeneration that is impeded in the CNS. In conclusion, there is increasing evidence that neuroinflammation represents a double edged sword. The opposing neurotoxic and neuroprotective properties of neuroinflammation during CNS injury provide a rich and currently unexplored set of research problems.	Univ Dusseldorf, Dept Neurol, D-40225 Dusseldorf, Germany; Univ Wurzburg, Dept Neurol, D-97080 Wurzburg, Germany	Stoll, G (corresponding author), Univ Dusseldorf, Dept Neurol, Noorenstr 5, D-40225 Dusseldorf, Germany.						Aguado A, 1982, ADV CELL NEUROBIOL, V3, P215; Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; Bandtlow CE, 2000, GLIA, V29, P175, DOI 10.1002/(SICI)1098-1136(20000115)29:2<175::AID-GLIA11>3.0.CO;2-F; Barone FC, 1997, STROKE, V28, P1233, DOI 10.1161/01.STR.28.6.1233; Becker KJ, 1997, P NATL ACAD SCI USA, V94, P10873, DOI 10.1073/pnas.94.20.10873; Bhat RV, 1996, J NEUROSCI, V16, P4146; Bidmon HJ, 1998, NEUROSCIENCE, V82, P377; Botchkina GI, 1997, MOL MED, V3, P765, DOI 10.1007/BF03401714; Braun JS, 1996, ACTA NEUROPATHOL, V92, P255, DOI 10.1007/s004010050516; Bredesen DE, 1995, ANN NEUROL, V38, P839, DOI 10.1002/ana.410380604; BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; BUTTINI M, 1994, MOL BRAIN RES, V23, P126, DOI 10.1016/0169-328X(94)90218-6; CAJAL RY, 1991, CAJALS DEGENERATION, P589; CHAMAK B, 1994, J NEUROSCI RES, V38, P221, DOI 10.1002/jnr.490380213; CHAO CC, 1992, J IMMUNOL, V149, P2736; Chen J, 1997, NEUROLOGY, V48, P306, DOI 10.1212/WNL.48.2.306; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; Chen Y, 2001, J CEREBR BLOOD F MET, V21, P34, DOI 10.1097/00004647-200101000-00005; Chopp M, 1996, J CEREBR BLOOD F MET, V16, P578, DOI 10.1097/00004647-199607000-00007; CLARK RK, 1993, BRAIN RES BULL, V31, P565, DOI 10.1016/0361-9230(93)90124-T; Clark WM, 1995, MOL CHEM NEUROPATHOL, V26, P213, DOI 10.1007/BF02815139; Connolly ES, 1996, J CLIN INVEST, V97, P209, DOI 10.1172/JCI118392; CONSTAM DB, 1992, J IMMUNOL, V148, P1404; Davies CA, 1999, J CEREBR BLOOD F MET, V19, P87, DOI 10.1097/00004647-199901000-00010; DIETRICH WD, 1994, J CEREBR BLOOD F MET, V14, P20, DOI 10.1038/jcbfm.1994.4; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Elkabes S, 1996, J NEUROSCI, V16, P2508; Ellison JA, 1998, STROKE, V29, P1698, DOI 10.1161/01.STR.29.8.1698; Endres H, 1998, J CEREBR BLOOD F MET, V18, P238, DOI 10.1097/00004647-199803000-00002; FEHSEL K, 1991, AM J PATHOL, V139, P251; Fields RD, 1999, NEUROSCIENTIST, V5, P12, DOI 10.1177/107385849900500103; FINSEN BR, 1993, GLIA, V7, P41, DOI 10.1002/glia.440070109; FLARIS NA, 1993, GLIA, V7, P34, DOI 10.1002/glia.440070108; Flavin MP, 1997, NEUROSCIENCE, V80, P437, DOI 10.1016/S0306-4522(97)00078-X; Friedlander RM, 1997, J EXP MED, V185, P933, DOI 10.1084/jem.185.5.933; GARCIA JH, 1994, AM J PATHOL, V144, P188; GARCIA JH, 1995, AM J PATHOL, V147, P1477; Garcia JH, 1996, AM J PATHOL, V148, P241; Gary DS, 1998, J CEREBR BLOOD F MET, V18, P1283, DOI 10.1097/00004647-199812000-00001; GEORGE R, 1994, EXP NEUROL, V129, P225, DOI 10.1006/exnr.1994.1164; Gillen C, 1998, J NEUROSCI RES, V51, P489, DOI 10.1002/(SICI)1097-4547(19980215)51:4<489::AID-JNR8>3.3.CO;2-5; GINIS I, 1999, AM J PHYSIOL, V45, pC1171; GIULIAN D, 1993, J NEUROSCI RES, V36, P681, DOI 10.1002/jnr.490360609; Goodman Y, 1996, J NEUROCHEM, V66, P869, DOI 10.1046/j.1471-4159.1996.66020869.x; Gourmala NG, 1997, J NEUROIMMUNOL, V74, P35, DOI 10.1016/S0165-5728(96)00203-2; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; Gregersen R, 2000, J CEREBR BLOOD F MET, V20, P53, DOI 10.1097/00004647-200001000-00009; GROSS CE, 1993, STROKE, V24, P558, DOI 10.1161/01.STR.24.4.558; Hagemann G, 1998, ANN NEUROL, V44, P255, DOI 10.1002/ana.410440217; Hammarberg H, 2000, J NEUROSCI, V20, P5283, DOI 10.1523/JNEUROSCI.20-14-05283.2000; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Heese K, 1998, J NEUROCHEM, V70, P699; HenrichNoack P, 1996, STROKE, V27, P1609, DOI 10.1161/01.STR.27.9.1609; HEWETT SJ, 1994, NEURON, V13, P487, DOI 10.1016/0896-6273(94)90362-X; Hirji N, 1998, J IMMUNOL, V160, P6004; Hirji NS, 1999, INT ARCH ALLERGY IMM, V118, P180, DOI 10.1159/000024060; Iadecola C, 1999, J EXP MED, V189, P719, DOI 10.1084/jem.189.4.719; Iadecola C, 1997, J NEUROSCI, V17, P9157; Iadecola C, 1997, TRENDS NEUROSCI, V20, P132, DOI 10.1016/S0166-2236(96)10074-6; Iglesias BM, 1997, J NEUROIMMUNOL, V72, P83, DOI 10.1016/S0165-5728(96)00155-5; Isenmann S, 1998, BRAIN PATHOL, V8, P49; Jander S, 2000, J NEUROIMMUNOL, V109, P181, DOI 10.1016/S0165-5728(00)00317-9; Jander S, 1998, EUR J NEUROSCI, V10, P680, DOI 10.1046/j.1460-9568.1998.00078.x; Jander S, 1998, AM J PATHOL, V152, P975; Jander S, 2001, J CEREBR BLOOD F MET, V21, P218, DOI 10.1097/00004647-200103000-00005; Jander S, 2001, BRAIN PATHOL, V11, P27; JANDER S, 1995, J CEREBR BLOOD F MET, V15, P42, DOI 10.1038/jcbfm.1995.5; Jander S, 1996, J NEUROIMMUNOL, V70, P75, DOI 10.1016/S0165-5728(96)00109-9; Jiang N, 1995, ANN NEUROL, V38, P935, DOI 10.1002/ana.410380615; JORGENSEN MB, 1993, EXP NEUROL, V120, P70, DOI 10.1006/exnr.1993.1041; Kerschensteiner M, 1999, J EXP MED, V189, P865, DOI 10.1084/jem.189.5.865; KIM JS, 1995, J NEUROIMMUNOL, V56, P127, DOI 10.1016/0165-5728(94)00138-E; KOBAYASHI S, 1995, J CEREBR BLOOD F MET, V15, P721, DOI 10.1038/jcbfm.1995.92; KOCHANEK PM, 1992, STROKE, V23, P1367, DOI 10.1161/01.STR.23.9.1367; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; LAURITZEN M, 1992, J CEREBR BLOOD F MET, V12, P223, DOI 10.1038/jcbfm.1992.32; Lavine SD, 1998, J CEREBR BLOOD F MET, V18, P52, DOI 10.1097/00004647-199801000-00005; LAWETZKY A, 1990, EUR J IMMUNOL, V20, P343, DOI 10.1002/eji.1830200217; Lazarov-Spiegler O, 1998, GLIA, V24, P329, DOI 10.1002/(SICI)1098-1136(199811)24:3<329::AID-GLIA7>3.0.CO;2-X; LEHRMANN E, 1995, EXP NEUROL, V131, P114, DOI 10.1016/0014-4886(95)90013-6; Lehrmann E, 1997, J COMP NEUROL, V386, P461; Lehrmann E, 1998, GLIA, V24, P437, DOI 10.1002/(SICI)1098-1136(199812)24:4<437::AID-GLIA9>3.0.CO;2-X; Leker RR, 1999, J NEUROL SCI, V162, P114, DOI 10.1016/S0022-510X(98)00301-3; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; LI Y, 1995, AM J PATHOL, V146, P1045; Lin BW, 1998, ACTA NEUROPATHOL, V95, P511, DOI 10.1007/s004010050832; Lindsberg PJ, 1996, CIRCULATION, V94, P939, DOI 10.1161/01.CIR.94.5.939; Liu J, 2000, AM J PHYSIOL-CELL PH, V278, pC144; LIU T, 1993, STROKE, V24, P1746, DOI 10.1161/01.STR.24.11.1746; LIU T, 1994, STROKE, V25, P1481, DOI 10.1161/01.STR.25.7.1481; Loddick SA, 1996, NEUROREPORT, V7, P1465, DOI 10.1097/00001756-199606170-00004; Martins-Ferreira H, 2000, BRAIN RES REV, V32, P215, DOI 10.1016/S0165-0173(99)00083-1; Mattson MP, 1997, NEUROSCI BIOBEHAV R, V21, P193, DOI 10.1016/S0149-7634(96)00010-3; MCAULEY MA, 1995, CEREBROVAS BRAIN MET, V7, P153; MCNEILL H, 1994, NEUROREPORT, V5, P901, DOI 10.1097/00001756-199404000-00012; MEIRSTRELL ME, 1997, SHOCK, V8, P341; MEMEZAWA H, 1992, STROKE, V23, P552, DOI 10.1161/01.STR.23.4.552; Menge T, 2001, J NEUROSCI RES, V65, P332, DOI 10.1002/jnr.1158; MILLER A, 1992, P NATL ACAD SCI USA, V89, P421, DOI 10.1073/pnas.89.1.421; Minghetti L, 1998, PROG NEUROBIOL, V54, P99, DOI 10.1016/S0301-0082(97)00052-X; Moalem G, 1999, NAT MED, V5, P49, DOI 10.1038/4734; MORIOKA T, 1991, J CEREBR BLOOD F MET, V11, P966, DOI 10.1038/jcbfm.1991.162; MORIOKA T, 1992, ACTA NEUROPATHOL, V83, P149, DOI 10.1007/BF00308474; Nawashiro H, 1997, J CEREBR BLOOD F MET, V17, P229, DOI 10.1097/00004647-199702000-00013; Ohtsuki T, 1996, J CEREBR BLOOD F MET, V16, P1137, DOI 10.1097/00004647-199611000-00007; OKADA Y, 1994, STROKE, V25, P202, DOI 10.1161/01.STR.25.1.202; ORDY JM, 1993, EXP NEUROL, V119, P128, DOI 10.1006/exnr.1993.1014; PERRY VH, 1987, J EXP MED, V166, P1138, DOI 10.1084/jem.166.4.1138; PERRY VH, 1987, J EXP MED, V165, P1218, DOI 10.1084/jem.165.4.1218; PERRY VH, 1993, TRENDS NEUROSCI, V16, P268, DOI 10.1016/0166-2236(93)90180-T; Peters O, 1998, J CEREBR BLOOD F MET, V18, P196, DOI 10.1097/00004647-199802000-00011; PIANI D, 1991, NEUROSCI LETT, V133, P159, DOI 10.1016/0304-3940(91)90559-C; PREHN JHM, 1993, J CEREBR BLOOD F MET, V13, P521, DOI 10.1038/jcbfm.1993.67; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; Qiu J, 2000, GLIA, V29, P166, DOI 10.1002/(SICI)1098-1136(20000115)29:2<166::AID-GLIA10>3.3.CO;2-7; Rabchevsky AG, 1997, J NEUROSCI RES, V47, P34; Rabuffetti M, 2000, J NEUROSCI, V20, P4398, DOI 10.1523/JNEUROSCI.20-12-04398.2000; Reichert F, 1996, J NEUROIMMUNOL, V70, P153, DOI 10.1016/S0165-5728(96)00112-9; Relton JK, 1996, EXP NEUROL, V138, P206, DOI 10.1006/exnr.1996.0059; RELTON JK, 1992, BRAIN RES BULL, V29, P243, DOI 10.1016/0361-9230(92)90033-T; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Rothwell NJ, 2000, TRENDS NEUROSCI, V23, P618, DOI 10.1016/S0166-2236(00)01661-1; Rupalla K, 1998, ACTA NEUROPATHOL, V96, P172, DOI 10.1007/s004010050878; Schafer MKH, 2000, J IMMUNOL, V164, P5446, DOI 10.4049/jimmunol.164.10.5446; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Schneider H, 1998, P NATL ACAD SCI USA, V95, P7778, DOI 10.1073/pnas.95.13.7778; SCHROETER M, 1994, J NEUROIMMUNOL, V55, P195, DOI 10.1016/0165-5728(94)90010-8; Schroeter M, 1997, STROKE, V28, P382, DOI 10.1161/01.STR.28.2.382; Schroeter M, 2001, ACTA NEUROPATHOL, V101, P114; Schroeter M, 2001, ACTA NEUROPATHOL, V101, P440; Schroeter M, 1999, NEUROSCIENCE, V89, P1367, DOI 10.1016/S0306-4522(98)00398-4; SCHROETER M, 1995, EXP BRAIN RES, V106, P1; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Soriano SG, 1996, ANN NEUROL, V39, P618, DOI 10.1002/ana.410390511; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Stichel CC, 1998, PROG NEUROBIOL, V56, P119, DOI 10.1016/S0301-0082(98)00033-1; Stoll G, 1999, PROG NEUROBIOL, V58, P233, DOI 10.1016/S0301-0082(98)00083-5; STOLL G, 1989, J NEUROSCI, V9, P2327; Stoll G, 1998, PROG NEUROBIOL, V56, P149, DOI 10.1016/S0301-0082(98)00034-3; Stoll G, 1999, BRAIN PATHOL, V9, P313; STOLL G, 1989, J NEUROCYTOL, V18, P671, DOI 10.1007/BF01187086; Stroemer RP, 1998, J CEREBR BLOOD F MET, V18, P833, DOI 10.1097/00004647-199808000-00003; Tasaki K, 1997, BRAIN RES, V748, P267, DOI 10.1016/S0006-8993(96)01383-2; Touzani O, 1999, J NEUROIMMUNOL, V100, P203, DOI 10.1016/S0165-5728(99)00202-7; VANROOIJEN N, 1989, J IMMUNOL METHODS, V124, P1, DOI 10.1016/0022-1759(89)90178-6; WANG XK, 1995, STROKE, V26, P1665, DOI 10.1161/01.STR.26.9.1665; Wang XK, 2000, J CEREBR BLOOD F MET, V20, P15, DOI 10.1097/00004647-200001000-00004; WANG XK, 1995, STROKE, V26, P661, DOI 10.1161/01.STR.26.4.661; Wang XK, 1997, STROKE, V28, P155, DOI 10.1161/01.STR.28.1.155; WATSON BD, 1985, ANN NEUROL, V17, P497, DOI 10.1002/ana.410170513; WEINER HL, 1994, ANNU REV IMMUNOL, V12, P809, DOI 10.1146/annurev.immunol.12.1.809; Wekerle H, 1993, Curr Opin Neurobiol, V3, P779, DOI 10.1016/0959-4388(93)90153-P; YAMASAKI Y, 1995, STROKE, V26, P318, DOI 10.1161/01.STR.26.2.318; YAMASAKI Y, 1995, STROKE, V26, P676, DOI 10.1161/01.STR.26.4.676; Yamashita K, 2000, CELL MOL NEUROBIOL, V20, P541, DOI 10.1023/A:1007007710703; Yamashita K, 1996, BRAIN RES, V735, P285, DOI 10.1016/0006-8993(96)00578-1; YAMASHITA K, 1995, CLIN EXP PHARM PH S1, V22, pS227; Yanamoto H, 1998, BRAIN RES, V784, P239, DOI 10.1016/S0006-8993(97)01344-9; Yrjanheikki J, 1999, P NATL ACAD SCI USA, V96, P13496, DOI 10.1073/pnas.96.23.13496; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769; Z'Graggen WJ, 1998, J NEUROSCI, V18, P4744; ZHANG RL, 1995, STROKE, V26, P1438, DOI 10.1161/01.STR.26.8.1438; ZHANG RL, 1995, BRAIN RES, V682, P182, DOI 10.1016/0006-8993(95)00346-R; Zhang ZG, 1997, BRAIN RES, V744, P189, DOI 10.1016/S0006-8993(96)01085-2; Zhang ZG, 1998, BRAIN RES, V784, P210, DOI 10.1016/S0006-8993(97)01317-6; Zielasek J, 1996, ADV NEUROIMMUNOL, V6, P191, DOI 10.1016/0960-5428(96)00017-4	169	207	217	0	14	KLUWER ACADEMIC/PLENUM PUBL	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0065-2598	2214-8019	0-306-47414-X	ADV EXP MED BIOL	Adv.Exp.Med.Biol.		2002	513						87	113					27	Medicine, Research & Experimental	Research & Experimental Medicine	BW92A	WOS:000183600500003	12575818				2021-06-18	
J	Schwarz, S; Hafner, K; Aschoff, A; Schwab, S				Schwarz, S; Hafner, K; Aschoff, A; Schwab, S			Incidence and prognostic significance of fever following intracerebral hemorrhage	NEUROLOGY			English	Article						fever; intracerebral hemorrhage; prognosis; temperature	TRAUMATIC BRAIN INJURY; MODERATE HYPOTHERMIA; ACUTE STROKE; TEMPERATURE; HYPERTHERMIA; ISCHEMIA; RISK; COMPLICATIONS; INFARCTION; MORTALITY	Objective: To investigate the incidence and prognostic significance of fever on presentation and during the subsequent 72 hours in patients with spontaneous supratentorial intracerebral hemorrhage (ICH). Methods: We analyzed 251 patients. On admission, body temperature, Glasgow Coma Scale (GCS) score, age, sex, blood pressure, blood glucose level, and presumed origin of hemorrhage were analyzed. From the initial CT scan, hematoma volume, location, and presence of intraventricular hemorrhage were determined. From the first 72 hours, hematoma enlargement, duration of increased temperatures, blood pressure, and blood glucose level were determined. Outcome was classified on discharge with the Glasgow Outcome Scale (GOS) score. Results: Outcomes included no symptoms in 23 (9%), moderate disability in 64 (26%), severe disability in 104 (41%), vegetative state in 5 (24%), and death in 55 (22%) patients. Prognostic factors retained from a logistic regression model with a dichotomized GOS scale (GOS score of 1 or 2 versus GOS score of 3 to 5) as response variables were GCS score of 7 or less, age older than 75 years, hematoma volume of more than 60 cm(3), ventricular hemorrhage, and presence of a coagulation disorder (p < 0.05). Fever was associated with intraventricular hemorrhage. From 196 patients, data from the first 72 hours were analyzed. A total of 18 patients (9%) had normal temperatures throughout the study. The duration of fever (greater than or equal to 37.5 degrees C) was less than 24 hours in 66 (34%), 24 to 48 hours in 70 (36%), and more than 48 hours in 42 patients (21%). Independent prognostic factors during the first 72 hours were duration of fever, secondary hemorrhage, GCS score of 7 or less, ventricular hemorrhage, hematoma volume of more than 60 cm(3), duration of increased blood pressure of more than 48 hours, and duration of increased blood glucose of more than 48 hours. Conclusions: The incidence of fever after supratentorial ICH is high, especially in patients with ventricular hemorrhage. In patients surviving the first 72 hours after hospital admission, the duration of fever is associated with poor outcome and seems to be an independent prognostic factor in these patients.	Univ Heidelberg, Dept Neurol, D-69120 Heidelberg, Germany; Univ Heidelberg, Dept Neurosurg, D-69120 Heidelberg, Germany	Schwarz, S (corresponding author), Univ Heidelberg, Dept Neurol, 400 Neuenheimer Feld, D-69120 Heidelberg, Germany.						Albrecht RF, 1998, MAYO CLIN PROC, V73, P629; Aring CD, 1935, ARCH INTERN MED, V56, P435, DOI 10.1001/archinte.1935.00170010023002; AZZIMONDI G, 1995, STROKE, V26, P2040, DOI 10.1161/01.STR.26.11.2040; BRODERICK JP, 1993, STROKE, V24, P987, DOI 10.1161/01.STR.24.7.987; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CAPLAN LR, 1992, LANCET, V339, P656, DOI 10.1016/0140-6736(92)90804-C; Castillo J, 1998, STROKE, V29, P2455, DOI 10.1161/01.STR.29.12.2455; CHEVRET S, 1993, INTENS CARE MED, V19, P256, DOI 10.1007/BF01690545; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1990, STROKE, V21, P1318, DOI 10.1161/01.STR.21.9.1318; Figueroa BE, 1998, STROKE, V29, P1202, DOI 10.1161/01.STR.29.6.1202; Ginsberg MD, 1998, STROKE, V29, P529, DOI 10.1161/01.STR.29.2.529; Grau AJ, 1998, NEUROLOGY, V50, P196, DOI 10.1212/WNL.50.1.196; Henker RA, 1998, NEUROSURGERY, V42, P1071, DOI 10.1097/00006123-199805000-00071; HINDFELT B, 1976, ACTA NEUROL SCAND, V53, P72, DOI 10.1111/j.1600-0404.1976.tb04326.x; JENNETT B, 1975, LANCET, V335, P480; KALRA L, 1995, STROKE, V26, P990, DOI 10.1161/01.STR.26.6.990; KASE CS, 1994, INTRACEREBRAL HEMORR, P467; KITANAKA C, 1994, STROKE, V25, P518, DOI 10.1161/01.STR.25.2.518; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Mendelow A. D., 1993, STROKE S1, V24, pI115; MORIKAWA E, 1992, J CEREBR BLOOD F MET, V12, P380, DOI 10.1038/jcbfm.1992.55; Pinto AN, 1998, CEREBROVASC DIS, V8, P204, DOI 10.1159/000015852; POMERANCE JJ, 1973, AM J DIS CHILD, V126, P854, DOI 10.1001/archpedi.1973.02110190696025; PORTENOY RK, 1987, J NEUROL NEUROSUR PS, V50, P976, DOI 10.1136/jnnp.50.8.976; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; Rosenberg GA, 1997, NEUROLOGY, V48, P921, DOI 10.1212/WNL.48.4.921; ROUSSEAUX P, 1993, NEUROCHIRURGIE, V39, P157; ROUSSEAUX P, 1980, SURG NEUROL, V14, P459; RUDY TA, 1978, EXP NEUROL, V58, P296, DOI 10.1016/0014-4886(78)90142-5; Schwab S, 1998, STROKE, V29, P2461, DOI 10.1161/01.STR.29.12.2461; Schwab S, 1997, NEUROLOGY, V48, P762, DOI 10.1212/WNL.48.3.762; Serlin S, 1991, J Clin Anesth, V3, P153, DOI 10.1016/0952-8180(91)90015-F; TEASDALE G, 1974, LANCET, V2, P81; TERENT A, 1981, UPSALA J MED SCI, V86, P63, DOI 10.3109/03009738109179211; Wagner KR, 1998, J NEUROSURG, V88, P1058, DOI 10.3171/jns.1998.88.6.1058; Wijdicks EFM, 1997, NEUROLOGY, V49, P1342, DOI 10.1212/WNL.49.5.1342	38	207	220	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	JAN 25	2000	54	2					354	361		10.1212/WNL.54.2.354			8	Clinical Neurology	Neurosciences & Neurology	279KW	WOS:000085043800016	10668696				2021-06-18	
J	Csuka, E; Morganti-Kossmann, MC; Lenzlinger, PM; Joller, H; Trentz, O; Kossmann, T				Csuka, E; Morganti-Kossmann, MC; Lenzlinger, PM; Joller, H; Trentz, O; Kossmann, T			IL-10 levels in cerebrospinal fluid and serum of patients with severe traumatic brain injury: relationship to IL-6, TNF-alpha, TGF-beta 1 and blood-brain barrier function	JOURNAL OF NEUROIMMUNOLOGY			English	Article						cytokines; interleukin-10; traumatic brain injury; blood-brain barrier; cerebrospinal fluid; anti-inflammatory	CENTRAL-NERVOUS-SYSTEM; TUMOR-NECROSIS-FACTOR; MESSENGER-RNA EXPRESSION; HUMORAL IMMUNE-RESPONSE; INTERLEUKIN-10 IL-10; MULTIPLE-SCLEROSIS; ENDOTHELIAL-CELLS; PLASMA-LEVELS; HEAD-INJURY; IN-VITRO	Controlling the extent of inflammatory responses following brain injury may be beneficial since posttraumatic intracranial inflammation has been associated with adverse outcome. In order to elucidate the potential role of anti-inflammatory mediators, the production of interleukin-10 (IL-10) was monitored in paired cerebrospinal fluid (CSF) and serum of 28 patients with severe traumatic brain injury (TBI) and compared to control samples. The pattern of IL-10 was analyzed with respect to the patterns of IL-6, tumor necrosis factor-alpha (TNF-alpha) and transforming growth factor-beta 1 (TGF-beta 1) in both fluids during a time period of up to 22 days. In parallel, the function/dysfunction of the blood-brain barrier (BBB) was monitored using the CSF-/serum-albumin quotient (Q(A)) and compared to intrathecal cytokine levels. Mean IL-10 concentration in CSF was elevated in 26 out of 28 TBI patients (range: 1.3-41.7 pg/ml) compared to controls (cut-off: 1.06 pg/ml), whereas only seven patients had elevated mean IL-10 concentration in serum (range: 5.4-23 pg/ml; cut-off: 5.14 pg/ml). The time course of IL-10 was similar in both fluids, showing a peak during the first days and a second, lower rise in the second week. Intrathecal IL-10 synthesis is hypothesized since CSF-IL-10 levels exceeded serum-IL-10 levels in most of the patients, IL-10-index (CSF/serum-IL-10/Q(A)) was elevated in 23 individuals, and elevation of CSF-IL-10 showed to be independent from severe BBB dysfunction. Neither CSF nor serum IL-10 values correlated with the dysfunction of the BBB. IL-10, IL-6 and TGF-beta 1 showed similar patterns in CSF over time, whereas rises of TNF-alpha corresponded to declines of IL-10 levels. Our results suggest that IL-10 is predominantly induced intrathecally after severe TBI where it may downregulate inflammatory events following traumatic brain damage. (C) 1999 Elsevier Science B.V. All rights reserved.	Univ Zurich Hosp, Div Trauma Surg, Dept Surg, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Div Res, Dept Surg, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Div Clin Immunol, Dept Internal Med, CH-8091 Zurich, Switzerland	Kossmann, T (corresponding author), Univ Zurich Hosp, Div Trauma Surg, Dept Surg, Raemistr 100, CH-8091 Zurich, Switzerland.		Lenzlinger, Philipp/A-3822-2008	Morganti-Kossmann, Cristina/0000-0002-0807-2063			BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; Balasingam V, 1996, J NEUROSCI, V16, P2945; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; BENVENISTE EN, 1995, INT J DEV NEUROSCI, V13, P341, DOI 10.1016/0736-5748(94)00061-7; BEUTLER B, 1993, CRIT CARE MED, V21, P235; CHAO CC, 1992, J IMMUNOL, V149, P2736; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; CONSTAM DB, 1992, J IMMUNOL, V148, P1404; Corsini E, 1996, SCAND J IMMUNOL, V44, P506, DOI 10.1046/j.1365-3083.1996.d01-343.x; CRUICKSHANK AM, 1990, CLIN SCI, V79, P161, DOI 10.1042/cs0790161; CUNHA FQ, 1992, BIOCHEM BIOPH RES CO, V182, P1155, DOI 10.1016/0006-291X(92)91852-H; DISANTO E, 1995, NEUROIMMUNOMODULAT, V2, P149, DOI 10.1159/000096885; Elenkov IJ, 1996, P ASSOC AM PHYSICIAN, V108, P374; FREI K, 1994, J IMMUNOL, V152, P2720; FREI K, 1993, J EXP MED, V178, P1255, DOI 10.1084/jem.178.4.1255; GALLO P, 1994, J NEUROL SCI, V126, P49, DOI 10.1016/0022-510X(94)90093-0; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; Hans VHJ, 1999, J CEREBR BLOOD F MET, V19, P184; Heesen M, 1996, ACTA NEUROCHIR, V138, P77, DOI 10.1007/BF01411728; Hiesmayr MJ, 1999, CLIN EXP IMMUNOL, V115, P315, DOI 10.1046/j.1365-2249.1999.00801.x; HISHII M, 1995, NEUROSURGERY, V37, P1160, DOI 10.1227/00006123-199512000-00016; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1993, J NEUROL NEUROSUR PS, V60, P5; KENNEDY MK, 1992, J IMMUNOL, V149, P2496; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Koedel U, 1996, J IMMUNOL, V157, P5185; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kossmann T, 1997, J CEREBR BLOOD F MET, V17, P280, DOI 10.1097/00004647-199703000-00005; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; KRAKAUER T, 1995, IMMUNOL LETT, V45, P61, DOI 10.1016/0165-2478(94)00226-H; MALEFYT RD, 1991, J EXP MED, V174, P1209; MARSHALL LF, 1991, J NEUROSURG S, V75, P28; Morganti-Kossmann MC, 1999, J NEUROTRAUM, V16, P617, DOI 10.1089/neu.1999.16.617; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; MORGANTIKOSSMAN.MC, 1995, IMMUNE RESPONSES NER, P159; Neidhardt R, 1997, J TRAUMA, V42, P863, DOI 10.1097/00005373-199705000-00017; NIJSTEN MWN, 1991, SURGERY, V109, P761; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; PIANI D, 1992, EUR J IMMUNOL, V22, P2429, DOI 10.1002/eji.1830220936; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; REIBER H, 1987, CLIN CHIM ACTA, V163, P319, DOI 10.1016/0009-8981(87)90250-6; RIECKMANN P, 1995, ANN NEUROL, V37, P82, DOI 10.1002/ana.410370115; Rudick RA, 1996, ANN NEUROL, V40, P618, DOI 10.1002/ana.410400412; SHENG WS, 1995, CLIN DIAGN LAB IMMUN, V2, P604, DOI 10.1128/CDLI.2.5.604-608.1995; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; STOCKER R, 1995, INTEGRATED APPROACH, P197; TEASDALE G, 1974, LANCET, V2, P81; TIBBLING G, 1977, SCAND J CLIN LAB INV, V37, P385, DOI 10.3109/00365517709091496; VANFURTH AM, 1995, CLIN INFECT DIS, V21, P220, DOI 10.1093/clinids/21.1.220; WANG P, 1994, J IMMUNOL, V153, P811; Woiciechowsky C, 1998, NAT MED, V4, P808, DOI 10.1038/nm0798-808; Wu DF, 1999, P NATL ACAD SCI USA, V96, P254, DOI 10.1073/pnas.96.1.254; Xiao BG, 1996, NEUROREPORT, V7, P1893, DOI 10.1097/00001756-199608120-00004	53	207	210	1	10	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-5728			J NEUROIMMUNOL	J. Neuroimmunol.	NOV 15	1999	101	2					211	221		10.1016/S0165-5728(99)00148-4			11	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	257LE	WOS:000083782700012	10580806				2021-06-18	
J	Matser, JT; Kessels, AGH; Jordan, BD; Lezak, MD; Troost, J				Matser, JT; Kessels, AGH; Jordan, BD; Lezak, MD; Troost, J			Chronic traumatic brain injury in professional soccer players	NEUROLOGY			English	Article							UNITED-STATES; CONCUSSION; SPORTS	Objective: To determine the presence of chronic traumatic brain injury in professional soccer players. Methods: Fifty-three active professional soccer players from several professional Dutch soccer clubs were compared with a control group of 27 elite noncontact sport athletes. All participants underwent neuropsychological examination. The main outcome measures were neuropsychological tests proven to be sensitive to cognitive changes incurred during contact and collision sports. Results: The professional soccer players exhibited impaired performances in memory, planning, and visuoperceptual processing when compared with control subjects. Among professional soccer players, performance on memory, planning, and visuoperceptual tasks were inversely related to the number of concussions incurred in soccer and the frequency of 'heading' the ball. Performance on neuropsychological testing also varied according to field position, with forward and defensive players exhibiting more impairment. Conclusion: Participation in professional soccer may affect adversely some aspects of cognitive functioning (i.e., memory, planning, and visuoperceptual processing).	St Anna Hosp, Dept Neuropsychol & Sports Neurol, NL-5660 AB Geldrop, Netherlands; Univ Maastricht, Dept Epidemiol, Maastricht, Netherlands; Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA USA; Charles R Drew Univ Med & Sci, Biobehav Res Ctr, Los Angeles, CA 90059 USA; Oregon Hlth Sci Univ, Dept Neurol, Portland, OR 97201 USA; Univ Hosp Maastricht, Dept Neurol, Maastricht, Netherlands	Matser, JT (corresponding author), St Anna Hosp, Dept Neuropsychol & Sports Neurol, POB 90, NL-5660 AB Geldrop, Netherlands.						American Academy of Pediatrics, 1988, PHYSICIAN SPORTSMED, V16, P165; Benton A.L., 1983, CONTRIBUTIONS NEUROP; Berg EA, 1948, J GEN PSYCHOL, V39, P15, DOI 10.1080/00221309.1948.9918159; CORSELLIS JA, 1976, LANCET, V1, P401; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; Deelman B, 1980, NEUROPSYCHOLOGIE NED; DEMARCO J, 1994, JAMA-J AM MED ASSOC, V271, P1233; Golden C., 1978, STROOP COLOR WORD TE; GRONWALL D, 1975, LANCET, V2, P995; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HUGHES R, 1974, SUNDAY TIMES LO 1110; JORDAN BD, 1987, ARCH NEUROL-CHICAGO, V44, P453, DOI 10.1001/archneur.1987.00520160083020; Jordan BD, 1996, PHYSICIAN SPORTSMED, V24, P87, DOI 10.3810/psm.1996.05.1358; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Keller D., 1979, LEISTUNGSSPORT, V9, P394; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Lauter J, 1996, BIOMETRICS, V52, P964, DOI 10.2307/2533057; Luteyn F, 1966, DUTCH J PSYCHOL, V2, P675; MATSER JT, 1996, GENEESKUNDE SPORT, V29, P66; MATSER JT, 1992, PSYCHOLOOG, V12, P515; MENDEZ MF, 1995, INT J PSYCHIAT MED, V25, P249, DOI 10.2190/CUMK-THT1-X98M-WB4C; MUELLER FO, 1990, MED SCI SPORT EXER, V22, P737, DOI 10.1249/00005768-199012000-00001; OBRIEN PC, 1984, BIOMETRICS, V40, P1079, DOI 10.2307/2531158; Osterrieth PA, 1944, ARCH PSYCHOLOGIE, V30, P206; Raven J., 1960, GUIDE STANDARD PROGR; ROBBERTS AH, 1969, BRAIN DAMAGE BOXERS; SORTLAND O, 1989, NEURORADIOLOGY, V31, P44; Spreen O., 1991, COMPENDIUM NEUROPSYC; *STAT 150 AFF NAT, 1982, FIFA NEWS, V235, P538; Tysvaer A, 1981, Br J Sports Med, V15, P163; TYSVAER AT, 1989, ACTA NEUROL SCAND, V80, P151, DOI 10.1111/j.1600-0404.1989.tb03858.x; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; Van De Loo L., 1956, TIJIKSCHRIFT PSYCHOL, V2, P33; VANDERVLUGT H, 1979, LATERALISATIES HERSE; VONSCHNEIDER PG, 1975, SPORTARTZ SPORTMEDIZ, V26, P222; Wechsler, 1981, WAIS R MANUAL; Wechsler D, 1974, WECHSLER MEMORY SCAL; WITOL A, 1994, ARCH CLIN NEUROPSYCH, V9, P104	38	207	210	0	27	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0028-3878			NEUROLOGY	Neurology	SEP	1998	51	3					791	796		10.1212/WNL.51.3.791			6	Clinical Neurology	Neurosciences & Neurology	119LR	WOS:000075898300028	9748028				2021-06-18	
J	GRONWALL, D; WRIGHTSON, P				GRONWALL, D; WRIGHTSON, P			MEMORY AND INFORMATION-PROCESSING CAPACITY AFTER CLOSED HEAD-INJURY	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article										GRONWALL, D (corresponding author), AUCKLAND HOSP,DEPT NEUROSURG,AUCKLAND,NEW ZEALAND.						AMMONS RB, 1962, PSYCHOL REP S1; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; Gorsuch R. L., 1974, FACTOR ANAL; GRONWALL D, 1976, Proceedings of the Australian Association of Neurologists, V13, P143; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; GRONWALL D, 1974, LANCET, V2, P995; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; KIRK S, 1968, EXAMINERS MANUAL ILL; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; MANDLEBERG IA, 1976, J NEUROL NEUROSUR PS, V39, P1001, DOI 10.1136/jnnp.39.10.1001; MANDLEBERG IA, 1975, J NEUROL NEUROSUR PS, V38, P1121, DOI 10.1136/jnnp.38.11.1121; RUSSELL WR, 1946, BRAIN, V69, P280, DOI 10.1093/brain/69.4.280; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Siegel S., 1956, NONPARAMETRIC STAT B; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3	17	207	208	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry		1981	44	10					889	895		10.1136/jnnp.44.10.889			7	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	MU445	WOS:A1981MU44500004	7310407	Bronze, Green Published			2021-06-18	
J	Meehan, WP; d'Hemecourt, P; Comstock, RD				Meehan, William P., III; d'Hemecourt, Pierre; Comstock, R. Dawn			High School Concussions in the 2008-2009 Academic Year Mechanism, Symptoms, and Management	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						concussion; sport-related concussion; mild traumatic brain injury; athletic injury; sports	CHRONIC TRAUMATIC ENCEPHALOPATHY; COLLEGIATE FOOTBALL PLAYERS; INTERNATIONAL-CONFERENCE; UNITED-STATES; HEAD IMPACTS; SPORT; PERFORMANCE; INJURIES; EPIDEMIOLOGY; BIOMECHANICS	Background: An estimated 136 000 concussions occur per academic year in high schools alone. The effects of repetitive concussions and the potential for catastrophic injury have made concussion an injury of significant concern for young athletes. Purpose: The objective of this study was to describe the mechanism of injury, symptoms, and management of sport-related concussions using the High School Reporting Information Online (HS RIO) surveillance system. Study Design: Descriptive epidemiology study. Methods: All concussions recorded by HS RIO during the 2008-2009 academic year were included. Analyses were performed using SPSS software. Chi-square analysis was performed for all categorical variables. Statistical significance was considered for P < .05. Results: A total of 544 concussions were recorded. The most common mechanism (76.2%) was contact with another player, usually a head-to-head collision (52.7%). Headache was experienced in 93.4%; 4.6% lost consciousness. Most (83.4%) had resolution of their symptoms within 1 week. Symptoms lasted longer than 1 month in 1.5%. Computerized neuropsychological testing was used in 25.7% of concussions. When neuropsychological testing was used, athletes were less likely to return to play within 1 week than those for whom it was not used (13.6% vs 32.9%; P< .01). Athletes who had neuropsychological testing appeared less likely to return to play on the same day (0.8% vs 4.2%; P = .056). A greater proportion of injured, nonfootball athletes had computerized neuropsychological testing than injured football players (23% vs 32%; P = .02) Conclusion: When computerized neuropsychological testing is used, high school athletes are less likely to be returned to play within 1 week of their injury. Concussed football players are less likely to have computerized neuropsychological testing than those participating in other sports. Loss of consciousness is relatively uncommon among high school athletes who sustain a sport-related concussion. The most common mechanism is contact with another player. Some athletes (1.5%) report symptoms lasting longer than 1 month.	[Meehan, William P., III; d'Hemecourt, Pierre; Comstock, R. Dawn] Childrens Hosp Boston, Div Sports Med, Sports Concuss Clin, Boston, MA 02115 USA	Meehan, WP (corresponding author), Childrens Hosp Boston, Div Sports Med, Sports Concuss Clin, 319 Longwood Ave, Boston, MA 02115 USA.	william.meehan@childrens.harvard.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [L40 NS071604-01] Funding Source: Medline		ALVES WM, 1987, CLIN SPORT MED, V6, P211; Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Cantu RC, 2007, NEUROSURGERY, V61, P223, DOI 10.1227/01.NEU.0000255514.73967.90; Cantu RC, 2009, NEUROSURGERY, V64, P786, DOI 10.1227/01.NEU.0000348539.13887.D3; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Comstock R. D., 2006, Morbidity and Mortality Weekly Report, V55, P1037; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gessel LM, 2007, J ATHL TRAINING, V42, P495; GRONWALL D, 1975, LANCET, V2, P995; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; McCaffrey MA, 2007, NEUROSURGERY, V61, P1236, DOI 10.1227/01.neu.0000306102.91506.8b; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Rechel JA, 2008, J ATHL TRAINING, V43, P197, DOI 10.4085/1062-6050-43.2.197; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Shankar PR, 2007, AM J SPORT MED, V35, P1295, DOI 10.1177/0363546507299745; Sullivan SJ, 2009, CLIN J SPORT MED, V19, P228, DOI 10.1097/JSM.0b013e3181a41e43; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0	30	206	207	0	30	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	DEC	2010	38	12					2405	2409		10.1177/0363546510376737			5	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	688FE	WOS:000284834400007	20716683	Green Accepted			2021-06-18	
J	Wozniak, JR; Krach, L; Ward, E; Mueller, BA; Muetzel, R; Schnoebelen, S; Kiragu, A; Lim, KO				Wozniak, Jeffrey R.; Krach, Linda; Ward, Erin; Mueller, Bryon A.; Muetzel, Ryan; Schnoebelen, Sarah; Kiragu, Andrew; Lim, Kelvin O.			Neurocognitive and neuroimaging correlates of pediatric traumatic brain injury: A diffusion tensor imaging (DTI) study	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						traumatic brain injury (TBI); diffusion tensor imaging (DTI); white matter; pediatric	CLOSED-HEAD-INJURY; ANISOTROPIC WATER DIFFUSION; AXONAL INJURY; CORPUS-CALLOSUM; WORKING-MEMORY; NEUROPSYCHOLOGICAL OUTCOMES; CHILDHOOD; CHILDREN; MILD; RECOVERY	This study examined the sensitivity of diffusion tensor imaging (DTI) to microstructural white matter (W/M) damage in mild and moderate pediatric traumatic brain injury (TBI). Fourteen children with TBI and 14 controls ages 10-18 had DTI scans and neurocognitive evaluations at 6-12 months post-injury. Groups did not differ in intelligence, but children with TBI showed slower processing speed. working memory and executive deficits, and greater behavioral dysregulation. The TBI group had lower fractional anisotropy (FA) in three WM regions: inferior frontal, superior frontal, and supracallosal. There were no group differences in corpus callosum. FA in the frontal and supracallosal regions was correlated with executive functioning. Supracallosal FA was also correlated with motor speed. Behavior ratings showed correlations with supracallosal FA. Parent-reported executive deficits were inversely correlated with FA. Results suggest that DTI measures are sensitive to long-term WM changes and associated with cognitive functioning following pediatric TBI. (C) 2007 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	Univ Minnesota, Med Ctr, Dept Psychiat, St Paul, MN USA; Gillette Childrens Specialty Healthcare, St Paul, MN USA; Hennepin Cty Med Ctr, Minneapolis, MN USA; Childrens Med Ctr, Dallas, TX 75235 USA	Wozniak, JR (corresponding author), Univ Minnesota, Dept Psychiat, F256-2B W,2450 Riverside Ave, Minneapolis, MN 55454 USA.	jwozniak@umn.edu	Kiragu, Andrew/G-1978-2019; Lim, Kelvin/AAF-6833-2020	Kiragu, Andrew/0000-0002-1067-2922; Krach, Linda/0000-0002-0993-8199; Lim, Kelvin/0000-0002-2390-7268; Wozniak, Jeffrey/0000-0002-7132-8519	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41 RR008079-13, M01 RR000400, P41 RR008079, M01 RR000400-397968, P41 RR 008079, M01 RR000400-416998, M01 RR000400-407508] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30 NS057091-04, P30 NS057091-01, P30 NS057091-03, P30 NS057091-02, P30 NS057091, P30 NS 057091, P30 NS057091-05] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000400, P41RR008079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS057091] Funding Source: NIH RePORTER		Anderson V, 1998, BRAIN INJURY, V12, P937, DOI 10.1080/026990598121990; Anderson V, 2005, BRAIN INJURY, V19, P699, DOI 10.1080/02699050400025281; Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; Ashtari M, 2005, BIOL PSYCHIAT, V57, P448, DOI 10.1016/j.biopsych.2004.11.047; Basser PJ, 1995, NMR BIOMED, V8, P333, DOI 10.1002/nbm.1940080707; Basser PJ, 2002, NMR BIOMED, V15, P456, DOI 10.1002/nbm.783; BAWDEN HN, 1985, J CLIN EXP NEUROPSYC, V7, P39, DOI 10.1080/01688638508401241; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Ben Bashat D, 2005, J MAGN RESON IMAGING, V21, P503, DOI 10.1002/jmri.20281; Benton AL, 1983, MULTILINGUAL APHASIA; Bigler ED, 1999, J HEAD TRAUMA REHAB, V14, P406, DOI 10.1097/00001199-199908000-00009; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Catroppa C, 2002, BRAIN INJURY, V16, P369, DOI 10.1080/02699050110104444; *CDCP, 2006, TRAUM BRAIN INJ; Culbertson W. C., 2000, TOWER LONDON; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; Donders J, 1997, CHILD NEUROPSYCHOL, V3, P71, DOI 10.1080/09297049708401369; Donders J, 2000, J HEAD TRAUMA REHAB, V15, P792, DOI 10.1097/00001199-200004000-00004; ELUVATHINGAL TJ, 2007, CEREB CORTEX, DOI DOI 10.1093/CECOR/BHM003; Ewing-Cobbs L, 2006, AM J NEURORADIOL, V27, P879; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; EWINGCOBBS L, 1998, TRAUMATIC BRAIN INJU, P11; Ezaki Y, 2006, ACTA RADIOL, V47, P733, DOI 10.1080/02841850600771486; FARMER MY, 1987, PEDIATR NEUROSCI, V13, P304, DOI 10.1159/000120348; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; Fenwick T, 1999, CHILD NEUROPSYCHOL, V5, P213, DOI 10.1076/0929-7049(199912)05:04;1-R;FT213; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GIOIA GA, 2000, BEAHV RATING INVENTO; Golden CJ, 1998, STROOP COLOR WORD TE; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; Heaton R., 1981, MANUAL WISCONSIN CAR; Hermoye L, 2006, NEUROIMAGE, V29, P493, DOI 10.1016/j.neuroimage.2005.08.017; Hoffman N, 2000, ARCH CLIN NEUROPSYCH, V15, P47, DOI 10.1016/S0887-6177(98)00156-5; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Hurley RA, 2004, J NEUROPSYCH CLIN N, V16, P1, DOI 10.1176/appi.neuropsych.16.1.1; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee ZI, 2003, AM J PHYS MED REHAB, V82, P556, DOI 10.1097/01.PHM.0000073830.15643.6A; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; Levin HS, 2004, J INT NEUROPSYCH SOC, V10, P305, DOI 10.1017/S1355617704102129; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; LEVINHS, 2000, NEUROLOGY, V54, P647; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Liston C, 2006, CEREB CORTEX, V16, P553, DOI 10.1093/cercor/bhj003; Mabbott DJ, 2006, NEUROIMAGE, V33, P936, DOI 10.1016/j.neuroimage.2006.07.024; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; MOSELEY ME, 1990, RADIOLOGY, V176, P439, DOI 10.1148/radiology.176.2.2367658; Naganawa S, 2004, AM J NEURORADIOL, V25, P1553; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Neil J, 2002, NMR BIOMED, V15, P543, DOI 10.1002/nbm.784; Povlishock J T, 2000, Clin Neurosurg, V46, P113; Reynolds C.R., 2004, BEHAV ASSESSMENT SYS; RIETAN RM, 1985, HALSTEAD REITAN NEUR; Roncadin C, 2004, DEV NEUROPSYCHOL, V25, P21; Salat DH, 2005, ANN NY ACAD SCI, V1064, P37, DOI 10.1196/annals.1340.009; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Salorio CF, 2005, J INT NEUROPSYCH SOC, V11, P686, DOI 10.1017/S1355617705050885; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Takaoka M, 2002, J NEUROL NEUROSUR PS, V73, P289, DOI 10.1136/jnnp.73.3.289; Taylor HG, 2004, DEV NEUROPSYCHOL, V25, P199, DOI 10.1207/s15326942dn2501&2_11; TEASDALE G, 1974, LANCET, V2, P81; Warschausky S, 2005, NEUROPSYCHOLOGY, V19, P193, DOI 10.1037/0894-4105.19.2.193; Wechsler D., 2003, WECHSLER INTELLIGENC; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wozniak JR, 2006, NEUROSCI BIOBEHAV R, V30, P762, DOI 10.1016/j.neubiorev.2006.06.003; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514; Yeates KO, 2001, J PEDIATR PSYCHOL, V26, P79, DOI 10.1093/jpepsy/26.2.79; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	83	206	209	1	27	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JUN	2007	22	5					555	568		10.1016/j.acn.2007.03.004			14	Psychology, Clinical; Psychology	Psychology	191YZ	WOS:000248169200001	17446039	Green Accepted, Bronze			2021-06-18	
J	McHugh, GS; Engel, DC; Butcher, I; Steyerberg, EW; Lu, J; Mushkudiani, N; Hernandez, AV; Marmarou, A; Maas, AIR; Murray, GD				McHugh, Gillian S.; Engel, Doortje C.; Butcher, Isabella; Steyerberg, Ewout W.; Lu, Juan; Mushkudiani, Nino; Hernandez, Adrian V.; Marmarou, Anthony; Maas, Andrew I. R.; Murray, Gordon D.			Prognostic value of secondary insults in traumatic brain injury: results from the IMPACT study	JOURNAL OF NEUROTRAUMA			English	Article						GOS; hypotension; hypothermia; hypoxia; prognosis	SEVERE HEAD-INJURY; HYPOTHERMIA; HYPOXIA; TRIAL	We determined the relationship between secondary insults (hypoxia, hypotension, and hypothermia) occurring prior to or on admission to hospital and 6-month outcome after traumatic brain injury (TBI). A meta-analysis of individual patient data, from seven Phase III randomized clinical trials (RCT) in moderate or severe TBI and three TBI population-based series, was performed to model outcome as measured by the Glasgow Outcome Scale (GOS). Proportional odds modeling was used to relate the probability of a poor outcome to hypoxia (N = 5661), hypotension (N = 6629), and hypothermia (N = 4195) separately. We additionally analyzed the combined effects of hypoxia and hypotension and performed exploratory analysis of associations with computerized tomography (CT) classification and month of injury. Having a pre-enrollment insult of hypoxia, hypotension or hypothermia is strongly associated with a poorer outcome (odds ratios of 2.1 95% CI [1.7-2.6], 2.7 95% CI [2.1-3.4], and 2.2 95%* CI [1.6-3.2], respectively). Patients with both hypoxia and hypotension had poorer outcomes than those with either insult alone. Radiological signs of raised intracranial pressure (CT class III or IV) were more frequent in patients who had sustained hypoxia or hypotension. A significant association was observed between month of injury and hypothermia. The occurrence of secondary insults prior to or on admission to hospital in TBI patients is strongly related to poorer outcome and should therefore be a priority for emergency department personnel.	Univ Edinburgh, Sch Med, Edinburgh EH8 9AG, Midlothian, Scotland; Erasmus MC, Dept Neurosurg, Rotterdam, Netherlands; Erasmus MC, Ctr Med Decis Making, Dept Publ Hlth, Rotterdam, Netherlands; Virginia Commonwealth Univ, Med Ctr, Dept Neurosurg, Richmond, VA USA	McHugh, GS (corresponding author), Univ Edinburgh, Sch Med, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.	Gillian.McHugh@ed.ac.uk	Maas, Andrew IR/C-5584-2013; Steyerberg, Ewout/C-1509-2018	Maas, Andrew IR/0000-0003-1612-1264; Lu, Juan/0000-0002-5389-7603; Murray, Gordon/0000-0001-9866-4734; Hernandez, Adrian V./0000-0002-9999-4003; Steyerberg, Ewout/0000-0002-7787-0122	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042691] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-042691] Funding Source: Medline		Butcher I, 2007, J NEUROTRAUM, V24, P294, DOI 10.1089/neu.2006.0032; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; JENNETT B, 1975, LANCET, V1, P480; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; McHugh GS, 2007, J NEUROTRAUM, V24, P251, DOI 10.1089/neu.2006.0026; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; STEINEMANN S, 1990, J TRAUMA, V30, P200, DOI 10.1097/00005373-199002000-00011; Strachan R D, 1989, Brain Inj, V3, P51, DOI 10.3109/02699058909008073; Walia S, 2002, INJURY, V33, P339, DOI 10.1016/S0020-1383(02)00053-0; Young B, 1996, JAMA-J AM MED ASSOC, V276, P538, DOI 10.1001/jama.276.7.538; Zauner A, 1998, NEUROL RES, V20, pS85	17	206	214	0	7	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	FEB	2007	24	2					287	293		10.1089/neu.2006.0031			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	150AL	WOS:000245187900008	17375993				2021-06-18	
J	Bondanelli, M; De Marinis, L; Ambrosio, MR; Monesi, M; Valle, D; Zatelli, MC; Fusco, A; Bianchi, A; Farneti, M; Uberti, ECD				Bondanelli, M; De Marinis, L; Ambrosio, MR; Monesi, M; Valle, D; Zatelli, MC; Fusco, A; Bianchi, A; Farneti, M; Uberti, ECD			Occurrence of pituitary dysfunction following traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						growth hormone deficiency; pituitary function; traumatic brain injury	GROWTH-HORMONE; HYPOPITUITARISM; AXIS; GH; REPLACEMENT; RESPONSES; TESTS	Traumatic brain injury (TBI) may be associated with impairment of pituitary hormone secretion, which may contribute to long-term physical, cognitive, and psychological disability. We studied the occurrence and risk factors of pituitary dysfunction, including growth hormone deficiency (GHD) in 50 patients (mean age 37.6 +/- 2.4 years; 40 males, age 20-60 years; 10 females, age 23-87 years) with TBI over 5 years. Cranial or facial fractures were documented in 12 patients, and neurosurgery was performed in 14. According to the Glasgow Coma Scale (GCS), 16 patients had suffered from mild, 7 moderate, and 27 severe TBI. Glasgow Outcome Scale (GOS) indicated severe disability in 5, moderate disability in 11, and good recovery in 34 cases. Basal pituitary hormone evaluation, performed once at times variable from 12 to 64 months after TBI, showed hypogonadotrophic hypogonadism in 7 (14%), central hypothyroidism in 5 (10%), low prolactin (PRL) levels in 4 (8%), and high PRL levels in 4 (8%) cases. All subjects had normal corticotrophic and posterior pituitary function. Seven patients showed low insulin-like growth factor-I (IGF-1) levels for age and sex. Results of GHRH plus arginine testing indicated partial GHD in 10 (20%) and severe GHD in 4 (8%) cases. Patients with GHD were older (p < 0.05) than patients with normal GH secretion. Magnetic resonance imaging demonstrated pituitary abnormalities in 2 patients; altogether pituitary dysfunction was observed in 27 (54%) patients. Six patients (12%) showed a combination of multiple abnormalities. Occurrence of pituitary dysfunction was 37.5%, 57.1%, and 59.3% in the patients with mild, moderate, and severe TBI, respectively. GCS scores were significantly (p < 0.02) lower in patients with pituitary dysfunction compared to those with normal pituitary function (8.3 +/- 0.5 vs. 10.2 +/- 0.6). No relationship was detected between pituitary dysfunction and years since TBI, type of injury, and outcome from TBI. In conclusion, subjects with a history of TBI frequently develop pituitary dysfunction, especially GHD. Therefore, evaluation of pituitary hormone secretion, including GH, should be included in the long-term follow-up of all TBI patients so that adequate hormone replacement therapy may be administered.	Univ Ferrara, Dept Biomed Sci & Adv Therapies, Endocrinol Sect, I-44100 Ferrara, Italy; Univ Cattolica Sacro Cuore, Inst Endocrinol, Rome, Italy; St Anna Hosp, Div Neurosurg, Ferrara, Italy	Uberti, ECD (corresponding author), Univ Ferrara, Dept Biomed Sci & Adv Therapies, Endocrinol Sect, Via Savonarola 9, I-44100 Ferrara, Italy.	ti8@unife.it	Zatelli, Maria Chiara/Y-1160-2019; Zatelli, Maria Chiara/U-2649-2018	degli Uberti, Ettore/0000-0002-9441-7223; Zatelli, Maria Chiara/0000-0001-8408-7796; ambrosio, maria rosaria/0000-0002-7911-9770; Bondanelli, Marta/0000-0001-8071-6559			Aimaretti G, 1998, J CLIN ENDOCR METAB, V83, P1615, DOI 10.1210/jc.83.5.1615; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Biller BMK, 2002, J CLIN ENDOCR METAB, V87, P2067, DOI 10.1210/jcem.87.5.8509; BISTRITZER T, 1981, AM J DIS CHILD, V135, P966, DOI 10.1001/archpedi.1981.02130340070022; Bondanelli M, 2002, METABOLISM, V51, P1363, DOI 10.1053/meta.2002.34714; Cernak I, 1999, BRAIN INJURY, V13, P1005; CLARK JDA, 1988, CLIN ENDOCRINOL, V29, P153, DOI 10.1111/j.1365-2265.1988.tb00257.x; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; Cyran E, 1918, DEUT MED WOCHENSCHR, V44, P1261; CYTOWIC RE, 1986, NEW ENGL J MED, V314, P715; DANIEL PM, 1959, LANCET, V2, P927; De Marinis L, 1999, CLIN ENDOCRINOL, V50, P741; Della Corte F, 1998, CRIT CARE MED, V26, P1419; EDWARDS OM, 1986, MEDICINE, V65, P281; GHIGO E, 1990, J CLIN ENDOCR METAB, V71, P874; Gilchrist FJ, 2002, CLIN ENDOCRINOL, V57, P363, DOI 10.1046/j.1365-2265.2002.01608.x; Giustina A, 1998, ENDOCR REV, V19, P717, DOI 10.1210/er.19.6.717; HACKL JM, 1991, INTENS CARE MED, V17, P25, DOI 10.1007/BF01708405; Hartman ML, 1998, GROWTH HORM IGF RES, V8, P25, DOI 10.1016/S1096-6374(98)80005-1; JENNETT B, 1975, LANCET, V1, P480; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Nyberg F, 2000, FRONT NEUROENDOCRIN, V21, P330, DOI 10.1006/frne.2000.0200; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Salazar, 2000, JAMA, V284, P1783; Scheepens A, 2000, J PEDIATR ENDOCR MET, V13, P1483; Scheepens A, 2001, NEUROSCIENCE, V104, P677, DOI 10.1016/S0306-4522(01)00109-9; Simpson H, 2002, GROWTH HORM IGF RES, V12, P1, DOI 10.1054/ghir.2001.0263; TEASDALE G, 1974, LANCET, V2, P81; Valetto MR, 1996, EUR J ENDOCRINOL, V135, P568, DOI 10.1530/eje.0.1350568; WOOLF PD, 1992, CRIT CARE MED, V20, P216, DOI 10.1097/00003246-199202000-00011; ZADIK Z, 1985, J CLIN ENDOCR METAB, V60, P513, DOI 10.1210/jcem-60-3-513	33	206	214	0	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2004	21	6					685	696		10.1089/0897715041269713			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	836EG	WOS:000222537600005	15253797				2021-06-18	
J	Khan, F; Baguley, IJ; Cameron, ID				Khan, F; Baguley, IJ; Cameron, ID			4: Rehabilitation after traumatic brain injury	MEDICAL JOURNAL OF AUSTRALIA			English	Article							COMMUNITY	Traumatic brain injury (TBI) commonly affects younger people and causes life-long impairments in physical, cognitive, behavioural and social function. The cognitive, behavioural and personality deficits are usually more disabling than the residual physical deficits. Recovery from TBI can continue for at least 5 years after injury. Rehabilitation is effective using an interdisciplinary approach, and close liaison with the patient, family and carers. The focus is on issues such as retraining in activities of daily living, pain management, cognitive and behavioural therapies, and pharmacological management. The social burden of TBI is significant, and therefore family education and counselling, and support of patient and carers, is important. General practitioners play an important role in providing ongoing support in the community, monitoring for medical complications, behavioural and personality issues, social reintegration, carer coping skills and return-to-work issues.	Univ Melbourne, Dept Med, Melbourne, Vic 3010, Australia; Westmead Hosp, Brain Injury Rehab Serv, Sydney, NSW, Australia; Univ Sydney, Rehab Studies Unit, Ryde, NSW, Australia	Khan, F (corresponding author), Univ Melbourne, Dept Med, Melbourne, Vic 3010, Australia.		Baguley, Ian/AAM-5828-2021; Baguley, Ian J/K-6878-2013	Baguley, Ian J/0000-0001-5650-3705			Bell KR, 1998, ARCH PHYS MED REHAB, V79, pS21, DOI 10.1016/S0003-9993(98)90116-2; CHESNUT RM, 1999, 2 AG HLTH CAR POL RE, P1; COCKRELL J, 1996, MED REABILITATION TR, P171; FORTUNE N, 1999, 15 DIS AUSTR I HLTH; HORN LJ, 1992, PHYS MED REHAB CLIN, V3, P475; JENNETT B, 1975, LANCET, V1, P480; JOSEPH AB, 1995, J HEAD TRAUMA REHAB, V10, P90, DOI 10.1097/00001199-199504000-00010; KATZ DI, 1992, J HEAD TRAUMA REHAB, V7, P1; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; Mateer CA, 2000, NEUROPSYCHOLOGICAL M, P3; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Powell J, 2002, J NEUROL NEUROSUR PS, V72, P193, DOI 10.1136/jnnp.72.2.193; ROSENTHAL M, 1990, REHABILITATION ADULT; Sandel ME, 1998, ARCH PHYS MED REHAB, V79, pS3, DOI 10.1016/S0003-9993(98)90113-7; SCHIERHOUT G, 2003, COCHRANE LIB; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; STEVENS M, 1982, POST CONCUSSION SYND; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; *US NIH, 1998, NIH CONS STAT 1998 O, V16, P1	21	206	214	0	10	AUSTRALASIAN MED PUBL CO LTD	SYDNEY	LEVEL 1, 76 BERRY ST, SYDNEY, NSW 2060, AUSTRALIA	0025-729X			MED J AUSTRALIA	Med. J. Aust.	MAR 17	2003	178	6					290	+		10.5694/j.1326-5377.2003.tb05199.x			7	Medicine, General & Internal	General & Internal Medicine	667FL	WOS:000182220500014	12633489				2021-06-18	
J	McDowell, S; Whyte, J; DEsposito, M				McDowell, S; Whyte, J; DEsposito, M			Working memory impairments in traumatic brain injury: evidence from a dual task paradigm	NEUROPSYCHOLOGIA			English	Article						executive function; frontal lobes; traumatic brain injury; working memory	FRONTAL-LOBE LESIONS; REPEATED-MEASURES DESIGNS; CLOSED-HEAD-INJURY; UTILIZATION BEHAVIOR; COGNITIVE ESTIMATION; CORTEX; INVOLVEMENT; DAMAGE; SUPPRESSION; PERFORMANCE	Although many individuals with traumatic brain injury (TBI) perform well on standard neuropsychological tests, they often exhibit marked functional difficulties. The functions which are impaired seem to be analogous to the role of the central executive system (CES) in Baddeley's [Working Memory, 1986, Oxford University Press, New York] widely accepted model of working memory. The purpose of this study was to investigate CES function in individuals with TBI with a dual-task paradigm. We studied 25 non-demented persons who were at various stages in their recovery from severe TBI and compared their performance on a dual-task paradigm to a group of age-matched controls. Our dual-task paradigm measured performance on a simple visual reaction time task both alone (baseline) and during concurrent tasks of articulation or digit span. Subjects were also assessed with other neuropsychological tests of executive function. TBI patients had slower reaction times on the primary task when performed alone (P<0.05) and greater decrements in performance during dual-task conditions (P<0.01). They also exhibited significantly greater deficits than control subjects on other measures of executive function. Although correlations between dual-task performance and other executive measures were quite low, principle components analysis suggested that a common factor does exist between these measures. These findings support the conclusion that TBI patients have a working memory impairment that is due to dysfunction of the CES and which may be related to executive function deficits as measured by standard neuropsychological testing. (C) 1997 Elsevier Science Ltd.	MOSS REHABIL RES INST, PHILADELPHIA, PA USA; TEMPLE UNIV, SCH MED, DEPT PHYS MED & REHABIL, PHILADELPHIA, PA 19122 USA; UNIV PENN, MED CTR, DEPT NEUROL, PHILADELPHIA, PA 19104 USA				Whyte, John/0000-0002-4381-1474	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5T32HD07425] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS01762] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD007425] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS001762] Funding Source: NIH RePORTER		ADAMS JH, 1980, NEUROPATH APPL NEURO, V6, P319, DOI 10.1111/j.1365-2990.1980.tb00217.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; AKRITAS MG, 1994, J AM STAT ASSOC, V89, P336, DOI 10.2307/2291230; AKRITAS MG, 1991, J AM STAT ASSOC, V86, P457, DOI 10.2307/2290594; Anderson CV, 1995, J CLIN EXP NEUROPSYC, V17, P900, DOI 10.1080/01688639508402438; Baddeley A. D., 1994, Neuropsychology, V8, P485, DOI [10.1037/0894-4105.8.4.485., 10.1037/0894-4105.8.4.485]; Baddeley A. D., 1986, WORKING MEMORY; BADDELEY AD, 1990, NEUROPSYCHOLOGICAL I; BADDELEY AD, 1978, RECENT ADV LEARNING, P47; Benton A., 1976, MULTILINGUAL APHASIA; Burgess PW, 1996, NEUROPSYCHOLOGIA, V34, P263, DOI 10.1016/0028-3932(95)00104-2; CICERONE KD, 1983, NEUROPSYCHOLOGIA, V21, P513, DOI 10.1016/0028-3932(83)90007-6; COHEN JD, 1992, PSYCHOL REV, V99, P45, DOI 10.1037/0033-295X.99.1.45; DESPOSITO M, 1995, NATURE, V378, P279, DOI 10.1038/378279a0; DREWE E A, 1975, Cortex, V11, P8; DREWE E A, 1974, Cortex, V10, P159; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; FREEDMAN M, 1986, BEHAV NEUROSCI, V100, P337, DOI 10.1037/0735-7044.100.3.337; FUNAHASHI S, 1989, J NEUROPHYSIOL, V61, P331; Fuster J, 1989, PREFRONTAL CORTEX; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; Goldman-Rakic P. S., 1987, NERVOUS SYSTEM, P373, DOI DOI 10.1002/CPHY.CP010509; GOLDMANRAKIC PS, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P72; GOLDMANRAKIC PS, 1993, BRAIN MECHANISMS OF PERCEPTION AND MEMORY: FROM NEURON TO BEHAVIOR, P445; GOLDSTEIN FC, 1994, J NEUROL NEUROSUR PS, V57, P961, DOI 10.1136/jnnp.57.8.961; HARTMAN A, 1992, CLIN REHABIL, V6, P133; HECK ET, 1986, J CLIN EXP NEUROPSYC, V8, P313, DOI 10.1080/01688638608401321; Holbourn AHS, 1943, LANCET, V2, P438; JANOWSKY JS, 1989, BEHAV NEUROSCI, V103, P548, DOI 10.1037/0735-7044.103.3.548; KIMBERG DY, 1993, J EXP PSYCHOL GEN, V122, P411, DOI 10.1037/0096-3445.122.4.411; KNIGHT RT, 1981, ELECTROEN CLIN NEURO, V52, P571, DOI 10.1016/0013-4694(81)91431-0; KOLB B, 1981, NEUROPSYCHOLOGIA, V19, P491, DOI 10.1016/0028-3932(81)90016-6; LEVIN HS, 1976, J NEUROL NEUROSUR PS, V39, P1062, DOI 10.1136/jnnp.39.11.1062; LHERMITTE F, 1983, BRAIN, V106, P237, DOI 10.1093/brain/106.2.237; LURIA AR, 1965, BRAIN, V88, P1, DOI 10.1093/brain/88.1.1; MARTZKE JS, 1991, NEUROPSYCHOLOGY, V5, P213, DOI DOI 10.1037/0894-4105.5.3.213; MCCARTHY G, 1995, NEUROSCIENTIST, V1, P155; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; MILNER B, 1985, HUM NEUROBIOL, V4, P137; MILNER B, 1991, NEUROPSYCHOLOGIA, V29, P601, DOI 10.1016/0028-3932(91)90013-X; MILNER B, 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI 10.1001/archneur.1963.00460070100010; Milner B, 1964, FRONTAL GRANULAR COR, P313; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; Owen AM, 1996, CEREB CORTEX, V6, P31, DOI 10.1093/cercor/6.1.31; PERRET E, 1974, NEUROPSYCHOLOGIA, V12, P323, DOI 10.1016/0028-3932(74)90047-5; PETRIDES M, 1985, NEUROPSYCHOLOGIA, V23, P601, DOI 10.1016/0028-3932(85)90062-4; PETRIDES M, 1993, P NATL ACAD SCI USA, V90, P873, DOI 10.1073/pnas.90.3.873; PETRIDES M, 1993, P NATL ACAD SCI USA, V90, P878, DOI 10.1073/pnas.90.3.878; Posner MI., 1978, CHRONOMETRIC EXPLORA; REITAN RM, UNPUB INSTRUCTIONS P; SALMASO D, 1982, PERCEPT MOTOR SKILL, V54, P1147, DOI 10.2466/pms.1982.54.3c.1147; SANDSON J, 1984, NEUROPSYCHOLOGIA, V22, P715, DOI 10.1016/0028-3932(84)90098-8; SARNO MT, 1980, J NERV MENT DIS, V168, P685, DOI 10.1097/00005053-198011000-00008; SCHACTER DL, 1987, PSYCHOBIOLOGY, V15, P21; SHALLICE T, 1978, CORTEX, V14, P294, DOI 10.1016/S0010-9452(78)80055-0; SHALLICE T, 1989, BRAIN, V112, P1587, DOI 10.1093/brain/112.6.1587; SHALLICE T, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P125; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; SMITH ML, 1984, NEUROPSYCHOLOGIA, V22, P697, DOI 10.1016/0028-3932(84)90096-4; Spreen O., 1991, COMPENDIUM NEUROPSYC; Spreen O, 1969, NEUROSENSORY CTR COM; STUSS D T, 1981, Journal of Clinical Neuropsychology, V3, P13, DOI 10.1080/01688638108403110; Stuss D.T., 1986, FRONTAL LOBES; STUSS DT, 1982, J COMP PHYSIOL PSYCH, V96, P913, DOI 10.1037/0735-7036.96.6.913; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; STUSS DT, 1983, NEUROPSYCHOLOGIA, V21, P235, DOI 10.1016/0028-3932(83)90040-4; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VENDRELL P, 1995, NEUROPSYCHOLOGIA, V33, P341, DOI 10.1016/0028-3932(94)00116-7; War Department, 1944, ARM IND TEST BATT MA	70	206	210	1	17	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia	OCT	1997	35	10					1341	1353		10.1016/S0028-3932(97)00082-1			13	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	YA205	WOS:A1997YA20500003	9347480				2021-06-18	
J	Midha, R				Midha, R			Epidemiology of brachial plexus injuries in a multitrauma population	NEUROSURGERY			English	Article; Proceedings Paper	46th Annual Meeting of the Congress of Neurological Surgeons	SEP 28-OCT 03, 1996	MONTREAL, CANADA			incidence; nerve; nerve injury; prevalence; trauma	TRAUMA; FRACTURES; RECORD	OBJECTIVE: The purpose was to identify the prevalence, causative factors, injury types, and associated injury patterns in multitrauma patients who sustained brachial plexus injuries. METHODS: A retrospective review of a prospectively collected and computerized database and a chart review were performed. RESULTS: Brachial plexus injuries were identified in 54 of 4538 (1.2%) patients presenting to a regional trauma facility. Young male patients predominated. Motor vehicle accidents were the most frequent cause overall, but only 0.67% of such accidents resulted in plexus injuries. Conversely, 4.2% of motorcycle accident victims and 4.8% of snowmobile accident victims suffered brachial plexus injuries. Injuries were supraclavicular for 62% of patients and infraclavicular for 38%. Supraclavicular injuries were more likely to be severe (Sunderland Grade 3 or 4), compared with infraclavicular injuries, which were neurapraxic in 50% of cases (P < 0.01). The former therefore required surgical exploration and reconstruction more often (52 versus 17%; P < 0.05). Associated injuries included closed head injuries with loss of consciousness in 72% of patients (coma in 19%), cervical spine fractures in 13%, and clavicle, scapular, or humeral fractures and shoulder dislocations or sprains in 15 to 22%. Rib fractures were observed in 41% and were complicated by internal thoracic injuries in a similar percentage of cases. The injury severity score ranged from 5 to 59, with a mean of 24, and two patients died. CONCLUSION: Brachial plexus injuries afflict slightly more than 1% of multitrauma victims. Motorcycle and snowmobile accidents carry especially high risks, with the incidence of injury approaching 5%. Head injuries, thoracic injuries, and fractures and dislocations affecting the shoulder girdle and cervical spine are particularly common associated injuries. Supraclavicular injuries are more common, are of more severe grade, more often require surgery, and are associated with worse prognosis, compared with infraclavicular injuries.		Midha, R (corresponding author), UNIV TORONTO, SUNNYBROOK HLTH SCI CTR,DEPT SURG,DIV NEUROSURG, SUITE A131,SHSC, 2075 BAYVIEW AVE, N YORK, ON M4N 3M5, CANADA.						ANDREW T, 1978, BRIT MED J, V1, P1668, DOI 10.1136/bmj.1.6128.1668; BARNES R, 1949, J BONE JOINT SURG BR, V31, P10; BEGHI E, 1985, ANN NEUROL, V18, P320, DOI 10.1002/ana.410180308; BONNEY G, 1959, J BONE JOINT SURG BR, V41, P4; BROPHY BP, 1978, AUST NZ J SURG, V48, P528, DOI 10.1111/j.1445-2197.1978.tb00037.x; Clancy W G Jr, 1977, Am J Sports Med, V5, P209, DOI 10.1177/036354657700500508; DAVIS L, 1947, ANN SURG, V125, P647, DOI 10.1097/00000658-194705000-00011; DUBUISSON A, 1992, NEUROL CLIN, V10, P935; DUBUISSON AS, 1993, J NEUROSURG, V79, P319, DOI 10.3171/jns.1993.79.3.0319; Fletcher I, 1969, HAND, V1, P129; FRYKHOLM R, 1951, ACTA CHIR SCAND, V102, P93; GARLAND DE, 1981, CLIN ORTHOP RELAT R, V155, P162; GRUNDY DJ, 1983, INJURY, V15, P57, DOI 10.1016/0020-1383(83)90164-X; HIRASAWA Y, 1983, AM J SPORT MED, V11, P420, DOI 10.1177/036354658301100607; HOULDEN DA, 1992, J TRAUMA, V33, P244, DOI 10.1097/00005373-199208000-00014; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; Kline D G, 1991, Neurosurg Clin N Am, V2, P151; Kline DG, 1995, NERVE INJURIES OPERA; KLINE DG, 1990, PERIPHERAL NERVE LES, P396; KONDZIOLKA D, 1989, J TRAUMA, V29, P730, DOI 10.1097/00005373-198906000-00005; LEFFERT R D, 1965, J Bone Joint Surg Br, V47, P9; LUSSKIN R, 1973, J BONE JOINT SURG AM, VA 55, P1159, DOI 10.2106/00004623-197355060-00003; MCGAHAN JP, 1980, J TRAUMA, V20, P880, DOI 10.1097/00005373-198010000-00011; MIDHA R, 1996, NEUROSURGERY, V39, P646; MILLESI H, 1988, CLIN ORTHOP RELAT R, P36; MILTON G W, 1953, Aust N Z J Surg, V23, P25, DOI 10.1111/j.1445-2197.1953.tb05013.x; NARAKAS AO, 1980, INT SURG, V65, P521; PHILIP P A, 1992, Brain Injury, V6, P53, DOI 10.3109/02699059209008122; RAJU S, 1981, ARCH SURG-CHICAGO, V116, P175; SEDDON HJ, 1947, JAMA-J AM MED ASSOC, V135, P691, DOI 10.1001/jama.1947.02890110009003; SEDEL L, 1982, J BONE JOINT SURG BR, V64, P54; STONE L, 1988, CLIN ORTHOP RELAT R, V233, P136; SUNDERLAND S, 1951, BRAIN, V74, P491, DOI 10.1093/brain/74.4.491; THOMPSON DA, 1985, J TRAUMA, V25, P974, DOI 10.1097/00005373-198510000-00008; TOMASZEK DE, 1984, J TRAUMA, V24, P161, DOI 10.1097/00005373-198402000-00014; WALTERS BC, 1990, J TRAUMA, V30, P398, DOI 10.1097/00005373-199030040-00005; YEOMAN PM, 1961, J BONE JOINT SURG BR, V43, P493; 1980, BRIT MED J, V280, P1242	38	206	216	0	17	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUN	1997	40	6					1182	1188		10.1097/00006123-199706000-00014			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	XC450	WOS:A1997XC45000032	9179891				2021-06-18	
J	Kim, DK; Nishida, H; An, SY; Shetty, AK; Bartosh, TJ; Prockop, DJ				Kim, Dong-ki; Nishida, Hidetaka; An, Su Yeon; Shetty, Ashok K.; Bartosh, Thomas J.; Prockop, Darwin J.			Chromatographically isolated CD63(+) CD81(+) extracellular vesicles from mesenchymal stromal cells rescue cognitive impairments after TBI	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						MSCs; neuroinflammation; exosomes; efficacy assay	TRAUMATIC BRAIN-INJURY; ANTIINFLAMMATORY PROTEIN TSG-6; STEM-CELLS; STEM/PROGENITOR CELLS; STEM/STROMAL CELLS; NEURODEGENERATIVE DISEASE; MITOCHONDRIAL TRANSFER; CLINICAL-APPLICATIONS; PATTERN SEPARATION; DONOR VARIATION	Extracellular vesicles (EVs) secreted by cells present an attractive strategy for developing new therapies, but progress in the field is limited by several issues: The quality of the EVs varies with the type and physiological status of the producer cells; protocols used to isolate the EVs are difficult to scale up; and assays for efficacy are difficult to develop. In the present report, we have addressed these issues by using human mesenchymal stem/stromal cells (MSCs) that produce EVs when incubated in a protein-free medium, pre-selecting the preparations of MSCs with a biomarker for their potency in modulating inflammation, incubating the cells in a chemically defined protein-free medium that provided a stable environment, isolating the EVs with a scalable chromatographic procedure, and developing an in vivo assay for efficacy of the cells in suppressing neuroinflammation after traumatic brain injury (TBI) in mice. In addition, we demonstrate that i.v. infusion of the isolated EVs shortly after induction of TBI rescued pattern separation and spatial learning impairments 1 mo later.	[Kim, Dong-ki; Nishida, Hidetaka; An, Su Yeon; Shetty, Ashok K.; Bartosh, Thomas J.; Prockop, Darwin J.] Texas A&M Hlth Sci Ctr, Inst Regenerat Med Scott & White, Coll Med, Temple, TX 76502 USA	Prockop, DJ (corresponding author), Texas A&M Hlth Sci Ctr, Inst Regenerat Med Scott & White, Coll Med, Temple, TX 76502 USA.	Prockop@medicine.tamhsc.edu	Shetty, Ashok/AAT-7273-2020; Shetty, Ashok K/A-2428-2008	Shetty, Ashok/0000-0001-5049-6671; Shetty, Ashok K/0000-0001-5049-6671			Boregowda SV, 2012, STEM CELLS, V30, P975, DOI 10.1002/stem.1069; Choi H, 2011, BLOOD, V118, P330, DOI 10.1182/blood-2010-12-327353; Cuiffo BG, 2014, CELL STEM CELL, V15, P762, DOI 10.1016/j.stem.2014.10.001; Forostyak S, 2013, BIOCHIMIE, V95, P2257, DOI 10.1016/j.biochi.2013.08.004; Gibb SL, 2015, STEM CELLS, V33, P3530, DOI 10.1002/stem.2189; Gyorgy B, 2015, ANNU REV PHARMACOL, V55, P439, DOI 10.1146/annurev-pharmtox-010814-124630; Heldring N, 2015, HUM GENE THER, V26, P506, DOI 10.1089/hum.2015.072; Heneka MT, 2014, NAT REV IMMUNOL, V14, P463, DOI 10.1038/nri3705; Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299; Islam MN, 2012, NAT MED, V18, P759, DOI 10.1038/nm.2736; Joyce N, 2010, REGEN MED, V5, P933, DOI [10.2217/rme.10.72, 10.2217/RME.10.72]; Keating A, 2012, CELL STEM CELL, V10, P709, DOI 10.1016/j.stem.2012.05.015; Kocsis JD, 2012, PROG BRAIN RES, V201, P79, DOI 10.1016/B978-0-444-59544-7.00005-6; Kramann R, 2015, CELL STEM CELL, V16, P51, DOI 10.1016/j.stem.2014.11.004; Lee RH, 2014, P NATL ACAD SCI USA, V111, P16766, DOI 10.1073/pnas.1416121111; Lee RH, 2009, CELL STEM CELL, V5, P54, DOI 10.1016/j.stem.2009.05.003; Leutgeb S, 2007, LEARN MEMORY, V14, P745, DOI 10.1101/lm.703907; Lim PK, 2010, CURR MED CHEM, V17, P2159, DOI 10.2174/092986710791299894; Liu KD, 2014, ANN INTENSIVE CARE, V4, DOI 10.1186/s13613-014-0022-z; Lo Cicero A, 2015, CURR OPIN CELL BIOL, V35, P69, DOI 10.1016/j.ceb.2015.04.013; Loane David J, 2015, Handb Clin Neurol, V127, P343, DOI 10.1016/B978-0-444-52892-6.00022-2; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Montzka K, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-16; Oh JY, 2012, MOL THER, V20, P2143, DOI 10.1038/mt.2012.165; Oh JY, 2010, P NATL ACAD SCI USA, V107, P16875, DOI 10.1073/pnas.1012451107; Ohtaki H, 2008, P NATL ACAD SCI USA, V105, P14638, DOI 10.1073/pnas.0803670105; Oksvold MP, 2015, METHODS MOL BIOL, V1218, P465, DOI 10.1007/978-1-4939-1538-5_27; Pati S, 2011, STEM CELLS DEV, V20, P89, DOI 10.1089/scd.2010.0013; Peng WJ, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0034-0; Phinney DG, 1999, J CELL BIOCHEM, V75, P424, DOI 10.1002/(SICI)1097-4644(19991201)75:3<424::AID-JCB8>3.3.CO;2-#; Phinney DG, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9472; Pochampally RR, 2004, BLOOD, V103, P1647, DOI 10.1182/blood-2003-06-1967; Prockop DJ, 2012, STEM CELLS, V30, P1051, DOI 10.1002/stem.1103; Prockop DJ, 2012, MOL THER, V20, P14, DOI 10.1038/mt.2011.211; Prockop DJ, 2010, J CELL MOL MED, V14, P2190, DOI 10.1111/j.1582-4934.2010.01151.x; Qu CS, 2008, BRAIN RES, V1208, P234, DOI 10.1016/j.brainres.2008.02.042; Reis C, 2015, INT J MOL SCI, V16, P11903, DOI 10.3390/ijms160611903; Schwarz EJ, 1999, HUM GENE THER, V10, P2539, DOI 10.1089/10430349950016870; Sekiya I, 2002, STEM CELLS, V20, P530, DOI 10.1634/stemcells.20-6-530; Sekiya I, 2015, CLIN ORTHOP RELAT R, V473, P2316, DOI 10.1007/s11999-015-4324-8; Sharma RR, 2014, TRANSFUSION, V54, P1418, DOI 10.1111/trf.12421; Siddappa R, 2007, J ORTHOP RES, V25, P1029, DOI 10.1002/jor.20402; Spees JL, 2006, P NATL ACAD SCI USA, V103, P1283, DOI 10.1073/pnas.0510511103; Uccelli A, 2011, BEST PRACT RES CL HA, V24, P59, DOI 10.1016/j.beha.2011.01.004; Vallabhaneni KC, 2015, ONCOTARGET, V6, P4953, DOI 10.18632/oncotarget.3211; Yanez-Mo M, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.27066; Yassa MA, 2011, TRENDS NEUROSCI, V34, P515, DOI 10.1016/j.tins.2011.06.006; Zhang R, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-106; Zhang YL, 2015, J NEUROSURG, V122, P856, DOI 10.3171/2014.11.JNS14770	50	205	213	1	25	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	JAN 5	2016	113	1					170	175		10.1073/pnas.1522297113			6	Multidisciplinary Sciences	Science & Technology - Other Topics	DA0XH	WOS:000367520400051	26699510	Green Published, Bronze			2021-06-18	
J	Colvin, AC; Mullen, J; Lovell, MR; West, RV; Collins, MW; Groh, M				Colvin, Alexis Chiang; Mullen, Jimmy; Lovell, Mark R.; West, Robin Vereeke; Collins, Micky W.; Groh, Megan			The Role of Concussion History and Gender in Recovery From Soccer-Related Concussion	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article; Proceedings Paper	34th Annual Meeting of the American-Orthopaedic-Society-for-Sports-Medicine	JUL, 2008	Orlando, FL	Amer Orthopaed Soc Sports Med		concussion; gender; soccer	INJURY SURVEILLANCE SYSTEM; SEX-DIFFERENCES; NEUROPSYCHOLOGICAL FUNCTION; DESCRIPTIVE EPIDEMIOLOGY; FOOTBALL PLAYERS; BRAIN-INJURY; SYMPTOMS; IMPACT; RISK; SPORT	Background: This study was designed to investigate differences in recovery in male and female soccer athletes. Hypotheses: Soccer players with a history of concussion will perform worse on neurocognitive testing than players without a history of concussion. Furthermore, female athletes will demonstrate poorer performance on neurocognitive testing than male athletes. Study Design: Cohort study (prognosis): Level of evidence, 2. Methods: Computer-based neuropsychological testing using reaction time, memory, and visual motor-speed composite scores of the ImPACT test battery was performed postconcussion in soccer players ranging in age from 8 to 24 years (N = 234; 141 females, 93 males). A multivariate analysis of variance was conducted to examine group differences in neurocognitive performance between male and female athletes with and without a history of concussion. Results: Soccer players with a history of at least 1 previous concussion performed significantly worse on ImPACT than those who had not sustained a prior concussion (F = 2.92, P = .03). In addition, female soccer players performed worse on neurocognitive testing (F = 2.72, P = .05) and also reported more symptoms (F = 20.1, P = .00001) than male soccer players. There was no significant difference in body mass index between male and female players (F = .04, P = .85). Conclusion: A history of concussion and gender may account for significant differences in postconcussive neurocognitive test scores in soccer players and may play a role in determining recovery. These differences do not appear to reflect differences in mass between genders and may be related to other gender-specific factors that deserve further study.	[Colvin, Alexis Chiang] Mt Sinai Med Ctr, Dept Orthopaed, New York, NY 10029 USA; [Mullen, Jimmy; Lovell, Mark R.; Collins, Micky W.; Groh, Megan] Univ Pittsburgh, Ctr Sports Med, Med Ctr, Pittsburgh, PA USA; [West, Robin Vereeke] Univ Pittsburgh, Dept Orthopaed, Med Ctr, Pittsburgh, PA USA	Colvin, AC (corresponding author), Mt Sinai Med Ctr, Dept Orthopaed, 5 E 98th St,Box 1188, New York, NY 10029 USA.	alexis.colvin@mountsinai.org					ADLER A, 1945, ARCH NEURO PSYCHIATR, V53, P34, DOI 10.1001/archneurpsyc.1945.02300010044003; Agel J, 2007, J ATHL TRAINING, V42, P270; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Brown CN, 2007, J ATHL TRAINING, V42, P515; Bruce JM, 2004, NEUROLOGY, V63, P1516; *CDCP, HEADS CONC YOUTH SPO; Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2003, J ATHL TRAINING, V38, P238; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Dick R, 2007, J ATHL TRAINING, V42, P278; EDNA TH, 1987, ACTA NEUROCHIR, V86, P12, DOI 10.1007/BF01419498; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Junge A, 2002, AM J SPORT MED, V30, P652, DOI 10.1177/03635465020300050401; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; Lidvall H F, 1974, Acta Neurol Scand Suppl, V56, P3; Matser EJT, 2004, STUD NEUROPSYCHOL DE, P193; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; *NAT FED STAT HIGH, 2009, HIGH SCH SPORTS PART; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; RUTHERFORD WH, 1977, LANCET, V1, P1; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; SILBERSTEIN SD, 2007, TXB CLIN NEUROLOGY, P1247; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	39	205	206	1	51	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	SEP	2009	37	9					1699	1704		10.1177/0363546509332497			6	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	487FO	WOS:000269256500004	19460813				2021-06-18	
J	Vaccari, JPD; Lotocki, G; Alonso, OF; Bramlett, HM; Dietrich, WD; Keane, RW				Vaccari, Juan Pablo de Rivero; Lotocki, George; Alonso, Ofelia F.; Bramlett, Helen M.; Dietrich, W. Dalton; Keane, Robert W.			Therapeutic neutralization of the NLRP1 inflammasome reduces the innate immune response and improves histopathology after traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						inflammasome; caspase-1 cytokines; innate immunity; traumatic brain injury; interleukins	INTERLEUKIN-1 RECEPTOR ANTAGONIST; SPINAL-CORD-INJURY; SYSTEMIC INFLAMMATION; MOLECULAR PLATFORM; CONVERTING-ENZYME; INHIBITION; IL-1; EXPRESSION; CASPASES; PROTEIN	Traumatic brain injury elicits acute inflammation that in turn exacerbates primary brain damage. A crucial part of innate immunity in the immune privileged central nervous system involves production of proinflammatory cytokines mediated by inflammasome signaling. Here, we show that the nucleotide-binding, leucine-rich repeat pyrin domain containing protein 1 (NLRP1) inflammasome consisting of NLRP1, caspase-1, caspase-11, apoptosis-associated speck-like protein containing a caspase recruitment domain ( ASC), the X-linked inhibitor of apoptosis protein, and pannexin 1 is expressed in neurons of the cerebral cortex. Moderate parasagittal fluid-percussion injury (FPI) induced processing of interleukin-1 beta, activation of caspase-1, cleavage of X-linked inhibitor of apoptosis protein, and promoted assembly of the NLRP1 inflammasome complex. Anti-ASC neutralizing antibodies administered immediately after fluid-percussion injury to injured rats reduced caspase-1 activation, X-linked inhibitor of apoptosis protein cleavage, and processing of interleukin-1 beta, resulting in a significant decrease in contusion volume. These studies show that the NLRP1 inflammasome constitutes an important component of the innate central nervous system inflammatory response after traumatic brain injury and may be a novel therapeutic target for reducing the damaging effects of posttraumatic brain inflammation. Journal of Cerebral Blood Flow & Metabolism (2009) 29, 1251-1261; doi: 10.1038/jcbfm.2009.46; published online 29 April 2009	[Keane, Robert W.] Univ Miami, Miller Sch Med, Dept Physiol & Biophys, Miami, FL 33136 USA; [Vaccari, Juan Pablo de Rivero; Lotocki, George; Alonso, Ofelia F.; Bramlett, Helen M.; Dietrich, W. Dalton; Keane, Robert W.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, Miami, FL 33136 USA	Keane, RW (corresponding author), Univ Miami, Miller Sch Med, Dept Physiol & Biophys, 1600 NW 10th Ave, Miami, FL 33136 USA.	rkeane@miami.edu	de Rivero Vaccari, Juan Pablo/ABE-3248-2020; de Rivero Vaccari, Juan Pablo/H-5718-2019	de Rivero Vaccari, Juan Pablo/0000-0002-5460-8834; 	NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30291, NN42133]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042133, P50NS030291, R01NS056072] Funding Source: NIH RePORTER	This work was supported by a grant from NIH/NINDS, NS30291 and, NN42133.	Abulafia DP, 2009, J CEREBR BLOOD F MET, V29, P534, DOI 10.1038/jcbfm.2008.143; Allan SM, 2005, NAT REV IMMUNOL, V5, P629, DOI 10.1038/nri1664; Arend WP, 2008, IMMUNOL REV, V223, P20, DOI 10.1111/j.1600-065X.2008.00624.x; Bhat RV, 1996, J NEUROSCI, V16, P4146; Braddock M, 2004, NAT REV DRUG DISCOV, V3, P1, DOI 10.1038/nrd1342; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Ciallella JR, 2002, J NEUROTRAUM, V19, P1555, DOI 10.1089/089771502762300229; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dinarello CA, 2006, AM J CLIN NUTR, V83, p447S; Dinarello CA, 2005, CRIT CARE MED, V33, pS460, DOI 10.1097/01.CCM.0000185500.11080.91; Dinarello CA, 2004, CURR OPIN PHARMACOL, V4, P378, DOI 10.1016/j.coph.2004.03.010; Dinarello CA, 2005, J EXP MED, V201, P1355, DOI 10.1084/jem.20050640; Emsley HCA, 2005, J NEUROL NEUROSUR PS, V76, P1366, DOI 10.1136/jnnp.2004.054882; FAN L, 1995, MOL BRAIN RES, V30, P125; Fassbender K, 2000, NEUROSCI LETT, V284, P135, DOI 10.1016/S0304-3940(00)00977-0; Fink KB, 1999, NEUROSCIENCE, V94, P1213, DOI 10.1016/S0306-4522(99)00345-0; FISHER CJ, 1994, JAMA-J AM MED ASSOC, V271, P1836, DOI 10.1001/jama.271.23.1836; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; Kanneganti TD, 2007, IMMUNITY, V26, P433, DOI 10.1016/j.immuni.2007.03.008; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; Knoblach SM, 2000, NEUROSCI LETT, V289, P5, DOI 10.1016/S0304-3940(00)01263-5; Kummer JA, 2007, J HISTOCHEM CYTOCHEM, V55, P443, DOI 10.1369/jhc.6A7101.2006; Li HF, 2008, J IMMUNOL, V181, P17, DOI 10.4049/jimmunol.181.1.17; LIAO Z, 1984, J EXP MED, V159, P126, DOI 10.1084/jem.159.1.126; Lotocki G, 2003, J CEREBR BLOOD F MET, V23, P1129, DOI 10.1097/01.WCB.0000086938.68719.E0; Marchionini DM, 2004, CELL TRANSPLANT, V13, P273, DOI 10.3727/000000004783983972; Martinon F, 2007, CELL DEATH DIFFER, V14, P10, DOI 10.1038/sj.cdd.4402038; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Morita-Fujimura Y, 1999, J CEREBR BLOOD F MET, V19, P634, DOI 10.1097/00004647-199906000-00006; Ogura Y, 2006, CELL, V126, P659, DOI 10.1016/j.cell.2006.08.002; Pelegrin P, 2006, EMBO J, V25, P5071, DOI 10.1038/sj.emboj.7601378; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Poyet JL, 2001, J BIOL CHEM, V276, P28309, DOI 10.1074/jbc.C100250200; Rast JP, 2006, SCIENCE, V314, P952, DOI 10.1126/science.1134301; So A, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2143; Ting JPY, 2008, IMMUNITY, V28, P285, DOI 10.1016/j.immuni.2008.02.005; Utagawa A, 2008, EXP NEUROL, V211, P283, DOI 10.1016/j.expneurol.2008.02.001; Vaccari JPDR, 2008, J NEUROSCI, V28, P3404, DOI 10.1523/JNEUROSCI.0157-08.2008; Zilles K., 1985, CORTEX RAT STEREOTAX	41	205	206	1	10	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JUL	2009	29	7					1251	1261		10.1038/jcbfm.2009.46			11	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	464DQ	WOS:000267485800003	19401709	Green Accepted, Bronze			2021-06-18	
J	Strauss, DJ; DeVivo, MJ; Paculdo, DR; Shavelle, RM				Strauss, David J.; DeVivo, Michael J.; Paculdo, David R.; Shavelle, Robert M.			Trends in life expectancy after spinal cord injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						epidemiology; life expectancy; mortality; rehabilitation; spinal cord injuries; survival	TRAUMATIC BRAIN-INJURY; LONG-TERM SURVIVAL; MORTALITY; DEATH; MANAGEMENT; RISK	Objective: To investigate whether there have been improvements in survival after spinal cord injury (SCI) over time, both in the critical first 2 years after injury and in the longer term. Design: Pooled repeated observations analysis of person-years. For each person-year, the outcome variable is survival and mortality, and the explanatory variables include age, level and grade of injury, and calendar year (the main focus of the analyses). The method can be viewed as a generalization of proportional hazards regression. Setting: Model spinal cord injury systems and hospital SCI units across the United States. Participants: Persons (N=30,822) admitted to a Spinal Cord Injury Model Systems facility a minimum of I day after injury. Only persons over 10 years of age and known not to be ventilator dependent were included. These persons contributed 323,618 person-years of data, with 4980 deaths, over the 1973 to 2004 study period. Interventions: Not applicable. Main Outcome Measure: Survival. Results: Other factors being equal, over the last 3 decades there has been a 40% decline in mortality during the critical first 2 years after injury. However, the decline in mortality over time in the post-2-year period is small and not statistically significant. Conclusions: The absence of a substantial decline in mortality after the first 2 years postinjury is contrary to widely held impressions. Nevertheless, the finding is based on a large database and sensitive analytic methods and is consistent with previous research. Improvements in critical care medicine after spinal cord injury may explain the marked decline in short-term mortality. In contrast, although there have no doubt been improvements in long-term rehabilitative care, their effect in enhancing the life span of persons with SCI appears to have been overstated.	Life Expectancy Project, San Francisco, CA 94122 USA; Univ Alabama, Dept Phys Med & Rehabil, Birmingham, AL USA	Strauss, DJ (corresponding author), Life Expectancy Project, 1439 17th Ave, San Francisco, CA 94122 USA.	Strauss@LifeExpectancy.com		Paculdo, David/0000-0002-2184-4603			American Spinal Injury Association, 2002, INT STAND NEUR CLASS; Belanger E, 2000, J AM COLL SURGEONS, V190, P603, DOI 10.1016/S1072-7515(00)00240-4; Coll JR, 1998, SPINAL CORD, V36, P275, DOI 10.1038/sj.sc.3100497; Collett D., 1994, MODELLING SURVIVAL D; Cupp les A, 1998, STAT MED, V7, P205; Devivo Michael J., 1995, P289; DeVivo Michael J, 2002, J Spinal Cord Med, V25, P335; DeVivo MJ, 1999, ARCH PHYS MED REHAB, V80, P1411, DOI 10.1016/S0003-9993(99)90252-6; DEVIVO MJ, 1987, ARCH NEUROL-CHICAGO, V44, P872, DOI 10.1001/archneur.1987.00520200074023; DeVivo MJ, 2004, BRAIN INJURY, V18, P1155, DOI 10.1080/02699050410001672323; DEVIVO MJ, 1992, ARCH PHYS MED REHAB, V73, P156; Frankel HL, 1998, SPINAL CORD, V36, P266, DOI 10.1038/sj.sc.3100638; GRIFFIN MR, 1985, J CHRON DIS, V38, P643, DOI 10.1016/0021-9681(85)90018-9; Gunnarsson T, 2003, CURR OPIN NEUROL, V16, P717, DOI 10.1097/00019052-200312000-00012; HADLEY MN, 2002, GUIDELINES MANAGEMEN; Hartkopp A, 1997, SPINAL CORD, V35, P76, DOI 10.1038/sj.sc.3100351; Hosmer D. W., 2000, APPL LOGISTIC REGRES; Imai K, 2004, IND HEALTH, V42, P213, DOI 10.2486/indhealth.42.213; Jackson AB, 2004, ARCH PHYS MED REHAB, V85, P1740, DOI 10.1016/j.apmr.2004.04.035; KIWERSKI J, 1981, PARAPLEGIA, V19, P347, DOI 10.1038/sc.1981.66; Krause JS, 2004, ARCH PHYS MED REHAB, V85, P1764, DOI 10.1016/j.apmr.2004.06.062; LE CT, 1982, J CHRON DIS, V35, P487, DOI 10.1016/0021-9681(82)90063-7; MESARD L, 1978, ARCH NEUROL-CHICAGO, V35, P78, DOI 10.1001/archneur.1978.00500260016003; SAMSA GP, 1993, ARCH NEUROL-CHICAGO, V50, P909, DOI 10.1001/archneur.1993.00540090018005; Schoen R, 1988, MODELING MULTIGROUP; SINGER JD, 1991, PSYCHOL BULL, V110, P268, DOI 10.1037/0033-2909.110.2.268; Stover SL, 1999, ARCH PHYS MED REHAB, V80, P1365, DOI 10.1016/S0003-9993(99)90246-0; Strauss D, 2000, J Insur Med, V32, P217; STRAUSS D, IN PRESS DEV MED CHI; Strauss David J, 2005, J Insur Med, V37, P20; Strauss DJ, 1999, PEDIATR NEUROL, V21, P626, DOI 10.1016/S0887-8994(99)00051-X; STRAUSS DJ, 2000, J INSURANCE MED, V32, P11; Waites KB, 1998, ARCH PHYS MED REHAB, V79, P1504, DOI 10.1016/S0003-9993(98)90410-5; WHITENECK GG, 1992, PARAPLEGIA, V30, P617, DOI 10.1038/sc.1992.124	34	205	211	0	15	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2006	87	8					1079	1085		10.1016/j.apmr.2006.04.022			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	072KW	WOS:000239673300009	16876553				2021-06-18	
J	Pellman, EJ; Viano, DC; Tucker, AM; Casson, IR				Pellman, EJ; Viano, DC; Tucker, AM; Casson, IR			Concussion in professional football: Location and direction of helmet impacts - Part 2	NEUROSURGERY			English	Article						biomechanics; concussion; football helmets; head injury criteria; impact tolerances; sport injury prevention; traumatic brain injury		OBJECTIVE: National Football League game video was analyzed for the typical locations of severe helmet impacts in professional football. By use of selected cases that were reconstructed in laboratory tests and reported previously, the magnitude and direction of force causing concussion was determined for these locations. METHODS: Multiple video views were obtained for 182 severe helmet impacts that occurred between 1996 and 2001. From a top view, the helmet was divided into 45-degree quadrants with 0 degrees eyes forward. From a side view, it was divided into seven equal levels, four (+Q1 to +Q4) above the head center of gravity and three below (-Q1 to -Q3). The initial helmet contact was located in these regions. Thirty-one impacts were reconstructed with helmeted Hybrid III dummies involving 25 concussions. Measurement of head translational and rotational acceleration was used to determine the average and 1 standard deviation in responses, with impacts reflected to the right side. RESULTS: From video, the majority (71%) of impact is to the helmet shell primarily from a striking player's helmet, arm, or shoulder pad to the side (45-135 degrees) or from ground contact to the back (135-180 degrees). Most impacts were high on the helmet at +Q2 to +Q4. The remainder (29%) were primarily from helmet contact on the facemask at an oblique frontal angle (0-45 degrees) and -Q3 to +Q1 height. From reconstructions, concussion occurred with the lowest peak head acceleration in facemask impacts at 78 18 g versus an average 107 to 117 g for impacts on other quadrants (t = 2.90, P < 0.005). There was a significantly higher head acceleration for concussed versus nonconcussed players (t = 2.85, P < 0.05). The vector of peak force was essentially horizontal for facemask impacts and downward at 12 to 27 degrees for impacts to the helmet side and back. Concussion in professional football involves four typical conditions, as follows: A, 0- to 45-degree quadrant, -Q3 to +Q3 level, peak force 49 +/- 18 degrees from front and horizontal; B, 45- to 90-degree quadrant, -Q2 to +Q3 level, peak force 73 +/- 12 degrees and horizontal; C, 90- to 135-degree quadrant, +Q1 to +Q4 level, peak force 97 +/- 9 degrees and 12 degrees downward; and D, 135- to 180-degree quadrant, +Q1 to +Q4 level, peak force 157 1 degrees and 27 degrees downward. Concussed players averaged 3.6 +/- 2.7 initial signs and symptoms. The most common were headaches, dizziness, immediate recall problems, and difficulty with information processing. CONCLUSION: The location, direction, and severity of helmet impacts causing concussion in the National Football League have been defined from analysis of game video and laboratory reconstruction. These conditions define the circumstances in which helmets need to reduce head injury risks in professional football.	ProBiomech LLC, Bloomfield, MI 48304 USA; Natl Football League, Mild Traumat Brain Injury Comm, New York, NY USA; Pro Hlth Care Associates LLP, New York, NY USA; Univ Maryland, Sch Med, Lutherville Timonium, MD USA; Long Isl Jewish Med Ctr, Dept Neurol, New Hyde Pk, NY 11042 USA; NYU, Med Ctr, Dept Neurol, New York, NY 10016 USA	Viano, DC (corresponding author), ProBiomech LLC, 265 Warrington Rd, Bloomfield, MI 48304 USA.						DIMASI FP, 1995, HS828 DOT US DEP TRA; Gadd C. W., 1966, P 10 STAPP CAR CRASH, P164; McCrory PR, 1998, SPORTS MED, V25, P131, DOI 10.2165/00007256-199825020-00005; *NAT OP COMM STAND, 2003, 00196 NOCSAE; Newman J. A., 1999, P INT RESEAR C BIOME, P17; NEWMAN JA, 2000, P INT RES C BIOM IMP, P223; NEWMAN JA, IN PRESS J BIOMECH; PADGAONKAR AJ, 1975, J APPL MECH-T ASME, V42, P552, DOI 10.1115/1.3423640; Pellman EJ, 2003, NEUROSURGERY, V53, P797, DOI 10.1093/neurosurgery/53.3.797; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799	10	205	205	0	41	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	DEC	2003	53	6					1328	1340		10.1227/01.NEU.0000093499.20604.21			13	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	752PN	WOS:000187176500020	14633299				2021-06-18	
J	Christodoulou, C; DeLuca, J; Ricker, JH; Madigan, NK; Bly, BM; Lange, G; Kalnin, AJ; Liu, WC; Steffener, J; Diamond, BJ; Ni, AC				Christodoulou, C; DeLuca, J; Ricker, JH; Madigan, NK; Bly, BM; Lange, G; Kalnin, AJ; Liu, WC; Steffener, J; Diamond, BJ; Ni, AC			Functional magnetic resonance imaging of working memory impairment after traumatic brain injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						traumatic brain injury; working memory; functional magnetic resonance imaging	POSITRON EMISSION TOMOGRAPHY; COMA-DATA-BANK; NEUROPSYCHOLOGICAL DEFICITS; HEAD-INJURY; ACTIVATION; CORTEX; RECOVERY; INVOLVEMENT; HEMISPHERE; PATTERNS	Objectives-To examine patterns of brain activation while performing a working memory task in persons with moderate to severe traumatic brain injury (TBI) and healthy controls. It is well established that working memory is an area of cognition that is especially vulnerable to disruption after TBI. Although much has been learned about the system of cerebral representation of working memory in healthy people, little is known about how this system is disrupted by TBI. Methods-Functional magnetic resonance imaging (fMRI) was used to assess brain activation during a working memory task (a modified version of the paced auditory serial addition test) in nine patients with TBI and seven healthy controls. Results-Patients with TBI were able to perform the task, but made significantly more errors than healthy controls. Cerebral activation in both groups was found in similar regions of the frontal, parietal, and temporal lobes, and resembled patterns of activation found in previous neuroimaging studies of working memory in healthy persons. However, compared with the healthy controls, the TBI group displayed a pattern of cerebral activation that was more regionally dispersed and more lateralised to the right hemisphere. Differences in lateralisation were particularly evident in the frontal lobes. Conclusions-Impairment of working memory in TBI seems to be associated with alterations in functional cerebral activity.	Kessler Med Rehabil Res & Educ Corp, Neuropsychol & Neurosci Lab, W Orange, NJ 07052 USA; Univ Med & Dent New Jersey, Dept Phys Med & Rehabil, Newark, NJ 07103 USA; Univ Med & Dent New Jersey, Dept Radiol, Newark, NJ 07103 USA; Univ Med & Dent New Jersey, Dept Neurosci, Newark, NJ 07103 USA; Univ Med & Dent New Jersey, Dept Psychiat, Newark, NJ 07103 USA; Rutgers State Univ, Dept Psychol, Piscataway, NJ 08855 USA	DeLuca, J (corresponding author), Kessler Med Rehabil Res & Educ Corp, Neuropsychol & Neurosci Lab, 1199 Pleasant Valley Way, W Orange, NJ 07052 USA.			Ricker, Joseph/0000-0003-3415-991X			Baddeley A. D., 1986, WORKING MEMORY; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; BURBAUD P, 1995, J NEUROPHYSIOL, V74, P2194; Chollet Francois, 1994, Current Opinion in Neurobiology, V4, P226, DOI 10.1016/0959-4388(94)90077-9; Cohen J D, 1994, Hum Brain Mapp, V1, P293, DOI 10.1002/hbm.460010407; Cohen JD, 1997, NATURE, V386, P604, DOI 10.1038/386604a0; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Holmes AP, 1998, NEUROIMAGE, V7, pS754, DOI DOI 10.1016/S1053-8119(18)31587-8; Jansen HML, 1996, J NEUROL NEUROSUR PS, V60, P221, DOI 10.1136/jnnp.60.2.221; KAPLAN CP, 1994, ARCH PHYS MED REHAB, V75, P643, DOI 10.1016/0003-9993(94)90186-4; KRAUS JF, 1998, REHABILITATION ADULT, P3; Lancaster J. L., 1997, NEUROIMAGE, V5, P5634; LANGE G, 1998, NEUROIMAGE, V7, pS853; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; Manoach DS, 1997, NEUROREPORT, V8, P545, DOI 10.1097/00001756-199701200-00033; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Miyai I, 1999, ANN NEUROL, V46, P467; Ohyama M, 1996, STROKE, V27, P897, DOI 10.1161/01.STR.27.5.897; PAPANICOLAOU AC, 1988, ARCH NEUROL-CHICAGO, V45, P1025, DOI 10.1001/archneur.1988.00520330117020; PAULESU E, 1993, NATURE, V362, P342, DOI 10.1038/362342a0; PETRIDES M, 1993, P NATL ACAD SCI USA, V90, P878, DOI 10.1073/pnas.90.3.878; Roman DD, 1991, CLIN NEUROPSYCHOL, V5, P33; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Rypma B, 1999, P NATL ACAD SCI USA, V96, P6558, DOI 10.1073/pnas.96.11.6558; Salmon E, 1996, BRAIN, V119, P1617, DOI 10.1093/brain/119.5.1617; Saykin AJ, 1999, J INT NEUROPSYCH SOC, V5, P377, DOI 10.1017/S135561779955501X; Seidman LJ, 1998, NEUROPSYCHOLOGY, V12, P505, DOI 10.1037/0894-4105.12.4.505; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; Talairach J., 1988, COPLANAR STEREOTAXIC; TEASDALE G, 1974, LANCET, V2, P81; WEILLER C, 1993, ANN NEUROL, V33, P181; ZAFONTE RD, 1996, MED REHABILITATION T, V251, P70	35	205	209	0	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	AUG	2001	71	2					161	168		10.1136/jnnp.71.2.161			8	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	456WH	WOS:000170105400006	11459886	Green Published, Bronze			2021-06-18	
J	HOVDA, DA; YOSHINO, A; KAWAMATA, T; KATAYAMA, Y; BECKER, DP				HOVDA, DA; YOSHINO, A; KAWAMATA, T; KATAYAMA, Y; BECKER, DP			DIFFUSE PROLONGED DEPRESSION OF CEREBRAL OXIDATIVE-METABOLISM FOLLOWING CONCUSSIVE BRAIN INJURY IN THE RAT - A CYTOCHROME-OXIDASE HISTOCHEMISTRY STUDY	BRAIN RESEARCH			English	Article						CONCUSSION; OXIDATIVE METABOLISM; CYTOCHROME OXIDASE HISTOCHEMISTRY; FLUID PERCUSSION; CEREBRAL CORTEX; HIPPOCAMPUS	EXPERIMENTAL HEAD-INJURY; FLUID-PERCUSSION MODEL; GLUCOSE-UTILIZATION; VISUAL-CORTEX; ENERGY-METABOLISM; INTERPEDUNCULAR NUCLEUS; SUPERIOR COLLICULUS; ARTERY OCCLUSION; MACAQUE MONKEY; STEM NEURONS	Utilizing a lateral fluid percussion injury as a model of cerebral concussion, rats were studied histochemically measuring the degree of cytochrome oxidase activity present within different structures at different times following injury. After concussion, the cerebral cortex ipsilateral to the site of injury exhibited a diffuse decrease in its level of chromotome oxidase (CO) activity beginning at as soon as one day and lasting for up to 10 days after the insult. The ipsilateral dorsal hippocampus also exhibited an injury-induced decrease in CO activity, however, it was not as severe as in the cortex. These results indicate that oxidative metabolism is depressed primarily within the cerebral cortex and hippocampus for several days following a cerebral concussion. We propose that this period of metabolic depression may delineate a period of time during which the injured brain is unable to function normally and thus would be vulnerable to a second insult.		HOVDA, DA (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DIV NEUROSURG,CHS 74140,LOS ANGELES,CA 90024, USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS27544, NS30308] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030308, R01NS027544] Funding Source: NIH RePORTER		ANDERSEN BJ, 1988, J NEUROSURG, V68, P601, DOI 10.3171/jns.1988.68.4.0601; BARR GA, 1987, BRAIN RES, V418, P301, DOI 10.1016/0006-8993(87)90097-7; BECK T, 1990, J CEREBR BLOOD F MET, V10, P542, DOI 10.1038/jcbfm.1990.96; BECKER D, 1989, Society for Neuroscience Abstracts, V15, P131; BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; BOYESON MG, 1989, J NEUROL REHABIL, V3, P35; BRAUN K, 1985, CELL TISSUE RES, V240, P101, DOI 10.1007/BF00217563; CHUGANI HT, 1990, IN PRESS J CEREB BLO; COLLE LM, 1986, BRAIN RES, V397, P27, DOI 10.1016/0006-8993(86)91366-1; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DARRIET D, 1986, J CEREBR BLOOD F MET, V6, P8, DOI 10.1038/jcbfm.1986.2; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DUCKROW RB, 1981, J NEUROSURG, V54, P607, DOI 10.3171/jns.1981.54.5.0607; DUNCAN GE, 1988, NEUROSCIENCE, V24, P877, DOI 10.1016/0306-4522(88)90074-7; DYSON SE, 1988, J NEUROSCI, V8, P1822; ECKENRODE TC, 1987, BRAIN RES, V418, P273, DOI 10.1016/0006-8993(87)90095-3; FEENEY DM, 1987, CRIT REV NEUROBIOL, V3, P135; FEENEY DM, 1985, PHYSIOL PSYCHOL, V13, P197; FINEMAN I, 1990, Society for Neuroscience Abstracts, V16, P778; GINSBERG MD, 1977, NEUROLOGY, V27, P1042, DOI 10.1212/WNL.27.11.1042; GRAYBIEL AM, 1971, ANAT REC, V169, P328; HILLERED L, 1989, J CEREBR BLOOD F MET, V9, P607, DOI 10.1038/jcbfm.1989.87; HORTON JC, 1981, NATURE, V292, P762, DOI 10.1038/292762a0; HOVDA DA, 1990, BEHAV BRAIN RES, V37, P119, DOI 10.1016/0166-4328(90)90087-U; HOVDA DA, 1987, EXP NEUROL, V97, P391, DOI 10.1016/0014-4886(87)90099-9; HOVDA DA, 1991, IN PRESS J NEUROTRAU; HUMPHREY AL, 1983, J NEUROSCI, V3, P345; HYDE GE, 1990, J COMP NEUROL, V297, P329, DOI 10.1002/cne.902970302; INAO S, 1988, J NEUROSURG, V69, P736, DOI 10.3171/jns.1988.69.5.0736; INAO S, 1990, J NEUROTRAUM, V7, P100; JEN LS, 1989, NEUROSCI LETT, V103, P133, DOI 10.1016/0304-3940(89)90564-8; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; KAGEYAMA GH, 1986, J COMP NEUROL, V246, P212, DOI 10.1002/cne.902460207; KAGEYAMA GH, 1988, J COMP NEUROL, V278, P521, DOI 10.1002/cne.902780405; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KATAYAMA Y, 1989, NEUROTRAUMA SOC, V6, P200; KAWAMATA T, 1991, IN PRESS J NEUROTRAU; KLEIHUES P, 1975, BRAIN RES, V95, P61, DOI 10.1016/0006-8993(75)90207-3; KUSHNER M, 1984, ANN NEUROL, V15, P425, DOI 10.1002/ana.410150505; LAND PW, 1987, BRAIN RES, V425, P178, DOI 10.1016/0006-8993(87)90497-5; MACMILLAN V, 1982, J CEREBR BLOOD F MET, V2, P457, DOI 10.1038/jcbfm.1982.52; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MEYER JS, 1970, J NEUROSURG, V32, P304, DOI 10.3171/jns.1970.32.3.0304; NILSSON B, 1977, J NEUROSURG, V47, P252, DOI 10.3171/jns.1977.47.2.0252; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; ONODERA H, 1988, NEUROSCI LETT, V89, P90, DOI 10.1016/0304-3940(88)90486-7; PAPPIUS HM, 1983, J CEREBR BLOOD F MET, V3, P448, DOI 10.1038/jcbfm.1983.71; PAPPIUS HM, 1988, METAB BRAIN DIS, V3, P303, DOI 10.1007/BF00999542; PAPPIUS HM, 1982, ANN NEUROL, V12, P157, DOI 10.1002/ana.410120205; Robertson CS, 1990, J NEUROTRAUM, V7, P1, DOI 10.1089/neu.1990.7.1; ROMHANYI RS, 1991, IN PRESS J NEUROTRAU; SCHWARTZ WJ, 1976, NATURE, V261, P155, DOI 10.1038/261155a0; SHIRAISHI K, 1989, J CEREBR BLOOD F MET, V9, P765, DOI 10.1038/jcbfm.1989.110; SILVERMAN MS, 1987, J NEUROSCI METH, V19, P1, DOI 10.1016/0165-0270(87)90016-1; SMITH M, 1991, IN PRESS J NEUROTRAU; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; SUTTON R L, 1989, Society for Neuroscience Abstracts, V15, P128; SUTTON RL, 1991, IN PRESS J NEUROTRAU; SUTTON RL, 1991, SOC NEUROSCI, V2, P1404; TANDIAN D, 1991, IN PRESS J NEUROTRAU; Tsubokawa T, 1983, No Shinkei Geka, V11, P563; UNTERBERG AW, 1988, J NEUROSURG, V68, P594, DOI 10.3171/jns.1988.68.4.0594; Vink R, 1990, J NEUROTRAUM, V7, P21, DOI 10.1089/neu.1990.7.21; WAGNER KR, 1990, J CEREBR BLOOD F MET, V10, P417, DOI 10.1038/jcbfm.1990.72; WARREN R, 1989, J COMP NEUROL, V288, P583, DOI 10.1002/cne.902880405; WEISEND MP, 1991, IN PRESS J NEUROTRAU; WONGRILEY M, 1983, BRAIN RES, V261, P185, DOI 10.1016/0006-8993(83)90622-4; WONGRILEY M, 1979, BRAIN RES, V171, P11, DOI 10.1016/0006-8993(79)90728-5; WONGRILEY MTT, 1989, TRENDS NEUROSCI, V12, P94, DOI 10.1016/0166-2236(89)90165-3; WONGRILEY MTT, 1978, BRAIN RES, V141, P185, DOI 10.1016/0006-8993(78)90629-7; WONGRILEY MTT, 1976, BRAIN RES, V108, P257, DOI 10.1016/0006-8993(76)90185-2; WONGRILEY MTT, 1980, P NATL ACAD SCI-BIOL, V77, P2333, DOI 10.1073/pnas.77.4.2333; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	76	205	205	0	8	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	DEC 13	1991	567	1					1	10		10.1016/0006-8993(91)91429-5			10	Neurosciences	Neurosciences & Neurology	GX158	WOS:A1991GX15800001	1667742				2021-06-18	
J	ODDY, M; HUMPHREY, M; UTTLEY, D				ODDY, M; HUMPHREY, M; UTTLEY, D			SUBJECTIVE IMPAIRMENT AND SOCIAL RECOVERY AFTER CLOSED HEAD-INJURY	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article									ST GEORGES HOSP,SCH MED,DEPT PSYCHOL,LONDON SW27 0RE,ENGLAND; ATKINSON MORLEYS HOSP,DEPT NEUROSURG,LONDON SW20,ENGLAND							BOND MR, 1976, SCAND J REHABIL MED, V8, P127; BOND MR, 1975, OUTCOME SEVERE DAMAG, P141; Bruckner F E, 1972, Rheumatol Phys Med, V11, P344, DOI 10.1093/rheumatology/11.7.344; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; FAHY TJ, 1967, LANCET, V2, P475; FIELD JH, 1976, EPIDEMIOLOGY HEAD IN; GERSTENBRAND F, 1969, LATE EFFECTS HEAD IN; Gjone R, 1972, Scand J Rehabil Med, V4, P2; HPAY H, 1971, P INT S HEAD INJURIE; KATZ MM, 1963, PSYCHOL REP, V13, P503, DOI 10.2466/pr0.1963.13.2.503; LECUIRE J, 1971, P INT S HEAD INJURIE; LEWIN W, 1968, BMJ-BRIT MED J, V1, P465, DOI 10.1136/bmj.1.5590.465; LONDON P S, 1967, Annals of the Royal College of Surgeons of England, V41, P460; MANDLEBERG IA, 1975, J NEUROL NEUROSUR PS, V38, P1121, DOI 10.1136/jnnp.38.11.1121; RICHARDSON J, 1971, P INT S HEAD INJURIE; ROWBOTHAM GF, 1954, BRIT MED J, V1, P726, DOI 10.1136/bmj.1.4864.726; RUSSELL WR, 1971, TRAUMATIC AMNESIAS, P32; SNAITH RP, 1971, PSYCHOL MED, V1, P143, DOI 10.1017/S0033291700000064; STEADMAN JH, 1970, P ROY SOC MED, V63, P23, DOI 10.1177/003591577006300109; Weissman MM, 1974, DEPRESSED WOMAN STUD; WILKINSON MI, 1969, P ROY SOC MED, V62, P541, DOI 10.1177/003591576906200605	21	205	205	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry		1978	41	7					611	616		10.1136/jnnp.41.7.611			6	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	FH823	WOS:A1978FH82300006	690638	Green Published, Bronze			2021-06-18	
J	Scott, JC; Matt, GE; Wrocklage, KM; Crnich, C; Jordan, J; Southwick, SM; Krystal, JH; Schweinsburg, BC				Scott, J. Cobb; Matt, Georg E.; Wrocklage, Kristen M.; Crnich, Cassandra; Jordan, Jessica; Southwick, Steven M.; Krystal, John H.; Schweinsburg, Brian C.			A Quantitative Meta-Analysis of Neurocognitive Functioning in Posttraumatic Stress Disorder	PSYCHOLOGICAL BULLETIN			English	Article						posttraumatic stress disorder; neuropsychology; meta-analysis; memory; attention	CONFIRMATORY FACTOR-ANALYSIS; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; TRAUMATIC BRAIN-INJURY; TEST-RETEST RELIABILITY; VERBAL-LEARNING TEST; GULF-WAR VETERANS; CARD SORTING TEST; SHORT-TERM-MEMORY; DEFICIT HYPERACTIVITY DISORDER; EXECUTIVE FUNCTION DEFICITS	Posttraumatic stress disorder (PTSD) is associated with regional alterations in brain structure and function that are hypothesized to contribute to symptoms and cognitive deficits associated with the disorder. We present here the first systematic meta-analysis of neurocognitive outcomes associated with PTSD to examine a broad range of cognitive domains and describe the profile of cognitive deficits, as well as modifying clinical factors and study characteristics. This report is based on data from 60 studies totaling 4,108 participants, including 1,779 with PTSD, 1,446 trauma-exposed comparison participants, and 895 healthy comparison participants without trauma exposure. Effect-size estimates were calculated using a mixed-effects meta-analysis for 9 cognitive domains: attention/working memory, executive functions, verbal learning, verbal memory, visual learning, visual memory, language, speed of information processing, and visuospatial abilities. Analyses revealed significant neurocognitive effects associated with PTSD, although these ranged widely in magnitude, with the largest effect sizes in verbal learning (d = -.62), speed of information processing (d = -.59), attention/working memory (d = -.50), and verbal memory (d = -.46). Effect-size estimates were significantly larger in treatment-seeking than community samples and in studies that did not exclude participants with attention-deficit/hyperactivity disorder, and effect sizes were affected by between-group IQ discrepancies and the gender composition of the PTSD groups. Our findings indicate that consideration of neuropsychological functioning in attention, verbal memory, and speed of information processing may have important implications for the effective clinical management of persons with PTSD. Results are further discussed in the context of cognitive models of PTSD and the limitations of this literature.	[Scott, J. Cobb] Philadelphia VA Med Ctr, Mental Illness Res Educ & Clin Ctr VISN4, Philadelphia, PA 19104 USA; [Scott, J. Cobb] Univ Penn, Perelman Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA; [Matt, Georg E.] San Diego State Univ, Dept Psychol, San Diego, CA 92182 USA; [Wrocklage, Kristen M.; Crnich, Cassandra; Jordan, Jessica; Southwick, Steven M.; Krystal, John H.; Schweinsburg, Brian C.] VA Connecticut Healthcare Syst, Natl Ctr PTSD, West Haven, CT USA; [Southwick, Steven M.; Krystal, John H.; Schweinsburg, Brian C.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06520 USA; [Krystal, John H.] Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT 06520 USA; [Krystal, John H.] Yale New Haven Med Ctr, Psychiat Serv, New Haven, CT 06504 USA	Scott, JC (corresponding author), Philadelphia VA Med Ctr, MIRECC 116,3900 Woodland Ave, Philadelphia, PA 19104 USA.	scott1@upenn.edu		Scott, J. Cobb/0000-0001-6538-9043; Matt, Georg/0000-0001-5604-4609	Department of Veterans Affairs Career Development AwardsUS Department of Veterans Affairs [1IK2CX000772, MH070345]; Clinical Neurosciences Division of the National Center for Posttraumatic Stress Disorder; VA National Center for PTSD; National Institute on Alcohol Abuse and AlcoholismUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [P50 AA012870]; National Center for Advancing Translational Sciences via Yale Center for Clinical Investigation [UL1 RR024139]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000142] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR024139] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH070345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [P50AA012870] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [IK2CX000772] Funding Source: NIH RePORTER	This work was supported by Department of Veterans Affairs Career Development Awards 1IK2CX000772 to J. Cobb Scott and MH070345 to Steven M. Southwick and by the Clinical Neurosciences Division of the National Center for Posttraumatic Stress Disorder. John H. Krystal's participation was supported by the VA National Center for PTSD, the National Institute on Alcohol Abuse and Alcoholism (P50 AA012870), and the National Center for Advancing Translational Sciences via its support for the Yale Center for Clinical Investigation (UL1 RR024139). We thank Henry Kranzler for his helpful feedback on the manuscript and Blake Buss for his assistance in data entry. J. Cobb Scott presented initial results of this meta-analysis at the February 2014 meeting of the International Neuropsychological Society in Seattle, Washington. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs.	Adler L A, 2004, J Atten Disord, V8, P11, DOI 10.1177/108705470400800102; Allen CC, 1999, ASSESSMENT, V6, P43, DOI 10.1177/107319119900600105; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; Andres P, 2000, J GERONTOL B-PSYCHOL, V55, pP373, DOI 10.1093/geronb/55.6.P373; Antshel K. M., 2014, J ATTENTION DISORDER; Antshel KM, 2013, J CLIN PSYCHIAT, V74, pE197, DOI 10.4088/JCP.12m07698; ARBIT J, 1978, J CLIN PSYCHOL, V34, P460, DOI 10.1002/1097-4679(197804)34:2<460::AID-JCLP2270340245>3.0.CO;2-C; ARCHIBALD HC, 1965, ARCH GEN PSYCHIAT, V12, P475; Arends LR, 2003, STAT MED, V22, P1335, DOI 10.1002/sim.1370; Aupperle RL, 2012, ARCH GEN PSYCHIAT, V69, P360, DOI 10.1001/archgenpsychiatry.2011.1539; Aupperle RL, 2012, NEUROPHARMACOLOGY, V62, P686, DOI 10.1016/j.neuropharm.2011.02.008; AXELROD BN, 1994, ARCH CLIN NEUROPSYCH, V9, P317; Baldo JV, 2001, J INT NEUROPSYCH SOC, V7, P586, DOI 10.1017/S1355617701755063; Barker MJ, 2005, J INT NEUROPSYCH SOC, V11, P281, DOI 10.1017/S1355617705050332; Barker MJ, 2004, CNS DRUGS, V18, P37, DOI 10.2165/00023210-200418010-00004; Barkley RA, 2001, J ABNORM CHILD PSYCH, V29, P541, DOI 10.1023/A:1012233310098; Barkley RA, 2008, CNS SPECTRUMS, V13, P977, DOI 10.1017/S1092852900014036; Barrash J, 2007, MIL MED, V172, P697, DOI 10.7205/MILMED.172.7.697; Barrett DH, 1996, AM J PSYCHIAT, V153, P1492; Bartzokis G, 2002, BIOL PSYCHIAT, V51, P605, DOI 10.1016/S0006-3223(02)01315-X; Bates ME, 2004, J INT NEUROPSYCH SOC, V10, P392, DOI 10.1017/S135561770410307X; Beckham JC, 1998, J TRAUMA STRESS, V11, P811, DOI 10.1023/A:1024409903617; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Benedict RHB, 2007, J NEUROL, V254, P22, DOI 10.1007/s00415-007-2007-4; Benedict RHB, 1998, CLIN NEUROPSYCHOL, V12, P43, DOI 10.1076/clin.12.1.43.1726; Benedict RHB, 1996, PSYCHOL ASSESSMENT, V8, P145, DOI 10.1037/1040-3590.8.2.145; Benton AL, 1974, VISUAL RETENTION TES; Biederman J, 2013, ACTA PSYCHIAT SCAND, V128, P78, DOI 10.1111/acps.12011; Biederman J, 2005, LANCET, V366, P237, DOI 10.1016/S0140-6736(05)66915-2; Bigler ED, 2013, CLIN NEUROPSYCHOL, V27, P176, DOI 10.1080/13854046.2012.693950; BLEICH A, 1986, BRIT J PSYCHIAT, V149, P365, DOI 10.1192/bjp.149.3.365; Boone KB, 1998, ARCH CLIN NEUROPSYCH, V13, P585, DOI 10.1016/S0887-6177(97)00074-7; Bornstein R A, 1989, Arch Clin Neuropsychol, V4, P15, DOI 10.1016/0887-6177(89)90003-6; Bowie CR, 2013, J NERV MENT DIS, V201, P680, DOI 10.1097/NMD.0b013e31829c5030; Boyle Eleanor, 2014, Arch Phys Med Rehabil, V95, pS230, DOI 10.1016/j.apmr.2013.08.297; Brandes D, 2002, PSYCHIAT RES, V110, P231, DOI 10.1016/S0165-1781(02)00125-7; Brannigan GG, 2003, BENDER VISUAL MOTOR; Bremner JD, 2007, PROG BRAIN RES, V167, P171, DOI 10.1016/S0079-6123(07)67012-5; BREMNER JD, 1993, AM J PSYCHIAT, V150, P1015; Bremner JD, 1995, PSYCHIAT RES, V59, P97; Bremner JD, 2003, AM J PSYCHIAT, V160, P924, DOI 10.1176/appi.ajp.160.5.924; Bremner JD, 2004, J NERV MENT DIS, V192, P643, DOI 10.1097/01.nmd.0000142027.52893.c8; Bremner JD, 1997, BIOL PSYCHIAT, V41, P23, DOI 10.1016/S0006-3223(96)00162-X; BREMNER JD, 1995, AM J PSYCHIAT, V152, P973; Breslau N, 2006, ARCH GEN PSYCHIAT, V63, P1238, DOI 10.1001/archpsyc.63.11.1238; Bressler SL, 2010, TRENDS COGN SCI, V14, P277, DOI 10.1016/j.tics.2010.04.004; Brewin CR, 2007, MEMORY, V15, P227, DOI 10.1080/09658210701256423; Brewin CR, 2007, J ABNORM PSYCHOL, V116, P448, DOI 10.1037/0021-843X.116.3.448; Brewin CR, 2010, PSYCHOL REV, V117, P210, DOI 10.1037/a0018113; Brewin CR, 2001, BEHAV RES THER, V39, P373, DOI 10.1016/S0005-7967(00)00087-5; Brown VM, 2012, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2012.00449; Bryant RA, 2005, BIOL PSYCHIAT, V58, P111, DOI 10.1016/j.biopsych.2005.03.021; Bryant Richard, 2011, Dialogues Clin Neurosci, V13, P251; Burgess PW., 1997, HAYLING SENTENCE COM; Burriss L, 2008, DEPRESS ANXIETY, V25, P149, DOI 10.1002/da.20291; BURSTEIN A, 1985, J CLIN PSYCHIAT, V46, P374; Burton DB, 2003, ARCH CLIN NEUROPSYCH, V18, P629, DOI 10.1093/arclin/18.6.629; Burton DB, 2002, ARCH CLIN NEUROPSYCH, V17, P371, DOI 10.1016/S0887-6177(01)00121-4; Bustamante V, 2001, J TRAUMA STRESS, V14, P791, DOI 10.1023/A:1013050423901; Calamia M, 2013, CLIN NEUROPSYCHOL, V27, P1077, DOI 10.1080/13854046.2013.809795; Campo P, 2003, CLIN NEUROPSYCHOL, V17, P220, DOI 10.1076/clin.17.2.220.16504; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Casada JH, 2005, J NERV MENT DIS, V193, P102, DOI 10.1097/01.nmd.0000152809.20938.37; Chapman SL, 2002, CLIN J PAIN, V18, pS83, DOI 10.1097/00002508-200207001-00010; Chung H, 2008, PSYCHOL MED, V38, P563, DOI 10.1017/S0033291707002589; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Clark C, 2000, J ABNORM CHILD PSYCH, V28, P403, DOI 10.1023/A:1005176320912; Cohen BE, 2013, J CLIN PSYCHIAT, V74, P1063, DOI 10.4088/JCP.12m08291; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Colom R, 2008, INTELLIGENCE, V36, P584, DOI 10.1016/j.intell.2008.01.002; Conners C., 2000, CONNERS CONTINUOUS P; Cottencin O, 2006, J PSYCHIAT RES, V40, P70, DOI 10.1016/j.jpsychires.2005.04.001; Craik FIM, 2006, TRENDS COGN SCI, V10, P131, DOI 10.1016/j.tics.2006.01.007; Crawford JR, 2008, J INT NEUROPSYCH SOC, V14, P1069, DOI 10.1017/S1355617708081228; Crawford JR, 1998, NEUROPSYCHOL REHABIL, V8, P255, DOI 10.1080/713755575; CROOK T, 1980, PSYCHOL REP, V47, P1315, DOI 10.2466/pr0.1980.47.3f.1315; Crowe SF, 1998, J CLIN PSYCHOL, V54, P585, DOI 10.1002/(SICI)1097-4679(199808)54:5<585::AID-JCLP4>3.0.CO;2-K; Crowell TA, 2002, CLIN NEUROPSYCHOL, V16, P310, DOI 10.1076/clin.16.3.310.13851; D'Elia L., 1996, COLOR TRAILS TEST PR; DALTON JE, 1989, INT J CLIN NEUROPSYC, V11, P121; Danckwerts A, 2003, NEUROPSYCHOL REV, V13, P221, DOI 10.1023/B:NERV.0000009485.76839.b7; Daniels JK, 2010, J PSYCHIATR NEUROSCI, V35, P258, DOI 10.1503/jpn.090010; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Demakis GJ, 2008, CLIN NEUROPSYCHOL, V22, P879, DOI 10.1080/13854040701564482; DIKMEN S, 2009, NEUROPSYCHOLOGICAL A, P597; Dikmen SS, 1999, J INT NEUROPSYCH SOC, V5, P346, DOI 10.1017/S1355617799544056; Dileo JF, 2008, PSYCHOL MED, V38, P523, DOI 10.1017/S0033291707001456; Donders J, 2008, J CLIN EXP NEUROPSYC, V30, P741, DOI 10.1080/13803390701689595; Donders J, 2008, ASSESSMENT, V15, P123, DOI 10.1177/1073191107310926; Dretsch MN, 2012, BRAIN BEHAV, V2, P357, DOI 10.1002/brb3.53; Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x; Dwan K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003081; Egeland J, 2010, J ATTEN DISORD, V13, P339, DOI 10.1177/1087054708323019; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Elsesser K, 2007, CLIN PSYCHOL PSYCHOT, V14, P464, DOI 10.1002/cpp.545; Emdad R, 2005, STRESS HEALTH, V21, P33, DOI 10.1002/smi.1034; EMDAD R, 2005, STRESS TRAUMA CRISIS, V8, P25, DOI DOI 10.1080/15434610590913612; Eren-Kocak E, 2009, ACTA PSYCHIAT SCAND, V119, P35, DOI 10.1111/j.1600-0447.2008.01281.x; Esterman M, 2013, J INT NEUROPSYCH SOC, V19, P835, DOI 10.1017/S135561771300057X; Etkin A, 2007, AM J PSYCHIAT, V164, P1476, DOI 10.1176/appi.ajp.2007.07030504; Etkin Amit, 2013, Dialogues Clin Neurosci, V15, P419; Eysenck MW, 2007, EMOTION, V7, P336, DOI 10.1037/1528-3542.7.2.336; Falconer E, 2008, J PSYCHIATR NEUROSCI, V33, P413; Falconer E, 2013, J CLIN PSYCHIAT, V74, P895, DOI 10.4088/JCP.12m08020; Falconer Erin M., 2008, Journal of Integrative Neuroscience, V7, P439, DOI 10.1142/S0219635208001873; Fani N, 2009, PSYCHOPHARMACOL BULL, V42, P53; Felmingham K, 2009, NEUROREPORT, V20, P1402, DOI 10.1097/WNR.0b013e3283300fbc; Felmingham KL, 2004, NEUROPSYCHOLOGY, V18, P564, DOI 10.1037/0894-4105.18.3.564; Fennig S, 2002, J NERV MENT DIS, V190, P677, DOI 10.1097/00005053-200210000-00004; Fernandez-Mendoza J, 2010, SLEEP, V33, P459, DOI 10.1093/sleep/33.4.459; First MB., 2002, STRUCTURED CLIN INTE; Flaks MK, 2014, J PSYCHIATR RES, V48, P32, DOI 10.1016/j.jpsychires.2013.10.009; Foa E.B., 1995, POSTTRAUMATIC STRESS; Fossati P, 1999, PSYCHIAT RES, V89, P171, DOI 10.1016/S0165-1781(99)00110-9; Gale CR, 2008, ARCH GEN PSYCHIAT, V65, P1410, DOI 10.1001/archpsyc.65.12.1410; Garavan H, 2002, NEUROIMAGE, V17, P1820, DOI 10.1006/nimg.2002.1326; Geffen Gina, 1990, Clin Neuropsychol, V4, P45, DOI 10.1080/13854049008401496; Gelowitz D. L., 1992, NEUROPSYCHOLOGY, V6, P287; Geuze E, 2008, NEUROIMAGE, V41, P675, DOI 10.1016/j.neuroimage.2008.03.007; Geuze E, 2009, DEPRESS ANXIETY, V26, P7, DOI 10.1002/da.20476; Gilbert J.G., 1970, GUILD MEMORY TEST MA; Gilbertson MW, 2006, J ABNORM PSYCHOL, V115, P484, DOI 10.1037/0021-843X.115.3.484; Gilbertson MW, 2001, J TRAUMA STRESS, V14, P413, DOI 10.1023/A:1011181305501; Gilbertson MW, 2002, NAT NEUROSCI, V5, P1242, DOI 10.1038/nn958; Gill T., 1990, J TRAUMA STRESS, V3, P29, DOI DOI 10.1002/JTS.2490030104; Golier J, 1997, INTEGR PHYS BEH SCI, V32, P52, DOI 10.1007/BF02688613; Golier JA, 2005, PSYCHIAT RES-NEUROIM, V139, P53, DOI 10.1016/j.pscychresns.2005.02.007; Golier JA, 2002, AM J PSYCHIAT, V159, P1682, DOI 10.1176/appi.ajp.159.10.1682; Golier JA, 2006, ANN NY ACAD SCI, V1071, P54, DOI 10.1196/annals.1364.006; GOW L, 1982, PERCEPT MOTOR SKILL, V54, P1043, DOI 10.2466/pms.1982.54.3c.1043; GRANT I, 1987, ARCH GEN PSYCHIAT, V44, P999; Greve KW, 2005, ARCH CLIN NEUROPSYCH, V20, P355, DOI 10.1016/j.acn.2004.09.004; Greve KW, 1998, ARCH CLIN NEUROPSYCH, V13, P597; Griffith HR, 2006, J INT NEUROPSYCH SOC, V12, P166, DOI 10.1017/S1355617706060267; Grilli L., 2006, REV RANDOM EFFECTS M; GURVITS TV, 1993, J NEUROPSYCH CLIN N, V5, P183; Gurvits TV, 2006, ARCH GEN PSYCHIAT, V63, P571, DOI 10.1001/archpsyc.63.5.571; Gurvits TV, 1996, BIOL PSYCHIAT, V40, P1091, DOI 10.1016/S0006-3223(96)00229-6; Gurvits TV, 2002, PSYCHIAT RES, V112, P263, DOI 10.1016/S0165-1781(02)00234-2; Gurvits TV, 2000, ARCH GEN PSYCHIAT, V57, P181, DOI 10.1001/archpsyc.57.2.181; Ham BJ, 2007, EUR J NEUROSCI, V25, P324, DOI 10.1111/j.1460-9568.2006.05253.x; Harrington KM, 2012, COMPR PSYCHIAT, V53, P679, DOI 10.1016/j.comppsych.2011.12.001; Hart J, 2008, J NEUROPSYCH CLIN N, V20, P309, DOI 10.1176/appi.neuropsych.20.3.309; Hayes JP, 2012, BIOL MOOD ANXIETY DI, V2, DOI 10.1186/2045-5380-2-9; Hayes JP, 2009, PSYCHIAT RES-NEUROIM, V172, P7, DOI 10.1016/j.pscychresns.2008.05.005; Hedges DW, 2010, COGN BEHAV NEUROL, V23, P124, DOI 10.1097/WNN.0b013e3181e1cbe1; Hedges L.V., 1985, STAT METHODS META AN; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Henry JD, 2004, NEUROPSYCHOLOGY, V18, P284, DOI 10.1037/0894-4105.18.2.284; Hervey AS, 2004, NEUROPSYCHOLOGY, V18, P485, DOI 10.1037/0894-4105.18.3.485; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Holdnack JA, 2011, ASSESSMENT, V18, P178, DOI 10.1177/1073191110393106; Horner MD, 2002, NEUROPSYCHOL REV, V12, P15, DOI 10.1023/A:1015439106231; Horner MD, 2013, CNS SPECTRUMS, V18, P90, DOI 10.1017/S1092852912000909; Howe LLS, 2009, CLIN NEUROPSYCHOL, V23, P1315, DOI 10.1080/13854040903266928; Hunkin NM, 2000, BRIT J CLIN PSYCHOL, V39, P169, DOI 10.1348/014466500163194; Isaac CL, 2006, CLIN PSYCHOL REV, V26, P939, DOI 10.1016/j.cpr.2005.12.004; Jelinek L, 2006, J CLIN EXP NEUROPSYC, V28, P940, DOI 10.1080/13803390591004347; Jelinek L, 2008, DEPRESS ANXIETY, V25, P175, DOI 10.1002/da.20300; Jelinek L, 2013, PSYCHIAT RES, V210, P584, DOI 10.1016/j.psychres.2013.06.037; Jelinek L, 2009, J ABNORM PSYCHOL, V118, P288, DOI 10.1037/a0015633; Jenkins MA, 1998, AM J PSYCHIAT, V155, P278; Jenkins MA, 2000, CLIN NEUROPSYCHOL, V14, P7, DOI 10.1076/1385-4046(200002)14:1;1-8;FT007; Johnsen GE, 2008, J AFFECT DISORDERS, V111, P74, DOI 10.1016/j.jad.2008.02.007; Johnsen GE, 2008, J ANXIETY DISORD, V22, P464, DOI 10.1016/j.janxdis.2007.04.007; Johnsen GE, 2009, PSYCHIAT RES, V165, P68, DOI 10.1016/j.psychres.2008.01.001; JOHNSTONE B, 1995, J CLIN PSYCHOL MED S, V2, P195, DOI 10.1007/BF01988643; Jovanovski D, 2005, J CLIN EXP NEUROPSYC, V27, P189, DOI 10.1080/13803390490515694; Joy S, 2004, ARCH CLIN NEUROPSYCH, V19, P759, DOI 10.1016/j.acn.2003.09.009; Kalaian HA, 1996, PSYCHOL METHODS, V1, P227, DOI 10.1037/1082-989X.1.3.227; Kanagaratnam P, 2007, J ANXIETY DISORD, V21, P510, DOI 10.1016/j.janxdis.2006.06.008; Karl A, 2006, NEUROSCI BIOBEHAV R, V30, P1004, DOI 10.1016/j.neubiorev.2006.03.004; Kasai K, 2008, BIOL PSYCHIAT, V63, P550, DOI 10.1016/j.biopsych.2007.06.022; Kelland DZ, 1996, ARCH CLIN NEUROPSYCH, V11, P339, DOI 10.1016/0887-6177(95)00032-1; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Kitayama N, 2005, J AFFECT DISORDERS, V88, P79, DOI 10.1016/j.jad.2005.05.014; Kivling-Boden G, 2003, NORD J PSYCHIAT, V57, P191, DOI 10.1080/08039480310001346; KNIGHT JA, 2004, ASSESSING PSYCHOL TR, P344; Koenen KC, 2007, PSYCHOL MED, V37, P181, DOI 10.1017/S0033291706009019; Koenen KC, 2001, BRAIN COGNITION, V45, P64, DOI 10.1006/brcg.2000.1256; Koenigs M, 2009, NEUROSCIENTIST, V15, P540, DOI 10.1177/1073858409333072; Kongs SK, 2000, WISCONSIN CARD SORTI; Koso M, 2006, EUR PSYCHIAT, V21, P167, DOI 10.1016/j.eurpsy.2005.06.004; Kreiner DS, 2001, CLIN NEUROPSYCHOL, V15, P109, DOI 10.1076/clin.15.1.109.1906; Krikorian R, 1998, CLIN NEUROPSYCHOL, V12, P305, DOI 10.1076/clin.12.3.305.1984; Kuhn S, 2013, BIOL PSYCHIAT, V73, P70, DOI 10.1016/j.biopsych.2012.06.029; Lange RT, 2012, J CLIN EXP NEUROPSYC, V34, P453, DOI 10.1080/13803395.2011.648175; LARRABEE GJ, 1995, J CLIN EXP NEUROPSYC, V17, P536, DOI 10.1080/01688639508405144; Lee RSC, 2012, J AFFECT DISORDERS, V140, P113, DOI 10.1016/j.jad.2011.10.023; Leskin LP, 2007, NEUROPSYCHOLOGY, V21, P275, DOI 10.1037/0894-4105.21.3.275; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Liberzon I, 2007, PROG BRAIN RES, V167, P151, DOI 10.1016/S0079-6123(07)67011-3; Lindauer RJL, 2006, BIOL PSYCHIAT, V59, P171, DOI 10.1016/j.biopsych.2005.06.033; Lindemer ER, 2013, NEUROIMAGE-CLIN, V2, P601, DOI 10.1016/j.nicl.2013.04.009; Lipsey M.W., 2001, PRACTICAL META ANAL; Litz BT, 1996, J TRAUMA STRESS, V9, P497, DOI 10.1007/BF02103661; Lopez MN, 2005, APPL NEUROPSYCHOL, V12, P19, DOI 10.1207/s15324826an1201_4; Lowe C, 1998, NEUROPSYCHOLOGIA, V36, P915, DOI 10.1016/S0028-3932(98)00036-0; LUINE V, 1994, BRAIN RES, V639, P167, DOI 10.1016/0006-8993(94)91778-7; LUPIEN S, 1994, J NEUROSCI, V14, P2893, DOI 10.1523/jneurosci.14-05-02893.1994; Mackin RS, 2012, INT J GERIATR PSYCH, V27, P637, DOI 10.1002/gps.2763; Macklin ML, 1998, J CONSULT CLIN PSYCH, V66, P323, DOI 10.1037/0022-006X.66.2.323; MACLEOD CM, 1991, PSYCHOL BULL, V109, P163, DOI 10.1037/0033-2909.109.2.163; Mahmutyazicioglu Kamran, 2005, Diagn Interv Radiol, V11, P125; MAJ M, 1993, ARCH CLIN NEUROPSYCH, V8, P123, DOI 10.1016/0887-6177(93)90030-5; Malina AC, 1998, PERCEPT MOTOR SKILL, V86, P1320, DOI 10.2466/pms.1998.86.3c.1320; Marcotte T. D., 2009, NEUROPSYCHOLOGY EVER; MARGRAF J, 1994, DIAGNOSTISCHES INTER; Marx BP, 2009, J INT NEUROPSYCH SOC, V15, P840, DOI 10.1017/S1355617709990488; Matsuo K, 2003, PSYCHIAT RES-NEUROIM, V124, P1, DOI 10.1016/S0925-4927(03)00093-3; Matt GE., 2009, HDB RES SYNTHESIS ME, V2, P537; Mattson SN, 1999, ALCOHOL CLIN EXP RES, V23, P1808, DOI 10.1097/00000374-199911000-00014; McAllister TW, 2010, ANN NY ACAD SCI, V1208, P46, DOI 10.1111/j.1749-6632.2010.05720.x; McCormick CL, 2013, ARCH CLIN NEUROPSYCH, V28, P808, DOI 10.1093/arclin/act050; MCEWEN BS, 1995, CURR OPIN NEUROBIOL, V5, P205, DOI 10.1016/0959-4388(95)80028-X; McGurk SR, 2007, AM J PSYCHIAT, V164, P1791, DOI 10.1176/appi.ajp.2007.07060906; McNally RJ, 2006, TRENDS COGN SCI, V10, P271, DOI 10.1016/j.tics.2006.04.007; MCNALLY RJ, 1995, AM J PSYCHIAT, V152, P936; Menon V, 2011, TRENDS COGN SCI, V15, P483, DOI 10.1016/j.tics.2011.08.003; Meyers J., 1995, REY COMPLEX FIGURE T; Mielke R, 1998, J NEURAL TRANSM, V105, P821, DOI 10.1007/s007020050097; Millis SR, 1999, J CLIN EXP NEUROPSYC, V21, P87, DOI 10.1076/jcen.21.1.87.937; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Moores KA, 2008, PSYCHIAT RES-NEUROIM, V163, P156, DOI 10.1016/j.pscychresns.2007.08.011; Morey RA, 2012, ARCH GEN PSYCHIAT, V69, P1169, DOI 10.1001/archgenpsychiatry.2012.50; Morey RA, 2009, J PSYCHIATR RES, V43, P809, DOI 10.1016/j.jpsychires.2008.10.014; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; Moses J A Jr, 1986, Arch Clin Neuropsychol, V1, P147, DOI 10.1016/0887-6177(86)90014-4; Moye J, 1997, NEUROPSYCHOL REV, V7, P157, DOI 10.1023/B:NERV.0000005907.34499.43; Nakahachi T, 2008, NEUROPSYCHOBIOLOGY, V57, P151, DOI 10.1159/000147467; Nakahachi T, 2010, BEHAV BRAIN RES, V215, P21, DOI 10.1016/j.bbr.2010.06.016; Neylan TC, 2004, J TRAUMA STRESS, V17, P41, DOI 10.1023/B:JOTS.0000014675.75686.ee; NICKS SD, 1992, ARCH CLIN NEUROPSYCH, V7, P387, DOI 10.1016/0887-6177(92)90151-C; Nigg JT, 2005, BIOL PSYCHIAT, V57, P1424, DOI 10.1016/j.biopsych.2004.11.011; Nuechterlein KH, 2008, AM J PSYCHIAT, V165, P203, DOI 10.1176/appi.ajp.2007.07010042; ODONNELL JP, 1994, J CLIN PSYCHOL, V50, P596, DOI 10.1002/1097-4679(199407)50:4<596::AID-JCLP2270500416>3.0.CO;2-S; Olff M, 2014, NEUROBIOL LEARN MEM, V112, P114, DOI 10.1016/j.nlm.2014.01.003; Park LQ, 2012, BRAIN IMAGING BEHAV, V6, P528, DOI 10.1007/s11682-012-9190-3; PARROTT AC, 1991, HUM PSYCHOPHARM CLIN, V6, P1, DOI 10.1002/hup.470060102; Parslow RA, 2007, AM J PSYCHIAT, V164, P509, DOI 10.1176/appi.ajp.164.3.509; Patel R, 2012, NEUROSCI BIOBEHAV R, V36, P2130, DOI 10.1016/j.neubiorev.2012.06.003; Paul RH, 2005, INT J NEUROSCI, V115, P1549, DOI 10.1080/00207450590957890; Pederson CL, 2004, J TRAUMA STRESS, V17, P37, DOI 10.1023/B:JOTS.0000014674.84517.46; PERRINE K, 1993, J CLIN EXP NEUROPSYC, V15, P461, DOI 10.1080/01688639308402571; Pessoa L, 2010, NAT REV NEUROSCI, V11, P773, DOI 10.1038/nrn2920; Pineles SL, 2009, BEHAV RES THER, V47, P1050, DOI 10.1016/j.brat.2009.08.001; Pitman RK, 2006, ANN NY ACAD SCI, V1071, P242, DOI 10.1196/annals.1364.019; Pitman RK, 2012, NAT REV NEUROSCI, V13, P769, DOI 10.1038/nrn3339; Pluck G, 2012, DRUG ALCOHOL DEPEN, V124, P181, DOI 10.1016/j.drugalcdep.2012.01.001; Polak AR, 2012, J AFFECT DISORDERS, V141, P11, DOI 10.1016/j.jad.2012.01.001; Porter RJ, 2003, BRIT J PSYCHIAT, V182, P214, DOI 10.1192/bjp.182.3.214; Qualls CE, 2000, ARCH CLIN NEUROPSYCH, V15, P159, DOI 10.1016/S0887-6177(98)00043-2; Qureshi SU, 2011, J NEUROPSYCH CLIN N, V23, P16, DOI 10.1176/appi.neuropsych.23.1.16; Rabe-Hesketh S, 2005, J ECONOMETRICS, V128, P301, DOI 10.1016/j.jeconom.2004.08.017; RABEHESKETH S, 2004, 160 U CAL DIV BIOST; Rauch SL, 2006, BIOL PSYCHIAT, V60, P376, DOI 10.1016/j.biopsych.2006.06.004; Riley RD, 2009, J R STAT SOC A STAT, V172, P789, DOI 10.1111/j.1467-985X.2008.00593.x; ROBBINS TW, 1994, DEMENTIA, V5, P266, DOI 10.1159/000106735; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Roca V, 2001, AM J PSYCHIAT, V158, P1738, DOI 10.1176/appi.ajp.158.10.1738-a; Rohling ML, 2012, CLIN NEUROPSYCHOL, V26, P197, DOI 10.1080/13854046.2011.647085; Rourke S.B., 2009, NEUROPSYCHOLOGICAL A, P398; Rourke SB, 1999, J INT NEUROPSYCH SOC, V5, P234, DOI 10.1017/S1355617799533067; Sachinvala N, 2000, J NERV MENT DIS, V188, P818, DOI 10.1097/00005053-200012000-00005; Salinsky MC, 2001, J INT NEUROPSYCH SOC, V7, P597, DOI 10.1017/S1355617701755075; Salthouse TA, 1996, NEUROPSYCHOLOGY, V10, P272, DOI 10.1037/0894-4105.10.2.272; Samuelson KW, 2006, NEUROPSYCHOLOGY, V20, P716, DOI 10.1037/0894-4105.20.6.716; SAPOLSKY RM, 1990, J NEUROSCI, V10, P2897, DOI 10.1523/jneurosci.10-09-02897.1990; Sapolsky RM, 2000, ARCH GEN PSYCHIAT, V57, P925, DOI 10.1001/archpsyc.57.10.925; Sarac-Hadzihalilovic A, 2008, BOSNIAN J BASIC MED, V8, P135, DOI 10.17305/bjbms.2008.2968; Schefft BK, 2003, EPILEPSY BEHAV, V4, P161, DOI 10.1016/S1525-5050(03)00026-X; Scherrer JF, 2008, COMPR PSYCHIAT, V49, P297, DOI 10.1016/j.comppsych.2007.11.001; Schnirman GM, 1998, ASSESSMENT, V5, P355, DOI 10.1177/107319119800500404; Schretlen DJ, 2013, BIPOLAR DISORD, V15, P422, DOI 10.1111/bdi.12075; Schroeder RW, 2011, CLIN NEUROPSYCHOL, V25, P437, DOI 10.1080/13854046.2011.556668; Schuff N, 2001, BIOL PSYCHIAT, V50, P952, DOI 10.1016/S0006-3223(01)01245-8; Schuff N, 2008, PSYCHIAT RES-NEUROIM, V162, P147, DOI 10.1016/j.pscychresns.2007.04.011; Scott JC, 2007, NEUROPSYCHOL REV, V17, P275, DOI 10.1007/s11065-007-9031-0; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Shadish W., 1999, ES COMPUTER PROGRAM; Shandera-Ochsner AL, 2013, CLIN NEUROPSYCHOL, V27, P881, DOI 10.1080/13854046.2013.802017; Shapiro AM, 1999, CLIN NEUROPSYCHOL, V13, P348, DOI 10.1076/clin.13.3.348.1749; Shorr J., 1992, NEUROPSYCHOLOGY, V6, P43, DOI DOI 10.1037/0894-4105.6.1.43; Shucard JL, 2008, BIOL PSYCHOL, V79, P223, DOI 10.1016/j.biopsycho.2008.05.005; SHUTE GE, 1990, DEV NEUROPSYCHOL, V6, P1, DOI 10.1080/87565649009540445; Silverstein SM, 2010, J CLIN EXP NEUROPSYC, V32, P937, DOI 10.1080/13803391003596496; SNOW WG, 1988, J CLIN EXP NEUROPSYC, V10, P60; Snyder HR, 2013, PSYCHOL BULL, V139, P81, DOI 10.1037/a0028727; Soble JR, 2013, J CLIN EXP NEUROPSYC, V35, P551, DOI 10.1080/13803395.2013.798398; Song F., 2000, HEALTH TECHNOL ASSES, V4, P1; SPITZER RL, 1992, ARCH GEN PSYCHIAT, V49, P624; Sripada RK, 2012, PSYCHOSOM MED, V74, P904, DOI 10.1097/PSY.0b013e318273bf33; Sripada RK, 2012, J PSYCHIATR NEUROSCI, V37, P241, DOI 10.1503/jpn.110069; StataCorp, 2011, STAT STAT SOFTW REL; Stavro K, 2013, ADDICT BIOL, V18, P203, DOI 10.1111/j.1369-1600.2011.00418.x; Stein MB, 1997, PSYCHOL MED, V27, P951, DOI 10.1017/S0033291797005242; Stein MB, 2002, BIOL PSYCHIAT, V52, P1079, DOI 10.1016/S0006-3223(02)01414-2; Sterne JAC, 2000, J CLIN EPIDEMIOL, V53, P1119, DOI 10.1016/S0895-4356(00)00242-0; Sterne JAC, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4002; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Strong CAH, 2008, J CLIN EXP NEUROPSYC, V30, P885, DOI 10.1080/13803390701858224; Sullivan K, 2003, J PSYCHOPATHOL BEHAV, V25, P95, DOI 10.1023/A:1023342915425; Tate RL, 1998, CLIN NEUROPSYCHOL, V12, P348, DOI 10.1076/clin.12.3.348.1988; Thompson WW, 2008, MIL MED, V173, P576, DOI 10.7205/MILMED.173.6.576; Tischler L, 2006, ANN NY ACAD SCI, V1071, P405, DOI 10.1196/annals.1364.031; Trahan D, 1988, CONTINUOUS VISUAL ME; Trahan DE, 1996, CLIN NEUROPSYCHOL, V10, P73, DOI 10.1080/13854049608406665; Trahan DE, 1998, ASSESSMENT, V5, P227, DOI 10.1177/107319119800500303; TROMMER BL, 1988, ANN NEUROL, V24, P610, DOI 10.1002/ana.410240504; Tulsky DS, 2003, PSYCHOL ASSESSMENT, V15, P149, DOI 10.1037/1040-3590.15.2.149; Twamley EW, 2012, J CLIN PSYCHIAT, V73, P1212, DOI 10.4088/JCP.12m07686; Twamley EW, 2009, J INT NEUROPSYCH SOC, V15, P879, DOI 10.1017/S135561770999049X; Twamley EW, 2004, PSYCHIAT RES, V126, P265, DOI 10.1016/j.psychres.2004.01.008; UCHIYAMA CL, 1994, ARCH CLIN NEUROPSYCH, V9, P215, DOI 10.1016/0887-6177(94)90027-2; UDDO M, 1993, J PSYCHOPATHOL BEHAV, V15, P43, DOI 10.1007/BF00964322; Uttl B, 2001, CLIN NEUROPSYCHOL, V15, P521, DOI 10.1076/clin.15.4.521.1881; van den Burg W, 1999, ARCH CLIN NEUROPSYCH, V14, P545, DOI 10.1016/S0887-6177(98)00042-0; Vasterling J., 2005, NEUROPSYCHOLOGY PTSD; Vasterling J.J., 2005, NEUROPSYCHOLOGY PTSD, P178; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Vasterling JJ, 2012, BRIT J PSYCHIAT, V201, P186, DOI 10.1192/bjp.bp.111.096461; Vasterling JJ, 1997, ASSESSMENT, V4, P51, DOI 10.1177/107319119700400107; Vasterling JJ, 2002, NEUROPSYCHOLOGY, V16, P5, DOI 10.1037//0894-4105.16.1.5; Vasterling JJ, 2000, J TRAUMA STRESS, V13, P241, DOI 10.1023/A:1007754611030; Vasterling JJ, 1998, NEUROPSYCHOLOGY, V12, P125, DOI 10.1037/0894-4105.12.1.125; Veltmeyer Melinda D., 2005, Journal of Integrative Neuroscience, V4, P145, DOI 10.1142/S0219635205000719; Vermetten E, 2003, BIOL PSYCHIAT, V54, P693, DOI 10.1016/S0006-3223(03)00634-6; Vlaar AMM, 2003, CLIN REHABIL, V17, P756, DOI 10.1191/0269215503cr674oa; Vythilingam M, 2005, PSYCHIAT RES-NEUROIM, V139, P89, DOI 10.1016/j.pscychresns.2005.04.003; Wang CE, 2006, J AFFECT DISORDERS, V92, P283, DOI 10.1016/j.jad.2006.02.008; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 1997, WAIS 3 WECHSLER ADUL; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; Werheid K, 2002, ARCH CLIN NEUROPSYCH, V17, P547, DOI 10.1016/S0887-6177(01)00134-2; Wessa M, 2006, NEUROPSYCHOLOGIA, V44, P1683, DOI 10.1016/j.neuropsychologia.2006.03.024; Wetzel L., 1987, SHORT CATEGORY TEST; Wild J, 2008, BRIT J PSYCHIAT, V193, P254, DOI 10.1192/bjp.bp.107.045922; Willcutt EG, 2005, DEV NEUROPSYCHOL, V27, P35, DOI 10.1207/s15326942dn2701_3; Willcutt EG, 2001, J ABNORM PSYCHOL, V110, P157, DOI 10.1037//0021-843X.1001.1.157; Williams LM, 2005, INT J NEUROSCI, V115, P1605, DOI 10.1080/00207450590958475; Wilson B.A., 2008, RIVERMEAD BEHAV MEMO; Wisdom NM, 2014, CLIN NEUROPSYCHOL, V28, P128, DOI 10.1080/13854046.2013.863977; Woods SP, 2006, ARCH CLIN NEUROPSYCH, V21, P413, DOI 10.1016/j.acn.2006.06.002; Woodward SH, 2009, ARCH GEN PSYCHIAT, V66, P1373, DOI 10.1001/archgenpsychiatry.2009.160; Woodward SH, 2009, J INT NEUROPSYCH SOC, V15, P830, DOI 10.1017/S1355617709990476; YEHUDA R, 1995, AM J PSYCHIAT, V152, P137; Yehuda R, 2005, PSYCHONEUROENDOCRINO, V30, P678, DOI 10.1016/j.psyneuen.2005.02.007; Yehuda R, 2005, J CLIN EXP NEUROPSYC, V27, P504, DOI 10.1080/138033990520223; Yehuda R, 2004, BIOL PSYCHIAT, V55, P291, DOI 10.1016/S0006-3223(03)00641-3; Yehuda R., 2005, NEUROPSYCHOLOGY PTSD, P208; Yehuda R, 2007, J PSYCHIATR RES, V41, P435, DOI 10.1016/j.jpsychires.2005.12.002; Zakzanis KK, 1998, NEUROPSY NEUROPSY BE, V11, P111; Zalewski, 1994, Assessment, V1, P133, DOI 10.1177/1073191194001002003; Zhang JN, 2013, BRAIN RES, V1531, P94, DOI 10.1016/j.brainres.2013.07.042	356	204	206	10	145	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0033-2909	1939-1455		PSYCHOL BULL	Psychol. Bull.	JAN	2015	141	1					105	140		10.1037/a0038039			36	Psychology; Psychology, Multidisciplinary	Psychology	AY6SX	WOS:000347696900005	25365762	Green Accepted	Y	N	2021-06-18	
J	Diaz-Arrastia, R; Wang, KKW; Papa, L; Sorani, MD; Yue, JK; Puccio, AM; McMahon, PJ; Inoue, T; Yuh, EL; Lingsma, HF; Maas, AIR; Valadka, AB; Okonkwo, DO; Manley, GT; Casey, SS; Cheong, M; Cooper, SR; Dams-O'Connor, K; Gordon, WA; Hricik, AJ; Menon, DK; Mukherjee, P; Schnyer, DM; Sinha, TK; Vassar, MJ				Diaz-Arrastia, Ramon; Wang, Kevin K. W.; Papa, Linda; Sorani, Marco D.; Yue, John K.; Puccio, Ava M.; McMahon, Paul J.; Inoue, Tomoo; Yuh, Esther L.; Lingsma, Hester F.; Maas, Andrew I. R.; Valadka, Alex B.; Okonkwo, David O.; Manley, Geoffrey T.; Casey, Scott S.; Cheong, Maxwell; Cooper, Shelly R.; Dams-O'Connor, Kristen; Gordon, Wayne A.; Hricik, Allison J.; Menon, David K.; Mukherjee, Pratik; Schnyer, David M.; Sinha, Tuhin K.; Vassar, Mary J.		TRACK-TBI Investigators	Acute Biomarkers of Traumatic Brain Injury: Relationship between Plasma Levels of Ubiquitin C-Terminal Hydrolase-L1 and Glial Fibrillary Acidic Protein	JOURNAL OF NEUROTRAUMA			English	Article						biomarker; common data elements; human studies; TBI	COMMON DATA ELEMENTS; INTRACRANIAL LESIONS; MILD; GFAP; S100B	Biomarkers are important for accurate diagnosis of complex disorders such as traumatic brain injury (TBI). For a complex and multifaceted condition such as TBI, it is likely that a single biomarker will not reflect the full spectrum of the response of brain tissue to injury. Ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) are among of the most widely studied biomarkers for TBI. Because UCH-L1 and GFAP measure distinct molecular events, we hypothesized that analysis of both biomarkers would be superior to analysis of each alone for the diagnosis and prognosis of TBI. Serum levels of UCH-L1 and GFAP were measured in a cohort of 206 patients with TBI enrolled in a multicenter observational study (Transforming Research and Clinical Knowledge in Traumatic Brain Injury [TRACK-TBI]). Levels of the two biomarkers were weakly correlated to each other (r=0.364). Each biomarker in isolation had good sensitivity and sensitivity for discriminating between TBI patients and healthy controls (area under the curve [AUC] 0.87 and 0.91 for UCH-L1 and GFAP, respectively). When biomarkers were combined, superior sensitivity and specificity for diagnosing TBI was obtained (AUC 0.94). Both biomarkers discriminated between TBI patients with intracranial lesions on CT scan and those without such lesions, but GFAP measures were significantly more sensitive and specific (AUC 0.88 vs. 0.71 for UCH-L1). For association with outcome 3 months after injury, neither biomarker had adequate sensitivity and specificity (AUC 0.65-0.74, for GFAP, and 0.59-0.80 for UCH-L1, depending upon Glasgow Outcome Scale Extended [GOS-E] threshold used). Our results support a role for multiple biomarker measurements in TBI research. (ClinicalTrials.gov Identifier NCT01565551)	[Diaz-Arrastia, Ramon] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Wang, Kevin K. W.] Univ Florida, McKnight Brain Inst, Gainesville, FL USA; [Papa, Linda] Orlando Reg Med Ctr Inc, Orlando, FL USA; [Sorani, Marco D.; Yue, John K.; Inoue, Tomoo; Manley, Geoffrey T.; Casey, Scott S.; Vassar, Mary J.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA; [Yuh, Esther L.; Cheong, Maxwell; Cooper, Shelly R.; Mukherjee, Pratik] Univ Calif San Francisco, Dept Radiol, San Francisco, CA USA; [Sinha, Tuhin K.] Univ Calif San Francisco, Dept Innovat Technol & Alliances, San Francisco, CA USA; [Puccio, Ava M.; McMahon, Paul J.; Okonkwo, David O.; Hricik, Allison J.] Univ Pittsburgh, Dept Neurol Surg, Med Ctr, Pittsburgh, PA 15260 USA; [Lingsma, Hester F.] Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands; [Maas, Andrew I. R.] Univ Antwerp Hosp, Dept Neurol Surg, Edegem, Belgium; [Valadka, Alex B.] Seton Brain & Spine Inst, Austin, TX USA; [Dams-O'Connor, Kristen; Gordon, Wayne A.] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA; [Menon, David K.] Univ Cambridge, Div Anaesthesia, Cambridge, England; [Schnyer, David M.] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA	Diaz-Arrastia, R (corresponding author), Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	Ramon.Diaz-Arrastia@usuhs.edu	Yue, John K/P-1348-2015	Yue, John K/0000-0001-9694-7722; Schnyer, David/0000-0002-7472-2853; Diaz-Arrastia, Ramon/0000-0001-6051-3594; Wang, Kevin/0000-0002-9343-6473; Cooper, Shelly/0000-0003-0026-6688; Mukherjee, Pratik/0000-0001-7473-7409	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1RC2 NS069409]; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10090] Funding Source: researchfish; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [ZIANS003138, RC2NS069409] Funding Source: NIH RePORTER	This study was funded by National Institutes of Health (NIH) Grant 1RC2 NS069409.	Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Berger RP, 2012, J NEUROTRAUM, V29, P162, DOI 10.1089/neu.2011.1989; Brophy GM, 2011, J NEUROTRAUM, V28, P861, DOI 10.1089/neu.2010.1564; Czeiter E, 2012, J NEUROTRAUM, V29, P1770, DOI 10.1089/neu.2011.2127; Duhaime AC, 2010, ARCH PHYS MED REHAB, V91, P1661, DOI 10.1016/j.apmr.2010.07.238; Food and Drug Administration, 2010, QUAL PROC DRUG DEV T; Gong B, 2007, DRUG NEWS PERSPECT, V20, P365, DOI 10.1358/dnp.2007.20.6.1138160; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; Manley GT, 2010, ARCH PHYS MED REHAB, V91, P1667, DOI 10.1016/j.apmr.2010.05.018; Metting Z, 2012, NEUROLOGY, V78, P1428, DOI 10.1212/WNL.0b013e318253d5c7; Mondello S, 2012, J NEUROTRAUM, V29, P1096, DOI 10.1089/neu.2011.2092; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; National Center for Injury Prevention and Control Report to Congress on Mild Traumatic Brain Injury in the United States, 2003, REP C MILD TRAUM BRA; Okonkwo DO, 2013, J NEUROTRAUM, V30, P1490, DOI 10.1089/neu.2013.2883; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Stein S. C., 1996, NEUROTRAUMA, P31; Thurman DJ, 2007, BRAIN INJURY MED PRI, P45; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yasuhara T, 2009, STEM CELLS DEV, V18, P1501, DOI 10.1089/scd.2009.0011; Yue J.K., 2013, J NEUROTRAUMA; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783; Zoltewicz JS, 2012, BIOMARK INSIGHTS, V7, P71, DOI 10.4137/BMI.S9873	27	204	208	2	40	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2014	31	1					19	25		10.1089/neu.2013.3040			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	302WJ	WOS:000330635500002	23865516	Green Published	Y	N	2021-06-18	
J	Lipton, ML; Gulko, E; Zimmerman, ME; Friedman, BW; Kim, M; Gellella, E; Gold, T; Shifteh, K; Ardekani, BA; Branch, CA				Lipton, Michael L.; Gulko, Edwin; Zimmerman, Molly E.; Friedman, Benjamin W.; Kim, Mimi; Gellella, Erik; Gold, Tamar; Shifteh, Keivan; Ardekani, Babak A.; Branch, Craig A.			Diffusion-Tensor Imaging Implicates Prefrontal Axonal Injury in Executive Function Impairment Following Very Mild Traumatic Brain Injury	RADIOLOGY			English	Article							WHITE-MATTER INTEGRITY; HEAD-INJURY; REGISTRATION; ABNORMALITIES; PATHOGENESIS; SEVERITY; SYMPTOMS; BATTERY; IMAGES; MRI	Purpose: To determine whether frontal white matter diffusion abnormalities can help predict acute executive function impairment after mild traumatic brain injury (mTBI). Materials and Methods: This study had institutional review board approval, included written informed consent, and complied with HIPAA. Diffusion-tensor imaging and standardized neuropsychologic assessments were performed in 20 patients with mTBI within 2 weeks of injury and 20 matched control subjects. Fractional anisotropy (FA) and mean diffusivity (MD) images (imaging parameters: 3.0 T, 25 directions, b = 1000 sec/mm(2)) were compared by using whole-brain voxelwise analysis. Spearman correlation analyses were performed to evaluate associations between diffusion measures and executive function. Results: Multiple clusters of lower frontal white matter FA, including the dorsolateral prefrontal cortex (DLPFC), were present in patients (P < .005), with several clusters also demonstrating higher MD (P < .005). Patients performed worse on tests of executive function. Lower DLPFC FA was significantly correlated with worse executive function performance in patients (P < .05). Conclusion: Impaired executive function following mTBI is associated with axonal injury involving the DLPFC. (C) RSNA, 2009	[Lipton, Michael L.; Branch, Craig A.] Albert Einstein Coll Med, Gruss Magnet Resonance Res Ctr, Bronx, NY 10461 USA; [Lipton, Michael L.; Gulko, Edwin; Shifteh, Keivan; Branch, Craig A.] Albert Einstein Coll Med, Dept Radiol, Bronx, NY 10461 USA; [Lipton, Michael L.] Albert Einstein Coll Med, Dept Psychiat & Behav Sci, Bronx, NY 10461 USA; [Zimmerman, Molly E.] Albert Einstein Coll Med, Dept Neurol, Bronx, NY 10461 USA; [Friedman, Benjamin W.] Albert Einstein Coll Med, Dept Emergency Med, Bronx, NY 10461 USA; [Kim, Mimi] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10461 USA; [Lipton, Michael L.; Gulko, Edwin; Shifteh, Keivan] Montefiore Med Ctr, Dept Radiol, Bronx, NY 10467 USA; [Friedman, Benjamin W.] Montefiore Med Ctr, Dept Emergency Med, Bronx, NY 10467 USA; [Gellella, Erik] New York Presbyterian Weill Cornell Med Ctr, Dept Radiol, New York, NY USA; [Gold, Tamar] Univ Penn, Sch Dent Med, Philadelphia, PA 19104 USA; [Ardekani, Babak A.] Nathan S Kline Inst Psychiat Res, Ctr Adv Brain Imaging, Orangeburg, NY 10962 USA; [Ardekani, Babak A.] NYU Med Ctr, Dept Psychiat, New York, NY 10016 USA	Lipton, ML (corresponding author), Albert Einstein Coll Med, Gruss Magnet Resonance Res Ctr, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	mlipton@aecom.yu.edu					Ardekani BA, 2005, J NEUROSCI METH, V142, P67, DOI 10.1016/j.jneumeth.2004.07.014; ARDEKANI BA, 1995, J COMPUT ASSIST TOMO, V19, P615, DOI 10.1097/00004728-199507000-00022; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Bigler ED, 2004, J INT NEUROPSYCH SOC, V10, P794, DOI 10.1017/S1355617704105146; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; BOHNEN N, 1992, NEUROSURGERY, V30, P692; Bonelli Raphael M, 2007, Dialogues Clin Neurosci, V9, P141; Brooks J, 1999, J TRAUMA, V46, P159, DOI 10.1097/00005373-199901000-00027; Centers for Disease Control and Prevention, 2003, REP C MILD TRAUM BRA; CROOKS DA, 1991, J PATHOL, V165, P5, DOI 10.1002/path.1711650103; CUMMINGS JL, 1993, ARCH NEUROL-CHICAGO, V50, P873, DOI 10.1001/archneur.1993.00540080076020; De Monte VE, 2005, J CLIN EXP NEUROPSYC, V27, P224, DOI 10.1080/13803390490515766; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; ESSELMAN PC, 1995, BRAIN INJURY, V9, P417, DOI 10.3109/02699059509005782; Hammoud DA, 2002, NEUROIMAG CLIN N AM, V12, P205, DOI 10.1016/S1052-5149(02)00011-4; Holmes CJ, 1998, J COMPUT ASSIST TOMO, V22, P324, DOI 10.1097/00004728-199803000-00032; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; Lim KO, 2006, AM J PSYCHIAT, V163, P2008, DOI 10.1176/appi.ajp.163.11.2008; LO C, 2006, P AM SOC NEUR SAN DI; LOVIBOND PF, 1995, BEHAV RES THER, V33, P335, DOI 10.1016/0005-7967(94)00075-U; Malojcic B, 2008, J NEUROTRAUM, V25, P30, DOI 10.1089/neu.2007.0384; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Nolin P, 2006, J HEAD TRAUMA REHAB, V21, P514, DOI 10.1097/00001199-200611000-00006; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Paul RH, 2005, INT J NEUROSCI, V115, P1549, DOI 10.1080/00207450590957890; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; POVLISHOCK JT, 1986, ACTA NEUROPATHOL, V70, P53, DOI 10.1007/BF00689514; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2007, NAT PROTOC, V2, P499, DOI 10.1038/nprot.2007.45; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Walsh K. W., 1985, UNDERSTANDING BRAIN; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Williams LM, 2005, INT J NEUROSCI, V115, P1605, DOI 10.1080/00207450590958475	46	204	209	0	16	RADIOLOGICAL SOC NORTH AMERICA	OAK BROOK	820 JORIE BLVD, OAK BROOK, IL 60523 USA	0033-8419			RADIOLOGY	Radiology	SEP	2009	252	3					816	824		10.1148/radiol.2523081584			9	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	506WZ	WOS:000270809500024	19567646				2021-06-18	
J	Temkin, NR				Temkin, Nancy R.			Preventing and treating posttraumatic seizures: The human experience	EPILEPSIA			English	Article						Antiepileptogenesis; Prophylaxis; Posttraumatic epilepsy; Meta-analysis; Antiepileptic drugs	POST-TRAUMATIC SEIZURES; SEVERE BRAIN INJURIES; RISK-FACTORS; EPILEPSY; PROPHYLAXIS; PHENYTOIN; TRIALS	Posttraumatic epilepsy presents an ideal target for prevention efforts. Traumatic brain injury (TBI) is common, characteristics that put people at high risk such as penetrating injury or subdural hematoma or provoked seizures are easily identified, and the latency between the injury and the onset of epileptic seizures is frequently short. Several drugs have been tested for their ability to prevent provoked seizures and epilepsy after TBI. We describe the design of those studies and their results. Phenytoin and carbamazepine significantly reduce the incidence of provoked seizures. Phenobarbital and the combination of phenobarbital and phenytoin also look promising for reducing provoked seizures, but small sample sizes in the studies evaluating these drugs do not allow definitive conclusions. None of the drugs studied (phenytoin, phenobarbital, their combination, carbamazepine, valproate, or magnesium) have shown reliable evidence that they prevent, or even suppress, epileptic seizures after TBI. For most of the regimens tested (the phenytoin/phenobarbital combination being the exception), the best estimate of effect is under a 25% reduction in posttraumatic seizures, well less than the 50% reduction most studies were designed to detect. The evaluation of the tested drugs has serious limitations, however, and antiepileptic drugs (AEDs) developed since 1980 and other compounds have barely been tested at all. Better understanding the process of epileptogenesis, testing treatments that demonstrate antiepileptogenic effects in the laboratory, and performing thorough preclinical and phase II evaluations before attempting definitive trials should greatly improve the chance of identifying ways to prevent posttraumatic epilepsy, providing the ultimate cure for this condition.	[Temkin, Nancy R.] Univ Washington, Dept Neurol Surg, Seattle, WA 98104 USA; [Temkin, Nancy R.] Univ Washington, Dept Biostat, Seattle, WA 98104 USA	Temkin, NR (corresponding author), Univ Washington, Dept Neurol Surg, POB 359924,325 9th Ave, Seattle, WA 98104 USA.	temkin@u.washington.edu	Ritter, Stefanie L/D-9312-2012		NIH/NICHD/NCMRRUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5 U01 HD042653]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U01HD042653] Funding Source: NIH RePORTER	Supported by 5 U01 HD042653 from NIH/NICHD/NCMRR.	Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; GLOTZNER FL, 1983, NEUROCHIRURGIA, V26, P66; Hoff H, 1947, MON PSYCHIATR NEUROL, V114, P105; Jennett B, 1975, EPILEPSY NONMISSILE; LANGENDORF FG, 2008, EPILEPSY COMPREHENSI, P2537; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; MANAKA S, 1992, JPN J PSYCHIAT NEUR, V46, P311; MCQUEEN JK, 1983, J NEUROL NEUROSUR PS, V46, P899, DOI 10.1136/jnnp.46.10.899; PECHADRE JC, 1991, PRESSE MED, V20, P841; PENRY JK, 1979, NEUROLOGY, V29, P600; Popek K, 1969, Cas Lek Cesk, V108, P133; Temkin NR, 2007, LANCET NEUROL, V6, P29, DOI 10.1016/S1474-4422(06)70630-5; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Temkin NR, 2003, EPILEPSIA, V44, P18, DOI 10.1046/j.1528-1157.44.s10.6.x; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; Temkin NRHM, 1996, NEUROLOGICAL SURG, P1834; YOUNG B, 1983, J NEUROSURG, V58, P236, DOI 10.3171/jns.1983.58.2.0236	18	204	210	1	23	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0013-9580			EPILEPSIA	Epilepsia		2009	50						10	13		10.1111/j.1528-1167.2008.02005.x			4	Clinical Neurology	Neurosciences & Neurology	399VN	WOS:000262827500003	19187289				2021-06-18	
J	Ansari, MA; Roberts, KN; Scheff, SW				Ansari, Mubeen A.; Roberts, Kelly N.; Scheff, Stephen W.			Oxidative stress and modification of synaptic proteins in hippocampus after traumatic brain injury	FREE RADICAL BIOLOGY AND MEDICINE			English	Article						hippocampus; oxidative stress; synaptic proteins; time course; traumatic brain injury	CENTRAL-NERVOUS-SYSTEM; SUPEROXIDE-DISMUTASE; CEREBRAL-ISCHEMIA; GENE-EXPRESSION; NITRIC-OXIDE; IMPAIRED MITOCHONDRIAL; LIPID-PEROXIDATION; IN-VIVO; GLUTATHIONE; DAMAGE	Oxidative stress, an imbalance between oxidants and antioxidants, contributes to the pathogenesis of traumatic brain injury (TBI). Oxidative neurodegeneration is a key mediator of exacerbated morphological responses and deficits in behavioral recoveries. The present study assessed early hippocampal sequential imbalance to possibly enhance antioxidant therapy. Young adult male Sprague-Dawley rats were subjected to a unilateral moderate cortical contusion. At various times post-TBI, animals were killed and the hippocampus was analyzed for antioxidants (GSH, GSSG, glutathione peroxidase, glutathione reductase, glutathione-S-transferase, glucose-6-phosphate dehydrogenase, superoxide dismutase, and catalase) and oxidants (acrolein, 4-hydroxynonenal, protein carbonyl, and 3-nitrotyrosine). Synaptic markers (synapsin 1, postsynaptic density protein 95, synapse-associated protein 97, growth-associated protein 43) were also analyzed. All values were compared with those for sham-operated animals. Significant time-dependent changes in antioxidants were observed as early as 3 h posttrauma and paralleled increases in oxidants (4-hydroxynonenal, acrolein, and protein carbonyl), with peak values obtained at 24-48 h. Time-dependent changes in synaptic proteins (synapsin 1, postsynaptic density protein 95, and synapse-associated protein 97) occurred well after levels of oxidants peaked. These results indicate that depletion of antioxidant systems following trauma could adversely affect synaptic function and plasticity. Early onset of oxidative stress suggests that the initial therapeutic window following TBI appears to be relatively short, and it may be necessary to stagger selective types of antioxidant therapy to target specific oxidative components. (c) 2008 Elsevier Inc. All rights reserved.	[Ansari, Mubeen A.; Roberts, Kelly N.; Scheff, Stephen W.] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; [Scheff, Stephen W.] Univ Kentucky, Spinal Cord Brain Injury Res Ctr, Lexington, KY 40536 USA	Scheff, SW (corresponding author), Univ Kentucky, Sanders Brown Ctr Aging 101, Lexington, KY 40536 USA.	sscheff@email.uky.edu			NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG21981, R01 AG021981-05, R01 AG021981] Funding Source: Medline; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG021981] Funding Source: NIH RePORTER		Acarin L, 2005, J NEUROTRAUM, V22, P189, DOI 10.1089/neu.2005.22.189; Ahmad AS, 2005, PHARMACOL BIOCHEM BE, V81, P805, DOI 10.1016/j.pbb.2005.06.007; Alexi T, 2000, PROG NEUROBIOL, V60, P409, DOI 10.1016/S0301-0082(99)00032-5; Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Ansari MA, 2004, BIOL TRACE ELEM RES, V101, P73, DOI 10.1385/BTER:101:1:73; Ansari MA, 2006, FREE RADICAL BIO MED, V41, P1694, DOI 10.1016/j.freeradbiomed.2006.09.002; Ates O, 2006, INT J DEV NEUROSCI, V24, P357, DOI 10.1016/j.ijdevneu.2006.08.003; Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; Bains JS, 1997, BRAIN RES REV, V25, P335, DOI 10.1016/S0165-0173(97)00045-3; Bayir H, 2007, J NEUROCHEM, V101, P168, DOI 10.1111/j.1471-4159.2006.04353.x; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Benowitz LI, 1997, TRENDS NEUROSCI, V20, P84, DOI 10.1016/S0166-2236(96)10072-2; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Buffo A, 2003, EUR J NEUROSCI, V18, P2146, DOI 10.1046/j.1460-9568.2003.02940.x; Cayabyab FS, 2000, EUR J NEUROSCI, V12, P1949, DOI 10.1046/j.1460-9568.2000.00083.x; Chen P, 2007, MOL PHARMACOL, V72, P40, DOI 10.1124/mol.107.034942; Choe H, 2001, J BIOCHEM MOL TOXIC, V15, P197, DOI 10.1002/jbt.17; de la Monte SM, 2000, CELL MOL LIFE SCI, V57, P1471, DOI 10.1007/PL00000630; DeKosky ST, 2004, J NEUROTRAUM, V21, P491, DOI 10.1089/089771504774129838; Dringen R, 2005, J NEUROSCI RES, V79, P157, DOI 10.1002/jnr.20280; Egles C, 2007, MOL CELL NEUROSCI, V34, P288, DOI 10.1016/j.mcn.2006.11.004; Ehrlich I, 2007, P NATL ACAD SCI USA, V104, P4176, DOI 10.1073/pnas.0609307104; Engle MR, 2004, TOXICOL APPL PHARM, V194, P296, DOI 10.1016/j.taap.2003.10.001; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fassio A, 2006, J CELL SCI, V119, P4257, DOI 10.1242/jcs.03194; Fineman I, 2000, J NEUROTRAUM, V17, P739, DOI 10.1089/neu.2000.17.739; FREEMAN BA, 1982, LAB INVEST, V47, P412; Futai K, 2007, NAT NEUROSCI, V10, P186, DOI 10.1038/nn1837; Gahm C, 2006, J NEUROTRAUM, V23, P1343, DOI 10.1089/neu.2006.23.1343; Gascon S, 2008, MOL PSYCHIATR, V13, P99, DOI 10.1038/sj.mp.4002017; Gorczyca D, 2007, J NEUROSCI, V27, P1033, DOI 10.1523/JNEUROSCI.3160-06.2007; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; Hughes-Davis EJ, 2005, NEUROSCIENCE, V135, P1231, DOI 10.1016/j.neuroscience.2005.07.017; Kline AE, 2004, J NEUROTRAUM, V21, P1712, DOI 10.1089/0897715042664849; Kotulska K, 2006, J NEUROSCI RES, V84, P1091, DOI 10.1002/jnr.21000; Krapivinsky G, 2006, NEURON, V52, P485, DOI 10.1016/j.neuron.2006.09.033; Lang SB, 2007, J NEUROSCI, V27, P1097, DOI 10.1523/JNEUROSCI.3590-06.2007; Lechuga-Sancho AM, 2006, ENDOCRINOLOGY, V147, P5314, DOI 10.1210/en.2006-0766; Martin LJ, 2003, J NEUROCHEM, V85, P234, DOI 10.1046/j.1471-4159.2003.01659.x; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; Mehta SL, 2007, BRAIN RES REV, V54, P34, DOI 10.1016/j.brainresrev.2006.11.003; Ozdemir D, 2005, PHYSIOL RES, V54, P631; Ozturk E, 2005, PROG NEURO-PSYCHOPH, V29, P920, DOI 10.1016/j.pnpbp.2005.04.028; Pandya JD, 2007, J NEUROTRAUM, V24, P798, DOI 10.1089/neu.2006.3673; Redell JB, 2003, EXP BIOL MED, V228, P261; Reiter RJ, 1998, PROG NEUROBIOL, V56, P359, DOI 10.1016/S0301-0082(98)00052-5; Sans N, 2001, J NEUROSCI, V21, P7506; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; Shah ZA, 2002, PHARMACOL TOXICOL, V90, P254, DOI 10.1034/j.1600-0773.2002.900505.x; Shao CX, 2006, FREE RADICAL BIO MED, V41, P77, DOI 10.1016/j.freeradbiomed.2006.03.007; Shen L, 2000, J NEUROSCI, V20, P7932; Sies H, 1999, FREE RADICAL BIO MED, V27, P916, DOI 10.1016/S0891-5849(99)00177-X; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Solaroglu I, 2005, J CLIN NEUROSCI, V12, P273, DOI 10.1016/j.jocn.2004.12.002; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Tsuriel S, 2006, PLOS BIOL, V4, P1572, DOI 10.1371/journal.pbio.0040271; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Valtschanoff JG, 2000, EUR J NEUROSCI, V12, P3605, DOI 10.1046/j.1460-9568.2000.00256.x; Wagner KR, 2005, CURR NEUROVASC RES, V2, P149, DOI 10.2174/1567202053586785; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Xie CS, 1998, FREE RADICAL BIO MED, V25, P979, DOI 10.1016/S0891-5849(98)00186-5; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Yunoki M, 2003, SURG NEUROL, V59, P156, DOI 10.1016/S0090-3019(02)01040-6; Yunoki M, 1998, ACT NEUR S, V71, P142	65	204	209	0	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0891-5849	1873-4596		FREE RADICAL BIO MED	Free Radic. Biol. Med.	AUG 15	2008	45	4					443	452		10.1016/j.freeradbiomed.2008.04.038			10	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	339ZB	WOS:000258614700009	18501200	Green Accepted			2021-06-18	
J	Teasdale, TW; Engberg, AW				Teasdale, TW; Engberg, AW			Suicide after traumatic brain injury: a population study	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						traumatic brain injury; concussion; suicide	RISK; DEPRESSION; DISORDERS	Objectives-To determine the rates of suicide among patients who have had a traumatic brain injury. Methods-From a Danish population register of admissions to hospital covering the years 1979-93 patients were selected who had had either a concussion (n=126 114), a cranial fracture (n=7560), or a cerebral contusion or traumatic intracranial haemorrhage (n=11 766). All cases of deaths by the end of the study period were identified. Results-In the three diagnostic groups there had been 750 (0.59%), 46 (0.61%), and 99 (0.84%) cases of suicide respectively. Standardised mortality ratios, stratified by sex and age, showed that the incidence of suicide among the three diagnostic groups was increased relative To the general population (3.0, 2.7, and 4.1 respectively). In all diagnosis groups the ratios were higher :For females than for males, and lower for patients injured before the age of 21 or after the age of 60. The presence of a codiagnosis relating to substance misuse was associated with increased suicide rates in all diagnosis groups. There was a tendency, among patients with cerebral contusions or traumatic intracranial haemorrhages, for suicide risk to increase with duration of stay in hospital. Cox regression analyses for proportional hazards confirmed that there was a significantly greater risk of suicide among patients with cerebral contusions or traumatic intracranial haemorrhages than among patients with concussion or cranial fractures (hazard ratios=1.42 and 1.50 respectively). There was, however, no evidence of a specific risk period for suicide after injury. Conclusion-The increased risk of suicide among patients who had a mild traumatic brain injury may result from concomitant risk factors such as psychiatric conditions and psychosocial disadvantage. The greater risk among the more serious cases implicates additionally the physical, psychological, and social consequences of the injuries as directly contributing to the suicides.	Univ Copenhagen, Dept Psychol, DK-2300 Copenhagen S, Denmark	Teasdale, TW (corresponding author), Univ Copenhagen, Dept Psychol, Njalsgade 88, DK-2300 Copenhagen S, Denmark.	teasdale@psy.ku.dk					ACHTE KA, 1971, ACTA PSYCHIAT SCAND, P1; DIEKSTRA RFW, 1993, ACTA PSYCHIAT SCAND, V87, P9, DOI 10.1111/j.1600-0447.1993.tb05368.x; Engberg A, 1995, Acta Neurol Scand Suppl, V164, P1; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; GURNS S, 1994, BRAIN INJURY, V8, P413, DOI 10.3109/02699059409150993; Harris EC, 1997, BRIT J PSYCHIAT, V170, P205, DOI 10.1192/bjp.170.3.205; Hartkopp A, 1998, ARCH PHYS MED REHAB, V79, P1356, DOI 10.1016/S0003-9993(98)90227-1; KLONOFF PS, 1995, J HEAD TRAUMA REHAB, V10, P16, DOI 10.1097/00001199-199512000-00005; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Leon-Carrion J, 1997, NEUROPSYCHOL REHABIL, P415; MACMAHON B, 1996, EPIDEMIOLOGY PRINCIP; Mann JJ, 1999, AM J PSYCHIAT, V156, P181; Moscicki EK, 1997, PSYCHIAT CLIN N AM, V20, P499, DOI 10.1016/S0193-953X(05)70327-0; Neeleman J, 1999, J EPIDEMIOL COMMUN H, V53, P204, DOI 10.1136/jech.53.4.204; Ownsworth TL, 1998, BRAIN INJURY, V12, P735, DOI 10.1080/026990598122133; PARMAR MKB, 1995, SURVIVAL ANAL PRACTI; PERSINGER MA, 1994, PSYCHOL REP, V75, P1059, DOI 10.2466/pr0.1994.75.3.1059; ROBERTS AH, 1979, SEVERE ACCIDENTAL HE; SORENSON SB, 1991, J HEAD TRAUMA REHAB, V6, P1, DOI DOI 10.1097/00001199-199106000-00003; Tate R, 1997, J HEAD TRAUMA REHAB, V12, P16, DOI 10.1097/00001199-199712000-00003; Teasdale TW, 2000, BRAIN INJURY, V14, P363; Teasdale TW, 1997, BRIT MED J, V315, P569; Teasdale TW, 1997, NEUROPSYCHOL REHABIL, V7, P23, DOI 10.1080/713755521; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; WILSON BA, 1994, TREATMENT ISSUES LON, P1	25	204	204	0	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	OCT	2001	71	4					436	440		10.1136/jnnp.71.4.436			5	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	478ZQ	WOS:000171379800005	11561024	Green Published, Bronze			2021-06-18	
J	Lau, LT; Yu, ACH				Lau, LT; Yu, ACH			Astrocytes produce and release interleukin-1, interleukin-6, tumor necrosis factor alpha and interferon-gamma following traumatic and metabolic injury	JOURNAL OF NEUROTRAUMA			English	Article						astrocytes; cytokine; IFN-gamma; IL-1 alpha; IL-6; injury; TNF alpha	CENTRAL-NERVOUS-SYSTEM; ANTIGEN PRESENTATION; MULTIPLE-SCLEROSIS; GENE-EXPRESSION; RAT ASTROCYTES; GROWTH-FACTOR; INDUCTION; CYTOKINES; BRAIN; LIPOPOLYSACCHARIDE	The brain is no longer considered immune-privileged due to its capability of producing cytokines in response to neurotrauma; however, the cellular sources of cytokines have not been defined. This study focused on the production of four inflammatory cytokines, interleukin-1 (IL-1 alpha), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF alpha), and interferon gamma (IFN-gamma) in primary culture of astrocytes under two different injury models which simulated in vivo mechanical trauma (scratch injury) and ischemia. Results demonstrated that astrocytes after scratch injury were positively immunostained with IL-1 alpha, IL-6, and TNF alpha. A slot-blot study of culture media showed that the release of IL-1 alpha, IL-6, TNF alpha, and IFN-gamma by astrocytes subsequent to scratch and ischemic injury reached approximately twice the control values, The temporal expression of these cytokines was different for the two models. All four cytokines began to increase 1 h postscratch and remained at high levels throughout the experiment. In the ischemic model, however, the increase of cytokine expression was delayed until 4-8 h of ischemia, when sharp increases were seen in all four cytokines, In this culture system, the exogenous influence of blood-borne factors and leukocytes, which occur with in vivo trauma and ischemia, was eliminated. Accordingly, the cytokines detected in the culture media were derived from astrocytes, This study provides the first evidence that astrocytes, without the influence from other cell types, can produce and release cytokines following mechanical and ischemic injury.	Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong, Peoples R China	Yu, ACH (corresponding author), Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong, Peoples R China.		Lau, Lok Ting/C-3866-2013	Lau, Lok Ting/0000-0001-7517-1486			AMES A, 1983, STROKE, V14, P233, DOI 10.1161/01.STR.14.2.233; ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; BALASINGAM V, 1994, J NEUROSCI, V14, P846; Benveniste EN., 1993, ASTROCYTES PHARM FUN, P355; BOURDIOL F, 1991, BRAIN RES, V543, P194, DOI 10.1016/0006-8993(91)90028-T; CHUNG IY, 1990, J IMMUNOL, V144, P2999; CHUNG IY, 1991, J EXP MED, V173, P801, DOI 10.1084/jem.173.4.801; DSOUZA SD, 1994, J NEUROIMMUNOL, V50, P17, DOI 10.1016/0165-5728(94)90210-0; FIERZ W, 1985, J IMMUNOL, V134, P3785; FREI K, 1989, EUR J IMMUNOL, V19, P689, DOI 10.1002/eji.1830190418; FROHMAN EM, 1989, J NEUROIMMUNOL, V23, P117, DOI 10.1016/0165-5728(89)90030-1; FU WY, 1995, 25 ANN M SOC NEUR SA; GEIGER KD, 1997, VIROLOGY, V238, P198; GHIRNIKAR RS, 1994, J NEUROSCI RES, V38, P376, DOI 10.1002/jnr.490380403; HARIRI RJ, 1994, BRAIN RES, V636, P139, DOI 10.1016/0006-8993(94)90188-0; HEWETT SJ, 1993, NEUROSCI LETT, V164, P229, DOI 10.1016/0304-3940(93)90898-U; Hickey WF, 1991, BRAIN PATHOL, V1, P97, DOI 10.1111/j.1750-3639.1991.tb00646.x; HOU YJ, 1995, J NEUROSCI RES, V40, P359, DOI 10.1002/jnr.490400310; KAKU DA, 1991, BRAIN RES, V554, P344, DOI 10.1016/0006-8993(91)90214-G; Kuchinke W, 1995, NEUROIMMUNOMODULAT, V2, P347, DOI 10.1159/000097214; LINDHOLM D, 1987, NATURE, V330, P658, DOI 10.1038/330658a0; MAEDA Y, 1994, J EXP MED, V180, P2297, DOI 10.1084/jem.180.6.2297; MERRILL JE, 1992, J IMMUNOTHER, V12, P167, DOI 10.1097/00002371-199210000-00004; MINAMI M, 1992, J NEUROCHEM, V58, P390, DOI 10.1111/j.1471-4159.1992.tb09324.x; Pawlinski R, 1997, J NEUROSCI RES, V50, P1018, DOI 10.1002/(SICI)1097-4547(19971215)50:6<1018::AID-JNR12>3.3.CO;2-T; POHLMAN TH, 1986, J IMMUNOL, V136, P4548; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; Rubio N, 1997, IMMUNOLOGY, V91, P560, DOI 10.1046/j.1365-2567.1997.00305.x; SCHMIDT B, 1990, BRAIN RES, V515, P347, DOI 10.1016/0006-8993(90)90621-H; SELMAJ KW, 1990, J IMMUNOL, V144, P129; SELMAJ KW, 1988, ANN NEUROL, V23, P339, DOI 10.1002/ana.410230405; Silberstein FC, 1996, J NEUROCHEM, V66, P1409; SZAFLARSKI J, 1995, STROKE, V26, P1093, DOI 10.1161/01.STR.26.6.1093; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TCHELINGERIAN JL, 1993, NEURON, V10, P213, DOI 10.1016/0896-6273(93)90312-F; TOULMOND S, 1992, NEUROSCI LETT, V144, P49, DOI 10.1016/0304-3940(92)90713-H; TRAUGOTT U, 1988, ANN NEUROL, V24, P243, DOI 10.1002/ana.410240211; WAAGE A, 1989, J EXP MED, V170, P1859, DOI 10.1084/jem.170.6.1859; Yu ACH, 2000, NEUROCHEM INT, V36, P369, DOI 10.1016/S0197-0186(99)00145-X; YU ACH, 1993, J NEUROSCI RES, V34, P295, DOI 10.1002/jnr.490340306; Yu ACH, 1995, PROG BRAIN RES, V105, P245; YUNG HW, 1998, NEUROSCI LETT S, V49, pS7	42	204	229	0	10	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	2001	18	3					351	359		10.1089/08977150151071035			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	414EM	WOS:000167653000011	11284554				2021-06-18	
J	Stahel, PF; Shohami, E; Younis, FM; Kariya, K; Otto, VI; Lenzlinger, PM; Grosjean, MB; Eugster, HP; Trentz, O; Kossmann, T; Morganti-Kossmann, MC				Stahel, PF; Shohami, E; Younis, FM; Kariya, K; Otto, VI; Lenzlinger, PM; Grosjean, MB; Eugster, HP; Trentz, O; Kossmann, T; Morganti-Kossmann, MC			Experimental closed head injury: Analysis of neurological outcome, blood-brain barrier dysfunction, intracranial neutrophil infiltration, and neuronal cell death in mice deficient in genes for pro-inflammatory cytokines	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article; Proceedings Paper	Keystone Symposium on Effectors of Inflammation in the CNS	MAR 09-14, 1999	TAOS, NM			traumatic brain injury; cytokines; blood-brain barrier; knockout mice	TUMOR-NECROSIS-FACTOR; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FACTOR-ALPHA; TNF-ALPHA; RAT-BRAIN; CEREBROSPINAL-FLUID; RECEPTOR FAMILIES; LYMPHOTOXIN-ALPHA; CEREBRAL-ISCHEMIA; CNS INFLAMMATION	Cytokines are important mediators of intracranial inflammation following traumatic brain injury (TBI). In the present study, the neurological impairment and mortality blood-brain barrier (BBB) function, intracranial polymorphonuclear leukocyte (PMN) accumulation, and posttraumatic neuronal cell death were monitored in mice lacking the genes for tumor necrosis factor (TNF)/lymphotoxin-alpha (LT-alpha) (TNF/LT-alpha-/-) and interleukin-6 (IL-6) and in wild-type (WT) littermates subjected to experimental closed head injury (total n = 107). The posttraumatic mortality was significantly increased in TNF/LT-alpha-/- mice (40%; P < 0.02) compared with WT animals (10%). The IL-6-/- mice also showed a higher mortality (17%) than their WT littermates (5.6%), but the difference was not statistically significant (P > 0.05). The neurological severity score was similar among all groups from 1 to 72 hours after trauma, whereas at 7 days, the TNF/LT-alpha-/- mice showed a tendency toward better neurological recovery than their WT littermates. Interestingly, neither the degree of BBB dysfunction nor the number of infiltrating PMNs in the injured hemisphere was different between WT and cytokine-deficient mice, Furthermore, the analysis of brain sections by in situ DNA nick end labeling (TUNEL histochemistry) at 24 hours and 7 days after head injury revealed a similar extent of posttraumatic intracranial cell death in all animals. These results show that the pathophysiological sequelae of TBI are not significantly altered in mice lacking the genes for the proinflammatory cytokines TNF, LT-alpha, and IL-6, Nevertheless, the increased posttraumatic mortality in TNF/LT-alpha-deficient mice suggests a protective effect of these cytokines by mechanisms that have not been elucidated yet.	Univ Zurich Hosp, Dept Surg, Div Trauma Surg, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Surg, Div Res, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Med, Clin Immunol Sect, CH-8091 Zurich, Switzerland; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Pharmacol, IL-91010 Jerusalem, Israel	Stahel, PF (corresponding author), Univ Zurich Hosp, Dept Surg, Div Trauma Surg, CH-8091 Zurich, Switzerland.		Lenzlinger, Philipp/A-3822-2008	Morganti-Kossmann, Cristina/0000-0002-0807-2063			BARGER SW, 1995, P NATL ACAD SCI USA, V92, P9328, DOI 10.1073/pnas.92.20.9328; Barone FC, 1997, STROKE, V28, P1233, DOI 10.1161/01.STR.28.6.1233; Bazzoni F, 1996, NEW ENGL J MED, V334, P1717, DOI 10.1056/NEJM199606273342607; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; BENIADANI L, 1998, P 28 ANN M SOC NEUR; BIAGAS KV, 1992, J NEUROTRAUM, V9, P363, DOI 10.1089/neu.1992.9.363; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; deVries HE, 1996, J NEUROIMMUNOL, V64, P37, DOI 10.1016/0165-5728(95)00148-4; Durum SK, 1998, CONT IMMUN, pVII; Ebadi M, 1997, NEUROCHEM INT, V30, P347, DOI 10.1016/S0197-0186(96)00071-X; Eugster HP, 1999, EUR J IMMUNOL, V29, P626, DOI 10.1002/(SICI)1521-4141(199902)29:02<626::AID-IMMU626>3.3.CO;2-1; Eugster HP, 1996, INT IMMUNOL, V8, P23, DOI 10.1093/intimm/8.1.23; Eugster HP, 1998, EUR J IMMUNOL, V28, P2178, DOI 10.1002/(SICI)1521-4141(199807)28:07<2178::AID-IMMU2178>3.0.CO;2-D; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Feuerstein G, 1998, CELL MOL NEUROBIOL, V18, P695, DOI 10.1023/A:1020226020062; Feuerstein GZ, 1998, NEUROIMMUNOMODULAT, V5, P143, DOI 10.1159/000026331; Fox GB, 1999, J NEUROTRAUM, V16, P377, DOI 10.1089/neu.1999.16.377; Frei K, 1997, J EXP MED, V185, P2177, DOI 10.1084/jem.185.12.2177; Gary DS, 1998, J CEREBR BLOOD F MET, V18, P1283, DOI 10.1097/00004647-199812000-00001; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; Gruol DL, 1997, MOL NEUROBIOL, V15, P307, DOI 10.1007/BF02740665; Hans VHJ, 1999, J CEREBR BLOOD F MET, V19, P184; Hans VHJ, 1999, NEUROREPORT, V10, P409; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; KIM KS, 1992, LYMPHOKINE CYTOK RES, V11, P293; Klein MA, 1997, GLIA, V19, P227, DOI 10.1002/(SICI)1098-1136(199703)19:3<227::AID-GLIA5>3.0.CO;2-W; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; Lavine SD, 1998, J CEREBR BLOOD F MET, V18, P52, DOI 10.1097/00004647-199801000-00005; Liu JL, 1998, NAT MED, V4, P78, DOI 10.1038/nm0198-078; LIU T, 1994, STROKE, V25, P1481, DOI 10.1161/01.STR.25.7.1481; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; MEGYERI P, 1992, NEUROSCI LETT, V148, P137, DOI 10.1016/0304-3940(92)90823-P; Meistrell ME, 1997, SHOCK, V8, P341; MERRILL JE, 1992, DEV NEUROSCI-BASEL, V14, P1, DOI 10.1159/000111642; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Nawashiro H, 1997, J CEREBR BLOOD F MET, V17, P483, DOI 10.1097/00004647-199705000-00001; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; Penkowa M, 1999, GLIA, V25, P343; Pollack A, 1990, Methods Cell Biol, V33, P19; Probert L, 1997, J NEUROIMMUNOL, V72, P137, DOI 10.1016/S0165-5728(96)00184-1; QUAGLIARELLO VJ, 1991, J CLIN INVEST, V87, P1360, DOI 10.1172/JCI115140; Raine CS, 1998, REV NEUROL-FRANCE, V154, P577; RAMILO O, 1990, J EXP MED, V172, P497, DOI 10.1084/jem.172.2.497; Ransohoff RM, 1998, TRENDS NEUROSCI, V21, P154, DOI 10.1016/S0166-2236(97)01198-3; Riminton DS, 1998, J EXP MED, V187, P1517, DOI 10.1084/jem.187.9.1517; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; RUDDLE NH, 1992, CURR OPIN IMMUNOL, V4, P327, DOI 10.1016/0952-7915(92)90084-R; SAUKKONEN K, 1990, J EXP MED, V171, P439, DOI 10.1084/jem.171.2.439; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; SELMAJ K, 1991, J IMMUNOL, V147, P1522; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; Stalder AK, 1998, AM J PATHOL, V153, P767, DOI 10.1016/S0002-9440(10)65620-9; Suen WE, 1997, J EXP MED, V186, P1233, DOI 10.1084/jem.186.8.1233; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TCHELINGERIAN JL, 1993, NEURON, V10, P213, DOI 10.1016/0896-6273(93)90312-F; UYAMA O, 1988, J CEREBR BLOOD F MET, V8, P282, DOI 10.1038/jcbfm.1988.59; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; YAN HQ, 1992, EUR J IMMUNOL, V22, P2963, DOI 10.1002/eji.1830221131; Yang GY, 1998, NEUROREPORT, V9, P2131, DOI 10.1097/00001756-199806220-00041	75	204	207	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	FEB	2000	20	2					369	380		10.1097/00004647-200002000-00019			12	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	285JE	WOS:000085385300019	10698075	Bronze			2021-06-18	
J	Bazarian, JJ; Wong, T; Harris, M; Leahey, N; Mookerjee, S; Dombovy, M				Bazarian, JJ; Wong, T; Harris, M; Leahey, N; Mookerjee, S; Dombovy, M			Epidemiology and predictors of post-concussive syndrome after minor head injury in an emergency population	BRAIN INJURY			English	Article							TRAUMATIC BRAIN INJURIES; FOLLOW-UP; POSTCONCUSSION SYNDROME; NATURAL-HISTORY; SEQUELAE; SYMPTOMS; CONSCIOUSNESS; RECOVERY	Objective: To determine if clinical variables or neurobehavioural test (NBT) scores obtained in the ED within 24 hours of minor head injury (MHI) predict the development of postconcussive syndrome (PCS). Methods: Prospective, observational study of 71 MHI patients and 60 orthopaedic controls. MHI defined as loss of consciousness < 10 minutes or amnesia, GCS 15, no skull fracture or new neurologic focality on PE, and no brain injury on CT (if done). All patients received a seven part NBT battery in the ED. Telephone follow-up was done at 1, 3 and 6 months to determine if patients met the DSM IV definition of PCS. Analysis: Stepwise, multivariate, logistic regression. Results: Predictors of PCS at 1 month were female gender (OR = 7.8; 95% CI = 41.6, 1.98), presence of both retrograde and anterograde amnesia (OR = 0.055; CI = 0.002, 0.47), Digit Span Forward Scores (OR = 0.748; CI = 0.52, 1.03) and Hopkins Verbal Learning A scores (OR = 0.786; CI = 0.65, 0.91); at 3 months, presence of both retrograde and anterograde amnesia (OR = 0.13; CI = 0.0, 0.93), Digit Span Forward Scores (OR = 0.744; CI = 0.58, 0.94). No variables Gt the model at 6 months. 92% of males scoring > 25 on Hopkins Verbal Learning A did not have PCS at 1 month, and 89% of females scoring < 9 on Digit Span Forward did have PCS at 1 month. Conclusions: Gender and two NBTs can help predict PCS after MHI.	Univ Rochester, Med Ctr, Dept Emergency Med, Rochester, NY 14642 USA; St Marys Hosp, Brain Injury Rehabil Unit, Rochester, NY USA	Bazarian, JJ (corresponding author), Univ Rochester, Med Ctr, Dept Emergency Med, Box 4-9200,601 Elmwood Ave, Rochester, NY 14642 USA.	jeff_bazarian@urmc.rochester.edu					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; *AM PSYCH ASS, 1994, DIAGN STAT MAN MENT, P704; Anderson SD, 1996, B AM ACAD PSYCH LAW, V24, P493; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; BARRETT K, 1994, J ACCID EMERG MED, V11, P79; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Blostein PA, 1997, J NEUROTRAUM, V14, P171, DOI 10.1089/neu.1997.14.171; BOREZUK P, 1997, EMERGENCY MED CLIN N, V15, P563; Bring G, 1996, ACCIDENT ANAL PREV, V28, P359, DOI 10.1016/0001-4575(96)00002-4; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; Chambers J, 1996, J TRAUMA, V41, P976, DOI 10.1097/00005373-199612000-00006; Cobaugh DJ, 1997, ACAD EMERG MED, V4, P231, DOI 10.1111/j.1553-2712.1997.tb03748.x; COONLEYHOGANSON R, 1984, NEUROSURGERY, V14, P315, DOI 10.1227/00006123-198403000-00009; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; EVANS RW, 1994, HEADACHE, V34, P268, DOI 10.1111/j.1526-4610.1994.hed3405268.x; EVANS RW, 1994, SEMIN NEUROL, V14, P32, DOI 10.1055/s-2008-1041056; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; Levin H. S., 1987, NEUROBEHAVIORAL RECO, P262; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MARSH NV, 1995, BRAIN INJURY, V9, P553, DOI 10.3109/02699059509008214; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Parker RS, 1996, BRAIN INJURY, V10, P287, DOI 10.1080/026990596124467; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rutherford W. H., 1989, MILD HEAD INJURY, P217; RUTHERFORD WH, 1977, LANCET, V1, P1; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Stablum F, 1996, CORTEX, V32, P261, DOI 10.1016/S0010-9452(96)80050-5; Stewart DP, 1996, ACAD EMERG MED, V3, P21, DOI 10.1111/j.1553-2712.1996.tb03297.x; Wechsler D., 1987, WECHSLER MEMORY SCAL	35	204	205	0	10	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	MAR	1999	13	3					173	189		10.1080/026990599121692			17	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	175LL	WOS:000079095900002	10081599				2021-06-18	
J	Brodie, HA; Thompson, TC				Brodie, HA; Thompson, TC			Management of complications from 820 temporal bone fractures	AMERICAN JOURNAL OF OTOLOGY			English	Article; Proceedings Paper	Annual Meeting of the American-Otological-Society	MAY 04-05, 1996	ORLANDO, FL	Amer Otol Soc		temporal bone fracture; CSF fistula; facial nerve paralysis; prophylactic antibiotics	BASILAR SKULL FRACTURE; FACIAL-NERVE; MIDDLE-EAR; HEAD-INJURY; MENINGITIS; TRAUMA; PARALYSIS; CHOLESTEATOMA; OBLITERATION	Objective: To review the incidence of complications resulting from temporal bone fractures and analyze the outcomes from surgical and nonsurgical management. Study Design: A retrospective review of 699 patients with 820 temporal bone fractures occurring over a 5-year period. Setting: A single level 1 trauma center. Patients: All patients with clinical or radiologic evidence of a temporal bone fracture. Results: A total of 820 fractured temporal bones resulted in 58 facial nerve injuries, 122 CSF fistulae, and 15 cases of meningitis. The two most important prognostic factors in recovery of facial paralysis were severity and delay of onset. All patients with incomplete paralysis recovered. All but one of the delayed onset palsies had good recovery of function. A total of 40% of patients with immediate onset complete paralysis had poor recovery of function. Ninety-five of the 122 CSF fistulae closed spontaneously within 1 week. CSF fistulae persisting for > 7 days had a significantly increased risk of developing meningitis (23%) compared with patients whose fistulae closed within 7 days (3%) (p = 0.001). Another important risk factor for the development of meningitis was concurrent infection. Conclusions: Facial function following temporal bone fractures should be evaluated in the emergency room. If facial motion is noted at any time after the injury, surgical intervention is rarely indicated. Prophylactic antibiotics should be considered in temporal bone fractures when CSF fistulae are present. Surgical closure of a CSF fistula is indicated if it persists for > 7-10 days.		Brodie, HA (corresponding author), UNIV CALIF DAVIS,SCH MED,OTOLARYNGOL RES LABS,MED CTR,DEPT OTOLARYNGOL HEAD & NECK SURG,DAVIS,CA 95616, USA.						ADKINS WY, 1983, LARYNGOSCOPE, V93, P1038; APPLEBAUM E, 1960, JAMA-J AM MED ASSOC, V173, P1818; BARRS DM, 1991, LARYNGOSCOPE, V101, P835; BRODIE HA, UNPUB ARCH OTOLARYNG; CANNON CR, 1983, ARCH OTOLARYNGOL, V109, P285; COKER NJ, 1986, ANN OTO RHINOL LARYN, V95, P5, DOI 10.1177/000348948609500102; COKER NJ, 1987, OTOLARYNG HEAD NECK, V97, P262, DOI 10.1177/019459988709700303; DAGI TF, 1983, AM J EMERG MED, V3, P295; EINHORN A, 1978, AM J DIS CHILD, V132, P1121, DOI 10.1001/archpedi.1978.02120360077015; FISCH U, 1974, LARYNGOSCOPE, V84, P2141, DOI 10.1288/00005537-197412000-00005; FISCH U, 1980, J LARYNGOL OTOL, V94, P129, DOI 10.1017/S0022215100088575; FISCH U, 1979, CLIN PLAST SURG, V178, P347; FRAZEE RC, 1988, POSTGRAD MED, V83, P267, DOI 10.1080/00325481.1988.11700238; FREDRICKSON JM, 1963, ARCHIV OTOLARYNGOL, V78, P770; GHORAYEB BY, 1992, LARYNGOSCOPE, V102, P129; GLASSCOCK ME, 1979, LARYNGOSCOPE, V89, P1743; GOIN DW, 1982, LARYNGOSCOPE, V92, P263; GRAHNE B, 1970, ACTA OTO-LARYNGOL, V70, P392, DOI 10.3109/00016487009181903; HEALY GB, 1982, NEW ENGL J MED, V306, P1029, DOI 10.1056/NEJM198204293061705; HELLING TS, 1988, J TRAUMA, V28, P1575, DOI 10.1097/00005373-198811000-00009; HOFF JT, 1976, J NEUROSURG, V44, P649; HOUGH JVD, 1969, ANN OTO RHINOL LARYN, V78, P210, DOI 10.1177/000348946907800202; HUGHES GB, 1982, OTOLARYNG HEAD NECK, V90, P117, DOI 10.1177/019459988209000120; IGNELZI RJ, 1975, J NEUROSURG, V43, P75; KAMERER DB, 1982, OTOLARYNG HEAD NECK, V90, P612, DOI 10.1177/019459988209000520; Kaufman B A, 1990, Infect Dis Clin North Am, V4, P677; Kelly K.E., 1994, NEUROTOLOGY, P340; Klastersky J, 1976, Surg Neurol, V6, P111; KRONENBERG J, 1988, AM J OTOL, V9, P127; KVETON JF, 1987, LARYNGOSCOPE, V97, P1385; LAMBERT PR, 1984, LARYNGOSCOPE, V94, P1022; LEECH PJ, 1973, LANCET, V1, P1013; MACGEE EE, 1970, J NEUROSURG, V33, P312, DOI 10.3171/jns.1970.33.3.0312; MAIMAN DJ, 1985, J TRAUMA, V25, P644, DOI 10.1097/00005373-198507000-00012; MAKASHIMA K, 1976, LARYNGOSCOPE, V86, P1303; MAY M, 1983, OTOLARYNG CLIN N AM, V16, P661; MAY M, 1979, LARYNGOSCOPE, V89, P906; MCCABE BF, 1970, PLAST RECONSTR SURG, V45, P70, DOI 10.1097/00006534-197001000-00010; MCKENNAN KX, 1992, AM J OTOL, V13, P167; MCKENNAN KX, 1989, LARYNGOSCOPE, V99, P779; MINCY JE, 1966, J TRAUM, V6, P618, DOI 10.1097/00005373-196609000-00007; NAGERIS B, 1995, AM J EMERG MED, V12, P211; Pearlmann HB, 1939, ARCH OTOLARYNGOL, V29, P287; POLLAK AM, 1991, AM J OTOLARYNG, V12, P56, DOI 10.1016/0196-0709(91)90075-Q; RATHORE MH, 1991, PEDIATR INFECT DIS J, V10, P87, DOI 10.1097/00006454-199102000-00001; SPETZLER RF, 1978, J NEUROSURG, V49, P393, DOI 10.3171/jns.1978.49.3.0393; TOS M, 1973, ACTA OTO-LARYNGOL, V75, P253; TRAVIS LW, 1977, J TRAUMA, V17, P761, DOI 10.1097/00005373-197710000-00003; TURNER JWA, 1944, LANCET, V246, P756; ULRICH K, 1926, ACTA OTOLARYNGOL S S, V4, P1; Virapongse C, 1987, RADIOLOGY DIAGNOSIS, V3; WARD PH, 1969, ANN OTO RHINOL LARYN, V78, P227, DOI 10.1177/000348946907800203; WIET RJ, 1985, AM J OTOL, V6, P207; YANAGIHARA N, 1982, OTOLARYNG HEAD NECK, V90, P616, DOI 10.1177/019459988209000521; Zrebeet H A, 1986, Del Med J, V58, P741	55	204	223	0	4	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0192-9763			AM J OTOL	Am. J. Otol.	MAR	1997	18	2					188	197					10	Otorhinolaryngology	Otorhinolaryngology	WQ042	WOS:A1997WQ04200014	9093676				2021-06-18	
J	Pierce, JES; Trojanowski, JQ; Graham, DI; Smith, DH; McIntosh, TK				Pierce, JES; Trojanowski, JQ; Graham, DI; Smith, DH; McIntosh, TK			Immunohistochemical characterization of alterations in the distribution of amyloid precursor proteins and beta-amyloid peptide after experimental brain injury in the rat	JOURNAL OF NEUROSCIENCE			English	Article						amyloid precursor proteins; amyloid precursor protein-like proteins; beta-amyloid; Alzheimer's disease; lateral fluid-percussion brain injury	DIFFUSE AXONAL INJURY; ALZHEIMERS-DISEASE; HEAD TRAUMA; NEUROFILAMENT SUBUNITS; MONOCLONAL-ANTIBODIES; CEREBRAL-ISCHEMIA; APOLIPOPROTEIN-E; HIPPOCAMPUS; EXPRESSION; ACCUMULATION	Recent reports suggest a relationship between traumatic brain injury and the precocious development of neurodegenerative cascades, including diffuse deposits of beta-amyloid peptides (A beta) in the injured brain. Because the lateral fluid-percussion (FP) model of experimental brain injury produces clinically relevant neuropathological sequelae in the rat brain, we used this model together with a series of antibodies specific for amyloid precursor proteins (APPs), APP-like proteins (APLPs), or A beta to identify acute neurodegenerative changes after brain trauma. Male Sprague-Dawley rats were anesthetized and subjected to lateral FP brain injury of moderate to high severity. At 1 hr, 2 hr, 48 hr, 1 week, or 2 weeks after injury, animals were killed and their brains were removed for immunohistochemical analysis. APP/APLP immunoreactivity increased in specific brain regions as early as 1 hr after injury and persisted for at least 2 weeks. Axons in the thalamus and subcortical white matter showed the greatest APP/APLP accumulation. Injured cortex, striatum, cingulum, and hippocampus also demonstrated significant axonal accumulations of APP/APLP. Accumulation of APP/APLPs occurred primarily ipsilateral to the injury, although bilateral changes were observed in some brain regions. No deposition of A beta was observed in any brain region at any lime point examined. These results demonstrate a pattern of widespread axonal pathology after lateral FP brain injury in the rat, characterized by intra-axonal accumulations of APP/APLP immunoreactivity in the absence of plaque-like deposits of A beta in the traumatized brain.	UNIV PENN, SCH MED, DIV NEUROSURG, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT PATHOL & LAB MED, PHILADELPHIA, PA 19104 USA; UNIV CONNECTICUT, CTR HLTH, NEUROSCI PROGRAM, FARMINGTON, CT 06030 USA; SO GEN HOSP, INST NEUROL SCI, DEPT NEUROPATHOL, GLASGOW G51 4TF, LANARK, SCOTLAND			smith, douglas/A-1321-2007		NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG10124] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS26818, NS08803] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026818, P50NS008803, R55NS026818, P01NS008803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG010124] Funding Source: NIH RePORTER		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ARAI H, 1990, P NATL ACAD SCI USA, V87, P2249, DOI 10.1073/pnas.87.6.2249; ARAI H, 1991, ANN NEUROL, V30, P686, DOI 10.1002/ana.410300509; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BROOKS DN, 1972, J NERV MENT DIS, V155, P350; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; CORDELL B, 1994, ANNU REV PHARMACOL, V34, P69; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FAN L, 1995, MOL BRAIN RES, V30, P125; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; FRASER PE, 1993, J NEUROCHEM, V61, P298, DOI 10.1111/j.1471-4159.1993.tb03568.x; GAMES D, 1995, NATURE, V373, P523, DOI 10.1038/373523a0; GANDY SE, 1992, J NEUROCHEM, V58, P383, DOI 10.1111/j.1471-4159.1992.tb09322.x; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTLEMAN SM, 1993, PROG BRAIN RES, V96, P237; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; HALL GF, 1989, J NEUROSCI, V9, P588; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HICKS R, 1996, IN PRESS ACTA NEUROP; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; HIGGINS GA, 1990, P NATL ACAD SCI USA, V87, P3032, DOI 10.1073/pnas.87.8.3032; HIGGINS LS, 1995, NEURODEGENERATION, V4, P117, DOI 10.1006/neur.1995.0015; JOHNSTONE EM, 1991, MOL BRAIN RES, V10, P299, DOI 10.1016/0169-328X(91)90088-F; KALARIA RN, 1993, NEUROREPORT, V4, P211, DOI 10.1097/00001756-199302000-00025; KAWARABAYASHI T, 1991, BRAIN RES, V563, P334, DOI 10.1016/0006-8993(91)91558-I; KIM KS, 1990, NEUROSCI RES COMMUN, V7, P113; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCLEAN JW, 1983, J BIOL CHEM, V258, P8993; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; NAKAMURA Y, 1992, NEUROSCI LETT, V136, P95, DOI 10.1016/0304-3940(92)90656-R; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; OTSUKA N, 1991, BRAIN RES, V568, P335, DOI 10.1016/0006-8993(91)91422-W; OUIMET CC, 1994, J COMP NEUROL, V348, P244, DOI 10.1002/cne.903480207; PHILLIPS LL, 1992, J NEUROTRAUM, V9, P323, DOI 10.1089/neu.1992.9.323; Pierce J. E. S., 1994, Society for Neuroscience Abstracts, V20, P196; PIERCE JES, 1993, BRAIN RES, V624, P199, DOI 10.1016/0006-8993(93)90078-2; Pilz P, 1983, Acta Neurochir Suppl (Wien), V32, P119; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Posmantur R. M., 1995, Society for Neuroscience Abstracts, V21, P1004; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; RAGHUPATHI R, 1995, J CEREBR BLOOD F MET, V15, P467, DOI 10.1038/jcbfm.1995.58; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; ROSES AD, 1994, J NEUROPATH EXP NEUR, V53, P429, DOI 10.1097/00005072-199409000-00002; ROYSTON MC, 1992, TRENDS PHARMACOL SCI, V13, P131; Saatman K. E., 1994, Society for Neuroscience Abstracts, V20, P1115; SAATMAN KE, 1995, J NEUROTRAUM, V12, pA138; Sandbrink R, 1994, Neurobiol Dis, V1, P13, DOI 10.1006/nbdi.1994.0003; SCHMIDT ML, 1994, EXP NEUROL, V130, P311, DOI 10.1006/exnr.1994.1209; SCHMIDT ML, 1994, FEBS LETT, V344, P69, DOI 10.1016/0014-5793(94)00259-2; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.ne.17.030194.002421; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; SHIGEMATSU K, 1992, AM J PATHOL, V140, P787; SHIN RW, 1993, P NATL ACAD SCI USA, V90, P6825, DOI 10.1073/pnas.90.14.6825; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; SIMAN R, 1989, NEURON, V3, P275, DOI 10.1016/0896-6273(89)90252-3; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SNOW AD, 1994, NEURON, V12, P219, DOI 10.1016/0896-6273(94)90165-1; SOARES HD, 1996, IN PRESS J NEUROSCI; STANDAERT DG, 1991, AM J PATHOL, V139, P681; STEPHENSON DT, 1992, BRAIN RES, V593, P128, DOI 10.1016/0006-8993(92)91274-I; STRICH SJ, 1961, LANCET, V2, P443; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P280, DOI 10.1007/BF00308813; TOMIMOTO H, 1994, J CEREBR BLOOD F MET, V14, P565, DOI 10.1038/jcbfm.1994.70; TOPPER R, 1995, ACTA NEUROPATHOL, V89, P23; TROJANOWSKI JQ, 1994, AM J PATHOL, V144, P449; UTERMANN G, 1994, CURR BIOL, V4, P362, DOI 10.1016/S0960-9822(00)00081-6; WAKITA H, 1992, NEUROSCI LETT, V146, P135, DOI 10.1016/0304-3940(92)90061-B; WALLACE WC, 1991, MOL BRAIN RES, V10, P173, DOI 10.1016/0169-328X(91)90108-A; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006	87	204	207	0	5	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	FEB 1	1996	16	3					1083	1090					8	Neurosciences	Neurosciences & Neurology	TQ573	WOS:A1996TQ57300024	8558237				2021-06-18	
J	James, SL; Theadom, A; Ellenbogen, RG; Bannick, MS; Mountjoy-Venning, WC; Lucchesi, LR; Abbasi, N; Abdulkader, R; Abraha, HN; Adsuar, JC; Afarideh, M; Agrawal, S; Ahmadi, A; Ahmed, MB; Aichour, AN; Aichour, I; Aichour, MTE; Akinyemi, RO; Akseer, N; Alahdab, F; Alebel, A; Alghnam, SA; Ali, BA; Alsharif, U; Altirkawi, K; Andrei, CL; Anjomshoa, M; Ansari, H; Ansha, MG; Antonio, CAT; Appiah, SCY; Ariani, F; Asefa, NG; Asgedom, SW; Atique, S; Awasthi, A; Quintanilla, BPA; Ayuk, TB; Azzopardi, PS; Badali, H; Badawi, A; Balalla, S; Banstola, A; Barker-Collo, SL; Barnighausen, TW; Bedi, N; Behzadifar, M; Behzadifar, M; Bekele, BB; Belachew, AB; Belay, YA; Bennett, DA; Bensenor, IM; Berhane, A; Beuran, M; Bhalla, A; Bhaumik, S; Bhutta, ZA; Biadgo, B; Biffino, M; Bijani, A; Bililign, N; Birungi, C; Boufous, S; Brazinova, A; Brown, AW; Car, M; Cardenas, R; Carrero, JJ; Carvalho, F; Castaneda-Orjuela, CA; Catala-Lopez, F; Chaiah, Y; Champs, AP; Chang, JC; Choi, JYJ; Christopher, DJ; Cooper, C; Crowe, CS; Dandona, L; Dandona, R; Daryani, A; Davitoiu, DV; Degefa, MG; Demoz, GT; Deribe, K; Djalalinia, S; Do, HP; Doku, DT; Drake, TM; Dubey, M; Dubljanin, E; El-Khatib, Z; Eskandarieh, S; Esteghamati, A; Esteghamati, S; Faro, A; Farzadfar, F; Farzaei, MH; Fereshtehnejad, SM; Fernandes, E; Feyissa, GT; Filip, I; Fischer, F; Fukumoto, T; Ganji, M; Gankpe, FG; Gebre, AK; Gebrehiwot, TT; Gezae, KE; Gopalkrishna, G; Goulart, AC; Haagsma, JA; Haj-Mirzaian, A; Haj-Mirzaian, A; Hamadeh, RR; Hamidi, S; Haro, JM; Hassankhani, H; Hassen, HY; Havmoeller, R; Hawley, C; Hay, SI; Hegazy, MI; Hendrie, D; Henok, A; Hibstu, DT; Hoffman, HJ; Hole, MK; Rad, EH; Hosseini, SM; Hostiuc, S; Hu, G; Hussen, MA; Ilesanmi, OS; Irvani, SN; Jakovljevic, M; Jayaraman, S; Jha, RP; Jonas, JB; Jones, KM; Shushtari, ZJ; Jozwiak, JJ; Jurisson, M; Kabir, A; Kahsay, A; Kahssay, M; Kalani, R; Karch, A; Kasaeian, A; Kassa, GM; Kassa, TD; Kassa, ZY; Kengne, AP; Khader, YS; Khafaie, MA; Khalid, N; Khalil, I; Khan, EA; Khan, MS; Khang, YH; Khazaie, H; Khoja, AT; Khubchandani, J; Kiadaliri, AA; Kim, D; Kim, YE; Kisa, A; Koyanagi, A; Krohn, KJ; Defo, BK; Bicer, BK; Kumar, GA; Kumar, M; Lalloo, R; Lami, FH; Lansingh, VC; Laryea, DO; Latifi, A; Leshargie, CT; Levi, M; Li, SS; Liben, ML; Lotufo, PA; Lunevicius, R; Mahotra, NB; Majdan, M; Majeed, A; Malekzadeh, R; Manda, AL; Mansournia, MA; Massenburg, BB; Mate, KKV; Mehndiratta, MM; Mehta, V; Meles, H; Melese, A; Memiah, PTN; Mendoza, W; Mengistu, G; Meretoja, A; Meretoja, TJ; Mestrovic, T; Miazgowski, T; Miller, TR; Mini, GK; Mirica, A; Mirrakhimov, EM; Moazen, B; Mohammadi, M; Mokdad, AH; Molokhia, M; Monasta, L; Mondello, S; Moosazadeh, M; Moradi, G; Moradi, M; Moradi-Lakeh, M; Moradinazar, M; Morrison, SD; Moschos, MM; Mousavi, SM; Murthy, S; Musa, KI; Mustafa, G; Naghavi, M; Naik, G; Najafi, F; Nangia, V; Nascimento, BR; Negoi, I; Nguyen, TH; Nichols, E; Ningrum, DNA; Nirayo, YL; Nyasulu, PS; Ofori-Asenso, R; Ogbo, FA; Oh, IH; Okoro, A; Olagunju, AT; Olagunju, TO; Olivares, PR; Otstavnov, SS; Owolabi, MO; Mahesh, PA; Pakhale, S; Pandey, AR; Pesudovs, K; Pinilla-Monsalve, GD; Polinder, S; Poustchi, H; Prakash, S; Qorbani, M; Radfar, A; Rafay, A; Rafiei, A; Rahimi-Movaghar, A; Rahimi-Movaghar, V; Rahman, M; Rahman, MA; Rai, RK; Rajati, F; Ram, U; Rawaf, DL; Rawaf, S; Reiner, RC; Reis, C; Renzaho, AMN; Resnikoff, S; Rezaei, S; Rezaeian, S; Roever, L; Ronfani, L; Roshandel, G; Roy, N; Ruhago, GM; Saddik, B; Safari, H; Safiri, S; Sahraian, MA; Salamati, P; Saldanha, RD; Samy, AM; Sanabria, J; Santos, JV; Milicevic, MMMS; Sartorius, B; Satpathy, M; Schneider, IJC; Schwebel, DC; Sepanlou, SG; Shabaninejad, H; Shaikh, MAA; Shams-Beyranvand, M; Sharif, M; Sharif-Alhoseini, M; Islam, SMS; She, J; Sheikh, A; Shen, JB; Sheth, KN; Shibuya, K; Shiferaw, MS; Shigematsu, M; Shiri, R; Shiue, I; Shoman, H; Siabani, S; Siddiqi, TJ; Silva, JP; Silveira, DGA; Sinha, DN; Smith, M; Soares, AM; Sobhani, S; Soofi, M; Soriano, JB; Soyiri, IN; Stein, DJ; Stokes, MA; Sufiyan, MB; Sunguya, BF; Sunshine, JE; Sykes, BL; Szoeke, CEI; Tabares-Seisdedos, R; Ao, BJT; Tehrani-Banihashemi, A; Tekle, MG; Temsah, MH; Temsah, O; Topor-Madry, R; Tortajada-Girbes, M; Tran, BX; Tran, KB; Car, LT; Ukwaja, KN; Ullah, I; Usman, MS; Uthman, OA; Valdez, PR; Vasankari, TJ; Venketasubramanian, N; Violante, FS; Wagnew, FS; Waheed, Y; Wang, YP; Weldegwergs, KG; Werdecker, A; Wijeratne, T; Winkler, AS; Wyper, GMA; Yano, Y; Yaseri, M; Yasin, YJ; Ye, PP; Yimer, EM; Yip, P; Yisma, E; Yonemoto, N; Yoon, SJ; Yost, MG; Younis, MZ; Yousefifard, M; Yu, CH; Zaidi, Z; Bin Zaman, S; Zamani, M; Zenebe, ZM; Zodpey, S; Feigin, VL; Vos, T; Murray, CJL				James, Spencer L.; Theadom, Alice; Ellenbogen, Richard G.; Bannick, Marlena S.; Mountjoy-Venning, W. Cliff; Lucchesi, Lydia R.; Abbasi, Nooshin; Abdulkader, Rizwan; Abraha, Haftom Niguse; Adsuar, Jose C.; Afarideh, Mohsen; Agrawal, Sutapa; Ahmadi, Alireza; Ahmed, Muktar Beshir; Aichour, Amani Nidhal; Aichour, Ibtihel; Aichour, Miloud Taki Eddine; Akinyemi, Rufus Olusola; Akseer, Nadia; Alahdab, Fares; Alebel, Animut; Alghnam, Suliman A.; Ali, Beriwan Abdulqadir; Alsharif, Ubai; Altirkawi, Khalid; Andrei, Catalina Liliana; Anjomshoa, Mina; Ansari, Hossein; Ansha, Mustafa Geleto; Antonio, Carl Abelardo T.; Appiah, Seth Christopher Yaw; Ariani, Filippo; Asefa, Nigus Gebremedhin; Asgedom, Solomon Weldegebreal; Atique, Suleman; Awasthi, Ashish; Quintanilla, Beatriz Paulina Ayala; Ayuk, Tambe B.; Azzopardi, Peter S.; Badali, Hamid; Badawi, Alaa; Balalla, Shivanthi; Banstola, Amrit; Barker-Collo, Suzanne Lyn; Barnighausen, Till Winfried; Bedi, Neeraj; Behzadifar, Masoud; Behzadifar, Meysam; Bekele, Bayu Begashaw; Belachew, Abate Bekele; Belay, Yihalem Abebe; Bennett, Derrick A.; Bensenor, Isabela M.; Berhane, Adugnaw; Beuran, Mircea; Bhalla, Ashish; Bhaumik, Soumyadeeep; Bhutta, Zulfiqar A.; Biadgo, Belete; Biffino, Marco; Bijani, Ali; Bililign, Nigus; Birungi, Charles; Boufous, Soufiane; Brazinova, Alexandra; Brown, Allen W.; Car, Mate; Cardenas, Rosario; Carrero, Juan J.; Carvalho, Felix; Castaneda-Orjuela, Carlos A.; Catala-Lopez, Ferran; Chaiah, Yazan; Champs, Ana Paula; Chang, Jung-Chen; Choi, Jee-Young J.; Christopher, Devasahayam J.; Cooper, Cyrus; Crowe, Christopher Stephen; Dandona, Lalit; Dandona, Rakhi; Daryani, Ahmad; Davitoiu, Dragos Virgil; Degefa, Meaza Girma; Demoz, Gebre Teklemariam; Deribe, Kebede; Djalalinia, Shirin; Huyen Phuc Do; Doku, David Teye; Drake, Thomas M.; Dubey, Manisha; Dubljanin, Eleonora; El-Khatib, Ziad; Eskandarieh, Sharareh; Esteghamati, Alireza; Esteghamati, Sadaf; Faro, Andre; Farzadfar, Farshad; Farzaei, Mohammad Hosein; Fereshtehnejad, Seyed-Mohammad; Fernandes, Eduarda; Feyissa, Garumma Tolu; Filip, Irina; Fischer, Florian; Fukumoto, Takeshi; Ganji, Morasaleh; Gankpe, Fortune Gbetoho; Gebre, Abadi Kahsu; Gebrehiwot, Tsegaye Tewelde; Gezae, Kebede Embaye; Gopalkrishna, Gururaj; Goulart, Alessandra C.; Haagsma, Juanita A.; Haj-Mirzaian, Arvin; Haj-Mirzaian, Arya; Hamadeh, Randah R.; Hamidi, Samer; Haro, Josep Maria; Hassankhani, Hadi; Hassen, Hamid Yimam; Havmoeller, Rasmus; Hawley, Caitlin; Hay, Simon I.; Hegazy, Mohamed I.; Hendrie, Delia; Henok, Andualem; Hibstu, Desalegn Tsegaw; Hoffman, Howard J.; Hole, Michael K.; Rad, Enayatollah Homaie; Hosseini, Seyed Mostafa; Hostiuc, Sorin; Hu, Guoqing; Hussen, Mamusha Aman; Ilesanmi, Olayinka Stephen; Irvani, Seyed Naghibi; Jakovljevic, Mihajlo; Jayaraman, Sudha; Jha, Ravi Prakash; Jonas, Jost B.; Jones, Kelly M.; Shushtari, Zahra Jorjoran; Jozwiak, Jacek Jerzy; Jurisson, Mikk; Kabir, Ali; Kahsay, Amaha; Kahssay, Molla; Kalani, Rizwan; Karch, Andre; Kasaeian, Amir; Kassa, Getachew Mullu; Kassa, Tesfaye Dessale; Kassa, Zemenu Yohannes; Kengne, Andre Pascal; Khader, Yousef Saleh; Khafaie, Morteza Abdullatif; Khalid, Nauman; Khalil, Ibrahim; Khan, Ejaz Ahmad; Khan, Muhammad Shahzeb; Khang, Young-Ho; Khazaie, Habibolah; Khoja, Abdullah T.; Khubchandani, Jagdish; Kiadaliri, Aliasghar A.; Kim, Daniel; Kim, Young-Eun; Kisa, Adnan; Koyanagi, Ai; Krohn, Kristopher J.; Defo, Barthelemy Kuate; Bicer, Burcu Kucuk; Kumar, G. Anil; Kumar, Manasi; Lalloo, Ratilal; Lami, Faris Hasan; Lansingh, Van C.; Laryea, Dennis Odai; Latifi, Arman; Leshargie, Cheru Tesema; Levi, Miriam; Li, Shanshan; Liben, Misgan Legesse; Lotufo, Paulo A.; Lunevicius, Raimundas; Mahotra, Narayan Bahadur; Majdan, Marek; Majeed, Azeem; Malekzadeh, Reza; Manda, Ana-Laura; Mansournia, Mohammad Ali; Massenburg, Benjamin Ballard; Mate, Kedar K. V.; Mehndiratta, Man Mohan; Mehta, Varshil; Meles, Hagazi; Melese, Addisu; Memiah, Peter T. N.; Mendoza, Walter; Mengistu, Getnet; Meretoja, Atte; Meretoja, Tuomo J.; Mestrovic, Tomislav; Miazgowski, Tomasz; Miller, Ted R.; Mini, G. K.; Mirica, Andreea; Mirrakhimov, Erkin M.; Moazen, Babak; Mohammadi, Moslem; Mokdad, Ali H.; Molokhia, Mariam; Monasta, Lorenzo; Mondello, Stefania; Moosazadeh, Mahmood; Moradi, Ghobad; Moradi, Mahmoudreza; Moradi-Lakeh, Maziar; Moradinazar, Mehdi; Morrison, Shane Douglas; Moschos, Marilita M.; Mousavi, Seyyed Meysam; Murthy, Srinivas; Musa, Kamarul Imran; Mustafa, Ghulam; Naghavi, Mohsen; Naik, Gurudatta; Najafi, Farid; Nangia, Vinay; Nascimento, Bruno Ramos; Negoi, Ionut; Trang Huyen Nguyen; Nichols, Emma; Ningrum, Dina Nur Anggraini; Nirayo, Yirga Legesse; Nyasulu, Peter S.; Ofori-Asenso, Richard; Ogbo, Felix Akpojene; Oh, In-Hwan; Okoro, Anselm; Olagunju, Andrew T.; Olagunju, Tinuke O.; Olivares, Pedro R.; Otstavnov, Stanislav S.; Owolabi, Mayowa Ojo; Mahesh, P. A.; Pakhale, Smita; Pandey, Achyut Raj; Pesudovs, Konrad; Pinilla-Monsalve, Gabriel D.; Polinder, Suzanne; Poustchi, Hossein; Prakash, Swayam; Qorbani, Mostafa; Radfar, Amir; Rafay, Anwar; Rafiei, Alireza; Rahimi-Movaghar, Afarin; Rahimi-Movaghar, Vafa; Rahman, Mahfuzar; Rahman, Muhammad Aziz; Rai, Rajesh Kumar; Rajati, Fatemeh; Ram, Usha; Rawaf, David Laith; Rawaf, Salman; Reiner, Robert C.; Reis, Cesar; Renzaho, Andre M. N.; Resnikoff, Serge; Rezaei, Satar; Rezaeian, Shahab; Roever, Leonardo; Ronfani, Luca; Roshandel, Gholamreza; Roy, Nobhojit; Ruhago, George Mugambage; Saddik, Basema; Safari, Hosein; Safiri, Saeid; Sahraian, Mohammad Ali; Salamati, Payman; Saldanha, Raphael de Freitas; Samy, Abdallah M.; Sanabria, Juan; Santos, Joao Vasco; Milicevic, Milena M. M. Santric; Sartorius, Benn; Satpathy, Maheswar; Schneider, Ione J. C.; Schwebel, David C.; Sepanlou, Sadaf G.; Shabaninejad, Hosein; Shaikh, Masood A. Ali; Shams-Beyranvand, Mehran; Sharif, Mehdi; Sharif-Alhoseini, Mahdi; Islam, Sheikh Mohammed Shariful; She, Jun; Sheikh, Aziz; Shen, Jiabin; Sheth, Kevin N.; Shibuya, Kenji; Shiferaw, Mekonnen Sisay; Shigematsu, Mika; Shiri, Rahman; Shiue, Ivy; Shoman, Haitham; Siabani, Soraya; Siddiqi, Tariq J.; Silva, Joao Pedro; Silveira, Dayane Gabriele Alves; Sinha, Dhirendra Narain; Smith, Mari; Soares Filho, Adauto Martins; Sobhani, Soheila; Soofi, Moslem; Soriano, Joan B.; Soyiri, Ireneous N.; Stein, Dan J.; Stokes, Mark A.; Sufiyan, Mu'awiyyah Babale; Sunguya, Bruno F.; Sunshine, Jacob E.; Sykes, Bryan L.; Szoeke, Cassandra E. I.; Tabares-Seisdedos, Rafael; Ao, Braden James Te; Tehrani-Banihashemi, Arash; Tekle, Merhawi Gebremedhin; Temsah, Mohamad-Hani; Temsah, Omar; Topor-Madry, Roman; Tortajada-Girbes, Miguel; Bach Xuan Tran; Khanh Bao Tran; Car, Lorainne Tudor; Ukwaja, Kingsley Nnanna; Ullah, Irfan; Usman, Muhammad Shariq; Uthman, Olalekan A.; Valdez, Pascual R.; Vasankari, Tommi Juhani; Venketasubramanian, Narayanaswamy; Violante, Francesco S.; Wagnew, Fasil Shiferaw; Waheed, Yasir; Wang, Yuan-Pang; Weldegwergs, Kidu Gidey; Werdecker, Andrea; Wijeratne, Tissa; Winkler, Andrea Sylvia; Wyper, Grant M. A.; Yano, Yuichiro; Yaseri, Mehdi; Yasin, Yasin Jemal; Ye, Pengpeng; Yimer, Ebrahim M.; Yip, Paul; Yisma, Engida; Yonemoto, Naohiro; Yoon, Seok-Jun; Yost, Michael G.; Younis, Mustafa Z.; Yousefifard, Mahmoud; Yu, Chuanhua; Zaidi, Zoubida; Bin Zaman, Sojib; Zamani, Mohammad; Zenebe, Zerihun Menlkalew; Zodpey, Sanjay; Feigin, Valery L.; Vos, Theo; Murray, Christopher J. L.		GBD 2016 Traumatic Brain Injury Sp	Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016	LANCET NEUROLOGY			English	Article							UNITED-STATES; NEW-ZEALAND; EPIDEMIOLOGY; SURVIVAL; RISK	Background Traumatic brain injury (TBI) and spinal cord injury (SCI) are increasingly recognised as global health priorities in view of the preventability of most injuries and the complex and expensive medical care they necessitate. We aimed to measure the incidence, prevalence, and years of life lived with disability (YLDs) for TBI and SCI from all causes of injury in every country, to describe how these measures have changed between 1990 and 2016, and to estimate the proportion of TBI and SCI cases caused by different types of injury. Methods We used results from the Global Burden of Diseases, Injuries, and Risk Factors (GBD) Study 2016 to measure the global, regional, and national burden of TBI and SCI by age and sex. We measured the incidence and prevalence of all causes of injury requiring medical care in inpatient and outpatient records, literature studies, and survey data. By use of clinical record data, we estimated the proportion of each cause of injury that required medical care that would result in TBI or SCI being considered as the nature of injury. We used literature studies to establish standardised mortality ratios and applied differential equations to convert incidence to prevalence of long-term disability. Finally, we applied GBD disability weights to calculate YLDs. We used a Bayesian meta-regression tool for epidemiological modelling, used cause-specific mortality rates for non-fatal estimation, and adjusted our results for disability experienced with comorbid conditions. We also analysed results on the basis of the Socio-demographic Index, a compound measure of income per capita, education, and fertility. Findings In 2016, there were 27.08 million (95% uncertainty interval [UI] 24.30-30.30 million) new cases of TBI and 0.93 million (0.78-1.16 million) new cases of SCI, with age-standardised incidence rates of 369 (331-412) per 100 000 population for TBI and 13 (11-16) per 100 000 for SCI. In 2016, the number of prevalent cases of TBI was 55.50 million (53.40-57.62 million) and of SCI was 27.04 million (24 .98-30 .15 million). From 1990 to 2016, the age-standardised prevalence of TBI increased by 8.4% (95% UI 7.7 to 9.2), whereas that of SCI did not change significantly (-0.2% [-2.1 to 2.7]). Age-standardised incidence rates increased by 3.6% (1.8 to 5.5) for TBI, but did not change significantly for SCI (-3.6% [-7.4 to 4.0]). TBI caused 8.1 million (95% UI 6. 0-10. 4 million) YLDs and SCI caused 9.5 million (6.7-12.4 million) YLDs in 2016, corresponding to age-standardised rates of 111 (82-141) per 100 000 for TBI and 130 (90-170) per 100 000 for SCI. Falls and road injuries were the leading causes of new cases of TBI and SCI in most regions. Interpretation TBI and SCI constitute a considerable portion of the global injury burden and are caused primarily by falls and road injuries. The increase in incidence of TBI over time might continue in view of increases in population density, population ageing, and increasing use of motor vehicles, motorcycles, and bicycles. The number of individuals living with SCI is expected to increase in view of population growth, which is concerning because of the specialised care that people with SCI can require. Our study was limited by data sparsity in some regions, and it will be important to invest greater resources in collection of data for TBI and SCI to improve the accuracy of future assessments. Copyright (C) 2018 The Author(s). Published by Elsevier Ltd.	[James, Spencer L.; Bannick, Marlena S.; Mountjoy-Venning, W. Cliff; Lucchesi, Lydia R.; Dandona, Lalit; Dandona, Rakhi; Hawley, Caitlin; Hay, Simon I.; Jakovljevic, Mihajlo; Khalil, Ibrahim; Krohn, Kristopher J.; Mokdad, Ali H.; Naghavi, Mohsen; Nichols, Emma; Reiner, Robert C.; Smith, Mari; Feigin, Valery L.; Vos, Theo; Murray, Christopher J. L.] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98121 USA; [Hay, Simon I.; Khalil, Ibrahim; Mokdad, Ali H.; Naghavi, Mohsen; Reiner, Robert C.; Vos, Theo; Murray, Christopher J. L.] Univ Washington, Dept Hlth Metr Sci, Seattle, WA 98195 USA; [Sunshine, Jacob E.] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA; [Yost, Michael G.] Univ Washington, Dept Environm & Occupat Hlth Sci, Seattle, WA 98195 USA; [Ellenbogen, Richard G.; Kalani, Rizwan] Univ Washington, Dept Neurol, Seattle, WA 98195 USA; [Morrison, Shane Douglas] Univ Washington, Dept Surg, Seattle, WA 98195 USA; [Crowe, Christopher Stephen; Massenburg, Benjamin Ballard] Univ Washington, Dept Surg, Div Plast Surg, Seattle, WA 98195 USA; [Theadom, Alice; Ao, Braden James Te; Feigin, Valery L.] Auckland Univ Technol, Natl Inst Stroke & Appl Neurosci, Auckland, New Zealand; [Balalla, Shivanthi] Auckland Univ Technol, Sch Publ Hlth, Auckland, New Zealand; [Jones, Kelly M.] Auckland Univ Technol, Auckland, New Zealand; [Ofori-Asenso, Richard] Monash Univ, Ctr Cardiovasc Res & Educ Therapeut, Melbourne, Vic, Australia; [Li, Shanshan] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia; [Sobhani, Soheila] Univ Tehran Med Sci, Dept Anat, Tehran, Iran; [Hosseini, Seyed Mostafa; Mansournia, Mohammad Ali; Yaseri, Mehdi] Univ Tehran Med Sci, Dept Epidemiol & Biostat, Tehran, Iran; [Anjomshoa, Mina; Mousavi, Seyyed Meysam] Univ Tehran Med Sci, Dept Hlth Management & Econ, Tehran, Iran; [Haj-Mirzaian, Arvin; Haj-Mirzaian, Arya] Univ Tehran Med Sci, Dept Pharmacol, Tehran, Iran; [Malekzadeh, Reza; Poustchi, Hossein; Roshandel, Gholamreza; Sepanlou, Sadaf G.] Univ Tehran Med Sci, Digest Dis Res Inst, Tehran, Iran; [Afarideh, Mohsen; Esteghamati, Alireza; Esteghamati, Sadaf; Ganji, Morasaleh] Univ Tehran Med Sci, Endocrinol & Metab Res Ctr, Tehran, Iran; [Kasaeian, Amir] Univ Tehran Med Sci, Hematol Malignancies Res Ctr, Tehran, Iran; [Kasaeian, Amir] Univ Tehran Med Sci, Hematol Oncol & Stem Cell Transplantat Res Ctr, Tehran, Iran; [Rahimi-Movaghar, Afarin] Univ Tehran Med Sci, Iranian Natl Ctr Addict Studies, Tehran, Iran; [Eskandarieh, Sharareh; Sahraian, Mohammad Ali] Univ Tehran Med Sci, MS Res Ctr, Tehran, Iran; [Abbasi, Nooshin; Farzadfar, Farshad; Irvani, Seyed Naghibi; Shams-Beyranvand, Mehran] Univ Tehran Med Sci, Noncommunicable Dis Res Ctr, Tehran, Iran; [Rahimi-Movaghar, Vafa; Salamati, Payman; Sharif-Alhoseini, Mahdi] Univ Tehran Med Sci, Sina Trauma & Surg Res Ctr, Tehran, Iran; [Abbasi, Nooshin] McGill Univ, Montreal Neuroimaging Ctr, Montreal, PQ, Canada; [Fereshtehnejad, Seyed-Mohammad] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada; [Mate, Kedar K. V.] McGill Univ, Sch Phys & Occupat Therapy, Montreal, PQ, Canada; [Abdulkader, Rizwan] Manonmaniam Sundaranar Univ, Dept Stat, Tirunelveli, India; [Abraha, Haftom Niguse; Kassa, Tesfaye Dessale; Nirayo, Yirga Legesse; Weldegwergs, Kidu Gidey] Mekelle Univ, Clin Pharm Unit, Mekelle, Ethiopia; [Gezae, Kebede Embaye] Mekelle Univ, Dept Biostat, Mekelle, Ethiopia; [Zenebe, Zerihun Menlkalew] Mekelle Univ, Dept Midwifery, Mekelle, Ethiopia; [Degefa, Meaza Girma; Kahsay, Amaha] Mekelle Univ, Dept Nutr & Dietet, Mekelle, Ethiopia; [Asgedom, Solomon Weldegebreal; Gebre, Abadi Kahsu; Yimer, Ebrahim M.] Mekelle Univ, Sch Pharm, Mekelle, Ethiopia; [Belachew, Abate Bekele] Mekelle Univ, Sch Publ Hlth, Mekelle, Ethiopia; [Meles, Hagazi] Mekelle Univ, Mekelle, Ethiopia; [Adsuar, Jose C.] Univ Extremadura, Sport Sci Dept, Badajoz, Spain; [Zodpey, Sanjay] Indian Inst Publ Hlth, Gurugram, India; [Agrawal, Sutapa; Awasthi, Ashish; Dandona, Lalit; Dandona, Rakhi; Kumar, G. Anil] Publ Hlth Fdn India, Gurugram, India; [Agrawal, Sutapa] Vital Strategies, Gurugram, India; [Ahmadi, Alireza] Kermanshah Univ Med Sci, Dept Anesthesiol, Kermanshah, Iran; [Najafi, Farid] Kermanshah Univ Med Sci, Dept Epidemiol & Biostat, Kermanshah, Iran; [Rajati, Fatemeh] Kermanshah Univ Med Sci, Dept Hlth Educ & Promot, Kermanshah, Iran; [Khazaie, Habibolah] Kermanshah Univ Med Sci, Dept Psychiat, Kermanshah, Iran; [Farzaei, Mohammad Hosein] Kermanshah Univ Med Sci, Dept Tradit & Complementary Med, Kermanshah, Iran; [Moradi, Mahmoudreza] Kermanshah Univ Med Sci, Dept Urol, Kermanshah, Iran; [Rezaei, Satar; Soofi, Moslem] Kermanshah Univ Med Sci, Environm Determinants Hlth Res Ctr, Kermanshah, Iran; [Siabani, Soraya] Kermanshah Univ Med Sci, Imam Ali Cardiovasc Res Ctr, Kermanshah, Iran; [Farzaei, Mohammad Hosein] Kermanshah Univ Med Sci, Pharmaceut Sci Res Ctr, Kermanshah, Iran; [Rezaeian, Shahab] Kermanshah Univ Med Sci, Kermanshah, Iran; [Ahmed, Muktar Beshir; Gebrehiwot, Tsegaye Tewelde] Jimma Univ, Dept Epidemiol, Jimma, Ethiopia; [Feyissa, Garumma Tolu; Hussen, Mamusha Aman] Jimma Univ, Dept Hlth Educ & Behav Sci, Jimma, Ethiopia; [Aichour, Amani Nidhal; Aichour, Ibtihel] Univ Ferhat Abbas Setif, Setif, Algeria; [Aichour, Miloud Taki Eddine] Higher Natl Sch Vet Med, Algiers, Algeria; [Akinyemi, Rufus Olusola; Owolabi, Mayowa Ojo] Univ Ibadan, Inst Adv Med Res & Training, Ibadan, Nigeria; [Akseer, Nadia; Bhutta, Zulfiqar A.] Univ Toronto, Ctr Global Child Hlth, Hosp Sick Children, Toronto, ON, Canada; [Badawi, Alaa] Univ Toronto, Dept Nutr Sci, Toronto, ON, Canada; [Alahdab, Fares] Mayo Clin, Fdn Med Educ & Res, Evidence Based Practice Ctr, Rochester, MN USA; [Alahdab, Fares] Syrian Amer Med Soc, Res Comm, Washington, DC USA; [Kassa, Getachew Mullu] Debre Markos Univ, Coll Hlth Sci, Debre Markos, Ethiopia; [Alebel, Animut; Wagnew, Fasil Shiferaw] Debre Markos Univ, Dept Nursing, Debre Markos, Ethiopia; [Belay, Yihalem Abebe; Leshargie, Cheru Tesema] Debre Markos Univ, Dept Publ Hlth, Debre Markos, Ethiopia; [Alghnam, Suliman A.] King Abdullah Int Med Res Ctr, Dept Populat Hlth Res, Riyadh, Saudi Arabia; [Ali, Beriwan Abdulqadir] Erbil Polytech Univ, Med Tech Inst, Erbil, Iraq; [Ali, Beriwan Abdulqadir] Ishik Univ, Fac Pharm, Erbil, Iraq; [Alsharif, Ubai] Charite, Med Ctr, Berlin, Germany; [Temsah, Mohamad-Hani] King Saud Univ, Dept Pediat, Riyadh, Saudi Arabia; [Altirkawi, Khalid] King Saud Univ, Riyadh, Saudi Arabia; [Davitoiu, Dragos Virgil] Carol Davila Univ Med & Pharm, Dept Gen Surg, Bucharest, Romania; [Hostiuc, Sorin] Carol Davila Univ Med & Pharm, Dept Legal Med & Bioeth, Bucharest, Romania; [Beuran, Mircea; Negoi, Ionut] Carol Davila Univ Med & Pharm, Emergency Hosp Bucharest, Bucharest, Romania; [Andrei, Catalina Liliana] Carol Davila Univ Med & Pharm, Bucharest, Romania; [Ansari, Hossein] Zahedan Univ Med Sci, Zahedan, Iran; [Ansha, Mustafa Geleto] Debre Berhan Univ, Dept Publ Hlth, Debre Berhan, Ethiopia; [Antonio, Carl Abelardo T.] Univ Philippines Manila, Dept Hlth Policy & Adm, Manila, Philippines; [Appiah, Seth Christopher Yaw] Kwame Nkrumah Univ Sci & Technol, Dept Sociol & Social Work, Kumasi, Ghana; [Appiah, Seth Christopher Yaw] Ludwig Maximilians Univ Munchen, Ctr Int Hlth, Munich, Germany; [Levi, Miriam] Reg Ctr Anal Data Occupat & Work Related Injuries, Florence, Italy; [Ariani, Filippo; Biffino, Marco] Tuscany Ctr, Local Hlth Unit, Florence, Italy; [Asefa, Nigus Gebremedhin] Univ Groningen, Univ Med Ctr Groningen, Groningen, Netherlands; [Atique, Suleman] Univ Lahore, Univ Inst Publ Hlth, Lahore, Pakistan; [Atique, Suleman] Univ Hail, Dept Publ Hlth, Hail, Saudi Arabia; [Awasthi, Ashish] Indian Inst Publ Hlth, Gandhinagar, India; [Rahman, Muhammad Aziz] La Trobe Univ, Austin Clin Sch Nursing, Melbourne, Vic, Australia; [Wijeratne, Tissa] La Trobe Univ, Dept Psychol, Melbourne, Vic, Australia; [Quintanilla, Beatriz Paulina Ayala] La Trobe Univ, Judith Lumley Ctr, Melbourne, Vic, Australia; [Quintanilla, Beatriz Paulina Ayala] Peruvian Natl Inst Hlth, Gen Off Res & Technol Transfer, Lima, Peru; [Ayuk, Tambe B.] Ctr Food & Nutr Res, Inst Med Res & Med Plant studies, Yaounde, Cameroon; [Azzopardi, Peter S.] Burnet Inst, Global Adolescent Hlth Grp, Melbourne, Vic, Australia; [Azzopardi, Peter S.] South Australian Hlth & Med Res Inst, Wardliparingga Aboriginal Res Unit, Adelaide, SA, Australia; [Rafiei, Alireza] Mazandaran Univ Med Sci, Dept Immunol, Sari, Iran; [Badali, Hamid] Mazandaran Univ Med Sci, Dept Med Mycol, Sari, Iran; [Mohammadi, Moslem] Mazandaran Univ Med Sci, Dept Physiol & Pharmacol, Sari, Iran; [Moosazadeh, Mahmood] Mazandaran Univ Med Sci, Hlth Sci Res Ctr, Sari, Iran; [Rafiei, Alireza] Mazandaran Univ Med Sci, Mol & Cell Biol Res Ctr, Sari, Iran; [Daryani, Ahmad] Mazandaran Univ Med Sci, Toxoplasmosis Res Ctr, Sari, Iran; [Badawi, Alaa] Publ Hlth Agcy Canada, Publ Hlth Risk Sci Div, Toronto, ON, Canada; [Banstola, Amrit] Publ Hlth Perspect Nepal, Dept Res, Pokhara Lekhnath, Nepal; [Khanh Bao Tran] Univ Auckland, Mol Med & Pathol, Auckland, New Zealand; [Ao, Braden James Te] Univ Auckland, Fac Med & Hlth Sci, Sch Populat Hlth, Auckland, New Zealand; [Barker-Collo, Suzanne Lyn] Univ Auckland, Sch Psychol, Auckland, New Zealand; [Barnighausen, Till Winfried] Heidelberg Univ Hosp, Inst Publ Hlth, Heidelberg, Germany; [Barnighausen, Till Winfried] Harvard Univ, TH Chan Sch Publ Hlth, Boston, MA 02115 USA; [Bedi, Neeraj] Gandhi Med Coll Bhopal, Dept Community Med, Bhopal, India; [Bedi, Neeraj] Jazan Univ, Jazan, Saudi Arabia; [Tehrani-Banihashemi, Arash] Iran Univ Med Sci, Dept Community Med, Tehran, Iran; [Shabaninejad, Hosein] Iran Univ Med Sci, Dept Hlth Policy, Tehran, Iran; [Behzadifar, Masoud] Iran Univ Med Sci, Hlth Management & Econ Res Ctr, Tehran, Iran; [Kabir, Ali] Iran Univ Med Sci, Minimally Invas Surg Res Ctr, Tehran, Iran; [Yousefifard, Mahmoud] Iran Univ Med Sci, Physiol Res Ctr, Tehran, Iran; [Moradi-Lakeh, Maziar; Tehrani-Banihashemi, Arash] Iran Univ Med Sci, Prevent Med & Publ Hlth Res Ctr, Tehran, Iran; [Behzadifar, Masoud; Behzadifar, Meysam] Lorestan Univ Med Sci, Social Determinants Hlth Res Ctr, Khorramabad, Iran; [Bekele, Bayu Begashaw; Hassen, Hamid Yimam] Mizan Tepi Univ, Dept Publ Hlth, Teppi, Ethiopia; [Henok, Andualem] Mizan Tepi Univ, Teppi, Ethiopia; [Biadgo, Belete] Univ Gondar, Dept Clin Chem, Gondar, Ethiopia; [Bekele, Bayu Begashaw] Univ Gondar, Inst Publ Hlth, Gondar, Ethiopia; [Bennett, Derrick A.] Univ Oxford, Nuffield Dept Populat Hlth, Oxford, England; [Goulart, Alessandra C.] Univ Sao Paulo, Ctr Clin & Epidemiol Res, Sao Paulo, Brazil; [Bensenor, Isabela M.] Univ Sao Paulo, Dept Internal Med, Sao Paulo, Brazil; [Lotufo, Paulo A.] Univ Sao Paulo, Dept Med, Sao Paulo, Brazil; [Wang, Yuan-Pang] Univ Sao Paulo, Dept Psychiat, Sao Paulo, Brazil; [Goulart, Alessandra C.] Univ Sao Paulo, Internal Med Dept, Sao Paulo, Brazil; [Yisma, Engida] Addis Ababa Univ, Sch Alaide Hlth Sci, Addis Ababa, Ethiopia; [Berhane, Adugnaw; Deribe, Kebede; Yasin, Yasin Jemal] Addis Ababa Univ, Sch Publ Hlth, Addis Ababa, Ethiopia; [Demoz, Gebre Teklemariam] Addis Ababa Univ, Addis Ababa, Ethiopia; [Bhalla, Ashish] Post Grad Inst Med Educ & Res, Dept Internal Med, Chandigarh, India; [Bhaumik, Soumyadeeep] George Inst Global Hlth, New Delhi, India; [Bhutta, Zulfiqar A.] Aga Khan Univ, Ctr Excellence Women & Child Hlth, Karachi, Pakistan; [Bijani, Ali] Babol Univ Med Sci, Social Determinant Hlth Res Ctr, Babol Sar, Iran; [Zamani, Mohammad] Babol Univ Med Sci, Student Res Comm, Babol Sar, Iran; [Bililign, Nigus] Woldia Univ, Woldia, Ethiopia; [Kumar, Manasi] UCL, Dept Psychol, London, England; [Birungi, Charles] UCL, UCL Ctr Global Hlth Econ, London, England; [Birungi, Charles] UNAIDS, Fast Track Implementat Dept, Gaborone, Botswana; [Boufous, Soufiane] Univ New South Wales, Transport & Rd Safety Res, Sydney, NSW, Australia; [Brazinova, Alexandra] Comenius Univ, Inst Epidemiol, Bratislava, Slovakia; [Brown, Allen W.] Mayo Clin, Coll Med, Dept Phys Med & Rehabil, Rochester, MN USA; [Car, Mate; Majeed, Azeem; Rawaf, Salman] Imperial Coll London, Dept Primary Care & Publ Hlth, London, England; [Rawaf, David Laith; Shoman, Haitham] Imperial Coll London, WHO Collaborating Ctr Publ Hlth Educ & Training, London, England; [Car, Mate] Minist Hlth, Riyadh, Saudi Arabia; [Cardenas, Rosario] Metropolitan Autonomous Univ, Dept Populat & Hlth, Mexico City, DF, Mexico; [Carrero, Juan J.] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden; [Fereshtehnejad, Seyed-Mohammad] Karolinska Inst, Dept Neurobiol Care Sci & Soc, Stockholm, Sweden; [El-Khatib, Ziad; Roy, Nobhojit] Karolinska Inst, Dept Publ Hlth Sci, Stockholm, Sweden; [Carvalho, Felix] Univ Porto, Appl Mol Biosci Unit, Porto, Portugal; [Santos, Joao Vasco] Univ Porto, Dept Community Med Informat & Hlth Decis Sci, CINTESIS, Fac Med, Porto, Portugal; [Carvalho, Felix] Univ Porto, Inst Publ Hlth, Porto, Portugal; [Fernandes, Eduarda] Univ Porto, REQUIMTE LAQV, Porto, Portugal; [Silva, Joao Pedro] Univ Porto, UCIBIO, Porto, Portugal; [Castaneda-Orjuela, Carlos A.] Natl Inst Hlth, Colombian Natl Hlth Observ, Bogota, Colombia; [Hoffman, Howard J.] Natl Inst Hlth, Natl Inst Deafness & Other Commun Disorders, Bogota, Colombia; [Castaneda-Orjuela, Carlos A.] Univ Nacl Colombia, Epidemiol & Publ Hlth Evaluat Grp, Bogota, Colombia; [Catala-Lopez, Ferran] Inst Hlth Carlos III, Dept Hlth Planning & Econ, Madrid, Spain; [Chaiah, Yazan; Temsah, Mohamad-Hani; Temsah, Omar] Alfaisal Univ, Coll Med, Riyadh, Saudi Arabia; [Chang, Jung-Chen] Natl Taiwan Univ, Coll Med, Taipei, Taiwan; [Choi, Jee-Young J.] Seoul Natl Univ Hosp, Biomed Sci, Biochem, Seoul, South Korea; [Christopher, Devasahayam J.] Christian Med Coll & Hosp, Dept Pulm Med, Vellore, Tamil Nadu, India; [Cooper, Cyrus] Univ Southampton, NIHR Oxford Biomed Res Ctr, Southampton, Hants, England; [Davitoiu, Dragos Virgil] Clin Emergency Hosp Sf Pantelimon, Dept Surg, Bucharest, Romania; [Demoz, Gebre Teklemariam] Aksum Univ, Dept Clin Pharm, Aksum, Ethiopia; [Deribe, Kebede] Brighton & Sussex Med Sch, Dept Global Hlth & Infect, Brighton, E Sussex, England; [Djalalinia, Shirin] Minist Hlth & Med Educ, Deputy Res & Technol, Tehran, Iran; [Huyen Phuc Do; Trang Huyen Nguyen] Duy Tan Univ, Inst Global Hlth Innovat, Hanoi, Vietnam; [Doku, David Teye] Univ Cape Coast, Dept Populat & Hlth, Cape Coast, Ghana; [Doku, David Teye] Univ Tampere, Fac Social Sci, Tampere, Finland; [Drake, Thomas M.] Univ Edinburgh, Dept Clin Surg, Edinburgh, Midlothian, Scotland; [Sheikh, Aziz; Soyiri, Ireneous N.] Univ Edinburgh, Usher Inst Populat Hlth Sci & Informat, Edinburgh, Midlothian, Scotland; [Dubey, Manisha] UN World Food Programme, New Delhi, India; [Milicevic, Milena M. M. Santric] Univ Belgrade, Ctr Sch Publ Hlth & Hlth Management, Belgrade, Serbia; [Dubljanin, Eleonora] Univ Belgrade, Fac Med, Belgrade, Serbia; [Ellenbogen, Richard G.] Seattle Childrens Hosp, Dept Surg, Seattle, WA USA; [Faro, Andre] Univ Fed Sergipe, Dept Psychol, Sao Cristovao, Brazil; [Filip, Irina] Kaiser Permanente, Psychiat, Fontana, CA USA; [Filip, Irina] AT Still Univ, Dept Hlth Sci, Mesa, AZ USA; [Radfar, Amir] AT Still Univ, Mesa, AZ USA; [Fischer, Florian] Bielefeld Univ, Dept Publ Hlth Med, Bielefeld, Germany; [Fukumoto, Takeshi] Canc Inst, Gene Express & Regulat Program, Philadelphia, PA USA; [Fukumoto, Takeshi] Kobe Univ, Dept Dermatol, Kobe, Hyogo, Japan; [Gankpe, Fortune Gbetoho] Univ Sidi Mohammed Ben Abdellah, Fac Med & Pharm Fez, Fes, Morocco; [Gankpe, Fortune Gbetoho] Non Communicable Dis Dept, Lab Studies & Res Act Hlth, Porto Novo, Benin; [Gopalkrishna, Gururaj] Natl Inst Mental Hlth & Neurosci, Dept Epidemiol, Bangalore, Karnataka, India; [Haagsma, Juanita A.; Polinder, Suzanne] Erasmus Univ, Med Ctr, Dept Publ Hlth, Rotterdam, Netherlands; [Yaseri, Mehdi] Shahid Beheshti Univ Med Sci, Ophthalm Res Ctr, Tehran, Iran; [Haj-Mirzaian, Arvin; Irvani, Seyed Naghibi] Shahid Beheshti Univ Med Sci, Res Inst Endocrine Sci, Tehran, Iran; [Khoja, Abdullah T.] Johns Hopkins Univ, Dept Hlth Policy & Management, Baltimore, MD 21218 USA; [Pinilla-Monsalve, Gabriel D.] Johns Hopkins Univ, Dept Neurol & Neurosurg, Baltimore, MD USA; [Haj-Mirzaian, Arya] Johns Hopkins Univ, Dept Radiol, Baltimore, MD USA; [Hamadeh, Randah R.] Arabian Gulf Univ, Dept Family & Community Med, Manama, Bahrain; [Hamidi, Samer] Hamdan Bin Mohammed Smart Univ, Sch Hlth & Environm Studies, Dubai, U Arab Emirates; [Haro, Josep Maria] Res & Dev Unit, Clin Microbiol & Parasitol Unit, San Juan De Dios Sanitary Pk, St Boi De Llobregat, Spain; [Haro, Josep Maria] Univ Barcelona, Dept Med, Barcelona, Spain; [Hassankhani, Hadi] Tabriz Univ Med Sci, Tabriz, Iran; [Havmoeller, Rasmus] Karolinska Univ Hosp, Clin Sci, Stockholm, Sweden; [Hegazy, Mohamed I.] Cairo Univ, Dept Neurol, Cairo, Egypt; [Hendrie, Delia; Miller, Ted R.] Curtin Univ, Sch Publ Hlth, Bentley, WA, Australia; [Hibstu, Desalegn Tsegaw] Hawassa Univ, Dept Reprod Hlth, Hawassa, Ethiopia; [Kassa, Zemenu Yohannes] Hawassa Univ, Sch Nursing & Midwifery, Hawassa, Ethiopia; [Hoffman, Howard J.] NIH, Div Sci Programs, Bldg 10, Bethesda, MD 20892 USA; [Hole, Michael K.] Univ Texas Austin, Austin, TX 78712 USA; [Rad, Enayatollah Homaie] Guilan Univ Med Sci, Guilan Rd Trauma Res Ctr & Sch, Rasht, Iran; [Hostiuc, Sorin] Natl Inst Legal Med Mina Minovici, Clin Legal Med, Bucharest, Romania; [Hu, Guoqing] Cent South Univ, Dept Epidemiol & Hlth Stat, Changsha, Hunan, Peoples R China; [Ilesanmi, Olayinka Stephen] Univ Liberia, Dept Publ Hlth & Community Med, Monrovia, Liberia; [Jakovljevic, Mihajlo] Univ Kragujevac, Med Sci Dept, Kragujevac, Serbia; [Jayaraman, Sudha] Virginia Commonwealth Univ, Dept Surg, Richmond, VA USA; [Jha, Ravi Prakash] Banaras Hindu Univ, Dept Community Med, Varanasi, Uttar Pradesh, India; [Jonas, Jost B.] Heidelberg Univ, Dept Ophthalmol, Mannheim, Germany; [Moazen, Babak] Heidelberg Univ, Inst Publ Hlth, Mannheim, Germany; [Jonas, Jost B.] Beijing Tongren Hosp, Beijing Inst Ophthalmol, Beijing, Peoples R China; [Shushtari, Zahra Jorjoran] Univ Social Welf & Rehabil Sci, Tehran, Iran; [Jozwiak, Jacek Jerzy] Czestochowa Tech Univ, Inst Hlth & Nutr Sci, Czestochowa, Poland; [Jozwiak, Jacek Jerzy] Univ Opole, Fac Med & Hlth Sci, Opole, Poland; [Jurisson, Mikk] Univ Tartu, Inst Family Med & Publ Hlth, Tartu, Estonia; [Kahssay, Molla; Liben, Misgan Legesse] Samara Univ, Dept Publ Hlth, Samara, Ethiopia; [Karch, Andre] Helmholtz Ctr Infect Res, Dept Epidemiol, Braunschweig, Germany; [Kengne, Andre Pascal] Med Res Council South Africa, Noncommunicable Dis Res Unit, Cape Town, South Africa; [Khader, Yousef Saleh] Jordan Univ Sci & Technol, Dept Publ Hlth & Community Med, Ramtha, Jordan; [Safari, Hosein] Ahvaz Jundishapur Univ Med Sci, Dept Neurosurg, Ahwaz, Iran; [Khafaie, Morteza Abdullatif] Ahvaz Jundishapur Univ Med Sci, Dept Publ Hlth, Ahwaz, Iran; [Khalid, Nauman] Univ Management & Technol, Sch Food & Agr Sci, Lahore, Pakistan; [Khan, Ejaz Ahmad] Hlth Serv Acad, Epidemiol & Biostat Dept, Islamabad, Pakistan; [Khan, Muhammad Shahzeb] John H Stroger Jr Hosp Cook Cty, Dept Internal Med, Chicago, IL USA; [Khan, Muhammad Shahzeb; Siddiqi, Tariq J.; Usman, Muhammad Shariq] Dow Univ Hlth Sci, Dept Internal Med, Karachi, Pakistan; [Khang, Young-Ho] Seoul Natl Univ, Dept Hlth Policy & Management, Seoul, South Korea; [Khang, Young-Ho] Seoul Natl Univ, Inst Hlth Policy & Management, Seoul, South Korea; [Khoja, Abdullah T.] Imam Muhammad Ibn Saud Islamic Univ, Dept Publ Hlth, Riyadh, Saudi Arabia; [Khubchandani, Jagdish] Ball State Univ, Dept Nutr & Hlth Sci, Muncie, IN 47306 USA; [Kiadaliri, Aliasghar A.] Lund Univ, Clin Epidemiol Unit, Lund, Sweden; [Kim, Daniel] Northeastern Univ, Dept Hlth Sci, Boston, MA 02115 USA; [Kim, Young-Eun; Yoon, Seok-Jun] Korea Univ, Dept Prevent Med, Seoul, South Korea; [Kisa, Adnan] Univ Oslo, Dept Hlth Management & Hlth Econ, Oslo, Norway; [Winkler, Andrea Sylvia] Univ Oslo, Inst Hlth & Soc, Oslo, Norway; [Kisa, Adnan] Tulane Univ, Dept Global Community Hlth & Behav Sci, New Orleans, LA 70118 USA; [Koyanagi, Ai] Res & Dev Unit, San Juan Dios De Sanitary Pk, St Boi De Llobregat, Spain; [Defo, Barthelemy Kuate] Univ Montreal, Dept Demog, Montreal, PQ, Canada; [Defo, Barthelemy Kuate] Univ Montreal, Dept Social & Prevent Med, Montreal, PQ, Canada; [Bicer, Burcu Kucuk] Yuksek Ihtisas Univ, Dept Publ Hlth, Fac Med, Ankara, Turkey; [Bicer, Burcu Kucuk] Hacettepe Univ, Dept Publ Hlth, Ankara, Turkey; [Kumar, Manasi] Univ Nairobi, Nairobi, Kenya; [Lalloo, Ratilal] Univ Queensland, Sch Dent, Brisbane, Qld, Australia; [Moradinazar, Mehdi] Acad Med Sci, Dept Epidemiol, Baghdad, Iraq; [Lami, Faris Hasan] Acad Med Sci, Dept Community & Family Med, Baghdad, Iraq; [Lansingh, Van C.] HelpMeSee, New York, NY USA; [Lansingh, Van C.] Mexican Inst Ophthalmol, Relaciones Int, Queretaro, Mexico; [Laryea, Dennis Odai] Ghana Hlth Serv, Dis Control Dept, Accra, Ghana; [Latifi, Arman] Maragheh Univ Med Sci, Dept Publ Hlth, Maragheh, Iran; [Safiri, Saeid] Maragheh Univ Med Sci, Managerial Epidemiol Res Ctr, Maragheh, Iran; [Levi, Miriam] Univ Florence, Dept Hlth Sci, Florence, Italy; [Lunevicius, Raimundas] Aintree Univ Hosp NHS Fdn Trust, Gen Surg Dept, Liverpool, Merseyside, England; [Lunevicius, Raimundas] Univ Liverpool, Surg Dept, Liverpool, Merseyside, England; [Mahotra, Narayan Bahadur] Tribhuvan Univ, Inst Med, Kathmandu, Nepal; [Majdan, Marek] Trnava Univ, Dept Publ Hlth, Trnava, Slovakia; [Malekzadeh, Reza; Sepanlou, Sadaf G.] Shiraz Univ Med Sci, Noncommunicable Dis Res Ctr, Shiraz, Iran; [Manda, Ana-Laura] Emergency Univ Hosp Bucharest, Surg Dept, Bucharest, Romania; [Mehndiratta, Man Mohan] Janakpuri Super Specialty Hosp Soc, Neurol Dept, New Delhi, India; [Mehta, Varshil] Sevenhills Hosp, Dept Internal Med, Bombay, Maharashtra, India; [Melese, Addisu] Debre Tabor Univ, Coll Hlth Sci, Debre Tabor, Ethiopia; [Memiah, Peter T. N.] Univ West Florida, Dept Publ Hlth, Pensacola, FL 32514 USA; [Mendoza, Walter] UNFPA, Peru Country Off, Lima, Peru; [Mengistu, Getnet; Shiferaw, Mekonnen Sisay] Haramaya Univ, Sch Pharm, Harar, Ethiopia; [Tekle, Merhawi Gebremedhin] Haramaya Univ, Sch Publ Hlth, Harar, Ethiopia; [Mengistu, Getnet] Wollo Univ, Dept Pharm, Dessie, Ethiopia; [Meretoja, Tuomo J.] Helsinki Univ Hosp, Breast Surg Unit, Helsinki, Finland; [Meretoja, Atte] Helsinki Univ Hosp, Neuroctr, Helsinki, Finland; [Wijeratne, Tissa] Univ Melbourne, Dept Med, Parkville, Vic, Australia; [Meretoja, Atte; Szoeke, Cassandra E. I.] Univ Melbourne, Sch Hlth Sci, Parkville, Vic, Australia; [Meretoja, Tuomo J.] Univ Helsinki, Helsinki, Finland; [Mestrovic, Tomislav] Dr Zora Profozic Polyclin, Zagreb, Croatia; [Mestrovic, Tomislav] Univ North, Univ Ctr Varazdin, Varazhdin, Croatia; [Miazgowski, Tomasz] Pomeranian Med Univ, Dept Hypertens, Szczecin, Poland; [Miller, Ted R.] Pacific Inst Res & Evaluat, Calverton, MD USA; [Mini, G. K.] Sree Chitra Tirunal Inst Med Sci & Technol, Achutha Menon Ctr Hlth Sci Studies, Trivandrum, Kerala, India; [Mini, G. K.] Amrita Inst Med Sci, Dept Publ Hlth, Kochi, Kerala, India; [Mirica, Andreea] Bucharest Univ Econ Studies, Dept Stat & Econometr, Bucharest, Romania; [Mirica, Andreea] Natl Inst Stat, Presidents Off, Bucharest, Romania; [Mirrakhimov, Erkin M.] Kyrgyz State Med Acad, Fac Gen Med, Bishkek, Kyrgyzstan; [Mirrakhimov, Erkin M.] Natl Ctr Cardiol & Internal Dis, Dept Atherosclerosis & Coronary Heart Dis, Bishkek, Kyrgyzstan; [Moazen, Babak] Frankfurt Univ Appl Sci, Inst Addict Res, Frankfurt, Germany; [Molokhia, Mariam] Kings Coll London, Fac Life Sci & Med, London, England; [Monasta, Lorenzo; Ronfani, Luca] Burlo Garofolo Inst Maternal & Child Hlth, Clin Epidemiol & Publ Hlth Res Unit, Trieste, Italy; [Mondello, Stefania] Univ Messina, Dept Biomed & Dent Sci & Morphofunct Imaging, Messina, Italy; [Mondello, Stefania] Oasi Res Inst, Dept Neurol, Troina, Italy; [Mondello, Stefania] Oasi Res Inst, Troina, Italy; [Moradi, Ghobad] Kurdistan Univ Med Sci, Dept Epidemiol & Biostat & Social Determinants, Hlth Res Ctr, Sanandaj, Iran; [Moschos, Marilita M.] Univ Athens, Gen Hosp Athens, Dept Ophthalmol 1, Athens, Greece; [Moschos, Marilita M.] Acad Athens, Biomed Res Fdn, Athens, Greece; [Murthy, Srinivas] Univ British Columbia, Dept Pediat, Vancouver, BC, Canada; [Musa, Kamarul Imran] Sci Univ Malaysia, Sch Med Sci, Kubang Kerian, Malaysia; [Mustafa, Ghulam] Nishtar Med Univ, Pediat Dept, Multan, Pakistan; [Mustafa, Ghulam] Inst Mother & Child Care, Pediat & Pediat Pulmonol, Multan, Pakistan; [Naik, Gurudatta] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL USA; [Schwebel, David C.] Univ Alabama Birmingham, Dept Psychol, Birmingham, AL 35294 USA; [Nangia, Vinay] Suraj Eye Inst, Ophthalmol, Nagpur, Maharashtra, India; [Nascimento, Bruno Ramos] Univ Fed Minas Gerais, Hosp Fed Univ Minas Gerais, Belo Horizonte, MG, Brazil; [Ningrum, Dina Nur Anggraini] State Univ Semarang, Publ Hlth Sci Dept, Gunungpati, Indonesia; [Ningrum, Dina Nur Anggraini] Taipei Univ, Grad Inst Biomed Informat, Taipei, Taiwan; [Nyasulu, Peter S.] Stellenbosch Univ, Fac Med & Hlth Sci, Cape Town, South Africa; [Renzaho, Andre M. N.] Western Sydney Univ, Sch Social Sci & Psychol, Penrith, NSW, Australia; [Ogbo, Felix Akpojene] Western Sydney Univ, Translat Hlth Res Inst, Penrith, NSW, Australia; [Oh, In-Hwan] Kyung Hee Univ, Sch Med, Dept Prevent Med, Dongdaemun Gu, South Korea; [Okoro, Anselm] Soc Family Hlth, Res Measurement & Results, Abuja, Nigeria; [Olagunju, Andrew T.] Univ Adelaide, Adelaide, SA, Australia; [Olagunju, Andrew T.] Univ Lagos, Dept Psychiat, Lagos, Nigeria; [Olagunju, Tinuke O.] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada; [Olivares, Pedro R.] Autonomous Univ Chile, Inst Phys Act & Hlth, Talca, Chile; [Otstavnov, Stanislav S.] Minist Hlth Russian Federat, Ctr Healthcare Qual Assessment & Control, Moscow, Russia; [Otstavnov, Stanislav S.] Moscow MV Lomonosov State Univ, Moscow Inst Phys & Technol, Dolgoprudnyi, Russia; Jagadguru Sri Shivarathreeswara Univ, Dept TB & Resp Med, Mysore, Karnataka, India; [Pakhale, Smita] Univ Ottawa, Dept Med, Ottawa, ON, Canada; [Pandey, Achyut Raj] Nepal Hlth Res Council, Res Sect, Kathmandu, Nepal; [Pinilla-Monsalve, Gabriel D.] Int Hosp Colombia, Cardiovasc Inst, Floridablanca, Colombia; [Prakash, Swayam] Sanjay Gandhi Postgrad Inst Med Sci, Dept Nephrol, Lucknow, Uttar Pradesh, India; [Qorbani, Mostafa] Alborz Univ Med Sci, Noncommunicable Dis Res Ctr, Karaj, Iran; [Radfar, Amir] Medichem, Barcelona, Spain; [Rafay, Anwar] Contech Sch Publ Hlth, Epidemiol & Biostat, Lahore, Pakistan; [Rahman, Mahfuzar] BRAC Univ, Res & Evaluat Div, Dhaka, Bangladesh; [Stokes, Mark A.] Deakin Univ, Dept Psychol, Waurn Ponds, Vic, Australia; [Islam, Sheikh Mohammed Shariful] Deakin Univ, Inst Phys Act & Nutr, Waurn Ponds, Vic, Australia; [Rahman, Muhammad Aziz] Deakin Univ, Sch Med, Waurn Ponds, Vic, Australia; [Rai, Rajesh Kumar] Soc Hlth & Demog Surveillance, Suri, India; [Rai, Rajesh Kumar] Univ Gottingen, Dept Econ, Gottingen, Germany; [Ram, Usha] Int Inst Populat Sci, Dept Publ Hlth & Mortal Studies, Bombay, Maharashtra, India; [Rawaf, David Laith] Univ Coll London Hosp, London, England; [Rawaf, Salman] Publ Hlth England, London, England; [Reis, Cesar] Loma Linda Univ, Med Ctr, Dept Prevent Med & Occupat Med, Loma Linda, CA 92350 USA; [Resnikoff, Serge] Brien Holden Vis Inst, Sydney, NSW, Australia; [Resnikoff, Serge] Org Prevent Blindness, Paris, France; [Roever, Leonardo] Univ Fed Uberlandia, Dept Clin Res, Uberlandia, MG, Brazil; [Roshandel, Gholamreza] Golestan Univ Med Sci, Golestan Res Ctr Gastroenterol & Hepatol, Gorgan, Iran; [Roy, Nobhojit] Natl Hlth Syst Resource Ctr, Publ Hlth Planning & Evidence Practice Area, New Delhi, India; [Sunguya, Bruno F.] Muhimbili Univ Hlth & Allied Sci, Dept Community Hlth, Dar Es Salaam, Tanzania; [Ruhago, George Mugambage] Muhimbili Univ Hlth & Allied Sci, Sch Publ Hlth, Dar Es Salaam, Tanzania; [Saddik, Basema] Univ Sharjah, Med Dept, Sharjah, U Arab Emirates; [Salamati, Payman] York Univ, Sch Hlth & Policy Management, Toronto, ON, Canada; [Saldanha, Raphael de Freitas] Fundacao Oswaldo Cruz, Inst Sci & Technol Commun & Informat Hlth, Rio De Janeiro, Brazil; [Samy, Abdallah M.] Ain Shams Univ, Dept Entomol, Cairo, Egypt; [Sanabria, Juan] Marshall Univ, Dept Surg, Huntington, WV USA; [Sanabria, Juan] Case Western Reserve Univ, Dept Nutr & Prevent Med, Cleveland, OH 44106 USA; [Santos, Joao Vasco] Reg Hlth Adm Norte IP, Dept Publ Hlth, Vila Nova De Gaia, Portugal; [Sartorius, Benn] Univ KwaZulu Natal, Dept Publ Hlth Med, Durban, South Africa; [Satpathy, Maheswar] Utkal Univ, UGC Ctr Adv Study Psychol, Bhubaneswar, India; [Satpathy, Maheswar] Udyam Global Assoc Sustainable Dev, Bhubaneswar, India; [Schneider, Ione J. C.] Univ Fed Santa Catarina, Sch Hlth Sci, Ararangua, Brazil; [Shams-Beyranvand, Mehran] Dezful Univ Med Sci, Sch Med, Dezful, Iran; [Sharif, Mehdi] Islamic Azad Univ, Dept Basic Sci, Sari, Iran; [She, Jun] Fudan Univ, Dept Pulm Med, Shanghai, Peoples R China; [Shen, Jiabin] Nationwide Childrens Hosp, Res Inst, Ctr Pediat Trauma Res, Columbus, OH USA; [Sheth, Kevin N.] Yale Univ, Dept Neurol, New Haven, CT USA; [Shibuya, Kenji] Univ Tokyo, Dept Global Hlth Policy, Bunkyo Ku, Tokyo, Japan; [Shigematsu, Mika] Natl Inst Infect Dis, Tokyo, Japan; [Shiri, Rahman] Finnish Inst Occupat Hlth, Helsinki, Finland; [Shiue, Ivy] Martin Luther Univ Halle Wittenberg, Inst Med Epidemiol, Halle, Germany; [Siabani, Soraya] Univ Technol Sydney, Sch Hlth, Sydney, NSW, Australia; [Silveira, Dayane Gabriele Alves] Brasilia Univ, Brasilia, DF, Brazil; [Soares Filho, Adauto Martins] Fed Minist Hlth, Dept Dis & Noncommunicable Dis & Hlth Promot, Brasilia, DF, Brazil; [Silveira, Dayane Gabriele Alves] Fed Minist Hlth, Dept Hlth Ind Complex & Innovat Hlth, Brasilia, DF, Brazil; [Sinha, Dhirendra Narain] Sch Prevent Oncol, Epidemiol, Patna, Bihar, India; [Soriano, Joan B.] Univ Hosp Princesa, Hlth Res Inst, Serv Pulmonol, Madrid, Spain; [Sinha, Dhirendra Narain] Healis Sekhsaria Inst Publ Hlth, Dept Epidemiol, Bombay, Maharashtra, India; [Soriano, Joan B.] Autonomous Univ Madrid, Pneumol Serv, Madrid, Spain; [Stein, Dan J.] Univ Cape Town, Dept Psychiat & Mental Hlth, Cape Town, South Africa; [Stein, Dan J.] South African Med Res Council, Cape Town, South Africa; [Sufiyan, Mu'awiyyah Babale] Ahmadu Bello Univ, Dept Community Med, Zaria, Nigeria; [Sykes, Bryan L.] Univ Calif Irvine, Dept Criminol Law & Soc, Irvine, CA USA; [Szoeke, Cassandra E. I.] Australian Catholic Univ, Brain Inst, Melbourne, Vic, Australia; [Tabares-Seisdedos, Rafael] Univ Valencia, Dept Med, Valencia, Spain; [Tortajada-Girbes, Miguel] Univ Valencia, Dept Pediat Obstetricts & Gynecol, Valencia, Spain; [Tabares-Seisdedos, Rafael] Carlos III Hlth Inst, Biomed Res Networking Ctr, Mental Hlth Network, Madrid, Spain; [Topor-Madry, Roman] Jagiellonian Univ, Med Coll, Inst Publ Hlth, Krakow, Poland; [Tortajada-Girbes, Miguel] Univ Hosp Doctor Peset, Pediat Dept, Valencia, Spain; [Bach Xuan Tran] Hanoi Med Univ, Dept Hlth Econ, Hanoi, Vietnam; [Khanh Bao Tran] Mil Med Univ, Clin Hematol & Toxicol, Hanoi, Vietnam; [Car, Lorainne Tudor] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore; [Ukwaja, Kingsley Nnanna] Fed Teaching Hosp, Dept Internal Med, Abakaliki, Nigeria; [Ullah, Irfan] Gomal Univ, Gomal Ctr Biochem & Biotechnol, Dera Ismail Khan, Pakistan; [Ullah, Irfan] Mufti Mehmood Mem Teaching Hosp, TB Culture Lab, Dera Ismail Khan, Pakistan; [Uthman, Olalekan A.] Univ Warwick, Div Hlth Sci, Coventry, W Midlands, England; [Valdez, Pascual R.] Argentine Soc Med, Buenos Aires, DF, Argentina; [Valdez, Pascual R.] Velez Sarsfield Hosp, Intens Care Unit Staff, Buenos Aires, DF, Argentina; [Vasankari, Tommi Juhani] UKK Inst, Tampere, Finland; [Venketasubramanian, Narayanaswamy] Raffles Hosp, Raffles Neurosci Ctr, Singapore, Singapore; [Venketasubramanian, Narayanaswamy] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore, Singapore; [Violante, Francesco S.] Univ Bologna, Dept Med & Surg Sci, Bologna, Italy; [Violante, Francesco S.] St Orsola Malpighi Hosp, Occupat Hlth Unit, Bologna, Italy; [Waheed, Yasir] Fdn Univ, Med Coll, Rawalpindi, Pakistan; [Werdecker, Andrea] Fed Inst Populat Res, Demog Change & Ageing Res Area, Wiesbaden, Germany; [Wyper, Grant M. A.] Natl Hlth Serv Scotland, Edinburgh, Midlothian, Scotland; [Wyper, Grant M. A.] Univ Strathclyde, Glasgow, Lanark, Scotland; [Yano, Yuichiro] Northwestern Univ, Dept Prevent Med, Chicago, IL 60611 USA; [Yasin, Yasin Jemal] King Fahd Univ Petr & Minerals, Dept Earth Sci, Dhahran, Saudi Arabia; [Ye, Pengpeng] Chinese Ctr Dis Control & Prevent, Div Injury Prevent & Mental Hlth Improvement, Beijing, Peoples R China; [Yip, Paul] Univ Hong Kong, Ctr Suicide Res & Prevent, Hong Kong, Peoples R China; [Yonemoto, Naohiro] Kyoto Univ, Dept Biostat, Kyoto, Japan; [Younis, Mustafa Z.] Jackson State Univ, Dept Hlth Policy & Management, Jackson, MS USA; [Younis, Mustafa Z.] Tsinghua Univ, Beijing, Peoples R China; [Yu, Chuanhua] Wuhan Univ, Dept Epidemiol & Biostat, Wuhan, Hubei, Peoples R China; [Yu, Chuanhua] Wuhan Univ, Global Hlth Inst, Wuhan, Hubei, Peoples R China; [Zaidi, Zoubida] Univ Hosp Setif, Setif, Algeria; [Bin Zaman, Sojib] Int Ctr Diarrhoeal Dis Res, Maternal & Child Hlth Div, Dhaka, Bangladesh	James, SL (corresponding author), Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98121 USA.; Theadom, A (corresponding author), Auckland Univ Technol, Inst Stroke & Appl Neurosci, North Campus,90 Akoranga Dr, Auckland 1142, New Zealand.	spencj@uw.edu; alice.theadom@aut.ac.nz	Radfar, Amir/I-8057-2019; Samy, Abdallah/B-4375-2010; Goulart, Alessandra C/J-2845-2014; Safiri, Saeid/A-1678-2017; Alebel, Animut/L-4278-2019; Adsuar, Jose C/R-1333-2019; Musa, Kamarul Imran/N-3198-2015; Mehta, Varshil/L-7416-2015; Awasthi, Ashish/Y-5915-2019; Catala-Lopez, Ferran/N-6018-2018; Feyissa, Garumma/AAP-9097-2020; Akinyemi, Rufus/X-2370-2019; Hassen, Hamid Y./A-1105-2019; Meles, Hagazi Gebre/AAM-5772-2020; Hay, Simon I/F-8967-2015; Ningrum, Dina Nur Anggraini/ABA-1698-2020; khafaie, morteza abdullatif/J-5659-2016; , Bennett/O-7998-2019; Barnighausen, Till/Y-2388-2019; Ullah, Irfan/L-5150-2017; rahim, fakher/AAC-3905-2019; Olivares, Pedro R/C-6287-2008; Kumar, Manasi/AAI-9488-2020; Khoja, Abdullah/AAD-8780-2020; Shams, Mehran/S-2695-2017; Tran, Khanh/A-2437-2019; Khader, Yousef/AAE-9620-2019; Miazgowski, Tomasz/H-9448-2014; Car, Lorainne Tudor/E-1205-2017; Topor-Madry, Roman/ABF-5449-2020; Roshandel, Gholamreza/AAJ-9562-2021; Rezaeian, Shahab/G-7482-2011; Yisma, Engida/ABA-4170-2020; Szoeke, Cassandra/AAI-8631-2021; Rajati, Fatemeh/S-1041-2017; Defo, Barthelemy Kuate/I-4818-2017; Antonio, Carl Abelardo/AAP-4280-2020; Altirkawi, Khalid A/D-7302-2017; Massenburg, Benjamin B./AAB-9349-2019; Waheed, Yasir/AAC-3896-2019; Khan, Shahzeb/AAN-1515-2020; moradinazar, mehdi/N-2129-2017; Rahman, Muhammad Aziz/B-3380-2009; Atique, Suleman/ABA-4998-2020; Kengne, Andre Pascal/ABB-3696-2020; Carvalho, Felix/D-4914-2013; Prakash, Swayam/ABB-6036-2020; Ram, Usha/AAS-4140-2020; Stokes, Mark A/P-8937-2017; Filho, Adauto Martins Soares/M-2176-2016; Hostiuc, Sorin/I-2017-2019; Khalid, Nauman/G-8134-2015; Alahdab, Fares/N-6680-2013; Mahesh, P A/R-1184-2019; Ayalew, Animut Alebel/U-6092-2019; Hamadeh, Randah R./AAE-9720-2020; Rafiei, Alireza/A-2314-2009; Deribe, Kebede/I-5422-2019; Safari, Hosein/AAA-4970-2019; Kasaeian, Amir/C-8290-2017; Niguse, Haftom/AAF-8975-2020; Rahimi-Movaghar, Afarin/E-9505-2011; Hassen, Hamid Y./K-6445-2019; Wang, Yuan Pang/A-4863-2008; Daryani, Ahmad/E-2186-2017; Manda, Ana Laura/AAD-3352-2019; Nacimento, Bruno Ramos/F-8066-2013; Shushtari, Zahra Jorjoran/G-9701-2019; KIM, YUN JIN/AAE-8281-2019; Otstavnov, Stanislav S/T-9893-2018; Bijani, Ali/B-1718-2017; Mondello, Stefania/A-1813-2012; Levi, Miriam/AAR-8512-2020; KISA, ADNAN/Q-2081-2019; Wijeratne, Tissa/I-2086-2019; Monasta, Lorenzo/B-1388-2012; Behzadifar, Masoud/H-1433-2016; Siddiqi, Tariq/AAH-1034-2020; Saddik, Basema/H-5679-2019; Soyiri, Ireneous/AAE-7617-2019; Moradi, Ghobad/R-1267-2016; Badali, Hamid/J-8036-2016; Ilesanmi, Olayinka/AAF-8628-2021; Appiah, Seth Christopher Yaw/J-8050-2019; Naohiro, Yonemoto/Y-3761-2019; Schneider, Ione J.C./J-8762-2013; Rad, Enayatollah Homaie/G-5567-2015; Szoeke, CAssandra/AAE-8715-2019; Islam, Mohammed Shariful/B-1219-2011; Faro, Andre/J-1696-2014; T., Olagunju Andrew/B-4746-2017; Irvani, Seyed Sina Naghibi/O-2413-2018; Christopher, DJ/R-1479-2019; Car, Mate/F-2184-2017; Soyiri, Ireneous N./H-4594-2011; Saldanha, Raphael/ABC-6120-2020; Feigin, Valery/AAF-2313-2019; Ahmed, Muktar B/G-6184-2019; Satpathy, Maheswar/J-3135-2017; Silva, Joao P/E-8444-2012; Pesudovs, Konrad/T-9403-2019; Usman, Muhammad/AAH-1076-2020; Jakovljevic, Mihajlo B/B-3002-2014; Renzaho, Andre M.N./AAH-7679-2021; Lalloo, Ratilal/O-5624-2014; Dubljanin, Eleonora/AAW-6278-2020; Tehrani-Banihashemi, Arash/L-5964-2018; Brazinova, Alexandra/C-4265-2016; Mirrakhimov, Erkin/E-6900-2017; Oh, In Hwan/AAI-9070-2020; Khubchandani, Jagdish/D-1831-2014; Temsah, Mohamad-Hani/AAJ-9703-2020; Shen, Jiabin/C-3655-2008; Mousavi, Seyyed Meysam/P-7797-2015; Banstola, Amrit/T-4242-2019; Negoi, Ionut/A-9039-2012; Haj-Mirzaian, Arvin/W-6013-2019; Afarideh, Mohsen/H-8945-2019; moosazadeh, mahmood/F-3730-2017; Pinilla-Monsalve, Gabriel David/AAT-2805-2020; Kisa, Adnan/AAA-6824-2021; Jozwiak, Jacek/AAN-6351-2020; Alsharif, Ubai/AAK-2088-2021; Yimer, Ebrahim M./N-4597-2018; Bicer, Burcu Kucuk/G-4922-2017; A, Rizwan S/F-5289-2014; Mirica, Andreea/AAN-8016-2020; Ahmed, Muktar/AAY-6783-2020; MHS, Leonardo Roever/F-5315-2012; Salamati, Payman/AAK-7086-2020; Jha, Ravi Prakash/ABC-6588-2020; Haro, Josep Maria/D-1423-2011; Bekele, Bayu Begashaw/R-9348-2017; Stein, Dan J/A-1752-2008; Koyanagi, Ai/D-3833-2018; Belachew, Abate Bekele/I-1758-2019; Jayaraman, Sudha/AAH-3059-2019; Violante, Francesco S/A-6934-2009; Phuc, Huyen/I-5061-2019; Quintanilla, Beatriz Paulina Ayala/C-8325-2016; Fereshtehnejad, Seyed-Mohammad/ABF-6020-2020; Ningrum, Dina Nur Anggraini/N-8045-2017; Zamani, Mohammad/A-7733-2016; Demoz, Gebre Teklemariam/K-6986-2019; Ukwaja, Kingsley N./A-7794-2013; Soriano, Joan B/O-1215-2017; Uthman, Olalekan/P-7916-2014; El-Khatib, Ziad/B-5161-2017; Yaseri, Mehdi/I-1645-2018; Jurisson, Mikk/M-1360-2017; Lunevicius, Raimundas/B-2528-2018; Soofi, Moslem/E-7665-2019; Fernandes, Eduarda/D-4943-2013; Karch, Andre/D-6973-2017	Radfar, Amir/0000-0001-6177-3048; Samy, Abdallah/0000-0003-3978-1134; Goulart, Alessandra C/0000-0003-1076-5210; Safiri, Saeid/0000-0001-7986-9072; Alebel, Animut/0000-0003-2822-2062; Adsuar, Jose C/0000-0001-7203-3168; Musa, Kamarul Imran/0000-0002-3708-0628; Mehta, Varshil/0000-0001-5804-9948; Awasthi, Ashish/0000-0002-9308-9782; Catala-Lopez, Ferran/0000-0002-3833-9312; Feyissa, Garumma/0000-0001-6179-0024; Hassen, Hamid Y./0000-0001-6485-4193; Meles, Hagazi Gebre/0000-0001-5773-4011; Hay, Simon I/0000-0002-0611-7272; khafaie, morteza abdullatif/0000-0002-1651-3017; rahim, fakher/0000-0002-2857-4562; Olivares, Pedro R/0000-0001-7371-343X; Khoja, Abdullah/0000-0003-1844-3742; Shams, Mehran/0000-0001-9474-0955; Tran, Khanh/0000-0002-8730-3340; Khader, Yousef/0000-0002-7830-6857; Miazgowski, Tomasz/0000-0002-4819-9376; Car, Lorainne Tudor/0000-0001-8414-7664; Roshandel, Gholamreza/0000-0002-5494-0722; Rezaeian, Shahab/0000-0002-5094-5315; Yisma, Engida/0000-0003-0703-1515; Szoeke, Cassandra/0000-0002-3698-2590; Rajati, Fatemeh/0000-0001-6426-664X; Defo, Barthelemy Kuate/0000-0002-6589-0564; Antonio, Carl Abelardo/0000-0001-7476-0553; Altirkawi, Khalid A/0000-0002-7331-4196; Massenburg, Benjamin B./0000-0002-8570-5178; Waheed, Yasir/0000-0002-5789-4215; moradinazar, mehdi/0000-0001-7033-6755; Rahman, Muhammad Aziz/0000-0003-1665-7966; Atique, Suleman/0000-0002-5149-0703; Carvalho, Felix/0000-0003-3858-3494; Ram, Usha/0000-0001-6722-7347; Stokes, Mark A/0000-0001-6488-4544; Filho, Adauto Martins Soares/0000-0002-0917-7473; Hostiuc, Sorin/0000-0003-4130-9402; Khalid, Nauman/0000-0002-8045-199X; Alahdab, Fares/0000-0001-5481-696X; Hamadeh, Randah R./0000-0002-4205-1354; Rafiei, Alireza/0000-0002-1766-6605; Deribe, Kebede/0000-0002-8526-6996; Safari, Hosein/0000-0003-3477-6344; Kasaeian, Amir/0000-0003-2018-9368; Rahimi-Movaghar, Afarin/0000-0002-5761-1668; Hassen, Hamid Y./0000-0001-6485-4193; Wang, Yuan Pang/0000-0001-7076-8312; Daryani, Ahmad/0000-0001-8571-5803; Nacimento, Bruno Ramos/0000-0002-5586-774X; KIM, YUN JIN/0000-0001-8853-6587; Otstavnov, Stanislav S/0000-0003-2043-495X; Bijani, Ali/0000-0003-2233-8726; Mondello, Stefania/0000-0002-8587-3614; Levi, Miriam/0000-0002-0086-3952; Wijeratne, Tissa/0000-0002-1701-7111; Monasta, Lorenzo/0000-0001-7774-548X; Behzadifar, Masoud/0000-0002-0271-4360; Soyiri, Ireneous/0000-0003-4697-5156; Moradi, Ghobad/0000-0003-2612-6528; Badali, Hamid/0000-0002-6010-8414; Ilesanmi, Olayinka/0000-0003-0827-6442; Appiah, Seth Christopher Yaw/0000-0002-9844-1036; Schneider, Ione J.C./0000-0001-6339-7832; Rad, Enayatollah Homaie/0000-0002-9064-0380; Islam, Mohammed Shariful/0000-0001-7926-9368; Faro, Andre/0000-0002-7348-6297; T., Olagunju Andrew/0000-0003-1736-9886; Irvani, Seyed Sina Naghibi/0000-0002-4566-7402; Car, Mate/0000-0002-7005-0500; Soyiri, Ireneous N./0000-0003-4697-5156; Ahmed, Muktar B/0000-0002-9524-7027; Satpathy, Maheswar/0000-0003-3521-4781; Silva, Joao P/0000-0002-5656-0897; Usman, Muhammad/0000-0001-9747-8892; Jakovljevic, Mihajlo B/0000-0002-9160-6846; Lalloo, Ratilal/0000-0001-5822-1269; Brazinova, Alexandra/0000-0003-0625-256X; Mirrakhimov, Erkin/0000-0003-2982-6108; Oh, In Hwan/0000-0002-5450-9887; Khubchandani, Jagdish/0000-0002-9058-4278; Mousavi, Seyyed Meysam/0000-0002-6795-7224; Banstola, Amrit/0000-0003-3185-9638; Negoi, Ionut/0000-0002-6950-9599; Haj-Mirzaian, Arvin/0000-0001-8977-6865; Afarideh, Mohsen/0000-0002-3578-5640; moosazadeh, mahmood/0000-0002-5452-514X; Pinilla-Monsalve, Gabriel David/0000-0003-1149-8193; Kisa, Adnan/0000-0001-7825-3436; Jozwiak, Jacek/0000-0002-2645-7274; Alsharif, Ubai/0000-0002-4024-3950; Yimer, Ebrahim M./0000-0003-3140-4967; Bicer, Burcu Kucuk/0000-0002-5615-264X; A, Rizwan S/0000-0002-3140-2614; Ahmed, Muktar/0000-0002-9524-7027; MHS, Leonardo Roever/0000-0002-7517-5548; Salamati, Payman/0000-0001-9313-3977; Jha, Ravi Prakash/0000-0001-5230-1436; Haro, Josep Maria/0000-0002-3984-277X; Bekele, Bayu Begashaw/0000-0001-8590-4874; Stein, Dan J/0000-0001-7218-7810; Koyanagi, Ai/0000-0002-9565-5004; Belachew, Abate Bekele/0000-0003-2583-9913; Jayaraman, Sudha/0000-0003-1094-5836; Violante, Francesco S/0000-0003-4084-2782; Phuc, Huyen/0000-0003-0461-7529; Quintanilla, Beatriz Paulina Ayala/0000-0002-2630-4569; Fereshtehnejad, Seyed-Mohammad/0000-0001-9255-9351; Esteghamati, Alireza/0000-0001-5114-3982; Ningrum, Dina Nur Anggraini/0000-0002-8557-2862; Filip, Irina/0000-0002-2466-2346; Prakash, Swayam/0000-0003-3986-890X; Kassa, Getachew Mullu/0000-0002-8095-7376; Roy, Nobhojit/0000-0003-2022-7416; Shen, Jiabin/0000-0001-6625-5215; Pakhale, Smita/0000-0002-4051-962X; Hamidi, Samer/0000-0002-6766-3728; Zamani, Mohammad/0000-0003-1916-3873; Legesse Liben, Misgan/0000-0001-7716-6787; Kim, Daniel/0000-0001-8907-6420; RENZAHO, ANDRE/0000-0002-6844-0833; Li, Shanshan/0000-0002-9021-8470; Kengne, Andre Pascal/0000-0002-5183-131X; Demoz, Gebre Teklemariam/0000-0002-2534-821X; Yasin, Yasin Jemal/0000-0002-2819-0235; Boufous, Soufiane/0000-0002-5686-1729; Alghnam, Suliman/0000-0001-5817-0481; Ukwaja, Kingsley N./0000-0002-1974-8735; Dubljanin, Eleonora/0000-0002-6484-3192; Soriano, Joan B/0000-0001-9740-2994; Majeed, Azeem/0000-0002-2357-9858; Akinyemi, Rufus/0000-0001-5286-428X; Sufiyan, Muawiyyah Babale/0000-0003-3630-6995; Uthman, Olalekan/0000-0002-8567-3081; Mirica, Andreea/0000-0002-3794-1387; Zaman, Sojib Bin/0000-0002-3043-7954; Degefa, Meaza/0000-0003-0175-6937; Feigin, Valery L./0000-0002-6372-1740; Hendrie, Delia/0000-0001-5022-5281; Shibuya, Kenji/0000-0003-2528-7530; El-Khatib, Ziad/0000-0003-0756-7280; G. Asefa, Nigus/0000-0001-5680-5527; Moradi-Lakeh, Maziar/0000-0001-7381-5305; Yaseri, Mehdi/0000-0002-4066-873X; Rawaf, Salman/0000-0001-7191-2355; Kumar, Manasi/0000-0002-9773-8014; Shiri, Rahman/0000-0002-9312-3100; , bennsartorius/0000-0001-6761-2325; Jurisson, Mikk/0000-0002-4487-7045; CHANG, JUNG-CHEN/0000-0001-8651-2602; Murthy, Srinivas/0000-0002-9476-839X; Okoro, Anselm/0000-0003-3952-1172; Tabares-Seisdedos, Rafael/0000-0002-1089-2204; Lunevicius, Raimundas/0000-0003-3295-0142; LARYEA, DENNIS/0000-0003-2212-084X; Soofi, Moslem/0000-0003-4922-8412; Fernandes, Eduarda/0000-0001-6424-0976; Karch, Andre/0000-0003-3014-8543; Berhane, Adugnaw/0000-0003-2160-958X; Farzadfar, Farshad/0000-0001-8288-4046; Saddik, Basema/0000-0002-4682-5927; Kim, Young-Eun/0000-0003-0694-6844; Te Ao, Braden/0000-0002-1050-200X; Santos, Joao Vasco/0000-0003-4696-1002; G/medhin, Merhawi/0000-0003-4770-6361; ZAIDI, ZOUBIDA/0000-0003-3378-4799; , Tariq/0000-0002-9672-6628; siabani, soraya/0000-0003-2856-0205; azzopardi, peter/0000-0002-9280-6997; Moazen, Babak/0000-0002-2552-0438; Dandona, Rakhi/0000-0003-0926-788X; Balalla, Shivanthi/0000-0001-5320-753X; Miller, Ted/0000-0002-0958-2639; Kahsay, Amaha/0000-0002-6242-8040; Sheikh, Aziz/0000-0001-7022-3056; Olagunju, Tinuke/0000-0003-4019-8755	Bill & Melinda Gates FoundationBill & Melinda Gates Foundation	Bill & Melinda Gates Foundation.	Barker-Collo S, 2016, NEUROEPIDEMIOLOGY, V47, P46, DOI 10.1159/000448403; Barker-Collo SL, 2009, NEUROEPIDEMIOLOGY, V32, P1, DOI 10.1159/000170084; Brown AW, 2014, J HEAD TRAUMA REHAB, V29, pE1, DOI 10.1097/HTR.0b013e318280d3e6; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Budisin B, 2016, J HEAD TRAUMA REHAB, V31, pE33, DOI 10.1097/HTR.0000000000000153; Burns JF, EUROPE ECHOES AM CON; Canadian Institute for Health Information, HEAD INJ CAN DEC CHA; Chen YH, 2011, STROKE, V42, P2733, DOI 10.1161/STROKEAHA.111.620112; Chiu WT, 2010, ASIA-PAC J PUBLIC HE, V22, P9, DOI 10.1177/1010539509355470; Emanuelson I, 1997, ACTA PAEDIATR, V86, P730, DOI 10.1111/j.1651-2227.1997.tb08576.x; Fann JR, 2018, LANCET PSYCHIAT, V5, P424, DOI 10.1016/S2215-0366(18)30065-8; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Foreman KJ, 2012, POPUL HEALTH METR, V10, DOI 10.1186/1478-7954-10-1; Gakidou E, 2017, LANCET, V390, P1345, DOI 10.1016/S0140-6736(17)32366-8; Hay SI, 2017, LANCET, V390, P1260, DOI 10.1016/S0140-6736(17)32130-X; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Mendez MF, 2017, J ALZHEIMERS DIS, V57, P667, DOI 10.3233/JAD-161002; Moorin R, 2014, J NEUROL, V261, P1726, DOI 10.1007/s00415-014-7411-y; Naghavi M, 2017, LANCET, V390, P1151, DOI 10.1016/S0140-6736(17)32152-9; Rahimi-Movaghar V, 2013, NEUROEPIDEMIOLOGY, V41, P65, DOI 10.1159/000350710; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Sabre L, 2012, SPINAL CORD, V50, P755, DOI 10.1038/sc.2012.54; Salomon JA, 2015, LANCET GLOB HEALTH, V3, pE712, DOI 10.1016/S2214-109X(15)00069-8; Scholten AC, 2015, ACCIDENT ANAL PREV, V81, P51, DOI 10.1016/j.aap.2015.04.022; Singh A, 2014, CLIN EPIDEMIOL, V6, P309, DOI 10.2147/CLEP.S68889; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; Te Ao B, 2014, NEUROLOGY, V83, P1645, DOI 10.1212/WNL.0000000000000933; UNDP, GOAL 3 TARG; Vos T, 2017, LANCET, V390, P1211, DOI 10.1016/S0140-6736(17)32154-2; Vos T, 2012, LANCET, V380, P2163, DOI 10.1016/S0140-6736(12)61729-2; Wang HD, 2017, LANCET, V390, P1084, DOI 10.1016/S0140-6736(17)31833-0; Williams WH, 2018, LANCET PSYCHIAT, V5, P836, DOI 10.1016/S2215-0366(18)30062-2; World Health Organization, ROAD TRAFF INJ; World Health Organization, FALLS	34	203	206	21	125	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2019	18	1					56	87		10.1016/S1474-4422(18)30415-0			32	Clinical Neurology	Neurosciences & Neurology	HE1CJ	WOS:000453007700023	30497965	Green Accepted, Green Published, Other Gold	Y	N	2021-06-18	
J	Halstead, ME; McAvoy, K; Devore, CD; Carl, R; Lee, M; Logan, K				Halstead, Mark E.; McAvoy, Karen; Devore, Cynthia D.; Carl, Rebecca; Lee, Michael; Logan, Kelsey		Council Sports Med Fitness; Council Sch Hlth	Returning to Learning Following a Concussion	PEDIATRICS			English	Article						head injury; mild traumatic brain injury; pediatrics; return to school; academics; return to learn; cognitive deficits	SCHOOL; STATEMENT	Following a concussion, it is common for children and adolescents to experience difficulties in the school setting. Cognitive difficulties, such as learning new tasks or remembering previously learned material, may pose challenges in the classroom. The school environment may also increase symptoms with exposure to bright lights and screens or noisy cafeterias and hallways. Unfortunately, because most children and adolescents look physically normal after a concussion, school officials often fail to recognize the need for academic or environmental adjustments. Appropriate guidance and recommendations from the pediatrician may ease the transition back to the school environment and facilitate the recovery of the child or adolescent. This report serves to provide a better understanding of possible factors that may contribute to difficulties in a school environment after a concussion and serves as a framework for the medical home, the educational home, and the family home to guide the student to a successful and safe return to learning.				Meijer, Anna/K-5118-2016				Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Devore CD, 2013, PEDIATRICS, V131, P178, DOI 10.1542/peds.2012-2995; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Harmon KG, 2013, CLIN J SPORT MED, V23, P1, DOI 10.1097/JSM.0b013e31827f5f93; Howell D, 2013, MED SCI SPORT EXER, V45, P1030, DOI 10.1249/MSS.0b013e3182814595; Master CL, 2012, PEDIATR ANN, V41, pE180, DOI 10.3928/00904481-20120827-09; McAvoy K, 2012, BRAIN INJ PROF, V9, P26; McAvoy K., 2012, COMMUNIQUE, V40, P23; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; McGrath N, 2010, J ATHL TRAINING, V45, P492, DOI 10.4085/1062-6050-45.5.492; McLeod TCV, 2010, ATHLET THER TODAY, V15, P1, DOI 10.1123/att.15.2.1; Moser RS, 2012, J PEDIATR-US, V161, P922, DOI 10.1016/j.jpeds.2012.04.012; Murray RD, 2008, PEDIATRICS, V121, P1052, DOI 10.1542/peds.2008-0382; Piebes SK, 2009, J SCH NURS, V25, P270, DOI 10.1177/1059840509339782; Rocky Mountain Youth Sports Medicine Institute Center for Concussion, REAP GUID; Sady MD, 2011, PHYS MED REH CLIN N, V22, P701, DOI 10.1016/j.pmr.2011.08.008; Zonfrillo MR, 2012, PEDIATRICS, V130, P1120, DOI 10.1542/peds.2012-1431	18	203	205	0	35	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	NOV	2013	132	5					948	957		10.1542/peds.2013-2867			10	Pediatrics	Pediatrics	245PE	WOS:000326475000065	24163302	Bronze			2021-06-18	
J	Harmon, KG; Drezner, J; Gammons, M; Guskiewicz, K; Halstead, M; Herring, S; Kutcher, J; Pana, A; Putukian, M; Roberts, W				Harmon, Kimberly G.; Drezner, Jonathan; Gammons, Matthew; Guskiewicz, Kevin; Halstead, Mark; Herring, Stan; Kutcher, Jeff; Pana, Andrea; Putukian, Margot; Roberts, William			American Medical Society for Sports Medicine Position Statement: Concussion in Sport	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; athlete; head injury; brain injury	TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL FOOTBALL; AGE-RELATED DIFFERENCES; PROFESSIONAL SOCCER PLAYERS; PREDICT PROTRACTED RECOVERY; REPETITIVE HEAD-INJURY; 2ND IMPACT SYNDROME; OF-THE-LITERATURE; BASE-LINE; NEUROCOGNITIVE PERFORMANCE		[Harmon, Kimberly G.; Drezner, Jonathan; Herring, Stan] Univ Washington, Seattle, WA 98195 USA; [Gammons, Matthew] Vermont Orthopaed Clin, Rutland, VT USA; [Guskiewicz, Kevin] Univ N Carolina Chapel Hill, Chapel Hill, NC USA; [Halstead, Mark] Washington Univ, St Louis, MO USA; [Kutcher, Jeff] Univ Michigan, Ann Arbor, MI 48109 USA; [Pana, Andrea] Univ Texas Austin, Austin, TX 78712 USA; [Putukian, Margot] Princeton Univ, Princeton, NJ 08544 USA; [Roberts, William] Univ Minnesota, Minneapolis, MN USA	Harmon, KG (corresponding author), Univ Washington, Box 35440, Seattle, WA 98195 USA.	kharmon@u.washington.edu		Roberts, William O/0000-0003-4517-4330; Guskiewicz, Kevin/0000-0002-8682-2130			Adler RH, 2011, PM&R, V3, pS468, DOI 10.1016/j.pmrj.2011.08.006; Agel J, 2007, J ATHL TRAINING, V42, P270; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Amen Daniel G, 2011, Open Neuroimag J, V5, P40, DOI 10.2174/1874440001105010040; Anderson SD, 2004, CAN MED ASSOC J, V170, P16; [Anonymous], 2011, MED SCI SPORT EXER, V43, P2412, DOI 10.1249/MSS.0b013e3182342e64; [Anonymous], ZACH LYST LAW; Atkinson JLD, 1998, J TRAUMA, V45, P941, DOI 10.1097/00005373-199811000-00016; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bailey CM, 2010, CLIN J SPORT MED, V20, P272, DOI 10.1097/JSM.0b013e3181e8f8d8; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Benson BW, 2009, BRIT J SPORT MED, V43, pI56, DOI 10.1136/bjsm.2009.058271; Bernhardt DT, 2010, PREPARTICIPATION PHY; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; BRUCE DA, 1984, PRIMARY CARE, V11, P175; Bruce JM, 2009, NEUROSURGERY, V64, P100, DOI 10.1227/01.NEU.0000336310.47513.C8; Bruce JM, 2004, NEUROLOGY, V63, P1516; Busch CR, 1998, NEUROPSYCHOL REV, V8, P95, DOI 10.1023/A:1025661200911; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cantu RC, 2003, CLIN SPORT MED, V22, P593, DOI 10.1016/S0278-5919(02)00095-9; Cantu RC, 2010, J NEUROTRAUM, V27, P1557, DOI 10.1089/neu.2010.1334; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; Collie A, 2004, BRIT J SPORT MED, V38, P273, DOI 10.1136/bjsm.2003.000293; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2003, J ATHL TRAINING, V38, P238; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Covassin T, 2012, CLIN J SPORT MED, V22, P98, DOI 10.1097/JSM.0b013e31823403d2; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Daneshvar DH, 2011, CLIN SPORT MED, V30, P145, DOI 10.1016/j.csm.2010.09.006; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Davis GA, 2009, BRIT J SPORT MED, V43, pI36, DOI 10.1136/bjsm.2009.058123; De Beaumont L, 2012, CEREB CORTEX, V22, P112, DOI 10.1093/cercor/bhr096; De Beaumont L, 2011, J ATHL TRAINING, V46, P234; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Depew AJ, 2008, AM SURGEON, V74, P906; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Dick R, 2007, J ATHL TRAINING, V42, P278; Ebell MH, 2004, AM FAM PHYSICIAN, V69, P548; Echemendia RJ, 2009, BRIT J SPORT MED, V43, pI32, DOI 10.1136/bjsm.2009.058164; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Echemendia RJ, 2012, CLIN NEUROPSYCHOL, V26, P1077, DOI 10.1080/13854046.2012.721006; Ellemberg D, 2009, J NEUROTRAUM, V26, P2365, DOI 10.1089/neu.2009.0906; Emery C, 2011, CAN MED ASSOC J, V183, P1249, DOI 10.1503/cmaj.101540; Engelborghs K, 1998, J NEUROSURG, V89, P796, DOI 10.3171/jns.1998.89.5.0796; Erdal K, 2012, ARCH CLIN NEUROPSYCH, V27, P473, DOI 10.1093/arclin/acs050; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; Esposito G, 1996, J NUCL MED, V37, P559; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Finnoff JT, 2009, PM&R, V1, P50, DOI 10.1016/j.pmrj.2008.06.002; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Gioia GA, 2008, J HEAD TRAUMA REHAB, V23, P230, DOI 10.1097/01.HTR.0000327255.38881.ca; Giza CC, 2001, J ATHL TRAINING, V36, P228; Gordon KE, 2006, BRIT J SPORT MED, V40, P184, DOI 10.1136/bjsm.2005.022251; Gosselin N, 2011, J NEUROTRAUM, V28, P329, DOI 10.1089/neu.2010.1493; Greenwald BD, 2001, J HEAD TRAUMA REHAB, V16, P238, DOI 10.1097/00001199-200106000-00003; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2011, PM&R, V3, P353, DOI 10.1016/j.pmrj.2010.12.006; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Hollis SJ, 2009, AM J SPORT MED, V37, P2328, DOI 10.1177/0363546509341032; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Huisman TAGM, 2003, EUR RADIOL, V13, P2283, DOI 10.1007/s00330-003-1843-6; Hunt TN, 2009, J ATHL TRAINING, V44, P405, DOI 10.4085/1062-6050-44.4.405; Hutchison M, 2011, AM J SPORT MED, V39, P2331, DOI 10.1177/0363546511413375; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Iverson G, 2007, CLIN J SPORT MED, V17, P31; Jantzen KJ, 2007, NEUROPSYCHOLOGIA, V45, P673, DOI 10.1016/j.neuropsychologia.2006.07.020; Jinguji TM, 2012, BRIT J SPORT MED, V46, P365, DOI 10.1136/bjsports-2011-090526; Johnson EW, 2011, CLIN SPORT MED, V30, P73, DOI 10.1016/j.csm.2010.08.007; Jones NJ, 2011, CLIN J SPORT MED, V21, P156; Jotwani V, 2010, CURR SPORT MED REP, V9, P21, DOI 10.1249/JSR.0b013e3181ccb55e; Kaufman KR, 2006, MED ENG PHYS, V28, P234, DOI 10.1016/j.medengphy.2005.05.005; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Keightley ML, 2007, SOC COGN AFFECT NEUR, V2, P292, DOI 10.1093/scan/nsm024; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; Kinart CM, 2002, HEADACHE, V42, P620, DOI 10.1046/j.1526-4610.2002.02149.x; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Kissick J, 2005, CLIN J SPORT MED, V15, P426, DOI 10.1097/01.jsm.0000186683.59158.8b; Koehler DM, 2011, J TRAUMA, V70, P324, DOI 10.1097/TA.0b013e31820b5d22; Kontos AP, 2012, ARCH PHYS MED REHAB, V93, P1751, DOI 10.1016/j.apmr.2012.03.032; Kors EE, 2001, ANN NEUROL, V49, P753, DOI 10.1002/ana.1031; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kristman VL, 2008, CLIN J SPORT MED, V18, P322, DOI 10.1097/JSM.0b013e31817e6f3e; Kutcher JS, 2010, CURR SPORT MED REP, V9, P16, DOI 10.1249/JSR.0b013e3181caa89d; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Lau BC, 2012, NEUROSURGERY, V70, P371, DOI 10.1227/NEU.0b013e31823150f0; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Lincoln AE, 2007, AM J SPORT MED, V35, P207, DOI 10.1177/0363546506293900; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lipton RB, 2004, JAMA-J AM MED ASSOC, V291, P493, DOI 10.1001/jama.291.4.493; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; Mansell JL, 2010, BRAIN INJURY, V24, P1070, DOI 10.3109/02699052.2010.494589; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; McAllister TW, 2012, NEUROLOGY, V78, P1777, DOI 10.1212/WNL.0b013e3182582fe7; McAllister TW, 2002, NEUROREHABILITATION, V17, P265; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2001, BRIT J SPORT MED, V35, P81, DOI 10.1136/bjsm.35.2.81; McCrory P, 2007, INJURY PREV, V13, P364, DOI 10.1136/ip.2007.017624; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2002, J SCI MED SPORT, V5, P169, DOI 10.1016/S1440-2440(02)80002-0; McCrory P, 2002, BRIT J SPORT MED, V36, P316, DOI 10.1136/bjsm.36.5.316; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; McCrory P, 2012, CURR SPORT MED REP, V11, P21, DOI 10.1249/JSR.0b013e3182423bfd; McCrory P, 2011, CLIN J SPORT MED, V21, P6, DOI 10.1097/JSM.0b013e318204db50; McCrory P, 2011, CLIN SPORT MED, V30, P201, DOI 10.1016/j.csm.2010.08.002; McCrory Paul, 2009, Scand J Med Sci Sports, V19, P452, DOI 10.1111/j.1600-0838.2009.00978.x; McCrory PR, 2000, NEUROLOGY, V54, P1488, DOI 10.1212/WNL.54.7.1488; McGrath N, 2010, J ATHL TRAINING, V45, P492, DOI 10.4085/1062-6050-45.5.492; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140; McLeod TCV, 2012, J ATHL TRAINING, V47, P221; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Mulligan I, 2012, J ORTHOP SPORT PHYS, V42, P625, DOI 10.2519/jospt.2012.3798; Navarro RR, 2011, CURR SPORT MED REP, V10, P27, DOI 10.1249/JSR.0b013e318205e072; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Norwood SH, 2008, J TRAUMA, V65, P1021, DOI 10.1097/TA.0b013e31818a0e74; Omalu Bennet I, 2010, J Forensic Nurs, V6, P130, DOI 10.1111/j.1939-3938.2010.01078.x; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Omalu BI, 2010, AM J FOREN MED PATH, V31, P130, DOI 10.1097/PAF.0b013e3181ca7f35; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Oni MB, 2010, J CHILD NEUROL, V25, P976, DOI 10.1177/0883073809356034; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Prabhu SP, 2011, CLIN SPORT MED, V30, P103, DOI 10.1016/j.csm.2010.09.003; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Provvidenza CF, 2009, BRIT J SPORT MED, V43, pI68, DOI 10.1136/bjsm.2009.058180; Ptito A, 2007, NEUROREHABILITATION, V22, P217; Pulsipher DT, 2011, CURR SPORT MED REP, V10, P14, DOI 10.1249/JSR.0b013e31820711b8; Putukian M, 2009, BRIT J SPORT MED, V43, pI28, DOI 10.1136/bjsm.2009.058230; Randolph C, 2005, J ATHL TRAINING, V40, P139; Randolph C, 2011, PM&R, V3, pS433, DOI 10.1016/j.pmrj.2011.08.002; Reddy C. C., J HEAD TRAUMA REHABI; Register-Mihalik JK, J HEAD TRAUMA REHABI; Register-Mihalik JK, 2008, NEUROSURGERY, V63, P76, DOI 10.1227/01.NEU.0000335073.39728.CE; Register-Mihalik JK, 2012, J ATHL TRAINING, V47, P297, DOI 10.4085/1062-6050-47.3.13; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Rinne MB, 2006, J REHABIL MED, V38, P224, DOI 10.1080/16501970600582989; Robbins MS, 2010, SEMIN NEUROL, V30, P107, DOI 10.1055/s-0030-1249220; Roberts WO, 1996, ARCH PEDIAT ADOL MED, V150, P140, DOI 10.1001/archpedi.1996.02170270022003; Rutherford A, 2009, J CLIN EXP NEUROPSYC, V31, P664, DOI 10.1080/13803390802484755; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Savica R, 2012, MAYO CLIN PROC, V87, P335, DOI 10.1016/j.mayocp.2011.12.016; Schaal K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019007; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; Schatz P, 2012, J ATHL TRAINING, V47, P289, DOI 10.4085/1062-6050-47.3.14; Schatz P, 2011, NEUROSURGERY, V68, P1562, DOI 10.1227/NEU.0b013e31820e382e; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Schmidt JD, 2012, MED SCI SPORT EXER, V44, P1621, DOI 10.1249/MSS.0b013e318258a9fb; Schneiders AG, 2012, SCAND J MED SCI SPOR, V22, P85, DOI 10.1111/j.1600-0838.2010.01141.x; Schreiber S, 2008, SLEEP MED, V9, P481, DOI 10.1016/j.sleep.2007.04.014; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Sedney CL, 2011, CLIN SPORT MED, V30, P189, DOI 10.1016/j.csm.2010.08.005; Seifert TD, 2010, CURR PAIN HEADACHE R, V14, P292, DOI 10.1007/s11916-010-0117-7; Shrey DW, 2011, PHYS MED REH CLIN N, V22, P577, DOI 10.1016/j.pmr.2011.08.002; Shuttleworth-Edwards AB, 2008, J CLIN EXP NEUROPSYC, V30, P870, DOI 10.1080/13803390701846914; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; SNOEK JW, 1984, BRAIN, V107, P15, DOI 10.1093/brain/107.1.15; Solomon GS, 2008, ARCH CLIN NEUROPSYCH, V23, P563, DOI 10.1016/j.acn.2008.05.008; Strupp M, 2011, J NEUROL, V258, P1207, DOI [10.1007/s00415-011-5999-8, 10.1007/s00415-011-6135-5, 10.1007/s00415-010-5874-z]; Sullivan SJ, 2009, CLIN J SPORT MED, V19, P228, DOI 10.1097/JSM.0b013e3181a41e43; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F; Terrell TR, 2008, CLIN J SPORT MED, V18, P10, DOI 10.1097/JSM.0b013e31815c1d4c; Terrell TR, 2012, CLIN J SPORT MED, V22, P172; Thornton AE, 2008, J CLIN EXP NEUROPSYC, V30, P398, DOI 10.1080/13803390701443662; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA; Tierney RT, 2010, CLIN J SPORT MED, V20, P464, DOI 10.1097/JSM.0b013e3181fc0a81; Tierney RT, 2008, J ATHL TRAINING, V43, P578, DOI 10.4085/1062-6050-43.6.578; Vagnozzi R, 2007, NEUROSURGERY, V61, P388, DOI DOI 10.1227/01.NEU.0000280002.41696; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; McLeod TCV, 2008, CLIN J SPORT MED, V18, P235, DOI 10.1097/JSM.0b013e3181705756; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Yard EE, 2008, AM J SPORT MED, V36, P1930, DOI 10.1177/0363546508318047; Yeo RA, 2011, J NEUROTRAUM, V28, P1, DOI 10.1089/neu.2010.1578; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3; Zuckerman SL, 2012, NEUROSURGERY, V71, pE558, DOI 10.1227/01.neu.0000417735.94052.d6	225	203	205	0	79	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	JAN	2013	23	1					1	18		10.1097/JSM.0b013e31827f5f93			18	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	063VO	WOS:000313030300001	23269325		Y	N	2021-06-18	
J	Bakhos, LL; Lockhart, GR; Myers, R; Linakis, JG				Bakhos, Lisa L.; Lockhart, Gregory R.; Myers, Richard; Linakis, James G.			Emergency Department Visits for Concussion in Young Child Athletes	PEDIATRICS			English	Article						brain concussion; pediatrics; sport medicine; emergency medicine	SPORT-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; SCHOOL FOOTBALL PLAYERS; HEAD-INJURIES; UNITED-STATES; HELMET USE; RECOVERY; HOCKEY; SNOWBOARDERS; MANAGEMENT	OBJECTIVES: The objective of this study was to characterize emergency department (ED) visits for pediatric sport-related concussion (SRC) in pre-high school-versus high school-aged athletes. METHODS: A stratified probability sample of US hospitals that provide emergency services in the National Electronic Injury Surveillance System (1997-2007) and All Injury Program (2001-2005) was used. Concussion-related ED visits were analyzed for 8- to 13- and 14- to 19-year-old patients. Population data were obtained from the US Census Bureau; sport participation data were obtained from National Sporting Goods Association. RESULTS: From 2001 to 2005, US children who were aged 8 to 19 years had an estimated 502 000 ED visits for concussion. The 8- to 13-year-old group accounted for similar to 35% of these visits. Approximately half of all ED visits for concussion were SRC. The 8- to 13-year-old group sustained 40% of these, which represents 58% of all concussions in this group. Approximately 25% of all SRC visits in the 8- to 13-year-old group occurred during organized team sport (OTS). During the study period, similar to 4 in 1000 children aged 8 to 13 years and 6 in 1000 children aged 14 to 19 years had an ED visit for SRC, and 1 in 1000 children aged 8 to 13 years and 3 in 1000 children aged 14 to 19 years had an ED visit for concussion sustained during OTS. From 1997 to 2007, although participation had declined, ED visits for concussions in OTS in 8- to 13-year-old children had doubled and had increased by >200% in the 14- to 19-year-old group. CONCLUSIONS: The number of SRCs in young athletes is noteworthy. Additional research is required. Pediatrics 2010;126:e550-e556	[Bakhos, Lisa L.; Lockhart, Gregory R.; Myers, Richard; Linakis, James G.] Brown Univ, Rhode Isl Hosp, Warren Alpert Med Sch, Injury Prevent Ctr,Hasbro Childrens Hosp, Providence, RI 02903 USA	Bakhos, LL (corresponding author), 593 Eddy St,Claverick Bldg 2nd Floor, Providence, RI 02903 USA.	lbakhos@gmail.com					Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Browne GJ, 2006, BRIT J SPORT MED, V40, P163, DOI 10.1136/bjsm.2005.021220; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cusimano MD, 2009, CAN J NEUROL SCI, V36, P315, DOI 10.1017/S0317167100007046; Diamond PT, 2001, BRAIN INJURY, V15, P537, DOI 10.1080/02699050010007362; Echemendia RJ, 2003, APPL NEUROPSYCHOL, V10, P48, DOI 10.1207/S15324826AN1001_7; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Goodman D, 2001, MED SCI SPORT EXER, V33, P2004, DOI 10.1097/00005768-200112000-00005; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hagel BE, 2005, BRIT MED J, V330, P281, DOI 10.1136/bmj.38314.480035.7C; Hostetler SG, 2004, PEDIATRICS, V114, pE661, DOI 10.1542/peds.2004-1565; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Kelly KD, 2001, CLIN J SPORT MED, V11, P77, DOI 10.1097/00042752-200104000-00003; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; LAWSON B, 2009, PEDIATRICS, V123; Lovell M, 2009, CLIN SPORT MED, V28, P95, DOI 10.1016/j.csm.2008.08.008; Lovell Mark R, 2002, Curr Sports Med Rep, V1, P7; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2002, BRIT J SPORT MED, V36, P314, DOI 10.1136/bjsm.36.5.314; McCrory P, 2009, J SCI MED SPORT, V12, P340, DOI 10.1016/j.jsams.2009.02.004; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140; Meehan WP, 2009, PEDIATRICS, V123, P114, DOI 10.1542/peds.2008-0309; Metzl JD, 2006, PEDIATRICS, V117, P1813, DOI 10.1542/peds.2006-0480; Mueller BA, 2008, EPIDEMIOLOGY, V19, P270, DOI 10.1097/EDE.0b013e318163567c; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Shields BJ, 2006, PEDIATRICS, V117, P122, DOI 10.1542/peds.2005-1139; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Skarbek-Borowska S, 2006, ACAD EMERG MED, V13, P181, DOI [10.1111/j.1553-2712.2006.tb01669.x, 10.1197/j.aem.2005.09.009]; Smith GA, 1998, ARCH PEDIAT ADOL MED, V152, P694; Sulheim S, 2006, JAMA-J AM MED ASSOC, V295, P919, DOI 10.1001/jama.295.8.919; *US DEP HHS, 2008, ALL INJ PROGR 2006 C; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401	38	203	203	0	21	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	SEP	2010	126	3					E550	E556		10.1542/peds.2009-3101			7	Pediatrics	Pediatrics	646JK	WOS:000281535700035	20805145	Bronze			2021-06-18	
J	Choi, Y; Kim, HS; Shin, KY; Kim, EM; Kim, M; Kim, HS; Park, CH; Jeong, YH; Yoo, J; Lee, JP; Chang, KA; Kim, S; Suh, YH				Choi, Yoori; Kim, Hye-Sun; Shin, Ki Young; Kim, Eun-Mee; Kim, Minji; Kim, Hyun-Soo; Park, Cheol Hyoung; Jeong, Yun Ha; Yoo, Jongman; Lee, Jean-Pyo; Chang, Keun-A; Kim, Seonghan; Suh, Yoo-Hun			Minocycline attenuates neuronal cell death and improves cognitive impairment in Alzheimer's Disease models	NEUROPSYCHOPHARMACOLOGY			English	Article						minocycline; Alzheimer's disease; amyloid beta peptide; PKR; eukaryotic translation initiation factor-2 alpha; Tg2576 mice	EUKARYOTIC INITIATION FACTOR-2-ALPHA; CYTOCHROME-C RELEASE; ENDOPLASMIC-RETICULUM; MICROGLIAL ACTIVATION; HUNTINGTONS-DISEASE; MOUSE MODEL; SYNAPTIC PLASTICITY; CEREBRAL-ISCHEMIA; TRANSGENIC MICE; AMYLOID-PROTEIN	Minocycline is a semi-synthetic tetracycline antibiotic that effectively crosses the blood-brain barrier. Minocycline has been reported to have significant neuroprotective effects in models of cerebral ischemia, traumatic brain injury, amyotrophic lateral sclerosis, and Huntington's and Parkinson's diseases. In this study, we demonstrate that minocycline has neuroprotective effects in in vitro and in vivo Alzheimer's disease models. Minocycline was found to attenuate the increases in the phosphorylation of double-stranded RNA-dependent serine/threonine protein kinase, eukaryotic translation initiation factor-2 alpha and caspase 12 activation induced by amyloid ss peptide(1-42) treatment in NGF-differentiated PC 12 cells. In addition, increases in the phosphorylation of eukaryotic translation initiation factor-2 alpha were attenuated by administration of minocycline in Tg2576 mice, which harbor mutated human APP695 gene including the Swedish double mutation and amyloid ss peptide(1-42)-infused rats. We found that minocycline administration attenuated deficits in learning and memory in amyloid ss peptide(1-42)-infused rats. Increased phosphorylated state of eukaryotic translation initiation factor-2 alpha is observed in Alzheimer's disease patients' brains and may result in impairment of cognitive functions in Alzheimer's disease patients by decreasing the efficacy of de novo protein synthesis required for synaptic plasticity. On the basis of these results, minocycline may prove to be a good candidate as an effective therapeutic agent for Alzheimer's disease.	Seoul Natl Univ, Coll Med, Dept Pharmacol,MRC, Natl Creat Res Inotiat Ctr Alzheimers Dementia &, Seoul 110799, South Korea; Univ Calif San Diego, Sch Med, Dept Pediat, La Jolla, CA 92093 USA	Suh, YH (corresponding author), Seoul Natl Univ, Coll Med, Dept Pharmacol,MRC, Natl Creat Res Inotiat Ctr Alzheimers Dementia &, Seoul 110799, South Korea.	yhsuh@snu.ac.kr	Suh, Yoo-Hun/J-2761-2012; Kim, Hye Sun/J-2752-2012; Dilger, Ryan N./E-7031-2010	Dilger, Ryan N./0000-0003-2538-2845			Baumann O, 2001, INT REV CYTOL, V205, P149, DOI 10.1016/S0074-7696(01)05004-5; Blum D, 2004, NEUROBIOL DIS, V17, P359, DOI 10.1016/j.nbd.2004.07.012; Bonelli RM, 2003, NEUROLOGY, V60, P883, DOI 10.1212/01.WNL.0000049936.85487.7A; Chang RCC, 2002, NEUROREPORT, V13, P2429, DOI 10.1097/00001756-200212200-00011; Chang RCC, 2002, J NEUROCHEM, V83, P1215, DOI 10.1046/j.1471-4159.2002.01237.x; Chen A, 2003, NEURON, V39, P655, DOI 10.1016/S0896-6273(03)00501-4; Chen M, 2000, NAT MED, V6, P797, DOI 10.1038/77528; Cho KO, 2006, J NEUROSCI RES, V83, P285, DOI 10.1002/jnr.20727; Cleary JP, 2005, NAT NEUROSCI, V8, P79, DOI 10.1038/nn1372; Costa-Mattioli M, 2005, NATURE, V436, P1166, DOI 10.1038/nature03897; DeGracia DJ, 2004, J NEUROCHEM, V91, P1, DOI 10.1111/j.1471-4159.2004.02703.x; Dommergues MA, 2003, NEUROSCIENCE, V121, P619, DOI 10.1016/S0306-4522(03)00558-X; DREHER D, 1995, CIRC RES, V76, P388, DOI 10.1161/01.RES.76.3.388; Du YS, 2001, P NATL ACAD SCI USA, V98, P14669, DOI 10.1073/pnas.251341998; Good ML, 2003, BRIT J DERMATOL, V149, P237, DOI 10.1046/j.1365-2133.2003.05497.x; Harding HP, 1999, NATURE, V397, P271; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Hayashi T, 2005, J CEREBR BLOOD F MET, V25, P41, DOI 10.1038/sj.jcbfm.9600005; He Y, 2001, BRAIN RES, V909, P187, DOI 10.1016/S0006-8993(01)02681-6; Heo K, 2006, NEUROSCI LETT, V398, P195, DOI 10.1016/j.neulet.2006.01.027; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Hunter CL, 2004, ANN NEUROL, V56, P675, DOI 10.1002/ana.20250; Hunter CL, 2004, EUR J NEUROSCI, V19, P3305, DOI 10.1111/j.0953-816X.2004.03439.x; Kandel ER, 2001, SCIENCE, V294, P1030, DOI 10.1126/science.1067020; Katayama T, 2004, J CHEM NEUROANAT, V28, P67, DOI 10.1016/j.jchemneu.2003.12.004; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Lindholm D, 2006, CELL DEATH DIFFER, V13, P385, DOI 10.1038/sj.cdd.4401778; Matsuki S, 2003, BIOCHEM BIOPH RES CO, V312, P843, DOI 10.1016/j.bbrc.2003.10.191; Mejia ROS, 2001, NEUROSURGERY, V48, P1393; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nitta A, 1997, JPN J PHARMACOL, V73, P51, DOI 10.1254/jjp.73.51; Paschen W, 2001, CELL CALCIUM, V29, P1, DOI 10.1054/ceca.2000.0162; Popovic N, 2002, ANN NEUROL, V51, P215, DOI 10.1002/ana.10092; Racay P, 1995, BIOCHEM MOL BIOL INT, V36, P569; Schuster D, 2005, NEUROPEPTIDES, V39, P419, DOI 10.1016/j.npep.2005.03.005; Seabrook TJ, 2006, GLIA, V53, P776, DOI 10.1002/glia.20338; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Selkoe DJ, 2001, PHYSIOL REV, V81, P741; Smith DL, 2003, ANN NEUROL, V54, P186, DOI 10.1002/ana.10614; Smith WW, 2005, HUM MOL GENET, V14, P3801, DOI 10.1093/hmg/ddi396; Sonenberg N, 2003, CURR OPIN STRUC BIOL, V13, P56, DOI 10.1016/S0959-440X(03)00009-5; Suen KC, 2003, J BIOL CHEM, V278, P49819, DOI 10.1074/jbc.M306503200; Suk K, 2004, NEUROSCI LETT, V366, P167, DOI 10.1016/j.neulet.2004.05.038; Taylor SS, 2005, CELL, V122, P823, DOI 10.1016/j.cell.2005.09.007; Van Den Bosch L, 2002, NEUROREPORT, V13, P1067, DOI 10.1097/00001756-200206120-00018; Viner RI, 1996, FREE RADICAL RES, V24, P243, DOI 10.3109/10715769609088022; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wang JZ, 2004, J BIOL CHEM, V279, P19948, DOI 10.1074/jbc.M313629200; Wang X, 2003, P NATL ACAD SCI USA, V100, P10483, DOI 10.1073/pnas.1832501100; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4; Yong VW, 2004, LANCET NEUROL, V3, P744, DOI 10.1016/S1474-4422(04)00937-8; Yrjanheikki J, 1999, P NATL ACAD SCI USA, V96, P13496, DOI 10.1073/pnas.96.23.13496; Zhu S, 2002, NATURE, V417, P74, DOI 10.1038/417074a	54	203	210	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0893-133X	1740-634X		NEUROPSYCHOPHARMACOL	Neuropsychopharmacology	NOV	2007	32	11					2393	2404		10.1038/sj.npp.1301377			12	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	221KL	WOS:000250226000016	17406652	Bronze			2021-06-18	
J	Vespa, P; Boonyaputthikul, R; McArthur, DL; Miller, C; Etchepare, M; Bergsneider, M; Glenn, T; Martin, N; Hovda, D				Vespa, P; Boonyaputthikul, R; McArthur, DL; Miller, C; Etchepare, M; Bergsneider, M; Glenn, T; Martin, N; Hovda, D			Intensive insulin therapy reduces microdialysis glucose values without altering glucose utilization or improving the lactate/pyruvate ratio after traumatic brain injury	CRITICAL CARE MEDICINE			English	Article						brain injury; microdialysis; insulin; glucose; intensive insulin therapy	HEAD-INJURY; LACTATE METABOLISM; HYPERGLYCEMIA; FLUID; SEVERITY; SEIZURES; MODERATE; OUTCOMES; TRIAL; CARE	Objective: To determine that intensive glycemic control does not reduce microdialysis glucose concentration brain metabolism of glucose. Design: Prospective monitoring followed by retrospective data analysis of cerebral microdialysis and global brain metabolism. Setting. Single center, academic neurointensive care unit. Patients. Forty-seven moderate to severe traumatic brain injury patients. Interventions: A nonrandomized, consecutive design was used for glycemic control with loose insulin (n = 33) for the initial 2 yrs or intensive insulin therapy (n = 14) for the last year. Measurements and Main Results: In 14 patients treated with intensive insulin therapy, there was a reduction in microdialysis glucose by 70% of baseline concentration compared with a 15% reduction in 33 patients treated with a loose insulin protocol. Despite this reduction in microdialysis glucose, the global metabolic rate of glucose did not change. However, intensive insulin therapy was associated with increased incidence of microdialysis markers of cellular distress, namely elevated glutamate (38 +/- 37% vs. 10 +/- 17%, p < .01), elevated lactate/pyruvate ratio (38 +/- 37% vs. 19 +/- 26%, p < .03) and low glucose (26 +/- 17% vs. 11 +/- 15%, p < .05, and increased global oxygen extraction fraction. Mortality was similar in the intensive and loose insulin treatment groups (14% vs. 15%, p = .9), as was 6-month clinical outcome (p = .3). Conclusions: Intensive insulin therapy results in a net reduction in microdialysis glucose and an increase in microdialysis glutamate and lactate/pyruvate without conveying a functional outcome advantage.	Univ Calif Los Angeles, Div Neurosurg, Los Angeles, CA 90024 USA; Barrow Neurol Inst, Phoenix, AZ 85013 USA	Vespa, P (corresponding author), Univ Calif Los Angeles, Div Neurosurg, Los Angeles, CA 90024 USA.		McArthur, David/E-6442-2013	McArthur, David/0000-0003-3385-1314; Martin, Neil/0000-0002-6565-4131; Glenn, Thomas/0000-0003-4273-3408	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS02089, NS03039] Funding Source: Medline		Abi-Saab WM, 2002, J CEREBR BLOOD F MET, V22, P271, DOI 10.1097/00004647-200203000-00004; Alessandri B, 2000, ACTA NEUROCHIR SUPPL, V76, P425; Alessandri B, 1999, ACT NEUR S, V75, P21; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; Bruno A, 2002, NEUROLOGY, V59, P669, DOI 10.1212/WNL.59.5.669; Ceremuzynski L, 1999, CARDIOVASC DRUG THER, V13, P191, DOI 10.1023/A:1007787924085; Cochran A, 2003, J TRAUMA, V55, P1035, DOI 10.1097/01.TA.0000031175.96507.48; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P191, DOI 10.1097/01.WCB.0000100045.07481.DE; Cornford EM, 1996, J NEUROTRAUM, V13, P523, DOI 10.1089/neu.1996.13.523; DESALLES AAF, 1987, NEUROSURGERY, V21, P45, DOI 10.1227/00006123-198707000-00009; DUSICK JR, 2005, J CEREB BLOOD FL S1, V25, pS564; Glenn TC, 2003, J CEREBR BLOOD F MET, V23, P1239, DOI 10.1097/01.WCB.0000089833.23606.7F; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; Hamlin GP, 2001, J NEUROTRAUM, V18, P1011, DOI 10.1089/08977150152693700; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Hopwood SE, 2005, J CEREBR BLOOD F MET, V25, P391, DOI 10.1038/sj.jcbfm.9600050; Hutchinson PJA, 2000, ACT NEUR S, V76, P431; Kinoshita K, 2002, J NEUROTRAUM, V19, P681, DOI 10.1089/08977150260139075; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; LANDOLT H, 1994, ACTA NEUROCHIR, P475; MARGULIES DR, 1994, AM SURGEON, V60, P387; Passero S, 2003, NEUROLOGY, V61, P1351, DOI 10.1212/01.WNL.0000094326.30791.2D; Pittas AG, 2004, ARCH INTERN MED, V164, P2005, DOI 10.1001/archinte.164.18.2005; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; VANDENBERGHE G, IN PRESS NEUROLOGY; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Wu HM, 2004, NEUROSURGERY, V55, P1306, DOI 10.1227/01.NEU.0000143028.08719.42; YOUNG B, 1989, ANN SURG, V210, P466, DOI 10.1097/00000658-198910000-00007; Zovein A, 2004, AM J PHYSIOL-REG I, V286, pR273, DOI 10.1152/ajpregu.00160.2003	35	203	206	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	MAR	2006	34	3					850	856		10.1097/01.CCM.0000201875.12245.6F			7	Critical Care Medicine	General & Internal Medicine	015YI	WOS:000235587100038	16505665				2021-06-18	
J	Moser, RS; Schatz, P; Jordan, BD				Moser, RS; Schatz, P; Jordan, BD			Prolonged effects of concussion in high school athletes	NEUROSURGERY			English	Article						baseline screening; concussion; mild head injury; neuropsychological testing; youth sports	TRAUMATIC BRAIN-INJURY; PROFESSIONAL FOOTBALL; HEAD-INJURY; GAME; PERFORMANCE; CHILDREN; IMPACTS	Objective: To identify enduring prolonged neuropsychological effects of cerebral concussion in high school youth athletes. Methods: High school athletes (n=223) underwent baseline neuropsychological evaluation between 1999 and 2000, assigned to independent groups on the basis of concussion history: athletes with no concussion history or present medical and/or neuropsychological complaints (n=82), symptom-free athletes who experienced one (n=56) or two or more (n=45) concussions (not in the prior 6 mo), and those who experienced a concussion 1 week before testing (n=40). Main outcome measures included a structured clinical interview, demographic form, symptom checklist, the Repeatable Battery for the Assessment of Neuropsychological Status, and the Trail Making Tests A and B. Analyses of variance were used to determine between-group differences. Results: Athletes with recent concussions performed significantly worse on measures of attention and concentration than youth athletes with no concussion history. Symptom-free athletes with a history of two or more concussions performed similar on testing to youth athletes who had just experienced a recent concussion. Similarly, cumulative academic grade point averages were significantly lower not only for youth. athletes with two or more previous concussion groups, but for youth athletes who experienced recent concussions, suggesting that athletes with lower grade point averages may be more prone to concussion. Conclusion: There seem to be subtle yet significant prolonged neuropsychological effects in youth athletes with a history of two or more previous concussions.	RSM Psychol Ctr LLC, Lawrenceville, NJ 08648 USA; St Josephs Univ, Dept Psychol, Philadelphia, PA 19131 USA; Burke Rehabil Hosp, Brain Injury Program, White Plains, NY USA	Moser, RS (corresponding author), RSM Psychol Ctr LLC, 3131 Princeton Pike,Bldg 5, Lawrenceville, NJ 08648 USA.	r.moser@rcn.com		Schatz, Philip/0000-0002-6222-6545			ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; ALVES WM, 1987, CLIN SPORT MED, V6, P211; Barth JT., 1989, MILD HEAD INJURY, P257; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Giza CC, 2001, J ATHL TRAINING, V36, P228; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kelly JP, 1997, NEUROLOGY, V48, P581; Kelly JP, 1999, JAMA-J AM MED ASSOC, V282, P989, DOI 10.1001/jama.282.10.989; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; Pellman E, 2004, NEUROSURGERY, V55, P860, DOI 10.1227/01.NEU.0000137657.00146.7D; Pellman EJ, 2005, NEUROSURGERY, V56, P79, DOI 10.1227/01.NEU.0000150180.16552.8D; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Pellman EJ, 2004, NEUROSURGERY, V55, P1100, DOI 10.1227/01.NEU.0000147063.12873.F5; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P797, DOI 10.1093/neurosurgery/53.3.797; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Randolph C, 1998, REPEATABLE BATTERY A; SNOEK JW, 1984, BRAIN, V107, P15, DOI 10.1093/brain/107.1.15; Wolfson D., 1993, HALSTEAD REITAN NEUR	32	203	204	0	50	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	AUG	2005	57	2					300	306		10.1227/01.NEU.0000166663.98616.E4			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	953WD	WOS:000231111200023	16094159				2021-06-18	
J	Blaivas, M; Theodoro, D; Sierzenski, PR				Blaivas, M; Theodoro, D; Sierzenski, PR			Elevated intracranial pressure detected by bedside emergency ultrasonography of the optic nerve sheath	ACADEMIC EMERGENCY MEDICINE			English	Article						emergency ultrasonography; ocular ultrasound; head injury; emergency medicine; elevated intracranial pressure; subarachnoid hemorrhage	CEREBROSPINAL-FLUID PRESSURE; HEAD-INJURY; HYPERTENSION; PHYSICIANS; SONOGRAPHY; DOPPLER	Patients with altered level of consciousness may be suffering from elevated intracranial pressure (EICP) from a variety of causes. A rapid, portable, and noninvasive means of detecting EICP is desirable when conventional imaging methods are unavailable. Objectives: The hypothesis of this study was that ultrasound (US) measurement of the optic nerve sheath diameter (ONSD) could accurately predict the presence of EICP Methods: The authors performed a prospective, blinded observational study on emergency department (ED) patients with a suspicion of EICP due to possible focal intracranial pathology. The study was conducted at a large community ED with an emergency medicine residency program and took place over a six-month period. Patients suspected of having EICP by an ED attending were enrolled when study physicians were available. Unstable patients were excluded. ONSD was measured 3 mm. behind the globe using a 10-MHz linear probe on the closed eyelids of supine patients, bilaterally. Based on prior literature, an ONSD above 5 mm on ultrasound was considered abnormal. Computed tomography (CT) findings defined as indicative of EICP were the presence of mass effect with a midline shift 3 mm or more, a collapsed third ventricle, hydrocephalus, the effacement of sulci with evidence of significant edema, and abnormal mesencephalic cisterns. For each patient, the average of the two ONSD measurements was calculated and his or her head CT scans were evaluated for signs of EICP Student's t-test was used to compare ONSDs in the normal and EICP groups. Sensitivity, specificity, and positive and negative predictive values were calculated. Results: Thirty-five patients were enrolled; 14 had CT results consistent with EICP. All cases of CT-determined EICP were correctly predicted by ONSD over 5 mm on US. One patient with ONSD of 5.7 mm in one eye and 3.7 mm in the other on US had a mass abutting the ipsilateral optic nerve; no shift was seen on CT. He was placed in the EICP category on his data collection sheet. The mean ONSD for the 14 patients with CT evidence of EICP was 6.27 mm (95% CI = 5.6 to 6.89); the mean ONSD for the others was 4.42 mm (95% CI = 4.15 to 4.72). The difference of 1.85 mm (95% CI = 1.23 to 2.39 mm) yielded a p = 0.001. The sensitivity and specificity for ONSD, when compared with CT results, were 100% and 95%, respectively. The positive and negative predictive values were 93% and 100%, respectively. Conclusions: Despite small numbers and selection bias, this study suggests that bedside ED US may be useful in the diagnosis of EICP.	Med Coll Georgia, Dept Emergency Med, Augusta, GA 30912 USA; N Shore Univ Hosp, Dept Emergency Med, Manhasset, NY 11030 USA; Christiana Care Med Syst, Dept Emergency Med, Newark, DE USA	Blaivas, M (corresponding author), Med Coll Georgia, Dept Emergency Med, 1120 15th St,AF-2056, Augusta, GA 30912 USA.		Theodoro, Daniel L/C-7278-2012				Blaivas M, 2000, ACAD EMERG MED, V7, P120, DOI 10.1111/j.1553-2712.2000.tb00512.x; Blaivas M, 2002, ACAD EMERG MED, V9, P791, DOI 10.1197/aemj.9.8.791; Blaivas M, 2001, ACAD EMERG MED, V8, P398, DOI 10.1111/j.1553-2712.2001.tb02122.x; Blaivas M, 2001, ACAD EMERG MED, V8, P90, DOI 10.1111/j.1553-2712.2001.tb00563.x; Coles W H, 1994, Heart Dis Stroke, V3, P304; Durston W, 2000, AM J EMERG MED, V18, P72, DOI 10.1016/S0735-6757(00)90054-8; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; GALETTA S, 1989, J CLIN NEURO-OPHTHAL, V9, P79; GANGEMI M, 1987, NEUROCHIRURGIA, V30, P53; GUTHOFF R, 1991, ULTRASOUND OPHTHALMO; Hansen HC, 1997, J NEUROSURG, V87, P34, DOI 10.3171/jns.1997.87.1.0034; HAYREH SS, 1968, DOC OPHTHALMOL, V24, P289, DOI 10.1007/BF02550944; Moore CL, 2002, ACAD EMERG MED, V9, P186, DOI 10.1197/aemj.9.3.186; Munch EC, 2001, CRIT CARE MED, V29, P976; Nemeth J, 2002, J CLIN ULTRASOUND, V30, P332, DOI 10.1002/jcu.10079; OSSOINIG KC, 1993, DOC OPHTH P, V55, P3; SARKISIAN AE, 1991, J TRAUMA, V31, P247, DOI 10.1097/00005373-199131020-00016; TEASDALE E, 1984, J NEUROL NEUROSUR PS, V47, P600, DOI 10.1136/jnnp.47.6.600; Valley VT, 1998, ACAD EMERG MED, V5, P309, DOI 10.1111/j.1553-2712.1998.tb02710.x	19	203	206	1	7	HANLEY & BELFUS INC	PHILADELPHIA	210 S 13TH ST, PHILADELPHIA, PA 19107 USA	1069-6563			ACAD EMERG MED	Acad. Emerg. Med.	APR	2003	10	4					376	381		10.1197/aemj.10.4.376			6	Emergency Medicine	Emergency Medicine	663FL	WOS:000181995500014	12670853				2021-06-18	
J	Delaney, TS; Lacroix, VJ; Leclerc, S; Johnston, KM				Delaney, TS; Lacroix, VJ; Leclerc, S; Johnston, KM			Concussions among university football and soccer players	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; soccer; football; university; mouthguard; risk factors	SPORT-RELATED CONCUSSION; TRAUMATIC BRAIN INJURY; HEAD-INJURIES; CEREBRAL CONCUSSION; CONTACT SPORTS; CERVICAL-SPINE; NECK-INJURY; EPIDEMIOLOGY; GUIDELINES; MANAGEMENT	Objective: A study to examine the incidence and characteristics of concussions among Canadian university athletes during 1 full year of football and soccer participation. Design: Retrospective survey. Participants: Three hundred eighty Canadian university football and 240 Canadian university soccer players reporting to 1999 fall training camp. Of these, 328 football and 201 soccer players returned a completed questionnaire. Main Outcome Measures: Based on self-reported symptoms, calculations were made to determine the number of concussions experienced during the previous full year of football or soccer participation, the duration of symptoms, the time for return to play, and any associated risk factors for concussions. Results: Of all the athletes who returned completed questionnaires, 70.4% of the football players and 62.7% of the soccer players had experienced symptoms of a concussion during the previous year. Only 23.4% of the concussed football players and 19.8% of the concussed soccer players realized they had suffered a concussion. More than one concussion was experienced by 84.6% of the concussed football players and 81.7% of the concussed soccer players. Examining symptom duration, 27.6% of all concussed football players and 18.8% of all concussed soccer players experienced symptoms for at least 1 day or longer. Tight end and defensive lineman were the positions most commonly affected in football, while goalies were the players most commonly affected in soccer. Variables that increased the odds of suffering a concussion during the previous year for football players included a history of a traumatic loss of consciousness or a recognized concussion in the past. Variables that increased the odds of suffering a concussion during the previous year for soccer players included a past history of a recognized concussion while playing soccer and being female. Conclusions: University football and soccer players seem to be experiencing a significant amount of concussions while participating in their respective sports. Variables that seem to increase the odds of suffering a concussion during the previous year for football and soccer players include a history of a recognized concussion. Despite being relatively common, symptoms of concussion may not be recognized by many players.	MDCM, McGill Sport Med Clin, Montreal, PQ H2W 1S4, Canada; McGill Univ, Ctr Hlth, Dept Emergency Med, Montreal, PQ, Canada; McGill Univ, Ctr Hlth, Dept Neurosurg, Montreal, PQ, Canada	Delaney, TS (corresponding author), MDCM, McGill Sport Med Clin, 475 Pine Ave W, Montreal, PQ H2W 1S4, Canada.	j.delaney@staff.mcgill.ca					Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Autti T, 1997, LANCET, V349, P1144, DOI 10.1016/S0140-6736(05)63019-X; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Barth J T, 2000, Dent Clin North Am, V44, P67; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Cantino PD, 1998, NOVON, V8, P1, DOI 10.2307/3391880; Cantu RC, 1996, BRIT J SPORT MED, V30, P289, DOI 10.1136/bjsm.30.4.289; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; Cantu RC, 1997, CLIN SPORT MED, V16, P531, DOI 10.1016/S0278-5919(05)70038-7; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; Cantu RC., 1997, AM COLL SPORTS MED E, P345; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Delaney JS, 2001, CLIN J SPORT MED, V11, P234, DOI 10.1097/00042752-200110000-00005; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; KASS RE, 1995, J AM STAT ASSOC, V90, P773, DOI 10.1080/01621459.1995.10476572; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; Labella CR, 2002, MED SCI SPORT EXER, V34, P41, DOI 10.1097/00005768-200201000-00007; Leclerc S, 2001, SPORTS MED, V31, P629, DOI 10.2165/00007256-200131080-00007; LINDSAY KW, 1980, BRIT MED J, V281, P789, DOI 10.1136/bmj.281.6243.789; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; Maroosis G, 1999, J Can Dent Assoc, V65, P90; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrory P, 2001, BRIT J SPORT MED, V35, P81, DOI 10.1136/bjsm.35.2.81; McCrory P, 2001, CLIN J SPORT MED, V11, P160, DOI 10.1097/00042752-200107000-00006; Mueller FO, 1998, CLIN SPORT MED, V17, P169, DOI 10.1016/S0278-5919(05)70071-5; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; ROBERTS WO, 1992, PHYSICIAN SPORTSMED, V20, P66, DOI 10.1080/00913847.1992.11710295; Sallis RE, 2000, MED SCI SPORT EXER, V32, P1820, DOI 10.1097/00005768-200011000-00002; SCHMIDTOLSEN S, 1991, AM J SPORT MED, V19, P273, DOI 10.1177/036354659101900311; Schneider R., 1973, HEAD NECK INJURIES F; TORG JS, 1985, MED SCI SPORT EXER, V17, P295; TORG JS, 1985, JAMA-J AM MED ASSOC, V254, P3439, DOI 10.1001/jama.254.24.3439; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; TYSVAER AT, 1989, AM J SPORT MED, V17, P573, DOI 10.1177/036354658901700421; Warren WL, 1998, CLIN SPORT MED, V17, P99, DOI 10.1016/S0278-5919(05)70064-8; WILBERGER JE, 1989, CLIN SPORT MED, V8, P1; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401; YARNELL PR, 1973, NEUROLOGY, V23, P196, DOI 10.1212/WNL.23.2.196; 1988, PHYS SPORTSMED, V16, P165	49	203	208	0	32	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	NOV	2002	12	6					331	338		10.1097/00042752-200211000-00003			8	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	625UM	WOS:000179834000003	12466687				2021-06-18	
J	Sullivan, PG; Geiger, JD; Mattson, MP; Scheff, SW				Sullivan, PG; Geiger, JD; Mattson, MP; Scheff, SW			Dietary supplement creatine protects against traumatic brain injury	ANNALS OF NEUROLOGY			English	Article							MITOCHONDRIAL DYSFUNCTION; CYCLOSPORINE-A; PERMEABILITY TRANSITION; CORTICAL CONTUSION; ERGOGENIC AID; HEAD-INJURY; DAMAGE; KINASE; RAT; CYCLOCREATINE	Creatine, one of the most common food supplements used by individuals at almost every level of athleticism, promote gains in performance, strength, and fat-free mass. Recent experimental findings have demonstrated that creatine affords significant neuroprotection against ischemic and oxidative insults. The present experiments investigated the possible effect of creatine dietary supplementation on brain tissue damage after experimental traumatic brain injury. Results demonstrate that chronic administration of creatine ameliorated the extent of cortical damage by as much as 36% in mice and 50% in rats. Protection seems to be related to creatine-induced maintenance of mitochondrial bioenergetics. Mitochondrial membrane potential was significantly increased, intramitochondrial levels of reactive oxygen species and calcium were significantly decreased, and adenosine triphosphate levels were maintained. Induction of mitochondrial permeability transition was significantly inhibited in animals fed creatine. This food supplement may provide clues to the mechanisms responsible for neuronal loss after traumatic brain injury and may find use as a neuroprotective agent against acute and delayed neurodegenerative processes.	Univ Kentucky, Sanders Brown Ctr Aging 233, Lexington, KY 40536 USA; Univ Manitoba, Dept Pharmacol & Therapeut, Winnipeg, MB, Canada; NIH, Neurosci Lab, Baltimore, MD USA	Scheff, SW (corresponding author), Univ Kentucky, Sanders Brown Ctr Aging 233, 800 S Limestone Ave, Lexington, KY 40536 USA.		Mattson, Mark P/F-6038-2012		NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL60287] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS39828, NS31220] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [P50HL060287] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS031220, R01NS039828] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [Z01AG000315, ZIAAG000315] Funding Source: NIH RePORTER		Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; Balestrino M, 1999, BRAIN RES, V816, P124, DOI 10.1016/S0006-8993(98)01131-7; BEAL MF, 1995, ANN NEUROL, V38, P357, DOI 10.1002/ana.410380304; Beutner G, 1998, BBA-BIOMEMBRANES, V1368, P7, DOI 10.1016/S0005-2736(97)00175-2; Beutner G, 1996, FEBS LETT, V396, P189, DOI 10.1016/0014-5793(96)01092-7; BRAUGHLER JM, 1992, J NEUROTRAUM, V9, pS1; BRDICZKA D, 1994, J BIOL CHEM, V269, P27640; CADOUXHUDSON TAD, 1990, ACTA NEUROCHIR, V104, P1, DOI 10.1007/BF01842884; Cantu RC, 1997, CLIN SPORT MED, V16, P531, DOI 10.1016/S0278-5919(05)70038-7; CHEN L, 1995, J COMP NEUL, V363, P3898; Choi D W, 1990, Adv Exp Med Biol, V268, P501; Clarke KS, 1998, CLIN SPORT MED, V17, P1, DOI 10.1016/S0278-5919(05)70056-9; ERECINSKA M, 1989, J CEREBR BLOOD F MET, V9, P2, DOI 10.1038/jcbfm.1989.2; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Feldman EB, 1999, NUTR REV, V57, P45, DOI 10.1111/j.1753-4887.1999.tb01777.x; Holtzman D, 1998, PEDIATR RES, V44, P410, DOI 10.1203/00006450-199809000-00024; Klivenyi P, 1999, NAT MED, V5, P347, DOI 10.1038/6568; Lai J C, 1979, Methods Enzymol, V55, P51; Matthews RT, 1998, J NEUROSCI, V18, P156; Matthews RT, 1999, EXP NEUROL, V157, P142, DOI 10.1006/exnr.1999.7049; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; Mattson MP, 1998, EXP NEUROL, V153, P35, DOI 10.1006/exnr.1998.6863; MCARDLE WD, 1999, SPORTS EXERCISE NUTR; McIntosh TK, 1996, LAB INVEST, V74, P315; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; McNair ND, 1999, NURS CLIN N AM, V34, P637; Melia P, 1996, CLIN J SPORT MED, V6, P9, DOI 10.1097/00042752-199601000-00004; MICHEL RP, 1988, J MICROSC-OXFORD, V150, P117, DOI 10.1111/j.1365-2818.1988.tb04603.x; MOCCHETTI I, 1995, J NEUROTRAUM, V12, P853, DOI 10.1089/neu.1995.12.853; Montal M, 1998, BBA-BIOENERGETICS, V1366, P113, DOI 10.1016/S0005-2728(98)00124-8; Mujika I, 1997, INT J SPORTS MED, V18, P491, DOI 10.1055/s-2007-972670; OGorman E, 1996, BBA-BIOENERGETICS, V1276, P161, DOI 10.1016/0005-2728(96)00074-6; OGorman E, 1997, FEBS LETT, V414, P253, DOI 10.1016/S0014-5793(97)01045-4; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; PROCTOR HJ, 1988, J TRAUMA, V28, P347, DOI 10.1097/00005373-198803000-00010; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Tibbs RE, 1998, ANAT REC, V253, P167; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; Wilken B, 1998, PEDIATR RES, V43, P8, DOI 10.1203/00006450-199801000-00002; Xiong Y, 1998, J NEUROTRAUM, V15, P531, DOI 10.1089/neu.1998.15.531; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23	49	203	213	0	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0364-5134			ANN NEUROL	Ann. Neurol.	NOV	2000	48	5					723	729		10.1002/1531-8249(200011)48:5<723::AID-ANA5>3.3.CO;2-N			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	370NW	WOS:000165130000005	11079535				2021-06-18	
J	Nemetz, PN; Leibson, C; Naessens, JM; Beard, M; Kokmen, E; Annegers, JF; Kurland, LT				Nemetz, PN; Leibson, C; Naessens, JM; Beard, M; Kokmen, E; Annegers, JF; Kurland, LT			Traumatic brain injury and time to onset of Alzheimer's disease: A population-based study	AMERICAN JOURNAL OF EPIDEMIOLOGY			English	Article						Alzheimer's disease; brain injuries; cohort studies; head injuries; incidence; medical records; risk factors; traumatology	AMYLOID PROTEIN DEPOSITION; APOLIPOPROTEIN-E GENOTYPE; SEVERE HEAD-INJURY; RISK-FACTORS; EPSILON-4 ALLELE; TYPE-4 ALLELE; UNITED-STATES; DEMENTIA; EPIDEMIOLOGY; PATHOGENESIS	Controversy continues as to whether traumatic brain injury is a risk factor for Alzheimer's disease. The authors examined a related hypothesis that among persons with traumatic brain injury who develop Alzheimer's disease, time to onset of the disease is reduced. They used data on all documented episodes of traumatic brain injury that occurred from 1935 to 1984 among Olmsted County, Minnesota, residents. Community-based medical records were used to follow traumatic brain injury cases who were aged 40 years or older at last contact prior to June 1, 1988, for Alzheimer's disease until last contact, death, or June 1, 1988. The test of the hypothesis was restricted to those cases who developed Alzheimer's disease. The expected time to onset of Alzheimer's disease was derived from a life table constructed by using age-of-onset distributions within sex groups:for a previously identified cohort of Rochester, Minnesota, Alzheimer's disease incidence cases without a history of head trauma. The authors found that of the 1,283 traumatic brain injury cases followed, 31 developed Alzheimer's disease, a number similar to that expected (standardized incidence ratio = 1.2, 95% confidence interval 0.8-1.7). However, the observed time from traumatic brain injury to Alzheimer's disease was less than the expected time to onset of Alzheimer's disease (median = 10 vs. 18 years, p = 0.015). The results suggest that traumatic brain injury reduces the time to onset of Alzheimer's disease among persons at risk of developing the, disease.	Mayo Clin, Dept Hlth Sci Res, Rochester, MN 55905 USA; Univ British Columbia, Fac Commerce & Business Adm, Policy Anal Div, Vancouver, BC, Canada; Mayo Clin, Dept Neurol, Rochester, MN USA; Univ Texas, Houston Sch Publ Hlth, Houston, TX USA	Nemetz, PN (corresponding author), Mayo Clin, Dept Hlth Sci Res, Rochester, MN 55905 USA.						AMADUCCI L, 1988, ACTA NEUROL SCAND, V77, P13, DOI 10.1111/j.1600-0404.1988.tb07982.x; AMADUCCI LA, 1986, NEUROLOGY, V36, P922, DOI 10.1212/WNL.36.7.922; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; BROE GA, 1990, NEUROLOGY, V40, P1698, DOI 10.1212/WNL.40.11.1698; CHANDRA V, 1987, NEUROLOGY, V37, P1295, DOI 10.1212/WNL.37.8.1295; CHANDRA V, 1989, NEUROLOGY, V39, P1576, DOI 10.1212/WNL.39.12.1576; CLINTON J, 1991, NEUROPATH APPL NEURO, V17, P69, DOI 10.1111/j.1365-2990.1991.tb00695.x; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; EVANS DA, 1990, MILBANK Q, V68, P267, DOI 10.2307/3350099; FERINISTRAMBI L, 1990, NEUROEPIDEMIOLOGY, V9, P39, DOI 10.1159/000110750; FRENCH LR, 1985, AM J EPIDEMIOL, V121, P414, DOI 10.1093/oxfordjournals.aje.a114013; GABRIEL SE, 1994, NEW ENGL J MED, V330, P1697, DOI 10.1056/NEJM199406163302401; GEDYE A, 1989, J AM GERIATR SOC, V37, P970, DOI 10.1111/j.1532-5415.1989.tb07283.x; GRAVES AB, 1990, AM J EPIDEMIOL, V131, P491, DOI 10.1093/oxfordjournals.aje.a115523; GRIFFIN WST, 1994, NEUROSCI LETT, V176, P133, DOI 10.1016/0304-3940(94)90066-3; HARRINGTON DP, 1982, BIOMETRIKA, V69, P553, DOI 10.2307/2335991; HAY JW, 1987, AM J PUBLIC HEALTH, V77, P1169, DOI 10.2105/AJPH.77.9.1169; HENDERSON AS, 1988, ACTA PSYCHIAT SCAND, V78, P257, DOI 10.1111/j.1600-0447.1988.tb06336.x; HEYMAN A, 1984, ANN NEUROL, V15, P335, DOI 10.1002/ana.410150406; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; KOKMEN E, 1991, NEUROLOGY, V41, P1393, DOI 10.1212/WNL.41.9.1393; KOKMEN E, 1993, NEUROLOGY, V43, P1887, DOI 10.1212/WNL.43.10.1887; KOKMEN E, 1991, ALZHEIMERS DISEASE : BASIC MECHANISMS, DIAGNOSIS AND THERAPEUTIC STRATEGIES, P343; KOSIK K, 1992, NEUROBIOL AGING, V13, P535, DOI 10.1016/0197-4580(92)90052-Y; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MAYEUX R, 1993, ANN NEUROL, V34, P752, DOI 10.1002/ana.410340527; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; MCKENZIE JE, 1994, NEUROREPORT, V6, P161, DOI 10.1097/00001756-199412300-00041; Melton LJ, 1996, MAYO CLIN PROC, V71, P266, DOI 10.4065/71.3.266; MOLGAARD CA, 1990, NEUROEPIDEMIOLOGY, V9, P233, DOI 10.1159/000110778; MORTIMER JA, 1985, NEUROLOGY, V35, P264, DOI 10.1212/WNL.35.2.264; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; Nicoll J. A. R., 1996, V777, P271; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; NOGUCHI S, 1993, LANCET, V342, P737, DOI 10.1016/0140-6736(93)91728-5; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; PASCHALIS C, 1990, DEMENTIA, V1, P52; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; PRICE DL, 1992, NEUROBIOL AGING, V13, P623, DOI 10.1016/0197-4580(92)90069-A; RASMUSSON DX, 1995, BRAIN INJURY, V9, P213, DOI 10.3109/02699059509008194; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; ROCCA WA, 1986, ANN NEUROL, V19, P415, DOI 10.1002/ana.410190502; ROCCA WA, 1989, NEUROBIOL AGING, V10, P440, DOI 10.1016/0197-4580(89)90090-0; ROCCA WA, 1987, J NEURAL TRANSM, P3; ROSES AD, 1994, EPILEPSIA, V35, pS20, DOI 10.1111/j.1528-1157.1994.tb05925.x; SAUNDERS AM, 1993, LANCET, V342, P710, DOI 10.1016/0140-6736(93)91709-U; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCHOENBERG B S, 1983, Neuroepidemiology, V2, P257, DOI 10.1159/000110529; SCHOENBERG BS, 1986, NEUROL CLIN, V4, P447, DOI 10.1016/S0733-8619(18)30981-2; SCHOENBERG BS, 1987, ANN NEUROL, V22, P724, DOI 10.1002/ana.410220608; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; SELKOE DJ, 1991, NATURE, V354, P432, DOI 10.1038/354432a0; SHALAT SL, 1987, NEUROLOGY, V37, P1630, DOI 10.1212/WNL.37.10.1630; SOININEN H, 1982, EUR NEUROL, V21, P401, DOI 10.1159/000115514; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; SULLIVAN P, 1987, JAMA-J AM MED ASSOC, V257, P2289, DOI 10.1001/jama.1987.03390170045014; VANDUIJN CM, 1992, AM J EPIDEMIOL, V135, P775, DOI 10.1093/oxfordjournals.aje.a116364; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WILLIAMS DB, 1991, NEUROLOGY, V41, P1554, DOI 10.1212/WNL.41.10.1554; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C; YANKNER BA, 1991, NEW ENGL J MED, V325, P1849; YANKNER BA, 1992, NEUROBIOL AGING, V10, P471	67	203	207	0	8	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9262	1476-6256		AM J EPIDEMIOL	Am. J. Epidemiol.	JAN 1	1999	149	1					32	40					9	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	152MF	WOS:000077780800005	9883791				2021-06-18	
J	KOSSMANN, T; HANS, VHJ; IMHOF, HG; STOCKER, R; GROB, P; TRENTZ, O; MORGANTIKOSSMANN, MC				KOSSMANN, T; HANS, VHJ; IMHOF, HG; STOCKER, R; GROB, P; TRENTZ, O; MORGANTIKOSSMANN, MC			INTRATHECAL AND SERUM INTERLEUKIN-6 AND THE ACUTE-PHASE RESPONSE IN PATIENTS WITH SEVERE TRAUMATIC BRAIN INJURIES	SHOCK			English	Article							CENTRAL-NERVOUS-SYSTEM; NECROSIS-FACTOR-ALPHA; HUMORAL IMMUNE-RESPONSE; SEVERE HEAD-INJURY; CEREBROSPINAL-FLUID; RAT-BRAIN; TNF-ALPHA; IL-6; ASTROCYTES; BLOOD	Patients with severe traumatic brain injury (TBI) show a profound acute-phase response. Because interleukin-6 (IL-6) is an important mediator of these pathophysiological changes, IL-6 levels were monitored in the cerebrospinal fluid (CSF) and serum of 20 patients with severe isolated TBI. All patients received indwelling ventricular catheters for intracranial pressure monitoring and for release of CSF when intracranial pressure exceeded 15 mmHg. CSF and blood samples were drawn daily for up to 14 days. The CSF/serum albumin ratio (Q(A)) served as a parameter of blood brain barrier dysfunction. Differential blood counts as well as the acute-phase proteins C-reactive protein, alpha 1-antitrypsin, and fibrinogen were recorded. IL-6 was detected in all CSF samples and reached values of up to 31,000 pg/mL, while serum levels remained significantly lower (alpha less than or equal to .01) and never exceeded 1,100 pg/mL during the entire study period. A correlation between CSF and serum IL-6 was found initially after the trauma and corresponded to a severe dysfunction of the blood brain barrier (r =.637, p =.001). Maximum IL-6 concentrations in serum correlated with peak levels of acute-phase proteins (C-reactive protein, alpha 1-antitrypsin, and fibrinogen). With regard to blood cell count, an initial leukocytosis combined with a borderline lymphocytopenia was observed. Thrombocytes decreased to a subnormal level during the first few days, but reached supranormal numbers by the end of the study period. Our results show that the increase of IL-6 levels in CSF and serum is followed by a profound acute-phase response in patients with TBI. Because cytokine concentrations are significantly lower in serum compared with CSF, we hypothesize that IL-6 produced in the central nervous system may play a role in initiating the acute-phase response.	UNIV ZURICH, SCH MED, DEPT NEUROSURG, CH-8091 ZURICH, SWITZERLAND; UNIV ZURICH, SCH MED, DEPT INTERNAL MED, DIV CLIN IMMUNOL, CH-8091 ZURICH, SWITZERLAND	KOSSMANN, T (corresponding author), UNIV ZURICH, SCH MED, DEPT SURG, DIV TRAUMA SURG, SCHMELZBERGSTR 12, CH-8091 ZURICH, SWITZERLAND.			Morganti-Kossmann, Cristina/0000-0002-0807-2063			AKIRA S, 1992, IMMUNOL REV, V127, P25, DOI 10.1111/j.1600-065X.1992.tb01407.x; BANKS WA, 1991, J PHARMACOL EXP THER, V259, P988; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; CASTELL JV, 1988, EUR J BIOCHEM, V177, P357, DOI 10.1111/j.1432-1033.1988.tb14384.x; CASTELL JV, 1989, FEBS LETT, V242, P237, DOI 10.1016/0014-5793(89)80476-4; CROSS EM, 1982, EDUC PSYCHOL MEAS, V42, P25, DOI 10.1177/0013164482421003; FABRY Z, 1994, IMMUNOL TODAY, V15, P218, DOI 10.1016/0167-5699(94)90247-X; FABRY Z, 1993, J NEUROIMMUNOL, V47, P23, DOI 10.1016/0165-5728(93)90281-3; FELDMAN Z, 1993, J TRAUMA, V34, P806, DOI 10.1097/00005373-199306000-00010; FREI K, 1989, EUR J IMMUNOL, V19, P689, DOI 10.1002/eji.1830190418; FREI K, 1990, ANN NY ACAD SCI, V594, P326; GUTIERREZ EG, 1993, J NEUROIMMUNOL, V47, P169, DOI 10.1016/0165-5728(93)90027-V; HAMA T, 1989, NEUROSCI LETT, V104, P340, DOI 10.1016/0304-3940(89)90600-9; HIROHATA S, 1993, CLIN IMMUNOL IMMUNOP, V66, P225, DOI 10.1006/clin.1993.1029; HOSFORD D, 1989, IMMUNE CONSEQUENCES, P311; HOUSSIAU FA, 1988, CLIN EXP IMMUNOL, V71, P320; HOYT DB, 1990, J TRAUMA, V30, P759, DOI 10.1097/00005373-199007000-00001; ISHIBASHI T, 1989, BLOOD, V74, P1241; JENNETT B, 1975, LANCET, V1, P480; KITAMURA T, 1994, TRENDS ENDOCRIN MET, V5, P8, DOI 10.1016/1043-2760(94)90115-5; KOSSMANN T, 1993, J NEUROTRAUM, V10, P60; KOSSMANN T, 1994, INTENS CARE MED, V20, P60; KUSHNER I, 1987, DIS MARKERS, V5, P1; LICHTOR T, 1994, NEUROSURGERY, V34, P669, DOI 10.1227/00006123-199404000-00015; LOTEM J, 1989, BLOOD, V74, P1545; MAIMONE D, 1993, J NEUROIMMUNOL, V47, P55, DOI 10.1016/0165-5728(93)90284-6; MAIMONE D, 1993, J NEUROIMMUNOL, V47, P73, DOI 10.1016/0165-5728(93)90286-8; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MATHIESEN T, 1993, J NEUROSURG, V78, P562, DOI 10.3171/jns.1993.78.4.0562; MCCLAIN C, 1991, J CLIN LAB MED, V118, P226; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; MORGANTIKOSSMANN MC, 1992, TRENDS PHARMACOL SCI, V13, P286, DOI 10.1016/0165-6147(92)90087-M; NIJSTEN MWN, 1991, SURGERY, V109, P761; NORRIS JG, 1993, J NEUROIMMUNOL, V45, P137; QUATTROCCHI KB, 1991, J NEUROSURG, V75, P766, DOI 10.3171/jns.1991.75.5.0766; REIBER H, 1987, CLIN CHIM ACTA, V163, P319, DOI 10.1016/0009-8981(87)90250-6; SATOH T, 1988, MOL CELL BIOL, V8, P3546, DOI 10.1128/MCB.8.8.3546; SAWADA M, 1992, BRAIN RES, V583, P296, DOI 10.1016/S0006-8993(10)80037-X; SHARIF SF, 1993, NEUROL RES, V15, P109; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TEASDALE G, 1974, LANCET, V2, P81; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.iy.08.040190.001345; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; YOUNG AB, 1988, J NEUROSURG, V69, P375, DOI 10.3171/jns.1988.69.3.0375	44	203	207	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1073-2322	1540-0514		SHOCK	Shock	NOV	1995	4	5					311	317		10.1097/00024382-199511000-00001			7	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	TD331	WOS:A1995TD33100001	8595516				2021-06-18	
J	Maas, AIR; Menon, DK; Steyerberg, EW; Citerio, G; Lecky, F; Manley, GT; Hill, S; Legrand, V; Sorgner, A				Maas, Andrew I. R.; Menon, David K.; Steyerberg, Ewout W.; Citerio, Giuseppe; Lecky, Fiona; Manley, Geoffrey T.; Hill, Sean; Legrand, Valerie; Sorgner, Annina		CENTER-TBI Participants	Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI): A Prospective Longitudinal Observational Study	NEUROSURGERY			English	Article						Clinical study; Comparative effectiveness research; Protocol; Traumatic brain injury	OUTCOMES; TRENDS	BACKGROUND: Current classification of traumatic brain injury (TBI) is suboptimal, and management is based on weak evidence, with little attempt to personalize treatment. A need exists for new precision medicine and stratified management approaches that incorporate emerging technologies. OBJECTIVE: To improve characterization and classification of TBI and to identify best clinical care, using comparative effectiveness research approaches. METHODS: This multicenter, longitudinal, prospective, observational study in 22 countries across Europe and Israel will collect detailed data from 5400 consenting patients, presenting within 24 hours of injury, with a clinical diagnosis of TBI and an indication for computed tomography. Broader registry-level data collection in approximately 20 000 patients will assess generalizability. Cross sectional comprehensive outcome assessments, including quality of life and neuropsychological testing, will be performed at 6 months. Longitudinal assessments will continue up to 24 months post TBI in patient subsets. Advanced neuroimaging and genomic and biomarker data will be used to improve characterization, and analyses will include neuroinformatics approaches to address variations in process and clinical care. Results will be integrated with living systematic reviews in a process of knowledge transfer. The study initiation was from October to December 2014, and the recruitment period was for 18 to 24 months. EXPECTED OUTCOMES: Collaborative European NeuroTrauma Effectiveness Research in TBI should provide novel multidimensional approaches to TBI characterization and classification, evidence to support treatment recommendations, and benchmarks for quality of care. Data and sample repositories will ensure opportunities for legacy research. DISCUSSION: Comparative effectiveness research provides an alternative to reductionistic clinical trials in restricted patient populations by exploiting differences in biology, care, and outcome to support optimal personalized patient management.	[Maas, Andrew I. R.] Univ Antwerp Hosp, Dept Neurosurg, Edegem, Belgium; [Maas, Andrew I. R.] Univ Antwerp, B-2650 Edegem, Belgium; [Menon, David K.] Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Cambridge CB2 2QQ, England; [Steyerberg, Ewout W.] Erasmus MC Univ Med Ctr Rotterdam, Dept Publ Hlth, Ctr Med Decis Making, Rotterdam, Netherlands; [Citerio, Giuseppe] Univ Milano Bicocca, Dept Hlth Sci, Milan, Italy; [Citerio, Giuseppe] San Gerardo Hosp, Dept Emergency & Intens Care, Monza, Italy; [Lecky, Fiona] Univ Sheffield, Hlth Serv Res Sect, Sch Hlth & Related Res ScHARR, Sheffield, S Yorkshire, England; [Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA; [Hill, Sean] Karolinska Inst, Int Neuroinformat Coordinating Facil, Stockholm, Sweden; [Legrand, Valerie] ICON Plc, VP Global Project Management, Dublin, Ireland; [Sorgner, Annina] GABO Mi, Int Projects Management, Munich, Germany	Maas, AIR (corresponding author), Univ Antwerp, Univ Antwerp Hosp, Dept Neurosurg, Wilrijkstr 10, B-2650 Edegem, Belgium.	andrew.maas@uza.be	Ripatti, Samuli/H-9446-2014; Verma, Vishwajit/K-8289-2019; Sahuquillo, Juan/B-3577-2008; Lanyon, Linda/L-9238-2019; Cooper, D. James/G-7961-2013; Kasprian, Gregor/AAJ-5052-2020; Lagares, Alfonso/B-2969-2011; Florian, Ioan Stefan I/D-5934-2016; Rusnak, Martin/K-9349-2016; Ercole, Ari/B-6288-2009; Oresic, Matej/K-7673-2016; Laureys, Steven/AAN-2097-2021; Citerio, Giuseppe/B-1839-2015; Castano-Leon, Ana M/ABF-6322-2020; Oddo, Mauro/R-3370-2016; Raj, Rahul/K-7693-2012; Stocchetti, Nino/O-7444-2017; Majdan, Marek/K-5017-2012; Belli, Antonio/I-3799-2015	Ripatti, Samuli/0000-0002-0504-1202; Sahuquillo, Juan/0000-0003-0713-5875; Lanyon, Linda/0000-0002-0885-1825; Cooper, D. James/0000-0002-5872-9051; Kasprian, Gregor/0000-0003-3858-3347; Lagares, Alfonso/0000-0003-3996-0554; Florian, Ioan Stefan I/0000-0001-7127-0946; Rusnak, Martin/0000-0003-3321-1042; Ercole, Ari/0000-0001-8350-8093; Oresic, Matej/0000-0002-2856-9165; Laureys, Steven/0000-0002-3096-3807; Citerio, Giuseppe/0000-0002-5374-3161; Castano-Leon, Ana M/0000-0002-7918-5049; Oddo, Mauro/0000-0002-6155-2525; Raj, Rahul/0000-0003-4243-9591; Dippel, Diederik/0000-0002-9234-3515; Cameron, Peter/0000-0002-1443-557X; Esser, Patrick/0000-0002-3227-0115; de witte, olivier/0000-0002-7700-8006; Forsyth, Faye/0000-0003-2107-3690; Pullens, Pim/0000-0003-2014-7248; Stocchetti, Nino/0000-0003-3250-6834; Morganti-Kossmann, Cristina/0000-0002-0807-2063; Lyttle, Mark/0000-0002-8634-7210; Stewart, William/0000-0003-2199-2582; Kondziella, Daniel/0000-0001-5562-9808; Carpenter, Keri/0000-0001-8236-7727; Martino, Costanza/0000-0002-2691-0059; MARTIN, Didier/0000-0001-7325-4958; Della Corte, Francesco/0000-0003-1736-2318; Rossi, Sandra/0000-0002-9963-8121; Anke, Audny/0000-0002-2491-2560; Wang, Kevin/0000-0002-9343-6473; Stamatakis, Emmanuel Andreas/0000-0001-6955-9601; Dreier, Jens/0000-0001-7459-2828; Coburn, Mark/0000-0002-7930-0270; czosnyka, marek/0000-0003-2446-8006; Newcombe, Virginia/0000-0001-6044-9035; Andelic, Nada/0000-0002-3719-4406; Feigin, Valery L./0000-0002-6372-1740; Godbolt, Alison/0000-0003-4511-6181; Hartings, Jed/0000-0001-8583-3471; Majdan, Marek/0000-0001-8037-742X; Parizel, Paul M./0000-0002-0221-2854; Dawes, Helen/0000-0002-2933-5213; Kolias, Angelos/0000-0003-3992-0587; Hutchinson, Peter/0000-0002-2796-1835; Belli, Antonio/0000-0002-3211-9933	Hannelore Kohl Foundation (Germany); Academy of Medical Sciences (AMS)Academy of Medical Sciences (AMS) [AMS-CSF4-Newcombe] Funding Source: researchfish; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0601025, G9439390, G0600986] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NIHR-RP-R3-12-013, ACF-2009-14-007, 12/35/57, NF-SI-0512-10090] Funding Source: researchfish; Direct For Biological SciencesNational Science Foundation (NSF)NSF - Directorate for Biological Sciences (BIO) [1120912] Funding Source: National Science Foundation	Funding of additional elements for this study has been provided by the Hannelore Kohl Foundation (Germany) and by the non-profit organization One Mind for Research (directly to International Neuroinformatics Coordinating Facility). The study registration is Clinicaltrials.gov: NCT02210221.	Brain Trauma Foundation, ONLINE TBI GUIDELINE; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Corrigan JD, 2012, BRAIN INJURY, V26, P139, DOI 10.3109/02699052.2011.648705; Eurosafe, INJURIES IN THE EURO; Faul M, 2007, J TRAUMA, V63, P1271, DOI 10.1097/TA.0b013e3181493080; Finkelstein EA, 2006, THE INCIDENCE AND EC, P208; Fuller G, 2011, BRIT J NEUROSURG, V25, P414, DOI 10.3109/02688697.2011.570882; Giacino J, THE CENTER FOR OUTCO; Institute of Medicine, 2009, INITIAL NATIONAL PRI; Levin HS, THE GALVESTON ORIENT; Lingsma HF, 2011, NEUROSURGERY, V68, P601, DOI 10.1227/NEU.0b013e318209333b; Maas AIR, 2013, LANCET NEUROL, V12, P1200, DOI 10.1016/S1474-4422(13)70234-5; Maas AIR, 2012, J NEUROTRAUM, V29, P32, DOI 10.1089/neu.2010.1599; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Massagli TL, 2004, ARCH PHYS MED REHAB, V85, P1428, DOI 10.1016/j.apmr.2003.12.036; National Research Council (US) Committee on A Framework for Developing a New Taxonomy of Disease, 2011, TOWARD PRECISION MED; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Tosetti P, 2013, J NEUROTRAUM, V30, P1211, DOI 10.1089/neu.2013.2896	18	202	205	0	42	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JAN	2015	76	1					67	80		10.1227/NEU.0000000000000575			14	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	AW9UC	WOS:000346602000015	25525693	Green Published, Green Accepted	Y	N	2021-06-18	
J	Larrabee, GJ				Larrabee, Glenn J.			Aggregation across multiple indicators improves the detection of malingering: Relationship to likelihood ratios	CLINICAL NEUROPSYCHOLOGIST			English	Article						aggregation; chaining; likelihood ratios; malingering; multiple indicators	FAKE-BAD SCALE; PERFORMANCE; INJURY; MMPI-2	Recent literature shows that aggregating across multiple symptom validity test (SVT) failures increases the probability of malingering over use of one indicator alone, supporting the criteria proposed by Slick, Sherman, and Iverson (1999) that require multiple sources of evidence for diagnosis of malingering. The present study reanalyzes with likelihood ratios data previously published by Larrabee (2003a) on litigants with definite malingering, contrasted with non-malingering patients with moderate and severe traumatic brain injury. Chaining of likelihood ratios demonstrated an increase in probability of malingering when multiple test scores were positive, with values ranging from. 713 to. 837 for one failed SVT,. 936 to. 973 for two failed SVTs, and. 989 to. 995 for three failed SVTs. Posterior probabilities of malingering derived from chaining of likelihood ratios closely approximated those obtained by direct computation of Positive Predictive Power, particularly when three SVTs were failed. Moreover, the five SVTs employed in these analyses did not intercorrelate significantly, satisfying the assumption that the tests be independent for chaining of likelihood ratios. Posterior probabilities derived from chaining of likelihood ratios, holding sensitivity and specificity constant at. 50 and. 90, respectively, and varying the malingering base rate from. 10 to. 90, showed a wide range of values,. 357 to. 978, for failure of one SVT. Failure of two SVTs yielded probabilities ranging from. .735 to .996. Failure of three SVTs yielded values ranging from .933 to .999, demonstrating high probabilities of malingering irrespective of the base rate. These data support the Slick et al. recommendation that multiple positive findings are necessary for diagnosis of malingering. Suggestions are made for modification of the Slick et al. criteria based on the current results.		Larrabee, GJ (corresponding author), 2650 Bahia Vista St,308, Sarasota, FL 34239 USA.	GLarrabee@aol.com					Arnold G, 2005, CLIN NEUROPSYCHOL, V19, P105, DOI 10.1080/13854040490888567; BALDESSARINI RJ, 1983, ARCH GEN PSYCHIAT, V40, P569; Benton A. L., 1994, CONTRIBUTIONS NEUROP; BINDER LM, 1993, J CLIN EXP NEUROPSYC, V15, P170, DOI 10.1080/01688639308402555; Boone KB, 2003, CLIN NEUROPSYCHOL, V17, P244, DOI 10.1076/clin.17.2.244.16497; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Fruchter B., 1973, FUNDAMENTAL STAT PSY; Glass GV, 1970, STAT METHODS ED PSYC; Green P., 2003, GREENS WORD MEMORY T; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve K. W., 2007, ASSESSMENT MALINGERE, P171; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; Grimes DA, 2005, LANCET, V365, P1500, DOI 10.1016/S0140-6736(05)66422-7; Heaton R.K., 1991, COMPREHENSIVE NORMS; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P54, DOI 10.1076/clin.17.1.54.15627; LARRABEE GJ, 2005, FORENSIC NEUROPSYCHO, P115; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Nelson NW, 2003, CLIN NEUROPSYCHOL, V17, P263, DOI 10.1076/clin.17.2.263.16511; Ross SR, 2004, J CLIN EXP NEUROPSYC, V26, P115, DOI 10.1076/jcen.26.1.115.23933; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Straus S. E., 2005, EVIDENCE BASED MED H; Suhr JA, 1999, J CLIN EXP NEUROPSYC, V21, P701, DOI 10.1076/jcen.21.5.701.868; Tombaugh T.N., 1996, TOMM TEST MEMORY MAL; Vickery CD, 2004, ARCH CLIN NEUROPSYCH, V19, P37, DOI 10.1016/S0887-6177(02)00170-1; Vickery CD, 2001, ARCH CLIN NEUROPSYCH, V16, P45, DOI 10.1016/S0887-6177(99)00058-X; VICTOR TL, 2006, 34 ANN M INT NEUR SO	28	202	202	0	15	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2008	22	4					666	679		10.1080/13854040701494987			14	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	321WH	WOS:000257336700006	17886147				2021-06-18	
J	Cremer, OL; van Dijk, GW; van Wensen, E; Brekelmans, GJF; Moons, KGM; Leenen, LPH; Kalkman, CJ				Cremer, OL; van Dijk, GW; van Wensen, E; Brekelmans, GJF; Moons, KGM; Leenen, LPH; Kalkman, CJ			Effect of intracranial pressure monitoring and targeted intensive care on functional outcome after severe head injury	CRITICAL CARE MEDICINE			English	Article						head injuries; closed; extended Glasgow Outcome Scale; intracranial pressure monitoring; cerebral perfusion pressure management; goal-directed treatment; therapy intensity level	BRAIN-INJURY; MANAGEMENT; GUIDELINES; RESPONSES	Objective: Intracranial hypertension after severe head injury is associated with case fatality, but there is no sound evidence that monitoring of intracranial pressure (ICP) and targeted management of cerebral perfusion pressure (CPP) improve outcome, despite widespread recommendation by experts in the field. The purpose was to determine the effect of ICP/CPP-targeted intensive care on functional outcome and therapy intensity levels after severe head injury. Design: Retrospective cohort study with prospective assessment of outcome. Setting: Two level I trauma centers in The Netherlands from 1996 to 2001. Patients: Three hundred thirty-three patients who had survived and remained comatose for > 24 hrs, from a total of 685 consecutive severely head-injured adults. Interventions: In center A (supportive intensive care), mean arterial pressure was maintained at approximately 90 mm Hg, and therapeutic interventions were based on clinical observations and computed tomography findings. In center B (ICP/CPP-targeted intensive care), management was aimed at maintaining ICP < 20 mm Hg and CPP > 70 mm Hg. Allocation to either trauma center was solely based on the site of the accident. Measurements and Main Results: We measured extended Glasgow Outcome Scale after >= 12 months. Patient characteristics were well balanced between the centers. ICP monitoring was used in zero of 122 (0%) and 142 of 211 (67%) patients in centers A and B, respectively. In-hospital mortality rate was 41 (34%) vs. 69 (33%; p =.87). The odds ratio for a more favorable functional outcome following ICP/CPP-targeted therapy was 0.95 (95% confidence interval, 0.62-1.44). This result remained after adjustment for potential confounders. Sedatives, vasopressors, mannitol, and barbiturates were much more frequently used in center B (all p <.01). The median number of days on ventilator support in survivors was 5 (25th-75th percentile, 2-9) in center A vs. 12 (7-19) in center B (p <.001). Conclusions: ICP/CPP-targeted intensive care results in prolonged mechanical ventilation and increased levels of therapy intensity, without evidence for improved outcome in patients who survive beyond 24 hrs following severe head injury.	Univ Utrecht, Med Ctr, Div Perioperat Care & Emergency Med, Utrecht, Netherlands; Univ Utrecht, Med Ctr, Dept Neurol, Utrecht, Netherlands; Univ Utrecht, Med Ctr, Dept Surg, Utrecht, Netherlands; Univ Utrecht, Med Ctr, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; St Elizabeth Hosp, Dept Neurol, Tilburg, Netherlands	Cremer, OL (corresponding author), Univ Utrecht, Med Ctr, Div Perioperat Care & Emergency Med, Utrecht, Netherlands.		Kalkman, Cor/O-3215-2019; Cremer, Olaf L/G-3855-2016	Kalkman, Cor/0000-0002-8372-6960; Cremer, Olaf L/0000-0003-4264-1108			Altman DG, 1998, BRIT MED J, V317, P1309, DOI 10.1136/bmj.317.7168.1309; *AM COLL SURG COMM, 1997, ADV TRAUM LIF SUPP A; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; Bolland K, 1998, STAT MED, V17, P2835, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2835::AID-SIM933>3.3.CO;2-#; Brain Trauma Foundation, GUID MAN SEV TRAUM B; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; CHAMPION HR, 1990, J TRAUMA, V30, P1356, DOI 10.1097/00005373-199011000-00008; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Cremer OL, 2004, ANESTH ANALG, V99, P1211, DOI 10.1213/01.ANE.0000133917.67728.2A; Cremer OL, 2001, LANCET, V357, P117, DOI 10.1016/S0140-6736(00)03547-9; GELPKE GJ, 1983, J NEUROSURG, V59, P745, DOI 10.3171/jns.1983.59.5.0745; Grande PO, 1997, J TRAUMA, V42, pS23, DOI 10.1097/00005373-199705001-00005; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Lane PL, 2000, CAN J SURG, V43, P442; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MICKEY RM, 1989, AM J EPIDEMIOL, V129, P125, DOI 10.1093/oxfordjournals.aje.a115101; Murphy LS, 1999, BRIT J NEUROSURG, V13, P564, DOI 10.1080/02688699943060; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; Rossi S, 1998, ACT NEUR S, V71, P91; Sahjpaul R, 2000, CAN J NEUROL SCI, V27, P143; Scott SC, 1997, J CLIN EPIDEMIOL, V50, P45, DOI 10.1016/S0895-4356(96)00312-5; Steiner LA, 2003, J CEREBR BLOOD F MET, V23, P1371, DOI 10.1097/01.WCB.0000090861.67713.10; Stocchetti N, 2001, INTENS CARE MED, V27, P400, DOI 10.1007/s001340000825; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; ten Duis HJ, 2003, INJURY, V34, P722, DOI 10.1016/S0020-1383(03)00162-1; The Brain Trauma Foundation; The American Association of Neurological Surgeons, 2000, J NEUROTRAUM, V17, P479; Wilkins IA, 2001, ANAESTHESIA, V56, P350, DOI 10.1046/j.1365-2044.2001.01708.x; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	33	202	216	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	OCT	2005	33	10					2207	2213		10.1097/01.CCM.0000181300.99078.B5			7	Critical Care Medicine	General & Internal Medicine	019YV	WOS:000235875600008	16215372				2021-06-18	
J	Ruff, R				Ruff, R			Two decades of advances in understanding of mild traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						mild traumatic brain injury; miserable minority; postconcussional disorder	POST-CONCUSSION SYMPTOMS; UNITED-STATES; HEAD-INJURY; SEQUELAE; COMA; DISABILITY; HISTORY	The aim of this article is to highlight advances achieved over the past 2 decades in understanding mild traumatic brain injury (MTBI). The first section provides a historical background, which establishes that research during the 1980s was focused on more severe TBI. During the 1990s MTBI received substantially more recognition. The second section explains why the diagnostic frameworks have evolved. The third section examines why 80% to 90% of all MTBI patients have favorable outcomes whereas 10% to 20% do not. This latter subgroup, also known as the Miserable Minority presents with a plethora of persistent physical, emotional, and cognitive symptoms. A dichotomy has emerged in the literature interpreting these postconcussional symptoms as being psychogenic or neurogenic. This article offers an alternate and more patient-based framework. Instead of the various disciplines focusing on select symptoms, the patient-based approach is aimed at phenomenologically understanding how the MTBI patient's life has changed. The fourth section provides practical steps for treatments. This historical review offers the conclusion that we have focused for too long on diagnostic challenges, without similarly focusing on treatment. It is time that we advance efficacious treatments for the Miserable Minority	Univ Calif San Francisco, San Francisco, CA 94143 USA	Ruff, R (corresponding author), San Francisco Clin Neurosci, 909 Hyde St,Suite 620, San Francisco, CA 94109 USA.	ronruff@mindspring.com					ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Berube J, 2001, J HEAD TRAUMA REHAB, V16, P210, DOI 10.1097/00001199-200104000-00009; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; *BRAIN INJ ASS, COSTS CAUS TRAUM BRA; *BRAIN INJ SOC, TRAUM BRAIN INJ; Burnett DM, 2003, ARCH PHYS MED REHAB, V84, P263, DOI 10.1053/apmr.2003.50091; *CDCP, TRAUM BRAIN INJ US; DEVIN HS, 1989, MILD HEAD INJURY; ECHMENDIA RJ, 2003, CLIN NEUROPSYCHOLOGY, P352; Evered L, 2003, ASSESSMENT, V10, P420, DOI 10.1177/1073191103259539; FOULKES MA, 1991, J NEUROSURG, V75, pS8, DOI 10.3171/sup.1991.75.1s.00s8; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Hall KM, 1998, NEUROREHABILITATION, V10, P3, DOI 10.3233/NRE-1998-10102; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; Kelly JP, 1998, J HEAD TRAUMA REHAB, V13, P53, DOI 10.1097/00001199-199804000-00008; Kelly JP, 1997, NEUROLOGY, V48, P581; KRAUS JF, 1996, NEUROTRAUMA, P13; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; Macmillan PJ, 2002, BRAIN INJURY, V16, P41, DOI 10.1080/0269905011008812; Mellick D, 2003, BRAIN INJURY, V17, P55, DOI 10.1080/0269905021000010159; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; National Institutes of Health, 1998, NIH CONSENSUS STATEM, V16, P1; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; POVLISHOCK JT, 1989, MILD HEAD INJURY, V37, pCH4; RASKIN SA, 2000, NEUROPSYCHOLOGICAL M; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROBERTSSTOLER D, 1998, COPING MILD TRAUMATI; Ruff R., 2003, YOUMANS NEUROLOGICAL, P5181; Ruff R. M., 2003, RUFF NEUROBEHAVIORAL; Ruff R. M., 1999, MILD HEAD INJURY CAU, P99; Ruff RM, 1999, BRAIN INJURY, V13, P943; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; RUFF RM, 1999, MILD HEAD INJURY CAU, P315; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Sosin DM, 1996, BRAIN INJURY, V10, P47; Sweet JJ, 2003, ARCH CLIN NEUROPSYCH, V18, P557, DOI 10.1016/S0887-6177(02)00215-9; Sweet JJ, 1999, STUD NEUROPSYCHOL DE, P255; TEASDALE G, 1974, LANCET, V2, P81; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3	50	202	203	0	20	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2005	20	1					5	18		10.1097/00001199-200501000-00003			14	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	894AT	WOS:000226762900002	15668567				2021-06-18	
J	Dutton, RP; McCunn, M; Hyder, M; D'Angelo, M; O'Connor, J; Hess, JR; Scalea, TM				Dutton, RP; McCunn, M; Hyder, M; D'Angelo, M; O'Connor, J; Hess, JR; Scalea, TM			Factor VIIa for correction of traumatic coagulopathy	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	62nd Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 11-13, 2003	MINNEAPOLIS, MN	Amer Assoc Surg Trauma			RECOMBINANT FACTOR VIIA; ACTIVATED FACTOR-VII; PREEXISTING COAGULOPATHY; BLOOD-TRANSFUSION; HEAD-INJURY; HEMORRHAGE; COAGULATION; PATIENT; ANTICOAGULATION; HYPOTHERMIA	Introduction: Activated factor VIIa (FVIIa) was developed to treat hemophiliacs with high-titer antibodies to factor VIIi. FVIIa initiates thrombin formation by binding with exposed tissue factor. Anecdotal reports have described the utility of FVIIa in correcting coagulopathy from trauma, but no large series exists. We present our experience with 81 coagulopathic trauma patients treated using FVIIa in years 2001-2003, compared with "control" patients matched from the trauma registry from the same time period. Methods: Use of FVIIa was restricted to active hemorrhage with clinical coagulopathy. We recorded the cause of coagulopathy, dose of FVIIa administered, effect on clinical coagulation, pertinent laboratory values, length of stay, number and type of blood products administered, and patient outcome. For the same time period we also examined outcomes in coagulopathic patients who did not receive FVIIa. Results: Causes of coagulopathy were diverse, and included acute traumatic hemorrhage (46 patients), traumatic brain injury (20), warfarin use (9), congenital Factor VII deficiency (2), and other acquired hematologic defects (4). Coagulopathy was reversed in 61/81 cases (75%), with an associated reduction in PT from 19.6 to 10.8 (p = 0.000018). 34 patients (42%) survived to hospital discharge (20/46 traumatic hemorrhage, 5/20 TBI, 4/9 on warfarin, 2/2 factor deficient, 3/4 other). Patients died from irreversible shock, multiple organ system failure, or traumatic brain injury. FVIIa patients had a higher mortality than coagulopathic controls matched by specific anatomic injuries, admission lactate value, and predicted probability of survival. Only a group identified by all three characteristics had a similar mortality to the FVIIa cohort, but the number of patients that could be matched this way was too small to be meaningful. Conclusion:. FVIIa therapy lead to an immediate reduction in coagulopathic hemorrhage in most cases, accompanied by a significant improvement in laboratory measures. Application of FVIIa as a therapy of last resort makes the identification of equivalent control patients difficult. Use of FVIIa should be considered for any patient with coagulopathic hemorrhage in which surgically-accessible bleeding has been controlled. Prospective trials of FVIIa in patients with traumatic coagulopathy are strongly indicated, and should focus on appropriate patient selection and the dose and timing of therapy.	Univ Maryland, Sch Med, Program Trauma, Baltimore, MD 21201 USA	Dutton, RP (corresponding author), R Adams Cowley Shock Trauma Ctr, 22 S Greene St, Baltimore, MD 21201 USA.	rdutton@umaryland.edu		holcomb, john/0000-0001-8312-9157			Aledort LM, 2000, THROMB HAEMOSTASIS, V84, P522; Allen GA, 2002, CAN J ANAESTH, V49, pS7; Armand R, 2003, TRANSFUS MED REV, V17, P223, DOI 10.1016/S0887-7963(03)00022-1; CHAMPION HR, 1990, J TRAUMA, V30, P1356, DOI 10.1097/00005373-199011000-00008; Clark AD, 2004, VOX SANG, V86, P120, DOI 10.1111/j.0042-9007.2004.00393.x; Como JJ, 2004, TRANSFUSION, V44, P809, DOI 10.1111/j.1537-2995.2004.03409.x; Deveras RAE, 2002, ANN INTERN MED, V137, P884, DOI 10.7326/0003-4819-137-11-200212030-00009; Dutton RP, 2003, J CLIN ANESTH, V15, P184, DOI 10.1016/S0952-8180(03)00034-5; Friederich PW, 2003, LANCET, V361, P201, DOI 10.1016/S0140-6736(03)12268-4; Hedner U, 2002, TRANSFUSION, V42, P114, DOI 10.1046/j.1537-2995.2002.00017.x; Hendriks HGD, 2001, TRANSPLANTATION, V71, P402, DOI 10.1097/00007890-200102150-00011; Ingerslev J, 1998, HAEMOPHILIA, V4, P689, DOI 10.1046/j.1365-2516.1998.440689.x; Kenet G, 1999, LANCET, V354, P1879, DOI 10.1016/S0140-6736(99)05155-7; MacLeod JBA, 2003, J TRAUMA, V55, P39, DOI 10.1097/01.TA.0000075338.21177.EF; Malone DL, 2003, J TRAUMA, V54, P898, DOI 10.1097/01.TA.0000060261.10597.5C; Martinowitz U, 2001, J TRAUMA, V51, P431, DOI 10.1097/00005373-200109000-00002; May AK, 1997, AM SURGEON, V63, P233; Meng ZH, 2003, J TRAUMA, V55, P886, DOI 10.1097/01.TA.0000066184.20808.A5; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; Moore EE, 1996, AM J SURG, V172, P405, DOI 10.1016/S0002-9610(96)00216-4; O'Connell NM, 2003, TRANSFUSION, V43, P1711, DOI 10.1046/j.0041-1132.2003.00577.x; O'Neill PA, 2002, J TRAUMA, V52, P400, DOI 10.1097/00005373-200202000-00034; Peerlinck K, 1999, THROMB HAEMOSTASIS, V82, P1775; RAPAPORT SI, 1992, ARTERIOSCLER THROMB, V12, P1111, DOI 10.1161/01.ATV.12.10.1111; ROBERTI A, 2001, RRD R C C M, V1, P101; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; van't Veer C, 2000, SEMIN THROMB HEMOST, V26, P367, DOI 10.1055/s-2000-8454; Vlot AJ, 2000, AM J MED, V108, P421, DOI 10.1016/S0002-9343(99)00398-8; Watts DD, 1998, J TRAUMA, V44, P846, DOI 10.1097/00005373-199805000-00017; WELTYWOLF K, 2001, BLOODLINE REV, V16, P16	31	202	205	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	2004	57	4					709	718		10.1097/01.TA.0000140646.66852.AB			10	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	871EN	WOS:000225112300007	15514523				2021-06-18	
J	TOULMOND, S; ROTHWELL, NJ				TOULMOND, S; ROTHWELL, NJ			INTERLEUKIN-1 RECEPTOR ANTAGONIST INHIBITS NEURONAL DAMAGE CAUSED BY FLUID PERCUSSION INJURY IN THE RAT	BRAIN RESEARCH			English	Article						BRAIN INJURY; FLUID PERCUSSION TRAUMA; INTERLEUKIN-1; INTERLEUKIN-1 RECEPTOR ANTAGONIST	TRAUMATIC BRAIN INJURY; MESSENGER-RNA; MAMMALIAN BRAIN; INVIVO; IL-1; INVOLVEMENT; INDUCTION	Increased expression of the cytokine interleukin-1 (IL-1) has been observed in rodent and human brain after injury, and IL-1 has been implicated in ischaemic and excitotoxic brain damage in the rat. These data suggest that neurodegeneration caused by brain injury may be mediated by local IL-1 production and action. This hypothesis was tested by studying the effects of central injection of recombinant human interleukin-1 receptor antagonist (rhIL-1ra) on brain damage (assessed histologically, H and E stain) induced by fluid percussion trauma in the rat. Injection of rhIL-1ra (10 mu g, i.c.v.) 15 min and 2, 4, 6, 8, 24 and 48 h after injury significantly reduced, by 44%, the extent of damage measured 3 days later. Similar protection was observed in animals killed 7 days after injury. Delayed administration of rhIL-1ra (4, 6, 8, 24 and 48 h) after injury also significantly reduced (by 28%) neuronal damage. These data indicate that endogenous IL-1 mediates damage caused by traumatic brain injury and that rhIL-1ra offers significant protection even when treatment is-delayed.	UNIV MANCHESTER, SCH BIOL SCI, MANCHESTER M13 9PT, LANCS, ENGLAND					Wellcome TrustWellcome TrustEuropean Commission Funding Source: Medline		BAN E, 1992, CYTOKINE, V4, P48, DOI 10.1016/1043-4666(92)90036-Q; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DEKOSKY ST, 1993, SOC NEUR ABSTR, V19; Dinarello C A, 1992, Eur Cytokine Netw, V3, P7; DINARELLO CA, 1991, IMMUNOL TODAY, V12, P404, DOI 10.1016/0167-5699(91)90142-G; DRIPPS DJ, 1991, J BIOL CHEM, V266, P10331; FAN L, 1993, SOC NEUR ABSTR, V19; FONTANA A, 1984, J IMMUNOL, V133, P1696; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; GIULIAN D, 1988, J NEUROSCI, V8, P2485; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; KENT S, 1992, P NATL ACAD SCI USA, V89, P9117, DOI 10.1073/pnas.89.19.9117; LICINIO J, 1991, ENDOCRINOLOGY, V129, P562, DOI 10.1210/endo-129-1-562; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MILLER LG, 1991, MOL PHARMACOL, V39, P105; MINAMI M, 1992, J NEUROCHEM, V58, P390, DOI 10.1111/j.1471-4159.1992.tb09324.x; NIETOSAMPEDRO M, 1987, J NEUROSCI RES, V17, P214, DOI 10.1002/jnr.490170303; PLATASALAMAN CR, 1992, BRAIN RES BULL, V29, P221, DOI 10.1016/0361-9230(92)90029-W; RELTON JK, 1992, BRAIN RES B, V29, P43; RELTON JK, 1993, SOC NEUR ABSTR, V19; ROTHWELL NJ, 1993, NEUROSCI BIOBEHAV R, V17, P217, DOI 10.1016/S0149-7634(05)80152-6; ROTHWELL NJ, 1992, PERG S NEUR, V5, P115; SPRANGER M, 1990, EUR J NEUROSCI, V2, P69, DOI 10.1111/j.1460-9568.1990.tb00382.x; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TOULMOND S, 1993, BRAIN RES, V620, P32, DOI 10.1016/0006-8993(93)90267-Q; TOULMOND S, 1993, BRAIN RES, V620, P24, DOI 10.1016/0006-8993(93)90266-P; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; YABUUCHI K, 1993, MOL BRAIN RES, V20, P153, DOI 10.1016/0169-328X(93)90121-5; YAMASAKI Y, 1992, NEUROSCI LETT, V142, P45, DOI 10.1016/0304-3940(92)90616-F	34	202	209	1	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	FEB 13	1995	671	2					261	266		10.1016/0006-8993(94)01343-G			6	Neurosciences	Neurosciences & Neurology	QH056	WOS:A1995QH05600010	7743213				2021-06-18	
J	Kontos, AP; Elbin, RJ; Schatz, P; Covassin, T; Henry, L; Pardini, J; Collins, MW				Kontos, Anthony P.; Elbin, R. J.; Schatz, Phillip; Covassin, Tracey; Henry, Luke; Pardini, Jamie; Collins, Michael W.			A Revised Factor Structure for the Post-Concussion Symptom Scale Baseline and Postconcussion Factors	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						baseline; concussion; factor analysis; mTBI; sports; symptoms	SPORTS-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; SEX-DIFFERENCES; NEUROPSYCHOLOGICAL FUNCTION; QUESTIONNAIRE; RECOVERY; VALIDITY	Background: Symptom reports play a critical role in the assessment and management of concussions. Symptoms are often conceptualized as factors comprising several related symptoms (eg, somatic factor = headache, nausea, vomiting). Previous research examining the factor structure of the 22-item Post-Concussion Symptom Scale (PCSS) has been limited to small samples and has not adequately evaluated factor loadings at both baseline and postconcussion for male and female athletes at the high school and collegiate levels. Purpose: To examine the factor structure of the 22-item PCSS in independent samples of high school and collegiate athletes reported at baseline and postconcussion, and to evaluate sex and age differences in the resulting baseline and postconcussion symptom factor scores. Study Design: Case series; Level of evidence, 4. Methods: Exploratory factor analytic (EFA) methods were applied to 2 separate samples of athletes who completed the PCSS at baseline (n = 30,455) and 1 to 7 days after a sport-related concussion (n = 1438). The baseline sample (mean +/- standard deviation) was 15.74 +/- 1.78 years, with a range of 13 to 22 years, and the postconcussion sample was 17.14 +/- 2.25 years, with a range of 13 to 24 years. Results: A 4-factor solution accounting for 49.1% of the variance at baseline included a cognitive-sensory, sleep-arousal, vestibular-somatic, and affective factor structure. A 4-factor solution that included cognitive-fatigue-migraine, affective, somatic, and sleep was revealed for the postconcussion EFA. High school athletes reported higher baseline levels of the cognitive-sensory and vestibular-somatic symptom factors and lower levels of the sleep-arousal factor than college athletes. Female participants reported higher symptoms on all postconcussion factors than male participants. Conclusion: The current findings reveal different symptom factors at baseline and postinjury and several age and sex differences on the symptom factors. At postconcussion, symptoms aggregated into a global concussion factor including cognitive, fatigue, and migraine symptoms. Symptoms reported at baseline are not the same as those reported after injury. The presence of a global postconcussion symptom comprising the fatigue factor highlights the importance of physical and cognitive rest during the first week after a concussion. Although headache was the most commonly reported symptom, it was not the greatest contributor to the global postconcussion symptom factor.	[Kontos, Anthony P.] Univ Pittsburgh, Med Ctr, Ctr Sports Med, Dept Orthopaed Surg, Pittsburgh, PA 15203 USA	Kontos, AP (corresponding author), Univ Pittsburgh, Med Ctr, Ctr Sports Med, Dept Orthopaed Surg, 3200 S Water St, Pittsburgh, PA 15203 USA.	akontos@pitt.edu		Kontos, Anthony/0000-0002-3749-4310; Schatz, Philip/0000-0002-6222-6545			Blume HK, 2012, PEDIATRICS, V129, pE31, DOI 10.1542/peds.2011-1742; Broglio SP, 2009, CLIN J SPORT MED, V19, P377, DOI 10.1097/JSM.0b013e3181b625fe; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Comrey A., 1992, 1 COURSE FACTOR ANAL; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2007, NEUROSURGERY, V61, P345, DOI 10.1227/01.NEU.0000279972.95060.CB; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Herrmann N, 2009, J NEUROPSYCH CLIN N, V21, P181, DOI 10.1176/appi.neuropsych.21.2.181; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR, 2006, J ATHL TRAINING, V41, P137; Lovell MR, 2006, J ATHL TRAINING, V41, P138; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Moser RS, 2012, J PEDIATR-US, V161, P922, DOI 10.1016/j.jpeds.2012.04.012; Pardini D., 2004, BR J SPORTS MED, V38, P661; Piland SG, 2006, MED SCI SPORT EXER, V38, P27, DOI 10.1249/01.mss.0000183186.98212.d5; Piland SG, 2003, J ATHL TRAINING, V38, P104; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Rhee H., 2005, PEDIAT NURS, V31, P350; Rhee Hyekyun, 2005, Pediatr Nurs, V31, P314; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; Tabachnick BG, 2007, USING MULTIVARIATE S	25	201	201	0	26	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	OCT	2012	40	10					2375	2384		10.1177/0363546512455400			10	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	014BV	WOS:000309351000031	22904209				2021-06-18	
J	Lau, BC; Kontos, AP; Collins, MW; Mucha, A; Lovell, MR				Lau, Brian C.; Kontos, Anthony P.; Collins, Michael W.; Mucha, Anne; Lovell, Mark R.			Which On-field Signs/Symptoms Predict Protracted Recovery From Sport-Related Concussion Among High School Football Players?	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						concussion; mild traumatic brain injury (mTBI); signs/symptoms; neurocognitive testing; recovery time; prognosis	TRAUMATIC BRAIN-INJURY; MODERATE HEAD-INJURY; NEUROPSYCHOLOGICAL DEFICITS; POSTCONCUSSION SYMPTOMS; POSTURAL STABILITY; DIZZINESS; MANAGEMENT; IMPACT; HANDICAP; BALANCE	Background: There has been increasing attention and understanding of sport-related concussions. Recent studies show that neurocognitive testing and symptom clusters may predict protracted recovery in concussed athletes. On-field signs and symptoms have not been examined empirically as possible predictors of protracted recovery. Purpose: This study was undertaken to determine which on-field signs and symptoms were predictive of a protracted (>= 21 days) versus rapid (<= 7 days) recovery after a sports-related concussion. On-field signs and symptoms included confusion, loss of consciousness, posttraumatic amnesia, retrograde amnesia, imbalance, dizziness, visual problems, personality changes, fatigue, sensitivity to light/noise, numbness, and vomiting. Study Design: Cohort study (prognosis); Level of evidence, 2. Methods: The sample included 107 male high school football athletes who completed computerized neurocognitive testing within an average 2.4 days after injury, and who were followed until returned to play as determined by neuropsychologists using international clinical concussion management guidelines. Athletes were then grouped into rapid (<= 7 days, n = 62) or protracted (>= 21 days, n = 36) recovery time groups. The presence of on-field signs and symptoms was determined at the time of injury by trained sports medicine professionals (ie, ATC [certified athletic trainer], team physician). A series of odds ratios with chi(2) analyses and subsequent logistic regression were used to determine which on-field signs and symptoms were associated with an increased risk for a protracted recovery. Results: Dizziness at the time of injury was associated with a 6.34 odds ratio (95% confidence interval = 1.34-29.91, chi(2) = 5.44, P = .02) of a protracted recovery from concussion. Surprisingly, the remaining on-field signs and symptoms were not associated with an increased risk of protracted recovery in the current study. Conclusion: Assessment of on-field dizziness may help identify high school athletes at risk for a protracted recovery. Such information will improve prognostic information and allow clinicians to manage and treat concussion more effectively in these at-risk athletes.	[Lau, Brian C.; Kontos, Anthony P.; Collins, Michael W.; Mucha, Anne; Lovell, Mark R.] Univ Pittsburgh, Med Ctr, Ctr Sports Med, Pittsburgh, PA USA	Lau, BC (corresponding author), 3200 S Water St, Pittsburgh, PA 15203 USA.	blau10@gmail.com		Kontos, Anthony/0000-0002-3749-4310			Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Chamelian L, 2004, ARCH PHYS MED REHAB, V85, P1662, DOI 10.1016/j.apmr.2004.02.012; COHEN H, 1993, PHYS THER, V73, P346, DOI 10.1093/ptj/73.6.346; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gartland S, 2001, BRIT J SPORT MED, V35, P308, DOI 10.1136/bjsm.35.5.308; Guskiewicz KM, 2011, CLIN SPORT MED, V30, P89, DOI 10.1016/j.csm.2010.09.004; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Honrubia V, 1996, AM J OTOL, V17, P595; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Iverson G, 2007, CLIN J SPORT MED, V17, P31; JACOBSON GP, 1990, ARCH OTOLARYNGOL, V116, P424; Kammerlind AS, 2005, EUR J PHYSIOTHER, V7, P96, DOI 10.1080/14038190510010403; Lanska DJ, 2000, NEUROLOGY, V55, P1201, DOI 10.1212/WNL.55.8.1201; LAU BC, 2011, AM J SPORTS MED 0207; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; Maskell F, 2006, BRAIN INJURY, V20, P293, DOI 10.1080/02699050500488041; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Randolph C, 2005, J ATHL TRAINING, V40, P139; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; van der Naalt J, 2001, J CLIN EXP NEUROPSYC, V23, P837, DOI 10.1076/jcen.23.6.837.1018; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Yang CC, 2007, J TRAUMA, V62, P657, DOI 10.1097/01.ta.0000203577.68764.b8; YARDLEY L, 1994, BRIT J CLIN PSYCHOL, V33, P101, DOI 10.1111/j.2044-8260.1994.tb01100.x; Yardley L, 2001, J PSYCHOSOM RES, V50, P1, DOI 10.1016/S0022-3999(00)00202-6	44	201	203	2	40	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	NOV	2011	39	11					2311	2318		10.1177/0363546511410655			8	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	838KG	WOS:000296287900004	21712482				2021-06-18	
J	Lu, DY; Sanberg, PR; Mahmood, A; Li, Y; Wang, L; Sanchez-Ramos, J; Chopp, M				Lu, DY; Sanberg, PR; Mahmood, A; Li, Y; Wang, L; Sanchez-Ramos, J; Chopp, M			Intravenous administration of human umbilical cord blood reduces neurological deficit in the rat after traumatic brain injury	CELL TRANSPLANTATION			English	Article; Proceedings Paper	8th Annual Conference of the American-Society-for-Neural-Transplantation-and-Repair	MAY 03-06, 2001	CLEARWATER, FL	Amer Soc Neural Transplantat & Repair		traumatic brain injury (TBI); rat; human umbilical cord blood (HUCB); intravenous administration	BONE-MARROW; CELL TRANSPLANTATION; EXPRESSION; RECEPTOR; ISCHEMIA; REPAIR; MOTOR; SOD	We measured the effect of treatment of traumatic brain injury (TBI) in the rat with human umbilical cord blood (HUCB) administered IV. HUCB cells were injected into the tail vein 24 h after TBI and the rats were sacrificed at day 28 after the treatment. The Rotarod test and the neurological severity score (NSS) were used to evaluate neurological function. The distribution of the donor cells in the brain, heart, lung, kidney, liver, spleen, bone marrow, and muscle were analyzed in recipient rats using immunohistochemical staining and laser confocal microscopy. HUCB cells injected IV significantly reduced motor and neurological deficits compared with control groups by day 28 after the treatment. The cells preferentially entered the brain and migrated into the parenchyma of the injured brain and expressed the neuronal markers, NeuN and MAP-2, and the astrocytic marker, GFAP. Some HUCB cells integrated into the vascular walls within the boundary zone of the injured area. Our data suggest that IV administration of HUCB may be useful in the treatment of TBI.	Henry Ford Hlth Sci Ctr, Dept Neurosurg, Detroit, MI USA; Henry Ford Hlth Sci Ctr, Dept Neurol, Detroit, MI USA; Oakland Univ, Dept Phys, Rochester, MI USA; Univ S Florida, Ctr Aging & Repair, Dept Neurosurg, Tampa, FL USA; Univ S Florida, Ctr Aging & Repair, Dept Neurol, Tampa, FL USA	Chopp, M (corresponding author), Henry Ford Hosp, Dept Neurol, 2799 W Grand Blvd, Detroit, MI 48202 USA.	chopp@neuro.hfh.edu	Sanchez-Ramos, Juan/O-7870-2014; Sanchez-Ramos, Juan/A-1188-2009	Sanchez-Ramos, Juan/0000-0002-3391-7857			BECKER DP, 1990, NEUROLOGICAL SURG, P2017; Bjorklund A, 2000, NAT NEUROSCI, V3, P537, DOI 10.1038/75705; Borlongan CV, 1996, NEUROL RES, V18, P297; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen Ruifeng, 2000, Journal of Medicine (Westbury), V31, P21; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Duncan ID, 1997, MOL MED TODAY, V3, P554, DOI 10.1016/S1357-4310(97)01162-3; Ende N, 2000, LIFE SCI, V67, P53, DOI 10.1016/S0024-3205(00)00602-0; Ende Norman, 1996, Journal of Emergency Medicine, V14, P673, DOI 10.1016/S0736-4679(96)00175-8; Erices A, 2000, BRIT J HAEMATOL, V109, P235, DOI 10.1046/j.1365-2141.2000.01986.x; FREDRIKSON S, 1993, J IMMUNOL, V151, P2217; Gluckman E, 1999, BEST PRACT RES CL HA, V12, P279, DOI 10.1053/beha.1999.0023; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Inoue S, 1998, Indian J Pediatr, V65, P163, DOI 10.1007/BF02752291; Li Y, 2000, J HEMATOTH STEM CELL, V9, P445, DOI 10.1089/152581600419107; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Miyazaki R, 2000, BRIT J HAEMATOL, V108, P602, DOI 10.1046/j.1365-2141.2000.01854.x; Murohara T, 2000, J CLIN INVEST, V105, P1527, DOI 10.1172/JCI8296; Postmantur R., 1997, NEUROSCIENCE, V77, P765; Raisman G, 1997, REV NEUROL, V153, P521; Romanic AM, 1998, STROKE, V29, P1020, DOI 10.1161/01.STR.29.5.1020; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Todaro AM, 2000, BLOOD PURIFICAT, V18, P144, DOI 10.1159/000014438; Welker P, 2000, IMMUNOLOGY, V99, P418, DOI 10.1046/j.1365-2567.2000.00984.x; Yunoki M, 1998, ACT NEUR S, V71, P142; Zhang ZG, 1999, J NEUROSCI, V19, P10898	27	201	229	0	8	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0963-6897	1555-3892		CELL TRANSPLANT	Cell Transplant.		2002	11	3					275	281					7	Cell & Tissue Engineering; Medicine, Research & Experimental; Transplantation	Cell Biology; Research & Experimental Medicine; Transplantation	561LD	WOS:000176141400011	12075993				2021-06-18	
J	Contant, CF; Valadka, AB; Gopinath, SP; Hannay, HJ; Robertson, CS				Contant, CF; Valadka, AB; Gopinath, SP; Hannay, HJ; Robertson, CS			Adult respiratory distress syndrome: a complication of induced hypertension after severe head injury	JOURNAL OF NEUROSURGERY			English	Article						cerebral perfusion pressure; traumatic brain injury; severe head injury; secondary ischemic insult; adult respiratory distress syndrome; intracranial hypertension	MULTIPLE TRAUMA; BRAIN INJURY; PULMONARY; INSUFFICIENCY; INSULTS	Object. The factors involved in the development of adult respiratory distress syndrome (ARDS) after severe head injury were studied. The presence of ARDS complicates the treatment of patients with severe head injury, both because hypoxia causes additional injury to the brain and because therapies that are used to protect the lungs and improve oxygenation in patients with ARDS can reduce cerebral blood flow (CBF) and increase intracranial pressure (ICP). In a recent randomized trial of two head-injury management strategies (ICP-targeted and CBF-targeted), a fivefold increase in the incidence of ARDS was observed in the CBF-targeted group. Methods. Injury severity, physiological data, and treatment data in 18 patients in whom ARDS had developed were compared with the remaining 171 patients in the randomized trial in whom it had not developed. Logistic regression analysis was used to study the interaction of the factors that were related to the development of ARDS. In the final exact logistic regression model, several factors were found to be significantly associated with an increased risk of ARDS: administration of epinephrine (5.7-fold increased risk), administration of dopamine in a larger than median dose (10.8-fold increased risk), and a history of drug abuse (3.1-fold increased risk). Conclusions. Although this clinical trial was not designed to study the association of management strategy and the occurrence of ARDS, the data strongly indicated that induced hypertension in this high-risk group of patients is associated with the development of symptomatic ARDS.	Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Univ Houston, Dept Psychol, Houston, TX USA	Robertson, CS (corresponding author), Baylor Coll Med, Dept Neurosurg, 6560 Fannin,Suite 944, Houston, TX 77030 USA.			Hannay, H. Julia/0000-0001-7023-912X	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS38660] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS038660] Funding Source: NIH RePORTER		BAIGELMAN W, 1981, NEUROSURGERY, V9, P729, DOI 10.1227/00006123-198112000-00021; BERNARD GR, 1994, J CRIT CARE, V9, P72, DOI 10.1016/0883-9441(94)90033-7; Bird DJ, 1997, ANESTH ANALG, V84, P1157, DOI 10.1097/00000539-199705000-00041; Bratton SL, 1997, NEUROSURGERY, V40, P707, DOI 10.1097/00006123-199704000-00009; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; DEMLING R, 1990, CRIT CARE MED, V18, P768, DOI 10.1097/00003246-199007000-00019; FULTON RL, 1975, SURG GYNECOL OBSTET, V140, P179; GARCIAURIA J, 1981, J NEUROSURG, V54, P632, DOI 10.3171/jns.1981.54.5.0632; HOYT DB, 1993, J TRAUMA, V35, P524, DOI 10.1097/00005373-199310000-00005; JENNETT B, 1975, LANCET, V1, P480; KATSURADA K, 1973, SURGERY, V73, P191; MACKERSIE RC, 1983, J TRAUMA, V23, P968, DOI 10.1097/00005373-198311000-00002; MARTIN AM, 1969, ANN SURG, V170, P30, DOI 10.1097/00000658-196907000-00004; MCCLELLAN MD, 1989, J APPL PHYSIOL, V67, P1185; MEISELS IS, 1993, CLEV CLIN J MED, V60, P325, DOI 10.3949/ccjm.60.4.325; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; PAPE HC, 1993, J TRAUMA, V35, P709, DOI 10.1097/00005373-199311000-00010; POOLE GV, 1992, AM SURGEON, V58, P225; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; REGEL G, 1995, J TRAUMA, V38, P70, DOI 10.1097/00005373-199501000-00020; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; SIMMONS RL, 1969, ANN SURG, V170, P39, DOI 10.1097/00000658-196907000-00005; Smith WS, 1997, CHEST, V111, P1326, DOI 10.1378/chest.111.5.1326; Sporer KA, 1999, ANN INTERN MED, V130, P584, DOI 10.7326/0003-4819-130-7-199904060-00019	24	201	209	1	5	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	OCT	2001	95	4					560	568		10.3171/jns.2001.95.4.0560			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	478NQ	WOS:000171352600004	11596949				2021-06-18	
J	HAYES, RL; JENKINS, LW; LYETH, BG				HAYES, RL; JENKINS, LW; LYETH, BG			NEUROTRANSMITTER-MEDIATED MECHANISMS OF TRAUMATIC BRAIN INJURY - ACETYLCHOLINE AND EXCITATORY AMINO-ACIDS	JOURNAL OF NEUROTRAUMA			English	Article							PROTEIN-KINASE-C; METHYL-D-ASPARTATE; LONG-TERM POTENTIATION; FLUID-PERCUSSION MODEL; CEREBRAL BLOOD-FLOW; NMDA ANTAGONISTS; EXTRACELLULAR POTASSIUM; INOSITOL TRISPHOSPHATE; HIPPOCAMPAL-NEURONS; ISCHEMIC-INJURY	Research into traumatic brain injury (TBI), focusing on changes in energy metabolism, cerebrovascular dysfunction, and brain parenchymal morphology, has not produced complete descriptions of mechanisms mediating the pathophysiology of TBI. New studies indicate that neurochemical alterations mediate important components of brain physiology associated with TBI, and these alterations may be responsive to pharmacologic therapy. We discuss rodent models of TBI, review current experimental evidence of muscarinic cholinergic and excitatory amino acid (EAA) receptor involvement in its pathophysiology, and address issues relevant to the interpretation of these data.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT NEUROSURG,RICHMOND,VA 23298				Lyeth, Bruce/0000-0003-4811-1474	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS012587, P50NS012587, R01NS021458, R01NS019550] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS12587, NS19550, NS21458] Funding Source: Medline		ABELE AE, 1990, NEUROSCI LETT, V115, P195, DOI 10.1016/0304-3940(90)90454-H; ANDINE P, 1988, J CEREBR BLOOD F MET, V8, P799, DOI 10.1038/jcbfm.1988.135; ANWYL R, 1989, TRENDS PHARMACOL SCI, V10, P236, DOI 10.1016/0165-6147(89)90268-X; BARABAN JM, TINS, V10, P57; BECKER DP, 1987, PHYSL BASIS MODERN S, P763; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1989, JAMA-J AM MED ASSOC, V262, P1834; BORNSTEIN MB, 1946, J NEUROPHYSIOL, V9, P349; BOUMA GJ, IN PRESS J NEUROSURG; BRIERLEY JB, 1976, GREENFIELDS NEUROPAT, P43; BUCHAN A, 1990, J NEUROSCI, V10, P311; BUCHAN AM, 1990, BRAIN RES, V512, P7, DOI 10.1016/0006-8993(90)91163-B; BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CARDELL M, 1990, SOC NEUROSCI, V19, P278; CHAUHAN A, 1989, BIOCHEMISTRY-US, V28, P4952, DOI 10.1021/bi00438a007; CHIARUGI VP, 1989, NEUROCHEM INT, V14, P1, DOI 10.1016/0197-0186(89)90002-8; CHOI DW, 1988, J NEUROSCI, V8, P185; CHOI DW, 1990, J NEUROSCI, V10, P2493; CHOU C-L, 1991, Society for Neuroscience Abstracts, V17, P722; CLIFTON GL, 1989, STROKE, V20, P1545, DOI 10.1161/01.STR.20.11.1545; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; COLLINS RC, 1986, METAB BRAIN DIS, V1, P231, DOI 10.1007/BF00999353; CONNOR JA, 1988, SCIENCE, V240, P649, DOI 10.1126/science.2452481; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; COTMAN CW, 1987, TRENDS NEUROSCI, V10, P263, DOI 10.1016/0166-2236(87)90170-6; DELAHUNTY TM, IN PRESS J NEUROTRAU; DEWITT DS, 1988, ANESTHESIOLOGY REV, V15, P31; DEWITT DS, 1989, J CEREB BLOOD FLOW S, V1, pS93; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; DINGLEDINE R, 1990, TRENDS PHARMACOL SCI, V11, P334, DOI 10.1016/0165-6147(90)90238-4; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, IN PRESS J NEUROSCI; DIXON CE, 1991, P SATELLITE M BRAIN, P41; DUNWIDDIE T, 1978, J PHYSIOL-LONDON, V276, P353, DOI 10.1113/jphysiol.1978.sp012239; ELLIS EF, 1989, J NEUROSURG, V71, P437, DOI 10.3171/jns.1989.71.3.0437; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEENEY D M, 1990, Society for Neuroscience Abstracts, V16, P779; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FIESCHI C, 1989, J CEREBR BLOOD F MET, V9, P573, DOI 10.1038/jcbfm.1989.82; FINEMAN I, 1990, Society for Neuroscience Abstracts, V16, P778; GARCIA JH, 1978, ACTA NEUROPATHOL, V43, P85; GILL R, 1988, NEUROSCIENCE, V25, P847, DOI 10.1016/0306-4522(88)90040-1; GLOBUS MYT, 1989, J CEREB BLOOD FLO S1, V9, pS5; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; GRAINGER SL, 1983, BRIT J CLIN PHARMACO, V16, P623, DOI 10.1111/j.1365-2125.1983.tb02231.x; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; HABER B, 1980, NEUROBIOLOGY CEREBRO, P345; HARA H, 1990, J CEREBR BLOOD F MET, V10, P646, DOI 10.1038/jcbfm.1990.117; HAYES R, 1987, IEEE T SOFTWARE ENG, V13, P1254, DOI 10.1109/TSE.1987.232879; Hayes R L, 1986, Cent Nerv Syst Trauma, V3, P163; HAYES RL, 1984, SCIENCE, V223, P301, DOI 10.1126/science.6701514; HAYES RL, 1983, J NEUROSURG, V58, P720, DOI 10.3171/jns.1983.58.5.0720; HAYES RL, 1990, UNPUB NMDA RECEPTOR; HAYES RL, 1988, J NEUROTRAUM, V5, P287; Hayes RL, 1989, MILD HEAD INJURY, P54; HUBSCHMANN OR, 1983, J NEUROSURG, V59, P289, DOI 10.3171/jns.1983.59.2.0289; ISHIGE N, 1987, J CEREB BLOOD FLOW M, V7, pS638; JENKINS L, 1989, Society for Neuroscience Abstracts, V15, P1113; JENKINS L W, 1988, Society for Neuroscience Abstracts, V14, P621; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JENKINS LW, 1989, J CEREB BLOOD FLOW M, V9, pS750; JENKINS LW, 1986, MECHANISMS SECONDARY, P273; JENKINS LW, 1988, J NEUROTRAUM, V5, P303; JENKINS LW, 1989, CONT ISSUES NEUROLOG, V1, P47; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; JIANG JY, 1991, P SATELLITE S BRAIN, P89; JOHNSON KM, 1987, PSYCHOPHARMACOLOGY 3, P1581; JULIAN FJ, 1962, J GEN PHYSIOL, V46, P297, DOI 10.1085/jgp.46.2.297; KACZMAREK LK, 1987, TRENDS NEUROSCI, V10, P30, DOI 10.1016/0166-2236(87)90122-6; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KATAYAMA Y, 1984, BRAIN RES, V296, P241, DOI 10.1016/0006-8993(84)90062-3; KAWAMATA T, 1990, Society for Neuroscience Abstracts, V16, P778; KAWAMATA T, 1990, 8TH P ANN M SOC NEUR; KEMP JA, 1987, TRENDS NEUROSCI, V10, P294, DOI 10.1016/0166-2236(87)90176-7; KENNEDY MB, 1989, TRENDS NEUROSCI, V12, P417, DOI 10.1016/0166-2236(89)90089-1; KOEK W, 1988, J PHARMACOL EXP THER, V245, P969; KOIDE T, 1986, J CEREBR BLOOD F MET, V6, P559, DOI 10.1038/jcbfm.1986.102; KURUMAJI A, 1989, BRAIN RES, V496, P268, DOI 10.1016/0006-8993(89)91074-3; LINDEN J, 1989, TRENDS PHARMACOL SCI, V10, P114, DOI 10.1016/0165-6147(89)90209-5; LYETH B G, 1989, Society for Neuroscience Abstracts, V15, P1113; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; LYETH BG, UNPUB THERAPEUTIC WI; LYETH BG, 1990, 8TH P ANN M SOC NEUR; MAKIYAMA Y, 1990, 8TH P ANN M SOC NEUR; MAKIYAMA Y, 1991, UNPUB ACTA NEUROPATH; MALENKA RC, 1986, NATURE, V321, P175, DOI 10.1038/321175a0; MAYER ML, 1990, TRENDS PHARMACOL SCI, V11, P254, DOI 10.1016/0165-6147(90)90254-6; MAYER ML, 1987, TRENDS NEUROSCI, V10, P59, DOI 10.1016/0166-2236(87)90023-3; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MCNAUGHTON BL, 1986, J NEUROSCI, V6, P263; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; METZ B, 1971, J NEUROSURG, V35, P523, DOI 10.3171/jns.1971.35.5.0523; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; MIYAZAKI S, 1988, INTRACRANIAL PRESSUR, V7, P651; MIYAZAKI S, 1991, IN PRESS BRAIN RES; MOORE SD, 1988, SCIENCE, V239, P278, DOI 10.1126/science.2892268; MORRISETT RA, 1989, BRAIN RES, V496, P25, DOI 10.1016/0006-8993(89)91048-2; NICOLL RA, 1988, SCIENCE, V241, P545, DOI 10.1126/science.2456612; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NISHIZUKA Y, 1989, JAMA-J AM MED ASSOC, V262, P1826, DOI 10.1001/jama.262.13.1826; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NOBLE EP, 1989, LIFE SCI, V44, P19, DOI 10.1016/0024-3205(89)90213-0; OKIYAMA K, 1990, 8TH P ANN M SOC NEUR; OLENIAK L D, 1988, Society for Neuroscience Abstracts, V14, P1151; OLNEY J W, 1990, Society for Neuroscience Abstracts, V16, P1122; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; OLTON DS, 1978, BRAIN RES, V139, P295, DOI 10.1016/0006-8993(78)90930-7; PHILLIPS LL, IN PRESS J NEUROTRAU; POVLISHOCK J T, 1989, Society for Neuroscience Abstracts, V15, P1113; Povlishock JT, 1985, CENTRAL NERVOUS SYST, P443; REYNOLDS IJ, 1989, J NEUROCHEM, V53, P226, DOI 10.1111/j.1471-4159.1989.tb07318.x; ROBINSON S E, 1991, Society for Neuroscience Abstracts, V17, P721; ROBINSON SE, 1990, BRAIN RES, V511, P141, DOI 10.1016/0006-8993(90)90233-2; ROBINSON SE, 1990, BRAIN RES, V509, P41, DOI 10.1016/0006-8993(90)90306-V; RUGE D, 1954, J NEUROSURG, V11, P77, DOI 10.3171/jns.1954.11.1.0077; SACHS E, 1957, J NEUROSURG, V14, P22, DOI 10.3171/jns.1957.14.1.0022; SAIJA A, 1988, Journal of Neurotrauma, V5, P161, DOI 10.1089/neu.1988.5.161; SAJIA A, 1988, BRAIN RES, V452, P303; SIESJO BK, 1985, CEREBROVASC DIS, P187; SIMON R P, 1988, Neurology, V38, P147; SMITH D H, 1990, Society for Neuroscience Abstracts, V16, P779; SUZUKI R, 1983, ACTA NEUROPATHOL, V60, P217, DOI 10.1007/BF00691869; SZEKELY AM, 1989, MOL PHARMACOL, V35, P401; TAKAHASHI H, 1981, J NEUROSURG, V55, P708, DOI 10.3171/jns.1981.55.5.0708; TECOMA ES, 1989, NEURON, V2, P1541, DOI 10.1016/0896-6273(89)90042-1; TOWER DB, 1949, CAN J RES E, V27, P105, DOI 10.1139/cjr49e-016; WARD A, 1950, J NEUROSURG, V7, P398, DOI 10.3171/jns.1950.7.5.0398; Weiner N, 1985, PHARMACOL BASIS THER, P130; WESTFALL TC, 1976, ESSENTIALS PHARM, P128; WORLEY PF, 1987, P NATL ACAD SCI USA, V84, P3467, DOI 10.1073/pnas.84.10.3467; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YANG K, IN PRESS J NEUROTRAU; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	140	201	208	0	4	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	1992	9			1			S173	S187					15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	HN806	WOS:A1992HN80600017	1350312				2021-06-18	
J	CROMPTON, MR				CROMPTON, MR			HYPOTHALAMIC LESIONS FOLLOWING CLOSED HEAD INJURY	BRAIN			English	Article																CROMPTON MR, 1963, BRAIN, V86, P301, DOI 10.1093/brain/86.2.301; Daniel PM, 1961, MOD TRENDS ENDOCR, P55; GRASCHENKOV NI, 1965, EXCERPTA MEDICA I 93, P78; Henzi H, 1952, MON PSYCHIATR NEUROL, V123, P292; ISHII S, 1966, HEAD INJURY, P276; Lewy FH, 1935, AM J PHYSIOL, V112, P504; PORTER RJ, 1946, J NEUROL NEUROSUR PS, V11, P258; Rand CW, 1934, ARCH NEURO PSYCHIATR, V31, P527, DOI 10.1001/archneurpsyc.1934.02250030067004; Schereschewsky NA, 1927, REV FRANC ENDOCR, V5, P275; STRICH SJ, 1961, LANCET, V2, P443; WITTER H, 1957, Fortschr Neurol Psychiatr Grenzgeb, V25, P523; WOLMAN L, 1956, J PATHOL BACTERIOL, V72, P575, DOI 10.1002/path.1700720225	12	201	202	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950			BRAIN	Brain		1971	94						165	&		10.1093/brain/94.1.165			0	Clinical Neurology; Neurosciences	Neurosciences & Neurology	I9134	WOS:A1971I913400014	5552160				2021-06-18	
J	Peters, DM; Fritz, SL; Krotish, DE				Peters, Denise M.; Fritz, Stacy L.; Krotish, Debra E.			Assessing the Reliability and Validity of a Shorter Walk Test Compared With the 10-Meter Walk Test for Measurements of Gait Speed in Healthy, Older Adults	JOURNAL OF GERIATRIC PHYSICAL THERAPY			English	Article						older adult; gait speed; measurement; reliability; validity	PHYSICAL PERFORMANCE-MEASURES; TRAUMATIC BRAIN-INJURY; MEANINGFUL CHANGE; BODY-COMPOSITION; CHANGE SCORES; PEOPLE; DISABILITY; STROKE; LIFE; REHABILITATION	Background and Purpose: Walking speed is associated with several health-related outcomes. Research examining how differences in test walking distance affect walking speed reliability and validity is limited. The primary purpose of this study was to examine the reliability and concurrent validity of gait speed measurements obtained from a 4-Meter Walk Test compared with the commonly used 10-Meter Walk Test. A second objective was to similarly examine 2 different timing methods: stopwatch and automatic timers. Methods: Forty-three healthy, older adults (mean age = 84.3 +/- 6.9 years) performed 3 consecutive walking trials on the 4- and 10-Meter Walk Tests at their self-selected walking speed. Results: Gait speed measurements for both tests were shown to have excellent test-retest reliability (ICC values of 0.96-0.98), with similar results for stopwatch and automatic timer assessments (ICC values of 0.99-1.00). Standard error of the measurement (SEM) values were small (0.004-0.008 m/s) across measurement methods. While the ICC value for gait speed measurements between the 2 walk tests was 0.93, the Bland-Altman analysis revealed a discrepancy of +/- 0.15 to +/- 0.17 m/s between measurement methods. Discussion: Both 4- and 10-m gait speed assessments had excellent test-retest reliability with similar SEM and minimal detectable change values. There was little difference in SEM values between the 2 timing methods. While the mean difference in gait speed between the 4- and 10-Meter Walk Tests was small, the range of the measurement differences was large enough to potentially mask meaningful changes in gait speed over time if both methods were used interchangeably. Conclusions: While the reliability of both walking tests is excellent, the 4-Meter Walk Test does not exhibit a high enough degree of concurrent validity with the 10-Meter Walk Test to be used interchangeably for gait speed assessments in healthy, older adults. We therefore recommend using the 10-Meter Walk Test to obtain the most valid clinical assessment of walking speed when using it as a 1-time indicator of health status.	[Peters, Denise M.; Krotish, Debra E.] Univ S Carolina, Dept Exercise Sci, Columbia, SC 29208 USA; [Fritz, Stacy L.] Palmetto Hlth, Div Geriatr, Columbia, SC USA	Peters, DM (corresponding author), Univ S Carolina, Dept Exercise Sci, 921 Assembly St,3rd Floor PHRC, Columbia, SC 29208 USA.	petersd20@gmail.com					Avlund K, 2006, J GERONTOL A-BIOL, V61, P1201, DOI 10.1093/gerona/61.11.1201; BLAND JM, 1995, LANCET, V346, P1085, DOI 10.1016/S0140-6736(95)91748-9; Bland JM, 1999, STAT METHODS MED RES, V8, P135, DOI 10.1191/096228099673819272; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Bohannon RW, 1996, J ORTHOP SPORT PHYS, V24, P86, DOI 10.2519/jospt.1996.24.2.86; Bowden MG, 2008, NEUROREHAB NEURAL RE, V22, P672, DOI 10.1177/1545968308318837; Brach JS, 2002, PHYS THER, V82, P320, DOI 10.1093/ptj/82.4.320; Cesari M, 2005, J AM GERIATR SOC, V53, P1675, DOI 10.1111/j.1532-5415.2005.53501.x; de Rekeneire N, 2003, J AM GERIATR SOC, V51, P841, DOI 10.1046/j.1365-2389.2003.51267.x; Fritz S, 2009, J GERIATR PHYS THER, V32, P2, DOI 10.1519/00139143-200932020-00002; Fritz SL, 2009, NEUROREHAB NEURAL RE, V23, P662, DOI 10.1177/1545968309335975; Goldie PA, 1996, ARCH PHYS MED REHAB, V77, P1074, DOI 10.1016/S0003-9993(96)90072-6; Graham JE, 2008, J EVAL CLIN PRACT, V14, P552, DOI 10.1111/j.1365-2753.2007.00917.x; Green J, 2002, CLIN REHABIL, V16, P306, DOI 10.1191/0269215502cr495oa; Haley SM, 2006, PHYS THER, V86, P735, DOI 10.1093/ptj/86.5.735; Hardy SE, 2007, J AM GERIATR SOC, V55, P1727, DOI 10.1111/j.1532-5415.2007.01413.x; Hollman JH, 2010, GAIT POSTURE, V32, P23, DOI 10.1016/j.gaitpost.2010.02.017; Jorgensen JR, 2010, PHYS THER, V90, P527, DOI 10.2522/ptj.20080404; Kressig RW, 2001, J AM GERIATR SOC, V49, P1456, DOI 10.1046/j.1532-5415.2001.4911237.x; Kuo HK, 2006, AM J PHYS MED REHAB, V85, P650, DOI 10.1097/01.phm.0000228527.34158.ed; Kwon S, 2009, J NUTR HEALTH AGING, V13, P538, DOI 10.1007/s12603-009-0104-z; Lindemann U, 2008, GAIT POSTURE, V27, P91, DOI 10.1016/j.gaitpost.2007.02.005; Maki BE, 1997, J AM GERIATR SOC, V45, P313, DOI 10.1111/j.1532-5415.1997.tb00946.x; Menz HB, 2004, GAIT POSTURE, V20, P20, DOI 10.1016/S0966-6362(03)00068-7; Montero-Odasso M, 2005, J GERONTOL A-BIOL, V60, P1304, DOI 10.1093/gerona/60.10.1304; Moseley AM, 2004, J HEAD TRAUMA REHAB, V19, P341, DOI 10.1097/00001199-200407000-00008; Ota A, 2007, J EPIDEMIOL, V17, P61, DOI 10.2188/jea.17.61; Penninx BWJH, 2000, J GERONTOL A-BIOL, V55, pM691, DOI 10.1093/gerona/55.11.M691; Perera S, 2006, J AM GERIATR SOC, V54, P743, DOI 10.1111/j.1532-5415.2006.00701.x; Purser JL, 2005, J REHABIL RES DEV, V42, P535, DOI 10.1682/JRRD.2004.07.0087; Rabadi MH, 2005, NEUROREHAB NEURAL RE, V19, P20; Salbach NM, 2001, ARCH PHYS MED REHAB, V82, P1204, DOI 10.1053/apmr.2001.24907; Schmid A, 2007, STROKE, V38, P2096, DOI 10.1161/STROKEAHA.106.475921; Steffen TM, 2002, PHYS THER, V82, P128, DOI 10.1093/ptj/82.2.128; Studenski S, 2003, J AM GERIATR SOC, V51, P314, DOI 10.1046/j.1532-5415.2003.51104.x; van Hedel HJA, 2007, NEUROREHAB NEURAL RE, V21, P295, DOI 10.1177/1545968306297861; Van Loo MA, 2004, BRAIN INJURY, V18, P1041, DOI 10.1080/02699050410001672314; Wyrwich KW, 1999, J CLIN EPIDEMIOL, V52, P861, DOI 10.1016/S0895-4356(99)00071-2	38	200	205	0	45	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1539-8412	2152-0895		J GERIATR PHYS THER	J. Geriatr. Phys. Ther.	JAN-MAR	2013	36	1					24	30		10.1519/JPT.0b013e318248e20d			7	Geriatrics & Gerontology; Rehabilitation	Geriatrics & Gerontology; Rehabilitation	060JX	WOS:000312774700004	22415358				2021-06-18	
J	Schwartz, L; Taylor, HG; Drotar, D; Yeates, KO; Wade, SL; Stancin, T				Schwartz, L; Taylor, HG; Drotar, D; Yeates, KO; Wade, SL; Stancin, T			Long-term behavior problems following pediatric traumatic brain injury: Prevalence, predictors, and correlates	JOURNAL OF PEDIATRIC PSYCHOLOGY			English	Article						traumatic brain injury; children; behavior problems; caseness; risk factors; family functioning	CLOSED-HEAD-INJURY; PSYCHIATRIC-DISORDERS; ACADEMIC-PERFORMANCE; FAMILY BURDEN; CHILDREN; ADOLESCENTS; OUTCOMES; VALIDITY; RECOVERY; RELIABILITY	Objective To study identified rates of long-term behavior problems in children with traumatic brain injury (TBI) compared to children with only orthopedic injuries and risk factors and correlates for new behavior problems following TBI. Methods Sample included children with severe TBI (n = 42), moderate TBI (n = 41), and orthopedic injuries only (ORTHO; n = 50). The baseline assessment measured child behavior, adaptation, and neuropsychological, academic, and family functioning. Follow-ups were conducted at 6 and 12 months and at an extended follow-up a mean of 4 years after injury. Results The prevalence of caseness, defined as elevated behavior problem ratings, was higher in one or both TBI groups than in the ORTHO group at each follow-up (e.g., 36% of severe TBI group, 22% of moderate TBI group, and 10% of ORTHO group at extended follow-up). Most instances of postinjury-onset caseness at the extended follow-up were evident within the first year after TBI. Predictors were severe TBI, socioeconomic disadvantage, and preinjury behavioral concerns. Concurrent correlates included weakness in working memory and adaptive behavior skills, poorer behavior and school competence, and adverse family outcomes. Conclusions Postinjury-onset caseness is persistent, risks are multifactorial, and correlates include child dysfunction and family sequelae.	Case Western Reserve Univ, Dept Psychol, Cleveland, OH 44106 USA; Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA; Ohio State Univ, Columbus, OH 43210 USA; Childrens Hosp, Columbus, OH 43205 USA; Univ Cincinnati, Cincinnati, OH 45221 USA; Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA; Metrohlth Med Ctr, Cleveland, OH USA	Schwartz, L (corresponding author), Case Western Reserve Univ, Dept Psychol, 10900 Euclid Ave, Cleveland, OH 44106 USA.		Stancin, Terry/L-7993-2019; Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036335] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS36335] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [18330] Funding Source: Medline		Achenbach T. M., 1991, MANUAL CHILD BEHAV C; Achenbach T.M., 1991, MANUAL TEACHERS REPO; Anderson P., 2000, CLIN NEUROPSYCHOL AS, V1, P247, DOI DOI 10.1076/chin.8.4.231.13509; Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; ARMSTRONG K, 2002, 13 ANN M INT NEUR SO; Barry CT, 1996, CHILD NEUROPSYCHOL, V2, P213, DOI 10.1080/09297049608402254; BEERY KE, 1989, REVISED ADM SCORING; Bernstein JH., 1996, DEV SCORING SYSTEM R; BIEDERMAN J, 1993, J CHILD PSYCHOL PSYC, V34, P1241, DOI 10.1111/j.1469-7610.1993.tb01785.x; Bloom DR, 2001, J AM ACAD CHILD PSY, V40, P572, DOI 10.1097/00004583-200105000-00017; BROOKS DN, 1990, TRAUMATIC BRAIN INJU, P77; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Brown L., 1990, TEST NONVERBAL INTEL; Burgess ES, 1999, J HEAD TRAUMA REHAB, V14, P394, DOI 10.1097/00001199-199908000-00008; DELIS DC, 1986, CALIFORNIA VERBAL LE; Dennis M, 2001, J INT NEUROPSYCH SOC, V7, P683, DOI 10.1017/S1355617701766040; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; DiSimoni F., 1978, TOKEN TEST CHILDREN; ESLINGER PJ, 1997, DEV PREFRONTAL CORTE, P295; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; Fletcher J M, 1991, Brain Inj, V5, P337, DOI 10.3109/02699059109008106; Fletcher JM, 1996, J CHILD NEUROL, V11, P283, DOI 10.1177/088307389601100404; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Green ML, 1998, J PEDIATR PSYCHOL, V23, P289, DOI 10.1093/jpepsy/23.5.289; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; Jensen PS, 1996, J ABNORM CHILD PSYCH, V24, P151, DOI 10.1007/BF01441482; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; KINSELLA G, 1995, J PEDIATR PSYCHOL, V20, P753, DOI 10.1093/jpepsy/20.6.753; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; KNIGHTS RM, 1980, REVISED SMOOTHED NOR; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; LINDGREN S, 1984, PEDIAT ASSESSMENT CO; Masten AS, 2001, AM PSYCHOL, V56, P227, DOI 10.1037/0003-066X.56.3.227; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; Max JE, 1998, J AM ACAD CHILD PSY, V37, P83, DOI 10.1097/00004583-199801000-00021; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 2000, J INT NEUROPSYCH SOC, V6, P279, DOI 10.1017/S1355617700633039; Max JE, 1998, J NERV MENT DIS, V186, P325, DOI 10.1097/00005053-199806000-00001; Max JE, 1998, ARCH PHYS MED REHAB, V79, P893, DOI 10.1016/S0003-9993(98)90084-3; MAYER T, 1980, J PEDIATR SURG, V15, P19; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; MOOS R, 1988, LIFE STRESSORS SOCIA; Paniak C, 1997, CLIN NEUROPSYCHOL, V11, P198, DOI 10.1080/13854049708407051; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; ROURKE BP, 1977, J ABNORM CHILD PSYCH, V5, P9, DOI 10.1007/BF00915756; Rutter M, 1983, DEV NEUROPSYCHIATRY, P83; Semel E., 1987, CELF R CLIN EVALUATI; Sparrow S., 1984, VINELAND ADAPTIVE BE; Spreen O., 1991, COMPENDIUM NEUROPSYC; Stein R, 1985, PACTS PAPERS AECOM T; STEVENS G, 1981, SOC SCI RES, V10, P364, DOI 10.1016/0049-089X(81)90011-9; STEVENSONHINDE J, 1995, FAM PROCESS, V34, P337, DOI 10.1111/j.1545-5300.1995.00337.x; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; Taylor HG, 2000, CHILD DEV, V71, P1495, DOI 10.1111/1467-8624.00242; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TEASDALE G, 1974, LANCET, V2, P81; WADE S, 1995, J PEDIATR PSYCHOL, V20, P737, DOI 10.1093/jpepsy/20.6.737; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; WECHSLER D, 1991, WISC, V3; Wiig E.H., 1985, TEST LANGUAGE COMPET; WOODCOCK RW, 1989, WOODCOCKJOHNSON TEST; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; YEATES KO, 1994, CLIN NEUROPSYCHOL, V8, P91, DOI 10.1080/13854049408401546	68	200	201	1	55	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0146-8693			J PEDIATR PSYCHOL	J. Pediatr. Psychol.	JUN	2003	28	4					251	263		10.1093/jpepsy/jsg013			13	Psychology, Developmental	Psychology	676GV	WOS:000182743700004	12730282	Bronze			2021-06-18	
J	Brown, RL; Brunn, MA; Garcia, VF				Brown, RL; Brunn, MA; Garcia, VF			Cervical spine injuries in children: A review of 103 patients treated consecutively at a level 1 pediatric trauma center	JOURNAL OF PEDIATRIC SURGERY			English	Article; Proceedings Paper	31st Annual Meeting of the Section-on-Surgery of the American-Academy-of-Pediatrics	OCT 28-NOV 01, 2000	CHICAGO, IL	Amer Acad Pediat, Sect Surg		cervical spine injuries; pediatric; trauma; spinal cord injury without radiographic abnormality	CORD INJURY; RADIOGRAPHIC ABNORMALITIES; ADOLESCENTS; EXPERIENCE	Purpose: Cervical spine (C-spine) injuries occur infrequently in children but may be associated with significant disability and mortality. The purpose of this study was to review the experience of a level 1 pediatric trauma center to determine the epidemiology, risk factors, mechanisms, levels, types of injury, comorbid factors, and outcomes associated with these potentially devastating injuries. Methods: A retrospective analysis of 103 consecutive C-spine injuries treated at a level 1 pediatric trauma center over a 91/2-year period (January 1991 through August 2000) was performed. Results: The mean age was 10.3 +/-5.2 years, and the male-to-female ratio was 1.6:1. The most common mechanism of injury was motor vehicle related (52%), followed by sporting injuries (27%). Football injuries accounted for 29% of all sports-related injuries. Sixty-eight percent of all children sustained injuries to C1 to C4; 25% to C5 to C7; and 7% to both. Spinal cord injury without radiographic abnormality (SCIWORA) occurred in 38%. Five patients had complete cord lesions involving the lower C-spine (C4 to C7); 4 of these were motor vehicle related, and all 4 patients died. Isolated C-spine injuries occurred in 43%, whereas 38% had associated closed head injuries (CHI). The overall mortality rate was 18.5%, most commonly motor vehicle related (95%), occurring in younger children (mean and median age 5 years) and associated with upper C-spine injuries (74%) and CHI (89%). C1 dislocations occurred in younger children (mean age, 6.6 years), most often as a result of motor vehicle-related trauma (especially pedestrians) and were associated with the highest injury severity score (ISS), longest length of stay (LOS), most CHIs, and the highest mortality rate (50%). C-spine fractures with or without SCI occurred most commonly as a result of falls and dives. Sporting injuries occurred almost exclusively in adolescent boys (mean age, 13.8 years) and were isolated injuries associated with a relatively low ISS and shorter LOS. Interestingly, 75% of sporting injuries showed SCIWORA, and all infants suffering from child abuse had SCIWORA. Conclusions: Mechanisms of injury are age related, with younger children sustaining C-spine injuries as a result of motor vehicle-related trauma and older adolescents commonly injured during sporting activities. C-spine injuries in children most commonly involve the upper C-spine, but complete lesions of the cord are associated more frequently with lower C-spine injuries. The type of C-spine injury is related to the mechanism of injury: SCIWORA is associated with sporting activities and child abuse, C-spine dislocations most commonly result from motor vehicle-related trauma (especially among pedestrians), and C-spine fractures occur most commonly as a result of falls and dives. Predictors of mortality include younger age, motor vehicle-related mechanism, C1 dislocations, high ISS greater than 25, and associated CHI. A high index of suspicion for SCIWORA is essential when evaluating adolescents with neck trauma associated with sporting injuries or victims of child abuse. J Pediatr Surg 36:1107-1114. Copyright (C) 2001 by W.B. Saunders Company.	Childrens Hosp, Med Ctr, Div Trauma Serv, Cincinnati, OH 45229 USA	Brown, RL (corresponding author), Childrens Hosp, Med Ctr, Div Pediat Surg, Trauma Serv, OSB-3,3333 Burnet Ave, Cincinnati, OH 45229 USA.						*AM AC PED, 1996, RE9618 AM AC PED; ANDERSON JM, 1980, MAYO CLIN PROC, V55, P499; Baker C, 1999, AM J EMERG MED, V17, P230, DOI 10.1016/S0735-6757(99)90111-0; BIRNEY TJ, 1989, SPINE, V14, P1277, DOI 10.1097/00007632-198912000-00001; BOHN D, 1990, J TRAUMA, V30, P463, DOI 10.1097/00005373-199030040-00017; BURKE DC, PARAPLEGIA, V11, P268; CHOI JU, 1986, J NEUROSURG, V65, P608, DOI 10.3171/jns.1986.65.5.0608; DICKMAN CA, 1991, J SPINAL DISORD, V4, P296, DOI 10.1097/00002517-199109000-00006; DIETRICH AM, 1991, J PEDIATR SURG, V26, P995, DOI 10.1016/0022-3468(91)90850-S; Eleraky MA, 2000, J NEUROSURG, V92, P12, DOI 10.3171/spi.2000.92.1.0012; FESMIRE F M, 1989, Journal of Emergency Medicine, V7, P133, DOI 10.1016/0736-4679(89)90258-8; Finch GD, 1998, J PEDIATR ORTHOPED, V18, P811, DOI 10.1097/00004694-199811000-00022; Givens TG, 1996, J TRAUMA, V41, P310, DOI 10.1097/00005373-199608000-00019; Gotschall CS, 1998, P ANN C ASS, P29; HACHEN HJ, 1977, PARAPLEGIA, V15, P55, DOI 10.1038/sc.1977.9; HADLEY MN, 1988, J NEUROSURG, V68, P18, DOI 10.3171/jns.1988.68.1.0018; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; HENRYS P, 1977, CLIN ORTHOP RELAT R, V129, P172; HILL SA, 1984, J NEUROSURG, V60, P700, DOI 10.3171/jns.1984.60.4.0700; HUBBARD DD, 1974, CLIN ORTHOP RELAT R, V100, P56; JAFFE DM, 1987, ANN EMERG MED, V16, P270, DOI 10.1016/S0196-0644(87)80171-3; KEWALRAMANI LS, 1980, PARAPLEGIA, V18, P206, DOI 10.1038/sc.1980.36; Kriss VM, 1996, CLIN PEDIATR, V35, P119, DOI 10.1177/000992289603500302; Manary MJ, 1996, PEDIATR ANN, V25, P423, DOI 10.3928/0090-4481-19960801-04; MELZAK J, 1969, LANCET, V2, P45; MICHAEL D B, 1989, Journal of Neurotrauma, V6, P177; *NAT HIGHW TRAFF S, 1997, PROT YOUR KIDS CAR; NITECKI S, 1994, J PEDIATR SURG, V29, P1409, DOI 10.1016/0022-3468(94)90131-7; ORENSTEIN JB, 1994, PEDIATR EMERG CARE, V10, P132, DOI 10.1097/00006565-199406000-00003; OSENBACH RK, 1992, NEUROSURGERY, V30, P385, DOI 10.1227/00006123-199203000-00012; PANG D, 1989, J TRAUMA, V29, P654, DOI 10.1097/00005373-198905000-00021; PANG D, 1982, J NEUROSURG, V57, P114, DOI 10.3171/jns.1982.57.1.0114; RACHESKY I, 1987, AM J DIS CHILD, V141, P199, DOI 10.1001/archpedi.1987.04460020089033; Rooks VJ, 1998, PEDIATR RADIOL, V28, P193, DOI 10.1007/s002470050330; RUGE JR, 1988, J NEUROSURG, V68, P25, DOI 10.3171/jns.1988.68.1.0025; STAUFFER ES, 1982, PEDIATR ANN, V11, P502, DOI 10.3928/0090-4481-19820601-07; Winston FK, 1999, JAMA-J AM MED ASSOC, V281, P2070, DOI 10.1001/jama.281.22.2070; WINSTON FK, 1999, 43 ANN P ASS ADV AUT, P59	38	200	205	0	9	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0022-3468	1531-5037		J PEDIATR SURG	J. Pediatr. Surg.	AUG	2001	36	8					1107	1114		10.1053/jpsu.2001.25665			8	Pediatrics; Surgery	Pediatrics; Surgery	457CV	WOS:000170120300001	11479837				2021-06-18	
J	Cantu, RC				Cantu, RC			Posttraumatic retrograde and anterograde amnesia: Pathophysiology and implications in grading and safe return to play	JOURNAL OF ATHLETIC TRAINING			English	Article						concussion; mild traumatic brain injury; athletic injury	BLUNT HEAD-INJURY; CEREBRAL CONCUSSION; COGNITIVE SEQUELAE; FOOTBALL PLAYERS; PRACTICAL SCALE; EARLY INDEXES; BRAIN INJURY; SEVERITY; RECOVERY; COMA	Objective: The presence of posttraumatic amnesia (PTA) and loss of consciousness have been main factors used in a number of concussion guidelines, In this article, the focus is on using PTA (both retrograde and anterograde) as salient indicators of traumatic brain injury severity and the most reliable index of outcome prediction, even in mild cases. Data Sources: A MEDLINE search for the years 1990-2000 using the key words posttraumatic retrograde and anterograde amnesia, concussion and mild traumatic brain injury was done. Data Synthesis: On-the-field testing of PTA is a salient and integral component of the initial and follow-up neurologic assessments of the head-injured athlete. Conclusions/Recommendations: Initial and follow-up assessments of PTA, anterograde and retrograde, are an essential part of the neurologic evaluation of the head-injured athlete. Increasingly, neuropsychological testing, including computer models, is being employed in this assessment. The importance of not just PTA but all postconcussion signs and symptoms being absent at rest and exertion before allowing the athlete to return to play is emphasized.	Emerson Hosp, Concord, MA 01742 USA	Cantu, RC (corresponding author), Emerson Hosp, 131 Old Rd,9 Acre Corner,John Cumming Bldg,Suite, Concord, MA 01742 USA.	rcantu@emersonhosp.org					ADAMS RD, 1997, PRINCIPLES NEUROLOGY, P427; ALEXANDER MP, 1982, PSYCHIAT ASPECTS NEU, P219; ALEXANDRE A, 1983, J NEUROSURG, V59, P751, DOI 10.3171/jns.1983.59.5.0751; BENSON DF, 1976, NEUROLOGY, V26, P147, DOI 10.1212/WNL.26.2.147; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; Bleiberg J, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199804000-00006; BLEIBERG J, 2000, NATL REHABILITATION; BROOKS DN, 1980, J NEUROL NEUROSUR PS, V43, P529, DOI 10.1136/jnnp.43.6.529; BROOKS DN, 1986, J NEUROL NEUROSUR PS, V49, P549, DOI 10.1136/jnnp.49.5.549; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; Cartlidge N E, 1981, HEAD INJURY; CROVITZ HF, 1983, CORTEX, V19, P407, DOI 10.1016/S0010-9452(83)80009-4; DANIEL WF, 1987, CORTEX, V23, P169, DOI 10.1016/S0010-9452(87)80030-8; ERLANGLER DM, 2000, NAT AC NEUR NOV 16 O; Evans C D, 1976, Rheumatol Rehabil, V15, P168, DOI 10.1093/rheumatology/15.3.168; GEFFEN GM, 1991, NEUROREPORT, V2, P105, DOI 10.1097/00001756-199102000-00010; Gennarelli T.A., 1982, HEAD INJURY BASIC CL, P129; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GILCHRIST E, 1979, ARCH NEUROL-CHICAGO, V36, P355, DOI 10.1001/archneur.1979.00500420065008; GILLINGHAM FJ, 1969, INJURY, V1, P142; GRONWALL D, 1975, LANCET, V2, P995; GRONWALL D, 1974, LANCET, V2, P605; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; HASLAM C, 1994, BRAIN INJURY, V8, P519, DOI 10.3109/02699059409151004; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JENKINS LW, 1986, MECHANISMS SECONDARY, P273; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; JORDAN BJ, 1989, SPORTS NEUROLOGY, P227; KATZ DI, 1992, J HEAD TRAUMA REHAB, V7, P1; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; LEE SM, 1955, J CEREB BLOOD FLOW M, V7, P22; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LIFSHITZ J, 1955, J NEUROTRAUM, V12, P129; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Nelson W. E., 1984, PHYSICIAN SPORTSMED, V12, P103; Ommaya A.K., 1985, BIOMECHANICS TRAUMA, P245; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; Report of the Sports Medicine Committee, 1990, GUID MAN CONC SPORTS; ROBERTS WO, 1992, PHYSICIAN SPORTSMED, V20, P66, DOI 10.1080/00913847.1992.11710295; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; SCHNEIDER RC, 1985, SPORTS INJURIES; SHORES EA, 1989, J NEUROL NEUROSUR PS, V52, P126, DOI 10.1136/jnnp.52.1.126-a; STOVER SL, 1976, ARCH PHYS MED REHAB, V57, P201; Stuss DT, 1995, ANN NY ACAD SCI, V769, P191, DOI 10.1111/j.1749-6632.1995.tb38140.x; Stuss DT, 1999, J NEUROSURG, V90, P635, DOI 10.3171/jns.1999.90.4.0635; SUTTON RL, 1994, ACTA NEUROCHIR, P446; SYMONDS C, 1962, LANCET, V1, P1; TEASDALE G, 1974, LANCET, V2, P81; TORG JS, 1991, ATHLETIC INJURIES HE, P226; Zemper Eric D., 1994, Journal of Athletic Training, V29, P44	51	200	201	0	18	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	JUL-SEP	2001	36	3					244	248					5	Sport Sciences	Sport Sciences	557NC	WOS:000175913800005	12937491				2021-06-18	
J	Hayes, RL; Jenkins, LW; Lyeth, BG; Balster, RL; Robinson, SE; Clifton, GL; Stubbins, JF; Young, HF				Hayes, R. L.; Jenkins, L. W.; Lyeth, B. G.; Balster, R. L.; Robinson, S. E.; Clifton, G. L.; Stubbins, J. F.; Young, H. F.			Pretreatment with Phencyclidine, an N-Methyl-D-Aspartate Antagonist, Attenuates Long-Term Behavioral Deficits in the Rat Produced by Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article							CEREBRAL-BLOOD-FLOW; FLUID-PERCUSSION INJURY; SPINAL-CORD-INJURY; ENTORHINAL CORTEX; KETAMINE; RECOVERY; ACETYLCHOLINE; VULNERABILITY; CONCUSSION; PROTECTS	This study examined the effects of pretreatment with phencyclidine (PCP), a selective /V-methyl-D-aspartate (NMDA) antagonist, on behavioral and physiologic responses of the rat to experimental traumatic brain injury (TBI). For the behavioral experiments, rats were administered either saline or PCP (1.0, 2.0, or 4.0 mg/kg, intrapentoneally [IP] 15 min before TBI. Rats were ventilated as necessary following injury. The duration of acute suppression of several reflexes (pinna, corneal, righting, and flexion) and responses (escape, head support, and spontaneous locomotion) was recorded for up to 70 min after trauma. Longer-term behavioral assessments (beam walking, beam balance, inclined plane, ambulatory activity, and body weight) were made for up to 10 days after trauma. PCP did not significantly alter the duration of acute behavioral suppression. At a dosage of 1.0 mg/kg, PCP significantly attenuated all long-term deficits except beam walking. Maximal protection against beam walking deficits was provided by the 4.0 mg/kg dosage of PCP. Sixty-three percent of saline-treated animals died within 10 days after injury. For rats pretreated with 1.0, 2.0, and 4.0 mg/kg of PCP, 40%, 23%, and 33% died, respectively. In physiologic experiments, pretreatment with 4.0 mg/kg of PCP (IP) 15 min before injury did not significantly affect systemic cardiovascular responses, plasma glucose levels, or blood gas levels observed within 30 min after injury. While the possibility of effects mediated by other neurotransmitter systems cannot be excluded, these data suggest that NMDA agonist-receptor interactions contribute to the pathophysiology of brain injury. In addition, neural mechanisms that mediate transient unconsciousness following moderate levels of head injury may differ from mechanisms that mediate more persistent neurologic deficits.	[Hayes, R. L.; Jenkins, L. W.; Lyeth, B. G.; Clifton, G. L.; Young, H. F.] Virginia Commonwealth Univ, Med Coll Virginia, Richard Roland Reynolds Neurosurg Res Labs, Dept Surg,Div Neurosurg, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Pharmacol & Toxicol, Richmond, VA 23298 USA; [Stubbins, J. F.] Virginia Commonwealth Univ, Med Coll Virginia, Dept Med Chem, Richmond, VA 23298 USA	Hayes, RL (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Richard Roland Reynolds Neurosurg Res Labs, Dept Surg,Div Neurosurg, Box 693,MCV Stn, Richmond, VA 23298 USA.			Lyeth, Bruce/0000-0003-4811-1474	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS21458, NS12587, NS19550, DA 01442]	We gratefully acknowledge the careful editorial contribution of Fay Akers. This work was supported by NIH Grants NS21458 (RLH), NS12587 (HFY), NS19550 (LWJ), and DA 01442 (RLB).	ANIS NA, 1983, BRIT J PHARMACOL, V79, P565, DOI 10.1111/j.1476-5381.1983.tb11031.x; BAKER HJ, 1979, LAB RAT, V1; Balster R.L., 1983, PHENCYCLIDINE RELATE; BENARDO LS, 1982, BRAIN RES, V249, P315, DOI 10.1016/0006-8993(82)90066-X; BENNETT DA, 1988, LIFE SCI, V42, P447, DOI 10.1016/0024-3205(88)90083-5; BORNSTEIN MB, 1946, J NEUROPHYSIOL, V9, P349; CHOI DW, 1987, J PHARMACOL EXP THER, V242, P713; CHOI DW, 1987, J NEUROSCI, V7, P369; Collier H., 1962, ASSESSMENT PAIN MAN, P262; COLLINS RC, 1986, METAB BRAIN DIS, V1, P231, DOI 10.1007/BF00999353; DeWitt DS, 1988, J NEUROTRAUM, V5, P303, DOI 10.1089/neu.1988.5.303; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; Dixon C.E., 1985, SOC NEUR ABST, V11, P434; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DUCKROW RB, 1981, J NEUROSURG, V54, P607, DOI 10.3171/jns.1981.54.5.0607; DURET H, 1878, THESIS PARIS; Faden AI, 1988, J NEUROTRAUM, V5, P33, DOI 10.1089/neu.1988.5.33; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; HAYES R L, 1988, Society for Neuroscience Abstracts, V14, P1153; Hayes R L, 1986, Cent Nerv Syst Trauma, V3, P163; Hayes R L, 1988, Brain Inj, V2, P31, DOI 10.3109/02699058809150930; Hayes R.L., 1988, MILD HEAD INJURY; Hayes R.L., 1987, SOC NEUR ABST, V2, P1254; HAYES RL, 1984, SCIENCE, V223, P301, DOI 10.1126/science.6701514; Jenkins L.W., MICHIGAN S IN PRESS; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JENKINS LW, 1986, MECHANISMS SECONDARY, P273; JOHNSON KM, 1987, PSYCHOPHARMACOLOGY 3, P1581; KATAYAMA Y., 1988, NEUR ABSTR, V14, P1154; KEMP JA, 1987, TRENDS NEUROSCI, V10, P294, DOI 10.1016/0166-2236(87)90176-7; Koek W., 1988, SIGMA PHENCYLIDINE L; KRNJEVIC K, 1971, J PHYSIOL-LONDON, V215, P223, DOI 10.1113/jphysiol.1971.sp009466; Leander J.D., 1987, EXCITATORY AMINO ACI, P197; LEANDER JD, 1988, BRAIN RES, V448, P115, DOI 10.1016/0006-8993(88)91107-9; LEONARD JP, 1979, J CELL BIOL, V82, P811, DOI 10.1083/jcb.82.3.811; LEWELT W, 1980, J NEUROSURG, V53, P500, DOI 10.3171/jns.1980.53.4.0500; LEWELT W, 1982, J NEUROSURG, V56, P332, DOI 10.3171/jns.1982.56.3.0332; LINDGREN S, 1966, BIOPHYSIK, V3, P174, DOI 10.1007/BF01191611; Lindgren S O, 1966, Acta Chir Scand Suppl, V360, P1; LOESCHE J, 1977, BRAIN RES BULL, V2, P31, DOI 10.1016/0361-9230(77)90022-3; LYETH B G, 1987, Society for Neuroscience Abstracts, V13, P1253; LYETH B G, 1986, Society for Neuroscience Abstracts, V12, P967; Lyeth B.G., 1988, NEUROTRAUMA MONITORI, V4; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; MARCOUX FW, 1988, BRAIN RES, V452, P329, DOI 10.1016/0006-8993(88)90037-6; MCDONALD JW, 1987, EUR J PHARMACOL, V140, P359, DOI 10.1016/0014-2999(87)90295-0; McIntosh T.K., 1988, RECENT ADV EXCITATOR; Miyazaki S., 7 INT S INT IN PRESS, V7; OLENIAK L D, 1988, Society for Neuroscience Abstracts, V14, P1151; OLNEY JW, 1983, NATURE, V301, P520, DOI 10.1038/301520a0; Quirion R, 1986, NEUROMETHODS, VIV, P499; RIVLIN AS, 1977, J NEUROSURG, V47, P577, DOI 10.3171/jns.1977.47.4.0577; Rosner M.J., 1982, P 5 INT S INTR PRESS; ROTHMAN SM, 1987, TRENDS NEUROSCI, V10, P299, DOI 10.1016/0166-2236(87)90177-9; ROTHMAN SM, 1987, NEUROSCIENCE, V21, P673, DOI 10.1016/0306-4522(87)90028-5; RUGE D, 1954, J NEUROSURG, V11, P77, DOI 10.3171/jns.1954.11.1.0077; RUTHERFORD WH, 1977, LANCET, V1, P1; SACHS E, 1957, J NEUROSURG, V14, P22, DOI 10.3171/jns.1957.14.1.0022; SAUNDERS ML, 1979, J NEUROSURG, V51, P18, DOI 10.3171/jns.1979.51.1.0018; SCHEFF SW, 1977, BEHAV BIOL, V21, P286, DOI 10.1016/S0091-6773(77)90374-1; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; TAKAHASHI H, 1981, J NEUROSURG, V55, P708, DOI 10.3171/jns.1981.55.5.0708; TEASDALE G, 1976, BRIT J ANAESTH, V48, P761, DOI 10.1093/bja/48.8.761; TECOMA E S, 1988, Society for Neuroscience Abstracts, V14, P621; TURSKI WA, 1983, EXPERIENTIA, V39, P1408, DOI 10.1007/BF01990130; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; Willetts J., 1988, SIGMA PHENCYLIDINE L; WORLEY PF, 1987, P NATL ACAD SCI USA, V84, P3467, DOI 10.1073/pnas.84.10.3467; ZUKIN SR, 1984, BRAIN RECEPTOR MET B, P231	70	200	201	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma		1988	5	4					259	U24		10.1089/neu.1988.5.259			22	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	V21VO	WOS:000208235300001	3225856				2021-06-18	
J	Montenigro, PH; Alosco, ML; Martin, BM; Daneshvar, DH; Mez, J; Chaisson, CE; Nowinski, CJ; Au, R; Mckee, AC; Cantu, RC; McClean, MD; Stern, RA; Tripodis, Y				Montenigro, Philip H.; Alosco, Michael L.; Martin, Brett M.; Daneshvar, Daniel H.; Mez, Jesse; Chaisson, Christine E.; Nowinski, Christopher J.; Au, Rhoda; Mckee, Ann C.; Cantu, Robert C.; McClean, Michael D.; Stern, Robert A.; Tripodis, Yorghos			Cumulative Head Impact Exposure Predicts Later-Life Depression, Apathy, Executive Dysfunction, and Cognitive Impairment in Former High School and College Football Players	JOURNAL OF NEUROTRAUMA			English	Article						behavior; cognition; concussion; football; long-term impairment; subconcussive impacts	TRAUMATIC BRAIN-INJURY; BEHAVIOR RATING INVENTORY; RECURRENT CONCUSSION; LONG-TERM; AMERICAN FOOTBALL; ADULT COGNITION; 1ST EXPOSURE; SPORTS; ENCEPHALOPATHY; IDENTIFICATION	The term "repetitive head impacts'' (RHI) refers to the cumulative exposure to concussive and subconcussive events. Although RHI are believed to increase risk for later-life neurological consequences (including chronic traumatic encephalopathy), quantitative analysis of this relationship has not yet been examined because of the lack of validated tools to quantify lifetime RHI exposure. The objectives of this study were: 1) to develop a metric to quantify cumulative RHI exposure from football, which we term the "cumulative head impact index'' (CHII); 2) to use the CHII to examine the association between RHI exposure and long-term clinical outcomes; and 3) to evaluate its predictive properties relative to other exposure metrics (i.e., duration of play, age of first exposure, concussion history). Participants included 93 former high school and collegiate football players who completed objective cognitive and self-reported behavioral/mood tests as part of a larger ongoing longitudinal study. Using established cutoff scores, we transformed continuous outcomes into dichotomous variables (normal vs. impaired). The CHII was computed for each participant and derived from a combination of self-reported athletic history (i.e., number of seasons, position[s], levels played), and impact frequencies reported in helmet accelerometer studies. A bivariate probit, instrumental variable model revealed a threshold dose-response relationship between the CHII and risk for later-life cognitive impairment (p < 0.0001), self-reported executive dysfunction (p < 0.0001), depression (p < 0.0001), apathy (p = 0.0161), and behavioral dysregulation (p < 0.0001). Ultimately, the CHII demonstrated greater predictive validity than other individual exposure metrics.	[Montenigro, Philip H.; Alosco, Michael L.; Daneshvar, Daniel H.; Mez, Jesse; Chaisson, Christine E.; Nowinski, Christopher J.; Mckee, Ann C.; Cantu, Robert C.; Stern, Robert A.; Tripodis, Yorghos] Boston Univ, Sch Med, Alzheimers Dis & CTE Ctr, Boston, MA 02118 USA; [Montenigro, Philip H.; Stern, Robert A.] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA; [Mez, Jesse; Au, Rhoda; Mckee, Ann C.; Stern, Robert A.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Au, Rhoda] Boston Univ, Sch Med, Framingham Heart Study, Boston, MA 02118 USA; [Mckee, Ann C.] Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA; [Cantu, Robert C.; Stern, Robert A.] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02118 USA; [Martin, Brett M.; Chaisson, Christine E.] Boston Univ, Sch Publ Hlth, Data Coordinating Ctr, Boston, MA USA; [Chaisson, Christine E.; Tripodis, Yorghos] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA; [McClean, Michael D.] Boston Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA; [Nowinski, Christopher J.; Cantu, Robert C.] Concuss Legacy Fdn, Waltham, MA USA; [Mckee, Ann C.] VA Boston Healthcare Syst, Boston, MA USA; [Cantu, Robert C.] Emerson Hosp, Dept Neurosurg, Concord, MA USA	Stern, RA (corresponding author), 72 E Concord St,Suite B7800, Boston, MA 02118 USA.	bobstern@bu.edu	, Bob/ABA-8507-2020	Tripodis, Yorghos/0000-0003-2190-7608; Daneshvar, Daniel/0000-0003-3691-9513; Montenigro, Philip/0000-0003-4442-9207	Concussion Legacy Foundation; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [U01NS093334]; Boston University School of Medicine Medical Student Summer Research Program Scholarship; Graduate Medical Sciences Student Organization Community Service Award;  [T32-AG06697]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS086659] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K23AG046377, P30AG013846, T32AG036697] Funding Source: NIH RePORTER	This study was funded in part by a grant from the Concussion Legacy Foundation, as well as National Institutes of Health (NIH) grant U01NS093334. Dr. Montenigro received partial support for this study from a Boston University School of Medicine Medical Student Summer Research Program Scholarship and from a Graduate Medical Sciences Student Organization Community Service Award. Dr. Alosco is supported by the T32-AG06697 post-doctoral fellowship. The authors thank the following individuals: Sarah Fairfield, Dr. Brandon Gavett, Kaitlin Perry, David Riley, Clifford Robbins, and members of the Boston University Alzheimer's Disease and CTE Center. The authors also extend their gratitude and appreciation to all the participants who made this study possible.	Abbas K, 2015, BRAIN CONNECT, V5, P91, DOI 10.1089/brain.2014.0279; Alosco Michael L., 2016, ALZHEIMERS DEMENTIA; Andersson S, 2002, NEUROPSY NEUROPSY BE, V15, P184, DOI 10.1097/01.WNN.0000026596.88167.8E; Angoa-Perez M, 2014, J NEUROCHEM, V129, P916, DOI 10.1111/jnc.12690; Angrist JD, 1996, J AM STAT ASSOC, V91, P444, DOI 10.2307/2291629; ANGRIST JD, 1991, Q J ECON, V106, P979, DOI 10.2307/2937954; Appaneal RN, 2009, J SPORT EXERCISE PSY, V31, P60, DOI 10.1123/jsep.31.1.60; Bar KJ, 2013, EUR ARCH PSY CLIN N, V263, pS205, DOI 10.1007/s00406-013-0458-4; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Baugh CM, 2015, J NEUROTRAUM, V32, P314, DOI 10.1089/neu.2014.3582; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2015, J HEAD TRAUMA REHABI; Bernick C, 2015, BRIT J SPORT MED, V49, P1007, DOI 10.1136/bjsports-2014-093877; Bernick C, 2013, ALZHEIMERS RES THER, V5, DOI 10.1186/alzrt177; Bernick C, 2013, AM J EPIDEMIOL, V178, P280, DOI 10.1093/aje/kws456; Bernick C, 2012, NEUROLOGY, V79, pE89; Bieniek KF, 2015, ACTA NEUROPATHOL, V130, P877, DOI 10.1007/s00401-015-1502-4; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Cantu RC, 2003, NEUROSURGERY, V53, P358, DOI 10.1227/01.NEU.0000073422.01886.88; Cantu RC, 2013, WORLD NEUROSURG, V80, P792, DOI 10.1016/j.wneu.2013.10.011; CARLIN BP, 1992, J R STAT SOC C-APPL, V41, P389, DOI 10.2307/2347570; Carman AJ, 2015, NAT REV NEUROL, V11, P230, DOI 10.1038/nrneurol.2015.30; Centers for Disease Control And Prevention, 2013, CONC SPORTS; Cherry JD, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0382-8; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Corrigan J. D., 2015, WHY SELF REPORT OHIO; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P315, DOI 10.1097/01.HTR.0000300226.67748.3e; Crisco JJ, 2011, J BIOMECH, V44, P2673, DOI 10.1016/j.jbiomech.2011.08.003; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Daniel RW, 2012, ANN BIOMED ENG, V40, P976, DOI 10.1007/s10439-012-0530-7; Dashnaw ML, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12284; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; Diane B., 2008, AM PSYCHIAT PUBLISHI, P223; Dompier TP, 2015, JAMA PEDIATR, V169, P659, DOI 10.1001/jamapediatrics.2015.0210; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Erlanger DM, 2015, BRAIN INJURY, V29, P171, DOI 10.3109/02699052.2014.965211; Fidan E., 2015, J NEUROTRAUM, V32, P1; Fredricks JA, 2006, DEV PSYCHOL, V42, P698, DOI 10.1037/0012-1649.42.4.698; Gavett B. E., 2011, NUTR TRAUMATIC BRAIN, P305; Gavett BE, 2013, NEUROREHABILITATION, V32, P253, DOI 10.3233/NRE-130842; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Gioia GA, 2000, CHILD NEUROPSYCHOL, V6, P235, DOI 10.1076/chin.6.3.235.3152; Giza CC, 2001, J ATHL TRAINING, V36, P228; Goldstein LE, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0064-3; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; Grinnon ST, 2012, CLIN TRIALS, V9, P322, DOI 10.1177/1740774512438980; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Guthrie RM, 2015, PHYSICIAN SPORTSMED, V43, P333, DOI 10.1080/00913847.2015.1081552; Gysland SM, 2012, ANN BIOMED ENG, V40, P14, DOI 10.1007/s10439-011-0421-3; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Harrison PA, 2003, J SCHOOL HEALTH, V73, P113, DOI 10.1111/j.1746-1561.2003.tb03585.x; HECKMAN JJ, 1979, ECONOMETRICA, V47, P153, DOI 10.2307/1912352; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Husaini B. A., 1980, J COMMUNITY PSYCHOL, V8, P20, DOI [10 .1002/1520-6629( 198001) 8:1 20:: AID-JCOP2290080105 3.0.CO; ~ ~ 2-Y, DOI 10.1002/1520-6629(198001]; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; JEDLINSKI J, 1971, Acta Medica Polona, V12, P443; Jordan BD, 1996, PHYSICIAN SPORTSMED, V24, P87, DOI 10.3810/psm.1996.05.1358; Kant R, 1998, BRAIN INJURY, V12, P87, DOI 10.1080/026990598122908; Katz MH, 2010, EVALUATING CLIN PUBL; Kerr ZY, 2015, J NEUROTRAUM, V32, P1083, DOI 10.1089/neu.2014.3666; Kerr ZY, 2012, MED SCI SPORT EXER, V44, P377, DOI 10.1249/MSS.0b013e31823240f2; Lane-Brown AT, 2009, BRAIN INJURY, V23, P999, DOI 10.3109/02699050903379347; Langburt W, 2001, J CHILD NEUROL, V16, P83, DOI 10.1177/088307380101600203; Leigh JP, 2004, J CLIN EPIDEMIOL, V57, P284, DOI 10.1016/j.jclinepi.2003.08.006; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Llewellyn T, 2014, CLIN J SPORT MED, V24, P76, DOI 10.1097/01.jsm.0000432853.77520.3d; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; MARIN RS, 1991, PSYCHIAT RES, V38, P143, DOI 10.1016/0165-1781(91)90040-V; MARTLAND HS, 1928, JAMA-J AM MED ASSOC, V91, P1103, DOI DOI 10.1001/JAMA.1928.02700150029009; McCauley SR, 2006, BRAIN INJURY, V20, P519, DOI 10.1080/02699050600676651; McCrory P, 2009, PM&R, V1, P406, DOI 10.1016/j.pmrj.2009.03.010; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Montenigro PH, 2017, J NEUROTRAUM, V34, P328, DOI 10.1089/neu.2016.4413; Montenigro PH, 2015, BRAIN PATHOL, V25, P304, DOI 10.1111/bpa.12250; Montenigro PH, 2015, ANNU REV CLIN PSYCHO, V11, P309, DOI 10.1146/annurev-clinpsy-032814-112814; Ng TP, 2006, BIOMED SCI INSTRUM, V42, P25; Petersen RC, 2005, ARCH NEUROL-CHICAGO, V62, P1160, DOI 10.1001/archneur.62.7.1160; Pettygrove S., 2008, ENCY EPIDEMIOLOGY, P283; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Radloff L.S., 1986, COMMUNITY SURVEYS PS, P177; Rassen JA, 2009, AM J EPIDEMIOL, V169, P273, DOI 10.1093/aje/kwn299; Redding R., 2015, 2015 NCAA FOOTBALL R; Riley DO, 2015, BRAIN INJURY, V29, P154, DOI 10.3109/02699052.2014.965215; Riley Edward T., J NEUROTRAUMA; Robbins CA, 2014, OPEN ACCESS J SPORTS, V5, P99, DOI 10.2147/OAJSM.S58005; Robinson ME, 2015, DEV NEUROPSYCHOL, V40, P74, DOI 10.1080/87565641.2015.1012204; Scheibel RS, 2009, J NEUROTRAUM, V26, P1447, DOI 10.1089/neu.2008.0736; Schneeweiss S, 2006, ARTHRITIS RHEUM-US, V54, P3390, DOI 10.1002/art.22219; Seichepine DR, 2013, J NEUROTRAUM, V30, P1299, DOI 10.1089/neu.2012.2690; Singh R, 2014, JAMA-J AM MED ASSOC, V311, P1883, DOI 10.1001/jama.2014.3313; Smith PJ, 2013, MENT HEALTH PHYS ACT, V6, P139, DOI 10.1016/j.mhpa.2013.06.008; Stamm JM, 2015, J NEUROTRAUM, V32, P1768, DOI 10.1089/neu.2014.3822; Stamm JM, 2015, NEUROLOGY, V84, P1114, DOI 10.1212/WNL.0000000000001358; Stein TD, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0522-z; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Stiller JW, 2014, FRONT PUBLIC HEALTH, V2, DOI 10.3389/fpubh.2014.00069; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Tun PA, 2006, AGE AGEING, V35, P629, DOI 10.1093/ageing/afl095; Vynorius KC, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00188; Waid-Ebbs JK, 2012, BRAIN INJURY, V26, P1646, DOI 10.3109/02699052.2012.700087; Wang PS, 2005, NEW ENGL J MED, V353, P2335, DOI 10.1056/NEJMoa052827; Wilson RS, 2005, NEUROEPIDEMIOLOGY, V25, P19, DOI 10.1159/000085309; Winship C, 1999, ANNU REV SOCIOL, V25, P659, DOI 10.1146/annurev.soc.25.1.659	119	199	199	14	143	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2017	34	2					328	+		10.1089/neu.2016.4413			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EH4QD	WOS:000391754800008	27029716	Green Published	Y	N	2021-06-18	
J	Wang, GH; Shi, YJ; Jiang, XY; Leak, RK; Hu, XM; Wu, Y; Pu, HJ; Li, WW; Tang, B; Wang, Y; Gao, YQ; Zheng, P; Bennett, MVL; Chen, J				Wang, Guohua; Shi, Yejie; Jiang, Xiaoyan; Leak, Rehana K.; Hu, Xiaoming; Wu, Yun; Pu, Hongjian; Li, Wei-Wei; Tang, Bo; Wang, Yun; Gao, Yanqin; Zheng, Ping; Bennett, Michael V. L.; Chen, Jun			HDAC inhibition prevents white matter injury by modulating microglia/macrophage polarization through the GSK3 beta/PTEN/Akt axis	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						traumatic brain injury; oligodendrocyte; microglial polarization; myelination; inflammation	TRAUMATIC BRAIN-INJURY; MICROGLIA; ACTIVATION; NEUROPROTECTION; DEGENERATION; INFLAMMATION; CHALLENGES; ISCHEMIA; DYNAMICS; DAMAGE	Severe traumatic brain injury (TBI) elicits destruction of both gray and white matter, which is exacerbated by secondary proinflammatory responses. Although white matter injury (WMI) is strongly correlated with poor neurological status, the maintenance of white matter integrity is poorly understood, and no current therapies protect both gray and white matter. One candidate approach that may fulfill this role is inhibition of class I/II histone deacetylases (HDACs). Here we demonstrate that the HDAC inhibitor Scriptaid protects white matter up to 35 d after TBI, as shown by reductions in abnormally dephosphorylated neurofilament protein, increases in myelin basic protein, anatomic preservation of myelinated axons, and improved nerve conduction. Furthermore, Scriptaid shifted microglia/macrophage polarization toward the protective M2 phenotype and mitigated inflammation. In primary cocultures of microglia and oligodendrocytes, Scriptaid increased expression of microglial glycogen synthase kinase 3 beta (GSK3 beta), which phosphorylated and inactivated phosphatase and tensin homologue (PTEN), thereby enhancing phosphatidylinositide 3-kinases (PI3K)/Akt signaling and polarizing microglia toward M2. The increase in GSK3 beta in microglia and their phenotypic switch to M2 was associated with increased preservation of neighboring oligodendrocytes. These findings are consistent with recent findings that microglial phenotypic switching modulates white matter repair and axonal remyelination and highlight a previously unexplored role for HDAC activity in this process. Furthermore, the functions of GSK3 beta may be more subtle than previously thought, in that GSK3 beta can modulate microglial functions via the PTEN/PI3K/Akt signaling pathway and preserve white matter homeostasis. Thus, inhibition of HDACs in microglia is a potential future therapy in TBI and other neurological conditions with white matter destruction.	[Wang, Guohua; Jiang, Xiaoyan; Pu, Hongjian; Li, Wei-Wei; Tang, Bo; Wang, Yun; Gao, Yanqin; Zheng, Ping; Chen, Jun] Fudan Univ, State Key Lab Med Neurobiol, Shanghai 200032, Peoples R China; [Wang, Guohua; Jiang, Xiaoyan; Pu, Hongjian; Li, Wei-Wei; Tang, Bo; Wang, Yun; Gao, Yanqin; Zheng, Ping; Chen, Jun] Fudan Univ, Inst Brain Sci, Shanghai 200032, Peoples R China; [Wang, Guohua; Shi, Yejie; Hu, Xiaoming; Wu, Yun; Pu, Hongjian; Gao, Yanqin; Chen, Jun] Univ Pittsburgh, Ctr Cerebrovasc Dis Res, Pittsburgh, PA 15213 USA; [Shi, Yejie; Hu, Xiaoming; Wu, Yun; Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15261 USA; [Leak, Rehana K.] Duquesne Univ, Mylan Sch Pharm, Div Pharmaceut Sci, Pittsburgh, PA 15282 USA; [Bennett, Michael V. L.] Albert Einstein Coll Med, Dominick P Purpura Dept Neurosci, Bronx, NY 10461 USA	Bennett, MVL (corresponding author), Albert Einstein Coll Med, Dominick P Purpura Dept Neurosci, Bronx, NY 10461 USA.	michael.bennett@einstein.yu.edu; chenj2@upmc.edu	Pu, Hongjian/AAW-3322-2020; Gao, Yanqin/I-6790-2016; Leak, Rehana K/I-2607-2019; Shi, Yejie/C-2355-2018	Gao, Yanqin/0000-0002-4915-9819; Leak, Rehana K/0000-0003-2817-7417; Shi, Yejie/0000-0001-7502-9201; Wang, Guohua/0000-0002-4810-8534	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS36736, NS43802, NS45048, NS45287]; US Department of Veterans Affairs Research Career Scientist AwardUS Department of Veterans Affairs; Chinese Natural Science FoundationNational Natural Science Foundation of China (NSFC) [81020108021, 81171149, 81371306, 81000497, 81471257, 81228008]; PhD Training Grant [20120071110042]; Ministry of Education of the People's Republic of China Talent Training Fellowship Grant [J1210041]; State Administration of Foreign Experts Affairs High-End Distinguished Professorship Grant [GDW20133100069]; Hillman Foundation Award; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045048, R01NS043802, R01NS045287, R01NS036736] Funding Source: NIH RePORTER	This research was supported by National Institutes of Health Grants NS36736, NS43802, and NS45048 (to J.C.) and NS45287 (to M.V.L.B.); US Department of Veterans Affairs Research Career Scientist Award (to J.C.); Chinese Natural Science Foundation Grants 81020108021, 81171149, and 81371306 (to Y.G.), 81000497 and 81471257 (to G.W.), and 81228008 (to J.C. and P.Z.), and PhD Training Grant 20120071110042 (to J.C.); Ministry of Education of the People's Republic of China Talent Training Fellowship Grant J1210041 (to B.T.); and State Administration of Foreign Experts Affairs High-End Distinguished Professorship Grant GDW20133100069 (to M.V.L.B.). R.K.L. is supported by a Hillman Foundation Award.	Adcock IM, 2007, BRIT J PHARMACOL, V150, P829, DOI 10.1038/sj.bjp.0707166; Betz J, 2012, J NEUROTRAUM, V29, P1292, DOI 10.1089/neu.2011.2215; Boche D, 2013, NEUROPATH APPL NEURO, V39, P3, DOI 10.1111/nan.12011; Borgens RB, 2012, Q REV BIOL, V87, P89, DOI DOI 10.1086/665457; Cohen MV, 2011, ANTIOXID REDOX SIGN, V14, P821, DOI 10.1089/ars.2010.3318; Cohen P, 2004, NAT REV DRUG DISCOV, V3, P479, DOI 10.1038/nrd1415; Dash PK, 2009, NEUROSCIENCE, V163, P1, DOI 10.1016/j.neuroscience.2009.06.028; Dash PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011383; Hellyer PJ, 2013, ANN NEUROL, V73, P489, DOI 10.1002/ana.23824; Hu XM, 2015, NAT REV NEUROL, V11, P56, DOI 10.1038/nrneurol.2014.207; Hu XM, 2012, STROKE, V43, P3063, DOI 10.1161/STROKEAHA.112.659656; Jin XM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041892; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kannan V, 2013, J NEUROSCI RES, V91, P1133, DOI 10.1002/jnr.23221; Kim HJ, 2014, AM J TRANSL RES, V6, P206; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Lazo-Gomez R, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00243; Liu XS, 2012, NEUROSCIENCE, V220, P313, DOI 10.1016/j.neuroscience.2012.06.012; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Maciejewski-Lenoir D, 1999, J IMMUNOL, V163, P1628; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Miron VE, 2013, NAT NEUROSCI, V16, P1211, DOI 10.1038/nn.3469; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Seira O, 2014, MOL NEUROBIOL, V49, P931, DOI 10.1007/s12035-013-8571-y; Shein NA, 2009, FASEB J, V23, P4266, DOI 10.1096/fj.09-134700; Sleiman SF, 2009, EXPERT OPIN INV DRUG, V18, P573, DOI [10.1517/13543780902810345, 10.1517/13543780902810345 ]; Spitz G, 2013, BRAIN TOPOGR, V26, P648, DOI 10.1007/s10548-013-0283-0; Wang GH, 2011, J NEUROTRAUM, V28, P2123, DOI 10.1089/neu.2011.1939; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Wang GH, 2013, NEUROTHERAPEUTICS, V10, P124, DOI 10.1007/s13311-012-0157-2; Yu FS, 2013, J NEUROSURG, V119, P766, DOI 10.3171/2013.6.JNS13135; Zhang B, 2008, BRAIN RES, V1226, P181, DOI 10.1016/j.brainres.2008.05.085	33	199	212	2	59	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	MAR 3	2015	112	9					2853	2858		10.1073/pnas.1501441112			6	Multidisciplinary Sciences	Science & Technology - Other Topics	CC3DK	WOS:000350224900065	25691750	Other Gold, Green Published	Y	N	2021-06-18	
J	Babcock, L; Byczkowski, T; Wade, SL; Ho, M; Mookerjee, S; Bazarian, JJ				Babcock, Lynn; Byczkowski, Terri; Wade, Shari L.; Ho, Mona; Mookerjee, Sohug; Bazarian, Jeffrey J.			Predicting Postconcussion Syndrome After Mild Traumatic Brain Injury in Children and Adolescents Who Present to the Emergency Department	JAMA PEDIATRICS			English	Article							POST-CONCUSSION SYMPTOMS; ROUTINE FOLLOW-UP; HEAD-INJURY; FAMILY BURDEN; HIGH-SCHOOL; EPIDEMIOLOGY; RECOVERY; IMPACT	Objective: To determine the acute predictors associated with the development of postconcussion syndrome (PCS) in children and adolescents after mild traumatic brain injury. Design: Retrospective analysis of a prospective observational study. Setting: Pediatric emergency department (ED) in a children's hospital. Participants: Four hundred six children and adolescents aged 5 to 18 years. Main Exposure: Closed head trauma. Main Outcome Measures: The Rivermead Post Concussion Symptoms Questionnaire administered 3 months after the injury. Results: Of the patients presenting to the ED with mild traumatic brain injury, 29.3% developed PCS. The most frequent PCS symptom was headache. Predictors of PCS, while controlling for other factors, were being of adolescent age, headache on presentation to the ED, and admission to the hospital. Patients who developed PCS missed a mean (SD) of 7.4 (13.9) days of school. Conclusions: Adolescents who have headache on ED presentation and require hospital admission at the ED encounter are at elevated risk for PCS after mild traumatic brain injury. Interventions to identify this population and begin early treatment may improve outcomes and reduce the burden of disease. JAMA Pediatr. 2013; 167(2): 156-161. Published online December 17, 2012. doi: 10.1001/jamapediatrics.2013.434	[Babcock, Lynn; Byczkowski, Terri; Ho, Mona] Cincinnati Childrens Hosp Med Ctr, Div Emergency Med, Cincinnati, OH 45229 USA; [Wade, Shari L.] Cincinnati Childrens Hosp Med Ctr, Div Phys Med & Rehabil, Cincinnati, OH 45229 USA; [Mookerjee, Sohug; Bazarian, Jeffrey J.] Univ Rochester, Med Ctr, Dept Emergency Med, Rochester, NY 14642 USA	Babcock, L (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Emergency Med, 3333 Burnet Ave,ML 2008, Cincinnati, OH 45229 USA.	lynn.babcock@cchmc.org		Babcock, Lynn/0000-0002-2658-6893	National Institute of Neurological Disorders and Stroke, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23 NS41952-02]; University of Cincinnati Center for Clinical and Translational Science and Training; Division of Emergency Medicine at Cincinnati Children's Hospital Medical Center; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2TR000078, UL1TR000077] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS041952] Funding Source: NIH RePORTER	This study was supported in part by Career Development Award K23 NS41952-02 from the National Institute of Neurological Disorders and Stroke, National Institutes of Health (Dr Bazarian); by the KL2 Mentored Career Development Program in Clinical and Translational Research from the University of Cincinnati Center for Clinical and Translational Science and Training (Dr Babcock); and by the Division of Emergency Medicine at Cincinnati Children's Hospital Medical Center.	Aitken ME, 2009, PEDIATRICS, V123, P199, DOI 10.1542/peds.2008-0607; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Beers SR, 2007, J NEUROTRAUM, V24, P97, DOI 10.1089/neu.2006.0055; Bergman DA, 1999, PEDIATRICS, V104, P1407; Blume HK, 2012, PEDIATRICS, V129, pE31, DOI 10.1542/peds.2011-1742; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FAY GC, 1993, ARCH PHYS MED REHAB, V74, P895; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Ganesalingam K, 2008, J PEDIATR PSYCHOL, V33, P621, DOI 10.1093/jpepsy/jsm133; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; Hooper SR, 2004, NEUROREHABILITATION, V19, P175; Hosmer D. W., 2000, APPL LOGISTIC REGRES; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Koepsell TD, 2011, PEDIATRICS, V128, P946, DOI 10.1542/peds.2010-2259; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau BC, 2011, AM J SPORT MED, V39, P2311, DOI 10.1177/0363546511410655; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Nigrovic LE, 2012, ARCH PEDIAT ADOL MED, V166, P356, DOI 10.1001/archpediatrics.2011.1156; Ponsford J, 2005, CURR OPIN NEUROL, V18, P692, DOI 10.1097/01.wco.0000186840.61431.44; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Wade DT, 1997, J NEUROL NEUROSUR PS, V62, P478, DOI 10.1136/jnnp.62.5.478; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Yeates KO, 2012, ARCH PEDIAT ADOL MED, V166, P615, DOI 10.1001/archpediatrics.2011.1082; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056	32	199	199	0	35	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6203	2168-6211		JAMA PEDIATR	JAMA Pediatr.	FEB	2013	167	2					156	161		10.1001/jamapediatrics.2013.434			6	Pediatrics	Pediatrics	115FQ	WOS:000316798400009	23247384	Green Accepted, Bronze	Y	N	2021-06-18	
J	Shitaka, Y; Tran, HT; Bennett, RE; Sanchez, L; Levy, MA; Dikranian, K; Brody, DL				Shitaka, Yoshitsugu; Tran, Hien T.; Bennett, Rachel E.; Sanchez, Laura; Levy, Marilyn A.; Dikranian, Krikor; Brody, David L.			Repetitive Closed-Skull Traumatic Brain Injury in Mice Causes Persistent Multifocal Axonal Injury and Microglial Reactivity	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Axonal injury; Electron microscopy; Microglia; Mouse; Repetitive concussion; Silver staining; Traumatic brain injury	CONTROLLED CORTICAL IMPACT; AMYLOID PRECURSOR PROTEIN; MILD HEAD-INJURY; COGNITIVE IMPAIRMENT; EXPLOSIVE BLAST; UNITED-STATES; MOUSE MODEL; VULNERABILITY; PERFORMANCE; FOOTBALL	Repetitive mild or "concussive" traumatic brain injury (TBI) can cause substantial neurologic impairment, but the pathological features of this type of injury are not fully understood. We report an experimental model of TBI in which the closed skulls of anesthetized male C57BL/6J mice are struck with an electromagnetically controlled rubber impactor twice with an interval of 24 hours between impacts. The mice had deficits in Morris water maze performance in the first week after injury that only partially resolved 7 weeks later. By routine histology, there was no apparent bleeding, neuronal cell loss, or tissue disruption, and amyloid precursor protein immunohistochemistry demonstrated very few immunoreactive axonal varicosities. In contrast, silver staining revealed extensive abnormalities in the corpus callosum and bilateral external capsule, the ipsilateral cortex and thalamus, and the contralateral hippocampal CA1 stratum radiatum and stratum oriens. Electron microscopy of white matter regions demonstrated axonal cytoskeletal disruption, intra-axonal organelle compaction, and irregularities in axon caliber. Reactive microglia were observed in the same areas as the injured axons by both electron microscopy and Iba1 immunohistochemistry. Quantitative analyses of silver staining and Iba1 immunohistochemistry at multiple time points demonstrated transient cortical and thalamic abnormalities but persistent white matter pathology as late as 7 weeks after injury. Thus, prominent and long-lasting abnormalities in this TBI model were underestimated using conventional approaches. The model may be useful for mechanistic investigations and preclinical assessment of candidate therapeutics.	[Shitaka, Yoshitsugu; Tran, Hien T.; Bennett, Rachel E.; Sanchez, Laura; Brody, David L.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Shitaka, Yoshitsugu] Astellas Pharma Inc, Pharmacol Res Labs, Dept Neurosci, Drug Discovery Res, Tsukuba, Ibaraki, Japan; [Levy, Marilyn A.] Washington Univ, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; [Dikranian, Krikor] Washington Univ, Dept Anat & Neurobiol, St Louis, MO 63110 USA; [Brody, David L.] Washington Univ, Hope Ctr Neurol Disorders, St Louis, MO 63110 USA	Brody, DL (corresponding author), Washington Univ, Sch Med, Dept Neurol, 660 S Euclid Ave, St Louis, MO 63110 USA.	brodyd@neuro.wustl.edu	Bennett, Rachel/AAU-6949-2020		Burroughs Wellcome FundBurroughs Wellcome Fund; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K08 NS049237, R01 NS065069]; Astellas Pharma, IncAstellas Pharmaceuticals; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS049237, R01NS065069] Funding Source: NIH RePORTER	Supported by Burroughs Wellcome Fund and the National Institutes of Health (grants K08 NS049237 and R01 NS065069). Yoshitsugu Shitaka's effort was supported by Astellas Pharma, Inc, while he was a visiting scientist.	Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Conte V, 2004, J NEUROCHEM, V90, P758, DOI 10.1111/j.1471-4159.2004.02560.x; CRAWLEY JN, 2000, WHATS WRONG MY MOUSE, pCH6; Creeley CE, 2004, ACAD EMERG MED, V11, P809, DOI 10.1197/j.aem.2004.03.006; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Edwards P, 2005, LANCET, V365, P1957; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Franklin KBJ, 2001, MOUSE BRAIN STEREOTA; Galarneau MR, 2008, J NEUROSURG, V108, P950, DOI 10.3171/JNS/2008/108/5/0950; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Kanayama G, 1996, METHOD FIND EXP CLIN, V18, P105; Kigerl KA, 2009, J NEUROSCI, V29, P13435, DOI 10.1523/JNEUROSCI.3257-09.2009; Kim HS, 2009, BEHAV BRAIN RES, V196, P168, DOI 10.1016/j.bbr.2008.09.040; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Muller GJ, 2001, EXP BRAIN RES, V141, P380, DOI 10.1007/s002210100879; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Perlbarg V, 2009, HUM BRAIN MAPP, V30, P3924, DOI 10.1002/hbm.20817; Perry VH, 2010, NAT REV NEUROL, V6, P193, DOI 10.1038/nrneurol.2010.17; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Shapiro LA, 2009, BRAIN RES, V1266, P29, DOI 10.1016/j.brainres.2009.02.031; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Van Boven RW, 2009, J REHABIL RES DEV, V46, P717, DOI 10.1682/JRRD.2008.12.0161; Venneti S, 2009, J NEUROIMMUNE PHARM, V4, P227, DOI 10.1007/s11481-008-9142-2	49	199	200	1	21	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-3069			J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	JUL	2011	70	7					551	567		10.1097/NEN.0b013e31821f891f			17	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	779NN	WOS:000291785100001	21666502	Bronze, Green Accepted			2021-06-18	
J	Helmy, A; Carpenter, KLH; Menon, DK; Pickard, JD; Hutchinson, PJA				Helmy, Adel; Carpenter, Keri L. H.; Menon, David K.; Pickard, John D.; Hutchinson, Peter J. A.			The cytokine response to human traumatic brain injury: temporal profiles and evidence for cerebral parenchymal production	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						arterio-jugular venous difference; brain trauma; chemokines; cytokine; inflammation; microdialysis	MULTIPLEX ASSESSMENT; INTENSIVE-CARE; MICRODIALYSIS; INFLAMMATION; INTERLEUKIN-1-BETA; MECHANISMS; CHILDREN	The role of neuroinflammation is increasingly being recognised in a diverse range of cerebral pathologies, including traumatic brain injury (TBI). We used cerebral microdialysis and paired arterial and jugular bulb plasma sampling to characterise the production of 42 cytokines after severe TBI in 12 patients over 5 days. We compared two microdialysis perfusates in six patients: central nervous system perfusion fluid and 3.5% human albumin solution (HAS); 3.5% HAS has a superior fluid recovery (95.8 versus 83.3%), a superior relative recovery in 18 of 42 cytokines (versus 8 of 42), and a qualitatively superior recovery profile. All 42 cytokines were recovered from the human brain. Sixteen cytokines showed a stereotyped temporal peak, at least twice the median value for that cytokine over the monitoring period; day 1: tumour necrosis factor, interleukin (IL) 7, IL8, macrophage inflammatory protein (MIP)1 alpha, soluble CD40 ligand, GRO, IL1 beta, platelet derived growth factor (PDGF)-AA, MIP1 beta, RANTES; day 2: IL1 receptor antagonist (ra). IL6, granulocyte-colony stimulating factor (G-CSF), chemokine CXC motif ligand 10 (IP10); days 4 to 5: IL12p70, IL10. Brain extracellular fluid concentrations were significantly higher than plasma concentrations for 19 cytokines: basic fibroblast growth factor (FGF2), G-CSF, IL1 alpha, IL1 beta, IL1ra, IL3, IL6, IL8, IL10, IL12p40, IL12p70, IP10, monocyte chemotactic protein (MCP)1, MCP3, MIP1 alpha, MIP1 beta, PDGF-AA, transforming growth factor (TGF)alpha and vascular endothelial growth factor. No clear arterio-jugular venous gradients were apparent. These data provide evidence for the cerebral production of these cytokines and show a stereotyped temporal pattern after TBI. Journal of Cerebral Blood Flow & Metabolism (2011) 31, 658-670; doi: 10.1038/jcbfm.2010.142; published online 18 August 2010	[Helmy, Adel; Carpenter, Keri L. H.; Pickard, John D.; Hutchinson, Peter J. A.] Univ Cambridge, Div Neurosurg, Dept Clin Neurosci, Cambridge CB2 0QQ, England; [Carpenter, Keri L. H.; Menon, David K.; Pickard, John D.; Hutchinson, Peter J. A.] Univ Cambridge, Wolfson Brain Imaging Ctr, Dept Clin Neurosci, Cambridge CB2 0QQ, England; [Menon, David K.] Univ Cambridge, Dept Med, Div Anaesthesia, Cambridge CB2 0QQ, England	Helmy, A (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Div Neurosurg, Box 167,Hills Rd, Cambridge CB2 0QQ, England.	adelhelmy@cantab.net	Helmy, Adel/AAS-3084-2020	Helmy, Adel/0000-0002-0531-0556; Carpenter, Keri/0000-0001-8236-7727	Medical Research Council/Royal College of Surgeons of EnglandUK Research & Innovation (UKRI)Medical Research Council UK (MRC); Raymond and Beverly Sackler Fellowship; National Institute of Health Research Biomedical Research Centre, CambridgeNational Institute for Health Research (NIHR); Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission; Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390 ID 65883, G0600986 ID 79068]; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986, G9439390, G0802251] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [ACF-2006-14-004] Funding Source: researchfish	AH is supported by a joint Medical Research Council/Royal College of Surgeons of England Clinical Research Training Fellowship and a Raymond and Beverly Sackler Fellowship. KLHC is supported by the National Institute of Health Research Biomedical Research Centre, Cambridge and by the Medical Research Council (Acute Brain Injury Programme Grant). PJAH is supported by the Academy of Medical Sciences/Health Foundation Senior Surgical Scientist Fellowship. Study support was provided by the Medical Research Council (grant numbers G9439390 ID 65883 and G0600986 ID 79068).	Banks WA, 2010, NEUROBIOL DIS, V37, P26, DOI 10.1016/j.nbd.2009.07.031; Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; Berger RP, 2009, PEDIATR RES, V65, P97, DOI 10.1203/PDR.0b013e31818c7e27; Buttram SDW, 2007, J NEUROTRAUM, V24, P1707, DOI 10.1089/neu.2007.0349; Chiaretti A, 2008, J NEUROTRAUM, V25, P225, DOI 10.1089/neu.2007.0405; Clark SR, 2008, J CEREBR BLOOD F MET, V28, P387, DOI 10.1038/sj.jcbfm.9600537; CZOSNYKA M, 1994, INT J CLIN MONIT COM, V11, P223, DOI 10.1007/BF01139874; Czosnyka M, 2009, NEUROCRIT CARE, V10, P373, DOI 10.1007/s12028-008-9175-7; Denes A, 2010, BRAIN BEHAV IMMUN, V24, P708, DOI 10.1016/j.bbi.2009.09.010; Fassbender K, 2000, NEUROSCI LETT, V284, P135, DOI 10.1016/S0304-3940(00)00977-0; Folkersma H, 2008, ACTA NEUROCHIR, V150, P1277, DOI 10.1007/s00701-008-0151-y; Gentleman SM, 2004, FORENSIC SCI INT, V146, P97, DOI 10.1016/j.forsciint.2004.06.027; Goodman JC, 2008, ACTA NEUROCHIR SUPPL, V102, P437, DOI 10.1007/978-3-211-85578-2_85; Graetz D, 2009, NEUROL RES      0813; Hailer NP, 2008, PROG NEUROBIOL, V84, P211, DOI 10.1016/j.pneurobio.2007.12.001; Hamrin K, 2002, J APPL PHYSIOL, V92, P385; Helmy A, 2007, BRIT J ANAESTH, V99, P32, DOI 10.1093/bja/aem139; Helmy A, 2007, CURR MED CHEM, V14, P1525, DOI 10.2174/092986707780831113; Helmy A, 2010, ACTA NEUROCHIR, V152, P953, DOI 10.1007/s00701-009-0584-y; Helmy A, 2009, J NEUROTRAUM, V26, P549, DOI 10.1089/neu.2008.0719; Hillman J, 2005, NEUROSURGERY, V56, P1264, DOI 10.1227/01.NEU.0000159711.93592.8D; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; Macmillan CSA, 2000, INTENS CARE MED, V26, P1028, DOI 10.1007/s001340051315; Maurer Martin H, 2003, Proteome Sci, V1, P7, DOI 10.1186/1477-5956-1-7; McKeating EG, 1997, BRIT J ANAESTH, V78, P520; Mellergard P, 2008, NEUROSURGERY, V62, P151, DOI 10.1227/01.NEU.0000311072.33615.3A; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Robertson CL, 2009, EXP NEUROL, V218, P371, DOI 10.1016/j.expneurol.2009.04.030; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Schultzberg M, 2007, PHYSIOL BEHAV, V92, P121, DOI 10.1016/j.physbeh.2007.05.050; Shiozaki T, 2005, SHOCK, V23, P406, DOI 10.1097/01.shk.0000161385.62758.24; Sykova E, 2008, PHYSIOL REV, V88, P1277, DOI 10.1152/physrev.00027.2007; Tsakiri N, 2008, MOL CELL NEUROSCI, V38, P259, DOI 10.1016/j.mcn.2008.02.015; UNGERSTEDT U, 1991, J INTERN MED, V230, P365, DOI 10.1111/j.1365-2796.1991.tb00459.x; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; YAN HQ, 1992, EUR J IMMUNOL, V22, P2963, DOI 10.1002/eji.1830221131; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001	38	199	200	0	15	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	FEB	2011	31	2					658	670		10.1038/jcbfm.2010.142			13	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	715XY	WOS:000286930100027	20717122	Green Published, Bronze			2021-06-18	
J	Longhi, L; Saatman, KE; Fujimoto, S; Raghupathi, R; Meaney, DF; Davis, J; McMillan, A; Conte, V; Laurer, HL; Stein, S; Stocchetti, N; McIntosh, TK				Longhi, L; Saatman, KE; Fujimoto, S; Raghupathi, R; Meaney, DF; Davis, J; McMillan, A; Conte, V; Laurer, HL; Stein, S; Stocchetti, N; McIntosh, TK			Temporal window of vulnerability to repetitive experimental concussive brain injury	NEUROSURGERY			English	Article						axional injury; cognition; concussion; microtubule-associated protein-2; repetitive brain injury	COLLEGIATE FOOTBALL PLAYERS; SPORT-RELATED CONCUSSION; MILD HEAD-INJURY; PROFESSIONAL FOOTBALL; CEREBRAL CONCUSSION; AXONAL INJURY; FLUORO-JADE; TIME-COURSE; CONVULSIONS; EDEMA	OBJECTIVE: Repetitive concussive brian injury (CBI) is associated with cognitive alterations and increased risk of neurodegenerative disease. METHODS: To evaluate the temporal window during which the concussed brain remains vulnerable to a second concussion, anesthetized mice were subjected to either sham injury or single or repetitive CBI (either 3, 5, or 7 days apart) using a clinically relevant model of CBI. Cognitive, vestibular, and sensorimotor function (balance and coordination) were evaluated, and postmortem histological analyses were performed to detect neuronal degeneration, cytoskeletal proteolysis, and axonal injury. RESULTS: No cognitive deficits were observed in sham-injured animals or those concussed once. Mice subjected to a second concussion within 3 or 5 days exhibited significantly impaired cognitive function compared with either sham-injured animals (P < 0.05) or mice receiving a single concussion (P < 0.01). No cognitive deficits were observed when the interconcussion interval was extended to 7 days, suggestive of a transient vulnerability of the brain during the first 5 days after an initial concussion. Although all concussed mice showed transient motor deficits, vestibulomotor dysfunction was more pronounced in the group that sustained two concussions 3 days apart (P < 0.01 compared with all other groups). Although scattered degenerating neurons, evidence of cytoskeletal damage, and axonal injury were detected in selective brain regions between 72 and 1 week after injury in all animals sustaining a single concussion, the occurrence of a second concussion 3 days later resulted in significantly greater traumatic axonal injury (P < 0.05) than that resulting from a single CBI. CONCLUSION: These data suggest that a single concussion is associated with behavioral dysfunction and subcellular alterations that may contribute to a transiently vulnerable state during which a second concussion within 3 to 5 days can lead to exacerbated and more prolonged axonal damage and greater behavioral dysfunction.	IRCCS, Osped Maggiore Policlin, Dept Anesthesia & Crit Care Med, Neurosurg Intens Care Unit, I-20122 Milan, Italy; Univ Penn, Dept Neurosurg, Traumat Brain Injury Lab, Philadelphia, PA 19104 USA; Drexel Univ, Coll Med, Dept Neurobiol & Anat, Philadelphia, PA 19104 USA; Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; Goethe Univ Frankfurt, Dept Trauma Surg, D-6000 Frankfurt, Germany; Vet Adm Med Ctr, Philadelphia, PA 19104 USA	Longhi, L (corresponding author), IRCCS, Osped Maggiore Policlin, Dept Anesthesia & Crit Care Med, Neurosurg Intens Care Unit, Via Sforza 35, I-20122 Milan, Italy.	lucalonghi@policlinico.mi.it	Stocchetti, Nino/O-7444-2017; Longhi, Luca/AAF-9903-2021	Stocchetti, Nino/0000-0003-3250-6834; Longhi, Luca/0000-0001-9894-8788; Meaney, David/0000-0002-0954-4122	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040978, P50NS008803, R01NS041561] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS-41561, P50-NS-08803, R01-NS-40978] Funding Source: Medline		Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bagley LJ, 2000, J MAGN RESON IMAGING, V11, P1, DOI 10.1002/(SICI)1522-2586(200001)11:1<1::AID-JMRI1>3.0.CO;2-H; Bailes JE, 2001, NEUROSURGERY, V48, P26, DOI 10.1097/00006123-200101000-00005; Bareyre F, 1997, J NEUROTRAUM, V14, P839, DOI 10.1089/neu.1997.14.839; *C NEUR SURG, 1966, CLIN NEUROSURG, V12, P386; Cantu RC, 1996, BRIT J SPORT MED, V30, P289, DOI 10.1136/bjsm.30.4.289; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cantu RC, 2003, NEUROSURGERY, V52, P846, DOI 10.1227/01.NEU.0000053210.76063.E4; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; Capruso D. X., 2000, HEAD INJURY, P525; Carbonell WS, 1998, J NEUROTRAUM, V15, P217, DOI 10.1089/neu.1998.15.217; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Colombo JA, 2002, J HISTOCHEM CYTOCHEM, V50, P1135, DOI 10.1177/002215540205000815; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; Grindel SH, 2001, CLIN J SPORT MED, V11, P134, DOI 10.1097/00042752-200107000-00003; GRONWALL D, 1975, LANCET, V2, P995; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Imai H, 2002, J CEREBR BLOOD F MET, V22, P1080, DOI 10.1097/00004647-200209000-00005; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Johnston KM, 2001, CLIN J SPORT MED, V11, P166, DOI 10.1097/00042752-200107000-00007; Kelly J, 1997, JAMA-J AM MED ASSOC, V277, P1190; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Laurer HL, 1999, CURR OPIN NEUROL, V12, P715, DOI 10.1097/00019052-199912000-00010; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Macciocchi SN, 1998, CLIN SPORT MED, V17, P27, DOI 10.1016/S0278-5919(05)70058-2; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory PR, 2000, NEUROLOGY, V54, P1488, DOI 10.1212/WNL.54.7.1488; McCrory PR, 1997, BRIT MED J, V314, P171, DOI 10.1136/bmj.314.7075.171; McCrory PR, 1998, SPORTS MED, V25, P131, DOI 10.2165/00007256-199825020-00005; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Perron AD, 2001, ACAD EMERG MED, V8, P296, DOI 10.1111/j.1553-2712.2001.tb01312.x; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Stephenson J, 1997, BRIT MED J, V314, P1283, DOI 10.1136/bmj.314.7089.1283a; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zanier ER, 2003, J NEUROTRAUM, V20, P409, DOI 10.1089/089771503765355496	64	199	199	1	22	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	FEB	2005	56	2					364	373		10.1227/01.NEU.0000149008.73513.44			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	895UO	WOS:000226889400035	15670384				2021-06-18	
J	Seel, RT; Kreutzer, JS; Rosenthal, M; Hammond, FM; Corrigan, JD; Black, K				Seel, RT; Kreutzer, JS; Rosenthal, M; Hammond, FM; Corrigan, JD; Black, K			Depression after traumatic brain injury: A national institute on disability and rehabilitation research model systems multicenter investigation	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; depression; rehabilitation; treatment outcome	MINOR HEAD-INJURIES; EMOTIONAL SEQUELAE; DISORDERS; RELATIVES; INVENTORY; SYMPTOMS; ANXIETY; MOOD	Objective: To identify the frequency and manifestations of depression after traumatic brain injury (TBI) and the factors that contribute to developing this mood disorder. Design: A prospective, nationwide, multicenter study; 17 centers supplied data from medical records and patient responses on a standardized criterion instrument. Setting: Traumatic Brain Injury Model Systems programs. Participants: A demographically diverse sample of 666 outpatients with TBI was evaluated 10 to 126 months after injury. Interventions: Not applicable. Main Outcome Measures: Depressive symptoms were characterized with the Neurobehavioral Functioning Inventory by using the Diagnostic and Statistical Manual of Mental Disorders (4th ed; DSM-IV) diagnostic framework. Analysis of variance and Pearson correlations were used to identify factors that were significantly related to depression. Results: Fatigue (29%), distractibility (28%), anger or irritability (28%), and rumination (25%) were the most commonly cited depressive symptoms in the sample. Twenty-seven percent of patients with TBI met the prerequisite number (greater than or equal to5) of criterion A symptoms for a DSM-IV diagnosis of major depressive disorder. Feeling hopeless, feeling worthless, and difficulty enjoying activities were the 3 symptoms that most differentiated depressed from nondepressed patients. Patients who were unemployed at the time of injury and who were impoverished were significantly more likely to report DSM-IV criterion A symptoms than patients who were employed, were students, or were retired due to age. Time after injury, injury severity, and postinjury marital status were not significantly related to depression. Conclusions: Patients with TBI are at great risk for developing depressive symptoms. Findings provide empirical support for the inclusion of depression evaluation and treatment protocols in brain injury programs. Unemployment and poverty may be substantial risk factors for the development of depressive symptoms. Future research should develop biopsychosocial predictive models to identify high-risk patients and examine the efficacy of treatment interventions.	Hunter Holmes McGuire Vet Adm Med Ctr, Def & Vet Brain Injury Ctr, Richmond, VA USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Phys Med & Rehabil, Richmond, VA 23298 USA; Kessler Med Rehabil Res & Educ Corp, W Orange, NJ USA; Charlotte Inst Rehabil, Dept Phys Med & Rehabil, Charlotte, NC USA; Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; Wayne State Univ, Dept Phys Med & Rehabil, Detroit, MI USA	Seel, RT (corresponding author), Vet Adm Med Ctr, Def & Vet Head Injury Program, Dept Phys Med & Rehabil 117, 1201 Broad Rock Blvd, Richmond, VA 23249 USA.		Corrigan, John D./E-2921-2011				Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; ATTEBERRYBENNETT J, 1986, INT J CLIN NEUROPSYC, V8, P114; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; CAVALLO M M, 1992, Brain Injury, V6, P327, DOI 10.3109/02699059209034947; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; Deb S, 1999, AM J PSYCHIAT, V156, P374; DIKMEN S, 1977, ANN NEUROL, V2, P492, DOI 10.1002/ana.410020608; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Kreutzer JS., 1999, NEUROBEHAVIORAL FUNC; LEININGER B E, 1991, Brain Injury, V5, P199, DOI 10.3109/02699059109008090; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; Lezak M. D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI [10.1097/00001199-198703000-00009, DOI 10.1097/00001199-198703000-00009]; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; LINN RT, 1994, BRAIN INJURY, V8, P135, DOI 10.3109/02699059409150965; Livingston MG., 1990, REHABILITATION ADULT, P225; Lykouras L, 1998, PSYCHOPATHOLOGY, V31, P213, DOI 10.1159/000029042; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; RUTHERFORD WH, 1977, LANCET, V1, P1; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; SCHOENHUBER R, 1988, J NEUROL NEUROSUR PS, V51, P722, DOI 10.1136/jnnp.51.5.722; Seel RT, 1997, ARCH PHYS MED REHAB, V78, P1254, DOI 10.1016/S0003-9993(97)90340-3; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Varney NR, 1987, NEUROPSYCHOLOGY, V1, P7, DOI 10.1037//0894-4105.1.1.7; WITOL AD, 1996, J VOCATIONAL REHABIL, V7, P159	40	199	201	0	17	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2003	84	2					177	184		10.1053/apmr.2003.50106			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	643QV	WOS:000180872700005	12601647				2021-06-18	
J	Mahmood, A; Lu, D; Wang, L; Li, Y; Lu, M; Chopp, M				Mahmood, A; Lu, D; Wang, L; Li, Y; Lu, M; Chopp, M			Treatment of traumatic brain injury in female rats with intravenous administration of bone marrow stromal cells	NEUROSURGERY			English	Article						marrow stromal cells; neural transplantation; stem cell; traumatic brain injury	CENTRAL-NERVOUS-SYSTEM; MESENCHYMAL STEM-CELLS; PROGENITOR CELLS; GROWTH-FACTOR; TRANSPLANTATION; OSTEOGENESIS; EXPRESSION; MODEL; CNS; DIFFERENTIATION	OBJECTIVE: To study the effect of bone marrow stromal cells administered intravenously to female rats subjected: to traumatic brain injury. METHODS: We injected marrow stromal cells harvested, from male rat bone marrow (n = 24) into the tail vein of the female rat (n = 8) 24 hours after traumatic brain injury; the rats were killed at Day 7 or 14 after treatment. The neurological function of the rats was evaluated using the rotarod test and the neurological severity score. The distribution of the male donor cells in brain, heart, lung, kidney, liver, muscle, spleen, and bone marrow of the female recipient rats was measured by identifying Y chromosome-positive cells using fluorescent in situ hybridization. RESULTS: We found that marrow stromal cells injected intravenously significantly reduced motor and neurological deficits compared with control groups by Day 15 after traumatic brain injury (P < 0.05, analysis of covariance for repeated measures). The transplanted cells preferentially engrafted into the parenchyma of the injured brain and expressed the neuronal marker NeuN and the astrocytic marker glial fibrillary acidic protein. Marrow stromal cells were also found in other organs in female rats subjected to traumatic brain injury without any obvious adverse effects. CONCLUSION: These data suggest that the intravenous administration of marrow stromal cells may be a promising therapeutic strategy that warrants further investigation for patients with traumatic brain injury.	Henry Ford Hlth Sci Ctr, Dept Neurosurg, Detroit, MI USA; Henry Ford Hlth Sci Ctr, Dept Neurol, Detroit, MI USA; Henry Ford Hlth Sci Ctr, Dept Biostat, Detroit, MI USA	Mahmood, A (corresponding author), Henry Ford Hosp, Dept Neurol, 2799 W Grand Blvd, Detroit, MI 48202 USA.	nsaam@neuro.hfh.edu					An J, 1997, J ANDROL, V18, P289; ANDERSON WF, 1994, HUM GENE THER, V5, P755, DOI 10.1089/hum.1994.5.6-755; Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; BJORKLUND A, 1979, BRAIN RES, V177, P555, DOI 10.1016/0006-8993(79)90472-4; Bjorklund A, 2000, NAT NEUROSCI, V3, P537, DOI 10.1038/75705; Borlongan CV, 1996, NEUROL RES, V18, P297; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Chen JL, 2000, NEUROPHARMACOLOGY, V39, P711, DOI 10.1016/S0028-3908(00)00006-X; CHENG SL, 1994, ENDOCRINOLOGY, V134, P277, DOI 10.1210/en.134.1.277; Clark BR, 1995, ANN NY ACAD SCI, V770, P70, DOI 10.1111/j.1749-6632.1995.tb31044.x; Cohnheim J., 1867, PATH ANAT PHYSL KLIN, V40, P1, DOI DOI 10.1007/BF02968135; DIXON CE, 1991, J NEUROSCI METH, V39, P253; EAVES CJ, 1991, BLOOD, V78, P110; FANG JM, 1995, INT J DEV BIOL, V39, P519; FRIEDENSTEIN AJ, 1987, CELL TISSUE KINET, V20, P263, DOI 10.1111/j.1365-2184.1987.tb01309.x; GERRITSEN WR, 1994, BONE MARROW TRANSPL, V13, P441; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; HEFTI F, 1986, J NEUROSCI, V6, P2155; HICKEY WF, 1988, SCIENCE, V239, P290, DOI 10.1126/science.3276004; Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529; Keating A, 1996, EXP HEMATOL, V24, P180; KEATING A, 1990, EXP HEMATOL, V18, P99; Kennedy DW, 1997, BLOOD, V90, P986, DOI 10.1182/blood.V90.3.986.986_986_993; Koc ON, 2000, J CLIN ONCOL, V18, P307, DOI 10.1200/JCO.2000.18.2.307; KOIDE K, 1993, RESTOR NEUROL NEUROS, V5, P205, DOI 10.3233/RNN-1993-5305; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; KORDOWER JH, 1995, NEW ENGL J MED, V332, P1118, DOI 10.1056/NEJM199504273321702; KRALL WJ, 1994, BLOOD, V83, P2737; KURTH MC, 1996, AM SOC NEUR TRANSPL, V3, P15; LAZARUS HM, 1995, BONE MARROW TRANSPL, V16, P557; Li Y, 2001, CELL TRANSPLANT, V10, P31; Li Y, 2000, J CEREBR BLOOD F MET, V20, P1311, DOI 10.1097/00004647-200009000-00006; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Majumdar MK, 1998, J CELL PHYSIOL, V176, P57, DOI 10.1002/(SICI)1097-4652(199807)176:1<57::AID-JCP7>3.0.CO;2-7; Maysinger D, 1996, EXP NEUROL, V141, P47, DOI 10.1006/exnr.1996.0138; MEHLER MF, 1993, NATURE, V362, P62, DOI 10.1038/362062a0; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Pereira RF, 1998, P NATL ACAD SCI USA, V95, P1142, DOI 10.1073/pnas.95.3.1142; PEREIRA RF, 1995, P NATL ACAD SCI USA, V92, P4857, DOI 10.1073/pnas.92.11.4857; Postmantur R., 1997, NEUROSCIENCE, V77, P765; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; REIER PJ, 1992, J NEUROTRAUM, V9, pS223; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; SINSON G, 1999, NEUROSURG FOCUS, V7, P1; SOARES H, 1991, Journal of Neural Transplantation and Plasticity, V2, P207; Soares HD, 1995, J NEUROTRAUM, V12, P1059, DOI 10.1089/neu.1995.12.1059; Svendsen CN, 1997, EXP NEUROL, V148, P135, DOI 10.1006/exnr.1997.6634; UNSICKER K, 1993, EXP NEUROL, V123, P167, DOI 10.1006/exnr.1993.1149; Unsicker Klaus, 1994, Progress in Growth Factor Research, V5, P73, DOI 10.1016/0955-2235(94)90018-3; WALKLEY SU, 1994, P NATL ACAD SCI USA, V91, P2970, DOI 10.1073/pnas.91.8.2970; WHITFIELD LS, 1993, NATURE, V364, P713, DOI 10.1038/364713a0; WILLIAMS LR, 1986, P NATL ACAD SCI USA, V83, P9231, DOI 10.1073/pnas.83.23.9231	54	199	230	0	10	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	NOV	2001	49	5					1196	1203		10.1097/00006123-200111000-00031			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	485NG	WOS:000171760000037	11846913				2021-06-18	
J	Beni-Adani, L; Gozes, I; Cohen, Y; Assaf, Y; Steingart, RA; Brenneman, DE; Eizenberg, O; Trembolver, V; Shohami, E				Beni-Adani, L; Gozes, I; Cohen, Y; Assaf, Y; Steingart, RA; Brenneman, DE; Eizenberg, O; Trembolver, V; Shohami, E			A peptide derived from activity-dependent neuroprotective protein (ADNP) ameliorates injury response in closed head injury in mice	JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS			English	Article							TUMOR-NECROSIS-FACTOR; TRAUMATIC BRAIN INJURY; NEUROTROPHIC FACTOR; AXONAL INJURY; FACTOR-ALPHA; COGNITIVE DEFICITS; ALZHEIMERS-DISEASE; NMDA ANTAGONIST; RAT-BRAIN; TNF-ALPHA	Brain injury induces disruption of the blood-brain barrier, edema, and release of autodestructive factors that produce delayed neuronal damage. NAPSVIPQ (NAP), a femtomolar-acting peptide, is shown to be neuroprotective in a mouse model of closed head injury. NAP injection after injury reduced mortality and facilitated neurobehavioral recovery (P< 0.005). Edema was reduced by 70% in the NAP-treated mice (P<0.01). Furthermore, in vivo magnetic resonance imaging demonstrated significant brain-tissue recovery in the NAP-treated animals. NAP treatment decreased tumor necrosis factor-alpha levels in the injured brain and was shown to protect pheochromocytoma (PC12 cells) against tumor necrosis factor-alpha -induced toxicity. Thus, NAP provides significant amelioration from the complex array of injuries elicited by head trauma.	Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, Hadassah Med Ctr, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Med Ctr, Dept Neurosurg, IL-91120 Jerusalem, Israel; Tel Aviv Univ, Sackler Fac Exact Sci, Sch Chem, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Fac Med, Dept Clin Biochem, IL-69978 Tel Aviv, Israel; NICHD, Sect Dev & Mol Pharmacol, Dev Neurobiol Lab, NIH, Bethesda, MD USA	Shohami, E (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, Hadassah Med Ctr, IL-91120 Jerusalem, Israel.	esty@cc.huji.ac.il		assaf, yaniv/0000-0001-6828-7595	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [Z01HD000047] Funding Source: NIH RePORTER		Assaf Y, 1997, MAGN RESON IMAGING, V15, P77, DOI 10.1016/S0730-725X(96)00246-9; Bassan M, 1999, J NEUROCHEM, V72, P1283, DOI 10.1046/j.1471-4159.1999.0721283.x; BeitYannai E, 1996, BRAIN RES, V717, P22, DOI 10.1016/0006-8993(95)01492-6; BeitYannai E, 1997, J CEREBR BLOOD F MET, V17, P273, DOI 10.1097/00004647-199703000-00004; Bjugstad KB, 1998, BRAIN RES, V795, P349, DOI 10.1016/S0006-8993(98)00351-5; BRENNEMAN DE, 1986, P NATL ACAD SCI USA, V83, P1159, DOI 10.1073/pnas.83.4.1159; Brenneman DE, 1996, J CLIN INVEST, V97, P2299, DOI 10.1172/JCI118672; Brenneman DE, 1998, J PHARMACOL EXP THER, V285, P619; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Dragunow M, 1997, REV NEUROSCIENCE, V8, P223; Gennarelli TA, 1996, NEUROPATH APPL NEURO, V22, P509, DOI 10.1111/j.1365-2990.1996.tb01126.x; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GOZES I, 1989, MOL NEUROBIOL, V3, P201, DOI 10.1007/BF02740606; Gozes I, 1999, CURR MED CHEM, V6, P1019; Gozes I, 2000, J PHARMACOL EXP THER, V293, P1091; Gozes I, 1997, DEV BRAIN RES, V99, P167, DOI 10.1016/S0165-3806(96)00215-5; Gozes I, 1996, J MOL NEUROSCI, V7, P235, DOI 10.1007/BF02737061; Haviv R, 1999, J NEUROSCI RES, V55, P269; Kim WK, 2000, J NEUROSCI, V20, P3622; Lapchak PA, 1998, MOVEMENT DISORD, V13, P49; LEVIMONTALCINI R, 1969, BRAIN RES, V12, P54, DOI 10.1016/0006-8993(69)90055-9; MATTSON MP, 1994, ANN NY ACAD SCI, V747, P50; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Oehmichen M, 1998, FORENSIC SCI INT, V95, P67, DOI 10.1016/S0379-0738(98)00075-9; Offen D, 2000, BRAIN RES, V854, P257, DOI 10.1016/S0006-8993(99)02375-6; Okiyama K, 1998, BRAIN RES, V792, P291, DOI 10.1016/S0006-8993(98)00158-9; OMMAYA AK, 1995, J NEUROTRAUM, V12, P527, DOI 10.1089/neu.1995.12.527; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; SAID SI, 1970, SCIENCE, V169, P1217, DOI 10.1126/science.169.3951.1217; Said SI, 1996, J CLIN INVEST, V97, P2163, DOI 10.1172/JCI118655; Schofield PW, 1997, J NEUROL NEUROSUR PS, V62, P119, DOI 10.1136/jnnp.62.2.119; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Trembovler V, 1999, J INTERF CYTOK RES, V19, P791, DOI 10.1089/107999099313640; Van Den Heuvel C, 1998, ACT NEUR S, V71, P209; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Zhao BY, 1998, J NEUROSCI RES, V52, P7, DOI 10.1002/(SICI)1097-4547(19980401)52:1<7::AID-JNR2>3.0.CO;2-I	40	199	202	0	19	AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA	0022-3565	1521-0103		J PHARMACOL EXP THER	J. Pharmacol. Exp. Ther.	JAN	2001	296	1					57	63					7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	384NM	WOS:000165951800008	11123362				2021-06-18	
J	Khanna, S; Davis, D; Peterson, B; Fisher, B; Tung, H; O'Quigley, J; Deutsch, R				Khanna, S; Davis, D; Peterson, B; Fisher, B; Tung, H; O'Quigley, J; Deutsch, R			Use of hypertonic saline in the treatment of severe refractory posttraumatic intracranial hypertension in pediatric traumatic brain injury	CRITICAL CARE MEDICINE			English	Article						hypertonic saline; sodium; osmolarity; creatinine; intracranial pressure; cerebral perfusion pressure; Glasgow Coma Scale score; Glasgow Outcome Scale score; computed tomography; head injury	SEVERE HEAD-INJURY; RANDOMIZED CLINICAL-TRIAL; LACTATED RINGERS SOLUTION; CEREBRAL BLOOD-FLOW; HEMORRHAGIC-SHOCK; PRESSURE; RESUSCITATION; HYPONATREMIA; TRANSPORT; CHILDREN	Objectives: To evaluate the effect of prolonged infusion of 3% hypertonic saline (514 mEq/L) and sustained hypernatremia on refractory intracranial hypertension in pediatric traumatic brain injury patients. Design: A prospective study. Setting: a 24-bed Pediatric Intensive Care Unit (Level III) at Children's Hospital. Patients: We present ten children with increased intracranial pressure (ICP) resistant to conventional therapy (head elevation at 30 degrees, normothermia, sedation, paralysis and analgesia, osmolar therapy with mannitol, loop diuretic, external vertricular drainage in five patients), controlled hyperventilation (PCO2, 28-35 mm Hg), and barbiturate coma. We continuously monitored ICP, cerebral perfusion pressure (CPP), mean arterial pressure, central venous pressure, serum sodium concentrations, serum osmolarity, and serum creatinine. Interventions: A continuous infusion of 3% saline on a sliding scale was used to achieve a target serum sodium level that would maintain ICP <20 mm Hg once the conventional therapy and barbiturate coma as outlined above failed to control intracranial hypertension. Measurements and Main Results: The mean duration of treatment with 3% saline was 7.6 days (range, 4-18 days). The mean highest serum sodium was 170.7 mEq/L (range, 157-187 mEq/L). The mean highest serum osmolarity was 364.8 mosm/L (range, 330-431 mosm/L). The mean highest serum creatinine was 1.31 mg/dL (range, 0.4-5.0 mg/dL). There was a steady increase in serum sodium versus time zero that reached statistical significance at 24, 48, and 72 hrs (p < .01). There was a statistically significant decrease in ICP spike frequency at 6, 12, 24, 48, and 72 hrs (p < .01). There was a statistically significant increase in CPP versus time zero at 6, 12, 24, 48, and 72 hrs (p < .01). There was a statistically significant increase in serum osmolarity versus time zero at 12 hrs (p < .05) and at 24, 48, and 72 hrs (p < .01). Two patients developed acute renal failure and required continuous veno-venous hemodialysis; these were concurrent with an episode of sepsis and multisystem organ dysfunction. Both recovered full renal function with no electrolyte abnormalities at the time of discharge. Conclusion: An increase in serum sodium concentration significantly decreases ICP and increases CPP. Hypertonic saline is an effective agent to increase serum sodium concentrations. Sustained hypernatremia and hyperosmolarity are safely tolerated in pediatric patients with traumatic brain injury. Controlled trials are needed before recommendation of widespread use.	Univ Calif San Diego, Childrens Hosp, Div Pediat Crit Care Med, San Diego, CA 92103 USA; Univ Calif San Diego, Dept Emergency Med, San Diego, CA 92103 USA; Univ Calif San Diego, Dept Math, San Diego, CA 92103 USA; Univ Calif San Diego, Gen Clin Res Ctr, San Diego, CA 92103 USA; Univ Calif San Diego, Dept Neurosurg, San Diego, CA 92103 USA	Peterson, B (corresponding author), Dept Crit Care Med, 3030 Childrens Way,Suite 115, San Diego, CA 92123 USA.		O'Quigley, John/E-2073-2017				Archer D, 1996, J NEUROSURG ANESTH, V8, P174; ARIEFF AI, 1986, NEW ENGL J MED, V314, P1529, DOI 10.1056/NEJM198606123142401; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; Bullock R, 1995, New Horiz, V3, P448; ETSTEN B, 1955, J CLIN INVEST, V34, P500, DOI 10.1172/JCI103099; FINBERG L, 1959, PEDIATRICS, V23, P46; FISHER B, 1992, J NEUROSURG ANESTH, V4, P4, DOI 10.1097/00008506-199201000-00002; GUNNAR WP, 1986, ANN SURG, V204, P686, DOI 10.1097/00000658-198612000-00012; HOLCROFT JW, 1987, ANN SURG, V206, P278; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KHANNA S, 1998, CRIT CARE MED, V26, P421; KOFKE WA, 1993, J NEUROSURG ANESTHES, V5, P103; MARION DW, 1991, NEUROSURGERY, V29, P869, DOI 10.1227/00006123-199112000-00011; MARMAROU A, 1991, J NEUROSURG, V75, P559; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; NAKAYAMA SI, 1985, J SURG RES, V38, P180, DOI 10.1016/0022-4804(85)90025-3; NERLICH M, 1983, CIRC SHOCK, V10, P179; NEUWELT EA, 1982, J NEUROSURG, V56, P254, DOI 10.3171/jns.1982.56.2.0254; OKEN DE, 1994, RENAL FAILURE, V16, P147, DOI 10.3109/08860229409044856; PROUGH DS, 1985, CRIT CARE MED, V13, P407, DOI 10.1097/00003246-198505000-00008; PROUGH DS, 1986, J NEUROSURG, V64, P627, DOI 10.3171/jns.1986.64.4.0627; Qureshi AI, 1998, CRIT CARE MED, V26, P440, DOI 10.1097/00003246-199803000-00011; SHACKFORD SR, 1992, J NEUROSURG, V76, P91, DOI 10.3171/jns.1992.76.1.0091; Shackford SR, 1998, J TRAUMA, V44, P50, DOI 10.1097/00005373-199801000-00004; Simma B, 1998, CRIT CARE MED, V26, P1265, DOI 10.1097/00003246-199807000-00032; STERNS RH, 1986, NEW ENGL J MED, V314, P1535, DOI 10.1056/NEJM198606123142402; Suarez JI, 1998, CRIT CARE MED, V26, P1118, DOI 10.1097/00003246-199806000-00038; TODD MM, 1987, NEUROSURGERY, V20, P559, DOI 10.1227/00006123-198704000-00009; VASSAR MJ, 1991, ARCH SURG-CHICAGO, V126, P1065; WORTHLEY LIG, 1988, J NEUROSURG, V68, P478, DOI 10.3171/jns.1988.68.3.0478; ZORNOW MH, 1989, J TRAUMA, V29, P484, DOI 10.1097/00005373-198904000-00011; Zornow MH, 1996, J NEUROSURG ANESTH, V8, P175, DOI 10.1097/00008506-199604000-00021	34	199	206	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0090-3493			CRIT CARE MED	Crit. Care Med.	APR	2000	28	4					1144	1151		10.1097/00003246-200004000-00038			8	Critical Care Medicine	General & Internal Medicine	311AV	WOS:000086862800038	10809296				2021-06-18	
J	Balestreri, M; Czosnyka, M; Hutchinson, P; Steiner, LA; Hiler, M; Smielewski, P; Pickard, JD				Balestreri, Marcella; Czosnyka, Marek; Hutchinson, Peter; Steiner, Luzius A.; Hiler, Magda; Smielewski, Piotr; Pickard, John D.			Impact of intracranial pressure and cerebral perfusion pressure on severe disability and mortality after head injury	NEUROCRITICAL CARE			English	Article						head injury; outcome; intracranial pressure (ICP); cerebral perfusion pressure (CPP)		Objective: To investigate the relationships between intracranial pressure (ICP), cerebral perfusion pressure (CPP), and outcome after traumatic brain injury. Material and Methods: A retrospective analysis of prospectively recorded data from 429 patients after head injury requiring intensive treatment on the Neuroscience Intensive Annex and the Neuro Critical Care Unit, Cambridge, UK. ICP, CPP, and arterial blood pressure (ABP) were continuously recorded. Mean values of pressures were compared to outcome assessed at 6 months after injury (using the Glasgow Outcome Scale). Results: The mortality rate was greater in those having mean ICP greater than 20 mmHg (17% below versus 47% above; p < 0.0001). The mortality rate was dramatically increased for CPP below 55 mmHg (81% below versus 23% above; p < 0.0001). For values of CPP greater than 95 mmHg, favorable outcome was less frequent (50% below versus 28% above; p < 0.033). The rate of severe disability showed the tendency to increase with CPP (r=0.87; p=0.02), suggesting that a higher CPP does not help in achieving favorable outcomes. ICP was greater in those who died in comparison to those who survived ( 27 +/- 19 mmHg versus 16 +/- 6 mmHg; p < 0.10-7), and CPP was lower (68 +/- 21 versus 76 +/- 10 mmHg; p < 0.0002). There was no difference between mean ICP and CPP in good/moderate and severe disability outcome groups. Conclusion: High ICP is strongly associated with fatal outcome. Excessive CPP seems to reduce the probability of achieving a favorable outcome following head trauma.	[Balestreri, Marcella; Czosnyka, Marek; Hutchinson, Peter; Steiner, Luzius A.; Hiler, Magda; Smielewski, Piotr; Pickard, John D.] Addenbrookes Hosp, Acad Neurosurg Unit, Cambridge CB2 2QQ, England; [Balestreri, Marcella] Univ Pavia, Policlin San Matteo, I-27100 Pavia, Italy; [Steiner, Luzius A.] Univ Basel Hosp, Dept Anaesthesia, Basel, Switzerland	Czosnyka, M (corresponding author), Addenbrookes Hosp, Acad Neurosurg Unit, Box 167, Cambridge CB2 2QQ, England.	mc141@medschl.cam.ac.uk	Steiner, Luzius/J-1987-2019; Steiner, Luzius/C-9836-2011	Smielewski, Peter/0000-0001-5096-3938; Hutchinson, Peter/0000-0002-2796-1835	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001237, G0601025, G9439390] Funding Source: Medline		Balestreri M, 2004, ACTA NEUROCHIR, V146, P131, DOI 10.1007/s00701-003-0187-y; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Balestreri M, 2003, J NEUROSURG, V99, P616; Chambers IR, 2001, J NEUROSURG, V94, P412, DOI 10.3171/jns.2001.94.3.0412; CZOSNYKA M, 1994, INT J CLIN MONIT COM, V11, P223, DOI 10.1007/BF01139874; Czosnyka M, 2005, J NEUROSURG, V102, P450, DOI 10.3171/jns.2005.102.3.0450; Eker C, 2000, BRAIN INJURY, V14, P605; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Grande PO, 2000, SCHWEIZ MED WSCHR, V130, P1538; Heuer GG, 2004, J NEUROSURG, V101, P408, DOI 10.3171/jns.2004.101.3.0408; Hutchinson PJ, 2002, J CEREBR BLOOD F MET, V22, P735, DOI 10.1097/00004647-200206000-00012; JENNETT B, 1975, LANCET, V1, P480; Jones PA, 2003, BRIT J NEUROSURG, V17, P29, DOI 10.1080/0268869031000093708; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Lee JH, 2001, J NEUROSURG, V95, P222, DOI 10.3171/jns.2001.95.2.0222; MARMONT AM, 1992, BONE MARROW TRANSPL, V9, P1; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Naredi S, 2001, ACTA ANAESTH SCAND, V45, P402, DOI 10.1034/j.1399-6576.2001.045004402.x; Oertel M, 2002, ACT NEUR S, V81, P67; Prabhakaran P, 2004, J NEUROSURG, V100, P454, DOI 10.3171/ped.2004.100.5.0454; ROBERTSON CS, 1992, J NEUROTRAUM, V9, pS349; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Tan H, 2001, Chin J Traumatol, V4, P156; UNGERSTEDT U, 1987, LIFE SCI, V41, P861, DOI 10.1016/0024-3205(87)90181-0; UNTERBERG A, 1993, NEUROSURGERY, V32, P17, DOI 10.1227/00006123-199301000-00003; UNTERBERG A, 1993, NEUROSURGERY, V32, P23; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110	30	198	213	0	8	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	FEB	2006	4	1					8	13		10.1385/NCC:4:1:008			6	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	V44KA	WOS:000203000400003	16498188				2021-06-18	
J	Whyte, J; Hart, T				Whyte, J; Hart, T			It's more than a black box; It's a Russian doll - Defining rehabilitation treatments	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						rehabilitation; treatment outcome; therapeutics; research design; health services research	TRAUMATIC BRAIN INJURY; RANDOMIZED CONTROLLED TRIAL; STROKE REHABILITATION; COGNITIVE THERAPY; ACQUIRED APHASIA; OUTCOMES; PSYCHOTHERAPY; DEPRESSION; MEMORY; PROGRAM	Research on treatment efficacy and effectiveness requires that the treatments of interest be objectively defined. Such definitions are relatively straightforward for pharmacologic and surgical treatments, in which the active ingredients can be specified in terms of chemical structure or anatomic result. Definitions of treatment are more difficult for the many experience-based interventions employed in rehabilitation. This has led to the criticism that much clinical rehabilitation research has characterized the treatments of interest as a "black box," allowing little insight into the active ingredients contained therein. Moreover, rehabilitation care may involve the simultaneous application of multiple different treatments, raising the question of whether to define the individual components or the service delivery system. In this article, we consider how the levels of analysis considered in rehabilitation (disease, impairment, activity, and participation) and the role of theory shape the definition of treatment, and we address the need to develop protocol-based treatments and tools to objectively verify their contents. Rigorous definition of rehabilitation treatments, supported by theory, will facilitate needed efficacy research, will allow replication of that research, and will ultimately foster dissemination of effective treatments into clinical practice.	Thomas Jefferson Univ, Albert Einstein Healthcare Network, Moss Rehabil Res Inst, Philadelphia, PA 19141 USA; Thomas Jefferson Univ, Moss Rehabil Res Inst, Dept Rehabil Med, Philadelphia, PA 19141 USA	Whyte, J (corresponding author), Thomas Jefferson Univ, Albert Einstein Healthcare Network, Moss Rehabil Res Inst, 1200 W Tabor Rd,Korman Bldg,Suite 213, Philadelphia, PA 19141 USA.			Whyte, John/0000-0002-4381-1474	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24 HD39621] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD039621] Funding Source: NIH RePORTER		Al-Adawi S, 1998, NEUROPSYCHOLOGY, V12, P115, DOI 10.1037/0894-4105.12.1.115; BORKOVEC TD, 1996, NIMH PSYCHOTHERAPY R, V5, P14; Brunswick E., 1952, CONCEPTUAL FRAMEWORK; BUTLER G, 1991, J CONSULT CLIN PSYCH, V59, P167, DOI 10.1037/0022-006X.59.1.167; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; Castonguay LG, 1996, J CONSULT CLIN PSYCH, V64, P497, DOI 10.1037/0022-006X.64.3.497; Chambless DL, 1998, J CONSULT CLIN PSYCH, V66, P7, DOI 10.1037/0022-006X.66.1.7; Chapman EH, 1999, J HEAD TRAUMA REHAB, V14, P521, DOI 10.1097/00001199-199912000-00002; Clare L, 2001, NEUROPSYCHOL REHABIL, V11, P477, DOI 10.1080/09602010042000213; Clark F, 1997, JAMA-J AM MED ASSOC, V278, P1321, DOI 10.1001/jama.278.16.1321; DAVID R, 1982, J NEUROL NEUROSUR PS, V45, P957, DOI 10.1136/jnnp.45.11.957; Dijkers M, 2002, AM J PHYS MED REHAB, V81, P21, DOI 10.1097/00002060-200201000-00005; Duncan PW, 1997, ASSESSING MED REHABI, P307; ELKIN I, 1985, ARCH GEN PSYCHIAT, V42, P305; Evans JJ, 2000, NEUROPSYCHOL REHABIL, V10, P67, DOI 10.1080/096020100389309; Field-Fote EC, 2001, ARCH PHYS MED REHAB, V82, P818, DOI 10.1053/apmr.2001.23752; Goldfried MR, 1998, J CONSULT CLIN PSYCH, V66, P143, DOI 10.1037/0022-006X.66.1.143; GORDON WA, 1985, ARCH PHYS MED REHAB, V66, P353; GRAF P, 1985, J EXP PSYCHOL LEARN, V11, P501, DOI 10.1037/0278-7393.11.3.501; HALEY SM, 1994, PHYS THER, V74, P443, DOI 10.1093/ptj/74.5.443; Harris GR, 2002, J FAM PRACTICE, V51, P1042; HARTMAN J, 1987, ARCH NEUROL-CHICAGO, V44, P646, DOI 10.1001/archneur.1987.00520180064018; Hawley KM, 2002, CLIN PSYCHOL-SCI PR, V9, P225, DOI 10.1093/clipsy/9.2.225; HENRY WP, 1993, J CONSULT CLIN PSYCH, V61, P434, DOI 10.1037/0022-006X.61.3.434; Hoenig H, 2000, ARCH PHYS MED REHAB, V81, P853, DOI 10.1053/apmr.2000.5569; Horn SD, 1998, AM J MANAG CARE, V4, P1105; HOWARD D, 1994, PHILOS T R SOC B, V346, P113, DOI 10.1098/rstb.1994.0135; HOWE D, 1999, CONTROVERSIES PSYCHO, P95; Hughes C, 1991, Prog Behav Modif, V27, P7; Hunkin NM, 1998, NEUROPSYCHOLOGIA, V36, P25, DOI 10.1016/S0028-3932(97)00106-1; JOHNSTON MV, 1997, ASSESSING MED REHABI, P1; Jones R. S. P., 1992, MENT HANDICAP RES, V5, P204, DOI DOI 10.1111/J.1468-3148.1992.TB00045.X; Kalra L, 1997, STROKE, V28, P1386, DOI 10.1161/01.STR.28.7.1386; Keith RA, 1997, ARCH PHYS MED REHAB, V78, P1298, DOI 10.1016/S0003-9993(97)90300-2; KEITH RA, 1997, ASSESSING MED REHABI, P257; Kosak MC, 2000, NEUROREHAB NEURAL RE, V14, P13, DOI 10.1177/154596830001400102; Kramer AM, 1997, JAMA-J AM MED ASSOC, V277, P396, DOI 10.1001/jama.277.5.396; Krause MS, 1999, J CLIN PSYCHOL, V55, P159; Kwakkel G, 1999, LANCET, V354, P191, DOI 10.1016/S0140-6736(98)09477-X; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Lorig K R, 2001, Eff Clin Pract, V4, P256; Lorig KR, 1999, MED CARE, V37, P5, DOI 10.1097/00005650-199901000-00003; Luria A.R., 1980, HIGHER CORTICAL FUNC, V2nd; Marshall JC, 2000, J NEUROLINGUIST, V13, P227, DOI 10.1016/S0911-6044(00)00018-X; Miranda J, 1999, J CLIN PSYCHOL, V55, P191; National Institutes of Health, 1998, NIH CONSENSUS STATEM, V16, P1; Needleman J, 2002, NEW ENGL J MED, V346, P1715, DOI 10.1056/NEJMsa012247; Neumayer LA, 2001, J SURG RES, V95, P73, DOI 10.1006/jsre.2000.6047; Nudo RJ, 2001, MUSCLE NERVE, V24, P1000, DOI 10.1002/mus.1104; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; Persons JB, 1999, COGNITIVE THER RES, V23, P535, DOI 10.1023/A:1018724505659; Powell J, 2002, J NEUROL NEUROSUR PS, V72, P193, DOI 10.1136/jnnp.72.2.193; Schulberg HC, 1996, ARCH GEN PSYCHIAT, V53, P913; Stineman MG, 2001, AM J PHYS MED REHAB, V80, P147, DOI 10.1097/00002060-200102000-00016; STRUPP HH, 1979, ARCH GEN PSYCHIAT, V36, P1125; Tate RL, 1999, CORTEX, V35, P39, DOI 10.1016/S0010-9452(08)70784-6; Taub E, 2001, Curr Atheroscler Rep, V3, P279, DOI 10.1007/s11883-001-0020-0; Taylor I, 1997, J APPL BEHAV ANAL, V30, P43, DOI 10.1901/jaba.1997.30-43; TERRACE HS, 1963, J EXP ANAL BEHAV, V6, P1, DOI 10.1901/jeab.1963.6-1; Thoene A I, 1995, J Int Neuropsychol Soc, V1, P29; TINETTI ME, 1994, NEW ENGL J MED, V331, P821, DOI 10.1056/NEJM199409293311301; WERTZ RT, 1981, J SPEECH HEAR RES, V24, P580, DOI 10.1044/jshr.2404.580; WHYTE J, 1994, AM J PHYS MED REHAB, V73, P428, DOI 10.1097/00002060-199411000-00008; Whyte J, 1997, ASSESSING MED REHABI, P43; Wiart L, 1997, ARCH PHYS MED REHAB, V78, P424, DOI 10.1016/S0003-9993(97)90236-7; Wilson BA, 1996, J HEAD TRAUMA REHAB, V11, P54, DOI 10.1097/00001199-199604000-00006; Wilson BA, 1997, J INT NEUROPSYCH SOC, V3, P487, DOI 10.1017/S1355617797004876; WOOD DA, 1993, J LEARN DISABIL, V26, P250, DOI 10.1177/002221949302600405; 2002, COCHRANE DATEBASE SY, V1	69	198	201	0	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	AUG	2003	82	8					639	652		10.1097/01.PHM.0000078200.61840.2D			14	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	702RW	WOS:000184238100010	12872021				2021-06-18	
J	Ergh, TC; Rapport, LJ; Coleman, RD; Hanks, RA				Ergh, TC; Rapport, LJ; Coleman, RD; Hanks, RA			Predictors of Caregiver and family functioning following traumatic brain injury: Social support moderates caregiver distress	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						awareness of deficit; caregiver distress; executive functioning; family functioning; neurobehavioral deficits; social support; traumatic brain injury	SEVERE HEAD-INJURY; RELATIVES; REHABILITATION; PATIENT; ADULTS; AWARENESS; VALIDITY; SYMPTOMS; PATTERNS; BURDEN	Objective: This study examined predictors of family dysfunction and caregiver distress among 60 pairs of persons who sustained a traumatic brain injury and their caregivers. Design: A cross-sectional design that used hierarchical multiple regression analyses evaluated the relative influences of time since injury, awareness of deficit, and neurobehavioral and neuropsychological functioning of the person with injury, and caregiver perceived social support. Results: The predictor model accounted for 52% of the variance in family dysfunction and 39% in caregiver psychological distress. Neurobehavioral disturbance in the person with injury was the strongest predictor of caregiver distress. Social support showed a direct and linear relationship to family functioning, and it was the strongest predictor of family functioning. Social support was a powerful moderator of caregiver psychological distress. In the absence of adequate social support, caregiver distress increased with longer time after injury, cognitive dysfunction, and unawareness of deficit in care recipients, whereas these characteristics were not associated with distress among caregivers with adequate social support. Conclusions: Rehabilitation professionals should stress the importance of caregivers and families of persons with TBI seeking and obtaining adequate social support.	Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA; Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Rehabil Inst Michigan, Detroit, MI 48202 USA; Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA; Rehabil Inst Michigan, Detroit, MI USA	Rapport, LJ (corresponding author), Wayne State Univ, Dept Psychol, 71 W Warren Ave, Detroit, MI 48202 USA.	rapport@sun.science.wayne.edu					BARRERA M, 1986, AM J COMMUN PSYCHOL, V14, P413, DOI 10.1007/BF00922627; BOUCUGNANI LL, 1989, ARCH CLIN NEUROPSYCH, V4, P161; Brooks D N, 1979, Int Rehabil Med, V1, P160; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; CHOI SC, 1983, J NEUROSURG, V59, P294, DOI 10.3171/jns.1983.59.2.0294; COBB S, 1976, PSYCHOSOM MED, V38, P300, DOI 10.1097/00006842-197609000-00003; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P29; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [10.1097/00001199-198909000-00008, DOI 10.1097/00001199-198909000-00008]; Cutrona CE., 1987, ADV PERSONAL RELATIO, V1, P37; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; DEROGATIS LR, 1977, SCL 90 REVISED VERSI; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; EPSTEIN NB, 1989, J MARITAL FAMILY THE, V9, P171; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; Gasquoine PG, 1994, J HEAD TRAUMA REHAB, V9, P16, DOI DOI 10.1097/00001199-199412000-00004; Goldman-Rakic P. S., 1993, J HEAD TRAUMA REHAB, V8, P13; Groom KN, 1998, ARCH CLIN NEUROPSYCH, V13, P695, DOI 10.1016/S0887-6177(98)00005-5; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; JONES GA, 1989, ALCOHOL HEALTH RES W, V13, P104; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; Kreutzer JS, 1996, J HEAD TRAUMA REHAB, V11, P58, DOI 10.1097/00001199-199610000-00006; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; KREUTZER JS, 1990, CRIME SUBSTANCE PATT; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; Liss M, 1990, Int J Rehabil Res, V13, P309, DOI 10.1097/00004356-199012000-00004; Livingston M G, 1987, Brain Inj, V1, P33, DOI 10.3109/02699058709034442; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; NELSON L, 1994, NEUROPSYCHOLOGY BEHA; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P96; Psychological Corporation, 1997, WAIS 3 WMS 3 TECHN M; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; Ross S R, 1997, Appl Neuropsychol, V4, P165, DOI 10.1207/s15324826an0403_4; Sander A, 1999, REHABILITATION ADULT; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; SARASON IG, 1985, PSYCHOSOM MED, V47, P156, DOI 10.1097/00006842-198503000-00007; Satz P., 1996, COLOR TRAILS TEST; SEATON JD, 1990, J HEAD TRAUMA REHAB, V5, P41; Semlyen JK, 1998, J NEUROL REHABIL, V12, P53; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; SHUTE GE, 1990, DEV NEUROPSYCHOL, V6, P1, DOI 10.1080/87565649009540445; SPARADEO FR, 1992, HDB ASSESSING TREATI; Tabachnick BG, 2013, USING MULTIVARIATE S; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Wallace CA, 1998, BRAIN INJURY, V12, P483, DOI 10.1080/02699052.1998.11910751; Wallace CA, 2000, BRAIN INJURY, V14, P549	61	198	201	0	32	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	APR	2002	17	2					155	174		10.1097/00001199-200204000-00006			20	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	535YT	WOS:000174674500006	11909512				2021-06-18	
J	McIntosh, TK; Saatman, KE; Raghupathi, R; Graham, DI; Smith, DH; Lee, VMY; Trojanowski, JQ				McIntosh, TK; Saatman, KE; Raghupathi, R; Graham, DI; Smith, DH; Lee, VMY; Trojanowski, JQ			The molecular and cellular sequelae of experimental traumatic brain injury: pathogenetic mechanisms	NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY			English	Article						brain injury; calcium; gene expression; inflammation; neurodegeneration	NERVE GROWTH-FACTOR; CLOSED-HEAD-INJURY; AMYLOID PRECURSOR PROTEIN; CORTICAL IMPACT INJURY; INTERLEUKIN 1-BETA-CONVERTING ENZYME; NECROSIS-FACTOR-ALPHA; MICROTUBULE-ASSOCIATED PROTEIN-2; APOLIPOPROTEIN-E POLYMORPHISM; TRANSIENT FOREBRAIN ISCHEMIA; COMPRESSION CONTUSION TRAUMA	The mechanisms underlying secondary or delayed cell death following traumatic brain injury (TBI) are poorly understood. Recent evidence from experimental models of TBI suggest that diffuse and widespread neuronal damage and loss is progressive and prolonged for months to years after the initial insult in selectively vulnerable regions of the cortex, hippocampus, thalamus, striatum, and subcortical nuclei. The development of new neuropathological and molecular techniques has generated new insights into the cellular and molecular sequelae of brain trauma, This paper will review the literature suggesting that alterations in intracellular calcium with resulting changes in gene expression, activation of reactive oxygen species (ROS), activation of intracellular proteases (calpains), expression of neurotrophic factors, and activation of cell death genes (apoptosis) mag play a role in mediating delayed cell death after trauma. Recent data suggesting that TBI should be considered as both an inflammatory and/or a neurodegenerative disease is also presented. Further research concerning the complex molecular and neuropathological cascades following brain trauma should be conducted, as novel therapeutic strategies continue to be developed.	Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; So Gen Hosp, Inst Neuropathol, Glasgow G51 4TF, Lanark, Scotland	McIntosh, TK (corresponding author), Univ Penn, Dept Neurosurg, 3320 Smith Walk,105 Hayden Hall, Philadelphia, PA 19104 USA.		smith, douglas/A-1321-2007		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS008803, R01NS026818] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS26818, P01-NS08803] Funding Source: Medline		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; AdleBiassette H, 1996, NEUROBIOL AGING, V17, P415, DOI 10.1016/0197-4580(96)00029-2; AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; Akins PT, 1996, STROKE, V27, P1682, DOI 10.1161/01.STR.27.9.1682; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; AMADUCCI LA, 1986, NEUROLOGY, V36, P922, DOI 10.1212/WNL.36.7.922; AMSTAD PA, 1992, CANCER RES, V52, P3952; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; ASHKENAS J, 1996, J EXP MED, P183; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; Bartus RT, 1997, NEUROSCIENTIST, V3, P314, DOI 10.1177/107385849700300513; BAZAN NG, 1993, PROG BRAIN RES, V96, P247; BAZAN NG, 1995, J NEUROTRAUM, V12, P791, DOI 10.1089/neu.1995.12.791; BeitYannai E, 1997, J CEREBR BLOOD F MET, V17, P273, DOI 10.1097/00004647-199703000-00004; BILLGER M, 1988, CELL CALCIUM, V9, P33, DOI 10.1016/0143-4160(88)90036-X; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BRAAKMAN R, 1994, J NEUROSURG, V80, P797; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; BRETELER MMB, 1992, EPIDEMIOL REV, V14, P59, DOI 10.1093/oxfordjournals.epirev.a036092; Bruce-Keller AJ, 1998, J NEUROCHEM, V70, P31; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; Carlos T. M., 1995, Journal of Neurotrauma, V12, P458; CASCIOLAROSENL, J EXP MED, P183; CHOI DW, 1987, J NEUROSCI, V7, P369; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; Clark RSB, 1996, J NEUROTRAUM, V13, P333, DOI 10.1089/neu.1996.13.333; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; Clark RSB, 1997, J NEUROSCI, V17, P9172; CLINTON J, 1991, NEUROPATH APPL NEURO, V17, P69, DOI 10.1111/j.1365-2990.1991.tb00695.x; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; CONTI AC, 1998, IN PRESS J NEUROSCI; D'MELLO SR, 1991, MOL BRAIN RES, V11, P255, DOI 10.1016/0169-328X(91)90034-U; DASH PK, 1995, J NEUROSCI, V15, P2030; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; DHILLON HS, 1994, J NEUROTRAUM, V11, P405, DOI 10.1089/neu.1994.11.405; DHILLON HS, 1995, BRAIN RES, V698, P100, DOI 10.1016/0006-8993(95)00840-M; Dietrich WD, 1996, J NEUROTRAUM, V13, P309, DOI 10.1089/neu.1996.13.309; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; DIXON CE, 1997, J NEUROTRAUM, V14, P159; DRAGUNOW M, 1993, MOL BRAIN RES, V18, P347, DOI 10.1016/0169-328X(93)90101-T; DUGAN LL, 1994, ANN NEUROL, V35, pS17, DOI 10.1002/ana.410350707; Eldadah BA, 1997, J NEUROSCI, V17, P6105; FAN L, 1995, MOL BRAIN RES, V30, P125; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Geddes JF, 1996, NEUROPATH APPL NEURO, V22, P12, DOI 10.1111/j.1365-2990.1996.tb00840.x; GENTLEMAN SM, 1993, PROG BRAIN RES, V96, P237; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GOLDBERG MP, 1993, J NEUROSCI, V13, P3510; GOLDGABER D, 1989, P NATL ACAD SCI USA, V86, P7606, DOI 10.1073/pnas.86.19.7606; Goss JR, 1997, EXP NEUROL, V146, P291, DOI 10.1006/exnr.1997.6515; Goss JR, 1998, EXP NEUROL, V149, P301, DOI 10.1006/exnr.1997.6712; Gourin CG, 1997, J TRAUMA, V42, P1101, DOI 10.1097/00005373-199706000-00020; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; GRIFFIN WST, 1994, NEUROSCI LETT, V176, P133, DOI 10.1016/0304-3940(94)90066-3; Gualtari CT, 1991, BRAIN INJURY, V5, P219; GUTH L, 1994, P NATL ACAD SCI USA, V91, P12308, DOI 10.1073/pnas.91.25.12308; HALL ED, 1992, J NEUROTRAUM, V9, pS425; HALL ED, 1986, PROCESSES RECOVERY N, P63; HAMAKUBO T, 1986, J NEUROSCI, V6, P3103, DOI 10.1523/jneurosci.06-11-03103.1986; HEYMAN A, 1984, ANN NEUROL, V15, P335, DOI 10.1002/ana.410150406; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Homayoun P, 1997, J NEUROCHEM, V69, P199; Isaksson J, 1997, ACTA NEUROPATHOL, V94, P16, DOI 10.1007/s004010050666; JOHNSON GVW, 1991, J NEUROCHEM, V56, P1630, DOI 10.1111/j.1471-4159.1991.tb02061.x; JORGENSEN MB, 1990, J CEREBR BLOOD F MET, V10, P243, DOI 10.1038/jcbfm.1990.41; KACZOROWSKI SL, 1993, 11 ANN NEUR S; KAMAKURA K, 1985, J NEUROSCI RES, V13, P391, DOI 10.1002/jnr.490130306; Kamme F, 1996, MOL BRAIN RES, V43, P51, DOI 10.1016/S0169-328X(96)00151-9; Kampfl A, 1996, J NEUROCHEM, V67, P1575; Kayalar C, 1996, P NATL ACAD SCI USA, V93, P2234, DOI 10.1073/pnas.93.5.2234; Kirino T, 1996, INT ACAD B, V11, P62; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KONTOS HA, 1985, CIRC RES, V57, P508, DOI 10.1161/01.RES.57.4.508; KONTOS HA, 1989, CHEM-BIOL INTERACT, V72, P229, DOI 10.1016/0009-2797(89)90001-X; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Leonard JR, 1997, EXP NEUROL, V143, P177, DOI 10.1006/exnr.1996.6366; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Loddick SA, 1996, J CEREBR BLOOD F MET, V16, P932, DOI 10.1097/00004647-199609000-00017; LONGO FM, 1984, EXP NEUROL, V84, P207, DOI 10.1016/0014-4886(84)90016-5; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; LOWENSTEIN DH, 1994, MOL BRAIN RES, V22, P299, DOI 10.1016/0169-328X(94)90058-2; LOWENSTEIN DH, 1991, NEURON, V7, P1053, DOI 10.1016/0896-6273(91)90349-5; MAHMOOD A, 1997, C NEUR SURG, P99; Massa SM, 1996, CEREBROVAS BRAIN MET, V8, P95; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; McDermott KL, 1997, J NEUROTRAUM, V14, P191, DOI 10.1089/neu.1997.14.191; McIntosh TK, 1997, NEUROSCIENTIST, V3, P169, DOI 10.1177/107385849700300310; Miller TM, 1996, J NEUROSCI, V16, P7487; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MORGAN JI, 1991, TRENDS PHARMACOL SCI, V12, P343, DOI 10.1016/0165-6147(91)90594-I; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MORGANTIKOSSMANN MC, 1992, TRENDS PHARMACOL SCI, V13, P286, DOI 10.1016/0165-6147(92)90087-M; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; NEWMAN SJ, 1995, RESEARCH ADVANCES IN ALZHEIMER'S DISEASE AND RELATED DISORDERS, P397; Nicholson DW, 1996, NAT BIOTECHNOL, V14, P297, DOI 10.1038/nbt0396-297; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; NICOTERA P, 1992, ANNU REV PHARMACOL, V32, P449, DOI 10.1146/annurev.pa.32.040192.002313; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Nilsson P, 1996, J NEUROTRAUM, V13, P201, DOI 10.1089/neu.1996.13.201; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; PATTERSON SL, 1993, BRAIN RES, V605, P43, DOI 10.1016/0006-8993(93)91354-U; PERLMUTTER LS, 1990, J COMP NEUROL, V296, P269, DOI 10.1002/cne.902960207; PHILLIPS LL, 1992, J NEUROTRAUM, V9, P323, DOI 10.1089/neu.1992.9.323; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; Pierce JES, 1996, J NEUROSCI, V16, P1083; PIERCE JES, 1998, NEUROSCIENCE; POIRIER J, 1993, LANCET, V342, P697, DOI 10.1016/0140-6736(93)91705-Q; POIRIER J, 1993, NEUROSCIENCE, V55, P81, DOI 10.1016/0306-4522(93)90456-P; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Posmantur RM, 1996, J NEUROTRAUM, V13, P125, DOI 10.1089/neu.1996.13.125; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Pravdenkova SV, 1996, BRAIN RES, V729, P151, DOI 10.1016/0006-8993(96)00222-3; QUATTROCCHI K B, 1990, Journal of Neurotrauma, V7, P77, DOI 10.1089/neu.1990.7.77; QUATTROCCHI KB, 1992, J NEUROTRAUM, V9, P1, DOI 10.1089/neu.1992.9.1; QUATTROCCHI KB, 1992, J NEUROSURG, V77, P694, DOI 10.3171/jns.1992.77.5.0694; RAGHUPATHI R, 1995, J CEREBR BLOOD F MET, V15, P467, DOI 10.1038/jcbfm.1995.58; Raghupathi R, 1996, MOL BRAIN RES, V37, P134, DOI 10.1016/0169-328X(95)00289-5; RAGHUPATHI R, 1995, J NEUROTRAUM, V12, P966; RAGHUPATHI R, 1997, J CEREB BLOOD FLOW M, V17, pS494; RAGHUPATHI R, 1998, IN PRESS J CEREB BLO; Raghupathi Ramesh, 1994, Society for Neuroscience Abstracts, V20, P542; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; Relton JK, 1996, EXP NEUROL, V138, P206, DOI 10.1006/exnr.1996.0059; RINK A, 1995, AM J PATHOL, V147, P1575; ROBERTS DE, 1988, LANCET, V2, P699; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; ROTHMAN SM, 1987, TRENDS NEUROSCI, V10, P299, DOI 10.1016/0166-2236(87)90177-9; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; SALZMAN SK, 1992, J NEUROTRAUM, V9, P69; SANDERSON KL, 1997, J NEUROTRAUM, V14, P799; Scherbel U., 1997, J NEUROTRAUM, V14, P781; SCHLAEPFER WW, 1990, INTRACELLULAR CALCIU, P241; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Schulz JB, 1996, J NEUROSCI, V16, P4696; Schwartz LM, 1996, TRENDS NEUROSCI, V19, P555, DOI 10.1016/S0166-2236(96)10067-9; Scripter JL, 1997, EXP NEUROL, V145, P329, DOI 10.1006/exnr.1997.6470; SHAPIRA Y, 1989, Neurological Research, V11, P169; SHENG M, 1989, NEURON, V4, P485; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Shimizu S, 1996, ONCOGENE, V12, P2251; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; SHOHAMI E, 1989, J NEUROCHEM, V53, P1541, DOI 10.1111/j.1471-4159.1989.tb08550.x; SIESJO BK, 1988, ANN NY ACAD SCI, V522, P638; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; SINSON G, 1995, J NEUROCHEM, V65, P2209; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Sinson G, 1996, J NEUROSURG, V84, P655, DOI 10.3171/jns.1996.84.4.0655; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SMITH DH, 1998, IN PRESS AM J PATHOL; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; Soares HD, 1995, J NEUROSCI, V15, P8223; Song QZ, 1996, J EXP MED, V184, P619, DOI 10.1084/jem.184.2.619; Spranger M, 1996, NEUROSCIENTIST, V2, P293, DOI 10.1177/107385849600200515; Srinivasan A, 1996, J NEUROSCI, V16, P5654; STRAUSS KI, 1996, J NEUROTRAUM, V13, P620; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P8098, DOI 10.1073/pnas.90.17.8098; STRITTMATTER WJ, 1994, P NATL ACAD SCI USA, V91, P11183, DOI 10.1073/pnas.91.23.11183; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; STRITTMATTER WJ, 1994, EXP NEUROL, V125, P163, DOI 10.1006/exnr.1994.1019; SUN FY, 1994, BRAIN RES, V661, P63, DOI 10.1016/0006-8993(94)91181-9; SUN FY, 1995, BRAIN RES, V673, P133, DOI 10.1016/0006-8993(94)01413-C; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; Takahashi A, 1996, J BIOL CHEM, V271, P32487, DOI 10.1074/jbc.271.51.32487; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; Takahashi K., 1990, INTRACELLULAR CALCIU, P55; TANNO H, 1993, J CEREBR BLOOD F MET, V13, P116, DOI 10.1038/jcbfm.1993.14; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; THOMAS WE, 1992, BRAIN RES REV, V17, P61; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P280, DOI 10.1007/BF00308813; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; Tseng MT, 1997, NEUROL RES, V19, P89; Tymianski M, 1996, NEUROSURGERY, V38, P1176; VARON S, 1991, ADV EXP MED BIOL, V296, P267; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6; Waterhouse N, 1996, J BIOL CHEM, V271, P29335, DOI 10.1074/jbc.271.46.29335; WATT C, 1993, ACTA NEUROPATHOL, V86, P136; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; Wiessner C, 1996, ACTA NEUROCHIR SUPPL, V66, P1; WILLIAMS BP, 1991, NEURON, V7, P685, DOI 10.1016/0896-6273(91)90381-9; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; YANG KY, 1993, J NEUROTRAUM, V10, P287, DOI 10.1089/neu.1993.10.287; Yao YH, 1996, BIOCHEMISTRY-US, V35, P2767, DOI 10.1021/bi951712i; YOUNG W, 1986, CENTRAL NERVOUS SYST, P235; Zhang ZY, 1996, J COMP NEUROL, V371, P485; Zhao XR, 1998, J CEREBR BLOOD F MET, V18, P161, DOI 10.1097/00004647-199802000-00006	218	198	204	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0305-1846	1365-2990		NEUROPATH APPL NEURO	Neuropathol. Appl. Neurobiol.	AUG	1998	24	4					251	267					17	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	117PQ	WOS:000075791300001	9775390				2021-06-18	
J	GHAJAR, J; HARIRI, RJ; NARAYAN, RK; IACONO, LA; FIRLIK, K; PATTERSON, RH				GHAJAR, J; HARIRI, RJ; NARAYAN, RK; IACONO, LA; FIRLIK, K; PATTERSON, RH			SURVEY OF CRITICAL CARE MANAGEMENT OF COMATOSE, HEAD-INJURED PATIENTS IN THE UNITED-STATES	CRITICAL CARE MEDICINE			English	Article						HEAD INJURY; HEAD TRAUMA; TRAUMATIC BRAIN INJURY; INTRACRANIAL PRESSURE; HYPERVENTILATION; STEROIDS; STANDARD OF CARE; BLOOD GAS ANALYSIS; NEUROLOGIC EMERGENCIES; COMA	CEREBRAL PERFUSION-PRESSURE; RANDOMIZED CLINICAL-TRIAL; INTRA-CRANICAL PRESSURE; INTRACRANIAL-PRESSURE; AGGRESSIVE TREATMENT; HYPERVENTILATION; HYPERTENSION; EXPERIENCE; STEROIDS; FAILURE	Objective: This survey was designed to study current practices in the monitoring and treatment of patients with severe head injury in the United States. Data Sources: The collected data represent answers to telephone interviews of nurse managers, clinical specialists, and staff nurses specializing in neurotrauma care at 277 randomly selected hospitals from a total pool of 624 trauma centers, Overall, 261 (94%) centers participated in the survey, Of the participating centers, 219 (84%) were providers of care for severely head-injured patients, In order to assess reliability and account for differences among respondents, personnel from 40 (15%) centers were resurveyed 6 months later and a different nursing professional was interviewed, although the questions remained the same. Data Extraction: The largest group of respondents came from level I centers (49%), followed by level II (32%) and level III (2%), Thirty-four percent of the surveyed hospitals had a designated neurologic/neurosurgical intensive care unit, and 24% of all units surveyed were under the direction of either a neurosurgeon or a neurologist. Twenty-eight percent of the centers routinely performed intracranial pressure monitoring, while 7% of the centers reported never using this technique, The use of ventriculostomy catheters for intracranial pressure monitoring was employed in 72% of the centers, but cerebrospinal fluid drainage was utilized by only 44% of the hospitals, The percentage of patients who had their intracranial pressure monitored was significantly higher in level I trauma centers and at hospitals that treated larger numbers of severely head-injured patients (15 to 30 patients per month, which represented 15% of the hospitals surveyed), Hyperventilation and osmotic diuretics were used in 83% of centers to reduce intracranial hypertension, The administration of barbiturates was reported in 33% of the units as a treatment for intracranial hypertension, Corticosteroids were used more than half of the time in 64% of trauma centers, Twenty-nine percent of the centers reported aiming for PaCO2 values of <25 torr (<3.3 kPa). Conclusions: The survey data indicate that there is a considerable variation in the management of patients with severe head injury in the United States, The establishment of guidelines for the management of head injury based on available scientific data and moderated by practical and financial considerations may lead to improvement in the standard of care.	BAYLOR COLL MED, DEPT SURG, DIV NEUROSURG, HOUSTON, TX 77030 USA	GHAJAR, J (corresponding author), CORNELL UNIV, COLL MED,DEPT SURG,DIV NEUROSURG, AITKEN NEUROSURG LAB,1300 YORK AVE, ROOM LC-807, NEW YORK, NY 10021 USA.						BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BECKER DP, 1987, TXB HEAD INJURY, P192; BOWERS SA, 1980, NEUROSURGERY, V6, P237; BRAAKMAN R, 1983, J NEUROSURG, V58, P326, DOI 10.3171/jns.1983.58.3.0326; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; CHESNUT RM, 1992, APR P AM ASS NEUR SU; COLD GE, 1989, ACTA NEUROCHIR, V96, P100, DOI 10.1007/BF01456166; COOPER PR, 1979, J NEUROSURG, V51, P307, DOI 10.3171/jns.1979.51.3.0307; COOPER PR, 1987, HEAD INJURY, P225; CRUZ J, 1993, J NEUROSURG, V79, P228, DOI 10.3171/jns.1993.79.2.0228; EICHHORN JH, 1986, JAMA-J AM MED ASSOC, V256, P1017; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; GHAJAR JBG, 1993, ADV NEUROS, V21, P173; GUDEMAN SK, 1979, J NEUROSURG, V51, P301, DOI 10.3171/jns.1979.51.3.0301; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; KING AS, 1989, JAMA-J AM MED ASSOC, V262, P2195, DOI 10.1001/jama.262.16.2195; KOLATA G, 1991, NY TIMES        1016, pC14; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; MARSHALL LF, 1990, NEUROSCIENCE CRITICA; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1992, J NEUROTRAUM, V9, pS317; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; Narayan RK, 1991, PRINCIPLES NEUROSURG, P235; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; ROBERTSON CS, 1985, J NEUROSURG, V63, P714, DOI 10.3171/jns.1985.63.5.0714; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; SAUL TG, 1981, J NEUROSURG, V54, P596, DOI 10.3171/jns.1981.54.5.0596; SCHWARTZ ML, 1984, CAN J NEUROL SCI, V11, P434, DOI 10.1017/S0317167100045960; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; TEASDALE G, 1974, LANCET, V2, P81; WARD JD, 1985, J NEUROSURG, V62, P383, DOI 10.3171/jns.1985.62.3.0383; Young B, 1991, Neurosurg Clin N Am, V2, P301; 1989, INTERAGENCY HEAD INJ; 1991, GUIDE HLTH CARE FIEL; 1990, CIRCULATION, V82, P664; 1993, STANDARDS BASIC ANES, P735; 1993, RESOURCES OPTIMAL CA; 1992, SPECIALTY COVERAGE H	46	198	204	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	MAR	1995	23	3					560	567		10.1097/00003246-199503000-00023			8	Critical Care Medicine	General & Internal Medicine	QL468	WOS:A1995QL46800023	7874910				2021-06-18	
J	SEWARD, H; ORCHARD, J; HAZARD, H; COLLINSON, D				SEWARD, H; ORCHARD, J; HAZARD, H; COLLINSON, D			FOOTBALL INJURIES IN AUSTRALIA AT THE ELITE LEVEL	MEDICAL JOURNAL OF AUSTRALIA			English	Article								Objective: To determine injury profiles for the elite level competitions of football played in Australia. Design: Over the 1992 seasons, all injuries were prospectively recorded from 26 clubs in football competitions which included the Australian Football League (AFL), New South Wales Rugby League (NSWRL) and New South Wales Rugby Union (NSWRU). Results: Some 2398 injuries were reported. In Australian Rules football, the most common injury was the hamstring tear (13%); this also accounted for the most time missed due to injury (16%). In rugby league and union, the most common injuries were head and facial lacerations (11% and 20%) followed by concussion (8% and 5%). The injuries accounting for most time missed were fractures and knee ligament injuries in the rugby codes. In Australian Rules football there were more lower limb muscle strain injuries, a high proportion of which were recurrences, with a significant incidence during training sessions. In the rugby codes, minor injuries to the head and neck were more common, particularly in forwards. While rugby league players suffered the most injuries, AFL injuries were on average more severe and consequently the total time missed through injury by players in these two codes was very similar. Rugby union had a significantly lower injury prevalence at the elite club competition level than rugby league or Australian Rules football. Conclusion: Injury rates in the elite football competitions are high, warranting ongoing analysis and further study in particular areas.	AUSTRALIAN INST SPORT,BELCONNEN,ACT 2616,AUSTRALIA; CANTERBURY BANKSTOWN RUGBY LEAGUE CLUB,BELMORE,NSW 2192,AUSTRALIA; SO DIST RUGBY UNION CLUB,CARINGBAH,NSW 2229,AUSTRALIA			Orchard, John W/AAY-7216-2020	Orchard, John W/0000-0003-3530-1711			ALEXANDER D, 1979, MED J AUSTRALIA, V2, P341, DOI 10.5694/j.1326-5377.1979.tb104138.x; CHAPMAN PJ, 1991, AUST J SCI MED SPORT, V23, P113; Collinson D, 1984, Aust Fam Physician, V13, P565; DAVIDSON RM, 1987, MED J AUSTRALIA, V147, P119, DOI 10.5694/j.1326-5377.1987.tb133299.x; Ferguson A, 1965, ANN GEN PRACT, P155; GIBBS N, IN PRESS AM J SPORTS; Hoy G, 1984, SPORT HLTH, V2, P23; MACDOUGAL GA, 1992, SPORT HLTH, V10, P23; MYERS PT, 1980, MED J AUSTRALIA, V2, P17, DOI 10.5694/j.1326-5377.1980.tb131804.x; Sali A, 1981, Aust Fam Physician, V10, P169; Seward H. G., 1992, AUST J SCI MED SPORT, V24, P51; Sparks J P, 1981, Br J Sports Med, V15, P30; Sugerman S, 1983, AUST J SPORTS MED EX, V15, P5; TAYLOR TKF, 1987, MED J AUSTRALIA, V147, P122; WEIGHTMAN D, 1974, BRIT J SPORT MED, V8, P183	15	198	199	2	33	AUSTRALASIAN MED PUBL CO LTD	SYDNEY	LEVEL 1, 76 BERRY ST, SYDNEY NSW 2060, AUSTRALIA	0025-729X			MED J AUSTRALIA	Med. J. Aust.	SEP 6	1993	159	5					298	301		10.5694/j.1326-5377.1993.tb137863.x			4	Medicine, General & Internal	General & Internal Medicine	LW483	WOS:A1993LW48300006	8361423				2021-06-18	
J	KAWAMATA, T; KATAYAMA, Y; HOVDA, DA; YOSHINO, A; BECKER, DP				KAWAMATA, T; KATAYAMA, Y; HOVDA, DA; YOSHINO, A; BECKER, DP			ADMINISTRATION OF EXCITATORY AMINO-ACID ANTAGONISTS VIA MICRODIALYSIS ATTENUATES THE INCREASE IN GLUCOSE-UTILIZATION SEEN FOLLOWING CONCUSSIVE BRAIN INJURY	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						CONCUSSION; EXCITATORY AMINO ACID ANTAGONIST; GLUCOSE UTILIZATION; HYPERMETABOLISM; IONIC FLUX; N-METHYL-D-ASPARTATE	EXPERIMENTAL HEAD-INJURY; METHYL-D-ASPARTATE; FLUID-PERCUSSION MODEL; CEREBRAL BLOOD-FLOW; EXTRACELLULAR POTASSIUM; ENERGY-METABOLISM; NMDA RECEPTORS; ISCHEMIC BRAIN; KYNURENIC ACID; RAT-BRAIN	Immediately following concussive brain injury, cells exhibit an increase of energy demand represented by the activation of glucose utilization. We have proposed that this trauma-induced hypermetabolism reflects the effort of cells to restore normal ionic balance disrupted by massive ionic fluxes through transmittergated ion channels. In the present study, changes in local CMR(glc) following fluid-percussion concussive injury were determined using [C-14]2-deoxy-D-glucose autoradiography, and the effects of in situ administration (via microdialysis) of excitatory amino acid (EAA) antagonists [kynurenic acid (KYN), 2-amino-5-phosphonovaleric acid (APV; 100-mu-M, 1 mM, and 10 mM), and 6-cyano-7-nitroquinoxaline-2,3-dine (CNQX; 300-mu-M, 1 mM, and 10 mM on glucose utilization were investigated. Animals that did not receive dialysis showed a remarkable increase (up to 181% of normal control) in cortical glucose utilization following injury. In contrast, this high demand for glucose was reduced in areas infiltrated with KYN, APV, and CNQX. These results indicate that EAA-activated ion channels are involved in the posttraumatic increase in glucose utilization, reflecting the energy demand of cells required to drive pumping mechanisms against an ionic perturbation seen immediately following the concussive injury. The effects of KYN, APV, and CNQX suggest that although all subtypes of the glutamate receptor appear to be involved in this phenomenon, N-methyl-D-aspartate-activated channels may play a major role.	UNIV CALIF LOS ANGELES, SCH MED, DIV NEUROSURG, CHS 74-140, LOS ANGELES, CA 90024 USA					NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS27544, NS30308-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027544, P50NS030308] Funding Source: NIH RePORTER		ANDERSEN BJ, 1989, J CEREB BLOOD FLOW M, V9, pS386; ANDERSEN BJ, 1989, INTRACRANIAL PRESSUR, V7, P575; ARMSTRONGJAMES M, 1985, EXP BRAIN RES, V60, P209; ARMSTRONGJAMES M, 1988, BRAIN RES, V451, P189, DOI 10.1016/0006-8993(88)90763-9; ASCHER P, 1987, TRENDS NEUROSCI, V10, P284, DOI 10.1016/0166-2236(87)90174-3; ASTRUP J, 1982, J NEUROSURG, V56, P482, DOI 10.3171/jns.1982.56.4.0482; ASTRUP J, 1981, STROKE, V12, P726, DOI 10.1161/01.STR.12.6.726; CHOI DW, 1988, J NEUROSCI, V8, P185; CHOI DW, 1987, J NEUROSCI, V7, P369; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DAVIES J, 1981, NEUROSCI LETT, V21, P77, DOI 10.1016/0304-3940(81)90061-6; DESALLES A A F, 1986, Society for Neuroscience Abstracts, V12, P967; DeWitt D S, 1988, Brain Inj, V2, P291, DOI 10.3109/02699058809150899; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DUCKROW RB, 1981, J NEUROSURG, V54, P607, DOI 10.3171/jns.1981.54.5.0607; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fieschi C, 1978, Adv Neurol, V20, P223; FINEMAN I, 1990, Society for Neuroscience Abstracts, V16, P778; FRIEDLI C, 1978, ADV EXP MED BIOL, V94, P747; GALVAN M, 1979, BRAIN RES, V160, P544, DOI 10.1016/0006-8993(79)91084-9; GANONG AH, 1986, J PHARMACOL EXP THER, V236, P293; GANONG AH, 1983, BRAIN RES, V273, P170, DOI 10.1016/0006-8993(83)91108-3; GARTHWAITE G, 1986, NEUROSCIENCE, V18, P437, DOI 10.1016/0306-4522(86)90164-8; GINSBERG M D, 1979, Acta Neurologica Scandinavica Supplementum, V60, P226; GINSBERG MD, 1977, NEUROLOGY, V27, P1042, DOI 10.1212/WNL.27.11.1042; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; Hayes R L, 1988, Brain Inj, V2, P31, DOI 10.3109/02699058809150930; HONORE T, 1988, SCIENCE, V241, P701, DOI 10.1126/science.2899909; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; JAHR CE, 1985, J NEUROSCI, V5, P2281; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; KATAYAMA Y, 1988, Society for Neuroscience Abstracts, V14, P1154; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KATAYAMA Y, 1989, INTRACRANIAL PRESSUR, V7, P584; LEVY DE, 1977, J NEUROCHEM, V28, P63, DOI 10.1111/j.1471-4159.1977.tb07709.x; LYSKO PG, 1989, BRAIN RES, V499, P258, DOI 10.1016/0006-8993(89)90773-7; MATA M, 1980, J NEUROCHEM, V34, P213, DOI 10.1111/j.1471-4159.1980.tb04643.x; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MELDRUM BS, 1983, NEUROSCIENCE, V9, P925, DOI 10.1016/0306-4522(83)90281-6; MEYER JS, 1970, J NEUROSURG, V32, P304, DOI 10.3171/jns.1970.32.3.0304; Nakai H, 1988, Neurol Med Chir (Tokyo), V28, P11, DOI 10.2176/nmc.28.11; Nakamura T, 1987, Neurol Med Chir (Tokyo), V27, P396, DOI 10.2176/nmc.27.396; NEDERGAARD M, 1988, J CEREBR BLOOD F MET, V8, P100, DOI 10.1038/jcbfm.1988.13; Nelson S, 1966, HEAD INJURY, P444; NILSSON B, 1977, J NEUROSURG, V47, P252, DOI 10.3171/jns.1977.47.2.0252; NILSSON B, 1977, J NEUROSURG, V47, P262, DOI 10.3171/jns.1977.47.2.0262; NILSSON B, 1977, J NEUROSURG, V47, P241, DOI 10.3171/jns.1977.47.2.0241; NILSSON B, 1977, J NEUROSURG, V47, P274, DOI 10.3171/jns.1977.47.2.0274; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NOVELLI A, 1988, BRAIN RES, V451, P205, DOI 10.1016/0006-8993(88)90765-2; Pappius H M, 1980, Adv Neurol, V28, P271; PAPPIUS HM, 1979, ANN NEUROL, V5, P211, DOI 10.1002/ana.410050302; PERKINS MN, 1982, BRAIN RES, V247, P184, DOI 10.1016/0006-8993(82)91048-4; POVLISHOCK JT, 1979, ACTA NEUROPATHOL, V47, P1, DOI 10.1007/BF00698266; RAO TS, 1990, NEUROPHARMACOLOGY, V29, P1031, DOI 10.1016/0028-3908(90)90109-5; RINDER L, 1968, ACTA NEUROPATHOL, V11, P201; RINDER L, 1968, ACTA NEUROPATHOL, V11, P183; ROBINSON MB, 1984, BRAIN RES, V309, P119, DOI 10.1016/0006-8993(84)91015-1; ROSENTHAL M, 1982, HEAD INJURY BASIC CL, P69; SHAH KR, 1983, NEUROSCI LETT, V40, P287, DOI 10.1016/0304-3940(83)90053-8; SHINOHARA M, 1979, SCIENCE, V203, P188, DOI 10.1126/science.758688; SHIRAISHI K, 1989, J CEREBR BLOOD F MET, V9, P765, DOI 10.1038/jcbfm.1989.110; SMITH M, 1991, IN PRESS J NEUROTRAU; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; SOKOLOFF L, 1981, J CEREBR BLOOD F MET, V1, P7, DOI 10.1038/jcbfm.1981.4; SOKOLOFF L, 1981, BASIC NEUROCHEMISTRY, P471; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; TAKAHASHI H, 1981, J NEUROSURG, V55, P708, DOI 10.3171/jns.1981.55.5.0708; THOMAS M J, 1990, Society for Neuroscience Abstracts, V16, P777; Tsubokawa T, 1983, No Shinkei Geka, V11, P563; Vink R, 1990, J NEUROTRAUM, V7, P21, DOI 10.1089/neu.1990.7.21; Walker AE, 1944, J NEUROSURG, V1, P103, DOI 10.3171/jns.1944.1.2.0103; WARD AA, 1966, CLIN NEUROSURG, V12, P95; WHITTAM R, 1962, BIOCHEM J, V82, P205, DOI 10.1042/bj0820205; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617; YOSHINO A, 1990, Society for Neuroscience Abstracts, V16, P778; YOUNG W, 1982, BRAIN RES, V253, P115, DOI 10.1016/0006-8993(82)90678-3	80	198	198	0	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JAN	1992	12	1					12	24		10.1038/jcbfm.1992.3			13	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	GV643	WOS:A1992GV64300002	1345756	Bronze			2021-06-18	
J	LUNDBERG, N; TROUPP, H; LORIN, H				LUNDBERG, N; TROUPP, H; LORIN, H			CONTINUOUS RECORDING OF VENTRICULAR-FLUID PRESSURE IN PATIENTS WITH SEVERE ACUTE TRAUMATIC BRAIN INJURY	JOURNAL OF NEUROSURGERY			English	Article																BRAGDON FH, 1945, RES PUBL ASS NERV ME, V24, P545; BROCKS S, 1960, INJURIES BRAIN SPINA, P69; BUSCH E, 1942, NERVSYSTEMETS TRAUMA; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; EVANS JP, 1956, SURG CLIN N AM, V36, P233; EVANS JP, 1963, ACUTE HEAD INJURY; GANSHIRT H, 1956, Dtsch Z Nervenheilkd, V174, P305; GUILLAUME J, 1951, REV NEUROL, V84, P131; JANNY P, 1950, THESIS PARIS; KETY SS, 1948, J CLIN INVEST, V27, P493, DOI 10.1172/JCI101996; LUNDBERG N, 1957, 1 P INT C NEUR SURG, P52; LUNDBERG N, 1963, ACTA NEUROL SCAND, V39, P264; LUNDBERG N, 1960, ACTA PSYCHIAT K S149; MUNRO D, 1945, RES PUBL ASS NERV ME, V24, P635; Noell W, 1948, ARCH PSYCHIAT NERVEN, V180, P713; Pilcher C, 1937, ARCH SURG-CHICAGO, V35, P512, DOI 10.1001/archsurg.1937.01190150095009; ROWBOTHAM GF, 1949, ACUTE INJURIES HEAD; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; RYDER HW, 1953, J LAB CLIN MED, V41, P428; SYMONDS C, 1960, INJURIES BRAIN SPINA, P69; White JC, 1943, ANN SURG, V119, P619, DOI 10.1097/00000658-194310000-00010	21	198	200	0	7	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.		1965	22	6					581	+		10.3171/jns.1965.22.6.0581			1	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	69491	WOS:A19656949100008	5832775				2021-06-18	
J	Myburgh, JA; Cooper, DJ; Finfer, SR; Venkatesh, B; Jones, D; Higgins, A; Bishop, N; Higlett, T				Myburgh, John A.; Cooper, D. James; Finfer, Simon R.; Venkatesh, Balasubramanian; Jones, Daryl; Higgins, Alisa; Bishop, Nicole; Higlett, Tracey		Australasian Traumatic Brain Injur; Australian & New Zealand Intensive	Epidemiology and 12-month outcomes from traumatic brain injury in Australia and New Zealand	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						traumatic brain injury; management; intracranial hypertension; Extended Glasgow Outcome Score	SEVERE HEAD-INJURY; SEVERITY; PROJECT; TRIALS; COMA	Background:. An epidermiologic profile of traumatic brain injury (TBI) in Australia and New Zealand was obtained following the publication of international evidence-based guidelines. Methods: Adult patients with TBI admitted to the intensive care units (ICU) of major trauma centers were studied in a 6-month prospective inception cohort study. Data including mechanisms of injury, pre-hospital interventions, secondary insults, operative and intensive care management, and outcome assessments 12-months postinjury were collected. Results: There were 635 patients recruited from 16 centers. The mean (+/- SD) age was 41.6 years +/- 19.6 years; 74.2% were men; 61.4% were due to vehicular trauma, 24.9% were falls in elderly patients, and 57.2% had severe TBI (Glasgow Coma Scale score :58). Secondary brain insults were recorded in 28.5% and 34.8% underwent neurosurgical procedures before ICU admission. There was concordance with TBI and ICU practice guidelines, although intracranial pressure monitoring was used in 44.5% patients with severe TBI. Twelve-month mortality was 26.9% in all patients and 35.1% in patients with severe TBI. Favorable outcomes at 12 months were recorded in 58.8% of all patients and in 48.5% of patients with severe TBI. Conclusions. In Australia and New Zealand, mortality and favorable neurologic outcomes after TBI were similar to published data before the advent of evidence-based guidelines. A high incidence of prehospital secondary brain insults and an ageing population may have contributed to these outcomes. Strategies to improve outcomes from TBI should be directed at preventive public health strategies and interventions to minimize secondary brain injuries in the prehospital period.	[Myburgh, John A.; Cooper, D. James; Finfer, Simon R.; Venkatesh, Balasubramanian; Jones, Daryl; Higgins, Alisa; Bishop, Nicole; Higlett, Tracey; Australasian Traumatic Brain Injur; Australian & New Zealand Intensive] St George Hosp, Dept Intens Care, Sydney, NSW, Australia	Myburgh, JA (corresponding author), St George Hosp, Dept Intens Care, Sydney, NSW, Australia.	jmyburgh@george.org.au; daryl.jones@med.monash.edu.au	Cooper, D. James/G-7961-2013; Venkatesh, Bala/F-4700-2010; Higgins, Alisa/AAM-8088-2020; Joyce, Christopher/B-7437-2013	Cooper, D. James/0000-0002-5872-9051; Higgins, Alisa/0000-0001-8295-7559; Venkatesh, Bala/0000-0002-3234-5244; Finfer, Simon/0000-0002-2785-5864			BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; *BRAIN TRAUM FDN, 1996, J NEUROTRAUM, V13, P639; Chesnut R M, 1995, New Horiz, V3, P366; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chesnut RM, 1997, J TRAUMA, V42, pS4, DOI 10.1097/00005373-199705001-00002; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Dickinson K, 2000, BMJ-BRIT MED J, V320, P1308, DOI 10.1136/bmj.320.7245.1308; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P643, DOI 10.3109/02688699308995093; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; *JOINT FAC INT CAR, 2003, IC I, P1; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; McGregor K, 1997, SOC SCI MED, V45, P295, DOI 10.1016/S0277-9536(96)00345-0; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Ozanne-Smith J, 2004, AUST NZ J PUBL HEAL, V28, P109, DOI 10.1111/j.1467-842X.2004.tb00921.x; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Pettigrew LEL, 1998, J NEUROSURG, V89, P939, DOI 10.3171/jns.1998.89.6.0939; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Wagner AK, 2000, J TRAUMA, V49, P404, DOI 10.1097/00005373-200009000-00004; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; 2000, J NEUROTRAUMA, V17, P457	29	197	202	0	20	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	APR	2008	64	4					854	862		10.1097/TA.0b013e3180340e77			9	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	287UN	WOS:000254942100002	18404048				2021-06-18	
J	Verkman, AS; Binder, DK; Bloch, O; Auguste, K; Papadopoulos, MC				Verkman, A. S.; Binder, Devin K.; Bloch, Orin; Auguste, Kurtis; Papadopoulos, Marios C.			Three distinct roles of aquaporin-4 in brain function revealed by knockout mice	BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES			English	Article; Proceedings Paper	4th International Conference on Aquaporins	SEP 10-13, 2005	Genval, BELGIUM			AQP4; water transport; transgenic mouse; brain edema; cell migration; epilepsy	INSENSITIVE WATER CHANNEL; EXTRACELLULAR-SPACE DIFFUSION; SPINAL-CORD; CELL-MIGRATION; GLIAL-CELLS; REACTIVE ASTROCYTES; TRANSGENIC MICE; ORTHOGONAL ARRAYS; GENE DISRUPTION; BULK FLOW	Aquaporin-4 (AQP4) is expressed in astrocytes throughout the central nervous system, particularly at the blood-brain and brain-cerebrospinal fluid barriers. Phenotype analysis of transgenic mice lacking AQP4 has provided compelling evidence for involvement of AQP4 in cerebral water balance, astrocyte migration, and neural signal transduction. AQP4-null mice have reduced brain swelling and improved neurological outcome in models of (cellular) cytotoxic cerebral edema including water intoxication, focal cerebral ischemia, and bacterial meningitis. However, brain swelling and clinical outcome are worse in AQP4-null mice in models of vasogenic (fluid leak) edema including cortical freeze-injury, brain tumor, brain abscess and hydrocephalus, probably due to impaired AQP4-dependent brain water clearance. AQP4 deficiency or knock-down slows astrocyte migration in response to a chemotactic stimulus in vitro, and AQP4 deletion impairs glial scar progression following injury in vivo. AQP4-null mice also manifest reduced sound- and light-evoked potentials, and increased threshold and prolonged duration of induced seizures. Impaired K+ reuptake by astrocytes in AQP4 deficiency may account for the neural signal transduction phenotype. Based on these findings, we propose modulation of AQP4 expression or function as a novel therapeutic strategy for a variety of cerebral disorders including stroke, tumor, infection, hydrocephalus, epilepsy, and traumatic brain injury. (c) 2006 Elsevier B.V. All rights reserved.	Univ Calif San Francisco, Dept Med, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, Cardiovasc Res Inst, San Francisco, CA 94143 USA	Verkman, AS (corresponding author), Univ Calif San Francisco, Dept Med, Cardiovasc Res Inst, 1246 Hlth Sci E Tower,Box 0521, San Francisco, CA 94143 USA.	verkman@itsa.ucsf.edu		Papadopoulos, Marios/0000-0001-9174-4176; Bloch, Orin/0000-0001-9810-6011			Abbott NJ, 2004, NEUROCHEM INT, V45, P545, DOI 10.1016/j.neuint.2003.11.006; Amiry-Moghaddam M, 2003, P NATL ACAD SCI USA, V100, P13615, DOI 10.1073/pnas.2336064100; Binder DK, 2006, GLIA, V53, P631, DOI 10.1002/glia.20318; Binder DK, 2004, J NEUROSCI, V24, P8049, DOI 10.1523/JNEUROSCI.2294-04.2004; Binder DK, 2004, NEUROREPORT, V15, P259, DOI 10.1097/00001756-200402090-00009; Bloch O, 2005, J NEUROCHEM, V95, P254, DOI 10.1111/j.1471-4159.2005.03362.x; BLOCH O, IN PRESS J CEREB BLO; Brightman MW, 2002, J NEUROCYTOL, V31, P595, DOI 10.1023/A:1025783326667; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; CONDEELIS J, 1990, DEV GENET, V11, P333, DOI 10.1002/dvg.1020110504; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Fields RD, 2002, SCIENCE, V298, P556, DOI 10.1126/science.298.5593.556; FISHMAN RA, 1975, NEW ENGL J MED, V293, P706, DOI 10.1056/NEJM197510022931407; FRIGERI A, 1995, J CELL SCI, V108, P2993; Grosche J, 1999, NAT NEUROSCI, V2, P139; Hampton DW, 2004, NEUROSCIENCE, V127, P813, DOI 10.1016/j.neuroscience.2004.05.028; HASEGAWA H, 1994, J BIOL CHEM, V269, P5497; Huttenlocher A, 2005, NAT CELL BIOL, V7, P336, DOI 10.1038/ncb0405-336; Jabs R, 2005, J CELL SCI, V118, P3791, DOI 10.1242/jcs.02515; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; KLATZO I, 1994, ACTA NEUROCHIR, P3; Klein M, 2000, J GEN PHYSIOL, V115, P599, DOI 10.1085/jgp.115.5.599; Li J, 2002, INVEST OPHTH VIS SCI, V43, P573; Li J, 2001, J BIOL CHEM, V276, P31233, DOI 10.1074/jbc.M104368200; Lin SC, 2004, GLIA, V47, P290, DOI 10.1002/glia.20060; Ma TH, 1997, J CLIN INVEST, V100, P957, DOI 10.1172/JCI231; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; MARMAROU A, 1994, AM J PHYSIOL, V267, pH514; Nedergaard M, 2003, TRENDS NEUROSCI, V26, P523, DOI 10.1016/j.tins.2003.08.008; Newman E A, 2001, Prog Brain Res, V132, P241; Nicholson C, 2000, PROG BRAIN RES, V125, P437; Nico B, 2003, GLIA, V42, P235, DOI 10.1002/glia.10216; Nielsen S, 1997, J NEUROSCI, V17, P171; Oshio K, 2004, NEUROSCIENCE, V127, P685, DOI 10.1016/j.neuroscience.2004.03.016; OSTER GF, 1987, J CELL SCI, P35; Padmawar P, 2005, NAT METHODS, V2, P825, DOI 10.1038/NMETH801; Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje; Papadopoulos MC, 2004, FASEB J, V18, P425, DOI 10.1096/fj.04-2834fje; Papadopoulos MC, 2005, BIOPHYS J, V89, P3660, DOI 10.1529/biophysj.105.068114; Papadopoulos MC, 2005, J BIOL CHEM, V280, P13906, DOI 10.1074/jbc.M413627200; Piet R, 2004, P NATL ACAD SCI USA, V101, P2151, DOI 10.1073/pnas.0308408100; Puwarawuttipanit W, 2006, NEUROSCIENCE, V137, P165, DOI 10.1016/j.neuroscience.2005.08.051; Rash JE, 1998, P NATL ACAD SCI USA, V95, P11981, DOI 10.1073/pnas.95.20.11981; REULEN HJ, 1977, J NEUROSURG, V46, P24, DOI 10.3171/jns.1977.46.1.0024; Rhodes KE, 2003, NEUROSCIENCE, V120, P41, DOI 10.1016/S0306-4522(03)00285-9; Roitbak T, 1999, GLIA, V28, P40, DOI 10.1002/(SICI)1098-1136(199910)28:1<40::AID-GLIA5>3.0.CO;2-6; Saadoun S, 2005, NATURE, V434, P786, DOI 10.1038/nature03460; Saadoun S, 2005, J CELL SCI, V118, P5691, DOI 10.1242/jcs.02680; Schwab A, 2001, AM J PHYSIOL-RENAL, V280, pF739; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Solenov E, 2004, AM J PHYSIOL-CELL PH, V286, pC426, DOI 10.1152/ajpcell.00298.2003; Solenov EI, 2002, J NEUROSCI METH, V113, P85, DOI 10.1016/S0165-0270(01)00481-2; Sykova E, 1997, NEUROSCIENTIST, V3, P28, DOI 10.1177/107385849700300113; Thiagarajah JR, 2005, J NEUROSCI RES, V80, P293, DOI 10.1002/jnr.20439; Vajda Z, 2002, P NATL ACAD SCI USA, V99, P13131, DOI 10.1073/pnas.192457099; Verbavatz JM, 1997, J CELL SCI, V110, P2855; Vitellaro-Zuccarello L, 2005, GLIA, V51, P148, DOI 10.1002/glia.20196; Wang K, 2004, BRAIN RES, V1024, P193, DOI 10.1016/j.brainres.2004.07.086; Weed LH, 1919, AM J PHYSIOL, V48, P531; Yang BX, 1996, J BIOL CHEM, V271, P4577; YANG BX, 1995, J BIOL CHEM, V270, P22907, DOI 10.1074/jbc.270.39.22907; ZHOU CF, 1986, NEUROSCIENCE, V17, P815, DOI 10.1016/0306-4522(86)90047-3	62	197	228	1	23	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0005-2736	0006-3002		BBA-BIOMEMBRANES	Biochim. Biophys. Acta-Biomembr.	AUG	2006	1758	8					1085	1093		10.1016/j.bbamem.2006.02.018			9	Biochemistry & Molecular Biology; Biophysics	Biochemistry & Molecular Biology; Biophysics	094XP	WOS:000241272900015	16564496				2021-06-18	
J	HUGENHOLTZ, H; STUSS, DT; STETHEM, LL; RICHARD, MT				HUGENHOLTZ, H; STUSS, DT; STETHEM, LL; RICHARD, MT			HOW LONG DOES IT TAKE TO RECOVER FROM A MILD CONCUSSION	NEUROSURGERY			English	Article									UNIV OTTAWA,SCH MED,OTTAWA K1N 6N5,ONTARIO,CANADA	HUGENHOLTZ, H (corresponding author), OTTAWA GEN HOSP,DIV NEUROSURG,501 SMYTH RD,OTTAWA K1H 8L6,ONTARIO,CANADA.						ALEXANDER MP, 1982, PSYCHIATRIC ASPECTS, V2, P219; ANNEGERS JF, 1979, CENTRAL NERVOUS SYST, P1; BAKAY L, 1980, HEAD INJURY, P97; BECKER DP, 1979, ARCH NEUROL-CHICAGO, V36, P750, DOI 10.1001/archneur.1979.00500480024005; BENTON A, 1979, CENTRAL NERVOUS SYST, P220; BROADBENT DE, 1977, AM PSYCHOL, V32, P109, DOI 10.1037/0003-066X.32.2.109; CONKEY RC, 1938, ARCH PSYCHOL, V33, P1; COONLEYHOGANSON R, 1984, NEUROSURGERY, V14, P315, DOI 10.1227/00006123-198403000-00009; DEWITT DS, 1986, J NEUROSURG, V64, P787, DOI 10.3171/jns.1986.64.5.0787; FAAS FH, 1968, J NEUROSURG, V28, P137, DOI 10.3171/jns.1968.28.2.0137; GENNARELLI TA, 1982, HEAD INJURY, P83; GENNARELLI TA, 1980, INTRACRANIAL PRESSUR, V4, P28; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GRONWALL D, 1975, LANCET, V2, P995; GRONWALL D, 1974, LANCET, V2, P605; GRONWALL D, 1981, INJURY, V12, P445; Gronwall D.M., 1974, PSYCHOL EFFECTS CONC; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; GRUBBS FE, 1969, TECHNOMETRICS, V11, P1, DOI 10.2307/1266761; Gurdjian E S, 1972, Clin Neurosurg, V19, P1; GUTHKELCH AN, 1980, EUR NEUROL, V19, P91, DOI 10.1159/000115133; HUGENHOLTZ H, 1982, CAN MED ASSOC J, V127, P827; Hugenholtz H, 1983, Phys Sportsmed, V11, P71, DOI 10.1080/00913847.1983.11708560; JENNETT B, 1979, CENTRAL NERVOUS SYST, P204; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LIDVALL HF, 1974, ACTA NEUROL SCAN S56, V50; Maroon J C, 1980, Clin Neurosurg, V27, P414; MCLAURIN RL, 1982, NEUROLOGICAL SURGERY, V4, P2084; MCLAURIN RL, 1982, NEUROLOGICAL SURGERY, V4, P2175; MERSKEY H, 1972, BRAIN, V95, P521, DOI 10.1093/brain/95.3.521; Miller E, 1970, Cortex, V6, P121; NORMAN B, 1961, ACTA PSYCHIAT SCAND, V37, P236; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PARSONS LC, 1982, NURS RES, V31, P260; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; REITAN RN, 1982, NEUROLOGICAL SURGERY, V4, P2195; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUTHERFORD WH, 1977, LANCET, V1, P1; SHIFFRIN RM, 1977, PSYCHOL REV, V84, P127, DOI 10.1037/0033-295X.84.2.127; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; TAYLOR AR, 1966, LANCET, V2, P178; TEASDALE G, 1974, LANCET, V2, P81; TREISMAN A, 1977, PERCEPT PSYCHOPHYS, V22, P1, DOI 10.3758/BF03206074; Treisman A., 1977, ATTENTION PERFORM, VVI, P333; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; VANZOMEREN AH, 1976, CLIN NEUROL NEUROSUR, V79, P81, DOI 10.1016/0303-8467(76)90001-9; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; WARD AA, 1966, CLIN NEUROSURG, V12, P95	49	197	198	0	4	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	MAY	1988	22	5					853	858		10.1227/00006123-198805000-00006			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	N2659	WOS:A1988N265900008	3380274				2021-06-18	
J	Sandroni, C; Cariou, A; Cavallaro, F; Cronberg, T; Friberg, H; Hoedemaekers, C; Horn, J; Nolan, JP; Rossetti, AO; Soar, J				Sandroni, Claudio; Cariou, Alain; Cavallaro, Fabio; Cronberg, Tobias; Friberg, Hans; Hoedemaekers, Cornelia; Horn, Janneke; Nolan, Jerry P.; Rossetti, Andrea O.; Soar, Jasmeet			Prognostication in comatose survivors of cardiac arrest: An advisory statement from the European Resuscitation Council and the European Society of Intensive Care Medicine	INTENSIVE CARE MEDICINE			English	Article						Heart arrest; Coma; Prognosis; Clinical examination; Somatosensory evoked potentials; Neuron specific enolase; CT scan; Magnetic resonance	NEURON-SPECIFIC ENOLASE; SOMATOSENSORY-EVOKED POTENTIALS; ANOXIC-ISCHEMIC ENCEPHALOPATHY; DIFFUSION-WEIGHTED MRI; TRAUMATIC BRAIN-INJURY; TARGETED TEMPERATURE MANAGEMENT; POSTANOXIC STATUS EPILEPTICUS; MILD THERAPEUTIC HYPOTHERMIA; CRITICALLY-ILL PATIENTS; CARDIOPULMONARY-RESUSCITATION	To review and update the evidence on predictors of poor outcome (death, persistent vegetative state or severe neurological disability) in adult comatose survivors of cardiac arrest, either treated or not treated with controlled temperature, to identify knowledge gaps and to suggest a reliable prognostication strategy. GRADE-based systematic review followed by expert consensus achieved using Web-based Delphi methodology, conference calls and face-to-face meetings. Predictors based on clinical examination, electrophysiology, biomarkers and imaging were included. Evidence from a total of 73 studies was reviewed. The quality of evidence was low or very low for almost all studies. In patients who are comatose with absent or extensor motor response at a parts per thousand yen72 h from arrest, either treated or not treated with controlled temperature, bilateral absence of either pupillary and corneal reflexes or N20 wave of short-latency somatosensory evoked potentials were identified as the most robust predictors. Early status myoclonus, elevated values of neuron-specific enolase at 48-72 h from arrest, unreactive malignant EEG patterns after rewarming, and presence of diffuse signs of postanoxic injury on either computed tomography or magnetic resonance imaging were identified as useful but less robust predictors. Prolonged observation and repeated assessments should be considered when results of initial assessment are inconclusive. Although no specific combination of predictors is sufficiently supported by available evidence, a multimodal prognostication approach is recommended in all patients.	[Sandroni, Claudio; Cavallaro, Fabio] Catholic Univ, Dept Anaesthesiol & Intens Care, Sch Med, I-00168 Rome, Italy; [Cariou, Alain] Paris Descartes Univ, Cochin Hosp APHP, Med ICU, Paris, France; [Cronberg, Tobias] Lund Univ, Dept Clin Sci, Div Neurol, Lund, Sweden; [Friberg, Hans] Lund Univ, Skane Univ Hosp, Lund, Sweden; [Hoedemaekers, Cornelia] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands; [Horn, Janneke] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands; [Nolan, Jerry P.] Royal United Hosp, Dept Anaesthesia & Intens Care Med, Bath BA1 3NG, Avon, England; [Rossetti, Andrea O.] CHU Vaudois, Dept Clin Neurosci, Lausanne, Switzerland; [Rossetti, Andrea O.] Univ Lausanne, Lausanne, Switzerland; [Soar, Jasmeet] Southmead Hosp, Dept Anaesthesia & Intens Care Med, Bristol, Avon, England	Sandroni, C (corresponding author), Catholic Univ, Dept Anaesthesiol & Intens Care, Sch Med, Largo Gemelli 8, I-00168 Rome, Italy.	sandroni@rm.unicatt.it	Nolan, Jerry P./ABF-2561-2020; Rossetti, Andrea O./A-6712-2008; Sandroni, Claudio/A-7320-2019	Rossetti, Andrea O./0000-0002-7878-172X; Nolan, Jerry/0000-0003-3141-3812; Soar, Jasmeet/0000-0001-5970-6073; Sandroni, Claudio/0000-0002-8878-2611	French Ministry of Health; Natus, Inc.; Bard Medical; EU Interreg; Dutch Heart FoundationNetherlands Heart Foundation [2007B039]; Dutch Brain Foundation [14F06.48]; Swiss National Science FoundationSwiss National Science Foundation (SNSF)European Commission [CR32I3_143780]	Alain Cariou is the Deputy of Trauma and Emergency Medicine (TEM) Section of the European Society of Intensive Care Medicine (ESICM) and Delegate from the ESICM in the General Assembly of the European Resuscitation Council (ERC). He received academic research grants from the French Ministry of Health for conducting clinical research in the field of cardiac arrest (all data controlled by the investigators).; Hans Friberg received lecture fees from Natus, Inc. (manufacturer of NervusMonitor, cont. EEG/aEEG) and from Bard Medical. He received grants from the EU Interreg. Programme IV A and academic research grants from multiple non-profit organisations for the Target Temperature Management trial (all data controlled by the investigators). He is the chair of the working party "Care after cardiac arrest", Swedish Resuscitation Council.; Janneke Horn received a grant from the Dutch Heart Foundation (2007B039) for the PROPAC II study and from the Dutch Brain Foundation (14F06.48) for research on SSEP during hypothermia treatment after cardiac arrest (data controlled by the investigator and no restrictions on publication). She is the principal investigator of the PROPACII study and co-author of a systematic review on diagnostic tools for prediction of poor outcome after cardiopulmonary resuscitation.; Andrea Rossetti received a grant from the Swiss National Science Foundation (grant no. CR32I3_143780).	ABRAMSON NS, 1986, NEW ENGL J MED, V314, P397; Accardo J, 2013, REP NEUROL MED, V2013; Al Thenayan E, 2008, NEUROLOGY, V71, P1535, DOI 10.1212/01.wnl.0000334205.81148.31; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Andrews J, 2013, J CLIN EPIDEMIOL, V66, P719, DOI 10.1016/j.jclinepi.2012.03.013; Andrews JC, 2013, J CLIN EPIDEMIOL, V66, P726, DOI 10.1016/j.jclinepi.2013.02.003; ARNOLDUS EPJ, 1995, ANN NEUROL, V38, P697, DOI 10.1002/ana.410380427; Balshem H, 2011, J CLIN EPIDEMIOL, V64, P401, DOI 10.1016/j.jclinepi.2010.07.015; BEAUFORT AM, 1995, EUR J ANAESTH, V12, P95; Becker LB, 2011, CIRCULATION, V124, P2158, DOI 10.1161/CIR.0b013e3182340239; BERTINI G, 1989, CRIT CARE MED, V17, P627, DOI 10.1097/00003246-198907000-00006; Bisschops LLA, 2011, RESUSCITATION, V82, P696, DOI 10.1016/j.resuscitation.2011.02.020; Bloomfield SM, 2007, NEUROCRIT CARE, V6, P121, DOI 10.1007/s12028-007-0008-x; BLYTH CR, 1986, J AM STAT ASSOC, V81, P843, DOI 10.2307/2289018; Booth CM, 2004, JAMA-J AM MED ASSOC, V291, P870, DOI 10.1001/jama.291.7.870; Bouwes A, 2009, NEUROLOGY, V73, P1457, DOI 10.1212/WNL.0b013e3181bf98f4; Bouwes A, 2012, BMC NEUROL, V12, DOI 10.1186/1471-2377-12-63; Bouwes A, 2012, ANN NEUROL, V71, P206, DOI 10.1002/ana.22632; Caldwell JE, 2000, ANESTHESIOLOGY, V92, P84, DOI 10.1097/00000542-200001000-00018; Choi SP, 2012, ACTA ANAESTH SCAND, V56, P116, DOI 10.1111/j.1399-6576.2011.02562.x; Choi SP, 2010, CRIT CARE, V14, DOI 10.1186/cc8874; Claassen J, 2013, INTENS CARE MED, V39, P1337, DOI 10.1007/s00134-013-2938-4; Cloostermans MC, 2012, CRIT CARE MED, V40, P2867, DOI 10.1097/CCM.0b013e31825b94f0; Crepeau AZ, 2013, NEUROLOGY, V80, P339, DOI 10.1212/WNL.0b013e31827f089d; Cronberg T, 2011, NEUROLOGY, V77, P623, DOI 10.1212/WNL.0b013e31822a276d; Cronberg T, 2013, SCAND J TRAUMA RESUS, V21, DOI 10.1186/1757-7241-21-45; Cronberg T, 2013, RESUSCITATION, V84, P867, DOI 10.1016/j.resuscitation.2013.01.019; Datta S, 2009, CRIT CARE RESUSC, V11, P39; EARNEST MP, 1979, NEUROLOGY, V29, P56, DOI 10.1212/WNL.29.1.56; Els T, 2004, ACTA NEUROL SCAND, V110, P361, DOI 10.1111/j.1600-0404.2004.00342.x; English WA, 2009, ANAESTHESIA, V64, P908, DOI 10.1111/j.1365-2044.2009.05939.x; Fritz HG, 2005, ANESTH ANALG, V100, P996, DOI 10.1213/01.ANE.0000146517.17910.54; Fugate JE, 2010, ANN NEUROL, V68, P907, DOI 10.1002/ana.22133; Geocadin RG, 2006, NEUROLOGY, V67, P105, DOI 10.1212/01.wnl.0000223335.86166.b4; Geocadin RG, 2012, CRIT CARE MED, V40, P979, DOI 10.1097/CCM.0b013e3182410146; Goh WC, 2002, BRIT J ANAESTH, V88, P719, DOI 10.1093/bja/88.5.719; Gold B, 2014, RESUSCITATION, V85, P211, DOI 10.1016/j.resuscitation.2013.10.030; Greer DM, 2013, RESUSCITATION, V84, P1546, DOI 10.1016/j.resuscitation.2013.07.028; Greer DM, 2013, RESUSCITATION, V84, pE81, DOI 10.1016/j.resuscitation.2013.02.011; Grossestreuer AV, 2013, RESUSCITATION, V84, P1741, DOI 10.1016/j.resuscitation.2013.07.009; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1294, DOI 10.1016/j.jclinepi.2011.03.017; Hirsch LJ, 2013, J CLIN NEUROPHYSIOL, V30, P1, DOI 10.1097/WNP.0b013e3182784729; Howell K, 2013, RESUSCITATION, V84, P1409, DOI 10.1016/j.resuscitation.2013.05.015; Hsu J, 2011, IMPLEMENT SCI, V6, DOI 10.1186/1748-5908-6-62; Huntgeburth M, 2014, NEUROCRIT CARE, V20, P358, DOI 10.1007/s12028-013-9848-8; Inamasu J, 2010, RESUSCITATION, V81, P534, DOI 10.1016/j.resuscitation.2010.01.012; Inamasu J, 2009, RESUSCITATION, V80, P977, DOI 10.1016/j.resuscitation.2009.05.010; Johnsson P, 2000, ANN THORAC SURG, V69, P750, DOI 10.1016/S0003-4975(99)01393-4; Jorgensen EO, 1998, RESUSCITATION, V36, P111, DOI 10.1016/S0300-9572(97)00094-4; Kamps MJA, 2013, INTENS CARE MED, V39, P1671, DOI 10.1007/s00134-013-3004-y; Kawai M, 2011, J CLIN NEUROPHYSIOL, V28, P483, DOI 10.1097/WNP.0b013e318231bfef; Kim J, 2013, RESUSCITATION, V84, P1393, DOI 10.1016/j.resuscitation.2013.04.011; Kim J, 2012, NEUROCRIT CARE, V17, P412, DOI 10.1007/s12028-012-9773-2; Kim SH, 2013, SCAND J TRAUMA RESUS, V21, DOI 10.1186/1757-7241-21-57; KRUMHOLZ A, 1988, NEUROLOGY, V38, P401, DOI 10.1212/WNL.38.3.401; LARSON MD, 1995, ARCH NEUROL-CHICAGO, V52, P369, DOI 10.1001/archneur.1995.00540280051018; Leary M, 2010, RESUSCITATION, V81, P1133, DOI 10.1016/j.resuscitation.2010.04.021; Lee BK, 2013, RESUSCITATION, V84, P1387, DOI 10.1016/j.resuscitation.2013.05.026; Legriel S, 2013, RESUSCITATION, V84, P343, DOI 10.1016/j.resuscitation.2012.11.001; Leithner C, 2010, NEUROLOGY, V74, P965, DOI 10.1212/WNL.0b013e3181d5a631; Lucas JM, 2012, RESUSCITATION, V83, P265, DOI 10.1016/j.resuscitation.2011.09.017; Luyt CE, 2012, ANESTHESIOLOGY, V117, P1311, DOI 10.1097/ALN.0b013e318275148c; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Mani R, 2012, RESUSCITATION, V83, P840, DOI 10.1016/j.resuscitation.2012.02.015; Mlynash M, 2010, STROKE, V41, P1665, DOI 10.1161/STROKEAHA.110.582452; MORIMOTO Y, 1993, CRIT CARE MED, V21, P104, DOI 10.1097/00003246-199301000-00020; Morris HR, 1998, J NEUROL NEUROSUR PS, V64, P267, DOI 10.1136/jnnp.64.2.267; Mortberg E, 2011, RESUSCITATION, V82, P26, DOI 10.1016/j.resuscitation.2010.10.011; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Newcommon NJ, 2003, STROKE, V34, P377, DOI 10.1161/01.STR.0000055766.99908.58; Nielsen N, 2013, NEW ENGL J MED, V369, P2197, DOI 10.1056/NEJMoa1310519; Noirhomme Q, 2014, CLIN EEG NEUROSCI, V45, P6, DOI 10.1177/1550059413509616; Oddo M, 2014, CRIT CARE MED, V42, P1340, DOI 10.1097/CCM.0000000000000211; Okada K, 2012, RESUSCITATION, V83, P734, DOI 10.1016/j.resuscitation.2011.12.036; Oksanen T, 2009, RESUSCITATION, V80, P165, DOI 10.1016/j.resuscitation.2008.08.017; Pfeifer R, 2005, RESUSCITATION, V65, P49, DOI 10.1016/j.resuscitation.2004.10.011; Pfeifer R, 2013, RESUSCITATION, V84, P1375, DOI 10.1016/j.resuscitation.2013.05.016; Reilly E. L., 1993, ELECTROENCEPHALOGRAP, P104; Reisinger J, 2007, EUR HEART J, V28, P52, DOI 10.1093/eurheartj/ehl316; Rifai N, 2008, CLIN CHEM, V54, P1101, DOI 10.1373/clinchem.2008.108993; Rittenberger JC, 2012, NEUROCRIT CARE, V16, P114, DOI 10.1007/s12028-011-9565-0; Rosen H, 1998, STROKE, V29, P473, DOI 10.1161/01.STR.29.2.473; Rosen H, 2001, RESUSCITATION, V49, P183, DOI 10.1016/S0300-9572(00)00348-8; Rossetti AO, 2012, NEUROLOGY, V78, P796, DOI 10.1212/WNL.0b013e318249f6bb; Rossetti AO, 2010, CRIT CARE, V14, DOI 10.1186/cc9276; Rossetti AO, 2010, ANN NEUROL, V67, P301, DOI 10.1002/ana.21984; Rossetti AO, 2009, NEUROLOGY, V72, P744, DOI 10.1212/01.wnl.0000343006.60851.62; Rothstein TL, 2000, J CLIN NEUROPHYSIOL, V17, P486, DOI 10.1097/00004691-200009000-00007; Rundgren M, 2010, CRIT CARE MED, V38, P1838, DOI 10.1097/CCM.0b013e3181eaa1e7; Rundgren M, 2009, RESUSCITATION, V80, P784, DOI 10.1016/j.resuscitation.2009.03.025; Samaniego EA, 2011, NEUROCRIT CARE, V15, P113, DOI 10.1007/s12028-010-9412-8; Sandroni C, 2013, RESUSCITATION, V84, P1324, DOI 10.1016/j.resuscitation.2013.06.020; Sandroni C, 2013, RESUSCITATION, V84, P1310, DOI 10.1016/j.resuscitation.2013.05.013; Schunemann HJ, 2008, BMJ-BRIT MED J, V336, P1106, DOI 10.1136/bmj.39500.677199.AE; Seder DB, 2010, INTENS CARE MED, V36, P281, DOI 10.1007/s00134-009-1691-1; Sharshar T, 2014, INTENS CARE MED, V40, P484, DOI 10.1007/s00134-014-3214-y; Stammet P, 2013, J AM COLL CARDIOL, V62, P851, DOI 10.1016/j.jacc.2013.04.039; Stammet P, 2009, RESUSCITATION, V80, P437, DOI 10.1016/j.resuscitation.2009.01.008; Steffen IG, 2010, CRIT CARE, V14, DOI 10.1186/cc8975; Stelzl T, 1995, Eur J Emerg Med, V2, P24, DOI 10.1097/00063110-199503000-00006; Stern P, 2007, TUMOR BIOL, V28, P84, DOI 10.1159/000098441; Stiell IG, 2011, NEW ENGL J MED, V365, P787, DOI 10.1056/NEJMoa1010076; Storm C, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-6; Suys T, 2014, NEUROCRIT C IN PRESS; Taccone FS, 2014, CRIT CARE, V18, DOI 10.1186/cc13696; TEASDALE G, 1974, LANCET, V2, P81; Thomke F, 2005, BMC NEUROL, V5, DOI 10.1186/1471-2377-5-14; Tiainen M, 2005, CRIT CARE MED, V33, P1736, DOI 10.1097/01.CCM.0000171536.63641.D9; Tiainen M, 2003, STROKE, V34, P2881, DOI 10.1161/01.STR.0000103320.90706.35; Topcuoglu MA, 2009, INTERNAL MED, V48, P1635, DOI 10.2169/internalmedicine.48.2091; van der Eerden AW, 2014, RADIOLOGY, V270, P506, DOI 10.1148/radiol.13122720; Wennervirta JE, 2009, CRIT CARE MED, V37, P2427, DOI 10.1097/CCM.0b013e3181a0ff84; Wijdicks EFM, 2006, NEUROLOGY, V67, P203, DOI 10.1212/01.wnl.0000227183.21314.cd; WIJDICKS EFM, 1994, LANCET, V343, P1642, DOI 10.1016/S0140-6736(94)93100-3; Wijdicks EFM, 2001, AM J NEURORADIOL, V22, P1561; Wijman CAC, 2009, ANN NEUROL, V65, P394, DOI 10.1002/ana.21632; World Health Organisation, 2003, EIPGPEEQC2003 WHO; Wu O, 2011, STROKE, V42, P985, DOI 10.1161/STROKEAHA.110.594879; Wu O, 2009, RADIOLOGY, V252, P173, DOI 10.1148/radiol.2521081232; Young GB, 2005, NEUROCRIT CARE, V2, P159, DOI 10.1385/NCC:2:2:159; Zanatta P, 2012, MINERVA ANESTESIOL, V78, P749; Zandbergen EGJ, 2006, CLIN NEUROPHYSIOL, V117, P1529, DOI 10.1016/j.clinph.2006.03.018; Zandbergen EGJ, 2006, NEUROLOGY, V66, P62, DOI 10.1212/01.wnl.0000191308.22233.88; Zellner T, 2013, RESUSCITATION, V84, P1382, DOI 10.1016/j.resuscitation.2013.03.021; Zingler VC, 2003, EUR NEUROL, V49, P79, DOI 10.1159/000068503	125	196	204	1	14	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0342-4642	1432-1238		INTENS CARE MED	Intensive Care Med.	DEC	2014	40	12					1816	1831		10.1007/s00134-014-3470-x			16	Critical Care Medicine	General & Internal Medicine	AU1WF	WOS:000345407500002	25398304	Green Published, Other Gold	Y	N	2021-06-18	
J	Levin, HS; Wilde, E; Troyanskaya, M; Petersen, NJ; Scheibel, R; Newsome, M; Radaideh, M; Wu, T; Yallampalli, R; Chu, ZL; Li, XQ				Levin, Harvey S.; Wilde, Elisabeth; Troyanskaya, Maya; Petersen, Nancy J.; Scheibel, Randall; Newsome, Mary; Radaideh, Majdi; Wu, Trevor; Yallampalli, Ragini; Chu, Zili; Li, Xiaoqi			Diffusion Tensor Imaging of Mild to Moderate Blast-Related Traumatic Brain Injury and Its Sequelae	JOURNAL OF NEUROTRAUMA			English	Article						blast-related traumatic brain injury; diffusion tensor imaging; outcome	OPERATION IRAQI FREEDOM; AXONAL INJURY; USE DISORDERS; HEAD-INJURY; AFGHANISTAN; MECHANISMS; MEMORY; DAMAGE; VETERANS; ALCOHOL	To evaluate the effects of mild to moderate blast-related traumatic brain injury (TBI) on the microstructure of brain white matter (WM) and neurobehavioral outcomes, we studied 37 veterans and service members (mean age 31.5 years, SD = 7.2; post-injury interval 871.5 days; SD = 343.1), whose report of acute neurological status was consistent with sustaining mild to moderate TBI due to blast while serving in Iraq or Afghanistan. Fifteen veterans without a history of TBI or exposure to blast (mean age 31.4 years, SD = 5.4) served as a comparison group, including seven subjects with extracranial injury (post-injury interval 919.5 days, SD = 455.1), and eight who were uninjured. Magnetic resonance imaging disclosed focal lesions in five TBI participants. Post-concussion symptoms (Neurobehavioral Symptom Inventory), post-traumatic stress disorder (PTSD) symptoms (PTSD Checklist-Civilian), and global distress and depression (Brief Symptom Inventory) were worse in the TBI participants than the comparison group, but no group differences were found in perceived physical or mental functioning (SF-12). Verbal memory (Selective Reminding) was less efficient in the TBI group, but there were no group differences in nonverbal memory (Selective Reminding) or decision making (Iowa Gambling Task). Verbal memory in the TBI group was unrelated to PTSD severity. Diffusion tensor imaging (DTI) using tractography, standard single-slice region-of-interest measurement, and voxel-based analysis disclosed no group differences in fractional anisotropy (FA) and apparent diffusion coefficient (ADC). However, FA of the left and right posterior internal capsule and left corticospinal tract was positively correlated with total words consistently recalled, whereas ADC for the left and right uncinate fasciculi and left posterior internal capsule was negatively correlated with this measure of verbal memory. Correlations of DTI variables with symptom measures were nonsignificant and inconsistent. Our data do not show WM injury in mild to moderate blast-related TBI in veterans despite their residual symptoms and difficulty in verbal memory. Limitations of the study and implications for future research are also discussed.	[Levin, Harvey S.; Wilde, Elisabeth; Troyanskaya, Maya; Scheibel, Randall; Newsome, Mary; Yallampalli, Ragini; Li, Xiaoqi] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Wilde, Elisabeth; Radaideh, Majdi; Chu, Zili] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Petersen, Nancy J.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Levin, Harvey S.; Wilde, Elisabeth; Petersen, Nancy J.; Scheibel, Randall; Newsome, Mary; Radaideh, Majdi] Michael E DeBakey VA Med Ctr, Houston, TX USA; [Wu, Trevor] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA	Levin, HS (corresponding author), Baylor Coll Med, Dept Phys Med & Rehabil, 1709 Dryden Rd,Suite 1200, Houston, TX 77030 USA.	hlevin@bcm.edu			Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development ServiceUS Department of Veterans Affairs [B4596]; Mental Illness Research, Education and Clinical Centers (MIRECC); Houston VA HSR&D Center of Excellence [HFP90-020]; Veterans AffairsUS Department of Veterans Affairs [I01RX000326] Funding Source: NIH RePORTER	This research was supported by grant B4596 by the Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service; the Mental Illness Research, Education and Clinical Centers (MIRECC); and by the Houston VA HSR&D Center of Excellence (HFP90-020). We gratefully acknowledge the assistance of Stacey K. Martin and Stephen R. McCauley, Ph.D. for their assistance in manuscript preparation. We are also indebted to the veterans and service members who participated in the study.	ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Bagley LJ, 2000, J MAGN RESON IMAGING, V11, P1, DOI 10.1002/(SICI)1522-2586(200001)11:1<1::AID-JMRI1>3.0.CO;2-H; BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bechara A, 2004, BRAIN COGNITION, V55, P30, DOI 10.1016/j.bandc.2003.04.001; Bechara A, 2000, BRAIN, V123, P2189, DOI 10.1093/brain/123.11.2189; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Brewin CR, 2010, PSYCHOL REV, V117, P210, DOI 10.1037/a0018113; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Champion HR, 2009, J TRAUMA, V66, P1468, DOI 10.1097/TA.0b013e3181a27e7f; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Damasio AR, 1996, PHILOS T R SOC B, V351, P1413, DOI 10.1098/rstb.1996.0125; Derogatis L., 1982, BRIEF SYMPTOM INVENT; FLETCHER JM, 1985, J EXP CHILD PSYCHOL, V40, P244, DOI 10.1016/0022-0965(85)90088-8; French LM, 2008, J CLIN PSYCHOL, V64, P1004, DOI 10.1002/jclp.20514; Galarneau MR, 2008, J NEUROSURG, V108, P950, DOI 10.3171/JNS/2008/108/5/0950; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; HOOGENRAAD F, 2002, MULTICENTER EVALUATI; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Kimura H, 1996, J COMPUT ASSIST TOMO, V20, P540, DOI 10.1097/00004728-199607000-00007; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Maisto SA, 2000, PSYCHOL ASSESSMENT, V12, P186, DOI 10.1037/1040-3590.12.2.186; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Netsch T, 2004, IEEE T MED IMAGING, V23, P789, DOI 10.1109/TMI.2004.827479; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Rolls ET, 1999, BRAIN EMOTION; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Seal KH, 2009, AM J PUBLIC HEALTH, V99, P1651, DOI 10.2105/AJPH.2008.150284; SKINNER HA, 1982, ADDICT BEHAV, V7, P363, DOI 10.1016/0306-4603(82)90005-3; SMITH DH, 1995, J NEUROTRAUM, V12, P573, DOI 10.1089/neu.1995.12.573; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; TONG KA, 2002, P 10 ANN M ISMRM HON, P46; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Wakana S, 2007, NEUROIMAGE, V36, P630, DOI 10.1016/j.neuroimage.2007.02.049; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wilde EA, 2009, J CLIN EXP NEUROPSYC, V31, P205, DOI 10.1080/13803390802098118; Wu TC, 2010, J NEUROTRAUM, V27, P303, DOI 10.1089/neu.2009.1110	55	196	198	3	39	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2010	27	4					683	694		10.1089/neu.2009.1073			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	584CG	WOS:000276727000003	20088647				2021-06-18	
J	Griesbach, GS; Hovda, DA; Gomez-Pinilla, F				Griesbach, Grace Sophia; Hovda, David Allen; Gomez-Pinilla, Fernando			Exercise-induced improvement in cognitive performance after traumatic brain injury in rats is dependent on BDNF activation	BRAIN RESEARCH			English	Article						TBI; Hippocampus; Fluid percussion injury; Synapsin I and CREB	HIPPOCAMPAL EXCITATORY SYNAPSES; CORTICAL IMPACT INJURY; LONG-TERM POTENTIATION; NEUROTROPHIC FACTOR; VOLUNTARY EXERCISE; SYNAPTIC-PLASTICITY; NEUROTRANSMITTER RELEASE; PROTEIN EXPRESSION; CONTUSION INJURY; MEMORY DEFICITS	We have previously shown that voluntary exercise upregulates brain derived neurotrophic factor (BDNF) within the hippocampus and is associated with an enhancement of cognitive recovery after a lateral fluid percussion injury (FPI). In order to determine if BDNF is critical to this effect we used an immunoadhesin chimera (TrkB-IgG) that inactivates free BDNF. This BDNF inhibitor was administered to adult male rats two weeks after they had received a mild fluid percussion injury (FPI) or sham surgery. These animals were then housed with or without access to a running wheel (RW) from post-injury-day (PID) 14 to 20. On PID 21, rats were tested for spatial learning in a Morris Water Maze. Results showed that exercise counteracted the cognitive deficits associated with the injury. However this exercise-induced cognitive improvement was attenuated in the FPI-RW rats that were treated with TrkB-IgG. Molecules important for synaptic plasticity and learning were measured in a separate group of rats that were sacrificed immediately after exercise (PID 21). Western blot analyses showed that exercise increased the mature form of BDNF, synapsin I and cyclic-AMP response-element-binding protein (CREB) in the vehicle treated Sham-RW group. However, only the mature form of BDNF and CREB were increased in the vehicle treated FPI-RW group. Blocking BDNF (pre administration of TrkB-IgG) greatly reduced the molecular effects of exercise in that exercise-induced increases of BDNF, synapsin I and CREB were not observed. These studies provide evidence that BDNF has a major role in exercise's cognitive effects in traumatically injured brain. (C) 2009 Elsevier B.V. All rights reserved.	[Griesbach, Grace Sophia] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA; [Hovda, David Allen] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA; [Gomez-Pinilla, Fernando] Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA 90095 USA; [Griesbach, Grace Sophia; Hovda, David Allen; Gomez-Pinilla, Fernando] Univ Calif Los Angeles, UCLA Brain Injury Res Ctr, Los Angeles, CA 90095 USA	Griesbach, GS (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Box 957030, Los Angeles, CA 90095 USA.	ggriesbach@mednet.ucla.edu			NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS048535, NS27544, NSS0465]; UCLA Brain Injury Research Center; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027544, R01NS061960, R21NS048535, R01NS050465] Funding Source: NIH RePORTER	This study was supported by NINDS awards NS048535, NS27544, NSS0465 and the UCLA Brain Injury Research Center. We would also wish to thank Yumei Chueng for her excellent technical help.	Abel T, 1998, BRAIN RES REV, V26, P360, DOI 10.1016/S0165-0173(97)00050-7; Adlard PA, 2004, NEUROSCIENCE, V124, P985, DOI 10.1016/j.neuroscience.2003.12.039; Albensi BC, 2001, J NEUROSCI RES, V65, P279, DOI 10.1002/jnr.1151; AMARAL DG, 1989, NEUROSCIENCE, V31, P571, DOI 10.1016/0306-4522(89)90424-7; Ashman TA, 2006, MT SINAI J MED, V73, P999; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Barco A, 2005, NEURON, V48, P123, DOI 10.1016/j.neuron.2005.09.005; Berninger B, 1999, LEARN MEMORY, V6, P232; Binder S, 2005, J HEAD TRAUMA REHAB, V20, P189, DOI 10.1097/00001199-200505000-00002; Blaha GR, 2000, NEUROSCIENCE, V99, P483, DOI 10.1016/S0306-4522(00)00214-1; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conte V, 2008, RESTOR NEUROL NEUROS, V26, P45; Cotman CW, 2002, TRENDS NEUROSCI, V25, P295, DOI 10.1016/S0166-2236(02)02143-4; Ding YH, 2006, ACTA NEUROPATHOL, V112, P74, DOI 10.1007/s00401-006-0076-6; Esper RM, 2004, J NEUROSCI, V24, P6218, DOI 10.1523/JNEUROSCI.1692-04.2004; Fang H, 2003, J BIOL CHEM, V278, P26401, DOI 10.1074/jbc.M211539200; Fineman I, 2000, J NEUROTRAUM, V17, P739, DOI 10.1089/neu.2000.17.739; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Ghiani CA, 2007, GLIA, V55, P966, DOI 10.1002/glia.20521; Giza CC, 2005, BEHAV BRAIN RES, V157, P11, DOI 10.1016/j.bbr.2004.06.003; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; Griesbach GS, 2008, NEUROSCIENCE, V154, P530, DOI 10.1016/j.neuroscience.2008.04.003; Griesbach GS, 2007, J NEUROTRAUM, V24, P1161, DOI 10.1089/neu.2006.0255; Griesbach GS, 2009, J NEUROSCI RES, V87, P795, DOI 10.1002/jnr.21893; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Gronli J, 2006, PHARMACOL BIOCHEM BE, V85, P842, DOI 10.1016/j.pbb.2006.11.021; Gurkoff GG, 2006, BRAIN RES, V1077, P24, DOI 10.1016/j.brainres.2006.01.011; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hicks RR, 2002, NEUROSCIENCE, V112, P631, DOI 10.1016/S0306-4522(02)00104-5; Hillman CH, 2008, NAT REV NEUROSCI, V9, P58, DOI 10.1038/nrn2298; Jovanovic JN, 2000, NAT NEUROSCI, V3, P323; Kang HJ, 1997, NEURON, V19, P653, DOI 10.1016/S0896-6273(00)80378-5; Kang HJ, 1996, SCIENCE, V273, P1402, DOI 10.1126/science.273.5280.1402; LEVINE ES, 1995, P NATL ACAD SCI USA, V92, P8074, DOI 10.1073/pnas.92.17.8074; Levine ES, 1998, P NATL ACAD SCI USA, V95, P10235, DOI 10.1073/pnas.95.17.10235; Lin SY, 1999, MOL BRAIN RES, V70, P18, DOI 10.1016/S0169-328X(99)00122-9; Lom B, 1999, J NEUROSCI, V19, P9928; Lu B, 2003, NEURON, V39, P735, DOI 10.1016/S0896-6273(03)00538-5; Matsumoto T, 2008, NAT NEUROSCI, V11, P131, DOI 10.1038/nn2038; Meyer A, 1996, BRAIN RES, V732, P121, DOI 10.1016/0006-8993(96)00502-1; Mowla SJ, 2001, J BIOL CHEM, V276, P12660, DOI 10.1074/jbc.M008104200; NEEPER SA, 1995, NATURE, V373, P109, DOI 10.1038/373109a0; Pang PT, 2004, SCIENCE, V306, P487, DOI 10.1126/science.1100135; Pozzo-Miller LD, 1999, J NEUROSCI, V19, P4972; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; QUATTROCHI JJ, 1989, SCIENCE, V245, P984, DOI 10.1126/science.2475910; Rex CS, 2007, J NEUROSCI, V27, P3017, DOI 10.1523/JNEUROSCI.4037-06.2007; Riddle DR, 1997, BIOTECHNIQUES, V23, P928, DOI 10.2144/97235rr02; Schaaf MJM, 1998, BRAIN RES, V813, P112, DOI 10.1016/S0006-8993(98)01010-5; Seidah NG, 1996, FEBS LETT, V379, P247, DOI 10.1016/0014-5793(95)01520-5; Silva AJ, 1998, ANNU REV NEUROSCI, V21, P127, DOI 10.1146/annurev.neuro.21.1.127; SMITH BWH, 1991, FAM PRACT, V8, P269, DOI 10.1093/fampra/8.3.269; Smith MA, 1995, ANN NY ACAD SCI, V771, P234, DOI 10.1111/j.1749-6632.1995.tb44684.x; Suen PC, 1997, P NATL ACAD SCI USA, V94, P8191, DOI 10.1073/pnas.94.15.8191; Takei N, 1997, J NEUROCHEM, V68, P370; Tyler WJ, 2006, J PHYSIOL-LONDON, V574, P787, DOI 10.1113/jphysiol.2006.111310; Tyler WJ, 2001, J NEUROSCI, V21, P4249, DOI 10.1523/JNEUROSCI.21-12-04249.2001; Ueyama T, 1997, NEUROSCI RES, V28, P103, DOI 10.1016/S0168-0102(97)00030-8; URFER R, 1995, EMBO J, V14, P2795, DOI 10.1002/j.1460-2075.1995.tb07279.x; Vaynman S, 2004, EUR J NEUROSCI, V20, P2580, DOI 10.1111/j.1460-9568.2004.03720.x; Vaynman S, 2003, NEUROSCIENCE, V122, P647, DOI 10.1016/j.neuroscience.2003.08.001; Vaynman SS, 2006, BRAIN RES, V1070, P124, DOI 10.1016/j.brainres.2005.11.062; Wilde MC, 2007, ARCH PHYS MED REHAB, V88, P1284, DOI 10.1016/j.apmr.2007.07.012	66	196	205	0	23	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	SEP 8	2009	1288						105	115		10.1016/j.brainres.2009.06.045			11	Neurosciences	Neurosciences & Neurology	497ZK	WOS:000270104200012	19555673	Green Accepted			2021-06-18	
J	Agel, J; Evans, TA; Dick, R; Putukian, M; Marshall, SW				Agel, Julie; Evans, Todd A.; Dick, Randall; Putukian, Margot; Marshall, Stephen W.			Descriptive epidemiology of collegiate men's soccer injuries: National Collegiate Athletic Association injury surveillance system, 1988-1989 through 2002-2003	JOURNAL OF ATHLETIC TRAINING			English	Article						athletic injuries; injury prevention; concussion; ankle injuries	ANKLE SPRAINS; PLAYERS	Objective: To review 15 years of National Collegiate Athletic Association (NCAA) injury surveillance data for men's soccer and to identify potential areas for injury prevention initiatives. Background. The NCAA sanctioned its first men's soccer championship in 1959. Since then, the sport has grown to include more than 18000 annual participants across 3 NCAA divisions. During the 15 years from 1988-1989 to 2002-2003, the NCAA Injury Surveillance System accumulated game and practice injury data for men's soccer across all 3 NCAA divisions. Main Results: The injury rate was 4 times higher in games compared with practices (18.75 versus 4.34 injuries per 1000 athlete-exposures, rate ratio = 4.3, 95% confidence interval = 4.2, 4.5), and preseason practices had a higher injury rate than in-season practices (7.98 versus 2.43 injuries per 1000 athleteexposures, rate ratio = 3.3, 95% confidence interval = 3.1, 3.5). In both games and practices, more than two thirds of men's soccer injuries occurred to the lower extremities, followed by the head and neck in games and the trunk and back in practices. Although player-to-player contact was the primary cause of injury during games, most practice injuries occurred without direct contact to the injured body part. Ankle ligament sprains represented the most common injury during practices and games, whereas knee internal derangements were the most common type of severe injury (defined as 10+ days of time loss). Recommendations: Sprains, contusions, and strains of the lower extremities were the most common injuries in men's collegiate soccer, with player-to-player contact the primary injury mechanism during games. Preventive efforts should focus on the player-to-player contact that often leads to these injuries and greater enforcement of the rules that are in place to limit their frequency and severity. Emphasis also should be placed on addressing the high rate of first-time and recurrent ankle ligament sprains.	Univ No Iowa, Cedar Falls, IA 50614 USA; Univ Minnesota, Minneapolis, MN 55455 USA; Natl Collegiate Athlet Assoc, Indianapolis, IN USA; Princeton Univ, Princeton, NJ 08544 USA; Univ N Carolina, Chapel Hill, NC 27515 USA	Evans, TA (corresponding author), Univ No Iowa, 203 WRC, Cedar Falls, IA 50614 USA.	todd.evans@uni.edu		Marshall, Stephen/0000-0002-2664-9233			ANDERSEN TE, 2004, AM J SPORTS MED S1, V32; Boden BP, 1999, KNEE SURG SPORT TR A, V7, P262, DOI 10.1007/s001670050160; Cattermole HR, 1996, BRIT J SPORT MED, V30, P171, DOI 10.1136/bjsm.30.2.171; Dick R, 2007, J ATHL TRAINING, V42, P173; Dvorak J, 2000, AM J SPORT MED, V28, pS69; EKSTRAND J, 1990, FOOT ANKLE, V11, P41, DOI 10.1177/107110079001100108; Elias SR, 2001, MED SCI SPORT EXER, V33, P359, DOI 10.1097/00005768-200103000-00004; FULLER CW, 2004, AM J SPORTS MED S1, V32; FULLER CW, 2004, AM J SPORTS MED S1, V32; Giza E, 2003, AM J SPORT MED, V31, P550, DOI 10.1177/03635465030310041201; *NAT COLL ATHL ASS, 1909, 1981 82 2004 05 NCAA; *NAT COLL ATHL ASS, 2006 MENS WOM SOCC R; Peterson L, 2000, AM J SPORT MED, V28, pS51; Putukian M, 2000, CLIN J SPORT MED, V10, P104, DOI 10.1097/00042752-200004000-00004; Putukian M, 1996, AM J SPORT MED, V24, P317, DOI 10.1177/036354659602400312; Schmitt DM, 2004, INT J SPORTS MED, V25, P326, DOI 10.1055/s-2004-819941; SURVE I, 1994, AM J SPORT MED, V22, P601, DOI 10.1177/036354659402200506; TROPP H, 1985, AM J SPORT MED, V13, P259, DOI 10.1177/036354658501300408; Woods C, 2003, BRIT J SPORT MED, V37, P233, DOI 10.1136/bjsm.37.3.233	19	196	199	0	23	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	APR-JUN	2007	42	2					270	277					8	Sport Sciences	Sport Sciences	180RC	WOS:000247382300014	17710176				2021-06-18	
J	Tanriverdi, F; Senyurek, H; Unluhizarci, K; Selcuklu, A; Casanueva, FF; Kelestimur, F				Tanriverdi, Fatih; Senyurek, Hakan; Unluhizarci, Kursad; Selcuklu, Ahmet; Casanueva, Felipe F.; Kelestimur, Fahrettin			High risk of hypopituitarism after traumatic brain injury: A prospective investigation of anterior pituitary function in the acute phase and 12 months after trauma	JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM			English	Article							GROWTH-HORMONE DEFICIENCY; GH-RELEASING HORMONE; STIMULATION TEST; NEUROENDOCRINE DYSFUNCTION; SUBARACHNOID HEMORRHAGE; HEAD-INJURY; ADULTS; ADRENOCORTICOTROPIN; PREVALENCE; DIAGNOSIS	Context: Recent data have demonstrated that traumatic brain injury (TBI)-mediated hypopituitarism could be more frequent than previously known. However, most previous data were obtained from retrospective studies. Objectives: The aim of this study was to determine 1) the prevalence of anterior pituitary hormone deficiencies in the acute phase of TBI and after 12 months, 2) whether severity of trauma correlated with basal hormone levels, and 3) whether initial hormone deficiencies predicted medium-term hormonal status. Design and Patients: Fifty-two TBI patients (43 men and nine women) were included in the prospective study. Pituitary function was evaluated within 24 h of admission and after 1 yr. Results: Some 5.8% of the patients had TSH deficiency, 41.6% had gonadotropin deficiency, 9.8% had ACTH deficiency, and 20.4% had GH deficiency (GHD). Twelve months after TBI, 5.8% had TSH deficiency, 7.7% had gonadotropin deficiency, 19.2% had ACTH deficiency, and 37.7% had GHD. Twenty-six patients (50.9%) had at least one anterior pituitary hormone deficiency, 21 patients (41.2%) had isolated hormone deficiencies, and five patients (9.7%) had combined hormone deficiencies. Overall, the pituitary hormone deficiencies recovered in 30 (57.7%) patients after 1 yr, and new pituitary hormone deficiencies were present in 27 (51.9%) patients after 1 yr. Conclusions: GHD is the most common pituitary deficit 12 months after TBI, and 50.9% of the patients had at least one anterior pituitary hormone deficiency. Pituitary function may improve or worsen in a considerable number of patients over 12 months.	Erciyes Univ, Sch Med, Dept Endocrinol, TR-38039 Kayseri, Turkey; Erciyes Univ, Sch Med, Dept Neurosurg, TR-38039 Kayseri, Turkey; Univ Santiago de Compostela, Sch Med, Dept Med, Santiago De Compostela, Spain; Univ Santiago de Compostela, Complejo Hosp Univ Santiago, Santiago De Compostela, Spain	Kelestimur, F (corresponding author), Erciyes Univ, Sch Med, Dept Endocrinol, TR-38039 Kayseri, Turkey.	fktimur@erciyes.edu.tr					Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; BARTON RN, 1987, J TRAUMA, V27, P384, DOI 10.1097/00005373-198704000-00007; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Bondanelli M, 2005, EUR J ENDOCRINOL, V152, P679, DOI 10.1530/eje.1.01895; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; BURKE CW, 1992, CLIN ENDOCRINOL, V36, P133, DOI 10.1111/j.1365-2265.1992.tb00946.x; Ceballos R, 1966, Ala J Med Sci, V3, P185; CHIOLERO R, 1988, J TRAUMA, V28, P1368, DOI 10.1097/00005373-198809000-00011; De Marinis L, 1999, CLIN ENDOCRINOL, V50, P741; DICKSTEIN G, 1991, J CLIN ENDOCR METAB, V72, P773, DOI 10.1210/jcem-72-4-773; Dimopoulou I, 2004, INTENS CARE MED, V30, P1216, DOI 10.1007/s00134-004-2297-2; EDWARDS OM, 1986, MEDICINE, V65, P281; FEIBEL J, 1983, J CLIN ENDOCR METAB, V57, P1245, DOI 10.1210/jcem-57-6-1245; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Greenwood E, 2003, NAT REV CANCER, V3, P7, DOI 10.1038/nrc978; HACKL JM, 1991, INTENS CARE MED, V17, P25, DOI 10.1007/BF01708405; Hartman ML, 2002, J CLIN ENDOCR METAB, V87, P477, DOI 10.1210/jc.87.2.477; Kelestimur F, 2004, J ENDOCRINOL INVEST, V27, pRC28, DOI 10.1007/BF03345299; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Lamberts SWJ, 1998, LANCET, V352, P127; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Mazaux JM, 1998, DISABIL REHABIL, V20, P435, DOI 10.3109/09638289809166108; PETERSEN SR, 1993, J TRAUMA, V34, P653, DOI 10.1097/00005373-199305000-00007; Popovic V, 2000, LANCET, V356, P1137, DOI 10.1016/S0140-6736(00)02755-0; ROSS R, 1991, CLIN ENDOCRINOL, V35, P47, DOI 10.1111/j.1365-2265.1991.tb03495.x; Shalet SM, 1998, ENDOCR REV, V19, P203, DOI 10.1210/er.19.2.203; Springer J, 2001, LANCET, V357, P1848, DOI 10.1016/S0140-6736(00)04953-9; TEASDALE G, 1974, LANCET, V2, P81; WOOLF PD, 1992, CRIT CARE MED, V20, P216, DOI 10.1097/00003246-199202000-00011; ZIEGLER MG, 1990, CRIT CARE MED, V18, P253, DOI 10.1097/00003246-199003000-00001	34	196	210	1	8	ENDOCRINE SOC	WASHINGTON	2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA	0021-972X	1945-7197		J CLIN ENDOCR METAB	J. Clin. Endocrinol. Metab.	JUN	2006	91	6					2105	2111		10.1210/jc.2005-2476			7	Endocrinology & Metabolism	Endocrinology & Metabolism	050NK	WOS:000238095000019	16522687	Bronze			2021-06-18	
J	Iverson, GL				Iverson, Grant L.			Misdiagnosis of the persistent postconcussion syndrome in patients with depression	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						postconcussion syndrome; mild traumatic brain injury; outcome; depression	MILD HEAD-INJURY; POSTTRAUMATIC-STRESS-DISORDER; POST-CONCUSSION SYNDROME; BASE RATES; SYMPTOMS; DEFICITS; PAIN; PERFORMANCE; DYSFUNCTION; COMPLAINT	The purpose of this study is to examine the prevalence of postconcussion-like symptoms in patients with depression. Participants were 64 physician-diagnosed inpatients or outpatients with depression who had independently-confirmed diagnoses on the Structured Clinical Interview for DSM-IV. All completed the British Columbia Postconcussion Symptom Inventory, a 16-item measure designed to assess the frequency and severity of symptoms based on 1CD-10 criteria for postconcussion syndrome. Specific endorsement rates of postconcussion-like symptoms ranged from 31.2% to 85.6% for symptoms rated mild or greater, and from 10.9% to 57.8% for symptoms rated moderate-to-severe. Approximately 9 out of 10 patients with depression met liberal self-report criteria for a postconcussion syndrome and more than 5 out of 10 met conservative criteria for the diagnosis. Implications for forensic neuropsychology will be discussed. (c) 2006 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	Univ British Columbia, Dept Psychiat, Vancouver, BC V6T 2A1, Canada; Riverview Hosp, Vancouver, BC V6T 2A1, Canada	Iverson, GL (corresponding author), Univ British Columbia, Dept Psychiat, 2255 Wesbrook Mall, Vancouver, BC V6T 2A1, Canada.	giverson@interchange.ubc.ca		Iverson, Grant/0000-0001-7348-9570			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; ATKINSON JH, 1991, PAIN, V45, P111, DOI 10.1016/0304-3959(91)90175-W; Austin MP, 1999, PSYCHOL MED, V29, P73, DOI 10.1017/S0033291798007788; BAXTER LR, 1989, ARCH GEN PSYCHIAT, V46, P243; BENOIT G, 1992, CAN J PSYCHOL, V46, P41, DOI 10.1037/h0084314; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; Campbell LC, 2003, BIOL PSYCHIAT, V54, P399, DOI 10.1016/S0006-3223(03)00545-6; Channon S, 1999, J NEUROL NEUROSUR PS, V66, P162, DOI 10.1136/jnnp.66.2.162; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Degl'Innocenti A, 1998, ACTA PSYCHIAT SCAND, V97, P182, DOI 10.1111/j.1600-0447.1998.tb09985.x; ELLIS HC, 1991, J EXP PSYCHOL GEN, V120, P310, DOI 10.1037/0096-3445.120.3.310; First M.B., 1998, STRUCTURED CLIN INTE; Foa EB, 1997, PSYCHOL ASSESSMENT, V9, P445, DOI 10.1037/1040-3590.9.4.445; FOX DD, 1995, CLIN NEUROPSYCHOL, V9, P89, DOI 10.1080/13854049508402064; Gasquoine P G, 2000, Appl Neuropsychol, V7, P83, DOI 10.1207/S15324826AN0702_3; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; Heilbronner RL, 1993, TRIAL DIPLOMACY J, V16, P161; ILSLEY JE, 1995, J AFFECT DISORDERS, V35, P1, DOI 10.1016/0165-0327(95)00032-I; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2004, STUD NEUROPSYCHOL DE, P323; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Lemelin S, 1997, J NERV MENT DIS, V185, P542, DOI 10.1097/00005053-199709000-00002; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Machulda MM, 1998, ARCH CLIN NEUROPSYCH, V13, P415, DOI 10.1016/S0887-6177(97)00031-0; Mayberg HS, 1997, J NEUROPSYCH CLIN N, V9, P471; MAYBERG HS, 1994, J NUCL MED, V35, P929; Merriam EP, 1999, AM J PSYCHIAT, V156, P780; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; RADANOV BP, 1992, SPINE, V17, P127, DOI 10.1097/00007632-199202000-00001; Sawchyn JM, 2000, ARCH CLIN NEUROPSYCH, V15, P1, DOI 10.1016/S0887-6177(98)00041-9; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Sheline YI, 1999, J NEUROSCI, V19, P5034; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; SOARS JC, 1997, ARCH GEN PSYCHIAT, V33, P219; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P981, DOI 10.1076/jcen.24.8.981.8372; Sullivan Michael J L, 2002, Pain Res Manag, V7, P120; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Wang PN, 2000, J AM GERIATR SOC, V48, P295, DOI 10.1111/j.1532-5415.2000.tb02649.x; WEINGARTNER H, 1981, ARCH GEN PSYCHIAT, V38, P42; Wilson KG, 2002, CLIN J PAIN, V18, P77, DOI 10.1097/00002508-200203000-00002; WOLFE J, 1987, J AFFECT DISORDERS, V13, P83, DOI 10.1016/0165-0327(87)90077-2; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3; World Health Organization, 1992, ICD 10 INT STAT CLAS; YOUNGJOHN JR, 1995, CLIN NEUROPSYCHOL, V9, P112, DOI 10.1080/13854049508401593; Zakzanis KK, 1998, NEUROPSY NEUROPSY BE, V11, P111	50	196	198	0	17	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAY	2006	21	4					303	310		10.1016/j.acn.2005.12.008			8	Psychology, Clinical; Psychology	Psychology	067GI	WOS:000239289500007	16797916	Bronze			2021-06-18	
J	Hukkelhoven, CWPM; Steyerberg, EW; Habbema, JDF; Farace, E; Marmarou, A; Murray, GD; Marshall, LF; Maas, AIR				Hukkelhoven, CWPM; Steyerberg, EW; Habbema, JDF; Farace, E; Marmarou, A; Murray, GD; Marshall, LF; Maas, AIR			Predicting outcome after traumatic brain injury: Development and validation of a prognostic score based on admission characteristics	JOURNAL OF NEUROTRAUMA			English	Article						Glasgow Outcome Scale; mortality; prognosis; statistical models; traumatic brain injury; validation studies	GLASGOW COMA SCALE; SIMPLE CLINICAL-VARIABLES; SEVERE HEAD-INJURY; INDIVIDUAL PATIENTS; REGRESSION; SELECTION; MORTALITY; TREE	The early prediction of outcome after traumatic brain injury (TBI) is important for several purposes, but no prognostic models have yet been developed with proven generalizability across different settings. The objective of this study was to develop and validate prognostic models that use information available at admission to estimate 6-month outcome after severe or moderate TBI. To this end, this study evaluated mortality and unfavorable outcome, that is, death, and vegetative or severe disability on the Glasgow Outcome Scale (GOS), at 6 months post-injury. Prospectively collected data on 2269 patients from two multi-center clinical trials were used to develop prognostic models for each outcome with logistic regression analysis. We included seven predictive characteristics-age, motor score, pupillary reactivity, hypoxia, hypotension, computed tomography classification, and traumatic subarachnoid hemorrhage. The models were validated internally with bootstrapping techniques. External validity was determined in prospectively collected data from two relatively unselected surveys in Europe (n = 796) and in North America (n = 746). We evaluated the discriminative ability, that is, the ability to distinguish patients with different outcomes, with the area under the receiver operating characteristic curve (AUC). Further, we determined calibration, that is, agreement between predicted and observed outcome, with the Hosmer-Lemeshow goodness-of-fit test. The models discriminated well in the development population (AUC 0.78-0.80). External validity was even better (AUC 0.83-0.89). Calibration was less satisfactory, with poor external validity in the North American survey (p < 0.001). Especially, observed risks were higher than predicted for poor prognosis patients. A score chart was derived from the regression models to facilitate clinical application. Relatively simple prognostic models using baseline characteristics can accurately predict 6-month outcome in patients with severe or moderate TBI. The high discriminative ability indicates the potential of this model for classifying patients according to prognostic risk.	Erasmus MC, Dept Neurol Surg, NL-3000 CA Rotterdam, Netherlands; Erasmus MC, Dept Publ Hlth, Ctr Clin Decis Sci, Rotterdam, Netherlands; Univ Virginia, Dept Neurol Surg, Charlottesville, VA USA; Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA USA; Univ Edinburgh, Dept Community Hlth Sci, Edinburgh, Midlothian, Scotland; Univ Calif San Diego, Dept Neurol Surg, San Diego, CA 92103 USA	Maas, AIR (corresponding author), Erasmus MC, Dept Neurol Surg, POB 2040, NL-3000 CA Rotterdam, Netherlands.	airmaas@erasmusmc.nl	Maas, Andrew IR/C-5584-2013; Steyerberg, Ewout/C-1509-2018	Maas, Andrew IR/0000-0003-1612-1264; Hukkelhoven, Chantal/0000-0002-0015-1883; Murray, Gordon/0000-0001-9866-4734; Steyerberg, Ewout/0000-0002-7787-0122	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042691] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 42691] Funding Source: Medline		Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; Baltas I, 1998, J Neurosurg Sci, V42, P85; BARLOW P, 1984, J MICROCOMPUT APPL, V7, P271, DOI 10.1016/0745-7138(84)90059-9; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; Buechler CM, 1998, J TRAUMA, V45, P429, DOI 10.1097/00005373-199809000-00001; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Califf RM, 1997, AM HEART J, V133, P630, DOI 10.1016/S0002-8703(97)70164-9; Chesnut RM, 2000, J NEUROTRAUM, V17, P555; CHOI SC, 1983, J NEUROSURG, V59, P294, DOI 10.3171/jns.1983.59.2.0294; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; FOULKES MA, 1991, J NEUROSURG, V75, pS8, DOI 10.3171/sup.1991.75.1s.00s8; HALL ED, 1992, J NEUROTRAUM, V9, pS425; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; Harrell Frank E., 2001, REGRESSION MODELING; Healey C, 2003, J TRAUMA, V54, P671, DOI 10.1097/01.TA.0000058130.30490.5D; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Hukkelhoven CWPM, 2002, J NEUROSURG, V97, P549, DOI 10.3171/jns.2002.97.3.0549; Hukkelhoven CWPM, 2000, J NEUROL NEUROSUR PS, V68, P396; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1976, LANCET, V1, P1031; Justice AC, 1999, ANN INTERN MED, V130, P515, DOI 10.7326/0003-4819-130-6-199903160-00016; Juul N, 2000, J NEUROSURG, V92, P1, DOI 10.3171/jns.2000.92.1.0001; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; LEMESHOW S, 1994, JAMA-J AM MED ASSOC, V272, P1049, DOI 10.1001/jama.272.13.1049; LITTLE RJA, 1992, J AM STAT ASSOC, V87, P1227, DOI 10.2307/2290664; Livingston BM, 2000, CRIT CARE MED, V28, P389, DOI 10.1097/00003246-200002000-00017; Machado SG, 1999, J NEUROTRAUM, V16, P1131, DOI 10.1089/neu.1999.16.1131; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Meredith W, 1998, J TRAUMA, V44, P839, DOI 10.1097/00005373-199805000-00016; Moons KGM, 2002, J CLIN EPIDEMIOL, V55, P1054, DOI 10.1016/S0895-4356(02)00453-5; Moskopp D, 1995, NEUROSURG REV, V18, P253, DOI 10.1007/BF00383876; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; Quigley MR, 1997, J TRAUMA, V42, P7, DOI 10.1097/00005373-199701000-00003; Schaan M, 2002, J TRAUMA, V52, P667, DOI 10.1097/00005373-200204000-00009; Schreiber MA, 2002, ARCH SURG-CHICAGO, V137, P285, DOI 10.1001/archsurg.137.3.285; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Sosin DM, 1996, BRAIN INJURY, V10, P47; STABLEIN DM, 1980, NEUROSURGERY, V6, P243; Steyerberg EW, 2000, STAT MED, V19, P1059, DOI 10.1002/(SICI)1097-0258(20000430)19:8<1059::AID-SIM412>3.0.CO;2-0; TEASDALE G, 1974, LANCET, V2, P81; Tibshirani, 1994, INTRO BOOTSTRAP, DOI 10.1201/9780429246593; van Houwelingen HC, 2000, STAT MED, V19, P3401, DOI 10.1002/1097-0258(20001230)19:24<3401::AID-SIM554>3.0.CO;2-2; YOUNG B, 1981, J NEUROSURG, V54, P300, DOI 10.3171/jns.1981.54.3.0300	47	196	211	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2005	22	10					1025	1039		10.1089/neu.2005.22.1025			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	977ZS	WOS:000232842600001	16238481				2021-06-18	
J	Collie, A; Maruff, P; Makdissi, M; McCrory, P; McStephen, M; Darby, D				Collie, A; Maruff, P; Makdissi, M; McCrory, P; McStephen, M; Darby, D			CogSport: Reliability cognitive tests used in and correlation with conventional postconcussion medical evaluations	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						computerized cognitive testing; concussion; head injury; traumatic brain injury; reliability; CogSport; neuropsychology	HEAD-INJURY; CONCUSSION; RECOVERY; FOOTBALL; SPORTS	Objective: To determine the repeatability of a computerized cognitive test designed to monitor recovery from concussion and assist team physicians make return to play decisions (CogSport(TM)). To determine the correlation between CogSport and two conventional neuropsychological tests. Design: Prospective, serial investigation of cognitive function. Setting: Professional and semi-professional Australian Football clubs and a university affiliated research institute in Melbourne, Australia. Participants: Three-hundred healthy young adults, including 240 elite athletes. Main Outcome Measures: Intra-class correlation (ICC) coefficients for CogSport performance measures administered serially. ICC between CogSport performance measures and conventional neuropsychological tests. Normative data for CogSport performance measures. Results: Measures of psychomotor function, decision making, working memory and learning were highly reliable. Some measures also displayed high correlations with conventional neuropsychological tests of information processing and attention. Preliminary normative data is described. Conclusions: CogSport is a highly reliable cognitive function test when administered to healthy young adults and elite athletes. CogSport measures similar cognitive functions as conventional tests used commonly in concussion research.	Univ Melbourne, Ctr Neurosci, Parkville, Vic 3052, Australia; CogState Ltd, Melbourne, Vic, Australia; Univ Melbourne, Ctr Sports Med Res & Educ, Parkville, Vic 3052, Australia; La Trobe Univ, Sch Psychol, Bundoora, Vic 3083, Australia; Univ Melbourne, Brain Res Inst, Heidelberg, Vic, Australia	Collie, A (corresponding author), CogState Ltd, 51 Leicester St, Carlton, Vic 3031, Australia.		Maruff, Paul/ABA-1673-2020; Maruff, Paul/AAD-2454-2021; McCrory, Paul/Q-8688-2019	Maruff, Paul/0000-0002-6947-9537; Collie, Alex/0000-0003-2617-9339			BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; BUTLER RJ, 1994, BRIT J SPORT MED, V28, P187, DOI 10.1136/bjsm.28.3.187; Collie A, 2002, ANN THORAC SURG, V73, P2005, DOI 10.1016/S0003-4975(01)03375-6; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; COLLIE A, IN PRESS J INT NEURO; Darby D., 1999, NEUROPSYCHOLOGY CLIN; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Fleiss J., 1986, DESIGN ANAL CLIN EXP; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; Kaplan R.M., 2001, PSYCHOL TESTING PRIN, V5th ed.; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lowe C, 1998, NEUROPSYCHOLOGIA, V36, P915, DOI 10.1016/S0028-3932(98)00036-0; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McCaffrey R.J., 2000, PRACTITIONERS GUIDE; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; Orchard J, 1998, J SCI MED SPORT, V1, P82; Schnirring L, 2001, PHYSICIAN SPORTSMED, V29, P11; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Stuss DT, 1994, NEUROPSYCHOLOGY, V8, P316, DOI DOI 10.1037/0894-4105.8.3.316; Tabachnick BG, 2013, USING MULTIVARIATE S; WESTERMAN R, 2001, ADF HLTH, V8, P3	25	196	198	0	27	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1050-642X			CLIN J SPORT MED	Clin. J. Sport Med.	JAN	2003	13	1					28	32		10.1097/00042752-200301000-00006			5	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	639MG	WOS:000180632500006	12544161				2021-06-18	
J	Smith, DH; Meaney, DF				Smith, DH; Meaney, DF			Axonal damage in traumatic brain injury	NEUROSCIENTIST			English	Article						traumatic axonal injury; diffuse axonal injury; inertial brain injury; diffuse brain injury; neurofilament; amyloid-beta; coma	MAGNETIC-RESONANCE SPECTROSCOPY; AMYLOID PRECURSOR PROTEIN; OPTIC-NERVE FIBERS; MILD HEAD-INJURY; CYCLOSPORINE-A; STRETCH-INJURY; ANOXIC INJURY; POSTTRAUMATIC HYPOTHERMIA; NEUROFILAMENT SUBUNITS; CYTOCHEMICAL EVIDENCE	Axonal damage is one of the most common and important pathologic features of traumatic brain injury. Severe diffuse axonal injury, resulting from inertial forces applied to the head, is associated with prolonged unconsciousness and poor outcome. The susceptibility of axons to mechanical injury appears to be due to both their viscoelastic properties and their highly organized structure in white matter tracts. Although axons are supple under normal conditions, they become brittle when exposed to rapid deformations associated with brain trauma. Accordingly, rapid stretch of axons can damage the axonal cytoskeleton, resulting in a lass of elasticity and impairment of axoplasmic transport. Subsequent swelling of the axon occurs in discrete bulb formations or in elongated varicosities that accumulate organelles. Calcium entry into damaged axons is thought to initiate further damage by the activation of proteases and the induction of mitochondrial swelling and dysfunction. Ultimately, swollen axons may become disconnected and contribute to additional neuropathologic changes in brain tissue. However, promising new therapies that reduce proteolytic activity or maintain mitochondrial integrity may attenuate progressive damage of injured axons following experimental brain trauma. Future advancements in the prevention and treatment of traumatic axonal injury will depend on our collective understanding of the relationship between the biomechanics and pathophysiology of various phases of axonal trauma.	Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA			smith, douglas/A-1321-2007	Meaney, David/0000-0002-0954-4122			Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; ADAMS JH, 1984, LANCET, V2, P1420; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Agrawal SK, 1996, J NEUROSCI, V16, P545; Alsop DC, 1996, J NEUROTRAUM, V13, P515, DOI 10.1089/neu.1996.13.515; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Buki A, 1999, EXP NEUROL, V159, P319, DOI 10.1006/exnr.1999.7139; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Buki A, 2000, J NEUROSCI, V20, P2825; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; CARDEN MJ, 1987, J NEUROSCI, V7, P3489; Cecil KM, 1998, J NEUROCHEM, V70, P2038; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Chen XH, 1999, J NEUROPATH EXP NEUR, V58, P588, DOI 10.1097/00005072-199906000-00003; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Gennarelli T, 1996, NEUROSURGERY, V2, P2611; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P134; GENTRY LR, 1989, RADIOLOGY, V171, P177, DOI 10.1148/radiology.171.1.2928523; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; Graham D I, 1983, Acta Neurochir Suppl (Wien), V32, P65; GRAHAM DI, 1995, NEUROPATH APPL NEURO, V21, P27, DOI 10.1111/j.1365-2990.1995.tb01025.x; GRAHAM DI, 1988, PROG CLIN BIOL RES, V234, P159; HALL GF, 1995, J COMP NEUROL, V353, P38, DOI 10.1002/cne.903530106; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; HISANAGA S, 1990, J MOL BIOL, V211, P871, DOI 10.1016/0022-2836(90)90080-6; Holbourn AHS, 1943, LANCET, V2, P438; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kimura H, 1996, J COMPUT ASSIST TOMO, V20, P540, DOI 10.1097/00004728-199607000-00007; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; LEE VMY, 1988, P NATL ACAD SCI USA, V85, P1998, DOI 10.1073/pnas.85.6.1998; LEONI MJ, 1999, J NEUROTRAUM, V16, P960; Li S, 1999, J NEUROSCI, V19, pRC1; Margulies SS, 1998, HDB BIOMATERIAL PROP, P70; Marion DW, 1996, J NEUROTRAUM, V13, P139, DOI 10.1089/neu.1996.13.139; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; Maxwell WL, 1995, J NEUROCYTOL, V24, P925, DOI 10.1007/BF01215643; Maxwell WL, 1999, J NEUROTRAUM, V16, P273, DOI 10.1089/neu.1999.16.273; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McCracken E, 1999, J NEUROTRAUM, V16, P749, DOI 10.1089/neu.1999.16.749; McGowan JC, 1999, MAGN RESON MED, V41, P727, DOI 10.1002/(SICI)1522-2594(199904)41:4<727::AID-MRM11>3.3.CO;2-Y; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Okonkwo DO, 1998, BRAIN RES, V784, P1, DOI 10.1016/S0006-8993(97)01075-5; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Ommaya A. K., 1967, P 11 STAPP CAR CRASH, V670906; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Pierce JES, 1996, J NEUROSCI, V16, P1083; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Povlishock J. T., 1995, Journal of Neurotrauma, V12, P417; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Raby CA, 1998, J NEUROCHEM, V71, P2505; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Smith D.C., 1996, NEW DIRECTIONS TEACH, V1996, P5, DOI [10.1002/tl.37219966604, DOI 10.1002/TL.37219966604]; Smith D H, 1995, New Horiz, V3, P562; Smith DH, 1999, J NEUROSCI, V19, P4263; Smith DH, 1999, J NEUROPATH EXP NEUR, V58, P982, DOI 10.1097/00005072-199909000-00008; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Smith DH, 1998, J NEUROTRAUM, V15, P665, DOI 10.1089/neu.1998.15.665; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; STYS PK, 1992, J NEUROSCI, V12, P430; THIBAULT LE, 1992, INT RES COUNCIL BIOM, V14, P3; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P281; WAXMAN SG, 1992, BRAIN RES, V574, P105, DOI 10.1016/0006-8993(92)90806-K; WAXMAN SG, 1994, BRAIN RES, V644, P197, DOI 10.1016/0006-8993(94)91680-2; WISNIEWS.H, 1970, J NEUROPATH EXP NEUR, V29, P163, DOI 10.1097/00005072-197004000-00001; Wolf JA, 1999, J NEUROTRAUM, V16, P966; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	91	196	198	0	21	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-8584			NEUROSCIENTIST	Neuroscientist	DEC	2000	6	6					483	495		10.1177/107385840000600611			13	Clinical Neurology; Neurosciences	Neurosciences & Neurology	375KD	WOS:000165397400023					2021-06-18	
J	Ito, J; Marmarou, A; Barzo, P; Fatouros, P; Corwin, F				Ito, J; Marmarou, A; Barzo, P; Fatouros, P; Corwin, F			Characterization of edema by diffusion-weighted imaging in experimental traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						brain edema; magnetic resonance imaging; traumatic brain injury; diffusion-weighted imaging; secondary insult; rat	MIDDLE CEREBRAL-ARTERY; T2-WEIGHTED MRI; ISCHEMIA; RATS; WATER; PERMEABILITY; OCCLUSION; SODIUM; CATS	The objective of this study was to use diffusion-weighted magnetic resonance imaging (DWI) to help detect the type of edema that develops after experimental trauma and trauma coupled with hypotension and hypoxia (THH). Reduction in the apparent diffusion coefficients (ADCs) is thought to represent cytotoxic edema. In a preliminary series of experiments, the infusion edema model and middle cerebral artery occlusion models were used to confirm the direction of ADC change in response to purely extracellular and cytotoxic edema, respectively. The ADCs increased (p < 0.05) in the case of extracellular edema and decreased (p < 0.001) in cytotoxic edema. Following these initial experiments, a new impact acceleration model was used to induce traumatic brain injury. Thirty-six adult Sprague-Dawley rats were separated into four groups: sham, trauma alone, hypoxia and hypotension (HH), and THH. Following trauma, a 30-minute insult of hypoxia (PaO2 of 40 mm Hg) and hypotension (mean arterial blood pressure (MABP) of 30 mm Hg) were imposed and the animals were resuscitated. The DWI was carried out at four 1-hour intervals postinjury, and MABP, intracranial pressure (ICP), cerebral perfusion pressure (CPP), and cerebral blood flow (CBF) were monitored. The ADCs in the control and III-I groups remained unchanged. The ADCs in the THH group rapidly decreased from a control level of 0.68 +/- 0.05 x 10(-3) mm(2)/second to 0.37 +/- 0.09 x 10(-3) mm(2)/second by 3 hours posttrauma (p < 0.001). In this group, the decreased CBF and CPP during secondary insult remained low despite resuscitation, with the ICP increasing to 56 +/- 7 mm Hg by 3 hours. In the trauma alone group, the rise in ICP reached a maximum value (28 +/- 3 mm Hg) at 30 minutes with a significant and sustained increase in CBF despite a gradual decrease in CPP. The ADCs in this group were not significantly reduced. The data lead the authors to suggest that the rise in ICP following severe trauma coupled with secondary insult in this model is predominately caused by cytotoxic edema and that ischemia plays a major role in the development of brain edema after head injury.	VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DIV NEUROSURG, RICHMOND, VA 23298 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT RADIOL, RICHMOND, VA 23298 USA					NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS19235-11] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019235, R56NS019235] Funding Source: NIH RePORTER		BENVENISTE H, 1992, STROKE, V23, P746, DOI 10.1161/01.STR.23.5.746; BUSZA AL, 1992, STROKE, V23, P1602, DOI 10.1161/01.STR.23.11.1602; EBISU T, 1993, JMRI-J MAGN RESON IM, V3, P863, DOI 10.1002/jmri.1880030612; GOTOH O, 1985, STROKE, V16, P101, DOI 10.1161/01.STR.16.1.101; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; ITO U, 1979, STROKE, V10, P542, DOI 10.1161/01.STR.10.5.542; JOHANSSON BB, 1981, J NEUROL NEUROSUR PS, V44, P402, DOI 10.1136/jnnp.44.5.402; KITA H, 1994, ACTA NEUROCHIR, P452; KNIGHT RA, 1991, STROKE, V22, P802, DOI 10.1161/01.STR.22.6.802; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARMAROU A, 1994, ACTA NEUROCHIR, P421; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MILLER JD, 1981, BRAIN EDEMA, P99; MINTOROVITCH J, 1991, MAGNET RESON MED, V18, P39, DOI 10.1002/mrm.1910180106; MOSELEY ME, 1990, MAGN RESON MED, V14, P330, DOI 10.1002/mrm.1910140218; NARAYAN RK, 1981, J NEUROSURG, V54, P751, DOI 10.3171/jns.1981.54.6.0751; OHATA K, 1992, J NEUROSURG, V77, P387, DOI 10.3171/jns.1992.77.3.0387; PETITO CK, 1976, DYNAMICS BRAIN EDEMA, P38; PIERPAOLI C, 1993, RADIOLOGY, V189, P439, DOI 10.1148/radiology.189.2.8210373; SCHUIER FJ, 1980, STROKE, V11, P593, DOI 10.1161/01.STR.11.6.593; SEVICK RJ, 1992, RADIOLOGY, V185, P687, DOI 10.1148/radiology.185.3.1438745; SIESJO BK, 1985, BRAIN EDEMA, P200; TAMURA A, 1981, J CEREBR BLOOD F MET, V1, P53, DOI 10.1038/jcbfm.1981.6; VANDENBRINK WA, 1994, ACTA NEUROCHIR, P456; YUAN XQ, 1991, J NEUROSURG, V75, P408, DOI 10.3171/jns.1991.75.3.0408	25	196	199	1	7	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JAN	1996	84	1					97	103		10.3171/jns.1996.84.1.0097			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	TL444	WOS:A1996TL44400015	8613843				2021-06-18	
J	FEDOROFF, JP; STARKSTEIN, SE; FORRESTER, AW; GEISLER, FH; JORGE, RE; ARNDT, SV; ROBINSON, RG				FEDOROFF, JP; STARKSTEIN, SE; FORRESTER, AW; GEISLER, FH; JORGE, RE; ARNDT, SV; ROBINSON, RG			DEPRESSION IN PATIENTS WITH ACUTE TRAUMATIC BRAIN INJURY	AMERICAN JOURNAL OF PSYCHIATRY			English	Article							POSTSTROKE MOOD DISORDERS; HEAD-INJURY; LESIONS; COMA	Objective: This study was undertaken to examine patients with closed bead injuries for the presence of depressive disorders. Method: A consecutive series of 66 patients with closed bead injuries but no significant spinal cord or other organ system injury were examined by means of a semistructured psychiatric interview. The Hamilton Rating Scale for Depression as well as scales measuring impairment in activities of daily living, intellectual functioning, and social functioning were administered. The patients' CT scans were also examined. Results: Seventeen patients had major depression and two bad minor depression. The presence of left dorsolateral frontal lesions and/or left basal ganglia lesions and, to a lesser extent, parietal-occipital and right hemisphere lesions was associated with an increased probability of developing major depression. Compared to the nondepressed group, the group with major depression had a higher frequency of previous psychiatric disorder and showed evidence of poorer social functioning. Conclusions: Major depression occurs in about one-quarter of patients after traumatic brain injury. This is the same frequency as in other major disorders such as stroke. Major depression appears to be provoked by one or more factors that include poor premorbid social functioning and previous psychiatric disorder or injury to certain critical brain locations.	UNIV IOWA, DEPT PSYCHIAT, MED EDUC BLDG, 500 NEWTON RD, IOWA CITY, IA 52242 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT PSYCHIAT, BALTIMORE, MD 21205 USA; UNIV MARYLAND, DEPT SURG,DIV NEUROSURG, MARYLAND INST EMERGENCY MED SERV SYST, SHOCK TRAUMA CTR, BALTIMORE, MD 21201 USA; INST NEUROL INVEST RAUL CARREA, BUENOS AIRES, ARGENTINA; CLARKE INST PSYCHIAT, DIV FORENS, TORONTO M5T 1R8, ONTARIO, CANADA			Robinson, Robert/AAF-6191-2021; Fedoroff, J. Paul/C-2738-2008; Arndt, Stephan/A-6976-2013; Fedoroff, Paul/X-4111-2019	Fedoroff, J. Paul/0000-0001-9944-9307; Arndt, Stephan/0000-0003-0783-8204; 	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH-00163, MH-40355] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-151178] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH040355] Funding Source: NIH RePORTER		ALEXANDRE A, 1983, J NEUROSURG, V59, P751, DOI 10.3171/jns.1983.59.5.0751; BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; CONOVER WJ, 1981, AM STAT, V35, P124, DOI 10.2307/2683975; FEDOROFF JP, 1991, J AFFECT DISORDERS, V22, P83, DOI 10.1016/0165-0327(91)90088-A; Finset A, 1988, CEREBRAL HEMISPHERE; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Frankowski R F, 1986, Adv Psychosom Med, V16, P153; GRAFMAN J, 1986, BRAIN, V109, P1127, DOI 10.1093/brain/109.6.1127; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; LEVINE DN, 1984, NEUROLOGY, V34, P577, DOI 10.1212/WNL.34.5.577; LIPSEY JR, 1984, LANCET, V1, P297; LIPSEY JR, 1986, AM J PSYCHIAT, V143, P527; LISHMAN WA, 1968, BRIT J PSYCHIAT, V114, P373, DOI 10.1192/bjp.114.509.373; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; Meyer A, 1904, AM J INSANITY, V60, P373, DOI 10.1176/ajp.60.3.373; MORRIS PLP, 1990, INT J PSYCHIAT MED, V20, P327; OSHANICK GJ, 1906, ADV PSYCHOSOM MED, V16, P173; ROBINSON RG, 1983, STROKE, V14, P736, DOI 10.1161/01.STR.14.5.736; ROBINSON RG, 1981, ANN NEUROL, V9, P447, DOI 10.1002/ana.410090506; ROBINSON RG, 1987, STROKE, V18, P837, DOI 10.1161/01.STR.18.5.837; Sartorius N, 1974, MEASUREMENT CLASSIFI; STARKSTEIN SE, 1989, BRIT J PSYCHIAT, V155, P79, DOI 10.1192/bjp.155.1.79; STARKSTEIN SE, 1987, BRAIN, V110, P1045, DOI 10.1093/brain/110.4.1045; STARKSTEIN SE, 1988, ARCH NEUROL-CHICAGO, V45, P725, DOI 10.1001/archneur.1988.00520310031013; STARR LB, 1983, EXP AGING RES, V9, P101, DOI 10.1080/03610738308258434; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P161; TEASDALE G, 1974, LANCET, V2, P81	29	196	198	0	13	AMER PSYCHIATRIC PUBLISHING, INC	ARLINGTON	1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA	0002-953X	1535-7228		AM J PSYCHIAT	Am. J. Psychiat.	JUL	1992	149	7					918	923					6	Psychiatry	Psychiatry	JB015	WOS:A1992JB01500011	1609872				2021-06-18	
J	Prins, M; Greco, T; Alexander, D; Giza, CC				Prins, Mayumi; Greco, Tiffany; Alexander, Daya; Giza, Christopher C.			The pathophysiology of traumatic brain injury at a glance	DISEASE MODELS & MECHANISMS			English	Article							CEREBRAL-BLOOD-FLOW; POSITRON-EMISSION-TOMOGRAPHY; OXIDE SYNTHASE EXPRESSION; CORTICAL IMPACT INJURY; FREE-RADICAL RELEASE; MITOCHONDRIAL DYSFUNCTION; KETOGENIC DIET; GLUCOSE-METABOLISM; OXIDATIVE STRESS; KETONE-BODIES	Traumatic brain injury (TBI) is defined as an impact, penetration or rapid movement of the brain within the skull that results in altered mental state. TBI occurs more than any other disease, including breast cancer, AIDS, Parkinson's disease and multiple sclerosis, and affects all age groups and both genders. In the US and Europe, the magnitude of this epidemic has drawn national attention owing to the publicity received by injured athletes and military personnel. This increased public awareness has uncovered a number of unanswered questions concerning TBI, and we are increasingly aware of the lack of treatment options for a crisis that affects millions. Although each case of TBI is unique and affected, individuals display different degrees of injury, different regional patterns of injury and different recovery profiles, this review and accompanying poster aim to illustrate some of the common underlying neurochemical and metabolic responses to TBI. Recognition of these recurrent features could allow elucidation of potential therapeutic targets for early intervention.	[Prins, Mayumi; Giza, Christopher C.] Univ Calif Los Angeles, Dept Neurosurg, Los Angeles, CA 90095 USA; [Prins, Mayumi; Alexander, Daya] Univ Calif Los Angeles, Interdept Program Neurosci, Los Angeles, CA 92697 USA; [Prins, Mayumi; Greco, Tiffany; Alexander, Daya; Giza, Christopher C.] Univ Calif Los Angeles, Brain Injury Res Ctr, Los Angeles, CA 90095 USA; [Giza, Christopher C.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90095 USA	Prins, M (corresponding author), Univ Calif Los Angeles, Dept Neurosurg, Los Angeles, CA 90095 USA.	mprins@mednet.ucla.edu	Prins, Mayumi/J-9571-2015	Prins, Mayumi/0000-0001-7694-9739	UCLA Brain Injury Research Center, NIH [NS 058489]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS058489] Funding Source: NIH RePORTER	This work was funded by the UCLA Brain Injury Research Center, NIH NS 058489.	Abramov AY, 2008, BBA-BIOENERGETICS, V1777, P953, DOI 10.1016/j.bbabio.2008.04.017; Alano CC, 2010, J NEUROSCI, V30, P2967, DOI 10.1523/JNEUROSCI.5552-09.2010; ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; Appelberg KS, 2009, J NEUROTRAUM, V26, P497, DOI 10.1089/neu.2008.0664; Balabanov R, 2001, NEUROL RES, V23, P175, DOI 10.1179/016164101101198514; Bartnik BL, 2005, J NEUROTRAUM, V22, P1052, DOI 10.1089/neu.2005.22.1052; BATES TE, 1994, DEV NEUROSCI-BASEL, V16, P321, DOI 10.1159/000112126; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Brennan AM, 2009, NAT NEUROSCI, V12, P857, DOI 10.1038/nn.2334; Chen SF, 2004, J CEREBR BLOOD F MET, V24, P1025, DOI 10.1097/01.WCB.0000129415.34520.47; Chen T, 2000, BRAIN RES, V861, P281, DOI 10.1016/S0006-8993(00)01992-2; Cipriani G, 2005, J BIOL CHEM, V280, P17227, DOI 10.1074/jbc.M414526200; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; Cohen JS, 2009, CURR OPIN PEDIATR, V21, P288, DOI 10.1097/MOP.0b013e32832b1195; Cornford EM, 1996, J NEUROTRAUM, V13, P523, DOI 10.1089/neu.1996.13.523; DAHLQUIST G, 1976, PEDIATR RES, V10, P910, DOI 10.1203/00006450-197611000-00002; Davis LM, 2008, J NEUROSCI RES, V86, P1812, DOI 10.1002/jnr.21628; Deng-Bryant Y, 2011, J NEUROTRAUM, V28, P1813, DOI 10.1089/neu.2011.1822; Deshpande LS, 2008, NEUROSCI LETT, V441, P115, DOI 10.1016/j.neulet.2008.05.113; Duan YT, 2007, J PHYSIOL-LONDON, V585, P741, DOI 10.1113/jphysiol.2007.145409; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Fan P, 2003, J NEUROTRAUM, V20, P437, DOI 10.1089/089771503765355513; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Frenzel J, 2005, GLIA, V52, P276, DOI 10.1002/glia.20244; Fukushima M, 2009, J NEUROTRAUM, V26, P1095, DOI 10.1089/neu.2008.0771; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; HALL ED, 1993, RES P ARNMD, V71, P81; HALL ED, 1993, J NEUROSCI RES, V34, P107, DOI 10.1002/jnr.490340111; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; Hattori N, 2003, J NUCL MED, V44, P1709; HAWKINS RA, 1986, AM J PHYSIOL, V250, pE169; HAWKINS RA, 1971, BIOCHEM J, V121, pP17; Holloway R, 2007, ACTA NEUROCHIR, V149, P919, DOI 10.1007/s00701-007-1241-y; Hovda D. A., 1994, Society for Neuroscience Abstracts, V20, P845; Hovda DA, 1996, J CEREBR BLOOD F MET, V16, P134, DOI 10.1097/00004647-199601000-00016; HOVDA DA, 1990, ACT NEUR S, V51, P331; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; Hsiang JNK, 1997, ACTA NEUROCHIR, V139, P464, DOI 10.1007/BF01808884; Hu ZG, 2009, ANN CLIN LAB SCI, V39, P76; Hu ZG, 2009, BRAIN INJURY, V23, P459, DOI 10.1080/02699050902788469; Hutson CB, 2011, J NEUROTRAUM, V28, P1783, DOI 10.1089/neu.2010.1723; Izumi Y, 2010, NEUROSCI LETT, V478, P131, DOI 10.1016/j.neulet.2010.04.078; Jagtap JC, 2003, J CHEM NEUROANAT, V26, P109, DOI 10.1016/S0891-0618(03)00037-1; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KATSURA K, 1994, BIOCHEM SOC T, V22, P991, DOI 10.1042/bst0220991; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; Kerr ME, 1996, HEART LUNG, V25, P200, DOI 10.1016/S0147-9563(96)80030-6; KREIS R, 1992, RADIOLOGY, V184, P123, DOI 10.1148/radiology.184.1.1319074; LaPlaca MC, 2001, J NEUROTRAUM, V18, P369, DOI 10.1089/089771501750170912; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P914, DOI 10.1097/00004647-200108000-00003; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Marklund N, 2001, J NEUROTRAUM, V18, P1217, DOI 10.1089/089771501317095250; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Moro N, 2011, NEUROSCI LETT, V491, P158, DOI 10.1016/j.neulet.2011.01.029; Moro N, 2010, EXP NEUROL, V225, P391, DOI 10.1016/j.expneurol.2010.07.013; Namjoshi DR, 2013, DIS MODEL MECH, V6, P1325, DOI 10.1242/dmm.011320; O'Connell KM, 2013, BIOL RES NURS, V15, P253, DOI 10.1177/1099800411431823; O'Connell MT, 2005, ACTA NEUROCHIR SUPPL, V95, P165; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; OWEN OE, 1967, J CLIN INVEST, V46, P1589, DOI 10.1172/JCI105650; Pan R, 2012, PEDIATR RES, V72, P479, DOI 10.1038/pr.2012.107; Peng TI, 2010, ANN NY ACAD SCI, V1201, P183, DOI 10.1111/j.1749-6632.2010.05634.x; Petronilho F, 2010, J SURG RES, V164, P316, DOI 10.1016/j.jss.2009.04.031; Prieto R, 2011, BRAIN RES, V1404, P39, DOI 10.1016/j.brainres.2011.06.006; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Prins M, 2008, EPILEPSIA, V49, P111, DOI 10.1111/j.1528-1167.2008.01852.x; Prins ML, 2009, J NEUROTRAUM, V26, P1083, DOI [10.1089/neu.2008.0769, 10.1089/neu.2008-0769]; Prins ML, 2005, J NEUROSCI RES, V82, P413, DOI 10.1002/jnr.20633; Prins ML, 2001, J NEUROTRAUM, V18, P31, DOI 10.1089/089771501750055758; Rao AM, 1998, BRAIN RES, V793, P265, DOI 10.1016/S0006-8993(98)00183-8; Rice AC, 2002, BRAIN RES, V928, P156, DOI 10.1016/S0006-8993(01)03299-1; Richards HK, 2001, J CEREBR BLOOD F MET, V21, P779, DOI 10.1097/00004647-200107000-00002; Robertson CL, 2004, J BIOENERG BIOMEMBR, V36, P363, DOI 10.1023/B:JOBB.0000041769.06954.e4; Robertson CL, 2007, J NEUROCHEM, V101, P1248, DOI 10.1111/j.1471-4159.2007.04489.x; Satchell MA, 2003, J NEUROCHEM, V85, P697, DOI 10.1046/j.1471-4159.2003.01707.x; Scafidi S, 2010, DEV NEUROSCI-BASEL, V32, P480, DOI 10.1159/000323178; SEN S, 1994, FREE RADICAL BIO MED, V16, P685, DOI 10.1016/0891-5849(94)90183-X; SEN S, 1993, NEUROSCI LETT, V162, P117, DOI 10.1016/0304-3940(93)90574-5; Sharma R, 2000, TOXICOLOGY, V156, P13, DOI 10.1016/S0300-483X(00)00328-0; Sheline CT, 2000, J NEUROSCI, V20, P3139, DOI 10.1523/JNEUROSCI.20-09-03139.2000; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Soane L, 2008, J NEUROSCI RES, V86, P1267, DOI 10.1002/jnr.21584; SOKOLOFF L, 1973, ANNU REV MED, V24, P271, DOI 10.1146/annurev.me.24.020173.001415; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sun DA, 2008, EUR J NEUROSCI, V27, P1659, DOI 10.1111/j.1460-9568.2008.06156.x; SUTTON RL, 1994, ACTA NEUROCHIR, P446; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Vagnozzi R, 1999, J NEUROTRAUM, V16, P903, DOI 10.1089/neu.1999.16.903; Vannucci RC, 2000, SEMIN PERINATOL, V24, P107, DOI 10.1053/sp.2000.6361; Veech RL, 2004, PROSTAG LEUKOTR ESS, V70, P309, DOI 10.1016/j.plefa.2003.09.007; Veech RL, 2001, IUBMB LIFE, V51, P241; Vergun O, 1999, J PHYSIOL-LONDON, V519, P451, DOI 10.1111/j.1469-7793.1999.0451m.x; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wahren J, 1999, DIABETOLOGIA, V42, P812, DOI 10.1007/s001250051231; WORLEY G, 1995, DEV MED CHILD NEUROL, V37, P213; Xing GQ, 2009, NEUROSCI LETT, V454, P38, DOI 10.1016/j.neulet.2009.01.047; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zeng JY, 2007, ANESTHESIOLOGY, V107, P630, DOI 10.1097/01.anes.0000281898.01966.1e	109	195	200	2	31	COMPANY BIOLOGISTS LTD	CAMBRIDGE	BIDDER BUILDING, STATION RD, HISTON, CAMBRIDGE CB24 9LF, ENGLAND	1754-8403	1754-8411		DIS MODEL MECH	Dis. Model. Mech.	NOV	2013	6	6					1307	1315		10.1242/dmm.011585			9	Cell Biology; Pathology	Cell Biology; Pathology	283VL	WOS:000329275000003	24046353	DOAJ Gold, Green Published			2021-06-18	
J	Breedlove, EL; Robinson, M; Talavage, TM; Morigaki, KE; Yoruk, U; O'Keefe, K; King, J; Leverenz, LJ; Gilger, JW; Nauman, EA				Breedlove, Evan L.; Robinson, Meghan; Talavage, Thomas M.; Morigaki, Katherine E.; Yoruk, Umit; O'Keefe, Kyle; King, Jeff; Leverenz, Larry J.; Gilger, Jeffrey W.; Nauman, Eric A.			Biomechanical correlates of symptomatic and asymptomatic neurophysiological impairment in high school football	JOURNAL OF BIOMECHANICS			English	Article						Traumatic brain injury; Athletic telemetry; Functional magnetic resonance imaging; Subconcussive neurotrauma	CHRONIC TRAUMATIC ENCEPHALOPATHY; BRAIN-INJURY; RECURRENT CONCUSSION; WORKING-MEMORY; LEAGUE PLAYER; HEAD-INJURY; ACCELERATION; IMPACT; DEFORMATION; MECHANICS	Concussion is a growing public health issue in the United States, and chronic traumatic encephalopathy (CTE) is the chief long-term concern linked to repeated concussions. Recently, attention has shifted toward subconcussive blows and the role they may play in the development of CTE. We recruited a cohort of high school football players for two seasons of observation. Acceleration sensors were placed in the helmets, and all contact activity was monitored. Pre-season computer-based neuropsychological tests and functional magnetic resonance imaging (fMRI) tests were also obtained in order to assess cognitive and neurophysiological health. In-season follow-up scans were then obtained both from individuals who had sustained a clinically-diagnosed concussion and those who had not. These changes were then related through stepwise regression to history of blows recorded throughout the football season up to the date of the scan. In addition to those subjects who had sustained a concussion, a substantial portion of our cohort who did not sustain concussions showed significant neurophysiological changes. Stepwise regression indicated significant relationships between the number of blows sustained by a subject and the ensuing neurophysiological change. Our findings reinforce the hypothesis that the effects of repetitive blows to the head are cumulative and that repeated exposure to subconcussive blows is connected to pathologically altered neurophysiology. (C) 2012 Elsevier Ltd. All rights reserved.	[Breedlove, Evan L.; O'Keefe, Kyle; Nauman, Eric A.] Purdue Univ, Sch Mech Engn, W Lafayette, IN 47907 USA; [Robinson, Meghan; Talavage, Thomas M.; Nauman, Eric A.] Purdue Univ, Weldon Sch Biomed Engn, W Lafayette, IN 47907 USA; [Talavage, Thomas M.; Yoruk, Umit; King, Jeff] Purdue Univ, Sch Elect & Comp Engn, W Lafayette, IN 47907 USA; [Morigaki, Katherine E.; Leverenz, Larry J.] Purdue Univ, Dept Hlth & Kinesiol, W Lafayette, IN 47907 USA; [Gilger, Jeffrey W.] Univ Calif, Dept Psychol Sci, Merced, CA 95343 USA; [Nauman, Eric A.] Purdue Univ, Dept Basic Med Sci, W Lafayette, IN 47907 USA	Nauman, EA (corresponding author), Purdue Univ, Sch Mech Engn, 585 Purdue Mall, W Lafayette, IN 47907 USA.	enauman@purdue.edu	Lang, Steven/AAE-8102-2021	Lang, Steven/0000-0003-1669-9146	Indiana State Department of Health Spinal Cord; General Electric HealthcareGE Healthcare; National Defense Science and Engineering; National Science FoundationNational Science Foundation (NSF)	This work was supported by grants from the Indiana State Department of Health Spinal Cord and Brain Injury Research Fund, General Electric Healthcare, and through the National Science Foundation and National Defense Science and Engineering Graduate Fellowships. The authors thank Jeff Clevenger for his assistance in collecting helmet telemetry data and coordinating weekly battery changes. Finally, the authors thank Dr. Gregory G. Tamer, Jr., and Dr. Ruwan D. Ranaweera for their assistance with data collection.	Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Chappell MH, 2006, J MAGN RESON IMAGING, V24, P537, DOI 10.1002/jmri.20656; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Goldsmith W, 2001, CRIT REV BIOMED ENG, V29, P441, DOI 10.1615/CritRevBiomedEng.v29.i56.10; Goldsmith Werner, 2005, Critical Reviews in Biomedical Engineering, V33, P105, DOI 10.1615/CritRevBiomedEng.v33.i2.20; Gonzalez-Castillo J, 2011, NEUROIMAGE, V54, P2138, DOI 10.1016/j.neuroimage.2010.09.082; Gradin V, 2010, PSYCHIAT RES-NEUROIM, V184, P86, DOI 10.1016/j.pscychresns.2010.08.010; Gundersen H, 2008, NEUROIMAGE, V42, P1587, DOI 10.1016/j.neuroimage.2008.05.037; Gundersen Hilde, 2008, Open Neuroimag J, V2, P65, DOI 10.2174/1874440000802010065; GURDJIAN ES, 1976, J TRAUMA, V16, P35, DOI 10.1097/00005373-197601000-00005; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Holbourn AHS, 1943, LANCET, V2, P438; Hoskison MM, 2009, NEUROSCIENCE, V159, P483, DOI 10.1016/j.neuroscience.2008.12.050; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; McCrory P, 2001, CLIN J SPORT MED, V11, P160, DOI 10.1097/00042752-200107000-00006; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Murphy K, 2006, AM J PSYCHIAT, V163, P1245, DOI 10.1176/appi.ajp.163.7.1245; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; OMMAYA AK, 1968, J AMER MED ASSOC, V204, P285, DOI 10.1001/jama.204.4.285; OMMAYA AK, 1971, J NEUROSURG, V35, P503, DOI 10.3171/jns.1971.35.5.0503; PARKINSON D, 1992, MED HYPOTHESES, V37, P37, DOI 10.1016/0306-9877(92)90010-A; Rawson S., 2009, J BIOMECHANICAL ENG, V131, P6; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; Talavage T.M., 2010, J NEUROTRAUMA UNPUB	35	195	195	3	59	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290			J BIOMECH	J. Biomech.	APR 30	2012	45	7					1265	1272		10.1016/j.jbiomech.2012.01.034			8	Biophysics; Engineering, Biomedical	Biophysics; Engineering	936YZ	WOS:000303627500022	22381736				2021-06-18	
J	Christensen, J; Pedersen, MG; Pedersen, CB; Sidenius, P; Olsen, J; Vestergaard, M				Christensen, Jakob; Pedersen, Marianne G.; Pedersen, Carsten B.; Sidenius, Per; Olsen, Jorn; Vestergaard, Mogens			Long-term risk of epilepsy after traumatic brain injury in children and young adults: a population-based cohort study	LANCET			English	Article							POSTTRAUMATIC EPILEPSY; PUBLIC-HEALTH; SEIZURES; EPIDEMIOLOGY; PREVENTION; DENMARK; DRUGS	Background The risk of epilepsy shortly after traumatic brain injury is high, but how long this high risk lasts is unknown. We aimed to assess the risk of epilepsy up to 10 years or longer after traumatic brain injury, taking into account sex, age, severity and family history. Methods We identified 1605 216 people born in Denmark (1977-2002) from the Civil Registration System. We obtained information on traumatic brain injury and epilepsy from the National Hospital Register and estimated relative risks (RR) with Poisson analyses. Findings Risk of epilepsy was increased after a mild brain injury (RR 2.22, 95% CI 2.07-2.38), severe brain injury (7.40, 6.16-8.89), and skull fracture (2.17, 1.73-2.71). The risk was increased more than 10 years after mild brain injury (1.51, 1.24-1.85), severe brain injury (4.29, 2.04-9.00), and skull fracture (2.06, 1.37-3.11). RR increased with age at mild and severe injury and was especially high among people older than 15 years of age with mild (3.51, 2.90-4.26) and severe (12.24, 8.52-17.57) injury. The risk was slightly higher in women (2.49, 2.25-2.76) than in men (2.01, 1.83-2.22). Patients with a family history of epilepsy had a notably high risk of epilepsy after mild (5.75, 4.56-7.27) and severe brain injury (10.09, 4.20-24.26). Interpretation The longlasting high risk of epilepsy after brain injury might provide a window for prevention of post-traumatic epilepsy. Funding Danish Research Agency, P A Messerschmidt and Wife's Foundation, Mrs Grethe Bonnelycke's Foundation.	[Christensen, Jakob; Sidenius, Per] Aarhus Univ Hosp, Dept Neurol, DK-8000 Aarhus C, Denmark; [Christensen, Jakob] Univ Aarhus, Dept Clin Pharmacol, DK-8000 Aarhus C, Denmark; [Pedersen, Marianne G.; Pedersen, Carsten B.] Univ Aarhus, Natl Ctr Register Based Res, DK-8000 Aarhus C, Denmark; [Olsen, Jorn] Univ Calif Los Angeles, Sch Publ Hlth, So Calif Injury Prevent Res Ctr, Los Angeles, CA 90024 USA; [Olsen, Jorn] Univ Aarhus, Inst Publ Hlth, Dept Epidemiol, Aarhus, Denmark; [Vestergaard, Mogens] Univ Aarhus, Inst Publ Hlth, Dept Gen Practice, Aarhus, Denmark	Christensen, J (corresponding author), Aarhus Univ Hosp, Dept Neurol, Norrebrogade 44, DK-8000 Aarhus C, Denmark.	jakob@farm.au.dk	Pedersen, Carsten B/B-8441-2013; Vestergaard, Mogens/M-9333-2014	Pedersen, Carsten B/0000-0003-2077-8533; Vestergaard, Mogens/0000-0001-8830-2174; Christensen, Jakob/0000-0002-9385-6435			Agrawal A, 2006, CLIN NEUROL NEUROSUR, V108, P433, DOI 10.1016/j.clineuro.2005.09.001; Andersen TF, 1999, DAN MED BULL, V46, P263; Angeleri F, 1999, EPILEPSIA, V40, P1222, DOI 10.1111/j.1528-1157.1999.tb00850.x; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; [Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; Benardo LS, 2003, EPILEPSIA, V44, P27, DOI 10.1046/j.1528-1157.44.s10.2.x; Berkovic SF, 2006, TRENDS NEUROSCI, V29, P391, DOI 10.1016/j.tins.2006.05.009; Breslow N E, 1987, IARC Sci Publ, P1; BRESLOW NE, 1996, STAT APPL, V8, P23; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Christensen J, 2005, EPILEPSIA, V46, P956, DOI 10.1111/j.1528-1167.2005.51204.x; Christensen J, 2007, EPILEPSY RES, V76, P60, DOI 10.1016/j.eplepsyres.2007.06.012; Christensen J, 2007, EPILEPSY RES, V75, P162, DOI 10.1016/j.eplepsyres.2007.05.009; Clayton DH M, 1993, STAT MODELS EPIDEMIO; D'Ambrosio R, 2004, CURR OPIN NEUROL, V17, P731, DOI 10.1097/00019052-200412000-00014; *DAN NAT BOARD HLT, 1997, 1208 DAN NAT BOARD H; Engberg A, 1998, EUR J EPIDEMIOL, V14, P165, DOI 10.1023/A:1007492025190; Engberg A, 1995, Acta Neurol Scand Suppl, V164, P1; Engberg Aase Worsaae, 2007, Ugeskr Laeger, V169, P199; Engberg AW, 2001, EUR J EPIDEMIOL, V17, P437, DOI 10.1023/A:1013733107520; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Hewson Paul J, 2005, Traffic Inj Prev, V6, P127, DOI 10.1080/15389580590931590; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kjeldsen MJ, 2003, EPILEPSY RES, V55, P137, DOI 10.1016/S0920-1211(03)00117-7; Macpherson A, 2008, COCHRANE DB SYST REV, V3; Metting Z, 2007, LANCET NEUROL, V6, P699, DOI 10.1016/S1474-4422(07)70191-6; Pedersen CB, 2006, DAN MED BULL, V53, P441; PINNER M, KONSENSUSRAPPORT COM; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; Robinson DL, 2006, BMJ-BRIT MED J, V332, P722, DOI 10.1136/bmj.332.7543.722-a; Rothman K. J., 1986, MODERN EPIDEMIOLOGY; Sun YL, 2006, EPIDEMIOLOGY, V17, P296, DOI 10.1097/01.ede.0000208478.47401.b6; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; Thompson DC, 2000, COCHRANE DB SYST REV, V2; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Vestergaard M, 2007, AM J EPIDEMIOL, V165, P911, DOI 10.1093/aje/kwk086	37	195	203	1	25	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR-APR	2009	373	9669					1105	1110		10.1016/S0140-6736(09)60214-2			6	Medicine, General & Internal	General & Internal Medicine	427IS	WOS:000264773600031	19233461				2021-06-18	
S	Huebner, EA; Strittmatter, SM		Koenig, E		Huebner, Eric A.; Strittmatter, Stephen M.			Axon Regeneration in the Peripheral and Central Nervous Systems	CELL BIOLOGY OF THE AXON	Results and Problems in Cell Differentiation		English	Article; Book Chapter							SPINAL-CORD-INJURY; MYELIN-ASSOCIATED GLYCOPROTEIN; CHONDROITIN SULFATE PROTEOGLYCANS; PROMOTES NEURITE OUTGROWTH; MONOCLONAL-ANTIBODY IN-1; RECEPTOR FAMILY-MEMBER; REPEAT PROTEIN 1A; NOGO-66 RECEPTOR; FUNCTIONAL RECOVERY; AXOTOMIZED NEURONS	Axon regeneration in the mature mammalian central nervous system (CNS) is extremely limited after injury. Consequently, functional deficits persist after spinal cord injury (SCI), traumatic brain injury, stroke, and related conditions that involve axonal disconnection. This situation differs from that in the mammalian peripheral nervous system (PNS), where long-distance axon regeneration and substantial functional recovery can occur in the adult. Both extracellular molecules and the intrinsic growth capacity of the neuron influence regenerative success. This chapter discusses determinants of axon regeneration in the PNS and CNS.	[Huebner, Eric A.; Strittmatter, Stephen M.] Yale Univ, Sch Med, Program Cellular Neurosci Neurodegenerat & Repair, New Haven, CT 06520 USA	Strittmatter, SM (corresponding author), Yale Univ, Sch Med, Program Cellular Neurosci Neurodegenerat & Repair, New Haven, CT 06520 USA.	stephen.strittmatter@yale.edu	Strittmatter, Stephen/F-5739-2011	Strittmatter, Stephen/0000-0001-8188-3092	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R37 NS033020-17, R01 NS056485-04, R01 NS056485, R01 NS042304, R01 NS039962-10, R01 NS042304-08, R37 NS033020, R01 NS039962] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R37NS033020, R01NS039962, R01NS056485, R01NS042304] Funding Source: NIH RePORTER		Asher RA, 2000, J NEUROSCI, V20, P2427; Atwal JK, 2008, SCIENCE, V322, P967, DOI 10.1126/science.1161151; Barritt AW, 2006, J NEUROSCI, V26, P10856, DOI 10.1523/JNEUROSCI.2980-06.2006; Bartsch U, 1995, NEURON, V15, P1375, DOI 10.1016/0896-6273(95)90015-2; BENFEY M, 1982, NATURE, V296, P150, DOI 10.1038/296150a0; Benson MD, 2005, P NATL ACAD SCI USA, V102, P10694, DOI 10.1073/pnas.0504021102; Boeshore KL, 2004, J NEUROBIOL, V59, P216, DOI 10.1002/neu.10308; Bomze HM, 2001, NAT NEUROSCI, V4, P38; Bonilla IE, 2002, J NEUROSCI, V22, P1303, DOI 10.1523/JNEUROSCI.22-04-01303.2002; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Cafferty WB, 2007, NEURON, V38, P187; Cafferty WBJ, 2007, NEURON, V54, P195, DOI 10.1016/j.neuron.2007.04.005; Cafferty WBJ, 2007, J NEUROSCI, V27, P2176, DOI 10.1523/JNEUROSCI.5176-06.2007; Cafferty WBJ, 2006, J NEUROSCI, V26, P12242, DOI 10.1523/JNEUROSCI.3827-06.2006; Cai DM, 2002, NEURON, V35, P711, DOI 10.1016/S0896-6273(02)00826-7; Chan CCM, 2008, J NEUROSCI RES, V86, P581, DOI 10.1002/jnr.21522; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; Costigan M, 2002, BMC NEUROSCI, V3, DOI 10.1186/1471-2202-3-16; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; Dimou L, 2006, J NEUROSCI, V26, P5591, DOI 10.1523/JNEUROSCI.1103-06.2006; Domeniconi M, 2002, NEURON, V35, P283, DOI 10.1016/S0896-6273(02)00770-5; DOU CL, 1994, J NEUROSCI, V14, P7616; Erschbamer M, 2007, J NEUROSCI, V27, P6428, DOI 10.1523/JNEUROSCI.1037-07.2007; Fernandes KJL, 1999, J COMP NEUROL, V414, P495, DOI 10.1002/(SICI)1096-9861(19991129)414:4<495::AID-CNE6>3.0.CO;2-S; Fournier AE, 2003, J NEUROSCI, V23, P1416; Fournier AE, 2001, NATURE, V409, P341, DOI 10.1038/35053072; Fu Q, 2007, J NEUROSCI, V27, P4154, DOI 10.1523/JNEUROSCI.4353-06.2007; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; GrandPre T, 2002, NATURE, V417, P547, DOI 10.1038/417547a; Hata K, 2006, J CELL BIOL, V173, P47, DOI 10.1083/jcb.200508143; Hsieh SHK, 2006, J NEUROSCI, V26, P1006, DOI 10.1523/JNEUROSCI.2806-05.2006; Hu FH, 2008, J NEUROSCI, V28, P1262, DOI 10.1523/JNEUROSCI.1068-07.2008; Hu FH, 2005, J NEUROSCI, V25, P5298, DOI 10.1523/JNEUROSCI.5235-04.2005; Inatani M, 2001, INVEST OPHTH VIS SCI, V42, P1930; Jankowski MP, 2009, BRAIN RES, V1256, P43, DOI 10.1016/j.brainres.2008.12.032; Kaneko S, 2006, NAT MED, V12, P1380, DOI 10.1038/nm1505; Kim JE, 2003, MOL CELL NEUROSCI, V23, P451, DOI 10.1016/S1044-7431(03)00076-9; Kim JE, 2003, NEURON, V38, P187, DOI 10.1016/S0896-6273(03)00147-8; Kim JE, 2004, NEURON, V44, P439, DOI 10.1016/j.neuron.2004.10.015; Koprivica V, 2005, SCIENCE, V310, P106, DOI 10.1126/science.1115462; Kottis V, 2002, J NEUROCHEM, V82, P1566, DOI 10.1046/j.1471-4159.2002.01146.x; Li SX, 2003, J NEUROSCI, V23, P4219; Li SX, 2005, MOL CELL NEUROSCI, V29, P26, DOI 10.1016/j.mcn.2004.12.008; Li SX, 2004, J NEUROSCI, V24, P10511, DOI 10.1523/JNEUROSCI.2828-04.2004; Liu BP, 2002, SCIENCE, V297, P1190, DOI 10.1126/science.1073031; Marklund N, 2006, EXP NEUROL, V197, P70, DOI 10.1016/j.expneurol.2005.08.029; Massey JM, 2006, J NEUROSCI, V26, P4406, DOI 10.1523/JNEUROSCI.5467-05.2006; MCKEON RJ, 1995, EXP NEUROL, V136, P32, DOI 10.1006/exnr.1995.1081; MCKERRACHER L, 1994, NEURON, V13, P805, DOI 10.1016/0896-6273(94)90247-X; Mehta NR, 2007, J BIOL CHEM, V282, P27875, DOI 10.1074/jbc.M704055200; Mi S, 2004, NAT NEUROSCI, V7, P221, DOI 10.1038/nn1188; Moreau-Fauvarque C, 2003, J NEUROSCI, V23, P9229; Morgenstern DA, 2002, PROG BRAIN RES, V137, P313; Neumann S, 2002, NEURON, V34, P885, DOI 10.1016/S0896-6273(02)00702-X; Neumann S, 1999, NEURON, V23, P83, DOI 10.1016/S0896-6273(00)80755-2; Niederost B, 2002, J NEUROSCI, V22, P10368; Nikulina E, 2004, P NATL ACAD SCI USA, V101, P8786, DOI 10.1073/pnas.0402595101; Park JB, 2005, NEURON, V45, P345, DOI 10.1016/j.neuron.2004.12.040; Pearse DD, 2004, NAT MED, V10, P610, DOI 10.1038/nm1056; Qiu J, 2002, NEURON, V34, P895, DOI 10.1016/S0896-6273(02)00730-4; Raivich G, 2004, NEURON, V43, P57, DOI 10.1016/j.neuron.2004.06.005; RICHARDSON PM, 1980, NATURE, V284, P264, DOI 10.1038/284264a0; RICHARDSON PM, 1984, J NEUROCYTOL, V13, P165, DOI 10.1007/BF01148324; Schmalfeldt M, 2000, J CELL SCI, V113, P807; Schmandke A, 2007, NEUROSCIENTIST, V13, P454, DOI 10.1177/1073858407303611; Seijffers R, 2006, MOL CELL NEUROSCI, V32, P143, DOI 10.1016/j.mcn.2006.03.005; Seymour AB, 2005, J CEREBR BLOOD F MET, V25, P1366, DOI 10.1038/sj.jcbfm.9600134; Shao ZH, 2005, NEURON, V45, P353, DOI 10.1016/j.neuron.2004.12.050; Simonen M, 2003, NEURON, V38, P201, DOI 10.1016/S0896-6273(03)00226-5; Sivasankaran R, 2004, NAT NEUROSCI, V7, P261, DOI 10.1038/nn1193; Tanabe K, 2003, J NEUROSCI, V23, P9675; Venkatesh K, 2005, J NEUROSCI, V25, P808, DOI 10.1523/JNEUROSCI.4464-04.2005; Vyas AA, 2002, P NATL ACAD SCI USA, V99, P8412, DOI 10.1073/pnas.072211699; Wang KC, 2002, NATURE, V420, P74, DOI 10.1038/nature01176; Wang XX, 2009, J NEUROTRAUM, V26, P81, DOI 10.1089/neu.2007.0464; Wiessner C, 2003, J CEREBR BLOOD F MET, V23, P154, DOI 10.1097/01.WCB.0000040400.30600.AF; Yamada H, 1997, J NEUROSCI, V17, P7784; Z'Graggen WJ, 2000, J NEUROSCI, V20, P6561, DOI 10.1523/JNEUROSCI.20-17-06561.2000	78	195	202	1	28	SPRINGER-VERLAG BERLIN	BERLIN	HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY	0080-1844		978-3-642-03018-5	RESULTS PROBL CELL D	Results Probl. Cell Differ.		2009	48						339	351		10.1007/400_2009_19	10.1007/978-3-642-03019-2		13	Cell Biology; Developmental Biology	Cell Biology; Developmental Biology	BLT06	WOS:000270967100016	19582408	Green Accepted			2021-06-18	
J	Yang, XF; Wen, L; Shen, F; Li, G; Lou, R; Liu, WG; Zhan, RY				Yang, X. F.; Wen, L.; Shen, F.; Li, G.; Lou, R.; Liu, W. G.; Zhan, R. Y.			Surgical complications secondary to decompressive craniectomy in patients with a head injury: a series of 108 consecutive cases	ACTA NEUROCHIRURGICA			English	Article						Complication; Decompressive craniectomy; Traumatic brain injury	POSTTRAUMATIC HYDROCEPHALUS; BRAIN; MANAGEMENT; HEMORRHAGE; SURGERY; HYPERTENSION; DURAPLASTY	Decompressive craniectomy is an important method for managing refractory intracranial hypertension in patients with head injury. We reviewed a large series of patients who underwent this surgical procedure to establish the incidence and type of postoperative complications. From 1998 to 2005, decompressive craniectomy was performed in 108 patients who suffered from a closed head injury. The incidence rates of complications secondary to decompressive craniectomy and risk factors for developing these complications were analysed. In addition, the relationship between outcome and clinical factors was analysed. Twenty-five of the 108 patients died within the first month after surgical decompression. A lower GCS at admission seemed to be associated with a poorer outcome. Complications related to surgical decompression occurred in 54 of the 108 (50%) patients; of these, 28 (25.9%) patients developed more than one type of complication. Herniation through the cranial defect was the most frequent complication within 1 week and 1 month, and subdural effusion was another frequent complication during this period. After 1 month, the "syndrome of the trephined" and hydrocephalus were the most frequent complications. Older patients and/or those with more severe head trauma had a higher occurrence rate of complications. The potential benefits of decompressive craniectomy can be adversely affected by the occurrence of complications. Each complication secondary to surgical decompression had its own typical time window for occurrence. In addition, the severity of head injury was related to the development of a complication.	[Yang, X. F.; Wen, L.; Shen, F.; Li, G.; Lou, R.; Liu, W. G.; Zhan, R. Y.] Zhejiang Univ, Dept Neurosurg, Affiliated Hosp 1, Coll Med, Hangzhou 310003, Zhejiang, Peoples R China; [Yang, X. F.; Wen, L.; Shen, F.; Li, G.; Lou, R.; Liu, W. G.; Zhan, R. Y.] Zhejiang Univ, Inst Brain Med, Hangzhou 310003, Zhejiang, Peoples R China	Zhan, RY (corresponding author), Zhejiang Univ, Dept Neurosurg, Affiliated Hosp 1, Coll Med, 79 Qingchun Rd, Hangzhou 310003, Zhejiang, Peoples R China.	wenlneuron@126.com	shen, fang/G-8439-2011				Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Adamides AA, 2006, ANZ J SURG, V76, P163, DOI 10.1111/j.1445-2197.2006.03674.x; BEYERL B, 1984, NEUROSURGERY, V15, P257, DOI 10.1227/00006123-198408000-00020; Boret H, 2006, ACTA ANAESTH SCAND, V50, P252, DOI 10.1111/j.1399-6576.2005.00862.x; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P507; BULLOCK R, 1990, J NEUROSURG, V72, P9, DOI 10.3171/jns.1990.72.1.0009; CARDOSO ER, 1985, SURG NEUROL, V23, P261, DOI 10.1016/0090-3019(85)90092-8; CARVI Y, 2006, NEUROL RES, V28, P139, DOI DOI 10.1179/016164106X98008; *CHIN MED ASS, 2006, CLIN GUID CHIN MED A; Chute DL, 2002, J HEAD TRAUMA REHAB, V17, P369, DOI 10.1097/00001199-200210000-00001; Coplin WM, 2001, J TRAUMA, V50, P1050, DOI 10.1097/00005373-200106000-00013; Csokay A, 2001, NEUROSURG REV, V24, P209, DOI 10.1007/s101430100158; D'Ambrosio R, 2004, CURR OPIN NEUROL, V17, P731, DOI 10.1097/00019052-200412000-00014; Dujovny M, 1999, CRIT REV NEUROSURG, V9, P271, DOI 10.1007/s003290050143; Guyot LL, 2000, NEUROL RES, V22, P25; Isago T, 2004, ANN PLAS SURG, V53, P288, DOI 10.1097/01.sap.0000106433.89983.72; Kan P, 2006, J NEUROSURG, V105, P337, DOI 10.3171/ped.2006.105.5.337; Kilincer C, 2005, CLIN NEUROL NEUROSUR, V107, P412, DOI 10.1016/j.clineuro.2004.09.018; Koller M, 1999, ACTA NEUROCHIR, V141, P587, DOI 10.1007/s007010050347; KONIG A, 1987, ACTA NEUROCHIR, V88, P104, DOI 10.1007/BF01404145; Kontopoulos V, 2002, ACTA NEUROCHIR, V144, P791, DOI 10.1007/s00701-002-0948-z; Landeiro JA, 2004, ARQ NEURO-PSIQUIAT, V62, P832, DOI 10.1590/S0004-282X2004000500017; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Miki T, 2006, J TRAUMA, V61, P985, DOI 10.1097/01.ta.0000239665.39237.8c; Mitchell P, 2004, ACTA NEUROCHIR, V146, P159, DOI 10.1007/s00701-003-0186-z; Piek Jurgen, 2002, Curr Opin Crit Care, V8, P134, DOI 10.1097/00075198-200204000-00008; Ruf B, 2003, CRIT CARE, V7, pR133, DOI 10.1186/cc2361; Schaller B, 2003, BRAIN RES, V982, P31, DOI 10.1016/S0006-8993(03)02900-7; STONE JL, 1981, NEUROSURGERY, V8, P542, DOI 10.1227/00006123-198105000-00005; Timofeev I, 2006, INJURY, V37, P1125, DOI 10.1016/j.injury.2006.07.031; van den Broek MD, 2005, J HEAD TRAUMA REHAB, V20, P464, DOI 10.1097/00001199-200509000-00007; Wen L, 2007, J CRANIOFAC SURG, V18, P526; Yamakami Iwao, 1993, Neurologia Medico-Chirurgica, V33, P616, DOI 10.2176/nmc.33.616; Yang Xue-Jun, 2003, Chin J Traumatol, V6, P99	34	195	221	0	20	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	DEC	2008	150	12					1241	1248		10.1007/s00701-008-0145-9			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	382FF	WOS:000261590000004	19005615				2021-06-18	
J	Rutgers, DR; Toulgoat, F; Cazejust, J; Fillard, P; Lasjaunias, P; Ducreux, D				Rutgers, D. R.; Toulgoat, F.; Cazejust, J.; Fillard, P.; Lasjaunias, P.; Ducreux, D.			White matter abnormalities in mild traumatic brain injury: A diffusion tensor imaging study	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article; Proceedings Paper	34th Annual Meeting of the French-Society-of-Neuroradiology/9th French Language Neuroradiology Meeting	MAR 26-28, 2007	Paris, FRANCE	French Soc Neuroradiol			NONMISSILE HEAD-INJURY; AXONAL INJURY; IMAGES; SEQUELAE; TRACKING; DAMAGE; MRI	BACKGROUND AND PURPOSE: Traumatic axonal injury is a primary brain abnormality in head trauma and is characterized by reduction of fractional anisotropy (FA) on diffusion tensor imaging (DTI). Our hypothesis was that patients with mild traumatic brain injury (TBI) have widespread brain white matter regions of reduced FA involving a variety of fiber bundles and show fiber disruption on fiber tracking in a minority of these regions. MATERIALS AND METHODS: Ethics committee approval and informed consent were obtained. Twenty-one patients with mild TBI were investigated (men:women, 12:9; mean age +/- SD, 32 9 years). In a voxel-based comparison with 11 control subjects (men:women, 8:3; mean age, 37 +/- 9 years) using z score analysis, patient regions with abnormally reduced FA were defined in brain white matter. MR imaging, DTI, and fiber tracking characteristics of these regions were described and analyzed using Pearson correlation, linear regression analysis, or the chi(2) test when appropriate. RESULTS: Patients had on average 9.1 regions with reduced FA, with a mean region volume of 525 mm(3), predominantly found in cerebral lobar white matter, cingulum, and corpus callosum. These regions mainly involved supratentorial projection fiber bundles, callosal fibers, and fronto-temporo-occipital association fiber bundles. Internal capsules and infratentorial white matter were relatively infrequently affected. Of all of the involved fiber bundles, 19.3% showed discontinuity on fiber tracking. CONCLUSION: Patients with mild TBI have multiple regions with reduced FA in various white matter locations and involving various fiber bundles. A minority of these fiber bundles show discontinuity on fiber tracking.	[Rutgers, D. R.; Toulgoat, F.; Cazejust, J.; Lasjaunias, P.; Ducreux, D.] Univ Bicetre, Ctr Hosp, Dept Neuroradiol, Le Kremlin Bicetre, France; [Fillard, P.] Inst Natl Rech Informat & Automat, Sophia Antipolis, France	Ducreux, D (corresponding author), CHU Bicetre, Dept Neuroradiol, 78 Rue Gen Leclerc, F-94270 Le Kremlin Bicetre, France.	denis.ducreux@bct.ap-hop-paris.fr		Cazejust, Julien/0000-0003-4212-4792			ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Basser PJ, 1998, MAGNET RESON MED, V39, P928, DOI 10.1002/mrm.1910390610; Basser PJ, 1995, NMR BIOMED, V8, P333, DOI 10.1002/nbm.1940080707; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; Ducreux D, 2005, NEURORADIOLOGY, V47, P604, DOI 10.1007/s00234-005-1389-1; EVANS RW, 1992, NEUROL CLIN, V10, P815; FILLARD P, 2003, MICCAI, V2, P967; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; GENTRY LR, 1994, RADIOLOGY, V191, P1; Haselgrove JC, 1996, MAGNET RESON MED, V36, P960, DOI 10.1002/mrm.1910360620; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jellison BJ, 2004, AM J NEURORADIOL, V25, P356; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; KRAUS JF, 1994, SEMIN NEUROL, V14, P1, DOI 10.1055/s-2008-1041052; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Parizel PM, 2005, EUR RADIOL, V15, P569, DOI 10.1007/s00330-004-2558-z; Ptak T, 2003, AM J ROENTGENOL, V181, P1401, DOI 10.2214/ajr.181.5.1811401; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; TAGHAFERRI F, 2006, ACTA NEUROCHIR, V148, P255; Westin CF, 2002, MED IMAGE ANAL, V6, P93, DOI 10.1016/S1361-8415(02)00053-1; Xu DR, 2002, NEUROIMAGE, V17, P1131, DOI 10.1006/nimg.2002.1285	32	195	202	0	14	AMER SOC NEURORADIOLOGY	OAK BROOK	2210 MIDWEST RD, OAK BROOK, IL 60521 USA	0195-6108			AM J NEURORADIOL	Am. J. Neuroradiol.	MAR	2008	29	3					514	519		10.3174/ajnr.A0856			6	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	275JC	WOS:000254066700020	18039754	Green Published, Other Gold			2021-06-18	
J	Cothren, CC; Osborn, PM; Moore, EE; Morgan, SJ; Johnson, JL; Smith, WR				Cothren, C. Clay; Osborn, Patrick M.; Moore, Ernest E.; Morgan, Steven J.; Johnson, Jeffrey L.; Smith, Wade R.			Preperitonal pelvic packing for hemodynamically unstable pelvic fractures: A paradigm shift	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	65th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 28-30, 2006	New Orleans, LA	Amer Assoc Surg Trauma		trauma; pelvic fracture; preperitoneal pelvic packing; hemorrhage	ANGIOGRAPHIC EMBOLIZATION; EARLY PREDICTORS; MANAGEMENT; HEMORRHAGE; MORTALITY; ARTERIOGRAPHY; TRANSFUSION; INJURIES	Background: The current management of pelvic fracture patients who are hemodynamically unstable in the United States consists of aggressive resuscitation, mechanical stabilization, and angioembolization. Despite this multidisciplinary approach, our recent analysis confirms an alarming 40% mortality in these high-risk patients. Therefore, we pursued alternate therapies to improve patient outcomes. European trauma groups have suggested the technique of pelvic packing via laparotomy to directly address the venous bleeding that comprises 85% of pelvic fracture hemorrhage. We hypothesized that a modified technique of direct preperitoneal pelvic packing (PPP) would reduce the need for angiography, decrease blood transfusion requirements, and lower mortality. Methods: Since September 2004, all patients at our ACS-verified level I trauma center with hemodynamic instability and pelvic fractures underwent PPP/external fixation, according to our protocol. Statistics are reported as mean +/- SEM and analyzed using Student's t test. Results: During the study period, 28 consecutive patients underwent PPP. There was one protocol deviation of prePPP angiography to evaluate an extremity vascular injury. The majority were men (68%) with a mean age of 40 +/- 3.9 years and a mean injury severity score of 55 +/- 3.0. The mean emergency department (ED) systolic blood pressure was 77 +/- 3.0 min Hg, heart rate was 120 +/- 4.3 bpm, and base deficit 13 +/- 0.8 mmol/L. Pelvic fracture classifications included lateral compression (LC) II (9), anteroposterior compression (APC) III (8), LC I (3), vertical shear (3), LC III (3), and APC II (2). Patients required 4 +/- 1.2 units of packed red blood cells (PRBCs) during 82 +/- 13 minutes in the ED. Blood transfusion requirements before postoperative surgical intensive care unit (SICU) admission compared with the subsequent 24 postoperative hours were significantly different (12 +/- 2.0 versus 6 +/- 1.1; p = 0.006). The first 4 patients underwent routine angiography postPPP, with 1 undergoing therapeutic embolization; 4 of the subsequent 24 patients underwent angioembolization with clinical concern of ongoing pelvic hemorrhage. Seven (25%) patients died from multiple organ failure (2), postinjury myocardial infarction/pulseless electrical activity (PEA) arrest (2), invasive mucormycosis (1), withdrawal of care (1), and closed head injury (1); there were no deaths as a result of acute blood loss. Conclusions: PPP is a rapid method for controlling pelvic fracture-related hemorrhage that can supplant the need for emergent angiography. There is a significant reduction in blood product transfusion after PPP, and this approach appears to reduce mortality in this select high-risk group of patients.	Denver Hlth Med Ctr, Dept Surg, Denver, CO 80204 USA; Denver Hlth Med Ctr, Dept Orthoped, Denver, CO 80204 USA; Univ Colorado, Sch Med, Denver, CO USA	Cothren, CC (corresponding author), Denver Hlth Med Ctr, Dept Surg, 777 Bannock St,MC 0206, Denver, CO 80204 USA.	clay.cothren@dhha.org					Agolini SF, 1997, J TRAUMA, V43, P395, DOI 10.1097/00005373-199709000-00001; Ciesla DJ, 2005, ARCH SURG-CHICAGO, V140, P432, DOI 10.1001/archsurg.140.5.432; Demetriades D, 2002, J AM COLL SURGEONS, V195, P1, DOI 10.1016/S1072-7515(02)01197-3; DiGiacomo JG, 2001, PRACTICE MANAGEMENT; Durkin A, 2006, AM J SURG, V192, P211, DOI 10.1016/j.amjsurg.2006.05.001; Ertel W, 2001, J ORTHOP TRAUMA, V15, P468, DOI 10.1097/00005131-200109000-00002; Ertel W, 2000, EUR J TRAUMA, V26, P278, DOI DOI 10.1007/PL00002452; Giannoudis PV, 2004, INJURY, V35, P671, DOI 10.1016/j.injury.2004.03.003; Gourlay D, 2005, J TRAUMA, V59, P1168, DOI 10.1097/01.ta.0000189043.29179.e4; Hak DJ, 2004, ORTHOP CLIN N AM, V35, P439, DOI 10.1016/S0030-5898(04)00045-8; Hamill J, 2000, AUST NZ J SURG, V70, P338, DOI 10.1046/j.1440-1622.2000.01822.x; HAWKINS L, 1970, J TRAUM, V10, P619, DOI 10.1097/00005373-197008000-00001; Heetveld MJ, 2004, WORLD J SURG, V28, P904, DOI 10.1007/s00268-004-7357-9; HUITTINEN VM, 1973, SURGERY, V73, P454; Kimbrell BJ, 2004, ARCH SURG-CHICAGO, V139, P728, DOI 10.1001/archsurg.139.7.728; MARGOLIES MN, 1972, NEW ENGL J MED, V287, P317, DOI 10.1056/NEJM197208172870701; Moore FA, 1997, ARCH SURG-CHICAGO, V132, P620; MUCHA P, 1988, SURG CLIN N AM, V68, P757; NAAM NH, 1983, ARCH SURG-CHICAGO, V118, P422; Parreira JG, 2000, INJURY, V31, P677; POHLEMANN T, 2000, OTA AAST ANN M; POOLE GV, 1994, ORTHOPEDICS, V17, P691; ROTHENBERGER DA, 1978, SURGERY, V84, P356; SAUAIA A, 1994, ARCH SURG-CHICAGO, V129, P39; Smith W, 2007, J ORTHOP TRAUMA, V21, P31, DOI 10.1097/BOT.0b013e31802ea951; Smith WR, 2005, J TRAUMA, V59, P1510, DOI 10.1097/01.ta.0000197330.81352.94; Starr AJ, 2002, J ORTHOP TRAUMA, V16, P553, DOI 10.1097/00005131-200209000-00003; Velmahos GC, 2002, J TRAUMA, V53, P303, DOI 10.1097/00005373-200208000-00019	28	195	216	1	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	APR	2007	62	4					834	839		10.1097/TA.0b013e31803c7632			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	157DJ	WOS:000245698500006	17426537				2021-06-18	
J	Sykova, E; Jendelova, P; Urdzikova, L; Lesny, P; Hejcl, A				Sykova, Eva; Jendelova, Pavla; Urdzikova, Lucia; Lesny, Petr; Hejcl, Ales			Bone marrow stem cells and polymer hydrogels-two strategies for spinal cord injury repair	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Article						cell transplantation; magnetic resonance; spinal cord lesion; repair; scaffold; polymers	CENTRAL-NERVOUS-SYSTEM; MAGNETIC-RESONANCE TRACKING; TRAUMATIC BRAIN INJURY; STROMAL CELLS; FUNCTIONAL RECOVERY; ADULT-RAT; AXONAL REGENERATION; IN-VIVO; PROGENITOR CELLS; CONTROLLED-TRIAL	1. Emerging clinical studies of treating brain and spinal cord injury (SCI) led us to examine the effect of autologous adult stem cell transplantation as well as the use of polymer scaffolds in spinal cord regeneration. We compared an intravenous injection of mesenchymal stem cells (MSCs) or the injection of a freshly prepared mononuclear fraction of bone marrow cells (BMCs) on the treatment of an acute or chronic balloon-induced spinal cord compression lesion in rats. Based on our experimental studies, autologous BMC implantation has been used in a Phase I/II clinical trial in patients (n=20) with a transversal spinal cord lesion. 2. MSCs were isolated from rat bone marrow by their adherence to plastic, labeled with iron-oxide nanoparticles and expanded in vitro. Macroporous hydrogels based on derivatives of 2-hydroxyethyl methacrylate (HEMA) or 2-hydroxypropyl methacrylamide (HPMA) were prepared, then modified by their copolymerization with a hydrolytically degradable crosslinker, N,O-dimethacryloylhydroxylamine, or by different surface electric charges. Hydrogels or hydrogels seeded with MSCs were implanted into rats with hemisected spinal cords. 3. Lesioned animals grafted with MSCs or BMCs had smaller lesions 35 days postgrafting and higher scores in BBB testing than did control animals and also showed a faster recovery of sensitivity in their hind limbs using the plantar test. The functional improvement was more pronounced in MSC-treated rats. In MR images, the lesion populated by grafted cells appeared as a dark hypointense area and was considerably smaller than in control animals. Morphometric measurements showed an increase in the volume of spared white matter in cell-treated animals. In the clinical trial, we compared intraarterial (via a. vertebralis, n=6) versus intravenous administration of BMCs (n=14) in a group of subacute (10-33 days post-SCI, n=8) and chronic patients (2-18 months, n=12). For patient follow-up we used MEP, SEP, MRI, and the ASIA score. Our clinical study revealed that the implantation of BMCs into patients is safe, as there were no complications following cell administration. Partial improvement in the ASIA score and partial recovery of MEP or SEP have been observed in all subacute patients who received cells via a. vertebralis (n=4) and in one out of four subacute patients who received cells intravenously. Improvement was also found in one chronic patient who received cells via a. vertebralis. A much larger population of patients is needed before any conclusions can be drawn. The implantation of hydrogels into hemisected rat spinal cords showed that cellular ingrowth was most pronounced in copolymers of HEMA with a positive surface electric charge. Although most of the cells had the morphological properties of connective tissue elements, we found NF-160-positive axons invading all the implanted hydrogels from both the proximal and distal stumps. The biodegradable hydrogels degraded from the border that was in direct contact with the spinal cord tissue. They were resorbed by macrophages and replaced by newly formed tissue containing connective tissue elements, blood vessels, GFAP-positive astrocytic processes, and NF-160-positive neurofilaments. Additionally, we implanted hydrogels seeded with nanoparticle-labeled MSCs into hemisected rat spinal cords. Hydrogels seeded with MSCs were visible on MR images as hypointense areas, and subsequent Prussian blue histological staining confirmed positively stained cells within the hydrogels. 4. We conclude that treatment with different bone marrow cell populations had a positive effect on behavioral outcome and histopathological assessment after SCI in rats; this positive effect was most pronounced following MSC treatment. Our clinical study suggests a possible positive effect in patients with SCI. Bridging the lesion cavity can be an approach for further improving regeneration. Our preclinical studies showed that macroporous polymer hydrogels based on derivatives of HEMA or HPMA are suitable materials for bridging cavities after SCI; their chemical and physical properties can be modified to a specific use, and 3D implants seeded with different cell types may facilitate the ingrowth of axons.	Acad Sci Czech Republ, Inst Expt Med, Prague 14220 4, Czech Republic; Charles Univ Prague, Ctr Cell Therapy & Tissue Repair, CR-11636 Prague 1, Czech Republic; Charles Univ Prague, Fac Med 2, Dept Neurosci, CR-11636 Prague 1, Czech Republic	Sykova, E (corresponding author), Acad Sci Czech Republ, Inst Expt Med, Videnska 1083, Prague 14220 4, Czech Republic.	sykova@biomed.cas.cz	Jendelova, Pavla/H-2516-2014; Sykova, Eva/H-2659-2014; Hejcl, Ales/H-2858-2014	Jendelova, Pavla/0000-0002-4644-9212; Hejcl, Ales/0000-0002-9206-1980; Machova Urdzikova, Lucia/0000-0001-7622-5837			Akiyama Y, 2002, GLIA, V39, P229, DOI 10.1002/glia.10102; Akiyama Y, 2002, J NEUROSCI, V22, P6623; Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; Basso DM, 1996, J NEUROTRAUM, V13, P343, DOI 10.1089/neu.1996.13.343; BIXBY JL, 1991, ANNU REV CELL BIOL, V7, P117, DOI 10.1146/annurev.cellbio.7.1.117; Bjorklund A, 2000, NAT NEUROSCI, V3, P537, DOI 10.1038/75705; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; Bracken MB, 1998, J NEUROSURG, V89, P699, DOI 10.3171/jns.1998.89.5.0699; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; BREGMAN BS, 1987, DEV BRAIN RES, V34, P265, DOI 10.1016/0165-3806(87)90214-8; Brustle O, 1999, SCIENCE, V285, P754, DOI 10.1126/science.285.5428.754; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; Chong ZZ, 2002, J CEREBR BLOOD F MET, V22, P503, DOI 10.1097/00004647-200205000-00001; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Chopp M, 2000, NEUROREPORT, V11, P3001, DOI 10.1097/00001756-200009110-00035; Coumans JV, 2001, J NEUROSCI, V21, P9334, DOI 10.1523/JNEUROSCI.21-23-09334.2001; Dame C, 2003, DEV BRAIN RES, V143, P217, DOI 10.1016/S0165-3806(03)00134-2; EAVES CJ, 1991, BLOOD, V78, P110; Eglitis MA, 1999, NEUROREPORT, V10, P1289, DOI 10.1097/00001756-199904260-00025; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Geisler FH, 2001, SPINE, V26, pS87, DOI 10.1097/00007632-200112151-00015; HEJCL A, 2005, 5 CZECH NEUR C PRAG; Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299; HORVAT JC, 1991, PARAPLEGIA, V29, P299, DOI 10.1038/sc.1991.44; HOULE JD, 1994, J NEURAL TRANSP PLAS, V5, P115, DOI 10.1155/NP.1994.115; Houweling DA, 1998, EXP NEUROL, V153, P49, DOI 10.1006/exnr.1998.6867; Hugenholtz H, 2002, CAN J NEUROL SCI, V29, P227, DOI 10.1017/S0317167100001992; Inoue M, 2003, GLIA, V44, P111, DOI 10.1002/glia.10285; Iwanami A, 2005, J NEUROSCI RES, V80, P182, DOI 10.1002/jnr.20436; Jendelova P, 2003, MAGNET RESON MED, V50, P767, DOI 10.1002/mrm.10585; Jendelova P, 2004, J NEUROSCI RES, V76, P232, DOI 10.1002/jnr.20041; JENDELOVA P, 2004, HYDROGEL IMPLANTATIO; KUHLENGEL KR, 1990, J COMP NEUROL, V293, P74, DOI 10.1002/cne.902930107; Lee DHS, 2003, NAT REV DRUG DISCOV, V2, P872, DOI 10.1038/nrd1228; Lesny P, 2002, J CHEM NEUROANAT, V23, P243, DOI 10.1016/S0891-0618(02)00011-X; LESNY P, IN PRESS J MAT SCI M; Liu S, 1998, J NEUROSCI RES, V51, P723, DOI 10.1002/(SICI)1097-4547(19980315)51:6<723::AID-JNR6>3.0.CO;2-D; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; Majumdar MK, 1998, J CELL PHYSIOL, V176, P57, DOI 10.1002/(SICI)1097-4652(199807)176:1<57::AID-JCP7>3.0.CO;2-7; Maquet V, 2001, BIOMATERIALS, V22, P1137, DOI 10.1016/S0142-9612(00)00357-4; MEHLER MF, 1993, NATURE, V362, P62, DOI 10.1038/362062a0; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Ogawa Y, 2002, J NEUROSCI RES, V69, P925, DOI 10.1002/jnr.10341; Okada S, 2005, FASEB J, V19, P1839, DOI 10.1096/fj.05-4082fje; Oudega M, 2001, BIOMATERIALS, V22, P1125, DOI 10.1016/S0142-9612(00)00346-X; Park HC, 2005, TISSUE ENG, V11, P913, DOI 10.1089/ten.2005.11.913; PITTS LH, 1995, J NEUROTRAUM, V12, P235, DOI 10.1089/neu.1995.12.235; Pointillart V, 2000, SPINAL CORD, V38, P71, DOI 10.1038/sj.sc.3100962; Pradny M, 2003, COLLECT CZECH CHEM C, V68, P812, DOI 10.1135/cccc20030812; PRADNY M, IN PRESS J MAT SCI M; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Sykova E, 2005, EXP NEUROL, V193, P261; Sykova E, 2005, ANN NY ACAD SCI, V1049, P146, DOI 10.1196/annals.1334.014; SYKOVA E, 2005, BONE MARROW CELLS TO; Teng YD, 2002, P NATL ACAD SCI USA, V99, P3024, DOI 10.1073/pnas.052678899; URDZIKOVA L, IN PRESS J NEUROTRAU; URDZIKOVA L, 2005, 5 INT S EXP CLIN NEU, P124; VENSTROM KA, 1993, FASEB J, V7, P996; Wang L, 2002, EXP HEMATOL, V30, P831, DOI 10.1016/S0301-472X(02)00829-9; Woerly S, 1998, J BIOMAT SCI-POLYM E, V9, P681, DOI 10.1163/156856298X00091; Woerly S, 2001, BIOMATERIALS, V22, P1095, DOI 10.1016/S0142-9612(00)00354-9; Woerly S, 2001, INT J DEV NEUROSCI, V19, P63, DOI 10.1016/S0736-5748(00)00064-2; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; WRATHALL JR, 1982, ACTA NEUROPATHOL, V57, P59, DOI 10.1007/BF00688878; Wu SF, 2003, J NEUROSCI RES, V72, P343, DOI 10.1002/jnr.10587; Xu XM, 1997, J NEUROCYTOL, V26, P1, DOI 10.1023/A:1018557923309	67	195	211	5	79	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0272-4340	1573-6830		CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.	NOV	2006	26	7-8					1113	1129		10.1007/s10571-006-9007-2			17	Cell Biology; Neurosciences	Cell Biology; Neurosciences & Neurology	114HO	WOS:000242657500004	16633897				2021-06-18	
J	Thibault, KL; Margulies, SS				Thibault, KL; Margulies, SS			Age-dependent material properties of the porcine cerebrum: effect on pediatric inertial head injury criteria	JOURNAL OF BIOMECHANICS			English	Article						scaling; brain injury; infant; constitutive properties; viscoelastic	BRAIN-TISSUE; TRAUMA	During growth and development, the immature central nervous system undergoes rapid alterations in constituents and structure. We hypothesize that these alterations are accompanied by changes in the mechanical properties of brain tissue which, in turn, influence the response of the brain to traumatic inertial loads. Samples of frontal cerebrum from neonatal (2-3 days) and adult pigs were harvested and tested within 3 h post-mortem. The complex shear modulus of the samples was measured in a custom-designed oscillatory shear testing device at engineering shear strain amplitudes of 2.5% or 5% from 20-200 Hz, at 25 degrees C and 100% humidity. In this range, the elastic and viscous components of the complex shear modulus increased significantly with the development of the cerebral region of the brain. Using an idealized model of the developing head, the age-dependent material properties of brain tissue were shown to affect the mechanical response of the brain to inertial loading. This study is a first step toward developing head injury tolerance criteria specifically for the pediatric population., (C) 1998 Elsevier Science Ltd. All rights reserved.	Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA	Margulies, SS (corresponding author), Univ Penn, Dept Bioengn, 240 S 33rd St, Philadelphia, PA 19104 USA.	margulies@seas.upenn.edu	Dilger, Ryan N./E-7031-2010	Dilger, Ryan N./0000-0003-2538-2845	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49CCR304684/5] Funding Source: Medline		Arbogast KB, 1997, J BIOMECH, V30, P757, DOI 10.1016/S0021-9290(97)00023-7; BRUCE DA, 1990, CURRENT PROBLEMS PED, P63; CALDER IM, 1984, J CLIN PATHOL, V37, P1095, DOI 10.1136/jcp.37.10.1095; DEJEAMMES M, 1984, 840530 SAE, P427; DICKERSON JW, 1967, PROC R SOC SER B-BIO, V166, P384, DOI 10.1098/rspb.1967.0002; DOBBING J, 1964, SCI FDN PAEDIATRICS; Donnelly BR, 1997, J BIOMECH ENG-T ASME, V119, P423, DOI 10.1115/1.2798289; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; FALLENSTEIN GT, 1969, J BIOMECH, V2, P217, DOI 10.1016/0021-9290(69)90079-7; Ferry J.D., 1980, VISCOELASTIC PROPERT, V3rd ed; FITZGERALD ER, 1970, MED BIOL ENG, V9, P459; HAYES WC, 1978, J BIOMECH, V11, P407, DOI 10.1016/0021-9290(78)90075-1; Holbourn AHS, 1943, LANCET, V2, P438; HOLBOURN AHS, 1956, COMMUNICATION   1013; KOENEMAN JB, 1966, THESIS CASE I TECHNO; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; McElhaney JH., 1976, HDB HUMAN TOLERANCE; MELVIN JW, 1995, P INT C EXP DETR MI; MENDIS KK, 1995, J BIOMECH ENG-T ASME, V117, P279, DOI 10.1115/1.2794182; METZ H, 1970, J BIOMECH, V3, P453, DOI 10.1016/0021-9290(70)90017-5; Miller K, 1997, J BIOMECH, V30, P1115, DOI 10.1016/S0021-9290(97)00092-4; MOHAN D, 1979, T ASME, V250, P250; OMMAYA A K, 1968, Journal of Biomechanics, V1, P127, DOI 10.1016/0021-9290(68)90015-8; Ommaya AK, 1967, P 11 STAPP CAR CRASH, P670906; PAMIDI MR, 1978, J BIOMECH ENG-T ASME, V100, P44, DOI 10.1115/1.3426188; PASCUCCI RC, 1988, INTENS CARE MED, V14, P185, DOI 10.1007/BF00717985; SHAPIRO K, 1985, HEAD INJURY CHILDREN, P243; SHUCK LZ, 1972, J BASIC ENG-T ASME, V94, P905, DOI 10.1115/1.3425588; STURTZ G, 1980, P 24 STAPP CAR CRASH; THIBAULT K, 1997, THESIS U PENNSYLVANI	31	195	200	0	20	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290			J BIOMECH	J. Biomech.	DEC	1998	31	12					1119	1126		10.1016/S0021-9290(98)00122-5			8	Biophysics; Engineering, Biomedical	Biophysics; Engineering	151CZ	WOS:000077704300006	9882044				2021-06-18	
J	Shahripour, RB; Harrigan, MR; Alexandrov, AV				Shahripour, Reza Bavarsad; Harrigan, Mark R.; Alexandrov, Andrei V.			N-acetylcysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunities	BRAIN AND BEHAVIOR			English	Article						N-acetylcysteine; neurological disorder; treatment	ACETYL-L-CYSTEINE; TRAUMATIC BRAIN-INJURY; PROGRESSIVE MYOCLONUS EPILEPSY; NECROSIS-FACTOR-ALPHA; SMOOTH-MUSCLE-CELLS; OXIDATIVE STRESS; PARKINSONS-DISEASE; REDOX REGULATION; INCREASED GENERATION; LIPID-PEROXIDATION	Background: There is an expanding field of research investigating the benefits of medicines with multiple mechanisms of action across neurological disorders. N-acetylcysteine (NAC), widely known as an antidote to acetaminophen overdose, is now emerging as treatment of vascular and nonvascular neurological disorders. NAC as a precursor to the antioxidant glutathione modulates glutamatergic, neurotrophic, and inflammatory pathways. Aim and discussion: Most NAC studies up to date have been carried out in animal models of various neurological disorders with only a few studies completed in humans. In psychiatry, NAC has been tested in over 20 clinical trials as an adjunctive treatment; however, this topic is beyond the scope of this review. Herein, we discuss NAC molecular, intracellular, and systemic effects, focusing on its potential applications in neurodegenerative diseases including spinocerebellar ataxia, Parkinson's disease, tardive dyskinesia, myoclonus epilepsy of the Unverricht-Lundbor type as well as multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer's disease. Conclusion: Finally, we review the potential applications of NAC to facilitate recovery after traumatic brain injury, cerebral ischemia, and in treatment of cerebrovascular vasospasm after subarachnoid hemorrhage.	[Shahripour, Reza Bavarsad; Alexandrov, Andrei V.] Univ Alabama Birmingham, Comprehens Stroke Ctr, Dept Neurol, Birmingham, AL 35249 USA; [Harrigan, Mark R.] Univ Alabama Birmingham, Dept Surg, Div Neurosurg, Birmingham, AL 35249 USA	Alexandrov, AV (corresponding author), Univ Alabama Birmingham, Comprehens Stroke Ctr, Dept Neurol, RWUH M226,619 19th St South, Birmingham, AL 35249 USA.	avalexandrov@att.net		Alexandrov, Andrei V/0000-0001-8871-1023			ABELLO PA, 1994, SHOCK, V2, P79, DOI 10.1097/00024382-199408000-00001; Adair JC, 2001, NEUROLOGY, V57, P1515, DOI 10.1212/WNL.57.8.1515; ADAMS JD, 1991, MOL CHEM NEUROPATHOL, V14, P213, DOI 10.1007/BF03159937; Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; Akca T, 2005, J SURG RES, V129, P38, DOI 10.1016/j.jss.2005.05.026; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Andrews NP, 2001, J AM COLL CARDIOL, V37, P117, DOI 10.1016/S0735-1097(00)01093-7; [Anonymous], 2000, ALTERN MED REV, V5, P467; Arakawa M, 2007, CEREBELLUM, V6, P308, DOI 10.1080/14734220601142878; Arrigo AP, 1999, FREE RADICAL BIO MED, V27, P936, DOI 10.1016/S0891-5849(99)00175-6; ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X; Atkuri KR, 2007, CURR OPIN PHARMACOL, V7, P355, DOI 10.1016/j.coph.2007.04.005; BANNAI S, 1986, J MEMBRANE BIOL, V89, P1, DOI 10.1007/BF01870891; Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633; Behar TN, 2003, FREE RADICAL BIO MED, V35, P566, DOI 10.1016/S0891-5849(03)00329-0; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; BUSCIGLIO J, 1995, NATURE, V378, P776, DOI 10.1038/378776a0; Cabassi A, 2001, J HYPERTENS, V19, P1233, DOI 10.1097/00004872-200107000-00008; Chandra J, 2000, FREE RADICAL BIO MED, V29, P323, DOI 10.1016/S0891-5849(00)00302-6; Chen G, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/716458; Clark J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012333; COTGREAVE IA, 1987, BIOPHARM DRUG DISPOS, V8, P365, DOI 10.1002/bdd.2510080407; Cuzzocrea S, 2000, BRIT J PHARMACOL, V130, P1219, DOI 10.1038/sj.bjp.0703421; Cuzzocrea S, 2000, CARDIOVASC RES, V47, P537, DOI 10.1016/S0008-6363(00)00018-3; Davis W, 2001, J PHARMACOL EXP THER, V296, P1; Dawson T., 1997, CEREBROVASC DIS, V7, P349; De Mattia G, 1998, DIABETOLOGIA, V41, P1392, DOI 10.1007/s001250051082; Dean O, 2011, J PSYCHIATR NEUROSCI, V36, P78, DOI 10.1503/jpn.100057; Dekhuijzen PNR, 2004, EUR RESPIR J, V23, P629, DOI 10.1183/09031936.04.00016804; Doi H, 2000, CIRCULATION, V102, P670, DOI 10.1161/01.CIR.102.6.670; ELDRIDGE R, 1983, LANCET, V2, P838, DOI 10.1016/s0140-6736(83)90749-3; EYLAR E, 1993, INT IMMUNOL, V5, P97, DOI 10.1093/intimm/5.1.97; Farr SA, 2003, J NEUROCHEM, V84, P1173, DOI 10.1046/j.1471-4159.2003.01580.x; FINDLAY JM, 1989, NEUROSURGERY, V25, P736, DOI 10.1227/00006123-198911000-00008; Fontaine M A, 2000, J Neurochem, V75, P1709, DOI 10.1046/j.1471-4159.2000.0751709.x; Frank J, 2000, FREE RADICAL BIO MED, V29, P1096, DOI 10.1016/S0891-5849(00)00395-6; Friehs G. M., 2014, J NEUROIMAG UNDER RE; Fu R, 2013, HUM MOL GENET, V22, P3508, DOI 10.1093/hmg/ddt206; Galili-Mosberg R, 2000, J NEURAL TRANSM, V107, P479, DOI 10.1007/s007020070089; Galis ZS, 1998, CIRCULATION, V97, P2445, DOI 10.1161/01.CIR.97.24.2445; Galle J, 1999, KIDNEY INT, V56, pS62, DOI 10.1046/j.1523-1755.1999.07116.x; Geller HM, 2001, J NEUROCHEM, V78, P265, DOI 10.1046/j.1471-4159.2001.00395.x; Gere-Paszti E, 2009, BIOMED CHROMATOGR, V23, P658, DOI 10.1002/bmc.1171; Ghigliotti G, 2001, THROMB HAEMOSTASIS, V85, P724; Giustarini D, 2012, BIOCHEM PHARMACOL, V84, P1522, DOI 10.1016/j.bcp.2012.09.010; GLABINSKI A, 1993, ACTA NEUROL SCAND, V88, P174; GRAY PN, 1980, BIOCHEM BIOPH RES CO, V95, P707; Guney O, 2010, WORLD NEUROSURG, V73, P42, DOI 10.1016/j.surneu.2009.06.003; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P501, DOI 10.1016/0003-9861(86)90305-X; Hans VHJ, 1999, J CEREBR BLOOD F MET, V19, P184; HARRISON PM, 1991, NEW ENGL J MED, V324, P1852, DOI 10.1056/NEJM199106273242604; Hicdonmez T, 2006, NEUROCHEM RES, V31, P473, DOI 10.1007/s11064-006-9040-z; Hoffer E, 2002, MEDIAT INFLAMM, V11, P321, DOI 10.1080/09629350210000015737; HOLDINESS MR, 1991, CLIN PHARMACOKINET, V20, P123, DOI 10.2165/00003088-199120020-00004; Holmay MJ, 2013, CLIN NEUROPHARMACOL, V36, P103, DOI 10.1097/WNF.0b013e31829ae713; Hsu BG, 2006, LIFE SCI, V79, P2010, DOI 10.1016/j.lfs.2006.06.040; Ichiki T, 2001, HYPERTENSION, V37, P535, DOI 10.1161/01.HYP.37.2.535; Ishige K, 2005, NEUROCHEM INT, V47, P545, DOI 10.1016/j.neuint.2005.07.010; JENNER P, 1994, LANCET, V344, P796, DOI 10.1016/S0140-6736(94)92347-7; Jiang CT, 2005, EXP NEUROL, V191, P154, DOI 10.1016/j.expneurol.2004.08.035; Kelly G S, 1998, Altern Med Rev, V3, P114; Kerksick Chad, 2005, J Int Soc Sports Nutr, V2, P38, DOI 10.1186/1550-2783-2-2-38; Khan M, 2004, J NEUROSCI RES, V76, P519, DOI 10.1002/jnr.20087; Kim YH, 2000, BIOCHEM BIOPH RES CO, V271, P747, DOI 10.1006/bbrc.2000.2676; Lander HM, 1997, FASEB J, V11, P118; Lee JS, 1998, EXP CELL RES, V239, P447, DOI 10.1006/excr.1997.3919; Lee SL, 1999, AM J PHYSIOL-LUNG C, V277, pL282; Lehesjoki AE, 1998, ANN MED, V30, P474, DOI 10.3109/07853899809002489; LEHESJOKI AE, 1993, NEUROLOGY, V43, P2384, DOI 10.1212/WNL.43.11.2384; LEHMANN D, 1994, J NEUROIMMUNOL, V50, P35, DOI 10.1016/0165-5728(94)90212-7; Li AE, 1999, CIRC RES, V85, P304, DOI 10.1161/01.RES.85.4.304; LOHR JB, 1995, PSYCHOPHARMACOL BULL, V31, P159; LOUWERSE ES, 1995, ARCH NEUROL-CHICAGO, V52, P559, DOI 10.1001/archneur.1995.00540300031009; Martin KR, 2000, IN VITRO MOL TOXICOL, V13, P237; Martinez M, 1999, LIFE SCI, V64, P1253, DOI 10.1016/S0024-3205(98)00472-X; MASS H, 1995, BIOCHEM BIOPH RES CO, V215, P613, DOI 10.1006/bbrc.1995.2508; MAY PC, 1985, J NEUROL SCI, V70, P101, DOI 10.1016/0022-510X(85)90192-3; MAYER M, 1994, P NATL ACAD SCI USA, V91, P7496, DOI 10.1073/pnas.91.16.7496; MCLELLAN LI, 1995, CARCINOGENESIS, V16, P2099, DOI 10.1093/carcin/16.9.2099; MEISTER A, 1995, METHOD ENZYMOL, V251, P3, DOI 10.1016/0076-6879(95)51106-7; Merrill JE, 1996, TRENDS NEUROSCI, V19, P331, DOI 10.1016/0166-2236(96)10047-3; Millea PJ, 2009, AM FAM PHYSICIAN, V80, P265; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Morris KC, 2011, J CEREBR BLOOD F MET, V31, P1003, DOI 10.1038/jcbfm.2010.229; Nagase M, 2001, BIOCHEM BIOPH RES CO, V281, P720, DOI 10.1006/bbrc.2001.4374; PAHL HL, 1994, BIOESSAYS, V16, P497, DOI 10.1002/bies.950160709; Pan J, 2009, NEUROCHEM INT, V54, P418, DOI 10.1016/j.neuint.2009.01.013; Pappert EJ, 1996, NEUROLOGY, V47, P1037, DOI 10.1212/WNL.47.4.1037; Rancan M, 2001, J NEUROSCI RES, V63, P438, DOI 10.1002/1097-4547(20010301)63:5<438::AID-JNR1039>3.0.CO;2-P; Reilly D K, 1983, Adv Neurol, V37, P51; Remington R, 2009, AM J ALZHEIMERS DIS, V24, P27, DOI 10.1177/1533317508325094; Reynaud E, 2010, NAT ED, V3, P28; RICHMAN PG, 1975, J BIOL CHEM, V250, P1422; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Sadan O, 2005, CLIN NEUROPHARMACOL, V28, P285, DOI 10.1097/01.wnf.0000191331.54649.e3; Samuni Y, 2013, BBA-GEN SUBJECTS, V1830, P4117, DOI 10.1016/j.bbagen.2013.04.016; Sandhir R, 2012, NEURODEGENER DIS, V9, P145, DOI 10.1159/000334273; Sarker KP, 1999, THROMB HAEMOSTASIS, V82, P1071; SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x; Sen CK, 1996, FASEB J, V10, P709; Sen CK, 1997, J NUTR BIOCHEM, V8, P660, DOI 10.1016/S0955-2863(97)00113-7; Sen O, 2006, NEUROL RES, V28, P859, DOI 10.1179/016164106X115099; SHARIEF MK, 1991, NEW ENGL J MED, V325, P467, DOI 10.1056/NEJM199108153250704; SHEFFNER AL, 1966, BIOCHEM PHARMACOL, V15, P1523, DOI 10.1016/0006-2952(66)90197-3; Shirvan A, 2000, MOL BRAIN RES, V83, P81, DOI 10.1016/S0169-328X(00)00198-4; SHOULSON I, 1993, NEW ENGL J MED, V328, P176, DOI 10.1056/NEJM199301213280305; SIAN J, 1994, ANN NEUROL, V36, P348, DOI 10.1002/ana.410360305; SOLEN G, 1993, INT J RADIAT BIOL, V64, P359, DOI 10.1080/09553009314551541; Stanislaus Romesh, 2005, J Autoimmune Dis, V2, P4, DOI 10.1186/1740-2557-2-4; Su B, 2001, CIRC RES, V89, P39, DOI 10.1161/hh1301.093615; Sunitha K, 2013, FREE RADICAL RES, V47, P357, DOI 10.3109/10715762.2013.781595; TALLEY AK, 1995, MOL CELL BIOL, V15, P2359; Tchantchou F, 2005, J ALZHEIMERS DIS, V7, P135; Tsai JC, 1996, J BIOL CHEM, V271, P3667; Tucker Stephanie, 2005, Current Alzheimer Research, V2, P249, DOI 10.2174/1567205053585855; Tyagi SC, 1998, AM J PHYSIOL-CELL PH, V274, pC396; Unnithan AS, 2012, NEUROCHEM INT, V61, P356, DOI 10.1016/j.neuint.2012.06.001; Vasdekis SN, 2013, BRAIN BEHAV, V3, P606, DOI 10.1002/brb3.161; WATSON WA, 1991, DICP ANN PHARMAC, V25, P1081; Wolberger C, 1998, CURR OPIN GENET DEV, V8, P552, DOI 10.1016/S0959-437X(98)80010-5; WOODS CG, 1992, Q J MED, V82, P169; Xiong Y, 1999, J NEUROTRAUM, V16, P1067, DOI 10.1089/neu.1999.16.1067; Xu XP, 1999, CIRCULATION, V99, P993, DOI 10.1161/01.CIR.99.8.993; Yan CYI, 1998, J NEUROSCI, V18, P4042; Yan ZP, 2000, J BIOL CHEM, V275, P4949, DOI 10.1074/jbc.275.7.4949; Yang G Q, 1984, Adv Nutr Res, V6, P203; Yi JH, 2006, J NEUROTRAUM, V23, P86, DOI 10.1089/neu.2006.23.86; YU BP, 1994, PHYSIOL REV, V74, P139; ZIMENT I, 1988, BIOMED PHARMACOTHER, V42, P513	129	194	197	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN, NJ 07030 USA	2162-3279			BRAIN BEHAV	Brain Behav.	MAR	2014	4	2					108	122		10.1002/brb3.208			15	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	AX5NJ	WOS:000346973200002	24683506	DOAJ Gold, Green Published			2021-06-18	
J	Dikmen, S; Machamer, J; Fann, JR; Temkin, NR				Dikmen, Sureyya; Machamer, Joan; Fann, Jesse R.; Temkin, Nancy R.			Rates of symptom reporting following traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Traumatic brain injuries; Neurobehavioral manifestations; Head injuries; Post-concussion syndrome; Post-traumatic symptoms; Post-concussion symptoms	MILD HEAD-INJURY; POST-CONCUSSION SYNDROME; COMPLAINT BASE RATES; POSTCONCUSSION SYNDROME; DIAGNOSTIC-CRITERIA; RECOVERY; PREVALENCE; COHORT	This study examines rates of reporting of new or worse post-traumatic symptoms for patients with a broad range of injury severity at 1 month and 1 year after traumatic brain injury (TB!), as compared with those whose injury spared the head, and assesses variables related to symptom reporting at 1 year post-injury. Seven hundred thirty two TBI subjects and 120 general trauma comparison (TC) subjects provided new or worse symptom information at 1 month and/or 1 year post-injury. Symptom reporting at I year post-injury was compared in subgroups based on basic demographics, preexisting conditions, and severity of brain injury. The TBI group reported significantly more symptoms at 1 month and I year after injury than TCs (each p < .001). Although symptom endorsement declined from I month to I year, 53% of people with TBI and 24% of TC continued to report 3 or more symptoms at 1 year post-injury. Symptom reporting in the TBI group was significantly related to age, gender, preinjury alcohol abuse, pre-injury psychiatric history, and severity of TBI. Symptom reporting is common following a traumatic injury and continues to be experienced by a substantial number of TBI subjects of all severity levels at 1 year post-injury. (JINS, 2010, 16, 401-411.)	[Dikmen, Sureyya] Univ Washington, Harborview Med Ctr, Dept Rehabil Med, Seattle, WA 98104 USA; [Dikmen, Sureyya; Temkin, Nancy R.] Univ Washington, Dept Neurol Surg, Seattle, WA 98104 USA; [Dikmen, Sureyya; Fann, Jesse R.] Univ Washington, Dept Psychiat, Seattle, WA 98104 USA; [Dikmen, Sureyya; Fann, Jesse R.] Univ Washington, Dept Behav Sci, Seattle, WA 98104 USA; [Temkin, Nancy R.] Univ Washington, Dept Biostat, Seattle, WA 98104 USA	Dikmen, S (corresponding author), Univ Washington, Harborview Med Ctr, Dept Rehabil Med, Mail Stop 359612,325 9th Ave, Seattle, WA 98104 USA.	Dikmen@u.washington.edu			National Institutes on Disability and Rehabilitation Research [H133A070032]; Agency for Health Care Research and QualityUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [HS04146, HS05304]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS- 19643]; AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [R01HS005304] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019643] Funding Source: NIH RePORTER	This study was supported by the following grants: H133A070032 from the National Institutes on Disability and Rehabilitation Research, HS04146 and HS05304 from the Agency for Health Care Research and Quality, and NS- 19643 from the National Institutes of Health. The authors have no conflict of interest to disclose.	American Psychiatric Association, 1994, DIAGN STAT MAN MENT; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bell KR, 2008, J NEUROL NEUROSUR PS, V79, P1275, DOI 10.1136/jnnp.2007.141762; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Boake C, 2004, J NEUROPSYCH CLIN N, V16, P493, DOI 10.1176/appi.neuropsych.16.4.493; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; DIKMEN S, 2007, J INT NEUROPSYCHO S2, V13, P64; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; DUNN JT, 1995, J CLIN PSYCHOL, V51, P577, DOI 10.1002/1097-4679(199507)51:4<577::AID-JCLP2270510418>3.0.CO;2-E; Gasquoine P G, 2000, Appl Neuropsychol, V7, P83, DOI 10.1207/S15324826AN0702_3; GERBER DJ, 1995, J HEAD TRAUMA REHAB, V10, P28, DOI 10.1097/00001199-199508000-00004; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; Gunstad J, 2002, J INT NEUROPSYCH SOC, V8, P37, DOI 10.1017/S1355617701020045; Heitger MH, 2007, J REHABIL MED, V39, P612, DOI 10.2340/16501977-0100; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; HORVITZ DG, 1952, J AM STAT ASSOC, V47, P663, DOI 10.2307/2280784; Institute of Medicine, 2009, GULF WAR HLTH LONG T, V7; Iverson G.L., 2007, BRAIN INJURY MED PRI, P373; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; Lannsjo M, 2009, BRAIN INJURY, V23, P213, DOI 10.1080/02699050902748356; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Machulda MM, 1998, ARCH CLIN NEUROPSYCH, V13, P415, DOI 10.1016/S0887-6177(97)00031-0; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; McCauley SR, 2005, J NERV MENT DIS, V193, P540, DOI 10.1097/01.nmd.0000172592.05801.71; McCrea M, 2008, MILD TRAUMATIC BRAIN; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; Mickeviciene D, 2002, EUR J NEUROL, V9, P581, DOI 10.1046/j.1468-1331.2002.00497.x; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Nolin P, 2006, BRAIN INJURY, V20, P1147, DOI 10.1080/02699050601049247; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; RADANOV BP, 1992, SPINE, V17, P127, DOI 10.1097/00007632-199202000-00001; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Sawchyn JM, 2000, ARCH CLIN NEUROPSYCH, V15, P1, DOI 10.1016/S0887-6177(98)00041-9; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; TEASDALE G, 1974, LANCET, V2, P81; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3; World Health Organization, 1992, ICD 10 INT STAT CLAS	49	194	197	0	22	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAY	2010	16	3					401	411		10.1017/S1355617710000196			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	594ZA	WOS:000277579000001	20188017				2021-06-18	
J	Castriotta, RJ; Wilde, MC; Lai, JM; Atanasov, S; Masel, BE; Kuna, ST				Castriotta, Richard J.; Wilde, Mark C.; Lai, Jenny M.; Atanasov, Strahil; Masel, Brent E.; Kuna, Samuel T.			Prevalence and Consequences of Sleep Disorders in Traumatic Brain Injury	JOURNAL OF CLINICAL SLEEP MEDICINE			English	Article						Trauma; brain injury; hypersomnia; sleep apnea; narcolepsy; sleep disorders	EXCESSIVE DAYTIME SLEEPINESS; MILD HEAD-INJURY; CPAP TREATMENT; SUSTAINED ATTENTION; APNEA; PERFORMANCE; NARCOLEPSY; INSTRUMENT; VIGILANCE; OUTCOMES	Study Objectives: Determine prevalence and consequences of sleepiness and sleep disorders after traumatic brain injury (TBI). Methods: Prospective evaluation with polysomnography (PSG), multiple sleep latency test (MSLT), Epworth Sleepiness Scale (ESS) and neuropsychological testing including Psychomotor Vigilance Test (PVT), Profile of Mood States (POMS), and Functional Outcome of Sleep Questionnaire (FOSQ). Setting: Three academic medical centers with level I trauma centers, accredited sleep disorders centers, and rehabilitative medicine programs. Participants: Eighty-seven (87) adults at least 3 months post TBI. Measurements And Results: Abnormal sleep studies were found in 40 subjects (46%), including 20 (23%) with obstructive sleep apnea (OSA), 10 (11%) with posttraumatic hypersomnia (PTH), 5 (6%) with narcolepsy, and 6 (7%) with periodic limb movements in sleep (PLMS). Among all subjects, 22 (25%) were found to have objective excessive daytime sleepiness with MSLT score <10 minutes. There was no correlation between ESS score and MSLT (r = 0.10). There were no differences in age, race, sex, or education between the sleepy and non-sleepy subjects. injury between sleepy and non-sleepy subjects. Sleepy subjects had a greater body mass index (BMI) than those who were not sleepy (p = 0.01). OSA was more common in obese subjects (BMI = 30, p <0.001). Sleepy subjects demonstrated poorer PVT scores (p <0.05), better self-reported sleep related quality of life (FOSQ scores [p <0.05]), and no differences in POMS. Conclusions: There is a high prevalence of sleep disorders (46%) and of excessive daytime sleepiness (25%) in subjects with TBI. Sleepy subjects may be more impaired than comparable non-sleepy TBI subjects, yet be unaware of problems. Given the high prevalence of OSA (23%), PTH (11%), and narcolepsy (7%) in this population, there is a clinical indication for NPSG and MSLT.	[Castriotta, Richard J.; Wilde, Mark C.; Lai, Jenny M.] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA; [Castriotta, Richard J.; Wilde, Mark C.; Lai, Jenny M.] Mem Hermann Hosp Sleep Disorders Ctr, Houston, TX USA; [Atanasov, Strahil] Univ Texas Med Branch, Galveston, TX 77555 USA; [Masel, Brent E.] Transit Learning Ctr, Galveston, TX USA; [Kuna, Samuel T.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA; [Kuna, Samuel T.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA	Castriotta, RJ (corresponding author), Univ Texas Hlth Sci Ctr Houston, Div Pulm Crit Care & Sleep Med, 6431 Fannin St,MSB 1-274, Houston, TX 77030 USA.	Richard.J.Castriotta@uth.tmc.edu	Lang, Steven/AAE-8102-2021	Lang, Steven/0000-0003-1669-9146; Castriotta, Richard/0000-0003-3502-4558	Moody Foundation; Cephalon, Inc.	This research was supported by the Moody Foundation and Cephalon, Inc. We would like to express our appreciation to Amal Abuelheiga, RPSGT for her assistance with this project.	Aloia MS, 2004, J INT NEUROPSYCH SOC, V10, P772, DOI 10.1017/S1355617704105134; American Academy of Sleep Medicine, 2005, INT CLASSIFICATION S, P185; [Anonymous], 1998, NIH Consens Statement, V16, P1; Bardwell WA, 2001, SLEEP, V24, P905, DOI 10.1093/sleep/24.8.905; CARSKADON MA, 1986, SLEEP, V9, P519, DOI 10.1093/sleep/9.4.519; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; Chesson AL, 1997, SLEEP, V20, P406; Coleman R, 1982, SLEEPING WAKING DISO, P265; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; Dinges DF, 2003, SLEEP MED, V4, P393, DOI 10.1016/S1389-9457(03)00108-4; Dinges DF, 1997, SLEEP, V20, P267; Ellen RLB, 2006, J CLIN SLEEP MED, V2, P193; Flemons WW, 1999, SLEEP, V22, P667, DOI 10.1093/sleep/22.5.667; Fronczek R, 2006, SLEEP, V29, P187; Fulda S, 2001, SLEEP MED REV, V5, P423, DOI 10.1053/smrv.2001.0157; Gooneratne NS, 2003, J AM GERIATR SOC, V51, P642, DOI 10.1034/j.1600-0579.2003.00208.x; GUILLEMINAULT C, 1983, NEUROLOGY, V33, P1584, DOI 10.1212/WNL.33.12.1584; Guilleminault C, 2000, NEUROLOGY, V54, P653, DOI 10.1212/WNL.54.3.653; JOHNS MW, 1993, CHEST, V103, P30, DOI 10.1378/chest.103.1.30; Kotterba S, 2004, CLIN NEUROL NEUROSUR, V106, P275, DOI 10.1016/j.clineuro.2003.12.003; KRIBBS NB, 1993, AM REV RESPIR DIS, V147, P1162, DOI 10.1164/ajrccm/147.5.1162; LANKFORD DA, 1994, SLEEP, V17, pS25, DOI 10.1093/sleep/17.suppl_8.S25; LEGER D, 1994, SLEEP, V17, P84, DOI 10.1093/sleep/17.1.84; Levin H S, 1991, Neurosurg Clin N Am, V2, P457; LEVIN HS, 1993, CURR OPIN NEUROL, V6, P841, DOI 10.1097/00019052-199312000-00003; LEVIN HS, 1992, J NEUROTRAUM, V9, pS359; Mansfield RT, 1997, CRIT CARE CLIN, V13, P611, DOI 10.1016/S0749-0704(05)70331-6; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; McNair D, 1971, MANUAL PROFILE MOOD; Montserrat JM, 2001, AM J RESP CRIT CARE, V164, P608, DOI 10.1164/ajrccm.164.4.2006034; Naumann A, 2003, BEHAV NEUROL, V14, P89, DOI 10.1155/2003/323060; Prigatano GP, 2005, ACT NEUR S, V93, P39; Rechtschaffen A, 1968, MANUAL STANDARDIZED; Rogers N L, 2001, Semin Clin Neuropsychiatry, V6, P295, DOI 10.1053/scnp.2001.27907; Schneider C, 2004, J SLEEP RES, V13, P373, DOI 10.1111/j.1365-2869.2004.00427.x; Sherer M, 2002, CLIN NEUROPSYCHOL, V16, P157, DOI 10.1076/clin.16.2.157.13238; Weaver TE, 2003, SLEEP, V26, P727; Weaver TE, 1997, SLEEP, V20, P835; Webster JB, 2001, ARCH PHYS MED REHAB, V82, P316, DOI 10.1053/apmr.2001.20840; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Yu BH, 1999, J PSYCHIAT RES, V33, P427, DOI 10.1016/S0022-3956(99)00020-5	41	194	198	1	11	AMER ACAD SLEEP MEDICINE	DARIEN	2510 N FRONTAGE RD, DARIEN, IL 60561 USA	1550-9389	1550-9397		J CLIN SLEEP MED	J. Clin. Sleep Med.		2007	3	4					349	356					8	Clinical Neurology	Neurosciences & Neurology	V44VK	WOS:000209776300003	17694722				2021-06-18	
J	Vanderploeg, RD; Curtiss, G; Belanger, HG				Vanderploeg, RD; Curtiss, G; Belanger, HG			Long-term neuropsychological outcomes following mild traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						brain concussion; head injury; minor; neuropsychological outcome; attention; proactive interference	PROACTIVE-INTERFERENCE; GAIT DISTURBANCE; SYMPTOMS	Mild traumatic brain injury (MTBI) is common, yet few studies have examined neuropsychological outcomes more than 1 year postinjury. Studies of nonreferred individuals with MTBI or studies with appropriate control groups are lacking, but necessary to draw conclusions regarding natural recovery from MTBI. We examined the long-term neuropsychological outcomes of a self-reported MTBI an average of 8 years postinjury in a nonreferred community-dwelling sample of male veterans. This was a cross-sectional cohort Study derived from the Vietnam Experience Study. Three groups matched on premorbid cognitive ability were examined, those who (1) had not been injured in a MVA nor had a head injury (Normal Control; n = 3214), (2) had been injured in a motor vehicle accident (MVA) but did not have a head injury (MVA Control; n = 539), and (3) had a head injury with altered consciousness (MTBI; n = 254). A MANOVA found no group differences on a standard neuropsychological test battery of 15 measures. Across 15 measures, the average neuropsychological effect size of MTBI compared with either control group was -.03. Subtle aspects of attention and working memory also were examined by comparing groups on Paced Auditory Serial Addition Test (PASAT) continuation rate and California Verbal Learning Test (CVLT) proactive interference (PI). Compared with normal controls, the MTBI group evidenced attention problems in their lower rate of continuation to completion on the PASAT (odds ratio = 1.32, CI = 1.0-1.73) and in excessive PI (odds ratio = 1.66, CI = 1.11-2.47). Unique to the MTBI group, PASAT continuation problems were associated with left-sided visual imperceptions and excessive PI was associated with impaired tandem gait. These results show that MTBI can have adverse long-term neuropsychological outcomes on subtle aspects of complex attention and working memory.	James A Haley Vet Hosp, Dept Mental Hlth & Behav Sci, Tampa, FL 33612 USA; Def & Vet Brain Injury Ctr, Tampa, FL USA; Univ S Florida, Dept Psychiat & Behav Med, Tampa, FL USA; Univ S Florida, Dept Psychol, Tampa, FL 33620 USA; Henry M Jackson Fdn, Rockville, MD USA	Vanderploeg, RD (corresponding author), James A Haley Vet Hosp, Dept Mental Hlth & Behav Sci, Tampa, FL 33612 USA.	Rodney.Vanderploeg@med.va.gov	Curtiss, Glenn/ABB-5566-2020				Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; [Anonymous], 1988, JAMA, V259, P2701; BELANGER HG, IN PRESS J INT NEURO; Benton A., 1976, MULTILINGUAL APHASIA; Berg EA, 1948, J GEN PSYCHOL, V39, P15, DOI 10.1080/00221309.1948.9918159; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Bowles RP, 2003, PSYCHOL AGING, V18, P608, DOI 10.1037/0882-7974.18.3.608; *CDC, 1989, HLTH STAT VIETN VET, V4; De Rosa E, 2003, NEUROPSYCHOLOGY, V17, P469, DOI 10.1037/0894-4105.17.3.469; Deb S, 1999, BRIT J PSYCHIAT, V174, P360, DOI 10.1192/bjp.174.4.360; DELIS D, 1983, CALIFORNIA VERBAL LE; DESTEFANO F, 1988, JAMA-J AM MED ASSOC, V259, P2708; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Goodglass H., 1983, BOSTON DIAGNOSTIC AP; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Hartlage LC, 2001, ARCH CLIN NEUROPSYCH, V16, P561, DOI 10.1016/S0887-6177(00)00067-6; Heaton R., 1993, WISCONSIN CARD SORTI; Heilman KM, 1994, LOCALIZATION NEUROIM, P495; Henson RNA, 2002, NEUROIMAGE, V17, P543, DOI 10.1006/nimg.2002.1229; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Matthews C, 1964, INSTRUCTION MANUAL A; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; MESULAM MM, 1990, ANN NEUROL, V28, P597, DOI 10.1002/ana.410280502; MONTAGUE E K, 1957, U S Armed Forces Med J, V8, P883; Nakamura T, 1997, ALZ DIS ASSOC DIS, V11, P132, DOI 10.1097/00002093-199709000-00005; Powell TJ, 1996, DISABIL REHABIL, V18, P231, DOI 10.3109/09638289609166306; Rey A., 1993, CLIN NEUROPSYCHOL, V7, P4; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Rossor MN, 1999, J NEUROL NEUROSUR PS, V67, P345, DOI 10.1136/jnnp.67.3.345; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; SMITH ML, 1995, NEUROPSYCHOLOGIA, V33, P275; Sosin DM, 1996, BRAIN INJURY, V10, P47; VANDERLINDEN M, 1993, J CLIN EXP NEUROPSYC, V15, P525, DOI 10.1080/01688639308402576; VANDERPLOEG RD, UNPUB LONG TERM MORB; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Zakzanis K. K., 1999, STUD NEUROPSYCHOL DE	42	194	195	0	20	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAY	2005	11	3					228	236		10.1017/S1355617705050289			9	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	924UL	WOS:000229005900002	15892899				2021-06-18	
J	Borg, J; Holm, L; Cassidy, JD; Peloso, PM; Carroll, LJ; von Holst, H; Ericson, K				Borg, J; Holm, L; Cassidy, JD; Peloso, PM; Carroll, LJ; von Holst, H; Ericson, K			Diagnostic procedures in mild traumatic brain injury: Results of the WHO Collaborating Centre Task Force on Mild Traumatic Brain Injury	JOURNAL OF REHABILITATION MEDICINE			English	Article						mild traumatic brain injury; concussion; diagnosis; computerized tomography scan; skull X-ray; loss of consciousness; post-traumatic amnesia; cognitive function	MINOR HEAD TRAUMA; COMA SCALE SCORE; COMPUTED-TOMOGRAPHY; INTRACRANIAL HEMATOMA; RISK-FACTORS; SKULL FRACTURE; CT-SCANS; MANAGEMENT; CHILDREN; CONCUSSION	We examined diagnostic procedures in mild traumatic brain injury by a systematic literature search. After screening 38,806 abstracts, we critically reviewed 228 diagnostic studies and accepted 73 (32%). The estimated prevalence of intracranial CT scan abnormalities is 5% in patients presenting to hospital with a Glasgow Coma Scale score of 15 and 30% or higher in patients presenting with a score of 13. About 1% of all treated patients with mild traumatic brain injury require neurosurgical intervention. There is strong evidence that clinical factors can predict computerized tomography scan abnormalities and the need for intervention in adults, but no such evidence for mild traumatic brain injury in children. We found evidence that skull fracture is a risk factor for intracranial lesions, but the diagnostic accuracy of radiologically diagnosed skull fracture as an indication of intracranial lesions is poor. There is only a little evidence for the diagnostic validity of cognitive testing and other diagnostic tools for mild traumatic brain injury.	Univ Uppsala Hosp, Dept Neurosci, S-78185 Uppsala, Sweden; Karolinska Inst, Dept Clin Neurosci, Sect Personal Injury Prevent, Stockholm, Sweden; Univ Alberta, Dept Publ Hlth Sci, Alberta Ctr Injury Control & Res, Edmonton, AB, Canada; Univ Alberta, Dept Med, Edmonton, AB, Canada; Univ Iowa, Ctr Hlth, Dept Internal Med, Iowa City, IA USA; Karolinska Inst, Dept Neurosurg, Stockholm, Sweden; Karolinska Inst, Dept Neuroradiol, Stockholm, Sweden	Borg, J (corresponding author), Univ Uppsala Hosp, Dept Neurosci, S-78185 Uppsala, Sweden.	jorgen.borg@rehab.uu.se		Carroll, Linda/0000-0003-0876-2336; Borg, Jorgen/0000-0002-2372-7478			American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; ARTIOLA L, 2002, J NEUROL NEUROSUR PS, V43, P377; ARTIOLAIFORTUNY L, 1980, J NEUROL NEUROSUR PS, V43, P377, DOI 10.1136/jnnp.43.5.377; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Bergman DA, 1999, PEDIATRICS, V104, P1407; BORCZUK P, 1995, ANN EMERG MED, V25, P731, DOI 10.1016/S0196-0644(95)70199-0; BRITTON M, 2000, 153 SBU SWED COUNC T; Brown FD, 2000, J ACCID EMERG MED, V17, P268; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Carroll LJ, 2004, J REHABIL MED, V36, P11, DOI 10.1080/16501960410023660; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; DAVIES RL, 1995, PEDIATRICS, V95, P345; DAVIS RL, 1994, ANN EMERG MED, V24, P640, DOI 10.1016/S0196-0644(94)70273-X; DOCZI T, 1982, NEUROSURGERY, V10, P685, DOI 10.1227/00006123-198206010-00001; Dunham CM, 1996, J TRAUMA, V41, P679, DOI 10.1097/00005373-199610000-00014; DUUS BR, 1994, ANN EMERG MED, V23, P1279, DOI 10.1016/S0196-0644(94)70352-3; Earle OJ, 2001, J EMERG MED, V21, P381, DOI 10.1016/S0736-4679(01)00405-X; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; Graham ID, 1998, ACAD EMERG MED, V5, P134, DOI 10.1111/j.1553-2712.1998.tb02598.x; GUTMAN MB, 1992, J NEUROSURG, V77, P9, DOI 10.3171/jns.1992.77.1.0009; HAHN YS, 1993, PEDIATR NEUROSURG, V19, P135, DOI 10.1159/000120718; HANNAY HJ, 1989, J CLIN EXP NEUROPSYC, V11, P444, DOI 10.1080/01688638908400905; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Hemphill RR, 1999, ACAD EMERG MED, V6, P957, DOI 10.1111/j.1553-2712.1999.tb01248.x; Hofman PAM, 2000, J NEUROL NEUROSUR PS, V68, P416, DOI 10.1136/jnnp.68.4.416; Holmes JF, 1997, ACAD EMERG MED, V4, P788, DOI 10.1111/j.1553-2712.1997.tb03786.x; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; Hung CC, 1996, J FORMOS MED ASSOC, V95, P294; Iverson GL, 2000, BRAIN INJURY, V14, P1057; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI 10.1016/j.jen.2008.12.010; Jan MMS, 1997, J PEDIATR-US, V130, P134, DOI 10.1016/S0022-3476(97)70322-6; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; Klassen TP, 2000, ACAD EMERG MED, V7, P739, DOI 10.1111/j.1553-2712.2000.tb02260.x; KNUCKEY NW, 1989, J NEUROSURG, V70, P392, DOI 10.3171/jns.1989.70.3.0392; KOONSMAN M, 1992, AM J SURG, V164, P487, DOI 10.1016/S0002-9610(05)81186-9; Lazar L, 1997, J PEDIATR SURG, V32, P88, DOI 10.1016/S0022-3468(97)90102-0; Lee JS, 2003, ACAD EMERG MED, V10, P1128, DOI 10.1197/S1069-6563(03)00372-5; LEE ST, 1995, ACTA NEUROCHIR, V135, P136, DOI 10.1007/BF02187757; Li J, 2001, LANCET, V357, P771, DOI 10.1016/S0140-6736(00)04163-5; Livingston DH, 2000, ANN SURG, V232, P126, DOI 10.1097/00000658-200007000-00018; LUSTIG A, 2002, J MED SPEECH-LANG PA, V6, P13; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; MADDOCKS DL, 1995, AUST PSYCHOL, V30, P125, DOI 10.1080/00050069508258916; MASTERS SJ, 1987, NEW ENGL J MED, V316, P84, DOI 10.1056/NEJM198701083160205; McCrory PR, 2000, NEUROLOGY, V54, P1488, DOI 10.1212/WNL.54.7.1488; MENDELOW AD, 1983, BRIT MED J, V287, P1173, DOI 10.1136/bmj.287.6400.1173; MENDELOW AD, 1982, BRIT MED J, V285, P1530, DOI 10.1136/bmj.285.6354.1530; Miller EC, 1996, ANN EMERG MED, V27, P290, DOI 10.1016/S0196-0644(96)70261-5; Miller Erik C., 1997, Journal of Emergency Medicine, V15, P453, DOI 10.1016/S0736-4679(97)00071-1; MILLER JD, 1985, LANCET, V1, P1141; MILLER JD, 1990, NEUROSURGERY, V27, P669, DOI 10.1227/00006123-199011000-00001; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Moss NEG, 1996, INJURY, V27, P159, DOI 10.1016/0020-1383(95)00217-0; Nagy KK, 1999, J TRAUMA, V46, P268, DOI 10.1097/00005373-199902000-00012; NEE PA, 1993, INJURY, V24, P471, DOI 10.1016/0020-1383(93)90153-W; Nee PA, 1999, J NEUROL NEUROSUR PS, V66, P470, DOI 10.1136/jnnp.66.4.470; Paniak C, 1998, J CLIN EXP NEUROPSYC, V20, P852, DOI 10.1076/jcen.20.6.852.1108; Peloso PM, 2004, J REHABIL MED, V36, P106, DOI 10.1080/16501960410023868; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; *ROYAL COLL RAD, LANCET, V2, P791; RUJIS MB, 1992, DEV MED CHILD NEUROL, V34, P885; Sackett DL, 2002, BRIT MED J, V324, P539, DOI 10.1136/bmj.324.7336.539; Schutzman SA, 2001, PEDIATRICS, V107, P983, DOI 10.1542/peds.107.5.983; SERVADEI F, 1988, SURG NEUROL, V30, P364, DOI 10.1016/0090-3019(88)90199-1; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Simon B, 2001, J TRAUMA, V51, P231, DOI 10.1097/00005373-200108000-00004; SNOEK JW, 1984, BRAIN, V107, P15, DOI 10.1093/brain/107.1.15; *STATSDIRECT LTD, 2002, STATSDIRECT COMP PRO; STEIN SC, 1992, J NEUROSURG, V77, P562, DOI 10.3171/jns.1992.77.4.0562; STEIN SC, 1990, NEUROSURGERY, V26, P638, DOI 10.1227/00006123-199004000-00012; Stiell IG, 1997, ANN EMERG MED, V30, P14, DOI 10.1016/S0196-0644(97)70104-5; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; TEASDALE GM, 1990, BRIT MED J, V300, P363, DOI 10.1136/bmj.300.6721.363; Viola L, 2000, ACTA NEUROCHIR, V142, P1281, DOI 10.1007/s007010070026; von Holst H, 2004, J REHABIL MED, V36, P8, DOI 10.1080/16501960410023633; VOSS M, 1995, BRIT MED J, V311, P1395, DOI 10.1136/bmj.311.7017.1395; Wang MY, 2000, NEUROSURGERY, V46, P1093, DOI 10.1097/00006123-200005000-00014; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	82	194	198	0	10	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	FEB	2004	36			43			61	75		10.1080/16501960410023822			15	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	800QR	WOS:000220043300008	15083871	DOAJ Gold			2021-06-18	
J	Lundborg, G				Lundborg, G			Nerve injury and repair - a challenge to the plastic brain	JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM			English	Article; Proceedings Paper	Meeting of the Peripheral-Nerve-Society	JUL, 2003	BANFF, CANADA	Peripheral Nerve Soc		cortical plasticity; nerve regeneration; nerve repair; receptive fields; sensory re-education	PRIMARY SOMATOSENSORY CORTEX; PRIMARY MOTOR CORTEX; FOCAL HAND DYSTONIA; TRANSCRANIAL MAGNETIC STIMULATION; MASSIVE CORTICAL REORGANIZATION; HYPERBARIC-OXYGEN TREATMENT; REPETITIVE STRAIN INJURY; LONG-TERM POTENTIATION; DORSAL-ROOT GANGLIA; ADULT OWL MONKEYS	Repair and reconstruction of major nerve trunks in the upper extremity is a very challenging surgical problem. Today, there is no surgical repair technique that can assure recovery of tactile discrimination in the hand of an adult patient following nerve repair, In contrast, young individuals usually attain a complete recovery of functional sensibility. The outcome from nerve repair depends mainly on central nervous system factors including functional cortical reorganizational processes caused by misdirection in axonal outgrowth. Deafferentation due to local anesthetic block, amputation or nerve transection in the upper extremity leads to very rapid cortical synaptic remodeling, resulting in a distorted cortical hand representation as well as in enlarged and overlapping cortical receptive fields. Sensory relearning programs are aimed at refinement of these receptive fields to normalize the distorted hand map and improve processing at a high-order cortical level in the context of the 'new language spoken by the hand'. As peripheral nerve repair techniques cannot be further refined, there is a need for new and improved strategies for sensory relearning following nerve repair. We propose the utilization of multimodal capacity of the brain, using another sense (hearing) to substitute for lost hand sensation and to provide an alternate sensory input from the hand early after transection. The purpose was to modulate cortical reorganizations due to deafferentation to preserve cortical hand representation. Preliminary results from a prospective clinical randomized study indicate that the use of a Sensor Glove System, which stereophonically transposes the friction sound elicited by active touch, results in improved recovery of tactile discrimination in the nerve-injured hand. Future strategies for treatment of nerve injuries should promote cellular methods to minimize post-traumatic nerve cell death and to improve axonal outgrowth rate and orientation, but high on the agenda are new strategies for refined sensory relearning following nerve repair.	Malmo Univ Hosp, Dept Hand Surg, SE-20502 Malmo 02, Sweden	Lundborg, G (corresponding author), Malmo Univ Hosp, Dept Hand Surg, SE-20502 Malmo 02, Sweden.	goran.lundborg@hand.mas.lu.se					Al-Majed AA, 2000, EUR J NEUROSCI, V12, P4381, DOI 10.1046/j.1460-9568.2000.01341.x; Al-Majed AA, 2000, J NEUROSCI, V20, P2602; ALDSKOGIUS H, 1992, SENSORY NEURONS DIVE, P363; ALLARD T, 1991, J NEUROPHYSIOL, V66, P1048; ALMQUIST EE, 1983, J HAND SURG-AM, V8, P406, DOI 10.1016/S0363-5023(83)80199-3; Bajrovic FF, 2002, J PERIPHER NERV SYST, V7, P141, DOI 10.1046/j.1529-8027.2002.02020.x; Bara-Jimenez W, 1998, ANN NEUROL, V44, P828, DOI 10.1002/ana.410440520; Bavelier D, 2002, NAT REV NEUROSCI, V3, P443, DOI 10.1038/nrn848; Birbaumer N, 1997, J NEUROSCI, V17, P5503; BIRCH R, 1991, J BONE JOINT SURG BR, V73, P154; Bodegard A, 2000, NEUROREPORT, V11, P187, DOI 10.1097/00001756-200001170-00037; Bodegard A, 2001, NEURON, V31, P317, DOI 10.1016/S0896-6273(01)00362-2; Bontioti EN, 2003, J PERIPHER NERV SYST, V8, P159, DOI 10.1046/j.1529-8027.2003.03023.x; Borsook D, 1998, NEUROREPORT, V9, P1013, DOI 10.1097/00001756-199804200-00011; Boyd JG, 2002, EUR J NEUROSCI, V15, P613, DOI 10.1046/j.1460-9568.2002.01891.x; Brand P., 1993, PAIN GIFT NOBODY WAN; BRASILNETO JP, 1993, BRAIN, V116, P511, DOI 10.1093/brain/116.3.511; BRASILNETO JP, 1992, NEUROLOGY, V42, P1302, DOI 10.1212/WNL.42.7.1302; Brown CE, 2002, J NEUROSCI, V22, P2617, DOI 10.1523/JNEUROSCI.22-07-02617.2002; Brushart TM, 2002, J NEUROSCI, V22, P6631; Buonomano DV, 1998, ANNU REV NEUROSCI, V21, P149, DOI 10.1146/annurev.neuro.21.1.149; Byl NN, 1997, PHYS THER, V77, P269, DOI 10.1093/ptj/77.3.269; Byl NN, 1996, NEUROLOGY, V47, P508, DOI 10.1212/WNL.47.2.508; CALFORD MB, 1991, SOMATOSENS MOT RES, V8, P249, DOI 10.3109/08990229109144748; CALLAHAN AD, 1990, REHABILITATION HAND, P611; CALLAHAN AD, 1995, REHABILITATION HAND, P701; Candia V, 1999, LANCET, V353, P42, DOI 10.1016/S0140-6736(05)74865-0; Candia V, 2002, ARCH PHYS MED REHAB, V83, P1342, DOI 10.1053/apmr.2002.35094; Chen R, 2002, NEUROSCIENCE, V111, P761, DOI 10.1016/S0306-4522(02)00025-8; CODE RA, 1992, EXP BRAIN RES, V88, P341, DOI 10.1007/BF02259109; CRISOSTOMO EA, 1988, ANN NEUROL, V23, P94, DOI 10.1002/ana.410230117; Dahlin LB, 1998, J HAND SURG-BRIT EUR, V23B, P334, DOI 10.1016/S0266-7681(98)80053-3; Dahlin LB, 1998, LANCET, V352, P328, DOI 10.1016/S0140-6736(05)60311-X; DELLON AL, 1997, SOMATOSENSORY TESTIN; Dellon AL, 1981, EVALUATION SENSIBILI; DONOGHUE JP, 1988, J NEUROSCI, V8, P3221; DONOGHUE JP, 1990, EXP BRAIN RES, V79, P492; Donoghue JP, 1996, ACQUISITION OF MOTOR BEHAVIOR IN VERTEBRATES, P363; EDIN BB, 1995, J PHYSIOL-LONDON, V487, P243, DOI 10.1113/jphysiol.1995.sp020875; Ehrsson HH, 2000, J NEUROPHYSIOL, V83, P528; Ehrsson HH, 2001, J NEUROPHYSIOL, V85, P2613; ELBERT T, 1994, NEUROREPORT, V5, P2593, DOI 10.1097/00001756-199412000-00047; Elbert T, 1998, NEUROREPORT, V9, P3571, DOI 10.1097/00001756-199811160-00006; ELBERT T, 1995, SCIENCE, V270, P305, DOI 10.1126/science.270.5234.305; EYRES AJ, 1972, SENSORY INTEGRATION; Flor H, 1998, EXP BRAIN RES, V119, P205, DOI 10.1007/s002210050334; FLOR H, 1995, NATURE, V375, P482, DOI 10.1038/375482a0; Florence SL, 1996, NATURE, V381, P69, DOI 10.1038/381069a0; Florence SL, 2001, EUR J NEUROSCI, V13, P1755, DOI 10.1046/j.0953-816x.2001.01555.x; FLORENCE SL, 1994, CEREB CORTEX, V4, P391, DOI 10.1093/cercor/4.4.391; Frostick SP, 1998, MICROSURG, V18, P397, DOI 10.1002/(SICI)1098-2752(1998)18:7<397::AID-MICR2>3.0.CO;2-F; Fu SY, 1997, MOL NEUROBIOL, V14, P67, DOI 10.1007/BF02740621; GARRAGHTY PE, 1994, SOMATOSENS MOT RES, V11, P109, DOI 10.3109/08990229409028864; Garraghty PE, 1996, J COMP NEUROL, V367, P319, DOI 10.1002/(SICI)1096-9861(19960401)367:2<319::AID-CNE12>3.0.CO;2-L; GARRAGHTY PE, 1991, P NATL ACAD SCI USA, V88, P6976, DOI 10.1073/pnas.88.16.6976; GELDER B, 2000, SCIENCE, V289, P1148; GIBSON JJ, 1962, PSYCHOL REV, V69, P477, DOI 10.1037/h0046962; Giraux P, 2001, NAT NEUROSCI, V4, P691, DOI 10.1038/89472; Godde B, 2003, NEUROREPORT, V14, P543, DOI 10.1097/00001756-200303240-00002; Goldstein L B, 1990, Restor Neurol Neurosci, V1, P311, DOI 10.3233/RNN-1990-1501; Graziano MSA, 2002, NEURON, V34, P841, DOI 10.1016/S0896-6273(02)00698-0; Greenebaum B, 1996, BIOELECTROMAGNETICS, V17, P293, DOI 10.1002/(SICI)1521-186X(1996)17:4<293::AID-BEM5>3.0.CO;2-Z; GREENOUGH WT, 1985, BEHAV NEURAL BIOL, V44, P301, DOI 10.1016/S0163-1047(85)90310-3; Grutzendler J, 2002, NATURE, V420, P812, DOI 10.1038/nature01276; Haapaniemi T, 2002, J PERIPHER NERV SYST, V7, P149, DOI 10.1046/j.1529-8027.2002.02021.x; Hand PJ, 1982, CHANGING CONCEPTS NE, P49; Hansson T, 1999, NEUROSCI LETT, V271, P29, DOI 10.1016/S0304-3940(99)00508-X; Harris JA, 2000, NEUROREPORT, V11, P263, DOI 10.1097/00001756-200002070-00008; Harris JA, 1999, P NATL ACAD SCI USA, V96, P7587, DOI 10.1073/pnas.96.13.7587; Hebb D.O., 1949, ORG BEHAV NEUROPSYCH; HEBB DO, 1947, AM PSYCHOL, V2, P737; HESS G, 1994, J NEUROPHYSIOL, V71, P2543; HIMES BT, 1989, J COMP NEUROL, V284, P215, DOI 10.1002/cne.902840206; HOVDA DA, 1984, BRAIN RES, V298, P358, DOI 10.1016/0006-8993(84)91437-9; IMAI H, 1991, J HAND SURG-AM, V16A, P60, DOI 10.1016/S0363-5023(10)80014-0; JACOBS KM, 1991, SCIENCE, V251, P944, DOI 10.1126/science.2000496; Jain N, 1998, NEWS PHYSIOL SCI, V13, P143; JENKINS WM, 1990, J NEUROPHYSIOL, V63, P82; JOHANSSON BB, 1994, BRAIN PATHOL, V4, P85; Johansson BB, 2000, STROKE, V31, P223, DOI 10.1161/01.STR.31.1.223; JOHANSSON RS, 1984, EXP BRAIN RES, V56, P550; JOHANSSON RS, 1983, TRENDS NEUROSCI, V6, P27, DOI 10.1016/0166-2236(83)90011-5; JOHNSON JS, 1991, COGNITION, V39, P215, DOI 10.1016/0010-0277(91)90054-8; JONES EG, 1993, CEREB CORTEX, V3, P361, DOI 10.1093/cercor/3.5.361-a; Kaas JH, 1997, BRAIN RES BULL, V44, P107, DOI 10.1016/S0361-9230(97)00094-4; Kaas JH, 1999, NEURON, V22, P657, DOI 10.1016/S0896-6273(00)80725-4; Kaas JH, 1997, ADV NEUROL, V73, P147; KAAS JH, 1983, PHYSIOL REV, V63, P206; KAAS JH, 1991, ANNU REV NEUROSCI, V14, P137, DOI 10.1146/annurev.ne.14.030191.001033; Katz D., 1989, WORLD TOUCH; KELAHAN AM, 1981, BRAIN RES, V223, P151, DOI 10.1016/0006-8993(81)90815-5; Kilgard MP, 1998, SCIENCE, V279, P1714, DOI 10.1126/science.279.5357.1714; KLATZKY RL, 1987, J EXP PSYCHOL GEN, V116, P356; Knecht S, 1995, NEUROSCI LETT, V201, P262, DOI 10.1016/0304-3940(95)12186-2; Knecht S, 1996, BRAIN, V119, P1213, DOI 10.1093/brain/119.4.1213; Knecht S, 1998, BRAIN, V121, P717, DOI 10.1093/brain/121.4.717; Knecht S, 1998, PAIN, V77, P209, DOI 10.1016/S0304-3959(98)00102-X; Kossut M, 1998, NEUROREPORT, V9, P4025, DOI 10.1097/00001756-199812210-00007; Krings T, 2000, NEUROSCI LETT, V278, P189, DOI 10.1016/S0304-3940(99)00930-1; LANZETTA M, 2003, IN PRESS SCAND J PLA; Lekan HA, 1997, NEUROSCIENCE, V81, P527, DOI 10.1016/S0306-4522(97)00173-5; Levy LM, 2002, ANN NEUROL, V52, P755, DOI 10.1002/ana.10372; LISS AG, 1994, SCAND J PLAST RECONS, V28, P177, DOI 10.3109/02844319409015978; Liss AG, 1996, SCAND J PLAST RECONS, V30, P1; Ljungberg C, 1999, NEUROSCI LETT, V262, P29, DOI 10.1016/S0304-3940(99)00040-3; Longo FM, 1999, J NEUROSCI RES, V55, P230, DOI 10.1002/(SICI)1097-4547(19990115)55:2<230::AID-JNR10>3.0.CO;2-3; Lundborg G, 2002, J PERIPHER NERV SYST, V7, P139, DOI 10.1046/j.1529-8027.2002.02019.x; Lundborg G, 2001, LANCET, V358, P809, DOI 10.1016/S0140-6736(01)06001-9; Lundborg G, 2000, J HAND SURG-AM, V25A, P391, DOI 10.1053/jhsu.2000.4165; Lundborg G, 2000, J HAND SURG-BRIT EUR, V25B, P242, DOI 10.1054/jhsb.1999.0339; LUNDBORG G, 2003, J HAND SURG AM S1, V28, P38; Lundborg G, 1988, NERVE INJURY REPAIR; LUNDBORG G, 2003, SEVERE TRAUMATIC DEF; LUNDBORG G, 2003, IN PRESS J HAND SURG; LUNDBORG G, 1999, HANDKIRURGI SKADOR S; LUNDBORG G, 1997, TENDON NERVE SURG HA; Ma JJ, 2003, SCAND J PLAST RECONS, V37, P1; Macaluso E, 2000, SCIENCE, V289, P1206, DOI 10.1126/science.289.5482.1206; Manger PR, 1996, P ROY SOC B-BIOL SCI, V263, P933, DOI 10.1098/rspb.1996.0138; MANO Y, 1995, ANN NEUROL, V38, P15, DOI 10.1002/ana.410380106; MARKS LE, 1983, INT J NEUROSCI, V19, P1, DOI 10.3109/00207458309148640; McKay Hart A., 2002, EXP BRAIN RES, V142, P308; MCKENNA TM, 1989, SYNAPSE, V4, P30, DOI 10.1002/syn.890040105; Merzenich M M, 1993, J Hand Ther, V6, P89; MERZENICH MM, 1978, J COMP NEUROL, V181, P41, DOI 10.1002/cne.901810104; MERZENICH MM, 1983, NEUROSCIENCE, V10, P639, DOI 10.1016/0306-4522(83)90208-7; MERZENICH MM, 1984, J COMP NEUROL, V224, P591, DOI 10.1002/cne.902240408; MERZENICH MM, 1983, NEUROSCIENCE, V8, P33, DOI 10.1016/0306-4522(83)90024-6; METZLER J, 1979, BRAIN RES, V177, P379, DOI 10.1016/0006-8993(79)90790-X; MOHAMMED AH, 1993, ACTA NEUROL SCAND, V88, P13; Myers WA, 2000, J COMP NEUROL, V418, P373; Nakai Y, 2002, J CELL BIOL, V159, P1097, DOI 10.1083/jcb.200209077; Nguyen QT, 2002, NAT NEUROSCI, V5, P861, DOI 10.1038/nn905; NICOLELIS MAL, 1993, NATURE, V361, P533, DOI 10.1038/361533a0; Nudo RJ, 1996, J NEUROSCI, V16, P785; Olausson H, 2002, NAT NEUROSCI, V5, P900, DOI 10.1038/nn896; Oliveri M, 1999, BRAIN, V122, P1721, DOI 10.1093/brain/122.9.1721; Olson L, 1997, NAT MED, V3, P1329, DOI 10.1038/nm1297-1329; ONNE L, 1962, Acta Chir Scand Suppl, VSuppl 300, P1; Ottersen OP, 2002, NATURE, V420, P751, DOI 10.1038/420751a; Pantev C, 2001, ANN NY ACAD SCI, V930, P300, DOI 10.1111/j.1749-6632.2001.tb05740.x; Pantev C, 2001, NEUROREPORT, V12, P169, DOI 10.1097/00001756-200101220-00041; Parry C B, 1976, Hand, V8, P250; Pascual-Leone A, 2001, PROG BRAIN RES, V134, P427; Pascual-Leone A, 2001, ANN NY ACAD SCI, V930, P315, DOI 10.1111/j.1749-6632.2001.tb05741.x; PascualLeone A, 1995, ANN NEUROL, V38, P910, DOI 10.1002/ana.410380611; PASCUALLEONE A, 1993, BRAIN, V116, P39, DOI 10.1093/brain/116.1.39; Patil MM, 1998, J NEUROPHYSIOL, V80, P2467; Penfield W, 1937, BRAIN, V60, P389, DOI 10.1093/brain/60.4.389; PONS TP, 1991, SCIENCE, V252, P1857, DOI 10.1126/science.1843843; Qi HX, 2000, J NEUROPHYSIOL, V84, P2133; RAMACHANDRAN VS, 1992, NEUROREPORT, V3, P583, DOI 10.1097/00001756-199207000-00009; Ramon YCajalS, 1928, DEGENERATION REGENER; Rasmussen, 1950, CEREBRAL CORTEX MAN; Rauschecker JP, 2001, ANN NY ACAD SCI, V930, P330, DOI 10.1111/j.1749-6632.2001.tb05742.x; Rose'n B., 2003, BR J HAND THER, V8, P48; Rosen B, 2003, SCAND J PLAST RECONS, V37, P54; ROSEN B, 1994, J HAND SURG-BRIT EUR, V19B, P452, DOI 10.1016/0266-7681(94)90209-7; ROSEN B, 2000, SENSATIONAL HAND CLI; ROSSINI PM, 1994, BRAIN RES, V642, P169, DOI 10.1016/0006-8993(94)90919-9; Sadato N, 1996, NATURE, V380, P526, DOI 10.1038/380526a0; SADATO N, 1995, ANN NEUROL, V37, P74, DOI 10.1002/ana.410370114; SANES JN, 1990, EXP BRAIN RES, V79, P479; Selma P, 1998, MICROSURG, V18, P192; Shuler MG, 2001, J NEUROSCI, V21, P5251, DOI 10.1523/JNEUROSCI.21-14-05251.2001; Silva AC, 1996, J COMP NEUROL, V366, P700, DOI 10.1002/(SICI)1096-9861(19960318)366:4<700::AID-CNE9>3.0.CO;2-8; SISKEN BF, 1989, BRAIN RES, V485, P309, DOI 10.1016/0006-8993(89)90575-1; STODDART DM, 1990, SCENTED APE; SUTTON RL, 1992, RESTOR NEUROL NEUROS, V4, P1, DOI 10.3233/RNN-1992-4101; Taub E, 2002, NAT REV NEUROSCI, V3, P228, DOI 10.1038/nrn754; Terenghi G, 1999, J ANAT, V194, P1, DOI 10.1046/j.1469-7580.1999.19410001.x; Terzis S, 1998, MUSCLE NERVE, V21, P1543, DOI 10.1002/(SICI)1097-4598(199811)21:11<1543::AID-MUS28>3.0.CO;2-#; Trachtenberg JT, 2002, NATURE, V420, P788, DOI 10.1038/nature01273; VALLBO AB, 1984, HUM NEUROBIOL, V3, P3; VANREEMPTS J, 1992, BEHAV BRAIN RES, V51, P179, DOI 10.1016/S0166-4328(05)80211-6; Vestergaard S, 1997, J COMP NEUROL, V388, P307; WALL JT, 1983, SCIENCE, V221, P771, DOI 10.1126/science.6879175; WALL JT, 1986, J NEUROSCI, V6, P218; Wall JT, 2002, BRAIN RES REV, V39, P181, DOI 10.1016/S0165-0173(02)00192-3; WANG XQ, 1995, NATURE, V378, P71, DOI 10.1038/378071a0; Weiss T, 2000, EXP BRAIN RES, V134, P199, DOI 10.1007/s002210000456; Werhahn KJ, 2002, NAT NEUROSCI, V5, P936, DOI 10.1038/nn917; WYNNPARRY CB, 1981, REHABILITATION HAND; Xerri C, 1996, J PHYSIOLOGY-PARIS, V90, P277, DOI 10.1016/S0928-4257(97)81438-6; Yin Q, 1998, J HAND SURG-BRIT EUR, V23B, P433, DOI 10.1016/S0266-7681(98)80117-4	185	194	202	0	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1085-9489	1529-8027		J PERIPHER NERV SYST	J. Peripher. Nerv. Syst.	DEC	2003	8	4					209	226		10.1111/j.1085-9489.2003.03027.x			18	Clinical Neurology; Neurosciences	Neurosciences & Neurology	755UF	WOS:000187429300004	14641646				2021-06-18	
J	Sterr, A; Elbert, T; Berthold, I; Kolbel, S; Rockstroh, B; Taub, E				Sterr, A; Elbert, T; Berthold, I; Kolbel, S; Rockstroh, B; Taub, E			Longer versus shorter daily constraint-induced movement therapy of chronic hemiparesis: An exploratory study	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						arm; motor activity; physical therapy; rehabilitation; stroke	CHRONIC STROKE PATIENTS; PHYSICAL REHABILITATION; FORCED USE; PHYSIOTHERAPY; RECOVERY	Objective: To evaluate and compare the effects of 3-hour versus 6-hour daily training sessions in constraint-induced movement therapy (CIMT). Design: Intervention study, 2-group randomized trial; baseline, pretreatment, and posttreatment measures; 1-month follow-up (weekly measures). Setting: University department of psychology in Germany. Participants: A convenience sample of 15 adults with chronic hemiparesis (13 stroke, 2 traumatic brain injury). Intervention: CIMT (14 consecutive days; constraint of unaffected hand for a target of 90% of waking hours) with either 6 hours (6h/d group, n=7) or 3 hours (3h/d group, n=8) of shaping training with the affected hand per day. Main Outcome Measures: The Motor Activity Log and Wolf Motor Function Test. Results: Significant improvements in motor function in the laboratory and increased use of the affected hand in the real-world environment were found in both groups. The beneficial effects were significantly greater in the 6h/d group than in the 3h/d group. Conclusion: The 3-hour CIMT training schedule significantly improved motor function in chronic hemiparesis, but it was less effective than the 6-hour training schedule.	Univ Liverpool, Dept Psychol, Liverpool L69 7ZA, Merseyside, England; Vet Adm Med Ctr, Birmingham, AL USA; Univ Alabama, Dept Psychol, Birmingham, AL 35294 USA; Hegau Jugendwerk, Gailingen, Germany; Univ Konstanz, Dept Psychol, D-7750 Constance, Germany	Sterr, A (corresponding author), Univ Liverpool, Dept Psychol, Eleanor Rathbone Bldg,Bedford St S, Liverpool L69 7ZA, Merseyside, England.	asterr@liverpool.ac.uk	Elbert, Thomas/C-8556-2009	Elbert, Thomas/0000-0003-1332-4939			BUTEFISCH C, 1995, J NEUROL SCI, V130, P59, DOI 10.1016/0022-510X(95)00003-K; Duncan P W, 1997, Top Stroke Rehabil, V3, P1, DOI 10.1080/10749357.1997.11754126; ERNST E, 1990, STROKE, V21, P1081, DOI 10.1161/01.STR.21.7.1081; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; HESSE S, 1995, STROKE, V26, P976, DOI 10.1161/01.STR.26.6.976; Huber W., 1983, AACHENER APHASIE TES; KRIZ G, 1995, ARCH PHYS MED REHAB, V76, P653, DOI 10.1016/S0003-9993(95)80635-0; Kunkel A, 1999, ARCH PHYS MED REHAB, V80, P624, DOI 10.1016/S0003-9993(99)90163-6; Mauritz KH, 1997, ADV NEUROL, V73, P395; Miltner WHR, 1999, STROKE, V30, P586, DOI 10.1161/01.STR.30.3.586; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; OTTENBACHER KJ, 1993, ARCH NEUROL-CHICAGO, V50, P37, DOI 10.1001/archneur.1993.00540010033014; PETER C, 1997, NEUROL REHABIL, V3, P137; Taub E, 1998, REHABIL PSYCHOL, V43, P152, DOI 10.1037/0090-5550.43.2.152; Taub E, 2002, NAT REV NEUROSCI, V3, P228, DOI 10.1038/nrn754; Taub E, 1996, COMP NEUR R, V9, P133; TAUB E, 1993, ARCH PHYS MED REHAB, V74, P347; Taub E, 1999, J REHABIL RES DEV, V36, P237; Taub E, 1980, BEHAV PSYCHOL REHABI, P371; van der Lee JH, 1999, STROKE, V30, P2369, DOI 10.1161/01.STR.30.11.2369; WILL BE, 1977, J COMP PHYSIOL PSYCH, V91, P33, DOI 10.1037/h0077306; WOLF SL, 1989, EXP NEUROL, V104, P125, DOI 10.1016/S0014-4886(89)80005-6	22	194	204	2	19	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	2002	83	10					1374	1377		10.1053/apmr.2002.35108			4	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	600NT	WOS:000178397800008	12370871	Green Published			2021-06-18	
J	Daniel, JM; Dohanich, GP				Daniel, JM; Dohanich, GP			Acetylcholine mediates the estrogen-induced increase in NMDA receptor binding in CA1 of the hippocampus and the associated improvement in working memory	JOURNAL OF NEUROSCIENCE			English	Article						estrogen; acetylcholine; hippocampus; learning; memory; NMDA receptors; M2 muscarinic receptors	DENDRITIC SPINE DENSITY; TRAUMATIC BRAIN INJURY; RADIAL-ARM MAZE; BASAL FOREBRAIN; FEMALE RATS; ESTRADIOL INCREASES; WATER MAZE; CHOLINE-ACETYLTRANSFERASE; COGNITIVE PERFORMANCE; ENHANCES ACQUISITION	Elevated levels of circulating estrogen in female rats result in increased spine and synapse density and parallel increases in NMDA receptor binding in area CA1 of the hippocampus. Estrogen also influences cholinergic neurochemistry in the basal forebrain and hippocampus. The objectives of the present study were to determine the role of acetylcholine in the estrogen-induced increase in NMDA receptor binding in CA1 of the hippocampus and to investigate the relationship between increased NMDA receptor binding in CA1 and performance on a task of working memory. In the current experiments, elevating endogenous levels of acetylcholine in ovariectomized rats by 3 d of continuous administration of physostigmine, an acetylcholinesterase inhibitor, increased NMDA receptor binding in CA1 as measured by quantitative autoradiography. This increase was comparable with the increase in NMDA receptor binding induced by injections of estradiol benzoate 72 and 48 hr before death. Additionally, the administration of 5,11-dihydro-8-chloro-11-[[4-[3-[(2,2-dimethyl-1-oxopentyl)ethylamino] propyl]-1-piperidinyl] acetyl] 6H-pyrido[2,3-b][1,4] benzodiazepin-6-one (BIBN 99), an M2 receptor antagonist, blocked the ability of both estrogen and physostigmine to increase NMDA receptor binding. The regimen of estradiol replacement that was demonstrated to increase NMDA receptor binding in CA1 of ovariectomized rats also improved arm-choice accuracy in a working memory task in an eight-arm radial maze. The estrogen-induced improvement in working memory performance was blocked by BIBN 99, which also blocked the increase in NMDA receptor binding. These results indicate that acetylcholine acts at M2 muscarinic receptors to mediate the estrogen-induced increase in NMDA receptor binding in CA1 of the hippocampus as well as the associated improvement in working memory.	Tulane Univ, Dept Psychol, New Orleans, LA 70118 USA	Daniel, JM (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol & Expt Therapeut, 1901 Perdido St, New Orleans, LA 70112 USA.			Daniel, Jill/0000-0002-0383-2414			Alreja M, 2000, J NEUROSCI, V20, P8103; Berry B, 1997, BEHAV NEUROSCI, V111, P267, DOI 10.1037/0735-7044.111.2.267; Bimonte HA, 1999, PSYCHONEUROENDOCRINO, V24, P161, DOI 10.1016/S0306-4530(98)00068-7; Chesler EJ, 2000, HORM BEHAV, V38, P234, DOI 10.1006/hbeh.2000.1626; Cyr M, 2000, J NEUROENDOCRINOL, V12, P445; Daniel JM, 1999, PHYSIOL BEHAV, V66, P11, DOI 10.1016/S0031-9384(98)00272-8; Daniel JM, 1997, HORM BEHAV, V32, P217, DOI 10.1006/hbeh.1997.1433; DOODS H, 1993, EUR J PHARMACOL, V242, P23, DOI 10.1016/0014-2999(93)90005-3; Fader AJ, 1999, PHARMACOL BIOCHEM BE, V62, P711, DOI 10.1016/S0091-3057(98)00219-6; Fader AJ, 1998, NEUROBIOL LEARN MEM, V69, P225, DOI 10.1006/nlme.1998.3820; Freund TF, 1997, CAN J PHYSIOL PHARM, V75, P479, DOI 10.1139/cjpp-75-5-479; FREUND TF, 1988, NATURE, V336, P170, DOI 10.1038/336170a0; GALEA LAM, 1995, HORM BEHAV, V29, P106, DOI 10.1006/hbeh.1995.1008; Gibbs RB, 2000, NEUROBIOL AGING, V21, P107, DOI 10.1016/S0197-4580(00)00103-2; Gibbs RB, 1997, BRAIN RES, V749, P143, DOI 10.1016/S0006-8993(96)01375-3; Gibbs RB, 1999, HORM BEHAV, V36, P222, DOI 10.1006/hbeh.1999.1541; GIBBS RB, 1992, EXP NEUROL, V116, P23, DOI 10.1016/0014-4886(92)90173-N; GIBBS RB, 1994, EXP NEUROL, V129, P70, DOI 10.1006/exnr.1994.1148; GOULD E, 1990, J NEUROSCI, V10, P1286; Hajos N, 1998, NEUROSCIENCE, V82, P355; Leranth C, 2000, NEUROSCIENCE, V101, P349, DOI 10.1016/S0306-4522(00)00369-9; LEVEY AI, 1995, J COMP NEUROL, V351, P339, DOI 10.1002/cne.903510303; LUINE VN, 1985, EXP NEUROL, V89, P484, DOI 10.1016/0014-4886(85)90108-6; Luine VN, 1998, HORM BEHAV, V34, P149, DOI 10.1006/hbeh.1998.1473; LYETH BG, 1992, BRAIN RES, V569, P281, DOI 10.1016/0006-8993(92)90640-U; MANDEL RJ, 1989, J PHARMACOL EXP THER, V251, P612; MESSER WS, 1988, NEUROSCI LETT, V89, P367, DOI 10.1016/0304-3940(88)90554-X; Miller MM, 1999, NEUROSCIENCE, V91, P1143, DOI 10.1016/S0306-4522(98)00690-3; Murphy DD, 1998, J NEUROSCI, V18, P2550; Murphy DD, 1996, J NEUROSCI, V16, P4059; Murphy DD, 1997, P NATL ACAD SCI USA, V94, P1482, DOI 10.1073/pnas.94.4.1482; OMALLEY CA, 1987, BRAIN RES, V403, P389, DOI 10.1016/0006-8993(87)90082-5; ONeal MF, 1996, PSYCHONEUROENDOCRINO, V21, P51, DOI 10.1016/0306-4530(95)00032-1; PAXINOS G, 1998, RAT BRAIN STEREOTAXI; Paxinos G., 1995, RAT NERVOUS SYSTEM; PIKE BR, 1995, BRAIN RES, V686, P37, DOI 10.1016/0006-8993(95)00448-Y; QUIRION R, 1995, J NEUROSCI, V15, P1455; Shughrue PJ, 2000, NEUROSCIENCE, V99, P605, DOI 10.1016/S0306-4522(00)00242-6; Shughrue PJ, 1997, J COMP NEUROL, V388, P507, DOI 10.1002/(SICI)1096-9861(19971201)388:4<507::AID-CNE1>3.0.CO;2-6; Shughrue PJ, 2000, NEUROSCIENCE, V96, P41, DOI 10.1016/S0306-4522(99)00520-5; SINGH M, 1994, BRAIN RES, V644, P305, DOI 10.1016/0006-8993(94)91694-2; Stackman RW, 1997, NEUROBIOL LEARN MEM, V67, P167, DOI 10.1006/nlme.1996.3753; Warren SG, 1997, BEHAV NEUROSCI, V111, P259, DOI 10.1037/0735-7044.111.2.259; WEILAND NG, 1992, ENDOCRINOLOGY, V131, P2697, DOI 10.1210/en.131.6.2697; Weiland NG, 1997, J COMP NEUROL, V388, P603, DOI 10.1002/(SICI)1096-9861(19971201)388:4<603::AID-CNE8>3.0.CO;2-6; WEILAND NG, 1992, ENDOCRINOLOGY, V131, P662, DOI 10.1210/en.131.2.662; Wilson IA, 1999, EUR J PHARMACOL, V381, P93, DOI 10.1016/S0014-2999(99)00583-X; WOLFF SC, 1997, SOC NEUR ABSTR, V23, P58813; Woolley CS, 1997, J NEUROSCI, V17, P1848; WOOLLEY CS, 1994, J NEUROSCI, V14, P7680; WOOLLEY CS, 1990, J NEUROSCI, V10, P4035	51	194	200	0	10	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	SEP 1	2001	21	17					6949	6956					8	Neurosciences	Neurosciences & Neurology	467FC	WOS:000170690900051	11517282				2021-06-18	
J	Sherer, M; Bergloff, P; Levin, E; High, WM; Oden, KE; Nick, TG				Sherer, M; Bergloff, P; Levin, E; High, WM; Oden, KE; Nick, TG			Impaired awareness and employment outcome after traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						awareness; Awareness Questionnaire; employment; outcome; rehabilitation; traumatic brain injury	HEAD-INJURY; BEHAVIORAL LIMITATIONS; RATING-SCALE; REHABILITATION; ADULTS; RECOVERY	Inaccurate self-awareness is a common finding after traumatic brain injury. Such impaired awareness has been hypothesized to limit patients' eventual functional outcomes by decreasing motivation for treatment and resulting in selection of inappropriate long-term goals. Previous investigations of the association between impaired awareness and employment outcome have produced inconsistent results. The present article reviews these studies and presents the results of our new investigation of this issue. In addition, we studied the comparability of two methods of measuring impaired awareness. Results provided strong support for a positive relationship between accurate self-awareness and favorable employment outcome at followup.	Mississippi Methodist Rehabil Ctr, Jackson, MS 39216 USA; Univ Michigan, Med Ctr, Ann Arbor, MI USA; Baylor Coll Med, Inst Rehabil & Res, Challenge Program, Houston, TX 77030 USA; Baylor Coll Med, Inst Rehabil & Res, Brain Injury Res Ctr, Houston, TX 77030 USA; HealthSouth Rehabil Hosp Beaumont, Beaumont, TX USA; Univ Mississippi, Med Ctr, Jackson, MS 39216 USA	Sherer, M (corresponding author), Mississippi Methodist Rehabil Ctr, 1350 E Woodrow Wilson, Jackson, MS 39216 USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133B40002, H133A70015] Funding Source: Medline		ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; Anderson S. W., 1989, CLIN NEUROPSYCHOL, V3, P327, DOI DOI 10.1080/13854048908401482; BENYISHAY Y, 1985, SEMIN NEUROL, V5, P252, DOI 10.1055/s-2008-1041522; CAVALLO M M, 1992, Brain Injury, V6, P327, DOI 10.3109/02699059209034947; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Fleming JM, 1996, BRAIN INJURY, V10, P1; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; Gasquoine PG, 1992, NEUROPSYCHOLOGY, V6, P187, DOI [10.1037/0894-4105.6.3.187., DOI 10.1037/0894-4105.6.3.187]; Gasquoine PG, 1994, J HEAD TRAUMA REHAB, V9, P16, DOI DOI 10.1097/00001199-199412000-00004; HEATON RK, 1981, J CONSULT CLIN PSYCH, V49, P807, DOI 10.1037/0022-006X.49.6.807; Heilbronner R L, 1989, Brain Inj, V3, P387, DOI 10.3109/02699058909004562; HENDRYX PM, 1989, ARCH PHYS MED REHAB, V70, P526; JENNETT B, 1977, LANCET, V1, P878; KAY T, 1988, ADM MANUAL NYU HEAD; Klein M, 1994, LOGISTIC REGRESSION; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; NAGELKERKE NJD, 1991, BIOMETRIKA, V78, P691, DOI 10.1093/biomet/78.3.691; Prigatano G. P., 1991, AWARENESS DEFICIT BR; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Prigatano G. P., 1994, J HEAD TRAUMA REHAB, V9, P91, DOI [DOI 10.1097/00001199-199403000-00011, 10.1097/00001199-199403000-00011]; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; RANSEEN JD, 1990, INT J CLIN NEUROPSYC, V12, P29; RAO N, 1992, ARCH PHYS MED REHAB, V73, P911; RUSK H A, 1969, Medical Clinics of North America, V53, P677; Sherer M, 1997, CANCER, V80, P250, DOI 10.1002/(SICI)1097-0142(19970715)80:2<250::AID-CNCR13>3.3.CO;2-T; Sherer M, 1998, NEUROREHABILITATION, V10, P25, DOI 10.3233/NRE-1998-10104; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Sherer M, 1998, ARCH CLIN NEUROPSYCH, V13, P149; SHERER M, 1994, 1994 INT NEUR SOC CI; Vogenthaler D R, 1989, Brain Inj, V3, P369, DOI 10.3109/02699058909004561; WALKER DE, 1987, J CLIN PSYCHOL, V43, P699, DOI 10.1002/1097-4679(198711)43:6<699::AID-JCLP2270430610>3.0.CO;2-9	36	194	194	0	14	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	1998	13	5					52	61		10.1097/00001199-199810000-00007			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	175UU	WOS:000079114600007	9753535				2021-06-18	
J	Cifu, DX; KeyserMarcus, L; Lopez, E; Wehman, P; Kreutzer, JS; Englander, J; High, W				Cifu, DX; KeyserMarcus, L; Lopez, E; Wehman, P; Kreutzer, JS; Englander, J; High, W			Acute predictors of successful return to work 1 year after traumatic brain injury: A multicenter analysis	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							CLOSED HEAD-INJURY; BEHAVIORAL SEQUELAE; PRACTICAL SCALE; RATING-SCALE; REHABILITATION; DISABILITY; RECOVERY; COMA	Objective: To investigate the influence of acute injury characteristics on subsequent return to work in traumatic brain injury (TBI) patients. Design: Descriptive statistics were performed in a comparative study of 49 TBI patients who were competitively employed at 1-year follow-up and 83 unemployed patients. Independent t tests were then performed to examine the differences between the two groups on specific measures including the Disability Rating Scale (DRS), Functional Assessment Measure (FIM), Rancho Los Amigos Scale (RLAS), Glasgow Coma Scale (GCS), Neurobehavioral Rating Scale (NRS), and neuropsychological test results. Setting: Four medical centers in the federally sponsored Traumatic Brain Injury Model Systems Project that provide emergency medical services, intensive and acute medical care, inpatient rehabilitation, and a spectrum of community rehabilitation services. Participants: Patients were selected from a national database of 245 rehabilitation inpatients admitted to acute care within 8 hours of TBI and seen at 1-year follow-up. Main Outcome Measure: Return to work at 1-year follow-up. Results: Persons employed at 1-year follow-up obtained significantly better scores on specific acute measures of physical functioning (Admission FIM, Admission DRS, Discharge DRS), cognitive functioning (Logical Memory Delay), behavioral functioning (Admission RLAS, Discharge RLAS, NRS Excitement factor), and injury severity (Admission GCS, Highest GCS, Length of Coma, Length of PTA) than their unemployed counterparts. Conclusions: Persons obtaining better scores on certain acute measures (eg, Admission GCS) are more likely to return to the workforce. Future research should focus on developing a standardized tool to assess a patient's ability to return to work, as well as an operational definition for successful employment. (C) 1997 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DIV NEUROL SURG,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,DEPT EDUC,RICHMOND,VA; UNIV PUERTO RICO,DEPT PHYS MED & REHABIL,SAN JUAN,PR 00936; SANTA CLARA VALLEY MED CTR,DEPT REHABIL,SANTA CLARA,CA; BAYLOR COLL MED,DEPT PHYS MED & REHABIL,HOUSTON,TX 77030	Cifu, DX (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHYS MED & REHABIL,MCV BOX 980661,RICHMOND,VA 23298, USA.			Keyser-Marcus, Lori/0000-0001-6014-2500; Cifu, David/0000-0003-1600-9387			ACKER MB, 1986, CLIN NEUROPSYCHOL IN, P85; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Chiu Wen-Ta, 1993, Journal of the Formosan Medical Association, V92, P255; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; FORER S, 1982, J ORGAN REHABIL EVAL, V2, P29; GOETHE KE, 1984, PSYCHIAT ANN, V14, P540, DOI 10.3928/0048-5713-19840701-11; Hagen C., 1972, LEVELS COGNITIVE FUN; HALL KM, 1994, ARCH PHYS MED REHA S, V75; HART T, 1986, CLIN NEUROPSYCHOLOGY, P21; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; KAY T, 1984, NEW YORK U MED CTR R, V1851; KEYSER L, 1995, NEUROREHABILITATION, V5, P255, DOI 10.3233/NRE-1995-5308; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MACKENZIE EJ, 1987, AM J PUBLIC HEALTH, V77, P329, DOI 10.2105/AJPH.77.3.329; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; REYES RL, 1981, ARCH PHYS MED REHAB, V62, P20; SIEGEL JH, 1991, CRIT CARE MED, V19, P1252, DOI 10.1097/00003246-199110000-00007; STAMBROOK M, 1990, CAN J SURG, V33, P115; TEASDALE G, 1974, LANCET, V2, P81; Vogenthaler D R, 1989, Brain Inj, V3, P369, DOI 10.3109/02699058909004561; Wehman Paul, 1993, Brain Injury, V7, P31, DOI 10.3109/02699059309008154; WEHMAN PH, 1995, J HEAD TRAUMA REHAB, V10, P27	30	194	195	0	27	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	1997	78	2					125	131		10.1016/S0003-9993(97)90252-5			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	WH072	WOS:A1997WH07200003	9041891				2021-06-18	
J	YING, Z; TATSUNO, T; CARNEY, JM; MATTSON, MP				YING, Z; TATSUNO, T; CARNEY, JM; MATTSON, MP			BASIC FGF, NGF, AND IGFS PROTECT HIPPOCAMPAL AND CORTICAL-NEURONS AGAINST IRON-INDUCED DEGENERATION	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						CALCIUM; DESFERAL; FREE RADICAL; GLUTAMATE; INSULIN-LIKE GROWTH FACTOR; ISCHEMIA; NERVE GROWTH FACTOR	NERVE GROWTH-FACTOR; OXYGEN FREE-RADICALS; LIPID-PEROXIDATION; BRAIN EDEMA; REPERFUSION INJURY; PARKINSONS-DISEASE; RAT; GLUTAMATE; RECEPTOR; INVOLVEMENT	Iron is believed to contribute to the process of cell damage and death resulting from ischemic and traumatic insults by catalyzing the oxidation of protein and lipids. Exposure of cultured rat hippocampal neurons to iron (FeSO4) caused a dose-dependent reduction in neuronal survival, which was potentiated by ascorbate. Damage to neurons was associated with a significant level of oxygen radical in the culture medium. The iron chelator desferal prevented both the neuronal degeneration caused by FeSO4 and the production of oxygen radical, demonstrating that ionic iron was responsible for the cell damage. Iron neurotoxicity was associated with an elevation of [Ca2+]i and was attenuated by NMDA receptor antagonists. Since recent findings demonstrated neuroprotective effects of growth factors in cell culture and in vivo models of ischemia, we examined the effects of growth factors on iron-induced damage. Basic fibroblast growth factor (bFGF), nerve growth factor (NGF), and insulin-like growth factors (IGF-I and IGF-II) each protected neurons against iron-induced damage. Both rat hippocampal and human cortical neurons were protected by these growth factors. Taken together, the data suggest that the neuroprotective effects of growth factors against excitotoxic/ischemic insults may result, in part, from a prevention or attenuation of oxidative damage.	UNIV KENTUCKY, SANDERS BROWN RES CTR AGING, 211 SANDERS BROWN BLDG, LEXINGTON, KY 40536 USA; UNIV KENTUCKY, DEPT ANAT & NEUROBIOL, LEXINGTON, KY 40536 USA; UNIV KENTUCKY, DEPT PHARMACOL, LEXINGTON, KY 40536 USA			Mattson, Mark P/F-6038-2012		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS29001, NS30583] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029001, R01NS030583] Funding Source: NIH RePORTER		AMBROSIO G, 1987, CIRCULATION, V76, P906, DOI 10.1161/01.CIR.76.4.906; BERG MM, 1991, P NATL ACAD SCI USA, V88, P7106, DOI 10.1073/pnas.88.16.7106; BRAUGHLER JM, 1986, J BIOL CHEM, V261, P282; BUCHER JR, 1983, BIOCHEM BIOPH RES CO, V111, P777, DOI 10.1016/0006-291X(83)91366-9; CAO W, 1988, NEUROSCI LETT, V88, P233, DOI 10.1016/0304-3940(88)90132-2; CARNEY JM, 1991, P NATL ACAD SCI USA, V88, P3633, DOI 10.1073/pnas.88.9.3633; CHENG B, 1992, J NEUROSCI, V12, P1558; CHENG B, 1992, EXP NEUROL, V117, P114, DOI 10.1016/0014-4886(92)90120-F; CHENG B, 1991, NEURON, V7, P1031, DOI 10.1016/0896-6273(91)90347-3; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; DELEO JA, 1986, NEUROSCI LETT, V67, P63, DOI 10.1016/0304-3940(86)90209-0; DEXTER DT, 1989, J NEUROCHEM, V52, P1830, DOI 10.1111/j.1471-4159.1989.tb07264.x; DEXTER DT, 1989, J NEUROCHEM, V52, P381, DOI 10.1111/j.1471-4159.1989.tb09133.x; FINKLESTEIN SP, 1988, BRAIN RES, V460, P253, DOI 10.1016/0006-8993(88)90370-8; FLOYD R A, 1986, Journal of Free Radicals in Biology and Medicine, V2, P13, DOI 10.1016/0748-5514(86)90118-2; FLOYD RA, 1990, FASEB J, V4, P2587; FRANDSEN A, 1991, J NEUROCHEM, V56, P1075, DOI 10.1111/j.1471-4159.1991.tb02031.x; GLUCKMAN P, 1992, BIOCHEM BIOPH RES CO, V182, P593, DOI 10.1016/0006-291X(92)91774-K; GOOD PF, 1992, ANN NEUROL, V31, P286, DOI 10.1002/ana.410310310; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HALLIWELL B, 1986, TRENDS BIOCHEM SCI, V11, P372, DOI 10.1016/0968-0004(86)90207-0; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HALLIWELL B, 1987, FASEB J, V1, P358; HEFTI F, 1984, BRAIN RES, V293, P305, DOI 10.1016/0006-8993(84)91237-X; HISANAGA K, 1992, ANN NEUROL, V31, P562, DOI 10.1002/ana.410310516; HOULGATTE R, 1989, J NEUROSCI RES, V24, P143, DOI 10.1002/jnr.490240204; IKEDA Y, 1989, J NEUROSURG, V71, P233, DOI 10.3171/jns.1989.71.2.0233; IKEDA Y, 1990, NEUROSURGERY, V27, P1; JACKSON GR, 1990, J NEUROSCI RES, V25, P360, DOI 10.1002/jnr.490250313; JESBERGER JA, 1991, INT J NEUROSCI, V57, P1, DOI 10.3109/00207459109150342; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KEBERLE H, 1964, ANN NY ACAD SCI, V119, P758; KIRSCH JR, 1992, J NEUROTRAUM, V9, pS157; LESNIAK MA, 1988, ENDOCRINOLOGY, V123, P2089, DOI 10.1210/endo-123-4-2089; LU B, 1989, EXP NEUROL, V104, P191, DOI 10.1016/0014-4886(89)90029-0; MATTSON MP, 1988, INT J DEV NEUROSCI, V6, P439, DOI 10.1016/0736-5748(88)90050-0; MATTSON MP, 1990, BRAIN RES, V522, P204, DOI 10.1016/0006-8993(90)91462-P; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; MATTSON MP, 1990, INT J DEV NEUROSCI, V8, P399, DOI 10.1016/0736-5748(90)90073-B; MATTSON MP, 1988, J NEUROSCI, V8, P2087; MATTSON MP, 1992, EXP GERONTOL, V27, P29, DOI 10.1016/0531-5565(92)90027-W; MATTSON MP, 1991, BRAIN RES, V542, P97, DOI 10.1016/0006-8993(91)91003-J; MATTSON MP, 1989, J NEUROSCI, V9, P3728; MATTSON MP, 1993, IN PRESS EXP NEUROL; MATTSON MP, 1992, IN PRESS STROKE; MICHEL PP, 1992, J NEUROCHEM, V59, P118, DOI 10.1111/j.1471-4159.1992.tb08882.x; MONYER H, 1990, NEURON, V5, P121, DOI 10.1016/0896-6273(90)90302-V; NISTICO G, 1992, FREE RADICAL BIO MED, V12, P177, DOI 10.1016/0891-5849(92)90024-B; NOZAKI K, 1993, J CEREBR BLOOD F MET, V13, P221, DOI 10.1038/jcbfm.1993.27; OLIVER CN, 1990, P NATL ACAD SCI USA, V87, P5144, DOI 10.1073/pnas.87.13.5144; PETTMANN B, 1986, NEUROSCI LETT, V68, P175, DOI 10.1016/0304-3940(86)90137-0; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; ROTWEIN P, 1988, P NATL ACAD SCI USA, V85, P265, DOI 10.1073/pnas.85.1.265; SHIGENO T, 1991, J NEUROSCI, V11, P2914; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; SMITH CD, 1991, P NATL ACAD SCI USA, V88, P10540, DOI 10.1073/pnas.88.23.10540; Smith-Swintosky V. L., 1992, Society for Neuroscience Abstracts, V18, P951; SPINA MB, 1992, J NEUROCHEM, V59, P99, DOI 10.1111/j.1471-4159.1992.tb08880.x; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; TIFFANYCASTIGLIONI E, 1981, NEUROSCI LETT, V26, P157, DOI 10.1016/0304-3940(81)90342-6; VANJAARSVELD H, 1992, BASIC RES CARDIOL, V87, P47; WANAKA A, 1990, NEURON, V5, P267, DOI 10.1016/0896-6273(90)90164-B; WATSON BD, 1989, ANN NY ACAD SCI, V559, P269; WILLMORE LJ, 1982, BRAIN RES, V246, P113, DOI 10.1016/0006-8993(82)90147-0	64	194	195	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAY	1993	13	3					378	388		10.1038/jcbfm.1993.51			11	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	KY458	WOS:A1993KY45800004	8478396	Bronze			2021-06-18	
J	Dagher, NN; Najafi, AR; Kayala, KMN; Elmore, MRP; White, TE; Medeiros, R; West, BL; Green, KN				Dagher, Nabil N.; Najafi, Allison R.; Kayala, Kara M. Neely; Elmore, Monica R. P.; White, Terra E.; Medeiros, Rodrigo; West, Brian L.; Green, Kim N.			Colony-stimulating factor 1 receptor inhibition prevents microglial plaque association and improves cognition in 3xTg-AD mice	JOURNAL OF NEUROINFLAMMATION			English	Article						Alzheimer's disease; Neuroinflammation; Cognition; Therapeutics	TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; A-BETA; TRANSGENIC MICE; INFLAMMATORY RESPONSE; TREM2; MOUSE; MODEL; MACROPHAGES; CLEARANCE	Background: Microglia are dependent upon colony-stimulating factor 1 receptor (CSF1R) signaling for their survival in the adult brain, with administration of the dual CSF1R/c-kit inhibitor PLX3397 leading to the near-complete elimination of all microglia brainwide. Here, we determined the dose-dependent effects of a specific CSF1R inhibitor (PLX5622) on microglia in both wild-type and the 3xTg-AD mouse model of Alzheimer's disease. Methods: Wild-type mice were treated with PLX5622 for up to 21 days, and the effects on microglial numbers were assessed. 3xTg-AD mice were treated with PLX5622 for 6 or 12 weeks and effects on microglial numbers and pathology subsequently assessed. Results: High doses of CSF1R inhibitor eliminate most microglia from the brain, but a 75 % lower-dose results in sustained elimination of similar to 30 % of microglia in both wild-type and 3xTg-AD mice. No behavioral or cognitive deficits were found in mice either depleted of microglia or treated with lower CSF1R inhibitor concentrations. Aged 3xTg-AD mice treated for 6 or 12 weeks with lower levels of PLX5622 resulted in improved learning and memory. A beta levels and plaque loads were not altered, but microglia in treated mice no longer associated with plaques, revealing a role for the CSF1R in the microglial reaction to plaques, as well as in mediating cognitive deficits. Conclusions: We find that inhibition of CSF1R alone is sufficient to eliminate microglia and that sustained microglial elimination is concentration-dependent. Inhibition of the CSF1R at lower levels in 3xTg-AD mice prevents microglial association with plaques and improves cognition.	[Dagher, Nabil N.; Najafi, Allison R.; Kayala, Kara M. Neely; Elmore, Monica R. P.; White, Terra E.; Medeiros, Rodrigo; Green, Kim N.] Univ Calif Irvine, Biol Sci 3 3208, Inst Memory Impairments & Neurol Disorders, Dept Neurobiol & Behav, Irvine, CA 92697 USA; [West, Brian L.] Plexxikon Inc, Berkeley, CA USA	Green, KN (corresponding author), Univ Calif Irvine, Biol Sci 3 3208, Inst Memory Impairments & Neurol Disorders, Dept Neurobiol & Behav, Irvine, CA 92697 USA.	kngreen@uci.edu		Medeiros, Rodrigo/0000-0002-9399-7852; West, Brian/0000-0002-5320-3691; Dagher, Nabil/0000-0002-8973-6588	National Institutes of Health (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1R01NS083801]; National Institutes of Health (NIA)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50 AG016573]; Whitehall foundation; American Federation of Aging Research; Alzheimer's AssociationAlzheimer's Association; NIH training fellowship [AG00538]; University of California Alzheimer's Disease Research Center (UCI-ADRC) NIH/NIA Grant [P50 AG16573]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS083801] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32AG000096, P50AG016573, P01AG000538] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health under awards 1R01NS083801 (NINDS) and P50 AG016573 (NIA) to KNG, as well as the Whitehall foundation to KNG, the American Federation of Aging Research to KNG, and the Alzheimer's Association to KNG. ARN and ME are supported by the NIH training fellowship AG00538. BLW is an employee of Plexxikon Inc. The A beta peptides and anti-A beta antibodies were provided by the University of California Alzheimer's Disease Research Center (UCI-ADRC) NIH/NIA Grant P50 AG16573.	Antunes M, 2012, COGN PROCESS, V13, P93, DOI 10.1007/s10339-011-0430-z; Billings LM, 2005, NEURON, V45, P675, DOI 10.1016/j.neuron.2005.01.040; Cavnar MJ, 2013, J EXP MED, V210, P2873, DOI 10.1084/jem.20130875; Coniglio SJ, 2012, MOL MED, V18, P519, DOI 10.2119/molmed.2011.00217; Edison P, 2008, NEUROBIOL DIS, V32, P412, DOI 10.1016/j.nbd.2008.08.001; Elmore MRP, 2014, NEURON, V82, P380, DOI 10.1016/j.neuron.2014.02.040; Erblich B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026317; Fuhrmann M, 2010, NAT NEUROSCI, V13, P411, DOI 10.1038/nn.2511; Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637; Gomez-Nicola D, 2013, J NEUROSCI, V33, P2481, DOI 10.1523/JNEUROSCI.4440-12.2013; Grathwohl SA, 2009, NAT NEUROSCI, V12, P1361, DOI 10.1038/nn.2432; Green KN, 2008, J NEUROSCI, V28, P11500, DOI 10.1523/JNEUROSCI.3203-08.2008; GUTIERREZ EG, 1993, J NEUROIMMUNOL, V47, P169, DOI 10.1016/0165-5728(93)90027-V; Jay TR, 2015, J EXP MED, V212, P287, DOI 10.1084/jem.20142322; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kettenmann H, 2013, NEURON, V77, P10, DOI 10.1016/j.neuron.2012.12.023; Kim TS, 2014, CLIN CANCER RES, V20, P2350, DOI 10.1158/1078-0432.CCR-13-3033; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Li J, 2006, GENESIS, V44, P328, DOI 10.1002/dvg.20219; Lin HS, 2008, SCIENCE, V320, P807, DOI 10.1126/science.1154370; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Neely KM, 2011, J NEUROSCI, V31, P2781, DOI 10.1523/JNEUROSCI.5156-10.2010; Oddo S, 2003, NEURON, V39, P409, DOI 10.1016/S0896-6273(03)00434-3; Oddo S, 2004, NEURON, V43, P321, DOI 10.1016/j.neuron.2004.07.003; Ohsawa K, 2000, J CELL SCI, V113, P3073; Otero K, 2012, J IMMUNOL, V188, P2612, DOI 10.4049/jimmunol.1102836; Parachikova A, 2010, J ALZHEIMERS DIS, V21, P527, DOI 10.3233/JAD-2010-100204; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Rice RA, 2015, J NEUROSCI, V35, P9977, DOI 10.1523/JNEUROSCI.0336-15.2015; Ulrich JD, 2014, MOL NEURODEGENER, V9, DOI 10.1186/1750-1326-9-20; Valdearcos M, 2014, CELL REP, V9, P2124, DOI 10.1016/j.celrep.2014.11.018; Wang Q, 2007, J NEUROIMMUNOL, V184, P53, DOI 10.1016/j.jneuroim.2006.11.014; Wang YM, 2015, CELL, V160, P1061, DOI 10.1016/j.cell.2015.01.049; Wyss-Coray T, 2001, NAT MED, V7, P612, DOI 10.1038/87945; Zhan Y, 2014, NAT NEUROSCI, V17, P400, DOI 10.1038/nn.3641	35	193	193	4	28	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	AUG 1	2015	12								139	10.1186/s12974-015-0366-9			14	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	CN9KV	WOS:000358768000001	26232154	DOAJ Gold, Green Published	Y	N	2021-06-18	
J	Cubon, VA; Putukian, M; Boyer, C; Dettwiler, A				Cubon, Valerie A.; Putukian, Margot; Boyer, Cynthia; Dettwiler, Annegret			A Diffusion Tensor Imaging Study on the White Matter Skeleton in Individuals with Sports-Related Concussion	JOURNAL OF NEUROTRAUMA			English	Article						diffuse axonal injury; diffusion tensor imaging; mean diffusivity; mild traumatic brain injury; sports-related concussion	TRAUMATIC BRAIN-INJURY; COLLEGIATE FOOTBALL PLAYERS; 3RD INTERNATIONAL-CONFERENCE; HIGH-SCHOOL FOOTBALL; PROFESSIONAL FOOTBALL; RECURRENT CONCUSSION; HEAD IMPACTS; CONSENSUS STATEMENT; FIBER TRACTS; MR	Recognizing and managing the effects of cerebral concussion is very challenging, given the discrete symptomatology. Most individuals with sports-related concussion will not score below 15 on the Glasgow Coma Scale, but will present with rapid onset of short-lived neurological impairment, demonstrating no structural changes on traditional magnetic resonance imaging (MRI) and computed tomography (CT) scans. The return-to-play decision is one of the most difficult responsibilities facing the physician, and so far this decision has been primarily based on neurological examination, symptom checklists, and neuropsychological (NP) testing. Diffusion tensor imaging (DTI) may be a more objective tool to assess the severity and recovery of function after concussion. We assessed white matter (WM) fiber tract integrity in varsity level college athletes with sports-related concussion without loss of consciousness, who experienced protracted symptoms for at least 1 month after injury. Evaluation of fractional anisotropy (FA) and mean diffusivity (MD) of the WM skeleton using tract-based spatial statistics (TBSS) revealed a large cluster of significantly increased MD for concussed subjects in several WM fiber tracts in the left hemisphere, including parts of the inferior/superior longitudinal and fronto-occipital fasciculi, the retrolenticular part of the internal capsule, and posterior thalamic and acoustic radiations. Qualitative comparison of average FA and MD suggests that with increasing level of injury severity (ranging from sports-related concussion to severe traumatic brain injury), MD might be more sensitive at detecting mild injury, whereas FA captures more severe injuries. In conclusion, the TBSS analysis used to evaluate diffuse axonal injury of the WM skeleton seems sensitive enough to detect structural changes in sports-related concussion.	[Cubon, Valerie A.; Dettwiler, Annegret] Princeton Univ, Princeton Neurosci Inst, Princeton, NJ 08544 USA; [Putukian, Margot] Princeton Univ, Univ Hlth Serv, Princeton, NJ 08544 USA; [Boyer, Cynthia] Bancroft NeuroHlth, Brain Injury Serv, Cherry Hill, NJ USA	Dettwiler, A (corresponding author), Princeton Univ, Princeton Neurosci Inst, Green Hall, Princeton, NJ 08544 USA.	adettwil@princeton.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HD049546-01]; Peter R. and Cynthia K. Kellogg Foundation; SIBIL Foundation for Self-determination and International Relations in Liechtenstein; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD049546] Funding Source: NIH RePORTER	This work was funded by National Institutes of Health grant no. HD049546-01, the Peter R. and Cynthia K. Kellogg Foundation, and the SIBIL Foundation for Self-determination and International Relations in Liechtenstein.	Acosta-Cabronero J, 2010, BRAIN, V133, P529, DOI 10.1093/brain/awp257; Anderson B, 1999, NEUROPSY NEUROPSY BE, V12, P247; ANDERSSON JLR, 2007, NONLINEAR OPTIMIZATI; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barrick TR, 2007, CEREB CORTEX, V17, P591, DOI 10.1093/cercor/bhk004; Basser PJ, 2002, NMR BIOMED, V15, P456, DOI 10.1002/nbm.783; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Buchel C, 2004, CEREB CORTEX, V14, P945, DOI 10.1093/cercor/bhh055; Burgel U, 2006, NEUROIMAGE, V29, P1092, DOI 10.1016/j.neuroimage.2005.08.040; Burgel U, 1999, NEUROIMAGE, V10, P489, DOI 10.1006/nimg.1999.0497; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Chen JK, 2008, CLIN J SPORT MED, V18, P241, DOI 10.1097/JSM.0b013e318170b59d; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Erlanger DM, 2002, J HEAD TRAUMA REHAB, V17, P458, DOI 10.1097/00001199-200210000-00007; Giorgio A, 2010, NEUROIMAGE, V51, P943, DOI 10.1016/j.neuroimage.2010.03.004; GRONWALL D, 1975, LANCET, V2, P995; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Heiervang E, 2006, NEUROIMAGE, V33, P867, DOI 10.1016/j.neuroimage.2006.07.037; HERRING SA, 2005, MED SCI SPORTS EXERC, V37, P2012; Horsfield MA, 1998, J NEUROL NEUROSUR PS, V64, pS80; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Johansen-Berg H, 2009, ANNU REV NEUROSCI, V32, P75, DOI 10.1146/annurev.neuro.051508.135735; Jones DK, 2004, MAGNET RESON MED, V51, P807, DOI 10.1002/mrm.20033; Jones DK, 1999, MAGNET RESON MED, V42, P515, DOI 10.1002/(SICI)1522-2594(199909)42:3<515::AID-MRM14>3.3.CO;2-H; KIM J, 2010, CTS-CLIN TRANSL SCI, V3, pS45; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; LOVELL MR, 2007, IMMEDIATE POST CONCU; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrory P, 2005, BRIT J SPORT MED, V39, DOI 10.1136/bjsm.2004.014860; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI 10.1016/j.jocn.2009.02.002; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Mori S., 2005, MRI ATLAS HUMAN WHIT; Mori S., 2007, INTRO DIFFUSION TENS; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Perlbarg V, 2009, HUM BRAIN MAPP, V30, P3924, DOI 10.1002/hbm.20817; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; Ptito A, 2007, NEUROREHABILITATION, V22, P217; Rademacher J, 2002, NEUROIMAGE, V17, P142, DOI 10.1006/nimg.2002.1178; Reese TG, 2003, MAGN RESON MED, V49, P177, DOI 10.1002/mrm.10308; Rueckert D, 1999, IEEE T MED IMAGING, V18, P712, DOI 10.1109/42.796284; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; TEASDALE G, 1974, LANCET, V2, P81; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Wakana S, 2004, RADIOLOGY, V230, P77, DOI 10.1148/radiol.2301021640; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	75	193	197	0	19	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2011	28	2					189	201		10.1089/neu.2010.1430			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	719UE	WOS:000287234700003	21083414	Green Published			2021-06-18	
J	Holmes, EA; James, EL; Coode-Bate, T; Deeprose, C				Holmes, Emily A.; James, Ella L.; Coode-Bate, Thomas; Deeprose, Catherine			Can Playing the Computer Game "Tetris'' Reduce the Build-Up of Flashbacks for Trauma? A Proposal from Cognitive Science	PLOS ONE			English	Article							POSTTRAUMATIC-STRESS-DISORDER; ELABORATED INTRUSION THEORY; WORKING-MEMORY; EMOTIONAL MEMORIES; EYE-MOVEMENTS; IMAGERY; RECONSOLIDATION; PROPRANOLOL; FILM; CONSOLIDATION	Background: Flashbacks are the hallmark symptom of Posttraumatic Stress Disorder (PTSD). Although we have successful treatments for full-blown PTSD, early interventions are lacking. We propose the utility of developing a 'cognitive vaccine' to prevent PTSD flashback development following exposure to trauma. Our theory is based on two key findings: 1) Cognitive science suggests that the brain has selective resources with limited capacity; 2) The neurobiology of memory suggests a 6-hr window to disrupt memory consolidation. The rationale for a 'cognitive vaccine' approach is as follows: Trauma flashbacks are sensory-perceptual, visuospatial mental images. Visuospatial cognitive tasks selectively compete for resources required to generate mental images. Thus, a visuospatial computer game (e.g. "Tetris'') will interfere with flashbacks. Visuospatial tasks post-trauma, performed within the time window for memory consolidation, will reduce subsequent flashbacks. We predicted that playing "Tetris'' half an hour after viewing trauma would reduce flashback frequency over 1-week. Methodology/Principal Findings: The Trauma Film paradigm was used as a well-established experimental analog for Posttraumatic Stress. All participants viewed a traumatic film consisting of scenes of real injury and death followed by a 30-min structured break. Participants were then randomly allocated to either a no-task or visuospatial ("Tetris'') condition which they undertook for 10-min. Flashbacks were monitored for 1-week. Results indicated that compared to the no-task condition, the "Tetris'' condition produced a significant reduction in flashback frequency over 1-week. Convergent results were found on a clinical measure of PTSD symptomatology at 1-week. Recognition memory between groups did not differ significantly. Conclusions/Significance: Playing "Tetris'' after viewing traumatic material reduces unwanted, involuntary memory flashbacks to that traumatic film, leaving deliberate memory recall of the event intact. Pathological aspects of human memory in the aftermath of trauma may be malleable using non-invasive, cognitive interventions. This has implications for a novel avenue of preventative treatment development, much-needed as a crisis intervention for the aftermath of traumatic events.	[Holmes, Emily A.; James, Ella L.; Coode-Bate, Thomas; Deeprose, Catherine] Univ Oxford, Dept Psychiat, Oxford, England	Holmes, EA (corresponding author), Univ Oxford, Dept Psychiat, Oxford, England.	emily.holmes@psych.ox.ac.uk	Holmes, Emily/D-8075-2011; Holmes, Emily/ABD-4367-2020; Deeprose, Catherine/G-3459-2012; James, Ella/D-8795-2011	Holmes, Emily/0000-0001-7319-3112; 	Royal Society Dorothy Hodgkin FellowshipRoyal Society of London	This research was supported by a Royal Society Dorothy Hodgkin Fellowship awarded to Emily A. Holmes. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript	American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Anderson C.A., 2007, VIOLENT VIDEO GAME E; Anderson MC, 2001, NATURE, V410, P366, DOI 10.1038/35066572; Andrade J, 1997, BRIT J CLIN PSYCHOL, V36, P209, DOI 10.1111/j.2044-8260.1997.tb01408.x; Baddeley A, 2003, NAT REV NEUROSCI, V4, P829, DOI 10.1038/nrn1201; Baddeley AD, 2000, J EXP PSYCHOL GEN, V129, P126, DOI 10.1037//0096-3445.129.1.126; Brewin CR, 2003, CLIN PSYCHOL REV, V23, P339, DOI 10.1016/S0272-7358(03)00033-3; Brunet A, 2008, J PSYCHIATR RES, V42, P503, DOI 10.1016/j.jpsychires.2007.05.006; BRYANT RA, 2000, BEHAV RES THER, V33, P631; Conway MA, 2000, PSYCHOL REV, V107, P261, DOI 10.1037//0033-295X.107.2.261; Dalgleish T, 2004, PSYCHOL BULL, V130, P228, DOI 10.1037/0033-2909.130.2.228; Depue BE, 2007, SCIENCE, V317, P215, DOI 10.1126/science.1139560; Dudai Y, 2006, CURR OPIN NEUROBIOL, V16, P174, DOI 10.1016/j.conb.2006.03.010; Ehlers A, 2004, MEMORY, V12, P403, DOI 10.1080/09658210444000025; Ehlers A, 2000, BEHAV RES THER, V38, P319, DOI 10.1016/S0005-7967(99)00123-0; Green CS, 2003, NATURE, V423, P534, DOI 10.1038/nature01647; Gunter RW, 2008, BEHAV RES THER, V46, P913, DOI 10.1016/j.brat.2008.04.006; HAIER RJ, 1992, BRAIN RES, V570, P134, DOI 10.1016/0006-8993(92)90573-R; Hartshorne JK, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002716; Henry M, 2007, AM J BIOETHICS, V7, P12, DOI 10.1080/15265160701518474; Hertel PT, 2005, PSYCHON B REV, V12, P484, DOI 10.3758/BF03193792; Holmes EA, 2005, J BEHAV THER EXP PSY, V36, P3, DOI 10.1016/j.jbtep.2004.11.002; Holmes EA, 2004, J EXP PSYCHOL GEN, V133, P3, DOI 10.1037/0096-3445.133.1.3; HOLMES EA, 2007, MEMORY SUPPRESSION P; Holmes EA, 2008, ACTA PSYCHOL, V127, P553, DOI 10.1016/j.actpsy.2007.11.002; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; HOROWITZ MJ, 1969, ARCH GEN PSYCHIAT, V20, P552; Kavanagh DJ, 2005, PSYCHOL REV, V112, P446, DOI 10.1037/0033-295X.112.2.446; Kavanagh DJ, 2001, BRIT J CLIN PSYCHOL, V40, P267, DOI 10.1348/014466501163689; Kemps E, 2004, INT J EAT DISORDER, V36, P31, DOI 10.1002/eat.20005; Kemps E, 2007, J EXP PSYCHOL-APPL, V13, P95, DOI 10.1037/1076-898X.13.2.95; Lee JLC, 2008, NAT NEUROSCI, V11, P1264, DOI 10.1038/nn.2205; LILLEY SA, BRIT J CLIN IN PRESS; Mayou RA, 2000, BRIT J PSYCHIAT, V176, P589, DOI 10.1192/bjp.176.6.589; McNally Richard J, 2003, Psychol Sci Public Interest, V4, P45, DOI 10.1111/1529-1006.01421; Nader K, 2003, TRENDS NEUROSCI, V26, P65, DOI 10.1016/S0166-2236(02)00042-5; *NIH CLIN EXC, 2005, POST TRAUM STRESS DI; Pitman RK, 2002, BIOL PSYCHIAT, V51, P189, DOI 10.1016/S0006-3223(01)01279-3; Rudy JW, 2008, NAT NEUROSCI, V11, P1241, DOI 10.1038/nn1108-1241; Schafe GE, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-18-j0003.2000; Sims VK, 2002, APPL COGNITIVE PSYCH, V16, P97, DOI 10.1002/acp.759; Stickgold R, 2000, SCIENCE, V290, P350, DOI 10.1126/science.290.5490.350; Stuart ADP, 2006, BEHAV RES THER, V44, P611, DOI 10.1016/j.brat.2005.04.004; *TETR HOLD LLC, PC VERS TETR; VANDENHOUT M, 2001, BRIT J CLIN PSYCHOL, V36, P209; Walker MP, 2003, NATURE, V425, P616, DOI 10.1038/nature01930; WESCHSLER D, 1981, WAIS R MANUAL; Wllper AP, 2008, HEALTH AFFAIR, V27, pW84, DOI 10.1377/hlthaff.27.2.w84	48	193	197	3	82	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 7	2009	4	1							e4153	10.1371/journal.pone.0004153			6	Multidisciplinary Sciences	Science & Technology - Other Topics	437FX	WOS:000265473300016	19127289	DOAJ Gold, Green Published			2021-06-18	
J	Rao, V; Lyketsos, C				Rao, V; Lyketsos, C			Neuropsychiatric sequelae of traumatic brain injury	PSYCHOSOMATICS			English	Article							HEAD-INJURY; PSYCHIATRIC SEQUELAE; DEPRESSION; AMANTADINE; MEMORY; REHABILITATION; CHILDREN; PATIENT; STROKE; MANIA	The authors review the psychiatric disturbances associated with traumatic brain injury. They highlight the close link between traumatic brain injury and psychiatry and provide an overview of the epidemiology, risk factors, classification, and mechanisms of traumatic brain injury. They describe various neuropsychiatric sequelae, and the respective treatments are outlined with emphasis on a multidisciplinary approach.	Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Neuropsychiat & Memory Grp, Baltimore, MD 21205 USA	Rao, V (corresponding author), Johns Hopkins Hosp, Osler 320, Baltimore, MD 21287 USA.						ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; AUERBACH SH, 1989, PHYSICAL MED REHABIL, V3, P1; BESSETTE RF, 1992, PSYCHOSOMATICS, V33, P224, DOI 10.1016/S0033-3182(92)72001-5; BLEIBERG J, 1993, NEUROPSY NEUROPSY BE, V6, P245; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CAMPBELL JJ, 1994, J NEUROPSYCH CLIN N, V6, P411; Capruso DX, 1995, COMPREHENSIVE TXB PS, V1, P207; Childs A, 1987, Brain Inj, V1, P49, DOI 10.3109/02699058709034444; Cripe LI, 1987, COGNITIVE REHABILITA, V5, P18; Davison K, 1969, BRIT J PSYCHIATRY SP, V4, P113; DOBKIN BH, 1993, ANN NEUROL, V33, P313, DOI 10.1002/ana.410330315; DUFFY JD, 1994, J NEUROPSYCH CLIN N, V6, P379; EPSTEIN NB, 1981, HDB FAMILY THERAPY, P444; EVANS RW, 1987, J NERV MENT DIS, V175, P106, DOI 10.1097/00005053-198702000-00007; EVANS RW, 1992, NEUROL CLIN, V10, P815; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; FEENEY DM, 1987, CRIT REV NEUROBIOL, V3, P135; Frankowski R F, 1986, Adv Psychosom Med, V16, P153; GENNARELLI TA, 1987, HEAD INJURY, V2, P108; Gerring J P, 1986, Pediatr Rev, V8, P115, DOI 10.1542/pir.8-4-115; GIAKAS WJ, 1990, J CLIN PSYCHIAT, V51, P525; GOLDBERG E, 1982, ARCH NEUROL-CHICAGO, V39, P581, DOI 10.1001/archneur.1982.00510210051012; GRAY BG, 1992, J NUCL MED, V33, P52; GUALITERI CT, 1988, J HEAD TRAUMA REHAB, V6, P90; Gualtieri C T, 1988, Brain Inj, V2, P273, DOI 10.3109/02699058809150898; GUALTIERI CT, 1991, NEUROPSYCHIATRY BEHA; HAMMILL RW, 1987, ANN NEUROL, V21, P438; HINKELDEY N S, 1990, Brain Injury, V4, P115, DOI 10.3109/02699059009026157; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; JORGE RE, 1993, AM J PSYCHIAT, V150, P916; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; Kant R, 1998, BRAIN INJURY, V12, P87, DOI 10.1080/026990598122908; Karli DC, 1999, BRAIN INJURY, V13, P63, DOI 10.1080/026990599121908; KLONOFF H, 1971, AM J PUBLIC HEALTH N, V61, P2405, DOI 10.2105/AJPH.61.12.2405; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; Kraus MF, 1997, BRAIN INJURY, V11, P455, DOI 10.1080/026990597123430; KRAUS MF, 1995, INT J PSYCHIAT MED, V25, P39, DOI 10.2190/BXRM-3M58-WBC5-A7EL; Kraus MF, 1999, TRAUMATIC BRAIN INJU, V14, P173; KWENTUS JA, 1985, PSYCHOSOMATICS, V26, P8, DOI 10.1016/S0033-3182(85)72900-3; Lal S, 1988, Brain Inj, V2, P225, DOI 10.3109/02699058809150946; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1987, HEAD INJURY; Levine A M, 1988, Brain Inj, V2, P165, DOI 10.3109/02699058809150940; LEVINE DN, 1982, NEUROLOGY, V32, P267, DOI 10.1212/WNL.32.3.267; Lewis A. J., 1942, P ROY SOC MED, V35, P607; LEWIS L, 1990, J NERV MENT DIS, V178, P69, DOI 10.1097/00005053-199002000-00001; LISHMAN WA, 1973, PSYCHOL MED, V3, P304, DOI 10.1017/S003329170004959X; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; LISHMAN WA, 1968, BRIT J PSYCHIAT, V114, P373, DOI 10.1192/bjp.114.509.373; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; Mattes J A, 1990, J Neuropsychiatry Clin Neurosci, V2, P159; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; Meyer A, 1904, AM J INSANITY, V60, P373, DOI 10.1176/ajp.60.3.373; NASRALLAH HA, 1981, PSYCHOSOMATICS, V22, P359; NICKELS JL, 1994, BRAIN INJURY, V8, P709, DOI 10.3109/02699059409151025; NIRENBERG AA, 1994, AM J PSYCHIAT, V151, P1069; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PAUL SM, 1988, J CLIN PSYCHIAT, V49, P13; PRESTON GC, 1989, PSYCHOPHARMACOLOGY, V97, P222, DOI 10.1007/BF00442254; ROBINSON RG, 1988, AM J PSYCHIAT, V145, P172; RUEDRICH SL, 1983, AM J PSYCHIAT, V140, P928; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; SARAN AS, 1985, J CLIN PSYCHIAT, V46, P335; SCHWAB RS, 1969, J AMER MED ASSOC, V208, P1168, DOI 10.1001/jama.208.7.1168; SELZER ML, 1968, AM J PSYCHIAT, V124, P1028, DOI 10.1176/ajp.124.8.1028; Silver Jonathan M., 1994, P631; Silver Jonathan M., 1994, P313; SOHLBERG MM, 1989, J CLIN EXP NEUROPSYC, V11, P871, DOI 10.1080/01688638908400941; SOKOL MS, 1988, PSYCHOPHARMACOLOGY D, P147; STARKSTEIN SE, 1987, BRAIN, V110, P1045, DOI 10.1093/brain/110.4.1045; STUART JW, 1988, J CLIN PSYCHIAT, V49, P74; Symonds C P, 1937, Proc R Soc Med, V30, P1081; Taverni JP, 1998, BRAIN INJURY, V12, P77; TENNANT FS, 1987, AM J PSYCHIAT, V144, P813; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; TIMBLE MR, 1987, EPILEPSIA S3, V28, pS37; VANREEKUM R, 1995, BRAIN INJURY, V9, P49, DOI 10.3109/02699059509004571; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VECHT CJ, 1995, ARCH NEUROL-CHICAGO, V32, P792; WHITLOCK FA, 1977, AUST NZ J PSYCHIAT, V11, P127, DOI 10.3109/00048677709159549; Wilson BA, 1997, J INT NEUROPSYCH SOC, V3, P487, DOI 10.1017/S1355617797004876; YUDOFSKY SC, 1987, PSYCHIAT ANN, V17, P397, DOI 10.3928/0048-5713-19870601-11	85	193	197	0	9	AMER PSYCHIATRIC PRESS, INC	WASHINGTON	1400 K ST, N W, STE 1101, WASHINGTON, DC 20005 USA	0033-3182			PSYCHOSOMATICS	Psychosomatics	MAR-APR	2000	41	2					95	103		10.1176/appi.psy.41.2.95			9	Psychiatry; Psychology	Psychiatry; Psychology	294PZ	WOS:000085920700002	10749946				2021-06-18	
J	Buki, A; Siman, R; Trojanowski, JQ; Povlishock, JT				Buki, A; Siman, R; Trojanowski, JQ; Povlishock, JT			The role of calpain-mediated spectrin proteolysis in traumatically induced axonal injury	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						axonal injury; calcium; calpain; cytoskeleton; immunohistochemistry; spectrin; traumatic brain injury	SPINAL-CORD INJURY; DOUBLE ANTIGEN LOCALIZATION; EXPERIMENTAL BRAIN INJURY; NEUROFILAMENT SUBUNITS; AXOLEMMAL PERMEABILITY; MONOCLONAL-ANTIBODIES; NERVOUS-SYSTEM; I ACTIVATION; RAT; DEGRADATION	In animals and man, traumatic brain injury (TBI) results in axonal injury (AI) that contributes to morbidity and mortality. Such injured axone show progressive change leading to axonal disconnection. Although several theories implicate calcium in the pathogenesis of AI, experimental studies have failed to confirm its pivotal role. To explore the contribution of Ca2+-induced proteolysis to axonal injury, this study was undertaken in an animal model of TBI employing antibodies targeting both calpain-mediated spectrin proteolysis (CMSP) and focal neurofilament compaction (NFC), a marker of intra-axonal cytoskeletal perturbation, at 15-120 minutes (min) postinjury. Light microscopy (LM) revealed that TBI consistently evoked focal, intra-axonal CMSP that was spatially and temporally correlated with NFC. These changes were seen at 15 min postinjury with significantly increasing number of axone demonstrating CMSP immunoreactivity over time postinjury. Electron microscopy (EM) demonstrated that at 15 min postinjury CMSP was confined primarily to the subaxolemmal network. With increasing survival (30-110 min) CMSP filled the axoplasm proper. These findings provide the first direct evidence for focal CMSP in the pathogenesis of generalized/diffuse AI. Importantly, they also reveal an initial subaxolemmal involvement prior to induction of a more widespread axoplasmic change indicating a spatial-temporal compartmentalization of the calcium-induced proteolytic process that may be amenable to rapid therapeutic intervention.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Richmond, VA 23298 USA; Univ Pecs, Sch Med, Dept Neurosurg, H-7624 Pecs, Hungary; Cephalon, W Chester, PA USA; Hosp Univ Penn, Sch Med, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	Povlishock, JT (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Anat, Richmond, VA 23298 USA.		Buki, Andras/B-1960-2010		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020193] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 20193] Funding Source: Medline		BALENTINE JD, 1978, LAB INVEST, V39, P254; BALENTINE JD, 1982, LAB INVEST, V47, P286; Banik NL, 1997, BRAIN RES, V752, P301, DOI 10.1016/S0006-8993(96)01488-6; BANIK NL, 1997, ANN NY ACAD SCI, V844, P120; Bartus RT, 1998, BRAIN RES, V790, P1, DOI 10.1016/S0006-8993(97)01414-5; Bartus RT, 1997, NEUROSCIENTIST, V3, P314, DOI 10.1177/107385849700300513; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Davis JQ, 1996, J CELL BIOL, V135, P1355, DOI 10.1083/jcb.135.5.1355; DIAKOWSKI W, 1995, BIOCHEMISTRY-US, V34, P13252, DOI 10.1021/bi00040a041; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; Faddis BT, 1997, J NEUROSCI, V17, P951; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; FRAPPIER T, 1992, EUR J BIOCHEM, V205, P85, DOI 10.1111/j.1432-1033.1992.tb16754.x; GOODMAN SR, 1995, BRAIN RES BULL, V36, P593, DOI 10.1016/0361-9230(94)00264-2; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; Grofova I, 1998, J COMP NEUROL, V395, P359; HU RJ, 1991, J BIOL CHEM, V266, P18200; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; LEE VMY, 1987, J NEUROSCI, V7, P3474; LEVEY AI, 1986, J HISTOCHEM CYTOCHEM, V34, P1449, DOI 10.1177/34.11.2430010; LI ZH, 1995, NEUROCHEM INT, V27, P425, DOI 10.1016/0197-0186(95)00024-3; Li ZH, 1996, NEUROCHEM RES, V21, P441, DOI 10.1007/BF02527708; MACK TGA, 1995, EUR J CELL BIOL, V67, P218; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; Okonkwo DO, 1998, BRAIN RES, V784, P1, DOI 10.1016/S0006-8993(97)01075-5; PETERS LL, 1991, J CELL BIOL, V114, P1233, DOI 10.1083/jcb.114.6.1233; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; POLLERBERG GE, 1986, NATURE, V324, P462, DOI 10.1038/324462a0; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; Povlishock JT, 1996, ACT NEUR S, V66, P81; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; SIMAN R, 1989, J NEUROSCI, V9, P1579; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; Springer JE, 1997, J NEUROCHEM, V69, P1592, DOI 10.1046/j.1471-4159.1997.69041592.x; STONE JP, 1999, IN PRESS ACTA NEUROP; Tymianski M, 1996, NEUROSURGERY, V38, P1176; Wang KKW, 1998, J BIOL CHEM, V273, P22490, DOI 10.1074/jbc.273.35.22490; ZAGON IS, 1986, J NEUROSCI, V6, P2977; Zhao XR, 1998, J CEREBR BLOOD F MET, V18, P161, DOI 10.1097/00004647-199802000-00006; Zhou M, 1995, J NEUROSCI METH, V62, P149, DOI 10.1016/0165-0270(95)00069-0	51	193	197	0	8	AMER ASSN NEUROPATHOLOGISTS INC	LAWRENCE	1041 NEW HAMPSHIRE ST, LAWRENCE, KS 66044 USA	0022-3069			J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	APR	1999	58	4					365	375					11	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	188FY	WOS:000079837200007	10218632				2021-06-18	
J	BINDER, LM				BINDER, LM			ASSESSMENT OF MALINGERING AFTER MILD HEAD TRAUMA WITH THE PORTLAND DIGIT RECOGNITION TEST	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							INJURY; SYMPTOMS; CONCUSSION	The Portland Digit Recognition Test (PDRT), a forced-choice measure of recognition memory designed for the purpose of assessing the possibility of malingering, was administered to two groups of clinically referred patients seeking financial compensation for injuries including a mild head trauma group and a brain dysfunction group and also to a third group with brain dysfunction not seeking compensation. The three groups were equated on verbal acquisition ability. The two groups seeking remuneration were impaired on the PDRT compared with the group not seeking compensation, and the brain dysfunction group seeking compensation was superior to the mild head trauma group. Cut-off scores were established for the group with brain dysfunction not seeking compensation, and 33% of the mild head trauma group and 18% of the brain dysfunction group seeking compensation fell below the cut-offs. Significantly below chance scores were found in 17% and 3% of the two groups seeking compensation, respectively. Difficult PDRT items were more sensitive than easy items to compensation-related deficit. The PDRT is recommended as a measure of exaggeration of memory deficits.		BINDER, LM (corresponding author), VET ADM MED CTR,PSYCHOL SERV 116B,POB 1034,PORTLAND,OR 97207, USA.						Barth JT., 1989, MILD HEAD INJURY, P257; Benton A. L, 1989, MILD HEAD INJURY, P3; Binder Laurence M, 1990, Clin Neuropsychol, V4, P25, DOI 10.1080/13854049008401494; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BINDER LM, 1987, J CLIN EXP NEUROPSYC, V9, P167, DOI 10.1080/01688638708405357; BINDER LM, 1991, PSYCHOBIOLOGICAL FAC; BRANDT J, 1988, CLIN ASSESSMENT MALI, P65; CHELUNE GJ, 1991, NEUROLOGY, V41, P399, DOI 10.1212/WNL.41.3.399; COHEN J, 1988, STATISTICAL POWER AN; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; FRANZEN M D, 1990, Neuropsychology Review, V1, P247, DOI 10.1007/BF01112573; Glass G. V., 1981, META ANAL SOCIAL RES; GRONWALL D, 1974, LANCET, V2, P605; Gronwall D, 1989, MILD HEAD INJURY, P153; Hayes RL, 1989, MILD HEAD INJURY, P54; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEVIN HS, 1989, MILD MODERATE HEAD I, P153; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; MILLER H, 1961, BRIT MED J, V1, P992, DOI 10.1136/bmj.1.5231.992; POVLISHOCK JT, 1989, MILD HEAD INJURY, P37; RAO SM, 1989, ARCH NEUROL-CHICAGO, V46, P40, DOI 10.1001/archneur.1989.00520370042017; ROGERS R, 1988, CLIN ASSESSMENT MALI, P293; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; SCHRETLEN DJ, 1988, CLIN PSYCHOL REV, V8, P451, DOI 10.1016/0272-7358(88)90074-8; TEASDALE G, 1974, LANCET, V2, P81; TRIMBLE MR, 1981, POST TRAUMATIC NEURO; WIENS AN, 1988, CLIN NEUROPSYCHOL, V2, P67, DOI DOI 10.1080/13854048808520087; Willis SC., 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI [10.1037/1040-3590.3.2.175, DOI 10.1037/1040-3590.3.2.175]; WRIGHTSON P, 1981, INJURY, V12, P445, DOI 10.1016/0020-1383(81)90161-3	34	193	195	0	6	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	MAR	1993	15	2					170	182		10.1080/01688639308402555			13	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	KX465	WOS:A1993KX46500003	8491843				2021-06-18	
J	Stender, J; Gosseries, O; Bruno, MA; Charland-Verville, V; Vanhaudenhuyse, A; Demertzi, A; Chatelle, C; Thonnard, M; Thibaut, A; Heine, L; Soddu, A; Boly, M; Schnakers, C; Gjedde, A; Laureys, S				Stender, Johan; Gosseries, Olivia; Bruno, Marie-Aurelie; Charland-Verville, Vanessa; Vanhaudenhuyse, Audrey; Demertzi, Athena; Chatelle, Camille; Thonnard, Marie; Thibaut, Aurore; Heine, Lizette; Soddu, Andrea; Boly, Melanie; Schnakers, Caroline; Gjedde, Albert; Laureys, Steven			Diagnostic precision of PET imaging and functional MRI in disorders of consciousness: a clinical validation study	LANCET			English	Article							REGIONAL CEREBRAL METABOLISM; BRAIN-DAMAGED PATIENTS; VEGETATIVE STATE; RECOVERY; SCALE; COMA; AWARENESS; NETWORKS; INJURY; RECOMMENDATIONS	Background Bedside clinical examinations can have high rates of misdiagnosis of unresponsive wakefulness syndrome (vegetative state) or minimally conscious state. The diagnostic and prognostic usefulness of neuroimaging-based approaches has not been established in a clinical setting. We did a validation study of two neuroimaging-based diagnostic methods: PET imaging and functional MRI (fMRI). Methods For this clinical validation study, we included patients referred to the University Hospital of Lige, Belgium, between January, 2008, and June, 2012, who were diagnosed by our unit with unresponsive wakefulness syndrome, locked-in syndrome, or minimally conscious state with traumatic or non-traumatic causes. We did repeated standardised clinical assessments with the Coma Recovery Scale-Revised (CRS-R), cerebral F-18 -fluorodeoxyglucose (FDG) PET, and fMRI during mental activation tasks. We calculated the diagnostic accuracy of both imaging methods with CRS-R diagnosis as reference. We assessed outcome after 12 months with the Glasgow Outcome Scale-Extended. Findings We included 41 patients with unresponsive wakefulness syndrome, four with locked-in syndrome, and 81 in a minimally conscious state (48=traumatic, 78=non-traumatic; 110=chronic, 16=subacute). F-18-FDG PET had high sensitivity for identification of patients in a minimally conscious state (93%, 95% CI 85-98) and high congruence (85%, 77-90) with behavioural CRS-R scores. The active fMRI method was less sensitive at diagnosis of a minimally conscious state (45%, 30-61) and had lower overall congruence with behavioural scores (63%, 51-73) than PET imaging. F-18-FDG PET correctly predicted outcome in 75 of 102 patients (74%, 64-81), and fMRI in 36 of 65 patients (56%, 43-67). 13 of 41 (32%) of the behaviourally unresponsive patients (ie, diagnosed as unresponsive with CRS-R) showed brain activity compatible with (minimal) consciousness (ie, activity associated with consciousness, but diminished compared with fully conscious individuals) on at least one neuroimaging test; 69% of these (9 of 13) patients subsequently recovered consciousness. Interpretation Cerebral F-18-FDG PET could be used to complement bedside examinations and predict long-term recovery of patients with unresponsive wakefulness syndrome. Active fMRI might also be useful for differential diagnosis, but seems to be less accurate.	[Stender, Johan; Gosseries, Olivia; Bruno, Marie-Aurelie; Charland-Verville, Vanessa; Vanhaudenhuyse, Audrey; Demertzi, Athena; Chatelle, Camille; Thonnard, Marie; Thibaut, Aurore; Heine, Lizette; Boly, Melanie; Schnakers, Caroline; Laureys, Steven] Univ Liege, Cyclotron Res Ctr, Coma Sci Grp, B-4000 Liege, Belgium; [Stender, Johan; Gosseries, Olivia; Bruno, Marie-Aurelie; Charland-Verville, Vanessa; Vanhaudenhuyse, Audrey; Demertzi, Athena; Chatelle, Camille; Thonnard, Marie; Thibaut, Aurore; Heine, Lizette; Boly, Melanie; Schnakers, Caroline; Laureys, Steven] Univ Liege, Dept Neurol, B-4000 Liege, Belgium; [Stender, Johan; Gosseries, Olivia; Bruno, Marie-Aurelie; Charland-Verville, Vanessa; Vanhaudenhuyse, Audrey; Demertzi, Athena; Chatelle, Camille; Thonnard, Marie; Thibaut, Aurore; Heine, Lizette; Boly, Melanie; Schnakers, Caroline; Laureys, Steven] Univ Hosp Liege, Liege, Belgium; [Soddu, Andrea] Univ Western Ontario, Brain & Mind Inst, Dept Phys & Astron, London, ON, Canada; [Stender, Johan; Gjedde, Albert] Univ Copenhagen, Dept Neurosci & Pharmacol, Copenhagen, Denmark	Laureys, S (corresponding author), Univ Liege, Cyclotron Res Ctr, Coma Sci Grp, B-4000 Liege, Belgium.	steven.laureys@ulg.ac.be	Laureys, Steven/A-3349-2011; Demertzi, Athena/I-1251-2019; Gosseries, Olivia/AAB-6469-2020; Gjedde, Albert/I-2452-2019; Laureys, Steven/AAN-2097-2021; Gjedde, Albert/U-3751-2019; Vanhaudenhuyse, Audrey/AAP-2455-2020; Soddu, Andrea/K-7087-2014; Thibaut, Aurore/U-8101-2019	Demertzi, Athena/0000-0001-8021-3759; Laureys, Steven/0000-0002-3096-3807; Gjedde, Albert/0000-0002-3756-7401; Soddu, Andrea/0000-0001-6833-745X; Boly, Melanie/0000-0001-9584-0907; Chatelle, Camille/0000-0002-7526-2107; Heine, Lizette/0000-0003-1369-8199; Gosseries, Olivia/0000-0001-9011-7496	Belgian National Funds for Scientific Research (FNRS)Fonds de la Recherche Scientifique - FNRS; Fonds Leon Fredericq; European CommissionEuropean CommissionEuropean Commission Joint Research Centre; James McDonnell Foundation; Mind Science Foundation; French Speaking Community Concerted Research Action; University of Copenhagen; University of LiegeUniversity of Liege	The Belgian National Funds for Scientific Research (FNRS), Fonds Leon Fredericq, the European Commission, the James McDonnell Foundation, the Mind Science Foundation, the French Speaking Community Concerted Research Action, the University of Copenhagen, and the University of Liege.	Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; Boly M, 2007, NEUROIMAGE, V36, P979, DOI 10.1016/j.neuroimage.2007.02.047; Boly M, 2008, LANCET NEUROL, V7, P1013, DOI 10.1016/S1474-4422(08)70219-9; Chatelle C, 2012, J NEUROL NEUROSUR PS, V83, P1233, DOI 10.1136/jnnp-2012-302987; Childs NL, 1996, BRIT MED J, V313, P944; Coleman MR, 2009, BRAIN, V132, P2541, DOI 10.1093/brain/awp183; Cruse D, 2012, NEUROLOGY, V78, P816, DOI 10.1212/WNL.0b013e318249f764; Cruse D, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-18; Cruse D, 2011, LANCET, V378, P2088, DOI 10.1016/S0140-6736(11)61224-5; Demertzi A, 2013, CURR OPIN NEUROBIOL, V23, P239, DOI 10.1016/j.conb.2012.12.003; Estraneo A, 2010, NEUROLOGY, V75, P239, DOI 10.1212/WNL.0b013e3181e8e8cc; Ferreira N, 2007, MED LAW, V26, P387; Fins JJ, 2008, AM J BIOETHICS, V8, P3, DOI 10.1080/15265160802318113; Fins JJ, 2010, HASTINGS CENT REP, V40, P21, DOI 10.1353/hcr.0.0257; Gevers S, 2005, EUR J HEALTH LAW, V12, P347, DOI 10.1163/157180905775088513; Giacino JT, 2009, PROG BRAIN RES, V177, P33, DOI 10.1016/S0079-6123(09)17704-X; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GIACINO JT, 1995, ARCH PHYS MED REHAB, V76, P205; Gosseries O, BRAIN INJ IN PRESS; Grill E, 2013, ARCH PHYS MED REHAB, V94, P1870, DOI 10.1016/j.apmr.2012.10.040; Hirschberg R, 2011, NEUROL CLIN, V29, P773, DOI 10.1016/j.ncl.2011.07.009; Langsjo JW, 2012, J NEUROSCI, V32, P4935, DOI 10.1523/JNEUROSCI.4962-11.2012; Laureys S, 2004, LANCET NEUROL, V3, P537, DOI 10.1016/S1474-4422(04)00852-X; Laureys S, 1999, J NEUROL NEUROSUR PS, V67, P121, DOI 10.1136/jnnp.67.1.121; Laureys S, 2012, NEUROIMAGE, V61, P478, DOI 10.1016/j.neuroimage.2011.12.041; Laureys S, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-68; Lochlainn MN, 2013, IRISH J MED SCI, V182, P7, DOI 10.1007/s11845-012-0825-6; Lovstad M, 2010, J HEAD TRAUMA REHAB, V25, P349, DOI 10.1097/HTR.0b013e3181cec841; Luaute J, 2010, NEUROLOGY, V75, P246, DOI 10.1212/WNL.0b013e3181e8e8df; Manning J, 2012, J LAW MED, V19, P430; Maquet P, 2000, J SLEEP RES, V9, P207; Monti MM, 2012, ANNU REV CLIN PSYCHO, V8, P431, DOI 10.1146/annurev-clinpsy-032511-143050; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.080523; Overgaard M, 2011, LANCET, V378, P2052, DOI 10.1016/S0140-6736(11)61591-2; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; Perry JE, 2005, ANN INTERN MED, V143, P744, DOI 10.7326/0003-4819-143-10-200511150-00012; Pisa FE, 2014, J HEAD TRAUMA REHAB, V29, pE23, DOI 10.1097/HTR.0b013e3182a4469f; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Schnakers C, 2008, BRAIN INJURY, V22, P786, DOI 10.1080/02699050802403557; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Schnakers C, 2009, NEUROCASE, V15, P271, DOI 10.1080/13554790902724904; Seel RT, 2010, ARCH PHYS MED REHAB, V91, P1795, DOI 10.1016/j.apmr.2010.07.218; Shulman RG, 2009, P NATL ACAD SCI USA, V106, P11096, DOI 10.1073/pnas.0903941106; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Thibaut A, 2012, J REHABIL MED, V44, P487, DOI 10.2340/16501977-0940; TOMMASINO C, 1995, J NEUROSURG ANESTH, V7, P109, DOI 10.1097/00008506-199504000-00006; Vanhaudenhuyse A, 2011, J COGNITIVE NEUROSCI, V23, P570, DOI 10.1162/jocn.2010.21488; Vanhaudenhuyse A, 2010, BRAIN, V133, P161, DOI 10.1093/brain/awp313	51	192	198	4	37	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 9	2014	384	9942					514	522		10.1016/S0140-6736(14)60042-8			9	Medicine, General & Internal	General & Internal Medicine	AM9JR	WOS:000340198300030	24746174		Y	N	2021-06-18	
J	Zhuo, JC; Xu, S; Proctor, JL; Mullins, RJ; Simon, JZ; Fiskum, G; Gullapalli, RP				Zhuo, Jiachen; Xu, Su; Proctor, Julie L.; Mullins, Roger J.; Simon, Jonathan Z.; Fiskum, Gary; Gullapalli, Rao P.			Diffusion kurtosis as an in vivo imaging marker for reactive astrogliosis in traumatic brain injury	NEUROIMAGE			English	Article						Magnetic resonance imaging; Diffusion tensor imaging; Diffusion Kurtosis Imaging; Traumatic brain injury; Astrogliosis; Rat brain	CONTROLLED CORTICAL IMPACT; GAUSSIAN WATER DIFFUSION; Q-SPACE; AXONAL INJURY; SIGNAL DECAY; TENSOR; MATTER; TIME; COEFFICIENT; ANISOTROPY	Diffusion Kurtosis Imaging (DKI) provides quantifiable information on the non-Gaussian behavior of water diffusion in biological tissue. Changes in water diffusion tensor imaging (DTI) parameters and DKI parameters in several white and gray matter regions were investigated in a mild controlled cortical impact (CCI) injury rat model at both the acute (2 h) and the sub-acute (7 days) stages following injury. Mixed model ANOVA analysis revealed significant changes in temporal patterns of both DTI and DKI parameters in the cortex, hippocampus, external capsule and corpus callosum. Post-hoc tests indicated acute changes in mean diffusivity (MD) in the bilateral cortex and hippocampus (p<0.0005) and fractional anisotropy (FA) in ipsilateral cortex (p<0.0005), hippocampus (p = 0.014), corpus callosum (p = 0.031) and contralateral external capsule (p = 0.011). These changes returned to baseline by the sub-acute stage. However, mean kurtosis (MK) was significantly elevated at the sub-acute stages in all ipsilateral regions and scaled inversely with the distance from the impacted site (cortex and corpus callosum: p<0.0005; external capsule: p = 0.003; hippocampus: p = 0.011). Further, at the sub-acute stage increased MK was also observed in the contralateral regions compared to baseline (cortex: p = 0.032; hippocampus: p = 0.039) while no change was observed with MD and FA. An increase in mean kurtosis was associated with increased reactive astrogliosis from immunohistochemistry analysis. Our results suggest that DKI is sensitive to microstructural changes associated with reactive astrogliosis which may be missed by standard DTI parameters alone. Monitoring changes in MK allows the investigation of molecular and morphological changes in vivo due to reactive astrogliosis and may complement information available from standard DTI parameters. To date the use of diffusion tensor imaging has been limited to study changes in white matter integrity following traumatic insults. Given the sensitivity of DKI to detect microstructural changes even in the gray matter in vivo, allows the extension of the technique to understand patho-morphological changes in the whole brain following a traumatic insult. (C) 2011 Elsevier Inc. All rights reserved.	[Zhuo, Jiachen; Xu, Su; Mullins, Roger J.; Gullapalli, Rao P.] Univ Maryland Sch Med, Dept Diagnost Radiol & Nucl Med, Baltimore, MD 21201 USA; [Zhuo, Jiachen; Simon, Jonathan Z.] Univ Maryland, Dept Elect & Comp Engn, College Pk, MD 20742 USA; [Proctor, Julie L.; Fiskum, Gary] Univ Maryland Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; [Proctor, Julie L.; Fiskum, Gary] Univ Maryland Sch Med, Ctr Shock Trauma & Anesthesiol Res, Baltimore, MD 21201 USA; [Mullins, Roger J.] Univ Maryland Sch Med, Program Neurosci, Baltimore, MD 21201 USA; [Simon, Jonathan Z.] Univ Maryland, Dept Biol, College Pk, MD 20742 USA	Gullapalli, RP (corresponding author), Univ Maryland Sch Med, Dept Diagnost Radiol & Nucl Med, 22 S Greene St, Baltimore, MD 21201 USA.	rgullapalli@umm.edu	Simon, Jonathan Z/A-8196-2008	Simon, Jonathan Z/0000-0003-0858-0698; Mullins, Roger/0000-0002-0561-4402	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1S10RR019935]; US ArmyUnited States Department of Defense [W81XWH-07-2-0118, W81XWH-09-2-0187]; Office of Naval ResearchOffice of Naval Research [N000141010886]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10RR019935] Funding Source: NIH RePORTER	The authors thank Dr. Lily Wang, University of Georgia for help with statistical analysis, Dr. Jens Jensen, New York University and Dr. Angelos Barmpoutis, University of Florida for their insights into analysis of diffusion kurtosis data. The authors also thank Dr. Yihong Yang, Chief of MRI Section, National Institute of Drug Abuse, for providing useful comments on the manuscript. This work was partly supported by grants from the NIH (1S10RR019935), US Army (W81XWH-07-2-0118 & W81XWH-09-2-0187), and the Office of Naval Research (N000141010886).	Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; Armitage PA, 1998, MAGN RESON MATER PHY, V6, P28, DOI 10.1016/S1352-8661(98)00007-6; Assaf Y, 1998, J MAGN RESON, V131, P69, DOI 10.1006/jmre.1997.1313; Assaf Y, 2000, MAGNET RESON MED, V43, P191, DOI 10.1002/(SICI)1522-2594(200002)43:2<191::AID-MRM5>3.0.CO;2-B; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bulakbasi N, 2003, AM J NEURORADIOL, V24, P225; Cercignani M, 2001, J NEUROL NEUROSUR PS, V70, P311, DOI 10.1136/jnnp.70.3.311; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Cheung MM, 2009, NEUROIMAGE, V45, P386, DOI 10.1016/j.neuroimage.2008.12.018; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Cohen Y, 2002, NMR BIOMED, V15, P516, DOI 10.1002/nbm.778; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Falangola MF, 2008, J MAGN RESON IMAGING, V28, P1345, DOI 10.1002/jmri.21604; Farrell JAD, 2010, MAGN RESON MED, V63, P1323, DOI 10.1002/mrm.22389; Finch CE, 2003, NEUROBIOL AGING, V24, pS123, DOI 10.1016/S0197-4580(03)00051-4; Guo AC, 2002, RADIOLOGY, V224, P177, DOI 10.1148/radiol.2241010637; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hui ES, 2008, NEUROIMAGE, V42, P122, DOI 10.1016/j.neuroimage.2008.04.237; Immonen RJ, 2009, EXP NEUROL, V215, P29, DOI 10.1016/j.expneurol.2008.09.009; Jansen JFA, 2010, AM J NEURORADIOL, V31, P741, DOI 10.3174/ajnr.A1919; Jensen JH, 2010, NMR BIOMED, V23, P698, DOI 10.1002/nbm.1518; Jensen JH, 2005, MAGNET RESON MED, V53, P1432, DOI 10.1002/mrm.20508; Jiang Q, 2011, NMR BIOMED, V24, P1119, DOI 10.1002/nbm.1667; Kiselev VG, 2007, MAGN RESON MED, V57, P464, DOI 10.1002/mrm.21164; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Lu HZ, 2006, NMR BIOMED, V19, P236, DOI 10.1002/nbm.1020; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Maier SE, 2004, MAGN RESON MED, V51, P321, DOI 10.1002/mrm.10685; Maier SE, 2001, RADIOLOGY, V219, P842, DOI 10.1148/radiology.219.3.r01jn02842; Maier SE, 2008, MAGN RESON IMAGING, V26, P897, DOI 10.1016/j.mri.2008.01.042; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Milne ML, 2009, J MAGN RESON, V197, P87, DOI 10.1016/j.jmr.2008.12.006; Mulkern RV, 1999, NMR BIOMED, V12, P51, DOI 10.1002/(SICI)1099-1492(199902)12:1<51::AID-NBM546>3.0.CO;2-E; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; Niendorf T, 1996, MAGN RESON MED, V36, P847, DOI 10.1002/mrm.1910360607; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Paxinos G, 1986, RAT BRAIN STEREOTAXI; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; Raab P, 2010, RADIOLOGY, V254, P876, DOI 10.1148/radiol.09090819; Shanmuganathan K, 2004, AM J NEURORADIOL, V25, P539; SHAW G, 2010, NEUROLOGY       1109; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; TERRY RD, 1987, ANN NEUROL, V21, P530, DOI 10.1002/ana.410210603; Trampel R, 2006, MAGN RESON MED, V56, P733, DOI 10.1002/mrm.21045; Veraart J, 2011, MAGN RESON MED, V65, P138, DOI 10.1002/mrm.22603; Wieshmann UC, 1999, NEUROIMAGE, V10, P225, DOI 10.1006/nimg.1999.0456; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wu EX, 2010, NMR BIOMED, V23, P836, DOI 10.1002/nbm.1506; Zelaya F, 1999, MAGN RESON IMAGING, V17, P331, DOI 10.1016/S0730-725X(98)00192-1; ZHUO J, 2011, P INT SOC MAGN RES M, P6633	59	192	203	1	25	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119			NEUROIMAGE	Neuroimage	JAN 2	2012	59	1			SI		467	477		10.1016/j.neuroimage.2011.07.050			11	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	838CX	WOS:000296265500046	21835250	Green Accepted			2021-06-18	
J	Mihalik, JP; Bell, DR; Marshall, SW; Guskiewicz, KM				Mihalik, Jason P.; Bell, David R.; Marshall, Stephen W.; Guskiewicz, Kevin M.			Measurement of head impacts in collegiate football players: An investigation of positional and event-type differences	NEUROSURGERY			English	Article						biomechanics; concussion; helmet; injury threshold; mild traumatic brain injury	PROFESSIONAL FOOTBALL; CONCUSSION; INJURY	OBJECTIVE: There exists a need to better understand the biomechanical forces associated with head impacts in American football. The purpose of this study was to investigate whether or not differences in head accelerations existed between different player positions and different event types in collegiate football. We also sought to identify whether or not any associations existed between high-magnitude impacts and location of head impacts. METHODS: We conducted a prospective field study in which accelerometers were embedded in the football helmets of 72 collegiate football players. Linear accelerations of all head impacts sustained over the course of the 2005 and 2006 National Collegiate Athletic Association football seasons were collected. One-way analyses of variance and chi(2) tests of association assessed positional, event type, and location of head impact differences. RESULTS: Football players consistently sustained head impacts between 21 and 23 g. Positional differences were identified within our sample. Impacts sustained during helmets-only practices were greater than those sustained in games or scrimmages. There was an association between position and high-magnitude impacts, as well as between high-magnitude impacts and location of head impact, with the likelihood of impacts to the top of the head much higher than those to the front, back, left, and right sides. CONCLUSION: Less than 0.35% of impacts exceeding theoretical injury thresholds resulted in concussion. More injury data are required before any theoretical thresholds for injury can be confirmed. Coaches and sports medicine professionals should recognize that head impacts sustained in helmets-only practices are as severe as games or scrimmages; there seem to be no "light" days for football players.	[Mihalik, Jason P.; Bell, David R.; Guskiewicz, Kevin M.] Univ N Carolina, Curriculum Human Movement Sci, Dept Exercise & Sport Sci, Chapel Hill, NC 27599 USA; [Marshall, Stephen W.; Guskiewicz, Kevin M.] Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC 27599 USA; [Marshall, Stephen W.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA	Guskiewicz, KM (corresponding author), Univ N Carolina, Curriculum Human Movement Sci, Dept Exercise & Sport Sci, 209 Fetzer Gymnasium CB 8700,S Rd, Chapel Hill, NC 27599 USA.	gus@email.unc.edu	Mihalik, Jason P/E-7059-2010	Mihalik, Jason/0000-0001-6085-8322; Marshall, Stephen/0000-0002-2664-9233; Guskiewicz, Kevin/0000-0002-8682-2130	NCIPC CDC HHS [5-R49-CE000196] Funding Source: Medline; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE000196] Funding Source: NIH RePORTER		Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Heck J F, 1996, J Athl Train, V31, P31; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; MIHALIK JP, 2005, J ATHL TRAINING, V40, pS82; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Nightingale RW, 1996, J BONE JOINT SURG AM, V78A, P412, DOI 10.2106/00004623-199603000-00013; Nightingale RW, 2000, J BIOMECH, V33, P191, DOI 10.1016/S0021-9290(99)00156-6; Nightingale RW, 1997, SPINE, V22, P2380, DOI 10.1097/00007632-199710150-00012; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; PUDENZ RH, 1946, J NEUROSURG, V3, P487, DOI 10.3171/jns.1946.3.6.0487; SCHNAKENBERGOTT SD, 2006, 114 ANN CONV AM PSYC; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Torg JS, 1991, ATHLETIC INJURIES HE, P97; WINTER DA, 2005, BIOMECHANICS MOTOR C, P59	20	192	193	0	27	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	DEC	2007	61	6					1229	1235		10.1227/01.neu.0000306101.83882.c8			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	246YN	WOS:000252044400032	18162902				2021-06-18	
J	Agha, A; Rogers, B; Mylotte, D; Taleb, F; Tormey, W; Phillips, J; Thompson, CJ				Agha, A; Rogers, B; Mylotte, D; Taleb, F; Tormey, W; Phillips, J; Thompson, CJ			Neuroendocrine dysfunction in the acute phase of traumatic brain injury	CLINICAL ENDOCRINOLOGY			English	Article							GROWTH-HORMONE DEFICIENCY; SUBCUTANEOUS GLUCAGON; ADULT PATIENTS; PITUITARY; SEVERITY; CORTISOL; HYPOPITUITARISM; ABNORMALITIES; RELEASE; TESTS	BACKGROUND Pituitary hormone abnormalities have been reported in up to 50% of survivors of traumatic brain injury (TBI) who were investigated several months or longer following the event. The frequency of pituitary dysfunction in the early post-TBI period is unknown. AIM To evaluate the prevalence of anterior and posterior pituitary dysfunction in the early phase following TBI. SUBJECTS Fifty consecutive patients admitted to the neurosurgical unit with severe or moderate TBI [initial Glasgow Coma Scale (GCS) score 3-13], and 31 matched healthy control volunteers were studied. METHODS The glucagon stimulation test (GST) was performed at a median of 12 days (range 7-20) following TBI. Baseline thyroid function, PRL, IGF-1, gonadotrophins, testosterone or oestradiol, plasma sodium, plasma and urine osmolalities or the standard observed water deprivation test were performed. The control subjects underwent the GST for GH and cortisol responses; other parameters were compared to locally derived reference ranges. RESULTS Control data indicated that peak serum GH of > 5 ng/ml and cortisol > 450 nmol/l following glucagon stimulation should be taken as normal. Nine TBI patients (18%) had GH response < 5 ng/ml (12 mU/l). Eight patients (16%) had peak cortisol responses < 450 nmol/l. Compared to controls, basal cortisol values were significantly lower in patients with subnormal cortisol responses to glucagon and significantly higher in patients with normal cortisol responses (P < 0.05). GH and cortisol deficiencies were unrelated to patient age, BMI, initial GCS or IGF-1 values (P > 0.05). Forty patients (80%) had gonadotrophin deficiency, with low sex steroid concentrations, which was unrelated to the presence of hyperprolactinaemia. In males there was a positive correlation between serum testosterone concentration and GCS (r = 0.32, P = 0.04). One patient had TSH deficiency. Hyperprolactinaemia was present in 26 patients (52%) and serum PRL levels correlated negatively with the GCS score (r =-0.36, P = 0.011). Thirteen patients (26%) had cranial diabetes insipidus (DI) and seven (14%) had syndrome of inappropriate ADH secretion. CONCLUSION Our data show that post-traumatic neuroendocrine abnormalities occur early and with high frequency, which may have significant implications for recovery and rehabilitation of TBI patients.	Beaumont Hosp, Acad Dept Endocrinol, Dublin 9, Ireland; Beaumont Hosp, Dept Neurosurg, Dublin 9, Ireland; Beaumont Hosp, Dept Clin Chem, Dublin 9, Ireland	Thompson, CJ (corresponding author), Beaumont Hosp, Dept Endocrinol, Beaumont Rd, Dublin 9, Ireland.	chris.thompson@beaumont.i.e					Attanasio A, 1998, J CLIN ENDOCR METAB, V83, P379; BARTON RN, 1987, J TRAUMA, V27, P384, DOI 10.1097/00005373-198704000-00007; Baylis P, 2001, PRINCIPLES PRACTICE; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; BINNERTS A, 1992, AM J CLIN NUTR, V55, P918; BJORK S, 1989, ACTA PAEDIATR SCAND, P55; BOHNEN N, 1993, EUR NEUROL, V33, P77, DOI 10.1159/000116907; CAIN JP, 1972, CAN MED ASSOC J, V107, P617; Cernak I, 1999, BRAIN INJURY, V13, P1005; CHIOLERO R, 1988, J TRAUMA, V28, P1368, DOI 10.1097/00005373-198809000-00011; Christiansen JS, 2001, J CLIN ENDOCR METAB, V86, P1868; Colao A, 1999, J CLIN ENDOCR METAB, V84, P1919, DOI 10.1210/jc.84.6.1919; Cooper MS, 2003, NEW ENGL J MED, V348, P727, DOI 10.1056/NEJMra020529; CUNEO RC, 1991, J APPL PHYSIOL, V70, P695; Della Corte F, 1998, CRIT CARE MED, V26, P1419; EDWARDS OM, 1986, MEDICINE, V65, P281; ELGIN RG, 1987, P NATL ACAD SCI USA, V84, P3254, DOI 10.1073/pnas.84.10.3254; Escamilla RF, 1942, J CLIN ENDOCRINOL, V2, P65, DOI 10.1210/jcem-2-2-65; HACKL JM, 1991, INTENS CARE MED, V17, P25, DOI 10.1007/BF01708405; HOFFMAN DM, 1994, LANCET, V343, P1064, DOI 10.1016/S0140-6736(94)90181-3; JEEVANANDAM M, 1995, METABOLISM, V44, P1205, DOI 10.1016/0026-0495(95)90017-9; KAUFMAN HH, 1993, MED CLIN N AM, V77, P43, DOI 10.1016/S0025-7125(16)30271-1; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; KING LR, 1981, NEUROSURGERY, V9, P229, DOI 10.1227/00006123-198109000-00002; KLASBEEK WD, 1980, J NEUROSURG, V53, P519; Leong KS, 2001, CLIN ENDOCRINOL, V54, P463, DOI 10.1046/j.1365-2265.2001.01169.x; LEVITAN D, 1984, AM J NEPHROL, V4, P99, DOI 10.1159/000166785; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; LITTLEY MD, 1989, CLIN ENDOCRINOL, V31, P527, DOI 10.1111/j.1365-2265.1989.tb01276.x; MATSUURA H, 1985, NEUROSURGERY, V16, P791, DOI 10.1227/00006123-198506000-00009; Mazaux JM, 1998, DISABIL REHABIL, V20, P435, DOI 10.3109/09638289809166108; MEROLA B, 1993, J CLIN ENDOCR METAB, V77, P1658, DOI 10.1210/jc.77.6.1658; MONSON JP, 2003, EUR J ENDOCRINOL S2, V148, P9; NOEL GL, 1972, J CLIN ENDOCR METAB, V35, P840, DOI 10.1210/jcem-35-6-840; Orme SM, 1996, CLIN ENDOCRINOL, V45, P135, DOI 10.1046/j.1365-2265.1996.d01-1562.x; Rahim A, 1996, CLIN ENDOCRINOL, V45, P557; RAO RH, 1987, METABOLISM, V36, P658, DOI 10.1016/0026-0495(87)90150-8; ROSS R, 1991, CLIN ENDOCRINOL, V35, P47, DOI 10.1111/j.1365-2265.1991.tb03495.x; SMITH GL, 1984, MOL CELL ENDOCRINOL, V34, P83, DOI 10.1016/0303-7207(84)90058-3; SPATHIS GS, 1974, CLIN ENDOCRINOL, V3, P175, DOI 10.1111/j.1365-2265.1974.tb01793.x; SPRATT DI, 1992, J CLIN ENDOCR METAB, V75, P1562, DOI 10.1210/jc.75.6.1562; Takala J, 1999, NEW ENGL J MED, V341, P785, DOI 10.1056/NEJM199909093411102; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE G, 1992, J NEUROTRAUM, V9, pS249; TRAINER PJ, 1995, BARTS ENDOCRINE PROT, P6; TWEEDLE D, 1972, BRIT J CLIN PRACT, V27, P130; Van Baalen B, 2003, DISABIL REHABIL, V25, P9, DOI 10.1080/713813430; Van den Berghe G, 2003, ENDOCRIN METAB CLIN, V32, P385, DOI 10.1016/S0889-8529(03)00005-7; Van den Berghe G, 1998, J CLIN ENDOCR METAB, V83, P1827, DOI 10.1210/jc.83.6.1827; VERBALIS JG, 1989, BAILLIERE CLIN ENDOC, V3, P499, DOI 10.1016/S0950-351X(89)80013-8; World Health Organization, 1980, INT CLASS IMP DIS HA; YUAN XQ, 1991, FRONT NEUROENDOCRIN, V12, P209	52	192	204	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0300-0664	1365-2265		CLIN ENDOCRINOL	Clin. Endocrinol.	MAY	2004	60	5					584	591		10.1111/j.1365-2265.2004.02023.x			8	Endocrinology & Metabolism	Endocrinology & Metabolism	814ZE	WOS:000221011800009	15104561				2021-06-18	
J	Chen, S; Pickard, JD; Harris, NG				Chen, S; Pickard, JD; Harris, NG			Time course of cellular pathology after controlled cortical impact injury	EXPERIMENTAL NEUROLOGY			English	Article						controlled cortical impact; trauma; animal model; neurofilament; gliosis; microglia; macrophage; oligodendrocyte; precursor; microvessel; histopathology	TRAUMATIC BRAIN-INJURY; CHONDROITIN-SULFATE PROTEOGLYCAN; ENDOTHELIAL GROWTH-FACTOR; FOCAL CEREBRAL-ISCHEMIA; NITRIC-OXIDE SYNTHASE; REACTIVE ASTROCYTES; NESTIN EXPRESSION; HEAD-INJURY; ADULT-RAT; NEUROFILAMENT COMPACTION	Several different models of brain trauma are currently used and each simulates different aspects of the clinical condition and to varying degrees of accuracy. While numerous studies have characterized the cellular pathology after weight-drop or fluid percussion injury, detailed information on the histopathology that evolves after the controlled cortical impact model is incomplete. We have determined the spatiotemporal pathologies of neuronal, axonal, vascular, and macro- and microglial elements at 1, 4, 7, and 28 days after moderate controlled cortical impact injury. Neuronal injury identified by pyknotic perikarya and disrupted neurofilament-stained axonal profiles were evident by I day in ipsilateral cortex and hippocampus and at later times in the thalamus. glial fibrillary acidic protein-reactive astrocytes were more widespread, reaching a maximum immunointensity at 4 days across the ipsilateral hemisphere but declining to control levels thereafter. Microglia/macrophage-OX42 staining was initially restricted to the contusion site and then later to the thalamus, consistent with the pattern of neuronal injury. Increases in nestin immunoreactivity-a postulated marker of neural progenitor cells, and in NG2 proteoglycan-a marker of oligodendrocyte precursor cells, were detected by I day, reaching maximal immunointensity at 4-7 days after injury. Mean density and diameter of cortical microvessels was significantly reduced and increased respectively but only at the initial time points, suggesting that some degree of vascular remodeling takes place after injury. We discuss these results in light of recent evidence that suggests there may be some degree of endogenous repair after central nervous system injury. (C) 2003 Elsevier Science (USA). All rights reserved.	Univ Cambridge, Ctr Brain Repair, Cambridge CB2 2PY, England; Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Cambridge, England; Cheng Hsin Gen Hosp, Dept Phys Med & Rehabil, Taipei, Taiwan	Harris, NG (corresponding author), Univ Cambridge, Ctr Brain Repair, Forvie Site,Box 85,Robinson Way, Cambridge CB2 2PY, England.	ngh22@cam.ac.uk	Chen, Szu-Fu/K-5040-2012; Messier, Claude/A-2322-2008; Ritter, Stefanie L/D-9312-2012	Messier, Claude/0000-0002-4791-1763; Harris, Neil/0000-0002-1965-6750			AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; Araque A, 2001, ANNU REV PHYSIOL, V63, P795, DOI 10.1146/annurev.physiol.63.1.795; Baldwin SA, 1996, GLIA, V16, P266; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; Cherian L, 2000, J NEUROPHYSIOL, V83, P2171; Cobbs CS, 1997, BRAIN RES, V751, P336, DOI 10.1016/S0006-8993(96)01429-1; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Daneyemez M, 1999, NEUROSCIENCE, V92, P783, DOI 10.1016/S0306-4522(99)00035-4; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Di Bello IC, 1999, J NEUROCYTOL, V28, P365, DOI 10.1023/A:1007069815302; Dietrich WD, 1999, J NEUROTRAUM, V16, P567, DOI 10.1089/neu.1999.16.567; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DOU CL, 1994, J NEUROSCI, V14, P7616; Duggal N, 1997, BRAIN RES, V768, P1, DOI 10.1016/S0006-8993(97)00588-X; DunnMeynell AA, 1997, BRAIN RES, V761, P25, DOI 10.1016/S0006-8993(97)00210-2; EAYRS JT, 1954, J ANAT, V88, P164; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Gahm C, 2000, NEUROSURGERY, V46, P169; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Goss JR, 1998, EXP NEUROL, V149, P301, DOI 10.1006/exnr.1997.6712; HA M, 1996, AM J PHYSIOL, V271, pH1717; Hermann DM, 2000, ACTA NEUROPATHOL, V99, P147, DOI 10.1007/PL00007418; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hill SJ, 1996, J NEUROPATH EXP NEUR, V55, P1221, DOI 10.1097/00005072-199612000-00005; Hill-Felberg SJ, 1999, J NEUROSCI RES, V57, P271, DOI 10.1002/(SICI)1097-4547(19990715)57:2<271::AID-JNR13>3.0.CO;2-Z; Holmin S, 1997, EUR J NEUROSCI, V9, P65, DOI 10.1111/j.1460-9568.1997.tb01354.x; Holmin S, 2001, NEUROSCI LETT, V314, P151, DOI 10.1016/S0304-3940(01)02292-3; Kaya SS, 1999, BRAIN RES, V840, P153, DOI 10.1016/S0006-8993(99)01757-6; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; Keirstead HS, 1998, GLIA, V22, P161, DOI 10.1002/(SICI)1098-1136(199802)22:2<161::AID-GLIA7>3.0.CO;2-A; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Leonard JR, 1997, EXP NEUROL, V143, P177, DOI 10.1006/exnr.1996.6366; Levasseur JE, 2000, J NEUROTRAUM, V17, P101, DOI 10.1089/neu.2000.17.101; LEVINE JM, 1994, J NEUROSCI, V14, P4716; Levine JM, 2001, TRENDS NEUROSCI, V24, P39, DOI 10.1016/S0166-2236(00)01691-X; Li Y, 1999, BRAIN RES, V838, P1, DOI 10.1016/S0006-8993(99)01502-4; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; Lin B, 2001, J NEUROTRAUM, V18, P389, DOI 10.1089/089771501750170958; LIN RCS, 1995, NEUROBIOL DIS, V2, P79, DOI 10.1006/nbdi.1995.0008; Lu J, 2001, J NEUROTRAUM, V18, P399, DOI 10.1089/089771501750170976; MATHEW P, 1994, ACTA NEUROCHIR, P428; MATHEWSON AJ, 1985, BRAIN RES, V327, P61, DOI 10.1016/0006-8993(85)91499-4; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Morshead CM, 2001, CURR OPIN NEUROBIOL, V11, P59, DOI 10.1016/S0959-4388(00)00174-4; Nag S, 1997, J NEUROPATH EXP NEUR, V56, P912, DOI 10.1097/00005072-199708000-00009; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; Okonkwo DO, 1998, BRAIN RES, V784, P1, DOI 10.1016/S0006-8993(97)01075-5; Ong WY, 1999, NEUROSCIENCE, V92, P83, DOI 10.1016/S0306-4522(98)00751-9; Posmantur RM, 2000, EXP NEUROL, V161, P15, DOI 10.1006/exnr.1999.7244; Prewitt CMF, 1997, EXP NEUROL, V148, P433, DOI 10.1006/exnr.1997.6694; RAGHAVENDRA RV, 2000, EXP NEUROL, V161, P102, DOI DOI 10.1006/exnr.1999.7269; Richards HK, 2001, J CEREBR BLOOD F MET, V21, P779, DOI 10.1097/00004647-200107000-00002; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Rogatsky G, 1996, J Basic Clin Physiol Pharmacol, V7, P23; Rosenstein JM, 1998, P NATL ACAD SCI USA, V95, P7086, DOI 10.1073/pnas.95.12.7086; Schwab JM, 2001, J NEUROTRAUM, V18, P377, DOI 10.1089/089771501750170930; Seri B, 2001, J NEUROSCI, V21, P7153, DOI 10.1523/JNEUROSCI.21-18-07153.2001; Soares HD, 1995, J NEUROSCI, V15, P8223; Sorensen JC, 1996, EXP BRAIN RES, V112, P203; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; TAKAMIYA Y, 1988, DEV BRAIN RES, V38, P201, DOI 10.1016/0165-3806(88)90045-4; Tanaka K, 2001, NEUROREPORT, V12, P2169, DOI 10.1097/00001756-200107200-00025; Watanabe H, 1997, NEUROSCI LETT, V233, P25, DOI 10.1016/S0304-3940(97)00617-4; WOLSWIJK G, 1989, DEVELOPMENT, V105, P387; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	73	192	196	1	11	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JUL	2003	182	1					87	102		10.1016/S0014-4886(03)00002-5			16	Neurosciences	Neurosciences & Neurology	695NQ	WOS:000183837400008	12821379				2021-06-18	
J	POVLISHOCK, JT				POVLISHOCK, JT			PATHOBIOLOGY OF TRAUMATICALLY INDUCED AXONAL INJURY IN ANIMALS AND MAN	ANNALS OF EMERGENCY MEDICINE			English	Article; Proceedings Paper	SYMP ON NEUROTRAUMA : CONCEPTS, CURRENT PRACTICE AND EMERGING THERAPIES	JUN 11-12, 1992	DEARBORN, MI	WAYNE STATE UNIV SCH MED, DEPT EMERGENCY MED		AXONAL INJURY; NEUROTRAUMA		Study objectives: Although diffuse axonal injury is recognized as a consistent feature of traumatic brain injury, there is confusion regarding its pathogenesis. To provide insight into its pathogenesis, animal models of traumatic brain injury complemented by post mortem human analyses were used. Design: In animals, anterograde tracers together with antibodies targeting the neurofilament subunits were used in light and electron microscopic analyses of axonal injury. In humans, antibodies to the neurofilament subunits also were used to follow diffuse axonal injury. Animals were followed from minutes to months after injury, whereas humans were studied from six hours to 59 days after injury. Measurements and main results: In neither animals nor humans did traumatic brain injury cause direct axonal tearing. Instead, the traumatic brain injury triggered focal intra-axonal change in the 68-kd neurofilament subunit, which became disordered in its alignment and resulted in impaired axoplasmic transport. This caused axonal swelling and disconnection. The sequence of axonal change was similar in animals and man; however, its temporal progression was slower in humans. Conclusion: Traumatically induced axonal damage is triggered first by focal intra-axonal change involving the neurofilament subunits. This neurofilament change is due to either direct mechanical failure of the axonal cytoskeleton or the initiation of a biochemical event that causes neurofilament disassembly. In general, the temporal progression of the intra-axonal changes that lead to ultimate disconnection is influenced by the severity of the traumatic injury and the species evaluated.		POVLISHOCK, JT (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT ANAT,POB 709,MCV STN,RICHMOND,VA 23298, USA.							0	192	197	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	JUN	1993	22	6					980	986		10.1016/S0196-0644(05)82738-6			7	Emergency Medicine	Emergency Medicine	LE338	WOS:A1993LE33800004	8503536				2021-06-18	
J	Avants, BB; Tustison, NJ; Stauffer, M; Song, G; Wu, BH; Gee, JC				Avants, Brian B.; Tustison, Nicholas J.; Stauffer, Michael; Song, Gang; Wu, Baohua; Gee, James C.			The Insight ToolKit image registration framework	FRONTIERS IN NEUROINFORMATICS			English	Article						registration; MRI; brain; open-source; death	TRAUMATIC BRAIN-INJURY; MULTIVARIATE-ANALYSIS; CORTICAL THICKNESS; MR-IMAGES; DEFORMATION; MORPHOMETRY; ANTS; MAPS; ITK	Publicly available scientific resources help establish evaluation standards, provide a platform for teaching and improve reproducibility. Version 4 of the Insight ToolKit (ITK4) seeks to establish new standards in publicly available image registration methodology. ITK4 makes several advances in comparison to previous versions of ITK. ITK4 supports both multivariate images and objective functions; it also unifies high-dimensional (deformation field) and low-dimensional (affine) transformations with metrics that are reusable across transform types and with composite transforms that allow arbitrary series of geometric mappings to be chained together seamlessly. Metrics and optimizers take advantage of multi-core resources, when available. Furthermore, ITK4 reduces the parameter optimization burden via principled heuristics that automatically set scaling across disparate parameter types (rotations vs. translations). A related approach also constrains steps sizes for gradient-based optimizers. The result is that tuning for different metrics and/or image pairs is rarely necessary allowing the researcher to more easily focus on design/comparison of registration strategies. In total, the ITK4 contribution is intended as a structure to support reproducible research practices, will provide a more extensive foundation against which to evaluate new work in image registration and also enable application level programmers a broad suite of tools on which to build. Finally, we contextualize this work with a reference registration evaluation study with application to pediatric brain labeling.(1)	[Avants, Brian B.; Stauffer, Michael; Song, Gang; Wu, Baohua; Gee, James C.] Univ Penn, Dept Radiol, Penn Image Comp & Sci Lab, Philadelphia, PA 19104 USA; [Tustison, Nicholas J.] Univ Virginia, Dept Radiol & Med Imaging, Charlottesville, VA USA	Avants, BB (corresponding author), Univ Penn, Dept Radiol, 3600 Market St,Suite 370, Philadelphia, PA 19104 USA.	avants@grasp.cis.upenn.edu		avants, brian/0000-0002-4212-3362; TUSTISON, NICHOLAS/0000-0001-9418-5103			Ackerman Michael J, 2003, AMIA Annu Symp Proc, P773; Avants B, 2008, ACAD RADIOL, V15, P1360, DOI 10.1016/j.acra.2008.07.007; Avants BB, 2011, NEUROIMAGE, V54, P2033, DOI 10.1016/j.neuroimage.2010.09.025; Baloch S, 2009, NEUROIMAGE, V45, pS73, DOI 10.1016/j.neuroimage.2008.10.048; Bearden CE, 2007, CEREB CORTEX, V17, P1889, DOI 10.1093/cercor/bhl097; Buckheit J. B., 1995, WAVELETS STAT, P55, DOI [10.1007/978-1-4612-2544-7_5., DOI 10.1007/978-1-4612-2544-7_5]; Chen ML, 2008, MED PHYS, V35, P81, DOI 10.1118/1.2816107; Cheung MR, 2009, ACAD RADIOL, V16, P351, DOI 10.1016/j.acra.2008.09.011; Christensen GE, 1996, IEEE T IMAGE PROCESS, V5, P1435, DOI 10.1109/83.536892; Dubb A, 2005, ACAD RADIOL, V12, P3, DOI 10.1016/j.acra.2004.06.009; Fedorov Andriy, 2011, Open Neuroimag J, V5, P186, DOI 10.2174/1874440001105010186; Floca R, 2007, COMPUT METH PROG BIO, V87, P81, DOI 10.1016/j.cmpb.2007.04.009; Gaser C, 2001, NEUROIMAGE, V13, P1140, DOI 10.1006/nimg.2001.0771; Gousias IS, 2008, NEUROIMAGE, V40, P672, DOI 10.1016/j.neuroimage.2007.11.034; Hermosillo G, 2002, INT J COMPUT VISION, V50, P329, DOI 10.1023/A:1020830525823; Jack CR, 2010, LANCET NEUROL, V9, P119, DOI 10.1016/S1474-4422(09)70299-6; Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6; Kikinis R, 2011, IEEE ENG MED BIO, P6982, DOI 10.1109/IEMBS.2011.6091765; Kim J, 2008, NEUROIMAGE, V39, P1014, DOI 10.1016/j.neuroimage.2007.10.005; Kim J, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00052; Kim J, 2010, J NEUROTRAUM, V27, P1399, DOI 10.1089/neu.2009.1215; Klein S, 2010, IEEE T MED IMAGING, V29, P196, DOI 10.1109/TMI.2009.2035616; Lepore N, 2006, LECT NOTES COMPUT SC, V4190, P191; Metz CT, 2011, MED IMAGE ANAL, V15, P238, DOI 10.1016/j.media.2010.10.003; Miller MI, 2005, P NATL ACAD SCI USA, V102, P9685, DOI 10.1073/pnas.0503892102; Murphy K, 2011, IEEE T MED IMAGING, V30, P1901, DOI 10.1109/TMI.2011.2158349; Nielsen M, 1997, J MATH IMAGING VIS, V7, P291, DOI 10.1023/A:1008282127190; Peyrat JM, 2010, IEEE T MED IMAGING, V29, P1351, DOI 10.1109/TMI.2009.2038908; Riddle WR, 2004, MAGN RESON IMAGING, V22, P769, DOI 10.1016/j.mri.2004.01.078; Rohlfing T, 2006, PSYCHIAT RES-NEUROIM, V146, P157, DOI 10.1016/j.pscychresns.2005.12.002; Rueckert D, 1999, IEEE T MED IMAGING, V18, P712, DOI 10.1109/42.796284; Shelton D, 2005, MED IMAGE ANAL, V9, P605, DOI 10.1016/j.media.2005.04.011; Studholme C, 2007, LECT NOTES COMPUT SC, V4792, P311; Tustison N, 2011, J NEUROTRAUM, V28, pA111; van Dalen JA, 2004, PHYS MED BIOL, V49, P5393, DOI 10.1088/0031-9155/49/23/014; Vercauteren T, 2009, NEUROIMAGE, V45, pS61, DOI 10.1016/j.neuroimage.2008.10.040; Yoo TS, 2002, STUD HEALTH TECHNOL, V85, P586; Yushkevich PA, 2010, NEUROIMAGE, V50, P434, DOI 10.1016/j.neuroimage.2009.12.007	38	191	192	2	11	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1662-5196			FRONT NEUROINFORM	Front. Neuroinformatics	APR 28	2014	8								44	10.3389/fninf.2014.00044			13	Mathematical & Computational Biology; Neurosciences	Mathematical & Computational Biology; Neurosciences & Neurology	AZ3EE	WOS:000348109700001	24817849	DOAJ Gold, Green Published			2021-06-18	
J	Lipton, ML; Kim, N; Zimmerman, ME; Kim, M; Stewart, WF; Branch, CA; Lipton, RB				Lipton, Michael L.; Kim, Namhee; Zimmerman, Molly E.; Kim, Mimi; Stewart, Walter F.; Branch, Craig A.; Lipton, Richard B.			Soccer Heading Is Associated with White Matter Microstructural and Cognitive Abnormalities	RADIOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; NEUROPSYCHOLOGICAL IMPAIRMENT; FOOTBALL SOCCER; INTEGRITY	Purpose: To investigate the association of soccer heading with subclinical evidence of traumatic brain injury. Materials and Methods: With institutional review board approval and compliance with HIPAA guidelines, 37 amateur soccer players (mean age, 30.9 years; 78% [29] men, 22% [eight] women) gave written informed consent and completed a questionnaire to quantify heading in the prior 12 months and lifetime concussions. Diffusion-tensor magnetic resonance (MR) imaging at 3.0 T was performed (32 directions; b value, 800 sec/mm(2); 2 x 2 x 2-mm voxels). Cognitive function was measured by using a computerized battery of tests. Voxelwise linear regression (heading vs fractional anisotropy [FA]) was applied to identify significant regional associations. FA at each location and cognition were tested for a nonlinear relationship to heading by using an inverse logit model that incorporated demographic covariates and history of concussion. Results: Participants had headed 32-5400 times (median, 432 times) over the previous year. Heading was associated with lower FA at three locations in temporo-occipital white matter with a threshold that varied according to location (885-1550 headings per year) (P < .00001). Lower levels of FA were also associated with poorer memory scores (P < .00001), with a threshold of 1800 headings per year. Lifetime concussion history and demographic features were not significantly associated with either FA or cognitive performance. Conclusion: Heading is associated with abnormal white matter microstructure and with poorer neurocognitive performance. This relationship is not explained by a history of concussion. (C)RSNA, 2013	[Lipton, Michael L.; Kim, Namhee; Branch, Craig A.] Yeshiva Univ Albert Einstein Coll Med, Gruss Magnet Resonance Res Ctr, Bronx, NY 10461 USA; [Lipton, Michael L.; Kim, Namhee; Branch, Craig A.] Yeshiva Univ Albert Einstein Coll Med, Dept Radiol, Bronx, NY 10461 USA; [Lipton, Michael L.] Yeshiva Univ Albert Einstein Coll Med, Dept Psychiat & Behav Sci, Bronx, NY 10461 USA; [Lipton, Michael L.] Yeshiva Univ Albert Einstein Coll Med, Dominick P Purpura Dept Neurosci, Bronx, NY 10461 USA; [Zimmerman, Molly E.; Lipton, Richard B.] Yeshiva Univ Albert Einstein Coll Med, Saul R Korey Dept Neurol, Bronx, NY 10461 USA; [Kim, Mimi; Lipton, Richard B.] Yeshiva Univ Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10461 USA; [Branch, Craig A.] Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; [Lipton, Michael L.] Montefiore Med Ctr, Dept Radiol, Bronx, NY 10467 USA; [Stewart, Walter F.] Sutter Hlth, Sacramento, CA USA	Lipton, ML (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Gruss Magnet Resonance Res Ctr, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	michael.lipton@einstein.yu.edu	Lipton, Richard B/B-5060-2011		National Headache Foundation; Migraine Research Fund; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS082432, K23NS047256] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG027734, R01AG022374, R01AG012101, P01AG003949, K23AG030857, R01AG025119, R01AG034119] Funding Source: NIH RePORTER	M.L.L. No relevant conflicts of interest to disclose. N.K. No relevant conflicts of interest to disclose. M.E.Z. No relevant conflicts of interest to disclose. M. K. No relevant conflicts of interest to disclose. W. F. S. No relevant conflicts of interest to disclose. C. A. B. No relevant conflicts of interesst to disclose. R. B. L. Financial activities related to the present article: none to disclose. Financial activities not related to the present article: receives research support from the National Headache Foundation, and the Migraine Research Fund; serves on the editorial boards of Neurology and Cephalalgia and as senior advisor to Headache; has reviewed for the National Institute on Aging and National Institute of Neurological Disorders and Stroke; holds stock options in eNeura Therapeutics (a company without commercial products); serves as consultant, advisory board member, or has received honoraria from Allergan, American Headache Society, Autonomic Technologies, Boehringer-Ingelheim Pharmaceuticals, Boston Scientific, Bristol Myers Squibb, Cognimed, Colucid, Eli Lilly, eNeura Therapeutics, GlaxoSmithKline, MAP, Merck, Nautilus Neuroscience, Novartis, NuPathe, Vedanta, and Zogenix. Other relationships: none to disclose.	Collie A, 2003, J INT NEUROPSYCH SOC, V9, P419, DOI 10.1017/S1355617703930074; Fox J., 2011, R COMPANION APPL REG, V2; Friston K., 1995, HUM BRAIN MAPP, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; Gysland SM, 2012, ANN BIOMED ENG, V40, P14, DOI 10.1007/s10439-011-0421-3; HOLLAND PW, 1977, COMMUN STAT A-THEOR, V6, P813, DOI 10.1080/03610927708827533; Kerut Edmund Kenneth, 2008, J La State Med Soc, V160, P95; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Koutures CG, 2010, PEDIATRICS, V125, P410, DOI 10.1542/peds.2009-3009; LINDSTROM MJ, 1990, BIOMETRICS, V46, P673, DOI 10.2307/2532087; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; Maruff P, 2009, ARCH CLIN NEUROPSYCH, V24, P165, DOI 10.1093/arclin/acp010; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Palacios EM, 2013, CORTEX, V49, P646, DOI 10.1016/j.cortex.2012.02.011; Patlak M, 2002, IS SOCCER BAD CHILDR; Pinheiro J., 2000, MIXED EFFECTS MODELS; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Rutherford A, 2003, NEUROPSYCHOL REV, V13, P153, DOI 10.1023/A:1025525613477; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Smith SM, 2007, NAT PROTOC, V2, P499, DOI 10.1038/nprot.2007.45; Spiotta AM, 2012, NEUROSURGERY, V70, P1, DOI 10.1227/NEU.0b013e31823021b2; Spiotta AM, 2011, WORLD NEUROSURG, V75, P175, DOI 10.1016/j.wneu.2011.01.019; Stephens R, 2005, CHILD NEUROPSYCHOL, V11, P513, DOI 10.1080/092970490959629	28	191	192	1	41	RADIOLOGICAL SOC NORTH AMERICA	OAK BROOK	820 JORIE BLVD, OAK BROOK, IL 60523 USA	0033-8419			RADIOLOGY	Radiology	SEP	2013	268	3					850	857		10.1148/radiol.13130545			8	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	205CR	WOS:000323419300026	23757503	Bronze, Green Published			2021-06-18	
J	Ji, J; Kline, AE; Amoscato, A; Samhan-Arias, AK; Sparvero, LJ; Tyurin, VA; Tyurina, YY; Fink, B; Manole, MD; Puccio, AM; Okonkwo, DO; Cheng, JP; Alexander, H; Clark, RSB; Kochanek, PM; Wipf, P; Kagan, VE; Bayir, H				Ji, Jing; Kline, Anthony E.; Amoscato, Andrew; Samhan-Arias, Alejandro K.; Sparvero, Louis J.; Tyurin, Vladimir A.; Tyurina, Yulia Y.; Fink, Bruno; Manole, Mioara D.; Puccio, Ava M.; Okonkwo, David O.; Cheng, Jeffrey P.; Alexander, Henry; Clark, Robert S. B.; Kochanek, Patrick M.; Wipf, Peter; Kagan, Valerian E.; Bayir, Huelya			Lipidomics identifies cardiolipin oxidation as a mitochondrial target for redox therapy of brain injury	NATURE NEUROSCIENCE			English	Article							CYTOCHROME-C RELEASE; PERMEABILITY TRANSITION; SUPEROXIDE-DISMUTASE; PEROXIDATION; NITROXIDE; DAMAGE; STRESS; LIPIDS; SCAVENGERS; REDUCTION	The brain contains a highly diversified complement of molecular species of a mitochondria-specific phospholipid, cardiolipin, which, because of its polyunsaturation, can readily undergo oxygenation. Using global lipidomics analysis in experimental traumatic brain injury (TBI), we found that TBI was accompanied by oxidative consumption of polyunsaturated cardiolipin and the accumulation of more than 150 new oxygenated molecular species of cardiolipin. RNAi-based manipulations of cardiolipin synthase and cardiolipin levels conferred resistance to mechanical stretch, an in vitro model of traumatic neuronal injury, in primary rat cortical neurons. By applying a brain-permeable mitochondria-targeted electron scavenger, we prevented cardiolipin oxidation in the brain, achieved a substantial reduction in neuronal death both in vitro and in vivo, and markedly reduced behavioral deficits and cortical lesion volume. We conclude that cardiolipin oxygenation generates neuronal death signals and that prevention of it by mitochondria-targeted small molecule inhibitors represents a new target for neuro-drug discovery.	[Ji, Jing; Alexander, Henry; Clark, Robert S. B.; Kochanek, Patrick M.; Bayir, Huelya] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Ji, Jing; Amoscato, Andrew; Samhan-Arias, Alejandro K.; Sparvero, Louis J.; Tyurin, Vladimir A.; Tyurina, Yulia Y.; Kagan, Valerian E.; Bayir, Huelya] Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA USA; [Ji, Jing; Amoscato, Andrew; Samhan-Arias, Alejandro K.; Sparvero, Louis J.; Tyurin, Vladimir A.; Tyurina, Yulia Y.; Kagan, Valerian E.; Bayir, Huelya] Univ Pittsburgh, Ctr Free Rad & Antioxidant Hlth, Pittsburgh, PA USA; [Ji, Jing; Kline, Anthony E.; Manole, Mioara D.; Cheng, Jeffrey P.; Alexander, Henry; Clark, Robert S. B.; Kochanek, Patrick M.; Bayir, Huelya] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; [Kline, Anthony E.; Cheng, Jeffrey P.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA; [Kline, Anthony E.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA USA; [Fink, Bruno] Noxygen Sci Transfer & Diagnost GmbH, Elzach, Germany; [Manole, Mioara D.; Clark, Robert S. B.; Kochanek, Patrick M.; Bayir, Huelya] Univ Pittsburgh, Childrens Hosp Pittsburgh, Med Ctr, Pittsburgh, PA 15213 USA; [Puccio, Ava M.; Okonkwo, David O.] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Wipf, Peter] Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15260 USA	Bayir, H (corresponding author), Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15260 USA.	bayihx@ccm.upmc.edu	Wipf, Peter/AAG-1771-2021; Samhan-Arias, Alejandro/J-3593-2014; Ji, J/O-2816-2013; Kochanek, Patrick M/D-2371-2015	Wipf, Peter/0000-0001-7693-5863; Samhan-Arias, Alejandro/0000-0001-9602-4848; Kochanek, Patrick M/0000-0002-2627-913X; Tyurina, Yulia/0000-0003-0287-2091; Cheng, Jeffrey/0000-0001-8285-3207; Kagan, Valerian E./0000-0002-7245-1885; Tyurin, Vladimir/0000-0002-3474-1697; Amoscato, Andrew/0000-0002-1340-9150	US National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS061817, NS060005, HL070755, ES020693, NS076511, U19AI068021]; US National Institute for Occupational Safety and HealthUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH) [OH008282]; US ArmyUnited States Department of Defense [W81XWH-09-0187]; La Junta de Extremadura y el Fondo Social Europeo [2010063090]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD069620] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL070755] Funding Source: NIH RePORTER; NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTHUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH) [R01OH008282] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [U19AI068021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [R01ES020693] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS076511, R01NS060005, R01NS061817] Funding Source: NIH RePORTER	The authors would like to thank J. Lewis for the technical assistance of unbiased stereology for cortical lesion volume, J. Davoren for the preparation of XJB-5-131 and Y.M. Frapart (Laboratoire de Chimie Biochimie Pharmacologique et Toxicologique, Universite Paris Descartes) for providing an L-band EPR spectrometer for in vivo imaging. This study was supported in part by grants from the US National Institutes of Health (NS061817 (H.B.), NS060005 (A.E.K.), HL070755 (V.E.K.), ES020693 (Y.Y.T. and V.E.K.), NS076511 and U19AI068021 (H.B. and V.E.K.)), the US National Institute for Occupational Safety and Health (OH008282 to V.E.K.) and the US Army (W81XWH-09-0187 to P.M.K.). A.K.S.-A. is a recipient of a research fellowship from La Junta de Extremadura y el Fondo Social Europeo (2010063090).	Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Bayir H, 2007, ANN NEUROL, V62, P154, DOI 10.1002/ana.21168; Betaneli V, 2012, BIOPHYS J, V102, P523, DOI 10.1016/j.bpj.2011.12.049; Bobko AA, 2007, FREE RADICAL BIO MED, V42, P404, DOI 10.1016/j.freeradbiomed.2006.11.007; Broadhurst CL, 2002, COMP BIOCHEM PHYS B, V131, P653, DOI 10.1016/S1096-4959(02)00002-7; CHAN PH, 1980, J NEUROCHEM, V35, P1004, DOI 10.1111/j.1471-4159.1980.tb07100.x; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Deng-Bryant Y, 2008, J CEREBR BLOOD F MET, V28, P1114, DOI 10.1038/jcbfm.2008.10; Fan P, 2003, J NEUROTRAUM, V20, P437, DOI 10.1089/089771503765355513; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Kagan VE, 2005, NAT CHEM BIOL, V1, P223, DOI 10.1038/nchembio727; Kiebish MA, 2008, J NEUROCHEM, V106, P299, DOI 10.1111/j.1471-4159.2008.05383.x; Kline AE, 2004, J NEUROTRAUM, V21, P1712, DOI 10.1089/0897715042664849; Korytowski W, 2011, J BIOL CHEM, V286, P26334, DOI 10.1074/jbc.M110.188516; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P914, DOI 10.1097/00004647-200108000-00003; Lo EH, 2001, BRAIN RES REV, V38, P140, DOI 10.1016/S0165-0173(01)00083-2; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; MITCHELL JB, 1990, BIOCHEMISTRY-US, V29, P2802, DOI 10.1021/bi00463a024; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; Nakagawa Y, 2004, ANN NY ACAD SCI, V1011, P177, DOI 10.1196/annals.1293.018; Nomura K, 2000, BIOCHEM J, V351, P183, DOI 10.1042/0264-6021:3510183; Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498; Petrosillo G, 2006, FEBS LETT, V580, P6311, DOI 10.1016/j.febslet.2006.10.036; Petrosillo G, 2010, J PINEAL RES, V48, P340, DOI 10.1111/j.1600-079X.2010.00758.x; Ran QT, 2004, J BIOL CHEM, V279, P55137, DOI 10.1074/jbc.M410387200; RAND, 2011, INV WOUNDS WAR STUD; Rostovtseva TK, 2006, J BIOL CHEM, V281, P37496, DOI 10.1074/jbc.M602548200; Scafidi S, 2010, DEV NEUROSCI-BASEL, V32, P480, DOI 10.1159/000323178; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; Schmued LC, 2005, BRAIN RES, V1035, P24, DOI 10.1016/j.brainres.2004.11.054; SIESJO BK, 1981, J CEREBR BLOOD F MET, V1, P155, DOI 10.1038/jcbfm.1981.18; Singh IN, 2007, J NEUROSCI RES, V85, P2216, DOI 10.1002/jnr.21360; Sorice M, 2004, CELL DEATH DIFFER, V11, P1133, DOI 10.1038/sj.cdd.4401457; Soule BP, 2007, FREE RADICAL BIO MED, V42, P1632, DOI 10.1016/j.freeradbiomed.2007.02.030; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Stoyanovsky DA, 1998, FREE RADICAL BIO MED, V25, P536, DOI 10.1016/S0891-5849(98)00081-1; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Trnka J, 2008, FREE RADICAL BIO MED, V44, P1406, DOI 10.1016/j.freeradbiomed.2007.12.036; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; Wilcox CS, 2008, PHARMACOL REV, V60, P418, DOI 10.1124/pr.108.000240; Wipf P, 2005, J AM CHEM SOC, V127, P12460, DOI 10.1021/ja053679l; Zhang RL, 1999, FREE RADICAL BIO MED, V26, P1245, DOI 10.1016/S0891-5849(98)00328-1; Zhao ZS, 2010, ENDOCRINOLOGY, V151, P3038, DOI 10.1210/en.2010-0016	48	191	199	3	90	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1097-6256	1546-1726		NAT NEUROSCI	Nat. Neurosci.	OCT	2012	15	10					1407	1413		10.1038/nn.3195			7	Neurosciences	Neurosciences & Neurology	013VZ	WOS:000309335300021	22922784	Green Accepted			2021-06-18	
J	Johnson, B; Zhang, K; Gay, M; Horovitz, S; Hallett, M; Sebastianelli, W; Slobounov, S				Johnson, Brian; Zhang, Kai; Gay, Michael; Horovitz, Silvina; Hallett, Mark; Sebastianelli, Wayne; Slobounov, Semyon			Alteration of brain default network in subacute phase of injury in concussed individuals: Resting-state fMRI study	NEUROIMAGE			English	Article						Default mode network; Resting state fMRI; Sub-acute mTBI	FUNCTIONAL CONNECTIVITY; WORKING-MEMORY; MODE NETWORK; FOOTBALL PLAYERS; CINGULATE CORTEX; MILD; DYSFUNCTION; MRI; ABNORMALITIES; DEFICITS	There are a number of symptoms, both neurological and behavioral, associated with a single episode of r mild traumatic brain injury (mTBI). Neuropsychological testing and conventional neuroimaging techniques are not sufficiently sensitive to detect these changes, which adds to the complexity and difficulty in relating symptoms from mTBI to their underlying structural or functional deficits. With the inability of traditional brain imaging techniques to properly assess the severity of brain damage induced by mTBI, there is hope that more advanced neuroimaging applications will be more sensitive, as well as specific, in accurately assessing mTBI. In this study, we used resting state functional magnetic resonance imaging to evaluate the default mode network (DMN) in the subacute phase of mTBI. Fourteen concussed student-athletes who were asymptomatic based upon clinical symptoms resolution and clearance for aerobic exercise by medical professionals were scanned using resting state functional magnetic resonance imaging. Nine additional asymptomatic yet not medically cleared athletes were recruited to investigate the effect of a single episode of mTBI versus multiple mTBIs on the resting state DMN. In concussed individuals the resting state DMN showed a reduced number of connections and strength of connections in the posterior cingulate and lateral parietal cortices. An increased number of connections and strength of connections was seen in the medial prefrontal cortex. Connections between the left dorso-lateral prefrontal cortex and left lateral parietal cortex showed a significant reduction in magnitude as the number of concussions increased. Regression analysis also indicated an overall loss of connectivity as the number of mTBI episodes increased. Our findings indicate that alterations in the brain resting state default mode network in the subacute phase of injury may be of use clinically in assessing the severity of mTBI and offering some insight into the pathophysiology of the disorder. (C) 2011 Elsevier Inc. All rights reserved.	[Johnson, Brian; Zhang, Kai; Gay, Michael; Slobounov, Semyon] Penn State Univ, Dept Kinesiol, University Pk, PA 16802 USA; [Horovitz, Silvina; Hallett, Mark; Slobounov, Semyon] Natl Inst Neurol Disorders & Stroke, NIH, Bethesda, MD USA; [Sebastianelli, Wayne; Slobounov, Semyon] Penn State Univ, Dept Orthopaed & Med Rehabil, HMC, University Pk, PA 16802 USA	Slobounov, S (corresponding author), Penn State Univ, Dept Kinesiol, 19 Recreat Bldg, University Pk, PA 16802 USA.	sms18@psu.edu	Zhang, Kai/F-3261-2015	Zhang, Kai/0000-0002-5460-6150; Horovitz, Silvina G./0000-0002-5501-5918	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS056227-01A2]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS056227, ZIANS002667] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health Grant RO1 NS056227-01A2 "Identification of Athletes at Risk for Traumatic Brain Injury" awarded to Dr. Slobounov, PI.	Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Beckmann CF, 2005, PHILOS T R SOC B, V360, P1001, DOI 10.1098/rstb.2005.1634; Behzadi Y, 2007, NEUROIMAGE, V37, P90, DOI 10.1016/j.neuroimage.2007.04.042; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bergman K, 2010, J EMERG NURS, V36, P221, DOI 10.1016/j.jen.2009.07.001; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Broyd SJ, 2009, NEUROSCI BIOBEHAV R, V33, P279, DOI 10.1016/j.neubiorev.2008.09.002; Cantu R, 2006, Foundations of Sport-Related Brain Injuries, P87, DOI 10.1007/0-387-32565-4_5; Cao C, 2010, IEEE T NEUR SYS REH, V18, P11, DOI 10.1109/TNSRE.2009.2027704; Castellanos FX, 2008, BIOL PSYCHIAT, V63, P332, DOI 10.1016/j.biopsych.2007.06.025; Cavanna AE, 2006, BRAIN, V129, P564, DOI 10.1093/brain/awl004; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Damoiseaux JS, 2006, P NATL ACAD SCI USA, V103, P13848, DOI 10.1073/pnas.0601417103; Davidson PSR, 2008, NEUROPSYCHOLOGIA, V46, P1743, DOI 10.1016/j.neuropsychologia.2008.01.011; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; de la Plata CDM, 2011, ARCH NEUROL-CHICAGO, V68, P74, DOI 10.1001/archneurol.2010.342; De Luca M, 2006, NEUROIMAGE, V29, P1359, DOI 10.1016/j.neuroimage.2005.08.035; Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201; Fransson P, 2008, NEUROIMAGE, V42, P1178, DOI 10.1016/j.neuroimage.2008.05.059; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; Govind V, 2010, J NEUROTRAUM, V27, P483, DOI 10.1089/neu.2009.1159; Greicius MD, 2004, P NATL ACAD SCI USA, V101, P4637, DOI 10.1073/pnas.0308627101; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Greicius MD, 2007, BIOL PSYCHIAT, V62, P429, DOI 10.1016/j.biopsych.2006.09.020; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Kiraly MA, 2007, THESCIENTIFICWORLDJO, V7, P1768, DOI 10.1100/tsw.2007.269; Koch W, 2012, NEUROBIOL AGING, V33, P466, DOI 10.1016/j.neurobiolaging.2010.04.013; Kumar S, 2009, J NEUROTRAUM, V26, P665, DOI [10.1089/neu.2008.0644, 10.1089/neu.2008-0644]; Li R, 2011, NEUROIMAGE, V56, P1035, DOI 10.1016/j.neuroimage.2011.03.010; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI 10.1016/j.jocn.2009.02.002; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; Murphy K, 2009, NEUROIMAGE, V44, P893, DOI 10.1016/j.neuroimage.2008.09.036; *NAT COLL ATHL ASS, 2010, SPORTS MED HDB, P52; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Pomarol-Clotet E, 2008, PSYCHOL MED, V38, P1185, DOI 10.1017/S0033291708003565; Ptito A, 2007, NEUROREHABILITATION, V22, P217; Raichle ME, 2001, P NATL ACAD SCI USA, V98, P676, DOI 10.1073/pnas.98.2.676; Randolph C, 2005, J ATHL TRAINING, V40, P139; Schrader Harald, 2009, BMC Med Imaging, V9, P11, DOI 10.1186/1471-2342-9-11; Slobounov SM, 2011, NEUROIMAGE, V55, P1716, DOI 10.1016/j.neuroimage.2011.01.024; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; Slobounov S, 2006, NEUROSURGERY, V59, P134, DOI 10.1227/01.NEU.0000219197.33182.3F; Slobounov S, 2009, CLIN NEUROPHYSIOL, V120, P862, DOI 10.1016/j.clinph.2009.03.009; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Smith SM, 2009, P NATL ACAD SCI USA, V106, P13040, DOI 10.1073/pnas.0905267106; Sponheim SR, 2011, NEUROIMAGE, V54, pS21, DOI 10.1016/j.neuroimage.2010.09.007; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Theriault M, 2011, J CLIN EXP NEUROPSYC, V33, P30, DOI 10.1080/13803391003772873; van Eimeren T, 2009, ARCH NEUROL-CHICAGO, V66, P877, DOI 10.1001/archneurol.2009.97; Weinberg MS, 2010, NEUROSCIENCE, V168, P744, DOI 10.1016/j.neuroscience.2010.04.006; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Witt ST, 2010, BRAIN IMAGING BEHAV, V4, P232, DOI 10.1007/s11682-010-9102-3; Wolf RC, 2011, J PSYCHIATR NEUROSCI, V36, P402, DOI 10.1503/jpn.100150; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3	63	191	195	1	34	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	JAN 2	2012	59	1			SI		511	518		10.1016/j.neuroimage.2011.07.081			8	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	838CX	WOS:000296265500050	21846504	Green Accepted			2021-06-18	
J	Glaesmer, H; Grande, G; Braehler, E; Roth, M				Glaesmer, Heide; Grande, Gesine; Braehler, Elmar; Roth, Marcus			The German Version of the Satisfaction with Life Scale (SWLS) Psychometric Properties, Validity, and Population-Based Norms	EUROPEAN JOURNAL OF PSYCHOLOGICAL ASSESSMENT			English	Article						Satisfaction with Life Scale (SWLS); German; psychometric properties; factorial invariance; norms	TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; CONFIRMATORY FACTOR-ANALYSIS; FACTORIAL INVARIANCE; REHABILITATION OUTCOMES; UNIVERSITY-STUDENTS; SOCIAL SUPPORT; FIT INDEXES; SAMPLE; DEPRESSION	The Satisfaction with Life Scale (SWLS) is the most commonly used measure for life satisfaction. Although there are numerous studies confirming factorial validity, most studies on dimensionality are based on small samples. A controversial debate continues on the factorial invariance across different subgroups. The present study aimed to test psychometric properties, factorial structure, factorial invariance across age and gender, and to deliver population-based norms for the German general population from a large cross-sectional sample of 2519 subjects. Confirmatory factor analyses supported that the scale is one-factorial, even though indications of inhomogeneity of the scale have been detected. Both findings show invariance across the seven age groups and both genders. As indicators of the convergent validity, a positive correlation with social support and negative correlation with depressiveness was shown. Population-based norms are provided to support the application in the context of individual diagnostics.	[Glaesmer, Heide; Braehler, Elmar] Univ Leipzig, Dept Med Psychol & Med Sociol, D-04103 Leipzig, Germany; [Grande, Gesine] Leipzig Univ Appl Sci, Dept Social Work, Leipzig, Germany; [Roth, Marcus] Univ Duisburg Essen, Dept Psychol, Duisburg, Germany	Glaesmer, H (corresponding author), Univ Leipzig, Dept Med Psychol & Med Sociol, Philipp Rosenthal Str 55, D-04103 Leipzig, Germany.	heide.glaesmer@medizin.uni-leipzig.de	Braehler, Elmar/C-6535-2009; Grande, Gesine/AAT-5671-2020	Braehler, Elmar/0000-0002-2648-2728; Grande, Gesine/0000-0003-1820-8347			Anderson CJ, 2004, J SPINAL CORD MED, V27, pS98, DOI 10.1080/10790268.2004.11753545; ARRINDELL WA, 1991, PERS INDIV DIFFER, V12, P117, DOI 10.1016/0191-8869(91)90094-R; Atienza FL, 2003, PERS INDIV DIFFER, V35, P1255, DOI 10.1016/S0191-8869(02)00332-X; Barrett JJ, 2002, J CLIN PSYCHOL MED S, V9, P219, DOI 10.1023/A:1016051311531; Bogner JA, 2001, ARCH PHYS MED REHAB, V82, P571, DOI 10.1053/apmr.2001.22340; Browne M. W., 1993, ALTERNATIVE WAYS ASS; Cheung GW, 2002, STRUCT EQU MODELING, V9, P233, DOI 10.1207/S15328007SEM0902_5; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P445, DOI 10.1097/00001199-200411000-00003; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Dahlberg CA, 2007, ARCH PHYS MED REHAB, V88, P1561, DOI 10.1016/j.apmr.2007.07.033; Dalgard OS, 2006, SOC PSYCH PSYCH EPID, V41, P444, DOI 10.1007/s00127-006-0051-5; Diener E, 2003, ANNU REV PSYCHOL, V54, P403, DOI 10.1146/annurev.psych.54.101601.145056; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; DIENER E, 1993, SOC INDIC RES, V28, P195, DOI 10.1007/BF01079018; Dierk JM, 2006, J PSYCHOSOM RES, V60, P219, DOI 10.1016/j.jpsychores.2005.06.083; Dowrick C, 1998, BRIT J PSYCHIAT, V172, P359, DOI 10.1192/bjp.172.4.359; Fisher KJ, 2004, ANN BEHAV MED, V28, P186, DOI 10.1207/s15324796abm2803_7; Hammarberg K, 2001, HUM REPROD, V16, P374, DOI 10.1093/humrep/16.2.374; Hu LT, 1998, PSYCHOL METHODS, V3, P424, DOI 10.1037/1082-989X.3.4.424; Hultell D, 2008, PERS INDIV DIFFER, V44, P1070, DOI 10.1016/j.paid.2007.10.030; JOERESKOG KG, 1993, LISREL 8 STRUCTURAL; Kimmel PL, 2003, AM J KIDNEY DIS, V42, P713, DOI 10.1016/S0272-6386(03)00907-7; Kritz-Silverstein D, 2002, J WOMEN HEALTH GEN-B, V11, P181, DOI 10.1089/152460902753645326; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; LEWIS CA, 1995, PERCEPT MOTOR SKILL, V80, P304, DOI 10.2466/pms.1995.80.1.304; Lievens F, 2004, J OCCUP ORGAN PSYCH, V77, P299, DOI 10.1348/0963179041752727; Lucas RE, 1996, J PERS SOC PSYCHOL, V71, P616, DOI 10.1037/0022-3514.71.3.616; Meyer C, 2004, SOC PSYCH PSYCH EPID, V39, P435, DOI 10.1007/s00127-004-0755-3; MUTHEN B, 1985, BRIT J MATH STAT PSY, V38, P171, DOI 10.1111/j.2044-8317.1985.tb00832.x; NETO F, 1993, J YOUTH ADOLESCENCE, V22, P125, DOI 10.1007/BF01536648; Oishi S, 2006, J RES PERS, V40, P411, DOI 10.1016/j.jrp.2005.02.002; Raju NS, 2002, J APPL PSYCHOL, V87, P517, DOI 10.1037/0021-9010.87.3.517; Rioux L, 2005, J ENVIRON PSYCHOL, V25, P231, DOI 10.1016/j.jenvp.2005.05.001; Sachs J, 2003, PSYCHOLOGIA, V46, P225, DOI 10.2117/psysoc.2003.225; Schumacher J., 2003, DIAGNOSTISCHE VERFAH, P305; Shevlin M, 1998, PERS INDIV DIFFER, V25, P911, DOI 10.1016/S0191-8869(98)00088-9; Smith AE, 2004, AGEING SOC, V24, P793, DOI 10.1017/S0144686X04002569; Tate DG, 1997, ARCH PHYS MED REHAB, V78, pS18, DOI 10.1016/S0003-9993(97)90217-3; Vassar M, 2008, SOC INDIC RES, V86, P47, DOI 10.1007/s11205-007-9113-7; Wu CH, 2008, SOC INDIC RES, V85, P447, DOI 10.1007/s11205-007-9136-0; Wu CH, 2006, PERS INDIV DIFFER, V40, P1259, DOI 10.1016/j.paid.2005.11.012	41	191	193	0	44	HOGREFE & HUBER PUBLISHERS	GOTTINGEN	ROHNSWEG 25, D-37085 GOTTINGEN, GERMANY	1015-5759			EUR J PSYCHOL ASSESS	Eur. J. Psychol. Assess.		2011	27	2					127	132		10.1027/1015-5759/a000058			6	Psychology, Applied	Psychology	800RV	WOS:000293384200009					2021-06-18	
J	Marmarou, A; Lu, J; Butcher, I; Mchugh, GS; Murray, GD; Steyerberg, EW; Mushkudiani, NA; Choi, S; Maas, AIR				Marmarou, Anthony; Lu, Juan; Butcher, Isabella; Mchugh, Gillian S.; Murray, Gordon D.; Steyerberg, Ewout W.; Mushkudiani, Nino A.; Choi, Sung; Maas, Andrew I. R.			Prognostic value of the Glasgow coma scale and pupil reactivity in traumatic brain injury assessed pre-hospital and on enrollment: An IMPACT analysis	JOURNAL OF NEUROTRAUMA			English	Article						GCS; IMPACT; motor score; prognosis; pupil reactivity; traumatic brain injury	SEVERE HEAD-INJURY; MOTOR RESPONSE; STEM REFLEXES; VARIABLES; SEVERITY; RECOVERY; TREE	We studied the prognostic strength of the individual components of the Glasgow Coma Scale (GCS) and pupil reactivity to Glasgow Outcome Score (GOS) at 6 months post-injury. A total of 8721 moderate or severe traumatic brain injury (TBI) patient data from the IMPACT database on traumatic brain injury comprised the study cohort. The associations between motor score and pupil reactivity and 6-month GOS were analyzed by binary logistic regression and proportional odds methodology. The strength of prognostic effects were expressed as the unadjusted odds ratios presented for all individual studies as well as in meta-analysis. We found a consistent strong association between motor score and 6-month GOS across all studies (OR 1.74-7.48). The Eye and Verbal components were also strongly associated with GOS. In the pooled population, one or both un-reactive pupils and lower motor scores were significantly associated with unfavorable outcome (range 2.71-7.31). We also found a significant change in motor score from pre-hospital direct to study hospital enrollment (p < 0.0001) and from the first in-hospital to study enrollment scores (p < 0.0001). Pupil reactivity was more robust between these time points. It is recommended that the study hospital enrollment GCS and pupil reactivity be used for prognostic analysis.	Virginia Commonwealth Univ, Med Ctr, Dept Neurosurg, Richmond, VA USA; Univ Edinburgh, Sch Med, Edinburgh, Midlothian, Scotland; Erasmus MC, Ctr Med Decis Making, Dept Publ Hlth, Rotterdam, Netherlands; Erasmus MC, Dept Neurosurg, Rotterdam, Netherlands	Marmarou, A (corresponding author), Virginia Commonwealth Univ Hlth Syst, Dept Neurosurg, 1001 E Broad St,Suite 235, Richmond, VA 23219 USA.	Marmarou@hsc.vcu.edu	Maas, Andrew IR/C-5584-2013; Steyerberg, Ewout/C-1509-2018	Maas, Andrew IR/0000-0003-1612-1264; Murray, Gordon/0000-0001-9866-4734; Lu, Juan/0000-0002-5389-7603; Steyerberg, Ewout/0000-0002-7787-0122	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042691] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-042691] Funding Source: Medline		Andrews PJD, 2002, J NEUROSURG, V97, P326, DOI 10.3171/jns.2002.97.2.0326; Arbabi S, 2004, J TRAUMA, V56, P1029, DOI 10.1097/01.TA.0000123036.20919.4B; BORN JD, 1988, ACTA NEUROCHIR, V91, P1, DOI 10.1007/BF01400520; BORN JD, 1985, NEUROSURGERY, V16, P595, DOI 10.1227/00006123-198505000-00002; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; Chambers IR, 2000, BRIT J NEUROSURG, V14, P424; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; CIRICILLO SF, 1992, J TRAUMA, V33, P899, DOI 10.1097/00005373-199212000-00018; CLIFTON GL, 1993, NEUROSURGERY, V33, P34; DANZE F, 1994, NEUROCHIRURGIE, V40, P348; DAVIS RA, 1984, SURG GYNECOL OBSTET, V159, P597; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Formisano R, 2005, ACT NEUR S, V93, P201; HARTLEY C, 1995, BRIT J NEUROSURG, V9, P179, DOI 10.1080/02688699550041520; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; JANE JA, 1982, CLIN NEUR, V29, P346; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Mamelak AN, 1996, J TRAUMA, V41, P91, DOI 10.1097/00005373-199607000-00014; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; MCHUGH GS, 2006, UNPUB J NEUROTRAUMA; Miller J D, 1993, Acta Neurochir Suppl (Wien), V57, P152; MILLER JD, 1992, J NEUROTRAUM, V9, pS317; Mukherjee K, 2000, NEUROL INDIA, V48, P43; Prat R, 1998, ACTA NEUROCHIR, V140, P1257, DOI 10.1007/s007010050247; Ritter AM, 1999, NEUROSURGERY, V44, P941, DOI 10.1097/00006123-199905000-00005; ROPPER AH, 1991, ARCH NEUROL-CHICAGO, V48, P1166, DOI 10.1001/archneur.1991.00530230074025; Ross A M, 1992, J Neurosci Nurs, V24, P88; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TEASDALE G, 1974, LANCET, V2, P81; Thatcher R W, 1991, Ann N Y Acad Sci, V620, P82, DOI 10.1111/j.1749-6632.1991.tb51576.x	40	191	199	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2007	24	2					270	280		10.1089/neu.2006.0029			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	150AL	WOS:000245187900006	17375991				2021-06-18	
J	McCrea, M; Kelly, JP; Randolph, C; Cisler, R; Berger, L				McCrea, M; Kelly, JP; Randolph, C; Cisler, R; Berger, L			Immediate neurocognitive effects of concussion	NEUROSURGERY			English	Article						amnesia; athletic injuries; brain concussion; brain injuries; unconsciousness	TRAUMATIC BRAIN-INJURY; MILD HEAD-INJURY; STANDARDIZED ASSESSMENT	OBJECTIVE: To prospectively measure the immediate neurocognitive effects and early course of recovery from concussion and to examine the effects of loss of consciousness (LOC) and posttraumatic amnesia (PTA) on the severity of neurocognitive impairment immediately after concussion. METHODS: A sports-related concussion research model was used to allow prospective immediate evaluation of concussion. A total of 2385 high school and college football players were studied. Ninety-one players (3.8%) sustained concussions during the study. A brief neurocognitive and neurological screening measure, the Standardized Assessment of Concussion, was used to assess cognitive functioning before the football season, immediately after injury, and 15 minutes, 48 hours, and 90 days after injury. RESULTS: Standardized Assessment of Concussion scores immediately after concussion were significantly lower than the preseason baseline score and the noninjured population baseline mean, even for injured subjects without LOC or PTA. Subjects with LOC were most severely impaired immediately after injury, whereas those without LOC or PTA were least impaired. Significant impairment was also detected 15 minutes after injury, but all three groups returned to baseline levels of cognitive functioning within 48 hours. CONCLUSION: These findings are the first to demonstrate not only that a gradient of increasing concussion severity is represented by PTA and LOC but also that measurable neurocognitive abnormalities are evident immediately after injury without PTA or LOC.	Waukesha Mem Hosp, Neuropsychol Serv, Waukesha, WI 53188 USA; Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA; Chicago Neurol Inst, Chicago, IL USA; Northwestern Univ, Sch Med, Dept Neurol, Evanston, IL USA; Loyola Univ, Sch Med, Dept Neurol, Chicago, IL 60611 USA; Univ Wisconsin, Ctr Addict & Behav Hlth Res, Milwaukee, WI 53201 USA	McCrea, M (corresponding author), Waukesha Mem Hosp, Neuropsychol Serv, 721 Amer Ave,Suite 501, Waukesha, WI 53188 USA.	michael.mccrea@phci.org					Alexander M. P., 1997, SEMIN CLIN NEUROPSYC, V2, P177; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; *C NEUR SURG, 1966, CLIN NEUROSURG, V12, P386; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; *CO MED SOC, 1991, REP SPORTS MED COMM; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; FISHER CM, 1966, NEUROLOGY, V16, P826, DOI 10.1212/WNL.16.8.826; Frankowski RF, 1985, CENTRAL NERVOUS SYST, P33; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; GUALTIERI CT, 1995, NEUROPSY NEUROPSY BE, V8, P127; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; Larrabee GJ., 1997, SEMIN CLIN NEUROPSYC, V2, P196, DOI [10.1053/SCNP00200196, DOI 10.1053/SCNP00200196]; LEVIN HS, 1992, J NEUROTRAUM, V9, pS359; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; MCCREA M, 2000, MANUAL ADM SCORING I; MILLER JD, 1993, J NEUROL NEUROSUR PS, V56, P440, DOI 10.1136/jnnp.56.5.440; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; *SPSS INC, 1999, ADV MOD VERS 10 0 SO; Stein S. C., 1996, NEUROTRAUMA, P31; STEIN SC, 1993, BRAIN INJURY, V7, P425, DOI 10.3109/02699059309029685; TEASDALE G, 1974, LANCET, V2, P81; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Weight DG, 1998, PSYCHIAT CLIN N AM, V21, P609, DOI 10.1016/S0193-953X(05)70026-5; YARNELL PR, 1970, LANCET, V1, P863	41	191	194	0	29	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	MAY	2002	50	5					1032	1040		10.1097/00006123-200205000-00017			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	548CC	WOS:000175370100023	11950406				2021-06-18	
J	Brosamle, C; Huber, AB; Fiedler, M; Skerra, A; Schwab, ME				Brosamle, C; Huber, AB; Fiedler, M; Skerra, A; Schwab, ME			Regeneration of lesioned corticospinal tract fibers in the adult rat induced by a recombinant, humanized IN-1 antibody fragment	JOURNAL OF NEUROSCIENCE			English	Article						CNS regeneration; Nogo-A; spinal cord injury; axonal tracing; recombinant antibody; corticospinal tract; rat	NEURITE GROWTH-INHIBITORS; CHEMOREPELLENT SEMAPHORIN-III; BLOOD-BRAIN-BARRIER; SPINAL-CORD INJURY; ESCHERICHIA-COLI; CNS MYELIN; INTRATHECAL BACLOFEN; FUNCTIONAL RECOVERY; NERVOUS-SYSTEM; FAB FRAGMENT	Axons in the CNS of higher vertebrates generally fail to regenerate after injury. This lack of regeneration is crucially influenced by neurite growth inhibitory protein constituents of CNS myelin. We have shown previously that a monoclonal antibody (mAb IN-1) capable of binding and neutralizing Nogo-A, a myelin-associated inhibitor of neurite growth, can induce long-distance axonal regeneration and increased structural plasticity with improved functional recovery in rat models of CNS injury. In this paper we demonstrate that a partially humanized, recombinant Fab fragment (rIN-1 Fab) derived from the original mAb IN-1, was able to promote long-distance regeneration of injured axons in the spinal cord of adult rats. When infused into a spinal cord injury site, regrowth of corticospinal fibers in 11 of 18 animals was observed after a survival time of 2 weeks. Regenerating fibers grew for >9 mm beyond the lesion site and arborized profusely in the distal cord. Regenerated fibers formed terminal arbors with varicosities in the spinal cord gray matter, strongly resembling synaptic points of contact to neurons in the spinal cord distal to the lesion. In animals that had received a bovine serum albumin solution or a recombinant IN-1 fragment that had been mutated in the antigen binding site (mutIN-1 Fab), no significant growth beyond normal lesion-induced sprouting was observed. Neutralization of endogenous nerve growth inhibitors represents a novel use of recombinant antibody technology with potential therapeutic applications after traumatic CNS lesions.	Univ Zurich, Dept Neuromorphol, Brain Res Inst, CH-9057 Zurich, Switzerland; Swiss Fed Inst Technol, CH-9057 Zurich, Switzerland; Tech Univ Munich, Lehrstuhl Biol Chem, D-85350 Freising Weihenstephan, Germany	Brosamle, C (corresponding author), Univ Zurich, Brain Res Inst, Winterthurer Str 190, CH-8057 Zurich, Switzerland.	broesam@hifo.unizh.ch	Skerra, Arne/A-2269-2013; Schwab, Martin E/B-6818-2016	Skerra, Arne/0000-0002-5717-498X			Bandtlow C, 1996, EUR J BIOCHEM, V241, P468, DOI 10.1111/j.1432-1033.1996.00468.x; Beattie MS, 1997, EXP NEUROL, V148, P453, DOI 10.1006/exnr.1997.6695; BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; Brosamle C, 1997, J COMP NEUROL, V386, P293, DOI 10.1002/(SICI)1096-9861(19970922)386:2<293::AID-CNE9>3.0.CO;2-X; CADELLI D, 1991, EUR J NEUROSCI, V3, P825, DOI 10.1111/j.1460-9568.1991.tb00093.x; CARONI P, 1988, NEURON, V1, P85, DOI 10.1016/0896-6273(88)90212-7; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; Davies SJA, 1997, NATURE, V390, P680; DIETZ V, 1994, LANCET, V344, P1260, DOI 10.1016/S0140-6736(94)90751-X; EDGERTON VR, 1992, J NEUROTRAUM, V9, pS119; Fiedler M, 1999, PROTEIN EXPRES PURIF, V17, P421, DOI 10.1006/prep.1999.1142; Fitch MT, 1997, EXP NEUROL, V148, P587, DOI 10.1006/exnr.1997.6701; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; GRILLNER S, 1975, PHYSIOL REV, V55, P247, DOI 10.1104/pp.55.2.247; Herzog A, 1997, J NEUROSCI METH, V72, P57, DOI 10.1016/S0165-0270(96)00156-2; Jaeger CB, 1997, EXP NEUROL, V144, P381, DOI 10.1006/exnr.1996.6405; LAZORTHES Y, 1990, J NEUROSURG, V72, P393, DOI 10.3171/jns.1990.72.3.0393; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; Miranda JD, 1999, EXP NEUROL, V156, P218, DOI 10.1006/exnr.1998.7012; ORLANDI R, 1989, P NATL ACAD SCI USA, V86, P3833, DOI 10.1073/pnas.86.10.3833; Pasterkamp RJ, 1999, MOL CELL NEUROSCI, V13, P143, DOI 10.1006/mcne.1999.0738; Pasterkamp RJ, 1998, J NEUROSCI, V18, P9962; PENN RD, 1989, NEW ENGL J MED, V320, P1517, DOI 10.1056/NEJM198906083202303; PLUCKTHUN A, 1989, METHOD ENZYMOL, V178, P497; Ramon y Cajal S, 1928, DEGENERATION REGENER; RUBIN BP, 1994, J NEUROCYTOL, V23, P209, DOI 10.1007/BF01275525; Rubin BP, 1995, EUR J NEUROSCI, V7, P2524, DOI 10.1111/j.1460-9568.1995.tb01052.x; Schiweck W, 1997, FEBS LETT, V414, P33, DOI 10.1016/S0014-5793(97)00983-6; Schiweck W, 1995, PROTEINS, V23, P561, DOI 10.1002/prot.340230411; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; SCHNELL L, 1993, EUR J NEUROSCI, V5, P1156, DOI 10.1111/j.1460-9568.1993.tb00970.x; SCHNELL L, 1994, NATURE, V367, P170, DOI 10.1038/367170a0; SCHWAB ME, 1988, J NEUROSCI, V8, P2381; SCHWAB ME, 1993, ANNU REV NEUROSCI, V16, P565, DOI 10.1146/annurev.ne.16.030193.003025; SCHWAB ME, 1985, J NEUROSCI, V5, P2415; Schwab ME, 1996, PHYSIOL REV, V76, P319; SKERRA A, 1988, SCIENCE, V240, P1038, DOI 10.1126/science.3285470; Spillmann AA, 1997, EUR J NEUROSCI, V9, P549, DOI 10.1111/j.1460-9568.1997.tb01631.x; Spillmann AA, 1998, J BIOL CHEM, V273, P19283, DOI 10.1074/jbc.273.30.19283; Thallmair M, 1998, NAT NEUROSCI, V1, P124, DOI 10.1038/373; WEIBEL D, 1994, BRAIN RES, V642, P259, DOI 10.1016/0006-8993(94)90930-X; Z'Graggen WJ, 1998, J NEUROSCI, V18, P4744	42	191	208	0	12	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	NOV 1	2000	20	21					8061	8068					8	Neurosciences	Neurosciences & Neurology	366KB	WOS:000090003600025	11050127				2021-06-18	
J	Smith, DH; Wolf, JA; Lusardi, TA; Lee, VMY; Meaney, DF				Smith, DH; Wolf, JA; Lusardi, TA; Lee, VMY; Meaney, DF			High tolerance and delayed elastic response of cultured axons to dynamic stretch injury	JOURNAL OF NEUROSCIENCE			English	Article						axon; trauma; elasticity; dynamic deformation; tolerance; axolemmal permeability; neurofilament	BRAIN INJURY; HEAD-INJURY; NEUROFILAMENT SUBUNITS; NTERA-2 CELLS; NEURONS; HUMANS; SYSTEM; DEATH; RATS	Although axonal injury is a common feature of brain trauma, little is known of the immediate morphological responses of individual axons to mechanical injury. Here, we developed an in vitro model system that selectively stretches axons bridging two populations of human neurons derived from the cell line N-Tera2. We found that these axons demonstrated a remarkably high tolerance to dynamic stretch injury, with no primary axotomy at strains <65%. In addition, the axolemma remained impermeable to small molecules after injury unless axotomy had occurred. We also found that injured axons exhibited the behavior of "delayed elasticity" after injury, going from a straight orientation before injury to developing an undulating course as an immediate response to injury, yet gradually recovering their original orientation. Surprisingly, some portions of the axons were found to be up to 60% longer immediately after injury. Subsequent to returning to their original length, injured axons developed swellings of appearance remarkably similar to that found in brain-injured humans. These findings may offer insight into mechanical-loading conditions leading to traumatic axonal injury and into potential mechanisms of axon reassembly after brain trauma.	Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	Smith, DH (corresponding author), Univ Penn, Dept Neurosurg, 3320 Smith Walk,105 Hayden Hall, Philadelphia, PA 19104 USA.		smith, douglas/A-1321-2007; Wolf, John A/A-1034-2007	Wolf, John A/0000-0002-6950-2303; Meaney, David/0000-0002-0954-4122; Lusardi, Theresa/0000-0003-0699-5662	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG12527, R01 AG012527] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50 NS008803, NS08803] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, P01NS008803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG012527] Funding Source: NIH RePORTER		ADAMS JH, 1984, LANCET, V2, P1420; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; BURGOYNE P, 1991, NEURONAL CYTOSKELETO; de Gennes P.G., 1979, SCALING CONCEPTS POL; EVANS EA, 1973, BIOPHYS J, V13, P941, DOI 10.1016/S0006-3495(73)86036-9; Flugge W., 1975, VISCOELASTICITY; GALBRAITH JA, 1993, J BIOMECH ENG-T ASME, V115, P13, DOI 10.1115/1.2895464; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; GRAHAM DI, 1988, PROG CLIN BIOL RES, V234, P159; GRAY JAB, 1954, J PHYSIOL-LONDON, V124, P84, DOI 10.1113/jphysiol.1954.sp005087; HIRAOKA Y, 1987, SCIENCE, V238, P36, DOI 10.1126/science.3116667; Jenkins OP, 1904, J COMP NEUROL PSYCHO, V14, P85, DOI 10.1002/cne.920140202; KRAUS JF, 1994, SEMIN NEUROL, V14, P1, DOI 10.1055/s-2008-1041052; LEE VMY, 1987, J NEUROSCI, V7, P3474; Leterrier JF, 1996, J BIOL CHEM, V271, P15687, DOI 10.1074/jbc.271.26.15687; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; Munir M, 1995, J NEUROSCI, V15, P7847; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; PLEASURE SJ, 1993, J NEUROSCI RES, V35, P585, DOI 10.1002/jnr.490350603; POVLISHOCK JT, 1985, LAB INVEST, V52, P540; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; PVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; RYDEVIK BL, 1990, J ORTHOPAED RES, V8, P694, DOI 10.1002/jor.1100080511; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; SPERLING LH, 1992, INTRO PHYSICAL POLYM; Thibault L.E., 1990, P INT C BIOM IMP LYO, P191; ZHENG J, 1991, J NEUROSCI, V11, P1117; Zhou C., 1994, P 38 STAPP CAR CRASH, P133	36	191	200	0	16	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUN 1	1999	19	11					4263	4269					7	Neurosciences	Neurosciences & Neurology	198ND	WOS:000080429600009	10341230				2021-06-18	
J	Pohl, D; Bittigau, P; Ishimaru, MJ; Stadthaus, D; Hubner, C; Olney, JW; Turski, L; Ikonomidou, C				Pohl, D; Bittigau, P; Ishimaru, MJ; Stadthaus, D; Hubner, C; Olney, JW; Turski, L; Ikonomidou, C			N-Methyl-D-aspartate antagonists and apoptotic cell death triggered by head trauma in developing rat brain	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						traumatic head injury; apoptosis; necrosis; excitotoxicity; neurodegeneration	INJURY; DAMAGE; DEGENERATION	Morbidity and mortality from head trauma is highest among children, No animal model mimicking traumatic brain injury in children has yet been established, and the mechanisms of neuronal degeneration after traumatic injury to the developing brain are not understood. In infant rats subjected to percussion head trauma, two types of brain damage could be characterized, The first type or primary damage evolved within 4 hr and occurred by an excitotoxic mechanism. The second type or secondary damage evolved within 6-24 hr and occurred by an apoptotic mechanism. Primary damage remained localized to the parietal cortex at the site of impact. Secondary damage affected distant sites such as the cingutate/retrosplenial cortex, subiculum, frontal cortex, thalamus and striatum, Secondary apoptotic damage was more severe than primary excitotoxic damage. Morphometric analysis demonstrated that the N-methyl-D-aspartate receptor antagonists 3-(2-carboxypiperazin-4-yl) propyl-1-phosphonate and dizocilpine protected against primary excitotoxic damage but increased severity of secondary apoptotic damage. 2-Sulfo-alpha-phenyl-N-tert-butyl-nitrone, a free radical scavenger, did not affect primary excitotoxic damage but mitigated apoptotic damage. These observations demonstrate that apoptosis and not excitotoxicity determine neuropathologic outcome after traumatic injury to the developing brain. Whereas free radical scavengers may prove useful in therapy of head trauma in children, N-methyl-D-aspartate antagonists should be avoided because of their propensity to increase severity of apoptotic damage.	Humboldt Univ, Sch Med, Childrens Hosp, Charite Virchow Clin,Dept Pediat Neurol, D-13353 Berlin, Germany; Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA; UCL, Eisai London Res Labs, London WC1E 6BT, England	Ikonomidou, C (corresponding author), Humboldt Univ, Sch Med, Childrens Hosp, Charite Virchow Clin,Dept Pediat Neurol, Augustenburger Pl 1, D-13353 Berlin, Germany.	hrissanthi.ikonomidou@charite.de					Adams JH, 1992, GREENFIELDS NEUROPAT, P106; Allen A.R., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; Bernert H, 1996, P NATL ACAD SCI USA, V93, P5235, DOI 10.1073/pnas.93.11.5235; Bullock R, 1995, ANN NY ACAD SCI, V765, P272, DOI 10.1111/j.1749-6632.1995.tb16584.x; CARNEY JM, 1991, P NATL ACAD SCI USA, V88, P3633, DOI 10.1073/pnas.88.9.3633; Cheng Y, 1997, ANN NEUROL, V41, P521, DOI 10.1002/ana.410410416; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; CRUZORIVE LM, 1990, AM J PHYSIOL, V258, P148; CUNITZ G, 1995, ANAESTHESIST, V44, P369, DOI 10.1007/s001010050166; DEOLMOS JS, 1971, BRAIN RES, V33, P523, DOI 10.1016/0006-8993(71)90130-2; Diamond PT, 1996, BRAIN INJURY, V10, P413, DOI 10.1080/026990596124278; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; GREENBERG J, 1993, HDB HEAD SPINE TRAUM; Gremmelt A, 1995, ANAESTHESIST, V44, pS559; Hensley K, 1997, INT REV NEUROBIOL, V40, P299; Ikonomidou C, 1995, CURR OPIN NEUROL, V8, P487, DOI 10.1097/00019052-199512000-00017; Ishimaru M. J., 1997, Society for Neuroscience Abstracts, V23, P895; LEHMANN J, 1987, J PHARMACOL EXP THER, V240, P737; OLNEY JW, 1970, NATURE, V227, P609, DOI 10.1038/227609b0; OLNEY JW, 1997, CELL DEATH DIS NERVO, P167; Povlishock John T., 1993, P185; RICE JE, 1981, ANN NEUROL, V9, P131, DOI 10.1002/ana.410090206; Stein SC, 1995, PEDIATR NEUROSURG, V23, P299, DOI 10.1159/000120975; TURSKI L, 1991, NATURE, V349, P414, DOI 10.1038/349414a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	27	191	197	0	3	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	MAR 2	1999	96	5					2508	2513		10.1073/pnas.96.5.2508			6	Multidisciplinary Sciences	Science & Technology - Other Topics	172ZP	WOS:000078956600126	10051673	Bronze, Green Published			2021-06-18	
J	FRANZEN, L; FUNEGARD, U; ERICSON, T; HENRIKSSON, R				FRANZEN, L; FUNEGARD, U; ERICSON, T; HENRIKSSON, R			PAROTID-GLAND FUNCTION DURING AND FOLLOWING RADIOTHERAPY OF MALIGNANCIES IN THE HEAD AND NECK - A CONSECUTIVE STUDY OF SALIVARY FLOW AND PATIENT DISCOMFORT	EUROPEAN JOURNAL OF CANCER			English	Article; Proceedings Paper	BREAST CANCER WORKING CONF : BREAST CANCER - LOTS OF DATA, STEADY BUT SLOW CLINICAL PROGRESS	SEP 03-06, 1991	PAUSCOLLEGE, LOUVAIN, BELGIUM	EUROPEAN ORG RES & TREATMENT CANC	PAUSCOLLEGE		RADIATION-THERAPY; CANCER; CELL; INJURY	Radiotherapy of tumours in the head and neck region usually involves the salivary glands in the treatment volume with ensuing dryness and discomfort. In the present study, a prospective evaluation of the same patients were performed before, during radiotherapy and 6, 12 and 18 months after the end of treatment. Three different groups were outlined, one receiving doses not exceeding 45 Gy, another 47-52 Gy and a third group treated with doses over 64 Gy. All but one of the patients receiving doses less than 52 Gy showed a recovery of secretion beginning after 2 months with a continuous improvement of the salivary flow up to 18 months. Doses exceeding 64 Gy caused irreversibly depressed parotid function in the vast majority of glands. The subjective experience of discomfort with dry mouth was not at all correlated to the initial flow rate. Treatment with unilateral technique and doses below 52 Gy caused just no or slight dryness and 3 out of 4 patients with bilateral involvement of the glands displayed problem with subjective dryness even after 18 months. Doses over 64 Gy with one gland involved had only slight dryness, however, patients with both glands affected showed severe problems with dryness. It has to be emphasised that there were relatively large interindividual differences with respect to salivary flow and discomfort of dryness. It is obvious that these patients need a careful dose planning and a close follow up with co-operation between radiotherapeutists and dentists.	UMEA UNIV HOSP,DEPT CARIOL,S-90185 UMEA,SWEDEN	FRANZEN, L (corresponding author), UMEA UNIV HOSP,DEPT ONCOL,S-90185 UMEA,SWEDEN.		Henriksson, Roger/AAI-8608-2020				Alper T, 1977, Adv Exp Med Biol, V84, P139; CHENCHARICK JD, 1983, CANCER, V51, P811, DOI 10.1002/1097-0142(19830301)51:5<811::AID-CNCR2820510511>3.0.CO;2-M; CHENG VST, 1981, INT J RADIAT ONCOL, V7, P253, DOI 10.1016/0360-3016(81)90444-2; DOWBEN RM, 1963, NATURE, V197, P400, DOI 10.1038/197400a0; DREIZEN S, 1977, POSTGRAD MED, V61, P85, DOI 10.1080/00325481.1977.11712115; ELMOFTY SK, 1975, AM J PATHOL, V79, P579; ENEROTH CM, 1972, ACTA OTO-LARYNGOL, V74, P436, DOI 10.3109/00016487209128474; ENEROTH CM, 1972, CANCER, V30, P1147, DOI 10.1002/1097-0142(197211)30:5<1147::AID-CNCR2820300502>3.0.CO;2-0; FARBER E, 1969, CANCER RES, V29, P136; FARBER JL, 1975, AM J PATHOL, V81, P237; FRANZEN L, 1991, LAB INVEST, V64, P279; FRANZEN L, UNPUB PAROTID GLAND; FRANZEN L, UNPUB ACTA ONCOL; JUDAH JD, 1974, CIBA F S CELLULAR IN, P187; JUNGLEE D, 1986, CLIN CHEM, V32, P609; KASHIMA HK, 1965, AMER J ROENTGENOL RA, V94, P271; LIEBERMAN MW, 1972, PATHOLOGY TRANSCRIPT, P37; MAKKONEN T A, 1986, Proceedings of the Finnish Dental Society, V82, P93; MAKKONEN TA, 1987, INT J ORAL MAX SURG, V16, P56, DOI 10.1016/S0901-5027(87)80031-0; MAKKONEN TA, 1987, ACTA ONCOL, V26, P307, DOI 10.3109/02841868709089980; MAKKONEN TA, 1986, ORAL SURG ORAL MED O, V62, P270, DOI 10.1016/0030-4220(86)90007-1; MARKS JE, 1981, INT J RADIAT ONCOL, V7, P1013, DOI 10.1016/0360-3016(81)90152-8; MERRICK TP, 1965, RADIAT RES, V24, P612, DOI 10.2307/3571879; MIRA JG, 1981, INT J RADIAT ONCOL, V7, P535, DOI 10.1016/0360-3016(81)90140-1; MIRA JG, 1982, ACTA RADIOL ONCOL, V21, P151, DOI 10.3109/02841868209133999; MITCHELL JB, 1978, INT J RADIAT BIOL, V34, P349, DOI 10.1080/09553007814550981; MOSSMAN K, 1982, INT J RADIAT ONCOL, V8, P991, DOI 10.1016/0360-3016(82)90166-3; Mossman K L, 1977, Ear Nose Throat J, V56, P145; MOSSMAN KL, 1983, RADIAT RES, V95, P392, DOI 10.2307/3576264; MUNRO T R, 1970, Radiation Research, V44, P748, DOI 10.2307/3573154; PARSONS JT, 1984, MANAGEMENT HEAD NECK, P173; Rubin P., 1972, FRONT RAD THER ONCOL, V6, P1; SHANNON IL, 1978, P SOC EXP BIOL MED, V157, P50; SHANNON IL, 1981, SALIVA SALIVATION, P313; SHAPIRO B, 1966, RADIAT RES, V27, P139, DOI 10.2307/3571821; SKARSGARD LD, 1967, RADIOBIOLOGY CULTURE, P420; STEPHENS LC, 1986, AM J PATHOL, V124, P469; STEPHENS LC, 1986, RADIOTHER ONCOL, V7, P165; SUTHERLAND RM, 1967, INT J RADIAT BIOL RE, V12, P551, DOI 10.1080/09553006714551161; WESCOTT WB, 1978, AM J ROENTGENOL, V130, P145, DOI 10.2214/ajr.130.1.145	40	191	197	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0959-8049			EUR J CANCER	Eur. J. Cancer	FEB-MAR	1992	28A	2-3					457	462		10.1016/S0959-8049(05)80076-0			6	Oncology	Oncology	HL783	WOS:A1992HL78300037	1591063				2021-06-18	
J	KAPUR, N; ELLISON, D; SMITH, MP; MCLELLAN, DL; BURROWS, EH				KAPUR, N; ELLISON, D; SMITH, MP; MCLELLAN, DL; BURROWS, EH			FOCAL RETROGRADE-AMNESIA FOLLOWING BILATERAL TEMPORAL-LOBE PATHOLOGY - A NEUROPSYCHOLOGICAL AND MAGNETIC-RESONANCE STUDY	BRAIN			English	Article							AUTOBIOGRAPHICAL MEMORY; HIPPOCAMPUS; IMPAIRMENT; LOBECTOMY; REMOTE	A patient who suffered a severe closed head injury was left with a dense retrograde amnesia for events which she had experienced prior to her injury, but she showed only mild, patchy anterograde memory impairment. Her retrograde amnesia included both public events and autobiographical material, and it extended back to her childhood. Previously learned skills such as playing a piano and driving a car were spared, even though she had no recollection at all of the original learning experience. A series of focused magnetic resonance scan images revealed major pathology in the anterior portion of both temporal lobes. No significant abnormality was found in the hippocampus, thalamus or other medial structures in the limbic-diencephalic system. Our findings indicate the independence of anterograde and retrograde memory mechanisms, and point to structures and pathways in the anterior temporal lobes as playing a critical role in memory for past events.	SOUTHAMPTON GEN HOSP,DEPT NEUROPATHOL,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND; SOUTHAMPTON GEN HOSP,DEPT REHABIL,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND	KAPUR, N (corresponding author), SOUTHAMPTON GEN HOSP,WESSEX NEUROL CTR,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND.						BARR WB, 1990, NEUROPSYCHOLOGIA, V28, P243, DOI 10.1016/0028-3932(90)90018-J; Benton A. L., 1975, TEST FACIAL RECOGNIT; Benton AL, 1978, MULTILINGUAL APHASIA; BORRINI G, 1989, PSYCHOL MED, V19, P215, DOI 10.1017/S0033291700011181; CORKIN S, 1984, SEMIN NEUROL, V4, P249, DOI 10.1055/s-2008-1041556; DALLORA P, 1989, CORTEX, V25, P197, DOI 10.1016/S0010-9452(89)80037-1; DAMASIO AR, 1985, ARCH NEUROL-CHICAGO, V42, P252, DOI 10.1001/archneur.1985.04060030070012; DERENZI E, 1987, CORTEX, V23, P575, DOI 10.1016/S0010-9452(87)80050-3; DUSOIR H, 1990, BRAIN, V113, P1695, DOI 10.1093/brain/113.6.1695; GABRIELI JDE, 1988, BRAIN COGNITION, V7, P157, DOI 10.1016/0278-2626(88)90027-9; GOLDBERG E, 1981, SCIENCE, V213, P1392, DOI 10.1126/science.7268442; GROSSI D, 1988, CORTEX, V24, P457, DOI 10.1016/S0010-9452(88)80009-1; KAPUR N, 1989, CORTEX, V25, P387, DOI 10.1016/S0010-9452(89)80053-X; KAPUR N, 1983, BRIT J PSYCHOL, V74, P409, DOI 10.1111/j.2044-8295.1983.tb01872.x; KAPUR N, 1988, MEMORY DISORDERS CLI; KOPELMAN MD, 1989, NEUROPSYCHOLOGIA, V27, P437, DOI 10.1016/0028-3932(89)90050-X; KOPELMAN MD, 1989, J CLIN EXP NEUROPSYC, V11, P724, DOI 10.1080/01688638908400928; MACKINNON DF, 1989, PSYCHOBIOLOGY, V17, P247, DOI 10.1007/BF03337776; MARSLENWILSON WD, 1975, NEUROPSYCHOLOGIA, V13, P353, DOI 10.1016/0028-3932(75)90013-5; McKenna P.W.E., 1983, GRADED NAMING TEST; MONTALDI D, 1989, DEV CLIN EXPT NEUROP, P213; Nelson H., 1982, NATIONAL ADULT READI; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; PENFIELD W, 1974, ARCH NEUROL-CHICAGO, V31, P145, DOI 10.1001/archneur.1974.00490390027001; PETITDUTAILLIS D, 1954, REV NEUROL, V91, P129; PRESS GA, 1989, NATURE, V341, P54, DOI 10.1038/341054a0; ROMANCAMPOS G, 1980, CORTEX, V16, P509, DOI 10.1016/S0010-9452(80)80053-0; ROUSSEAUX M, 1984, CORTEX, V20, P575, DOI 10.1016/S0010-9452(84)80060-X; RUSSELL WR, 1971, TRAUMATIC AMNESIAS; SCOVILLE WB, 1968, NEUROPSYCHOLOGIA, V6, P211, DOI 10.1016/0028-3932(68)90020-1; SQUIRE LR, 1989, J NEUROSCI, V9, P828; TERZIAN H, 1955, NEUROLOGY, V5, P373, DOI 10.1212/WNL.5.6.373; Teuber H-L, 1969, LATE EFFECTS HEAD IN, P13; VANHOESEN GW, 1990, BRAIN ORG MEMORY CEL, P234; Warrington EK., 1984, RECOGNITION MEMORY T; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	38	191	197	0	8	OXFORD UNIV PRESS UNITED KINGDOM	OXFORD	WALTON ST JOURNALS DEPT, OXFORD, ENGLAND OX2 6DP	0006-8950			BRAIN	Brain	FEB	1992	115		1				73	85		10.1093/brain/115.1.73			13	Clinical Neurology; Neurosciences	Neurosciences & Neurology	HQ077	WOS:A1992HQ07700005	1559164				2021-06-18	
J	SHAPIRA, Y; SHOHAMI, E; SIDI, A; SOFFER, D; FREEMAN, S; COTEV, S				SHAPIRA, Y; SHOHAMI, E; SIDI, A; SOFFER, D; FREEMAN, S; COTEV, S			EXPERIMENTAL CLOSED HEAD-INJURY IN RATS - MECHANICAL, PATHOPHYSIOLOGIC, AND NEUROLOGIC PROPERTIES	CRITICAL CARE MEDICINE			English	Article									HADASSAH UNIV HOSP,DEPT ANESTHESIOL,INTENS CARE UNIT,POB 12000,IL-91120 JERUSALEM,ISRAEL; HADASSAH UNIV HOSP,TRAUMA RES CTR,DEPT PHARMACOL,IL-91120 JERUSALEM,ISRAEL; HADASSAH UNIV HOSP,TRAUMA RES CTR,DEPT PATHOL,IL-91120 JERUSALEM,ISRAEL; HADASSAH UNIV HOSP,TRAUMA RES CTR,DEPT PHYSIOL,IL-91120 JERUSALEM,ISRAEL; HEBREW UNIV JERUSALEM,HADASSAH MED SCH,IL-91010 JERUSALEM,ISRAEL							BENSON VM, 1970, ARCH NEUROL-CHICAGO, V23, P179, DOI 10.1001/archneur.1970.00480260085012; BOTHE HW, 1984, ACTA NEUROPATHOL, V64, P37, DOI 10.1007/BF00695604; BULLOCK R, 1985, J NEUROSURG, V63, P64, DOI 10.3171/jns.1985.63.1.0064; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; CROCKARD A, 1982, J NEUROSURG, V57, P203, DOI 10.3171/jns.1982.57.2.0203; DICK AR, 1976, J NEUROSURG, V45, P141, DOI 10.3171/jns.1976.45.2.0141; Ferszt R, 1980, Adv Neurol, V28, P15; Fujiwara K, 1981, Neurol Res, V3, P345; GOBIET W, 1977, NEUROCHIRURGIA, V20, P35; Gurdjian E. S., 1944, SURG GYNECOL AND OBSTET, V78, P618; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; KLATZO I, 1958, J NEUROPATH EXP NEUR, V17, P548, DOI 10.1097/00005072-195810000-00002; MARMAROU A, 1982, J NEUROSURG, V56, P246, DOI 10.3171/jns.1982.56.2.0246; MARMAROU A, 1978, J NEUROSURG, V49, P530, DOI 10.3171/jns.1978.49.4.0530; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; NELSON SR, 1971, J APPL PHYSIOL, V30, P268; NILSSON B, 1977, J NEUROSURG, V47, P252, DOI 10.3171/jns.1977.47.2.0252; NILSSON B, 1977, J NEUROSURG, V47, P262, DOI 10.3171/jns.1977.47.2.0262; NILSSON B, 1977, J NEUROSURG, V47, P241, DOI 10.3171/jns.1977.47.2.0241; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PAPPIUS HM, 1983, J CEREBR BLOOD F MET, V3, P448, DOI 10.1038/jcbfm.1983.71; PICOZZI P, 1985, J NEUROSURG, V62, P704, DOI 10.3171/jns.1985.62.5.0704; SHIGENO T, 1982, J NEUROSURG, V57, P99, DOI 10.3171/jns.1982.57.1.0099; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; SMITH AL, 1976, ANESTHESIOLOGY, V45, P64, DOI 10.1097/00000542-197607000-00012; Tornheim P A, 1976, Surg Neurol, V5, P171; TORNHEIM PA, 1981, J NEUROSURG, V55, P407, DOI 10.3171/jns.1981.55.3.0407; WAGA S, 1979, SURG NEUROL, V11, P191; WAGER KR, 1985, J NEUROSURG, V63, P88	29	191	192	0	9	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0090-3493			CRIT CARE MED	Crit. Care Med.	MAR	1988	16	3					258	265		10.1097/00003246-198803000-00010			8	Critical Care Medicine	General & Internal Medicine	M5367	WOS:A1988M536700010	3277783				2021-06-18	
J	Brady, KM; Lee, JK; Kibler, KK; Smielewski, P; Czosnyka, M; Easley, RB; Koehler, RC; Shaffner, DH				Brady, Ken M.; Lee, Jennifer K.; Kibler, Kathleen K.; Smielewski, Piotr; Czosnyka, Marek; Easley, R. Blaine; Koehler, Raymond C.; Shaffner, Donald H.			Continuous time-domain analysis of cerebrovascular autoregulation using near-infrared spectroscopy	STROKE			English	Article						autoregulation; cerebral blood flow; hypotension; neonate; oxygenation; piglet	TRAUMATIC BRAIN-INJURY; CEREBRAL-BLOOD-FLOW; PRESSURE REACTIVITY; AUTO-REGULATION; HEAD-INJURY; CHILDREN; METABOLISM; HUMANS	Background and Purpose - Assessment of autoregulation in the time domain is a promising monitoring method for actively optimizating cerebral perfusion pressure (CPP) in critically ill patients. The ability to detect loss of autoregulatory vasoreactivity to spontaneous fluctuations in CPP was tested with a new time-domain method that used near-infrared spectroscopic measurements of tissue oxyhemoglobin saturation in an infant animal model. Methods - Piglets were made progressively hypotensive over 4 to 5 hours by inflation of a balloon catheter in the inferior vena cava, and the breakpoint of autoregulation was determined using laser-Doppler flowmetry. The cerebral oximetry index (COx) was determined as a moving linear correlation coefficient between CPP and INVOS cerebral oximeter waveforms during 300-second periods. A laser-Doppler derived time-domain analysis of spontaneous autoregulation with the same parameters (LDx) was also determined. Results - An increase in the correlation coefficient between cerebral oximetry values and dynamic CPP fluctuations, indicative of a pressure-passive relationship, occurred when CPP was below the steady state autoregulatory breakpoint. This COx had 92% sensitivity (73% to 99%) and 63% specificity (48% to 76%) for detecting loss of autoregulation attributable to hypotension when COx was above a threshold of 0.36. The area under the receiver-operator characteristics curve for the COx was 0.89. COx correlated with LDx when values were sorted and averaged according to the CPP at which they were obtained (r = 0.67). Conclusions - The COx is sensitive for loss of autoregulation attributable to hypotension and is a promising monitoring tool for determining optimal CPP for patients with acute brain injury.	Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21287 USA; Addenbrookes Hosp, Dept Acad Neurosurg, Cambridge, England	Brady, KM (corresponding author), Johns Hopkins Univ, Sch Med, Dept Anesthesiol, Div Pediat Anesthesiol & Crit Care Med, 600 N Wolfe St,Balock 904, Baltimore, MD 21287 USA.	kbrady5@jhmi.edu		SHAFFNER, DONALD/0000-0001-5530-0746; Smielewski, Peter/0000-0001-5096-3938	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS020020] Funding Source: NIH RePORTER; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, G0001237, G0600986] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS020020, P01 NS020020-240002, NS20020] Funding Source: Medline		AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; BERKOWITZ ID, 1993, PEDIATR RES, V33, P48, DOI 10.1203/00006450-199301000-00010; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Dawson SL, 2003, CEREBROVASC DIS, V16, P69, DOI 10.1159/000070118; Giller CA, 2003, MED ENG PHYS, V25, P633, DOI 10.1016/S1350-4533(03)00028-6; Hiler M, 2006, J NEUROSURG, V104, P731, DOI 10.3171/jns.2006.104.5.731; Jaeger M, 2006, CRIT CARE MED, V34, P1783, DOI 10.1097/01.CCM.0000218413.51546.9E; Lam JMK, 1997, J NEUROSURG, V86, P438, DOI 10.3171/jns.1997.86.3.0438; Lang EW, 2003, CRIT CARE MED, V31, P267, DOI 10.1097/00003246-200301000-00042; LAPTOOK AR, 1983, PEDIATR RES, V17, P77, DOI 10.1203/00006450-198301000-00015; Mertineit C, 2000, CAN J PHYSIOL PHARM, V78, P217, DOI 10.1139/cjpp-78-3-217; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; O'Rourke MM, 2000, CRIT CARE MED, V28, P157, DOI 10.1097/00003246-200001000-00026; Panerai RB, 2003, MED ENG PHYS, V25, P621, DOI 10.1016/S1350-4533(03)00027-4; Panerai RB, 1998, PHYSIOL MEAS, V19, P305, DOI 10.1088/0967-3334/19/3/001; Slater AJ, 1997, AM J PHYSIOL-HEART C, V273, pH380; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Tsuji M, 2000, PEDIATRICS, V106, P625, DOI 10.1542/peds.106.4.625; Vavilala MS, 2006, DEV NEUROSCI-BASEL, V28, P348, DOI 10.1159/000094161	21	190	192	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	OCT	2007	38	10					2818	2825		10.1161/STROKEAHA.107.485706			8	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	213VJ	WOS:000249694900032	17761921	Green Accepted, Green Published, Bronze			2021-06-18	
J	O'Donnell, ML; Creamer, M; Pattison, P; Atkin, C				O'Donnell, ML; Creamer, M; Pattison, P; Atkin, C			Psychiatric morbidity following injury	AMERICAN JOURNAL OF PSYCHIATRY			English	Article; Proceedings Paper	17th Annual Meeting of the International-Society-for-Traumatic-Stress-Studies	DEC 04-09, 2001	NEW ORLEANS, LA	Int Soc Traumat Stress Studies			POSTTRAUMATIC-STRESS-DISORDER; MOTOR-VEHICLE ACCIDENTS; PSYCHOMETRIC PROPERTIES; TRAUMA SURVIVORS; MENTAL-HEALTH; BRAIN-INJURY; PREDICTORS; SCALE; COMORBIDITY; PREVALENCE	Objective: Accurate information regarding the psychopathological consequences of surviving traumatic injury is of great importance for effective health service design and planning. Regrettably, existing studies vary dramatically in reported prevalence rates of psychopathology within this population. The aim of this study was to identify the prevalence of psychiatric morbidity following severe injury by adopting a longitudinal design with close attention to optimizing the research methodology. Method: Consecutive admissions (N= 363) to a level 1 trauma service, excluding those with moderate or severe traumatic brain injury, were assessed at three time periods: just before discharge and 3 and 12 months after their injury. Structured clinical interviews were used to assess anxiety disorders, depressive disorders, and substance use disorders. Results: Posttraumatic stress disorder (PTSD) and major depressive disorder were the most frequent diagnoses at both 3 and 12 months, with 10% of participants meeting diagnostic criteria for each disorder at 12 months. Over 20% of the group met criteria for at least one psychiatric diagnosis 12 months after their injury. Comorbidity was common, with the most frequent being PTSD with major depressive disorder. Conclusions: Psychopathology following injury is a frequent and persistent occurrence. Despite the adoption of a rigorous and potentially conservative methodology, one-fifth of participants met criteria for one or more psychiatric diagnoses 12 months after their injury. These findings have major implications for injury health care providers.	Australian Ctr Posttraumat Mental Hlth, Heidelberg, Vic 3081, Australia; Univ Melbourne, Dept Psychol, Parkville, Vic 3052, Australia; Univ Melbourne, Dept Psychiat, Parkville, Vic 3052, Australia; Alfred Hosp, Dept Trauma Serv, Prague, Czech Republic	O'Donnell, ML (corresponding author), Australian Ctr Posttraumat Mental Hlth, POB 5444, Heidelberg, Vic 3081, Australia.	mod@unimelb.edu.au		Pattison, Philippa/0000-0001-9626-2897; O'Donnell, Meaghan/0000-0003-4349-0022			Andrews G, 2001, BRIT J PSYCHIAT, V178, P145, DOI 10.1192/bjp.178.2.145; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Beck A. T., 1996, BECK DEPRESSION INVE, VII; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; BLAKE DD, 1998, CLIN ADM PTSD SCALE, P1; Breslau N, 1998, ARCH GEN PSYCHIAT, V55, P626, DOI 10.1001/archpsyc.55.7.626; Breslau N, 1997, ARCH GEN PSYCHIAT, V54, P1044; Bryant RA, 1997, CLIN PSYCHOL REV, V17, P757, DOI 10.1016/S0272-7358(97)00052-4; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Bryant RA, 2001, J CLIN EXP NEUROPSYC, V23, P718, DOI 10.1076/jcen.23.6.718.1024; Creamer M, 2001, PSYCHOL MED, V31, P1237, DOI 10.1017/S0033291701004287; Ehlers A, 1998, J ABNORM PSYCHOL, V107, P508, DOI 10.1037/0021-843X.107.3.508; First M.B., 1996, STRUCTURED CLIN INTE; Freedman SA, 1999, BRIT J PSYCHIAT, V174, P353, DOI 10.1192/bjp.174.4.353; GREEN BL, 1990, J APPL SOC PSYCHOL, V20, P1632, DOI 10.1111/j.1559-1816.1990.tb01498.x; Harvey AG, 1999, J NERV MENT DIS, V187, P443, DOI 10.1097/00005053-199907000-00009; Harvey AG, 1999, J CONSULT CLIN PSYCH, V67, P985, DOI 10.1037/0022-006X.67.6.985; Harvey AG, 1999, J TRAUMA STRESS, V12, P519, DOI 10.1023/A:1024723205259; Holbrook TL, 1998, J TRAUMA, V45, P315, DOI 10.1097/00005373-199808000-00018; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kessler RC, 1999, AM J PSYCHIAT, V156, P115, DOI 10.1176/ajp.156.1.115; KOOPMAN C, 1995, J TRAUMA STRESS, V8, P29, DOI 10.1007/BF02105405; Koren D, 1999, AM J PSYCHIAT, V156, P367; Marshall RD, 1999, AM J PSYCHIAT, V156, P1677; Mayou R, 2001, BRIT J PSYCHIAT, V179, P528, DOI 10.1192/bjp.179.6.528; Mayou R, 2001, AM J PSYCHIAT, V158, P1231, DOI 10.1176/appi.ajp.158.8.1231; MCCAIG LF, 2001, NATL HOSPITAL AMBULA, V320; Mellman TA, 2001, DEPRESS ANXIETY, V14, P226, DOI 10.1002/da.1071; Michaels AJ, 1999, J TRAUMA, V47, P460, DOI 10.1097/00005373-199909000-00005; Murray J, 2002, BRIT J PSYCHIAT, V180, P363, DOI 10.1192/bjp.180.4.363; *NAT CTR HLTH STAT, 1997, HLTH STAT US 1996 97; O'Donnell ML, 2003, CLIN PSYCHOL REV, V23, P587, DOI 10.1016/S0272-7358(03)00036-9; RIVARA FP, 1993, ARCH SURG-CHICAGO, V128, P907; ROTHBAUM BO, 1993, POSTTRAUMATIC STRESS, P23; Schnyder U, 2001, AM J PSYCHIAT, V158, P594, DOI 10.1176/appi.ajp.158.4.594; SHACKFORD SR, 1987, ARCH SURG-CHICAGO, V122, P523; Shalev AY, 1998, ARCH GEN PSYCHIAT, V55, P553, DOI 10.1001/archpsyc.55.6.553; Shalev AY, 1996, AM J PSYCHIAT, V153, P219; Shalev AY, 1998, AM J PSYCHIAT, V155, P630, DOI 10.1176/ajp.155.5.630; Shalev AY, 2000, J CLIN PSYCHIAT, V61, P33; Simon GE, 2002, PSYCHOL MED, V32, P585, DOI 10.1017/S0033291702005457; Soderstrom CA, 2001, J TRAUMA, V51, P557, DOI 10.1097/00005373-200109000-00024; TEASDALE G, 1974, LANCET, V2, P81; Watson WL, 2000, ACCIDENT ANAL PREV, V32, P277, DOI 10.1016/S0001-4575(99)00121-9; Weathers FW, 1999, PSYCHOL ASSESSMENT, V11, P124, DOI 10.1037/1040-3590.11.2.124; Weathers FW, 2001, DEPRESS ANXIETY, V13, P132, DOI 10.1002/da.1029; Wilson J, 1996, ASSESSING PSYCHOL TR; Zatzick DF, 2002, AM J PSYCHIAT, V159, P941, DOI 10.1176/appi.ajp.159.6.941	48	190	195	0	18	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0002-953X	1535-7228		AM J PSYCHIAT	Am. J. Psychiat.	MAR	2004	161	3					507	514		10.1176/appi.ajp.161.3.507			8	Psychiatry	Psychiatry	818WU	WOS:000221276000017	14992977				2021-06-18	
J	Fischer, D; Pavlidis, M; Thanos, S				Fischer, D; Pavlidis, M; Thanos, S			Cataractogenic lens injury prevents traumatic ganglion cell death and promotes axonal regeneration both in vivo and in culture	INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE			English	Article							BCL-2 TRANSGENIC MICE; OPTIC-NERVE SECTION; NEUROTROPHIC FACTOR; ADULT-RATS; GROWTH-FACTORS; IN-VIVO; SURVIVAL; INHIBITION; INVITRO; AXOTOMY	PURPOSE. To examine and quantify neuroprotective and neurite-promoting activity on retinal ganglion cells (RGCs) after injury of the lens. METHODS. In adult albino rats, penetrating lens injury was performed by intraocular injection. To test for injury-induced neuroprotective effects in vivo, fluorescence-prelabeled RGCs were axotomized by subsequent crush of the optic nerve (ON) with concomitant lens injury to cause cataract. The numbers of surviving RGCs were determined in retinal wholemounts and compared between the different experimental and control groups. To examine axonal regeneration in vivo, the ON was cut and replaced with an autologous piece of sciatic nerve (SN). Retinal ganglion cells with axons that had regenerated within the SN under lens injury or control conditions were retrogradely labeled with a fluorescent dye and counted on retinal wholemounts. Neurite regeneration was also studied in adult retinal explants obtained either after lens injury or without injury. The numbers of axons were determined after 1 and 2 days in culture. Putative neurotrophins (NTs) were studied within immunohistochemistry and Western blot analysis. RESULTS. Cataractogenic lens injury performed at the same time as ON crush resulted in highly significant rescue of 746 +/- 126 RGCs/mm(2) (mean +/- SD; approximately 39% of total RGCs) 14 days after injury compared with controls without injury or with injection of buffer into the vitreous body (30 +/- 18 RGCs/mm(2)). When lens injury was performed with a delay of 3 days after ON crush, 49% of RGCs survived, whereas delay of 5 days still rescued 45% of all RGCs. In the grafting paradigm virtually all surviving RGCs after lens injury appeared to have regenerated an axon within the SN graft (763 +/- 114 RGCs/mm(2) versus 79 +/- 17 RGCs/mm(2) in controls). This rate of regeneration corresponds to approximately 40% of all RGCs. In the regeneration paradigm in vitro preceding lens injury and ON crush 5 days previous resulted in a maximum of regeneration of 273 +/- 39 fibers/explant after 1 day and 574 +/- 38 fibers/explant after 2 days in vitro. In comparison, in control retinal pieces without lens injury 28 +/- 13 fibers/explant grew out at 1 day, and 97 +/- 37 fibers/explant grew out at 2 days in culture. Immunohistochemical and Western blot analysis of potential NTs in the injured lens revealed no expression of ciliary neurotrophic factor (CNTF), brain-derived neurotrophic factor (BDNF), NT-4, nerve growth factor (NGF), and basic fibroblast growth factor (bFGF). CONCLUSIONS. The findings indicate that the lens contains high neuroprotective and neuritogenic activity, which is not caused by NT. Compared with the data available in the literature, this neuroprotection is quantitatively among the highest ever reported within the adult rat visual system.	Univ Munster, Sch Med, Dept Expt Ophthalmol, D-48149 Munster, Germany	Thanos, S (corresponding author), Univ Munster, Sch Med, Dept Expt Ophthalmol, Domagkstr 15, D-48149 Munster, Germany.			Fischer, Dietmar/0000-0002-1816-3014			ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; BAHR M, 1988, EXP BRAIN RES, V73, P393; Bennett JL, 1999, INVEST OPHTH VIS SCI, V40, P2996; BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; Berry M, 1996, J NEUROCYTOL, V25, P147, DOI 10.1007/BF02284793; CARMIGNOTO G, 1989, J NEUROSCI, V9, P1263; Cenni MC, 1996, EUR J NEUROSCI, V8, P1735, DOI 10.1111/j.1460-9568.1996.tb01317.x; Chen DF, 1997, NATURE, V385, P434, DOI 10.1038/385434a0; Chierzi S, 1999, J NEUROSCI, V19, P8367; COHEN C, 1994, APPL IMMUNOHISTOCHEM, V2, P9; Cui Q, 1999, INVEST OPHTH VIS SCI, V40, P760; DAVID S, 1990, NEURON, V5, P463, DOI 10.1016/0896-6273(90)90085-T; DAVIES AM, 1995, TRENDS NEUROSCI, V18, P355, DOI 10.1016/0166-2236(95)93928-Q; EATON JW, 1994, DOC OPHTHALMOL, V88, P233; EBENDAL T, 1982, J NEUROSCI RES, V8, P153, DOI 10.1002/jnr.490080206; FAKTOROVICH EG, 1990, NATURE, V347, P83, DOI 10.1038/347083a0; Fournier AE, 1997, J NEUROSCI RES, V47, P561, DOI 10.1002/(SICI)1097-4547(19970315)47:6<561::AID-JNR1>3.3.CO;2-Q; Fromm L, 1997, DEV GENET, V20, P276, DOI 10.1002/(SICI)1520-6408(1997)20:3<276::AID-DVG10>3.0.CO;2-6; HIGHTOWER KR, 1995, CURR EYE RES, V14, P71, DOI 10.3109/02713689508999916; Jo SA, 1999, NEUROSCIENCE, V89, P579, DOI 10.1016/S0306-4522(98)00546-6; Kermer P, 1998, J NEUROSCI, V18, P4656; Klocker N, 1997, NEUROREPORT, V8, P3439; Klocker N, 1998, J NEUROSCI, V18, P1038; LAVAIL MM, 1992, P NATL ACAD SCI USA, V89, P11249, DOI 10.1073/pnas.89.23.11249; MAHMOUD TH, 1994, INVEST OPHTH VIS SCI, V40, P722; MANSOURROBAEY S, 1994, P NATL ACAD SCI USA, V91, P1632, DOI 10.1073/pnas.91.5.1632; MEY J, 1993, BRAIN RES, V602, P304, DOI 10.1016/0006-8993(93)90695-J; Porciatti V, 1996, P NATL ACAD SCI USA, V93, P14955, DOI 10.1073/pnas.93.25.14955; RUSSELL P, 1991, EXP EYE RES, V52, P613, DOI 10.1016/0014-4835(91)90064-L; Sawai H, 1996, J NEUROSCI, V16, P3887; SIEVERS J, 1987, NEUROSCI LETT, V76, P157, DOI 10.1016/0304-3940(87)90708-7; THANOS S, 1989, EUR J NEUROSCI, V1, P19, DOI 10.1111/j.1460-9568.1989.tb00770.x; THANOS S, 1993, J NEUROSCI, V13, P455; VIDALSANZ M, 1987, J NEUROSCI, V7, P2894; VILLEGASPEREZ MP, 1993, J NEUROBIOL, V24, P23, DOI 10.1002/neu.480240103; Weinreb O, 1996, EXP EYE RES, V63, P591, DOI 10.1006/exer.1996.0150; WEN R, 1995, J NEUROSCI, V15, P7377; WISTOW G, 1993, TRENDS BIOCHEM SCI, V18, P301, DOI 10.1016/0968-0004(93)90041-K	39	190	204	0	9	ASSOC RESEARCH VISION OPHTHALMOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0146-0404			INVEST OPHTH VIS SCI	Invest. Ophthalmol. Vis. Sci.	NOV	2000	41	12					3943	3954					12	Ophthalmology	Ophthalmology	369LH	WOS:000165066400039	11053298				2021-06-18	
J	Hubbard, IJ; Parsons, MW; Neilson, C; Carey, LM				Hubbard, Isobel J.; Parsons, Mark W.; Neilson, Cheryl; Carey, Leeanne M.			Task-specific training: evidence for and translation to clinical practice	OCCUPATIONAL THERAPY INTERNATIONAL			English	Article						motor rehabilitation; stroke; task specific training	INDUCED MOVEMENT THERAPY; TRAUMATIC BRAIN-INJURY; SIT-TO-STAND; STROKE RECOVERY; UPPER-LIMB; REHABILITATION; REORGANIZATION; PLASTICITY; PATTERNS; EXERCISE	There is mounting evidence of the value of task-specific training as a neuromotor intervention in neurological rehabilitation. The evidence is founded in the psychology of motor skill learning and in the neuroscience of experience-dependent and learning-dependent neural plastic changes in the brain in animals and humans. Further, there is growing empirical evidence for the effectiveness of task-specific training in rehabilitation and for neural plastic changes following task-oriented training. In this paper, we position the evidence for task-specific training in the context of rehabilitation; review its relevance for occupation-based neurological rehabilitation, particularly in relation to upper limb function and everyday activities; and recommend evidence-driven strategies for its application. We recommend that task-specific training be routinely applied by occupational therapists as a component of their neuromotor interventions, particularly in management related to post-stroke upper limb recovery. Specifically, we propose five implementation strategies based on review of the evidence. These are: task-specific training should be relevant to the patient/client and to the context; be randomly assigned; be repetitive and involve massed practice; aim towards reconstruction of the whole task; and be reinforced with positive and timely feedback. Copyright (C) 2009 John Wiley & Sons, Ltd.	[Carey, Leeanne M.] Natl Stroke Res Inst, Florey Neurosci Inst, Melbourne, Vic, Australia; [Carey, Leeanne M.] La Trobe Univ, Sch Occupat Therapy, Bundoora, Vic, Australia; [Neilson, Cheryl] Mt Alexander Hosp, Castlemaine, Australia; [Hubbard, Isobel J.; Parsons, Mark W.] John Hunter Hosp, Acute Stroke Unit, Hunter New England Area Hlth Serv, Newcastle, NSW, Australia; [Hubbard, Isobel J.; Parsons, Mark W.] Univ Newcastle, Newcastle, NSW 2308, Australia	Carey, LM (corresponding author), Austin Hlth, Level 2,Neurosci Bldg,Repatriat Campus,300 Waterd, Heidelberg Hts, Vic 3081, Australia.	lcarey@nsri.org.au	Parsons, Mark W./G-3750-2014; Hubbard, Isobel/G-7444-2013				Armstrong J., 2008, NZ J OCCUP THER, V55, P20; AYRES AJ, 1965, PERCEPT MOTOR SKILL, V20, P335, DOI 10.2466/pms.1965.20.2.335; Bayona Nestor A, 2005, Top Stroke Rehabil, V12, P58; Bernhardt J, 2007, J REHABIL MED, V39, P43, DOI 10.2340/16501977-0013; Betker AL, 2007, PHYS THER, V87, P1389, DOI 10.2522/ptj.20060229; Blennerhassett J, 2004, AUST J PHYSIOTHER, V50, P219, DOI 10.1016/S0004-9514(14)60111-2; BOBATH K, 1980, CLIN DEV MED SPASTIC, V75; Byl N, 2003, NEUROREHAB NEURAL RE, V17, P176, DOI 10.1177/0888439003257137; Calautti C, 2001, NEUROREPORT, V12, P3883, DOI 10.1097/00001756-200112210-00005; CALVANIO R, 1993, NEUROL CLIN, V11, P25; Canning CG, 2003, CLIN REHABIL, V17, P355, DOI 10.1191/0269215503cr620oa; Carey JR, 2002, BRAIN, V125, P773, DOI 10.1093/brain/awf091; Carey L, 2006, TXB NEURAL REPAIR RE, P231; Carey L, 2007, INT J THER REHABIL, V14, P250, DOI 10.12968/ijtr.2007.14.6.23893; Carey LM, 2007, INT J STROKE, V2, P245, DOI 10.1111/j.1747-4949.2007.00164.x; CAREY LM, 1993, ARCH PHYS MED REHAB, V74, P602, DOI 10.1016/0003-9993(93)90158-7; Carr J.H., 2000, MOVEMENT SCI FDN PHY; CARR JH, 1982, MOTOR RELEARNING PRO; Case-Smith J., 2005, OCCUPATIONAL THERAPY; Christiansen CH., 2004, INTRO OCCUPATION; Chua KSG, 2007, ANN ACAD MED SINGAP, V36, P31; Daniels R, 2002, SCAND J OCCUP THER, V9, P167, DOI DOI 10.1080/110381202605; DAVIES PM, 1994, STEPS FOLLOW GUIDE T; Davis JZ, 2006, TOP STROKE REHABIL, V13, P1, DOI 10.1310/D91V-2NEY-6FL5-26Y2; DOBKIN BH, 2005, RECOVERY STROKE, P47, DOI DOI 10.1017/CBO9781316135297.003; Drabsch Tracey, 1998, Aust J Physiother, V44, P193; Duffau H, 2006, J CLIN NEUROSCI, V13, P885, DOI 10.1016/j.jocn.2005.11.045; Feys HM, 1998, STROKE, V29, P785, DOI 10.1161/01.STR.29.4.785; French B, 2008, HEALTH TECHNOL ASSES, V12, P1; Goldstone RL, 1998, ANNU REV PSYCHOL, V49, P585, DOI 10.1146/annurev.psych.49.1.585; Guadagno JV, 2003, BRIT MED BULL, V65, P145, DOI 10.1093/bmb/65.1.145; Hakkennes S, 2005, AUST J PHYSIOTHER, V51, P221, DOI 10.1016/S0004-9514(05)70003-9; Hamzei F, 2006, NEUROIMAGE, V31, P710, DOI 10.1016/j.neuroimage.2005.12.035; Hesse S, 1999, NEUROREHAB NEURAL RE, V13, P179, DOI 10.1177/154596839901300306; Hubbard I, 2007, INT J THER REHABIL, V14, P357, DOI 10.12968/ijtr.2007.14.8.24355; JOHANSSON BB, 2005, RECOVERY STROKE, P88; KARNI A, 1995, NATURE, V377, P155; Kelly C, 2006, ARCH PHYS MED REHAB, V87, pS20, DOI 10.1016/j.apmr.2006.08.333; Kim YH, 2004, YONSEI MED J, V45, P241, DOI 10.3349/ymj.2004.45.2.241; KNAPP HD, 1963, EXP NEUROL, V7, P305, DOI 10.1016/0014-4886(63)90077-3; KNAPP HD, 1958, SCIENCE, V128, P842, DOI 10.1126/science.128.3328.842; Krakauer JW, 2006, CURR OPIN NEUROL, V19, P84, DOI 10.1097/01.wco.0000200544.29915.cc; Kubasak MD, 2008, BRAIN, V131, P264, DOI 10.1093/brain/awm267; Langhammer B, 2000, CLIN REHABIL, V14, P361, DOI 10.1191/0269215500cr338oa; Law M., 2005, CANADIAN OCCUPATIONA, V4th ed; LEMON RN, 1991, NATO ADV SCI I D-BEH, V62, P477; Mak MKY, 2008, MOVEMENT DISORD, V23, P501, DOI 10.1002/mds.21509; Mathiowetz V., 2004, STROKE REHABILITATIO, P59; McCannon Robin, 2005, Work, V24, P139; Michaelsen SM, 2006, STROKE, V37, P186, DOI 10.1161/01.STR.0000196940.20446.c9; MOULTON C, 1997, OCCUPATIONAL THERAPY, V4, P31, DOI DOI 10.1002/OTI.46; National Stroke Foundation, 2005, CLIN GUID STROK REH; Nelles G, 2001, NEUROIMAGE, V13, P1146, DOI 10.1006/nimg.2001.0757; Nelson DL, 1996, AM J OCCUP THER, V50, P639, DOI 10.5014/ajot.50.8.639; Nudo RJ, 2000, NEUROPHARMACOLOGY, V39, P733, DOI 10.1016/S0028-3908(99)00254-3; Nudo RJ, 1996, J NEUROPHYSIOL, V75, P2144; NUDO RJ, 1996, SCIENCE, V39, P733; Page SJ, 2003, AM J PHYS MED REHAB, V82, P730, DOI 10.1097/01.PHM.0000078226.36000.A5; Page SJ, 2005, NEUROREHAB NEURAL RE, V19, P27, DOI 10.1177/1545968304272701; Page SJ, 2004, ARCH PHYS MED REHAB, V85, P14, DOI 10.1016/S0003-9993(03)00481-7; Peurala SH, 2004, J NEUROL, V251, P449, DOI 10.1007/s00415-004-0352-0; Platz T, 2004, RESTOR NEUROL NEUROS, V22, P301; Plautz EJ, 2000, NEUROBIOL LEARN MEM, V74, P27, DOI 10.1006/nlme.1999.3934; Richards LG, 2008, NEUROPSYCHOLOGIA, V46, P3, DOI 10.1016/j.neuropsychologia.2007.08.013; Ross LM, 2000, OCCUP THER J RES, V20, P45, DOI 10.1177/153944920002000103; Rossi F, 2007, PROG NEUROBIOL, V81, P1, DOI 10.1016/j.pneurobio.2006.12.001; Rossini PM, 2003, LANCET NEUROL, V2, P493, DOI 10.1016/S1474-4422(03)00485-X; Schaechter JD, 2002, NEUROREHAB NEURAL RE, V16, P326, DOI 10.1177/154596830201600403; Schmidt R.A., 2005, MOTOR CONTROL LEARNI, V4, 89-122; Schmidt RA, 1991, MOTOR LEARNING PERFO; Seitz RJ, 2005, RECOVERY STROKE, P88; Shumway-Cook A., 1995, MOTOR CONTROL THEORY; Stinear CM, 2007, BRAIN, V130, P170, DOI 10.1093/brain/awl333; Sullivan KJ, 2007, PHYS THER, V87, P1580, DOI 10.2522/ptj.20060310; Taub E, 2002, NAT REV NEUROSCI, V3, P228, DOI 10.1038/nrn754; TAUB E, 1993, ARCH PHYS MED REHAB, V74, P347; Teasell Robert, 2005, Top Stroke Rehabil, V12, P11; Teasell RW, 2008, ARCH PHYS MED REHAB, V89, P575, DOI 10.1016/j.apmr.2007.08.164; Trombly CA, 1999, AM J OCCUP THER, V53, P333, DOI 10.5014/ajot.53.4.333; TROMBLY CA, 1995, OCCUPATIONAL THERAPY; TURTON A, 1993, SPASTICITY MECH MANA, P8; UMPHRED DA, 1995, NEUROLOGICAL REHABIL; VANVLIET P, 1995, NEUROLOGY REPORT, V19, P11; WALKER MF, 2000, BRIT J OCCUPATIONAL, V63, P367, DOI DOI 10.1177/030802260006300803; Winstein C. J., 2006, TXB NEURAL REPAIR RE, P89, DOI [10.1017/CBO9780511545078.009, DOI 10.1017/CBO9780511545078.009]; Winstein CJ, 2004, ARCH PHYS MED REHAB, V85, P620, DOI 10.1016/j.apmr.2003.06.027; Wolf SL, 2002, NEUROLOGIST, V8, P325, DOI 10.1097/00127893-200211000-00001; Wolf SL, 2006, JAMA-J AM MED ASSOC, V296, P2095, DOI 10.1001/jama.296.17.2095; WOODDAUPHINEE S, 2005, RECOVERY STROKE, P161; Wu CY, 2000, ARCH PHYS MED REHAB, V81, P95, DOI 10.1053/apmr.2000.0810095	90	189	192	4	37	WILEY-HINDAWI	LONDON	ADAM HOUSE, 3RD FL, 1 FITZROY SQ, LONDON, WIT 5HE, ENGLAND	0966-7903	1557-0703		OCCUP THER INT	Occup. Ther. Int.	SEP-DEC	2009	16	3-4			SI		175	189		10.1002/oti.275			15	Rehabilitation	Rehabilitation	V16VG	WOS:000207896500002	19504501				2021-06-18	
J	Bauman, RA; Ling, G; Tong, L; Januszkiewicz, A; Agoston, D; Delanerolle, N; Kim, Y; Ritzel, D; Bell, R; Ecklund, J; Armonda, R; Bandak, F; Parks, S				Bauman, Richard A.; Ling, Geoffrey; Tong, Lawrence; Januszkiewicz, Adolph; Agoston, Denes; Delanerolle, Nihal; Kim, Young; Ritzel, Dave; Bell, Randy; Ecklund, James; Armonda, Rocco; Bandak, Faris; Parks, Steven			An Introductory Characterization of a Combat-Casualty-Care Relevant Swine Model of Closed Head Injury Resulting from Exposure to Explosive Blast	JOURNAL OF NEUROTRAUMA			English	Article						blast tube; brain injury; explosive blast; free field; overpressure; vasospasm	BASIC-PROTEIN ISOFORMS; TRAUMATIC BRAIN-INJURY; SHOCK-WAVES; RESUSCITATION; NEUROTRAUMA; BIOMARKERS; INDUCTION; APOPTOSIS; SYSTEM; DAMAGE	Explosive blast has been extensively used as a tactical weapon in Operation Iraqi Freedom (OIF) and more recently in Operation Enduring Freedom(OEF). The polytraumatic nature of blast injuries is evidence of their effectiveness, and brain injury is a frequent and debilitating form of this trauma. In-theater clinical observations of brain-injured casualties have shown that edema, intracranial hemorrhage, and vasospasm are the most salient pathophysiological characteristics of blast injury to the brain. Unfortunately, little is known about exactly how an explosion produces these sequelae as well as others that are less well documented. Consequently, the principal objective of the current report is to present a swine model of explosive blast injury to the brain. This model was developed during Phase I of the DARPA (Defense Advanced Research Projects Agency) PREVENT (Preventing Violent Explosive Neurotrauma) blast research program. A second objective is to present data that illustrate the capabilities of this model to study the proximal biomechanical causes and the resulting pathophysiological, biochemical, neuropathological, and neurological consequences of explosive blast injury to the swine brain. In the concluding section of this article, the advantages and limitations of the model are considered, explosive and air-overpressure models are compared, and the physical properties of an explosion are identified that potentially contributed to the in-theater closed head injuries resulting from explosions of improvised explosive devices (IEDs).	[Bauman, Richard A.; Januszkiewicz, Adolph] Walter Reed Army Inst Res, Div Brain Dysfunct & Blast Injury, Silver Spring, MD 20910 USA; [Ling, Geoffrey] DARPA, Arlington, VA USA; [Tong, Lawrence; Parks, Steven] ORA Inc, Fredericksburg, VA USA; [Agoston, Denes] Uniformed Serv Univ Hlth Sci, Dept Anat, Bethesda, MD 20814 USA; [Bandak, Faris] Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA; [Delanerolle, Nihal] Yale Univ, Sch Med, Dept Anat, New Haven, CT USA; [Kim, Young] Yale Univ, Sch Med, Dept Neuropathol, New Haven, CT USA; [Bell, Randy; Armonda, Rocco] Walter Reed Army Med Ctr, Dept Neurosurg, Washington, DC 20307 USA; [Ecklund, James] Inova Fairfax Hosp, Fairfax, VA USA; [Ritzel, Dave] DYNFX Consulting, Windsor, ON, Canada	Bauman, RA (corresponding author), Walter Reed Army Inst Res, Div Brain Dysfunct & Blast Injury, 502 Robert Grant Ave, Silver Spring, MD 20910 USA.	richard.bauman@amedd.army.mil					Agoston DV, 2009, J NEUROTRAUM, V26, P901, DOI 10.1089/neu.2008.0724; Ananiadou OG, 2008, J CARDIAC SURG, V23, P31, DOI 10.1111/j.1540-8191.2007.00485.x; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Avidan V, 2005, AM J SURG, V190, P927, DOI 10.1016/j.amjsurg.2005.08.022; Carpentier P, 2001, NEUROTOXICOLOGY, V22, P299, DOI 10.1016/S0161-813X(01)00019-5; Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Dondelinger RF, 1998, EUR RADIOL, V8, P1254, DOI 10.1007/s003300050545; DUDKIEWICZ PK, 2008, CRIT CARE MED, V36, P2703; Earle SA, 2007, J AM COLL SURGEONS, V204, P261, DOI 10.1016/j.jamcollsurg.2006.11.014; Frasch MG, 2006, ACTA NEUROBIOL EXP, V66, P43; Friess SH, 2007, EXP NEUROL, V204, P234, DOI 10.1016/j.expneurol.2006.10.010; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hrapko M, 2008, J BIOMECH ENG-T ASME, V130, DOI 10.1115/1.2907746; Kato K, 2007, J NEUROSURG, V106, P667, DOI 10.3171/jns.2007.106.4.667; Kaur C., 1997, Annals Academy of Medicine Singapore, V26, P27; Kaur C, 1996, ARCH HISTOL CYTOL, V59, P239, DOI 10.1679/aohc.59.239; KAUR C, 1995, NEUROPATHOLOGY APPL, V21, P787; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; Liu MC, 2006, J NEUROCHEM, V98, P700, DOI 10.1111/j.1471-4159.2006.03882.x; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Lukatch HS, 2005, CEREB CORTEX, V15, P1322, DOI 10.1093/cercor/bhi015; Manley GT, 2006, J NEUROTRAUM, V23, P128, DOI 10.1089/neu.2006.23.128; Massoud TF, 2000, AM J NEURORADIOL, V21, P1268; Ottens AK, 2008, J NEUROCHEM, V104, P1404, DOI 10.1111/j.1471-4159.2007.05086.x; Petras JM, 1997, TOXICOLOGY, V121, P41, DOI 10.1016/S0300-483X(97)03654-8; Rosenthal G, 2008, J NEUROSURG, V108, P575, DOI 10.3171/JNS/2008/108/3/0575; Saljo A, 2003, J NEUROTRAUM, V20, P787, DOI 10.1089/089771503767870014; Saljo A, 2002, J NEUROTRAUM, V19, P985, DOI 10.1089/089771502320317131; SALJO A, 2009, J NEUROTRAUMA; Settles GS, 2006, AM SCI, V94, P22, DOI 10.1511/2006.1.22; Sips RJA, 2008, CONNECT TISSUE RES, V49, P22, DOI 10.1080/03008200701818678; Soehle M, 2004, ANESTH ANALG, V98, P1133, DOI 10.1213/01.ANE.0000111101.41190.99; Suneson A, 2000, MIL MED, V165, P119, DOI 10.1093/milmed/165.2.119	34	189	197	1	43	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2009	26	6					841	860		10.1089/neu.2008.0898			20	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	455OV	WOS:000266773600004	19215189				2021-06-18	
J	You, ZR; Savitz, SI; Yang, JS; Degterev, A; Yuan, JY; Cuny, GD; Moskowitz, MA; Whalen, MJ				You, Zerong; Savitz, Sean I.; Yang, Jinsheng; Degterev, Alexei; Yuan, Junying; Cuny, Gregory D.; Moskowitz, Michael A.; Whalen, Michael J.			Necrostatin-1 reduces histopathology and improves functional outcome after controlled cortical impact in mice	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						necroptosis; necrostatin; traumatic brain injury; mice; necrosis; inflammation	TRAUMATIC BRAIN-INJURY; TUMOR-NECROSIS-FACTOR; NECROTIC CELL-DEATH; FAS RECEPTOR; NECROPTOSIS INHIBITORS; UP-REGULATION; L929 CELLS; APOPTOSIS; CASPASE-3; CULTURES	Necroptosis is a newly identified type of programmed necrosis initiated by the activation of tumor necrosis factor alpha (TNF alpha)/Fas. Necrostatin-1 is a specific inhibitor of necroptosis that reduces ischemic tissue damage in experimental stroke models. We previously reported decreased tissue damage and improved functional outcome after controlled cortical impact (CCI) in mice deficient in TNFa and Fas. Hence, we hypothesized that necrostatin-1 would reduce histopathology and improve functional outcome after CCI in mice. Compared with vehicle-/inactive analog-treated controls, mice administered necrostatin-1 before CCI had decreased propidium iodide-positive cells in the injured cortex and dentate gyrus (6 h), decreased brain tissue damage (days 14, 35), improved motor (days 1 to 7), and Morris water maze performance (days 8 to 14) after CCI. Improved spatial memory was observed even when drug was administered 15 mins after CCI. Necrostatin-1 treatment did not reduce caspase-3-positive cells in the dentate gyrus or cortex, consistent with a known caspase-independent mechanism of necrostatin-1. However, necrostatin-1 reduced brain neutrophil influx and microglial activation at 48 h, suggesting a novel anti-inflammatory effect in traumatic brain injury (TBI). The data suggest that necroptosis plays a significant role in the pathogenesis of cell death and functional outcome after TBI and that necrostatin-1 may have therapeutic potential for patients with TBI.	[You, Zerong; Savitz, Sean I.; Yang, Jinsheng; Moskowitz, Michael A.; Whalen, Michael J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pediat Crit Care Med,Neurosci Ctr, Charlestown, MA 02129 USA; [You, Zerong; Yang, Jinsheng; Whalen, Michael J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pediat, Charlestown, MA 02129 USA; [Savitz, Sean I.] Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA; [Degterev, Alexei; Yuan, Junying] Harvard Univ, Sch Med, Dept Cell Biol, Charlestown, MA 02129 USA; [Cuny, Gregory D.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Lab Drug Discovery Neurodegenerat, Cambridge, MA 02138 USA; [Moskowitz, Michael A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol, Charlestown, MA 02129 USA	Whalen, MJ (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pediat Crit Care Med,Neurosci Ctr, 149 13th St, Charlestown, MA 02129 USA.	MWhalen@Partners.org	Moskowitz, Michael A/D-9916-2011	Cuny, Gregory/0000-0002-3188-4748	NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RO1NS47447, P30NS45776]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS067497, R01NS061255, P30NS045776, R01NS047447] Funding Source: NIH RePORTER	This work was supported by grants from NIH/NINDS (RO1NS47447 to MJW) and P30NS45776.	Aoyama N, 2002, BRAIN RES, V934, P117, DOI 10.1016/S0006-8993(02)02366-1; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Bermpohl D, 2007, J CEREBR BLOOD F MET, V27, P1806, DOI 10.1038/sj.jcbfm.9600487; Bermpohl D, 2006, J CEREBR BLOOD F MET, V26, P625, DOI 10.1038/sj.jcbfm.9600258; Cevik IU, 2003, CELL DEATH DIFFER, V10, P928, DOI 10.1038/sj.cdd.4401250; Clark RSB, 2007, J CEREBR BLOOD F MET, V27, P316, DOI 10.1038/sj.jcbfm.9600338; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Colige A, 2002, J BIOL CHEM, V277, P5756, DOI 10.1074/jbc.M105601200; Degterev A, 2005, NAT CHEM BIOL, V1, P112, DOI 10.1038/nchembio711; Denecker G, 2001, CELL MOL LIFE SCI, V58, P356, DOI 10.1007/PL00000863; Denecker G, 2001, CELL DEATH DIFFER, V8, P829, DOI 10.1038/sj.cdd.4400883; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Jagtap PG, 2007, J MED CHEM, V50, P1886, DOI 10.1021/jm061016o; Kristensen BW, 2003, BRAIN RES, V964, P264, DOI 10.1016/S0006-8993(02)04080-5; Lee RC, 1999, ANN NY ACAD SCI, V888, P266, DOI 10.1111/j.1749-6632.1999.tb07961.x; Lotocki G, 2004, J NEUROSCI, V24, P11010, DOI 10.1523/JNEUROSCI.3823-04.2004; Matsumura H, 2000, J CELL BIOL, V151, P1247, DOI 10.1083/jcb.151.6.1247; Qiu JH, 2002, J NEUROSCI, V22, P3504; Ranaivo HR, 2006, J NEUROSCI, V26, P662, DOI 10.1523/JNEUROSCI.4652-05.2006; Srinivasan A, 1998, CELL DEATH DIFFER, V5, P1004, DOI 10.1038/sj.cdd.4400449; Teng X, 2005, BIOORG MED CHEM LETT, V15, P5039, DOI 10.1016/j.bmcl.2005.07.077; Unal-Cevik I, 2004, STROKE, V35, P2189, DOI 10.1161/01.STR.0000136149.81831.c5; Vanden Berghe T, 2004, J BIOL CHEM, V279, P7925, DOI 10.1074/jbc.M307807200; Vanden Berghe Tom, 2004, Methods Mol Med, V98, P101; Vercammen D, 1998, J EXP MED, V188, P919, DOI 10.1084/jem.188.5.919; Vercammen D, 1997, CYTOKINE, V9, P801, DOI 10.1006/cyto.1997.0252; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Wang K, 2007, BIOORG MED CHEM LETT, V17, P1455, DOI 10.1016/j.bmcl.2006.11.056; Whalen MJ, 2008, J CEREBR BLOOD F MET, V28, P490, DOI 10.1038/sj.jcbfm.9600544; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950; Zhang XP, 2002, J NEUROCHEM, V82, P181, DOI 10.1046/j.1471-4159.2002.00975.x	32	189	208	0	16	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	SEP	2008	28	9					1564	1573		10.1038/jcbfm.2008.44			10	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	341LQ	WOS:000258716400005	18493258	Green Accepted, Bronze			2021-06-18	
J	Covassin, T; Schatz, P; Swanik, CB				Covassin, Tracey; Schatz, Philip; Swanik, C. Buz			Sex differences in neuropsychological function and post-concussion symptoms of concussed collegiate athletes	NEUROSURGERY			English	Article						concussion; Immediate Post-concussion Assessment and Cognitive Testing; neuropsychological functioning; sex differences	TRAUMATIC BRAIN-INJURY; HEAD-INJURY; RECOVERY; IMPACT; PERFORMANCE	OBJECTIVE: Our purpose was to determine whether sex differences exist with respect to post-concussion symptoms and neurocognitive function in concussed collegiate athletes. METHODS: A prospective dependent-sample cohort design was used to compare baseline and post-concussion neuropsychological test scores and endorsed symptoms as functions of serial post-concussion assessment with respect to time and sex. The Immediate Post-concussion Assessment and Cognitive Testing (ImPACT) battery was administered to a multicenter analysis group of 79 concussed athletes. This computerized neuropsychological test was given to the athletes during the preseason and, on average, 2 and 8 days postinjury. RESULTS: Multivariate analyses revealed no significant between-group differences on baseline test performance with respect to sex on any of the ImPACT composite scores or on the total symptom score. Multivariate analyses of post-concussion data revealed a significant main effect of time on ImPACT scores, but no main effect of sex was identified, and no time-by-sex interaction existed. Post hoc analysis revealed that concussed female athletes performed significantly worse than concussed male athletes on visual memory tasks (P = 0.001), and analysis of endorsed post-concussion symptoms revealed that concussed men were significantly more likely than concussed women to report post-concussion symptoms of vomiting (P = 0.001) and sadness (P = 0.017). Athletes' scores were examined individually using the reliable-change methodology. At 2 days post-injury, 58% of concussed athletes had one or more reliable incidents of performance decline or increases in symptom reporting. At 8 days post-concussion, 30% of concussed athletes were still showing one or more reliable change from preseason values. CONCLUSIONS: College athletes exhibit differences on visual memory composite scores and symptoms post-concussion as a function of sex. These data support the importance of evaluating neuropsychological status and post-concussion symptoms in concussed athletes. In addition, these data illustrate the importance of analyzing an individual athlete's recovery pattern, because individual differences in recovery trajectories may be overshadowed by global norm-group comparisons.	Michigan State Univ, Dept Kinesiol, E Lansing, MI 48824 USA; St Josephs Univ, Dept Psychol, Philadelphia, PA 19131 USA; Univ Delaware, Dept Hlth Nutr & Exercise Sci, Newark, DE 19716 USA	Covassin, T (corresponding author), Michigan State Univ, Dept Kinesiol, 105 IM Sports Circle Bldg, E Lansing, MI 48824 USA.	covassin@msu.edu	Swanik, Charles/C-4377-2014	Swanik, Charles/0000-0001-9701-2005; Schatz, Philip/0000-0002-6222-6545			Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; BARTH JT, 1998, MILD HEAD INJURY, P257; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Brooks J, 2004, STUD NEUROPSYCHOL DE, P443; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Chan RCK, 2001, CLIN REHABIL, V15, P266, DOI 10.1191/026921501675253420; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Covassin T, 2003, J ATHL TRAINING, V38, P238; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Gartland S, 2001, BRIT J SPORT MED, V35, P308, DOI 10.1136/bjsm.35.5.308; Granito VJ., 2002, J SPORT BEHAV, V25, P243; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Iverson GL, 2002, ARCH CLIN NEUROPSYCH, V17, P770; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; KELLY J, 1995, CURRENT THERAPY SPOR, P32; Kimura D, 2002, PSYCHOL REP, V91, P1137, DOI 10.2466/PR0.91.7.1137-1142; LEWIS RS, 1987, BRAIN COGNITION, V6, P142, DOI 10.1016/0278-2626(87)90115-1; LOVELL M, 2001, IMMEDIATE POST CONCU; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; LUINE VN, 1985, EXP NEUROL, V89, P484, DOI 10.1016/0014-4886(85)90108-6; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MASTERS SJ, 1987, NEW ENGL J MED, V316, P84, DOI 10.1056/NEJM198701083160205; Murphy DGM, 1996, ARCH GEN PSYCHIAT, V53, P585; *NAT ATHL TRAIN AS, 1994, P MILD BRAIN INJ SUM; *NAT COLL ATHL ASS, NCAA INJ SURV SYST A; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; SPSS. SPSS Inc, 2001, STAT PACK SOC SCI; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Weiss EM, 2003, PERS INDIV DIFFER, V35, P863, DOI 10.1016/S0191-8869(02)00288-X; 1997, NEUROLOGY, V4, P581	41	189	190	0	23	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	AUG	2007	61	2					345	350		10.1227/01.NEU.0000279972.95060.CB			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	197AN	WOS:000248525400028	17762747				2021-06-18	
J	Elkin, BS; Azeloglu, EU; Costa, KD; Morrison, B				Elkin, Benjamin S.; Azeloglu, Evren U.; Costa, Kevin D.; Morrison, Barclay, III			Mechanical heterogeneity of the rat hippocampus measured by atomic force microscope indentation	JOURNAL OF NEUROTRAUMA			English	Article						brain tissue; elasticity; heterogeneity; hippocampus; mechanical properties	TRAUMATIC BRAIN-INJURY; NEUROTROPHIC FACTOR; ELASTIC-MODULUS; IN-VIVO; TISSUE; MODEL; NEURONS; NEUROFILAMENTS; ACCELERATION; DEFORMATION	Knowledge of brain tissue mechanical properties may be critical for formulating hypotheses about traumatic brain injury TBI) mechanisms and for accurate TBI simulations. To determine the local mechanical properties of anatomical subregions within the rat hippocampus, the atomic force microscope (AFM) was adapted for use on living brain tissue. The AFM provided advantages over alternative methods for measuring local mechanical properties of brain because of its high spatial resolution, high sensitivity, and ability to measure live samples under physiologic conditions. From AFM indentations, a mean pointwise or depth-dependent apparent elastic modulus, E, was determined for the following hippocampal subregions: CAI pyramidal cell layer (CA1P) and stratum radiatum (CA1SR), CA3 pyramidal cell layer (CA3P) and stratum radiatum (CA3SR), and the dentate gyrus (DG). For all regions, E was indentation-depth-dependent, reflecting the nonlinearity of brain tissue. At an indentation depth of 3 mu m, E was 234 +/- 152 Pa for CA3P, 308 +/- 184 Pa for CA3SR, 137 +/- 97 Pa for CA1P, 169 +/- 52 Pa for CA1SR, and 201 133 Pa for DG (mean SD). Our results demonstrate for the first time that the hippocampus is mechanically heterogeneous. Based on our findings, we discuss hypotheses accounting for experimentally observed patterns of hippocampal cell death, which can be tested with biofidelic finite element models of TBI.	Columbia Univ, Dept Biomed Engn, New York, NY 10027 USA	Morrison, B (corresponding author), Columbia Univ, Dept Biomed Engn, 351 Engn Terrace,1210 Amsterdam Ave MC 8904, New York, NY 10027 USA.	bm2119@columbia.edu	Morrison, Barclay/B-7132-2008	Morrison, Barclay/0000-0001-7676-0864; Azeloglu, Evren/0000-0001-6137-109X			Alessandrini A, 2005, MEAS SCI TECHNOL, V16, pR65, DOI 10.1088/0957-0233/16/6/R01; Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Arbogast KB, 1998, J BIOMECH, V31, P801, DOI 10.1016/S0021-9290(98)00068-2; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Capani F, 2001, BRAIN RES, V923, P1, DOI 10.1016/S0006-8993(01)03189-4; Cater HL, 2007, J NEUROCHEM, V101, P434, DOI 10.1111/j.1471-4159.2006.04379.x; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Coats B, 2006, J BIOMECH, V39, P2521, DOI 10.1016/j.jbiomech.2005.07.020; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Costa KD, 2006, J BIOMECH ENG-T ASME, V128, P176, DOI 10.1115/1.2165690; Costa KD, 2003, DIS MARKERS, V19, P139, DOI 10.1155/2004/482680; Costa KD, 1999, J BIOMECH ENG-T ASME, V121, P462, DOI 10.1115/1.2835074; Crick SL, 2007, BIOMECH MODEL MECHAN, V6, P199, DOI 10.1007/S10237-006-0046-x; Darling EM, 2006, OSTEOARTHR CARTILAGE, V14, P571, DOI 10.1016/j.joca.2005.12.003; Darvish KK, 2001, MED ENG PHYS, V23, P633, DOI 10.1016/S1350-4533(01)00101-1; Dimitriadis EK, 2002, BIOPHYS J, V82, P2798, DOI 10.1016/S0006-3495(02)75620-8; Donnelly BR, 1997, J BIOMECH ENG-T ASME, V119, P423, DOI 10.1115/1.2798289; Fountoulakis M, 2001, EXP NEUROL, V167, P86, DOI 10.1006/exnr.2000.7529; Fung Y., 1993, BIOMECHANICS MECH PR; Gefen A, 2003, J NEUROTRAUM, V20, P1163, DOI 10.1089/089771503770802853; Gefen A, 2004, J BIOMECH, V37, P1339, DOI 10.1016/j.jbiomech.2003.12.032; Georges PC, 2006, BIOPHYS J, V90, P3012, DOI 10.1529/biophysj.105.073114; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Hamberger A, 2003, J NEUROTRAUM, V20, P169, DOI 10.1089/08977150360547080; HARDY WN, 1994, INT J IMPACT ENG, V15, P561, DOI 10.1016/0734-743X(94)80034-7; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Huang H, 2002, NEUROSCI LETT, V332, P141, DOI 10.1016/S0304-3940(02)00836-4; Kim BT, 2001, J NEUROSURG, V95, P674, DOI 10.3171/jns.2001.95.4.0674; LaPlaca MC, 2005, J BIOMECH, V38, P1093, DOI 10.1016/j.jbiomech.2004.05.032; Lippert SA, 2004, BIORHEOLOGY, V41, P681; Lopez-Picon FR, 2003, HIPPOCAMPUS, V13, P767, DOI 10.1002/hipo.10122; Mahaffy RE, 2000, PHYS REV LETT, V85, P880, DOI 10.1103/PhysRevLett.85.880; Mahaffy RE, 2004, BIOPHYS J, V86, P1777, DOI 10.1016/S0006-3495(04)74245-9; Maniotis AJ, 1997, P NATL ACAD SCI USA, V94, P849, DOI 10.1073/pnas.94.3.849; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; McCullers D, 2002, NEUROSCIENCE, V109, P219, DOI 10.1016/S0306-4522(01)00477-8; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; METZ H, 1970, J BIOMECH, V3, P453, DOI 10.1016/0021-9290(70)90017-5; Miga MI, 2000, IEEE T BIO-MED ENG, V47, P266, DOI 10.1109/10.821778; MIGA MI, 2000, COMPUT METHOD BIOMEC, V3, P129; Miller K, 1999, J BIOMECH, V32, P531, DOI 10.1016/S0021-9290(99)00010-X; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; Morrison B., 2003, STAPP CAR CRASH J, V47, P93; Nicolle S, 2005, BIORHEOLOGY, V42, P209; Nirula R, 2004, J TRAUMA, V57, P779, DOI 10.1097/01.TA.0000106506.34691.B6; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Roberts DW, 1999, NEUROSURGERY, V45, P1199, DOI 10.1097/00006123-199911000-00037; Rosenberg LJ, 1997, BRAIN RES, V775, P209, DOI 10.1016/S0006-8993(97)00954-2; Rotsch C, 2000, BIOPHYS J, V78, P520, DOI 10.1016/S0006-3495(00)76614-8; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; Stolz M, 2004, BIOPHYS J, V86, P3269, DOI 10.1016/S0006-3495(04)74375-1; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Takai E, 2005, ANN BIOMED ENG, V33, P963, DOI 10.1007/s10439-005-3555-3; Thibault KL, 1998, J BIOMECH, V31, P1119, DOI 10.1016/S0021-9290(98)00122-5; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950; Zhou C, 1995, P 39 STAPP CAR CRASH, V39, P121, DOI DOI 10.4271/952714	62	189	192	0	24	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2007	24	5					812	822		10.1089/neu.2006.0169			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	167YT	WOS:000246489300006	17518536				2021-06-18	
J	Ost, M; Nylen, K; Csajbok, L; Ohrfelt, AO; Tullberg, M; Wikkelso, C; Nellgard, P; Rosengren, L; Blennow, K; Nellgard, B				Ost, M.; Nylen, K.; Csajbok, L.; Ohrfelt, A. Olsson; Tullberg, M.; Wikkelso, C.; Nellgard, P.; Rosengren, L.; Blennow, K.; Nellgard, B.			Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury	NEUROLOGY			English	Article							NORMAL-PRESSURE HYDROCEPHALUS; CEREBROSPINAL-FLUID; ALZHEIMERS-DISEASE; HEAD-INJURY; INTRACRANIAL-PRESSURE; APOLIPOPROTEIN-E; PROTEIN; DAMAGE	Objective: We investigated if tau, microtubular binding protein, in serum and ventricular CSF (vCSF) in patients with severe traumatic brain injury (TBI) during the initial posttraumatic days correlated to 1-year outcome. Methods: Patients with severe TBI (n = 39, Glasgow Coma Scale score <= 8) were included. We measured serum and vCSF total tau on days 0 to 14, using ELISA. vCSF total tau correlated to 1-year Extended Glasgow Outcome Scale (GOSE), the NIH Stroke Scale (NIHSS) neurologic status, and the Bartel Daily Living Index. Patients (n = 20) with normal pressure hydrocephalus (NPH) served as reference. Results: Higher levels of tau were found in TBI patients vs patients with NPH. A correlation was found between initial vCSF total tau and GOSE levels (R = 0.42, p < 0.001) but not between vCSF total tau and NIHSS or Bartel scores at 1 year. A vCSF total tau level of > 2,126 pg/mL on days 2 to 3 discriminated between dead and alive ( sensitivity of 100% and a specificity of 81%). A vCSF total tau level of > 702 pg/mL on days 2 to 3 discriminated between bad ( GOSE 1 to 4) and good ( GOSE 5 to 8) outcome ( sensitivity of 83% and a specificity of 69%). Patients with GOSE 1 (dead) had higher vCSF total tau levels on days 2 to 3 (p < 0.001) vs both surviving patients (GOSE 2 to 8) and those with NPH. Total tau was not detected in serum throughout the study. Conclusion: The increase in ventricular CSF (vCSF) total tau probably reflects axonal damage, known to be a central pathologic mechanism in traumatic brain injury ( TBI). These results suggest that vCSF total tau may be an important early biochemical neuromarker for predicting long-term outcome in patients with a severe TBI.	Sahlgrens Univ Hosp, Dept Anesthesiol & Intens Care Med, S-41138 Gothenburg, Sweden; Sahlgrens Univ Hosp, Dept Neurol, S-41345 Gothenburg, Sweden; Sahlgrens Univ Hosp, Dept Neurochem, S-41345 Gothenburg, Sweden; Sahlgrens Univ Hosp, Inst Clin Neurosci, S-41345 Gothenburg, Sweden	Ost, M (corresponding author), Sahlgrens Univ Hosp, Dept Anesthesiol & Intens Care Med, S-41138 Gothenburg, Sweden.	martin.ost@vgregion.se	Ohrfelt, Annika/ABB-5174-2020; Ost, Martin/AAY-5827-2020	Ohrfelt, Annika/0000-0001-8942-4181; Rosengren, Lars/0000-0003-0505-8896			ARAI H, 1995, ANN NEUROL, V38, P649, DOI 10.1002/ana.410380414; BENNETT M, 1995, IRISH MED J, V88, P59; BLENNOW K, 1995, ACTA NEUROCHIR, V136, P135, DOI 10.1007/BF01410615; Blennow K, 2004, NEUROLOGY, V62, P159, DOI 10.1212/WNL.62.1.159; Blomgren K, 2001, J BIOL CHEM, V276, P10191, DOI 10.1074/jbc.M007807200; Chatfield DA, 2002, BRIT J NEUROSURG, V16, P471, DOI 10.1080/0268869021000030285; CORKIN S, 1989, J NEUROSCI, V9, P3876; Franz G, 2003, NEUROLOGY, V60, P1457, DOI 10.1212/01.WNL.0000063313.57292.00; Genis L, 2000, J NEUROSCI RES, V60, P559, DOI 10.1002/(SICI)1097-4547(20000515)60:4<559::AID-JNR15>3.0.CO;2-K; GOEDERT M, 1993, TRENDS NEUROSCI, V16, P460, DOI 10.1016/0166-2236(93)90078-Z; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; Grande PO, 2002, ACTA ANAESTH SCAND, V46, P929, DOI 10.1034/j.1399-6576.2002.460802.x; Hulstaert F, 1999, NEUROLOGY, V52, P1555, DOI 10.1212/WNL.52.8.1555; Kay AD, 2003, J NEUROTRAUM, V20, P943, DOI 10.1089/089771503770195795; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Otto M, 1997, NEUROSCI LETT, V225, P210, DOI 10.1016/S0304-3940(97)00215-2; Pelinka LE, 2005, SHOCK, V24, P119, DOI 10.1097/01.shk.0000168876.68154.43; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; Selkoe DJ, 2005, ARCH NEUROL-CHICAGO, V62, P192, DOI 10.1001/archneur.62.2.192; Sjogren M, 2001, J NEUROL NEUROSUR PS, V70, P624, DOI 10.1136/jnnp.70.5.624; Tisell M, 2004, EUR J NEUROL, V11, P17, DOI 10.1046/j.1351-5101.2003.00698.x; Tullberg M, 2000, J NEUROL NEUROSUR PS, V69, P74, DOI 10.1136/jnnp.69.1.74; TULLBERG M, IN PRESS EUR J NEURO; VANDERMEEREN M, 1993, J NEUROCHEM, V61, P1828, DOI 10.1111/j.1471-4159.1993.tb09823.x; VIGOPELFREY C, 1995, NEUROLOGY, V45, P788, DOI 10.1212/WNL.45.4.788; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zemlan FP, 1999, J NEUROCHEM, V72, P741, DOI 10.1046/j.1471-4159.1999.0720741.x; Zemlan FP, 2002, BRAIN RES, V947, P131, DOI 10.1016/S0006-8993(02)02920-7	29	189	190	1	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	NOV 14	2006	67	9					1600	1604		10.1212/01.wnl.0000242732.06714.0f			5	Clinical Neurology	Neurosciences & Neurology	104WN	WOS:000241991400013	17101890				2021-06-18	
J	Baptiste, DC; Fehlings, MG				Baptiste, DC; Fehlings, MG			Pharmacological approaches to repair the injured spinal cord	JOURNAL OF NEUROTRAUMA			English	Article						acute spinal cord injury; apoptosis; clinical trials; neuroprotection; neurotrauma; pharmacological approaches	THYROTROPIN-RELEASING-HORMONE; NEUROLOGICAL FUNCTION; CYCLOSPORINE-A; CONTROLLED-TRIAL; ACTIVE IMMUNIZATION; FUNCTIONAL RECOVERY; LIPID-PEROXIDATION; MOTOR FUNCTION; METHYLPREDNISOLONE; INHIBITION	Acute traumatic spinal cord injury (SCI) results in a devastating loss of neurological function below the level of injury and adversely affects multiple systems within the body. The pathobiology of SCI involves a primary mechanical insult to the spinal cord and activation of a delayed secondary cascade of events, which ultimately causes progressive degeneration of the spinal cord. Whereas cell death from the mechanical injury is predominated by necrosis, secondary injury events trigger a continuum of necrotic and apoptotic cell death mechanisms. These secondary events include vascular abnormalities, ischemia-reperfusion, glutamate excitotoxicity and disturbances in ionic homeostasis, oxidative cell injury, and a robust inflammatory response. No gold standard therapy for SCI has been established, although clinical trials with methylprednisolone (NASCIS II and III) and GM-1 ganglioside (Maryland and Sygen) have demonstrated modest, albeit potentially important therapeutic benefits. In light of the overwhelming impact of SCI on the individual, other therapeutic interventions are urgently needed. A number of promising pharmacological therapies are currently under investigation for neuroprotective abilities in animal models of SCI. These include the sodium (Na+) channel blocker riluzole, the tetracycline derivative minocycline, the fusogen copolymer polyethylene glycol (PEG), and the tissue-protective hormone erythropoietin (EPO). Moreover, clinical trials investigating the putative neuroprotective and neuroregenerative properties ascribed to the Rho pathway antagonist, Cethrin (R) (BioAxone Therapeutic, Inc.), and implantation of activated autologous macrophages (ProCord (R); Proneuron Biotechnologies) in patients with thoracic and cervical SCI are now underway. We anticipate that these studies will harken an era of renewed interest in translational clinical trials. Ultimately, due to the multi-factorial pathophysiology of traumatic SCI, effective therapies will require combined approaches.	Univ Hlth Network, Toronto Western Hosp, Toronto Western Res Inst, Div Cell & Mol Biol, Toronto, ON, Canada; Univ Hlth Network, Toronto Western Hosp, Krembil Neurosci Ctr, Toronto, ON, Canada; Univ Toronto, Toronto Western Hosp, Krembil Neurosci Ctr, Div Neurosurg, Toronto, ON, Canada	Fehlings, MG (corresponding author), Univ Hlth Network, Toronto Western Hosp, Toronto Western Res Inst, Div Cell & Mol Biol, Toronto, ON, Canada.	Michael.Fehlings@uhn.on.ca		Fehlings, Michael/0000-0002-5722-6364			Agrawal SK, 1996, J NEUROSCI, V16, P545; BENSIMON G, 1994, NEW ENGL J MED, V330, P585, DOI 10.1056/NEJM199403033300901; Bomstein Y, 2003, J NEUROIMMUNOL, V142, P10, DOI 10.1016/S0165-5728(03)00260-1; Borgens RB, 2004, J NEUROSCI RES, V76, P141, DOI 10.1002/jnr.20053; BRACKEN MB, 1984, JAMA-J AM MED ASSOC, V251, P45, DOI 10.1001/jama.251.1.45; BRACKEN MB, 1993, J NEUROSURG, V79, P500, DOI 10.3171/jns.1993.79.4.0500; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BRACKEN MB, 1992, J NEUROSURG, V76, P23, DOI 10.3171/jns.1992.76.1.0023; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; Casha S, 2001, NEUROSCIENCE, V103, P203, DOI 10.1016/S0306-4522(00)00538-8; Cifu DX, 1999, J NEUROTRAUM, V16, P805, DOI 10.1089/neu.1999.16.805; Dergham P, 2002, J NEUROSCI, V22, P6570; Diaz-Ruiz A, 1999, NEUROSCI LETT, V266, P61, DOI 10.1016/S0304-3940(99)00255-4; Diaz-Ruiz A, 2000, NEUROREPORT, V11, P1765, DOI 10.1097/00001756-200006050-00033; Diaz-Ruiz A, 2004, NEUROSCI LETT, V357, P49, DOI 10.1016/j.neulet.2003.12.042; Dumont RJ, 2001, CLIN NEUROPHARMACOL, V24, P265, DOI 10.1097/00002826-200109000-00003; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911; Erbayraktar S, 2003, P NATL ACAD SCI USA, V100, P6741, DOI 10.1073/pnas.1031753100; FEHLINGS MG, 1989, J NEUROSURG, V71, P403, DOI 10.3171/jns.1989.71.3.0403; FEHLINGS MG, 1995, EXP NEUROL, V132, P220, DOI 10.1016/0014-4886(95)90027-6; Fehlings MG, 2001, SPINE, V26, pS56, DOI 10.1097/00007632-200112151-00012; Gaviria M, 2000, BRAIN RES, V874, P200, DOI 10.1016/S0006-8993(00)02581-6; GEISLER FH, 1991, NEW ENGL J MED, V324, P1829, DOI 10.1056/NEJM199106273242601; Geisler FH, 2001, SPINE, V26, pS87, DOI 10.1097/00007632-200112151-00015; Gottlieb AB, 2002, ARCH DERMATOL, V138, P591, DOI 10.1001/archderm.138.5.591; Gris D, 2004, J NEUROSCI, V24, P4043, DOI 10.1523/JNEUROSCI.5343-03.2004; Hadley MN, 2002, NEUROSURGERY, V50, pS63; HALL ED, 1993, ANN EMERG MED, V22, P1022, DOI 10.1016/S0196-0644(05)82745-3; HALL ED, 1984, J NEUROSURG, V61, P124, DOI 10.3171/jns.1984.61.1.0124; HASHIMOTO T, 1991, EUR J PHARMACOL, V203, P25, DOI 10.1016/0014-2999(91)90786-P; Hauben E, 2000, J NEUROSCI, V20, P6421, DOI 10.1523/JNEUROSCI.20-17-06421.2000; Hauben E, 2003, J NEUROSCI, V23, P8808; HEUMANN R, 1987, P NATL ACAD SCI USA, V84, P8735, DOI 10.1073/pnas.84.23.8735; Hurlbert RJ, 2001, SPINE, V26, pS39, DOI 10.1097/00007632-200112151-00009; Ibarra A, 2003, BRAIN RES, V979, P165, DOI 10.1016/S0006-8993(03)02898-1; Jacobs WB, 2003, NEUROSURGERY, V53, P943, DOI 10.1227/01.NEU.0000083592.74383.B1; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Jelkmann W, 1996, ANN ANAT, V178, P391, DOI 10.1016/S0940-9602(96)80124-5; Jones TB, 2004, J NEUROSCI, V24, P3752, DOI 10.1523/JNEUROSCI.0406-04.2004; Laufs U, 2000, J CLIN INVEST, V106, P15, DOI 10.1172/JCI9639; Lazarov-Spiegler O, 1998, GLIA, V24, P329, DOI 10.1002/(SICI)1098-1136(199811)24:3<329::AID-GLIA7>3.0.CO;2-X; Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313; Li M, 2000, NEUROSCIENCE, V99, P333, DOI 10.1016/S0306-4522(00)00173-1; Long J B, 1986, Cent Nerv Syst Trauma, V3, P295; Mabon PJ, 2000, EXP NEUROL, V166, P52, DOI 10.1006/exnr.2000.7488; Madura T, 2004, EMBO REP, V5, P412, DOI 10.1038/sj.embor.7400117; Marks Jeremy D., 2001, FASEB Journal, V15, P1107; Mills CD, 2002, J NEUROTRAUM, V19, P23, DOI 10.1089/089771502753460213; Mu XJ, 2000, J NEUROTRAUM, V17, P773, DOI 10.1089/neu.2000.17.773; Otani K., 1994, SEKITSUI SEKIZUI, V7, P633; Ozawa H, 2002, EXP NEUROL, V177, P306, DOI 10.1006/exnr.2002.7998; PERRY VH, 1987, J EXP MED, V165, P1218, DOI 10.1084/jem.165.4.1218; Petitjean ME, 1998, ANN FR ANESTH, V17, P114, DOI 10.1016/S0750-7658(98)80058-0; PITTS LH, 1995, J NEUROTRAUM, V12, P235, DOI 10.1089/neu.1995.12.235; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; Rosenberg LJ, 1999, J NEUROSCI, V19, P6122, DOI 10.1523/JNEUROSCI.19-14-06122.1999; Schumacher PA, 2000, J NEUROCHEM, V74, P1646, DOI 10.1046/j.1471-4159.2000.0741646.x; Schumacher PA, 1999, NEUROSCIENCE, V91, P733, DOI 10.1016/S0306-4522(98)00552-1; Schwartz G, 2001, J NEUROSURG, V94, P245, DOI 10.3171/spi.2001.94.2.0245; Sekhon LHS, 2001, SPINE, V26, pS2, DOI 10.1097/00007632-200112151-00002; Shi R, 2000, J NEUROCYTOL, V29, P633, DOI 10.1023/A:1010879219775; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; Stirling DP, 2004, J NEUROSCI, V24, P2182, DOI 10.1523/JNEUROSCI.5275-03.2004; Stys PK, 2004, CURR MOL MED, V4, P113, DOI 10.2174/1566524043479220; TADIE M, 1999, SOCN EUR ABSTR, P1090; Taoka Y, 1997, NEUROSCIENCE, V79, P1177, DOI 10.1016/S0306-4522(97)00011-0; Tenneti L, 2000, J NEUROCHEM, V74, P134, DOI 10.1046/j.1471-4159.2000.0740134.x; Thomas M, 2003, CLIN NEUROPHARMACOL, V26, P18, DOI 10.1097/00002826-200301000-00005; Wang SJ, 2004, NEUROSCIENCE, V125, P191, DOI 10.1016/j.neuroscience.2004.01.019; Wells JEA, 2003, BRAIN, V126, P1628, DOI 10.1093/brain/awg178; Wiessner C, 2001, J CEREBR BLOOD F MET, V21, P857, DOI 10.1097/00004647-200107000-00011; Wrathall JR, 1997, EXP NEUROL, V145, P565, DOI 10.1006/exnr.1997.6506; Xu J, 1998, MOL BRAIN RES, V59, P135, DOI 10.1016/S0169-328X(98)00142-9; Zhang SX, 2003, J NEUROTRAUM, V20, P59, DOI 10.1089/08977150360517182	75	189	208	1	18	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR-APR	2006	23	3-4					318	334		10.1089/neu.2006.23.318			17	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	039WF	WOS:000237337700007	16629619				2021-06-18	
J	Lu, DY; Mahmood, A; Qu, CS; Goussev, A; Schallert, T; Chopp, M				Lu, DY; Mahmood, A; Qu, CS; Goussev, A; Schallert, T; Chopp, M			Erythropoietin enhances neurogenesis and restores spatial memory in rats after traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						erythropoietin; neurogenesis; neuroprotection; rat; traumatic brain injury	HIPPOCAMPAL NEUROGENESIS; RECEPTOR; TRANSPLANTATION; IMPAIRMENTS; EXPRESSION; REDUCTION; DEFICITS; NEURONS; BARRIER; CELLS	Erythropoietin (EPO) is neuroprotective in models of stroke and traumatic brain injury (TBI) when administered prior to or within the first few hours after injury. We seek to demonstrate that EPO also has neurorestorative effects when administered late (i.e., 1 day) after TBI in the rat. Twelve rats were subjected to TBI. Six rats were treated with EPO daily for 14 days starting 1 day after injury, and an additional six rats were treated with saline. Bromodeoxyuridine (BrdU) was administered daily for 14 days. Memory tests using a Morris Water Maze were performed prior to and after injury and treatment. Animals were sacrificed at 15 days after TBI, and their brains were prepared for histological analysis of damage to the dentate gyrus (DG) and for evaluation of newly formed neurons using double labeling of BrdU and MAP-2. The data revealed a significant improvement in spatial memory and significant increase in the number of newly formed neurons with EPO treatment compared with control animals. These data suggest that EPO treatment initiated 1 day after TBI is neurorestorative by enhancing neurogenesis, as well as neuroprotective.	Henry Ford Hlth Sci Ctr, Dept Neurosurg, Detroit, MI USA; Henry Ford Hlth Sci Ctr, Dept Neurol, Detroit, MI USA; Oakland Univ, Dept Phys, Rochester, MI 48063 USA; Univ Texas, Dept Psychol, Austin, TX 78712 USA; Univ Texas, Inst Neurosci, Austin, TX 78712 USA	Chopp, M (corresponding author), Henry Ford Hosp, Dept Neurol, 2799 W Grand Blvd, Detroit, MI 48202 USA.	chopp@neuro.hfh.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042259] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS 42259] Funding Source: Medline; OAPP OPHS HHS [PPG NS 23393] Funding Source: Medline		Aydin A, 2003, BRAIN DEV-JPN, V25, P494, DOI 10.1016/S0387-7604(03)00039-1; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Buemi M, 2003, J NEUROPATH EXP NEUR, V62, P228, DOI 10.1093/jnen/62.3.228; Cerami A, 2002, NEPHROL DIAL TRANSPL, V17, P8, DOI 10.1093/ndt/17.suppl_1.8; Dame C, 2001, BIOL NEONATE, V79, P228; Day LB, 1996, BEHAV NEUROSCI, V110, P998; Day LB, 1999, ANIM BEHAV, V57, P393, DOI 10.1006/anbe.1998.1007; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Eid T, 2004, J NEUROPATH EXP NEUR, V63, P73, DOI 10.1093/jnen/63.1.73; Hallbergson AF, 2003, J CLIN INVEST, V112, P1128, DOI 10.1172/JCI200320098; JUMBE NL, 2002, ONCOLOGY HUNTING, V9, P91; Kempermann G, 2003, DEVELOPMENT, V130, P391, DOI 10.1242/dev.00203; Kempermann G, 2004, CURR OPIN NEUROBIOL, V14, P186, DOI 10.1016/j.conb.2004.03.001; Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313; Lu DY, 2003, J NEUROSURG, V99, P351, DOI 10.3171/jns.2003.99.2.0351; Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Martinez-Estrada OM, 2003, EUR J NEUROSCI, V18, P2538, DOI 10.1046/j.1460-9568.2003.02987.x; MASUDA S, 1993, J BIOL CHEM, V268, P11208; Morishita E, 1996, BLOOD, V88, P465, DOI 10.1182/blood.V88.2.465.bloodjournal882465; Mulcahy L, 2001, SEMIN ONCOL, V28, P19, DOI 10.1053/sonc.2001.25394; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Raber J, 2004, RADIAT RES, V162, P39, DOI 10.1667/RR3206; Rhodes JS, 2003, BEHAV NEUROSCI, V117, P1006, DOI 10.1037/0735-7044.117.5.1006; Rola R, 2004, EXP NEUROL, V188, P316, DOI 10.1016/j.expneurol.2004.05.005; Sasaki R, 2000, BIOSCI BIOTECH BIOCH, V64, P1775, DOI 10.1271/bbb.64.1775; Sasaki R, 2001, NEWS PHYSIOL SCI, V16, P110; TABIRA T, 1995, INT J DEV NEUROSCI, V13, P241, DOI 10.1016/0736-5748(94)00020-4; Tong EM, 2001, SEMIN NEPHROL, V21, P190, DOI 10.1053/snep.2001.20939; Vallieres L, 2002, J NEUROSCI, V22, P486, DOI 10.1523/JNEUROSCI.22-02-00486.2002; van Praag H, 1999, P NATL ACAD SCI USA, V96, P13427, DOI 10.1073/pnas.96.23.13427; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Wang L, 2004, NEUROREPORT, V15, P1225, DOI 10.1097/01.wnr.0000127636.15181.c1; Wen TC, 2004, NEUROSCI LETT, V355, P165, DOI 10.1016/j.neulet.2003.10.078; Yamada K, 1999, BRIT J PHARMACOL, V126, P235, DOI 10.1038/sj.bjp.0702309; Yoshimura S, 2003, J CLIN INVEST, V112, P1202, DOI 10.1172/JCI200316618; Yu XB, 2002, DEVELOPMENT, V129, P505	38	189	201	0	17	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2005	22	9					1011	1017		10.1089/neu.2005.22.1011			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	967HP	WOS:000232082600008	16156716				2021-06-18	
J	Barlow, KM; Thomson, E; Johnson, D; Minns, RA				Barlow, KM; Thomson, E; Johnson, D; Minns, RA			Late neurologic and cognitive sequelae of inflicted traumatic brain injury in infancy	PEDIATRICS			English	Article						behavior disorders/problems; head trauma; infants; neurobehavioral outcomes; shaken baby syndrome	NONACCIDENTAL HEAD-INJURY; SHAKEN BABY SYNDROME; YOUNG-CHILDREN; CHILDHOOD; DAMAGE; AGE; CONSEQUENCES; SEVERITY; OUTCOMES; IMPACT	Objective. There is limited information regarding the long-term outcome of inflicted traumatic brain injury ( TBI), including shaken infant syndrome. The purpose of this study was to describe the long-term neurologic, behavioral, and cognitive sequelae seen in this population. Methods. A cross-sectional and prospective longitudinal study was conducted of 25 children with inflicted TBI in Scotland between 1980 and 1999. After consent was obtained, neurologic and cognitive examinations were performed on all participants and sequentially in the prospective cohort. Two global outcome measures were used: Glasgow Outcome Score (GOS) and Seshia's outcome score. Cognitive outcome was assessed using the Bayley Scales of Infant Development, British Ability Scales, and the Vineland Adaptive Behavior Scales. Results. The mean length of follow-up was 59 months. A total of 68% of survivors were abnormal on follow-up, 36% had severe difficulties and were totally dependant, 16% had moderate difficulties, and 16% had mild difficulties on follow-up. A wide range of neurologic sequelae were seen, including motor deficits (60%), visual deficits (48%), epilepsy (20%), speech and language abnormalities (64%), and behavioral problems (52%). There was a wide range of cognitive abilities: the mean psychomotor index, 69.9 ( SD: +/- 25.73); and mean mental development index, 74.53 ( SD: +/- 28.55). Adaptive functioning showed a wide range of difficulties across all domains: communication domain (mean: 76.1; SD: +/- 25.4), Daily living skills domain ( mean: 76.9; SD: +/- 24.3), and socialization domain ( mean: 79.1; SD: +/- 23.1). Outcome was found to correlate with the Pediatric Trauma Score and the Glasgow Coma Score but did not correlate with age at injury or mechanism of injury. Conclusions. Inflicted TBI has a very poor prognosis and correlates with severity of injury. Extended followup is necessary so as not to underestimate problems such as specific learning difficulties and attentional and memory problems that may become apparent only once the child is in school. Behavioral problems are present in 52% and begin to manifest clinically between the second and third years of life, although the consequences of frontal lobe injury may be underestimated unless followup is extended into adolescence and early adulthood.	Univ Calgary, Alberta Childrens Prov Gen Hosp, Calgary, AB T2T 5C7, Canada; Univ Edinburgh, Dept Pediat Neurol, Edinburgh, Midlothian, Scotland; Univ Edinburgh, Dept Child Life & Hlth, Edinburgh, Midlothian, Scotland	Barlow, KM (corresponding author), Univ Calgary, Alberta Childrens Prov Gen Hosp, 1820 Richmond Rd, Calgary, AB T2T 5C7, Canada.	karen.barlow@calgaryhealthregion.ca	Barlow, Karen/I-6492-2019; Barlow, Karen/C-1323-2014	Barlow, Karen/0000-0003-2612-8507			Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Barlow Karen, 2004, Pediatr Rehabil, V7, P195, DOI 10.1080/13638490410001715331; Barlow KM, 2000, DEV MED CHILD NEUROL, V42, P591, DOI 10.1017/S0012162200001110; Barlow KM, 1999, DEV MED CHILD NEUROL, V41, P220, DOI 10.1017/S0012162299000481; Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; BILLMIRE ME, 1985, PEDIATRICS, V75, P340; Bonnier C, 1995, DEV MED CHILD NEUROL, V37, P943; Bonnier C, 2003, PEDIATRICS, V112, P808, DOI 10.1542/peds.112.4.808; BROWN JK, 1993, DEV MED CHILD NEUROL, V35, P849; Dashti SR, 1999, PEDIATR NEUROSURG, V31, P302, DOI 10.1159/000028880; DUHAIME AC, 1992, PEDIATRICS, V90, P179; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; EICHELBERGER MR, 1989, ANN EMERG MED, V18, P1053, DOI 10.1016/S0196-0644(89)80930-8; Eslinger PJ, 2004, BRAIN COGNITION, V55, P84, DOI 10.1016/s0278-2626(03)00281-1; ESLINGER PJ, 1992, ARCH NEUROL-CHICAGO, V49, P764, DOI 10.1001/archneur.1992.00530310112021; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Ewing-Cobbs L, 1999, PEDIATR NEUROSURG, V31, P251, DOI 10.1159/000028872; FILLEY CM, 1987, ARCH NEUROL-CHICAGO, V44, P194, DOI 10.1001/archneur.1987.00520140058018; GOLDSTEIN B, 1993, CRIT CARE MED, V21, P1328, DOI 10.1097/00003246-199309000-00016; GOLDSTEIN FC, 1987, J LEARN DISABIL, V20, P518, DOI 10.1177/002221948702000903; HADLEY MN, 1989, NEUROSURGERY, V24, P536, DOI 10.1227/00006123-198904000-00008; HAHN YS, 1988, CHILD NERV SYST, V4, P34; Han D P, 1990, J Pediatr Ophthalmol Strabismus, V27, P299; Haviland J, 1997, ARCH DIS CHILD, V77, P504, DOI 10.1136/adc.77.6.504; JENNETT B, 1975, LANCET, V1, P480; KAUFMANN CR, 1990, JAMA-J AM MED ASSOC, V263, P69, DOI 10.1001/jama.263.1.69; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; Kemp AM, 2003, ARCH DIS CHILD, V88, P472, DOI 10.1136/adc.88.6.472; Kivlin JD, 2000, OPHTHALMOLOGY, V107, P1246, DOI 10.1016/S0161-6420(00)00161-5; Landry SH, 2004, DEV NEUROPSYCHOL, V26, P707, DOI 10.1207/s15326942dn2603_4; Makaroff KL, 2003, DEV MED CHILD NEUROL, V45, P497, DOI 10.1017/S0012162203000926; MINER ME, 1986, NEURAL TRAUMA TREATM, P233; NELLIS L, 1994, J SCHOOL PSYCHOL, V32, P201, DOI 10.1016/0022-4405(94)90011-6; OAKLAND T, 1985, J COUNS DEV, V63, P585, DOI 10.1002/j.1556-6676.1985.tb00689.x; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Prasad MR, 2005, ARCH DIS CHILD, V90, P82, DOI 10.1136/adc.2003.045583; Prasad MR, 2002, PEDIATR NEUROSURG, V36, P64, DOI 10.1159/000048355; SESHIA SS, 1983, DEV MED CHILD NEUROL, V25, P493; SESHIA SS, 1994, BAILLIERES CLIN PAED, P173; Shannon P, 1998, ACTA NEUROPATHOL, V95, P625, DOI 10.1007/s004010050849; TASKER RC, 1988, ARCH DIS CHILD, V63, P895, DOI 10.1136/adc.63.8.895; TASKER RC, 1988, ARCH DIS CHILD, V63, P888, DOI 10.1136/adc.63.8.888; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; WILKINSON WS, 1989, ARCH OPHTHALMOL-CHIC, V107, P1472, DOI 10.1001/archopht.1989.01070020546037	44	189	191	0	25	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	AUG	2005	116	2					E174	E185		10.1542/peds.2004-2739			12	Pediatrics	Pediatrics	951FU	WOS:000230915600001	16061571	Bronze			2021-06-18	
J	Vriezen, ER; Pigott, SE				Vriezen, ER; Pigott, SE			The relationship between parental report on the BRIEF and performance-based measures of executive function in children with moderate to severe traumatic brain injury	CHILD NEUROPSYCHOLOGY			English	Article							LESION; TESTS	The Behavior Rating Inventory of Executive Function (BRIEF) is a questionnaire that assesses parental observations of behaviors associated with executive function in children in the home environment. The current investigation examines the relationship between the BRIEF and individually-administered neuropsychological tests in children with traumatic brain injury. Forty-eight children with moderate to severe traumatic brain injury were administered the WISC-III and several performance-based tests of executive function (the Wisconsin Card Sorting Test, Trail Making Test Part B, verbal fluency), and a parent completed the BRIEF. Results indicate that the Metacognition Index from the BRIEF correlates with Verbal IQ, but none of the index scores from the BRIEF correlate with any of the performance-based tests of executive function. Results are discussed with respect to the ecological validity of standardized clinical neuropsychological tests of executive function.	London Hlth Sci Ctr, London, ON, Canada	Vriezen, ER (corresponding author), Childrens Hosp Western Ontario, London Hlth Sci Ctr, 800 Commissioners Rd E, London, ON N6A 4G5, Canada.						Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; DIAMOND A, 1989, EXP BRAIN RES, V74, P24; Eslinger PJ, 1999, DEV NEUROPSYCHOL, V15, P157, DOI 10.1080/87565649909540744; Gioia G. A., 2000, BRIEF BEHAV RATING I; Heaton R., 1993, WISCONSIN CARD SORTI; JACOBS R, 2000, BRIEF BEHAV RATING I; LEVIN HS, 1991, DEV NEUROPSYCHOL, V7, P377, DOI 10.1080/87565649109540499; Luria A. R., 1966, HIGHER CORTICAL FUNC; LURIA AR, 1961, ROLE SPEECH NORMAL A; MARLOWE WB, 1992, BRAIN COGNITION, V20, P205, DOI 10.1016/0278-2626(92)90070-3; MILNER B, 1984, TRENDS NEUROSCI, V7, P403, DOI 10.1016/S0166-2236(84)80143-5; Passler MA, 1985, DEV NEUROPSYCHOL, V1, P349, DOI 10.1080/87565648509540320; SMITH ML, 1992, HDB NEUROPSYCHOLOGY, V7, P309; Spreen O., 1998, COMPENDIUM NEUROPSYC; STUSS DT, 1992, BRAIN COGNITION, V20, P8, DOI 10.1016/0278-2626(92)90059-U; TAYLOR HG, 2000, UNPUB BRIEF BEHAV RA; Vriezen ER, 2001, BRAIN COGNITION, V47, P222; Vygotsky L. S, 1978, THOUGHT LANGUAGE; WELSH MC, 1988, DEV NEUROPSYCHOL, V4, P199, DOI 10.1080/87565648809540405; WELSH MC, 1991, DEV NEUROPSYCHOL, V7, P131, DOI 10.1080/87565649109540483	20	189	191	0	13	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	0929-7049			CHILD NEUROPSYCHOL	Child Neuropsychol.	DEC	2002	8	4					296	303		10.1076/chin.8.4.296.13505			8	Clinical Neurology	Neurosciences & Neurology	680QW	WOS:000182989700008	12759826				2021-06-18	
J	Clark, C; Prior, M; Kinsella, G				Clark, C; Prior, M; Kinsella, G			The relationship between executive function abilities, adaptive behaviour, and academic achievement in children with externalising behaviour problems	JOURNAL OF CHILD PSYCHOLOGY AND PSYCHIATRY AND ALLIED DISCIPLINES			English	Article						ADHD; executive functions; adaptive behaviour	ATTENTION-DEFICIT HYPERACTIVITY; CLOSED HEAD-INJURY; READING-DISABILITY; CONDUCT DISORDER; FOLLOW-UP; PREADOLESCENT CHILDREN; MIDDLE CHILDHOOD; COMPARISON BOYS; FAMILY; SAMPLE	Background: Specific domains of adaptive behaviours and academic achievement may, in part, depend on executive function capacities. Executive function deficits have been found to be associated with Attention Deficit Hyperactivity Disorder (ADHD), not Oppositional Defiant Disorder/Conduct Disorder (ODD/CD). Method: Using a sample of 110 adolescents, comprising four groups, ADHD only, co-morbid ADHD and ODD/CD, ODD/CD only, and a normal community control group, we assessed socialisation and communication skills with the Vineland Adaptive Behaviour Scales, along with reading ability, and executive functioning. Results: Poorer adaptive communication skills were specifically associated with ADHD when compared with either ODD/CD or the control group, and the social competence of adolescents with ADHD was as low as the levels associated with ODD/CD. Presence of ADHD was associated with lower word recognition scores, while the reading levels of adolescents with ODD/CD were equivalent to those without behaviour problems. Executive function test scores correlated with all adaptive behaviour outcomes. Multiple regression analyses indicated that verbal ability predicted communication and reading scores, with executive function abilities contributing significant variance to the prediction in the adaptive behaviour, communication, and socialisation domains. Conclusions: Further research with other samples, both community and clinical groups, is needed to assess the generalisability of the findings. Small numbers of girls in the groups gave us insufficient power to adequately address potential gender differences.	Univ Melbourne, Dept Psychol, Parkville, Vic 3052, Australia; La Trobe Univ, Bundoora, Vic, Australia	Prior, M (corresponding author), Univ Melbourne, Dept Psychol, Parkville, Vic 3052, Australia.		Kinsella, Glynda/O-6347-2017	Kinsella, Glynda/0000-0002-5859-0934			ABIKOFF H, 1992, J CONSULT CLIN PSYCH, V60, P881, DOI 10.1037/0022-006X.60.6.881; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; ANDERSON P, IN PRESS CLIN NEUROP, V15, P81; Barkley RA, 1997, PSYCHOL BULL, V121, P65, DOI 10.1037/0033-2909.121.1.65; BARKLEY RA, 1991, J CHILD PSYCHOL PSYC, V32, P233, DOI 10.1111/j.1469-7610.1991.tb00304.x; Barkley RA, 1990, ATTENTION DEFICIT HY; Burgess P. W., 1996, BEHAV ASSESSMENT DYS; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Burgess PW, 1996, NEUROPSYCHOLOGIA, V34, P263, DOI 10.1016/0028-3932(95)00104-2; Burgess PW., 1997, HAYLING SENTENCE COM; CAMPBELL SB, 1994, J ABNORM CHILD PSYCH, V22, P147, DOI 10.1007/BF02167897; Chadwick O, 1999, J CHILD PSYCHOL PSYC, V40, P1039, DOI 10.1111/1469-7610.00522; Clark C, 2000, J ABNORM CHILD PSYCH, V28, P403, DOI 10.1023/A:1005176320912; Cooper R, 2000, COGN NEUROPSYCHOL, V17, P297, DOI 10.1080/026432900380427; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; DODGE KA, 1984, CHILD DEV, V55, P163, DOI 10.2307/1129842; DRAEGER S, 1986, J ABNORM CHILD PSYCH, V14, P411, DOI 10.1007/BF00915435; ERHARDT D, 1994, J CONSULT CLIN PSYCH, V62, P833, DOI 10.1037/0022-006X.62.4.833; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; FARRINGTON DP, 1990, STRAIGHT DEVIOUS PAT; Fergusson DM, 1997, J CHILD PSYCHOL PSYC, V38, P633, DOI 10.1111/j.1469-7610.1997.tb01690.x; FRICK PJ, 1991, J CONSULT CLIN PSYCH, V59, P289, DOI 10.1037/0022-006X.59.2.289; GRATTAN LM, 1992, BRAIN COGNITION, V20, P185, DOI 10.1016/0278-2626(92)90068-W; Greene RW, 1996, J AM ACAD CHILD PSY, V35, P571, DOI 10.1097/00004583-199605000-00011; HINSHAW SP, 1992, PSYCHOL BULL, V111, P127, DOI 10.1037/0033-2909.111.1.127; Kurdek LA, 2000, J EDUC PSYCHOL, V92, P449, DOI 10.1037//0022-0663.92.3.449; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; Maughan B, 1996, J CHILD PSYCHOL PSYC, V37, P405, DOI 10.1111/j.1469-7610.1996.tb01421.x; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; MCGEE R, 1985, J CHILD PSYCHOL PSYC, V26, P727, DOI 10.1111/j.1469-7610.1985.tb00587.x; MCGEE R, 1991, J AM ACAD CHILD PSY, V30, P224, DOI 10.1097/00004583-199103000-00010; MCGEE R, 1986, J CHILD PSYCHOL PSYC, V27, P597, DOI 10.1111/j.1469-7610.1986.tb00185.x; MCGEE R, 2001, IN PRESS J CHILD PSY; Melnick SM, 1996, J ABNORM CHILD PSYCH, V24, P169, DOI 10.1007/BF01441483; MOFFITT TE, 1993, DEV PSYCHOPATHOL, V5, P135, DOI 10.1017/S0954579400004302; Norman DA, 1986, CONSCIOUSNESS SELF R; Oberklaid F, 2000, PATHWAYS INFANCY ADO; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Prior M, 1999, J AM ACAD CHILD PSY, V38, P429, DOI 10.1097/00004583-199904000-00016; Prior M, 1999, J CHILD PSYCHOL PSYC, V40, P563, DOI 10.1111/1469-7610.00474; Purvis KL, 1997, J ABNORM CHILD PSYCH, V25, P133, DOI 10.1023/A:1025731529006; Rey A, 1964, EXAMEN CLIN PSYCHOL; ROIZEN NJ, 1994, ARCH PEDIAT ADOL MED, V148, P1137, DOI 10.1001/archpedi.1994.02170110023004; RUTTER M, 1987, BRIT J MED PSYCHOL, V60, P1, DOI 10.1111/j.2044-8341.1987.tb02712.x; RUTTER M, 1970, ED HTLH BEHAV; SANSON A, 1996, J CHILD PSYCHOL PSYC, V37, P527; Sattler J. M., 1992, ASSESSMENT CHILDREN; SCHACHAR RJ, 1991, CAN J BEHAV SCI, V23, P332, DOI 10.1037/h0079018; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Shallice T, 1996, PHILOS T R SOC B, V351, P1405, DOI 10.1098/rstb.1996.0124; Smart D, 2001, AUST J PSYCHOL, V53, P45, DOI 10.1080/00049530108255121; Smart D, 1996, J ABNORM CHILD PSYCH, V24, P363, DOI 10.1007/BF01441636; SNOW P, 1986, BRAIN IMP P 11 ANN B; Sparrow S., 1984, VINELAND ADAPTIVE BE; STEIN MA, 1995, J CHILD PSYCHOL PSYC, V36, P663, DOI 10.1111/j.1469-7610.1995.tb02320.x; Stuss DT, 2000, PSYCHOL RES-PSYCH FO, V63, P289, DOI 10.1007/s004269900007; TANNOCK R, 1995, J CHILD ADOL PSYCHOP, V5, P177, DOI 10.1089/cap.1995.5.177; Taylor E, 1996, J AM ACAD CHILD PSY, V35, P1213, DOI 10.1097/00004583-199609000-00019; TAYLOR HG, 1988, BEHAV ASSESSMENT CHI; Wechsler, 1991, WESCHLER INTELLIGENC; Wilkinson G. S., 1993, WIDE RANGE ACHIEVEME; Willcutt EG, 2000, J CHILD PSYCHOL PSYC, V41, P1039, DOI 10.1111/1469-7610.00691; WILLIAMS D, 1992, BRAIN COGNITION, V20, P196, DOI 10.1016/0278-2626(92)90069-X; Wilson BA, 1996, BEHAV ASSESSMENT DYS; ZIMMERMAN BJ, 1990, EDUC PSYCHOL, V25, P3, DOI 10.1207/s15326985ep2501_2	65	189	196	2	60	BLACKWELL PUBL LTD	OXFORD	108 COWLEY RD, OXFORD OX4 1JF, OXON, ENGLAND	0021-9630			J CHILD PSYCHOL PSYC	J. Child Psychol. Psychiatry Allied Discip.	SEP	2002	43	6					785	796		10.1111/1469-7610.00084			12	Psychology, Developmental; Psychiatry; Psychology	Psychology; Psychiatry	584QG	WOS:000177478700010	12236613				2021-06-18	
J	Dore-Duffy, P; Owen, C; Balabanov, R; Murphy, S; Beaumont, T; Rafols, JA				Dore-Duffy, P; Owen, C; Balabanov, R; Murphy, S; Beaumont, T; Rafols, JA			Pericyte migration from the vascular wall in response to traumatic brain injury	MICROVASCULAR RESEARCH			English	Article						pericyte; urokinase plasminogen activator; endothelial cell; traumatic brain injury; microvessels; apoptosis; migration	CENTRAL-NERVOUS-SYSTEM; UROKINASE PLASMINOGEN-ACTIVATOR; CYTOKINE-MEDIATED ACTIVATION; CEREBRAL BLOOD-VOLUME; ENDOTHELIAL-CELLS; MICROVASCULAR PERICYTES; DIABETIC-RETINOPATHY; CONTRACTILE PROTEINS; BASEMENT-MEMBRANE; HEAD-INJURY	Any perturbation of the blood brain barrier, whether from changes in cell physiology or from direct injury, may result in microvascular dysfunction and disease. We examined, at the ultrastructural level, microvascular pericyte responses in a well-defined model of traumatic brain injury in the rat. In areas close to the site of impact cortical pericytes underwent a number of changes within the first hour. Approximately 40% of pericytes migrated from their microvascular location. Migration occurred concomitant with a thinning of the abluminal surface of the basal lamina and an accumulation of the receptor for the urokinase plasminogen activator on the leading surface of the migrating cell. Migrated pericytes appeared viable and remained in a perivascular location in the adjacent neuropil. Nonmigrating pericytes in the same section displayed cytoplasmic alterations and nuclear chromatin changes consistent with a rapid degenerative process. (C) 2000 Academic Press.	Wayne State Univ, Sch Med, Dept Neurol, Div Neuroimmunol, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Detroit Neurotrauma Inst, Med Ctr, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Anat, Detroit, MI 48201 USA	Dore-Duffy, P (corresponding author), Wayne State Univ, Sch Med, Dept Neurol, Div Neuroimmunol, 421 E Canfield Ave,3124 Elliman Bldg,4201 St Anto, Detroit, MI 48201 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS031287] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5 P01 NS31287-05] Funding Source: Medline		ANTONELLIORLIDGE A, 1989, P NATL ACAD SCI USA, V86, P4544, DOI 10.1073/pnas.86.12.4544; AUER RN, 1986, ACTA NEUROPATHOL, V71, P207, DOI 10.1007/BF00688041; Balabanov R, 1998, J NEUROSCI RES, V53, P637, DOI 10.1002/(SICI)1097-4547(19980915)53:6<637::AID-JNR1>3.0.CO;2-6; Balabanov R, 1996, MICROVASC RES, V52, P127, DOI 10.1006/mvre.1996.0049; BALABANOV R, 1996, J NEUROSCI, V22, P772; BAR T, 1972, Z ZELLFORSCH MIK ANA, V133, P231, DOI 10.1007/BF00307145; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.immunol.11.1.767; Blasi F, 1997, IMMUNOL TODAY, V18, P415, DOI 10.1016/S0167-5699(97)01121-3; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; CANCILLA PA, 1972, LAB INVEST, V26, P376; Chibber R, 1997, DIABETOLOGIA, V40, P156, DOI 10.1007/s001250050657; DAMORE PA, 1987, ANNU REV PHYSIOL, V49, P453; DEFOUW DO, 1993, J VASC RES, V30, P154, DOI 10.1159/000158990; DIAZFLORES L, 1994, HISTOL HISTOPATHOL, V9, P807; DIAZFLORES L, 1991, HISTOL HISTOPATHOL, V6, P269; Dore-Duffy P, 1999, MICROVASC RES, V57, P75, DOI 10.1006/mvre.1998.2112; DOREDUFFY P, 1994, J CEREBR BLOOD F MET, V14, P837, DOI 10.1038/jcbfm.1994.105; FARRELL CR, 1987, ANAT REC, V218, P466, DOI 10.1002/ar.1092180416; FISHER EJ, 1994, MICROVASC RES, V48, P179, DOI 10.1006/mvre.1994.1048; FRANK RN, 1987, INVEST OPHTH VIS SCI, V28, P1089; GIANNINI C, 1995, ANN NEUROL, V37, P498, DOI 10.1002/ana.410370412; GILTIN D, 1985, MICROVASC RES, V24, P74; HERMAN IM, 1985, J CELL BIOL, V101, P43, DOI 10.1083/jcb.101.1.43; Hickey WF, 1999, SEMIN IMMUNOL, V11, P125, DOI 10.1006/smim.1999.0168; Hirschi K K, 1997, EXS, V79, P419; JEYNES B, 1985, STROKE, V16, P121, DOI 10.1161/01.STR.16.1.121; JOYCE NC, 1985, J CELL BIOL, V100, P1379, DOI 10.1083/jcb.100.5.1379; JOYCE NC, 1985, J CELL BIOL, V100, P1387, DOI 10.1083/jcb.100.5.1387; KING JS, 1970, Z ZELLFORSCH MIK ANA, V106, P309, DOI 10.1007/BF00335775; KUCHI H, 1994, ACTA NEUROCHIR, V60, P471; LANGE W, 1972, Z ZELLFORSCH MIK ANA, V128, P83, DOI 10.1007/BF00306890; Li WY, 1997, CHINESE MED J-PEKING, V110, P659; LIOTTA LA, 1981, CANCER RES, V41, P4629; MANDARINO LJ, 1993, EXP EYE RES, V57, P609, DOI 10.1006/exer.1993.1166; Marmarou A, 1997, ACT NEUR S, V70, P68; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MAXWELL DS, 1965, EXP NEUROL, V12, P33, DOI 10.1016/0014-4886(65)90097-X; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MAYNARD EA, 1957, AM J ANAT, V100, P409, DOI 10.1002/aja.1001000306; MIN HY, 1992, J IMMUNOL, V148, P3636; Mizutani M, 1996, J CLIN INVEST, V97, P2883, DOI 10.1172/JCI118746; MOVAT HZ, 1989, PATHOL IMMUNOPATH R, V8, P35, DOI 10.1159/000157136; NEHLS V, 1992, CELL TISSUE RES, V270, P469, DOI 10.1007/BF00645048; NEHLS V, 1991, J CELL BIOL, V113, P147, DOI 10.1083/jcb.113.1.147; Noble LJ, 1996, J COMP NEUROL, V376, P542; Pardridge W. M., 1998, INTRO BLOOD BRAIN BA, P1; Paxinos G, 1986, RAT BRAIN STEREOTAXI; Peters A, 1991, FINE STRUCTURE NERVO; Petrov RV, 1996, BIOSCIENCE REP, V16, P189, DOI 10.1007/BF01206205; POBER JS, 1988, AM J PATHOL, V133, P426; Povlishock J. T., 1981, CEREBRAL MICROCIRCUL, P67; Povlishock J.T, 1998, INTRO BLOOD BRAIN BA, P441; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; RAFOLS J, 1996, NEUROLOGY, V46, P467; RINNER WA, 1995, GLIA, V14, P257, DOI 10.1002/glia.440140403; Rosenblum William I., 1996, Microcirculation (Philadelphia), V3, P187, DOI 10.3109/10739689609148287; SATO Y, 1990, J CELL BIOL, V111, P757, DOI 10.1083/jcb.111.2.757; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; Schroder ML, 1998, NEUROSURGERY, V42, P1276, DOI 10.1097/00006123-199806000-00042; Schroder ML, 1998, ACT NEUR S, V71, P127; SHEPRO D, 1993, FASEB J, V7, P1031; SIMS DE, 1991, CAN J CARDIOL, V7, P431; STOPPELLI MP, 1985, P NATL ACAD SCI USA, V82, P4939, DOI 10.1073/pnas.82.15.4939; Takahashi A, 1997, ACTA NEUROPATHOL, V93, P354, DOI 10.1007/s004010050627; TAMM E, 1991, EXP EYE RES, V53, P375, DOI 10.1016/0014-4835(91)90244-9; USHIWATA I, 1990, J NEUROSURG, V73, P82, DOI 10.3171/jns.1990.73.1.0082; Varner JA, 1996, CURR OPIN CELL BIOL, V8, P724, DOI 10.1016/S0955-0674(96)80115-3; Washington RA, 1996, J NEUROSCI RES, V45, P392; WOLFF JR, 1972, BRAIN RES, V41, P17, DOI 10.1016/0006-8993(72)90613-0; Yamamoto T, 1997, ACT NEUR S, V70, P71	70	189	193	1	16	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0026-2862			MICROVASC RES	Microvasc. Res.	JUL	2000	60	1					55	69		10.1006/mvre.2000.2244			15	Peripheral Vascular Disease	Cardiovascular System & Cardiology	333UT	WOS:000088149700007	10873515				2021-06-18	
J	Bramlett, HM; Kraydieh, S; Green, EJ; Dietrich, WD				Bramlett, HM; Kraydieh, S; Green, EJ; Dietrich, WD			Temporal and regional patterns of axonal damage following traumatic brain injury: A beta-amyloid precursor protein immunocytochemical study in rats	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						beta-amyloid precursor protein; diffuse axonal injury; fluid-percussion; head injury; immunocytochemistry	HEAD-INJURY; MODERATE HYPOTHERMIA; VENTRICULAR DILATION; SECRETED FORMS; NEURONS; PROTECTION; MODEL; APP; VULNERABILITY; ACCELERATION	Diffuse axonal injury (DAI) is an important consequence of human head trauma. This experimental investigation utilized the immunocytochemical visualization of beta-amyloid precursor protein (beta-APP) to document regional patterns of axonal injury after traumatic brain injury (TBI) and to determine the importance of injury severity on the magnitude of axonal damage. Rats underwent moderate (1.84-2.11 atm) or severe (2.38-2.52 atm) parasagittal fluid-percussion (F-P) brain injury or sham procedures. At 1, 3, 7 or 30 days after TBI, rats were perfusion-fixed and sections immunostained for the visualization of beta-APP. A regionally specific axonal response to TBI was documented after moderate F-P injury. Within the dorsolateral striatum, an early increase in beta-APP-positive axonal profiles at 24 hours (h) was followed by a significant decline at subsequent survival periods. In contrast, the frequency of reactive profiles was initially low within the thalamus, but increased significantly by day 7. Within the external capsule at the injury epicenter, numbers of immunoreactive axons increased significantly at 24 h and remained elevated throughout the subsequent survival periods. At multiple periods after TBI, selective cortical and thalamic neurons displayed increased staining of the perikarya. A significant increase in the overall frequency of beta-APP profiles was documented in the severe vs moderately injured rats at 72 h after TBI. These data indicate that parasagittal F-P brain injury (a) results in widespread axonal damage, (b) that axonal damage includes both reversible and delayed patterns, and (c) that injury severity is an important factor in determining the severity of the axonal response to TBI.	UNIV MIAMI,SCH MED,DEPT NEUROL,NEUROTRAUMA RES CTR,MIAMI,FL 33101; UNIV MIAMI,SCH MED,DEPT PSYCHOL,NEUROTRAUMA RES CTR,MIAMI,FL 33101					NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30291] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030291] Funding Source: NIH RePORTER		ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Adams JH, 1992, GREENFIELDS NEUROPAT, P106; ANDERSON CV, 1995, J NEUROPSYCH CLIN N, V7, P42; Anderson CV, 1996, J NEUROTRAUM, V13, P35, DOI 10.1089/neu.1996.13.35; ANDERSON CV, 1994, BRAIN INJURY, V8, P565, DOI 10.3109/02699059409151008; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Chesnut R M, 1995, New Horiz, V3, P366; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; Dietrich WD, 1996, J NEUROTRAUM, V13, P309, DOI 10.1089/neu.1996.13.309; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIETRICH WD, 1997, J CEREB BLOOD FLO S1, V17, pS83; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; Graham DI, 1996, NEUROTRAUMA, P43; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; KOH JY, 1990, BRAIN RES, V533, P315, DOI 10.1016/0006-8993(90)91355-K; LEBLANC AC, 1992, J NEUROSCI RES, V31, P635, DOI 10.1002/jnr.490310407; LEWEN A, 1995, NEUROREPORT, V6, P357, DOI 10.1097/00001756-199501000-00032; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; MACNAMARA SE, 1992, ARCH CLIN NEUROPSYCH, V7, P275, DOI 10.1016/0887-6177(92)90169-N; Marion DW, 1996, J NEUROTRAUM, V13, P139, DOI 10.1089/neu.1996.13.139; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; MAXWELL WL, 1992, ACTA NEUROPATHOL, V84, P289; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; McDermott KL, 1997, J NEUROTRAUM, V14, P191, DOI 10.1089/neu.1997.14.191; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; McLellan D, 1986, COMA TRAUMATIQUE, P165; OSTSUKA N, 1991, BRAIN RES, V568, P335; Paxinos G., 1982, RAT BRAIN STEREOTAXI; Perri BR, 1997, J NEUROTRAUM, V14, P15, DOI 10.1089/neu.1997.14.15; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; PETTUS EH, 1996, BRAIN RES, V772, P1; Pierce JES, 1996, J NEUROSCI, V16, P1083; PIKE CJ, 1991, BRAIN RES, V563, P311, DOI 10.1016/0006-8993(91)91553-D; Povlishock JT, 1996, ACT NEUR S, V66, P81; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P41; Price Joseph L., 1995, P629; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; ROSS DT, 1993, J NEUROTRAUM, V10, P151, DOI 10.1089/neu.1993.10.151; SCHUBERT D, 1989, NEURON, V3, P689, DOI 10.1016/0896-6273(89)90237-7; SHERIFF FE, 1994, ACTA NEUROPATHOL, P55; SHIGEMATSU K, 1992, AM J PATHOL, V140, P787; SHIGEMATSU K, 1992, J NEUROSCI RES, V31, P443, DOI 10.1002/jnr.490310306; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SMITHSWINTOSKY VL, 1994, J NEUROCHEM, V63, P781, DOI 10.1046/j.1471-4159.1994.63020781.x; VANEZIS P, 1987, FORENSIC SCI INT, V35, P1, DOI 10.1016/0379-0738(87)90018-1; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; YAMADA K, 1991, J CEREBR BLOOD F MET, V11, P472, DOI 10.1038/jcbfm.1991.90	63	189	194	0	7	AMER ASSN NEUROPATHOLOGISTS INC	LAWRENCE	1041 NEW HAMPSHIRE ST, LAWRENCE, KS 66044	0022-3069			J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	OCT	1997	56	10					1132	1141		10.1097/00005072-199710000-00007			10	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	XZ763	WOS:A1997XZ76300007	9329457	Bronze			2021-06-18	
J	Ruff, RM; Camenzuli, L; Mueller, J				Ruff, RM; Camenzuli, L; Mueller, J			Miserable minority: Emotional risk factors that influence the outcome of a mild traumatic brain injury	BRAIN INJURY			English	Article							HEAD-INJURY	Emotional risk factors are explored in four case studies, each of whom had sustained a mild traumatic brain injury (MTBI). Selected pre-existing personality traits that compounded the symptom presentation included over-achievement, dependency, grandiosity and borderline personality traits. Premorbid risk factors are described and their influence on co-morbid and post-morbid difficulties is discussed. We also touched upon the therapeutic issues involved in our cases. General treatment considerations are highlighted for dealing with grandiosity, narcissistic features and borderline traits. Over-achievement and perfectionism are discussed in the context of providing treatment for stress management. Finally, the effect of pre-existing emotional trauma combined with the MTBI is discussed.	UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143	Ruff, RM (corresponding author), SAN FRANCISCO NEUROPSYCHIAT ASSOCIATES,909 HYDE ST,SUITE 620,SAN FRANCISCO,CA 94109, USA.						BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; Gronwall D, 1989, MILD HEAD INJURY, P153; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P74, DOI DOI 10.1097/00001199-199309000-00009; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Ruff R, 1991, COGNITIVE REHABILITA, P23; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3; Zasler N., 1993, J HEAD TRAUMA REHAB, V8, P13	12	189	190	0	11	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	AUG	1996	10	8					551	565		10.1080/026990596124124			15	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	UZ656	WOS:A1996UZ65600001	8836512				2021-06-18	
J	Wenzel, SE; Tyurina, YY; Zhao, JM; Croix, CMS; Dar, HH; Mao, GW; Tyurin, VA; Anthonymuthu, TS; Kapralov, AA; Amoscato, AA; Mikulska-Ruminska, K; Shrivastava, IH; Kenny, EM; Yang, Q; Rosenbaum, JC; Sparvero, LJ; Emlet, DR; Wen, XY; Minami, Y; Qu, F; Watkins, SC; Holman, TR; VanDemark, AP; Kellum, JA; Bahar, I; Bayir, H; Kagan, VE				Wenzel, Sally E.; Tyurina, Yulia Y.; Zhao, Jinming; Croix, Claudette M. St.; Dar, Haider H.; Mao, Gaowei; Tyurin, Vladimir A.; Anthonymuthu, Tamil S.; Kapralov, Alexandr A.; Amoscato, Andrew A.; Mikulska-Ruminska, Karolina; Shrivastava, Indira H.; Kenny, Elizabeth M.; Yang, Qin; Rosenbaum, Joel C.; Sparvero, Louis J.; Emlet, David R.; Wen, Xiaoyan; Minami, Yoshinori; Qu, Feng; Watkins, Simon C.; Holman, Theodore R.; VanDemark, Andrew P.; Kellum, John A.; Bahar, Ivet; Bayir, Hulya; Kagan, Valerian E.			PEBP1 Wardens Ferroptosis by Enabling Lipoxygenase Generation of Lipid Death Signals	CELL			English	Article							ACUTE KIDNEY INJURY; PHOSPHATIDYLETHANOLAMINE-BINDING PROTEIN; KINASE INHIBITOR PROTEIN; TRAUMATIC BRAIN-INJURY; CRYSTAL-STRUCTURE; RAF KINASE; CELL-DEATH; PSEUDOMONAS-AERUGINOSA; MODEL; EXPRESSION	Ferroptosis is a form of programmed cell death that is pathogenic to several acute and chronic diseases and executed via oxygenation of polyunsaturated phosphatidylethanolamines (PE) by 15-lipoxygenases (15-LO) that normally use free polyunsaturated fatty acids as substrates. Mechanisms of the altered 15-LO substrate specificity are enigmatic. We sought a common ferroptosis regulator for 15LO. We discovered that PEBP1, a scaffold protein inhibitor of protein kinase cascades, complexes with two 15LO isoforms, 15LO1 and 15LO2, and changes their substrate competence to generate hydroperoxy-PE. Inadequate reduction of hydroperoxy-PE due to insufficiency or dysfunction of a selenoperoxidase, GPX4, leads to ferroptosis. We demonstrated the importance of PEBP1-dependent regulatory mechanisms of ferroptotic death in airway epithelial cells in asthma, kidney epithelial cells in renal failure, and cortical and hippocampal neurons in brain trauma. As master regulators of ferroptotic cell death with profound implications for human disease, PEBP1/15LO complexes represent a new target for drug discovery.	[Wenzel, Sally E.; Zhao, Jinming; Minami, Yoshinori] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA; [Wenzel, Sally E.] Univ Pittsburgh, Dept Immunol, Pittsburgh, PA 15260 USA; [Tyurina, Yulia Y.; Dar, Haider H.; Tyurin, Vladimir A.; Kapralov, Alexandr A.; Amoscato, Andrew A.; Shrivastava, Indira H.; Sparvero, Louis J.; Qu, Feng; Bayir, Hulya; Kagan, Valerian E.] Univ Pittsburgh, Ctr Free Radical & Antioxidant Hlth, Dept Environm & Occupat Hlth, Pittsburgh, PA 15260 USA; [Croix, Claudette M. St.; Watkins, Simon C.] Univ Pittsburgh, Dept Cell Biol, Pittsburgh, PA 15260 USA; [Mao, Gaowei; Anthonymuthu, Tamil S.; Kenny, Elizabeth M.; Yang, Qin; Emlet, David R.; Wen, Xiaoyan; Kellum, John A.; Bayir, Hulya] Univ Pittsburgh, Ctr Crit Care Nephrol, Safar Ctr Resuscitat Res, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Mikulska-Ruminska, Karolina; Shrivastava, Indira H.; Bahar, Ivet] Univ Pittsburgh, Dept Computat & Syst Biol, Pittsburgh, PA 15260 USA; [Rosenbaum, Joel C.; VanDemark, Andrew P.] Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA; [Kagan, Valerian E.] Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15260 USA; [Kagan, Valerian E.] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15260 USA; [Kagan, Valerian E.] Univ Pittsburgh, Dept Radiat Oncol, Pittsburgh, PA 15260 USA; [Holman, Theodore R.] Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA; [Mikulska-Ruminska, Karolina] Nicolaus Copernicus Univ, Inst Phys, Torun, Poland; [Bayir, Hulya] UPMC, Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA	Wenzel, SE (corresponding author), Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA.; Wenzel, SE (corresponding author), Univ Pittsburgh, Dept Immunol, Pittsburgh, PA 15260 USA.; Bayir, H; Kagan, VE (corresponding author), Univ Pittsburgh, Ctr Free Radical & Antioxidant Hlth, Dept Environm & Occupat Hlth, Pittsburgh, PA 15260 USA.; Bayir, H (corresponding author), Univ Pittsburgh, Ctr Crit Care Nephrol, Safar Ctr Resuscitat Res, Dept Crit Care Med, Pittsburgh, PA 15260 USA.; Kagan, VE (corresponding author), Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15260 USA.; Kagan, VE (corresponding author), Univ Pittsburgh, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15260 USA.; Kagan, VE (corresponding author), Univ Pittsburgh, Dept Radiat Oncol, Pittsburgh, PA 15260 USA.; Bayir, H (corresponding author), UPMC, Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA.	wenzelse@upmc.edu; bayihx@ccm.upmc.edu; kagan@pitt.edu	Anthonymuthu, Tamil/I-5534-2019; Mikulska-Ruminska, Karolina/AAL-1993-2021; Kellum, John/AAP-3072-2020; Dar, Haider/AAE-3582-2021; Bahar, Ivet/AAH-2921-2020; Mikulska-Ruminska, Karolina/D-2843-2015	Mikulska-Ruminska, Karolina/0000-0001-7227-5503; Kellum, John/0000-0003-1995-2653; Mikulska-Ruminska, Karolina/0000-0001-7227-5503; VanDemark, Andrew/0000-0003-3424-4831; Tyurin, Vladimir/0000-0002-3474-1697; Tyurina, Yulia/0000-0003-0287-2091; Dar, Haider H./0000-0001-9586-7288; Yang, Qin/0000-0001-8690-4809; Kapralov, Oleksandr/0000-0002-3006-916X; Kagan, Valerian E./0000-0002-7245-1885; watkins, simon/0000-0003-4092-1552; Zhao, Jinming/0000-0003-4700-9734; Wenzel, Sally/0000-0002-4242-0164	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HL114453, U19AI068021, NS076511, NS061817, GM097204, AI106684, AI40600, HL109152, DK070910, DK083961, HG008540, P30 DA035778, P30 CA047904, P41 GM103712, S10OD021540]; NIH (Human Frontier Science Program); NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [U10HL109152, U10HL098177, P01HL114453] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI) [U54HG008540] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [U19AI068021, R01AI040600, P01AI106684] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK070910, R01DK083961] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [R01ES020693] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM097204] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS061817, R01NS076511] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [P30DA035778] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [S10OD021540] Funding Source: NIH RePORTER	We thank John C. Freedman (UCSC) for help in expression and purification of P. LoxA. This work was supported by NIH (HL114453, U19AI068021, NS076511, NS061817, GM097204, AI106684, AI40600, HL109152, DK070910, DK083961, HG008540, P30 DA035778, P30 CA047904, P41 GM103712, S10OD021540, and Human Frontier Science Program).	Aldrovandi M, 2017, REDOX BIOL, V11, P663, DOI 10.1016/j.redox.2017.01.001; Angeli JPF, 2014, NAT CELL BIOL, V16, P1180, DOI 10.1038/ncb3064; Bakan A, 2011, BIOINFORMATICS, V27, P1575, DOI 10.1093/bioinformatics/btr168; Banfield MJ, 1998, STRUCTURE, V6, P1245, DOI 10.1016/S0969-2126(98)00125-7; Banthiya S, 2016, BBA-MOL CELL BIOL L, V1861, P1681, DOI 10.1016/j.bbalip.2016.08.002; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Deiss K, 2012, J BIOL CHEM, V287, P23407, DOI 10.1074/jbc.M112.363812; Dennis EA, 2015, NAT REV IMMUNOL, V15, P511, DOI 10.1038/nri3859; Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042; Dunn KW, 2011, AM J PHYSIOL-CELL PH, V300, pC723, DOI 10.1152/ajpcell.00462.2010; Dweik RA, 2011, AM J RESP CRIT CARE, V184, P602, DOI 10.1164/rccm.9120-11ST; Emlet DR, 2017, AM J PHYSIOL-RENAL, V312, pF284, DOI 10.1152/ajprenal.00271.2016; Eyal E, 2015, BIOINFORMATICS, V31, P1487, DOI 10.1093/bioinformatics/btu847; Gata JL, 1996, J AGR FOOD CHEM, V44, P2573, DOI 10.1021/jf960149n; Hopper JTS, 2014, ANGEW CHEM INT EDIT, V53, P14002, DOI 10.1002/anie.201403741; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Ji J, 2012, NAT NEUROSCI, V15, P1407, DOI 10.1038/nn.3195; Kagan VE, 2017, NAT CHEM BIOL, V13, P81, DOI [10.1038/nchembio.2238, 10.1038/NCHEMBIO.2238]; Kalms J, 2017, BBA-MOL CELL BIOL L, V1862, P463, DOI 10.1016/j.bbalip.2017.01.003; Kellum JA, 2017, AM J RESP CRIT CARE, V195, P784, DOI 10.1164/rccm.201604-0799OC; Li HC, 2016, NUCLEIC ACIDS RES, V44, pD415, DOI 10.1093/nar/gkv1236; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Linkermann A, 2014, P NATL ACAD SCI USA, V111, P16836, DOI 10.1073/pnas.1415518111; Linkermann A, 2013, P NATL ACAD SCI USA, V110, P12024, DOI 10.1073/pnas.1305538110; Marrink SJ, 2007, J PHYS CHEM B, V111, P7812, DOI 10.1021/jp071097f; Martin-Sanchez D, 2017, J AM SOC NEPHROL, V28, P218, DOI 10.1681/ASN.2015121376; Morgan AH, 2009, J BIOL CHEM, V284, P21185, DOI 10.1074/jbc.M109.021634; Palevsky PM, 2008, NEW ENGL J MED, V359, P7, DOI 10.1056/NEJMoa0802639; Robichaud G, 2013, J AM SOC MASS SPECTR, V24, P718, DOI 10.1007/s13361-013-0607-z; Rudnitskaya AN, 2012, J PHYS CHEM B, V116, P10176, DOI 10.1021/jp303140j; Serhan CN, 2014, NATURE, V510, P92, DOI 10.1038/nature13479; Shemon AN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010479; Skouta R, 2014, J AM CHEM SOC, V136, P4551, DOI 10.1021/ja411006a; Sparvero LJ, 2016, J NEUROCHEM, V139, P659, DOI 10.1111/jnc.13840; Tavel L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036187; Toppo S, 2009, BBA-GEN SUBJECTS, V1790, P1486, DOI 10.1016/j.bbagen.2009.04.007; Tsai J, 2008, P NATL ACAD SCI USA, V105, P3041, DOI 10.1073/pnas.0711741105; Uderhardt S, 2012, IMMUNITY, V36, P834, DOI 10.1016/j.immuni.2012.03.010; Wen XY, 2012, NEPHROL DIAL TRANSPL, V27, P3100, DOI 10.1093/ndt/gfr766; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Wu YL, 2007, NAT PROTOC, V2, P3278, DOI 10.1038/nprot.2007.459; Xu S, 2012, STRUCTURE, V20, P1490, DOI 10.1016/j.str.2012.06.003; Yeung K, 1999, NATURE, V401, P173; Zhao JM, 2011, P NATL ACAD SCI USA, V108, P14246, DOI 10.1073/pnas.1018075108	44	188	192	4	79	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 19	2017	171	3					628	+		10.1016/j.cell.2017.09.044			40	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	FK1SP	WOS:000413263300013	29053969	Green Accepted, Bronze	Y	N	2021-06-18	
J	McNab, JA; Edlow, BL; Witzel, T; Huang, SY; Bhat, H; Heberlein, K; Feiweier, T; Liu, KC; Keil, B; Cohen-Adad, J; Tisdall, MD; Folkerth, RD; Kinney, HC; Wald, LL				McNab, Jennifer A.; Edlow, Brian L.; Witzel, Thomas; Huang, Susie Y.; Bhat, Himanshu; Heberlein, Keith; Feiweier, Thorsten; Liu, Kecheng; Keil, Boris; Cohen-Adad, Julien; Tisdall, M. Dylan; Folkerth, Rebecca D.; Kinney, Hannah C.; Wald, Lawrence L.			The Human Connectome Project and beyond: Initial applications of 300 mT/m gradients	NEUROIMAGE			English	Article						Human connectome; Diffusion MRI; Tractography; Traumatic coma; Consciousness; Axon diameter; Corpus callosum; In vivo; Postmortem	AXON DIAMETER DISTRIBUTION; ASCENDING AROUSAL SYSTEM; HEAD-INJURY; HUMAN BRAIN; RETICULAR-FORMATION; CORPUS-CALLOSUM; NERVE-FIBERS; DIFFUSION; MRI; CONSCIOUSNESS	The engineering of a 3 T human MRI scanner equipped with 300 mT/m gradients - the strongest gradients ever built for an in vivo human MRI scanner - was a major component of the NIH Blueprint Human Connectome Project (HCP). This effort was motivated by the HCP's goal of mapping, as completely as possible, the macroscopic structural connections of the in vivo healthy, adult human brain using diffusion tractography. Yet, the 300 mT/m gradient system is well suited to many additional types of diffusion measurements. Here, we present three initial applications of the 300 mT/m gradients that fall outside the immediate scope of the HCP. These include: 1) diffusion tractography to study the anatomy of consciousness and the mechanisms of brain recovery following traumatic coma; 2) q-space measurements of axon diameter distributions in the in vivo human brain and 3) postmortem diffusion tractography as an adjunct to standard histopathological analysis. We show that the improved sensitivity and diffusion-resolution provided by the gradients are rapidly enabling human applications of techniques that were previously possible only for in vitro and animal models on small-bore scanners, thereby creating novel opportunities to map the microstructure of the human brain in health and disease. (C) 2013 Elsevier Inc. All rights reserved.	[McNab, Jennifer A.] Stanford Univ, RM Lucas Ctr Imaging, Dept Radiol, Stanford, CA 94305 USA; [Edlow, Brian L.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; [Edlow, Brian L.; Witzel, Thomas; Huang, Susie Y.; Keil, Boris; Tisdall, M. Dylan; Wald, Lawrence L.] Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02114 USA; [Bhat, Himanshu; Heberlein, Keith; Liu, Kecheng] Siemens Med Solut USA Inc, Alpharetta, GA USA; [Feiweier, Thorsten] Siemens AG, Healthcare Sect, Erlangen, Germany; [Cohen-Adad, Julien] Ecole Polytech, Dept Elect Engn, Montreal, PQ H3C 3A7, Canada; [Folkerth, Rebecca D.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA; [Folkerth, Rebecca D.; Kinney, Hannah C.] Harvard Univ, Sch Med, Dept Pathol, Childrens Hosp Boston, Boston, MA 02115 USA	McNab, JA (corresponding author), Stanford Univ, RM Lucas Ctr Imaging, Dept Radiol, Stanford, CA 94305 USA.	mcnabj@stanford.edu	Jovicich, Jorge/D-2293-2010; Wald, Lawrence L/D-4151-2009; Keil, Boris/AAX-9557-2020; Huang, Susie/H-8357-2019; Witzel, Thomas/P-1402-2014; Keil, Boris/P-1411-2014; Witzel, Thomas/E-7276-2019	Wald, Lawrence L/0000-0001-8278-6307; Witzel, Thomas/0000-0002-5806-4897; Tisdall, Dylan/0000-0002-0454-3112; Huang, Susie/0000-0003-2950-7254	CIHR FellowshipCanadian Institutes of Health Research (CIHR); NIH Blueprint for Neuroscience Research Grant [U01MH093765]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NCRR P41RR14075, NIBIB RO1 EB006847, NINDS R25NS065743]; Center for Integration of Medicine and Innovative Technology (Boston, MA); NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41RR014075] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB006847] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [U01MH093765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R25NS065743] Funding Source: NIH RePORTER	This work was funded by: a CIHR Fellowship and an NIH Blueprint for Neuroscience Research Grant: U01MH093765, as well as NIH funding from NCRR P41RR14075, NIBIB RO1 EB006847 and NINDS R25NS065743 and the Center for Integration of Medicine and Innovative Technology (Boston, MA). We are grateful to the patient who volunteered for this study and whose recovery from traumatic coma continues to inspire this work. Thank you to Louis Vinke for assistance with processing postmortem brain specimens. Thank you to Emi Takahashi and Guangping Dai for assistance with acquisition of brainstem-diencephalon postmortem data acquired on the small-bore scanner.	ABOITIZ F, 1992, BRAIN RES, V598, P143, DOI 10.1016/0006-8993(92)90178-C; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Aggarwal M, 2013, NEUROIMAGE, V74, P117, DOI 10.1016/j.neuroimage.2013.01.061; Alexander DC, 2010, NEUROIMAGE, V52, P1374, DOI 10.1016/j.neuroimage.2010.05.043; Anwander A., 2010, P INT SOC MAGN RESON, V18, P109; Assaf Y, 2008, MAGN RESON MED, V59, P1347, DOI 10.1002/mrm.21577; Barazany D, 2009, BRAIN, V132, P1210, DOI 10.1093/brain/awp042; Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609; Bell RS, 2009, J TRAUMA, V66, pS104, DOI 10.1097/TA.0b013e31819d88c8; Bodammer N, 2004, MAGNET RESON MED, V51, P188, DOI 10.1002/mrm.10690; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Callaghan P. T., 1991, PRINCIPLES NUCL MAGN; CALLAGHAN PT, 1988, J PHYS E SCI INSTRUM, V21, P820, DOI 10.1088/0022-3735/21/8/017; Chung K, 2013, NATURE, V497, P332, DOI 10.1038/nature12107; Cluskey S, 2001, J CLIN PATHOL-MOL PA, V54, P386; CORY DG, 1990, MAGNET RESON MED, V14, P435, DOI 10.1002/mrm.1910140303; D'Arceuil HE, 2007, NEUROIMAGE, V35, P553, DOI 10.1016/j.neuroimage.2006.12.028; DuBose JJ, 2011, J TRAUMA, V70, P11, DOI 10.1097/TA.0b013e318207c563; Dyrby TB, 2013, MAGN RESON MED, V70, P711, DOI 10.1002/mrm.24501; Edlow BL, 2013, J NEUROPATH EXP NEUR, V72, P505, DOI 10.1097/NEN.0b013e3182945bf6; Edlow BL, 2012, J NEUROPATH EXP NEUR, V71, P531, DOI 10.1097/NEN.0b013e3182588293; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fernandez-Espejo D, 2012, ANN NEUROL, V72, P335, DOI 10.1002/ana.23635; Fuller P, 2011, J COMP NEUROL, V519, P933, DOI 10.1002/cne.22559; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GESCHWIN.N, 1965, BRAIN, V88, P237, DOI 10.1093/brain/88.2.237; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; HEADS T, 1991, ACTA NEUROPATHOL, V82, P316, DOI 10.1007/BF00308818; Heidemann RM, 2010, MAGN RESON MED, V64, P9, DOI 10.1002/mrm.22480; Hess CP, 2006, MAGN RESON MED, V56, P104, DOI 10.1002/mrm.20931; HOFFMEISTER B, 1991, NEUROSCIENCE, V42, P603, DOI 10.1016/0306-4522(91)90402-A; Horowitz A., 2012, P INT SOC MAGN RESON, V3619; Hursh J.B., 1939, AM J PHYSIOL, V127, P29; Jbabdi S, 2012, MAGN RESON MED, V68, P1846, DOI 10.1002/mrm.24204; Jones DK, 2013, NEUROIMAGE, V73, P239, DOI 10.1016/j.neuroimage.2012.06.081; KAUFMAN EFS, 1985, BRAIN RES, V335, P281, DOI 10.1016/0006-8993(85)90479-2; Keil B, 2013, MAGN RESON MED, V70, P248, DOI 10.1002/mrm.24427; KINNEY HC, 1994, J NEUROPATH EXP NEUR, V53, P548, DOI 10.1097/00005072-199411000-00002; Kinomura S, 1996, SCIENCE, V271, P512, DOI 10.1126/science.271.5248.512; Leuze CWU, 2014, CEREB CORTEX, V24, P328, DOI 10.1093/cercor/bhs311; LINDSLEY DB, 1949, ELECTROEN CLIN NEURO, V1, P475, DOI 10.1016/0013-4694(49)90068-1; Mai JK, 2008, ATLAS HUMAN BRAIN; Marner L, 2003, J COMP NEUROL, V462, P144, DOI 10.1002/cne.10714; McNab JA, 2013, NEUROIMAGE, V69, P87, DOI 10.1016/j.neuroimage.2012.11.065; Mcnab JA, 2009, NEUROIMAGE, V46, P775, DOI 10.1016/j.neuroimage.2009.01.008; Miller KL, 2011, NEUROIMAGE, V57, P167, DOI 10.1016/j.neuroimage.2011.03.070; Morel A, 1997, J COMP NEUROL, V387, P588, DOI 10.1002/(SICI)1096-9861(19971103)387:4<588::AID-CNE8>3.0.CO;2-Z; MORUZZI G, 1949, ELECTROEN CLIN NEURO, V1, P455, DOI 10.1016/0013-4694(49)90219-9; Nauta W.J.H., 1958, RETICULAR FORMATION, P3; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Ong HH, 2010, NEUROIMAGE, V51, P1360, DOI 10.1016/j.neuroimage.2010.03.063; Parvizi J, 2003, BRAIN, V126, P1524, DOI 10.1093/brain/awg166; Parvizi J, 2001, COGNITION, V79, P135, DOI 10.1016/S0010-0277(00)00127-X; Paxinos G., 2011, ORG BRAINSTEM NUCL; Piven J, 1997, AM J PSYCHIAT, V154, P1051; REESE NB, 1995, PROG NEUROBIOL, V47, P105, DOI 10.1016/0301-0082(95)00023-O; RINGO JL, 1994, CEREB CORTEX, V4, P331, DOI 10.1093/cercor/4.4.331; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Schiff ND, 2000, J CLIN NEUROPHYSIOL, V17, P438, DOI 10.1097/00004691-200009000-00002; Schmahmann JD, 2008, CORTEX, V44, P1037, DOI 10.1016/j.cortex.2008.04.004; Setsompop K, 2013, NEUROIMAGE, V80, P220, DOI 10.1016/j.neuroimage.2013.05.078; SHUTE CCD, 1963, NATURE, V199, P1160, DOI 10.1038/1991160a0; Silva S, 2010, NEUROLOGY, V74, P313, DOI 10.1212/WNL.0b013e3181cbcd96; Skandsen T, 2011, J NEUROTRAUM, V28, P691, DOI 10.1089/neu.2010.1590; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Stanisz GJ, 1997, MAGNET RESON MED, V37, P103, DOI 10.1002/mrm.1910370115; STARZL TE, 1951, J NEUROPHYSIOL, V14, P461; STERIADE M, 1982, J NEUROPHYSIOL, V48, P352; STRICH SJ, 1961, LANCET, V2, P443; Tournier JD, 2004, NEUROIMAGE, V23, P1176, DOI 10.1016/j.neuroimage.2004.07.037; Van Essen DC, 2012, NEUROIMAGE, V62, P2222, DOI 10.1016/j.neuroimage.2012.02.018; Vanhaudenhuyse A, 2010, BRAIN, V133, P161, DOI 10.1093/brain/awp313; VERTES RP, 1988, J COMP NEUROL, V275, P511, DOI 10.1002/cne.902750404; Wang R, 2007, P INT SOC MAG RESON, V15, P3720; Wedeen VJ, 2008, NEUROIMAGE, V41, P1267, DOI 10.1016/j.neuroimage.2008.03.036; Wedeen VJ, 2005, MAGN RESON MED, V54, P1377, DOI 10.1002/mrm.20642; Whyte J, 2009, AM J PHYS MED REHAB, V88, P410, DOI 10.1097/PHM.0b013e3181a0e3a0; Zhang H, 2011, NEUROIMAGE, V56, P1301, DOI 10.1016/j.neuroimage.2011.01.084	78	188	189	0	52	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	OCT 15	2013	80						234	245		10.1016/j.neuroimage.2013.05.074			12	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	191MB	WOS:000322416000018	23711537	Green Accepted			2021-06-18	
J	Bazarian, JJ; Zhu, T; Blyth, B; Borrino, A; Zhong, JH				Bazarian, Jeffrey J.; Zhu, Tong; Blyth, Brian; Borrino, Allyson; Zhong, Jianhui			Subject-specific changes in brain white matter on diffusion tensor imaging after sports-related concussion	MAGNETIC RESONANCE IMAGING			English	Article; Proceedings Paper	62nd Annual Meeting of the American-Academy-of-Neurology	APR 10-17, 2010	Toronto, CANADA	Amer Acad Neurol			AXONAL INJURY; WILD BOOTSTRAP; DT-MRI; DEFICIT; TIME	Background and Purpose: Current approaches to diffusion tensor imaging (DTI) analysis do not permit identification of individual-level changes in DTI indices. We investigated the ability of wild bootstrapping analysis to detect subject-specific changes in brain white matter (WM) before and after sports-related concussion. Materials and Methods: A prospective cohort study was performed in nine high school athletes engaged in hockey or football and six controls. Subjects underwent DTI pre- and postseason within a 3-month interval. One athlete was diagnosed with concussion (scanned within 72 h), and eight suffered between 26 and 399 subconcussive head blows. Fractional anisotropy (FA) and mean diffusivity (MD) were measured in each WM voxel. Bootstrap samples were generated, and a permuted t test was used to compare voxel-wise FA/MD changes in each subject pre- vs. postseason. Results: The percentage of WM voxels with significant (p<.05) pre-post FA changes was highest for the concussion subject (3.2%),intermediary for those with subconcussive head blows (mean 1.05%+/-.15%) and lowest for controls (mean 0.28%+/-.01%). Similarly, the percentage of WM voxels with significant MD changes was highest for the concussion subject (3.44%), intermediary for those with subconcussive head blows (mean 1.48%+/-.17%) and lowest for controls (mean 0.48%+/-.05%). Significantly changed FA and MD voxels colocalized in the concussion subject to the right corona radiata and right inferior longitudinal fasciculus. Conclusions: Wild bootstrap analysis detected significantly changed WM in a single concussed athlete. Athletes with multiple subconcussive head blows had significant changes in a percentage of their WM that was over three times higher than controls. Efforts to understand the significance of these WM changes and their relationship to head impact forces appear warranted. (C) 2012 Elsevier Inc. All rights reserved.	[Bazarian, Jeffrey J.; Zhu, Tong; Blyth, Brian; Borrino, Allyson; Zhong, Jianhui] Univ Rochester, Sch Med, Rochester, NY 14642 USA	Bazarian, JJ (corresponding author), Univ Rochester, Sch Med, Rochester, NY 14642 USA.	jeff_bazarian@urmc.rochester.edu; tong_zhu@urmc.rochester.edu; brian_blyth@urmc.rochester.edu; allyson_borrino@urmc.rochester.edu; jianhui_zhong@urmc.rochester.edu	Zhu, Tong/A-9402-2011; Zhong, Jianhui/AAE-6061-2020		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K24HD064754] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD051865] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD051865, K24 HD064754, 1R01HD051865, R01 HD051865-03] Funding Source: Medline		Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Efron B., 1993, INTRO BOOTSTRAP, P436, DOI DOI 10.1007/978-1-4899-4541-9; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Immonen RJ, 2009, EXP NEUROL, V215, P29, DOI 10.1016/j.expneurol.2008.09.009; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; JEZZARD P, 1995, MAGNET RESON MED, V34, P65, DOI 10.1002/mrm.1910340111; Jones DK, 2005, NEUROIMAGE, V26, P546, DOI 10.1016/j.neuroimage.2005.02.013; Langburt W, 2001, J CHILD NEUROL, V16, P83, DOI 10.1177/088307380101600203; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Li J, 2011, EUR J NEUROSCI, V33, P933, DOI 10.1111/j.1460-9568.2010.07573.x; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Mandonnet E, 2007, BRAIN, V130, P623, DOI 10.1093/brain/awl361; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; O'Gorman RL, 2006, MAGN RESON MED, V56, P884, DOI 10.1002/mrm.21014; Obenaus A, 2007, J NEUROTRAUM, V24, P1147, DOI 10.1089/neu.2006.0211; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Pasco A, 2007, J NEUROTRAUM, V24, P1321, DOI 10.1089/neu.2006.0136; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Shinoura N, 2007, NEUROCASE, V13, P127, DOI 10.1080/13554790701399254; Shinoura N, 2010, NEUROCASE, V16, P135, DOI 10.1080/13554790903329174; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Whitcher B, 2008, HUM BRAIN MAPP, V29, P346, DOI 10.1002/hbm.20395; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Zhu T, 2008, NEUROIMAGE, V40, P1144, DOI 10.1016/j.neuroimage.2008.01.016	33	188	189	0	25	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0730-725X			MAGN RESON IMAGING	Magn. Reson. Imaging	FEB	2012	30	2					171	180		10.1016/j.mri.2011.10.001			10	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	881BB	WOS:000299453200004	22079073	Green Accepted			2021-06-18	
J	Bernard, SA; Nguyen, V; Cameron, P; Masci, K; Fitzgerald, M; Cooper, DJ; Walker, T; Myles, P; Murray, L; Taylor, D; Smith, K; Patrick, I; Edington, J; Bacon, A; Rosenfeld, JV; Judson, R				Bernard, Stephen A.; Nguyen, Vina; Cameron, Peter; Masci, Kevin; Fitzgerald, Mark; Cooper, David J.; Walker, Tony; Myles, Paul; Murray, Lynne; Taylor, David; Smith, Karen; Patrick, Ian; Edington, John; Bacon, Andrew; Rosenfeld, Jeffrey V.; Judson, Rodney			Prehospital Rapid Sequence Intubation Improves Functional Outcome for Patients With Severe Traumatic Brain Injury A Randomized Controlled Trial	ANNALS OF SURGERY			English	Article							AIRWAY MANAGEMENT; IMPACT	Objective: To determine whether paramedic rapid sequence intubation in patients with severe traumatic brain injury (TBI) improves neurologic outcomes at 6 months compared with intubation in the hospital. Background: Severe TBI is associated with a high rate of mortality and long-term morbidity. Comatose patients with TBI routinely undergo endo-tracheal intubation to protect the airway, prevent hypoxia, and control ventilation. In many places, paramedics perform intubation prior to hospital arrival. However, it is unknown whether this approach improves outcomes. Methods: In a prospective, randomized, controlled trial, we assigned adults with severe TBI in an urban setting to either prehospital rapid sequence intubation by paramedics or transport to a hospital emergency department for intubation by physicians. The primary outcome measure was the median extended Glasgow Outcome Scale (GOSe) score at 6 months. Secondary end-points were favorable versus unfavorable outcome at 6 months, length of intensive care and hospital stay, and survival to hospital discharge. Results: A total of 312 patients with severe TBI were randomly assigned to paramedic rapid sequence intubation or hospital intubation. The success rate for paramedic intubation was 97%. At 6 months, the median GOSe score was 5 (interquartile range, 1-6) in patients intubated by paramedics compared with 3 (interquartile range, 1-6) in the patients intubated at hospital (P = 0.28). The proportion of patients with favorable outcome (GOSe, 5-8) was 80 of 157 patients (51%) in the paramedic intubation group compared with 56 of 142 patients (39%) in the hospital intubation group (risk ratio, 1.28; 95% confidence interval, 1.00-1.64; P = 0.046). There were no differences in intensive care or hospital length of stay, or in survival to hospital discharge. Conclusions: In adults with severe TBI, prehospital rapid sequence intubation by paramedics increases the rate of favorable neurologic outcome at 6 months compared with intubation in the hospital.	[Bernard, Stephen A.] Monash Univ, Alfred Hosp, Intens Care Unit, Sch Publ Hlth & Prevent Med, Melbourne, Vic 3181, Australia; [Nguyen, Vina] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic 3181, Australia; [Taylor, David; Judson, Rodney] Royal Melbourne Hosp, Melbourne, Vic, Australia	Bernard, SA (corresponding author), Monash Univ, Alfred Hosp, Intens Care Unit, Sch Publ Hlth & Prevent Med, Commercial Rd, Melbourne, Vic 3181, Australia.	Stephen.bernard@alfred.org.au	Cooper, D. James/G-7961-2013; Myles, Paul/AAU-9524-2020; Rosenfeld, Jeffrey V/B-7249-2011	Cooper, D. James/0000-0002-5872-9051; Myles, Paul/0000-0002-3324-5456; Cameron, Peter/0000-0002-1443-557X; Fitzgerald, Mark/0000-0003-0183-7761; Smith, Karen/0000-0002-9057-0685	National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of AustraliaUK Research & Innovation (UKRI)Medical Research Council UK (MRC); Victorian Transport Accident Commission	Supported by The National Health and Medical Research Council of Australia and the Victorian Transport Accident Commission. Monash University School of Public Health and Preventive Medicine.	Bernard Stephen, 2002, Emerg Med (Fremantle), V14, P406, DOI 10.1046/j.1442-2026.2002.00382.x; Bernard Stephen A, 2006, Emerg Med Australas, V18, P221, DOI 10.1111/j.1742-6723.2006.00850.x; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Bushby Nathan, 2005, Emerg Med Australas, V17, P443, DOI 10.1111/j.1742-6723.2005.00775.x; Cameron PA, 2008, MED J AUSTRALIA, V189, P546, DOI 10.5694/j.1326-5377.2008.tb02176.x; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Cobas MA, 2009, ANESTH ANALG, V109, P489, DOI 10.1213/ane.0b013e3181aa3063; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; Davis DP, 2004, J TRAUMA, V57, P1, DOI 10.1097/01.TA.0000135503.71684.C8; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; Fakhry SM, 2006, J TRAUMA, V60, P997, DOI 10.1097/01.ta.0000217285.94057.5e; Langeron O, 2009, MINERVA ANESTESIOL, V75, P307; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Nortje J, 2008, CRIT CARE MED, V36, P273, DOI 10.1097/01.CCM.0000292014.60835.15; Sakles JC, 1998, ANN EMERG MED, V31, P325, DOI 10.1016/S0196-0644(98)70342-7; Stiell IG, 2008, CAN MED ASSOC J, V178, P1141, DOI 10.1503/cmaj.071154; Timmermann A, 2006, RESUSCITATION, V70, P179, DOI 10.1016/j.resuscitation.2006.01.010; von Elm E, 2009, BRIT J ANAESTH, V103, P371, DOI 10.1093/bja/aep202; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; Wayne M A, 1999, Prehosp Emerg Care, V3, P107, DOI 10.1080/10903129908958916; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	21	188	197	0	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-4932	1528-1140		ANN SURG	Ann. Surg.	DEC	2010	252	6					959	965		10.1097/SLA.0b013e3181efc15f			7	Surgery	Surgery	685CS	WOS:000284603800009	21107105				2021-06-18	
J	Dick, R; Ferrara, MS; Agel, J; Courson, R; Marshall, SW; Hanley, MJ; Reifsteck, F				Dick, Randall; Ferrara, Michael S.; Agel, Julie; Courson, Ron; Marshall, Stephen W.; Hanley, Michael J.; Reifsteck, Fred			Descriptive epidemiology of collegiate men's football injuries: National Collegiate Athletic Association injury surveillance system, 1988-1989 through 2003-2004	JOURNAL OF ATHLETIC TRAINING			English	Article						athletic injuries; injury prevention; concussions; knee injuries; ankle injuries; heat illness	POSITION STATEMENT; NCAA CONCUSSION; PLAYERS; MANAGEMENT; PATTERNS; RETURN; RATES	Objective: To review 16 years of National Collegiate Athletic Association (NCAA) injury surveillance data for men's football and identify potential areas for injury prevention initiatives. Background: Football is a high-velocity collision sport in which injuries are expected. Football tends to have one of the highest injury rates in sports. Epidemiologic data helps certified athletic trainers and other clinicians identify injury trends and patterns to appropriately design and institute injury prevention protocols and then measure their effects. Main Results: During the 16-year reporting period, about 19% of the Division I, II, and III NCAA institutions sponsoring football participated in the Injury Surveillance System. The results from the 16-year study period show little variation in the injury rates over time: games averaged 36 injuries per 1000 athlete-exposures (A-Es); fall practice, approximately 4 injuries per 1000 A-Es; and spring practice, about 10 injuries per 1000 A-Es. The game injury rate was more than 9 times higher than the in-season practice injury rate (35.90 versus 3.80 injuries per 1000 A-Es, rate ratio = 9.1, 95% confidence interval = 9.0, 9.2), and the spring practice injury rate was more than 2 times higher than the fall practice injury rate (9.62 versus 3.80 injuries per 1000 A-Es, rate ratio = 2.5, 95% confidence interval = 2.5, 2.6). The rate ratio for games versus fall practices was greatest for upper leg contusions (18.1 per 1000 A-Es), acrornioclavicular joint sprains (14.0 per 1000 A-Es), knee internal derangements (13.4 per 1000 A-Es), ankle ligament sprains (12.0 per 1000 A-Es), and concussions (11.1 per 1000 A-Es). Recommendations: Football is a complex sport that requires a range of skills performed by athletes with a wide variety of body shapes and types. Injury risks are greatest during games. Thus, injury prevention measures should focus on position-specific activities to reduce the injury rate. As equipment technology improves for the helmet, shoulder pads, and other protective devices, appropriate injury surveillance procedures should be performed to determine the effect of the new equipment on injury rates. A consistent evaluation of injury trends and patterns will assist decision makers in designing injury prevention techniques in areas that warrant the greatest attention and suggesting rule changes and modifications based on the data.	Univ Georgia, Dept Exercise Sci, Athens, GA 30602 USA; Natl Collegiate Athlet Assoc, Indianapolis, IN USA; Univ Minnesota, Minneapolis, MN 55455 USA; Univ N Carolina, Chapel Hill, NC 27515 USA; E Carolina Univ, Greenville, NC 27858 USA	Ferrara, MS (corresponding author), Univ Georgia, Dept Exercise Sci, 300 River Rd, Athens, GA 30602 USA.	mferrara@uga.edu		Marshall, Stephen/0000-0002-2664-9233			Albright JP, 2004, AM J SPORT MED, V32, P1394, DOI 10.1177/0363546504264159; ALLES W, 1980, ATHL TRAIN J NATA, V15, P98; Binkley HM, 2002, J ATHL TRAINING, V37, P329; BUCKLEY WE, 1988, AM J SPORT MED, V16, P51, DOI 10.1177/036354658801600109; BUCKLEY WE, 1982, ATHL TRAIN, V17, P279; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Cooper ER, 2006, J ATHL TRAINING, V41, P332; Dick R, 2007, J ATHL TRAINING, V42, P173; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Ferrara MS, 2001, J ATHL TRAINING, V36, P145; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; *NAT COLL ATHL ASS, 2006, 1981 82 2004 05 NCAA; Notebaert AJ, 2005, J ATHL TRAINING, V40, P320; Orchard JW, 2003, MED SCI SPORT EXER, V35, P1118, DOI 10.1249/01.MSS.0000074563.61975.9B; Powell J., 1985, ATHLETIC TRAINING, V20, P104; Powell JW, 2004, J ATHL TRAINING, V39, P56; Reider B, 2004, AM J SPORT MED, V32, P1383, DOI 10.1177/0363546504268028; Steiner ME, 2005, AM J SPORT MED, V33, P1545, DOI 10.1177/0363546505275491	21	188	189	0	29	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050			J ATHL TRAINING	J. Athl. Train.	APR-JUN	2007	42	2					221	233					13	Sport Sciences	Sport Sciences	180RC	WOS:000247382300008	17710170				2021-06-18	
J	Maas, AIR; Marmarou, A; Murray, GD; Teasdale, GM; Steyerberg, EW				Maas, Andrew I. R.; Marmarou, Anthony; Murray, Gordon D.; Teasdale, Sir Graham M.; Steyerberg, Ewout W.			Prognosis and clinical trial design in traumatic brain injury: the IMPACT study	JOURNAL OF NEUROTRAUMA			English	Article						methodology; outcome; prognosis; traumatic brain injury; randomized clinical trials	SEVERE HEAD-INJURY; NEUROPROTECTIVE AGENTS; MULTICENTER TRIAL; UNITED-STATES; EFFICACY; EXPERIENCE; MANAGEMENT; OUTCOMES	Traumatic brain injury (TBI) is a major health and socio-economic problem throughout the world. Many randomized controlled trials (RCTs) have been performed to investigate the effectiveness of new therapies, but none have convincingly demonstrated benefit. Clinical trials in TBI pose complex methodological challenges and meeting these requires new approaches. The challenges are related to the heterogeneity of head injuries, to optimum analysis of outcome and to aspects of the design of trials. To address these, we have created the IMPACT database on TBI through merging individual patient data from eight RCTs and three observational surveys. This database forms a culture medium in which innovative approaches to improving trial design and analysis are being explored. We hypothesize that the statistical power of TBI trials may be increased by adjusting for heterogeneity with covariate adjustment and/or prognostic targeting, by exploiting the ordinal nature of the Glasgow Outcome Scale and by relating the outcome obtained in individual patients to their baseline prognostic risk. Extensive prognostic analysis was required as a first step towards our aim of optimizing the chance of demonstrating benefit of new therapies in future trials. The fruits of this analysis are reported in detail in the subsequent reports in this issue of the Journal of Neurotrauma. The results will lead to the development and validation of new prognostic models, which will be applied to deal with heterogeneity. The findings will be synthesized into recommendations for the design and analysis of future RCTs, with the expectation of increasing the likelihood of demonstrating the benefit of a truly effective new therapy or therapeutic agent in victims of a head injury.	Erasmus MC, Dept Neurosurg, NL-3000 CA Rotterdam, Netherlands; Erasmus MC, Ctr Med Decis Making, Dept Publ Hlth, NL-3000 CA Rotterdam, Netherlands; Virginia Commonwealth Univ, Med Ctr, Dept Neurosurg, Richmond, VA USA; Univ Edinburgh, Sch Med, Edinburgh, Midlothian, Scotland; Univ Glasgow, Glasgow, Lanark, Scotland; Royal Coll Phys & Surg, Glasgow, Lanark, Scotland	Maas, AIR (corresponding author), Erasmus MC, Dept Neurosurg, POB 2040, NL-3000 CA Rotterdam, Netherlands.	airmaas@erasmusmc.nl	Maas, Andrew IR/C-5584-2013; Steyerberg, Ewout/C-1509-2018	Maas, Andrew IR/0000-0003-1612-1264; Murray, Gordon/0000-0001-9866-4734; Steyerberg, Ewout/0000-0002-7787-0122	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 42691] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042691] Funding Source: NIH RePORTER		BAILEY I, 1991, ACTA NEUROCHIR, V110, P97, DOI 10.1007/BF01400674; BRAAKMAN R, 1994, J NEUROSURG, V80, P797; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; BULLOCK MR, 2000, J NEUROTRAUM, V17, P451; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; Edwards P, 2005, LANCET, V365, P1957; Finfer SR, 2001, RESUSCITATION, V48, P77, DOI 10.1016/S0300-9572(00)00321-X; Gaab M R, 1994, Zentralbl Neurochir, V55, P135; GRUMME T, 1995, RES EXP MED, V195, P217, DOI 10.1007/BF02576791; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; Hernandez AV, 2006, J NEUROTRAUM, V23, P1295, DOI 10.1089/neu.2006.23.1295; Hukkelhoven CWPM, 2002, J NEUROSURG, V97, P549, DOI 10.3171/jns.2002.97.3.0549; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; Maas AIR, 2006, LANCET NEUROL, V5, P38, DOI 10.1016/S1474-4422(05)70253-2; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Machado SG, 1999, J NEUROTRAUM, V16, P1131, DOI 10.1089/neu.1999.16.1131; Marmarou A, 1999, J NEUROTRAUM, V16, P431, DOI 10.1089/neu.1999.16.431; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; Murray GD, 2005, J NEUROTRAUM, V22, P511, DOI 10.1089/neu.2005.22.511; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Sosin DM, 1996, BRAIN INJURY, V10, P47; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; WOLF AL, 1993, J NEUROSURG, V78, P54, DOI 10.3171/jns.1993.78.1.0054; Young B, 1996, JAMA-J AM MED ASSOC, V276, P538, DOI 10.1001/jama.276.7.538	29	188	198	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2007	24	2					232	238		10.1089/neu.2006.0024			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	150AL	WOS:000245187900002	17375987				2021-06-18	
J	Williamson, IJS; Goodman, D				Williamson, IJS; Goodman, D			Converging evidence for the under-reporting of concussions in youth ice hockey	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							MILD HEAD-INJURY; PLAYERS; EPIDEMIOLOGY; COLLEGIATE; RECOVERY; SEASON; BRAIN	Background: Concussions are potentially serious injuries. The few investigations of prevalence or incidence in youth ice hockey have typically relied on prospective reports from physicians or trainers and did not survey players, despite the knowledge that many athletes do not report probable concussions. Objective: This study sought to compare concussion rates in youth ice hockey that were estimated from a variety of reporting strategies. Methods: Rates were calculated from British Columbia Amateur Hockey Association ( BCAHA) official injury reports, from direct game observation by minor hockey volunteers ( such as coaches and managers), as well as from retrospective surveys of both elite and non-elite youth players. All research was conducted within the BCAHA. Results: Estimates from official injury reports for male players were between 0.25 and 0.61 concussions per 1000 player game hours (PGH). Concussion estimates from volunteer reports were between 4.44 and 7.94 per 1000 PGH. Player survey estimates were between 6.65 and 8.32 per 1000 PGH, and 9.72 and 24.30 per 1000 PGH for elite and non-elite male youth hockey, respectively. Conclusion: It was found that concussions are considerably under-reported to the BCAHA by youth hockey players and team personnel.	Simon Fraser Univ, Burnaby, BC V5A 1S6, Canada; McGill Univ, McGill Sport Med Clin, Montreal, PQ H3A 2T5, Canada	Goodman, D (corresponding author), Simon Fraser Univ, Burnaby, BC V5A 1S6, Canada.	goodman@sfu.ca					Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; BRUST JD, 1992, AM J DIS CHILD, V146, P741, DOI 10.1001/archpedi.1992.02160180101026; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; DAFFNER RH, 1977, J FAM PRACTICE, V4, P225; Dryden DM, 2000, MED SCI SPORT EXER, V32, P1378, DOI 10.1097/00005768-200008000-00004; Gabbe BJ, 2003, BRIT J SPORT MED, V37, P545, DOI 10.1136/bjsm.37.6.545; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Gennarelli TA, 1998, NEUROSCIENTIST, V4, P202, DOI 10.1177/107385849800400316; GERBERICH SG, 1987, CHILD NERV SYST, V3, P59, DOI 10.1007/BF00271123; Goodman D, 2001, MED SCI SPORT EXER, V33, P2004, DOI 10.1097/00005768-200112000-00005; GRINDEL SH, 2003, CURR SPORTS MED REP, V3, P18; Groger A, 2001, SPORTVERLETZ SPORTSC, V15, P82, DOI 10.1055/s-2001-19047; GRONWALL D, 1974, LANCET, V2, P605; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Macciocchi SN, 1998, CLIN SPORT MED, V17, P27, DOI 10.1016/S0278-5919(05)70058-2; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; MCFAULL S, 2001, CHIRPP NEWS, V19, P1; Molsa J, 2000, AM J SPORT MED, V28, P322; PATTERSSON M, 1993, BRIT J SPORT MED, V27, P251, DOI 10.1136/bjsm.27.4.251; PELLETIER RL, 1993, AM J SPORT MED, V21, P78, DOI 10.1177/036354659302100114; Pinto M, 1999, CLIN J SPORT MED, V9, P70, DOI 10.1097/00042752-199904000-00005; Reid SR, 1999, PEDIATR EMERG CARE, V15, P310, DOI 10.1097/00006565-199910000-00002; Roberts WO, 1999, MED SCI SPORT EXER, V31, P46, DOI 10.1097/00005768-199901000-00009; ROBERTS WO, 1966, ARCH PEDIAT ADOLESC, V150, P140; ROY MA, 1989, PHYSICIAN SPORTSMED, V17, P119, DOI 10.1080/00913847.1989.11709735; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Smith AM, 1997, AM J SPORT MED, V25, P500, DOI 10.1177/036354659702500413; STUART MJ, 1995, MAYO CLIN PROC, V70, P350, DOI 10.4065/70.4.350; Sutherland G W, 1976, Am J Sports Med, V4, P264, DOI 10.1177/036354657600400605; Tegner Y, 1991, Br J Sports Med, V25, P87; TYSVAER AT, 1989, ACTA NEUROL SCAND, V80, P151, DOI 10.1111/j.1600-0404.1989.tb03858.x	35	188	189	0	24	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	FEB	2006	40	2					128	132		10.1136/bjsm.2005.021832			5	Sport Sciences	Sport Sciences	005NP	WOS:000234831400010	16431999	Green Published			2021-06-18	
J	Englander, J; Bushnik, T; Duong, TT; Cifu, DX; Zafonte, R; Wright, J; Hughes, R; Bergman, W				Englander, J; Bushnik, T; Duong, TT; Cifu, DX; Zafonte, R; Wright, J; Hughes, R; Bergman, W			Analyzing risk factors for late posttraumatic seizures: A prospective, multicenter investigation	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	62nd Annual Meeting of the American-Academy-of-Physical-Medicine-and-Rehabilitation	NOV 02-05, 2000	SAN FRANCISCO, CA	Amer Acad Phys Med & Rehabil		multicenter studies; rehabilitation; risk factors; seizure disorders; post-traumatic; surgery; tomography; x-ray computed	POST-TRAUMATIC EPILEPSY; PENETRATING HEAD-INJURY; SEVERE BRAIN INJURIES; FOLLOW-UP; PREVENTION; CARBAMAZEPINE; POPULATION; VALPROATE; PHENYTOIN	Objectives: To ascertain the natural history and to stratify risks for the development of late posttraumatic seizures in individuals with moderate to severe traumatic brain injury (TBI). Design: Prospective, observational study of individuals with TBI admitted to 4 trauma centers within 24 hours of injury. Setting: Four tertiary care trauma centers in urban areas. Participants: A total of 647 individuals (greater than or equal to16y) with any of the following abnormal computed tomography (CT) scan findings: extent of midline shift and/or cisternal compression or presence of any focal pathology (eg, punctate, subarachnoid, or intraventricular hemorrhage; cortical or subcortical contusion; extra-axial lesions) during the first 7 days postinjury or best Glasgow Coma Scale (GCS) score of less than or equal to10 during the first 24 hours post-TBI. Subjects were enrolled from August 1993 through September 1997 and followed for up to 24 months, until death or their first late posttraumatic seizures. Interventions: Not applicable. Main Outcome Measures: Cumulative probability, relative risk, and survival analyses were used to stratify risks for development of late posttraumatic seizures on the basis of demographic factors, etiology of injury, initial GCS, early posttraumatic seizures, time post-TBI, types of intracerebral lesion by CT scan, and number and types of intracranial procedures. Results: Sixty-six individuals had a late posttraumatic seizures; 337 had no late posttraumatic seizures during full 24-month follow-up; 167 had no late posttraumatic seizures during time followed (<24mo); and 54 were placed on anticonvulsants without a late posttraumatic seizures, whereas 23 died before their first late posttraumatic seizures. The highest cumulative probability for late posttraumatic seizures included biparietal contusions (66%), dural penetration with bone and metal fragments (62.5%), multiple intracranial operations (36.5%), multiple subcortical contusions (33.4%), subdural hematoma with evacuation (27.8%), midline shift greater than 5mm (25.8%), or multiple or bilateral cortical contusions (25%). Initial GCS score was associated with the following cumulative probabilities for development of late posttraumatic seizures at 24 months: GCS score of 3 to 8, 16.8%; GCS score of 9 to 12, 24.3%; and GCS score of 13 to 15, 8.0%. Conclusions: Stratification by CT scan findings and neurosurgical procedures performed were the most useful findings in defining individuals at highest risk for late posttraumatic seizures.	Santa Clara Valley Med Ctr, Dept Phys Med & Rehabil, San Jose, CA 95128 USA; Santa Clara Valley Med Ctr, Rehabil Res Ctr TBI & SCI, San Jose, CA 95128 USA; Stanford Univ, Med Ctr, Sch Med, Dept Funct Restorat Phys Med & Rehabil, Stanford, CA 94305 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Phys Med & Rehabil, Richmond, VA 23298 USA; Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA; Univ Colorado, Sch Med, Denver, CO USA; Denver Hlth Med Ctr, Div Neurol, Denver, CO USA	Englander, J (corresponding author), Santa Clara Valley Med Ctr, Dept Phys Med & Rehabil, 751 S Bascom Ave, San Jose, CA 95128 USA.	Jeffrey.Englander@hhs.co.santa-clara.ca.us		Cifu, David/0000-0003-1600-9387; Bushnik, Tamara/0000-0003-3328-257X			ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; [Anonymous], 1961, VETERANS ADM MED MON; Ascroft PB, 1941, BMJ-BRIT MED J, V1941, P739, DOI 10.1136/bmj.1.4193.739; ASKENASY JJM, 1989, ACTA NEUROL SCAND, V79, P47, DOI 10.1111/j.1600-0404.1989.tb03708.x; BRANDVOLD B, 1990, J NEUROSURG, V72, P15, DOI 10.3171/jns.1990.72.1.0015; BULLOCK R, 1995, GUIDELINES MANAGEMEN; CAREY ME, 1984, J NEUROSURG, V60, P947, DOI 10.3171/jns.1984.60.5.0947; CAVENESS WF, 1961, EPILEPSIA, V2, P123; CAVENESS WF, 1979, J NEUROSURG, V50, P545, DOI 10.3171/jns.1979.50.5.0545; CAVENESS WF, 1963, J NEUROSURG, V20, P570, DOI 10.3171/jns.1963.20.7.0570; Cohen M, 1991, EPILEPSIA S1, V32, pS55; COURJON J, 1970, EPILEPSIA, V11, P29, DOI 10.1111/j.1528-1157.1970.tb03863.x; DASILVA AM, 1990, ACT NEUR S, V50, P48; De Santis A, 1979, J Neurosurg Sci, V23, P207; DESAI BT, 1983, EPILEPSIA, V24, P289, DOI 10.1111/j.1528-1157.1983.tb04892.x; EVANS JH, 1962, NEUROLOGY, V12, P665, DOI 10.1212/WNL.12.10.665; FEENEY DM, 1979, ARCH NEUROL-CHICAGO, V36, P8, DOI 10.1001/archneur.1979.00500370038005; GLOTZNER FL, 1983, NEUROCHIRURGIA, V26, P66; Grafman J, 1992, Adv Neurol, V57, P369; Gruber FA, 1999, J SPEECH LANG HEAR R, V42, P432, DOI 10.1044/jslhr.4202.432; Guidice M A, 1987, Brain Inj, V1, P61; HAHN YS, 1988, NEUROSURGERY, V22, P864, DOI 10.1227/00006123-198805000-00008; Haltiner AM, 1997, ARCH PHYS MED REHAB, V78, P835, DOI 10.1016/S0003-9993(97)90196-9; HAUSER WA, 1984, NEUROLOGY, V34, P746, DOI 10.1212/WNL.34.6.746; HAUSER WA, 1991, EPILEPSIA, V32, P429, DOI 10.1111/j.1528-1157.1991.tb04675.x; HEIKKINEN ER, 1990, STEREOT FUNCT NEUROS, V54-5, P25, DOI 10.1159/000100186; JENNETT B, 1975, EPILEPSIA, V16, P251, DOI 10.1111/j.1528-1157.1975.tb06055.x; JENNETT B, 1973, LANCET, V2, P652; JENNETT B, 1973, SCOT MED J, V18, P8, DOI 10.1177/003693307301800103; Jennett B, 1975, EPILEPSY NONMISSILE; *KESSL MED REH RES, 2000, TRAUM BRAIN INJ MOD; Kollevold T, 1979, J Oslo City Hosp, V29, P35; Kollevold T, 1978, J OSLO CITY HOSP, V28, P78; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MATTSON RH, 1992, NEW ENGL J MED, V327, P765, DOI 10.1056/NEJM199209103271104; PAILLAS JE, 1970, EPILEPSIA, V11, P5, DOI 10.1111/j.1528-1157.1970.tb03860.x; PECHADRE JC, 1991, PRESSE MED, V20, P841; PHILLIPS G, 1954, J NEUROL NEUROSUR PS, V17, P1, DOI 10.1136/jnnp.17.1.1; RUSSELL WR, 1951, J NEUROL NEUROSUR PS, V14, P35, DOI 10.1136/jnnp.14.1.35; RUSSELL WR, 1952, J NEUROL NEUROSUR PS, V15, P93, DOI 10.1136/jnnp.15.2.93; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; SALAZAR AM, 1987, ADV EPILEPTOL, V16, P627; SALAZAR AM, 1987, ADV EPILEPSY, V16, P753; SAZBON L, 1990, J NEUROSURG, V72, P75, DOI 10.3171/jns.1990.72.1.0075; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; WALKER AE, 1959, J NEUROSURG, V16, P600, DOI 10.3171/jns.1959.16.6.0600; WALKER AE, 1970, EPILEPSIA, V11, P17, DOI 10.1111/j.1528-1157.1970.tb03861.x; WATSON CW, 1952, AMA ARCH NEUROL PSY, V68, P831, DOI 10.1001/archneurpsyc.1952.02320240106011; WEISS GH, 1986, ARCH NEUROL-CHICAGO, V43, P771, DOI 10.1001/archneur.1986.00520080019013; WEISS GH, 1983, ARCH NEUROL-CHICAGO, V40, P7, DOI 10.1001/archneur.1983.04050010027006; WIEDERHOLT WC, 1989, NEUROLOGY, V39, P96, DOI 10.1212/WNL.39.1.96; WILSON DM, 1951, NZ MED J, V50, P383; YABLON SA, 1993, ARCH PHYS MED REHAB, V74, P983; Yablon SA, 1998, ARCH PHYS MED REHAB, V79, P594; YUAN XQ, 1993, FASEB J, V7, pA853; YUAN XQ, 1992, FASEB J, V6, pA1516; YUAN XQ, 1993, CIRC SHOCK S2, V41, P53	60	188	197	1	8	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAR	2003	84	3					365	373		10.1053/apmr.2003.50022			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	653KL	WOS:000181434300008	12638104				2021-06-18	
J	Mesiwala, AH; Farrell, L; Wenzel, HJ; Silbergeld, DL; Crum, LA; Winn, HR; Mourad, PD				Mesiwala, AH; Farrell, L; Wenzel, HJ; Silbergeld, DL; Crum, LA; Winn, HR; Mourad, PD			High-intensity focused ultrasound selectively disrupts the blood-brain barrier in vivo	ULTRASOUND IN MEDICINE AND BIOLOGY			English	Article						blood-brain barrier; HIFU; permeability; tight junctions; ultrasound	CLOSED-HEAD INJURY; LOCALIZED HYPERTHERMIA; HORSERADISH-PEROXIDASE; RADIATION FORCE; RATS; PERMEABILITY; JUNCTIONS; BREAKDOWN; PRESSURE; PROTEIN	High-intensity focused ultrasound (HIFU) has been shown to generate lesions that destroy brain tissue while disrupting the blood-brain barrier (BBB) in the periphery of the lesion. BBB opening, however, has not been shown without damage, and the mechanisms by which HIFU induces BBB disruption remain unknown. We show that HIFU is capable of reversible, nondestructive, BBB disruption in a targeted region-of-interest (1101) (29 of 55 applications; 26 of 55 applications showed no effect); this opening reverses after 72 h. Light microscopy demonstrates that HIFU either entirely preserves brain architecture while opening the BBB (18 of 29 applications), or generates tissue damage in a small volume within the region of BBB opening (11 of 29 applications). Electron microscopy supports these observations and suggests that HIFU disrupts the BBB by opening capillary endothelial cell tight junctions, an isolated ultrastructural effect that is different from the mechanisms through which other (untargeted) modalities, such as hyperosmotic solutions, hyperthermia and percussive injury disrupt the BBB. (E-mail: pierre@apl.washington.edu) (C) 2002 World Federation for Ultrasound in Medicine Biology.	Univ Washington, Appl Phys Lab, Ctr Ind & Med Ultrasound, Seattle, WA 98105 USA; Univ Washington, Dept Neurol Surg, Seattle, WA 98105 USA	Mourad, PD (corresponding author), Univ Washington, Appl Phys Lab, Ctr Ind & Med Ultrasound, 1013 NE 40th St, Seattle, WA 98105 USA.	pierre@apl.washington.edu			NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R29 CA69640] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1F32 NS10897-01, K-25 NS02234-01, K08 NS01730] Funding Source: Medline; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R29CA069640] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F32NS010897, K25NS002234, K08NS001730] Funding Source: NIH RePORTER		ASTROEM KE, 1961, J NEUROPATH EXP NEUR, V20, P484, DOI 10.1097/00005072-196120040-00002; BAKAY L, 1956, ARCH NEURO PSYCHIATR, V76, P457, DOI 10.1001/archneurpsyc.1956.02330290001001; BALLANTINE HT, 1960, J NEUROSURG, V17, P858, DOI 10.3171/jns.1960.17.5.0858; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Barzo P, 1997, ACT NEUR S, V70, P243; BAUMBACH GL, 1988, HYPERTENSION, V12, P89, DOI 10.1161/01.HYP.12.2.89; BONATE PL, 1995, J NEUROSCI METH, V56, P1, DOI 10.1016/0165-0270(94)00081-Q; Boucher BA, 1998, CLIN PHARMACOKINET, V35, P209, DOI 10.2165/00003088-199835030-00004; CAVENESS WF, 1978, LATE BIOL EFFECTS IO, P221; CEREIJIDO M, 1993, J CELL SCI, P127; Chen XC, 1997, J ACOUST SOC AM, V101, P2443, DOI 10.1121/1.418539; Curra FP, 2000, IEEE T ULTRASON FERR, V47, P1077, DOI 10.1109/58.852092; FARRELL CL, 1984, ACTA NEUROPATHOL, V63, P179, DOI 10.1007/BF00685243; Fatemi M, 2000, PHYS MED BIOL, V45, P1449, DOI 10.1088/0031-9155/45/6/304; Foster KA, 2000, CURR DRUG METAB, V1, P333, DOI 10.2174/1389200003338901; FRANGO JA, 1993, PHYSICAL FORCES MAMM; FRY F J, 1970, Journal of the Acoustical Society of America, V48, P1413, DOI 10.1121/1.1912301; FRY W J, 1958, Adv Biol Med Phys, V6, P281; FUKUDA K, 1995, J NEUROTRAUM, V12, P315, DOI 10.1089/neu.1995.12.315; Hickey WF, 2001, GLIA, V36, P118, DOI 10.1002/glia.1101; HILL CR, 1970, PHYS MED BIOL, V15, P241, DOI 10.1088/0031-9155/15/2/001; Hill CR, 1995, BRIT J RADIOL, V68, P1296, DOI 10.1259/0007-1285-68-816-1296; HYHYNEN K, 2001, RADIOLOGY, V220, P640; Hynynen K, 1998, ULTRASOUND MED BIOL, V24, P275, DOI 10.1016/S0301-5629(97)00269-X; JOHANSSON BB, 1980, BRAIN RES, V181, P219, DOI 10.1016/0006-8993(80)91274-3; JOHANSSON BB, 1978, STROKE, V9, P588, DOI 10.1161/01.STR.9.6.588; Kroll RA, 1998, NEUROSURGERY, V42, P1083, DOI 10.1097/00006123-199805000-00082; Leighton TG, 1994, ACOUSTIC BUBBLE; Lynn JG, 1944, AM J PATHOL, V20, P637; MACKENZIE ET, 1976, CIRC RES, V39, P33, DOI 10.1161/01.RES.39.1.33; Mayhan WG, 2001, MICROCIRCULATION, V8, P89, DOI 10.1038/sj.mn.7300154; MAYHAN WG, 1986, CIRC RES, V59, P216, DOI 10.1161/01.RES.59.2.216; Mitome H, 1998, ELECTRON COMM JPN 3, V81, P1, DOI 10.1002/(SICI)1520-6440(199810)81:10<1::AID-ECJC1>3.0.CO;2-9; Mourad P.D., 1999, ENCY ELECT ELECT ENG, V2, P368; NAGY Z, 1984, LAB INVEST, V50, P313; NAKATA H, 1995, ACTA NEUROCHIR, V136, P82, DOI 10.1007/BF01411440; NAWASHIRO H, 1995, J NEUROTRAUM, V12, P189, DOI 10.1089/neu.1995.12.189; Ohmoto Y, 1996, INT J HYPERTHER, V12, P321, DOI 10.3109/02656739609022521; Oztas B, 1998, INT J HYPERTHER, V14, P395, DOI 10.3109/02656739809018241; Patrick J T, 1990, Adv Exp Med Biol, V267, P369; Poliachik SL, 1999, ULTRASOUND MED BIOL, V25, P991, DOI 10.1016/S0301-5629(99)00043-5; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; Prophet EB, 1994, LAB METHODS HISTOTEC; Rapoport SI, 1996, J DRUG TARGET, V3, P417, DOI 10.3109/10611869609015962; Rubin LL, 1999, ANNU REV NEUROSCI, V22, P11, DOI 10.1146/annurev.neuro.22.1.11; TANNO H, 1993, J CEREBR BLOOD F MET, V13, P116, DOI 10.1038/jcbfm.1993.14; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; ter Haar G, 1999, Eur J Ultrasound, V9, P3; TERHAAR GR, 1986, IEEE T ULTRASON FERR, V33, P162, DOI 10.1109/T-UFFC.1986.26809; URAKAWA M, 1995, INT J HYPERTHER, V11, P709, DOI 10.3109/02656739509022502; VYKHODTSEVA NI, 1995, ULTRASOUND MED BIOL, V21, P969, DOI 10.1016/0301-5629(95)00038-S; Wenzel HJ, 1997, P NATL ACAD SCI USA, V94, P12676, DOI 10.1073/pnas.94.23.12676; WESTRUM LE, 1966, J CELL SCI, V1, P229; WESTRUM LE, 1973, J NEUROCYTOL, V2, P189, DOI 10.1007/BF01474720; *WFUMB, 1992, ULTRASOUND MED BIOL; *WFUMB, 1996, ULTRASOUND MED BIOL, V24, P1; WIJSMAN JA, 1993, ACTA NEUROPATHOL, V86, P49, DOI 10.1007/BF00454898; YANG R, 1992, J PEDIATR SURG, V27, P246, DOI 10.1016/0022-3468(92)90321-W	58	188	193	0	27	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0301-5629	1879-291X		ULTRASOUND MED BIOL	Ultrasound Med. Biol.	MAR	2002	28	3					389	400		10.1016/S0301-5629(01)00521-X			12	Acoustics; Radiology, Nuclear Medicine & Medical Imaging	Acoustics; Radiology, Nuclear Medicine & Medical Imaging	546KC	WOS:000175272400014	11978420				2021-06-18	
J	Margulies, SS; Thibault, KH				Margulies, SS; Thibault, KH			Infant skull and suture properties: Measurements and implications for mechanisms of pediatric brain injury	JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME			English	Article								The mechanical properties of the adult human skull are well documented, but little information is available for the infant skull. To determine the age-dependent fchanges in skull properties, we tested human and porcine infant cranial bone in three-point bending. The measurement of elastic modulus in the human and porcine infant cranial bone agrees with and extends previous published data [McPherson, G. K., and Kriewall, T.J. (1980), J. Biomech, 13, pp. 9-16] for human infant cranial bone. After confirming that the porcine and human cranial bone properties were comparable, additional tensile and three-point bending studies were conducted on porcine cranial bone and suture. Comparisons of the porcine infant data with previously published adult human data demonstrate that the elastic modulus, ultimate stress, and energy absorbed to failure increase, and the ultimate strain decreases with age for cranial bone. Likewise, we conclude that the elastic modulus, ultimate stress and energy absorbed to failure increase with age for sutures. We constructed two finite element models of an idealized one-month old infant head, one with pediatric and the other adult skull properties, and subjected them to impact loading to investigate the contribution of the cranial bone properties on the intracranial tissue deformation pattern. The computational simulations demonstrate that the comparatively compliant skull and membranous suture properties of the infant brain case are associated with large cranial shape changes, and a more diffuse pattern of brain distortion than when the skull takes on adult properties. These studies are a fundamental initial step in predicting the unique mechanical response of the pediatric skull to traumatic loads associated with head injury and, thus, for defining head injury thresholds for children. [S0148-0731(00)00904-3].	Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA	Margulies, SS (corresponding author), Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA.						DATSKO J, 1986, STANDARD HDB MACHINE, pCH7; DEJEAMMES M, 1984, 840530 SAE, P427; DICKERSON JW, 1967, PROC R SOC SER B-BIO, V166, P384, DOI 10.1098/rspb.1967.0002; DOBBING J, 1964, SCI FDN PAEDIAT; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; EVANS FG, 1957, J APPL PHYSIOL, V10, P493; Gennarelli T, 1996, NEUROSURGERY, V2, P2611; HUBBARD RP, 1971, J BIOMECH, V4, P251, DOI 10.1016/0021-9290(71)90031-5; HUBBARD RP, 1971, J BIOMECH, V4, P491, DOI 10.1016/0021-9290(71)90039-X; JASLOW CR, 1990, J BIOMECH, V23, P313, DOI 10.1016/0021-9290(90)90059-C; JOHNSON AF, 1986, COMPOSITES, V17, P321, DOI 10.1016/0010-4361(86)90749-4; KRIEWALL TJ, 1981, J BIOMECH, V14, P73, DOI 10.1016/0021-9290(81)90166-4; KRIEWALL TJ, 1982, AM J OBSTET GYNECOL, V143, P707, DOI 10.1016/0002-9378(82)90119-3; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; MCELHANEY JH, 1970, J BIOMECH, V3, P495, DOI 10.1016/0021-9290(70)90059-X; MCPHERSON GK, 1980, J BIOMECH, V13, P9, DOI 10.1016/0021-9290(80)90003-2; Melvin JW., 1969, DEV, V5, P811; MOHAN D, 1979, ASME, V101, P250; Shreiber D.I., 1997, STAPP CAR CRASH J, V41, P277; STURTZ G, 1980, 801313 SAE; Thibault KL, 1998, J BIOMECH, V31, P1119, DOI 10.1016/S0021-9290(98)00122-5; Timoshenko S., 1951, THEORY ELASTICITY; Wainwright S. A., 1976, MECH DESIGN ORGANISM; WOOD JL, 1971, J BIOMECH, V4, P1, DOI 10.1016/0021-9290(71)90010-8	24	188	202	0	17	ASME-AMER SOC MECHANICAL ENG	NEW YORK	THREE PARK AVE, NEW YORK, NY 10016-5990 USA	0148-0731			J BIOMECH ENG-T ASME	J. Biomech. Eng.-Trans. ASME	AUG	2000	122	4					364	371		10.1115/1.1287160			8	Biophysics; Engineering, Biomedical	Biophysics; Engineering	404QC	WOS:000167111100009	11036559				2021-06-18	
J	Knoblach, SM; Fan, L; Faden, AI				Knoblach, SM; Fan, L; Faden, AI			Early neuronal expression of tumor necrosis factor-alpha after experimental brain injury contributes to neurological impairment	JOURNAL OF NEUROIMMUNOLOGY			English	Article						tumor necrosis factor-alpha; traumatic injury; brain injury; antagonist; cerebral cortex; behavioral dysfunction	CLOSED-HEAD INJURY; FOCAL CEREBRAL-ISCHEMIA; CENTRAL-NERVOUS-SYSTEM; TNF-ALPHA; FACTOR RECEPTOR; RAT-BRAIN; IN-VITRO; CYTOKINE EXPRESSION; ENDOTHELIAL-CELLS; PROTEIN	Tumor necrosis factor-alpha (TNF alpha) is a pleiotropic cytokine involved in inflammatory cascades associated with CNS injury. To examine the role of TNF alpha in the acute pathophysiology of traumatic brain injury (TBI), we studied its expression, localization and modulation in a clinically relevant rat model of non-penetrating head trauma. TNF alpha levels increased significantly in the injured cortex at I and 4, but not at 12, 14 or 72 h after severe lateral fluid-percussion trauma (2.6-2.7 atm). TNF alpha was not elevated after mild injury. At I and 4 h after severe TBI, marked increases of TNF alpha were localized immunocytochemically to neurons of the injured cerebral cortex. A small population of astrocytes, ventricular cells and microvessels, also showed positive TNF alpha staining, but this expression was not injury-dependent. Macrophages that were present in a hemorrhagic zone along the external capsule, corpus callosum and alveus hippocampus at 4 h after TBI did not express TNF alpha. Intracerebroventricular administration of a selective TNF alpha antagonist-soluble TNF alpha receptor fusion protein (sTNFR:Fc) (37.5 mu g)-at 15 min before and 1 h after TBI, improved performance in a series of standardized motor tasks after injury. In contrast: intravenous administration of sTNFR:Fc (0.2, 1 or 5 mg/kg) at 15 min after trauma did not improve motor outcome. Collectively, this evidence suggests that enhanced early neuronal expression of TNF alpha after TBI contributes to subsequent neurological dysfunction. (C) 1999 Elsevier Science B.V. All rights reserved.	Georgetown Univ, Med Ctr, Georgetown Inst Cognit & Computat Sci, Washington, DC 20007 USA	Knoblach, SM (corresponding author), Georgetown Univ, Med Ctr, Georgetown Inst Cognit & Computat Sci, Rm EP-04,Res Bldg,3970 Reservoir Rd NW, Washington, DC 20007 USA.	knoblachs@giccs.geogetown.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD007459] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5T32HD07459] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49CCR3-6634-07] Funding Source: Medline		Akassoglou K, 1997, J IMMUNOL, V158, P438; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P249; Arvin B, 1995, ANN NY ACAD SCI, V765, P62, DOI 10.1111/j.1749-6632.1995.tb16561.x; Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; BODSCH W, 1985, PROG BRAIN RES, V63, P197; Boehme MWJ, 1996, IMMUNOLOGY, V87, P134; Botchkina GI, 1997, MOL MED, V3, P765, DOI 10.1007/BF03401714; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; CHAO CC, 1994, DEV NEUROSCI-BASEL, V16, P172, DOI 10.1159/000112104; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DAMOISEAUX JGMC, 1994, IMMUNOLOGY, V83, P140; DEBUS E, 1983, DIFFERENTIATION, V25, P193, DOI 10.1111/j.1432-0436.1984.tb01355.x; deVries HE, 1996, J NEUROIMMUNOL, V64, P37, DOI 10.1016/0165-5728(95)00148-4; DSOUZA S, 1995, J NEUROSCI, V15, P7293; Duchini A, 1996, J INVEST MED, V44, P474; ESTRADA C, 1995, J CEREBR BLOOD F MET, V15, P920, DOI 10.1038/jcbfm.1995.117; FADEN AI, 1992, AM J PHYSIOL, V263, pR909; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; FRANKS AK, 1991, INFECT IMMUN, V59, P2609, DOI 10.1128/IAI.59.8.2609-2614.1991; GADIENT RA, 1990, NEUROSCI LETT, V117, P335, DOI 10.1016/0304-3940(90)90687-5; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2; Hisahara S, 1997, J NEUROCHEM, V69, P10; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; JOHNSON GD, 1981, J IMMUNOL METHODS, V43, P349, DOI 10.1016/0022-1759(81)90183-6; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; MATTSON MP, 1995, J NEUROSCI RES, V42, P357, DOI 10.1002/jnr.490420310; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MEGYERI P, 1992, NEUROSCI LETT, V148, P137, DOI 10.1016/0304-3940(92)90823-P; MERRILL JE, 1993, J IMMUNOL, V151, P2132; MOHLER KM, 1993, J IMMUNOL, V151, P1548; Moreland LW, 1997, NEW ENGL J MED, V337, P141, DOI 10.1056/NEJM199707173370301; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Nawashiro H, 1997, J CEREBR BLOOD F MET, V17, P483, DOI 10.1097/00004647-199705000-00001; Paxinos G, 1986, RAT BRAIN STEREOTAXI; PEPPEL K, 1991, J EXP MED, V174, P1483, DOI 10.1084/jem.174.6.1483; Rosenberg GA, 1995, BRAIN RES, V703, P151, DOI 10.1016/0006-8993(95)01089-0; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Scherbel U., 1997, J NEUROTRAUM, V14, P781; SCHOENFELD HJ, 1991, J BIOL CHEM, V266, P3863; SCHWARTZ M, 1991, BRAIN RES, V545, P334, DOI 10.1016/0006-8993(91)91309-O; Semple-Rowland SL, 1997, RES LEG MED, V17, P121; Shen Y, 1997, J BIOL CHEM, V272, P3550, DOI 10.1074/jbc.272.6.3550; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Sipe KJ, 1996, MOL BRAIN RES, V38, P222, DOI 10.1016/0169-328X(95)00310-O; SMITH MR, 1990, J IMMUNOL, V144, P162; SternerKock A, 1996, IMMUNOLOGY, V87, P454; SULLIVAN P, 1997, J NEUROTRAUM, V14, P770; TALLEY AK, 1995, MOL CELL BIOL, V15, P2359; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TCHELINGERIAN JL, 1993, NEURON, V10, P213, DOI 10.1016/0896-6273(93)90312-F; TETI G, 1993, INFECT IMMUN, V61, P227, DOI 10.1128/IAI.61.1.227-235.1993; THILMANN R, 1986, ACTA NEUROPATHOL, V71, P88, DOI 10.1007/BF00687967; Wallach D, 1997, TRENDS BIOCHEM SCI, V22, P107, DOI 10.1016/S0968-0004(97)01015-3; Wee SL, 1997, TRANSPLANTATION, V63, P570, DOI 10.1097/00007890-199702270-00015; YAKOVLEV AG, 1995, J NEUROTRAUM, V12, P767, DOI 10.1089/neu.1995.12.767; Yuan JY, 1997, CURR OPIN CELL BIOL, V9, P247, DOI 10.1016/S0955-0674(97)80069-5	62	188	195	0	7	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-5728			J NEUROIMMUNOL	J. Neuroimmunol.	MAR 1	1999	95	1-2					115	125		10.1016/S0165-5728(98)00273-2			11	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	183JT	WOS:000079551000012	10229121				2021-06-18	
J	Fan, L; Young, PR; Barone, FC; Feuerstein, GZ; Smith, DH; McIntosh, TK				Fan, L; Young, PR; Barone, FC; Feuerstein, GZ; Smith, DH; McIntosh, TK			Experimental brain injury induces differential expression of tumor necrosis factor-alpha mRNA in the CNS	MOLECULAR BRAIN RESEARCH			English	Article						TNF-alpha; mRNA; Northern blot; cortex; injury; fluid percussion	RAT-BRAIN; TNF; CYTOTOXICITY; MICROGLIA; BREAKDOWN; BARRIER; IL-1	In the present study, we examined the expression of tumor necrosis factor-alpha (TNF-alpha) mRNA in specific brain regions following experimental lateral fluid percussion traumatic brain injury (TBI) in rats. Adult Sprague-Dawley rats (n = 42) were anesthetized with sodium pentobarbital (60 mg/kg, i.p.) and subjected to lateral fluid percussion brain injury of moderate severity (2.4 atm.) centered over the left temporoparietal cortex, or 'sham' treatment (anesthesia and surgery without injury). Animals were killed by decapitation at 1, 6 or 24 h post injury, brains removed, and tissue samples of left (injured) parietal cortex (LC), right parietal cortex (RC), left adjacent cortex (LA), right adjacent cortex (RA), left hippocampus (LH) and right hippocampus (RH) were prepared. Total RNA was isolated and Northern blot hybridization was performed. TNF-alpha mRNA is expressed as the percent relative radioactivity of macrophage (positive control) RNA. In sham or naive animals, no consistent changes in expression of TNF-alpha mRNA were observed in any of the six brain areas at any times (less than 5%). A marked increase of TNF-alpha mRNA expression was observed in LH (104 +/- 17, P < 0.05 compared with sham), LC (105 +/- 21, P < 0.05) and LA (69 +/- 8, P < 0.01) in the traumatized hemisphere 1 h following injury. An increased TNF-alpha mRNA expression was also observed in LH (46 +/- 8, P < 0.05), LC (30 +/- 3, P < 0.01) and LA (32 +/- 3, P < 0.01) at 6 h which resolved by 24 h following injury. In the contralateral hemisphere, expression of TNF-alpha mRNA was increased in RH (46 +/- 2, P < 0.01) at 1 h and in RA (26 +/- 6%, P < 0.05) at 6 h. These results indicate that following parasagittal fluid percussion brain injury, the temporal expression of TNF-alpha mRNA is altered in specific brain regions, including those of the non-traumatized hemisphere. Post-traumatic alteration in gene expression of TNF-alpha might play an important role in both the acute and regenerative response to CNS trauma.	UNIV PENN, DIV NEUROSURG, PHILADELPHIA, PA 19104 USA; SMITHKLINE BEECHAM PHARMACEUT, DEPT MOLEC GENET, KING OF PRUSSIA, PA 19406 USA; SMITHKLINE BEECHAM PHARMACEUT, DEPT CARDIOVASC PHARMACOL, KING OF PRUSSIA, PA 19406 USA			smith, douglas/A-1321-2007		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P0I-NS08803, R0I-NS26818] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026818, P01NS008803] Funding Source: NIH RePORTER		Abraham E, 1991, Methods Achiev Exp Pathol, V14, P45; BERGSMA DJ, 1991, J BIOL CHEM, V266, P23204; BERKENBOSCH F, 1991, NEUR CONT B, V6, P131; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DEMEULES JE, 1992, J TRAUMA, V32, P686, DOI 10.1097/00005373-199206000-00003; DUBRAVEC DB, 1990, P NATL ACAD SCI USA, V87, P6758, DOI 10.1073/pnas.87.17.6758; EDDY LJ, 1992, BIOCHEM BIOPH RES CO, V184, P1056, DOI 10.1016/0006-291X(92)90698-K; EICHACKER PQ, 1991, J APPL PHYSIOL, V71, P1979; Fan Lei, 1995, Molecular Brain Research, V30, P125, DOI 10.1016/0169-328X(94)00287-O; GANTER S, 1992, J NEUROSCI RES, V33, P218, DOI 10.1002/jnr.490330205; GLOWINSKI J, 1966, J NEUROCHEM, V13, P655, DOI 10.1111/j.1471-4159.1966.tb09873.x; GOODMAN JC, 1990, J NEUROIMMUNOL, V30, P213; LIU T, 1994, STROKE, V25, P1481, DOI 10.1161/01.STR.25.7.1481; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; SELMAJ K, 1991, J IMMUNOL, V147, P1522; SHOHAMI E, 1993, 11 ANN NEUR S WASH; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Soares HD, 1995, J NEUROSCI, V15, P8223; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; TANNO H, 1992, J NEUROTRAUM, V9, P335, DOI 10.1089/neu.1992.9.335; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TCHELINGERIAN JL, 1993, NEURON, V10, P213, DOI 10.1016/0896-6273(93)90312-F; TERADA LS, 1992, INFLAMMATION, V16, P13, DOI 10.1007/BF00917511; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; ZHENG H, 1990, AM REV RESPIR DIS, V142, P1073, DOI 10.1164/ajrccm/142.5.1073	26	188	196	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0169-328X			MOL BRAIN RES	Mol. Brain Res.	MAR	1996	36	2					287	291		10.1016/0169-328X(95)00274-V			5	Neurosciences	Neurosciences & Neurology	UD315	WOS:A1996UD31500010	8965649				2021-06-18	
J	GENTLEMAN, SM; ROBERTS, GW; GENNARELLI, TA; MAXWELL, WL; ADAMS, JH; KERR, S; GRAHAM, DI				GENTLEMAN, SM; ROBERTS, GW; GENNARELLI, TA; MAXWELL, WL; ADAMS, JH; KERR, S; GRAHAM, DI			AXONAL INJURY - A UNIVERSAL CONSEQUENCE OF FATAL CLOSED-HEAD INJURY	ACTA NEUROPATHOLOGICA			English	Article						BETA-AMYLOID PRECURSOR PROTEIN; HEAD INJURY; DIFFUSE AXONAL INJURY; IMMUNOCYTOCHEMISTRY; DIAGNOSIS	NEUROFILAMENT SUBUNITS; BRAIN-DAMAGE; APP	beta-Amyloid precursor protein immunostaining has recently been shown to be a reliable method for detecting the damage to axons associated with fatal head injury. In an attempt to compare the efficacy of this technique with conventional histological detection of axonal damage, we have reanalysed sections from a large well-characterised series of head-injured and control patients. The results indicate that the frequency of axonal injury has been vastly underestimated using conventional silver techniques, and that axonal injury may in fact be an almost universal consequence of fatal head injury.	CHARING CROSS & WESTMINSTER MED SCH, DEPT ANAT, LONDON W6 8RP, ENGLAND; SMITHKLINE BEECHAM PHARMACEUT, DIV MOLEC NEUROPATHOL, HARLOW, ESSEX, ENGLAND; HOSP UNIV PENN, DIV NEUROSURG, PHILADELPHIA, PA 19104 USA; UNIV GLASGOW, DEPT ANAT, GLASGOW, LANARK, SCOTLAND; UNIV GLASGOW, SO GEN HOSP, INST NEUROL SCI, DEPT NEUROPATHOL, GLASGOW G51 4TF, LANARK, SCOTLAND	GENTLEMAN, SM (corresponding author), CHARING CROSS & WESTMINSTER MED SCH, DEPT PSYCHIAT, ST DUNSTANS RD, LONDON W6 8RP, ENGLAND.						ABE K, 1991, NEUROSCI LETT, V125, P172, DOI 10.1016/0304-3940(91)90020-T; ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Adams JH, 1992, GREENFIELDS NEUROPAT, P106; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; CROOKS DA, 1991, NEUROPATH APPL NEURO, V17, P421, DOI 10.1111/j.1365-2990.1991.tb00742.x; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; Gennarelli T.A., 1986, MECHANISMS SECONDARY, P15; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GENNARELLI TA, 1983, ACTA NEUROCHIR     S, P1; Gennarelli TA, 1993, HEAD INJURY, P137; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; GRCEVIC N, 1982, RAD JUGOSL AKAD ZNAN, V402, P265; GULTEKIN SH, 1994, ARCH PATHOL LAB MED, V118, P168; Jellinger K, 1973, PROGR NEUROPATHOLOGY, V2, P129; KAWARABAYASHI T, 1991, BRAIN RES, V563, P334, DOI 10.1016/0006-8993(91)91558-I; MAXWELL WL, 1991, J NEUROCYTOL, V20, P157, DOI 10.1007/BF01186989; McLellan D, 1986, COMA TRAUMATIQUE, P165; NG HK, 1994, CLIN NEUROL NEUROSUR, V96, P24, DOI 10.1016/0303-8467(94)90025-6; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; Pilz P, 1983, Acta Neurochir Suppl (Wien), V32, P119; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; POVLISHOCK JT, 1986, ACTA NEUROPATHOL, V70, P53, DOI 10.1007/BF00689514; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; ZIMMERMAN RA, 1978, RADIOLOGY, V127, P393, DOI 10.1148/127.2.393	34	188	196	0	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	JUN	1995	89	6					537	543					7	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	QZ538	WOS:A1995QZ53800010	7676809				2021-06-18	
J	Mouzon, BC; Bachmeier, C; Ferro, A; Ojo, JO; Crynen, G; Acker, CM; Davies, P; Mullan, M; Stewart, W; Crawford, F				Mouzon, Benoit C.; Bachmeier, Corbin; Ferro, Austin; Ojo, Joseph-Olubunmi; Crynen, Gogce; Acker, Christopher M.; Davies, Peter; Mullan, Michael; Stewart, William; Crawford, Fiona			Chronic neuropathological and neurobehavioral changes in a repetitive mild traumatic brain injury model	ANNALS OF NEUROLOGY			English	Article							HEAD-INJURY; COGNITIVE IMPAIRMENT; DEMENTIA-PUGILISTICA; EXECUTIVE FUNCTION; FOOTBALL PLAYERS; RECOVERY-TIME; AXONAL INJURY; HIGH-SCHOOL; ENCEPHALOPATHY; CONCUSSION	Objective Traumatic brain injury (TBI) is a recognized risk factor for later development of neurodegenerative disease. However, the mechanisms contributing to neurodegeneration following TBI remain obscure. Methods In this study, we have utilized a novel mild TBI (mTBI) model to examine the chronic neurobehavioral and neuropathological outcomes following single and repetitive mTBI at time points from 6 to 18 months following injury. Results Our results reveal that at 6, 12, and 18 months after injury, animals exposed to a single mTBI have learning impairments when compared to their sham controls without exhibiting spatial memory retention deficits. In contrast, animals exposed to repetitive injury displayed persistent cognitive deficits, slower rate of learning, and progressive behavioral impairment over time. These deficits arise in parallel with a number of neuropathological abnormalities, including progressive neuroinflammation and continuing white matter degradation up to 12 months following repetitive injury. Neither single nor repetitive mTBI was associated with elevated brain levels of amyloid beta or abnormal tau phosphorylation at 6 or 12 months after injury. Interpretation Importantly, these data provide evidence that, although a single mTBI produces a clinical syndrome and pathology that remain static in the period following injury, repetitive injuries produce behavioral and pathological changes that continue to evolve many months after the initial injuries. As such, this model recapitulates many aspects described in human studies of TBI, providing a suitable platform on which to investigate the evolving pathologies following mild TBI and potential strategies for therapeutic intervention. ANN NEUROL 2014;75:241-254	[Mouzon, Benoit C.; Bachmeier, Corbin; Ferro, Austin; Ojo, Joseph-Olubunmi; Crynen, Gogce; Mullan, Michael; Crawford, Fiona] Roskamp Inst, Sarasota, FL 34243 USA; [Mouzon, Benoit C.; Mullan, Michael; Crawford, Fiona] James A Haley Vet Adm Med Ctr, Tampa, FL 33612 USA; [Mouzon, Benoit C.; Bachmeier, Corbin; Crynen, Gogce; Mullan, Michael; Crawford, Fiona] Open Univ, Dept Life Sci, Milton Keynes MK7 6AA, Bucks, England; [Acker, Christopher M.; Davies, Peter] North Shore LIJ Hlth Syst, Feinstein Inst Med Res, Litwin Zucker Ctr Res Alzheimers Dis, Manhasset, NY USA; [Stewart, William] So Gen Hosp, Dept Neuropathol, Glasgow G51 4TF, Lanark, Scotland; [Stewart, William] Univ Glasgow, Glasgow, Lanark, Scotland	Mouzon, BC (corresponding author), Roskamp Inst, 2040 Whitfield Ave, Sarasota, FL 34243 USA.	bmouzon@rfdn.org		Crynen, Gogce/0000-0001-6066-9900; Stewart, William/0000-0003-2199-2582	Department of DefenseUnited States Department of Defense [W81XWH-10-1-0759]; Roskamp Foundation	This research was funded by a Department of Defense award (W81XWH-10-1-0759; F.C.), and by the Roskamp Foundation. The contents do not represent the views of the Department of Veterans Affairs, or the United States Government.	Acker CM, 2013, NEUROBIOL AGING, V34, P338, DOI 10.1016/j.neurobiolaging.2012.05.010; Blaylock Russell L, 2011, Surg Neurol Int, V2, P107, DOI 10.4103/2152-7806.83391; Brooks J, 1999, J TRAUMA, V46, P159, DOI 10.1097/00005373-199901000-00027; Chen HL, 2007, AM J EPIDEMIOL, V166, P810, DOI 10.1093/aje/kwm153; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Costanza A, 2011, NEUROPATH APPL NEURO, V37, P570, DOI 10.1111/j.1365-2990.2011.01186.x; Daneshvar DH, 2011, PHYS MED REH CLIN N, V22, P683, DOI 10.1016/j.pmr.2011.08.009; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; DeWitt DS, 2013, J NEUROTRAUM, V30, P688, DOI 10.1089/neu.2012.2349; Farbota KDM, 2012, J INT NEUROPSYCH SOC, V18, P1006, DOI 10.1017/S1355617712000835; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; Goldman SM, 2006, ANN NEUROL, V60, P65, DOI 10.1002/ana.20882; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Henry LC, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-105; Huber BR, 2013, J ALZHEIMERS DIS, V37, P309, DOI 10.3233/JAD-130182; Hylin MJ, 2013, J NEUROTRAUM, V30, P716, DOI 10.1089/neu.2012.2717; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; King A, 2010, NEUROPATHOLOGY, V30, P408, DOI 10.1111/j.1440-1789.2009.01085.x; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Levin HS, 2013, J NEUROTRAUM, V30, P610, DOI 10.1089/neu.2012.2394; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; LISTER RG, 1990, PHARMACOL THERAPEUT, V46, P321, DOI 10.1016/0163-7258(90)90021-S; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Mannix R, 2013, ANN NEUROL, V74, P65, DOI 10.1002/ana.23858; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Millspaugh J., 1937, US NAVAL MED B, V35, P297; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu Bennet I, 2010, J Forensic Nurs, V6, P130, DOI 10.1111/j.1939-3938.2010.01078.x; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Ozen LJ, 2012, ARCH CLIN NEUROPSYCH, V27, P85, DOI 10.1093/arclin/acr087; Perry VH, 2010, NAT REV NEUROL, V6, P193, DOI 10.1038/nrneurol.2010.17; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Ruifrok AC, 2001, ANAL QUANT CYTOL, V23, P291; Saing T, 2012, J NEUROTRAUM, V29, P1054, DOI 10.1089/neu.2011.1957; Sharp DJ, 2011, CURR OPIN NEUROL, V24, P558, DOI 10.1097/WCO.0b013e32834cd523; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Sosa MAG, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-51; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Tomaiuolo F, 2012, BRAIN RES BULL, V87, P373, DOI 10.1016/j.brainresbull.2012.01.008; Tsitsopoulos PP, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00079; Walf AA, 2007, NAT PROTOC, V2, P322, DOI 10.1038/nprot.2007.44	55	187	187	1	51	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	FEB	2014	75	2					241	254		10.1002/ana.24064			14	Clinical Neurology; Neurosciences	Neurosciences & Neurology	AD1PD	WOS:000333005000011	24243523				2021-06-18	
J	Broglio, SP; Sosnoff, JJ; Shin, S; He, XM; Alcaraz, C; Zimmerman, J				Broglio, Steven P.; Sosnoff, Jacob J.; Shin, SungHoon; He, Xuming; Alcaraz, Christopher; Zimmerman, Jerrad			Head Impacts During High School Football: A Biomechanical Assessment	JOURNAL OF ATHLETIC TRAINING			English	Article						concussions; mild traumatic brain injuries; Head Impact Telemetry System; acceleration	TRAUMATIC BRAIN-INJURY; SPORT-RELATED CONCUSSION; PROFESSIONAL FOOTBALL; NCAA CONCUSSION; PLAYERS; COLLEGIATE; ACCELERATION; EPIDEMIOLOGY; SEVERITY; RISK	Context: Little is known about the impact biomechanics sustained by players during interscholastic football. Objective: To characterize the location and magnitude of impacts sustained by players during an interscholastic football season. Design: Observational design. Setting: On the field. Patients or Other Participants: High school varsity football team (n = 35; age = 16.85 +/- 0.75 years, height = 183.49 +/- 5.31 cm, mass = 89.42 +/- 12.88 kg). Main Outcome Measure(s): Biomechanical variables (linear acceleration, rotational acceleration, jerk, force, impulse, and impact duration) related to head impacts were categorized by session type, player position, and helmet impact location. Results: Differences in grouping variables were found for each impact descriptor. Impacts occurred more frequently and with greater intensity during games. Linear acceleration was greatest in defensive linemen and offensive skill players and when the impact occurred at the top of the helmet. The largest rotational acceleration occurred in defensive linemen and with impacts to the front of the helmet. Impacts with the highest-magnitude jerk, force, and impulse and shortest duration occurred in the offensive skill, defensive line, offensive line, and defensive skill players, respectively. Top-of-the-helmet impacts yielded the greatest magnitude for the same variables. Conclusions: We are the first to provide a biomechanical characterization of head impacts in an interscholastic football team across a season of play. The intensity of game play manifested with more frequent and intense impacts. The highest-magnitude variables were distributed across all player groups, but impacts to the top of the helmet yielded the highest values. These high school football athletes appeared to sustain greater accelerations after impact than their older counterparts did. How this finding relates to concussion occurrence has yet to be elucidated.	[Broglio, Steven P.] Univ Illinois, Dept Kinesiol & Community Hlth, Urbana, IL 61801 USA; [Alcaraz, Christopher; Zimmerman, Jerrad] Carle Fdn Hosp, Urbana, IL USA	Broglio, SP (corresponding author), Univ Illinois, Dept Kinesiol & Community Hlth, 906 S Goodwin Ave, Urbana, IL 61801 USA.	broglio@uiuc.edu	Shin, Sunghoon/O-2070-2019; Sosnoff, Jacob/P-3397-2019; Lang, Steven/AAE-8102-2021	Shin, Sunghoon/0000-0001-5355-2157; Sosnoff, Jacob/0000-0002-0286-9207; Lang, Steven/0000-0003-1669-9146			Barth JT, 2001, J ATHL TRAINING, V36, P253; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GLIER R, 2007, HIGH SCH TRY TEAMWOR; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Kleiven S, 2003, J NEUROTRAUM, V20, P365, DOI 10.1089/089771503765172327; Kleiven S, 2002, J BIOMECH, V35, P153, DOI 10.1016/S0021-9290(01)00202-0; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LISSNER HR, 1960, SURG GYNECOL OBSTET, V111, P329; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; REID SE, 1971, SURG GYNECOL OBSTETR, V133, P929; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Schnebel B, 2007, NEUROSURGERY, V60, P490, DOI 10.1227/01.NEU.0000249286.92255.7F; Swartz EE, 2005, J ATHL TRAINING, V40, P155; Viano DC, 2005, NEUROSURGERY, V57, P1154, DOI 10.1227/01.NEU.0000187541.87937.D9; ZATSIORSKY VM, 2002, KINETICS HUMAN MOTIO, P577	32	187	188	2	43	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050			J ATHL TRAINING	J. Athl. Train.	JUL-AUG	2009	44	4					342	349		10.4085/1062-6050-44.4.342			8	Sport Sciences	Sport Sciences	474EZ	WOS:000268266600002	19593415	Green Published			2021-06-18	
J	Zhao, J; Moore, AN; Redell, JB; Dash, PK				Zhao, Jing; Moore, Anthony N.; Redell, John B.; Dash, Pramod K.			Enhancing expression of Nrf2-driven genes protects the blood-brain barrier after brain injury	JOURNAL OF NEUROSCIENCE			English	Article						brain edema; endothelial cells; neurovascular unit; tight junction proteins; TBI; capillary	CLOSED-HEAD INJURY; CORTICAL IMPACT MODEL; ISOTHIOCYANATE SULFORAPHANE; OLIGONUCLEOTIDE MICROARRAY; CHEMOPREVENTIVE AGENTS; PERMEABILITY CHANGES; OXIDATIVE STRESS; SPATIAL MEMORY; RAT; NRF2	The integrity of the blood-brain barrier (BBB) is critical for normal brain function, and its compromise contributes to the pathophysiology of a number of CNS diseases and injuries. Using a rodent model of brain injury, the present study examines the pathophysiology of BBB disruption. Western blot and immunohistochemical analyses indicate that brain injury causes a loss of capillary endothelial cells and tight junction proteins, two critical components of the BBB. Activation of the transcription factor NF-E2-related factor-2 (Nrf2) by sulforaphane, a naturally occurring compound present in high levels in cruciferous vegetables, significantly increased the expression of endogenous cytoprotective genes in brain tissue and microvessels as indicated by real-time PCR analysis. Postinjury administration of sulforaphane reduced the loss of endothelial cell markers and tight junction proteins and preserved BBB function. These protective effects were dependent on the activity of Nrf2. Injured rats pretreated with decoy oligonucleotides containing the binding site of Nrf2, and mice lacking the nrf2 gene, did not benefit from sulforaphane administration. These findings indicate a potential therapeutic usefulness for Nrf2-activating molecules to improve the function of the neurovascular unit after injury.	Univ Texas, Sch Med, Dept Neurobiol & Anat, Houston, TX 77225 USA; Univ Texas, Sch Med, Dept Neurosurg, Houston, TX 77225 USA; Univ Texas, Sch Med, Vivian L Smith Ctr Neurol Res, Houston, TX 77225 USA	Dash, PK (corresponding author), Univ Texas, Sch Med, Dept Neurobiol & Anat, POB 20708, Houston, TX 77225 USA.	p.dash@uth.tmc.edu		Dash, Pramod/0000-0001-6746-1002	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH072933] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035457, R01NS049160] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01 MH072933, MH072933] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS035457, NS049160, NS035457, R01 NS049160] Funding Source: Medline		ALFORD MF, 1994, J HISTOCHEM CYTOCHEM, V42, P283, DOI 10.1177/42.2.8288869; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; CHAN PH, 1984, NEUROLOGY, V34, P315, DOI 10.1212/WNL.34.3.315; Danton GH, 2003, J NEUROPATH EXP NEUR, V62, P127, DOI 10.1093/jnen/62.2.127; Dash PK, 2005, J NEUROCHEM, V93, P269, DOI 10.1111/j.1471-4159.2004.03016.x; DASH PK, 1995, J NEUROSCI, V15, P2030; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FISHMAN RA, 1975, NEW ENGL J MED, V293, P706, DOI 10.1056/NEJM197510022931407; Gao XQ, 2001, P NATL ACAD SCI USA, V98, P15221, DOI 10.1073/pnas.261572998; Giudice A, 2006, BIOESSAYS, V28, P169, DOI 10.1002/bies.20359; Hu R, 2004, J PHARMACOL EXP THER, V310, P263, DOI 10.1124/jpet.103.064261; Hu R, 2006, CANCER LETT, V243, P170, DOI 10.1016/j.canlet.2005.11.050; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Kang MI, 2004, P NATL ACAD SCI USA, V101, P2046, DOI 10.1073/pnas.0308347100; Kobayashi M, 2006, ADV ENZYME REGUL, V46, P113, DOI 10.1016/j.advenzreg.2006.01.007; Lee JM, 2003, J BIOL CHEM, V278, P12029, DOI 10.1074/jbc.M211558200; LYETH BG, 1993, BRAIN RES, V617, P69, DOI 10.1016/0006-8993(93)90614-S; MASLIAH E, 1992, J NEUROPATH EXP NEUR, V51, P404, DOI 10.1097/00005072-199207000-00003; MCINTOSH TK, 1990, ACT NEUR S, V51, P263; McMahon M, 2001, CANCER RES, V61, P3299; McMahon M, 2003, J BIOL CHEM, V278, P21592, DOI 10.1074/jbc.M300931200; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; Mikawa S, 1996, J NEUROSURG, V85, P885, DOI 10.3171/jns.1996.85.5.0885; Oby E, 2006, EPILEPSIA, V47, P1761, DOI 10.1111/j.1528-1167.2006.00817.x; Petty MA, 2002, PROG NEUROBIOL, V68, P311, DOI 10.1016/S0301-0082(02)00128-4; Pi JB, 2003, EXP CELL RES, V290, P234, DOI 10.1016/S0014-4827(03)00341-0; Povlishock J T, 1992, Hum Cell, V5, P345; Qiu JX, 2004, J NEUROSCI RES, V77, P108, DOI 10.1002/jnr.20156; Redell JB, 2003, EXP BIOL MED, V228, P261; ROSENSTEIN JM, 1992, DEV BRAIN RES, V66, P47, DOI 10.1016/0165-3806(92)90138-M; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; Shen GX, 2005, ANTIOXID REDOX SIGN, V7, P1648, DOI 10.1089/ars.2005.7.1648; SHOHAMI E, 1993, J NEUROTRAUM, V10, P109, DOI 10.1089/neu.1993.10.109; SHOHAMI E, 1994, ACTA NEUROCHIR, P443; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Thimmulappa RK, 2002, CANCER RES, V62, P5196; VERSCHURE PJ, 1994, J HISTOCHEM CYTOCHEM, V42, P765, DOI 10.1177/42.6.8189038; Wagnerova J, 2002, J NEUROL SCI, V195, P51, DOI 10.1016/S0022-510X(01)00685-2; Zhang DD, 2003, MOL CELL BIOL, V23, P8137, DOI 10.1128/MCB.23.22.8137-8151.2003; Zhang DD, 2004, MOL CELL BIOL, V24, P10941, DOI 10.1128/MCB.24.24.10941-10953.2004; Zipper LM, 2002, J BIOL CHEM, V277, P36544, DOI 10.1074/jbc.M206530200; Zlokovic BV, 2002, ADV DRUG DELIVER REV, V54, P1553, DOI 10.1016/S0169-409X(02)00150-3	43	187	195	0	10	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	SEP 19	2007	27	38					10240	10248		10.1523/JNEUROSCI.1683-07.2007			9	Neurosciences	Neurosciences & Neurology	212HC	WOS:000249584100019	17881530	Green Published, Bronze			2021-06-18	
J	Verhaeghe, S; Defloor, T; Grypdonck, M				Verhaeghe, S; Defloor, T; Grypdonck, M			Stress and coping among families of patients with traumatic brain injury: a review of the literature	JOURNAL OF CLINICAL NURSING			English	Article						brain injury; coping; family; nursing; relative; stress; support; trauma	SEVERE HEAD-INJURY; FOLLOW-UP; RELATIVES VIEW; MEMBERS; SYMPTOMS; RECOVERY; DAMAGE; MODELS; IMPACT; STAGE	This literature review aims to structure the available information on the psychological reactions of family members confronted with traumatic brain injury. The stress-coping theory and the systems theory provide the theoretical framework for this review. Literature review. The level of stress experienced by the family members of patients who have traumatic brain injury is such that professional intervention is appropriate, even after 10-15 years. Not the severity of the injury but the nature of the injuries determines the level of stress. Partners experience more stress than parents. Children have specific difficulties. Young families with little social support, financial, psychiatric and/or medical problems are the most vulnerable. Coping with traumatic brain injury can be described in phases. The better family members can cope with the situation, the better the patient's recovery. There are functional and non-functional coping mechanisms and coping is influenced by such factors as gender, social and professional support and the possibility to have reciprocal communication or an affective relation with the patient. Support from professionals reduces the stress being experienced and encourages people to cope effectively. Conflicts with professional carers should be avoided. Every attempt should be made to develop models of long-term support and care that alleviate sources of burden on relatives. Further research is necessary to develop such models.	Univ Ghent, B-9000 Ghent, Belgium	Verhaeghe, S (corresponding author), Univ Ghent, De Pintelaan 185 UZ Blok A2, B-9000 Ghent, Belgium.	sofie.verhaeghe@ugent.be		Verhaeghe, Sofie/0000-0002-2063-5033; Beeckman, Dimitri/0000-0003-3080-8716			Albert SM, 2002, J HEAD TRAUMA REHAB, V17, P175, DOI 10.1097/00001199-200204000-00007; Anderson MI, 2002, BRAIN INJURY, V16, P743, DOI 10.1080/02699050210128906; Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; ARMSTRONG K, 2002, PEDIAT REHABILITATIO, V3, P149; BACHYRITA P, 1990, CAN J PSYCHOL, V44, P148, DOI 10.1037/h0084247; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS DN, 1987, J CLIN EXPT NEUROPSY, V1, P155; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; CAVALLO MM, 1992, BRAIN INJURY, V4, P327; COSTELLO B, 1998, FORENSIC EXAMINER, V9, P33; Curtiss G, 2000, J HEAD TRAUMA REHAB, V15, P1113, DOI 10.1097/00001199-200010000-00005; Degeneffe CE, 2001, HEALTH SOC WORK, V26, P257, DOI 10.1093/hsw/26.4.257; DeMarle DJ, 2001, J LOSS TRAUMA, V6, P29, DOI 10.1080/108114401753197459; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Ergh TC, 2003, J CLIN EXP NEUROPSYC, V25, P1090, DOI 10.1076/jcen.25.8.1090.16735; Florian V, 1989, Brain Inj, V3, P219, DOI 10.3109/02699058909029637; FRANK RG, 1990, BRAIN INJURY, V3, P289; GILES GM, 1994, AM J OCCUP THER, V48, P295, DOI 10.5014/ajot.48.4.295; GLECKMAN AD, 1995, BRAIN INJURY, V9, P385, DOI 10.3109/02699059509005778; Groom KN, 1998, ARCH CLIN NEUROPSYCH, V13, P695, DOI 10.1016/S0887-6177(98)00005-5; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; HALLETT JD, 1994, AM J OCCUP THER, V48, P241, DOI 10.5014/ajot.48.3.241; Harris JKJ, 2001, BRAIN INJURY, V15, P223; Hawley CA, 2003, BRAIN INJURY, V17, P1, DOI 10.1080/0269905021000010096; Hibbard MR, 2002, J HEAD TRAUMA REHAB, V17, P112, DOI 10.1097/00001199-200204000-00004; KALSBECK WD, 1989, BRAIN INJURY, V3, P219; KASOWSKY JC, 1994, AM J OCCUPATIONAL TH, V3, P257; KAY T, 1990, TRAUMATIC BRAIN INJU; Kay Thomas, 1994, P533; KLONOFF P, 1990, COMMUNITY INTEGRATIO, P229; Kolakowsky-Hayner SA, 1999, NEUROREHABILITATION, V13, P27; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Kozloff R, 1987, J HEAD TRAUMA REHAB, V2, P14, DOI DOI 10.1097/00001199-198709000-00004; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; KREUTZER JS, 1994, BRAIN INJURY, V1, P102; KWASNICA CM, 1994, ARCH PHYS MED REHAB, V75, P384, DOI 10.1016/0003-9993(94)90159-7; LAUGHLIN AM, 1993, BRAIN INJURY, V1, P45; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; LEAF LE, 1993, BRAIN INJURY, V7, P543, DOI 10.3109/02699059309008182; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LEZAK MD, 1986, REHABIL PSYCHOL, V31, P241, DOI 10.1037//0090-5550.31.4.241; LINN RT, 1994, BRAIN INJURY, V8, P135, DOI 10.3109/02699059409150965; Livingston M G, 1987, Brain Inj, V1, P33, DOI 10.3109/02699058709034442; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; Machamer J, 2002, J CLIN EXP NEUROPSYC, V24, P420, DOI 10.1076/jcen.24.4.420.1040; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; Max JE, 1998, J NERV MENT DIS, V186, P589, DOI 10.1097/00005053-199810000-00001; McKinlay W W, 1987, Brain Inj, V1, P3, DOI 10.3109/02699058709034438; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; McMahon MA, 2001, J HEAD TRAUMA REHAB, V16, P587, DOI 10.1097/00001199-200112000-00006; Minnes P, 2000, BRAIN INJURY, V14, P737; MINTZ MC, 1995, BRAIN INJURY, V9, P173, DOI 10.3109/02699059509008190; Monat A., 1985, STRESS COPING ANTHOL, V2nd ed.; MOORE A, 1993, BRAIN INJURY, V7, P247, DOI 10.3109/02699059309029677; Morris KC, 2001, BRAIN INJURY, V15, P239, DOI 10.1080/02699050010004068; NOVACK TA, 1991, ARCH PHYS MED REHAB, V72, P521; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; PANTING A, 1970, J REHABIL, V38, P33; Pelletier PM, 2000, BRAIN COGNITION, V44, P45; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; PRESSARO LF, 1993, BRAIN INJURY, V3, P231; RAPE RN, 1992, REHABIL PSYCHOL, V37, P3, DOI 10.1037/h0079094; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; RIDLEY B, 1989, SOC SCI MED, V29, P555, DOI 10.1016/0277-9536(89)90201-3; ROMANO MD, 1974, SCAND J REHABIL MED, V6, P1; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; Rosenthal M, 1988, J HEAD TRAUMA REHAB, V3, P42; Sander AM, 2003, ARCH PHYS MED REHAB, V84, P197, DOI 10.1053/apmr.2003.50105; Sander AM, 2002, BRAIN INJURY, V16, P649, DOI 10.1080/02699050210128889; Siders CT, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P483; STRATTON MC, 1994, BRAIN INJURY, V8, P631, DOI 10.3109/02699059409151016; Swift EE, 2003, J DEV BEHAV PEDIATR, V24, P24, DOI 10.1097/00004703-200302000-00007; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Tyerman A, 2001, NEUROREHABILITATION, V16, P59; UOMOTO JM, 1992, ARCH PHYS MED REHAB, V73, P674; Wade SL, 2002, J HEAD TRAUMA REHAB, V17, P96, DOI 10.1097/00001199-200204000-00003; WALKER AE, 1972, SCANDINAVIAN J REHAB, V6, P185; Watanabe Y, 2001, DISABIL REHABIL, V23, P370; Watanabe Y, 2000, CLIN REHABIL, V14, P172, DOI 10.1191/026921500666833742; WHYTE J, 1994, J HEAD TRAUMA REHAB, V9, pR6, DOI 10.1097/00001199-199409000-00002; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460; Williams J.M., 1991, HEAD INJURY FAMILY M, P299; WRINGLEY JM, 1994, ARCH PHYS MED REHAB, V75, P149	93	187	191	1	39	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0962-1067	1365-2702		J CLIN NURS	J. Clin. Nurs.	SEP	2005	14	8					1004	1012		10.1111/j.1365-2702.2005.01126.x			9	Nursing	Nursing	952GW	WOS:000230993000012	16102152				2021-06-18	
J	Newschaffer, CJ; Falb, MD; Gurney, JG				Newschaffer, CJ; Falb, MD; Gurney, JG			National autism prevalence trends from United States special education data	PEDIATRICS			English	Article						autism; prevalence; trends		Objective. Reports of large increases in autism prevalence have been a matter of great concern to clinicians, educators, and parents. This analysis uses a national data source to compare the prevalence of autism with that of other disabilities among successive birth cohorts of US school-aged children. Design. Comparison of birth cohort curves constructed from administrative data. Setting and Population. US children 6 to 17 years of age between 1992 and 2001. Main Outcome Measures. A disability category classification of autism, mental retardation, speech and language impairment, traumatic brain injury, or other health impairment, as documented by state departments of education and reported to the Office of Special Education Programs, US Department of Education. Results. Prevalences of disability category classifications for annual birth cohorts from 1975 to 1995 were calculated by using denominators from US Census Bureau estimates. For the autism classification, there were birth cohort differences, with prevalences increasing among successive (younger) cohorts. The increases were greatest for annual cohorts born from 1987 to 1992. For cohorts born after 1992, the prevalence increased with each successive year but the increases did not appear to be as great, although there were fewer data points available within cohorts. No concomitant decreases in categories of mental retardation or speech/language impairment were seen. Curves for other health impairments, the category including children with attention-deficit/hyperactivity disorder, also showed strong cohort differences. Conclusions. Cohort curves suggest that autism prevalence has been increasing with time, as evidenced by higher prevalences among younger birth cohorts. The narrowing in vertical separation of the cohort curves in recent years may mark a slowing in the autism prevalence increase.	Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Autism & Dev Disabilities Epidemiol, Dept Epidemiol, Baltimore, MD 21205 USA; Univ Minnesota, Div Epidemiol, Minneapolis, MN 55455 USA; Univ Minnesota, Div Clin Res, Minneapolis, MN 55455 USA	Newschaffer, CJ (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Ctr Autism & Dev Disabilities Epidemiol, Dept Epidemiol, 615 N Wolfe St,Suite E6030, Baltimore, MD 21205 USA.	cnewscha@jhsph.edu			ODCDC CDC HHS [U10CCU320408] Funding Source: Medline		Croen LA, 2002, J AUTISM DEV DISORD, V32, P207, DOI 10.1023/A:1015453830880; Fombonne E, 2002, MOL PSYCHIATR, V7, pS4, DOI 10.1038/sj.mp.4001162; GOODE E, 2004, NY TIMES        0126, pA1; GROSS J, 2003, NY TIMES        1119, pA20; Gurney JG, 2003, ARCH PEDIAT ADOL MED, V157, P622, DOI 10.1001/archpedi.157.7.622; Jick H, 2003, PHARMACOTHERAPY, V23, P1524, DOI 10.1592/phco.23.15.1524.31955; Jick H, 2003, EPIDEMIOLOGY, V14, P630, DOI 10.1097/01.EDE.0000082044.88833.c4; Lingam R, 2003, ARCH DIS CHILD, V88, P666, DOI 10.1136/adc.88.8.666; Markowitz J., 2001, TRAUMATIC BRAIN INJU; National Research Council Division of Behavioral and Social Sciences Education, 2001, ED CHILDR AUT; U.S. Department of Education, 2002, 24 US DEP ED OFF SPE; U. S. Department of Education Office of Special Education and Rehabilitative Services Office of Special Education Programs, 2003, 25 US DEP ED OFF SPE; U.S. Department of Education Office of Special Education and Rehabilitative Services Office of Special Education Programs, 1998, 20 US DEP ED OFF SPE; *US CENS BUR, PROJ RES POP AG SEX; *US CENS BUR, POP EST US STAT SING; *US DEP ED, 2000, 22 US DEP ED OFF SPE; *US DEP ED, 1995, 17 US DEP ED OFF SPE; *US DEP ED, 2001, 23 US DEP ED OFF SPE; *US DEP ED, CLAR POL ADDR NEEDS; *US DEP ED, 1996, 18 US DEP ED OFF SPE; *US DEP ED, 1994, 16 US DEP ED OFF SPE; *US DEP ED, 1999, 21 US DEP ED OFF SPE; *US DEP ED, 1997, 19 US DEP ED OFF SPE; VERSTAG B, 2004, JAMA-J AM MED ASSOC, V291, P29; Yeargin-Allsopp M, 2003, JAMA-J AM MED ASSOC, V289, P49, DOI 10.1001/jama.289.1.49	25	187	195	0	18	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	MAR	2005	115	3					E277	E282		10.1542/peds.2004-1958			6	Pediatrics	Pediatrics	905UV	WOS:000227596900005	15741352	Bronze			2021-06-18	
J	Gefen, A; Gefen, N; Zhu, QL; Raghupathi, R; Margulies, SS				Gefen, A; Gefen, N; Zhu, QL; Raghupathi, R; Margulies, SS			Age-dependent changes in material properties of the brain and braincase of the rat	JOURNAL OF NEUROTRAUMA			English	Article						constitutive properties; finite element analysis; head injury; pediatric animal model; skull; suture	TISSUE IN-VIVO; MECHANICAL-PROPERTIES; HEAD-INJURY; CRANIAL SUTURES; FINITE-ELEMENT; BIOMECHANICAL ANALYSIS; ELASTIC PROPERTIES; LARGE-DEFORMATION; BONE; COLLAGEN	Clinical and biomechanical evidence indicates that mechanisms and pathology of head injury in infants and young children may be different from those in adults. Biomechanical computer-based modeling, which can be used to provide insight into the thresholds for traumatic tissue injury, requires data on material properties of the brain, skull, and sutures that are specific for the pediatric population. In this study, brain material properties were determined for rats at postnatal days (PND) 13, 17, 43, and 90, and skull/suture composite (braincase) properties were determined at PND 13, 17, and 43. Controlled I mm indentation of a force probe into the brain was used to measure naive, non-preconditioned (NPC) and preconditioned (PC) instantaneous (G(i)) and long-term (G(infinity)) shear moduli of brain tissue both in situ and in vitro. Brains at 13 and 17 PND exhibited statistically indistinguishable shear moduli, as did brains at 43 and 90 PND. However, the immature (average of 13 and 17 PND) rat brain (G(i) = 3336 Pa NPC, 1754 Pa PC; G(infinity) = 786 Pa NPC, 626 Pa PC) was significantly stiffer (p < 0.05) than the mature (average of 43 and 90 PND) brains (G(i) = 1721 Pa NPC, 1232 Pa PC; G(infinity) = 508 Pa NPC, 398 Pa PC). A "reverse engineering" finite element model approach, which simulated the indentation of the force probe into the intact braincase, was used to estimate the effective elastic moduli of the braincase. Although the skull of older rats was significantly thicker than that of the younger rats, there was no significant age-dependent change in the effective elastic modulus of the braincase (average value = 6.3 MPa). Thus, the increase in structural rigidity of the braincase with age (up to 43 PND) was due to an increase in skull thickness rather than stiffening of the tissue. These observations of a stiffer brain and more compliant braincase in the immature rat compared with the adult rat will aid in the development of age-specific experimental models and in computational head injury simulations. Specifically, these results will assist in the selection of forces to induce comparable mechanical stresses, strains and consequent injury profiles in brain tissues of immature and adult animals.	Drexel Univ, Coll Med, Dept Neurobiol & Anat, Philadelphia, PA 19129 USA; Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA	Raghupathi, R (corresponding author), Drexel Univ, Coll Med, Dept Neurobiol & Anat, 2900 Queen Lane, Philadelphia, PA 19129 USA.		Gefen, Amit/M-4720-2015	Gefen, Amit/0000-0002-0223-7218	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS-39679, R01-NS-41562] Funding Source: Medline; ODCDC CDC HHS [R49-CCR-312712] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041562, R01NS039679] Funding Source: NIH RePORTER		Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; Arbogast KB, 1999, J BIOMECH, V32, P865, DOI 10.1016/S0021-9290(99)00042-1; ASHMAN RB, 1985, J BIOMECH, V18, P717, DOI 10.1016/0021-9290(85)90026-0; Bilston LE, 2001, BIORHEOLOGY, V38, P335; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Blange T, 1997, J MUSCLE RES CELL M, V18, P125, DOI 10.1023/A:1018649420778; BRUCE DA, 1990, HEAD INJURIES PEDIAT, P63; CALDER IM, 1984, J CLIN PATHOL, V37, P1095, DOI 10.1136/jcp.37.10.1095; Carew EO, 2000, ANN BIOMED ENG, V28, P1093, DOI 10.1114/1.1310221; Cowin SC, 2001, BONE MECH HDB; DEJEAMMES M, 1984, SAE T, P427; Dobbing J, 1981, SCI F PAEDIATRICS, P744; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Duhaime AC, 2000, J NEUROSURG, V93, P455, DOI 10.3171/jns.2000.93.3.0455; Durham SR, 2000, PEDIATR NEUROSURG, V33, P76, DOI 10.1159/000028980; Fung Y., 1993, BIOMECHANICS MECH PR; GALFORD JE, 1970, J BIOMECH, V3, P211, DOI 10.1016/0021-9290(70)90007-2; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; Gefen A, 2001, CLIN BIOMECH, V16, P921, DOI 10.1016/S0268-0033(01)00074-2; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; HAYES WC, 1978, J BIOMECH, V11, P407, DOI 10.1016/0021-9290(78)90075-1; Herring SW, 2000, AM J PHYS ANTHROPOL, V112, P575, DOI 10.1002/1096-8644(200008)112:4&lt;575::AID-AJPA10&gt;3.0.CO;2-0; Hibbett Karlsson and Sorensen, 1998, ABAQUS STAND US MAN; HUBBARD RP, 1971, J BIOMECH, V4, P491, DOI 10.1016/0021-9290(71)90039-X; JACOBSON S, 1963, J COMP NEUROL, V121, P5, DOI 10.1002/cne.901210103; JASLOW CR, 1990, J BIOMECH, V23, P313, DOI 10.1016/0021-9290(90)90059-C; JOHANSON CE, 1976, BRAIN RES, V116, P35, DOI 10.1016/0006-8993(76)90247-X; Jones HC, 1998, EXP NEUROL, V154, P126, DOI 10.1006/exnr.1998.6934; KUIJPERS AHWM, 1995, J NEUROTRAUM, V12, P715, DOI 10.1089/neu.1995.12.715; Kumaresan S, 2002, BIOMED SCI INSTRUM, V38, P453; KVAM E, 1975, ACTA ODONTOL SCAND, V33, P227, DOI 10.3109/00016357509027565; LAIFOOK SJ, 1976, J APPL PHYSIOL, V40, P508; Laurer HL, 2000, EUR J TRAUMA, V26, P95, DOI DOI 10.1007/S000680050007; Lee E.H., 1960, J APPL MECH, V27, P438, DOI DOI 10.1115/1.3644020; Leterrier JF, 1996, J BIOL CHEM, V271, P15687, DOI 10.1074/jbc.271.26.15687; Levine JP, 1998, PLAST RECONSTR SURG, V101, P1441, DOI 10.1097/00006534-199805000-00002; MADELINE LA, 1995, RADIOLOGY, V196, P747, DOI 10.1148/radiology.196.3.7644639; Margulies SS, 2000, J BIOMECH ENG-T ASME, V122, P364, DOI 10.1115/1.1287160; McLaughlin E, 2000, CLEFT PALATE-CRAN J, V37, P590, DOI 10.1597/1545-1569(2000)037<0590:TLDCON>2.0.CO;2; MCPHERSON GK, 1980, J BIOMECH, V13, P9, DOI 10.1016/0021-9290(80)90003-2; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; MENDIS KK, 1995, J BIOMECH ENG-T ASME, V117, P279, DOI 10.1115/1.2794182; Miller K, 2002, J BIOMECH, V35, P483, DOI 10.1016/S0021-9290(01)00234-2; Miller K, 2000, J BIOMECH, V33, P1369, DOI 10.1016/S0021-9290(00)00120-2; MILLER RT, 1998, 42 STAPP CAR CRASH C; Misch CE, 1999, J ORAL MAXIL SURG, V57, P700, DOI 10.1016/S0278-2391(99)90437-8; MIZRAHI J, 1986, BIORHEOLOGY, V23, P311; MOHAN D, 1979, ASME, V101, P250; Norton WT., 2013, MYELIN, V21, P147, DOI [10.1007/978-1-4757-1830-0_5, DOI 10.1007/978-1-4757-1830-0_5]; O'Mahony AM, 2000, CLIN ORAL IMPLAN RES, V11, P415, DOI 10.1034/j.1600-0501.2000.011005415.x; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; Ommaya AK, 1967, 11 STAPP CAR CRASH C; PASCUCCI RC, 1998, CARE MED, V14, P185; PORTERFIELD SP, 1993, ENDOCR REV, V14, P94, DOI 10.1210/er.14.1.94; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; PRANGE MT, 2001, SUMM BIOENG C ASME; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; RANG EM, 2001, SUMM ASME BIOENG C S; Salvati S, 2000, DEV NEUROSCI-BASEL, V22, P481, DOI 10.1159/000017479; Sasaki N, 1996, J BIOMECH, V29, P655, DOI 10.1016/0021-9290(95)00110-7; SHAPIRO K, 1985, HEAD INJURY CHILDREN; SHUCK LZ, 1972, J BASIC ENG-T ASME, V94, P905, DOI 10.1115/1.3425588; STURTZ G, 1980, SAE T, P513; Tanaka E, 2000, ARCH ORAL BIOL, V45, P1049, DOI 10.1016/S0003-9969(00)00083-2; THIBAULT K, 1997, THESIS U PENNSYLVANI; Thibault KL, 1998, J BIOMECH, V31, P1119, DOI 10.1016/S0021-9290(98)00122-5; Vannah WM, 1996, J REHABIL RES DEV, V33, P239; Yamada S, 2000, BIOPHYS J, V78, P1736, DOI 10.1016/S0006-3495(00)76725-7; Zheng YP, 1999, J REHABIL RES DEV, V36, P71	69	187	193	1	40	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	NOV	2003	20	11					1163	1177		10.1089/089771503770802853			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	747BE	WOS:000186784600002	14651804				2021-06-18	
J	Scheid, R; Preul, C; Gruber, O; Wiggins, C; von Cramon, DY				Scheid, R; Preul, C; Gruber, O; Wiggins, C; von Cramon, DY			Diffuse axonal injury associated with chronic traumatic brain injury: Evidence from T2*-weighted gradient-echo imaging at 3 T	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article; Proceedings Paper	Meeting of the Deutschen-Gesellschaft-fur-Neurologie	SEP   27, 2002	MANNHEIM, GERMANY	Deutschen Gesellschaft Neurologie			AMYLOID PRECURSOR PROTEIN; NONMISSILE HEAD-INJURY; CEREBRAL MICROBLEEDS; CORPUS-CALLOSUM; PRACTICAL SCALE; FOCAL LESIONS; MRI EVIDENCE; FIELD MR; HEMORRHAGE; DIAGNOSIS	BACKGROUND AND PURPOSE: Diffuse axonal injury is frequently accompanied by tissue tear hemorrhages. We examined whether high field strength T2*-weighted gradient-echo imaging performed during the chronic stage of traumatic brain injury may have advantages in the evaluation of diffuse axonal injury as compared with T1- and T2-weighted MR imaging. METHODS: Prospective MR imaging of 66 patients (age range, 17-57 years) was performed using a 3-T system 3 to 292 months (median, 23.5 months) after traumatic brain injury. T1-, T2-, T2*-hypointense and T2-hyperintense foci of 1- to 15-mm diameter were registered in 10 brain regions by two readers separately. Foci that appeared hypointense both on the T1- and T2- and/or on the T2*-weighted images were defined as traumatic microbleeds. RESULTS: For 46 (69.7%) of the patients, T2*-weighted gradient-echo imaging revealed traumatic microbleeds. Hyperintense foci were observed on the T2-weighted images of only 15 (22.7%) patients. T2*-weighted imaging showed significantly more traumatic microbleeds (P = .000) than did T1- and T2-weighted imaging. Interobserver agreement was strong (kappa = 0.79, tau = 0.749, P = .000). For 14 (21.2%) of the patients, T2*-weighted gradient-echo imaging revealed traumatic microbleeds in the corpus callosum, whereas for only two (3%), hyperintense callosal lesions were seen on the T2-weighted images. Although a significant correlation existed between the total amount and callosal appearance of traumatic microbleeds and Glasgow Coma Scale scores (P = .000), no correlation existed with extended Glasgow Outcome Scale scores. CONCLUSION: T2*-weighted gradient-echo imaging at high field strength is a useful tool for the evaluation of diffuse axonal injury during the chronic stage of traumatic brain injury. Diffuse axonal injury-related brain lesions are mainly hemorrhagic. The relevance of diffuse axonal injury for long-term clinical outcome is uncertain.	Univ Leipzig, Day Clin Cognit Neurol, D-04103 Leipzig, Germany; Max Planck Inst Cognit Neurosci, Leipzig, Germany; Univ Ulm, Dept Psychiat, Ulm, Germany; Massachusetts Gen Hosp, MGH NMR Ctr, Charlestown, MA USA	Scheid, R (corresponding author), Univ Leipzig, Day Clin Cognit Neurol, Liebigstr 22A, D-04103 Leipzig, Germany.		Gruber, Oliver/AAY-5563-2020				ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1986, J NEUROL NEUROSUR PS, V49, P1039, DOI 10.1136/jnnp.49.9.1039; ATLAS SW, 1988, RADIOLOGY, V168, P803, DOI 10.1148/radiology.168.3.3406410; BOWEN BC, 1990, AM J ROENTGENOL, V154, P1285, DOI 10.2214/ajr.154.6.2110743; BRADLEY WG, 1993, RADIOLOGY, V189, P15, DOI 10.1148/radiology.189.1.8372185; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; EDELMAN RR, 1986, AM J NEURORADIOL, V7, P751; Fazekas F, 1999, AM J NEURORADIOL, V20, P637; FLEISS JL, 1981, STAT METHODS RATES P, P321; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; GOMORI JM, 1985, RADIOLOGY, V157, P87, DOI 10.1148/radiology.157.1.4034983; GRAHAM DI, 1997, GREENFIELDS NEUROPAT, P197; Graham DI GT, 2000, HEAD INJURY, P133; Greenberg SM, 1999, NEUROLOGY, V53, P1135, DOI 10.1212/WNL.53.5.1135; Greenberg SM, 1996, NEUROLOGY, V46, P1751, DOI 10.1212/WNL.46.6.1751; Hermier M, 2001, NEURORADIOLOGY, V43, P809, DOI 10.1007/s002340100601; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; Kendall M., 1990, RANK CORRELATION MET, V5, P260; Kinoshita T, 2000, STROKE, V31, P1646, DOI 10.1161/01.STR.31.7.1646; Leclercq PD, 2001, J NEUROTRAUM, V18, P1, DOI 10.1089/089771501750055721; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; MUNOZ DG, 1993, ARCH NEUROL-CHICAGO, V50, P492, DOI 10.1001/archneur.1993.00540050044013; Norris DG, 2000, JMRI-J MAGN RESON IM, V11, P445, DOI 10.1002/(SICI)1522-2586(200004)11:4<445::AID-JMRI13>3.0.CO;2-T; Pierallini A, 2000, NEURORADIOLOGY, V42, P860, DOI 10.1007/s002340000447; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Roob G, 1999, NEUROLOGY, V52, P991, DOI 10.1212/WNL.52.5.991; Roob G, 1999, NERVENARZT, V70, P1082, DOI 10.1007/s001150050542; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; TEASDALE G, 1974, LANCET, V2, P81; Tomlinson B E, 1970, J Clin Pathol Suppl (R Coll Pathol), V4, P154; Tsushima Y, 2002, NEURORADIOLOGY, V44, P31, DOI 10.1007/s002340100649; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; Wallesch CW, 2001, J NEUROTRAUM, V18, P11, DOI 10.1089/089771501750055730; WILSON JTL, 1995, J NEUROL NEUROSUR PS, V59, P328, DOI 10.1136/jnnp.59.3.328; Yanagawa Y, 2000, J TRAUMA, V49, P272, DOI 10.1097/00005373-200008000-00013; YOKOTA H, 1991, J TRAUMA, V31, P351, DOI 10.1097/00005373-199103000-00007	47	187	197	0	3	AMER SOC NEURORADIOLOGY	OAK BROOK	2210 MIDWEST RD, OAK BROOK, IL 60521 USA	0195-6108			AM J NEURORADIOL	Am. J. Neuroradiol.	JUN-JUL	2003	24	6					1049	1056					8	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	691TB	WOS:000183620600006	12812926				2021-06-18	
J	Mechoulam, R; Panikashvili, D; Shohami, E				Mechoulam, R; Panikashvili, D; Shohami, E			Cannabinoids and brain injury: therapeutic implications	TRENDS IN MOLECULAR MEDICINE			English	Article							CLOSED-HEAD INJURY; N-ACYLETHANOLAMINES; ENDOCANNABINOID SYSTEM; RECEPTOR LIGANDS; ANANDAMIDE; ISCHEMIA; RATS; EXCITOTOXICITY; GENERATION; CULTURES	Mounting in vitro and in vivo data suggest that the endocannabinoids anandamide and 2-arachidonoyl glycerol, as well as some plant and synthetic cannabinoids, have neuroprotective effects following brain injury. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission and reduce the production of tumour necrosis factor-a and reactive oxygen intermediates, which are factors in causing neuronal damage. The formation of the endocannabinoids anandamide and 2-arachidonoyl glycerol is strongly enhanced after brain injury, and there is evidence that these compounds reduce the secondary damage incurred. Some plant and synthetic cannabinoids, which do not bind to the cannabinoid receptors, have also been shown to be neuroprotective, possibly through their direct effect on the excitatory glutamate system and/or as antioxidants.	Hebrew Univ Jerusalem, Dept Med Chem & Nat Prod, Fac Med, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Dept Pharmacol, IL-91120 Jerusalem, Israel	Mechoulam, R (corresponding author), Hebrew Univ Jerusalem, Dept Med Chem & Nat Prod, Fac Med, IL-91120 Jerusalem, Israel.				NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA9789] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [P01DA009789] Funding Source: NIH RePORTER		Ameri A, 1999, PROG NEUROBIOL, V58, P315, DOI 10.1016/S0301-0082(98)00087-2; Assaf Y, 1999, J NEUROTRAUM, V16, P1165, DOI 10.1089/neu.1999.16.1165; Axelrod J, 1998, NEUROCHEM RES, V23, P575, DOI 10.1023/A:1022418217479; BARONE FC, 1994, J CEREBR BLOOD F MET, V14, P337, DOI 10.1038/jcbfm.1994.41; Barone FC, 2000, J CARDIOVASC PHARM, V36, pS357, DOI 10.1097/00005344-200036001-00104; BARONE FC, 1995, NEUROL RES, V17, P259, DOI 10.1080/01616412.1995.11740323; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Berdyshev EV, 2000, CHEM PHYS LIPIDS, V108, P169, DOI 10.1016/S0009-3084(00)00195-X; Breivogel CS, 2001, MOL PHARMACOL, V60, P155; CHAN BF, 2001, J CEREB BLOOD FLOW M, V21, P2; Chen Y, 2000, CIRC RES, V87, P323, DOI 10.1161/01.RES.87.4.323; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Marzo V, 2001, NATURE, V410, P822, DOI 10.1038/35071088; Di Marzo V, 1998, TRENDS NEUROSCI, V21, P521, DOI 10.1016/S0166-2236(98)01283-1; Doble A, 1999, PHARMACOL THERAPEUT, V81, P163, DOI 10.1016/S0163-7258(98)00042-4; Elphick MR, 2001, PHILOS T R SOC B, V356, P381, DOI 10.1098/rstb.2000.0787; Fowler CJ, 2001, BIOCHEM PHARMACOL, V62, P517, DOI 10.1016/S0006-2952(01)00712-2; Fride E, 2001, EUR J PHARMACOL, V419, P207, DOI 10.1016/S0014-2999(01)00953-0; Gallily R, 2000, EUR J PHARMACOL, V406, pR5, DOI 10.1016/S0014-2999(00)00653-1; Giuffrida A, 2000, CHEM PHYS LIPIDS, V108, P151, DOI 10.1016/S0009-3084(00)00193-6; Giuffrida A, 2001, J PHARMACOL EXP THER, V298, P7; Hampson AJ, 1998, P NATL ACAD SCI USA, V95, P8268, DOI 10.1073/pnas.95.14.8268; Hampson AJ, 1998, J NEUROCHEM, V70, P671; Hansen HH, 2001, J NEUROCHEM, V78, P1415, DOI 10.1046/j.1471-4159.2001.00542.x; Hansen HS, 1998, BIOCHEM PHARMACOL, V55, P719, DOI 10.1016/S0006-2952(97)00396-1; Hansen HS, 2000, CHEM PHYS LIPIDS, V108, P135, DOI 10.1016/S0009-3084(00)00192-4; Hanus L, 2001, P NATL ACAD SCI USA, V98, P3662, DOI 10.1073/pnas.061029898; Jin KL, 2000, ANN NEUROL, V48, P257, DOI 10.1002/1531-8249(200008)48:2<257::AID-ANA18>3.3.CO;2-G; Kim D, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-10-j0004.2001; Kirkham TC, 2001, NUTR RES REV, V14, P65, DOI 10.1079/NRR200118; Klein TW, 1998, IMMUNOL TODAY, V19, P373, DOI 10.1016/S0167-5699(98)01300-0; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Kunos G, 2000, CHEM PHYS LIPIDS, V108, P159, DOI 10.1016/S0009-3084(00)00194-8; Lichtman AH, 2000, EUR J PHARMACOL, V404, P175, DOI 10.1016/S0014-2999(00)00615-4; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Mechoulam R, 1998, EUR J PHARMACOL, V359, P1, DOI 10.1016/S0014-2999(98)00649-9; Nagayama T, 1999, J NEUROSCI, V19, P2987; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Paria BC, 2000, CHEM PHYS LIPIDS, V108, P211, DOI 10.1016/S0009-3084(00)00197-3; PATEL TR, 1995, J CARDIOVASC PHARM, V26, pS412; Pertwee RG, 2001, PROG NEUROBIOL, V63, P569, DOI 10.1016/S0301-0082(00)00031-9; Pertwee RG, 1999, CURR MED CHEM, V6, P635; Piomelli D, 2000, TRENDS PHARMACOL SCI, V21, P218, DOI 10.1016/S0165-6147(00)01482-6; Porter AC, 2001, PHARMACOL THERAPEUT, V90, P45, DOI 10.1016/S0163-7258(01)00130-9; Reiter RJ, 1998, P W PHARMACOL SOC, V41, P229; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; SCHMID HHO, 1990, PROG LIPID RES, V29, P1, DOI 10.1016/0163-7827(90)90004-5; Schmid HHO, 2000, CHEM PHYS LIPIDS, V108, P71, DOI 10.1016/S0009-3084(00)00188-2; SCHMID PC, 1995, FEBS LETT, V375, P117, DOI 10.1016/0014-5793(95)01194-J; Shen MX, 1998, MOL PHARMACOL, V54, P459; Shen MX, 1996, J NEUROSCI, V16, P4322; Shohami E, 2000, DRUG DEVELOP RES, V50, P211, DOI 10.1002/1098-2299(200007/08)50:3/4<211::AID-DDR3>3.0.CO;2-G; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; Sinor AD, 2000, NEUROSCI LETT, V278, P157, DOI 10.1016/S0304-3940(99)00922-2; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Sugiura T, 2000, BIOCHEM BIOPH RES CO, V271, P654, DOI 10.1006/bbrc.2000.2686; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; van der Stelt M, 2001, J NEUROSCI, V21, P6475; VANDERSTELT M, 2001, IN PRESS J NEUROSCI; Wu W, 1996, Chin Med Sci J, V11, P228	61	187	191	0	10	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1471-4914			TRENDS MOL MED	Trends Mol. Med	FEB	2002	8	2					58	61		10.1016/S1471-4914(02)02276-1			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	520FE	WOS:000173769700002	11815270				2021-06-18	
J	Tyurin, VA; Tyurina, YY; Borisenko, GG; Sokolova, TV; Ritov, VB; Quinn, PJ; Rose, M; Kochanek, P; Graham, SH; Kagan, VE				Tyurin, VA; Tyurina, YY; Borisenko, GG; Sokolova, TV; Ritov, VB; Quinn, PJ; Rose, M; Kochanek, P; Graham, SH; Kagan, VE			Oxidative stress following traumatic brain injury in rats: Quantitation of biomarkers and detection of free radical intermediates	JOURNAL OF NEUROCHEMISTRY			English	Article						traumatic brain injury; oxidative stress; ascorbate; spin traps; thiols; 8-epi-prostaglandin F-2 alpha	ELECTRON-SPIN-RESONANCE; LIPID-PEROXIDATION; VITAMIN-E; IN-VIVO; CEREBRAL-ISCHEMIA; PHENOXYL RADICALS; MODEL SYSTEMS; HEAD-INJURY; CYCLOOXYGENASE; ASCORBATE	Oxidative stress may contribute to many pathophysiologic changes that occur after traumatic brain injury. In the current study, contemporary methods of detecting oxidative stress were used in a rodent model of traumatic brain injury. The level of the stable product derived from peroxidation of arachidonyl residues in phospholipids, 8-epi-prostaglandin F-2 alpha, was increased at 6 and 24 h after traumatic brain injury. Furthermore, relative amounts of fluorescent end products of lipid peroxidation in brain extracts were increased at 6 and 24 h after trauma compared with sham-operated controls. The total antioxidant reserves of brain homogenates and water-soluble antioxidant reserves as well as tissue concentrations of ascorbate, GSH, and protein sulfhydryls were reduced after traumatic brain injury. A selective inhibitor of cyclooxygenase-2, SC 58125, prevented depletion of ascorbate and thiols, the two major water-soluble antioxidants in traumatized brain. Electron paramagnetic resonance (EPR) spectroscopy of rat cortex homogenates failed to detect any radical adducts with a spin trap, 5,5-dimethyl-1-pyrroline N-oxide, but did detect ascorbate radical signals. The ascorbate radical EPR signals increased in brain homogenates derived from traumatized brain samples compared with sham-operated controls. These results along with detailed model experiments in vitro indicate that ascorbate is a major antioxidant in brain and that the EPR assay of ascorbate radicals may be used to monitor production of free radicals in brain tissue after traumatic brain injury.	Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA 15238 USA; Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA; VA Pittsburgh Hlth Syst, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA USA; Kings Coll London, Div Life Sci, London W8 7AH, England; Russian Acad Sci, Inst Evolutionary Physiol & Biochem, St Petersburg 196140, Russia	Kagan, VE (corresponding author), Univ Pittsburgh, Dept Environm & Occupat Hlth, 260 Kappa Dr, Pittsburgh, PA 15238 USA.	kagan@pitt.edu	Kochanek, Patrick M/D-2371-2015; Quinn, Peter/E-4019-2010; Sokolova, Tatyana/AAM-6031-2020	Kochanek, Patrick M/0000-0002-2627-913X; Sokolova, Tatyana/0000-0001-9642-6388; Tyurina, Yulia/0000-0003-0287-2091; Tyurin, Vladimir/0000-0002-3474-1697	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30318] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS030318, P50NS030318, P20NS030318] Funding Source: NIH RePORTER		Awasthi D, 1997, SURG NEUROL, V47, P575, DOI 10.1016/S0090-3019(96)00461-2; BUETTNER GR, 1990, METHOD ENZYMOL, V186, P127; BUETTNER GR, 1993, FREE RADICAL BIO MED, V14, P49, DOI 10.1016/0891-5849(93)90508-R; CHAN PH, 1987, ANN NEUROL, V21, P540, DOI 10.1002/ana.410210604; Cheng W, 1999, PEDIATR SURG INT, V15, P8, DOI 10.1007/s003830050500; Chiabrando C, 1999, J BIOL CHEM, V274, P1313, DOI 10.1074/jbc.274.3.1313; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Dash PK, 2000, J NEUROTRAUM, V17, P69, DOI 10.1089/neu.2000.17.69; DEMEDIUK P, 1985, PROG BRAIN RES, V63, P211; DILLARD CJ, 1984, METHOD ENZYMOL, V105, P337; DIXON CE, 1991, J NEUROSCI METH, V39, P253; FENG L, 1993, ARCH BIOCHEM BIOPHYS, V307, P361, DOI 10.1006/abbi.1993.1601; Feuerstein GZ, 1997, ANN NY ACAD SCI, V825, P179, DOI 10.1111/j.1749-6632.1997.tb48428.x; GANTCHEV TG, 1994, METHOD ENZYMOL, V234, P631; GRUNEWALD RA, 1993, BRAIN RES REV, V18, P123, DOI 10.1016/0165-0173(93)90010-W; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HASTINGS TG, 1995, J NEUROCHEM, V64, P919; HILLERED L, 1990, NEUROSCI LETT, V113, P328, DOI 10.1016/0304-3940(90)90606-A; Hsiang JNK, 1997, ACTA NEUROCHIR, V139, P464, DOI 10.1007/BF01808884; IKEDA Y, 1990, NEUROSURGERY, V27, P1; Inci S, 1998, NEUROSURGERY, V43, P330, DOI 10.1097/00006123-199808000-00095; Juurlink B H, 1998, J Spinal Cord Med, V21, P309; KAGAN VE, 1992, J LIPID RES, V33, P385; KAGAN VE, 1994, BIOCHEMISTRY-US, V33, P9651, DOI 10.1021/bi00198a034; Kagan VE., 1988, LIPID PEROXIDATION B; KIHARA T, 1995, J NEUROCHEM, V65, P282; Kim HJ, 2000, FREE RADICAL BIO MED, V28, P683, DOI 10.1016/S0891-5849(99)00274-9; Kim HY, 1999, ADV EXP MED BIOL, V447, P75; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; Kotake Y, 1999, ARCH BIOCHEM BIOPHYS, V371, P129, DOI 10.1006/abbi.1999.1417; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; KUKREJA RC, 1986, CIRC RES, V59, P612, DOI 10.1161/01.RES.59.6.612; Lewen A, 1998, J NEUROTRAUM, V15, P521, DOI 10.1089/neu.1998.15.521; MORI A, 1994, NEUROCHEM INT, V24, P201, DOI 10.1016/0197-0186(94)90076-0; MORROW JD, 1992, P NATL ACAD SCI USA, V89, P10721, DOI 10.1073/pnas.89.22.10721; Nakayama M, 1998, P NATL ACAD SCI USA, V95, P10954, DOI 10.1073/pnas.95.18.10954; NIKI E, 1990, METHOD ENZYMOL, V186, P100; NIMURA N, 1988, ANAL CHEM, V60, P2067, DOI 10.1021/ac00170a017; Nishio S, 1997, ACT NEUR S, V70, P84; Nogawa S, 1998, P NATL ACAD SCI USA, V95, P10966, DOI 10.1073/pnas.95.18.10966; O'Banion MK, 1999, METH MOL B, V120, P55; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; PACKER JE, 1979, NATURE, V278, P737, DOI 10.1038/278737a0; Povlishock J T, 1992, Hum Cell, V5, P345; PRATICO D, 1995, J BIOL CHEM, V270, P9800, DOI 10.1074/jbc.270.17.9800; Pratico D, 1999, J NEUROCHEM, V73, P736, DOI 10.1046/j.1471-4159.1999.0730736.x; Raju VS, 1997, BBA-GENE STRUCT EXPR, V1351, P89, DOI 10.1016/S0167-4781(96)00183-2; REDDY CC, 1982, LIFE SCI, V31, P571, DOI 10.1016/0024-3205(82)90486-6; Resnick DK, 1998, J NEUROTRAUM, V15, P1005, DOI 10.1089/neu.1998.15.1005; Rice ME, 1998, NEUROSCIENCE, V82, P1213; Roberts LJ, 1998, J BIOL CHEM, V273, P13605, DOI 10.1074/jbc.273.22.13605; SEN S, 1994, FREE RADICAL BIO MED, V16, P685, DOI 10.1016/0891-5849(94)90183-X; SENTJURC M, 1992, FREE RADICAL BIO MED, V13, P151, DOI 10.1016/0891-5849(92)90077-T; Shvedova AA, 2000, J INVEST DERMATOL, V114, P354, DOI 10.1046/j.1523-1747.2000.00865.x; Stoyanovsky DA, 1998, FREE RADICAL BIO MED, V25, P536, DOI 10.1016/S0891-5849(98)00081-1; Stoyanovsky DA, 1996, ARCH BIOCHEM BIOPHYS, V330, P3, DOI 10.1006/abbi.1996.0219; TYURINA YY, 1995, TOXICOL APPL PHARM, V131, P277, DOI 10.1006/taap.1995.1070; WILSON JT, 1995, J TRAUMA, V39, P473; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T; Zhang RL, 1998, FREE RADICAL BIO MED, V24, P332, DOI 10.1016/S0891-5849(97)00267-0	61	187	192	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	NOV	2000	75	5					2178	2189		10.1046/j.1471-4159.2000.0752178.x			12	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	365AA	WOS:000089925200043	11032908	Bronze			2021-06-18	
J	ANNEGERS, JF; HAUSER, WA; LEE, JRJ; ROCCA, WA				ANNEGERS, JF; HAUSER, WA; LEE, JRJ; ROCCA, WA			INCIDENCE OF ACUTE SYMPTOMATIC SEIZURES IN ROCHESTER, MINNESOTA, 1935-1984	EPILEPSIA			English	Article						SEIZURES; INCIDENCE; ETIOLOGY; TRAUMATIC BRAIN INJURY; CEREBROVASCULAR DISEASE; DRUG WITHDRAWAL; CNS INFECTION; ROCHESTER; MINNESOTA	EPILEPTIC SEIZURES; OLMSTED-COUNTY; HEAD TRAUMA; POPULATION; PREVALENCE	We determined the incidence of seizures due to acute CNS insults for residents of Rochester, Minnesota, U.S.A., from 1935 though 1984. The age-adjusted incidence rates for 1955-1984, the period of most complete case ascertainment, was 39.0/100,000 person-years (United States 1970 population as standard). The age-adjusted incidence was considerably higher in men: 52.0 as compared with 29.5 in women. The 3.6% risk of experiencing an acute symptomatic seizure in an 80-year lifespan approaches that of developing epilepsy. The major causes of acute symptomatic seizures were traumatic brain injury, cerebrovascular disease, drug withdrawal, and CNS infections. Each type of acute symptomatic seizure has age, gender, and time period patterns that reflect the occurrence of the underlying cause.	COLUMBIA UNIV, COLL PHYS & SURG, GERTRUDE H SERGIEVSKY CTR, NEW YORK, NY USA; MAYO CLIN & MAYO FDN, DEPT HLTH SCI RES, ROCHESTER, MN 55905 USA	ANNEGERS, JF (corresponding author), UNIV TEXAS, HLTH SCI CTR, SCH PUBL HLTH, DIV EPIDEMIOL, POB 20186, HOUSTON, TX 77225 USA.		Hauser, W Allen/AAB-5277-2020; Rocca, Walter/Z-5335-2019		NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5-P50 NS-16308] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS016308] Funding Source: NIH RePORTER		ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; [Anonymous], 1981, Epilepsia, V22, P489; BRODERICK JP, 1989, STROKE, V20, P577, DOI 10.1161/01.STR.20.5.577; HAUSER WA, 1991, EPILEPSIA, V32, P429, DOI 10.1111/j.1528-1157.1991.tb04675.x; HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x; LOISEAU J, 1990, ANN NEUROL, V27, P232, DOI 10.1002/ana.410270304; LOISEAU J, 1987, THESIS U BORDEAUX; NICOLOSI A, 1986, J INFECT DIS, V154, P399, DOI 10.1093/infdis/154.3.399; PLACENCIA M, 1992, BRAIN, V115, P771, DOI 10.1093/brain/115.3.771; Rothman K. J., 1986, MODERN EPIDEMIOLOGY; SAID DA, 1993, THESIS U TEXAS HOUST; SANDER JWAS, 1990, LANCET, V336, P1267, DOI 10.1016/0140-6736(90)92959-L; SCHROEDER DJ, 1982, TECHNICAL REPORT SER, V20, P5	14	187	194	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	APR	1995	36	4					327	333		10.1111/j.1528-1157.1995.tb01005.x			7	Clinical Neurology	Neurosciences & Neurology	QQ264	WOS:A1995QQ26400002	7607110				2021-06-18	
J	CASCARDI, M; OLEARY, KD				CASCARDI, M; OLEARY, KD			DEPRESSIVE SYMPTOMATOLOGY, SELF-ESTEEM, AND SELF-BLAME IN BATTERED WOMEN	JOURNAL OF FAMILY VIOLENCE			English	Article						SPOUSE ABUSE; DEPRESSION; SELF-ESTEEM	VIOLENCE; ATTRIBUTIONS	Thirty three currently battered women who sought counseling/support services from a Nassau County, New York community agency that provides services to victims of domestic violence participated. Eighty-nine percent of the women experienced severe acts of physical abuse and 31% of the women required surgery or suffered concussions as a result of their injuries. Fifty-two percent of the women scored above 20 on the Beck Depression Inventory. As the number, form, and consequences of physically aggressive acts increased and/or worsened, the women's depressive symptoms increased and self-esteem decreased. However, only 12% of the women in this sample blamed themselves for causing their partner's violence. Further, neither self-blame nor partner blame was associated with length of abuse or the frequency and severity of physical aggression. However, self-blame was marginally associated with depressive symptomatology.		CASCARDI, M (corresponding author), SUNY STONY BROOK,DEPT PSYCHOL,STONY BROOK,NY 11790, USA.						ANDREASSEN NC, 1991, INTRO TXB PSYCHIATRY; ANDREWS B, 1990, J MARRIAGE FAM, V52, P757, DOI 10.2307/352940; *Barling J., 1987, J FAM VIOLENCE, V2, P37, DOI [DOI 10.1007/13F00976369, 10.1007/BF00976369, DOI 10.1007/BF00976369]; Beach SRH, 1990, DEPRESSION MARRIAGE; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; BECK AT, 1979, COGNITIVE THERAPY DE; CRAIGHEAD E, 1991, DATA COLLECTED PART; FRIEZE I, 1979, NEW APPROACHES SOCIA; GOLDSTEIN D, 1985, FAM RELAT, V34, P425, DOI 10.2307/583583; HOLTZWORTHMUNROE A, 1988, CLIN PSYCHOL REV, V8, P331, DOI 10.1016/0272-7358(88)90095-5; JANOFFBULMAN R, 1983, J SOC ISSUES, V39, P1, DOI 10.1111/j.1540-4560.1983.tb00138.x; MILLER DT, 1983, J SOC ISSUES, V39, P139, DOI 10.1111/j.1540-4560.1983.tb00145.x; NEIDIG PH, 1984, SPOUSE ABUSE TREATME; NELSON GM, 1990, BEHAV THER, V21, P167, DOI 10.1016/S0005-7894(05)80275-8; OLEARY KD, 1990, BEHAV THER, V21, P413, DOI 10.1016/S0005-7894(05)80355-7; OLEARY KD, 1985, J MARITAL FAM THER, V11, P319, DOI 10.1111/j.1752-0606.1985.tb00625.x; SCHMALING KB, 1990, J ABNORM PSYCHOL, V99, P229, DOI 10.1037/0021-843X.99.3.229; Straus M., 1980, BEHIND CLOSED DOORS; STRAUS MA, 1979, J MARRIAGE FAM, V41, P75, DOI 10.2307/351733; Walker L.E.A., 1979, BATTERED WOMAN; Walker LE, 1984, BATTERED WOMAN SYNDR	21	187	192	0	18	PLENUM PUBL CORP	NEW YORK	233 SPRING ST, NEW YORK, NY 10013	0885-7482			J FAM VIOLENCE	J. Fam. Violence	DEC	1992	7	4					249	259		10.1007/BF00994617			11	Psychology, Clinical; Family Studies	Psychology; Family Studies	JY424	WOS:A1992JY42400001					2021-06-18	
J	ALDRICH, EF; EISENBERG, HM; SAYDJARI, C; LUERSSEN, TG; FOULKES, MA; JANE, JA; MARSHALL, LF; MARMAROU, A; YOUNG, HF				ALDRICH, EF; EISENBERG, HM; SAYDJARI, C; LUERSSEN, TG; FOULKES, MA; JANE, JA; MARSHALL, LF; MARMAROU, A; YOUNG, HF			DIFFUSE BRAIN-SWELLING IN SEVERELY HEAD-INJURED CHILDREN - A REPORT FROM THE NIH TRAUMATIC COMA DATA-BANK	JOURNAL OF NEUROSURGERY			English	Article						BRAIN INJURY; HEAD INJURY; TRAUMATIC-COMA-DATA-BANK; BRAIN SWELLING; CHILDREN		In this study, data were prospectively collected from 753 patients (111 children and 642 adults) with severe head injury and examined for evidence of diffuse brain swelling and its association with outcome. Diffuse brain swelling occurred approximately twice as often in children (aged 16 years or younger) as in adults. A high mortality rate (53%) was found in these children, which was three times that of the children without diffuse brain swelling (16%). Adults with diffuse brain swelling had a mortality rate (46%) similar to that of children, but only slightly higher than that for adults without diffuse brain swelling (39%). When the diagnosis of diffuse brain swelling was expanded to include patients with diffuse brain swelling plus small parenchymal hemorrhages (< 15 cu cm), these mortality rates were virtually unchanged.	NINCDS, BIOMETRY & FIELD STUDIES BRANCH, BETHESDA, MD 20892 USA; JAMES WHITCOMB RILEY HOSP CHILDREN, INDIANAPOLIS, IN 46202 USA; UNIV VIRGINIA, DEPT NEUROSURG, CHARLOTTESVILLE, VA 22903 USA; UNIV CALIF SAN DIEGO, DIV NEUROSURG, LA JOLLA, CA 92093 USA; VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DIV NEUROSURG, RICHMOND, VA 23298 USA	ALDRICH, EF (corresponding author), UNIV TEXAS, MED BRANCH, DIV NEUROSURG E17, GALVESTON, TX 77550 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [N01NS032341, N01NS032340, N01NS032339] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [N01-NS32340, N01-NS32339, N01-NS32341] Funding Source: Medline		BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; CORDOBES F, 1987, CHILD NERV SYST, V3, P235, DOI 10.1007/BF00274055; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; Hendrick E B, 1964, Clin Neurosurg, V11, P46; HUMPHREYS RP, 1983, CONCEPTS PEDIATR NEU, V4, P230; KOBAYASHI S, 1983, INTRACRANIAL PRESSUR, V5, P527; SNOEK JW, 1984, BRAIN, V107, P15, DOI 10.1093/brain/107.1.15; TEASDALE E, 1984, J NEUROL NEUROSUR PS, V47, P600, DOI 10.1136/jnnp.47.6.600; TEASDALE G, 1974, LANCET, V2, P81; ZIMMERMAN RA, 1978, RADIOLOGY, V126, P403, DOI 10.1148/126.2.403; ZIMMERMAN RA, 1978, RADIOLOGY, V127, P393, DOI 10.1148/127.2.393	13	187	192	0	7	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAR	1992	76	3					450	454		10.3171/jns.1992.76.3.0450			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	HF274	WOS:A1992HF27400010	1738026				2021-06-18	
J	Papa, L; Lewis, LM; Falk, JL; Zhang, ZQ; Silvestri, S; Giordano, P; Brophy, GM; Demery, JA; Dixit, NK; Ferguson, I; Liu, MC; Mo, JX; Akinyi, L; Schmid, K; Mondello, S; Robertson, CS; Tortella, FC; Hayes, RL; Wang, KKW				Papa, Linda; Lewis, Lawrence M.; Falk, Jay L.; Zhang, Zhiqun; Silvestri, Salvatore; Giordano, Philip; Brophy, Gretchen M.; Demery, Jason A.; Dixit, Neha K.; Ferguson, Ian; Liu, Ming Cheng; Mo, Jixiang; Akinyi, Linnet; Schmid, Kara; Mondello, Stefania; Robertson, Claudia S.; Tortella, Frank C.; Hayes, Ronald L.; Wang, Kevin K. W.			Elevated Levels of Serum Glial Fibrillary Acidic Protein Breakdown Products in Mild and Moderate Traumatic Brain Injury Are Associated With Intracranial Lesions and Neurosurgical Intervention	ANNALS OF EMERGENCY MEDICINE			English	Article							NEURON-SPECIFIC-ENOLASE; CT HEAD RULE; COMPUTED-TOMOGRAPHY; OUTCOME PREDICTION; S-100B PROTEIN; CANCER-RISKS; DAMAGE; S100B; MARKERS; GFAP	Study objective: This study examines whether serum levels of glial fibrillary acidic protein breakdown products (GFAP-BDP) are elevated in patients with mild and moderate traumatic brain injury compared with controls and whether they are associated with traumatic intracranial lesions on computed tomography (CT) scan (positive CT result) and with having a neurosurgical intervention. Methods: This prospective cohort study enrolled adult patients presenting to 3 Level I trauma centers after blunt head trauma with loss of consciousness, amnesia, or disorientation and a Glasgow Coma Scale (GCS) score of 9 to 15. Control groups included normal uninjured controls and trauma controls presenting to the emergency department with orthopedic injuries or a motor vehicle crash without traumatic brain injury. Blood samples were obtained in all patients within 4 hours of injury and measured by enzyme.linked immunosorbent assay for GFAP-BDP (nanograms/milliliter). Results: Of the 307 patients enrolled, 108 were patients with traumatic brain injury (97 with GCS score 13 to 15 and 11 with GCS score 9 to 12) and 199 were controls (176 normal controls and 16 motor vehicle crash controls and 7 orthopedic controls). Receiver operating characteristic curves demonstrated that early GFAP-BDP levels were able to distinguish patients with traumatic brain injury from uninjured controls with an area under the curve of 0.90 (95% confidence interval [Cl] 0.86 to 0.94) and differentiated traumatic brain injury with a GCS score of 15 with an area under the curve of 0.88 (95% Cl 0.82 to 0.93). Thirty-two patients with traumatic brain injury (30%) had lesions on CT. The area under these curves for discriminating patients with CT lesions versus those without CT lesions was 0.79 (95% Cl 0.69 to 0.89). Moreover, the receiver operating characteristic curve for distinguishing neurosurgical intervention from no neurosurgical intervention yielded an area under the curve of 0.87 (95% Cl 0.77 to 0.96). Conclusion: GFAP-BDP is detectable in serum within an hour of injury and is associated with measures of injury severity, including the GCS score, CT lesions, and neurosurgical intervention. Further study is required to validate these findings before clinical application. [Ann Emerg Med. 2012;59:471-483.]	[Papa, Linda; Falk, Jay L.; Silvestri, Salvatore; Giordano, Philip] Orlando Reg Med Ctr Inc, Dept Emergency Med, Orlando, FL USA; [Lewis, Lawrence M.; Ferguson, Ian] Washington Univ, Sch Med, Div Emergency Med, St Louis, MO USA; [Zhang, Zhiqun; Liu, Ming Cheng; Mo, Jixiang; Akinyi, Linnet; Mondello, Stefania; Hayes, Ronald L.; Wang, Kevin K. W.] Banyan Biomarkers Inc, Alachua, FL USA; [Brophy, Gretchen M.] Virginia Commonwealth Univ, Richmond, VA USA; [Demery, Jason A.] Univ Florida, Forens Inst, UF Springhill Hlth Ctr, Gainesville, FL USA; [Dixit, Neha K.] NF SG Vet Hlth Syst, Psychol Serv, Gainesville, FL USA; [Schmid, Kara; Tortella, Frank C.] Walter Reed Army Inst Res, Dept Appl Neurobiol, Div Psychiat & Neurosci, Silver Spring, MD USA; [Robertson, Claudia S.] Baylor Coll Med, Dept Crit Care & Neurosurg, Houston, TX 77030 USA	Papa, L (corresponding author), Orlando Reg Med Ctr Inc, Dept Emergency Med, Orlando, FL USA.	lpstat@aol.com; kawangwang17@gmail.com	Mondello, Stefania/A-1813-2012; Ferguson, Ian/C-1874-2016	Mondello, Stefania/0000-0002-8587-3614; Ferguson, Ian/0000-0003-3060-414X; Wang, Kevin/0000-0002-9343-6473; Brophy, Gretchen/0000-0002-4749-2693	Department of DefenseUnited States Department of Defense [DoD W81XWH-06-1-0517]; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS057676]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS057676] Funding Source: NIH RePORTER	By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org). This study was supported in part by Department of Defense Award number DoD W81XWH-06-1-0517. Material has been reviewed by the Walter Reed Army Institute of Research. There is no objection to its presentation or publication. The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting true views of Department of the Army or Department of Defense. The project described was supported in part by award number R01NS057676 from the National Institute of Neurological Disorders and Stroke. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Neurological Disorders and Stroke or the National Institutes of Health. Drs. Papa, Brophy, and Demery are consultants of Banyan Biomarkers, Inc. but receive no stocks or royalties from the company and will not benefit financially from this publication. Drs. Liu, Mo, Zhang, and Mondello and Ms. Akinyi are employees of Banyan Biomarkers, Inc. Drs. Wang and Hayes own stock, receive royalties from, and are officers of Banyan Biomarkers Inc. and as such may benefit financially as a result of the outcomes of this research or work reported in this publication.	Baydas G, 2003, EUR J PHARMACOL, V462, P67, DOI 10.1016/S0014-2999(03)01294-9; Bazarian JJ, 2006, BRAIN INJURY, V20, P759, DOI 10.1080/02699050500488207; Berger RP, 2007, J NEUROTRAUM, V24, P1793, DOI 10.1089/neu.2007.0316; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; Berger RP, 2002, J NEUROTRAUM, V19, P1405, DOI 10.1089/089771502320914633; Brenner DJ, 2010, RADIAT RES, V174, P809, DOI 10.1667/RR1859.1; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Cantu RC, 1998, CLIN SPORT MED, V17, P45, DOI 10.1016/S0278-5919(05)70060-0; Carey ME, 1996, J TRAUMA, V40, pS165, DOI 10.1097/00005373-199603001-00036; de Gonzalez AB, 2009, ARCH INTERN MED, V169, P2071, DOI 10.1001/archinternmed.2009.440; de Kruijk JR, 2001, ACTA NEUROL SCAND, V103, P175, DOI 10.1034/j.1600-0404.2001.103003175.x; DEARMOND SJ, 1983, BRAIN RES, V262, P275, DOI 10.1016/0006-8993(83)91018-1; Duchen L. W, 1984, GREENFIELDS NEUROPAT, P1; Dula K, 1996, EUR J ORAL SCI, V104, P503, DOI 10.1111/j.1600-0722.1996.tb00133.x; ENG LF, 1971, BRAIN RES, V28, P351, DOI 10.1016/0006-8993(71)90668-8; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fayngersh V, 2009, LUNG, V187, P143, DOI 10.1007/s00408-009-9143-9; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gallagher CN, 2007, CURR OPIN NEUROL, V20, P403, DOI 10.1097/WCO.0b013e32821b987b; Hall EJ, 2008, BRIT J RADIOL, V81, P362, DOI 10.1259/bjr/01948454; Heilbrun Marta E, 2005, J Am Coll Radiol, V2, P889, DOI 10.1016/j.jacr.2005.06.013; Herrmann M, 2000, STROKE, V31, P2670, DOI 10.1161/01.STR.31.11.2670; Jagoda AS, 2002, ANN EMERG MED, V40, P231, DOI 10.1016/j.jen.2008.12.010; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Korfias S, 2007, INTENS CARE MED, V33, P255, DOI 10.1007/s00134-006-0463-4; LIVINGSTON DH, 1991, J TRAUMA, V31, P483, DOI 10.1097/00005373-199104000-00006; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; Long A E, 1985, Emerg Med Clin North Am, V3, P437; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Macgregor DM, 2005, EMERG MED J, V22, P541, DOI 10.1136/emj.2004.017160; Martens P, 1996, ACAD EMERG MED, V3, P126, DOI 10.1111/j.1553-2712.1996.tb03399.x; Mettler FA, 2008, HEALTH PHYS, V95, P502, DOI 10.1097/01.HP.0000326333.42287.a2; Mirvis S E, 1994, J Intensive Care Med, V9, P305; Missler U, 1999, CLIN CHEM, V45, P138; Mondello S, 2011, CRIT CARE, V15, DOI 10.1186/cc10286; Morochovic R, 2009, EUR J NEUROL, V16, P1112, DOI 10.1111/j.1468-1331.2009.02653.x; Mouser PE, 2006, AM J PATHOL, V168, P936, DOI 10.2353/ajpath.2006.050798; Naeimi ZS, 2006, BRAIN INJURY, V20, P463, DOI 10.1080/02699050600664418; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Papa Linda, 2008, Expert Opin Med Diagn, V2, P937, DOI 10.1517/17530059.2.8.937; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Piazza O, 2007, PEDIATR NEUROSURG, V43, P258, DOI 10.1159/000103304; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Rainey T, 2009, RESUSCITATION, V80, P341, DOI 10.1016/j.resuscitation.2008.11.021; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Ross SA, 1996, BRIT J NEUROSURG, V10, P471, DOI 10.1080/02688699647104; Ryu WHA, 2009, CAN J NEUROL SCI, V36, P42, DOI 10.1017/S0317167100006296; Sapsford W, 2003, J R Army Med Corps, V149, P5; Stein SC, 2009, ANN EMERG MED, V53, P180, DOI 10.1016/j.annemergmed.2008.01.002; Stiell IG, 2005, JAMA-J AM MED ASSOC, V294, P1511, DOI 10.1001/jama.294.12.1511; Stiell IG, 1997, ANN EMERG MED, V30, P14, DOI 10.1016/S0196-0644(97)70104-5; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TEASDALE G, 1974, LANCET, V2, P81; van Geel WJA, 2002, CLIN CHIM ACTA, V326, P151, DOI 10.1016/S0009-8981(02)00330-3; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Wang KKW, 2005, EXPERT REV PROTEOMIC, V2, P603, DOI 10.1586/14789450.2.4.603; Wardlaw JM, 2004, HEALTH TECHNOL ASSES, V8, P1; Watt SE, 2006, BRAIN INJURY, V20, P1007, DOI 10.1080/02699050600909698; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6; Zhang Z, 2010, J NEUROTRAUM, V27, pA1; Zhang Z, 2010, ANN ADV TECHN APPL C	67	186	192	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644	1097-6760		ANN EMERG MED	Ann. Emerg. Med.	JUN	2012	59	6					471	483		10.1016/j.annemergmed.2011.08.021			13	Emergency Medicine	Emergency Medicine	959HA	WOS:000305302300007	22071014	Green Accepted			2021-06-18	
J	Hou, RH; Moss-Morris, R; Peveler, R; Mogg, K; Bradley, BP; Belli, A				Hou, Ruihua; Moss-Morris, Rona; Peveler, Robert; Mogg, Karin; Bradley, Brendan P.; Belli, Antonio			When a minor head injury results in enduring symptoms: a prospective investigation of risk factors for postconcussional syndrome after mild traumatic brain injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							POST-CONCUSSION SYMPTOMS; COGNITIVE-BEHAVIORAL MODEL; CHRONIC-FATIGUE-SYNDROME; CHRONIC PAIN; QUESTIONNAIRE; PSYCHOGENESIS; PHYSIOGENESIS; RELIABILITY; POPULATION; DEPRESSION	Objective A significant proportion (15-30%) of patients with mild traumatic brain injury (MTBI) are at risk of developing postconcussional syndrome (PCS). The aim of this study was to investigate the contributions of cognitive, emotional, behavioural and social factors to the development of PCS and identify early predictors. Methods A prospective cohort design was employed. 126 MTBI patients completed baseline questionnaire assessments within 2 weeks of the injury and 107 completed follow-up questionnaire assessments at 3 and 6 months. A series of self-report measures were used to assess cognitive, behavioural and emotional responses to MTBI. The primary outcome was the ICD-10 diagnosis for PCS. Demographic and clinical characteristic variables were compared between PCS cases and non-cases using independent sample t tests and chi(2) tests. Individual and multivariate logistic regression analyses were used to detect predictors of PCS. Results Of 107 MTBI patients, 24 (22%) met the criteria for PCS at 3 months and 22 (21%) at 6 months. Individual logistic regression analysis indicated that negative MTBI perceptions, stress, anxiety, depression and all-or-nothing behaviour were associated with the risk of PCS. Multivariate analysis revealed that all-or-nothing behaviour was the key predictor for the onset of PCS at 3 months while negative MTBI perceptions predicted PCS at 6 months. Conclusions The study provides good support for the proposed cognitive behavioural model. Patients' perceptions of their head injury and their behavioural responses play important roles in the development of PCS, indicating that cognitive and behavioural factors may be potential targets for early preventive interventions.	[Hou, Ruihua] Univ Southampton, Fac Med, Univ Dept Psychiat, Acad Ctr,Coll Keep, Southampton SO14 3DT, Hants, England; [Moss-Morris, Rona] Kings Coll London, Inst Psychiat, Dept Psychol, London WC2R 2LS, England; [Mogg, Karin; Bradley, Brendan P.] Univ Southampton, Sch Psychol, Southampton SO14 3DT, Hants, England	Hou, RH (corresponding author), Univ Southampton, Fac Med, Univ Dept Psychiat, Acad Ctr,Coll Keep, 4-12 Terminus Terrace, Southampton SO14 3DT, Hants, England.	r.hou@soton.ac.uk	Belli, Antonio/I-3799-2015; Bradley, Brendan P/B-9724-2008; Mogg, Karin/C-1181-2008	Belli, Antonio/0000-0002-3211-9933; Mogg, Karin/0000-0002-2738-7378; Moss-Morris, Rona/0000-0002-2927-3446; Hou, Ruihua/0000-0001-6127-1478; Bradley, Brendan/0000-0003-2801-4271	Faculty of Medicine Research Management Committee at the University of Southampton [503836112]	This study was funded by the Faculty of Medicine Research Management Committee at the University of Southampton (grant reference code: 503836112).	Al Sayegh A, 2010, J NEUROL NEUROSUR PS, V81, P1128, DOI 10.1136/jnnp.2008.170092; Broadbent E, 2006, J PSYCHOSOM RES, V60, P631, DOI 10.1016/j.jpsychores.2005.10.020; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Field A. P, 2009, DISCOVERING STAT USI; Garden N, 2010, APPL NEUROPSYCHOL, V17, P1, DOI 10.1080/09084280903297495; Herrmann N, 2009, J NEUROPSYCH CLIN N, V21, P181, DOI 10.1176/appi.neuropsych.21.2.181; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; JACOBSON RR, 1995, J PSYCHOSOM RES, V39, P675, DOI 10.1016/0022-3999(95)00006-5; Joseph S, 2000, J TRAUMA STRESS, V13, P101, DOI 10.1023/A:1007777032063; Kay A, 2001, WORLD J SURG, V25, P1210, DOI 10.1007/s00268-001-0084-6; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 2003, BRIT J PSYCHIAT, V183, P276, DOI 10.1192/bjp.183.4.276; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; Lannsjo M, 2009, BRAIN INJURY, V23, P213, DOI 10.1080/02699050902748356; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Macleod AD, 2010, MED HYPOTHESES, V74, P1033, DOI 10.1016/j.mehy.2010.01.002; MARZIALI EA, 1987, J NERV MENT DIS, V175, P327, DOI 10.1097/00005053-198706000-00002; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Meares S, 2006, J INT NEUROPSYCH SOC, V12, P792, DOI 10.1017/S1355617706060978; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; Moss-Morris R, 2011, PSYCHOL MED, V41, P1099, DOI 10.1017/S003329171000139X; Mulhern S, 2006, J PSYCHOSOM RES, V61, P439, DOI 10.1016/j.jpsychores.2006.03.004; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Roe C, 2009, DISABIL REHABIL, V31, P1235, DOI 10.1080/09638280802532720; Ruff RM, 2009, PSYCHOL INJ LAW, V2, P34, DOI 10.1007/s12207-009-9029-4; RUTHERFORD WH, 1977, LANCET, V1, P1; Sharpe M, 1996, PSYCHIAT CLIN N AM, V19, P549, DOI 10.1016/S0193-953X(05)70305-1; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Spence M, 2005, PSYCHOL MED, V35, P583, DOI 10.1017/S0033291704003484; Spence MJ, 2007, GUT, V56, P1066, DOI 10.1136/gut.2006.108811; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; Tsanadis J, 2008, CLIN NEUROPSYCHOL, V22, P1080, DOI 10.1080/13854040701796928; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; Williams WH, 2010, J NEUROL NEUROSUR PS, V81, P1116, DOI 10.1136/jnnp.2008.171298; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; World Health Organisation, 1993, ICD 10 CLASSIFICATIO; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	46	186	187	2	35	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	FEB	2012	83	2					217	223		10.1136/jnnp-2011-300767			7	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	877IC	WOS:000299170100019	22028384				2021-06-18	
J	de Almeida, JRC; Versace, A; Mechelli, A; Hassel, S; Quevedo, K; Kupfer, DJ; Phillips, ML				Cardoso de Almeida, Jorge Renner; Versace, Amelia; Mechelli, Andrea; Hassel, Stefanie; Quevedo, Karina; Kupfer, David Jerome; Phillips, Mary Louise			Abnormal Amygdala-Prefrontal Effective Connectivity to Happy Faces Differentiates Bipolar from Major Depression	BIOLOGICAL PSYCHIATRY			English	Article						Amygdala; bipolar disorder; dynamic causal modeling; fMRI; major depression disorder; orbitomedial prefrontal cortex	TRAUMATIC BRAIN INJURY; WHITE-MATTER; FACIAL EXPRESSIONS; DISORDER; MEDICATION; RESPONSES; STIMULI; MANIA; SCHIZOPHRENIA; MISDIAGNOSIS	Background: Bipolar disorder is frequently misdiagnosed as major depressive disorder, delaying appropriate treatment and worsening outcome for many bipolar individuals. Emotion dysregulation is a core feature of bipolar disorder. Measures of dysfunction in neural systems supporting emotion regulation might therefore help discriminate bipolar from major depressive disorder. Methods: Thirty-one depressed individuals-15 bipolar depressed (BD) and 16 major depressed (MDD), DSM-IV diagnostic criteria, ages 18-55 years, matched for age, age of illness onset, illness duration, and depression severity-and 16 age- and gender-matched healthy control subjects performed two event-related paradigms: labeling the emotional intensity of happy and sad faces, respectively. We employed dynamic causal modeling to examine significant among-group alterations in effective connectivity (EC) between right- and left-sided neural regions supporting emotion regulation: amygdala and orbitomedial prefrontal cortex (OMPFC). Results: During classification of happy faces, we found profound and asymmetrical differences in EC between the OMPFC and amygdala. Left-sided differences involved top-down connections and discriminated between depressed and control subjects. Furthermore, greater medication load was associated with an amelioration of this abnormal top-down EC. Conversely, on the right side the abnormality was in bottom-up EC that was specific to bipolar disorder. These effects replicated when we considered only female subjects. Conclusions: Abnormal, left-sided, top-down OMPFC-amygdala and right-sided, bottom-up, amygdala-OMPFC EC during happy labeling distinguish BD and MDD, suggesting different pathophysiological mechanisms associated with the two types of depression.	[Cardoso de Almeida, Jorge Renner; Versace, Amelia; Hassel, Stefanie; Quevedo, Karina; Kupfer, David Jerome; Phillips, Mary Louise] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA; [Cardoso de Almeida, Jorge Renner] Univ Sao Paulo, Sch Med, Dept Psychiat, Sao Paulo, Brazil; [Mechelli, Andrea] Kings Coll London, Inst Psychiat, Dept Psychol, London WC2R 2LS, England; [Phillips, Mary Louise] Cardiff Univ, Dept Psychol Med, Cardiff, S Glam, Wales	Phillips, ML (corresponding author), Western Psychiat Inst & Clin, Funct Neuroimaging Program, 3811 OHara St, Pittsburgh, PA USA.	phillipsml@upmc.edu	anand, amit/A-7222-2009; Mechelli, Andrea/B-1114-2011; Versace, Amelia/G-1772-2018; Almeida, Jorge/O-5185-2014	Versace, Amelia/0000-0001-9925-5203; Almeida, Jorge/0000-0002-1213-1986	National Alliance for Research on Schizophrenia and Depression (NARSAD)French National Research Agency (ANR)NARSAD [5R01 MH076971-01]; Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) FoundationCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) [190105-2]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH076971] Funding Source: NIH RePORTER	All work, was carried out within the Department of Psychiatry, University of Pittsburgh. Neuroimaging data were collected at the Brain Imaging Research Center University of Pittsburgh, and Carnegie Mellon University. the thank Dr. K.J. Jung, S. Kurdilla, and D. Vizslay for their help acquiring neuroimaging data. Dr. Phillips reports having support from National Alliance for Research on Schizophrenia and Depression (NARSAD) Independent Investigator Award and 5R01 MH076971-01. Dr. Almeida reports having support from Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) Foundation (#190105-2). Dr. Hassel reports having support from NARSAD. Dr. Mechelli, Dr. Versace, Dr. Quevedo and Dr. Kupfer reported no biomedical financial interests or potential conflicts of interest.; Supplementary material cited ita this article is available online.	Adler CM, 2006, CNS SPECTRUMS, V11, P312, DOI 10.1017/S1092852900020800; ALLEN JJ, 1993, BIOL PSYCHIAT, V33, P642, DOI 10.1016/0006-3223(93)90104-L; Altshuler L, 2005, AM J PSYCHIAT, V162, P1211, DOI 10.1176/appi.ajp.162.6.1211; Anand A, 2007, J NEUROPSYCH CLIN N, V19, P274, DOI 10.1176/appi.neuropsych.19.3.274; Baldessarini RJ, 2003, JAMA-J AM MED ASSOC, V290, P1517, DOI 10.1001/jama.290.11.1517; Beck AT, 1967, DEPRESSION CAUSES TR; Blackhart GC, 2006, BIOL PSYCHOL, V72, P46, DOI 10.1016/j.biopsycho.2005.06.010; Blumberg HP, 2005, PSYCHOPHARMACOLOGY, V183, P308, DOI 10.1007/s00213-005-0156-7; Bowden CL, 2001, PSYCHIAT SERV, V52, P51, DOI 10.1176/appi.ps.52.1.51; Chen CH, 2006, BIOL PSYCHIAT, V59, P31, DOI 10.1016/j.biopsych.2005.06.008; Chen CH, 2008, NEUROPSYCHOPHARMACOL, V33, P1909, DOI 10.1038/sj.npp.1301593; Davidson RJ, 1999, TRENDS COGN SCI, V3, P11, DOI 10.1016/S1364-6613(98)01265-0; Elliott R, 2004, BIOL PSYCHIAT, V55, P1163, DOI 10.1016/j.biopsych.2004.03.007; Epstein J, 2006, AM J PSYCHIAT, V163, P1784, DOI 10.1176/appi.ajp.163.10.1784; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; Foland LC, 2008, PSYCHIAT RES-NEUROIM, V162, P27, DOI 10.1016/j.pscychresns.2007.04.007; Friston KJ, 2000, NEUROIMAGE, V12, P466, DOI 10.1006/nimg.2000.0630; Friston KJ, 2003, NEUROIMAGE, V19, P1273, DOI 10.1016/S1053-8119(03)00202-7; Ghaemi SN, 2002, CAN J PSYCHIAT, V47, P125, DOI 10.1177/070674370204700202; Goodwin F.J.K., 2007, MANIC DEPRESSIVE ILL, V2nd; Hassel S, 2008, BIPOLAR DISORD, V10, P916, DOI 10.1111/j.1399-5618.2008.00641.x; Haznedar MM, 2005, BIOL PSYCHIAT, V57, P733, DOI 10.1016/j.biopsych.2005.01.002; HENRIQUES JB, 1990, J ABNORM PSYCHOL, V99, P22, DOI 10.1037/0021-843X.99.1.22; Hirschfeld RMA, 2005, AM J MANAG CARE, V11, pS85; Hirschfeld RMA, 2003, J CLIN PSYCHIAT, V64, P161, DOI 10.4088/JCP.v64n0209; Houenou J, 2007, MOL PSYCHIATR, V12, P1001, DOI 10.1038/sj.mp.4002010; Irwin W, 2004, NEUROIMAGE, V21, P674, DOI 10.1016/j.neuroimage.2003.09.057; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Kafantaris V, 2009, J AM ACAD CHILD PSY, V48, P79, DOI 10.1097/CHI.0b013e3181900421; Keedwell PA, 2005, BIOL PSYCHIAT, V58, P495, DOI 10.1016/j.biopsych.2005.04.035; Keener Matthew T, 2007, Curr Psychiatry Rep, V9, P512, DOI 10.1007/s11920-007-0070-2; Kupfer DJ, 2005, JAMA-J AM MED ASSOC, V293, P2528, DOI 10.1001/jama.293.20.2528; Lawrence NS, 2004, BIOL PSYCHIAT, V55, P578, DOI 10.1016/j.biopsych.2003.11.017; Mahon K, 2009, NEUROPSYCHOPHARMACOL, V34, P1590, DOI 10.1038/npp.2008.216; Malhi GS, 2005, BIPOLAR DISORD, V7, P58, DOI 10.1111/j.1399-5618.2005.00255.x; Manning JS, 2003, J CLIN PSYCHIAT, V64, P24; Mechelli A, 2003, J COGNITIVE NEUROSCI, V15, P925, DOI 10.1162/089892903770007317; Murray CJL, 1996, SCIENCE, V274, P740, DOI 10.1126/science.274.5288.740; Nakamura M, 2005, BIOL PSYCHIAT, V58, P468, DOI 10.1016/j.biopsych.2005.04.016; Nestor PG, 2008, NEUROPSYCHOLOGY, V22, P246, DOI 10.1037/0894-4105.22.2.246; Phillips M, 2008, MOL PSYCHIATR, V13, P833, DOI 10.1038/mp.2008.65; Phillips ML, 2007, SCHIZOPHRENIA BULL, V33, P893, DOI 10.1093/schbul/sbm060; Price G, 2008, NEUROIMAGE, V39, P949, DOI 10.1016/j.neuroimage.2007.09.012; Robinson JL, 2008, PSYCHIAT RES-NEUROIM, V164, P106, DOI 10.1016/j.pscychresns.2007.12.004; ROBINSON RG, 1984, BRAIN, V107, P81, DOI 10.1093/brain/107.1.81; Surguladze S, 2005, BIOL PSYCHIAT, V57, P201, DOI 10.1016/j.biopsych.2004.10.028; Surguladze SA, 2003, NEUROIMAGE, V19, P1317, DOI 10.1016/S1053-8119(03)00085-5; Sussmann JE, 2009, BIPOLAR DISORD, V11, P11, DOI 10.1111/j.1399-5618.2008.00646.x; Swann AC, 2006, AM J PSYCHIAT, V163, P177, DOI 10.1176/appi.ajp.163.2.177; Versace A, 2008, ARCH GEN PSYCHIAT, V65, P1041, DOI 10.1001/archpsyc.65.9.1041; Wang F, 2008, BRIT J PSYCHIAT, V193, P126, DOI 10.1192/bjp.bp.107.048793	51	186	197	0	35	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0006-3223	1873-2402		BIOL PSYCHIAT	Biol. Psychiatry	SEP 1	2009	66	5					451	459		10.1016/j.biopsych.2009.03.024			9	Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	488EC	WOS:000269330900007	19450794	Green Accepted			2021-06-18	
J	Belanger, HG; Kretzmer, T; Yoash-Gantz, R; Pickett, T; Tupler, LA				Belanger, Heather G.; Kretzmer, Tracy; Yoash-Gantz, Ruth; Pickett, Treven; Tupler, Larry A.			Cognitive sequelae of blast-related versus other mechanisms of brain trauma	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Blast injury; Traumatic brain injury; Mild TBI; Neuropsychological; Concussion; PTSD	POSTTRAUMATIC-STRESS-DISORDER; OPERATION-IRAQI-FREEDOM; MENTAL-HEALTH PROBLEMS; NEUROPSYCHOLOGICAL OUTCOMES; INJURY; AFGHANISTAN; WAR; VETERANS; NEUROTRAUMA; CONCUSSION	The use of improvised explosive devices has become the hallmark of modern warfare and has resulted in an ever-increasing number of blast-related traumatic brain injuries (TBIs). Despite this fact, very little is actually known about the cognitive sequelae of blast-related TB Is. The purpose of the current study was to compare patterns of performance on neuropsychological measures in subjects who have sustained TBIs as a result of blast (or explosion) with those who have sustained TBIs from non-blast or blunt force trauma (motor vehicle accident, fall, assault, etc.). Participants were categorized as blast-related TBI or non-blast-related TBI and according to severity Of injury (mild or moderate-to-severe). No main effects were observed in analysis of covariance between blast-related TBI participants and non-blast-related TBI participants across any of the neuropsychological variables, although an interaction was observed Oil a visual memory test showing stronger performance for mild blast-related and poorer performance for moderate-to-severe blast-related participants compared with both non-blast groups. Overall, the results do not provide any strong evidence that blast is categorically different from other TBI mechanisms, at least with regard to cognitive sequelae on select measures. Additional findings included a marginally increased incidence of reported posttraumatic stress disorder symptoms among blast-injured participants. (JINS, 2009, 15, 1-8.)	[Belanger, Heather G.] James A Haley Vet Hosp, Psychol Serv, Dept Mental Hlth & Behav Sci, Tampa, FL 33612 USA; [Belanger, Heather G.] Univ S Florida, Dept Psychol, Tampa, FL 33620 USA; [Yoash-Gantz, Ruth] Hefner Vet Affairs Med Ctr, Dept Mental Hlth & Behav Sci, Salisbury, NC USA; [Yoash-Gantz, Ruth] Wake Forest Univ, Bowman Gray Sch Med, Dept Psychiat & Behav Sci, Winston Salem, NC USA; [Pickett, Treven] Virginia Commonwealth Univ, Sch Med, Dept Phys Med & Rehabil, Richmond, VA USA; [Tupler, Larry A.] Durham Vet Affairs Med Ctr, Mental Hlth Serv, Durham, NC USA; [Tupler, Larry A.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC USA	Belanger, HG (corresponding author), James A Haley Vet Hosp, Psychol Serv, Dept Mental Hlth & Behav Sci, 116B 13000 Bruce B Down Blvd, Tampa, FL 33612 USA.	heather.belanger@va.gov					Barnfield TV, 1998, BRAIN INJURY, V12, P951, DOI 10.1080/026990598122007; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Benedict R., 1997, BRIEF VISUOSPATIAL M; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Brewin CR, 2007, J ABNORM PSYCHOL, V116, P448, DOI 10.1037/0021-843X.116.3.448; Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Coupland RM, 1999, BRIT MED J, V319, P407, DOI 10.1136/bmj.319.7207.407; Delis DC, 2000, CALIFORNIA VERBAL LE; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Elsayed NM, 1997, TOXICOLOGY, V121, P1, DOI 10.1016/S0300-483X(97)03651-2; Erbes C, 2007, MIL MED, V172, P359, DOI 10.7205/MILMED.172.4.359; Friedman MJ, 2006, AM J PSYCHIAT, V163, P586, DOI 10.1176/appi.ajp.163.4.586; Glaesser J, 2004, BMC PSYCHIATRY, V4, DOI 10.1186/1471-244X-4-5; Green P, 1996, MANUAL COMPUTERIZED; Green P., 2003, MED SYMPTOM VALIDITY; Greenspan AI, 2006, BRAIN INJURY, V20, P733, DOI 10.1080/02699050600773276; Grieger TA, 2007, MIL MED, V172, P451, DOI 10.7205/MILMED.172.5.451; Heaton R.K., 1991, COMPREHENSIVE NORMS; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Jakupcak M, 2007, J TRAUMA STRESS, V20, P945, DOI 10.1002/jts.20258; Jones C, 2005, J TRAUMA STRESS, V18, P181, DOI 10.1002/jts.20031; KAUR C, 1995, NEUROPATH APPL NEURO, V21, P369, DOI 10.1111/j.1365-2990.1995.tb01073.x; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Keane, 1991, PCL C DSM 4; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; Murray CK, 2005, MIL MED, V170, P516, DOI 10.7205/MILMED.170.6.516; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; REITAN RM, 1985, H REITAN NEUROPSYCHO; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Scott SG, 2005, FEDERAL PRACTITIONER, V22, P67; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; Van Der Kolk Bessel A., 1996, P214; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Warden DL, 1997, J NEUROPSYCH CLIN N, V9, P18; Warden DL, 2005, J NEUROTRAUM, V22, P1178; Wechsler D., 2001, WECHSLER TEST ADULT; Wechsler D, 1997, WAIS 3 ADM SCORING M	48	186	187	0	22	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	2009	15	1					1	8		10.1017/S1355617708090036			8	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	398NR	WOS:000262739300001	19128523				2021-06-18	
J	Yatsiv, I; Grigoriadis, N; Simeonidou, C; Stahel, PF; Schmidt, OI; Alexandrovich, AG; Tsenter, J; Shohami, E				Yatsiv, I; Grigoriadis, N; Simeonidou, C; Stahel, PF; Schmidt, OI; Alexandrovich, AG; Tsenter, J; Shohami, E			Erythropoietin is neuroprotective, improves functional recovery, and reduces neuronal apoptosis and inflammation in a rodent model of experimental closed head injury	FASEB JOURNAL			English	Article						apoptosis; traumatic brain injury; cytokines; therapy	TRAUMATIC BRAIN-INJURY; RECOMBINANT-HUMAN-ERYTHROPOIETIN; PERMANENT CEREBRAL-ISCHEMIA; COGNITIVE FUNCTION; DIALYSIS PATIENTS; NERVOUS-SYSTEM; MOUSE-BRAIN; MICE; RECEPTOR; RATS	Traumatic brain injury (TBI) is a leading cause of morbidity and mortality in young people in industrialized countries. Although various anti-inflammatory and antiapoptotic modalities have shown neuroprotective effects in experimental models of TBI, to date, no specific pharmacological agent aimed at blocking the progression of secondary brain damage has been approved for clinical use. Erythropoietin (Epo) belongs to the cytokine superfamily and has traditionally been viewed as a hematopoiesis-regulating hormone. The newly discovered neuroprotective properties of Epo lead us to investigate its effect in TBI in a mouse model of closed head injury. Recombinant human erythropoietin (rhEpo) was injected at 1 and 24 h after TBI, and the effect on recovery of motor and cognitive functions, tissue inflammation, axonal degeneration, and apoptosis was evaluated up to 14 days. Motor deficits were lower, cognitive function was restored faster, and less apoptotic neurons and caspase-3 expression were found in rhEpo-treated as compared with vehicle-treated animals (P<0.05). Axons at the trauma area in rhEpo-treated mice were relatively well preserved compared with controls (shown by their density; P<0.01). Immunohistochemical analysis revealed a reduced activation of glial cells by staining for GFAP and complement receptor type 3 (CD11b/CD18) in the injured hemisphere of Epo- vs. vehicle-treated animals. We propose that further studies on Epo in TBI should be conducted in order to consider it as a novel therapy for TBI.	Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Med Ctr, Dept Rehabil Med, Jerusalem, Israel; AHEPA Univ Hosp, Dept Neurol, Thessaloniki, Greece; Aritotle Univ, Fac Med, Dept Physiol, Thessaloniki, Greece; Chairte Univ Med Sch, Dept Trauma & Reconstruct Surg, Berlin, Germany	Shohami, E (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel.	esty@cc.huji.ac.il					Adembri C, 2004, J NEUROTRAUM, V21, P1103, DOI 10.1089/0897715041651079; Agnello D, 2002, BRAIN RES, V952, P128, DOI 10.1016/S0006-8993(02)03239-0; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Bernaudin M, 2000, GLIA, V30, P271, DOI 10.1002/(SICI)1098-1136(200005)30:3<271::AID-GLIA6>3.3.CO;2-8; Bernaudin M, 2002, J CEREBR BLOOD F MET, V22, P393, DOI 10.1097/00004647-200204000-00003; Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Buemi M, 2002, CLIN SCI, V103, P275, DOI 10.1042/cs1030275; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Catania MA, 2002, EUR J PHARMACOL, V437, P147, DOI 10.1016/S0014-2999(02)01292-X; Celik M, 2002, P NATL ACAD SCI USA, V99, P2258, DOI 10.1073/pnas.042693799; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Coleman T, 2004, CRIT CARE, V8, P337, DOI 10.1186/cc2897; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; DIGICAYLIOGLU M, 1995, P NATL ACAD SCI USA, V92, P3717, DOI 10.1073/pnas.92.9.3717; Ehrenreich H, 2004, METAB BRAIN DIS, V19, P195, DOI 10.1023/B:MEBR.0000043969.96895.3c; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Erbayraktar Serhat, 2003, Curr Hematol Rep, V2, P465; Genc S, 2004, BRAIN RES, V1000, P19, DOI 10.1016/j.brainres.2003.12.037; Genc S, 2001, NEUROSCI LETT, V298, P139, DOI 10.1016/S0304-3940(00)01716-X; Ghezzi P, 2004, CELL DEATH DIFFER, V11, pS37, DOI 10.1038/sj.cdd.4401450; Gorio A, 2002, P NATL ACAD SCI USA, V99, P9450, DOI 10.1073/pnas.142287899; Juul SE, 1999, PEDIATR RES, V46, P543, DOI 10.1203/00006450-199911000-00009; Juul SE, 1998, PEDIATR RES, V43, P40, DOI 10.1203/00006450-199801000-00007; Juul SE, 2000, CLIN PERINATOL, V27, P527, DOI 10.1016/S0095-5108(05)70037-3; Kumral A, 2004, BEHAV BRAIN RES, V153, P77, DOI 10.1016/j.bbr.2003.11.002; Kumral A, 2003, BIOL NEONATE, V83, P224, DOI 10.1159/000068926; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Litchfield S, 2001, ACTA NEUROPATHOL, V101, P17; Macdougall Iain C, 2003, Curr Hematol Rep, V2, P459; MARSH JT, 1991, KIDNEY INT, V39, P155, DOI 10.1038/ki.1991.20; MASUDA S, 1994, J BIOL CHEM, V269, P19488; Matsushita H, 2003, NEUROREPORT, V14, P1757, DOI 10.1097/00001756-200309150-00020; Mogensen J, 2004, PHARMACOL BIOCHEM BE, V77, P381, DOI 10.1016/j.pbb.2003.11.017; Morishita E, 1997, NEUROSCIENCE, V76, P105, DOI 10.1016/s0306-4522(96)00306-5; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; *NAT CTR INJ PREV, 2001, INJ FACT BOOK 2001 2, P1; Nortje J, 2004, CURR OPIN NEUROL, V17, P711, DOI 10.1097/00019052-200412000-00011; Otto VI, 2001, NEUROREPORT, V12, P2059, DOI 10.1097/00001756-200107030-00053; Pickett JL, 1999, AM J KIDNEY DIS, V33, P1122, DOI 10.1016/S0272-6386(99)70150-2; Prass K, 2003, STROKE, V34, P1981, DOI 10.1161/01.STR.0000080381.76409.B2; Ribatti D, 1999, BLOOD, V93, P2627, DOI 10.1182/blood.V93.8.2627.408k21_2627_2636; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Schmidt OI., 2004, EUR J TRAUMA, V30, P135, DOI [10.1007/s00068-004-1394-9, DOI 10.1007/S00068-004-1394-9]; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Silva M, 1996, BLOOD, V88, P1576, DOI 10.1182/blood.V88.5.1576.1576; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Smith KJ, 2003, CARDIOVASC RES, V59, P538, DOI 10.1016/S0008-6363(03)00468-1; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stahel PF, 2000, J NEUROIMMUNOL, V109, P164, DOI 10.1016/S0165-5728(00)00304-0; TEMPLE RM, 1995, NEPHROL DIAL TRANSPL, V10, P1733; Villa P, 2003, J EXP MED, V198, P971, DOI 10.1084/jem.20021067; Wagner KU, 2000, DEVELOPMENT, V127, P4949; Wojchowski DM, 1999, EXP CELL RES, V253, P143, DOI 10.1006/excr.1999.4673; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; Yu XB, 2002, DEVELOPMENT, V129, P505; 2004, PHARMOS ANNOUNCES RE	60	186	206	1	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2005	19	10					1701	+		10.1096/fj.05-3907fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	963YW	WOS:000231843700015	16099948				2021-06-18	
J	Wang, HE; Peitzman, AB; Cassidy, LD; Adelson, PD; Yealy, DM				Wang, HE; Peitzman, AB; Cassidy, LD; Adelson, PD; Yealy, DM			Out-of-hospital endotracheal intubation and outcome after traumatic brain injury	ANNALS OF EMERGENCY MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the National-Association-of-Emergency-Medical-Services-Physicians	JAN, 2004	Tucson, AZ	Natl Assoc Emergency Med Serv Phys			SEVERE HEAD-INJURY; RAPID-SEQUENCE INTUBATION; EMERGENCY MEDICAL-SERVICES; DISABILITY RATING-SCALE; SEVERITY SCORE TRISS; CLINICAL-TRIAL; SURVIVAL; CARE; CHILDREN; PROBABILITY	Study objective: Previous studies disagree about the effect of out-of-hospital endotracheal intubation on traumatic brain injury. This study compares the effects of out-of-hospital endotracheal intubation versus emergency department (ED) endotracheal intubation on mortality and neurologic and functional outcome after severe traumatic brain injury. Methods: From the 2000 to 2002 Pennsylvania Trauma Outcome Study (a registry of all patients treated at trauma centers in the Commonwealth of Pennsylvania), adult patients with head/neck Abbreviated Injury Scale score of 3 or greater and undergoing out-of-hospital endotracheal intubation or ED endotracheal intubation were included. Transferred patients were excluded. The primary outcome was death (on hospital discharge). The secondary outcomes were neurologic (good versus poor, inferred from discharge to home versus long-term care facility) and functional outcome (determined from a Functional Impairment Score). The key exposure was endotracheal intubation (out-of-hospital endotracheal intubation versus ED endotracheal intubation). Using multivariate logistic regression, odds estimates for out-of-hospital endotracheal intubation were adjusted using age, sex, head/neck Abbreviated Injury Scale score, Injury Severity Score, mechanism of injury (penetrating versus blunt), admission systolic blood pressure, mode of transport (ground only versus helicopter or helicopter + ground), and the use of out-of-hospital neuromuscular blocking agents. A propensity score adjustment accounted for the potential effects of preexisting conditions, inhospital complications, and social factors (drug and alcohol use, race, and insurance coverage). Results: There were 4,098 patients with head/neck Abbreviated Injury Scale score of 3 or greater who received either out-of-hospital endotracheal intubation (n=1,797, 43.9%) or ED endotracheal intubation (n=2,301, 56.1%). Adjusted odds of death were higher for out-of-hospital endotracheal intubation than ED endotracheal intubation (odds ratio [OR] 3.99; 95% confidence interval [CI] 3.21 to 4.93). Out-of-hospital endotracheal intubation was associated with an increased adjusted odds of poor neurologic outcome (OR 1.61; 95% CI 1.15 to 2.26), moderate or severe functional impairment (Functional Impairment Score 6 to 15; OR 1.92; 95% CI 1.40 to 2.64), and severe functional impairment (Functional Impairment Score 11 to 15; OR 1.80; 95% CI 1.29 to 2.52). Conclusion: Out-of-hospital endotracheal intubation was associated with adverse outcomes after severe traumatic brain injury. The implications for current clinical care remain undefined.	Univ Pittsburgh, Sch Med, Dept Emergency Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15213 USA	Wang, HE (corresponding author), Univ Pittsburgh, Sch Med, Dept Emergency Med, 230 McKee Pl,Suite 400, Pittsburgh, PA 15213 USA.		Adelson, David/W-2083-2019		AHRQ HHSUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [1 K08 HSO13628, K08 HS013628] Funding Source: Medline; NINR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01 NR012726] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [K08HS013628] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR012726] Funding Source: NIH RePORTER		Association for the Advancement of Automotive Medicine, 1998, ABBR INJ SCAL 1990; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Becker SO, 2002, STATA J, V2, P358, DOI 10.1177/1536867X0200200403; Biros M H, 2001, Curr Opin Crit Care, V7, P444, DOI 10.1097/00075198-200112000-00012; Blondell RD, 2002, J STUD ALCOHOL, V63, P380, DOI 10.15288/jsa.2002.63.380; Bochicchio GV, 2003, J TRAUMA, V54, P307, DOI 10.1097/01.TA.0000046252.97590.BE; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; *BRAIN TRAUM FDN, 2004, GUID PREH MAN TRAUM; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Cassidy LD, 2003, J PEDIATR SURG, V38, P482, DOI 10.1053/jpsu.2003.50084; Champion HR, 1996, J TRAUMA, V40, P42, DOI 10.1097/00005373-199601000-00009; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Choi SC, 2001, NEUROL RES, V23, P190, DOI 10.1179/016164101101198325; Cone DC, 2000, ACAD EMERG MED, V7, P188, DOI 10.1111/j.1553-2712.2000.tb00526.x; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; Davis EG, 2003, J TRAUMA, V55, P53, DOI 10.1097/01.TA.0000075340.22097.B5; Doran J V, 1995, Prehosp Disaster Med, V10, P259; Dunford JV, 2003, ANN EMERG MED, V42, P721, DOI 10.1016/S0196-0644(03)00660-7; Ferrera PC, 2000, AM J EMERG MED, V18, P575, DOI 10.1053/ajem.2000.9266; Garrison HG, 2002, ANN EMERG MED, V40, P81, DOI 10.1067/mem.2002.124758; Gausche M, 2000, JAMA-J AM MED ASSOC, V283, P783, DOI 10.1001/jama.283.6.783; HANNAN EL, 1995, J TRAUMA, V38, P697, DOI 10.1097/00005373-199505000-00004; Harbrecht BG, 2004, J AM COLL SURGEONS, V198, P232, DOI 10.1016/j.jamcollsurg.2003.10.007; Hosmer D. W., 2000, APPL LOGISTIC REGRES; Hoyt DB, 1998, LANCET, V352, P920, DOI 10.1016/S0140-6736(98)00014-2; Hsiao A K, 1993, Prehosp Disaster Med, V8, P229; Jemmett ME, 2003, ACAD EMERG MED, V10, P961, DOI 10.1197/S1069-6563(03)00315-4; Katz SH, 2001, ANN EMERG MED, V37, P32, DOI 10.1067/mem.2001.112098; Krisanda T J, 1992, Prehosp Disaster Med, V7, P121; Langdorf M I, 2002, Eur J Emerg Med, V9, P115, DOI 10.1097/00063110-200206000-00003; Marcin JP, 2003, AM J PUBLIC HEALTH, V93, P461, DOI 10.2105/AJPH.93.3.461; McCauley SR, 2001, J INT NEUROPSYCH SOC, V7, P457, DOI 10.1017/S1355617701744025; McDonald C C, 1998, Prehosp Emerg Care, V2, P29, DOI 10.1080/10903129808958836; MORRIS JA, 1990, J TRAUMA, V30, P1476, DOI 10.1097/00005373-199012000-00006; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Murray JA, 2000, J TRAUMA, V49, P1065, DOI 10.1097/00005373-200012000-00015; Ochs M, 2002, ANN EMERG MED, V40, P159, DOI 10.1067/mem.2002.126397; Page RB, 2004, NEUROSURGERY, V54, P143, DOI 10.1227/01.NEU.0000097514.60813.1B; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Potoka DA, 2001, J TRAUMA, V51, P824, DOI 10.1097/00005373-200111000-00002; Previdi J K, 1996, Prehosp Disaster Med, V11, P27; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Reilly PM, 2003, ANN SURG, V238, P596, DOI 10.1097/01.sla.0000090448.499779.f3; Rutledge R, 1998, J TRAUMA, V44, P41, DOI 10.1097/00005373-199801000-00003; Rutledge R, 1996, J TRAUMA, V40, P944, DOI 10.1097/00005373-199606000-00013; Schall LC, 2002, J TRAUMA, V52, P235, DOI 10.1097/00005373-200202000-00006; WALLS RM, 1993, ANN EMERG MED, V22, P1008, DOI 10.1016/S0196-0644(05)82743-X; Wang HE, 2003, RESUSCITATION, V58, P49, DOI 10.1016/S0300-9572(03)00058-3; Wang HE, 2003, ACAD EMERG MED, V10, P717, DOI 10.1111/j.1553-2712.2003.tb00065.x; Winchell RJ, 1997, ARCH SURG-CHICAGO, V132, P592; Zink BJ, 2001, ANN EMERG MED, V37, P318, DOI 10.1067/mem.2001.113505	52	186	189	1	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644	1097-6760		ANN EMERG MED	Ann. Emerg. Med.	NOV	2004	44	5					439	450		10.1016/j.annemergmed.2004.04.008			12	Emergency Medicine	Emergency Medicine	866JC	WOS:000224768800001	15520702				2021-06-18	
J	Milders, M; Fuchs, S; Crawford, JR				Milders, M; Fuchs, S; Crawford, JR			Neuropsychological impairments and changes in emotional and social behaviour following severe traumatic brain injury	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD INJURY; PSYCHOSOCIAL ADJUSTMENT; SEQUELAE; MIND; PERSONALITY; CHILDREN; VALIDITY; EMPATHY; TBI	Changes in emotional and social behaviour are relatively common following severe traumatic brain injury (TBI). Despite the serious consequences of these changes, little is known about the underlying neuropsychological. deficits. In this study, we investigated which deficits might underlie these behavioural changes. The emotional and social behaviour of 17 patients with severe TBI was assessed with questionnaires, completed by the patient and a relative. Neuropsychological tests assessed recognition of emotional expressions, understanding of other people's mental states and cognitive fluency. Ratings from patients and relatives revealed changes in emotional and social behaviour after injury. Compared to matched healthy controls, the patients were impaired at recognising facial and vocal expressions of emotions, detecting social faux pas and nonverbal fluency. None of these impairments was significantly associated with the relatives' ratings of behavioural problems following TBI, although the correlation with detecting social faux pas was relatively high (r = -.61).	Univ Aberdeen, Dept Psychol, Aberdeen AB24 2UB, Scotland	Milders, M (corresponding author), Univ Aberdeen, Dept Psychol, Aberdeen AB24 2UB, Scotland.		Milders, Maarten/C-5560-2008; Crawford, John R/A-4165-2008	Crawford, John R/0000-0003-3403-3428			BARONCOHEN S, 1986, BRIT J DEV PSYCHOL, V4, P113, DOI 10.1111/j.2044-835X.1986.tb01003.x; BaronCohen S, 1997, J CHILD PSYCHOL PSYC, V38, P813, DOI 10.1111/j.1469-7610.1997.tb01599.x; BARONCOHEN S, 1999, UNDERSTANDING OTHER; Benton A. L., 1983, FACIAL RECOGNITION S; Blair RJR, 2000, BRAIN, V123, P1122, DOI 10.1093/brain/123.6.1122; Bowers D, 1998, FLORIDA AFFECT BATTE; Bowman ML, 1996, CLIN NEUROPSYCHOL, V10, P382, DOI 10.1080/13854049608406699; Braun C M, 1989, Brain Inj, V3, P5, DOI 10.3109/02699058909008068; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Cicerone KD, 1997, ARCH CLIN NEUROPSYCH, V12, P173, DOI 10.1016/S0887-6177(96)00022-4; Corrigan PW, 1997, PSYCHIATRY, V60, P309, DOI 10.1080/00332747.1997.11024809; Crawford JR, 1995, J INT NEUROPSYCH SOC, V1, P321; Ekman P., 1976, PICTURES FACIAL AFFE; Eslinger PJ, 1998, EUR NEUROL, V39, P193, DOI 10.1159/000007933; Freeman J, 2001, BRIT J CLIN PSYCHOL, V40, P221, DOI 10.1348/014466501163562; GETZELS JW, 1961, CREATIVITY INTELLIGE; Grattan LM, 1989, NEUROPSYCHOLOGY, V3, P175, DOI 10.1037//0894-4105.3.3.175; Happe F, 2001, NEUROPSYCHOLOGIA, V39, P83, DOI 10.1016/S0028-3932(00)00093-2; Happe F, 1999, COGNITION, V70, P211, DOI 10.1016/S0010-0277(99)00005-0; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; JACKSON H F, 1992, Brain Injury, V6, P109, DOI 10.3109/02699059209029650; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; Kendall E, 1996, NEUROPSYCHOL REHABIL, V6, P101, DOI 10.1080/713755502; KINSELLA G, 1991, J NEUROL NEUROSUR PS, V54, P422, DOI 10.1136/jnnp.54.5.422; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; LEVIN HS, 1995, J NEUROTRAUM, V12, P601, DOI 10.1089/neu.1995.12.601; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LISHMAN WA, 1973, PSYCHOL MED, V3, P304, DOI 10.1017/S003329170004959X; MALIA K, 1995, BRAIN INJURY, V9, P697, DOI 10.3109/02699059509008226; Mathias JL, 1999, J CLIN EXP NEUROPSYC, V21, P200, DOI 10.1076/jcen.21.2.200.930; MEHRABIAN A, 1972, J PERS, V40, P525, DOI 10.1111/j.1467-6494.1972.tb00078.x; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; MOSS AR, 1991, BRIT J CLIN PSYCHOL, V30, P179, DOI 10.1111/j.2044-8260.1991.tb00934.x; Nelson LD, 1998, ARCH CLIN NEUROPSYCH, V13, P549, DOI 10.1016/S0887-6177(97)00052-8; PETTERSEN L, 1991, PERCEPT MOTOR SKILL, V73, P1139, DOI 10.2466/pms.1991.73.3f.1139; PRIGATANO GP, 1992, J CONSULT CLIN PSYCH, V60, P360, DOI 10.1037/0022-006X.60.3.360; REGARD M, 1982, PERCEPT MOTOR SKILL, V55, P839, DOI 10.2466/pms.1982.55.3.839; RUFF RM, 1996, RFFT RUFF FIGURAL TE; Stone VE, 1998, J COGNITIVE NEUROSCI, V10, P640, DOI 10.1162/089892998562942; Tate RL, 1999, CORTEX, V35, P39, DOI 10.1016/S0010-9452(08)70784-6; Tate RL, 1999, PSYCHOL MED, V29, P713, DOI 10.1017/S0033291799008466; VILLKI J, 1994, J CLIN EXPT NEUROPSY, V16, P325; Watt KJ, 1999, J NEUROL NEUROSUR PS, V66, P474, DOI 10.1136/jnnp.66.4.474; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Wilson, 1991, NATL ADULT READING T	46	186	188	1	47	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	APR	2003	25	2					157	172		10.1076/jcen.25.2.157.13642			16	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	670ER	WOS:000182394900001	12754675				2021-06-18	
J	Chang, BS; Lowenstein, DH				Chang, BS; Lowenstein, DH			Practice parameter: Antiepileptic drug prophylaxis in severe traumatic brain injury - Report of the Quality Standards Subcommittee of the American Academy of Neurology	NEUROLOGY			English	Article							PROPHYLACTICALLY ADMINISTERED PHENYTOIN; POSTTRAUMATIC EPILEPSY; HEAD-INJURY; RANDOMIZED TRIAL; FOLLOW-UP; SEIZURES; PREVENTION; FAILURE; DEPARTMENTS; VALPROATE	Objective: To review the evidence regarding antiepileptic drug (AED) prophylaxis in patients with severe traumatic brain injury (TBI) in order to make practice recommendations. Methods: The authors identified relevant studies by searching multiple databases and reviewing reference lists of other sources. They included studies that prospectively compared post-traumatic seizure rates in patients given AED prophylaxis vs controls. Each study was graded (class I to IV) according to a standard classification-of-evidence scheme and results were analyzed and pooled. Results: Pooled class I studies demonstrated a significantly lower risk of early post-traumatic seizures (those occurring within 7 days after injury) in patients given phenytoin prophylaxis compared to controls (relative risk 0.37, 95% CI 0.18 to 0.74). Pooled class I and class II studies demonstrated no significant difference in the risk of late post-traumatic seizures (those occurring beyond 7 days after injury) in patients given AED prophylaxis compared to controls (relative risk 1.05, 95% CI 0.82 to 1.35). Serum AED levels were suboptimal in these studies and adverse effects were mild but frequent. Conclusions: For adult patients with severe TBI, prophylaxis with phenytoin is effective in decreasing the risk of early post-traumatic seizures. AED prophylaxis is probably not effective in decreasing the risk of late post-traumatic seizures. Further studies addressing milder forms of TBI, the use of newer AEDs, the utility of EEG, and the applicability of these findings to children are recommended.	Beth Israel Deaconess Med Ctr, Dept Neurol, Comprehens Epilepsy Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA	Chang, BS (corresponding author), Amer Acad Neurol, 1080 Montreal Ave, St Paul, MN 55116 USA.						Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Dauch WA, 1996, ZBL NEUROCHIR, V57, P190; Dikmen SS, 2000, NEUROLOGY, V54, P895, DOI 10.1212/WNL.54.4.895; DIKMEN SS, 1991, JAMA-J AM MED ASSOC, V265, P1271, DOI 10.1001/jama.265.10.1271; GLOTZNER FL, 1983, NEUROCHIRURGIA, V26, P66; GOLDSTEIN LB, 1995, J NEUROL NEUROSUR PS, V58, P753, DOI 10.1136/jnnp.58.6.753; Haltiner AM, 1999, J NEUROSURG, V91, P588, DOI 10.3171/jns.1999.91.4.0588; HAUSER WA, 1990, NEW ENGL J MED, V323, P540, DOI 10.1056/NEJM199008233230809; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Jennett B, 1975, EPILEPSY NONMISSILE; LEPPIK IE, 1988, EPILEPSIA S2, V29, P79; MANAKA S, 1992, JPN J PSYCHIAT NEUR, V46, P311; MCQUEEN JK, 1983, J NEUROL NEUROSUR PS, V46, P899, DOI 10.1136/jnnp.46.10.899; PECHADRE JC, 1991, PRESSE MED, V20, P841; Petitti DB, 1994, METAANALYSIS DECISIO, P90; RAPPORT RL, 1973, J NEUROSURG, V38, P159, DOI 10.3171/jns.1973.38.2.0159; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; SCHMUTZ M, 1988, J NEURAL TRANSM, V72, P245, DOI 10.1007/BF01243423; SERVIT Z, 1981, EPILEPSIA, V22, P315, DOI 10.1111/j.1528-1157.1981.tb04115.x; SILVER JM, 1991, ANN NEUROL, V29, P356, DOI 10.1002/ana.410290404; Soroker N, 1989, Brain Inj, V3, P137, DOI 10.3109/02699058909004544; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; Temkin NRHM, 1996, NEUROLOGICAL SURG, P1834; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Yablon SA, 1998, ARCH PHYS MED REHAB, V79, P594; YOUNG B, 1983, J NEUROSURG, V58, P236, DOI 10.3171/jns.1983.58.2.0236; YOUNG B, 1983, J NEUROSURG, V58, P231, DOI 10.3171/jns.1983.58.2.0231; YOUNG B, 1983, CHILD BRAIN, V10, P185; 2000, J NEUROTRAUMA, V17, P549; 2001, J TRAUMA S, V51, pS41	32	186	195	1	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	JAN 14	2003	60	1					10	16		10.1212/01.WNL.0000031432.05543.14			7	Clinical Neurology	Neurosciences & Neurology	633ZU	WOS:000180316000004	12525711	Bronze			2021-06-18	
J	Starkov, AA; Polster, BM; Fiskum, G				Starkov, AA; Polster, BM; Fiskum, G			Regulation of hydrogen peroxide production by brain mitochondria by calcium and Bax	JOURNAL OF NEUROCHEMISTRY			English	Article						apoptosis; BH3 domain; cytochrome c; membrane potential; respiration; superoxide	PERMEABILITY TRANSITION PORE; CYTOCHROME-C; OXIDATIVE-PHOSPHORYLATION; CELL-DEATH; MEMBRANE-PERMEABILITY; CEREBRAL-ISCHEMIA; RESPIRATORY-CHAIN; INDUCED RELEASE; STEADY-STATE; RAT-BRAIN	Abnormal accumulation of Ca2+ and exposure to pro-apoptotic proteins, such as Bax, is believed to stimulate mitochondrial generation of reactive oxygen species (ROS) and contribute to neural cell death during acute ischemic and traumatic brain injury, and in neurodegenerative diseases, e.g. Parkinson's disease. However, the mechanism by which Ca2+ or apoptotic proteins stimulate mitochondrial ROS production is unclear. We used a sensitive fluorescent probe to compare the effects of Ca2+ on H-2 O-2 emission by isolated rat brain mitochondria in the presence of physiological concentrations of ATP and Mg2+ and different respiratory substrates. In the absence of respiratory chain inhibitors, Ca2+ suppressed H-2 O-2 generation and reduced the membrane potential of mitochondria oxidizing succinate, or glutamate plus malate. In the presence of the respiratory chain Complex I inhibitor rotenone, accumulation of Ca2+ stimulated H-2 O-2 production by mitochondria oxidizing succinate, and this stimulation was associated with release of mitochondrial cytochrome c . In the presence of glutamate plus malate, or succinate, cytochrome c release and H-2 O-2 formation were stimulated by human recombinant full-length Bax in the presence of a BH3 cell death domain peptide. These results indicate that in the presence of ATP and Mg2+ , Ca2+ accumulation either inhibits or stimulates mitochondrial H-2 O-2 production, depending on the respiratory substrate and the effect of Ca2+ on the mitochondrial membrane potential. Bax plus a BH3 domain peptide stimulate H-2 O-2 production by brain mitochondria due to release of cytochrome c and this stimulation is insensitive to changes in membrane potential.	Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA	Fiskum, G (corresponding author), Univ Maryland, Sch Med, Dept Anesthesiol, 685 W Baltimore St,MSTF-5-34, Baltimore, MD 21201 USA.	gfisk001@umaryland.edu	Starkov, Anatoly/B-2688-2012	Starkov, Anatoly/0000-0002-1334-4828; Polster, Brian/0000-0003-2571-7510	NIEHS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [ES 11838] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 34152] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [R21ES011838] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS034152] Funding Source: NIH RePORTER		Andreyev A, 1999, CELL DEATH DIFFER, V6, P825, DOI 10.1038/sj.cdd.4400565; Andreyev AY, 1998, FEBS LETT, V439, P373, DOI 10.1016/S0014-5793(98)01394-5; Atlante A, 2000, J BIOL CHEM, V275, P37159, DOI 10.1074/jbc.M002361200; BENZI G, 1982, J NEUROSCI RES, V7, P193, DOI 10.1002/jnr.490070210; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; De Giorgi F, 2002, FASEB J, V16, P607, DOI 10.1096/fj.01-0269fje; DYKENS JA, 1994, J NEUROCHEM, V63, P584; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Fiskum G, 2001, J NEUROCHEM, V77, P30; Fiskum G, 1999, J CEREBR BLOOD F MET, V19, P351, DOI 10.1097/00004647-199904000-00001; HACKENBR.CR, 1968, P NATL ACAD SCI USA, V61, P598, DOI 10.1073/pnas.61.2.598; HACKENBROCK CR, 1966, J CELL BIOL, V30, P269, DOI 10.1083/jcb.30.2.269; Hansford RG, 1997, J BIOENERG BIOMEMBR, V29, P89, DOI 10.1023/A:1022420007908; HINKLE PC, 1967, J BIOL CHEM, V242, P5169; KAMO N, 1979, J MEMBRANE BIOL, V49, P105, DOI 10.1007/BF01868720; Korshunov SS, 1997, FEBS LETT, V416, P15, DOI 10.1016/S0014-5793(97)01159-9; Korshunov SS, 1999, FEBS LETT, V462, P192, DOI 10.1016/S0014-5793(99)01525-2; Kowaltowski AJ, 1998, ARCH BIOCHEM BIOPHYS, V359, P77, DOI 10.1006/abbi.1998.0870; Kowaltowski AJ, 1998, J BIOL CHEM, V273, P12766, DOI 10.1074/jbc.273.21.12766; KOWALTOWSKI AJ, 1995, AM J PHYSIOL-CELL PH, V269, pC141; Kowaltowski AJ, 1996, FEBS LETT, V378, P150, DOI 10.1016/0014-5793(95)01449-7; Lass A, 1998, FREE RADICAL BIO MED, V25, P1089, DOI 10.1016/S0891-5849(98)00144-0; Liu YB, 2002, J NEUROCHEM, V80, P780, DOI 10.1046/j.0022-3042.2002.00744.x; Maciel EN, 2001, J NEUROCHEM, V79, P1237, DOI 10.1046/j.1471-4159.2001.00670.x; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; Murphy AN, 1999, J CEREBR BLOOD F MET, V19, P231, DOI 10.1097/00004647-199903000-00001; Nicholls DG, 2000, PHYSIOL REV, V80, P315; Plesnila N, 2001, P NATL ACAD SCI USA, V98, P15318, DOI 10.1073/pnas.261323298; Polster BM, 2001, J BIOL CHEM, V276, P37887; ROLFE DFS, 1994, BBA-BIOENERGETICS, V1188, P405, DOI 10.1016/0005-2728(94)90062-0; ROTTENBERG H, 1984, J MEMBRANE BIOL, V81, P127, DOI 10.1007/BF01868977; SCIAMANNA MA, 1992, BIOCHIM BIOPHYS ACTA, V1134, P223, DOI 10.1016/0167-4889(92)90180-J; SIMS NR, 1990, J NEUROCHEM, V55, P698, DOI 10.1111/j.1471-4159.1990.tb04189.x; Turrens JF, 1997, BIOSCIENCE REP, V17, P3, DOI 10.1023/A:1027374931887; Vila M, 2001, P NATL ACAD SCI USA, V98, P2837, DOI 10.1073/pnas.051633998; VILLALOBO A, 1980, J BIOL CHEM, V255, P2457; Votyakova TV, 2001, J NEUROCHEM, V79, P266, DOI 10.1046/j.1471-4159.2001.00548.x; Zhou MJ, 1997, ANAL BIOCHEM, V253, P162, DOI 10.1006/abio.1997.2391	38	186	189	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	OCT	2002	83	1					220	228		10.1046/j.1471-4159.2002.01153.x			9	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	595DB	WOS:000178090600024	12358746	Bronze			2021-06-18	
J	Meythaler, JM; Brunner, RC; Johnson, A; Novack, TA				Meythaler, JM; Brunner, RC; Johnson, A; Novack, TA			Amantadine to improve neurorecovery in traumatic brain injury-associated diffuse axonal injury: A pilot double-blind randomized trial	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						amantadine; diffuse axonal injury	NEUROLEPTIC MALIGNANT SYNDROME; UNITED-STATES; HEAD-INJURY; HALOPERIDOL; EXPERIENCE; DEMENTIA; RECOVERY; EFFICACY; THERAPY; NEURONS	Background. Traumatic brain injury (TBI) caused by a high-speed transportation accident results in a mechanism of injury commonly described as diffuse axonal injury (DAI), which is associated with a reduction in dopamine turnover in the brain. Because of its affect on both dopamine and N-methyl-D-aspartate (NMDA) channels, amantadine has been the subject of considerable interest and clinical use in acute TBI. Participants: In this study, 35 subjects, who had a TBI in a transportation accident and were initially seen with a Glasgow Coma Scale score of 10 or less within the first 24 hours after admission, were randomly assigned to a double-blind, placebo-controlled, crossover design trial. Main Outcome Measures: Amantadine, 200 mg, or placebo was each administered for 6 weeks (12 weeks total) to patients who were recruited consecutively. Results: There was an improvement in the Mini-Mental Status (MMSE) scores of 14.3 points (P=.0185), Disability Rating Scale (DRS) score of 9.8 points (P=.0022), Glasgow Outcome Scale (GOS) score of 0.8 points (P=.0077), and in the FIM Cognitive score (FIM-cog)(TM) of 15.1 points (P=.0033) in the group that received amantadine during the first 6 weeks (group 1), but there was no improvement in the second 6 weeks on placebo (P>.05). In group 2 (active drug second 6 weeks), there was an improvement in the MMSE of 10.5 points, in the DRS of 9.4 points (P=.0006), in the GOS of 0.5 points (P=.0231), and in the FIM-cog of 11.3 points (P=.0030, Wdcoxon signed rank) spontaneously in the first 6 weeks on placebo (P=.0015). However, group 2 gained a statistically significant additional 6.3 points of recovery in the MMSE (P=.0409), 3.8 points in the DRS (P=.0099), 0.5 points in the GOS (P=.4008), and 5.2 points in the FIM-cog (P=.0173, Wilcoxon signed rank) between the sixth week and the twelfth week of treatment on the active drug. Conclusions: There was a consistent trend toward a more rapid functional improvement regardless of when a patient with DAI-associated TBI was started on amantadine in the first 3 months after injury.	Univ Alabama Birmingham, Sch Med, Dept Phys Med & Rehabil, Spain Rehab, Birmingham, AL 35249 USA	Meythaler, JM (corresponding author), Univ Alabama Birmingham, Sch Med, Dept Phys Med & Rehabil, Spain Rehab, 619 6th Ave S, Birmingham, AL 35249 USA.	Jmeythal@uab.edu					AOKI FY, 1985, CLIN PHARMACOL THER, V37, P128, DOI 10.1038/clpt.1985.24; AOKI FY, 1988, CLIN PHARMACOKINET, V14, P35, DOI 10.2165/00003088-198814010-00003; AZMITIA EC, 1990, ANN NY ACAD SCI, V600, P343, DOI 10.1111/j.1749-6632.1990.tb16894.x; BAKAY RAE, 1986, NEUROSURGERY, V18, P234, DOI 10.1227/00006123-198602000-00023; BENNETT M, 1995, IRISH MED J, V88, P59; BROWN CS, 1986, PHARMACOTHERAPY, V6, P193; BULLOCK J, 2000, J NEUROTRAUM, V17, P451; Busch AE, 1998, MOL PHARMACOL, V54, P342; CARDENAS DD, 1992, PHYS MED REH CLIN N, V3, P273; CARUS J, 1993, HEAD INJURY; *CDC NAT CTR INJ P, 1996, UNPUB DAT MULT CAUS; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P8; Chandler M C, 1988, Brain Inj, V2, P309; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; CRUM RM, 1993, JAMA-J AM MED ASSOC, V269, P2386, DOI 10.1001/jama.269.18.2386; Diaz-Marchan P.G., 1996, NEUROTRAUMA, P137; DRAKE ME, 1991, ACTA NEUROL BELG, V91, P159; EVANS RW, 1987, J NERV MENT DIS, V175, P106, DOI 10.1097/00005053-198702000-00007; FEARNSIDE MR, 1997, HEAD INJURY, P8; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Frankowski RF, 1985, CENTRAL NERVOUS SYST, P33; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GIANUTSOS G, 1985, EUR J PHARMACOL, V110, P357, DOI 10.1016/0014-2999(85)90564-3; GILMAN AG, 1980, PHARMACOL BASIS THER, P71; GILMAN AG, 1989, PHARMACOL BASIS THER, P472; GOLDSTEIN LB, 1991, J NEUROL REHABIL, V5, P129; GUALTIERI T, 1989, CLIN NEUROPHARMACOL, V12, P258, DOI 10.1097/00002826-198908000-00003; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; HAIG AJ, 1990, ARCH PHYS MED REHAB, V71, P1081; HAMBURG P, 1986, COMPR PSYCHIAT, V27, P272, DOI 10.1016/0010-440X(86)90002-7; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; Hannay HJ, 1996, J HEAD TRAUMA REHAB, V11, P41, DOI 10.1097/00001199-199612000-00007; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; Heinemann AW, 1991, RATING SCALE ANAL FU; HORIGUCHI J, 1990, CLIN NEUROPHARMACOL, V13, P84, DOI 10.1097/00002826-199002000-00009; Horn J, 2000, PHYSICAL MED REHABIL, P1281; JACK RA, 1984, ARCH GEN PSYCHIAT, V41, P726; Karli DC, 1999, BRAIN INJURY, V13, P63, DOI 10.1080/026990599121908; LAUDER JM, 1990, ANN NY ACAD SCI, V600, P297, DOI 10.1111/j.1749-6632.1990.tb16891.x; Lehmkuhl L, 1993, J HEAD TRAUMA REHAB, V8, P88; LIPPER S, 1976, J NERV MENT DIS, V162, P366, DOI 10.1097/00005053-197605000-00008; MACCHIO GJ, 1993, ARCH PHYS MED REHAB, V74, P1119, DOI 10.1016/0003-9993(93)90072-I; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; McLean A. J., 1997, HEAD INJURY, P25; MCLELLAN DR, 1990, PHYSICAL MED REHABIL, V4, P389; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; *MMWR, 1987, JAMA-J AM MED ASSOC, V258, P599; MOONEY GF, 1993, ARCH PHYS MED REHAB, V74, P153; MUIR KW, 1995, STROKE, V26, P503, DOI 10.1161/01.STR.26.3.503; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Povlishock JT, 1996, TRAUMATIC BRAIN INJU, P51; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; RAPPAPORT M, 1992, ARCH PHYS MED REHAB, V73, P628; Ruther E, 2000, PHARMACOPSYCHIATRY, V33, P103, DOI 10.1055/s-2000-341; SANDEL ME, 1993, AM J PHYS MED REHAB, V72, P325, DOI 10.1097/00002060-199310000-00013; SARTORI M, 1984, AM J MED, V77, P388, DOI 10.1016/0002-9343(84)90728-9; Schneider WN, 1999, BRAIN INJURY, V13, P863; SCHWAB RS, 1972, J AMER MED ASSOC, V222, P792, DOI 10.1001/jama.222.7.792; SCOTT DE, 1995, EXP NEUROL, V131, P23, DOI 10.1016/0014-4886(95)90004-7; SHAHAR EM, 1992, J PEDIATR-US, V121, P819, DOI 10.1016/S0022-3476(05)81922-5; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; SYMMETREL, 2001, PHYSICIANS DESK REFE, P1213; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Thurman DJ., 1995, GUIDELINES SURVEILLA; TOIDE K, 1990, PHARMACEUT RES, V7, P670, DOI 10.1023/A:1015890800131; VANWOERKOM TCAM, 1977, LANCET, V1, P812; Vasconcellos J, 1978, JAMA-J AM MED ASSOC, V240, P380; WHITAKERAZMITIA PM, 1990, ANN NY ACAD SCI, V600, P315, DOI 10.1111/j.1749-6632.1990.tb16892.x; WHITAKERAZMITIA PM, 1992, CURRENT CONCEPTS; Whyte J, 1998, REHABILITATION MED P, P1191; Wilkinson R, 1999, BRAIN INJURY, V13, P1025; Winblad B, 1999, INT J GERIATR PSYCH, V14, P135, DOI 10.1002/(SICI)1099-1166(199902)14:2<135::AID-GPS906>3.0.CO;2-0; Zafonte RD, 2000, J HEAD TRAUMA REHAB, V15, P1179, DOI 10.1097/00001199-200010000-00014; Zafonte RD, 2001, J HEAD TRAUMA REHAB, V16, P112, DOI 10.1097/00001199-200102000-00014	77	186	194	0	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	AUG	2002	17	4					300	313		10.1097/00001199-200208000-00004			14	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	578UY	WOS:000177140200004	12105999				2021-06-18	
J	Verweij, BH; Muizelaar, JP; Vinas, FC; Peterson, PL; Xiong, Y; Lee, CP				Verweij, BH; Muizelaar, JP; Vinas, FC; Peterson, PL; Xiong, Y; Lee, CP			Impaired cerebral mitochondrial function after traumatic brain injury in humans	JOURNAL OF NEUROSURGERY			English	Article						cerebral energy metabolism; cerebral mitochondria; oxidative phosphorylation; cerebral blood flow; traumatic brain injury; cerebral ischemia	SEVERE HEAD-INJURY; BLOOD-FLOW; OXYGEN-SATURATION; COMATOSE PATIENTS; METABOLISM; ISCHEMIA; DYSFUNCTION; CALCIUM; PATHOPHYSIOLOGY; CIRCULATION	Object. Oxygen supply to the brain is often insufficient after traumatic brain injury (TBI), and this results in decreased energy production (adenosine triphosphate [ATP]) with consequent neuronal cell death. It is obviously important to restore oxygen delivery after TBI; however, increasing oxygen delivery alone may not improve ATP production if the patient's mitochondria (the source of ATP) are impaired. Traumatic brain injury has been shown to impair mitochondrial function in animals; however, no human studies have been previously reported. Methods. Using tissue fractionation procedures, living mitochondria derived from therapeutically removed brain tissue were analyzed in 16 patients with head injury (Glasgow Coma Scale Scores 3-14) and two patients without head injury. Results revealed that in head-injured patients mitochondrial function was impaired, with subsequent decreased ATP production. Conclusions. Decreased oxygen metabolism due to mitochondrial dysfunction must be taken into account when clinically defining ischemia and interpreting oxygen measurements such as jugular venous oxygen saturation, arteriovenous difference in oxygen content, direct tissue oxygen tension, and cerebral blood oxygen content determined using near-infrared spectroscopy. Restoring mitochondrial function might be as important as maintaining oxygen delivery.	Univ Calif Davis, Med Ctr, Dept Neurosurg, Sacramento, CA 95817 USA; Wayne State Univ, Dept Neurosurg, Detroit, MI USA; Wayne State Univ, Dept Neurol, Detroit, MI USA; Wayne State Univ, Dept Biochem & Mol Biol, Detroit, MI USA	Muizelaar, JP (corresponding author), Univ Calif Davis, Med Ctr, Dept Neurosurg, 4860 Y St,Room 3740, Sacramento, CA 95817 USA.	J.Paul.Muizelaar@UCDMC.ucdavis.edu		Xiong, Ye/0000-0001-9770-6031			ASTRUP J, 1982, J NEUROSURG, V56, P482, DOI 10.3171/jns.1982.56.4.0482; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Berman RF, 2000, J NEUROSURG, V93, P821, DOI 10.3171/jns.2000.93.5.0821; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BRODERSEN P, 1974, J NEUROL NEUROSUR PS, V37, P384, DOI 10.1136/jnnp.37.4.384; Cormio M, 1999, J NEUROSURG, V90, P9, DOI 10.3171/jns.1999.90.1.0009; CRUZ J, 1993, J NEUROSURG, V78, P522; DESALLES AAF, 1987, NEUROSURGERY, V21, P45, DOI 10.1227/00006123-198707000-00009; ERECINSKA M, 1994, PROG NEUROBIOL, V43, P37, DOI 10.1016/0301-0082(94)90015-9; ERNSTER L, 1993, ACTIVE OXYGENS, LIPID PEROXIDES, AND ANTIOXIDANTS, P1; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Kiening KL, 1996, J NEUROSURG, V85, P751, DOI 10.3171/jns.1996.85.5.0751; Lee C. P., 1993, V2, P41; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; MUIZELAAR JP, 1993, J NEUROSURG, V78, P523; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Rappaport Z H, 1981, Prog Neurol Surg, V10, P1, DOI 10.1159/000384765; ROBERTSON CS, 1989, J NEUROSURG, V70, P222, DOI 10.3171/jns.1989.70.2.0222; SHALIT MN, 1972, NEUROLOGY, V22, P155, DOI 10.1212/WNL.22.2.155; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P145, DOI 10.1136/jnnp.58.2.145; SIESJO BK, 1992, J NEUROSURG, V77, P337, DOI 10.3171/jns.1992.77.3.0337; SIESJO BK, 1984, J NEUROSURG, V60, P883, DOI 10.3171/jns.1984.60.5.0883; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; TABADDOR K, 1972, J TRAUMA, V12, P1053, DOI 10.1097/00005373-197212000-00006; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Verweij BH, 2000, J NEUROSURG, V93, P829, DOI 10.3171/jns.2000.93.5.0829; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Vinas FC, 1998, CRIT REV NEUROSURG, V8, P31, DOI 10.1007/s003290050058; Xiong Y, 1997, J NEUROTRAUM, V14, P907, DOI 10.1089/neu.1997.14.907; Xiong Y, 1998, J NEUROTRAUM, V15, P531, DOI 10.1089/neu.1998.15.531; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23	34	186	188	0	6	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	NOV	2000	93	5					815	820		10.3171/jns.2000.93.5.0815			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	366YL	WOS:000090033800013	11059663				2021-06-18	
J	Sattler, R; Xiong, ZG; Lu, WY; MacDonald, JF; Tymianski, M				Sattler, R; Xiong, ZG; Lu, WY; MacDonald, JF; Tymianski, M			Distinct roles of synaptic and extrasynaptic NMDA receptors in excitotoxicity	JOURNAL OF NEUROSCIENCE			English	Article						NMDA receptors; actin filament; latrunculin A; cytochalasin D; excitotoxicity; oxygen glucose deprivation; cortical neurons	NITRIC-OXIDE SYNTHASE; CORTICAL CELL-CULTURE; DISRUPT MICROFILAMENT ORGANIZATION; CEREBELLAR GRANULE CELLS; DENSITY PROTEIN PSD-95; TRAUMATIC BRAIN INJURY; EXCITATORY AMINO-ACIDS; D-ASPARTATE RECEPTORS; HIPPOCAMPAL-NEURONS; DENDRITIC SPINES	Excitatory synaptic activity governs excitotoxicity and modulates the distribution of NMDA receptors (NMDARs) among synaptic and extrasynaptic sites of central neurons. We investigated whether NMDAR localization was functionally linked to excitotoxicity by perturbing F-actin, a cytoskeletal protein that participates in targeting synaptic NMDARs in dendritic spines. Depolymerizing F-actin did not affect NMDA-evoked whole-cell currents. However, the number of dendritic NMDAR clusters and the NMDAR-mediated component of miniature spontaneous EPSCs were reduced, whereas the number of AMPA receptor clusters and AMPA receptor-mediated component of EPSCs was unchanged. This selective perturbation of synaptically activated NMDARs had no effect on neuronal death or the accumulation of Ca-45(2+) evoked by applying exogenous NMDA or L-glutamate, which reach both synaptic and extrasynaptic receptors. However, it increased survival and decreased Ca-45(2+) accumulation in neurons exposed to oxygen glucose deprivation, which causes excitotoxicity by glutamate release at synapses. Thus, synaptically and extrasynaptically activated NMDARs are equally capable of excitotoxicity. However, their relative contributions vary with the location of extracellular excitotoxin accumulation, a factor governed by the mechanism of extracellular neurotransmitter accumulation, not the synaptic activation of NMDARs.	Univ Toronto, Toronto Western Hosp, Inst Neurosci, Lab 11 416,MC PAV, Toronto, ON M5T 2S8, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5G 1X8, Canada	Tymianski, M (corresponding author), Univ Toronto, Toronto Western Hosp, Inst Neurosci, Lab 11 416,MC PAV, 399 Bathurst St, Toronto, ON M5T 2S8, Canada.	mike_t@playfair.utoronto.ca	Lu, Wei-Yang/K-4404-2013	Tymianski, Mike/0000-0002-6311-9565	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039060] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 39060] Funding Source: Medline		AbdelHamid KM, 1997, J NEUROSCI, V17, P3538; AHNERTHILGER G, 1995, PROG NEUROBIOL, V46, P83, DOI 10.1016/0301-0082(95)00003-E; Allison DW, 1998, J NEUROSCI, V18, P2423; ATTWELL D, 1993, NEURON, V11, P401, DOI 10.1016/0896-6273(93)90145-H; BANKER GA, 1977, BRAIN RES, V126, P397, DOI 10.1016/0006-8993(77)90594-7; BERGEY GK, 1987, J NEUROPHYSIOL, V57, P121; Bernard V, 1997, J NEUROSCI, V17, P819; Bonfoco E, 1996, J NEUROCHEM, V67, P2484; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Brenman JE, 1996, J NEUROSCI, V16, P7407; Brorson JR, 1997, J NEUROCHEM, V68, P95; Brown JIM, 1998, J NEUROTRAUM, V15, P253, DOI 10.1089/neu.1998.15.253; BRUNO VMG, 1994, J NEUROCHEM, V63, P1398; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; CHOI DW, 1988, J NEUROSCI, V8, P185; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; CHOI DW, 1987, J NEUROSCI, V7, P369; Clark BA, 1997, J NEUROSCI, V17, P107; COHEN RS, 1977, J CELL BIOL, V74, P181, DOI 10.1083/jcb.74.1.181; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; CRAIG AM, 1994, P NATL ACAD SCI USA, V91, P12373, DOI 10.1073/pnas.91.26.12373; David JC, 1996, J NEUROSCI, V16, P200; DAWSON VL, 1993, J NEUROSCI, V13, P2651; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; DURING MJ, 1993, LANCET, V341, P1607; Ehlers MD, 1998, J NEUROSCI, V18, P720; EIMERL S, 1994, J NEUROCHEM, V62, P1223; Faddis BT, 1997, J NEUROSCI, V17, P951; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FURUKAWA K, 1995, EXP NEUROL, V133, P153, DOI 10.1006/exnr.1995.1018; Furukawa K, 1997, J NEUROSCI, V17, P8178, DOI 10.1523/jneurosci.17-21-08178.1997; FURUKAWA K, 1995, J NEUROCHEM, V65, P1061; Garey LJ, 1998, J NEUROL NEUROSUR PS, V65, P446, DOI 10.1136/jnnp.65.4.446; GOLDBERG MP, 1987, J PHARMACOL EXP THER, V243, P784; GOLDBERG MP, 1993, J NEUROSCI, V13, P3510; Gomperts SN, 1996, CELL, V84, P659, DOI 10.1016/S0092-8674(00)81043-0; Goslin K., 1991, CULTURING NERVE CELL, P251; Halpain S, 1998, J NEUROSCI, V18, P9835; HARRIS KM, 1994, ANNU REV NEUROSCI, V17, P341, DOI 10.1146/annurev.ne.17.030194.002013; HARTLEY DM, 1993, J NEUROSCI, V13, P1993; Jeffrey M, 1997, NEUROPATH APPL NEURO, V23, P93, DOI 10.1111/j.1365-2990.1997.tb01191.x; Jiang MH, 1998, J NEUROSCI, V18, P8356; Jones OT, 1997, J NEUROSCI, V17, P6152; Kaech S, 1997, J NEUROSCI, V17, P9565; Kennedy MB, 1997, TRENDS NEUROSCI, V20, P264, DOI 10.1016/S0166-2236(96)01033-8; Kharazia VN, 1997, NEUROSCI LETT, V238, P41, DOI 10.1016/S0304-3940(97)00846-X; Kim CH, 1999, J NEUROSCI, V19, P4314; Kim E, 1996, NEUROPHARMACOLOGY, V35, P993, DOI 10.1016/0028-3908(96)00093-7; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Krupp JJ, 1999, J NEUROSCI, V19, P1165; Liao DH, 1999, NAT NEUROSCI, V2, P37; Lu WY, 1999, NAT NEUROSCI, V2, P331; MATUS A, 1982, P NATL ACAD SCI-BIOL, V79, P7590, DOI 10.1073/pnas.79.23.7590; MONYER H, 1992, NEURON, V8, P967, DOI 10.1016/0896-6273(92)90211-U; Muller BM, 1996, NEURON, V17, P255, DOI 10.1016/S0896-6273(00)80157-9; Niethammer M, 1996, J NEUROSCI, V16, P2157; O'Brien RJ, 1998, NEURON, V21, P1067, DOI 10.1016/S0896-6273(00)80624-8; O'Brien RJ, 1998, CURR OPIN NEUROBIOL, V8, P364, DOI 10.1016/S0959-4388(98)80062-7; Park JS, 1996, NEUROBIOL DIS, V3, P215, DOI 10.1006/nbdi.1996.0022; PETITO CK, 1987, NEUROLOGY, V37, P1281, DOI 10.1212/WNL.37.8.1281; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Rao A, 1997, NEURON, V19, P801, DOI 10.1016/S0896-6273(00)80962-9; ROSENMUND C, 1995, J NEUROSCI, V15, P2788; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; ROTHMAN S, 1984, J NEUROSCI, V4, P1884; ROTHMAN SM, 1983, SCIENCE, V220, P536, DOI 10.1126/science.6836300; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; Sattler R, 1998, J NEUROCHEM, V71, P2349; Sattler R, 1997, J CEREBR BLOOD F MET, V17, P455, DOI 10.1097/00004647-199704000-00011; Sattler R, 1999, SCIENCE, V284, P1845, DOI 10.1126/science.284.5421.1845; Shorte SL, 1997, J NEUROPHYSIOL, V78, P1135; SPECTOR I, 1989, CELL MOTIL CYTOSKEL, V13, P127, DOI 10.1002/cm.970130302; SPECTOR I, 1983, SCIENCE, V219, P493, DOI 10.1126/science.6681676; Stricker NL, 1997, NAT BIOTECHNOL, V15, P336, DOI 10.1038/nbt0497-336; SZATKOWSKI M, 1994, TRENDS NEUROSCI, V17, P359, DOI 10.1016/0166-2236(94)90040-X; TECOMA ES, 1989, NEURON, V2, P1541, DOI 10.1016/0896-6273(89)90042-1; Tymianski M, 1998, J CEREBR BLOOD F MET, V18, P848, DOI 10.1097/00004647-199808000-00005; Tymianski M, 1996, ADV NEUROL, V71, P85; TYMIANSKI M, 1993, J NEUROSCI, V13, P2085; Wenthold RJ, 1996, J NEUROSCI, V16, P1982; Wyszynski M, 1997, NATURE, V385, P439, DOI 10.1038/385439a0; Wyszynski M, 1998, J NEUROSCI, V18, P1383; Xiong ZG, 1997, P NATL ACAD SCI USA, V94, P7012, DOI 10.1073/pnas.94.13.7012; YUSTE R, 1995, NATURE, V375, P682, DOI 10.1038/375682a0; Zhang S, 1998, NEURON, V21, P443, DOI 10.1016/S0896-6273(00)80553-X	90	186	189	1	11	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JAN 1	2000	20	1					22	33		10.1523/JNEUROSCI.20-01-00022.2000			12	Neurosciences	Neurosciences & Neurology	271ET	WOS:000084581800008	10627577	Green Published, Bronze			2021-06-18	
J	Kossmann, T; Stahel, PF; Lenzlinger, PM; Redl, H; Dubs, RW; Trentz, O; Schlag, G; MorgantiKossmann, MC				Kossmann, T; Stahel, PF; Lenzlinger, PM; Redl, H; Dubs, RW; Trentz, O; Schlag, G; MorgantiKossmann, MC			Interleukin-8 released into the cerebrospinal fluid after brain injury is associated with blood-brain barrier dysfunction and nerve growth factor production	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						brain injury; interleukin-6; interleukin-8; blood-brain barrier; nerve growth factor; astrocyte	TUMOR-NECROSIS-FACTOR; HUMAN ASTROCYTES; HEAD-INJURY; RAT-BRAIN; SCIATIC-NERVE; FACTOR-ALPHA; CYTOKINES; NEUTROPHIL; SECRETION; CULTURES	Interleukin (IL) 8 was measured in CSF of 14 patients with severe traumatic brain injury. IL-8 levels were significantly higher in CSF (up to 8,000 pg/ml) than serum (up to 2,400 pg/ml) (p < 0.05), suggesting intrathecal production. Maximal IL-8 values in CSF correlated with a severe dysfunction of the blood-brain barrier. Nerve growth factor (NGF) was detected in CSF of 7 of 14 patients (range of maximal NGF: 62-12,130 pg/ml). IL-8 concentrations were significantly higher in these patients than in those without NGF (p < 0.01), CSF containing high IL-8 (3,800-7,900 pg/ml) induced greater NGF production in cultured astrocytes (202-434 pg/ml) than samples with low IL-8 (600-1,000 pg/ml), which showed a smaller NGF increase (0-165 pg/ml). Anti-IL-8 antibodies strongly reduced (52-100%) the release of NGF in the group of high IL-8, whereas in the group with low IL-8, this effect was lower (0-52%). The inability of anti-IL-8 antibodies to inhibit the synthesis of NGF completely may depend on cytokines like tumor necrosis factor alpha and IL-6 found in these CSF samples, which may act in association with IL-8. Thus, IL-8 may represent a pivotal cytokine in the pathology of brain injury.	UNIV ZURICH,DIV EXPT SURG,SCH MED,DEPT SURG,CH-8091 ZURICH,SWITZERLAND; UNIV ZURICH,SCH MED,DIV CLIN IMMUNOL,DEPT INTERNAL MED,ZURICH,SWITZERLAND; LUDWIG BOLTZMANN INST EXPT & CLIN TRAUMATOL,VIENNA,AUSTRIA	Kossmann, T (corresponding author), UNIV ZURICH,DIV TRAUMA SURG,SCH MED,DEPT SURG,CH-8091 ZURICH,SWITZERLAND.		Redl, Heinz/AAD-8157-2019; Lenzlinger, Philipp/A-3822-2008	Morganti-Kossmann, Cristina/0000-0002-0807-2063			ALOISI F, 1992, J IMMUNOL, V149, P2358; APFEL SC, 1991, ANN NEUROL, V29, P87, DOI 10.1002/ana.410290115; ARAUJO DM, 1993, BRAIN RES, V600, P49, DOI 10.1016/0006-8993(93)90400-H; AWATSUJI H, 1993, J NEUROSCI RES, V34, P539, DOI 10.1002/jnr.490340506; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BANKS WA, 1991, J PHARMACOL EXP THER, V259, P988; BANKS WA, 1989, BRAIN RES BULL, V23, P433, DOI 10.1016/0361-9230(89)90185-8; BAZZONI F, 1991, J EXP MED, V173, P771, DOI 10.1084/jem.173.3.771; BOWES MP, 1993, EXP NEUROL, V119, P215, DOI 10.1006/exnr.1993.1023; CARMANKRZAN M, 1991, J NEUROCHEM, V56, P636, DOI 10.1111/j.1471-4159.1991.tb08197.x; CHAN PH, 1984, NEUROLOGY, V34, P315, DOI 10.1212/WNL.34.3.315; DINARELLO CA, 1991, J INFECT DIS, V163, P1177, DOI 10.1093/infdis/163.6.1177; FURUKAWA Y, 1989, FEBS LETT, V247, P395; GADIENT RA, 1990, NEUROSCI LETT, V117, P335, DOI 10.1016/0304-3940(90)90687-5; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; GIULIAN D, 1988, J NEUROSCI, V8, P2485; HALSTENSEN A, 1993, J INFECT DIS, V167, P471, DOI 10.1093/infdis/167.2.471; Handa Shoichi, 1992, Kurume Medical Journal, V39, P257; HEUMANN R, 1987, J CELL BIOL, V104, P1623, DOI 10.1083/jcb.104.6.1623; JENNETT B, 1975, LANCET, V1, P480; KIM KS, 1992, LYMPHOKINE CYTOK RES, V11, P293; Kossmann T, 1996, BRAIN RES, V713, P143, DOI 10.1016/0006-8993(95)01501-9; KOSSMANN T, 1995, SHOCK, V4, P3111; KROMER LF, 1987, SCIENCE, V235, P214, DOI 10.1126/science.3798108; LACY M, 1995, J NEUROIMMUNOL, V61, P71, DOI 10.1016/0165-5728(95)00075-D; LEVIMONTALCINI R, 1968, PHYSIOL REV, V48, P534; Lindholm D, 1990, Neuroreport, V1, P9; LINDHOLM D, 1987, NATURE, V330, P658, DOI 10.1038/330658a0; MARTICH GD, 1991, J EXP MED, V173, P1021, DOI 10.1084/jem.173.4.1021; MASTROIANNI CM, 1994, PEDIATR INFECT DIS J, V13, P1008; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; MORGANTIKOSSMAN.C, 1995, IMMUNE RESPONSES NER, P159; MORGANTIKOSSMANN MC, 1992, J NEUROIMMUNOL, V39, P163, DOI 10.1016/0165-5728(92)90185-N; MORGANTIKOSSMANN MC, 1992, TRENDS PHARMACOL SCI, V13, P286, DOI 10.1016/0165-6147(92)90087-M; MORITA M, 1993, EUR CYTOKINE NETW, V4, P351; Mukaida N, 1992, Cytokines, V4, P41; NIETOSAMPEDRO M, 1982, SCIENCE, V217, P860, DOI 10.1126/science.7100931; NIETOSAMPEDRO M, 1987, J NEUROSCI RES, V17, P214, DOI 10.1002/jnr.490170303; NITTA T, 1992, NEUROSURG REV, V15, P203, DOI 10.1007/BF00345934; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; PATTERSON SL, 1993, BRAIN RES, V605, P43, DOI 10.1016/0006-8993(93)91354-U; REIBER H, 1987, CLIN CHIM ACTA, V163, P319, DOI 10.1016/0009-8981(87)90250-6; SEKI T, 1993, IMMUNOLOGY, V80, P333; SHIGA Y, 1991, NEUROSCI LETT, V125, P110, DOI 10.1016/0304-3940(91)90003-C; SPRANGER M, 1990, EUR J NEUROSCI, V2, P69, DOI 10.1111/j.1460-9568.1990.tb00382.x; STOCKER R, 1995, INTEGRATED APPROACH, P197; TADA M, 1993, J NEURO-ONCOL, V16, P25, DOI 10.1007/BF01324831; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TEASDALE G, 1974, LANCET, V2, P81; VAN MEIR E, 1992, CANCER RES, V52, P4297; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; YOSHIDA K, 1991, BRAIN RES, V538, P118, DOI 10.1016/0006-8993(91)90385-9	54	186	193	0	5	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAR	1997	17	3					280	289		10.1097/00004647-199703000-00005			10	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	WQ178	WOS:A1997WQ17800005	9119901	Bronze			2021-06-18	
J	Hart, J; Kraut, MA; Womack, KB; Strain, J; Didehbani, N; Bartz, E; Conover, H; Mansinghani, S; Lu, HZ; Cullum, CM				Hart, John, Jr.; Kraut, Michael A.; Womack, Kyle B.; Strain, Jeremy; Didehbani, Nyaz; Bartz, Elizabeth; Conover, Heather; Mansinghani, Sethesh; Lu, Hanzhang; Cullum, C. Munro			Neuroimaging of Cognitive Dysfunction and Depression in Aging Retired National Football League Players A Cross-sectional Study	JAMA NEUROLOGY			English	Article							CHRONIC TRAUMATIC ENCEPHALOPATHY; RECURRENT CONCUSSION; ALZHEIMERS-DISEASE; SPORTS CONCUSSION; FUNCTIONAL MRI; BRAIN-INJURY; HEAD-INJURY; MILD; IMPAIRMENT; RECOVERY	Objectives: To assess cognitive impairment and depression in aging former professional football (National Football League [NFL]) players and to identify neuroimaging correlates of these dysfunctions. Design: We compared former NFL players with cognitive impairment and depression, cognitively normal retired players who were not depressed, and matched healthy control subjects. Setting: Research center in the North Texas region of the United States. Patients: Cross-sectional sample of former NFL players with and without a history of concussion recruited from the North Texas region and age-, education-, and IQ-matched controls. Thirty-four retired NFL players (mean age, 61.8 years) underwent neurological and neuropsychological assessment. A subset of 26 players also underwent detailed neuroimaging; imaging data in this subset were compared with imaging data acquired in 26 healthy matched controls. Main Outcome Measures: Neuropsychological measures, clinical diagnoses of depression, neuroimaging measures of white matter pathology, and a measure of cerebral blood flow. Results: Of the 34 former NFL players, 20 were cognitively normal. Four were diagnosed as having a fixed cognitive deficit; 8, mild cognitive impairment; 2, dementia; and 8, depression. Of the subgroup in whom neuroimaging data were acquired, cognitively impaired participants showed the greatest deficits on tests of naming, word finding, and visual/verbal episodic memory. We found significant differences in white matter abnormalities in cognitively impaired and depressed retired players compared with their respective controls. Regional blood flow differences in the cognitively impaired group (left temporal pole, inferior parietal lobule, and superior temporal gyrus) corresponded to regions associated with impaired neurocognitive performance (problems with memory, naming, and word finding). Conclusions: Cognitive deficits and depression appear to be more common in aging former NFL players compared with healthy controls. These deficits are correlated with white matter abnormalities and changes in regional cerebral blood flow. JAMA Neurol. 2013;70(3):326-335. Published online January 7, 2013. doi: 10.1001/2013.jamaneurol.340	[Hart, John, Jr.; Kraut, Michael A.; Womack, Kyle B.; Strain, Jeremy; Didehbani, Nyaz; Bartz, Elizabeth; Conover, Heather; Mansinghani, Sethesh] Univ Texas Dallas, Berman Lab Learning & Memory, Ctr BrainHlth, Sch Behav & Brain Sci, Dallas, TX 75235 USA; [Hart, John, Jr.; Womack, Kyle B.; Cullum, C. Munro] Univ Texas SW Med Ctr Dallas, Dept Neurol & Neurotherapeut, Dallas, TX 75390 USA; [Hart, John, Jr.; Womack, Kyle B.; Cullum, C. Munro] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA; [Lu, Hanzhang] Univ Texas SW Med Ctr Dallas, Adv Imaging Res Ctr, Dallas, TX 75390 USA; [Kraut, Michael A.] Johns Hopkins Univ, Sch Med, Dept Radiol, Baltimore, MD 21205 USA	Hart, J (corresponding author), Univ Texas Dallas, Berman Lab Learning & Memory, Ctr BrainHlth, Sch Behav & Brain Sci, 2200 W Mockingbird Ln, Dallas, TX 75235 USA.	jhart@utdallas.edu	Womack, Kyle/O-5422-2018; Cullum, C. Munro/AAC-2496-2019	Womack, Kyle/0000-0002-6060-9075; Cullum, C. Munro/0000-0001-9706-5465; Didehbani, Nyaz/0000-0001-6121-5759	BrainHealth Institute for Athletes at the Center for BrainHealth, a research center at The University of Texas at Dallas; National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [5K23AG030006]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG012300, K23AG030006] Funding Source: NIH RePORTER	This study was supported by the BrainHealth Institute for Athletes at the Center for BrainHealth, a research center at The University of Texas at Dallas, and in part by grant 5K23AG030006 from the National Institute on Aging.	Abel EL, 2007, PERCEPT MOTOR SKILL, V104, P1251, DOI 10.2466/PMS.104.4.1251-1254; Alexander M.P., 1992, J HEAD TRAUMA REHAB, V7, P60, DOI DOI 10.1097/00001199-199206000-00009; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Aslan S, 2010, MAGN RESON MED, V63, P765, DOI 10.1002/mrm.22245; Beck AT., 1996, BECK DEPRESSION INVE, V2; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Benton A., 1976, MULTILINGUAL APHASIA; Cantu RC, 2007, NEUROSURGERY, V61, P223, DOI 10.1227/01.NEU.0000255514.73967.90; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Delis DC, 2000, CALIFORNIA VERBAL LE; Ellemberg D, 2009, J NEUROTRAUM, V26, P2365, DOI 10.1089/neu.2009.0906; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Gardner A, 2010, EVOLUTION, V64, P25, DOI 10.1111/j.1558-5646.2009.00842.x; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Goodglass H., 2001, BOSTON DIAGNOSTIC AP; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; HART J, 1990, ANN NEUROL, V27, P226, DOI 10.1002/ana.410270303; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Kaplan E., 1983, BOSTON NAMING TEST; Kelly JP, 1997, NEUROLOGY, V48, P581; Kraut MA, 2008, J CEREBR BLOOD F MET, V28, P190, DOI 10.1038/sj.jcbfm.9600512; Kraut MA, 2006, COGN BEHAV NEUROL, V19, P177, DOI 10.1097/01.wnn.0000213922.41008.22; Larrieu S, 2002, NEUROLOGY, V59, P1594, DOI 10.1212/01.WNL.0000034176.07159.F8; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Nichols TE, 2002, HUM BRAIN MAPP, V15, P1, DOI 10.1002/hbm.1058; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Palmer K, 2008, AM J GERIAT PSYCHIAT, V16, P603, DOI 10.1097/JGP.0b013e3181753a64; Petersen RC, 1999, ARCH NEUROL-CHICAGO, V56, P303, DOI 10.1001/archneur.56.3.303; Reddy CC, 2009, CURR SPORT MED REP, V8, P10, DOI 10.1249/JSR.0b013e31819539ca; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Schwenk TL, 2007, MED SCI SPORT EXER, V39, P599, DOI 10.1249/mss.0b013e31802fa679; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, BRIT J RADIOL, V77, pS167, DOI 10.1259/bjr/33553595; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Spreen O, 1969, NEUROSENSORY CTR COM; Tremblay S, 2013, CEREB CORTEX, V23, P1159, DOI 10.1093/cercor/bhs102; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Wechsler D., 2011, WECHLSER ABBREVIATED; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; Weir Dr, 2009, NATL FOOTBALL LEAGUE; World Health Organization, 1992, INT STAT CLASS DIS 1; Zhang H, 2006, MED IMAGE ANAL, V10, P764, DOI 10.1016/j.media.2006.06.004	56	185	186	1	96	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6149	2168-6157		JAMA NEUROL	JAMA Neurol.	MAR	2013	70	3					326	335		10.1001/2013.jamaneurol.340			10	Clinical Neurology	Neurosciences & Neurology	115HY	WOS:000316804400006	23303193	Bronze, Green Accepted			2021-06-18	
J	Whelan-Goodinson, R; Ponsford, J; Johnston, L; Grant, F				Whelan-Goodinson, Rochelle; Ponsford, Jennie; Johnston, Lisa; Grant, Fiona			Psychiatric Disorders Following Traumatic Brain Injury: Their Nature and Frequency	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						anxiety; brain injuries; depression; psychotic disorders	AXIS-I; HEAD-INJURY; DEPRESSION; ALCOHOL; PSYCHOPATHOLOGY; INDIVIDUALS; OUTPATIENTS; DISABILITY; MOOD	Objectives: To retrospectively establish the nature and frequency of Axis I psychiatric disorders pre- and post-TBI. Participants: One hundred participants who were 0.5 to 5.5 years post mild to severe TBI and 87 informants, each evaluated at a single time point. Main Measure: The Structured Clinical Interview for DSM-IV Disorders (SCID-I). Results: Preinjury, 52% received a psychiatric diagnosis, most commonly substance use disorder (41%), followed by major depressive disorder (17%) and anxiety (13%). Postinjury, 65% received a diagnosis, of which major depression became the most common (45%), followed by anxiety (38%) and substance use disorder (21%). Frequency of depression, generalized anxiety disorder, posttraumatic stress disorder, panic disorder, and phobias rose from preinjury to postinjury. More than two-thirds of postinjury depression and anxiety cases were novel and showed poor resolution rates. Few novel cases of substance use disorder were noted. Psychotic disorders, somatoform disorders, and eating disorders occurred at frequencies similar to those in the general population. Conclusions: A high frequency of postinjury psychiatric disorders was evident up to 5.5 years postinjury, with many novel cases of depression and anxiety. Individuals with TBI should be screened for psychiatric disorders at various time points postinjury without reliance on history of psychiatric problems to predict who is at risk, so that appropriate intervention can be offered.	[Whelan-Goodinson, Rochelle; Ponsford, Jennie; Grant, Fiona] Monash Univ, Sch Psychol Psychiat & Psychol Med, Melbourne, Vic 3004, Australia; [Ponsford, Jennie; Johnston, Lisa] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [Ponsford, Jennie] Natl Trauma Res Inst, Melbourne, Vic, Australia	Ponsford, J (corresponding author), Monash Univ, Dept Psychol, Clayton, Vic 3800, Australia.	jennie.ponsford@med.monash.edu.au					American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; *AUSTR I HLTH WELF, 1999, 13 PHE AIHW; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P29; Dawson DR, 2000, BRAIN COGNITION, V44, P35; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; Deb S, 1999, AM J PSYCHIAT, V156, P374; DICKER BG, 1989, J HEAD TRAUMA REHAB, V4, P73; Drubach D A, 1993, Md Med J, V42, P989; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; FIRST MB, 2004, COMPUTER ASSISTED SC; Fujii DE, 2001, J NEUROPSYCH CLIN N, V13, P61, DOI 10.1176/appi.neuropsych.13.1.61; Glenn MB, 2001, BRAIN INJURY, V15, P811, DOI 10.1080/02699050010025777; Green A, 2001, BRAIN INJURY, V15, P1021, DOI 10.1080/02699050110074187; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hibbard MR, 2000, BRAIN INJURY, V14, P45, DOI 10.1080/026990500120925; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; JORGE R, 2004, J NEUROSURG, V8, P726; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; Jorge RE, 2005, ARCH GEN PSYCHIAT, V62, P742, DOI 10.1001/archpsyc.62.7.742; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kreutzer JS, 1996, J HEAD TRAUMA REHAB, V11, P58, DOI 10.1097/00001199-199610000-00006; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Macmillan PJ, 2002, BRAIN INJURY, V16, P41, DOI 10.1080/0269905011008812; Ponsford J., 1995, TRAUMATIC BRAIN INJU; Ponsford J, 2007, BRAIN INJURY, V21, P1385, DOI 10.1080/02699050701796960; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; ROBINSON RG, 1988, AM J PSYCHIAT, V145, P172; Robinson RG, 2005, TXB TRAUMATIC BRAIN, P201; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; Sachdev P, 2001, PSYCHOL MED, V31, P231, DOI 10.1017/S0033291701003336; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Sparadeo F. R., 1989, J HEAD TRAUMA REHAB, V4, P75, DOI DOI 10.1097/00001199-198903000-00010; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Varney NR, 1987, NEUROPSYCHOLOGY, V1, P7, DOI 10.1037//0894-4105.1.1.7; WARDEN DL, 2005, TXB TRAUMATIC BRAIN, P231; WHELANGOODINSON R, J HEAD TRAU IN PRESS	41	185	188	0	21	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2009	24	5					324	332		10.1097/HTR.0b013e3181a712aa			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	509WG	WOS:000271049300003	19858966				2021-06-18	
J	Lu, DY; Qu, CS; Goussev, A; Jiang, H; Lu, C; Schallert, T; Mahmood, A; Chen, JL; Li, Y; Chopp, M				Lu, Dunyue; Qu, Changsheng; Goussev, Anton; Jiang, Hao; Lu, Chang; Schallert, Timothy; Mahmood, Asim; Chen, Jieli; Li, Yi; Chopp, Michael			Statins increase neurogenesis in the dentate gyrus, reduce delayed neuronal death in the hippocampal CA3 region, and improve spatial learning in rat after traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						neurogenesis; rat; spatial learning; statins	MICE DEFICIENT; PLASMINOGEN-ACTIVATOR; CELLS; ATORVASTATIN; ACQUISITION; MOTOR; SYNAPTOGENESIS; ANGIOGENESIS; STROKE	Traumatic brain injury (TBI) remains a major public health problem globally. Presently, there is no way to restore cognitive deficits caused by TBI. In this study, we seek to evaluate the effect of statins (simvastatin and atorvastatin) on the spatial learning and neurogenesis in rats subjected to controlled cortical impact. Rats were treated with atorvastatin and simvastatin 1 day after TBI and daily for 14 days. Morris water maze tests were performed during weeks 2 and 5 after TBI. Bromodeoxyuridine (BrdU; 50 mg/kg) was intraperitoneally injected 1 day after TBI and daily for 14 days. Brain tissue was processed for immunohistochemical staining to identify newly generated cells and vessels. Our data show that (1) treatment of TBI with statins improves spatial learning on days 31-35 after onset of TBI; (2) in the non-neurogenic region of the hippocampal CA3 region, statin treatment reduces the neuronal loss after TBI, demonstrating the neuroprotective effect of statins; (3) in the neurogenic region of the dentate gyrus, treatment of TBI with statins enhances neurogenesis; (4) statin treatment augments TBI-induced angiogenesis; and (5) treatment with simvastatin at the same dose provides a therapeutic effect superior to treatment with atorvastatin. These results suggest that statins may be candidates for treatment of TBI.	Henry Ford Hlth Syst, Dept Neurol, Detroit, MI USA; Oakland Univ, Dept Phys, Rochester, MN USA; Univ Texas, Dept Psychol, Austin, TX 78712 USA	Chopp, M (corresponding author), Henry Ford Hosp, Dept Neurol, 2799 W Grand Blvd, Detroit, MI 48202 USA.	chopp@neuro.hfh.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS052280, R01 NS52280, P01 NS042345, R01 NS052280-01A1] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [P01 42345] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052280, P01NS042345] Funding Source: NIH RePORTER		Becher A, 1999, EUR J CELL BIOL, V78, P650, DOI 10.1016/S0171-9335(99)80050-8; Chen JL, 2005, J CEREBR BLOOD F MET, V25, P281, DOI 10.1038/sj.jcbfm.9600034; Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Davidson MH, 2004, INT J CLIN PRACT, V58, P746, DOI 10.1111/j.1368-5031.2004.00289.x; Day LB, 1996, BEHAV NEUROSCI, V110, P998; Day LB, 1999, ANIM BEHAV, V57, P393, DOI 10.1006/anbe.1998.1007; Dimmeler S, 2001, J CLIN INVEST, V108, P391, DOI 10.1172/JCI13152; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Essig M, 1998, J AM SOC NEPHROL, V9, P1377; Eto M, 2002, CIRCULATION, V105, P1756, DOI 10.1161/01.CIR.0000015465.73933.3B; Fox GB, 1998, J NEUROSCI RES, V53, P718, DOI 10.1002/(SICI)1097-4547(19980915)53:6<718::AID-JNR9>3.0.CO;2-8; Fox GB, 1998, J NEUROTRAUM, V15, P1037, DOI 10.1089/neu.1998.15.1037; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Joukhadar C, 2001, THROMB HAEMOSTASIS, V85, P47; Kempermann G, 2002, EUR J NEUROSCI, V16, P129, DOI 10.1046/j.1460-9568.2002.02042.x; Kempermann G, 2004, TRENDS NEUROSCI, V27, P447, DOI 10.1016/j.tins.2004.05.013; Kempermann G, 2004, CURR OPIN NEUROBIOL, V14, P186, DOI 10.1016/j.conb.2004.03.001; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Laufs U, 2003, EUR J CLIN PHARMACOL, V58, P719, DOI 10.1007/s00228-002-0556-0; Lu DY, 2004, J NEUROTRAUM, V21, P1756, DOI 10.1089/0897715042664885; Lu DY, 2004, J NEUROTRAUM, V21, P21, DOI 10.1089/089771504772695913; Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813; Maeda T, 2005, J NEUROTRAUM, V22, P763, DOI 10.1089/neu.2005.22.763; Maeda T, 2003, ENDOCRINOLOGY, V144, P681, DOI 10.1210/en.2002-220682; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; McKenney JM, 2003, CLIN CARDIOL, V26, P32, DOI 10.1002/clc.4960261507; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Palmer TD, 1999, J NEUROSCI, V19, P8487; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Royo NC, 2003, CURR OPIN PHARMACOL, V3, P27, DOI 10.1016/S1471-4892(02)00006-1; Sheehy N, 2001, EXPERT OPIN INV DRUG, V10, P1847, DOI 10.1517/13543784.10.10.1847; Stein EA, 2003, CLIN CARDIOL, V26, P25, DOI 10.1002/clc.4960261506; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Whalen MJ, 2000, J LEUKOCYTE BIOL, V67, P160; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Zhang L, 2005, CIRCULATION, V112, P3486, DOI 10.1161/CIRCULATIONAHA.104.516757; Zhu YH, 2003, FASEB J, V17, P186, DOI 10.1096/fj.02-0515com	40	185	192	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2007	24	7					1132	1146		10.1089/neu.2007.0288			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	186DV	WOS:000247760200005	17610353	Green Accepted			2021-06-18	
J	Brown, MR; Sullivan, PG; Geddes, JW				Brown, MR; Sullivan, PG; Geddes, JW			Synaptic mitochondria are more susceptible to Ca2+ overload than nonsynaptic mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA-2&-INDUCED MEMBRANE TRANSITION; INDUCED PERMEABILITY TRANSITION; CULTURED HIPPOCAMPAL-NEURONS; PERCOLL GRADIENT PROCEDURE; TRAUMATIC BRAIN-INJURY; CYCLOSPORINE-A; LIVER-MITOCHONDRIA; RAT-BRAIN; QUANTITATIVE-EVALUATION; ALZHEIMERS-DISEASE	Mitochondria in nerve terminals are subjected to extensive Ca2+ fluxes and high energy demands, but the extent to which the synaptic mitochondria buffer Ca2+ is unclear. In this study, we identified a difference in the Ca2+ clearance ability of nonsynaptic versus synaptic mitochondrial populations enriched from rat cerebral cortex. Mitochondria were isolated using Percoll discontinuous gradients in combination with high pressure nitrogen cell disruption. Mitochondria in the nonsynaptic fraction originate from neurons and other cell types including glia, whereas mitochondria enriched from a synaptosomal fraction are predominantly neuronal and presynaptic in origin. There were no differences in respiration or initial Ca2+ loads between nonsynaptic and synaptic mitochondrial populations. Following both bolus and infusion Ca2+ addition, nonsynaptic mitochondria were able to accumulate significantly more exogenously added Ca2+ than the synaptic mitochondria before undergoing mitochondrial permeability transition, observed as a loss in mitochondrial membrane potential and decreased Ca2+ uptake. The limited ability of synaptic mitochondria to accumulate Ca2+ could result from several factors including a primary function of ATP production to support the high energy demand of presynaptic terminals, their relative isolation in comparison with the threads or clusters of mitochondria found in the soma of neurons and glia, or the older age and increased exposure to oxidative damage of synaptic versus nonsynaptic mitochondria. By more readily undergoing permeability transition, synaptic mitochondria may initiate neuron death in response to insults that elevate synaptic levels of intracellular Ca2+, consistent with the early degeneration of distal axon segments in neurodegenerative disorders.	Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; Univ Kentucky, Grad Ctr Gerontol, Lexington, KY 40536 USA; Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA	Geddes, JW (corresponding author), Univ Kentucky, Sanders Brown Ctr Aging, B379 BBSRB, Lexington, KY 40536 USA.	jgeddes@uky.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048191, R21NS046426] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG010836] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG10836] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS045276, NS046426, NS048191] Funding Source: Medline		Andreyev A, 1999, CELL DEATH DIFFER, V6, P825, DOI 10.1038/sj.cdd.4400565; BATTINO M, 1991, J BIOENERG BIOMEMBR, V23, P345, DOI 10.1007/BF00762227; Battino M, 2000, J BIOENERG BIOMEMBR, V32, P163, DOI 10.1023/A:1005559930210; Battino M, 2002, FREE RADICAL RES, V36, P479, DOI 10.1080/10715760290021351; Berman SB, 2000, EXP NEUROL, V164, P415, DOI 10.1006/exnr.2000.7438; Bernardi P, 1999, PHYSIOL REV, V79, P1127; Billups B, 2002, J NEUROSCI, V22, P5840; Brocard JB, 2001, J PHYSIOL-LONDON, V531, P793, DOI 10.1111/j.1469-7793.2001.0793h.x; Brown MR, 2004, J BIOENERG BIOMEMBR, V36, P401, DOI 10.1023/B:JOBB.0000041775.10388.23; Brown MR, 2004, J NEUROSCI METH, V137, P299, DOI 10.1016/j.jneumeth.2004.02.028; Brustovetsky N, 2003, J NEUROSCI, V23, P4858; Brustovetsky N, 2002, NEUROSCI LETT, V332, P91, DOI 10.1016/S0304-3940(02)00948-5; Budd SL, 1996, J NEUROCHEM, V66, P403, DOI 10.1046/j.1471-4159.1996.66010403.x; Chalmers S, 2003, J BIOL CHEM, V278, P19062, DOI 10.1074/jbc.M212661200; CHANCE B, 1955, J BIOL CHEM, V217, P383; Collins TJ, 2002, EMBO J, V21, P1616, DOI 10.1093/emboj/21.7.1616; David G, 2003, CELL CALCIUM, V33, P197, DOI 10.1016/S0143-4160(02)00229-4; DAVIDSON AM, 1990, BIOCHEM J, V268, P147, DOI 10.1042/bj2680147; Drummond RM, 2000, J PHYSIOL-LONDON, V522, P375, DOI 10.1111/j.1469-7793.2000.t01-2-00375.x; DUNKLEY PR, 1988, BRAIN RES, V441, P59, DOI 10.1016/0006-8993(88)91383-2; Friberg H, 1999, J NEUROCHEM, V72, P2488, DOI 10.1046/j.1471-4159.1999.0722488.x; Friel DD, 2000, CELL CALCIUM, V28, P307, DOI 10.1054/ceca.2000.0172; Glantz LA, 2006, SCHIZOPHR RES, V81, P47, DOI 10.1016/j.schres.2005.08.014; GRAY EG, 1963, J ANAT, V97, P101; GRAY EG, 1962, J ANAT, V96, P79; GUNTER TE, 1994, AM J PHYSIOL, V267, pC313; Hagen TM, 1997, P NATL ACAD SCI USA, V94, P3064, DOI 10.1073/pnas.94.7.3064; HAWORTH RA, 1979, ARCH BIOCHEM BIOPHYS, V195, P460, DOI 10.1016/0003-9861(79)90372-2; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P453, DOI 10.1016/0003-9861(79)90371-0; HUNTER DR, 1979, ARCH BIOCHEM BIOPHYS, V195, P468, DOI 10.1016/0003-9861(79)90373-4; Ikegami K, 2003, NEUROSCIENCE, V122, P617, DOI 10.1016/j.neuroscience.2003.08.057; ITZHAK Y, 1995, DEV BRAIN RES, V84, P62, DOI 10.1016/0165-3806(94)00163-T; Kim JS, 2003, BIOCHEM BIOPH RES CO, V304, P463, DOI 10.1016/S0006-291X(03)00618-1; Kong DJ, 2005, MOL CELL BIOCHEM, V272, P187, DOI 10.1007/s11010-005-7323-3; Kristian T, 2006, J NEUROSCI METH, V152, P136, DOI 10.1016/j.jneumeth.2005.08.018; Kristian T, 2002, J NEUROCHEM, V83, P1297, DOI 10.1046/j.1471-4159.2002.01238.x; Kristian T, 2000, J NEUROCHEM, V74, P1999, DOI 10.1046/j.1471-4159.2000.0741999.x; Lai J C, 1979, Methods Enzymol, V55, P51; LAI JCK, 1977, J NEUROCHEM, V28, P625, DOI 10.1111/j.1471-4159.1977.tb10434.x; LAI JCK, 1989, CARBOHYDRATES ENERGY, P43; LEONG SF, 1984, J NEUROCHEM, V42, P1306, DOI 10.1111/j.1471-4159.1984.tb02788.x; Lifshitz J, 2004, MITOCHONDRION, V4, P705, DOI 10.1016/j.mito.2004.07.021; Ligon LA, 2000, J COMP NEUROL, V427, P340, DOI 10.1002/1096-9861(20001120)427:3<340::AID-CNE2>3.0.CO;2-Y; Ligon LA, 2000, J COMP NEUROL, V427, P351, DOI 10.1002/1096-9861(20001120)427:3<351::AID-CNE3>3.0.CO;2-R; Luo LQ, 2005, ANNU REV NEUROSCI, V28, P127, DOI 10.1146/annurev.neuro.28.061604.135632; MASLIAH E, 1995, HISTOL HISTOPATHOL, V10, P509; MASSARI S, 1972, BIOCHIM BIOPHYS ACTA, V238, P23; Mattson MP, 1998, EXP NEUROL, V153, P35, DOI 10.1006/exnr.1998.6863; MCGUINNESS O, 1990, EUR J BIOCHEM, V194, P671, DOI 10.1111/j.1432-1033.1990.tb15667.x; McStay GP, 2002, BIOCHEM J, V367, P541, DOI 10.1042/BJ20011672; MENZIES RA, 1971, J BIOL CHEM, V246, P2425; Miller KE, 2004, J CELL SCI, V117, P2791, DOI 10.1242/jcs.01130; MORRIS RL, 1993, J CELL SCI, V104, P917; Muller M, 2005, EXP CELL RES, V303, P114, DOI 10.1016/j.yexcr.2004.09.025; Murchison D, 2004, CELL CALCIUM, V36, P61, DOI 10.1016/j.ceca.2003.11.010; NICHOLLS D, 1982, BIOCHIM BIOPHYS ACTA, V683, P57, DOI 10.1016/0304-4173(82)90013-1; Nicholls DG, 2000, PHYSIOL REV, V80, P315; Nicholls DG, 2003, CELL CALCIUM, V34, P407, DOI 10.1016/S0143-4160(03)00144-1; NICHOLLS DG, 1993, EUR J BIOCHEM, V212, P613, DOI 10.1111/j.1432-1033.1993.tb17700.x; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; Panov AV, 2004, ARCH BIOCHEM BIOPHYS, V424, P44, DOI 10.1016/j.abb.2004.01.013; Peinado MA, 1997, ANAT REC, V247, P420; RENDON A, 1985, J NEUROSCI METH, V14, P41, DOI 10.1016/0165-0270(85)90113-X; ROTTENBERG H, 1989, FEBS LETT, V247, P483, DOI 10.1016/0014-5793(89)81396-1; Rowland KC, 2000, J NEUROSCI, V20, P9135; SCOTT ID, 1980, BIOCHEM J, V192, P873, DOI 10.1042/bj1920873; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; SIMS NR, 1990, J NEUROCHEM, V55, P698, DOI 10.1111/j.1471-4159.1990.tb04189.x; Smirnova E, 1998, J CELL BIOL, V143, P351, DOI 10.1083/jcb.143.2.351; Smirnova E, 2001, MOL BIOL CELL, V12, P2245, DOI 10.1091/mbc.12.8.2245; Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5&lt;723::AID-ANA5&gt;3.0.CO;2-W; Sullivan PG, 2004, J COMP NEUROL, V474, P524, DOI 10.1002/cne.20130; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2003, ANN NEUROL, V53, P711, DOI 10.1002/ana.10543; Sullivan PG, 2005, J NEUROSCI RES, V79, P231, DOI 10.1002/jnr.20292; SULLIVAN PG, 2004, J BIOL CHEM, P79200; Talbot JD, 2003, J NEUROPHYSIOL, V90, P491, DOI 10.1152/jn.00012.2003; Vergun O, 2005, BBA-BIOENERGETICS, V1709, P127, DOI 10.1016/j.bbabio.2005.07.006; Verstreken P, 2005, NEURON, V47, P365, DOI 10.1016/j.neuron.2005.06.018; WAATAJA JJ, 2005, 35 ANN M NOV 12 16 2; WERTH JL, 1994, J NEUROSCI, V14, P348; Yang F, 2003, J CELL BIOL, V163, P511, DOI 10.1083/jcb.200307027; Zenisek D, 2000, NEURON, V25, P229, DOI 10.1016/S0896-6273(00)80885-5; ZOCCARATO F, 1982, EUR J BIOCHEM, V127, P333, DOI 10.1111/j.1432-1033.1982.tb06875.x; Zoratti M, 2005, BBA-BIOENERGETICS, V1706, P40, DOI 10.1016/j.bbabio.2004.10.006	85	185	185	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 28	2006	281	17					11658	11668		10.1074/jbc.M510303200			11	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	035GH	WOS:000236988100029	16517608	Other Gold			2021-06-18	
J	Scheff, SW; Sullivan, PG				Scheff, SW; Sullivan, PG			Cyclosporin A significantly ameliorates cortical damage following experimental traumatic brain injury in rodents	JOURNAL OF NEUROTRAUMA			English	Article						trauma; cortical contusion; immunosuppressant; mitochondria; MPTP	CENTRAL-NERVOUS-SYSTEM; MITOCHONDRIAL PERMEABILITY TRANSITION; NITRIC-OXIDE; CELL-DEATH; FOREBRAIN ISCHEMIA; CEREBRAL-ISCHEMIA; RAT HIPPOCAMPUS; AMINO-ACIDS; CALCIUM; GLUTAMATE	Experimental traumatic brain injury (TBI) results in a rapid and significant necrosis of cortical tissue at the site of injury. In the ensuing hours and days, secondary injury exacerbates the original damage, resulting in significant neurological dysfunction, Young adult animals were treated either 5 min before or immediately after a cortical injury with the immunosuppressant cyclosporin A (CsA), All animals treated with CsA demonstrated a significant reduction in the amount of cortical damage 7 days following TBI, The effect was observed in adult rats and in two different strains of adult mice following systemic administration of the drug. Cyclosporin A has known effects on mitochondria by inhibiting the opening of the permeability transition pore and maintaining calcium homeostasis, These results with a clinically approved drug demonstrate an almost 50% reduction in lesion volume and suggest that the mechanisms responsible for tissue necrosis following TBI are amenable to manipulation, Since CsA also has known interactions with calcineurin and may be providing neuroprotection through that mechanism, additional animals were treated with the immunosuppressant FK 506, FK 506 failed to protect against the cortical damage, Amelioration of cortical damage with CsA indicates that pharmacological therapies can be devised that will significantly alter neurological outcome after injury.	Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA	Scheff, SW (corresponding author), Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA.	sscheff@pop.uky.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS031220] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS31220] Funding Source: Medline		Ankarcrona M, 1996, FEBS LETT, V394, P321, DOI 10.1016/0014-5793(96)00959-3; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; BEGLEY DJ, 1990, J NEUROCHEM, V55, P1222, DOI 10.1111/j.1471-4159.1990.tb03128.x; BERDEN JHM, 1985, LANCET, V1, P219; Bernardi P, 1996, BBA-BIOENERGETICS, V1275, P5, DOI 10.1016/0005-2728(96)00041-2; Bernardi P, 1996, J BIOENERG BIOMEMBR, V28, P131, DOI 10.1007/BF02110643; BREDT DS, 1992, J BIOL CHEM, V267, P10976; Budd SL, 1996, J NEUROCHEM, V66, P403, DOI 10.1046/j.1471-4159.1996.66010403.x; Butcher SP, 1997, J NEUROSCI, V17, P6939; CAZEVIEILLE C, 1993, FREE RADICAL BIO MED, V14, P389, DOI 10.1016/0891-5849(93)90088-C; CLEETER MWJ, 1994, FEBS LETT, V345, P50, DOI 10.1016/0014-5793(94)00424-2; CONNERN CP, 1992, BIOCHEM J, V284, P381, DOI 10.1042/bj2840381; DAWSON VL, 1993, J NEUROSCI, V13, P2651; Dawson VL, 1996, J NEUROSCI, V16, P2479; DEGROEN PC, 1987, NEW ENGL J MED, V317, P861, DOI 10.1056/NEJM198710013171404; DESHPANDE JK, 1987, J CEREBR BLOOD F MET, V7, P89, DOI 10.1038/jcbfm.1987.13; DUX E, 1987, NEUROSCI LETT, V78, P295, DOI 10.1016/0304-3940(87)90376-4; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FAMIGLIO L, 1989, TRANSPLANTATION, V48, P316, DOI 10.1097/00007890-198908000-00025; Folbergrova J, 1997, EXP BRAIN RES, V114, P44, DOI 10.1007/PL00005622; Friberg H, 1998, J NEUROSCI, V18, P5151; FRIEDMAN J, 1991, CELL, V66, P799, DOI 10.1016/0092-8674(91)90123-G; GUNTER TE, 1994, AM J PHYSIOL, V267, pC313; HUGHES RL, 1990, NEW ENGL J MED, V323, P420; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KRAUS JF, 1996, NEUROTRAUMA, P12; Kristal BS, 1997, J NEUROCHEM, V69, P524; Kristian T, 1998, STROKE, V29, P705, DOI 10.1161/01.STR.29.3.705; Li PA, 1997, BRAIN RES, V753, P133, DOI 10.1016/S0006-8993(97)00005-X; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MICHEL RP, 1988, J MICROSC-OXFORD, V150, P117, DOI 10.1111/j.1365-2818.1988.tb04603.x; Nicholls DG, 1998, BBA-BIOENERGETICS, V1366, P97, DOI 10.1016/S0005-2728(98)00123-6; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; Nieminen AL, 1996, NEUROSCIENCE, V75, P993; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; PAAKKARI I, 1995, ANN MED, V27, P369, DOI 10.3109/07853899509002590; PACKER MA, 1995, EUR J BIOCHEM, V234, P231, DOI 10.1111/j.1432-1033.1995.231_c.x; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; PATCHELL RA, 1994, ANN NEUROL, V36, P688, DOI 10.1002/ana.410360503; Paxinos G., 1982, RAT BRAIN STEREOTAXI; REECE DE, 1991, BONE MARROW TRANSPL, V8, P393; Schauwecker PE, 1997, P NATL ACAD SCI USA, V94, P4103, DOI 10.1073/pnas.94.8.4103; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Schinder AF, 1996, J NEUROSCI, V16, P6125; SCHWEIZER M, 1994, BIOCHEM BIOPH RES CO, V204, P169, DOI 10.1006/bbrc.1994.2441; SHARKEY J, 1994, NATURE, V371, P336, DOI 10.1038/371336a0; SHIGA Y, 1992, BRAIN RES, V595, P145, DOI 10.1016/0006-8993(92)91465-Q; Siesjo BK, 1996, EUR J ANAESTH, V13, P247, DOI 10.1046/j.1365-2346.1996.00976.x; SIMS NR, 1987, J NEUROCHEM, V49, P1367, DOI 10.1111/j.1471-4159.1987.tb01001.x; Stout AK, 1998, NAT NEUROSCI, V1, P366; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Tokime T, 1996, NEUROSCI LETT, V206, P81, DOI 10.1016/S0304-3940(96)12438-1; Uchino H, 1995, ACTA PHYSIOL SCAND, V155, P469, DOI 10.1111/j.1748-1716.1995.tb09999.x; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; WALKER RW, 1988, NEUROL CLIN, V6, P261, DOI 10.1016/S0733-8619(18)30869-7; Wang GJ, 1996, J NEUROPHYSIOL, V76, P1611; White RJ, 1996, J NEUROSCI, V16, P5688; WIJDICKS EFM, 1995, NEUROLOGY, V45, P1962, DOI 10.1212/WNL.45.11.1962; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; ZAIDAN E, 1994, J NEUROCHEM, V63, P1812; Zamzami N, 1997, J BIOENERG BIOMEMBR, V29, P185, DOI 10.1023/A:1022694131572; ZORATTI M, 1994, J BIOENERG BIOMEMBR, V26, P543, DOI 10.1007/BF00762739	70	185	192	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	1999	16	9					783	792		10.1089/neu.1999.16.783			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	241EL	WOS:000082869700004	10521138				2021-06-18	
J	Grealy, MA; Johnson, DA; Rushton, SK				Grealy, MA; Johnson, DA; Rushton, SK			Improving cognitive function after brain injury: The use of exercise and virtual reality	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							CEREBRAL BLOOD-FLOW; PHYSICAL-ACTIVITY; REHABILITATION; PERFORMANCE; HIPPOCAMPAL; TECHNOLOGY; BENEFITS; FITNESS; ADULTS; HUMANS	Objective: To assess the impact of exercise and virtual reality (VR) on the cognitive rehabilitation of persons with traumatic brain injury (TBI). Design: Before-after trial assessed cognitive function after a 4-week intervention program. A random allocation crossover assessed changes in reaction and movement times after a single bout of VR exercise and a no-exercise control condition. Setting: Brain injury rehabilitation unit in Edinburgh, Scotland. Patients: (1) Four-week intervention: a consecutive sample of 13 suitable TBI adults were compared to control populations (n > 25) of previous TBI patients of similar age, severity, and time postinjury. (2) Single-bout intervention: a consecutive sample of 13 suitable adults with moderate TBI, 6.29 to 202.86 weeks postinjury. Intervention: Nonimmersive VR exercise. Main Outcome Measures: (1) Tests of attention, information processing, learning, and memory. (2) Reaction and movement times. Results: After the 4-week intervention patients performed significantly better than controls on the digit symbol (p <.01), verbal (p <.01), and visual learning tasks (p <.05). Significant improvements in reaction times (p <.01) and movement times (p <.05) were gained following a single bout of VR exercise. Conclusion: Exercising in a virtual environment offers the potential for significant gains in cognitive function. (C) 1999 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland; Astley Ainslie Hosp, Edinburgh, Midlothian, Scotland	Grealy, MA (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, W Med Bldg, Glasgow G12 8QQ, Lanark, Scotland.		Rushton, Simon/A-1659-2010	Grealy, Madeleine/0000-0002-2823-8841			Andreae MH, 1996, BMJ-BRIT MED J, V312, P4, DOI 10.1136/bmj.312.7022.4; BECKER E, 1978, SCAND J REHABIL MED, V10, P47; BLACK JE, 1990, P NATL ACAD SCI USA, V87, P5568, DOI 10.1073/pnas.87.14.5568; BLACKBURN H, 1988, NEW ENGL J MED, V319, P1217, DOI 10.1056/NEJM198811033191808; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; BROWN BS, 1979, J APPL PHYSIOL, V46, P19; Brown D., 1995, ABILITY, V15, P24; BROWN SW, 1992, PERCEPT MOTOR SKILL, V74, P555, DOI 10.2466/PMS.74.2.555-560; Christiansen C, 1998, ARCH PHYS MED REHAB, V79, P888, DOI 10.1016/S0003-9993(98)90083-1; DECKER MW, 1991, SYNAPSE, V7, P151, DOI 10.1002/syn.890070209; Etnier JL, 1997, J SPORT EXERCISE PSY, V19, P249, DOI 10.1123/jsep.19.3.249; ETNIER JL, 1995, SPORTS MED, V19, P81, DOI 10.2165/00007256-199519020-00001; FORDYCE DE, 1991, BEHAV BRAIN RES, V46, P123, DOI 10.1016/S0166-4328(05)80105-6; GROSS PM, 1980, J APPL PHYSIOL, V48, P213; HERHOLZ K, 1987, J NEUROL, V234, P9, DOI 10.1007/BF00314001; Hetherington CR, 1996, BRAIN INJURY, V10, P473, DOI 10.1080/026990596124197; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P14, DOI 10.1097/00001199-199502000-00004; Hirsh A, 1996, J VOCAT REHABIL, V7, P217; INGVAR DH, 1976, ELECTROEN CLIN NEURO, V41, P268, DOI 10.1016/0013-4694(76)90119-X; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; JANKOWSKI LW, 1990, ARCH PHYS MED REHAB, V71, P500; JOHNSON DA, 1996, P 1 EUR C DIS VIRT R, P247; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; LOFTIN RB, 1995, IEEE COMPUT GRAPH, V15, P31, DOI 10.1109/38.403825; MARTINSEN EW, 1990, SPORTS MED, V9, P380, DOI 10.2165/00007256-199009060-00006; MORAN AJ, 1972, MED J AUSTRALIA, V2, P782, DOI 10.5694/j.1326-5377.1972.tb103537.x; MORAN AJ, 1976, MED J AUSTRALIA, V1, P396, DOI 10.5694/j.1326-5377.1976.tb140699.x; NEEPER SA, 1995, NATURE, V373, P109, DOI 10.1038/373109a0; PUGNETTI L, 1995, COMPUT BIOL MED, V25, P213, DOI 10.1016/0010-4825(94)00040-W; Renner M.J., 1987, ENRICHED IMPOVERISHE; RENNER MJ, 1987, DEV PSYCHOBIOL, V20, P19, DOI 10.1002/dev.420200106; ROGERS HB, 1990, J APPL PHYSIOL, V68, P2358; ROGERS RL, 1990, J AM GERIATR SOC, V38, P123, DOI 10.1111/j.1532-5415.1990.tb03472.x; ROSE F D, 1988, Medical Science Research, V16, P257; ROSE FD, 1994, MED SCI RES, V22, P82; Rose FD, 1996, CURR OPIN NEUROL, V9, P461, DOI 10.1097/00019052-199612000-00012; ROSS KL, 1992, USE PHARM TREATMENT; SATAVA RM, 1992, MINIM INVASIV THER, V1, P357; SCHERZER BP, 1986, ARCH PHYS MED REHAB, V67, P366; SchmitterEdgecombe M, 1996, J HEAD TRAUMA REHAB, V11, P17, DOI 10.1097/00001199-199604000-00003; SMITH M, 1996, BRAIN INJURY IMPROVE, P21; SORYAL I, 1992, CLIN REHABIL, V6, P103; SPIRDUSO WW, 1995, QUEST, V47, P395, DOI 10.1080/00336297.1995.10484166; SULLIVAN S J, 1990, Brain Injury, V4, P407, DOI 10.3109/02699059009026194; THOMAS SN, 1989, J APPL PHYSIOL, V67, P744; vansZomeren AH, 1987, NEUROBEHAVIORAL RECO, P398; Vitale AE, 1996, BRAIN INJURY, V10, P367, DOI 10.1080/026990596124377; VONSTEINBUCHEL N, 1993, BEHAV BRAIN RES, V56, P1, DOI 10.1016/0166-4328(93)90017-K; Wolman RL, 1994, CLIN REHABIL, V8, P253	49	185	189	2	60	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUN	1999	80	6					661	667		10.1016/S0003-9993(99)90169-7			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	204LG	WOS:000080765300009	10378492				2021-06-18	
J	Jakeman, LB; Wei, P; Guan, Z; Stokes, BT				Jakeman, LB; Wei, P; Guan, Z; Stokes, BT			Brain-derived neurotrophic factor stimulates hindlimb stepping and sprouting of cholinergic fibers after spinal cord injury	EXPERIMENTAL NEUROLOGY			English	Article						neurotrophin; BDNF; trauma; spinal pattern generator; regeneration; functional recovery	CENTRAL-NERVOUS-SYSTEM; ADULT-RAT; AXONAL REGENERATION; MOTOR-NEURONS; SYNAPTIC TRANSMISSION; HIPPOCAMPAL-NEURONS; FACTOR PROMOTES; TRKB PROTEIN; IN-VIVO; BDNF	Neurotrophic factors have been proposed as a therapeutic treatment for traumatic brain and spinal cord injury The present study determined whether exogenous administration of one such factor, brain derived neurotrophic factor (BDNF), could effect behavioral recovery and/or histopathological changes after spinal cord injury. Adult rats received a mild or moderate contusion injury or complete transection of the midthoracic spinal cord. Immediately thereafter, they were infused intrathecally with vehicle or BDNF for 28 days. Behavioral recovery was evaluated for 6 weeks after injury, at which time the rats were sacrificed and the spinal cord tissue was examined histologically. The infusion of BDNF resulted in acute stimulation of hindlimb activity. These effects included activation of alternating airstepping in injured rats when the hindlimbs mere unloaded as well as slight improvements in the rate of recovery in open field locomotion score. BDNF infusion was also associated with enhanced growth of cholinergic fibers at the injury epicenter, but did not affect white matter sparing or density of serotonergic axons at or below the injury site. Based on immunohistochemical detection of BDNF protein distribution, these described effects are likely to be mediated by the activation of cells and axons within the central injury region and the along the peripheral rim of the spinal cord. Together, these findings demonstrate that the exogenous infusion of BDNF after spinal trauma can influence postinjury outcome through mechanisms that include acute stimulation of hindlimb activity and neuritogenesis at the injury site. (C) 1998 Academic Press.	Ohio State Univ, Dept Physiol, Columbus, OH 43210 USA; Ohio State Univ, Spinal Cord Injury Res Ctr, Columbus, OH 43210 USA	Jakeman, LB (corresponding author), Ohio State Univ, Dept Physiol, 1645 Neil Ave, Columbus, OH 43210 USA.			Jakeman, Lyn/0000-0002-1760-8819	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-10124/2, NS-37321] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037321] Funding Source: NIH RePORTER		Anderson TE, 1995, J URBAN TECHNOL, V3, P29, DOI 10.1080/10630739508724515; BARBEAU H, 1987, BRAIN RES, V412, P84, DOI 10.1016/0006-8993(87)91442-9; BARBEAU H, 1991, BRAIN RES, V546, P250, DOI 10.1016/0006-8993(91)91489-N; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; BECK T, 1994, J CEREBR BLOOD F MET, V14, P689, DOI 10.1038/jcbfm.1994.86; BEHRMANN DL, 1992, J NEUROTRAUM, V9, P197, DOI 10.1089/neu.1992.9.197; BELLUARDO N, 1995, NEUROSCI LETT, V196, P1, DOI 10.1016/0304-3940(95)11819-I; BREGMAN BS, 1997, EXP NEUROL, V148, P474; BRESNAHAN JC, 1987, EXP NEUROL, V95, P548, DOI 10.1016/0014-4886(87)90299-8; CABELLI RJ, 1995, SCIENCE, V267, P1662, DOI 10.1126/science.7886458; Cabelli RJ, 1997, NEURON, V19, P63, DOI 10.1016/S0896-6273(00)80348-7; Cheng H, 1996, SCIENCE, V273, P510, DOI 10.1126/science.273.5274.510; CLATTERBUCK RE, 1994, J COMP NEUROL, V342, P45, DOI 10.1002/cne.903420106; DIENER PS, 1994, NEUROREPORT, V5, P1913, DOI 10.1097/00001756-199410000-00018; Dittrich F, 1996, EXP NEUROL, V141, P225, DOI 10.1006/exnr.1996.0157; EDGERTON VR, 1992, J NEUROTRAUM, V9, pS119; Edgerton VR, 1997, NEUROSCIENTIST, V3, P287, DOI 10.1177/107385849700300510; ERNFORS P, 1993, MOL BRAIN RES, V17, P217, DOI 10.1016/0169-328X(93)90005-A; Fawcett JW, 1997, CELL TISSUE RES, V290, P371, DOI 10.1007/s004410050943; FORSSBERG H, 1973, BRAIN RES, V50, P184, DOI 10.1016/0006-8993(73)90606-9; Frank L, 1996, EUR J NEUROSCI, V8, P1220, DOI 10.1111/j.1460-9568.1996.tb01290.x; Frank L, 1997, EXP NEUROL, V145, P62, DOI 10.1006/exnr.1997.6440; FRIEDMAN B, 1995, J NEUROSCI, V15, P1044; FRISEN J, 1993, P NATL ACAD SCI USA, V90, P4971, DOI 10.1073/pnas.90.11.4971; GARCIARILL E, 1987, BRAIN RES, V411, P1, DOI 10.1016/0006-8993(87)90675-5; GRILLNER S, 1985, ANNU REV NEUROSCI, V8, P233, DOI 10.1146/annurev.ne.08.030185.001313; Harkema SJ, 1997, J NEUROPHYSIOL, V77, P797; HORNER PJ, 1995, J NEUROTRAUM, V12, P982; IWAHARA T, 1992, BRAIN RES BULL, V28, P99, DOI 10.1016/0361-9230(92)90235-P; IWAHARA T, 1991, DEV BRAIN RES, V58, P257, DOI 10.1016/0165-3806(91)90013-9; IWASHITA Y, 1994, NATURE, V367, P167, DOI 10.1038/367167a0; KAKULAS B, 1996, ANN REV INT SPINAL R, P28; Kakulas B A, 1984, Cent Nerv Syst Trauma, V1, P117; KANG HJ, 1995, SCIENCE, V267, P1658, DOI 10.1126/science.7886457; Kim DH, 1996, NEUROREPORT, V7, P2221, DOI 10.1097/00001756-199609020-00033; Kishino A, 1997, EXP NEUROL, V144, P273, DOI 10.1006/exnr.1996.6367; LEVINE ES, 1995, P NATL ACAD SCI USA, V92, P8074, DOI 10.1073/pnas.92.17.8074; Levine ES, 1996, MOL BRAIN RES, V38, P300, DOI 10.1016/0169-328X(96)00025-3; LINDA H, 1992, J COMP NEUROL, V318, P188, DOI 10.1002/cne.903180205; LINDSAY RM, 1994, TRENDS NEUROSCI, V17, P182, DOI 10.1016/0166-2236(94)90099-X; LINDVALL O, 1994, TRENDS NEUROSCI, V17, P490, DOI 10.1016/0166-2236(94)90139-2; Liu XZ, 1997, J NEUROSCI, V17, P5395; Mamounas LA, 1995, J NEUROSCI, V15, P7929; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; McTigue DM, 1998, J NEUROSCI, V18, P5354; MOCCHETTI I, 1995, J NEUROTRAUM, V12, P853, DOI 10.1089/neu.1995.12.853; MUFSON EJ, 1994, EXP NEUROL, V129, P15, DOI 10.1006/exnr.1994.1143; Novikov L, 1997, NEUROSCIENCE, V79, P765, DOI 10.1016/S0306-4522(96)00665-3; Novikova L, 1996, NEUROSCI LETT, V220, P203, DOI 10.1016/S0304-3940(96)13267-5; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; Rossignol S, 1993, J Am Paraplegia Soc, V16, P190; Sawai H, 1996, J NEUROSCI, V16, P3887; Schabitz WR, 1997, J CEREBR BLOOD F MET, V17, P500, DOI 10.1097/00004647-199705000-00003; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; SCHNELL L, 1994, NATURE, V367, P170, DOI 10.1038/367170a0; Schwab ME, 1996, PHYSIOL REV, V76, P319; SHEN RY, 1994, P NATL ACAD SCI USA, V91, P8920, DOI 10.1073/pnas.91.19.8920; Siuciak JA, 1996, BRAIN RES, V710, P11, DOI 10.1016/0006-8993(95)01289-3; SNIDER WD, 1996, MOL CELL NEUROSCI, V7, P442; SOMERSON SK, 1987, EXP NEUROL, V96, P82, DOI 10.1016/0014-4886(87)90170-1; STOKES BT, 1992, EXP NEUROL, V116, P1, DOI 10.1016/0014-4886(92)90171-L; STOKES BT, 1992, J NEUROTRAUM, V9, P187, DOI 10.1089/neu.1992.9.187; TETZLAFF W, 1994, PROG BRAIN RES, V103, P271; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; Tuszynski MH, 1996, NEUROSCIENCE, V71, P761, DOI 10.1016/0306-4522(95)00440-8; VANHARTESVELDT C, 1991, DEV BRAIN RES, V58, P251, DOI 10.1016/0165-3806(91)90012-8; Winer B.J., 1991, STAT PRINCIPLES EXPT; XU XM, 1995, J COMP NEUROL, V351, P145, DOI 10.1002/cne.903510113; XU XM, 1995, EXP NEUROL, V134, P261, DOI 10.1006/exnr.1995.1056; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0; YAN Q, 1994, EXP NEUROL, V127, P23, DOI 10.1006/exnr.1994.1076; YAN Q, 1994, J NEUROSCI, V14, P5281; Ye JH, 1997, EXP NEUROL, V143, P70, DOI 10.1006/exnr.1996.6353; Zhang ZY, 1997, EXP NEUROL, V143, P141, DOI 10.1006/exnr.1996.6355	75	185	202	0	10	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	NOV	1998	154	1					170	184		10.1006/exnr.1998.6924			15	Neurosciences	Neurosciences & Neurology	144TX	WOS:000077332100017	9875278				2021-06-18	
J	Wade, DT; King, NS; Wenden, FJ; Crawford, S; Caldwell, FE				Wade, DT; King, NS; Wenden, FJ; Crawford, S; Caldwell, FE			Routine follow up after head injury: a second randomised controlled trial	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						head injury; follow up service; randomised controlled trial; outcome	MILD; SYMPTOMS; CONCUSSION; SCALE; QUESTIONNAIRE; EPIDEMIOLOGY; MODERATE	Objective-To confirm that patients admitted to hospital with a head injury benefit from a routinely offered early intervention service. Patients and methods-A mixed rural and urban Health District of 560 000 people with two accident and emergency departments provided the setting. Existing routine services for most patients with head injury are minimal. All patients aged 16-65 years admitted to hospital after a head injury of any severity, with or without other injuries entered the trial. Prospective randomisation, with a block randomisation procedure was used to allocate all eligible patients to either: a group offered an additional service by a specialist team; or a group receiving existing standard services. Patients were assessed at follow up six months after injury. The primary outcome measure was the Rivermead head injury follow up questionnaire, a validated and reliable measure of social disability. The Rivermead post-concussion symptoms questionnaire was used to estimate severity of post-concussion symptoms. Each patient in the trial group was contacted 7-10 days after injury, and offered assessment and interventions as needed. These initially focused on the provision of information, support, and advice. Forty six per cent of patients in the trial group also received further outpatient intervention or additional support by telephone. Results-314 patients were registered: 184 were randomised into the trial group, 130 into the control group. For prognostic data, the groups were comparable at randomisation, and remained comparable when assessed at six months. 132 trial and 86 control patients were followed up at six months after injury. Patients' posttraumatic amnesia ranged from mild (n=79, 40%), and moderate (n=62, 32%), to severe (n=38, 19%) and very severe (n=17, 9%). The trial group patients had significantly less social disability (p=0.01) and significantly less severe post-concussion symptoms (p=0.02) at follow up at six months after injury than the control group patients. Conclusions-The early interventions offered by a specialist service significantly reduced social morbidity and severity of post-concussion symptoms in trial group patients at six months after head injury. Recommendations about how specialist services should be targeted are made both in the Light of these results and those from a previous randomised controlled trial.	Rivermead Rehabil Ctr, Oxford OX1 4XD, England	Wade, DT (corresponding author), Rivermead Rehabil Ctr, Abingdon Rd, Oxford OX1 4XD, England.			Wade, Derick/0000-0002-1188-8442			Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; ARTIOLA I, 1980, J NEUROL NEUROSUR PS, V43, P77; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; DIKMEN S, 1989, MILD HEAD INJURY; EVANS RW, 1992, NEUROL CLIN, V10, P815; EWING R, 1980, Journal of Clinical Neuropsychology, V2, P147, DOI 10.1080/01688638008403789; GREENWOOD RJ, 1994, BRIT MED J, V308, P1199, DOI 10.1136/bmj.308.6938.1199; GRONWALL D, 1974, LANCET, V2, P605; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; KATZMAN R, 1983, AM J PSYCHIAT, V140, P737; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; King NS, 1997, J NEUROL NEUROSUR PS, V62, P82, DOI 10.1136/jnnp.62.1.82; King NS, 1997, CLIN REHABIL, V11, P13, DOI 10.1177/026921559701100104; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; MANDEL S, 1989, POSTGRAD MED, V85, P213; *MED DIS SOC, 1988, MAN TRAUM BRAIN INJ; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; Moss NE, 1996, DISABIL REHABIL, V18, P169, DOI 10.3109/09638289609166296; Moss NEG, 1996, INJURY, V27, P159, DOI 10.1016/0020-1383(95)00217-0; MOSS NEG, 1994, CLIN REHABIL, V8, P149; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; RELANDER M, 1972, BMJ-BRIT MED J, V4, P777, DOI 10.1136/bmj.4.5843.777; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; VARNEY NR, 1995, J HEAD TRAUMA REHAB, V10, P18; Wade DT, 1997, J NEUROL NEUROSUR PS, V62, P478, DOI 10.1136/jnnp.62.5.478; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	33	185	187	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	AUG	1998	65	2					177	183		10.1136/jnnp.65.2.177			7	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	105QG	WOS:000075084700008	9703167	Green Published, Bronze			2021-06-18	
J	Kossmann, T; Hans, V; Imhof, HG; Trentz, O; MorgantiKossmann, MC				Kossmann, T; Hans, V; Imhof, HG; Trentz, O; MorgantiKossmann, MC			Interleukin-6 released in human cerebrospinal fluid following traumatic brain injury may trigger nerve growth factor production in astrocytes	BRAIN RESEARCH			English	Article						cytokine; interleukin-6; nerve growth factor; traumatic brain injury; astrocyte; human	ADULT-RAT BRAIN; STIMULATORY FACTOR-II; TUMOR NECROSIS FACTOR; FACTOR MESSENGER-RNA; ALZHEIMERS-DISEASE; GENE-EXPRESSION; GLIAL-CELLS; NGF; SECRETION; SYSTEM	Cytokines are involved in nerve regeneration by modulating the synthesis of neurotrophic factors. The role played by interleukin-6 (IL-6) in promoting nerve growth factor (NGF) after brain injury was investigated by monitoring the release of IL-6 and NGF in ventricular cerebrospinal fluid (CSF) of 22 patients with severe traumatic brain injuries. IL-6 was found in the CSF of all individuals and remained elevated for the whole study period. NGF appeared in the CSF if IL-6 levels reached high concentrations and was often detected simultaneously with or following an IL-6 peak. The amounts of NGF correlated with the severity of the injury, as indicated by the clinical outcome of the patients. The functional relationship of IL-6 and NGF was investigated utilizing cultured mouse astrocytes. The CSF of 8 patients containing IL-6 induced NGF production in astrocytes, whereas control CSF without IL-6 had no effect. The induction of NGF was inhibited up to 100% by adding anti-IL-6 antibodies. These results were corroborated when astrocytes were exposed to recombinant IL-6 at different concentrations resulting in NGF production. Thus, the production of IL-6 within the injured brain may likely contribute to the release of neurotrophic factors by astrocytes.	UNIV ZURICH HOSP, DEPT NEUROSURG, CH-8091 ZURICH, SWITZERLAND; UNIV ZURICH HOSP, DIV EXPT SURG, CH-8091 ZURICH, SWITZERLAND; UNIV ZURICH HOSP, DEPT SURG, DIV TRAUMA SURG, CH-8091 ZURICH, SWITZERLAND				Morganti-Kossmann, Cristina/0000-0002-0807-2063			AARDEN LA, 1987, EUR J IMMUNOL, V17, P1411, DOI 10.1002/eji.1830171004; AWATSUJI H, 1993, J NEUROSCI RES, V34, P539, DOI 10.1002/jnr.490340506; BANDTLOW CE, 1990, J CELL BIOL, V111, P1701, DOI 10.1083/jcb.111.4.1701; BENVENISTE EN, 1990, J NEUROIMMUNOL, V30, P201, DOI 10.1016/0165-5728(90)90104-U; BENVENISTE EN, IN PRESS IMMUNOLOGY; BUTCHER LL, 1989, NEUROBIOL AGING, V10, P557, DOI 10.1016/0197-4580(89)90130-9; BYRAVAN S, 1994, P NATL ACAD SCI USA, V91, P8812, DOI 10.1073/pnas.91.19.8812; CARMANKRZAN M, 1991, J NEUROCHEM, V56, P636, DOI 10.1111/j.1471-4159.1991.tb08197.x; FONTANA A, 1982, J IMMUNOL, V129, P2414; FREI K, 1988, J EXP MED, V168, P449, DOI 10.1084/jem.168.1.449; FREI K, 1989, EUR J IMMUNOL, V19, P689, DOI 10.1002/eji.1830190418; FURUKAWA Y, 1989, FEBS LETT, V247, P395; GADIENT RA, 1990, NEUROSCI LETT, V117, P335, DOI 10.1016/0304-3940(90)90687-5; GALLO P, 1989, J NEUROIMMUNOL, V23, P109, DOI 10.1016/0165-5728(89)90029-5; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; HAGG T, 1990, J NEUROSCI, V10, P3087; HAMA T, 1989, NEUROSCI LETT, V104, P340, DOI 10.1016/0304-3940(89)90600-9; HEUMANN R, 1987, J CELL BIOL, V104, P1623, DOI 10.1083/jcb.104.6.1623; HIRANO T, 1985, P NATL ACAD SCI USA, V82, P5490, DOI 10.1073/pnas.82.16.5490; JENNETT B, 1975, LANCET, V1, P482; JUNARD EO, 1990, EXP NEUROL, V110, P25, DOI 10.1016/0014-4886(90)90048-W; KITAMURA T, 1994, TRENDS ENDOCRIN MET, V5, P8, DOI 10.1016/1043-2760(94)90115-5; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; KUMAR S, 1993, MOL BRAIN RES, V17, P163, DOI 10.1016/0169-328X(93)90086-5; LEPPERT D, 1989, J NEUROIMMUNOL, V24, P259, DOI 10.1016/0165-5728(89)90124-0; LEVIMONTALCINI R, 1968, PHYSIOL REV, V48, P534; Lindholm D, 1990, Neuroreport, V1, P9; LINDSAY RM, 1979, NATURE, V282, P80, DOI 10.1038/282080a0; LINDSAY RM, 1990, EUR J NEUROSCI, V2, P389, DOI 10.1111/j.1460-9568.1990.tb00431.x; LOGAN A, 1992, BRAIN RES, V587, P216, DOI 10.1016/0006-8993(92)91000-5; LONGO FM, 1984, EXP NEUROL, V84, P207, DOI 10.1016/0014-4886(84)90016-5; LU B, 1991, J NEUROSCI, V11, P318; MAIMONE D, 1991, J NEUROIMMUNOL, V32, P67, DOI 10.1016/0165-5728(91)90073-G; MATHIESEN T, 1993, J NEUROSURG, V78, P562, DOI 10.3171/jns.1993.78.4.0562; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; MOBLEY WC, 1988, P NATL ACAD SCI USA, V85, P9811, DOI 10.1073/pnas.85.24.9811; MORGANTI MC, 1990, EXP NEUROL, V109, P98, DOI 10.1016/S0014-4886(05)80012-3; MORGANTIKOSSMAN.MC, IN PRESS IMMUNE RESP; MORGANTIKOSSMANN MC, 1992, J NEUROIMMUNOL, V39, P163, DOI 10.1016/0165-5728(92)90185-N; NIETOSAMPEDRO M, 1982, SCIENCE, V217, P860, DOI 10.1126/science.7100931; NIETOSAMPEDRO M, 1987, J NEUROSCI RES, V17, P214, DOI 10.1002/jnr.490170303; OKADA M, 1983, J EXP MED, V157, P583, DOI 10.1084/jem.157.2.583; PATTERSON SL, 1993, BRAIN RES, V605, P43, DOI 10.1016/0006-8993(93)91354-U; ROBBINS DS, 1987, J IMMUNOL, V139, P2593; ROBERTS GN, 1991, LANCET, V337, P1342; ROSENBERG MB, 1988, SCIENCE, V242, P1575, DOI 10.1126/science.3201248; RUDGE JS, 1994, EUR J NEUROSCI, V6, P218, DOI 10.1111/j.1460-9568.1994.tb00264.x; SATOH T, 1988, MOL CELL BIOL, V8, P3546, DOI 10.1128/MCB.8.8.3546; SAWADA M, 1993, NEUROSCI LETT, V160, P131, DOI 10.1016/0304-3940(93)90396-3; SELMAJ KW, 1990, J IMMUNOL, V144, P129; SPRANGER M, 1990, EUR J NEUROSCI, V2, P69, DOI 10.1111/j.1460-9568.1990.tb00382.x; STOCKER R, 1995, INTEGRATED APPROACH, P197; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; TEASDALE G, 1974, LANCET, V2, P81; TEDESCHI B, 1986, J CELL BIOL, V102, P2244, DOI 10.1083/jcb.102.6.2244; VANDENABEELE P, 1991, IMMUNOL TODAY, V12, P217, DOI 10.1016/0167-5699(91)90032-O; VANSNICK J, 1990, ANNU REV IMMUNOL, V8, P253, DOI 10.1146/annurev.iy.08.040190.001345; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; YOSHIDA K, 1991, BRAIN RES, V538, P118, DOI 10.1016/0006-8993(91)90385-9; YOSHIDA K, 1992, BRAIN RES, V569, P14, DOI 10.1016/0006-8993(92)90364-F	61	185	187	1	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAR 25	1996	713	1-2					143	152		10.1016/0006-8993(95)01501-9			10	Neurosciences	Neurosciences & Neurology	UE900	WOS:A1996UE90000017	8724985				2021-06-18	
J	HALL, KM; KARZMARK, P; STEVENS, M; ENGLANDER, J; OHARE, P; WRIGHT, J				HALL, KM; KARZMARK, P; STEVENS, M; ENGLANDER, J; OHARE, P; WRIGHT, J			FAMILY STRESSORS IN TRAUMATIC BRAIN INJURY - A 2-YEAR FOLLOW-UP	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							SEVERE HEAD-INJURY; RELATIVES		SANTA CLARA VALLEY MED CTR,DEPT PHYS MED & REHABIL RES,SAN JOSE,CA 95128; SANTA CLARA VALLEY MED CTR,TBI MODEL SYST PROJECT,SAN JOSE,CA 95128							Bond M R, 1975, Ciba Found Symp, P141; BROOK DN, 1979, 2ND EUR C INT NEUR S; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N., 1984, CLOSED HEAD INJURY P; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; DONALD CA, 1982, HLTH INSURANCE EXPT; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; FAHY TJ, 1967, LANCET, V2, P475; Florian V, 1989, Brain Inj, V3, P219, DOI 10.3109/02699058909029637; HAAS JF, 1987, J NEUROL NEUROSUR PS, V50, P52, DOI 10.1136/jnnp.50.1.52; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; Holmes T., 1974, STRESSFUL LIFE EVENT, P45; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; Kubler-Ross E., 1969, DEATH DYING; LEWIN W, 1979, BRIT MED J, V2, P1533, DOI 10.1136/bmj.2.6204.1533; Lezak M. D., 1987, J HEAD TRAUMA REHAB, V2, P57, DOI [10.1097/00001199-198703000-00009, DOI 10.1097/00001199-198703000-00009]; LEZAK MD, 1986, REHABIL PSYCHOL, V3, P241; LEZAK MD, 1980, 8TH ANN M INT NEUR S; Livingston M G, 1987, Brain Inj, V1, P33, DOI 10.3109/02699058709034442; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P870, DOI 10.1136/jnnp.48.9.870; LIVINGSTON MG, 1985, J NEUROL NEUROSUR PS, V48, P876, DOI 10.1136/jnnp.48.9.876; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; ODDY M, 1984, CLOSED HEAD INJURY; PANTING P, 1970, J REHABIL, V38, P33; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; RAPPAPORT M, 1989, ARCH PHYS MED REHAB, V70, P885; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; ROMANO MD, 1974, SCAND J REHABIL MED, V6, P1; ROSENBAUM M, 1976, J CONSULT CLIN PSYCH, V44, P881, DOI 10.1037/0022-006X.44.6.881; Stern J M, 1988, Brain Inj, V2, P259, DOI 10.3109/02699058809150951; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; WILLER B, 1989, SUNY895 REH RES TRAI; WILLER B, 1989, SUNY892 REH RES TRAI; 1987, AM PSYCHIATRIC ASS D	40	185	189	0	5	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	1994	75	8					876	884		10.1016/0003-9993(94)90112-0			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	PB621	WOS:A1994PB62100007	8053794				2021-06-18	
J	MARTIN, NA; DOBERSTEIN, C; ZANE, C; CARON, MJ; THOMAS, K; BECKER, DP				MARTIN, NA; DOBERSTEIN, C; ZANE, C; CARON, MJ; THOMAS, K; BECKER, DP			POSTTRAUMATIC CEREBRAL ARTERIAL SPASM - TRANSCRANIAL DOPPLER ULTRASOUND, CEREBRAL BLOOD-FLOW, AND ANGIOGRAPHIC FINDINGS	JOURNAL OF NEUROSURGERY			English	Article						CEREBRAL BLOOD FLOW; CEREBRAL ISCHEMIA; HEAD INJURY; TRANSCRANIAL DOPPLER ULTRASOUND; VASOSPASM	ACUTE HEAD-INJURY; SUBARACHNOID HEMORRHAGE; CONTROLLED TRIAL; VASOSPASM; HYPERTENSION; VELOCITY; NIMODIPINE; METABOLISM; DIAGNOSIS; ISCHEMIA	Thirty patients admitted after suffering closed head injuries, with Glasgow Coma Scale scores ranging from 3 to 15, were evaluated with transcranial Doppler ultrasound monitoring. Blood flow velocity was determined in the middle cerebral artery (MCA) and the intracranial portion of the internal carotid artery (ICA) in all patients. Because proximal flow in the extracranial ICA declines in velocity when arterial narrowing becomes hemodynamically significant, the extracranial ICA velocity was concurrently monitored in 19 patients. To assess cerebral perfusion, cerebral blood flow (CBF) measurements obtained with the intravenous Xe-133 technique were completed in 16 patients. Vasospasm, designated as MCA velocity exceeding 120 cm/sec, was found in eight patients (26.7%). Severe vasospasm, defined as MCA velocity greater than 200 cm/sec, occurred in three patients, and was confirmed by angiography in all three. Subarachnoid hemorrhage (SAH) was documented by computerized tomography in five (62.5%) of the eight patients with vasospasm. All cases of severe vasospasm were associated with subarachnoid blood. The time course of vasospasm in patients with traumatic SAH was similar to that found in patients with aneurysmal SAH; in contrast, arterial spasm not associated with SAH demonstrated an uncharacteristically short duration (mean 1.25 days), suggesting that this may be a different type of spasm. A significant correlation (p < 0.05) was identified between the lowest CBF and highest MCA velocity in patients during the period of vasospasm, indicating that arterial narrowing can lead to impaired CBF. Ischemic brain damage was found in one patient who had evidence of cerebral infarction in the territories supplied by the arteries affected by spasm. These findings demonstrate that delayed cerebral arterial spasm is a frequent complication of closed head injury and that the severity of spasm is, in some cases, comparable to that seen in aneurysmal SAH. This experience suggests that vasospasm is an important secondary posttraumatic insult that is potentially treatable.		MARTIN, NA (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,MED CTR,DIV NEUROSURG,CEREBRAL BLOOD FLOW LAB,74-140 CHS,LOS ANGELES,CA 90024, USA.			Martin, Neil/0000-0002-6565-4131			AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; AGNOLI A, 1969, CEREBRAL BLOOD FLOW, P31; ALLEN GS, 1983, NEW ENGL J MED, V308, P619, DOI 10.1056/NEJM198303173081103; AWAD IA, 1987, STROKE, V18, P365, DOI 10.1161/01.STR.18.2.365; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Eskridge J M, 1990, Neurosurg Clin N Am, V1, P387; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; HARDERS AG, 1987, J NEUROSURG, V66, P718, DOI 10.3171/jns.1987.66.5.0718; JENNETT B, 1975, LANCET, V1, P480; KASSELL NF, 1982, NEUROSURGERY, V11, P337, DOI 10.1227/00006123-198209000-00001; LINDEGAARD KF, 1989, ACTA NEUROCHIR, V100, P12, DOI 10.1007/BF01405268; MACPHERSON P, 1978, J NEUROL NEUROSUR PS, V41, P122, DOI 10.1136/jnnp.41.2.122; MILLER JD, 1980, CEREBRAL ARTERIAL SP, P476; MUIZELAAR JP, 1986, SURG NEUROL, V25, P317, DOI 10.1016/0090-3019(86)90205-3; MUIZELAAR JP, 1989, TXB HEAD INJURY, P221; Newell D W, 1990, Neurosurg Clin N Am, V1, P319; NEWELL DW, 1989, J NEUROSURG, V71, P654, DOI 10.3171/jns.1989.71.5.0654; NEWELL DW, 1992, IN PRESS CLIN NEUROS, V39; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; PETRUK KC, 1988, J NEUROSURG, V68, P505, DOI 10.3171/jns.1988.68.4.0505; ROBERTSON CS, 1987, J NEUROSURG, V67, P361, DOI 10.3171/jns.1987.67.3.0361; SEILER RW, 1986, J NEUROSURG, V64, P594, DOI 10.3171/jns.1986.64.4.0594; SEKHAR LN, 1988, NEUROSURGERY, V22, P813, DOI 10.1227/00006123-198805000-00002; SUWANWELA C, 1972, J NEUROSURG, V36, P314, DOI 10.3171/jns.1972.36.3.0314; TEASDALE G, 1974, LANCET, V2, P81; WEBER M, 1990, NEUROSURGERY, V27, P106, DOI 10.1227/00006123-199007000-00015; Wilkins R H, 1990, Neurosurg Clin N Am, V1, P329; WILKINS RH, 1970, J NEUROSURG, V32, P626, DOI 10.3171/jns.1970.32.6.0626	29	185	199	0	10	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	OCT	1992	77	4					575	583		10.3171/jns.1992.77.4.0575			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	JP648	WOS:A1992JP64800014	1527618				2021-06-18	
J	Moussa, C; Hebron, M; Huang, X; Ahn, J; Rissman, RA; Aisen, PS; Turner, RS				Moussa, Charbel; Hebron, Michaeline; Huang, Xu; Ahn, Jaeil; Rissman, Robert A.; Aisen, Paul S.; Turner, R. Scott			Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer's disease	JOURNAL OF NEUROINFLAMMATION			English	Article						Resveratrol; Matrix metalloproteinase-(MMP)-9; Alzheimer; Interleukin-4; Macrophage-derived chemokine (MDC)	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; TRAUMATIC BRAIN-INJURY; GENE KNOCK-OUT; MATRIX METALLOPROTEINASES; MULTIPLE-SCLEROSIS; TISSUE INHIBITORS; CEREBROSPINAL-FLUID; CEREBRAL-ISCHEMIA; MMP-9; MATRIX-METALLOPROTEINASE-9	Background: Treatment of mild-moderate Alzheimer's disease (AD) subjects (N = 119) for 52 weeks with the SIRT1 activator resveratrol (up to 1 g by mouth twice daily) attenuates progressive declines in CSF A beta 40 levels and activities of daily living (ADL) scores. Methods: For this retrospective study, we examined banked CSF and plasma samples from a subset of AD subjects with CSF A beta 42 < 600 ng/ml (biomarker-confirmed AD) at baseline (N = 19 resveratrol-treated and N = 19 placebo-treated). We utilized multiplex Xmap technology to measure markers of neurodegenerative disease and metalloproteinases (MMPs) in parallel in CSF and plasma samples. Results: Compared to the placebo-treated group, at 52 weeks, resveratrol markedly reduced CSF MMP9 and increased macrophage-derived chemokine (MDC), interleukin (IL)-4, and fibroblast growth factor (FGF)-2. Compared to baseline, resveratrol increased plasma MMP10 and decreased IL-12P40, IL12P70, and RANTES. In this subset analysis, resveratrol treatment attenuated declines in mini-mental status examination (MMSE) scores, change in ADL (ADCS-ADL) scores, and CSF A beta 42 levels during the 52-week trial, but did not alter tau levels. Conclusions: Collectively, these data suggest that resveratrol decreases CSF MMP9, modulates neuro-inflammation, and induces adaptive immunity. SIRT1 activation may be a viable target for treatment or prevention of neurodegenerative disorders.	[Moussa, Charbel; Hebron, Michaeline; Huang, Xu] Georgetown Univ, Med Ctr, Dept Neurol,Natl Parkinsons Fdn Ctr Excellence, Lab Dementia & Parkinsonism,Translat Neurotherape, 4000 Reservoir Rd NW, Washington, DC 20057 USA; [Ahn, Jaeil] Georgetown Univ, Dept Neurol, Memory Disorders Program, Translat Neurotherapeut Program, Washington, DC USA; [Rissman, Robert A.] Georgetown Univ, Med Ctr, Dept Biostat, 4000 Reservoir Rd NW, Washington, DC 20057 USA; [Aisen, Paul S.] Univ Southern Calif, ATRI, San Diego, CA USA; [Turner, R. Scott] Univ Calif San Diego, Dept Neurosci, ADCS, San Diego, CA 92103 USA	Moussa, C (corresponding author), Georgetown Univ, Med Ctr, Dept Neurol,Natl Parkinsons Fdn Ctr Excellence, Lab Dementia & Parkinsonism,Translat Neurotherape, 4000 Reservoir Rd NW, Washington, DC 20057 USA.	cem46@georgetown.edu	Turner, Raymond Scott/G-2263-2011	Turner, Raymond Scott/0000-0001-7534-2935	NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [U01 AG010483]; Georgetown University; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [U01AG010483] Funding Source: NIH RePORTER	This work was supported by NIA U01 AG010483 (to PSA) for original trial, Georgetown University support (to CM) to conduct the biomarker studies and write the manuscript, and a philanthropic gift from Ms. Pat Harvey (to RST) to purchase ELISA kits for biomarkers. The original trial may be found at ClinicalTrials.gov NCT01504854.	Abraham M, 2005, J NEUROIMMUNOL, V163, P157, DOI 10.1016/j.jneuroim.2005.02.001; Agrawal S, 2006, J EXP MED, V203, P1007, DOI 10.1084/jem.20051342; Asahi M, 2000, J CEREBR BLOOD F MET, V20, P1681, DOI 10.1097/00004647-200012000-00007; Barkho BZ, 2008, STEM CELLS, V26, P3139, DOI 10.1634/stemcells.2008-0519; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; Candelario-Jalil E, 2009, NEUROSCIENCE, V158, P983, DOI 10.1016/j.neuroscience.2008.06.025; Chakrabarty P, 2015, NEURON, V85, P519, DOI 10.1016/j.neuron.2014.11.020; Chaturvedi M, 2014, MOL NEUROBIOL, V49, P563, DOI 10.1007/s12035-013-8538-z; Columba-Cabezas S, 2002, J NEUROIMMUNOL, V130, P10, DOI 10.1016/S0165-5728(02)00170-4; Conant K, 2010, NEUROSCIENCE, V166, P508, DOI 10.1016/j.neuroscience.2009.12.061; De Stefano N, 2014, CNS DRUGS, V28, P147, DOI 10.1007/s40263-014-0140-z; Dubois B, 1999, J CLIN INVEST, V104, P1507, DOI 10.1172/JCI6886; Dziembowska M, 2012, J NEUROSCI, V32, P14538, DOI 10.1523/JNEUROSCI.6028-11.2012; Dzwonek J, 2004, FEBS LETT, V567, P129, DOI 10.1016/j.febslet.2004.03.070; Fields J, 2014, J NEUROIMMUNE PHARM, V9, P102, DOI 10.1007/s11481-013-9520-2; Fox NC, 2005, NEUROLOGY, V64, P1563, DOI 10.1212/01.WNL.0000159743.08996.99; Glabinski AR, 1999, J NEUROVIROL, V5, P3, DOI 10.3109/13550289909029740; Goetzl EJ, 1996, J IMMUNOL, V156, P1; Gramegna P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028499; Guillot-Sestier MV, 2015, NEURON, V85, P534, DOI 10.1016/j.neuron.2014.12.068; Hayashi T, 2009, BRAIN RES, V1280, P172, DOI 10.1016/j.brainres.2009.05.040; Imai T, 1999, INT IMMUNOL, V11, P81, DOI 10.1093/intimm/11.1.81; Jugde F, 2001, EUR CYTOKINE NETW, V12, P468; Khokha R, 2013, NAT REV IMMUNOL, V13, P649, DOI 10.1038/nri3499; Lee SR, 2006, J NEUROSCI, V26, P3491, DOI 10.1523/JNEUROSCI.4085-05.2006; Leppert D, 2000, CLIN INFECT DIS, V31, P80, DOI 10.1086/313922; Lu L, 2008, HIPPOCAMPUS, V18, P1074, DOI 10.1002/hipo.20466; Michaluk P, 2007, J BIOL CHEM, V282, P16036, DOI 10.1074/jbc.M700641200; Michaud JP, 2015, NEURON, V85, P450, DOI 10.1016/j.neuron.2015.01.021; Mroczko B, 2014, J ALZHEIMERS DIS, V40, P351, DOI 10.3233/JAD-131634; Mroczko B, 2013, J ALZHEIMERS DIS, V37, P273, DOI 10.3233/JAD-130647; Murase S, 2016, MOL NEUROBIOL, V53, P3477, DOI 10.1007/s12035-015-9295-y; Na H, 2016, IMMUNE NETW, V16, P1, DOI 10.4110/in.2016.16.1.1; Pasinetti GM, 2015, BBA-MOL BASIS DIS, V1852, P1202, DOI 10.1016/j.bbadis.2014.10.006; Reijerkerk A, 2006, FASEB J, V20, P2550, DOI 10.1096/fj.06-6099fje; Reinhard SM, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00280; Romero JR, 2010, NEUROBIOL AGING, V31, P2128, DOI 10.1016/j.neurobiolaging.2008.11.004; Rosenberg GA, 2002, GLIA, V39, P279, DOI 10.1002/glia.10108; Safciuc F, 2007, CURR NEUROVASC RES, V4, P228, DOI 10.2174/156720207782446351; Stawarski M, 2014, FRONT NEUROANAT, V8, DOI 10.3389/fnana.2014.00068; Svedin P, 2007, J NEUROSCI, V27, P1511, DOI 10.1523/JNEUROSCI.4391-06.2007; Tian L, 2007, J CELL BIOL, V178, P687, DOI 10.1083/jcb.200612097; Turner RS, 2015, NEUROLOGY, V85, P1383, DOI 10.1212/WNL.0000000000002035; Vafadari B, 2016, J NEUROCHEM, V139, P91, DOI 10.1111/jnc.13415; Verslegers M, 2013, PROG NEUROBIOL, V105, P60, DOI 10.1016/j.pneurobio.2013.03.004; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Wingerchuk DM, 2001, LAB INVEST, V81, P263, DOI 10.1038/labinvest.3780235; Wisniewski T, 2016, EXPERT REV VACCINES, V15, P401, DOI 10.1586/14760584.2016.1121815; Wu Dafang, 2005, NeuroRx, V2, P120, DOI 10.1007/BF03206648; Yamanishi Y, 2016, SEMIN IMMUNOPATHOL, V38, P615, DOI 10.1007/s00281-016-0568-y; Yang Y, 2015, BRAIN RES, V1623, P30, DOI 10.1016/j.brainres.2015.04.024; Yong VW, 2007, J NEUROL SCI, V259, P79, DOI 10.1016/j.jns.2006.11.021; Yong VW, 1998, TRENDS NEUROSCI, V21, P75	53	184	193	4	42	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	JAN 3	2017	14								1	10.1186/s12974-016-0779-0			10	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	EH6PE	WOS:000391894900001	28086917	DOAJ Gold, Green Published	Y	N	2021-06-18	
J	Hammer, C; Stepniak, B; Schneider, A; Papiol, S; Tantra, M; Begemann, M; Siren, AL; Pardo, LA; Sperling, S; Jofrry, SM; Gurvich, A; Jensen, N; Ostmeier, K; Luhder, F; Probst, C; Martens, H; Gillis, M; Saher, G; Assogna, F; Spalletta, G; Stocker, W; Schulz, TF; Nave, KA; Ehrenreich, H				Hammer, C.; Stepniak, B.; Schneider, A.; Papiol, S.; Tantra, M.; Begemann, M.; Siren, A-L; Pardo, L. A.; Sperling, S.; Jofrry, S. Mohd; Gurvich, A.; Jensen, N.; Ostmeier, K.; Luehder, F.; Probst, C.; Martens, H.; Gillis, M.; Saher, G.; Assogna, F.; Spalletta, G.; Stoecker, W.; Schulz, T. F.; Nave, K-A; Ehrenreich, H.			Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood-brain barrier integrity	MOLECULAR PSYCHIATRY			English	Article						APOE; ApoE null mutant mice; autoimmunity; GWAS; influenza; NFIA	ENCEPHALITIS; ANTIBODIES; SCHIZOPHRENIA; INFECTIONS; MICE	In 2007, a multifaceted syndrome, associated with anti-NMDA receptor autoantibodies (NMDAR-AB) of immunoglobulin-G isotype, has been described, which variably consists of psychosis, epilepsy, cognitive decline and extrapyramidal symptoms. Prevalence and significance of NMDAR-AB in complex neuropsychiatric disease versus health, however, have remained unclear. We tested sera of 2817 subjects (1325 healthy, 1081 schizophrenic, 263 Parkinson and 148 affective-disorder subjects) for presence of NMDAR-AB, conducted a genome-wide genetic association study, comparing AB carriers versus non-carriers, and assessed their influenza AB status. For mechanistic insight and documentation of AB functionality, in vivo experiments involving mice with deficient blood-brain barrier (ApoE(-/-)) and in vitro endocytosis assays in primary cortical neurons were performed. In 10.5% of subjects, NMDAR-AB (NR1 subunit) of any immunoglobulin isotype were detected, with no difference in seroprevalence, titer or in vitro functionality between patients and healthy controls. Administration of extracted human serum to mice influenced basal and MK-801-induced activity in the open field only in ApoE(-/-) mice injected with NMDAR-AB-positive serum but not in respective controls. Seropositive schizophrenic patients with a history of neurotrauma or birth complications, indicating an at least temporarily compromised blood-brain barrier, had more neurological abnormalities than seronegative patients with comparable history. A common genetic variant (rs524991, P = 6.15E-08) as well as past influenza A (P = 0.024) or B (P = 0.006) infection were identified as predisposing factors for NMDAR-AB seropositivity. The >10% overall seroprevalence of NMDAR-AB of both healthy individuals and patients is unexpectedly high. Clinical significance, however, apparently depends on association with past or present perturbations of blood-brain barrier function.	[Hammer, C.; Stepniak, B.; Papiol, S.; Tantra, M.; Begemann, M.; Sperling, S.; Jofrry, S. Mohd; Gurvich, A.; Jensen, N.; Ostmeier, K.; Ehrenreich, H.] Max Planck Inst Expt Med, D-37075 Gottingen, Germany; [Schneider, A.] Univ Med Gottingen, Dept Psychiat & Psychotherapy, Gottingen, Germany; [Schneider, A.; Papiol, S.; Tantra, M.; Nave, K-A; Ehrenreich, H.] Brain CNMPB, DFG Res Ctr Nanoscale Microscopy & Mol Physiol, Gottingen, Germany; [Schneider, A.] German Ctr Neurodegenerat Dis DZNE, Gottingen, Germany; [Siren, A-L] Univ Clin Wurzburg, Dept Neurosurg, Wurzburg, Germany; [Pardo, L. A.] Max Planck Inst Expt Med, Dept Mol Biol Neuronal Signals, D-37075 Gottingen, Germany; [Luehder, F.] Univ Med Gottingen, Inst Multiple Sclerosis Res, Dept Neuroimmunol, Gottingen, Germany; [Luehder, F.] Univ Med Gottingen, Hertie Fdn, Gottingen, Germany; [Probst, C.; Stoecker, W.] Euroimmun, Inst Expt Immunol, Lubeck, Germany; [Martens, H.] Synapt Syst GmbH, Gottingen, Germany; [Gillis, M.; Schulz, T. F.] Hannover Med Sch, Inst Virol, Hannover, Germany; [Saher, G.; Nave, K-A] Max Planck Inst Expt Med, Dept Neurogenet, D-37075 Gottingen, Germany; [Assogna, F.; Spalletta, G.] IRCCS Santa Lucia Fdn, Dept Clin & Behav Neurol, Rome, Italy	Ehrenreich, H (corresponding author), Max Planck Inst Expt Med, Hermann Rein Str 3, D-37075 Gottingen, Germany.	ehrenreich@em.mpg.de	Siren, Anna-Leena/AAE-1374-2019; Pardo, Luis/C-5066-2013; Schulz, Thomas/AAA-1634-2019; Hammer, Christian/C-5827-2014; Assogna, Francesca/J-9968-2016; Spalletta, Gianfranco/K-3828-2018; Saher, Gesine/AAH-1826-2021	Siren, Anna-Leena/0000-0002-2217-0081; Pardo, Luis/0000-0003-1375-4349; Hammer, Christian/0000-0003-4548-7548; Assogna, Francesca/0000-0003-4315-7879; Spalletta, Gianfranco/0000-0002-7432-4249; Saher, Gesine/0000-0003-3507-9604; Mohd Jofrry, Suhaidah/0000-0001-5132-5751; Ehrenreich, Hannelore/0000-0001-8371-5711; Jensen, Niels/0000-0001-8171-3333; Schulz, Thomas/0000-0001-8792-5345; Papiol, Sergi/0000-0001-9366-8728	Max Planck SocietyMax Planck Society; Max Planck ForderstiftungMax Planck Society; DFG (CNMPB)German Research Foundation (DFG); Daimler and Benz Foundation; Brain and Behavior Foundation; Ministry of Higher Education MalaysiaMinistry of Education, Malaysia	This work was supported by the Max Planck Society, the Max Planck Forderstiftung, and the DFG (CNMPB). Christian Hammer acknowledges grant support by the Daimler and Benz Foundation as well as by the Brain and Behavior Foundation. Suhaidah Mohd Jofrry, through support by the Faculty of Pharmacy, Universiti Teknologi MARA, Bandar Puncak Alam, Selangor, Malaysia, received a scholarship from the Ministry of Higher Education Malaysia. We are grateful to Sylvia Siefarth, Euroimmun, for excellent technical assistance.	Ascherio A, 2012, NAT REV NEUROL, V8, P602, DOI 10.1038/nrneurol.2012.198; Avitsur R, 2011, HORM BEHAV, V59, P257, DOI 10.1016/j.yhbeh.2010.12.002; Baburamani AA, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00424; Bechter K, 2010, J PSYCHIATR RES, V44, P321, DOI 10.1016/j.jpsychires.2009.08.008; Begemann M, 2010, ARCH GEN PSYCHIAT, V67, P879, DOI 10.1001/archgenpsychiatry.2010.107; Bell RD, 2012, NATURE, V485, P512, DOI 10.1038/nature11087; Blanpied TA, 2005, J NEUROSCI, V25, P3312, DOI 10.1523/JNEUROSCI.4262-04.2005; Choe CU, 2013, PSYCHIAT RES, V208, P194, DOI 10.1016/j.psychres.2012.09.035; Dale RC, 2009, ANN NEUROL, V66, P704, DOI 10.1002/ana.21807; Dalmau J, 2007, ANN NEUROL, V61, P25, DOI 10.1002/ana.21050; Dalmau J, 2011, LANCET NEUROL, V10, P63, DOI 10.1016/S1474-4422(10)70253-2; Dalmau J, 2008, LANCET NEUROL, V7, P1091, DOI 10.1016/S1474-4422(08)70224-2; Doria A, 2008, AUTOIMMUN REV, V8, P24, DOI 10.1016/j.autrev.2008.07.019; Ek CJ, 2012, NEUROTOXICOLOGY, V33, P586, DOI 10.1016/j.neuro.2011.12.009; Fullerton SM, 2001, EXP NEUROL, V169, P13, DOI 10.1006/exnr.2001.7631; Grzeda E, 2007, PHARMACOL REP, V59, P656; Homayoun H, 2007, J NEUROSCI, V27, P11496, DOI 10.1523/JNEUROSCI.2213-07.2007; Hughes EG, 2010, J NEUROSCI, V30, P5866, DOI 10.1523/JNEUROSCI.0167-10.2010; Larrauri A, 2007, Euro Surveill, V12, pE5; Lau CG, 2007, NAT REV NEUROSCI, V8, P413, DOI 10.1038/nrn2153; Li F, 2009, NEW ENGL J MED, V361, P302, DOI 10.1056/NEJMcibr0902052; Manto M, 2011, J NEUROL, V258, P27, DOI 10.1007/s00415-010-5674-5; Masdeu JC, 2012, AM J PSYCHIAT, V169, P1120, DOI 10.1176/appi.ajp.2012.12050646; OLNEY JW, 1995, ARCH GEN PSYCHIAT, V52, P998; PIEDRAHITA JA, 1992, P NATL ACAD SCI USA, V89, P4471, DOI 10.1073/pnas.89.10.4471; Pruss H, 2012, NEUROLOGY, V78, P1743, DOI 10.1212/WNL.0b013e318258300d; Pruss H, 2012, ANN NEUROL, V72, P902, DOI 10.1002/ana.23689; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Radyushkin K, 2010, GENES BRAIN BEHAV, V9, P592, DOI 10.1111/j.1601-183X.2010.00590.x; Randone SB, 2008, AUTOIMMUN REV, V8, P36, DOI 10.1016/j.autrev.2008.07.022; Reiber H, 2001, J NEUROL SCI, V184, P101, DOI 10.1016/S0022-510X(00)00501-3; Ribbe K, 2010, BMC PSYCHIATRY, V10, DOI 10.1186/1471-244X-10-91; Saher G, 2012, NAT MED, V18, P1130, DOI 10.1038/nm.2833; Sfriso P, 2010, J LEUKOCYTE BIOL, V87, P385, DOI 10.1189/jlb.0709517; Sharp FR, 2007, EPILEPSY BEHAV, V10, P515, DOI 10.1016/j.yebeh.2007.02.014; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Steiner J, 2013, JAMA PSYCHIAT, V70, P271, DOI 10.1001/2013.jamapsychiatry.86; Tan A, 2010, J CLIN NEUROSCI, V17, P1204, DOI 10.1016/j.jocn.2010.01.010; Titulaer MJ, 2013, LANCET NEUROL, V12, P157, DOI 10.1016/S1474-4422(12)70310-1; TOYKA KV, 1975, SCIENCE, V190, P397, DOI 10.1126/science.1179220; Tsutsui K, 2012, BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-37; Visscher PM, 2012, AM J HUM GENET, V90, P7, DOI 10.1016/j.ajhg.2011.11.029; Wandinger KP, 2011, J NEUROIMMUNOL, V231, P86, DOI 10.1016/j.jneuroim.2010.09.012; Zandi MS, 2011, J NEUROL, V258, P686, DOI 10.1007/s00415-010-5788-9; Zheng S, 2010, J CLIN INVEST, V120, P2446, DOI 10.1172/JCI33144	45	184	189	0	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1359-4184	1476-5578		MOL PSYCHIATR	Mol. Psychiatr.	OCT	2014	19	10					1143	1149		10.1038/mp.2013.110			7	Biochemistry & Molecular Biology; Neurosciences; Psychiatry	Biochemistry & Molecular Biology; Neurosciences & Neurology; Psychiatry	AR5ZN	WOS:000343661700014	23999527				2021-06-18	
J	Looney, CB; Smith, JK; Merck, LH; Wolfe, HM; Chescheir, NC; Hamer, RM; Gilmore, JH				Looney, Christopher B.; Smith, J. Keith; Merck, Lisa H.; Wolfe, Honor M.; Chescheir, Nancy C.; Hamer, Robert M.; Gilmore, John H.			Intracranial hemorrhage in asymptomatic neonates: Prevalence on MR images and relationship to obstetric and neonatal risk factors	RADIOLOGY			English	Article							FULL-TERM INFANTS; INTRACEREBRAL HEMORRHAGE; SUBDURAL-HEMATOMA; VACUUM EXTRACTION; POSTERIOR-FOSSA; DELIVERY; BRAIN; NEWBORNS; INJURY; BIRTH	Purpose: To retrospectively evaluate the prevalence of neonatal intracranial hemorrhage (ICH) and its relationship to obstetric and neonatal risk factors. Materials and Methods: Pregnant women were recruited for a prospective study of neonatal brain development; the study was approved by the institutional review board and complied with HIPAA regulations. After informed consent was obtained from a parent, neonates were imaged with 3.0-T magnetic resonance (MR) imaging without sedation. The images were reviewed by a neuroradiologist with 12 years of experience for the presence of ICH. Medical records were prospectively and retrospectively reviewed for selected risk factors, which included method of delivery, duration of labor, and evidence of maternal or neonatal birth trauma. Risk factors were assessed for relationship to ICH by using Fisher exact test statistics. Results: Ninety-seven neonates (mean age at MR imaging, 20.8 days +/- 6.9 [standard deviation]) underwent MR imaging between the ages of 1 and 5 weeks. Eighty-eight (44 male and 44 female) neonates (65 with vaginal delivery and 23 with cesarean delivery) completed the MR imaging evaluation. Seventeen neonates with ICHs (16 subdural, two subarachnoid, and six parenchymal hemorrhages) were identified. Seven infants had two or more types of hemorrhages. All neonates with ICH were delivered vaginally, with a prevalence of 26% in vaginal births. ICH was significantly associated with vaginal birth (P < .005) but not with prolonged duration of labor or with traumatic or assisted vaginal birth. Conclusion: Asymptomatic ICH following vaginal birth in full-term neonates appears to be common, with a prevalence of 26% in this study.	Univ N Carolina, Sch Med, Dept Psychiat, Chapel Hill, NC 27599 USA	Gilmore, JH (corresponding author), Univ N Carolina, Sch Med, Dept Psychiat, CB 7160,7025A Neurosci Hosp, Chapel Hill, NC 27599 USA.	jgilmore@med.unc.edu	Smith, J Keith/AAD-3968-2021; Gilmore, John H./AAE-1398-2019	Gilmore, John H./0000-0002-0939-6764; Chescheir, Nancy/0000-0002-0205-5051; Smith, J Keith/0000-0001-7588-3520	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [P50MH064065] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [1 P50 MH064065] Funding Source: Medline		AVRAHAMI E, 1993, NEURORADIOLOGY, V35, P107, DOI 10.1007/BF00593964; BERGMAN I, 1985, PEDIATRICS, V75, P488; BROOKS RA, 1989, J COMPUT ASSIST TOMO, V13, P194, DOI 10.1097/00004728-198903000-00002; CASTILLO M, 1995, AM J NEURORADIOL, V16, P816; Chamnanvanakij S, 2002, PEDIATR NEUROL, V26, P301, DOI 10.1016/S0887-8994(01)00420-9; CHAPLIN ER, 1979, PEDIATRICS, V63, P812; Fink S, 2000, Neonatal Netw, V19, P13; Gardella C, 2001, AM J OBSTET GYNECOL, V185, P896, DOI 10.1067/mob.2001.117309; Gilmore J.H., 2006, TXB SCHIZOPHRENIA, P55; Gilmore JH, 2004, PSYCHIAT RES-NEUROIM, V132, P81, DOI 10.1016/j.pscychresns.2004.04.004; HANIGAN WC, 1990, PEDIATRICS, V85, P534; HAYASHI T, 1987, CHILD NERV SYST, V3, P161, DOI 10.1007/BF00717893; HAYASHI T, 1987, CHILD NERV SYST, V3, P23, DOI 10.1007/BF00707189; HEIBEL M, 1993, NEURORADIOLOGY, V35, P85, DOI 10.1007/BF00593960; HERNANSANZ J, 1984, J NEUROSURG, V61, P972, DOI 10.3171/jns.1984.61.5.0972; Holden KR, 1999, J CHILD NEUROL, V14, P708, DOI 10.1177/088307389901401104; Huang AH, 2004, AM J NEURORADIOL, V25, P469; KEENEY SE, 1991, PEDIATRICS, V87, P431; Kidwell CS, 2004, JAMA-J AM MED ASSOC, V292, P1823, DOI 10.1001/jama.292.15.1823; Lonergan GJ, 2003, RADIOGRAPHICS, V23, P811, DOI 10.1148/rg.234035030; MCARDLE CB, 1987, RADIOLOGY, V163, P387, DOI 10.1148/radiology.163.2.3550881; MERCURI E, 1995, ARCH DIS CHILD, V73, P67; Odita JC, 1996, PEDIATR RADIOL, V26, P782, DOI 10.1007/BF01396201; PAINTER MJ, 1986, PEDIATR CLIN N AM, V33, P91; Palmer T W, 1991, J Perinatol, V11, P112; Perlman JM, 2004, SEMIN PERINATOL, V28, P415, DOI 10.1053/j.semperi.2004.10.003; PIERREKAHN A, 1986, CHILD NERV SYST, V2, P191, DOI 10.1007/BF00706809; Pollina J, 2001, PEDIATR NEUROSURG, V35, P113, DOI 10.1159/000050403; ROLAND EH, 1990, PEDIATRICS, V85, P737; SACHS BP, 1987, CLIN PEDIATR, V26, P355, DOI 10.1177/000992288702600706; Sandberg DI, 2001, NEUROSURGERY, V48, P1042, DOI 10.1097/00006123-200105000-00015; SCOTTI G, 1981, J COMPUT ASSIST TOMO, V5, P68, DOI 10.1097/00004728-198102000-00013; TANAKA Y, 1988, J NEUROSURG, V68, P211, DOI 10.3171/jns.1988.68.2.0211; Tavani F, 2003, NEURORADIOLOGY, V45, P253, DOI 10.1007/s00234-003-0946-8; Towner D, 1999, NEW ENGL J MED, V341, P1709, DOI 10.1056/NEJM199912023412301; VOLP JJ, 2001, NEUROLOGY NEWBORN; VOLPE J J, 1977, Clinics in Perinatology, V4, P77; WELCH K, 1986, DEV MED CHILD NEUROL, V28, P156; Wen SW, 2001, AM J EPIDEMIOL, V153, P103, DOI 10.1093/aje/153.2.103; Whitby EH, 2004, LANCET, V363, P846, DOI 10.1016/S0140-6736(04)15730-9; Whitby EH, 2003, ARCH DIS CHILD-FETAL, V88, P203; Williamson W D, 1985, Pediatr Neurol, V1, P356	42	184	191	2	15	RADIOLOGICAL SOC NORTH AMERICA	OAK BROOK	820 JORIE BLVD, OAK BROOK, IL 60523 USA	0033-8419			RADIOLOGY	Radiology	FEB	2007	242	2					535	541		10.1148/radiol.2422060133			7	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	133RY	WOS:000244032100026	17179400				2021-06-18	
J	Wilde, EA; Chu, ZL; Bigler, ED; Hunter, JV; Fearing, MA; Hanten, G; Newsome, MR; Scheibel, RSQ; Li, X; Levin, HS				Wilde, Elisabeth A.; Chu, Zili; Bigler, Erin D.; Hunter, Jill V.; Fearing, Michael A.; Hanten, Gerri; Newsome, Mary R.; Scheibel, Randall S.; Li, Xiaoqi; Levin, Harvey S.			Diffusion tensor imaging in the corpus callosum in children after moderate to severe traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	14th Annual Conference on Traumatic Brain Injury - From Molecule to Family Systems	2004	Rotman Res Inst, Toronto, CANADA		Rotman Res Inst	child; corpus callosum; diffuse axonal injury; diffusion tensor imaging; fiber tracking; morphometry; traumatic brain injury	CLOSED-HEAD-INJURY; AXONAL INJURY; MAGNETIC-RESONANCE; WHITE-MATTER; FIBER TRACKING; FRACTIONAL ANISOTROPY; CLINICAL-FEATURES; PRACTICAL SCALE; MRI; LESIONS	Diffusion tensor imaging (DTI) is a recent imaging technique that assesses the microstructure of the cerebral white matter (WM) based on anisotropic diffusion (i.e., water molecules move faster in parallel to nerve fibers than perpendicular to them). Fractional anisotropy (FA), which ranges from 0 to 1.0, increases with myelination of WM tracts and is sensitive to diffuse axonal injury (DAI) in adults with traumatic brain injury (TBI). However, previous DTI studies of pediatric TBI were case reports without detailed outcome measures. Using mean FA derived from DTI fiber tractography, we compared DTI findings of the corpus callosum for 16 children who were at least 1 year (mean 3.1 years) post-severe TBI and individually matched, uninjured children. Interexaminer and intraexaminer reliability in measuring FA was satisfactory. FA was significantly lower in the patients for the genu, body, and splenium of the corpus callosum. Higher FA was related to increased cognitive processing speed and faster interference resolution on an inhibition task. In the TBI patients, higher FA was related to better functional outcome as measured by the dichotomized Glasgow Outcome Scale (GOS). FA also increased as a function of the area of specific regions of the corpus callosum such as the genu and splenium, and FA in the splenium was reduced with greater volume of lesions in this region. DTI may be useful in identifying biomarkers related to DAI and outcome of TBI in children.	Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat, Houston, TX 77030 USA; Texas Childrens Hosp, Dept Diagnost Imaging, Houston, TX 77030 USA; Brigham Young Univ, Dept Psychol, Provo, UT USA; Brigham Young Univ, Dept Neurosci, Provo, UT USA; Univ Utah, Dept Radiol, Salt Lake City, UT USA; Univ Utah, Dept Psychiat, Salt Lake City, UT USA; Boston VA Healthcare Syst, Geriatr Res Educ & Clin Ctr, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA USA	Levin, HS (corresponding author), Cognit Neurosci Lab, 1709 Dryden Rd,Ste 725, Houston, TX 77030 USA.	hlevin@bcm.tmc.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U19HD035476] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U19 HD035476] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline		ABOITIZ F, 1992, BRAIN RES, V598, P143, DOI 10.1016/0006-8993(92)90178-C; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ANDERSON CV, 1994, BRAIN INJURY, V8, P565, DOI 10.3109/02699059409151008; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Baird AA, 2005, J COGNITIVE NEUROSCI, V17, P687, DOI 10.1162/0898929053467569; Basser PJ, 2000, MAGNET RESON MED, V44, P41, DOI 10.1002/1522-2594(200007)44:1<41::AID-MRM8>3.0.CO;2-O; Benavidez DA, 1999, CORTEX, V35, P315, DOI 10.1016/S0010-9452(08)70803-7; BLATTER DD, 1995, AM J NEURORADIOL, V16, P241; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Bunge SA, 2002, NEURON, V33, P301, DOI 10.1016/S0896-6273(01)00583-9; Chan JHM, 2003, NEURORADIOLOGY, V45, P34, DOI 10.1007/s00234-002-0891-y; Chepuri NB, 2002, AM J NEURORADIOL, V23, P803; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; Committee on Injury Scaling, 1998, ABBR INJ SCAL; Ducreux D, 2005, NEURORADIOLOGY, V47, P604, DOI 10.1007/s00234-005-1389-1; ERIKSEN BA, 1974, PERCEPT PSYCHOPHYS, V16, P143, DOI 10.3758/BF03203267; Fry AF, 1996, PSYCHOL SCI, V7, P237, DOI 10.1111/j.1467-9280.1996.tb00366.x; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli TA, 1997, NEUROSCIENTIST, V3, P73, DOI 10.1177/107385849700300117; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Glenn OA, 2003, J MAGN RESON IMAGING, V18, P641, DOI 10.1002/jmri.10420; Goetz P, 2004, J NEUROTRAUM, V21, P645, DOI 10.1089/0897715041269731; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; Gorrie C, 2001, J NEUROTRAUM, V18, P849, DOI 10.1089/089771501750451776; Hasan KM, 2005, J MAGN RESON IMAGING, V21, P735, DOI 10.1002/jmri.20296; Hazeltine E, 2000, J COGNITIVE NEUROSCI, V12, P118, DOI 10.1162/089892900563984; HILLARY FG, 2006, HUM BRAIN MAPP; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; JENNETT B, 1975, LANCET, V1, P480; KAIL R, 1993, J EXP CHILD PSYCHOL, V56, P254, DOI 10.1006/jecp.1993.1034; KRAUS JF, 1990, AM J DIS CHILD, V144, P684, DOI 10.1001/archpedi.1990.02150300082022; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Le TH, 2005, NEUROSURGERY, V56, P189, DOI 10.1227/01.NEU.0000144846.00569.3A; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; Lee ZI, 2003, AM J PHYS MED REHAB, V82, P556, DOI 10.1097/01.PHM.0000073830.15643.6A; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; Levin HS, 2004, J CLIN EXP NEUROPSYC, V26, P589, DOI 10.1080/13803390490504434; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; Madden DJ, 2004, NEUROIMAGE, V21, P1174, DOI 10.1016/j.neuroimage.2003.11.004; Masutani Y, 2003, EUR J RADIOL, V46, P53, DOI 10.1016/S0720-048X(02)00328-5; Mathias JL, 2004, APPL NEUROPSYCHOL, V11, P134, DOI 10.1207/s15324826an1103_2; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; MENDELSOHN DB, 1992, NEURORADIOLOGY, V34, P384, DOI 10.1007/BF00596495; Mori S, 2002, MAGN RESON MED, V47, P215, DOI 10.1002/mrm.10074; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Mori S, 2002, NMR BIOMED, V15, P468, DOI 10.1002/nbm.781; Mori S., 2005, MRI ATLAS HUMAN WHIT; Naganawa S, 2004, AM J NEURORADIOL, V25, P1553; Netsch T, 2001, INT C COMP VIS VANC; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Pfefferbaum A, 2003, J MAGN RESON IMAGING, V18, P427, DOI 10.1002/jmri.10377; Pierpaoli C, 1996, MAGNET RESON MED, V36, P893, DOI 10.1002/mrm.1910360612; Pollmann S, 2004, NEUROPSYCHOLOGY, V18, P710, DOI 10.1037/0894-4105.18.4.710; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Rice SA, 2005, J CHILD NEUROL, V20, P34, DOI 10.1177/08830738050200010601; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; SACKEIM HA, 1990, ARCH GEN PSYCHIAT, V47, P60; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Schulte T, 2005, CEREB CORTEX, V15, P1384, DOI 10.1093/cercor/bhi020; Stieltjes B, 2001, NEUROIMAGE, V14, P723, DOI 10.1006/nimg.2001.0861; Takaoka M, 2002, J NEUROL NEUROSUR PS, V73, P289, DOI 10.1136/jnnp.73.3.289; Tasker RC, 2005, PEDIATR RES, V58, P302, DOI 10.1203/01.PDR.0000169965.08854.25; TEASDALE G, 1974, LANCET, V2, P81; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Wakana S, 2004, RADIOLOGY, V230, P77, DOI 10.1148/radiol.2301021640; Westerhausen R, 2004, COGNITIVE BRAIN RES, V21, P418, DOI 10.1016/j.cogbrainres.2004.07.002; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; WITELSON SF, 1989, BRAIN, V112, P799, DOI 10.1093/brain/112.3.799	73	184	193	0	16	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2006	23	10					1412	1426		10.1089/neu.2006.23.1412			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	093XL	WOS:000241203500004	17020479				2021-06-18	
J	Ouellet, MC; Beaulieu-Bonneau, S; Morin, CM				Ouellet, MC; Beaulieu-Bonneau, S; Morin, CM			Insomnia in patients with traumatic brain injury - Frequency, characteristics, and risk factors	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injuries; insomnia; rehabilitation; risk factors	MULTIDIMENSIONAL FATIGUE INVENTORY; SLEEP DISTURBANCE; FIBROSITIS SYNDROME; HEAD-INJURY; PAIN; VALIDATION; COMPLAINTS; SYMPTOMS; PATTERNS	Objectives: To document the frequency of insomnia (according to DSM-TV and ICSD criteria), to describe its sociodemographic and clinical characteristics, and to identify potential predictors of insomnia in persons with traumatic brain injury (TBI). Participants and procedure: Four hundred fifty-two participants aged 16 years and older with minor to severe TBI answered a questionnaire pertaining to quality of sleep and fatigue. Main outcome measures: Proportion of participants fulfilling criteria for insomnia symptoms or syndrome. Validated measures of insomnia severity, fatigue level, and psychologic distress. Results of a logistic regression analysis. Results: Overall, 50.2% of the sample reported insomnia symptoms and 29.4% fulfilled the diagnostic criteria for an insomnia syndrome. For the latter participants, insomnia was a severe and chronic condition remaining untreated in almost 60% of cases. Risk factors associated with insomnia were milder TBIs, and higher levels of fatigue, depression, and pain. Conclusion: Insomnia is a prevalent condition after TBI requiring more clinical and scientific attention as it may have important repercussions on rehabilitation.	Univ Laval, Ecole Psychol, Quebec City, PQ G1K 7P4, Canada	Ouellet, MC (corresponding author), Univ Laval, Ecole Psychol, Pavill Felix Antoine Savard, Quebec City, PQ G1K 7P4, Canada.	marie-christine.ouellet.1@ulaval.ca	Morin, Charles/G-1021-2011; Morin, Charles M./A-4700-2008	Morin, Charles M./0000-0002-8649-8895; Beaulieu-Bonneau, Simon/0000-0002-9544-5023; Ouellet, Marie-Christine/0000-0003-3477-1893			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; American Sleep Disorders Association, 1990, INT CLASS SLEEP DIS; ATKINSON JH, 1988, CLIN J PAIN, V4, P225, DOI 10.1097/00002508-198812000-00007; Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; Blais FC, 1997, ENCEPHALE, V23, P447; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; COHEN M, 1992, J NEUROL NEUROSUR PS, V55, P313, DOI 10.1136/jnnp.55.4.313; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; *ENQ SANT QUEB, 1987, 8706 ENQ SANT QUEB; Fichtenberg NL, 2000, BRAIN INJURY, V14, P659; Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940; Fillion L, 2003, CANCER NURS, V26, P143, DOI 10.1097/00002820-200304000-00008; FORD DE, 1989, JAMA-J AM MED ASSOC, V262, P1479, DOI 10.1001/jama.262.11.1479; GERVAIS M, 1999, ETUDE EXPLORATOIRE; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P47, DOI 10.1097/00001199-199808000-00005; ILFELD FW, 1976, PSYCHOL REP, V39, P1215, DOI 10.2466/pr0.1976.39.3f.1215; KESHAVAN MS, 1981, BRIT J PSYCHIAT, V138, P157, DOI 10.1192/bjp.138.2.157; Kraus JF, 1993, HEAD INJURY, P1; MELLINGER GD, 1985, ARCH GEN PSYCHIAT, V42, P225, DOI 10.1001/archpsyc.1985.01790260019002; MOLDOFSKY H, 1989, RHEUM DIS CLIN N AM, V15, P91; Morin CM, 1996, APPL PREV PSYCHOL, V5, P211, DOI 10.1016/S0962-1849(96)80013-8; Morin CM., 1993, INSOMNIA PSYCHOL ASS; Ohayon MM, 1997, BRIT J PSYCHIAT, V171, P382, DOI 10.1192/bjp.171.4.382; PARSONS LC, 1982, NURS RES, V31, P260; Perlis ML, 1997, PERCEPT MOTOR SKILL, V84, P595, DOI 10.2466/pms.1997.84.2.595; PILOWSKY I, 1985, PAIN, V23, P27, DOI 10.1016/0304-3959(85)90227-1; PRESSMAN MR, 1997, UNDERSTANDING SLEEP, P371; PREVILLE M, 1992, 7 MIN SANT SEV SOC; RIZZO M, 1996, HEAD INJURY POSTCONC; SASKIN P, 1986, PSYCHOSOM MED, V48, P319, DOI 10.1097/00006842-198605000-00002; SEGALOWITZ SJ, 1995, J LEARN DISABIL, V28, P309, DOI 10.1177/002221949502800507; SMETS EMA, 1995, J PSYCHOSOM RES, V39, P315, DOI 10.1016/0022-3999(94)00125-O; WALSLEBEN JA, 1997, UNDERSTANDING SLEEP, P359; WEBB WB, 1975, PSYCHOPHYSIOLOGY, V12, P637, DOI 10.1111/j.1469-8986.1975.tb00063.x; WITTIG RM, 1982, J NERV MENT DIS, V170, P429, DOI 10.1097/00005053-198207000-00011	36	184	186	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2006	21	3					199	212		10.1097/00001199-200605000-00001			14	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	044YL	WOS:000237709600001	16717498				2021-06-18	
J	Koh, DW; Dawson, TM; Dawson, VL				Koh, DW; Dawson, TM; Dawson, VL			Mediation of cell death by poly(ADP-ribose) polymerase-1	PHARMACOLOGICAL RESEARCH			English	Article						apoptosis; poly(ADP-ribose); excitotoxicity; PARG; apoptosis-inducing factor	APOPTOSIS-INDUCING FACTOR; NF-KAPPA-B; TRAUMATIC BRAIN-INJURY; PARKINSONS-DISEASE; DNA-BINDING; FACTOR AIF; ACTIVATION; GLYCOHYDROLASE; NEURODEGENERATION; 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE	Poly(ADP-ribosyl)ation plays an important role in modulating the cellular response to stress. The extent of poly(ADP-ribosyl)ation, chiefly via the activation of the poly(ADP-ribose) polymerase-1(PARP- 1), correlates with the severity of genotoxic stress and this determines the cellular response. Under mild and moderate stress, it plays important roles in DNA processing and it participates in the proinflammatory/cellular defense via transcriptional regulation. However, severe stress following acute neuronal injury causes the overactivation of PARP-1, which results in unregulated poly(ADP-ribose) (PAR) synthesis and widespread neuronal cell death. Previously, this PARP-1-dependent cell death mechanism was manifest solely through necrosis, but apoptotic mechanisms are also evident. Poly(ADP-ribosyl)ation directly induces the nuclear translocation of apoptosis-inducing factor, which results in cas pase-in dependent cell death significant in many neurodegenerative conditions. Further, the hydrolysis of PAR by poly(ADP-ribose) glycohydrolase (PARG) has a protective role, since the accumulation of PAR leads to cell death by apoptosis. Thus, PAR signaling, regulated by PARP-1 and PARG, mediates cell death. Accordingly, modulation of PAR synthesis or degradation through the targeting of PARP-1 or PARG holds particular promise in the treatment of conditions such as cancer, stroke, and Parkinson's disease. (c) 2005 Elsevier Ltd. All rights reserved.	Johns Hopkins Univ, Sch Med, Inst Cell Engn, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA	Dawson, VL (corresponding author), Johns Hopkins Univ, Sch Med, Inst Cell Engn, 733 N Broadway St,Suite 711, Baltimore, MD 21205 USA.	vdawson@jhmi.edu	Dawson, Valina/Y-9757-2019; Koh, David/AAI-6850-2020	Koh, David/0000-0002-1847-4330; Dawson, Valina/0000-0002-2915-3970			AME JC, 2000, DNA DAMAGE STRESS SI, P1; Arnoult D, 2002, J CELL BIOL, V159, P923, DOI 10.1083/jcb.200207071; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; Braun JS, 2001, J INFECT DIS, V184, P1300, DOI 10.1086/324013; Chiarugi A, 2003, J NEUROCHEM, V85, P306, DOI 10.1046/j.1471-4159.2003.01684.x; CHOI DW, 1994, PROG BRAIN RES, V100, P47; Cortes U, 2004, MOL CELL BIOL, V24, P7163, DOI 10.1128/MCB.24.16.7163-7178.2004; Cosi C, 1997, ANN NY ACAD SCI, V825, P366, DOI 10.1111/j.1749-6632.1997.tb48447.x; Cregan SP, 2004, ONCOGENE, V23, P2785, DOI 10.1038/sj.onc.1207517; D'Amours D, 2001, J CELL SCI, V114, P3771; DANI JA, 1995, CURR OPIN NEUROBIOL, V5, P310, DOI 10.1016/0959-4388(95)80043-3; Daugas E, 2000, FEBS LETT, V476, P118, DOI 10.1016/S0014-5793(00)01731-2; Dawson Ted M., 1997, P319; Dawson TM, 2000, CELL, V101, P115, DOI 10.1016/S0092-8674(00)80629-7; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; Dawson VL, 1996, J CHEM NEUROANAT, V10, P179, DOI 10.1016/0891-0618(96)00148-2; DEMURCIA G, 2000, DNA DAMAGE STRESS CE; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Falsig J, 2004, EUR J PHARMACOL, V497, P7, DOI 10.1016/j.ejphar.2004.06.042; FORNO LS, 1986, ANN NEUROL, V20, P449, DOI 10.1002/ana.410200403; Gallego MA, 2004, ONCOGENE, V23, P6282, DOI 10.1038/sj.onc.1207835; Hanai S, 2004, P NATL ACAD SCI USA, V101, P82, DOI 10.1073/pnas.2237114100; Jacobson MK, 1999, TRENDS BIOCHEM SCI, V24, P415, DOI 10.1016/S0968-0004(99)01481-4; KAISER P, 1992, MOL GEN GENET, V232, P231, DOI 10.1007/BF00280001; Klein JA, 2002, NATURE, V419, P367, DOI 10.1038/nature01034; Koedel U, 2002, J CEREBR BLOOD F MET, V22, P39, DOI 10.1097/00004647-200201000-00005; Koh DW, 2003, J MED CHEM, V46, P4322, DOI 10.1021/jm020541u; Koh DW, 2003, BIOCHEMISTRY-US, V42, P4855, DOI 10.1021/bi0272048; Koh LP, 2004, BIOL BLOOD MARROW TR, V10, P1, DOI 10.1016/j.bbmt.2003.09.009; Kraus WL, 2003, CELL, V113, P677, DOI 10.1016/S0092-8674(03)00433-1; Lang AE, 1998, NEW ENGL J MED, V339, P1130, DOI 10.1056/NEJM199810153391607; Lang AE, 1998, NEW ENGL J MED, V339, P1044, DOI 10.1056/NEJM199810083391506; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LEE CS, 1994, BRAIN, V117, P501, DOI 10.1093/brain/117.3.501; Mabuchi T, 2000, STROKE, V31, P1735, DOI 10.1161/01.STR.31.7.1735; Mandir AS, 1999, P NATL ACAD SCI USA, V96, P5774, DOI 10.1073/pnas.96.10.5774; Mate MJ, 2002, NAT STRUCT BIOL, V9, P442, DOI 10.1038/nsb793; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MIZUNO Y, 1987, J NEUROCHEM, V48, P1787, DOI 10.1111/j.1471-4159.1987.tb05737.x; Nicotera P, 1997, Adv Neurol, V72, P95; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; Perkins E, 2001, CANCER RES, V61, P4175; Piret B, 1999, ONCOGENE, V18, P2261, DOI 10.1038/sj.onc.1202541; Robertson JD, 2004, EMBO REP, V5, P643, DOI 10.1038/sj.embor.7400153; Ruchalski K, 2003, AM J PHYSIOL-CELL PH, V285, pC1483, DOI 10.1152/ajpcell.00049.2003; Samdani AF, 1997, STROKE, V28, P1283, DOI 10.1161/01.STR.28.6.1283; Sampei K, 2000, STROKE, V31, P2685, DOI 10.1161/01.STR.31.11.2685; Schapira AHV, 1996, ADV NEUROL, V69, P161; Stoll G, 1998, PROG NEUROBIOL, V56, P149, DOI 10.1016/S0301-0082(98)00034-3; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; TURSKI L, 1991, NATURE, V349, P414, DOI 10.1038/349414a0; Ullrich O, 2001, NAT CELL BIOL, V3, P1035, DOI 10.1038/ncb1201-1035; Vahsen N, 2004, EMBO J, V23, P4679, DOI 10.1038/sj.emboj.7600461; Wang HM, 2004, J NEUROSCI, V24, P10963, DOI 10.1523/JNEUROSCI.3461-04.2004; Wang HM, 2003, ANN NY ACAD SCI, V991, P132; Wang XC, 2002, SCIENCE, V298, P1587, DOI 10.1126/science.1076194; Xiao CY, 2004, J PHARMACOL EXP THER, V310, P498, DOI 10.1124/jpet.104.066803; XIAO CY, 2004, J PHARM EXP THER; Ye H, 2002, NAT STRUCT BIOL, V9, P680, DOI 10.1038/nsb836; Ying WH, 2001, P NATL ACAD SCI USA, V98, P12227, DOI 10.1073/pnas.211202598; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Yu SW, 2003, NEUROBIOL DIS, V14, P303, DOI 10.1016/j.nbd.2003.08.008; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500; Zhang XP, 2002, J NEUROCHEM, V82, P181, DOI 10.1046/j.1471-4159.2002.00975.x	66	184	204	0	20	ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	1043-6618			PHARMACOL RES	Pharmacol. Res.	JUL	2005	52	1					5	14		10.1016/j.phrs.2005.02.011			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	938AW	WOS:000229973300002	15911329				2021-06-18	
J	Kimelberg, HK				Kimelberg, HK			Astrocytic swelling in cerebral ischemia as a possible cause of injury and target for therapy	GLIA			English	Article						tamoxifen; astrocytic swelling; EAA release; VRACs; anion channels; ischemia; cellular edema	K+-CL-COTRANSPORTER; REGULATORY VOLUME DECREASE; AMINO-ACID RELEASE; CULTURED ASTROCYTES; GLIAL-CELLS; ARTERY OCCLUSION; BRAIN EDEMA; GLUTAMATE; TAMOXIFEN; TRANSPORT	In this viewpoint article, I summarize data showing that the astrocytic swelling that occurs early after the acute CNS pathologies ischemia and traumatic brain injury is damaging. We have proposed that one reason may be the release of excitatory amino acids (EAA) via volume-activated anion channels (VRACs) that are activated by such swelling. This release could be a target for therapy, which could involve blocking the astrocytic swelling or the release mechanisms. The transport mechanisms likely causing the early astrocytic swelling are therefore summarized. In terms of targeting the release mechanisms, we have found a potent inhibitor of VRACs, tamoxifen, to be strongly neuroprotective in focal ischemia with a therapeutic window of 3 h after initiation of the ischemia. The question, however, of whether neuroprotection by tamoxifen can be solely attributed to VRAC inhibition in astrocytes has yet to be resolved. (c) 2005 Wiley-Liss, Inc.	Ordway Res Inst, Neural & Vasc Biol, Albany, NY 12208 USA	Kimelberg, HK (corresponding author), Ordway Res Inst, Neural & Vasc Biol, 150 New Scotland Ave, Albany, NY 12208 USA.	hkimelberg@ordwayresearch.org			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 35205] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035205] Funding Source: NIH RePORTER		Amiry-Moghaddam M, 2003, NAT REV NEUROSCI, V4, P991, DOI 10.1038/nrn1252; BARRON KD, 1988, ACTA NEUROPATHOL, V75, P295, DOI 10.1007/BF00690538; Bender AS, 1998, J NEUROSCI RES, V52, P307, DOI 10.1002/(SICI)1097-4547(19980501)52:3<307::AID-JNR7>3.0.CO;2-H; Biegon A, 1996, CANCER RES, V56, P4328; Bourne G. H., 1972, STRUCTURE FUNCTION N, P449; Brookes N, 2000, NEUROCHEM INT, V37, P121, DOI 10.1016/S0197-0186(00)00015-2; Bushnell CD, 2004, NEUROLOGY, V63, P1230, DOI 10.1212/01.WNL.0000140491.54664.50; CHAN PH, 1984, RECENT PROGR STUDY T, P193; Chen WZ, 2004, J NEUROSCI, V24, P1136, DOI 10.1523/JNEUROSCI.1586-03.2004; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; DAMELIO FE, 1990, GLIA, V3, P229, DOI 10.1002/glia.440030402; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Deitmer JW, 1996, PROG NEUROBIOL, V48, P73, DOI 10.1016/0301-0082(95)00039-9; Dhandapani KM, 2002, BIOL REPROD, V67, P1379, DOI 10.1095/biolreprod.102.003848; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Feustel PJ, 2004, STROKE, V35, P1164, DOI 10.1161/01.STR.0000124127.57946.a1; GARCIA JH, 1977, VIRCHOWS ARCH B, V25, P191; Ginsberg MD, 2003, STROKE, V34, P214, DOI 10.1161/01.STR.0000048846.09677.62; Gladstone DJ, 2002, STROKE, V33, P2123, DOI 10.1161/01.STR.0000025518.34157.51; Gross P, 2001, KIDNEY INT, V60, P2417, DOI 10.1046/j.1523-1755.2001.00063.x; GROSSMAN RG, 1972, SCI FDN NEUROLOGY, P9; Haskew RE, 2002, J NEUROCHEM, V82, P903, DOI 10.1046/j.1471-4159.2002.01037.x; HODGKIN AL, 1959, J PHYSIOL-LONDON, V148, P127, DOI 10.1113/jphysiol.1959.sp006278; JAKUBOVICZ DE, 1987, BRAIN RES, V435, P138, DOI 10.1016/0006-8993(87)91594-0; Jentsch TJ, 2002, PHYSIOL REV, V82, P503, DOI 10.1152/physrev.00029.2001; KATZMAN R, 1975, NEURONAL ACTIVITY PO, P149; KEMPSKI O, 1988, NEUROCHEM PATHOL, V9, P109; Kimelberg H.K., 1982, HEAD INJURY BASIC CL, P31; KIMELBERG HK, 1990, BRAIN RES, V529, P262, DOI 10.1016/0006-8993(90)90836-Z; Kimelberg HK, 2003, J NEUROSURG, V99, P138, DOI 10.3171/jns.2003.99.1.0138; Kimelberg HK, 2004, NEUROCHEM INT, V45, P191, DOI 10.1016/j.neuint.2003.08.015; Kimelberg HK, 2004, NEUROSCIENCE, V129, P851, DOI 10.1016/j.neuroscience.2004.07.033; KIMELBERG HK, 1979, BRAIN RES, V173, P111; Kimelberg HK, 2000, NEUROSCIENTIST, V6, P14, DOI 10.1177/107385840000600110; Kimelberg HK, 2000, NEUROREPORT, V11, P2675, DOI 10.1097/00001756-200008210-00014; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; KIMLEE MH, 1992, GLIA, V5, P56, DOI 10.1002/glia.440050109; KOYAMA Y, 1991, NEUROSCI LETT, V122, P210, DOI 10.1016/0304-3940(91)90860-V; LAMBERT I H, 1991, Cellular Physiology and Biochemistry, V1, P177, DOI 10.1159/000154605; Lang F, 1998, PHYSIOL REV, V78, P247; Macaulay N, 2004, NEUROSCIENCE, V129, P1031, DOI 10.1016/j.neuroscience.2004.06.045; MACKNIGHT ADC, 1977, PHYSIOL REV, V57, P510; Malatesta P, 2003, NEURON, V37, P751, DOI 10.1016/S0896-6273(03)00116-8; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Marcaggi P, 2001, PROG NEUROBIOL, V64, P157, DOI 10.1016/S0301-0082(00)00043-5; MARTINEZHERNANDEZ A, 1977, SCIENCE, V195, P1356, DOI 10.1126/science.14400; Mehta SH, 2003, NEUROENDOCRINOLOGY, V77, P44, DOI 10.1159/000068332; Mongin A. A., 2005, NEUROGLIA, P550; MONGIN AA, 1994, BRAIN RES, V655, P110, DOI 10.1016/0006-8993(94)91603-9; Mongin AA, 2002, AM J PHYSIOL-CELL PH, V283, pC569, DOI 10.1152/ajpcell.00438.2001; Nagaraja TN, 1998, AM J PHYSIOL-CELL PH, V274, pC883; Nicotera P, 1999, J CEREBR BLOOD F MET, V19, P583, DOI 10.1097/00004647-199906000-00001; Nilius B, 2003, ACTA PHYSIOL SCAND, V177, P119, DOI 10.1046/j.1365-201X.2003.01060.x; NORENBERG MD, 1991, NEUROCHEM RES, V16, P833, DOI 10.1007/BF00965694; NORENBERG MD, 1987, NEUROCHEM PATHOL, V6, P13, DOI 10.1007/BF02833599; Olney J, 1978, KAINIC ACID TOOL NEU, P95; Osuka K, 2001, J NEUROCHEM, V76, P1842, DOI 10.1046/j.1471-4159.2001.00198.x; Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje; Papahadjopoulos D., 1974, PROG SURF SCI, V4, P141; PASANTESMORALES H, 1994, AM J PHYSIOL, V266, pC165; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Rutledge EM, 1998, AM J PHYSIOL-CELL PH, V274, pC1511; Schliess F, 2004, GLIA, V47, P21, DOI 10.1002/glia.20019; Seki Y, 1999, STROKE, V30, P433, DOI 10.1161/01.STR.30.2.433; Smets I, 2002, AM J PHYSIOL-CELL PH, V283, pC535, DOI 10.1152/ajpcell.00371.2001; SOMJEN GG, 2004, IONS BRAIN NORMAL FU, P63; STAUB F, 1994, J CEREBR BLOOD F MET, V14, P1030, DOI 10.1038/jcbfm.1994.135; STRUPP M, 1993, GLIA, V9, P136, DOI 10.1002/glia.440090207; Su G, 2002, AM J PHYSIOL-CELL PH, V282, pC1136, DOI 10.1152/ajpcell.00478.2001; Su G, 2002, AM J PHYSIOL-CELL PH, V282, pC1147, DOI 10.1152/ajpcell.00538.2001; SWAIN MS, 1991, AM J PHYSIOL, V261, pR1491; Sykova E, 2000, NEUROCHEM INT, V36, P397, DOI 10.1016/S0197-0186(99)00131-X; van der Wijk T, 2000, CELL PHYSIOL BIOCHEM, V10, P289, DOI 10.1159/000016359; VANHARREVELD A, 1966, BRAIN TISSUE ELECTRO, P50; Venero JL, 2001, PROG NEUROBIOL, V63, P321, DOI 10.1016/S0301-0082(00)00035-6; Verkman AS, 2000, J MEMBRANE BIOL, V173, P73, DOI 10.1007/s002320001009; Verkman AS, 2000, AM J PHYSIOL-RENAL, V278, pF13; VITARELLA D, 1994, J NEUROCHEM, V63, P1143; WillardMack CL, 1996, NEUROSCIENCE, V71, P589, DOI 10.1016/0306-4522(95)00462-9; Winkler AS, 2000, MOL BRAIN RES, V76, P419, DOI 10.1016/S0169-328X(00)00017-6; Yan YP, 2001, J CEREBR BLOOD F MET, V21, P711, DOI 10.1097/00004647-200106000-00009	81	184	197	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	JUN	2005	50	4			SI		389	397		10.1002/glia.20174			9	Neurosciences	Neurosciences & Neurology	922WW	WOS:000228871600010	15846797				2021-06-18	
J	McDonald, S; Flanagan, S				McDonald, S; Flanagan, S			Social perception deficits after traumatic brain injury: Interaction between emotion recognition, mentalizing ability, and social communication	NEUROPSYCHOLOGY			English	Article							CLOSED-HEAD-INJURY; FRONTAL-LOBE DAMAGE; AMYGDALA DAMAGE; FACIAL EXPRESSION; MIND; IMPAIRMENTS; ADJUSTMENT; COGNITION; LESIONS; PATIENT	Thirty-four adults with severe traumatic brain injuries (TBI) and 34 matched control participants were asked to interpret videotaped conversational exchanges. Study participants were asked to judge the speakers' emotions, the speakers' beliefs (first-order theory of mind), what the speakers intended their conversational partners to believe (second-order theory of mind), and what they meant by remarks that were sincere or literally untrue (i.e., a lie or sarcastic retort). The TBI group had marked difficulty judging most facets of social information. They could recognize speaker beliefs only when this information was explicitly provided. In general, emotion recognition and first-order theory of mind judgments were not related to the ability to understand social (conversational) inference, whereas second-order theory of mind judgments were related to that ability.	Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia	McDonald, S (corresponding author), Univ New S Wales, Sch Psychol, Sydney, NSW 2052, Australia.	s.mcdonald@unsw.edu.au	McDonald, Skye/G-4118-2014	McDonald, Skye/0000-0003-0723-6094			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; Adolphs R, 2002, J COGNITIVE NEUROSCI, V14, P1264, DOI 10.1162/089892902760807258; Adolphs R, 2002, CURR OPIN NEUROBIOL, V12, P169, DOI 10.1016/S0959-4388(02)00301-X; Bara BG, 1997, BRAIN LANG, V59, P7, DOI 10.1006/brln.1997.1812; Bechara A, 2002, BRAIN, V125, P1673, DOI 10.1093/brain/awf169; BOND MR, 1976, ACTA NEUROCHIR, V34, P57, DOI 10.1007/BF01405863; BOND MR, 1975, CIBA FDN S, V34; Broks P, 1998, NEUROPSYCHOLOGIA, V36, P59, DOI 10.1016/S0028-3932(97)00105-X; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Channon S, 2000, NEUROPSYCHOLOGIA, V38, P1006, DOI 10.1016/S0028-3932(99)00154-2; Cicerone KD, 1997, ARCH CLIN NEUROPSYCH, V12, P173, DOI 10.1016/S0887-6177(96)00022-4; CORRIGAN PW, 1995, SCHIZOPHRENIA BULL, V21, P395, DOI 10.1093/schbul/21.3.395; COWLAND AJ, 1996, COGNITIVE NEUROPSYCH, V13, P699; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; Fine C, 2001, BRAIN, V124, P287, DOI 10.1093/brain/124.2.287; Happe F, 2001, NEUROPSYCHOLOGIA, V39, P83, DOI 10.1016/S0028-3932(00)00093-2; Heaton R., 1993, WISCONSIN CARD SORTI; Hopkins MJ, 2002, BRAIN INJURY, V16, P245, DOI 10.1080/02699050110103346; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; Kendall E, 1997, J HEAD TRAUMA REHAB, V12, P68, DOI 10.1097/00001199-199706000-00007; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; MCDONALD S, 1992, APPL PSYCHOLINGUIST, V13, P295, DOI 10.1017/S0142716400005658; McDonald S, 1996, BRAIN LANG, V53, P81, DOI 10.1006/brln.1996.0038; MCDONALD S, IN PRESS NEUROPSYCHO; McDonald S., 2002, AWARENESS SOCIAL INF; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Pearce S, 1998, BRAIN COGNITION, V38, P150, DOI 10.1006/brcg.1998.1018; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; PRIGATANO GP, 1982, J PERCEPTUAL MOTOR S, V54, P859; SANTORO J, 1994, BRAIN INJURY, V8, P265, DOI 10.3109/02699059409150978; SPERBER D, 1987, BEHAV BRAIN SCI, V10, P697, DOI 10.1017/S0140525X00055345; Stone VE, 2003, NEUROPSYCHOLOGIA, V41, P209, DOI 10.1016/S0028-3932(02)00151-3; Stone VE, 1998, J COGNITIVE NEUROSCI, V10, P640, DOI 10.1162/089892998562942; Stuss DT, 2001, BRAIN, V124, P279, DOI 10.1093/brain/124.2.279; SULLIVAN K, 1995, BRIT J DEV PSYCHOL, V13, P191, DOI 10.1111/j.2044-835X.1995.tb00673.x; TATE RL, 1991, J NERV MENT DIS, V179, P117, DOI 10.1097/00005053-199103000-00001; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; Tate RL, 1999, PSYCHOL MED, V29, P713, DOI 10.1017/S0033291799008466; Turkstra LS, 2001, J HEAD TRAUMA REHAB, V16, P469, DOI 10.1097/00001199-200110000-00006; Van Horn K R, 1992, Brain Inj, V6, P15, DOI 10.3109/02699059209008118; VILKKI J, 1994, J CLIN EXP NEUROPSYC, V16, P325, DOI 10.1080/01688639408402643; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; Young AW, 1996, NEUROPSYCHOLOGIA, V34, P31, DOI 10.1016/0028-3932(95)00062-3	47	184	185	1	34	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105			NEUROPSYCHOLOGY	Neuropsychology	JUL	2004	18	3					572	579		10.1037/0894-4105.18.3.572			8	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	838IK	WOS:000222706700018	15291735				2021-06-18	
J	D'Ambrosio, R; Fairbanks, JP; Fender, JS; Born, DE; Doyle, DL; Miller, JW				D'Ambrosio, R; Fairbanks, JP; Fender, JS; Born, DE; Doyle, DL; Miller, JW			Post-traumatic epilepsy following fluid percussion injury in the rat	BRAIN			English	Article						traumatic brain injury; epileptogenesis; electrocorticography; drug screening; gliosis	TRAUMATIC BRAIN-INJURY; ELECTROPHYSIOLOGICAL PROPERTIES; SEIZURE ACTIVITY; ISOLATED CORTEX; DENTATE GYRUS; CNS INJURY; HIPPOCAMPUS; EPILEPTOGENESIS; STIMULATION; EXPRESSION	The lack of an adequate model of post-traumatic epilepsy (PTE), in which, similarly to the human condition, chronic spontaneous focal seizures follow a single episode of traumatic brain injury, has hampered the identification of clinically relevant epileptogenic mechanisms and the development of effective therapies. We studied the electrophysiological, behavioural and structural consequences of a clinically relevant model of closed head injury, the lateral fluid percussion injury (FPI), in the rat. We found that a single episode of severe FPI is sufficient to cause PTE. Chronic electrocorticography (ECoG) demonstrated spontaneous chronic seizures that were partial, originated from the neocortex at the site of injury, and progressively worsened and spread over time. The cases of epilepsy in the post-traumatic population increased over time following injury. Post-FPI epileptic rats exhibited pauses in their behaviour, facial automatisms and myoclonus at the time of epileptiform ECoG events. In vitro local field potential recordings demonstrated persistent hyperexcitability of the neocortex at and around the site of injury that was associated with intense glial reactivity. These results for the first time demonstrate persistent hyperexcitability of the injured neocortex and define a useful model for pathophysiological studies of basic mechanisms of spontaneous epileptogenesis and for preclinical screening of effective antiepileptogenic drugs.	Univ Washington, Harborview Med Ctr, Sch Med, Dept Neurol Surg, Seattle, WA 98104 USA; Univ Washington, Harborview Med Ctr, Sch Med, Dept Neurol, Seattle, WA 98104 USA; Univ Washington, Harborview Med Ctr, Sch Med, Reg Epilepsy Ctr, Seattle, WA 98104 USA; Univ Washington, Harborview Med Ctr, Sch Med, Dept Pathol, Seattle, WA 98104 USA; Univ Washington, Harborview Med Ctr, Sch Med, Ctr Human Dev & Disabil, Seattle, WA 98104 USA	D'Ambrosio, R (corresponding author), Univ Washington, Harborview Med Ctr, Dept Neurosurg, Box 359914,325 9th Ave, Seattle, WA 98104 USA.	raid@u.washington.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040823] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 40823, R01 NS040823-02, R01 NS040823] Funding Source: Medline		Annegers JF, 1996, MAYO CLIN PROC, V71, P570, DOI 10.4065/71.6.570; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Binder DK, 2001, TRENDS NEUROSCI, V24, P47, DOI 10.1016/S0166-2236(00)01682-9; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Coulter DA, 1996, EPILEPSY RES, V26, P81, DOI 10.1016/S0920-1211(96)00044-7; D'Ambrosio R, 1999, J NEUROSCI, V19, P8152; D'Ambrosio R, 2002, J NEUROPHYSIOL, V87, P87, DOI 10.1152/jn.00240.2001; DAMBROSIO R, 2003, YOUMANS NEUROLOGICAL, P2449; Diaz-Arrastia R, 2000, ARCH NEUROL-CHICAGO, V57, P1611, DOI 10.1001/archneur.57.11.1611; ECHLIN FA, 1963, ARCH NEUROL-CHICAGO, V9, P154, DOI 10.1001/archneur.1963.00460080064009; FEENEY DM, 1979, ARCH NEUROL-CHICAGO, V36, P8, DOI 10.1001/archneur.1979.00500370038005; Floyd CL, 2002, J NEUROTRAUM, V19, P303, DOI 10.1089/089771502753594873; GODDARD GV, 1967, NATURE, V214, P1020, DOI 10.1038/2141020a0; Golarai G, 2001, J NEUROSCI, V21, P8523; Graber KD, 1999, ANN NEUROL, V46, P234, DOI 10.1002/1531-8249(199908)46:2<234::AID-ANA13>3.0.CO;2-Q; GRAFSTEIN B, 1957, ELECTROEN CLIN NEURO, V9, P723, DOI 10.1016/0013-4694(57)90096-2; HALL ED, 1989, CRIT CARE CLIN, V5, P793; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hicks RR, 1999, EXP NEUROL, V160, P469, DOI 10.1006/exnr.1999.7216; Hill-Felberg SJ, 1999, J NEUROSCI RES, V57, P271, DOI 10.1002/(SICI)1097-4547(19990715)57:2<271::AID-JNR13>3.0.CO;2-Z; HOFFMAN SN, 1994, J NEUROPHYSIOL, V71, P1762; Jennett B, 1975, EPILEPSY NONMISSILE; Juurlink B H, 1998, J Spinal Cord Med, V21, P309; Loscher W, 2002, EPILEPSY RES, V50, P3, DOI 10.1016/S0920-1211(02)00063-3; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Marklund N, 2001, J NEUROTRAUM, V18, P821, DOI 10.1089/089771501316919184; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; Povlishock J T, 1992, Hum Cell, V5, P345; PRINCE DA, 1993, J NEUROPHYSIOL, V69, P1276; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Rao VLR, 1998, J NEUROCHEM, V70, P2020; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Scharfman HE, 2002, EXP NEUROL, V174, P201, DOI 10.1006/exnr.2002.7869; Schmidt D, 2002, EPILEPSY RES, V50, P71, DOI 10.1016/S0920-1211(02)00070-0; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; Schroder W, 1999, GLIA, V28, P166, DOI 10.1002/(SICI)1098-1136(199911)28:2<166::AID-GLIA8>3.3.CO;2-K; SHARPLESS SK, 1962, ELECTROEN CLIN NEURO, V14, P244, DOI 10.1016/0013-4694(62)90034-2; Stables James P., 2002, Epilepsia, V43, P1410, DOI 10.1046/j.1528-1157.2002.06702.x; STEWARD O, 1991, P NATL ACAD SCI USA, V88, P6819, DOI 10.1073/pnas.88.15.6819; Temkin NR, 2001, DRUGS, V61, P1045, DOI 10.2165/00003495-200161080-00002; Temkin NRHM, 1996, NEUROLOGICAL SURG, P1834; Vezzani A, 1999, J NEUROSCI, V19, P5054; Vezzani A, 2000, P NATL ACAD SCI USA, V97, P11534, DOI 10.1073/pnas.190206797; White HS, 2002, NEUROLOGY, V59, pS7, DOI 10.1212/WNL.59.9_suppl_5.S7; WILLMORE LJ, 1978, SCIENCE, V200, P1501, DOI 10.1126/science.96527; WILLMORE LJ, 1984, EXP NEUROL, V83, P62, DOI 10.1016/0014-4886(84)90046-3	49	184	187	0	9	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	FEB	2004	127		2				304	314		10.1093/brain/awh038			11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	766RT	WOS:000188389900007	14607786	Green Accepted, Bronze			2021-06-18	
J	Kreutzer, JS; Marwitz, JH; Walker, W; Sander, A; Sherer, M; Bogner, J; Fraser, R; Bushnik, T				Kreutzer, JS; Marwitz, JH; Walker, W; Sander, A; Sherer, M; Bogner, J; Fraser, R; Bushnik, T			Moderating factors in return to work and job stability after traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						employment outcome; job stability; return to work; traumatic brain injury	SEVERE HEAD TRAUMA; QUALITY-OF-LIFE; COMMUNITY INTEGRATION; ACUTE PREDICTORS; EMPLOYMENT; REHABILITATION; DISABILITY; OUTCOMES; COMA	Objective: To examine job stability moderating variables and develop a postinjury work stability prediction model. Design: Multicenter analysis of individuals with traumatic brain injury (TBI) who returned for follow-up at 1, 2, and 3, or 4 years postinjury, were of working age (between 18 and 62 years of age at injury), and were working preinjury. Setting: Six National Institute on Disability and Rehabilitation Research TBI Model System centers for coordinated acute and rehabilitation care. Participants: A total of 186 adults with TBI were included in the study. Main outcome measures: job stability was categorized as stably employed (employed at all 3 follow-up intervals); unstably employed (employed at one or two of all three follow-up intervals); and unemployed (unemployed at all three follow-up intervals). Results: After injury, 34% were stably employed, 27% were unstably employed, and 39% were unemployed at all three follow-up intervals. Minority group members, people who did not complete high school, and unmarried people were more likely to be unemployed. Driving independence was highly influential and significantly related to employment stability. A discriminant function analysis, which included age, length of unconsciousness and Disability Rating Scale scores at I year postinjury, accurately predicted job stability groupings. Conclusion: Data analysis provided evidence that employment stability is predictable with a combination of functional, demographic, and injury severity variables. Identification of people at risk for poor employment outcomes early on can facilitate rehabilitation planning and intervention.	Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Neurol Surg, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Dept Psychiat, Richmond, VA 23298 USA; Brain Injury Res Ctr, Houston, TX USA; Methodist Rehabil Ctr, Neuropsychol Dept, Jackson, MS USA; Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; Santa Clara Valley Med Ctr, Dept Phys Med & Rehabil, San Jose, CA 95128 USA	Kreutzer, JS (corresponding author), Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Med Coll Virginia Campus,Box 980542, Richmond, VA 23298 USA.			Bushnik, Tamara/0000-0003-3328-257X			Bell KR, 1998, ARCH PHYS MED REHAB, V79, pS21, DOI 10.1016/S0003-9993(98)90116-2; BENYISHAY Y, 1987, J HEAD TRAUMA REHAB, V2, P35, DOI DOI 10.1097/00001199-198703000-00007; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; CRISP R, 1992, J REHABIL, V58, P27; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Felmingham KL, 2001, ARCH PHYS MED REHAB, V82, P435, DOI 10.1053/apmr.2001.21985; Fleming J, 1999, BRAIN INJURY, V13, P417; FORER S, 1982, J ORGAN REHABIL EVAL, V2, P29; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; Granger CV, 1986, TOP GERIATR REHABIL, V1, P59, DOI 10.1097/00013614-198604000-00007; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pSC10; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; HUMPHREY M, 1980, INJURY, V12, P107, DOI 10.1016/0020-1383(80)90133-3; IP RY, 1995, BRAIN INJURY, V9, P517, DOI 10.3109/02699059509008211; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Johnson R, 1998, NEUROPSYCHOL REHABIL, V8, P61, DOI 10.1080/713755552; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; KREUTZER JS, 1999, BRAIN INJURY WORK BO; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LUBUSKO AA, 1994, BRAIN INJURY, V8, P65, DOI 10.3109/02699059409150959; MACKENZIE EJ, 1987, AM J PUBLIC HEALTH, V77, P329, DOI 10.2105/AJPH.77.3.329; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Possl O, 2001, BRAIN INJURY, V15, P15; Prigatano G. P., 1994, J HEAD TRAUMA REHAB, V9, P91, DOI [DOI 10.1097/00001199-199403000-00011, 10.1097/00001199-199403000-00011]; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Ruffolo CF, 1999, ARCH PHYS MED REHAB, V80, P392, DOI 10.1016/S0003-9993(99)90275-7; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; STAMBROOK M, 1990, Brain Injury, V4, P183, DOI 10.3109/02699059009026164; *STAT U, 1996, GUID UN DAT SET MED; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Tabachnick B.G., 1989, USING MULTIVARIATE S; Vogenthaler D R, 1989, Brain Inj, V3, P369, DOI 10.3109/02699058909004561; Wagner AK, 2002, ARCH PHYS MED REHAB, V83, P107, DOI 10.1053/apmr.2002.27470; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; WEHMAN P, 1993, AM J PHYS MED REHAB, V72, P355; WEST MD, 1992, J ASSOC PERS SEVERE, V17, P47, DOI 10.1177/154079699201700109	45	184	187	0	25	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2003	18	2					128	138		10.1097/00001199-200303000-00004			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	663DU	WOS:000181991600004	12802222				2021-06-18	
J	Riess, P; Zhang, C; Saatman, KE; Laurer, HL; Longhi, LG; Raghupathi, R; Lenzlinger, PM; Lifshitz, J; Boockvar, J; Neugebauer, E; Snyder, EY; McIntosh, TK				Riess, P; Zhang, C; Saatman, KE; Laurer, HL; Longhi, LG; Raghupathi, R; Lenzlinger, PM; Lifshitz, J; Boockvar, J; Neugebauer, E; Snyder, EY; McIntosh, TK			Transplanted neural stem cells survive, differentiate, and improve neurological motor function after experimental traumatic brain injury	NEUROSURGERY			English	Article						behavior; cell engraftment; C17.2; head injury; transplantation	CONTROLLED CORTICAL IMPACT; SPINAL-CORD; COGNITIVE DEFICITS; PROGENITOR CELLS; PRECURSOR CELLS; NEURONS; MOUSE; REPLACEMENT; RECOVERY; NEUROGENESIS	OBJECTIVE: Using the neural stem cell (NSC) clone C17.2, we evaluated the ability of transplanted murine NSCs to attenuate cognitive and neurological motor deficits after traumatic brain injury. METHODS: Nonimmunosuppressed C57BL/6 mice (n = 65) were anesthetized and subjected to lateral controlled cortical impact brain injury (n = 52) or surgery without injury (sham operation group, n = 13). At 3 days postinjury, all brain-injured animals were, reanesthetized and, randomized to receive stereotactic injection of NSCs or control Cells (human embryonic kidney cells) into the cortex-hippocampus interface in either the ipsilateral-or the contralateral hemisphere. One group of animals (n = 7) was killed. at either 1 or 3 weeks postinjury to assess NSC survival in the acute posttraumatic period. Motor function was evaluated at weekly intervals for 12 weeks in the remaining animals, and cognitive (i.e., learning) deficits were assessed at 13 and 12 weeks after transplantation. RESULTS: Brain-injured animals that, received either ipsilateral or contralateral NSC transplants showed significantly improved motor function in selected tests as compared with human embryonic kidney cell-transplanted animals during the 12-week observation period. Cognitive, dysfunction was unaffected by transplantation at either 3 or. 12 weeks postinjury. Histological analyses showed that NSCs survive for as long as 13 weeks after transplantation and were detected in the hippocampus and/or cortical areas adjacent to the, injury cavity. At 13 weeks, the, NSCs transplanted ipsilateral to the impact site expressed neuronal (NeuN) or astrocytic (glial fibrillary acidic protein) markers, but not, markers of oligodendrocytes (2'3'cyclic nucleotide 3'-phoshodiesterase), whereas, the contralaterally transplanted NSCs expressed neuronal but not glial markers (double-labeled immunofluorescence and confocal microscopy). CONCLUSION: These data suggest that transplanted NSCs can survive in the traumatically injured brain, differentiate into neurons and/or glia, and attenuate motor dysfunction after traumatic brain injury.	Univ Penn, Sch Med, Dept Neurosurg, Head Injury Ctr, Philadelphia, PA 19104 USA; Univ Cologne, Dept Surg 2, Biochem & Expt Div, Cologne, Germany; Harvard Univ, Childrens Hosp, Sch Med, Dept Neurol, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Sch Med, Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Childrens Hosp, Sch Med, Dept Neurosurg, Boston, MA 02115 USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA	McIntosh, TK (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, Head Injury Ctr, 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.	mcintosh@seas.upenn.edu	Lenzlinger, Philipp/A-3822-2008		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040978, R01NS033852, P01NS008803, R01NS034247] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS08803, R01-NS33852, R01-NS-40978, R01 NS34247] Funding Source: Medline		Aboody KS, 2000, P NATL ACAD SCI USA, V97, P12846, DOI 10.1073/pnas.97.23.12846; Andsberg G, 1998, EUR J NEUROSCI, V10, P2026, DOI 10.1046/j.1460-9568.1998.00214.x; Bachoud-Levi A, 2000, LANCET, V356, P1975, DOI 10.1016/S0140-6736(00)03310-9; Bjorklund A, 2000, NAT NEUROSCI, V3, P537, DOI 10.1038/75705; Borlongan CV, 1998, EXP NEUROL, V149, P310, DOI 10.1006/exnr.1997.6730; Clarkson ED, 1999, LIFE SCI, V65, P2427, DOI 10.1016/S0024-3205(99)00254-4; Covolan L, 2000, HIPPOCAMPUS, V10, P169, DOI 10.1002/(SICI)1098-1063(2000)10:2<169::AID-HIPO6>3.3.CO;2-N; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Doering LC, 2000, J NEUROSCI RES, V61, P597, DOI 10.1002/1097-4547(20000915)61:6<597::AID-JNR3>3.0.CO;2-L; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Foster J, 1996, AACN Clin Issues, V7, P168, DOI 10.1097/00044067-199602000-00016; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; GRABOWSKI M, 1995, EXP NEUROL, V133, P96, DOI 10.1006/exnr.1995.1011; Gray JA, 1999, PHILOS T R SOC B, V354, P1407, DOI 10.1098/rstb.1999.0488; Hammerman MR, 2000, PEDIATR NEPHROL, V14, P513, DOI 10.1007/s004670050805; Himes BT, 2001, J NEUROSCI RES, V65, P549, DOI 10.1002/jnr.1185; Kukekov VG, 1999, EXP NEUROL, V156, P333, DOI 10.1006/exnr.1999.7028; Liu Y, 1999, EXP NEUROL, V158, P9, DOI 10.1006/exnr.1999.7079; LU P, 2001, AM SOC NEURAL TRANSP, V8, P22; MartinezSerrano A, 1997, TRENDS NEUROSCI, V20, P530, DOI 10.1016/S0166-2236(97)01119-3; Mattiasson GJ, 2000, J NEUROSCI METH, V95, P75, DOI 10.1016/S0165-0270(99)00162-4; McDonald JW, 1999, NAT MED, V5, P1410, DOI 10.1038/70986; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Murai H, 1998, J COMP NEUROL, V392, P428, DOI 10.1002/(SICI)1096-9861(19980323)392:4<428::AID-CNE2>3.0.CO;2-2; Nakamura M, 1999, J CEREBR BLOOD F MET, V19, P762, DOI 10.1097/00004647-199907000-00006; *NAT RES COUNC, 1996, GUID CAR US LAB AN; Park KI, 1999, J NEUROTRAUM, V16, P675, DOI 10.1089/neu.1999.16.675; Philips MF, 1999, J NEUROSURG, V90, P116, DOI 10.3171/jns.1999.90.1.0116; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Rosario CM, 1997, DEVELOPMENT, V124, P4213; Roy NS, 2000, NAT MED, V6, P271; RYDER EF, 1990, J NEUROBIOL, V21, P356, DOI 10.1002/neu.480210209; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Sinden JD, 1997, NEUROSCIENCE, V81, P599, DOI 10.1016/S0306-4522(97)00330-8; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; Sinson G, 1996, J NEUROSURG, V84, P655, DOI 10.3171/jns.1996.84.4.0655; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; SNYDER EY, 1992, CELL, V68, P33, DOI 10.1016/0092-8674(92)90204-P; Snyder EY, 1997, P NATL ACAD SCI USA, V94, P11663, DOI 10.1073/pnas.94.21.11663; SNYDER EY, 1992, SEMIN PERINATOL, V16, P106; SNYDER EY, 1995, P ASSOC AM PHYSICIAN, V107, P195; SOARES H, 1991, Journal of Neural Transplantation and Plasticity, V2, P207; Soares HD, 1995, J NEUROTRAUM, V12, P1059, DOI 10.1089/neu.1995.12.1059; Takagi Y, 1999, BRAIN RES, V831, P283, DOI 10.1016/S0006-8993(99)01411-0; Teng YD, 2002, P NATL ACAD SCI USA, V99, P3024, DOI 10.1073/pnas.052678899; Wagner J, 1999, NAT BIOTECHNOL, V17, P653; Whittemore SR, 1996, MOL NEUROBIOL, V12, P13, DOI 10.1007/BF02740745; Yandava BD, 1999, P NATL ACAD SCI USA, V96, P7029, DOI 10.1073/pnas.96.12.7029	50	184	218	0	15	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	OCT	2002	51	4					1043	1052		10.1097/00006123-200210000-00035			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	598ZV	WOS:000178308500053	12234415				2021-06-18	
J	Jiang, JY; Gao, GY; Li, WP; Yu, MK; Zhu, C				Jiang, JY; Gao, GY; Li, WP; Yu, MK; Zhu, C			Early indicators of prognosis in 846 cases of severe traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						early indicators; prognosis; severe traumatic brain injury	SEVERE HEAD-INJURY; HYPERTHERMIA; HYPOTHERMIA; PREDICTION; MORTALITY; CARE; COMA	A number of factors, including Glasgow coma scale (GCS) score, age, pupillary response and size, hypoxia, hyperthermia, and high intracranial pressure, may play an important role in predicting the outcome of traumatic brain injury. Eight hundred forty-six cases of severe traumatic brain injury (GCS less than or equal to 8) were analyzed retrospectively to clarify the effects of multiple factors on the prognosis of patients. At I year after injury, the outcomes in these cases were as follows: good recovery, 31.56%; moderate disability, 14.07%; severe disability 24.35%; vegetative status, 0.59%; and death, 29.43%. The outcomes were strongly correlated (p < 0.05) with GCS score, age, pupillary response and size, hypoxia, hyperthermia, and high intracranial pressure (ICP). These findings indicate that prevention of hypoxia, control of high ICP, and prevention of hyperthermia may be useful means for improving the outcome of patients with severe head injury.	Chang Zheng Hosp, Dept Neurosurg, Shanghai Neurosurg Inst, Shanghai 200003, Peoples R China	Jiang, JY (corresponding author), Chang Zheng Hosp, Dept Neurosurg, Shanghai Neurosurg Inst, 415 Feng Yang Rd, Shanghai 200003, Peoples R China.	Jiangjyb@online.sh.cn					BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; CARREL M, 1994, ANN FR ANESTH, V13, P326, DOI 10.1016/S0750-7658(94)80041-3; Chatzipanteli K, 2000, J CEREBR BLOOD F MET, V20, P531, DOI 10.1097/00004647-200003000-00012; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Chesnut RM, 2000, J NEUROTRAUM, V17, P555; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; COLOHAN ART, 1989, J NEUROSURG, V71, P202, DOI 10.3171/jns.1989.71.2.0202; COOPER PJ, 1987, HEAD INJURY, P1; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; DIETRICH WD, 1992, J NEUROTRAUM, V9, pS475; EDNA TH, 1983, ACTA NEUROCHIR, V69, P15, DOI 10.1007/BF02055848; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; GHAJAR JBG, 1993, ADV NEUROS, V21, P173; HERNESNIEMI J, 1979, ACTA NEUROCHIR, V49, P67, DOI 10.1007/BF01809175; MAMAROU A, 1991, J NEUROSURG, V75, pS59; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; PHUENPATHOM N, 1993, SURG NEUROL, V40, P22, DOI 10.1016/0090-3019(93)90164-V; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; TEASDALE G, 1974, LANCET, V2, P81; YOUNG B, 1981, J NEUROSURG, V54, P300, DOI 10.3171/jns.1981.54.3.0300	23	184	216	1	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2002	19	7					869	874		10.1089/08977150260190456			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	577JL	WOS:000177057700006	12184856				2021-06-18	
J	Pettus, EH; Povlishock, JT				Pettus, EH; Povlishock, JT			Characterization of a distinct set of intra-axonal ultrastructural changes associated with traumatically induced alteration in axolemmal permeability	BRAIN RESEARCH			English	Article						axonal injury; axotomy; traumatic brain injury; cytoskeleton; neurofilament; microtubule; mitochondrion; membrane	NONMISSILE HEAD-INJURY; BRAIN INJURY; NEUROFILAMENT PHOSPHORYLATION; CALPAIN-I; MICROTUBULES; NERVE; TRANSPORT; SUBUNITS; CALCIUM; CALIBER	It has recently been demonstrated [Pettus et al., J. Neurotrauma, 11 (1994) 507-522] that moderate traumatic brain injury evokes alterations in axolemmal permeability associated with rapid local compaction of axonal neurofilaments (NF). The current communication fully characterizes these local NF changes, while also exploring the possibility of other related cytoskeletal abnormalities. A tracer normally excluded by the intact axolemma (horseradish peroxidase) was administered intrathecally in cats, which were then subjected to moderate/severe fluid percussion brain injury (FPI). After survival times ranging from 5 min to 6 h post-traumatic brain injury (TBI), the animals were perfused and processed for light microscopic (LM) and electron microscopic (EM) visualization of horseradish peroxidase (HRP). HRP-containing axons identified by LM, were investigated by EM in both the sagittal and coronal planes. Electron micrographs were videographically captured, digitized, and analyzed for cytoskeletal distribution. Local alterations in axolemmal permeability to HRP were detected, and consistently linked with distinct cytoskeletal changes. Within 5 min of injury, the injured HRP-containing axons displayed a significant decrease in inter-NE spacing associated with a lack of NF side arm projections. Density analysis proved a significant increase in NF packing in the HRP-containing axons, and further revealed an associated significant decrease in microtubule (MT) density. All ultrastructural changes were seen within 5 min of injury, and persisted unchanged for up to 6 h post-TBI. Collectively, these abnormalities suggest that altered axolemmal permeability triggers a rapid, yet persisting general cytoskeletal change most likely linked to local ionic disregulation. We posit that this local cytoskeletal collapse/alteration marks a site of impaired axonal transport, associated with upstream axoplasmic swelling and eventual axonal detachment.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT ANAT,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DIV NEUROSURG,RICHMOND,VA 23298					NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS20193] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020193] Funding Source: NIH RePORTER		ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; BANAYSCHWARTZ M, 1994, NEUROCHEM RES, V19, P563, DOI 10.1007/BF00971331; BILLGER M, 1988, CELL CALCIUM, V9, P33, DOI 10.1016/0143-4160(88)90036-X; Brady Scott T., 1993, P7; CHRISTMAN CW, 1994, J NEUROTRAUMA; COTTIN P, 1991, BIOCHIM BIOPHYS ACTA, V1079, P139, DOI 10.1016/0167-4838(91)90118-J; DEWAEGH SM, 1992, CELL, V68, P451, DOI 10.1016/0092-8674(92)90183-D; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; FRIEDE RL, 1970, ANAT REC, V167, P379, DOI 10.1002/ar.1091670402; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; GRAFSTEIN B, 1980, PHYSIOL REV, V60, P1167; HALL GF, 1995, J COMP NEUROL, V353, P38, DOI 10.1002/cne.903530106; HSIEH ST, 1994, J NEUROSCI, V14, P6392; ISHIZAKI Y, 1994, J NEUROSCI, V14, P3934; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; JOB D, 1981, P NATL ACAD SCI-BIOL, V78, P4679, DOI 10.1073/pnas.78.8.4679; KAMAKURA K, 1985, J NEUROSCI RES, V13, P391, DOI 10.1002/jnr.490130306; Maxwell W. L., 1995, Journal of Neurotrauma, V12, P363; MAXWELL WL, 1993, ACTA NEUROPATHOL, V85, P1; MCHALE MK, 1995, J COMP NEUROL, V353, P25, DOI 10.1002/cne.903530105; NEVIN NC, 1967, J NEUROPATH EXP NEUR, V26, P77, DOI 10.1097/00005072-196701000-00006; NIXON RA, 1991, TRENDS NEUROSCI, V14, P501, DOI 10.1016/0166-2236(91)90062-Y; NIXON RA, 1994, J CELL BIOL, V126, P1031, DOI 10.1083/jcb.126.4.1031; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; POVLISHOCK JT, 1985, LAB INVEST, V52, P540; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; POVLISHOCK JT, 1996, UNPUB J NEUROPATHOL; POVLISHOCK JT, 1996, IN PRESS ACTA NEUR S; RELES A, 1991, J NEUROCYTOL, V20, P450, DOI 10.1007/BF01252273; Strich S J, 1970, J Clin Pathol Suppl (R Coll Pathol), V4, P166; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; WEISENBERG RC, 1981, BIOCHEM BIOPH RES CO, V102, P924, DOI 10.1016/0006-291X(81)91626-0; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006	42	184	189	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	MAY 25	1996	722	1-2					1	11		10.1016/0006-8993(96)00113-8			11	Neurosciences	Neurosciences & Neurology	UT996	WOS:A1996UT99600002	8813344				2021-06-18	
J	WU, W; LIUZZI, FJ; SCHINCO, FP; DEPTO, AS; LI, Y; MONG, JA; DAWSON, TM; SNYDER, SH				WU, W; LIUZZI, FJ; SCHINCO, FP; DEPTO, AS; LI, Y; MONG, JA; DAWSON, TM; SNYDER, SH			NEURONAL NITRIC-OXIDE SYNTHASE IS INDUCED IN SPINAL NEURONS BY TRAUMATIC INJURY	NEUROSCIENCE			English	Article							DORSAL-ROOT GANGLIA; NADPH-DIAPHORASE; INSITU HYBRIDIZATION; INCREASED EXPRESSION; PERIPHERAL AXOTOMY; BRAIN; RAT; IMMUNOREACTIVITY; REGENERATION; MECHANISMS	Nitric oxide appears to mediate the immune functions of macrophages, the influence of endothelial cells on blood vessel relaxation, and also to serve as a neurotransmitter in the central and peripheral nervous system.(1,17) Macrophage nitric oxide synthase is inducible with massive increases in new nitric oxide synthase protein synthesis following immune stimulation of macrophages.(18) By contrast, endothelial nitric oxide synthase and neuronal nitric oxide synthase are thought to tie constitutive with activation induced by calcium entry into cells in the absence of new protein synthesis.(4,9,15) Developmental studies showing the transient expression of neuronal nitric oxide synthase in embryonic and early postnatal life in rodent spinal motoneurons and cerebral cortical plate neurons (Bredt and Snyder, unpublished observations) implies inducibility of neuronal nitric oxide synthase. Moreover, neuronal nitric oxide synthase expression is greatly enhanced in sensory ganglia following peripheral axotomy.(8,20) Staining for NADPH diaphorase in spinal motoneurons is greatly increased following ventral root avulsion.(22) In many parts of the Central Nervous System NADPH diaphorase staining reflects nitric oxide synthase.(3,11) In the present study, we have combined in situ hybridization for neuronal nitric oxide synthase, immunohistochemical staining of neuronal nitric oxide synthase, and NADPH diaphorase staining to establish that neuronal nitric oxide synthase expression is markedly augmented in spinal motoneurons following avulsion. The generality of this effect is evident from augmented staining in nucleus dorsalis following spinal cord transection.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,BALTIMORE,MD 21205; EASTERN VIRGINIA MED SCH,DEPT NEUROSURG,NORFOLK,VA 23501; EASTERN VIRGINIA MED SCH,INST DIABET,DEPT INTERNAL MED,NORFOLK,VA 23501; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOLEC SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT & BEHAV SCI,BALTIMORE,MD 21205					NIDA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [DA-00074, DA-00266] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-01578] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS001578] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [P50DA000266] Funding Source: NIH RePORTER		BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; DAWSON TM, 1991, P NATL ACAD SCI USA, V88, P7797, DOI 10.1073/pnas.88.17.7797; DAWSON TM, 1994, IN PRESS J NEUROSCI; DAWSON VL, 1993, J NEUROSCI, V13, P2651; DINERMAN JL, 1994, P NATL ACAD SCI USA, V91, P4214, DOI 10.1073/pnas.91.10.4214; FIALLOSESTRADA CE, 1993, NEUROSCI LETT, V150, P169, DOI 10.1016/0304-3940(93)90528-S; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GONZALEZ MF, 1987, BRAIN RES BULL, V18, P417, DOI 10.1016/0361-9230(87)90016-5; HOPE BT, 1991, P NATL ACAD SCI USA, V88, P2811, DOI 10.1073/pnas.88.7.2811; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; INGHAM PW, 1985, NATURE, V318, P439, DOI 10.1038/318439a0; LEBEAU JM, 1991, J NEUROSCI RES, V28, P299, DOI 10.1002/jnr.490280217; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MATSUMOTO T, 1993, NEUROSCI LETT, V155, P61, DOI 10.1016/0304-3940(93)90673-9; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; NATHAN C, 1992, FASEB J, V6, P3051; ROSKAMS AJ, 1994, IN PRESS NEURON; SNIDER WD, 1989, ANN NEUROL, V26, P489, DOI 10.1002/ana.410260402; VERGE VMK, 1992, P NATL ACAD SCI USA, V89, P11617, DOI 10.1073/pnas.89.23.11617; VINCENT SR, 1992, NEUROSCIENCE, V46, P755, DOI 10.1016/0306-4522(92)90184-4; WU W, 1989, BRAIN RES BULL, V22, P399, DOI 10.1016/0361-9230(89)90067-1; WU W, 1993, 5TH INT S NEUR REG P; WU WT, 1993, EXP NEUROL, V121, P279, DOI 10.1006/exnr.1993.1097; WU WT, 1993, NEUROSCI LETT, V153, P121, DOI 10.1016/0304-3940(93)90303-3; WU WT, 1993, EXP NEUROL, V120, P153, DOI 10.1006/exnr.1993.1050; ZHANG X, 1993, J COMP NEUROL, V335, P563, DOI 10.1002/cne.903350408	28	184	201	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0306-4522			NEUROSCIENCE	Neuroscience	AUG	1994	61	4					719	726		10.1016/0306-4522(94)90394-8			8	Neurosciences	Neurosciences & Neurology	PE797	WOS:A1994PE79700001	7530816				2021-06-18	
J	FRERICHS, KU; KENNEDY, C; SOKOLOFF, L; HALLENBECK, JM				FRERICHS, KU; KENNEDY, C; SOKOLOFF, L; HALLENBECK, JM			LOCAL CEREBRAL BLOOD-FLOW DURING HIBERNATION, A MODEL OF NATURAL TOLERANCE TO CEREBRAL-ISCHEMIA	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						CEREBRAL ISCHEMIA; GROUND SQUIRREL; HIBERNATION; IODOANTIPYRINE	TRAUMATIC BRAIN INJURY; MODERATE HYPOTHERMIA; INTERPEDUNCULAR NUCLEUS; MAMMALIAN HIBERNATION; PROFOUND HYPOTHERMIA; CIRCULATORY ARREST; NEURONAL INJURY; TEMPERATURE; METABOLISM; DAMAGE	The breakdown of cellular homeostasis and progressive neuronal destruction in cerebral ischemia appears to be mediated by a complex network of causes that are intricately interrelated. We have investigated a physiological state existing normally in nature in which mammals appear to tolerate the ordinarily detrimental effects of ischemia with reduced oxygen availability and to resist activation of self-destructive processes, i.e., mammalian hibernation. Ground squirrels (Spermophilus tridecemlineatus) were chronically implanted with arterial and ve nous catheters and telemetry devices for electroencephalography, electrocardiography, and monitoring of body temperature. The animals were placed in an environmental chamber at an ambient temperature of 5 degrees C. Entrance into hibernation was characterized by a drop in heart rate followed by a gradual decline in body temperature and an isoelectric electroencephalogram. Cold-adapted active animals that were not hibernating served as controls. Cerebral blood flow (CBF) was measured in both groups with the autoradiographic [C-14]iodoantipyrine method. Mean (+/- SD) mass-weighted CBF in the brain as a whole was 62 +/- 16 ml/100 g/min (n = 4) in the control group but was reduced to ischemic levels, 7 +/- 4 ml/100 g/min (n = 4), in the hibernating animals (p < 0.001). No neuropathological changes were found in similarly hibernating animals aroused from hibernation. Hibernation appears to be actively regulated, and hormonal factors may be involved. The identification and characterization of such factors and of the mechanisms used by hibernating species to increase ischemic tolerance and to blunt the destructive effects of ischemia may enable us to prevent or minimize the loss of homeostatic control during and after cerebral ischemia in other species.	NIMH, CEREBRAL METAB LAB, BETHESDA, MD 20892 USA	FRERICHS, KU (corresponding author), NINCDS, STROKE BRANCH, BLDG 36, ROOM 4D04, BETHESDA, MD 20892 USA.						ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; BUSTO R, 1989, NEUROSCI LETT, V101, P299, DOI 10.1016/0304-3940(89)90549-1; CAPRETTE DR, 1984, AM J PHYSIOL, V247, pR722; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; DAWE AR, 1969, SCIENCE, V163, P298, DOI 10.1126/science.163.3864.298; ECKENRODE TC, 1992, J NEUROSCI, V12, P3272; FLAMM ES, 1978, STROKE, V9, P445, DOI 10.1161/01.STR.9.5.445; FREYGANG W H Jr, 1958, Adv Biol Med Phys, V6, P263; GARCIA JH, 1992, J NEUROPATH EXP NEUR, V51, P387, DOI 10.1097/00005072-199207000-00001; GAUDET RJ, 1980, J NEUROCHEM, V35, P653, DOI 10.1111/j.1471-4159.1980.tb03704.x; GEISER F, 1988, J COMP PHYSIOL B, V158, P25, DOI 10.1007/BF00692726; GINSBERG MD, 1992, CEREBROVAS BRAIN MET, V4, P189; GIULIAN D, 1990, ANN NEUROL, V27, P33, DOI 10.1002/ana.410270107; HACHINSKI V, 1985, ACUTE STROKE, P123; HALLENBECK JM, 1986, STROKE, V17, P246, DOI 10.1161/01.STR.17.2.246; HALLENBECK JM, 1993, ARCH NEUROL-CHICAGO, V50, P768, DOI 10.1001/archneur.1993.00540070080020; HAUN F, 1992, J NEUROSCI, V12, P3282; HEISS WD, 1992, J CEREBR BLOOD F MET, V12, P193, DOI 10.1038/jcbfm.1992.29; HELDMAIER G, 1992, J COMP PHYSIOL B, V162, P696, DOI 10.1007/BF00301619; Heller HC, 1978, STRATEGIES COLD NATU, P225; HOCHACHKA PW, 1986, SCIENCE, V231, P234, DOI 10.1126/science.2417316; JAY TM, 1988, J CEREBR BLOOD F MET, V8, P121, DOI 10.1038/jcbfm.1988.16; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; JOSEPH SA, 1966, EASP10012 US ARM EDG; KELMAN GR, 1966, J APPL PHYSIOL, V21, P1484; KILDUFF TS, 1982, J NEUROSCI, V2, P143; KULUZ JW, 1992, STROKE, V23, P1792, DOI 10.1161/01.STR.23.12.1792; Landau BR, 1960, B MUS COMP ZOOL HARV, P173; LECHLER E, 1963, AM J PHYSIOL, V205, P985; LYMAN CP, 1955, PHYSIOL REV, V35, P403; Malan A., 1986, P61; MENDLER N, 1972, HIBERNATION HYPOTHER, P167; MICHENFELDER JD, 1968, ANESTHESIOLOGY, V29, P1107, DOI 10.1097/00000542-196811000-00005; MINAMISAWA H, 1990, J CEREBR BLOOD F MET, V10, P365, DOI 10.1038/jcbfm.1990.66; MOYER DJ, 1992, STROKE, V23, P1812, DOI 10.1161/01.STR.23.12.1812; MUSACCHIA XJ, 1984, CRYOBIOLOGY, V21, P583, DOI 10.1016/0011-2240(84)90219-0; NEDERGAARD J, 1990, PHILOS T ROY SOC B, V326, P669, DOI 10.1098/rstb.1990.0038; PEHOWICH DJ, 1984, J COMP PHYSIOL, V154, P495, DOI 10.1007/BF02515154; PENGELLEY ET, 1963, CAN J ZOOLOG, V41, P1103, DOI 10.1139/z63-087; PETITO CK, 1987, NEUROLOGY, V37, P1281, DOI 10.1212/WNL.37.8.1281; Popovic V, 1974, HYPOTHERMIA BIOL MED; PREWITT RL, 1972, P SOC EXP BIOL MED, V140, P1279; REDDICK RL, 1973, LAB INVEST, V28, P270; REEVES RB, 1977, ANNU REV PHYSIOL, V39, P559, DOI 10.1146/annurev.ph.39.030177.003015; RIDENOUR TR, 1992, STROKE, V23, P733, DOI 10.1161/01.STR.23.5.733; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; SAKURADA O, 1978, AM J PHYSIOL, V234, pH59; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; Sokoloff L, 1978, Ciba Found Symp, P171; SPURRIER WA, 1973, COMP BIOCHEM PHYSIOL, V44, P267, DOI 10.1016/0300-9629(73)90479-9; STOREY KB, 1990, Q REV BIOL, V65, P145, DOI 10.1086/416717; STOREY KB, 1988, PHYSIOL REV, V68, P27; STOREY KB, 1987, J BIOL CHEM, V262, P1670; SWAN H, 1977, SCIENCE, V195, P84, DOI 10.1126/science.831261; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; THARION J, 1982, J THORAC CARDIOV SUR, V84, P66; Wang L.C.H., 1988, Advances in Comparative and Environmental Physiology, V2, P1; WANG LCH, 1988, CRYOBIOLOGY, V25, P355, DOI 10.1016/0011-2240(88)90043-0; WHITE RJ, 1978, MAYO CLIN PROC, V53, P450; WILLIAMS MD, 1991, ANN THORAC SURG, V52, P1069, DOI 10.1016/0003-4975(91)91284-3; Willis J.S., 1986, P27; Willis J.S., 1987, Symposia of the Society for Experimental Biology, P285; WILLIS JS, 1979, ANNU REV PHYSIOL, V41, P275, DOI 10.1146/annurev.ph.41.030179.001423	64	184	190	0	10	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAR	1994	14	2					193	205		10.1038/jcbfm.1994.26			13	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	MX608	WOS:A1994MX60800002	8113316	Bronze			2021-06-18	
J	Prins, ML; Alexander, D; Giza, CC; Hovda, DA				Prins, Mayumi L.; Alexander, Daya; Giza, Christopher C.; Hovda, David A.			Repeated Mild Traumatic Brain Injury: Mechanisms of Cerebral Vulnerability	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; juvenile; metabolism; repeated; vulnerability	POSITRON-EMISSION-TOMOGRAPHY; CORTICAL IMPACT INJURY; GLUCOSE-UTILIZATION; BLOOD-FLOW; RAT-BRAIN; TEMPORAL WINDOW; AXONAL INJURY; IMMATURE RAT; HEAD-INJURY; FDG-PET	Among the 3.5 million annual new head injury cases is a subpopulation of children and young adults who experience repeated traumatic brain injury (TBI). The duration of vulnerability after a single TBI remains unknown, and biomarkers have yet to be determined. Decreases in glucose metabolism (cerebral metabolic rate of glucose [CMRglc]) are consistently observed after experimental and human TBI. In the current study, it is hypothesized that the duration of vulnerability is related to the duration of decreased CMRglc and that a single mild TBI (mTBI) increases the brain's vulnerability to a second insult for a period, during which a subsequent mTBI will worsen the outcome. Postnatal day 35 rats were given sham, single mTBI, or two mTBI at 24-h or 120-h intervals. C-14-2-deoxy-D-glucose autoradiography was conducted at 1 or 3 days post-injury to calculate CMRglc. At 24 h after a single mTBI, CMRglc is decreased by 19% in both the parietal cortex and hippocampus, but approached sham levels by 3 days post-injury. When a second mTBI is introduced during the CMRglc depression of the first injury, the consequent CMRglc is depressed (36.5%) at 24 h and remains depressed (25%) at 3 days. In contrast, when the second mTBI is introduced after the metabolic recovery of the first injury, the consequent CMRglc depression is similar to that seen with a single injury. Results suggest that the duration of metabolic depression reflects the time-course of vulnerability to second injury in the juvenile brain and could serve as a valuable biomarker in establishing window of vulnerability guidelines.	[Giza, Christopher C.] Univ Calif Los Angeles, Sch Med, Dept Neurol, Los Angeles, CA 90024 USA; [Hovda, David A.] Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA USA; [Prins, Mayumi L.; Alexander, Daya; Hovda, David A.] Univ Calif Los Angeles, Sch Med, Interdept Program Neurosci, Los Angeles, CA USA; [Prins, Mayumi L.; Alexander, Daya; Hovda, David A.] Univ Calif Los Angeles, Sch Med, UCLA Brain Injury Res Ctr, Los Angeles, CA USA; [Prins, Mayumi L.; Giza, Christopher C.; Hovda, David A.] Univ Calif Los Angeles, Sch Med, Div Neurosurg, Los Angeles, CA 90024 USA	Prins, ML (corresponding author), UCLS Sch Med, UCLA Dept Neurosurg, Sch Med, NPI 18-228, Los Angeles, CA 90095 USA.	mprins@mednet.ucla.edu	Prins, Mayumi/J-9571-2015	Prins, Mayumi/0000-0001-7694-9739	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS027544] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027544] Funding Source: NIH RePORTER		ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; Balabanov R, 2001, NEUROL RES, V23, P175, DOI 10.1179/016164101101198514; Bartnik BL, 2005, J NEUROTRAUM, V22, P1052, DOI 10.1089/neu.2005.22.1052; Becelewski Janusz, 2003, Neurol Neurochir Pol, V37, P339; Bell MJ, 1998, J NEUROTRAUM, V15, P163, DOI 10.1089/neu.1998.15.163; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Biagas KV, 1996, J NEUROTRAUM, V13, P189, DOI 10.1089/neu.1996.13.189; Bonne O, 2003, PSYCHIAT RES-NEUROIM, V124, P141, DOI 10.1016/S0925-4927(03)00109-4; Browne SE, 2001, EXP NEUROL, V170, P36, DOI 10.1006/exnr.2001.7700; Bruckner BA, 1999, METABOLISM, V48, P422, DOI 10.1016/S0026-0495(99)90098-7; Chen SF, 2004, J CEREBR BLOOD F MET, V24, P1025, DOI 10.1097/01.WCB.0000129415.34520.47; Clark RSB, 1997, NEUROSURGERY, V41, P1284, DOI 10.1097/00006123-199712000-00010; COLLE LM, 1986, BRAIN RES, V397, P27, DOI 10.1016/0006-8993(86)91366-1; CORNFORD EM, 1986, FED PROC, V45, P2065; Cosi C, 1998, BRAIN RES, V809, P58, DOI 10.1016/S0006-8993(98)00829-4; Counotte DS, 2010, EUR J NEUROSCI, V32, P1452, DOI 10.1111/j.1460-9568.2010.07404.x; Derache N, 2006, J NEUROL SCI, V245, P103, DOI 10.1016/j.jns.2005.09.017; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; ELHAMDI G, 1992, DEV BRAIN RES, V69, P233, DOI 10.1016/0165-3806(92)90164-R; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Garcia-Panach J, 2011, J NEUROTRAUM, V28, P1707, DOI 10.1089/neu.2011.1851; Giedd JN, 2009, J ADOLESCENT HEALTH, V45, P319, DOI 10.1016/j.jadohealth.2009.07.007; Golding EM, 1999, AM J PHYSIOL-HEART C, V277, pH1457; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; Hattori N, 2003, J NUCL MED, V44, P1709; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Hovda D. A., 1994, Society for Neuroscience Abstracts, V20, P845; Hovda D. A, 1996, METABOLIC DYSFUNCTIO, P1459; HUMAYUN MS, 1989, NUCL MED COMMUN, V10, P335, DOI 10.1097/00006231-198905000-00004; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; Jiang XB, 2000, NEUROL MED-CHIR, V40, P16, DOI 10.2176/nmc.40.16; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KMIECIAKKOLADA K, 1987, POL J PHARMACOL PHAR, V39, P47; Lee SM, 1999, ANN NY ACAD SCI, V893, P337, DOI 10.1111/j.1749-6632.1999.tb07849.x; Liu YH, 1996, NEUROL RES, V18, P505; Lull N, 2010, BRAIN INJURY, V24, P1098, DOI 10.3109/02699052.2010.494592; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Marklund N, 2001, J NEUROTRAUM, V18, P1217, DOI 10.1089/089771501317095250; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; MIES G, 1990, J CEREBR BLOOD F MET, V10, P638, DOI 10.1038/jcbfm.1990.116; Moore AH, 2000, J CEREBR BLOOD F MET, V20, P1492, DOI 10.1097/00004647-200010000-00011; NEHLIG A, 1990, EUR J PHARMACOL, V179, P271, DOI 10.1016/0014-2999(90)90165-3; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; O'Connell MT, 2005, ACTA NEUROCHIR SUPPL, V95, P165; Okumura Ayumi, 2005, No To Shinkei, V57, P115; Otori T, 2004, J NEUROTRAUM, V21, P707, DOI 10.1089/0897715041269623; PALMER C, 1990, J CEREBR BLOOD F MET, V10, P227, DOI 10.1038/jcbfm.1990.39; Pappius HM, 1995, NEUROCHEM RES, V20, P1311, DOI 10.1007/BF00992506; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Prins ML, 2009, J NEUROTRAUM, V26, P1083, DOI [10.1089/neu.2008.0769, 10.1089/neu.2008-0769]; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Prins ML, 2001, J NEUROTRAUM, V18, P31, DOI 10.1089/089771501750055758; Queen SA, 1997, BRAIN RES, V777, P42, DOI 10.1016/S0006-8993(97)00717-8; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Reger ML, 2009, DEV PSYCHOBIOL, V51, P672, DOI 10.1002/dev.20402; Richards HK, 2001, J CEREBR BLOOD F MET, V21, P779, DOI 10.1097/00004647-200107000-00002; ROBERTS MA, 1995, BRAIN INJURY, V9, P427, DOI 10.3109/02699059509008202; ROMIJN HJ, 1991, EARLY HUM DEV, V26, P61, DOI 10.1016/0378-3782(91)90044-4; Schneider G, 2002, MAGN RESON MATER PHY, V14, P233, DOI 10.1016/S1352-8661(02)00068-6; Sheline CT, 2000, J NEUROSCI, V20, P3139, DOI 10.1523/JNEUROSCI.20-09-03139.2000; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; Spear LP, 2000, NEUROSCI BIOBEHAV R, V24, P417, DOI 10.1016/S0149-7634(00)00014-2; Spear LP, 2004, ANN NY ACAD SCI, V1021, P23, DOI 10.1196/annals.1308.002; SUTTON RL, 1994, ACTA NEUROCHIR, P446; Tavazzi B, 2007, NEUROSURGERY, V61, P390, DOI 10.1227/01.NEU.0000255525.34956.3F; Thomas S, 2000, J NEUROTRAUM, V17, P649, DOI 10.1089/089771500415409; TSUIKI K, 1995, J NEUROCHEM, V64, P1319; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; Vannucci SJ, 1996, J CEREBR BLOOD F MET, V16, P77, DOI 10.1097/00004647-199601000-00009; Vavilala MS, 2006, DEV NEUROSCI-BASEL, V28, P348, DOI 10.1159/000094161; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Yakushev I, 2011, BRAIN STRUCT FUNCT, V216, P219, DOI 10.1007/s00429-011-0302-4; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Ying WH, 2003, BIOCHEM BIOPH RES CO, V308, P809, DOI 10.1016/S0006-291X(03)01483-9; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	84	183	186	0	41	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2013	30	1					30	38		10.1089/neu.2012.2399			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	061GU	WOS:000312837300006	23025820	Green Published			2021-06-18	
J	Rohling, ML; Binder, LM; Demakis, GJ; Larrabee, GJ; Ploetz, DM; Langhinrichsen-Rohling, J				Rohling, Martin L.; Binder, Laurence M.; Demakis, George J.; Larrabee, Glenn J.; Ploetz, Danielle M.; Langhinrichsen-Rohling, Jennifer			A Meta-Analysis of Neuropsychological Outcome After Mild Traumatic Brain Injury: Re-analyses and Reconsiderations of Binder et al. (1997), Frencham et al. (2005), and Pertab et al. (2009)	CLINICAL NEUROPSYCHOLOGIST			English	Article						Traumatic brain injury; Meta-analysis; Post concussion; Effect size calculations	POSTCONCUSSION-SYNDROME; HEAD-INJURY; SYMPTOMS; PERFORMANCE; MYTHS	The meta-analytic findings of Binder etal. (1997) and Frencham etal. (2005) showed that the neuropsychological effect of mild traumatic brain injury (mTBI) was negligible in adults by 3 months post injury. Pertab etal. (2009) reported that verbal paired associates, coding tasks, and digit span yielded significant differences between mTBI and control groups. We re-analyzed data from the 25 studies used in the prior meta-analyses, correcting statistical and methodological limitations of previous efforts, and analyzed the chronicity data by discrete epochs. Three months post injury the effect size of -0.07 was not statistically different from zero and similar to that which has been found in several other meta-analyses (Belanger etal., 2005; Schretlen Shapiro, 2003). The effect size 7 days post injury was -0.39. The effect of mTBI immediately post injury was largest on Verbal and Visual Memory domains. However, 3 months post injury all domains improved to show non-significant effect sizes. These findings indicate that mTBI has an initial small effect on neuropsychological functioning that dissipates quickly. The evidence of recovery in the present meta-analysis is consistent with previous conclusions of both Binder etal. and Frencham etal. Our findings may not apply to people with a history of multiple concussions or complicated mTBIs.	[Langhinrichsen-Rohling, Jennifer] Univ S Alabama, Dept Psychol, Mobile, AL 36688 USA; [Binder, Laurence M.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA; [Demakis, George J.] Univ N Carolina, Charlotte, NC 28223 USA	Langhinrichsen-Rohling, J (corresponding author), Univ S Alabama, Dept Psychol, 331 Life Sci Univ, Mobile, AL 36688 USA.	mrohling@usouthal.edu	Langhinrichsen-Rohling, Jennifer/W-1756-2019				Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Binder LM, 2009, ARCH CLIN NEUROPSYCH, V24, P31, DOI 10.1093/arclin/acn001; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BOHNEN N, 1993, NEUROPSY NEUROPSY BE, P6193; Boone, 2007, ASSESSMENT FEIGNED C; Bornstein R. A., 1993, NEUROPSYCHOLOGY, V7, P228, DOI DOI 10.1037/0894-4105.7.2.228; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Clarke M, 2007, J ROY SOC MED, V100, P187, DOI 10.1258/jrsm.100.4.187; COLFORD JM, 2001, AM J EPIDEMIOL, V154, P972; Demakis GJ, 2010, ARCH CLIN NEUROPSYCH, V25, P191, DOI 10.1093/arclin/acq004; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Glasziou PP, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-23; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Gouvier WD, 1998, CRIT ISS NE, P55; Greiffenstein M, 2009, CLIN NEUROPSYCHOL, V23, P286, DOI 10.1080/13854040802104873; Greiffenstein MF, 2003, CLIN NEUROPSYCHOL, V17, P561, DOI 10.1076/clin.17.4.561.27937; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; Hedges L. V., 1981, J EDUC STAT, V6, P107; Hedges LV, 1998, PSYCHOL METHODS, V3, P486, DOI 10.1037/1082-989X.3.4.486; Hilsabeck RC, 1998, J CLIN EXP NEUROPSYC, V20, P328, DOI 10.1076/jcen.20.3.328.813; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Iverson G.L., 2001, J FORENSIC NEUROPSYC, V2, P19, DOI [https://doi.org/10.1300/J151v02n01_02, DOI 10.1300/J151v02n01_02]; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Iverson GL, 2010, BRAIN INJURY, V24, P1246, DOI 10.3109/02699052.2010.490513; KRAUS JF, 2005, TXB TRAUMATIC BRAIN, P3; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; Larrabee G.J., 2007, ASSESSMENT MALINGERE; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Lipsey M.W., 2001, PRACTICAL META ANAL; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Mapou R. L., 2008, ADULT LEARNING DISAB; McCrea M, 2008, MILD TRAUMATIC BRAIN; MEEHL PE, 1955, PSYCHOL BULL, V52, P194, DOI 10.1037/h0048070; Pertab JL, 2009, BRAIN INJURY, V23, P498, DOI 10.1080/02699050902927984; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Putnam S. H., 1996, NEUROPSYCHOLOGICAL A, P529; Ruff RM, 2009, PSYCHOL INJ LAW, V2, P34, DOI 10.1007/s12207-009-9029-4; Sawchyn JM, 2000, ARCH CLIN NEUROPSYCH, V15, P1, DOI 10.1016/S0887-6177(98)00041-9; SCHMIDT FL, 1992, AM PSYCHOL, V47, P1173, DOI 10.1037/0003-066X.47.10.1173; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P981, DOI 10.1076/jcen.24.8.981.8372; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; Wiggins J. S., 1973, Personality and prediction: Principles of personality assessment; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Zakzanis KK, 2001, ARCH CLIN NEUROPSYCH, V16, P653, DOI 10.1016/S0887-6177(00)00076-7	53	183	183	1	16	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2011	25	4					608	623	PII 936723779	10.1080/13854046.2011.565076			16	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	761QD	WOS:000290411700175	21512956				2021-06-18	
J	Broglio, SP; Ferrara, MS; Macciocchi, SN; Baumgartner, TA; Elliott, R				Broglio, Steven P.; Ferrara, Michael S.; Macciocchi, Stephen N.; Baumgartner, Ted A.; Elliott, Ronald			Test-retest reliability of computerized concussion assessment programs	JOURNAL OF ATHLETIC TRAINING			English	Article						intraclass correlation coefficient; effort; ImPACT; concussion sentinel; concussion resolution index	SPORT-RELATED CONCUSSION; NEUROPSYCHOLOGICAL TEST PROTOCOL; PROFESSIONAL FOOTBALL; RECOVERY; MANAGEMENT; STABILITY; STATEMENT; AGREEMENT; IMPACT; RETURN	Context: Computer-based neurocognitive assessment programs commonly are used to assist in concussion diagnosis and management. These tests have been adopted readily by many clinicians based on existing test-retest reliability data provided by test developers. Objective: To examine the test-retest reliability of 3 commercially available computer-based neurocognitive assessments using clinically relevant time frames. Design: Repeated-measures design. Setting: Research laboratory. Patients or Other Participants: 118 healthy student volunteers. Main Outcome Measure(s): The participants completed the ImPACT, Concussion Sentinel, and Headminder Concussion Resolution Index tests on 3 days: baseline, day 45, and day 50. Each participant also completed the Green Memory and Concentration Test to evaluate effort. Intraclass correlation coefficients were calculated for all output scores generated by each computer program as an estimate of test-retest reliability. Results: The intraclass correlation coefficient estimates from baseline to day 45 assessments ranged from .15 to .39 on the ImPACT, .23 to .65 on the Concussion Sentinel, and .15 to .66 on the Concussion Resolution Index. The intraclass correlation coefficient estimates from the day 45 to day 50 assessments ranged from .39 to .61 on the ImPACT, .39 to .66 on the Concussion Sentinel, and .03 to .66 on the Concussion Resolution Index. All participants demonstrated high levels of effort on all days of testing, according to Memory and Concentration Test interpretive guidelines. Conclusions: Three contemporary computer-based concussion assessment programs evidenced low to moderate test-retest reliability coefficients. Our findings do not appear to be due to suboptimal effort or other factors related to poor test performance, because persons identified by individual programs as having poor baseline data were excluded from the analyses. The neurocognitive evaluation should continue to be part of a multifaceted concussion assessment program, with priority given to those scores showing the highest reliability.	[Broglio, Steven P.] Univ Illinois, Dept Kinesiol & Community Hlth, Urbana, IL 61801 USA; [Ferrara, Michael S.; Macciocchi, Stephen N.; Baumgartner, Ted A.; Elliott, Ronald] Univ Georgia, Athens, GA 30602 USA; [Macciocchi, Stephen N.] Shepherd Ctr, Atlanta, GA USA	Broglio, SP (corresponding author), Univ Illinois, Dept Kinesiol & Community Hlth, 906 S Goodwin Ave, Urbana, IL 61801 USA.	broglio@uiuc.edu					Anastasi A., 1998, PSYCHOL TESTING; Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; Baumgartner T.A., 2001, MEAS PHYS EDUC EXERC, V5, P179, DOI [10.1207/S15327841MPEE0503_4, DOI 10.1207/S15327841MPEE0503_4]; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Collie A, 2003, BRIT J SPORT MED, V37, P556, DOI 10.1136/bjsm.37.6.556; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Erlanger D, 2001, J ATHL TRAINING, V36, P280; ERLANGER DM, 2002, HEADMINDER CONCUSSIO; Gottselig JM, 2006, J SLEEP RES, V15, P31, DOI 10.1111/j.1365-2869.2006.00497.x; Green DR, 2000, NAT IMMUNOL, V1, P15, DOI 10.1038/76868; GREEN P, 2004, GREENS MEMORY CONCER; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Hillman CH, 2006, INT J PSYCHOPHYSIOL, V59, P30, DOI 10.1016/j.ijpsycho.2005.04.009; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; IVERSON GL, 2003, ANN C INT NEUR SOC F; Kissick J, 2005, CLIN J SPORT MED, V15, P426, DOI 10.1097/01.jsm.0000186683.59158.8b; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; LOVELL MR, 2005, IMPACT 2005 4 0 CLIN; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McGraw KO, 1996, PSYCHOL METHODS, V1, P30, DOI 10.1037/1082-989X.1.4.390; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Portney LG., 1993, FDN CLIN RES APPL PR, V3rd; Randolph C, 2005, J ATHL TRAINING, V40, P139; Shors TJ, 2004, LEARN MEMORY, V11, P137, DOI 10.1101/lm.66604; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420	36	183	185	0	25	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	OCT-DEC	2007	42	4					509	514					6	Sport Sciences	Sport Sciences	251AQ	WOS:000252343100011	18174939				2021-06-18	
J	Vagnozzi, R; Tavazzi, B; Signoretti, S; Amorini, AM; Belli, A; Cimatti, M; Delfini, R; Di Pietro, V; Finocchiaro, A; Lazzarino, G				Vagnozzi, Roberto; Tavazzi, Barbara; Signoretti, Stefano; Amorini, Angela M.; Belli, Antonio; Cimatti, Marco; Delfini, Roberto; Di Pietro, Valentina; Finocchiaro, Antonino; Lazzarino, Giuseppe			Temporal window of metabolic brain vulnerability to concussions: Mitochondrial-related impairment - Part I	NEUROSURGERY			English	Article						brain vulnerability; concussion; energy metabolism; N-acetylaspartate metabolism; repeat or multiple concussions; second impact syndrome	MILD HEAD-INJURY; SPORT-RELATED CONCUSSION; DIFFUSE AXONAL INJURY; N-ACETYLASPARTATE; MAGNETIC-RESONANCE; GLUCOSE-METABOLISM; ENERGY-METABOLISM; NAAG PEPTIDASE; NITRIC-OXIDE; RATS	OBJECTIVE: In the present study, we investigate the existence of a temporal window of brain vulnerability in rats undergoing repeat mild traumatic brain injury (mTBI) delivered at increasing time intervals. METHODS: Rats were subjected to two diffuse mTBIs (450 g/1 m height) with the second mTBI delivered after 1 (n = 6), 2 (n = 6), 3 (n = 6), 4 (n = 6), and 5 days (n = 6) and sacrificed 48 hours after the last impact. Sham-operated animals were used as controls (n = 6). Two further groups of six rats each received a second mTBI after 3 days and were sacrificed at 120 and 168 hours postinjury. Concentrations of adenine nucleotides, N-acetylated amino acids, oxypurines, nucleosides, free coenzyme A, acetyl CoA, and oxidized and reduced nicotinamide adenine dinucleotides, oxidized nicotinamide adenine dinucleotide phosphate, and reduced nicotinamide adenine dinucleotide, reduced nicotinamide adenine dinucleotide phosphate nicotinic coenzymes were measured in deproteinized cerebral tissue extracts (three right and three left hemispheres), whereas the gene expression of N-acetylaspartate acylase, the enzyme responsible for N-acetylaspartate (NAA) degradation, was evaluated in extracts of three left and three right hemispheres. RESULTS: A decrease of adenosine triphosphate, adenosine triphosphate /adenosine diphosphate ratio, NAA, N-acetylaspartylglutamate, oxidized and reduced nicotinamide adenine dinucleotide, reduced nicotinamide adenine dinucleotide, and acetyl CoA and increase of N-acetylaspartate acylase expression were related to the interval between impacts with maximal changes recorded when mTBIs were spaced by 3 days. In these animals, protracting the time of sacrifice after the second mTBI up to 1 week failed to show cerebral metabolic recovery, indicating that this type of damage is difficult to reverse. A metabolic pattern similar to controls was observed only in animals receiving mTBIs 5 days apart. CONCLUSION: This study shows the existence of a temporal window of brain vulnerability after mTBI. A second concussive event failing within this time range had profound consequences on mitochondrial-related metabolism. Furthermore, because NAA recovery coincided with normalization of ail other metabolites, it is conceivable to hypothesize that NAA measurement by H-1-NMR spectroscopy might be a valid tool in assessing full cerebral metabolic recovery in the clinical setting and with particular reference to sports medicine in establishing when to return mTBI-affected athletes to play. This study also shows, for the first time, the influence of TBI on acetyl-CoA, N-acetylaspartate acylase gene expression, and N-acetylaspartylglutamate, thus providing novel data on cerebral biochemical changes occurring in head injury.	Univ Catania, Biochem Lab, Dept Chem Sci, I-95125 Catania, Italy; Univ Roma Tor Vergata, Dept Neurosci, I-00173 Rome, Italy; Univ Cattolica Sacro Cuore, Inst Biochem & Clin Biochem, Rome, Italy; San Camillo Hosp, Div Neurosurg, Rome, Italy; Univ Southampton, Div Clin Neurosci, Southampton SO9 5NH, Hants, England; Univ Roma La Sapienza, Dept Neurol Sci Neurosurg, I-00185 Rome, Italy	Lazzarino, G (corresponding author), Univ Catania, Biochem Lab, Dept Chem Sci, Viale A Doria 6, I-95125 Catania, Italy.	lazzarig@mbox.unict.it	Belli, Antonio/I-3799-2015; Signoretti, stefano/AAL-5631-2020; TAVAZZI, BARBARA/AAB-9830-2019; lazzarino, giuseppe/K-2277-2015	Belli, Antonio/0000-0002-3211-9933; Signoretti, stefano/0000-0002-8086-1622; TAVAZZI, BARBARA/0000-0001-8743-0895; Di Pietro, Valentina/0000-0001-9430-4723; AMORINI, Angela Maria/0000-0003-3525-9955; lazzarino, giuseppe/0000-0002-5917-7279			Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Baslow MH, 2006, DRUG NEWS PERSPECT, V19, P145, DOI 10.1358/dnp.2006.19.3.985930; Baslow MH, 2003, J MOL NEUROSCI, V21, P185, DOI 10.1385/JMN:21:3:185; Belli A, 2006, J NEUROCHEM, V96, P861, DOI 10.1111/j.1471-4159.2005.03602.x; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cantu RC, 2003, CLIN SPORT MED, V22, P593, DOI 10.1016/S0278-5919(02)00095-9; Carpentier A, 2006, J NEUROTRAUM, V23, P674, DOI 10.1089/neu.2006.23.674; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P224; Cherian L, 2004, BRAIN PATHOL, V14, P195, DOI 10.1111/j.1750-3639.2004.tb00053.x; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Giza CC, 2001, J ATHL TRAINING, V36, P228; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hlatky R, 2003, J CEREBR BLOOD F MET, V23, P582, DOI 10.1097/01.WCB.0000059586.71206.F3; Holshouser BA, 2005, AM J NEURORADIOL, V26, P1276; Hovda DA, 1999, SPORTS-RELATED CONCUSSION, P12; HOVDA DA, 1983, INTRACRANIAL PRESSUR, P469; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Kissick J, 2005, CLIN J SPORT MED, V15, P426, DOI 10.1097/01.jsm.0000186683.59158.8b; Larner SF, 2004, J NEUROCHEM, V88, P78, DOI 10.1046/j.1471-4159.2003.02141.x; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Lazzarino G, 2003, ANAL BIOCHEM, V322, P51, DOI 10.1016/j.ab.2003.07.013; Lifshitz J, 2003, J CEREBR BLOOD F MET, V23, P219, DOI 10.1097/01.WCB.0000040581.43808.03; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Marciano PG, 2004, J NEUROSCI, V24, P2866, DOI 10.1523/JNEUROSCI.5051-03.2004; Marmarou A, 2005, ACT NEUR S, V95, P149; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; Moreno A, 2001, J NEUROCHEM, V77, P347, DOI 10.1046/j.1471-4159.2001.00282.x; Movsesyan VA, 2006, J NEUROTRAUM, V23, P117, DOI 10.1089/neu.2006.23.117; Neale JH, 2005, TRENDS PHARMACOL SCI, V26, P477, DOI 10.1016/j.tips.2005.07.004; Pellman E, 2004, NEUROSURGERY, V55, P860, DOI 10.1227/01.NEU.0000137657.00146.7D; Ponsford J, 2005, CURR OPIN NEUROL, V18, P692, DOI 10.1097/01.wco.0000186840.61431.44; Putukian M, 1996, PHYSICIAN SPORTSMED, V24, P25, DOI 10.3810/psm.1996.11.1283; Putukian Margot, 2006, Curr Sports Med Rep, V5, P15; Randolph C, 2005, J ATHL TRAINING, V40, P139; Rose ME, 2002, BRAIN RES, V935, P40, DOI 10.1016/S0006-8993(02)02445-9; Santos A, 2005, NEUROCHEM RES, V30, P625, DOI 10.1007/s11064-005-2750-9; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Sheline CT, 2006, NEUROSCIENCE, V140, P235, DOI 10.1016/j.neuroscience.2006.02.019; Signoretti S, 2004, J NEUROTRAUM, V21, P1154, DOI 10.1089/neu.2004.21.1154; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; Slusher BS, 1999, NAT MED, V5, P1396, DOI 10.1038/70971; Tavazzi B, 2005, CLIN BIOCHEM, V38, P997, DOI 10.1016/j.clinbiochem.2005.08.002; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; Vagnozzi R, 2005, NEUROSURGERY, V57, P164, DOI 10.1227/01.NEU.0000163413.90259.85; Vagnozzi R, 1999, J NEUROTRAUM, V16, P903, DOI 10.1089/neu.1999.16.903; Viant MR, 2005, NMR BIOMED, V18, P507, DOI 10.1002/nbm.980; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; Wroblewska B, 2006, ADV EXP MED BIOL, V576, P317; Zhong CL, 2005, J NEUROTRAUM, V22, P266, DOI 10.1089/neu.2005.22.266; 2005, BR J SPORT MED, V39, P78	59	183	186	0	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	AUG	2007	61	2					379	388		10.1227/01.NEU.0000280002.41696.D8			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	197AN	WOS:000248525400036	17762751				2021-06-18	
J	Brune, M; Abdel-Hamid, M; Lehmkamper, C; Sonntag, C				Bruene, Martin; Abdel-Hamid, Mona; Lehmkaemper, Caroline; Sonntag, Claudia			Mental state attribution, neurocognitive functioning, and psychopathology: What predicts poor social competence in schizophrenia best?	SCHIZOPHRENIA RESEARCH			English	Article						mental state attribution; neurocognition; psychopathology; social competence	1ST-EPISODE SCHIZOPHRENIA; MIND; COGNITION; DEFICITS; RECOGNITION; PERCEPTION; MEDIATOR; BEHAVIOR; BRAIN	Background: Research into mental state attribution has repeatedly shown that patients with schizophrenia are impaired in their capacity to reflect upon their own and others' beliefs, knowledge and intentions, with important confounds being executive functioning, intelligence, duration of illness, and medication. Furthermore, the extent to which impaired mental state attribution, neurocognition and psychopathology explain abnormal social behavior in schizophrenic patients has been a matter of debate. We sought to determine whether mental state attribution in schizophrenia predicts poor social competence better than "non-social" cognitive factors or psychopathology. Methods: Intelligence, executive functioning, mental state attribution, psychopathology and social behavior were assessed in 38 patients diagnosed with schizophrenia according to DSM-IV criteria and compared with 29 healthy controls paralleled for age and sex. All patients received antipsychotic treatment, and all participants had no history of substance abuse or traumatic brain injury. Results: In the entire schizophrenia group impaired mental state attribution alone accounted for about 50% of the variance of deviant social behavior, whereas the PANSS positive score and the duration of illness contributed an additional small amount of variance. This effect was even more pronounced in a subgroup of patients with at least normal intelligence, where neither the PANSS score nor the chronicity of the disorder remained significant predictors of poor social competence. Medication was not associated with any one of the neurocognitive measures including mental state attribution, psychopathology or social behavior. Conclusions: Impaired capacity to appreciate one's own and others' mental states is the single-best predictor of poor social competence in schizophrenia, and should perhaps be included in future definitions of the "core" symptomatology of schizophrenic disorders. (c) 2007 Elsevier B.V. All rights reserved.	Ruhr Univ Bochum, Ctr Psychiat Psychotherapy Psychosomat & Prevent, D-44791 Bochum, Germany	Brune, M (corresponding author), Ruhr Univ Bochum, Ctr Psychiat Psychotherapy Psychosomat & Prevent, Alexandrinenstr 1, D-44791 Bochum, Germany.	Martin.Bruene@rub.de	Brune, Martin/AAX-3202-2020	Brune, Martin/0000-0002-2507-0561			Addington J, 2006, SCHIZOPHR RES, V85, P142, DOI 10.1016/j.schres.2006.03.028; Adolphs R, 2001, CURR OPIN NEUROBIOL, V11, P231, DOI 10.1016/S0959-4388(00)00202-6; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; BADDELEY A, 1993, BRIT J CLIN PSYCHOL, V32, P55, DOI 10.1111/j.2044-8260.1993.tb01027.x; BLEUER E, 1995, DEMETIA PRAECOX ODER; Brekke J, 2005, SCHIZOPHR RES, V80, P213, DOI 10.1016/j.schres.2005.07.008; Brune M, 2006, CLIN NEUROPSYCHIATR, V3, P132; Brune M, 2005, SCHIZOPHR RES, V75, P233, DOI 10.1016/j.schres.2004.11.006; Brune M, 2005, SCHIZOPHRENIA BULL, V31, P21, DOI 10.1093/schbul/sbi002; Brune M, 2003, SCHIZOPHR RES, V60, P57, DOI 10.1016/s0920-9964(02)00162-7; Brune M, 2005, PSYCHIAT RES, V133, P135, DOI 10.1016/j.psychres.2004.10.007; Brune M., 2003, SOCIAL BRAIN EVOLUTI, P277, DOI [DOI 10.1002/0470867221.CH13, 10.1002/0470867221.ch13]; Corcoran R, 2005, EVOL PSYCHOL, V3, P1, DOI DOI 10.1177/147470490500300101; Doody GA, 1998, PSYCHOL MED, V28, P397, DOI 10.1017/S003329179700648X; Frith CD., 1992, COGN NEUROPSYCHOL; Green MF, 2005, SCHIZOPHRENIA BULL, V31, P882, DOI 10.1093/schbul/sbi049; Harrington Leigh, 2005, Cogn Neuropsychiatry, V10, P249, DOI 10.1080/13546800444000056; Herbener ES, 2005, AM J PSYCHIAT, V162, P1746, DOI 10.1176/appi.ajp.162.9.1746; Kahlbaum KL, 1874, KATATONIE ODER SPANN; KAY S R, 1989, British Journal of Psychiatry, V155, P59; Kayser N, 2006, NEUROPSYCHOL REHABIL, V16, P83, DOI 10.1080/09602010443000236; Koren D, 2005, BIOL PSYCHIAT, V57, P609, DOI 10.1016/j.biopsych.2004.11.029; KRAEPELIN E, 1893, PSYCHIATRIE; Langdon R, 1997, Cogn Neuropsychiatry, V2, P167, DOI 10.1080/135468097396324; Lee KH, 2004, PSYCHOL MED, V34, P391, DOI 10.1017/S0033291703001284; Lehrl S, 1976, NEUROLOGIE PSYCHIAT, V7, P488; Lysaker PH, 2005, ACTA PSYCHIAT SCAND, V112, P64, DOI 10.1111/j.1600-0447.2005.00514.x; McCabe R, 2004, PSYCHOL MED, V34, P401, DOI 10.1017/S0033291703001338; MIZRAHI R, 2006, PSYCHOL MED; MORITZ S, 2005, METACOGNITIVE SKILL; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; Penn DL, 1997, PSYCHOL BULL, V121, P114, DOI 10.1037/0033-2909.121.1.114; Pickup GJ, 2001, PSYCHOL MED, V31, P207, DOI 10.1017/S0033291701003385; Pinkham AE, 2003, AM J PSYCHIAT, V160, P815, DOI 10.1176/appi.ajp.160.5.815; Pollice R, 2002, PSYCHOPATHOLOGY, V35, P280, DOI 10.1159/000067062; Sarfati Y, 1999, SCHIZOPHR RES, V37, P183, DOI 10.1016/S0920-9964(98)00154-6; Sergi MJ, 2006, AM J PSYCHIAT, V163, P448, DOI 10.1176/appi.ajp.163.3.448; Stone VE, 2006, TRENDS COGN SCI, V10, P3, DOI 10.1016/j.tics.2005.11.010; Tewes U., 1991, HAMBURG WECHSLER INT, V2; WILSON BA, 1996, BEAHV ASSESSMENT DYS; Woods SW, 2003, J CLIN PSYCHIAT, V64, P663, DOI 10.4088/JCP.v64n0607; WYKES T, 1986, BRIT J PSYCHIAT, V148, P1, DOI 10.1192/bjp.148.1.1	42	183	186	0	17	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0920-9964			SCHIZOPHR RES	Schizophr. Res.	MAY	2007	92	1-3					151	159		10.1016/J.SCHRES.2007.01.006			9	Psychiatry	Psychiatry	167CZ	WOS:000246429800019	17346931				2021-06-18	
J	McAllister, TW; Flashman, LA; McDonald, BC; Saykin, AJ				McAllister, Thomas W.; Flashman, Laura A.; McDonald, Brenna C.; Saykin, Andrew J.			Mechanisms of working memory dysfunction after mild and moderate TBI: Evidence from functional MRI and neurogenetics	JOURNAL OF NEUROTRAUMA			English	Article; Proceedings Paper	14th Annual Conference on Traumatic Brain Injury - From Molecule to Family Systems	2004	Rotman Res Inst, Toronto, CANADA		Rotman Res Inst	catecholamines; episodic memory; functional MRI; traumatic brain injury; working memory	TRAUMATIC BRAIN-INJURY; CLOSED HEAD-INJURY; APOLIPOPROTEIN-E; NEUROPSYCHOLOGICAL DEFICITS; METHYLPHENIDATE TREATMENT; DIVIDED ATTENTION; PREFRONTAL CORTEX; RECOVERY; PERFORMANCE; BROMOCRIPTINE	Cognitive complaints are a frequent source of distress and disability after mild and moderate traumatic brain injury (TBI). While there are deficits in several cognitive domains, many aspects of these complaints and deficits suggest that problems in working memory (WM) play an important role. Functional imaging studies in healthy individuals have outlined the neural substrate of WM and have shown that regions important in WM circuitry overlap with regions commonly vulnerable to damage in TBI. Use of functional MRI (fMRI) in individuals with mild and moderate TBI suggests that they can have problems in the activation and allocation of WM, and several lines of evidence suggest that subtle alterations in central catecholaminergic sensitivity may underlie these problems. We review the evidence from fMRI and neurogenetic studies that support the role of catecholaminergic dysregulation in the etiology of WM complaints and deficits after mild and moderate TBI.	Dartmouth Med Sch, Brain Imaging Lab, Neuropsychol Program, Sect Neuropsychiat, Lebanon, NH USA	McAllister, TW (corresponding author), Dartmouth Coll, Hitchcock Med Ctr, Dept Psychiat, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	thomas.w.mcallister@dartmouth.edu	Saykin, Andrew/A-1318-2007	Saykin, Andrew/0000-0002-1376-8532	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048176] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040472] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01 HD048176] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS40472] Funding Source: Medline		ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; Arnsten A F, 1998, Adv Pharmacol, V42, P764; Arnsten AFT, 1998, TRENDS COGN SCI, V2, P436, DOI 10.1016/S1364-6613(98)01240-6; BARTUS RT, 1978, J GERONTOL, V33, P858, DOI 10.1093/geronj/33.6.858; Bigler E, 1990, TRAUMATIC BRAIN INJU, P13; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BOYESON MG, 1984, ANN M SOC NEUROSCIEN, V10, P68; BROZOSKI TJ, 1979, SCIENCE, V205, P929, DOI 10.1126/science.112679; Buckner RL, 2001, J COGNITIVE NEUROSCI, V13, P406, DOI 10.1162/08989290151137430; CAI JX, 1993, BRAIN RES, V614, P191; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Cripe LI, 1987, COGNITIVE REHABILITA, V5, P18; CRISMON ML, 1988, CLIN NEUROPHARMACOL, V11, P462, DOI 10.1097/00002826-198810000-00007; DOBKIN BH, 1993, ANN NEUROL, V33, P313, DOI 10.1002/ana.410330315; Dolan RJ, 1997, NATURE, V388, P582, DOI 10.1038/41561; Egan MF, 2001, P NATL ACAD SCI USA, V98, P6917, DOI 10.1073/pnas.111134598; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FEENEY DM, 1987, CRIT REV NEUROBIOL, V3, P135; FEENEY DM, 1983, PSYCHOPHARMACOLOGY, V79, P67, DOI 10.1007/BF00433018; Flashman L.A., 2004, J NEUROPSYCHIATRY CL, V16, P238; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Friston K., 1995, HUM BRAIN MAPP, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; GENTILINI M, 1989, MILD HEAD INJURY, P163; Glenn MB, 1998, J HEAD TRAUMA REHAB, V13, P87, DOI 10.1097/00001199-199810000-00010; Gronwall D, 1989, MILD HEAD INJURY, P153; Gronwall D, 1991, NEUROPSYCHOLOGY, V5, P253, DOI DOI 10.1037/0894-4105.5.4.253; Gualtieri C T, 1988, Brain Inj, V2, P101, DOI 10.3109/02699058809150936; Hartman RE, 2002, J NEUROSCI, V22, P10083; Holmes AP, 1998, NEUROIMAGE, V7, pS754, DOI DOI 10.1016/S1053-8119(18)31587-8; Jakala P, 1999, NEUROPSYCHOPHARMACOL, V20, P460, DOI 10.1016/S0893-133X(98)00127-4; Jakala P, 1999, NEUROPSYCHOPHARMACOL, V20, P119, DOI 10.1016/S0893-133X(98)00055-4; Jonides J, 1998, J NEUROSCI, V18, P5026; Kaelin DL, 1996, ARCH PHYS MED REHAB, V77, P6, DOI 10.1016/S0003-9993(96)90211-7; KAPUR S, 1995, NEUROREPORT, V6, P1880, DOI 10.1097/00001756-199510020-00014; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kimberg DY, 1997, NEUROREPORT, V8, P3581, DOI 10.1097/00001756-199711100-00032; Kimberg DY, 2001, HUM BRAIN MAPP, V12, P246, DOI 10.1002/1097-0193(200104)12:4<246::AID-HBM1019>3.0.CO;2-9; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; KRAUS JF, 2005, NEUROPSYCHIATRY TRAU, P3; Lal S, 1988, Brain Inj, V2, P225, DOI 10.3109/02699058809150946; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; Lipsky RH, 2005, J NEUROPSYCH CLIN N, V17, P465, DOI 10.1176/appi.neuropsych.17.4.465; LUCIANA M, 1992, J COGNITIVE NEUROSCI, V4, P58, DOI 10.1162/jocn.1992.4.1.58; Luciana M, 1997, J COGNITIVE NEUROSCI, V9, P330, DOI 10.1162/jocn.1997.9.3.330; LUINE V, 1990, BRAIN RES, V537, P271, DOI 10.1016/0006-8993(90)90368-L; Malhotra AK, 2002, AM J PSYCHIAT, V159, P652, DOI 10.1176/appi.ajp.159.4.652; McAllister T., 2001, J NEUROPSYCHIATRY CL, V13, P141; McAllister T. W., 2004, J NEUROPSYCHIATRY CL, V16, P240; McAllister TW, 2005, AM J PSYCHIAT, V162, P1749, DOI 10.1176/appi.ajp.162.9.1749; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; MCALLISTER TW, 2002, J NEUROPSYCHIATRY CL, V14, P166; MCALLISTER TW, 2003, J NEUROPSYCHIATRY CL, V15, P278; McAllister TW, 2005, J NEUROPSYCHIATRY CL, V17, P287; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; McMillan TM, 1997, CURR OPIN NEUROL, V10, P479, DOI 10.1097/00019052-199712000-00008; MCMILLAN TM, 1987, J NEUROL NEUROSUR PS, V50, P393, DOI 10.1136/jnnp.50.4.393; MOONEY GF, 1993, ARCH PHYS MED REHAB, V74, P153; Nyberg L, 1996, NATURE, V380, P715, DOI 10.1038/380715a0; Nyberg L, 1995, NEUROREPORT, V7, P249, DOI 10.1097/00001756-199512000-00060; Nyberg L, 1996, PSYCHON B REV, V3, P135, DOI 10.3758/BF03212412; Park NW, 1999, NEUROPSYCHOLOGIA, V37, P1119, DOI 10.1016/S0028-3932(99)00034-2; Paule MG, 2000, NEUROTOXICOL TERATOL, V22, P631, DOI 10.1016/S0892-0362(00)00095-7; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; Powell JH, 1996, J NEUROL NEUROSUR PS, V60, P416, DOI 10.1136/jnnp.60.4.416; PRASAD MR, 1992, J NEUROTRAUM, V9, P269, DOI 10.1089/neu.1992.9.269; Romhanyi R, 1990, J NEUROTRAUM, V9, P164; Sarter M, 2002, DEMENT GERIATR COGN, V13, P46, DOI 10.1159/000048633; Sarter M, 2001, BRAIN RES REV, V35, P146, DOI 10.1016/S0165-0173(01)00044-3; Sarter M, 2000, NEUROSCIENCE, V95, P933; Savoy RL, 2001, ACTA PSYCHOL, V107, P9, DOI 10.1016/S0001-6918(01)00018-X; Saykin AJ, 1999, BRAIN, V122, P1963, DOI 10.1093/brain/122.10.1963; Silver JM, 1997, J NEUROPSYCH CLIN N, V9, P102; Smith EE, 1998, P NATL ACAD SCI USA, V95, P12061, DOI 10.1073/pnas.95.20.12061; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; SUTTON RL, 1992, RESTOR NEUROL NEUROS, V4, P1, DOI 10.3233/RNN-1992-4101; Tandian D, 1990, J NEUROTRAUM, V9, P174; Thurman DJ, 1999, TRAUMATIC BRAIN INJU; Villringer A, 1997, ADV EXP MED BIOL, V413, P177	100	183	184	1	25	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2006	23	10					1450	1467		10.1089/neu.2006.23.1450			18	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	093XL	WOS:000241203500007	17020482				2021-06-18	
J	Pettus, EH; Wright, DW; Stein, DG; Hoffman, SW				Pettus, EH; Wright, DW; Stein, DG; Hoffman, SW			Progesterone treatment inhibits the inflammatory agents that accompany traumatic brain injury	BRAIN RESEARCH			English	Article						progesterone; traumatic brain injury; neuroprotection; cytokines; blood-brain barrier; GFAP	NF-KAPPA-B; DECAY-ACCELERATING FACTOR; C3 GENE-EXPRESSION; HUMAN ASTROGLIOMA CELLS; COMPLEMENT ACTIVATION; CORTICAL CONTUSION; INTERFERON-GAMMA; HEAD-INJURY; TNF-ALPHA; RATS	Progesterone given after traumatic brain injury (TBI) has been shown to reduce the initial cytotoxic surge of inflammatory factors. We used Western blot techniques to analyze how progesterone might affect three inflammation-related factors common to TBI: complement factor C3 (C3), glial fibrillary acidic protein (GFAP), and nuclear factor kappa beta (NF kappa B). One hour after bilateral injury to the medial frontal cortex, adult male rats were given injections of progesterone (16 mg/kg) for 2 days. Brains were harvested 48 h post-TBI, proteins were extracted from samples, each of which contained tissue from both the contused and peri-contused areas, then measured by Western blot densitometry. Complete C3, GFAP, and NF kappa B p65 were increased in all injured animals. However, in animals given progesterone post-TBI, NF kappa B p65 and the inflammatory metabolites of C3 (9 kDa and 75 kDa) were decreased in comparison to vehicle-treated animals. Measures of NF kappa B p50 showed no change after injury or progesterone treatment, and progesterone did not alter the expression of GFAP. The therapeutic benefit of post-TBI progesterone administration may be due to its salutary effect on inflammatory proteins known to increase immune cell invasion and cerebral edema. (c) 2005 Elsevier B.V. All rights reserved.	Emory Univ, Dept Emergency Med, Atlanta, GA 30322 USA; Emory Univ, Dept Cell Biol, Atlanta, GA 30322 USA	Hoffman, SW (corresponding author), Emory Univ, Dept Emergency Med, Evans Bldg,Room 255,1648 Pierce Dr NE, Atlanta, GA 30322 USA.	swhoffm@emory.edu	Stein, Donald/AAJ-5139-2020; Wright, David/F-1209-2013	Wright, David/0000-0002-7145-9105	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038664, R01NS040825] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1 R01 NS40825, 1 R01 NS38664] Funding Source: Medline		Allport VC, 2001, MOL HUM REPROD, V7, P581, DOI 10.1093/molehr/7.6.581; Allport VC, 2000, MOL HUM REPROD, V6, P561, DOI 10.1093/molehr/6.6.561; Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; Barnum SR, 1996, GLIA, V18, P107, DOI 10.1002/(SICI)1098-1136(199610)18:2<107::AID-GLIA3>3.0.CO;2-Y; BARNUM SR, 1995, NEUROSCI LETT, V197, P121, DOI 10.1016/0304-3940(95)11923-K; BARNUM SR, 1993, GLIA, V7, P225, DOI 10.1002/glia.440070306; Baulieu EE, 1998, PSYCHONEUROENDOCRINO, V23, P963, DOI 10.1016/S0306-4530(98)00071-7; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; Bellander BM, 2001, J NEUROTRAUM, V18, P1295, DOI 10.1089/08977150152725605; Brodbeck WG, 2000, J IMMUNOL, V165, P3999, DOI 10.4049/jimmunol.165.7.3999; DeBosscher K, 1997, P NATL ACAD SCI USA, V94, P13504, DOI 10.1073/pnas.94.25.13504; Dietrich WD, 1999, J NEUROTRAUM, V16, P567, DOI 10.1089/neu.1999.16.567; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; FAN L, 1995, MOL BRAIN RES, V30, P125; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Garcia-Estrada J, 1999, INT J DEV NEUROSCI, V17, P145, DOI 10.1016/S0736-5748(98)00065-3; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Goodman YD, 1996, J NEUROCHEM, V66, P1836; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Grossman KJ, 2004, BRAIN RES, V1008, P29, DOI 10.1016/j.brainres.2004.02.022; Gu ZZ, 2000, INT J DEV NEUROSCI, V18, P185, DOI 10.1016/S0736-5748(99)00087-8; Harukuni I, 1998, ANESTH ANALG, V87, P1299, DOI 10.1097/00000539-199812000-00016; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; Holmin S, 1999, NEUROREPORT, V10, P1889, DOI 10.1097/00001756-199906230-00017; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; HUGLI T E, 1986, Complement, V3, P111; Jauneau AC, 2003, FEBS LETT, V537, P17, DOI 10.1016/S0014-5793(03)00060-7; Kalkhoven E, 1996, J BIOL CHEM, V271, P6217, DOI 10.1074/jbc.271.11.6217; KAUL A, 1995, AM J REPROD IMMUNOL, V34, P236, DOI 10.1111/j.1600-0897.1995.tb00947.x; Keeling KL, 2000, J NEUROIMMUNOL, V105, P20, DOI 10.1016/S0165-5728(00)00183-1; Kirschfink M, 1997, IMMUNOPHARMACOLOGY, V38, P51, DOI 10.1016/S0162-3109(97)00057-X; Kossmann T, 1997, J NEUROIMMUNOL, V73, P63, DOI 10.1016/S0165-5728(96)00164-6; Kyrkanides S, 2001, J NEUROIMMUNOL, V119, P269, DOI 10.1016/S0165-5728(01)00404-0; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Lundeen SG, 2001, J STEROID BIOCHEM, V78, P137, DOI 10.1016/S0960-0760(01)00091-7; Mattson MP, 1997, BRAIN RES REV, V23, P47, DOI 10.1016/S0165-0173(96)00014-8; MONNET FP, 1995, P NATL ACAD SCI USA, V92, P3774, DOI 10.1073/pnas.92.9.3774; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; NISHIO M, 2002, J NEUROTRAUM, V19, P1333; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Raivich Gennadij, 1996, Keio Journal of Medicine, V45, P239; Rinder CS, 1999, CIRCULATION, V100, P553, DOI 10.1161/01.CIR.100.5.553; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; Roof R. L., 1994, Society for Neuroscience Abstracts, V20, P191; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; Rose ME, 2002, BRAIN RES, V943, P15, DOI 10.1016/S0006-8993(02)02471-X; Rostworowski M, 1997, J NEUROSCI, V17, P3664; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Soares HD, 1995, J NEUROSCI, V15, P8223; Stahel PF, 1997, MOL BRAIN RES, V50, P205, DOI 10.1016/S0169-328X(97)00189-7; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X; Stein Donald G, 2003, Pediatr Rehabil, V6, P13, DOI 10.1080/1363849031000095279; Takabayashi T, 1996, J IMMUNOL, V156, P3455; TANAKA H, 1994, ACTA NEUROCHIR, P524; Trembovler V, 1999, J INTERF CYTOK RES, V19, P791, DOI 10.1089/107999099313640; van Beek J, 2005, J IMMUNOL, V174, P2353, DOI 10.4049/jimmunol.174.4.2353; Wissink S, 1998, MOL ENDOCRINOL, V12, P355, DOI 10.1210/me.12.3.355; Wright DW, 2001, J NEUROTRAUM, V18, P901, DOI 10.1089/089771501750451820; WU FS, 1990, MOL PHARMACOL, V37, P597; YANG KY, 1995, NEUROSCI LETT, V197, P101, DOI 10.1016/0304-3940(95)11919-N	63	183	194	0	15	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JUL 5	2005	1049	1					112	119		10.1016/j.brainres.2005.05.004			8	Neurosciences	Neurosciences & Neurology	942QO	WOS:000230297100014	15932748				2021-06-18	
J	Mahmood, A; Lu, D; Chopp, M				Mahmood, A; Lu, D; Chopp, M			Marrow stromal cell transplantation after traumatic brain injury promotes cellular proliferation within the brain	NEUROSURGERY			English	Article						cellular proliferation; marrow stromal tells; traumatic brain injury	STEM-CELLS; RAT-BRAIN; IN-VITRO; NEUROGENESIS; THYMIDINE; RECOVERY; DEFICITS; MODEL; MOTOR	OBJECTIVE: This study was designed to investigate the effects of intracerebral as well as intravenous administration of bone marrow stromal cells (MSCs) on endogenous cellular proliferation after traumatic brain injury (TBI). METHODS: Two experimental groups of Wistar rats were studied. One group received MSCs intracerebrally, and the other group received MSCs intravenously after injury by controlled cortical impact. MSCs were harvested from the bone marrow of male Wistar rats. For the intracerebral study, 24 male rats were divided into three groups (eight rats per group): rats injected with MSCs (1 x 10(6)) intracerebrally 1 day after TBI; 2) rats injected with phosphate-buffered saline intracerebrally 1 day after TBI; and 3) sham group not subjected to injury and not administered treatment. For the intravenous study, 10 female Wistar rats were injected 1 day after TBI with either MSCs (2 x 10(6)) (n = 5) or phosphate-buffered saline (n = 5) via the tail vein. Neurological function of the rats was evaluated with modified neurological severity scores and rotarod motor test. All rats were injected with bromodeoxyuridine intraperitoneally, to label the newly generating cells. Rats were killed 15 days after TBI, and coronal brain sections were stained immunohistochemically with diaminobenzidine to identify newly generating bromodeoxyuridine-positive cells. To study the differentiation of newly generating cells into neurons, sections were also double-stained for neuronal markers (Tuj1, doublecortin, NeuN) with fluorescein isothiocyanate. RESULTS: The data demonstrate that newly generating cells were mainly present in the subventricular zone, hippocampal formation, and boundary zone of contusion of both treated and control animals. Intracerebral MSC treatment significantly increased the progenitor cell proliferation in the subventricular zone and boundary zone compared with the controls, whereas intravenous MSC treatment enhanced this endogenous proliferation in subventricular zone, hippocampus, and boundary zone. In both groups, some of the new cells revealed positive staining for neuronal markers. A statistically significant functional improvement was observed in both the intracerebrally as well as intravenously treated groups. CONCLUSION: Intracerebral and intravenous MSC administration promotes endogenous cellular proliferation after TBI in rats. This may contribute to the functional improvement observed in these rats.	Henry Ford Hosp, Dept Neurosurg, Detroit, MI 48202 USA; Henry Ford Hosp, Dept Neurol, Detroit, MI 48202 USA	Mahmood, A (corresponding author), Henry Ford Hosp, Dept Neurosurg, 2799 W Grand Blvd, Detroit, MI 48202 USA.	nssma@neuro.hfh.edu					ALTMAN J, 1966, J COMP NEUROL, V128, P431, DOI 10.1002/cne.901280404; ALTMAN J, 1981, J COMP NEUROL, V198, P677, DOI 10.1002/cne.901980409; ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; [Anonymous], 1970, Anat Rec, V166, P257; Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD; BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145; Borlongan CV, 1996, NEUROL RES, V18, P297; Chen XG, 2002, J NEUROSCI RES, V69, P687, DOI 10.1002/jnr.10334; CHENG SL, 1994, ENDOCRINOLOGY, V134, P277, DOI 10.1210/en.134.1.277; Clark BR, 1995, ANN NY ACAD SCI, V770, P70, DOI 10.1111/j.1749-6632.1995.tb31044.x; DIXON CE, 1991, J NEUROSCI METH, V39, P253; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529; Jin KL, 2002, P NATL ACAD SCI USA, V99, P11946, DOI 10.1073/pnas.182296499; Koc ON, 2000, J CLIN ONCOL, V18, P307, DOI 10.1200/JCO.2000.18.2.307; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Lee J, 2002, J NEUROCHEM, V82, P1367, DOI 10.1046/j.1471-4159.2002.01085.x; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2003, J HEAD TRAUMA REHAB, V18, P357, DOI 10.1097/00001199-200307000-00006; Lu DY, 2002, J NEUROSURG, V97, P935, DOI 10.3171/jns.2002.97.4.0935; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; Menard C, 2002, NEURON, V36, P597, DOI 10.1016/S0896-6273(02)01026-7; Postmantur R., 1997, NEUROSCIENCE, V77, P765; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Tao Y, 1996, J COMP NEUROL, V376, P653, DOI 10.1002/(SICI)1096-9861(19961223)376:4<653::AID-CNE11>3.0.CO;2-N; Zhao LR, 2002, EXP NEUROL, V174, P11, DOI 10.1006/exnr.2001.7853	30	183	227	1	19	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	NOV	2004	55	5					1185	1192		10.1227/01.NEU.0000141042.14476.3C			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	871FA	WOS:000225114000046	15509325				2021-06-18	
J	Balestreri, M; Czosnyka, M; Chatfield, DA; Steiner, LA; Schmidt, EA; Smielewski, P; Matta, B; Pickard, JD				Balestreri, M; Czosnyka, M; Chatfield, DA; Steiner, LA; Schmidt, EA; Smielewski, P; Matta, B; Pickard, JD			Predictive value of Glasgow coma scale after brain trauma: change in trend over the past ten years	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							SEVERE HEAD-INJURY	Background: Age and the Glasgow Coma Scale (GCS) score on admission are considered important predictors of outcome after traumatic brain injury. We investigated the predictive value of the GCS in a large group of patients whose computerised multimodal bedside monitoring data had been collected over the previous 10 years. Methods: Data from 358 subjects with head injury, collected between 1992 and 2001, were analysed retrospectively. Patients were grouped according to year of admission. Glasgow Outcome Scores (GOS) were determined at six months. Spearman's correlation coefficients between GCS and GOS scores were calculated for each year. Results: On average 34 (SD: 7) patients were monitored every year. We found a significant correlation between the GCS and GOS for the first five years ( overall 1992 - 1996: r = 0.41; p, 0.00001; n = 183) and consistent lack of correlations from 1997 onwards ( overall 1997 - 2001: r = 0.091; p = 0.226; n = 175). In contrast, correlations between age and GOS were in both time periods significant and similar (r = -0.24 v r = -0.24; p< 0.002). Conclusions: The admission GCS lost its predictive value for outcome in this group of patients from 1997 onwards. The predictive value of the GCS should be carefully reconsidered when building prognostic models incorporating multimodality monitoring after head injury.	Addenbrookes Hosp, Acad Neurosurg Unit, Cambridge CB2 2QQ, England; Addenbrookes Hosp, Dept Anaesthesiol, Cambridge, England; Warsaw Univ Technol, PL-00661 Warsaw, Poland	Czosnyka, M (corresponding author), Addenbrookes Hosp, Acad Neurosurg Unit, Box 167, Cambridge CB2 2QQ, England.		Steiner, Luzius/C-9836-2011; Steiner, Luzius/J-1987-2019	Smielewski, Peter/0000-0001-5096-3938	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390] Funding Source: Medline		CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; CZOSNYKA M, 1994, INT J CLIN MONIT COM, V11, P223, DOI 10.1007/BF01139874; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; Kirkpatrick PJ, 1997, J NEUROL NEUROSUR PS, V62, P109, DOI 10.1136/jnnp.62.2.109; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; MARSHALL LF, 1991, J NEUROSURG S, V75, P28; MURRAY GD, 1986, STAT MED, V5, P403, DOI 10.1002/sim.4780050504; TEASDALE G, 1974, LANCET, V2, P81	10	183	191	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JAN 1	2004	75	1					161	162					2	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	760CC	WOS:000187792300037	14707332				2021-06-18	
J	Collins, MW; Field, M; Lovell, MR; Iverson, G; Johnston, KM; Maroona, J; Fu, FH				Collins, MW; Field, M; Lovell, MR; Iverson, G; Johnston, KM; Maroona, J; Fu, FH			Relationship between postconcussion headache and neuropsychological test performance in high school athletes	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article							UNITED-STATES; BRAIN-INJURY; CONCUSSION; SPORTS; MILD; EPIDEMIOLOGY; PREVALENCE; COLLEGIATE	Background: The relevance of headache to outcome after sports-related concussion is poorly understood. Hypotheses: High school athletes reporting headache approximately 1 week after injury will have significantly more other concussion symptoms and will perform more poorly on neuropsychological tests than athletes not experiencing headache. Study Design: Prospective cohort study. Methods: Study participants included 109 high school athletes who had sustained concussion and who were divided into two groups: those reporting headache 7 days after injury and those reporting no headaches. The two groups were compared regarding on-field markers of concussion severity at the time of injury and symptoms and neurocognitive test results collected via ImPACT, a computerized neuropsychological test battery and postconcussion symptom scale, at a mean of 6.8 days after injury. Results: Athletes reporting posttraumatic headache demonstrated significantly worse performance on reaction time and memory ImPACT neurocognitive composite scores. These athletes also reported significantly more symptoms other than headache and were more likely to have demonstrated on-field anterograde amnesia. Conclusions: Findings suggest that any degree of postconcussion headache in high school athletes 7 days after injury is likely associated with an incomplete recovery after concussion. (C) 2003 American Orthopaedic Society for Sports Medicine.	Univ Pittsburgh, Dept Orthopaed Surg, Ctr Sports Med, Med Ctr Sports Concuss Program, Pittsburgh, PA 15203 USA; Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Pittsburgh, PA 15203 USA; Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada; McGill Univ, Dept Neurosurg, Montreal, PQ H3A 2T5, Canada	Collins, MW (corresponding author), Univ Pittsburgh, Dept Orthopaed Surg, Ctr Sports Med, Med Ctr Sports Concuss Program, 3200 S Water St, Pittsburgh, PA 15203 USA.			Iverson, Grant/0000-0001-7348-9570			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Gaetz M, 2000, BRAIN INJURY, V14, P1077; GEORGE J K, 1989, Journal of Nuclear Medicine, V30, P802; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; *INT HEAD SOC, 1997, CEPHALGIA S, V18, P43; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Johnston KM, 2001, CLIN J SPORT MED, V11, P166, DOI 10.1097/00042752-200107000-00007; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McCrory P, 2000, SPORTS MED, V30, P221, DOI 10.2165/00007256-200030030-00006; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; Sallis RE, 2000, MED SCI SPORT EXER, V32, P1820, DOI 10.1097/00005768-200011000-00002; Sosin DM, 1996, BRAIN INJURY, V10, P47; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; WILLIAMS SJ, 1994, BRIT J SPORT MED, V28, P90, DOI 10.1136/bjsm.28.2.90; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401	28	183	184	0	16	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	MAR-APR	2003	31	2					168	173		10.1177/03635465030310020301			6	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	655WD	WOS:000181574900003	12642248				2021-06-18	
J	Tateno, A; Jorge, RE; Robinson, RG				Tateno, A; Jorge, RE; Robinson, RG			Clinical correlates of aggressive behavior after traumatic brain injury	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							CLOSED HEAD-INJURY; COMPUTERIZED-TOMOGRAPHY; STROKE PATIENTS; SEQUELAE; DEPRESSION; MILD; AGITATION; VIOLENCE; TRENDS; SCALE	The authors assessed aggressive behavior in 89 patients with traumatic brain injury (TBI) and 26 patients with multiple trauma but without TBI using a quantitative scale (the Overt Aggression Scale) and examined its clinical correlates. Aggressive behavior was found in 33.7% of TBI patients and 11.5% of patients without TBI during the first 6 months after injury. Aggressive behavior was significantly associated with the presence of major depression, frontal lobe lesions, poor pre-morbid social functioning, and a history of alcohol and substance abuse. Interventions aimed at treatment of depression and substance abuse and enhancing social support may help reduce the severity of this disruptive behavior.	Univ Iowa, Coll Med, Dept Psychiat, Iowa City, IA 52242 USA; Nippon Med Coll, Dept Neuropsychiat, Tokyo 113, Japan	Jorge, RE (corresponding author), Univ Iowa, Coll Med, Dept Psychiat, 500 Newton Rd, Iowa City, IA 52242 USA.		Robinson, Robert/AAF-6191-2021		NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH-52879, MH-53592, MH-40355] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH040355, R01MH053592, R01MH052879] Funding Source: NIH RePORTER		Alderman N, 1999, BRAIN INJURY, V13, P669; Anderson K., 1998, SEMIN CLIN NEUROPSYC, V3, P232; BAILLY D, 1993, PSYCHIAT RES, V47, P57, DOI 10.1016/0165-1781(93)90055-L; BROOKE MM, 1992, ARCH PHYS MED REHAB, V73, P320, DOI 10.1016/0003-9993(92)90003-F; BRUKE WH, 1988, INT J REHABIL RES, V11, P235; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; EVANS RW, 1992, NEUROL CLIN, V10, P815; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; Fava M, 2000, PSYCHIAT RES, V94, P9, DOI 10.1016/S0165-1781(00)00120-7; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; Granger CV, 1986, TOP GERIATR REHABIL, V1, P59, DOI 10.1097/00013614-198604000-00007; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HAMILTON M, 1959, BRIT J MED PSYCHOL, V32, P50, DOI 10.1111/j.2044-8341.1959.tb00467.x; HERZBERG JL, 1988, BRIT J PSYCHIAT, V153, P50, DOI 10.1192/bjp.153.1.50; HIGLEY JD, 1991, PSYCHOPHARMACOLOGY, V103, P551, DOI 10.1007/BF02244258; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Kim SH, 1999, J NERV MENT DIS, V187, P327, DOI 10.1097/00005053-199906000-00001; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; London ED, 2000, CEREB CORTEX, V10, P334, DOI 10.1093/cercor/10.3.334; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Mysiw WJ, 1997, ARCH PHYS MED REHAB, V78, P213, DOI 10.1016/S0003-9993(97)90266-5; Paradiso S, 1996, J NERV MENT DIS, V184, P746, DOI 10.1097/00005053-199612000-00005; RAO N, 1985, ARCH PHYS MED REHAB, V66, P30; ROBINSON RG, 1985, AM J PSYCHIAT, V142, P1424; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Sandel ME, 1996, ARCH PHYS MED REHAB, V77, P617, DOI 10.1016/S0003-9993(96)90306-8; Sartorius N, 1974, MEASUREMENT CLASSIFI; SILVER JM, 1991, J NEUROPSYCHIAT, V3, P22; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sparadeo F. R., 1989, J HEAD TRAUMA REHAB, V4, P75, DOI DOI 10.1097/00001199-198903000-00010; Spitzer RL, 1990, STRUCTURED CLIN INTE; STARR LB, 1983, EXP AGING RES, V9, P101, DOI 10.1080/03610738308258434; SWANSON JW, 1990, HOSP COMMUNITY PSYCH, V41, P761; TEASDALE G, 1974, LANCET, V2, P81; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; TONKONOGY TM, 1991, J NEUROPSYCHIAT, V3, P189; VANWOERKOM TCAM, 1977, LANCET, V1, P812; YUDOFSKY SC, 1986, AM J PSYCHIAT, V143, P35	42	183	187	0	21	AMER PSYCHIATRIC PRESS, INC	WASHINGTON	1400 K ST, N W, STE 1101, WASHINGTON, DC 20005 USA	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	SPR	2003	15	2					155	160		10.1176/appi.neuropsych.15.2.155			6	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	672VQ	WOS:000182544000004	12724455				2021-06-18	
J	Barr, WB; McCrea, M				Barr, WB; McCrea, M			Sensitivity and specificity of standardized neurocognitive testing immediately following sports concussion	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						sports injuries; concussion; test-retest reliability; traumatic brain injury	MILD HEAD-INJURY; NEUROPSYCHOLOGICAL CHANGE; EPILEPSY SURGERY; FOOTBALL PLAYERS; RECOVERY; PERFORMANCE; RELIABILITY; MANAGEMENT; REGRESSION; DEMENTIA	Neuropsychology, with its emphasis on standardized and empirically based methods, has made a number of scientific contributions to address growing concerns about concussions resulting from sports injuries. This study employs a test-retest paradigm to determine the immediate effects of concussion in high-school and college athletes. The Standardized Assessment of Concussion (SAC) was administered to 1,313 mate athletes prior to the beginning of the competitive season. Reliable change indices and multiple regression models were computed on retest scores obtained from 68 noninjured athletes who were readministered the SAC at either 60 or 120 days following baseline testing. Receiver operating characteristic (ROC) curve analyses were used to test these models with data obtained on 50 athletes tested immediately following concussion. The results indicate that a decline of 1 point on the SAC at retesting classified injured and noninjured participants with a level of 94% sensitivity and 76% specificity. The RCI and multiple regression models provided comparable levels of group classification, but provided cut-offs that are conservative for use with this population. The results support and extend previous research findings indicating that the SAC is a valid instrument for detecting the immediate effects of mild traumatic brain injury.	NYU Med Ctr, Dept Neurol, New York, NY 10016 USA; NYU Med Ctr, Dept Psychiat, New York, NY 10016 USA; Waukesha Mem Hosp, Neuropsychol Serv, Waukesba, WI USA; Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA	Barr, WB (corresponding author), NYU, Comprehens Epilepsy Ctr, 560 1st Ave,Rivergate 4th Floor, New York, NY 10016 USA.	william.barr@med.nyu.edu		Barr, William/0000-0001-7711-7758			Alexander M. P., 1997, SEMIN CLIN NEUROPSYC, V2, P177; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Barr WB, 1997, PSYCHOL ASSESSMENT, V9, P171; Barth JT., 1989, MILD HEAD INJURY, P257; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Bruggemans EF, 1997, J CLIN EXP NEUROPSYC, V19, P543, DOI 10.1080/01688639708403743; Chelune GJ, 1993, NEUROPSYCHOLOGY, V7, P41, DOI DOI 10.1037/0894-4105.7.1.41; *COL MED SOC SPORT, 1991, GUID MAN CONC SPORTS; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Dikmen SS, 1999, J INT NEUROPSYCH SOC, V5, P346, DOI 10.1017/S1355617799544056; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Hermann BP, 1996, EPILEPSIA, V37, P942, DOI 10.1111/j.1528-1157.1996.tb00531.x; HERMANN BP, 1991, J EPILEPSY, V4, P139, DOI 10.1016/S0896-6974(05)80039-8; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; KEEFE RSE, 1995, AM J PSYCHIAT, V152, P6; Kelly JP, 1997, NEUROLOGY, V48, P581; LEVIN HS, 1994, ARCH NEUROL-CHICAGO, V51, P854, DOI 10.1001/archneur.1994.00540210024009; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M., 1997, STANDARDIZED ASSESSM; McSweeny A., 1993, CLIN NEUROPSYCHOL, V7, P300, DOI DOI 10.1080/13854049308401901; MONSCH AU, 1992, ARCH NEUROL-CHICAGO, V49, P1253, DOI 10.1001/archneur.1992.00530360051017; Pottinger LS, 1999, ARCH CLIN NEUROPSYCH, V14, P39, DOI 10.1093/arclin/14.1.39a; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; Sawrie S M, 1996, J Int Neuropsychol Soc, V2, P556; STEIN SC, 1993, BRAIN INJURY, V7, P425, DOI 10.3109/02699059309029685; TEASDALE G, 1974, LANCET, V2, P81; Temkin NR, 1999, J INT NEUROPSYCH SOC, V5, P357, DOI 10.1017/S1355617799544068; YARNELL PR, 1970, LANCET, V1, P863	39	183	186	1	23	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2001	7	6					693	702		10.1017/S1355617701766052			10	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	471YE	WOS:000170955600005	11575591				2021-06-18	
J	Kipnis, J; Yoles, E; Schori, H; Hauben, E; Shaked, I; Schwartz, M				Kipnis, J; Yoles, E; Schori, H; Hauben, E; Shaked, I; Schwartz, M			Neuronal survival after CNS insult is determined by a genetically encoded autoimmune response	JOURNAL OF NEUROSCIENCE			English	Article						protective autoimmunity; encephalitogenicity; neuroprotection; autoimmune disease; CNS; EAE	EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; TRAUMATIC BRAIN INJURY; SPINAL-CORD CONTUSION; REGULATORY T-CELLS; MOUSE STRAINS; OPTIC-NERVE; TORPEDO-CALIFORNICA; MYASTHENIA-GRAVIS; IMMUNE PRIVILEGE	Injury to the CNS is often followed by a spread of damage (secondary degeneration), resulting in neuronal losses that are substantially greater than might have been predicted from the severity of the primary insult. Studies in our laboratory have shown that injured CNS neurons can benefit from active or passive immunization with CNS myelin-associated antigens. The fact that autoimmune T-cells can be both beneficial and destructive, taken together with the established phenomenon of genetic predisposition to autoimmune diseases, raises the question: will genetic predisposition to autoimmune diseases affect the outcome of traumatic insult to the CNS? Here we show that the survival rate of retinal ganglion cells in adult mice or rats after crush injury of the optic nerve or intravitreal injection of a toxic dosage of glutamate is up to twofold higher in strains that are resistant to the CNS autoimmune disease experimental autoimmune encephalomyelitis (EAE) than in susceptible strains. The difference was found to be attributed, at least in part, to a beneficial T-cell response that was spontaneously evoked after CNS insult in the resistant but not in the susceptible strains. In animals of EAE-resistant but not of EAE-susceptible strains devoid of mature T-cells (as a result of having undergone thymectomy at birth), the numbers of surviving neurons after optic nerve injury were significantly lower (by 60%) than in the corresponding normal animals. Moreover, the rate of retinal ganglion cell survival was higher when the optic nerve injury was preceded by an unrelated CNS (spinal cord) injury in the resistant strains but not in the susceptible strains. It thus seems that, in normal animals of EAE-resistant strains (but not of susceptible strains), the injury evokes an endogenous protective response that is T-cell dependent. These findings imply that a protective T-cell-dependent response and resistance to autoimmune disease are regulated by a common mechanism. The results of this study compel us to modify our understanding of autoimmunity and autoimmune diseases, as well as the role of autoimmunity in non-autoimmune CNS disorders. They also obviously have far-reaching clinical implications in terms of prognosis and individual therapy.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel	Schwartz, M (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.		Hauben, Ehud/R-8692-2019; Shaked, Iftach/AAS-9961-2020	Hauben, Ehud/0000-0002-6062-411X			ARNON R, 1981, IMMUNOL REV, V55, P5, DOI 10.1111/j.1600-065X.1981.tb00337.x; Basso DM, 1996, J NEUROTRAUM, V13, P343, DOI 10.1089/neu.1996.13.343; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Bebo BF, 1998, J NEUROIMMUNOL, V84, P122, DOI 10.1016/S0165-5728(97)00214-2; BELLONE M, 1991, EUR J IMMUNOL, V21, P2303, DOI 10.1002/eji.1830211003; BURNET FM, 1959, CLONAL SELECTION THE; COHEN IR, 1992, IMMUNOL TODAY, V13, P490, DOI 10.1016/0167-5699(92)90024-2; Cohen IR, 1999, J NEUROIMMUNOL, V100, P111, DOI 10.1016/S0165-5728(99)00190-3; DEROSBO NK, 1995, EUR J IMMUNOL, V25, P985, DOI 10.1002/eji.1830250419; DUONG TT, 1994, J NEUROIMMUNOL, V53, P101, DOI 10.1016/0165-5728(94)90069-8; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Goebels N, 2000, BRAIN, V123, P508, DOI 10.1093/brain/123.3.508; Gold R, 1997, TRENDS NEUROSCI, V20, P399, DOI 10.1016/S0166-2236(97)01079-5; Hauben E, 2000, J NEUROSCI, V20, P6421, DOI 10.1523/JNEUROSCI.20-17-06421.2000; Hauben E, 2000, LANCET, V355, P286, DOI 10.1016/S0140-6736(99)05140-5; HICKEY WF, 1991, J NEUROSCI RES, V28, P254, DOI 10.1002/jnr.490280213; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; Juurlink B H, 1998, J Spinal Cord Med, V21, P309; Kipnis J, 2000, P NATL ACAD SCI USA, V97, P7446, DOI 10.1073/pnas.97.13.7446; Kuchroo VK, 1998, RES IMMUNOL, V149, P759, DOI 10.1016/S0923-2494(99)80003-0; KUNZ HW, 1989, IMMUNOGENETICS, V30, P181, DOI 10.1007/BF02421204; Ligier S, 1999, ENVIRON HEALTH PERSP, V107, P701, DOI 10.2307/3434330; LIU DX, 1994, J NEUROCHEM, V62, P37; Livingstone KD, 1995, AUTOIMMUNITY, V21, P195, DOI 10.3109/08916939509008016; Mattson MP, 2000, J NEUROSCI, V20, P1358; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MENDEL I, 1995, EUR J IMMUNOL, V25, P1951, DOI 10.1002/eji.1830250723; Moalem G, 1999, NAT MED, V5, P49, DOI 10.1038/4734; Moalem G, 1999, FASEB J, V13, P1207; Oshima M, 1998, AUTOIMMUNITY, V27, P79, DOI 10.3109/08916939809008038; Schwartz M, 2000, IMMUNOL TODAY, V21, P265, DOI 10.1016/S0167-5699(00)01633-9; Schwartz M, 1999, TRENDS NEUROSCI, V22, P295, DOI 10.1016/S0166-2236(99)01405-8; Schwartz M, 2001, TRENDS MOL MED, V7, P252, DOI 10.1016/S1471-4914(01)01993-1; Schwartz M, 1999, MOL MED TODAY, V5, P470, DOI 10.1016/S1357-4310(99)01592-0; Seddon B, 2000, IMMUNOL TODAY, V21, P95, DOI 10.1016/S0167-5699(99)01559-5; Shevach EM, 2000, ANNU REV IMMUNOL, V18, P423, DOI 10.1146/annurev.immunol.18.1.423; Smith D H, 1995, New Horiz, V3, P562; STREILEIN JW, 1995, SCIENCE, V270, P1158, DOI 10.1126/science.270.5239.1158; Sun DM, 1999, EUR J IMMUNOL, V29, P1101, DOI 10.1002/(SICI)1521-4141(199904)29:04<1101::AID-IMMU1101>3.0.CO;2-#; Yang GM, 1997, BRAIN RES, V752, P209, DOI 10.1016/S0006-8993(96)01453-9; Yocum DE, 1999, SEMIN ARTHRITIS RHEU, V29, P27, DOI 10.1016/S0049-0172(99)80035-3; YOLES E, 1992, INVEST OPHTH VIS SCI, V33, P3586; Yoles E, 1998, EXP NEUROL, V153, P1, DOI 10.1006/exnr.1998.6811; Yoles E, 2001, J NEUROSCI, V21, P3740, DOI 10.1523/JNEUROSCI.21-11-03740.2001; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; Zhu J, 1998, J NEUROSCI RES, V54, P373, DOI 10.1002/(SICI)1097-4547(19981101)54:3<373::AID-JNR8>3.0.CO;2-Z	50	183	188	0	3	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUL 1	2001	21	13					4564	4571		10.1523/JNEUROSCI.21-13-04564.2001			8	Neurosciences	Neurosciences & Neurology	445JP	WOS:000169454600005	11425884	Green Published, Bronze			2021-06-18	
J	Ingebrigtsen, T; Waterloo, K; Jacobsen, EA; Langbakk, B; Romner, B				Ingebrigtsen, T; Waterloo, K; Jacobsen, EA; Langbakk, B; Romner, B			Traumatic brain damage in minor head injury: Relation of serum S-100 protein measurements to magnetic resonance imaging and neurobehavioral outcome	NEUROSURGERY			English	Article						computed tomographic scan; head injury; magnetic resonance imaging; neurobehavioral outcome; S-100 protein	CEREBROSPINAL-FLUID; COMPUTED-TOMOGRAPHY; SERIAL S-100; CT FINDINGS; FOLLOW-UP; MILD; CONCUSSION; MANAGEMENT; SYMPTOMS; SPECT	OBJECTIVE: The present study was conducted to validate S-100 protein as a marker of brain damage after minor head injury. METHODS: We studied 50 patients with minor head injuries and Glasgow Coma Scale scores of 13 to 15 in whom computed tomographic scans of the brain revealed no abnormalities. Serum levels of S-100 protein were measured at admittance and hourly thereafter until 12 hours after injury. Magnetic resonance imaging and baseline neuropsychological examinations were performed within 48 hours, and neuropsychological follow-up was conducted at 3 months postinjury. RESULTS: Fourteen patients (28%) had detectable serum levels of S-100 protein (mean peak value, 0.4 mu g/L [standard deviation, +/- 0.3]). The S-100 protein levels were highest immediately after the trauma, and they declined each hour thereafter. At 6 hours postinjury, the serum level was below the detection limit (0.2 mu g/L) in five (36%) of the patients with initially detectable levels. Magnetic resonance imaging revealed brain contusions in five patients, four of whom demonstrated detectable levels of S-100 protein in serum. The proportion of patients with detectable serum levels was significantly higher when magnetic resonance imaging revealed a brain contusion. In patients with detectable serum levels, we observed a trend toward impaired neuropsychological functioning on measures of attention, memory, and information processing speed. CONCLUSION: Determination of S-100 protein levels in serum provides a valid measure of the presence and severity of traumatic brain damage if performed within the first hours after minor head injury.	Univ Lund Hosp, Dept Neurosurg, S-22185 Lund, Sweden; Univ Tromso Hosp, Dept Neurosurg, N-9012 Tromso, Norway; Univ Tromso Hosp, Dept Neurol, N-9012 Tromso, Norway; Univ Tromso Hosp, Dept Radiol, N-9012 Tromso, Norway; Univ Tromso Hosp, Dept Clin Chem, N-9012 Tromso, Norway	Romner, B (corresponding author), Univ Lund Hosp, Dept Neurosurg, S-22185 Lund, Sweden.			Ingebrigtsen, Tor/0000-0001-5966-9786			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; ARCIA E, 1994, BRAIN INJURY, V8, P395, DOI 10.3109/02699059409150991; Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; BAKAY RAE, 1983, J NEUROSURG, V58, P27, DOI 10.3171/jns.1983.58.1.0027; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Blomquist S, 1997, J CARDIOTHOR VASC AN, V11, P699, DOI 10.1016/S1053-0770(97)90160-9; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; Cicerone KD, 1997, CLIN NEUROPSYCHOL, V11, P266, DOI 10.1080/13854049708400455; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; ELSON LM, 1994, SEMIN NEUROL, V14, P8, DOI 10.1055/s-2008-1041053; FAGNART OC, 1988, CLIN CHEM, V34, P1387; GANDY SE, 1984, ANN NEUROL, V16, P254, DOI 10.1002/ana.410160217; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; HAIMOTO H, 1987, LAB INVEST, V57, P489; HAN JS, 1984, RADIOLOGY, V150, P71, DOI 10.1148/radiology.150.1.6689790; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; INGEBRIGTSEN T, 1995, J NEUROL NEUROSUR PS, V59, P103, DOI 10.1136/jnnp.59.1.103-a; Ingebrigtsen T, 1996, J NEUROSURG, V85, P945, DOI 10.3171/jns.1996.85.5.0945; Ingebrigtsen T, 1997, J CLIN NEUROSCI, V4, P29, DOI 10.1016/S0967-5868(97)90007-2; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Jacobs A, 1996, J NUCL MED, V37, P1605; JENKINS A, 1986, LANCET, V2, P445; JENSEN R, 1985, J NEUROCHEM, V45, P700, DOI 10.1111/j.1471-4159.1985.tb04048.x; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; MAXWELL WL, 1988, J PATHOL, V155, P327, DOI 10.1002/path.1711550408; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; MILLER EN, 1991, NEUROLOGY, V41, P1608, DOI 10.1212/WNL.41.10.1608; MILLER EN, 1993, CALCAP CALIFORNIA CO; Mitchener A, 1997, J NEUROL NEUROSUR PS, V62, P633, DOI 10.1136/jnnp.62.6.633; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; MOORE BW, 1965, BIOCHEM BIOPH RES CO, V19, P739, DOI 10.1016/0006-291X(65)90320-7; Nygaard O, 1997, CLIN CHEM, V43, P541; Reitan R, 1974, CLIN NEUROPSYCHOLOGY; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROBINSON AL, 1980, J CONSULT CLIN PSYCH, V48, P605, DOI 10.1037/0022-006X.48.5.605; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; Shatz M W, 1981, J Clin Neuropsychol, V3, P171, DOI 10.1080/01688638108403123; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; TEASDALE G, 1974, LANCET, V2, P81; The Mild Traumatic Brain Injury Committee of the Head Injury Interdisciplinary Special Interest Group of the American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86; USUI A, 1989, CLIN CHEM, V35, P1942; Waterloo K, 1997, ACTA NEUROCHIR, V139, P26, DOI 10.1007/BF01850864; WECHSLER D, 1987, MANUAL MEMORY SCALE; Wiesmann M, 1997, ACTA NEUROCHIR, V139, P1155, DOI 10.1007/BF01410976; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Woertgen C, 1997, ACTA NEUROCHIR, V139, P1161, DOI 10.1007/BF01410977; Wolfson D., 1993, HALSTEAD REITAN NEUR; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	56	183	194	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	SEP	1999	45	3					468	475		10.1097/00006123-199909000-00010			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	235MT	WOS:000082546000024	10493368				2021-06-18	
J	Carlos, TM; Clark, RSB; FranicolaHiggins, D; Schiding, JK; Kochanekt, PM				Carlos, TM; Clark, RSB; FranicolaHiggins, D; Schiding, JK; Kochanekt, PM			Expression of endothelial adhesion molecules and recruitment of neutrophils after traumatic brain injury in rats	JOURNAL OF LEUKOCYTE BIOLOGY			English	Article						E-selectin; ICAM-1; PECAM-1	ISCHEMIC CELL-DAMAGE; CEREBRAL-ARTERY OCCLUSION; MONOCLONAL-ANTIBODY; SELECTIVE DEPLETION; TRANSIENT; ACCUMULATION; ANTI-CD11B	Traumatic brain injury (TBI) is often accompanied by an acute inflammatory reaction mediated initially by neutrophils, Adhesion molecules expressed on vascular endothelium are requisite elements during recruitment of leukocytes at sites of inflammation., In a rat model of TBI the induction and persistent expression of E-selectin (CD62E) on cerebrovascular endothelium ipsilateral, but not contralateral, to the site of contusion was demonstrated (P < 0.05 at 4 and 48 h posttrauma), In addition, these studies confirmed up-regulation and prolonged expression of ICAM-1 (CD54) on endothelium in the traumatized hemisphere (P < 0.05 at 4, 24, 48, and 72 h posttrauma), It is of interest that increased expression of CD54 was noted on blood vessels in the contralateral, non-traumatized hemisphere 48 h posttrauma, Expression of a third endothelial adhesion molecule, PECAM-1 (CD31), was unchanged following trauma, Administration of a murine monoclonal antibody (TM-8) that inhibits the adhesive function of CD54 blocked a significant portion (37.9%) of neutrophil recruitment 24 h posttrauma (P = 0.04), Employing immunocytochemistry and a monoclonal antibody specific for rat neutrophils (RP-3), peak infiltration of neutrophils was shown to occur 48 h after trauma, In contrast to emigration of neutrophils from blood vessels within the contusion, however, entry of neutrophils occurred from the surrounding leptomeninges and choroidal vessels, These studies demonstrate the relevance of CD54 (ICAM-1) in recruitment of neutrophils following TBI, However, the majority of neutrophil influx relies on endothelial adhesion molecules other than CD54. Because emigration of neutrophils was shown to occur predominantly from vessels within the leptomeninges and choroid plexus, intrathecal delivery of agents that inhibit the adhesive interactions between neutrophils, endothelial CD54, and other endothelial adhesion molecules to be defined may offer a novel form of therapy to prevent the acute inflammatory response that follows TBI.	UNIV PITTSBURGH, DEPT MED, PITTSBURGH, PA USA; UNIV PITTSBURGH, DEPT ANESTHESIOL CRIT CARE MED, PITTSBURGH, PA USA; UNIV PITTSBURGH, SAFAR CTR RESUSCITAT RES, PITTSBURGH, PA USA			Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [2P50 NS 30318-04A21] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318] Funding Source: NIH RePORTER		BIAGAS KV, 1992, J NEUROTRAUM, V9, P363, DOI 10.1089/neu.1992.9.363; CARLOS TM, 1994, BLOOD, V84, P2068; CHEN H, 1994, ANN NEUROL, V35, P458, DOI 10.1002/ana.410350414; CHOPP M, 1994, STROKE, V25, P869, DOI 10.1161/01.STR.25.4.869; Chopp M, 1996, J CEREBR BLOOD F MET, V16, P578, DOI 10.1097/00004647-199607000-00007; Clark RSB, 1996, J NEUROTRAUM, V13, P333, DOI 10.1089/neu.1996.13.333; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Connolly ES, 1996, J CLIN INVEST, V97, P209, DOI 10.1172/JCI118392; HINES D, 1993, SOC NEUR ABSTR, V18, P1875; Horner H. C., 1992, Society for Neuroscience Abstracts, V18, P173; KUDO C, 1993, J IMMUNOL, V150, P3728; MATSUO Y, 1994, STROKE, V25, P1469, DOI 10.1161/01.STR.25.7.1469; MAXWELL WL, 1992, ACTA NEUROPATHOL, V84, P78, DOI 10.1007/BF00427218; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; MULLER WA, 1993, J EXP MED, V178, P449, DOI 10.1084/jem.178.2.449; Murohara T, 1996, J IMMUNOL, V156, P3550; OKADA Y, 1994, STROKE, V25, P202, DOI 10.1161/01.STR.25.1.202; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; SEKIYA S, 1989, J LEUKOCYTE BIOL, V46, P96; SHACKFORD SR, 1989, J TRAUMA, V29, P1392, DOI 10.1097/00005373-198910000-00018; SMITH CW, 1993, CAN J PHYSIOL PHARM, V71, P76, DOI 10.1139/y93-012; Soares HD, 1995, J NEUROSCI, V15, P8223; Soriano SG, 1996, ANN NEUROL, V39, P618, DOI 10.1002/ana.410390511; Tang T, 1996, J CLIN INVEST, V97, P2485, DOI 10.1172/JCI118695; TUOMANEN EI, 1989, J EXP MED, V170, P959, DOI 10.1084/jem.170.3.959; UHL MW, 1994, J NEUROTRAUM, V11, P303, DOI 10.1089/neu.1994.11.303; VAPORCIYAN AA, 1993, SCIENCE, V262, P1580, DOI 10.1126/science.8248808; WANG XK, 1995, STROKE, V26, P1665, DOI 10.1161/01.STR.26.9.1665; WANG XK, 1995, J NEUROTRAUM, V12, P825, DOI 10.1089/neu.1995.12.825; ZHANG RL, 1995, STROKE, V26, P1438, DOI 10.1161/01.STR.26.8.1438; ZHANG RL, 1994, NEUROLOGY, V44, P1747, DOI 10.1212/WNL.44.9.1747; ZHANG ZG, 1995, BRAIN RES, V698, P79, DOI 10.1016/0006-8993(95)00830-J	34	183	187	1	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0741-5400	1938-3673		J LEUKOCYTE BIOL	J. Leukoc. Biol.	MAR	1997	61	3					279	285					7	Cell Biology; Hematology; Immunology	Cell Biology; Hematology; Immunology	WN150	WOS:A1997WN15000005	9060450				2021-06-18	
J	McCauley, SR; Wilde, EA; Anderson, VA; Bedell, G; Beers, SR; Campbell, TF; Chapman, SB; Ewing-Cobbs, L; Gerring, JP; Gioia, GA; Levin, HS; Michaud, LJ; Prasad, MR; Swaine, BR; Turkstra, LS; Wade, SL; Yeates, KO				McCauley, Stephen R.; Wilde, Elisabeth A.; Anderson, Vicki A.; Bedell, Gary; Beers, Sue R.; Campbell, Thomas F.; Chapman, Sandra B.; Ewing-Cobbs, Linda; Gerring, Joan P.; Gioia, Gerard A.; Levin, Harvey S.; Michaud, Linda J.; Prasad, Mary R.; Swaine, Bonnie R.; Turkstra, Lyn S.; Wade, Shari L.; Yeates, Keith O.			Recommendations for the Use of Common Outcome Measures in Pediatric Traumatic Brain Injury Research	JOURNAL OF NEUROTRAUMA			English	Article						children; infants; outcome assessment, TBI	CLOSED-HEAD-INJURY; VERBAL-LEARNING-TEST; QUALITY-OF-LIFE; TEST-CHILDRENS VERSION; DIFFICULTIES-QUESTIONNAIRE SDQ; MOTOR FUNCTION MEASURE; PORTLAND ADAPTABILITY INVENTORY; FUNCTIONAL INDEPENDENCE MEASURE; BEHAVIOR RATING INVENTORY; POST-CONCUSSIVE SYMPTOMS	This article addresses the need for age-relevant outcome measures for traumatic brain injury (TBI) research and summarizes the recommendations by the inter-agency Pediatric TBI Outcomes Workgroup. The Pediatric Workgroup's recommendations address primary clinical research objectives including characterizing course of recovery from TBI, prediction of later outcome, measurement of treatment effects, and comparison of outcomes across studies. Consistent with other Common Data Elements (CDE) Workgroups, the Pediatric TBI Outcomes Workgroup adopted the standard three-tier system in its selection of measures. In the first tier, core measures included valid, robust, and widely applicable outcome measures with proven utility in pediatric TBI from each identified domain including academics, adaptive and daily living skills, family and environment, global outcome, health-related quality of life, infant and toddler measures, language and communication, neuropsychological impairment, physical functioning, psychiatric and psychological functioning, recovery of consciousness, social role participation and social competence, social cognition, and TBI-related symptoms. In the second tier, supplemental measures were recommended for consideration in TBI research focusing on specific topics or populations. In the third tier, emerging measures included important instruments currently under development, in the process of validation, or nearing the point of published findings that have significant potential to be superior to measures in the core and supplemental lists and may eventually replace them as evidence for their utility emerges.	[McCauley, Stephen R.] Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [McCauley, Stephen R.; Wilde, Elisabeth A.; Levin, Harvey S.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [McCauley, Stephen R.; Levin, Harvey S.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [McCauley, Stephen R.; Wilde, Elisabeth A.; Levin, Harvey S.] Michael E DeBakey Vet Adm Med Ctr, Houston, TX USA; [Wilde, Elisabeth A.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [Anderson, Vicki A.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Bedell, Gary] Tufts Univ, Dept Occupat Therapy, Medford, MA 02155 USA; [Beers, Sue R.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA; [Campbell, Thomas F.] Univ Texas Dallas, Callier Ctr Commun Disorders, Commun Disorders Sch Behav & Brain Sci, Dallas, TX 75235 USA; [Chapman, Sandra B.] Univ Texas Dallas, Ctr BrainHlth Behav & Brain Sci, Dallas, TX 75235 USA; [Ewing-Cobbs, Linda; Prasad, Mary R.] Univ Texas Hlth Sci Ctr Houston, Childrens Learning Inst, Houston, TX USA; [Ewing-Cobbs, Linda; Prasad, Mary R.] Univ Texas Hlth Sci Ctr Houston, Dept Psychiat & Behav Sci, Houston, TX USA; [Gerring, Joan P.] Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA; [Gerring, Joan P.] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; [Gioia, Gerard A.] George Washington Univ, Sch Med, Dept Pediat, Washington, DC 20052 USA; [Gioia, Gerard A.] George Washington Univ, Sch Med, Dept Psychiat, Washington, DC 20052 USA; [Michaud, Linda J.; Wade, Shari L.] Univ Cincinnati, Dept Phys Med & Rehabil, Cincinnati, OH USA; [Michaud, Linda J.; Wade, Shari L.] Univ Cincinnati, Dept Pediat, Cincinnati, OH 45221 USA; [Michaud, Linda J.; Wade, Shari L.] Cincinnati Childrens Hosp, Med Ctr, Cincinnati, OH USA; [Swaine, Bonnie R.] Univ Montreal, Ecole Readaptat, Ctr Interdisciplinary Rehabil Res CRIR, Montreal, PQ, Canada; [Turkstra, Lyn S.] Univ Wisconsin, Neurosci Training Program, Madison, WI 53706 USA; [Turkstra, Lyn S.] Univ Wisconsin, Dept Communicat Disorders & Neurol Surg, Madison, WI USA; [Yeates, Keith O.] Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; [Yeates, Keith O.] Nationwide Childrens Hosp, Res Inst, Ctr Biobehav Hlth, Columbus, OH USA	McCauley, SR (corresponding author), Baylor Coll Med, Cognit Neurosci Lab, Dept Phys Med & Rehabil, 1709 Dryden Rd,Suite 1200,BCM635, Houston, TX 77030 USA.	mccauley@bcm.edu	Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892	National Institutes of Health (National Institute of Neurological Disorders and Stroke; NIH/NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); United States Department of Education/National Institute on Disability and Rehabilitation Research (DOE/NIDRR)	This project was jointly supported by the National Institutes of Health (National Institute of Neurological Disorders and Stroke; NIH/NINDS) and the United States Department of Education/National Institute on Disability and Rehabilitation Research (DOE/NIDRR).	Achenbach T. M., 1991, MANUAL CHILD BEHAV C; Ader DN, 2007, MED CARE, V45, pS1, DOI 10.1097/01.mlr.0000260537.45076.74; Aitken ME, 2009, PEDIATRICS, V123, P199, DOI 10.1542/peds.2008-0607; Alexander AI, 2005, ARCH CLIN NEUROPSYCH, V20, P587, DOI 10.1016/j.acn.2004.12.005; Ali R, 2002, ADDICTION, V97, P1183; Allen DN, 2010, PSYCHOL ASSESSMENT, V22, P57, DOI 10.1037/a0016056; Anderson V, 1998, BRAIN INJURY, V12, P937, DOI 10.1080/026990598121990; Anderson VA, 2002, CHILD NEUROPSYCHOL, V8, P231, DOI 10.1076/chin.8.4.231.13509; Angold A, 1995, INT J METHOD PSYCH, V5, P237; [Anonymous], 2010, PCT patent application, Patent No. [PCT/US2010/046849, 20100486849]; Ayr LK, 2009, J INT NEUROPSYCH SOC, V15, P19, DOI 10.1017/S1355617708090188; Badr LK, 2006, INFANT BEHAV DEV, V29, P80, DOI 10.1016/j.infbeh.2005.08.003; Badr LK, 2009, CLIN NURS RES, V18, P136, DOI 10.1177/1054773809332120; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Barney MC, 2005, BRAIN INJURY, V19, P801, DOI 10.1080/02699050400024961; Baron-Cohen S, 2001, J DEV LEARNING DISOR, V5, P47, DOI DOI 10.1111/J.1467-7687.2008.00720.X; Bauman Johnson WL, 2010, ARCH CLIN NEUROPSYCH, V25, P601, DOI 10.1093/arclin/acq049; Bayley N., 2005, BAYLEY SCALES INFANT, VThird; Bedell G, 2009, DEV NEUROREHABIL, V12, P342, DOI 10.3109/17518420903087277; Bedell GM, 2008, BRAIN INJURY, V22, P313, DOI 10.1080/02699050801978948; Bedell GM, 2004, NEUROREHABILITATION, V19, P191; Bedell GM, 2004, BRAIN INJURY, V18, P65, DOI 10.1080/0269905031000110517; Beebe DW, 2007, J PEDIATR PSYCHOL, V32, P845, DOI 10.1093/jpepsy/jsm003; Beers S., J NEUROTRAU IN PRESS; Beers SR, 2005, J NEUROTRAUM, V22, P1224; Beers SR, 2007, J NEUROTRAUM, V24, P97, DOI 10.1089/neu.2006.0055; Beery K.E, 2010, BEERY BUKTENICA DEV, V6th; Biddle KR, 1996, J COMMUN DISORD, V29, P447, DOI 10.1016/0021-9924(95)00038-0; Birmaher B, 1999, J AM ACAD CHILD PSY, V38, P1230, DOI 10.1097/00004583-199910000-00011; Birmaher B, 1997, J AM ACAD CHILD PSY, V36, P545, DOI 10.1097/00004583-199704000-00018; Bonnier C, 2007, J CHILD NEUROL, V22, P519, DOI 10.1177/0883073807302604; Briggs-Gowan M, 2006, BRIEF INFANT TODDLER; Brookshire B, 2004, DEV NEUROPSYCHOL, V25, P61, DOI 10.1207/s15326942dn2501&2_5; Bruininks R, 2005, BRUININKS OSERETSKY; Burgess ES, 1999, J HEAD TRAUMA REHAB, V14, P394, DOI 10.1097/00001199-199908000-00008; Calvert S, 2008, DEV MED CHILD NEUROL, V50, P426, DOI 10.1111/j.1469-8749.2008.02061.x; Campbell T., 2009, UNDERSTANDING SPEECH; Campbell T., 1999, SEMIN SPEECH LANG, V19, P223; Campbell T., 1994, PHONOLOGICAL SPEECH; CAMPBELL TF, 1990, J SPEECH HEAR DISORD, V55, P567, DOI 10.1044/jshd.5503.567; CAMPBELL TF, 1995, J SPEECH HEAR RES, V38, P864, DOI 10.1044/jshr.3804.864; Campbell TF, 2007, J SPEECH LANG HEAR R, V50, P1110, DOI 10.1044/1092-4388(2007/077); Carlsson M, 2008, DEV MED CHILD NEUROL, V50, P784, DOI 10.1111/j.1469-8749.2008.03090.x; Carrow-Woolfolk E., 1999, COMPREHENSIVE ASSESS; Catroppa C, 2004, BRAIN LANG, V88, P68, DOI 10.1016/S0093-934X(03)00159-7; Catroppa C, 2009, DEV NEUROREHABIL, V12, P361, DOI 10.3109/17518420903087335; CHAPLIN D, 1993, ARCH PHYS MED REHAB, V74, P161; Chapman LA, 2010, REHABIL PSYCHOL, V55, P48, DOI 10.1037/a0018418; Chapman S.B., 2012, ADOLESCENT BRAIN LEA; Chapman S. B., 1997, AM J SPEECH-LANG PAT, V6, P66; Chapman S.B., 2009, [No title captured], Patent No. [61/237,525, 61237525]; Chapman SB, 1998, BRAIN LANG, V61, P420, DOI 10.1006/brln.1997.1885; Chapman SB, 2006, BRAIN LANG, V97, P178, DOI 10.1016/j.bandl.2005.10.002; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; Chapman SB, 2004, DEV NEUROPSYCHOL, V25, P37, DOI 10.1207/s15326942dn2501&2_4; Chen CC, 2005, AM J PHYS MED REHAB, V84, P671, DOI 10.1097/01.phm.0000176439.32318.36; Chevignard MP, 2009, DEV NEUROREHABIL, V12, P76, DOI 10.1080/17518420902777019; Clover A., 2006, BMC PUBLIC HEALTH, V6, P105; Coelho Carl, 2005, Seminars in Speech and Language, V26, P223, DOI 10.1055/s-2005-922102; Conklin HM, 2008, BRAIN INJURY, V22, P847, DOI 10.1080/02699050802403565; Connelly J, 2007, KEYMATH 3 DIAGNOSTIC; Conners CK, 2004, CONTINUOUS PERFORMAN; COPLAN J, 1988, PEDIATRICS, V82, P447; COSTELLO EJ, 1988, J AM ACAD CHILD PSY, V27, P726, DOI 10.1097/00004583-198811000-00011; COSTER WJ, 1994, AM J OCCUP THER, V48, P211, DOI 10.5014/ajot.48.3.211; Curran A., 2003, ARCH DIS CHILD S, V88, pA24; Delis D, 1994, CALIFORNIA VERBAL LE; Delis D.C., 2001, DELIS KAPLAN EXECUTI; DENNIS M, 1994, BRAIN LANG, V46, P129, DOI 10.1006/brln.1994.1008; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; Dickey WC, 2004, J AM ACAD CHILD PSY, V43, P1159, DOI 10.1097/01.chi.0000132808.36708.a9; Donders J, 2004, ASSESSMENT, V11, P275, DOI 10.1177/1073191104268914; Donders J, 2004, J INT NEUROPSYCH SOC, V10, P482, DOI 10.1017/S1355617704104025; Donders J, 1997, ASSESSMENT, V4, P107, DOI 10.1177/107319119700400114; Donders J, 2002, NEUROPSYCHOLOGY, V16, P491, DOI 10.1037//0894-4105.16.4.491; Donders J, 2008, J INT NEUROPSYCH SOC, V14, P651, DOI 10.1017/S1355617708080752; Donders J, 2010, J NEUROPSYCHOL, V4, P197, DOI 10.1348/174866409X478970; Dumas H M, 2001, Pediatr Rehabil, V4, P177, DOI 10.1080/13638490210121720; Dumas Helene M., 2001, Physical and Occupational Therapy in Pediatrics, V21, P7; Dumas HM, 2004, PHYS THER, V84, P232, DOI 10.1093/ptj/84.3.232; Dunn, 1986, TEST VOCABULARIO IM; Dunn L., 2007, PEABODY PICTURE VOCA, V4th ed.; Elliott S.N., 1988, J PSYCHOEDUC ASSESS, V6, P152, DOI [DOI 10.1177/073428298800600206, 10.1177/073428298800600206]; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; Erickson SJ, 2010, DEV NEUROREHABIL, V13, P175, DOI 10.3109/17518420903479867; ERIKSEN BA, 1974, PERCEPT PSYCHOPHYS, V16, P143, DOI 10.3758/BF03203267; Espy K., 2004, CLIN NEUROPSYCHOL, V18, P1; Espy KA, 1997, DEV NEUROPSYCHOL, V13, P495, DOI 10.1080/87565649709540690; Ewing-Cobbs L, 1998, BRAIN LANG, V61, P395, DOI 10.1006/brln.1997.1884; Ewing-Cobbs L, 2006, AM J NEURORADIOL, V27, P879; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Ewing-Cobbs L, 1999, PEDIATR NEUROSURG, V31, P251, DOI 10.1159/000028872; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Ewing-Cobbs Linda, 2002, Semin Pediatr Neurol, V9, P209, DOI 10.1053/spen.2002.35502; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; Farmer JE, 1999, DEV NEUROPSYCHOL, V15, P269, DOI 10.1080/87565649909540749; Fay TB, 2010, J INT NEUROPSYCH SOC, V16, P94, DOI 10.1017/S1355617709991007; Fay TB, 2009, NEUROPSYCHOLOGY, V23, P271, DOI 10.1037/a0014936; Flanagan DP, 2004, ESSENTIALS WISC 4 AS; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Folio M., 2000, PEABODY DEV MOTOR SC; Foster SL., 1989, NEGOTIATING PARENT A; Fragala MA, 2002, BRAIN INJURY, V16, P149, DOI 10.1080/02699050110103328; Gagnon I, 2004, J HEAD TRAUMA REHAB, V19, P391, DOI 10.1097/00001199-200409000-00004; Gagnon I, 2004, ARCH PHYS MED REHAB, V85, P444, DOI 10.1016/j.apmr.2003.06.014; Gagnon I, 1998, BRAIN INJURY, V12, P843, DOI 10.1080/026990598122070; Galvin J, 2010, AUST OCCUP THER J, V57, P118, DOI 10.1111/j.1440-1630.2009.00822.x; Gamino JF, 2010, FRONT PSYCHOL, V1, DOI 10.3389/fpsyg.2010.00188; Gamino JF, 2009, TOP LANG DISORD, V29, P224, DOI 10.1097/TLD.0b013e3181b531da; Gannotti Mary E., 2001, Physical and Occupational Therapy in Pediatrics, V20, P7; Gannotti ME, 2001, PHYS THER, V81, P1512; Gerring JP, 1996, PSYCHIAT RES, V63, P205, DOI 10.1016/0165-1781(96)02841-7; Gerson AC, 1996, PSYCHIAT RES, V65, P189, DOI 10.1016/S0165-1781(96)02851-X; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; Gioia G.A., 2003, BEHAV RATING INVENTO; Gioia G. A., 2000, BRIEF BEHAV RATING I; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P121, DOI 10.1076/chin.8.2.121.8727; Gioia GA, 2010, J HEAD TRAUMA REHAB, V25, P433, DOI 10.1097/HTR.0b013e3181fbc272; Goldman R., 2000, GOLDMAN FRISTOE TEST; Goodman AM, 1999, CLIN NEUROPSYCHOL, V13, P274, DOI 10.1076/clin.13.3.274.1748; Goodman R, 2001, J AM ACAD CHILD PSY, V40, P1337, DOI 10.1097/00004583-200111000-00015; Goodman R, 1999, J ABNORM CHILD PSYCH, V27, P17, DOI 10.1023/A:1022658222914; Goodman R, 2000, BRIT J PSYCHIAT, V177, P534, DOI 10.1192/bjp.177.6.534; Goodman R., 1997, J CHILD PSYCHOL PSYC, V43, P1159; Gragert M., 2010, POSTTRAUMATIC STRESS; Granger CV, 1998, ARCH PHYS MED REHAB, V79, P235, DOI 10.1016/S0003-9993(98)90000-4; Guy S. C., 2004, BRIEF SR BEHAV RATIN; Hajek CA, 2011, CHILD NEUROPSYCHOL, V17, P17, DOI 10.1080/09297049.2010.495058; Hale WW, 2005, J AM ACAD CHILD PSY, V44, P283, DOI 10.1097/00004583-200503000-00013; Haley S.M., 1992, PEDIAT EVALUATION DI; Haley SM, 2003, DEV MED CHILD NEUROL, V45, P671, DOI 10.1017/S0012162203001257; Hallett T L, 1997, Pediatr Rehabil, V1, P219; Hanten G, 2008, NEUROPSYCHOLOGY, V22, P357, DOI 10.1037/0894-4105.22.3.357; Hanten G, 2009, TOP LANG DISORD, V29, P236, DOI 10.1097/TLD.0b013e3181b531f0; Harrison P., 2003, ADAPTIVE BEHAV ASSES; Harrison PL, 2000, ADAPTIVE BEHAV ASSES; Hawley CA, 2004, BRAIN INJURY, V18, P645, DOI 10.1080/02699050310001646189; Hayden D, 1999, VERBAL MOTOR ASSESSM; Hoffman N, 2000, ARCH CLIN NEUROPSYCH, V15, P47, DOI 10.1016/S0887-6177(98)00156-5; Hotz G, 2010, PEDIAT TEST BRAIN IN; Humeniuk R, 2008, EFFECTIVENESS BRIEF; Isaki E, 2000, BRAIN INJURY, V14, P441; Isquith P, 2010, TASKS EXECUTIVE CONT; Ivnik RJ, 1992, CLIN NEUROPSYCHOL, V6, P83; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Johnson H, 2005, DEV MED CHILD NEUROL, V47, P237, DOI 10.1017/S0012162205000460; Josie KL, 2008, J HEAD TRAUMA REHAB, V23, P357, DOI 10.1097/01.HTR.0000341431.29133.a8; Karunanayaka PR, 2007, NEUROREHABILITATION, V22, P355; Kaufman J, 1997, J AM ACAD CHILD PSY, V36, P980, DOI 10.1097/00004583-199707000-00021; KAY SR, 1988, J NERV MENT DIS, V176, P539, DOI 10.1097/00005053-198809000-00007; Keenan HT, 2007, PEDIATRICS, V119, pE616, DOI 10.1542/peds.2006-2313; Klasen H, 2000, EUR CHILD ADOLES PSY, V9, P271, DOI 10.1007/s007870070030; Koskelainen M, 2000, EUR CHILD ADOLES PSY, V9, P277, DOI 10.1007/s007870070031; Kothari DH, 2003, PHYS THER, V83, P776, DOI 10.1093/ptj/83.9.776; Kuhtz-Buschbeck JP, 2003, DEV MED CHILD NEUROL, V45, P821, DOI 10.1017/S001216220300152X; Landry SH, 2004, DEV NEUROPSYCHOL, V26, P707, DOI 10.1207/s15326942dn2603_4; Law M, 2007, ARCH PHYS MED REHAB, V88, P1636, DOI 10.1016/j.apmr.2007.07.035; Levin HS, 2004, J CLIN EXP NEUROPSYC, V26, P589, DOI 10.1080/13803390490504434; Levin HS, 2001, NEUROPSYCHOLOGIA, V39, P122, DOI 10.1016/S0028-3932(00)00111-1; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Linder-Lucht M, 2007, PEDIATRICS, V120, P880, DOI 10.1542/peds.2006-2258; Lowther JL, 2004, ARCH CLIN NEUROPSYCH, V19, P105, DOI 10.1016/S0887-6177(02)00222-6; Macdonald S, 2005, BRAIN INJURY, V19, P895, DOI 10.1080/02699050400004294; MacDonald S., FUNCTIONAL IN PRESS; MacDonald S, 1998, FUNCTIONAL ASSESSMEN; MacWhinney B., 2000, CHILDES PROJECT TOOL CHILDES PROJECT TOOL CHILDES PROJECT TOOL CHILDES PROJECT TOOL CHILDES PROJECT CHILDES PROJECT TOOL CHILDES PROJECT TOOL CHILDES PROJECT TOOL CHILDES PROJECT TOOL; Maillard-Wermelinger A, 2009, DEV NEUROREHABIL, V12, P330, DOI 10.3109/17518420903087251; Malec JF, 2003, J HEAD TRAUMA REHAB, V18, P479, DOI 10.1097/00001199-200311000-00002; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; Manly T., 1999, TEA CH TEST EVERYDAY; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; MATHEWS CG, 1964, INSTRUCTION MANUAL A; Max JE, 1998, ARCH PHYS MED REHAB, V79, P893, DOI 10.1016/S0003-9993(98)90084-3; McCarthy ML, 2006, ARCH PEDIAT ADOL MED, V160, P252, DOI 10.1001/archpedi.160.3.252; McCarthy ML, 2005, ARCH PHYS MED REHAB, V86, P1901, DOI 10.1016/j.apmr.2005.03.026; Merkley TL, 2008, J NEUROTRAUM, V25, P1343, DOI 10.1089/neu.2008.0615; Miller A., 2011, J NEUROTRAU IN PRESS; Miller DM, 2005, QUAL LIFE RES, V14, P2031; Miller J., 2004, SALT GUIDE; Mitrushina M., 2005, HDB NORMATIVE DATA N; Monga S, 2000, DEPRESS ANXIETY, V12, P85, DOI 10.1002/1520-6394(2000)12:2<85::AID-DA4>3.0.CO;2-2; Moon R., J NEUROTRAU IN PRESS, V27, P1827; Moran L., J HEAD TRAU IN PRESS; Mottram L, 2005, PSYCHOL ASSESSMENT, V17, P212, DOI 10.1037/1040-3590.17.2.212; Mottram L, 2006, DEV NEUROPSYCHOL, V30, P865, DOI 10.1207/s15326942dn3003_6; MSALL ME, 1994, CLIN PEDIATR, V33, P431, DOI 10.1177/000992289403300709; Mullen E. M., 1995, MULLEN SCALES EARLY; Muscara F, 2008, DEV NEUROPSYCHOL, V33, P623, DOI 10.1080/87565640802171162; Muscara F, 2009, NEUROPSYCHOL REHABIL, V19, P541, DOI 10.1080/09602010802365223; Muscara F, 2008, J NEUROPSYCHOL, V2, P445, DOI 10.1348/174866407X250820; Nadebaum C, 2007, DEV NEUROPSYCHOL, V32, P703, DOI 10.1080/87565640701376086; Nichols D.S., 1996, PEDIATR PHYS THER, V8, DOI [https://doi.org/10.1097/00001577-199600810-00004, DOI 10.1097/00001577-199600810-00004]; Nosarti C, 2007, J INT NEUROPSYCH SOC, V13, P571, DOI 10.1017/S1355617707070725; Oddson B, 2006, DEV MED CHILD NEUROL, V48, P918, DOI 10.1017/S0012162206002003; Olsson GM, 2008, NORD J PSYCHIAT, V62, P66, DOI 10.1080/08039480801979586; Ottenbacher KJ, 1996, DEV MED CHILD NEUROL, V38, P907; Ottenbacher KJ, 1997, ARCH PHYS MED REHAB, V78, P1309, DOI 10.1016/S0003-9993(97)90302-6; Ottenbacher KJ, 2000, ARCH PHYS MED REHAB, V81, P1317, DOI 10.1053/apmr.2000.9387; Perez Lori, 2007, J Neurosci Nurs, V39, P342; Power T, 2007, BRAIN INJURY, V21, P279, DOI 10.1080/02699050701253095; Prasad MR, 1999, J CHILD NEUROL, V14, P496, DOI 10.1177/088307389901400803; Prasad MR, 2002, PEDIATR NEUROSURG, V36, P64, DOI 10.1159/000048355; Prifitera A., 2005, WISC 4 CLIN USE INTE; Prigatano GP, 2008, CLIN NEUROPSYCHOL, V22, P603, DOI 10.1080/13854040701440501; Prigatano GP, 2008, BRAIN INJURY, V22, P491, DOI 10.1080/02699050802084902; PRINZ RJ, 1979, J APPL BEHAV ANAL, V12, P691, DOI 10.1901/jaba.1979.12-691; Ramsay MC, 1995, NEUROPSYCHOL REV, V5, P151, DOI 10.1007/BF02214760; Reitan R.M., 1992, NEUROPSYCHOLOGICAL E; Reynolds C. R., 2007, TEST MEMORY LEARNING; Reynolds CR, 1996, ARCH CLIN NEUROPSYCH, V11, P29, DOI 10.1016/0887-6177(95)00027-5; Rice SA, 2005, ARCH PHYS MED REHAB, V86, P834, DOI 10.1016/j.apmr.2004.11.006; Roman MJ, 1998, J CLIN EXP NEUROPSYC, V20, P245, DOI 10.1076/jcen.20.2.245.1168; Rosselli M, 2001, DEV NEUROPSYCHOL, V20, P355, DOI 10.1207/S15326942DN2001_3; RUSSELL DJ, 1989, DEV MED CHILD NEUROL, V31, P341; Russell DJ, 2000, PHYS THER, V80, P873, DOI 10.1093/ptj/80.9.873; Rust J. O., 2004, J PSYCHOEDUCATIONAL, V22, P367; Salorio CF, 2005, J INT NEUROPSYCH SOC, V11, P686, DOI 10.1017/S1355617705050885; Sattler J. M., 2004, ASSESSMENT CHILDREN; Schmidt M., 1996, REY AUDITORY VERBAL; Schrank F., 2005, BATERI 3 WOODCOCK MU; Secord, 1989, TEST LANGUAGE COMPET; Semel W, 2003, CLIN EVALUATION LANG; Sesma HW, 2008, PEDIATRICS, V121, pE1686, DOI 10.1542/peds.2007-2461; Sheslow D., 2003, WIDE RANGE ASSESSMEN, V2nd; Shriberg LD, 1997, J SPEECH LANG HEAR R, V40, P708, DOI 10.1044/jslhr.4004.708; Slomine BS, 2006, PEDIATRICS, V117, pE663, DOI 10.1542/peds.2005-1892; Sparrow S, 2005, VINELAND ADAPTIVE BE; Sparrow S., 1984, VINELAND ADAPTIVE BE; Sroufe NS, 2010, PEDIATRICS, V125, pE1331, DOI 10.1542/peds.2008-2364; Steinberg Alan M, 2004, Curr Psychiatry Rep, V6, P96, DOI 10.1007/s11920-004-0048-2; Stronach ST, 2008, APHASIOLOGY, V22, P1054, DOI 10.1080/02687030701632187; Strong CAH, 2011, J INT NEUROPSYCH SOC, V17, P230, DOI 10.1017/S1355617710001451; Su LY, 2008, J ANXIETY DISORD, V22, P612, DOI 10.1016/j.janxdis.2007.05.011; Swaine BR, 2000, AM J PHYS MED REHAB, V79, P412, DOI 10.1097/00002060-200009000-00002; Taylor GH, 1992, ADV CLIN NEUROPSYCHO, V1, P50; Taylor HG, 2008, J INT NEUROPSYCH SOC, V14, P734, DOI 10.1017/S1355617708081150; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Taylor HG, 2001, J INT NEUROPSYCH SOC, V7, P755, DOI 10.1017/S1355617701766118; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Thomas-Stonell N, 2006, Pediatr Rehabil, V9, P14, DOI 10.1080/13638490500050097; Thurmond VA, 2010, ARCH PHYS MED REHAB, V91, P1633, DOI 10.1016/j.apmr.2010.06.034; Tokcan Gul, 2003, Pediatr Phys Ther, V15, P16, DOI 10.1097/01.PEP.0000050765.71924.6C; Tonks J, 2008, BRAIN INJURY, V22, P325, DOI 10.1080/02699050801968303; Tonks J, 2007, BRAIN INJURY, V21, P731, DOI 10.1080/02699050701426899; Torgesen JK, 2009, TEST WORD READING EF; TOWNE RL, 1993, LANG SPEECH HEAR SER, V24, P100; Tremont G, 1999, CHILD NEUROPSYCHOL, V5, P104, DOI 10.1076/chin.5.2.104.3166; Turkstra LS, 2001, J HEAD TRAUMA REHAB, V16, P469, DOI 10.1097/00001199-200110000-00006; Turkstra LS, 2008, BRAIN INJURY, V22, P397, DOI 10.1080/02699050802027059; Turkstra LS, 2008, NEUROREHABILITATION, V23, P501; van de Looij-Jansen PM, 2011, BRIT J CLIN PSYCHOL, V50, P127, DOI 10.1348/014466510X498174; van Widenfelt BM, 2003, EUR CHILD ADOLES PSY, V12, P281, DOI 10.1007/s00787-003-0341-3; Varni JW, 2003, AMBUL PEDIATR, V3, P329, DOI 10.1367/1539-4409(2003)003<0329:TPAAPP>2.0.CO;2; Varni JW, 2001, MED CARE, V39, P800, DOI 10.1097/00005650-200108000-00006; Varni JW, 1999, MED CARE, V37, P126, DOI 10.1097/00005650-199902000-00003; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; Wade SL, 2006, J CONSULT CLIN PSYCH, V74, P445, DOI 10.1037/0022-006X.74.3.445; Wade SL, 2008, J HEAD TRAUMA REHAB, V23, P369, DOI 10.1097/01.HTR.0000341432.67251.48; Wade SL, 2004, J CONSULT CLIN PSYCH, V72, P776, DOI 10.1037/0022-006X.72.5.776; Wade SL, 2003, J HEAD TRAUMA REHAB, V18, P164, DOI 10.1097/00001199-200303000-00007; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; Wagner RK., 1999, COMPREHENSIVE TEST P; Wallen MA, 2001, ARCH PHYS MED REHAB, V82, P642, DOI 10.1053/apmr.2001.22620; Walz NC, 2008, J NEUROTRAUM, V25, P94, DOI 10.1089/neu.2007.0362; Warschausky S, 2005, NEUROPSYCHOLOGY, V19, P193, DOI 10.1037/0894-4105.19.2.193; Wechsler, 2002, WECHSLER PRESCHOOL P; Wechsler D., 2004, WISC 4 SPANISH TECHN; Wechsler D, 2003, WISC 4 TECHNICAL INT; Wechsler D, 2003, WISC 4 ADM MANUAL; Wechsler D., 1999, WESCHLER ABBREVIATED; Weitkamp Katharina, 2010, Child Adolesc Psychiatry Ment Health, V4, P19, DOI 10.1186/1753-2000-4-19; Wells R, 2009, DEV NEUROREHABIL, V12, P12, DOI 10.1080/17518420902773109; Whiteneck GG, 2004, ARCH PHYS MED REHAB, V85, P1324, DOI 10.1016/j.apmr.2003.09.027; Wiederholt JL, 2001, GRAY ORAL READING TE; Wiig E. H, 2005, CLIN EVALUATION LANG; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; WILLIAMS J, 1995, DEV NEUROPSYCHOL, V11, P201, DOI 10.1080/87565649509540613; Wilson BM, 2002, BRAIN INJURY, V16, P1011, DOI 10.1080/02699050210147248; Woodcock R. W., 2001, WOODCOCK JOHNSON TES; Woodcock R.W., 1989, WOODCOCK JOHNSON TES; Woodward H, 1998, APPL NEUROPSYCHOL, V5, P113, DOI 10.1207/s15324826an0503_1; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Wren TAL, 2008, J PEDIATR ORTHOPED, V28, P199, DOI 10.1097/BPO.0b013e318165216d; Yeates K., 2005, WISC 4 CLIN USE INTE; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; Yeates KO, 2010, NEUROPSYCHOLOGY, V24, P345, DOI 10.1037/a0018387; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Yeates KO, 1997, J CLIN EXP NEUROPSYC, V19, P825, DOI 10.1080/01688639708403763; YEATES KO, 1991, MERRILL PALMER QUART, V37, P369; YEATES KO, 1990, CLIN PSYCHOL REV, V10, P567, DOI 10.1016/0272-7358(90)90097-T; Youse KM, 2005, BRAIN INJURY, V19, P1001, DOI 10.1080/02699050500109951; YUDOFSKY SC, 1986, AM J PSYCHIAT, V143, P35; Ziviani J, 2010, BRAIN IMPAIR, V11, P93, DOI 10.1375/brim.11.2.93; Ziviani Jenny, 2001, Physical and Occupational Therapy in Pediatrics, V21, P91, DOI 10.1080/J006v21n02_08	298	182	182	3	41	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2012	29	4					678	705		10.1089/neu.2011.1838			28	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	901SQ	WOS:000300987500007	21644810	Green Published			2021-06-18	
J	Hartings, JA; Bullock, MR; Okonkwo, DO; Murray, LS; Murray, GD; Fabricius, M; Maas, AIR; Woitzik, J; Sakowitz, O; Mathern, B; Roozenbeek, B; Lingsma, H; Dreier, JP; Puccio, AM; Shutter, LA; Pahl, C; Strong, AJ				Hartings, Jed A.; Bullock, M. Ross; Okonkwo, David O.; Murray, Lilian S.; Murray, Gordon D.; Fabricius, Martin; Maas, Andrew I. R.; Woitzik, Johannes; Sakowitz, Oliver; Mathern, Bruce; Roozenbeek, Bob; Lingsma, Hester; Dreier, Jens P.; Puccio, Ava M.; Shutter, Lori A.; Pahl, Clemens; Strong, Anthony J.		Co-Operative Study Brain Injury	Spreading depolarisations and outcome after traumatic brain injury: a prospective observational study	LANCET NEUROLOGY			English	Article							RANDOMIZED CONTROLLED-TRIALS; SUBARACHNOID HEMORRHAGE; CEREBRAL-ISCHEMIA; DEPRESSION; CLASSIFICATION; VALIDATION; MODERATE; DESIGN; STROKE	Background Pathological waves of spreading mass neuronal depolarisation arise repeatedly in injured, but potentially salvageable, grey matter in 50-60% of patients after traumatic brain injury (TBI). We aimed to ascertain whether spreading depolarisations are independently associated with unfavourable neurological outcome. Methods We did a prospective, observational, multicentre study at seven neurological centres. We enrolled 109 adults who needed neurosurgery for acute TBI. Spreading depolarisations were monitored by electrocorticography during intensive care and were classified as cortical spreading depression (CSD) if they took place in spontaneously active cortex or as isoelectric spreading depolarisation (ISD) if they took place in isoelectric cortex. Investigators who treated patients and assessed outcome were masked to electrocorticographic results. Scores on the extended Glasgow outcome scale at 6 months were fitted to a multivariate model by ordinal regression. Prognostic score (based on variables at admission, as validated by the IMPACT studies) and spreading depolarisation category (none, CSD only, or at least one ISD) were assessed as outcome predictors. Findings Six individuals were excluded because of poor-quality electrocorticography. A total of 1328 spreading depolarisations arose in 58 (56%) patients. In 38 participants, all spreading depolarisations were classified as CSD; 20 patients had at least one ISD. By multivariate analysis, both prognostic score (p=0.0009) and spreading depolarisation category (p=0.0008) were significant predictors of neurological outcome. CSD and ISD were associated with an increased risk of unfavourable outcome (common odds ratios 1.56 [95% CI 0.72-3.37] and 7.58 [2.64-21.8], respectively). Addition of depolarisation category to the regression model increased the proportion of variance in outcome that could be attributed to predictors from 9% to 22%, compared with the prognostic score alone. Interpretation Spreading depolarisations were associated with unfavourable outcome, after controlling for conventional prognostic variables. The possibility that spreading depolarisations have adverse effects on the traumatically injured brain, and therefore might be a target in the treatment of TBI, deserves further research.	[Hartings, Jed A.; Shutter, Lori A.] Univ Cincinnati, Dept Neurosurg, Inst Neurosci, UC Coll Med, Cincinnati, OH 45219 USA; [Bullock, M. Ross] Univ Miami, Dept Neurol Surg, Miami, FL USA; [Okonkwo, David O.; Puccio, Ava M.] Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA USA; [Murray, Lilian S.] Univ Glasgow, Sch Med, Glasgow, Lanark, Scotland; [Murray, Gordon D.] Univ Edinburgh, Sch Med, Ctr Populat Hlth Sci, Edinburgh, Midlothian, Scotland; [Fabricius, Martin] Glostrup Cty Hosp, Dept Clin Neurophysiol, Copenhagen, Denmark; [Maas, Andrew I. R.; Roozenbeek, Bob] Univ Antwerp Hosp, Dept Neurosurg, Edegem, Belgium; [Woitzik, Johannes] Charite, Dept Neurosurg, D-13353 Berlin, Germany; [Woitzik, Johannes; Dreier, Jens P.] Charite, Ctr Stroke Res, D-13353 Berlin, Germany; [Sakowitz, Oliver] Univ Heidelberg Hosp, Dept Neurosurg, Heidelberg, Germany; [Mathern, Bruce] Virginia Commonwealth Univ, Div Neurosurg, Richmond, VA USA; [Roozenbeek, Bob; Lingsma, Hester] Erasmus MC, Ctr Med Decis Making, Dept Publ Hlth, Rotterdam, Netherlands; [Pahl, Clemens] Kings Coll London, Dept Crit Care Med, London WC2R 2LS, England; [Strong, Anthony J.] Kings Coll London, Dept Clin Neurosci, London WC2R 2LS, England	Hartings, JA (corresponding author), Univ Cincinnati, Dept Neurosurg, Inst Neurosci, UC Coll Med, 260 Stetson St,Suite 2200, Cincinnati, OH 45219 USA.	jed.hartings@uc.edu	Maas, Andrew IR/C-5584-2013; Shutter, Lori A/G-2957-2013	Maas, Andrew IR/0000-0003-1612-1264; Shutter, Lori/0000-0002-1390-0628; Hartings, Jed/0000-0001-8583-3471; Dreier, Jens/0000-0001-7459-2828; Murray, Gordon/0000-0001-9866-4734	US Army CDMRP PH/TBI [W81XWH-08-2-0016]; Deutsche Forschungsgemeinschaft (DFG)German Research Foundation (DFG) [DR 323/3-1, 323/5-1]; Bundesministerium fur Bildung und ForschungFederal Ministry of Education & Research (BMBF) [CSB 01 EO 0801, BCCN 01GQ1001C B2]; HeadFirst; Kings College Hospital Foundation Trust; ZNS-Hannelore Kohl Stiftung [2004006]; US National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R-01-NS-042691]; Novo Nordisk FoundationNovo Nordisk Foundation; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0800803] Funding Source: researchfish	Funding US Army CDMRP PH/TBI research programme.; This work was funded in part by the US Army CDMRP PH/TBI research programme (contract number W81XWH-08-2-0016). JPD received support from the Deutsche Forschungsgemeinschaft (DFG DR 323/3-1,323/5-1) and Bundesministerium fur Bildung und Forschung (CSB 01 EO 0801, BCCN 01GQ1001C B2); AJS from HeadFirst; CP from Kings College Hospital Foundation Trust's Research and Development Fund; OS from ZNS-Hannelore Kohl Stiftung (2004006); AIRM, HL, and BR from the US National Institutes of Health (R-01-NS-042691); and MF from the Novo Nordisk Foundation. We thank Mary Kemper for editing assistance.	ASTRUP J, 1977, STROKE, V8, P51, DOI 10.1161/01.STR.8.1.51; ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; Back T, 1996, J CEREBR BLOOD F MET, V16, P202, DOI 10.1097/00004647-199603000-00004; Bosche B, 2010, ANN NEUROL, V67, P607, DOI 10.1002/ana.21943; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Busch E, 1996, J CEREBR BLOOD F MET, V16, P1090, DOI 10.1097/00004647-199611000-00002; Dohmen C, 2008, ANN NEUROL, V63, P720, DOI 10.1002/ana.21390; Dreier JP, 2006, BRAIN, V129, P3224, DOI 10.1093/brain/awl297; Dreier JP, 2011, NAT MED, V17, P439, DOI 10.1038/nm.2333; Dreier JP, 2009, BRAIN, V132, P1866, DOI 10.1093/brain/awp102; Fabricius M, 2006, BRAIN, V129, P778, DOI 10.1093/brain/awh716; Hartings JA, 2011, BRAIN, V134, P1529, DOI 10.1093/brain/awr048; Hartings JA, 2009, J NEUROTRAUM, V26, P1857, DOI [10.1089/neu.2009.0961, 10.1089/neu.2009-0961]; Hossmann KA, 1996, CEREBROVAS BRAIN MET, V8, P195; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Lauritzen M, 2011, J CEREBR BLOOD F MET, V31, P17, DOI 10.1038/jcbfm.2010.191; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; MAAS AIR, 2011, J NEUROTRAUM, DOI DOI 10.1089/NEU.2010.1599; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P127, DOI 10.1016/j.nurt.2009.10.020; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; McHugh GS, 2010, CLIN TRIALS, V7, P44, DOI 10.1177/1740774509356580; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Nakamura H, 2010, BRAIN, V133, P1994, DOI 10.1093/brain/awq117; Piilgaard H, 2009, J CEREBR BLOOD F MET, V29, P1517, DOI 10.1038/jcbfm.2009.73; Roozenbeek B, 2009, CRIT CARE MED, V37, P2683, DOI 10.1097/CCM.0b013e3181ab85ec; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Sakowitz OW, 2009, STROKE, V40, pE519, DOI 10.1161/STROKEAHA.109.549303; Somjen GG, 2001, PHYSIOL REV, V81, P1065; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09; Strong AJ, 2007, BRAIN, V130, P995, DOI 10.1093/brain/awl392	34	182	184	0	19	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	DEC	2011	10	12					1058	1064		10.1016/S1474-4422(11)70243-5			7	Clinical Neurology	Neurosciences & Neurology	859SH	WOS:000297895600007	22056157				2021-06-18	
J	Loane, DJ; Pocivavsek, A; Moussa, CEH; Thompson, R; Matsuoka, Y; Faden, AI; Rebeck, GW; Burns, MP				Loane, David J.; Pocivavsek, Ana; Moussa, Charbel E-H; Thompson, Rachel; Matsuoka, Yasuji; Faden, Alan I.; Rebeck, G. William; Burns, Mark P.			Amyloid precursor protein secretases as therapeutic targets for traumatic brain injury	NATURE MEDICINE			English	Article							LONG-TERM ACCUMULATION; ALZHEIMERS-DISEASE; BETA-SECRETASE; HEAD TRAUMA; PRESENILIN-1; MOUSE; EXPRESSION; DEPOSITION; AXONS; INHIBITORS	Amyloid-beta (A beta) peptides, found in Alzheimer's disease brain, accumulate rapidly after traumatic brain injury (TBI) in both humans and animals. Here we show that blocking either beta- or gamma-secretase, enzymes required for production of A beta from amyloid precursor protein (APP), can ameliorate motor and cognitive deficits and reduce cell loss after experimental TBI in mice. Thus, APP secretases are promising targets for treatment of TBI.	[Loane, David J.; Pocivavsek, Ana; Moussa, Charbel E-H; Thompson, Rachel; Faden, Alan I.; Rebeck, G. William; Burns, Mark P.] Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20007 USA; [Matsuoka, Yasuji] Georgetown Univ, Med Ctr, Dept Neurol, Washington, DC 20007 USA	Burns, MP (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20007 USA.	mpb37@georgetown.edu	Pocivavsek, Ana/AAW-8923-2020; Rebeck, George William/J-2192-2012	Rebeck, George William/0000-0001-6276-248X; Burns, Mark P/0000-0003-4750-2000; Pocivavsek, Ana/0000-0002-3817-3201; Loane, David/0000-0003-0393-3503	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R03NS57635, R24HD050845]; Klingel Family Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD050845] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R03NS057635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [K01AG030378] Funding Source: NIH RePORTER	We would like to thank A. Pajoohesh-Ganji and P. Washington for technical assistance; S. Fricke and O. Rodriguez of the Small Animal Imaging Laboratory at Georgetown University; and P. Mathews (Nathan S. Kline Institute) for antibody C1/6.1. This work was funded by grant R03NS57635 (M. P. B.) and a pilot award from the National Capital Area Rehabilitation Research Network R24HD050845 (M. P. B.), both from the US National Institutes of Health, and by the Klingel Family Foundation (M. P. B.).	Abramowski D, 2008, J PHARMACOL EXP THER, V327, P411, DOI 10.1124/jpet.108.140327; Arumugam TV, 2006, NAT MED, V12, P621, DOI 10.1038/nm1403; Blasko I, 2004, J NEURAL TRANSM, V111, P523, DOI 10.1007/s00702-003-0095-6; Brody DL, 2008, SCIENCE, V321, P1221, DOI 10.1126/science.1161591; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Cribbs DH, 1996, NEUROREPORT, V7, P1773, DOI 10.1097/00001756-199607290-00016; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; El Mouedden M, 2006, CURR PHARM DESIGN, V12, P671; Esposito L, 2004, J NEUROCHEM, V91, P1260, DOI 10.1111/j.1471-4159.2004.02816.x; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Iwata A, 2002, J NEUROPATH EXP NEUR, V61, P1056, DOI 10.1093/jnen/61.12.1056; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Matsuoka Y, 2001, AM J PATHOL, V158, P1345, DOI 10.1016/S0002-9440(10)64085-0; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; Nadler Y, 2008, GLIA, V56, P552, DOI 10.1002/glia.20638; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; Rockenstein E, 2005, J BIOL CHEM, V280, P32957, DOI 10.1074/jbc.M507016200; Thornton E, 2006, BRAIN RES, V1094, P38, DOI 10.1016/j.brainres.2006.03.107; Uryu K, 2007, EXP NEUROL, V208, P185, DOI 10.1016/j.expneurol.2007.06.018; VANDUIJN CM, 1992, AM J EPIDEMIOL, V135, P775, DOI 10.1093/oxfordjournals.aje.a116364; Wyss-Coray T, 2002, NEURON, V35, P419, DOI 10.1016/S0896-6273(02)00794-8; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; Zhang XP, 2005, CRIT CARE, V9, P66, DOI 10.1186/cc2950	29	182	188	1	8	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	APR	2009	15	4					377	379		10.1038/nm.1940			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	429RG	WOS:000264937200023	19287391	Green Accepted			2021-06-18	
J	Temkin, NR; D Anderson, G; Winn, HR; Ellenbogen, RG; Britz, GW; Schuster, J; Lucas, T; Newell, DW; Mansfield, PN; Machamer, JE; Barber, J; Dikmen, SS				Temkin, Nancy R.; D Anderson, Gail; Winn, H. Richard; Ellenbogen, Richard G.; Britz, Gavin W.; Schuster, James; Lucas, Timothy; Newell, David W.; Mansfield, Pamela Nelson; Machamer, Joan E.; Barber, Jason; Dikmen, Sureyya S.			Magnesium sulfate for neuroprotection after traumatic brain injury: a randomised controlled trial	LANCET NEUROLOGY			English	Article							ACUTE MYOCARDIAL-INFARCTION; CLOSED-HEAD INJURY; CLINICAL-TRIALS; ACUTE STROKE; RATS; GUIDELINES; THERAPY; SCALE; MGSO4	Background Traumatic brain injuries represent an important and costly health problem. Supplemental magnesium positively affects many of the processes involved in secondary injury after traumatic brain injury and consistently improves outcome in animal models. We aimed to test whether treatment with magnesium favourably affects outcome in head-injured patients. Methods In a double-blind trial, 499 patients aged 14 years or older admitted to a level 1 regional trauma Centre between August, 1998, and October, 2004, with moderate or severe traumatic brain injury were randomly assigned one of two doses of magnesium or placebo within 8 h of injury and continuing for 5 days. Magnesium doses were targeted to achieve serum magnesium ranges of 1.0-1.85 mmol/L or 1.25-2.5 mmol/L. The primary outcome was a composite of mortality, seizures, functional measures, and neuropsychological tests assessed up to 6 months after injury. Analyses were done according to the intention-to-treat principle. This trial is registered with ClinicalTrials.gov, number NCT00004730. Findings Magnesium showed no significant positive effect on the composite primary outcome measure at the higher dose (mean=55 average percentile ranking on magnesium vs 52 on placebo, 95% CI for difference -7 to 14; p=0.70). Those randomly assigned magnesium at the lower dose did significantly worse than those assigned placebo (48 vs 54, 95% CI -10.5 to -2; p=0.007). Furthermore, there was higher mortality with the higher magnesium dose than with placebo. Other major medical complications were similar between groups, except for a slight excess of pulmonary oedema and respiratory failure in the lower magnesium target group. No subgroups were identified in which magnesium had a significantly positive effect. Interpretation Continuous infusions of magnesium for 5 days given to patients within 8 h of moderate or severe traumatic brain injury were not neuroprotective and might even have a negative effect in the treatment of significant head injury.	Univ Washington, Harborview Med Ctr, Dept Neurol Surg, Seattle, WA 98104 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Dept Pharm, Seattle, WA 98195 USA; CUNY Mt Sinai Sch Med, Dept Neurosurg & Neurosci, New York, NY 10029 USA; Univ Penn, Sch Med, Dept Neurol Surg, Philadelphia, PA 19104 USA; Swedish Med Ctr, Seattle Neurosci Inst, Seattle, WA USA	Temkin, NR (corresponding author), Univ Washington, Harborview Med Ctr, Dept Neurol Surg, Box 359924,325 9th Ave, Seattle, WA 98104 USA.	temkin@u.washington.edu		Britz, Gavin/0000-0002-2358-3005	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019643] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS19643] Funding Source: Medline		Bareyre FM, 2000, J NEUROTRAUM, V17, P1029, DOI 10.1089/neu.2000.17.1029; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Browne KD, 2004, J NEUROSCI RES, V77, P878, DOI 10.1002/jnr.20215; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; COLLINS R, 1995, LANCET, V345, P669; COX DR, 1972, J R STAT SOC B, V34, P187; Dikmen S, 2001, J NEUROTRAUM, V18, P127, DOI 10.1089/08977150150502578; GENNARELLI T, 1997, R49CCR303687 CDCP; HALLAK M, 1992, AM J OBSTET GYNECOL, V167, P1605, DOI 10.1016/0002-9378(92)91749-Z; Heath DL, 1998, J NEUROTRAUM, V15, P183, DOI 10.1089/neu.1998.15.183; Heath DL, 1999, J PHARMACOL EXP THER, V288, P1311; Heath DL, 1999, J NEUROSURG, V90, P504, DOI 10.3171/jns.1999.90.3.0504; Heath DL, 1999, MAGNESIUM RES, V12, P269; Lees KR, 2004, LANCET, V363, P439; Lehmann E.L., 1975, NONPARAMETRICS STAT; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; McKee JA, 2005, CRIT CARE MED, V33, P661, DOI 10.1097/01.ccm.0000156293.35868.b2; Memon ZI, 1995, SCAND J CLIN LAB INV, V55, P671, DOI 10.3109/00365519509075397; MUIR KW, 1995, STROKE, V26, P1183, DOI 10.1161/01.STR.26.7.1183; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; OBRIEN PC, 1984, BIOMETRICS, V40, P1079, DOI 10.2307/2531158; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Psychological Corporation, 1999, WASI MAN; Reitan R.M., 1993, HALSTEADREITAN NEURO; Saatman KE, 2001, J NEUROPATH EXP NEUR, V60, P183, DOI 10.1093/jnen/60.2.183; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; TEASDALE G, 1974, LANCET, V2, P81; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Wechsler D., 1997, WAIS 3 ADM SCORING M; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Witkop B, 1999, P AM PHILOS SOC, V143, P540; WOLF G, 1991, NEUROSCIENCE, V43, P31, DOI 10.1016/0306-4522(91)90413-I; WOODS KL, 1992, LANCET, V339, P1553, DOI 10.1016/0140-6736(92)91828-V	35	182	194	0	18	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1474-4422			LANCET NEUROL	Lancet Neurol.	JAN	2007	6	1					29	38		10.1016/S1474-4422(06)70630-5			10	Clinical Neurology	Neurosciences & Neurology	119UI	WOS:000243039000016	17166799				2021-06-18	
J	Wu, SF; Suzuki, Y; Ejiri, Y; Noda, T; Bai, HL; Kitada, M; Kataoka, K; Ohta, M; Chou, H; Ide, C				Wu, SF; Suzuki, Y; Ejiri, Y; Noda, T; Bai, HL; Kitada, M; Kataoka, K; Ohta, M; Chou, H; Ide, C			Bone marrow stromal cells enhance differentiation of cocultured neurosphere cells and promote regeneration of injured spinal	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						bone marrow; stromal cell; spinal cord injury; coculture; neurosphere	TRAUMATIC BRAIN INJURY; CENTRAL-NERVOUS-SYSTEM; IN-VITRO; CORD INJURY; CEREBROSPINAL-FLUID; NEURAL CELLS; STEM-CELLS; ADULT RATS; TRANSPLANTATION; MACROPHAGES	Transplantation of bone marrow stromal cells (MSCs) has been regarded as a potential approach for promoting nerve regeneration. In the present study, we investigated the influence of MSCs on spinal cord neurosphere cells in vitro and on the regeneration of injured spinal cord in vivo by grafting. MSCs from adult rats were cocultured with fetal spinal cord-derived neurosphere cells by either cell mixing or making monolayered-feeder cultures. In the mixed cell cultures, neuroshpere cells were stimulated to develop extensive processes. In the monolayered-feeder cultures, numerous processes from neurosphere cells appeared to be attracted to MSCs. In an in vivo experiment, grafted MSCs promoted the regeneration of injured spinal cord by enhancing tissue repair of the lesion, leaving apparently smaller cavities than in controls. Although the number of grafted MSCs gradually decreased, some treated animals showed remarkable functional recovery. These results suggest that MSCs might have profound effects on the differentiation of neurosphere cells and be able to promote regeneration of the spinal cord by means of grafting. (C) 2003 Wiley-Liss, Inc.	Kyoto Univ, Grad Sch Med, Dept Plast & Reconstruct Surg, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Dept Anat & Neurobiol, Sakyo Ku, Kyoto, Japan	Suzuki, Y (corresponding author), Kyoto Univ, Grad Sch Med, Dept Plast & Reconstruct Surg, Sakyo Ku, Kyoto 6068507, Japan.		Kitada, Masaaki/I-1591-2017	Kitada, Masaaki/0000-0002-4103-9767	Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [15390342] Funding Source: KAKEN		Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; BEUCHE W, 1984, J NEUROCYTOL, V13, P767, DOI 10.1007/BF01148493; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Chen JL, 2000, NEUROPHARMACOLOGY, V39, P711, DOI 10.1016/S0028-3908(00)00006-X; CONSTANTINI S, 1994, J NEUROSURG, V80, P97, DOI 10.3171/jns.1994.80.1.0097; Deng WW, 2001, BIOCHEM BIOPH RES CO, V282, P148, DOI 10.1006/bbrc.2001.4570; Dezawa M, 2001, EUR J NEUROSCI, V14, P1771, DOI 10.1046/j.0953-816x.2001.01814.x; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Fitch MT, 1999, J NEUROSCI, V19, P8182; Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299; Ito T, 2001, EXP NEPHROL, V9, P444; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Kawasaki H, 2000, NEURON, V28, P31, DOI 10.1016/S0896-6273(00)00083-0; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; LazarovSpiegler O, 1996, FASEB J, V10, P1296; Li Y, 2001, NEUROLOGY, V56, P1666, DOI 10.1212/WNL.56.12.1666; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu DY, 2001, J NEUROTRAUM, V18, P813, DOI 10.1089/089771501316919175; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mahmood A, 2001, J NEUROSURG, V94, P589, DOI 10.3171/jns.2001.94.4.0589; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; Nakano K, 2001, TRANSPLANTATION, V71, P1735, DOI 10.1097/00007890-200106270-00006; Norflus F, 1998, J CLIN INVEST, V101, P1881, DOI 10.1172/JCI2127; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Ousman SS, 2000, GLIA, V30, P92, DOI 10.1002/(SICI)1098-1136(200003)30:1<92::AID-GLIA10>3.0.CO;2-W; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; Phinney DG, 1999, J CELL BIOCHEM, V72, P570; Popovich PG, 1999, EXP NEUROL, V158, P351, DOI 10.1006/exnr.1999.7118; Priller J, 2001, NAT MED, V7, P1356, DOI 10.1038/nm1201-1356; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; Sasaki M, 2001, GLIA, V35, P26, DOI 10.1002/glia.1067; West NR, 2001, NEUROPATHOLOGY, V21, P188, DOI 10.1046/j.1440-1789.2001.00398.x; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; Wu SF, 2002, NEUROSCI LETT, V318, P81, DOI 10.1016/S0304-3940(01)02488-0; Wu SF, 2002, J NEUROSCI RES, V69, P940, DOI 10.1002/jnr.10346; Wu SF, 2001, NEUROSCI LETT, V312, P173, DOI 10.1016/S0304-3940(01)02219-4; Zhang ZY, 1997, EXP NEUROL, V143, P141, DOI 10.1006/exnr.1996.6355	43	182	209	0	8	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	MAY 1	2003	72	3					343	351		10.1002/jnr.10587			9	Neurosciences	Neurosciences & Neurology	669LF	WOS:000182352200007	12692901				2021-06-18	
J	Taylor, HG; Yeates, KO; Wade, SL; Drotar, D; Stancin, T; Burant, C				Taylor, HG; Yeates, KO; Wade, SL; Drotar, D; Stancin, T; Burant, C			Bidirectional child-family influences on outcomes of traumatic brain injury in children	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						traumatic brain injury; behavior outcomes; family factors; predictors	CLOSED-HEAD-INJURY; NEUROBEHAVIORAL SYMPTOMS; FOLLOW-UP; PREDICTORS; SEVERITY; RECOVERY; PARENT; ADOLESCENTS; BURDEN; ADAPTATION	Child behavior problems, injury-related family burden, and parent psychological distress were assessed longitudinally over the first year post injury in 40 children with severe traumatic brain injury (TBT), 52 with moderate TBI, and 55 with orthopedic injuries not involving brain insult. Parents rated children's preinjury behavior soon after injury. Postinjury child behavior and family outcomes were assessed at 6- and 12-month follow-ups. Findings from path analysis revealed both direct and indirect effects of TBI on child behavior and family outcomes, as well as cross-lagged child-family associations. Higher parent distress at 6 months predicted more child behavior problems at 12 months, controlling for earlier behavior problems; and more behavior problems at 6 months predicted poorer family outcomes at 12 months, controlling for earlier family outcomes. Support for bidirectional influences is tentative given that limited sample size precluded use of structural equation modeling. The findings nevertheless provide impetus for considering the influences of person-environment interactions on outcomes of TBI.	Case Western Reserve Univ, Dept Pediat, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH USA; Ohio State Univ, Dept Pediat, Columbus, OH 43210 USA; Columbus Childrens Hosp, Columbus, OH USA; Univ Cincinnati, Dept Phys Med & Rehabil, Cincinnati, OH USA; Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA; Metrohlth Med Ctr, Cleveland, OH USA; Case Western Reserve Univ, Div Gen Internal Med, Cleveland, OH USA	Taylor, HG (corresponding author), Rainbow Babies & Childrens Hosp, Dept Pediat, 11100 Euclid Ave, Cleveland, OH 44106 USA.	hgt2@po.cwru.edu	Stancin, Terry/L-7993-2019; Yeates, Keith/AAJ-4223-2020	Yeates, Keith/0000-0001-7680-2892	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS036335] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS36335] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [MCJ-390611] Funding Source: Medline		Achenbach T. M., 1991, MANUAL CHILD BEHAV C; ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/h0080313; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; AYLWARD GP, 1985, J DEV BEHAV PEDIATR, V6, P3; Barry CT, 1996, CHILD NEUROPSYCHOL, V2, P213, DOI 10.1080/09297049608402254; Bowen JM, 1997, DEV MED CHILD NEUROL, V39, P17; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Burgess ES, 1999, J HEAD TRAUMA REHAB, V14, P394, DOI 10.1097/00001199-199908000-00008; Conoley JC, 1996, J LEARN DISABIL-US, V29, P662, DOI 10.1177/002221949602900610; DEPOMPEI R, 1994, TOP LANG DISORD, V15, P68, DOI 10.1097/00011363-199411000-00007; DEROGATIS LR, 1982, BRIEF SYMPTOM INVENT, V1; Drotar D, 1997, J PEDIATR PSYCHOL, V22, P149; Eisenberg N, 1999, CHILD DEV, V70, P513, DOI 10.1111/1467-8624.00037; Farmer J.E., 1996, RECOVERY TRAUMATIC B, P275; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FILLEY CM, 1987, ARCH NEUROL-CHICAGO, V44, P194, DOI 10.1001/archneur.1987.00520140058018; Finkel S, 1995, CAUSAL ANAL PANEL DA; Fletcher J M, 1991, Brain Inj, V5, P337, DOI 10.3109/02699059109008106; Fletcher JM, 1996, J CHILD NEUROL, V11, P283, DOI 10.1177/088307389601100404; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FLETCHER JM, 1988, HDB PEDIATRIC PSYCHO, P258; FLETCHER JM, 1995, TRAUMATIC HEAD INJUR, P3; FRANCIS DJ, 1991, J CONSULT CLIN PSYCH, V59, P27, DOI 10.1037/0022-006X.59.1.27; GE XJ, 1995, DEV PSYCHOL, V31, P406, DOI 10.1037/0012-1649.31.3.406; Ge XJ, 1996, DEV PSYCHOL, V32, P574, DOI 10.1037/0012-1649.32.4.574; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; GEST SD, 1993, DEV PSYCHOPATHOL, V5, P663, DOI 10.1017/S0954579400006222; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; Kinsella G, 1999, J CONSULT CLIN PSYCH, V67, P116, DOI 10.1037/0022-006X.67.1.116; Klem L., 1995, READING UNDERSTANDIN, P65; Koelfen W, 1997, EUR J PEDIATR, V156, P230, DOI 10.1007/s004310050590; Kreutzer J, 1988, J HEAD TRAUMA REHAB, V3, P51, DOI DOI 10.1097/00001199-198812000-00008; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LEVIN HS, 1994, NEUROPSYCHOLOGY, V8, P171, DOI DOI 10.1037/0894-4105.8.2.171; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LEVIN HS, 1995, TRAUMATIC HEAD INJUR, P70; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; LYTTON H, 1990, DEV PSYCHOL, V26, P683, DOI 10.1037/0012-1649.26.5.683; Masten AS, 1999, DEV PSYCHOPATHOL, V11, P143, DOI 10.1017/S0954579499001996; Max JE, 1998, BRAIN INJURY, V12, P31; Max JE, 1998, J AM ACAD CHILD PSY, V37, P83, DOI 10.1097/00004583-199801000-00021; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; Max JE, 1998, J NERV MENT DIS, V186, P325, DOI 10.1097/00005053-199806000-00001; Max JE, 1998, ARCH PHYS MED REHAB, V79, P893, DOI 10.1016/S0003-9993(98)90084-3; MAYER T, 1980, J PEDIATR SURG, V15, P719, DOI 10.1016/S0022-3468(80)80271-5; MCDONALD CM, 1994, ARCH PHYS MED REHAB, V75, P328, DOI 10.1016/0003-9993(94)90038-8; MOOS R, 1988, LIFE STRESSORS SOCIA; ODDY M, 1993, NEUROPSYCHOL REHABIL, V3, P301, DOI 10.1080/09602019308401444; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; RUTTER M, 1987, AM J ORTHOPSYCHIAT, V57, P316, DOI 10.1111/j.1939-0025.1987.tb03541.x; Rutter M, 1993, Paediatr Perinat Epidemiol, V7, P105; RUTTER M, 1985, J CHILD PSYCHOL PSYC, V26, P349, DOI 10.1111/j.1469-7610.1985.tb01938.x; Rutter M, 1983, DEV NEUROPSYCHIATRY, P83; STEVENS G, 1981, SOC SCI RES, V10, P364, DOI 10.1016/0049-089X(81)90011-9; STICE E, 1995, DEV PSYCHOL, V31, P322, DOI 10.1037/0012-1649.31.2.322; Tarter S B, 1990, Arch Clin Neuropsychol, V5, P15; Taylor H.G., 1995, TRAUMATIC HEAD INJUR, P188; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TEASDALE G, 1974, LANCET, V2, P81; TELZROW CF, 1987, J LEARN DISABIL, V20, P536, DOI 10.1177/002221948702000905; WAALAND P, 1991, NEUROPSYCHOL REHABIL, V1, P19; WADE S, 1995, J PEDIATR PSYCHOL, V20, P737, DOI 10.1093/jpepsy/20.6.737; Wade SL, 1996, J LEARN DISABIL, V29, P652, DOI 10.1177/002221949602900609; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110; Yeates K O, 1997, J Int Neuropsychol Soc, V3, P617; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; Yeates KO, 2001, J PEDIATR PSYCHOL, V26, P79, DOI 10.1093/jpepsy/26.2.79	76	182	183	2	18	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	SEP	2001	7	6					755	767		10.1017/S1355617701766118			13	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	471YE	WOS:000170955600011	11575597				2021-06-18	
J	McGuire, SO; Ling, ZD; Lipton, JW; Sortwell, CE; Collier, TJ; Carvey, PM				McGuire, SO; Ling, ZD; Lipton, JW; Sortwell, CE; Collier, TJ; Carvey, PM			Tumor necrosis factor alpha is toxic to embryonic mesencephalic dopamine neurons	EXPERIMENTAL NEUROLOGY			English	Article						Parkinson's disease; dopamine neuron; neurodegeneration; cell death; tumor necrosis factor; tumor necrosis factor receptors; mesencephalon; cytokine; oxidative stress; rat	DEVELOPMENTAL CELL-DEATH; FOCAL CEREBRAL-ISCHEMIA; CENTRAL-NERVOUS-SYSTEM; KAPPA-B ACTIVATION; CLOSED-HEAD INJURY; PARKINSONS-DISEASE; TNF-ALPHA; BRAIN INJURY; SUBSTANTIA-NIGRA; OXIDATIVE STRESS	Levels of the proinflammatory cytokine tumor necrosis factor alpha (TNF alpha) are increased in postmortem brain and cerebral spinal fluid from patients with Parkinson's disease (PD), This observation provides a basis for associating TNF alpha with neurodegeneration, but a specific toxicity in dopamine (DA) neurons has not been firmly established. Therefore, we investigated TNF alpha -induced toxicity in DA neurons by utilizing primary cultures of embryonic rat mesencephalon. Exposure to TNF alpha resulted in a dose-dependent decrease in DA neurons as evidenced by decreased numbers of tyrosine hydroxylase-immunoreactive (THir) cells. TNF alpha toxicity was selective for DA neurons in that neither glial cell counts nor the total number of neurons was decreased and no general cytotoxicity was evidenced by lactate dehydrogenase assay. Many of the cells which remained immunoreactive for TH had shrunken and rounded cell bodies with broken, blunted, or absent processes. However, TNF alpha -treated cultures also contained some THir cells which appeared to be undamaged and possibly resistant to TNF alpha -induced toxicity. Additionally, immunocytochemistry revealed basal expression of TNF alpha receptor 1 (p55, R1) and TNF alpha receptor 2 (p75, R2) on all cells within the mesencephalic cultures to some degree, even though only DA neurons were affected by TNF alpha treatment. These data strongly suggest that TNF alpha mediates cell death in a sensitive population of DA neurons and support the potential involvement of proinflammatory cytokines in the degeneration of DA neurons in PD. (C) 2001 Academic Press.	Rush Presbyterian St Lukes Med Ctr, Dept Pharmacol, Chicago, IL 60612 USA; Rush Presbyterian St Lukes Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA; Rush Presbyterian St Lukes Med Ctr, Dept Pediat, Chicago, IL 60612 USA	McGuire, SO (corresponding author), Rush Presbyterian St Lukes Med Ctr, Dept Pharmacol, 1653 W Congress Pkwy, Chicago, IL 60612 USA.		Lipton, Jack/L-3631-2019; McGuire, Susan O/AAD-8582-2020	Lipton, Jack/0000-0003-0991-8275; 	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG00257-04] Funding Source: Medline		AGID Y, 1993, ADV NEUROL, V60, P148; AGID Y, 1991, LANCET, V337, P1321, DOI 10.1016/0140-6736(91)92989-F; Anglade P, 1997, HISTOL HISTOPATHOL, V12, P603; BARGER SW, 1995, P NATL ACAD SCI USA, V92, P9328, DOI 10.1073/pnas.92.20.9328; Barone FC, 1997, STROKE, V28, P1233, DOI 10.1161/01.STR.28.6.1233; Benveniste EN, 1995, FASEB J, V9, P1577; BLANCHARD V, 1994, MOL BRAIN RES, V22, P29, DOI 10.1016/0169-328X(94)90029-9; BOKA G, 1994, NEUROSCI LETT, V172, P151, DOI 10.1016/0304-3940(94)90684-X; Bongioanni P, 1996, NEURODEGENERATION, V5, P351, DOI 10.1006/neur.1996.0047; Borovansky J, 1996, Sb Lek, V97, P49; Botchkina GI, 1997, MOL MED, V3, P765, DOI 10.1007/BF03401714; Bowenkamp KE, 1996, EXP BRAIN RES, V111, P1; BOWENKAMP KE, 1995, J COMP NEUROL, V355, P479, DOI 10.1002/cne.903550402; BREDER CD, 1993, J COMP NEUROL, V337, P543, DOI 10.1002/cne.903370403; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Brugg B, 1996, J NEUROCHEM, V66, P733; CHAO CC, 1994, DEV NEUROSCI-BASEL, V16, P172, DOI 10.1159/000112104; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; Ciccone CD, 1998, PHYS THER, V78, P313, DOI 10.1093/ptj/78.3.313; Courtney MJ, 1997, J NEUROSCI, V17, P4201; Deshmukh M, 1997, MOL PHARMACOL, V51, P897; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; FAN L, 1994, J NEUROTRAUM, V11, P108; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; Fiers W, 1996, J INFLAMM, V47, P67; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; GENDRON RL, 1991, INT J NEUROSCI, V60, P129, DOI 10.3109/00207459109082043; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; GROOTEN J, 1993, CYTOKINE, V5, P546, DOI 10.1016/S1043-4666(05)80003-1; HANNUN YA, 1995, TRENDS BIOCHEM SCI, V20, P73, DOI 10.1016/S0968-0004(00)88961-6; Heuschling Paul, 1995, Society for Neuroscience Abstracts, V21, P885; Hirsch E. C., 1992, Neurodegeneration, V1, P83; Hirsch EC, 1998, MOVEMENT DISORD, V13, P39; HIRSCH EC, 1993, EUR NEUROL, V33, P52, DOI 10.1159/000118538; HIRSCH EC, 1997, J NEURAL TRANSM, V50, pS79; Hunot S, 1999, J NEUROSCI, V19, P3440; Hunot S, 1996, NEUROSCIENCE, V72, P355, DOI 10.1016/0306-4522(95)00578-1; Hunot S, 1997, P NATL ACAD SCI USA, V94, P7531, DOI 10.1073/pnas.94.14.7531; Jackson-Lewis V, 2000, J COMP NEUROL, V424, P476, DOI 10.1002/1096-9861(20000828)424:3<476::AID-CNE6>3.0.CO;2-0; JACKSONLEWIS V, 1995, NEURODEGENERATION, V4, P257, DOI 10.1016/1055-8330(95)90015-2; Jarskog LF, 1997, INT J DEV NEUROSCI, V15, P711, DOI 10.1016/S0736-5748(97)00029-4; Jenner P, 1996, PATHOL BIOL, V44, P57; Jenner P, 1996, NEUROLOGY, V47, pS161, DOI 10.1212/WNL.47.6_Suppl_3.161S; Jenner P, 1998, ANN NEUROL, V44, pS72, DOI 10.1002/ana.410440712; Jenner P, 1998, MOVEMENT DISORD, V13, P24; KINOUCHI K, 1991, BIOCHEM BIOPH RES CO, V181, P1532, DOI 10.1016/0006-291X(91)92113-X; Knoblach SM, 1999, J NEUROIMMUNOL, V95, P115, DOI 10.1016/S0165-5728(98)00273-2; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KOLESNICK R, 1994, MOL CHEM NEUROPATHOL, V21, P287, DOI 10.1007/BF02815356; LARRICK JW, 1990, FASEB J, V4, P3215; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; Ling ZD, 1998, EXP NEUROL, V149, P411, DOI 10.1006/exnr.1998.6715; Ling ZD, 1999, J PHARMACOL EXP THER, V289, P202; Liu JL, 1998, NAT MED, V4, P78, DOI 10.1038/nm0198-078; LIU T, 1994, STROKE, V25, P1481, DOI 10.1161/01.STR.25.7.1481; Liu WS, 1998, EUR PHYS J D, V2, P1, DOI 10.1007/s100530050101; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Mattson MP, 1997, J NEUROSCI RES, V49, P681, DOI 10.1002/(SICI)1097-4547(19970915)49:6<681::AID-JNR3>3.0.CO;2-3; Mattson MP, 1997, BRAIN RES REV, V23, P47, DOI 10.1016/S0165-0173(96)00014-8; MATTSON MP, 1995, J NEUROSCI RES, V42, P357, DOI 10.1002/jnr.490420310; McCord JM, 1998, SEMIN HEMATOL, V35, P5; MERRILL JE, 1991, DEV NEUROSCI-BASEL, V13, P130, DOI 10.1159/000112150; Meyer M, 1999, CELL TRANSPLANT, V8, P25, DOI 10.1177/096368979900800112; MOGI M, 1994, NEUROSCI LETT, V165, P208, DOI 10.1016/0304-3940(94)90746-3; Natoli G, 1998, BIOCHEM PHARMACOL, V56, P915, DOI 10.1016/S0006-2952(98)00154-3; Nawashiro H, 1997, J CEREBR BLOOD F MET, V17, P483, DOI 10.1097/00004647-199705000-00001; OLANOW CW, 1992, ANN NEUROL, V32, pS2, DOI 10.1002/ana.410320703; Olanow CW, 1997, NEUROLOGY, V49, pS26, DOI 10.1212/WNL.49.1_Suppl_1.S26; Oo TF, 1997, DEV BRAIN RES, V98, P191, DOI 10.1016/S0165-3806(96)00173-3; OURESHI GA, 1995, NEUROREPORT, V6, P1642, DOI 10.1097/00001756-199508000-00013; Owen AD, 1996, ANN NY ACAD SCI, V786, P217, DOI 10.1111/j.1749-6632.1996.tb39064.x; Pan WH, 1997, NEUROSCI BIOBEHAV R, V21, P603, DOI 10.1016/S0149-7634(96)00047-4; Pan WH, 1999, J NEUROSCI, V19, P3649; Przedborski S, 1998, CURR OPIN NEUROL, V11, P335, DOI 10.1097/00019052-199808000-00009; RENNO T, 1995, J IMMUNOL, V154, P944; ROTHWELL NJ, 1995, INT J DEV NEUROSCI, V13, P179, DOI 10.1016/0736-5748(95)00018-C; SAUER H, 1994, NEUROSCIENCE, V59, P401, DOI 10.1016/0306-4522(94)90605-X; SAWADA M, 1989, BRAIN RES, V491, P394, DOI 10.1016/0006-8993(89)90078-4; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; Spencer JPE, 1996, FREE RADICAL RES, V24, P95, DOI 10.3109/10715769609088005; St Pierre B A, 1995, Adv Pharmacol, V34, P415; Stefanis L, 1996, NEUROSCIENCE, V74, P997, DOI 10.1016/0306-4522(96)00175-3; Sullivan PG, 1999, J NEUROSCI, V19, P6248; TALLEY AK, 1995, MOL CELL BIOL, V15, P2359; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; Venters HD, 1999, P NATL ACAD SCI USA, V96, P9879, DOI 10.1073/pnas.96.17.9879; Venters HD, 2000, TRENDS NEUROSCI, V23, P175, DOI 10.1016/S0166-2236(99)01533-7; WILDE GJC, 1995, J CEREB BLOOD FLOW M, V15, pS263; WOLVERS DAW, 1993, EUR CYTOKINE NETW, V4, P377; YAMADA T, 1990, BRAIN RES, V526, P303, DOI 10.1016/0006-8993(90)91236-A; YAMASU K, 1989, J BIOL RESP MODIF, V8, P644	97	182	194	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JUN	2001	169	2					219	230		10.1006/exnr.2001.7688			12	Neurosciences	Neurosciences & Neurology	440TF	WOS:000169189800001	11358437				2021-06-18	
J	Hart, RP; Martelli, MF; Zasler, ND				Hart, RP; Martelli, MF; Zasler, ND			Chronic pain and neuropsychological functioning	NEUROPSYCHOLOGY REVIEW			English	Article						chronic pain; neuropsychological functioning	EOSINOPHILIA-MYALGIA-SYNDROME; TRAUMATIC BRAIN INJURY; MINOR HEAD-INJURY; FIBROMYALGIA SYNDROME; COGNITIVE IMPAIRMENT; MAJOR DEPRESSION; HEALTHY CONTROLS; COMMON WHIPLASH; CERVICAL-SPINE; MEMORY	This review article examines the effect of chronic pain on neuropsychological functioning. Primary attention is given to studies that include patient groups without a history of traumatic brain injury (TBI) or neurologic disorders. Numerous studies were identified that demonstrate neuropsychological impairment in patients with chronic pain, particularly on measures assessing attentional capacity, processing speed, and psychomotor speed. Despite suggestive findings, further studies an needed to clarify the variables that mediate the impact of pain on neuropsychological functioning and the unique role of various symptoms often associated with chronic pain.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Psychiat, Richmond, VA 23298 USA; Tree Life LLC, Pinnacle Rehabil, Richmond, VA USA	Hart, RP (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Psychiat, POB 980268, Richmond, VA 23298 USA.						Andary MT, 1997, CLIN J PAIN, V13, P244, DOI 10.1097/00002508-199709000-00010; Armstrong C, 1997, J NEUROL NEUROSUR PS, V63, P633, DOI 10.1136/jnnp.63.5.633; ASTRAND NE, 1987, BRIT J IND MED, V44, P327; ATKINSON JH, 1988, CLIN J PAIN, V4, P225, DOI 10.1097/00002508-198812000-00007; Bell BD, 1999, ARCH CLIN NEUROPSYCH, V14, P389, DOI 10.1016/S0887-6177(98)00020-1; CODERRE TJ, 1993, PAIN, V52, P259, DOI 10.1016/0304-3959(93)90161-H; Cote KA, 1997, J RHEUMATOL, V24, P2014; de Quervain DJF, 1998, NATURE, V394, P787, DOI 10.1038/29542; Denys P, 1996, BRAIN INJURY, V10, P149, DOI 10.1080/026990596124656; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIPIERO V, 1991, PAIN, V46, P9, DOI 10.1016/0304-3959(91)90026-T; DISTEFANO G, 1995, ACTA NEUROL SCAND, V91, P346; DUFTON BD, 1989, INT J PSYCHIAT MED, V19, P291, DOI 10.2190/JDJK-0795-5BFL-5N6K; Eccleston C, 1999, PSYCHOL BULL, V125, P356, DOI 10.1037/0033-2909.125.3.356; ECCLESTON C, 1994, BRIT J CLIN PSYCHOL, V33, P535, DOI 10.1111/j.2044-8260.1994.tb01150.x; ECCLESTON C, 1995, BEHAV RES THER, V33, P391, DOI 10.1016/0005-7967(94)00057-Q; Eccleston C, 1997, PAIN, V72, P209, DOI 10.1016/S0304-3959(97)00030-4; EIMER BN, 1995, PSYCHOL ASSESSMENT T; GETTO CJ, 1985, PSYCHOSOCIAL PAIN IN; Gimse R, 1997, J CLIN EXP NEUROPSYC, V19, P838, DOI 10.1080/01688639708403764; Goldberg Michael B., 1996, Journal of Orofacial Pain, V10, P126; Grace GM, 1999, J CLIN EXP NEUROPSYC, V21, P477, DOI 10.1076/jcen.21.4.477.876; GRACE GM, 1995, J INT NEUROPSYCH SOC, V1, P137; GRIGSBY J, 1995, PERCEPT MOTOR SKILL, V81, P403, DOI 10.2466/pms.1995.81.2.403; HARKINS SW, 1989, PAIN, V36, P209, DOI 10.1016/0304-3959(89)90025-0; HINNANT DW, 1994, HDB CHRONIC PAIN MAN, P18; JAMISON RN, 1988, INT J PSYCHIAT MED, V18, P183; JARVIS P, 1998, B NATL ACAD NEUROPSY, V14, P7; KAPLAN RF, 1992, NEUROLOGY, V42, P1263, DOI 10.1212/WNL.42.7.1263; KEWMAN DG, 1991, INT J PSYCHIAT MED, V21, P253, DOI 10.2190/FRYK-TMGA-AULW-BM5G; KING DA, 1995, NEUROPSYCHOLOGY, V9, P399, DOI 10.1037/0894-4105.9.3.399; Kulich RJ, 1999, EVALUATION TREATMENT, P301; Lake AE, 1999, J HEAD TRAUMA REHAB, V14, P70, DOI 10.1097/00001199-199902000-00008; Landro NI, 1997, J PSYCHOSOM RES, V42, P297, DOI 10.1016/S0022-3999(96)00301-7; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LOESER JD, 1982, CHRONIC LOW BACK PAI, P145; Lorenz J, 1997, PAIN, V73, P369, DOI 10.1016/S0304-3959(97)00123-1; Martelli MF, 1999, J HEAD TRAUMA REHAB, V14, P49, DOI 10.1097/00001199-199902000-00007; MARTELLI MF, 1999, GUIDE FUNCTIONAL CAP; MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971; Melzack R, 1996, PAIN FORUM, V5, P128; Melzack R, 1999, PAIN S, V6, P121; MILLER L, 1990, COGNITIVE REHABILITA, V8, P12; Morin CM, 1998, CLIN J PAIN, V14, P311, DOI 10.1097/00002508-199812000-00007; MOUNTZ JM, 1995, ARTHRITIS RHEUM, V38, P926, DOI 10.1002/art.1780380708; Mountz JM, 1998, AM J MED SCI, V315, P385, DOI 10.1097/00000441-199806000-00007; NICHOLSON K, 1998, M NAT AC NEUR WASH D; Pilcher JJ, 1996, SLEEP, V19, P318, DOI 10.1093/sleep/19.4.318; Pincus T, 1998, BRIT J CLIN PSYCHOL, V37, P49, DOI 10.1111/j.2044-8260.1998.tb01278.x; Pollina DA, 1998, J NEUROPSYCH CLIN N, V10, P338, DOI 10.1176/jnp.10.3.338; Price DD, 1988, PSYCHOL NEURAL MECH, Vx; Puca FM, 1997, INT J CLIN PHARM RES, V17, P111; RADANOV BP, 1992, SPINE, V17, P127, DOI 10.1097/00007632-199202000-00001; RADANOV BP, 1992, ACTA NEUROL SCAND, V85, P358; RADANOV BP, 1993, ARCH NEUROL-CHICAGO, V50, P87, DOI 10.1001/archneur.1993.00540010081022; Rudy TE, 1989, MULTIAXIAL ASSESSMEN; Schmand B, 1998, J NEUROL NEUROSUR PS, V64, P339, DOI 10.1136/jnnp.64.3.339; SCHNURR RF, 1995, CLIN J PAIN, V11, P103, DOI 10.1097/00002508-199506000-00004; SCHWARTZ DP, 1987, CLIN J PAIN, V3, P94; Sendrowski DP, 1997, OPTOMETRY VISION SCI, V74, P660, DOI 10.1097/00006324-199708000-00027; SLETVOLD H, 1995, J RHEUMATOL, V22, P137; Taylor AE, 1996, ARCH PHYS MED REHAB, V77, P529, DOI 10.1016/S0003-9993(96)90290-7; Treede RD, 1999, PAIN, V79, P105, DOI 10.1016/S0304-3959(98)00184-5; Tsushima WT, 1996, HEADACHE, V36, P613, DOI 10.1046/j.1526-4610.1996.3610613.x; TURK DC, 1987, BEHAV RES THER, V25, P237, DOI 10.1016/0005-7967(87)90002-7; Turk DC, 1986, PAIN MANAGEMENT HDB, P1; VEILL HOF, 1997, J CLIN EXPT PSYCHOL, V19, P587; Vernon-Wilkinson R, 1993, ARCH CLIN NEUROPSYCH, V9, P2; Vogt BA, 1996, EUR J NEUROSCI, V8, P1461, DOI 10.1111/j.1460-9568.1996.tb01608.x; WADE JB, 1992, PAIN, V51, P67, DOI 10.1016/0304-3959(92)90010-9; WALSH NE, 1988, REHABILITATION MED P; WOOLF CJ, 1991, PAIN, V44, P293, DOI 10.1016/0304-3959(91)90100-C; ZIEGLER DK, 1995, ARCH NEUROL-CHICAGO, V52, P602, DOI 10.1001/archneur.1995.00540300076016	73	182	188	0	31	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1040-7308	1573-6660		NEUROPSYCHOL REV	Neuropsychol. Rev.	SEP	2000	10	3					131	149		10.1023/A:1009020914358			19	Psychology, Clinical; Neurosciences	Psychology; Neurosciences & Neurology	349FA	WOS:000089031900001	10983898				2021-06-18	
J	Corrigan, JD; Smith-Knapp, K; Granger, CV				Corrigan, JD; Smith-Knapp, K; Granger, CV			Outcomes in the first 5 years after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							FUNCTIONAL ASSESSMENT SCALES; CLOSED HEAD-INJURY; REHABILITATION OUTCOMES; HEALTH; ALCOHOL; MODEL	Objective: To examine the extent to which outcomes from traumatic brain injury differ as a function of time and can be predicted at discharge from inpatient rehabilitation. Design: Survey method employing cross-sectional analyses. Setting: An inpatient brain injury rehabilitation unit in a large midwestern academic medical center. Subjects: Ninety-five adults with traumatic brain injuries, 6 months to 5 years after inpatient rehabilitation, stratified by time postdischarge. Main Outcome Measures: Functional Independence Measure (FIMSM), Sickness Impact Profile (SIP), Medical Outcomes Survey SF-36, Community Integration Questionnaire (CIQ), Craig Handicap Assessment and Reporting Technique (CHART), Brief Symptom Inventory (BSI), Satisfaction With Life Scale (SWLS), and indices of current psychosocial functioning. Results: Substance abuse, need for supervision life satisfaction, and selected subscales of the CIQ and CHART differed over the period 6 months to 5 years after discharge. Approximately 75% of the variance in current FIM scores, and 40% to 50% of CHART, CIQ, and SIP total scores, could be predicted at time of discharge. Conclusions: Outcomes over the first 5 years after discharge were dynamic, with most change being improvement, at least after the first 2 years. Important aspects of outcome could not be predicted based on premorbid characteristics, injury severity, and initial functional abilities. (C) 1998 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation.	Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; Med Coll Ohio, Dept Phys Med & Rehabil, Toledo, OH 43699 USA; SUNY Buffalo, Dept Rehabil Med, Buffalo, NY 14260 USA	Corrigan, JD (corresponding author), Dodd Hall,480 W 9th Ave, Columbus, OH 43210 USA.		Corrigan, John D./E-2921-2011		PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133B30041, H235L20001] Funding Source: Medline		BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Corrigan J D, 1994, NeuroRehabilitation, V4, P109, DOI 10.3233/NRE-1994-4207; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P132, DOI 10.1016/S0003-9993(97)90253-7; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P828, DOI 10.1016/S0003-9993(97)90195-7; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P29; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; DIENER E, 1984, PSYCHOL BULL, V95, P542, DOI 10.1037/0033-2909.95.3.542; FUHRER MJ, 1994, AM J PHYS MED REHAB, V73, P358, DOI 10.1097/00002060-199409000-00010; GRANGER CV, 1993, ARCH PHYS MED REHAB, V74, P133; GRANGER CV, 1990, ARCH PHYS MED REHAB, V71, P870; GRANGER CV, 1995, AM J PHYS MED REHAB, V74, P107; Granger CV, 1986, TOP GERIATR REHABIL, V1, P59, DOI 10.1097/00013614-198604000-00007; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; JACOBS HE, 1987, J HEAD TRAUMA REHAB, V2, P37; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Kreutzer JS, 1996, J HEAD TRAUMA REHAB, V11, P58, DOI 10.1097/00001199-199610000-00006; Kreutzer JS, 1996, J LEARN DISABIL, V29, P643, DOI 10.1177/002221949602900608; Lehmkuhl L, 1993, J HEAD TRAUMA REHAB, V8, P88; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Pavot W., 1993, PSYCHOL ASSESSMENT, V5, P164, DOI DOI 10.1037/1040-3590.5.2.164; Rawlings J.O., 1989, APPL REGRESSION ANAL; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Silver J. M., 1991, NEUROPSY NEUROPSY BE, V4, P12; STRUPP HH, 1977, AM PSYCHOL, V32, P187, DOI 10.1037/0003-066X.32.3.187; Thomsen I V, 1987, Brain Inj, V1, P131, DOI 10.3109/02699058709034452; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WILLER B, 1997, MED REHABILITATION O, P127; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; WILLER B, 1993, BRAIN INJURY REHABIL, P335; World Health Organization, 1980, INT CLASS IMP DIS HA	36	182	183	0	12	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAR	1998	79	3					298	305		10.1016/S0003-9993(98)90010-7			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	ZB671	WOS:000072495900011	9523782				2021-06-18	
J	McCrory, PR; Berkovic, SF				McCrory, PR; Berkovic, SF			Second impact syndrome	NEUROLOGY			English	Article							MINOR HEAD-INJURY; DELAYED DETERIORATION; BRAIN EDEMA; 2ND IMPACT; CONCUSSION; TALK; MANAGEMENT; CHILDREN; HEMATOMA; RECOVERY	Diffuse cerebral swelling with delayed catastrophic deterioration, a known complication of brain trauma, has been postulated to occur after repeated concussive brain injury in sports-the "second impact syndrome" (SIS). Certain current concussion management guidelines are contingent upon this assumption. We established criteria for definite, probable, and possible SIS and analyzed all published cases. A total of 17 cases were identified in which the reports described the cases as being consistent with SIS. Of these, only five probable cases of SIS were found based on our diagnostic criteria. We also studied the accuracy of recalled episodes of minor concussion in football players by their teammates because the diagnosis of SIS is usually based on such accounts. We found overreporting of recalled episodes of concussion in teammates when compared with self reports and videotape analysis. Based on case reports, the claim that SIS is a risk factor for diffuse cerebral swelling is not established. Prevention strategies for sports-related cerebral swelling are difficult to implement in the absence of established risk factors.	Univ Melbourne, Austin & Repatriat Med Ctr, Dept Med Neurol, Heidelberg, Vic 3084, Australia; Olymp Pk Sports Med Ctr, Melbourne, Vic, Australia	McCrory, PR (corresponding author), Univ Melbourne, Austin & Repatriat Med Ctr, Dept Med Neurol, Heidelberg, Vic 3084, Australia.		McCrory, Paul/Q-8688-2019	Berkovic, Samuel/0000-0003-4580-841X			BOLLINGER O, 1891, INT BEITRAGE WEISSEN, P457; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; BRUCE DA, 1984, BRIT MED J, V289, P715, DOI 10.1136/bmj.289.6447.715; Bullock R, 1992, Acta Neurochir Suppl (Wien), V55, P14; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; CANTU RC, 1992, PHYSICIAN SPORTSMED, V20, P55, DOI 10.1080/00913847.1992.11947483; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; CANTU RC, 1995, BOXING MED, P19; *COL MED SOC, 1991, REP SPORTS MED COMM; CORALES RL, 1980, INTRACRANIAL PRESSUR, V4, P280; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; *DCD, 1997, MMWR-MORBID MORTAL W, V46, P224; FEKETE JF, 1968, CAN MED ASSOC J, V99, P1234; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL D, 1974, LANCET, V2, P605; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; JOKL E, 1941, MED ASPECTS BOXING, P21; JORDAN B, 1993, MED ASPECTS BOXING, P169; JORDAN BD, 1988, PHYSICIAN SPORTSMED, V16, P87, DOI 10.1080/00913847.1988.11709407; JORDAN BD, 1991, HOSP MED, V27, P93; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; KOBRINE AI, 1977, J NEUROSURG, V46, P256, DOI 10.3171/jns.1977.46.2.0256; LEVIN HS, 1989, MILD MODERATE HEAD I, P153; LOBATO RD, 1991, J NEUROSURG, V75, P526; MADDOCKS DL, 1991, J CLIN EXP NEUROPSYC, V13, P439; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; MARSHALL LF, 1991, J NEUROSURG, V75, pS25; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; MCQUILLEN JB, 1988, AM J FOREN MED PATH, V9, P12, DOI 10.1097/00000433-198803000-00004; MELLION BT, 1992, COMPLICATIONS SEQUEL, P51; MUELLER FO, 1996, CATASTROPHIC INJURIE, P14; NEE PA, 1993, BRIT MED J, V306, P1665, DOI 10.1136/bmj.306.6893.1665; PICKLES W, 1950, NEW ENGL J MED, V242, P607, DOI 10.1056/NEJM195004202421602; REILLY PL, 1975, LANCET, V2, P375; ROCKSWOLD GL, 1993, ANN EMERG MED, V22, P1004, DOI 10.1016/S0196-0644(05)82742-8; ROCKSWOLD GL, 1987, NEUROSURGERY, V21, P51, DOI 10.1227/00006123-198707000-00010; SACKETT DL, 1991, CLIN EPIDEMIOLOGY BA, P285; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Schneider R., 1973, HEAD NECK INJURIES F, P35; SCHNITKER MT, 1949, J PEDIATR-US, V35, P557, DOI 10.1016/S0022-3476(49)80138-7; SHELL D, 1993, PHYSICIAN SPORTSMED, V21, P74, DOI 10.1080/00913847.1993.11710364; SNOEK JW, 1984, BRAIN, V107, P15, DOI 10.1093/brain/107.1.15; Wako N, 1989, INTRACRANIAL PRESSUR, P593; WILBERGER JE, 1987, NEUROSURGERY, V20, P571, DOI 10.1227/00006123-198704000-00011	48	182	184	0	25	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106 USA	0028-3878			NEUROLOGY	Neurology	MAR	1998	50	3					677	683		10.1212/WNL.50.3.677			7	Clinical Neurology	Neurosciences & Neurology	ZD472	WOS:000072689400020	9521255				2021-06-18	
J	Zhang, L; Rzigalinski, BA; Ellis, EF; Satin, LS				Zhang, L; Rzigalinski, BA; Ellis, EF; Satin, LS			Reduction of voltage-dependent Mg2+ blockade of NMDA current in mechanically injured neurons	SCIENCE			English	Article							CONCUSSIVE BRAIN INJURY; EXCITATORY AMINO-ACIDS; D-ASPARTIC ACID; CHANNELS; ANTAGONISTS; RECEPTORS; RELEASE; CULTURE; CELLS	Activation of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptors is implicated in the pathophysiology of traumatic brain injury. Here, the effects of mechanical injury on the voltage-dependent magnesium (Mg2+) block of NMDA currents in cultured rat cortical neurons were examined. Stretch-induced injury was found to reduce the Mg2+ blockade, resulting in significantly larger ionic currents and increases in intracellular free calcium (Ca2+) concentration after NMDA stimulation of injured neurons. The Mg2+ blockade was partially restored by increased extracellular Mg2+ concentration or by pretreatment with the protein kinase C inhibitor calphostin C. These findings could account for the secondary pathological changes associated with traumatic brain injury.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHARMACOL & TOXICOL,RICHMOND,VA 23298					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027214] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL07537-14] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 27214] Funding Source: Medline		BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; BULLOCK R, 1994, INTRACRANIAL PRESSUR, P264; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; DELEAN A, 1978, AM J PHYSIOL, V235, pE97; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAYES RL, 1988, J NEUROTRAUM, V5, P287; HERRINGTON J, 1994, PULSE CONTROL V 4 3; HUETTNER JE, 1988, P NATL ACAD SCI USA, V85, P1307, DOI 10.1073/pnas.85.4.1307; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; MAYER ML, 1985, J PHYSIOL-LONDON, V361, P65, DOI 10.1113/jphysiol.1985.sp015633; MCBAIN CJ, 1994, PHYSIOL REV, V74, P723; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; McKinney JS, 1996, STROKE, V27, P934, DOI 10.1161/01.STR.27.5.934; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; PERSSON K, 1995, AM J PHYSIOL-CELL PH, V269, pC1018; Schreiber D., 1995, P 1995 INT RES C BIO, P233; Tavalin SJ, 1995, J NEUROPHYSIOL, V74, P2767; TECOMA ES, 1989, NEURON, V2, P1541, DOI 10.1016/0896-6273(89)90042-1	26	182	191	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 13	1996	274	5294					1921	1923		10.1126/science.274.5294.1921			3	Multidisciplinary Sciences	Science & Technology - Other Topics	VY200	WOS:A1996VY20000047	8943207				2021-06-18	
J	BAKER, AJ; MOULTON, RJ; MACMILLAN, VH; SHEDDEN, PM				BAKER, AJ; MOULTON, RJ; MACMILLAN, VH; SHEDDEN, PM			EXCITATORY AMINO-ACIDS IN CEREBROSPINAL-FLUID FOLLOWING TRAUMATIC BRAIN INJURY IN HUMANS	JOURNAL OF NEUROSURGERY			English	Article						TRAUMATIC BRAIN INJURY; GLUTAMATE; CEREBROSPINAL FLUID; EXCITOTOXICITY	EXTRACELLULAR CONCENTRATIONS; GLUTAMATE NEUROTOXICITY; RAT HIPPOCAMPUS; HEAD-INJURIES; DAMAGE; ASPARTATE; METABOLITES; RECEPTORS; ISCHEMIA; RELEASE	Evidence from models of traumatic brain injury implicates excitotoxicity as an integral process in the ultimate neuronal damage that follows. Concentrations of the excitatory amino acid glutamate were serially measured in the cerebrospinal fluid (CSF) of patients with traumatic brain injuries and in control patients for comparison. The purpose of the study was to determine whether glutamate concentrations were significantly elevated following traumatic brain injury and, if so, whether they were elevated in a time frame that would allow the use of antagonist therapy. Cerebrospinal fluid was sampled fresh from ventricular drains every 12 hours and analyzed using high-performance liquid chromatography for the excitatory amino acids. The peak concentrations of glutamate in the CSF of the 12 brain-injured patients ranged from 14 to 474 muM and were significantly higher than those in the three control patients, 4.9 to 17 muM (Mann-Whitney U-test, p < 0.02). Glutamate concentrations in five of the eight patients who were still being sampled on Day 3 were beyond the control group range. The implication of this study is that severely head-injured patients are exposed to high concentrations of a neurotoxic amino acid for days following injury and thus may benefit from antagonist intervention.	UNIV TORONTO,ST MICHAELS HOSP,DEPT NEUROSURG,TORONTO M5B 1W8,ONTARIO,CANADA; UNIV TORONTO,ST MICHAELS HOSP,DEPT MED,TORONTO M5B 1W8,ONTARIO,CANADA	BAKER, AJ (corresponding author), UNIV TORONTO,ST MICHAELS HOSP,DEPT ANAESTHESIA,30 BOND ST,TORONTO M5B 1W8,ONTARIO,CANADA.						BAKER AJ, 1991, J NEUROCHEM, V57, P1370, DOI 10.1111/j.1471-4159.1991.tb08303.x; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; BENVENISTE H, 1989, J CEREBR BLOOD F MET, V9, P629, DOI 10.1038/jcbfm.1989.90; BONDOLI A, 1981, RESUSCITATION, V9, P119, DOI 10.1016/0300-9572(81)90021-6; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; CHOI DW, 1990, CEREBROVAS BRAIN MET, V2, P105; CHOI DW, 1987, J NEUROSCI, V7, P357; Davson H., 1967, PHYSL CEREBROSPINAL; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GRAHAM DI, 1971, LANCET, V1, P265; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; GREENAMYRE JT, 1989, NEUROBIOL AGING, V10, P593, DOI 10.1016/0197-4580(89)90143-7; GRIFFITHS T, 1984, NEUROSCIENCE, V12, P557, DOI 10.1016/0306-4522(84)90073-3; Hayes R. L., 1992, J HEAD TRAUMA REHAB, V7, P16; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; MCCULLOCH J, 1992, BRIT J CLIN PHARMACO, V34, P106, DOI 10.1111/j.1365-2125.1992.tb04118.x; MCINTOSH TK, 1992, J NEUROTRAUM, V9, pS201; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; PLAITAKIS A, 1987, ANN NEUROL, V22, P575, DOI 10.1002/ana.410220503; TEASDALE G, 1974, LANCET, V2, P81; WIELOCH T, 1985, SCIENCE, V230, P681, DOI 10.1126/science.2996146; YOUNG AB, 1988, SCIENCE, V241, P981, DOI 10.1126/science.2841762	26	182	191	0	11	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	SEP	1993	79	3					369	372		10.3171/jns.1993.79.3.0369			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	LU690	WOS:A1993LU69000008	8103092				2021-06-18	
J	STEIN, SC; SPETTELL, C; YOUNG, G; ROSS, SE				STEIN, SC; SPETTELL, C; YOUNG, G; ROSS, SE			DELAYED AND PROGRESSIVE BRAIN INJURY IN CLOSED-HEAD TRAUMA - RADIOLOGICAL DEMONSTRATION	NEUROSURGERY			English	Article						CENTRAL NERVOUS SYSTEM INJURY; COAGULATION; COMPUTED TOMOGRAPHY; DELAYED BRAIN INJURIES; DISSEMINATED INTRAVASCULAR COAGULOPATHY; HEAD INJURIES	COMPUTERIZED-TOMOGRAPHY; ABNORMALITIES; COAGULATION; MANAGEMENT; HEMATOMA; DAMAGE	THE IMPORTANCE OF delayed or secondary brain insults in the eventual outcome of closed-head trauma has been documented in experimental models. To understand this phenomenon in the clinical setting, we studied a series of head-injured patients in whom multiple cranial computed tomographic (CT) scans were obtained. Patients whose follow-up CT studies revealed new intracranial lesions or worsening, compared with admission findings, were considered to have delayed cerebral injury. One hundred forty-nine (44.5%) of 337 consecutively studied patients developed delayed brain injury. There were highly significant associations (P < 0.001) between the appearance of delayed cerebral insults and the severity of the initial brain injury, the need for cardiopulmonary resuscitation in the field, the presence of coagulopathy at admission, and subdural hematoma on the initial CT scan. In addition, delayed injury was associated (P < 0.001) with higher mortality, slowed recovery, and poorer outcome at 6 months. Delayed brain injury was not significantly associated with patient age, sex, injury mechanism, associated injury, the need for endotracheal intubation in the field, early talking, CT abnormality other than intracranial hematoma, or type of residual neurological deficits. We used multiple regression analysis to explore the relationship between severity of injury, delayed insults, and outcome. As expected, the severity of the initial brain trauma contributed significantly to neurological outcome. The presence of delayed cerebral injury makes the outcome dramatically worse for each category of initial injury severity. The relationship between initial and secondary brain injury is discussed.	UNIV MED & DENT NEW JERSEY,COOPER HOSP UNIV MED CTR,ROBERT WOOD JOHNSON MED SCH,DIV TRAUMA,CAMDEN,NJ; UNIV MED & DENT NEW JERSEY,COOPER HOSP UNIV MED CTR,ROBERT WOOD JOHNSON MED SCH,DEPT SURG,CAMDEN,NJ; UNIV MED & DENT NEW JERSEY,COOPER HOSP UNIV MED CTR,ROBERT WOOD JOHNSON MED SCH,CAMDEN,NJ; INST BRAIN INJURY RES & TRAINING,MEDIPLEX REHAB CAMDEN,CAMDEN,NJ	STEIN, SC (corresponding author), UNIV MED & DENT NEW JERSEY,COOPER HOSP UNIV MED CTR,ROBERT WOOD JOHNSON MED SCH,DIV NEUROSURG,CAMDEN,NJ 08103, USA.		Shaheen, Ahmed/AAP-4054-2021	Shaheen, Ahmed/0000-0002-2216-1951			AUER LM, 1979, ACTA NEUROCHIR, V49, P219, DOI 10.1007/BF01808961; Berkson J, 1944, J AM STAT ASSOC, V39, P357, DOI 10.2307/2280041; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; COOPER PR, 1979, NEUROSURGERY, V5, P566, DOI 10.1227/00006123-197911000-00004; COOPER PR, 1985, CENTRAL NERVOUS SYST, P217; CRONE KC, 1987, NEUROSURGERY, V21, P523; DIAZ FG, 1979, J NEUROSURG, V50, P217, DOI 10.3171/jns.1979.50.2.0217; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FRENCH BN, 1977, SURG NEUROL, V7, P171; FRERICHS KU, 1990, J NEUROSURG, V73, P223, DOI 10.3171/jns.1990.73.2.0223; GRAHAM DI, 1971, LANCET, V1, P265; HALLENBECK JM, 1990, ARCH NEUROL-CHICAGO, V47, P1245, DOI 10.1001/archneur.1990.00530110107027; IKEDA Y, 1990, NEUROSURGERY, V27, P1; Jenkins LW, 1988, J NEUROTRAUM, V5, P275, DOI 10.1089/neu.1988.5.275; JENNETT B, 1975, LANCET, V1, P480; KOBAYASHI S, 1983, SURG NEUROL, V20, P25, DOI 10.1016/0090-3019(83)90101-5; KUMURA E, 1987, ACTA NEUROCHIR, V85, P23, DOI 10.1007/BF01402365; LIPPER MH, 1979, RADIOLOGY, V133, P645, DOI 10.1148/133.3.645; LOBATO RD, 1988, J NEUROSURG, V68, P417, DOI 10.3171/jns.1988.68.3.0417; LOBATO RD, 1991, J NEUROSURG, V75, P256, DOI 10.3171/jns.1991.75.2.0256; MIRVIS SE, 1990, AM J NEURORADIOL, V11, P355; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; POZZATI E, 1986, J NEUROSURG, V65, P611, DOI 10.3171/jns.1986.65.5.0611; RAM Z, 1989, J NEUROSURG, V71, P608, DOI 10.3171/jns.1989.71.4.0608; ROBERSON FC, 1979, SURG NEUROL, V12, P161; STATHAM PF, 1989, J NEUROL NEUROSUR PS, V52, P351, DOI 10.1136/jnnp.52.3.351; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; TOUHO H, 1986, NEUROSURGERY, V19, P523, DOI 10.1227/00006123-198610000-00005; VANDERSANDE JJ, 1981, J NEUROSURG, V55, P718, DOI 10.3171/jns.1981.55.5.0718; 1990, ABBREVIATED INJURY S, P15; 1989, LANCET, V2, P957	31	182	193	0	6	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	JAN	1993	32	1					25	31		10.1227/00006123-199301000-00004			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	KF376	WOS:A1993KF37600004	8421553				2021-06-18	
J	Dewan, MC; Rattani, A; Fieggen, G; Arraez, MA; Servadei, F; Boop, FA; Johnson, WD; Warf, BC; Park, KB				Dewan, Michael C.; Rattani, Abbas; Fieggen, Graham; Arraez, Miguel A.; Servadei, Franco; Boop, Frederick A.; Johnson, Walter D.; Warf, Benjamin C.; Park, Kee B.			Global neurosurgery: the current capacity and deficit in the provision of essential neurosurgical care. Executive Summary of the Global Neurosurgery Initiative at the Program in Global Surgery and Social Change	JOURNAL OF NEUROSURGERY			English	Article						capacity; epidemiology; global; incidence; volume; workforce; worldwide		OBJECTIVE Worldwide disparities in the provision of surgical care result in otherwise preventable disability and death. There is a growing need to quantify the global burden of neurosurgical disease specifically, and the workforce necessary to meet this demand. METHODS Results from a multinational collaborative effort to describe the global neurosurgical burden were aggregated and summarized. First, country registries, third-party modeled data, and meta-analyzed published data were combined to generate incidence and volume figures for 10 common neurosurgical conditions. Next, a global mapping survey was performed to identify the number and location of neurosurgeons in each country. Finally, a practitioner survey was conducted to quantify the proportion of disease requiring surgery, as well as the median number of neurosurgical cases per annum. The neurosurgical case deficit was calculated as the difference between the volume of essential neurosurgical cases and the existing neurosurgical workforce capacity. RESULTS Every year, an estimated 22.6 million patients suffer from neurological disorders or injuries that warrant the expertise of a neurosurgeon, of whom 13.8 million require surgery. Traumatic brain injury, stroke-related conditions, tumors, hydrocephalus, and epilepsy constitute the majority of essential neurosurgical care worldwide. Approximately 23,300 additional neurosurgeons are needed to address more than 5 million essential neurosurgical cases-all in low- and middle-income countries-that go unmet each year. There exists a gross disparity in the allocation of the surgical workforce, leaving large geographic treatment gaps, particularly in Africa and Southeast Asia. CONCLUSIONS Each year, more than 5 million individuals suffering from treatable neurosurgical conditions will never undergo therapeutic surgical intervention. Populations in Africa and Southeast Asia, where the proportion of neurosurgeons to neurosurgical disease is critically low, are especially at risk. Increasing access to essential neurosurgical care in low-and middle-income countries via neurosurgical workforce expansion as part of surgical system strengthening is necessary to prevent severe disability and death for millions with neurological disease.	[Dewan, Michael C.; Rattani, Abbas; Park, Kee B.] Harvard Med Sch, Dept Global Hlth & Social Med, Program Global Surg & Social Change, Global Neurosurg Initiat, Boston, MA 02115 USA; [Dewan, Michael C.] Vanderbilt Univ, Med Ctr, Dept Neurol Surg, Nashville, TN USA; [Rattani, Abbas] Meharry Med Coll, Sch Med, Nashville, TN 37208 USA; [Fieggen, Graham] Univ Cape Town, Dept Surg, Rondebosch, South Africa; [Arraez, Miguel A.] Carlos Haya Univ Hosp, Dept Neurosurg, Malaga, Spain; [Servadei, Franco] Humanitas Univ & Res Inst, Dept Neurosurg, Milan, Italy; [Boop, Frederick A.] Univ Tennessee, Hlth Sci Ctr, LeBonheur Childrens Hosp, Semmes Murphey Clin,Dept Neurol Surg,Neurosci Ins, Memphis, TN 38163 USA; [Johnson, Walter D.] World Hlth Org, Emergency & Essential Surg Care Programme Lead, Geneva, Switzerland; [Warf, Benjamin C.] Harvard Med Sch, Boston Childrens Hosp, Dept Neurol Surg, Boston, MA 02115 USA; [Warf, Benjamin C.] CURE Childrens Hosp Uganda, Mbale, Uganda	Dewan, MC (corresponding author), Vanderbilt Univ, Med Ctr, Nashville, TN 37235 USA.	dewan.michael@gmail.com	Baticulon, Ronnie/AAW-7768-2020	Baticulon, Ronnie/0000-0002-2781-1845	Boston Children's Hospital Global Hydrocephalus and Spina Bifida Fund; Harvard Medical School Department of Global Health and Social Medicine; John D. and Catherine T. MacArthur Foundation; Kellogg Institute for International Studies at the University of Notre Dame; Vanderbilt Medical Scholars Program; Vanderbilt University Medical Center; WFNS	We would like to thank Ron Baticulon, MD, for his graphical expertise. The work in this report was enhanced by the logistical, financial, or in-kind support that we received from the following organizations: Boston Children's Hospital Global Hydrocephalus and Spina Bifida Fund, Harvard Medical School Department of Global Health and Social Medicine, John D. and Catherine T. MacArthur Foundation, Kellogg Institute for International Studies at the University of Notre Dame, Vanderbilt Medical Scholars Program, Vanderbilt University Medical Center, and the WFNS.	Albright AL, 2016, J NEUROSURG-PEDIATR, V18, P127, DOI 10.3171/2015.8.PEDS15403; Andrews RJ, 2016, WORLD NEUROSURG, V85, P22, DOI 10.1016/j.wneu.2015.08.002; Bell JS, 2017, C NEUR SURG ANN M BO; Debas HT., 2015, DIS CONTROL PRIORITI; Dewan M.C., 2018, J NEUROSURG; Hughes JD, 2018, WORLD NEUROSURG; Hughes JD, 2017, C NEUR SURG ANN M BO; Kancherla V, 2017, PREV MED, V99, P13, DOI 10.1016/j.ypmed.2017.01.022; Kumar R, 2018, WORLD NEUROSURG; Meara JG, 2015, LANCET, V386, P569, DOI 10.1016/S0140-6736(15)60160-X; Park KB, 2016, WORLD NEUROSURG, V88, P32, DOI 10.1016/j.wneu.2015.12.048; Punchak M, 2018, WORLD NEUROSURG, V112, pE240, DOI 10.1016/j.wneu.2018.01.029; Ravindra V, 2018, GLOBAL SPINE J; Robertson FC, 2018, J NEUROSURG; Shrime MG, 2015, LANCET GLOB HEALTH, V3, pS8, DOI 10.1016/S2214-109X(14)70384-5; United Nations (UN), TRANSF OUR WORLD 203; Vaughan KA, 2018, J NEUROSURG; Warf BC, 2015, WORLD NEUROSURG, V84, P1547, DOI 10.1016/j.wneu.2015.07.052	18	181	183	4	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	APR	2019	130	4					1055	1064		10.3171/2017.11.JNS171500			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	HR1CV	WOS:000462866700004	29701548	Bronze	Y	N	2021-06-18	
J	Norden, DM; Trojanowski, PJ; Villanueva, E; Navarro, E; Godbout, JP				Norden, Diana M.; Trojanowski, Paige J.; Villanueva, Emmanuel; Navarro, Elisa; Godbout, Jonathan P.			Sequential Activation of Microglia and Astrocyte Cytokine Expression Precedes Increased Iba-1 or GFAP Immunoreactivity Following Systemic Immune Challenge	GLIA			English	Article						neuroinflammation; microglia; astrocytes; lipopolysaccharide; sickness behavior	INDUCED SICKNESS BEHAVIOR; DEPRESSIVE-LIKE BEHAVIOR; TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; REACTIVE ASTROCYTES; AGED MICE; ENDOTHELIAL-CELLS; LIPOPOLYSACCHARIDE; RECEPTOR; INNATE	Activation of the peripheral immune system elicits a coordinated response from the central nervous system. Key to this immune to brain communication is that glia, microglia, and astrocytes, interpret and propagate inflammatory signals in the brain that influence physiological and behavioral responses. One issue in glial biology is that morphological analysis alone is used to report on glial activation state. Therefore, our objective was to compare behavioral responses after in vivo immune (lipopolysaccharide, LPS) challenge to glial specific mRNA and morphological profiles. Here, LPS challenge induced an immediate but transient sickness response with decreased locomotion and social interaction. Corresponding with active sickness behavior (2-12 h), inflammatory cytokine mRNA expression was elevated in enriched microglia and astrocytes. Although proinflammatory cytokine expression in microglia peaked 2-4 h after LPS, astrocyte cytokine, and chemokine induction was delayed and peaked at 12 h. Morphological alterations in microglia (Iba-1(+)) and astrocytes (GFAP(+)), however, were undetected during this 2-12 h timeframe. Increased Iba-1 immunoreactivity and de-ramified microglia were evident 24 and 48 h after LPS but corresponded to the resolution phase of activation. Morphological alterations in astrocytes were undetected after LPS. Additionally, glial cytokine expression did not correlate with morphology after four repeated LPS injections. In fact, repeated LPS challenge was associated with immune and behavioral tolerance and a less inflammatory microglial profile compared with acute LPS challenge. Overall, induction of glial cytokine expression was sequential, aligned with active sickness behavior, and preceded increased Iba-1 or GFAP immunoreactivity after LPS challenge.	[Norden, Diana M.; Trojanowski, Paige J.; Villanueva, Emmanuel; Navarro, Elisa; Godbout, Jonathan P.] Ohio State Univ, Dept Neurosci, Columbus, OH 43210 USA; [Godbout, Jonathan P.] Ohio State Univ, Inst Behav Med Res, Columbus, OH 43210 USA	Godbout, JP (corresponding author), Ohio State Univ, 259 IBMR Bldg,460 Med Ctr Dr, Columbus, OH 43210 USA.	jonathan.godbout@osumc.edu	Trojanowski, Paige/AAT-1422-2020	Trojanowski, Paige/0000-0002-4118-9087	NIAUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01-AG-033028]; OSU Presidential Fellowship; OSU Undergraduate Research Office Summer Fellowship; MARCS fellowship; FPI-UAM from Universidad Autonoma de Madrid, Spain; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG033028] Funding Source: NIH RePORTER	Grant sponsor: NIA grant; Grant number: R01-AG-033028; Grant sponsor: OSU Presidential Fellowship.; Grant sponsor: OSU Undergraduate Research Office Summer Fellowship; Grant sponsor: MARCS fellowship; Grant sponsor: FPI-UAM from Universidad Autonoma de Madrid, Spain.	Berg BM, 2004, BRAIN BEHAV IMMUN, V18, P149, DOI 10.1016/S0889-1591(03)00113-2; Biber K, 2007, TRENDS NEUROSCI, V30, P596, DOI 10.1016/j.tins.2007.08.007; Biswas SK, 2009, TRENDS IMMUNOL, V30, P475, DOI 10.1016/j.it.2009.07.009; Bluthe RM, 2000, EUR J NEUROSCI, V12, P4447, DOI 10.1111/j.1460-9568.2000.01348.x; Bluthe RM, 2000, PHYSIOL BEHAV, V70, P367, DOI 10.1016/S0031-9384(00)00269-9; Bodea LG, 2014, J NEUROSCI, V34, P8546, DOI 10.1523/JNEUROSCI.5002-13.2014; Cameron B, 2012, J NEUROSCI, V32, P15112, DOI 10.1523/JNEUROSCI.1729-12.2012; Cao T, 2012, NEUROSCIENCE, V225, P65, DOI 10.1016/j.neuroscience.2012.08.058; Cardona AE, 2006, NAT NEUROSCI, V9, P917, DOI 10.1038/nn1715; Carpentier PA, 2005, GLIA, V49, P360, DOI 10.1002/glia.20117; Carson MJ, 2006, IMMUNOL REV, V213, P48, DOI 10.1111/j.1600-065X.2006.00441.x; Cazareth J, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-132; Chen ZH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5486; Chen ZH, 2012, J NEUROSCI, V32, P11706, DOI 10.1523/JNEUROSCI.0730-12.2012; Ching S, 2007, J NEUROSCI, V27, P10476, DOI 10.1523/JNEUROSCI.3357-07.2007; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; Cunningham C, 2005, J NEUROSCI, V25, P9275, DOI 10.1523/JNEUROSCI.2614-05.2005; Cunningham C, 2005, J VIROL, V79, P5174, DOI 10.1128/JVI.79.8.5174-5184.2005; Cunningham C, 2013, GLIA, V61, P71, DOI 10.1002/glia.22350; Dantzer R, 2001, ANN NY ACAD SCI, V933, P222; Dantzer R, 2008, NAT REV NEUROSCI, V9, P46, DOI 10.1038/nrn2297; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Detloff MR, 2008, EXP NEUROL, V212, P337, DOI 10.1016/j.expneurol.2008.04.009; Donnelly DJ, 2009, J NEUROSCI METH, V181, P36, DOI 10.1016/j.jneumeth.2009.04.010; Elmore MRP, 2014, NEURON, V82, P380, DOI 10.1016/j.neuron.2014.02.040; Farina C, 2007, TRENDS IMMUNOL, V28, P138, DOI 10.1016/j.it.2007.01.005; Fenn AM, 2014, BIOL PSYCHIAT, V76, P575, DOI 10.1016/j.biopsych.2013.10.014; Fenn AM, 2014, J NEUROSCI, V34, P8904, DOI 10.1523/JNEUROSCI.1146-14.2014; Fenn AM, 2012, BRAIN BEHAV IMMUN, V26, P766, DOI 10.1016/j.bbi.2011.10.003; Godbout JP, 2008, NEUROPSYCHOPHARMACOL, V33, P2341, DOI 10.1038/sj.npp.1301649; Godbout JP, 2005, FASEB J, V19, P1329, DOI 10.1096/fj.05-3776fje; Gosselin D, 2008, MOL PSYCHIATR, V13, P480, DOI 10.1038/sj.mp.4002122; Hansen MK, 2001, AM J PHYSIOL-REG I, V280, pR929; Hayakawa K, 2014, J NEUROSCI RES, V92, P1647, DOI 10.1002/jnr.23448; Henry CJ, 2009, BRAIN BEHAV IMMUN, V23, P309, DOI 10.1016/j.bbi.2008.09.002; Henry CJ, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-15; John GR, 2004, J NEUROSCI, V24, P2837, DOI 10.1523/JNEUROSCI.4789-03.2004; Kongsui R, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0182-7; Kreisel T, 2014, MOL PSYCHIATR, V19, P699, DOI 10.1038/mp.2013.155; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Lacroix S, 1998, BRAIN PATHOL, V8, P625, DOI 10.1111/j.1750-3639.1998.tb00189.x; Laflamme N, 1999, J NEUROSCI, V19, P10923; Laye S, 2000, AM J PHYSIOL-REG I, V279, pR93; Liu W, 2011, LIFE SCI, V89, P141, DOI 10.1016/j.lfs.2011.05.011; Min KJ, 2006, J NEUROSCI, V26, P1880, DOI 10.1523/JNEUROSCI.3696-05.2006; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Nayak D, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003395; Norden DM, 2013, NEUROPATH APPL NEURO, V39, P19, DOI 10.1111/j.1365-2990.2012.01306.x; Norden DM, 2015, NEUROPHARMACOLOGY, V96, P29, DOI 10.1016/j.neuropharm.2014.10.028; Norden DM, 2014, GLIA, V62, P881, DOI 10.1002/glia.22647; Parrow NL, 2013, INFECT IMMUN, V81, P3503, DOI 10.1128/IAI.00602-13; Paxinos G., 2004, MOUSE BRAIN STEREOTA; Pepe G, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0211-6; Puntener U, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-146; Puntambekar SS, 2011, BRAIN BEHAV IMMUN, V25, P629, DOI 10.1016/j.bbi.2010.12.016; Rivest S, 2009, NAT REV IMMUNOL, V9, P429, DOI 10.1038/nri2565; Sauerbeck A, 2013, EXP NEUROL, V248, P53, DOI 10.1016/j.expneurol.2013.05.011; Sawicki CM, 2014, J NEUROSCIENCE; Serrats J, 2010, NEURON, V65, P94, DOI 10.1016/j.neuron.2009.11.032; Sierra A, 2007, GLIA, V55, P412, DOI 10.1002/glia.20468; Skelly DT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069123; Sofroniew MV, 2005, NEUROSCIENTIST, V11, P400, DOI 10.1177/1073858405278321; Stevens SL, 2011, J NEUROSCI, V31, P8456, DOI 10.1523/JNEUROSCI.0821-11.2011; Voskuhl RR, 2009, J NEUROSCI, V29, P11511, DOI 10.1523/JNEUROSCI.1514-09.2009; Wohleb ES, 2014, J NEUROSCI, V34, P2583, DOI 10.1523/JNEUROSCI.3723-13.2014; Wohleb ES, 2013, J NEUROSCI, V33, P13820, DOI 10.1523/JNEUROSCI.1671-13.2013; Wohleb ES, 2012, PSYCHONEUROENDOCRINO, V37, P1491, DOI 10.1016/j.psyneuen.2012.02.003; Wohleb ES, 2011, J NEUROSCI, V31, P6277, DOI 10.1523/JNEUROSCI.0450-11.2011; Wynne AM, 2010, BRAIN BEHAV IMMUN, V24, P1190, DOI 10.1016/j.bbi.2010.05.011; Zamanian JL, 2012, J NEUROSCI, V32, P6391, DOI 10.1523/JNEUROSCI.6221-11.2012; Zhang Y, 2010, CURR OPIN NEUROBIOL, V20, P588, DOI 10.1016/j.conb.2010.06.005; Zhao XR, 2009, J NEUROSCI, V29, P15819, DOI 10.1523/JNEUROSCI.3776-09.2009	73	181	186	7	58	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	FEB	2016	64	2					300	316		10.1002/glia.22930			17	Neurosciences	Neurosciences & Neurology	DA3EC	WOS:000367678500008	26470014	Green Accepted	Y	N	2021-06-18	
J	Carlson, KF; Kehle, SM; Meis, LA; Greer, N; MacDonald, R; Rutks, I; Sayer, NA; Dobscha, SK; Wilt, TJ				Carlson, Kathleen F.; Kehle, Shannon M.; Meis, Laura A.; Greer, Nancy; MacDonald, Roderick; Rutks, Indulis; Sayer, Nina A.; Dobscha, Steven K.; Wilt, Timothy J.			Prevalence, Assessment, and Treatment of Mild Traumatic Brain Injury and Posttraumatic Stress Disorder: A Systematic Review of the Evidence	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						blast-related injury; comorbidity; military; postconcussive syndrome; posttraumatic stress disorder; systematic review; traumatic brain injury; veterans	MINOR HEAD-INJURY; WAR VETERANS; SELF-REPORT; POSTCONCUSSIVE SYMPTOMS; TERROR VICTIMS; PTSD; TBI; AFGHANISTAN; DEPLOYMENT; BLAST	Background: Iraq and Afghanistan war veterans are returning from combat having sustained traumatic brain injury, most commonly mild traumatic brain injury (mTBI), and experiencing posttraumatic stress disorder (PTSD). Clinical guidelines for mTBI and PTSD do not focus on the co-occurrence of these conditions (mTBI/PTSD). A synthesis of the evidence on prevalence, diagnostic accuracy, and treatment effectiveness for mTBI/PTSD would be of use to clinicians, researchers, and policymakers. Methods: We conducted a systematic review of studies identified through PubMed, PsycINFO, REHABDATA, Cochrane Library, pearling, and expert recommendations. Peer-reviewed English language studies published between 1980 and June, 2009 were included if they reported frequencies of traumatic brain injury and PTSD, or diagnostic accuracy or treatment effectiveness specific to mTBI/PTSD. Results: Thirty-four studies met inclusion criteria. None evaluated diagnostic accuracy or treatment effectiveness. Studies varied considerably in design. Frequency of mTBI/PTSD ranged from 0% to 89%. However, in 3 large studies evaluating Iraq and Afghanistan war veterans, frequencies of probable mTBI/PTSD were from 5% to 7%; among those with probable mTBI, frequencies of probable PTSD were from 33% to 39%. Discussion: The wide range of mTBI/PTSD frequency levels was likely due to variation across study parameters, including aims and assessment methods. Studies using consistent, validated methods to define and measure mTBI history and PTSD are needed.	[Carlson, Kathleen F.] Minneapolis VA Med Ctr 152 2E, VA Hlth Serv Res & Dev Serv, Ctr Chron Dis Outcomes Res, Minneapolis, MN 55417 USA; [Carlson, Kathleen F.; Kehle, Shannon M.; Meis, Laura A.; Sayer, Nina A.; Wilt, Timothy J.] Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA; [Sayer, Nina A.] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA; [Dobscha, Steven K.] Portland VA Med Ctr, Portland Ctr Study Chron ComorbidMental & Phys Di, Portland, OR USA	Carlson, KF (corresponding author), Minneapolis VA Med Ctr 152 2E, VA Hlth Serv Res & Dev Serv, Ctr Chron Dis Outcomes Res, 1 Vet Dr, Minneapolis, MN 55417 USA.	kathleen.carlson@va.gov	Sayer, Nina/E-3249-2016		Department of Veterans Affairs, Veterans Health Administration, Office of Research and DevelopmentUS Department of Veterans Affairs [ESP 09-009]; Postdoctoral Training Program [TPP 67-005]; Career Development Award Program [CDA 08-025]	This work was supported by Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development Evidence-based Synthesis Pilot Program (ESP 09-009), Postdoctoral Training Program (TPP 67-005), and Career Development Award Program (CDA 08-025) grants.	American Psychiatric Association, 1987, DIAGN STAT MAN MENT; American Psychiatric Association, 1980, DIAGN STAT MAN MENT, V3rd; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Barker-Collo SL, 2009, NEUROEPIDEMIOLOGY, V32, P1, DOI 10.1159/000170084; Batten SV, 2008, J CLIN PSYCHOL, V64, P928, DOI 10.1002/jclp.20513; Berthier ML, 2001, NEUROPSY NEUROPSY BE, V14, P23; Bombardier CH, 2006, J NEUROPSYCH CLIN N, V18, P501, DOI 10.1176/appi.neuropsych.18.4.501; Bossuyt PM, 2003, ANN INTERN MED, V138, P40, DOI 10.7326/0003-4819-138-1-200301070-00010; Brenner LA, 2009, MIL MED, V174, P347, DOI 10.7205/MILMED-D-01-5808; Brewin CR, 2005, J TRAUMA STRESS, V18, P53, DOI 10.1002/jts.20007; Bryant RA, 2004, PSYCHOSOM MED, V66, P760, DOI 10.1097/01.psy.0000138121.13198.84; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Bryant RA, 2001, CLIN PSYCHOL REV, V21, P931; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; Bryant RA, 2003, AM J PSYCHIAT, V160, P585, DOI 10.1176/appi.ajp.160.3.585; Bryant RA, 2000, BRAIN INJURY, V14, P175, DOI 10.1080/026990500120826; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Bryant RA, 2001, J NERV MENT DIS, V189, P109, DOI 10.1097/00005053-200102000-00006; Bryant RA, 1999, BRAIN INJURY, V13, P15, DOI 10.1080/026990599121836; Bryant RA, 2006, COGN BEHAV PRACT, V13, P17, DOI 10.1016/j.cbpra.2005.03.002; Carlson K, 2009, ASSESSMENT TREATMENT; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Centers for Disease Control and Prevention, 1999, TRAUM BRAIN INJ US R; Chalton LD, 2009, BRAIN INJURY, V23, P77, DOI 10.1080/02699050802635273; Creamer M, 2005, BEHAV RES THER, V43, P1383, DOI 10.1016/j.brat.2004.11.001; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; [Department of Veterans Affairs Office of Research and Development National Institute of Mental Health US Army Medical Research and Materiel Command], 2006, MAPP LANDS DEPL REL; Foa E.B., 2008, EFFECTIVE TREATMENTS; Gaylord KM, 2008, J TRAUMA, V64, pS200, DOI 10.1097/TA.0b013e318160ba42; Gil S, 2005, AM J PSYCHIAT, V162, P963, DOI 10.1176/appi.ajp.162.5.963; Golding H, 2009, J REHABIL RES DEV, V46, pVII, DOI 10.1682/JRRD.2009.06.0081; Greenspan AI, 2006, BRAIN INJURY, V20, P733, DOI 10.1080/02699050600773276; Harvey AG, 2000, AM J PSYCHIAT, V157, P626, DOI 10.1176/appi.ajp.157.4.626; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hickling EJ, 1998, BRAIN INJURY, V12, P265, DOI 10.1080/026990598122566; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2009, NEW ENGL J MED, V360, P1588, DOI 10.1056/NEJMp0810606; Hoofien D, 2001, BRAIN INJURY, V15, P189; Howe LLS, 2009, CLIN NEUROPSYCHOL, V23, P1315, DOI 10.1080/13854040903266928; Institute of Medicine, 2009, GULF WAR HLTH, V7; Jones C, 2005, J TRAUMA STRESS, V18, P181, DOI 10.1002/jts.20031; Kang HK, 2009, VHA ENV EPIDEMIOLOGY; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Kessler RC, 2000, J CLIN PSYCHIAT, V61, P4; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; King NS, 2008, BRAIN INJURY, V22, P1, DOI 10.1080/02699050701829696; Koenigs M, 2008, NAT NEUROSCI, V11, P232, DOI 10.1038/nn2032; Management of Concussion/mTBI Working Group, 2009, VA DOD CLIN PRACT GU; McAllister TW, 2009, CLIN NEUROPSYCHOL, V23, P1338, DOI 10.1080/13854040903277289; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCrea MA, 2007, MILD TRAUMATIC BRAIN; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; McGrath J, 1997, NEUROPSYCHOL REHABIL, V7, P231, DOI 10.1080/713755532; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; Mora AG, 2009, J TRAUMA, V66, pS178, DOI 10.1097/TA.0b013e31819ce2d6; Powell TJ, 1996, DISABIL REHABIL, V18, P231, DOI 10.3109/09638289609166306; President's Commission on Care for America's Returning Wounded Warriors, 2007, SERV SUPP SIMPL; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ruff RL, 2008, J REHABIL RES DEV, V45, P941, DOI 10.1682/JRRD.2008.02.0028; Sayer NA, 2009, J REHABIL RES DEV, V46, P703, DOI 10.1682/JRRD.2009.01.0008; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schnurr PP, 2006, J CONSULT CLIN PSYCH, V74, P707, DOI 10.1037/0022-006X.74.4.707; Schwab KA, 2006, NEUROLOGY, V66, pA235; Schwartz I, 2008, BRAIN INJURY, V22, P255, DOI 10.1080/02699050801941763; Schwartz I, 2007, ARCH PHYS MED REHAB, V88, P440, DOI 10.1016/j.apmr.2007.01.001; Sigford B, 2009, NEW ENGL J MED, V361, P536, DOI 10.1056/NEJMc096180; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Sumpter RE, 2006, BRAIN INJURY, V20, P93, DOI 10.1080/02699050500394090; Sumpter RE, 2005, BRIT J PSYCHIAT, V186, P423, DOI 10.1192/bjp.186.5.423; Sundin J, 2010, PSYCHOL MED, V40, P367, DOI 10.1017/S0033291709990791; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Task Force on Returning Global War on Terror Heroes, 2007, TASK FORC REP; Terhakopian A, 2008, J TRAUMA STRESS, V21, P290, DOI 10.1002/jts.20341; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; Turnbull SJ, 2001, BRAIN INJURY, V15, P775, DOI 10.1080/02699050110034334; US Department of Veterans Affairs Health Services Research and Development Service, VA EV SYNTH PROG ESP; Veterans Health Administration and Department of Defense, 2004, VA DOD CLIN PRACT GU; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Warden DL, 1997, J NEUROPSYCH CLIN N, V9, P18; Williams WH, 2002, BRAIN INJURY, V16, P673, DOI 10.1080/02699050210128861	86	181	182	0	31	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2011	26	2					103	115		10.1097/HTR.0b013e3181e50ef1			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	732OR	WOS:000288197200001	20631631				2021-06-18	
J	DePrince, AP; Weinzierl, KM; Combs, MD				DePrince, Anne P.; Weinzierl, Kristin M.; Combs, Melody D.			Executive function performance and trauma exposure in a community sample of children	CHILD ABUSE & NEGLECT			English	Article						Trauma; Child abuse; Executive function; Cognition; Dissociation; Anxiety	POSTTRAUMATIC-STRESS-DISORDER; NEUROPSYCHOLOGICAL FUNCTION; DISCIPLINARY PROBLEMS; ATTENTION; ADOLESCENTS; MALTREATMENT; DEPRESSION; PRETRAUMA; THREAT; ABUSE	Objective: Though children exposed to familial violence are reported to have difficulties with a range of emotional and behavioral problems (e.g., lower school achievement) that implicate executive function (EF) deficits, relatively little research has specifically examined EF as a function of trauma exposure in children. Methods: Based on parent report of children's exposure to potentially traumatic events, children (N = 110; Age(Mean) = 10.39) from an ethnically diverse community sample were compared across three trauma-exposure groups: familial trauma, non-familial trauma, and no trauma. Children completed a battery of tests to assess working memory, behavioral inhibition, processing speed, auditory attention, and interference control. Results: Familial trauma (relative to non-familial and no trauma exposure) was associated with poorer performance on an EF composite (composed of working memory, inhibition, auditory attention, and processing speed tasks); the effect size was medium. Both trauma-exposure status and dissociation symptoms explained unique variance in EF performance after controlling for anxiety symptoms, socio-economic status, and potential traumatic brain injury. While IQ and EF performance were related, SES predicted unique variance in IQ(and not EF) scores, while familial-trauma exposure did not. Conclusions: The contribution of trauma exposure to basic executive functioning held after taking into account symptoms (anxiety and dissociation), socio-econonnic status, and possible traumatic brain injury exposure. EF problems May Provide one route via which maltreated children become at risk for peer, academic, and behavior problems relative to their peers. Practice implications: EF problems may Provide one route via which maltreated children become at risk for peer, academic, psychological, and behavior problems relative to their peers. Recently, intervention strategies have emerged in the anxiety and mood disorder treatment literatures that appear to effectively target EFs. As future research continues to specify the relationship between child trauma exposure and EF performance, these innovative treatments may have important practice implications for addressing EF deficits. (C) 2009 Elsevier Ltd. All rights reserved.	[DePrince, Anne P.] Univ Denver, Dept Psychol, Denver, CO 80208 USA; [Combs, Melody D.] Univ Colorado, Denver, CO 80202 USA	DePrince, AP (corresponding author), Univ Denver, Dept Psychol, 2155 S Race St, Denver, CO 80208 USA.						Achenbach T. M., 1991, MANUAL CHILD BEHAV C; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Becker-Blease K. A., 2004, J TRAUMA DISSOCIATIO, V5, P113, DOI [10.1300/J229v05n01_07, DOI 10.1300/J229V05N01_07]; Beers SR, 2002, AM J PSYCHIAT, V159, P483, DOI 10.1176/appi.ajp.159.3.483; Bruce AS, 2007, J CLIN EXP NEUROPSYC, V29, P626, DOI 10.1080/13803390600878901; Cromer Lisa DeMarni, 2006, J Trauma Dissociation, V7, P135, DOI 10.1300/J229v07n04_08; Dalgleish T, 2001, PSYCHOL MED, V31, P541, DOI 10.1017/S0033291701003567; DePrince Anne P, 2005, J Trauma Dissociation, V6, P125, DOI 10.1300/J229v06n01_08; DePrince AP, 1999, PSYCHOL SCI, V10, P449, DOI 10.1111/1467-9280.00185; ECKENRODE J, 1993, DEV PSYCHOL, V29, P53, DOI 10.1037/0012-1649.29.1.53; El-Hage Wissam, 2006, Cogn Neuropsychiatry, V11, P33; FOA EB, 1991, J ABNORM PSYCHOL, V100, P156, DOI 10.1037/0021-843X.100.2.156; Freyd JJ, 2007, MEMORY, V15, P295, DOI 10.1080/09658210701256514; Friedman NP, 2006, PSYCHOL SCI, V17, P172, DOI 10.1111/j.1467-9280.2006.01681.x; Furr R. M., 2004, Understanding Statistics, V3, P1, DOI 10.1207/s15328031us0301_1; GORDON M, 1998, ATTENTION DEFICIT HY; Hollingshead AA, 1975, 4 FACTOR INDEX UNPUB; Ishikawa A, 2003, J NEUROSCI, V23, P9987; Jackson H, 2002, PROF PSYCHOL-RES PR, V33, P39, DOI 10.1037//0735-7028.33.1.39; KendallTackett KA, 1996, CHILD ABUSE NEGLECT, V20, P161, DOI 10.1016/S0145-2134(95)00139-5; Kremen WS, 2007, ARCH GEN PSYCHIAT, V64, P361, DOI 10.1001/archpsyc.64.3.361; Loftus GR, 1996, CURR DIR PSYCHOL SCI, V5, P161, DOI 10.1111/1467-8721.ep11512376; Ma SH, 2004, J CONSULT CLIN PSYCH, V72, P31, DOI 10.1037/0022-006X.72.1.31; MASTEN AS, 1998, J AGGRESS MALTREAT T, V2, P7, DOI DOI 10.1300/J146V02N01_02; MCKENNA FP, 1995, J EXP PSYCHOL LEARN, V21, P1595, DOI 10.1037/0278-7393.21.6.1595; Miller GA, 2001, J ABNORM PSYCHOL, V110, P40, DOI 10.1037//0021-843X.110.1.40; Mohlman J, 2004, BEHAV THERAPIST, V27, P37; Moradi AR, 1999, PSYCHOL MED, V29, P415, DOI 10.1017/S0033291798008009; Navalta CP, 2006, J NEUROPSYCH CLIN N, V18, P45, DOI 10.1176/appi.neuropsych.18.1.45; Papageorgiou C, 2000, COGN BEHAV PRACT, V7, P407, DOI 10.1016/S1077-7229(00)80051-6; Parslow RA, 2007, AM J PSYCHIAT, V164, P509, DOI 10.1176/appi.ajp.164.3.509; Pollak SD, 2000, DEV PSYCHOL, V36, P679, DOI [10.1037/0012-1649.36.5.679, 10.1037//0012-1649.36.5.679]; Putnam F.W., 1997, DISSOCIATION CHILDRE; Pynoos R., 1998, UCLA PTSD INDEX DSM; Rodriguez N., 2001, S COND ANN M INT SOC; Roussos A, 2005, AM J PSYCHIAT, V162, P530, DOI 10.1176/appi.ajp.162.3.530; Schretlen D, 1996, CLIN NEUROPSYCHOL, V10, P80, DOI 10.1080/13854049608406666; Segal Z.V., 2002, MINDFULNESS BASED CO; Shonk SM, 2001, DEV PSYCHOL, V37, P3, DOI 10.1037//0012-1649.37.1.3; SIMEON D, 2006, ANN M INT SOC TRAUM; Stein MB, 2002, BIOL PSYCHIAT, V52, P1079, DOI 10.1016/S0006-3223(02)01414-2; Tarullo AR, 2006, HORM BEHAV, V50, P632, DOI 10.1016/j.yhbeh.2006.06.010; Turkheimer E, 2003, PSYCHOL SCI, V14, P623, DOI 10.1046/j.0956-7976.2003.psci_1475.x; U. S. Census Bureau, 2008, US CENS BUR STAT COU; UDDO M, 1993, J PSYCHOPATHOL BEHAV, V15, P43, DOI 10.1007/BF00964322; Wechsler D., 2003, WECHSLER INTELLIGENC; Willcutt EG, 2005, CONTEMPORARY CLIN NE, P185; Willcutt EG, 2001, J ABNORM PSYCHOL, V110, P157, DOI 10.1037//0021-843X.1001.1.157	48	181	188	5	78	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0145-2134	1873-7757		CHILD ABUSE NEGLECT	Child Abuse Negl.	JUN	2009	33	6					353	361		10.1016/j.chiabu.2008.08.002			9	Family Studies; Psychology, Social; Social Work	Family Studies; Psychology; Social Work	459QN	WOS:000267118800008	19477515				2021-06-18	
J	Shames, J; Treger, I; Ring, H; Giaquinto, S				Shames, Jeffrey; Treger, Iuly; Ring, Haim; Giaquinto, Salvatore			Return to work following traumatic brain injury: Trends and challenges	DISABILITY AND REHABILITATION			English	Article						traumatic brain injury; work; vocational rehabilitation	MOTOR-VEHICLE ACCIDENTS; CLOSED-HEAD INJURY; SUPPORTED EMPLOYMENT; ACUTE PREDICTORS; SERUM-LEVELS; OUTCOMES; REHABILITATION; SEQUELAE; MODERATE; NEUROREHABILITATION	Purpose. The aim of this paper is to present the current knowledge regarding return to work (RTW) following traumatic brain injury (TBI). Method. Based on a Medline search, the authors reviewed the current TBI rehabilitation literature regarding (a) predictive factors for successful RTW, and (b) current concepts in rehabilitative strategies for successful RTW. Results. The functional consequences to the victim of traumatic brain injury (TBI) can be severe. Intensive rehabilitative efforts typically emphasize the early phase and address mainly the accompanying functional deficits in the realm of basic activities of daily living and mobility. An otherwise successful medical rehabilitation may end unsuccessfully because of the failure to return to work, with profound consequences to the individual and family, both economic and psychosocial. Even mild TBI may cause lasting problems in tasks calling for sustained attention. There appears to be a complex interaction between pre-morbid characteristics, injury factors, post injury impairments, personal and environmental factors in TBI patients, which influences RTW outcomes in ways that make prediction difficult. Injury severity and lack of self-awareness appear to be the most significant indicators of failure to RTW. Several medical, psychosocial and rehabilitative therapies are currently being implemented in rehabilitation settings which improve the chances of returning to work. Conclusion. Accurate prediction of whether a particular TBI patient will successfully return to work is not feasible, with RTW rates in the 12 - 70% range. A significant proportion of TBI patients, including those who are severely injured, are able to return to productive employment if sufficient and appropriate effort is invested. A comprehensive approach-medical and psychosocial-eventually entailing adequate vocational rehabilitation with supported employment can improve outcomes.	Loewenstein Hosp & Rehabil Ctr, Neurol Rehabil Dept, IL-43100 Raanana, Israel; Day Rehabil Ctr, Maccabi Hlth Serv, Rishon Leziyyon, Israel; Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel; IRCCS San Raffaele Pisana, Dept Neurol Rehabil, Rome, Italy	Ring, H (corresponding author), Loewenstein Hosp & Rehabil Ctr, Neurol Rehabil Dept, POB 3, IL-43100 Raanana, Israel.	hring@post.tau.ac.il	Treger, Iuly/H-6791-2015				Alexander M. P., 1997, SEMIN CLIN NEUROPSYC, V2, P177; Ben-Yishay Y., 1989, NEUROPSYCHOLOGICAL T, P271; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; Cattelani R, 2002, BRAIN INJURY, V16, P51, DOI 10.1080/02699050110088821; Chamelian L, 2004, ARCH PHYS MED REHAB, V85, P1662, DOI 10.1016/j.apmr.2004.02.012; Chua KSG, 1999, INT J REHABIL RES, V22, P189, DOI 10.1097/00004356-199909000-00005; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Devitt R, 2006, DISABIL REHABIL, V28, P547, DOI 10.1080/00222930500219258; Dijkers M, COMMUNITY INTEGRATIO; Dombovy ML, 1997, BRAIN INJURY, V11, P305, DOI 10.1080/026990597123467; Franulic A, 2004, BRAIN INJURY, V18, P119, DOI 10.1080/0269905031000149515; Freed S, 1997, BRAIN INJURY, V11, P25, DOI 10.1080/026990597123782; Friedland JF, 2001, J NERV MENT DIS, V189, P426, DOI 10.1097/00005053-200107000-00003; Gard Gunvor, 2006, Work, V26, P191; Gil M, 1996, BRAIN INJURY, V10, P39, DOI 10.1080/026990596124700; Girard D, 1996, BRAIN INJURY, V10, P663, DOI 10.1080/026990596124089; Gollaher K, 1998, BRAIN INJURY, V12, P255, DOI 10.1080/026990598122557; Greenspan AI, 1996, BRAIN INJURY, V10, P207, DOI 10.1080/026990596124520; Greenwald BA, 2003, ARCH PHYS MED REHAB, V84, pS3, DOI 10.1053/apmr.2003.50052; Groswasser Z, 2002, BRAIN INJURY, V16, P681, DOI 10.1080/02699050110119835; Gurka JA, 1999, J HEAD TRAUMA REHAB, V14, P247, DOI 10.1097/00001199-199906000-00005; Haboubi NHJ, 2001, DISABIL REHABIL, V23, P635; Harradine PG, 2004, MED J AUSTRALIA, V181, P130, DOI 10.5694/j.1326-5377.2004.tb06202.x; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Johansson U, 2001, DISABIL REHABIL, V23, P474; Kaipio ML, 2000, NEUROREPORT, V11, P1463; Keren O, 2001, BRAIN INJURY, V15, P531, DOI 10.1080/02699050010007371; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Klonoff PS, 2006, BRAIN INJURY, V20, P601, DOI 10.1080/02699050600744301; Klonoff PS, 1998, ARCH PHYS MED REHAB, V79, P684, DOI 10.1016/S0003-9993(98)90045-4; Klonoff PS, 2001, BRAIN INJURY, V15, P413, DOI 10.1080/02699050010005968; Kolakowsky-Hayner SA, 2001, NEUROREHABILITATION, V16, P41; KRAFT JF, 1993, ARCH PHYS MED REHAB, V74, P596, DOI 10.1016/0003-9993(93)90157-6; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Leung K L, 2005, Work, V25, P333; Malec JF, 1996, ARCH PHYS MED REHAB, V77, P198, DOI 10.1016/S0003-9993(96)90168-9; Matsushima Yasuyuki, 2001, Journal of UOEH, V23, P451; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; PAPATHANASOPOULOS P, 1994, EUR NEUROL, V34, P268, DOI 10.1159/000117054; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Possl O, 2001, BRAIN INJURY, V15, P15; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; REIDERGROSWASSER I, 1993, AM J ROENTGENOL, V160, P147, DOI 10.2214/ajr.160.1.8416613; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; RUFF RM, 1993, BRAIN INJURY, V7, P99; Ruffolo CF, 1999, ARCH PHYS MED REHAB, V80, P392, DOI 10.1016/S0003-9993(99)90275-7; RYAN T V, 1992, Brain Injury, V6, P175, DOI 10.3109/02699059209029656; Sangal RB, 1996, BIOL PSYCHIAT, V39, P305, DOI 10.1016/0006-3223(95)00447-5; Sbordone RJ, 2001, NEUROREHABILITATION, V16, P199; Segalowitz SJ, 2001, BRAIN COGNITION, V45, P342, DOI 10.1006/brcg.2000.1263; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; SHERER M, AWARENESS QUESTIONNA; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; Stranjalis G, 2004, J NEUROTRAUM, V21, P1070, DOI 10.1089/0897715041651088; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Vuadens P, 2006, COLLECT ACAD EUR MED, P143, DOI 10.1007/2-287-29745-6_10; Wagner AK, 2002, ARCH PHYS MED REHAB, V83, P107, DOI 10.1053/apmr.2002.27470; Walker WC, 2006, ARCH PHYS MED REHAB, V87, P1576, DOI 10.1016/j.apmr.2006.08.335; Watanabe TK, 2003, ARCH PHYS MED REHAB, V84, pS23, DOI 10.1053/apmr.2003.50054; Wehman P, 2005, J HEAD TRAUMA REHAB, V20, P115, DOI 10.1097/00001199-200503000-00001; Wehman P, 2003, ARCH PHYS MED REHAB, V84, P192, DOI 10.1053/apmr.2003.50027; WEHMAN P, 1994, AM J PHYS MED REHAB, V73, P280, DOI 10.1097/00002060-199407000-00010; WEHMAN P, 1989, J APPL BEHAV ANAL, V22, P395, DOI 10.1901/jaba.1989.22-395; WEHMAN P, 1993, AM J PHYS MED REHAB, V72, P355; Wright J, 2000, GLASGOW OUTCOME SCAL; WRIGHT J, FUNCTIONAL ASSESSMEN; Wright J., 2000, DISABILITY RATING SC	68	181	185	0	33	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.	SEP 15	2007	29	17					1387	1395		10.1080/09638280701315011			9	Rehabilitation	Rehabilitation	211XZ	WOS:000249558600007	17729084				2021-06-18	
J	McClincy, MP; Lovell, MR; Pardini, J; Collins, MW; Spore, MK				McClincy, MP; Lovell, MR; Pardini, J; Collins, MW; Spore, MK			Recovery from sports concussion in high school and collegiate athletes	BRAIN INJURY			English	Article						concussion; sport; TBI	TRAUMATIC BRAIN-INJURY; FOOTBALL PLAYERS; PERFORMANCE; STATEMENT	Introduction: Neuropsychological testing is a valuable tool in concussion diagnosis and management. ImPACT, a computerized neuropsychological testing program, consists of eight cognitive tasks and a 21-item symptom inventory. Method: ImPACT was used to examine the cognitive performance of 104 concussed athletes at baseline, 2, 7 and 14 days post-injury. Dependent measures included composite scores from the ImPACT computerized test battery, as well as a total symptom score from the Post-Concussion Symptom Scale. Results: Differences between baseline and day 2 post-injury scores were observed for all ImPACT composites (Verbal memory-VERM, visual memory-VISM, processing speed-PROC and reaction time-RT) as well as in total symptom score (SX). At day 7, concussed athletes continued to perform significantly poorer on VERM, VISM, RT and SX. At day 14, only VERM scores were significantly different from baseline. Conclusions: Cognitive performance deficits in concussed athletes may persist to 7 and even to 14 days in some cases. In addition to symptom status, the athlete's post-concussion cognitive functioning should be considered when making return-to-play decisions.	Dartmouth Coll, Dept Math, Hanover, NH 03755 USA; Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA	McClincy, MP (corresponding author), Dartmouth Coll, Dept Math, Hinman Box 1956, Hanover, NH 03755 USA.	dart97@dartmouth.edu					Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; Benedict RHB, 1998, CLIN NEUROPSYCHOL, V12, P43, DOI 10.1076/clin.12.1.43.1726; CANTU RC, 1995, PHYSICIAN SPORTSMED, V34, P2327; *CO MED SOC, 1991, REP SPORTS MED COMM; Collins Michael W, 2002, Curr Sports Med Rep, V1, P12; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; Hovda DA, 1999, SPORTS-RELATED CONCUSSION, P12; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Kelly JP, 1997, NEUROLOGY, V48, P581; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; LOVELL MR, 2001, NEUROLOGICAL SPORTS, P169; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Maroon JC, 2000, NEUROSURGERY, V47, P669; MCCREA M, 2000, J NEUROSURG, V50, P1032; MCCREA M, 2003, JAMA-J AM MED ASSOC, V290, P922; McKeag DB, 2003, JAMA-J AM MED ASSOC, V290, P2604, DOI 10.1001/jama.290.19.2604; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; *STATS, 2003, STAT V6 0	27	181	181	0	28	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2006	20	1					33	39		10.1080/02699050500309817			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	001AQ	WOS:000234505000004	16403698				2021-06-18	
J	Schulz, MR; Marshall, SW; Mueller, FO; Yang, JZ; Weaver, NL; Kalsbeek, WD; Bowling, JM				Schulz, MR; Marshall, SW; Mueller, FO; Yang, JZ; Weaver, NL; Kalsbeek, WD; Bowling, JM			Incidence and risk factors for concussion in high school athletes, North Carolina, 1996-1999	AMERICAN JOURNAL OF EPIDEMIOLOGY			English	Article						athletic injuries; brain concussion; Poisson distribution; risk factors; sports; students	COLLEGE FOOTBALL; INJURY INCIDENCE; UNITED-STATES; BRAIN-INJURY; PLAYERS; SPORTS; PERFORMANCE	A prospective cohort study was used to quantify risk factors for sports concussions. Analysis was based on a stratified cluster sample of North Carolina high school athletes followed during 1996-1999., Clustering was by school and sport, and the sample included 15,802 athletes with 1-8 seasons of follow-up per athlete. Concussion rates were estimated for 12 sports, and risk factors were quantified using generalized Poisson regression. Concussion rates ranged from 9.36 (96% confidence interval: 1.93,16.80) per 100,000 athlete-exposures in cheerleading to 33.09 (95% confidence interval: 24.74, 41.44) per 100,000 athlete-exposures in football, where "athlete-exposure" is one athlete participating in,one practice or game. The overall rate of concussion was 17.15 (95% confidence interval: 13.30i 21.00) per 100,000 athlete-exposures. Cheerleading was the only sport for which the practice rate was greater than the game rate. Almost two thirds of cheerleading concussions involved two-level pyramids. Concussion, rates were elevated for athletes with a history of concussion, and they increased with the increasing level of body contact permitted in the sport. After adjustment for sport, body mass index, and year in school, history of concussion(s) remained a moderately strong risk factor for concussion (rate ratio = 2.28, 95% confidence interval: 1.24, 4.19). The fact that concussion history is an important predictor of concussion incidence, even in this. young population, underscores the importance of primary prevention efforts, timely identification, and careful clinical management of these injuries.	Univ N Carolina, Sch Hlth & Human Performance, Dept Publ Hlth Educ, Greensboro, NC 27402 USA; Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC USA; Univ N Carolina, Sch Publ Hlth, Dept Orthoped, Chapel Hill, NC USA; Univ N Carolina, Sch Publ Hlth, Injury Prevent Res Ctr, Chapel Hill, NC USA; Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC USA; Univ N Carolina, Sch Publ Hlth, Dept Hlth Behav & Hlth Educ, Chapel Hill, NC USA; St Louis Univ, Hlth Commun Res Lab, St Louis, MO 63103 USA; St Louis Univ, Dept Community Hlth, St Louis, MO 63103 USA; Univ N Carolina, Sch Publ Hlth, Dept Biostat, Survey Res Unit, Chapel Hill, NC USA	Schulz, MR (corresponding author), Univ N Carolina, Sch Hlth & Human Performance, Dept Publ Hlth Educ, 437 HHP Bldg,POB 26170, Greensboro, NC 27402 USA.	mrschulz@uncg.edu	Yang, Jingzhen/N-4786-2014	Marshall, Stephen/0000-0002-2664-9233	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [R01AR042297] Funding Source: NIH RePORTER; NIAMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [R01AR42297] Funding Source: Medline; ODCDC CDC HHS [R49/CCR402444] Funding Source: Medline		ALBRIGHT JP, 1985, AM J SPORT MED, V13, P147, DOI 10.1177/036354658501300301; BRESLOW NE, 1987, IARC SCI PUBL, V82, P132; BUCKLEY WE, 1988, AM J SPORT MED, V16, P51, DOI 10.1177/036354658801600109; *C NEUR SURG, 1966, CLIN NEUROSURG, V12, P386; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; DICK RW, 1994, AM SOC TEST MATER, V1229, P13, DOI 10.1520/STP12799S; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Goodman D, 2001, MED SCI SPORT EXER, V33, P2004, DOI 10.1097/00005768-200112000-00005; GREENLAND S, 1998, MODERN EPIDEMIOLOGY, P350; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; GUSKIEWICZ KM, 2000, AM J SPORTS MED, V28, P1; HAREL Y, 1994, AM J PUBLIC HEALTH, V84, P599, DOI 10.2105/AJPH.84.4.599; Jackson CO, 1944, RES QUART, V15, P303, DOI 10.1080/10671188.1944.10621230; LANDRY GL, 1992, PEDIATR ANN, V21, P165, DOI 10.3928/0090-4481-19920301-07; LLOYD FS, 1939, SAFETY ATHLETICS PRE; LYSENS RJ, 1991, SPORTS MED, V12, P281, DOI 10.2165/00007256-199112050-00001; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; Marshall SW, 2001, J ATHL TRAINING, V36, P334; MUELLER FO, 2002, FINAL REPORT N CAROL, pCH2; *NAT FED STAT HIGH, 2001, NFHS 2001 HIGH SCH A; Phillips LH, 2000, BRIT J SPORT MED, V34, P133, DOI 10.1136/bjsm.34.2.133; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; *RES TRIANGL I, 2001, SUDAAN US MAN REL 8; RYAN AJ, 1959, AM J SURG, V98, P325, DOI 10.1016/0002-9610(59)90521-5; Schulz MR, 2004, AM J SPORT MED, V32, P396, DOI 10.1177/0363546503261715; Sosin DM, 1996, BRAIN INJURY, V10, P47; Stokes ME, 2000, CATEGORICAL DATA ANA, P469; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Walter S D, 1990, Exerc Sport Sci Rev, V18, P417; Weaver NL, 1999, MED SCI SPORT EXER, V31, P176, DOI 10.1097/00005768-199901000-00027	31	181	182	1	18	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9262			AM J EPIDEMIOL	Am. J. Epidemiol.	NOV 15	2004	160	10					937	944		10.1093/aje/kwh304			8	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	871KW	WOS:000225133600002	15522850	Bronze			2021-06-18	
J	Whiteneck, GG; Harrison-Felix, CL; Mellick, DC; Brooks, C; Charlifue, SB; Gerhart, KA				Whiteneck, GG; Harrison-Felix, CL; Mellick, DC; Brooks, C; Charlifue, SB; Gerhart, KA			Quantifying environmental factors: A measure of physical, attitudinal, service, productivity, and policy barriers	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						barriers; architectural; disabled persons; environment design; rehabilitation	WITH-DISABILITIES-ACT; WHEELCHAIR ACCESSIBILITY; PUBLIC BUILDINGS; PEOPLE; HEALTH	Objective: To develop and test a new instrument to assess environmental barriers encountered by people with and without disabilities by using a questionnaire format. Design: New instrument development. Setting: A rehabilitation hospital and community. Participants: Two convenience samples: (1) 97 subjects, 50 with disabilities and 47 without disability, and (2) 409 subjects with disabilities from spinal cord injury, traumatic brain injury, multiple sclerosis, amputation, or auditory or visual impairments. In addition, a population-based sample in Colorado of 2269 people (mean age, 44y; 57% men) with and without disabilities. Interventions: Not applicable. Main Outcome Measures: Item development; factor structure; test-retest, subject-proxy and internal consistency reliability; content, construct, and discriminant validity; and subscale and abbreviated version development. Results: Panels of experts on disability developed items for the Craig Hospital Inventory of Environmental Factors (CHIEF). The instrument measured the frequency and magnitude of environmental barriers reported by individuals. Five subscales were derived from factor analysis measuring (1) attitudes and support, (2) services and assistance, (3) physical and structural, (4) policy, and (5) work and school environmental barriers. The CHIEF total score had high test-retest reliability (intraclass correlation coefficient [ICC]=.93) and high internal consistency (Cronbach a=.93), but lower participant-proxy agreement (ICC=.62). Significant differences were found in CHIEF scores among groups of people with known differences in disability levels and disability categories. Conclusions: The CHIEF has good test-retest and internal consistency reliability with evidence of content, construct, and discriminant validity resulting from its development strategy and psychometric assessments in samples of the general population and among people with a variety of disabilities.	Craig Hosp, Res Dept, Englewood, CO 80113 USA	Harrison-Felix, CL (corresponding author), Craig Hosp, Res Dept, 3425 S Clarkson St, Englewood, CO 80113 USA.	charrison-felix@craighospital.org			ODCDC CDC HHS [R04/CCR814132] Funding Source: Medline		Ahn Helen C., 1994, Journal of Burn Care and Rehabilitation, V15, P176; Antonak RF, 2000, DISABIL REHABIL, V22, P211; BRONFENBRENNER U, 1977, AM PSYCHOL, V32, P513, DOI 10.1037/0003-066x.32.7.513; Craig Hospital Research Department, 2001, CRAIG HOSP INV ENV F; Cusick CP, 2001, ARCH PHYS MED REHAB, V82, P1018, DOI 10.1053/apmr.2001.25098; Danford S, 1997, FUNCTIONAL ASSESSMEN, P37; Figoni SF, 1998, TOPICS SPINAL CORD I, V3, P66; FOUGEYROLLAS P, 1995, DISABIL REHABIL, V17, P145, DOI 10.3109/09638289509166709; FOUGEYROLLAS P, 1993, ICIDH INT NETWORK NE, V6; GO BK, 2002, MODEL SPINAL CORD IN; Grabois EW, 1999, ARCH FAM MED, V8, P44, DOI 10.1001/archfami.8.1.44; Gray DB, 2003, J ARCHIT PLAN RES, V20, P29; *I MED, 1997, EN AM ASS ROL REH SC; JOHNSON VM, 1994, IEEE EXPERT, V9, P3, DOI 10.1109/64.311273; *KESSL MED REH RES, 2002, TRAUM BRAIN INJ MOD; Lochner K, 1999, HEALTH PLACE, V5, P259, DOI 10.1016/S1353-8292(99)00016-7; MARTIN LM, 1987, AM J OCCUP THER, V41, P217, DOI 10.5014/ajot.41.4.217; MCCLAIN L, 1990, AM J OCCUP THER, V44, P487, DOI 10.5014/ajot.44.6.487; McClain L, 2000, PUBLIC HEALTH NURS, V17, P178, DOI 10.1046/j.1525-1446.2000.00178.x; MCCLAIN L, 1993, AM J OCCUP THER, V47, P619, DOI 10.5014/ajot.47.7.619; Nary DE, 2000, TOP SPINAL CORD INJ, V6, P87, DOI DOI 10.1310/B9FH-7X8B-HUBR-3RHN; *NAT CTR CHRON DIS, 1999 BEH RISK FACT S; *NAT CTR CHRON DIS, BEH RISK FACT SURV; *NAT CTR CHRON DIS, TECHN INF DAT TECHN; Rimmer JH, 1999, PHYS THER, V79, P495, DOI 10.1093/ptj/79.5.495; Roberts K K, 1986, Rehabil Nurs, V11, P20; *SPSS, 2002, STAT PACK SOC SCI RE; U.S Department of Health and Human Services, 2000, HLTH PEOPL 2010; Useh U, 2001, DISABIL REHABIL, V23, P490; Veenstra G, 2000, SOC SCI MED, V50, P619, DOI 10.1016/S0277-9536(99)00307-X; Whiteneck G. G., 1997, ASSESSING MED REHABI, P91; WHITENECK GG, 2000, PHYS MED REHABILITAT, P19; World Health Organization, 2001, INT CLASS FUNCT DIS; ZISSERMANN L, 1989, PARAPLEGIA, V27, P370, DOI 10.1038/sc.1989.57; 2000, MMWR MORB MORTAL WKL, V49, P711	35	181	184	2	33	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2004	85	8					1324	1335		10.1016/j.apmr.2003.09.027			12	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	846CK	WOS:000223292200018	15295760				2021-06-18	
J	Jiang, JY; Yu, MK; Zhu, C				Jiang, JY; Yu, MK; Zhu, C			Effect of long-term mild hypothermia therapy in patients with severe traumatic brain injury: 1-year follow-up review of 87 cases	JOURNAL OF NEUROSURGERY			English	Article						hypothermia; traumatic brain injury; outcome	CONTROLLED CORTICAL IMPACT; SEVERE HEAD-INJURY; MODERATE HYPOTHERMIA; NEURONAL INJURY; RAT; TEMPERATURE; ISCHEMIA; HYPOXIA	Object. The goal of this study was to investigate the protective effects of long-term (3-14 days) mild hypothermia therapy (33-35 degrees C) on outcome in 87 patients with severe traumatic brain injury (TBI) (Glasgow Coma Scale score less than or equal to 8). Methods. In 43 patients assigned to a mild hypothermia group, body temperatures were cooled to 33 to 35 degrees C a mean of 15 hours after injury and kept at 33 to 35 degrees C for 3 to 14 days. Rewarming commenced when the individual patient's intracranial pressure (ICP) returned to the normal level. Body temperatures in 44 patients assigned to a normothermia group were maintained at 37 to 38 degrees C. Each patient's outcome was evaluated 1 year later by using the Glasgow Outcome Scale. One year after TBI, the mortality rate was 25.58% (11 of 43 patients) and the rate of favorable outcome (good recovery or moderate disability) was 46.51% (20 of 43 patients) in the mild hypothermia group. In the normothermia group, the mortality rate was 45.45% (20 of 44 patients) and the rate of favorable outcome was 27.27% (12 of 44 patients) (p < 0.05). Induced mild hypothermia also markedly reduced ICP (p < 0.01) and inhibited hyperglycemia (p < 0.05). The rates of complication were not significantly different between the two groups. Conclusions. The data produced by this study demonstrate that long-term mild hypothermia therapy significantly improves outcomes in patients with severe TBI.	Chang Zheng Hosp, Dept Neurosurg, Shanghai Neurosurg Inst, Shanghai 2000003, Peoples R China	Jiang, JY (corresponding author), Chang Zheng Hosp, Dept Neurosurg, Shanghai Neurosurg Inst, 415 Feng Yang Rd, Shanghai 2000003, Peoples R China.						BUSTO R, 1989, STROKE, V20, P904, DOI 10.1161/01.STR.20.7.904; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CHOPP M, 1991, STROKE, V22, P37, DOI 10.1161/01.STR.22.1.37; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CLIFTON GL, 1995, J NEUROTRAUM, V12, P923, DOI 10.1089/neu.1995.12.923; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; GREEN EJ, 1992, BRAIN RES, V580, P197, DOI 10.1016/0006-8993(92)90945-6; HAGERDAL M, 1979, ACTA ANAESTH SCAND, V23, P89; Hayashi N, 1997, NEUROCHEMISTRY, P97; JENNETT B, 1975, LANCET, V1, P480; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; JIANG JY, 1996, INT C NEUR ABSTR, P209; Kaibara T, 1999, J NEUROSURG, V90, P339, DOI 10.3171/jns.1999.90.2.0339; LIANG YM, 1997, CHIN J NEUROSURG, V13, P351; Marion DW, 1996, J NEUROTRAUM, V13, P139, DOI 10.1089/neu.1996.13.139; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Metz C, 1996, J NEUROSURG, V85, P533, DOI 10.3171/jns.1996.85.4.0533; MITANI A, 1991, BRAIN RES, V562, P159, DOI 10.1016/0006-8993(91)91201-B; MITANI A, 1991, NEUROSCIENCE, V42, P661, DOI 10.1016/0306-4522(91)90035-M; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; TAFT WC, 1993, J CEREBR BLOOD F MET, V13, P796, DOI 10.1038/jcbfm.1993.101; TEASDALE G, 1974, LANCET, V2, P81; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; WELSH FA, 1990, J CEREBR BLOOD F MET, V10, P557, DOI 10.1038/jcbfm.1990.98; Yamamoto M, 1999, J NEUROTRAUM, V16, P487, DOI 10.1089/neu.1999.16.487; 1996, J NEUROTRAUMA, V13, P639	30	181	201	0	9	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903 USA	0022-3085			J NEUROSURG	J. Neurosurg.	OCT	2000	93	4					546	549		10.3171/jns.2000.93.4.0546			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	357BH	WOS:000089478300002	11014530				2021-06-18	
J	Zausinger, S; Hungerhuber, E; Baethmann, A; Reulen, HJ; Schmid-Elsaesser, R				Zausinger, S; Hungerhuber, E; Baethmann, A; Reulen, HJ; Schmid-Elsaesser, R			Neurological impairment in rats after transient middle cerebral artery occlusion: a comparative study under various treatment paradigms	BRAIN RESEARCH			English	Article						animal studies; rats; cerebral ischemia; focal; behavior; rotarod	TRAUMATIC BRAIN INJURY; FOCAL ISCHEMIA; NEUROPROTECTIVE EFFICACY; SUBARACHNOID HEMORRHAGE; SENSORIMOTOR FUNCTION; COMBINATION THERAPY; FOREBRAIN ISCHEMIA; MOTOR DYSFUNCTION; RECOVERY; MODEL	The assessment of the functional outcome - in addition to the conventional endpoints as histomorphometry of the ischemic brain damage - for the evaluation of cerebroprotective therapies is increasingly recommended, although there is little consensus on appropriate procedures. We evaluated a battery of sensorimotor tasks in rats after transient middle cerebral artery occlusion (MCAO) to select those with the highest potential to discriminate between various degrees of neuronal damage. A total of 40 Sprague-Dawley rats were subjected to 90 min of MCAO and assigned to one of four treatment arms: (1) sham-operated controls, (2) vehicle-treated controls, (3) moderately effective neuroprotection by 2x100 mg/kg alpha-phenyl-N-tert-butyl nitrone (PBN), (4) highly effective neuroprotection by mild hypothermia (33 degrees C). Functional deficits were daily quantified using the beam balance task (1.5 cm, 2.5 cm diameter rectangular and 2.5 cm diameter cylindrical beam), the prehensile traction task, the rotarod, and a six-point neum-score. Infarction of cerebral cortex and basal ganglia was assessed one week after ischemia. Treatment with PEN significantly reduced cortical infarction (-31%), while treatment with hypothermia resulted in a significantly smaller infarct volume of cortex (-94%) and basal ganglia (-27%). Beam balance, prehensile traction and rotarod failed to demonstrate any difference in motor performance. The six-point neuro-score showed a significant correlation with cortical infarction from day 2 and with total infarct volume from day 3. The smaller the reduction of infarct volume, the later the corresponding difference in neuro-score became apparent. Functional outcome after MCAO in rats can be assessed by a relatively simple measurement of neurological deficit. The slope of functional recovery is closely related with the degree of the morphological, particularly cortical damage. If expected treatment effects are small, an observation period of at least 3 days should be planned far the study design. The functional impairment from focal brain ischemia and its subsequent recovery could provide valuable information for future studies evaluating the neuroprotective potential of novel agents and procedures. (C) 2000 Elsevier Science B.V. All rights reserved.	Univ Munich, Klinikum Grosshadern, Dept Neurosurg, D-81377 Munich, Germany; Univ Munich, Klinikum Grosshadern, Inst Surg Res, D-81377 Munich, Germany	Zausinger, S (corresponding author), Univ Munich, Klinikum Grosshadern, Dept Neurosurg, Marchioninistr 15, D-81377 Munich, Germany.						Alexis NE, 1996, BRAIN RES, V706, P273, DOI 10.1016/0006-8993(95)01180-3; ANDERSEN CS, 1991, PHYSIOL BEHAV, V50, P263, DOI 10.1016/0031-9384(91)90065-V; Aronowski J, 1996, J CEREBR BLOOD F MET, V16, P705, DOI 10.1097/00004647-199607000-00022; BARONE FC, 1992, NEUROSCI BIOBEHAV R, V16, P219, DOI 10.1016/S0149-7634(05)80182-4; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Bolay H, 1998, STROKE, V29, P1988, DOI 10.1161/01.STR.29.9.1988; BORLONGAN CV, 1995, PHYSIOL BEHAV, V58, P909, DOI 10.1016/0031-9384(95)00103-P; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CAO XH, 1994, BRAIN RES, V644, P267, DOI 10.1016/0006-8993(94)91689-6; CARTMELL SM, 1991, J PHARMACOL METHOD, V26, P149, DOI 10.1016/0160-5402(91)90063-B; CASTRO AJ, 1972, BRAIN RES, V37, P173, DOI 10.1016/0006-8993(72)90665-8; CHEN H, 1994, ANN NEUROL, V35, P458, DOI 10.1002/ana.410350414; COMBS DJ, 1987, STROKE, V18, P503, DOI 10.1161/01.STR.18.2.503; Corbett D, 1998, PROG NEUROBIOL, V54, P531, DOI 10.1016/S0301-0082(97)00078-6; DEGRABA TJ, 1994, J CEREBR BLOOD F MET, V14, P262, DOI 10.1038/jcbfm.1994.33; DERYCK M, 1990, STROKE, V21, P158; DERYCK M, 1990, EUR NEUROL, V30, P21; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DUNNMEYNELL AA, 1995, BRAIN RES, V675, P143, DOI 10.1016/0006-8993(95)00050-Z; GARCIA JH, 1995, STROKE, V26, P627, DOI 10.1161/01.STR.26.4.627; GERMANO AF, 1994, J NEUROTRAUM, V11, P345, DOI 10.1089/neu.1994.11.345; GIONET TX, 1991, STROKE, V22, P1040, DOI 10.1161/01.STR.22.8.1040; GOLDSTEIN LB, 1993, J NEUROSCI METH, V48, P35, DOI 10.1016/S0165-0270(05)80005-6; GRABOWSKI M, 1993, STROKE, V24, P889, DOI 10.1161/01.STR.24.6.889; HALL RD, 1974, BRAIN RES, V66, P23, DOI 10.1016/0006-8993(74)90076-6; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; Heath DL, 1997, NEUROSCI LETT, V228, P175, DOI 10.1016/S0304-3940(97)00394-7; Hunter AJ, 1998, TRENDS PHARMACOL SCI, V19, P59, DOI 10.1016/S0165-6147(97)01157-7; KARIBE H, 1995, J NEUROSURG, V83, P93, DOI 10.3171/jns.1995.83.1.0093; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; MARKGRAF CG, 1994, STROKE, V25, P153, DOI 10.1161/01.STR.25.1.153; MARKGRAF CG, 1992, BRAIN RES, V575, P238, DOI 10.1016/0006-8993(92)90085-N; MENZIES SA, 1992, NEUROSURGERY, V31, P100, DOI 10.1227/00006123-199207000-00014; MONTOYA CP, 1991, J NEUROSCI METH, V36, P219, DOI 10.1016/0165-0270(91)90048-5; Nagayama M, 1998, J CEREBR BLOOD F MET, V18, P1107, DOI 10.1097/00004647-199810000-00007; NEAFSEY EJ, 1982, BRAIN RES, V232, P151, DOI 10.1016/0006-8993(82)90617-5; OKADA M, 1995, J CEREBR BLOOD F MET, V15, P505, DOI 10.1038/jcbfm.1995.62; Pellegrino L.J., 1979, STEREOTAXIC ATLAS RA; PERSSON L, 1989, STROKE, V20, P641, DOI 10.1161/01.STR.20.5.641; ROBINSON SE, 1990, BRAIN RES, V511, P141, DOI 10.1016/0006-8993(90)90233-2; Rogers DC, 1997, STROKE, V28, P2060, DOI 10.1161/01.STR.28.10.2060; Sakai N, 1996, BEHAV BRAIN RES, V77, P181, DOI 10.1016/0166-4328(95)00232-4; Schmid-Elsaesser R, 1998, STROKE, V29, P2162, DOI 10.1161/01.STR.29.10.2162; Schmid-Elsaesser R, 2000, EXP BRAIN RES, V130, P60, DOI 10.1007/s002210050006; Schmid-Elsaesser R, 1999, NEUROSURGERY, V44, P163, DOI 10.1097/00006123-199901000-00100; Schmid-Elsaesser R, 1999, STROKE, V30, P1891, DOI 10.1161/01.STR.30.9.1891; Schmid-Elsaesser R, 1998, EXP BRAIN RES, V122, P121, DOI 10.1007/s002210050498; Schmid-Elsaesser R, 1999, BRAIN RES, V816, P471, DOI 10.1016/S0006-8993(98)01197-4; SchmidElsaesser R, 1997, STROKE, V28, P2018, DOI 10.1161/01.STR.28.10.2018; Scremin Oscar U., 1995, P3; Smith SE, 1997, NEUROSCIENCE, V77, P1123, DOI 10.1016/S0306-4522(96)00530-1; TUPPER DE, 1980, ACTA NEUROBIOL EXP, V40, P999; vanderStaay FJ, 1996, BRAIN RES, V715, P180, DOI 10.1016/0006-8993(95)01581-7; WAHL F, 1992, STROKE, V23, P267, DOI 10.1161/01.STR.23.2.267; WARNER DS, 1995, J CEREBR BLOOD F MET, V15, P188, DOI 10.1038/jcbfm.1995.24; WHISHAW IQ, 1986, BRAIN, V109, P805, DOI 10.1093/brain/109.5.805; Wood NI, 1996, BEHAV BRAIN RES, V78, P113, DOI 10.1016/0166-4328(95)00237-5; YAMAMOTO M, 1988, BRAIN RES, V452, P323, DOI 10.1016/0006-8993(88)90036-4; YANG GY, 1994, NEUROSURGERY, V34, P339, DOI 10.1097/00006123-199402000-00018; Yonemori F, 1998, J CEREBR BLOOD F MET, V18, P1099, DOI 10.1097/00004647-199810000-00006; ZHAO Q, 1994, BRAIN RES, V649, P253, DOI 10.1016/0006-8993(94)91071-5	63	181	233	0	13	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	APR 28	2000	863	1-2					94	105		10.1016/S0006-8993(00)02100-4			12	Neurosciences	Neurosciences & Neurology	309BQ	WOS:000086747800011	10773197				2021-06-18	
J	Yoles, E; Schwartz, M				Yoles, E; Schwartz, M			Degeneration of spared axons following partial white matter lesion: Implications for optic nerve neuropathies	EXPERIMENTAL NEUROLOGY			English	Article						neuroprotection; secondary degeneration; optic nerve; CNS trauma	TRAUMATIC BRAIN INJURY; PHARMACOLOGICAL TREATMENT; EXPERIMENTAL-MODEL; SPINAL-CORD; CELL-DEATH; GLAUCOMA; DAMAGE; REGENERATION; MECHANISMS; STRATEGIES	Neuroprotective therapy is a relatively new development in the approach to the treatment of acute and chronic brain damage. Though initially viewed in the framework of acute CNS injuries, the concept was recently extended to include chronic injuries, in which at any given time there are some neurons in an acute phase of degeneration coexisting with others that are healthy, marginally damaged, or dead. The healthy neurons and those that are only marginally damaged are the potential targets for neuroprotection. For the development of neuroprotective therapies, it is essential to employ an animal model in which the damage resulting from secondary degeneration can be quantitatively distinguished from primary degeneration. This is of particular relevance when the site of the damage is in the white matter (nerve fibers) rather than in the gray matter (cell bodies). In the present work we reexamine the concepts of secondary degeneration and neuroprotection in white matter lesions. Using a partial crush injury of the adult rat optic nerve as a model, we were able to assess both primary and secondary nerve damage. We show that neurons whose axons were not damaged or only marginally damaged after an acute insult will eventually degenerate as a consequence of their existence in the degenerative environment produced by the injury. This secondary degeneration does not occur in all of the neurons at once, but affects them in a stepwise fashion related to the severity of the damage inflicted. These findings, which may be applicable to the progression of acute or chronic neuropathy, imply that neuroprotective therapy may have a beneficial effect even if there is a time lag between injury and treatment. (C) 1998 Academic Press.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel	Schwartz, M (corresponding author), Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel.						ASSIA E, 1989, BRAIN RES, V476, P205, DOI 10.1016/0006-8993(89)91240-7; Basso DM, 1996, J NEUROTRAUM, V13, P343, DOI 10.1089/neu.1996.13.343; BAZAN NG, 1995, J NEUROTRAUM, V12, P791, DOI 10.1089/neu.1995.12.791; Bernert H, 1996, P NATL ACAD SCI USA, V93, P5235, DOI 10.1073/pnas.93.11.5235; Brubaker RF, 1996, AM J OPHTHALMOL, V121, P473, DOI 10.1016/S0002-9394(14)75421-2; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; DUVDEVANI R, 1990, RESTOR NEUROL NEUROS, V2, P31, DOI 10.3233/RNN-1990-2104; Faden AI, 1996, JAMA-J AM MED ASSOC, V276, P569, DOI 10.1001/jama.276.7.569; Faden AI, 1996, PHARMACOL TOXICOL, V78, P12, DOI 10.1111/j.1600-0773.1996.tb00173.x; Gean A D, 1995, New Horiz, V3, P549; GROTTA J, 1995, J INTERN MED, V237, P89, DOI 10.1111/j.1365-2796.1995.tb01145.x; Hilton G, 1994, J Neurosci Nurs, V26, P251; Kimura H, 1996, J COMPUT ASSIST TOMO, V20, P540, DOI 10.1097/00004728-199607000-00007; KORNHUBER J, 1994, J NEURAL TRANSM-SUPP, P91; LIU DX, 1994, J NEUROCHEM, V62, P37; LIU DX, 1993, J NEUROTRAUM, V10, P349, DOI 10.1089/neu.1993.10.349; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MORGAN JE, 1994, BRIT J OPHTHALMOL, V78, P875, DOI 10.1136/bjo.78.11.875; OLANOW CW, 1993, TRENDS NEUROSCI, V16, P439, DOI 10.1016/0166-2236(93)90070-3; PEARSON HE, 1993, EXP NEUROL, V119, P113, DOI 10.1006/exnr.1993.1012; QUIGLEY HA, 1987, INVEST OPHTH VIS SCI, V28, P913; Schulz JB, 1996, NEUROSCIENCE, V71, P1043, DOI 10.1016/0306-4522(95)00527-7; SCHUMER RA, 1994, ARCH OPHTHALMOL-CHIC, V112, P37, DOI 10.1001/archopht.1994.01090130047015; Schwartz M, 1996, PROG RETIN EYE RES, V15, P569, DOI 10.1016/1350-9462(96)00013-4; SIESJO BK, 1995, J NEUROTRAUM, V12, P943, DOI 10.1089/neu.1995.12.943; Smith D H, 1995, New Horiz, V3, P562; THANOS S, 1993, J NEUROSCI, V13, P455; Trembly B, 1995, ANN NY ACAD SCI, V765, P1, DOI 10.1111/j.1749-6632.1995.tb16554.x; YAKOVLEV AG, 1995, J NEUROTRAUM, V12, P767, DOI 10.1089/neu.1995.12.767; YOLES E, 1992, INVEST OPHTH VIS SCI, V33, P3586; Yoles E, 1996, J NEUROTRAUM, V13, P49, DOI 10.1089/neu.1996.13.49; ZAUNER A, 1995, J NEUROTRAUM, V12, P547, DOI 10.1089/neu.1995.12.547	34	181	192	0	3	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	SEP	1998	153	1					1	7		10.1006/exnr.1998.6811			7	Neurosciences	Neurosciences & Neurology	124KJ	WOS:000076181200001	9743562				2021-06-18	
J	Scheff, SW; Baldwin, SA; Brown, RW; Kraemer, PJ				Scheff, SW; Baldwin, SA; Brown, RW; Kraemer, PJ			Morris water maze deficits in rats following traumatic brain injury: Lateral controlled cortical impact	JOURNAL OF NEUROTRAUMA			English	Article						Morris water maze; cognitive deficits; hippocampus; spatial learning; head injury; concussion; cortical contusion	CLOSED-HEAD-INJURY; FLUID-PERCUSSION MODEL; SPATIAL LOCALIZATION; COGNITIVE DEFICITS; PHOSPHATIDYLINOSITOL BISPHOSPHATE; HIPPOCAMPAL-FORMATION; REGIONAL LEVELS; AMINO-ACIDS; LONG-TERM; MEMORY	This experiment utilized a laterally placed controlled cortical impact model of traumatic brain injury (TBI) to assess changes on spatial learning and memory in the Morris water maze (MWM), Adult rats were subjected to one of two different levels of cortical injury, mild (1 mm) or moderate (2 mm) deformation, and subsequently tested for their ability to learn (acquisition) or remember (retention) a spatial task, 7 or 14 days after injury, Results revealed an injury-dependent deficit for experimental animals compared to sham-operated controls. Not only did the TBI result in longer escape latencies, but also significant deficits in search time and relative target visits, Although the moderately injured animals demonstrated significant histopathology in the cortex and hippocampus, mildly injured subjects demonstrated no obvious tissue destruction, but did manifest significant behavioral change. These results demonstrate that a laterally placed controlled cortical impact is capable of producing significant cognitive deficits on both acquisition and retention paradigms utilizing the MWM.	UNIV KENTUCKY,DEPT PSYCHOL,LEXINGTON,KY 40536	Scheff, SW (corresponding author), UNIV KENTUCKY,SANDERS BROWN CTR AGING,311 SANDERS BROWN,LEXINGTON,KY 40536, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS031220] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS31220] Funding Source: Medline		Baldwin SA, 1996, GLIA, V16, P266; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Baldwin SA, 1996, J NEUROSURG, V85, P476, DOI 10.3171/jns.1996.85.3.0476; BANNERMAN DM, 1995, NATURE, V378, P182, DOI 10.1038/378182a0; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BRANDEIS R, 1989, INT J NEUROSCI, V48, P29, DOI 10.3109/00207458909002151; Brown RW, 1997, DEV PSYCHOBIOL, V30, P329, DOI 10.1002/(SICI)1098-2302(199705)30:4<329::AID-DEV6>3.0.CO;2-Q; DASH PK, 1995, J NEUROSCI, V15, P2030; DHILLON HS, 1994, J NEUROTRAUM, V11, P405, DOI 10.1089/neu.1994.11.405; DHILLON HS, 1995, BRAIN RES, V698, P100, DOI 10.1016/0006-8993(95)00840-M; DIMATTIA BD, 1988, BEHAV NEUROSCI, V102, P471, DOI 10.1037/0735-7044.102.4.471; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; EICHENBAUM H, 1990, J NEUROSCI, V10, P3531; EWERT J, 1989, ARCH NEUROL-CHICAGO, V46, P911, DOI 10.1001/archneur.1989.00520440105027; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GONG QZ, 1995, BRAIN RES, V700, P299, DOI 10.1016/0006-8993(95)01081-6; GORMAN LK, 1993, BRAIN RES, V614, P29, DOI 10.1016/0006-8993(93)91014-J; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; HALL S, 1991, J NEUROSURG, V75, P378, DOI 10.3171/jns.1991.75.3.0378; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; HUBSCHMANN OR, 1983, J NEUROSURG, V59, P289, DOI 10.3171/jns.1983.59.2.0289; JARRARD LE, 1993, BEHAV NEURAL BIOL, V60, P9, DOI 10.1016/0163-1047(93)90664-4; JASPERS RMA, 1990, NEUROSCI LETT, V117, P149, DOI 10.1016/0304-3940(90)90135-V; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KOLB B, 1983, BEHAV NEUROSCI, V97, P13, DOI 10.1037/0735-7044.97.1.13; KRAEMER PJ, 1995, PSYCHOBIOLOGY, V23, P144; Kraemer PJ, 1996, BRAIN RES BULL, V39, P17, DOI 10.1016/0361-9230(95)02028-4; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P14, DOI 10.1136/jnnp.51.1.14; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MICHEL RP, 1988, J MICROSC-OXFORD, V150, P117, DOI 10.1111/j.1365-2818.1988.tb04603.x; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1990, EUR J NEUROSCI, V2, P1016, DOI 10.1111/j.1460-9568.1990.tb00014.x; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; MOSER MB, 1995, P NATL ACAD SCI USA, V92, P9697, DOI 10.1073/pnas.92.21.9697; MUTTER SA, 1994, J CLIN EXP NEUROPSYC, V16, P271, DOI 10.1080/01688639408402638; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Paxinos G., 1982, RAT BRAIN STEREOTAXI; PIERCE JES, 1993, BRAIN RES, V624, P199, DOI 10.1016/0006-8993(93)90078-2; Posmantur RM, 1996, J NEUROTRAUM, V13, P125, DOI 10.1089/neu.1996.13.125; PRASAD MR, 1994, J NEUROCHEM, V63, P1086; PRASAD MR, 1994, J NEUROCHEM, V63, P773; Prasad RM, 1995, RESTOR NEUROL NEUROS, V9, P65, DOI 10.3233/RNN-1995-9201; SCHENK F, 1985, EXP BRAIN RES, V58, P11; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; SMITH DH, 1993, J NEUROSCI, V13, P5383; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SUTHERLAND RJ, 1983, BEHAV BRAIN RES, V7, P133, DOI 10.1016/0166-4328(83)90188-2; SUTHERLAND RJ, 1982, NEUROSCI LETT, V31, P271, DOI 10.1016/0304-3940(82)90032-5; Temple MD, 1996, BRAIN RES, V741, P246, DOI 10.1016/S0006-8993(96)00940-7	61	181	185	0	10	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	1997	14	9					615	627		10.1089/neu.1997.14.615			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	XZ489	WOS:A1997XZ48900003	9337124				2021-06-18	
J	Colicos, MA; Dash, PK				Colicos, MA; Dash, PK			Apoptotic morphology of dentate gyrus granule cells following experimental cortical impact injury in rats: Possible role in spatial memory deficits	BRAIN RESEARCH			English	Article						spatial memory; apoptosis; cortical impact; granule cell	TRAUMATIC BRAIN INJURY; CENTRAL-NERVOUS-SYSTEM; DNA FRAGMENTATION; NEURONAL DEATH; MACROMOLECULAR-SYNTHESIS; THYMOCYTE APOPTOSIS; HIPPOCAMPAL-NEURONS; FACTOR DEPRIVATION; MODEL; DEGENERATION	Loss of hippocampal neurons as a result of traumatic brain injury (TBI) is thought to contribute to the observed spatial memory deficits. Using a rodent model of experimental brain injury, we have examined the nature of hippocampal cell death following TBI. Light microscope examination of stained sections showed the presence of a large number of hyperchromatic and dystrophic neurons in the dentate gyrus of the hippocampus. These cells appeared to be undergoing nuclear condensation. Electron microscope examination demonstrated the presence of cell shrinkage, condensed chromatin, nuclear segmentation, and cytoplasmic vacuolization. Detection of a DNA ladder and in situ labeling (TUNEL) were also consistent with the process of apoptosis. However, in some dystrophic neurons these morphologies were also accompanied by the presence of swollen mitochondria and a lack of distinctive rough endoplasmic reticulum which are typically associated with necrosis. These findings show that cortical impact injury produces cell death in the hippocampus which has both apoptotic and necrotic features.	UNIV TEXAS, HLTH SCI CTR, DEPT NEUROBIOL & ANAT, HOUSTON, TX 77225 USA					NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH49962] Funding Source: Medline		ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; BATISTATOU A, 1991, J CELL BIOL, V115, P461, DOI 10.1083/jcb.115.2.461; BOLL TJ, 1982, HEAD INJURY, P363; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; BROWN DG, 1993, J BIOL CHEM, V268, P3037; CAIN K, 1994, FEBS LETT, V349, P385, DOI 10.1016/0014-5793(94)80001-4; CATCHPOOLE DR, 1993, CANCER RES, V53, P4287; CHARRIAUTMARLANGUE C, 1995, J CEREBR BLOOD F MET, V15, P385, DOI 10.1038/jcbfm.1995.48; CharriautMarlangue C, 1996, TRENDS NEUROSCI, V19, P109, DOI 10.1016/S0166-2236(96)80039-7; CHOI DW, 1995, TRENDS NEUROSCI, V18, P58; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; COSSARIZZA A, 1994, EXP CELL RES, V214, P323, DOI 10.1006/excr.1994.1264; DASH PK, 1995, J NEUROSCI, V15, P2030; DECKWERTH TL, 1993, ANN NY ACAD SCI, V679, P121, DOI 10.1111/j.1749-6632.1993.tb18293.x; DIXON CE, 1991, J NEUROSCI METH, V39, P253; DIXON CE, 1996, IN PRESS J NEROTRAUM; DUVALL E, 1985, IMMUNOLOGY, V56, P351; DUVALL E, 1986, IMMUNOL TODAY, V7, P115, DOI 10.1016/0167-5699(86)90152-0; EARNSHAW WC, 1986, CURR OPIN CELL BIOL, V7, P115; FADOK VA, 1992, J IMMUNOL, V148, P2207; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; GALLYAS F, 1980, STAIN TECHNOL, V55, P299, DOI 10.3109/10520298009067258; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GERSCHENSON LE, 1992, FASEB J, V6, P2450; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; Gwag B. J., 1994, Society for Neuroscience Abstracts, V20, P248; HAMBURGER V, 1982, NEUROSCI COMMENT, V1, P39; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Kerr J.F.R., 1987, P93; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LI Y, 1995, STROKE, V26, P1252, DOI 10.1161/01.STR.26.7.1252; Long DA, 1996, BRAIN RES, V717, P109, DOI 10.1016/0006-8993(95)01500-0; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MACMANUS JP, 1993, NEUROSCI LETT, V164, P89, DOI 10.1016/0304-3940(93)90864-H; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; NITATORI T, 1995, J NEUROSCI, V15, P1001; POLLARD H, 1994, NEUROSCIENCE, V63, P7, DOI 10.1016/0306-4522(94)90003-5; RATAN RR, 1994, J NEUROSCI, V14, P4385; SLOVITER RS, 1993, J COMP NEUROL, V330, P324, DOI 10.1002/cne.903300304; SLOVITER RS, 1993, J COMP NEUROL, V330, P337, DOI 10.1002/cne.903300305; SQUIRE LR, 1995, CURR OPIN NEUROBIOL, V5, P169, DOI 10.1016/0959-4388(95)80023-9; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; WALKER PR, 1994, EXP CELL RES, V213, P100, DOI 10.1006/excr.1994.1178; WATT JA, 1994, BRAIN RES, V661, P147, DOI 10.1016/0006-8993(94)91191-6; WEIS M, 1995, EXP CELL RES, V219, P699, DOI 10.1006/excr.1995.1281; WOOD KA, 1993, NEURON, V11, P621, DOI 10.1016/0896-6273(93)90074-2; WYLLIE AH, 1981, HISTOCHEM J, V13, P681, DOI 10.1007/BF01002719; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0	55	181	185	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	NOV 11	1996	739	1-2					120	131		10.1016/S0006-8993(96)00824-4			12	Neurosciences	Neurosciences & Neurology	VV253	WOS:A1996VV25300015	8955932				2021-06-18	
J	Forsberg, JA; Pepek, JM; Wagner, S; Wilson, K; Flint, J; Andersen, RC; Tadaki, D; Gage, FA; Stojadinovic, A; Elster, EA				Forsberg, Jonathan Agner; Pepek, Joseph M.; Wagner, Scott; Wilson, Kevin; Flint, James; Andersen, Romney C.; Tadaki, Doug; Gage, Frederick A.; Stojadinovic, Alexander; Elster, Eric A.			Heterotopic Ossification in High-Energy Wartime Extremity Injuries: Prevalence and Risk Factors	JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME			English	Article							TRAUMATIC BRAIN-INJURY; TOTAL HIP-ARTHROPLASTY; BONE-FORMATION; ACETABULAR FRACTURES; OPERATIVE TREATMENT; ECTOPIC OSSIFICATION; EXTERNAL FIXATION; HEAD-INJURIES; FOLLOW-UP; KNEE	Background: Heterotopic ossification in the extremities remains a common complication in the setting of high-energy wartime trauma, particularly in blast-injured amputees and in those in whom the definitive amputation was performed within the zone of injury. The purposes of this cohort study were to report the experience of one major military medical center with high-energy wartime extremity wounds, to define the prevalence of heterotopic ossification in these patients, and to explore the relationship between heterotopic ossification and other potential independent predictors. Methods: We retrospectively reviewed the records and radiographs of all combat-wounded patients admitted to this institution between March 1, 2003, and December 31, 2006. Patients with a minimum of two months of radiographic follow-up who underwent at least one orthopaedic procedure on an extremity constituted our study group; those who underwent at least one orthopaedic procedure but had not had heterotopic ossification develop constituted the control group. Variables recorded for each study subject included age and sex, location and mechanism of injury, method(s) of fracture fixation, number of debridement procedures, duration of negative pressure therapy, location of heterotopic ossification, presence and severity of traumatic brain injury, and Injury Severity Scores. Results: During the study period, 1213 war-wounded patients were admitted. Of those patients, 243 (157 in the heterotopic ossification group and eighty-six controls) met the inclusion criteria. The observed rate of heterotopic ossification was 64.6%. A significant relationship was detected between heterotopic ossification and the presence (p = 0.006) and severity(p= 0.003) of a traumatic brain injury. Risk factors for the development of heterotopic ossification were found to be an age of less than thirty years (p = 0.007, odds ratio = 3.0), an amputation (p = 0.048, odds ratio = 2.9), multiple extremity injuries (p = 0.002, odds ratio = 3.9), and an Injury Severity Score of >= 16 (p = 0.02, odds ratio = 2.2). Conclusions: The prevalence of heterotopic ossification in war-wounded patients is higher than that in civilian trauma. Although trends associated with local wound conditions were identified, the risk factors for the development of heterotopic ossification found in this study suggest that systemic causes predominate. Level of Evidence: Prognostic Level II. See Instructions to Authors for a complete description of levels of evidence.	[Forsberg, Jonathan Agner; Pepek, Joseph M.; Wagner, Scott; Wilson, Kevin; Flint, James; Andersen, Romney C.; Tadaki, Doug; Gage, Frederick A.; Stojadinovic, Alexander; Elster, Eric A.] Natl Naval Med Ctr, Bethesda, MD USA	Forsberg, JA (corresponding author), Natl Mil Med Ctr, Integrated Dept Orthopaed & Rehabil, 8901 Wisconsin Ave, Bethesda, MD 20889 USA.	jaforsberg@mac.com	Elster, Eric A/G-2332-2010; Forsberg, Jonathan/K-2116-2012	Elster, Eric/0000-0002-0981-2748; Stojadinovic, Alexander/0000-0002-2829-8967			Andermahr J, 2006, J NEUROTRAUM, V23, P708, DOI 10.1089/neu.2006.23.708; Andersen Romney C, 2006, J Am Acad Orthop Surg, V14, pS24; Barei DP, 2004, J ORTHOP TRAUMA, V18, P649, DOI 10.1097/00005131-200411000-00001; Boes M, 2006, J BONE JOINT SURG AM, V88A, P738, DOI 10.2106/JBJS.D.02648; BROOKER AF, 1973, J BONE JOINT SURG AM, VA 55, P1629; BRUMBACK RJ, 1990, J BONE JOINT SURG AM, V72A, P1067, DOI 10.2106/00004623-199072070-00017; Burd TA, 2001, J BONE JOINT SURG AM, V83A, P1783, DOI 10.2106/00004623-200112000-00003; BURD TA, 2002, J BONE JOINT SURG AM, V84, P100; CASSCELLS SW, HA POLICY 07 030 TRA; Covey Dana C, 2006, J Am Acad Orthop Surg, V14, pS10; Dalury DF, 2004, J ARTHROPLASTY, V19, P447, DOI 10.1016/j.arth.2003.12.064; Daum W J, 1992, J Orthop Trauma, V6, P427, DOI 10.1097/00005131-199212000-00006; EASTELL R, 1988, J CLIN ENDOCR METAB, V67, P741, DOI 10.1210/jcem-67-4-741; Ebraheim NA, 2007, INJURY, V38, P1177, DOI 10.1016/j.injury.2007.01.005; Gajewski Donald, 2006, J Am Acad Orthop Surg, V14, pS183; GARLAND BE, 1991, CLIN ORTHOP RELAT R, V263, P59; GARLAND DE, 1983, PHYS THER, V63, P2004, DOI 10.1093/ptj/63.12.2004; GARLAND DE, 1983, CLIN ORTHOP RELAT R, P190; GARLAND DE, 1982, CLIN ORTHOP RELAT R, P219; GARLAND DE, 1980, CLIN ORTHOP RELAT R, P198; GARLAND DE, 1982, CLIN ORTHOP RELAT R, P133; GARLAND DE, 1991, CLIN ORTHOP RELAT R, P13; GARLAND DE, 1988, CLIN ORTHOP RELAT R, V233, P86; Gautschi OP, 2007, J NEUROTRAUM, V24, P154, DOI 10.1089/neu.2006.0166; Giannoudis PV, 2006, INJURY, V37, pS18, DOI 10.1016/j.injury.2006.08.020; Giannoudis PV, 2005, J BONE JOINT SURG BR, V87B, P2; Giannoudis PV, 2007, INJURY, V38, P1224; Griffin DB, 2005, J BONE JOINT SURG BR, V87B, P1391, DOI 10.1302/0301-620X.87B10.16538; Hedin H, 2003, J ORTHOP TRAUMA, V17, P250, DOI 10.1097/00005131-200304000-00002; Hendricks HT, 2007, CLIN REHABIL, V21, P545, DOI 10.1177/0269215507075260; HIERTON C, 1983, ACTA ORTHOP SCAND, V54, P698, DOI 10.3109/17453678308996614; Higo T, 2006, J ARTHROPLASTY, V21, P852, DOI 10.1016/j.arth.2005.10.016; HOFFER MM, 1971, J BONE JOINT SURG AM, VA 53, P567, DOI 10.2106/00004623-197153030-00014; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Ippolito E, 1999, J BONE JOINT SURG AM, V81A, P783, DOI 10.2106/00004623-199906000-00005; Ippolito E, 1999, CLIN ORTHOP RELAT R, P130, DOI 10.1097/00003086-199908000-00018; Jones E, 2007, AM J PSYCHIAT, V164, P1641, DOI 10.1176/appi.ajp.2007.07071180; Kaplan FS, 2004, J AM ACAD ORTHOP SUR, V12, P116, DOI 10.5435/00124635-200403000-00007; Kasetti RJ, 2001, J ARTHROPLASTY, V16, P1038, DOI 10.1054/arth.2001.25550; Kypson AP, 2003, J SURG ONCOL, V82, P132, DOI 10.1002/jso.10181; LAZANSKY MG, 1973, CLIN ORTHOP RELAT R, P96; LINDHOLM TS, 1986, ARCH ORTHOP TRAUM SU, V105, P263, DOI 10.1007/BF00449923; Lynch JR, 2006, J BONE JOINT SURG AM, V88A, P2265, DOI 10.2106/JBJS.E.01441; MENDELSON L, 1975, SCAND J REHABIL MED, V7, P141; Mills WJ, 2003, J ORTHOP TRAUMA, V17, P338, DOI 10.1097/00005131-200305000-00004; MORREY BF, 1984, CLIN ORTHOP RELAT R, P160; Oh CW, 2006, J ORTHOP SCI, V11, P478, DOI 10.1007/s00776-006-1045-6; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Owens Brett D, 2006, J Am Acad Orthop Surg, V14, pS37; Ozer H, 2006, ARCH ORTHOP TRAUM SU, V126, P574, DOI 10.1007/s00402-006-0158-x; Panagiotis T, 2007, J TRAUMA, V62, P378, DOI 10.1097/01.ta.0000196540.81630.4e; Petsatodis G, 2007, INJURY, V38, P334, DOI 10.1016/j.injury.2006.09.017; Pittenger D E, 1991, Orthop Rev, V20, P33; Potter Benjamin K, 2006, J Am Acad Orthop Surg, V14, pS191; Potter BK, 2007, J BONE JOINT SURG AM, V89A, P476, DOI 10.2106/JBJS.F.00412; Rath EMS, 2002, INJURY, V33, P751, DOI 10.1016/S0020-1383(01)00194-2; RIEGLER HF, 1976, CLIN ORTHOP RELAT R, P209; RITTER MA, 1977, J BONE JOINT SURG AM, V59, P345, DOI 10.2106/00004623-197759030-00009; Sarafis KA, 1999, J TRAUMA, V46, P104, DOI 10.1097/00005373-199901000-00017; Schara K, 2001, Acta Chir Orthop Traumatol Cech, V68, P105; Siebert CH, 1997, ARCH ORTHOP TRAUM SU, V116, P390; Simonsen LL, 2007, INJURY, V38, P1146, DOI 10.1016/j.injury.2007.03.019; Sneath RJS, 2001, J ARTHROPLASTY, V16, P547, DOI 10.1054/arth.2001.23562; SOBALLE K, 1988, CLIN ORTHOP RELAT R, P57; SPENCER RF, 1987, J BONE JOINT SURG BR, V69, P525; STEINBERG GG, 1993, J ORTHOP TRAUMA, V7, P536, DOI 10.1097/00005131-199312000-00009; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Usami N, 2005, GEN THORAC CARDIOVAS, V53, P102, DOI 10.1007/s11748-005-0010-1; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004	69	180	182	0	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0021-9355	1535-1386		J BONE JOINT SURG AM	J. Bone Joint Surg.-Am. Vol.	MAY	2009	91A	5					1084	1091		10.2106/JBJS.H.00792			8	Orthopedics; Surgery	Orthopedics; Surgery	441FK	WOS:000265754500007	19411456				2021-06-18	
J	Takagi, T; Nakamura, M; Yamada, M; Hikishima, K; Momoshima, S; Fujiyoshi, K; Shibata, S; Okano, HJ; Toyama, Y; Okano, H				Takagi, Takehiko; Nakamura, Masaya; Yamada, Masayuki; Hikishima, Keigo; Momoshima, Suketaka; Fujiyoshi, Kanehiro; Shibata, Shinsuke; Okano, Hirotaka James; Toyama, Yoshiaki; Okano, Hideyuki			Visualization of peripheral nerve degeneration and regeneration: Monitoring with diffusion tensor tractography	NEUROIMAGE			English	Article						Diffusion tensor imaging; Diffusion tensor tractography; Peripheral nerve injury; Fractional anisotropy; Wallerian degeneration; Magnetic resonance imaging	RAT SPINAL-CORD; MAGNETIC-RESONANCE NEUROGRAPHY; TRAUMATIC AXONAL INJURY; IN-VIVO; WATER DIFFUSION; WALLERIAN DEGENERATION; RETINAL ISCHEMIA; HUMAN BRAIN; DIAGNOSIS; DETECTS	We applied diffusion tensor tractography (DTT), a recently developed MRI technique that reveals the microstructures of tissues based on its ability to monitor the random movements of water molecules, to the visualization of peripheral nerves after injury. The rat sciatic nerve was subjected to contusive injury, and the data obtained from diffusion tensor imaging (DTI) were used to determine the tracks of nerve fibers (DTT). The DTT images obtained using the fractional anisotropy (FA) threshold value of 0.4 clearly revealed the recovery process of the contused nerves. Immediately after the injury, fiber tracking from the designated proximal site could not be continued beyond the lesion epicenter, but the intensity improved thereafter, returning to its pre-injury level by 3 weeks later. We compared the FA value, a parameter computed from the DTT data, with the results of histological and functional examinations of the injured nerves, during recovery. The FA values of the peripheral nerves were more strongly correlated with axon-related (axon density and diameter) than with myelin-related (myelin density and thickness) parameters, supporting the theories that axonal membranes play a major role in anisotropic water diffusion and that myelination can modulate the degree of anisotropy. Moreover, restoration of the FA value at the lesion epicenter was strongly correlated with parameters of motor and sensory functional recovery. These correlations of the FA values with both the histological and functional changes demonstrate the potential usefulness of DTT for evaluating clinical events associated with Wallerian degeneration and the regeneration of peripheral nerves. (C) 2008 Elsevier Inc. All rights reserved.	[Takagi, Takehiko; Fujiyoshi, Kanehiro; Shibata, Shinsuke; Okano, Hirotaka James; Okano, Hideyuki] Keio Univ, Dept Physiol, Sch Med, Shinjuku Ku, Tokyo 1608582, Japan; [Takagi, Takehiko; Nakamura, Masaya; Fujiyoshi, Kanehiro; Toyama, Yoshiaki] Keio Univ, Dept Orthopaed Surg, Sch Med, Shinjuku Ku, Tokyo 1608582, Japan; [Momoshima, Suketaka] Keio Univ, Dept Diagnost Radiol, Sch Med, Shinjuku Ku, Tokyo 1608582, Japan; [Hikishima, Keigo] Keio Univ, Ctr Integrated Med Res, Shinjuku Ku, Tokyo 1608582, Japan; [Yamada, Masayuki; Hikishima, Keigo] Cent Inst Expt Anim, Miyamae Ku, Kanagawa 2160001, Japan; [Yamada, Masayuki] Fujita Hlth Univ, Fac Radiol Technol, Sch Hlth Sci, Toyoake, Aichi 4701192, Japan	Okano, H (corresponding author), Keio Univ, Dept Physiol, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	hidokano@sc.itc.keio.ac.jp	Hikishima, Keigo/AAP-9586-2020; Toyama, Yoshiaki/K-5743-2013; Hikishima, Keigo/L-1202-2013; Shibata, Shinsuke/AAM-6620-2020; Nakamura, Masaya/K-4111-2013; Okano, Hideyuki/I-7584-2019	Hikishima, Keigo/0000-0003-1133-1297; Hikishima, Keigo/0000-0003-1133-1297; Okano, Hirotaka James/0000-0003-4611-7098	Ministry of Education, Culture, Sports, Science and Technology (MEXT), JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT); Japan Science and Technology Corporation (JST)Japan Science & Technology Agency (JST); General Insurance Association of Japan; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [19500276] Funding Source: KAKEN	This work was supported by grants from the Leading Project for Realization of Regenerative Medicine from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan, from the Japan Science and Technology Corporation (JST), and from the General Insurance Association of Japan. This work was also supported by a Keio University grant-in-aid for encouragement of young medical scientists, by grants-in-aid for scientific research of MEXT, Japan, and by a grant-in-aid from the 21st Century COE Program of MEXT, Japan to Keio University. We thank Tokuko Harada and Hisako Takeuchi for tender animal care, Toshihiro Nagai for technical assistance with the electron microscope, and to all the other members of the spinal cord injury research team at Keio University School of Medicine for their enthusiastic discussions, encouragement, and invaluable comments on this study.	BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1; Beaulieu C, 1996, MAGNET RESON MED, V36, P627, DOI 10.1002/mrm.1910360419; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; Bendszus M, 2005, ANN NEUROL, V57, P388, DOI 10.1002/ana.20404; Bendszus M, 2003, J NEUROSCI, V23, P10892; Bendszus M, 2002, AM J NEURORADIOL, V23, P1427; BRIDGE PM, 1994, EXP NEUROL, V127, P284, DOI 10.1006/exnr.1994.1104; Conturo TE, 1999, P NATL ACAD SCI USA, V96, P10422, DOI 10.1073/pnas.96.18.10422; Filler AG, 2004, NEUROL CLIN, V22, P643, DOI 10.1016/j.ncl.2004.03.005; FILLER AG, 1993, LANCET, V341, P659, DOI 10.1016/0140-6736(93)90422-D; Fujiyoshi K, 2007, J NEUROSCI, V27, P11991, DOI 10.1523/JNEUROSCI.3354-07.2007; Gulani V, 2001, MAGNET RESON MED, V45, P191, DOI 10.1002/1522-2594(200102)45:2<191::AID-MRM1025>3.0.CO;2-9; Hiltunen J, 2005, CLIN NEUROPHYSIOL, V116, P2315, DOI 10.1016/j.clinph.2005.05.014; HOWE FA, 1992, MAGNET RESON MED, V28, P328, DOI 10.1002/mrm.1910280215; Kato N, 2005, NEUROSCI RES, V52, P299, DOI 10.1016/j.neures.2005.04.004; Kikuchi Y, 2003, RADIOLOGY, V229, P861, DOI 10.1148/radiol.2293020904; Lundborg G., 2004, NERVE INJURY REPAIR; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Madi S, 2005, MAGN RESON MED, V53, P118, DOI 10.1002/mrm.20304; Masutani Y, 2003, EUR J RADIOL, V46, P53, DOI 10.1016/S0720-048X(02)00328-5; MATSUZAWA H, 1995, J NEUROSURG, V83, P1023, DOI 10.3171/jns.1995.83.6.1023; Meek MF, 2006, EXP NEUROL, V198, P479, DOI 10.1016/j.expneurol.2005.12.014; Mori S, 2006, NEURON, V51, P527, DOI 10.1016/j.neuron.2006.08.012; Pierpaoli C, 1996, MAGNET RESON MED, V36, P893, DOI 10.1002/mrm.1910360612; Skorpil M, 2004, MAGN RESON IMAGING, V22, P743, DOI 10.1016/j.mri.2004.01.073; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Stanisz GJ, 2001, MAGN RESON MED, V45, P415, DOI 10.1002/1522-2594(200103)45:3<415::AID-MRM1054>3.0.CO;2-M; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; Sun SW, 2008, NEUROIMAGE, V40, P1, DOI 10.1016/j.neuroimage.2007.11.049; Sunderland S, 1991, NERVE INJURIES THEIR; Takahashi M, 2002, P NATL ACAD SCI USA, V99, P16192, DOI 10.1073/pnas.252249999; Tamae A, 2005, J PHYSIOL-LONDON, V568, P243, DOI 10.1113/jphysiol.2005.091843; Tuch DS, 2001, P NATL ACAD SCI USA, V98, P11697, DOI 10.1073/pnas.171473898; Varejao ASP, 2004, J NEUROTRAUM, V21, P1652, DOI 10.1089/neu.2004.21.1652; Wessig C, 2008, EXP NEUROL, V210, P137, DOI 10.1016/j.expneurol.2007.10.014	36	180	199	1	25	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	FEB 1	2009	44	3					884	892		10.1016/j.neuroimage.2008.09.022			9	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	392KL	WOS:000262301500028	18948210				2021-06-18	
J	Simi, A; Tsakiri, N; Wang, P; Rothwell, NJ				Simi, A.; Tsakiri, N.; Wang, P.; Rothwell, N. J.			Interleukin-1 and inflammatory neurodegeneration	BIOCHEMICAL SOCIETY TRANSACTIONS			English	Article; Proceedings Paper	Focus Topic at Life Sciences 2007 Conference	JUL 09-12, 2007	Glasgow, SCOTLAND			inflammation; interleukin-1 (IL-1); interleukin-1 receptor antagonist (IL-1RA); ischaemia; neurodegenerative disease; stroke	ISCHEMIC BRAIN-DAMAGE; RECEPTOR ANTAGONIST IL-1RA; CEREBRAL-ISCHEMIA; DEFICIENT MICE; I RECEPTOR; RAT; INJURY; IL-1-BETA; STROKE; ACTIVATION	Inflammation occurs rapidly in response to acute brain insults such as stroke, haemorrhage or trauma, and can be sustained for long periods of time, for example in Alzheimer's or Parkinson's diseases and multiple sclerosis. Experimental evidence indicates that inflammation plays a major role in neurodegeneration under these conditions, and that the cytokine IL-1 (interleukin-1) is a pivotal mediator. IL-1 is expressed rapidly in response to neuronal injury, predominantly by microglia, and elevated levels of endogenous or exogenous IL-1 markedly exacerbate injury. The naturally occurring IL-1RA (IL-1 receptor antagonist) markedly inhibits ischaemic, excitotoxic and traumatic brain injury in rodents, and has shown promise in a Phase 11 clinical trial in stroke patients. The mechanisms of IL-1 expression, release and action in neurodegeneration are not fully elucidated and appear multiple. Systemic IL-1 markedly enhances ischaemic brain injury via release of neutrophils into circulation, neutrophil adhesion to injured cerebrovasculature and CNS (central nervous system) invasion, and cell death via activation of matrix metalloproteinase-9. IL-1 also influences the release of toxins from glial and endothelial cells. Neuronal responses to excitotoxins and physiological factors may have an impact on neuronal survival. IL-1RA, delivered peripherally, can enter the CNS in animals and humans and has no adverse effects in stroke or subarachnoid haemorrhage patients, but shows potential benefit in acute stroke patients.	Karolinska Inst, Div Mol Neurobiol, Dept Neurosci, S-17177 Stockholm, Sweden; Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England	Rothwell, NJ (corresponding author), Karolinska Inst, Div Mol Neurobiol, Dept Neurosci, S-17177 Stockholm, Sweden.	nancy.rothwell@manchester.ac.uk			Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9219675] Funding Source: Medline		Allan SM, 2005, NAT REV IMMUNOL, V5, P629, DOI 10.1038/nri1664; Andre R, 2006, GLIA, V53, P477, DOI 10.1002/glia.20302; Andrei C, 2004, P NATL ACAD SCI USA, V101, P9745, DOI 10.1073/pnas.0308558101; AZZIMONDI G, 1995, STROKE, V26, P2040, DOI 10.1161/01.STR.26.11.2040; BETZ AL, 1995, J CEREBR BLOOD F MET, V15, P547, DOI 10.1038/jcbfm.1995.68; Boutin H, 2001, J NEUROSCI, V21, P5528; Bresnihan B, 2001, SEMIN ARTHRITIS RHEU, V30, P17, DOI 10.1053/sarh.2001.23701; Brough D, 2002, MOL CELL NEUROSCI, V19, P272, DOI 10.1006/mcne.2001.1054; Desson SE, 2003, J PHYSIOL-LONDON, V550, P113, DOI 10.1113/jphysiol.2003.041210; Emsley HCA, 2005, J NEUROL NEUROSUR PS, V76, P1366, DOI 10.1136/jnnp.2004.054882; Ferrari CC, 2004, AM J PATHOL, V165, P1827, DOI 10.1016/S0002-9440(10)63438-4; GIULIAN D, 1988, J NEUROSCI, V8, P2485; Glaccum MB, 1997, J IMMUNOL, V159, P3364; Griffin WST, 1998, BRAIN PATHOL, V8, P65; Grundy RI, 1999, BRAIN RES, V830, P32, DOI 10.1016/S0006-8993(99)01377-3; GUEORGUIEVA I, 2007, BR J CLIN PHARM; Hara H, 1997, J CEREBR BLOOD F MET, V17, P370, DOI 10.1097/00004647-199704000-00002; Hayashi Y, 2001, BRAIN RES, V893, P113, DOI 10.1016/S0006-8993(00)03307-2; John GR, 2004, J NEUROSCI, V24, P2837, DOI 10.1523/JNEUROSCI.4789-03.2004; John GR, 2005, GLIA, V49, P161, DOI 10.1002/glia.20109; KATSUKI H, 1990, EUR J PHARMACOL, V181, P323, DOI 10.1016/0014-2999(90)90099-R; Konsman JP, 2007, CLIN SCI, V112, P1, DOI 10.1042/CS20060043; Kostulas N, 1999, STROKE, V30, P2174, DOI 10.1161/01.STR.30.10.2174; Lawrence CB, 1998, EUR J NEUROSCI, V10, P1188, DOI 10.1046/j.1460-9568.1998.00136.x; Loddick SA, 1997, BIOCHEM BIOPH RES CO, V234, P211, DOI 10.1006/bbrc.1997.6436; Loddick SA, 1996, J CEREBR BLOOD F MET, V16, P932, DOI 10.1097/00004647-199609000-00017; Lucas SM, 2006, BRIT J PHARMACOL, V147, pS232, DOI 10.1038/sj.bjp.0706400; MARTIN D, 1995, J NEUROIMMUNOL, V61, P241, DOI 10.1016/0165-5728(95)00108-E; Mazzotta G, 2004, EUR J NEUROL, V11, P377, DOI 10.1111/j.1468-1331.2004.00798.x; McColl BW, 2007, J NEUROSCI, V27, P4403, DOI 10.1523/JNEUROSCI.5376-06.2007; O'Neill LAJ, 1998, J LEUKOCYTE BIOL, V63, P650; Parker LC, 2002, BRIT J PHARMACOL, V136, P312, DOI 10.1038/sj.bjp.0704715; Pinteaux E, 2006, GLIA, V53, P551, DOI 10.1002/glia.20308; Ranaivo HR, 2006, J NEUROSCI, V26, P662, DOI 10.1523/JNEUROSCI.4652-05.2006; RELTON JK, 1991, J EXP MED, V174, P305, DOI 10.1084/jem.174.2.305; RELTON JK, 1992, BRAIN RES BULL, V29, P243, DOI 10.1016/0361-9230(92)90033-T; Schielke GP, 1998, J CEREBR BLOOD F MET, V18, P180, DOI 10.1097/00004647-199802000-00009; Simi A, 2007, NEUROPHARMACOLOGY, V52, P1563, DOI 10.1016/j.neuropharm.2007.02.011; Smith CJ, 2004, BMC NEUROL, V4, DOI 10.1186/1471-2377-4-2; STRIJBOS PJLM, 1995, J NEUROSCI, V15, P3468; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; THOMBERRY NA, 1992, NATURE, V356, P768; THORNTON P, 2007, MOL CELL NEUROSCI; Thornton P, 2006, J NEUROCHEM, V98, P258, DOI 10.1111/j.1471-4159.2006.03872.x; Touzani O, 2002, J NEUROSCI, V22, P38, DOI 10.1523/JNEUROSCI.22-01-00038.2002; Vezzani A, 2000, P NATL ACAD SCI USA, V97, P11534, DOI 10.1073/pnas.190206797; Viviani B, 2003, J NEUROSCI, V23, P8692; YAMASAKI Y, 1995, STROKE, V26, P676, DOI 10.1161/01.STR.26.4.676; ZEISE ML, 1992, REGUL PEPTIDES, V39, P1, DOI 10.1016/0167-0115(92)90002-C	49	180	187	0	20	PORTLAND PRESS LTD	LONDON	THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND	0300-5127			BIOCHEM SOC T	Biochem. Soc. Trans.	NOV	2007	35		5				1122	1126		10.1042/BST0351122			5	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	236CE	WOS:000251279800065	17956293				2021-06-18	
J	Draper, K; Ponsford, J; Schonberger, M				Draper, Kristy; Ponsford, Jennie; Schoenberger, Michael			Psychosocial and emotional outcomes 10 years following traumatic drain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						outcome; predictors; psychosocial; traumatic brain injury	SEVERE HEAD-INJURY; BRAIN-INJURY; IMPAIRED AWARENESS; SUBSTANCE-ABUSE; SCALE; RECOVERY; FATIGUE; REHABILITATION; ADJUSTMENT; COMMUNITY	Objectives: To investigate the association of psychosocial outcome 10 years following traumatic brain injury (TBI) with demographic variables, injury severity, current cognitive functioning, emotional state, aggression, alcohol use, and fatigue. Setting: Community-based follow-up. Participants: Fifty-three participants with mild to very severe TBI sustained 10 years previously and significant others. Measures: Sydney Psychosocial Reintegration Scale, Extended Glasgow Outcome Scale, Hospital Anxiety and Depression Scale, NFI Aggression scale, Fatigue Severity Scale, Alcohol Use Disorders Identification Test, neuropsychological tests of attention/processing speed, memory, and executive function. Results: Psychosocial functioning was lowest in the occupational activity domain and highest in the living skills domains. Variables including education, posttraumatic amnesia duration, numerous cognitive measures, concurrent fatigue, aggression, anxiety, and depression were all significantly associated with psychosocial outcome, although the strength of correlations varied between ratings of participants with TBI and relatives. Posttraumatic amnesia duration was most strongly associated with psychosocial outcome measured by relatives; anxiety aggression, and depression were the strongest predictors when ratings were assigned by participants with TBI. Self-reported fatigue, depression, and alcohol use were the strongest predictors of aggression. Conclusions: It is important to address problems with anxiety, depression, fatigue, and alcohol use as a possible means of improving long-term psychosocial outcome following TBI.	Monash Univ, Sch Psychol Psychiat & Psychol Med, Monash Epworth Rehabil Res Ctr, Epworth Hosp, Melbourne, Vic 3004, Australia; Natl Trauma Res Inst, Melbourne, Vic, Australia	Ponsford, J (corresponding author), Monash Univ, Dept Psychol, Clayton, Vic 3800, Australia.	jennie.ponsford@med.monash.edu.au					Anson K, 2006, BRAIN INJURY, V20, P167, DOI 10.1080/02699050500442956; Arlinghaus KA, 2005, TXB TRAUMATIC BRAIN, P59; Baddeley A, 1994, DOORS PEOPLE; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Benton A., 1994, MULTILINGUAL APHASIA; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Bombardier CH, 2003, ARCH PHYS MED REHAB, V84, P185, DOI 10.1053/apmr.2003.50002; Bombardier CH, 1999, REHABIL PSYCHOL, V44, P52, DOI 10.1037/0090-5550.44.1.52; BOND MR, 1984, CLOSED HEAD INJURY P, P148; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; DIKMEN SS, 1993, BRAIN INJURY, V15, P747; Franulic A, 2004, BRAIN INJURY, V18, P119, DOI 10.1080/0269905031000149515; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Hoofien D, 2001, BRAIN INJURY, V15, P189; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; Johnson R, 1998, NEUROPSYCHOL REHABIL, V8, P61, DOI 10.1080/713755552; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Kreutzer JS, 1996, J HEAD TRAUMA REHAB, V11, P58, DOI 10.1097/00001199-199610000-00006; Kreutzer JS., 1999, NEUROBEHAVIORAL FUNC; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; Lezak M. D., 1976, NEUROPSYCHOLOGICAL A; Medd J, 2000, NEUROPSYCHOL REHABIL, V10, P185, DOI 10.1080/096020100389246; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; O'Connor C, 2005, PSYCHOL REP, V97, P169, DOI 10.2466/PR0.97.5.169-179; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ouellet MC, 2006, REHABIL PSYCHOL, V51, P140, DOI 10.1037/0090-5550.51.2.140; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; Porteus S.D., 1965, PORTEUS MAZE TEST 50; Powell J, 2002, J NEUROL NEUROSUR PS, V72, P193, DOI 10.1136/jnnp.72.2.193; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; Reitan R., 1988, HALSTEAD REITAN NEUR; Rey A., 1958, LEXAMEN CLIN PSYCHOL; RIMEL RW, 1984, REHABILITATION HEAD, P9; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Shallice, 1997, HAYLING BRIXTON TEST; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Smith A., 1973, SYMBOL DIGIT MODALIT; Snaith R.P., 1994, HOSP ANXIETY DEPRESS; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; Tate R., 2005, BRAIN IMPAIR, V6, P75, DOI DOI 10.1375/BRIM.2005.6.2.75; Tate RL, 2004, ARCH PHYS MED REHAB, V85, P538, DOI 10.1016/j.apmr.2003.08.078; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; Taylor LA, 2003, NEUROPSYCHOL REHABIL, V13, P165, DOI 10.1080/09602010244000336; Teasdale TW, 2005, BRAIN INJURY, V19, P1041, DOI 10.1080/02699050500110397; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Wechsler D, 1997, WAIS 3 ADM SCORING M; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI DOI 10.1097/00001199-199308020-00009; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wood RL, 2006, ARCH CLIN NEUROPSYCH, V21, P239, DOI 10.1016/j.acn.2005.12.004; Wood RL, 2006, J NEUROL NEUROSUR PS, V77, P71, DOI 10.1136/jnnp.2005.065540; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498; Ziino C, 2005, J INT NEUROPSYCH SOC, V11, P416, DOI 10.1017/S1355617705050472	69	180	184	0	20	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2007	22	5					278	287		10.1097/01.HTR.0000290972.63753.a7			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	216RA	WOS:000249895500003	17878769				2021-06-18	
J	Borland, M; Jacobs, I; King, B; O'Brien, D				Borland, Meredith; Jacobs, Ian; King, Barbara; O'Brien, Debra			A randomized controlled trial comparing intranasal fentanyl to intravenous morphine for managing acute pain in children in the emergency department	ANNALS OF EMERGENCY MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the Australasian College for Emergency Medicine	NOV, 2005	Melbourne, AUSTRALIA				POSTOPERATIVE ANALGESIA; ORAL MORPHINE; MANAGEMENT	Study objective: We compare the efficacy of intranasal fentanyl versus intravenous morphine in a pediatric population presenting to an emergency department (ED) with acute long-bone fractures. Methods: We conducted a prospective, randomized, double-blind, placebo-controlled, clinical trial in a tertiary pediatric ED between September 2001 and January 2005. A convenience sample of children aged 7 to 15 years with clinically deformed closed long-bone fractures was included to receive either active intravenous morphine (10 mg/mL) and intranasal placebo or active intranasal concentrated fentanyl (150 mu g/mL) and intravenous placebo. Exclusion criteria were narcotic analgesia within 4 hours of arrival, significant head injury, allergy to opiates, nasal blockage, or inability to per-form pain scoring. Pain scores were rated by using a 100-mm visual analog scale at 0, 5, 10, 20, and 30 minutes. Routine clinical observations and adverse events were recorded. Results: Sixty-seven children were enrolled (mean age 10.9 years [SD 2.4]). Fractures were radius or ulna 53 (79.1%), humerus 9 (13.4%), tibia or fibula 4 (6.0%), and femur 1 (1.5%). Thirty-four children received intravenous (IV) morphine and 33 received intranasal fentanyl. Statistically significant differences in visual analog scale scores were not observed between the 2 treatment arms either preanalgesia or at 5, 10, 20, or 30 minutes postanalgesia (P=.333). At 10 minutes, the difference in mean visual analog scale between the morphine and fentanyl groups was -5 mm (95% confidence interval -16 to 7 mm). Reductions in combined pain scores occurred at 5 minutes (20 mm; P=.000), 10 minutes (4 mm; P=.012), and 20 minutes (8 mm; P=.000) postanalgesia. The mean total INF dose was 1.7 mu g/kg, and the mean total IV morphine dose was 0.11 mg/kg. There were no serious adverse events. Conclusion: Intranasal fentanyl delivered as 150 mu g/mL at a dose of 1.7 mu g/kg was shown to be an effective analgesic in children aged 7 to 15 years presenting to an ED with an acute fracture when compared to intravenous morphine at 0.1 mg/kg.	Princess Margaret Hosp Children, Subiaco, WA, Australia; Univ Western Australia, Sch Paediat & Child Hlth, Perth, WA 6009, Australia; Univ Western Australia, Discipline Emergency Med, Perth, WA 6009, Australia; Sir Charles Gairdner Hosp, Emergency Dept, Nedlands, WA, Australia	Borland, M (corresponding author), GPO Box D184, Perth, WA 6840, Australia.	Meredith.Borland@health.wa.gov.au					Borland Meredith L, 2002, Emerg Med (Fremantle), V14, P275, DOI 10.1046/j.1442-2026.2002.00344.x; Borland ML, 2005, BURNS, V31, P831, DOI 10.1016/j.burns.2005.05.001; Brent ASG, 2000, PEDIATR CLIN N AM, V47, P651; *COMM AUSTR CANB, 1999, NHMRC GUID ETH RES; Finn J, 2004, BURNS, V30, P262, DOI 10.1016/j.burns.2003.10.017; Friedland LR, 1997, PEDIATR EMERG CARE, V13, P103, DOI 10.1097/00006565-199704000-00005; Galinkin JL, 2000, ANESTHESIOLOGY, V93, P1378, DOI 10.1097/00000542-200012000-00006; Ho K, 1996, ANN EMERG MED, V27, P427, DOI 10.1016/S0196-0644(96)70223-8; Holdgate Anna, 2003, Emerg Med (Fremantle), V15, P441, DOI 10.1046/j.1442-2026.2003.00499.x; Kendall JM, 2001, BMJ-BRIT MED J, V322, P261, DOI 10.1136/bmj.322.7281.261; Kennedy RM, 1999, PEDIATR CLIN N AM, V46, P1215, DOI 10.1016/S0031-3955(05)70184-X; Lim Stephen C. B., 2003, Journal of Pharmacy Practice and Research, V33, P59; Manjushree R, 2002, CAN J ANAESTH, V49, P190; ONeil G, 1997, ANAESTH INTENS CARE, V25, P408, DOI 10.1177/0310057X9702500414; Paech MJ, 2003, ANAESTHESIA, V58, P740, DOI 10.1046/j.1365-2044.2003.03286.x; Powell CV, 2001, ANN EMERG MED, V37, P28; Simpson N, 1998, BRIT MED J, V316, P396; Spagrud LJ, 2003, AM J NURS, V103, P62, DOI 10.1097/00000446-200312000-00020; STRIEBEL HW, 1993, ANAESTHESIA, V48, P753, DOI 10.1111/j.1365-2044.1993.tb07583.x; Todd KH, 1996, ANN EMERG MED, V27, P485, DOI 10.1016/S0196-0644(96)70238-X; Wong P, 2003, ANAESTHESIA, V58, P818, DOI 10.1046/j.1365-2044.2003.03295_24.x; Younge P, 1999, EMERGEN MED, V11, P90	22	180	182	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644	1097-6760		ANN EMERG MED	Ann. Emerg. Med.	MAR	2007	49	3					335	340		10.1016/j.annemergmed.2006.06.016			6	Emergency Medicine	Emergency Medicine	142GI	WOS:000244637000016	17067720				2021-06-18	
J	Hall, ED; Detloff, MR; Johnson, K; Kupina, NC				Hall, ED; Detloff, MR; Johnson, K; Kupina, NC			Peroxynitrite-mediated protein nitration and lipid peroxidation in a mouse model of traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						neurodegeneration; oxidative damage; reactive oxygen species; traumatic brain injury	NITRIC-OXIDE SYNTHASE; CLOSED-HEAD INJURY; OXIDATIVE STRESS; RAT-BRAIN; IMPAIRED MITOCHONDRIAL; NITROXIDE RADICALS; CORTICAL CONTUSION; HYDROXYL RADICALS; TRANSGENIC MICE; EXPRESSION	The role of reactive oxygen-induced oxidative damage to lipids (i.e., lipid peroxidation, LP) and proteins has been strongly supported in previous work. Most notably, a number of free radical scavengers and lipid antioxidants have been demonstated to be neuroprotective in traumatic brain injury (TBI) models. However, the specific sources of reactive oxygen species (ROS), the time course of oxidative, damage and its relationship to post-traumatic neurodegeneration in the injured brain have been incompletely defined. The present study was directed at an investigation of the role of the ROS, peroxynitrite (PON), in the acute pathophysiology of TBI and its temporal relationship to neurodegeneration in the context of the mouse model of diffuse head injury model. Male CF-1 mice were subjected to a moderately severe head injury and assessed at 1-, 3-, 6-, 12-, 24-, 48-, 72, 96- and 120-h post-injury for neurodegeneration using quantitative image analysis of silver staining and semi-quantitative analysis of PON-mediated oxidative damage to proteins (3-nitrotyrosine, 3-NT) and lipids (4-hydroxynonenal, 4-HNE). Significant evidence of silver staining was not apparent until 24-h post-injury, with peak staining seen between 72- and 120-h. This time-course of neurodegeneration was preceded by intense immunostaining for 3-NT and 4-HNE, which occurred within the first hour post-injury. The time course and staining pattern for 3-NT and 4-HNE were similar, with the highest staining intensity noted within the first 48-h in areas surrounding trauma-induced contusions. In the case of 3-NT, neuronal perikarya and processes and microvessels displayed staining. The temporal and spatial coincidence of protein nitration and LP damage suggests that PON is involved in both. However, lipid-peroxidative (4-HNE) immunoreactivity was broader and more diffuse than 3-NT, suggesting that other reactive oxygen mechanisms, such as iron-dependent LP, may also contribute to the more widespread 4-HNE immunoreactivity. This indicates that optimal pharmacological inhibition of post-traumatic oxidative damage in TBI may need to combine two functionalities: one to scavenge PON or PON-derived radicals, and the second to inhibit LP caused by multiple ROS species.	Univ Kentucky, Albert B Chandler Med Ctr, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; Pfizer Global Res & Dev, CNS Pharmacol, Ann Arbor, MI USA	Hall, ED (corresponding author), Univ Kentucky, Albert B Chandler Med Ctr, Spinal Cord & Brain Injury Res Ctr, 232 Hlth Sci Res Bldg,800 Rose St, Lexington, KY 40536 USA.	edhall@uky.edu	Hall, Edward D/F-8930-2013				Althaus JS, 2000, FREE RADICAL BIO MED, V29, P1085, DOI 10.1016/S0891-5849(00)00350-6; Awasthi D, 1997, SURG NEUROL, V47, P575, DOI 10.1016/S0090-3019(96)00461-2; Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; Bao F, 2003, NEUROSCIENCE, V116, P59, DOI 10.1016/S0306-4522(02)00571-7; Bartus RT, 1997, NEUROSCIENTIST, V3, P314, DOI 10.1177/107385849700300513; BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; BECKMAN JS, 1991, J DEV PHYSIOL, V15, P53; Behringer W, 2002, J CEREBR BLOOD F MET, V22, P105, DOI 10.1097/00004647-200201000-00013; BeitYannai E, 1996, BRAIN RES, V717, P22, DOI 10.1016/0006-8993(95)01492-6; BeitYannai E, 1997, J CEREBR BLOOD F MET, V17, P273, DOI 10.1097/00004647-199703000-00004; BONNI MG, 2002, CHEM RES TOXICOL, V15, P506; Carroll RT, 2000, CHEM RES TOXICOL, V13, P294, DOI 10.1021/tx990159t; Chabrier PE, 1999, P NATL ACAD SCI USA, V96, P10824, DOI 10.1073/pnas.96.19.10824; CHAN PH, 1995, J NEUROTRAUM, V12, P815, DOI 10.1089/neu.1995.12.815; Cirak B, 1999, PEDIATR NEUROSURG, V31, P298, DOI 10.1159/000028879; Cobbs CS, 1997, BRAIN RES, V751, P336, DOI 10.1016/S0006-8993(96)01429-1; Cuzzocrea S, 2000, BRAIN RES, V875, P96, DOI 10.1016/S0006-8993(00)02582-8; DEOLMOS JS, 1994, NEUROTOXICOL TERATOL, V16, P545, DOI 10.1016/0892-0362(94)90033-7; Gahm C, 2002, NEUROSURGERY, V50, P1319, DOI 10.1097/00006123-200206000-00024; Gahm C, 2000, NEUROSURGERY, V46, P169; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GRAFE MR, 1980, J NEUROPATH EXP NEUR, V39, P555, DOI 10.1097/00005072-198009000-00005; Hall E D, 1994, Adv Pharmacol, V28, P221, DOI 10.1016/S1054-3589(08)60497-4; Hall E.D., 1995, CENTRAL NERVOUS SYST, P213; Hall ED, 1999, ANN NY ACAD SCI, V890, P462, DOI 10.1111/j.1749-6632.1999.tb08025.x; HALL ED, 1993, RES P ARNMD, V71, P81; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; Hall ED, 1997, J PHARMACOL EXP THER, V281, P895; HALL ED, 1995, NEUROSURGERY 96 MANU, P505; HALL ED, 1992, J NEUROTRAUMA, V9, P425; HALL ED, 1998, PATHOPHYSIOLOGY DIAG, P710; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kasprzak HA, 2001, J NEUROTRAUM, V18, P793, DOI 10.1089/089771501316919157; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Kruman I, 1997, J NEUROSCI, V17, P5089; Kupina NC, 2001, J NEUROTRAUM, V18, P1229, DOI 10.1089/089771501317095269; Kupina NC, 2002, J CEREBR BLOOD F MET, V22, P1212; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; Marklund N, 2001, ACTA NEUROCHIR, V143, P73, DOI 10.1007/s007010170141; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; Matsushita M, 1997, J COMP NEUROL, V377, P251, DOI 10.1002/(SICI)1096-9861(19970113)377:2<251::AID-CNE7>3.0.CO;2-2; Mesenge C, 1998, J PINEAL RES, V25, P41, DOI 10.1111/j.1600-079X.1998.tb00384.x; Mesenge C, 1998, EUR J PHARMACOL, V353, P53, DOI 10.1016/S0014-2999(98)00432-4; Mesenge C, 1996, J NEUROTRAUM, V13, P209, DOI 10.1089/neu.1996.13.209; Mikawa S, 1996, J NEUROSURG, V85, P885, DOI 10.3171/jns.1996.85.5.0885; Mori T, 1998, ACT NEUR S, V71, P120; Neely MD, 1999, J NEUROCHEM, V72, P2323, DOI 10.1046/j.1471-4159.1999.0722323.x; Nishio S, 1997, ACT NEUR S, V70, P84; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; PANTER SS, 1992, J NEUROTRAUM, V9, P47, DOI 10.1089/neu.1992.9.47; Park CO, 2001, YONSEI MED J, V42, P518, DOI 10.3349/ymj.2001.42.5.518; PELLEGRINIGIAMPIETRO DE, 1990, J NEUROSCI, V10, P1035, DOI 10.1523/jneurosci.10-03-01035.1990; Petrov T, 2000, ACTA NEUROPATHOL, V100, P196, DOI 10.1007/s004019900167; Rak R, 2000, J NEUROSURG, V92, P646, DOI 10.3171/jns.2000.92.4.0646; Rao VLR, 1999, J NEUROTRAUM, V16, P865, DOI 10.1089/neu.1999.16.865; Rohn TT, 1998, BIOCHEM PHARMACOL, V56, P1371, DOI 10.1016/S0006-2952(98)00266-4; Sarrafzadeh AS, 2000, ACTA NEUROCHIR, V142, P1293, DOI 10.1007/s007010070028; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; Silberstein M, 2002, AM J NEURORADIOL, V23, P389; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Switzer RC, 2000, TOXICOL PATHOL, V28, P70, DOI 10.1177/019262330002800109; UCHIDA K, 1993, J BIOL CHEM, V268, P6388; Wada K, 1999, J NEUROTRAUM, V16, P203, DOI 10.1089/neu.1999.16.203; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; YAMAMOTO T, 1986, BRAIN RES, V374, P419, DOI 10.1016/0006-8993(86)90442-7; Zhang RL, 1998, FREE RADICAL BIO MED, V24, P332, DOI 10.1016/S0891-5849(97)00267-0	71	180	183	0	7	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	2004	21	1					9	20		10.1089/089771504772695904			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	766GU	WOS:000188368700002	14987461				2021-06-18	
J	Jeremitsky, E; Omert, L; Dunham, CM; Protetch, J; Rodriguez, A				Jeremitsky, E; Omert, L; Dunham, CM; Protetch, J; Rodriguez, A			Harbingers of poor outcome the day after severe brain injury: Hypothermia, hypoxia, and hypoperfusion	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	15th Annual Meeting of the Eastern-Association-for-the-Surgery-of-Trauma	JAN 16-19, 2002	ORLANDO, FL	Eastern Assoc Surg Trauma		secondary brain injury; hypothermia; hypoxia	SEVERE HEAD-INJURY; VENOUS OXYGEN-SATURATION; MODERATE HYPOTHERMIA; SECONDARY INSULTS; PRESSURE; TRAUMA; HYPERGLYCEMIA; HYPOTENSION; MANAGEMENT; ISCHEMIA	Background. Traumatic brain injury (TBI) can be compounded by physiologic derangements that produce secondary brain injury. The purpose of this study is to elucidate the frequency with which physiologic factors that are associated with secondary brain injury occur in patients with severe closed head injuries and to determine the impact of these factors on outcome. Methods. The records of 81 adult blunt trauma patients with Glasgow Coma Scale scores :5 8 and transport times < 2 hours to a Level I trauma center were retrospectively reviewed searching for the following 11 secondary brain injury factors (SBIFs) in the first 24 hours postinjury: hypotension, hypoxia, hypercapnia, hypocapnia, hypothermia, hyperthermia, metabolic acidosis, seizures, coagulopathy, hyperglycemia, and intracranial hypertension. We recorded the worst SBIF during six time periods: hours 1, 2, 3, 4, 5 to 14, and 16 to 24. Occurrence of each SBIF was then correlated with outcome. Results Hypocapnia, hypotension, and acidosis occurred more frequently than other SBIFs (60-80%). Hypotension, hyperglycemia, and hypothermia were associated with increased mortality rate. Patients with episodes of hypocapnia, acidosis, and hypoxia had significantly longer intensive care unit length of stay (LOS). These three SBIFs and hyperglycemia related to longer hospital LOS as well. Hypotension and acidosis were associated with discharge to a rehabilitation facility rather than home. Finally, multivariate regression analysis revealed that hypotension, hypothermia, and Abbreviated Injury Scale score of the head were independently related to mortality, whereas other SBIFs, age, Injury Severity Score, and Glasgow Coma Scale score were not. Metabolic acidosis and hypoxia were related to longer intensive care unit and hospital LOS. Conclusion. Our early management of head-injured patients stresses avoidance and correction of SBIFs at all costs. Nonetheless, SBIFs occur frequently in the first 24 hours after traumatic brain injury. Six of the 11 factors studied are associated with significantly worse outcomes. Hypotension and hypothermia are independently related to mortality. Because these SBIFs are potentially preventable, protocols could be developed to decrease their frequency.	Allegheny Gen Hosp, Ctr Shock Trauma, Dept Surg, Pittsburgh, PA 15212 USA; Elizabeth Hlth Ctr, Dept Surg, Youngstown, OH USA	Omert, L (corresponding author), Allegheny Gen Hosp, Ctr Shock Trauma, Dept Surg, 30 East Ave,5th Floor,South Tower, Pittsburgh, PA 15212 USA.						BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Chesnut RM, 1997, J TRAUMA, V42, pS4, DOI 10.1097/00005373-199705001-00002; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; CHOPP M, 1989, J CEREBR BLOOD F MET, V9, P141, DOI 10.1038/jcbfm.1989.21; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; COOPER PR, 2000, HEAD INJURY, P239; CRUZ J, 1991, NEUROSURGERY, V29, P743, DOI 10.1227/00006123-199111000-00017; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; FORTUNE JB, 1994, J NEUROSURG, V80, P461, DOI 10.3171/jns.1994.80.3.0461; JEREMITSKY E, 2000, J NEUROTRAUM, V17, P493; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1991, J NEUROSURG, V74, P407, DOI 10.3171/jns.1991.74.3.0407; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; McGraw CP, 1989, INTRACRANIAL PRESSUR, P839; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; PIETROPAOLI JA, 1992, J TRAUMA, V33, P403, DOI 10.1097/00005373-199209000-00011; PULSINELLI WA, 1982, NEUROLOGY, V32, P1239, DOI 10.1212/WNL.32.11.1239; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; RUTHERFORD EJ, 1992, J TRAUMA, V33, P417, DOI 10.1097/00005373-199209000-00014; Sarrafzadeh AS, 2001, CRIT CARE MED, V29, P1116, DOI 10.1097/00003246-200106000-00004; SCHNEIDER GH, 1995, ACTA NEUROCHIR, V134, P71, DOI 10.1007/BF01428507; SHACKFORD SR, 1989, J TRAUMA, V29, P1392, DOI 10.1097/00005373-198910000-00018; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; SILVERSTON P, 1989, BRIT MED J, V298, P711, DOI 10.1136/bmj.298.6675.711; Smith SL, 1996, J NEUROTRAUM, V13, P1, DOI 10.1089/neu.1996.13.1; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; WALD S, 1991, J TRAUMA, V31, P104; YOUNG B, 1989, ANN SURG, V210, P466, DOI 10.1097/00000658-198910000-00007	35	180	193	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	FEB	2003	54	2					312	319		10.1097/01.TA.0000037876.37236.D6			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	644KL	WOS:000180916400016	12579057				2021-06-18	
J	LEVIN, HS; GROSSMAN, RG				LEVIN, HS; GROSSMAN, RG			BEHAVIORAL SEQUELAE OF CLOSED HEAD-INJURY - QUANTITATIVE STUDY	ARCHIVES OF NEUROLOGY			English	Article										LEVIN, HS (corresponding author), UNIV TEXAS,MED BRANCH,DEPT SURG,DIV NEUROSURG,GALVESTON,TX 77550, USA.						BENTON AL, 1969, J NEUROL SCI, V9, P39, DOI 10.1016/0022-510X(69)90057-4; Bond M R, 1975, Ciba Found Symp, P141; FIELD JH, 1975, EPIDEMIOLOGY HEAD IN; GRONWALL D, 1976, Proceedings of the Australian Association of Neurologists, V13, P143; GRONWALL D, LANCET, V2, P605; HILLBOM E, 1951, ACTA PSYCHIAT NEUROL, V60, P36; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1976, J NEUROL NEUROSUR PS, V39, P647, DOI 10.1136/jnnp.39.7.647; JENNETT WB, 1969, CURRENT PROBLEMS NEU; Kirschbichler T, 1972, Scand J Rehabil Med, V4, P106; LEVIN HS, 1976, DIS NERV SYST, V37, P68; LEVIN HS, 1976, J NEUROL NEUROSUR PS, V39, P1062, DOI 10.1136/jnnp.39.11.1062; LISHMAN WA, 1973, PSYCHOL MED, V3, P304, DOI 10.1017/S003329170004959X; MERSKEY H, 1972, BRAIN, V95, P521, DOI 10.1093/brain/95.3.521; MILLER H, 1961, BRIT MED J, V1, P919, DOI 10.1136/bmj.1.5230.919; MILLER H, 1961, BRIT MED J, V1, P992, DOI 10.1136/bmj.1.5231.992; MINTZ J, 1976, ARCH GEN PSYCHIAT, V33, P1183; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OVERALL JE, 1962, PSYCHOL REP, V10, P799; OVERALL JE, 1972, APPLIED MULTIVARIATE; PAXSON CL, 1976, PEDIATRICS, V57, P893; RUESCH J, 1945, AM J PSYCHIAT, V102, P145, DOI 10.1176/ajp.102.2.145; RUTHERFORD WH, 1977, LANCET, V1, P1; SPREEN O, 1966, MANUAL NEUROSENSORY; TAYLOR AR, 1966, LANCET, V2, P178; VANWOERKOM TCAM, 1977, LANCET, V1, P812	26	180	180	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0003-9942			ARCH NEUROL-CHICAGO	Arch. Neurol.		1978	35	11					720	727		10.1001/archneur.1978.00500350024005			8	Clinical Neurology	Neurosciences & Neurology	FV039	WOS:A1978FV03900005	31155				2021-06-18	
J	Mao, HJ; Zhang, LY; Jiang, BH; Genthikatti, VV; Jin, X; Zhu, F; Makwana, R; Gill, A; Jandir, G; Singh, A; Yang, KH				Mao, Haojie; Zhang, Liying; Jiang, Binhui; Genthikatti, Vinay V.; Jin, Xin; Zhu, Feng; Makwana, Rahul; Gill, Amandeep; Jandir, Gurdeep; Singh, Amrinder; Yang, King H.			Development of a Finite Element Human Head Model Partially Validated With Thirty Five Experimental Cases	JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME			English	Article						finite element modeling; head injury; brain injury; skull impact; facial impact; brain pressure; brain contusion	BRAIN-TISSUE; DYNAMIC-RESPONSE; BRIDGING VEINS; MECHANICAL-PROPERTIES; BIOMECHANICS; BEHAVIOR; IMPACT; INJURY	This study is aimed to develop a high quality, extensively validated finite element (FE) human head model for enhanced head injury prediction and prevention. The geometry of the model was based on computed tomography (CT) and magnetic resonance imaging scans of an adult male who has the average height and weight of an American. A feature-based multiblock technique was adopted to develop hexahedral brain meshes including the cerebrum, cerebellum, brainstem, corpus callosum, ventricles, and thalamus. Conventional meshing methods were used to create the bridging veins, cerebrospinal fluid, skull, facial bones, flesh, skin, and membranes-including falx, tentorium, pia, arachnoid, and dura. The head model has 270,552 elements in total. Thirty five loading cases were selected from a range of experimental head impacts to check the robustness of the model predictions based on responses including the brain pressure, relative skull-brain motion, skull response, and facial response. The brain pressure was validated against intracranial pressure data reported by Nahum et al. (1977, "Intracranial Pressure Dynamics During Head Impact,"Proc. 21st Stapp Car Crash Conference, SAE Technical Paper No. 770922) and Trosseille et al. (1992, "Development of a F. E. M. of the Human Head According to a Specific Test Protocol,"Proc. 36th Stapp Car Crash Conference, SAE Technical Paper No. 922527). The brain motion was validated against brain displacements under sagittal, coronal, and horizontal blunt impacts performed by Hardy et al. (2001, "Investigation of Head Injury Mechanisms Using Neutral Density Technology and High-Speed Biplanar X-Ray,"Stapp Car Crash Journal, 45, pp. 337-368; and 2007, "A Study of the Response of the Human Cadaver Head to Impact,"Stapp Car Crash Journal, 51, pp. 17-80). The facial bone responses were validated under nasal impact (Nyquist et al. 1986, "Facial Impact Tolerance and Response,"Proc. 30th Stapp Car Crash Conference, SAE Technical Paper No. 861896), zygoma and maxilla impact (Allsop et al. 1988, "Facial Impact Response - A Comparison of the Hybrid III Dummy and Human Cadaver,"Proc. 32nd Stapp Car Crash Conference, SAE Technical Paper No. 881719)]. The skull bones were validated under frontal angled impact, vertical impact, and occipital impact (Yoganandan et al. 1995, "Biomechanics of Skull Fracture," J Neurotrauma, 12(4), pp. 659-668) and frontal horizontal impact (Hodgson et al. 1970, "Fracture Behavior of the Skull Frontal Bone Against Cylindrical Surfaces,"14th Stapp Car Crash Conference, SAE International, Warrendale, PA). The FE head model was further used to study injury mechanisms and tolerances for brain contusion (Nahum et al. 1976, "An Experimental Model for Closed Head Impact Injury,"20th Stapp Car Crash Conference, SAE International, Warrendale, PA). Studies from 35 loading cases demonstrated that the FE head model could predict head responses which were comparable to experimental measurements in terms of pattern, peak values, or time histories. Furthermore, tissue-level injury tolerances were proposed. A maximum principal strain of 0.42% was adopted for skull cortical layer fracture and maximum principal stress of 20 MPa was used for skull diploe e layer fracture. Additionally, a plastic strain threshold of 1.2% was used for facial bone fracture. For brain contusion, 277 kPa of brain pressure was calculated from reconstruction of one contusion case.	[Mao, Haojie; Zhang, Liying; Genthikatti, Vinay V.; Jin, Xin; Zhu, Feng; Makwana, Rahul; Gill, Amandeep; Jandir, Gurdeep; Singh, Amrinder; Yang, King H.] Wayne State Univ, Bioengn Ctr, Detroit, MI 48201 USA; [Jiang, Binhui] Hunan Univ, Changsha 410082, Hunan, Peoples R China	Yang, KH (corresponding author), Wayne State Univ, Bioengn Ctr, 818 West Hancock, Detroit, MI 48201 USA.	hmao@wayne.edu; lzang@wayne.edu; jjhhzz123@163.com; ei5627@wayne.edu; mail.jinxin@gmail.com; fengzhume@gmail.com; rahulmakwana25@gmail.com; amandeep171@gmail.com; gssaini13@gmail.com; amrinder703@gmail.com; king.yang@wayne.edu	chinnasamy, Suresh/G-2048-2015; Jin, Xin/J-6476-2015; Jiang, Binhui/V-9272-2019; MAKWANA, RAHUL/H-9629-2019; Mao, Haojie/Q-7514-2018	Jiang, Binhui/0000-0001-9255-5780; Mao, Haojie/0000-0002-7563-9234	Global Human Body Model Consortium (GHBMC)	This project was supported by the Global Human Body Model Consortium (GHBMC). The authors would like to acknowledge constant inputs from the Technical Committee of GHBMC, especially Dr. Chin-hsu Lin, throughout the development phase. Thanks to Mr. Chintan Shelat's help in part of simulations and manuscript preparation.	ALBSHARAT A, 1999, 43 STAPP CAR CRASH C; Allsop D. L., 1988, P 32 STAPP CAR CRASH; Bilston LE, 2011, STUD MECHANOBIOL TIS, V3, P11, DOI 10.1007/8415_2010_36; Chatelin S, 2010, BIORHEOLOGY, V47, P255, DOI 10.3233/BIR-2010-0576; Cloots RJH, 2008, ANN BIOMED ENG, V36, P1203, DOI 10.1007/s10439-008-9510-3; Cormier J, 2011, J BIOMECH ENG-T ASME, V133, DOI 10.1115/1.4003312; Darvish KK, 2001, MED ENG PHYS, V23, P633, DOI 10.1016/S1350-4533(01)00101-1; De Santis G, 2011, MED ENG PHYS, V33, P1318, DOI 10.1016/j.medengphy.2011.06.007; Delye Hans, 2006, Stapp Car Crash J, V50, P625; Depreitere B, 2006, J NEUROSURG, V104, P950, DOI 10.3171/jns.2006.104.6.950; Elkin BS, 2011, J NEUROTRAUM, V28, P2235, DOI 10.1089/neu.2010.1604; Elkin BS, 2010, J BIOMECH ENG-T ASME, V132, DOI 10.1115/1.4000164; Fice JB, 2011, ANN BIOMED ENG, V39, P2152, DOI 10.1007/s10439-011-0315-4; Franceschini G, 2006, J MECH PHYS SOLIDS, V54, P2592, DOI 10.1016/j.jmps.2006.05.004; Gayzik FS, 2011, ANN BIOMED ENG, V39, P2568, DOI 10.1007/s10439-011-0359-5; Han H, 2007, NEURORADIOLOGY, V49, P169, DOI 10.1007/s00234-006-0175-z; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; Ho J, 2007, J BIOMECH, V40, P3006, DOI 10.1016/j.jbiomech.2007.02.011; Ho J, 2009, J BIOMECH, V42, P2074, DOI 10.1016/j.jbiomech.2009.06.051; Hodgson V. R., 1970, 14 STAPP CAR CRASH C; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Hrapko M, 2008, BIORHEOLOGY, V45, P663, DOI 10.3233/BIR-2008-0512; Jin X, 2011, J BIOMECH, V44, P467, DOI 10.1016/j.jbiomech.2010.09.035; Jin X, 2007, STAPP CAR CRASH JO, V51, P115; Kallemeyn NA, 2009, COMPUT METH PROG BIO, V95, P227, DOI 10.1016/j.cmpb.2009.03.005; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; LEE MC, 1989, J BIOMECH, V22, P537, DOI 10.1016/0021-9290(89)90005-5; Lynnerup Niels, 2005, Head Face Med, V1, P13, DOI 10.1186/1746-160X-1-13; Mao HJ, 2013, COMPUT METHOD BIOMEC, V16, P271, DOI 10.1080/10255842.2011.617005; MCELHANEY JH, 1970, J BIOMECH, V3, P495, DOI 10.1016/0021-9290(70)90059-X; MCELHANEY JH, 1995, J NEUROTRAUM, V12, P669, DOI 10.1089/neu.1995.12.669; Melvin JW., 1969, DEV, V5, P811; Miller K, 2002, J BIOMECH, V35, P483, DOI 10.1016/S0021-9290(01)00234-2; Nahum AM, 1976, 20 STAPP CAR CRASH C; Nahum AM, 1977, P STAPP CAR CRASH CO; Nicolle S, 2005, BIORHEOLOGY, V42, P209; Nyquist G. W., 1986, P 30 STAPP CAR CRASH; OKA K, 1985, NEUROSURGERY, V17, P711, DOI 10.1227/00006123-198511000-00003; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907; Ruan J, 2001, Stapp Car Crash J, V45, P395; Ruan J. S., 1993, STAPP CAR CRASH C; RUAN JS, 1991, J BIOMECH ENG-T ASME, V113, P276, DOI 10.1115/1.2894885; Schonning A, 2009, COMPUT AIDED DESIGN, V41, P566, DOI 10.1016/j.cad.2007.10.007; Shivanna KH, 2010, COMPUT AIDED DESIGN, V42, P1108, DOI 10.1016/j.cad.2010.07.005; Takhounts E., 2003, STAPP CAR CRASH J, V47, P107, DOI DOI 10.4271/2003-22-0007; Takhounts EG, 2008, STAPP CAR C, V52, P1; Trosseille X., 1992, P 36 STAPP CAR CRASH, DOI 10.4271/922527; Ward C. C., 1975, 19 STAPP CAR CRASH C; Willinger R, 1999, ANN BIOMED ENG, V27, P403, DOI 10.1114/1.165; WOOD JL, 1971, J BIOMECH, V4, P1, DOI 10.1016/0021-9290(71)90010-8; YAMASHIMA T, 1984, J NEUROL NEUROSUR PS, V47, P121, DOI 10.1136/jnnp.47.2.121; Yang KH, 2011, STUD MECHANOBIOL TIS, V3, P69, DOI 10.1007/8415_2010_62; YOGANANDAN N, 1995, J NEUROTRAUM, V12, P659, DOI 10.1089/neu.1995.12.659; Yue N., 2011, 2011011128 SAE; Zhang L, 2001, Stapp Car Crash J, V45, P369; Zhang Liying, 2002, Stapp Car Crash J, V46, P145	57	179	192	3	87	ASME	NEW YORK	TWO PARK AVE, NEW YORK, NY 10016-5990 USA	0148-0731	1528-8951		J BIOMECH ENG-T ASME	J. Biomech. Eng.-Trans. ASME	NOV	2013	135	11							111002	10.1115/1.4025101			15	Biophysics; Engineering, Biomedical	Biophysics; Engineering	240IF	WOS:000326088100002	24065136		Y	N	2021-06-18	
J	Higashida, T; Kreipke, CW; Rafols, JA; Peng, CY; Schafer, S; Schafer, P; Ding, JY; Dornbos, D; Li, XH; Guthikonda, M; Rossi, NF; Ding, YC				Higashida, Tetsuhiro; Kreipke, Christian W.; Rafols, Jose A.; Peng, Changya; Schafer, Steven; Schafer, Patrick; Ding, Jamie Y.; Dornbos, David, III; Li, Xiaohua; Guthikonda, Murali; Rossi, Noreen F.; Ding, Yuchuan			The role of hypoxia-inducible factor-la, aquaporin-4, and matrix metalloproteinase-9 in blood-brain barrier disruption and brain edema after traumatic brain injury Laboratory investigation	JOURNAL OF NEUROSURGERY			English	Article						basal lamina; tight junction protein; blood-brain barrier permeability	MODEL; INTEGRITY; ISCHEMIA; RATS; MICE; INHIBITION	Object. The present study investigated the role of hypoxia-inducible factor-la (HIF-1 alpha), aquaporin-4 (AQP-4), and matrix metalloproteinase-9 (MMP-9) in blood-brain barrier (BBB) permeability alterations and brain edema formation in a rodent traumatic brain injury (TB!) model. Methods. The brains of adult male Sprague-Dawley rats (400-425 g) were injured using the Marmarou closed-head force impact model. Anti AQP-4 antibody, minocycline (an inhibitor of MMP-9), or 2-methoxyestradiol (2ME2, an inhibitor of HIF-1 alpha), was administered intravenously 30 minutes after injury. The rats were killed 24 hours after injury and their brains were examined for protein expression, BBB permeability, and brain edema. Expression of HIF-1 alpha, AQP-4, and MMP-9 as well as expression of the vascular basal lamina protein (laminin) and tight junction proteins (zona occludens-1 and occludin) was determined by Western blotting. Blood-brain barrier disruption was assessed by FITC-dextran extravasation, and brain edema was measured by the brain water content. Results. Significant (p < 0.05) edema and BBB extravasations were observed following TBI induction. Compared with sham-operated controls, the injured animals were found to have significantly (p < 0.05) enhanced expression of HIP-1 alpha, AQP-4, and MMP-9, in addition to reduced amounts (p < 0.05) of laminin and tight junction proteins. Edema was significantly (p < 0.01) decreased after inhibition of AQP-4, MMP-9, or HIF-1 alpha. While BBB permeability was significantly (p < 0.01) ameliorated after inhibition of either HIF-1 alpha or MMP-9, it was not affected following inhibition of AQP-4. Inhibition of MMP reversed the loss of laminin (p < 0.01). Finally, while inhibition of HIF-1 alpha significantly (p < 0.05) suppressed the expression of AQP-4 and MMP-9, such inhibition significantly (p < 0.05) increased the expression of laminin and tight junction proteins. Conclusions. The data support the notion that HIF-1 alpha plays a role in brain edema formation and BBB disruption via a molecular pathway cascade involving AQP-4 and MMP-9. Pharmacological blockade of this pathway in patients with TBI may provide a novel therapeutic strategy. (DOI: 10.3171/2010.6.JNS10207)	[Higashida, Tetsuhiro; Peng, Changya; Dornbos, David, III; Guthikonda, Murali; Ding, Yuchuan] Wayne State Univ, Dept Neurol Surg, Sch Med, Detroit, MI 48201 USA; [Kreipke, Christian W.; Rafols, Jose A.; Schafer, Steven; Schafer, Patrick; Ding, Jamie Y.] Wayne State Univ, Dept Anat & Cell Biol, Sch Med, Detroit, MI 48201 USA; [Li, Xiaohua] Wayne State Univ, Dept Pathol, Sch Med, Detroit, MI 48201 USA; [Rossi, Noreen F.] Wayne State Univ, Dept Med, Sch Med, Detroit, MI 48201 USA; [Rossi, Noreen F.] Wayne State Univ, Dept Physiol, Sch Med, Detroit, MI 48201 USA; [Rossi, Noreen F.] John D Dingell Vet Affairs Med Ctr, Detroit, MI USA	Ding, YC (corresponding author), Wayne State Univ, Dept Neurol Surg, Sch Med, 550 E Canfield, Detroit, MI 48201 USA.	yding@med.wayne.edu	Dornbos, David/AAF-5091-2019		Wayne State University School of Medicine Department of Neurological Surgery; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS 39860, NS064976]; Veterans AffairsUS Department of Veterans Affairs; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039860, R01NS064976] Funding Source: NIH RePORTER	This work was supported partially by the Wayne State University School of Medicine Department of Neurological Surgery Fund (Y.D.), NIH NS 39860 (J.A.R.), NIH NS064976, and Veterans Affairs Rehabilitation Research & Development funding (C.W.K. and N.F.R.).	Agre P, 2002, J PHYSIOL-LONDON, V542, P3, DOI 10.1113/jphysiol.2002.020818; Amorini AM, 2003, ACT NEUR S, V86, P261; Badaut T, 2002, J CEREBR BLOOD F MET, V22, P367, DOI 10.1097/00004647-200204000-00001; Baranova O, 2007, J NEUROSCI, V27, P6320, DOI 10.1523/JNEUROSCI.0449-07.2007; Bauer AT, 2010, J CEREBR BLOOD F MET, V30, P837, DOI 10.1038/jcbfm.2009.248; Chen WQ, 2008, NEUROBIOL DIS, V31, P433, DOI 10.1016/j.nbd.2008.05.020; Ding JY, 2009, BRAIN RES, V1268, P125, DOI 10.1016/j.brainres.2009.02.060; Ding JY, 2009, NEUROSCI LETT, V453, P68, DOI 10.1016/j.neulet.2009.01.077; Feng XC, 2009, J NEUROSCI RES, V87, P1150, DOI 10.1002/jnr.21927; Gao P, 2009, J CEREBR BLOOD F MET, V29, P1482, DOI 10.1038/jcbfm.2009.67; Griesdale DEG, 2004, SURG NEUROL, V61, P418, DOI 10.1016/j.surneu.2003.10.047; Kaur C, 2006, GLIA, V54, P826, DOI 10.1002/glia.20420; Kawamata T, 2000, ACTA NEUROCHIR SUPPL, V76, P9; Leonardo CC, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-13; Machado LS, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-56; Marmarou A, 2006, J NEUROSURG, V104, P720, DOI 10.3171/jns.2006.104.5.720; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; Mori T, 2002, J NEUROTRAUM, V19, P1411, DOI 10.1089/089771502320914642; Nag S, 2009, ACTA NEUROPATHOL, V118, P197, DOI 10.1007/s00401-009-0541-0; Nicchia GP, 2004, NEUROSCIENCE, V129, P935, DOI 10.1016/j.neuroscience.2004.07.055; Papadopoulos MC, 2007, PEDIATR NEPHROL, V22, P778, DOI 10.1007/s00467-006-0411-0; Papadopoulos MC, 2008, PROG BRAIN RES, V170, P589, DOI 10.1016/S0079-6123(08)00446-9; Park E, 2009, J CEREBR BLOOD F MET, V29, P575, DOI 10.1038/jcbfm.2008.151; Rafols JA, 2007, NEUROL RES, V29, P348, DOI 10.1179/016164107X204657; Reyes R, 2009, J NEUROSURG, V110, P1218, DOI 10.3171/2008.8.JNS08382; Rosenberg Gary A, 2007, Neurosurg Focus, V22, pE4; Saadoun S, 2010, NEUROSCIENCE, V168, P1036, DOI 10.1016/j.neuroscience.2009.08.019; Saadoun S, 2009, NEUROSCIENCE, V161, P764, DOI 10.1016/j.neuroscience.2009.03.069; Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1; Stroop R, 1998, ACT NEUR S, V71, P303; Sun MC, 2003, J NEUROSURG, V98, P565, DOI 10.3171/jns.2003.98.3.0565; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Veenith Tonny, 2009, World J Emerg Surg, V4, P7, DOI 10.1186/1749-7922-4-7; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Yang Y, 2007, J CEREBR BLOOD F MET, V27, P697, DOI 10.1038/sj.jcbfm.9600375; Yu R, 2001, Chin J Traumatol, V4, P218; Zhou JP, 2008, NEUROREPORT, V19, P1, DOI 10.1097/WNR.0b013e3282f2b4eb	38	179	197	0	37	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JAN	2011	114	1					92	101		10.3171/2010.6.JNS10207			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	699NG	WOS:000285669500021	20617879				2021-06-18	
J	Kashluba, S; Hanks, RA; Casey, JE; Millis, SR				Kashluba, Shauna; Hanks, Robin A.; Casey, Joseph E.; Millis, Scott R.			Neuropsychologic and functional outcome after complicated mild traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						brain injuries; neuropsychological tests; rehabilitation	DISABILITY RATING-SCALE; HEAD-INJURY; COMMUNITY INTEGRATION; COMA; REHABILITATION; PREDICTORS; COMPLAINTS; RECOVERY; RETURN	Objective: To investigate the extent to which neuropsychologic and functional outcome after complicated mild traumatic brain injury (TBI) parallels that of moderate TBI recovery. Design: A longitudinal study comparing neuropsychologic and functional status of persons with complicated mild TBI and moderate TBI at discharge from inpatient rehabilitation and at I year postinjury. Setting: Rehabilitation hospital with a Traumatic Brain Injury Model System. Participants: Persons with complicated mild TBI (n = 102) each with an intracranial brain lesion documented through neuroimaging and a highest Glasgow Coma Scale (GCS) score in the emergency department between 13 and 15, and 127 persons with moderate TBI. Interventions: Not applicable. Main Outcome Measures: FIM instrument. Disability Rating Scale, Community Integration Questionnaire, Wechsler Memory Scale logical memory I and II, Rey Auditory Verbal Learning Test, Trail-Making Test, Controlled Oral Word Association Test. Symbol Digit Modalities Test. Wisconsin Card Sorting Test. and block design. Results: Few differences in neuropsychologic performance existed between the TBI groups. Less severely impaired information processing speed and verbal learning were seen in the complicated mild TBI group at rehabilitation discharge and I year postinjury. Despite overall improvement across cognitive domains within the complicated mild TBI group, sonic degree of impairment remained at I year postinjury on those measures that had identified participants as impaired soon after injury. No differences on functional ability measures were found between the TBI groups at either time period postinjury, with both groups exhibiting incomplete recovery of functional Status at the 1-year follow-up. Conclusions: When classifying severity of TBI based on GCS scores, consideration of a moderate injury designation should be given to persons with an intracranial bleed and a GCS score between 13 and 15.	[Kashluba, Shauna; Hanks, Robin A.; Casey, Joseph E.] Univ Windsor, Dept Psychol, Windsor, ON N9B 3P4, Canada; [Kashluba, Shauna; Hanks, Robin A.; Millis, Scott R.] Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI USA; [Kashluba, Shauna; Hanks, Robin A.] Rehabil Inst Michigan, Dept Rehabil Psychol & Neuropsychol, Detroit, MI USA	Kashluba, S (corresponding author), Univ Windsor, Dept Psychol, 401 Sunset Ave, Windsor, ON N9B 3P4, Canada.	kashlub@uwindsor.ca			Social sciences and Humanities Research Council of CanadaSocial Sciences and Humanities Research Council of Canada (SSHRC); National Institute on Disability and Rehabilitation Research [H133A020515]	Supported by the Social sciences and Humanities Research Council of Canada and the National Institute on Disability and Rehabilitation Research (grant no. H133A020515).	Benton A, 1989, MULTILINGUAL APHASIA; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; Cicerone KD, 2004, ARCH PHYS MED REHAB, V85, P943, DOI 10.1016/j.apmr.2003.07.019; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; Goldstein FC, 2001, J INT NEUROPSYCH SOC, V7, P373, DOI 10.1017/S1355617701733115; GRANT DA, 1948, J EXP PSYCHOL, V38, P404, DOI 10.1037/h0059831; Gronwall D, 1986, J HEAD TRAUMA REHAB, V1, P53, DOI DOI 10.1097/00001199-198606000-00009; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; JENNETT B, 1975, LANCET, V1, P480; JERET JS, 1993, NEUROSURGERY, V32, P9, DOI 10.1227/00006123-199301000-00002; Kashluba S, 2004, ARCH CLIN NEUROPSYCH, V19, P805, DOI 10.1016/j.acn.2003.09.005; KASHLUBA S, 2007, CLIN NEUROPSYCHOL, V27, P1; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; Little AJ, 1996, J CLIN PSYCHOL, V52, P455, DOI 10.1002/(SICI)1097-4679(199607)52:4<455::AID-JCLP11>3.0.CO;2-F; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; Novack TA, 2000, BRAIN INJURY, V14, P987; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rey A., 1958, LEXAMEN CLINIQUE PSY; Ross S R, 1997, Appl Neuropsychol, V4, P165, DOI 10.1207/s15324826an0403_4; Rubin DB., 1987, MULTIPLE IMPUTATION; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; Smith A, 1982, SYMBOL DIGITS MODALI; Tabachnick B., 2001, USING MULTIVARIATE S; TEASDALE G, 1974, LANCET, V2, P81; *UN DAT SYST MED R, 1993, UN DAT SYST FUNCT IN; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Vollmer D G, 1991, Neurosurg Clin N Am, V2, P437; War Department Adjutant General's Office, 1944, ARM IND TEST BATT MA; Wechsler, 1981, WAIS R MANUAL; WECHSLER D, 1997, MEMORY SCALE REVISED; Willer B., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI DOI 10.1097/00001199-199308020-00009; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	44	179	182	0	21	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2008	89	5					904	911		10.1016/j.apmr.2007.12.029			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	341ST	WOS:000258735900017	18452740				2021-06-18	
J	Whitnall, L; McMillan, TM; Murray, GD; Teasdale, GM				Whitnall, L; McMillan, TM; Murray, GD; Teasdale, GM			Disability in young people and adults after head injury: 5-7 year follow up of a prospective cohort study	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; PREDICTORS; RELATIVES; RETURN	Background: Improvement 1-2 years after head injury is well established but the pattern thereafter is unclear. Past studies have not examined representative head injury populations and typically report findings in terms of functioning across social, psychological, neurobehavioural, or cognitive domains rather than global outcome. Objective: To determine the late outcome of a representative cohort of participants admitted to hospital after a head injury 5-7 years previously and to identify early and late factors correlating with persisting disability and change between one and 5-7 years. Methods: A representative cohort of head injured people whose outcome one year after injury was reported previously, were followed up 5-7 years after injury. Participants were assessed using structured and validated measures of global outcome (Glasgow Outcome Scale Extended), cognitive impairment, psychological wellbeing, health status, and social factors. Results: Of 475 survivors studied at one year, 115 (24%) had died by seven years. In survivors at 5-7 years, disability remained frequent (53%); and the rate, similar to that found at one year (57%). Sixty three participants (29%) had improved but 55 (25%) deteriorated. The persistence of disability and its development after previous recovery each showed stronger associations with indices of depression, anxiety, and low self-esteem than with initial severity of injury or persisting cognitive impairment. Conclusions: Admission to hospital after head injury is followed 5-7 years later by disability in a high proportion of survivors. Persistence of disability and development of new disability are strongly associated with psychosocial factors that may be open to remediation, even late after injury.	Univ Glasgow, Gartnavel Royal Hosp, Dept Med Psychol, Glasgow G12 0XH, Lanark, Scotland; Univ Glasgow, So Gen Hosp, Dept Neurosurg, Glasgow G12 0XH, Lanark, Scotland; Univ Edinburgh, Sch Med, Div Community Hlth Sci, Edinburgh, Midlothian, Scotland	McMillan, TM (corresponding author), Univ Glasgow, Gartnavel Royal Hosp, Dept Med Psychol, 1055 Great Western Rd, Glasgow G12 0XH, Lanark, Scotland.			Murray, Gordon/0000-0001-9866-4734			Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; Babor T.F., 1992, GUIDELINES USE PRIMA; Baddeley A.D., 1992, SPEED CAPACITY LANGU; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Coughlan AK, 1986, ADULT MEMORY INFORM; Crawford JR, 2001, BRIT J CLIN PSYCHOL, V40, P97, DOI 10.1348/014466501163517; Hammond FM, 2004, NEUROREHABILITATION, V19, P25; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; MAHONEY F I, 1965, Md State Med J, V14, P61; Masson F, 1997, J CLIN EPIDEMIOL, V50, P595, DOI 10.1016/S0895-4356(97)00012-7; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; McMillan T, 2003, STUD NEUROPSYCHOL DE, P271; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Rosenberg M., 1989, SOC ADOLESCENT SELF; Roy CW, 2002, BRAIN INJURY, V16, P1057, DOI 10.1080/02699050210154231; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; *SCOTT EX, 2000, FAIR SHAR ALL FIN RE; Shallice, 1997, HAYLING BRIXTON TEST; Skinner HA, 1982, DRUG ABUSE SCREENING; Snaith R.P., 1994, HOSP ANXIETY DEPRESS; Strauss DJ, 1998, ARCH PHYS MED REHAB, V79, P1095, DOI 10.1016/S0003-9993(98)90177-0; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; WALLSTON KA, 1978, RES LOCUS CONTROL CO, V1; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204	30	179	180	0	17	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	MAY	2006	77	5					640	645		10.1136/jnnp.2005.078246			6	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	038QM	WOS:000237238000018	16614025	Green Published			2021-06-18	
J	Glenn, TC; Kelly, DF; Boscardin, WJ; McArthur, DL; Vespa, P; Oertel, M; Hovda, DA; Bergsneider, M; Hillered, L; Martin, NA				Glenn, TC; Kelly, DF; Boscardin, WJ; McArthur, DL; Vespa, P; Oertel, M; Hovda, DA; Bergsneider, M; Hillered, L; Martin, NA			Energy dysfunction as a predictor of outcome after moderate or severe head injury: Indices of oxygen, glucose, and lactate metabolism	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						cerebral blood flow; glucose; hyperglycolysis; intracranial hypertension; lactate; oxidative metabolism; traumatic brain injury	TRAUMATIC BRAIN-INJURY; CEREBRAL BLOOD-FLOW; LONGITUDINAL DATA-ANALYSIS; ACUTE SUBDURAL-HEMATOMA; TISSUE OXYGENATION; AMINO-ACIDS; MICRODIALYSIS; RAT; HUMANS; CONTUSION	The purpose of this study was to determine if the relationship between abnormalities in glucose, lactate, and oxygen metabolism were predictive of neurologic outcome after moderate or severe head injury, relative to other known prognostic factors. Serial assessments of the cerebral metabolic rates for glucose, lactate, and oxygen were performed using a modified Kety-Schmidt method. In total, 31 normal control subjects were studied once, and 49 TBI patients (mean age 36+/-16 years, median GCS 7) were studied five times median per patient from postinjury days 0 to 9. Univariate and multivariate analyses were performed. Univariate analysis showed that the 6-month postinjury Glasgow Outcome Scale (GOS) was most strongly associated with the mean cerebral metabolic rate of oxygen (CMRO2) (P = 0.0001), mean arterial lactate level (P = 0.0001), mean arterial glucose (P = 0.0008), mean cerebral blood flow (CBF), (P = 0.002), postresuscitation GCS (P = 0.003), and pupillary status LP = 0.004). Brain lactate uptake was observed in 44% of all metabolic studies, and 76% of patients had at least one episode of brain lactate uptake. By dichotomized GOS, patients achieving a favorable outcome (GOS 4-5) were distinguished from those with an unfavorable outcome (GOS 1-3) by having a higher CMRO2 (P = 0.003) a higher rate of abnormal brain lactate uptake relative to arterial lactate levels (P = 0.04), and lesser degrees of blood-brain barrier damage based on CT findings (P = 0.03). Conclusions: During the first 6 days after moderate or severe TBI, CMRO2 and arterial lactate levels are the strongest predictors of neurologic outcome. However, the frequent occurrence of abnormal brain lactate uptake despite only moderate elevations in arterial lactate levels in the favorable outcome patients suggests the brain's ability to use lactate as a fuel may be another key outcome predictor. Future studies are needed to determine to what degree nonglycolytic energy production from alternative fuels such as lactate occurs after TBI and whether alternative fuel administration is a viable therapy for TBI patients.	Univ Calif Los Angeles, David Geffen Sch Med, Div Neurosurg, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Cerebral Blood Flow Lab, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Harbor Med Ctr, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Res & Educ Inst, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Dept Epidemiol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Dept Biostat, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Hlth Sci Ctr, Los Angeles, CA 90024 USA; Univ Uppsala Hosp, Dept Neurosci, Uppsala, Sweden	Kelly, DF (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Div Neurosurg, 200 Med Plaza,Suite 504,Box 718224, Los Angeles, CA 90095 USA.	dfkelly@ucla.edu	McArthur, David/E-6442-2013	McArthur, David/0000-0003-3385-1314; Glenn, Thomas/0000-0003-4273-3408; Martin, Neil/0000-0002-6565-4131	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030308] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30308] Funding Source: Medline		Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; Alessandri B, 1999, ACT NEUR S, V75, P25; AMARAL JF, 1986, SURGERY, V100, P252; Barzo P, 1996, J NEUROSURG, V85, P1113, DOI 10.3171/jns.1996.85.6.1113; Beaumont A, 2002, ACT NEUR S, V81, P217; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Bouzier-Sore AK, 2001, J NEUROSCI RES, V65, P543, DOI 10.1002/jnr.1184; BRANDT RB, 1984, P SOC EXP BIOL MED, V175, P328; Brooks GA, 2002, BIOCHEM SOC T, V30, P258, DOI 10.1042/bst0300258; Chen T, 2000, J NEUROTRAUM, V17, P135, DOI 10.1089/neu.2000.17.135; Chen T, 2000, BRAIN RES, V861, P281, DOI 10.1016/S0006-8993(00)01992-2; Chieregato A, 2002, ACT NEUR S, V81, P289; Choi SC, 1998, J NEUROTRAUM, V15, P771, DOI 10.1089/neu.1998.15.771; Cicalese L, 2001, JPEN-PARENTER ENTER, V25, P216, DOI 10.1177/0148607101025004216; Clausen T, 2001, BRAIN RES, V908, P35, DOI 10.1016/S0006-8993(01)02566-5; Cormio M, 1999, J NEUROTRAUM, V16, P927, DOI 10.1089/neu.1999.16.927; DESALLES AAF, 1986, J NEUROSURG, V65, P615, DOI 10.3171/jns.1986.65.5.0615; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; FOBBEN ES, 1989, AM J ROENTGENOL, V153, P589, DOI 10.2214/ajr.153.3.589; Goodman JC, 1999, CRIT CARE MED, V27, P1965, DOI 10.1097/00003246-199909000-00041; HOVDA DA, 1992, J NEUROTRAUM, V9, pS47; HOVDA DA, 1996, NEUROTRAUMA, P1459; INAO S, 1988, J NEUROSURG, V69, P736, DOI 10.3171/jns.1988.69.5.0736; INGLIS F, 1992, J NEUROTRAUM, V9, P75, DOI 10.1089/neu.1992.9.75; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; JENNETT B, 1975, LANCET, V1, P480; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KATAYAMA Y, 1989, INTRACRANIAL PRESSUR, P584; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kelly DF, 1997, J NEUROSURG, V86, P633, DOI 10.3171/jns.1997.86.4.0633; Kelly DF, 1999, J NEUROSURG, V90, P1042, DOI 10.3171/jns.1999.90.6.1042; KURODA Y, 1992, J NEUROSURG, V76, P471, DOI 10.3171/jns.1992.76.3.0471; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; MADSEN PL, 1995, J CEREBR BLOOD F MET, V15, P485, DOI 10.1038/jcbfm.1995.60; Magistretti PJ, 1999, SCIENCE, V283, P496, DOI 10.1126/science.283.5401.496; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Mathew P, 1996, J NEUROTRAUM, V13, P465, DOI 10.1089/neu.1996.13.465; Meixensberger J, 2001, NEUROL RES, V23, P801, DOI 10.1179/016164101101199379; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; NEIMOTO EM, 1974, STROKE, V5, P81; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; Obrist W.D., 1996, NEUROTRAUMA, P471; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; OBRIST WD, 1993, J CEREB BLOOD FLO S1, V13, pS571; Ochiai K, 2001, AM J PHYSIOL-HEART C, V281, pH1823; Oertel M, 2002, J NEUROSURG, V97, P1045, DOI 10.3171/jns.2002.97.5.1045; Okauchi M, 2002, J NEUROTRAUM, V19, P741, DOI 10.1089/08977150260139110; Reinert M, 2000, ACTA NEUROCHIR SUPPL, V76, P439; Rice AC, 2002, BRAIN RES, V928, P156, DOI 10.1016/S0006-8993(01)03299-1; RIVERS EP, 1991, J CEREBR BLOOD F MET, V11, P479, DOI 10.1038/jcbfm.1991.91; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; ROBERTSON CS, 1987, J NEUROSURG, V67, P361, DOI 10.3171/jns.1987.67.3.0361; Ros J, 2001, J NEUROSCI RES, V66, P790, DOI 10.1002/jnr.10043; ROSENTHAL RE, 1992, STROKE, V23, P1312, DOI 10.1161/01.STR.23.9.1312; Sheline CT, 2000, J NEUROSCI, V20, P3139, DOI 10.1523/JNEUROSCI.20-09-03139.2000; SIMONSEN L, 1994, AM J PHYSIOL, V266, pE357; SUNAMI K, 1989, Neurosurgical Review, V12, P400, DOI 10.1007/BF01790682; Suzuki M, 2001, JPN J PHARMACOL, V87, P143, DOI 10.1254/jjp.87.143; TABADDOR K, 1972, J TRAUMA, V12, P1053, DOI 10.1097/00005373-197212000-00006; TENJIN H, 1990, NEUROSURGERY, V26, P971, DOI 10.1227/00006123-199006000-00009; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; Xi GH, 2001, STROKE, V32, P2932, DOI 10.1161/hs1201.099820; Yamaki T, 1996, J NUCL MED, V37, P1166; Ying WH, 2002, J CEREBR BLOOD F MET, V22, P774, DOI 10.1097/00004647-200207000-00002; YOSHINO A, 1992, J CEREBR BLOOD F MET, V12, P996, DOI 10.1038/jcbfm.1992.137; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	81	179	186	0	15	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	OCT	2003	23	10					1239	1250		10.1097/01.WCB.0000089833.23606.7F			12	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	729DD	WOS:000185755500014	14526234	Bronze			2021-06-18	
J	Shain, W; Spataro, L; Dilgen, J; Haverstick, K; Retterer, S; Isaacson, M; Saltzman, M; Turner, JN				Shain, W; Spataro, L; Dilgen, J; Haverstick, K; Retterer, S; Isaacson, M; Saltzman, M; Turner, JN			Controlling cellular reactive responses around neural prosthetic devices using peripheral and local intervention strategies	IEEE TRANSACTIONS ON NEURAL SYSTEMS AND REHABILITATION ENGINEERING			English	Article; Proceedings Paper	2nd International Meeting on the Brain-Computer Interfaces for Communication and Control	JUN, 2002	RENSSELAERVILLE, NEW YORK			biocompatible polymers; cyclosporin; dexamethasone; drug delivery	TRAUMATIC BRAIN INJURY; CYCLOSPORINE-A; MITOCHONDRIAL DYSFUNCTION; SUBTHALAMIC NUCLEUS; STIMULATION; DAMAGE	While chronic use of indwelling micromachined neural prosthetic devices has great potential, the development of reactive responses around them results in a decrease. in electrode function over timed. Since the cellular events responsible for these responses may be anti-inflammatory in nature, we have tested the effectiveness of dexamethasone and cyclosporin A as potential drugs for developing intervention strategies following insertion of single-shank micromachined silicon devices. Peripheral injection of dexamethasone was effective in attenuating increased expression of glial fibrillary acidic protein and astrocyte hyperplasia observed during both initial- and sustained-reactive responses observed at one and six weeks post insertion, respectively. Peripheral injection of cyclosporin A had no positive effect. If anything, application of this drug increased the early reactive response. Effectiveness of local release of dexamethasone in rat neocortex was tested by inserting ribbons of poly (ethyl-vinyl) acetate containing 35% (w/w) dexamethasone. Initial concentrations of dexamethasone were, similar to those obtained by peripheral injection. Local drug release provided continued control of cellular reactive responses during the six-week study period. These results demonstrate that peripheral delivery of dexamethasone can be used to control reactive responses and that local drug delivery by slow-release from biocompatible polymers may be a more effective method of drug intervention. Incorporating these strategies on micromachined devices may provide an intervention strategy that will insure the chronic functioning of electrodes on intracortical neuroprosthetic devices.	New York State Dept Hlth, Wadsworth Ctr Labs & Res, Albany, NY 12201 USA; SUNY Albany, Sch Publ Hlth, Dept Biomed Sci, Albany, NY 12201 USA; Univ Colorado, Dept Psychol, Boulder, CO 80309 USA; Albany Med Coll, Albany, NY 12208 USA; Cornell Univ, Dept Chem Engn, Ithaca, NY 14853 USA; Cornell Univ, Sch Appl & Engn Phys, Ithaca, NY 14853 USA; Univ Calif Santa Cruz, Dept Elect Engn, Santa Cruz, CA 95064 USA; Yale Univ, Dept Chem Engn, New Haven, CT 06520 USA	Shain, W (corresponding author), New York State Dept Hlth, Wadsworth Ctr Labs & Res, Albany, NY 12201 USA.		saltzman, matthew/T-8665-2019; Retterer, Scott/A-5256-2011	Retterer, Scott/0000-0001-8534-1979	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB000359] Funding Source: NIH RePORTER; NIBIB NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [EB-000359] Funding Source: Medline		Dostrovsky JO, 2000, J NEUROPHYSIOL, V84, P570; EDELL DJ, 1992, IEEE T BIO-MED ENG, V39, P635, DOI 10.1109/10.141202; Faist M, 2001, BRAIN, V124, P1590, DOI 10.1093/brain/124.8.1590; GIULIAN D, 1989, J NEUROSCI, V9, P4416; Guillory KS, 1999, J NEUROSCI METH, V91, P21, DOI 10.1016/S0165-0270(99)00076-X; Li PA, 2000, EXP NEUROL, V165, P153, DOI 10.1006/exnr.2000.7459; Lopiano L, 2001, NEUROLOGY, V56, P552, DOI 10.1212/WNL.56.4.552; Maynard EM, 1997, ELECTROEN CLIN NEURO, V102, P228, DOI 10.1016/S0013-4694(96)95176-0; Maynard EM, 1999, J NEUROSCI, V19, P8083; SAKAMOTO T, 1995, BIOCHEM BIOPH RES CO, V215, P511, DOI 10.1006/bbrc.1995.2494; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; SZAROWSKI DH, IN PRESS BRAIN RES; Taylor DM, 2002, SCIENCE, V296, P1829, DOI 10.1126/science.1070291; Turner JN, 1999, EXP NEUROL, V156, P33, DOI 10.1006/exnr.1998.6983; WISE K, 1994, P NEUR PROSTH WORKSH, P18	17	179	183	0	10	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855 USA	1534-4320			IEEE T NEUR SYS REH	IEEE Trans. Neural Syst. Rehabil. Eng.	JUN	2003	11	2					186	188		10.1109/TNSRE.2003.814800			3	Engineering, Biomedical; Rehabilitation	Engineering; Rehabilitation	705EL	WOS:000184382700024	12899270				2021-06-18	
J	Santhakumar, V; Ratzliff, ADH; Jeng, J; Toth, Z; Soltesz, I				Santhakumar, V; Ratzliff, ADH; Jeng, J; Toth, Z; Soltesz, I			Long-term hyperexcitability in the hippocampus after experimental head trauma	ANNALS OF NEUROLOGY			English	Article							TEMPORAL-LOBE EPILEPSY; INHIBITORY POSTSYNAPTIC CURRENTS; FIBER SYNAPTIC REORGANIZATION; DENTATE HILAR NEURONS; BRAIN INJURY; EPILEPTIFORM ACTIVITY; GABAERGIC INHIBITION; GABA(A) RECEPTORS; PYRAMIDAL NEURONS; FEBRILE SEIZURES	Head injury is a causative factor in the development of temporal lobe epilepsy. However, whether a single episode of concussive head trauma causes a persistent increase in neuronal excitability in the limbic system has not been unequivocally determined. This study used the rodent fluid percussion injury (FPI) model, in combination with electrophysiological and histochemical techniques, to investigate the early (1 week) and long-term (1 month or longer) changes in the hippocampus after head trauma. Low-frequency, single-shock stimulation of the perforant path revealed an early granule cell hyperexcitability in head-injured animals that returned to control levels by 1 month. However, there was a persistent decrease in threshold to induction of seizure-like electrical activity in response to high-frequency tetanic stimulation in the hippocampus after head injury. Timm staining revealed both early- and long-term mossy fiber sprouting at low to moderate levels in the dentate gyrus of animals that experienced FPI. There was a long-lasting increase in the frequency of spontaneous inhibitory postsynaptic currents in dentate granule cells after FPI, and ionotropic glutamate receptor antagonists selectively decreased the spontaneous inhibitory postsynaptic current frequency in the head-injured animals. These results demonstrate that a single episode of experimental closed head trauma induces long-lasting alterations in the hippocampus. These persistent structural and functional alterations in inhibitory and excitatory circuits are likely to influence the development of hyperexcitable foci in posttraumatic limbic circuits.	Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92697 USA; Univ Calif Irvine, Reeve Irvine Res Ctr, Irvine, CA 92697 USA	Santhakumar, V (corresponding author), Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92697 USA.		Santhakumar, Vijayalakshmi/M-4192-2013	Ratzliff, Anna/0000-0002-6654-8007; Santhakumar, Vijayalakshmi/0000-0001-6278-4187	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS35915] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035915, R37NS035915, R29NS035915] Funding Source: NIH RePORTER		Angeleri F, 1999, EPILEPSIA, V40, P1222, DOI 10.1111/j.1528-1157.1999.tb00850.x; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; BABB TL, 1991, NEUROSCIENCE, V42, P351, DOI 10.1016/0306-4522(91)90380-7; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Brooks-Kayal AR, 1998, NAT MED, V4, P1166, DOI 10.1038/2661; Bruton CJ, 1988, NEUROPATHOLOGY TEMPO; BUHL EH, 1994, NATURE, V368, P823, DOI 10.1038/368823a0; Buhl EH, 1996, SCIENCE, V271, P369, DOI 10.1126/science.271.5247.369; CAVAZOS JE, 1991, J NEUROSCI, V11, P2795; CAVENESS WF, 1979, J NEUROSURG, V50, P545, DOI 10.3171/jns.1979.50.5.0545; Chen K, 1999, NAT MED, V5, P888, DOI 10.1038/11330; Chen K, 2001, NAT MED, V7, P331, DOI 10.1038/85480; Cossart R, 2001, NAT NEUROSCI, V4, P52; Coulter DA, 1996, EPILEPSY RES, V26, P81, DOI 10.1016/S0920-1211(96)00044-7; DANSCHER G, 1981, HISTOCHEMISTRY, V71, P1, DOI 10.1007/BF00592566; DAVIES CH, 1990, J PHYSIOL-LONDON, V424, P513, DOI 10.1113/jphysiol.1990.sp018080; DREIER JP, 1991, EXP BRAIN RES, V87, P581; Dube C, 2000, ANN NEUROL, V47, P336, DOI 10.1002/1531-8249(200003)47:3<336::AID-ANA9>3.0.CO;2-W; Freund TF, 1996, HIPPOCAMPUS, V6, P347, DOI 10.1002/(SICI)1098-1063(1996)6:4<347::AID-HIPO1>3.0.CO;2-I; GOLARI G, 1998, SOC NEUR ABSTR, V24, P1728; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; Graber KD, 1999, ANN NEUROL, V46, P234, DOI 10.1002/1531-8249(199908)46:2<234::AID-ANA13>3.0.CO;2-Q; Halasy K, 1993, J Hirnforsch, V34, P299; Hill S. J., 1994, Society for Neuroscience Abstracts, V20, P424; Hollrigel GS, 1996, J NEUROPHYSIOL, V76, P2412; HOUSER CR, 1990, J NEUROSCI, V10, P267; Jennet B, 1975, EPILEPSY NONMISSILE; Jeub M, 1999, NEUROSCIENCE, V94, P465, DOI 10.1016/S0306-4522(99)00249-3; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; MARGERISON JH, 1966, BRAIN, V89, P499, DOI 10.1093/brain/89.3.499; MATHERN GW, 1995, J NEUROSURG, V82, P220, DOI 10.3171/jns.1995.82.2.0220; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Nusser Z, 1998, NATURE, V395, P172, DOI 10.1038/25999; OKAZAKI MM, 1995, J COMP NEUROL, V352, P515, DOI 10.1002/cne.903520404; OTIS TS, 1994, P NATL ACAD SCI USA, V91, P7698, DOI 10.1073/pnas.91.16.7698; OTIS TS, 1992, NEUROSCIENCE, V49, P13, DOI 10.1016/0306-4522(92)90073-B; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Prince DA, 1998, EPILEPSY RES, V32, P83, DOI 10.1016/S0920-1211(98)00042-4; RAFIQ A, 1995, J NEUROPHYSIOL, V74, P2028; RAFIQ A, 1993, J NEUROPHYSIOL, V70, P1962; Ross ST, 2000, J NEUROPHYSIOL, V83, P2916; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Salin P, 1995, J NEUROSCI, V15, P8234; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; Santhakumar V, 2000, J PHYSIOL-LONDON, V524, P117, DOI 10.1111/j.1469-7793.2000.00117.x; Shumate Melissa, 1995, Epilepsia, V36, P118; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SOLTESZ I, 1995, NEURON, V14, P1273, DOI 10.1016/0896-6273(95)90274-0; SOLTESZ I, 1994, J NEUROSCI, V14, P2365; STALEY KJ, 1995, SCIENCE, V269, P977, DOI 10.1126/science.7638623; SUTULA T, 1988, SCIENCE, V239, P1147, DOI 10.1126/science.2449733; SUTULA T, 1989, ANN NEUROL, V26, P321, DOI 10.1002/ana.410260303; TAUCK DL, 1985, J NEUROSCI, V5, P1016; Temkin N R, 1998, Adv Neurol, V76, P179; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Toth Z, 1997, J NEUROSCI, V17, P8106; WILLMORE LJ, 1990, EPILEPSIA, V31, P67; Wong TP, 2000, J NEUROSCI, V20, P8596, DOI 10.1523/JNEUROSCI.20-22-08596.2000; Zhang NH, 1999, J COMP NEUROL, V405, P472	61	179	186	0	5	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0364-5134			ANN NEUROL	Ann. Neurol.	DEC	2001	50	6					708	717		10.1002/ana.1230			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	496RV	WOS:000172410900005	11761468	Green Published			2021-06-18	
J	Tate, MC; Shear, DA; Hoffman, SW; Stein, DG; LaPlaca, MC				Tate, MC; Shear, DA; Hoffman, SW; Stein, DG; LaPlaca, MC			Biocompatibility of methylcellulose-based constructs designed for intracerebral gelation following experimental traumatic brain injury	BIOMATERIALS			English	Article						neurotrauma; neural tissue engineering; methylcellulose; traumatic brain injury; cell scaffold	NERVE GROWTH-FACTOR; CORTICAL IMPACT INJURY; ENCAPSULATED CELLS; SPINAL-CORD; NEUROTROPHIC FACTORS; IMPROVES SURVIVAL; RAT-BRAIN; ADULT; NEURONS; TRANSPLANTS	Tissue engineering in the post-injury brain represents a promising option for cellular replacement and rescue, providing a cell scaffold for either transplanted or resident cells. We have characterized the use of methylcellulose (MC) as a scaffolding material, whose concentration and solvent were varied to manipulate its physical properties. MC solutions were produced to exhibit low viscosity at 23 degreesC and form a soft gel at 37 degreesC, thereby making MC attractive for minimally invasive procedures in vivo. Degradation and swelling studies in vitro demonstrated a small amount of initial polymer erosion followed by relative polymer stability over the 2-week period tested as well as increased hydrogel mass due to solvent uptake. Concentrations up to 8% did not elicit cell death in primary rat astrocytes or neurons at 1 or 7 days. Acellular 2% MC (30 mul) was microinjected into the brains of rats 1 week after cortical impact injury (velocity = 3 m/s, depth = 2 mm) and examined at 2 days (n = 8; n = 3, vehicle injected) and 2 weeks (n = 5; n = 3, vehicle injected). The presence of MC did not alter the size of the injury cavity or change the patterns of gliosis as compared to injured, vehicle-injected rats (detected using antibodies against GFAP and ED1). Collectively, these data indicate that MC is well suited as a biocompatible injectable scaffold for the repair of defects in the brain. (C) 2001 Elsevier Science Ltd. All rights reserved.	Georgia Tech Emory Biomed Engn, Lab Neuroengn, Atlanta, GA 30332 USA; Emory Univ, Dept Psychol, Atlanta, GA 30322 USA; Emory Univ, Dept Neurol, Brain Res Lab, Atlanta, GA 30322 USA	LaPlaca, MC (corresponding author), Georgia Tech Emory Biomed Engn, Lab Neuroengn, 315 Ferst Dr, Atlanta, GA 30332 USA.		Stein, Donald/AAJ-5139-2020; Shear, Deborah/B-3607-2011				BELLAMKONDA R, 1995, J BIOMED MATER RES, V29, P663, DOI 10.1002/jbm.820290514; Branton RL, 1998, NEUROREPORT, V9, P3223, DOI 10.1097/00001756-199810050-00017; Chauhan NB, 1999, INT J DEV NEUROSCI, V17, P255, DOI 10.1016/S0736-5748(99)00003-9; Clark RSB, 1997, J NEUROSCI, V17, P9172; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conti AC, 1998, J NEUROSCI, V18, P5663; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Emerich DF, 1997, NATURE, V386, P395, DOI 10.1038/386395a0; Faden AI, 1996, PHARMACOL TOXICOL, V78, P12, DOI 10.1111/j.1600-0773.1996.tb00173.x; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; FULOP Z, 1992, P 22 ANN M SOC NEUR; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; Graeber MB, 1998, BRAIN RES, V813, P241, DOI 10.1016/S0006-8993(98)00859-2; HAGUE A, 1993, CARBOHYD POLYM, V22, P161; HAMMANG JP, 1995, CELL TRANSPLANT, V4, pS27, DOI 10.1016/0963-6897(94)00069-V; Heymann E, 1935, T FARADAY SOC, V31, P0846, DOI 10.1039/tf9353100846; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HOFFMAN D, 1993, EXP NEUROL, V122, P100, DOI 10.1006/exnr.1993.1111; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; HOOVLER DW, 1991, ACTA NEUROPATHOL, V81, P303, DOI 10.1007/BF00305872; KESSLAK JP, 1986, EXP NEUROL, V94, P615, DOI 10.1016/0014-4886(86)90241-4; KORDOWER JH, 1994, P NATL ACAD SCI USA, V91, P10898, DOI 10.1073/pnas.91.23.10898; Lindvall Olle, 1994, Current Opinion in Neurobiology, V4, P752, DOI 10.1016/0959-4388(94)90019-1; Logan Ann, 1994, Progress in Growth Factor Research, V5, P379, DOI 10.1016/0955-2235(94)00008-9; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; MonteroMenei CN, 1996, BRAIN RES, V724, P55, DOI 10.1016/0006-8993(96)00268-5; NIETOSAMPEDRO M, 1983, J NEUROSCI, V3, P2219; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; RINK A, 1995, AM J PATHOL, V147, P1575; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; Saporta S, 1997, CELL TRANSPLANT, V6, P579, DOI 10.1016/S0963-6897(97)00115-2; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Sautter J, 1998, EXP NEUROL, V149, P230, DOI 10.1006/exnr.1997.6718; SHETTY AK, 1995, NEUROSCIENCE, V67, P561, DOI 10.1016/0306-4522(95)00025-E; Sinclair SR, 1999, NEUROREPORT, V10, P1263, DOI 10.1097/00001756-199904260-00020; SINSON G, 1995, J NEUROCHEM, V65, P2209; STEIN DG, 1988, BEHAV NEUROSCI, V102, P260, DOI 10.1037/0735-7044.102.2.260; Stichel CC, 1998, PROG NEUROBIOL, V56, P119, DOI 10.1016/S0301-0082(98)00033-1; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Wells MR, 1997, EXP NEUROL, V146, P395, DOI 10.1006/exnr.1997.6543; WINN SR, 1994, P NATL ACAD SCI USA, V91, P2324, DOI 10.1073/pnas.91.6.2324; Woerly S, 1999, TISSUE ENG, V5, P467, DOI 10.1089/ten.1999.5.467; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	48	179	185	1	71	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0142-9612			BIOMATERIALS	Biomaterials	MAY	2001	22	10					1113	1123		10.1016/S0142-9612(00)00348-3			11	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	425ZT	WOS:000168325100011	11352091				2021-06-18	
J	Garnett, MR; Blamire, AM; Corkill, RG; Cadoux-Hudson, TAD; Rajagopalan, B; Styles, P				Garnett, MR; Blamire, AM; Corkill, RG; Cadoux-Hudson, TAD; Rajagopalan, B; Styles, P			Early proton magnetic resonance spectroscopy in normal-appearing brain correlates with outcome in patients following traumatic brain injury	BRAIN			English	Article						traumatic brain injury; proton magnetic resonance spectroscopy; outcome; N-acetylaspartate; choline	DIFFUSE AXONAL INJURY; MODERATE HEAD-INJURY; PROBABLE ALZHEIMER-DISEASE; FRONTAL-LOBE DEGENERATION; METABOLITE CONCENTRATIONS; MR SPECTROSCOPY; ABSOLUTE QUANTITATION; NMR-SPECTROSCOPY; H-1 MRS; INVIVO	The long-term clinical outcome following traumatic brain injury (TBI) can be difficult to predict. Proton magnetic resonance spectroscopy (MRS) has previously been used to demonstrate abnormalities in regions of white matter that appear normal on conventional imaging in patients following TBI. We report MRI and MRS studies of 26 patients performed at an early time point following injury (mean 12 days, n = 21) and at a later time point (mean 6.2 months, n = 15). The proton MRS was acquired from the posterior part of a normal-appearing frontal lobe containing predominantly white matter using stimulated echo acquisition mode to localize, with a relaxation time of 3000 ms and echo time of 30 ms. At both the early and late time points the N-acetylaspartate/creatine ratio (NAA/Cr) was significantly reduced (P = 0.03, P = 0.005, respectively), the choline/creatine ratio (Cho/Cr) significantly increased (P = 0.001, P = 0.004, respectively) and the myo-inositol/creatine ratio (Ins/Cr) significantly increased (P = 0.03, P = 0.03, respectively) compared with controls. There was a small, but significant, further reduction (P = 0.02) in the NAA/Cr between the two studies in the 10 patients for whom data was available, at both time points. The NAA/Cr acquired at the early time point significantly correlated with the clinical outcome of the patients, assessed using either the Glasgow outcome scale (P = 0.005, n = 17) or the disability rating scale (P < 0.001, n = 17). We conclude that there is a sustained alteration in NAA and Cho. These findings provide possible evidence for cellular injury (NAA loss reflecting neuroaxonal cell damage and raised Cho and Ins reflecting glial proliferation) not visible by conventional imaging techniques. This may be relevant to understanding the extent of disability following TBI.	Univ Oxford, Dept Biochem, MRC, Biochem & Clin Magnet Resonance Unit, Oxford OX1 3QU, England; Radcliffe Infirm, Dept Neurosurg, Oxford OX2 6HE, England; Radcliffe Infirm, Dept Neurol, Oxford OX2 6HE, England	Garnett, MR (corresponding author), Oxford Radcliffe Hosp, MRC, Biochem & Clin Magnet Resonance Unit, Oxford OX3 9DU, England.			Blamire, Andrew/0000-0002-8749-1257			ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; BRAND A, 1993, DEV NEUROSCI-BASEL, V15, P289, DOI 10.1159/000111347; BROWN TR, 1982, P NATL ACAD SCI-BIOL, V79, P3523, DOI 10.1073/pnas.79.11.3523; BRUHN H, 1989, RADIOLOGY, V172, P541, DOI 10.1148/radiology.172.2.2748837; BRUN A, 1987, ARCH GERONTOL GERIAT, V6, P193, DOI 10.1016/0167-4943(87)90021-5; BRUN A, 1993, DEMENTIA, V4, P126, DOI 10.1159/000107311; Cecil KM, 1998, J NEUROCHEM, V70, P2038; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; Condon B, 1998, J NEUROTRAUM, V15, P563, DOI 10.1089/neu.1998.15.563; De Stefano N, 1998, BRAIN, V121, P1469, DOI 10.1093/brain/121.8.1469; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; DESTEFANO N, 1995, MAGN RESON MED, V34, P721; ERNST T, 1993, J MAGN RESON SER B, V102, P1, DOI 10.1006/jmrb.1993.1055; Ernst T, 1997, RADIOLOGY, V203, P829, DOI 10.1148/radiology.203.3.9169712; FRAHM J, 1989, MAGNET RESON MED, V9, P79, DOI 10.1002/mrm.1910090110; FRAHM J, 1989, MAGNET RESON MED, V11, P47, DOI 10.1002/mrm.1910110105; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; HAASE A, 1985, PHYS MED BIOL, V30, P341, DOI 10.1088/0031-9155/30/4/008; HENNIG J, 1992, NMR BIOMED, V5, P193, DOI 10.1002/nbm.1940050406; HESSELINK JR, 1988, AM J ROENTGENOL, V150, P1133; JENNETT B, 1975, LANCET, V1, P480; King NS, 1997, CLIN REHABIL, V11, P13, DOI 10.1177/026921559701100104; KREIS R, 1993, J MAGN RESON SER B, V102, P9, DOI 10.1006/jmrb.1993.1056; Lee MA, 2000, ARCH NEUROL-CHICAGO, V57, P65, DOI 10.1001/archneur.57.1.65; LIEN YHH, 1990, J CLIN INVEST, V85, P1427, DOI 10.1172/JCI114587; McBride DQ, 1995, SURG NEUROL, V44, P137, DOI 10.1016/0090-3019(95)00139-5; MILLER BL, 1993, RADIOLOGY, V187, P433, DOI 10.1148/radiology.187.2.8475286; Miller BL, 1996, LIFE SCI, V58, P1929, DOI 10.1016/0024-3205(96)00182-8; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; MOATS RA, 1994, MAGNET RESON MED, V32, P110, DOI 10.1002/mrm.1910320115; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Pearl GS, 1998, CLIN LAB MED, V18, P39; Pendlebury ST, 1999, STROKE, V30, P956, DOI 10.1161/01.STR.30.5.956; Pouwels PJW, 1998, MAGN RESON MED, V39, P53, DOI 10.1002/mrm.1910390110; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Rubin Y, 1997, J NEUROTRAUM, V14, P441, DOI 10.1089/neu.1997.14.441; RYAN GA, 1994, J TRAUMA, V36, P469; SEGEBARTH CM, 1990, MAGN RESON MED, V13, P62, DOI 10.1002/mrm.1910130108; SHONK TK, 1995, RADIOLOGY, V195, P65, DOI 10.1148/radiology.195.1.7892497; Smith DH, 1998, J NEUROTRAUM, V15, P665, DOI 10.1089/neu.1998.15.665; TEASDALE G, 1974, LANCET, V2, P81; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; VANCE DE, 1991, NEW COMPREHENSIVE BI, V20, P205; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391	53	179	186	0	5	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950			BRAIN	Brain	OCT	2000	123		10				2046	2054		10.1093/brain/123.10.2046			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	364RU	WOS:000089907400007	11004122	Bronze			2021-06-18	
J	Chang, V; Hartzfeld, P; Langlois, M; Mahmood, A; Seyfried, D				Chang, Victor; Hartzfeld, Paul; Langlois, Marianne; Mahmood, Asim; Seyfried, Donald			Outcomes of cranial repair after craniectomy - Clinical article	JOURNAL OF NEUROSURGERY			English	Article						cranioplasty; craniectomy; cranial repair	CEREBRAL-ARTERY INFARCTION; TRAUMATIC BRAIN-INJURY; DECOMPRESSIVE CRANIECTOMY; HEAD-INJURIES; BLOOD-FLOW; CRANIOPLASTY; MULTICENTER; SURGERY	Object. Hemicraniectomy is a commonly practiced neurosurgical intervention with a wide range of indications and clinical data supporting its use. The extensive use of this procedure directly results in more cranioplasties to repair skull defects. The complication rate for cranial repair after craniectomy seems to be higher than that of the typical elective craniotomy. This finding prompted the authors to review their experience with patients undergoing cranial repair. Methods. The authors performed a retrospective review of 212 patients who underwent cranial repair over a 13-year period at their institution. A database tracking age, presenting diagnosis, side of surgery, length of time before cranial repair, bone graft material used, presence of a ventricular shunt, presence of a postoperative drain, and complications was created and analyzed. Results. The overall complication rate was 16.4% (35 of 213 patients). Patients 0-39 years of age had the lowest complication rate of 8% (p = 0.028). For patients 40-59 years of age and older than 60, complication rates were 20 and 26%, respectively. Patients who originally presented with traumatic injuries had a lower rate of complications than those who did not (10 vs 20%; p = 0.049). Conversely, patients who presented with tumors had a higher complication rate than those without (38 vs 15%; p = 0.027). Patients who received autologous bone graft placement had a statistically significant lower risk of postoperative infection (4.6 vs 18.4%; p = 0.002). Patients who underwent cranioplasty with a 0-3 month interval between operations had a complication rate of 9%, 3-6 months 18.8%, and > 6 months 26%. Pairwise comparisons showed that the difference between the 0-3 month interval and the > 6-month interval was significant (p = 0.007). The difference between the 0-3 month interval and the 4-6 month interval showed a trend (p = 0.07). No difference was detected between the 4-6 month interval and > 6-month interval (p = 0.35). Conclusions. The overall rate of complications related to cranioplasty after craniectomy is not negligible, and certain factors may be associated with increased risk. Therefore, when evaluating the need to perform a large decompressive craniectomy, the surgeon should also be aware that the patient is not only subject to the risks of the initial operation, but also the risks of subsequent cranioplasty. (DOI: 10.3171/2009.6.JNS09133)	[Chang, Victor; Hartzfeld, Paul; Mahmood, Asim; Seyfried, Donald] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI 48202 USA; [Langlois, Marianne] Baystate Hlth Syst, Div Neurosurg, Springfield, MA USA	Seyfried, D (corresponding author), Henry Ford Hlth Syst, Dept Neurosurg, 2799 W Grand Blvd, Detroit, MI 48202 USA.	nsdos@neuro.hfh.edu					Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Bakay L., 1985, EARLY HIST CRANIOTOM; Colohan Austin R T, 2005, Clin Neurosurg, V52, P19; Compagnone C, 2005, NEUROSURGERY, V57, P1183; Dujovny M, 1999, CRIT REV NEUROSURG, V9, P271, DOI 10.1007/s003290050143; Dujovny M, 1997, NEUROL RES, V19, P311, DOI 10.1080/01616412.1997.11740818; FODSTAD H, 1984, ACTA NEUROCHIR, V70, P21, DOI 10.1007/BF01406039; Grant FC, 1939, ANN SURG, V110, P488, DOI 10.1097/00000658-193910000-00002; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Iwama T, 2003, NEUROSURGERY, V52, P591, DOI 10.1227/01.NEU.0000047891.86938.46; Juttler E, 2007, STROKE, V38, P2518, DOI 10.1161/STROKEAHA.107.485649; Marion DW, 2006, NEUROSURGERY, V58, P655; Meier U, 2005, ACT NEUR S, V95, P55; RICHAUD J, 1985, NEUROCHIRURGIE, V31, P183; Sahuquillo J, 2006, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD003983-PUB2; Schiffer J, 1997, SURG NEUROL, V47, P231, DOI 10.1016/S0090-3019(96)00376-X; Schwab S, 1998, STROKE, V29, P1888, DOI 10.1161/01.STR.29.9.1888; Skoglund TS, 2006, J NEUROTRAUM, V23, P1502, DOI 10.1089/neu.2006.23.1502; Smith ER, 2002, NEUROSURGERY, V51, P117, DOI 10.1097/00006123-200207000-00018; Stiver SI, 2009, J NEUROSURG, V110, P1242, DOI 10.3171/2008.8.JNS08314; SUZUKI N, 1993, ACTA NEUROCHIR, V122, P49, DOI 10.1007/BF01446986; Timmons RL, 1982, NEUROLOGICAL SURGERY, V4, P2228; Timofeev I, 2006, ACTA NEUROCHIR SUPPL, V96, P11; Unterberg A, 2007, CURR OPIN CRIT CARE, V13, P175; Vahedi K, 2007, STROKE, V38, P2506, DOI 10.1161/STROKEAHA.107.485235; Vanaclocha V, 1997, ACTA NEUROCHIR, V139, P970, DOI 10.1007/BF01411307; Wen L, 2007, J CRANIOFAC SURG, V18, P526; Winkler PA, 2000, J NEUROSURG, V93, P53, DOI 10.3171/jns.2000.93.1.0053	28	178	186	0	19	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAY	2010	112	5					1120	1124		10.3171/2009.6.JNS09133			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	591BW	WOS:000277273600031	19612971				2021-06-18	
J	Buckmaster, PS; Ingram, EA; Wen, XL				Buckmaster, Paul S.; Ingram, Elizabeth A.; Wen, Xiling			Inhibition of the Mammalian Target of Rapamycin Signaling Pathway Suppresses Dentate Granule Cell Axon Sprouting in a Rodent Model of Temporal Lobe Epilepsy	JOURNAL OF NEUROSCIENCE			English	Article							TUBEROUS SCLEROSIS COMPLEX; LOCAL PROTEIN-SYNTHESIS; TRAUMATIC BRAIN-INJURY; KAINATE-TREATED RATS; SYNAPTIC REORGANIZATION; KAINIC ACID; PROLONGED INFUSION; PILOCARPINE MODEL; SPONTANEOUS SEIZURES; HIPPOCAMPAL-NEURONS	Dentate granule cell axon (mossy fiber) sprouting is a common abnormality in patients with temporal lobe epilepsy. Mossy fiber sprouting creates an aberrant positive-feedback network among granule cells that does not normally exist. Its role in epileptogenesis is unclear and controversial. If it were possible to block mossy fiber sprouting from developing after epileptogenic treatments, its potential role in the pathogenesis of epilepsy could be tested. Previous attempts to block mossy fiber sprouting have been unsuccessful. The present study targeted the mammalian target of rapamycin (mTOR) signaling pathway, which regulates cell growth and is blocked by rapamycin. Rapamycin was focally, continuously, and unilaterally infused into the dorsal hippocampus for prolonged periods beginning within hours after rats sustained pilocarpine-induced status epilepticus. Infusion for 1 month reduced aberrant Timm staining (a marker of mossy fibers) in the granule cell layer and molecular layer. Infusion for 2 months inhibited mossy fiber sprouting more. However, after rapamycin infusion ceased, aberrant Timm staining developed and approached untreated levels. When onset of infusion began after mossy fiber sprouting had developed for 2 months, rapamycin did not reverse aberrant Timm staining. These findings suggest that inhibition of the mTOR signaling pathway suppressed development of mossy fiber sprouting. However, suppression required continual treatment, and rapamycin treatment did not reverse already established axon reorganization.	[Buckmaster, Paul S.; Ingram, Elizabeth A.; Wen, Xiling] Stanford Univ, Dept Comparat Med, Stanford, CA 94305 USA; [Buckmaster, Paul S.] Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; [Ingram, Elizabeth A.] Western Univ, Coll Vet Med, Pomona, CA 91766 USA	Buckmaster, PS (corresponding author), Stanford Univ, Dept Comparat Med, 300 Pasteur Dr,R321 Edwards Bldg, Stanford, CA 94305 USA.	psb@stanford.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [T35RR017188] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040276, R01NS039110] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T35OD010989] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health (National Institute of Neurological Disorders and Stroke and National Center for Research Resources).	Alirezaei M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002906; BABB TL, 1991, NEUROSCIENCE, V42, P351, DOI 10.1016/0306-4522(91)90380-7; Bromberg KD, 2008, SCIENCE, V320, P903, DOI 10.1126/science.1152662; Buckmaster PS, 2004, COMPARATIVE MED, V54, P473; Buckmaster PS, 2004, EPILEPSIA, V45, P452, DOI 10.1111/j.0013-9580.2004.67103.x; Buckmaster PS, 1997, J COMP NEUROL, V385, P385; Buckmaster PS, 2002, J NEUROSCI, V22, P6650; Cammalleri M, 2003, P NATL ACAD SCI USA, V100, P14368, DOI 10.1073/pnas.2336098100; Campbell DS, 2001, NEURON, V32, P1013, DOI 10.1016/S0896-6273(01)00551-7; Casadio A, 1999, CELL, V99, P221, DOI 10.1016/S0092-8674(00)81653-0; Chen SY, 2007, J CEREBR BLOOD F MET, V27, P939, DOI 10.1038/sj.jcbfm.9600393; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Dash PK, 2006, J NEUROSCI, V26, P8048, DOI 10.1523/JNEUROSCI.0671-06.2006; Deguil J, 2008, TOXICOL LETT, V182, P91, DOI 10.1016/j.toxlet.2008.08.012; DELANEROLLE NC, 1989, BRAIN RES, V495, P387, DOI 10.1016/0006-8993(89)90234-5; Engel J, 1997, EPILEPSY COMPREHENSI, P2417; Galvan CD, 2000, J NEUROSCI, V20, P2904; Golarai G, 2001, J NEUROSCI, V21, P8523; Gong R, 2006, J BIOL CHEM, V281, P18802, DOI 10.1074/jbc.M512524200; Harris Thurl E, 2003, Sci STKE, V2003, pre15; HAUG FMS, 1967, HISTOCHEMISTRY, V8, P355, DOI 10.1007/BF00401978; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; HOLTZMAN DM, 1995, J NEUROSCI, V15, P7062; Hou LF, 2004, J NEUROSCI, V24, P6352, DOI 10.1523/JNEUROSCI.0995-04.2004; HOUSER CR, 1990, J NEUROSCI, V10, P267; Huang YF, 2007, J NEUROSCI, V27, P449, DOI 10.1523/JNEUROSCI.4489-06.2007; Ikegaya Y, 2000, NEUROSCIENCE, V98, P647, DOI 10.1016/S0306-4522(00)00188-3; Ikegaya Y, 1999, J NEUROSCI, V19, P802; Ingram EA, 2009, EPILEPSIA, V50, P56, DOI 10.1111/j.1528-1167.2008.01704.x; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Jaworski J, 2005, J NEUROSCI, V25, P11300, DOI 10.1523/JNEUROSCI.2270-05.2005; Jiao YQ, 2007, EXP NEUROL, V205, P569, DOI 10.1016/j.expneurol.2007.03.025; Kadam SD, 2007, J COMP NEUROL, V505, P716, DOI 10.1002/cne.21533; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kumar V, 2005, J NEUROSCI, V25, P11288, DOI 10.1523/JNEUROSCI.2284-05.2005; Kwon CH, 2003, P NATL ACAD SCI USA, V100, P12923, DOI 10.1073/pnas.2132711100; Li LB, 2006, J NEUROCHEM, V97, P759, DOI 10.1111/j.1471-4159.2006.03743.x; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Longo BM, 1998, EPILEPSY RES, V32, P172, DOI 10.1016/S0920-1211(98)00049-7; Longo BM, 1997, NEUROSCI LETT, V226, P163, DOI 10.1016/S0304-3940(97)00267-X; Lynch M, 2000, J NEUROPHYSIOL, V83, P693; Masukawa LM, 1996, BRAIN RES, V721, P132, DOI 10.1016/0006-8993(96)00153-9; Meikle L, 2008, J NEUROSCI, V28, P5422, DOI 10.1523/JNEUROSCI.0955-08.2008; MELLO LEAM, 1993, EPILEPSIA, V34, P985, DOI 10.1111/j.1528-1157.1993.tb02123.x; Moriwaki A, 1996, NEUROSCI RES, V25, P191; NADLER JV, 1980, BRAIN RES, V182, P1; Nissinen J, 2000, EPILEPSY RES, V38, P177, DOI 10.1016/S0920-1211(99)00088-1; Nissinen J, 2001, HIPPOCAMPUS, V11, P299, DOI 10.1002/hipo.1044; Pan TH, 2008, NEUROBIOL DIS, V32, P16, DOI 10.1016/j.nbd.2008.06.003; Park KK, 2008, SCIENCE, V322, P963, DOI 10.1126/science.1161566; Parsons RG, 2006, J NEUROSCI, V26, P12977, DOI 10.1523/JNEUROSCI.4209-06.2006; QIAO XX, 1993, J NEUROSCI, V13, P4622; Raab-Graham KF, 2006, SCIENCE, V314, P144, DOI 10.1126/science.1131693; Ribak CE, 1998, J COMP NEUROL, V401, P266; Ruegg S, 2007, EPILEPSY RES, V77, P85, DOI 10.1016/j.eplepsyres.2007.09.009; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; Sabatini DM, 1999, SCIENCE, V284, P1161, DOI 10.1126/science.284.5417.1161; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Scharfman HE, 2003, J NEUROPHYSIOL, V90, P2536, DOI 10.1152/jn.00251.2003; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; SENDELBECK SL, 1985, BRAIN RES, V328, P251; Sloviter RS, 2006, J COMP NEUROL, V494, P944, DOI 10.1002/cne.20850; SLOVITER RS, 1992, NEUROSCI LETT, V137, P91, DOI 10.1016/0304-3940(92)90306-R; SUTULA T, 1988, SCIENCE, V239, P1147, DOI 10.1126/science.2449733; SUTULA T, 1989, ANN NEUROL, V26, P321, DOI 10.1002/ana.410260303; Swiech L, 2008, BBA-PROTEINS PROTEOM, V1784, P116, DOI 10.1016/j.bbapap.2007.08.015; Takei N, 2004, J NEUROSCI, V24, P9760, DOI 10.1523/JNEUROSCI.1427-04.2004; Tang SJ, 2002, P NATL ACAD SCI USA, V99, P467, DOI 10.1073/pnas.012605299; TAUCK DL, 1985, J NEUROSCI, V5, P1016; Tavazoie SF, 2005, NAT NEUROSCI, V8, P1727, DOI 10.1038/nn1566; Toyoda I, 2005, EPILEPSIA, V46, P1017, DOI 10.1111/j.1528-1167.2005.04605.x; Verma P, 2005, J NEUROSCI, V25, P331, DOI 10.1523/JNEUROSCI.3073-04.2005; Wang YL, 2006, NEUROSCI LETT, V401, P35, DOI 10.1016/j.neulet.2006.03.011; Wenzel HJ, 1997, P NATL ACAD SCI USA, V94, P12676, DOI 10.1073/pnas.94.23.12676; Williams PA, 2002, J NEUROPHYSIOL, V88, P2075, DOI 10.1152/jn.2002.88.4.2075; Wuarin JP, 1996, J NEUROSCI, V16, P4438; Zeng LH, 2008, ANN NEUROL, V63, P444, DOI 10.1002/ana.21331	78	178	186	0	9	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	JUN 24	2009	29	25					8259	8269		10.1523/JNEUROSCI.4179-08.2009			11	Neurosciences	Neurosciences & Neurology	462GL	WOS:000267339000032	19553465	Bronze, Green Published, Green Accepted			2021-06-18	
J	Berger, RP; Adelson, PD; Pierce, MC; Dulani, T; Cassidy, LD; Kochanek, PM				Berger, RP; Adelson, PD; Pierce, MC; Dulani, T; Cassidy, LD; Kochanek, PM			Serum neuron-specific enolase, S100B, and myelin basic protein concentrations after inflicted and noninflicted traumatic brain injury in children	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; child abuse; neuron-specific enolase; S100B; myelin basic protein; biomarkers; pediatric neurosurgery	MINOR HEAD-INJURY; CEREBROSPINAL-FLUID; YOUNG-CHILDREN; RETINAL HEMORRHAGES; OUTCOME PREDICTION; S-100B LEVELS; INFANTS; MARKERS; DAMAGE; COMA	Object. Misdiagnosis of inflicted traumatic brain injury (iTBI) is common. Serum biomarkers may be able to assist in the detection of iTBIs that would otherwise be missed. The authors investigated whether serum concentrations of biomarkers were increased after noninflicted (n)TBI and iTBI in pediatric cases of varying severity. Methods. This prospective, case-control study involved 100 patients (56 with nTBI, 44 with iTBI) and 64 controls. Blood was collected in patients within 12 hours of injury; a subset had serial samples. A single sample was collected from controls. Serum neuron-specific enolase (NSE), S100B, and myelin basic protein concentrations were measured. Abnormal concentrations were defined using receiver-operator characteristic (ROC) curves. The sensitivity and specificity of initial NSE and S100B and peak myelin basic protein concentrations for identifying TBI at ROC curve-defined cutoffs were 71 and 64% (NSE), 77 and 72% (S100B), and 44 and 96% (myelin basic protein), respectively. Eighty-six percent of patients having suffered iTBI had one or more biomarkers increased, including 82% of children with iTBI and a Glasgow Coma Scale score of 15, and two children with iTBI who were initially misdiagnosed. Children with iTBI had a later peak concentration of all three biomarkers and were more likely to have increased myelin basic protein levels at admission compared with patients with nTBI. Conclusions. Serum NSE, S100B, or myelin basic protein are increased in the majority of children with acute nTBI and iTBI, including well-appearing children with iTBI in whom the diagnosis might otherwise have been missed. Differences in the time course of NSE, S100B, and myelin basic protein after nTBI and iTBI may provide insight into the pathophysiology of iTBI. These serum markers should be prospectively evaluated in a target population of infants.	Childrens Hosp Pittsburgh, Pittsburgh Child Advocacy Ctr, Dept Pediat, Pittsburgh, PA 15217 USA; Childrens Hosp Pittsburgh, Pittsburgh Child Advocacy Ctr, Dept Neurosurg, Pittsburgh, PA 15217 USA; Univ Pittsburgh, Sch Publ Hlth, Dept Biostat, Pittsburgh, PA 15260 USA; Univ Louisville, Kosair Childrens Hosp, Dept Pediat, Louisville, KY 40292 USA	Berger, RP (corresponding author), Childrens Hosp Pittsburgh, Pittsburgh Child Advocacy Ctr, Dept Pediat, 3705 5th Ave, Pittsburgh, PA 15217 USA.	rberger@pitt.edu	Kochanek, Patrick M/D-2371-2015; Pierce, Mary Clyde/AAQ-3509-2021; Adelson, David/W-2083-2019	Kochanek, Patrick M/0000-0002-2627-913X; 	NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [1K23HD43843-01] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD043843] Funding Source: NIH RePORTER		Akhtar Javed I, 2003, Pediatr Crit Care Med, V4, P322; Anderson RE, 2000, ANN THORAC SURG, V69, P847, DOI 10.1016/S0003-4975(99)01526-X; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Anderson RE, 2001, ANN THORAC SURG, V71, P1512, DOI 10.1016/S0003-4975(01)02399-2; Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; Beers SR, 2004, PEDIATR RES, V55, p70A; Bell MJ, 1999, CRIT CARE MED, V27, P493, DOI 10.1097/00003246-199903000-00023; Berger Rachel, 2003, Pediatr Crit Care Med, V4, P391, DOI 10.1097/01.PCC.0000075324.45784.8A; Berger RP, 2004, PEDIATR RES, V55, p233A; BILLMIRE ME, 1985, PEDIATRICS, V75, P340; DEGIORGIO CM, 1995, NEUROLOGY, V45, P1134, DOI 10.1212/WNL.45.6.1134; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; Duhaime AC, 2002, NEUROSURG CLIN N AM, V13, P149, DOI 10.1016/S1042-3680(02)00002-5; Durham SR, 2000, J NEUROTRAUM, V17, P729, DOI 10.1089/neu.2000.17.729; Ettaro L, 2004, CHILD ABUSE NEGLECT, V28, P1099, DOI 10.1016/j.chiabu.2004.06.006; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Ewing-Cobbs L, 1999, PEDIATR NEUROSURG, V31, P251, DOI 10.1159/000028872; Fridriksson T, 2000, ACAD EMERG MED, V7, P816, DOI 10.1111/j.1553-2712.2000.tb02276.x; Gazzolo D, 2003, CLIN CHEM, V49, P967, DOI 10.1373/49.6.967; HADDOW JE, 1992, NEW ENGL J MED, V327, P588, DOI 10.1056/NEJM199208273270902; HAHN YS, 1988, CHILD NERV SYST, V4, P34; Haviland J, 1997, ARCH DIS CHILD, V77, P504, DOI 10.1136/adc.77.6.504; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Ingebrigtsen T, 1996, J NEUROSURG, V85, P945, DOI 10.3171/jns.1996.85.5.0945; Ingebrigtsen T, 2002, J TRAUMA, V52, P798, DOI 10.1097/00005373-200204000-00038; Jayawant S, 1998, BMJ-BRIT MED J, V317, P1558, DOI 10.1136/bmj.317.7172.1558; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; JIMI T, 1992, CLIN CHIM ACTA, V211, P37, DOI 10.1016/0009-8981(92)90103-W; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; KOCHANEK PM, 2002, YB INTENSIVE CARE EM, P688; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; McKeating EG, 1998, ACT NEUR S, V71, P117; Morad Y, 2003, J PEDIATR-US, V142, P431, DOI 10.1067/mpd.2003.161; Morris MW, 2000, PEDIATRICS, V105, P549, DOI 10.1542/peds.105.3.549; MUKHERJEE A, 1985, CLIN BIOCHEM, V18, P304, DOI 10.1016/S0009-9120(85)80037-0; NOSEWORTHY TW, 1985, CRIT CARE MED, V13, P743, DOI 10.1097/00003246-198509000-00010; ONEILL JA, 1973, J TRAUMA, V13, P332, DOI 10.1097/00005373-197304000-00012; Pitetti RD, 2002, PEDIATRICS, V110, P557, DOI 10.1542/peds.110.3.557; Portela LVC, 2002, CLIN CHEM, V48, P950; Prasad MR, 2002, PEDIATR NEUROSURG, V36, P64, DOI 10.1159/000048355; Raabe A, 1999, BRIT J NEUROSURG, V13, P56, DOI 10.1080/02688699944195; Raabe A, 2001, NEUROSURGERY, V49, P1491, DOI 10.1097/00006123-200112000-00055; Romner B, 2000, J NEUROTRAUM, V17, P641, DOI 10.1089/089771500415391; Romner B, 2001, NEUROSURGERY, V49, P1490, DOI 10.1097/00006123-200112000-00053; Ross SA, 1996, BRIT J NEUROSURG, V10, P471, DOI 10.1080/02688699647104; Ruppel RA, 2001, J PEDIATR-US, V138, P18, DOI 10.1067/mpd.2001.110979; SKOGSEID IM, 1992, ACTA NEUROCHIR, V115, P106, DOI 10.1007/BF01406367; Spinella PC, 2003, CRIT CARE MED, V31, P939, DOI 10.1097/01.CCM.0000053644.16336.52; TEASDALE G, 1974, LANCET, V2, P81; THOMAS DGT, 1977, LANCET, V1, P113; THOMAS DGT, 1984, J NEUROL NEUROSUR PS, V47, P173, DOI 10.1136/jnnp.47.2.173; VANDEPOL M, 1994, J NEURO-ONCOL, V19, P149, DOI 10.1007/BF01306456; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; YAMAZAKI Y, 1995, SURG NEUROL, V43, P267, DOI 10.1016/0090-3019(95)80012-6	55	178	184	1	14	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUL	2005	103	1		S			61	68		10.3171/ped.2005.103.1.0061			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	955GY	WOS:000231215100012	16122007				2021-06-18	
J	Biegon, A; Fry, PA; Paden, CM; Alexandrovich, A; Tsenter, J; Shohami, E				Biegon, A; Fry, PA; Paden, CM; Alexandrovich, A; Tsenter, J; Shohami, E			Dynamic changes in N-methyl-D-aspartate receptors after closed head injury in mice: Implications for treatment of neurological and cognitive deficits	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article							TRAUMATIC BRAIN-INJURY; PERIPHERAL BENZODIAZEPINE-RECEPTORS; EXCITATORY AMINO-ACIDS; NMDA RECEPTORS; RECOGNITION MEMORY; CEREBRAL-ISCHEMIA; METABOLIC-CHANGES; IN-VIVO; BINDING; RAT	Traumatic brain injury is a leading cause of mortality and morbidity among young people. For the last couple of decades, it was believed that excess stimulation of brain receptors for the excitatory neurotransmitter glutamate was a major cause of delayed neuronal death after head injury, and several major clinical trials in severely head injured patients used blockers of the glutamate N-methyl-D-aspartate (NMDA) receptor. All of these trials failed to show efficacy. Using a mouse model of traumatic brain injury and quantitative autoradiography of the activity-dependent NMDA receptor antagonist MK801, we show that hyperactivation of glutamate NMDA receptors after injury is short-lived ( < 1 h) and is followed by a profound and long-lasting ( greater than or equal to 7 days) loss of function. Furthermore, stimulation of NMDA receptors by NMDA 24 and 48 h postinjury produced a significant attenuation of neurological deficits (blocked by coadministration of MK801) and restored cognitive performance 14 days postinjury. These results provide the underlying mechanism for the well known but heretofore unexplained short therapeutic window of glutamate antagonists after brain injury and support a pharmacological intervention with a relatively long ( greater than or equal to 24 h) time window easily attainable for treatment of human accidental head injury.	Univ Calif Berkeley, Dept Funct Imaging, Berkeley, CA 94720 USA; Montana State Univ, Dept Cell Biol & Neurosci, Bozeman, MT 59717 USA; Hebrew Univ Jerusalem, Dept Pharmacol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Rehabil Ctr haddasah Med Ctr, IL-91120 Jerusalem, Israel	Biegon, A (corresponding author), Brookhaven Natl Lab, Bldg 490, Upton, NY 11973 USA.	biegon@bnl.gov					Baker KB, 2002, LEARN MEMORY, V9, P58, DOI 10.1101/lm.46102; BARTH TM, 1990, STROKE, V21, P153; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; Bergsneider M, 2001, J HEAD TRAUMA REHAB, V16, P135, DOI 10.1097/00001199-200104000-00004; Biegon A, 2002, J NEUROCHEM, V82, P924, DOI 10.1046/j.1471-4159.2002.01050.x; BIEGON A, 1989, BRAIN IMAGING TECHNI, P130; BOWERY NG, 1988, BRIT J PHARMACOL, V93, P944, DOI 10.1111/j.1476-5381.1988.tb11484.x; Broersen LM, 2000, PROG BRAIN RES, V126, P79; Brown MW, 2001, NAT REV NEUROSCI, V2, P51, DOI 10.1038/35049064; Bullock R, 1995, ANN NY ACAD SCI, V765, P290, DOI 10.1111/j.1749-6632.1995.tb16586.x; Butefisch CM, 2002, ANN NEUROL, V51, P59, DOI 10.1002/ana.10056; CHEN M, 1991, ANN NEUROL, V30, P62, DOI 10.1002/ana.410300112; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; Davalos A, 1997, STROKE, V28, P708, DOI 10.1161/01.STR.28.4.708; Di X, 1996, J NEUROSURG, V85, P655, DOI 10.3171/jns.1996.85.4.0655; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fisher M, 1998, EUR NEUROL, V40, P65, DOI 10.1159/000007959; FOSTER AC, 1987, BRIT J PHARMACOL, V91, P403, DOI 10.1111/j.1476-5381.1987.tb10295.x; Friedman LK, 2001, MOL BRAIN RES, V86, P34, DOI 10.1016/S0169-328X(00)00252-7; Gibbs AR, 2002, J LABELLED COMPD RAD, V45, P395, DOI 10.1002/jlcr.561; GIBSON RE, 1992, NUCL MED BIOL, V19, P319; Grossman R, 2003, NEUROIMAGE, V20, P1971, DOI 10.1016/j.neuroimage.2003.06.003; Hoofien D, 2001, BRAIN INJURY, V15, P189; Hornstein A, 1996, BRAIN INJURY, V10, P145, DOI 10.1080/026990596124647; IZQUIERDO I, 1991, TRENDS PHARMACOL SCI, V12, P128, DOI 10.1016/0165-6147(91)90527-Y; Kroppenstedt SN, 1998, J NEUROTRAUM, V15, P191, DOI 10.1089/neu.1998.15.191; LEVIN HS, 1990, J CLIN EXP NEUROPSYC, V12, P129, DOI 10.1080/01688639008400960; LOSADA MEO, 1993, NEUROENDOCRINOLOGY, V57, P960, DOI 10.1159/000126460; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; Mautes AEM, 2001, J MOL NEUROSCI, V16, P33, DOI 10.1385/JMN:16:1:33; McCoy L, 1996, BRAIN RES, V710, P103, DOI 10.1016/0006-8993(95)01357-1; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; Moore AH, 2000, J CEREBR BLOOD F MET, V20, P1492, DOI 10.1097/00004647-200010000-00011; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; Obrenovitch TP, 2000, INT J DEV NEUROSCI, V18, P281, DOI 10.1016/S0736-5748(99)00096-9; Owens J, 2000, NUCL MED BIOL, V27, P557, DOI 10.1016/S0969-8051(00)00102-5; Paxinos G., 2001, MOUSE BRAIN STEREOTA; PORTER RHP, 1994, NEUROSCI LETT, V169, P105, DOI 10.1016/0304-3940(94)90367-0; Quirion R, 1983, NIDA Res Monogr, V43, P217; RAINBOW TC, 1982, J NEUROSCI METH, V5, P127, DOI 10.1016/0165-0270(82)90059-0; ROD MR, 1989, CAN J NEUROL SCI, V16, P340, DOI 10.1017/S031716710002919X; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; Shohami E, 2003, J CEREBR BLOOD F MET, V23, P728, DOI 10.1097/01.WCB.0000067704.86573.83; Sihver S, 2001, J NEUROCHEM, V78, P417, DOI 10.1046/j.1471-4159.2001.00428.x; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Sutton RL, 2000, NEURAL PLAST, V7, P109, DOI 10.1155/NP.2000.109; VONLUBITZ DKJE, 1994, EUR J PHARMACOL, V253, P95, DOI 10.1016/0014-2999(94)90762-5; WALLACE MC, 1992, J NEUROSURG, V76, P127, DOI 10.3171/jns.1992.76.1.0127; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	58	178	185	0	10	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	APR 6	2004	101	14					5117	5122		10.1073/pnas.0305741101			6	Multidisciplinary Sciences	Science & Technology - Other Topics	811GU	WOS:000220761200071	15044697	Green Published, Bronze			2021-06-18	
J	Smith-Seemiller, L; Fow, NR; Kant, R; Franzen, MD				Smith-Seemiller, L; Fow, NR; Kant, R; Franzen, MD			Presence of post-concussion syndrome symptoms in patients with chronic pain vs mild traumatic brain injury	BRAIN INJURY			English	Article							HEAD-INJURY	Primary objective: Post-concussion syndrome (PCS) is a controversial diagnosis, in part because many symptoms may be present in other conditions, such as chronic pain (CP). However, direct comparisons between people with CP and mild traumatic brain injury (MTBI) are limited. The purpose of this study was to compare people with CP and MTBI on a measure of PCS symptoms. Design: Group comparison between patients with CP and MTBI on the Rivermead Post-Concussion Questionnaire (RPCQ). Methods: Sixty-three patients with CP and 32 with MTBI were evaluated at the authors institutions. Patients completed the RPCQ as part of their initial evaluation. Results: No group differences were found for total RPCQ scores. There were some differences in the proportion of patients endorsing specific symptoms. However, most people with CP endorsed symptoms consistent with PCS. Conclusions: PCS symptoms are not unique to MTBI, and may be seen in conditions such as CP.	HealthS Rehabil Hosp Sewickley, Sewickley, PA 15143 USA; Health S Rehabil Hosp Greater Pittsburgh, Monroeville, PA USA; Head Jury Clin, Bridgeville, PA USA; Allegheny Gen Hosp, Pittsburgh, PA 15212 USA	Smith-Seemiller, L (corresponding author), HealthS Rehabil Hosp Sewickley, 303 Camp Meeting Rd, Sewickley, PA 15143 USA.		Kant, Ravi/F-7025-2013	Kant, Ravi/0000-0003-3878-9775			ANDARY MT, 1993, PHYS MED REHABIL CLI, V4, P141; Binder LM, 1996, AM J PSYCHIAT, V153, P7; FEE CRA, 1988, ARCH EMERG MED, V5, P12; GERBER DJ, 1995, J HEAD TRAUMA REHAB, V10, P28, DOI 10.1097/00001199-199508000-00004; GRIGSBY J, 1995, PERCEPT MOTOR SKILL, V81, P401; Hart RP, 2000, NEUROPSYCHOL REV, V10, P131, DOI 10.1023/A:1009020914358; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; POVLISHOCK JT, 1989, MILD HEAD INJURY, P37; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; RUTHERFORD WH, 1989, MILD HEAD INJURY; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61	15	178	180	0	9	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2003	17	3					199	206		10.1080/0269905021000030823			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	645CB	WOS:000180957700002	12623496				2021-06-18	
J	Masson, F; Thicoipe, M; Aye, P; Mokni, T; Senjean, P; Schmitt, V; Dessalles, PH; Cazaugade, M; Labadens, P				Masson, F; Thicoipe, M; Aye, P; Mokni, T; Senjean, P; Schmitt, V; Dessalles, PH; Cazaugade, M; Labadens, P		Aquitaine Grp Severe Brain Injur	Epidemiology of severe brain injuries: A prospective population-based study	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	40th Congres National D Anesthesie et de Reanimation	SEP 24-27, 1998	PARIS, FRANCE			severe brain injury; epidemiology; outcome; population-based study	GLASGOW COMA SCALE; SEVERE HEAD-INJURY; TRAUMA; DEATH; MORTALITY; PREVENTION; GUIDELINES; CALIFORNIA; MANAGEMENT; DISABILITY	Background: The aim of this prospective study was to estimate annual incidences of hospitalization for severe traumatic brain injury (TBI) (maximum Abbreviated Injury Score in the head region [HAIS] 4 or 5) in a defined population of 2.8 million. Methods. Severe TBI patients were included in the emergency departments in the 19 hospitals of the region. A prospective data form was completed with initial neurologic state, computed tomographic scan lesions, associated injuries, length of unconsciousness, and length of stay in acute care centers. Outcome at the time the patient left acute hospitalization was retrospectively assessed from medical notes. Results. During the 1-year period (1996), 497 residents fulfilled the inclusion criteria, leading to an annual incidence rate of 17.3 per 100,000 population; 58.1% were HAIS5. Mortality rate was 5.2 per 100,000. Men accounted for 71.4% of cases. Median age was 44 years, with a quarter of patients more than 70 years old. Traffic accidents were the most frequent causes (48.3%), but falls accounted for 41.8% of all patients. Age and severity were different according to the major categories of external causes. In HAIS5 patients, 86.5% were considered as comatose (coma lasting more than 24 hours or leading to immediate death) but only 60.9% had an initial Glasgow Coma Scale score < 9. In the HAIS4 group, 7.2% had an initial Glasgow Coma Scale score < 9. Fatality rates were 30.0% in the whole study group, 7.7% in HAIS4, 12.8% in HAIS5 without coma, and 51.2% in HAIS5 with coma. Conclusion. This study shows a decrease in severe TBI incidence when results are compared with another study conducted 10 years earlier in the same region. This is because of a decrease in traffic accidents. However, this results in an increase in the proportion of falls in elderly patients and an increase in the median age in our patients. This increased age influences the mortality rate.	Univ Hosp Bordeaux, Dept Anesthesia, Bordeaux, France; Univ Hosp Bordeaux, Dept Emergency, Bordeaux, France; Univ Hosp Bordeaux, SAMU, Bordeaux, France; Hosp Pau, Emergency Dept, Pau, France; Hosp Bayonne, Emergency Dept, Bayonne, France; Hosp Dax, Emergency Dept, Dax, France; Hosp Perigueux, Emergency Dept, Perigueux, France; Hosp Mt Marsan, Emergency Dept, Mont De Marsan, France; Hosp Arcachon, Emergency Dept, Arcachon, France	Masson, F (corresponding author), Hop Pellegrin, Serv Reanimat, F-33076 Bordeaux, France.						Acosta JA, 1998, J AM COLL SURGEONS, V186, P528, DOI 10.1016/S1072-7515(98)00082-9; American Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; Bruder N, 1997, ANN FR ANESTH, V16, P227, DOI 10.1016/S0750-7658(97)86405-2; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Close J, 1999, LANCET, V353, P93, DOI 10.1016/S0140-6736(98)06119-4; GENNARELLI TA, 1989, J TRAUMA, V29, P1193, DOI 10.1097/00005373-198909000-00002; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; GENTLEMAN D, 1993, BRIT MED J, V307, P547, DOI 10.1136/bmj.307.6903.547; GREENSPAN L, 1985, J TRAUMA, V25, P60, DOI 10.1097/00005373-198501000-00010; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; KLAUBER MR, 1985, J NEUROSURG, V62, P528, DOI 10.3171/jns.1985.62.4.0528; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; KRAUS JF, 1995, J NEUROTRAUM, V12, P873, DOI 10.1089/neu.1995.12.873; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MacKenzie E J, 1989, Md Med J, V38, P725; MACKENZIE EJ, 1989, MED CARE, V27, P412, DOI 10.1097/00005650-198904000-00008; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; Masson F, 1997, J CLIN EPIDEMIOL, V50, P595, DOI 10.1016/S0895-4356(97)00012-7; MCKENZIE EJ, 1988, J TRAUMA, V28, P281; Meyer AA, 1998, J TRAUMA, V44, P1, DOI 10.1097/00005373-199801000-00001; *OBS NAT INT SEC R, 1998, BIL ANN STAT COMM AN, P1; RAMADAN A, 1986, NEUROCHIRURGIE, V32, P423; REILLY PL, 1975, LANCET, V2, P375; ROSS SE, 1992, ACCIDENT ANAL PREV, V24, P181, DOI 10.1016/0001-4575(92)90035-H; SHACKFORD SR, 1993, ARCH SURG-CHICAGO, V128, P571, DOI 10.1001/archsurg.1993.01420170107016; SMITH GS, 1991, AM J EPIDEMIOL, V134, P1146, DOI 10.1093/oxfordjournals.aje.a116018; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Spaite D, 1998, ANN EMERG MED, V32, P480, DOI 10.1016/S0196-0644(98)70178-7; Stocchetti N, 1999, INTENS CARE MED, V25, P371, DOI 10.1007/s001340050860; TEASDALE G, 1974, LANCET, V2, P81; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; TIRET L, 1989, AM J PUBLIC HEALTH, V79, P316, DOI 10.2105/AJPH.79.3.316; TIRET L, 1986, INT J EPIDEMIOL, V19, P133; Vollmer DG, 1991, J NEUROSURG S, V75, P37; WINKLER J V, 1984, Journal of Emergency Medicine, V2, P1, DOI 10.1016/0736-4679(84)90038-6	36	178	182	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	2001	51	3					481	489		10.1097/00005373-200109000-00010			9	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	471WW	WOS:000170952500013	11535895				2021-06-18	
J	Schnyder, U; Moergeli, H; Klaghofer, R; Buddeberg, C				Schnyder, U; Moergeli, H; Klaghofer, R; Buddeberg, C			Incidence and prediction of posttraumatic stress disorder symptoms in severely injured accident victims	AMERICAN JOURNAL OF PSYCHIATRY			English	Article							TRAUMATIC BRAIN INJURY; MOTOR-VEHICLE ACCIDENTS; ROAD TRAFFIC ACCIDENTS; PSYCHIATRIC CONSEQUENCES; SCALE; IMPACT; COMMUNITY; SEVERITY; EVENT; PTSD	Objective: This study was designed to assess the incidence of posttraumatic stress disorder (PTSD) in severely injured accident victims and to predict the presence of PTSD symptoms at a 12-month follow-up. Method: A longitudinal, 1-year follow-up study was carried out with 106 consecutive patients with severe accidental injuries who were admitted to the trauma surgeons' intensive care unit at a university hospital. Patients were interviewed within 1 month and 12 months after the accident. Assessments included an extensive clinical interview the impact of Event Scale, the Clinician-Ad ministered PTSD Scale, the Sense of Coherence questionnaire, and the Freiburg Questionnaire of Coping With Illness. Results: A total of 13.4 days (SD=6.6) after the accident, five patients (4.7%) met all criteria for PTSD with the exception of the time criterion. A total of 22 other patients (20.8%) had subsyndromal PTSD. At the 1-year follow-up, two patients (1.9%) had PTSD, and 13(12.3%) had subsyndromal PTSD. Multiple regression analysis explained 34% of the variance of PTSD symptoms 12 months after the accident. Biographical risk factors, the sense of a death threat, symptoms of intrusion, and problem-oriented coping each contributed significantly to the predictive model. Conclusions: in severely injured accident victims who were healthy before experiencing trauma, the incidence of PTSD was low. One-third of the variance of PTSD symptoms at I-year follow-up could be predicted by mainly psychosocial variables.	Univ Zurich Hosp, Dept Psychiat, CH-8091 Zurich, Switzerland; Univ Zurich Hosp, Dept Psychosocial Med, CH-8091 Zurich, Switzerland	Schnyder, U (corresponding author), Univ Zurich Hosp, Dept Psychiat, Culmannstr 8, CH-8091 Zurich, Switzerland.						ANTONOVSKY A, 1993, SOC SCI MED, V36, P725, DOI 10.1016/0277-9536(93)90033-Z; Antonovsky A., 1987, UNRAVELING MYSTERY H; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BERKMAN LF, 1979, AM J EPIDEMIOL, V109, P186, DOI 10.1093/oxfordjournals.aje.a112674; Blake D. D., 1990, BEHAV THER, V13, P187; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; BLANCHARD EB, 1995, J NERV MENT DIS, V183, P495, DOI 10.1097/00005053-199508000-00001; BLANCHARD EB, 1995, BEHAV RES THER, V33, P529, DOI 10.1016/0005-7967(94)00079-Y; Blanchard EB, 1997, J TRAUMA STRESS, V10, P215, DOI 10.1023/A:1024826028483; Breslau N, 1998, ARCH GEN PSYCHIAT, V55, P626, DOI 10.1001/archpsyc.55.7.626; Breslau N, 1997, ARCH GEN PSYCHIAT, V54, P1044; Bryant RA, 2000, AM J PSYCHIAT, V157, P629, DOI 10.1176/appi.ajp.157.4.629; Bryant RA, 1996, J TRAUMA STRESS, V9, P223, DOI 10.1002/jts.2490090206; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Egle UT, 1997, NERVENARZT, V68, P683, DOI 10.1007/s001150050183; Erichsen John Eric, 1866, RAILWAY OTHER INJURI; FEINSTEIN A, 1991, PSYCHOL MED, V21, P85, DOI 10.1017/S0033291700014689; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; Koren D, 1999, AM J PSYCHIAT, V156, P367; LIM L C C, 1991, SMJ Singapore Medical Journal, V32, P92; MALT U, 1988, BRIT J PSYCHIAT, V153, P810, DOI 10.1192/bjp.153.6.810; Malt U F, 1992, Psychiatr Med, V10, P135; Malt U F, 1992, Psychiatr Med, V10, P117; Malt U. F., 1993, European Psychiatry, V8, P227; Mayou R, 1997, PSYCHOSOM MED, V59, P578, DOI 10.1097/00006842-199711000-00004; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; MAYOU R, 1991, INJURY, V22, P365, DOI 10.1016/0020-1383(91)90095-V; MCFALL ME, 1990, AM J PSYCHIAT, V147, P645; Moore A D, 1994, Int J Rehabil Res, V17, P39, DOI 10.1097/00004356-199403000-00004; Muthny FA., 1989, FREIBURGER FRAGEBOGE; NORRIS FH, 1992, J CONSULT CLIN PSYCH, V60, P409, DOI 10.1037/0022-006X.60.3.409; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106; SCHAEFER C, 1981, Journal of Behavioral Medicine, V4, P381, DOI 10.1007/BF00846149; Schnyder U, 2000, CRIT CARE MED, V28, P86, DOI 10.1097/00003246-200001000-00014; Schnyder U, 1996, LANGENBECK ARCH CHIR, V381, P125; Schnyder U, 1998, J PSYCHOSOM RES, V45, P419, DOI 10.1016/S0022-3999(98)00008-7; Stein MB, 1997, AM J PSYCHIAT, V154, P1114; Tabachnick BG, 2013, USING MULTIVARIATE S; TEASDALE G, 1974, LANCET, V2, P81; Ursano RJ, 1999, AM J PSYCHIAT, V156, P589; Warden DL, 1997, J NEUROPSYCH CLIN N, V9, P18; WEISAETH L, 1989, ACTA PSYCHIAT SCAN S, V355, P131; ZIEGRIST J, 1983, ZUMA HDB SOZIALWISSE	43	178	184	0	11	AMER PSYCHIATRIC PRESS, INC	WASHINGTON	1400 K ST, N W, STE 1101, WASHINGTON, DC 20005 USA	0002-953X			AM J PSYCHIAT	Am. J. Psychiat.	APR	2001	158	4					594	599		10.1176/appi.ajp.158.4.594			6	Psychiatry	Psychiatry	419CN	WOS:000167931900012	11282694				2021-06-18	
J	Bittigau, D; Sifringer, M; Pohl, D; Stadthaus, D; Ishimaru, M; Shimizu, H; Ikeda, M; Lang, D; Speer, A; Olney, JW; Ikonomidou, C				Bittigau, D; Sifringer, M; Pohl, D; Stadthaus, D; Ishimaru, M; Shimizu, H; Ikeda, M; Lang, D; Speer, A; Olney, JW; Ikonomidou, C			Apoptotic neurodegeneration following trauma is markedly enhanced in the immature brain	ANNALS OF NEUROLOGY			English	Article							CORTICAL IMPACT INJURY; SPINAL-CORD INJURY; METHYL-D-ASPARTATE; REGIONAL CEREBRAL EDEMA; DEVELOPING RAT-BRAIN; CLOSED-HEAD INJURY; INDUCED CELL-DEATH; C-JUN; NONCOMPETITIVE BLOCKADE; TRANSCRIPTION FACTOR	Age dependency of apoptotic neurodegeneration was studied in the developing rat brain after percussion head trauma. In 7-day-old rats, mechanical trauma, applied by means of a weight drop device, was shown to trigger widespread cell death in the hemisphere ipsilateral to the trauma site, which first appeared at 6 hours, peaked at 24 hours, and subsided by 5 days after trauma. Ultrastructurally, degenerating neurons displayed features consistent with apoptosis. A decrease of bcl-2 in conjunction with an increase of c-jun mRNA levels, which were evident at 1 hour after trauma and were accompanied by elevation of CPP 32-like proteolytic activity and oligonucleosomes in vulnerable brain regions, confirmed the apoptotic nature of this process, Severity of trauma-triggered apoptosis in the brains of 3- to 30-day-old rats was age dependent, was highest in 3- and 7-day-old animals, and demonstrated a subsequent rapid decline. Adjusting the mechanical force in accordance with age-specific brain weights revealed a similar vulnerability profile. Thus, apoptotic neurodegeneration contributes in an age-dependent fashion to neuropathological outcome after head trauma, with the immature brain being exceedingly vulnerable. These results help explain unfavorable outcomes of very young pediatric head trauma patients and imply that, in this group, an antiapoptotic regimen may constitute a successful neuroprotective approach.	Humboldt Univ, Childrens Hosp, Dept Pediat Neurol, D-13353 Berlin, Germany; Tech Fachhsch Berlin, Berlin, Germany; Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA; Eisai & Co Ltd, Tsukuba Res Labs Drug Discovery, Ibaraki, Osaka, Japan	Ikonomidou, C (corresponding author), Humboldt Univ, Childrens Hosp, Dept Pediat Neurol, Virchow Campus,Augustenburger Pl 1, D-13353 Berlin, Germany.						Adams JH, 1992, GREENFIELDS NEUROPAT, P106; Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; Allen A.R., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; Almog N, 1997, BBA-REV CANCER, V1333, pF1, DOI 10.1016/S0304-419X(97)00012-7; Barinaga M, 1996, SCIENCE, V273, P735, DOI 10.1126/science.273.5276.735; BELLUARDO N, 1996, NEUROCHEMISTRY, V26, P443; Bittigau P., 1998, Society for Neuroscience Abstracts, V24, P1728; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Borovitskaya AE, 1996, MOL BRAIN RES, V35, P19, DOI 10.1016/0169-328X(95)00177-T; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; BURSCH W, 1990, BIOCHEM CELL BIOL, V68, P1071, DOI 10.1139/o90-160; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clark RSB, 1997, J NEUROSCI, V17, P9172; COHEN JJ, 1993, IMMUNOL TODAY, V14, P126, DOI 10.1016/0167-5699(93)90214-6; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; COMPTON MM, 1992, CANCER METAST REV, V11, P105, DOI 10.1007/BF00048058; Conti AC, 1998, J NEUROSCI, V18, P5663; Corso TD, 1997, BRAIN RES, V752, P1, DOI 10.1016/S0006-8993(96)01347-9; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; DEOLMOS JS, 1971, BRAIN RES, V33, P523, DOI 10.1016/0006-8993(71)90130-2; Diamond PT, 1996, BRAIN INJURY, V10, P413, DOI 10.1080/026990596124278; Eilers A, 1998, J NEUROSCI, V18, P1713; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Ferrer I, 1996, EUR J NEUROSCI, V8, P1286, DOI 10.1111/j.1460-9568.1996.tb01297.x; GOLDING EM, 1995, MOL CHEM NEUROPATHOL, V24, P137, DOI 10.1007/BF02962139; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; Herdegen T, 1997, TRENDS NEUROSCI, V20, P227, DOI 10.1016/S0166-2236(96)01000-4; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; IKONOMIDOU C, 1989, J NEUROSCI, V9, P2809; Ikonomidou C, 1996, PEDIATR RES, V39, P1020, DOI 10.1203/00006450-199606000-00015; Ishimaru M. J., 1997, Society for Neuroscience Abstracts, V23, P895; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; Katoh H, 1997, BRAIN RES, V758, P153, DOI 10.1016/S0006-8993(97)00213-8; Katoh K, 1996, NEUROSCI LETT, V216, P9; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Kroppenstedt SN, 1998, J NEUROTRAUM, V15, P191, DOI 10.1089/neu.1998.15.191; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; Li GL, 1996, J NEUROPATH EXP NEUR, V55, P280, DOI 10.1097/00005072-199603000-00003; Linnik MD, 1996, RESTOR NEUROL NEUROS, V9, P219, DOI 10.3233/RNN-1996-9404; Liu XZ, 1997, J NEUROSCI, V17, P5395; LOHMANN J, 1995, BIOTECHNIQUES, V18, P200; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mattson MP, 1996, RESTOR NEUROL NEUROS, V9, P191, DOI 10.3233/RNN-1996-9401; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCDONALD JW, 1988, BRAIN RES, V459, P200, DOI 10.1016/0006-8993(88)90306-X; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; McIntosh TK, 1996, J NEUROTRAUM, V13, P767, DOI 10.1089/neu.1996.13.767; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; Norimura T, 1996, NAT MED, V2, P577, DOI 10.1038/nm0596-577; Okiyama K, 1998, BRAIN RES, V792, P291, DOI 10.1016/S0006-8993(98)00158-9; Okiyama K, 1997, J NEUROTRAUM, V14, P211, DOI 10.1089/neu.1997.14.211; OLNEY JW, 1971, SCIENCE, V172, P294, DOI 10.1126/science.172.3980.294; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; Phillips LL, 1997, J NEUROSCI RES, V49, P197; Pohl D., 1997, Society for Neuroscience Abstracts, V23, P1123; Porciatti V, 1996, P NATL ACAD SCI USA, V93, P14955, DOI 10.1073/pnas.93.25.14955; Pravdenkova SV, 1996, BRAIN RES, V729, P151, DOI 10.1016/0006-8993(96)00222-3; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; RAGHUPATHI R, 1995, J CEREBR BLOOD F MET, V15, P467, DOI 10.1038/jcbfm.1995.58; Raghupathi R, 1998, J NEUROTRAUM, V15, P555, DOI 10.1089/neu.1998.15.555; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; RINK A, 1995, AM J PATHOL, V147, P1575; Shah PT, 1997, NEUROSCIENCE, V79, P999, DOI 10.1016/S0306-4522(97)00013-4; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; Sherwood N.M., 1970, STEREOTAXIC ATLAS DE; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; Stein SC, 1995, PEDIATR NEUROSURG, V23, P299, DOI 10.1159/000120975; Thomaidou D, 1997, J NEUROSCI, V17, P1075, DOI 10.1523/jneurosci.17-03-01075.1997; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; TOULMOND S, 1993, BRAIN RES, V620, P32, DOI 10.1016/0006-8993(93)90267-Q; WEST MJ, 1990, J COMP NEUROL, V296, P1, DOI 10.1002/cne.902960102; WRATHALL JR, 1994, J NEUROSCI, V14, P6598; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533	86	178	185	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	JUN	1999	45	6					724	735		10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P			12	Clinical Neurology; Neurosciences	Neurosciences & Neurology	203PC	WOS:000080715200006	10360764				2021-06-18	
J	Chen, Y; Lomnitski, L; Michaelson, DM; Shohami, E				Chen, Y; Lomnitski, L; Michaelson, DM; Shohami, E			Motor and cognitive deficits in apolipoprotein E-deficient mice after closed head injury	NEUROSCIENCE			English	Article						Alzheimer's disease; apolipoprotein E; closed head injury; histopathology; motor function; memory	TRAUMATIC BRAIN INJURY; CONTROLLED CORTICAL IMPACT; ALZHEIMERS-DISEASE; RAT; ABSENCE; HU-211; MOUSE; GENE	Previous studies suggest that traumatic brain injury is associated with increased risk Factor for developing Alzheimer's disease. Furthermore, the extent of the risk seems to be most pronounced in Alzheimer's disease patients who carry the epsilon 4 allele of apolipoprotein E, suggesting a connection between susceptibility to head trauma and the apolipoprotein E genotype. Apolipoprotein E-deficient mice provide a useful model for investigating the role of this lipoprotein in neuronal maintenance and repair. In the present study apolipoprotein E-deficient mice and a closed head injury experimental paradigm were used to examine the role of apolipoprotein E in brain susceptibility to head trauma and in neuronal repair. Apolipoprotein E-deficient mice were assessed up to 40 days after closed head injury for neurological and cognitive functions, as well as for histopathological changes in the hippocampus. A neurological severity score used for clinical assessment revealed more severe motor and behavioural deficits in the apolipoprotein E-deficient mice than in the controls, the impairment persisting for at least 40 days after injury. Performance in the Morris water maze, which tests spatial memory, showed a marked learning deficit of the apolipoprotein E-deficient mice when compared with injured controls, which was apparent for at least 40 days. At this time, histopathological examination revealed overt neuronal cell death bilaterally in the hippocampus of the injured apolipoprotein E-deficient mice. The finding that apolipoprotein E-deficient mice exhibit an impaired ability to recover from closed head injury suggests that apolipoprotein E plays an important role in neuronal repair following injury and highlights the applicability of this mouse model to the study of the cellular and molecular mechanisms involved. (C) 1997 IBRO. Published by Elsevier Science Ltd.	HEBREW UNIV JERUSALEM,SCH PHARM,DEPT PHARMACOL,IL-91120 JERUSALEM,ISRAEL; TEL AVIV UNIV,GEORGE S WISE FAC LIFE SCI,DEPT NEUROBIOCHEM,IL-69978 RAMAT AVIV,ISRAEL							BREWER HB, 1989, HEART DISEASE TXB CA, P121; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; FRENCH LR, 1985, AM J EPIDEMIOL, V121, P414, DOI 10.1093/oxfordjournals.aje.a114013; GENTLEMAN SM, 1993, PROG BRAIN RES, V96, P237; GORDON I, 1995, NEUROSCI LETT, V199, P1, DOI 10.1016/0304-3940(95)12006-P; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; Ignatius MJ, 1987, PROG BRAIN RES <D>, V71, P177; KAKU Y, 1993, J CEREBR BLOOD F MET, V13, P402, DOI 10.1038/jcbfm.1993.54; Levin H. S., 1985, CENTRAL NERVOUS SYST, P281; LOHSE P, 1992, J LIPID RES, V33, P1583; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MASLIAH E, 1995, EXP NEUROL, V136, P107, DOI 10.1006/exnr.1995.1088; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; NATHAN BP, 1994, SCIENCE, V264, P850, DOI 10.1126/science.8171342; NICHOLLS JG, 1992, NEURON BRAIN, P317; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; POPKO B, 1993, J NEUROCHEM, V60, P1155, DOI 10.1111/j.1471-4159.1993.tb03268.x; ROSES AD, 1994, J NEUROPATH EXP NEUR, V53, P429, DOI 10.1097/00005072-199409000-00002; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHOHAMI E, 1993, J NEUROTRAUM, V10, P109, DOI 10.1089/neu.1993.10.109; SHOHAMI E, 1992, EXP NEUROL, V117, P189, DOI 10.1016/0014-4886(92)90126-B; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; SOININEN H, 1995, NEUROSCI LETT, V187, P79, DOI 10.1016/0304-3940(95)11343-6; Sutton R. L., 1992, Society for Neuroscience Abstracts, V18, P170; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509	32	178	187	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0306-4522			NEUROSCIENCE	Neuroscience	OCT	1997	80	4					1255	1262		10.1016/S0306-4522(97)00007-9			8	Neurosciences	Neurosciences & Neurology	XR557	WOS:A1997XR55700023	9284075				2021-06-18	
J	Cernak, I; Merkle, AC; Koliatsos, VE; Bilik, JM; Luong, QT; Mahota, TM; Xu, LY; Slack, N; Windle, D; Ahmed, FA				Cernak, Ibolja; Merkle, Andrew C.; Koliatsos, Vassilis E.; Bilik, Justin M.; Luong, Quang T.; Mahota, Theresa M.; Xu, Leyan; Slack, Nicole; Windle, David; Ahmed, Farid A.			The pathobiology of blast injuries and blast-induced neurotrauma as identified using a new experimental model of injury in mice	NEUROBIOLOGY OF DISEASE			English	Article						Blast; Blast injury; Traumatic brain injury; Blast-induced neurotrauma; Mouse; Behavior; Motor function; Cognitive function; PCR; Inflammation	TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; INFLAMMATORY RESPONSE; DELAYED EXPRESSION; GLIAL RESPONSES; REFERENCE GENES; PATHOLOGY; OSTEOPONTIN; STRESS; INVOLVEMENT	Current experimental models of blast injuries used to study blast-induced neurotrauma (BINT) vary widely, which makes the comparison of the experimental results extremely challenging. Most of the blast injury models replicate the ideal Friedlander type of blast wave, without the capability to generate blast signatures with multiple shock fronts and refraction waves as seen in real-life conditions; this significantly reduces their clinical and military relevance. Here, we describe the pathophysiological consequences of graded blast injuries and BINT generated by a newly developed, highly controlled, and reproducible model using a modular, multi-chamber shock tube capable of tailoring pressure wave signatures and reproducing complex shock wave signatures seen in theater. While functional deficits due to blast exposure represent the principal health problem for today's warfighters, the majority of available blast models induces tissue destruction rather than mimic functional deficits. Thus, the main goal of our model is to reliably reproduce long-term neurological impairments caused by blast. Physiological parameters, functional (motor, cognitive, and behavioral) outcomes, and underlying molecular mechanisms involved in inflammation measured in the brain over the 30 day post-blast period showed this model is capable of reproducing major neurological changes of clinical BINT. (c) 2010 Elsevier Inc. All rights reserved.	[Cernak, Ibolja; Merkle, Andrew C.; Bilik, Justin M.; Luong, Quang T.; Mahota, Theresa M.; Slack, Nicole; Windle, David; Ahmed, Farid A.] Johns Hopkins Univ, Biomed Business Area, Appl Phys Lab, Natl Secur Technol Dept, Laurel, MD 20723 USA; [Koliatsos, Vassilis E.; Xu, Leyan] Johns Hopkins Univ, Sch Med, Dept Pathol, Laurel, MD 20723 USA	Cernak, I (corresponding author), Johns Hopkins Univ, Biomed Business Area, Appl Phys Lab, Natl Secur Technol Dept, 11100 Johns Hopkins Rd,Mail Stop MP2 N108, Laurel, MD 20723 USA.	ibolja.cernak@jhuapl.edu		Ibolja, Cernak/0000-0003-3214-698X	JHU/APL; JHU/APL-JHU SOM	This work was supported by the JHU/APL internal research and development funds and the JHU/APL-JHU SOM Partnership Grant. The sponsor did not influence the study design; data collection, analysis and interpretation of data; or the writing of the report.	Allan SM, 2003, PHILOS T R SOC B, V358, P1669, DOI 10.1098/rstb.2003.1358; Anderson J., 2003, MODERN COMPRESSIBLE; Banati RB, 1998, MOVEMENT DISORD, V13, P221, DOI 10.1002/mds.870130205; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Ben-Dor C, 2001, HDB SHOCK WAVES; Beschorner R, 2000, ACTA NEUROPATHOL, V100, P627, DOI 10.1007/s004010000232; Boda E, 2009, J MOL NEUROSCI, V37, P238, DOI 10.1007/s12031-008-9128-9; Bowen I.G., 1968, ESTIMATE MANS TOLERA, P1; BOWEN IG, 1968, ANN NY ACAD SCI, V152, P122, DOI 10.1111/j.1749-6632.1968.tb11971.x; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I., 1990, J TRAUMA S, V6, P267; Cernak I, 2010, J CEREBR BLOOD F MET, V30, P255, DOI 10.1038/jcbfm.2009.203; Chari R, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-32; Chiffelle T. L., 1966, DA49146XY055 DEP DEF; Choi JS, 2007, BRAIN RES, V1151, P195, DOI 10.1016/j.brainres.2007.03.016; Cordeau P, 2008, STROKE, V39, P935, DOI 10.1161/STROKEAHA.107.501460; DAMOISEAUX JGMC, 1994, IMMUNOLOGY, V83, P140; DAMON EG, 1968, AEROSPACE MED, V39, P1039; Dennis AM, 2009, J NEUROTRAUM, V26, P889, DOI 10.1089/neu.2008.0512; DeWitt DS, 2009, J NEUROTRAUM, V26, P877, DOI 10.1089/neu.2007.0439; DODD KT, 1990, J OCCUP ENVIRON MED, V32, P260, DOI 10.1097/00043764-199003000-00015; Engel S, 2000, ACTA NEUROPATHOL, V100, P313, DOI 10.1007/s004019900172; Flurkey K., 2007, MOUSE BIOMEDICAL RES, P637, DOI [DOI 10.1016/B978-012369454-6/50074-1, 10.1016/B978-012369454-6/50074-1.]; Gruss E, 2006, J TRAUMA, V60, P1284, DOI 10.1097/01.ta.0000220015.21948.ec; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Harting MT, 2008, SURGERY, V144, P803, DOI 10.1016/j.surg.2008.05.017; Irwin RJ, 1999, J TRAUMA, V47, P105, DOI 10.1097/00005373-199907000-00023; Izumizaki M, 2005, COMP BIOCHEM PHYS A, V141, P133, DOI 10.1016/j.cbpb.2005.04.004; Kaur C, 1997, NEUROSCI RES, V27, P317, DOI 10.1016/S0168-0102(97)01164-4; Larsson F, 2002, PHARMACOL BIOCHEM BE, V73, P193, DOI 10.1016/S0091-3057(02)00782-7; Liem RKH, 2009, J CLIN INVEST, V119, P1814, DOI 10.1172/JCI38003; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Martin EM, 2008, AM J NURS, V108, P40, DOI 10.1097/01.NAJ.0000315260.92070.3f; Martin M, 2002, PSYCHOPHARMACOLOGY, V159, P379, DOI 10.1007/s00213-001-0946-5; Mellor S G, 1988, Br J Hosp Med, V39, P536; Moxon-Emre I, 2010, J NEUROPATH EXP NEUR, V69, P1, DOI 10.1097/NEN.0b013e3181c3ce6c; Nacken W, 2003, MICROSC RES TECHNIQ, V60, P569, DOI 10.1002/jemt.10299; Nelson LA, 2009, J HEAD TRAUMA REHAB, V24, P32, DOI 10.1097/HTR.0b013e3181957016; Nishida M., 2001, HDB SHOCK WAVES, V1, P553, DOI DOI 10.1016/B978-012086430-0/50041-5; Owen-Smith MS, 1981, MED B US ARMY EUR, V38, P36; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Richmond D.R., 1967, 1854 DASA LOV FDN ME, P1; Richmond D. R., 2005, RELATIONSHIP SELECTE; RICHMOND DR, 1968, ANN NY ACAD SCI, V152, P103, DOI 10.1111/j.1749-6632.1968.tb11970.x; Risling M, 2011, NEUROIMAGE, V54, pS89, DOI 10.1016/j.neuroimage.2010.05.031; Ritenour AE, 2010, ANN SURG, V251, P1140, DOI 10.1097/SLA.0b013e3181e01270; Robey R., 2001, HDB SHOCK WAVES, V1, P623; Saljo Annette, 2001, Pathophysiology, V8, P105, DOI 10.1016/S0928-4680(01)00067-0; Saljo A, 2009, J NEUROTRAUM, V26, P1345, DOI [10.1089/neu.2008.0856, 10.1089/neu.2008-0856]; Salter MG, 2008, J CEREBR BLOOD F MET, V28, P588, DOI 10.1038/sj.jcbfm.9600555; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P459, DOI 10.1038/jcbfm.2009.240; Souza-Rodrigues RD, 2008, BRAIN RES, V1200, P78, DOI 10.1016/j.brainres.2007.11.025; Stoll G, 1998, PROG NEUROBIOL, V56, P149, DOI 10.1016/S0301-0082(98)00034-3; Suneson A, 2000, MIL MED, V165, P119, DOI 10.1093/milmed/165.2.119; Suzuki H., 2009, CRIT CARE MED; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; The Jackson Laboratory, 2010, LIF BIOM; Trigo JM, 2008, PSYCHOPHARMACOLOGY, V197, P391, DOI 10.1007/s00213-007-1045-z; Urrea C, 2007, RESTOR NEUROL NEUROS, V25, P65; Vallee M, 1997, J NEUROSCI, V17, P2626; Voggenreiter G, 1999, CRIT CARE MED, V27, P2375, DOI 10.1097/00003246-199911000-00009; Vogl T, 2007, NAT MED, V13, P1042, DOI 10.1038/nm1638; Wan GQ, 2010, BIOCHEM BIOPH RES CO, V400, P575, DOI 10.1016/j.bbrc.2010.08.106; Wang XK, 1998, J NEUROSCI, V18, P2075; Warden DL, 2009, NEUROIMAGE, V47, pT152, DOI 10.1016/j.neuroimage.2009.01.060; Wasserman JK, 2008, EUR J NEUROSCI, V28, P1316, DOI 10.1111/j.1460-9568.2008.06442.x; Wharton SB, 2009, DEMENT GERIATR COGN, V27, P465, DOI 10.1159/000217729; WILSON MA, 1994, GLIA, V11, P18, DOI 10.1002/glia.440110105; Yan YP, 2009, J NEUROCHEM, V109, P1624, DOI 10.1111/j.1471-4159.2009.06059.x; Yelverton JT, 1996, J TRAUMA, V40, pS111, DOI 10.1097/00005373-199603001-00025; Zhou LH, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-75; Zhu H, 2007, J NEUROSCI RES, V85, P2783, DOI 10.1002/jnr.21257; Ziegler G, 2009, BBA-MOL BASIS DIS, V1792, P1198, DOI 10.1016/j.bbadis.2009.10.003; Zuckerman S, 1940, LANCET, V2, P219	79	177	183	0	21	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	FEB	2011	41	2					538	551		10.1016/j.nbd.2010.10.025			14	Neurosciences	Neurosciences & Neurology	705QZ	WOS:000286154300031	21074615				2021-06-18	
J	Meaney, DF; Smith, DH				Meaney, David F.; Smith, Douglas H.			Biomechanics of Concussion	CLINICS IN SPORTS MEDICINE			English	Article						Biomechanics; Tolerance; Mild traumatic Brain injury; Concussion	TRAUMATIC BRAIN-INJURY; DIFFUSE AXONAL INJURY; IN-VITRO; MECHANICAL INJURY; PROFESSIONAL FOOTBALL; INTRACRANIAL-PRESSURE; CULTURED ASTROCYTES; GLUR2 ENDOCYTOSIS; HEAD-INJURY; STRETCH	The rising awareness of the long-term health problems associated with concussions re-emphasizes the need for understanding the mechanical etiology of concussions. This article reviews past studies defining the common mechanisms for mild traumatic brain injury and summarizes efforts to convert the external input to the head (force, acceleration, and velocity) into estimates of motions and deformations of the brain that occur during mild traumatic brain injury. Studies of how these mechanical conditions contribute to the cellular mechanisms of damage in mild traumatic brain injury are reviewed. Finally, future directions for improving understanding concussion biomechanics are discussed.	[Meaney, David F.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Smith, Douglas H.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA	Meaney, DF (corresponding author), Univ Penn, Dept Bioengn, 240 Skirkanich Hall,210 S 33rd St, Philadelphia, PA 19104 USA.	dmeaney@seas.upenn.edu	smith, douglas/A-1321-2007	Meaney, David/0000-0002-0954-4122	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS35712, HD41699, NS056202]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD041699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035712, P01NS056202] Funding Source: NIH RePORTER	Funding provided by NIH NS35712, HD41699, and NS056202.	Aarts M, 2002, SCIENCE, V298, P846, DOI 10.1126/science.1072873; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.741951000000000.x; Arbogast KB, 1997, J BIOMECH, V30, P757, DOI 10.1016/S0021-9290(97)00023-7; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bell JD, 2009, CELL DEATH DIFFER, V16, P1665, DOI 10.1038/cdd.2009.106; Bell JD, 2007, BRAIN, V130, P2528, DOI 10.1093/brain/awm164; Brolinson P Gunnar, 2006, Curr Sports Med Rep, V5, P23; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; CHARLES AC, 1991, NEURON, V6, P983, DOI 10.1016/0896-6273(91)90238-U; Cui H, 2007, J NEUROSCI, V27, P9901, DOI 10.1523/JNEUROSCI.1464-07.2007; Darvish K., 2003, STAPP CAR CRASH J, V47, P79; Denny-Brown D E, 1941, Proc R Soc Med, V34, P691; DeRidder MN, 2006, NEUROBIOL DIS, V22, P165, DOI 10.1016/j.nbd.2005.10.011; Di X, 2000, ACT NEUR S, V76, P379; Donnelly BR, 1997, J BIOMECH ENG-T ASME, V119, P423, DOI 10.1115/1.2798289; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Eibner C, 2009, NEW ENGL J MED, V361, P537; Elkin BS, 2007, STAPP CAR CRASH JO, V51, P127; Floyd CL, 2001, GLIA, V33, P12, DOI 10.1002/1098-1136(20010101)33:1<12::AID-GLIA1002>3.0.CO;2-V; Franklyn Melanie, 2005, Stapp Car Crash J, V49, P1; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; Geddes DM, 2003, EXP NEUROL, V184, P420, DOI 10.1016/S0014-4886(03)00254-1; Geddes-Klein DM, 2006, J NEUROTRAUM, V23, P193, DOI 10.1089/neu.2006.23.193; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Girard J, 1996, EUR J PHARMACOL, V300, P43, DOI 10.1016/0014-2999(95)00804-7; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; GURDJIAN ES, 1961, SURG GYNECOL OBSTET, V113, P185; GURDJIAN ES, 1949, AM J SURG, V78, P736, DOI 10.1016/0002-9610(49)90315-3; GURDJIAN ES, 1947, SURG GYNECOL OBSTET, V85, P195; GURDJIAN ES, 1950, J NEUROSURG, V7, P106, DOI 10.3171/jns.1950.7.2.0106; GURDJIAN ES, 1954, NEUROLOGY, V4, P674, DOI 10.1212/WNL.4.9.674; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hoffman SW, 2000, J NEUROTRAUM, V17, P415, DOI 10.1089/neu.2000.17.415; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Ishikawa R, 2006, Conf Proc IEEE Eng Med Biol Soc, V2006, P1327; Ivarsson J, 2002, J BIOMECH ENG-T ASME, V124, P422, DOI 10.1115/1.1485752; Ivarsson J, 2000, J BIOMECH, V33, P181, DOI 10.1016/S0021-9290(99)00144-X; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; Kao CQ, 2004, J NEUROTRAUM, V21, P259, DOI 10.1089/089771504322972059; Kiraly MA, 2007, THESCIENTIFICWORLDJO, V7, P1768, DOI 10.1100/tsw.2007.269; Lamb RG, 1997, J NEUROCHEM, V68, P1904; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LaPlaca MC, 2005, J BIOMECH, V38, P1093, DOI 10.1016/j.jbiomech.2004.05.032; Li JR, 2007, BIOMED SCI INSTRUM, V43, P24; LINDGREN S, 1966, BIOPHYSIK, V3, P174, DOI 10.1007/BF01191611; Lucas J H, 1985, Cent Nerv Syst Trauma, V2, P231; LUCAS JH, 1987, BRAIN RES, V425, P384, DOI 10.1016/0006-8993(87)90526-9; LUCAS JH, 1991, BRAIN RES, V543, P181, DOI 10.1016/0006-8993(91)90027-S; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; MCELHANEY JH, 1995, J NEUROTRAUM, V12, P669, DOI 10.1089/neu.1995.12.669; Miller K, 1997, J BIOMECH, V30, P1115, DOI 10.1016/S0021-9290(97)00092-4; Miller WJ, 2009, J NEUROTRAUM, V26, P789, DOI [10.1089/neu.2008.0727, 10.1089/neu.2008-0727]; Morrison B, 2006, J NEUROSCI METH, V150, P192, DOI 10.1016/j.jneumeth.2005.06.014; Morrison B, 2000, NEUROSCIENCE, V96, P131, DOI 10.1016/S0306-4522(99)00537-0; Morrison B, 2000, J BIOMECH ENG-T ASME, V122, P224, DOI 10.1115/1.429650; Morrison B., 2003, STAPP CAR CRASH J, V47, P93; MURPHY EJ, 1993, J NEUROTRAUM, V10, P431, DOI 10.1089/neu.1993.10.431; Nahum AM, 1977, 21 ANN STAPP CAR CRA; Nishimoto T, 1998, J BIOMECH ENG-T ASME, V120, P140, DOI 10.1115/1.2834294; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Panizzon KL, 1996, NEUROREPORT, V7, P662, DOI 10.1097/00001756-199601310-00067; Panizzon KL, 1998, NEUROREPORT, V9, P4131, DOI 10.1097/00001756-199812210-00024; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Prange M T, 2000, Stapp Car Crash J, V44, P205; Preiss-Farzanegan SJ, 2009, PM&R, V1, P245, DOI 10.1016/j.pmrj.2009.01.011; Raymond D, 2009, J BIOMECH, V42, P2479, DOI 10.1016/j.jbiomech.2009.07.018; Rzigalinski BA, 1999, J BIOL CHEM, V274, P175, DOI 10.1074/jbc.274.1.175; Sattler R, 1999, SCIENCE, V284, P1845, DOI 10.1126/science.284.5421.1845; Shreiber DI, 1999, NEUROSCI LETT, V259, P5, DOI 10.1016/S0304-3940(98)00853-2; Smith DH, 1999, J NEUROSCI, V19, P4263; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Spaethling JM, 2008, J NEUROTRAUM, V25, P1207, DOI 10.1089/neu.2008.0532; STALHAMMAR D, 1975, ACTA NEUROL SCAND, V52, P38; STERN MB, 1991, MOVEMENT DISORD, V6, P95, DOI 10.1002/mds.870060202; Takahashi T, 2007, P ANN INT IEEE EMBS, P3613, DOI 10.1109/IEMBS.2007.4353113; Takhounts EG, 2008, STAPP CAR C, V52, P1; THIBAULT LE, 1992, J NEUROTRAUM, V9, P311, DOI 10.1089/neu.1992.9.311; THOMAS LM, 1966, J NEUROL NEUROSUR PS, V29, P404, DOI 10.1136/jnnp.29.5.404; UNTERHARNSCHEIDT F, 1969, TEX REP BIOL MED, V27, P127; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; von Reyn CR, 2009, J NEUROSCI, V29, P10350, DOI 10.1523/JNEUROSCI.2339-09.2009; Wallis RA, 1996, BRAIN RES, V710, P169, DOI 10.1016/0006-8993(95)01278-8; Wallis RA, 1995, EUR J PHARMACOL, V294, P475, DOI 10.1016/0014-2999(95)00568-4; Weber JT, 1999, CELL CALCIUM, V26, P289, DOI 10.1054/ceca.1999.0082; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Yoganandan N, 2004, CLIN BIOMECH, V19, P225, DOI 10.1016/j.clinbiomech.2003.12.014; Yu Z, 2009, IEEE ENG MED BIO, P4210, DOI 10.1109/IEMBS.2009.5333791; Yu Z, 2009, IEEE ENG MED BIO, P1135; Yu Z, 2010, J NEUROPHYSIOL, V103, P499, DOI 10.1152/jn.00775.2009; Yu Z, 2009, J NEUROTRAUM, V26, P1135, DOI 10.1089/neu.2008.0810; Zhang JY, 2006, BIOMED SCI INSTRUM, V42, P501; Zhang L, 2001, Stapp Car Crash J, V45, P369; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921; Zhang Liying, 2002, Stapp Car Crash J, V46, P145; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749	98	177	179	0	65	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0278-5919	1556-228X		CLIN SPORT MED	Clin. Sports Med.	JAN	2011	30	1					19	+		10.1016/j.csm.2010.08.009			14	Sport Sciences	Sport Sciences	691XR	WOS:000285114800004	21074079	Green Accepted			2021-06-18	
J	Vespa, PM; McArthur, DL; Xu, Y; Eliseo, M; Etchepare, M; Dinov, I; Alger, J; Glenn, TP; Hovda, D				Vespa, P. M.; McArthur, D. L.; Xu, Y.; Eliseo, M.; Etchepare, M.; Dinov, I.; Alger, J.; Glenn, T. P.; Hovda, D.			Nonconvulsive seizures after traumatic brain injury are associated with hippocampal atrophy	NEUROLOGY			English	Article							METABOLIC CRISIS; MICRODIALYSIS; LACTATE; DAMAGE	Objective: To determine if posttraumatic nonconvulsive electrographic seizures result in long-term brain atrophy. Methods: Prospective continuous EEG (cEEG) monitoring was done in 140 patients with moderate to severe traumatic brain injury (TBI) and in-depth study of 16 selected patients was done using serial volumetric MRI acutely and at 6 months after TBI. Fluorodeoxyglucose PET was done in the acute stage in 14/16 patients. These data were retrospectively analyzed after collection of data for 7 years. Results: cEEG detected seizures in 32/140 (23%) of the entire cohort. In the selected imaging subgroup, 6 patients with seizures were compared with a cohort of 10 age- and GCS-matched patients with TBI without seizures. In this subgroup, the seizures were repetitive and constituted status epilepticus in 4/6 patients. Patients with seizures had greater hippocampal atrophy as compared to those without seizures (21 +/- 9 vs 12 +/- 6%, p = 0.017). Hippocampi ipsilateral to the electrographic seizure focus demonstrated a greater degree of volumetric atrophy as compared with nonseizure hippocampi (28 +/- 5 vs 13 +/- 9%, p = 0.007). A single patient had an ictal PET scan which demonstrated increased hippocampal glucose uptake. Conclusion: Acute posttraumatic nonconvulsive seizures occur frequently after TBI and, in a selected subgroup, appear to be associated with disproportionate long-term hippocampal atrophy. These data suggest anatomic damage is potentially elicited by nonconvulsive seizures in the acute postinjury setting. Neurology (R) 2010;75:792-798	[Vespa, P. M.; McArthur, D. L.; Eliseo, M.; Etchepare, M.; Glenn, T. P.; Hovda, D.] Univ Calif Los Angeles, Dept Neurosurg, Los Angeles, CA USA; [Vespa, P. M.; Dinov, I.; Alger, J.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA; [Xu, Y.] Capital Med Univ, Xuanwu Hosp, Beijing, Peoples R China	Vespa, PM (corresponding author), Ronald Reagan UCLA Med Ctr, 757 Westwood Blvd,Room 63236A, Los Angeles, CA 90095 USA.	Pvespa@mednet.ucla.edu	McArthur, David/E-6442-2013	McArthur, David/0000-0003-3385-1314; Dinov, Ivo/0000-0003-3825-4375	NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 02089, NS 049471, RO1 NS 049471, 1 RO1 NS049471, 1R21NS057252-01A1]; State of California Neurotrauma Initiative; NIH (NIBIB)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01 EB00822]; NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50 NS044378, R01 NS036524, R01 NS049471, R01 NS46018]; NINDS/NMSSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)National Multiple Sclerosis Society [R01 NS051591/RG3915]; NIMHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH081864, R21 MH075658]; NHLBIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [P50 HL60296]; NEIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [RO1 EY15311]; NINRUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [RO1 NR009116]; US Department of Defense (DOD)United States Department of Defense [W81XWH-08-2-0699]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1 P01 NS 058489-01, 1 R21 NS057252-01A1, 1 R01 NS27544, 1 R01 NS055910-01A1, R01 NS 49471, 1 R01 NS052406]; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY015311] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [P50HL060296] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB000822] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH081864, R21MH075658] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS046018, R01NS036524, R21NS057252, P50NS044378, R01NS027544, R01NS055910, R01NS049471, P01NS058489, R01NS051591, R01NS052406] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR009116] Funding Source: NIH RePORTER	Supported by NIH/NINDS (NS 02089, NS 049471) and the State of California Neurotrauma Initiative.; Dr. Vespa has served as a consultant for General Electric and Neuren Pharmaceuticals Limited; estimates that 2% of his clinical effort is spent on EEG monitoring; receives research support from the NIH (NINDS RO1 NS 049471 [principal investigator]); owns stock in InTouch Health; and has given expert testimony in brain trauma cases. Dr. McArthur has received research support from the NIH (NINDS 1 RO1 NS049471 [Key Investigator]). Dr. Xu, M. Eliseo, M. Etchepare, and Dr. Dinov report no disclosures. Dr. Alger serves on the editorial board of Magnetic Resonance Imaging; has served as a consultant for MedQIA and Carrot Capital/Remedy Pharmaceuticals; and receives/has received research support from the NIH (NIBIB R01 EB00822 [coinvestigator], NINDS P50 NS044378 [coinvestigator], NINDS R01 NS036524 [coinvestigator], NINDS R01 NS049471 [coinvestigator], NINDS/NMSS R01 NS051591/RG3915 [coinvestigator], NIMH R01MH081864 [coinvestigator], NIMH R21 MH075658 [coinvestigator], NINDS R01 NS46018 [coinvestigator], NHLBI P50 HL60296 [coinvestigator], NEI RO1 EY15311 [coinvestigator], NINR RO1 NR009116 [coinvestigator]) and the US Department of Defense (DOD W81XWH-08-2-0699 [coinvestigator]). Dr. Glenn receives research support from the NIH (NINDS 1R21NS057252-01A1 [PI]). Dr. Hovda serves on the editorial boards of Developmental Brain Dysfunction, Restorative Neurology and Neuroscience, the Journal of Neurotrauma, the Journal of Cerebral Blood Flow & Metabolism, Developmental Neurorehabilitation, and Eye and Brain; receives/has received research support from the NIH (1 P01 NS 058489-01 [coinvestigator], 1 R21 NS057252-01A1 [PI], 1 R01 NS27544 [coinvestigator], 1 R01 NS055910-01A1 [coinvestigator], R01 NS 49471 [coinvestigator], and 1 R01 NS052406 [principal investigator]); and serves as Program Director, UCLA Brain Injury Research Center University of California.	Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; Dinov Ivo D, 2009, Front Neuroinform, V3, P22, DOI 10.3389/neuro.11.022.2009; Liu RSN, 2005, EPILEPSIA, V46, P1482, DOI 10.1111/j.1528-1167.2005.51603.x; Marcoux J, 2008, CRIT CARE MED, V36, P2871, DOI 10.1097/CCM.0b013e318186a4a0; Parmar H, 2006, NEUROLOGY, V66, P1732, DOI 10.1212/01.wnl.0000218207.18707.f4; Salmenpera T, 2000, SEIZURE-EUR J EPILEP, V9, P208, DOI 10.1053/seiz.1999.0373; TEMKIN NR, 2002, EPILEPSY CURR, V4, P105; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Vespa P, 2005, J CLIN NEUROPHYSIOL, V22, P99, DOI 10.1097/01.WNP.0000154919.54202.E0; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF; Vespa PM, 2003, NEUROLOGY, V60, P1441, DOI 10.1212/01.WNL.0000063316.47591.B4; VESPA PM, 2007, CRIT CARE MED, V35, P1; Vincent JL, 2005, CRIT CARE MED, V33, P1392, DOI 10.1097/01.CCM.0000166890.93559.2D; Wilde EA, 2007, DEV MED CHILD NEUROL, V49, P294, DOI 10.1111/j.1469-8749.2007.00294.x; Zanier ER, 2003, J NEUROTRAUM, V20, P409, DOI 10.1089/089771503765355496	18	177	182	1	15	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	AUG 31	2010	75	9					792	798		10.1212/WNL.0b013e3181f07334			7	Clinical Neurology	Neurosciences & Neurology	648KF	WOS:000281691800008	20805525	Green Published			2021-06-18	
J	Vitek, MP; Brown, CM; Colton, CA				Vitek, Michael P.; Brown, Candice M.; Colton, Carol A.			APOE genotype-specific differences in the innate immune response	NEUROBIOLOGY OF AGING			English	Article						Microglia; Apolipoprotein E; Innate immunity; Cytokine; Neuroinflammation	NITRIC-OXIDE PRODUCTION; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; E-DEFICIENT MICE; APOLIPOPROTEIN-E; MICROGLIAL ACTIVATION; TARGETED REPLACEMENT; PLASMA-LIPOPROTEINS; ALZHEIMERS-DISEASE; GENETIC RISK	Apolipoprotein-E protein is an endogenous immunomodulatory agent that affects both the innate and the adaptive immune responses. Since individuals with the APOE4 gene demonstrate worsened pathology and poorer outcomes in many neurological disorders, we examined isoform-specific differences in the response of microglia, the primary cellular component of the brain's innate immune response, in detail. Our data demonstrate that microglia derived from APOE4/4 targeted replacement mice demonstrate a pro-inflammatory phenotype that includes altered cell morphology, increased NO production associated with increased NOS2 mRNA levels, and higher pro-inflammatory cytokine production (TNF alpha, IFL-6, IL12p40) compared to microglia derived from APOE-3/3 targeted replacement mice. The effect is gene dose-dependent and increases with the number of APOE4 gene alleles. The APOE genotype-specific immune profile observed in the microglial immune response is also observed in the cortex of aged APOE3/3 and APOE4/4 mice treated with lipopolysacchride (LPS) and in peripheral (peritoneal) macrophages. To determine if APOE4's action resulted from an isoform-specific difference in effective levels of the apolipoproteins, we generated mice expressing only a single allele of APOE3. Immune-stimulated macrophages from APOE3/0 mice demonstrated an increased inflammatory response compared to APOE3/3 mice, but less than in APOE4/4 mice. These data suggest that inhibition of inflammation depends upon the dose of apoE3 protein available and that apoE4 protein may alter inflammation partly by dose effects and partly by being qualitatively different than apoE3. Overall, these data emphasize the important role of apolipoprotein E and of the APOE genotype on the immune responses that are evident in most, if not all, neurological disease. (C) 2007 Elsevier Inc. All rights reserved.	[Vitek, Michael P.; Brown, Candice M.; Colton, Carol A.] Duke Univ, Med Ctr, Div Neurol, Durham, NC 27710 USA	Colton, CA (corresponding author), Duke Univ, Med Ctr, Div Neurol, Box 2900, Durham, NC 27710 USA.	mikevitek@cognosci.com; canbrown@u.washington.edu; glia01@aol.com	Brown, Candice/AAD-4982-2019	Brown, Candice/0000-0001-5845-0221; Vitek, Michael/0000-0001-8140-8048; Colton, Carol/0000-0003-3305-370X	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG023802-01, AG019780, AG05128]; NSF Predoctoral FellowshipNational Science Foundation (NSF); NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005128, R01AG019780, R01AG023802, R01AG019740] Funding Source: NIH RePORTER	This work was supported by a grant from NIH to CAC (AG023802-01), MPV (AG019780), and CMB (Minority Research Supplement to P50 AG05128) and a NSF Predoctoral Fellowship (CMB).	ADAMS DO, 1984, ANNU REV IMMUNOL, V2, P283, DOI 10.1146/annurev.immunol.2.1.283; AVILA EM, 1982, J BIOL CHEM, V257, P5900; Barger SW, 1997, NATURE, V388, P878, DOI 10.1038/42257; BROWN C, 2007, NEUROBIOL ENG   0604; Brown CM, 2007, ENDOCRINOLOGY, V148, P3383, DOI 10.1210/en.2006-1200; Brown CM, 2002, FREE RADICAL BIO MED, V32, P1071, DOI 10.1016/S0891-5849(02)00803-1; Chapman J, 2001, NEUROLOGY, V56, P312, DOI 10.1212/WNL.56.3.312; Colton CA, 2005, NEUROBIOL AGING, V26, P363, DOI 10.1016/j.neurobiolaging.2004.08.001; Colton CA, 2002, NEUROBIOL AGING, V23, P777, DOI 10.1016/S0197-4580(02)00016-7; Colton CA, 2002, ANN NY ACAD SCI, V962, P212, DOI 10.1111/j.1749-6632.2002.tb04070.x; Coon KD, 2007, J CLIN PSYCHIAT, V68, P613, DOI 10.4088/JCP.v68n0419; Corder EH, 1998, NAT MED, V4, P1182, DOI 10.1038/2677; CZAPIGA M, 2002, J NEUROIMMUNOL, V4673, P1; de Bont N, 1999, J LIPID RES, V40, P680; Finch CE, 2007, CURR ALZHEIMER RES, V4, P185, DOI 10.2174/156720507780362254; Garvey EP, 1997, J BIOL CHEM, V272, P4959, DOI 10.1074/jbc.272.8.4959; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Grocott HP, 2001, J THORAC CARDIOV SUR, V122, P622, DOI 10.1067/mtc.2001.115152; Guo L, 2004, J MOL NEUROSCI, V23, P205, DOI 10.1385/JMN:23:3:205; HUI DY, 1980, J BIOL CHEM, V255, P1775; Jofro-Monseny L, 2007, BIOCHEM BIOPH RES CO, V357, P319, DOI 10.1016/j.bbrc.2007.03.150; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P2143; Kakuda DK, 1999, BIOCHEM J, V340, P549, DOI 10.1042/0264-6021:3400549; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; Laskowitz DT, 2007, J NEUROTRAUM, V24, P1093, DOI 10.1089/neu.2006.0192; Laskowitz DT, 2000, J LIPID RES, V41, P613; Laskowitz DT, 2001, EXP NEUROL, V167, P74, DOI 10.1006/exnr.2001.7541; Lehnardt S, 2003, P NATL ACAD SCI USA, V100, P8514, DOI 10.1073/pnas.1432609100; LERMA J, 1986, BRAIN RES, V384, P145, DOI 10.1016/0006-8993(86)91230-8; Licastro F, 2007, NEUROBIOL AGING, V28, P1637, DOI 10.1016/j.neurobiolaging.2006.07.007; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lynch JR, 2001, J NEUROIMMUNOL, V114, P107, DOI 10.1016/S0165-5728(00)00459-8; MACY M, 1983, CANCER RES, V43, P2496; Maezawa I, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-10; Maezawa I, 2006, FASEB J, V20, P797, DOI 10.1096/fj.05-5423fje; Mahley RW, 2006, P NATL ACAD SCI USA, V103, P5644, DOI 10.1073/pnas.0600549103; Nathoo N, 2003, J CLIN PATHOL-MOL PA, V56, P132, DOI 10.1136/mp.56.3.132; Ophir G, 2005, NEUROBIOL DIS, V20, P709, DOI 10.1016/j.nbd.2005.05.002; PERRY VH, 1989, NEUROIMMUNE NETWORKS, P119; Ramassamy C, 2001, MOL BRAIN RES, V86, P76, DOI 10.1016/S0169-328X(00)00268-0; Roselaar SE, 1998, J LIPID RES, V39, P1740; Roses AD, 1997, NEUROBIOL DIS, V4, P170, DOI 10.1006/nbdi.1997.0161; STREIT WJ, 1995, SCI AM, V273, P54, DOI 10.1038/scientificamerican1195-54; Sullivan PM, 1998, J CLIN INVEST, V102, P130, DOI 10.1172/JCI2673; Vitek MP, 1997, BIOCHEM BIOPH RES CO, V240, P391, DOI 10.1006/bbrc.1997.7408; Xu PT, 1996, NEUROBIOL DIS, V3, P229, DOI 10.1006/nbdi.1996.0023	46	177	183	1	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0197-4580	1558-1497		NEUROBIOL AGING	Neurobiol. Aging	SEP	2009	30	9					1350	1360		10.1016/j.neurobiolaging.2007.11.014			11	Geriatrics & Gerontology; Neurosciences	Geriatrics & Gerontology; Neurosciences & Neurology	481CA	WOS:000268783200002	18155324	Green Accepted			2021-06-18	
J	Chen, JK; Johnston, KM; Petrides, M; Ptito, A				Chen, Jen-Kai; Johnston, Karen M.; Petrides, Michael; Ptito, Alain			Neural substrates of symptoms of depression following concussion in male athletes with persisting postconcussion symptoms	ARCHIVES OF GENERAL PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; TRANSCRANIAL MAGNETIC STIMULATION; POSITRON-EMISSION-TOMOGRAPHY; CEREBRAL BLOOD-FLOW; MAJOR DEPRESSION; WORKING-MEMORY; PREFRONTAL CORTEX; DEFAULT-MODE; DOPAMINE RELEASE; MOOD-DISORDERS	Context: Depressed mood is frequently reported by individuals who have sustained cerebral concussion but little is known about the nature of this alteration in mood state. Objective: To investigate whether the symptoms of depression reflect an ongoing pathophysiological change following concussion. Design: Cohort study with male athletes using functional and structural neuroimaging. Setting: Hospital laboratory and imaging facility. Participants: Fifty-six male athletes with and without concussion were divided into (1) a no depression symptom, concussed group, (2) a mild depression symptom, concussed group, (3) a moderate depression symptom, concussed group, and (4) a healthy control group. Interventions: All athletes filled out a postconcussive symptoms checklist and the Beck Depression Inventory II and underwent a magnetic resonance imaging session, which included T1, T2, and fluid-attenuated inversion recovery sequences, as well as functional magnetic resonance imaging (fMRI), during which they performed a working memory task. Main Outcome Measures: (1) Behavioral: response speed and accuracy on the working memory task performed during the fMRI session; (2) functional imaging: brain activation patterns associated with the working memory task obtained using blood oxygen level dependent fMRI; and (3) structural imaging: voxel-based morphometry examining gray matter concentration. Results: (1) Behavioral: there was no performance difference between the groups; and (2) imaging: athletes with concussion with depression symptoms showed reduced activation in the dorsolateral prefrontal cortex and striatum and attenuated deactivation in medial frontal and temporal regions. The severity of symptoms of depression correlated with neural responses in brain areas that are implicated in major depression. Voxel-based morphometry confirmed gray matter loss in these areas. Conclusions: The results suggest that depressed mood following a concussion may reflect an underlying pathophysiology consistent with a limbic-frontal model of depression. Given that depression is associated with considerable functional disability, this finding has important clinical implications for the management of individuals with a cerebral concussion.	[Chen, Jen-Kai; Petrides, Michael; Ptito, Alain] Montreal Neurol Inst, Neuropsychol Cognit Neurosci Unit, Montreal, PQ H3A 2B4, Canada; [Petrides, Michael] McGill Univ, Dept Psychol, Montreal, PQ, Canada; [Johnston, Karen M.] Univ Toronto, Toronto Rehabil Div Neurosurg, Concuss Clin NeuroRehabil Program, Toronto, ON, Canada	Ptito, A (corresponding author), Montreal Neurol Inst, Neuropsychol Cognit Neurosci Unit, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.	alain.ptito@mcgill.ca					BAXTER LR, 1989, ARCH GEN PSYCHIAT, V46, P243; Beck A. T., 1996, BD1 2 BECK DEPRESSIO; BENCH CJ, 1993, PSYCHOL MED, V23, P579, DOI 10.1017/S0033291700025368; Boyer P, 1999, NEUROPSYCHOBIOLOGY, V39, P25, DOI 10.1159/000026556; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Corrigan MH, 2000, DEPRESS ANXIETY, V11, P58, DOI 10.1002/(SICI)1520-6394(2000)11:2<58::AID-DA2>3.0.CO;2-H; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; Drevets WC, 1999, ANN NY ACAD SCI, V877, P614, DOI 10.1111/j.1749-6632.1999.tb09292.x; Drevets WC, 1997, NATURE, V386, P824, DOI 10.1038/386824a0; Esposito F, 2006, BRAIN RES BULL, V70, P263, DOI 10.1016/j.brainresbull.2006.06.012; Fransson P, 2006, NEUROPSYCHOLOGIA, V44, P2836, DOI 10.1016/j.neuropsychologia.2006.06.017; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; George MS, 1997, AM J PSYCHIAT, V154, P1752, DOI 10.1176/ajp.154.12.1752; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; Greicius MD, 2003, P NATL ACAD SCI USA, V100, P253, DOI 10.1073/pnas.0135058100; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Johnston Karen M, 2004, Curr Sports Med Rep, V3, P316; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Kennedy SH, 2001, AM J PSYCHIAT, V158, P899, DOI 10.1176/appi.ajp.158.987.899; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Lambert G, 2000, ARCH GEN PSYCHIAT, V57, P787, DOI 10.1001/archpsyc.57.8.787; Levin HS, 2005, ARCH GEN PSYCHIAT, V62, P523, DOI 10.1001/archpsyc.62.5.523; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Liotti M, 2002, AM J PSYCHIAT, V159, P1830, DOI 10.1176/appi.ajp.159.11.1830; Liotti M, 2000, BIOL PSYCHIAT, V48, P30, DOI 10.1016/S0006-3223(00)00874-X; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; MARTINOT JL, 1990, AM J PSYCHIAT, V147, P1313; Mayberg HS, 1997, J NEUROPSYCH CLIN N, V9, P471; Mayberg HS, 1999, AM J PSYCHIAT, V156, P675; Mayberg HS, 2000, BIOL PSYCHIAT, V48, P830, DOI 10.1016/S0006-3223(00)01036-2; Mazoyer B, 2001, BRAIN RES BULL, V54, P287, DOI 10.1016/S0361-9230(00)00437-8; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McKiernan KA, 2003, J COGNITIVE NEUROSCI, V15, P394, DOI 10.1162/089892903321593117; PascualLeone A, 1996, LANCET, V348, P233, DOI 10.1016/S0140-6736(96)01219-6; Paus T, 1998, NEUROREPORT, V9, pR37, DOI 10.1097/00001756-199806220-00001; Paus T, 2004, J PSYCHIATR NEUROSCI, V29, P268; PETRIDES M, 2001, 7 INT C FUNCT MAPP H; Pogarell O, 2006, J PSYCHIATR RES, V40, P307, DOI 10.1016/j.jpsychires.2005.09.001; RAMPELLO L, 1995, NEUROPSYCHOBIOLOGY, V31, P130, DOI 10.1159/000119183; Rose EJ, 2006, NEUROIMAGE, V29, P203, DOI 10.1016/j.neuroimage.2005.07.002; ROY A, 1992, ARCH GEN PSYCHIAT, V49, P447; Seminowicz DA, 2004, NEUROIMAGE, V22, P409, DOI 10.1016/j.neuroimage.2004.01.015; Simpson JR, 2001, P NATL ACAD SCI USA, V98, P688, DOI 10.1073/pnas.98.2.688; Sled JG, 1998, IEEE T MED IMAGING, V17, P87, DOI 10.1109/42.668698; Spreen O., 1998, COMPENDIUM NEUROPSYC; Tomaiuolo F, 2005, J NEUROTRAUM, V22, P76, DOI 10.1089/neu.2005.22.76; Tomasi D, 2006, HUM BRAIN MAPP, V27, P694, DOI 10.1002/hbm.20211; Triggs WJ, 1999, BIOL PSYCHIAT, V45, P1440, DOI 10.1016/S0006-3223(99)00031-1; Worsley KJ, 2002, NEUROIMAGE, V15, P1, DOI 10.1006/nimg.2001.0933; Worsley KJ, 2003, STAT METHODS MED RES, V12, P401, DOI 10.1191/0962280203sm340ra; Zarate CA, 2004, BIOL PSYCHIAT, V56, P54, DOI 10.1016/j.biopsych.2004.03.013; ZIJDENBOS AP, 1998, P 1 INT C MED IM COM, P439	59	177	178	0	47	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0003-990X	1538-3636		ARCH GEN PSYCHIAT	Arch. Gen. Psychiatry	JAN	2008	65	1					81	89		10.1001/archgenpsychiatry.2007.8			9	Psychiatry	Psychiatry	248ST	WOS:000252176400011	18180432	Bronze			2021-06-18	
J	Chen, JK; Johnston, KM; Collie, A; McCrory, P; Ptito, A				Chen, Jen-Kai; Johnston, Karen M.; Collie, Alex; McCrory, Paul; Ptito, Alain			A validation of the post concussion symptom scale in the assessment of complex concussion using cognitive testing and functional MRI	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							DORSOLATERAL PREFRONTAL CORTEX; TRAUMATIC BRAIN-INJURY; TEST-PERFORMANCE; ACTIVATION; MECHANISMS	Background: Clinical assessment of cerebral concussion relies on the presence and duration of post concussive symptoms (PCS). Given that these PCS are subjective reports and not always specific to concussion, their usefulness remains to be validated. Objective: To evaluate the usefulness of self-reported PCS by means of cognitive tests and functional MRI (fMRI). Method: 28 male athletes with and without concussion were grouped according to their PCS score. They were then administered a computerised cognitive test battery and submitted to an fMRI session where cerebral activations associated with verbal and non-verbal working memory tasks were analysed. Results: Behaviourally, response accuracy and speed on the cognitive test battery were comparable for the control and low PCS group. The moderate PCS group showed significantly slower response times than the control group on the matching (p < 0.05) and one-back tasks (p < 0.05). The functional MRI study showed reduced task related activation patterns in the dorsolateral prefrontal cortex for both low and moderate PCS groups. Activation peaks outside the regions of interest, not seen in the control group, were also noted for both PCS groups. Regression analyses indicated an inverse relationship between PCS scores and performances on several CogSport subtests. Severity of PCS also predicted fMRI blood oxygen level dependent signal changes in cerebral prefrontal regions. Conclusion: Self-reported PCS is associated with an ongoing cerebral haemodynamic abnormality as well as with mild cognitive impairment. These results support the use of the PCS scale in the assessment of cerebral concussion and in monitoring recovery.	McGill Univ, Montreal Neurol Inst, Neuropsychol Dept, Cognit Neurosci Unit, Montreal, PQ H3A 2B4, Canada; Univ Toronto, Toronto Rehabil Div Neurosurg, Concuss Clin NeuroRehabil Program, Toronto, ON, Canada; Univ Melbourne, Ctr Hlth Exercise & Sports Med, Melbourne, Vic, Australia	Ptito, A (corresponding author), McGill Univ, Montreal Neurol Inst, Neuropsychol Dept, Cognit Neurosci Unit, 3801 Univ St, Montreal, PQ H3A 2B4, Canada.	alain.ptito@mcgill.ca	McCrory, Paul/Q-8688-2019	Collie, Alex/0000-0003-2617-9339			Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Collie A, 2003, J INT NEUROPSYCH SOC, V9, P419, DOI 10.1017/S1355617703930074; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Hinton-Bayre AD, 2004, J SCI MED SPORT, V7, P400, DOI 10.1016/S1440-2440(04)80035-5; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Machulda MM, 1998, ARCH CLIN NEUROPSYCH, V13, P415, DOI 10.1016/S0887-6177(97)00031-0; Makdissi Michael, 2003, Medicine & Science in Sports & Exercise, V35, pS321, DOI 10.1097/00005768-200305001-01778; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McCrory Paul, 2005, Clin J Sport Med, V15, P48; Owen AM, 2000, EXP BRAIN RES, V133, P33, DOI 10.1007/s002210000398; Petrides M, 2002, P NATL ACAD SCI USA, V99, P5649, DOI 10.1073/pnas.072092299; PETRIDES M, 2001, P 7 INT C FUNCT MAPP, V7, pS721; Piland SG, 2003, J ATHL TRAINING, V38, P104; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Sled JG, 1998, IEEE T MED IMAGING, V17, P87, DOI 10.1109/42.668698; Stern CE, 2000, NEUROIMAGE, V11, P392, DOI 10.1006/nimg.2000.0569; Tegner Y, 1996, BRIT J SPORT MED, V30, P251, DOI 10.1136/bjsm.30.3.251; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3; Worsley KJ, 2002, NEUROIMAGE, V15, P1, DOI 10.1006/nimg.2001.0933; Worsley KJ, 1996, HUM BRAIN MAPP, V4, P58, DOI 10.1002/(SICI)1097-0193(1996)4:1<58::AID-HBM4>3.0.CO;2-O	33	177	181	0	25	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	NOV	2007	78	11					1231	1238		10.1136/jnnp.2006.110395			8	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	225LE	WOS:000250518600017	17371902	Green Published			2021-06-18	
J	Chen, HL; Richard, M; Sandier, DP; Umbach, DM; Kamel, F				Chen, Honglei; Richard, Marie; Sandier, Dale P.; Umbach, David M.; Kamel, Freya			Head injury and amyotrophic lateral sclerosis	AMERICAN JOURNAL OF EPIDEMIOLOGY			English	Article						amyotrophic lateral sclerosis; craniocerebral trauma; head injuries; closed; head injuries; penetrating	MOTOR-NEURON-DISEASE; RISK-FACTORS; CIGARETTE-SMOKING; BRAIN-INJURY; TRAUMA; ASSOCIATION; PLAYERS; HISTORY; SOCCER; ALS	Recent data showed that soccer players in Italy had an unusually high risk of amyotrophic lateral sclerosis (ALS) and that repeated head trauma might have contributed to this increase. The authors examined whether head injury was related to ALS risk in a case-control study of 109 New England ALS cases diagnosed in 1993-1996 and 255 matched controls. They also conducted a meta-analysis of the published literature. Overall, ever having experienced a head injury was nonsignificantly associated with a higher ALS risk. When compared with persons without a head injury, a statistically significant ALS risk elevation was found for participants with more than one head injury (odds ratio (OR) = 3.1, 95 percent confidence interval (Cl): 1.2, 8.1) and patients who had had a head injury during the past 10 years (OR = 3.2, 95 percent Cl: 1.0, 10.2). For participants who had had multiple head injuries with the latest occurring in the past 10 years, risk was elevated more than 11-fold. The meta-analysis also indicated a moderately elevated risk of ALS among persons with previous head injuries (OR = 1.7, 95 percent Cl: 1.3, 2.2). In this study population, physical injuries to other body parts, including the trunk, arms, or legs, were not related to ALS risk. These data support the notion that head injury may increase the risk of ALS.	Natl Inst Environm Hlth Sci, Epidemiol Branch, Res Triangle Pk, NC 27709 USA; Nat Inst Environm Hlth Sci, Natl Inst Hlth, Epidemiol Branch, Res Triangle Pk, NC USA; Westat Corp, Durham, NC USA; Nat Inst Environm Hlth Sci, Natl Inst Hlth, Biostat Branch, Res Triangle Pk, NC USA	Chen, HL (corresponding author), Natl Inst Environm Hlth Sci, Epidemiol Branch, 111 TW Alexander Dr,PO Box 12233, Res Triangle Pk, NC 27709 USA.	chenh2@niehs.nih.gov		Kamel, Freya/0000-0001-5052-6615; Chen, Honglei/0000-0003-3446-7779; Sandler, Dale/0000-0002-6776-0018	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [Z01ES049028, Z01ES049004, Z01ES049005] Funding Source: NIH RePORTER; Intramural NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [Z01 ES049005-16] Funding Source: Medline		Aggarwal A, 2002, J NEUROL NEUROSUR PS, V73, P199, DOI 10.1136/jnnp.73.2.199; Armon C, 2003, NEUROEPIDEMIOLOGY, V22, P217, DOI 10.1159/000070562; Belli S, 2005, EUR J EPIDEMIOL, V20, P237, DOI 10.1007/s10654-004-6879-7; BROOKS BR, 1994, J NEUROL SCI, V124, P96, DOI 10.1016/0022-510X(94)90191-0; CHANCELLOR AM, 1993, J NEUROL NEUROSUR PS, V56, P1200, DOI 10.1136/jnnp.56.11.1200; Chio A, 2005, BRAIN, V128, P472, DOI 10.1093/brain/awh373; CHIO A, 1991, NEUROEPIDEMIOLOGY, V10, P174, DOI 10.1159/000110267; Cruz DC, 1999, NEUROEPIDEMIOLOGY, V18, P101, DOI 10.1159/000069413; DEAPEN DM, 1986, AM J EPIDEMIOL, V123, P790, DOI 10.1093/oxfordjournals.aje.a114308; Feeney SJ, 2001, MUSCLE NERVE, V24, P1510, DOI 10.1002/mus.1176; GALLAGHER JP, 1987, ACTA NEUROL SCAND, V75, P145, DOI 10.1111/j.1600-0404.1987.tb07909.x; Goldman SM, 2006, ANN NEUROL, V60, P65, DOI 10.1002/ana.20882; GRANIERI E, 1988, NEUROLOGY, V38, P1604, DOI 10.1212/WNL.38.10.1604; GRESHAM LS, 1987, NEUROLOGY, V37, P717, DOI 10.1212/WNL.37.4.717; Jelliffe SE, 1935, J NERV MENT DIS, V82, P415, DOI 10.1097/00005053-193510000-00005; Kamel F, 1999, NEUROEPIDEMIOLOGY, V18, P194, DOI 10.1159/000026211; Kamel F, 2002, EPIDEMIOLOGY, V13, P311, DOI 10.1097/00001648-200205000-00012; KONDO K, 1981, ARCH NEUROL-CHICAGO, V38, P220, DOI 10.1001/archneur.1981.00510040046007; KURLAND LT, 1992, J NEUROL SCI, V113, P133, DOI 10.1016/0022-510X(92)90241-C; KURTZKE JF, 1980, NEUROLOGY, V30, P453, DOI 10.1212/WNL.30.5.453; Logroscino G, 2005, J NEUROL NEUROSUR PS, V76, P1094, DOI 10.1136/jnnp.2004.039180; Longnecker MP, 2000, NEUROEPIDEMIOLOGY, V19, P210, DOI 10.1159/000026258; Millul A, 2005, NEUROEPIDEMIOLOGY, V25, P114, DOI 10.1159/000086353; Nelson LM, 2000, AM J EPIDEMIOL, V151, P156, DOI 10.1093/oxfordjournals.aje.a010183; Piazza O, 2004, CURR MED RES OPIN, V20, P505, DOI 10.1185/030079904125003296; Plato CC, 2002, NEUROLOGY, V58, P765, DOI 10.1212/WNL.58.5.765; RIGGS JE, 1993, MIL MED, V158, P55; Szczygielski J, 2005, J NEURAL TRANSM, V112, P1547, DOI 10.1007/s00702-005-0326-0; WILLIAMS DB, 1991, NEUROLOGY, V41, P1554, DOI 10.1212/WNL.41.10.1554	29	177	178	3	15	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9262			AM J EPIDEMIOL	Am. J. Epidemiol.	OCT 1	2007	166	7					810	816		10.1093/aje/kwm153			7	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	212PW	WOS:000249610300009	17641152	Green Accepted			2021-06-18	
J	Shankar, PR; Fields, SK; Collins, CL; Dick, RW; Comstock, RD				Shankar, Prasad R.; Fields, Sarah K.; Collins, Christy L.; Dick, Randall W.; Comstock, R. Dawn			Epidemiology of high school and collegiate football injuries in the United States, 2005-2006	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						high school; football; injury; NCAA	RISK-FACTORS; DATA-COLLECTION; PLAYERS; CONCUSSION; SPORTS	Background: Football, one of the most popular sports among male high school students in the United States, is a leading cause of sports-related injuries, with an injury rate almost twice that of basketball, the second most popular sport. Hypothesis: Injury patterns will vary between competition and practice exposures and between levels of play (ie, high school vs. National Collegiate Athletic Association [NCAA]). Study Design: Descriptive epidemiology study. Methods: Football-related injury data were collected over the 2005-2006 school year from 100 nationally representative high schools via High School RIO (TM) (Reporting Information Online) and from 55 Division I, II, and III colleges via the NCAA Injury Surveillance System. Results: Nationally, an estimated 517 726 high school football-related injuries (1881 unweighted injuries) occurred during the 2005-2006 season. The rate of injury per 1000 athlete-exposures was greater during high school competitions (12.04) than during practices (2.56). The rate of injury per 1000 athlete-exposures was also greater during collegiate competitions (40.23) than during practices (5.77). While the overall rate of injury per 1000 athlete-exposures was greater in the NCAA (8.61) than in high school (4.36), high school football players sustained a greater proportion of fractures and concussions. Running plays were the leading cause of injury, with running backs and linebackers being the positions most commonly injured. Conclusion: Patterns of football injuries vary, especially by type of exposure and level of play. Future studies should continue to compare differences in injury patterns in high school and collegiate football, with particular emphasis placed on high-risk plays (running plays) and positions (running backs and linebackers).	Childrens Hosp, Ctr Injury Res & Policy, Columbus Childrens Res Inst, Columbus, OH 43205 USA; Ohio State Univ, Sch Phys Activ & Educ Serv, Columbus, OH 43210 USA; Ohio State Univ, Coll Med, Columbus, OH 43210 USA; Ohio State Univ, Coll Med & Publ Hlth, Dept Pediat, Columbus, OH 43210 USA	Comstock, RD (corresponding author), Childrens Hosp, Ctr Injury Res & Policy, Columbus Childrens Res Inst, 700 Childrens Dr, Columbus, OH 43205 USA.	comstocd@pediatrics.ohio-state.edu		Shankar, Prasad/0000-0002-6488-8382	NCIPC CDC HHS [R49/CE000674-01] Funding Source: Medline; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49CE000674] Funding Source: NIH RePORTER		Adickes MS, 2004, SPORTS MED, V34, P201, DOI 10.2165/00007256-200434030-00005; CULPEPPER MI, 1983, SOUTHERN MED J, V76, P873, DOI 10.1097/00007611-198307000-00014; DELEE JC, 1992, AM J SPORT MED, V20, P575, DOI 10.1177/036354659202000515; Fuller CW, 2006, CLIN J SPORT MED, V16, P97, DOI 10.1097/00042752-200603000-00003; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; HALPERN B, 1987, AM J SPORT MED, V15, P316, DOI 10.1177/036354658701500404; Langburt W, 2001, J CHILD NEUROL, V16, P83, DOI 10.1177/088307380101600203; *NAT COLL ATHL ASS, NCAA INJ SURV SYST; *NAT COLL ATHL ASS, 2005, 198182200405 NCAA; *NAT FED STAT HIGH, 2005 06 HIGH SCH ATH; *NAT FED STAT HIGH, NFHS PART FIG SEARCH; Powell JW, 1999, J ATHL TRAINING, V34, P277; PRAGER BI, 1989, AM J SPORT MED, V17, P681, DOI 10.1177/036354658901700516; Ramirez M, 2006, AM J SPORT MED, V34, P1147, DOI 10.1177/0363546505284385; Stocker B D, 1997, J Ky Med Assoc, V95, P458; TEITZ CC, 1987, J BONE JOINT SURG AM, V69A, P2, DOI 10.2106/00004623-198769010-00002; THOMPSON N, 1987, AM J SPORT MED, V15, P117, DOI 10.1177/036354658701500204; Turbeville SD, 2003, AM J SPORT MED, V31, P276, DOI 10.1177/03635465030310022001; Turbeville SD, 2003, AM J SPORT MED, V31, P974, DOI 10.1177/03635465030310063801; Tyler TF, 2006, AM J SPORT MED, V34, P471, DOI 10.1177/0363546505280429; US Census Bureau, CENS REG US	22	177	180	0	44	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465			AM J SPORT MED	Am. J. Sports Med.	AUG	2007	35	8					1295	1303		10.1177/0363546507299745			9	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	196AB	WOS:000248452500009	17369559				2021-06-18	
J	Van Vliet, PM; Wulf, G				Van Vliet, Paulette M.; Wulf, Gabriele			Extrinsic feedback for motor learning after stroke: What is the evidence?	DISABILITY AND REHABILITATION			English	Article						motor learning; feedback; stroke; rehabilitation; physiotherapy	RANDOMIZED CONTROLLED-TRIAL; TRAUMATIC BRAIN INJURY; SKILL ACQUISITION; EXTERNAL-FOCUS; BANDWIDTH KNOWLEDGE; RELATIVE FREQUENCY; REDUCED-FREQUENCY; VISUAL FEEDBACK; PERFORMANCE FEEDBACK; INFORMATION FEEDBACK	Purpose. There is little guidance on using extrinsic feedback to enhance motor learning after stroke. This narrative review synthesises research findings and identifies questions remaining to be answered. Method. A summary is given relating to the use of extrinsic feedback in healthy subjects. Then, research concerning content of feedback, feedback scheduling, and attentional focus is discussed in relation to patients with stroke. Results. Though research is scarce, preliminary key findings were as follows: Patients' balance performance can improve from receiving visual feedback about weight distribution during practice; auditory feedback of force production may improve performance of sit-to-stand; providing feedback on less than 100% of trials, and giving summary or average feedback may enhance learning; instructions or feedback inducing an external focus may be more effective than those with an internal focus. Further research is needed concerning the relative benefits of verbal, visual, video and kinematic feedback; reduced feedback frequencies and summary feedback schedules; feedback delays, error estimation, and self-controlled feedback; and attentional focus of feedback. Conclusions. Although there are some indications that feedback might enhance motor learning after stroke, there are many areas as yet not examined and there is clearly a need for considerable research in this area.	Univ Nevada, Dept Kinesiol, Las Vegas, NV 89154 USA		paulette.vanvliet@ntlworld.com	Wulf, Gabriele/A-3239-2009; van Vliet, Paulette/F-4616-2010	Wulf, Gabriele/0000-0002-5175-6962			Altschuler EL, 1999, LANCET, V353, P2035, DOI 10.1016/S0140-6736(99)00920-4; BANDURA A, 1993, EDUC PSYCHOL, V28, P117, DOI 10.1207/s15326985ep2802_3; Batavia M, 1997, ARCH PHYS MED REHAB, V78, P1389, DOI 10.1016/S0003-9993(97)90317-8; Boekaerts M, 1996, EUR PSYCHOL, V1, P100, DOI 10.1027/1016-9040.1.2.100; Boyd LA, 2001, NEUROSCI LETT, V298, P65, DOI 10.1016/S0304-3940(00)01734-1; BUEKERS MJA, 1992, Q J EXP PSYCHOL-A, V44, P105, DOI 10.1080/14640749208401285; Canning C, 1985, Aust J Physiother, V31, P152, DOI 10.1016/S0004-9514(14)60632-2; CHEN DP, 1992, INT J SPORT PSYCHOL, V23, P277; Chiviacowsky S, 2002, RES Q EXERCISE SPORT, V73, P408, DOI 10.1080/02701367.2002.10609040; CHIVIACOWSKY S, 2005, UNPUB FEEDBACK GOOD; Croce R, 1996, PERCEPT MOTOR SKILL, V82, P507, DOI 10.2466/pms.1996.82.2.507; Dursun E, 1996, STROKE, V27, P1354, DOI 10.1161/01.STR.27.8.1354; ENGARDT M, 1993, SCAND J REHABIL MED, V25, P41; Ezekiel HJ, 2001, PHYSIOTHER CAN, V53, P33; Fasoli SE, 2002, AM J OCCUP THER, V56, P380, DOI 10.5014/ajot.56.4.380; Ferrari M, 1996, DEV REV, V16, P203, DOI 10.1006/drev.1996.0008; Fowler V, 1996, INT J REHABIL RES, V19, P265, DOI 10.1097/00004356-199609000-00008; Gentile A. M., 1987, MOVEMENT SCI FDN PHY; Guadagnoli MA, 2001, J MOTOR BEHAV, V33, P217, DOI 10.1080/00222890109603152; Guadagnoli MA, 1996, RES Q EXERCISE SPORT, V67, P239, DOI 10.1080/02701367.1996.10607950; Hanlon RE, 1996, ARCH PHYS MED REHAB, V77, P811, DOI 10.1016/S0003-9993(96)90262-2; HERBERT E, 1998, J SPORT PEDAGOGY, V4, P12; Hermsdorfer J, 2004, PHYS MED REHAB KUROR, V14, P187, DOI 10.1055/s-2003-814987; Hopper DM, 2003, PHYS THER SPORT, V4, P182, DOI 10.1016/S1466-853X(03)00068-3; Jack D, 2001, IEEE T NEUR SYS REH, V9, P308, DOI 10.1109/7333.948460; Janelle CM, 1997, RES Q EXERCISE SPORT, V68, P269, DOI 10.1080/02701367.1997.10608008; JANELLE CM, 1995, PERCEPT MOTOR SKILL, V81, P627, DOI 10.2466/pms.1995.81.2.627; KERNODLE MW, 1992, J MOTOR BEHAV, V24, P187, DOI 10.1080/00222895.1992.9941614; Lai Q, 1998, J MOTOR BEHAV, V30, P51, DOI 10.1080/00222899809601322; Lai Q, 1999, RES Q EXERCISE SPORT, V70, P79, DOI 10.1080/02701367.1999.10607734; Langhammer B, 2000, CLIN REHABIL, V14, P361, DOI 10.1191/0269215500cr338oa; LEE TD, 1990, Q J EXP PSYCHOL-A, V42, P777, DOI 10.1080/14640749008401249; Liu J, 1997, RES Q EXERCISE SPORT, V68, P145, DOI 10.1080/02701367.1997.10607990; MAGILL RA, 2003, MOTOR LEARNING CONTR; McNevin NH, 2003, PSYCHOL RES-PSYCH FO, V67, P22, DOI 10.1007/s00426-002-0093-6; Merians AS, 2002, PHYS THER, V82, P898, DOI 10.1093/ptj/82.9.898; MORRIS ME, 1992, ARCH PHYS MED REHAB, V73, P1147; Park JH, 2000, J MOTOR BEHAV, V32, P287, DOI 10.1080/00222890009601379; Platz T, 2001, ARCH PHYS MED REHAB, V82, P961, DOI 10.1053/apmr.2001.23982; Reber PJ, 1998, J COGNITIVE NEUROSCI, V10, P248, DOI 10.1162/089892998562681; Reinkensmeyer DJ, 2002, IEEE T NEUR SYS REH, V10, P102, DOI 10.1109/TNSRE.2002.1031978; Rothstein A. L., 1976, MOTOR SKILLS THEORY, V1, P36; Sackley CM, 1997, DISABIL REHABIL, V19, P536, DOI 10.3109/09638289709166047; SALADIN LS, 1994, PHYS THER, V5, pS122; SALMONI AW, 1984, PSYCHOL BULL, V95, P355, DOI 10.1037/0033-2909.95.3.355; Schmidt R. A. R., 2000, MOTOR LEARNING PERFO; SCHMIDT RA, 1991, NATO ADV SCI I D-BEH, V62, P59; SCHMIDT RA, 1990, HUM MOVEMENT SCI, V9, P325, DOI 10.1016/0167-9457(90)90007-Z; Schmidt RA, 1997, HUM FACTORS, V39, P509, DOI 10.1518/001872097778667979; SCHMIDT RA, 1989, J EXP PSYCHOL LEARN, V15, P352, DOI 10.1037/0278-7393.15.2.352; Shea CH, 1999, HUM MOVEMENT SCI, V18, P553, DOI 10.1016/S0167-9457(99)00031-7; SHERWOOD DE, 1988, PERCEPT MOTOR SKILL, V66, P535, DOI 10.2466/pms.1988.66.2.535; SOLMON MA, 1993, RES Q EXERCISE SPORT, V64, P418, DOI 10.1080/02701367.1993.10607595; SUNDERLAND A, 1992, J NEUROL NEUROSUR PS, V55, P530, DOI 10.1136/jnnp.55.7.530; SWINNEN SP, 1990, J EXP PSYCHOL LEARN, V16, P706, DOI 10.1037/0278-7393.16.4.706; SWINNEN SP, 1993, J EXP PSYCHOL LEARN, V19, P1328, DOI 10.1037/0278-7393.19.6.1328; Talvitie U, 2000, Physiother Res Int, V5, P173, DOI 10.1002/pri.197; THOMAS DM, 1996, NEUROL REP, V20, P60; Thorpe Deborah E, 2002, Pediatr Phys Ther, V14, P2; Totsika V, 2003, RES Q EXERCISE SPORT, V74, P220, DOI 10.1080/02701367.2003.10609084; VANDERLINDEN DW, 1993, PHYS THER, V73, P79, DOI 10.1093/ptj/73.2.79; Walker C, 2000, PHYS THER, V80, P886, DOI 10.1093/ptj/80.9.886; WATKINS D, 1984, HUM LEARN, V3, P33, DOI 10.1080/0729436840030103; Weeks DL, 1998, RES Q EXERCISE SPORT, V69, P224, DOI 10.1080/02701367.1998.10607689; WINSTEIN C, 2005, HDB NEUROPSYCHOLOGY, V9; Winstein CJ, 1996, PHYS THER, V76, P985, DOI 10.1093/ptj/76.9.985; WINSTEIN CJ, 1990, J EXP PSYCHOL LEARN, V16, P677, DOI 10.1037/0278-7393.16.4.677; Winstein CJ, 1999, NEUROPSYCHOLOGIA, V37, P975, DOI 10.1016/S0028-3932(98)00145-6; WOOD CA, 1992, J HUM MOVEMENT STUD, V22, P213; WULF G, 1993, J EXP PSYCHOL LEARN, V19, P1134, DOI 10.1037/0278-7393.19.5.1134; WULF G, 1989, J EXP PSYCHOL LEARN, V15, P748, DOI 10.1037/0278-7393.15.4.748; Wulf G, 2002, PSYCHON B REV, V9, P185, DOI 10.3758/BF03196276; Wulf G, 2002, J MOTOR BEHAV, V34, P171, DOI 10.1080/00222890209601939; Wulf G, 2001, PSYCHON B REV, V8, P648, DOI 10.3758/BF03196201; Wulf G, 2001, RES Q EXERCISE SPORT, V72, P335, DOI 10.1080/02701367.2001.10608970; Wulf G, 2001, Q J EXP PSYCHOL-A, V54, P1143, DOI 10.1080/02724980143000118; Wulf G, 1996, J MOTOR BEHAV, V28, P371, DOI 10.1080/00222895.1996.10544606; Wulf G., 2004, SKILL ACQUISITION SP, P121; YAO WX, 1994, J MOTOR BEHAV, V26, P273, DOI 10.1080/00222895.1994.9941683; YOUNG DE, 1992, J MOTOR BEHAV, V24, P261, DOI 10.1080/00222895.1992.9941621; Zimmeman B. J., 1989, SELF REGULATED LEARN, P51	81	177	179	4	57	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.	JUL	2006	28	13-14					831	840		10.1080/09638280500534937			10	Rehabilitation	Rehabilitation	053LJ	WOS:000238306300006	16777770				2021-06-18	
J	Maas, AIR; Murray, G; Henney, H; Kassem, N; Legrand, V; Mangelus, M; Muizelaar, JP; Stocchetti, N; Knoller, N				Maas, AIR; Murray, G; Henney, H; Kassem, N; Legrand, V; Mangelus, M; Muizelaar, JP; Stocchetti, N; Knoller, N		Pharmos TBI investigators	Efficacy and safety of dexanabinol in severe traumatic brain injury: results of a phase III randomised, placebo-controlled, clinical trial	LANCET NEUROLOGY			English	Article							CLOSED-HEAD INJURY; GUIDELINES; HU-211; MANAGEMENT; INDUCTION; AGENTS; SIZE	Background Traumatic brain injury is a major cause of death and disability. We sought to assess the safety and efficacy of dexanabinol, a synthetic cannabinoid analogue devoid of psychotropic activity, in severe traumatic brain injury. Methods 861 patients with severe traumatic brain injury admitted to 86 specialist centres from 15 countries were included in a multi-centre, placebo-controlled, phase III trial. Patients were randomised to receive a single intravenous 150 mg dose of dexanabinol or placebo within 6 h of injury. The primary outcome was the extended Glasgow outcome scale assessed at 6 months, with the point of dichotomisation into unfavourable versus favourable outcome differentiated by baseline prognostic risk. Prespecified subgroup analyses were defined by injury severity, recruitment rate, and time to dosing. Secondary analysis included control of intracranial pressure and quality of life. Analysis were prespecified in the protocol and the statistical analysis plan. This study is registered with ClinicalTrials.gov, number NCT00129857. Findings 846 patients were included in the efficacy analysis. The extended Glasgow outcome scale at 6 months did not differ between groups; 215 (50%) patients in the dexanabinol group and 214 (51%) patients in the placebo group had an unfavourable outcome (odds ratio for a favourable response 1.04; 95% CI 0.79-1.36). Improvements in the control of intracranial pressure or quality of life were not recorded and subgroup analysis showed no indication of differential treatment effects. Dexanabinol was not associated with hepatic, renal, or cardiac toxic effects. Interpretation Dexanabinol is safe, but is not efficacious in the treatment of traumatic brain injury.	Univ Med Ctr Rotterdam, Erasmus MC, Dept Neurosurg, NL-3000 CA Rotterdam, Netherlands; Univ Edinburgh, Sch Med, Edinburgh, Midlothian, Scotland; Pharmos Corp, Iselin, NJ USA; Quintiles, Paris, France; Calif State Univ Sacramento, Dept Neurosurg, Sacramento, CA 95819 USA; Univ Milan, Neurosci ICU, Osped Policlin IRCCS, Milan, Italy; Chaim Sheba Med Ctr, Dept Neurosurg, IL-52621 Tel Hashomer, Israel	Maas, AIR (corresponding author), Univ Med Ctr Rotterdam, Erasmus MC, Dept Neurosurg, NL-3000 CA Rotterdam, Netherlands.	airmaas@erasmusmc.nl	Maas, Andrew IR/C-5584-2013; Stocchetti, Nino/O-7444-2017	Maas, Andrew IR/0000-0003-1612-1264; Stocchetti, Nino/0000-0003-3250-6834; Murray, Gordon/0000-0001-9866-4734			Bolland K, 1998, STAT MED, V17, P2835, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2835::AID-SIM933>3.3.CO;2-#; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Brewster ME, 1997, INT J CLIN PHARM TH, V35, P361; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Collin C, 1988, Int Disabil Stud, V10, P61; Dickinson K, 2000, BMJ-BRIT MED J, V320, P1308, DOI 10.1136/bmj.320.7245.1308; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; ESHHAR N, 1995, EUR J PHARMACOL, V283, P19, DOI 10.1016/0014-2999(95)00271-L; EVANS JM, 1977, BRIT MED J, V2, P735, DOI 10.1136/bmj.2.6089.735; FEIGENBAUM JJ, 1989, P NATL ACAD SCI USA, V86, P9584, DOI 10.1073/pnas.86.23.9584; Galluccio A, 2001, J COMB THEORY B, V83, P1, DOI 10.1006/jctb.2000.2009; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; HOFF JT, 1986, J NEUROSURG, V65, P579, DOI 10.3171/jns.1986.65.5.0579; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Knoller N, 2002, CRIT CARE MED, V30, P548, DOI 10.1097/00003246-200203000-00009; Maas AIR, 1999, NEUROSURGERY, V44, P1286, DOI 10.1097/00006123-199906000-00076; Maas AIR, 2004, ACT NEUR S, V89, P113; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MARMAROU A, 1991, J NEUROSURG, V75, pS21, DOI 10.3171/sup.1991.75.1s.0s21; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Morris GF, 1998, NEUROSURGERY, V43, P1369, DOI 10.1097/00006123-199812000-00063; Murray GD, 2005, J NEUROTRAUM, V22, P511, DOI 10.1089/neu.2005.22.511; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; THEIS JGW, 1995, J CLIN ONCOL, V13, P2508, DOI 10.1200/JCO.1995.13.10.2508; THURMAN DJ, 2001, HEAD TRAUMA BASIC PR; TOUTANT SM, 1984, J NEUROSURG, V61, P691, DOI 10.3171/jns.1984.61.4.0691; WAHL M, 1993, ACTA NEUROCHIR, P3; Ware JE., 1993, SF 36 HLTH SURVEY MA; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	33	177	181	0	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1474-4422	1474-4465		LANCET NEUROL	Lancet Neurol.	JAN	2006	5	1					38	45		10.1016/S1474-4422(05)70253-2			8	Clinical Neurology	Neurosciences & Neurology	998OI	WOS:000234328100026	16361021				2021-06-18	
J	Iverson, GL; Lovell, MR; Collins, MW				Iverson, GL; Lovell, MR; Collins, MW			Validity of ImPACT for measuring processing speed following sports-related concussion	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							NEUROPSYCHOLOGICAL TEST-PERFORMANCE; MILD HEAD-INJURY; HIGH-SCHOOL; COLLEGIATE; FOOTBALL; RECOVERY; PLAYERS; RETURN; TIME	The purpose of this study was to examine the validity of ImPACT (Immediate Post-Concussion Assessment and Cognitive Testing), a computerized neuropsychological test battery, for measuring attention and processing speed in athletes with concussions. This was accomplished by comparing the computerized testing to a traditional neuropsychological measure, the Symbol Digit Modalities Test (SDMT). Participants were 72 amateur athletes who were seen within 21 days of sustaining a sports-related concussion (Mean=9.4, SD=5.4 days). As predicted, the SDMT correlated more highly with the Processing Speed and Reaction Time composites than the Verbal Memory and Visual Memory Composites from ImPACT. The composite scores from IMPACT and the SDMT were subjected to exploratory factor analysis, revealing a two-factor solution interpreted as Speed/Reaction Time and Memory. It appears as if the Processing Speed Composite, Reaction Time Composite, and SDMT are measuring a similar underlying construct in this sample of concussed amateur athletes.	Univ British Columbia, Dept Psychiat, Vancouver, BC V6T 2A1, Canada; Riverview Hosp, Vancouver, BC, Canada; Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA	Iverson, GL (corresponding author), Univ British Columbia, Dept Psychiat, 2255 Wesbrook Mall, Vancouver, BC V6T 2A1, Canada.	giverson@interchange.ubc.ca					Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; COLLINS MW, 2001, ANN WINT M MAJ LEAG; Delaney JS, 2001, CLIN J SPORT MED, V11, P234, DOI 10.1097/00042752-200110000-00005; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; Franzen M. D., 1989, RELIABILITY VALIDITY; Franzen MD, 2000, RELIABILITY VALIDITY, V2nd; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Giza CC, 2004, STUD NEUROPSYCHOL DE, P45; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; Iverson G, 2002, ARCH CLIN NEUROPSYCH, V17, P769; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Kelly JP, 2001, J ATHL TRAINING, V36, P249; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Lovell MR, 1999, SPORTS-RELATED CONCUSSION, P200; LOVELL MR, 2000, NEUROLOGIC ATHLETIC, P109; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; Mrazik M, 2000, BRAIN INJURY, V14, P921, DOI 10.1080/026990500445736; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Randolph C, 2001, J ATHL TRAINING, V36, P288; Smith A., 1982, SYMBOL DIGIT MODALIT; Spreen O., 1998, COMPENDIUM NEUROPSYC; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524; Zillmer EA, 2003, APPL NEUROPSYCHOL, V10, P23, DOI 10.1207/S15324826AN1001_4	41	177	177	1	32	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	AUG	2005	27	6					683	689		10.1081/13803390490918435			7	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	946NO	WOS:000230579300004	16019644				2021-06-18	
J	Brown, M; Dijkers, MPJM; Gordor, WA; Ashman, T; Charatz, H; Cheng, ZF				Brown, M; Dijkers, MPJM; Gordor, WA; Ashman, T; Charatz, H; Cheng, ZF			Participation objective, participation subjective - A measure of participation combining outsider and insider perspectives	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injuries; consumer participation; disabled persons; outcome assessment (healthcare); questionnaires; rehabilitation; reproducibility of results; treatment outcome	TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; MENTALLY-RETARDED ADULTS; COMMUNITY INTEGRATION; HEAD-INJURY; REHABILITATION; QUESTIONNAIRE; DISABILITY; HANDICAP; SATISFACTION	Background: Participation now replaces community integration or handicap as concepts reflecting the social and interpersonal aspects of disability. If rehabilitation is to adequately measure participation, new measures of participation are needed. To represent the voice of the consumer, such measures should reflect not just "objective," normative aspects, but also subjective ones, tapping the consumer's view of participation. Objectives: To describe the development of and preliminary metrological information on a new measure of participation, Participation Objective, Participation Subjective (POPS). Methods: A total of 454 community-living individuals with traumatic brain injury (TBI) completed the POPS, as well as measures of quality of life (Life 3), depressive mood (BDI), and TBI symptoms (BISQ). The POPS requires reporting of the share of household activities performed, or the frequency or hours of nonhousehold activities. For each, the subject indicates whether he or she wants to perform more, the same, or less of the activity, and the importance of the activity to well-being. Five subscales and a total scale are calculated, for an objective component (PO), and a subjective component (PS) that reflects importance-weighted satisfaction with activity level. Results: Individuals with mild TBI scored minimally higher than those with moderate-severe TBI on PO subscores, but desired more change on the PS. Test-retest reliability for the PO and the PS and the subscales was from weak (intraclass correlation coefficient 0.28) to adequate (0.89), with PS components having better reliability. The PS component scores had the expected correlations with TBI symptoms, depressed mood, and life satisfaction, among both those with mild injury and those with moderate-severe injury. Injury severity and time since onset were not related to PO or PS scores. Conclusions: The POPS shows promise as a measure of participation. It fills a void in that it reflects both insider and outsider perspectives on participation after TBI.	CUNY Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA	Brown, M (corresponding author), CUNY Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA.	marbrown@optonline.net	Heinemann, Allen W/K-6283-2012; Ashman, Teresa/B-1621-2013	Heinemann, Allen W/0000-0003-2782-7326; Dijkers, Marcel/0000-0002-8362-5596			American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Andrews F. M., 1976, SOCIAL INDICATORS WE; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Beck A. T., 1996, BECK DEPRESSION INVE; Beck A.T., 1987, BECK DEPRESSION INVE; BIGELOW DA, 1991, COMMUNITY MENT HLT J, V27, P43, DOI 10.1007/BF00752714; BIGELOW DA, 1990, PSYCHOSOC REHABIL, V14, P94; BROWN M, 1984, REHABIL PSYCHOL, V29, P21; Brown M, 2004, ARCH PHYS MED REHAB, V85, pS13, DOI 10.1016/j.apmr.2003.08.110; Brown M, 1999, MT SINAI J MED, V66, P160; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Brown M, 2000, BRAIN INJURY, V14, P5, DOI 10.1080/026990500120899; BROWN ME, 1984, FUNCTIONAL ASSESSMEN, P187; BURCKHARDT CS, 1989, RES NURS HEALTH, V12, P347, DOI 10.1002/nur.4770120604; Cantor JB, 2004, ARCH PHYS MED REHAB, V85, pS54, DOI 10.1016/j.apmr.2003.08.113; Cardol M, 2001, ARCH PHYS MED REHAB, V82, P210, DOI 10.1053/apmr.2001.18218; Cardol M, 1999, CLIN REHABIL, V13, P411, DOI 10.1191/026921599668601325; Cicerone KD, 2004, ARCH PHYS MED REHAB, V85, P943, DOI 10.1016/j.apmr.2003.07.019; Colantonio A, 1998, ARCH PHYS MED REHAB, V79, P550, DOI 10.1016/S0003-9993(98)90072-7; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; DEMBO T, 1964, REHABIL LIT, V25, P231; Dijkers M., 2002, QUAL LIFE RES, V11, P672; Dijkers Marcel P J M, 2003, J Allied Health, V32, P38; Donnelly Catherine, 2002, Can J Occup Ther, V69, P84; FEINSTEIN AR, 1983, ANN INTERN MED, V99, P843, DOI 10.7326/0003-4819-99-6-843; Felce D, 2001, MENT RETARD DEV D R, V7, P75, DOI 10.1002/mrdd.1011; Felmingham KL, 2001, ARCH PHYS MED REHAB, V82, P435, DOI 10.1053/apmr.2001.21985; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; FLANAGAN JC, 1978, AM PSYCHOL, V33, P138, DOI 10.1037/0003-066X.33.2.138; FLANAGAN JC, 1982, ARCH PHYS MED REHAB, V63, P56; FUHRER MJ, 1992, ARCH PHYS MED REHAB, V73, P552; GORDON WA, 1998, LIVING LIFE TBI; GORDON WA, 1999, REHABILITATION ADULT, P312; GORDON WA, 1997, BRAIN INJURY SCREENI; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; Jette AM, 2003, J REHABIL MED, V35, P145, DOI 10.1080/16501970310010501; JOHNSTON MV, IN PRESS ARCH PHYS M; KRUZICH JM, 1985, AM J COMMUN PSYCHOL, V13, P553, DOI 10.1007/BF00923267; LAMAN H, 1994, DISABIL REHABIL, V16, P198, DOI 10.3109/09638289409166613; Law M, 1990, Can J Occup Ther, V57, P82; Lehmkuhl D., 1998, TIRR SYMPTOM CHECKLI; MALEC JF, 1991, ARCH PHYS MED REHAB, V72, P138; McColl MA, 2001, ARCH PHYS MED REHAB, V82, P429, DOI 10.1053/apmr.2001.22195; McColl MA, 1998, BRAIN INJURY, V12, P15, DOI 10.1080/026990598122827; *MED COLL VIRG DEP, TBI SYMPT CHECKL; MELLICK D, 1999, J REHABIL OUTCOMES, V3, P12; Millis S R, 1994, Int J Neurosci, V79, P165; Minnes P, 2003, BRAIN INJURY, V17, P149, DOI 10.1080/02699050301828; ONEILL J, 1981, APPL RES MENT RETARD, V2, P367, DOI 10.1016/0270-3092(81)90031-X; ONEILL J, 1985, APPL RES MENT RETARD, V6, P361, DOI 10.1016/0270-3092(85)90008-6; Picard M, 1991, HELPS BRIEF SCREENIN; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; SCHALOCK RL, 1981, AM J MENT DEF, V85, P478; Stineman MG, 2000, SCAND J REHABIL MED, V32, P143; Stineman MG, 2003, ARCH PHYS MED REHAB, V84, pS15, DOI 10.1053/apmr.2003.50242; Wagner AK, 2002, ARCH PHYS MED REHAB, V83, P107, DOI 10.1053/apmr.2002.27470; WAINER H, 1976, PSYCHOL BULL, V83, P213, DOI 10.1037/0033-2909.83.2.213; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WHERLEY M, 1987, HOSP COMMUNITY PSYCH, V38, P852; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; World Health Organization, 1980, INT CLASS IMP DIS HA; World Health Organization, 2001, INT CLASS FUNCT DIS	63	177	177	1	24	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2004	19	6					459	481		10.1097/00001199-200411000-00004			23	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	873LZ	WOS:000225283100004	15602309				2021-06-18	
J	Dijkers, MP				Dijkers, MP			Quality of life after traumatic brain injury: A review of research approaches and findings	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	State of the Science Conference	APR, 2002	Geroge Washington Univ, Washington, DC	Rehabilitat Res & Training Ctr, NIDRR	Geroge Washington Univ	brain injuries; outcome assessment (health care); quality of life; rehabilitation	PREFERENCE-BASED MEASURES; HEALTH UTILITIES INDEX; CLOSED-HEAD INJURY; SPINAL-CORD-INJURY; FOLLOW-UP; PATIENT PREFERENCES; MULTIPLE TRAUMA; SELF-AWARENESS; MODEL SYSTEMS; BASIC ISSUES	Objectives: To assess existing knowledge of quality of life (QOL) of people with traumatic brain injury (TBI) and to make recommendations for methodologic and substantive research in this area. Data Sources: Published research on QOL of persons with TBI, identified from databases, ancestry search, and the author's files. Study Selection: Empirical, theoretical, and methodologic articles relevant to 5 areas: QOL as achievements, QOL as subjective well-being (SWB), QOL as utility, QOL experienced, and QOL measurement instruments applicable to TBI or specifically developed for people with this impairment. Data Extraction: Selection of QOL indicators, with focus on TBI versus non-TBI differences. Data Synthesis: Studies of QOL as achievements show that in almost all areas, people with TBI score lower than they did before injury and lower than comparisons groups. There are limited gaps in our knowledge in this area. Research into QOL as SWB shows that after TBI, people typically report, for example, somewhat lower life satisfaction and affect than do comparison groups, and that injury severity is not necessarily a predictor of SWB. There are almost no studies of QOL as utility of life after TBI. Conclusions: Major research recommendations include: exploring the ability of TBI subjects to self-report; determining the salience of domains of life for this group; developing utility instruments that are sensitive to differences in deficits in cognition and other health and life domains; and doing qualitative studies that explore the experience of QOL.	Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA	Dijkers, MP (corresponding author), Mt Sinai Sch Med, Dept Rehabil Med, Box 1240,1 Gustave Levy Pl, New York, NY 10029 USA.	marcel.dijkers@mssm.edu		Dijkers, Marcel/0000-0002-8362-5596			Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; BALABAN DJ, 1986, MED CARE, V24, P973, DOI 10.1097/00005650-198611000-00001; Berger E, 1999, RESTOR NEUROL NEUROS, V14, P93; BERGLAND MM, 1991, REHABIL COUNS BULL, V35, P5; Bogan AM, 1997, BRAIN INJURY, V11, P431; Brazier J, 1998, J CLIN EPIDEMIOL, V51, P1115, DOI 10.1016/S0895-4356(98)00103-6; BRICKMAN P, 1978, J PERS SOC PSYCHOL, V36, P917, DOI 10.1037/0022-3514.36.8.917; Brod M, 1999, GERONTOLOGIST, V39, P25, DOI 10.1093/geront/39.1.25; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; Brown M, 2000, BRAIN INJURY, V14, P5, DOI 10.1080/026990500120899; BROWNE JP, 1994, QUAL LIFE RES, V3, P235, DOI 10.1007/BF00434897; Bryant RA, 2001, J NERV MENT DIS, V189, P109, DOI 10.1097/00005053-200102000-00006; Brzuzy S, 1997, SOC WORK HEALTH CARE, V26, P77, DOI 10.1300/J010v26n01_05; Bullinger M, 2002, RESTOR NEUROL NEUROS, V20, P111; Bushnik T, 2003, ARCH PHYS MED REHAB, V84, P151, DOI 10.1053/apmr.2003.50123; CALMAN KC, 1984, J MED ETHICS, V10, P124, DOI 10.1136/jme.10.3.124; Colantonio A, 1998, ARCH PHYS MED REHAB, V79, P550, DOI 10.1016/S0003-9993(98)90072-7; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Dawson DR, 2000, BRAIN COGNITION, V44, P35; Diener E., 1993, HDB EMOTIONS, P405; Dijkers M., 2002, QUAL LIFE RES, V11, P672; DIJKERS M, 2001, QUAL LIFE RES, V10, P584; Dijkers MP, 2003, ARCH PHYS MED REHAB, V84, pS3, DOI 10.1053/apmr.2003.50241; Duggan CH, 2001, REHABIL PSYCHOL, V46, P3, DOI 10.1037/0090-5550.46.1.3; DUGGAN CH, 2000, QUALITY LIFE SURVIVO; Dupuis G., 2000, ADV CARDIOPULMONARY, P247; DUQUETTE RL, 1994, CAN J CARDIOL, V10, P106; Feeny D, 2002, MED CARE, V40, P113, DOI 10.1097/00005650-200202000-00006; Fernandez V, 2001, UNFALLCHIRURG, V104, P938, DOI 10.1007/s001130170034; FERRANS CE, 1992, RES NURS HEALTH, V15, P29, DOI 10.1002/nur.4770150106; FERRANS CE, 1985, ADV NURS SCI, V8, P15, DOI 10.1097/00012272-198510000-00005; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; FINSET A, 1995, BRAIN INJURY, V9, P141, DOI 10.3109/02699059509008187; FLANAGAN JC, 1978, AM PSYCHOL, V33, P138, DOI 10.1037/0003-066X.33.2.138; FLANAGAN JC, 1982, ARCH PHYS MED REHAB, V63, P56; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Goldstein FC, 1999, J NEUROPSYCH CLIN N, V11, P38, DOI 10.1176/jnp.11.1.38; Gordon WA, 2000, BRAIN INJURY, V14, P21, DOI 10.1080/026990500120907; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; HALLETT JD, 1994, AM J OCCUP THER, V48, P241, DOI 10.5014/ajot.48.3.241; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; Hawley CA, 2002, BRAIN INJURY, V16, P969, DOI 10.1080/02699050210147239; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; HENDRYX PM, 1989, ARCH PHYS MED REHAB, V70, P526; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Hibbard MR, 2002, J HEAD TRAUMA REHAB, V17, P112, DOI 10.1097/00001199-200204000-00004; Hickey A, 1999, INDIVIDUAL QUALITY L, P119; Hill H, 1999, BRAIN INJURY, V13, P839, DOI 10.1080/026990599121043; Hollingworth W, 2002, HEALTH ECON, V11, P71, DOI 10.1002/hec.650; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; JOHANSSON E, 1991, SCAND J REHABIL MED, V23, P179; KAPLAN RM, 1979, MED CARE, V17, P501, DOI 10.1097/00005650-197905000-00005; KAPLAN RM, 1993, QUAL LIFE RES, V2, P467, DOI 10.1007/BF00422221; KEANY KCMH, 1993, REHABIL PSYCHOL, V38, P199, DOI 10.1037/0090-5550.38.3.199; Kersel DA, 2001, BRAIN INJURY, V15, P683, DOI 10.1080/02699050010013662; Kinsella G, 1989, Int Disabil Stud, V11, P9; Kolakowsky-Hayner SA, 2001, J HEAD TRAUMA REHAB, V16, P374, DOI 10.1097/00001199-200108000-00007; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Kozloff R, 1987, J HEAD TRAUMA REHAB, V2, P14, DOI DOI 10.1097/00001199-198709000-00004; KRAFT JF, 1993, ARCH PHYS MED REHAB, V74, P596, DOI 10.1016/0003-9993(93)90157-6; Kreuter M, 1998, SPINAL CORD, V36, P252, DOI 10.1038/sj.sc.3100592; Kreuter M, 1998, BRAIN INJURY, V12, P349, DOI 10.1080/026990598122494; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Kuo RL, 1999, J UROLOGY, V162, P1913, DOI 10.1016/S0022-5347(05)68067-6; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; Laforce R, 2001, PERCEPT MOTOR SKILL, V93, P281, DOI 10.2466/PMS.93.5.281-288; Lee JE, 2000, QUAL LIFE RES, V9, P1127, DOI 10.1023/A:1016645523769; Lenert L, 2000, MED CARE, V38, P138; LESSLER JT, 1995, MED CARE, V33, pAS203; LINN RT, 1994, BRAIN INJURY, V8, P135, DOI 10.3109/02699059409150965; LUBORSKY MR, 1994, J AGING STUD, V8, P239, DOI 10.1016/0890-4065(94)90002-7; MAAS A, 1992, MED DECIS MAKING, V12, P288, DOI 10.1177/0272989X9201200408; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; MacKenzie EJ, 2002, J TRAUMA, V52, P527, DOI 10.1097/00005373-200203000-00018; MAITZ EA, 2000, REHABIL OUTLOOK, V5, P7; MAITZ EA, 2000, REHABIL OUTLOOK, V5, P10; Martin C, 2001, BRAIN INJURY, V15, P947, DOI 10.1080/02699050110065655; Maslow A., 1954, MOTIVATION PERSONALI; Mathias SD, 1997, STROKE, V28, P1888, DOI 10.1161/01.STR.28.10.1888; McAllister TW, 2002, NEUROREHABILITATION, V17, P265; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McColl MA, 2000, DISABIL REHABIL, V22, P555, DOI 10.1080/096382800416805; McColl MA, 2000, ARCH PHYS MED REHAB, V81, P817, DOI 10.1053/apmr.2000.5567; MCGEE HM, 1991, PSYCHOL MED, V21, P749, DOI 10.1017/S0033291700022388; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; MCNEIL BJ, 1981, NEW ENGL J MED, V305, P982, DOI 10.1056/NEJM198110223051704; Meletiche DM, 1999, CLIN THER, V21, P2016, DOI 10.1016/S0149-2918(00)86747-8; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; *MOUNT SIN MED CTR, 1998, LIV LIF TBI; Murphy R, 2001, J NEUROL NEUROSUR PS, V70, P679, DOI 10.1136/jnnp.70.5.679; Murray Christopher JL, 1996, GLOBAL BURDEN DIS IN, P11; Nease RF, 2000, MED CARE, V38, P155; Nochi M, 1998, QUAL HEALTH RES, V8, P665, DOI 10.1177/104973239800800507; Nochi M, 2000, SOC SCI MED, V51, P1795, DOI 10.1016/S0277-9536(00)00111-8; Nochi M, 1998, SOC SCI MED, V46, P869, DOI 10.1016/S0277-9536(97)00211-6; O'CARROLL R E, 1991, Brain Injury, V5, P303, DOI 10.3109/02699059109008100; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; OBOYLE CA, 1992, LANCET, V339, P1088, DOI 10.1016/0140-6736(92)90673-Q; Ormel J, 1997, SOC SCI MED, V45, P1051, DOI 10.1016/S0277-9536(97)00032-4; Paniak C, 1999, J HEAD TRAUMA REHAB, V14, P211, DOI 10.1097/00001199-199906000-00002; Patterson TL, 1996, PSYCHIAT RES, V63, P169, DOI 10.1016/0165-1781(96)02797-7; Pavot W., 1993, PSYCHOL ASSESSMENT, V5, P164, DOI DOI 10.1037/1040-3590.5.2.164; Post PN, 2001, STROKE, V32, P1425, DOI 10.1161/01.STR.32.6.1425; Powell JH, 1998, ARCH PHYS MED REHAB, V79, P1213, DOI 10.1016/S0003-9993(98)90265-9; *PRES COMM NAT GOA, 1960, GOALS AM PROGR ACT 6; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Rao Vani, 2002, Curr Treat Options Neurol, V4, P77, DOI 10.1007/s11940-002-0006-4; Ravens-Sieberer U, 2002, RESTOR NEUROL NEUROS, V20, P151; Revicki DA, 1998, CHEST, V114, P998, DOI 10.1378/chest.114.4.998; Revicki DA, 1996, INT CLIN PSYCHOPHARM, V11, P101, DOI 10.1097/00004850-199611020-00004; Riemsma R P, 2001, Health Technol Assess, V5, P1; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; Smith DS, 2002, J UROLOGY, V167, P2117, DOI 10.1016/S0022-5347(05)65099-9; Smith Y R, 1998, J Pediatr Adolesc Gynecol, V11, P13; Snead SL, 2002, BRAIN INJURY, V16, P947, DOI 10.1080/02699050210147211; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; Snow P, 1997, BRAIN INJURY, V11, P409; Sprangers MAG, 1999, SOC SCI MED, V48, P1507, DOI 10.1016/S0277-9536(99)00045-3; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; TEMKIN N, 1988, J CLIN EPIDEMIOL, V41, P47, DOI 10.1016/0895-4356(88)90008-X; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tourangeau R, 2000, SCIENCE OF SELF-REPORT, P29; Tourangeau R., 2000, PSYCHOL SURVEY RESPO; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; Verri A, 1999, J INTELL DISABIL RES, V43, P513, DOI 10.1046/j.1365-2788.1999.00241.x; Wagner AK, 2002, ARCH PHYS MED REHAB, V83, P107, DOI 10.1053/apmr.2002.27470; WALKER GC, 1991, ARCH PHYS MED REHAB, V72, P469; Webster G, 1999, BRAIN INJURY, V13, P593; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WHITTY RW, 1985, SOFTW MICROSYST, V4, P2, DOI 10.1049/sm.1985.0002; Wood RL, 1997, BRAIN INJURY, V11, P491, DOI 10.1080/713802183; Wright B.A., 1983, PHYS DISABILITY PSYC, V2nd edition; Ylvisaker M, 2002, J HEAD TRAUMA REHAB, V17, P191, DOI 10.1097/00001199-200206000-00002	140	177	180	0	29	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	2004	85	4		2			S21	S35		10.1016/j.apmr.2003.08.119			15	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	812FL	WOS:000220825300004	15083419				2021-06-18	
J	Pellman, EJ; Powell, JW; Viano, DC; Casson, IR; Tucker, AM; Feuer, H; Lovell, M; Waeckerle, JF; Robertson, DW				Pellman, EJ; Powell, JW; Viano, DC; Casson, IR; Tucker, AM; Feuer, H; Lovell, M; Waeckerle, JF; Robertson, DW			Concussion in professional football: Epidemiological features of game injuries and review of the literature - Part 3	NEUROSURGERY			English	Article						concussion; injury epidemiology; sports injury prevention; traumatic brain injury	MINOR HEAD-INJURY; NEUROPSYCHOLOGICAL TEST-PERFORMANCE; TRAUMATIC BRAIN-INJURY; CEREBRAL CONCUSSION; PLAYERS; SYMPTOMS; SEIZURES; REGISTRY; RECOVERY; IMPACTS	OBJECTIVE: A 6-year study was performed to determine the circumstances, causes, and outcomes of concussions in the National Football League. METHODS: Between 1996 and 2001, the epidemiological features of concussions were recorded by National Football League teams with a standardized reporting form. Symptoms were reported and grouped as general symptoms, cranial nerve symptoms, memory or cognitive problems, somatic complaints, and loss of consciousness. The medical actions taken were recorded. In total, 787 game-related cases were reported, with information on the players involved, type of helmet impact, symptoms, medical actions, and days lost. Concussion risks were calculated according to player game positions. RESULTS: There were 0.41 concussions per National Football League game. The relative risk was highest for quarterbacks (1.62 concussions/100 game-positions), followed by wide receivers (1.23 concussions/100 game-positions), tight ends (0.94 concussion/100 game-positions), and defensive secondaries (0.93 concussion/100 game-positions). The majority of concussions (67.7%) involved impact by another player's helmet. The remainder involved impact by other body regions of the striking player (20.9%) or ground contact (11.4%). The three most common symptoms of mild traumatic brain injury were headaches (55.0%), dizziness (41.8%), and blurred vision (16.3%). The most common signs noted in physical examinations were problems with immediate recall (25.5%), retrograde amnesia (18.0%), and information-processing problems (17.5%). In 58 of the reported cases (9.3%), the players lost consciousness; 19 players (2.4%) were hospitalized. A total of 92% of concussed players returned to practice in less than 7 days, but that value decreased to 69% with unconsciousness. CONCLUSION: The professional football players most vulnerable to concussions are quarterbacks, wide receivers, and defensive secondaries. Concussions involved 2.74 symptoms/injury, and players were generally removed from the game. More than one-half of the players returned to play within 1 day, and symptoms resolved in a short time in the vast majority of cases.	Amer Hlth Network, Carmel, IN USA; Natl Football League, Mild Traumat Brain Injury Comm, New York, NY USA; Acute Care & Emergency Specialist, Leawood, KS USA; Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA; Indianapolis Neurosurg Grp, Indianapolis, IN USA; Univ Maryland, Sch Med, Lutherville Timonium, MD USA; NYU, Med Ctr, Dept Neurol, New York, NY 10016 USA; Long Isl Jewish Med Ctr, Dept Neurol, New Hyde Pk, NY 11042 USA; Michigan State Univ, Dept Kinesiol, Lansing, MI USA; Michigan State Univ, Dept Phys Med & Rehabil, Lansing, MI USA; ProHlth Care Associates, Lake Success, NY USA	Viano, DC (corresponding author), ProBiomechanics, 265 Warrington Rd, Bloomfield Hills, MI 48304 USA.	dviano@comcast.net					ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; BLONSTEIN JL, 1957, BRIT MED J, V1, P362, DOI 10.1136/bmj.1.5015.362; *C NEUR SURG, 1966, CLIN NEUROSURG, V12, P386; CANTU RC, 2001, NEUROLOGICAL SPORTS, P25; Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P224; CLARKE KS, 1989, SPORTS NEUROLOGY, P63; Collie A, 2001, BRIT J SPORT MED, V35, P297, DOI 10.1136/bjsm.35.5.297; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; ENZENAUER RW, 1989, JAMA-J AM MED ASSOC, V261, P1463, DOI 10.1001/jama.261.10.1463; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Evans R. W., 1996, NEUROLOGY TRAUMA, P91; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GERBERICH SG, 1987, CHILD NERV SYST, V3, P59, DOI 10.1007/BF00271123; GRONWALL D, 1974, LANCET, V2, P605; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; IVERSON G, 2002, NAT AC NEUR ANN C MI; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; JORDAN BD, 1989, SPORTS NEUROLOGY, P75; KAPLAN HA, 1954, JAMA-J AM MED ASSOC, V156, P1138, DOI 10.1001/jama.1954.02950120012004; KRAUS JF, 1996, NEUROLOGY TRAUMA, P3; KWARTZ J, 1990, INJURY, V21, P351, DOI 10.1016/0020-1383(90)90116-C; Larsson LE, 1954, ACTA PSYCH NEUROL SC, V95, P7; LEE ST, 1992, J NEUROSURG, V76, P435, DOI 10.3171/jns.1992.76.3.0435; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; MCCOWN IA, 1959, AM J SURG, V98, P509, DOI 10.1016/0002-9610(59)90545-8; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; MINDERHOUD JM, 1980, CLIN NEUROL NEUROSUR, V82, P127, DOI 10.1016/0303-8467(80)90007-4; *NAT FOOTB LEAG, 1997, OFF NFL REC FACT BOO; PARSONS LC, 1982, NURS RES, V31, P260; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P797, DOI 10.1093/neurosurgery/53.3.797; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUTHERFORD WH, 1977, LANCET, V1, P1; Schneider R., 1973, HEAD NECK INJURIES F; SLAGLE DA, 1990, INT J PSYCHIAT MED, V20, P1, DOI 10.2190/BE6W-DCY1-V71N-N7J7; TORG JS, 1979, JAMA-J AM MED ASSOC, V241, P1477, DOI 10.1001/jama.241.14.1477; TORG JS, 1985, JAMA-J AM MED ASSOC, V254, P3439, DOI 10.1001/jama.254.24.3439; TUOHIMAA P, 1978, ACTA OTO-LARYNGOL, V359, P1; Warden Deborah L., 2003, Neurology, V60, pA362; WINTERSTEIN CE, 1937, LANCET, V2, P719	48	177	180	0	15	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JAN	2004	54	1					81	94		10.1227/01.NEU.0000097267.54786.54			14	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	761ZA	WOS:000187944300019	14683544				2021-06-18	
J	Dunford, JV; Davis, DP; Ochs, M; Doney, M; Hoyt, DB				Dunford, JV; Davis, DP; Ochs, M; Doney, M; Hoyt, DB			Incidence of transient hypoxia and pulse rate reactivity during paramedic rapid sequence intubation	ANNALS OF EMERGENCY MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the National-Association-of-Emergency-Medical-Services-Physicians	JAN, 2003	PANAMA CITY, FL	Natl Assoc Emergency Med Serv Phys			ENDOTRACHEAL INTUBATION; BRAIN-INJURY; NEUROMUSCULAR BLOCKADE; PRE-OXYGENATION; TRAUMA PATIENTS; HYPOTENSION; PREOXYGENATION; HYPOXEMIA; FIELD; DESATURATION	Study objective: We determine the incidence of desaturation and pulse rate reactivity during paramedic rapid sequence intubation of patients with severe head injuries (Glasgow Coma Scale score less than or equal to58). Methods: Adult patients with severe head injuries had recording oximeter-capnometers applied before rapid sequence intubation. Desaturation was defined as a reduction in oxygen saturation (Sp(O2)) to less than 90% from an initial Sp(O2) of greater than or equal to 90% or a decrease from a baseline of less than 90%. Event records were analyzed with emergency medical services (EMS) run sheets and debriefing reports. Results: Thirty-one (57%) of 54 patients demonstrated desaturation during rapid sequence intubation. Twenty-six (84%) of these 31 events occurred in patients whose initial Sp(O2) value with basic airway skills was greater than or equal to 90%. The median duration of desaturation was 160 seconds (interquartile range 48 to 272 seconds), and the median decrease in Sp(O2) was 22%. Six (19%) patients experienced marked bradycardia (pulse rate <50 beats/min) during desaturation events. Paramedics described rapid sequence intubation as "easy" in 26 (84%) of 31 patients with desaturation. Conclusion: Out-of-hospital rapid sequence intubation by paramedics was complicated by a concerning incidence of desaturation and bradycardia. Paramedic reports did not reflect the presence of these concerning derangements. Most patients had acceptable Sp(O2) values before rapid sequence intubation. An effective strategy for preoxygenation is needed before it can be concluded that rapid sequence intubation is of value in the out-of-hospital care of patients with serious closed head injury.	Univ Calif San Diego, San Diego Med Ctr, Dept Emergency Med, San Diego, CA 92103 USA; Univ Calif San Diego, San Diego Cty Emergency Med Serv, San Diego, CA 92103 USA; Univ Calif San Diego, Dept Surg, Div Trauma, San Diego, CA 92103 USA	Dunford, JV (corresponding author), Univ Calif San Diego, San Diego Med Ctr, Dept Emergency Med, 200 W Arbor Dr,8676, San Diego, CA 92103 USA.	jdunford@ucsd.edu					Adnet F, 2001, CRIT CARE, V5, P290; Baraka AS, 1999, ANESTHESIOLOGY, V91, P612, DOI 10.1097/00000542-199909000-00009; Benumof JL, 1997, ANESTHESIOLOGY, V87, P979, DOI 10.1097/00000542-199710000-00034; Benumof JL, 1999, ANESTHESIOLOGY, V91, P603, DOI 10.1097/00000542-199909000-00006; BERTHOUD M, 1983, ANAESTHESIA, V38, P96, DOI 10.1111/j.1365-2044.1983.tb13925.x; Bochicchio GV, 2003, J TRAUMA, V54, P307, DOI 10.1097/01.TA.0000046252.97590.BE; Bramlett HM, 1999, J NEUROSURG, V91, P653, DOI 10.3171/jns.1999.91.4.0653; Brownstein D, 1996, ANN EMERG MED, V28, P34, DOI 10.1016/S0196-0644(96)70136-1; Bullock RM, 2000, J NEUROTRAUM, V17, P449; BYRNE F, 1987, ANAESTHESIA, V42, P148, DOI 10.1111/j.1365-2044.1987.tb02987.x; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Cooper A, 2001, Semin Pediatr Surg, V10, P3, DOI 10.1053/spsu.2001.19379; Davis Bradley D, 2002, Curr Opin Crit Care, V8, P571, DOI 10.1097/00075198-200212000-00015; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; DAVIS DP, 2003, PREHOSP EMERG CARE, V7, P163; Farmery AD, 1996, BRIT J ANAESTH, V76, P284; GAMBEE AM, 1987, ANESTH ANALG, V66, P468, DOI 10.1213/00000539-198705000-00019; Garner A, 1999, AUST NZ J SURG, V69, P697, DOI 10.1046/j.1440-1622.1999.01688.x; Garner AA, 2002, INJURY, V33, P329, DOI 10.1016/S0020-1383(02)00011-6; Gausche M, 2000, JAMA-J AM MED ASSOC, V283, P783, DOI 10.1001/jama.283.6.783; GOLD MI, 1981, ANESTH ANALG, V60, P313; HEDGES JR, 1988, ANN EMERG MED, V17, P469, DOI 10.1016/S0196-0644(88)80238-5; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; Laffey JG, 2002, NEW ENGL J MED, V347, P43, DOI 10.1056/NEJMra012457; Ma OJ, 1998, AM J EMERG MED, V16, P125, DOI 10.1016/S0735-6757(98)90027-4; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; MATEER JR, 1993, ANN EMERG MED, V22, P675, DOI 10.1016/S0196-0644(05)81846-3; MIZELLE HL, 2002, PREHOSP EMERG CARE, V6, P473; MURPHYMACABOBBY M, 1992, ANN EMERG MED, V21, P664, DOI 10.1016/S0196-0644(05)82776-3; Murray JA, 2000, J TRAUMA, V49, P1065, DOI 10.1097/00005373-200012000-00015; Ochs M, 2002, ANN EMERG MED, V40, P159, DOI 10.1067/mem.2002.126397; Omert L, 2001, J TRAUMA, V51, P1065, DOI 10.1097/00005373-200112000-00007; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; RAEMER DB, 1987, J CLIN MONITOR, V3, P244; RHEE KJ, 1994, ANN EMERG MED, V23, P37, DOI 10.1016/S0196-0644(94)70005-2; Rocca B, 2000, Prehosp Emerg Care, V4, P164, DOI 10.1080/10903120090941443; RUSSELL GN, 1987, ANAESTHESIA, V42, P346, DOI 10.1111/j.1365-2044.1987.tb03972.x; Sing RF, 1996, ACAD EMERG MED, V3, P41, DOI 10.1111/j.1553-2712.1996.tb03301.x; Sing RF, 1998, AM J EMERG MED, V16, P598, DOI 10.1016/S0735-6757(98)90227-3; Sloane C, 2000, J EMERG MED, V19, P259, DOI 10.1016/S0736-4679(00)00235-3; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; SYVERUD SA, 1988, ANN EMERG MED, V17, P236, DOI 10.1016/S0196-0644(88)80114-8; Vilke Gary M., 1994, Journal of Emergency Medicine, V12, P217, DOI 10.1016/0736-4679(94)90702-1; Walls Ron M., 1993, Emergency Medicine Clinics of North America, V11, P53; Wayne M A, 1999, Prehosp Emerg Care, V3, P107, DOI 10.1080/10903129908958916; Winchell RJ, 1997, ARCH SURG-CHICAGO, V132, P592	48	177	179	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644	1097-6760		ANN EMERG MED	Ann. Emerg. Med.	DEC	2003	42	6					721	728		10.1016/S0196-0644(03)00660-7			8	Emergency Medicine	Emergency Medicine	750QW	WOS:000187009300001	14634593				2021-06-18	
J	Elf, K; Nilsson, P; Enblad, P				Elf, K; Nilsson, P; Enblad, P			Outcome after traumatic brain injury improved by an organized secondary insult program and standardized neurointensive care	CRITICAL CARE MEDICINE			English	Article						traumatic brain injury; neurointensive care; secondary insults; standardized treatment protocol; outcome	SEVERE HEAD-INJURY; AGGRESSIVE TREATMENT; GUIDELINES; MANAGEMENT; COMA; TALK	Objective. To evaluate today's refined neurosurgical intensive care of patients with traumatic brain injury after implementation of an organized secondary insult program focused on the importance of avoiding secondary brain damage together with a Standardized treatment protocol system. Design: Clinical observational patient study. Patients: A total of 154 patients 16-79 yrs of age with acute. head trauma and pathologic computed tomographic findings treated between 1996 and 1997. Setting: Neurointensive care unit. Interventions: None. Measurements and Main Results: Good recovery was obtained in 44% of the patients, moderate disability in 35%, severe disability in 16%, and no patient remained in a vegetative state. Six percent of the patients died, but only two of these patients (1.3%) died as direct result of their head injury. When the results for patients with Glasgow Coma Scale motor scores of greater than or equal to4 were compared with the periods 1980-1981 (preneurosurgical intensive care) and 1987-1988 (basic neurosurgical intensive care), mortality had decreased from 40% in the first period to 27% in the second period and to 2.8% in the present series. Favorable outcome in the same group of patients had increased steadily from 40% in the first period, to 68% in the second period, and finally, to 84% in the present series. Conclusions: The main observation in this hospital series of traumatic brain injury patients was a low rate of death directly caused by head injury and a high rate of favorable outcome. The comparison of patients with Glasgow Coma Scale motor scores of greater than or equal to4 with the previously reported results from the same unit indicate that substantial improvement in outcome has been achieved.	Univ Uppsala Hosp, Neurosurg Sect, Dept Neurosci, S-75185 Uppsala, Sweden	Enblad, P (corresponding author), Univ Uppsala Hosp, Neurosurg Sect, Dept Neurosci, S-75185 Uppsala, Sweden.	Per.Enblad@neurokir.uu.se					ANDREWS BT, 1991, NEUROSURGERY, V29, P227, DOI 10.1227/00006123-199108000-00010; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BOWERS SA, 1980, NEUROSURGERY, V6, P237; Bullock MR, 1996, J NEUROTRAUM, V13, P643; Combes P, 1996, INTENS CARE MED, V22, P1391, DOI 10.1007/s001340050269; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARSHALL LF, 1979, J NEUROSURG, V50, P26, DOI 10.3171/jns.1979.50.1.0026; NORDSTROM CH, 1988, BRAIN INJURY, V3, P267; REILLY PL, 1975, LANCET, V2, P375; ROSE J, 1977, BRIT MED J, V2, P615, DOI 10.1136/bmj.2.6087.615; TEASDALE G, 1974, LANCET, V2, P81; WARME PE, 1991, ACTA NEUROCHIR, V110, P57, DOI 10.1007/BF01402049; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	17	177	181	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	SEP	2002	30	9					2129	2134		10.1097/00003246-200209000-00029			6	Critical Care Medicine	General & Internal Medicine	599XC	WOS:000178359600028	12352052				2021-06-18	
J	Esenaliev, RO; Larina, IV; Larin, KV; Deyo, DJ; Motamedi, M; Prough, DS				Esenaliev, RO; Larina, IV; Larin, KV; Deyo, DJ; Motamedi, M; Prough, DS			Optoacoustic technique for noninvasive monitoring of blood oxygenation: a feasibility study	APPLIED OPTICS			English	Article							BRAIN; HEMOGLOBIN; SATURATION	Replacement of invasive monitoring of cerebral venous oxygenation with noninvasive techniques offers great promise in the management of life-threatening neurologic illnesses including traumatic brain injury. We developed and built an optoacoustic system to noninvasively monitor cerebral venous oxygenation; the system includes a nanosecond Nd:YAG laser and a specially designed optoacoustic probe. We tested the system in vitro in sheep blood with experimentally varied oxygenation. Our results demonstrated that (1) the amplitude and temporal profile of the optoacoustic waves increase with blood oxygenation in the range from 24% to 92%, (2) optoacoustic signals can be detected despite optical and acoustic attenuation by thick bone, and (3) the system is capable of real-time and continuous measurements. These results suggest that the optoacoustic technique is technically feasible for continuous, noninvasive monitoring of cerebral venous oxygenation. (C) 2002 Optical Society of America.	Univ Texas, Med Branch, Lab Opt Sensing & Monitoring, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Physiol & Biophys, Galveston, TX 77555 USA; Univ Texas, Med Branch, Ctr Biomed Engn, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA	Esenaliev, RO (corresponding author), Univ Texas, Med Branch, Lab Opt Sensing & Monitoring, 301 Univ Blvd, Galveston, TX 77555 USA.	rinat.esenaliev@utmb.edu	Esenaliev, Rinat/Y-4361-2019; Prough, Donald S/G-5793-2013	Esenaliev, Rinat/0000-0002-2848-5906; Prough, Donald S/0000-0001-7994-532X	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1 R21 NS40531-01] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS040531] Funding Source: NIH RePORTER		CHANCE B, 1988, P NATL ACAD SCI USA, V85, P4971, DOI 10.1073/pnas.85.14.4971; CROUGHWELL ND, 1994, ANN THORAC SURG, V58, P1702, DOI 10.1016/0003-4975(94)91666-7; Esenaliev R, 2000, PROC SPIE, V3916, P302, DOI 10.1117/12.386334; Esenaliev RO, 1999, IEEE J SEL TOP QUANT, V5, P981, DOI 10.1109/2944.796320; Esenaliev RO, 1998, P SOC PHOTO-OPT INS, V3254, P294, DOI 10.1117/12.308176; Esenaliev RO, 2000, OSA TRENDS OPT PHOTO, V38, P272; ESENALIEV RO, 1993, LASER SURG MED, V13, P470, DOI 10.1002/lsm.1900130412; GOPINATH SP, 1994, J NEUROL NEUROSUR PS, V57, P717, DOI 10.1136/jnnp.57.6.717; Gusev V.E., 1993, LASER OPTOACOUSTICS; Larin K, 2000, PROC SPIE, V3916, P311, DOI 10.1117/12.386336; Newman MF, 1997, ANESTH ANALG, V84, pS111; ORAEVSKY AA, 1994, P SOC PHOTO-OPT INS, V2134, P122; ORAEVSKY AA, 1996, OSA TRENDS OPTICS PH, V2, P316; PATTERSON MS, 1989, APPL OPTICS, V28, P2331, DOI 10.1364/AO.28.002331; Pollard V, 1996, ANESTH ANALG, V82, P278, DOI 10.1097/00000539-199602000-00011; Pollard V, 1996, ANESTH ANALG, V82, P269, DOI 10.1097/00000539-199602000-00010; Pollard V., 1988, PRINCIPLES PRACTICE, P1019; Prough D. S., 1999, MISSILE WOUNDS HEAD, P221; WELCH AJ, 1981, OPTICAL THERMAL RESP; WRAY S, 1988, BIOCHIM BIOPHYS ACTA, V933, P184, DOI 10.1016/0005-2728(88)90069-2; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011	21	177	182	0	10	OPTICAL SOC AMER	WASHINGTON	2010 MASSACHUSETTS AVE NW, WASHINGTON, DC 20036 USA	1559-128X	2155-3165		APPL OPTICS	Appl. Optics	AUG 1	2002	41	22					4722	4731		10.1364/AO.41.004722			10	Optics	Optics	579NY	WOS:000177185800041	12153109				2021-06-18	
J	Miller, IW; Ryan, CE; Keitner, GI; Bishop, DS; Epstein, NB				Miller, IW; Ryan, CE; Keitner, GI; Bishop, DS; Epstein, NB			The McMaster Approach to Families: theory, assessment, treatment and research	JOURNAL OF FAMILY THERAPY			English	Article							TRAUMATIC BRAIN INJURY; ONTARIO-CHILD-HEALTH; ASSESSMENT DEVICE; MAJOR DEPRESSION; PSYCHIATRIC-INPATIENTS; SUICIDAL-BEHAVIOR; POOR ADJUSTMENT; CHRONIC ILLNESS; STROKE; ADOLESCENTS	The McMaster Approach to Families is a comprehensive model of family assessment and treatment. This paper provides an overview of the McMaster Approach and consists of five major sections. First, the underlying theoretical model (McMaster Model of Family Functioning) is described. Second, the three assessment instruments of the approach (Family Assessment Device, McMaster Clinical Rating Scale, McMaster Structured Interview of Family Functioning) and their psychometric properties are summarized. Third, the family treatment model (Problem Centered Systems Therapy of the Family) is presented. Fourth, the research conducted using the McMaster Approach is reviewed. Finally, the clinical uses and advantages of the McMaster Approach are discussed.	Brown Univ, Rhode Isl Hosp, Dept Psychiat & Human Behav, Providence, RI 02903 USA	Miller, IW (corresponding author), Brown Univ, Rhode Isl Hosp, Dept Psychiat & Human Behav, Potter 3,593 Eddy St, Providence, RI 02903 USA.						AKISTER J, 1991, FAMILY THERAPY, V13, P63; ARPIN K, 1990, J CLIN EPIDEMIOL, V43, P373, DOI 10.1016/0895-4356(90)90123-7; BISHOP D, 1984, J FAM THER, V6, P323, DOI 10.1046/j.1467-6427.1984.00653.x; BISHOP D, UNPUB TELEPHONE ADM; BISHOP D, 1987, ARCH PHYSICAL MED RE, V68, P79; Bishop D., 1980, MCMASTER STRUCTURED; Bishop D., 1997, FAMILY INTERVENTION; BISHOP DS, 1986, ARCH PHYS MED REHAB, V67, P84, DOI 10.1016/0003-9993(86)90107-3; Bishop DS, 1988, J HEAD TRAUMA REHAB, V3, P16; BISHOP DS, 1984, FAM SYST MED, V2, P380; BROWNE GB, 1990, MED CARE, V28, P43, DOI 10.1097/00005650-199001000-00006; BYLES J, 1988, FAM PROCESS, V27, P97, DOI 10.1111/j.1545-5300.1988.00097.x; BYLES J, 1983, J MARITAL FAM THER, V9, P299, DOI 10.1111/j.1752-0606.1983.tb01514.x; CUNNINGHAM CE, 1988, J CLIN CHILD PSYCHOL, V17, P169, DOI 10.1207/s15374424jccp1702_10; Dickstein S, 1998, J FAM PSYCHOL, V12, P23, DOI 10.1037/0893-3200.12.1.23; EPSTEIN N, 1982, NORMAL FAMILY PROCES, P15; Epstein N. B., 1993, NORMAL FAMILY PROCES, P138; EPSTEIN NB, 1981, J MARITAL FAM THER, V7, P23, DOI 10.1111/j.1752-0606.1981.tb01348.x; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; EPSTEIN NB, 1978, J MARRIAGE FAM COUNS, V4, P19, DOI 10.1111/j.1752-0606.1978.tb00537.x; EPSTEIN NB, 1988, TREATMENT MANUAL PRO; EPSTEIN NB, 1990, HDB BRIEF PSYCHOTHER, P405; EVANS R, 1986, ARCH PHYSICAL MED RE, V67, P84; EVANS RL, 1987, PSYCHOL REP, V60, P691, DOI 10.2466/pr0.1987.60.3.691; EVANS RL, 1987, ARCH PHYS MED REHAB, V68, P508; EVANS RL, 1987, ARCH PHYS MED REHAB, V68, P513; EVANS RL, 1984, SOC WORK HEALTH CARE, V9, P77, DOI 10.1300/J010v09n03_07; EVANS RL, 1991, ARCH PHYS MED REHAB, V72, P144; EVANS RL, 1988, STROKE, V19, P1243, DOI 10.1161/01.STR.19.10.1243; First M., 1994, STRUCTURED CLIN INTE; Friedmann MS, 1997, FAM PROCESS, V36, P357, DOI 10.1111/j.1545-5300.1997.00357.x; FRISTAD MA, 1989, J MARITAL FAM THER, V15, P259, DOI 10.1111/j.1752-0606.1989.tb00808.x; GOODYER I, 1982, J FAM THER, V4, P373, DOI 10.1046/j..1982.00599.x; Hayden LC, 1998, J FAM PSYCHOL, V12, P7, DOI 10.1037/0893-3200.12.1.7; JOFFE RT, 1988, AM J PSYCHIAT, V145, P1420; Kabacoff R.I., 1990, J FAMILY PSYCHOL, V3, P431, DOI [10.1037/h0080547, DOI 10.1037/H0080547]; KEITNER GI, 1987, PSYCHIATRY, V50, P242, DOI 10.1080/00332747.1987.11024356; KEITNER GI, 1987, COMPR PSYCHIAT, V28, P54; KEITNER GI, 1992, AM J PSYCHIAT, V149, P93; KEITNER GI, 1991, AM J PSYCHIAT, V148, P345; KEITNER GI, 1995, AM J PSYCHIAT, V152, P1002; KEITNER GI, 1990, PSYCHIATRY, V53, P17; KEITNER GL, 1986, INT J FAM THER, V18, P203; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; LIEPMAN MR, 1989, FAM PROCESS, V28, P239, DOI 10.1111/j.1545-5300.1989.00239.x; LIVINGSTON B, 1988, OBSESSIONS COMPULSIO, P248; Max JE, 1998, J AM ACAD CHILD PSY, V37, P83, DOI 10.1097/00004583-199801000-00021; Max JE, 1997, J AM ACAD CHILD PSY, V36, P1278, DOI 10.1097/00004583-199709000-00021; MAZIADE M, 1985, AM J PSYCHIAT, V142, P943; MAZIADE M, 1987, AM J PSYCHIAT, V144, P144; MCDERMUT W, UNPUB FAMILY FUNCTIO; MCKAY JR, 1991, J AM ACAD CHILD PSY, V30, P967, DOI 10.1097/00004583-199111000-00015; MILLER I, UNPUB FAMILY FUNCTIO; MILLER IW, 1994, FAM PROCESS, V33, P53, DOI 10.1111/j.1545-5300.1994.00053.x; MILLER IW, 1986, COMPR PSYCHIAT, V27, P302, DOI 10.1016/0010-440X(86)90006-4; MILLER IW, 1992, J ABNORM PSYCHOL, V101, P637, DOI 10.1037/0021-843X.101.4.637; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; MILLER IW, UNPUB MATCHED VS MIS; MORRIS TM, 1990, FAM PROCESS, V29, P105, DOI 10.1111/j.1545-5300.1990.00105.x; North C, 1997, BRIT J PSYCHIAT, V171, P545, DOI 10.1192/bjp.171.6.545; ROY R, 1990, CONTEMP FAM THER, V12, P489, DOI 10.1007/BF00901037; SAAYMAN GS, 1988, J DIVORCE, V12, P329; SAWYER MG, 1988, J MARITAL FAM THER, V14, P287, DOI 10.1111/j.1752-0606.1988.tb00748.x; WALLER G, 1990, BRIT J PSYCHIAT, V156, P546, DOI 10.1192/bjp.156.4.546; WENNIGER WFMDB, 1993, PERS INDIV DIFFER, V14, P769, DOI 10.1016/0191-8869(93)90090-P; WOODWARD CA, 1978, AM J ORTHOPSYCHIAT, V48, P464, DOI 10.1111/j.1939-0025.1978.tb01335.x; ZARSKI J, 1988, J HEAD TRAUMA REHAB, V3, P31	67	177	205	2	43	BLACKWELL PUBL LTD	OXFORD	108 COWLEY RD, OXFORD OX4 1JF, OXON, ENGLAND	0163-4445			J FAM THER	J. Fam. Ther.	MAY	2000	22	2					168	189		10.1111/1467-6427.00145			22	Psychology, Clinical; Family Studies	Psychology; Family Studies	317NQ	WOS:000087231800004					2021-06-18	
J	Signorini, DF; Andrews, PJD; Jones, PA; Wardlaw, JM; Miller, JD				Signorini, DF; Andrews, PJD; Jones, PA; Wardlaw, JM; Miller, JD			Predicting survival using simple clinical variables: a case study in traumatic brain injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article						traumatic brain injury; prognosis; trauma; clinical audit; survival	SEVERE HEAD-INJURY; MORTALITY PROBABILITY-MODELS; INTENSIVE-CARE UNIT; INDIVIDUAL PATIENTS; PROGNOSTIC MODELS; CLASSIFICATION; PROTEIN; SCORE; COMA	Objectives-Prediction of patient outcome can be useful as an aid to clinical decision making, to explore possible biological mechanisms, and as part of the clinical audit process. Many studies have constructed predictive models for survival after traumatic brain injury, but these have often used expensive, time consuming, or highly specialised measurements. The aim of this study was to develop a simple easy to use model involving only variables which are rapidly and easily clinically achievable in routine practice. Methods-All consecutive patients admitted to a regional trauma centre with moderate or severe head injury were enrolled in the study. Basic demographic, injury, and CT characteristics were recorded. Patient survival at 1 year was used to construct a simple predictive model which was then validated on a very similar patient group. Results-372 patients were included in the study, of whom 365 (98%) were followed up for survival at 1 year. Multiple logistic regression resulted in a model containing age (p<0.001), Glasgow coma scale score (p<0.001), injury severity score (p<0.001), pupil reactivity (p=0.004), and presence of haematoma on CT (p=0.004) as independently significant predictors of survival. The model was validated on an independent set of 520 patients, showing good discrimination and adequate calibration, but with a tendency to be pessimistic about very severely injured patients. It is presented as an easy to use nomogram. Conclusions-All five variables have previously been shown co be related to survival. All variables in the model are clinically simple and easy to measure rapidly in a centre with access to 24 hour CT, resulting in a model that is both well validated and clinically useful.	Univ Edinburgh, Dept Clin Neurosci, Edinburgh EH8 9YL, Midlothian, Scotland; Univ Edinburgh, Dept Anaesthet, Edinburgh EH8 9YL, Midlothian, Scotland	Signorini, DF (corresponding author), Univ Edinburgh, Western Gen Hosp, Dept Clin Neurosci, Bramwell Dott Bldg,Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.						ALEXANDER E, 1992, SURG NEUROL, V38, P478, DOI 10.1016/0090-3019(92)90124-6; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BARLOW P, 1984, J MICROCOMPUT APPL, V7, P271, DOI 10.1016/0745-7138(84)90059-9; Braitman LE, 1996, ANN INTERN MED, V125, P406, DOI 10.7326/0003-4819-125-5-199609010-00008; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; CHOI SC, 1988, J NEUROSURG, V69, P381, DOI 10.3171/jns.1988.69.3.0381; Cormio M, 1997, J CLIN NEUROSCI, V4, P132, DOI 10.1016/S0967-5868(97)90062-X; Dybowski R, 1996, LANCET, V347, P1146, DOI 10.1016/S0140-6736(96)90609-1; FELDMAN Z, 1991, LANCET, V337, P1451, DOI 10.1016/0140-6736(91)93137-X; GENNARELLI TA, 1989, J TRAUMA, V29, P1193, DOI 10.1097/00005373-198909000-00002; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GIBSON RM, 1989, LANCET, V2, P369; Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4; HARRELL FE, 1997, DESIGN S PLUS FUNCTI; Hastie T.J., 1990, GEN ADDITIVE MODELS; Heinzelmann M, 1996, INJURY, V27, P345, DOI 10.1016/0020-1383(95)00223-5; Hosmer D, 1989, APPL LOGISTIC REGRES; JENCKS SF, 1988, JAMA-J AM MED ASSOC, V260, P3611, DOI 10.1001/jama.260.24.3611; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; JENNETT B, 1976, LANCET, V1, P1031; LEMESHOW S, 1993, JAMA-J AM MED ASSOC, V270, P2478, DOI 10.1001/jama.270.20.2478; LEMESHOW S, 1994, CRIT CARE MED, V22, P1351, DOI 10.1097/00003246-199409000-00003; MARSHALL LF, 1991, J NEUROSURG S, V75, P28; Marshall SB, 1991, J NEUROSURG S, V75, P14; Nicoll JAR, 1996, ANN NY ACAD SCI, V777, P271, DOI 10.1111/j.1749-6632.1996.tb34431.x; PIPER IR, 1991, BR J INTENS CARE, V1, P73; PREGIBON D, 1981, ANN STAT, V9, P705, DOI 10.1214/aos/1176345513; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; STABLEIN DM, 1980, NEUROSURGERY, V6, P243; TEASDALE GM, 1997, J NEUROL NEUROSUR PS, V63, P123; TEMKIN NR, 1995, J NEUROSURG, V82, P764, DOI 10.3171/jns.1995.82.5.0764; TITTERINGTON DM, 1981, J ROY STAT SOC A STA, V144, P145, DOI 10.2307/2981918; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; WILLIAMS JM, 1984, J NEUROSURG, V61, P581, DOI 10.3171/jns.1984.61.3.0581; WYATT JC, 1995, BMJ-BRIT MED J, V311, P1539, DOI 10.1136/bmj.311.7019.1539	39	177	187	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JAN	1999	66	1					20	25		10.1136/jnnp.66.1.20			6	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	154DC	WOS:000077872500007	9886445	Green Published, Bronze			2021-06-18	
J	Marsh, NV; Kersel, DA; Havill, JH; Sleigh, JW				Marsh, NV; Kersel, DA; Havill, JH; Sleigh, JW			Caregiver burden at 1 year following severe traumatic brain injury	BRAIN INJURY			English	Article							SOCIAL ADJUSTMENT; HEAD-INJURY; SELF-REPORT; FAMILY; DEPRESSION; ADULTS	Sixty-nine primary caregivers of adults with a severe traumatic brain injury (TBI) were assessed at 1-year post-injury. Caregivers completed questionnaires on the physical, cognitive, emotional, behavioural, and social functioning of the person with TBI. Caregiver objective burden, psychosocial functioning and subjective burden were also assessed. Clinically significant levels of anxiety and depression were evident in over a third of the caregivers. Similarly, a quarter of the caregivers reported poor social adjustment. There was no consistent relationship between the prevalence of various types of objective burden and the level of subjective distress that resulted from these changes. The person with TBI's emotional difficulties, in particular their anger, apathy, and dependency, caused the greatest distress for caregivers. With regard to the impact that caregiving had on their own lives, caregivers were most distressed by the loss of personal free time. Results from a regression analysis indicated that the person with TBI's physical impairment, number of behavioural problems, and social isolation were the strongest predictors of caregiver burden. The impact that caring for a person with severe TBI can have on the extended family unit is discussed.	Univ Waikato, Dept Psychol, Hamilton, New Zealand; Waikato Hosp, Intens Care Unit, Hamilton, New Zealand	Marsh, NV (corresponding author), Univ Waikato, Dept Psychol, Private Bag 3105, Hamilton, New Zealand.		Marsh, Nigel V./F-5433-2019	Marsh, Nigel V./0000-0002-4060-6432			ALLEN K, 1994, REHABIL PSYCHOL, V39, P29, DOI 10.1037/h0080313; BECK AT, 1972, POSTGRAD MED, V52, P81, DOI 10.1080/00325481.1972.11713319; BROOKS DN, 1991, J CLIN EXP NEUROPSYC, V13, P155, DOI 10.1080/01688639108407214; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; FLORIAN V, 1991, NEUROPSYCHOLOGY, V5, P267, DOI DOI 10.1037/0894-4105.5.4.267; GILLEN RW, 1994, ARCH CLIN NEUROPSYCH, V9, P130; GRAD J, 1963, LANCET, V1, P544; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; HAMMELL KRW, 1994, INT J REHABIL RES, V17, P319; Havill JH, 1998, NEW ZEAL MED J, V111, P161; JENNETT B, 1975, LANCET, V1, P480; KAUSAR R, 1996, CLIN REHABIL, V10, P159; KNIGHT RG, 1984, J CLIN PSYCHOL, V40, P751, DOI 10.1002/1097-4679(198405)40:3<751::AID-JCLP2270400320>3.0.CO;2-Y; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; LIVINGSTON M, 1988, J HEAD TRAUMA REHAB, V3, P6, DOI DOI 10.1097/00001199-198812000-00004; Marsh NV, 1990, NEUROPSYCHOLOGY, V4, P13, DOI 10.1037/0894-4105.4.1.13; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; McGregor K, 1997, SOC SCI MED, V45, P295, DOI 10.1016/S0277-9536(96)00345-0; MITCHLEY N, 1996, CLIN REHABIL, V10, P3; NOVACK TA, 1991, J HEAD TRAUMA REHAB, V6, P69, DOI DOI 10.1097/00001199-199112000-00014; Panting A., 1972, REHABILITATION, V38, P33; Smith L.M., 1995, FAMILY SUPPORT PROGR; SPIELBERGER CD, 1983, MANUAL STATE TRAIT A; Tabachnick BG, 2013, USING MULTIVARIATE S; TEASDALE G, 1974, LANCET, V2, P81; Walker A E, 1972, Scand J Rehabil Med, V4, P5; WEISSMAN MM, 1978, J NERV MENT DIS, V166, P317, DOI 10.1097/00005053-197805000-00002; WEISSMAN MM, 1976, ARCH GEN PSYCHIAT, V33, P1111	32	177	182	0	5	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	DEC	1998	12	12					1045	1059		10.1080/026990598121954			15	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	150BW	WOS:000077643400005	9876864				2021-06-18	
J	ASGEIRSSON, B; GRANDE, PO; NORDSTROM, CH				ASGEIRSSON, B; GRANDE, PO; NORDSTROM, CH			A NEW THERAPY OF POSTTRAUMA BRAIN EDEMA BASED ON HEMODYNAMIC PRINCIPLES FOR BRAIN VOLUME REGULATION	INTENSIVE CARE MEDICINE			English	Article						HEAD TRAUMA; BRAIN EDEMA; CAPILLARY HYDROSTATIC PRESSURE; COLLOID OSMOTIC PRESSURE; DIHYDROERGOTAMINE; HYPOTENSION	CEREBRAL BLOOD-FLOW; SEVERE HEAD-INJURY; RAISED INTRACRANIAL-PRESSURE; BARBITURATE THERAPY; PERFUSION-PRESSURE; COMATOSE PATIENTS; HYPERTENSION; MANAGEMENT; VASOREACTIVITY; CHILDREN	Objective: To evaluate a new therapy of post-traumatic brain oedema, with the main concept that opening of the blood-brain barrier upsets the normal brain volume regulation, inducing oedema formation. This means that transcapillary fluid fluxes will be controlled by hydrostatic capillary and colloid osmotic pressures, rather than by crystalloid osmotic pressure. If so, brain oedema therapy should include reduction of hydrostatic capillary pressure and preservation of normal colloid osmotic pressure. Patients: 11 severely head injured comatose patients with brain swelling, raised intracranial pressure (ICP), and impaired cerebrovascular response to hyperventilation. Interventions: To reduce capillary hydrostatic pressure the patients were given hypotensive therapy (beta1-antagonist, metoprolol and alpha2-agonist, clonidine) and a potential precapillary vasoconstrictor (dihydroergotamine). The latter may also decrease cerebral blood volume through venous capacitance constriction. Colloid osmotic pressure was maintained by albumin infusions. The concept implies the need of a negative fluid balance with preserved normovolaemia. Results: ICP decreased significantly within a few hours of treatment with unaltered perfusion pressure in spite of lowered blood pressure. Of 11 patients 9 survived with good recovery/moderate disability, 2 died. This was compared to outcome in a historical control group with identical entry criteria, given conventional brain oedema therapy, where mortality/vegetativity/severe disability was 100%. Conclusion: The results indicate that the therapy should focus on extracellular rather than intracellular oedema and that ischemia is not the main triggering mechanism behind oedema formation. We suggest that our therapy is superior to conventional therapy by preventing herniation during the healing period of the blood-brain barrier.	UNIV LUND HOSP,DEPT ANAESTHESIA & INTENS CARE,S-22185 LUND,SWEDEN; LUND UNIV,DEPT PHYSIOL & BIOPHYS,S-22362 LUND,SWEDEN; UNIV LUND HOSP,DEPT NEUROSURG,S-22185 LUND,SWEDEN							ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; BOREL C, 1990, CHEST, V198, P180; BOUMA GJ, 1992, J NEUROTRAUMA S1, V9, P333; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; CLIFTON GL, 1983, J NEUROSURG, V59, P447, DOI 10.3171/jns.1983.59.3.0447; COLD GE, 1989, ACTA NEUROCHIR, V96, P100, DOI 10.1007/BF01456166; COLD GE, 1977, ACTA ANAESTH SCAND, V21, P222; CRUICKSHANK JM, 1987, LANCET, V1, P585; DEARDEN NM, 1986, BRIT J HOSP MED, V36, P94; DOCZI T, 1987, TRAUMATIC BRAIN OEDE, V8, P153; FENSTERMACHER JD, 1984, VOLUME REGULATION CE, P383; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; GRANDE PO, 1990, INTENS CARE MED, V16, P399, DOI 10.1007/BF01735179; GRANDE PO, 1989, INTENS CARE MED, V15, P523, DOI 10.1007/BF00273564; GRANDE PO, 1993, RECENT ADVANCES IN NEUROTRAUMATOLOGY, P319; GUNNING K, 1989, UPDATE INTENSIVE CAR, V9, P198; JENNETT B, 1989, GENERAL ANAESTHESIA, V109, P1304; Jennett B, 1991, J NEUROTRAUMA S1, V8, P15; KAUFMANN AM, 1992, J NEUROSURG, V77, P584, DOI 10.3171/jns.1992.77.4.0584; LANGFITT TW, 1982, J NEUROSURG, V56, P19, DOI 10.3171/jns.1982.56.1.0019; MARMAROU A, 1991, J NEUROSURG S, V75, P59; MCCLAIN CJ, 1988, J NEUROSURG, V69, P386, DOI 10.3171/jns.1988.69.3.0386; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; MESSETER K, 1986, J NEUROSURG, V64, P231, DOI 10.3171/jns.1986.64.2.0231; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; MILLER JD, 1992, J NEUROTRAUMA S1, V9, P317; NORDSTROM CH, 1988, J NEUROSURG, V68, P424, DOI 10.3171/jns.1988.68.3.0424; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; PAPPIUS HM, 1989, IMPLICATIONS BLOOD B, V1, P293; PIATT JH, 1984, NEUROSURGERY, V15, P427, DOI 10.1227/00006123-198409000-00023; PO Grande, 1992, SWEDISH SOC ANAESTHE, V6, P41; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; ROTH B, 1993, INTENS CARE MED, V19, P111, DOI 10.1007/BF01708372; SCHALEN W, 1992, ACTA ANAESTH SCAND, V36, P369, DOI 10.1111/j.1399-6576.1992.tb03483.x; SCHALEN W, 1991, ACTA ANAESTH SCAND, V35, P113, DOI 10.1111/j.1399-6576.1991.tb03258.x; SCHUTTA HS, 1986, BRAIN, V91, P281; SIMARD JM, 1989, AM J CARDIOL, V63, pC32, DOI 10.1016/0002-9149(89)90403-7; TODD NV, 1990, ACT NEUR S, V51, P296; WARD JD, 1985, J NEUROSURG, V62, P383, DOI 10.3171/jns.1985.62.3.0383; WHITE RJ, 1992, NEW ENGL J MED, V327, P1507; YADA K, 1973, J NEUROSURG, V39, P723, DOI 10.3171/jns.1973.39.6.0723	43	177	184	0	10	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0342-4642			INTENS CARE MED	Intensive Care Med.	APR	1994	20	4					260	267		10.1007/BF01708961			8	Critical Care Medicine	General & Internal Medicine	NJ338	WOS:A1994NJ33800006	8046119				2021-06-18	
J	GENTRY, LR				GENTRY, LR			IMAGING OF CLOSED-HEAD INJURY	RADIOLOGY			English	Article						BRAIN, HEMORRHAGE; HEAD, INJURIES; STATE-OF-ART REVIEWS	TRAUMATIC BRAIN INJURY; CEREBRAL BLOOD-FLOW; MAGNETIC-RESONANCE SPECTROSCOPY; DIFFUSE AXONAL INJURY; FAST SPIN-ECHO; MR ANGIOGRAPHY; MP-RAGE; COMPUTERIZED-TOMOGRAPHY; INITIAL EXPERIENCE; CLINICAL MR			GENTRY, LR (corresponding author), UNIV WISCONSIN HOSP & CLIN, DEPT RADIOL, NEURORADIOL SECT, E3-311 CSC, MADISON, WI 53792 USA.						ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; ADAMS JH, 1984, GREENFIELDS NEUROPAT, P85; ATLAS SW, 1988, RADIOLOGY, V168, P803, DOI 10.1148/radiology.168.3.3406410; BAYKANER K, 1988, SURG NEUROL, V30, P339, DOI 10.1016/0090-3019(88)90195-4; BRANTZAWADZKI M, 1992, RADIOLOGY, V182, P769, DOI 10.1148/radiology.182.3.1535892; COHEN Y, 1991, MAGNET RESON MED, V17, P225, DOI 10.1002/mrm.1910170125; COOPER PR, 1987, HEAD INJURY, P238; DEAN BL, 1992, AM J NEURORADIOL, V13, P39; Frankowski RF, 1985, CENTRAL NERVOUS SYST, P33; GENNARELLI TA, 1985, TRAUMA CENTRAL NERVO, P169; Gentry L.R., 1990, MAGNETIC RESONANCE I, P439; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1988, AM J NEURORADIOL, V9, P91; GENTRY LR, 1989, RADIOLOGY, V171, P177, DOI 10.1148/radiology.171.1.2928523; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; GENTRY LR, 1990, MAR ANN M AM SOC NEU; GODERSKY JC, 1990, ACT NEUR S, V51, P311; GOMORI JM, 1985, RADIOLOGY, V157, P87, DOI 10.1148/radiology.157.1.4034983; GOOD WF, 1991, AM J NEURORADIOL, V12, P83; GRAY BG, 1992, J NUCL MED, V33, P52; Hardman J M, 1979, Adv Neurol, V22, P15; HENNIG J, 1986, MAGNET RESON MED, V3, P823, DOI 10.1002/mrm.1910030602; Holbourn AHS, 1943, LANCET, V2, P438; HOLBOURN AHS, 1945, BRIT MED BULL, V3, P147, DOI 10.1093/oxfordjournals.bmb.a071895; JENKINS A, 1986, LANCET, V2, P445; JOHNSON DW, 1991, AM J NEURORADIOL, V12, P201; JONES KM, 1992, AM J ROENTGENOL, V158, P1313, DOI 10.2214/ajr.158.6.1590133; JONES KM, 1992, RADIOLOGY, V182, P53, DOI 10.1148/radiology.182.1.1727309; KALENDER WA, 1990, RADIOLOGY, V176, P181, DOI 10.1148/radiology.176.1.2353088; KANAL E, 1992, RADIOLOGY, V185, P623, DOI 10.1148/radiology.185.3.1438733; KARLIK SJ, 1988, MAGNET RESON MED, V7, P210, DOI 10.1002/mrm.1910070209; KATZ DI, 1989, NEUROLOGY, V39, P897, DOI 10.1212/WNL.39.7.897; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; KING MD, 1992, MAGNET RESON MED, V24, P288, DOI 10.1002/mrm.1910240210; KUCHARCZYK J, 1991, MAGNET RESON MED, V19, P311, DOI 10.1002/mrm.1910190220; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; LEE C, 1992, AM J NEURORADIOL, V13, P277; LEVIN DN, 1988, RADIOLOGY, V169, P817, DOI 10.1148/radiology.169.3.3263666; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; MASARYK TJ, 1989, RADIOLOGY, V171, P793, DOI 10.1148/radiology.171.3.2717754; MATTLE H, 1991, RADIOLOGY, V181, P527, DOI 10.1148/radiology.181.2.1924799; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; MOHANTY SK, 1991, J TRAUMA, V31, P801, DOI 10.1097/00005373-199106000-00010; MUGLER JP, 1991, JMRI-J MAGN RESON IM, V1, P561, DOI 10.1002/jmri.1880010509; ORRISON WW, IN PRESS AJNR; PISTOIA F, 1991, AM J NEURORADIOL, V12, P97; RANGO M, 1990, ANN NEUROL, V28, P661, DOI 10.1002/ana.410280510; RAO N, 1984, ARCH PHYS MED REHAB, V65, P780; REID RH, 1990, CLIN NUCL MED, V15, P383, DOI 10.1097/00003072-199006000-00003; RIPPE DJ, 1990, AM J NEURORADIOL, V11, P199; ROSEN BR, 1991, MAGNET RESON MED, V22, P293, DOI 10.1002/mrm.1910220227; RUNGE VM, 1991, JMRI-J MAGN RESON IM, V1, P493, DOI 10.1002/jmri.1880010417; SATO Y, 1989, RADIOLOGY, V173, P653, DOI 10.1148/radiology.173.3.2813768; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Shellock F G, 1986, Med Electron, V17, P93; SHELLOCK FG, 1992, AM J ROENTGENOL, V158, P663, DOI 10.2214/ajr.158.3.1739016; SHIOGAI T, 1990, Neurological Research, V12, P205; SHOGRY MEC, 1992, J COMPUT ASSIST TOMO, V16, P48, DOI 10.1097/00004728-199201000-00009; STEIN SC, 1990, NEUROSURGERY, V26, P638, DOI 10.1227/00006123-199004000-00012; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Tomei G, 1991, J Neurosurg Sci, V35, P61; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; Vink R, 1988, J NEUROTRAUM, V5, P315, DOI 10.1089/neu.1988.5.315; WAGLE WA, 1989, AM J NEURORADIOL, V10, P911; WARACH S, 1992, RADIOLOGY, V182, P41, DOI 10.1148/radiology.182.1.1727307; WEBER M, 1990, NEUROSURGERY, V27, P106, DOI 10.1227/00006123-199007000-00015; WILBERGER JE, 1987, NEUROSURGERY, V20, P571, DOI 10.1227/00006123-198704000-00011; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; ZIMMERMAN RA, 1982, RADIOLOGY, V144, P809, DOI 10.1148/radiology.144.4.7111729; ZIMMERMAN RA, 1991, NEUROIMAG CLIN N AM, V1, P443	75	177	196	0	0	RADIOLOGICAL SOC NORTH AMERICA	OAK BROOK	820 JORIE BLVD, OAK BROOK, IL 60523 USA	0033-8419			RADIOLOGY	Radiology	APR	1994	191	1					1	17					17	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	NB685	WOS:A1994NB68500002	8134551				2021-06-18	
J	Eisenberg, MA; Meehan, WP; Mannix, R				Eisenberg, Matthew A.; Meehan, William P., III; Mannix, Rebekah			Duration and Course of Post-Concussive Symptoms	PEDIATRICS			English	Article						brain concussion; emergency medicine; pediatrics; post-concussion syndrome; traumatic brain injury	SPORT-RELATED CONCUSSION; POSTCONCUSSIVE SYMPTOMS; HIGH-SCHOOL; CONSTRUCT-VALIDITY; CHILDREN; QUESTIONNAIRE; EPIDEMIOLOGY; PERFORMANCE; HEADACHE; INJURY	OBJECTIVES: To examine the incidence, duration, and clinical course of individual post-concussive symptoms in patients presenting to a pediatric emergency department (ED) with a concussion. METHODS: We conducted secondary analysis of a prospective cohort study of patients 11 to 22 years old presenting to the ED of a children's hospital with an acute concussion. The main outcome measure was duration of symptoms, assessed by the Rivermead Post-Concussion Symptoms Questionnaire (RPSQ). Patients initially completed a questionnaire describing mechanism of injury, associated symptoms, past medical history, and the RPSQ, then were serially administered the RPSQ for 3 months after the concussion or until all symptoms resolved. RESULTS: Headache, fatigue, dizziness, and taking longer to think were the most common symptoms encountered at presentation, whereas sleep disturbance, frustration, forgetfulness, and fatigue were the symptoms most likely to develop during the follow-up period that had not initially been present. Median duration of symptoms was the longest for irritability (16 days), sleep disturbance (16 days), frustration (14 days), and poor concentration (14 days), whereas nausea, depression, dizziness, and double-vision abated most quickly. One month after injury, nearly a quarter of children still complained of headache, >20% suffered from fatigue, and nearly 20% reported taking longer to think. CONCLUSIONS: Among patients presenting to a pediatric ED after a concussion, physical symptoms such as headache predominate immediately after the injury, emotional symptoms tend to develop later in the recovery period, and cognitive symptoms may be present throughout.	[Eisenberg, Matthew A.; Meehan, William P., III; Mannix, Rebekah] Harvard Univ, Sch Med, Boston Childrens Hosp, Div Emergency Med, Boston, MA USA	Eisenberg, MA (corresponding author), Boston Childrens Hosp, Div Emergency Med, 300 Longwood Ave, Boston, MA 02115 USA.	matthew.eisenberg@childrens.harvard.edu	Mannix, Rebekah/AAD-8702-2020; Meijer, Anna/K-5118-2016		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD018655] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30 HD018655] Funding Source: Medline		Ayr LK, 2009, J INT NEUROPSYCH SOC, V15, P19, DOI 10.1017/S1355617708090188; Babcock L, 2012, ARCH PEDIAT ADOLESC, V167, P156; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Blinman TA, 2009, J PEDIATR SURG, V44, P1223, DOI 10.1016/j.jpedsurg.2009.02.027; Blume H, 2012, CURR OPIN PEDIATR, V24, P724, DOI 10.1097/MOP.0b013e328359e4cc; Blume HK, 2012, PEDIATRICS, V129, pE31, DOI 10.1542/peds.2011-1742; Blume HK, 2011, PHYS MED REH CLIN N, V22, P665, DOI 10.1016/j.pmr.2011.08.007; CASEY R, 1986, PEDIATRICS, V78, P497; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Faux S, 2011, BRAIN INJURY, V25, P14, DOI 10.3109/02699052.2010.531686; Gagnon I, 2005, J HEAD TRAUMA REHAB, V20, P436, DOI 10.1097/00001199-200509000-00005; Grubenhoff JA, 2011, BRAIN INJURY, V25, P943, DOI 10.3109/02699052.2011.597043; Guerriero RM, 2012, CURR OPIN PEDIATR, V24, P696, DOI 10.1097/MOP.0b013e3283595175; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Lannsjo M, 2011, J REHABIL MED, V43, P997, DOI 10.2340/16501977-0875; Lee LK, 2007, PEDIATR EMERG CARE, V23, P580, DOI 10.1097/PEC.0b013e31813444ea; McCauley SR, 2013, J NEUROTRAUMA; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Meehan WP, 2010, J PEDIATR-US, V157, P889, DOI 10.1016/j.jpeds.2010.06.040; Meehan WP, 2009, PEDIATRICS, V123, P114, DOI 10.1542/peds.2008-0309; Mihalik JP, 2005, J NEUROSURG, V102, P850, DOI 10.3171/jns.2005.102.5.0850; Piland SG, 2006, MED SCI SPORT EXER, V38, P27, DOI 10.1249/01.mss.0000183186.98212.d5; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Register-Mihalik J, 2007, CLIN J SPORT MED, V17, P282, DOI 10.1097/JSM.0b013e31804ca68a; Ropper AH, 2007, NEW ENGL J MED, V356, P166, DOI 10.1056/NEJMcp064645; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056	31	176	177	0	41	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	JUN	2014	133	6					999	1006		10.1542/peds.2014-0158			8	Pediatrics	Pediatrics	AI8MY	WOS:000337172600049	24819569	Green Published, Bronze	Y	N	2021-06-18	
J	Zhu, HT; Bian, C; Yuan, JC; Chu, WH; Xiang, X; Chen, F; Wang, CS; Feng, H; Lin, JK				Zhu, Hai-tao; Bian, Chen; Yuan, Ji-chao; Chu, Wei-hua; Xiang, Xin; Chen, Fei; Wang, Cheng-shi; Feng, Hua; Lin, Jiang-kai			Curcumin attenuates acute inflammatory injury by inhibiting the TLR4/MyD88/NF-kappa B signaling pathway in experimental traumatic brain injury	JOURNAL OF NEUROINFLAMMATION			English	Article						Toll-like receptor 4; Curcumin; Traumatic brain injury; Inflammation	TOLL-LIKE RECEPTORS; MICROGLIAL ACTIVATION; INTRACEREBRAL HEMORRHAGE; OXIDATIVE STRESS; ISCHEMIC-INJURY; NERVOUS-SYSTEM; EXPRESSION; MICE; RATS; TLR4	Background: Traumatic brain injury (TBI) initiates a neuroinflammatory cascade that contributes to substantial neuronal damage and behavioral impairment, and Toll-like receptor 4 (TLR4) is an important mediator of thiscascade. In the current study, we tested the hypothesis that curcumin, a phytochemical compound with potent anti-inflammatory properties that is extracted from the rhizome Curcuma longa, alleviates acute inflammatory injury mediated by TLR4 following TBI. Methods: Neurological function, brain water content and cytokine levels were tested in TLR4-/-mice subjected to weight-drop contusion injury. Wild-type (WT) mice were injected intraperitoneally with different concentrations of curcumin or vehicle 15 minutes after TBI. At 24 hours post-injury, the activation of microglia/macrophages and TLR4 was detected by immunohistochemistry; neuronal apoptosis was measured by FJB and TUNEL staining; cytokines were assayed by ELISA; and TLR4, MyD88 and NF-kappa B levels were measured by Western blotting. In vitro, a co-culture system comprised of microglia and neurons was treated with curcumin following lipopolysaccharide (LPS) stimulation. TLR4 expression and morphological activation in microglia and morphological damage to neurons were detected by immunohistochemistry 24 hours post-stimulation. Results: The protein expression of TLR4 in pericontusional tissue reached a maximum at 24 hours post-TBI. Compared with WT mice, TLR4-/-mice showed attenuated functional impairment, brain edema and cytokine release post-TBI. In addition to improvement in the above aspects, 100 mg/kg curcumin treatment post-TBI significantly reduced the number of TLR4-positive microglia/macrophages as well as inflammatory mediator release and neuronal apoptosis in WT mice. Furthermore, Western blot analysis indicated that the levels of TLR4 and its known downstream effectors (MyD88, and NF-kappa B) were also decreased after curcumin treatment. Similar outcomes were observed in the microglia and neuron co-culture following treatment with curcumin after LPS stimulation. LPS increased TLR4 immunoreactivity and morphological activation in microglia and increased neuronal apoptosis, whereas curcumin normalized this upregulation. The increased protein levels of TLR4, MyD88 and NF-kappa B in microglia were attenuated by curcumin treatment. Conclusions: Our results suggest that post-injury, curcumin administration may improve patient outcome by reducing acute activation of microglia/macrophages and neuronal apoptosis through a mechanism involving the TLR4/MyD88/NF-kappa B signaling pathway in microglia/macrophages in TBI.	[Zhu, Hai-tao; Yuan, Ji-chao; Chu, Wei-hua; Xiang, Xin; Chen, Fei; Wang, Cheng-shi; Feng, Hua; Lin, Jiang-kai] Third Mil Med Univ, Southwest Hosp, Dept Neurosurg, Chongqing 400038, Peoples R China; [Bian, Chen] Third Mil Med Univ, Dept Neurobiol, Chongqing 400038, Peoples R China	Lin, JK (corresponding author), Third Mil Med Univ, Southwest Hosp, Dept Neurosurg, 30 Gaotanyan St, Chongqing 400038, Peoples R China.	jklin@tmmu.edu.cn			National Science Foundation of China (NSFC)National Natural Science Foundation of China (NSFC) [81070979, 81000531]; National '973' Project of ChinaNational Basic Research Program of China [2014CB541605]	We gratefully thank MD Peng-fei Wang and MD Huang Fang for their generous assistance. This work was supported by the National Science Foundation of China (NSFC, number 81070979, 81000531) and National '973' Project of China (2014CB541605).	Agarwal NB, 2011, PHYTOMEDICINE, V18, P756, DOI 10.1016/j.phymed.2010.11.007; Ahmad A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057208; Anand P, 2007, MOL PHARMACEUT, V4, P807, DOI 10.1021/mp700113r; Barton GM, 2003, SCIENCE, V300, P1524, DOI 10.1126/science.1085536; Bian C, 2012, SYNAPSE, V66, P849, DOI 10.1002/syn.21574; Buchanan MM, 2010, J NEUROCHEM, V114, P13, DOI 10.1111/j.1471-4159.2010.06736.x; Carlson NG, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-5; Carpentier PA, 2008, BRAIN BEHAV IMMUN, V22, P140, DOI 10.1016/j.bbi.2007.08.011; Chearwae W, 2008, J CLIN IMMUNOL, V28, P558, DOI 10.1007/s10875-008-9202-7; Chen CC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030294; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; Chen SF, 2008, BRIT J PHARMACOL, V155, P1279, DOI 10.1038/bjp.2008.345; Chen ZH, 2012, J NEUROSCI, V32, P11706, DOI 10.1523/JNEUROSCI.0730-12.2012; Covert MW, 2005, SCIENCE, V309, P1854, DOI 10.1126/science.1112304; Fang H, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-27; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Hanke ML, 2011, CLIN SCI, V121, P367, DOI 10.1042/CS20110164; Heger M, 2014, PHARMACOL REV, V66, P222, DOI 10.1124/pr.110.004044; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Hyakkoku K, 2010, NEUROSCIENCE, V171, P258, DOI 10.1016/j.neuroscience.2010.08.054; Karlstetter M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-125; King MD, 2011, J NEUROSURG, V115, P116, DOI 10.3171/2011.2.JNS10784; Laird MD, 2010, J NEUROCHEM, V113, P637, DOI 10.1111/j.1471-4159.2010.06630.x; Lee H, 2013, CURR PROTEIN PEPT SC, V14, P33, DOI 10.2174/1389203711314010006; Lehnardt S, 2008, J NEUROSCI, V28, P2320, DOI 10.1523/JNEUROSCI.4760-07.2008; Lehnardt S, 2010, GLIA, V58, P253, DOI 10.1002/glia.20928; Li GZ, 2011, BRAIN RES, V1396, P96, DOI 10.1016/j.brainres.2011.04.014; Lin Q, 2011, INT IMMUNOPHARMACOL, V11, P1422, DOI 10.1016/j.intimp.2011.04.026; Lin S, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-46; Liu K, 2012, J SURG RES, V174, P73, DOI 10.1016/j.jss.2010.12.002; Longhi L, 2011, J CEREBR BLOOD F MET, V31, P1919, DOI 10.1038/jcbfm.2011.42; Lubbad A, 2009, MOL CELL BIOCHEM, V322, P127, DOI 10.1007/s11010-008-9949-4; Lumpkins K, 2008, J TRAUMA, V64, P358, DOI 10.1097/TA.0b013e318160df9b; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mao SS, 2012, J NEUROTRAUM, V29, P1941, DOI 10.1089/neu.2011.2244; Marsh B, 2009, J NEUROSCI, V29, P9839, DOI 10.1523/JNEUROSCI.2496-09.2009; Meng Z, 2013, ACTA PHARMACOL SIN, V34, P901, DOI 10.1038/aps.2013.24; Pan MH, 1999, DRUG METAB DISPOS, V27, P486; RAVINDRANATH V, 1980, TOXICOLOGY, V16, P259, DOI 10.1016/0300-483X(80)90122-5; Rivest S, 2009, NAT REV IMMUNOL, V9, P429, DOI 10.1038/nri2565; Roof RL, 1996, EXP NEUROL, V138, P246, DOI 10.1006/exnr.1996.0063; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Sharma S, 2009, NEUROSCIENCE, V161, P1037, DOI 10.1016/j.neuroscience.2009.04.042; Sharma S, 2010, EXP NEUROL, V226, P191, DOI 10.1016/j.expneurol.2010.08.027; Shoba G, 1998, PLANTA MED, V64, P353, DOI 10.1055/s-2006-957450; Takeuchi O, 2010, CELL, V140, P805, DOI 10.1016/j.cell.2010.01.022; Tu CT, 2012, FOOD CHEM TOXICOL, V50, P3343, DOI 10.1016/j.fct.2012.05.050; Tu CT, 2012, INT IMMUNOPHARMACOL, V12, P151, DOI 10.1016/j.intimp.2011.11.005; Vartanian KB, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-140; Walker PA, 2012, SURGERY, V152, P790, DOI 10.1016/j.surg.2012.06.006; Wang XY, 2009, J IMMUNOL, V183, P7471, DOI 10.4049/jimmunol.0900762; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Wu AG, 2011, NEUROREHAB NEURAL RE, V25, P332, DOI 10.1177/1545968310397706; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Yang FS, 2005, J BIOL CHEM, V280, P5892, DOI 10.1074/jbc.M404751200; Yang QW, 2011, J CEREBR BLOOD F MET, V31, P593, DOI 10.1038/jcbfm.2010.129; Yang SF, 2008, NEUROCHEM RES, V33, P2044, DOI 10.1007/s11064-008-9675-z; Yao LL, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-23; Youn HS, 2006, BIOCHEM PHARMACOL, V72, P62, DOI 10.1016/j.bcp.2006.03.022; Zeng ZJ, 2013, PLANTA MED, V79, P102, DOI 10.1055/s-0032-1328057; Zhao L, 2011, NUTR REV, V69, P310, DOI 10.1111/j.1753-4887.2011.00394.x; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016; Zujovic V, 2003, METHODS, V29, P345, DOI 10.1016/S1046-2023(02)00358-4	64	176	190	2	40	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	MAR 27	2014	11								59	10.1186/1742-2094-11-59			17	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	AF8EW	WOS:000334949300001	24669820	DOAJ Gold, Green Published			2021-06-18	
J	Rowson, S; Duma, SM				Rowson, Steven; Duma, Stefan M.			Brain Injury Prediction: Assessing the Combined Probability of Concussion Using Linear and Rotational Head Acceleration	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Mild traumatic brain injury; Biomechanics; Football; Helmet; Angular; Risk curve	HIGH-SCHOOL FOOTBALL; CHRONIC TRAUMATIC ENCEPHALOPATHY; DIFFUSE AXONAL INJURY; CEREBRAL CONCUSSION; COLLEGIATE; IMPACTS; PLAYERS; EPIDEMIOLOGY; VALIDATION; CURVES	Recent research has suggested possible long term effects due to repetitive concussions, highlighting the importance of developing methods to accurately quantify concussion risk. This study introduces a new injury metric, the combined probability of concussion, which computes the overall risk of concussion based on the peak linear and rotational accelerations experienced by the head during impact. The combined probability of concussion is unique in that it determines the likelihood of sustaining a concussion for a given impact, regardless of whether the injury would be reported or not. The risk curve was derived from data collected from instrumented football players (63,011 impacts including 37 concussions), which was adjusted to account for the underreporting of concussion. The predictive capability of this new metric is compared to that of single biomechanical parameters. The capabilities of these parameters to accurately predict concussion incidence were evaluated using two separate datasets: the Head Impact Telemetry System (HITS) data and National Football League (NFL) data collected from impact reconstructions using dummies (58 impacts including 25 concussions). Receiver operating characteristic curves were generated, and all parameters were significantly better at predicting injury than random guessing. The combined probability of concussion had the greatest area under the curve for all datasets. In the HITS dataset, the combined probability of concussion and linear acceleration were significantly better predictors of concussion than rotational acceleration alone, but not different from each other. In the NFL dataset, there were no significant differences between parameters. The combined probability of concussion is a valuable method to assess concussion risk in a laboratory setting for evaluating product safety.	[Rowson, Steven; Duma, Stefan M.] Virginia Tech Wake Forest, Ctr Injury Biomech, Blacksburg, VA 24061 USA	Rowson, S (corresponding author), Virginia Tech Wake Forest, Ctr Injury Biomech, 440 ICTAS Bldg,Stanger St, Blacksburg, VA 24061 USA.	srowson@vt.edu	Duma, Stefan/A-8368-2012; Rowson, Steven/B-1270-2012	Rowson, Steven/0000-0002-3227-0596	National Highway Traffic Safety Administration; National Institutes of Health (National Institute for Child Health and Human Development)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048638] Funding Source: NIH RePORTER	The authors gratefully acknowledge our sponsors for this research, including the National Highway Traffic Safety Administration and National Institutes of Health (National Institute for Child Health and Human Development) (Contract No. R01HD048638).	Beckwith J. G., 2012, MED SCI SPORTS EXERC, DOI [10.1249/MSS.0b013e318 2793067, DOI 10.1249/MSS.0B013E318]; Beckwith JG, 2007, J APPL BIOMECH, V23, P238, DOI 10.1123/jab.23.3.238; Booher MA, 2003, CLIN J SPORT MED, V13, P93, DOI 10.1097/00042752-200303000-00005; Brainard LL, 2012, MED SCI SPORT EXER, V44, P297, DOI 10.1249/MSS.0b013e31822b0ab4; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Broglio SP, 2009, J ATHL TRAINING, V44, P342, DOI 10.4085/1062-6050-44.4.342; Cormier J., 2011, J BIOMECH ENG, V133; Cormier J, 2011, J BIOMECH ENG-T ASME, V133, DOI 10.1115/1.4004248; Crisco JJ, 2011, CURR SPORT MED REP, V10, P7, DOI 10.1249/JSR.0b013e318205e063; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Daniel RW, 2012, ANN BIOMED ENG, V40, P976, DOI 10.1007/s10439-012-0530-7; Davidsson J., 2009, 2009 INT IRC C BIOM, P43; Duhaime AC, 2012, J NEUROSURG, V117, P1092, DOI 10.3171/2012.8.JNS112298; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Duma SM, 2011, EXERC SPORT SCI REV, V39, P2, DOI 10.1097/JES.0b013e318203dfdb; Fournier E., 2000, IRCOBI INT RES COUNC, V2000, P223; Funk JR, 2012, ANN BIOMED ENG, V40, P79, DOI 10.1007/s10439-011-0400-8; Gadd C. W., 1966, P 10 STAPP CAR CRASH; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Greenwald RM, 2012, CLIN J SPORT MED, V22, P83, DOI 10.1097/JSM.0b013e31824cc5d3; GURDJIAN ES, 1966, J TRAUM, V6, P600, DOI 10.1097/00005373-196609000-00005; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; HANLEY JA, 1983, RADIOLOGY, V148, P839, DOI 10.1148/radiology.148.3.6878708; Hanlon E, 2010, J APPL BIOMECH, V26, P424, DOI 10.1123/jab.26.4.424; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; Hootman JM, 2007, J ATHL TRAINING, V42, P311; King A.I., 2003, P INT RES C BIOM IMP; Langburt W, 2001, J CHILD NEUROL, V16, P83, DOI 10.1177/088307380101600203; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; McCaffrey MA, 2007, NEUROSURGERY, V61, P1236, DOI 10.1227/01.neu.0000306102.91506.8b; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Newman J, 1999, INT RES COUNC BIOM I, P17; Newman J A, 2000, Stapp Car Crash J, V44, P215; NOCSAE, 2011, ND00111M11 NOCSAE; NOCSAE, 2011, ND00211M11A NOCSAE; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Ommaya A. K., 1967, P 11 STAPP CAR CRASH, V670906; Ommaya A. K, 1985, BIOMECHANICS HEAD IN; OMMAYA AK, 1966, SCIENCE, V153, P211, DOI 10.1126/science.153.3732.211; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Rowson S, 2008, CLIN J SPORT MED, V18, P316, DOI 10.1097/JSM.0b013e31817f016a; Rowson S, 2012, ANN BIOMED ENG, V40, P2512, DOI 10.1007/s10439-012-0660-y; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Rowson S, 2011, ANN BIOMED ENG, V39, P2130, DOI 10.1007/s10439-011-0322-5; Rowson S, 2011, J APPL BIOMECH, V27, P8, DOI 10.1123/jab.27.1.8; Rowson S, 2010, CLIN J SPORT MED, V20, P344, DOI 10.1097/JSM.0b013e3181ed7e50; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Shain KS, 2010, CLIN J SPORT MED, V20, P422, DOI 10.1097/JSM.0b013e3181f7db25; Unterharnscheidt F. J., 1971, P 15 STAPP CAR CRASH; Versace J., 1971, SAE TECHNICAL PAPER; Williamson I. J., 2006, BRIT J SPORT MED, V40, P132; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832	60	176	179	1	75	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	MAY	2013	41	5					873	882		10.1007/s10439-012-0731-0			10	Engineering, Biomedical	Engineering	124LJ	WOS:000317465000001	23299827	Green Published, Other Gold			2021-06-18	
J	Galetta, KM; Brandes, LE; Maki, K; Dziemianowicz, MS; Laudano, E; Allen, M; Lawler, K; Sennett, B; Wiebe, D; Devick, S; Messner, LV; Galetta, SL; Balcer, LJ				Galetta, Kristin M.; Brandes, Lauren E.; Maki, Karl; Dziemianowicz, Mark S.; Laudano, Eric; Allen, Megan; Lawler, Kathy; Sennett, Brian; Wiebe, Douglas; Devick, Steve; Messner, Leonard V.; Galetta, Steven L.; Balcer, Laura J.			The King-Devick test and sports-related concussion: Study of a rapid visual screening tool in a collegiate cohort	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						Vision; Eye movements; Sports-related concussion; King-Devick test	TRAUMATIC BRAIN-INJURY; PROFESSIONAL FOOTBALL PLAYERS; RECURRENT CONCUSSION; EPIDEMIOLOGY; RELIABILITY; DEPRESSION; RISK	Objective: Concussion, defined as an impulse blow to the head or body resulting in transient neurologic signs or symptoms, has received increasing attention in sports at all levels. The King-Devick (K-D) test is based on the time to perform rapid number naming and captures eye movements and other correlates of suboptimal brain function. In a study of boxers and mixed martial arts (MMA) fighters, the K-D test was shown to have high degrees of test-retest and inter-rater reliability and to be an accurate method for rapidly identifying boxers and mixed martial arts fighters with concussion. We performed a study of the K-D test as a rapid sideline screening tool in collegiate athletes to determine the effect of concussion on K-D scores compared to a pre-season baseline. Methods: In this longitudinal study, athletes from the University of Pennsylvania varsity football, sprint football, and women's and men's soccer and basketball teams underwent baseline K-D testing prior to the start of the 2010-11 playing season. Post-season testing was also performed. For athletes who had concussions during the season, K-D testing was administered immediately on the sidelines and changes in score from baseline were determined. Results: Among 219 athletes tested at baseline, post-season K-D scores were lower (better) than the best pre-season scores (35.1 vs. 37.9 s, P = 0.03, Wilcoxon signed-rank test), reflecting mild learning effects in the absence of concussion. For the 10 athletes who had concussions. K-D testing on the sidelines showed significant worsening from baseline (46.9 vs. 37.0 s, P = 0.009), with all except one athlete demonstrating worsening from baseline (median 5.9 s). Conclusion: This study of collegiate athletes provides initial evidence in support of the K-D test as a strong candidate rapid sideline visual screening tool for concussion. Data show worsening of scores following concussion, and ongoing follow-up in this study with additional concussion events and different athlete populations will further examine the effectiveness of the K-D test. (C) 2011 Elsevier B.V. All rights reserved.	[Galetta, Kristin M.; Brandes, Lauren E.; Maki, Karl; Dziemianowicz, Mark S.; Lawler, Kathy; Galetta, Steven L.; Balcer, Laura J.] Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA; [Laudano, Eric] Univ Penn, Dept Recreat & Intercollegiate Athlet, Philadelphia, PA 19104 USA; [Allen, Megan; Messner, Leonard V.] Illinois Coll Optometry, Chicago, IL USA; [Sennett, Brian] Univ Penn, Sch Med, Dept Orthoped, Philadelphia, PA 19104 USA; [Wiebe, Douglas; Balcer, Laura J.] Univ Penn, Sch Med, Dept Epidemiol, Philadelphia, PA 19104 USA; [Devick, Steve] King Devick Test LLC, Downers Grove, IL USA; [Galetta, Steven L.; Balcer, Laura J.] Univ Penn, Sch Med, Dept Ophthalmol, Philadelphia, PA 19104 USA	Balcer, LJ (corresponding author), Univ Penn, Sch Med, Dept Neurol, 3 E Gates Bldg,3400 Spruce St, Philadelphia, PA 19104 USA.	lbalcer@mail.med.upenn.edu	Wiebe, Douglas J/Q-1168-2017		 [K24 EY 018136]; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [K24EY018136] Funding Source: NIH RePORTER	Funding/support: This study was supported in part by K24 EY 018136 to Dr. Balcer for research mentoring.	Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Casson IR, 2009, NEUROL CLIN, V26, P195; Coldren RL, 2010, MIL MED, V175, P477, DOI 10.7205/MILMED-D-09-00258; Covassin T, 2009, J ATHL TRAINING, V44, P400, DOI 10.4085/1062-6050-44.4.400; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Dooren JC, 2010, WALL ST J       0830; Ferullo SM, 2010, J FAM PRACTICE, V59, P428; Galetta KM, 2011, NEUROLOGY, V76, P1456, DOI 10.1212/WNL.0b013e31821184c9; Gardner A, 2010, ARCH CLIN NEUROPSYCH, V25, P174, DOI 10.1093/arclin/acq007; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Gregory S, 2010, TIME            0208; Grubenhoff JA, 2010, PEDIATRICS, V126, P688, DOI 10.1542/peds.2009-2804; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Heitger MH, 2008, IEEE ENG MED BIO, P3570, DOI 10.1109/IEMBS.2008.4649977; Hunt TN, 2009, CLIN J SPORT MED, V19, P471, DOI 10.1097/JSM.0b013e3181c12c7b; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kluger Jeffrey, 2011, Time, V177, P42; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lau BK, 2011, AM J SPORTS MED; Maruta J, 2010, J HEAD TRAUMA REHAB, V25, P293, DOI 10.1097/HTR.0b013e3181e67936; McCrea M, 2009, NEUROSURGERY, V65, P876, DOI 10.1227/01.NEU.0000350155.89800.00; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McGrath Ben, 2011, NEW YORKER      0131; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Miller G, 2009, SCIENCE, V325, P670, DOI 10.1126/science.325_670; Mitka M, 2010, JAMA-J AM MED ASSOC, V304, P1775, DOI 10.1001/jama.2010.1487; Norrie J, 2010, BRAIN INJURY, V24, P1528, DOI 10.3109/02699052.2010.531687; Nunnally J.C., 1978, PSYCHOMETRIC THEORY; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; ORIDE MKH, 1986, AM J OPTOM PHYS OPT, V63, P419; Reddy CC, 2009, CURR SPORT MED REP, V8, P10, DOI 10.1249/JSR.0b013e31819539ca; SAMSON K, 2010, NEUROLOGY TODAY, V10, P1; Talavage TM, 2010, J NEUROTRAUMA   1001; Villemure R, 2011, BRAIN INJURY, V25, P53, DOI 10.3109/02699052.2010.531881; Wetjen NM, 2010, J AM COLL SURGEONS, V211, P553, DOI 10.1016/j.jamcollsurg.2010.05.020; Yuen TJ, 2009, J NEUROSCI RES, V87, P3620, DOI 10.1002/jnr.22161	40	176	176	4	43	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X			J NEUROL SCI	J. Neurol. Sci.	OCT 15	2011	309	1-2					34	39		10.1016/j.jns.2011.07.039			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	825SV	WOS:000295303300009	21849171				2021-06-18	
J	Kurimoto, T; Yin, YQ; Omura, K; Gilbert, HY; Kim, D; Cen, LP; Moko, L; Kugler, S; Benowitz, LI				Kurimoto, Takuji; Yin, Yuqin; Omura, Kumiko; Gilbert, Hui-ya; Kim, Daniel; Cen, Ling-Ping; Moko, Lilamarie; Kuegler, Sebastian; Benowitz, Larry I.			Long-Distance Axon Regeneration in the Mature Optic Nerve: Contributions of Oncomodulin, cAMP, and pten Gene Deletion	JOURNAL OF NEUROSCIENCE			English	Article							RETINAL GANGLION-CELLS; CILIARY NEUROTROPHIC FACTOR; LENS-INJURY; CYCLIC-AMP; CORTICOSPINAL TRACT; SUPERIOR COLLICULUS; MEDIATED EXPRESSION; ARGINASE-I; GROWTH; PATHWAY	The inability of retinal ganglion cells (RGCs) to regenerate damaged axons through the optic nerve has dire consequences for victims of traumatic nerve injury and certain neurodegenerative diseases. Several strategies have been shown to induce appreciable regeneration in vivo, but the regrowth of axons through the entire optic nerve and on into the brain remains a major challenge. We show here that the induction of a controlled inflammatory response in the eye, when combined with elevation of intracellular cAMP and deletion of the gene encoding pten (phosphatase and tensin homolog), enables RGCs to regenerate axons the full length of the optic nerve in mature mice; approximately half of these axons cross the chiasm, and a rare subset (similar to 1%) manages to enter the thalamus. Consistent with our previous findings, the axon-promoting effects of inflammation were shown to require the macrophage-derived growth factor Oncomodulin (Ocm). Elevation of cAMP increased the ability of Ocm to bind to its receptors in the inner retina and augmented inflammation-induced regeneration twofold. Inflammation combined with elevated cAMP and PTEN deletion increased activation of the phosphatidylinositol 3-kinase and mitogen-activated protein kinase signaling pathways and augmented regeneration similar to 10-fold over the level induced by either pten deletion or Zymosan alone. Thus, treatments that synergistically alter the intrinsic growth state of RGCs produce unprecedented levels of axon regeneration in the optic nerve, a CNS pathway long believed to be incapable of supporting such growth.	[Benowitz, Larry I.] Childrens Hosp, Lab Neurosci Res Neurosurg, CLSB 13071, Boston, MA 02115 USA; [Kurimoto, Takuji; Yin, Yuqin; Omura, Kumiko; Gilbert, Hui-ya; Kim, Daniel; Cen, Ling-Ping; Moko, Lilamarie; Benowitz, Larry I.] Childrens Hosp, FM Kirby Neurobiol Ctr, Boston, MA 02115 USA; [Kurimoto, Takuji; Yin, Yuqin; Cen, Ling-Ping; Benowitz, Larry I.] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA; [Benowitz, Larry I.] Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA; [Kuegler, Sebastian] Univ Med Gottingen, Dept Neurol, Deutsch Forschungsgemeinschaft Res Ctr Mol Physio, D-37073 Gottingen, Germany	Benowitz, LI (corresponding author), Childrens Hosp, Lab Neurosci Res Neurosurg, CLSB 13071, 115 Longwood Ave, Boston, MA 02115 USA.	larry.benowitz@childrens.harvard.edu	Cen Ling-Ping, Cen Lingping/O-4216-2015	Cen Ling-Ping, Cen Lingping/0000-0003-3876-0606	National Eye InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI); National Eye InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [2 R01 EY05690-29A1, 3 R01 EY05690-29A1S1]; Miriam and Sheldon Adelson Medical Research Foundation; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [H P30 HD018655]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD018655] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY005690] Funding Source: NIH RePORTER	This work was supported by National Eye Institute Grants 2 R01 EY05690-29A1 and 3 R01 EY05690-29A1S1 and the Miriam and Sheldon Adelson Medical Research Foundation. We thank Dr. Zhigang He and members of his laboratory (Dr. Kevin Park and Lauren Connolly) for providing PTEN <SUP>flx/flx</SUP> mice, assistance with breeding, and validation of viral infection efficiency, Dr. Mustafa Sahin for providing several antibodies, and Dr. Lihong Bu and the Developmental Disabilities Research Center (National Institutes of Health Grant H P30 HD018655 for assistance with imaging.	Bahr M, 1996, J NEUROSCI, V16, P5106; Berry M, 1996, J NEUROCYTOL, V25, P147, DOI 10.1007/BF02284793; Berry M, 1999, J NEUROCYTOL, V28, P721, DOI 10.1023/A:1007086004022; Cai DM, 2002, NEURON, V35, P711, DOI 10.1016/S0896-6273(02)00826-7; Carracedo A, 2008, ONCOGENE, V27, P5527, DOI 10.1038/onc.2008.247; Cen LP, 2007, INVEST OPHTH VIS SCI, V48, P4257, DOI 10.1167/iovs.06-0791; Chalhoub N, 2009, ANNU REV PATHOL-MECH, V4, P127, DOI 10.1146/annurev.pathol.4.110807.092311; Cheng L, 2002, J NEUROSCI, V22, P3977, DOI 10.1523/JNEUROSCI.22-10-03977.2002; Chierzi S, 1999, J NEUROSCI, V19, P8367; Cui Q, 2003, MOL CELL NEUROSCI, V22, P49, DOI 10.1016/S1044-7431(02)00037-4; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; Deng KW, 2009, J NEUROSCI, V29, P9545, DOI 10.1523/JNEUROSCI.1175-09.2009; EITAN S, 1994, SCIENCE, V264, P1764, DOI 10.1126/science.7911602; Fischer D, 2004, J NEUROSCI, V24, P1646, DOI 10.1523/JNEUROSCI.5119-03.2004; Fischer D, 2004, J NEUROSCI, V24, P8726, DOI 10.1523/JNEUROSCI.2774-04.2004; Fischer D, 2001, EXP NEUROL, V172, P257, DOI 10.1006/exnr.2001.7822; Groszer M, 2001, SCIENCE, V294, P2186, DOI 10.1126/science.1065518; Guest JD, 1997, J NEUROSCI RES, V50, P888, DOI 10.1002/(SICI)1097-4547(19971201)50:5<888::AID-JNR24>3.0.CO;2-W; Hannila SS, 2008, EXP NEUROL, V209, P321, DOI 10.1016/j.expneurol.2007.06.020; Kadoya K, 2009, NEURON, V64, P165, DOI 10.1016/j.neuron.2009.09.016; Knoll B, 2001, MECH DEVELOP, V106, P119, DOI 10.1016/S0925-4773(01)00431-2; Leaver SG, 2006, GENE THER, V13, P1328, DOI 10.1038/sj.gt.3302791; Lehmann M, 1999, J NEUROSCI, V19, P7537, DOI 10.1523/JNEUROSCI.19-17-07537.1999; Leon S, 2000, J NEUROSCI, V20, P4615, DOI 10.1523/JNEUROSCI.20-12-04615.2000; Lingor P, 2008, BRAIN, V131, P250, DOI 10.1093/brain/awm284; Lorber B, 2008, J NEUROSCI RES, V86, P894, DOI 10.1002/jnr.21545; Lu P, 2004, J NEUROSCI, V24, P6402, DOI 10.1523/JNEUROSCI.1492-04.2004; Martin KRG, 2002, METHODS, V28, P267, DOI 10.1016/S1046-2023(02)00232-3; Meyer-Franke A, 1998, NEURON, V21, P681, DOI 10.1016/S0896-6273(00)80586-3; Ming GL, 1997, NEURON, V19, P1225, DOI 10.1016/S0896-6273(00)80414-6; Monsul NT, 2004, EXP NEUROL, V186, P124, DOI 10.1016/S0014-4886(03)00311-X; Muller A, 2009, MOL CELL NEUROSCI, V41, P233, DOI 10.1016/j.mcn.2009.03.002; Neumann S, 2002, NEURON, V34, P885, DOI 10.1016/S0896-6273(02)00702-X; Park KK, 2008, SCIENCE, V322, P963, DOI 10.1126/science.1161566; Pearse DD, 2004, NAT MED, V10, P610, DOI 10.1038/nm1056; Pernet V, 2006, BRAIN, V129, P1014, DOI 10.1093/brain/awl015; Qiu J, 2002, NEURON, V34, P895, DOI 10.1016/S0896-6273(02)00730-4; Rodger J, 2001, EUR J NEUROSCI, V14, P1929, DOI 10.1046/j.0953-816x.2001.01822.x; SCHNELL L, 1994, NATURE, V367, P170, DOI 10.1038/367170a0; Smith PD, 2009, NEURON, V64, P617, DOI 10.1016/j.neuron.2009.11.021; Song HJ, 1998, SCIENCE, V281, P1515, DOI 10.1126/science.281.5382.1515; Symonds ACE, 2007, EUR J NEUROSCI, V25, P744, DOI 10.1111/j.1460-9568.2007.05321.x; Verma P, 2008, NEUROREHAB NEURAL RE, V22, P429, DOI 10.1177/1545968307313500; Weise J, 2000, NEUROBIOL DIS, V7, P212, DOI 10.1006/nbdi.2000.0285; Wizenmann A, 1998, J NEUROBIOL, V35, P379, DOI 10.1002/(SICI)1097-4695(19980615)35:4<379::AID-NEU5>3.0.CO;2-W; Yart A, 2001, J BIOL CHEM, V276, P8856, DOI 10.1074/jbc.M006966200; Yin YQ, 2003, J NEUROSCI, V23, P2284; Yin YQ, 2006, NAT NEUROSCI, V9, P843, DOI 10.1038/nn1701; Yin YQ, 2009, P NATL ACAD SCI USA, V106, P19587, DOI 10.1073/pnas.0907085106	49	176	181	1	21	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	NOV 17	2010	30	46					15654	15663		10.1523/JNEUROSCI.4340-10.2010			10	Neurosciences	Neurosciences & Neurology	681XU	WOS:000284358500031	21084621	Bronze, Green Accepted, Green Published			2021-06-18	
J	Collins, M; Lovell, MR; Iverson, GL; Ide, T; Maroon, J				Collins, M; Lovell, MR; Iverson, GL; Ide, T; Maroon, J			Examining concussion rates and return to play in high school football players wearing newer helmet technology: A three-year prospective cohort study	NEUROSURGERY			English	Article						cohort study; concussion; football; helmet design; ImPACT; return to play	PROFESSIONAL FOOTBALL; COLLEGE FOOTBALL; NECK INJURIES; HEAD-INJURY; ICE HOCKEY; IMPACT; RECOVERY; PERFORMANCE; SPORT; EVOLUTION	OBJECTIVE: The purpose of this study was to compare concussion rates and recovery times for athletes wearing newer helmet technology compared to traditional helmet design. METHODS: This was a three-year, prospective, naturalistic, cohort study. Participants were 2,141 high school athletes from Western Pennsylvania. Approximately half of the sample wore the Revolution helmet manufactured by Riddell, Inc. (n = 1,173) and the remainder of the sample used standard helmets (n = 968). Athletes underwent computerized neurocognitive testing through the use of ImPACT at the beginning of the study. Following a concussion, players were reevaluated at various time intervals until recovery was complete. RESULTS: In the total sample, the concussion rate in athletes wearing the Revolution was 5.3% and in athletes wearing standard helmets was 7.6% [chi(2) (1, 2, 141) = 4.96, P < 0.027]. The relative risk estimate was 0.69 (95% confidence interval = 0.499-0.958). Wearing the Revolution helmet was associated with approximately a 31% decreased relative risk and 2.3% decreased absolute risk for sustaining a concussion in this cohort study. The athletes wearing the Revolution did not differ from athletes wearing standard helmets on the mechanism of injury (e.g., head-to-head strike), on-field concussion markers (e.g., amnesia or loss of consciousness), or on-field presentation of symptoms (e.g., headaches, dizziness, or balance problems). CONCLUSION: Recent sophisticated laboratory research has better elucidated injury biomechanics associated with concussion in professional football players. This data has led to changes in helmet design and new helmet technology, which appears to have beneficial effects in reducing the incidence of cerebral concussion in high school football players.	UPMC, Ctr Sports Med, Sports Concuss Program, Dept Orthopaed Surg, Pittsburgh, PA 15206 USA; Univ British Columbia, Dept Psychiat, Vancouver, BC V5Z 1M9, Canada; Riddell Inc, Res & Prod Dev, Rosemont, IL USA; Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Pittsburgh Steelers Football Club, Pittsburgh, PA USA	Collins, M (corresponding author), UPMC, Ctr Sports Med, Sports Concuss Program, Dept Orthopaed Surg, 3200 S Water St, Pittsburgh, PA 15206 USA.	collinsmw@upmc.edu		Iverson, Grant/0000-0001-7348-9570			ALBRIGHT JP, 1985, AM J SPORT MED, V13, P147, DOI 10.1177/036354658501300301; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barr WB, 2001, J INT NEUROPSYCH SOC, V7, P693, DOI 10.1017/S1355617701766052; Benson BW, 1999, JAMA-J AM MED ASSOC, V282, P2328, DOI 10.1001/jama.282.24.2328; Benson BW, 2002, BRIT J SPORT MED, V36, P27, DOI 10.1136/bjsm.36.1.27; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Delaney JS, 2001, CLIN J SPORT MED, V11, P234, DOI 10.1097/00042752-200110000-00005; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Iverson G, 2002, ARCH CLIN NEUROPSYCH, V17, P769; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2004, ARCH CLIN NEUROPSYCH, V19, P961; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Iverson GL, 2002, ARCH CLIN NEUROPSYCH, V17, P770; Iverson GL, 2004, STUD NEUROPSYCHOL DE, P323; Janusz A, 2004, BRIT J SPORT MED, V38, P659; Levy ML, 2004, NEUROSURGERY, V55, P649, DOI 10.1227/01.NEU.0000134598.06114.89; Levy ML, 2004, NEUROSURGERY, V55, P656, DOI 10.1227/01.NEU.0000134599.01917.AA; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; LOVELL MR, 2005, APPL NEUROPSYCHOL, V21, P91; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Makdissi M, 2001, BRIT J SPORT MED, V35, P354, DOI 10.1136/bjsm.35.5.354; Marshall SW, 2005, INT J EPIDEMIOL, V34, P113, DOI 10.1093/ije/dyh346; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McIntosh AS, 2000, BRIT J SPORT MED, V34, P337, DOI 10.1136/bjsm.34.5.337; McIntosh AS, 2001, BRIT J SPORT MED, V35, P167, DOI 10.1136/bjsm.35.3.167; *NAT OP COMM STAND, STAND PERF SPEC NEWL; *NAT OP COMM STAND, STAND DROP TEST METH; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Norman R W, 1980, Can J Appl Sport Sci, V5, P208; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Pellman EJ, 2004, NEUROSURGERY, V55, P1100, DOI 10.1227/01.NEU.0000147063.12873.F5; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Pettersen JA, 2002, BRIT J SPORT MED, V36, P19, DOI 10.1136/bjsm.36.1.19; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; SHATZ P, IN PRESS ARCH CLIN N; Torg J S, 1999, Am J Orthop (Belle Mead NJ), V28, P128; Warden DL, 2001, NEUROLOGY, V57, P524, DOI 10.1212/WNL.57.3.524; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA; Zemper Eric D., 1994, Journal of Athletic Training, V29, P44	53	176	178	2	61	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	FEB	2006	58	2					275	284		10.1227/01.NEU.0000200441.92742.46			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	011CT	WOS:000235246000024	16462481				2021-06-18	
J	Wilde, EA; Hunter, JV; Newsome, MR; Scheibel, RS; Bigler, ED; Johnson, JL; Fearing, MA; Cleavinger, HB; Li, XQ; Swank, PR; Pedroza, C; Roberson, GS; Bachevalier, J; Levin, HS				Wilde, EA; Hunter, JV; Newsome, MR; Scheibel, RS; Bigler, ED; Johnson, JL; Fearing, MA; Cleavinger, HB; Li, XQ; Swank, PR; Pedroza, C; Roberson, GS; Bachevalier, J; Levin, HS			Frontal and temporal morphometric findings on MRI in children after moderate to severe traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						children; frontal lobes; morphometry; MRI; temporal lobes; traumatic brain injury	DIFFUSE AXONAL INJURY; CEREBRAL BLOOD-FLOW; CLOSED-HEAD INJURY; COMA DATA-BANK; PRACTICAL SCALE; LOBE; ADOLESCENTS; CHILDHOOD; RATS; IMMATURE	In vivo MRI volumetric analysis enables investigators to evaluate the extent of tissue loss following traumatic brain injury (TBI). However, volumetric studies of pediatric TBI are sparse, and there have been no volumetric studies to date in children examining specific subregions of the prefrontal and temporal lobes. In this study, MRI volumetry was used to evaluate brain volume differences in the whole brain, and prefrontal, temporal, and posterior regions of children following moderate to severe TBI as compared to uninjured children of similar age and demographic characteristics. The TBI group had significantly reduced whole brain, and prefrontal and temporal regional tissue volumes as well as increased cerebrospinal fluid (CSF). Confidence interval testing further revealed group differences on gray matter (GM) and white matter (WM) in the superior medial and ventromedial prefrontal regions, WM in the lateral frontal region, and GM, WM, and CSF in the temporal region, Whole brain volume and total brain GM were reduced, and total ventricular volume, total CSF volume, and ventricle-to-brain ratio (VBR) were increased in the TBI group. Additional analyses comparing volumetric data from typically developing children and subgroups of TBI patients with and without regional focal lesions suggested that GM loss in the frontal areas was primarily attributable to focal injury, while WM loss in the frontal and temporal lobes was related to both diffuse and focal injury. Finally, volumetric measures of preserved frontotemporal tissue were related to functional recovery as measured by the Glasgow Outcome Scale (adapted for children) with greater tissue preservation predicting better recovery.	Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat, Houston, TX 77030 USA; Texas Childrens Hosp, Dept Diagnost Imaging, Houston, TX USA; Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; Brigham Young Univ, Dept Neurosci, Provo, UT 84602 USA; Univ Utah, Dept Radiol, Salt Lake City, UT 84132 USA; Univ Utah, Dept Psychiat, Salt Lake City, UT 84132 USA; Univ Texas, Ctr Hlth Sci, Dept Pediat, Houston, TX USA; Univ Texas, Ctr Hlth Sci, Dept Anat & Neurobiol, Houston, TX USA; Univ Texas, Ctr Hlth Sci, Dept Pediat, Houston, TX USA	Levin, HS (corresponding author), Cognit Neurosci Lab, 6560 Fannin St,Ste 1144,Box 67, Houston, TX 77030 USA.	hlevin@bcm.tmc.edu		Pedroza, Claudia/0000-0003-4235-1282	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U19HD035476] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U19 HD035476] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline		ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Adelson PD, 2001, J NEUROTRAUM, V18, P967, DOI 10.1089/08977150152693674; Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Anderson CV, 1995, J CLIN EXP NEUROPSYC, V17, P900, DOI 10.1080/01688639508402438; Anderson V, 2002, PRINCIPLES FRONTAL L, P504; BERRYHILL P, 1995, NEUROSURGERY, V37, P392, DOI 10.1227/00006123-199509000-00004; Biagas KV, 1996, J NEUROTRAUM, V13, P189, DOI 10.1089/neu.1996.13.189; Bigler ED, 2003, AM J NEURORADIOL, V24, P2066; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Bigler ED, 1999, J HEAD TRAUMA REHAB, V14, P406, DOI 10.1097/00001199-199908000-00009; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Bramlett HM, 2002, ACTA NEUROPATHOL, V103, P607, DOI 10.1007/s00401-001-0510-8; Brennan R.L., 1983, ELEMENTS GEN THEORY; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; Castellanos FX, 2002, JAMA-J AM MED ASSOC, V288, P1740, DOI 10.1001/jama.288.14.1740; *COMM INJ, 1998, ABBR INJ SCAL; Cronbach L. J., 1972, DEPENDABILITY BEHAV; Dennis M, 1996, DEV NEUROPSYCHOL, V12, P77, DOI 10.1080/87565649609540641; Di Stefano G, 2000, J NEUROL NEUROSUR PS, V69, P210, DOI 10.1136/jnnp.69.2.210; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; Gorrie C, 2001, J NEUROTRAUM, V18, P849, DOI 10.1089/089771501750451776; GRAHAM DI, 1989, J CLIN PATHOL, V42, P18, DOI 10.1136/jcp.42.1.18; GRAHAM DI, 2002, GREENFIELDS NEUROPAT, V2, P823; GRUNDL PD, 1994, J NEUROTRAUM, V11, P135, DOI 10.1089/neu.1994.11.135; JENNETT B, 1975, LANCET, V1, P480; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; Levin HS, 2000, NEUROLOGY, V54, P647, DOI 10.1212/WNL.54.3.647; Max JE, 1998, J AM ACAD CHILD PSY, V37, P832, DOI 10.1097/00004583-199808000-00013; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Pierallini A, 2000, NEURORADIOLOGY, V42, P860, DOI 10.1007/s002340000447; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Reiss AL, 1996, BRAIN, V119, P1763, DOI 10.1093/brain/119.5.1763; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Sowell ER, 2001, J INT NEUROPSYCH SOC, V7, P312, DOI 10.1017/S135561770173305X; TEASDALE G, 1974, LANCET, V2, P81; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Verger K, 2001, BRAIN INJURY, V15, P211; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78	55	176	178	2	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2005	22	3					333	344		10.1089/neu.2005.22.333			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	911QM	WOS:000228019500001	15785229				2021-06-18	
J	Lu, DY; Li, Y; Wang, L; Chen, JL; Mahmood, A; Chopp, M				Lu, DY; Li, Y; Wang, L; Chen, JL; Mahmood, A; Chopp, M			Intraarterial administration of marrow stromal cells in a rat model of traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						marrow stromal cell; transplantation; traumatic brain injury	CONTROLLED CORTICAL IMPACT; CENTRAL-NERVOUS-SYSTEM; STEM-CELLS; CYCLIN D1; EXPRESSION; DIFFERENTIATE; ASTROCYTES; PROTEINS; NESTIN; BONE	To test the efficacy of various delivery routes of stem cells to treat cerebral injury, we investigated the parenchymal distribution of marrow stromal cells (MSCs) injected into the internal carotid artery (ICA) of the adult rat after traumatic brain injury (TBI). Bromodeoxyuridine (BrdU)-labeled MSCs were injected via the ipsilateral ICA at 24 h after TBI. Using histology and immunohistochemistry, the distribution of implanted MSCs was analyzed at 7 days after transplantation. Four groups (n = 4/group) were studied: group 1, animals transplanted with MSCs cultured with NGF and BDNF at 24 h after TBI; group 2, animals transplanted with MSCs cultured without NGF and BDNF; group 3, animals injected with a placebo, phosphate buffered saline into the ICA at 24 h after TBI; and group 4, rats subjected to TBI only. In groups 1 and 2, BrdU-positive cells were localized to the boundary zone of the lesion, corpus callosum and cortex of the ipsilateral hemisphere. The number of BrdU-positive cells was significantly higher in the ipsilateral hemisphere than in the contralateral hemisphere. More MSCs infused intraarterially engrafted in group 1 (18.9%) than in group 2 (14.4%, p < 0.05). Using double staining, BrdU-positive cells expressed MAP-2, NeuN, and GFAP in both groups 1 and 2, with this expression being greater in group 1 and the difference between two groups reaching statistical significance in case of MAP-2. Our data suggest that intraarterial transplantation of MSCs is a viable route for the intracerebral administration of MSCs for the treatment of TBI, since MSCs infused intraarterially after TBI survive and migrate into the brain. Some implanted MSCs express proteins specific to neurons and astrocytes. The addition of NGF and BDNF promote migration of MSCs into the brain and subsequent expression of neuronal protein MAP-2.	Henry Ford Hlth Sci Ctr, Dept Neurol, Detroit, MI USA; Oakland Univ, Dept Phys, Rochester, MI 48063 USA							Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; CANEVA L, 1995, BLOOD CELL MOL DIS, V21, P738; CAPLAN AI, 1991, J ORTHOP RES, V9, P641, DOI 10.1002/jor.1100090504; Chen JL, 2000, NEUROPHARMACOLOGY, V39, P711, DOI 10.1016/S0028-3908(00)00006-X; Cramer SC, 2000, TRENDS NEUROSCI, V23, P265, DOI 10.1016/S0166-2236(00)01562-9; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Eglitis MA, 1997, P NATL ACAD SCI USA, V94, P4080, DOI 10.1073/pnas.94.8.4080; Eglitis MA, 1999, NEUROREPORT, V10, P1289, DOI 10.1097/00001756-199904260-00025; FISHER LJ, 1993, PHYSIOL REV, V73, P583; Kaya SS, 1999, BRAIN RES, V840, P153, DOI 10.1016/S0006-8993(99)01757-6; Kaya SS, 1999, J NEUROTRAUM, V16, P1187, DOI 10.1089/neu.1999.16.1187; Kaya SS, 1999, BRAIN RES, V818, P23, DOI 10.1016/S0006-8993(98)01204-9; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; Krum JM, 1999, EXP NEUROL, V160, P348, DOI 10.1006/exnr.1999.7222; Li Y, 2001, CELL TRANSPLANT, V10, P31; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; PEREIRA RF, 1995, P NATL ACAD SCI USA, V92, P4857, DOI 10.1073/pnas.92.11.4857; Philips MF, 1999, J NEUROSURG, V90, P116, DOI 10.3171/jns.1999.90.1.0116; Phinney DG, 1999, J CELL BIOCHEM, V72, P570; Postmantur R., 1997, NEUROSCIENCE, V77, P765; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Quesenberry PJ, 1999, J NEUROTRAUM, V16, P661, DOI 10.1089/neu.1999.16.661; Sharkis SJ, 1998, NAT MED, V4, P896, DOI 10.1038/nm0898-896; Weissman IL, 2000, SCIENCE, V287, P1442, DOI 10.1126/science.287.5457.1442; Zhang RL, 1997, BRAIN RES, V766, P83, DOI 10.1016/S0006-8993(97)00580-5; Ziegler BL, 1999, SCIENCE, V285, P1553, DOI 10.1126/science.285.5433.1553	26	176	202	0	7	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	2001	18	8					813	819		10.1089/089771501316919175			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	464AG	WOS:000170509600007	11526987				2021-06-18	
J	Sinz, EH; Kochanek, PM; Dixon, CE; Clark, RSB; Carcillo, JA; Schiding, JK; Chen, MZ; Wisniewski, SR; Carlos, TM; Williams, D; DeKosky, ST; Watkins, SC; Marion, DW; Billiar, TR				Sinz, EH; Kochanek, PM; Dixon, CE; Clark, RSB; Carcillo, JA; Schiding, JK; Chen, MZ; Wisniewski, SR; Carlos, TM; Williams, D; DeKosky, ST; Watkins, SC; Marion, DW; Billiar, TR			Inducible nitric oxide synthase is an endogenous neuroprotectant after traumatic brain injury in rats and mice	JOURNAL OF CLINICAL INVESTIGATION			English	Article							CONTROLLED CORTICAL IMPACT; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CEREBRAL BLOOD-FLOW; INFLAMMATORY RESPONSE; NEUTROPHIL ACCUMULATION; SUPEROXIDE-DISMUTASE; SYNAPTIC PLASTICITY; SELECTIVE INHIBITOR; MOUSE ASTROCYTES; GENE-EXPRESSION	Nitric oxide (NO) derived from the inducible isoform of NO synthase (iNOS) is an inflammatory product implicated both in secondary damage and in recovery from brain injury. To address the role of iNOS in experimental traumatic brain injury (TBI), we used in paradigms in 2 species. In a model of controlled cortical impact (CCI) with secondary hypoxemia, rats were treated with vehicle or with 1 of 2 iNOS inhibitors (aminoguanidine and L-N-iminoethyl-lysine), administered by Alzet pump for 5 days and 1.5 days after injury, respectively. In a model of CCI, knockout mice lacking the iNOS gene (iNOS(-/-)) were compared with wild-type (iNOS(+/+)) mice. Functional outcome (motor and cognitive) during the first 20 days after injury, and histopathology at 21 days, were assessed in both studies. Treatment of rats with either of the iNOS inhibitors after TBI significantly exacerbated deficits in cognitive performance, as assessed by Morris water maze (MWM) and increased neuron loss in vulnerable regions (CA3 and CA1) of hippocampus. Uninjured iNOS(+/+) and iNOS(-/-) mice performed equally well in both motor and cognitive tasks. However, after TBI, iNOS(-/-) mice showed markedly worse performance in the MWM task than iNOS(+/+) mice. A beneficial role for iNOS in TBI is supported.	Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Epidemiol & Publ Hlth, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Physiol & Cell Biol, Pittsburgh, PA 15260 USA	Kochanek, PM (corresponding author), Safar Ctr Resuscitat Res, 3434 5th Ave,201 Hill Bldg, Pittsburgh, PA 15260 USA.	kochanek@smtp.anes.upmc.edu	Kochanek, Patrick M/D-2371-2015; Marion, Donald/AAR-5749-2021	Kochanek, Patrick M/0000-0002-2627-913X; Sinz, Elizabeth/0000-0001-7129-6193; watkins, simon/0000-0003-4092-1552; Wisniewski, Stephen/0000-0002-3877-9860	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R37GM044100, R29GM044100, R01GM044100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038620, P20NS030318, P50NS030318, P01NS030318] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [GM-44100, R01 GM044100, R37 GM044100] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50 NS030318, NS-30318, NS38620, R01 NS038620, P01 NS030318] Funding Source: Medline		AWATSUJI H, 1993, J NEUROSCI RES, V34, P539, DOI 10.1002/jnr.490340506; BILLIAR TR, 1995, ANN SURG, V221, P339, DOI 10.1097/00000658-199504000-00003; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; Brodie C, 1996, FEBS LETT, V394, P117, DOI 10.1016/0014-5793(96)00911-8; Brodie C, 1998, J NEUROIMMUNOL, V81, P20, DOI 10.1016/S0165-5728(97)00154-9; Brown GC, 1997, MOL CELL BIOCHEM, V174, P189, DOI 10.1023/A:1006800322719; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Bryk R, 1998, BIOCHEMISTRY-US, V37, P4844, DOI 10.1021/bi972065t; Campbell IL, 1996, J NEUROIMMUNOL, V71, P31, DOI 10.1016/S0165-5728(96)00129-4; CARCILLO JA, 1994, PCR METH APPL, V3, P292; CHENG B, 1994, NEURON, V12, P139, DOI 10.1016/0896-6273(94)90159-7; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; Clark RSB, 1997, J NEUROSCI, V17, P9172; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Cockroft KM, 1996, STROKE, V27, P1393, DOI 10.1161/01.STR.27.8.1393; D'Ambrosio R, 1998, BRAIN RES, V786, P64, DOI 10.1016/S0006-8993(97)01412-1; DeKosky ST, 1996, ANN NEUROL, V39, P123, DOI 10.1002/ana.410390118; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; DINERMAN JL, 1994, P NATL ACAD SCI USA, V91, P4214, DOI 10.1073/pnas.91.10.4214; Ding MZ, 1997, J NEUROIMMUNOL, V77, P99, DOI 10.1016/S0165-5728(97)00065-9; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Estevez AG, 1998, J NEUROSCI, V18, P3708; Farinelli SE, 1996, J NEUROSCI, V16, P2325; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Fenyk-Melody JE, 1998, J IMMUNOL, V160, P2940; Feuerstein GZ, 1997, ANN NY ACAD SCI, V825, P179, DOI 10.1111/j.1749-6632.1997.tb48428.x; Forbes ML, 1997, J CEREBR BLOOD F MET, V17, P865, DOI 10.1097/00004647-199708000-00005; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; Hallenbeck JM, 1996, ACT NEUR S, V66, P27; Hickey MJ, 1997, FASEB J, V11, P955; Hierholzer C, 1998, J EXP MED, V187, P917, DOI 10.1084/jem.187.6.917; Holscher C, 1997, TRENDS NEUROSCI, V20, P298, DOI 10.1016/S0166-2236(97)01065-5; Huang ZH, 1996, J CEREBR BLOOD F MET, V16, P981, DOI 10.1097/00004647-199609000-00023; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; IADECOLA C, 1995, AM J PHYSIOL-REG I, V268, pR286; IADECOLA C, 1995, J CEREBR BLOOD F MET, V15, P378, DOI 10.1038/jcbfm.1995.47; Iadecola C, 1997, J NEUROSCI, V17, P9157; Iadecola C, 1996, STROKE, V27, P1373, DOI 10.1161/01.STR.27.8.1373; Kantor DB, 1996, SCIENCE, V274, P1744, DOI 10.1126/science.274.5293.1744; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Lassmann H, 1997, J NEURAL TRANSM-SUPP, P183; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MacLean A, 1998, J GEN VIROL, V79, P825, DOI 10.1099/0022-1317-79-4-825; Mattson MP, 1997, J NEUROSCI RES, V49, P681, DOI 10.1002/(SICI)1097-4547(19970915)49:6<681::AID-JNR3>3.0.CO;2-3; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MOORE WM, 1994, J MED CHEM, V37, P3886, DOI 10.1021/jm00049a007; ODELL TJ, 1994, SCIENCE, V265, P542, DOI 10.1126/science.7518615; Okuda Y, 1998, J NEUROIMMUNOL, V81, P201, DOI 10.1016/S0165-5728(97)00180-X; Pfister HW, 1997, CURR OPIN NEUROL, V10, P254, DOI 10.1097/00019052-199706000-00015; Sahrbacher UC, 1998, EUR J IMMUNOL, V28, P1332, DOI 10.1002/(SICI)1521-4141(199804)28:04<1332::AID-IMMU1332>3.3.CO;2-7; Scherbel U., 1997, J NEUROTRAUM, V14, P781; Schulz JB, 1995, J NEUROSCI, V15, P8419; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; Silva AJ, 1997, NEURON, V19, P755, DOI 10.1016/S0896-6273(00)80958-7; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Southan GJ, 1996, BIOCHEM PHARMACOL, V51, P383, DOI 10.1016/0006-2952(95)02099-3; STOFFEL M, 1999, P 11 INT S BRAIN OED, P62; Taylor BS, 1998, J BIOL CHEM, V273, P15148, DOI 10.1074/jbc.273.24.15148; Tzeng E, 1997, SURGERY, V122, P255, DOI 10.1016/S0039-6060(97)90016-7; VONSTRUCK SL, 1996, J NEUROTRAUM, V13, P618; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; WEI XQ, 1995, NATURE, V375, P408, DOI 10.1038/375408a0; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; Whalen MJ, 1998, ACT NEUR S, V71, P212; Wray GM, 1998, SHOCK, V9, P329, DOI 10.1097/00024382-199805000-00003; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YOSHIDA T, 1994, J CEREBR BLOOD F MET, V14, P924, DOI 10.1038/jcbfm.1994.123; Zhang FY, 1996, STROKE, V27, P317, DOI 10.1161/01.STR.27.2.317	74	176	179	0	7	AMER SOC CLINICAL INVESTIGATION INC	ANN ARBOR	2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA	0021-9738	1558-8238		J CLIN INVEST	J. Clin. Invest.	SEP	1999	104	5					647	656		10.1172/JCI6670			10	Medicine, Research & Experimental	Research & Experimental Medicine	251WF	WOS:000083468800015	10487779	Green Published, Bronze			2021-06-18	
J	MUIZELAAR, JP; MARMAROU, A; YOUNG, HF; CHOI, SC; WOLF, A; SCHNEIDER, RL; KONTOS, HA				MUIZELAAR, JP; MARMAROU, A; YOUNG, HF; CHOI, SC; WOLF, A; SCHNEIDER, RL; KONTOS, HA			IMPROVING THE OUTCOME OF SEVERE HEAD-INJURY WITH THE OXYGEN RADICAL SCAVENGER POLYETHYLENE GLYCOL-CONJUGATED SUPEROXIDE-DISMUTASE - A PHASE-II TRIAL	JOURNAL OF NEUROSURGERY			English	Article						SEVERE HEAD INJURY; OXYGEN RADICAL SCAVENGER; POLYETHYLENE GLYCOL; SUPEROXIDE DISMUTASE; PHASE-II TRIAL; GLASGOW OUTCOME SCALE	EXPERIMENTAL BRAIN INJURY; EXTRACELLULAR POTASSIUM; NITRIC-OXIDE; ISCHEMIA; METABOLISM; PREDICTION; CORTEX; EDEMA; ANION; COMA	Formation of the oxygen radical superoxide anion is one of the final events of several metabolic pathways in the cascade that leads to delayed neuronal death after traumatic or ischemic brain injury. In the laboratory, scavenging of the superoxide anion with native superoxide dismutase (SOD) or polyethylene glycol (PEG)-conjugated SOD (PEG-SOD) has been shown to be beneficial in several types of traumatic and ischemic injury. Accordingly, PEG-SOD was utilized in a randomized controlled Phase II trial to evaluate its safety and efficacy in severely head-injured patients with a Glasgow Coma Scale score of 8 or less. At two institutions, 104 patients were randomly assigned to receive either placebo or PEG-SOD (2000, 5000, or 10,000 U/kg) intravenously as a bolus, an average of 4 hours after injury. Prognostic factors were evenly distributed in the four groups, except for mean age which was significantly higher in the group receiving 10,000 U/kg than in the placebo group (mean age 34 years vs. 25 years). No complications attributed to the study medication were noted. The average intracranial pressure (ICP) was similar in the four groups, but the percentage of time during which ICP was above 20 mm Hg was less in the groups receiving 5000 or 10,000 U/kg of PEG-SOD. Patients in the group receiving 10,000 U/kg also required less mannitol for ICP control than the placebo group. Outcome was assessed using the Glasgow Outcome Scale at 3 and 6 months postinjury in 91 and 93 patients, respectively, by blinded observers not involved in the clinical management of the patients. At 3 months, 44% of patients in the placebo group were vegetative or had died, while only 20% of patients in the group receiving 10,000 U/kg of PEG-SOD were in these outcome categories (p < 0.03, multiple logistic regression test), at 6 months, these figures were 36% and 21%, respectively (p = 0.04). Differences in outcome between the placebo group and either of the other two dosage groups were not statistically significant. It is concluded that PEG-SOD was generally well tolerated and appears promising in improving outcome after severe head injury. A larger, multicenter, Phase III trial, using a higher dose (20,000 U/kg) compared to placebo and to 10,000 U/kg of PEG-SOD is planned.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DIV CARDIOL,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT BIOSTAT,RICHMOND,VA 23298; UNIV MARYLAND,MED CTR,MARYLAND INST EMERGENCY MED SERV SYST,CTR SHOCK TRAUMA,BALTIMORE,MD 21201; STERLING WINTHROP INC,CLIN RES CTR,MALVERN,PA	MUIZELAAR, JP (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DIV NEUROSURG,BOX 631,RICHMOND,VA 23298, USA.				PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [1A 54600-1758-A1] Funding Source: Medline		BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BRAUGHLER JM, 1985, J NEUROSURG, V62, P806, DOI 10.3171/jns.1985.62.6.0806; CHAN PH, 1982, J NEUROCHEM, V38, P525, DOI 10.1111/j.1471-4159.1982.tb08659.x; CHOI SC, 1983, J NEUROSURG, V59, P294, DOI 10.3171/jns.1983.59.2.0294; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; DAVIS RJ, 1988, CEREBRAL HYPEREMIA I, P151; DESALLES A A F, 1986, Society for Neuroscience Abstracts, V12, P967; ELLIS EF, 1981, J NEUROCHEM, V37, P892, DOI 10.1111/j.1471-4159.1981.tb04476.x; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FOULKES MA, 1991, J NEUROSURG, V75, pS8, DOI 10.3171/sup.1991.75.1s.00s8; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; HAUN SE, 1991, STROKE, V22, P655, DOI 10.1161/01.STR.22.5.655; IMAIZUMI S, 1990, STROKE, V21, P1312, DOI 10.1161/01.STR.21.9.1312; JENNETT B, 1975, LANCET, V1, P480; JONSSON G, 1976, MED BIOL, V54, P406; KATAYAMA Y, 1988, Society for Neuroscience Abstracts, V14, P1154; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KATUSIC ZS, 1989, AM J PHYSIOL, V257, pH33; KONTOS H, 1986, J NEUROTRAUM, V3, P257; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; KONTOS HA, 1989, CENT NERV SYST TRAUM, V7, P787; LEVASSEUR JE, 1989, J NEUROSURG, V71, P573, DOI 10.3171/jns.1989.71.4.0573; LIU TH, 1989, AM J PHYSIOL, V256, pH589; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL JJ, 1988, AM J PHYSIOL, V255, pH847; MATSUMIYA N, 1991, STROKE, V22, P1193, DOI 10.1161/01.STR.22.9.1193; MAYER ML, 1987, TRENDS NEUROSCI, V10, P59, DOI 10.1016/0166-2236(87)90023-3; MISRA HP, 1972, J BIOL CHEM, V247, P3170; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; MUIZELAAR JP, IN PRESS J NEUROTRAU; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; RUBANYI GM, 1986, AM J PHYSIOL, V250, pH822; SCHETTINI A, 1989, J NEUROSURG, V71, P578, DOI 10.3171/jns.1989.71.4.0578; SCHLAEPFER WW, 1980, CELL CALCIUM, V2, P235; SCHWARTZ D, 1967, J CHRON DIS, V20, P637, DOI 10.1016/0021-9681(67)90041-0; SNELLING L K, 1987, Anesthesiology (Hagerstown), V67, pA153, DOI 10.1097/00000542-198709001-00153; TAKAHASHI H, 1981, J NEUROSURG, V55, P708, DOI 10.3171/jns.1981.55.5.0708; TEASDALE G, 1974, LANCET, V2, P81; WEI EP, 1982, J NEUROSURG, V56, P695, DOI 10.3171/jns.1982.56.5.0695; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; YOSHIDA K, 1992, J NEUROTRAUM, V9, P85, DOI 10.1089/neu.1992.9.85; YOSHIDA K, 1992, STROKE, V23, P865, DOI 10.1161/01.STR.23.6.865; ZIMMERMAN RS, 1989, INTRACRANIAL PRESSUR, V7, P804	48	176	179	2	12	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	MAR	1993	78	3					375	382		10.3171/jns.1993.78.3.0375			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	KN936	WOS:A1993KN93600001	8433137				2021-06-18	
J	Henry, LC; Tremblay, J; Tremblay, S; Lee, A; Brun, C; Lepore, N; Theoret, H; Ellemberg, D; Lassonde, M				Henry, Luke C.; Tremblay, Julie; Tremblay, Sebastien; Lee, Agatha; Brun, Caroline; Lepore, Natasha; Theoret, Hugo; Ellemberg, Dave; Lassonde, Maryse			Acute and Chronic Changes in Diffusivity Measures after Sports Concussion	JOURNAL OF NEUROTRAUMA			English	Article						acute; chronic; diffusion tensor imaging; sports concussion	TRAUMATIC BRAIN-INJURY; WHITE-MATTER INJURY; AXONAL INJURY; INTERNATIONAL-CONFERENCE; FIBER TRACTOGRAPHY; CELL-VOLUME; ACUTE MILD; LONG-TERM; ANISOTROPY; STATEMENT	Despite negative neuroimaging findings in concussed athletes, studies indicate that the acceleration and deceleration of the brain after concussive impacts result in metabolic and electrophysiological alterations that may be attributable to changes in white matter resulting from biomechanical strain. In the present study we investigated the effects of sports concussion on white matter using three different diffusion tensor imaging (DTI) measures: fractional anisotropy (FA), mean diffusivity (MD), and axial diffusivity (AD). We compared a group of 10 non-concussed athletes with a group of 18 concussed athletes of the same age (mean age 22.5 years) and education (mean 16 years) using a voxel-based approach (VBA) in both the acute and chronic post-injury phases. All concussed athletes were scanned 1-6 days post-concussion and again 6 months later in a 3T Siemens Trio (TM) MRI. Three 2 x 2 repeated-measures analyses of variance (ANOVAs) were conducted, one for each measure of DTI used in the current study. There was a main group effect of FA, which was increased in dorsal regions of both corticospinal tracts (CST) and in the corpus callosum in concussed athletes at both time points. There was a main group effect of AD in the right CST, where concussed athletes showed elevated values relative to controls at both time points. MD values were decreased in concussed athletes, in whom analyses revealed significant group differences in the CST and corpus callosum at both time points. Although the use of VBA does limit the analyses to large tracts, and it has clinical limitations with regard to individual analyses, our results nevertheless indicate that sports concussions do result in changes in diffusivity in the corpus callosum and CST that are not detected using conventional neuroimaging techniques.	[Henry, Luke C.; Tremblay, Sebastien; Theoret, Hugo; Ellemberg, Dave; Lassonde, Maryse] Univ Montreal, Dept Psychol, Montreal, PQ H2V 2S9, Canada; [Tremblay, Julie; Theoret, Hugo; Lassonde, Maryse] Hop Ste Justine, Montreal, PQ, Canada; [Ellemberg, Dave] Univ Montreal, Dept Kinesiol, Montreal, PQ H2V 2S9, Canada; [Brun, Caroline] Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA; [Lepore, Natasha] Univ So Calif, Dept Neurol, Los Angeles, CA USA; [Lee, Agatha] Univ Calif Los Angeles, Lab Neuroimaging, Los Angeles, CA USA	Henry, LC (corresponding author), Univ Montreal, Dept Psychol, 90 Ave Vincent DIndy, Montreal, PQ H2V 2S9, Canada.	luke.henry@umontreal.ca		Theoret, Hugo/0000-0002-7458-8797; Tremblay, Sebastien/0000-0001-6251-9797			Alexander DC, 2001, IEEE T MED IMAGING, V20, P1131, DOI 10.1109/42.963816; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bain AC, 2000, J BIOMECH ENG-T ASME, V122, P615, DOI 10.1115/1.1324667; Barr M., 2005, HUMAN NERVOUS SYSTEM; Bhagat YA, 2006, J CEREBR BLOOD F MET, V26, P1442, DOI 10.1038/sj.jcbfm.9600294; Bigler ED, 1999, J HEAD TRAUMA REHAB, V14, P406, DOI 10.1097/00001199-199908000-00009; Bruce JM, 2009, NEUROSURGERY, V64, P100, DOI 10.1227/01.NEU.0000336310.47513.C8; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Chappell MH, 2006, J MAGN RESON IMAGING, V24, P537, DOI 10.1002/jmri.20656; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; De Beaumont L., NEUROLOGY IN PRESS; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Ducreux D, 2005, NEURORADIOLOGY, V47, P604, DOI 10.1007/s00234-005-1389-1; Ducreux D, 2005, AM J NEURORADIOL, V26, P1840; Ellemberg D, 2009, J NEUROTRAUM, V26, P2365, DOI 10.1089/neu.2009.0906; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; Gennarelli TA, 1996, NEUROPATH APPL NEURO, V22, P509, DOI 10.1111/j.1365-2990.1996.tb01126.x; GENTRY LR, 1994, RADIOLOGY, V191, P1; Gerberding J.L., 2003, REPORT C MILD TRAUMA, P56; Giza CC, 2001, J ATHL TRAINING, V36, P228; Green HAL, 2002, STROKE, V33, P1517, DOI 10.1161/01.STR.0000016973.80180.7B; Guskiewicz KM, 2004, NEUROSURGERY, V55, P891, DOI 10.1227/01.NEU.0000143800.49798.19; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hartikainen KM, 2010, J CLIN EXP NEUROPSYC, V32, P767, DOI 10.1080/13803390903521000; Henry L.C., METABOLIC CHAN UNPUB; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Hinton-Bayre AD, 2002, NEUROLOGY, V59, P1068, DOI 10.1212/WNL.59.7.1068; Hofer S, 2006, NEUROIMAGE, V32, P989, DOI 10.1016/j.neuroimage.2006.05.044; Holbourn AHS, 1943, LANCET, V2, P438; HOLBOURN AHS, 1945, BRIT MED BULL, V3, P147, DOI 10.1093/oxfordjournals.bmb.a071895; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Hurley RA, 2004, J NEUROPSYCH CLIN N, V16, P1, DOI 10.1176/appi.neuropsych.16.1.1; Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6; Johnston KM, 2001, CLIN J SPORT MED, V11, P166, DOI 10.1097/00042752-200107000-00007; Kochunov P, 2001, J COMPUT ASSIST TOMO, V25, P805, DOI 10.1097/00004728-200109000-00023; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Lang F, 1998, PHYSIOL REV, V78, P247; Le TH, 2005, NEUROSURGERY, V56, P189, DOI 10.1227/01.NEU.0000144846.00569.3A; Lee JW, 2006, J HEAD TRAUMA REHAB, V21, P272, DOI 10.1097/00001199-200605000-00007; Lepore N, 2008, IEEE T MED IMAGING, V27, P129, DOI 10.1109/TMI.2007.906091; Lepore N, 2006, LECT NOTES COMPUT SC, V4190, P191; MAXWELL WL, 1988, ACTA NEUROPATHOL, V76, P395, DOI 10.1007/BF00686977; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; Newcombe VFJ, 2008, ACTA NEUROCHIR SUPPL, V102, P247, DOI 10.1007/978-3-211-85578-2_47; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Okumura Ayumi, 2005, No To Shinkei, V57, P115; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; Pfefferbaum A, 2003, MAGNET RESON MED, V49, P953, DOI 10.1002/mrm.10452; Pierpaoli C, 1996, RADIOLOGY, V201, P637, DOI 10.1148/radiology.201.3.8939209; PUDENZ RH, 1946, J NEUROSURG, V3, P487, DOI 10.3171/jns.1946.3.6.0487; Quality Standards Subcommittee and Neurology AAo, 1997, NEUROBIOLOGY BP, P1; Shen S, 2007, MAGN RESON IMAGING, V25, P1385, DOI 10.1016/j.mri.2007.03.025; Song SK, 2002, NEUROIMAGE, V17, P1429, DOI 10.1006/nimg.2002.1267; STRANGE K, 1992, J AM SOC NEPHROL, V3, P12; Theriault M, 2010, J CLIN EXP NEUROPSYC, V17, P1; Toga A.W., 2002, BRAIN MAPPING METHOD; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; Westlye LT, 2010, CEREB CORTEX, V20, P2055, DOI 10.1093/cercor/bhp280; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2010, DEV NEUROPSYCHOL, V35, P333, DOI 10.1080/87565641003696940; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Wozniak JR, 2006, NEUROSCI BIOBEHAV R, V30, P762, DOI 10.1016/j.neubiorev.2006.06.003; Zhang H, 2006, MED IMAGE ANAL, V10, P764, DOI 10.1016/j.media.2006.06.004; Zillmer E. A., 2001, PRINCIPLES NEUROPSYC	83	175	180	1	22	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2011	28	10					2049	2059		10.1089/neu.2011.1836			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	839OX	WOS:000296378500006	21864134				2021-06-18	
J	Makdissi, M; Darby, D; Maruff, P; Ugoni, A; Brukner, P; McCrory, PR				Makdissi, Michael; Darby, David; Maruff, Paul; Ugoni, Antony; Brukner, Peter; McCrory, Paul R.			Natural History of Concussion in Sport Markers of Severity and Implications for Management	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						brain trauma; concussion; sport; injury severity	TRAUMATIC BRAIN-INJURY; NEUROPSYCHOLOGICAL TEST-PERFORMANCE; COLLEGIATE FOOTBALL PLAYERS; PROFESSIONAL FOOTBALL; RECURRENT CONCUSSION; AGREEMENT STATEMENT; AUSTRALIAN FOOTBALL; NCAA CONCUSSION; CONTACT SPORTS; RECOVERY	Background: Evidence-based clinical data are required for safe return to play after concussion in sport. Purpose: The objective of this study was to describe the natural history of concussion in sport and identify clinical features associated with more severe concussive injury, using return-to-sport decisions as a surrogate measure of injury severity. Study Design: Cohort study (prognosis); Level of evidence, 3. Methods: Male elite senior, elite junior, and community-based Australian Rules football players had preseason baseline cognitive testing (Digit Symbol Substitution Test, Trail-Making Test-Part B, and CogSport computerized test battery). Players were recruited into the study after a concussive injury sustained while playing football. Concussed players were tested serially until all clinical features of their injury had resolved. Results: Of 1015 players, 88 concussions were observed in 78 players. Concussion-associated symptoms lasted an average of 48.6 hours (95% confidence interval, 39.5-57.7 hours) with delayed return to sport correlated with >= 4 symptoms, headache lasting >= 60 hours, or self-reported "fatigue/fogginess." Cognitive deficits using the Digit Symbol Substitution Test and Trail-Making Test-part B recovered concomitantly with symptoms, but computerized test results recovered 2 to 3 days later and remained impaired in 35% of concussed players after symptom resolution. Conclusion: Delayed return to sport was associated with initially greater symptom load, prolonged headache, or subjective concentration deficits. Cognitive testing recovery varied, taking 2 to 3 days longer for computerized tests, suggesting greater sensitivity to impairment. Therefore, symptom assessment alone may be predictive of but may underestimate time to complete recovery, which may be better estimated with computerized cognitive testing.	[Makdissi, Michael; Ugoni, Antony; Brukner, Peter; McCrory, Paul R.] Univ Melbourne, Ctr Hlth Exercise & Sports Med, Parkville, Vic 3052, Australia; [Darby, David; Maruff, Paul] CogState Ltd, Melbourne, Australia	Makdissi, M (corresponding author), Univ Melbourne, Ctr Hlth Exercise & Sports Med, Parkville, Vic 3052, Australia.	makdissi@unimelb.edu.au	McCrory, Paul/Q-8688-2019; Maruff, Paul/AAD-2454-2021; Maruff, Paul/ABA-1673-2020	Maruff, Paul/0000-0002-6947-9537; McCrory, Paul/0000-0003-4850-0568	CogState Ltd	One or more of the authors has declared a potential conflict of interest: Drs Darby and Maruff were employees of and held stock in CogState Ltd, the suppliers of the computerized cognitive test battery used in this study. Dr McCrory received research grant support from CogState Ltd.	[Anonymous], 1944, ARMY INDIVIDUAL TEST; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barth JT., 1989, MILD HEAD INJURY, P257; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; *C NEUR SURG, 1966, CLIN NEUROSURG, V12, P386; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Collie A, 2004, BRIT J SPORT MED, V38, P273, DOI 10.1136/bjsm.2003.000293; Collie A, 2003, BRIT J SPORT MED, V37, P556, DOI 10.1136/bjsm.37.6.556; Collie A, 2003, J INT NEUROPSYCH SOC, V9, P419, DOI 10.1017/S1355617703930074; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Koh JO, 2003, BRAIN INJURY, V17, P901, DOI 10.1080/0269905031000088869; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Leclerc S, 2001, SPORTS MED, V31, P629, DOI 10.2165/00007256-200131080-00007; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; MADDOCKS D, 1989, SPORT HLTH S, V7, P6; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; Makdissi M, 2009, AM J SPORT MED, V37, P877, DOI 10.1177/0363546508328118; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory PR, 2000, CLIN J SPORT MED, V10, P235, DOI 10.1097/00042752-200010000-00002; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; WESCHLER D, 1981, WESCHLER ADULT INTEL	40	175	177	2	29	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	MAR	2010	38	3					464	471		10.1177/0363546509349491			8	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	559ED	WOS:000274803800004	20194953				2021-06-18	
J	Vanderploeg, RD; Belanger, HG; Curtiss, G				Vanderploeg, Rodney D.; Belanger, Heather G.; Curtiss, Glenn			Mild Traumatic Brain Injury and Posttraumatic Stress Disorder and Their Associations With Health Symptoms	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain concussion; Mental disorders; Neurobehavioral manifestations; Rehabilitation; Social support	MINOR HEAD-INJURY; POSTCONCUSSION SYMPTOMS; MODERATE	Mild traumatic brain injury and posttraumatic stress disorder and their associations with health symptoms. Objective: To determine the association of various symptoms and psychiatric diagnoses with a remote history of mild traumatic brain injury (MTBI) and a current diagnosis of posttraumatic stress disorder (PTSD). Design: Cross-sectional cohort Study. Setting: Nonclinical. Participants: Three groups of randomly selected community dwelling male U.S. Army Vietnam-era veterans: healthy control (n=3218), those injured in a motor vehicle collision (MVC) but without a head injury (MVC injury control; n=548), and those who had an MTBI (n=278). Interventions: None. Main Outcome Measures: Prevalence of psychiatric diagnoses, physical, cognitive, and emotional symptoms, and course of PTSD across time. Results: Logistic regression procedures were used to determine group association with symptoms and psychiatric diagnosis after controlling for demographic variables, combat intensity, medical disorders, and other current psychiatric conditions. MTBI was associated with headaches, memory problems, sleep problems, and fainting even after controlling for current psychiatric problems (including PTSD), as well as demographic variables, combat intensity, and comorbid medical conditions. MTBI also was associated with a current diagnosis of PTSD even controlling for other demographic, psychiatric, and medical covariates. MTBI did not moderate or mediate the relationship between PTSD and current symptomatology. However, MTBI did adversely affect long-term recovery from PTSD (odds ratio = 1.59, 95% CI, 1.07-2.37). PTSD also was associated with physical, cognitive, and emotional symptoms, and had a larger effect size than MTBI. Conclusions: MTBI, even in the chronic phase years postinjury, is not a benign condition. It is associated with increased rates of headaches, sleep problems, and memory difficulties. Furthermore, it can complicate or prolong recovery from preexisting or comorbid conditions such as PTSD. Similarly, PTSD is a potent cocontributor to physical, cognitive, and emotional symptoms.	[Vanderploeg, Rodney D.; Belanger, Heather G.; Curtiss, Glenn] James A Haley Vet Affairs Med Ctr, Dept Mental Hlth & Behav Sci, Tampa, FL USA; [Vanderploeg, Rodney D.; Belanger, Heather G.; Curtiss, Glenn] James A Haley Vet Affairs Med Ctr, Def & Vet Brain Injury Ctr, Tampa, FL USA; [Vanderploeg, Rodney D.; Curtiss, Glenn] Univ S Florida, Dept Psychiat, Tampa, FL USA; [Vanderploeg, Rodney D.; Curtiss, Glenn] Univ S Florida, Dept Behav Med, Tampa, FL USA; [Vanderploeg, Rodney D.; Belanger, Heather G.] Univ S Florida, Dept Psychol, Tampa, FL 33620 USA	Vanderploeg, RD (corresponding author), James A Haley Vet Hosp, Psychol Serv 116B, Tampa, FL 33612 USA.	Rodney.Vanderploeg@va.gov	Curtiss, Glenn/ABB-5566-2020		Department of Veterans Affairs, Veterans Health AdministrationUS Department of Veterans Affairs; Defense and Veterans Brain Injury CenterUS Department of Veterans Affairs; James A. Haley Veterans HospitalUS Department of Veterans Affairs	Supported by the Department of Veterans Affairs, Veterans Health Administration; the Defense and Veterans Brain Injury Center; and James A. Haley Veterans Hospital where the study was completed. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs.	Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; American Psychiatric Association, 1980, DIAGN STAT MAN MENT, V3rd; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; [Anonymous], 1988, JAMA, V259, P2701; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; *CDC, 1989, HLTH STAT VIETN VET, V4; Deb S, 1999, BRIT J PSYCHIAT, V174, P360, DOI 10.1192/bjp.174.4.360; DESTEFANO F, 1988, JAMA-J AM MED ASSOC, V259, P2708; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; Eisenberg H. M., 1989, MILD HEAD INJURY, P133; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Hartlage LC, 2001, ARCH CLIN NEUROPSYCH, V16, P561, DOI 10.1016/S0887-6177(00)00067-6; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Kibby MY, 1996, BRAIN INJURY, V10, P159, DOI 10.1080/026990596124494; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; KRAUS JF, 1988, J TRAUMA, V28, P1637, DOI 10.1097/00005373-198812000-00004; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Luis CA, 2003, J INT NEUROPSYCH SOC, V9, P1001, DOI 10.1017/S1355617703970044; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; MONTAGUE E K, 1957, U S Armed Forces Med J, V8, P883; Nicholson K, 2000, NEUROREHABILITATION, V14, P95; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Perlis ML, 1997, PERCEPT MOTOR SKILL, V84, P595, DOI 10.2466/pms.1997.84.2.595; Powell TJ, 1996, DISABIL REHABIL, V18, P231, DOI 10.3109/09638289609166306; ROBINS LN, 1981, ARCH GEN PSYCHIAT, V38, P381; SCOTT BA, 1986, NEUROSURGERY, V18, P107, DOI 10.1227/00006123-198601000-00020; Scott SG, 2005, FEDERAL PRACTITIONER, V22, P67; Sobel M.E., 1982, SOCIOL METHODOL, P290, DOI [DOI 10.2307/270723, 10.2307/270723]; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; WOOD F, 1984, INT J PSYCHIAT MED, V14, P277	32	175	177	0	18	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUL	2009	90	7					1084	1093		10.1016/j.apmr.2009.01.023			10	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	470SA	WOS:000267999000003	19577020				2021-06-18	
J	Wu, AG; Ying, Z; Gomez-Pinilla, F				Wu, AG; Ying, Z; Gomez-Pinilla, F			Dietary curcumin counteracts the outcome of traumatic brain injury on oxidative stress, synaptic plasticity, and cognition	EXPERIMENTAL NEUROLOGY			English	Article						traumatic brain injury; hippocampus; learning; BDNF; curcumin	LONG-TERM POTENTIATION; SATURATED-FAT DIET; NEUROTROPHIC FACTOR; VITAMIN-E; NEURONAL PLASTICITY; LIPID-PEROXIDATION; LEARNING-DEFICITS; SPATIAL MEMORY; MUTANT MICE; SYNAPSIN-I	The pervasive action of oxidative stress oil neuronal function and plasticity after traumatic brain injury (TBI) is becoming increasingly recognized. Here, we evaluated the capacity of the powerful antioxidant curry spice curcumin ingested in the diet to counteract the oxidative damage encountered in the injured brain. In addition, we have examined the possibility that dietary curcumin may favor the injured brain by interacting with molecular mechanisms that maintain synaptic plasticity and cognition. The analysis was focused on the BDNF system based oil its action on synaptic plasticity and cognition by modulating synapsin I and CREB. Rats were exposed to a regular diet or a diet high in saturated fat, with or without 500 ppm curcumin for 4 weeks (n = 8/group), before a mild fluid percussion injury (FPI) was performed. The high-fat diet has been shown to exacerbate the effects of TBI oil synaptic plasticity and cognitive function. Supplementation of curcumin in the diet dramatically reduced oxidative damage and normalized levels of BDNF, synapsin I, and CREB that had been altered after TBI. Furthermore, curcumin supplementation counteracted the cognitive impairment caused by TBI. These results are in agreement with previous evidence, showing that oxidative stress can affect the injured brain by acting through the BDNF system to affect synaptic plasticity and cognition. The fact that oxidative stress is an intrinsic component of the neurological sequel of TBI and other insults indicates that dietary antioxidant therapy is a realistic approach to promote protective mechanisms in the injured brain. (c) 2005 Elsevier Inc. All rights reserved.	Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Div Neurosurg, Brain Injury Res Ctr, Los Angeles, CA 90095 USA	Gomez-Pinilla, F (corresponding author), Univ Calif Los Angeles, Dept Physiol Sci, 621 Charles E Young Dr, Los Angeles, CA 90095 USA.	tgomezpi@ucla.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS39522, NS45804] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS045804, R01NS039522] Funding Source: NIH RePORTER		Bolton MM, 2000, PROG BRAIN RES, V128, P203; BROCK TO, 1987, J NEUROSCI, V7, P931; Butterfield DA, 2002, FREE RADICAL BIO MED, V32, P1050, DOI 10.1016/S0891-5849(02)00794-3; Drapeau E, 2003, P NATL ACAD SCI USA, V100, P14385, DOI 10.1073/pnas.2334169100; Finkbeiner S, 2000, NEURON, V25, P11, DOI 10.1016/S0896-6273(00)80866-1; Frautschy SA, 2001, NEUROBIOL AGING, V22, P993, DOI 10.1016/S0197-4580(01)00300-1; Fukui K, 2002, ANN NY ACAD SCI, V959, P275, DOI 10.1111/j.1749-6632.2002.tb02099.x; Hariri AR, 2003, J NEUROSCI, V23, P6690, DOI 10.1523/jneurosci.23-17-06690.2003; Joseph JA, 1998, J NEUROSCI, V18, P8047; Jovanovic JN, 1996, P NATL ACAD SCI USA, V93, P3679, DOI 10.1073/pnas.93.8.3679; Kafitz KW, 1999, NATURE, V401, P918, DOI 10.1038/44847; Kang HJ, 1996, SCIENCE, V273, P1402, DOI 10.1126/science.273.5280.1402; Kelly A, 2003, J NEUROSCI, V23, P5354; KORTE M, 1995, P NATL ACAD SCI USA, V92, P8856, DOI 10.1073/pnas.92.19.8856; Levine ES, 1998, P NATL ACAD SCI USA, V95, P10235, DOI 10.1073/pnas.95.17.10235; Lim GP, 2001, J NEUROSCI, V21, P8370; Linnarsson S, 1997, EUR J NEUROSCI, V9, P2581, DOI 10.1111/j.1460-9568.1997.tb01687.x; Liu RL, 2003, P NATL ACAD SCI USA, V100, P8526, DOI 10.1073/pnas.1332809100; Marklund N, 2001, J NEUROTRAUM, V18, P1217, DOI 10.1089/089771501317095250; MartinAragon S, 1997, J PHARM PHARMACOL, V49, P49, DOI 10.1111/j.2042-7158.1997.tb06751.x; Molteni R, 2004, NEUROSCIENCE, V123, P429, DOI 10.1016/j.neuroscience.2003.09.020; Molteni R, 2002, NEUROSCIENCE, V112, P803, DOI 10.1016/S0306-4522(02)00123-9; Mu JS, 1999, BRAIN RES, V835, P259, DOI 10.1016/S0006-8993(99)01592-9; Nagai T, 2002, FASEB J, V16, P50, DOI 10.1096/fj.02-0448fje; Ono K, 2004, J NEUROSCI RES, V75, P742, DOI 10.1002/jnr.20025; Paolin A, 2002, NEUROSURGERY, V51, P949, DOI 10.1227/01.NEU.0000027881.33381.3F; Patterson SL, 1996, NEURON, V16, P1137, DOI 10.1016/S0896-6273(00)80140-3; Sherwood NT, 1999, J NEUROSCI, V19, P7025, DOI 10.1523/JNEUROSCI.19-16-07025.1999; Steffenach HA, 2002, P NATL ACAD SCI USA, V99, P3194, DOI 10.1073/pnas.042700999; Sugaya K, 1996, J NEUROSCI, V16, P3427; Sung S, 2003, FASEB J, V17, P323, DOI 10.1096/fj.03-0961fje; Thiyagarajan M, 2004, LIFE SCI, V74, P969, DOI 10.1016/j.lfs.2003.06.042; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; Tyler WJ, 2001, J NEUROSCI, V21, P4249, DOI 10.1523/JNEUROSCI.21-12-04249.2001; Veinbergs I, 2000, EUR J NEUROSCI, V12, P4541, DOI 10.1111/j.1460-9568.2000.01308.x; WANG T, 1995, J NEUROSCI, V15, P4796; Wilson IA, 2004, J NEUROSCI, V24, P3870, DOI 10.1523/JNEUROSCI.5205-03.2004; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Wu A, 2003, NEUROSCIENCE, V119, P365, DOI 10.1016/S0306-4522(03)00154-4; Wu AG, 2004, EUR J NEUROSCI, V19, P1699, DOI 10.1111/j.1460-9568.2004.03246.x; Yang FS, 2005, J BIOL CHEM, V280, P5892, DOI 10.1074/jbc.M404751200; Ying SW, 2002, J NEUROSCI, V22, P1532, DOI 10.1523/JNEUROSCI.22-05-01532.2002	42	175	181	0	26	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	FEB	2006	197	2					309	317		10.1016/j.expneurol.2005.09.004			9	Neurosciences	Neurosciences & Neurology	009RV	WOS:000235131000006	16364299				2021-06-18	
J	Cohan, P; Wang, C; McArthur, DL; Cook, SW; Dusick, JR; Armin, B; Swerdloff, R; Vespa, P; Muizelaar, JP; Cryer, HG; Christenson, PD; Kelly, DF				Cohan, P; Wang, C; McArthur, DL; Cook, SW; Dusick, JR; Armin, B; Swerdloff, R; Vespa, P; Muizelaar, JP; Cryer, HG; Christenson, PD; Kelly, DF			Acute secondary adrenal insufficiency after traumatic brain injury: A prospective study	CRITICAL CARE MEDICINE			English	Article						traumatic brain injury; adrenal insufficiency; pituitary; hypopituitarism; cortisol; stress response; vasopressor; etomidate; pentobarbital; propofol	SEVERE HEAD-INJURY; PROPOFOL INFUSION; NEUROENDOCRINE DYSFUNCTION; SUBARACHNOID HEMORRHAGE; CORTISOL RESPONSE; PLASMA-CORTISOL; CLINICAL-TRIALS; CARE PATIENTS; SEPTIC SHOCK; DOUBLE-BLIND	Objective: To determine the prevalence, time course, clinical characteristics, and effect of adrenal insufficiency (AI) after traumatic brain injury (TBI). Design: Prospective intensive care unit-based cohort study. Setting: Three level 1 trauma centers. Patients: A total of 80 patients with moderate or severe TBI (Glasgow Coma Scale score, 3-13) and 41 trauma patients without TBI (Injury Severity Score, > 15) enrolled between June 2002 and November 2003. Measurements: Serum cortisol and adrenocorticotropic hormone levels were drawn twice daily for up to 9 days postinjury; AI was defined as two consecutive cortisols of <= 15 mu g/dL (25th percentile for extracranial trauma patients) or one cortisol of < 5 mu g/dL. Principal outcome measures included: injury characteristics, hemodynamic data, usage of vasopressors, metabolic suppressive agents (high-dose pentobarbital and propotol), etomidate, and AI status. Main Results: AI occurred in 42 TBI patients (53%). Adrenocorticotropic hormone levels were lower at the time of AI (median, 18.9 vs. 36.1 pg/mL; p = .0001). Compared with patients without AI, those with AI were younger (p = .01), had higher injury severity (p = .02), had a higher frequency of early ischemic insults (hypotension, hypoxia, severe anemia) (p = .02), and were more likely to have received etomidate (p = .049). Over the acute postinjury period, patients with AI had lower trough mean arterial pressure (p = .001) and greater vasopressor use (p = .047). Mean arterial pressure was lower in the 8 hrs preceding a low (<= 15 mu g/dL) cortisol level (p = .003). There was an inverse relationship between cortisol levels and vasopressor use (p = .0005) and between cortisol levels within 24 hrs of injury and etomidate use (p = .002). Use of high-dose propofol and pentobarbital was strongly associated with lower cortisol levels (p < .0001). Conclusions: Approximately 50% of patients with moderate or severe TBI have at least transient AI. Younger age, greater injury severity, early ischemic insults, and the use of etomidate and metabolic suppressive agents are associated with AI. Because lower cortisol levels were associated with lower blood pressure and higher vasopressor use, consideration should be given to monitoring cortisol levels in intubated TBI patients, particularly those receiving high-dose pentobarbital or propofol. A randomized trial of stress-dose hydrocortisone in TBI patients with AI is underway.	Univ Calif Los Angeles, Sch Med, Div Neurosurg, Los Angeles, CA USA; Univ Calif Los Angeles, Sch Med, Div Endocrinol, Los Angeles, CA USA; Univ Calif Los Angeles, Sch Med, Gonda Diabet Ctr, Los Angeles, CA USA; Univ Calif Los Angeles, Sch Med, Div Gen Surg, Los Angeles, CA USA; Harbor UCLA Med Ctr, Div Endocrinol, Torrance, CA 90509 USA; Los Angeles Biomed Res Inst, Torrance, CA USA; Univ Calif Davis, Med Ctr, Div Neurosurg, Sacramento, CA 95817 USA	Kelly, DF (corresponding author), 410 Chautauqua Rd, Pacific Palisades, CA 90272 USA.		McArthur, David/E-6442-2013	McArthur, David/0000-0003-3385-1314	NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [K23RR017298, M01RR019975, M01RR000865, M01RR000425] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040777] Funding Source: NIH RePORTER; NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [K23 RR 17298-01, M01 RR 00425, M01 RR 00865, M01 RR 19975] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS 40777] Funding Source: Medline		Abdu TAM, 1999, J CLIN ENDOCR METAB, V84, P838, DOI 10.1210/jc.84.3.838; Absalom A, 1999, ANAESTHESIA, V54, P861; ADAMS JH, 1966, J NEUROL NEUROSUR PS, V29, P545, DOI 10.1136/jnnp.29.6.545; Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; ADFELDT VH, 1969, ACTA ENDOCRINOL-COP, V61, P551; Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; AITKENHEAD AR, 1989, LANCET, V2, P704, DOI 10.1016/S0140-6736(89)90770-8; ALBANESE J, 1990, ANESTHESIOLOGY, V73, P214, DOI 10.1097/00000542-199008000-00004; Annane D, 2002, JAMA-J AM MED ASSOC, V288, P862, DOI 10.1001/jama.288.7.862; Ariza M, 2004, J NEUROTRAUM, V21, P864, DOI 10.1089/0897715041526203; BAILIE GR, 1992, BRIT J ANAESTH, V68, P486, DOI 10.1093/bja/68.5.486; Barquist E, 1997, J TRAUMA, V42, P27, DOI 10.1097/00005373-199701000-00006; BARTON RN, 1987, J TRAUMA, V27, P384, DOI 10.1097/00005373-198704000-00007; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Bollaert PE, 1998, CRIT CARE MED, V26, P645, DOI 10.1097/00003246-199804000-00010; BOUACHOUR G, 1994, INTENS CARE MED, V20, P138, DOI 10.1007/BF01707669; Briegel J, 1999, CRIT CARE MED, V27, P723, DOI 10.1097/00003246-199904000-00025; BROOKS SM, 1972, NEW ENGL J MED, V286, P1125, DOI 10.1056/NEJM197205252862103; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Ceballos R, 1966, Ala J Med Sci, V3, P185; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHIOLERO R, 1988, J TRAUMA, V28, P1368, DOI 10.1097/00005373-198809000-00011; Choi SC, 1998, J NEUROTRAUM, V15, P771, DOI 10.1089/neu.1998.15.771; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Cooper MS, 2003, NEW ENGL J MED, V348, P727, DOI 10.1056/NEJMra020529; COOPER PR, 1979, J NEUROSURG, V51, P307, DOI 10.3171/jns.1979.51.3.0307; Cormio M, 1999, J NEUROTRAUM, V16, P927, DOI 10.1089/neu.1999.16.927; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; CROZIER TA, 1987, ANESTHESIOLOGY, V66, P628, DOI 10.1097/00000542-198705000-00006; CUNNINGHAM SK, 1983, ARCH INTERN MED, V143, P2276, DOI 10.1001/archinte.143.12.2276; DAMIANO R, 1989, HDB SURG INTENSIVE C, P79; DANIEL PM, 1959, LANCET, V2, P927; DEARDEN NM, 1986, J NEUROSURG, V64, P81, DOI 10.3171/jns.1986.64.1.0081; Dimopoulou I, 2004, INTENS CARE MED, V30, P1051, DOI 10.1007/s00134-004-2257-x; Dimopoulou L, 2004, CRIT CARE MED, V32, P404, DOI 10.1097/01.CCM.0000108885.37811.CA; Drake WM, 1998, J CLIN ENDOCR METAB, V83, P3542, DOI 10.1210/jc.83.10.3542; EDWARDS OM, 1986, MEDICINE, V65, P281; FELLOWS IW, 1983, BRIT MED J, V287, P1835, DOI 10.1136/bmj.287.6408.1835; GILMAN AG, 1980, GOODMAN GILMANS PHAR; GUDEMAN SK, 1979, J NEUROSURG, V51, P301, DOI 10.3171/jns.1979.51.3.0301; Hamrahian AH, 2004, NEW ENGL J MED, V350, P1629, DOI 10.1056/NEJMoa020266; Hoen S, 2002, ANESTHESIOLOGY, V97, P807, DOI 10.1097/00000542-200210000-00010; Iglesias P, 1996, J ENDOCRINOL INVEST, V19, P320, DOI 10.1007/BF03347870; ILLIEVICH UM, 1993, ANESTH ANALG, V77, P155; JENNETT B, 1975, LANCET, V1, P480; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; Kelestimur Fahrettin, 2003, Pituitary, V6, P181, DOI 10.1023/B:PITU.0000023425.20854.8e; Kelly DF, 1999, J NEUROSURG, V90, P1042, DOI 10.3171/jns.1999.90.6.1042; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; KIDESS AI, 1993, MAYO CLIN PROC, V68, P435, DOI 10.1016/S0025-6196(12)60188-8; KING LR, 1970, ANN SURG, V172, P975, DOI 10.1097/00000658-197012000-00008; KLINGBEIL GEG, 1985, ARCH PHYS MED REHAB, V66, P44; Koiv L, 1997, ACTA NEUROL SCAND, V96, P52; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Malerba G, 2005, INTENS CARE MED, V31, P388, DOI 10.1007/s00134-004-2550-8; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; Minneci PC, 2004, ANN INTERN MED, V141, P47, DOI 10.7326/0003-4819-141-1-200407060-00014; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; NEWMAN LH, 1987, ANAESTHESIA, V42, P929, DOI 10.1111/j.1365-2044.1987.tb05362.x; Putignano P, 1998, HORM METAB RES, V30, P389, DOI 10.1055/s-2007-978903; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; RINNE UK, 1967, MED PHARMACOL EXP, V17, P409; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Sarrafzadeh AS, 2001, CRIT CARE MED, V29, P1116, DOI 10.1097/00003246-200106000-00004; SAUL TG, 1981, J NEUROSURG, V54, P596, DOI 10.3171/jns.1981.54.5.0596; Schenarts CL, 2001, ACAD EMERG MED, V8, P1, DOI 10.1111/j.1553-2712.2001.tb00537.x; Servadei E, 2000, BRIT J NEUROSURG, V14, P110; STEINBOK P, 1979, NEUROSURGERY, V5, P559, DOI 10.1227/00006123-197911000-00003; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P591; Vandesteene A, 1988, Anaesthesia, V43 Suppl, P42, DOI 10.1111/j.1365-2044.1988.tb09067.x; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; WAGNER B, 1995, TXB CRITICAL CARE, P1154; WAGNER RL, 1984, NEW ENGL J MED, V310, P1415, DOI 10.1056/NEJM198405313102202; WOOLF PD, 1990, ALCOHOL CLIN EXP RES, V14, P917, DOI 10.1111/j.1530-0277.1990.tb01838.x; Zarkovic M, 1999, J CLIN ENDOCR METAB, V84, P3170, DOI 10.1210/jc.84.9.3170	81	175	185	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	OCT	2005	33	10					2358	2366		10.1097/01.CCM.0000181735.51183.A7			9	Critical Care Medicine	General & Internal Medicine	019YV	WOS:000235875600029	16215393				2021-06-18	
J	Clark, RSB; Kochanek, PM; Chen, MZ; Watkins, SC; Marion, DW; Chen, J; Hamilton, RL; Loeffert, JE; Graham, SH				Clark, RSB; Kochanek, PM; Chen, MZ; Watkins, SC; Marion, DW; Chen, J; Hamilton, RL; Loeffert, JE; Graham, SH			Increases in Bcl-2 and cleavage of caspase-1 and caspase-3 in human brain after head injury	FASEB JOURNAL			English	Article						apoptosis; Bax; Bclx(L); Cpp32; interleukin-1 beta converting enzyme	INTERLEUKIN-1-BETA CONVERTING-ENZYME; CORTICAL IMPACT INJURY; APOPTOTIC CELL-DEATH; CEREBRAL-ISCHEMIA; TRANSGENIC MICE; RAT-BRAIN; REGULATING APOPTOSIS; PROTOONCOGENE BCL-2; ALZHEIMERS-DISEASE; GLOBAL-ISCHEMIA	The bcl-2 and caspase families are important regulators of programmed cell death in experimental models of ischemic, excitotoxic, and traumatic brain injury. The Bcl-2 family members Bcl-2 and Bcl-x(L) suppress programmed cell death, whereas Bax promotes programmed cell death. Activated caspase-1 (interleukin-1 beta converting enzyme) and caspase-3 (Yama/Apopain/Cpp32) cleave proteins that are important in maintaining cytoskeletal integrity and DNA repair, and activate deoxyribonucleases, producing cell death with morphological features of apoptosis. To address the question of whether these Bcl-2 and caspase family members participate in the process of delayed neuronal death in humans, we examined brain tissue samples removed from adult patients during surgical decompression for intracranial hypertension in the acute phase after traumatic brain injury (n=8) and com pared these samples to brain tissue obtained at autopsy from non-trauma patients (n=6). An increase in Bcl-2 but not Bcl-x(L) or Bax, cleavage of caspase-1, up-regulation and cleavage of caspase-3, and evidence for DNA fragmentation with both apoptotic and necrotic morphologies were found in tissue from traumatic brain injury patients compared with controls. These findings are the first to demonstrate that programmed cell death occurs in human brain after acute injury, and identify potential pharmacological and molecular targets for the treatment of human head injury.	Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Anesthesiol & Crit Care Med, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Pediat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Cell Biol & Physiol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Neurol Surg, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Neurol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Pathol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Brain Trauma Res Ctr, Pittsburgh, PA 15260 USA; Dept Vet Affairs Med Ctr, Neurol Serv 127, Pittsburgh, PA 15260 USA	Clark, RSB (corresponding author), Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Anesthesiol & Crit Care Med, 3434 5th Ave Pittsburgh, Pittsburgh, PA 15260 USA.		Kochanek, Patrick M/D-2371-2015; Marion, Donald/AAR-5749-2021	Kochanek, Patrick M/0000-0002-2627-913X; watkins, simon/0000-0003-4092-1552	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P30HD028836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038620, K08NS001946] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5P30 HD28836] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1KO8 NS01946, 1RO1 NS 38620-01] Funding Source: Medline		ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ALNEMRI ES, 1995, J BIOL CHEM, V270, P4312, DOI 10.1074/jbc.270.9.4312; Ashkenas J, 1996, J EXP MED, V183, P1947, DOI 10.1084/jem.183.5.1947; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; Chen J, 1996, J NEUROCHEM, V67, P64; Chen J, 1998, J NEUROSCI, V18, P4914; Chen J, 1997, J CEREBR BLOOD F MET, V17, P2, DOI 10.1097/00004647-199701000-00002; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Clark RSB, 1997, J NEUROSCI, V17, P9172; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; DeKosky ST, 1996, ANN NEUROL, V39, P123, DOI 10.1002/ana.410390118; DOPPENBERG EMR, 1997, ANN NY ACAD SCI, V825, P305; Eliasson MJL, 1997, NAT MED, V3, P1089, DOI 10.1038/nm1097-1089; Enari M, 1998, NATURE, V391, P43; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; Friedlander RM, 1997, J EXP MED, V185, P933, DOI 10.1084/jem.185.5.933; GARCIAVALENZUELA E, 1994, J NEUROBIOL, V25, P431, DOI 10.1002/neu.480250408; Graham SH, 1996, RESTOR NEUROL NEUROS, V9, P243, DOI 10.3233/RNN-1996-9407; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Hara H, 1997, J CEREBR BLOOD F MET, V17, P370, DOI 10.1097/00004647-199704000-00002; Hayasaki K, 1997, ACT NEUR S, V70, P75; Hsu YT, 1997, J BIOL CHEM, V272, P13829, DOI 10.1074/jbc.272.21.13829; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; JENNETT B, 1985, LANCET, V1, P480; KANE DJ, 1995, J NEUROSCI RES, V40, P269, DOI 10.1002/jnr.490400216; Kitamura Y, 1998, BRAIN RES, V780, P260, DOI 10.1016/S0006-8993(97)01202-X; KRAJEWSKI S, 1995, J NEUROSCI, V15, P6364; Kroemer G, 1997, NAT MED, V3, P614, DOI 10.1038/nm0697-614; Lawrence MS, 1997, J CEREBR BLOOD F MET, V17, P740; LINNIK MD, 1995, STROKE, V26, P1670, DOI 10.1161/01.STR.26.9.1670; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; Mogi M, 1996, NEUROSCI LETT, V215, P137, DOI 10.1016/0304-3940(96)12961-X; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; RINK A, 1995, AM J PATHOL, V147, P1575; Rossiter JP, 1996, EXP NEUROL, V138, P33, DOI 10.1006/exnr.1996.0044; SHAW K, 1998, J NEUROTRAUM, V15, P871; Smith F. M., 1998, Journal of Neurotrauma, V15, P54; SU JH, 1994, NEUROREPORT, V5, P2529, DOI 10.1097/00001756-199412000-00031; TEASDALE G, 1974, LANCET, V2, P81; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	51	175	185	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	1999	13	8					813	821					9	Biochemistry & Molecular Biology; Biology; Cell Biology	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	197NZ	WOS:000080372500005	10224225				2021-06-18	
J	LEESHALEY, PR; BROWN, RS				LEESHALEY, PR; BROWN, RS			NEUROPSYCHOLOGICAL COMPLAINT BASE RATES OF 170 PERSONAL-INJURY CLAIMANTS	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article							CLOSED HEAD-INJURY	Reports base rate data for 50 controls and 170 personal injury claimants' self-reported symptoms associated with neuropsychological impairment. These base rates were obtained from claimants with no history of brain injury or toxic exposure and no documented neuropsychological impairments. Personal injury claimants reported high rates of complaints generally recognized as being associated with neuropsychological impairment. For example, 93% reported anxiety or nervousness, 92% sleeping problems, 89% depression, 88% headaches, 79% fatigue, 78% concentration problems, 77% irritability, 65% impatience, 61% feeling disorganized, 59% confusion, 56% loss of efficiency with everyday tasks, 53% memory problems, 44% dizziness, 39% numbness, and 34% word finding problems. These results underscore the need for caution when relying on self-reported symptoms as evidence of brain damage in patients involved in litigation.								BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; FAUST D, 1991, BRAIN DAMAGE CLAIMS; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Hartman DE, 1988, NEUROPSYCHOLOGICAL T; LEESHALEY P, IN PRESS FORENSIC RE; LEESHALEY P, 1990, FORENSIC REPORTS, V3, P421; LEESHALEY P, 1989, DEFENSE COUNSEL J, V56, P110; LEESHALEY PR, 1990, PERCEPT MOTOR SKILL, V70, P1379, DOI 10.2466/PMS.70.3.1379-1382; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; MATARAZZO J. D., 1989, PSYCHOL ASSESSMENT J, V1, P186, DOI DOI 10.1037/1040-3590.1.3.186; Matarazzo J. D., 1987, CLIN NEUROPSYCHOL, V1, P307; MATARAZZO JD, 1990, AM PSYCHOL, V45, P999, DOI 10.1037/0003-066X.45.9.999; MATARAZZO JD, 1988, J CLIN PSYCHOL, V44, P940, DOI 10.1002/1097-4679(198811)44:6<940::AID-JCLP2270440615>3.0.CO;2-A; MEEHL P, 1954, CLIN VERSUS STATISTI; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; PRICE R, 1990, COMPENDIUM MALINGERI; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; RUTHERFORD WH, 1977, LANCET           JAN, P1; WEISSMAN H, IN PRESS FORENSIC RE; Weissman HN., 1990, BEHAV SCI LAW, V8, P67, DOI [10.1002/bsl.2370080108, DOI 10.1002/BSL.2370080108]; ZISKIN J, 1988, COPING PSYCHIATRIC P	24	175	176	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAY-JUN	1993	8	3					203	209		10.1016/0887-6177(93)90036-Z			7	Psychology, Clinical; Psychology	Psychology	KW011	WOS:A1993KW01100002	14589632				2021-06-18	
J	JORGE, RE; ROBINSON, RG; ARNDT, SV; STARKSTEIN, SE; FORRESTER, AW; GEISLER, F				JORGE, RE; ROBINSON, RG; ARNDT, SV; STARKSTEIN, SE; FORRESTER, AW; GEISLER, F			DEPRESSION FOLLOWING TRAUMATIC BRAIN INJURY - A 1 YEAR LONGITUDINAL-STUDY	JOURNAL OF AFFECTIVE DISORDERS			English	Article						MAJOR DEPRESSION; TRAUMATIC BRAIN INJURY	BLUNT HEAD-INJURY; COMPUTERIZED-TOMOGRAPHY; SEQUELAE; RELATIVES; DISORDERS; STROKE; COMA	A group of 66 patients hospitalized for the treatment of closed head injury, were assessed for the presence of mood disorders during their hospital admission and at 3, 6 and 12 months follow-up. A total 28 patients met DSM-III-R diagnostic criteria for major depression at some time during the study (17 in the acute stage, 11 during follow-up). The mean duration of major depression was 4.7 months. However, there appeared to be a group of transiently depressed patients (41%) who where depressed inhospital but were no longer depressed at 3 months follow-up. Throughout the follow-up period, major depression showed a strong relationship with poor social functioning. There was not, however, a consistent relationship between depression and quantitative measures of either physical or cognitive impairment. Location of the brain lesion was associated with the development of major depression only in the acute stage. Transient depressive syndromes were associated with left dorsolateral frontal and/or left basal ganglia lesions.	UNIV IOWA,COLL MED,DEPT PSYCHIAT,IOWA CITY,IA 52242; UNIV IOWA,MENTAL HLTH CLIN RES CTR,BIOSTAT CORE UNIT,IOWA CITY,IA 52242; INST NEUROL INVEST,DR RAUL CARREA,DEPT BEHAV NEUROL,BUENOS AIRES,ARGENTINA; JOHNS HOPKINS UNIV,SCH MED,DEPT PSYCHIAT,BALTIMORE,MD 21205; UNIV MARYLAND,MARYLAND INST EMERGENCY MED SERV SYST,CTR SHOCK TRAUMA,DEPT SURG,BALTIMORE,MD 21201			Arndt, Stephan/A-6976-2013; Robinson, Robert/AAF-6191-2021	Arndt, Stephan/0000-0003-0783-8204; 	NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH 40355, MH 000163] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS151178] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH040355] Funding Source: NIH RePORTER		BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; CHOLLET F, 1991, ANN NEUROL, V29, P63, DOI 10.1002/ana.410290112; CONOVER WJ, 1981, AM STAT, V35, P124, DOI 10.2307/2683975; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; DIKMEN S, 1977, ANN NEUROL, V2, P492, DOI 10.1002/ana.410020608; Eisenberg, 1987, NEUROBEHAVIORAL RECO, P215; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fuster J, 1989, PREFRONTAL CORTEX; GRANT I, 1987, NEUROBEHAVIORAL RECO, P232; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEVINE DN, 1984, NEUROLOGY, V34, P577, DOI 10.1212/WNL.34.5.577; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROBINSON RG, 1984, BRAIN, V107, P81, DOI 10.1093/brain/107.1.81; ROBINSON RG, 1981, ANN NEUROL, V9, P447, DOI 10.1002/ana.410090506; ROBINSON RG, 1987, STROKE, V18, P837, DOI 10.1161/01.STR.18.5.837; RUFF RM, 1991, J NEUROSURG S, V75, P50; RUTHERFORD WH, 1977, LANCET, V1, P1; Sartorius N, 1974, MEASUREMENT CLASSIFI; Silver J. M., 1991, NEUROPSY NEUROPSY BE, V4, P12; STARKSTEIN SE, 1990, ARCH GEN PSYCHIAT, V47, P246, DOI 10.1001/archpsyc.1990.01810150046008; STARR LB, 1983, EXP AGING RES, V9, P101, DOI 10.1080/03610738308258434; STEWARD O, 1989, Journal of Neurotrauma, V6, P99, DOI 10.1089/neu.1989.6.99; TEASDALE G, 1974, LANCET, V2, P81; VANZOMEREN AH, 1990, HDB CLIN NEUROLOGY, V13, P397	32	175	177	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0327			J AFFECT DISORDERS	J. Affect. Disord.	APR	1993	27	4					233	243		10.1016/0165-0327(93)90047-N			11	Clinical Neurology; Psychiatry	Neurosciences & Neurology; Psychiatry	LA051	WOS:A1993LA05100003	8509524				2021-06-18	
J	Reade, MC; Eastwood, GM; Bellomo, R; Bailey, M; Bersten, A; Cheung, B; Davies, A; Delaney, A; Ghosh, A; van Haren, F; Harley, N; Knight, D; McGuiness, S; Mulder, J; O'Donoghue, S; Simpson, N; Young, P				Reade, Michael C.; Eastwood, Glenn M.; Bellomo, Rinaldo; Bailey, Michael; Bersten, Andrew; Cheung, Benjamin; Davies, Andrew; Delaney, Anthony; Ghosh, Angaj; van Haren, Frank; Harley, Nerina; Knight, David; McGuiness, Shay; Mulder, John; O'Donoghue, Steve; Simpson, Nicholas; Young, Paul		DahLIA Investigators Australian	Effect of Dexmedetomidine Added to Standard Care on Ventilator-Free Time in Patients With Agitated Delirium A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CRITICALLY-ILL PATIENTS; SEDATION SCALE; UNIT PATIENTS; CAM-ICU; RELIABILITY; MIDAZOLAM; VALIDITY	IMPORTANCE Effective therapy has not been established for patients with agitated delirium receiving mechanical ventilation. OBJECTIVE To determine the effectiveness of dexmedetomidine when added to standard care in patients with agitated delirium receiving mechanical ventilation. DESIGN, SETTING, AND PARTICIPANTS The Dexmedetomidine to Lessen ICU Agitation (DahLIA) study was a double-blind, placebo-controlled, parallel-group randomized clinical trial involving 74 adult patients in whom extubation was considered inappropriate because of the severity of agitation and delirium. The study was conducted at 15 intensive care units in Australia and New Zealand from May 2011 until December 2013. Patients with advanced dementia or traumatic brain injury were excluded. INTERVENTIONS Bedside nursing staff administered dexmedetomidine (or placebo) initially at a rate of 0.5 mu g/kg/h and then titrated to rates between 0 and 1.5 mu g/kg/h to achieve physician-prescribed sedation goals. The study drug or placebo was continued until no longer required or up to 7 days. All other care was at the discretion of the treating physician. MAIN OUTCOMES AND MEASURES Ventilator-free hours in the 7 days following randomization. There were 21 reported secondary outcomes that were defined a priori. RESULTS Of the 74 randomized patients (median age, 57 years; 18 [24%] women), 2 withdrew consent later and 1 was found to have been randomized incorrectly, leaving 39 patients in the dexmedetomidine group and 32 patients in the placebo group for analysis. Dexmedetomidine increased ventilator-free hours at 7 days compared with placebo (median, 144.8 hours vs 127.5 hours, respectively; median difference between groups, 17.0 hours [95% CI, 4.0 to 33.2 hours]; P = .01). Among the 21 a priori secondary outcomes, none were significantly worse with dexmedetomidine, and several showed statistically significant benefit, including reduced time to extubation (median, 21.9 hours vs 44.3 hours with placebo; median difference between groups, 19.5 hours [95% CI, 5.3 to 31.1 hours]; P < .001) and accelerated resolution of delirium (median, 23.3 hours vs 40.0 hours; median difference between groups, 16.0 hours [95% CI, 3.0 to 28.0 hours]; P = .01). Using hierarchical Cox modeling to adjust for imbalanced baseline characteristics, allocation to dexmedetomidine was significantly associated with earlier extubation (hazard ratio, 0.47 [95% CI, 0.27-0.82]; P = .007). CONCLUSIONS AND RELEVANCE Among patients with agitated delirium receiving mechanical ventilation in the intensive care unit, the addition of dexmedetomidine to standard care compared with standard care alone (placebo) resulted in more ventilator-free hours at 7 days. The findings support the use of dexmedetomidine in patients such as these.	[Reade, Michael C.] Univ Queensland, Burns Trauma & Crit Care Res Ctr, Brisbane, Qld, Australia; [Reade, Michael C.] Australian Def Force, Joint Hlth Command, Brisbane, Qld, Australia; [Eastwood, Glenn M.; Bellomo, Rinaldo] Austin Hosp, Melbourne, Vic 3084, Australia; [Bellomo, Rinaldo] Univ Melbourne, Sch Med, Melbourne, Vic, Australia; [Bailey, Michael] Monash Univ, Sch Publ Hlth & Prevent Med, Australian & New Zealand Intens Care Res Ctr, Melbourne, Vic 3004, Australia; [Bersten, Andrew] Flinders Med Ctr, Adelaide, SA, Australia; [Cheung, Benjamin] Toowoomba Hosp, Toowoomba, Qld, Australia; [Davies, Andrew] Peninsula Hlth, Melbourne, Vic, Australia; [Delaney, Anthony] Royal North Shore Hosp Sydney, Sydney, NSW, Australia; [Ghosh, Angaj] Northern Hosp, Melbourne, Vic, Australia; [van Haren, Frank] Canberra Hosp, Canberra, ACT, Australia; [Harley, Nerina] Royal Melbourne Hosp, Melbourne, Vic, Australia; [Knight, David] Christchurch Hosp, Christchurch, New Zealand; [McGuiness, Shay] Auckland City Hosp, Auckland, New Zealand; [Mulder, John] Western Hosp, Melbourne, Vic, Australia; [O'Donoghue, Steve] Royal Brisbane & Womens Hosp, Brisbane, Qld, Australia; [Simpson, Nicholas] Geelong Hosp, Geelong, Vic, Australia; [Young, Paul] Wellington Hosp, Wellington, New Zealand; [Young, Paul] Med Res Inst New Zealand, Wellington, New Zealand	Reade, MC (corresponding author), Univ Queensland, Hlth Sci Bldg, Herston, Qld 4029, Australia.	m.reade@uq.edu.au	Roberts, Jason A/F-6272-2010; Bailey, Michael J/A-4499-2012; Delaney, Anthony/AAE-3365-2019; cheung, benjamin k/F-6452-2014; Van Haren, Frank/G-1335-2015; /X-2859-2019; Reade, Michael/G-7035-2012	Roberts, Jason A/0000-0001-6218-435X; Bailey, Michael J/0000-0002-5551-1401; cheung, benjamin k/0000-0002-6139-7756; Van Haren, Frank/0000-0001-8037-4229; /0000-0002-2067-7276; Reade, Michael/0000-0003-1570-0707; Bersten, Andrew/0000-0001-9908-394X; Bellomo, Rinaldo/0000-0002-1650-8939; Young, Paul/0000-0002-3428-3083	Hospira Australia; Wellington Hospital Research Office; Austin Hospital Intensive Care Specialists Trust Fund	This study was partly funded by Hospira Australia through an unrestricted grant of A$25000 plus free study drug supply. Individual site funding was supplemented by grants from the Wellington Hospital Research Office and the Austin Hospital Intensive Care Specialists Trust Fund.	Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; Bergeron N, 2001, INTENS CARE MED, V27, P859, DOI 10.1007/s001340100909; Devlin JW, 2010, CRIT CARE MED, V38, P419, DOI 10.1097/CCM.0b013e3181b9e302; Devlin JW, 1999, CRIT CARE MED, V27, P1271, DOI 10.1097/00003246-199907000-00008; Dubois MJ, 2001, INTENS CARE MED, V27, P1297, DOI 10.1007/s001340101017; Ely EW, 2007, CRIT CARE MED, V35, P112, DOI 10.1097/01.CCM.0000251925.18961.CA; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; Haenggi M, 2013, INTENS CARE MED, V39, P2171, DOI 10.1007/s00134-013-3034-5; Hart Graeme K, 2008, Crit Care Resusc, V10, P83; Hoy SM, 2011, DRUGS, V71, P1481, DOI 10.2165/11207190-000000000-00000; Jakob SM, 2012, JAMA-J AM MED ASSOC, V307, P1151, DOI 10.1001/jama.2012.304; Lehmann E. L., 2006, NONPARAMETRICS STAT; Mo Y, 2013, ANN PHARMACOTHER, V47, P869, DOI 10.1345/aph.1AR708; Pandharipande PP, 2013, NEW ENGL J MED, V369, P1306, DOI 10.1056/NEJMoa1301372; Pandharipande PP, 2007, JAMA-J AM MED ASSOC, V298, P2644, DOI 10.1001/jama.298.22.2644; Patel SB, 2014, AM J RESP CRIT CARE, V189, P658, DOI 10.1164/rccm.201310-1815OC; Reade MC, 2012, CRIT CARE RESUSC, V14, P236; Reade MC, 2009, CRIT CARE, V13, DOI 10.1186/cc7890; Riker RR, 2009, JAMA-J AM MED ASSOC, V301, P489, DOI 10.1001/jama.2009.56; Riker RR, 1999, CRIT CARE MED, V27, P1325, DOI 10.1097/00003246-199907000-00022; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Therapeutic Goods Administration, 2014, DEXM HYDR PREC PROD; van den Boogaard M, 2012, CRIT CARE MED, V40, P112, DOI 10.1097/CCM.0b013e31822e9fc9; Yapici N, 2011, HEART SURG FORUM, V14, pE93, DOI 10.1532/HSF98.201011102	25	174	187	1	48	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 12	2016	315	14					1460	1468		10.1001/jama.2016.2707			9	Medicine, General & Internal	General & Internal Medicine	DJ0EE	WOS:000373873800012	26975647	Bronze	Y	N	2021-06-18	
J	Kahn, JM; Le, T; Angus, DC; Cox, CE; Hough, CL; White, DB; Yende, S; Carson, SS				Kahn, Jeremy M.; Le, Tri; Angus, Derek C.; Cox, Christopher E.; Hough, Catherine L.; White, Douglas B.; Yende, Sachin; Carson, Shannon S.		ProVent Study Grp Investigators	The Epidemiology of Chronic Critical Illness in the United States	CRITICAL CARE MEDICINE			English	Article						ICU; long-term care; mechanical ventilation; sepsis	PROLONGED MECHANICAL VENTILATION; RESOURCE UTILIZATION; SEVERE SEPSIS; LUNG INJURY; CARE; MORTALITY; HOSPITALIZATION; PROTOCOL; TRIAL; COSTS	Objectives: The epidemiology of chronic critical illness is not well characterized. We sought to determine the prevalence, outcomes, and associated costs of chronic critical illness in the United States. Design: Population-based cohort study using data from the United States Healthcare Costs and Utilization Project from 2004 to 2009. Setting: Acute care hospitals in Massachusetts, North Carolina, Nebraska, New York, and Washington. Patients: Adult and pediatric patients meeting a consensus-derived definition for chronic critical illness, which included one of six eligible clinical conditions (prolonged acute mechanical ventilation, tracheotomy, stroke, traumatic brain injury, sepsis, or severe wounds) plus at least 8 days in an ICU. Interventions: None. Measurements and Main Results: Out of 3,235,741 admissions to an ICU during the study period, 246,151 (7.6%) met the consensus definition for chronic critical illness. The most common eligibility conditions were prolonged acute mechanical ventilation (72.0% of eligible admissions) and sepsis (63.7% of eligible admissions). Among patients meeting chronic critical illness criteria through sepsis, the infections were community acquired in 48.5% and hospital acquired in 51.5%. In-hospital mortality was 30.9% with little change over the study period. The overall population-based prevalence was 34.4 per 100,000. The prevalence varied substantially with age, peaking at 82.1 per 100,000 individuals 75-79 years old but then declining coincident with a rise in mortality before day 8 in otherwise eligible patients. Extrapolating to the entire United States, for 2009, we estimated a total of 380,001 cases; 107,880 in-hospital deaths and $26 billion in hospital-related costs. Conclusions: Using a consensus-based definition, the prevalence, hospital mortality, and costs of chronic critical illness are substantial. Chronic critical illness is particularly common in the elderly although in very old patients the prevalence declines, in part because of an increase in early mortality among potentially eligible patients.	[Kahn, Jeremy M.; Angus, Derek C.; White, Douglas B.; Yende, Sachin] Univ Pittsburgh, Sch Med, Clin Res Invest & Syst Modeling Acute Illness CRI, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Kahn, Jeremy M.; Le, Tri; Angus, Derek C.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA USA; [Cox, Christopher E.] Duke Univ, Sch Med, Div Pulm Allergy & Crit Care Med, Durham, NC USA; [Hough, Catherine L.] Univ Washington, Sch Med, Div Pulm & Crit Care Med, Seattle, WA USA; [Carson, Shannon S.] Univ N Carolina, Div Pulm Dis & Crit Care Med, Chapel Hill, NC USA	Kahn, JM (corresponding author), Univ Pittsburgh, Sch Med, Clin Res Invest & Syst Modeling Acute Illness CRI, Dept Crit Care Med, Pittsburgh, PA 15260 USA.	kahnjm@upmc.edu	Cox, Christopher/ABH-7957-2020; Angus, Derek C/E-9671-2012	Cox, Christopher/0000-0002-4486-0681; Kahn, Jeremy/0000-0001-9688-5576	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01HL096651]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; U.S. Patient-centered Outcomes Research Institute (PCORI)Patient-Centered Outcomes Research Institute - PCORI; PCORIPatient-Centered Outcomes Research Institute - PCORI; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL096651] Funding Source: NIH RePORTER	Supported, in part, by National Institutes of Health (R01HL096651).; Dr. Kahn lectured for the National Association of Long-term Hospitals (speaking honoraria) and received support for article research from the National Institutes of Health (NIH). His institution received grant support from the NIH and the U.S. Patient-centered Outcomes Research Institute (PCORI). Dr. Hough's institution received grant support from the NIH and PCORI. Dr. Carson consulted for the Research Triangle Institute. Her institution received grant support from the NIH. The remaining authors have disclosed that they do not have any potential conflicts of interest.	Andaluz N, 2009, J NEUROSURG, V110, P403, DOI 10.3171/2008.5.17559; Angus DC, 2006, CRIT CARE MED, V34, P1016, DOI 10.1097/01.CCM.0000206105.05626.15; Angus DC, 2001, CRIT CARE MED, V29, P1303, DOI 10.1097/00003246-200107001-00035; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Burgmann H, 2010, INTENS CARE MED, V36, P1597, DOI 10.1007/s00134-010-1941-2; Carson SS, 2007, CHEST, V131, P2, DOI 10.1378/chest.06-2513; Carson Shannon S, 2006, J Intensive Care Med, V21, P173, DOI 10.1177/0885066605282784; Carson SS, 2012, RESP CARE, V57, P848, DOI 10.4187/respcare.01736; Carson SS, 2012, CRIT CARE MED, V40, P1171, DOI 10.1097/CCM.0b013e3182387d43; Carson SS, 2002, CRIT CARE CLIN, V18, P461, DOI 10.1016/S0749-0704(02)00015-5; Cox CE, 2004, CRIT CARE MED, V32, P2219, DOI 10.1097/01.CCM.0000145232.46143.40; Erickson SE, 2009, CRIT CARE MED, V37, P1574, DOI 10.1097/CCM.0b013e31819fefdf; Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1; Hall WB, 2012, AM J RESP CRIT CARE, V185, P53, DOI 10.1164/rccm.201106-1084OC; Iwashyna TJ, 2014, MED CARE, V52, pE39, DOI 10.1097/MLR.0b013e318268ac86; Kahn JM, 2013, MED CARE, V51, P4, DOI 10.1097/MLR.0b013e31826528a7; Kahn JM, 2010, JAMA-J AM MED ASSOC, V303, P2253, DOI 10.1001/jama.2010.761; Kandilov A, 2014, CHRONICALLY CRITICAL; MacIntyre NR, 2005, CHEST, V128, P3937, DOI 10.1378/chest.128.6.3937; Nelson JE, 2010, AM J RESP CRIT CARE, V182, P446, DOI 10.1164/rccm.201002-0210CI; OECD, 2011, HLTH GLANC OECD IND; Prendergast TJ, 1997, AM J RESP CRIT CARE, V155, P15, DOI 10.1164/ajrccm.155.1.9001282; Quan H, 2004, MED CARE, V42, P801, DOI 10.1097/01.mlr.0000132391.59713.0d; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Riley GF, 2009, MED CARE, V47, pS51, DOI 10.1097/MLR.0b013e31819c95aa; Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333; Schweickert WD, 2009, LANCET, V373, P1874, DOI 10.1016/S0140-6736(09)60658-9; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Seymour CW, 2012, AM J RESP CRIT CARE, V186, P1264, DOI 10.1164/rccm.201204-0713OC; Unroe M, 2010, ANN INTERN MED, V153, P167, DOI 10.7326/0003-4819-153-3-201008030-00007; Villar J, 2011, MINERVA ANESTESIOL, V77, P647; White DB, 2007, ARCH INTERN MED, V167, P461, DOI 10.1001/archinte.167.5.461; Wiedemann HP, 2006, NEW ENGL J MED, V354, P2564; Yealy DM, 2014, NEW ENGL J MED, V370, P1683, DOI 10.1056/NEJMoa1401602; Zilberberg MD, 2008, CRIT CARE MED, V36, P724, DOI 10.1097/CCM.0B013E31816536F7	35	174	182	0	35	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	FEB	2015	43	2					282	287		10.1097/CCM.0000000000000710			6	Critical Care Medicine	General & Internal Medicine	AZ2YX	WOS:000348096200004	25377018	Green Accepted	Y	N	2021-06-18	
J	Bazarian, JJ; Blyth, B; Mookerjee, S; He, H; McDermott, MP				Bazarian, Jeffrey J.; Blyth, Brian; Mookerjee, Sohug; He, Hua; McDermott, Michael P.			Sex Differences in Outcome after Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						mild traumatic brain injury; outcome; post-concussive symptoms; sex; unemployment	MINOR HEAD-INJURY; POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE DEFICITS; COMPLICATED MILD; CELL-DEATH; PROGESTERONE; SYMPTOMS; CONCUSSION; GENDER; PREDICTION	The objective of this study was to estimate the independent association of sex with outcome after mild traumatic brain injury (mTBI). We performed an analysis of a subset of an established cohort involving 1425 mTBI patients presenting to an academic emergency department (ED). The associations between sex and three outcomes determined 3 months after the initial ED visit were examined: post-concussive symptom (PCS) score ( 0, 1-5, 6-16, and >16), the number of days to return of normal activities (0, 1-7, and >7), and the number of days of work missed (0, 1-7, and >7). Logistic regression analyses were used to determine the relationship between sex and each outcome after controlling for 12 relevant subject-level variables. Of the 1425 subjects, 643 (45.1%) were female and 782 (54.9%) were male. Three months after mTBI, males had significantly lower odds of being in a higher PCS score category (odds ratio [ OR] 0.62, 95% confidence interval [CI]: 0.50, 0.78); this association appeared to be more prominent during child-bearing years for females. Males and females did not significantly differ with respect to the odds of poorer outcome as defined by the number of days to return of normal activities or the number of days of work missed. Female sex is associated with significantly higher odds of poor outcome after mTBI, as measured by PCS score, after control for appropriate confounders. The observed pattern of peak disability for females during the child-bearing years suggests disruption of endogenous estrogen or progesterone production. Attempts to better understand how mTBI affects production of these hormones acutely after injury and during the recovery period may shed light on the mechanism behind poorer outcome among females and putative therapeutic interventions.	[Bazarian, Jeffrey J.] Univ Rochester, Sch Med, Ctr Neural Dev & Dis, Dept Emergency Med, Rochester, NY 14642 USA; [Bazarian, Jeffrey J.] Univ Rochester, Sch Med, Dept Neurol, Rochester, NY 14642 USA; [Bazarian, Jeffrey J.] Univ Rochester, Sch Med, Dept Neurosurg, Rochester, NY 14642 USA; [He, Hua; McDermott, Michael P.] Univ Rochester, Sch Med, Dept Biostat & Computat Biol, Rochester, NY 14642 USA	Bazarian, JJ (corresponding author), Univ Rochester, Sch Med, Ctr Neural Dev & Dis, Dept Emergency Med, 601 Elmwood Ave, Rochester, NY 14642 USA.	jeff_bazarian@urmc.rochester.edu			National Institutes of Neurologic Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [1K23NS41952]; National Center for Research Resources (NCRR)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [5 MO1 RR00044]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000044] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS041952] Funding Source: NIH RePORTER	This work was supported by National Institutes of Neurologic Disorders and Stroke grant 1K23NS41952 (J.J.B.). This publication was made possible by grant number 5 MO1 RR00044 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of NCRR or NIH. Thanks to Thomas Richardson, Ph.D., and Shuolun Ruan for their editorial assistance.	Agha Amar, 2005, Pituitary, V8, P245, DOI 10.1007/s11102-005-3463-4; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Banik NL, 2000, NEUROCHEM RES, V25, P1509, DOI 10.1023/A:1007684311023; Barsky AJ, 2001, J GEN INTERN MED, V16, P266, DOI 10.1046/j.1525-1497.2001.016004266.x; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bazarian JJ, 2001, ACAD EMERG MED, V8, P788, DOI 10.1111/j.1553-2712.2001.tb00208.x; Borgaro SR, 2003, BRAIN INJURY, V17, P189, DOI 10.1080/0269905021000013183; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Browne KD, 2006, EXP NEUROL, V201, P301, DOI 10.1016/j.expneurol.2006.04.008; Bryant RA, 1999, BRAIN INJURY, V13, P15, DOI 10.1080/026990599121836; CARPENTER C, 2009, EMERGENCY PHYS  0127; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Corrigan JD, 2007, ARCH PHYS MED REHAB, V88, P1400, DOI 10.1016/j.apmr.2007.08.006; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; Creamer M, 2005, BEHAV RES THER, V43, P1383, DOI 10.1016/j.brat.2004.11.001; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; Dash PK, 2004, J NEUROTRAUM, V21, P1573, DOI 10.1089/neu.2004.21.1573; David Hosmer SL, 2000, APPL LOGISTIC REGRES; Davis DP, 2006, J NEUROTRAUM, V23, P140, DOI 10.1089/neu.2006.23.140; de Nadal M, 2000, ANESTHESIOLOGY, V92, P11, DOI 10.1097/00000542-200001000-00008; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Djebaili M, 2005, J NEUROTRAUM, V22, P106, DOI 10.1089/neu.2005.22.106; Donders J, 2003, J HEAD TRAUMA REHAB, V18, P106, DOI 10.1097/00001199-200303000-00002; EDNA TH, 1987, ACTA NEUROCHIR, V86, P12, DOI 10.1007/BF01419498; ENGLANDER J, 1992, Brain Injury, V6, P161, DOI 10.3109/02699059209029654; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Farin A, 2004, ACT NEUR S, V89, P101; Farin A, 2003, J NEUROSURG, V98, P32, DOI 10.3171/jns.2003.98.1.0032; Feinstein A, 2001, MED SCI LAW, V41, P116, DOI 10.1177/002580240104100206; Fu Q, 2007, J NEUROSCI, V27, P4154, DOI 10.1523/JNEUROSCI.4353-06.2007; HARAD FT, 1992, J TRAUMA, V32, P359, DOI 10.1097/00005373-199203000-00014; Hinton-Bayre AD, 2002, NEUROLOGY, V59, P1068, DOI 10.1212/WNL.59.7.1068; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hurley SD, 2002, J NEUROTRAUM, V19, P1, DOI 10.1089/089771502753460196; Iverson GL, 2006, BRAIN INJURY, V20, P1335, DOI 10.1080/02699050601082156; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Janis LS, 1998, J NEUROTRAUM, V15, P105, DOI 10.1089/neu.1998.15.105; JENSEN OK, 1990, CEPHALALGIA, V10, P285, DOI 10.1046/j.1468-2982.1990.1006285.x; JOELE LJ, 1975, APPL NEUROPHYSIOL, V38, P110; KAPLAN C P, 1992, Brain Injury, V6, P337, DOI 10.3109/02699059209034948; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kirkness Catherine J, 2004, Biol Res Nurs, V5, P299, DOI 10.1177/1099800404263050; Klose M, 2007, CLIN ENDOCRINOL, V67, P598, DOI 10.1111/j.1365-2265.2007.02931.x; Kraus J F, 2000, Neurosurg Focus, V8, pe5; LEE SC, 1994, BRAIN INJURY, V8, P571; Leker RR, 2002, ACTA NEUROCHIR SUPPL, V83, P49; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCullagh S, 2001, BRAIN INJURY, V15, P489, DOI 10.1080/02699050010007353; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; Morrison Wynne E, 2004, Pediatr Crit Care Med, V5, P145, DOI 10.1097/01.PCC.0000112373.71645.2A; O'Connor CA, 2003, J NEUROTRAUM, V20, P533, DOI 10.1089/089771503767168465; O'Phelan K, 2008, J TRAUMA, V65, P674, DOI 10.1097/TA.0b013e31817db0a5; Paniak C, 2002, J CLIN EXP NEUROPSYC, V24, P187, DOI 10.1076/jcen.24.2.187.999; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ragnarsson KT, 1999, JAMA-J AM MED ASSOC, V282, P974; Ratan SK, 2001, CLIN PEDIATR, V40, P375, DOI 10.1177/000992280104000702; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Ripley DL, 2008, ARCH PHYS MED REHAB, V89, P1090, DOI 10.1016/j.apmr.2007.10.038; ROOF RL, 1994, EXP NEUROL, V129, P64, DOI 10.1006/exnr.1994.1147; Rutherford W. H., 1989, MILD HEAD INJURY, P217; RUTHERFORD WH, 1977, LANCET, V1, P1; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Salim A, 2009, ARCH SURG-CHICAGO, V144, P865, DOI 10.1001/archsurg.2009.158; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Slavik RS, 1999, NEUROL RES, V21, P491; Statler KD, 2006, J NEUROTRAUM, V23, P97, DOI 10.1089/neu.2006.23.97; Stein Donald G, 2003, Pediatr Rehabil, V6, P13, DOI 10.1080/1363849031000095279; STRUGAR J, 1993, J TRAUMA, V34, P555, DOI 10.1097/00005373-199304000-00012; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; Thurman DJ., 1995, GUIDELINES SURVEILLA; Vickery CD, 2008, ARCH PHYS MED REHAB, V89, P48, DOI 10.1016/j.apmr.2007.07.047; Wagner AK, 2004, BRAIN RES, V998, P113, DOI 10.1016/j.brainres.2003.11.027; Wenden FJ, 1998, CLIN REHABIL, V12, P53, DOI 10.1191/026921598675567949; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Winkler AE, 2005, DEMOGRAPHY, V42, P523, DOI 10.1353/dem.2005.0028; WOOLF PD, 1986, CLIN ENDOCRINOL, V25, P265, DOI 10.1111/j.1365-2265.1986.tb01691.x; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887	88	174	177	0	20	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2010	27	3					527	539		10.1089/neu.2009.1068			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	575PJ	WOS:000276079100007	19938945	Green Published			2021-06-18	
J	Harting, MT; Jimenez, F; Xue, H; Fischer, UM; Baumgartner, J; Dash, PK; Cox, CS				Harting, Matthew T.; Jimenez, Fernando; Xue, Hasan; Fischer, Uwe M.; Baumgartner, James; Dash, Pramod K.; Cox, Charles S., Jr.			Intravenous mesenchymal stem cell therapy for traumatic brain injury Laboratory investigation	JOURNAL OF NEUROSURGERY			English	Article						adult stem cell; cellular therapy; in vivo tracking; mesenchymal stem cell; traumatic brain injury	CORD BLOOD-CELLS; PROGENITOR-CELLS; MARROW-CELLS; TRANSPLANTATION; RECOVERY; DELIVERY; RATS; OSTEOGENESIS; DIFFERENTIATE; EXPRESSION	Object. Cell therapy has shown preclinical promise in the treatment of many diseases, and its application is being translated to the clinical arena. Intravenous mesenchymal stein cell (MSC) therapy has been shown to improve functional recovery after traumatic brain injury (TBI). Herein, the authors report on their attempts to reproduce such observations, including detailed characterizations of the MSC Population, non-bromodeoxyuridine-based cell labeling, macroscopic and microscopic cell tracking, quantification of cells traversing the pulmonary microvasculature, and well-validated measurement of motor and cognitive function recovery. Methods. Rat MSCs were isolated, expanded in vitro, immunophenotyped, and labeled. Four million MSCs were intravenously infused into Sprague-Dawley rats 24 hours after receiving a moderate, unilateral controlled cortical impact TBI. Infrared macroscopic cell tracking was used to identify cell distribution. Immunohistochemical analysis of brain and lung tissues 48 hours and 2 weeks postinfusion revealed transplanted cells in these locations, and these cells were quantified. Intraarterial blood sampling and flow cytometry were used to quantity the number of transplanted cells reaching the arterial circulation. Motor and cognitive behavioral testing was performed to evaluate functional recovery. Results. At 48 hours post-MSC infusion, the majority of cells were localized to the lungs. Between 1.5 and 3.7% of the infused cells were estimated to traverse the lungs and reach the arterial circulation, 0.295% reached the carotid artery, and a very small percentage reached the cerebral parenchyma (0.0005%) and remained there. Almost no cells were identified in the brain tissue at 2 weeks postinfusion. No motor or cognitive functional improvements in recovery were identified. Conclusions. The intravenous infusion of MSCs appeared neither to result in significant acute or prolonged cerebral engraftment of cells nor to modify the recovery of motor or cognitive function. Less than 4% of the infused cells were likely to traverse the Pulmonary microvasculature and reach the arterial circulation, a phenomenon termed the "pulmonary first-pass effect," which may limit the efficacy of this therapeutic approach. The data in this study contradict the findings of previous reports and highlight the potential shortcomings of acute, single-dose, intravenous MSC therapy for TBI. (DOI: 10.3171/2008.9.JNS08158)	[Harting, Matthew T.; Jimenez, Fernando; Xue, Hasan; Fischer, Uwe M.; Baumgartner, James; Cox, Charles S., Jr.] Univ Texas Houston, Sch Med, Dept Pediat Surg, Houston, TX 77030 USA; [Dash, Pramod K.] Univ Texas Houston, Sch Med, Dept Neurobiol & Anat, Houston, TX 77030 USA; [Dash, Pramod K.] Univ Texas Houston, Sch Med, Vivian L Smith Ctr Neurol Res, Houston, TX 77030 USA	Cox, CS (corresponding author), Univ Texas Houston, Sch Med, Dept Pediat Surg, 6431 Fannin St,MSB 5-254, Houston, TX 77030 USA.	charles.s.cox@uth.tmc.edu		Dash, Pramod/0000-0001-6746-1002; Harting, Matthew/0000-0002-8929-8311	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 GM008792-06, MO1 RR 02558, R21 HD 04 2659-01A1]; Children's Memorial Hermann Hospital Foundation; Texas Higher Education Coordinating Board; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD042659] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR002558, UL1RR024148] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008792] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health Grant Nos. T32 GM008792-06 (M.T.H.), MO1 RR 02558 (C.S.C.), and R21 HD 04 2659-01A1 (C.S.C.), as well as funds from the Children's Memorial Hermann Hospital Foundation (C.S.C.) and Texas Higher Education Coordinating Board (C.S.C.).	Badillo AT, 2007, BIOL BLOOD MARROW TR, V13, P412, DOI 10.1016/j.bbmt.2006.12.447; Barbash IM, 2003, CIRCULATION, V108, P863, DOI 10.1161/01.CIR.0000084828.50310.6A; Bentzon JF, 2005, BIOCHEM BIOPH RES CO, V330, P633, DOI 10.1016/j.bbrc.2005.03.072; Breyer A, 2006, EXP HEMATOL, V34, P1596, DOI 10.1016/j.exphem.2006.07.013; Burns TC, 2006, STEM CELLS, V24, P1121, DOI 10.1634/stemcells.2005-0463; Castro RF, 2002, SCIENCE, V297, P1299, DOI 10.1126/science.297.5585.1299; Chamberlain JR, 2004, SCIENCE, V303, P1198, DOI 10.1126/science.1088757; English D, 2006, EXP NEUROL, V199, P10, DOI 10.1016/j.expneurol.2006.03.005; FANG JM, 1995, INT J DEV BIOL, V39, P519; Freyman T, 2006, EUR HEART J, V27, P1114, DOI 10.1093/eurheartj/ehi818; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Garbuzova-Davis S, 2003, J HEMATOTH STEM CELL, V12, P255, DOI 10.1089/152581603322022990; Guzowski JF, 1997, P NATL ACAD SCI USA, V94, P2693, DOI 10.1073/pnas.94.6.2693; Horwitz EM, 1999, NAT MED, V5, P309, DOI 10.1038/6529; Khakoo AY, 2006, J EXP MED, V203, P1235, DOI 10.1084/jem.20051921; Klass M, 2007, ANESTH ANALG, V104, P944, DOI 10.1213/01.ane.0000258021.03211.d0; Koc ON, 2000, J CLIN ONCOL, V18, P307, DOI 10.1200/JCO.2000.18.2.307; Kong KY, 2004, STEM CELLS, V22, P981, DOI 10.1634/stemcells.22-6-981; Krause U, 2007, STEM CELLS DEV, V16, P31, DOI 10.1089/scd.2006.0089; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; LAZARUS HM, 1995, BONE MARROW TRANSPL, V16, P557; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Lorenzini S, 2007, STEM CELLS, V25, P2383, DOI 10.1634/stemcells.2007-0056; Losordo DW, 2004, CIRCULATION, V109, P2692, DOI 10.1161/01.CIR.0000128596.49339.05; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Magliocca JF, 2006, STEM CELLS DEV, V15, P707, DOI 10.1089/scd.2006.15.707; Mahmood A, 2006, J NEUROSURG, V104, P272, DOI 10.3171/jns.2006.104.2.272; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Mezey E, 2003, SCIENCE, V299; Perin EC, 2003, CIRCULATION, V107, P2294, DOI 10.1161/01.CIR.0000070596.30552.8B; Priddle H, 2006, STEM CELLS, V24, P815, DOI 10.1634/stemcells.2005-0356; SCHENK F, 1985, EXP BRAIN RES, V58, P11; Schrepfer S, 2007, TRANSPL P, V39, P573, DOI 10.1016/j.transproceed.2006.12.019; Shindo T, 2006, J MED INVESTIG, V53, P42, DOI 10.2152/jmi.53.42; Song L, 2004, FASEB J, V18, P980, DOI 10.1096/fj.03-1100fje; Srivastava D, 2006, NATURE, V441, P1097, DOI 10.1038/nature04961; Theise ND, 2003, SCIENCE, V299, p1317A, DOI 10.1126/science.1078412; Tolar J, 2006, BLOOD, V107, P4182, DOI 10.1182/blood-2005-08-3289; Ukai R, 2007, J NEUROTRAUM, V24, P508, DOI 10.1089/neu.2006.0161; Wagers AJ, 2002, SCIENCE, V297, P2256, DOI 10.1126/science.1074807; Wolf D, 2007, J AM SOC ECHOCARDIOG, V20, P512, DOI 10.1016/j.echo.2006.11.008; Xin H, 2007, STEM CELLS, V25, P1618, DOI 10.1634/stemcells.2006-0461; Xu JG, 2007, AM J PHYSIOL-LUNG C, V293, pL131, DOI 10.1152/ajplung.00431.2006; Ziv Y, 2006, P NATL ACAD SCI USA, V103, P13174, DOI 10.1073/pnas.0603747103	48	174	185	0	12	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUN	2009	110	6					1189	1197		10.3171/2008.9.JNS08158			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	451HH	WOS:000266460800012	19301973	Green Accepted			2021-06-18	
J	Silver, JM; McAllister, TW; Arciniegas, DB				Silver, Jonathan M.; McAllister, Thomas W.; Arciniegas, David B.			Depression and Cognitive Complaints Following Mild Traumatic Brain Injury	AMERICAN JOURNAL OF PSYCHIATRY			English	Article							UNITED-STATES; INDIVIDUALS; REHABILITATION; SERTRALINE; SYMPTOMS; TBI; MISCONCEPTIONS; NEUROPATHOLOGY; RIVASTIGMINE; PREVALENCE	Traumatic brain injury (TBI) is a common occurrence with multiple possible neuropsychiatric sequelae, including problems with cognition, emotion, and behavior. While many individuals experience significant improvement over the first months following mild TBI, a nontrivial minority will develop persistent, functionally impairing post-TBI symptoms. Depression and cognitive impairment are among the most common such symptoms, and they may respond to a combination of rehabilitative and pharmacologic treatments. This article discusses the clinical approach to treating an individual with depression and cognitive complaints following mild TBI. Recommendations regarding the diagnosis, evaluation, and treatment of these problems are offered.	NYU, Dept Psychiat, New York, NY 10003 USA; Dartmouth Med Sch, Lebanon, NH USA; Hlth ONE Spalding Rehabil Hosp, Brain Injury Rehabil Unit, Aurora, CO USA; Univ Colorado, Denver Sch Med, Dept Psychiat, Neurobehav Disorders Program, Aurora, CO USA	Silver, JM (corresponding author), 40 E 83rd St, New York, NY 10028 USA.	jonsilver@gmail.com			HealthONE Spalding Rehabilitation Hospital; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS40472-01, RO1 HD048176-01, RO1 NS055020, R01HD48638]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD048176, R01HD048638] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS040472, R01NS055020] Funding Source: NIH RePORTER	Supported in part by HealthONE Spalding Rehabilitation Hospital and NIH grants RO1 NS40472-01, RO1 HD048176-01, RO1 NS055020, and R01HD48638.	Alderfer BS, 2005, J HEAD TRAUMA REHAB, V20, P544, DOI 10.1097/00001199-200511000-00006; Alper K, 2007, BIOL PSYCHIAT, V62, P345, DOI 10.1016/j.biopsych.2006.09.023; [Anonymous], 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Anson K, 2006, BRAIN INJURY, V20, P1, DOI 10.1080/02699050500309791; Anson K, 2006, BRAIN INJURY, V20, P167, DOI 10.1080/02699050500442956; Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Arciniegas DB, 2006, BEHAV NEUROL, V17, P25, DOI 10.1155/2006/460592; ASHMAN TA, ARCH PHYS M IN PRESS; Bay Esther, 2004, Res Theory Nurs Pract, V18, P213, DOI 10.1891/088971804780957108; Bell KR, 2008, J NEUROL NEUROSUR PS, V79, P1275, DOI 10.1136/jnnp.2007.141762; Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Dikmen S, 2001, J CLIN EXP NEUROPSYC, V23, P729, DOI 10.1076/jcen.23.6.729.1019; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Ghaffar O, 2006, J PSYCHOSOM RES, V61, P153, DOI 10.1016/j.jpsychores.2005.07.018; Gordon WR, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199812000-00006; Green A, 2001, BRAIN INJURY, V15, P1021, DOI 10.1080/02699050110074187; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Groom KN, 1998, ARCH CLIN NEUROPSYCH, V13, P695, DOI 10.1016/S0887-6177(98)00005-5; Gualtieri C T, 1988, Brain Inj, V2, P273, DOI 10.3109/02699058809150898; Guilmette TJ, 2004, ARCH CLIN NEUROPSYCH, V19, P183, DOI 10.1016/S0887-6177(03)00025-8; Harris JKJ, 2001, BRAIN INJURY, V15, P223; Hessen E, 2007, BRAIN INJURY, V21, P963, DOI 10.1080/02699050701528454; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P47, DOI 10.1097/00001199-199808000-00005; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hibbard MR, 2002, J HEAD TRAUMA REHAB, V17, P112, DOI 10.1097/00001199-200204000-00004; Horsfield SA, 2002, INT J PSYCHIAT MED, V32, P337, DOI 10.2190/KQ48-XT0L-2H14-5UMV; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; KIM YW, CLIN NEUROPHARMACOL; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; Lee H, 2005, HUM PSYCHOPHARM CLIN, V20, P97, DOI 10.1002/hup.668; Marr A, 2002, CENTRAL NERVOUS SYST; McAllister TW, 2008, BRAIN INJURY, V22, P705, DOI 10.1080/02699050802263019; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; McAllister TW, 2002, NEUROREHABILITATION, V17, P265; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Pagulayan KF, 2008, ARCH PHYS MED REHAB, V89, P1887, DOI 10.1016/j.apmr.2008.03.019; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Powell JM, 2008, ARCH PHYS MED REHAB, V89, P1550, DOI 10.1016/j.apmr.2007.12.035; Rapoport MJ, 2008, J PSYCHOPHARMACOL, V22, P860, DOI 10.1177/0269881107083845; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Ritenour AE, 2008, CRIT CARE MED, V36, pS311, DOI 10.1097/CCM.0b013e31817e2a8c; Schmitt JAJ, 2001, J PSYCHOPHARMACOL, V15, P173, DOI 10.1177/026988110101500304; Silver JM, 2006, NEUROLOGY, V67, P748, DOI 10.1212/01.wnl.0000234062.98062.e9; Silver JM, 2005, TXB TRAUMATIC BRAIN; Silver JM, 2009, BRAIN INJURY, V23, P123, DOI 10.1080/02699050802649696; Snell DL, 2008, J CLIN EXP NEUROPSYC, V2, P1; Starkstein SE, 2002, NEUROREHABILITATION, V17, P105; Swift TL, 2001, BRAIN INJURY, V15, P149, DOI 10.1080/026990501458380; Tanielian T, 2008, INVISIBLE WOUNDS WAR; TEASDALE G, 1974, LANCET, V2, P81; Tenovuo O, 2005, PROG NEURO-PSYCHOPH, V29, P61, DOI 10.1016/j.pnpbp.2004.10.006; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Turner-Stokes L, 2002, CLIN REHABIL, V16, P261, DOI 10.1191/0269215502cr489oa; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zhang L, 2004, ARCH PHYS MED REHAB, V85, P1050, DOI 10.1016/j.apmr.2003.10.014	73	174	174	1	22	AMER PSYCHIATRIC PUBLISHING, INC	ARLINGTON	1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA	0002-953X			AM J PSYCHIAT	Am. J. Psychiat.	JUN	2009	166	6					653	661		10.1176/appi.ajp.2009.08111676			9	Psychiatry	Psychiatry	452KQ	WOS:000266539300007	19487401				2021-06-18	
J	Hazell, AS				Hazell, Alan S.			Excitotoxic mechanisms in stroke: An update of concepts and treatment strategies	NEUROCHEMISTRY INTERNATIONAL			English	Article; Proceedings Paper	Symposium on Excitotoxicity in Neurologic Disease held at the 37th Annual Meeting of the American-Society-for-Neurochemistry	MAR 11-15, 2006	Portland, OR	Amer Soc Neurochem		glutamate transporter; cerebral ischemia; excitotoxicity; therapeutic; complexin; astrocyte; glutamate; neurogenesis	FOCAL CEREBRAL-ISCHEMIA; GLUTAMATE TRANSPORTER GLT-1; TRAUMATIC BRAIN-INJURY; AMINO-ACID TRANSPORTER; CENTRAL-NERVOUS-SYSTEM; RECEPTOR-MEDIATED EXCITOTOXICITY; CULTURED HIPPOCAMPAL-NEURONS; TISSUE-PLASMINOGEN ACTIVATOR; RANDOMIZED EFFICACY TRIAL; N-ACETYLCYSTEINE	Cerebral damage as a consequence of glutamate-mediated excitotoxicity represents a major consequence of stroke. However, the development of effective clinical treatments for this potentially devastating condition has been largely unsuccessful to date, despite promising basic research. This review will focus on the latest advances in our understanding of the excitotoxic process including the release of glutamate as a neurotransmitter and the potential contribution of complexins, the important role of astrocytes, including its involvement in glutamate uptake, alterations in glutamate transporter levels, reversed glutamate uptake, and the vesicular release of glutamate. Recent progress in our understanding of the involvement of excitotoxicity in white matter injury following ischemic insults is also discussed, as is oxidative stress and ischemic tolerance, along with an update on the use of treatment strategies with potential therapeutic benefit including stimulation of neurogenesis. Such key issues are at the heart of future interventions directed at limiting the extent of the excitotoxic process, and remain a viable consideration for effective stroke management. (C) 2007 Elsevier Ltd. All rights reserved.	Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada	Hazell, AS (corresponding author), CHUM, NeuroRescue Lab, Hop St Luc, 1058 St Denis, Montreal, PQ H2X 3J4, Canada.	alan.stewart.hazell@umontreal.ca					Aebischer P, 1996, NAT MED, V2, P696, DOI 10.1038/nm0696-696; Agostinho P, 1997, FASEB J, V11, P154; Agrawal SK, 1997, J NEUROSCI, V17, P1055; Alberdi E, 2002, NEUROBIOL DIS, V9, P234, DOI 10.1006/nbdi.2001.0457; AMERISO SF, 1997, PRIMER CEREBROVASCUL, P104; Andersen M, 1999, STROKE, V30, P1464, DOI 10.1161/01.STR.30.7.1464; Anderson CM, 2000, GLIA, V32, P1; Angulo MC, 2004, J NEUROSCI, V24, P6920, DOI 10.1523/JNEUROSCI.0473-04.2004; Araque A, 2000, J NEUROSCI, V20, P666, DOI 10.1523/JNEUROSCI.20-02-00666.2000; Araque A, 1998, J NEUROSCI, V18, P6822; Araque A, 1998, EUR J NEUROSCI, V10, P2129, DOI 10.1046/j.1460-9568.1998.00221.x; Aronowski J, 1996, NEUROL RES, V18, P570; Arriza JL, 1997, P NATL ACAD SCI USA, V94, P4155, DOI 10.1073/pnas.94.8.4155; Atochin DN, 2003, STROKE, V34, P1299, DOI 10.1161/01.STR.0000066870.70976.57; Benchenane K, 2005, CIRCULATION, V111, P2241, DOI 10.1161/01.CIR.0000163542.48611.A2; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; Bezzi P, 2004, NAT NEUROSCI, V7, P613, DOI 10.1038/nn1246; Bezzi P, 1998, NATURE, V391, P281; BRUNO V, 1994, EUR J PHARMACOL, V256, P109, DOI 10.1016/0014-2999(94)90624-6; Busch E, 1996, J CEREBR BLOOD F MET, V16, P1090, DOI 10.1097/00004647-199611000-00002; Callaway JK, 2004, NEUROPHARMACOLOGY, V47, P146, DOI 10.1016/j.neuropharm.2004.03.003; Castillo J, 1997, LANCET, V349, P79, DOI 10.1016/S0140-6736(96)04453-4; Chen J, 1996, J CEREBR BLOOD F MET, V16, P566, DOI 10.1097/00004647-199607000-00006; Chen WZ, 2002, J NEUROSCI, V22, P2142, DOI 10.1523/JNEUROSCI.22-06-02142.2002; CHOI DW, 1987, J NEUROSCI, V7, P369; Chu K, 2007, STROKE, V38, P177, DOI 10.1161/01.STR.0000252091.36912.65; Clark WM, 1999, STROKE, V30, P2592, DOI 10.1161/01.STR.30.12.2592; Clark WM, 2001, NEUROLOGY, V57, P1595, DOI 10.1212/WNL.57.9.1595; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; DANBOLT NC, 1992, NEUROSCIENCE, V51, P295, DOI 10.1016/0306-4522(92)90316-T; Davalos A, 2002, STROKE, V33, P2850, DOI 10.1161/01.STR.0000038691.03334.71; DeFranco Donald B, 2004, Curr Atheroscler Rep, V6, P295, DOI 10.1007/s11883-004-0061-2; Demougeot C, 2004, NEUROSCI LETT, V362, P17, DOI 10.1016/j.neulet.2004.01.034; Dennery PA, 2003, FREE RADICAL BIO MED, V34, P124, DOI 10.1016/S0891-5849(02)01295-9; Deplanque D, 2003, J NEUROSCI, V23, P6264; DREJER J, 1983, NEUROCHEM RES, V8, P231, DOI 10.1007/BF00963923; Dronne MA, 2007, BRAIN RES, V1138, P231, DOI 10.1016/j.brainres.2006.12.062; Eastwood SL, 2005, SCHIZOPHR RES, V73, P159, DOI 10.1016/j.schres.2004.05.010; Ehrenreich H, 2002, MOL MED, V8, P495, DOI 10.1007/BF03402029; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; FERN R, 1995, J NEUROPHYSIOL, V74, P369; Fernandez-Monreal M, 2004, J BIOL CHEM, V279, P50850, DOI 10.1074/jbc.M407069200; FOLBERGROVA J, 1992, J CEREBR BLOOD F MET, V12, P25, DOI 10.1038/jcbfm.1992.4; GALLO V, 1994, GLIA, V10, P149, DOI 10.1002/glia.440100209; GARDNERMEDWIN AR, 1981, BRAIN RES, V209, P452, DOI 10.1016/0006-8993(81)90169-4; Gegelashvili G, 2000, NEUROCHEM INT, V37, P163, DOI 10.1016/S0197-0186(00)00019-X; GIFFARD RG, 1990, BRAIN RES, V530, P138, DOI 10.1016/0006-8993(90)90670-7; GLAUM SR, 1994, MOL PHARMACOL, V45, P1221; GOLDBERG MP, 2002, STROKE TRIALS DIRECT; Gottlieb M, 2003, J NEUROCHEM, V87, P119, DOI 10.1046/j.1471-4159.2003.01972.x; Grieb P, 2001, FOLIA NEUROPATHOL, V39, P141; Griffin JH, 2004, CRIT CARE MED, V32, pS247, DOI 10.1097/01.CCM.0000126127.87484.2B; HANSSON E, 1994, NEUROSCIENCE, V63, P1057, DOI 10.1016/0306-4522(94)90572-X; Harrison PJ, 1998, LANCET, V352, P1669, DOI 10.1016/S0140-6736(98)03341-8; Hazell AS, 2005, J NEUROSCI RES, V79, P200, DOI 10.1002/jnr.20278; Hazell AS, 2003, GLIA, V43, P175, DOI 10.1002/glia.10241; HERTZ L, 1965, NATURE, V206, P1091, DOI 10.1038/2061091a0; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; Hu KA, 2002, J BIOL CHEM, V277, P41652, DOI 10.1074/jbc.M205044200; Hurtado O, 2005, NEUROBIOL DIS, V18, P336, DOI 10.1016/j.nbd.2004.10.006; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Inage YW, 2000, PEDIATR NEUROL, V23, P42, DOI 10.1016/S0887-8994(00)00142-9; Iwashita A, 2007, J PHARMACOL EXP THER, V320, P1087, DOI 10.1124/jpet.106.115758; Jatana M, 2006, PEDIATR RES, V59, P684, DOI 10.1203/01.pdr.0000215045.91122.44; Juurlink B H, 1998, J Spinal Cord Med, V21, P309; KAKIHANA M, 1988, STROKE, V19, P217, DOI 10.1161/01.STR.19.2.217; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KARWOSKI CJ, 1989, SCIENCE, V244, P578, DOI 10.1126/science.2785716; Kawahara K, 2005, GLIA, V49, P349, DOI 10.1002/glia.20114; KIMELBERG HK, 1988, GLIA, V1, P219, DOI 10.1002/glia.440010307; KIMELBERG HK, 1992, J NEUROTRAUM, V9, pS71; Kirino T, 2002, J CEREBR BLOOD F MET, V22, P1283, DOI 10.1097/01.WCB.0000040942.89393.88; KITAGAWA K, 1990, BRAIN RES, V528, P21, DOI 10.1016/0006-8993(90)90189-I; KNUCKEY NW, 1995, STROKE, V26, P305, DOI 10.1161/01.STR.26.2.305; Kosugi T, 2005, NEUROCHEM RES, V30, P1109, DOI 10.1007/s11064-005-8219-z; Kosugi T, 2006, NEUROCHEM RES, V31, P933, DOI 10.1007/s11064-006-9099-6; KUFFLER SW, 1966, J NEUROPHYSIOL, V29, P768; Lebeurrier N, 2005, MOL CELL NEUROSCI, V30, P552, DOI 10.1016/j.mcn.2005.09.005; Lebeurrier N, 2004, EXPERT OPIN THER TAR, V8, P309, DOI 10.1517/14728222.8.4.309; LEES GJ, 1991, BRAIN RES REV, V16, P283, DOI 10.1016/0165-0173(91)90011-V; Lees KR, 2004, LANCET, V363, P439; LEHRE KP, 1995, J NEUROSCI, V15, P1835; Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313; Levy LM, 1998, J NEUROSCI, V18, P9620, DOI 10.1523/jneurosci.18-23-09620.1998; Li S, 1999, J NEUROSCI, V19, pRC16; Li SX, 2000, J NEUROSCI, V20, P1190, DOI 10.1523/JNEUROSCI.20-03-01190.2000; LIPSKI J, 2007, NEUROPROTECTIVE POTE; Liu HQ, 2006, NEUROCHEM RES, V31, P967, DOI 10.1007/s11064-006-9102-2; LONGUEMARE MC, 1995, J NEUROSCI RES, V40, P379, DOI 10.1002/jnr.490400312; Luo YM, 2006, J NEUROCHEM, V97, P435, DOI 10.1111/j.1471-4159.2006.03758.x; Mallolas J, 2006, J EXP MED, V203, P711, DOI 10.1084/jem.20051979; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Manoonkitiwongsa PS, 2004, J CEREBR BLOOD F MET, V24, P693, DOI 10.1097/01.WCB.0000126236.54306.21; Maragakis NJ, 2006, NAT CLIN PRACT NEURO, V2, P679, DOI 10.1038/ncpneuro0355; Matute C, 1997, P NATL ACAD SCI USA, V94, P8830, DOI 10.1073/pnas.94.16.8830; McDonald JW, 1998, NAT MED, V4, P291, DOI 10.1038/nm0398-291; MCMAHON HT, 1995, CELL, V83, P111, DOI 10.1016/0092-8674(95)90239-2; MIES G, 1993, NEUROREPORT, V4, P709, DOI 10.1097/00001756-199306000-00027; MIYAMOTO M, 1994, EUR J PHARMACOL, V256, P109; Montana V, 2004, J NEUROSCI, V24, P2633, DOI 10.1523/JNEUROSCI.3770-03.2004; Montana V, 2006, GLIA, V54, P700, DOI 10.1002/glia.20367; MUIR KW, 2003, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD001244; Nagai N, 1999, CIRCULATION, V99, P2440, DOI 10.1161/01.CIR.99.18.2440; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Namura S, 2002, NEUROSCI LETT, V324, P117, DOI 10.1016/S0304-3940(02)00193-3; NEDERGAARD M, 1993, J CEREBR BLOOD F MET, V13, P568, DOI 10.1038/jcbfm.1993.74; Newman EA, 2003, TRENDS NEUROSCI, V26, P536, DOI 10.1016/S0166-2236(03)00237-6; NICHOLLS D, 1990, TRENDS PHARMACOL SCI, V11, P462, DOI 10.1016/0165-6147(90)90129-V; Nishino K, 2004, J CEREBR BLOOD F MET, V24, P167, DOI 10.1097/01.WCB.0000100853.67976.8B; NORENBERG MD, 1979, BRAIN RES, V161, P303, DOI 10.1016/0006-8993(79)90071-4; OBRENOVITCH TP, 1994, BRIT J PHARMACOL, V113, P1295, DOI 10.1111/j.1476-5381.1994.tb17139.x; OH TE, 1980, MED J AUSTRALIA, V1, P664, DOI 10.5694/j.1326-5377.1980.tb135217.x; Onal MZ, 1997, STROKE, V28, P1060, DOI 10.1161/01.STR.28.5.1060; Ono S, 1998, EUR J NEUROSCI, V10, P2143, DOI 10.1046/j.1460-9568.1998.00225.x; Ostrow JD, 2003, EUR J CLIN INVEST, V33, P988, DOI 10.1046/j.1365-2362.2003.01261.x; Pabst S, 2002, J BIOL CHEM, V277, P7838, DOI 10.1074/jbc.M109507200; Pabst S, 2000, J BIOL CHEM, V275, P19808, DOI 10.1074/jbc.M002571200; Paoli M, 2002, DNA CELL BIOL, V21, P271, DOI 10.1089/104454902753759690; Park SW, 2007, J PHARMACOL EXP THER, V320, P1002, DOI 10.1124/jpet.106.113472; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; Petralia RS, 1996, NEUROSCIENCE, V71, P949, DOI 10.1016/0306-4522(95)00533-1; PHILLIS JW, 1994, BRAIN RES BULL, V34, P457, DOI 10.1016/0361-9230(94)90019-1; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; Pulsinelli W.A., 1997, PRIMER CEREBROVASCUL, P104; Rakic P, 2004, NATURE, V427, P685, DOI 10.1038/427685a; Rao VLR, 2001, NEUROCHEM RES, V26, P497; RATAN RR, 1994, J NEUROSCI, V14, P4385; Reim K, 2001, CELL, V104, P71, DOI 10.1016/S0092-8674(01)00192-1; Ribo M, 2006, CURR NEUROL NEUROSCI, V6, P17, DOI 10.1007/s11910-996-0004-0; Romera C, 2004, J NEUROSCI, V24, P1350, DOI 10.1523/JNEUROSCI.1596-03.2004; ROMERA C, 2007, J CEREB BLOOD FLOW M; Rosen CJ, 1999, J CLIN DENSITOM, V2, P3, DOI 10.1385/JCD:2:1:3; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Rothstein JD, 2005, NATURE, V433, P73, DOI 10.1038/nature03180; Sanai N, 2004, NATURE, V427, P740, DOI 10.1038/nature02301; Sanchez-Gomez MV, 1999, NEUROBIOL DIS, V6, P475, DOI 10.1006/nbdi.1999.0264; SARNSTRAND B, 1995, CHEM-BIOL INTERACT, V94, P157, DOI 10.1016/0009-2797(94)03332-3; Saver JL, 2004, STROKE, V35, pE106, DOI 10.1161/01.STR.0000124458.98123.52; Schabitz WR, 1996, J NEUROL SCI, V138, P21, DOI 10.1016/0022-510X(95)00341-X; Schmitt A, 2002, NEUROSCIENCE, V109, P45, DOI 10.1016/S0306-4522(01)00451-1; Schousboe A, 1981, Int Rev Neurobiol, V22, P1, DOI 10.1016/S0074-7742(08)60289-5; Sekhon B, 2003, BRAIN RES, V971, P1, DOI 10.1016/S0006-8993(03)02244-3; Seki Y, 1999, STROKE, V30, P433, DOI 10.1161/01.STR.30.2.433; Shimada F, 1999, EUR J PHARMACOL, V386, P263, DOI 10.1016/S0014-2999(99)00735-9; Shuaib A, 2000, EXP NEUROL, V161, P733, DOI 10.1006/exnr.1999.7314; Silbergleit R, 1999, RESUSCITATION, V40, P181, DOI 10.1016/S0300-9572(99)00027-1; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; STYS PK, 1990, P NATL ACAD SCI USA, V87, P4212, DOI 10.1073/pnas.87.11.4212; Sung JH, 2001, J NEUROVIROL, V7, P454; SWANSON RA, 1992, NEUROSCI LETT, V147, P143, DOI 10.1016/0304-3940(92)90580-Z; Swanson RA, 1997, GLIA, V21, P142, DOI 10.1002/(SICI)1098-1136(199709)21:1<142::AID-GLIA16>3.0.CO;2-S; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; TAKAHASHI S, 1995, FEBS LETT, V368, P455, DOI 10.1016/0014-5793(95)00713-J; Takahashi S, 2000, EUR J PHARMACOL, V408, P127, DOI 10.1016/S0014-2999(00)00790-1; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; Tang J, 2006, CELL, V126, P1175, DOI 10.1016/j.cell.2006.08.030; Taniguchi M, 2000, MOL BRAIN RES, V78, P131, DOI 10.1016/S0169-328X(00)00084-X; TAZAKI Y, 1988, STROKE, V19, P211, DOI 10.1161/01.STR.19.2.211; Tekkok SB, 2001, J NEUROSCI, V21, P4237, DOI 10.1523/JNEUROSCI.21-12-04237.2001; TEKKOK SB, 2007, J CEREB BLOOD FLOW M; Tomimoto H, 1999, ACTA NEUROPATHOL, V97, P22, DOI 10.1007/s004010050951; Trotti D, 1996, J BIOL CHEM, V271, P5976, DOI 10.1074/jbc.271.11.5976; Trotti D, 1998, TRENDS PHARMACOL SCI, V19, P328, DOI 10.1016/S0165-6147(98)01230-9; TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0; Tureyen K, 2007, J NEUROCHEM, V101, P41, DOI 10.1111/j.1471-4159.2006.04376.x; TYMIANSKI M, 1993, J NEUROSCI, V13, P2085; Umemura K, 1996, STROKE, V27, P1624, DOI 10.1161/01.STR.27.9.1624; UtsunomiyaTate N, 1997, FEBS LETT, V416, P312, DOI 10.1016/S0014-5793(97)01232-5; VOLTERRA A, 1994, J NEUROSCI, V14, P2924; Wagner KR, 2003, J CEREBR BLOOD F MET, V23, P629, DOI 10.1097/01.WCB.0000073905.87928.6D; WAGNER PD, 1989, EUR RESPIR J, V2, P116; WALZ W, 1987, CAN J PHYSIOL PHARM, V65, P1051, DOI 10.1139/y87-166; WALZ W, 1982, J NEUROCHEM, V39, P70, DOI 10.1111/j.1471-4159.1982.tb04702.x; Wang JA, 2007, BRAIN, V130, P1643, DOI 10.1093/brain/awm095; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Wang YMF, 1998, NAT MED, V4, P228, DOI 10.1038/nm0298-228; Warner DS, 2004, J EXP BIOL, V207, P3221, DOI 10.1242/jeb.01022; Wiltrout C, 2007, NEUROCHEM INT, V50, P1028, DOI 10.1016/j.neuint.2007.04.011; Wisman LAB, 2003, NEUROREPORT, V14, P1967, DOI 10.1097/00001756-200310270-00017; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Wong LF, 2005, MOL THER, V11, P89, DOI 10.1016/j.ymthe.2004.08.026; Yamada M, 1999, NEUROSCIENCE, V93, P7, DOI 10.1016/S0306-4522(99)00104-9; Yamagata K, 2004, HYPERTENS RES, V27, P271, DOI 10.1291/hypres.27.271; Yeh TH, 2005, NEUROBIOL DIS, V18, P476, DOI 10.1016/j.nbd.2004.12.011; Yepes M, 2000, BLOOD, V96, P569; Yi JH, 2006, J NEUROTRAUM, V23, P86, DOI 10.1089/neu.2006.23.86; Yi JH, 2005, GLIA, V49, P121, DOI 10.1002/glia.20099; YI JH, 2007, BRAIN RES; ZHANG M, 2007, J CEREB BLOOD FLOW M; Zhang Q, 2004, J BIOL CHEM, V279, P12724, DOI 10.1074/jbc.M312845200; Zlotnik A, 2007, EXP NEUROL, V203, P213, DOI 10.1016/j.expneurol.2006.08.021; Zwienenberg M, 2001, NEUROSURGERY, V48, P1119, DOI 10.1097/00006123-200105000-00031	194	174	183	1	18	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	JUN	2007	50	7-8			SI		941	953		10.1016/j.neuint.2007.04.026			13	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	195UH	WOS:000248436900008	17576023				2021-06-18	
